


APPROVED DRUG PRODUCTS

With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)



APPROVED DRUG PRODUCTS

WITH

**THERAPEUTIC
EQUIVALENCE
EVALUATIONS**

33rd EDITION

**THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER
SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF PHARMACEUTICAL SCIENCE
OFFICE OF GENERIC DRUGS

2013

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2012.

33rd EDITION



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF PHARMACEUTICAL SCIENCE
OFFICE OF GENERIC DRUGS

2013

**FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
APPROVED DRUG PRODUCTS
with
Therapeutic Equivalence Evaluations**

CONTENTS

PAGE

PREFACE TO THIRTY THIRD EDITION.....	iv
1 INTRODUCTION.....	vi
1.1 Content and Exclusion.....	vi
1.2 Therapeutic Equivalence-Related Terms	vi
1.3 Statistical Criteria for Bioequivalence	viii
1.4 Reference Listed Drug.....	x
1.5 General Policies and Legal Status	xi
1.6 Practitioner/User Responsibilities.....	xi
1.7 Therapeutic Equivalence Evaluations Codes	xiii
1.8 Description of Special Situations.....	xx
1.9 Therapeutic Equivalence Code Change for a Drug Entity.....	xxii
1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product	xxiii
1.11 Discontinued Section.....	xxiii
1.12 Changes to the Orange Book	xxiii
1.13 Availability of the Edition.....	xxiv
2 HOW TO USE THE DRUG PRODUCTS LISTS	2-1
2.1 Key Sections for Using the Drug Product Lists	2-1
2.2 Drug Product Illustration	2-3
2.3 Therapeutic Equivalence Evaluations Illustration	2-4
DRUG PRODUCT LISTS	
Prescription Drug Product List	3-1
OTC Drug Product List	4-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	5-1
Discontinued Drug Product List	6-1
Orphan Products Designations and Approvals List	7-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	8-1
APPENDICES	
A. Product Name Index	A-1
B. Product Name Index Listed by Applicant	B-1
C. Uniform Terms	C-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	AD1
A. Patent and Exclusivity Lists	ADA1
B. Patent and Exclusivity Terms	ADB1

**FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
APPROVED DRUG PRODUCTS
with
Therapeutic Equivalence Evaluations**

PREFACE TO THIRTY THIRD EDITION

The publication, *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act). Drugs on the market approved only on the basis of safety (covered by the ongoing Drug Efficacy Study Implementation [DESI] review [e.g., Donnatal® Tablets and Librax® Capsules] or pre-1938 drugs [e.g., Phenobarbital Tablets]) are not included in this publication. The main criterion for the inclusion of any product is that the product is the subject of an application with an effective approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products on the List is independent of any current regulatory action through administrative or judicial means against a drug product. In addition, the List contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the Act.

Background of the Publication. To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state stating FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The List was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the Act.

The therapeutic equivalence evaluations in the List reflect FDA's application of specific criteria to the multisource prescription drug products on the List approved under Section 505 of the Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the code appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register*

on October 31, 1980 (45 FR 72582). The first publication, October 1980, of the final version of the List incorporated appropriate corrections and additions. Each subsequent edition has included the new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act (1984 Amendments). The 1984 Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The *Approved Drug Products with Therapeutic Equivalence Evaluations* publication and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that qualify under the 1984 Amendments for periods of exclusivity (during which ANDAs or applications described in Section 505(b)(2) of the Act for those drugs may not be submitted for a specified period of time and, if allowed to be submitted, would be tentatively approved) and provides patent information concerning the listed drugs which also may delay the approval of ANDAs or Section 505(b)(2) applications. The *Addendum* also provides additional information that may be helpful to those submitting a new drug application to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Director, Division of Labeling and Program Support, HFD-610, Office of Generic Drugs, Center for Drug and Evaluation and Research, 7620 Standish Place, Rockville, MD 20855. Comments received are publicly available to the extent allowable under the Freedom of Information regulations.

1. INTRODUCTION

1.1 Content and Exclusion

The List is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing.¹ This publication also includes indices of prescription and OTC drug products by trade or established name (if no trade name exists) and by applicant name (holder of the approved application). All established names for active ingredients generally conform to official compendial names or *United States Adopted Names* (USAN) as prescribed in (21 CFR 299.4(e)). The latter list includes applicants' names as abbreviated in this publication; in addition, a list of uniform terms is provided.

An *Addendum* contains drug patent and exclusivity information for the Prescription, OTC, Discontinued Drug Product Lists, and for the Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research. The publication may include additional information that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research because the main purpose of the publication was to provide information to states regarding FDA's recommendation as to which generic prescription drug products were acceptable candidates for drug product selection. The 1984 Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required.

Under the 1984 Amendments, some drug products are given tentative approvals. The Agency will not include drug products with tentative approval in the List. Tentative approval lists are available at [ANDA \(Generic\) Drug Approvals](#). When the tentative approval becomes a full approval through a subsequent action letter to the application holder, the Agency will list the drug product and the final approval date in the appropriate approved drug product list.

Distributors or repackagers of products on the List are not identified. Because distributors or repackagers are not required to notify FDA when they shift their sources of supply from one approved manufacturer to another, it is not possible to maintain complete information linking product approval with the distributor or repackager handling the products.

1.2 Therapeutic Equivalence-Related Terms

Pharmaceutical Equivalents. Drug products are considered pharmaceutical equivalents if they contain the same active ingredient(s), are of the same

¹ Newly approved products are added to parts 1, 2, or 3, of the List, depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Orange Book staff is otherwise notified before publication.

dosage form, route of administration and are identical in strength or concentration (e.g., chlorthalidone hydrochloride, 5mg capsules). Pharmaceutically equivalent drug products are formulated to contain the same amount of active ingredient in the same dosage form and to meet the same or compendial or other applicable standards (i.e., strength, quality, purity, and identity), but they may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration time, and, within certain limits, labeling.

Pharmaceutical Alternatives. Drug products are considered pharmaceutical alternatives if they contain the same therapeutic moiety, but are different salts, esters, or complexes of that moiety, or are different dosage forms or strengths (e.g., tetracycline hydrochloride, 250mg capsules vs. tetracycline phosphate complex, 250mg capsules; quinidine sulfate, 200mg tablets vs. quinidine sulfate, 200mg capsules). Data are generally not available for FDA to make the determination of tablet to capsule bioequivalence. Different dosage forms and strengths within a product line by a single manufacturer are thus pharmaceutical alternatives, as are extended-release products when compared with immediate-release or standard-release formulations of the same active ingredient.

Therapeutic Equivalents. Drug products are considered to be therapeutic equivalents only if they are pharmaceutical equivalents and if they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

FDA classifies as therapeutically equivalent those products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. *The concept of therapeutic equivalence, as used to develop the List, applies only to drug products containing the same active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., propoxyphene hydrochloride vs. pentazocine hydrochloride for the treatment of pain).* Any drug product in the List repackaged and/or distributed by other than the application holder is considered to be therapeutically equivalent to the application holder's drug product even if the application holder's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, distributors or repackagers of an application holder's drug product are considered to have the same code as the application holder. Therapeutic equivalence determinations are not made for unapproved, off-label indications.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time and minor aspects of labeling (e.g., the presence of specific pharmacokinetic information) and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a particular brand be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product will produce the same clinical effect and safety profile as the prescribed product.

Bioavailability. This term means the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes

available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.

Bioequivalent Drug Products. This term describes pharmaceutical equivalent or pharmaceutical alternative products that display comparable bioavailability when studied under similar experimental conditions. Section 505 (j)(8)(B) of the Act describes one set of conditions under which a test and reference listed drug (see Section 1.4) shall be considered bioequivalent:

the rate and extent of absorption of the test drug do not show a significant difference from the rate and extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or

the extent of absorption of the test drug does not show a significant difference from the extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the reference drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

Bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.

1.3 Statistical Criteria for Bioequivalence

Under the Drug Price Competition and Patent Term Restoration Act of 1984, manufacturers seeking approval to market a generic drug product must submit data demonstrating that the drug product is bioequivalent to the pioneer (innovator) drug product. A major premise underlying the 1984 law is that bioequivalent drug products are therapeutically equivalent, and therefore, interchangeable.

Bioavailability refers to the rate and extent to which the active ingredient or therapeutic ingredient is absorbed from a drug product and becomes available at the site of drug action (Federal Food, Drug and Cosmetic Act, section 505(j)(8)). Bioequivalence refers to equivalent release of the same drug substance from two or more drug products or formulations. This leads to an equivalent rate and extent of absorption from these formulations. Underlying the concept of bioequivalence is the thesis that, if a drug product contains a drug substance that is chemically identical and is delivered to the site of action at the same rate and extent as another drug product, then it is equivalent and can be substituted for that drug product. Methods used to define bioequivalence can be found in 21 CFR 320.24, and include (1) pharmacokinetic (PK) studies, (2) pharmacodynamic (PD) studies, (3) comparative clinical trials, and (4) in-vitro studies. The choice of study used is based on the site of action of the drug and the ability of the study design to compare drug delivered to that site by the two products.

The standard bioequivalence (PK) study is conducted using a two-treatment crossover study design in a limited number of volunteers, usually 24 to 36

adults. Alternately, a four-period, replicate design crossover study may also be used. Single doses of the test and reference drug products are administered and blood or plasma levels of the drug are measured over time. Pharmacokinetic parameters characterizing rate and extent of drug absorption are evaluated statistically. The PK parameters of interest are the resulting area under the plasma concentration-time curve (AUC), calculated to the last measured concentration ($AUC_{(0-t)}$) and extrapolated to infinity ($AUC_{(0-inf)}$), for extent of absorption; and the maximum or peak drug concentrations (C_{max}), for rate of absorption. Crossover studies may not be practical in drugs with a long half-life in the body, and a parallel study design may be used instead. Alternate study methods, such as in-vitro studies or equivalence studies with clinical or pharmacodynamic endpoints, are used for drug products where plasma concentrations are not useful to determine delivery of the drug substance to the site of activity (such as inhalers, nasal sprays and topical products applied to the skin).

The statistical methodology for analyzing these bioequivalence studies is called the two one-sided test procedure. Two situations are tested with this statistical methodology. The first of the two one-sided tests determines whether a generic product (test), when substituted for a brand-name product (reference) is significantly less bioavailable. The second of the two one-sided tests determines whether a brand-name product when substituted for a generic product is significantly less bioavailable. Based on the opinions of FDA medical experts, a difference of greater than 20% for each of the above tests was determined to be significant, and therefore, undesirable for all drug products. Numerically, this is expressed as a limit of test-product average/reference-product average of 80% for the first statistical test and a limit of reference-product average/test-product average of 80% for the second statistical test. By convention, all data is expressed as a ratio of the average response (AUC and C_{max}) for test/reference, so the limit expressed in the second statistical test is 125% (reciprocal of 80%).

For statistical reasons, all data is log-transformed prior to conducting statistical testing. In practice, these statistical tests are carried out using an analysis of variance procedure (ANOVA) and calculating a 90% confidence interval for each pharmacokinetic parameter (C_{max} and AUC). The confidence interval for both pharmacokinetic parameters, AUC and C_{max} , must be entirely within the 80% to 125% boundaries cited above. Because the mean of the study data lies in the center of the 90% confidence interval, the mean of the data is usually close to 100% (a test/reference ratio of 1). Different statistical criteria are sometimes used when bioequivalence is demonstrated through comparative clinical trials pharmacodynamic studies, or comparative in-vitro methodology.

The bioequivalence methodology and criteria described above simultaneously control for both differences in the average response between test and reference, as well as the precision with which the average response in the population is estimated. This precision depends on the within-subject (normal volunteer or patient) variability in the pharmacokinetic parameters (AUC and C_{max}) of the two products and on the number of subjects in the study. The width of the 90% confidence interval is a reflection in part of the within-subject variability of the test and reference products in the bioequivalence study. A test product with no differences in the average response when compared to the reference might still fail to pass the bioequivalence criteria if the variability of one or both products is high and the bioequivalence study has insufficient statistical power (i.e., insufficient number of subjects). Likewise, a test product with low variability may pass the bioequivalence criteria, when there are somewhat larger differences in the average response.

This system of assessing bioequivalence of generic products assures that these substitutable products do not deviate substantially in in-vivo performance from the reference product. The Office of Generic Drugs has conducted two surveys to quantify the differences between generic and brand name products. The first survey included 224 bioequivalence studies submitted

in approved applications during 1985 and 1986. The observed average differences between reference and generic products for AUC was 3.5% (JAMA, Sept. 4, 1987, Vol. 258, No. 9). The second survey included 127 bioequivalence studies submitted to the agency in 273 ANDAs approved in 1997. The three measures reviewed include $AUC_{(0-t)}$, $AUC_{(0-inf)}$, and C_{max} . The observed average differences between the reference and generic products were $+ 3.47\%$ (SD 2.84) for $AUC_{(0-t)}$, $+ 3.25\%$ (SD 2.97) for $AUC_{(0-inf)}$, and $+ 4.29\%$ (SD 3.72) for C_{max} (JAMA, Dec. 1, 1999, Vol. 282, No. 21).

The primary concern from the regulatory point of view is the protection of the patient against approval of products that are not bioequivalent. The current practice of carrying out two one-sided tests at the 0.05 level of significance ensures that there is no more than a 5% chance that a generic product that is not truly equivalent to the reference will be approved.

1.4 Reference Listed Drug

A reference listed drug (21 CFR 314.94(a)(3)) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.

FDA has identified in the Prescription Drug Product and OTC Drug Product Lists those reference listed drugs to which the *in vivo* bioequivalence (reference standard) and, in some instances, the *in vitro* bioequivalence of the applicant's product is compared. By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. Such variations could result if generic drugs were compared to different reference listed drugs. However, in some instances when listed drugs are approved for a single drug product, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. A firm wishing to market a generic version of a listed drug that is not designated as the reference listed drug may petition the Agency through the Citizen Petition procedure (see 21 CFR 10.25(a) and CFR 10.30). When the Citizen Petition is approved, the second listed drug will be designated as an additional reference listed drug and the petitioner may submit an Abbreviated New Drug Application citing the designated reference listed drug. Section 1.7, *Therapeutic Equivalence Evaluations Codes products meeting necessary bioequivalence requirements* explains the (AB, AB1, AB2, AB3... coding system for multisource drug products listed under the same heading with two reference listed drugs.

In addition, there are two situations in which two listed drugs that have been shown to be bioequivalent to each other may both be designated as reference listed drugs. The first situation occurs when the *in vivo* determination of bioequivalence is self-evident and a waiver of the *in vivo* bioequivalence may be granted. The second situation occurs when the bioequivalence of two listed products may be determined through *in vitro* methodology. The reference listed drug is identified by the symbol "+" in the Prescription and Over-the-Counter (OTC) Drug Product Lists. These identified reference listed drugs represent the best judgment of the Division of Bioequivalence at this time. The Prescription and OTC Drug Product Lists identify reference drugs for oral dosage forms, Injectables, ophthalmics, otics, and topical products. It is recommended that a firm planning to conduct an *in vivo* bioequivalence study, or planning to manufacture a batch of a drug product for which an *in vivo* waiver of bioequivalence will be requested, contact the Division of Bioequivalence, Office of Generic Drugs, to confirm the appropriate reference listed drug.

1.5 General Policies and Legal Status

The List contains public information and advice. It does not mandate the drug products which is purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the List sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, intended to reduce the cost of drugs to consumers. To the extent that the List identifies drug products approved under Section 505 of the Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the List does not necessarily mean that the drug product is either in violation of Section 505 of the Act, or that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion is based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

1.6 Practitioner/User Responsibilities

Professional care and judgment should be exercised in using the List.

Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have equivalent clinical effect and no difference in their potential for adverse effects when used under the conditions of their labeling. However, these products may differ in other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. There may also be better stability of one product over another under adverse storage conditions, or allergic reactions in rare cases due to a coloring or a preservative ingredient, as well as differences in cost to the patient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the physician's specification of that product is appropriate. Pharmacists must also be familiar with the expiration dates/times and labeling directions for storage of the different products, particularly for reconstituted products, to assure that patients are properly advised when one product is substituted for another.

Multisource and single-source drug products. FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the Act, which in most instances means those pharmaceutical equivalents available from more than one manufacturer. For such products, a therapeutic equivalence code is included and, in addition, product information is highlighted in bold face and underlined. Those products with approved applications that are single-source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included on the List, but no

therapeutic equivalence code is included with such products. Any drug product in the List repackaged and/or distributed by other than the application holder is considered to be therapeutically equivalent to the application holder's drug product even if the application holder's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, although not identified in the List, distributors or repackagers of an application holder's drug product are considered to have the same code as the application holder. The details of these codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*.

Products on the List are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product. The applicant may have had its product manufactured by a contract manufacturer and may simply be distributing the product for which it has obtained approval. In most instances, however, the manufacturer of the product is also the applicant. The name of the manufacturer is permitted by regulation to appear on the label, even when the manufacturer is not the marketer.

Although the products on the List are identified by the names of the applicants, circumstances, such as changing corporate ownership, have sometimes made identification of the applicant difficult. The Agency believes, based on continuing document review and communication with firms, that the applicant designations on the List are, in most cases, correct.

To relate firm name information on a product label to that on the List, the following should be noted: the applicant's name always appears on the List. This applies whether the applicant (firm name on the Form FDA 356h in the application) is the marketer (firm name in largest letters on the label) or not. However, the applicant's name may not always appear on the label of the product.

If the applicant is the marketer, its name appears on the List and on the label; if the applicant is not the marketer, and the Agency is aware of a corporate relationship (e.g., parent and subsidiary) between the applicant and the marketer, the name of the applicant appears on the List and both firm names may appear on the label. Firms with known corporate relationships are displayed in Appendix B. If there is no known corporate relationship between the applicant and the marketer, the applicant's name appears on the List; however, unless the applicant is the manufacturer, packager, or distributor, the applicant's name may not appear on the label. In this case, the practitioner, from labeling alone, will not be able to relate the marketed product to an applicant cited in the List, and hence to a specific approved drug product. In such cases, to assure that the product in question is the subject of an approved application, the firm named on the label should be contacted.

To relate trade name (proprietary name) information on a product label to that on the List, the following should be noted: if the applicant is the marketer, its name appears on the List and on the label; if the Agency is aware of a corporate relationship between the applicant and the marketer, the trade name (proprietary name) of the drug product (established drug name if no trade name exists) appears on the List. If a corporate relationship exists between an application holder and a marketer and both firms are distributing the drug product, the FDA reserves the right to select the trade name of either the marketer or the application holder to appear on the List. If there is no known corporate relationship between the applicant and the marketer, the established drug name appears on the List.

Every product on the List is subject at all times to regulatory action. From time to time, approved products may be found in violation of one or more provisions of the Act. In such circumstances, the Agency will commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however,

independent of the inclusion of a product on the List. The main criterion for inclusion of a product is that it has an application with an effective approval that has not been withdrawn for safety or efficacy reasons. FDA believes that retention of a violative product on the List will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the data upon which the Agency's assessment of whether a product meets the criteria for therapeutic equivalence was made.

1.7 Therapeutic Equivalence Evaluations Codes

The coding system for therapeutic equivalence evaluations is constructed to allow users to determine quickly whether the Agency has evaluated a particular approved product as therapeutically equivalent to other pharmaceutically equivalent products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With few exceptions, the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter as follows:

A Drug products that FDA considers to be therapeutically equivalent to other pharmaceutically equivalent products, i.e., drug products for which:

- (1) there are no known or suspected bioequivalence problems. These are designated **AA, AN, AO, AP, or AT**, depending on the dosage form; or
- (2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

B Drug products that FDA at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products, i.e.,

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC, BD, BE, BN, BP, BR, BS, BT, BX, or B***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

"A" CODES

Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.

"A" products are those for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bio-equivalence. Drug products designated with an "A" code fall under one of two main policies:

- (1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is presumed and considered self-evident based on other data in the

application for some dosage forms (e.g., solutions) or satisfied for solid oral dosage forms by a showing that an acceptable *in vitro* dissolution standard is met. A therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form, as described below); or

- (2) for those DESI drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products in a dosage form presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional. For example, pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution. An FDA evaluation that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in the labeling of that product.

The Agency will use notes in this publication to point out special situations such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Special Situations*.

For example, in rare instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. Such differences may be due to patent or exclusivity rights associated with such use. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note will be added to Section 1.8.

Also, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, the Agency has considered products to be

pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts and esters of the same therapeutic moiety are regarded as pharmaceutical alternatives. For the purpose of this publication, such products are not considered to be therapeutically equivalent. There are no instances in this List where pharmaceutical alternatives are evaluated or coded with regard to therapeutic equivalence. Anhydrous and hydrated entities, as well as different polymorphs, are considered pharmaceutical equivalents and must meet the same standards and, where necessary, as in the case of ampicillin/ampicillin trihydrate, their equivalence is supported by appropriate bioavailability/bioequivalence studies.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives may differ among some therapeutically equivalent drug products. Differences in preservatives and other inactive ingredients do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

AA Products in conventional dosage forms not presenting bioequivalence problems

Products coded as **AA** contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements

Multisource drug products listed under the same heading (i.e., identical active ingredient(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents*) generally will be coded **AB** if a study is submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1**, **AB2**, **AB3**, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

For example, Adalat® CC (Miles) and Procardia XL® (Pfizer), extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved, Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. The generic

drug products bioequivalent to Adalat® CC would be assigned a rating of **AB1** and those bioequivalent to Procardia XL® would be assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or repackagers are not included in the List, they are considered therapeutically equivalent to the application holder's drug product if the application holder's drug product is rated either with an **AB** or three-character code or is single source in the List. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

AN Solutions and powders for aerosolization

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in any of several delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon *in vitro* methodology, if bioequivalence needs to be demonstrated by *in vivo* methodology then the drug products will be coded **AB**.

AO Injectable oil solutions

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included on the List (e.g., dextrose injection 5%,

dextrose injection 10%, sodium chloride injection 0.9%) since these products are on the market without FDA approval and the FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

The strength of parenteral drugs products is defined as the total drug content of the container. Until recently the strength of liquid parenteral drug products in the Orange Book have not been displayed. The concentration of the liquid parenteral drug product in the Orange Book has been shown as xmg/ml. The amount of dry powder or freeze dried powder in a container has always been identified as the strength.

With the finalization of the Waxman-Hatch amendments that characterized each strength of a drug product as a listed drug, it became evident that the format of the Orange Book should be changed to reflect each strength of a parenteral solution. To this end the OGD has started to display the strength of all new approvals of parenteral solutions. Previously we would have displayed only the concentration of an approved parenteral solution, e.g. 50mg/ml. If this drug product had a 20 ml and 60 ml container approved the two products would be shown as 1Gm / 20ml (50mg/ml) and 3Gm / 60ml (50mg/ml).

AT Topical products

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate bioequivalence data, and **BT** in the absence of such data.

"B" CODES

Drug products that FDA, at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products.

"B" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a "B" code fall under one of three main policies:

- (1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bio-equivalence problems or a significant potential for

such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or

- (2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or
- (3) the drug products are under regulatory review.

The specific coding definitions and policies for the "B" sub-codes are as follows:

B* Drug products requiring further FDA investigation and review to determine therapeutic equivalence

The code **B*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

BC Extended-release dosage forms (capsules, injectables and tablets)

Extended-release tablets are formulated in such a manner as to make the contained medicament available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because firms developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

BD Active ingredients and dosage forms with documented bioequivalence problems

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

BE Delayed-release oral dosage forms

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of "enteric" coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach. Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have

demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

BN Products in aerosol-nebulizer drug delivery systems

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore, the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard, such products are coded **AB**.

BP Active ingredients and dosage forms with potential bioequivalence problems

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate *in vivo* bioequivalence data are submitted, such products are coded **AB**. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence, such products would be coded **AB**.

BR Suppositories or enemas that deliver drugs for systemic absorption

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bio-equivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is available, the product is coded **AB**. If such evidence is not available, the products are coded **BR**.

BS Products having drug standard deficiencies

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

BT Topical products with bioequivalence issues

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, ointments, gels, lotions, pastes, and sprays, as well as suppositories not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

BX Drug products for which the data are insufficient to determine therapeutic equivalence

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

1.8 Description of Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. Following is a description of those special situations:

Amino Acid and Protein Hydrolysate Injections. These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be considered therapeutically equivalent.

Follitropin Alfa and Beta. Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

Gaviscon®. Gaviscon® is an OTC product which has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test which is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon®'s activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, *all ANDAs which cite Gaviscon® tablets as the listed drug must contain the inactive ingredients sodium bicarbonate and alginic acid.* A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

Levothyroxine Sodium. Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine

sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBOTT	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBOTT	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	076752	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	076752	001
LEVOTHEROID	LLOYD	0.025MG	AB4	021116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

Patent Certification(s) Reference Listed Drug based upon a suitability petition. An abbreviated new drug application that refers to a Reference Listed Drug (RLD) approved pursuant to a suitability petition must demonstrate that the proposed product is bioequivalent to the RLD, and it must include appropriate patent certification(s) and an exclusivity statement with respect to the listed drug which served as the basis for the approved suitability petition. This concept also applies to an ANDA applicant that cites a RLD that was based upon an NDA that is still covered by patent (s) and/or

exclusivity, e.g. a second RLD that was selected when the in vivo determination of bioequivalence of the original RLD is self evident and the waiver of the in vivo determination of bioequivalence may be granted.

Waived exclusivity. If a new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (Act) qualifies for exclusivity under sections 505(c)(3)(D) and 505(j)(5)(D), the exclusivity is listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, the FDA will delay the approval of a 505(b)(2) application or an abbreviated new drug application (ANDA) under section 505(j) of the Act until the expiration of the exclusivity. If the listed drug is also protected by one or more patents, the approval date for the 505(b)(2) application or ANDA will be determined by the latest expiring patent or exclusivity listed in the Orange Book. However, the holder of the NDA may waive its exclusivity as to any or all 505(b)(2) and ANDA applications referencing the protected drug product. If an NDA sponsor waives its right to the exclusivity protection, qualified 505(b)(2) or ANDA applications may be approved without regard to the NDA holder's exclusivity. An NDA for which the holder has waived its exclusivity as to all 505(b)(2) and ANDA applications will be coded with a W in the Patent and Exclusivity Section of the Orange Book and be referred to this section. The applicant referencing this listed drug should indicate in the exclusivity statement that the holder of the listed drug has waived its exclusivity.

1.9 Therapeutic Equivalence Code Change for a Drug Entity

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multi-source drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of drug products in the List (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific drug entity and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying a bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of drugs, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comment. Comments, along with scientific data, may be sent to the Director, Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, HFD-650, 7620 Standish Place, Rockville, MD 20855.

The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submission is an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. These submissions should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and such submissions are discouraged. Copies

of supporting reports published in the scientific literature or unpublished material, however, are welcome.

1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The aforementioned procedure does not apply to a change in a single drug product code. For example, a change in a single drug product's code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

1.11 Discontinued Section

Those drug products in the Discontinued Section of the Orange Book in which a determination has already been made that the products were not withdrawn for safety or efficacy reasons have "***Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons***" following the product strength. Those drug products are only reflective of citizen petitions determinations made since 1995. The identification of these drug products in the Discontinued Section of the Orange Book should avoid the submission of multiple citizen petitions for the same drug product. FR notices no longer applicable are removed from the Annual Edition (i.e., there is a currently marketed Reference Listed Drug and no applicable patent or exclusivity). [FR Safety or Effectiveness Determinations List](#) lists products that have current and removed notices. The list is updated quarterly. Notices issued during the year are added to the [Electronic Orange Book Query](#) in the month they become effective.

Generally, approved products are added to the Discontinued Section of the Orange Book when the applicant holder notifies the Orange Book staff of the products' not marketed status. Products may also be added if annual reports indicate the product is no longer marketed or other Agency administrative action (e.g., Withdrawal of an Application). Changes to the Orange Book are not affected by the drug registration and listing requirements of Section 510 of the Act.

1.12 Changes to the Orange Book

Every effort is made to ensure the Annual Edition is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. Please inform the OBS when products are no longer marketed. Notification of the Orange Book staff to include the newly approved product in the Discontinued Drug Product List rather than parts 1, 2 or 3 of the List (as discussed in Section 1.1) must occur by the end of the month in which the product is approved to ensure that the product is not included in the "active" portions of the next published Orange Book update

We can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855

1.13 Availability of the Edition

Commencing with the 25th edition, the Annual Edition and current monthly Cumulative Supplement are available in a Portable Document Format (PDF) at the EOB home page, [Electronic Orange Book Query](#), by clicking on Publications. The PDF annual format duplicates previous paper versions except for the Orphan Products Designations and Approvals List. An annual subscription of the PDF format may be obtained from the U.S. Government Printing Office, 866-512-1800.

2. HOW TO USE THE DRUG PRODUCT LISTS

2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

Illustrations. The annotated *Drug Product Illustration*, see Section 2.2, and the *Therapeutic Equivalence Evaluations Illustration*, see Section 2.3, are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

Drug Product Lists. The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, application holders, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982. The application number preceded by "N" is a New Drug Application (NDA or commonly the innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or commonly the generic).

The Discontinued Product List, arranged alphabetically by active ingredient(s), contains product identification information (dosage form, product name, strength, and application number).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with "A" and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form and route heading. The OTC Drug Product List, Discontinued Drug Product List, and

Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly.

The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing, are for military use, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the 12th Cumulative Supplement of the 32nd Edition List have been added to the Discontinued Drug Product List appearing in the 33rd Edition. In addition, approved drug products that are not in the commercial distribution channel e.g., approved drug products in applications for export only are also listed in the Discontinued Section of the Orange Book.

Product Name Index (*Prescription and OTC Drug Product Lists*). This is an index of drug products by established or trade name. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

Product Name Index Listed by Applicant (*Prescription and OTC Drug Product Lists*). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

Uniform Terms. To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.

2.2 DRUG PRODUCT ILLUSTRATION

SINGLE INGREDIENT									
ACTIVE INGREDIENT	MEPERIDINE HYDROCHLORIDE								
DOSAGE FORM; ROUTE OF ADMINISTRATION	INJECTABLE; INJECTION								
TRADE OR GENERIC NAMES	HEXANON								
REFERENCE LISTED DRUG	AP + PAGE PHARMA	25MG/ML	N013111	001	AUG	22,	1983		
	AP +	50MG/ML	N013111	002	AUG	22,	1983		
	AP +	75MG/ML	N013111	003	AUG	22,	1983		
	AP +	100MG/ML	N013111	004	JAN	04,	1989		
MEPERIDINE HCL									
THERAPEUTIC EQUIVALENCE (TE) CODE FOR MULTISOURCE PRODUCT	AP GREENBERG PHARM	25MG/ML	A064890	001	FEB	29,	1987		
	AP	50MG/ML	A064890	002	FEB	29,	1987		
	AP	75MG/ML	A064890	003	FEB	29,	1987		
	AP	100MG/ML	A064890	004	MAR	08,	1992		
SINGLE SOURCE PRODUCT (NO TE CODE)	AP HOLOVAC LLC	10MG/ML	A099225	001	DEC	12,	1995		
	AP JOHNSON MED	25MG/ML	A099226	001	NOV	27,	1993		
	AP RHONDA PHARM	150MG/ML	A079444	001	OCT	31,	1999		
APPLICANT									
AVAILABLE STRENGTH(S) OF A PRODUCT									
APPLICATION NUMBER AND PRODUCT NUMBER									
PRODUCT NUMBER IS FOR FDA INTERNAL COMPUTER DATA USE ONLY									
APPROVAL DATE									

MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION									
ALPHABETICALLY SORTED BY ACTIVE INGREDIENT	HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE								
PRODUCT INFORMATION	TABLET; ORAL HYDROCHLOROTHIAZIDE, RESERPINE AND HYDRALAZINE HCL MADISON 25MG; 15MG; 0.1MG A069808 001 JAN 18, 1982								

THIS EXAMPLE IS FOR PURPOSE OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH "B") AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A "B") ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE *INTRODUCTION*.

SULFASALAZINE

TABLET; ORAL

FAZINE

AB PARKLAND **500MG** **A042999** **001**

SULAZINE

AB URSA **500MG** **A042222** **001**

SULFASALAZINE

BP BROWN 500MG A041297 001

SULFASALAZINE

TABLET; ORAL

FAZINE

AB PARKLAND **500MG** **A042999** **001**

SULFASALAZINE

BP BROWN 500MG A041297 001

SOUTH 500MG A067627 001

PRODUCTS CONSIDERED THERAPEUTICALLY
EQUIVALENT TO EACH OTHER

PRODUCTS CONSIDERED **NOT** THERAPEUTICALLY
EQUIVALENT TO ANY OTHER PRODUCTS LISTED

PRODUCTS CONSIDERED **NOT** THERAPEUTICALLY
EQUIVALENT TO EACH OTHER

NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 1 (of 428)

ABACAVIR SULFATESOLUTION; ORAL
ZIAGEN

+ VIVV HLTHCARE EQ 20MG BASE/ML N020978 001 Dec 17, 1998

TABLET; ORAL

ABACAVIR SULFATEAB APOTEX INC EQ 300MG BASE A201570 001 Dec 17, 2012AB AUROBINDO PHARMA LTD EQ 300MG BASE A077844 001 Dec 17, 2012AB MYLAN PHARMS INC EQ 300MG BASE A091294 001 Jun 18, 2012ZIAGENAB + VIVV HLTHCARE EQ 300MG BASE N020977 001 Dec 17, 1998ABACAVIR SULFATE; LAMIVUDINETABLET; ORAL
EPZICOM

+ VIVV HLTHCARE EQ 600MG BASE;300MG N021652 001 Aug 02, 2004

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINETABLET; ORAL
TRIZIVIR

+ VIVV HLTHCARE EQ 300MG BASE;150MG;300MG N021205 001 Nov 14, 2000

ABIRATERONE ACETATETABLET; ORAL
ZYTIGA

+ JANSSEN BIOTECH 250MG N202379 001 Apr 28, 2011

ACAMPROSATE CALCIUMTABLET, DELAYED RELEASE; ORAL
CAMPRAL

+ FOREST LABS 333MG N021431 001 Jul 29, 2004

ACARBOSE

TABLET; ORAL

ACARBOSEAB EMCURE PHARMS LTD 25MG A202271 001 Feb 07, 2012AB 50MG A202271 002 Feb 07, 2012AB 100MG A202271 003 Feb 07, 2012AB IMPAX LABS 25MG A078441 001 May 14, 2009AB 50MG A078441 002 May 14, 2009AB 100MG A078441 003 May 14, 2009AB MYLAN 25MG A091053 001 Jan 06, 2011AB 50MG A091053 002 Jan 06, 2011AB 100MG A091053 003 Jan 06, 2011AB ROXANE 25MG A078470 001 May 07, 2008AB 50MG A078470 002 May 07, 2008AB 100MG A078470 003 May 07, 2008AB STRIDES ARCOLAB LTD 25MG A090912 001 Jul 27, 2011AB 50MG A090912 002 Jul 27, 2011AB 100MG A090912 003 Jul 27, 2011AB WATSON LABS 25MG A077532 001 May 07, 2008AB 50MG A077532 002 May 07, 2008AB 100MG A077532 003 May 07, 2008PRECOSEAB + BAYER HLTHCARE 25MG N020482 004 May 29, 1997AB 50MG N020482 001 Sep 06, 1995AB 100MG N020482 002 Sep 06, 1995ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDEAB AMNEAL PHARM EQ 200MG BASE A075047 001 Dec 30, 1999

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 2 (of 428)

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARM	<u>EQ 400MG BASE</u>	<u>A075047</u>	<u>002</u>	Dec 30, 1999
<u>AB</u>	MYLAN	<u>EQ 200MG BASE</u>	<u>A074288</u>	<u>001</u>	Apr 24, 1995
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A074288</u>	<u>002</u>	Apr 24, 1995
<u>AB</u>	WATSON LABS	<u>EQ 200MG BASE</u>	<u>A074007</u>	<u>001</u>	Oct 18, 1995
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A074007</u>	<u>002</u>	Oct 18, 1995
<u>SECTRAL</u>					
<u>AB</u>	PROMIUS PHARMA	<u>EQ 200MG BASE</u>	<u>N018917</u>	<u>001</u>	Dec 28, 1984
<u>AB</u>	+	<u>EQ 400MG BASE</u>	<u>N018917</u>	<u>003</u>	Dec 28, 1984

ACETAMINOPHEN

SOLUTION; IV (INFUSION)

+	CADENCE PHARMS	1000MG/100ML (10MG/ML)	N022450	001	Nov 02, 2010

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

PHRENILIN FORTE

+	VALEANT	650MG;50MG	A088831	001	Jun 19, 1985

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

+	NEXGEN PHARMA	300MG;50MG	A090956	001	Aug 23, 2011

BUTAPAP

+	MIKART	325MG;50MG	A089987	001	Oct 26, 1992

+		650MG;50MG	A089988	001	Oct 26, 1992

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

<u>AA</u>	WEST WARD	<u>500MG;50MG;40MG</u>	<u>A040261</u>	<u>001</u>	Oct 28, 1998

ESGIC-PLUS

<u>AA</u>	+	MIKART	<u>500MG;50MG;40MG</u>	<u>A040085</u>	<u>001</u>	Mar 28, 1996

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

+	MIKART	325MG;50MG;40MG	A089007	001	Mar 17, 1986

+	NEXGEN PHARMA	300MG;50MG;40MG	A040885	001	Nov 16, 2009

SOLUTION; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

+	MIKART	325MG/15ML;50MG/15ML;40MG/15ML	A040387	001	Jan 31, 2003

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

<u>AA</u>	LANNETT HOLDINGS INC	<u>325MG;50MG;40MG</u>	<u>A200243</u>	<u>001</u>	Sep 13, 2012

<u>AA</u>	MALLINCKRODT	<u>325MG;50MG;40MG</u>	<u>A087804</u>	<u>001</u>	Jan 24, 1985

<u>AA</u>	MIKART	<u>325MG;50MG;40MG</u>	<u>A089175</u>	<u>001</u>	Jan 21, 1987

<u>AA</u>	MIRROR PHARMS	<u>325MG;50MG;40MG</u>	<u>A040864</u>	<u>001</u>	Dec 01, 2008

<u>AA</u>		<u>500MG;50MG;40MG</u>	<u>A040883</u>	<u>001</u>	Dec 23, 2008

<u>AA</u>	VINTAGE PHARMS	<u>325MG;50MG;40MG</u>	<u>A040511</u>	<u>001</u>	Aug 27, 2003

<u>AA</u>		<u>500MG;50MG;40MG</u>	<u>A040513</u>	<u>001</u>	Aug 25, 2003

<u>AA</u>	WATSON LABS	<u>500MG;50MG;40MG</u>	<u>A040267</u>	<u>001</u>	Jul 30, 1998

<u>AA</u>	WEST WARD	<u>325MG;50MG;40MG</u>	<u>A089718</u>	<u>001</u>	Jun 12, 1995

<u>AA</u>		<u>500MG;50MG;40MG</u>	<u>A040336</u>	<u>001</u>	Aug 18, 1999

ESGIC-PLUS

<u>AA</u>	+	MIKART	<u>500MG;50MG;40MG</u>	<u>A089451</u>	<u>001</u>	May 23, 1988

FIORICET

<u>AA</u>	+	WATSON PHARMS	<u>325MG;50MG;40MG</u>	<u>A088616</u>	<u>001</u>	Nov 09, 1984

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

+	MIKART	750MG;50MG;40MG	A040496	001	Dec 23, 2003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 3 (of 428)

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

<u>AB</u>	NEXGEN PHARMA INC	<u>325MG;50MG;40MG;30MG</u>	<u>A076560</u>	<u>001</u>	Jun 10, 2004
<u>AB</u>	VINTAGE PHARMS	<u>325MG;50MG;40MG;30MG</u>	<u>A075929</u>	<u>001</u>	Apr 22, 2002
<u>AB</u>	WEST WARD	<u>325MG;50MG;40MG;30MG</u>	<u>A075618</u>	<u>001</u>	Mar 23, 2001
<u>FIORICET W/ CODEINE</u>					
<u>AB</u> +	WATSON LABS INC	<u>325MG;50MG;40MG;30MG</u>	<u>N020232</u>	<u>001</u>	Jul 30, 1992
<u>PHRENILIN WITH CAFFEINE AND CODEINE</u>					
<u>AB</u>	VALEANT	<u>325MG;50MG;40MG;30MG</u>	<u>A074911</u>	<u>001</u>	Aug 22, 2001
	BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE				
	NEXGEN PHARMA INC	300MG;50MG;40MG;30MG	A076560	002	Jul 19, 2012

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

<u>AA</u> +	MIKART	<u>356.4MG;30MG;16MG</u>	<u>A040109</u>	<u>001</u>	Aug 26, 1997
<u>AA</u>	WRASER PHARMS LLC	<u>356.4MG;30MG;16MG</u>	<u>A040688</u>	<u>001</u>	Apr 03, 2007

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

<u>AA</u>	BOCA PHARMA	<u>712.8MG;60MG;32MG</u>	<u>A040701</u>	<u>001</u>	Apr 03, 2007
<u>AA</u> +	MIKART	<u>712.8MG;60MG;32MG</u>	<u>A040316</u>	<u>001</u>	Apr 28, 1999

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<u>AA</u>	HI TECH PHARMA	<u>120MG/5ML;12MG/5ML</u>	<u>A040119</u>	<u>001</u>	Apr 26, 1996
<u>AA</u>	MIKART	<u>120MG/5ML;12MG/5ML</u>	<u>A089450</u>	<u>001</u>	Oct 27, 1992
<u>AA</u> +	PHARM ASSOC	<u>120MG/5ML;12MG/5ML</u>	<u>A087508</u>	<u>001</u>	
<u>AA</u>	VINTAGE PHARMS	<u>120MG/5ML;12MG/5ML</u>	<u>A091238</u>	<u>001</u>	Nov 10, 2011
<u>AA</u>	WOCKHARDT	<u>120MG/5ML;12MG/5ML</u>	<u>A087006</u>	<u>001</u>	

SUSPENSION; ORAL

CAPITAL AND CODEINE

+	VALEANT PHARMS LLC	120MG/5ML;12MG/5ML	A086024	001	

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<u>AA</u>	AMNEAL PHARMS NY	<u>300MG;30MG</u>	<u>A040779</u>	<u>001</u>	May 29, 2008
<u>AA</u> +	MALLINCKRODT INC	<u>300MG;15MG</u>	<u>A040419</u>	<u>001</u>	May 31, 2001
<u>AA</u>		<u>300MG;30MG</u>	<u>A040419</u>	<u>002</u>	May 31, 2001
<u>AA</u>		<u>300MG;60MG</u>	<u>A040419</u>	<u>003</u>	May 31, 2001
<u>AA</u>	MIKART	<u>300MG;30MG</u>	<u>A089238</u>	<u>001</u>	Feb 25, 1986
<u>AA</u>	RANBAXY	<u>300MG;30MG</u>	<u>A085868</u>	<u>001</u>	
<u>AA</u>		<u>300MG;60MG</u>	<u>A087083</u>	<u>001</u>	
<u>AA</u>	TEVA	<u>300MG;15MG</u>	<u>A088627</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>		<u>300MG;30MG</u>	<u>A088628</u>	<u>001</u>	Mar 06, 1985
<u>AA</u> +		<u>300MG;60MG</u>	<u>A088629</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>	VINTAGE	<u>300MG;15MG</u>	<u>A089990</u>	<u>001</u>	Sep 30, 1988
<u>AA</u>		<u>300MG;30MG</u>	<u>A089805</u>	<u>001</u>	Sep 30, 1988
<u>AA</u>	VINTAGE PHARMS	<u>300MG;60MG</u>	<u>A089828</u>	<u>001</u>	Sep 30, 1988
<u>TYLENOL W/ CODEINE NO. 3</u>					
<u>AA</u> +	JANSSEN PHARMS	<u>300MG;30MG</u>	<u>A085055</u>	<u>003</u>	
<u>TYLENOL W/ CODEINE NO. 4</u>					
<u>AA</u>	JANSSEN PHARMS	<u>300MG;60MG</u>	<u>A085055</u>	<u>004</u>	
	ACETAMINOPHEN AND CODEINE PHOSPHATE				
+	MIKART	650MG;30MG	A089231	001	Mar 03, 1986
+		650MG;60MG	A089363	001	Sep 09, 1991

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	MIKART	<u>500MG;5MG</u>	<u>A081067</u>	<u>001</u>	Nov 30, 1989
<u>AA</u>		<u>500MG;5MG</u>	<u>A089008</u>	<u>001</u>	Feb 21, 1986

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 4 (of 428)

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	BOCA PHARMA	<u>325MG/15ML;7.5MG/15ML</u>	<u>A040894</u>	<u>001</u>	Jul 19, 2011
<u>AA</u>	MALLINCKRODT	<u>500MG/15ML;7.5MG/15ML</u>	<u>A040418</u>	<u>001</u>	Jun 27, 2001
<u>AA</u>	+ MIKART	<u>325MG/15ML;7.5MG/15ML</u>	<u>A040482</u>	<u>001</u>	Sep 25, 2003
<u>AA</u>	+	<u>500MG/15ML;7.5MG/15ML</u>	<u>A081051</u>	<u>001</u>	Aug 28, 1992
<u>AA</u>	PHARM ASSOC	<u>500MG/15ML;7.5MG/15ML</u>	<u>A040182</u>	<u>001</u>	Mar 13, 1998
<u>AA</u>	VINTAGE PHARMS	<u>500MG/15ML;7.5MG/15ML</u>	<u>A040520</u>	<u>001</u>	Oct 30, 2003
<u>AA</u>	VISTAPHARM	<u>325MG/15ML;7.5MG/15ML</u>	<u>A200343</u>	<u>001</u>	Jan 25, 2012
<u>HYDROCODONE BITARTRATE AND ACETAMINOPHEN</u>					
	+ MIKART	300MG/15ML;10MG/15ML	A040881	001	Feb 25, 2010
	+ PHARM ASSOC	325MG/15ML;10MG/15ML	A040834	001	Apr 18, 2008

TABLET; ORAL

ANEXSIA

<u>AA</u>	MALLINCKRODT	<u>500MG;5MG</u>	<u>A089160</u>	<u>001</u>	Apr 23, 1987
<u>AA</u>		<u>750MG;10MG</u>	<u>A040468</u>	<u>001</u>	Oct 31, 2002
<u>ANEXSIA 5/325</u>					
<u>AA</u>	MALLINCKRODT	<u>325MG;5MG</u>	<u>A040409</u>	<u>001</u>	Oct 20, 2000
<u>ANEXSIA 7.5/325</u>					
<u>AA</u>	MALLINCKRODT	<u>325MG;7.5MG</u>	<u>A040405</u>	<u>001</u>	Sep 08, 2000
<u>ANEXSIA 7.5/650</u>					
<u>AA</u>	MALLINCKRODT	<u>650MG;7.5MG</u>	<u>A089725</u>	<u>001</u>	Sep 30, 1987
<u>CO-GESIC</u>					
<u>AA</u>	UCB INC	<u>500MG;5MG</u>	<u>A087757</u>	<u>001</u>	May 03, 1982
<u>HYDROCODONE BITARTRATE AND ACETAMINOPHEN</u>					
<u>AA</u>	AMNEAL PHARMS NY	<u>325MG;5MG</u>	<u>A040736</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>		<u>325MG;10MG</u>	<u>A040746</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>		<u>500MG;5MG</u>	<u>A040729</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>		<u>500MG;7.5MG</u>	<u>A040748</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>		<u>500MG;10MG</u>	<u>A040813</u>	<u>001</u>	Feb 23, 2007
<u>AA</u>		<u>650MG;7.5MG</u>	<u>A040754</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>		<u>650MG;10MG</u>	<u>A040757</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>		<u>750MG;7.5MG</u>	<u>A040769</u>	<u>001</u>	Aug 28, 2006
<u>AA</u>	AUROLIFE PHARMA LLC	<u>325MG;5MG</u>	<u>A201013</u>	<u>001</u>	Apr 11, 2012
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A201013</u>	<u>002</u>	Apr 11, 2012
<u>AA</u>		<u>325MG;10MG</u>	<u>A201013</u>	<u>003</u>	Apr 11, 2012
<u>AA</u>	BOCA PHARMA	<u>300MG;5MG</u>	<u>A090415</u>	<u>001</u>	Jan 24, 2011
<u>AA</u>		<u>300MG;7.5MG</u>	<u>A090415</u>	<u>002</u>	Jan 24, 2011
<u>AA</u>		<u>300MG;10MG</u>	<u>A090415</u>	<u>003</u>	Jan 24, 2011
<u>AA</u>	MALLINCKRODT	<u>325MG;10MG</u>	<u>A040400</u>	<u>001</u>	Jul 26, 2000
<u>AA</u>		<u>500MG;5MG</u>	<u>A040084</u>	<u>002</u>	Jun 01, 1995
<u>AA</u>		<u>500MG;7.5MG</u>	<u>A040201</u>	<u>001</u>	Feb 27, 1998
<u>AA</u>		<u>500MG;10MG</u>	<u>A040201</u>	<u>002</u>	Feb 27, 1998
<u>AA</u>		<u>650MG;10MG</u>	<u>A040084</u>	<u>004</u>	Oct 16, 1996
<u>AA</u>	+	<u>660MG;10MG</u>	<u>A040084</u>	<u>003</u>	Jul 29, 1996
<u>AA</u>		<u>750MG;7.5MG</u>	<u>A040084</u>	<u>001</u>	Jun 01, 1995
<u>AA</u>	+ MIKART	<u>300MG;5MG</u>	<u>A040658</u>	<u>001</u>	Jan 19, 2006
<u>AA</u>	+	<u>300MG;7.5MG</u>	<u>A040556</u>	<u>002</u>	Mar 24, 2006
<u>AA</u>	+	<u>300MG;10MG</u>	<u>A040556</u>	<u>001</u>	Jun 23, 2004
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A040432</u>	<u>001</u>	Jan 22, 2003
<u>AA</u>	+	<u>500MG;2.5MG</u>	<u>A089698</u>	<u>001</u>	Aug 25, 1989
<u>AA</u>	+	<u>500MG;7.5MG</u>	<u>A089699</u>	<u>001</u>	Aug 25, 1989
<u>AA</u>	+	<u>650MG;7.5MG</u>	<u>A089689</u>	<u>001</u>	Jun 29, 1988
<u>AA</u>	+	<u>650MG;10MG</u>	<u>A081223</u>	<u>001</u>	May 29, 1992
<u>AA</u>	SUN PHARM INDS INC	<u>325MG;5MG</u>	<u>A090118</u>	<u>001</u>	Dec 23, 2008
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A090118</u>	<u>002</u>	Dec 23, 2008
<u>AA</u>		<u>325MG;10MG</u>	<u>A090118</u>	<u>003</u>	Dec 23, 2008
<u>AA</u>		<u>500MG;5MG</u>	<u>A090265</u>	<u>001</u>	Dec 23, 2008
<u>AA</u>		<u>500MG;7.5MG</u>	<u>A090265</u>	<u>002</u>	Dec 23, 2008
<u>AA</u>		<u>500MG;10MG</u>	<u>A090265</u>	<u>003</u>	Dec 23, 2008

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 5 (of 428)

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	SUN PHARM INDS INC	650MG;7.5MG	A090380	001	Dec 23, 2008	
AA		650MG;10MG	A090380	002	Dec 23, 2008	
AA		660MG;10MG	A090380	003	Dec 23, 2008	
AA		750MG;7.5MG	A090380	004	Dec 23, 2008	
AA	VINTAGE PHARMS	325MG;5MG	A040655	001	Jan 19, 2006	
AA		325MG;7.5MG	A040656	001	Jan 19, 2006	
AA		325MG;10MG	A040355	001	May 31, 2000	
AA		500MG;2.5MG	A040144	002	Apr 25, 1997	
AA		500MG;5MG	A089971	001	Dec 02, 1988	
AA		500MG;7.5MG	A040144	001	Feb 22, 1996	
AA		500MG;10MG	A040356	001	May 31, 2000	
AA		650MG;7.5MG	A040155	001	Apr 14, 1997	
AA		650MG;10MG	A040143	001	Feb 22, 1996	
AA		660MG;10MG	A040358	001	May 31, 2000	
AA		750MG;7.5MG	A040157	001	Apr 12, 1996	
AA	WATSON LABS	500MG;2.5MG	A081079	001	Aug 30, 1991	
AA		500MG;5MG	A089883	001	Dec 01, 1988	
AA		500MG;7.5MG	A081080	001	Aug 30, 1991	
AA		500MG;10MG	A040148	002	Feb 14, 1997	
AA		650MG;7.5MG	A040094	001	Sep 29, 1995	
AA		650MG;10MG	A040094	002	Sep 29, 1995	
AA		660MG;10MG	A040094	003	Aug 08, 2000	
AA		750MG;7.5MG	A081083	001	Aug 30, 1991	
AA	+	750MG;10MG	A040094	004	Mar 22, 1999	
AA	WATSON LABS FLORIDA	660MG;10MG	A040495	001	May 28, 2003	
	LORTAB					
AA	UCB INC	500MG;5MG	A087722	001	Jul 09, 1982	
AA	+	500MG;10MG	A040100	001	Jan 26, 1996	
	NORCO					
AA	+	325MG;5MG	A040099	001	Jun 25, 1997	
AA	+	325MG;7.5MG	A040148	003	Sep 12, 2000	
AA	+	325MG;10MG	A040148	001	Feb 14, 1997	
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN					
	MIKART	325MG;2.5MG	A040846	001	Jun 09, 2010	
		650MG;5MG	A040849	001	Jun 09, 2010	
	ZYDONE					
	+	VINTAGE PHARMS LLC	400MG;5MG	A040288	001	Nov 27, 1998
	+		400MG;7.5MG	A040288	002	Nov 27, 1998
	+		400MG;10MG	A040288	003	Nov 27, 1998

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>	DURAMED PHARMS BARR	<u>500MG;5MG</u>	<u>A040289</u>	<u>001</u>	Mar 16, 1999
<u>AA</u>	MALLINCKRODT	<u>500MG;5MG</u>	<u>A040257</u>	<u>001</u>	Aug 04, 1998
<u>AA</u>	VINTAGE PHARMS	<u>500MG;5MG</u>	<u>A040106</u>	<u>001</u>	Jul 30, 1996
<u>AA</u>	WATSON LABS	<u>500MG;5MG</u>	<u>A040234</u>	<u>001</u>	Oct 30, 1997
	<u>ROXILOX</u>				
<u>AA</u>	ROXANE	<u>500MG;5MG</u>	<u>A040061</u>	<u>001</u>	Jul 03, 1995
	<u>TYLOX</u>				
<u>AA</u>	+ JANSSEN PHARMS	<u>500MG;5MG</u>	<u>A088790</u>	<u>001</u>	Dec 12, 1984
	SOLUTION; ORAL				
	<u>ROXICET</u>				
<u>AA</u>	+ ROXANE	<u>325MG/5ML;5MG/5ML</u>	<u>A089351</u>	<u>001</u>	Dec 03, 1986
	TABLET; ORAL				
	<u>OXYCET</u>				
<u>AA</u>	MALLINCKRODT	<u>325MG;5MG</u>	<u>A087463</u>	<u>001</u>	Dec 07, 1983

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 6 (of 428)

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>	ACTAVIS TOTOWA	<u>325MG; 7.5MG</u>	<u>A040800</u>	<u>001</u>	Apr 03, 2012
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040800</u>	<u>002</u>	Apr 03, 2012
<u>AA</u>	ALVOGEN INC	<u>325MG; 7.5MG</u>	<u>A202677</u>	<u>001</u>	Jul 26, 2012
<u>AA</u>		<u>325MG; 10MG</u>	<u>A202677</u>	<u>002</u>	Jul 26, 2012
<u>AA</u>	AMNEAL PHARMS NY	<u>325MG; 5MG</u>	<u>A040777</u>	<u>001</u>	Nov 27, 2007
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040778</u>	<u>001</u>	Nov 27, 2007
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A040789</u>	<u>001</u>	Nov 27, 2007
<u>AA</u>		<u>650MG; 10MG</u>	<u>A040789</u>	<u>002</u>	Nov 27, 2007
<u>AA</u>	COASTAL PHARMS	<u>325MG; 2.5MG</u>	<u>A090177</u>	<u>001</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 5MG</u>	<u>A090177</u>	<u>002</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090177</u>	<u>003</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090177</u>	<u>004</u>	Oct 20, 2008
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A090177</u>	<u>005</u>	Oct 20, 2008
<u>AA</u>		<u>650MG; 10MG</u>	<u>A090177</u>	<u>006</u>	Oct 20, 2008
<u>AA</u>	MALLINCKRODT	<u>325MG; 7.5MG</u>	<u>A040545</u>	<u>001</u>	Jun 30, 2004
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040545</u>	<u>002</u>	Jun 30, 2004
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A040550</u>	<u>001</u>	Jun 30, 2004
<u>AA</u>		<u>650MG; 10MG</u>	<u>A040550</u>	<u>002</u>	Jun 30, 2004
<u>AA</u>	VINTAGE PHARMS	<u>325MG; 5MG</u>	<u>A040105</u>	<u>001</u>	Jul 30, 1996
<u>AA</u>	WATSON LABS	<u>325MG; 5MG</u>	<u>A040171</u>	<u>001</u>	Oct 30, 1997
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A040535</u>	<u>001</u>	Sep 05, 2003
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040535</u>	<u>002</u>	Sep 05, 2003
<u>AA</u>		<u>500MG; 7.5MG</u>	<u>A040371</u>	<u>001</u>	Dec 29, 2000
<u>AA</u>		<u>650MG; 10MG</u>	<u>A040371</u>	<u>002</u>	Dec 29, 2000

PERCOCET

<u>AA</u>	+ VINTAGE PHARMS LLC	<u>325MG; 2.5MG</u>	<u>A040330</u>	<u>001</u>	Jun 25, 1999
<u>AA</u>	+	<u>325MG; 5MG</u>	<u>A040330</u>	<u>002</u>	Jun 25, 1999
<u>AA</u>	+	<u>325MG; 7.5MG</u>	<u>A040434</u>	<u>001</u>	Nov 23, 2001
<u>AA</u>	+	<u>325MG; 10MG</u>	<u>A040434</u>	<u>002</u>	Nov 23, 2001
<u>AA</u>	+	<u>500MG; 7.5MG</u>	<u>A040341</u>	<u>001</u>	Jul 26, 1999
<u>AA</u>	+	<u>650MG; 10MG</u>	<u>A040341</u>	<u>002</u>	Jul 26, 1999

ROXICET

<u>AA</u>	ROXANE	<u>325MG; 5MG</u>	<u>A087003</u>	<u>001</u>	
	OXYCODONE AND ACETAMINOPHEN				
	+ MIKART	300MG; 2.5MG	A040608	001	Dec 30, 2005
	+	300MG; 5MG	A040608	002	Dec 30, 2005
	+	300MG; 7.5MG	A040608	003	Dec 30, 2005
	+	300MG; 10MG	A040608	004	Dec 30, 2005
	+	400MG; 2.5MG	A040679	001	May 16, 2006
	+	400MG; 5MG	A040687	001	Apr 27, 2006
	+	400MG; 7.5MG	A040698	001	Apr 27, 2006
	+	400MG; 10MG	A040692	001	Apr 27, 2006
		500MG; 10MG	A040676	001	Apr 19, 2006
	ROXICET 5/500				
	+ ROXANE	500MG; 5MG	A089775	001	Jan 12, 1989

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE

<u>AB</u>	GAVIS PHARMS	<u>650MG; EQ 25MG BASE</u>	<u>A076202</u>	<u>001</u>	Aug 02, 2002
<u>AB</u>	+ WATSON LABS	<u>650MG; EQ 25MG BASE</u>	<u>A074699</u>	<u>001</u>	Mar 24, 2000

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

<u>AB</u>	ALVOGEN INC	<u>325MG; 37.5MG</u>	<u>A202076</u>	<u>001</u>	Mar 30, 2012
<u>AB</u>	AMNEAL PHARMS	<u>325MG; 37.5MG</u>	<u>A090485</u>	<u>001</u>	Dec 09, 2009
<u>AB</u>	CARACO	<u>325MG; 37.5MG</u>	<u>A077184</u>	<u>001</u>	Dec 16, 2005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 7 (of 428)

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

<u>AB</u>	MICRO LABS LTD INDIA	<u>325MG;37.5MG</u>	<u>A201952</u>	<u>001</u>	Dec 14, 2012
<u>AB</u>	MYLAN	<u>325MG;37.5MG</u>	<u>A077858</u>	<u>001</u>	Sep 26, 2008
<u>AB</u>	PAR PHARM	<u>325MG;37.5MG</u>	<u>A076475</u>	<u>001</u>	Apr 21, 2005
<u>AB</u>	WATSON LABS	<u>325MG;37.5MG</u>	<u>A076914</u>	<u>001</u>	Jul 26, 2006
<u>AB</u>	ZYDUS PHARMS USA INC	<u>325MG;37.5MG</u>	<u>A090460</u>	<u>001</u>	Sep 06, 2012

ULTRACET

<u>AB</u>	+ JANSSSEN PHARMS	<u>325MG;37.5MG</u>	<u>N021123</u>	<u>001</u>	Aug 15, 2001

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

<u>AB</u>	HERITAGE PHARMS INC	<u>500MG</u>	<u>A090779</u>	<u>001</u>	Jul 14, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>500MG</u>	<u>A040904</u>	<u>001</u>	Dec 10, 2008

DIAMOX

<u>AB</u>	+ DURAMED PHARMS BARR	<u>500MG</u>	<u>N012945</u>	<u>001</u>	

TABLET; ORAL

ACETAZOLAMIDE

<u>AB</u>	LANNETT	<u>250MG</u>	<u>A084840</u>	<u>001</u>	
<u>AB</u>	MUTUAL PHARM	<u>125MG</u>	<u>A089752</u>	<u>001</u>	Jun 22, 1988
<u>AB</u>	TARO	<u>125MG</u>	<u>A040195</u>	<u>001</u>	May 28, 1997
<u>AB</u>	+	<u>250MG</u>	<u>A040195</u>	<u>002</u>	May 28, 1997
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A088882</u>	<u>001</u>	Oct 22, 1985

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

<u>AP</u>	BEDFORD	<u>EQ 500MG BASE/VIAL</u>	<u>A040089</u>	<u>001</u>	Feb 28, 1995
<u>AP</u>	SAGENT STRIDES	<u>EQ 500MG BASE/VIAL</u>	<u>A200880</u>	<u>001</u>	May 09, 2012
<u>AP</u>	+ X GEN PHARMS	<u>EQ 500MG BASE/VIAL</u>	<u>A040784</u>	<u>001</u>	Dec 10, 2008

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

<u>AT</u>	B BRAUN	<u>250MG/100ML</u>	<u>N018161</u>	<u>001</u>	
<u>AT</u>	BAXTER HLTHCARE	<u>250MG/100ML</u>	<u>N018523</u>	<u>001</u>	Feb 19, 1982
<u>AT</u>	HOSPIRA	<u>250MG/100ML</u>	<u>N017656</u>	<u>001</u>	

SOLUTION/DROPS; OTIC

ACETIC ACID

<u>AT</u>	TARO	<u>2%</u>	<u>A088638</u>	<u>001</u>	Sep 06, 1984
<u>AT</u>	VINTAGE	<u>2%</u>	<u>A040607</u>	<u>001</u>	Feb 24, 2005
<u>AT</u>	+ WOCHKHARDT	<u>2%</u>	<u>A040166</u>	<u>001</u>	Jul 26, 1996

VOSOL

<u>AT</u>	HI TECH PHARMA	<u>2%</u>	<u>N012179</u>	<u>001</u>	

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

	+ BAUSCH AND LOMB	<u>2%;0.79%</u>	<u>A040063</u>	<u>001</u>	Feb 25, 1994

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

ACETASOL HC

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>2%;1%</u>	<u>A087143</u>	<u>001</u>	Jan 13, 1982

HYDROCORTISONE AND ACETIC ACID

<u>AT</u>	TARO	<u>2%;1%</u>	<u>A088759</u>	<u>001</u>	Mar 04, 1985
<u>AT</u>	VINTAGE	<u>2%;1%</u>	<u>A040609</u>	<u>001</u>	Feb 06, 2006

VOSOL HC

<u>AT</u>	+ HI TECH PHARMA	<u>2%;1%</u>	<u>N012770</u>	<u>001</u>	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 8 (of 428)

ACETOHEXAMIDETABLET; ORAL
ACETOHEXAMIDE

WATSON LABS	250MG	A071893	001	Nov 25, 1987
+	500MG	A071894	001	Nov 25, 1987

ACETOHYDROXAMIC ACIDTABLET; ORAL
LITHOSTAT

+ MISSION PHARMA	250MG	N018749	001	May 31, 1983

ACETYLCHOLINE CHLORIDEFOR SOLUTION; OPHTHALMIC
MIOCHOL-E

+ BAUSCH AND LOMB	20MG/VIAL	N020213	001	Sep 22, 1993

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETADOTE

<u>AP</u> + CUMBERLAND PHARMS	<u>6GM/30ML (200MG/ML)</u>	<u>N021539</u>	<u>001</u>	Jan 23, 2004

ACETYLCYSTEINE

<u>AP</u> INNOPHARMA INC	<u>6GM/30ML (200MG/ML)</u>	<u>A200644</u>	<u>001</u>	Nov 07, 2012

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

<u>AN</u> BEDFORD	<u>10%</u>	<u>A072323</u>	<u>001</u>	Apr 30, 1992
<u>AN</u>	<u>20%</u>	<u>A072324</u>	<u>001</u>	Apr 30, 1992
<u>AN</u> HOSPIRA	<u>10%</u>	<u>A073664</u>	<u>001</u>	Aug 30, 1994
<u>AN</u>	<u>20%</u>	<u>A074037</u>	<u>001</u>	Aug 30, 1994
<u>AN</u> INNOPHARMA INC	<u>20%</u>	<u>A203853</u>	<u>001</u>	Jun 21, 2012
<u>AN</u> + LUITPOLD	<u>10%</u>	<u>A072489</u>	<u>001</u>	Jul 28, 1995
<u>AN</u> +	<u>20%</u>	<u>A072547</u>	<u>001</u>	Jul 28, 1995

ACITRETINCAPSULE; ORAL
SORIATANE

STIEFEL LABS INC	10MG	N019821	001	Oct 28, 1996
	17.5MG	N019821	003	Aug 06, 2009
	22.5MG	N019821	004	Aug 06, 2009
+	25MG	N019821	002	Oct 28, 1996

ACLIDINIUM BROMIDEPOWDER, METERED; INHALATION
TUDORZA PRESSAIR

+ FOREST LABS INC	0.375MG/INH	N202450	001	Jul 23, 2012

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDECAPSULE; ORAL
SEMPREX-D

+ UCB INC	8MG;60MG	N019806	001	Mar 25, 1994

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

<u>AB</u> APOTEX INC	<u>200MG</u>	<u>A075677</u>	<u>001</u>	Sep 28, 2005
<u>AB</u> DAVA PHARMS INC	<u>200MG</u>	<u>A074833</u>	<u>001</u>	Apr 22, 1997
<u>AB</u> MYLAN	<u>200MG</u>	<u>A074727</u>	<u>001</u>	Apr 22, 1997
<u>AB</u>	<u>200MG</u>	<u>A074977</u>	<u>001</u>	Apr 13, 1998
<u>AB</u> RANBAXY	<u>200MG</u>	<u>A074975</u>	<u>001</u>	Sep 30, 1998
<u>AB</u> STASON	<u>200MG</u>	<u>A075090</u>	<u>001</u>	Jan 26, 1999
<u>AB</u> TEVA	<u>200MG</u>	<u>A074578</u>	<u>001</u>	Apr 22, 1997
<u>AB</u> WATSON LABS	<u>200MG</u>	<u>A075101</u>	<u>001</u>	Apr 15, 1998

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 9 (of 428)

ACYCLOVIR

CAPSULE; ORAL

ZOVIRAX

<u>AB</u> + GLAXOSMITHKLINE	<u>200MG</u>	<u>N018828</u>	<u>001</u>	Jan 25, 1985

CREAM; TOPICAL

ZOVIRAX

+ VALEANT INTL	5%	N021478	001	Dec 30, 2002

OINTMENT; TOPICAL

ZOVIRAX

+ VALEANT INTL	5%	N018604	001	Mar 29, 1982

SUSPENSION; ORAL

ACYCLOVIR

<u>AB</u> ACTAVIS MID ATLANTIC	<u>200MG/5ML</u>	<u>A074738</u>	<u>001</u>	Apr 28, 1997

<u>AB</u> HI TECH PHARMA	<u>200MG/5ML</u>	<u>A077026</u>	<u>001</u>	Jun 07, 2005

ZOVIRAX

<u>AB</u> + GLAXOSMITHKLINE	<u>200MG/5ML</u>	<u>N019909</u>	<u>001</u>	Dec 22, 1989

TABLET; ORAL

ACYCLOVIR

<u>AB</u> APOTEX INC	<u>400MG</u>	<u>A077309</u>	<u>001</u>	Sep 29, 2005

<u>AB</u>	<u>800MG</u>	<u>A077309</u>	<u>002</u>	Sep 29, 2005

<u>AB</u> CARLSBAD	<u>400MG</u>	<u>A075382</u>	<u>001</u>	Apr 30, 1999

<u>AB</u>	<u>800MG</u>	<u>A075382</u>	<u>002</u>	Apr 30, 1999

<u>AB</u> DAVA PHARMS INC	<u>400MG</u>	<u>A074946</u>	<u>001</u>	Nov 19, 1997

<u>AB</u>	<u>800MG</u>	<u>A074946</u>	<u>002</u>	Nov 19, 1997

<u>AB</u> MYLAN	<u>400MG</u>	<u>A074976</u>	<u>001</u>	Apr 13, 1998

<u>AB</u>	<u>400MG</u>	<u>A075211</u>	<u>001</u>	Sep 28, 1998

<u>AB</u>	<u>800MG</u>	<u>A074976</u>	<u>002</u>	Apr 13, 1998

<u>AB</u>	<u>800MG</u>	<u>A075211</u>	<u>002</u>	Sep 28, 1998

<u>AB</u> RANBAXY	<u>400MG</u>	<u>A074980</u>	<u>001</u>	Sep 30, 1998

<u>AB</u>	<u>800MG</u>	<u>A074980</u>	<u>002</u>	Sep 30, 1998

<u>AB</u> TEVA	<u>400MG</u>	<u>A074556</u>	<u>002</u>	Apr 22, 1997

<u>AB</u>	<u>800MG</u>	<u>A074556</u>	<u>003</u>	Apr 22, 1997

ZOVIRAX

<u>AB</u> GLAXOSMITHKLINE	<u>400MG</u>	<u>N020089</u>	<u>001</u>	Apr 30, 1991

<u>AB</u> +	<u>800MG</u>	<u>N020089</u>	<u>002</u>	Apr 30, 1991

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

<u>AP</u> BEDFORD	<u>EQ 500MG BASE/VIAL</u>	<u>A074596</u>	<u>002</u>	Apr 22, 1997

<u>AP</u>	<u>EQ 1GM BASE/VIAL</u>	<u>A074596</u>	<u>001</u>	Apr 22, 1997

<u>AP</u> + FRESENIUS KABI USA	<u>EQ 50MG BASE/ML</u>	<u>A074930</u>	<u>001</u>	May 13, 1998

<u>AP</u> +	<u>EQ 500MG BASE/VIAL</u>	<u>A075015</u>	<u>001</u>	Apr 30, 1998

<u>AP</u> HIKMA MAPLE	<u>EQ 500MG BASE/VIAL</u>	<u>A074913</u>	<u>001</u>	Oct 15, 1997

<u>AP</u>	<u>EQ 1GM BASE/VIAL</u>	<u>A074913</u>	<u>002</u>	Oct 15, 1997

ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE

+ HIKMA MAPLE	EQ 500MG BASE/VIAL	A074885	001	Dec 19, 1997

EQ 1GM BASE/VIAL	A074885	002	Dec 19, 1997

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

XERESE

+ VALEANT INTL	5%;1%	N022436	001	Jul 31, 2009

ADAPALENE

CREAM; TOPICAL

ADAPALENE

<u>AB</u> FOUGERA PHARMS	<u>0.1%</u>	<u>A090824</u>	<u>001</u>	Jun 30, 2010

DIFFERIN

<u>AB</u> + GALDERMA LABS LP	<u>0.1%</u>	<u>N020748</u>	<u>001</u>	May 26, 2000

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 10 (of 428)

ADAPALENE

GEL; TOPICAL

ADAPALENE

<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A091314</u>	<u>001</u>	Jul 01, 2010

<u>AB</u>	PLIVA HRVATSKA DOO	<u>0.1%</u>	<u>A090962</u>	<u>001</u>	Jun 02, 2010

<u>AB</u>	TOLMAR	<u>0.3%</u>	<u>A200298</u>	<u>001</u>	Jun 14, 2012

DIFFERIN

<u>AB</u>	+ GALDERMA LABS LP	<u>0.1%</u>	<u>N020380</u>	<u>001</u>	May 31, 1996

<u>AB</u>	+	<u>0.3%</u>	<u>N021753</u>	<u>001</u>	Jun 19, 2007

LOTION; TOPICAL

DIFFERIN

+	GALDERMA LABS LP	0.1%	N022502	001	Mar 17, 2010

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

EPIDUO

+	GALDERMA LABS LP	0.1%;2.5%	N022320	001	Dec 08, 2008

ADEFOVIR DIPIVOXIL

TABLET; ORAL

HEPSERA

+	GILEAD	10MG	N021449	001	Sep 20, 2002

ADENOSINE

INJECTABLE; INJECTION

ADENOCARD

<u>AP</u>	+ ASTELLAS	<u>3MG/ML</u>	<u>N019937</u>	<u>002</u>	Oct 30, 1989

ADENOSINE

<u>AP</u>	AKORN	<u>3MG/ML</u>	<u>A078076</u>	<u>001</u>	Oct 31, 2008

<u>AP</u>	BEDFORD	<u>3MG/ML</u>	<u>A076404</u>	<u>001</u>	Jun 16, 2004

<u>AP</u>	FRESENIUS KABI USA	<u>3MG/ML</u>	<u>A077133</u>	<u>001</u>	Apr 27, 2005

<u>AP</u>	GLAND PHARMA LTD	<u>3MG/ML</u>	<u>A077283</u>	<u>001</u>	Jun 14, 2007

<u>AP</u>	HIKMA MAPLE	<u>3MG/ML</u>	<u>A076500</u>	<u>001</u>	Jun 16, 2004

<u>AP</u>	LUITPOLD	<u>3MG/ML</u>	<u>A090010</u>	<u>001</u>	Apr 28, 2009

<u>AP</u>	STRIDES ARCOLAB LTD	<u>3MG/ML</u>	<u>A078686</u>	<u>001</u>	May 13, 2009

<u>AP</u>	WOCKHARDT	<u>3MG/ML</u>	<u>A090220</u>	<u>001</u>	Jul 20, 2009

ADENOSCAN

+	ASTELLAS	3MG/ML	N020059	001	May 18, 1995

ALBENDAZOLE

TABLET; ORAL

ALBENZA

+	COREPHARMA	200MG	N020666	001	Jun 11, 1996

ALBUMIN HUMAN

INJECTABLE; INJECTION

OPTISON

+	GE HEALTHCARE	10MG/ML	N020899	001	Dec 31, 1997

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

JEANATOPE

ISO TEX 100UCI/10ML (10UCI/ML)

N017836	003	Jun 08, 2004

500uCi/0.5ML	N017836	001

+	1,000uCi/ML	N017836	002

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION

MEGATOPE

+	ISO TEX	0.5mCi/VIAL	N017837	001

+		1mCi/VIAL	N017837	002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 11 (of 428)

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

PROAIR HFA

BX + TEVA GLOBAL EQ 0.09MG BASE/INH N021457 001 Oct 29, 2004

PROVENTIL-HFA

BX + 3M EQ 0.09MG BASE/INH N020503 001 Aug 15, 1996

VENTOLIN HFA

BX + GLAXOSMITHKLINE EQ 0.09MG BASE/INH N020983 001 Apr 19, 2001

SOLUTION; INHALATION

ACCUNEb

AN + DEY EQ 0.021% BASE N020949 002 Apr 30, 2001

AN + EQ 0.042% BASE N020949 001 Apr 30, 2001

ALBUTEROL SULFATE

AN APOTEX INC EQ 0.021% BASE A078623 001 Apr 05, 2010

AN EQ 0.042% BASE A078623 002 Apr 05, 2010

AN EQ 0.083% BASE A075717 001 Feb 02, 2007

AN + BAUSCH AND LOMB EQ 0.5% BASE A075050 001 Jun 18, 1998

AN + DEY EQ 0.083% BASE A072652 001 Feb 21, 1992

AN HI TECH PHARMA EQ 0.083% BASE A075063 001 Feb 09, 1999

AN EQ 0.5% BASE A074543 001 Jan 15, 1998

AN LANDELA PHARM EQ 0.083% BASE A077569 001 Apr 04, 2006

AN NEPHRON EQ 0.021% BASE A076355 002 Mar 31, 2010

AN EQ 0.042% BASE A076355 001 Jun 28, 2004

AN EQ 0.083% BASE A074880 001 Sep 17, 1997

AN EQ 0.5% BASE A075664 001 Jun 26, 2001

AN NOVEX EQ 0.5% BASE A076391 001 Apr 01, 2003

AN RITEDOSE CORP EQ 0.083% BASE A077839 001 Dec 16, 2008

AN TEVA PHARMS EQ 0.083% BASE A075343 001 Nov 09, 1999

AN WATSON LABS EQ 0.021% BASE A077772 001 Sep 25, 2007

AN EQ 0.042% BASE A077772 002 Sep 25, 2007

AN WATSON LABS INC EQ 0.083% BASE A076370 001 Nov 24, 2003

AN WOCKHARDT EQ 0.083% BASE A075394 001 Nov 22, 1999

SYRUP; ORAL

ALBUTEROL SULFATE

AA ACTAVIS MID ATLANTIC EQ 2MG BASE/5ML A074454 001 Sep 25, 1995

AA AMNEAL PHARMS EQ 2MG BASE/5ML A079241 001 May 12, 2010

AA HI TECH PHARMA EQ 2MG BASE/5ML A074749 001 Jan 30, 1998

AA + TEVA EQ 2MG BASE/5ML A073419 001 Mar 30, 1992

AA VINTAGE EQ 2MG BASE/5ML A078105 001 Dec 27, 2006

AA VISTAPHARM EQ 2MG BASE/5ML A077788 001 Jun 26, 2007

TABLET; ORAL

ALBUTEROL SULFATE

AB MUTUAL PHARM EQ 2MG BASE A072637 002 Dec 05, 1989

AB EQ 4MG BASE A072637 001 Dec 05, 1989

AB MYLAN EQ 2MG BASE A072894 002 Jan 17, 1991

AB + EQ 4MG BASE A072894 001 Jan 17, 1991

AB WATSON LABS EQ 2MG BASE A072764 001 Aug 28, 1991

TABLET, EXTENDED RELEASE; ORAL

ALBUTEROL SULFATE

AB MYLAN EQ 4MG BASE A078092 002 Jan 29, 2007

AB EQ 8MG BASE A078092 001 Jan 29, 2007

VOSPIRE ER

AB DAVA PHARMS INC EQ 4MG BASE A076130 002 Sep 26, 2002

AB + EQ 8MG BASE A076130 003 Sep 26, 2002

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

COMBIVENT

+ BOEHRINGER INGELHEIM EQ 0.09MG BASE/INH;0.018MG/INH N020291 001 Oct 24, 1996

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 12 (of 428)

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

<u>AN</u>	APOTEX CORP	<u>EQ 0.083% BASE;0.017%</u>	<u>A077117</u>	<u>001</u>	Dec 31, 2007
<u>AN</u>	NEPHRON	<u>EQ 0.083% BASE;0.017%</u>	<u>A076749</u>	<u>001</u>	Dec 31, 2007
<u>AN</u>	RITEDOSE CORP	<u>EQ 0.083% BASE;0.017%</u>	<u>A202496</u>	<u>001</u>	Oct 01, 2012
<u>AN</u>	TEVA PHARMS	<u>EQ 0.083% BASE;0.017%</u>	<u>A076724</u>	<u>001</u>	Dec 31, 2007
<u>AN</u>	WATSON LABS	<u>EQ 0.083% BASE;0.017%</u>	<u>A077063</u>	<u>001</u>	Dec 31, 2007
<u>AN</u>		<u>EQ 0.083% BASE;0.017%</u>	<u>A077559</u>	<u>001</u>	Dec 31, 2007

DUONEB

<u>AN</u>	+ DEY	<u>EQ 0.083% BASE;0.017%</u>	<u>N020950</u>	<u>001</u>	Mar 21, 2001
	SPRAY, METERED; INHALATION				
	COMBIVENT RESPIMAT				
	+ BOEHRINGER INGELHEIM	EQ 0.1MG BASE/INH;0.02MG/INH	N021747	001	Oct 07, 2011

ALCAFTADINE

SOLUTION/DROPS; OPHTHALMIC

	+ ALLERGAN	0.25%	N022134	001	Jul 28, 2010

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ACLOVATE

<u>AB</u>	+ FOUGERA PHARMS	<u>0.05%</u>	<u>N018707</u>	<u>001</u>	Dec 14, 1982
	<u>ALCLOMETASONE DIPROPIONATE</u>				
<u>AB</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A076973</u>	<u>001</u>	Jul 12, 2005
<u>AB</u>	GLENMARK GENERICS	<u>0.05%</u>	<u>A079061</u>	<u>001</u>	Jun 23, 2009
<u>AB</u>	TARO	<u>0.05%</u>	<u>A076587</u>	<u>001</u>	Sep 15, 2005

OINTMENT; TOPICAL

ACLOVATE

<u>AB</u>	+ FOUGERA PHARMS	<u>0.05%</u>	<u>N018702</u>	<u>001</u>	Dec 14, 1982
	<u>ALCLOMETASONE DIPROPIONATE</u>				
<u>AB</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A076884</u>	<u>001</u>	Jul 18, 2005
<u>AB</u>	GLENMARK GENERICS	<u>0.05%</u>	<u>A079227</u>	<u>001</u>	Jul 30, 2009
<u>AB</u>	TARO	<u>0.05%</u>	<u>A076730</u>	<u>001</u>	Jul 29, 2004

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 5% AND DEXTROSE 5%

<u>AP</u>	+ B BRAUN	<u>5ML/100ML;5GM/100ML</u>	<u>N004589</u>	<u>004</u>	
	ALCOHOL 10% AND DEXTROSE 5%				
	+ B BRAUN	10ML/100ML;5GM/100ML	N004589	006	

ALENDRONATE SODIUM

SOLUTION; ORAL

FOSAMAX

	+ MERCK	EQ 70MG BASE/75ML	N021575	001	Sep 17, 2003

TABLET; ORAL

ALENDRONATE SODIUM

<u>AB</u>	APOTEX	<u>EQ 5MG BASE</u>	<u>A077982</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077982</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A077982</u>	<u>003</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A077982</u>	<u>004</u>	Aug 04, 2008
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A090124</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090124</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090124</u>	<u>003</u>	Aug 04, 2008
<u>AB</u>	AUSTARPHARMA LLC	<u>EQ 5MG BASE</u>	<u>A090258</u>	<u>001</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090258</u>	<u>002</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090258</u>	<u>003</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090258</u>	<u>004</u>	Sep 24, 2009
<u>AB</u>	CADISTA PHARMS	<u>EQ 5MG BASE</u>	<u>A090557</u>	<u>001</u>	Feb 18, 2010
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090557</u>	<u>002</u>	Feb 18, 2010

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 13 (of 428)

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

<u>AB</u>	CADISTA PHARMS	<u>EQ 35MG BASE</u>	<u>A090557</u>	<u>003</u>	Feb 18, 2010
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090557</u>	<u>004</u>	Feb 18, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 5MG BASE</u>	<u>A079109</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A079109</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A079049</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A079049</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076584</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076584</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A076584</u>	<u>003</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A078638</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076584</u>	<u>004</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A078638</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 5MG BASE</u>	<u>A090022</u>	<u>001</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090022</u>	<u>002</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090022</u>	<u>003</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090022</u>	<u>004</u>	Sep 10, 2008
<u>AB</u>	TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A075710</u>	<u>001</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075710</u>	<u>002</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A075710</u>	<u>003</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075710</u>	<u>004</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A075710</u>	<u>005</u>	Feb 06, 2008
<u>AB</u>	WATSON LABS	<u>EQ 5MG BASE</u>	<u>A076768</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076768</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A076768</u>	<u>003</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A076984</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076768</u>	<u>004</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076984</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076768</u>	<u>005</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076984</u>	<u>003</u>	Aug 04, 2008
<u>FOSAMAX</u>					
<u>AB</u>	MERCK AND CO INC	<u>EQ 5MG BASE</u>	<u>N020560</u>	<u>003</u>	Apr 25, 1997
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>N020560</u>	<u>001</u>	Sep 29, 1995
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>N020560</u>	<u>004</u>	Oct 20, 2000
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>N020560</u>	<u>002</u>	Sep 29, 1995
<u>AB</u>	+	<u>EQ 70MG BASE</u>	<u>N020560</u>	<u>005</u>	Oct 20, 2000

TABLET, EFFERVESCENT; ORAL
BINOSTO

+ MISSION PHARMA EQ 70MG BASE N202344 001 Mar 12, 2012

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET; ORAL

FOSAMAX PLUS D

MERCK

EQ 70MG BASE;2,800 IU

N021762 001 Apr 07, 2005

+

EQ 70MG BASE;5,600 IU

N021762 002 Apr 26, 2007

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

AP + AKORN EQ 0.5MG BASE/ML N019353 001 Dec 29, 1986

ALFENTANIL

AP HOSPIRA EQ 0.5MG BASE/ML A075221 001 Oct 28, 1999

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A079013</u>	<u>001</u>	Jul 18, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>10MG</u>	<u>A079060</u>	<u>001</u>	Aug 30, 2012
<u>AB</u>	INVAGEN PHARMS	<u>10MG</u>	<u>A090284</u>	<u>001</u>	Jan 17, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 14 (of 428)

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>10MG</u>	<u>A079014</u>	<u>001</u>	Jul 18, 2011
<u>AB</u>	SUN PHARMA GLOBAL	<u>10MG</u>	<u>A079057</u>	<u>001</u>	Jul 18, 2011
<u>AB</u>	TEVA PHARMS	<u>10MG</u>	<u>A079056</u>	<u>001</u>	Jul 18, 2011
<u>AB</u>	TORRENT PHARMS	<u>10MG</u>	<u>A079054</u>	<u>001</u>	Jul 18, 2011
<u>AB</u>	WOCKHARDT LTD	<u>10MG</u>	<u>A090221</u>	<u>001</u>	Aug 10, 2012

UROXATRAL

<u>AB</u>	+ SANOFI AVENTIS US	<u>10MG</u>	<u>N021287</u>	<u>001</u>	Jun 12, 2003

ALISKIREN HEMIFUMARATE

TABLET; ORAL

TEKTURNA

	NOVARTIS	EQ 150MG BASE	N021985	001	Mar 05, 2007
+		EQ 300MG BASE	N021985	002	Mar 05, 2007

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

TABLET; ORAL

TEKAMLO

	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE	N022545	001	Aug 26, 2010
		EQ 150MG BASE;EQ 10MG BASE	N022545	002	Aug 26, 2010
		EQ 300MG BASE;EQ 5MG BASE	N022545	003	Aug 26, 2010
+		EQ 300MG BASE;EQ 10MG BASE	N022545	004	Aug 26, 2010

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMTURNIDE

	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE;12.5MG	N200045	001	Dec 21, 2010
		EQ 300MG BASE;EQ 5MG BASE;12.5MG	N200045	002	Dec 21, 2010
		EQ 300MG BASE;EQ 5MG BASE;25MG	N200045	003	Dec 21, 2010
		EQ 300MG BASE;EQ 10MG BASE;12.5MG	N200045	004	Dec 21, 2010
+		EQ 300MG BASE;EQ 10MG BASE;25MG	N200045	005	Dec 21, 2010

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEKTURNA HCT

	NOVARTIS	EQ 150MG BASE;12.5MG	N022107	001	Jan 18, 2008
		EQ 150MG BASE;25MG	N022107	002	Jan 18, 2008
+		EQ 300MG BASE;12.5MG	N022107	003	Jan 18, 2008
+		EQ 300MG BASE;25MG	N022107	004	Jan 18, 2008

ALISKIREN HEMIFUMARATE; VALSARTAN

TABLET; ORAL

VALTURNA

	NOVARTIS	EQ 150MG BASE;160MG	N022217	001	Sep 16, 2009
+		EQ 300MG BASE;320MG	N022217	002	Sep 16, 2009

ALITRETINOIN

GEL; TOPICAL

PANRETIN

+	EISAI INC	EQ 0.1% BASE	N020886	001	Feb 02, 1999

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A077353</u>	<u>001</u>	Sep 08, 2005
<u>AB</u>		<u>300MG</u>	<u>A077353</u>	<u>002</u>	Sep 08, 2005
<u>AB</u>	CARACO	<u>100MG</u>	<u>A078390</u>	<u>001</u>	Aug 30, 2007
<u>AB</u>		<u>300MG</u>	<u>A078390</u>	<u>002</u>	Aug 30, 2007
<u>AB</u>	IPCA LABS LTD	<u>100MG</u>	<u>A090637</u>	<u>001</u>	Mar 16, 2011
<u>AB</u>		<u>300MG</u>	<u>A090637</u>	<u>002</u>	Mar 16, 2011

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 15 (of 428)

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

<u>AB</u>	MUTUAL PHARM	<u>100MG</u>	<u>A071449</u>	<u>001</u>	Jan 09, 1987
<u>AB</u>		<u>300MG</u>	<u>A071450</u>	<u>001</u>	Jan 09, 1987
<u>AB</u>	MYLAN	<u>100MG</u>	<u>N018659</u>	<u>001</u>	Oct 24, 1986
<u>AB</u>		<u>300MG</u>	<u>N018659</u>	<u>002</u>	Oct 24, 1986
<u>AB</u>	NORTHSTAR HLTHCARE	<u>100MG</u>	<u>A078253</u>	<u>001</u>	Sep 11, 2007
<u>AB</u>		<u>300MG</u>	<u>A078253</u>	<u>002</u>	Sep 11, 2007
<u>AB</u>	VINTAGE PHARMS	<u>100MG</u>	<u>A075798</u>	<u>001</u>	Jun 27, 2003
<u>AB</u>		<u>300MG</u>	<u>A075798</u>	<u>002</u>	Jun 27, 2003
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>N018832</u>	<u>002</u>	Sep 28, 1984
<u>AB</u>		<u>300MG</u>	<u>N018877</u>	<u>001</u>	Sep 28, 1984
	<u>LOPURIN</u>				
<u>AB</u>	DR REDDYS LA	<u>100MG</u>	<u>A071586</u>	<u>001</u>	Apr 02, 1987
<u>AB</u>		<u>300MG</u>	<u>A071587</u>	<u>001</u>	Apr 02, 1987
	<u>ZYLOPRIM</u>				
<u>AB</u>	PROMETHEUS LABS	<u>100MG</u>	<u>N016084</u>	<u>001</u>	
<u>AB</u>	+	<u>300MG</u>	<u>N016084</u>	<u>002</u>	

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALLOPURINOL SODIUM

<u>AP</u>	BEDFORD LABS	<u>EQ 500MG BASE/VIAL</u>	<u>A076870</u>	<u>001</u>	Aug 26, 2004
	<u>ALOPRIM</u>				
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 500MG BASE/VIAL</u>	<u>N020298</u>	<u>001</u>	May 17, 1996

ALMOTRIPTAN MALATE

TABLET; ORAL

AXERT

	JANSSEN PHARMS	EQ 6.25MG BASE	N021001	001	May 07, 2001
+		EQ 12.5MG BASE	N021001	002	May 07, 2001

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

LOTRONEX

	PROMETHEUS LABS	EQ 0.5MG BASE	N021107	002	Dec 23, 2003
+		EQ 1MG BASE	N021107	001	Feb 09, 2000

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+	SANDOZ	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163	001	May 18, 2000

INJECTABLE; IV (INFUSION)

+	SANDOZ	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021559	001	Jun 16, 2003

ALPRAZOLAM

CONCENTRATE; ORAL

ALPRAZOLAM

+	ROXANE	1MG/ML	A074312	001	Oct 31, 1993

TABLET; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.25MG</u>	<u>A074342</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074342</u>	<u>002</u>	Oct 31, 1993

PRESCRIPTION DRUG PRODUCT LIST

3 - 16 (of 428)

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>1MG</u>	<u>A074342</u>	<u>003</u>	Oct 31, 1993
<u>AB</u>		<u>2MG</u>	<u>A074342</u>	<u>004</u>	Oct 31, 1993
<u>AB</u>	APOTEX INC	<u>0.25MG</u>	<u>A077741</u>	<u>001</u>	Jan 19, 2007
<u>AB</u>		<u>0.5MG</u>	<u>A077741</u>	<u>002</u>	Jan 19, 2007
<u>AB</u>		<u>1MG</u>	<u>A077741</u>	<u>003</u>	Jan 19, 2007
<u>AB</u>		<u>2MG</u>	<u>A077741</u>	<u>004</u>	Jan 19, 2007
<u>AB</u>	BOCA PHARMA	<u>0.25MG</u>	<u>A090248</u>	<u>001</u>	Sep 17, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090248</u>	<u>002</u>	Sep 17, 2010
<u>AB</u>		<u>1MG</u>	<u>A090248</u>	<u>003</u>	Sep 17, 2010
<u>AB</u>		<u>2MG</u>	<u>A090248</u>	<u>004</u>	Sep 17, 2010
<u>AB</u>	DAVA INTL INC	<u>0.25MG</u>	<u>A074174</u>	<u>001</u>	Oct 19, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074174</u>	<u>002</u>	Oct 19, 1993
<u>AB</u>		<u>1MG</u>	<u>A074174</u>	<u>003</u>	Oct 19, 1993
<u>AB</u>		<u>2MG</u>	<u>A074174</u>	<u>004</u>	Oct 19, 1993
<u>AB</u>	MYLAN	<u>0.25MG</u>	<u>A074215</u>	<u>001</u>	Jan 27, 1994
<u>AB</u>		<u>0.5MG</u>	<u>A074215</u>	<u>002</u>	Jan 27, 1994
<u>AB</u>		<u>1MG</u>	<u>A074215</u>	<u>003</u>	Jan 27, 1994
<u>AB</u>		<u>2MG</u>	<u>A074215</u>	<u>004</u>	Jan 27, 1994
<u>AB</u>	MYLAN PHARMS INC	<u>0.25MG</u>	<u>A074046</u>	<u>001</u>	Oct 19, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074046</u>	<u>002</u>	Oct 19, 1993
<u>AB</u>		<u>1MG</u>	<u>A074046</u>	<u>003</u>	Oct 19, 1993
<u>AB</u>		<u>2MG</u>	<u>A074046</u>	<u>004</u>	May 07, 1997
<u>AB</u>	SANDOZ	<u>0.25MG</u>	<u>A074112</u>	<u>001</u>	Dec 29, 1995
<u>AB</u>		<u>0.5MG</u>	<u>A074112</u>	<u>002</u>	Dec 29, 1995
<u>AB</u>		<u>1MG</u>	<u>A074112</u>	<u>003</u>	Dec 29, 1995
<u>AB</u>		<u>2MG</u>	<u>A074909</u>	<u>001</u>	Mar 25, 1998
<u>AB</u>	SUN PHARMA GLOBAL	<u>0.25MG</u>	<u>A090082</u>	<u>001</u>	Jun 17, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090082</u>	<u>002</u>	Jun 17, 2010
<u>AB</u>		<u>1MG</u>	<u>A090082</u>	<u>003</u>	Jun 17, 2010
<u>AB</u>		<u>2MG</u>	<u>A090082</u>	<u>004</u>	Jun 17, 2010
<u>AB</u>	VINTAGE	<u>0.25MG</u>	<u>A078491</u>	<u>001</u>	Sep 25, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078491</u>	<u>002</u>	Sep 25, 2008
<u>AB</u>		<u>1MG</u>	<u>A078491</u>	<u>003</u>	Sep 25, 2008
<u>AB</u>		<u>2MG</u>	<u>A078491</u>	<u>004</u>	Dec 12, 2008

XANAX

<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.25MG</u>	<u>N018276</u>	<u>001</u>	
<u>AB</u>		<u>0.5MG</u>	<u>N018276</u>	<u>002</u>	
<u>AB</u>	+	<u>1MG</u>	<u>N018276</u>	<u>003</u>	
<u>AB</u>		<u>2MG</u>	<u>N018276</u>	<u>004</u>	Nov 27, 1985

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A078056</u>	<u>001</u>	Feb 13, 2007
<u>AB</u>		<u>1MG</u>	<u>A078056</u>	<u>002</u>	Feb 13, 2007
<u>AB</u>		<u>2MG</u>	<u>A078056</u>	<u>003</u>	Feb 13, 2007
<u>AB</u>		<u>3MG</u>	<u>A078056</u>	<u>004</u>	Feb 13, 2007
<u>AB</u>	AMNEAL PHARMS NY	<u>0.5MG</u>	<u>A078387</u>	<u>001</u>	May 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A078387</u>	<u>002</u>	May 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A078387</u>	<u>003</u>	May 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A078387</u>	<u>004</u>	May 30, 2008
<u>AB</u>	ANCHEN PHARMS	<u>0.5MG</u>	<u>A078469</u>	<u>001</u>	Sep 29, 2011
<u>AB</u>		<u>1MG</u>	<u>A078469</u>	<u>002</u>	Sep 29, 2011
<u>AB</u>		<u>2MG</u>	<u>A078469</u>	<u>003</u>	Sep 29, 2011
<u>AB</u>		<u>3MG</u>	<u>A078469</u>	<u>004</u>	Sep 29, 2011
<u>AB</u>	APOTEX INC	<u>0.5MG</u>	<u>A078449</u>	<u>001</u>	Nov 12, 2008
<u>AB</u>		<u>2MG</u>	<u>A078449</u>	<u>002</u>	Nov 12, 2008
<u>AB</u>		<u>3MG</u>	<u>A078449</u>	<u>003</u>	Nov 12, 2008
<u>AB</u>	AUROBINDO PHARMA USA	<u>0.5MG</u>	<u>A090871</u>	<u>001</u>	Jun 07, 2011
<u>AB</u>		<u>1MG</u>	<u>A090871</u>	<u>002</u>	Jun 07, 2011

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 17 (of 428)

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

<u>AB</u>	AUROBINDO PHARMA USA	<u>2MG</u>	<u>A090871</u>	<u>003</u>	Jun 07, 2011
<u>AB</u>		<u>3MG</u>	<u>A090871</u>	<u>004</u>	Jun 07, 2011
<u>AB</u>	BARR	<u>0.5MG</u>	<u>A077725</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>		<u>1MG</u>	<u>A077725</u>	<u>002</u>	Jul 31, 2006
<u>AB</u>		<u>2MG</u>	<u>A077725</u>	<u>004</u>	Jul 31, 2006
<u>AB</u>		<u>3MG</u>	<u>A077725</u>	<u>003</u>	Jul 31, 2006
<u>AB</u>	COREPHARMA	<u>0.5MG</u>	<u>A077996</u>	<u>001</u>	Jan 31, 2007
<u>AB</u>		<u>1MG</u>	<u>A077996</u>	<u>002</u>	Jan 31, 2007
<u>AB</u>		<u>2MG</u>	<u>A077996</u>	<u>003</u>	Jan 31, 2007
<u>AB</u>		<u>3MG</u>	<u>A077996</u>	<u>004</u>	Jan 31, 2007
<u>AB</u>	IMPAX LABS	<u>0.5MG</u>	<u>A077968</u>	<u>004</u>	May 24, 2007
<u>AB</u>		<u>1MG</u>	<u>A077968</u>	<u>003</u>	May 24, 2007
<u>AB</u>		<u>2MG</u>	<u>A077968</u>	<u>002</u>	May 24, 2007
<u>AB</u>		<u>3MG</u>	<u>A077968</u>	<u>001</u>	May 24, 2007
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A077391</u>	<u>002</u>	Jan 26, 2006
<u>AB</u>		<u>1MG</u>	<u>A077391</u>	<u>003</u>	Jan 26, 2006
<u>AB</u>		<u>2MG</u>	<u>A077391</u>	<u>004</u>	Jan 26, 2006
<u>AB</u>		<u>3MG</u>	<u>A077391</u>	<u>001</u>	Jan 26, 2006
<u>AB</u>	TEVA PHARMS	<u>0.5MG</u>	<u>A077979</u>	<u>001</u>	Feb 28, 2007
<u>AB</u>		<u>1MG</u>	<u>A077979</u>	<u>002</u>	Feb 28, 2007
<u>AB</u>		<u>2MG</u>	<u>A077979</u>	<u>003</u>	Feb 28, 2007
<u>AB</u>		<u>3MG</u>	<u>A077979</u>	<u>004</u>	Feb 28, 2007
<u>AB</u>	WATSON LABS FLORIDA	<u>0.5MG</u>	<u>A077198</u>	<u>001</u>	May 13, 2010
<u>AB</u>		<u>1MG</u>	<u>A077198</u>	<u>002</u>	May 13, 2010
<u>AB</u>		<u>2MG</u>	<u>A077198</u>	<u>003</u>	May 13, 2010
<u>AB</u>		<u>3MG</u>	<u>A077198</u>	<u>004</u>	May 13, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.5MG</u>	<u>A078489</u>	<u>001</u>	Oct 17, 2008
<u>AB</u>		<u>1MG</u>	<u>A078489</u>	<u>002</u>	Oct 17, 2008
<u>AB</u>		<u>2MG</u>	<u>A078489</u>	<u>003</u>	Oct 17, 2008
<u>AB</u>		<u>3MG</u>	<u>A078489</u>	<u>004</u>	Oct 17, 2008
<u>XANAX XR</u>					
<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.5MG</u>	<u>N021434</u>	<u>001</u>	Jan 17, 2003
<u>AB</u>		<u>1MG</u>	<u>N021434</u>	<u>002</u>	Jan 17, 2003
<u>AB</u>		<u>2MG</u>	<u>N021434</u>	<u>003</u>	Jan 17, 2003
<u>AB</u>	+	<u>3MG</u>	<u>N021434</u>	<u>004</u>	Jan 17, 2003

TABLET, ORALLY DISINTEGRATING; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.25MG</u>	<u>A078561</u>	<u>001</u>	Mar 16, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078561</u>	<u>002</u>	Mar 16, 2010
<u>AB</u>		<u>1MG</u>	<u>A078561</u>	<u>003</u>	Mar 16, 2010
<u>AB</u>		<u>2MG</u>	<u>A078561</u>	<u>004</u>	Mar 16, 2010
<u>AB</u>	PAR PHARM	<u>0.25MG</u>	<u>A078088</u>	<u>001</u>	Jan 09, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078088</u>	<u>002</u>	Jan 09, 2009
<u>AB</u>		<u>1MG</u>	<u>A078088</u>	<u>003</u>	Jan 09, 2009
<u>AB</u>		<u>2MG</u>	<u>A078088</u>	<u>004</u>	Jan 09, 2009
<u>NIRAVAM</u>					
<u>AB</u>	UCB INC	<u>0.25MG</u>	<u>N021726</u>	<u>001</u>	Jan 19, 2005
<u>AB</u>		<u>0.5MG</u>	<u>N021726</u>	<u>002</u>	Jan 19, 2005
<u>AB</u>	+	<u>1MG</u>	<u>N021726</u>	<u>003</u>	Jan 19, 2005
<u>AB</u>		<u>2MG</u>	<u>N021726</u>	<u>004</u>	Jan 19, 2005

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

<u>AP</u>	BEDFORD	<u>0.5MG/ML</u>	<u>A074815</u>	<u>001</u>	Jan 20, 1998
<u>AP</u>	TEVA PARENTERAL	<u>0.5MG/ML</u>	<u>A075196</u>	<u>001</u>	Apr 30, 1999
<u>CAVERJECT</u>					
<u>AP</u>	PHARMACIA AND UPJOHN	<u>0.01MG/VIAL</u>	<u>N020379</u>	<u>001</u>	Jul 06, 1995

PRESCRIPTION DRUG PRODUCT LIST

3 - 18 (of 428)

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>0.02MG/VIAL</u>	<u>N020379</u>	<u>002</u>	Jul 06, 1995

<u>AP</u>	+		<u>0.04MG/VIAL</u>	<u>N020379</u>	<u>004</u>	May 19, 1997

EDEX

<u>AP</u>		ACTIENT PHARMS	<u>0.01MG/VIAL</u>	<u>N020649</u>	<u>002</u>	Jun 12, 1997

<u>AP</u>			<u>0.02MG/VIAL</u>	<u>N020649</u>	<u>003</u>	Jun 12, 1997

<u>AP</u>	+		<u>0.04MG/VIAL</u>	<u>N020649</u>	<u>004</u>	Jun 12, 1997

PROSTIN VR PEDIATRIC

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>0.5MG/ML</u>	<u>N018484</u>	<u>001</u>	

CAVERJECT

		PHARMACIA AND UPJOHN	0.005MG/VIAL	N020379	003	Jun 27, 1996

CAVERJECT IMPULSE

		PHARMACIA AND UPJOHN	0.01MG/VIAL	N021212	001	Jun 11, 2002

			0.02MG/VIAL	N021212	002	Jun 11, 2002

EDEX

	+	ACTIENT PHARMS	0.01MG/VIAL	N020649	005	Jul 30, 1998

	+		0.02MG/VIAL	N020649	006	Jul 30, 1998

	+		0.04MG/VIAL	N020649	007	Jul 30, 1998

SUPPOSITORY; URETHRAL

MUSE

		MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996

			0.25MG	N020700	002	Nov 19, 1996

			0.5MG	N020700	003	Nov 19, 1996

	+		1MG	N020700	004	Nov 19, 1996

ALTRETAMINE

CAPSULE; ORAL

HEXALEN

	+	EISAI INC	50MG	N019926	001	Dec 26, 1990

ALVIMOPAN

CAPSULE; ORAL

ENTEREG

	+	CUBIST PHARMS	12MG	N021775	001	May 20, 2008

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

<u>AB</u>		BANNER PHARMACAPS	<u>100MG</u>	<u>A078720</u>	<u>001</u>	May 29, 2008

<u>AB</u>		SANDOZ	<u>100MG</u>	<u>A071293</u>	<u>001</u>	Feb 18, 1987

<u>AB</u>	+	USL PHARMA	<u>100MG</u>	<u>A070589</u>	<u>001</u>	Aug 05, 1986

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

<u>AA</u>	+	CAROLINA MEDCL	<u>50MG/5ML</u>	<u>A075819</u>	<u>001</u>	Sep 11, 2002

<u>AA</u>	+	HI TECH PHARMA	<u>50MG/5ML</u>	<u>A074170</u>	<u>001</u>	Oct 28, 1994

<u>AA</u>	+	MIKART	<u>50MG/5ML</u>	<u>A074028</u>	<u>001</u>	Jun 28, 1993

<u>AA</u>	+	PHARM ASSOC	<u>50MG/5ML</u>	<u>A074509</u>	<u>001</u>	Jul 17, 1995

<u>AA</u>	+	SILARX	<u>50MG/5ML</u>	<u>A076352</u>	<u>001</u>	Sep 10, 2004

<u>AA</u>	+	VINTAGE	<u>50MG/5ML</u>	<u>A077992</u>	<u>001</u>	Dec 12, 2006

<u>AA</u>	+	WOCKHARDT	<u>50MG/5ML</u>	<u>A075060</u>	<u>001</u>	Dec 24, 1998

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

	+	USL PHARMA	100MG	A076186	001	Dec 16, 2002

AMBENONIUM CHLORIDE

TABLET; ORAL

MYTELASE

	+	SANOFI AVENTIS US	10MG	N010155	002	

PRESCRIPTION DRUG PRODUCT LIST

3 - 19 (of 428)

AMBRISENTAN

TABLET; ORAL
LETAIRIS
GILEAD

5MG
10MG

N022081 001 Jun 15, 2007
N022081 002 Jun 15, 2007

AMCINONIDE

CREAM; TOPICAL
AMCINONIDE

AB + FOUGERA PHARMS 0.1%
AB TARO PHARM INDS 0.1%

A076065 001 May 15, 2003
A076229 001 May 31, 2002

LOTION; TOPICAL
AMCINONIDE

+ FOUGERA PHARMS 0.1%

A076329 001 Nov 06, 2002

OINTMENT; TOPICAL
AMCINONIDE

AB + FOUGERA PHARMS 0.1%
AB TARO PHARM INDS 0.1%

A076096 001 Nov 19, 2002
A076367 001 Mar 19, 2003

AMIFOISTINE

INJECTABLE; INJECTION
AMIFOISTINE

AP SUN PHARMA GLOBAL 500MG/VIAL

A077126 001 Mar 14, 2008

ETHYOL

AP + MEDIMMUNE 500MG/VIAL

N020221 001 Dec 08, 1995

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN SULFATE

AP + BEDFORD EQ 50MG BASE/ML
AP + EQ 250MG BASE/ML
AP HOSPIRA EQ 250MG BASE/ML
AP TEVA PARENTERAL EQ 250MG BASE/ML

A063313 001 Apr 11, 1994
A063315 001 Apr 11, 1994
A063264 001 Nov 30, 1994
A064045 002 Sep 28, 1993

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

AB + PAR PHARM 5MG
AB SIGMAPHARM LABS LLC 5MG

A070346 001 Jan 22, 1986
A079133 001 Jan 30, 2009

MIDAMOR

AB PADDOCK LLC 5MG

N018200 001

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB BARR EQ 5MG ANHYDROUS;50MG
AB + MYLAN EQ 5MG ANHYDROUS;50MG

A071111 001 May 10, 1988
A073209 001 Oct 31, 1991

AMINO ACIDS

INJECTABLE; INJECTION
AMINO ACIDS

B BRAUN 15%(300GM/2000ML)
15%(150GM/1000ML)

A091112 002 Apr 13, 2012
A091112 001 Apr 13, 2012

AMINOSYN 10%
HOSPIRA 10% (10GM/100ML)

N017673 003

AMINOSYN 10% (PH6)
HOSPIRA 10% (10GM/100ML)

N017673 008 Nov 18, 1985

AMINOSYN 3.5%
HOSPIRA 3.5% (3.5GM/100ML)

N017789 004

AMINOSYN 5%
HOSPIRA 5% (5GM/100ML)

N017673 001

PRESCRIPTION DRUG PRODUCT LIST

3 - 20 (of 428)

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN 7%				
HOSPIRA	7% (7GM/100ML)	N017673	002	
AMINOSYN 7% (PH6)				
HOSPIRA	7% (7GM/100ML)	N017673	006	Nov 18, 1985
AMINOSYN 8.5%				
HOSPIRA	8.5% (8.5GM/100ML)	N017673	004	
AMINOSYN 8.5% (PH6)				
HOSPIRA	8.5% (8.5GM/100ML)	N017673	007	Nov 18, 1985
AMINOSYN II 10%				
HOSPIRA	10% (10GM/100ML)	N019438	005	Apr 03, 1986
AMINOSYN II 10% IN PLASTIC CONTAINER				
HOSPIRA	10% (10GM/100ML)	N020015	001	Dec 19, 1991
AMINOSYN II 15% IN PLASTIC CONTAINER				
HOSPIRA	15% (15GM/100ML)	N020041	001	Dec 19, 1991
AMINOSYN II 7%				
HOSPIRA	7% (7GM/100ML)	N019438	003	Apr 03, 1986
AMINOSYN II 8.5%				
HOSPIRA	8.5% (8.5GM/100ML)	N019438	004	Apr 03, 1986
AMINOSYN-HBC 7%				
HOSPIRA	7% (7GM/100ML)	N019374	001	Jul 12, 1985
AMINOSYN-HF 8%				
HOSPIRA	8% (8GM/100ML)	N020345	001	Apr 04, 1996
AMINOSYN-PF 10%				
HOSPIRA	10% (10GM/100ML)	N019492	002	Oct 17, 1986
AMINOSYN-PF 7%				
HOSPIRA	7% (7GM/100ML)	N019398	001	Sep 06, 1985
AMINOSYN-RF 5.2%				
HOSPIRA	5.2% (5.2GM/100ML)	N018429	001	
BRANCHAMIN 4% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4% (4GM/100ML)	N018684	001	Sep 28, 1984
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	15% (15GM/100ML)	A020512	001	Aug 30, 1996
FREAMINE HBC 6.9%				
B BRAUN	6.9% (6.9GM/100ML)	N016822	006	May 17, 1983
FREAMINE III 10%				
B BRAUN	10% (10GM/100ML)	N016822	005	
FREAMINE III 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	004	
HEPATAMINE 8%				
B BRAUN	8% (8GM/100ML)	N018676	001	Aug 03, 1982
HEPATASOL 8%				
BAXTER HLTHCARE	8% (8GM/100ML)	A020360	001	Apr 04, 1996
NEPHRAMINE 5.4%				
B BRAUN	5.4% (5.4GM/100ML)	N017766	001	
PREMASOL 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	10% (10GM/100ML)	A075880	002	Jun 19, 2003
PREMASOL 6% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	6% (6GM/100ML)	A075880	001	Jun 19, 2003
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	20% (20GM/100ML)	N020849	001	Aug 26, 1998
RENAMIN W/O ELECTROLYTES				
BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N017493	007	Oct 15, 1982
TRAVASOL 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	10% (10MG/100ML)	N018931	003	Aug 23, 1984
TRAVASOL 10% W/O ELECTROLYTES				
BAXTER HLTHCARE	10% (10GM/100ML)	N017493	006	
TRAVASOL 5.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N018931	001	Aug 23, 1984
TRAVASOL 5.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N017493	004	

PRESCRIPTION DRUG PRODUCT LIST

3 - 21 (of 428)

AMINO ACIDS

INJECTABLE; INJECTION

TRAVASOL 8.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 8.5% (8.5GM/100ML)	N018931 002	Aug 23, 1984

TRAVASOL 8.5% W/O ELECTROLYTES

BAXTER HLTHCARE 8.5% (8.5GM/100ML)	N017493 005	

TROPHAMINE

+ B BRAUN 6% (6GM/100ML)	N019018 001	Jul 20, 1984

TROPHAMINE 10%

+ B BRAUN 10% (10GM/100ML)	N019018 003	Sep 07, 1988

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PROCALAMINE

B BRAUN 3%;26MG/100ML;3GM/100ML;54MG/100ML;41MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML	N018582 001	May 08, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 2.75%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678 002	Mar 26, 1997

CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 2.75%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678 005	Mar 26, 1997

CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 2.75%;33MG/100ML;5GM/100ML;51MG/100ML;61MG/100ML;217MG/100ML;112MG/100ML	N020678 001	Mar 26, 1997

CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 4.25%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678 009	Mar 26, 1997

CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 4.25%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678 011	Mar 26, 1997

CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 4.25%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678 012	Mar 26, 1997

CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 4.25%;33MG/100ML;5GM/100ML;51MG/100ML;61MG/100ML;297MG/100ML;77MG/100ML	N020678 008	Mar 26, 1997

CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678 016	Mar 26, 1997

CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678 017	Mar 26, 1997

CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678 018	Mar 26, 1997

CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678 019	Mar 26, 1997

CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 5%;33MG/100ML;35GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678 021	Mar 26, 1997

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE 2.75%;10GM/100ML	N020734 002	Sep 29, 1997

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 22 (of 428)

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;25GM/100ML	N020734	005	Sep 29, 1997
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;5GM/100ML	N020734	001	Sep 29, 1997
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;10GM/100ML	N020734	008	Sep 29, 1997
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;20GM/100ML	N020734	010	Sep 29, 1997
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;25GM/100ML	N020734	011	Sep 29, 1997
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;5GM/100ML	N020734	007	Sep 29, 1997
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5%;10GM/100ML	N020734	014	Sep 29, 1997
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5%;15GM/100ML	N020734	015	Sep 29, 1997
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5%;20GM/100ML	N020734	016	Sep 29, 1997
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5%;25GM/100ML	N020734	017	Sep 29, 1997
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5%;35GM/100ML	N020734	018	Sep 29, 1997

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES

B BRAUN	8.5%;110MG/100ML;230MG/100ML;10MG/100ML ;440MG/100ML;690MG/100ML	N016822	007	Jul 01, 1988

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

HOSPIRA	3.5%;21MG/100ML;40MG/100ML;128MG/100ML; 234MG/100ML	N017789	003	

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

FREAMINE III 3% W/ ELECTROLYTES

B BRAUN	3%;54MG/100ML;40MG/100ML;150MG/100ML;20 0MG/100ML;120MG/100ML	N016822	003	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

HOSPIRA	10%;102MG/100ML;45MG/100ML;522MG/100ML; 410MG/100ML	N019437	004	Apr 03, 1986

AMINOSYN II 8.5% W/ ELECTROLYTES

HOSPIRA	8.5%;102MG/100ML;45MG/100ML;522MG/100ML ;410MG/100ML	N019437	005	Apr 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML ;35MG/100ML	N020177	001	Oct 23, 1995

TRAVASOL 3.5% W/ ELECTROLYTES

BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML ;35MG/100ML	N017493	003	

PRESCRIPTION DRUG PRODUCT LIST

3 - 23 (of 428)

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER					
BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N020173	001	Oct 27, 1995	
TRAVASOL 5.5% W/ ELECTROLYTES					
BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N017493	001		
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER					
BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML	N020173	002	Oct 27, 1995	
TRAVASOL 8.5% W/ ELECTROLYTES					
BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML	N017493	002		

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES					
HOSPIRA	7%;102MG/100ML;522MG/100ML;410MG/100ML	N017789	002		
AMINOSYN 8.5% W/ ELECTROLYTES					
HOSPIRA	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N017673	005		

AMINOCAPROIC ACID

INJECTABLE; INJECTION

<u>AMINOCAPROIC ACID</u>					
<u>AP</u>	LUITPOLD	<u>250MG/ML</u>	<u>A071192</u>	<u>001</u>	Dec 01, 1987
<u>AMINOCAPROIC ACID IN PLASTIC CONTAINER</u>					
<u>AP</u>	+ HOSPIRA	<u>250MG/ML</u>	<u>A070010</u>	<u>001</u>	Mar 09, 1987
SYRUP; ORAL					
<u>AMICAR</u>					
<u>AA</u>	+ CLOVER PHARMS	<u>1.25GM/5ML</u>	<u>N015230</u>	<u>002</u>	
<u>AMINOCAPROIC ACID</u>					
<u>AA</u>	MIKART	<u>1.25GM/5ML</u>	<u>A074759</u>	<u>001</u>	Sep 02, 1998
TABLET; ORAL					
<u>AMICAR</u>					
<u>AB</u>	CLOVER PHARMS	<u>500MG</u>	<u>N015197</u>	<u>001</u>	
<u>AMINOCAPROIC</u>					
<u>AB</u>	MIKART	<u>500MG</u>	<u>A075602</u>	<u>001</u>	May 24, 2001
AMICAR					
+ CLOVER PHARMS			N015197	002	Jun 24, 2004

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION

AMINOHIPPURATE SODIUM					
+ MERCK	20%	N005619	001		

AMINOLEVULINIC ACID HYDROCHLORIDE

SOLUTION; TOPICAL

LEVULAN					
+ DUSA	20%	N020965	001	Dec 03, 1999	

AMINOPHYLLINE

INJECTABLE; INJECTION

<u>AMINOPHYLLINE</u>					
<u>AP</u>	+ HOSPIRA	<u>25MG/ML</u>	<u>A087242</u>	<u>001</u>	Oct 26, 1983
<u>AP</u>	INTL MEDICATION	<u>25MG/ML</u>	<u>A087209</u>	<u>001</u>	Feb 01, 1982
<u>AP</u>	LUITPOLD	<u>25MG/ML</u>	<u>A087600</u>	<u>001</u>	
<u>AP</u>	PHARMA SERVE NY	<u>25MG/ML</u>	<u>A087392</u>	<u>001</u>	Dec 15, 1983
TABLET; ORAL					
AMINOPHYLLINE					
+ WEST WARD			A084540	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 24 (of 428)

AMINOPHYLLINETABLET; ORAL
AMINOPHYLLINE

+ WEST WARD 200MG A085003 001

AMINOSALICYLIC ACIDGRANULE, DELAYED RELEASE; ORAL
PASER

+ JACOBUS 4GM/PACKET A074346 001 Jun 30, 1994

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

<u>AP</u>	+	AKORN	<u>50MG/ML</u>	<u>A076232</u>	<u>001</u>	Jul 05, 2006
<u>AP</u>	+	BIONICHE PHARMA	<u>50MG/ML</u>	<u>A076217</u>	<u>001</u>	Oct 15, 2002
<u>AP</u>	+	CLARIS LIFESCIENCES	<u>50MG/ML</u>	<u>A076394</u>	<u>001</u>	Apr 25, 2003
<u>AP</u>	+	FRESENIUS KABI USA	<u>50MG/ML</u>	<u>A075761</u>	<u>001</u>	Oct 15, 2002
<u>AP</u>	+	GLAND PHARMA LTD	<u>50MG/ML</u>	<u>A077161</u>	<u>001</u>	Apr 20, 2005
<u>AP</u>		HIKMA FARMACEUTICA	<u>50MG/ML</u>	<u>A077234</u>	<u>001</u>	Feb 25, 2008
<u>AP</u>	+	HOSPIRA	<u>50MG/ML</u>	<u>A075955</u>	<u>001</u>	Oct 18, 2002
<u>AP</u>		WOCKHARDT	<u>50MG/ML</u>	<u>A077610</u>	<u>001</u>	Oct 30, 2008
<u>AP</u>			<u>50MG/ML</u>	<u>A077834</u>	<u>001</u>	Oct 30, 2008

NEXTERONE

<u>AP</u>		BAXTER HLTHCARE	<u>50MG/ML</u>	<u>N022325</u>	<u>001</u>	Dec 24, 2008
		NEXTERONE				
	+	BAXTER HLTHCARE	150MG/100ML (1.5MG/ML)	N022325	002	Nov 16, 2010
	+		360MG/200ML (1.8MG/ML)	N022325	003	Nov 16, 2010

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

<u>AB</u>		APOTEX CORP	<u>200MG</u>	<u>A078578</u>	<u>001</u>	Nov 06, 2008
<u>AB</u>		BARR	<u>200MG</u>	<u>A075389</u>	<u>001</u>	Jan 25, 2001
<u>AB</u>		MURTY PHARMS	<u>200MG</u>	<u>A077069</u>	<u>001</u>	Apr 08, 2005
<u>AB</u>			<u>400MG</u>	<u>A077069</u>	<u>002</u>	Apr 08, 2005
<u>AB</u>		MYLAN	<u>200MG</u>	<u>A075188</u>	<u>001</u>	Feb 24, 1999
<u>AB</u>		SANDOZ	<u>200MG</u>	<u>A075315</u>	<u>001</u>	Dec 23, 1998
<u>AB</u>			<u>400MG</u>	<u>A075315</u>	<u>002</u>	Jun 30, 2000
<u>AB</u>		TARO	<u>100MG</u>	<u>A075424</u>	<u>002</u>	Dec 18, 2002
<u>AB</u>			<u>200MG</u>	<u>A075424</u>	<u>001</u>	Mar 30, 2001
<u>AB</u>			<u>400MG</u>	<u>A076362</u>	<u>001</u>	Nov 29, 2002
<u>AB</u>		TEVA PHARMS	<u>200MG</u>	<u>A074739</u>	<u>001</u>	Nov 30, 1998
<u>AB</u>		ZYDUS PHARMS USA INC	<u>200MG</u>	<u>A079029</u>	<u>001</u>	Sep 16, 2008

CORDARONE

<u>AB</u>	+	WYETH PHARMS INC	<u>200MG</u>	<u>N018972</u>	<u>001</u>	Dec 24, 1985

PACERONE

<u>AB</u>		UPSHER SMITH	<u>100MG</u>	<u>A075135</u>	<u>002</u>	Apr 12, 2005
<u>AB</u>			<u>200MG</u>	<u>A075135</u>	<u>001</u>	Apr 30, 1998

AMIODARONE HYDROCHLORIDE

TARO 300MG A076362 002 Dec 02, 2003

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

<u>AB</u>		CARACO	<u>10MG</u>	<u>A040816</u>	<u>002</u>	Jun 27, 2008
<u>AB</u>			<u>25MG</u>	<u>A040816</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>			<u>50MG</u>	<u>A040816</u>	<u>003</u>	Jun 27, 2008
<u>AB</u>			<u>75MG</u>	<u>A040816</u>	<u>004</u>	Jun 27, 2008
<u>AB</u>			<u>100MG</u>	<u>A040816</u>	<u>005</u>	Jun 27, 2008
<u>AB</u>			<u>150MG</u>	<u>A040816</u>	<u>006</u>	Jun 27, 2008
<u>AB</u>		MUTUAL PHARM	<u>10MG</u>	<u>A089398</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>			<u>25MG</u>	<u>A089399</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>			<u>50MG</u>	<u>A089400</u>	<u>001</u>	Jul 14, 1987

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 25 (of 428)

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

<u>AB</u>	MUTUAL PHARM	<u>75MG</u>	<u>A089401</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>100MG</u>	<u>A089402</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>150MG</u>	<u>A089403</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A086009</u>	<u>002</u>	
<u>AB</u>		<u>25MG</u>	<u>A086009</u>	<u>003</u>	
<u>AB</u>		<u>50MG</u>	<u>A086009</u>	<u>001</u>	
<u>AB</u>		<u>75MG</u>	<u>A086009</u>	<u>004</u>	
<u>AB</u>		<u>100MG</u>	<u>A086009</u>	<u>005</u>	
<u>AB</u>		<u>150MG</u>	<u>A086009</u>	<u>006</u>	
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A085969</u>	<u>001</u>	
<u>AB</u>	+	<u>25MG</u>	<u>A085966</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A085968</u>	<u>001</u>	
<u>AB</u>		<u>75MG</u>	<u>A085971</u>	<u>001</u>	
<u>AB</u>		<u>100MG</u>	<u>A085967</u>	<u>001</u>	
<u>AB</u>		<u>150MG</u>	<u>A085970</u>	<u>001</u>	
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A040218</u>	<u>001</u>	Sep 11, 1997
<u>AB</u>		<u>25MG</u>	<u>A040218</u>	<u>002</u>	Sep 11, 1997
<u>AB</u>		<u>50MG</u>	<u>A040218</u>	<u>003</u>	Sep 11, 1997
<u>AB</u>		<u>75MG</u>	<u>A040218</u>	<u>004</u>	Sep 11, 1997
<u>AB</u>		<u>100MG</u>	<u>A040218</u>	<u>005</u>	Sep 11, 1997
<u>AB</u>		<u>150MG</u>	<u>A040218</u>	<u>006</u>	Sep 11, 1997

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986
+	EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

MYLAN	10MG;2MG	A071443	002	Nov 10, 1988
	10MG;4MG	A071443	003	Nov 10, 1988
+	25MG;2MG	A071443	004	Nov 10, 1988
+	25MG;4MG	A071443	005	Nov 10, 1988
+	50MG;4MG	A071443	001	Nov 10, 1988

AMLEXANOX

PASTE; DENTAL

APHTHASOL

+	ULURU	5%	N020511	001	Dec 17, 1996

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>	ALKEM	<u>EQ 2.5MG BASE</u>	<u>A078925</u>	<u>001</u>	May 04, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078925</u>	<u>002</u>	May 04, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078925</u>	<u>003</u>	May 04, 2009
<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 2.5MG BASE</u>	<u>A078477</u>	<u>001</u>	Jan 16, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078477</u>	<u>002</u>	Jan 16, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078477</u>	<u>003</u>	Jan 16, 2008
<u>AB</u>	APOTEX	<u>EQ 2.5MG BASE</u>	<u>A076719</u>	<u>001</u>	May 23, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076719</u>	<u>002</u>	May 23, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076719</u>	<u>003</u>	May 23, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 2.5MG BASE</u>	<u>A078021</u>	<u>001</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078021</u>	<u>002</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078021</u>	<u>003</u>	Jul 17, 2007
<u>AB</u>	CARACO	<u>EQ 2.5MG BASE</u>	<u>A078231</u>	<u>001</u>	Nov 30, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 26 (of 428)

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>	CARACO	<u>EQ 5MG BASE</u>	<u>A078231</u>	<u>002</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078231</u>	<u>003</u>	Nov 30, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A076692</u>	<u>001</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076692</u>	<u>002</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076692</u>	<u>003</u>	Jul 20, 2007
<u>AB</u>	EPIC PHARMA LLC	<u>EQ 2.5MG BASE</u>	<u>A078552</u>	<u>001</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078552</u>	<u>002</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078552</u>	<u>003</u>	Apr 08, 2009
<u>AB</u>	HIKMA PHARMS	<u>EQ 2.5MG BASE</u>	<u>A077771</u>	<u>001</u>	Apr 12, 2011
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077771</u>	<u>002</u>	Apr 12, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077771</u>	<u>003</u>	Apr 12, 2011
<u>AB</u>	INVAGEN PHARMS	<u>EQ 2.5MG BASE</u>	<u>A077955</u>	<u>001</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077955</u>	<u>002</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077955</u>	<u>003</u>	Aug 28, 2007
<u>AB</u>	LUPIN	<u>EQ 2.5MG BASE</u>	<u>A078043</u>	<u>001</u>	Jul 12, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078043</u>	<u>002</u>	Jul 12, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078043</u>	<u>003</u>	Jul 12, 2007
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A201380</u>	<u>001</u>	Apr 13, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201380</u>	<u>002</u>	Apr 13, 2012
<u>AB</u>	MATRIX LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A078224</u>	<u>001</u>	Feb 27, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078224</u>	<u>002</u>	Feb 27, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078224</u>	<u>003</u>	Feb 27, 2008
<u>AB</u>	MYLAN	<u>EQ 2.5MG BASE</u>	<u>A076418</u>	<u>001</u>	Oct 03, 2005
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076418</u>	<u>002</u>	Oct 03, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076418</u>	<u>003</u>	Oct 03, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A078453</u>	<u>001</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078453</u>	<u>002</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078453</u>	<u>003</u>	Jul 02, 2009
<u>AB</u>	PURACAP PHARM	<u>EQ 2.5MG BASE</u>	<u>A078131</u>	<u>001</u>	Sep 04, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078131</u>	<u>002</u>	Sep 04, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078131</u>	<u>003</u>	Sep 04, 2007
<u>AB</u>	RANBAXY	<u>EQ 2.5MG BASE</u>	<u>A077974</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077974</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077974</u>	<u>003</u>	Jul 09, 2007
<u>AB</u>	ROXANE	<u>EQ 2.5MG BASE</u>	<u>A077262</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077262</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077262</u>	<u>003</u>	Jul 09, 2007
<u>AB</u>	SECAN PHARMS	<u>EQ 5MG BASE</u>	<u>A090752</u>	<u>001</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090752</u>	<u>002</u>	Apr 15, 2011
<u>AB</u>	TEVA	<u>EQ 2.5MG BASE</u>	<u>A076846</u>	<u>001</u>	Jun 28, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076846</u>	<u>002</u>	Jun 28, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076846</u>	<u>003</u>	Jun 28, 2007
<u>AB</u>	TORRENT PHARMS	<u>EQ 2.5MG BASE</u>	<u>A078573</u>	<u>001</u>	Sep 22, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078573</u>	<u>002</u>	Sep 22, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078573</u>	<u>003</u>	Sep 22, 2008
<u>AB</u>	UPSHER SMITH	<u>EQ 2.5MG BASE</u>	<u>A077759</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077759</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077759</u>	<u>003</u>	Jul 09, 2007
<u>AB</u>	VINTAGE	<u>EQ 2.5MG BASE</u>	<u>A078414</u>	<u>001</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078414</u>	<u>002</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078414</u>	<u>003</u>	Apr 07, 2010
<u>AB</u>	WATSON LABS	<u>EQ 2.5MG BASE</u>	<u>A077073</u>	<u>001</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A077671</u>	<u>001</u>	Jul 19, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077073</u>	<u>002</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077671</u>	<u>002</u>	Jul 19, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077073</u>	<u>003</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077671</u>	<u>003</u>	Jul 19, 2007
<u>AB</u>	WOCKHARDT	<u>EQ 2.5MG BASE</u>	<u>A078500</u>	<u>001</u>	Sep 06, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 27 (of 428)

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>	WOCKHARDT	<u>EQ 5MG BASE</u>	<u>A078500</u>	<u>002</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078500</u>	<u>003</u>	Sep 06, 2007
<u>AB</u>	WORLD GEN	<u>EQ 2.5MG BASE</u>	<u>A077516</u>	<u>001</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077516</u>	<u>002</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077516</u>	<u>003</u>	Jul 11, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 2.5MG BASE</u>	<u>A078226</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078226</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078226</u>	<u>003</u>	Jul 09, 2007
	<u>NORVASC</u>				
<u>AB</u>	PFIZER	<u>EQ 2.5MG BASE</u>	<u>N019787</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N019787</u>	<u>002</u>	Jul 31, 1992
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N019787</u>	<u>003</u>	Jul 31, 1992

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

CADUET

PFIZER

EQ 2.5MG BASE;EQ 10MG BASE	N021540	009	Jul 29, 2004
EQ 2.5MG BASE;EQ 20MG BASE	N021540	010	Jul 29, 2004
EQ 2.5MG BASE;EQ 40MG BASE	N021540	011	Jul 29, 2004
EQ 5MG BASE;EQ 10MG BASE	N021540	001	Jan 30, 2004
EQ 5MG BASE;EQ 20MG BASE	N021540	002	Jan 30, 2004
EQ 5MG BASE;EQ 40MG BASE	N021540	003	Jan 30, 2004
EQ 5MG BASE;EQ 80MG BASE	N021540	004	Jan 30, 2004
EQ 10MG BASE;EQ 10MG BASE	N021540	005	Jan 30, 2004
EQ 10MG BASE;EQ 20MG BASE	N021540	006	Jan 30, 2004
EQ 10MG BASE;EQ 40MG BASE	N021540	007	Jan 30, 2004
+	N021540	008	Jan 30, 2004

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 2.5MG BASE;10MG</u>	<u>A202239</u>	<u>001</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A202239</u>	<u>002</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A202239</u>	<u>003</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A202239</u>	<u>004</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A202239</u>	<u>005</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A202239</u>	<u>006</u>	Sep 05, 2012
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 2.5MG BASE;10MG</u>	<u>A077183</u>	<u>001</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077183</u>	<u>002</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077183</u>	<u>003</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A090149</u>	<u>001</u>	Jul 05, 2011
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077183</u>	<u>004</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A090149</u>	<u>002</u>	Jul 05, 2011
<u>AB</u>	LUPIN PHARMS	<u>EQ 2.5MG BASE;10MG</u>	<u>A078466</u>	<u>001</u>	Feb 05, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A078466</u>	<u>002</u>	Feb 05, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A078466</u>	<u>003</u>	Feb 05, 2010
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A078466</u>	<u>005</u>	Jul 05, 2011
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A078466</u>	<u>004</u>	Feb 05, 2010
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A078466</u>	<u>006</u>	Jul 05, 2011
<u>AB</u>	MYLAN	<u>EQ 2.5MG BASE;10MG</u>	<u>A077375</u>	<u>001</u>	May 21, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077375</u>	<u>002</u>	May 21, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077375</u>	<u>003</u>	May 21, 2010
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A079047</u>	<u>001</u>	Jul 05, 2011
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077375</u>	<u>004</u>	May 21, 2010
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A079047</u>	<u>002</u>	Jul 05, 2011
<u>AB</u>	PAR PHARM	<u>EQ 2.5MG BASE;10MG</u>	<u>A078381</u>	<u>001</u>	Jul 29, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A078381</u>	<u>002</u>	Jul 29, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A078381</u>	<u>003</u>	Jul 29, 2010

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 28 (of 428)

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	PAR PHARM	<u>EQ 5MG BASE;40MG</u>	<u>A078381</u>	<u>005</u>	Jul 29, 2010
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A078381</u>	<u>004</u>	Jul 29, 2010
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A078381</u>	<u>006</u>	Jul 29, 2010
<u>AB</u>	TEVA PHARMS	<u>EQ 2.5MG BASE;10MG</u>	<u>A077179</u>	<u>001</u>	May 18, 2007
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077179</u>	<u>002</u>	May 18, 2007
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077179</u>	<u>003</u>	May 18, 2007
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A077179</u>	<u>005</u>	Jul 05, 2011
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077179</u>	<u>004</u>	May 18, 2007
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A077179</u>	<u>006</u>	Jul 05, 2011
<u>AB</u>	WATSON LABS	<u>EQ 2.5MG BASE;10MG</u>	<u>A077890</u>	<u>001</u>	Oct 14, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077890</u>	<u>002</u>	Oct 14, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077890</u>	<u>003</u>	Oct 14, 2010
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077890</u>	<u>004</u>	Oct 14, 2010
<u>AB</u>	WATSON LABS INC	<u>EQ 5MG BASE;40MG</u>	<u>A090364</u>	<u>001</u>	Jul 05, 2011
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A090364</u>	<u>002</u>	Jul 05, 2011
<u>LOTREL</u>					
<u>AB</u>	NOVARTIS	<u>EQ 2.5MG BASE;10MG</u>	<u>N020364</u>	<u>002</u>	Mar 03, 1995
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>N020364</u>	<u>003</u>	Mar 03, 1995
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>N020364</u>	<u>004</u>	Mar 03, 1995
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>N020364</u>	<u>007</u>	Apr 11, 2006
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>N020364</u>	<u>005</u>	Jun 20, 2002
<u>AB</u>	+	<u>EQ 10MG BASE;40MG</u>	<u>N020364</u>	<u>006</u>	Apr 11, 2006

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

TRIBENZOR

	DAIICHI SANKYO	EQ 5MG BASE;12.5MG;20MG	N200175	001	Jul 23, 2010
		EQ 5MG BASE;12.5MG;40MG	N200175	002	Jul 23, 2010
		EQ 5MG BASE;25MG;40MG	N200175	003	Jul 23, 2010
		EQ 10MG BASE;12.5MG;40MG	N200175	004	Jul 23, 2010
	+	EQ 10MG BASE;25MG;40MG	N200175	005	Jul 23, 2010

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

EXFORGE HCT

<u>AB</u>	NOVARTIS	<u>5MG;12.5MG;160MG</u>	<u>N022314</u>	<u>001</u>	Apr 30, 2009
<u>AB</u>		<u>5MG;25MG;160MG</u>	<u>N022314</u>	<u>002</u>	Apr 30, 2009
<u>AB</u>		<u>10MG;12.5MG;160MG</u>	<u>N022314</u>	<u>003</u>	Apr 30, 2009
<u>AB</u>		<u>10MG;25MG;160MG</u>	<u>N022314</u>	<u>004</u>	Apr 30, 2009
<u>AB</u>	+	<u>10MG;25MG;320MG</u>	<u>N022314</u>	<u>005</u>	Apr 30, 2009

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AZOR

	DAIICHI SANKYO	EQ 5MG BASE;20MG	N022100	001	Sep 26, 2007
		EQ 5MG BASE;40MG	N022100	002	Sep 26, 2007
		EQ 10MG BASE;20MG	N022100	003	Sep 26, 2007
	+	EQ 10MG BASE;40MG	N022100	004	Sep 26, 2007

AMLODIPINE BESYLATE; TELMISARTAN

TABLET; ORAL

TWINSTA

	BOEHRINGER INGELHEIM	EQ 5MG BASE;40MG	N022401	001	Oct 16, 2009
		EQ 5MG BASE;80MG	N022401	003	Oct 16, 2009
		EQ 10MG BASE;40MG	N022401	002	Oct 16, 2009
	+	EQ 10MG BASE;80MG	N022401	004	Oct 16, 2009

PRESCRIPTION DRUG PRODUCT LIST

3 - 29 (of 428)

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL
EXFORGE

NOVARTIS	EQ 5MG BASE;160MG	N021990	002	Jun 20, 2007
	EQ 5MG BASE;320MG	N021990	004	Jun 20, 2007
+	EQ 10MG BASE;160MG	N021990	003	Jun 20, 2007
+	EQ 10MG BASE;320MG	N021990	005	Jun 20, 2007

AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>	TEVA PHARMS	<u>5MG;12.5MG;160MG</u>	<u>A200435</u>	<u>001</u>	Sep 25, 2012
<u>AB</u>		<u>5MG;25MG;160MG</u>	<u>A200435</u>	<u>002</u>	Sep 25, 2012
<u>AB</u>		<u>10MG;12.5MG;160MG</u>	<u>A200435</u>	<u>005</u>	Sep 25, 2012
<u>AB</u>		<u>10MG;25MG;160MG</u>	<u>A200435</u>	<u>003</u>	Sep 25, 2012
<u>AB</u>		<u>10MG;25MG;320MG</u>	<u>A200435</u>	<u>004</u>	Sep 25, 2012

AMMONIA N-13

INJECTABLE; INTRAVENOUS
AMMONIA N 13

HOUSTON CYCLOTRON	3.75-260mCi/ML	A203543	001	Dec 14, 2012

AMMONIA, N-13

INJECTABLE; INTRAVENOUS
AMMONIA N 13

+ FEINSTEIN	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	N022119	001	Aug 23, 2007

AMMONIUM CHLORIDE

INJECTABLE; INJECTION
AMMONIUM CHLORIDE IN PLASTIC CONTAINER
+ HOSPIRA

5MEQ/ML	A088366	001	Jun 13, 1984

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	PERRIGO NEW YORK	<u>EQ 12% BASE</u>	<u>A075774</u>	<u>001</u>	May 01, 2002
<u>AB</u>	TARO	<u>EQ 12% BASE</u>	<u>A075883</u>	<u>001</u>	Apr 10, 2003
<u>AB</u>	WATSON LABS INC	<u>EQ 12% BASE</u>	<u>A076829</u>	<u>001</u>	Feb 07, 2006

LAC-HYDRIN

<u>AB</u> + RANBAXY	<u>EQ 12% BASE</u>	<u>N020508</u>	<u>001</u>	Aug 29, 1996

LOTION; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	PERRIGO NEW YORK	<u>EQ 12% BASE</u>	<u>A075570</u>	<u>001</u>	Jun 23, 2004
<u>AB</u>	TARO	<u>EQ 12% BASE</u>	<u>A076216</u>	<u>001</u>	May 28, 2004
<u>AB</u>	WATSON LABS INC	<u>EQ 12% BASE</u>	<u>A075575</u>	<u>001</u>	Jun 11, 2002

LAC-HYDRIN

<u>AB</u> + RANBAXY	<u>EQ 12% BASE</u>	<u>N019155</u>	<u>001</u>	Apr 24, 1985

AMOXAPINE

TABLET; ORAL
AMOXAPINE

WATSON LABS	25MG	A072688	001	Aug 28, 1992
	50MG	A072689	001	Aug 28, 1992
	100MG	A072690	001	Aug 28, 1992
+	150MG	A072691	001	Aug 28, 1992

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

<u>AB</u>	AM ANTIBIOTICS	<u>250MG</u>	<u>A062058</u>	<u>001</u>	
<u>AB</u>		<u>500MG</u>	<u>A062058</u>	<u>002</u>	
<u>AB</u>	AUROBINDO	<u>250MG</u>	<u>A065271</u>	<u>001</u>	Nov 09, 2005

PRESCRIPTION DRUG PRODUCT LIST

3 - 30 (of 428)

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>500MG</u>	<u>A065271</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>	DAVA PHARMS INC	<u>250MG</u>	<u>A062884</u>	<u>001</u>	Feb 25, 1988
<u>AB</u>		<u>500MG</u>	<u>A062881</u>	<u>001</u>	Feb 25, 1988
<u>AB</u>	HIKMA PHARMS	<u>250MG</u>	<u>A065291</u>	<u>001</u>	Feb 05, 2007
<u>AB</u>		<u>500MG</u>	<u>A065291</u>	<u>002</u>	Feb 05, 2007
<u>AB</u>	RANBAXY	<u>250MG</u>	<u>A065016</u>	<u>001</u>	Apr 08, 1999
<u>AB</u>		<u>500MG</u>	<u>A065016</u>	<u>002</u>	Apr 08, 1999
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A064076</u>	<u>001</u>	Sep 30, 1994
<u>AB</u>		<u>500MG</u>	<u>A064076</u>	<u>002</u>	Sep 30, 1994
<u>AB</u>	TEVA	<u>250MG</u>	<u>A061926</u>	<u>001</u>	
<u>AB</u>	+	<u>500MG</u>	<u>A061926</u>	<u>003</u>	

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>250MG</u>	<u>A062216</u>	<u>001</u>	
<u>AB</u>		<u>500MG</u>	<u>A062216</u>	<u>004</u>	

FOR SUSPENSION; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>200MG/5ML</u>	<u>A065334</u>	<u>001</u>	Dec 28, 2006
<u>AB</u>		<u>400MG/5ML</u>	<u>A065334</u>	<u>002</u>	Dec 28, 2006
<u>AB</u>	DAVA PHARMS INC	<u>125MG/5ML</u>	<u>A062927</u>	<u>001</u>	Nov 25, 1988
<u>AB</u>		<u>250MG/5ML</u>	<u>A062927</u>	<u>002</u>	Nov 25, 1988
<u>AB</u>	HIKMA	<u>125MG/5ML</u>	<u>A065322</u>	<u>002</u>	Jun 19, 2006
<u>AB</u>		<u>200MG/5ML</u>	<u>A065325</u>	<u>002</u>	Jun 19, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065322</u>	<u>001</u>	Jun 19, 2006
<u>AB</u>		<u>400MG/5ML</u>	<u>A065325</u>	<u>001</u>	Jun 19, 2006
<u>AB</u>	RANBAXY	<u>200MG/5ML</u>	<u>A065113</u>	<u>001</u>	Nov 29, 2002
<u>AB</u>		<u>400MG/5ML</u>	<u>A065113</u>	<u>002</u>	Nov 29, 2002
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065387</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>		<u>200MG/5ML</u>	<u>A065378</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065387</u>	<u>002</u>	Mar 26, 2007
<u>AB</u>		<u>400MG/5ML</u>	<u>A065378</u>	<u>002</u>	Mar 26, 2007
<u>AB</u>	TEVA	<u>125MG/5ML</u>	<u>A061931</u>	<u>001</u>	
<u>AB</u>		<u>200MG/5ML</u>	<u>A065119</u>	<u>001</u>	Dec 04, 2002
<u>AB</u>	+	<u>250MG/5ML</u>	<u>A061931</u>	<u>002</u>	
<u>AB</u>	+	<u>400MG/5ML</u>	<u>A065119</u>	<u>002</u>	Dec 04, 2002
<u>AB</u>	WOCKHARDT	<u>400MG/5ML</u>	<u>A065319</u>	<u>002</u>	Jun 18, 2007

AMOXICILLIN PEDIATRIC

<u>AB</u>	TEVA	<u>50MG/ML</u>	<u>A061931</u>	<u>003</u>	Dec 01, 1982

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>50MG/ML</u>	<u>A062226</u>	<u>005</u>	
<u>AB</u>		<u>125MG/5ML</u>	<u>A062226</u>	<u>001</u>	
<u>AB</u>		<u>200MG/5ML</u>	<u>N050760</u>	<u>001</u>	Apr 15, 1999
<u>AB</u>		<u>250MG/5ML</u>	<u>A062226</u>	<u>002</u>	
<u>AB</u>		<u>400MG/5ML</u>	<u>N050760</u>	<u>002</u>	Apr 15, 1999

LAROTID

<u>AB</u>	DR REDDYS LABS INC	<u>125MG/5ML</u>	<u>A062226</u>	<u>003</u>	
<u>AB</u>		<u>250MG/5ML</u>	<u>A062226</u>	<u>004</u>	

TABLET; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>500MG</u>	<u>A065256</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>875MG</u>	<u>A065256</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>	DAVA PHARMS INC	<u>875MG</u>	<u>A065344</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>	HIKMA	<u>875MG</u>	<u>A065255</u>	<u>001</u>	Mar 29, 2006
<u>AB</u>	RANBAXY	<u>500MG</u>	<u>A065059</u>	<u>001</u>	Nov 24, 2000
<u>AB</u>		<u>875MG</u>	<u>A065059</u>	<u>002</u>	Nov 24, 2000
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A065228</u>	<u>001</u>	Jul 13, 2005
<u>AB</u>		<u>875MG</u>	<u>A065228</u>	<u>002</u>	Jul 13, 2005
<u>AB</u>	TEVA	<u>500MG</u>	<u>A065056</u>	<u>001</u>	Sep 18, 2000
<u>AB</u>	+	<u>875MG</u>	<u>A065056</u>	<u>002</u>	Sep 18, 2000

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 31 (of 428)

AMOXICILLIN

TABLET; ORAL

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>500MG</u>	<u>N050754</u>	<u>002</u>	Jul 10, 1998
<u>AB</u>		<u>875MG</u>	<u>N050754</u>	<u>001</u>	Jul 10, 1998

TABLET, CHEWABLE; ORAL

AMOXICILLIN

<u>AB</u>	DAVA PHARMS INC	<u>125MG</u>	<u>A064139</u>	<u>001</u>	Jan 29, 1996
<u>AB</u>		<u>250MG</u>	<u>A064139</u>	<u>002</u>	Jan 29, 1996
<u>AB</u>	RANBAXY	<u>125MG</u>	<u>A065021</u>	<u>001</u>	Dec 23, 1999
<u>AB</u>		<u>250MG</u>	<u>A065021</u>	<u>002</u>	Dec 23, 1999
<u>AB</u>	TEVA	<u>125MG</u>	<u>A064013</u>	<u>002</u>	Sep 11, 1995
<u>AB</u>	+	<u>250MG</u>	<u>A064013</u>	<u>001</u>	Dec 22, 1992

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>125MG</u>	<u>N050542</u>	<u>002</u>	
<u>AB</u>		<u>200MG</u>	<u>N050761</u>	<u>001</u>	Apr 15, 1999
<u>AB</u>		<u>250MG</u>	<u>N050542</u>	<u>001</u>	
<u>AB</u>		<u>400MG</u>	<u>N050761</u>	<u>002</u>	Apr 15, 1999

AMOXICILLIN

	RANBAXY	200MG	A065060	001	Nov 29, 2000
		400MG	A065060	002	Nov 29, 2000

TABLET, EXTENDED RELEASE; ORAL

MOXATAG

+	SHIONOGI INC	775MG	N050813	001	Jan 23, 2008

TABLET, FOR SUSPENSION; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO PHARMA	<u>200MG</u>	<u>A065324</u>	<u>001</u>	Jan 17, 2007
<u>AB</u>		<u>400MG</u>	<u>A065324</u>	<u>002</u>	Jan 17, 2007

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

PREVPAC

+	TAKEDA PHARMS USA	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG	N050757	001	Dec 02, 1997

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE, TABLET; ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+	GASTROENTERO	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 20MG	N050824	001	Feb 08, 2011

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	HIKMA PHARMS	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065191</u>	<u>002</u>	Jan 25, 2005
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065191</u>	<u>001</u>	Jan 25, 2005
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065373</u>	<u>001</u>	Nov 09, 2007
<u>AB</u>	RANBAXY	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065132</u>	<u>001</u>	Mar 19, 2003
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065132</u>	<u>002</u>	Mar 19, 2003
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065207</u>	<u>002</u>	Jan 30, 2007
<u>AB</u>	SANDOZ	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065066</u>	<u>001</u>	Jun 05, 2002
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065066</u>	<u>002</u>	Jun 05, 2002
<u>AB</u>	SANDOZ INC	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065098</u>	<u>001</u>	Dec 16, 2002
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065098</u>	<u>002</u>	Dec 16, 2002
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065358</u>	<u>001</u>	Aug 13, 2007
<u>AB</u>	TEVA	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065089</u>	<u>001</u>	May 25, 2004
<u>AB</u>	+	<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065089</u>	<u>002</u>	May 25, 2004
<u>AB</u>	+	<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065162</u>	<u>001</u>	Mar 12, 2004
<u>AB</u>	WOCKHARDT	<u>250MG/5ML;EQ 62.5MG BASE/5ML</u>	<u>A065431</u>	<u>001</u>	Nov 25, 2008
<u>AUGMENTIN '125'</u>					
<u>AB</u>	DR REDDYS LABS INC	<u>125MG/5ML;EQ 31.25MG BASE/5ML</u>	<u>N050575</u>	<u>001</u>	Aug 06, 1984

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 32 (of 428)

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AUGMENTIN '200'

<u>AB</u>	DR REDDYS LABS INC	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>N050725</u>	<u>001</u>	May 31, 1996

AUGMENTIN '250'

<u>AB</u>	+ DR REDDYS LABS INC	<u>250MG/5ML;EQ 62.5MG BASE/5ML</u>	<u>N050575</u>	<u>002</u>	Aug 06, 1984

AUGMENTIN '400'

<u>AB</u>	DR REDDYS LABS INC	<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>N050725</u>	<u>002</u>	May 31, 1996

AUGMENTIN ES-600

<u>AB</u>	DR REDDYS LABS INC	<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>N050755</u>	<u>001</u>	Jun 22, 2001

SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	AUROBINDO PHARMA LTD	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A201090</u>	<u>001</u>	Dec 20, 2011

<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A201090</u>	<u>002</u>	Dec 20, 2011

<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A201091</u>	<u>001</u>	Dec 20, 2011

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	APOTEX	<u>250MG;EQ 125MG BASE</u>	<u>A065333</u>	<u>001</u>	Feb 24, 2009

<u>AB</u>		<u>500MG;EQ 125MG BASE</u>	<u>A065333</u>	<u>002</u>	Feb 24, 2009

<u>AB</u>	APOTEX INC	<u>875MG;EQ 125MG BASE</u>	<u>A065317</u>	<u>003</u>	Oct 20, 2008

<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG;EQ 125MG BASE</u>	<u>A091569</u>	<u>001</u>	Jan 20, 2012

<u>AB</u>		<u>500MG;EQ 125MG BASE</u>	<u>A091569</u>	<u>002</u>	Jan 20, 2012

<u>AB</u>		<u>875MG;EQ 125MG BASE</u>	<u>A091568</u>	<u>001</u>	Jan 20, 2012

<u>AB</u>	RANBAXY	<u>500MG;EQ 125MG BASE</u>	<u>A065109</u>	<u>001</u>	Nov 04, 2002

<u>AB</u>		<u>875MG;EQ 125MG BASE</u>	<u>A065102</u>	<u>001</u>	Sep 17, 2002

<u>AB</u>	SANDOZ	<u>250MG;EQ 125MG BASE</u>	<u>A065189</u>	<u>001</u>	Aug 23, 2005

<u>AB</u>		<u>500MG;EQ 125MG BASE</u>	<u>A065064</u>	<u>001</u>	Mar 15, 2002

<u>AB</u>		<u>875MG;EQ 125MG BASE</u>	<u>A065063</u>	<u>001</u>	Mar 14, 2002

<u>AB</u>	SANDOZ INC	<u>500MG;EQ 125MG BASE</u>	<u>A065117</u>	<u>001</u>	Nov 27, 2002

<u>AB</u>		<u>875MG;EQ 125MG BASE</u>	<u>A065093</u>	<u>001</u>	Nov 21, 2002

<u>AB</u>	TEVA	<u>500MG;EQ 125MG BASE</u>	<u>A065101</u>	<u>001</u>	Oct 30, 2002

<u>AB</u>	+	<u>875MG;EQ 125MG BASE</u>	<u>A065096</u>	<u>001</u>	Oct 29, 2002

AUGMENTIN '250'

<u>AB</u>	DR REDDYS LABS INC	<u>250MG;EQ 125MG BASE</u>	<u>N050564</u>	<u>001</u>	Aug 06, 1984

AUGMENTIN '500'

<u>AB</u>	DR REDDYS LABS INC	<u>500MG;EQ 125MG BASE</u>	<u>N050564</u>	<u>002</u>	Aug 06, 1984

AUGMENTIN '875'

<u>AB</u>	DR REDDYS LABS INC	<u>875MG;EQ 125MG BASE</u>	<u>N050720</u>	<u>001</u>	Feb 13, 1996

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	RANBAXY	<u>200MG;EQ 28.5MG BASE</u>	<u>A065161</u>	<u>001</u>	Dec 03, 2003

<u>AB</u>		<u>400MG;EQ 57MG BASE</u>	<u>A065161</u>	<u>002</u>	Dec 03, 2003

<u>AB</u>	SANDOZ	<u>200MG;EQ 28.5MG BASE</u>	<u>A065065</u>	<u>001</u>	Apr 18, 2002

<u>AB</u>		<u>400MG;EQ 57MG BASE</u>	<u>A065065</u>	<u>002</u>	Apr 18, 2002

<u>AB</u>	TEVA	<u>200MG;EQ 28.5MG BASE</u>	<u>A065205</u>	<u>001</u>	Feb 09, 2005

<u>AB</u>	+	<u>400MG;EQ 57MG BASE</u>	<u>A065205</u>	<u>002</u>	Feb 09, 2005

AUGMENTIN '125'

<u>AB</u>	DR REDDYS LABS INC	<u>125MG;EQ 31.25MG BASE</u>	<u>N050597</u>	<u>001</u>	Jul 22, 1985

AUGMENTIN '200'

<u>AB</u>	DR REDDYS LABS INC	<u>200MG;EQ 28.5MG BASE</u>	<u>N050726</u>	<u>001</u>	May 31, 1996

AUGMENTIN '250'

<u>AB</u>	DR REDDYS LABS INC	<u>250MG;EQ 62.5MG BASE</u>	<u>N050597</u>	<u>002</u>	Jul 22, 1985

AUGMENTIN '400'

<u>AB</u>	DR REDDYS LABS INC	<u>400MG;EQ 57MG BASE</u>	<u>N050726</u>	<u>002</u>	May 31, 1996

TABLET, EXTENDED RELEASE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	SANDOZ	<u>1GM;EQ 62.5MG BASE</u>	<u>A090227</u>	<u>001</u>	Apr 21, 2010

AUGMENTIN XR

<u>AB</u>	+	<u>1GM;EQ 62.5MG BASE</u>	<u>N050785</u>	<u>001</u>	Sep 25, 2002

PRESCRIPTION DRUG PRODUCT LIST

3 - 33 (of 428)

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

<u>ADDERALL XR 10</u>				
<u>AB</u>	SHIRE	<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>N021303</u>	<u>001</u> Oct 11, 2001
<u>ADDERALL XR 15</u>				
<u>AB</u>	SHIRE	<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>N021303</u>	<u>006</u> May 22, 2002
<u>ADDERALL XR 20</u>				
<u>AB</u>	SHIRE	<u>5MG;5MG;5MG;5MG</u>	<u>N021303</u>	<u>002</u> Oct 11, 2001
<u>ADDERALL XR 25</u>				
<u>AB</u>	SHIRE	<u>6.25MG;6.25MG;6.25MG;6.25MG</u>	<u>N021303</u>	<u>004</u> May 22, 2002
<u>ADDERALL XR 30</u>				
<u>AB</u>	+ SHIRE	<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>N021303</u>	<u>003</u> Oct 11, 2001
<u>ADDERALL XR 5</u>				
<u>AB</u>	SHIRE	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>N021303</u>	<u>005</u> May 22, 2002
<u>DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE</u>				
<u>AB</u>	ACTAVIS ELIZABETH	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A077302</u>	<u>001</u> Jun 22, 2012
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A077302</u>	<u>002</u> Jun 22, 2012
<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A077302</u>	<u>003</u> Jun 22, 2012
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A077302</u>	<u>004</u> Jun 22, 2012
<u>AB</u>		<u>6.25MG;6.25MG;6.25MG;6.25MG</u>	<u>A077302</u>	<u>005</u> Jun 22, 2012
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A077302</u>	<u>006</u> Jun 22, 2012

TABLET; ORAL

<u>DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE</u>				
<u>AB</u>	BARR	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040422</u>	<u>001</u> Feb 11, 2002
<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040422</u>	<u>005</u> Mar 19, 2003
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040422</u>	<u>002</u> Feb 11, 2002
<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040422</u>	<u>006</u> Mar 19, 2003
<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040422</u>	<u>007</u> Mar 19, 2003
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040422</u>	<u>003</u> Feb 11, 2002
<u>AB</u>	+ COREPHARMA	<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040422</u>	<u>004</u> Feb 11, 2002
<u>AB</u>		<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040444</u>	<u>001</u> Jun 19, 2002
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040444</u>	<u>002</u> Jun 19, 2002
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040444</u>	<u>003</u> Jun 19, 2002
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040444</u>	<u>004</u> Jun 19, 2002
<u>AB</u>	SANDOZ	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040439</u>	<u>004</u> Sep 27, 2002
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040439</u>	<u>001</u> Jun 14, 2002
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040439</u>	<u>002</u> Jun 14, 2002
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040439</u>	<u>003</u> Jun 14, 2002
<u>AB</u>	TEVA PHARMS	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040472</u>	<u>001</u> Sep 30, 2003
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040472</u>	<u>002</u> Sep 30, 2003
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040472</u>	<u>003</u> Sep 30, 2003
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040472</u>	<u>004</u> Sep 30, 2003

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE				
	ARBOR PHARMS INC	5MG	A200166	001 Aug 09, 2012
	+	10MG	A200166	002 Aug 09, 2012

AMPHOTERICIN B

INJECTABLE; INJECTION

<u>AMPHOTERICIN B</u>				
<u>AP</u>	+ X GEN PHARMS	<u>50MG/VIAL</u>	<u>A063206</u>	<u>001</u> Apr 29, 1992
INJECTABLE, LIPID COMPLEX; INJECTION				
ABELCET				
	+ SIGMA TAU	5MG/ML	N050724	001 Nov 20, 1995
AMPHOTEC				
	+ ALKOPHARMA USA	50MG/VIAL	N050729	001 Nov 22, 1996
	+	100MG/VIAL	N050729	002 Nov 22, 1996

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 34 (of 428)

AMPHOTERICIN B

INJECTABLE, LIPOSOMAL; INJECTION

AMBISOME

+ ASTELLAS

50MG/VIAL

N050740

001

Aug 11, 1997

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

<u>AP</u>	<u>ANTIBIOTICE</u>	<u>EQ 250MG BASE/VIAL</u>	<u>A090354</u>	<u>001</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A090354</u>	<u>002</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090354</u>	<u>003</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090354</u>	<u>004</u>	Dec 28, 2009
<u>AP</u>	<u>AUROBINDO PHARMA</u>	<u>EQ 125MG BASE/VIAL</u>	<u>A065499</u>	<u>001</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A065499</u>	<u>002</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065499</u>	<u>003</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065499</u>	<u>004</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065499</u>	<u>005</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065493</u>	<u>001</u>	Aug 17, 2010
<u>AP</u>	<u>HANFORD GC</u>	<u>EQ 250MG BASE/VIAL</u>	<u>A063145</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A063146</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062772</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A063140</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A063142</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>	<u>IBI</u>	<u>EQ 125MG BASE/VIAL</u>	<u>A062797</u>	<u>001</u>	Jul 12, 1993
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A062719</u>	<u>001</u>	May 12, 1987
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A062719</u>	<u>003</u>	May 12, 1987
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062719</u>	<u>002</u>	May 12, 1987
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A062797</u>	<u>002</u>	Jul 12, 1993
<u>AP</u>	<u>+ SANDOZ</u>	<u>EQ 125MG BASE/VIAL</u>	<u>A061395</u>	<u>001</u>	
<u>AP</u>	<u>+</u>	<u>EQ 250MG BASE/VIAL</u>	<u>A061395</u>	<u>002</u>	
<u>AP</u>	<u>+</u>	<u>EQ 500MG BASE/VIAL</u>	<u>A061395</u>	<u>003</u>	
<u>AP</u>	<u>+</u>	<u>EQ 1GM BASE/VIAL</u>	<u>A061395</u>	<u>004</u>	
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062738</u>	<u>001</u>	Feb 19, 1987
<u>AP</u>	<u>+</u>	<u>EQ 2GM BASE/VIAL</u>	<u>A061395</u>	<u>005</u>	
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A062738</u>	<u>002</u>	Feb 19, 1987
<u>AP</u>	<u>+</u>	<u>EQ 10GM BASE/VIAL</u>	<u>A061395</u>	<u>006</u>	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

<u>AP</u>	<u>ACS DOBFAR</u>	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065406</u>	<u>001</u>	Dec 22, 2009
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065406</u>	<u>002</u>	Dec 22, 2009
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065403</u>	<u>001</u>	Dec 23, 2009
<u>AP</u>	<u>AUROBINDO PHARMA</u>	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090340</u>	<u>001</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090349</u>	<u>001</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090340</u>	<u>002</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090349</u>	<u>002</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090339</u>	<u>001</u>	Sep 20, 2010
<u>AP</u>	<u>BIONICHE PHARMA</u>	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065316</u>	<u>001</u>	Jun 29, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065316</u>	<u>002</u>	Jun 29, 2007
<u>AP</u>	<u>HANFORD GC</u>	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065176</u>	<u>001</u>	Nov 30, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065176</u>	<u>002</u>	Nov 30, 2005
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065188</u>	<u>001</u>	Nov 25, 2005
<u>AP</u>	<u>HIKMA MAPLE</u>	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065074</u>	<u>001</u>	Mar 19, 2002
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065074</u>	<u>002</u>	Mar 19, 2002
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065076</u>	<u>001</u>	Mar 19, 2002
<u>AP</u>	<u>HOSPIRA INC</u>	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090375</u>	<u>001</u>	Dec 21, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090653</u>	<u>001</u>	Dec 21, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090375</u>	<u>002</u>	Dec 21, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090653</u>	<u>002</u>	Dec 21, 2011
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090646</u>	<u>001</u>	Dec 21, 2011

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 35 (of 428)

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

<u>AP</u>	<u>IBI</u>	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065222</u>	<u>001</u>	Nov 29, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065222</u>	<u>002</u>	Nov 29, 2005
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065314</u>	<u>001</u>	Nov 27, 2006
<u>AP</u>	<u>SANDOZ</u>	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065241</u>	<u>001</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065310</u>	<u>001</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065241</u>	<u>002</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065310</u>	<u>002</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065240</u>	<u>001</u>	Jul 25, 2006
	<u>UNASYN</u>				
<u>AP</u>	<u>PFIZER</u>	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A062901</u>	<u>001</u>	Nov 23, 1988
<u>AP</u>	<u>+</u>	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050608</u>	<u>002</u>	Dec 31, 1986
<u>AP</u>	<u>+</u>	<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>N050608</u>	<u>001</u>	Dec 31, 1986
<u>AP</u>	<u>+</u>	<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>N050608</u>	<u>005</u>	Dec 10, 1993

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

<u>AB</u>	<u>DAVA PHARMS INC</u>	<u>EQ 250MG BASE</u>	<u>A062883</u>	<u>001</u>	Feb 25, 1988
<u>AB</u>	<u>+</u>	<u>EQ 500MG BASE</u>	<u>A062882</u>	<u>001</u>	Feb 25, 1988
<u>AB</u>	<u>SANDOZ</u>	<u>EQ 250MG BASE</u>	<u>A064082</u>	<u>001</u>	Aug 29, 1995
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A064082</u>	<u>002</u>	Aug 29, 1995
	<u>FOR SUSPENSION; ORAL</u>				
	<u>AMPICILLIN TRIHYDRATE</u>				
	<u>DAVA PHARMS INC</u>	<u>EQ 125MG BASE/5ML</u>	<u>A062982</u>	<u>001</u>	Feb 10, 1989
	<u>+</u>	<u>EQ 250MG BASE/5ML</u>	<u>A062982</u>	<u>002</u>	Feb 10, 1989

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

<u>AB</u>	<u>SHIRE LLC</u>	<u>EQ 0.5MG BASE</u>	<u>N020333</u>	<u>001</u>	Mar 14, 1997
	<u>ANAGRELIDE HYDROCHLORIDE</u>				
<u>AB</u>	<u>BARR</u>	<u>EQ 0.5MG BASE</u>	<u>A076530</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A076530</u>	<u>002</u>	Apr 18, 2005
<u>AB</u>	<u>IMPAX LABS</u>	<u>EQ 0.5MG BASE</u>	<u>A076910</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A076910</u>	<u>002</u>	Apr 18, 2005
<u>AB</u>	<u>IVAX SUB TEVA PHARMS</u>	<u>EQ 0.5MG BASE</u>	<u>A076468</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>	<u>+</u>	<u>EQ 1MG BASE</u>	<u>A076468</u>	<u>002</u>	Apr 18, 2005
<u>AB</u>	<u>MYLAN</u>	<u>EQ 0.5MG BASE</u>	<u>A076811</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A076811</u>	<u>002</u>	Apr 18, 2005
<u>AB</u>	<u>MYLAN PHARMS INC</u>	<u>EQ 0.5MG BASE</u>	<u>A077613</u>	<u>001</u>	Jun 27, 2006
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A077613</u>	<u>002</u>	Jun 27, 2006
<u>AB</u>	<u>WATSON LABS</u>	<u>EQ 0.5MG BASE</u>	<u>A076417</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A076417</u>	<u>002</u>	Apr 18, 2005

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

<u>AB</u>	<u>ACCORD HLTHCARE INC</u>	<u>1MG</u>	<u>A090568</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	<u>APOTEX INC</u>	<u>1MG</u>	<u>A200654</u>	<u>001</u>	May 11, 2012
<u>AB</u>	<u>DR REDDYS LABS LTD</u>	<u>1MG</u>	<u>A090732</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	<u>FRESENIUS KABI ONCOL</u>	<u>1MG</u>	<u>A090088</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	<u>IMPAX LABS INC</u>	<u>1MG</u>	<u>A091242</u>	<u>001</u>	May 31, 2012
<u>AB</u>	<u>KUDCO IRELAND</u>	<u>1MG</u>	<u>A091331</u>	<u>001</u>	Jan 05, 2011
<u>AB</u>	<u>MYLAN</u>	<u>1MG</u>	<u>A091051</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	<u>NATCO PHARMA LTD</u>	<u>1MG</u>	<u>A079220</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	<u>ROXANE</u>	<u>1MG</u>	<u>A078485</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	<u>SANDOZ</u>	<u>1MG</u>	<u>A079007</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	<u>SANTOS BIOTECH</u>	<u>1MG</u>	<u>A078944</u>	<u>001</u>	Jun 28, 2010

PRESCRIPTION DRUG PRODUCT LIST

3 - 36 (of 428)

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

<u>AB</u>	SUN PHARM INDS LTD	<u>1MG</u>	<u>A091177</u>	<u>001</u>	Jul 15, 2011
<u>AB</u>	TEVA PHARMS	<u>1MG</u>	<u>A078058</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	THREE RIVERS PHARMS	<u>1MG</u>	<u>A091164</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	WATSON LABS	<u>1MG</u>	<u>A078984</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>1MG</u>	<u>A078921</u>	<u>001</u>	Jun 28, 2010

ARIMIDEX

<u>AB</u>	+ ASTRAZENECA	<u>1MG</u>	<u>N020541</u>	<u>001</u>	Dec 27, 1995

ANIDULAFUNGIN

INJECTABLE; IV (INFUSION)

ERAXIS

+	VICURON	50MG/VIAL	N021632	001	Feb 17, 2006
+		100MG/VIAL	N021632	002	Nov 14, 2006

APIXABAN

TABLET; ORAL

ELIQUIS

	BRISTOL MYERS SQUIBB	2.5MG	N202155	001	Dec 28, 2012
+		5MG	N202155	002	Dec 28, 2012

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

+	US WORLDMEDS	30MG/3ML (10MG/ML)	N021264	002	Apr 20, 2004

APRACLOPIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

APRACLOPIDINE HYDROCHLORIDE

<u>AT</u>	AKORN INC	<u>EQ 0.5% BASE</u>	<u>A077764</u>	<u>001</u>	Mar 12, 2009
	<u>IOPIDINE</u>				
<u>AT</u>	+ ALCON	<u>EQ 0.5% BASE</u>	<u>N020258</u>	<u>001</u>	Jul 30, 1993
	<u>IOPIDINE</u>				
+	ALCON	EQ 1% BASE	N019779	001	Dec 31, 1987

APREPITANT

CAPSULE; ORAL

APREPITANT

<u>AB</u>	SANDOZ	<u>40MG</u>	<u>A090999</u>	<u>001</u>	Sep 24, 2012
<u>AB</u>		<u>80MG</u>	<u>A090999</u>	<u>002</u>	Sep 24, 2012
<u>AB</u>		<u>125MG</u>	<u>A090999</u>	<u>003</u>	Sep 24, 2012
	<u>EMEND</u>				
<u>AB</u>	MERCK	<u>40MG</u>	<u>N021549</u>	<u>003</u>	Jun 30, 2006
<u>AB</u>		<u>80MG</u>	<u>N021549</u>	<u>001</u>	Mar 26, 2003
<u>AB</u>	+	<u>125MG</u>	<u>N021549</u>	<u>002</u>	Mar 26, 2003

ARFORMOTEROL TARTRATE

SOLUTION; INHALATION

BROVANA

+	SUNOVION	EQ 0.015MG BASE/2ML	N021912	001	Oct 06, 2006

ARGATROBAN

INJECTABLE; INJECTION

ACOVA

<u>AP</u>	+ PFIZER	<u>250MG/2.5ML (100MG/ML)</u>	<u>N020883</u>	<u>001</u>	Jun 30, 2000
	<u>ARGATROBAN</u>				
<u>AP</u>	HIKMA PHARM CO LTD	<u>250MG/2.5ML (100MG/ML)</u>	<u>N203049</u>	<u>001</u>	Jan 05, 2012
	INJECTABLE; IV (INFUSION)				
+	EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 37 (of 428)

ARGATROBAN

INJECTABLE; IV (INFUSION)

+	SANDOZ	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011

ARGININE HYDROCHLORIDEINJECTABLE; INJECTION
R-GENE 10

+	PHARMACIA AND UPJOHN	10GM/100ML	N016931	001	

ARIPIPRAZOLEINJECTABLE; INTRAMUSCULAR
ABILIFY

+	OTSUKA	9.75MG/1.3ML (7.5MG/ML)	N021866	001	Sep 20, 2006

SOLUTION; ORAL
ABILIFY

+	OTSUKA	1MG/ML	N021713	001	Dec 10, 2004

TABLET; ORAL
ABILIFY

	OTSUKA	2MG	N021436	006	Nov 15, 2002
+		5MG	N021436	005	Nov 15, 2002
+		10MG	N021436	001	Nov 15, 2002
		15MG	N021436	002	Nov 15, 2002
		20MG	N021436	003	Nov 15, 2002
		30MG	N021436	004	Nov 15, 2002

TABLET, ORALLY DISINTEGRATING; ORAL
ABILIFY

+	OTSUKA	10MG	N021729	002	Jun 07, 2006
		15MG	N021729	003	Jun 07, 2006

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A200043</u>	<u>001</u>	Jun 01, 2012
<u>AB</u>		<u>150MG</u>	<u>A200043</u>	<u>002</u>	Jun 01, 2012
<u>AB</u>		<u>250MG</u>	<u>A200043</u>	<u>003</u>	Jun 01, 2012

NUVIGIL

<u>AB</u>	CEPHALON	<u>50MG</u>	<u>N021875</u>	<u>001</u>	Jun 15, 2007
<u>AB</u>		<u>150MG</u>	<u>N021875</u>	<u>003</u>	Jun 15, 2007
<u>AB</u>	+	<u>250MG</u>	<u>N021875</u>	<u>004</u>	Jun 15, 2007

ARMODAFINIL

	WATSON LABS INC	100MG	A200156	002	Aug 29, 2012
		200MG	A200156	004	Aug 29, 2012

ARSENIC TRIOXIDEINJECTABLE; INJECTION
TRISENOX

+	CEPHALON	1MG/ML	N021248	001	Sep 25, 2000

ARTEMETHER; LUMEFANTRINETABLET; ORAL
COARTEM

+	NOVARTIS	20MG;120MG	N022268	001	Apr 07, 2009

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

<u>AP</u>	HOSPIRA	<u>4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)</u>	<u>A079138</u>	<u>001</u>	Jun 18, 2010

SEPTOCAINE

<u>AP</u>	+ DEPROCO	<u>4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)</u>	<u>N020971</u>	<u>001</u>	Apr 03, 2000

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 38 (of 428)

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

ARTICAINE HYDROCHLORIDE WITH EPINEPHRINE

PIERREL	4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML)	N022466	001	Feb 26, 2010
+	4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)	N022466	002	Feb 26, 2010
SEPTOCAINE				
+	DEPROCO 4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)	N022010	001	Mar 30, 2006

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

+	SANDOZ	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	001	Feb 21, 2001
	INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)				
+	SANDOZ	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021646	001	Jan 29, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+	HOSPIRA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N018920	001	Sep 21, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 (WITHOUT VITAMIN K)

+	HOSPIRA	20MG/ML;0.006MG/ML;0.05MCG/ML;1.5MG/ML;0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;0.36MG/ML;0.6MG/ML;0.1MG/ML;1MG/ML	N008809	006	Sep 09, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; IV (INFUSION)

M.V.I. ADULT

+	HOSPIRA	200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL	N021625	001	Jan 30, 2004
	M.V.I. ADULT (PHARMACY BULK PACKAGE)				
+	HOSPIRA	200MG/5ML;0.06MG/5ML;0.005MG/5ML;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML	N021643	001	Feb 18, 2004

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM

AA	NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	A090145	001	Jan 25, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 39 (of 428)

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE;
SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

MOVIPREP

AA + SALIX PHARMS 4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM N021881 001 Aug 02, 2006

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

ORGANON SUB MERCK EQ 5MG BASE N022117 001 Aug 13, 2009

+ EQ 10MG BASE N022117 002 Aug 13, 2009

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL

AA + WATSON LABS INC 325MG;50MG;40MG N017534 005 Apr 16, 1986

LANORINAL

AA LANNETT 325MG;50MG;40MG A086996 002 Oct 11, 1985

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA + WEST WARD 325MG;50MG;40MG A086162 002 Feb 16, 1984

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

AB NEXGEN PHARMA INC 325MG;50MG;40MG;30MG A075231 001 Nov 30, 2001

AB STEVENS J 325MG;50MG;40MG;30MG A074951 001 Aug 31, 1998

AB WATSON LABS 325MG;50MG;40MG;30MG A074359 001 Aug 31, 1995

FIORINAL W/CODEINE

AB + WATSON LABS INC 325MG;50MG;40MG;30MG N019429 003 Oct 26, 1990

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC

+ CARACO 356.4MG;30MG;16MG N011483 004 Sep 06, 1983

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

NORGESIC

AB MEDICIS 385MG;30MG;25MG N013416 003 Oct 27, 1982

NORGESIC FORTE

AB + MEDICIS 770MG;60MG;50MG N013416 004 Oct 27, 1982

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

AB SANDOZ 385MG;30MG;25MG A074654 001 Dec 31, 1996

AB 770MG;60MG;50MG A074654 002 Dec 31, 1996

AB STEVENS J 385MG;30MG;25MG A074988 001 Apr 30, 1999

AB 770MG;60MG;50MG A074988 002 Apr 30, 1999

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB HERITAGE PHARMS INC 325MG;200MG A089594 001 Mar 31, 1989

AB MIRROR PHARMS 325MG;200MG A040832 001 Jan 07, 2010

AB PROSAM LABS 325MG;200MG A040252 001 Dec 10, 1997

AB SANDOZ 325MG;200MG A040116 001 Apr 25, 1996

SOMA COMPOUND

AB + MEDA PHARMS 325MG;200MG N012365 005 Jul 11, 1983

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB MIRROR PHARMS 325MG;200MG;16MG A040860 001 Jan 07, 2010

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 40 (of 428)

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

<u>AB</u>	PROSAM LABS	<u>325MG;200MG;16MG</u>	<u>A040283</u>	<u>001</u>	Dec 29, 1998
<u>AB</u>	SANDOZ	<u>325MG;200MG;16MG</u>	<u>A040118</u>	<u>001</u>	Apr 16, 1996
<u>SOMA COMPOUND W/ CODEINE</u>					
<u>AB</u>	+ MEDA PHARMS	<u>325MG;200MG;16MG</u>	<u>N012366</u>	<u>002</u>	Jul 11, 1983

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

AGGRENOX

<u>AB</u>	+ BOEHRINGER INGELHEIM	<u>25MG;200MG</u>	<u>N020884</u>	<u>001</u>	Nov 22, 1999
<u>ASPIRIN AND DIPYRIDAMOLE</u>					
<u>AB</u>	BARR	<u>25MG;200MG</u>	<u>A078804</u>	<u>001</u>	Aug 14, 2009

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

	+ STEVENS J	325MG;400MG	A081145	001	Jan 31, 1995

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

<u>AA</u>	COASTAL PHARMS	<u>325MG;4.8355MG</u>	<u>A091670</u>	<u>001</u>	Mar 16, 2011
<u>AA</u>	WATSON LABS	<u>325MG;4.8355MG</u>	<u>A090084</u>	<u>001</u>	Mar 22, 2011
<u>PERCODAN</u>					
<u>AA</u>	+ ENDO PHARMS	<u>325MG;4.8355MG</u>	<u>N007337</u>	<u>007</u>	Aug 05, 2005

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

	WATSON LABS	325MG;4.5MG;0.38MG	A040255	001	Feb 27, 1998

ATAZANAVIR SULFATE

CAPSULE; ORAL

REYATAZ

	BRISTOL MYERS SQUIBB	EQ 100MG BASE	N021567	001	Jun 20, 2003
		EQ 150MG BASE	N021567	002	Jun 20, 2003
		EQ 200MG BASE	N021567	003	Jun 20, 2003
	+	EQ 300MG BASE	N021567	004	Oct 16, 2006

ATENOLOL

TABLET; ORAL

ATENOLOL

<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078512</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>		<u>50MG</u>	<u>A078512</u>	<u>002</u>	Oct 31, 2007
<u>AB</u>		<u>100MG</u>	<u>A078512</u>	<u>003</u>	Oct 31, 2007
<u>AB</u>	CARACO	<u>25MG</u>	<u>A078210</u>	<u>001</u>	Jul 10, 2007
<u>AB</u>		<u>50MG</u>	<u>A078210</u>	<u>002</u>	Jul 10, 2007
<u>AB</u>		<u>100MG</u>	<u>A078210</u>	<u>003</u>	Jul 10, 2007
<u>AB</u>	DAVA PHARMS INC	<u>25MG</u>	<u>A074099</u>	<u>001</u>	Apr 28, 1992
<u>AB</u>		<u>50MG</u>	<u>A073542</u>	<u>001</u>	Dec 19, 1991
<u>AB</u>		<u>100MG</u>	<u>A073543</u>	<u>001</u>	Dec 19, 1991
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A077877</u>	<u>001</u>	Dec 27, 2006
<u>AB</u>		<u>50MG</u>	<u>A077877</u>	<u>002</u>	Dec 27, 2006
<u>AB</u>		<u>100MG</u>	<u>A077877</u>	<u>003</u>	Dec 27, 2006
<u>AB</u>	IPR	<u>25MG</u>	<u>A073646</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>		<u>50MG</u>	<u>A072303</u>	<u>001</u>	Jul 15, 1988
<u>AB</u>		<u>100MG</u>	<u>A072304</u>	<u>001</u>	Jul 15, 1988
<u>AB</u>	MUTUAL PHARM	<u>25MG</u>	<u>A074499</u>	<u>001</u>	Jul 30, 1997
<u>AB</u>		<u>50MG</u>	<u>A073475</u>	<u>001</u>	Mar 30, 1993
<u>AB</u>		<u>100MG</u>	<u>A073476</u>	<u>001</u>	Mar 30, 1993

PRESCRIPTION DRUG PRODUCT LIST

3 - 41 (of 428)

ATENOLOL

TABLET; ORAL

ATENOLOL

<u>AB</u>	MYLAN	<u>25MG</u>	<u>A073457</u>	<u>002</u>	Apr 26, 1999
<u>AB</u>		<u>25MG</u>	<u>A074126</u>	<u>003</u>	Aug 26, 1998
<u>AB</u>		<u>50MG</u>	<u>A073456</u>	<u>001</u>	Jan 24, 1992
<u>AB</u>		<u>50MG</u>	<u>A074126</u>	<u>001</u>	Mar 23, 1994
<u>AB</u>		<u>100MG</u>	<u>A073457</u>	<u>001</u>	Jan 24, 1992
<u>AB</u>		<u>100MG</u>	<u>A074126</u>	<u>002</u>	Mar 23, 1994
<u>AB</u>	NORTHSTAR HLTHCARE	<u>25MG</u>	<u>A078254</u>	<u>001</u>	Sep 25, 2009
<u>AB</u>		<u>50MG</u>	<u>A078254</u>	<u>002</u>	Sep 25, 2009
<u>AB</u>		<u>100MG</u>	<u>A078254</u>	<u>003</u>	Sep 25, 2009
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A074052</u>	<u>001</u>	May 01, 1992
<u>AB</u>		<u>50MG</u>	<u>A073025</u>	<u>001</u>	Sep 17, 1991
<u>AB</u>		<u>100MG</u>	<u>A073026</u>	<u>001</u>	Sep 17, 1991
<u>AB</u>	TEVA	<u>25MG</u>	<u>A074056</u>	<u>003</u>	Jul 19, 2004
<u>AB</u>		<u>50MG</u>	<u>A074056</u>	<u>001</u>	Jan 18, 1995
<u>AB</u>		<u>100MG</u>	<u>A074056</u>	<u>002</u>	Jan 18, 1995
<u>AB</u>	UNIQUE PHARM LABS	<u>25MG</u>	<u>A077443</u>	<u>001</u>	Sep 13, 2006
<u>AB</u>		<u>50MG</u>	<u>A077443</u>	<u>002</u>	Sep 13, 2006
<u>AB</u>		<u>100MG</u>	<u>A077443</u>	<u>003</u>	Sep 13, 2006
<u>AB</u>	WATSON LABS	<u>50MG</u>	<u>A073352</u>	<u>001</u>	Dec 27, 1991
<u>AB</u>		<u>100MG</u>	<u>A073353</u>	<u>001</u>	Dec 27, 1991
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A076900</u>	<u>001</u>	Jan 28, 2005
<u>AB</u>		<u>50MG</u>	<u>A076900</u>	<u>002</u>	Jan 28, 2005
<u>AB</u>		<u>100MG</u>	<u>A076900</u>	<u>003</u>	Jan 28, 2005
<u>TENORMIN</u>					
<u>AB</u>	ASTRAZENECA	<u>25MG</u>	<u>N018240</u>	<u>004</u>	Apr 09, 1990
<u>AB</u>		<u>50MG</u>	<u>N018240</u>	<u>001</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N018240</u>	<u>002</u>	

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

<u>AB</u>	IPR	<u>50MG; 25MG</u>	<u>A072301</u>	<u>001</u>	May 31, 1990
<u>AB</u>		<u>100MG; 25MG</u>	<u>A072302</u>	<u>001</u>	May 31, 1990
<u>AB</u>	MUTUAL PHARM	<u>50MG; 25MG</u>	<u>A073581</u>	<u>001</u>	Apr 29, 1993
<u>AB</u>		<u>100MG; 25MG</u>	<u>A073582</u>	<u>001</u>	Apr 29, 1993
<u>AB</u>	MYLAN	<u>50MG; 25MG</u>	<u>A074203</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>		<u>100MG; 25MG</u>	<u>A074203</u>	<u>002</u>	Oct 31, 1993
<u>AB</u>	WATSON LABS	<u>50MG; 25MG</u>	<u>A073665</u>	<u>001</u>	Jul 02, 1992
<u>AB</u>		<u>100MG; 25MG</u>	<u>A073665</u>	<u>002</u>	Jul 02, 1992
<u>TENORETIC 100</u>					
<u>AB</u>	+ ASTRAZENECA	<u>100MG; 25MG</u>	<u>N018760</u>	<u>001</u>	Jun 08, 1984
<u>TENORETIC 50</u>					
<u>AB</u>	ASTRAZENECA	<u>50MG; 25MG</u>	<u>N018760</u>	<u>002</u>	Jun 08, 1984

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

STRATTERA

LILLY

+

10MG	N021411	002	Nov 26, 2002
18MG	N021411	003	Nov 26, 2002
25MG	N021411	004	Nov 26, 2002
40MG	N021411	005	Nov 26, 2002
60MG	N021411	006	Nov 26, 2002
80MG	N021411	007	Feb 14, 2005
100MG	N021411	008	Feb 14, 2005

PRESCRIPTION DRUG PRODUCT LIST

3 - 42 (of 428)

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

<u>AB</u>	APOTEX INC	<u>EQ 10MG BASE</u>	<u>A090548</u>	<u>001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090548</u>	<u>002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090548</u>	<u>003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A090548</u>	<u>004</u>	May 29, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A091650</u>	<u>001</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A091650</u>	<u>002</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091650</u>	<u>003</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A202357</u>	<u>001</u>	Jul 17, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A091226</u>	<u>001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A091226</u>	<u>002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091226</u>	<u>003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091226</u>	<u>004</u>	May 29, 2012
<u>AB</u>	RANBAXY LABS LTD	<u>EQ 10MG BASE</u>	<u>A076477</u>	<u>001</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076477</u>	<u>002</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076477</u>	<u>003</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A076477</u>	<u>004</u>	Nov 30, 2011
<u>AB</u>	SANDOZ INC	<u>EQ 10MG BASE</u>	<u>A077575</u>	<u>001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077575</u>	<u>002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077575</u>	<u>003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077575</u>	<u>004</u>	May 29, 2012
<u>LIPITOR</u>					
<u>AB</u>	PFIZER	<u>EQ 10MG BASE</u>	<u>N020702</u>	<u>001</u>	Dec 17, 1996
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>N020702</u>	<u>002</u>	Dec 17, 1996
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>N020702</u>	<u>003</u>	Dec 17, 1996
<u>AB</u>	+	<u>EQ 80MG BASE</u>	<u>N020702</u>	<u>004</u>	Apr 07, 2000

ATOVAQUONE

SUSPENSION; ORAL

MEPRON

+ GLAXOSMITHKLINE LLC 750MG/5ML N020500 001 Feb 08, 1995

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

<u>AB</u>	GLENMARK GENERICS	<u>250MG;100MG</u>	<u>A091211</u>	<u>001</u>	Jan 12, 2011
<u>MALARONE</u>					
<u>AB</u>	+ GLAXOSMITHKLINE	<u>250MG;100MG</u>	<u>N021078</u>	<u>001</u>	Jul 14, 2000
	MALARONE PEDIATRIC				
	GLAXOSMITHKLINE	62.5MG;25MG	N021078	002	Jul 14, 2000

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

<u>AP</u>	+ BEDFORD	<u>10MG/ML</u>	<u>A074901</u>	<u>001</u>	Jul 18, 1997
<u>AP</u>	HOSPIRA INC	<u>10MG/ML</u>	<u>A090761</u>	<u>001</u>	Oct 18, 2012
<u>AP</u>	SAGENT PHARMS	<u>10MG/ML</u>	<u>A091489</u>	<u>001</u>	Feb 17, 2012
<u>ATRACURIUM BESYLATE PRESERVATIVE FREE</u>					
<u>AP</u>	+ BEDFORD	<u>10MG/ML</u>	<u>A074900</u>	<u>001</u>	Jul 18, 1997
<u>AP</u>	HOSPIRA INC	<u>10MG/ML</u>	<u>A090782</u>	<u>001</u>	Oct 18, 2012
<u>AP</u>	SAGENT PHARMS	<u>10MG/ML</u>	<u>A091488</u>	<u>001</u>	Feb 17, 2012

ATROPINE

INJECTABLE; INJECTION

ATROPEN

+	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004
+		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003
+		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003
+		EQ 2MG SULFATE/0.7ML	N017106	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 43 (of 428)

ATROPINE SULFATE

INJECTABLE; IM-IV-SC

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

HOSPIRA 0.05MG/ML

N021146 002 Jul 09, 2001

+ 0.1MG/ML

N021146 001 Jul 09, 2001

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

+ VALEANT 0.025MG;1MG

N017744 002

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATEAA + ROXANE 0.025MG/5ML;2.5MG/5MLA087708 001 May 03, 1982

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATEAA LANNETT 0.025MG;2.5MGA085372 001AA MYLAN 0.025MG;2.5MGA085762 001AA PAR PHARM 0.025MG;2.5MGA040357 001 May 02, 2000LOMOTILAA + GD SEARLE LLC 0.025MG;2.5MGN012462 001LONOXAA SANDOZ 0.025MG;2.5MGA085311 002ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

+ MYLAN INSTITUTIONAL 0.14MG/ML;10MG/ML

N019678 001 Nov 06, 1991

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

DUODOTE

+ MERIDIAN MEDCL 2.1MG/0.7ML;600MG/2ML

N021983 001 Sep 28, 2006

AURANOFIN

CAPSULE; ORAL

RIDAURA

+ PROMETHEUS LABS 3MG

N018689 001 May 24, 1985

AVANAFIL

TABLET; ORAL

STENDRA

VIVUS 50MG

N202276 001 Apr 27, 2012

100MG

N202276 002 Apr 27, 2012

+ 200MG

N202276 003 Apr 27, 2012

AXITINIB

TABLET; ORAL

INLYTA

PFIZER 1MG

N202324 001 Jan 27, 2012

+ 5MG

N202324 002 Jan 27, 2012

AZACITIDINE

INJECTABLE; IV-SC

VIDAZA

+ CELGENE 100MG/VIAL

N050794 001 May 19, 2004

AZATHIOPRINE

TABLET; ORAL

AZASANAB AAIPHARMA LLC 25MGA075252 002 Feb 03, 2003

PRESCRIPTION DRUG PRODUCT LIST

3 - 44 (of 428)

AZATHIOPRINE

TABLET; ORAL

AZASAN

<u>AB</u>	AAIPHARMA LLC	<u>50MG</u>	<u>A075252</u>	<u>001</u>	Jun 07, 1999
<u>AB</u>		<u>75MG</u>	<u>A075252</u>	<u>003</u>	Feb 03, 2003
<u>AB</u>		<u>100MG</u>	<u>A075252</u>	<u>004</u>	Feb 03, 2003

AZATHIOPRINE

<u>AB</u>	MYLAN	<u>50MG</u>	<u>A075568</u>	<u>001</u>	Dec 13, 1999
<u>AB</u>	ROXANE	<u>50MG</u>	<u>A074069</u>	<u>001</u>	Feb 16, 1996
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077621</u>	<u>002</u>	Sep 05, 2008
<u>AB</u>		<u>50MG</u>	<u>A077621</u>	<u>001</u>	Mar 15, 2007
<u>AB</u>		<u>75MG</u>	<u>A077621</u>	<u>003</u>	Sep 05, 2008
<u>AB</u>		<u>100MG</u>	<u>A077621</u>	<u>004</u>	Sep 05, 2008

IMURAN

<u>AB</u>	+ PROMETHEUS LABS	<u>50MG</u>	<u>N016324</u>	<u>001</u>	

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

AZATHIOPRINE SODIUM

	+ BEDFORD	EQ 100MG BASE/VIAL	A074419	001	Mar 31, 1995

AZELAIC ACID

CREAM; TOPICAL

AZELEX

	+ ALLERGAN	20%	N020428	001	Sep 13, 1995

GEL; TOPICAL

FINACEA

	+ BHP DERMATOLOGY	15%	N021470	001	Dec 24, 2002

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

<u>AT</u>	ALCON PHARMA	<u>0.05%</u>	<u>A202305</u>	<u>001</u>	May 31, 2012
<u>AT</u>	APOTEX INC	<u>0.05%</u>	<u>A078621</u>	<u>001</u>	Aug 03, 2009
<u>AT</u>	SUN PHARMA GLOBAL	<u>0.05%</u>	<u>A078738</u>	<u>001</u>	Jun 21, 2010

OPTIVAR

<u>AT</u>	+ MEDA PHARMS	<u>0.05%</u>	<u>N021127</u>	<u>001</u>	May 22, 2000

SPRAY, METERED; NASAL

ASTELIN

<u>AB</u>	+ MEDA PHARMS	<u>EQ 0.125MG BASE/SPRAY</u>	<u>N020114</u>	<u>001</u>	Nov 01, 1996

ASTEPRO

<u>AB</u>	+ MEDA PHARMS	<u>EQ 0.1876MG BASE/SPRAY</u>	<u>N022371</u>	<u>001</u>	Aug 31, 2009

AZELASTINE HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>EQ 0.125MG BASE/SPRAY</u>	<u>A077954</u>	<u>001</u>	Apr 30, 2009
<u>AB</u>		<u>EQ 0.1876MG BASE/SPRAY</u>	<u>A201846</u>	<u>001</u>	Aug 31, 2012
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 0.125MG BASE/SPRAY</u>	<u>A090423</u>	<u>001</u>	May 23, 2012

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

DYMISTA

	+ MEDA PHARMS	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

	TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011

	+	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

	TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 45 (of 428)

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONETABLET; ORAL
EDARBYCLOR

+ TAKEDA PHARMS USA

EQ 40MG MEDOXOMIL;25MG

N202331

002

Dec 20, 2011

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCINAB PLIVAEQ 100MG BASE/5MLA065246002

Jul 05, 2006

ABEQ 200MG BASE/5MLA065246001

Jul 05, 2006

AB TEVA PHARMSEQ 100MG BASE/5MLA065419001

Jun 24, 2008

ABEQ 200MG BASE/5MLA065419002

Jun 24, 2008

ZITHROMAXAB PFIZEREQ 100MG BASE/5MLN050710001

Oct 19, 1995

AB +EQ 200MG BASE/5MLN050710002

Oct 19, 1995

ZITHROMAX

+ PFIZER

EQ 1GM BASE/PACKET

N050693

001

Sep 28, 1994

FOR SUSPENSION, EXTENDED RELEASE; ORAL

ZMAX

+ PFIZER GLOBAL

EQ 2GM BASE/BOT

N050797

001

Jun 10, 2005

INJECTABLE; INJECTION

AZITHROMYCINAP FRESENIUS KABI USAEQ 500MG BASE/VIALA065179001

Dec 13, 2005

AP GLAND PHARMA LTDEQ 500MG BASE/VIALA065501001

Nov 09, 2009

AP HOSPIRAEQ 500MG BASE/VIALA065500001

Jun 26, 2009

APEQ 500MG BASE/VIALA065511001

Jun 26, 2009

AP SAGENT STRIDESEQ 500MG BASE/VIALA065506001

Mar 24, 2009

ZITHROMAXAP + PFIZEREQ 500MG BASE/VIALN050733001

Jan 30, 1997

SOLUTION/DROPS; OPHTHALMIC

+ INSPIRE

1%

N050810

001

Apr 27, 2007

TABLET; ORAL

AZITHROMYCINAB APOTEX CORPEQ 250MG BASEA065507001

Jul 13, 2011

ABEQ 500MG BASEA065509001

Jul 13, 2011

ABEQ 600MG BASEA065508001

Jul 13, 2011

AB MYLANEQ 250MG BASEA065365001

May 30, 2007

ABEQ 500MG BASEA065366001

May 30, 2007

ABEQ 600MG BASEA065360001

Jan 08, 2007

AB PLIVAEQ 250MG BASEA065225001

Nov 14, 2005

ABEQ 500MG BASEA065223001

Nov 14, 2005

ABEQ 600MG BASEA065218001

Nov 14, 2005

AB SANDOZEQ 250MG BASEA065211001

Nov 14, 2005

ABEQ 500MG BASEA065212001

Nov 14, 2005

ABEQ 600MG BASEA065209001

Nov 14, 2005

AB TEVAEQ 250MG BASEA065153001

Nov 14, 2005

ABEQ 500MG BASEA065193001

Nov 14, 2005

ABEQ 600MG BASEA065150001

Nov 14, 2005

AB WOCKHARDTEQ 250MG BASEA065404001

Feb 11, 2008

ABEQ 500MG BASEA065405001

Feb 11, 2008

ABEQ 600MG BASEA065302003

Feb 11, 2008

ZITHROMAXAB PFIZEREQ 250MG BASEN050711001

Jul 18, 1996

ABEQ 500MG BASEN050784001

May 24, 2002

AB +EQ 600MG BASEN050730001

Jun 12, 1996

AZTREONAM

FOR SOLUTION; INHALATION

CAYSTON

+ GILEAD

75MG/VIAL

N050814

001

Feb 22, 2010

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 46 (of 428)

AZTREONAM

INJECTABLE; INJECTION

AZACTAM

<u>AP</u>	+	BRISTOL MYERS SQUIBB	<u>1GM/VIAL</u>	<u>N050580</u>	<u>002</u>	Dec 31, 1986
<u>AP</u>	+		<u>2GM/VIAL</u>	<u>N050580</u>	<u>003</u>	Dec 31, 1986
		<u>AZTREONAM</u>				
<u>AP</u>		BEDFORD	<u>1GM/VIAL</u>	<u>A065286</u>	<u>001</u>	Mar 23, 2011
<u>AP</u>			<u>2GM/VIAL</u>	<u>A065286</u>	<u>002</u>	Mar 23, 2011
<u>AP</u>		FRESENIUS KABI USA	<u>1GM/VIAL</u>	<u>A065439</u>	<u>002</u>	Jun 18, 2010
<u>AP</u>			<u>2GM/VIAL</u>	<u>A065439</u>	<u>003</u>	Jun 18, 2010
		AZACTAM IN PLASTIC CONTAINER				
	+	BRISTOL MYERS SQUIBB	20MG/ML	N050632	002	May 24, 1989
	+		40MG/ML	N050632	001	May 24, 1989
		AZTREONAM				
		FRESENIUS KABI USA	500MG/VIAL	A065439	001	Jun 18, 2010

BACITRACIN

INJECTABLE; INJECTION

BACIIM

<u>AP</u>		X GEN PHARMS	<u>50,000 UNITS/VIAL</u>	<u>A064153</u>	<u>001</u>	May 09, 1997
		<u>BACITRACIN</u>				
<u>AP</u>		FRESENIUS KABI USA	<u>50,000 UNITS/VIAL</u>	<u>A065116</u>	<u>001</u>	Dec 03, 2002
<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>50,000 UNITS/VIAL</u>	<u>A060733</u>	<u>002</u>	
<u>AP</u>		SAGENT STRIDES	<u>50,000 UNITS/VIAL</u>	<u>A090211</u>	<u>001</u>	May 11, 2010
		BACITRACIN				
		PHARMACIA AND UPJOHN	10,000 UNITS/VIAL	A060733	001	
		OINTMENT; OPHTHALMIC				
		BACITRACIN				
	+	FERA PHARMS	500 UNITS/GM	A061212	001	
		POWDER; FOR RX COMPOUNDING				
		BACI-RX				
		X GEN PHARMS	5,000,000 UNITS/BOT	A061580	001	

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

<u>AT</u>		AKORN	<u>400 UNITS/GM;1%;EQ 3.5MG</u> <u>BASE/GM;10,000 UNITS/GM</u>	<u>A065213</u>	<u>001</u>	Jul 25, 2012
<u>AT</u>	+	BAUSCH AND LOMB	<u>400 UNITS/GM;1%;EQ 3.5MG</u> <u>BASE/GM;10,000 UNITS/GM</u>	<u>A064068</u>	<u>001</u>	Oct 30, 1995
		OINTMENT; TOPICAL				
		CORTISPORIN				
	+	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N050168	002	May 04, 1984

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

<u>AT</u>		AKORN	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000</u> <u>UNITS/GM</u>	<u>A065088</u>	<u>001</u>	Feb 06, 2004
<u>AT</u>	+	BAUSCH AND LOMB	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000</u> <u>UNITS/GM</u>	<u>A064064</u>	<u>001</u>	Oct 30, 1995
<u>AT</u>		FERA PHARMS	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000</u> <u>UNITS/GM</u>	<u>A060764</u>	<u>002</u>	

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

<u>AT</u>		AKORN	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A064028</u>	<u>001</u>	Jan 30, 1995
<u>AT</u>	+	BAUSCH AND LOMB	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A064046</u>	<u>001</u>	Jan 26, 1995
<u>AT</u>		FERA PHARMS	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A065022</u>	<u>001</u>	Feb 27, 2002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 47 (of 428)

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

+ FERA PHARMS	400 UNITS/GM;1%;EQ 3.5MG	A062166	002	
	BASE/GM;10,000 UNITS/GM			

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

<u>AP</u>	CNS THERAPS INC	<u>0.05MG/ML</u>	<u>N022462</u>	<u>001</u>	Nov 19, 2010
<u>AP</u>		<u>0.5MG/ML</u>	<u>N022462</u>	<u>002</u>	Nov 19, 2010
<u>AP</u>		<u>2MG/ML</u>	<u>N022462</u>	<u>003</u>	Nov 19, 2010
<u>LIORESAL</u>					
<u>AP</u>	+ MEDTRONIC	<u>0.05MG/ML</u>	<u>N020075</u>	<u>003</u>	Nov 07, 1996
<u>AP</u>	+	<u>0.5MG/ML</u>	<u>N020075</u>	<u>001</u>	Jun 17, 1992
<u>AP</u>	+	<u>2MG/ML</u>	<u>N020075</u>	<u>002</u>	Jun 17, 1992
GABLOFEN					
	CNS THERAPS INC	1MG/ML	N022462	004	Jun 22, 2012

TABLET; ORAL

BACLOFEN

<u>AB</u>	CARACO	<u>10MG</u>	<u>A077984</u>	<u>001</u>	Aug 14, 2006
<u>AB</u>		<u>20MG</u>	<u>A077862</u>	<u>002</u>	Aug 14, 2006
<u>AB</u>	IMPAX LABS	<u>10MG</u>	<u>A078146</u>	<u>001</u>	Oct 26, 2007
<u>AB</u>		<u>20MG</u>	<u>A077971</u>	<u>002</u>	Oct 26, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>10MG</u>	<u>A072234</u>	<u>001</u>	Jul 21, 1988
<u>AB</u>	+	<u>20MG</u>	<u>A072235</u>	<u>001</u>	Jul 21, 1988
<u>AB</u>	LANNETT	<u>10MG</u>	<u>A078220</u>	<u>001</u>	Jul 06, 2007
<u>AB</u>		<u>20MG</u>	<u>A077241</u>	<u>001</u>	Dec 20, 2005
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A077181</u>	<u>001</u>	Jul 29, 2005
<u>AB</u>		<u>20MG</u>	<u>A077121</u>	<u>002</u>	Jul 29, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A090334</u>	<u>001</u>	Feb 18, 2010
<u>AB</u>		<u>20MG</u>	<u>A090334</u>	<u>002</u>	Feb 18, 2010
<u>AB</u>	NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A078504</u>	<u>001</u>	Sep 18, 2009
<u>AB</u>		<u>20MG</u>	<u>A078401</u>	<u>001</u>	Sep 18, 2009
<u>AB</u>	PROSAM LABS	<u>10MG</u>	<u>A077089</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>		<u>20MG</u>	<u>A077088</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>	USL PHARMA	<u>10MG</u>	<u>A074584</u>	<u>001</u>	Aug 19, 1996
<u>AB</u>		<u>20MG</u>	<u>A074584</u>	<u>002</u>	Aug 19, 1996
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A077156</u>	<u>001</u>	Aug 30, 2005
<u>AB</u>		<u>20MG</u>	<u>A077068</u>	<u>001</u>	Aug 30, 2005
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A072824</u>	<u>001</u>	Sep 18, 1991
<u>AB</u>		<u>20MG</u>	<u>A072825</u>	<u>001</u>	Sep 18, 1991

BALSALAZIDE DISODIUM

CAPSULE; ORAL

BALSALAZIDE DISODIUM

<u>AB</u>	APOTEX INC	<u>750MG</u>	<u>A077883</u>	<u>001</u>	Dec 28, 2007
<u>AB</u>	MYLAN	<u>750MG</u>	<u>A077807</u>	<u>001</u>	Dec 28, 2007
<u>AB</u>	ROXANE	<u>750MG</u>	<u>A077806</u>	<u>001</u>	Dec 28, 2007
<u>COLAZAL</u>					
<u>AB</u>	+ SALIX PHARMS	<u>750MG</u>	<u>N020610</u>	<u>001</u>	Jul 18, 2000
TABLET; ORAL					
GIAZO					
	+ SALIX PHARMS	1.1GM	N022205	001	Feb 03, 2012

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

QVAR 40

+ TEVA BRANDED PHARM	0.04MG/INH	N020911	002	Sep 15, 2000

QVAR 80

+ TEVA BRANDED PHARM	0.08MG/INH	N020911	001	Sep 15, 2000

PRESCRIPTION DRUG PRODUCT LIST

3 - 48 (of 428)

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; NASAL
QNASL

+ TEVA BRANDED PHARM	0.08MG/ACTUATION	N202813	001	Mar 23, 2012

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL
BECONASE AQ

+ GLAXOSMITHKLINE	EQ 0.042MG DIPROP/SPRAY	N019389	001	Jul 27, 1987

BEDAQUILINE FUMARATE

TABLET; ORAL
SIRTURO

+ JANSSEN THERAP	EQ 100MG BASE	N204384	001	Dec 28, 2012

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A077128</u>	<u>001</u>	Mar 08, 2006
<u>AB</u>		<u>10MG</u>	<u>A077128</u>	<u>002</u>	Mar 08, 2006
<u>AB</u>		<u>20MG</u>	<u>A077128</u>	<u>003</u>	Mar 08, 2006
<u>AB</u>		<u>40MG</u>	<u>A077128</u>	<u>004</u>	Mar 08, 2006
<u>AB</u>	AUROBINDO PHARMA	<u>10MG</u>	<u>A078212</u>	<u>001</u>	May 22, 2008
<u>AB</u>		<u>20MG</u>	<u>A078212</u>	<u>002</u>	May 22, 2008
<u>AB</u>		<u>40MG</u>	<u>A078212</u>	<u>003</u>	May 22, 2008
<u>AB</u>	BIOKEY	<u>5MG</u>	<u>A076820</u>	<u>001</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A076820</u>	<u>002</u>	Feb 03, 2006
<u>AB</u>		<u>20MG</u>	<u>A076820</u>	<u>003</u>	Feb 03, 2006
<u>AB</u>		<u>40MG</u>	<u>A076820</u>	<u>004</u>	Feb 03, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG</u>	<u>A076333</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076333</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076333</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076333</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076430</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076430</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076430</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076430</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	PRINSTON INC	<u>5MG</u>	<u>A076118</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076118</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076118</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076118</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A076344</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076344</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076344</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076344</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A076402</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076402</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076402</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076402</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076211</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076211</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076211</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076211</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	WATSON LABS FLORIDA	<u>5MG</u>	<u>A076267</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076267</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076267</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076267</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A078848</u>	<u>001</u>	May 23, 2008
<u>AB</u>		<u>10MG</u>	<u>A078848</u>	<u>002</u>	May 23, 2008
<u>AB</u>		<u>20MG</u>	<u>A078848</u>	<u>003</u>	May 23, 2008
<u>AB</u>		<u>40MG</u>	<u>A078848</u>	<u>004</u>	May 23, 2008

PRESCRIPTION DRUG PRODUCT LIST

3 - 49 (of 428)

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

LOTENSIN

<u>AB</u>	US PHARMS HOLDINGS I	<u>5MG</u>	<u>N019851</u>	<u>001</u>	Jun 25, 1991
<u>AB</u>		<u>10MG</u>	<u>N019851</u>	<u>002</u>	Jun 25, 1991
<u>AB</u>		<u>20MG</u>	<u>N019851</u>	<u>003</u>	Jun 25, 1991
<u>AB</u>	+	<u>40MG</u>	<u>N019851</u>	<u>004</u>	Jun 25, 1991

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG; 6.25MG</u>	<u>A076348</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076348</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076348</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076348</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	MYLAN	<u>5MG; 6.25MG</u>	<u>A076688</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076688</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076688</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076688</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	RANBAXY	<u>5MG; 6.25MG</u>	<u>A077483</u>	<u>001</u>	Sep 08, 2005
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A077483</u>	<u>002</u>	Sep 08, 2005
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A077483</u>	<u>003</u>	Sep 08, 2005
<u>AB</u>		<u>20MG; 25MG</u>	<u>A077483</u>	<u>004</u>	Sep 08, 2005
<u>AB</u>	SANDOZ	<u>5MG; 6.25MG</u>	<u>A076631</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076631</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076631</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076631</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	WATSON LABS FLORIDA	<u>5MG; 6.25MG</u>	<u>A076342</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076342</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076342</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076342</u>	<u>004</u>	Feb 11, 2004
	<u>LOTENSIN HCT</u>				
<u>AB</u>	US PHARMS HOLDINGS I	<u>5MG; 6.25MG</u>	<u>N020033</u>	<u>001</u>	May 19, 1992
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>N020033</u>	<u>002</u>	May 19, 1992
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>N020033</u>	<u>004</u>	May 19, 1992
<u>AB</u>	+	<u>20MG; 25MG</u>	<u>N020033</u>	<u>003</u>	May 19, 1992

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

+	CEPHALON	25MG/VIAL	N022249	002	May 01, 2009
+		100MG/VIAL	N022249	001	Mar 20, 2008

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

CORZIDE

<u>AB</u>	KING PHARMS	<u>5MG; 40MG</u>	<u>N018647</u>	<u>001</u>	May 25, 1983
<u>AB</u>	+	<u>5MG; 80MG</u>	<u>N018647</u>	<u>002</u>	May 25, 1983

NADOLOL AND BENDROFLUMETHIAZIDE

<u>AB</u>	MYLAN	<u>5MG; 40MG</u>	<u>A078688</u>	<u>001</u>	Feb 15, 2008
<u>AB</u>		<u>5MG; 80MG</u>	<u>A078688</u>	<u>002</u>	Feb 15, 2008

NADOLOL AND BENDROFLUMETHIAZIDE

<u>AB</u>	IMPAX LABS	<u>5MG; 40MG</u>	<u>A077833</u>	<u>001</u>	Mar 30, 2007
<u>AB</u>		<u>5MG; 80MG</u>	<u>A077833</u>	<u>002</u>	Mar 30, 2007

BENZONATATE

CAPSULE; ORAL

BENZONATATE

<u>AA</u>	BANNER PHARMACAPS	<u>100MG</u>	<u>A081297</u>	<u>001</u>	Jan 29, 1993
<u>AA</u>		<u>200MG</u>	<u>A081297</u>	<u>002</u>	Oct 30, 2007
<u>AA</u>	MIKART	<u>100MG</u>	<u>A040851</u>	<u>001</u>	Nov 09, 2009

PRESCRIPTION DRUG PRODUCT LIST

3 - 50 (of 428)

BENZONATATE

CAPSULE; ORAL

BENZONATATE

<u>AA</u>	MIKART	<u>200MG</u>	<u>A040851</u>	<u>003</u>	Nov 09, 2009
<u>AA</u>	ORIT LABS LLC	<u>100MG</u>	<u>A040682</u>	<u>001</u>	Jul 30, 2007
<u>AA</u>		<u>200MG</u>	<u>A040682</u>	<u>002</u>	Jul 30, 2007
<u>AA</u>	SUN PHARM INDS INC	<u>100MG</u>	<u>A040587</u>	<u>001</u>	Mar 19, 2008
<u>AA</u>		<u>200MG</u>	<u>A040587</u>	<u>002</u>	Mar 19, 2008
<u>AA</u>	THE PHARMA NETWORK	<u>100MG</u>	<u>A040627</u>	<u>001</u>	Mar 30, 2007
<u>AA</u>		<u>200MG</u>	<u>A040749</u>	<u>001</u>	Jul 25, 2007
<u>AA</u>	ZYDUS PHARMS USA	<u>100MG</u>	<u>A040597</u>	<u>001</u>	Jun 08, 2007
<u>AA</u>		<u>200MG</u>	<u>A040597</u>	<u>002</u>	Jun 08, 2007

TESSALON

<u>AA</u>	+ PFIZER	<u>100MG</u>	<u>N011210</u>	<u>001</u>	
<u>AA</u>		<u>200MG</u>	<u>N011210</u>	<u>003</u>	Jun 25, 1999
	BENZONATATE				
	MIKART	150MG	A040851	002	Nov 09, 2009

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

<u>AB</u>	VALEANT INTL	<u>5%;EQ 1% BASE</u>	<u>N050756</u>	<u>001</u>	Dec 21, 2000
	<u>CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE</u>				
<u>AB</u>	MYLAN PHARMS INC	<u>5%;EQ 1% BASE</u>	<u>A065443</u>	<u>001</u>	Aug 11, 2009
<u>AB</u>	PERRIGO ISRAEL	<u>5%;1.2%</u>	<u>A090979</u>	<u>001</u>	Jun 26, 2012
	<u>DUAC</u>				
<u>AB</u>	+ STIEFEL	<u>5%;1.2%</u>	<u>N050741</u>	<u>001</u>	Aug 26, 2002
	BENZACLIN				
BT	+ VALEANT INTL	5%;EQ 1% BASE	N050756	002	Apr 20, 2007
	ACANYA				
	+ DOW PHARM SCI	2.5%;1.2%	N050819	001	Oct 23, 2008

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

<u>AB</u>	+ VALEANT INTL	<u>5%;3%</u>	<u>N050557</u>	<u>001</u>	Oct 26, 1984
	<u>ERYTHROMYCIN AND BENZOYL PEROXIDE</u>				
<u>AB</u>	TOLMAR	<u>5%;3%</u>	<u>A065112</u>	<u>001</u>	Mar 29, 2004
	BENZAMYCIN PAK				
	+ VALEANT INTL	5%;3%	N050769	001	Nov 27, 2000

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

<u>AA</u>	COREPHARMA	<u>50MG</u>	<u>A040714</u>	<u>001</u>	Oct 29, 2007
<u>AA</u>	EMCURE PHARMS LTD	<u>50MG</u>	<u>A202061</u>	<u>001</u>	Jan 27, 2012
<u>AA</u>	IMPAX LABS	<u>50MG</u>	<u>A040845</u>	<u>001</u>	Nov 18, 2008
<u>AA</u>	KVK TECH	<u>50MG</u>	<u>A090968</u>	<u>001</u>	Jul 20, 2010
<u>AA</u>	MALLINCKRODT INC	<u>50MG</u>	<u>A040773</u>	<u>001</u>	Apr 25, 2007
<u>AA</u>	MIKART	<u>25MG</u>	<u>A090473</u>	<u>001</u>	Sep 15, 2010
<u>AA</u>		<u>50MG</u>	<u>A090473</u>	<u>002</u>	Sep 15, 2010
<u>AA</u>	PADDOCK	<u>50MG</u>	<u>A040578</u>	<u>001</u>	Apr 17, 2006
<u>AA</u>	TEDOR PHARM	<u>50MG</u>	<u>A040747</u>	<u>001</u>	Mar 30, 2007

DIDREX

<u>AA</u>	+ PHARMACIA AND UPJOHN	<u>50MG</u>	<u>N012427</u>	<u>002</u>	

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

<u>AP</u>	FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A090233</u>	<u>001</u>	Jul 28, 2009
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A090287</u>	<u>001</u>	Aug 31, 2009
<u>AP</u>	LUITPOLD	<u>1MG/ML</u>	<u>A091152</u>	<u>001</u>	Mar 29, 2010

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 51 (of 428)

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

COGENTIN

AP + OAK PHARMS AKORN

1MG/MLN012015001

TABLET; ORAL

BENZTROPINE MESYLATE

AA COREPHARMA

0.5MGA072264001

Feb 27, 1989

AA

1MGA072265001

Feb 27, 1989

AA

2MGA072266001

Feb 27, 1989

AA

EXCELLIUM

0.5MGA090168001

Nov 28, 2012

AA

1MGA090168002

Nov 28, 2012

AA

2MGA090168003

Nov 28, 2012

AA

INVAGEN PHARMS

0.5MGA090294001

Mar 29, 2010

AA

1MGA090294002

Mar 29, 2010

AA

2MGA090294003

Mar 29, 2010

AA

PLIVA

0.5MGA089058001

Aug 10, 1988

AA

1MGA089059001

Aug 10, 1988

AA

2MGA089060001

Aug 10, 1988

AA

PROSAM LABS

0.5MGA040699001

Feb 14, 2008

AA

1MGA040705001

Feb 14, 2008

AA

2MGA040706001

Feb 14, 2008

AA

+ USL PHARMA

0.5MGA040103001

Dec 12, 1996

AA

+

1MGA040103002

Dec 12, 1996

AA

+

2MGA040103003

Dec 12, 1996

AA

VINTAGE

0.5MGA040738001

Aug 27, 2007

AA

1MGA040742001

Aug 27, 2007

AA

2MGA040715003

Aug 27, 2007

BENZYL ALCOHOL

LOTION; TOPICAL

ULESFIA

+ SHIONOGI INC

5%

N022129

001

Apr 09, 2009

BENZYL PENICILLOYL POLYLYSINE

INJECTABLE; INJECTION

PRE-PEN

+ ALLERQUEST

60UMOLAR

N050114

001

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPREVE

+ ISTA PHARMS

1.5%

N022288

001

Sep 08, 2009

BERACTANT

SUSPENSION; INTRATRACHEAL

SURVANTA

+ ABBVIE

25MG/ML

N020032

001

Jul 01, 1991

BESIFLOXACIN HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

+ BAUSCH AND LOMB

EQ 0.6% BASE

N022308

001

May 28, 2009

BETAINE HYDROCHLORIDE

FOR SOLUTION; ORAL

CYSTADANE

+ RARE DIS THERAP

1GM/SCOOPFUL

N020576

001

Oct 25, 1996

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

AB LUITPOLD

3MG/ML;EQ 3MG BASE/MLA090747001

Jul 31, 2009

PRESCRIPTION DRUG PRODUCT LIST

3 - 52 (of 428)

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

CELESTONE SOLUSPAN

<u>AB</u>	+ SCHERING	<u>3MG/ML;EQ 3MG BASE/ML</u>	<u>N014602</u>	<u>001</u>

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE</u>	<u>A070885</u>	<u>001</u>	Feb 03, 1987
<u>AB</u>	+ FOUGERA PHARMS	<u>EQ 0.05% BASE</u>	<u>N019137</u>	<u>001</u>	Jun 26, 1984
<u>AB</u>	TARO	<u>EQ 0.05% BASE</u>	<u>A073552</u>	<u>001</u>	Apr 30, 1992

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	FOUGERA PHARMS	<u>EQ 0.05% BASE</u>	<u>A076215</u>	<u>001</u>	Dec 09, 2003
<u>AB</u>	GLENMARK GENERICS	<u>EQ 0.05% BASE</u>	<u>A078930</u>	<u>001</u>	Sep 23, 2008
<u>AB</u>	PERRIGO NEW YORK	<u>EQ 0.05% BASE</u>	<u>A076592</u>	<u>001</u>	Dec 09, 2003
<u>AB</u>	TARO	<u>EQ 0.05% BASE</u>	<u>A076543</u>	<u>001</u>	Dec 09, 2003
<u>AB</u>	TOLMAR	<u>EQ 0.05% BASE</u>	<u>A076603</u>	<u>001</u>	Jan 23, 2004

DIPROLENE AF

<u>AB</u>	+ MERCK SHARP DOHME	<u>EQ 0.05% BASE</u>	<u>N019555</u>	<u>001</u>	Apr 27, 1987

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	+ FOUGERA PHARMS	<u>EQ 0.05% BASE</u>	<u>A075276</u>	<u>001</u>	May 13, 2003
<u>AB</u>	TARO	<u>EQ 0.05% BASE</u>	<u>A076508</u>	<u>001</u>	Dec 02, 2003

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE</u>	<u>A070281</u>	<u>001</u>	Jul 31, 1985
<u>AB</u>	+ FOUGERA	<u>EQ 0.05% BASE</u>	<u>A070275</u>	<u>001</u>	Aug 12, 1985
<u>AB</u>	PERRIGO NEW YORK	<u>EQ 0.05% BASE</u>	<u>A072538</u>	<u>001</u>	Jan 31, 1990
<u>AB</u>	TEVA	<u>EQ 0.05% BASE</u>	<u>A071467</u>	<u>001</u>	Aug 10, 1987

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	FOUGERA PHARMS	<u>EQ 0.05% BASE</u>	<u>A077111</u>	<u>001</u>	May 21, 2007
<u>AB</u>	TARO	<u>EQ 0.05% BASE</u>	<u>A077477</u>	<u>001</u>	May 21, 2007

DIPROLENE

<u>AB</u>	+ MERCK SHARP DOHME	<u>EQ 0.05% BASE</u>	<u>N019716</u>	<u>001</u>	Aug 01, 1988

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE</u>	<u>A071012</u>	<u>001</u>	Feb 03, 1987
<u>AB</u>	+ FOUGERA	<u>EQ 0.05% BASE</u>	<u>N019141</u>	<u>001</u>	Sep 04, 1984
<u>AB</u>	TARO	<u>EQ 0.05% BASE</u>	<u>A074271</u>	<u>001</u>	Sep 15, 1994

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE</u>	<u>A074304</u>	<u>001</u>	Aug 31, 1995
<u>AB</u>	FOUGERA PHARMS	<u>EQ 0.05% BASE</u>	<u>A075373</u>	<u>001</u>	Jun 22, 1999
<u>AB</u>	TARO	<u>EQ 0.05% BASE</u>	<u>A076753</u>	<u>001</u>	Oct 12, 2004

DIPROLENE

<u>AB</u>	+ MERCK SHARP DOHME	<u>EQ 0.05% BASE</u>	<u>N018741</u>	<u>001</u>	Jul 27, 1983

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

<u>AB</u>	TOLMAR	<u>0.064%;0.005%</u>	<u>A201615</u>	<u>001</u>	Jan 14, 2013

TACLONEX

<u>AB</u>	+ LEO PHARMA AS	<u>0.064%;0.005%</u>	<u>N021852</u>	<u>001</u>	Jan 09, 2006

SUSPENSION; TOPICAL

TACLONEX

	+ LEO PHARM	0.064%;0.005%	N022185	001	May 09, 2008

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 53 (of 428)

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE;1%</u>	<u>A076002</u>	<u>001</u>	Aug 02, 2002
<u>AB</u>	FOUGERA PHARMS	<u>EQ 0.05% BASE;1%</u>	<u>A075502</u>	<u>001</u>	Jun 05, 2001
<u>AB</u>	TARO	<u>EQ 0.05% BASE;1%</u>	<u>A075673</u>	<u>001</u>	May 29, 2001

LOTTRISONE

<u>AB</u>	+ MERCK SHARP DOHME	<u>EQ 0.05% BASE;1%</u>	<u>N018827</u>	<u>001</u>	Jul 10, 1984

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

<u>AB</u>	FOUGERA PHARMS	<u>EQ 0.05% BASE;1%</u>	<u>A076516</u>	<u>001</u>	Jun 16, 2005
<u>AB</u>	TARO	<u>EQ 0.05% BASE;1%</u>	<u>A076493</u>	<u>001</u>	Jul 28, 2004

LOTTRISONE

<u>AB</u>	+ SCHERING CORP	<u>EQ 0.05% BASE;1%</u>	<u>N020010</u>	<u>001</u>	Dec 08, 2000

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

BETAMETHASONE VALERATE

<u>AB</u>	PERRIGO	<u>EQ 0.12% BASE</u>	<u>A078337</u>	<u>001</u>	Nov 26, 2012
<u>AB</u>	+ STIEFEL	<u>EQ 0.12% BASE</u>	<u>N020934</u>	<u>001</u>	Feb 28, 1999

CREAM; TOPICAL

BETAMETHASONE VALERATE

<u>AB</u>	+ FOUGERA	<u>EQ 0.1% BASE</u>	<u>N018861</u>	<u>001</u>	Aug 31, 1983

BETA-VAL

<u>AB</u>	TEVA	<u>EQ 0.1% BASE</u>	<u>N018642</u>	<u>001</u>	Mar 24, 1983

DERMABET

<u>AB</u>	TARO	<u>EQ 0.1% BASE</u>	<u>A072041</u>	<u>001</u>	Jan 06, 1988

VALNAC

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>EQ 0.1% BASE</u>	<u>A070050</u>	<u>001</u>	Oct 10, 1984

LOTION; TOPICAL

BETAMETHASONE VALERATE

<u>AB</u>	+ FOUGERA	<u>EQ 0.1% BASE</u>	<u>N018866</u>	<u>001</u>	Aug 31, 1983
<u>AB</u>	STI PHARMA LLC	<u>EQ 0.1% BASE</u>	<u>A070052</u>	<u>001</u>	Jul 31, 1985

BETA-VAL

<u>AB</u>	TEVA	<u>EQ 0.1% BASE</u>	<u>A070072</u>	<u>001</u>	Jun 27, 1985

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>EQ 0.1% BASE</u>	<u>A070051</u>	<u>001</u>	Oct 10, 1984
<u>AB</u>	+ FOUGERA	<u>EQ 0.1% BASE</u>	<u>N018865</u>	<u>001</u>	Aug 31, 1983

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

<u>AT</u>	AKORN	<u>EQ 0.5% BASE</u>	<u>A075386</u>	<u>001</u>	Jun 30, 2000
<u>AT</u>	BAUSCH AND LOMB	<u>EQ 0.5% BASE</u>	<u>A075630</u>	<u>001</u>	Apr 12, 2001
<u>AT</u>	NOVEX	<u>EQ 0.5% BASE</u>	<u>A075446</u>	<u>001</u>	Sep 28, 2000
<u>AT</u>	WOCKHARDT	<u>EQ 0.5% BASE</u>	<u>A078694</u>	<u>001</u>	Nov 16, 2009

BETOPTIC

<u>AT</u>	+ ALCON	<u>EQ 0.5% BASE</u>	<u>N019270</u>	<u>001</u>	Aug 30, 1985

SUSPENSION/DROPS; OPHTHALMIC

+ ALCON

EQ 0.25% BASE

N019845 001 Dec 29, 1989

TABLET; ORAL

BETAXOLOL HYDROCHLORIDE

<u>AB</u>	EPIC PHARMA	<u>10MG</u>	<u>A075541</u>	<u>001</u>	Oct 22, 1999
<u>AB</u>	+	<u>20MG</u>	<u>A075541</u>	<u>002</u>	Oct 22, 1999
<u>AB</u>	KVK TECH	<u>10MG</u>	<u>A078962</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>		<u>20MG</u>	<u>A078962</u>	<u>002</u>	Jun 27, 2008

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 54 (of 428)

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

<u>AA</u>	AMNEAL PHARM	<u>5MG</u>	<u>A040855</u>	<u>001</u>	Nov 21, 2007
<u>AA</u>		<u>10MG</u>	<u>A040855</u>	<u>002</u>	Nov 21, 2007
<u>AA</u>		<u>25MG</u>	<u>A040855</u>	<u>003</u>	Nov 21, 2007
<u>AA</u>		<u>50MG</u>	<u>A040855</u>	<u>004</u>	Nov 21, 2007
<u>AA</u>	EMCURE USA	<u>5MG</u>	<u>A091256</u>	<u>001</u>	May 04, 2010
<u>AA</u>		<u>10MG</u>	<u>A091256</u>	<u>002</u>	May 04, 2010
<u>AA</u>		<u>25MG</u>	<u>A091256</u>	<u>003</u>	May 04, 2010
<u>AA</u>		<u>50MG</u>	<u>A091256</u>	<u>004</u>	May 04, 2010
<u>AA</u>	IMPAX LABS	<u>5MG</u>	<u>A040739</u>	<u>001</u>	Nov 01, 2006
<u>AA</u>		<u>10MG</u>	<u>A040741</u>	<u>001</u>	Nov 01, 2006
<u>AA</u>		<u>25MG</u>	<u>A040740</u>	<u>001</u>	Nov 01, 2006
<u>AA</u>		<u>50MG</u>	<u>A040721</u>	<u>004</u>	Nov 01, 2006
<u>AA</u>	LANNETT	<u>5MG</u>	<u>A040703</u>	<u>001</u>	Mar 27, 2008
<u>AA</u>		<u>10MG</u>	<u>A040704</u>	<u>001</u>	Mar 27, 2008
<u>AA</u>		<u>25MG</u>	<u>A040678</u>	<u>003</u>	Mar 27, 2008
<u>AA</u>		<u>50MG</u>	<u>A040677</u>	<u>001</u>	Mar 27, 2008
<u>AA</u>	PHARMAX	<u>5MG</u>	<u>A040725</u>	<u>001</u>	Oct 26, 2007
<u>AA</u>		<u>10MG</u>	<u>A040726</u>	<u>001</u>	Oct 26, 2007
<u>AA</u>		<u>25MG</u>	<u>A040727</u>	<u>001</u>	Oct 26, 2007
<u>AA</u>		<u>50MG</u>	<u>A040728</u>	<u>001</u>	Oct 26, 2007
<u>AA</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A040897</u>	<u>001</u>	Apr 22, 2009
<u>AA</u>		<u>10MG</u>	<u>A040897</u>	<u>002</u>	Apr 22, 2009
<u>AA</u>		<u>25MG</u>	<u>A040897</u>	<u>003</u>	Apr 22, 2009
<u>AA</u>		<u>50MG</u>	<u>A040897</u>	<u>004</u>	Apr 22, 2009
<u>AA</u>	UPSHER SMITH	<u>5MG</u>	<u>A040633</u>	<u>001</u>	Jun 01, 2005
<u>AA</u>		<u>10MG</u>	<u>A040634</u>	<u>001</u>	Jun 01, 2005
<u>AA</u>		<u>25MG</u>	<u>A040635</u>	<u>001</u>	Jun 01, 2005
<u>AA</u>		<u>50MG</u>	<u>A040636</u>	<u>001</u>	Jun 01, 2005
<u>AA</u>	WOCKHARDT	<u>5MG</u>	<u>A040532</u>	<u>001</u>	Sep 29, 2003
<u>AA</u>		<u>10MG</u>	<u>A040533</u>	<u>001</u>	Sep 29, 2003
<u>AA</u>		<u>25MG</u>	<u>A040534</u>	<u>001</u>	Sep 29, 2003
<u>AA</u>		<u>50MG</u>	<u>A040518</u>	<u>001</u>	Sep 29, 2003
<u>DUVOID</u>					
<u>AA</u>	WELLSPRING PHARM	<u>10MG</u>	<u>A086262</u>	<u>001</u>	
<u>AA</u>		<u>25MG</u>	<u>A086263</u>	<u>001</u>	
<u>AA</u>		<u>50MG</u>	<u>A085882</u>	<u>003</u>	
<u>URECHOLINE</u>					
<u>AA</u>	+ ODYSSEY PHARMS	<u>5MG</u>	<u>A089095</u>	<u>001</u>	Dec 19, 1985
<u>AA</u>	+	<u>10MG</u>	<u>A088440</u>	<u>001</u>	May 29, 1984
<u>AA</u>	+	<u>25MG</u>	<u>A088441</u>	<u>001</u>	May 29, 1984
<u>AA</u>	+	<u>50MG</u>	<u>A089096</u>	<u>001</u>	Dec 19, 1985

BEXAROTENE

CAPSULE; ORAL

TARGRETIN

+ EISAI INC 75MG N021055 001 Dec 29, 1999

GEL; TOPICAL

TARGRETIN

+ EISAI INC 1% N021056 001 Jun 28, 2000

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

<u>AB</u>	ACCORD HLTHCARE INC	<u>50MG</u>	<u>A078917</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>	ACTAVIS TOTOWA	<u>50MG</u>	<u>A078634</u>	<u>001</u>	Aug 28, 2009
<u>AB</u>	FRESENIUS KABI ONCOL	<u>50MG</u>	<u>A079045</u>	<u>001</u>	May 13, 2010
<u>AB</u>	KUDCO IRELAND	<u>50MG</u>	<u>A077995</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A079185</u>	<u>001</u>	Jul 06, 2009

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 55 (of 428)

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

<u>AB</u>	ROXANE	<u>50MG</u>	<u>A078285</u>	<u>001</u>	Mar 24, 2011
<u>AB</u>	SANDOZ	<u>50MG</u>	<u>A078575</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>	SUN PHARMA GLOBAL	<u>50MG</u>	<u>A079110</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>	SYNTHON PHARMS	<u>50MG</u>	<u>A077973</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>	TEVA	<u>50MG</u>	<u>A076932</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A079089</u>	<u>001</u>	Jul 06, 2009

CASODEX

<u>AB</u>	+ ASTRAZENECA	<u>50MG</u>	<u>N020498</u>	<u>001</u>	Oct 04, 1995

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

LUMIGAN

	+ ALLERGAN	0.01%	N022184	001	Aug 31, 2010
	+	0.03%	N021275	001	Mar 16, 2001

SOLUTION/DROPS; TOPICAL

	+ ALLERGAN	0.03%	N022369	001	Dec 24, 2008

BIPERIDEN HYDROCHLORIDE

TABLET; ORAL

AKINETON

	+ ABBVIE	2MG	N012003	001	

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; TABLET, DELAYED RELEASE; ORAL

HALFLYTELY

	+ BRAINTREE	5MG, N/A; N/A, 210GM; N/A, 0.74GM; N/A, 2.86GM ; N/A, 5.6GM	N021551	003	Jul 16, 2010

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL

PYLERA

	+ APTALIS PHARMA US	140MG; 125MG; 125MG	N050786	001	Sep 28, 2006

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HELIDAC

	+ PROMETHEUS LABS	262.4MG, N/A, N/A; N/A, 250MG, N/A; N/A, N/A, 5 00MG	N050719	001	Aug 15, 1996

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A077910</u>	<u>001</u>	Dec 27, 2006
<u>AB</u>		<u>10MG</u>	<u>A077910</u>	<u>002</u>	Dec 27, 2006
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A075831</u>	<u>001</u>	Dec 14, 2005
<u>AB</u>		<u>10MG</u>	<u>A075831</u>	<u>002</u>	Dec 14, 2005
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A075643</u>	<u>001</u>	Nov 16, 2000
<u>AB</u>		<u>10MG</u>	<u>A075643</u>	<u>002</u>	Nov 16, 2000
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A075644</u>	<u>001</u>	Jun 26, 2001
<u>AB</u>		<u>10MG</u>	<u>A075644</u>	<u>002</u>	Jun 26, 2001
<u>AB</u>	UNICHEM PHARMS (USA)	<u>5MG</u>	<u>A078635</u>	<u>001</u>	Aug 18, 2009
<u>AB</u>		<u>10MG</u>	<u>A078635</u>	<u>002</u>	Aug 18, 2009
<u>ZEBETA</u>					
<u>AB</u>	TEVA WOMENS	<u>5MG</u>	<u>N019982</u>	<u>002</u>	Jul 31, 1992
<u>AB</u>	+	<u>10MG</u>	<u>N019982</u>	<u>001</u>	Jul 31, 1992

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 56 (of 428)

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	MYLAN	<u>2.5MG;6.25MG</u>	<u>A075768</u>	<u>001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG;6.25MG</u>	<u>A075768</u>	<u>002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG;6.25MG</u>	<u>A075768</u>	<u>003</u>	Sep 25, 2000
<u>AB</u>	SANDOZ	<u>2.5MG;6.25MG</u>	<u>A075579</u>	<u>001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG;6.25MG</u>	<u>A075579</u>	<u>002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG;6.25MG</u>	<u>A075579</u>	<u>003</u>	Sep 25, 2000
<u>AB</u>	UNICHEM	<u>2.5MG;6.25MG</u>	<u>A079106</u>	<u>001</u>	Jul 28, 2010
<u>AB</u>		<u>5MG;6.25MG</u>	<u>A079106</u>	<u>002</u>	Jul 28, 2010
<u>AB</u>		<u>10MG;6.25MG</u>	<u>A079106</u>	<u>003</u>	Jul 28, 2010
<u>AB</u>	WATSON LABS	<u>2.5MG;6.25MG</u>	<u>A075469</u>	<u>001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG;6.25MG</u>	<u>A075469</u>	<u>002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG;6.25MG</u>	<u>A075469</u>	<u>003</u>	Sep 25, 2000
	<u>ZIAC</u>				
<u>AB</u>	TEVA WOMENS	<u>2.5MG;6.25MG</u>	<u>N020186</u>	<u>003</u>	Mar 26, 1993
<u>AB</u>		<u>5MG;6.25MG</u>	<u>N020186</u>	<u>001</u>	Mar 26, 1993
<u>AB</u>	+	<u>10MG;6.25MG</u>	<u>N020186</u>	<u>002</u>	Mar 26, 1993

BIVALIRUDININJECTABLE; INTRAVENOUS
ANGIOMAX

+ MEDICINES CO 250MG/VIAL N020873 001 Dec 15, 2000

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

<u>AP</u>	BEDFORD	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065042</u>	<u>002</u>	Oct 17, 2001
<u>AP</u>		<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065042</u>	<u>001</u>	Oct 17, 2001
<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065185</u>	<u>001</u>	Jan 28, 2008
<u>AP</u>	+	<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065185</u>	<u>002</u>	Jan 28, 2008
<u>AP</u>	HOSPIRA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065031</u>	<u>001</u>	Mar 10, 2000
<u>AP</u>		<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065031</u>	<u>002</u>	Mar 10, 2000
<u>AP</u>	PHARMACHEMIE BV	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065201</u>	<u>001</u>	Dec 13, 2007
<u>AP</u>	TEVA PARENTERAL	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065033</u>	<u>001</u>	Jun 27, 2000
<u>AP</u>		<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065033</u>	<u>002</u>	Jun 27, 2000

BOCEPREVIRCAPSULE; ORAL
VICTRELIS

+ MERCK SHARP DOHME 200MG N202258 001 May 13, 2011

BORTEZOMIBINJECTABLE; INTRAVENOUS, SUBCUTANEOUS
VELCADE

+ MILLENNIUM PHARMS 3.5MG/VIAL N021602 001 May 13, 2003

BOSENTANTABLET; ORAL
TRACLEER

ACTELION PHARMS LTD	62.5MG	N021290	001	Nov 20, 2001
+	125MG	N021290	002	Nov 20, 2001

BOSUTINIB MONOHYDRATETABLET; ORAL
BOSULIF

WYETH PHARMS INC	EQ 100MG BASE	N203341	001	Sep 04, 2012
+	EQ 500MG BASE	N203341	002	Sep 04, 2012

PRESCRIPTION DRUG PRODUCT LIST

3 - 57 (of 428)

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+	B BRAUN	100MG/100ML	N019121	001	Apr 29, 1986
+		200MG/100ML	N019121	002	Apr 29, 1986
+		400MG/100ML	N019121	003	Apr 29, 1986

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN P

<u>AT</u>	+	ALLERGAN	0.15%	N021262	001	Mar 16, 2001
		<u>BRIMONIDINE TARTRATE</u>				
<u>AT</u>		AKORN	0.2%	A076439	001	Mar 14, 2006
<u>AT</u>		ALCON PHARMS LTD	0.15%	N021764	001	May 22, 2006
<u>AT</u>			0.2%	A076254	001	Sep 16, 2003
<u>AT</u>	+	BAUSCH AND LOMB	0.2%	A076260	001	May 28, 2003
<u>AT</u>		SANDOZ	0.2%	A078075	001	Jan 30, 2008
		ALPHAGAN P				
	+	ALLERGAN	0.1%	N021770	001	Aug 19, 2005

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COMBIGAN

+	ALLERGAN	0.2%;0.5%	N021398	001	Oct 30, 2007

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

+	ALCON PHARMS LTD	1%	N020816	001	Apr 01, 1998

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMFENAC SODIUM

<u>AT</u>	COASTAL PHARMS	0.09%	A201211	001	May 11, 2011	
<u>AT</u>	PHARMAFORCE	0.09%	A202030	001	Jan 09, 2013	
	BROMDAY					
	+	ISTA PHARMS INC	0.09%	N021664	002	Oct 16, 2010

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

BROMOCRIPTINE MESYLATE

<u>AB</u>	MYLAN	EQ 5MG BASE	A077226	001	Apr 04, 2005	
<u>AB</u>	ZYDUS PHARMS USA INC	EQ 5MG BASE	A078899	001	Jul 30, 2008	
	<u>PARLODEL</u>					
<u>AB</u>	+	US PHARMS HOLDINGS I	EQ 5MG BASE	N017962	002	Mar 01, 1982

TABLET; ORAL

BROMOCRIPTINE MESYLATE

<u>AB</u>	LEK PHARMS	EQ 2.5MG BASE	A074631	001	Jan 13, 1998	
<u>AB</u>	MYLAN	EQ 2.5MG BASE	A076962	001	Sep 24, 2004	
<u>AB</u>	PADDOCK LLC	EQ 2.5MG BASE	A077646	001	Oct 01, 2008	
	<u>PARLODEL</u>					
<u>AB</u>	+	US PHARMS HOLDINGS I	EQ 2.5MG BASE	N017962	001	
		CYCLOSET				
	+	VEROSCIENCE	EQ 0.8MG BASE	N020866	001	May 05, 2009

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMFED-DM

+	WOCKHARDT	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 58 (of 428)

BUDESONIDE

CAPSULE; ORAL

BUDESONIDE

<u>AB</u>	MYLAN	<u>3MG</u>	<u>A090410</u>	<u>001</u>	May 16, 2011

ENTOCORT EC

<u>AB</u>	+ ASTRAZENECA	<u>3MG</u>	<u>N021324</u>	<u>001</u>	Oct 02, 2001

POWDER, METERED; INHALATION

PULMICORT FLEXHALER

ASTRAZENECA

0.08MG/INH

N021949

001

Jul 12, 2006

+

0.16MG/INH

N021949

002

Jul 12, 2006

SPRAY, METERED; NASAL

RHINOCORT

+ ASTRAZENECA

0.032MG/INH

N020746

001

Oct 01, 1999

SUSPENSION; INHALATION

BUDESONIDE

<u>AN</u>	APOTEX	<u>0.25MG/2ML</u>	<u>A078202</u>	<u>001</u>	Mar 30, 2009

<u>AN</u>		<u>0.5MG/2ML</u>	<u>A078202</u>	<u>002</u>	Mar 30, 2009

<u>AN</u>	TEVA PHARMS	<u>0.25MG/2ML</u>	<u>A077519</u>	<u>001</u>	Nov 18, 2008

<u>AN</u>		<u>0.5MG/2ML</u>	<u>A077519</u>	<u>002</u>	Nov 18, 2008

<u>AN</u>	WATSON LABS INC	<u>0.25MG/2ML</u>	<u>A078404</u>	<u>001</u>	Jul 31, 2012

<u>AN</u>		<u>0.5MG/2ML</u>	<u>A078404</u>	<u>002</u>	Jul 31, 2012

PULMICORT RESPULES

<u>AN</u>	ASTRAZENECA	<u>0.25MG/2ML</u>	<u>N020929</u>	<u>001</u>	Aug 08, 2000

<u>AN</u>		<u>0.5MG/2ML</u>	<u>N020929</u>	<u>002</u>	Aug 08, 2000

PULMICORT RESPULES

+ ASTRAZENECA

1MG/2ML

N020929

003

Aug 08, 2000

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION

SYMBICORT

+ ASTRAZENECA

0.08MG/INH;0.0045MG/INH

N021929

001

Jul 21, 2006

+

0.16MG/INH;0.0045MG/INH

N021929

002

Jul 21, 2006

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

<u>AP</u>	+ BEDFORD	<u>0.25MG/ML</u>	<u>A074441</u>	<u>001</u>	Jan 27, 1995

<u>AP</u>	HIKMA MAPLE	<u>0.25MG/ML</u>	<u>A079196</u>	<u>001</u>	Apr 30, 2008

<u>AP</u>	HOSPIRA	<u>0.25MG/ML</u>	<u>A074332</u>	<u>001</u>	Oct 31, 1994

TABLET; ORAL

BUMETANIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>0.5MG</u>	<u>A074225</u>	<u>001</u>	Apr 24, 1995

<u>AB</u>		<u>1MG</u>	<u>A074225</u>	<u>002</u>	Apr 24, 1995

<u>AB</u>		<u>2MG</u>	<u>A074225</u>	<u>003</u>	Apr 24, 1995

<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A074700</u>	<u>001</u>	Nov 21, 1996

<u>AB</u>		<u>1MG</u>	<u>A074700</u>	<u>002</u>	Nov 21, 1996

<u>AB</u>	+	<u>2MG</u>	<u>A074700</u>	<u>003</u>	Nov 21, 1996

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

+ PACIRA PHARMS INC

266MG/20ML (13.3MG/ML)

N022496

002

Oct 28, 2011

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>0.25%</u>	<u>A070583</u>	<u>001</u>	Feb 17, 1987

<u>AP</u>		<u>0.25%</u>	<u>A070586</u>	<u>001</u>	Mar 03, 1987

<u>AP</u>		<u>0.25%</u>	<u>A070590</u>	<u>001</u>	Feb 17, 1987

<u>AP</u>		<u>0.25%</u>	<u>N018053</u>	<u>002</u>	

<u>AP</u>		<u>0.5%</u>	<u>A070584</u>	<u>001</u>	Feb 17, 1986

<u>AP</u>		<u>0.5%</u>	<u>A070597</u>	<u>001</u>	Mar 03, 1987

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 59 (of 428)

BUPIVACAINE HYDROCHLORIDEINJECTABLE; INJECTIONBUPIVACAINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>0.5%</u>	<u>A070609</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>		<u>0.5%</u>	<u>N018053</u>	<u>001</u>	
<u>AP</u>		<u>0.75%</u>	<u>A070585</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>		<u>0.75%</u>	<u>A070587</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>		<u>0.75%</u>	<u>N018053</u>	<u>003</u>	
<u>AP</u>	SAGENT AGILA	<u>0.25%</u>	<u>A091503</u>	<u>001</u>	Oct 18, 2011
<u>AP</u>		<u>0.5%</u>	<u>A091503</u>	<u>002</u>	Oct 18, 2011

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	INTL MEDICATED	<u>0.25%</u>	<u>A076012</u>	<u>001</u>	Jan 09, 2002
<u>AP</u>		<u>0.5%</u>	<u>A076012</u>	<u>002</u>	Jan 09, 2002
<u>AP</u>		<u>0.75%</u>	<u>A076012</u>	<u>003</u>	Jan 09, 2002
<u>AP</u>	SAGENT AGILA	<u>0.25%</u>	<u>A091487</u>	<u>002</u>	Oct 18, 2011
<u>AP</u>		<u>0.5%</u>	<u>A091487</u>	<u>001</u>	Oct 18, 2011
<u>AP</u>		<u>0.75%</u>	<u>A091487</u>	<u>003</u>	Oct 18, 2011

MARCAINE HYDROCHLORIDE

<u>AP</u>	+ HOSPIRA	<u>0.25%</u>	<u>N016964</u>	<u>001</u>	
<u>AP</u>	+	<u>0.5%</u>	<u>N016964</u>	<u>006</u>	

MARCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	+ HOSPIRA	<u>0.25%</u>	<u>N016964</u>	<u>012</u>	
<u>AP</u>	+	<u>0.5%</u>	<u>N016964</u>	<u>005</u>	
<u>AP</u>	+	<u>0.75%</u>	<u>N016964</u>	<u>009</u>	

SENSORCAINE

<u>AP</u>	FRESENIUS KABI USA	<u>0.25%</u>	<u>A070552</u>	<u>001</u>	May 21, 1986
<u>AP</u>		<u>0.25%</u>	<u>N018304</u>	<u>001</u>	
<u>AP</u>		<u>0.5%</u>	<u>A070553</u>	<u>001</u>	May 21, 1986
<u>AP</u>		<u>0.5%</u>	<u>N018304</u>	<u>002</u>	
<u>AP</u>		<u>0.75%</u>	<u>A070554</u>	<u>001</u>	May 21, 1986
<u>AP</u>		<u>0.75%</u>	<u>N018304</u>	<u>003</u>	

INJECTABLE; SPINALBUPIVACAINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>0.75%</u>	<u>A071810</u>	<u>001</u>	Dec 11, 1987
	<u>MARCAINE</u>				
<u>AP</u>	+ HOSPIRA	<u>0.75%</u>	<u>N018692</u>	<u>001</u>	May 04, 1984
	<u>SENSORCAINE</u>				
<u>AP</u>	FRESENIUS KABI USA	<u>0.75%</u>	<u>A071202</u>	<u>001</u>	Apr 15, 1987

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINEINJECTABLE; INJECTIONBUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

<u>AP</u>	+ HOSPIRA	<u>0.5%;0.005MG/ML</u>	<u>A071168</u>	<u>001</u>	Jun 16, 1988
<u>AP</u>		<u>0.5%;0.005MG/ML</u>	<u>A071170</u>	<u>001</u>	Jun 16, 1988
	BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE				
	+ HOSPIRA	0.25%;0.005MG/ML	A071165	001	Jun 16, 1988
		0.25%;0.005MG/ML	A071167	001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATEINJECTABLE; INJECTIONBUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

<u>AP</u>	SEPTODONT	<u>0.5%;0.0091MG/ML</u>	<u>A077250</u>	<u>001</u>	Sep 27, 2006
	<u>BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE</u>				
<u>AP</u>	+ HOSPIRA	<u>0.5%;0.0091MG/ML</u>	<u>N022046</u>	<u>001</u>	Jul 13, 1983
	<u>MARCAINE HYDROCHLORIDE W/ EPINEPHRINE</u>				
<u>AP</u>	+ HOSPIRA	<u>0.25%;0.0091MG/ML</u>	<u>N016964</u>	<u>004</u>	
<u>AP</u>	+	<u>0.5%;0.0091MG/ML</u>	<u>N016964</u>	<u>008</u>	
	<u>MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE</u>				
<u>AP</u>	+ HOSPIRA	<u>0.25%;0.0091MG/ML</u>	<u>N016964</u>	<u>013</u>	
<u>AP</u>	+	<u>0.5%;0.0091MG/ML</u>	<u>N016964</u>	<u>007</u>	
<u>AP</u>	+	<u>0.75%;0.0091MG/ML</u>	<u>N016964</u>	<u>010</u>	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 60 (of 428)

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

SENSORCAINE

<u>AP</u>	FRESENIUS KABI USA	<u>0.25%;0.0091MG/ML</u>	<u>A070966</u>	<u>001</u>	Oct 13, 1987
<u>AP</u>		<u>0.25%;0.0091MG/ML</u>	<u>A070967</u>	<u>001</u>	Oct 13, 1987
<u>AP</u>		<u>0.5%;0.0091MG/ML</u>	<u>A070968</u>	<u>001</u>	Oct 13, 1987
<u>AP</u>		<u>0.5%;0.0091MG/ML</u>	<u>N018304</u>	<u>004</u>	Sep 02, 1983
<u>AP</u>		<u>0.75%;0.0091MG/ML</u>	<u>N018304</u>	<u>005</u>	Sep 02, 1983

BUPRENORPHINEFILM, EXTENDED RELEASE; TRANSDERMAL
BUTRANS

	PURDUE PHARMA LP	5MCG/HR	N021306	001	Jun 30, 2010
		10MCG/HR	N021306	002	Jun 30, 2010
+		20MCG/HR	N021306	003	Jun 30, 2010

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENEX

<u>AP</u>	+ RECKITT BENCKISER	<u>EQ 0.3MG BASE/ML</u>	<u>N018401</u>	<u>001</u>	
		<u>BUPRENORPHINE HYDROCHLORIDE</u>			
<u>AP</u>	BEDFORD	<u>EQ 0.3MG BASE/ML</u>	<u>A076931</u>	<u>001</u>	Mar 02, 2005
<u>AP</u>	HOSPIRA	<u>EQ 0.3MG BASE/ML</u>	<u>A074137</u>	<u>001</u>	Jun 03, 1996
<u>AP</u>	LUITPOLD	<u>EQ 0.3MG BASE/ML</u>	<u>A078331</u>	<u>001</u>	Mar 27, 2007

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>EQ 2MG BASE</u>	<u>A090360</u>	<u>001</u>	May 07, 2010
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090360</u>	<u>002</u>	May 07, 2010
<u>AB</u>	ETHYPHARM	<u>EQ 2MG BASE</u>	<u>A090622</u>	<u>001</u>	Sep 24, 2010
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090622</u>	<u>002</u>	Sep 24, 2010
<u>AB</u>	ROXANE	<u>EQ 2MG BASE</u>	<u>A078633</u>	<u>001</u>	Oct 08, 2009
<u>AB</u>	+	<u>EQ 8MG BASE</u>	<u>A078633</u>	<u>002</u>	Oct 08, 2009

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDEFILM; SUBLINGUAL
SUBOXONE

	RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N022410	001	Aug 30, 2010
		EQ 4MG BASE;EQ 1MG BASE	N022410	003	Aug 10, 2012
+		EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010
		EQ 12MG BASE;EQ 3MG BASE	N022410	004	Aug 10, 2012

TABLET; SUBLINGUAL
SUBOXONE

	RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N020733	001	Oct 08, 2002
+		EQ 8MG BASE;EQ 2MG BASE	N020733	002	Oct 08, 2002

BUPROPION HYDROBROMIDETABLET, EXTENDED RELEASE; ORAL
APLENZIN

	VALEANT INTL	174MG	N022108	001	Apr 23, 2008
+		348MG	N022108	002	Apr 23, 2008
		522MG	N022108	003	Apr 23, 2008

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>75MG</u>	<u>A076143</u>	<u>001</u>	Jan 17, 2006
<u>AB</u>		<u>100MG</u>	<u>A076143</u>	<u>002</u>	Jan 17, 2006
<u>AB</u>	MYLAN	<u>75MG</u>	<u>A075491</u>	<u>001</u>	Apr 17, 2000
<u>AB</u>		<u>100MG</u>	<u>A075491</u>	<u>002</u>	Apr 17, 2000
<u>AB</u>	SANDOZ	<u>75MG</u>	<u>A075584</u>	<u>001</u>	Feb 07, 2000
<u>AB</u>		<u>100MG</u>	<u>A075584</u>	<u>002</u>	Feb 07, 2000

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 61 (of 428)

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

<u>AB</u>	TEVA	<u>75MG</u>	<u>A075310</u>	<u>001</u>	Nov 29, 1999
<u>AB</u>		<u>100MG</u>	<u>A075310</u>	<u>002</u>	Nov 29, 1999

WELLBUTRIN

<u>AB</u>	GLAXOSMITHKLINE	<u>75MG</u>	<u>N018644</u>	<u>002</u>	Dec 30, 1985
<u>AB</u> +		<u>100MG</u>	<u>N018644</u>	<u>003</u>	Dec 30, 1985

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

<u>AB1</u>	ACTAVIS	<u>100MG</u>	<u>A077455</u>	<u>001</u>	Jul 19, 2010
<u>AB1</u>		<u>150MG</u>	<u>A077455</u>	<u>002</u>	Mar 12, 2008
<u>AB1</u>		<u>200MG</u>	<u>A077455</u>	<u>003</u>	Jul 19, 2010
<u>AB1</u>	ANCHEN PHARMS	<u>100MG</u>	<u>A091459</u>	<u>001</u>	Jun 09, 2011
<u>AB1</u>		<u>150MG</u>	<u>A091459</u>	<u>002</u>	Jun 09, 2011
<u>AB1</u>		<u>200MG</u>	<u>A091459</u>	<u>003</u>	Jun 09, 2011
<u>AB1</u>	IMPAX LABS	<u>100MG</u>	<u>A075913</u>	<u>001</u>	Jan 28, 2004
<u>AB1</u>		<u>150MG</u>	<u>A075913</u>	<u>002</u>	Mar 22, 2004
<u>AB1</u>		<u>200MG</u>	<u>A076711</u>	<u>001</u>	Dec 03, 2004
<u>AB1</u>	MYLAN	<u>100MG</u>	<u>A090325</u>	<u>001</u>	Apr 08, 2010
<u>AB1</u>		<u>150MG</u>	<u>A090325</u>	<u>002</u>	Apr 08, 2010
<u>AB1</u>		<u>200MG</u>	<u>A090325</u>	<u>003</u>	Apr 08, 2010
<u>AB1</u>	SANDOZ	<u>100MG</u>	<u>A075932</u>	<u>001</u>	Nov 25, 2003
<u>AB1</u>		<u>150MG</u>	<u>A075932</u>	<u>002</u>	Mar 22, 2004
<u>AB1</u>		<u>200MG</u>	<u>A075932</u>	<u>003</u>	Jun 22, 2005
<u>AB1</u>	SUN PHARMA GLOBAL	<u>100MG</u>	<u>A078866</u>	<u>001</u>	Apr 06, 2010
<u>AB1</u>		<u>150MG</u>	<u>A078866</u>	<u>002</u>	Apr 06, 2010
<u>AB1</u>		<u>200MG</u>	<u>A078866</u>	<u>003</u>	Apr 06, 2010
<u>AB1</u>	WATSON LABS FLORIDA	<u>100MG</u>	<u>A079095</u>	<u>001</u>	Mar 24, 2009
<u>AB1</u>		<u>150MG</u>	<u>A079095</u>	<u>002</u>	Mar 24, 2009
<u>AB1</u>		<u>200MG</u>	<u>A079095</u>	<u>003</u>	Mar 24, 2009
<u>AB1</u>	WOCKHARDT LTD	<u>100MG</u>	<u>A201331</u>	<u>001</u>	Aug 30, 2012
<u>AB1</u>		<u>150MG</u>	<u>A201331</u>	<u>002</u>	Aug 30, 2012
<u>AB1</u>		<u>200MG</u>	<u>A201331</u>	<u>003</u>	Aug 30, 2012

WELLBUTRIN SR

<u>AB1</u>	GLAXOSMITHKLINE	<u>100MG</u>	<u>N020358</u>	<u>002</u>	Oct 04, 1996
<u>AB1</u>		<u>150MG</u>	<u>N020358</u>	<u>003</u>	Oct 04, 1996
<u>AB1</u> +		<u>200MG</u>	<u>N020358</u>	<u>004</u>	Jun 14, 2002

BUPROPION HYDROCHLORIDE

<u>AB2</u>	ACTAVIS	<u>150MG</u>	<u>A077475</u>	<u>001</u>	Mar 12, 2008
<u>AB2</u>	ANCHEN PHARMS	<u>150MG</u>	<u>A091520</u>	<u>001</u>	Jun 09, 2011
<u>AB2</u>	IMPAX LABS	<u>150MG</u>	<u>A075914</u>	<u>001</u>	May 27, 2004
<u>AB2</u>	MYLAN	<u>150MG</u>	<u>A090941</u>	<u>001</u>	May 03, 2010
<u>AB2</u>	WATSON LABS FLORIDA	<u>150MG</u>	<u>A079094</u>	<u>001</u>	Mar 24, 2009

ZYBAN

<u>AB2</u> +	GLAXOSMITHKLINE	<u>150MG</u>	<u>N020711</u>	<u>003</u>	May 14, 1997

BUPROPION HYDROCHLORIDE

<u>AB3</u>	ACTAVIS	<u>150MG</u>	<u>A077285</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>		<u>300MG</u>	<u>A077285</u>	<u>002</u>	Aug 15, 2008
<u>AB3</u>	ANCHEN PHARMS	<u>150MG</u>	<u>A077284</u>	<u>001</u>	Dec 14, 2006
<u>AB3</u>		<u>300MG</u>	<u>A077284</u>	<u>002</u>	Dec 14, 2006
<u>AB3</u>	IMPAX LABS	<u>150MG</u>	<u>A077415</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>	MYLAN	<u>150MG</u>	<u>A090942</u>	<u>001</u>	Jul 14, 2010
<u>AB3</u>		<u>300MG</u>	<u>A090942</u>	<u>002</u>	Jul 14, 2010
<u>AB3</u>	WATSON LABS	<u>150MG</u>	<u>A077715</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>		<u>300MG</u>	<u>A077715</u>	<u>002</u>	Jun 13, 2007
<u>AB3</u>	WOCKHARDT LTD	<u>150MG</u>	<u>A202189</u>	<u>001</u>	Nov 21, 2012

WELLBUTRIN XL

<u>AB3</u>	VALEANT INTL	<u>150MG</u>	<u>N021515</u>	<u>001</u>	Aug 28, 2003
<u>AB3</u> +		<u>300MG</u>	<u>N021515</u>	<u>002</u>	Aug 28, 2003

PRESCRIPTION DRUG PRODUCT LIST

3 - 62 (of 428)

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL BUPROPION HYDROCHLORIDE					
BX	IMPAX LABS	300MG	A077415	002	Dec 15, 2006
	FORFIVO XL				
	+ EDGEMONT PHARMS LLC	450MG	N022497	001	Nov 10, 2011

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL BUSPIRONE HYDROCHLORIDE					
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A078246</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>		<u>10MG</u>	<u>A078246</u>	<u>002</u>	Feb 27, 2009
<u>AB</u>		<u>15MG</u>	<u>A078246</u>	<u>003</u>	Feb 27, 2009
<u>AB</u>		<u>30MG</u>	<u>A078246</u>	<u>004</u>	Feb 27, 2009
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A075272</u>	<u>001</u>	Mar 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075467</u>	<u>001</u>	Feb 28, 2002
<u>AB</u>		<u>7.5MG</u>	<u>A075467</u>	<u>002</u>	Mar 28, 2001
<u>AB</u>		<u>10MG</u>	<u>A075272</u>	<u>002</u>	Mar 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075467</u>	<u>003</u>	Feb 28, 2002
<u>AB</u>		<u>15MG</u>	<u>A075272</u>	<u>003</u>	Mar 28, 2001
<u>AB</u>		<u>15MG</u>	<u>A075467</u>	<u>004</u>	Feb 28, 2002
<u>AB</u>		<u>30MG</u>	<u>A076008</u>	<u>001</u>	Jun 28, 2001
<u>AB</u>	PROSAM LABS	<u>30MG</u>	<u>A078302</u>	<u>001</u>	Dec 17, 2007
<u>AB</u>	TEVA	<u>5MG</u>	<u>A075022</u>	<u>001</u>	Feb 28, 2002
<u>AB</u>		<u>10MG</u>	<u>A075022</u>	<u>002</u>	Feb 28, 2002
<u>AB</u>	+	<u>15MG</u>	<u>A075022</u>	<u>003</u>	Feb 28, 2002
<u>AB</u>		<u>30MG</u>	<u>A075022</u>	<u>004</u>	Mar 25, 2004
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A074253</u>	<u>001</u>	Mar 28, 2001
<u>AB</u>		<u>10MG</u>	<u>A074253</u>	<u>002</u>	Mar 28, 2001
<u>AB</u>		<u>15MG</u>	<u>A074253</u>	<u>003</u>	Mar 13, 2002

BUSULFAN

INJECTABLE; INJECTION BUSULFEX					
	+ OTSUKA PHARM	6MG/ML	N020954	001	Feb 04, 1999
TABLET; ORAL MYLERAN					
	+ ASPEN GLOBAL	2MG	N009386	001	

BUTABARBITAL SODIUM

ELIXIR; ORAL BUTISOL SODIUM					
	+ MEDA PHARMS	30MG/5ML	A085380	001	
TABLET; ORAL BUTISOL SODIUM					
	+ MEDA PHARMS	30MG	N000793	004	
	+	50MG	N000793	003	

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL MENTAX					
	+ MYLAN	1%	N020524	001	Oct 18, 1996
MENTAX-TC					
	+ MYLAN	1%	N021408	001	Oct 17, 2002

BUTOCONAZOLE NITRATE

CREAM; VAGINAL BUTOCONAZOLE NITRATE					
<u>AB</u>	PERRIGO ISRAEL	<u>2%</u>	<u>A200923</u>	<u>001</u>	May 18, 2012
GYNAZOLE-1					
<u>AB</u>	+ KV PHARM	<u>2%</u>	<u>N019881</u>	<u>001</u>	Feb 07, 1997

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 63 (of 428)

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

<u>AP</u>	BEDFORD	<u>2MG/ML</u>	<u>A075046</u>	<u>001</u>	Aug 12, 1998
<u>AP</u>	CLARIS LIFESCIENCES	<u>2MG/ML</u>	<u>A075697</u>	<u>001</u>	Oct 23, 2001
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A078400</u>	<u>001</u>	May 01, 2009
<u>AP</u>		<u>2MG/ML</u>	<u>A078247</u>	<u>001</u>	Apr 29, 2009
<u>AP</u>		<u>2MG/ML</u>	<u>A078400</u>	<u>002</u>	May 01, 2009

BUTORPHANOL TARTRATE PRESERVATIVE FREE

<u>AP</u>	BEDFORD	<u>1MG/ML</u>	<u>A075045</u>	<u>001</u>	Aug 12, 1998
<u>AP</u>		<u>2MG/ML</u>	<u>A075045</u>	<u>002</u>	Aug 12, 1998
<u>AP</u>	CLARIS LIFESCIENCES	<u>1MG/ML</u>	<u>A075695</u>	<u>001</u>	Oct 23, 2001
<u>AP</u>		<u>2MG/ML</u>	<u>A075695</u>	<u>002</u>	Oct 23, 2001
<u>AP</u>	HOSPIRA	<u>1MG/ML</u>	<u>A074626</u>	<u>001</u>	Jan 23, 1997
<u>AP</u>		<u>2MG/ML</u>	<u>A074626</u>	<u>002</u>	Jan 23, 1997

STADOL

<u>AP</u>	+ APOTHECON	<u>2MG/ML</u>	<u>N017857</u>	<u>004</u>	

STADOL PRESERVATIVE FREE

<u>AP</u>	+ APOTHECON	<u>1MG/ML</u>	<u>N017857</u>	<u>001</u>	
<u>AP</u>	+	<u>2MG/ML</u>	<u>N017857</u>	<u>002</u>	

SPRAY, METERED; NASAL

BUTORPHANOL TARTRATE

<u>AB</u>	+ MYLAN	<u>1MG/SPRAY</u>	<u>A075759</u>	<u>001</u>	Aug 08, 2001
<u>AB</u>	NOVEX	<u>1MG/SPRAY</u>	<u>A075499</u>	<u>001</u>	Dec 04, 2002
<u>AB</u>	ROXANE	<u>1MG/SPRAY</u>	<u>A075824</u>	<u>001</u>	Mar 12, 2002

CABAZITAXEL

SOLUTION; IV (INFUSION)

	+ SANOFI AVENTIS US	60MG/1.5ML (40MG/ML)	N201023	001	Jun 17, 2010

CABERGOLINE

TABLET; ORAL

CABERGOLINE

<u>AB</u>	IMPAX LABS INC	<u>0.5MG</u>	<u>A077843</u>	<u>001</u>	Jul 03, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>0.5MG</u>	<u>A077750</u>	<u>001</u>	Mar 07, 2007
<u>AB</u>	+ PAR PHARM	<u>0.5MG</u>	<u>A076310</u>	<u>001</u>	Dec 29, 2005
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A078035</u>	<u>001</u>	Apr 21, 2008

CABOZANTINIB S-MALATE

CAPSULE; ORAL

COMETRIQ

	EXELIXIS	EQ 20MG BASE	N203756	001	Nov 29, 2012
+		EQ 80MG BASE	N203756	002	Nov 29, 2012

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAF CIT

<u>AP</u>	+ BEDFORD LABS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>N020793</u>	<u>001</u>	Sep 21, 1999
	<u>CAFFEINE CITRATE</u>				
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077997</u>	<u>001</u>	Jul 20, 2007
<u>AP</u>	LUITPOLD	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077906</u>	<u>001</u>	May 15, 2007
<u>AP</u>	PADDOCK LLC	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077233</u>	<u>001</u>	Sep 21, 2006
<u>AP</u>	SAGENT PHARMS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090827</u>	<u>001</u>	Aug 29, 2012
<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090077</u>	<u>001</u>	Sep 30, 2009

SOLUTION; ORAL

CAF CIT

<u>AA</u>	+ BEDFORD LABS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>N020793</u>	<u>002</u>	Apr 12, 2000
	<u>CAFFEINE CITRATE</u>				
<u>AA</u>	FRESENIUS KABI USA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A078002</u>	<u>001</u>	Jan 31, 2008
<u>AA</u>	LUITPOLD	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090064</u>	<u>001</u>	Nov 20, 2009
<u>AA</u>	PADDOCK LLC	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077304</u>	<u>001</u>	Sep 21, 2006

PRESCRIPTION DRUG PRODUCT LIST

3 - 64 (of 428)

CAFFEINE CITRATE

SOLUTION; ORAL					
<u>CAFFEINE CITRATE</u>					
<u>AA</u>	SAGENT PHARMS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A091102</u>	<u>001</u>	Aug 29, 2012
<u>AA</u>	SUN PHARMA GLOBAL	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090357</u>	<u>001</u>	Sep 30, 2009

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL					
MIGERGOT					
	+ G AND W LABS	100MG;2MG	A086557	001	Oct 04, 1983
TABLET; ORAL					
<u>CAFERGOT</u>					
<u>AA</u>	+ SANDOZ	<u>100MG;1MG</u>	<u>A084294</u>	<u>001</u>	
<u>ERGOTAMINE TARTRATE AND CAFFEINE</u>					
<u>AA</u>	MIKART	<u>100MG;1MG</u>	<u>A040590</u>	<u>001</u>	Sep 16, 2005
<u>AA</u>	WEST WARD	<u>100MG;1MG</u>	<u>A040510</u>	<u>001</u>	Sep 17, 2004

CALCIPOTRIENE

AEROSOL, FOAM; TOPICAL					
SORILUX					
	+ STIEFEL LABS INC	0.005%	N022563	001	Oct 06, 2010
CREAM; TOPICAL					
<u>CALCIPOTRIENE</u>					
<u>AB</u>	TOLMAR	<u>0.005%</u>	<u>A200935</u>	<u>001</u>	May 30, 2012
<u>DOVONEX</u>					
<u>AB</u>	+ LEO PHARMA AS	<u>0.005%</u>	<u>N020554</u>	<u>001</u>	Jul 22, 1996
OINTMENT; TOPICAL					
CALCIPOTRIENE					
	+ GLENMARK GENERICS	0.005%	A090633	001	Mar 24, 2010
SOLUTION; TOPICAL					
<u>CALCIPOTRIENE</u>					
<u>AT</u>	FOUGERA PHARMS	<u>0.005%</u>	<u>A078305</u>	<u>001</u>	May 06, 2008
<u>AT</u>	G AND W LABS INC	<u>0.005%</u>	<u>A078468</u>	<u>001</u>	Mar 24, 2011
<u>AT</u>	HI TECH PHARMA	<u>0.005%</u>	<u>A077579</u>	<u>001</u>	Nov 19, 2009
<u>AT</u>	TOLMAR	<u>0.005%</u>	<u>A077029</u>	<u>001</u>	Nov 20, 2009
<u>DOVONEX</u>					
<u>AT</u>	+ LEO PHARM	<u>0.005%</u>	<u>N020611</u>	<u>001</u>	Mar 03, 1997

CALCITONIN SALMON

INJECTABLE; INJECTION					
MIACALCIN					
	+ NOVARTIS	200 IU/ML	N017808	002	Mar 29, 1991
SPRAY, METERED; NASAL					
<u>CALCITONIN-SALMON</u>					
<u>AB</u>	APOTEX INC	<u>200 IU/SPRAY</u>	<u>A076396</u>	<u>001</u>	Nov 17, 2008
<u>AB</u>	PAR PHARM	<u>200 IU/SPRAY</u>	<u>A076979</u>	<u>001</u>	Jun 08, 2009
<u>MIACALCIN</u>					
<u>AB</u>	+ NOVARTIS	<u>200 IU/SPRAY</u>	<u>N020313</u>	<u>002</u>	Aug 17, 1995

CALCITONIN SALMON RECOMBINANT

SPRAY, METERED; NASAL					
FORTICAL					
	+ UPSHER SMITH	200 IU/SPRAY	N021406	001	Aug 12, 2005

CALCITRIOL

CAPSULE; ORAL					
<u>CALCITRIOL</u>					
<u>AB</u>	ROXANE	<u>0.25MCG</u>	<u>A076917</u>	<u>001</u>	Mar 27, 2006
<u>AB</u>	TEVA	<u>0.25MCG</u>	<u>A075765</u>	<u>001</u>	Oct 12, 2001
<u>AB</u>		<u>0.5MCG</u>	<u>A075765</u>	<u>002</u>	Oct 12, 2001
<u>ROCALTROL</u>					
<u>AB</u>	VALIDUS PHARMS	<u>0.25MCG</u>	<u>N018044</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

3 - 65 (of 428)

CALCITRIOL

CAPSULE; ORAL					
<u>ROCALTROL</u>					
<u>AB</u>	+	VALIDUS PHARMS	<u>0.5MCG</u>	<u>N018044</u>	<u>002</u>
INJECTABLE; INJECTION					
<u>CALCIJEX</u>					
<u>AP</u>	+	ABBVIE	<u>0.001MG/ML</u>	<u>N018874</u>	<u>001</u> Sep 25, 1986
<u>AP</u>	+		<u>0.002MG/ML</u>	<u>N018874</u>	<u>002</u> Sep 25, 1986
<u>CALCITRIOL</u>					
<u>AP</u>		AKORN	<u>0.001MG/ML</u>	<u>A078066</u>	<u>001</u> Jan 29, 2008
<u>AP</u>			<u>0.002MG/ML</u>	<u>A078066</u>	<u>002</u> Jan 29, 2008
<u>AP</u>		FRESENIUS KABI USA	<u>0.001MG/ML</u>	<u>A075836</u>	<u>001</u> Dec 31, 2002
<u>AP</u>			<u>0.002MG/ML</u>	<u>A075836</u>	<u>002</u> Dec 31, 2002
<u>AP</u>		FRESENIUS MEDCL	<u>0.001MG/ML</u>	<u>A075766</u>	<u>001</u> Feb 20, 2003
<u>AP</u>			<u>0.002MG/ML</u>	<u>A075766</u>	<u>002</u> Feb 20, 2003
<u>AP</u>		LUITPOLD	<u>0.001MG/ML</u>	<u>A075746</u>	<u>001</u> Sep 26, 2003
<u>AP</u>			<u>0.002MG/ML</u>	<u>A075746</u>	<u>002</u> Sep 26, 2003
<u>AP</u>		ROCKWELL MEDCL	<u>0.001MG/ML</u>	<u>A076206</u>	<u>001</u> Sep 17, 2003
<u>AP</u>		SAGENT PHARMS	<u>0.001MG/ML</u>	<u>A077102</u>	<u>001</u> Feb 08, 2006
<u>AP</u>		TEVA PARENTERAL	<u>0.002MG/ML</u>	<u>A075823</u>	<u>002</u> Mar 31, 2003
OINTMENT; TOPICAL					
VECTICAL					
	+	GALDERMA LABS LP	3MCG/GM	N022087	001 Jan 23, 2009
SOLUTION; ORAL					
<u>CALCITRIOL</u>					
<u>AA</u>		ROXANE	<u>1MCG/ML</u>	<u>A076242</u>	<u>001</u> Jul 18, 2003
<u>ROCALTROL</u>					
<u>AA</u>	+	VALIDUS PHARMS	<u>1MCG/ML</u>	<u>N021068</u>	<u>001</u> Nov 20, 1998

CALCIUM ACETATE

CAPSULE; ORAL					
<u>CALCIUM ACETATE</u>					
<u>AB</u>		PADDOCK LLC	<u>EQ 169MG CALCIUM</u>	<u>A091312</u>	<u>001</u> Jun 01, 2012
<u>AB</u>		ROXANE	<u>EQ 169MG CALCIUM</u>	<u>A077728</u>	<u>001</u> Feb 26, 2008
<u>PHOSLO GELCAPS</u>					
<u>AB</u>	+	FRESENIUS MEDCL	<u>EQ 169MG CALCIUM</u>	<u>N021160</u>	<u>003</u> Apr 02, 2001
SOLUTION; ORAL					
PHOSLYRA					
	+	FRESENIUS MEDCL	EQ 169MG CALCIUM/5ML	N022581	001 Apr 18, 2011
TABLET; ORAL					
<u>CALCIUM ACETATE</u>					
<u>AB</u>		PADDOCK LLC	<u>EQ 169MG CALCIUM</u>	<u>A091561</u>	<u>001</u> Apr 13, 2011
<u>ELIPHOS</u>					
<u>AB</u>	+	CYPRESS PHARM	<u>EQ 169MG CALCIUM</u>	<u>A078502</u>	<u>001</u> Nov 25, 2008

CALCIUM CHLORIDE

INJECTABLE; INJECTION					
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER					
	+	HOSPIRA	100MG/ML	N021117	001 Jan 28, 2000

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION					
<u>BSS PLUS</u>					
<u>AT</u>	+	ALCON	<u>0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/M</u> <u>L;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/M</u> <u>L</u>	<u>N018469</u>	<u>001</u>
<u>ENDOSOL EXTRA</u>					
<u>AT</u>	+	AKORN	<u>0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/M</u> <u>L;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/M</u> <u>L</u>	<u>N020079</u>	<u>001</u> Nov 27, 1991

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 66 (of 428)

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE;
SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML	N021703	010	Oct 10, 2008

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML	N021703	011	Oct 10, 2008

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML	N021703	013	Oct 10, 2008

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML	N021703	006	Oct 25, 2006

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML	N021703	002	Oct 25, 2006

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML	N021703	003	Oct 25, 2006

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML	N021703	015	Oct 10, 2008

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML	N021703	004	Oct 25, 2006

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML	N021703	014	Oct 10, 2008

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML	N021703	001	Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE;
SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

NAVSTEL

+ ALCON PHARMS LTD	0.154MG/ML;0.92MG/ML;0.2MG/ML;0.184MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N022193	001	Jul 24, 2008

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE;
SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

+ B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML	N019864	001	Jun 10, 1993

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE;
SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

+ B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N019867	001	Dec 20, 1993

PRESCRIPTION DRUG PRODUCT LIST

3 - 67 (of 428)

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	37MG/100ML;5GM/100ML;30MG/100ML;119MG/100ML;161MG/100ML;94MG/100ML;138MG/100ML	N017390 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER

+ B BRAUN	510MG/100ML;30GM/100ML;200MG/100ML;9.4GM/100ML;11GM/100ML	N018807 003	Aug 26, 1983

+	510MG/100ML;30GM/100ML;200MG/100ML;9.2GM/100ML;9.6GM/100ML	N018807 001	Aug 26, 1983

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

+ B BRAUN	510MG/100ML;50GM/100ML;200MG/100ML;9.4GM/100ML;11GM/100ML	N018807 004	Aug 26, 1983

+	510MG/100ML;50GM/100ML;200MG/100ML;9.2GM/100ML;9.6GM/100ML	N018807 002	Aug 26, 1983

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML</u>	<u>N018379 002</u>	

<u>AT</u>		<u>25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML</u>	<u>N018883 001</u>	Nov 30, 1984

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;38MG/100ML;448MG/100ML</u>	<u>N018883 004</u>	Nov 30, 1984

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;38MG/100ML;448MG/100ML</u>	<u>N020171 001</u>	Aug 19, 1992

DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML</u>	<u>N018379 003</u>	

<u>AT</u>		<u>25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML</u>	<u>N018883 002</u>	Nov 30, 1984

DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;38MG/100ML;448MG/100ML</u>	<u>N018883 005</u>	Nov 30, 1984

DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;38MG/100ML;448MG/100ML</u>	<u>N020171 002</u>	Aug 19, 1992

DELFLX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML</u>	<u>N018379 007</u>	Jun 24, 1988

DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML</u>	<u>N018379 001</u>	

<u>AT</u>		<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML</u>	<u>N018883 003</u>	Nov 30, 1984

DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML</u>	<u>N018883 006</u>	Nov 30, 1984

DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML</u>	<u>N020171 003</u>	Aug 19, 1992

DELFLX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;38MG/100ML;448MG/100ML</u>	<u>N018379 004</u>	Jul 07, 1982

DELFLX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;38MG/100ML;448MG/100ML</u>	<u>N018379 005</u>	Jul 07, 1982

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 68 (of 428)

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

<u>SOLUTION; INTRAPERITONEAL</u>						
<u>DELFLX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER</u>						
<u>AT</u>	<u>FRESENIUS MEDCL</u>	<u>25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N018379</u>	<u>008</u>		<u>Jun 24, 1988</u>
<u>DELFLX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>						
<u>AT</u>	<u>FRESENIUS MEDCL</u>	<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;</u> <u>538MG/100ML;448MG/100ML</u>	<u>N018379</u>	<u>006</u>		<u>Jul 07, 1982</u>
<u>DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>						
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5</u> <u>67MG/100ML;392MG/100ML</u>	<u>N017512</u>	<u>001</u>		
<u>DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>						
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5</u> <u>67MG/100ML;392MG/100ML</u>	<u>N017512</u>	<u>003</u>		
<u>DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>						
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;</u> <u>567MG/100ML;392MG/100ML</u>	<u>N017512</u>	<u>002</u>		
<u>DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>						
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N020183</u>	<u>001</u>		<u>Dec 04, 1992</u>
<u>DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>						
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5</u> <u>67MG/100ML;392MG/100ML</u>	<u>N017512</u>	<u>007</u>		<u>Jul 09, 1984</u>
<u>DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>						
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5</u> <u>67MG/100ML;392MG/100ML</u>	<u>N017512</u>	<u>008</u>		<u>Jul 09, 1984</u>
<u>DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER</u>						
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;5</u> <u>67MG/100ML;392MG/100ML</u>	<u>N017512</u>	<u>010</u>		<u>Nov 18, 1985</u>
<u>DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>						
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;</u> <u>567MG/100ML;392MG/100ML</u>	<u>N017512</u>	<u>009</u>		<u>Jul 09, 1984</u>
<u>DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>						
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N017512</u>	<u>004</u>		
<u>AT</u>		<u>25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N020163</u>	<u>001</u>		<u>Dec 04, 1992</u>
<u>DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>						
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N017512</u>	<u>005</u>		
<u>AT</u>		<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N020163</u>	<u>002</u>		<u>Dec 04, 1992</u>
<u>DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER</u>						
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N017512</u>	<u>011</u>		<u>Nov 18, 1985</u>
<u>DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>						
<u>AT</u>	<u>BAXTER HLTHCARE</u>	<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;</u> <u>538MG/100ML;448MG/100ML</u>	<u>N017512</u>	<u>006</u>		
<u>AT</u>		<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;</u> <u>538MG/100ML;448MG/100ML</u>	<u>N020163</u>	<u>003</u>		<u>Dec 04, 1992</u>
<u>INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>						
<u>AT</u>	<u>FRESENIUS</u>	<u>18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N020374</u>	<u>001</u>		<u>Jun 13, 1994</u>
<u>INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>						
<u>AT</u>	<u>FRESENIUS</u>	<u>18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;5</u> <u>38MG/100ML;448MG/100ML</u>	<u>N020374</u>	<u>002</u>		<u>Jun 13, 1994</u>
<u>INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER</u>						
<u>AT</u>	<u>FRESENIUS</u>	<u>18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;</u> <u>538MG/100ML;448MG/100ML</u>	<u>N020374</u>	<u>004</u>		<u>Jun 13, 1994</u>
<u>DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER</u>						
	<u>B BRAUN</u>	<u>26MG/100ML;1.5GM/100ML;5MG/100ML;530MG/</u> <u>100ML;450MG/100ML</u>	<u>N018460</u>	<u>007</u>		<u>Jan 29, 1986</u>
<u>DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER</u>						
	<u>B BRAUN</u>	<u>26MG/100ML;2.5GM/100ML;5MG/100ML;530MG/</u> <u>100ML;450MG/100ML</u>	<u>N018460</u>	<u>005</u>		<u>Nov 02, 1983</u>

PRESCRIPTION DRUG PRODUCT LIST

3 - 69 (of 428)

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML;4.25GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460	009	Jan 29, 1986

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	002	Dec 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	003	Dec 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	004	Dec 04, 1992

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

FRESENIUS	18.4MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020374	003	Jun 13, 1994

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

ELLIOTTS B SOLUTION

+ QOL MEDCL	0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML;1.9MG/ML;7.3MG/ML;0.2MG/ML	N020577	001	Sep 27, 1996

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER

+ B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML;380MG/100ML;600MG/100ML	N018258	001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

AP	HOSPIRA	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N018254	001	

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N020000	001	Apr 17, 1992

AP	BAXTER HLTHCARE	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N016695	001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	HOSPIRA	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N017608	001	

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N019634	003	Feb 24, 1988

LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N016679	001	

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019367	006	Apr 05, 1985

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019367	004	Apr 05, 1985

AP		20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML	N019367	005	Apr 05, 1985

AP	HOSPIRA	20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019685	002	Oct 17, 1988

AP		20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML	N019685	008	Oct 17, 1988

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 70 (of 428)

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N019367</u>	<u>007</u>	Apr 05, 1985

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N019367</u>	<u>008</u>	Apr 05, 1985

<u>AP</u>	HOSPIRA	<u>20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N019685</u>	<u>004</u>	Oct 17, 1988

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	10MG/100ML;2.5GM/100ML;15MG/100ML;300MG/100ML;160MG/100ML	N019634	001	Feb 24, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML;600MG/100ML;310MG/100ML	N019367	002	Apr 05, 1985

		20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019367	003	Apr 05, 1985

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML;600MG/100ML;310MG/100ML	N019367	001	Apr 05, 1985

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

+	HOSPIRA	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;16.1MG/ML	N018895	001	Jul 20, 1984

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

+	B BRAUN	35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N019718	001	Sep 29, 1989

SOLUTION; IRRIGATION

BALANCED SALT

<u>AT</u>	AKORN	<u>0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML</u>	<u>A075503</u>	<u>001</u>	Sep 27, 2006

<u>AT</u>	B BRAUN	<u>0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML</u>	<u>A091387</u>	<u>001</u>	Feb 03, 2010

BSS

<u>AT</u>	+	ALCON	<u>0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML</u>	<u>N020742</u>	<u>001</u>	Dec 10, 1997

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	36.8MG/100ML;30.5MG/100ML;74.6MG/100ML;640MG/100ML;496MG/100ML;89.6MG/100ML	N017438	001	

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML</u>	<u>A075323</u>	<u>001</u>	Apr 21, 2000

PLEGISOL IN PLASTIC CONTAINER

<u>AT</u>	+	HOSPIRA	<u>17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML</u>	<u>N018608</u>	<u>001</u>	Feb 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>33MG/100ML;30MG/100ML;860MG/100ML</u>	<u>N020002</u>	<u>001</u>	Apr 17, 1992

PRESCRIPTION DRUG PRODUCT LIST

3 - 71 (of 428)

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>33MG/100ML;30MG/100ML;860MG/100ML</u>	<u>N016693</u>	<u>001</u>	
<u>AP</u>	HOSPIRA	<u>33MG/100ML;30MG/100ML;860MG/100ML</u>	<u>N018251</u>	<u>001</u>	

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

<u>AT</u>	B BRAUN	<u>33MG/100ML;30MG/100ML;860MG/100ML</u>	<u>N018156</u>	<u>001</u>	
<u>AT</u>	BAXTER HLTHCARE	<u>33MG/100ML;30MG/100ML;860MG/100ML</u>	<u>N018495</u>	<u>001</u>	Feb 19, 1982
<u>AT</u>	HOSPIRA	<u>33MG/100ML;30MG/100ML;860MG/100ML</u>	<u>N017635</u>	<u>001</u>	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N019632</u>	<u>001</u>	Feb 29, 1988
<u>AP</u>	BAXTER HLTHCARE	<u>20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N016682</u>	<u>001</u>	
<u>AP</u>	HOSPIRA	<u>20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N017641</u>	<u>001</u>	

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AT</u>	+ B BRAUN	<u>20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N018681</u>	<u>001</u>	Dec 27, 1982
<u>AT</u>	BAXTER HLTHCARE	<u>20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N018494</u>	<u>001</u>	Feb 19, 1982
<u>AT</u>	+	<u>20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N018921</u>	<u>001</u>	Apr 03, 1984
<u>AT</u>	+	<u>20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N019933</u>	<u>001</u>	Aug 29, 1989
<u>AT</u>	+ HOSPIRA	<u>20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML</u>	<u>N019416</u>	<u>001</u>	Jan 17, 1986

CALFACTANT

SUSPENSION; INTRATRACHEAL

INFASURF PRESERVATIVE FREE

+	ONY	35MG/ML	N020521	001	Jul 01, 1998

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

ASTRAZENECA

4MG	N020838	001	Jun 04, 1998
8MG	N020838	002	Jun 04, 1998
16MG	N020838	003	Jun 04, 1998
+	N020838	004	Jun 04, 1998

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ATACAND HCT

<u>AB</u>	ASTRAZENECA	<u>16MG;12.5MG</u>	<u>N021093</u>	<u>001</u>	Sep 05, 2000
<u>AB</u>		<u>32MG;12.5MG</u>	<u>N021093</u>	<u>002</u>	Sep 05, 2000
<u>AB</u>	+	<u>32MG;25MG</u>	<u>N021093</u>	<u>003</u>	May 16, 2008

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>16MG;12.5MG</u>	<u>A202884</u>	<u>001</u>	Dec 04, 2012
<u>AB</u>		<u>32MG;12.5MG</u>	<u>A202884</u>	<u>002</u>	Dec 04, 2012
<u>AB</u>	MYLAN LABS	<u>16MG;12.5MG</u>	<u>A090704</u>	<u>001</u>	Dec 04, 2012
<u>AB</u>		<u>32MG;12.5MG</u>	<u>A090704</u>	<u>002</u>	Dec 04, 2012
<u>AB</u>		<u>32MG;25MG</u>	<u>A090704</u>	<u>003</u>	Dec 04, 2012

CAPECITABINE

TABLET; ORAL

XELODA

HOFFMANN LA ROCHE

150MG	N020896	001	Apr 30, 1998

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 72 (of 428)

CAPECITABINETABLET; ORAL
XELODA

+ HOFFMANN LA ROCHE 500MG N020896 002 Apr 30, 1998

CAPREOMYCIN SULFATEINJECTABLE; INJECTION
CAPASTAT SULFATE

+ AKORN EQ 1GM BASE/VIAL N050095 001

CAPSAICINPATCH; TOPICAL
QUTENZA

+ NEUROGESX 8% N022395 001 Nov 16, 2009

CAPTOPRIL

TABLET; ORAL

CAPOTEN

AB PAR PHARM 12.5MG N018343 005 Jan 17, 1985

AB 25MG N018343 002

AB 50MG N018343 001

AB + 100MG N018343 003

CAPTOPRIL

AB APOTEX 12.5MG A074737 001 Oct 28, 1998

AB 25MG A074737 002 Oct 28, 1998

AB 50MG A074737 003 Oct 28, 1998

AB 100MG A074737 004 Oct 28, 1998

AB MYLAN 12.5MG A074434 001 Feb 13, 1996

AB 25MG A074434 002 Feb 13, 1996

AB 50MG A074434 003 Feb 13, 1996

AB 100MG A074434 004 Feb 13, 1996

AB PRINSTON INC 12.5MG A074477 001 Feb 13, 1996

AB 25MG A074477 002 Feb 13, 1996

AB 50MG A074477 003 Feb 13, 1996

AB 100MG A074477 004 Feb 13, 1996

AB SANDOZ 12.5MG A074363 001 Nov 09, 1995

AB 25MG A074363 002 Nov 09, 1995

AB 50MG A074363 003 Nov 09, 1995

AB 100MG A074363 004 Nov 09, 1995

AB STASON 12.5MG A074677 004 May 30, 1997

AB 25MG A074677 002 May 30, 1997

AB 50MG A074677 001 May 30, 1997

AB 100MG A074677 003 May 30, 1997

AB TEVA 12.5MG A074322 001 Feb 13, 1996

AB 12.5MG A074483 001 Feb 13, 1996

AB 25MG A074322 002 Feb 13, 1996

AB 25MG A074483 002 Feb 13, 1996

AB 50MG A074322 003 Feb 13, 1996

AB 50MG A074483 003 Feb 13, 1996

AB 100MG A074322 004 Feb 13, 1996

AB 100MG A074483 004 Feb 13, 1996

AB WATSON LABS 12.5MG A074386 001 May 23, 1996

AB 12.5MG A074451 001 Feb 13, 1996

AB 25MG A074386 002 May 23, 1996

AB 25MG A074451 002 Feb 13, 1996

AB 50MG A074386 003 May 23, 1996

AB 50MG A074451 003 Feb 13, 1996

AB 100MG A074386 004 May 23, 1996

AB 100MG A074451 004 Feb 13, 1996

AB WEST WARD 12.5MG A074505 001 Feb 13, 1996

AB 25MG A074505 002 Feb 13, 1996

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 73 (of 428)

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

<u>AB</u>	WEST WARD	<u>50MG</u>	<u>A074505</u>	<u>003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074505</u>	<u>004</u>	Feb 13, 1996
<u>AB</u>	WOCKHARDT	<u>12.5MG</u>	<u>A074532</u>	<u>001</u>	Mar 28, 1997
<u>AB</u>		<u>25MG</u>	<u>A074532</u>	<u>002</u>	Mar 28, 1997
<u>AB</u>		<u>50MG</u>	<u>A074532</u>	<u>003</u>	Mar 28, 1997
<u>AB</u>		<u>100MG</u>	<u>A074532</u>	<u>004</u>	Mar 28, 1997

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPOZIDE 25/15

<u>AB</u>	APOTHECON	<u>25MG;15MG</u>	<u>N018709</u>	<u>001</u>	Oct 12, 1984
	<u>CAPOZIDE 25/25</u>				
<u>AB</u>	+ APOTHECON	<u>25MG;25MG</u>	<u>N018709</u>	<u>002</u>	Oct 12, 1984
	<u>CAPOZIDE 50/15</u>				
<u>AB</u>	+ APOTHECON	<u>50MG;15MG</u>	<u>N018709</u>	<u>004</u>	Oct 12, 1984
	<u>CAPOZIDE 50/25</u>				
<u>AB</u>	APOTHECON	<u>50MG;25MG</u>	<u>N018709</u>	<u>003</u>	Oct 12, 1984
	<u>CAPTOPRIL AND HYDROCHLOROTHIAZIDE</u>				
<u>AB</u>	MYLAN	<u>25MG;15MG</u>	<u>A074896</u>	<u>001</u>	Dec 29, 1997
<u>AB</u>		<u>25MG;25MG</u>	<u>A074896</u>	<u>002</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;15MG</u>	<u>A074896</u>	<u>004</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;25MG</u>	<u>A074896</u>	<u>003</u>	Dec 29, 1997
<u>AB</u>	TEVA	<u>25MG;15MG</u>	<u>A074827</u>	<u>001</u>	Dec 29, 1997
<u>AB</u>		<u>25MG;25MG</u>	<u>A074827</u>	<u>002</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;15MG</u>	<u>A074827</u>	<u>004</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;25MG</u>	<u>A074827</u>	<u>003</u>	Dec 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

MIOSTAT

+	ALCON	0.01%	N016968	001	

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A078986</u>	<u>001</u>	Nov 25, 2011
<u>AB</u>		<u>200MG</u>	<u>A078986</u>	<u>002</u>	Nov 25, 2011
<u>AB</u>		<u>300MG</u>	<u>A078986</u>	<u>003</u>	Nov 25, 2011
<u>AB</u>	NOSTRUM	<u>100MG</u>	<u>A076697</u>	<u>001</u>	May 20, 2011
<u>AB</u>		<u>200MG</u>	<u>A076697</u>	<u>002</u>	May 20, 2011
<u>AB</u>		<u>300MG</u>	<u>A076697</u>	<u>003</u>	May 20, 2011
<u>AB</u>	TEVA PHARMS	<u>100MG</u>	<u>A078592</u>	<u>001</u>	Sep 20, 2012
<u>AB</u>		<u>200MG</u>	<u>A078592</u>	<u>002</u>	Sep 20, 2012
<u>AB</u>		<u>300MG</u>	<u>A078592</u>	<u>003</u>	Sep 20, 2012
	<u>CARBATROL</u>				
<u>AB</u>	SHIRE	<u>100MG</u>	<u>N020712</u>	<u>003</u>	Sep 30, 1997
<u>AB</u>		<u>200MG</u>	<u>N020712</u>	<u>001</u>	Sep 30, 1997
<u>AB</u>	+	<u>300MG</u>	<u>N020712</u>	<u>002</u>	Sep 30, 1997
	EQUETRO				
	VALIDUS PHARMS INC	100MG	N021710	001	Dec 10, 2004
		200MG	N021710	002	Dec 10, 2004
	+	300MG	N021710	003	Dec 10, 2004

SUSPENSION; ORAL

CARBAMAZEPINE

<u>AB</u>	WOCKHARDT	<u>100MG/5ML</u>	<u>A075714</u>	<u>001</u>	Jun 05, 2002
	<u>TEGRETOL</u>				
<u>AB</u>	+ NOVARTIS	<u>100MG/5ML</u>	<u>N018927</u>	<u>001</u>	Dec 18, 1987

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 74 (of 428)

CARBAMAZEPINE

SUSPENSION; ORAL

TERIL

<u>AB</u>	TARO	<u>100MG/5ML</u>	<u>A076729</u>	<u>001</u>	Sep 20, 2004

TABLET; ORAL

CARBAMAZEPINE

<u>AB</u>	APOTEX INC	<u>200MG</u>	<u>A075948</u>	<u>001</u>	Feb 27, 2002

<u>AB</u>	TARO	<u>200MG</u>	<u>A074649</u>	<u>001</u>	Oct 03, 1996

<u>AB</u>	TORRENT PHARMS	<u>200MG</u>	<u>A077272</u>	<u>002</u>	Dec 07, 2005

EPITOL

<u>AB</u>	TEVA	<u>200MG</u>	<u>A070541</u>	<u>001</u>	Sep 17, 1986

TEGRETOL

<u>AB</u>	+ NOVARTIS	<u>200MG</u>	<u>N016608</u>	<u>001</u>	

CARBAMAZEPINE

	TORRENT PHARMS	100MG	A077272	001	Dec 07, 2005

		300MG	A077272	003	Dec 07, 2005

		400MG	A077272	004	Dec 07, 2005

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

<u>AB</u>	TARO PHARM INDS	<u>100MG</u>	<u>A075687</u>	<u>001</u>	Oct 24, 2000

<u>AB</u>	TORRENT PHARMS	<u>100MG</u>	<u>A075712</u>	<u>001</u>	Jul 05, 2001

EPITOL

<u>AB</u>	TEVA	<u>100MG</u>	<u>A073524</u>	<u>001</u>	Jul 29, 1992

TEGRETOL

<u>AB</u>	+ NOVARTIS	<u>100MG</u>	<u>N018281</u>	<u>001</u>	

CARBAMAZEPINE

	+ TARO PHARM INDS	200MG	A075687	002	Jul 29, 2002

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

<u>AB</u>	TARO	<u>100MG</u>	<u>A078115</u>	<u>001</u>	Mar 31, 2009

<u>AB</u>		<u>200MG</u>	<u>A078115</u>	<u>002</u>	Mar 31, 2009

<u>AB</u>		<u>400MG</u>	<u>A078115</u>	<u>003</u>	Mar 31, 2009

TEGRETOL - XR

<u>AB</u>	NOVARTIS	<u>100MG</u>	<u>N020234</u>	<u>001</u>	Mar 25, 1996

<u>AB</u>		<u>200MG</u>	<u>N020234</u>	<u>002</u>	Mar 25, 1996

<u>AB</u>	+	<u>400MG</u>	<u>N020234</u>	<u>003</u>	Mar 25, 1996

CARBIDOPA

TABLET; ORAL

LODOSYN

	+ ATON	25MG	N017830	001	

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

<u>AB</u>	SUN PHARMA GLOBAL	<u>25MG;200MG;100MG</u>	<u>A079085</u>	<u>001</u>	May 10, 2012

<u>AB</u>		<u>37.5MG;200MG;150MG</u>	<u>A079085</u>	<u>002</u>	May 10, 2012

<u>AB</u>	WOCKHARDT LTD	<u>12.5MG;200MG;50MG</u>	<u>A090786</u>	<u>001</u>	Nov 20, 2012

<u>AB</u>		<u>18.75MG;200MG;75MG</u>	<u>A090833</u>	<u>001</u>	Nov 20, 2012

<u>AB</u>		<u>25MG;200MG;100MG</u>	<u>A090833</u>	<u>002</u>	Nov 20, 2012

<u>AB</u>		<u>31.25MG;200MG;125MG</u>	<u>A090833</u>	<u>003</u>	Nov 20, 2012

<u>AB</u>		<u>37.5MG;200MG;150MG</u>	<u>A090833</u>	<u>004</u>	Nov 20, 2012

<u>AB</u>		<u>50MG;200MG;200MG</u>	<u>A090833</u>	<u>005</u>	Nov 20, 2012

STALEVO 100

<u>AB</u>	ORION PHARMA	<u>25MG;200MG;100MG</u>	<u>N021485</u>	<u>002</u>	Jun 11, 2003

STALEVO 125

<u>AB</u>	ORION PHARMA	<u>31.25MG;200MG;125MG</u>	<u>N021485</u>	<u>006</u>	Aug 29, 2008

STALEVO 150

<u>AB</u>	ORION PHARMA	<u>37.5MG;200MG;150MG</u>	<u>N021485</u>	<u>003</u>	Jun 11, 2003

STALEVO 200

<u>AB</u>	+ ORION PHARMA	<u>50MG;200MG;200MG</u>	<u>N021485</u>	<u>004</u>	Aug 02, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 75 (of 428)

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

STALEVO 50

<u>AB</u>	+	ORION PHARMA	<u>12.5MG;200MG;50MG</u>	<u>N021485</u>	<u>001</u>	Jun 11, 2003

STALEVO 75

<u>AB</u>		ORION PHARMA	<u>18.75MG;200MG;75MG</u>	<u>N021485</u>	<u>005</u>	Aug 29, 2008

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>		ACTAVIS ELIZABETH	<u>10MG;100MG</u>	<u>A074260</u>	<u>001</u>	Sep 03, 1993

<u>AB</u>			<u>25MG;100MG</u>	<u>A074260</u>	<u>002</u>	Sep 03, 1993

<u>AB</u>			<u>25MG;250MG</u>	<u>A074260</u>	<u>003</u>	Sep 03, 1993

<u>AB</u>		APOTEX INC	<u>10MG;100MG</u>	<u>A077120</u>	<u>001</u>	Jun 02, 2008

<u>AB</u>			<u>25MG;100MG</u>	<u>A077120</u>	<u>002</u>	Jun 02, 2008

<u>AB</u>			<u>25MG;250MG</u>	<u>A077120</u>	<u>003</u>	Jun 02, 2008

<u>AB</u>		MYLAN	<u>10MG;100MG</u>	<u>A090324</u>	<u>001</u>	Sep 28, 2009

<u>AB</u>			<u>25MG;100MG</u>	<u>A090324</u>	<u>002</u>	Sep 28, 2009

<u>AB</u>			<u>25MG;250MG</u>	<u>A090324</u>	<u>003</u>	Sep 28, 2009

<u>AB</u>		SUN PHARM INDS	<u>10MG;100MG</u>	<u>A078536</u>	<u>001</u>	Oct 28, 2008

<u>AB</u>			<u>25MG;100MG</u>	<u>A078536</u>	<u>002</u>	Oct 28, 2008

<u>AB</u>			<u>25MG;250MG</u>	<u>A078536</u>	<u>003</u>	Oct 28, 2008

<u>AB</u>		TEVA	<u>10MG;100MG</u>	<u>A073618</u>	<u>001</u>	Aug 28, 1992

<u>AB</u>			<u>25MG;100MG</u>	<u>A073589</u>	<u>001</u>	Aug 28, 1992

<u>AB</u>			<u>25MG;250MG</u>	<u>A073607</u>	<u>001</u>	Aug 28, 1992

SINEMET

<u>AB</u>		MERCK SHARP DOHME	<u>10MG;100MG</u>	<u>N017555</u>	<u>001</u>	

<u>AB</u>			<u>25MG;100MG</u>	<u>N017555</u>	<u>003</u>	

<u>AB</u>	+		<u>25MG;250MG</u>	<u>N017555</u>	<u>002</u>	

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>		APOTEX	<u>25MG;100MG</u>	<u>A076212</u>	<u>001</u>	Jun 16, 2004

<u>AB</u>			<u>50MG;200MG</u>	<u>A076212</u>	<u>002</u>	Jun 16, 2004

<u>AB</u>		IMPAX LABS	<u>25MG;100MG</u>	<u>A076521</u>	<u>001</u>	May 14, 2004

<u>AB</u>			<u>50MG;200MG</u>	<u>A076521</u>	<u>002</u>	May 14, 2004

<u>AB</u>		MYLAN	<u>25MG;100MG</u>	<u>A075091</u>	<u>002</u>	Apr 21, 2000

<u>AB</u>			<u>50MG;200MG</u>	<u>A075091</u>	<u>001</u>	Sep 30, 1999

<u>AB</u>		SUN PHARM INDS	<u>25MG;100MG</u>	<u>A077828</u>	<u>001</u>	Aug 23, 2007

<u>AB</u>			<u>50MG;200MG</u>	<u>A077828</u>	<u>002</u>	Aug 23, 2007

SINEMET CR

<u>AB</u>		MERCK SHARP DOHME	<u>25MG;100MG</u>	<u>N019856</u>	<u>002</u>	Dec 24, 1992

<u>AB</u>	+		<u>50MG;200MG</u>	<u>N019856</u>	<u>001</u>	May 30, 1991

TABLET, ORALLY DISINTEGRATING; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>		IMPAX LABS	<u>10MG;100MG</u>	<u>A090631</u>	<u>001</u>	Jun 08, 2010

<u>AB</u>			<u>25MG;100MG</u>	<u>A090631</u>	<u>002</u>	Jun 08, 2010

<u>AB</u>			<u>25MG;250MG</u>	<u>A090631</u>	<u>003</u>	Jun 08, 2010

<u>AB</u>		MYLAN	<u>10MG;100MG</u>	<u>A078893</u>	<u>001</u>	Sep 18, 2008

<u>AB</u>			<u>25MG;100MG</u>	<u>A078893</u>	<u>002</u>	Sep 18, 2008

<u>AB</u>			<u>25MG;250MG</u>	<u>A078893</u>	<u>003</u>	Sep 18, 2008

<u>AB</u>		SUN PHARM INDS	<u>10MG;100MG</u>	<u>A078690</u>	<u>001</u>	Jul 31, 2009

<u>AB</u>			<u>25MG;100MG</u>	<u>A078690</u>	<u>002</u>	Jul 31, 2009

<u>AB</u>			<u>25MG;250MG</u>	<u>A078690</u>	<u>003</u>	Jul 31, 2009

PARCOPA

<u>AB</u>		UCB INC	<u>10MG;100MG</u>	<u>A076699</u>	<u>001</u>	Aug 27, 2004

<u>AB</u>			<u>25MG;100MG</u>	<u>A076699</u>	<u>002</u>	Aug 27, 2004

<u>AB</u>	+		<u>25MG;250MG</u>	<u>A076699</u>	<u>003</u>	Aug 27, 2004

PRESCRIPTION DRUG PRODUCT LIST

3 - 76 (of 428)

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

<u>AA</u>	BOCA PHARMA	<u>4MG/5ML</u>	<u>A040814</u>	<u>001</u>	Feb 26, 2008
<u>AA</u>	CYPRESS PHARM	<u>4MG/5ML</u>	<u>A090418</u>	<u>001</u>	May 04, 2010
<u>AA</u> +	MIKART	<u>4MG/5ML</u>	<u>A040458</u>	<u>001</u>	Apr 25, 2003

TABLET; ORAL

CARBINOXAMINE MALEATE

<u>AA</u>	BOCA PHARMA	<u>4MG</u>	<u>A040639</u>	<u>002</u>	May 30, 2008
<u>AA</u>	CYPRESS PHARM	<u>4MG</u>	<u>A090417</u>	<u>001</u>	Aug 23, 2010
<u>AA</u>	INVAGEN PHARMS	<u>4MG</u>	<u>A090435</u>	<u>001</u>	Apr 15, 2010
<u>AA</u>	LYNROSE LABS	<u>4MG</u>	<u>A090756</u>	<u>001</u>	May 27, 2011
<u>AA</u> +	MIKART	<u>4MG</u>	<u>A040442</u>	<u>001</u>	Mar 19, 2003

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

<u>AP</u>	BEDFORD	<u>50MG/VIAL</u>	<u>A076099</u>	<u>001</u>	Oct 14, 2004
<u>AP</u>		<u>150MG/VIAL</u>	<u>A076099</u>	<u>002</u>	Oct 14, 2004
<u>AP</u>		<u>450MG/VIAL</u>	<u>A076099</u>	<u>003</u>	Oct 14, 2004
<u>AP</u>	CIPLA LTD	<u>50MG/VIAL</u>	<u>A077383</u>	<u>001</u>	Jan 27, 2006
<u>AP</u>		<u>150MG/VIAL</u>	<u>A077383</u>	<u>002</u>	Jan 27, 2006
<u>AP</u>		<u>450MG/VIAL</u>	<u>A077383</u>	<u>003</u>	Jan 27, 2006
<u>AP</u>	FRESENIUS KABI USA	<u>50MG/VIAL</u>	<u>A076235</u>	<u>001</u>	Oct 14, 2004
<u>AP</u>		<u>150MG/VIAL</u>	<u>A076235</u>	<u>002</u>	Oct 14, 2004
<u>AP</u>		<u>450MG/VIAL</u>	<u>A076235</u>	<u>003</u>	Oct 14, 2004
<u>AP</u>	ONCO THERAPIES LTD	<u>50MG/VIAL</u>	<u>A091510</u>	<u>001</u>	May 29, 2012
<u>AP</u>		<u>150MG/VIAL</u>	<u>A091510</u>	<u>002</u>	May 29, 2012
<u>AP</u>		<u>450MG/VIAL</u>	<u>A091510</u>	<u>003</u>	May 29, 2012
<u>AP</u>	PLIVA	<u>50MG/VIAL</u>	<u>A076602</u>	<u>001</u>	Nov 16, 2004
<u>AP</u>		<u>150MG/VIAL</u>	<u>A076602</u>	<u>002</u>	Nov 16, 2004
<u>AP</u>		<u>450MG/VIAL</u>	<u>A076602</u>	<u>003</u>	Nov 16, 2004
<u>AP</u>	SANDOZ	<u>50MG/VIAL</u>	<u>A076959</u>	<u>001</u>	Mar 18, 2005
<u>AP</u>		<u>150MG/VIAL</u>	<u>A076959</u>	<u>002</u>	Mar 18, 2005
<u>AP</u>		<u>450MG/VIAL</u>	<u>A076959</u>	<u>003</u>	Mar 18, 2005
<u>AP</u> +	WATSON LABS	<u>50MG/VIAL</u>	<u>A076162</u>	<u>001</u>	Oct 14, 2004
<u>AP</u> +		<u>150MG/VIAL</u>	<u>A076162</u>	<u>002</u>	Oct 14, 2004
<u>AP</u> +		<u>450MG/VIAL</u>	<u>A076162</u>	<u>003</u>	Oct 14, 2004

INJECTABLE; IV (INFUSION)

CARBOPLATIN

<u>AP</u>	ACTAVIS TOTOWA	<u>50MG/5ML (10MG/ML)</u>	<u>A078732</u>	<u>001</u>	Feb 06, 2012
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078732</u>	<u>002</u>	Feb 06, 2012
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A078732</u>	<u>003</u>	Feb 06, 2012
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A078732</u>	<u>004</u>	Feb 06, 2012
<u>AP</u>	AKORN	<u>50MG/5ML (10MG/ML)</u>	<u>A090475</u>	<u>001</u>	Jul 29, 2009
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A090475</u>	<u>002</u>	Jul 29, 2009
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A090475</u>	<u>003</u>	Jul 29, 2009
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A091268</u>	<u>002</u>	Jul 28, 2010
<u>AP</u>	BEDFORD LABS	<u>50MG/5ML (10MG/ML)</u>	<u>A077244</u>	<u>001</u>	Oct 15, 2004
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077244</u>	<u>002</u>	Oct 15, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077244</u>	<u>003</u>	Oct 15, 2004
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077244</u>	<u>004</u>	Jan 20, 2006
<u>AP</u>	BIONICHE PHARMA USA	<u>50MG/5ML (10MG/ML)</u>	<u>A077998</u>	<u>001</u>	Apr 24, 2007
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077998</u>	<u>002</u>	Apr 24, 2007
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077998</u>	<u>003</u>	Apr 24, 2007
<u>AP</u>	CIPLA LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A077861</u>	<u>001</u>	Jan 18, 2007
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077861</u>	<u>002</u>	Jan 18, 2007
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077861</u>	<u>003</u>	Jan 18, 2007
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077861</u>	<u>004</u>	Jan 18, 2007
<u>AP</u>	EBEWE PHARMA	<u>50MG/5ML (10MG/ML)</u>	<u>A078280</u>	<u>001</u>	May 08, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078280</u>	<u>002</u>	May 08, 2008

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 77 (of 428)

CARBOPLATIN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

<u>AP</u>	EBEWE PHARMA	<u>450MG/45ML (10MG/ML)</u>	<u>A078280</u>	<u>003</u>	May 08, 2008
<u>AP</u>	FRESENIUS KABI ONCOL	<u>150MG/15ML (10MG/ML)</u>	<u>A077432</u>	<u>002</u>	Sep 29, 2006
<u>AP</u>		<u>50MG/5ML (10MG/ML)</u>	<u>A077432</u>	<u>001</u>	Sep 29, 2006
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077432</u>	<u>003</u>	Sep 29, 2006
<u>AP</u>	FRESENIUS KABI USA	<u>50MG/5ML (10MG/ML)</u>	<u>A077266</u>	<u>001</u>	Feb 15, 2006
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077266</u>	<u>002</u>	Feb 15, 2006
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077247</u>	<u>003</u>	Oct 21, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077266</u>	<u>003</u>	Feb 15, 2006
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077266</u>	<u>004</u>	Feb 15, 2006
<u>AP</u>	HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A076517</u>	<u>001</u>	Oct 14, 2004
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A076517</u>	<u>002</u>	Oct 14, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A076517</u>	<u>003</u>	Oct 14, 2004
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077059</u>	<u>001</u>	Nov 23, 2004
<u>AP</u>	ONCO THERAPIES LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A091063</u>	<u>001</u>	Nov 09, 2011
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A091063</u>	<u>002</u>	Nov 09, 2011
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A091063</u>	<u>003</u>	Nov 09, 2011
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A091063</u>	<u>004</u>	Nov 09, 2011
<u>AP</u>	+ PHARMACHEMIE	<u>50MG/5ML (10MG/ML)</u>	<u>A077269</u>	<u>001</u>	Oct 14, 2004
<u>AP</u>	+	<u>150MG/15ML (10MG/ML)</u>	<u>A077269</u>	<u>002</u>	Oct 14, 2004
<u>AP</u>	+	<u>450MG/45ML (10MG/ML)</u>	<u>A077269</u>	<u>003</u>	Oct 14, 2004
<u>AP</u>	+	<u>600MG/60ML (10MG/ML)</u>	<u>A077269</u>	<u>004</u>	Dec 28, 2007
<u>AP</u>	PHARMACHEMIE BV	<u>50MG/5ML (10MG/ML)</u>	<u>A077679</u>	<u>001</u>	Feb 25, 2009
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077679</u>	<u>002</u>	Feb 25, 2009
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077679</u>	<u>003</u>	Feb 25, 2009
<u>AP</u>	PLIVA LACHEMA	<u>50MG/5ML (10MG/ML)</u>	<u>A078631</u>	<u>001</u>	Dec 02, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078631</u>	<u>002</u>	Dec 02, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A078631</u>	<u>003</u>	Dec 02, 2008
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A078631</u>	<u>004</u>	Dec 02, 2008
<u>AP</u>	SUN PHARMA GLOBAL	<u>50MG/5ML (10MG/ML)</u>	<u>A077926</u>	<u>001</u>	Sep 19, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077926</u>	<u>002</u>	Sep 19, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077926</u>	<u>003</u>	Sep 19, 2008
<u>AP</u>	+ TEVA PARENTERAL	<u>50MG/5ML (10MG/ML)</u>	<u>A077139</u>	<u>001</u>	Sep 21, 2005
<u>AP</u>	+	<u>150MG/15ML (10MG/ML)</u>	<u>A077139</u>	<u>002</u>	Sep 21, 2005
<u>AP</u>	+	<u>450MG/45ML (10MG/ML)</u>	<u>A077139</u>	<u>003</u>	Sep 21, 2005
<u>AP</u>	+	<u>600MG/60ML (10MG/ML)</u>	<u>A077139</u>	<u>004</u>	Sep 21, 2005
	CARBOPLATIN				
	+ ONCO THERAPIES LTD	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

HEMABATE

+ PHARMACIA AND UPJOHN EQ 0.25MG BASE/ML N017989 001

CARFILZOMIB

POWDER; INTRAVENOUS

KYPROLIS

+ ONYX PHARMS 60MG/VIAL N202714 001 Jul 20, 2012

CARGLUMIC ACID

TABLET; ORAL

CARBAGLU

+ ORPHAN EUROPE 200MG N022562 001 Mar 18, 2010

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

<u>AA</u>	ADVENT PHARMS	<u>350MG</u>	<u>A040576</u>	<u>001</u>	Jun 07, 2005
<u>AA</u>	AUROBINDO PHARMA	<u>350MG</u>	<u>A040792</u>	<u>001</u>	Aug 06, 2009

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 78 (of 428)

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

<u>AA</u>	COREPHARMA	<u>350MG</u>	<u>A040397</u>	<u>001</u>	Sep 21, 2000
<u>AA</u>	MIRROR PHARMS	<u>350MG</u>	<u>A040823</u>	<u>001</u>	Oct 22, 2008
<u>AA</u>	MUTUAL PHARM	<u>350MG</u>	<u>A089346</u>	<u>001</u>	Oct 17, 1991
<u>AA</u>	PROSAM LABS	<u>350MG</u>	<u>A040188</u>	<u>001</u>	Mar 07, 1997
<u>AA</u>	SUN PHARM INDS LTD	<u>350MG</u>	<u>A040755</u>	<u>001</u>	Feb 27, 2007
<u>AA</u>	VINTAGE PHARMS	<u>350MG</u>	<u>A040245</u>	<u>001</u>	Sep 08, 1997
<u>AA</u>	WATSON LABS	<u>350MG</u>	<u>A087499</u>	<u>001</u>	Apr 20, 1982
<u>AA</u>	WEST WARD	<u>350MG</u>	<u>A040124</u>	<u>001</u>	Jan 24, 1996
<u>SOMA</u>					
<u>AA</u>	MEDA PHARMS	<u>350MG</u>	<u>N011792</u>	<u>001</u>	
SOMA					
	+ MEDA PHARMS	250MG	N011792	004	Sep 13, 2007

CARMUSTINEIMPLANT; INTRACRANIAL
GLIADEL

+ ARBOR PHARMS INC 7.7MG N020637 001 Sep 23, 1996

INJECTABLE; INJECTION
BICNU

+ BRISTOL 100MG/VIAL N017422 001

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

<u>AT</u>	ALCON	<u>1%</u>	<u>A075476</u>	<u>001</u>	Jan 03, 2000
<u>AT</u>	BAUSCH AND LOMB	<u>1%</u>	<u>A075546</u>	<u>001</u>	Jan 20, 2000
<u>AT</u>	NOVEX	<u>1%</u>	<u>A076097</u>	<u>001</u>	Feb 06, 2002
<u>OCUPRESS</u>					
<u>AT</u>	+ NOVARTIS	<u>1%</u>	<u>N019972</u>	<u>001</u>	May 23, 1990

CARVEDILOL

TABLET; ORAL

CARVEDILOL

<u>AB</u>	APOTEX INC	<u>3.125MG</u>	<u>A078165</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078165</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078165</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078165</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>3.125MG</u>	<u>A078332</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078332</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078332</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078332</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	BEXIMCO USA	<u>3.125MG</u>	<u>A078384</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078384</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078384</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078384</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	CARACO	<u>3.125MG</u>	<u>A077346</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077346</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077346</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077346</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>3.125MG</u>	<u>A076649</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076649</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076649</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076649</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	GLENMARK GENERICS	<u>3.125MG</u>	<u>A078251</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078251</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078251</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078251</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	HIKMA	<u>3.125MG</u>	<u>A077887</u>	<u>001</u>	Sep 07, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 79 (of 428)

CARVEDILOL

TABLET; ORAL

CARVEDILOL

<u>AB</u>	HIKMA	<u>6.25MG</u>	<u>A077887</u>	<u>002</u>	Sep 07, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077887</u>	<u>003</u>	Sep 07, 2007
<u>AB</u>		<u>25MG</u>	<u>A077887</u>	<u>004</u>	Sep 07, 2007
<u>AB</u>	LUPIN	<u>3.125MG</u>	<u>A078217</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078217</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078217</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078217</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	MYLAN	<u>3.125MG</u>	<u>A077316</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077316</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077316</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077316</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	PLIVA HRVATSKA DOO	<u>3.125MG</u>	<u>A078240</u>	<u>001</u>	Oct 30, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078240</u>	<u>002</u>	Oct 30, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078240</u>	<u>003</u>	Oct 30, 2007
<u>AB</u>		<u>25MG</u>	<u>A078240</u>	<u>004</u>	Oct 30, 2007
<u>AB</u>	RANBAXY	<u>3.125MG</u>	<u>A076989</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076989</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076989</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076989</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	SANDOZ	<u>3.125MG</u>	<u>A078227</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078227</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078227</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078227</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	TARO	<u>3.125MG</u>	<u>A077780</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077780</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077780</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077780</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	TEVA	<u>3.125MG</u>	<u>A076373</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076373</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076373</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076373</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	WATSON LABS	<u>3.125MG</u>	<u>A077474</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077474</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077474</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077474</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	WOCKHARDT	<u>3.125MG</u>	<u>A078786</u>	<u>001</u>	Dec 22, 2009
<u>AB</u>		<u>6.25MG</u>	<u>A078786</u>	<u>002</u>	Dec 22, 2009
<u>AB</u>		<u>12.5MG</u>	<u>A078786</u>	<u>003</u>	Dec 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A078786</u>	<u>004</u>	Dec 22, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>3.125MG</u>	<u>A077614</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077614</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077614</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077614</u>	<u>003</u>	Sep 05, 2007
<u>COREG</u>					
<u>AB</u>	SMITHKLINE BEECHAM	<u>3.125MG</u>	<u>N020297</u>	<u>004</u>	May 29, 1997
<u>AB</u>		<u>6.25MG</u>	<u>N020297</u>	<u>003</u>	Sep 14, 1995
<u>AB</u>	+	<u>12.5MG</u>	<u>N020297</u>	<u>002</u>	Sep 14, 1995
<u>AB</u>		<u>25MG</u>	<u>N020297</u>	<u>001</u>	Sep 14, 1995

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

COREG CR

SB PHARMCO

10MG

N022012 001 Oct 20, 2006

20MG

N022012 002 Oct 20, 2006

+

40MG

N022012 003 Oct 20, 2006

80MG

N022012 004 Oct 20, 2006

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 80 (of 428)

CASPOFUNGIN ACETATE

INJECTABLE; IV (INFUSION)

+	MERCK	50MG/VIAL	N021227	001	Jan 26, 2001
+		70MG/VIAL	N021227	002	Jan 26, 2001

CEFACLOR

CAPSULE; ORAL

CEFACLOR

<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A065350</u>	<u>001</u>	Apr 03, 2007
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A065350</u>	<u>002</u>	Apr 03, 2007
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065146</u>	<u>001</u>	Jan 22, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065146</u>	<u>002</u>	Jan 22, 2004

FOR SUSPENSION; ORAL

CEFACLOR

<u>AB</u>	YUNG SHIN PHARM	<u>EQ 125MG BASE/5ML</u>	<u>A065412</u>	<u>001</u>	Feb 17, 2012
<u>AB</u>		<u>EQ 187MG BASE/5ML</u>	<u>A065412</u>	<u>002</u>	Feb 17, 2012
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065412</u>	<u>003</u>	Feb 17, 2012
<u>AB</u>		<u>EQ 375MG BASE/5ML</u>	<u>A065412</u>	<u>004</u>	Feb 17, 2012

TABLET, EXTENDED RELEASE; ORAL

CEFACLOR

	TEVA	EQ 375MG BASE	A065058	001	Sep 04, 2002
+		EQ 500MG BASE	A065058	002	Sep 04, 2002

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 500MG BASE</u>	<u>A065352</u>	<u>001</u>	Jan 25, 2007
<u>AB</u>	HIKMA	<u>EQ 500MG BASE</u>	<u>A065311</u>	<u>001</u>	Feb 07, 2006
<u>AB</u>	LUPIN	<u>EQ 500MG BASE</u>	<u>A065392</u>	<u>001</u>	May 29, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 500MG BASE</u>	<u>A065309</u>	<u>001</u>	Sep 18, 2006
<u>AB</u>	SANDOZ	<u>EQ 500MG BASE</u>	<u>A062291</u>	<u>001</u>	
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A065282</u>	<u>001</u>	Jan 20, 2006

FOR SUSPENSION; ORAL

CEFADROXIL

<u>AB</u>	HIKMA PHARMS	<u>EQ 250MG BASE/5ML</u>	<u>A091036</u>	<u>001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A091036</u>	<u>002</u>	Nov 28, 2012
<u>AB</u>	LUPIN	<u>EQ 250MG BASE/5ML</u>	<u>A065396</u>	<u>001</u>	Feb 21, 2008
<u>AB</u>	+	<u>EQ 500MG BASE/5ML</u>	<u>A065396</u>	<u>002</u>	Feb 21, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 250MG BASE/5ML</u>	<u>A065307</u>	<u>002</u>	Oct 16, 2006
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A065307</u>	<u>003</u>	Oct 16, 2006
<u>AB</u>	RANBAXY	<u>EQ 250MG BASE/5ML</u>	<u>A065115</u>	<u>002</u>	Mar 26, 2003
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A065115</u>	<u>003</u>	Mar 26, 2003
<u>AB</u>	TEVA PHARMS	<u>EQ 250MG BASE/5ML</u>	<u>A065278</u>	<u>001</u>	Jan 20, 2006
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A065278</u>	<u>002</u>	Jan 20, 2006

CEFADROXIL

RANBAXY

	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003

TABLET; ORAL

CEFADROXIL

<u>AB</u>	HIKMA	<u>EQ 1GM BASE</u>	<u>A065260</u>	<u>001</u>	Mar 30, 2006
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1GM BASE</u>	<u>A065301</u>	<u>001</u>	Sep 18, 2006
	CEFADROXIL				
+	TEVA PHARMS	EQ 1GM BASE	A062774	001	Apr 08, 1987

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

<u>AP</u>	ACS DOBFAR	<u>EQ 500MG BASE/VIAL</u>	<u>A065303</u>	<u>001</u>	Oct 22, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065303</u>	<u>002</u>	Oct 22, 2008
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065306</u>	<u>001</u>	Oct 22, 2008
<u>AP</u>	AUROBINDO PHARMA	<u>EQ 500MG BASE/VIAL</u>	<u>A065395</u>	<u>001</u>	Aug 08, 2008

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 81 (of 428)

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

<u>AP</u>	AUROBINDO PHARMA	<u>EQ 1GM BASE/VIAL</u>	<u>A065395</u>	<u>002</u>	Aug 08, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 500MG BASE/VIAL</u>	<u>A065047</u>	<u>001</u>	Sep 18, 2001
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065047</u>	<u>002</u>	Sep 18, 2001
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065143</u>	<u>001</u>	Oct 18, 2004
<u>AP</u>	HOSPIRA INC	<u>EQ 500MG BASE/VIAL</u>	<u>A065226</u>	<u>001</u>	Apr 21, 2005
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065226</u>	<u>002</u>	Apr 21, 2005
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065244</u>	<u>001</u>	Aug 12, 2005
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065247</u>	<u>001</u>	Aug 12, 2005
<u>AP</u>	SANDOZ	<u>EQ 500MG BASE/VIAL</u>	<u>A062831</u>	<u>001</u>	Dec 09, 1988
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062831</u>	<u>002</u>	Dec 09, 1988
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065345</u>	<u>001</u>	May 09, 2007
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A062831</u>	<u>003</u>	Sep 25, 1992
<u>AP</u>	STERI PHARMA	<u>EQ 500MG BASE/VIAL</u>	<u>A063214</u>	<u>001</u>	Dec 27, 1991
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A063216</u>	<u>001</u>	Dec 27, 1991
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A063207</u>	<u>001</u>	Dec 27, 1991
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A063208</u>	<u>001</u>	Dec 27, 1991
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A063209</u>	<u>001</u>	Dec 27, 1991
<u>AP</u>		<u>EQ 20GM BASE/VIAL</u>	<u>A063209</u>	<u>002</u>	Apr 30, 1999
<u>KEFZOL</u>					
<u>AP</u>	ACS DOBFAR	<u>EQ 500MG BASE/VIAL</u>	<u>A061773</u>	<u>002</u>	
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A061773</u>	<u>003</u>	
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A061773</u>	<u>004</u>	
ANCEF IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	EQ 10MG BASE/ML	A063002	001	Mar 28, 1991
+		EQ 20MG BASE/ML	A063002	002	Mar 28, 1991
CEFAZOLIN AND DEXTROSE					
+	B BRAUN	EQ 1GM BASE/VIAL	N050779	002	Jul 27, 2000
		EQ 2GM BASE/VIAL	N050779	003	Jan 13, 2012
CEFAZOLIN SODIUM					
+	SAMSON MEDCL	EQ 100GM BASE/VIAL	A065141	001	Nov 29, 2006
+		EQ 300GM BASE/VIAL	A065141	002	Nov 29, 2006

CEFDINIR

CAPSULE; ORAL

CEFDINIR

<u>AB</u>	AUROBINDO PHARMA	<u>300MG</u>	<u>A065434</u>	<u>001</u>	Jan 07, 2008
<u>AB</u>	LUPIN	<u>300MG</u>	<u>A065264</u>	<u>001</u>	May 19, 2006
<u>AB</u>	ORCHID HLTHCARE	<u>300MG</u>	<u>A065418</u>	<u>001</u>	Jul 18, 2007
<u>AB</u>	+ SANDOZ	<u>300MG</u>	<u>A065330</u>	<u>001</u>	Apr 06, 2007
<u>AB</u>	TEVA PHARMS	<u>300MG</u>	<u>A065368</u>	<u>001</u>	May 09, 2007

FOR SUSPENSION; ORAL

CEFDINIR

<u>AB</u>	AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065473</u>	<u>001</u>	Dec 14, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065473</u>	<u>002</u>	Dec 14, 2007
<u>AB</u>	LUPIN	<u>125MG/5ML</u>	<u>A065259</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065259</u>	<u>002</u>	May 07, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065429</u>	<u>001</u>	Jul 18, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065429</u>	<u>002</u>	Jul 18, 2007
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065337</u>	<u>001</u>	Apr 06, 2007
<u>AB</u>	+	<u>250MG/5ML</u>	<u>A065337</u>	<u>002</u>	Apr 06, 2007
<u>AB</u>	TEVA PHARMS	<u>125MG/5ML</u>	<u>A065332</u>	<u>001</u>	May 04, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065332</u>	<u>002</u>	May 04, 2007

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

	VANSEN PHARMA	200MG	N021222	001	Aug 29, 2001
+		400MG	N021222	002	Jul 21, 2008

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 82 (of 428)

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065441</u>	<u>001</u>	Mar 20, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065441</u>	<u>002</u>	Mar 20, 2008
<u>AP</u>	HOSPIRA INC	<u>EQ 500MG BASE/VIAL</u>	<u>A065369</u>	<u>001</u>	Jun 18, 2007
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065369</u>	<u>002</u>	Jun 18, 2007
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A202268</u>	<u>001</u>	Jul 30, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065369</u>	<u>003</u>	Jun 18, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A202268</u>	<u>002</u>	Jul 30, 2012
<u>AP</u>	SANDOZ	<u>EQ 500MG BASE/VIAL</u>	<u>A090291</u>	<u>001</u>	Dec 21, 2010
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090291</u>	<u>002</u>	Dec 21, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090291</u>	<u>003</u>	Dec 21, 2010
	<u>MAXIPIME</u>				
<u>AP</u>	+ HOSPIRA INC	<u>EQ 500MG BASE/VIAL</u>	<u>N050679</u>	<u>001</u>	Jan 18, 1996
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>N050679</u>	<u>002</u>	Jan 18, 1996
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>N050679</u>	<u>003</u>	Jan 18, 1996
	CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER				
	B BRAUN	EQ 1GM BASE/VIAL	N050821	001	May 06, 2010
		EQ 2GM BASE/VIAL	N050821	002	May 06, 2010
	CEFEPIME IN PLASTIC CONTAINER				
	+ BAXTER HLTHCARE	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N050817	001	Aug 05, 2008
	+	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N050817	002	Aug 05, 2008

CEFIXIME

CAPSULE; ORAL

SUPRAX

	+ LUPIN LTD	400MG	N203195	001	Jun 01, 2012
	SUSPENSION; ORAL				
	SUPRAX				
	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004
	+	200MG/5ML	A065355	001	Apr 10, 2007
	TABLET; ORAL				
	SUPRAX				
	+ LUPIN PHARMS	400MG	A065130	001	Feb 12, 2004
	TABLET, CHEWABLE; ORAL				
	SUPRAX				
	LUPIN LTD	100MG	A065380	001	Oct 25, 2010
		150MG	A065380	002	Oct 25, 2010
	+	200MG	A065380	003	Oct 25, 2010

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

<u>AP</u>	HIKMA	<u>EQ 500MG BASE/VIAL</u>	<u>A065072</u>	<u>001</u>	Nov 20, 2002
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065072</u>	<u>002</u>	Nov 20, 2002
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065072</u>	<u>003</u>	Nov 20, 2002
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065071</u>	<u>001</u>	Nov 20, 2002
<u>AP</u>	WOCKHARDT	<u>EQ 1GM BASE/VIAL</u>	<u>A065197</u>	<u>001</u>	Aug 29, 2006
	<u>CEFOTAXIME SODIUM</u>				
<u>AP</u>	AUROBINDO PHARMA	<u>EQ 500MG BASE/VIAL</u>	<u>A065517</u>	<u>001</u>	Nov 06, 2009
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065517</u>	<u>002</u>	Nov 06, 2009
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065517</u>	<u>003</u>	Nov 06, 2009
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065516</u>	<u>001</u>	Nov 06, 2009
<u>AP</u>	HOSPIRA INC	<u>EQ 500MG BASE/VIAL</u>	<u>A065290</u>	<u>001</u>	Aug 11, 2006
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065290</u>	<u>002</u>	Aug 11, 2006
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065293</u>	<u>001</u>	Aug 10, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065290</u>	<u>003</u>	Aug 11, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065293</u>	<u>002</u>	Aug 10, 2006
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065292</u>	<u>001</u>	Aug 10, 2006
<u>AP</u>	LUPIN	<u>EQ 500MG BASE/VIAL</u>	<u>A065124</u>	<u>001</u>	Sep 24, 2003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 83 (of 428)

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

<u>AP</u>	LUPIN	<u>EQ 1GM BASE/VIAL</u>	<u>A065124</u>	<u>002</u>	Sep 24, 2003
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065124</u>	<u>003</u>	Sep 24, 2003
<u>AP</u>	WOCKHARDT	<u>EQ 500MG BASE/VIAL</u>	<u>A065197</u>	<u>002</u>	Jun 20, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065197</u>	<u>003</u>	Jun 20, 2008
	<u>CLAFORAN</u>				
<u>AP</u>	+ SANOFI AVENTIS US	<u>EQ 500MG BASE/VIAL</u>	<u>N050547</u>	<u>001</u>	
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062659</u>	<u>001</u>	Jan 13, 1987
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>N050547</u>	<u>002</u>	
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A062659</u>	<u>002</u>	Jan 13, 1987
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>N050547</u>	<u>003</u>	
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>N050547</u>	<u>004</u>	Dec 29, 1983
	CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER				
	+ SANOFI AVENTIS US	EQ 20MG BASE/ML	N050596	002	May 20, 1985
	+	EQ 40MG BASE/ML	N050596	004	May 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTETAN

<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 1GM BASE/VIAL</u>	<u>A065374</u>	<u>001</u>	Aug 09, 2007
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A065374</u>	<u>002</u>	Aug 09, 2007
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A065375</u>	<u>001</u>	Aug 09, 2007
<u>AP</u>	WEST-WARD PHARM CORP	<u>EQ 1GM BASE/VIAL</u>	<u>A091031</u>	<u>001</u>	Oct 26, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091031</u>	<u>002</u>	Oct 26, 2011
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A091030</u>	<u>001</u>	Oct 26, 2011
	CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER				
	+ B BRAUN	EQ 1GM BASE/VIAL	A065430	001	Aug 09, 2007
	+	EQ 2GM BASE/VIAL	A065430	002	Aug 09, 2007

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065414</u>	<u>001</u>	Jun 12, 2009
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065414</u>	<u>002</u>	Jun 12, 2009
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065415</u>	<u>001</u>	May 19, 2010
<u>AP</u>	ANTIBIOTICOS BRASIL	<u>EQ 1GM BASE/VIAL</u>	<u>A065467</u>	<u>001</u>	Aug 31, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065467</u>	<u>002</u>	Aug 31, 2011
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065464</u>	<u>001</u>	Aug 31, 2011
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1GM BASE/VIAL</u>	<u>A065238</u>	<u>001</u>	Mar 12, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065238</u>	<u>002</u>	Mar 12, 2010
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065239</u>	<u>001</u>	Mar 02, 2010
<u>AP</u>	HIKMA MAPLE	<u>EQ 1GM BASE/VIAL</u>	<u>A065051</u>	<u>001</u>	Sep 11, 2000
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065051</u>	<u>002</u>	Sep 11, 2000
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065050</u>	<u>001</u>	Sep 11, 2000
<u>AP</u>	HOSPIRA INC	<u>EQ 1GM BASE/VIAL</u>	<u>A065313</u>	<u>001</u>	Jan 23, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065313</u>	<u>002</u>	Jan 23, 2006
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065312</u>	<u>001</u>	Feb 13, 2006
	CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER				
<u>AP</u>	B BRAUN	<u>EQ 1GM BASE/VIAL</u>	<u>A065214</u>	<u>001</u>	Mar 10, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065214</u>	<u>002</u>	Mar 10, 2006
	MEFOXIN IN PLASTIC CONTAINER				
	+ BIONICHE PHARMA	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993
	+	EQ 40MG BASE/ML	A063182	002	Jan 25, 1993

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 50MG BASE/5ML</u>	<u>A065409</u>	<u>001</u>	Jun 08, 2007
<u>AB</u>		<u>EQ 100MG BASE/5ML</u>	<u>A065409</u>	<u>002</u>	Jun 08, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 84 (of 428)

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>	RANBAXY	<u>EQ 50MG BASE/5ML</u>	<u>A065082</u>	<u>001</u>	May 31, 2002
<u>AB</u>		<u>EQ 100MG BASE/5ML</u>	<u>A065082</u>	<u>002</u>	May 31, 2002
<u>AB</u>	SANDOZ	<u>EQ 50MG BASE/5ML</u>	<u>A090031</u>	<u>001</u>	Jan 14, 2009
<u>AB</u>	+	<u>EQ 100MG BASE/5ML</u>	<u>A090031</u>	<u>002</u>	Jan 14, 2009

TABLET; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 100MG BASE</u>	<u>A065370</u>	<u>001</u>	Jun 11, 2007
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A065370</u>	<u>002</u>	Jun 11, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 100MG BASE</u>	<u>A065388</u>	<u>001</u>	Nov 14, 2007
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A065388</u>	<u>002</u>	Nov 14, 2007
<u>AB</u>	RANBAXY	<u>EQ 100MG BASE</u>	<u>A065083</u>	<u>001</u>	Aug 20, 2003
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A065083</u>	<u>002</u>	Aug 20, 2003
<u>AB</u>	SANDOZ	<u>EQ 100MG BASE</u>	<u>A065462</u>	<u>001</u>	May 28, 2008
<u>AB</u>	+	<u>EQ 200MG BASE</u>	<u>A065462</u>	<u>002</u>	May 28, 2008

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

<u>AB</u>	APOTEX INC	<u>125MG/5ML</u>	<u>A065351</u>	<u>001</u>	Feb 29, 2012
<u>AB</u>		<u>250MG/5ML</u>	<u>A065351</u>	<u>002</u>	Feb 29, 2012
<u>AB</u>	AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065381</u>	<u>001</u>	Jan 30, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065381</u>	<u>002</u>	Jan 30, 2007
<u>AB</u>	LUPIN	<u>125MG/5ML</u>	<u>A065261</u>	<u>001</u>	Dec 19, 2005
<u>AB</u>	+	<u>250MG/5ML</u>	<u>A065261</u>	<u>002</u>	Dec 19, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065284</u>	<u>002</u>	Dec 30, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065284</u>	<u>001</u>	Dec 30, 2005
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065257</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065257</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>	TEVA PHARMS	<u>125MG/5ML</u>	<u>A065236</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065236</u>	<u>002</u>	Dec 08, 2005

TABLET; ORAL

CEFPROZIL

<u>AB</u>	APOTEX INC	<u>250MG</u>	<u>A065327</u>	<u>001</u>	Mar 26, 2008
<u>AB</u>		<u>500MG</u>	<u>A065327</u>	<u>002</u>	Mar 26, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A065340</u>	<u>001</u>	May 24, 2007
<u>AB</u>		<u>500MG</u>	<u>A065340</u>	<u>002</u>	May 24, 2007
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A065276</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>	+	<u>500MG</u>	<u>A065276</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A065267</u>	<u>001</u>	Dec 19, 2005
<u>AB</u>		<u>500MG</u>	<u>A065267</u>	<u>002</u>	Dec 19, 2005
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A065235</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>500MG</u>	<u>A065235</u>	<u>002</u>	Nov 14, 2005
<u>AB</u>	TEVA	<u>250MG</u>	<u>A065208</u>	<u>001</u>	Dec 06, 2005
<u>AB</u>		<u>500MG</u>	<u>A065208</u>	<u>002</u>	Dec 06, 2005
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A065428</u>	<u>001</u>	Jun 14, 2007
<u>AB</u>		<u>500MG</u>	<u>A065428</u>	<u>002</u>	Jun 14, 2007

CEFTAROLINE FOSAMIL

POWDER; IV (INFUSION)

	CEREXA	400MG/VIAL	N200327	001	Oct 29, 2010
	+	600MG/VIAL	N200327	002	Oct 29, 2010

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

<u>AP</u>	ACS DOBFAR	<u>500MG/VIAL</u>	<u>A062640</u>	<u>001</u>	Nov 20, 1985
<u>AP</u>		<u>1GM/VIAL</u>	<u>A062640</u>	<u>002</u>	Nov 20, 1985

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 85 (of 428)

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

<u>AP</u>	ACS DOBFAR	<u>2GM/VIAL</u>	<u>A062640</u>	<u>003</u>	Nov 20, 1985
<u>AP</u>		<u>6GM/VIAL</u>	<u>A062640</u>	<u>004</u>	Feb 03, 1992
<u>AP</u>	AUROBINDO PHARMA	<u>500MG/VIAL</u>	<u>A065481</u>	<u>001</u>	May 28, 2010
<u>AP</u>		<u>1GM/VIAL</u>	<u>A065481</u>	<u>002</u>	May 28, 2010
<u>AP</u>		<u>2GM/VIAL</u>	<u>A065481</u>	<u>003</u>	May 28, 2010
<u>AP</u>		<u>6GM/VIAL</u>	<u>A065482</u>	<u>001</u>	May 28, 2010
<u>AP</u>	WOCKHARDT	<u>1GM/VIAL</u>	<u>A065196</u>	<u>001</u>	Oct 15, 2008
<u>FORTAZ</u>					
<u>AP</u>	+ COVIS PHARMA	<u>500MG/VIAL</u>	<u>N050578</u>	<u>001</u>	Jul 19, 1985
<u>AP</u>	+	<u>1GM/VIAL</u>	<u>N050578</u>	<u>002</u>	Jul 19, 1985
<u>AP</u>	+	<u>2GM/VIAL</u>	<u>N050578</u>	<u>003</u>	Jul 19, 1985
<u>AP</u>	+	<u>6GM/VIAL</u>	<u>N050578</u>	<u>004</u>	Jul 19, 1985
<u>TAZICEF</u>					
<u>AP</u>	HOSPIRA	<u>500MG/VIAL</u>	<u>A062662</u>	<u>001</u>	Mar 06, 1986
<u>AP</u>		<u>1GM/VIAL</u>	<u>A062662</u>	<u>002</u>	Mar 06, 1986
<u>AP</u>		<u>1GM/VIAL</u>	<u>A064032</u>	<u>001</u>	Oct 31, 1993
<u>AP</u>		<u>2GM/VIAL</u>	<u>A062662</u>	<u>003</u>	Mar 06, 1986
<u>AP</u>		<u>2GM/VIAL</u>	<u>A064032</u>	<u>002</u>	Oct 31, 1993
<u>AP</u>		<u>6GM/VIAL</u>	<u>A062662</u>	<u>004</u>	Mar 06, 1986
CEFTAZIDIME IN DEXTROSE CONTAINER					
	B BRAUN	EQ 1GM BASE	N050823	001	Jun 13, 2011
	+	EQ 2GM BASE	N050823	002	Jun 13, 2011

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

+	COVIS PHARMA	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989
+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

+	PERNIX THERAP	EQ 400MG BASE	N050685	002	Dec 20, 1995

FOR SUSPENSION; ORAL

CEDAX

+	PERNIX THERAP	EQ 90MG BASE/5ML	N050686	001	Dec 20, 1995

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAXONE

<u>AP</u>	AKORN INC	<u>EQ 250MG BASE/VIAL</u>	<u>A065305</u>	<u>001</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065305</u>	<u>002</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065305</u>	<u>003</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065305</u>	<u>004</u>	Jan 11, 2008
<u>AP</u>	AUROBINDO PHARMA	<u>EQ 250MG BASE/VIAL</u>	<u>A065505</u>	<u>001</u>	Jul 31, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065505</u>	<u>002</u>	Jul 31, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065505</u>	<u>003</u>	Jul 31, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065505</u>	<u>004</u>	Jul 31, 2008
<u>AP</u>	BEDFORD	<u>EQ 250MG BASE/VIAL</u>	<u>A065465</u>	<u>001</u>	Aug 18, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065465</u>	<u>002</u>	Aug 18, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065465</u>	<u>003</u>	Aug 18, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065465</u>	<u>004</u>	Aug 18, 2008
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 250MG BASE/VIAL</u>	<u>A065245</u>	<u>001</u>	Feb 15, 2006
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 250MG BASE/VIAL</u>	<u>A065342</u>	<u>001</u>	Jan 10, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065342</u>	<u>002</u>	Jan 10, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065342</u>	<u>003</u>	Jan 10, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065342</u>	<u>004</u>	Jan 10, 2008
<u>AP</u>	HOSPIRA INC	<u>EQ 250MG BASE/VIAL</u>	<u>A065230</u>	<u>001</u>	Aug 02, 2005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 86 (of 428)

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAXONE

<u>AP</u>	HOSPIRA INC	<u>EQ 500MG BASE/VIAL</u>	<u>A065230</u>	<u>002</u>	Aug 02, 2005
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065230</u>	<u>003</u>	Aug 02, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065230</u>	<u>004</u>	Aug 02, 2005
<u>AP</u>	LUPIN	<u>EQ 250MG BASE/VIAL</u>	<u>A065125</u>	<u>001</u>	Sep 30, 2003
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065125</u>	<u>002</u>	Sep 30, 2003
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065125</u>	<u>003</u>	Sep 30, 2003
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065125</u>	<u>004</u>	Sep 30, 2003
<u>AP</u>	+ SANDOZ	<u>EQ 250MG BASE/VIAL</u>	<u>A065169</u>	<u>001</u>	May 09, 2005
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A065169</u>	<u>002</u>	May 09, 2005
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A065169</u>	<u>003</u>	May 09, 2005
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A065169</u>	<u>004</u>	May 09, 2005
<u>AP</u>	STERI PHARMA	<u>EQ 1GM BASE/VIAL</u>	<u>A065268</u>	<u>001</u>	Feb 28, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065268</u>	<u>002</u>	Feb 28, 2007
<u>AP</u>	TEVA	<u>EQ 1GM BASE/VIAL</u>	<u>A065262</u>	<u>001</u>	Jun 29, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065262</u>	<u>002</u>	Jun 29, 2006
<u>AP</u>	TEVA PHARMS	<u>EQ 250MG BASE/VIAL</u>	<u>A065227</u>	<u>001</u>	Mar 15, 2007
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065227</u>	<u>002</u>	Mar 15, 2007
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065227</u>	<u>003</u>	Mar 15, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065227</u>	<u>004</u>	Mar 15, 2007
<u>AP</u>	WOCKHARDT	<u>EQ 250MG BASE/VIAL</u>	<u>A065391</u>	<u>001</u>	Apr 12, 2007
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065391</u>	<u>002</u>	Apr 12, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065391</u>	<u>003</u>	Apr 12, 2007

INJECTABLE; INJECTION

CEFTRIAXONE

<u>AP</u>	ACS DOBFAR	<u>EQ 500MG BASE/VIAL</u>	<u>A065329</u>	<u>001</u>	Jul 24, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065329</u>	<u>002</u>	Jul 24, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065329</u>	<u>003</u>	Jul 24, 2008
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065328</u>	<u>001</u>	Jul 24, 2008
<u>AP</u>	AUROBINDO PHARMA	<u>EQ 10GM BASE/VIAL</u>	<u>A065504</u>	<u>001</u>	Jul 31, 2008
<u>AP</u>	BEDFORD	<u>EQ 10GM BASE/VIAL</u>	<u>A065475</u>	<u>001</u>	Aug 18, 2008
<u>AP</u>	HOSPIRA INC	<u>EQ 1GM BASE/VIAL</u>	<u>A065231</u>	<u>001</u>	Aug 02, 2005
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A202563</u>	<u>001</u>	Aug 20, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065231</u>	<u>002</u>	Aug 02, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A202563</u>	<u>002</u>	Aug 20, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065232</u>	<u>001</u>	Aug 02, 2005
<u>AP</u>	LUPIN	<u>EQ 10GM BASE/VIAL</u>	<u>A065263</u>	<u>001</u>	Sep 12, 2006
<u>AP</u>	+ SANDOZ	<u>EQ 10GM BASE/VIAL</u>	<u>A065168</u>	<u>001</u>	May 17, 2005
<u>AP</u>	+ SANDOZ INC	<u>EQ 1GM BASE/VIAL</u>	<u>A065204</u>	<u>001</u>	May 03, 2005
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A065204</u>	<u>002</u>	May 03, 2005
<u>AP</u>	STERI PHARMA	<u>EQ 10GM BASE/VIAL</u>	<u>A065269</u>	<u>001</u>	Feb 28, 2007
<u>AP</u>	STRIDES ARCOLAB LTD	<u>EQ 10GM BASE/VIAL</u>	<u>A091068</u>	<u>001</u>	Jan 07, 2013
<u>AP</u>	TEVA	<u>EQ 10GM BASE/VIAL</u>	<u>A065274</u>	<u>001</u>	May 01, 2006
<u>AP</u>	WOCKHARDT	<u>EQ 1GM BASE/VIAL</u>	<u>A065180</u>	<u>001</u>	May 12, 2006

CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER

<u>AP</u>	+ B BRAUN	<u>EQ 1GM BASE/VIAL</u>	<u>N050796</u>	<u>001</u>	Apr 20, 2005
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>N050796</u>	<u>002</u>	Apr 20, 2005

ROCEPHIN

<u>AP</u>	+ HOFFMANN LA ROCHE	<u>EQ 500MG BASE/VIAL</u>	<u>A063239</u>	<u>002</u>	Aug 13, 1993
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A063239</u>	<u>003</u>	Aug 13, 1993

CEFTRIAXONE IN PLASTIC CONTAINER

	BAXTER HLTHCARE	EQ 20MG BASE/ML	A065224	001	Aug 23, 2005
		EQ 40MG BASE/ML	A065224	002	Aug 23, 2005

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

CEFTIN

<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 125MG BASE/5ML</u>	<u>N050672</u>	<u>001</u>	Jun 30, 1994
<u>AB</u>	+	<u>EQ 250MG BASE/5ML</u>	<u>N050672</u>	<u>002</u>	Apr 29, 1997

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 87 (of 428)

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

CEFUROXIME AXETIL

<u>AB</u>	RANBAXY	<u>EQ 125MG BASE/5ML</u>	<u>A065323</u>	<u>001</u>	Feb 05, 2008
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065323</u>	<u>002</u>	Feb 05, 2008

TABLET; ORAL

CEFTIN

<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 125MG BASE</u>	<u>N050605</u>	<u>001</u>	Dec 28, 1987
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>N050605</u>	<u>002</u>	Dec 28, 1987
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>N050605</u>	<u>003</u>	Dec 28, 1987

CEFUROXIME AXETIL

<u>AB</u>	ALKEM LABS LTD	<u>EQ 250MG BASE</u>	<u>A065496</u>	<u>001</u>	Jun 07, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065496</u>	<u>002</u>	Jun 07, 2010
<u>AB</u>	APOTEX	<u>EQ 250MG BASE</u>	<u>A065069</u>	<u>001</u>	Oct 02, 2002
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065069</u>	<u>002</u>	Oct 02, 2002
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 125MG BASE</u>	<u>A065308</u>	<u>001</u>	Mar 29, 2006
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065308</u>	<u>002</u>	Mar 29, 2006
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065308</u>	<u>003</u>	Mar 29, 2006
<u>AB</u>	LUPIN	<u>EQ 250MG BASE</u>	<u>A065135</u>	<u>001</u>	Jul 25, 2003
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065135</u>	<u>002</u>	Jul 25, 2003
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG BASE</u>	<u>A065359</u>	<u>001</u>	Feb 15, 2008
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065359</u>	<u>002</u>	Feb 15, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065359</u>	<u>003</u>	Feb 15, 2008
<u>AB</u>	RANBAXY	<u>EQ 125MG BASE</u>	<u>A065118</u>	<u>001</u>	Apr 25, 2003
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065118</u>	<u>002</u>	Apr 25, 2003
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065118</u>	<u>003</u>	Apr 25, 2003
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A065190</u>	<u>001</u>	Oct 18, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065190</u>	<u>002</u>	Oct 18, 2004
<u>AB</u>	WOCKHARDT	<u>EQ 125MG BASE</u>	<u>A065166</u>	<u>001</u>	Jul 29, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065166</u>	<u>002</u>	Jul 29, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065166</u>	<u>003</u>	Jul 29, 2005

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

<u>AB</u>	HIKMA FARMACEUTICA	<u>EQ 750MG BASE/VIAL</u>	<u>A065048</u>	<u>001</u>	Jan 09, 2004
<u>AB</u>	STERI PHARMA	<u>EQ 750MG BASE/VIAL</u>	<u>A064125</u>	<u>001</u>	May 30, 1997
<u>AB</u>	TEVA PHARMS	<u>EQ 750MG BASE/VIAL</u>	<u>A064192</u>	<u>002</u>	Apr 16, 1998

ZINACEF

<u>AB</u>	+	<u>COVIS PHARMA</u>	<u>EQ 750MG BASE/VIAL</u>	<u>N050558</u>	<u>002</u>	Oct 19, 1983

CEFUROXIME SODIUM

<u>AP</u>	HOSPIRA INC	<u>EQ 750MG BASE/VIAL</u>	<u>A065483</u>	<u>001</u>	Oct 15, 2008

INJECTABLE; INJECTION

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

<u>AP</u>	+	<u>B BRAUN</u>	<u>EQ 750MG BASE/VIAL</u>	<u>N050780</u>	<u>001</u>	Feb 21, 2001
<u>AP</u>	+		<u>EQ 1.5GM BASE/VIAL</u>	<u>N050780</u>	<u>002</u>	Feb 21, 2001

CEFUROXIME SODIUM

<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065048</u>	<u>002</u>	Jan 09, 2004
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A065046</u>	<u>001</u>	Jan 09, 2004
<u>AP</u>	HOSPIRA INC	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065483</u>	<u>002</u>	Oct 15, 2008
<u>AP</u>		<u>EQ 1.5GM BASE/VIAL</u>	<u>A065503</u>	<u>001</u>	Oct 15, 2008
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A065484</u>	<u>001</u>	Oct 15, 2008
<u>AP</u>	STERI PHARMA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A064125</u>	<u>002</u>	May 30, 1997
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A064124</u>	<u>001</u>	May 30, 1997
<u>AP</u>	TEVA PHARMS	<u>EQ 1.5GM BASE/VIAL</u>	<u>A064192</u>	<u>001</u>	Apr 16, 1998
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A064191</u>	<u>001</u>	Apr 16, 1998

ZINACEF

<u>AP</u>	+	<u>COVIS PHARMA</u>	<u>EQ 1.5GM BASE/VIAL</u>	<u>N050558</u>	<u>003</u>	Oct 19, 1983
<u>AP</u>	+		<u>EQ 7.5GM BASE/VIAL</u>	<u>N050558</u>	<u>004</u>	Oct 23, 1986

CEFUROXIME SODIUM IN PLASTIC CONTAINER

	+	<u>SAMSON MEDCL</u>	<u>EQ 75GM BASE/VIAL</u>	<u>A065251</u>	<u>001</u>	Dec 30, 2009

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 88 (of 428)

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME SODIUM IN PLASTIC CONTAINER

+	SAMSON MEDCL	EQ 225GM BASE/VIAL	A065251	002	Dec 30, 2009
	ZINACEF IN PLASTIC CONTAINER				
+	COVIS PHARMA	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989
+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989

CELECOXIB

CAPSULE; ORAL

CELEBREX

	GD SEARLE	50MG	N020998	004	Dec 15, 2006
		100MG	N020998	001	Dec 31, 1998
		200MG	N020998	002	Dec 31, 1998
+		400MG	N020998	003	Aug 29, 2002

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

<u>AB</u>	ALKEM	<u>EQ 250MG BASE</u>	<u>A090836</u>	<u>001</u>	Dec 20, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A090836</u>	<u>002</u>	Dec 20, 2010
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A065253</u>	<u>001</u>	Nov 16, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065253</u>	<u>002</u>	Nov 16, 2005
<u>AB</u>	BELCHER PHARMS	<u>EQ 250MG BASE</u>	<u>A062713</u>	<u>001</u>	Jul 15, 1988
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062713</u>	<u>002</u>	Jul 15, 1988
<u>AB</u>	FACTA FARMA	<u>EQ 250MG BASE</u>	<u>A062118</u>	<u>001</u>	
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062118</u>	<u>002</u>	
<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A065215</u>	<u>001</u>	Jan 24, 2006
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065215</u>	<u>002</u>	Jan 24, 2006
<u>AB</u>	LUPIN	<u>EQ 250MG BASE</u>	<u>A065229</u>	<u>001</u>	Nov 25, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065229</u>	<u>002</u>	Nov 25, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 250MG BASE</u>	<u>A065248</u>	<u>001</u>	Jun 28, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065248</u>	<u>002</u>	Jun 28, 2005
<u>AB</u>	RANBAXY	<u>EQ 250MG BASE</u>	<u>A065007</u>	<u>001</u>	Sep 16, 1999
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065007</u>	<u>002</u>	Sep 16, 1999
<u>AB</u>	STEVENS J	<u>EQ 250MG BASE</u>	<u>A062870</u>	<u>001</u>	Mar 17, 1988
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 250MG BASE</u>	<u>A062791</u>	<u>001</u>	Jun 11, 1987
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062791</u>	<u>002</u>	Jun 11, 1987
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A062702</u>	<u>001</u>	Feb 13, 1987
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062702</u>	<u>002</u>	Feb 13, 1987
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065152</u>	<u>001</u>	Feb 24, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065152</u>	<u>002</u>	Feb 24, 2005

KEFLEX

<u>AB</u>	SHIONOGI INC	<u>EQ 250MG BASE</u>	<u>N050405</u>	<u>002</u>	
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>N050405</u>	<u>003</u>	
	KEFLEX				
+	SHIONOGI INC	EQ 750MG BASE	N050405	005	May 12, 2006

FOR SUSPENSION; ORAL

CEPHALEXIN

<u>AB</u>	FACTA FARMA	<u>EQ 125MG BASE/5ML</u>	<u>A062117</u>	<u>002</u>	
<u>AB</u>	+	<u>EQ 250MG BASE/5ML</u>	<u>A062117</u>	<u>003</u>	
<u>AB</u>	HIKMA PHARMS	<u>EQ 125MG BASE/5ML</u>	<u>A065444</u>	<u>001</u>	Aug 28, 2009
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065444</u>	<u>002</u>	Aug 28, 2009
<u>AB</u>	LUPIN	<u>EQ 125MG BASE/5ML</u>	<u>A065234</u>	<u>001</u>	Aug 17, 2005
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065234</u>	<u>002</u>	Aug 17, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG BASE/5ML</u>	<u>A065326</u>	<u>001</u>	Jul 10, 2006
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065326</u>	<u>002</u>	Jul 10, 2006
<u>AB</u>	RANBAXY	<u>EQ 125MG BASE/5ML</u>	<u>A065081</u>	<u>001</u>	Jul 27, 2001
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065081</u>	<u>002</u>	Jul 27, 2001
<u>AB</u>	TEVA	<u>EQ 125MG BASE/5ML</u>	<u>A062703</u>	<u>001</u>	Feb 13, 1987
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A062703</u>	<u>002</u>	Feb 13, 1987

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 89 (of 428)

CEPHALEXIN

FOR SUSPENSION; ORAL

CEPHALEXIN

<u>AB</u>	YUNG SHIN PHARM	<u>EQ 125MG BASE/5ML</u>	<u>A065336</u>	<u>001</u>	Jul 25, 2007

<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065336</u>	<u>002</u>	Jul 25, 2007

TABLET; ORAL

CEPHALEXIN

TEVA

EQ 250MG BASE

A063023 001 Jan 12, 1989

+

EQ 500MG BASE

A063024 001 Jan 12, 1989

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>5MG/5ML</u>	<u>A090766</u>	<u>001</u>	Oct 07, 2009

<u>AA</u>	APOTEX INC	<u>5MG/5ML</u>	<u>A078412</u>	<u>001</u>	Jun 18, 2008

<u>AA</u>	AUROBINDO PHARMA	<u>5MG/5ML</u>	<u>A090751</u>	<u>001</u>	Dec 16, 2009

<u>AA</u>	CYPRESS PHARM	<u>5MG/5ML</u>	<u>A078488</u>	<u>001</u>	Oct 06, 2008

<u>AA</u>	DR REDDYS LABS LTD	<u>5MG/5ML</u>	<u>A078870</u>	<u>001</u>	Apr 27, 2009

<u>AA</u>	PERRIGO R AND D	<u>5MG/5ML</u>	<u>A078398</u>	<u>001</u>	Jun 17, 2008

<u>AA</u>	SILARX	<u>5MG/5ML</u>	<u>A078876</u>	<u>001</u>	May 11, 2012

<u>AA</u>	SUN PHARM INDS INC	<u>5MG/5ML</u>	<u>A090191</u>	<u>001</u>	Nov 12, 2009

<u>AA</u>	TARO	<u>5MG/5ML</u>	<u>A076601</u>	<u>001</u>	Jun 20, 2008

<u>AA</u>	TEVA PHARMS	<u>5MG/5ML</u>	<u>A077279</u>	<u>001</u>	May 27, 2008

<u>AA</u>	VINTAGE	<u>5MG/5ML</u>	<u>A078496</u>	<u>001</u>	Sep 25, 2009

<u>AA</u>	WOCKHARDT	<u>5MG/5ML</u>	<u>A078757</u>	<u>001</u>	Aug 28, 2009

ZYRTEC

<u>AA</u>	+ MCNEIL CONSUMER	<u>5MG/5ML</u>	<u>N020346</u>	<u>001</u>	Sep 27, 1996

CETRORELIX

INJECTABLE; INJECTION

CETROTIDE

+ EMD SERONO

EQ 0.25MG BASE/ML

N021197 001 Aug 11, 2000

+

EQ 3MG BASE/ML

N021197 002 Aug 11, 2000

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE

<u>AB</u>	APOTEX INC	<u>30MG</u>	<u>A091260</u>	<u>001</u>	Aug 25, 2011

EVOXAC

<u>AB</u>	+ DAIICHI SANKYO CO	<u>30MG</u>	<u>N020989</u>	<u>002</u>	Jan 11, 2000

CHENODIOL

TABLET; ORAL

CHENODIOL

+ NEXGEN PHARMA

250MG

A091019 001 Oct 22, 2009

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

+ ASPEN GLOBAL INC

2MG

N010669 002

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

+ FRESENIUS KABI USA

EQ 1GM BASE/VIAL

A062365 001 Aug 25, 1982

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

<u>AB</u>	BARR	<u>5MG</u>	<u>A084768</u>	<u>001</u>	

<u>AB</u>		<u>10MG</u>	<u>A083116</u>	<u>001</u>	

<u>AB</u>		<u>25MG</u>	<u>A084769</u>	<u>001</u>	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 90 (of 428)

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

<u>AB</u>	USL PHARMA	<u>10MG</u>	<u>A084623</u>	<u>001</u>	
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A086383</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>A086294</u>	<u>001</u>	
<u>AB</u>		<u>25MG</u>	<u>A086382</u>	<u>001</u>	
<u>LIBRIUM</u>					
<u>AB</u>	VALEANT PHARM INTL	<u>5MG</u>	<u>A085461</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>A085472</u>	<u>001</u>	
<u>AB</u>	+	<u>25MG</u>	<u>A085475</u>	<u>001</u>	

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

<u>AT</u>	HI TECH PHARMA	<u>0.12%</u>	<u>A074356</u>	<u>001</u>	May 07, 1996
<u>AT</u>	JOHN O BUTLER CO	<u>0.12%</u>	<u>A076434</u>	<u>001</u>	Nov 29, 2005
<u>AT</u>	LYNE	<u>0.12%</u>	<u>A074291</u>	<u>001</u>	Dec 28, 1995
<u>AT</u>	NOVEX	<u>0.12%</u>	<u>A075561</u>	<u>001</u>	Nov 14, 2000
<u>AT</u>	TEVA	<u>0.12%</u>	<u>A074522</u>	<u>001</u>	Dec 15, 1995
<u>AT</u>	WOCKHARDT	<u>0.12%</u>	<u>A075006</u>	<u>001</u>	Mar 03, 2004
<u>AT</u>	XTTRIUM	<u>0.12%</u>	<u>A077789</u>	<u>001</u>	Jun 18, 2009
<u>PERIDEX</u>					
<u>AT</u>	+	<u>3M</u>	<u>N019028</u>	<u>001</u>	Aug 13, 1986
<u>PERIOGARD</u>					
<u>AT</u>	COLGATE	<u>0.12%</u>	<u>A073695</u>	<u>001</u>	Jan 14, 1994
TABLET; DENTAL					
PERIOCHIP					
	+	DEXCEL PHARMA	2.5MG	N020774	001 May 15, 1998

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLOROPROCAINE HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>2%</u>	<u>A040273</u>	<u>001</u>	Sep 09, 1998
<u>AP</u>		<u>3%</u>	<u>A040273</u>	<u>002</u>	Sep 09, 1998
<u>AP</u>	HOSPIRA	<u>2%</u>	<u>A087447</u>	<u>001</u>	Apr 16, 1982
<u>AP</u>		<u>3%</u>	<u>A087446</u>	<u>001</u>	Apr 16, 1982
<u>NESACAINE</u>					
<u>AP</u>	FRESENIUS KABI USA	<u>2%</u>	<u>N009435</u>	<u>002</u>	
<u>NESACAINE-MPF</u>					
<u>AP</u>	+	FRESENIUS KABI USA	<u>2%</u>	<u>N009435</u>	<u>006</u> May 02, 1996
<u>AP</u>	+		<u>3%</u>	<u>N009435</u>	<u>007</u> May 02, 1996
NESACAINE					
	+	FRESENIUS KABI USA	1%	N009435	001

CHLOROQUINE PHOSPHATE

TABLET; ORAL

ARALEN

<u>AA</u>	+	SANOFI AVENTIS US	<u>EQ 300MG BASE</u>	<u>N006002</u>	<u>001</u>	
		<u>CHLOROQUINE PHOSPHATE</u>				
<u>AA</u>		IMPAX LABS	<u>EQ 150MG BASE</u>	<u>A080880</u>	<u>001</u>	
<u>AA</u>			<u>EQ 300MG BASE</u>	<u>A040516</u>	<u>001</u>	Aug 29, 2003
<u>AA</u>		IPCA LABS LTD	<u>EQ 150MG BASE</u>	<u>A090610</u>	<u>001</u>	Dec 03, 2009
<u>AA</u>			<u>EQ 300MG BASE</u>	<u>A090249</u>	<u>001</u>	Dec 03, 2009
<u>AA</u>		NATCO PHARMA LTD	<u>EQ 150MG BASE</u>	<u>A091621</u>	<u>001</u>	Jan 21, 2011
<u>AA</u>			<u>EQ 300MG BASE</u>	<u>A090612</u>	<u>001</u>	Jan 21, 2011
<u>AA</u>	+	WEST WARD	<u>EQ 150MG BASE</u>	<u>A083082</u>	<u>001</u>	
<u>AA</u>			<u>EQ 300MG BASE</u>	<u>A083082</u>	<u>002</u>	Sep 17, 1999

PRESCRIPTION DRUG PRODUCT LIST

3 - 91 (of 428)

CHLOROTHIAZIDE

SUSPENSION; ORAL				
DIURIL				
	+ SALIX PHARMS	250MG/5ML	N011870	001
TABLET; ORAL				
<u>CHLOROTHIAZIDE</u>				
<u>AB</u>	+ MYLAN	<u>250MG</u>	<u>A084388</u>	<u>001</u>
<u>AB</u>		<u>500MG</u>	<u>A084217</u>	<u>001</u>
<u>AB</u>	WEST WARD	<u>250MG</u>	<u>A086028</u>	<u>001</u> Jul 14, 1982
<u>AB</u>		<u>500MG</u>	<u>A087736</u>	<u>001</u> Jul 14, 1982

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION				
<u>CHLOROTHIAZIDE SODIUM</u>				
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A090896</u>	<u>001</u> Oct 16, 2009
<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 500MG BASE/VIAL</u>	<u>A091546</u>	<u>001</u> Jul 26, 2011
<u>DIURIL</u>				
<u>AP</u>	+ LUNDBECK INC	<u>EQ 500MG BASE/VIAL</u>	<u>N011145</u>	<u>005</u>

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL				
ZUTRIPRO				
	+ CYPRESS PHARM	4MG/5ML;5MG/5ML;60MG/5ML	N022439	001 Jun 08, 2011

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE; ORAL				
TUSSICAPS				
	HI TECH PHARMA CO	EQ 4MG MALEATE;EQ 5MG BITARTRATE	A077273	002 Sep 24, 2007
	+	EQ 8MG MALEATE;EQ 10MG BITARTRATE	A077273	001 Sep 24, 2007
SUSPENSION, EXTENDED RELEASE; ORAL				
<u>HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX</u>				
<u>AB</u>	TRIS PHARMA INC	<u>EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML</u>	<u>A091632</u>	<u>001</u> Oct 01, 2010
<u>HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX</u>				
<u>AB</u>	CORNERSTONE THERAP	<u>EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML</u>	<u>A091671</u>	<u>001</u> Jun 29, 2012
<u>TUSSIONEX PENNKINETIC</u>				
<u>AB</u>	+ UCB INC	<u>EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML</u>	<u>N019111</u>	<u>001</u> Dec 31, 1987

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION				
CHLORPROMAZINE HYDROCHLORIDE				
	+ HIKMA MAPLE	25MG/ML	A083329	001
TABLET; ORAL				
CHLORPROMAZINE HYDROCHLORIDE				
BP	SANDOZ	10MG	A080439	001
BP		25MG	A080439	002
BP		50MG	A080439	003
BP	+	100MG	A080439	004
BP		200MG	A080439	005
BP	USL PHARMA	10MG	A083386	001
BP		25MG	A084112	001
BP		50MG	A084113	001
BP		100MG	A084114	001
BP		200MG	A084115	001

CHLORPROPAMIDE

TABLET; ORAL				
<u>CHLORPROPAMIDE</u>				
<u>AB</u>	MYLAN	<u>100MG</u>	<u>A088549</u>	<u>002</u> Jun 01, 1984
<u>AB</u>		<u>250MG</u>	<u>A088549</u>	<u>001</u> Jun 01, 1984

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 92 (of 428)

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

<u>AB</u>	PLIVA	<u>100MG</u>	<u>A088921</u>	<u>001</u>	Apr 12, 1985
<u>AB</u>		<u>250MG</u>	<u>A088922</u>	<u>001</u>	Apr 12, 1985
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>A088852</u>	<u>001</u>	Sep 26, 1984
<u>AB</u>		<u>250MG</u>	<u>A088826</u>	<u>001</u>	Sep 26, 1984
<u>DIABINESE</u>					
<u>AB</u>	PFIZER	<u>100MG</u>	<u>N011641</u>	<u>003</u>	
<u>AB</u>	+	<u>250MG</u>	<u>N011641</u>	<u>006</u>	

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

<u>AB</u>	MYLAN	<u>25MG</u>	<u>A086831</u>	<u>002</u>	
<u>AB</u>	+	<u>50MG</u>	<u>A086831</u>	<u>001</u>	
<u>AB</u>	PLIVA	<u>25MG</u>	<u>A088902</u>	<u>001</u>	Sep 19, 1985
<u>AB</u>		<u>50MG</u>	<u>A088903</u>	<u>001</u>	Sep 19, 1985
	THALITONE				
	+ MONARCH PHARMS	15MG	N019574	001	Dec 20, 1988

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLORPRES

MYLAN

		15MG;0.1MG	A071325	003	Feb 09, 1987
		15MG;0.2MG	A071325	002	Feb 09, 1987
	+	15MG;0.3MG	A071325	001	Feb 09, 1987

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

<u>AA</u>	BARR	<u>500MG</u>	<u>A089895</u>	<u>001</u>	May 04, 1988
<u>AA</u>	WATSON LABS	<u>500MG</u>	<u>A040137</u>	<u>001</u>	Aug 09, 1996
<u>AA</u>		<u>500MG</u>	<u>A081040</u>	<u>001</u>	Aug 22, 1989
<u>AA</u>		<u>500MG</u>	<u>A089859</u>	<u>001</u>	May 04, 1988
<u>PARAFON FORTE DSC</u>					
<u>AA</u>	+ JANSEN R AND D	<u>500MG</u>	<u>N011529</u>	<u>002</u>	Jun 15, 1987
	CHLORZOXAZONE				
	MIKART	375MG	A040861	001	Jun 01, 2010
		750MG	A040861	002	Jun 01, 2010

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

<u>AB</u>	PAR PHARM	<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A077204</u>	<u>002</u>	Aug 26, 2005
<u>AB</u>		<u>EQ 4GM RESIN/PACKET</u>	<u>A077204</u>	<u>001</u>	Aug 26, 2005
<u>AB</u>	+ SANDOZ	<u>EQ 4GM RESIN/PACKET</u>	<u>A074557</u>	<u>001</u>	Aug 15, 1996
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A074557</u>	<u>002</u>	Aug 15, 1996
<u>CHOLESTYRAMINE LIGHT</u>					
<u>AB</u>	PAR PHARM	<u>EQ 4GM RESIN/PACKET</u>	<u>A077203</u>	<u>001</u>	Aug 26, 2005
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A077203</u>	<u>002</u>	Aug 26, 2005
<u>AB</u>	+ SANDOZ	<u>EQ 4GM RESIN/PACKET</u>	<u>A074558</u>	<u>001</u>	Aug 15, 1996
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A074558</u>	<u>002</u>	Aug 15, 1996
<u>PREVALITE</u>					
<u>AB</u>	UPSHER SMITH	<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A073263</u>	<u>002</u>	Oct 30, 1997
<u>AB</u>		<u>EQ 4GM RESIN/PACKET</u>	<u>A073263</u>	<u>001</u>	Feb 22, 1996

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

	+	MCPRF	4-33.1mCi/ML	N203155	001	Sep 12, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 93 (of 428)

CHOLINE FENOFIBRATECAPSULE, DELAYED RELEASE; ORAL
TRILIPIX

ABBVIE	EQ 45MG FENOFIBRIC ACID	N022224	001	Dec 15, 2008
+	EQ 135MG FENOFIBRIC ACID	N022224	002	Dec 15, 2008

CHORIOGONADOTROPIN ALFAINJECTABLE; SUBCUTANEOUS
OVIDREL

+ EMD SERONO	EQ 0.25MG /0.5ML	N021149	002	Oct 06, 2003

CHROMIC CHLORIDEINJECTABLE; INJECTION
CHROMIC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA	EQ 0.004MG CHROMIUM/ML	N018961	001	Jun 26, 1986

CICLESONIDEAEROSOL, METERED; INHALATION
ALVESCO

TAKEDA GMBH	0.08MG/INH	N021658	002	Jan 10, 2008
+	0.16MG/INH	N021658	003	Jan 10, 2008

AEROSOL, METERED; NASAL
ZETONNA

+ TAKEDA GMBH	0.037MG/INH	N202129	001	Jan 20, 2012

SPRAY, METERED; NASAL
OMNARIS

+ TAKEDA GMBH	0.05MG/INH	N022004	001	Oct 20, 2006

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

<u>AB</u>	FOUGERA PHARMS	<u>0.77%</u>	<u>A076435</u>	<u>001</u>	Dec 29, 2004
<u>AB</u>	G AND W LABS INC	<u>0.77%</u>	<u>A078463</u>	<u>001</u>	Dec 20, 2010
<u>AB</u>	GLENMARK PHARMS	<u>0.77%</u>	<u>A090273</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>	PERRIGO	<u>0.77%</u>	<u>A077364</u>	<u>001</u>	Mar 03, 2006
<u>AB</u>	TARO	<u>0.77%</u>	<u>A076790</u>	<u>001</u>	Apr 12, 2005

LOPROX

<u>AB</u>	+ MEDICIS	<u>0.77%</u>	<u>N018748</u>	<u>001</u>	Dec 30, 1982

GEL; TOPICAL

CICLOPIROX

<u>AB</u>	FOUGERA PHARMS	<u>0.77%</u>	<u>A077896</u>	<u>001</u>	Jun 10, 2008
<u>AB</u>	GLENMARK GENERICS	<u>0.77%</u>	<u>A091595</u>	<u>001</u>	Feb 29, 2012
<u>AB</u>	PADDOCK LLC	<u>0.77%</u>	<u>A078266</u>	<u>001</u>	Jan 07, 2009

LOPROX

<u>AB</u>	+ MEDICIS	<u>0.77%</u>	<u>N020519</u>	<u>001</u>	Jul 21, 1997

SHAMPOO; TOPICAL

CICLOPIROX

<u>AT</u>	FOUGERA PHARMS	<u>1%</u>	<u>A090146</u>	<u>001</u>	May 25, 2010
<u>AT</u>	PERRIGO	<u>1%</u>	<u>A078594</u>	<u>001</u>	Feb 16, 2010
<u>AT</u>	TARO	<u>1%</u>	<u>A090269</u>	<u>001</u>	Feb 23, 2011
<u>AT</u>	WATSON LABS INC	<u>1%</u>	<u>A090490</u>	<u>001</u>	Nov 24, 2009

LOPROX

<u>AT</u>	+ MEDICIS	<u>1%</u>	<u>N021159</u>	<u>001</u>	Feb 28, 2003

SOLUTION; TOPICAL

CICLOPIROX

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>8%</u>	<u>A078046</u>	<u>001</u>	Sep 18, 2007
<u>AT</u>	APOTEX CORP	<u>8%</u>	<u>A078172</u>	<u>001</u>	Sep 18, 2007
<u>AT</u>	G AND W LABS	<u>8%</u>	<u>A078233</u>	<u>001</u>	Sep 18, 2007
<u>AT</u>	HI TECH PHARMA	<u>8%</u>	<u>A078270</u>	<u>001</u>	Sep 18, 2007
<u>AT</u>	MYLAN PHARMS INC	<u>8%</u>	<u>A078567</u>	<u>001</u>	Sep 18, 2007
<u>AT</u>	PERRIGO NEW YORK	<u>8%</u>	<u>A077623</u>	<u>001</u>	Sep 18, 2007
<u>AT</u>	TARO PHARM INDS	<u>8%</u>	<u>A078144</u>	<u>001</u>	Sep 18, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 94 (of 428)

CICLOPIROX

SOLUTION; TOPICAL

CICLOPIROX

<u>AT</u>	TEVA PHARMS	<u>8%</u>	<u>A078079</u>	<u>001</u>	Sep 18, 2007
<u>AT</u>	TOLMAR	<u>8%</u>	<u>A077687</u>	<u>001</u>	Sep 18, 2007
<u>AT</u>	VERSAPHARM	<u>8%</u>	<u>A078975</u>	<u>001</u>	Feb 17, 2010
<u>AT</u>	WATSON LABS	<u>8%</u>	<u>A078124</u>	<u>001</u>	Sep 18, 2007

PENLAC

<u>AT</u>	+ SANOFI AVENTIS US	<u>8%</u>	<u>N021022</u>	<u>001</u>	Dec 17, 1999

SUSPENSION; TOPICAL

CICLOPIROX

<u>AB</u>	FOUGERA PHARMS	<u>0.77%</u>	<u>A076422</u>	<u>001</u>	Aug 06, 2004
<u>AB</u>	PERRIGO NEW YORK	<u>0.77%</u>	<u>A077676</u>	<u>001</u>	Dec 15, 2006
<u>AB</u>	TARO	<u>0.77%</u>	<u>A077092</u>	<u>001</u>	Aug 10, 2005

LOPROX

<u>AB</u>	+ MEDICIS	<u>0.77%</u>	<u>N019824</u>	<u>001</u>	Dec 30, 1988

CIDOFOVIR

INJECTABLE; INJECTION

CIDOFOVIR

<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 75MG BASE/ML</u>	<u>A202501</u>	<u>001</u>	Jul 26, 2012
<u>AP</u>	MYLAN LLC	<u>EQ 75MG BASE/ML</u>	<u>A201276</u>	<u>001</u>	Jun 27, 2012

VISTIDE

<u>AP</u>	+ GILEAD SCIENCES INC	<u>EQ 75MG BASE/ML</u>	<u>N020638</u>	<u>001</u>	Jun 26, 1996

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION

IMIPENEM AND CILASTATIN

<u>AP</u>	ACS DOBFAR	<u>EQ 250MG BASE/VIAL;250MG/VIAL</u>	<u>A090577</u>	<u>001</u>	Dec 21, 2011
<u>AP</u>		<u>EQ 500MG BASE/VIAL;500MG/VIAL</u>	<u>A090577</u>	<u>002</u>	Dec 21, 2011
<u>AP</u>	HOSPIRA INC	<u>EQ 250MG BASE/VIAL;250MG/VIAL</u>	<u>A090825</u>	<u>001</u>	Nov 16, 2011
<u>AP</u>		<u>EQ 500MG BASE/VIAL;500MG/VIAL</u>	<u>A090825</u>	<u>002</u>	Nov 16, 2011
<u>AP</u>		<u>EQ 500MG BASE/VIAL;500MG/VIAL</u>	<u>A091007</u>	<u>001</u>	Nov 16, 2011

PRIMAXIN

<u>AP</u>	MERCK	<u>EQ 250MG BASE/VIAL;250MG/VIAL</u>	<u>A062756</u>	<u>001</u>	Jan 08, 1987
<u>AP</u>	+	<u>EQ 250MG BASE/VIAL;250MG/VIAL</u>	<u>N050587</u>	<u>001</u>	Nov 26, 1985
<u>AP</u>		<u>EQ 500MG BASE/VIAL;500MG/VIAL</u>	<u>A062756</u>	<u>002</u>	Jan 08, 1987
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL;500MG/VIAL</u>	<u>N050587</u>	<u>002</u>	Nov 26, 1985
<u>AP</u>		<u>EQ 500MG BASE/VIAL;500MG/VIAL</u>	<u>N050630</u>	<u>001</u>	Dec 14, 1990

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

<u>AB</u>	APOTEX INC	<u>50MG</u>	<u>A077030</u>	<u>001</u>	Dec 10, 2004
<u>AB</u>		<u>100MG</u>	<u>A077030</u>	<u>002</u>	Dec 10, 2004
<u>AB</u>	BIOKEY	<u>50MG</u>	<u>A077722</u>	<u>001</u>	Sep 24, 2012
<u>AB</u>		<u>100MG</u>	<u>A077831</u>	<u>001</u>	Sep 24, 2012
<u>AB</u>	BRECKENRIDGE PHARM	<u>50MG</u>	<u>A077708</u>	<u>001</u>	Sep 28, 2009
<u>AB</u>		<u>100MG</u>	<u>A077708</u>	<u>002</u>	Sep 28, 2009
<u>AB</u>	COREPHARMA	<u>50MG</u>	<u>A077150</u>	<u>001</u>	Mar 11, 2005
<u>AB</u>		<u>100MG</u>	<u>A077022</u>	<u>001</u>	Nov 23, 2004
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A077323</u>	<u>002</u>	Apr 20, 2006
<u>AB</u>		<u>100MG</u>	<u>A077323</u>	<u>001</u>	Apr 20, 2006
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A077019</u>	<u>001</u>	Nov 23, 2004
<u>AB</u>		<u>100MG</u>	<u>A077019</u>	<u>002</u>	Nov 23, 2004
<u>AB</u>	PLIVA HRVATSKA DOO	<u>50MG</u>	<u>A077898</u>	<u>001</u>	Oct 29, 2007
<u>AB</u>		<u>100MG</u>	<u>A077898</u>	<u>002</u>	Oct 29, 2007
<u>AB</u>	ROXANE	<u>50MG</u>	<u>A077024</u>	<u>001</u>	May 17, 2005
<u>AB</u>		<u>100MG</u>	<u>A077024</u>	<u>002</u>	May 17, 2005
<u>AB</u>	SANDOZ	<u>50MG</u>	<u>A077310</u>	<u>001</u>	Nov 08, 2005
<u>AB</u>		<u>100MG</u>	<u>A077021</u>	<u>001</u>	Nov 23, 2004

PRESCRIPTION DRUG PRODUCT LIST

3 - 95 (of 428)

CILOSTAZOL

TABLET; ORAL				
<u>CILOSTAZOL</u>				
<u>AB</u>	TEVA	<u>50MG</u>	<u>A077027</u>	<u>001</u> Nov 24, 2004
<u>AB</u>		<u>100MG</u>	<u>A077027</u>	<u>002</u> Nov 24, 2004
<u>PLETAL</u>				
<u>AB</u>	+ OTSUKA	<u>50MG</u>	<u>N020863</u>	<u>001</u> Jan 15, 1999
<u>AB</u>	+	<u>100MG</u>	<u>N020863</u>	<u>002</u> Jan 15, 1999

CIMETIDINE

TABLET; ORAL				
<u>CIMETIDINE</u>				
<u>AB</u>	APOTEX	<u>200MG</u>	<u>A074890</u>	<u>001</u> Dec 18, 1998
<u>AB</u>		<u>300MG</u>	<u>A074890</u>	<u>002</u> Dec 18, 1998
<u>AB</u>		<u>400MG</u>	<u>A074890</u>	<u>003</u> Dec 18, 1998
<u>AB</u>		<u>800MG</u>	<u>A074890</u>	<u>004</u> Dec 18, 1998
<u>AB</u>	DAVA PHARMS INC	<u>300MG</u>	<u>A074340</u>	<u>001</u> Jun 23, 1995
<u>AB</u>		<u>400MG</u>	<u>A074340</u>	<u>002</u> Jun 23, 1995
<u>AB</u>		<u>800MG</u>	<u>A074339</u>	<u>001</u> Jun 23, 1995
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>200MG</u>	<u>A074424</u>	<u>001</u> Jul 28, 1995
<u>AB</u>		<u>300MG</u>	<u>A074424</u>	<u>002</u> Jul 28, 1995
<u>AB</u>		<u>400MG</u>	<u>A074424</u>	<u>003</u> Jul 28, 1995
<u>AB</u>		<u>800MG</u>	<u>A074424</u>	<u>004</u> Jul 28, 1995
<u>AB</u>	MYLAN	<u>200MG</u>	<u>A074246</u>	<u>001</u> May 17, 1994
<u>AB</u>		<u>300MG</u>	<u>A074246</u>	<u>002</u> May 17, 1994
<u>AB</u>		<u>400MG</u>	<u>A074246</u>	<u>003</u> May 17, 1994
<u>AB</u>		<u>800MG</u>	<u>A074246</u>	<u>004</u> May 17, 1994
<u>AB</u>	PLIVA	<u>200MG</u>	<u>A074568</u>	<u>001</u> Feb 27, 1997
<u>AB</u>		<u>300MG</u>	<u>A074568</u>	<u>002</u> Feb 27, 1997
<u>AB</u>		<u>400MG</u>	<u>A074568</u>	<u>003</u> Feb 27, 1997
<u>AB</u>		<u>800MG</u>	<u>A074566</u>	<u>001</u> Feb 27, 1997
<u>AB</u>	TEVA	<u>200MG</u>	<u>A074151</u>	<u>001</u> May 17, 1994
<u>AB</u>		<u>300MG</u>	<u>A074151</u>	<u>002</u> May 17, 1994
<u>AB</u>		<u>400MG</u>	<u>A074151</u>	<u>003</u> May 17, 1994
<u>AB</u>		<u>800MG</u>	<u>A074463</u>	<u>001</u> May 17, 1994
<u>AB</u>	WATSON LABS	<u>200MG</u>	<u>A074349</u>	<u>001</u> Aug 30, 1996
<u>AB</u>		<u>300MG</u>	<u>A074349</u>	<u>002</u> Aug 30, 1996
<u>AB</u>		<u>400MG</u>	<u>A074349</u>	<u>003</u> Aug 30, 1996
<u>AB</u>		<u>800MG</u>	<u>A074316</u>	<u>001</u> Feb 28, 1996
<u>TAGAMET</u>				
<u>AB</u>	GLAXOSMITHKLINE	<u>200MG</u>	<u>N017920</u>	<u>002</u>
<u>AB</u>		<u>300MG</u>	<u>N017920</u>	<u>003</u>
<u>AB</u>		<u>400MG</u>	<u>N017920</u>	<u>004</u> Dec 14, 1983
<u>AB</u>	+	<u>800MG</u>	<u>N017920</u>	<u>005</u> Apr 30, 1986

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION				
<u>CIMETIDINE HYDROCHLORIDE</u>				
<u>AP</u>	DAVA PHARMS INC	<u>EQ 300MG BASE/2ML</u>	<u>A074428</u>	<u>001</u> Apr 25, 1996
SOLUTION; ORAL				
<u>CIMETIDINE HYDROCHLORIDE</u>				
<u>AA</u>	+ HI TECH PHARMA	<u>EQ 300MG BASE/5ML</u>	<u>A074664</u>	<u>001</u> Oct 28, 1997
<u>AA</u>	NOVEX	<u>EQ 300MG BASE/5ML</u>	<u>A075560</u>	<u>001</u> Mar 15, 2000
<u>AA</u>	PHARM ASSOC	<u>EQ 300MG BASE/5ML</u>	<u>A074553</u>	<u>001</u> Jan 27, 1997
<u>AA</u>	TEVA	<u>EQ 300MG BASE/5ML</u>	<u>A074610</u>	<u>001</u> Sep 26, 1996
<u>AA</u>	WOCKHARDT	<u>EQ 300MG BASE/5ML</u>	<u>A074757</u>	<u>001</u> Oct 17, 1997

CINACALCET HYDROCHLORIDE

TABLET; ORAL				
SENSIPAR				
	AMGEN	EQ 30MG BASE	N021688	001 Mar 08, 2004

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 96 (of 428)

CINACALCET HYDROCHLORIDETABLET; ORAL
SENSIPAR

AMGEN	EQ 60MG BASE	N021688	002	Mar 08, 2004
+	EQ 90MG BASE	N021688	003	Mar 08, 2004

CIPROFLOXACINFOR SUSPENSION; ORAL
CIPRO

BAYER HLTHCARE	250MG/5ML	N020780	001	Sep 26, 1997
+	500MG/5ML	N020780	002	Sep 26, 1997

INJECTABLE; INJECTION

CIPRO

<u>AP</u>	+	BAYER HLTHCARE	<u>200MG/20ML (10MG/ML)</u>	<u>N019847</u>	<u>002</u>	Dec 26, 1990
<u>AP</u>	+		<u>400MG/40ML (10MG/ML)</u>	<u>N019847</u>	<u>001</u>	Dec 26, 1990

CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	BAYER HLTHCARE	<u>200MG/100ML</u>	<u>N019857</u>	<u>001</u>	Dec 26, 1990
<u>AP</u>	+		<u>400MG/200ML</u>	<u>N019857</u>	<u>002</u>	Dec 26, 1990

CIPROFLOXACIN

<u>AP</u>		CLARIS LIFESCIENCES	<u>200MG/20ML (10MG/ML)</u>	<u>A078062</u>	<u>001</u>	Apr 29, 2008
<u>AP</u>			<u>400MG/40ML (10MG/ML)</u>	<u>A078062</u>	<u>002</u>	Apr 29, 2008
<u>AP</u>		HIKMA FARMACEUTICA	<u>200MG/20ML (10MG/ML)</u>	<u>A076717</u>	<u>001</u>	Dec 22, 2009
<u>AP</u>			<u>400MG/40ML (10MG/ML)</u>	<u>A076717</u>	<u>002</u>	Dec 22, 2009
<u>AP</u>		HOSPIRA	<u>400MG/40ML (10MG/ML)</u>	<u>A077245</u>	<u>002</u>	Aug 28, 2006
<u>AP</u>			<u>200MG/20ML (10MG/ML)</u>	<u>A077245</u>	<u>001</u>	Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>		ACS DOBFAR INFO SA	<u>200MG/100ML</u>	<u>A078252</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>			<u>400MG/200ML</u>	<u>A078252</u>	<u>002</u>	Mar 18, 2008
<u>AP</u>		CLARIS LIFESCIENCES	<u>200MG/100ML</u>	<u>A078024</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>			<u>400MG/200ML</u>	<u>A078024</u>	<u>002</u>	Mar 18, 2008
<u>AP</u>		HIKMA FARMACEUTICA	<u>400MG/200ML</u>	<u>A078431</u>	<u>001</u>	Nov 18, 2009
<u>AP</u>		HOSPIRA	<u>200MG/100ML</u>	<u>A077753</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>			<u>400MG/200ML</u>	<u>A077753</u>	<u>002</u>	Mar 18, 2008

CIPROFLOXACIN HYDROCHLORIDEOINTMENT; OPHTHALMIC
CILOXAN

+	ALCON PHARMS LTD	EQ 0.3% BASE	N020369	001	Mar 30, 1998

SOLUTION/DROPS; OPHTHALMIC

CILOXAN

<u>AT</u>	+	ALCON PHARMS LTD	<u>EQ 0.3% BASE</u>	<u>N019992</u>	<u>001</u>	Dec 31, 1990

CIPROFLOXACIN HYDROCHLORIDE

<u>AT</u>		AKORN INC	<u>EQ 0.3% BASE</u>	<u>A076555</u>	<u>001</u>	Dec 11, 2008
<u>AT</u>		APOTEX	<u>EQ 0.3% BASE</u>	<u>A075928</u>	<u>001</u>	Jun 09, 2004
<u>AT</u>		BAUSCH AND LOMB	<u>EQ 0.3% BASE</u>	<u>A076754</u>	<u>001</u>	Jun 09, 2004
<u>AT</u>		FDC LTD	<u>EQ 0.3% BASE</u>	<u>A077568</u>	<u>001</u>	Jun 30, 2008
<u>AT</u>		HITECH PHARMA	<u>EQ 0.3% BASE</u>	<u>A076673</u>	<u>001</u>	Jan 21, 2005
<u>AT</u>		NEXUS PHARMS	<u>EQ 0.3% BASE</u>	<u>A077689</u>	<u>001</u>	Dec 13, 2006
<u>AT</u>		PHARMAFORCE	<u>EQ 0.3% BASE</u>	<u>A078598</u>	<u>001</u>	Jan 16, 2008

SOLUTION/DROPS; OTIC
CETRAXAL

+	WRASER PHARMS	EQ 0.2% BASE	N021918	001	May 01, 2009

TABLET; ORAL

CIPRO

<u>AB</u>		BAYER HLTHCARE	<u>EQ 100MG BASE</u>	<u>N019537</u>	<u>001</u>	Apr 08, 1996
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>N019537</u>	<u>002</u>	Oct 22, 1987
<u>AB</u>	+		<u>EQ 500MG BASE</u>	<u>N019537</u>	<u>003</u>	Oct 22, 1987
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>N019537</u>	<u>004</u>	Oct 22, 1987

CIPROFLOXACIN HYDROCHLORIDE

<u>AB</u>		APOTEX	<u>EQ 250MG BASE</u>	<u>A076896</u>	<u>001</u>	Nov 04, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076896</u>	<u>002</u>	Nov 04, 2004

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 97 (of 428)

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 750MG BASE</u>	<u>A076896</u>	<u>003</u>	Nov 04, 2004
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A077859</u>	<u>001</u>	Apr 26, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A077859</u>	<u>002</u>	Apr 26, 2007
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A077859</u>	<u>003</u>	Apr 26, 2007
<u>AB</u>	CARLSBAD	<u>EQ 250MG BASE</u>	<u>A076126</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076126</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076126</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 100MG BASE</u>	<u>A075593</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A075593</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075593</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075593</u>	<u>001</u>	Jun 09, 2004
<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A076558</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076558</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076558</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 250MG BASE</u>	<u>A076089</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076089</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076089</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>	MYLAN	<u>EQ 100MG BASE</u>	<u>A075817</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A075685</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A075817</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075685</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075817</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075685</u>	<u>001</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075817</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>	RANBAXY	<u>EQ 250MG BASE</u>	<u>A075747</u>	<u>001</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075747</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075747</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>	TARO	<u>EQ 100MG BASE</u>	<u>A076912</u>	<u>001</u>	Feb 18, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A076912</u>	<u>002</u>	Oct 06, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076912</u>	<u>003</u>	Oct 06, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076912</u>	<u>004</u>	Oct 06, 2004
<u>AB</u>	UNIQUE PHARM LABS	<u>EQ 250MG BASE</u>	<u>A076639</u>	<u>001</u>	Sep 10, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076639</u>	<u>002</u>	Sep 10, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076639</u>	<u>003</u>	Sep 10, 2004
<u>AB</u>	WATSON LABS	<u>EQ 100MG BASE</u>	<u>A076794</u>	<u>001</u>	Feb 10, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A076794</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076794</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076794</u>	<u>004</u>	Jun 09, 2004

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC

+	ALCON PHARMS LTD	EQ 0.2% BASE;1%	N020805	001	Feb 10, 1998

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPRO XR

<u>AB</u>	+	BAYER HLTHCARE	<u>212.6MG;EQ 287.5MG BASE</u>	<u>N021473</u>	<u>001</u>	Dec 13, 2002
<u>AB</u>	+		<u>425.2MG;EQ 574.9MG BASE</u>	<u>N021473</u>	<u>002</u>	Aug 28, 2003
<u>CIPROFLOXACIN EXTENDED RELEASE</u>						
<u>AB</u>		ANCHEN PHARMS	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A078166</u>	<u>002</u>	Nov 27, 2007
<u>AB</u>			<u>425.2MG;EQ 574.9MG BASE</u>	<u>A078166</u>	<u>001</u>	Nov 27, 2007
<u>AB</u>		DR REDDYS LABS LTD	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A077701</u>	<u>002</u>	Oct 31, 2007
<u>AB</u>			<u>425.2MG;EQ 574.9MG BASE</u>	<u>A077701</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>		MYLAN	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A078183</u>	<u>001</u>	Mar 22, 2007
<u>AB</u>			<u>425.2MG;EQ 574.9MG BASE</u>	<u>A078183</u>	<u>002</u>	Mar 22, 2007
<u>AB</u>		WATSON LABS FLORIDA	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A077417</u>	<u>001</u>	Nov 30, 2010
<u>AB</u>			<u>425.2MG;EQ 574.9MG BASE</u>	<u>A077809</u>	<u>001</u>	Nov 30, 2010

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 98 (of 428)

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS; OTIC

+	ALCON PHARMS LTD	0.3%;0.1%	N021537	001	Jul 18, 2003

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

<u>AP</u>	SANDOZ INC	EQ 2MG BASE/ML	<u>A200159</u>	<u>001</u>	Feb 03, 2012

CISATRACURIUM BESYLATE PRESERVATIVE FREE

<u>AP</u>	SANDOZ INC	EQ 2MG BASE/ML	<u>A200154</u>	<u>001</u>	Feb 03, 2012

<u>AP</u>		EQ 10MG BASE/ML	<u>A200154</u>	<u>002</u>	Feb 03, 2012

NIMBEX

<u>AP</u>	+ ABBVIE	EQ 2MG BASE/ML	<u>N020551</u>	<u>001</u>	Dec 15, 1995

NIMBEX PRESERVATIVE FREE

<u>AP</u>	+ ABBVIE	EQ 2MG BASE/ML	<u>N020551</u>	<u>003</u>	Dec 15, 1995

<u>AP</u>	+	EQ 10MG BASE/ML	<u>N020551</u>	<u>002</u>	Dec 15, 1995

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

<u>AP</u>	BEDFORD	1MG/ML	<u>A075036</u>	<u>001</u>	Nov 07, 2000

<u>AP</u>	+ FRESENIUS KABI USA	1MG/ML	<u>A074735</u>	<u>001</u>	Jul 16, 1999

<u>AP</u>	ONCO THERAPIES LTD	1MG/ML	<u>A091062</u>	<u>001</u>	Apr 18, 2012

<u>AP</u>	PHARMACHEMIE	1MG/ML	<u>A074656</u>	<u>001</u>	May 16, 2000

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

	MYLAN PHARMS INC	EQ 10MG BASE	A077668	001	Feb 28, 2007

		EQ 20MG BASE	A077668	002	Feb 28, 2007

	+	EQ 40MG BASE	A077668	003	Feb 28, 2007

SOLUTION; ORAL

CELEXA

<u>AA</u>	+ FOREST LABS	EQ 10MG BASE/5ML	<u>N021046</u>	<u>001</u>	Dec 22, 1999

CITALOPRAM HYDROBROMIDE

<u>AA</u>	AUROBINDO PHARMA LTD	EQ 10MG BASE/5ML	<u>A077812</u>	<u>001</u>	Aug 28, 2006

<u>AA</u>	ROXANE	EQ 10MG BASE/5ML	<u>A077043</u>	<u>001</u>	Dec 13, 2004

<u>AA</u>	SILARX	EQ 10MG BASE/5ML	<u>A077629</u>	<u>001</u>	Jun 15, 2006

TABLET; ORAL

CELEXA

<u>AB</u>	FOREST LABS	EQ 10MG BASE	<u>N020822</u>	<u>001</u>	Apr 27, 2000

<u>AB</u>		EQ 20MG BASE	<u>N020822</u>	<u>002</u>	Jul 17, 1998

<u>AB</u>	+	EQ 40MG BASE	<u>N020822</u>	<u>003</u>	Jul 17, 1998

CITALOPRAM HYDROBROMIDE

<u>AB</u>	AMNEAL PHARMS NY	EQ 10MG BASE	<u>A077289</u>	<u>001</u>	Nov 30, 2006

<u>AB</u>		EQ 20MG BASE	<u>A077289</u>	<u>002</u>	Nov 30, 2006

<u>AB</u>		EQ 40MG BASE	<u>A077289</u>	<u>003</u>	Nov 30, 2006

<u>AB</u>	APOTEX INC	EQ 10MG BASE	<u>A077046</u>	<u>001</u>	Nov 24, 2004

<u>AB</u>		EQ 20MG BASE	<u>A077046</u>	<u>002</u>	Nov 24, 2004

<u>AB</u>		EQ 40MG BASE	<u>A077046</u>	<u>003</u>	Nov 24, 2004

<u>AB</u>	AUROBINDO	EQ 10MG BASE	<u>A077031</u>	<u>001</u>	Oct 28, 2004

<u>AB</u>		EQ 20MG BASE	<u>A077031</u>	<u>002</u>	Oct 28, 2004

<u>AB</u>		EQ 40MG BASE	<u>A077031</u>	<u>003</u>	Oct 28, 2004

<u>AB</u>	CARACO	EQ 10MG BASE	<u>A077032</u>	<u>001</u>	Nov 12, 2004

<u>AB</u>		EQ 20MG BASE	<u>A077032</u>	<u>002</u>	Nov 12, 2004

<u>AB</u>		EQ 40MG BASE	<u>A077032</u>	<u>003</u>	Nov 12, 2004

<u>AB</u>	COREPHARMA	EQ 10MG BASE	<u>A077036</u>	<u>001</u>	Oct 28, 2004

<u>AB</u>		EQ 20MG BASE	<u>A077036</u>	<u>002</u>	Oct 28, 2004

<u>AB</u>		EQ 40MG BASE	<u>A077036</u>	<u>003</u>	Oct 28, 2004

<u>AB</u>	DR REDDYS LABS LTD	EQ 10MG BASE	<u>A077038</u>	<u>001</u>	Oct 28, 2004

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 99 (of 428)

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 20MG BASE</u>	<u>A077038</u>	<u>002</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077038</u>	<u>003</u>	Oct 28, 2004
<u>AB</u>	EPIC PHARMA	<u>EQ 10MG BASE</u>	<u>A077045</u>	<u>003</u>	Apr 29, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077045</u>	<u>002</u>	Apr 29, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077045</u>	<u>001</u>	Apr 29, 2005
<u>AB</u>	GLENMARK GENERICS	<u>EQ 10MG BASE</u>	<u>A077654</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077654</u>	<u>002</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077654</u>	<u>003</u>	Feb 27, 2009
<u>AB</u>	INVAGEN PHARMS	<u>EQ 10MG BASE</u>	<u>A077534</u>	<u>001</u>	Oct 03, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077534</u>	<u>002</u>	Oct 03, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077534</u>	<u>003</u>	Oct 03, 2006
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A077039</u>	<u>001</u>	Feb 03, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077042</u>	<u>001</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077039</u>	<u>002</u>	Feb 03, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077042</u>	<u>002</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077039</u>	<u>003</u>	Feb 03, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077042</u>	<u>003</u>	Nov 05, 2004
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A077037</u>	<u>001</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077037</u>	<u>002</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077037</u>	<u>003</u>	Nov 05, 2004
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A077141</u>	<u>002</u>	Apr 10, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077141</u>	<u>001</u>	Apr 10, 2008
<u>AB</u>	PLIVA	<u>EQ 10MG BASE</u>	<u>A077232</u>	<u>001</u>	Oct 31, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077232</u>	<u>002</u>	Oct 31, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077232</u>	<u>003</u>	Oct 31, 2005
<u>AB</u>	TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A077048</u>	<u>001</u>	Nov 16, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077048</u>	<u>002</u>	Nov 16, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077048</u>	<u>003</u>	Nov 16, 2004
<u>AB</u>	TORRENT PHARMS	<u>EQ 10MG BASE</u>	<u>A078216</u>	<u>001</u>	Mar 27, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078216</u>	<u>002</u>	Mar 27, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078216</u>	<u>003</u>	Mar 27, 2007
<u>AB</u>	WATSON LABS	<u>EQ 10MG BASE</u>	<u>A077034</u>	<u>001</u>	Jun 30, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077044</u>	<u>001</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077034</u>	<u>002</u>	Jun 30, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077044</u>	<u>002</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077034</u>	<u>003</u>	Jun 30, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077044</u>	<u>003</u>	Nov 05, 2004

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION; IRRIGATION

RENACIDIN

+ UNITED GUARDIAN 6.602GM/100ML;198MG/100ML;3.177GM/100ML N019481 001 Oct 02, 1990

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION; ORAL

PREPOPIK

+ FERRING PHARMS AS 12GM/PACKET;3.5GM/PACKET;10MG/PACKET N202535 001 Jul 16, 2012

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION; ORAL

IDKIT:HP

+ EXALENZ BIOSCIENCE N/A, 4GM; 75MG, N/A N021314 001 Dec 17, 2002

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINE

<u>AP</u>	BEDFORD	<u>1MG/ML</u>	<u>A075405</u>	<u>001</u>	Feb 28, 2000
<u>AP</u>	FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A076571</u>	<u>001</u>	Apr 22, 2004

PRESCRIPTION DRUG PRODUCT LIST

3 - 100 (of 428)

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINE

<u>AP</u>	ONCO THERAPIES LTD	<u>1MG/ML</u>	<u>A200510</u>	<u>001</u>	Oct 06, 2011

LEUSTATIN

<u>AP</u>	+ JANSSSEN PHARMS	<u>1MG/ML</u>	<u>N020229</u>	<u>001</u>	Feb 26, 1993

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

<u>AB</u>	ABBVIE	<u>125MG/5ML</u>	<u>N050698</u>	<u>001</u>	Dec 23, 1993

<u>AB</u>	+	<u>250MG/5ML</u>	<u>N050698</u>	<u>002</u>	Dec 23, 1993

CLARITHROMYCIN

<u>AB</u>	RANBAXY	<u>125MG/5ML</u>	<u>A065382</u>	<u>001</u>	Aug 30, 2007

<u>AB</u>		<u>250MG/5ML</u>	<u>A065382</u>	<u>002</u>	Aug 30, 2007

<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065283</u>	<u>002</u>	Sep 04, 2007

<u>AB</u>		<u>250MG/5ML</u>	<u>A065283</u>	<u>003</u>	Sep 04, 2007

TABLET; ORAL

BIAXIN

<u>AB</u>	+ ABBVIE	<u>250MG</u>	<u>N050662</u>	<u>001</u>	Oct 31, 1991

<u>AB</u>	+	<u>500MG</u>	<u>N050662</u>	<u>002</u>	Oct 31, 1991

CLARITHROMYCIN

<u>AB</u>	APOTEX CORP	<u>250MG</u>	<u>A065384</u>	<u>001</u>	Aug 20, 2007

<u>AB</u>		<u>500MG</u>	<u>A065384</u>	<u>002</u>	Aug 20, 2007

<u>AB</u>	AUROBINDO	<u>250MG</u>	<u>A065489</u>	<u>001</u>	Jul 25, 2012

<u>AB</u>		<u>500MG</u>	<u>A065489</u>	<u>002</u>	Jul 25, 2012

<u>AB</u>	MYLAN	<u>250MG</u>	<u>A065195</u>	<u>001</u>	Mar 11, 2005

<u>AB</u>		<u>500MG</u>	<u>A065195</u>	<u>002</u>	Mar 11, 2005

<u>AB</u>	RANBAXY	<u>250MG</u>	<u>A065174</u>	<u>001</u>	Sep 24, 2004

<u>AB</u>		<u>500MG</u>	<u>A065174</u>	<u>002</u>	Sep 24, 2004

<u>AB</u>	ROXANE	<u>250MG</u>	<u>A065178</u>	<u>002</u>	May 25, 2004

<u>AB</u>		<u>500MG</u>	<u>A065178</u>	<u>001</u>	May 25, 2004

<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A065144</u>	<u>001</u>	Oct 18, 2005

<u>AB</u>		<u>500MG</u>	<u>A065136</u>	<u>001</u>	Aug 25, 2005

<u>AB</u>	TEVA	<u>250MG</u>	<u>A065155</u>	<u>001</u>	May 31, 2005

<u>AB</u>		<u>500MG</u>	<u>A065155</u>	<u>002</u>	May 31, 2005

<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A065266</u>	<u>001</u>	May 31, 2006

<u>AB</u>		<u>500MG</u>	<u>A065266</u>	<u>002</u>	May 31, 2006

TABLET, EXTENDED RELEASE; ORAL

BIAXIN XL

<u>AB</u>	+ ABBVIE	<u>500MG</u>	<u>N050775</u>	<u>001</u>	Mar 03, 2000

CLARITHROMYCIN

<u>AB</u>	TEVA	<u>500MG</u>	<u>A065154</u>	<u>001</u>	May 18, 2005

<u>AB</u>	WATSON LABS FLORIDA	<u>500MG</u>	<u>A065145</u>	<u>001</u>	Jun 24, 2004

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TIMENTIN

+	GLAXOSMITHKLINE	EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987

		EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	A062691	001	Dec 19, 1986

+		EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	001	Apr 01, 1985

+		EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	002	Apr 01, 1985

TIMENTIN IN PLASTIC CONTAINER

+	GLAXOSMITHKLINE	EQ 100MG BASE/100ML;EQ 3GM BASE/100ML	N050658	001	Dec 15, 1989

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

<u>AA</u>	NOVEX	<u>EQ 0.5MG BASE/5ML</u>	<u>A075703</u>	<u>001</u>	Nov 27, 2000

<u>AA</u>	SILARX	<u>EQ 0.5MG BASE/5ML</u>	<u>A074884</u>	<u>001</u>	Dec 17, 1997

<u>AA</u>	+ TEVA	<u>EQ 0.5MG BASE/5ML</u>	<u>A073399</u>	<u>001</u>	Jun 30, 1994

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 101 (of 428)

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

<u>AA</u>	WOCKHARDT	<u>EQ 0.5MG BASE/5ML</u>	<u>A074863</u>	<u>001</u>	Mar 13, 1998

TABLET; ORAL

CLEMASTINE FUMARATE

<u>AB</u>	SANDOZ	<u>2.68MG</u>	<u>A073459</u>	<u>001</u>	Oct 31, 1993

<u>AB</u>	+ TEVA	<u>2.68MG</u>	<u>A073283</u>	<u>001</u>	Jan 31, 1992

CLEVIDIPINE BUTYRATE

EMULSION; INTRAVENOUS

CLEVIPREX

+	MEDICINES CO	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008

+		50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN HYDROCHLORIDE

<u>AB</u>	PHARMACIA AND UPJOHN	<u>EQ 75MG BASE</u>	<u>N050162</u>	<u>001</u>	

<u>AB</u>		<u>EQ 150MG BASE</u>	<u>N050162</u>	<u>002</u>	

<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N050162</u>	<u>003</u>	Apr 14, 1988

CLINDAMYCIN HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 150MG BASE</u>	<u>A065442</u>	<u>001</u>	Aug 26, 2009

<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065442</u>	<u>002</u>	Aug 26, 2009

<u>AB</u>	COREPHARMA	<u>EQ 150MG BASE</u>	<u>A065194</u>	<u>001</u>	Mar 22, 2004

<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065194</u>	<u>002</u>	Mar 22, 2004

<u>AB</u>	LANNETT	<u>EQ 75MG BASE</u>	<u>A065242</u>	<u>001</u>	Aug 12, 2005

<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065242</u>	<u>002</u>	Aug 12, 2005

<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065243</u>	<u>001</u>	Aug 12, 2005

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 75MG BASE</u>	<u>A091225</u>	<u>001</u>	May 31, 2011

<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091225</u>	<u>002</u>	May 31, 2011

<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A091225</u>	<u>003</u>	May 31, 2011

<u>AB</u>	RANBAXY	<u>EQ 150MG BASE</u>	<u>A065061</u>	<u>001</u>	Feb 02, 2001

<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065061</u>	<u>002</u>	Feb 02, 2001

<u>AB</u>	TEVA	<u>EQ 150MG BASE</u>	<u>A063029</u>	<u>001</u>	Sep 20, 1989

<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A063029</u>	<u>002</u>	Aug 05, 2005

<u>AB</u>	WATSON LABS	<u>EQ 150MG BASE</u>	<u>A063083</u>	<u>001</u>	Jul 31, 1991

<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A063083</u>	<u>002</u>	Mar 18, 2003

<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 75MG BASE</u>	<u>A065217</u>	<u>001</u>	Jan 31, 2005

<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065217</u>	<u>002</u>	Jan 31, 2005

<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065217</u>	<u>003</u>	Jan 31, 2005

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

<u>AA</u>	+	PHARMACIA AND UPJOHN	<u>EQ 75MG BASE/5ML</u>	<u>A062644</u>	<u>001</u>	Apr 07, 1986

CLINDAMYCIN PALMITATE HYDROCHLORIDE

<u>AA</u>	LYNE	<u>EQ 75MG BASE/5ML</u>	<u>A201821</u>	<u>001</u>	Aug 28, 2012

<u>AA</u>	PADDOCK LABS	<u>EQ 75MG BASE/5ML</u>	<u>A090902</u>	<u>001</u>	Jul 07, 2010

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM; TOPICAL

CLINDAMYCIN PHOSPHATE

<u>AT</u>	PERRIGO UK FINCO	<u>1%</u>	<u>A090785</u>	<u>001</u>	Mar 31, 2010

EVOCLIN

<u>AT</u>	+	STIEFEL LABS INC	<u>1%</u>	<u>N050801</u>	<u>001</u>	Oct 22, 2004

CREAM; VAGINAL

CLEOCIN

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>EQ 2% BASE</u>	<u>N050680</u>	<u>002</u>	Mar 02, 1998

CLINDAMYCIN PHOSPHATE

<u>AB</u>	FOUGERA PHARMS	<u>EQ 2% BASE</u>	<u>A065139</u>	<u>001</u>	Dec 27, 2004

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 102 (of 428)

CLINDAMYCIN PHOSPHATE

	CREAM; VAGINAL				
	CLINDESSE				
	+ KV PHARM	EQ 2% BASE	N050793	001	Nov 30, 2004
	GEL; TOPICAL				
	<u>CLEOCIN T</u>				
<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050615</u>	<u>001</u>	Jan 07, 1987
	<u>CLINDAMYCIN PHOSPHATE</u>				
<u>AB</u>	FOUGERA PHARMS	<u>EQ 1% BASE</u>	<u>A064160</u>	<u>001</u>	Jan 28, 2000
	CLINDAGEL				
BT	+ GALDERMA LABS LP	EQ 1% BASE	N050782	001	Nov 27, 2000
	INJECTABLE; INJECTION				
	<u>CLEOCIN PHOSPHATE</u>				
<u>AP</u>	PHARMACIA AND UPJOHN	<u>EQ 150MG BASE/ML</u>	<u>A062803</u>	<u>001</u>	Oct 16, 1987
<u>AP</u>	+	<u>EQ 150MG BASE/ML</u>	<u>N050441</u>	<u>001</u>	
	<u>CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER</u>				
<u>AP</u>	+ PHARMACIA AND UPJOHN	<u>EQ 6MG BASE/ML</u>	<u>N050639</u>	<u>001</u>	Aug 30, 1989
<u>AP</u>	+	<u>EQ 12MG BASE/ML</u>	<u>N050639</u>	<u>002</u>	Aug 30, 1989
<u>AP</u>	+	<u>EQ 18MG BASE/ML</u>	<u>N050639</u>	<u>003</u>	Apr 10, 1991
	<u>CLINDAMYCIN PHOSPHATE</u>				
<u>AP</u>	BEDFORD	<u>EQ 150MG BASE/ML</u>	<u>A065206</u>	<u>001</u>	Sep 24, 2004
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 150MG BASE/ML</u>	<u>A065346</u>	<u>001</u>	Mar 29, 2007
<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A065347</u>	<u>001</u>	May 09, 2007
<u>AP</u>	HIKMA MAPLE	<u>EQ 150MG BASE/ML</u>	<u>A062889</u>	<u>001</u>	Apr 25, 1988
<u>AP</u>	HOSPIRA	<u>EQ 150MG BASE/ML</u>	<u>A062800</u>	<u>001</u>	Jul 24, 1987
<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A062801</u>	<u>001</u>	Jul 24, 1987
<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A062943</u>	<u>001</u>	Sep 29, 1988
<u>AP</u>	SAGENT STRIDES	<u>EQ 150MG BASE/ML</u>	<u>A090108</u>	<u>001</u>	Sep 30, 2011
<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A090109</u>	<u>001</u>	Sep 30, 2011
	<u>CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER</u>				
<u>AP</u>	SANDOZ INC	<u>EQ 6MG BASE/ML</u>	<u>A201692</u>	<u>001</u>	May 31, 2012
<u>AP</u>		<u>EQ 12MG BASE/ML</u>	<u>A201692</u>	<u>002</u>	May 31, 2012
<u>AP</u>		<u>EQ 18MG BASE/ML</u>	<u>A201692</u>	<u>003</u>	May 31, 2012
	CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%				
	+ ABRAXIS PHARM	EQ 900MG BASE/100ML	N050635	001	Dec 22, 1989
	LOTION; TOPICAL				
	<u>CLEOCIN T</u>				
<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050600</u>	<u>001</u>	May 31, 1989
	<u>CLINDAMYCIN PHOSPHATE</u>				
<u>AB</u>	FOUGERA PHARMS	<u>EQ 1% BASE</u>	<u>A065067</u>	<u>001</u>	Jan 31, 2002
	SOLUTION; TOPICAL				
	<u>CLEOCIN T</u>				
<u>AT</u>	+ PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050537</u>	<u>001</u>	
	<u>CLINDA-DERM</u>				
<u>AT</u>	PADDOCK LLC	<u>EQ 1% BASE</u>	<u>A063329</u>	<u>001</u>	Sep 30, 1992
	<u>CLINDAMYCIN PHOSPHATE</u>				
<u>AT</u>	FOUGERA	<u>EQ 1% BASE</u>	<u>A064159</u>	<u>001</u>	Jun 05, 1997
<u>AT</u>	FOUGERA PHARMS	<u>EQ 1% BASE</u>	<u>A065254</u>	<u>001</u>	Feb 14, 2006
<u>AT</u>	PERRIGO NEW YORK	<u>EQ 1% BASE</u>	<u>A064050</u>	<u>001</u>	Nov 30, 1995
<u>AT</u>	TARO PHARM INDS	<u>EQ 1% BASE</u>	<u>A065184</u>	<u>001</u>	Mar 31, 2004
<u>AT</u>	WOCKHARDT	<u>EQ 1% BASE</u>	<u>A063304</u>	<u>001</u>	Jul 15, 1997
	SUPPOSITORY; VAGINAL				
	CLEOCIN				
	+ PHARMACIA AND UPJOHN	100MG	N050767	001	Aug 13, 1999
	SWAB; TOPICAL				
	<u>CLEOCIN</u>				
<u>AT</u>	PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050537</u>	<u>002</u>	Feb 22, 1994
	<u>CLINDAMYCIN PHOSPHATE</u>				
<u>AT</u>	PERRIGO NEW YORK	<u>EQ 1% BASE</u>	<u>A065049</u>	<u>001</u>	May 25, 2000
<u>AT</u>	VERSAPHARM	<u>EQ 1% BASE</u>	<u>A065513</u>	<u>001</u>	Jun 17, 2010
	<u>CLINDETS</u>				
<u>AT</u>	PERRIGO	<u>EQ 1% BASE</u>	<u>A064136</u>	<u>001</u>	Sep 30, 1996

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 103 (of 428)

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL					
VELTIN					
BX +	STIEFEL GSK	1.2%;0.025%	N050803	001	Jul 16, 2010
ZIANA					
BX +	MEDICIS	1.2%;0.025%	N050802	001	Nov 07, 2006

CLOBAZAM

SUSPENSION; ORAL					
ONFI					
+	LUNDBECK LLC	2.5MG/ML	N203993	001	Dec 14, 2012
TABLET; ORAL					
ONFI					
	LUNDBECK LLC	5MG	N202067	001	Oct 21, 2011
		10MG	N202067	002	Oct 21, 2011
+		20MG	N202067	003	Oct 21, 2011

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL					
<u>CLOBETASOL PROPIONATE</u>					
<u>AB1</u>	PERRIGO ISRAEL	<u>0.05%</u>	<u>A077763</u>	<u>001</u>	Mar 10, 2008
<u>OLUX</u>					
<u>AB1</u> +	STIEFEL LABS INC	<u>0.05%</u>	<u>N021142</u>	<u>001</u>	May 26, 2000
<u>CLOBETASOL PROPIONATE</u>					
<u>AB2</u>	PERRIGO ISRAEL	<u>0.05%</u>	<u>A201402</u>	<u>001</u>	Aug 14, 2012
<u>OLUX E</u>					
<u>AB2</u> +	STIEFEL LABS INC	<u>0.05%</u>	<u>N022013</u>	<u>001</u>	Jan 12, 2007
CREAM; TOPICAL					
<u>CLOBETASOL PROPIONATE</u>					
<u>AB1</u>	FOUGERA	<u>0.05%</u>	<u>A074392</u>	<u>001</u>	Sep 30, 1996
<u>AB1</u>	TARO	<u>0.05%</u>	<u>A074249</u>	<u>001</u>	Jul 08, 1996
<u>AB1</u>	TEVA PHARMS	<u>0.05%</u>	<u>A074087</u>	<u>001</u>	Feb 16, 1994
<u>CORMAX</u>					
<u>AB1</u>	HI TECH PHARMA	<u>0.05%</u>	<u>A074220</u>	<u>001</u>	May 16, 1997
<u>TEMOVATE</u>					
<u>AB1</u> +	FOUGERA PHARMS	<u>0.05%</u>	<u>N019322</u>	<u>001</u>	Dec 27, 1985
<u>CLOBETASOL PROPIONATE (EMOLLIENT)</u>					
<u>AB2</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A075430</u>	<u>001</u>	May 26, 1999
<u>AB2</u>	TARO	<u>0.05%</u>	<u>A075633</u>	<u>001</u>	May 17, 2000
<u>EMBELINE E</u>					
<u>AB2</u>	HI TECH PHARMA	<u>0.05%</u>	<u>A075325</u>	<u>001</u>	Dec 24, 1998
<u>TEMOVATE E</u>					
<u>AB2</u> +	FOUGERA PHARMS	<u>0.05%</u>	<u>N020340</u>	<u>001</u>	Jun 17, 1994
GEL; TOPICAL					
<u>CLOBETASOL PROPIONATE</u>					
<u>AB</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A075368</u>	<u>001</u>	Feb 15, 2000
<u>AB</u>	PERRIGO	<u>0.05%</u>	<u>A075027</u>	<u>001</u>	Oct 31, 1997
<u>AB</u>	TARO	<u>0.05%</u>	<u>A075279</u>	<u>001</u>	May 28, 1999
<u>EMBELINE</u>					
<u>AB</u>	HI TECH PHARMA	<u>0.05%</u>	<u>A076141</u>	<u>001</u>	Apr 12, 2002
<u>TEMOVATE</u>					
<u>AB</u> +	FOUGERA PHARMS	<u>0.05%</u>	<u>N020337</u>	<u>001</u>	Apr 29, 1994
LOTION; TOPICAL					
<u>CLOBETASOL PROPIONATE</u>					
<u>AB</u>	ACTAVIS MID ATLANTIC	<u>0.05%</u>	<u>A078223</u>	<u>001</u>	Dec 04, 2008
<u>AB</u>	TARO	<u>0.05%</u>	<u>A200302</u>	<u>001</u>	Jul 02, 2012
<u>CLOBEX</u>					
<u>AB</u> +	GALDERMA LABS LP	<u>0.05%</u>	<u>N021535</u>	<u>001</u>	Jul 24, 2003
OINTMENT; TOPICAL					
<u>CLOBETASOL PROPIONATE</u>					
<u>AB</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A074407</u>	<u>001</u>	Feb 23, 1996
<u>AB</u>	TARO	<u>0.05%</u>	<u>A074248</u>	<u>001</u>	Jul 12, 1996

PRESCRIPTION DRUG PRODUCT LIST

3 - 104 (of 428)

CLOBETASOL PROPIONATE

 OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

<u>AB</u>	TEVA PHARMS	<u>0.05%</u>	<u>A074089</u>	<u>001</u>	Feb 16, 1994

EMBELINE

<u>AB</u>	HI TECH PHARMA	<u>0.05%</u>	<u>A074221</u>	<u>001</u>	Mar 31, 1995

TEMOVATE

<u>AB</u>	+ FOUGERA PHARMS	<u>0.05%</u>	<u>N019323</u>	<u>001</u>	Dec 27, 1985

 SHAMPOO; TOPICAL

CLOBETASOL PROPIONATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>0.05%</u>	<u>A078854</u>	<u>001</u>	Jun 07, 2011

<u>AB</u>	PERRIGO ISRAEL	<u>0.05%</u>	<u>A090974</u>	<u>001</u>	Aug 09, 2012

CLOBEX

<u>AB</u>	+ GALDERMA LABS	<u>0.05%</u>	<u>N021644</u>	<u>001</u>	Feb 05, 2004

 SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

<u>AT</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A075391</u>	<u>001</u>	Feb 08, 1999

<u>AT</u>	TARO	<u>0.05%</u>	<u>A075224</u>	<u>001</u>	Nov 16, 1998

<u>AT</u>		<u>0.05%</u>	<u>A075363</u>	<u>001</u>	Dec 29, 2000

<u>AT</u>	TOLMAR	<u>0.05%</u>	<u>A076977</u>	<u>001</u>	Aug 05, 2005

<u>AT</u>	WOCKHARDT	<u>0.05%</u>	<u>A075205</u>	<u>001</u>	Nov 13, 1998

EMBELINE

<u>AT</u>	HI TECH PHARMA	<u>0.05%</u>	<u>A074222</u>	<u>001</u>	Dec 06, 1995

TEMOVATE

<u>AT</u>	+ FOUGERA PHARMS	<u>0.05%</u>	<u>N019966</u>	<u>001</u>	Feb 22, 1990

 SPRAY; TOPICAL

CLOBETASOL PROPIONATE

<u>AT</u>	PADDOCK LLC	<u>0.05%</u>	<u>A090898</u>	<u>001</u>	Jun 16, 2011

CLOBEX

<u>AT</u>	+ GALDERMA LABS LP	<u>0.05%</u>	<u>N021835</u>	<u>001</u>	Oct 27, 2005

CLOCORTOLONE PIVALATE

 CREAM; TOPICAL

 CLODERM

	+ PROMIUS PHARMA LLC	0.1%	N017765	001	

CLOFARABINE

 INJECTABLE; IV (INFUSION)

	+ GENZYME	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004

CLOFAZIMINE

 CAPSULE; ORAL

 LAMPRENE

	+ NOVARTIS	50MG	N019500	002	Dec 15, 1986

CLOMIPHENE CITRATE

 TABLET; ORAL

CLOMID

<u>AB</u>	+ SANOFI AVENTIS US	<u>50MG</u>	<u>N016131</u>	<u>002</u>	

CLOMIPHENE CITRATE

<u>AB</u>	PAR PHARM	<u>50MG</u>	<u>A075528</u>	<u>001</u>	Aug 30, 1999

SEROPHENE

<u>AB</u>	EMD SERONO	<u>50MG</u>	<u>N018361</u>	<u>001</u>	Mar 22, 1982

CLOMIPRAMINE HYDROCHLORIDE

 CAPSULE; ORAL

ANAFRANIL

<u>AB</u>	MALLINCKRODT LLC	<u>25MG</u>	<u>N019906</u>	<u>001</u>	Dec 29, 1989

<u>AB</u>	+	<u>50MG</u>	<u>N019906</u>	<u>002</u>	Dec 29, 1989

<u>AB</u>		<u>75MG</u>	<u>N019906</u>	<u>003</u>	Dec 29, 1989

PRESCRIPTION DRUG PRODUCT LIST

3 - 105 (of 428)

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>25MG</u>	<u>A074947</u>	<u>001</u>	Apr 30, 1998
<u>AB</u>		<u>50MG</u>	<u>A074947</u>	<u>002</u>	Apr 30, 1998
<u>AB</u>		<u>75MG</u>	<u>A074947</u>	<u>003</u>	Apr 30, 1998
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A074364</u>	<u>001</u>	Mar 29, 1996
<u>AB</u>		<u>50MG</u>	<u>A074364</u>	<u>002</u>	Mar 29, 1996
<u>AB</u>		<u>75MG</u>	<u>A074364</u>	<u>003</u>	Mar 29, 1996
<u>AB</u>	TARO	<u>25MG</u>	<u>A074694</u>	<u>001</u>	Dec 31, 1996
<u>AB</u>		<u>50MG</u>	<u>A074694</u>	<u>002</u>	Dec 31, 1996
<u>AB</u>		<u>75MG</u>	<u>A074694</u>	<u>003</u>	Dec 31, 1996
<u>AB</u>	TEVA	<u>25MG</u>	<u>A074958</u>	<u>001</u>	Aug 26, 1997
<u>AB</u>		<u>50MG</u>	<u>A074958</u>	<u>002</u>	Aug 26, 1997
<u>AB</u>		<u>75MG</u>	<u>A074958</u>	<u>003</u>	Aug 26, 1997

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

<u>AB</u>	ACCORD HLTHCARE INC	<u>0.5MG</u>	<u>A077147</u>	<u>001</u>	May 02, 2005
<u>AB</u>		<u>1MG</u>	<u>A077147</u>	<u>002</u>	May 02, 2005
<u>AB</u>		<u>2MG</u>	<u>A077147</u>	<u>003</u>	May 02, 2005
<u>AB</u>	ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A074869</u>	<u>001</u>	Oct 31, 1996
<u>AB</u>		<u>1MG</u>	<u>A074869</u>	<u>002</u>	Oct 31, 1996
<u>AB</u>		<u>2MG</u>	<u>A074869</u>	<u>003</u>	Oct 31, 1996
<u>AB</u>	APOTEX	<u>0.5MG</u>	<u>A075468</u>	<u>001</u>	Oct 06, 2000
<u>AB</u>		<u>1MG</u>	<u>A075468</u>	<u>002</u>	Oct 06, 2000
<u>AB</u>		<u>2MG</u>	<u>A075468</u>	<u>003</u>	Oct 06, 2000
<u>AB</u>	CARACO	<u>0.5MG</u>	<u>A075423</u>	<u>001</u>	Apr 27, 2001
<u>AB</u>		<u>1MG</u>	<u>A075423</u>	<u>002</u>	Apr 27, 2001
<u>AB</u>		<u>2MG</u>	<u>A075423</u>	<u>003</u>	Apr 27, 2001
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A075150</u>	<u>001</u>	Oct 05, 1998
<u>AB</u>		<u>1MG</u>	<u>A075150</u>	<u>002</u>	Oct 05, 1998
<u>AB</u>		<u>2MG</u>	<u>A075150</u>	<u>003</u>	Oct 05, 1998
<u>AB</u>	MYLAN PHARMS INC	<u>0.5MG</u>	<u>A074940</u>	<u>001</u>	Oct 30, 1997
<u>AB</u>		<u>1MG</u>	<u>A074940</u>	<u>002</u>	Oct 30, 1997
<u>AB</u>		<u>2MG</u>	<u>A074940</u>	<u>003</u>	Oct 30, 1997
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A074979</u>	<u>001</u>	Aug 29, 1997
<u>AB</u>		<u>1MG</u>	<u>A074979</u>	<u>002</u>	Aug 29, 1997
<u>AB</u>		<u>2MG</u>	<u>A074979</u>	<u>003</u>	Aug 29, 1997
<u>AB</u>	TEVA	<u>0.5MG</u>	<u>A074569</u>	<u>001</u>	Sep 10, 1996
<u>AB</u>		<u>1MG</u>	<u>A074569</u>	<u>002</u>	Sep 10, 1996
<u>AB</u>		<u>2MG</u>	<u>A074569</u>	<u>003</u>	Sep 10, 1996
<u>AB</u>	VINTAGE PHARMS	<u>0.5MG</u>	<u>A077856</u>	<u>001</u>	Jun 28, 2006
<u>AB</u>		<u>1MG</u>	<u>A077856</u>	<u>002</u>	Jun 28, 2006
<u>AB</u>		<u>2MG</u>	<u>A077856</u>	<u>003</u>	Jun 28, 2006
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A074964</u>	<u>001</u>	Dec 30, 1997
<u>AB</u>		<u>1MG</u>	<u>A074964</u>	<u>002</u>	Dec 30, 1997
<u>AB</u>		<u>2MG</u>	<u>A074964</u>	<u>003</u>	Dec 30, 1997

KLONOPIN

<u>AB</u>	ROCHE	<u>0.5MG</u>	<u>N017533</u>	<u>001</u>	
<u>AB</u>	+	<u>1MG</u>	<u>N017533</u>	<u>002</u>	
<u>AB</u>		<u>2MG</u>	<u>N017533</u>	<u>003</u>	

TABLET, ORALLY DISINTEGRATING; ORAL

CLONAZEPAM

<u>AB</u>	BARR	<u>0.125MG</u>	<u>A077194</u>	<u>001</u>	Aug 10, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077194</u>	<u>002</u>	Aug 10, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077194</u>	<u>003</u>	Aug 10, 2005
<u>AB</u>		<u>1MG</u>	<u>A077194</u>	<u>004</u>	Aug 10, 2005
<u>AB</u>		<u>2MG</u>	<u>A077194</u>	<u>005</u>	Aug 10, 2005
<u>AB</u>	PAR PHARM	<u>0.125MG</u>	<u>A077171</u>	<u>001</u>	Aug 03, 2005

PRESCRIPTION DRUG PRODUCT LIST

3 - 106 (of 428)

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING; ORAL

CLONAZEPAM

<u>AB</u>	PAR PHARM	<u>0.25MG</u>	<u>A077171</u>	<u>002</u>	Aug 03, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077171</u>	<u>003</u>	Aug 03, 2005
<u>AB</u>	+	<u>1MG</u>	<u>A077171</u>	<u>004</u>	Aug 03, 2005
<u>AB</u>		<u>2MG</u>	<u>A077171</u>	<u>005</u>	Aug 03, 2005

CLONIDINE

FILM, EXTENDED RELEASE; TRANSDERMAL

CATAPRES-TTS-1

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.1MG/24HR</u>	<u>N018891</u>	<u>001</u>	Oct 10, 1984

CATAPRES-TTS-2

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.2MG/24HR</u>	<u>N018891</u>	<u>002</u>	Oct 10, 1984

CATAPRES-TTS-3

<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>0.3MG/24HR</u>	<u>N018891</u>	<u>003</u>	Oct 10, 1984

CLONIDINE

<u>AB</u>	AVEVA	<u>0.1MG/24HR</u>	<u>A076157</u>	<u>001</u>	Aug 18, 2009
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076157</u>	<u>002</u>	Aug 18, 2009
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076157</u>	<u>003</u>	Aug 18, 2009
<u>AB</u>	BARR	<u>0.1MG/24HR</u>	<u>A079090</u>	<u>001</u>	Aug 20, 2010
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A079090</u>	<u>002</u>	Aug 20, 2010
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A079090</u>	<u>003</u>	Aug 20, 2010
<u>AB</u>	MYLAN TECHNOLOGIES	<u>0.1MG/24HR</u>	<u>A076166</u>	<u>001</u>	Jul 16, 2010
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076166</u>	<u>002</u>	Jul 16, 2010
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076166</u>	<u>003</u>	Jul 16, 2010

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

<u>AP</u>	FRESENIUS KABI USA	<u>1MG/10ML (0.1MG/ML)</u>	<u>A200673</u>	<u>001</u>	Jul 08, 2011
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A200673</u>	<u>002</u>	Jul 08, 2011
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/10ML (0.1MG/ML)</u>	<u>A200300</u>	<u>001</u>	Jan 26, 2011
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A200300</u>	<u>002</u>	Jan 26, 2011
<u>AP</u>	LUITPOLD	<u>1 MG/10 ML (0.1 MG/ML)</u>	<u>A091104</u>	<u>001</u>	Oct 08, 2009
<u>AP</u>		<u>5 MG/10 ML (0.5 MG/ML)</u>	<u>A091104</u>	<u>002</u>	Oct 08, 2009

DURACLON

<u>AP</u>	MYLAN INSTITUTIONAL	<u>1 MG/10 ML (0.1 MG/ML)</u>	<u>N020615</u>	<u>001</u>	Oct 02, 1996
<u>AP</u>	+	<u>5 MG/10 ML (0.5 MG/ML)</u>	<u>N020615</u>	<u>002</u>	Apr 27, 1999

TABLET; ORAL

CATAPRES

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.1MG</u>	<u>N017407</u>	<u>001</u>	
<u>AB</u>		<u>0.2MG</u>	<u>N017407</u>	<u>002</u>	
<u>AB</u>	+	<u>0.3MG</u>	<u>N017407</u>	<u>003</u>	

CLONIDINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A070974</u>	<u>001</u>	Dec 16, 1986
<u>AB</u>		<u>0.2MG</u>	<u>A070975</u>	<u>001</u>	Dec 16, 1986
<u>AB</u>		<u>0.3MG</u>	<u>A070976</u>	<u>001</u>	Dec 16, 1986
<u>AB</u>	ALEMBIC PHARMS LTD	<u>0.1MG</u>	<u>A091368</u>	<u>001</u>	Dec 06, 2011
<u>AB</u>		<u>0.2MG</u>	<u>A091368</u>	<u>002</u>	Dec 06, 2011
<u>AB</u>		<u>0.3MG</u>	<u>A091368</u>	<u>003</u>	Dec 06, 2011
<u>AB</u>	DAVA PHARMS INC	<u>0.1MG</u>	<u>A071783</u>	<u>001</u>	Apr 05, 1988
<u>AB</u>		<u>0.2MG</u>	<u>A071784</u>	<u>001</u>	Apr 05, 1988
<u>AB</u>		<u>0.3MG</u>	<u>A071785</u>	<u>001</u>	Apr 05, 1988
<u>AB</u>	IMPAX LABS	<u>0.1MG</u>	<u>A078099</u>	<u>001</u>	Aug 27, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078099</u>	<u>002</u>	Aug 27, 2009
<u>AB</u>		<u>0.3MG</u>	<u>A078099</u>	<u>003</u>	Aug 27, 2009
<u>AB</u>	MUTUAL PHARM	<u>0.1MG</u>	<u>A070925</u>	<u>001</u>	Sep 04, 1987
<u>AB</u>		<u>0.2MG</u>	<u>A070924</u>	<u>001</u>	Sep 04, 1987
<u>AB</u>		<u>0.3MG</u>	<u>A070923</u>	<u>001</u>	Sep 04, 1987
<u>AB</u>	MYLAN	<u>0.1MG</u>	<u>A070317</u>	<u>002</u>	Jul 09, 1987

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 107 (of 428)

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>0.2MG</u>	<u>A070317</u>	<u>003</u>	Jun 09, 1987
<u>AB</u>		<u>0.3MG</u>	<u>A070317</u>	<u>001</u>	Jun 09, 1987
<u>AB</u>	UNICHEM	<u>0.1MG</u>	<u>A078895</u>	<u>001</u>	Aug 26, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078895</u>	<u>002</u>	Aug 26, 2009
<u>AB</u>		<u>0.3MG</u>	<u>A078895</u>	<u>003</u>	Aug 26, 2009
<u>AB</u>	VINTAGE	<u>0.1MG</u>	<u>A077901</u>	<u>001</u>	Mar 09, 2007
<u>AB</u>		<u>0.2MG</u>	<u>A077901</u>	<u>002</u>	Mar 09, 2007
<u>AB</u>		<u>0.3MG</u>	<u>A077901</u>	<u>003</u>	Mar 09, 2007
<u>AB</u>	WATSON LABS	<u>0.3MG</u>	<u>A070963</u>	<u>001</u>	Jul 08, 1986
TABLET, EXTENDED RELEASE; ORAL					
KAPVAY					
	+ SHIONOGI INC	0.1MG	N022331	003	Sep 28, 2010
		0.2MG	N022331	004	Sep 28, 2010

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

<u>AB</u>	APOTEX INC	<u>EQ 75MG BASE</u>	<u>A076274</u>	<u>001</u>	May 17, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 75MG BASE</u>	<u>A090540</u>	<u>001</u>	May 17, 2012
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 75MG BASE</u>	<u>A076273</u>	<u>001</u>	Jan 14, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 300MG BASE</u>	<u>A091023</u>	<u>001</u>	May 17, 2012
<u>AB</u>	GATE PHARMS	<u>EQ 300MG BASE</u>	<u>A091216</u>	<u>001</u>	May 17, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 75MG BASE</u>	<u>A077665</u>	<u>001</u>	May 17, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077665</u>	<u>002</u>	May 17, 2012
<u>AB</u>	ROXANE	<u>EQ 75MG BASE</u>	<u>A078004</u>	<u>001</u>	May 17, 2012
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 75MG BASE</u>	<u>A090494</u>	<u>001</u>	May 17, 2012
<u>AB</u>	TEVA	<u>EQ 75MG BASE</u>	<u>A076999</u>	<u>001</u>	May 17, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 300MG BASE</u>	<u>A090625</u>	<u>001</u>	May 17, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A090844</u>	<u>001</u>	May 17, 2012
<u>AB</u>	WOCKHARDT LTD	<u>EQ 75MG BASE</u>	<u>A202266</u>	<u>001</u>	Aug 14, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202266</u>	<u>002</u>	Nov 20, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 75MG BASE</u>	<u>A201686</u>	<u>001</u>	Oct 10, 2012
<u>PLAVIX</u>					
<u>AB</u>	SANOFI AVENTIS US	<u>EQ 75MG BASE</u>	<u>N020839</u>	<u>001</u>	Nov 17, 1997
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N020839</u>	<u>002</u>	Sep 20, 2007

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

<u>AB</u>	MYLAN	<u>3.75MG</u>	<u>A071858</u>	<u>002</u>	Jul 17, 1987
<u>AB</u>		<u>7.5MG</u>	<u>A071858</u>	<u>003</u>	Jul 17, 1987
<u>AB</u>		<u>15MG</u>	<u>A071858</u>	<u>001</u>	Jul 17, 1987
<u>AB</u>	RANBAXY	<u>3.75MG</u>	<u>A076911</u>	<u>001</u>	Sep 29, 2004
<u>AB</u>		<u>7.5MG</u>	<u>A076911</u>	<u>002</u>	Sep 29, 2004
<u>AB</u>		<u>15MG</u>	<u>A076911</u>	<u>003</u>	Sep 29, 2004
<u>AB</u>	TARO	<u>3.75MG</u>	<u>A075731</u>	<u>003</u>	Apr 27, 2000
<u>AB</u>		<u>7.5MG</u>	<u>A075731</u>	<u>002</u>	Apr 27, 2000
<u>AB</u>		<u>15MG</u>	<u>A075731</u>	<u>001</u>	Apr 27, 2000
<u>AB</u>	WATSON LABS	<u>3.75MG</u>	<u>A071852</u>	<u>001</u>	Feb 09, 1988
<u>AB</u>		<u>7.5MG</u>	<u>A071853</u>	<u>001</u>	Feb 09, 1988
<u>AB</u>		<u>15MG</u>	<u>A071854</u>	<u>001</u>	Feb 09, 1988
<u>GEN-XENE</u>					
<u>AB</u>	ALRA	<u>3.75MG</u>	<u>A071787</u>	<u>001</u>	Apr 26, 1988
<u>AB</u>		<u>7.5MG</u>	<u>A071788</u>	<u>001</u>	Apr 26, 1988
<u>AB</u>		<u>15MG</u>	<u>A071789</u>	<u>001</u>	Apr 26, 1988
<u>TRANXENE</u>					
<u>AB</u>	LUNDBECK LLC	<u>3.75MG</u>	<u>N017105</u>	<u>006</u>	
<u>AB</u>		<u>7.5MG</u>	<u>N017105</u>	<u>007</u>	

PRESCRIPTION DRUG PRODUCT LIST

3 - 108 (of 428)

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

TRANXENE

<u>AB</u>	+ LUNDBECK LLC	<u>15MG</u>	<u>N017105</u>	<u>008</u>

CLOTTRIMAZOLE

CREAM; TOPICAL

CLOTTRIMAZOLE

<u>AB</u>	FOUGERA PHARMS	1%	<u>A078338</u>	<u>001</u>	Sep 02, 2008
<u>AB</u>	GLENMARK PHARMS	1%	<u>A090219</u>	<u>001</u>	Aug 03, 2010
<u>AB</u>	+ TARO	1%	<u>A072640</u>	<u>001</u>	Aug 31, 1993

SOLUTION; TOPICAL

CLOTTRIMAZOLE

<u>AT</u>	TARO	1%	<u>A074580</u>	<u>001</u>	Jul 29, 1996
<u>AT</u>	TEVA	1%	<u>A073306</u>	<u>001</u>	Feb 28, 1995

MYCELEX

<u>AT</u>	+ BAYER HLTHCARE	1%	<u>N018181</u>	<u>001</u>

TROCHE/LOZENGE; ORAL

CLOTTRIMAZOLE

<u>AB</u>	PADDOCK LLC	<u>10MG</u>	<u>A076763</u>	<u>001</u>	Oct 28, 2005
<u>AB</u>	+ ROXANE	<u>10MG</u>	<u>A076387</u>	<u>001</u>	Jul 29, 2004

CLOZAPINE

TABLET; ORAL

CLOZAPINE

<u>AB</u>	CARACO	<u>25MG</u>	<u>A075713</u>	<u>001</u>	Nov 15, 2002
<u>AB</u>		<u>50MG</u>	<u>A075713</u>	<u>003</u>	Aug 19, 2005
<u>AB</u>		<u>100MG</u>	<u>A075713</u>	<u>002</u>	Nov 15, 2002
<u>AB</u>	IVAX SUB TEVA PHARMS	25MG	<u>A074949</u>	<u>001</u>	Nov 26, 1997
<u>AB</u>		50MG	<u>A074949</u>	<u>004</u>	Apr 25, 2005
<u>AB</u>		50MG	<u>A076809</u>	<u>003</u>	Dec 16, 2005
<u>AB</u>		100MG	<u>A074949</u>	<u>002</u>	Nov 26, 1997
<u>AB</u>		100MG	<u>A076809</u>	<u>002</u>	Dec 16, 2005
<u>AB</u>	MYLAN	25MG	<u>A075417</u>	<u>001</u>	May 27, 1999
<u>AB</u>		100MG	<u>A075417</u>	<u>002</u>	May 27, 1999

CLOZARIL

<u>AB</u>	NOVARTIS	<u>25MG</u>	<u>N019758</u>	<u>001</u>	Sep 26, 1989
<u>AB</u>	+	<u>100MG</u>	<u>N019758</u>	<u>002</u>	Sep 26, 1989

CLOZAPINE

IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003
	200MG	A076809	001	Dec 16, 2005

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

JAZZ PHARMS III	12.5MG	N021590	004	May 30, 2007
	25MG	N021590	001	Feb 10, 2004
+	100MG	N021590	002	Feb 10, 2004
	150MG	N021590	005	Jul 09, 2010
	200MG	N021590	006	Jul 09, 2010

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

STRIBILD

+ GILEAD SCIENCES INC	150MG;150MG;200MG;300MG	N203100	001	Aug 27, 2012

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

<u>AA</u>	VINTAGE	<u>10MG/5ML; 5MG/5ML; 6.25MG/5ML</u>	<u>A040660</u>	<u>001</u>	Dec 07, 2006
<u>AA</u>	+	<u>ACTAVIS MID ATLANTIC</u>	<u>10MG/5ML; 5MG/5ML; 6.25MG/5ML</u>	<u>A088764</u>	<u>001</u>
					Oct 31, 1984

PRESCRIPTION DRUG PRODUCT LIST

3 - 109 (of 428)

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

<u>AA</u>	+	ACTAVIS MID ATLANTIC	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A088763</u>	<u>001</u>	Oct 31, 1984
<u>AA</u>		HI TECH PHARMA	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A040151</u>	<u>001</u>	Aug 26, 1997
<u>AA</u>		PHARM ASSOC	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A089647</u>	<u>001</u>	Dec 22, 1988
<u>AA</u>		SUN PHARM INDS INC	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A090180</u>	<u>001</u>	Mar 17, 2010
<u>AA</u>		TRIS PHARMA INC	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A200386</u>	<u>001</u>	Jun 29, 2012
<u>AA</u>		WOCKHARDT	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A088875</u>	<u>001</u>	Dec 17, 1984
<u>PROMETHAZINE WITH CODEINE</u>						
<u>AA</u>		VINTAGE	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A040650</u>	<u>001</u>	Jan 31, 2006

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIACIN-C

+	STI PHARMA LLC	10MG/5ML; 30MG/5ML; 1.25MG/5ML	A088704	001	Mar 22, 1985

CODEINE SULFATE

SOLUTION; ORAL

CODEINE SULFATE

+	ROXANE	30MG/5ML	N022245	001	Jun 30, 2011

TABLET; ORAL

CODEINE SULFATE

	ROXANE	15MG	N022402	001	Jul 16, 2009
		30MG	N022402	002	Jul 16, 2009
+		60MG	N022402	003	Jul 16, 2009

COLCHICINE

TABLET; ORAL

COLCRYS

+	TAKEDA PHARMS USA	0.6MG	N022352	001	Jul 29, 2009

COLCHICINE; PROBENECID

TABLET; ORAL

COL-PROBENECID

<u>AB</u>	+	WATSON LABS	<u>0.5MG; 500MG</u>	<u>A084279</u>	<u>001</u>	
<u>PROBENECID AND COLCHICINE</u>						
<u>AB</u>		MIRROR PHARMS	<u>0.5MG; 500MG</u>	<u>A040618</u>	<u>001</u>	May 13, 2008

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL

WELCHOL

	DAIICHI SANKYO	1.875GM/PACKET	N022362	001	Oct 02, 2009
+		3.75GM/PACKET	N022362	002	Oct 02, 2009

TABLET; ORAL

WELCHOL

+	DAIICHI SANKYO	625MG	N021176	001	May 26, 2000

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

COLESTID

<u>AB</u>		PHARMACIA AND UPJOHN	<u>5GM/SC00PFUL</u>	<u>N017563</u>	<u>003</u>	Sep 22, 1995
<u>AB</u>	+		<u>5GM/PACKET</u>	<u>N017563</u>	<u>004</u>	Sep 22, 1995
<u>COLESTIPOL HYDROCHLORIDE</u>						
<u>AB</u>		IMPAX LABS	<u>5GM/PACKET</u>	<u>A077277</u>	<u>002</u>	May 02, 2006
<u>AB</u>			<u>5GM/SC00PFUL</u>	<u>A077277</u>	<u>001</u>	May 02, 2006
FLAVORED COLESTID						
		PHARMACIA AND UPJOHN	5GM/SC00PFUL	N017563	002	
			5GM/PACKET	N017563	001	
TABLET; ORAL						
<u>COLESTID</u>						
<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>1GM</u>	<u>N020222</u>	<u>001</u>	Jul 19, 1994

PRESCRIPTION DRUG PRODUCT LIST

3 - 110 (of 428)

COLESTIPOL HYDROCHLORIDE

TABLET; ORAL

COLESTIPOL HYDROCHLORIDE

<u>AB</u>	IMPAX LABS	<u>1GM</u>	<u>A077510</u>	<u>001</u>	Oct 24, 2006

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 150MG BASE/VIAL</u>	<u>A202359</u>	<u>001</u>	Sep 28, 2012

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 150MG BASE/VIAL</u>	<u>A065364</u>	<u>001</u>	Apr 17, 2008

<u>AP</u>	PADDOK LLC	<u>EQ 150MG BASE/VIAL</u>	<u>A065177</u>	<u>001</u>	Mar 19, 2004

<u>AP</u>	X GEN PHARMS	<u>EQ 150MG BASE/VIAL</u>	<u>A064216</u>	<u>001</u>	Feb 26, 1999

COLY-MYCIN M

<u>AP</u>	+ JHP PHARMS	<u>EQ 150MG BASE/VIAL</u>	<u>N050108</u>	<u>002</u>	

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

	+ JHP PHARMS	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356	001	

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

	+ ASTELLAS	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

	+ TEVA WOMENS	309MG/COPPER	N018680	001	Nov 15, 1984

CORTICORELIN OVINE TRIFLUTATE

INJECTABLE; INJECTION

ACTHREL

	+ FERRING	EQ 0.1MG BASE/VIAL	N020162	001	May 23, 1996

CORTICOTROPIN

INJECTABLE; INJECTION

H.P. ACTHAR GEL

	+ QUESTCOR PHARMS	80 UNITS/ML	N008372	008	

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATE

	+ WEST WARD	25MG	A080776	002	

COSYNTROPIN

INJECTABLE; INJECTION

CORTROSYN

<u>AP</u>	+ AMPHASTAR PHARMS INC	<u>0.25MG/VIAL</u>	<u>N016750</u>	<u>001</u>	

COSYNTROPIN

<u>AP</u>	BIONICHE PHARMA	<u>0.25MG/VIAL</u>	<u>A090574</u>	<u>001</u>	Dec 17, 2009

<u>AP</u>	SANDOZ	<u>0.25MG/VIAL</u>	<u>A202147</u>	<u>001</u>	Jun 29, 2012

SOLUTION; INTRAVENOUS

COSYNTROPIN

	SANDOZ	0.25MG/ML (0.25MG/ML)	N022028	001	Feb 21, 2008

CRIZOTINIB

CAPSULE; ORAL

XALKORI

	PFIZER	200MG	N202570	001	Aug 26, 2011

	+	250MG	N202570	002	Aug 26, 2011

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 111 (of 428)

CROFELEMERTABLET, DELAYED RELEASE; ORAL
FULYZAQ

+ SALIX PHARMS 125MG N202292 001 Dec 31, 2012

CROMOLYN SODIUM

CONCENTRATE; ORAL

CROMOLYN SODIUM

AA PACK PHARMS LLC 100MG/5ML A202583 001 Oct 27, 2011

GASTROCROM

AA + MEDA PHARMS 100MG/5ML N020479 001 Feb 29, 1996

SOLUTION; INHALATION

CROMOLYN SODIUM

AN BAUSCH AND LOMB 10MG/ML A075585 001 Dec 21, 2000

AN DEY 10MG/ML A074209 001 Apr 26, 1994

AN NOVEX 10MG/ML A075333 001 Apr 30, 2002

AN + TEVA PHARMS 10MG/ML A075271 001 Jan 18, 2000

AN WATSON LABS 10MG/ML A076469 001 Jun 17, 2005

AN WOCHKHARDT 10MG/ML A075346 001 Oct 25, 1999

SOLUTION/DROPS; OPHTHALMIC

CROLOM

AT BAUSCH AND LOMB 4% A074443 001 Jan 30, 1995

CROMOLYN SODIUM

AT AKORN 4% A074706 001 Apr 29, 1998

AT ALCON 4% A075282 001 Jun 16, 1999

AT NOVEX 4% A075615 001 Jan 26, 2001

OPTICROM

AT + ALLERGAN 4% N018155 001 Oct 03, 1984

CROTAMITON

CREAM; TOPICAL

EURAX

+ RANBAXY 10% N006927 001

LOTION; TOPICAL

CROTAN

AT SUMMERS 10% A087204 001

EURAX

AT + RANBAXY 10% N009112 003

CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA EQ 0.4MG COPPER/ML N018960 001 Jun 26, 1986

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

AP + LUITPOLD 1MG/ML A080737 001

VIBISONE

AP + FRESENIUS KABI USA 1MG/ML A080557 003

SPRAY, METERED; NASAL

NASCOBAL

+ PAR PHARM 0.5MG/SPRAY N021642 001 Jan 31, 2005

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

AB TEVA 15MG N021777 001 Feb 01, 2007

AB + 30MG N021777 002 Feb 01, 2007

CYCLOBENZAPRINE HYDROCHLORIDE

AB MYLAN 15MG A090738 001 Apr 18, 2011

AB 30MG A090738 002 Apr 18, 2011

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 112 (of 428)

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078643</u>	<u>001</u>	Sep 26, 2008
<u>AB</u>		<u>10MG</u>	<u>A078643</u>	<u>002</u>	Sep 26, 2008
<u>AB</u>	INVAGEN PHARMS	<u>5MG</u>	<u>A090478</u>	<u>001</u>	Jul 23, 2010
<u>AB</u>		<u>10MG</u>	<u>A090478</u>	<u>002</u>	Jul 23, 2010
<u>AB</u>	JUBILANT CADISTA	<u>5MG</u>	<u>A077563</u>	<u>001</u>	Apr 19, 2006
<u>AB</u>		<u>10MG</u>	<u>A077563</u>	<u>002</u>	Apr 19, 2006
<u>AB</u>	KVK TECH	<u>5MG</u>	<u>A078048</u>	<u>001</u>	Feb 28, 2011
<u>AB</u>		<u>10MG</u>	<u>A078048</u>	<u>002</u>	Feb 28, 2011
<u>AB</u>	MUTUAL PHARM	<u>5MG</u>	<u>A073541</u>	<u>002</u>	Apr 06, 2006
<u>AB</u>		<u>10MG</u>	<u>A073541</u>	<u>001</u>	May 23, 1995
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A073144</u>	<u>002</u>	Feb 03, 2006
<u>AB</u>	+	<u>10MG</u>	<u>A073144</u>	<u>001</u>	May 30, 1991
<u>AB</u>	ORIT LABS LLC	<u>10MG</u>	<u>A078218</u>	<u>001</u>	Apr 18, 2008
<u>AB</u>	PLIVA	<u>10MG</u>	<u>A074421</u>	<u>001</u>	Sep 29, 1995
<u>AB</u>	PROSAM LABS	<u>5MG</u>	<u>A077291</u>	<u>001</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A077209</u>	<u>001</u>	Oct 04, 2005
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A078722</u>	<u>001</u>	May 12, 2008
<u>AB</u>		<u>7.5MG</u>	<u>A078722</u>	<u>002</u>	May 12, 2008
<u>AB</u>		<u>10MG</u>	<u>A078722</u>	<u>003</u>	May 12, 2008
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A072854</u>	<u>002</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A072854</u>	<u>001</u>	Nov 19, 1991
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A077797</u>	<u>001</u>	Feb 28, 2007
<u>AB</u>		<u>10MG</u>	<u>A077797</u>	<u>002</u>	Feb 28, 2007
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A071611</u>	<u>002</u>	Feb 03, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A071611</u>	<u>003</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A071611</u>	<u>001</u>	May 03, 1989

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE

<u>AT</u>	AKORN	<u>1%</u>	<u>A040164</u>	<u>001</u>	Jan 13, 1997
<u>AT</u>		<u>2%</u>	<u>A040165</u>	<u>001</u>	Jan 13, 1997
	<u>CYCLOGYL</u>				
<u>AT</u>	+	<u>1%</u>	<u>A084110</u>	<u>001</u>	
<u>AT</u>	+	<u>2%</u>	<u>A084108</u>	<u>001</u>	
	<u>PENTOLAIR</u>				
<u>AT</u>	BAUSCH AND LOMB	<u>1%</u>	<u>A040075</u>	<u>001</u>	Apr 29, 1994
	CYCLOGYL				
	+	0.5%	A084109	001	

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

+	ALCON	0.2%;1%	A084300	001	

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

<u>AP</u>	+	BAXTER HLTHCARE	<u>500MG/VIAL</u>	<u>A040745</u>	<u>001</u>	May 21, 2008
<u>AP</u>	+		<u>1GM/VIAL</u>	<u>A040745</u>	<u>002</u>	May 21, 2008
<u>AP</u>	+		<u>2GM/VIAL</u>	<u>A040745</u>	<u>003</u>	May 21, 2008
	<u>CYTOXAN</u>					
<u>AP</u>	+	BAXTER HLTHCARE	<u>500MG/VIAL</u>	<u>N012142</u>	<u>003</u>	
<u>AP</u>	+		<u>1GM/VIAL</u>	<u>N012142</u>	<u>004</u>	Aug 30, 1982
<u>AP</u>	+		<u>2GM/VIAL</u>	<u>N012142</u>	<u>005</u>	Aug 30, 1982

TABLET; ORAL

CYCLOPHOSPHAMIDE

	ROXANE	25MG	A040032	001	Aug 17, 1999

PRESCRIPTION DRUG PRODUCT LIST

3 - 113 (of 428)

CYCLOPHOSPHAMIDE

TABLET; ORAL
CYCLOPHOSPHAMIDE
+ ROXANE

50MG

A040032 002 Aug 17, 1999

CYCLOSERINE

CAPSULE; ORAL
SEROMYCIN
+ PURDUE GMP

250MG

A060593 001

CYCLOSPORINE

CAPSULE; ORAL
CYCLOSPORINE

AB1 IVAX SUB TEVA PHARMS

25MG

A065110 003 Mar 29, 2005

AB1 50MG

A065110 001 Mar 29, 2005

AB1 100MG

A065110 002 Mar 29, 2005

AB1 SANDOZ 25MG

A065017 002 Jan 13, 2000

AB1 100MG

A065017 001 Jan 13, 2000

AB1 WATSON LABS INC 25MG

A065044 002 Dec 20, 2000

AB1 100MG

A065044 001 Dec 20, 2000

GENGRAF

AB1 ABBVIE 25MG

A065003 001 May 12, 2000

AB1 50MG

A065003 002 May 12, 2000

AB1 100MG

A065003 003 May 12, 2000

NEORAL

AB1 NOVARTIS 25MG

N050715 001 Jul 14, 1995

AB1 + 100MG

N050715 002 Jul 14, 1995

CYCLOSPORINE

AB2 APOTEX 25MG

A065040 001 May 09, 2002

AB2 100MG

A065040 002 May 09, 2002

SANDIMMUNE

AB2 NOVARTIS 25MG

N050625 001 Mar 02, 1990

AB2 + 100MG

N050625 002 Mar 02, 1990

BX SANDIMMUNE NOVARTIS 50MG

N050625 003 Nov 23, 1992

EMULSION; OPHTHALMIC
RESTASIS
+ ALLERGAN

0.05%

N050790 001 Dec 23, 2002

INJECTABLE; INJECTION
CYCLOSPORINE

AP BEDFORD 50MG/ML

A065004 001 Oct 29, 1999

AP LUITPOLD 50MG/ML

A065151 001 Oct 07, 2003

SANDIMMUNE

AP + NOVARTIS 50MG/ML

N050573 001 Nov 14, 1983

SOLUTION; ORAL
CYCLOSPORINE

AB1 ABBVIE 100MG/ML

A065025 001 Mar 03, 2000

AB1 IVAX SUB TEVA PHARMS 100MG/ML

A065078 001 Mar 25, 2005

AB1 NOVEX 100MG/ML

A065167 001 Jan 05, 2005

AB1 WATSON LABS 100MG/ML

A065054 001 Dec 18, 2001

NEORAL

AB1 + NOVARTIS 100MG/ML

N050716 001 Jul 14, 1995

CYCLOSPORINE

AB2 WOCKHARDT 100MG/ML

A065133 001 Sep 17, 2004

SANDIMMUNE

AB2 + NOVARTIS 100MG/ML

N050574 001 Nov 14, 1983

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL
CYPROHEPTADINE HYDROCHLORIDE

AA + LYNE 2MG/5ML

A040668 001 Jun 28, 2006

PRESCRIPTION DRUG PRODUCT LIST

3 - 114 (of 428)

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

<u>AA</u>	COREPHARMA	<u>4MG</u>	<u>A040537</u>	<u>001</u>	Sep 30, 2003
<u>AA</u>	+	IVAX SUB TEVA PHARMS	<u>4MG</u>	<u>A087056</u>	<u>001</u>
<u>AA</u>		PAR PHARM	<u>4MG</u>	<u>A087129</u>	<u>001</u>
<u>AA</u>		STASON PHARMS	<u>4MG</u>	<u>A040644</u>	<u>001</u> May 30, 2006

CYSTEAMINE BITARTRATE

CAPSULE; ORAL

CYSTAGON

	MYLAN	EQ 50MG BASE	N020392	001	Aug 15, 1994
+		EQ 150MG BASE	N020392	002	Aug 15, 1994

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

+	SIGMA TAU	EQ 0.44% BASE	N200740	001	Oct 02, 2012

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

<u>AP</u>	BEDFORD	<u>100MG/VIAL</u>	<u>A071471</u>	<u>001</u>	Aug 02, 1989
<u>AP</u>		<u>500MG/VIAL</u>	<u>A071472</u>	<u>001</u>	Aug 02, 1989
<u>AP</u>		<u>1GM/VIAL</u>	<u>A074245</u>	<u>001</u>	Aug 31, 1994
<u>AP</u>		<u>2GM/VIAL</u>	<u>A074245</u>	<u>002</u>	Aug 31, 1994
<u>AP</u>	+	FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A076512</u>	<u>001</u> Jan 15, 2004
<u>AP</u>	+	HOSPIRA	<u>20MG/ML</u>	<u>A071868</u>	<u>001</u> Jun 04, 1990
<u>AP</u>	+		<u>20MG/ML</u>	<u>A072168</u>	<u>001</u> Aug 31, 1990
<u>AP</u>	+		<u>20MG/ML</u>	<u>A072945</u>	<u>001</u> Feb 28, 1994
<u>AP</u>		<u>100MG/ML</u>	<u>A075383</u>	<u>001</u>	Nov 22, 1999
<u>AP</u>	ONCO THERAPIES LTD	<u>20MG/ML</u>	<u>A200914</u>	<u>001</u>	Dec 13, 2011
<u>AP</u>		<u>20MG/ML</u>	<u>A200915</u>	<u>001</u>	Dec 13, 2011
<u>AP</u>		<u>20MG/ML</u>	<u>A200916</u>	<u>001</u>	Dec 13, 2011
<u>AP</u>		<u>100MG/ML</u>	<u>A201784</u>	<u>001</u>	Jan 30, 2012
<u>CYTOSAR-U</u>					
<u>AP</u>	TEVA PARENTERAL	<u>100MG/VIAL</u>	<u>A075206</u>	<u>001</u>	Dec 30, 1998
<u>AP</u>	+	<u>500MG/VIAL</u>	<u>A075206</u>	<u>002</u>	Dec 30, 1998
<u>AP</u>	+	<u>1GM/VIAL</u>	<u>A075206</u>	<u>004</u>	Dec 30, 1998
<u>AP</u>	+	<u>2GM/VIAL</u>	<u>A075206</u>	<u>003</u>	Dec 30, 1998

INJECTABLE, LIPOSOMAL; INJECTION

DEPOCYT

+	PACIRA PHARMS INC	10MG/ML	N021041	001	Apr 01, 1999

DABIGATRAN ETEXILATE MESYLATE

CAPSULE; ORAL

PRADAXA

	BOEHRINGER INGELHEIM	EQ 75MG BASE	N022512	001	Oct 19, 2010
+		EQ 150MG BASE	N022512	002	Oct 19, 2010

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

<u>AP</u>	BEDFORD	<u>200MG/VIAL</u>	<u>A075812</u>	<u>001</u>	Jun 15, 2001
<u>AP</u>		<u>500MG/VIAL</u>	<u>A075812</u>	<u>002</u>	Oct 31, 2002
<u>AP</u>	FRESENIUS KABI USA	<u>100MG/VIAL</u>	<u>A075371</u>	<u>001</u>	Aug 27, 1999
<u>AP</u>		<u>200MG/VIAL</u>	<u>A075371</u>	<u>002</u>	Aug 27, 1999
<u>AP</u>	HOSPIRA	<u>200MG/VIAL</u>	<u>A075940</u>	<u>001</u>	Oct 18, 2001
<u>AP</u>	TEVA PARENTERAL	<u>200MG/VIAL</u>	<u>A075259</u>	<u>002</u>	Aug 27, 1998
<u>AP</u>	+	<u>500MG/VIAL</u>	<u>A075259</u>	<u>001</u>	Sep 22, 2000

PRESCRIPTION DRUG PRODUCT LIST

3 - 115 (of 428)

DACARBAZINE

INJECTABLE; INJECTION

DTIC-DOME

<u>AP</u>	+ BAYER HLTHCARE	<u>100MG/VIAL</u>	<u>N017575</u>	<u>001</u>	
<u>AP</u>	+	<u>200MG/VIAL</u>	<u>N017575</u>	<u>002</u>	

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

<u>AP</u>	+ LUNDBECK LLC	<u>0.5MG/VIAL</u>	<u>N050682</u>	<u>001</u>	

DACTINOMYCIN

<u>AP</u>	BEDFORD	<u>0.5MG/VIAL</u>	<u>A090304</u>	<u>001</u>	Mar 16, 2010

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

AMPYRA

	+ ACORDA	10MG	N022250	001	Jan 22, 2010

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

	+ KING PHARMS	350MG/VIAL;150MG/VIAL	N050748	001	Sep 21, 1999

DALTEPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

FRAGMIN

EISAI INC

2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994
5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996
7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002
10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998
10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007
12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007
15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007
18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007
95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002
95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002

DANAZOL

CAPSULE; ORAL

DANAZOL

<u>AB</u>	BARR	<u>50MG</u>	<u>A074582</u>	<u>003</u>	May 29, 1998
<u>AB</u>		<u>100MG</u>	<u>A074582</u>	<u>002</u>	May 29, 1998
<u>AB</u>	+	<u>200MG</u>	<u>A074582</u>	<u>001</u>	Aug 09, 1996
<u>AB</u>	LANNETT	<u>50MG</u>	<u>A078214</u>	<u>001</u>	Apr 19, 2007
<u>AB</u>		<u>100MG</u>	<u>A078214</u>	<u>002</u>	Apr 19, 2007
<u>AB</u>		<u>200MG</u>	<u>A077246</u>	<u>001</u>	Sep 28, 2005

DANTROLENE SODIUM

CAPSULE; ORAL

DANTRIUM

<u>AB</u>	JHP PHARMS	<u>25MG</u>	<u>N017443</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>N017443</u>	<u>003</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N017443</u>	<u>002</u>	

DANTROLENE SODIUM

<u>AB</u>	IMPAX LABS	<u>25MG</u>	<u>A076856</u>	<u>001</u>	Mar 01, 2005
<u>AB</u>		<u>50MG</u>	<u>A076856</u>	<u>002</u>	Mar 01, 2005
<u>AB</u>		<u>100MG</u>	<u>A076856</u>	<u>003</u>	Mar 01, 2005

INJECTABLE; INJECTION

DANTRIUM

<u>AP</u>	+ JHP PHARMS	<u>20MG/VIAL</u>	<u>N018264</u>	<u>001</u>	

DANTROLENE SODIUM

<u>AP</u>	US WORLDMEDS	<u>20MG/VIAL</u>	<u>A078378</u>	<u>001</u>	Jul 24, 2007

PRESCRIPTION DRUG PRODUCT LIST

3 - 116 (of 428)

DAPSONE

GEL; TOPICAL					
ACZONE					
+	ALLERGAN	5%	N021794	001	Jul 07, 2005
TABLET; ORAL					
DAPSONE					
	JACOBUS	25MG	A086841	001	
+		100MG	A086842	001	

DAPTOMYCIN

INJECTABLE; IV (INFUSION)					
+	CUBIST	500MG/VIAL	N021572	002	Sep 12, 2003

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL					
ENABLEX					
	WARNER CHILCOTT LLC	EQ 7.5MG BASE	N021513	001	Dec 22, 2004
+		EQ 15MG BASE	N021513	002	Dec 22, 2004

DARUNAVIR ETHANOLATE

SUSPENSION; ORAL					
PREZISTA					
+	JANSSEN PRODS	EQ 100MG BASE/ML	N202895	001	Dec 16, 2011
TABLET; ORAL					
PREZISTA					
	JANSSEN PRODS	EQ 75MG BASE	N021976	004	Dec 18, 2008
		EQ 150MG BASE	N021976	005	Dec 18, 2008
		EQ 400MG BASE	N021976	003	Oct 21, 2008
		EQ 600MG BASE	N021976	002	Feb 25, 2008
+		EQ 800MG BASE	N021976	006	Nov 09, 2012

DASATINIB

TABLET; ORAL					
SPRYCEL					
	BRISTOL MYERS SQUIBB	20MG	N021986	001	Jun 28, 2006
		50MG	N021986	002	Jun 28, 2006
		70MG	N021986	003	Jun 28, 2006
		80MG	N021986	005	Oct 28, 2010
		100MG	N021986	004	May 30, 2008
+		140MG	N021986	006	Oct 28, 2010

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION					
DAUNOXOME					
+	GALEN (UK)	EQ 2MG BASE/ML	N050704	002	Apr 08, 1996

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION						
<u>CERUBIDINE</u>						
<u>AP</u>	+	BEDFORD	<u>EQ 20MG BASE/VIAL</u>	<u>A064103</u>	<u>001</u>	Feb 03, 1995
<u>DAUNORUBICIN HYDROCHLORIDE</u>						
<u>AP</u>	+	BEDFORD	<u>EQ 5MG BASE/ML</u>	<u>N050731</u>	<u>001</u>	Jan 30, 1998
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 20MG BASE/VIAL</u>	<u>A065000</u>	<u>001</u>	May 25, 1999
<u>AP</u>		TEVA PARENTERAL	<u>EQ 5MG BASE/ML</u>	<u>A065035</u>	<u>001</u>	Jan 24, 2000
DAUNORUBICIN HYDROCHLORIDE						
		FRESENIUS KABI USA	EQ 5MG BASE/VIAL	A065034	001	Nov 20, 2001

DECITABINE

INJECTABLE; INTRAVENOUS					
DACOGEN					
+	EISAI INC	50MG/VIAL	N021790	001	May 02, 2006

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 117 (of 428)

DEFERASIROXTABLET, FOR SUSPENSION; ORAL
EXJADE

NOVARTIS	125MG	N021882	001	Nov 02, 2005
	250MG	N021882	002	Nov 02, 2005
+	500MG	N021882	003	Nov 02, 2005

DEFERIPRONETABLET; ORAL
FERRIPROX

+ AOPHARMA INC	500MG	N021825	001	Oct 14, 2011

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

<u>AP</u>	BEDFORD	<u>500MG/VIAL</u>	<u>A078086</u>	<u>001</u>	May 30, 2007
<u>AP</u>		<u>2GM/VIAL</u>	<u>A078086</u>	<u>002</u>	May 30, 2007
<u>AP</u>	FRESENIUS KABI USA	<u>500MG/VIAL</u>	<u>A078718</u>	<u>001</u>	Sep 15, 2009
<u>AP</u>		<u>2GM/VIAL</u>	<u>A078718</u>	<u>002</u>	Sep 15, 2009
<u>AP</u>	HOSPIRA	<u>500MG/VIAL</u>	<u>A076019</u>	<u>001</u>	Mar 17, 2004
<u>AP</u>		<u>2GM/VIAL</u>	<u>A076019</u>	<u>002</u>	Mar 17, 2004
<u>AP</u>	WATSON LABS	<u>500MG/VIAL</u>	<u>A076806</u>	<u>001</u>	Mar 31, 2006
<u>AP</u>		<u>2GM/VIAL</u>	<u>A076806</u>	<u>002</u>	Mar 31, 2006
	<u>DESFERAL</u>				
<u>AP</u> +	NOVARTIS	<u>500MG/VIAL</u>	<u>N016267</u>	<u>001</u>	
<u>AP</u> +		<u>2GM/VIAL</u>	<u>N016267</u>	<u>002</u>	May 25, 2000

DEGARELIX ACETATEPOWDER; SUBCUTANEOUS
FIRMAGON

FERRING	EQ 80MG BASE/VIAL	N022201	001	Dec 24, 2008
+	EQ 120MG BASE/VIAL	N022201	002	Dec 24, 2008

DELAVIDINE MESYLATETABLET; ORAL
RESCRIPTOR

VIIV HLTHCARE	100MG	N020705	001	Apr 04, 1997
+	200MG	N020705	002	Jul 14, 1999

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DEMECLOCYCLINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARM	<u>150MG</u>	<u>A065425</u>	<u>001</u>	Feb 27, 2008
<u>AB</u> +		<u>300MG</u>	<u>A065425</u>	<u>002</u>	Feb 27, 2008
<u>AB</u>	BARR	<u>150MG</u>	<u>A065171</u>	<u>001</u>	Dec 13, 2004
<u>AB</u>		<u>300MG</u>	<u>A065171</u>	<u>002</u>	Dec 13, 2004
<u>AB</u>	IMPAX LABS	<u>150MG</u>	<u>A065094</u>	<u>001</u>	Mar 22, 2004
<u>AB</u>		<u>300MG</u>	<u>A065094</u>	<u>002</u>	Mar 22, 2004
<u>AB</u>	VERSAPHARM	<u>150MG</u>	<u>A065389</u>	<u>001</u>	Dec 01, 2008
<u>AB</u>		<u>300MG</u>	<u>A065389</u>	<u>002</u>	Dec 01, 2008

DESFLURANELIQUID; INHALATION
SUPRANE

+ BAXTER HLTHCARE	99.9%	N020118	001	Sep 18, 1992

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>10MG</u>	<u>A074430</u>	<u>001</u>	Feb 09, 1996
<u>AB</u>		<u>25MG</u>	<u>A071601</u>	<u>001</u>	Jun 05, 1987
<u>AB</u>		<u>50MG</u>	<u>A071588</u>	<u>001</u>	Jun 05, 1987

PRESCRIPTION DRUG PRODUCT LIST

3 - 118 (of 428)

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>75MG</u>	<u>A071602</u>	<u>001</u>	Oct 05, 1987
<u>AB</u>		<u>100MG</u>	<u>A071766</u>	<u>001</u>	Oct 05, 1987
<u>AB</u>		<u>150MG</u>	<u>A074430</u>	<u>002</u>	Feb 09, 1996
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A072099</u>	<u>001</u>	May 24, 1988
<u>AB</u>		<u>25MG</u>	<u>A072100</u>	<u>001</u>	May 24, 1988
<u>AB</u>		<u>50MG</u>	<u>A072101</u>	<u>001</u>	May 24, 1988
<u>AB</u>		<u>75MG</u>	<u>A072102</u>	<u>001</u>	Jun 20, 1988
<u>AB</u>		<u>100MG</u>	<u>A072103</u>	<u>001</u>	Jun 20, 1988
<u>AB</u>		<u>150MG</u>	<u>A072104</u>	<u>001</u>	Jun 20, 1988
	<u>NORPRAMIN</u>				
<u>AB</u>	SANOFI AVENTIS US	<u>10MG</u>	<u>N014399</u>	<u>007</u>	Feb 11, 1982
<u>AB</u>		<u>25MG</u>	<u>N014399</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>N014399</u>	<u>003</u>	
<u>AB</u>		<u>75MG</u>	<u>N014399</u>	<u>004</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N014399</u>	<u>005</u>	
<u>AB</u>		<u>150MG</u>	<u>N014399</u>	<u>006</u>	

DESIRUDIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

IPRIVASK

+	CANYON	15MG/VIAL	N021271	001	Apr 04, 2003

DESLOMATADINE

SYRUP; ORAL

CLARINEX

+	MERCK SHARP DOHME	0.5MG/ML	N021300	001	Sep 01, 2004

TABLET; ORAL

CLARINEX

<u>AB</u>	+	MERCK SHARP DOHME	<u>5MG</u>	<u>N021165</u>	<u>001</u>	Dec 21, 2001
		<u>DESLOMATADINE</u>				
<u>AB</u>		BELCHER PHARMS	<u>5MG</u>	<u>A078355</u>	<u>001</u>	Apr 19, 2012
<u>AB</u>		DR REDDYS LABS LTD	<u>5MG</u>	<u>A078365</u>	<u>001</u>	Mar 08, 2011
<u>AB</u>		LUPIN PHARMS	<u>5MG</u>	<u>A078352</u>	<u>001</u>	Oct 25, 2010
<u>AB</u>		MYLAN PHARMS INC	<u>5MG</u>	<u>A078351</u>	<u>001</u>	Feb 10, 2012
<u>AB</u>		ORCHID HLTHCARE	<u>5MG</u>	<u>A078357</u>	<u>001</u>	Feb 19, 2010
<u>AB</u>		PERRIGO R AND D	<u>5MG</u>	<u>A078361</u>	<u>001</u>	Dec 22, 2011
<u>AB</u>		SANDOZ	<u>5MG</u>	<u>A078364</u>	<u>001</u>	Dec 03, 2010
<u>AB</u>		SUN PHARM INDS	<u>5MG</u>	<u>A078359</u>	<u>001</u>	Nov 16, 2010

TABLET, ORALLY DISINTEGRATING; ORAL

CLARINEX

<u>AB</u>		MERCK SHARP DOHME	<u>2.5MG</u>	<u>N021312</u>	<u>002</u>	Jul 14, 2005
<u>AB</u>	+		<u>5MG</u>	<u>N021312</u>	<u>001</u>	Jun 26, 2002
		<u>DESLOMATADINE</u>				
<u>AB</u>		REDDYS	<u>2.5MG</u>	<u>A078367</u>	<u>001</u>	Jul 12, 2010
<u>AB</u>			<u>5MG</u>	<u>A078367</u>	<u>002</u>	Jul 12, 2010

DESLOMATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOUR

<u>AB</u>	+	MERCK SHARP DOHME	<u>5MG;240MG</u>	<u>N021605</u>	<u>001</u>	Mar 03, 2005
		<u>DESLOMATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR</u>				
<u>AB</u>		DR REDDYS LABS LTD	<u>5MG;240MG</u>	<u>A078366</u>	<u>001</u>	Apr 26, 2011
		CLARINEX-D 12 HOUR				
	+	MERCK SHARP DOHME	2.5MG;120MG	N021313	001	Feb 01, 2006

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

<u>AP</u>	+	SANOFI AVENTIS US	<u>0.004MG/ML</u>	<u>N018938</u>	<u>001</u>	Mar 30, 1984

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 119 (of 428)

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DESMOPRESSIN ACETATE

<u>AP</u>	HOSPIRA	<u>0.004MG/ML</u>	<u>A075220</u>	<u>001</u>	Aug 28, 2000
<u>AP</u>	TEVA PARENTERAL	<u>0.004MG/ML</u>	<u>A074888</u>	<u>001</u>	Oct 15, 1997

SOLUTION; NASAL

DDAVP

<u>AB</u>	+ SANOFI AVENTIS US	<u>0.01%</u>	<u>N017922</u>	<u>001</u>	

DESMOPRESSIN ACETATE

<u>AB</u>	SUN PHARM INDS	<u>0.01%</u>	<u>A077212</u>	<u>001</u>	Apr 12, 2012

SPRAY, METERED; NASAL

DDAVP (NEEDS NO REFRIGERATION)

<u>AB</u>	+ SANOFI AVENTIS US	<u>0.01MG/SPRAY</u>	<u>N017922</u>	<u>003</u>	Aug 07, 1996

DESMOPRESSIN ACETATE

<u>AB</u>	+ BAUSCH AND LOMB	<u>0.01MG/SPRAY</u>	<u>A074830</u>	<u>001</u>	Jan 25, 1999

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

<u>AB</u>	APOTEX INC	<u>0.01MG/SPRAY</u>	<u>A076703</u>	<u>001</u>	Jan 27, 2005

MINIRIN

<u>AB</u>	+ FERRING	<u>0.01MG/SPRAY</u>	<u>N021333</u>	<u>001</u>	Sep 16, 2002

STIMATE (NEEDS NO REFRIGERATION)

	+ CSL BEHRING	1.5MG/SPRAY	N020355	002	Oct 24, 2007

TABLET; ORAL

DDAVP

<u>AB</u>	SANOFI AVENTIS US	<u>0.1MG</u>	<u>N019955</u>	<u>001</u>	Sep 06, 1995

<u>AB</u>	+	<u>0.2MG</u>	<u>N019955</u>	<u>002</u>	Sep 06, 1995

DESMOPRESSIN ACETATE

<u>AB</u>	APOTEX INC	<u>0.1MG</u>	<u>A077414</u>	<u>001</u>	Mar 07, 2006

<u>AB</u>		<u>0.2MG</u>	<u>A077414</u>	<u>002</u>	Mar 07, 2006

<u>AB</u>	TEVA PHARMS	<u>0.1MG</u>	<u>A077122</u>	<u>001</u>	Jan 25, 2006

<u>AB</u>		<u>0.2MG</u>	<u>A077122</u>	<u>002</u>	Jan 25, 2006

<u>AB</u>	WATSON LABS	<u>0.1MG</u>	<u>A076470</u>	<u>001</u>	Jul 01, 2005

<u>AB</u>		<u>0.2MG</u>	<u>A076470</u>	<u>002</u>	Jul 01, 2005

DESMOPRESSIN ACETATE

	FERRING	0.1MG	N021795	001	May 08, 2008

+		0.2MG	N021795	002	May 08, 2008

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

CYCLESSA

<u>AB</u>	+ ORGANON USA INC	<u>0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG</u>	<u>N021090</u>	<u>001</u>	Dec 20, 2000

DESOGEN

<u>AB</u>	ORGANON USA INC	<u>0.15MG; 0.03MG</u>	<u>N020071</u>	<u>002</u>	Dec 10, 1992

DESOGESTREL AND ETHINYL ESTRADIOL

<u>AB</u>	DURAMED PHARMS BARR	<u>0.15MG; 0.03MG</u>	<u>A075256</u>	<u>002</u>	Aug 12, 1999

<u>AB</u>	WATSON LABS	<u>0.15MG, N/A; 0.02MG, 0.01MG</u>	<u>A076916</u>	<u>001</u>	Dec 29, 2008

<u>AB</u>		<u>0.15MG; 0.03MG</u>	<u>A076915</u>	<u>001</u>	Jul 29, 2005

EMOQUETTE

<u>AB</u>	VINTAGE PHARMS LLC	<u>0.15MG; 0.03MG</u>	<u>A076675</u>	<u>001</u>	Feb 25, 2011

KARIVA

<u>AB</u>	BARR	<u>0.15MG, N/A; 0.02MG, 0.01MG</u>	<u>A075863</u>	<u>001</u>	Apr 05, 2002

MIRCETTE

<u>AB</u>	+ TEVA BRANDED PHARM	<u>0.15MG, N/A; 0.02MG, 0.01MG</u>	<u>N020713</u>	<u>001</u>	Apr 22, 1998

ORTHO-CEPT

<u>AB</u>	+ JANSSEN PHARMS	<u>0.15MG; 0.03MG</u>	<u>N020301</u>	<u>002</u>	Dec 14, 1992

VELIVET

<u>AB</u>	DURAMED PHARMS BARR	<u>0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG</u>	<u>A076455</u>	<u>001</u>	Feb 24, 2004

VIORALE

<u>AB</u>	GLENMARK GENERICS	<u>0.15MG, N/A; 0.02MG, 0.01MG</u>	<u>A091346</u>	<u>001</u>	Apr 02, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 120 (of 428)

DESONIDE

AEROSOL, FOAM; TOPICAL					
VERDESO					
+	STIEFEL LABS INC	0.05%	N021978	001	Sep 19, 2006
CREAM; TOPICAL					
<u>DESONIDE</u>					
<u>AB</u>	+ PERRIGO NEW YORK	<u>0.05%</u>	<u>N017010</u>	<u>001</u>	
<u>AB</u>	TARO	<u>0.05%</u>	<u>A073548</u>	<u>001</u>	Jun 30, 1992
<u>DESOWEN</u>					
<u>AB</u>	GALDERMA LABS LP	<u>0.05%</u>	<u>N019048</u>	<u>001</u>	Dec 14, 1984
GEL; TOPICAL					
DESONATE					
+	BHP DERMATOLOGY	0.05%	N021844	001	Oct 20, 2006
LOTION; TOPICAL					
<u>DESONIDE</u>					
<u>AB</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A075860</u>	<u>001</u>	Mar 19, 2002
<u>DESOWEN</u>					
<u>AB</u>	+ GALDERMA LABS LP	<u>0.05%</u>	<u>A072354</u>	<u>001</u>	Jan 24, 1992
OINTMENT; TOPICAL					
<u>DESONIDE</u>					
<u>AB</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A075751</u>	<u>001</u>	Mar 12, 2001
<u>AB</u>	+ PERRIGO NEW YORK	<u>0.05%</u>	<u>N017426</u>	<u>001</u>	
<u>AB</u>	TARO	<u>0.05%</u>	<u>A074254</u>	<u>001</u>	Aug 03, 1994
<u>DESOWEN</u>					
<u>AB</u>	GALDERMA LABS LP	<u>0.05%</u>	<u>A071425</u>	<u>001</u>	Jun 15, 1988

DESOXIMETASONE

CREAM; TOPICAL					
<u>DESOXIMETASONE</u>					
<u>AB</u>	FOUGERA PHARMS	<u>0.25%</u>	<u>A078369</u>	<u>001</u>	Jun 29, 2010
<u>AB</u>	PERRIGO NEW YORK	<u>0.25%</u>	<u>A076510</u>	<u>001</u>	Jul 01, 2003
<u>TOPICORT</u>					
<u>AB</u>	+ TARO	<u>0.25%</u>	<u>A073193</u>	<u>001</u>	Nov 30, 1990
TOPICORT					
	+ TARO	0.05%	A073210	001	Nov 30, 1990
GEL; TOPICAL					
<u>DESOXIMETASONE</u>					
<u>AB</u>	PERRIGO NEW YORK	<u>0.05%</u>	<u>A077552</u>	<u>001</u>	Jan 09, 2006
<u>AB</u>	VERSAPHARM	<u>0.05%</u>	<u>A090727</u>	<u>001</u>	Mar 10, 2011
<u>TOPICORT</u>					
<u>AB</u>	+ TARO	<u>0.05%</u>	<u>A074904</u>	<u>001</u>	Jul 14, 1998
OINTMENT; TOPICAL					
<u>DESOXIMETASONE</u>					
<u>AB</u>	FOUGERA PHARMS	<u>0.25%</u>	<u>A078657</u>	<u>001</u>	Sep 28, 2012
<u>TOPICORT</u>					
<u>AB</u>	+ TARO	<u>0.25%</u>	<u>A074286</u>	<u>001</u>	Jun 07, 1996
TOPICORT					
	+ TARO PHARMS NORTH	0.05%	N018594	001	Jan 17, 1985

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL					
PRISTIQ					
	+ WYETH PHARMS INC	EQ 50MG BASE	N021992	001	Feb 29, 2008
	+	EQ 100MG BASE	N021992	002	Feb 29, 2008

DEXAMETHASONE

CONCENTRATE; ORAL					
DEXAMETHASONE INTENSOL					
	+ ROXANE	1MG/ML	A088252	001	Sep 01, 1983
ELIXIR; ORAL					
<u>DEXAMETHASONE</u>					
<u>AA</u>	LYNE	<u>0.5MG/5ML</u>	<u>A090891</u>	<u>001</u>	Jul 12, 2011

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 121 (of 428)

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

<u>AA</u>	+	STI PHARMA LLC	<u>0.5MG/5ML</u>	<u>A084754</u>	<u>001</u>	
<u>AA</u>		VINTAGE PHARMS	<u>0.5MG/5ML</u>	<u>A091188</u>	<u>001</u>	May 11, 2011
<u>AA</u>	+	WOCKHARDT	<u>0.5MG/5ML</u>	<u>A088254</u>	<u>001</u>	Jul 27, 1983

IMPLANT; INTRAVITREAL

OZURDEX

	+	ALLERGAN	0.7MG	N022315	001	Jun 17, 2009

SOLUTION; ORAL

DEXAMETHASONE

	+	ROXANE	0.5MG/5ML	A088248	001	Sep 01, 1983

SUSPENSION/DROPS; OPHTHALMIC

	+	ALCON	0.1%	N013422	001	

TABLET; ORAL

DEXAMETHASONE

<u>AB</u>		ECR	<u>1.5MG</u>	<u>A040700</u>	<u>001</u>	Aug 15, 2008
<u>AB</u>		ROXANE	<u>1.5MG</u>	<u>A084610</u>	<u>001</u>	
		DEXAMETHASONE				
BP		PAR PHARM	0.5MG	A088148	001	Apr 28, 1983
BP			0.75MG	A088160	001	Apr 28, 1983
BP			1.5MG	A088237	001	Apr 28, 1983
BP			4MG	A088238	001	Apr 28, 1983
BP	+		6MG	A088481	001	Nov 28, 1983
BP		ROXANE	0.5MG	A084611	001	
BP			0.75MG	A084613	001	
BP			1MG	A088306	001	Sep 15, 1983
BP			2MG	A087916	001	Aug 26, 1982
BP			4MG	A084612	001	
BP	+		6MG	A088316	001	Sep 15, 1983

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

<u>AP</u>		FRESENIUS KABI USA	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A084916</u>	<u>001</u>	
<u>AP</u>	+		<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040491</u>	<u>001</u>	Apr 11, 2003
<u>AP</u>	+		<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040572</u>	<u>001</u>	Apr 22, 2005
<u>AP</u>	+	HIKMA MAPLE	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A087702</u>	<u>001</u>	Sep 07, 1982
<u>AP</u>	+	LUITPOLD	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A087440</u>	<u>001</u>	Jul 21, 1982
<u>AP</u>		PFIZER	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A040803</u>	<u>001</u>	Aug 29, 2008
<u>AP</u>			<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040802</u>	<u>001</u>	Aug 29, 2008

SOLUTION/DROPS; OPHTHALMIC, OTIC

DEXAMETHASONE SODIUM PHOSPHATE

<u>AT</u>	+	ALCON PHARMS LTD	<u>EQ 0.1% PHOSPHATE</u>	<u>A088771</u>	<u>001</u>	Jan 16, 1985
<u>AT</u>		BAUSCH AND LOMB	<u>EQ 0.1% PHOSPHATE</u>	<u>A040069</u>	<u>001</u>	Jul 26, 1996

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

MAXITROL

<u>AT</u>	+	FALCON PHARMS	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>N050065</u>	<u>002</u>	
		<u>NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE</u>				
<u>AT</u>		BAUSCH AND LOMB	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064063</u>	<u>001</u>	Jul 25, 1994
<u>AT</u>		FERA PHARMS	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A062938</u>	<u>001</u>	Jul 31, 1989

SUSPENSION; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

<u>AT</u>		ALCON PHARMS LTD	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062721</u>	<u>001</u>	Nov 17, 1986

SUSPENSION/DROPS; OPHTHALMIC

DEXASPORIN

<u>AT</u>		BAUSCH AND LOMB	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A064135</u>	<u>001</u>	Sep 13, 1995
		<u>MAXITROL</u>				
<u>AT</u>		ALCON	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062341</u>	<u>001</u>	May 22, 1984

PRESCRIPTION DRUG PRODUCT LIST

3 - 122 (of 428)

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

MAXITROL

<u>AT</u>	+ FALCON PHARMS	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>N050023</u>	<u>002</u>

DEXAMETHASONE; TOBRAMYCIN

OINTMENT; OPHTHALMIC

TOBRADEX

	+ ALCON	0.1%;0.3%	N050616	001	Sep 28, 1988

SUSPENSION/DROPS; OPHTHALMIC

TOBRADEX

<u>AB</u>	+ ALCON	<u>0.1%;0.3%</u>	<u>N050592</u>	<u>001</u>	Aug 18, 1988

TOBRAMYCIN AND DEXAMETHASONE

<u>AB</u>	BAUSCH AND LOMB	<u>0.1%;0.3%</u>	<u>A064134</u>	<u>001</u>	Oct 27, 1999

TOBRADEX ST

	+ ALCON PHARMS LTD	0.05%;0.3%	N050818	001	Feb 13, 2009

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

DEXCHLORPHENIRAMINE MALEATE

	+ WOCKHARDT	2MG/5ML	A088251	001	Mar 23, 1984

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

DEXILANT

	TAKEDA PHARMS	30MG	N022287	001	Jan 30, 2009

	+	60MG	N022287	002	Jan 30, 2009

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRECEDEX

	+ HOSPIRA	EQ 100MCG BASE/ML (EQ100MCG BASE/ML)	N021038	001	Dec 17, 1999

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FOCALIN XR

	NOVARTIS	5MG	N021802	001	May 26, 2005
		10MG	N021802	002	May 26, 2005
		15MG	N021802	004	Aug 01, 2006
		20MG	N021802	003	May 26, 2005
		25MG	N021802	008	Apr 21, 2011
		30MG	N021802	005	Oct 23, 2009
		35MG	N021802	007	Apr 21, 2011
		40MG	N021802	006	Aug 11, 2010

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A077107</u>	<u>003</u>	Jan 29, 2007

<u>AB</u>		<u>5MG</u>	<u>A077107</u>	<u>001</u>	Jan 29, 2007

<u>AB</u>		<u>10MG</u>	<u>A077107</u>	<u>002</u>	Jan 29, 2007

FOCALIN

<u>AB</u>	NOVARTIS	<u>2.5MG</u>	<u>N021278</u>	<u>001</u>	Nov 13, 2001

<u>AB</u>		<u>5MG</u>	<u>N021278</u>	<u>002</u>	Nov 13, 2001

<u>AB</u>	+	<u>10MG</u>	<u>N021278</u>	<u>003</u>	Nov 13, 2001

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>EQ 250MG BASE/VIAL</u>	<u>A076068</u>	<u>001</u>	Sep 28, 2004

<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A076068</u>	<u>002</u>	Sep 28, 2004

<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 250MG BASE/VIAL</u>	<u>A200752</u>	<u>001</u>	Oct 19, 2011

<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A200752</u>	<u>002</u>	Oct 19, 2011

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 123 (of 428)

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

ZINECARD

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>EQ 250MG BASE/VIAL</u>	<u>N020212</u>	<u>001</u>	May 26, 1995
<u>AP</u>	+		<u>EQ 500MG BASE/VIAL</u>	<u>N020212</u>	<u>002</u>	May 26, 1995
		TOTECT				
	+	APRICUS PHARMS	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

<u>AB</u>		AMEDRA PHARMS	<u>5MG</u>	<u>N017078</u>	<u>001</u>	
<u>AB</u>			<u>10MG</u>	<u>N017078</u>	<u>002</u>	
<u>AB</u>	+		<u>15MG</u>	<u>N017078</u>	<u>003</u>	
		<u>DEXTROAMPHETAMINE SULFATE</u>				
<u>AB</u>		ACTAVIS ELIZABETH	<u>5MG</u>	<u>A203901</u>	<u>001</u>	Nov 30, 2012
<u>AB</u>			<u>10MG</u>	<u>A203901</u>	<u>002</u>	Nov 30, 2012
<u>AB</u>			<u>15MG</u>	<u>A203901</u>	<u>003</u>	Nov 30, 2012
<u>AB</u>		BARR	<u>5MG</u>	<u>A076137</u>	<u>001</u>	Jan 18, 2002
<u>AB</u>			<u>10MG</u>	<u>A076137</u>	<u>002</u>	Jan 18, 2002
<u>AB</u>			<u>15MG</u>	<u>A076137</u>	<u>003</u>	Jan 18, 2002
<u>AB</u>		MALLINCKRODT	<u>5MG</u>	<u>A076353</u>	<u>001</u>	May 06, 2003
<u>AB</u>			<u>10MG</u>	<u>A076353</u>	<u>002</u>	May 06, 2003
<u>AB</u>			<u>15MG</u>	<u>A076353</u>	<u>003</u>	May 06, 2003

SOLUTION; ORAL

DEXTROAMPHETAMINE SULFATE

	+	OUTLOOK PHARMS	5MG/5ML	A040776	001	Jan 29, 2008

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>		BARR	<u>5MG</u>	<u>A040361</u>	<u>001</u>	Jan 31, 2001
<u>AA</u>	+		<u>10MG</u>	<u>A040361</u>	<u>002</u>	Jan 31, 2001
<u>AA</u>		MALLINCKRODT	<u>5MG</u>	<u>A040436</u>	<u>001</u>	Jan 29, 2002
<u>AA</u>			<u>10MG</u>	<u>A040436</u>	<u>002</u>	Jan 29, 2002
<u>AA</u>		MIKART	<u>5MG</u>	<u>A090533</u>	<u>002</u>	Oct 25, 2011
<u>AA</u>			<u>10MG</u>	<u>A090533</u>	<u>004</u>	Oct 25, 2011
		<u>DEXTROAMPHETAMINE SULFATE</u>				
		MIKART	2.5MG	A090533	001	Oct 25, 2011
			7.5MG	A090533	003	Oct 25, 2011
			15MG	A090533	005	Oct 25, 2011
			20MG	A090533	006	Oct 25, 2011
			30MG	A090533	007	Oct 25, 2011

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH W/ DEXTROMETHORPHAN

<u>AA</u>	+	ACTAVIS MID ATLANTIC	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A088762</u>	<u>001</u>	Oct 31, 1984
		<u>PROMETHAZINE DM</u>				
<u>AA</u>		VINTAGE	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A040649</u>	<u>001</u>	Feb 14, 2006
		<u>PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE</u>				
<u>AA</u>		AMNEAL PHARMS	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A090575</u>	<u>001</u>	Feb 08, 2011
<u>AA</u>		HI TECH PHARMA	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A040027</u>	<u>001</u>	Jul 31, 1996
<u>AA</u>		TRIS PHARMA INC	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A091687</u>	<u>001</u>	Jun 28, 2012
		<u>PROMETHAZINE W/ DEXTROMETHORPHAN</u>				
<u>AA</u>		WOCKHARDT	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A088864</u>	<u>001</u>	Jan 04, 1985

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE; ORAL

NUEDEXTA

	+	AVANIR PHARMS	20MG;10MG	N021879	001	Oct 29, 2010

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 124 (of 428)

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

<u>AP</u>	+ B BRAUN	<u>10GM/100ML</u>	<u>N019626</u>	<u>004</u>	Feb 02, 1988
<u>AP</u>	+ BAXTER HLTHCARE	<u>10GM/100ML</u>	<u>N016694</u>	<u>001</u>	
<u>AP</u>	+ HOSPIRA	<u>10GM/100ML</u>	<u>N018080</u>	<u>001</u>	

DEXTROSE 20% IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>20GM/100ML</u>	<u>N017521</u>	<u>004</u>	
<u>AP</u>	+ HOSPIRA	<u>20GM/100ML</u>	<u>N018564</u>	<u>001</u>	Mar 23, 1982

DEXTROSE 30% IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>30GM/100ML</u>	<u>N017521</u>	<u>003</u>	
<u>AP</u>	+ HOSPIRA	<u>30GM/100ML</u>	<u>N019345</u>	<u>001</u>	Jan 26, 1985

DEXTROSE 40% IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>40GM/100ML</u>	<u>N017521</u>	<u>002</u>	
<u>AP</u>	+ HOSPIRA	<u>40GM/100ML</u>	<u>N018562</u>	<u>001</u>	Mar 23, 1982

DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+ B BRAUN	<u>50MG/ML</u>	<u>N016730</u>	<u>002</u>	
<u>AP</u>	+	<u>5GM/100ML</u>	<u>N016730</u>	<u>001</u>	
<u>AP</u>	+	<u>5GM/100ML</u>	<u>N019626</u>	<u>002</u>	Feb 02, 1988
<u>AP</u>	+ BAXTER HLTHCARE	<u>50MG/ML</u>	<u>N016673</u>	<u>003</u>	Oct 30, 1985
<u>AP</u>	+	<u>50MG/ML</u>	<u>N020179</u>	<u>002</u>	Dec 07, 1992
<u>AP</u>	+	<u>5GM/100ML</u>	<u>N016673</u>	<u>001</u>	
<u>AP</u>	+	<u>5GM/100ML</u>	<u>N020179</u>	<u>001</u>	Dec 07, 1992
<u>AP</u>	+ HOSPIRA	<u>50MG/ML</u>	<u>N016367</u>	<u>002</u>	
<u>AP</u>	+	<u>50MG/ML</u>	<u>N019222</u>	<u>001</u>	Jul 13, 1984
<u>AP</u>	+	<u>5GM/100ML</u>	<u>N019466</u>	<u>001</u>	Jul 15, 1985
<u>AP</u>	+	<u>5GM/100ML</u>	<u>N019479</u>	<u>001</u>	Sep 17, 1985

DEXTROSE 50% IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>50GM/100ML</u>	<u>N017521</u>	<u>001</u>	
<u>AP</u>	+	<u>50GM/100ML</u>	<u>N020047</u>	<u>001</u>	Jul 02, 1991
<u>AP</u>	HOSPIRA	<u>500MG/ML</u>	<u>N019445</u>	<u>001</u>	Jun 03, 1986
<u>AP</u>	+	<u>50GM/100ML</u>	<u>N018563</u>	<u>001</u>	Mar 23, 1982
<u>AP</u>	+	<u>50GM/100ML</u>	<u>N019894</u>	<u>001</u>	Dec 26, 1989

DEXTROSE 60% IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>60GM/100ML</u>	<u>N017521</u>	<u>005</u>	Mar 26, 1982

DEXTROSE 70% IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>70GM/100ML</u>	<u>N017521</u>	<u>006</u>	Mar 26, 1982
<u>AP</u>	+	<u>70GM/100ML</u>	<u>N020047</u>	<u>003</u>	Jul 02, 1991
<u>AP</u>	+ HOSPIRA	<u>70GM/100ML</u>	<u>N018561</u>	<u>001</u>	Mar 23, 1982
<u>AP</u>	+	<u>70GM/100ML</u>	<u>N019893</u>	<u>001</u>	Dec 26, 1989

DEXTROSE 25%

+	HOSPIRA	250MG/ML	N019445	002	Nov 23, 1998

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;32MG/100ML;128MG/100ML;234MG/100ML	N017385	001	

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;21MG/100ML;128MG/100ML;234MG/100ML	N017610	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML;26MG/100ML;320MG/100ML	N019873	001	Jun 10, 1993

PRESCRIPTION DRUG PRODUCT LIST

3 - 125 (of 428)

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC;
SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 53MG/100ML; 100MG/100ML; 100MG/100ML; 180MG/100ML; 280MG/100ML; 16MG/100ML	N019515	001	May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC;
SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 31MG/100ML; 141MG/100ML; 20MG/100ML; 12MG/100ML; 260MG/100ML	N017484	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC;
SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 30MG/100ML; 141MG/100ML; 15MG/100ML; 260MG/100ML; 25MG/100ML	N019513	001	May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 97MG/100ML; 220MG/100ML; 140MG/100ML	N019844	001	Jun 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE;
SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N019843	001	Aug 09, 1993

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	N017609	001	

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017451	001	

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML; 75MG/100ML	N017634	004	

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML; 150MG/100ML	N017634	001	

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML; 224MG/100ML	N017634	003	

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML; 300MG/100ML	N017634	002	

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML; 75MG/100ML	N018744	001	Nov 09, 1982

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML; 150MG/100ML	N018744	002	Nov 09, 1982

		5GM/100ML; 150MG/100ML	N019699	004	Sep 29, 1989

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML; 300MG/100ML	N018744	004	Nov 09, 1982

AP		5GM/100ML; 300MG/100ML	N019699	006	Sep 29, 1989

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HOSPIRA	5GM/100ML; 224MG/100ML	N018371	003	

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 220MG/100ML	N018744	003	Nov 09, 1982

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 126 (of 428)

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;149MG/100ML N018371 001

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;298MG/100ML N018371 002

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;150MG/100ML;130MG/100ML;280MG /100ML;91MG/100ML N019870 001 Jun 10, 1993

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER

BAXTER HLTHCARE 5GM/100ML;205MG/100ML;100MG/100ML;120MG /100ML;220MG/100ML N018840 001 Jun 29, 1983

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQAP BAXTER HLTHCARE 5GM/100ML;75MG/100ML;200MG/100ML N018037 006 Apr 13, 1982AP 5GM/100ML;150MG/100ML;200MG/100ML N018037 007 Apr 13, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)AP BAXTER HLTHCARE 5GM/100ML;224MG/100ML;200MG/100ML N018037 004DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQAP BAXTER HLTHCARE 5GM/100ML;150MG/100ML;200MG/100ML N018037 008 Apr 13, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)AP BAXTER HLTHCARE 5GM/100ML;300MG/100ML;200MG/100ML N018037 001DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQAP BAXTER HLTHCARE 5GM/100ML;224MG/100ML;200MG/100ML N018037 005 Apr 13, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQAP BAXTER HLTHCARE 5GM/100ML;300MG/100ML;200MG/100ML N018037 009 Apr 13, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQAP BAXTER HLTHCARE 5GM/100ML;75MG/100ML;200MG/100ML N018037 002DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)AP BAXTER HLTHCARE 5GM/100ML;150MG/100ML;200MG/100ML N018037 003DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINERAP BAXTER HLTHCARE 5GM/100ML;75MG/100ML;330MG/100ML N018629 005 Mar 23, 1982AP 5GM/100ML;150MG/100ML;330MG/100ML N018629 002 Mar 23, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINERAP BAXTER HLTHCARE 5GM/100ML;224MG/100ML;330MG/100ML N018629 003 Mar 23, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINERAP BAXTER HLTHCARE 5GM/100ML;150MG/100ML;330MG/100ML N018629 004 Mar 23, 1982AP 5GM/100ML;300MG/100ML;330MG/100ML N018629 006 Mar 23, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINERAP BAXTER HLTHCARE 5GM/100ML;224MG/100ML;330MG/100ML N018629 007 Mar 23, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINERAP BAXTER HLTHCARE 5GM/100ML;300MG/100ML;330MG/100ML N018629 008 Mar 23, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINERAP BAXTER HLTHCARE 5GM/100ML;75MG/100ML;330MG/100ML N018629 001 Mar 23, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINERAP BAXTER HLTHCARE 5GM/100ML;300MG/100ML;450MG/100ML N018008 010POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINERAP B BRAUN 5GM/100ML;75MG/100ML;200MG/100ML N019630 008 Feb 17, 1988POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINERAP B BRAUN 5GM/100ML;75MG/100ML;330MG/100ML N019630 014 Feb 17, 1988POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINERAP B BRAUN 5GM/100ML;75MG/100ML;450MG/100ML N019630 020 Feb 17, 1988

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 127 (of 428)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTION

<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;75MG/100ML;900MG/100ML</u>	<u>N019630</u>	<u>026</u>	<u>Feb 17,</u>	<u>1988</u>
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;150MG/100ML;200MG/100ML</u>	<u>N019630</u>	<u>010</u>	<u>Feb 17,</u>	<u>1988</u>
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;150MG/100ML;330MG/100ML</u>	<u>N019630</u>	<u>016</u>	<u>Feb 17,</u>	<u>1988</u>
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N019630</u>	<u>022</u>	<u>Feb 17,</u>	<u>1988</u>
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019630</u>	<u>028</u>	<u>Feb 17,</u>	<u>1988</u>
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;300MG/100ML;200MG/100ML</u>	<u>N019630</u>	<u>012</u>	<u>Feb 17,</u>	<u>1988</u>
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;300MG/100ML;330MG/100ML</u>	<u>N019630</u>	<u>018</u>	<u>Feb 17,</u>	<u>1988</u>
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;300MG/100ML;450MG/100ML</u>	<u>N019630</u>	<u>024</u>	<u>Feb 17,</u>	<u>1988</u>
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>B BRAUN</u>	<u>5GM/100ML;300MG/100ML;900MG/100ML</u>	<u>N019630</u>	<u>030</u>	<u>Feb 17,</u>	<u>1988</u>
<u>POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;75MG/100ML;450MG/100ML</u>	<u>N018008</u>	<u>005</u>	<u>Apr 28,</u>	<u>1982</u>
<u>AP</u>		<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N018008</u>	<u>006</u>	<u>Apr 28,</u>	<u>1982</u>
<u>AP</u>	<u>HOSPIRA</u>	<u>5GM/100ML;74.5MG/100ML;450MG/100ML</u>	<u>N018362</u>	<u>009</u>	<u>Jul 05,</u>	<u>1983</u>
<u>AP</u>		<u>5GM/100ML;74.5MG/100ML;450MG/100ML</u>	<u>N018362</u>	<u>005</u>	<u>Mar 28,</u>	<u>1988</u>
<u>POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;75MG/100ML;900MG/100ML</u>	<u>N019308</u>	<u>004</u>	<u>Apr 05,</u>	<u>1985</u>
<u>AP</u>		<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019308</u>	<u>002</u>	<u>Apr 05,</u>	<u>1985</u>
<u>AP</u>	<u>HOSPIRA</u>	<u>5GM/100ML;74.5MG/100ML;900MG/100ML</u>	<u>N019691</u>	<u>002</u>	<u>Mar 24,</u>	<u>1988</u>
<u>AP</u>		<u>5GM/100ML;149MG/100ML;900MG/100ML</u>	<u>N019691</u>	<u>004</u>	<u>Mar 24,</u>	<u>1988</u>
<u>POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>HOSPIRA</u>	<u>5GM/100ML;224MG/100ML;450MG/100ML</u>	<u>N018362</u>	<u>006</u>	<u>Mar 28,</u>	<u>1988</u>
<u>POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>HOSPIRA</u>	<u>5GM/100ML;224MG/100ML;900MG/100ML</u>	<u>N019691</u>	<u>006</u>	<u>Mar 24,</u>	<u>1988</u>
<u>POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N018008</u>	<u>007</u>	<u>Apr 28,</u>	<u>1982</u>
<u>AP</u>	<u>HOSPIRA</u>	<u>5GM/100ML;149MG/100ML;450MG/100ML</u>	<u>N018362</u>	<u>010</u>	<u>Jul 05,</u>	<u>1983</u>
<u>AP</u>		<u>5GM/100ML;298MG/100ML;450MG/100ML</u>	<u>N018362</u>	<u>007</u>	<u>Mar 28,</u>	<u>1988</u>
<u>POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019308</u>	<u>005</u>	<u>Apr 05,</u>	<u>1985</u>
<u>AP</u>		<u>5GM/100ML;300MG/100ML;900MG/100ML</u>	<u>N019308</u>	<u>003</u>	<u>Apr 05,</u>	<u>1985</u>
<u>AP</u>	<u>HOSPIRA</u>	<u>5GM/100ML;149MG/100ML;900MG/100ML</u>	<u>N019691</u>	<u>005</u>	<u>Mar 24,</u>	<u>1988</u>
<u>AP</u>		<u>5GM/100ML;298MG/100ML;900MG/100ML</u>	<u>N019691</u>	<u>008</u>	<u>Mar 24,</u>	<u>1988</u>
<u>POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;224MG/100ML;450MG/100ML</u>	<u>N018008</u>	<u>008</u>	<u>Apr 28,</u>	<u>1982</u>
<u>AP</u>	<u>HOSPIRA</u>	<u>5GM/100ML;224MG/100ML;450MG/100ML</u>	<u>N018362</u>	<u>002</u>		
<u>POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;224MG/100ML;900MG/100ML</u>	<u>N019308</u>	<u>006</u>	<u>Apr 05,</u>	<u>1985</u>
<u>AP</u>	<u>HOSPIRA</u>	<u>5GM/100ML;224MG/100ML;900MG/100ML</u>	<u>N019691</u>	<u>007</u>	<u>Mar 24,</u>	<u>1988</u>
<u>POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;300MG/100ML;450MG/100ML</u>	<u>N018008</u>	<u>009</u>	<u>Apr 28,</u>	<u>1982</u>
<u>AP</u>	<u>HOSPIRA</u>	<u>5GM/100ML;298MG/100ML;450MG/100ML</u>	<u>N018362</u>	<u>003</u>		
<u>POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;300MG/100ML;900MG/100ML</u>	<u>N019308</u>	<u>007</u>	<u>Apr 05,</u>	<u>1985</u>
<u>AP</u>	<u>HOSPIRA</u>	<u>5GM/100ML;298MG/100ML;900MG/100ML</u>	<u>N019691</u>	<u>009</u>	<u>Mar 24,</u>	<u>1988</u>
<u>POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;150MG/100ML;450MG/100ML</u>	<u>N018008</u>	<u>004</u>		
<u>AP</u>	<u>HOSPIRA</u>	<u>5GM/100ML;74.5MG/100ML;450MG/100ML</u>	<u>N018362</u>	<u>008</u>	<u>Mar 28,</u>	<u>1988</u>
<u>AP</u>		<u>5GM/100ML;149MG/100ML;450MG/100ML</u>	<u>N018362</u>	<u>004</u>	<u>Mar 28,</u>	<u>1988</u>
<u>POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
<u>AP</u>	<u>BAXTER HLTHCARE</u>	<u>5GM/100ML;150MG/100ML;900MG/100ML</u>	<u>N019308</u>	<u>001</u>	<u>Apr 05,</u>	<u>1985</u>

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 128 (of 428)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTION

<u>POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	HOSPIRA	<u>5GM/100ML; 74.5MG/100ML; 900MG/100ML</u>	<u>N019691</u>	<u>001</u>	Mar 24, 1988
<u>AP</u>		<u>5GM/100ML; 149MG/100ML; 900MG/100ML</u>	<u>N019691</u>	<u>003</u>	Mar 24, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML; 37MG/100ML; 200MG/100ML	N019630	031	Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML; 37MG/100ML; 450MG/100ML	N019630	037	Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML; 37MG/100ML; 900MG/100ML	N019630	043	Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML; 37MG/100ML; 110MG/100ML	N019630	001	Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML; 37MG/100ML; 200MG/100ML	N019630	007	Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML; 37MG/100ML; 330MG/100ML	N019630	013	Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML; 37MG/100ML; 450MG/100ML	N019630	019	Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML; 37MG/100ML; 900MG/100ML	N019630	025	Feb 17, 1988
	POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML; 75MG/100ML; 200MG/100ML	N019630	032	Feb 17, 1988
	POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML; 75MG/100ML; 450MG/100ML	N019630	038	Feb 17, 1988
	POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML; 75MG/100ML; 900MG/100ML	N019630	044	Feb 17, 1988
	POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	B BRAUN	3.3GM/100ML; 75MG/100ML; 300MG/100ML	N019630	049	May 07, 1992
	POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML; 75MG/100ML; 110MG/100ML	N019630	002	Feb 17, 1988
	POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML; 110MG/100ML; 200MG/100ML	N019630	033	Feb 17, 1988
	POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML; 110MG/100ML; 450MG/100ML	N019630	039	Feb 17, 1988
	POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML; 110MG/100ML; 900MG/100ML	N019630	045	Feb 17, 1988
	POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	B BRAUN	3.3GM/100ML; 110MG/100ML; 300MG/100ML	N019630	050	May 07, 1992
	POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML; 110MG/100ML; 110MG/100ML	N019630	003	Feb 17, 1988
	POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML; 110MG/100ML; 200MG/100ML	N019630	009	Feb 17, 1988
	POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML; 110MG/100ML; 330MG/100ML	N019630	015	Feb 17, 1988
	POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML; 110MG/100ML; 450MG/100ML	N019630	021	Feb 17, 1988
	POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML; 110MG/100ML; 900MG/100ML	N019630	027	Feb 17, 1988
	POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML; 150MG/100ML; 200MG/100ML	N019630	034	Feb 17, 1988
	POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML; 150MG/100ML; 450MG/100ML	N019630	040	Feb 17, 1988
	POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML; 150MG/100ML; 900MG/100ML	N019630	046	Feb 17, 1988
	POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	B BRAUN	3.3GM/100ML; 150MG/100ML; 300MG/100ML	N019630	051	May 07, 1992
	POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML; 150MG/100ML; 110MG/100ML	N019630	004	Feb 17, 1988
	POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML; 220MG/100ML; 200MG/100ML	N019630	035	Feb 17, 1988

PRESCRIPTION DRUG PRODUCT LIST

3 - 129 (of 428)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;220MG/100ML;450MG/100ML	N019630 041	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;220MG/100ML;900MG/100ML	N019630 047	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	3.3GM/100ML;220MG/100ML;300MG/100ML	N019630 052	May 07, 1992
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;110MG/100ML	N019630 005	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;200MG/100ML	N019630 011	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;330MG/100ML	N019630 017	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;450MG/100ML	N019630 023	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;900MG/100ML	N019630 029	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;300MG/100ML;200MG/100ML	N019630 036	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;300MG/100ML;450MG/100ML	N019630 042	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;300MG/100ML;900MG/100ML	N019630 048	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	3.3GM/100ML;300MG/100ML;300MG/100ML	N019630 053	May 07, 1992
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;300MG/100ML;110MG/100ML	N019630 006	Feb 17, 1988
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365 002	Jul 05, 1983
	5GM/100ML;149MG/100ML;225MG/100ML	N018365 006	Mar 28, 1988
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876 001	Jan 17, 1986
	5GM/100ML;149MG/100ML;300MG/100ML	N018876 006	Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;224MG/100ML;225MG/100ML	N018365 008	Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;224MG/100ML;300MG/100ML	N018876 007	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;149MG/100ML;225MG/100ML	N018365 001	
	5GM/100ML;298MG/100ML;225MG/100ML	N018365 009	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;298MG/100ML;300MG/100ML	N018876 008	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;149MG/100ML;300MG/100ML	N018876 002	Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;224MG/100ML;225MG/100ML	N018365 003	Jul 05, 1983
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;224MG/100ML;300MG/100ML	N018876 003	Jan 17, 1986
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;298MG/100ML;225MG/100ML	N018365 004	Jul 05, 1983
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;298MG/100ML;300MG/100ML	N018876 004	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365 005	Mar 28, 1988
	5GM/100ML;149MG/100ML;225MG/100ML	N018365 007	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876 005	Mar 28, 1988
	5GM/100ML;149MG/100ML;300MG/100ML	N018876 009	Mar 28, 1988

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 130 (of 428)

DEXTROSE; SODIUM CHLORIDEINJECTABLE; INJECTIONDEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>10GM/100ML;900MG/100ML</u>	<u>N019631</u>	<u>015</u>	Feb 24, 1988

<u>AP</u>	BAXTER HLTHCARE	<u>10GM/100ML;900MG/100ML</u>	<u>N016696</u>	<u>001</u>	

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>2.5GM/100ML;450MG/100ML</u>	<u>N019631</u>	<u>004</u>	Feb 24, 1988

<u>AP</u>	BAXTER HLTHCARE	<u>2.5GM/100ML;450MG/100ML</u>	<u>N016697</u>	<u>001</u>	

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>5GM/100ML;200MG/100ML</u>	<u>N019631</u>	<u>007</u>	Feb 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>5GM/100ML;330MG/100ML</u>	<u>N019631</u>	<u>008</u>	Feb 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>5GM/100ML;450MG/100ML</u>	<u>N019631</u>	<u>009</u>	Feb 24, 1988

<u>AP</u>	HOSPIRA	<u>5GM/100ML;450MG/100ML</u>	<u>N017607</u>	<u>001</u>	

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>5GM/100ML;900MG/100ML</u>	<u>N019631</u>	<u>010</u>	Feb 24, 1988

<u>AP</u>	HOSPIRA	<u>5GM/100ML;900MG/100ML</u>	<u>N017585</u>	<u>001</u>	

DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;200MG/100ML</u>	<u>N016689</u>	<u>001</u>	

DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;330MG/100ML</u>	<u>N016687</u>	<u>001</u>	

DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;450MG/100ML</u>	<u>N016683</u>	<u>001</u>	

DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;900MG/100ML</u>	<u>N016678</u>	<u>001</u>	

DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;110MG/100ML	N019631	011	Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;200MG/100ML	N019631	012	Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;330MG/100ML	N019631	013	Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;450MG/100ML	N019631	014	Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;110MG/100ML	N019631	001	Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;200MG/100ML	N019631	002	Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;330MG/100ML	N019631	003	Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;900MG/100ML	N019631	005	Feb 24, 1988

DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	B BRAUN	3.3GM/100ML;300MG/100ML	N019631	016	Jan 19, 1990

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;110MG/100ML	N019631	006	Feb 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	HOSPIRA	5GM/100ML;225MG/100ML	N017606	001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	HOSPIRA	5GM/100ML;300MG/100ML	N017799	001	

DIATRIZOATE MEGLUMINESOLUTION; URETHRALCYSTOGRAFIN

	BRACCO	30%	N010040	018	

CYSTOGRAFIN DILUTE

	BRACCO	18%	N010040	022	Nov 09, 1982

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUMINJECTABLE; INJECTIONMD-76R

<u>AP</u>	+ MALLINCKRODT	<u>66%;10%</u>	<u>N019292</u>	<u>001</u>	Sep 29, 1989

PRESCRIPTION DRUG PRODUCT LIST

3 - 131 (of 428)

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

RENOGRAFIN-76

<u>AP</u>	+ BRACCO	<u>66%;10%</u>	<u>N010040</u>	<u>001</u>

SOLUTION; ORAL, RECTAL

GASTROGRAFIN

<u>AA</u>	+ BRACCO	<u>66%;10%</u>	<u>N011245</u>	<u>003</u>

MD-GASTROVIEW

<u>AA</u>	MALLINCKRODT	<u>66%;10%</u>	<u>A087388</u>	<u>001</u>

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION; INTRAUTERINE

SINOGRAPHIN

	+ BRACCO	52.7%;26.8%	N011324	002

DIAZEPAM

CONCENTRATE; ORAL

DIAZEPAM INTENSOL

	+ ROXANE	5MG/ML	A071415	001	Apr 03, 1987

GEL; RECTAL

DIASAT

	VALEANT	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997

DIASAT ACUDIAL

	VALEANT	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005

	+	20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005

INJECTABLE; INJECTION

DIAZEPAM

<u>AP</u>	+ HOSPIRA	<u>5MG/ML</u>	<u>A071583</u>	<u>001</u>	Oct 13, 1987

<u>AP</u>		<u>5MG/ML</u>	<u>A072079</u>	<u>001</u>	Dec 20, 1988

<u>AP</u>	WATSON LABS	<u>5MG/ML</u>	<u>A070296</u>	<u>001</u>	Feb 12, 1986

SOLUTION; ORAL

DIAZEPAM

	+ ROXANE	5MG/5ML	A070928	001	Apr 03, 1987

TABLET; ORAL

DIAZEPAM

<u>AB</u>	BARR	<u>2MG</u>	<u>A070152</u>	<u>001</u>	Nov 01, 1985

<u>AB</u>		<u>10MG</u>	<u>A070154</u>	<u>001</u>	Nov 01, 1985

<u>AB</u>	DAVA PHARMS INC	<u>2MG</u>	<u>A070226</u>	<u>001</u>	Sep 26, 1985

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>2MG</u>	<u>A071307</u>	<u>001</u>	Dec 10, 1986

<u>AB</u>		<u>5MG</u>	<u>A071321</u>	<u>001</u>	Dec 10, 1986

<u>AB</u>		<u>10MG</u>	<u>A071322</u>	<u>001</u>	Dec 10, 1986

<u>AB</u>	MYLAN	<u>2MG</u>	<u>A070325</u>	<u>002</u>	Sep 04, 1985

<u>AB</u>		<u>5MG</u>	<u>A070325</u>	<u>003</u>	Sep 04, 1985

<u>AB</u>		<u>10MG</u>	<u>A070325</u>	<u>001</u>	Sep 04, 1985

<u>AB</u>	VINTAGE PHARMS	<u>2MG</u>	<u>A077749</u>	<u>001</u>	Mar 31, 2006

<u>AB</u>		<u>5MG</u>	<u>A077749</u>	<u>002</u>	Mar 31, 2006

<u>AB</u>		<u>10MG</u>	<u>A077749</u>	<u>003</u>	Mar 31, 2006

<u>AB</u>	WATSON LABS	<u>2MG</u>	<u>A071134</u>	<u>001</u>	Feb 03, 1987

<u>AB</u>		<u>5MG</u>	<u>A071135</u>	<u>001</u>	Feb 03, 1987

<u>AB</u>		<u>10MG</u>	<u>A071136</u>	<u>001</u>	Feb 03, 1987

VALIUM

<u>AB</u>	ROCHE	<u>2MG</u>	<u>N013263</u>	<u>002</u>	

<u>AB</u>		<u>5MG</u>	<u>N013263</u>	<u>004</u>	

<u>AB</u>	+	<u>10MG</u>	<u>N013263</u>	<u>006</u>	

DIAZOXIDE

SUSPENSION; ORAL

PROGLYCEM

	+ TEVA GLOBAL	50MG/ML	N017453	001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 132 (of 428)

DICLOFENAC EPOLAMINEPATCH; TOPICAL
FLECTOR

+ INST BIOCHEM 1.3% N021234 001 Jan 31, 2007

DICLOFENAC POTASSIUMCAPSULE; ORAL
ZIPSOR

+ DEPOMED INC 25MG N022202 001 Jun 16, 2009

FOR SOLUTION; ORAL
CAMBIA

+ NAUTILUS NEUROSCIENC 50MG N022165 001 Jun 17, 2009

TABLET; ORAL

CATAFLAMAB + NOVARTIS 50MG N020142 002 Nov 24, 1993DICLOFENAC POTASSIUMAB APOTEX 50MG A076561 001 Mar 18, 2004AB MYLAN 50MG A075463 001 Jul 26, 1999AB SANDOZ 50MG A075229 001 Nov 20, 1998AB TEVA 50MG A075219 001 Aug 06, 1998DICLOFENAC SODIUMGEL; TOPICAL
SOLARAZE

+ FOUGERA PHARMS 3% N021005 001 Oct 16, 2000

VOLTAREN

+ NOVARTIS 1% N022122 001 Oct 17, 2007

SOLUTION; TOPICAL
PENNSAID

+ MALLINCKRODT 1.5% N020947 001 Nov 04, 2009

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUMAT AKORN 0.1% A077845 001 Apr 17, 2008AT ALCON PHARMS LTD 0.1% A078031 001 Feb 06, 2008AT APOTEX INC 0.1% A077600 001 Nov 13, 2008AT BAUSCH AND LOMB 0.1% A078792 001 Dec 28, 2007AT NEXUS PHARMS 0.1% A078553 001 Dec 28, 2007VOLTARENAT + NOVARTIS 0.1% N020037 001 Mar 28, 1991

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUMAB ACTAVIS ELIZABETH 50MG A074514 001 Mar 26, 1996AB 75MG A074514 002 Mar 26, 1996AB CARLSBAD 25MG A075185 002 Nov 13, 1998AB 50MG A075185 003 Nov 13, 1998AB 75MG A075185 001 Nov 13, 1998AB MYLAN PHARMS INC 50MG A075281 002 Feb 12, 2002AB 75MG A075281 003 Feb 12, 2002AB + SANDOZ 25MG A074376 001 Sep 28, 1995AB + 50MG A074376 002 Sep 28, 1995AB + 75MG A074394 001 Nov 30, 1995AB UNIQUE PHARM LABS 25MG A090066 001 Dec 01, 2010AB 50MG A090066 002 Dec 01, 2010AB 75MG A077863 003 Jun 08, 2007

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUMAB ACTAVIS ELIZABETH 100MG A075910 001 Jan 07, 2002AB DEXCEL LTD 100MG A076201 001 Nov 06, 2002AB MYLAN 100MG A076152 001 Dec 13, 2001AB VALEANT INTL 100MG A075492 001 Feb 11, 2000VOLTAREN-XRAB + NOVARTIS 100MG N020254 001 Mar 08, 1996

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 133 (of 428)

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

ARTHROTEC

<u>AB</u>	GD SEARLE LLC	<u>50MG;0.2MG</u>	<u>N020607</u>	<u>001</u>	Dec 24, 1997
<u>AB</u>	+	<u>75MG;0.2MG</u>	<u>N020607</u>	<u>002</u>	Dec 24, 1997
	<u>DICLOFENAC SODIUM AND MISOPROSTOL</u>				
<u>AB</u>	WATSON LABS INC	<u>50MG;0.2MG</u>	<u>A201089</u>	<u>001</u>	Jul 09, 2012
<u>AB</u>		<u>75MG;0.2MG</u>	<u>A201089</u>	<u>002</u>	Jul 09, 2012

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DICLOXACILLIN SODIUM

<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A061454</u>	<u>001</u>	
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A061454</u>	<u>003</u>	
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A062286</u>	<u>001</u>	Jun 03, 1982
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062286</u>	<u>002</u>	Jun 03, 1982
	<u>DICLOXACILLIN SODIUM</u>				
	SANDOZ	<u>EQ 125MG BASE</u>	<u>A061454</u>	<u>002</u>	

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

BENTYL

<u>AB</u>	+	APTALIS PHARMA US	<u>10MG</u>	<u>N007409</u>	<u>003</u>	Oct 15, 1984
	<u>DICYCLOMINE HYDROCHLORIDE</u>					
<u>AB</u>		LANNETT	<u>10MG</u>	<u>A084285</u>	<u>001</u>	
<u>AB</u>		MYLAN	<u>10MG</u>	<u>A040319</u>	<u>001</u>	Sep 07, 1999
<u>AB</u>		WATSON LABS	<u>10MG</u>	<u>A085082</u>	<u>001</u>	Jun 19, 1986
<u>AB</u>		WEST WARD	<u>10MG</u>	<u>A040204</u>	<u>001</u>	Feb 28, 1997

INJECTABLE; INJECTION

BENTYL

<u>AP</u>	+	APTALIS PHARMA US	<u>10MG/ML</u>	<u>N008370</u>	<u>001</u>	Oct 15, 1984
	<u>BENTYL PRESERVATIVE FREE</u>					
<u>AP</u>	+	APTALIS PHARMA US	<u>10MG/ML</u>	<u>N008370</u>	<u>002</u>	Oct 15, 1984
	<u>DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE)</u>					
<u>AP</u>		BEDFORD	<u>10MG/ML</u>	<u>A040465</u>	<u>001</u>	Jun 30, 2003

SYRUP; ORAL

BENTYL

<u>AA</u>	+	APTALIS PHARMA US	<u>10MG/5ML</u>	<u>N007961</u>	<u>002</u>	Oct 15, 1984
	<u>DICYCLOMINE HYDROCHLORIDE</u>					
<u>AA</u>		MIKART	<u>10MG/5ML</u>	<u>A040169</u>	<u>001</u>	Mar 24, 2005

TABLET; ORAL

BENTYL

<u>AB</u>	+	APTALIS PHARMA US	<u>20MG</u>	<u>N007409</u>	<u>001</u>	Oct 15, 1984
	<u>DICYCLOMINE HYDROCHLORIDE</u>					
<u>AB</u>		LANNETT	<u>20MG</u>	<u>A040230</u>	<u>001</u>	Feb 26, 1999
<u>AB</u>		MYLAN	<u>20MG</u>	<u>A040317</u>	<u>001</u>	Sep 07, 1999
<u>AB</u>		WATSON LABS	<u>20MG</u>	<u>A085223</u>	<u>001</u>	Jul 30, 1986
<u>AB</u>		WEST WARD	<u>20MG</u>	<u>A040161</u>	<u>001</u>	Oct 01, 1996

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINE

<u>AB</u>	AUROBINDO PHARMA	<u>125MG</u>	<u>A090094</u>	<u>001</u>	Sep 24, 2008
<u>AB</u>		<u>200MG</u>	<u>A090094</u>	<u>002</u>	Sep 24, 2008
<u>AB</u>		<u>250MG</u>	<u>A090094</u>	<u>003</u>	Sep 24, 2008
<u>AB</u>		<u>400MG</u>	<u>A090094</u>	<u>004</u>	Sep 24, 2008
<u>AB</u>	BARR	<u>200MG</u>	<u>A077167</u>	<u>001</u>	Dec 03, 2004
<u>AB</u>		<u>250MG</u>	<u>A077167</u>	<u>002</u>	Dec 03, 2004
<u>AB</u>		<u>400MG</u>	<u>A077167</u>	<u>003</u>	Dec 03, 2004
<u>AB</u>	MYLAN PHARMS INC	<u>125MG</u>	<u>A090788</u>	<u>001</u>	Apr 08, 2010
<u>AB</u>		<u>200MG</u>	<u>A090788</u>	<u>002</u>	Apr 08, 2010
<u>AB</u>		<u>250MG</u>	<u>A090788</u>	<u>003</u>	Apr 08, 2010

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 134 (of 428)

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINE

<u>AB</u>	MYLAN PHARMS INC	<u>400MG</u>	<u>A090788</u>	<u>004</u>	Apr 08, 2010

VIDEX EC

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>125MG</u>	<u>N021183</u>	<u>001</u>	Oct 31, 2000

<u>AB</u>		<u>200MG</u>	<u>N021183</u>	<u>002</u>	Oct 31, 2000

<u>AB</u>		<u>250MG</u>	<u>N021183</u>	<u>003</u>	Oct 31, 2000

<u>AB</u>	+	<u>400MG</u>	<u>N021183</u>	<u>004</u>	Oct 31, 2000

FOR SOLUTION; ORAL

DIDANOSINE

<u>AA</u>	AUROBINDO PHARMA	<u>10MG/ML</u>	<u>A078112</u>	<u>001</u>	Mar 08, 2007

VIDEX

<u>AA</u>	+	BRISTOL MYERS SQUIBB	<u>10MG/ML</u>	<u>N020156</u>	<u>001</u>	Oct 09, 1991

TABLET, CHEWABLE; ORAL

DIDANOSINE

	AUROBINDO	100MG	A077275	001	Aug 14, 2012

		150MG	A077275	002	Aug 14, 2012

+		200MG	A077275	003	Aug 14, 2012

DIENOGEST; ESTRADIOL VALERATE

TABLET; ORAL, ORAL-28

NATAZIA

+	BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1MG, N/A	N022252	001	May 06, 2010

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

<u>AA</u>	AVANTHI INC	<u>25MG</u>	<u>A201212</u>	<u>001</u>	Dec 22, 2010

<u>AA</u>	COREPHARMA	<u>25MG</u>	<u>A040828</u>	<u>001</u>	Nov 05, 2008

<u>AA</u>	LANNETT HOLDINGS INC	<u>25MG</u>	<u>A200177</u>	<u>001</u>	Jul 18, 2011

TENUATE

<u>AA</u>	+	WATSON PHARMS	<u>25MG</u>	<u>N011722</u>	<u>002</u>

TABLET, EXTENDED RELEASE; ORAL

DIETHYLPROPION HYDROCHLORIDE

<u>AB</u>	LANNETT HOLDINGS INC	<u>75MG</u>	<u>A091680</u>	<u>001</u>	Oct 24, 2011

TENUATE DOSPAN

<u>AB</u>	+	WATSON PHARMS	<u>75MG</u>	<u>N012546</u>	<u>001</u>

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

<u>AB1</u>	+	FOUGERA PHARMS	<u>0.05%</u>	<u>A075187</u>	<u>001</u>	Mar 30, 1998

<u>AB1</u>		TARO	<u>0.05%</u>	<u>A075508</u>	<u>001</u>	Apr 24, 2000

DIFLORASONE DIACETATE

BX	+	FOUGERA PHARMS	0.05%	A076263	001	Dec 20, 2002

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

<u>AB</u>		FOUGERA PHARMS	<u>0.05%</u>	<u>A075374</u>	<u>001</u>	Apr 27, 1999

<u>AB</u>	+	TARO	<u>0.05%</u>	<u>A075331</u>	<u>001</u>	May 14, 1999

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

<u>AB</u>	EMCURE PHARMS USA	<u>500MG</u>	<u>A202845</u>	<u>001</u>	Mar 08, 2012

<u>AB</u>	+	TEVA	<u>500MG</u>	<u>A073673</u>	<u>001</u>	Jul 31, 1992

DIFLUPREDNATE

EMULSION; OPHTHALMIC

DUREZOL

+	ALCON PHARMS LTD	0.05%	N022212	001	Jun 23, 2008

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 135 (of 428)

DIGOXIN

ELIXIR; ORAL					
DIGOXIN					
	+ ROXANE	0.05MG/ML	N021648	001	Aug 26, 2004
INJECTABLE; INJECTION					
<u>DIGOXIN</u>					
<u>AP</u>	HIKMA MAPLE	<u>0.25MG/ML</u>	<u>A083391</u>	<u>001</u>	
<u>AP</u>	SANDOZ	<u>0.25MG/ML</u>	<u>A040481</u>	<u>001</u>	Aug 21, 2003
<u>LANOXIN</u>					
<u>AP</u>	+ COVIS PHARMA	<u>0.25MG/ML</u>	<u>N009330</u>	<u>002</u>	
LANOXIN PEDIATRIC					
	+ COVIS PHARMA	0.1MG/ML	N009330	004	
TABLET; ORAL					
<u>DIGOXIN</u>					
<u>AB</u>	CARACO	<u>0.125MG</u>	<u>A076363</u>	<u>001</u>	Jan 31, 2003
<u>AB</u>		<u>0.25MG</u>	<u>A076363</u>	<u>002</u>	Jan 31, 2003
<u>AB</u>	IMPAX LABS	<u>0.125MG</u>	<u>A078556</u>	<u>001</u>	Jul 20, 2009
<u>AB</u>		<u>0.25MG</u>	<u>A078556</u>	<u>002</u>	Jul 20, 2009
<u>AB</u>	STEVENS J	<u>0.125MG</u>	<u>A076268</u>	<u>001</u>	Jul 26, 2002
<u>AB</u>		<u>0.25MG</u>	<u>A076268</u>	<u>002</u>	Jul 26, 2002
<u>AB</u>	WEST WARD	<u>0.125MG</u>	<u>A077002</u>	<u>002</u>	Oct 30, 2007
<u>AB</u>		<u>0.25MG</u>	<u>A077002</u>	<u>001</u>	Oct 30, 2007
<u>LANOXIN</u>					
<u>AB</u>	COVIS PHARMA	<u>0.125MG</u>	<u>N020405</u>	<u>002</u>	Sep 30, 1997
<u>AB</u>	+	<u>0.25MG</u>	<u>N020405</u>	<u>004</u>	Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION					
<u>D.H.E. 45</u>					
<u>AP</u>	+ VALEANT	<u>1MG/ML</u>	<u>N005929</u>	<u>001</u>	
<u>DIHYDROERGOTAMINE MESYLATE</u>					
<u>AP</u>	BEDFORD LABS	<u>1MG/ML</u>	<u>A040453</u>	<u>001</u>	Jun 09, 2003
<u>AP</u>	PADDOCK LLC	<u>1MG/ML</u>	<u>A040475</u>	<u>001</u>	Apr 28, 2003
SPRAY, METERED; NASAL					
MIGRANAL					
	+ VALEANT	0.5MG/INH	N020148	001	Dec 08, 1997

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL					
<u>DILACOR XR</u>					
<u>AB2</u>	WATSON LABS	<u>120MG</u>	<u>N020092</u>	<u>001</u>	May 29, 1992
<u>AB2</u>		<u>180MG</u>	<u>N020092</u>	<u>002</u>	May 29, 1992
<u>AB2</u>	+	<u>240MG</u>	<u>N020092</u>	<u>003</u>	May 29, 1992
<u>DILTIAZEM HYDROCHLORIDE</u>					
<u>AB2</u>	APOTEX	<u>120MG</u>	<u>A074943</u>	<u>003</u>	Dec 19, 2000
<u>AB2</u>		<u>180MG</u>	<u>A074943</u>	<u>002</u>	Dec 19, 2000
<u>AB2</u>		<u>240MG</u>	<u>A074943</u>	<u>001</u>	Aug 06, 1998
<u>AB2</u>	MYLAN	<u>120MG</u>	<u>A075124</u>	<u>002</u>	Mar 18, 1998
<u>AB2</u>		<u>180MG</u>	<u>A075124</u>	<u>003</u>	Mar 18, 1998
<u>AB2</u>		<u>240MG</u>	<u>A075124</u>	<u>001</u>	Mar 18, 1998
<u>AB2</u>	WATSON LABS FLORIDA	<u>120MG</u>	<u>A074852</u>	<u>001</u>	Oct 10, 1997
<u>AB2</u>		<u>180MG</u>	<u>A074852</u>	<u>002</u>	Oct 10, 1997
<u>AB2</u>		<u>240MG</u>	<u>A074852</u>	<u>003</u>	Oct 10, 1997
<u>CARDIZEM CD</u>					
<u>AB3</u>	VALEANT INTL	<u>120MG</u>	<u>N020062</u>	<u>001</u>	Aug 10, 1992
<u>AB3</u>		<u>180MG</u>	<u>N020062</u>	<u>002</u>	Dec 27, 1991
<u>AB3</u>		<u>240MG</u>	<u>N020062</u>	<u>003</u>	Dec 27, 1991
<u>AB3</u>		<u>300MG</u>	<u>N020062</u>	<u>004</u>	Dec 27, 1991
<u>AB3</u>	+	<u>360MG</u>	<u>N020062</u>	<u>005</u>	Aug 24, 1999
<u>CARTIA XT</u>					
<u>AB3</u>	WATSON LABS FLORIDA	<u>120MG</u>	<u>A074752</u>	<u>002</u>	Jul 09, 1998

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 136 (of 428)

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARTIA XT

<u>AB3</u>	WATSON LABS FLORIDA	<u>180MG</u>	<u>A074752</u>	<u>001</u>	Jul 09, 1998
<u>AB3</u>		<u>240MG</u>	<u>A074752</u>	<u>003</u>	Jul 09, 1998
<u>AB3</u>		<u>300MG</u>	<u>A074752</u>	<u>004</u>	Jul 09, 1998

DILT-CD

<u>AB3</u>	APOTEX	<u>120MG</u>	<u>A076151</u>	<u>001</u>	May 20, 2004
<u>AB3</u>		<u>180MG</u>	<u>A076151</u>	<u>002</u>	May 20, 2004
<u>AB3</u>		<u>240MG</u>	<u>A076151</u>	<u>003</u>	May 20, 2004
<u>AB3</u>		<u>300MG</u>	<u>A076151</u>	<u>004</u>	May 20, 2004

DILTIAZEM HYDROCHLORIDE

<u>AB3</u>	ACTAVIS ELIZABETH	<u>120MG</u>	<u>A074984</u>	<u>001</u>	Dec 20, 1999
<u>AB3</u>		<u>180MG</u>	<u>A074984</u>	<u>002</u>	Dec 20, 1999
<u>AB3</u>		<u>240MG</u>	<u>A074984</u>	<u>003</u>	Dec 20, 1999
<u>AB3</u>		<u>300MG</u>	<u>A074984</u>	<u>004</u>	Dec 20, 1999
<u>AB3</u>	ACTAVIS INC	<u>360MG</u>	<u>A202463</u>	<u>001</u>	Dec 07, 2012
<u>AB3</u>	SUN PHARMA GLOBAL	<u>120MG</u>	<u>A090492</u>	<u>001</u>	Oct 28, 2011
<u>AB3</u>		<u>180MG</u>	<u>A090492</u>	<u>002</u>	Oct 28, 2011
<u>AB3</u>		<u>240MG</u>	<u>A090492</u>	<u>003</u>	Oct 28, 2011
<u>AB3</u>		<u>300MG</u>	<u>A090492</u>	<u>004</u>	Oct 28, 2011
<u>AB3</u>		<u>360MG</u>	<u>A090492</u>	<u>005</u>	Oct 28, 2011
<u>AB3</u>	VALEANT INTL	<u>120MG</u>	<u>A075116</u>	<u>001</u>	Dec 23, 1999
<u>AB3</u>		<u>180MG</u>	<u>A075116</u>	<u>002</u>	Dec 23, 1999
<u>AB3</u>		<u>240MG</u>	<u>A075116</u>	<u>003</u>	Dec 23, 1999
<u>AB3</u>		<u>300MG</u>	<u>A075116</u>	<u>004</u>	Dec 23, 1999

DILTIAZEM HYDROCHLORIDE

<u>AB4</u>	ACTAVIS ELIZABETH	<u>120MG</u>	<u>A091022</u>	<u>001</u>	Sep 28, 2012
<u>AB4</u>		<u>180MG</u>	<u>A091022</u>	<u>002</u>	Sep 28, 2012
<u>AB4</u>		<u>240MG</u>	<u>A091022</u>	<u>003</u>	Sep 28, 2012
<u>AB4</u>		<u>300MG</u>	<u>A091022</u>	<u>004</u>	Sep 28, 2012
<u>AB4</u>		<u>360MG</u>	<u>A091022</u>	<u>005</u>	Sep 28, 2012
<u>AB4</u>		<u>420MG</u>	<u>A091022</u>	<u>006</u>	Sep 28, 2012
<u>AB4</u>	NESHER PHARMS	<u>120MG</u>	<u>A076563</u>	<u>002</u>	Sep 12, 2006
<u>AB4</u>		<u>180MG</u>	<u>A076563</u>	<u>003</u>	Sep 12, 2006
<u>AB4</u>		<u>240MG</u>	<u>A076563</u>	<u>004</u>	Sep 12, 2006
<u>AB4</u>		<u>300MG</u>	<u>A076563</u>	<u>005</u>	Sep 12, 2006
<u>AB4</u>		<u>360MG</u>	<u>A076563</u>	<u>006</u>	Sep 12, 2006
<u>AB4</u>		<u>420MG</u>	<u>A076563</u>	<u>001</u>	Sep 12, 2006
<u>AB4</u>	SUN PHARMA GLOBAL	<u>120MG</u>	<u>A090421</u>	<u>001</u>	Nov 15, 2010
<u>AB4</u>		<u>180MG</u>	<u>A090421</u>	<u>002</u>	Nov 15, 2010
<u>AB4</u>		<u>240MG</u>	<u>A090421</u>	<u>003</u>	Nov 15, 2010
<u>AB4</u>		<u>300MG</u>	<u>A090421</u>	<u>004</u>	Nov 15, 2010
<u>AB4</u>		<u>360MG</u>	<u>A090421</u>	<u>005</u>	Nov 15, 2010

DILTZAC

<u>AB4</u>	APOTEX INC	<u>120MG</u>	<u>A076395</u>	<u>001</u>	Feb 01, 2006
<u>AB4</u>		<u>180MG</u>	<u>A076395</u>	<u>002</u>	Feb 01, 2006
<u>AB4</u>		<u>240MG</u>	<u>A076395</u>	<u>003</u>	Feb 01, 2006
<u>AB4</u>		<u>300MG</u>	<u>A076395</u>	<u>004</u>	Feb 01, 2006
<u>AB4</u>		<u>360MG</u>	<u>A076395</u>	<u>005</u>	Feb 01, 2006

TAZTIA XT

<u>AB4</u>	WATSON LABS FLORIDA	<u>120MG</u>	<u>A075401</u>	<u>001</u>	Apr 10, 2003
<u>AB4</u>		<u>180MG</u>	<u>A075401</u>	<u>002</u>	Apr 10, 2003
<u>AB4</u>		<u>240MG</u>	<u>A075401</u>	<u>003</u>	Apr 10, 2003
<u>AB4</u>		<u>300MG</u>	<u>A075401</u>	<u>004</u>	Apr 10, 2003
<u>AB4</u>		<u>360MG</u>	<u>A075401</u>	<u>005</u>	Apr 10, 2003

TIAZAC

<u>AB4</u>	VALEANT INTL	<u>120MG</u>	<u>N020401</u>	<u>001</u>	Sep 11, 1995
<u>AB4</u>		<u>180MG</u>	<u>N020401</u>	<u>002</u>	Sep 11, 1995
<u>AB4</u>		<u>240MG</u>	<u>N020401</u>	<u>003</u>	Sep 11, 1995
<u>AB4</u>		<u>300MG</u>	<u>N020401</u>	<u>004</u>	Sep 11, 1995

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 137 (of 428)

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TIAZAC

<u>AB4</u>	VALEANT INTL	<u>360MG</u>	<u>N020401</u>	<u>005</u>	Sep 11, 1995
<u>AB4</u> +		<u>420MG</u>	<u>N020401</u>	<u>006</u>	Oct 16, 1998
	DILTIAZEM HYDROCHLORIDE				
BC	+ MYLAN	120MG	A074910	003	May 02, 1997
	DILTIAZEM HYDROCHLORIDE				
	MYLAN	60MG	A074910	001	May 02, 1997
		90MG	A074910	002	May 02, 1997

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

<u>AP</u>	AGILA SPECLTS	<u>5MG/ML</u>	<u>A075375</u>	<u>001</u>	Sep 30, 1999
<u>AP</u> +	BEDFORD	<u>5MG/ML</u>	<u>A074617</u>	<u>001</u>	Feb 28, 1996
<u>AP</u>	HIKMA FARMACEUTICA	<u>5MG/ML</u>	<u>A202651</u>	<u>001</u>	Aug 09, 2012
<u>AP</u>	HIKMA MAPLE	<u>5MG/ML</u>	<u>A078538</u>	<u>001</u>	Dec 17, 2008
<u>AP</u>	HOSPIRA	<u>5MG/ML</u>	<u>A074941</u>	<u>001</u>	Apr 15, 1998
<u>AP</u>	INTL MEDICATION	<u>5MG/ML</u>	<u>A075749</u>	<u>001</u>	Nov 21, 2001
<u>AP</u>	TAYLOR PHARMA	<u>5MG/ML</u>	<u>A075086</u>	<u>001</u>	Apr 09, 1998
	DILTIAZEM HYDROCHLORIDE				
	+ HOSPIRA	100MG/VIAL	A075853	001	Dec 17, 2002
	+ TEVA PARENTERAL	10MG/ML	A074894	002	Apr 19, 2002

TABLET; ORAL

CARDIZEM

<u>AB</u>	VALEANT INTL	<u>30MG</u>	<u>N018602</u>	<u>001</u>	Nov 05, 1982
<u>AB</u>		<u>60MG</u>	<u>N018602</u>	<u>002</u>	Nov 05, 1982
<u>AB</u>		<u>90MG</u>	<u>N018602</u>	<u>003</u>	Dec 08, 1986
<u>AB</u> +		<u>120MG</u>	<u>N018602</u>	<u>004</u>	Dec 08, 1986
	<u>DILTIAZEM HYDROCHLORIDE</u>				
<u>AB</u>	DAVA PHARMS INC	<u>30MG</u>	<u>A074093</u>	<u>001</u>	Nov 05, 1992
<u>AB</u>		<u>60MG</u>	<u>A074093</u>	<u>002</u>	Nov 05, 1992
<u>AB</u>		<u>90MG</u>	<u>A074093</u>	<u>003</u>	Nov 05, 1992
<u>AB</u>		<u>120MG</u>	<u>A074093</u>	<u>004</u>	Nov 05, 1992
<u>AB</u>	MYLAN	<u>30MG</u>	<u>A072838</u>	<u>004</u>	Nov 05, 1992
<u>AB</u>		<u>60MG</u>	<u>A072838</u>	<u>003</u>	Nov 05, 1992
<u>AB</u>		<u>90MG</u>	<u>A072838</u>	<u>002</u>	Nov 05, 1992
<u>AB</u>		<u>120MG</u>	<u>A072838</u>	<u>001</u>	Nov 05, 1992
<u>AB</u>	TEVA	<u>30MG</u>	<u>A074185</u>	<u>001</u>	May 31, 1995
<u>AB</u>		<u>60MG</u>	<u>A074185</u>	<u>002</u>	May 31, 1995
<u>AB</u>		<u>90MG</u>	<u>A074185</u>	<u>003</u>	May 31, 1995
<u>AB</u>		<u>120MG</u>	<u>A074185</u>	<u>004</u>	May 31, 1995

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

<u>AB</u>	VALEANT INTL	<u>120MG</u>	<u>N021392</u>	<u>001</u>	Feb 06, 2003
<u>AB</u>		<u>180MG</u>	<u>N021392</u>	<u>002</u>	Feb 06, 2003
<u>AB</u>		<u>240MG</u>	<u>N021392</u>	<u>003</u>	Feb 06, 2003
<u>AB</u>		<u>300MG</u>	<u>N021392</u>	<u>004</u>	Feb 06, 2003
<u>AB</u>		<u>360MG</u>	<u>N021392</u>	<u>005</u>	Feb 06, 2003
<u>AB</u> +		<u>420MG</u>	<u>N021392</u>	<u>006</u>	Feb 06, 2003
	<u>DILTIAZEM HYDROCHLORIDE</u>				
<u>AB</u>	WATSON LABS FLORIDA	<u>120MG</u>	<u>A077686</u>	<u>006</u>	Mar 15, 2010
<u>AB</u>		<u>180MG</u>	<u>A077686</u>	<u>005</u>	Mar 15, 2010
<u>AB</u>		<u>240MG</u>	<u>A077686</u>	<u>004</u>	Mar 15, 2010
<u>AB</u>		<u>300MG</u>	<u>A077686</u>	<u>003</u>	Mar 15, 2010
<u>AB</u>		<u>360MG</u>	<u>A077686</u>	<u>002</u>	Mar 15, 2010
<u>AB</u>		<u>420MG</u>	<u>A077686</u>	<u>001</u>	Mar 15, 2010

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

<u>AP</u>	FRESENIUS KABI USA	<u>50MG/ML</u>	<u>A040519</u>	<u>001</u>	Jun 23, 2004

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 138 (of 428)

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

<u>AP</u>	+ WATSON LABS	<u>50MG/ML</u>	<u>A080615</u>	<u>001</u>	

DIMERCAPROL

INJECTABLE; INJECTION

BAL

	+ AKORN	10%	N005939	001	

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

DIMETHYL SULFOXIDE

<u>AT</u>	BIONICHE PHARMA	<u>50%</u>	<u>A076185</u>	<u>001</u>	Nov 29, 2002

RIMSO-50

<u>AT</u>	+ BIONICHE PHARMA	<u>50%</u>	<u>N017788</u>	<u>001</u>	

DINOPROSTONE

GEL; ENDOCERVICAL

PREPIDIL

	+ PHARMACIA AND UPJOHN	0.5MG/3GM	N019617	001	Dec 09, 1992

INSERT, EXTENDED RELEASE; VAGINAL

CERVIDIL

	+ FERRING CONTROLLED	10MG	N020411	001	Mar 30, 1995

SUPPOSITORY; VAGINAL

PROSTIN E2

	+ PHARMACIA AND UPJOHN	20MG	N017810	001	

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

	+ BARR	50MG	A080738	001	

ELIXIR; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

	+ PHARM ASSOC	12.5MG/5ML	A087513	001	Feb 10, 1982

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

<u>AP</u>	APP PHARMS	<u>50MG/ML</u>	<u>A040466</u>	<u>001</u>	May 28, 2002

<u>AP</u>	BIONICHE PHARMA	<u>50MG/ML</u>	<u>A040498</u>	<u>001</u>	Jul 12, 2005

<u>AP</u>	+ HIKMA MAPLE	<u>50MG/ML</u>	<u>A080817</u>	<u>002</u>	

<u>AP</u>	HOSPIRA	<u>50MG/ML</u>	<u>A040140</u>	<u>001</u>	Nov 20, 1998

<u>AP</u>	WATSON LABS	<u>50MG/ML</u>	<u>A080873</u>	<u>002</u>	

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	INTL MEDICATION	<u>50MG/ML</u>	<u>A084094</u>	<u>001</u>	

<u>AP</u>	WATSON LABS	<u>50MG/ML</u>	<u>A080873</u>	<u>003</u>	

DIPHENHYDRAMINE HYDROCHLORIDE

	+ WATSON LABS	10MG/ML	A080873	001	

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPRO

<u>AT</u>	AKORN	<u>0.1%</u>	<u>A074382</u>	<u>001</u>	Sep 29, 1995

DIPIVEFRIN HYDROCHLORIDE

<u>AT</u>	FALCON PHARMS	<u>0.1%</u>	<u>A073636</u>	<u>001</u>	Jun 30, 1994

PROPINE

<u>AT</u>	+ ALLERGAN	<u>0.1%</u>	<u>N018239</u>	<u>001</u>	

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

<u>AP</u>	+ BEDFORD	<u>5MG/ML</u>	<u>A074939</u>	<u>001</u>	Apr 13, 1998

<u>AP</u>	CLARIS LIFESCIENCES	<u>5MG/ML</u>	<u>A075769</u>	<u>001</u>	Nov 27, 2002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 139 (of 428)

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

<u>AP</u>	FRESENIUS KABI USA	<u>5MG/ML</u>	<u>A074956</u>	<u>001</u>	Sep 30, 1998
<u>AP</u>	HIKMA MAPLE	<u>5MG/ML</u>	<u>A074521</u>	<u>001</u>	Oct 18, 1996

TABLET; ORAL

DIPYRIDAMOLE

<u>AB</u>	BARR	<u>25MG</u>	<u>A087184</u>	<u>001</u>	Oct 03, 1990
<u>AB</u>		<u>50MG</u>	<u>A087716</u>	<u>001</u>	Oct 03, 1990
<u>AB</u>		<u>75MG</u>	<u>A087717</u>	<u>001</u>	Oct 03, 1990
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A088999</u>	<u>001</u>	Feb 05, 1991
<u>AB</u>		<u>50MG</u>	<u>A089000</u>	<u>001</u>	Feb 05, 1991
<u>AB</u>		<u>75MG</u>	<u>A089001</u>	<u>001</u>	Feb 05, 1991
<u>AB</u>	IMPAX LABS	<u>25MG</u>	<u>A040782</u>	<u>001</u>	Jul 18, 2007
<u>AB</u>		<u>50MG</u>	<u>A040782</u>	<u>002</u>	Jul 18, 2007
<u>AB</u>		<u>75MG</u>	<u>A040782</u>	<u>003</u>	Jul 18, 2007
<u>AB</u>	LANNETT	<u>25MG</u>	<u>A040898</u>	<u>001</u>	Apr 23, 2008
<u>AB</u>		<u>50MG</u>	<u>A040898</u>	<u>002</u>	Apr 23, 2008
<u>AB</u>		<u>75MG</u>	<u>A040898</u>	<u>003</u>	Apr 23, 2008
<u>AB</u>	MURTY PHARMS	<u>25MG</u>	<u>A040733</u>	<u>001</u>	Feb 13, 2007
<u>AB</u>		<u>50MG</u>	<u>A040733</u>	<u>002</u>	Feb 13, 2007
<u>AB</u>		<u>75MG</u>	<u>A040733</u>	<u>003</u>	Feb 13, 2007
<u>AB</u>	PROSAM LABS	<u>25MG</u>	<u>A040542</u>	<u>001</u>	Apr 21, 2006
<u>AB</u>		<u>50MG</u>	<u>A040542</u>	<u>002</u>	Apr 21, 2006
<u>AB</u>		<u>75MG</u>	<u>A040542</u>	<u>003</u>	Apr 21, 2006
<u>AB</u>	PUREPAC PHARM	<u>25MG</u>	<u>A089425</u>	<u>001</u>	Jul 12, 1990
<u>AB</u>	WATSON LABS	<u>50MG</u>	<u>A087160</u>	<u>001</u>	Jun 07, 1996
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A040874</u>	<u>001</u>	Jan 28, 2008
<u>AB</u>		<u>50MG</u>	<u>A040874</u>	<u>002</u>	Jan 28, 2008
<u>AB</u>		<u>75MG</u>	<u>A040874</u>	<u>003</u>	Jan 28, 2008
	<u>PERSANTINE</u>				
<u>AB</u>	BOEHRINGER INGELHEIM	<u>25MG</u>	<u>N012836</u>	<u>003</u>	Dec 22, 1986
<u>AB</u>		<u>50MG</u>	<u>N012836</u>	<u>004</u>	Feb 06, 1987
<u>AB</u>	+	<u>75MG</u>	<u>N012836</u>	<u>005</u>	Feb 06, 1987

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

<u>AB</u>	TEVA	<u>EQ 100MG BASE</u>	<u>A070101</u>	<u>001</u>	Feb 22, 1985
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A070102</u>	<u>001</u>	Feb 22, 1985
<u>AB</u>	WATSON LABS	<u>EQ 100MG BASE</u>	<u>A070173</u>	<u>001</u>	May 31, 1985
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A070174</u>	<u>001</u>	May 31, 1985
	<u>NORPACE</u>				
<u>AB</u>	GD SEARLE LLC	<u>EQ 100MG BASE</u>	<u>N017447</u>	<u>001</u>	
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>N017447</u>	<u>002</u>	

CAPSULE, EXTENDED RELEASE; ORAL

NORPACE CR

<u>AB</u>	+	GD SEARLE LLC	<u>EQ 150MG BASE</u>	<u>N018655</u>	<u>002</u>	Jul 20, 1982
		NORPACE CR				
		GD SEARLE LLC	EQ 100MG BASE	N018655	001	Jul 20, 1982

DISULFIRAM

TABLET; ORAL

ANTABUSE

<u>AB</u>	ODYSSEY PHARMS	<u>250MG</u>	<u>A088482</u>	<u>001</u>	Dec 08, 1983
<u>AB</u>	+	<u>500MG</u>	<u>A088483</u>	<u>001</u>	Dec 08, 1983

DISULFIRAM

<u>AB</u>	SIGMAPHARM LABS LLC	<u>250MG</u>	<u>A091619</u>	<u>001</u>	Mar 28, 2011
<u>AB</u>		<u>500MG</u>	<u>A091619</u>	<u>002</u>	Mar 28, 2011
<u>AB</u>	VINTAGE PHARMS	<u>250MG</u>	<u>A091563</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>500MG</u>	<u>A091563</u>	<u>002</u>	Dec 31, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 140 (of 428)

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DEPAKOTE

<u>AB</u>	+	ABBVIE	<u>EQ 125MG VALPROIC ACID</u>	<u>N019680</u>	<u>001</u>	Sep 12, 1989

DIVALPROEX SODIUM

<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078979</u>	<u>001</u>	Jan 23, 2009

<u>AB</u>		MYLAN	<u>EQ 125MG VALPROIC ACID</u>	<u>A090407</u>	<u>001</u>	Mar 28, 2011

<u>AB</u>		ZYDUS PHARMS USA INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A078919</u>	<u>001</u>	Jan 27, 2009

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE

<u>AB</u>		ABBVIE	<u>EQ 125MG VALPROIC ACID</u>	<u>N018723</u>	<u>003</u>	Oct 26, 1984

<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>N018723</u>	<u>001</u>	Mar 10, 1983

<u>AB</u>	+		<u>EQ 500MG VALPROIC ACID</u>	<u>N018723</u>	<u>002</u>	Mar 10, 1983

DIVALPROEX SODIUM

<u>AB</u>		ANCHEN PHARMS	<u>EQ 500MG VALPROIC ACID</u>	<u>A078411</u>	<u>001</u>	Nov 03, 2008

<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A090554</u>	<u>001</u>	Apr 21, 2011

<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A090554</u>	<u>002</u>	Apr 21, 2011

<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A090554</u>	<u>003</u>	Apr 21, 2011

<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078755</u>	<u>001</u>	Jul 29, 2008

<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A078755</u>	<u>002</u>	Jul 29, 2008

<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A078755</u>	<u>003</u>	Jul 29, 2008

<u>AB</u>		LUPIN	<u>EQ 125MG VALPROIC ACID</u>	<u>A078790</u>	<u>001</u>	Jul 29, 2008

<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A078790</u>	<u>002</u>	Jul 29, 2008

<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A078790</u>	<u>003</u>	Jul 29, 2008

<u>AB</u>		MYLAN	<u>EQ 125MG VALPROIC ACID</u>	<u>A077254</u>	<u>001</u>	Jul 29, 2008

<u>AB</u>			<u>EQ 125MG VALPROIC ACID</u>	<u>A090062</u>	<u>001</u>	Mar 17, 2009

<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A077254</u>	<u>002</u>	Jul 29, 2008

<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A090062</u>	<u>002</u>	Mar 17, 2009

<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A077254</u>	<u>003</u>	Jul 29, 2008

<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A090062</u>	<u>003</u>	Mar 17, 2009

<u>AB</u>		NU PHARM	<u>EQ 125MG VALPROIC ACID</u>	<u>A077615</u>	<u>003</u>	Jul 29, 2008

<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A077615</u>	<u>002</u>	Jul 29, 2008

<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A077615</u>	<u>001</u>	Jul 29, 2008

<u>AB</u>		ORCHID HLTHCARE	<u>EQ 125MG VALPROIC ACID</u>	<u>A078853</u>	<u>001</u>	Nov 25, 2008

<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A078853</u>	<u>002</u>	Nov 25, 2008

<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A078853</u>	<u>003</u>	Nov 25, 2008

<u>AB</u>		SANDOZ	<u>EQ 125MG VALPROIC ACID</u>	<u>A078290</u>	<u>003</u>	Jul 29, 2008

<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A078290</u>	<u>002</u>	Jul 29, 2008

<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A078290</u>	<u>001</u>	Jul 29, 2008

<u>AB</u>		SUN PHARM INDS	<u>EQ 125MG VALPROIC ACID</u>	<u>A078597</u>	<u>001</u>	Jul 29, 2008

<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A078597</u>	<u>002</u>	Jul 29, 2008

<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A078597</u>	<u>003</u>	Jul 29, 2008

<u>AB</u>		TEVA	<u>EQ 125MG VALPROIC ACID</u>	<u>A076941</u>	<u>001</u>	Jul 29, 2008

<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A076941</u>	<u>002</u>	Jul 29, 2008

<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A076941</u>	<u>003</u>	Jul 29, 2008

<u>AB</u>		UNICHEM LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A079163</u>	<u>001</u>	Apr 05, 2011

<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A079163</u>	<u>002</u>	Apr 05, 2011

<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A079163</u>	<u>003</u>	Apr 05, 2011

<u>AB</u>		UPSHER SMITH	<u>EQ 125MG VALPROIC ACID</u>	<u>A078182</u>	<u>001</u>	Jul 29, 2008

<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A078182</u>	<u>002</u>	Jul 29, 2008

<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A078182</u>	<u>003</u>	Jul 29, 2008

<u>AB</u>		VINTAGE	<u>EQ 125MG VALPROIC ACID</u>	<u>A090210</u>	<u>001</u>	Nov 30, 2009

<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A090210</u>	<u>002</u>	Nov 30, 2009

<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A090210</u>	<u>003</u>	Nov 30, 2009

<u>AB</u>		WATSON LABS FLORIDA	<u>EQ 500MG VALPROIC ACID</u>	<u>A079080</u>	<u>001</u>	Feb 25, 2011

<u>AB</u>		WOCKHARDT	<u>EQ 125MG VALPROIC ACID</u>	<u>A077296</u>	<u>001</u>	Jul 31, 2008

<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A077296</u>	<u>002</u>	Jul 31, 2008

<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A077296</u>	<u>003</u>	Jul 31, 2008

<u>AB</u>		ZYDUS PHARMS USA INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A077100</u>	<u>001</u>	Mar 05, 2009

<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A077100</u>	<u>002</u>	Mar 05, 2009

<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A077100</u>	<u>003</u>	Mar 05, 2009

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 141 (of 428)

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DEPAKOTE ER

<u>AB</u>	ABBVIE	<u>EQ 250MG VALPROIC ACID</u>	<u>N021168</u>	<u>002</u>	May 31, 2002
<u>AB</u>	+	<u>EQ 500MG VALPROIC ACID</u>	<u>N021168</u>	<u>001</u>	Aug 04, 2000
<u>DIVALPROEX SODIUM</u>					
<u>AB</u>	ANCHEN PHARMS	<u>EQ 250MG VALPROIC ACID</u>	<u>A078445</u>	<u>001</u>	Feb 26, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078445</u>	<u>002</u>	Aug 04, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A090161</u>	<u>001</u>	Mar 15, 2012
<u>AB</u>	IMPAX LABS	<u>EQ 250MG VALPROIC ACID</u>	<u>A078791</u>	<u>001</u>	May 06, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078791</u>	<u>002</u>	Aug 04, 2009
<u>AB</u>	MYLAN	<u>EQ 250MG VALPROIC ACID</u>	<u>A077567</u>	<u>001</u>	Jan 29, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077567</u>	<u>002</u>	Jan 29, 2009
<u>AB</u>	REDDYS	<u>EQ 500MG VALPROIC ACID</u>	<u>A090070</u>	<u>001</u>	Mar 12, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 500MG VALPROIC ACID</u>	<u>A078700</u>	<u>001</u>	Aug 03, 2009
<u>AB</u>	WOCKHARDT	<u>EQ 250MG VALPROIC ACID</u>	<u>A078705</u>	<u>002</u>	Feb 10, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078705</u>	<u>001</u>	Aug 04, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 250MG VALPROIC ACID</u>	<u>A078239</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078239</u>	<u>002</u>	Aug 04, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>EQ 12.5MG BASE/ML</u>	<u>A074277</u>	<u>001</u>	Oct 31, 1994
<u>AP</u>	HOSPIRA	<u>EQ 12.5MG BASE/ML</u>	<u>A074086</u>	<u>001</u>	Nov 29, 1993
<u>AP</u>	+	<u>EQ 12.5MG BASE/ML</u>	<u>A074292</u>	<u>001</u>	Feb 16, 1995
<u>AP</u>	WATSON LABS	<u>EQ 12.5MG BASE/ML</u>	<u>A074114</u>	<u>001</u>	Nov 30, 1993
<u>DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%</u>					
<u>AP</u>	+	<u>EQ 50MG BASE/100ML</u>	<u>N020269</u>	<u>001</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 100MG BASE/100ML</u>	<u>N020269</u>	<u>002</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 200MG BASE/100ML</u>	<u>N020269</u>	<u>003</u>	Oct 19, 1993
<u>DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
<u>AP</u>	+	<u>EQ 50MG BASE/100ML</u>	<u>N020255</u>	<u>001</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 100MG BASE/100ML</u>	<u>N020255</u>	<u>003</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 200MG BASE/100ML</u>	<u>N020255</u>	<u>004</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 400MG BASE/100ML</u>	<u>N020255</u>	<u>005</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 50MG BASE/100ML</u>	<u>N020201</u>	<u>003</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 100MG BASE/100ML</u>	<u>N020201</u>	<u>002</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 200MG BASE/100ML</u>	<u>N020201</u>	<u>001</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 400MG BASE/100ML</u>	<u>N020201</u>	<u>006</u>	Jul 07, 1994

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

<u>AP</u>	ACCORD HLTHCARE	<u>20MG/ML (20MG/ML)</u>	<u>N201195</u>	<u>003</u>	Apr 20, 2012
<u>AP</u>		<u>20MG/0.5ML (40MG/ML)</u>	<u>N201195</u>	<u>001</u>	Jun 08, 2011
<u>AP</u>		<u>80MG/2ML (40MG/ML)</u>	<u>N201195</u>	<u>002</u>	Jun 08, 2011
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>N201195</u>	<u>004</u>	Apr 20, 2012
<u>AP</u>	APOTEX INC	<u>20MG/0.5ML (40MG/ML)</u>	<u>N022312</u>	<u>001</u>	Jan 11, 2012
<u>AP</u>		<u>80MG/2ML (40MG/ML)</u>	<u>N022312</u>	<u>002</u>	Jan 11, 2012
<u>AP</u>	+	<u>20MG/2ML (10MG/ML)</u>	<u>N022234</u>	<u>001</u>	Mar 08, 2011
<u>AP</u>	+	<u>80MG/8ML (10MG/ML)</u>	<u>N022234</u>	<u>002</u>	Mar 08, 2011
<u>AP</u>	+	<u>160MG/16ML (10MG/ML)</u>	<u>N022234</u>	<u>003</u>	Mar 08, 2011
<u>AP</u>	SANDOZ	<u>20MG/2ML (10MG/ML)</u>	<u>N201525</u>	<u>001</u>	Jun 29, 2011
<u>AP</u>		<u>80MG/8ML (10MG/ML)</u>	<u>N201525</u>	<u>002</u>	Jun 29, 2011
<u>AP</u>		<u>160MG/16ML (10MG/ML)</u>	<u>N201525</u>	<u>003</u>	Jun 29, 2011
<u>TAXOTERE</u>					
<u>AP</u>	+	<u>20MG/ML (20MG/ML)</u>	<u>N020449</u>	<u>003</u>	Aug 03, 2010
<u>AP</u>	+	<u>80MG/4ML (20MG/ML)</u>	<u>N020449</u>	<u>004</u>	Aug 02, 2010
<u>DOCEFREZ</u>					
	+	SUN PHARMA GLOBAL	20MG/VIAL	N022534	001 May 03, 2011

PRESCRIPTION DRUG PRODUCT LIST

3 - 142 (of 428)

DOCETAXEL

INJECTABLE; INJECTION
DOCEFREZ

+ SUN PHARMA GLOBAL	80MG/VIAL	N022534	002	May 03, 2011
DOCETAXEL				
ACCORD HLTHCARE	160MG/8ML (20MG/ML)	N201195	005	Apr 20, 2012

DOFETILIDE

CAPSULE; ORAL
TIKOSYN

PFIZER	0.125MG	N020931	001	Oct 01, 1999
	0.25MG	N020931	002	Oct 01, 1999
+	0.5MG	N020931	003	Oct 01, 1999

DOLASETRON MESYLATE

INJECTABLE; INJECTION
ANZEMET

+ SANOFI AVENTIS US	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997
+	100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997
+	500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001

TABLET; ORAL
ANZEMET

SANOFI AVENTIS US	50MG	N020623	001	Sep 11, 1997
+	100MG	N020623	002	Sep 11, 1997

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

ARICEPT

<u>AB</u> EISAI INC	<u>5MG</u>	<u>N020690</u>	<u>002</u>	Nov 25, 1996
<u>AB</u> +	<u>10MG</u>	<u>N020690</u>	<u>001</u>	Nov 25, 1996

DONEPEZIL HYDROCHLORIDE

<u>AB</u> ACCORD HLTHCARE	<u>5MG</u>	<u>A201335</u>	<u>001</u>	Aug 29, 2011
<u>AB</u>	<u>10MG</u>	<u>A201335</u>	<u>002</u>	Aug 29, 2011
<u>AB</u> ACTAVIS PHARMA	<u>5MG</u>	<u>A090551</u>	<u>001</u>	May 31, 2011
<u>AB</u>	<u>10MG</u>	<u>A090551</u>	<u>002</u>	May 31, 2011
<u>AB</u> APOTEX	<u>5MG</u>	<u>A078841</u>	<u>001</u>	Jun 02, 2011
<u>AB</u>	<u>10MG</u>	<u>A078841</u>	<u>002</u>	Jun 02, 2011
<u>AB</u> AUROBINDO	<u>5MG</u>	<u>A090056</u>	<u>001</u>	May 31, 2011
<u>AB</u>	<u>10MG</u>	<u>A090056</u>	<u>002</u>	May 31, 2011
<u>AB</u> CIPLA LTD	<u>5MG</u>	<u>A077518</u>	<u>001</u>	May 31, 2011
<u>AB</u>	<u>10MG</u>	<u>A077518</u>	<u>002</u>	May 31, 2011
<u>AB</u> DR REDDYS LABS LTD	<u>5MG</u>	<u>A201001</u>	<u>001</u>	May 31, 2011
<u>AB</u>	<u>10MG</u>	<u>A201001</u>	<u>002</u>	May 31, 2011
<u>AB</u> HIKMA PHARMS	<u>5MG</u>	<u>A090247</u>	<u>001</u>	May 31, 2011
<u>AB</u>	<u>10MG</u>	<u>A090247</u>	<u>002</u>	May 31, 2011
<u>AB</u> INDICUS PHARMA	<u>5MG</u>	<u>A201634</u>	<u>001</u>	Jun 13, 2012
<u>AB</u>	<u>10MG</u>	<u>A201634</u>	<u>002</u>	Jun 13, 2012
<u>AB</u> JUBILANT LIFE	<u>5MG</u>	<u>A090768</u>	<u>001</u>	May 31, 2011
<u>AB</u>	<u>10MG</u>	<u>A090768</u>	<u>002</u>	May 31, 2011
<u>AB</u> MACLEODS PHARMS LTD	<u>5MG</u>	<u>A201146</u>	<u>001</u>	Aug 17, 2012
<u>AB</u>	<u>10MG</u>	<u>A201146</u>	<u>002</u>	Aug 17, 2012
<u>AB</u> MYLAN PHARMS INC	<u>5MG</u>	<u>A090521</u>	<u>001</u>	May 31, 2011
<u>AB</u>	<u>10MG</u>	<u>A090521</u>	<u>002</u>	May 31, 2011
<u>AB</u> PLIVA HRVATSKA DOO	<u>5MG</u>	<u>A090425</u>	<u>001</u>	May 31, 2011
<u>AB</u>	<u>10MG</u>	<u>A090425</u>	<u>002</u>	May 31, 2011
<u>AB</u> PRINSTON INC	<u>5MG</u>	<u>A200292</u>	<u>001</u>	May 31, 2011
<u>AB</u>	<u>10MG</u>	<u>A200292</u>	<u>002</u>	May 31, 2011
<u>AB</u> RANBAXY	<u>5MG</u>	<u>A076786</u>	<u>001</u>	Nov 26, 2010
<u>AB</u>	<u>10MG</u>	<u>A076786</u>	<u>002</u>	Nov 26, 2010
<u>AB</u> ROXANE	<u>5MG</u>	<u>A078662</u>	<u>001</u>	May 31, 2011
<u>AB</u>	<u>10MG</u>	<u>A078662</u>	<u>002</u>	May 31, 2011

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 143 (of 428)

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A090290</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090290</u>	<u>002</u>	May 31, 2011
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A090493</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090493</u>	<u>002</u>	May 31, 2011
<u>AB</u>	TEVA	<u>5MG</u>	<u>A077344</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A077344</u>	<u>002</u>	May 31, 2011
<u>AB</u>	TORRENT PHARMS	<u>5MG</u>	<u>A090686</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090686</u>	<u>002</u>	May 31, 2011
<u>AB</u>	WOCKHARDT	<u>5MG</u>	<u>A091267</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A091267</u>	<u>002</u>	May 31, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A090100</u>	<u>001</u>	Oct 24, 2012
<u>AB</u>		<u>10MG</u>	<u>A090100</u>	<u>002</u>	Oct 24, 2012

ARICEPT

+ EISAI INC 23MG

N022568 001 Jul 23, 2010

TABLET, ORALLY DISINTEGRATING; ORAL

ARICEPT ODT

<u>AB</u>	EISAI INC	<u>5MG</u>	<u>N021720</u>	<u>001</u>	Oct 18, 2004
<u>AB</u>	+	<u>10MG</u>	<u>N021720</u>	<u>002</u>	Oct 18, 2004
	<u>DONEPEZIL HYDROCHLORIDE</u>				
<u>AB</u>	BARR	<u>5MG</u>	<u>A078388</u>	<u>002</u>	Nov 26, 2010
<u>AB</u>		<u>10MG</u>	<u>A078388</u>	<u>001</u>	Nov 26, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A201787</u>	<u>001</u>	Dec 14, 2012
<u>AB</u>		<u>10MG</u>	<u>A201787</u>	<u>002</u>	Dec 14, 2012
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A091198</u>	<u>001</u>	May 10, 2011
<u>AB</u>		<u>10MG</u>	<u>A091198</u>	<u>002</u>	May 10, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A090175</u>	<u>001</u>	May 10, 2011
<u>AB</u>		<u>10MG</u>	<u>A090175</u>	<u>002</u>	May 10, 2011

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

<u>AP</u>	+	<u>HOSPIRA</u>	<u>40MG/ML</u>	<u>N018132</u>	<u>001</u>	
<u>AP</u>	+		<u>80MG/100ML</u>	<u>N018132</u>	<u>002</u>	Feb 04, 1982
<u>AP</u>	+		<u>80MG/ML</u>	<u>N018132</u>	<u>004</u>	Jul 09, 1982
<u>AP</u>	+		<u>160MG/100ML</u>	<u>N018132</u>	<u>003</u>	Feb 04, 1982
<u>AP</u>	+	<u>LUITPOLD</u>	<u>40MG/ML</u>	<u>A070799</u>	<u>001</u>	Feb 11, 1987
<u>AP</u>	+		<u>80MG/ML</u>	<u>A070820</u>	<u>001</u>	Feb 11, 1987
<u>AP</u>	+		<u>160MG/ML</u>	<u>A070826</u>	<u>001</u>	Feb 11, 1987

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

<u>AP</u>	+	<u>B BRAUN</u>	<u>80MG/100ML</u>	<u>N019099</u>	<u>002</u>	Oct 15, 1986
<u>AP</u>	+		<u>320MG/100ML</u>	<u>N019099</u>	<u>004</u>	Oct 15, 1986

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	<u>B BRAUN</u>	<u>160MG/100ML</u>	<u>N019099</u>	<u>003</u>	Oct 15, 1986

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	<u>BAXTER HLTHCARE</u>	<u>80MG/100ML</u>	<u>N019615</u>	<u>001</u>	Mar 27, 1987
<u>AP</u>	+		<u>160MG/100ML</u>	<u>N019615</u>	<u>002</u>	Mar 27, 1987
<u>AP</u>	+		<u>320MG/100ML</u>	<u>N019615</u>	<u>003</u>	Mar 27, 1987
<u>AP</u>	+	<u>HOSPIRA</u>	<u>80MG/100ML</u>	<u>N018826</u>	<u>001</u>	Sep 30, 1983
<u>AP</u>	+		<u>160MG/100ML</u>	<u>N018826</u>	<u>002</u>	Sep 30, 1983
<u>AP</u>	+		<u>320MG/100ML</u>	<u>N018826</u>	<u>003</u>	Sep 30, 1983

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

+ B BRAUN 40MG/100ML N019099 001 Oct 15, 1986

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 640MG/100ML N019615 004 Mar 27, 1987

PRESCRIPTION DRUG PRODUCT LIST

3 - 144 (of 428)

DORIPENEM

INJECTABLE; IV (INFUSION)

JANSSEN PHARMS	250MG/VIAL	N022106	002	Oct 05, 2010
+	500MG/VIAL	N022106	001	Oct 12, 2007

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

<u>AT</u>	ALCON PHARMS LTD	EQ 2% BASE	A078981	001	Apr 13, 2009
<u>AT</u>	APOTEX INC	EQ 2% BASE	A078395	001	Oct 28, 2008
<u>AT</u>	BAUSCH AND LOMB	EQ 2% BASE	A090143	001	Jun 25, 2009
<u>AT</u>	HI TECH PHARMA	EQ 2% BASE	A077846	001	Oct 28, 2008
<u>AT</u>	LUITPOLD	EQ 2% BASE	A079186	001	Nov 18, 2009
<u>AT</u>	SANDOZ	EQ 2% BASE	A078748	001	Nov 06, 2008
<u>AT</u>	TEVA PHARMS	EQ 2% BASE	A078756	001	Dec 04, 2008

TRUSOPT

<u>AT</u>	+ MERCK	EQ 2% BASE	N020408	001	Dec 09, 1994

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT

<u>AT</u>	+ MERCK	EQ 2% BASE;EQ 0.5% BASE	N020869	001	Apr 07, 1998

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

<u>AT</u>	ALCON RES	EQ 2% BASE;EQ 0.5% BASE	A090604	001	Nov 18, 2009
<u>AT</u>	APOTEX INC	EQ 2% BASE;EQ 0.5% BASE	A078201	001	Oct 28, 2008
<u>AT</u>	BAUSCH AND LOMB	EQ 2% BASE;EQ 0.5% BASE	A090037	001	Jul 14, 2009
<u>AT</u>	HI TECH PHARMA	EQ 2% BASE;EQ 0.5% BASE	A077847	001	Oct 28, 2008
<u>AT</u>	SANDOZ	EQ 2% BASE;EQ 0.5% BASE	A078749	001	Nov 06, 2008
<u>AT</u>	TEVA PHARMS	EQ 2% BASE;EQ 0.5% BASE	A078704	001	Sep 28, 2009

COSOPT PF

	+ MERCK SHARP DOHME	EQ 2% BASE;EQ 0.5% BASE	N202667	001	Feb 01, 2012

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

<u>AP</u>	+ BAXTER HLTHCARE	20MG/ML	N014879	001	

DOXAPRAM HYDROCHLORIDE

<u>AP</u>	BEDFORD	20MG/ML	A076266	001	Jan 10, 2003
<u>AP</u>	WATSON LABS	20MG/ML	A073529	001	Jan 30, 1992

DOXAZOSIN MESYLATE

TABLET; ORAL

CARDURA

<u>AB</u>	+ PFIZER	EQ 1MG BASE	N019668	001	Nov 02, 1990
<u>AB</u>		EQ 2MG BASE	N019668	002	Nov 02, 1990
<u>AB</u>		EQ 4MG BASE	N019668	003	Nov 02, 1990
<u>AB</u>		EQ 8MG BASE	N019668	004	Nov 02, 1990

DOXAZOSIN MESYLATE

<u>AB</u>	APOTEX	EQ 1MG BASE	A075580	001	Oct 18, 2000
<u>AB</u>		EQ 2MG BASE	A075580	002	Oct 18, 2000
<u>AB</u>		EQ 4MG BASE	A075580	003	Oct 18, 2000
<u>AB</u>		EQ 8MG BASE	A075580	004	Oct 18, 2000
<u>AB</u>	DAVA PHARMS INC	EQ 1MG BASE	A076161	001	Jun 10, 2004
<u>AB</u>		EQ 2MG BASE	A076161	002	Jun 10, 2004
<u>AB</u>		EQ 4MG BASE	A076161	003	Jun 10, 2004
<u>AB</u>		EQ 8MG BASE	A076161	004	Jun 10, 2004
<u>AB</u>	MYLAN	EQ 1MG BASE	A075509	001	Oct 19, 2000
<u>AB</u>		EQ 2MG BASE	A075509	002	Oct 19, 2000
<u>AB</u>		EQ 4MG BASE	A075509	003	Oct 19, 2000
<u>AB</u>		EQ 8MG BASE	A075509	004	Oct 19, 2000

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 145 (of 428)

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

<u>AB</u>	PLIVA	<u>EQ 1MG BASE</u>	<u>A075750</u>	<u>001</u>	Jun 08, 2001
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075750</u>	<u>002</u>	Jun 08, 2001
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075750</u>	<u>003</u>	Jun 08, 2001
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075750</u>	<u>004</u>	Jun 08, 2001
<u>AB</u>	TEVA	<u>EQ 1MG BASE</u>	<u>A075536</u>	<u>001</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075536</u>	<u>002</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075536</u>	<u>003</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075536</u>	<u>004</u>	Oct 18, 2000
<u>AB</u>	WATSON LABS	<u>EQ 1MG BASE</u>	<u>A075426</u>	<u>001</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075426</u>	<u>002</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075426</u>	<u>003</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075426</u>	<u>004</u>	Oct 18, 2000
TABLET, EXTENDED RELEASE; ORAL					
	CARDURA XL				
	PFIZER	EQ 4MG BASE	N021269	001	Feb 22, 2005
	+	EQ 8MG BASE	N021269	002	Feb 22, 2005

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A070791</u>	<u>002</u>	May 13, 1986
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A070791</u>	<u>003</u>	May 13, 1986
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A070791</u>	<u>001</u>	May 13, 1986
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A070791</u>	<u>004</u>	May 13, 1986
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A070791</u>	<u>005</u>	May 13, 1986
<u>AB</u>	PAR PHARM	<u>EQ 10MG BASE</u>	<u>A071697</u>	<u>001</u>	Nov 09, 1987
<u>AB</u>	+	<u>EQ 25MG BASE</u>	<u>A071437</u>	<u>001</u>	Nov 09, 1987
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A071595</u>	<u>001</u>	Nov 09, 1987
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A071608</u>	<u>001</u>	Nov 09, 1987
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>A071422</u>	<u>001</u>	Nov 09, 1987
<u>AB</u>	WATSON LABS	<u>EQ 10MG BASE</u>	<u>A071485</u>	<u>001</u>	Apr 30, 1987
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A071486</u>	<u>001</u>	Apr 30, 1987
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A071238</u>	<u>001</u>	Apr 30, 1987
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A071326</u>	<u>001</u>	Apr 30, 1987
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A071239</u>	<u>001</u>	Apr 30, 1987
DOXEPIN HYDROCHLORIDE					
	PAR PHARM	EQ 150MG BASE	A071669	001	Nov 09, 1987

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AA</u>	PHARM ASSOC	<u>EQ 10MG BASE/ML</u>	<u>A075924</u>	<u>001</u>	Jan 15, 2004
<u>AA</u>	SILARX	<u>EQ 10MG BASE/ML</u>	<u>A074721</u>	<u>001</u>	Dec 29, 1998
<u>AA</u>	+	<u>EQ 10MG BASE/ML</u>	<u>A071609</u>	<u>001</u>	Nov 09, 1987
<u>AA</u>	WOCKHARDT	<u>EQ 10MG BASE/ML</u>	<u>A071918</u>	<u>001</u>	Jul 20, 1988

CREAM; TOPICAL

ZONALON

	+	FOUGERA PHARMS	5%	N020126	001	Apr 01, 1994

TABLET; ORAL

SILENOR

SOMAXON

	+		EQ 3MG BASE	N022036	001	Mar 17, 2010
			EQ 6MG BASE	N022036	002	Mar 17, 2010

DOXERCALCIFEROL

CAPSULE; ORAL

DOXERCALCIFEROL

<u>AB</u>	ROXANE	<u>0.5MCG</u>	<u>A091433</u>	<u>001</u>	Sep 23, 2011
<u>HECTOROL</u>					
<u>AB</u>	GENZYME CORP	<u>0.5MCG</u>	<u>N020862</u>	<u>002</u>	Apr 23, 2004

PRESCRIPTION DRUG PRODUCT LIST

3 - 146 (of 428)

DOXERCALCIFEROL

CAPSULE; ORAL
HECTOROL

GENZYME CORP	1MCG	N020862	003	Jul 13, 2009
+	2.5MCG	N020862	001	Jun 09, 1999

INJECTABLE; INJECTION
HECTOROL

GENZYME CORP	2MCG/ML (2MCG/ML)	N021027	002	Apr 06, 2000
+	4MCG/2ML (2MCG/ML)	N021027	001	Apr 06, 2000

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

<u>AP</u>	ALVOGEN INC	2MG/ML	A065515	001	Nov 08, 2012
<u>AP</u>	+	BEDFORD	A062975	001	Mar 17, 1989
<u>AP</u>	+		A062921	001	Mar 17, 1989
<u>AP</u>	+		A062921	002	Mar 17, 1989
<u>AP</u>	+		A062921	003	Mar 17, 1989
<u>AP</u>	+		A064097	001	Sep 13, 1994
<u>AP</u>	FRESENIUS KABI USA	2MG/ML	A063277	001	Oct 26, 1995
<u>AP</u>	ONCO THERAPIES LTD	2MG/ML	A200901	001	Feb 14, 2012
<u>AP</u>		10MG/VIAL	A200170	001	Oct 28, 2011
<u>AP</u>		50MG/VIAL	A200170	002	Oct 28, 2011
<u>AP</u>	PHARMACHEMIE	2MG/ML	A063336	001	Feb 28, 1995
<u>AP</u>		10MG/VIAL	A063097	001	May 21, 1990
<u>AP</u>		20MG/VIAL	A063097	002	May 21, 1990
<u>AP</u>		50MG/VIAL	A063097	003	May 21, 1990
<u>AP</u>		200MG/100ML	A063336	004	Feb 28, 1995
<u>AP</u>	SANDOZ INC	2MG/ML	A200146	001	Jul 18, 2012
<u>AP</u>	SUN PHARM INDS	2MG/ML	A091418	001	Feb 15, 2012
<u>AP</u>	TEVA PARENTERAL	2MG/ML	A064140	001	Jul 28, 1995
<u>AP</u>		200MG/100ML	A064140	002	Jul 28, 1995

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

+	JANSSEN R AND D	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995
+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

<u>AB</u>	IMPAX LABS INC	EQ 150MG BASE	A200065	001	Feb 17, 2011
<u>AB</u>	MYLAN	40MG	A090855	001	Jul 01, 2010
<u>AB</u>	MYLAN PHARMS INC	EQ 150MG BASE	A202778	001	Jun 08, 2012
<u>AB</u>	PAR PHARM	EQ 50MG BASE	A065055	001	Dec 01, 2000
<u>AB</u>		EQ 100MG BASE	A065055	002	Dec 01, 2000
<u>AB</u>	+	EQ 150MG BASE	A065055	003	Jul 15, 2005
<u>AB</u>	RANBAXY	EQ 50MG BASE	A065053	001	Nov 22, 2000
<u>AB</u>		EQ 75MG BASE	A065053	003	Sep 10, 2003
<u>AB</u>		EQ 100MG BASE	A065053	002	Nov 22, 2000
<u>AB</u>	WATSON LABS	EQ 50MG BASE	A065041	001	Apr 28, 2000
<u>AB</u>		EQ 100MG BASE	A065041	002	Apr 28, 2000

MONODOX

<u>AB</u>	AQUA PHARMS	EQ 50MG BASE	N050641	002	Feb 10, 1992
<u>AB</u>		EQ 75MG BASE	N050641	003	Oct 18, 2006
<u>AB</u>	+	EQ 100MG BASE	N050641	001	Dec 29, 1989

ORACEA

<u>AB</u>	+ GALDERMA LABS LP	40MG	N050805	001	May 26, 2006

FOR SUSPENSION; ORAL

DOXYCYCLINE

<u>AB</u>	IVAX SUB TEVA PHARMS	EQ 25MG BASE/5ML	A065454	001	Jul 16, 2008

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 147 (of 428)

DOXYCYCLINE

FOR SUSPENSION; ORAL

VIBRAMYCINAB + PFIZEREQ 25MG BASE/5MLN050006 001

TABLET; ORAL

DOXYCYCLINEAB HERITAGE PHARMS INCEQ 50MG BASEA091605 001

Dec 20, 2011

ABEQ 75MG BASEA091605 002

Dec 20, 2011

ABEQ 100MG BASEA091605 003

Dec 20, 2011

ABEQ 150MG BASEA091605 004

Dec 20, 2011

AB

LANNETT

EQ 50MG BASEA065285 001

Dec 08, 2005

ABEQ 75MG BASEA065285 003

Jul 30, 2008

ABEQ 100MG BASEA065285 002

Dec 08, 2005

ABEQ 150MG BASEA065285 004

Jul 30, 2008

AB

MYLAN

EQ 50MG BASEA065377 001

Nov 07, 2006

ABEQ 75MG BASEA065377 002

Nov 07, 2006

ABEQ 100MG BASEA065377 003

Nov 07, 2006

ABEQ 150MG BASEA065427 001

Jun 07, 2007

AB

PAR PHARM

EQ 50MG BASEA065070 001

Dec 15, 2000

ABEQ 75MG BASEA065070 003

Dec 30, 2002

ABEQ 100MG BASEA065070 002

Dec 15, 2000

AB +EQ 150MG BASEA065070 004

Jul 14, 2005

AB

RANBAXY

EQ 50MG BASEA065356 001

May 31, 2006

ABEQ 75MG BASEA065356 002

May 31, 2006

ABEQ 100MG BASEA065356 003

May 31, 2006

DOXYCYCLINE CALCIUM

SUSPENSION; ORAL

VIBRAMYCIN

+ PFIZER

EQ 50MG BASE/5MLN050480 001DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATEAB IVAX SUB TEVA PHARMSEQ 50MG BASEA062500 001

Sep 11, 1984

ABEQ 100MG BASEA062500 002

Sep 11, 1984

AB

MUTUAL PHARM

EQ 50MG BASEA062675 001

Jul 10, 1986

ABEQ 100MG BASEA062676 001

Jul 10, 1986

AB

WATSON LABS FLORIDA

EQ 50MG BASEA062031 002

Oct 13, 1982

ABEQ 100MG BASEA062031 001AB

WEST WARD

EQ 50MG BASEA062396 002

Nov 07, 1984

ABEQ 100MG BASEA062396 001

May 07, 1984

VIBRAMYCINAB PFIZEREQ 50MG BASEN050007 001AB +EQ 100MG BASEN050007 002

DOXYCYCLINE HYCLATE

+ WEST WARD

EQ 20MG BASEA065103 001

May 13, 2005

CAPSULE, DELAYED RELEASE; ORAL

DOXYCYCLINE HYCLATE

MEDICIS

EQ 75MG BASEA065281 001

Dec 21, 2005

+

EQ 100MG BASEA065281 002

Dec 21, 2005

INJECTABLE; INJECTION

DOXY 100AP + FRESENIUS KABI USAEQ 100MG BASE/VIALA062475 001

Dec 09, 1983

DOXYCYCLINEAP + BEDFORDEQ 100MG BASE/VIALA062569 001

Mar 09, 1988

AP

PFIZER

EQ 100MG BASE/VIALA091406 001

Aug 21, 2012

DOXY 200

+ FRESENIUS KABI USA

EQ 200MG BASE/VIALA062475 002

Dec 09, 1983

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 148 (of 428)

DOXYCYCLINE HYCLATESYSTEM, EXTENDED RELEASE; PERIODONTAL
ATRIDOX

+ TOLMAR 50MG N050751 001 Sep 03, 1998

TABLET; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	COREPHARMA	<u>EQ 20MG BASE</u>	<u>A065182</u>	<u>001</u>	May 13, 2005
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A065163</u>	<u>001</u>	May 13, 2005
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062505</u>	<u>001</u>	Sep 11, 1984
<u>AB</u>	LANNETT	<u>EQ 20MG BASE</u>	<u>A065277</u>	<u>001</u>	Nov 10, 2005
<u>AB</u>	LARKEN LABS	<u>EQ 20MG BASE</u>	<u>A065287</u>	<u>001</u>	Feb 28, 2006
<u>AB</u>	MUTUAL PHARM	<u>EQ 100MG BASE</u>	<u>A062677</u>	<u>001</u>	Jul 10, 1986
<u>AB</u>	MUTUAL PHARMA	<u>EQ 20MG BASE</u>	<u>A065134</u>	<u>001</u>	May 13, 2005
<u>AB</u>	VINTAGE PHARMS	<u>EQ 100MG BASE</u>	<u>A062538</u>	<u>001</u>	Apr 07, 1986
<u>AB</u>	WATSON LABS INC FL	<u>EQ 100MG BASE</u>	<u>A062421</u>	<u>001</u>	Feb 02, 1983
<u>AB</u>	+ WEST-WARD PHARM CORP	<u>EQ 100MG BASE</u>	<u>A065095</u>	<u>001</u>	Jul 02, 2003

PERIOSTAT

<u>AB</u>	+ GALDERMA LABS LP	<u>EQ 20MG BASE</u>	<u>N050783</u>	<u>001</u>	Feb 02, 2001

TABLET, DELAYED RELEASE; ORAL

DORYX

<u>AB</u>	MAYNE PHARMA	<u>EQ 75MG BASE</u>	<u>N050795</u>	<u>001</u>	May 06, 2005
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>N050795</u>	<u>002</u>	May 06, 2005
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>N050795</u>	<u>003</u>	Jun 20, 2008

DOXYCYCLINE HYCLATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 75MG BASE</u>	<u>A090134</u>	<u>001</u>	Dec 14, 2011
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090134</u>	<u>002</u>	Dec 14, 2011
<u>AB</u>	IMPAX LABS INC	<u>EQ 75MG BASE</u>	<u>A090505</u>	<u>001</u>	Dec 28, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090505</u>	<u>002</u>	Dec 28, 2010
<u>AB</u>	MYLAN	<u>EQ 75MG BASE</u>	<u>A090431</u>	<u>001</u>	Dec 28, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090431</u>	<u>002</u>	Dec 28, 2010
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 150MG BASE</u>	<u>A091052</u>	<u>001</u>	Feb 08, 2012

DRONABINOL

CAPSULE; ORAL

DRONABINOL

<u>AB</u>	INSYS THERAP	<u>2.5MG</u>	<u>A078501</u>	<u>001</u>	Aug 19, 2011
<u>AB</u>		<u>5MG</u>	<u>A078501</u>	<u>002</u>	Aug 19, 2011
<u>AB</u>		<u>10MG</u>	<u>A078501</u>	<u>003</u>	Aug 19, 2011
<u>AB</u>	SVC PHARMA	<u>2.5MG</u>	<u>A078292</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>		<u>5MG</u>	<u>A078292</u>	<u>002</u>	Jun 27, 2008
<u>AB</u>		<u>10MG</u>	<u>A078292</u>	<u>003</u>	Jun 27, 2008

MARINOL

<u>AB</u>	ABBVIE	<u>2.5MG</u>	<u>N018651</u>	<u>001</u>	May 31, 1985
<u>AB</u>	+	<u>5MG</u>	<u>N018651</u>	<u>002</u>	May 31, 1985
<u>AB</u>		<u>10MG</u>	<u>N018651</u>	<u>003</u>	May 31, 1985

DRONEDARONE HYDROCHLORIDE

TABLET; ORAL

MULTAQ

+ SANOFI AVENTIS US EQ 400MG BASE N022425 001 Jul 01, 2009

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

<u>AP</u>	HOSPIRA	<u>2.5MG/ML</u>	<u>A071981</u>	<u>001</u>	Feb 29, 1988
<u>AP</u>	LUITPOLD	<u>2.5MG/ML</u>	<u>A072123</u>	<u>001</u>	Oct 24, 1988

INAPSINE

<u>AP</u>	+ AKORN INC	<u>2.5MG/ML</u>	<u>N016796</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

3 - 149 (of 428)

DROSPIRENONE; ESTRADIOL

TABLET; ORAL
ANGELIQ

BAYER HLTHCARE	0.25MG;0.5MG	N021355	001	Feb 29, 2012
+	0.5MG;1MG	N021355	002	Sep 28, 2005

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

<u>AB</u> BARR	<u>3MG;0.02MG</u>	<u>A078515</u>	<u>001</u>	Mar 30, 2009
<u>AB</u> WATSON LABS	<u>3MG;0.02MG</u>	<u>A078833</u>	<u>001</u>	Nov 28, 2011
<u>LORYNA</u>				
<u>AB</u> SANDOZ	<u>3MG;0.02MG</u>	<u>A079221</u>	<u>001</u>	Mar 28, 2011
<u>YAZ</u>				
<u>AB</u> + BAYER HLTHCARE	<u>3MG;0.02MG</u>	<u>N021676</u>	<u>001</u>	Mar 16, 2006

TABLET; ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

<u>AB</u> BARR	<u>3MG;0.03MG</u>	<u>A077527</u>	<u>001</u>	May 09, 2008
<u>AB</u> LUPIN LTD	<u>3MG;0.03MG</u>	<u>A201663</u>	<u>001</u>	Dec 18, 2012
<u>AB</u> WATSON LABS	<u>3MG;0.03MG</u>	<u>A090081</u>	<u>001</u>	Sep 07, 2010
<u>SYEDA</u>				
<u>AB</u> SANDOZ	<u>3MG;0.03MG</u>	<u>A090114</u>	<u>001</u>	Mar 28, 2011
<u>YASMIN</u>				
<u>AB</u> + BAYER HLTHCARE	<u>3MG;0.03MG</u>	<u>N021098</u>	<u>001</u>	May 11, 2001

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET; ORAL

BEYAZ

+ BAYER HLTHCARE	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	N022532	001	Sep 24, 2010
SAFYRAL				
BAYER HLTHCARE	3MG,N/A;0.03MG,N/A;0.451MG,0.451MG	N022574	001	Dec 16, 2010

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

CYMBALTA

LILLY	EQ 20MG BASE	N021427	001	Aug 03, 2004
	EQ 30MG BASE	N021427	002	Aug 03, 2004
+	EQ 60MG BASE	N021427	004	Aug 03, 2004

DUTASTERIDE

CAPSULE; ORAL

AVODART

<u>AB</u> + GLAXOSMITHKLINE	<u>0.5MG</u>	<u>N021319</u>	<u>001</u>	Nov 20, 2001
<u>DUTASTERIDE</u>				
<u>AB</u> BARR	<u>0.5MG</u>	<u>A090095</u>	<u>001</u>	Dec 21, 2010

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

JALYN

+ GLAXOSMITHKLINE	0.5MG;0.4MG	N022460	001	Jun 14, 2010

DYPHYLLINE

TABLET; ORAL

LUFYLLIN

MEDA PHARMS	200MG	A084566	001	
+	400MG	A084566	002	

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC

PHOSPHOLINE IODIDE

+ WYETH PHARMS INC	0.125%	N011963	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 150 (of 428)

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

<u>AB</u>	+	FOUGERA PHARMS	<u>1%</u>	<u>A076075</u>	<u>001</u>	Nov 26, 2002
<u>AB</u>		PERRIGO NEW YORK	<u>1%</u>	<u>A076479</u>	<u>001</u>	Jun 23, 2004
<u>AB</u>		PRASCO	<u>1%</u>	<u>A076574</u>	<u>001</u>	Dec 17, 2004
<u>AB</u>		TARO	<u>1%</u>	<u>A076005</u>	<u>001</u>	Nov 26, 2002

EDETATE CALCIUM DISODIUM

INJECTABLE; INJECTION

CALCIUM DISODIUM VERSENATE

+	MEDICIS	200MG/ML	N008922	001	

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON

<u>AP</u>		BIONICHE PHARMA	<u>10MG/ML</u>	<u>A088873</u>	<u>001</u>	Aug 06, 1985

TENSILON

<u>AP</u>	+	VALEANT PHARM INTL	<u>10MG/ML</u>	<u>N007959</u>	<u>001</u>	

TENSILON PRESERVATIVE FREE

<u>AP</u>	+	VALEANT PHARM INTL	<u>10MG/ML</u>	<u>N007959</u>	<u>002</u>	

EFAVIRENZ

CAPSULE; ORAL

SUSTIVA

		BRISTOL MYERS SQUIBB	50MG	N020972	001	Sep 17, 1998

+			200MG	N020972	003	Sep 17, 1998

TABLET; ORAL

SUSTIVA

+		BRISTOL MYERS SQUIBB	600MG	N021360	002	Feb 01, 2002

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

ATRIPLA

+		GILEAD	600MG;200MG;300MG	N021937	001	Jul 12, 2006

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL

VANIQA

+		SKINMEDICA	13.9%	N021145	001	Jul 27, 2000

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

RELPAK

		PFIZER IRELAND	EQ 20MG BASE	N021016	001	Dec 26, 2002

+			EQ 40MG BASE	N021016	002	Dec 26, 2002

ELTROMBOPAG OLAMINE

TABLET; ORAL

PROMACTA

		GLAXOSMITHKLINE	EQ 12.5MG ACID	N022291	004	Oct 20, 2011

			EQ 25MG ACID	N022291	001	Nov 20, 2008

+			EQ 50MG ACID	N022291	002	Nov 20, 2008

			EQ 75MG ACID	N022291	003	Sep 08, 2009

			EQ 100MG ACID	N022291	005	Nov 16, 2012

EMEDASTINE DIFUMARATE

SOLUTION/DROPS; OPHTHALMIC

+		ALCON	0.05%	N020706	001	Dec 29, 1997

PRESCRIPTION DRUG PRODUCT LIST

3 - 151 (of 428)

EMTRICITABINE

CAPSULE; ORAL					
EMTRIVA					
+ GILEAD	200MG	N021500	001	Jul 02, 2003	
SOLUTION; ORAL					
EMTRIVA					
+ GILEAD	10MG/ML	N021896	001	Sep 28, 2005	

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL					
COMPLERA					
+ GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123	001	Aug 10, 2011	

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL					
TRUVADA					
+ GILEAD	200MG;300MG	N021752	001	Aug 02, 2004	

ENALAPRIL MALEATE

TABLET; ORAL					
<u>ENALAPRIL MALEATE</u>					
AB APOTEX	2.5MG	A075178	002	Mar 23, 2001	
AB	5MG	A075178	001	Mar 23, 2001	
AB	10MG	A075178	003	Mar 23, 2001	
AB	20MG	A075178	004	Mar 23, 2001	
AB MYLAN	2.5MG	A075472	001	Aug 22, 2000	
AB	2.5MG	A075480	001	Aug 22, 2000	
AB	5MG	A075472	002	Aug 22, 2000	
AB	5MG	A075480	002	Aug 22, 2000	
AB	10MG	A075472	003	Aug 22, 2000	
AB	10MG	A075480	003	Aug 22, 2000	
AB	20MG	A075472	004	Aug 22, 2000	
AB	20MG	A075480	004	Aug 22, 2000	
AB TARO	2.5MG	A075657	001	Jan 23, 2001	
AB	5MG	A075657	002	Jan 23, 2001	
AB	10MG	A075657	003	Jan 23, 2001	
AB	20MG	A075657	004	Jan 23, 2001	
AB TEVA	2.5MG	A075479	001	Aug 22, 2000	
AB	5MG	A075479	002	Aug 22, 2000	
AB	10MG	A075479	003	Aug 22, 2000	
AB	20MG	A075479	004	Aug 22, 2000	
AB WATSON LABS	2.5MG	A075501	001	Aug 22, 2000	
AB	5MG	A075501	002	Aug 22, 2000	
AB	10MG	A075501	003	Aug 22, 2000	
AB	20MG	A075501	004	Aug 22, 2000	
AB WOCKHARDT USA	2.5MG	A075483	001	Aug 22, 2000	
AB	5MG	A075483	002	Aug 22, 2000	
AB	10MG	A075483	003	Aug 22, 2000	
AB	20MG	A075483	004	Aug 22, 2000	
<u>VASOTEC</u>					
AB VALEANT INTL	2.5MG	N018998	005	Jul 26, 1988	
AB	5MG	N018998	001	Dec 24, 1985	
AB	10MG	N018998	002	Dec 24, 1985	
AB +	20MG	N018998	003	Dec 24, 1985	

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL					
<u>ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE</u>					
AB APOTEX INC	5MG;12.5MG	A076486	001	Oct 27, 2004	
AB	10MG;25MG	A076486	002	Oct 27, 2004	
AB DR REDDYS LABS LTD	5MG;12.5MG	A075909	001	Oct 15, 2001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 152 (of 428)

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>10MG;25MG</u>	<u>A075909</u>	<u>002</u>	Oct 15, 2001
<u>AB</u>	MYLAN	<u>5MG;12.5MG</u>	<u>A075624</u>	<u>001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075624</u>	<u>002</u>	Sep 18, 2001
<u>AB</u>	TARO PHARM INDS	<u>5MG;12.5MG</u>	<u>A075788</u>	<u>001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075788</u>	<u>002</u>	Sep 18, 2001
<u>AB</u>	TEVA	<u>5MG;12.5MG</u>	<u>A075727</u>	<u>001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075727</u>	<u>002</u>	Sep 18, 2001
	<u>VASERETIC</u>				
<u>AB</u>	VALEANT INTL	<u>5MG;12.5MG</u>	<u>N019221</u>	<u>003</u>	Jul 12, 1995
<u>AB</u>	+	<u>10MG;25MG</u>	<u>N019221</u>	<u>001</u>	Oct 31, 1986

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

<u>AP</u>	+	BEDFORD	<u>1.25MG/ML</u>	<u>A075634</u>	<u>001</u>	Aug 22, 2000
<u>AP</u>		HIKMA FARMACEUTICA	<u>1.25MG/ML</u>	<u>A078687</u>	<u>001</u>	Dec 23, 2008
<u>AP</u>	+	HOSPIRA	<u>1.25MG/ML</u>	<u>A075458</u>	<u>001</u>	Aug 22, 2000
<u>AP</u>		TEVA PARENTERAL	<u>1.25MG/ML</u>	<u>A075578</u>	<u>001</u>	Aug 22, 2000

ENFLURANE

LIQUID; INHALATION

ENFLURANE

<u>AN</u>		PIRAMAL CRITICAL	<u>99.9%</u>	<u>A074396</u>	<u>001</u>	Jul 29, 1994
		<u>ETHRANE</u>				
<u>AN</u>	+	BAXTER HLTHCARE	<u>99.9%</u>	<u>N017087</u>	<u>001</u>	

ENFUVIRTIDE

INJECTABLE; SUBCUTANEOUS

FUZEON

	+	ROCHE	90MG/VIAL	N021481	001	Mar 13, 2003

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

<u>AB</u>		SANDOZ INC	<u>300MG/3ML (100MG/ML)</u>	<u>A078660</u>	<u>001</u>	Nov 28, 2011
		<u>LOVENOX</u>				
<u>AB</u>		SANOFI AVENTIS US	<u>300MG/3ML (100MG/ML)</u>	<u>N020164</u>	<u>009</u>	Jan 23, 2003

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

<u>AP</u>		AMPHASTAR PHARM	<u>30MG/0.3ML (100MG/ML)</u>	<u>A076684</u>	<u>001</u>	Sep 19, 2011
<u>AP</u>			<u>40MG/0.4ML (100MG/ML)</u>	<u>A076684</u>	<u>002</u>	Sep 19, 2011
<u>AP</u>			<u>60MG/0.6ML (100MG/ML)</u>	<u>A076684</u>	<u>003</u>	Sep 19, 2011
<u>AP</u>			<u>80MG/0.8ML (100MG/ML)</u>	<u>A076684</u>	<u>004</u>	Sep 19, 2011
<u>AP</u>			<u>100MG/ML (100MG/ML)</u>	<u>A076684</u>	<u>005</u>	Sep 19, 2011
<u>AP</u>			<u>120MG/0.8ML (150MG/ML)</u>	<u>A076684</u>	<u>006</u>	Sep 19, 2011
<u>AP</u>			<u>150MG/ML (150MG/ML)</u>	<u>A076684</u>	<u>007</u>	Sep 19, 2011
<u>AP</u>		SANDOZ	<u>30MG/0.3ML (100MG/ML)</u>	<u>A077857</u>	<u>002</u>	Jul 23, 2010
<u>AP</u>			<u>40MG/0.4ML (100MG/ML)</u>	<u>A077857</u>	<u>003</u>	Jul 23, 2010
<u>AP</u>			<u>60MG/0.6ML (100MG/ML)</u>	<u>A077857</u>	<u>004</u>	Jul 23, 2010
<u>AP</u>			<u>80MG/0.8ML (100MG/ML)</u>	<u>A077857</u>	<u>005</u>	Jul 23, 2010
<u>AP</u>			<u>100MG/ML (100MG/ML)</u>	<u>A077857</u>	<u>001</u>	Jul 23, 2010
<u>AP</u>			<u>120MG/0.8ML (150MG/ML)</u>	<u>A077857</u>	<u>006</u>	Jul 23, 2010
<u>AP</u>			<u>150MG/ML (150MG/ML)</u>	<u>A077857</u>	<u>007</u>	Jul 23, 2010
		<u>LOVENOX (PRESERVATIVE FREE)</u>				
<u>AP</u>		SANOFI AVENTIS US	<u>30MG/0.3ML (100MG/ML)</u>	<u>N020164</u>	<u>001</u>	Mar 29, 1993
<u>AP</u>			<u>40MG/0.4ML (100MG/ML)</u>	<u>N020164</u>	<u>002</u>	Jan 30, 1998
<u>AP</u>			<u>60MG/0.6ML (100MG/ML)</u>	<u>N020164</u>	<u>003</u>	Mar 27, 1998
<u>AP</u>			<u>80MG/0.8ML (100MG/ML)</u>	<u>N020164</u>	<u>004</u>	Mar 27, 1998

PRESCRIPTION DRUG PRODUCT LIST

3 - 153 (of 428)

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX (PRESERVATIVE FREE)

<u>AP</u>	+	SANOFI AVENTIS US	<u>100MG/ML (100MG/ML)</u>	<u>N020164</u>	<u>005</u>	Mar 27, 1998
<u>AP</u>			<u>120MG/0.8ML (150MG/ML)</u>	<u>N020164</u>	<u>007</u>	Jun 02, 2000
<u>AP</u>			<u>150MG/ML (150MG/ML)</u>	<u>N020164</u>	<u>008</u>	Jun 02, 2000

ENTACAPONE

TABLET; ORAL

COMTAN

<u>AB</u>	+	ORION PHARMA	<u>200MG</u>	<u>N020796</u>	<u>001</u>	Oct 19, 1999

ENTACAPONE

<u>AB</u>		SUN PHARMA GLOBAL	<u>200MG</u>	<u>A090690</u>	<u>001</u>	Jul 16, 2012
<u>AB</u>		WOCKHARDT LTD	<u>200MG</u>	<u>A078941</u>	<u>001</u>	Aug 16, 2012

ENTECAVIR

SOLUTION; ORAL

BARACLUDE

	+	BRISTOL MYERS SQUIBB	0.05MG/ML	N021798	001	Mar 29, 2005

TABLET; ORAL

BARACLUDE

		BRISTOL MYERS SQUIBB	0.5MG	N021797	001	Mar 29, 2005
	+		1MG	N021797	002	Mar 29, 2005

ENZALUTAMIDE

CAPSULE; ORAL

XTANDI

	+	ASTELLAS	40MG	N203415	001	Aug 31, 2012

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ELESTAT

<u>AT</u>	+	ALLERGAN	<u>0.05%</u>	<u>N021565</u>	<u>001</u>	Oct 16, 2003

EPINASTINE HYDROCHLORIDE

<u>AT</u>		APOTEX	<u>0.05%</u>	<u>A090919</u>	<u>001</u>	Oct 31, 2011
<u>AT</u>		CYPRESS PHARM	<u>0.05%</u>	<u>A090870</u>	<u>001</u>	Mar 14, 2011
<u>AT</u>		LUITPOLD	<u>0.05%</u>	<u>A090951</u>	<u>001</u>	Oct 31, 2011
<u>AT</u>		SUN PHARM INDS	<u>0.05%</u>	<u>A091626</u>	<u>001</u>	Oct 31, 2011

EPINEPHRINE

INJECTABLE; IM-SC

ADRENALIN

BX	+	AMEDRA PHARMS	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009
BX	+		EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009

AUVI-Q

BX	+	SANOFI AVENTIS US	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012
BX			EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012

TWINJECT 0.15

BX	+	AMEDRA PHARMS	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004

TWINJECT 0.3

BX	+	AMEDRA PHARMS	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003

INJECTABLE; INTRAMUSCULAR

EPIPEN

BX	+	MERIDIAN MEDCL TECHN	0.3MG/DELIVERY	N019430	001	Dec 22, 1987

EPIPEN JR.

BX	+	MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N019430	002	Dec 22, 1987

INJECTABLE; INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS

ADRENALIN

	+	JHP PHARMS	1MG/ML	N204200	001	Dec 07, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 154 (of 428)

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTION
LIGNOSPAN FORTE

+ DEPROCO EQ 0.02MG BASE/ML;2% A088389 001 Jan 22, 1985

LIGNOSPAN STANDARD
+ DEPROCO EQ 0.01MG BASE/ML;2% A088390 001 Jan 22, 1985EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE DENTAL

AP + DENTSPLY PHARM 0.005MG/ML;4% N021383 001

PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

AP SEPTODONT INC 0.005MG/ML;4% A078959 001 Aug 30, 2011

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

AP EASTMAN KODAK 0.01MG/ML;2% A040057 002 Feb 26, 1993

AP 0.02MG/ML;2% A040057 001 Feb 26, 1993

AP HOSPIRA 0.005MG/ML;0.5% A089635 001 Jun 21, 1988

AP 0.005MG/ML;1.5% A088571 001 Sep 13, 1985

AP 0.005MG/ML;1.5% A089645 001 Jun 21, 1988

AP 0.005MG/ML;2% A089651 001 Jun 21, 1988

AP 0.01MG/ML;1% A089644 001 Jun 21, 1988

AP 0.01MG/ML;2% A078772 001 May 12, 2008

AP 0.01MG/ML;2% A089646 001 Jun 21, 1988

AP 0.02MG/ML;2% A078772 002 May 12, 2008

OCTOCAINE

AP + SEPTODONT 0.01MG/ML;2% A084048 001

AP + 0.02MG/ML;2% A084048 002

XYLOCAINE W/ EPINEPHRINE

AP + FRESENIUS KABI USA 0.005MG/ML;0.5% N006488 012

AP + 0.005MG/ML;1% N006488 018 Nov 13, 1986

AP + 0.005MG/ML;1.5% N006488 017

AP + 0.005MG/ML;2% N006488 019 Nov 13, 1986

AP + 0.01MG/ML;1% N006488 004

AP + 0.02MG/ML;2% N006488 005

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ELLEENCE

AP PFIZER INC 50MG/25ML (2MG/ML) N050778 002 Sep 15, 1999

AP + 200MG/100ML (2MG/ML) N050778 001 Sep 15, 1999

EPIRUBICIN HYDROCHLORIDE

AP ACTAVIS TOTOWA 10MG/5ML (2MG/ML) A065445 001 Sep 18, 2008

AP 50MG/25ML (2MG/ML) A065445 002 Sep 18, 2008

AP 200MG/100ML (2MG/ML) A065445 003 Sep 18, 2008

AP AKORN INC 50MG/25ML (2MG/ML) A090163 001 Jun 24, 2009

AP BEDFORD 200MG/100ML (2MG/ML) A065289 002 Jun 27, 2007

AP 50MG/25ML (2MG/ML) A065289 001 Jun 27, 2007

AP BIONICHE PHARMA USA 50MG/25ML (2MG/ML) A065371 001 Nov 28, 2007

AP 200MG/100ML (2MG/ML) A065371 002 Nov 28, 2007

AP CIPLA LTD 50MG/25ML (2MG/ML) A065361 001 Oct 22, 2007

AP 200MG/100ML (2MG/ML) A065361 002 Oct 22, 2007

AP EBWE PHARMA 50MG/25ML (2MG/ML) A065339 001 Dec 22, 2009

AP 200MG/100ML (2MG/ML) A065339 002 Dec 22, 2009

AP FRESENIUS KABI ONCOL 200MG/100ML (2MG/ML) A065411 001 Aug 20, 2007

AP 50MG/25ML (2MG/ML) A065411 002 Aug 20, 2007

AP FRESENIUS KABI USA 150MG/75ML (2MG/ML) A065408 003 Oct 15, 2007

AP 50MG/25ML (2MG/ML) A065408 002 Oct 15, 2007

AP 10MG/5ML (2MG/ML) A065408 001 Oct 15, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 155 (of 428)

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

<u>AP</u>	FRESENIUS KABI USA	<u>200MG/100ML (2MG/ML)</u>	<u>A065408</u>	<u>004</u>	Oct 15, 2007
<u>AP</u>	HISUN PHARM HANGZHOU	<u>50MG/25ML (2MG/ML)</u>	<u>A090075</u>	<u>001</u>	Mar 25, 2010
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A090075</u>	<u>002</u>	Mar 25, 2010
<u>AP</u>	HOSPIRA	<u>200MG/100ML (2MG/ML)</u>	<u>A065343</u>	<u>004</u>	Apr 19, 2007
<u>AP</u>		<u>50MG/25ML (2MG/ML)</u>	<u>A065343</u>	<u>002</u>	Apr 19, 2007
<u>AP</u>		<u>10MG/5ML (2MG/ML)</u>	<u>A065343</u>	<u>001</u>	Apr 19, 2007
<u>AP</u>		<u>150MG/75ML (2MG/ML)</u>	<u>A065343</u>	<u>003</u>	Apr 19, 2007
<u>AP</u>	MUSTAFA NEVSAT	<u>200MG/100ML (2MG/ML)</u>	<u>A090266</u>	<u>002</u>	Apr 15, 2011
<u>AP</u>		<u>50MG/25ML (2MG/ML)</u>	<u>A090266</u>	<u>001</u>	Apr 15, 2011
<u>AP</u>	ONCO THERAPIES LTD	<u>50MG/25ML (2MG/ML)</u>	<u>A091599</u>	<u>001</u>	Mar 12, 2012
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A091599</u>	<u>002</u>	Mar 12, 2012
<u>AP</u>	TEVA PARENTERAL	<u>50MG/25ML (2MG/ML)</u>	<u>A065331</u>	<u>001</u>	Aug 09, 2007
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A065331</u>	<u>002</u>	Aug 09, 2007

INJECTABLE; IV (INFUSION)

+	HOSPIRA	50MG/VIAL	N050807	001	Sep 15, 2006

EPLERENONE

TABLET; ORAL

EPLERENONE

<u>AB</u>	APOTEX	<u>25MG</u>	<u>A078482</u>	<u>001</u>	Jul 30, 2008
<u>AB</u>		<u>50MG</u>	<u>A078482</u>	<u>002</u>	Jul 30, 2008
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A078510</u>	<u>001</u>	Aug 01, 2008
<u>AB</u>		<u>50MG</u>	<u>A078510</u>	<u>002</u>	Aug 01, 2008
	<u>INSPIRA</u>				
<u>AB</u>	GD SEARLE LLC	<u>25MG</u>	<u>N021437</u>	<u>001</u>	Sep 27, 2002
<u>AB</u>	+	<u>50MG</u>	<u>N021437</u>	<u>002</u>	Sep 27, 2002

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUM

<u>AP</u>	TEVA PARENTERAL	<u>EQ 0.5MG BASE/VIAL</u>	<u>A078396</u>	<u>001</u>	Apr 23, 2008
<u>AP</u>		<u>EQ 1.5MG BASE/VIAL</u>	<u>A078396</u>	<u>002</u>	Apr 23, 2008
	<u>FLOLAN</u>				
<u>AP</u>	+ GLAXOSMITHKLINE LLC	<u>EQ 0.5MG BASE/VIAL</u>	<u>N020444</u>	<u>001</u>	Sep 20, 1995
<u>AP</u>	+	<u>EQ 1.5MG BASE/VIAL</u>	<u>N020444</u>	<u>002</u>	Sep 20, 1995
	VELETRI				
	ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012
	+	EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008

EPROSARTAN MESYLATE

TABLET; ORAL

EPROSARTAN MESYLATE

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 400MG BASE</u>	<u>A202012</u>	<u>001</u>	Nov 16, 2011
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A202012</u>	<u>002</u>	Nov 16, 2011
	<u>TEVETEN</u>				
<u>AB</u>	ABBVIE	<u>EQ 400MG BASE</u>	<u>N020738</u>	<u>005</u>	Dec 22, 1997
<u>AB</u>	+	<u>EQ 600MG BASE</u>	<u>N020738</u>	<u>006</u>	May 27, 1999

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEVETEN HCT

ABBVIE	600MG;12.5MG	N021268	001	Nov 01, 2001
+	600MG;25MG	N021268	002	Nov 01, 2001

EPTIFIBATIDE

INJECTABLE; INJECTION

INTEGRILIN

+	SCHERING	2MG/ML	N020718	001	May 18, 1998

PRESCRIPTION DRUG PRODUCT LIST

3 - 156 (of 428)

EPTIFIBATIDE

INJECTABLE; INJECTION
INTEGRILIN
+ SCHERING

75MG/100ML

N020718 002 May 18, 1998

ERGOCALCIFEROL

CAPSULE; ORAL

DRISDOL

AA + SANOFI AVENTIS US

50,000 IU

N003444 001

ERGOCALCIFEROL

AA ORIT LABS LLC

50,000 IU

A040833 001 May 20, 2009

AA SIGMAPHARM LABS LLC

50,000 IU

A091004 001 Jul 14, 2010

AA STRIDES ARCOLAB LTD

50,000 IU

A090455 001 Aug 03, 2010

AA SUN PHARM INDS INC

50,000 IU

A040865 001 Dec 29, 2009

VITAMIN D

AA BANNER PHARMACAPS

50,000 IU

A080704 001

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES

AB MUTUAL PHARM

1MG

A081113 001 Oct 31, 1991

HYDERGINE

AB + NOVARTIS

1MG

N017993 001

TABLET; SUBLINGUAL

ERGOLOID MESYLATES

WATSON LABS

0.5MG

A087233 001

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

ERGOMAR

+ ROSEDALE THERAPEUTIC 2MG

A087693 001 Feb 24, 1983

ERIBULIN MESYLATE

SOLUTION; INTRAVENOUS

HALAVEN

+ EISAI INC 1MG/2ML (0.5MG/ML)

N201532 001 Nov 15, 2010

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

TARCEVA

OSI PHARMS

EQ 25MG BASE

N021743 001 Nov 18, 2004

EQ 100MG BASE

N021743 002 Nov 18, 2004

+ EQ 150MG BASE

N021743 003 Nov 18, 2004

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, IV (INFUSION)

+ MERCK

EQ 1GM BASE/VIAL

N021337 001 Nov 21, 2001

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

AB + HOSPIRA

250MG

N050536 001

AB WARNER CHILCOTT LLC

250MG

A062338 001

ERYTHROMYCIN

AB ARBOR PHARMS INC

250MG

A062746 001 Dec 22, 1986

GEL; TOPICAL

ERYGEL

AT + MERZ PHARMS

2%

N050617 001 Oct 21, 1987

ERYTHROMYCIN

AT FOUGERA PHARMS

2%

A064184 001 Sep 30, 1997

AT PERRIGO

2%

A063211 001 Jan 29, 1993

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 157 (of 428)

ERYTHROMYCIN

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

<u>AT</u>	AKORN	<u>0.5%</u>	<u>A064030</u>	<u>001</u>	Jul 18, 1996
<u>AT</u>	BAUSCH AND LOMB	<u>0.5%</u>	<u>A064067</u>	<u>001</u>	Jul 29, 1994
<u>AT</u>	+ FERA PHARMS	<u>0.5%</u>	<u>A062447</u>	<u>001</u>	Sep 26, 1983

OINTMENT; TOPICAL

AKNE-MYCIN

	+ DOW PHARM SCIENCES	2%	N050584	001	Jan 10, 1985

SOLUTION; TOPICAL

C-SOLVE-2

<u>AT</u>	FOUGERA PHARMS	<u>2%</u>	<u>A062468</u>	<u>001</u>	Jul 03, 1985

ERYTHRA-DERM

<u>AT</u>	PADDOCK LLC	<u>2%</u>	<u>A062687</u>	<u>001</u>	Feb 05, 1988

ERYTHROMYCIN

<u>AT</u>	+ FOUGERA PHARMS	<u>2%</u>	<u>A064187</u>	<u>001</u>	Sep 30, 1997

<u>AT</u>	PERRIGO NEW YORK	<u>2%</u>	<u>A063038</u>	<u>001</u>	Jan 11, 1991

<u>AT</u>	WOCKHARDT	<u>2%</u>	<u>A062825</u>	<u>001</u>	Oct 23, 1987

ERYTHRO-STATIN

<u>AT</u>	HI TECH PHARMA	<u>2%</u>	<u>A064101</u>	<u>001</u>	Oct 22, 1996

SWAB; TOPICAL

ERYTHROMYCIN

<u>AT</u>	+ FOUGERA PHARMS	<u>2%</u>	<u>A065320</u>	<u>001</u>	Jul 25, 2006

<u>AT</u>	+ PERRIGO	<u>2%</u>	<u>A064126</u>	<u>001</u>	Jul 03, 1996

<u>AT</u>	VERSAPHARM	<u>2%</u>	<u>A090215</u>	<u>001</u>	May 12, 2010

TABLET; ORAL

ERYTHROMYCIN

	ARBOR PHARMS INC	250MG	A061621	001	
	+	500MG	A061621	002	

TABLET, COATED PARTICLES; ORAL

PCE

	ARBOR PHARMS INC	333MG	N050611	001	Sep 09, 1986
	+	500MG	N050611	002	Aug 22, 1990

TABLET, DELAYED RELEASE; ORAL

ERY-TAB

	+ ARBOR PHARMS INC	250MG	A062298	001	
	+	333MG	A062298	003	Mar 29, 1982
	+	500MG	A062298	002	

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

E.E.S.

<u>AB</u>	ARBOR PHARMS INC	<u>EQ 200MG BASE/5ML</u>	<u>N050207</u>	<u>001</u>	

ERYPED

<u>AB</u>	ARBOR PHARMS INC	<u>EQ 200MG BASE/5ML</u>	<u>N050207</u>	<u>003</u>	Mar 30, 1987

ERYPED

	+ ARBOR PHARMS INC	EQ 400MG BASE/5ML	N050207	002	

SUSPENSION; ORAL

E.E.S. 200

<u>AB</u>	ARBOR PHARMS INC	<u>EQ 200MG BASE/5ML</u>	<u>A061639</u>	<u>001</u>	

E.E.S. 400

<u>AB</u>	+ ARBOR PHARMS INC	<u>EQ 400MG BASE/5ML</u>	<u>A061639</u>	<u>002</u>	

PEDIAMYCIN

<u>AB</u>	ARBOR PHARMS INC	<u>EQ 200MG BASE/5ML</u>	<u>A062304</u>	<u>001</u>	

PEDIAMYCIN 400

<u>AB</u>	ARBOR PHARMS INC	<u>EQ 400MG BASE/5ML</u>	<u>A062304</u>	<u>002</u>	

TABLET; ORAL

E.E.S. 400

BX	+ ARBOR PHARMS INC	EQ 400MG BASE	A061905	002	Aug 12, 1982

ERYTHROMYCIN ETHYLSUCCINATE

BX	+ ARBOR PHARMS INC	EQ 400MG BASE	A061904	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 158 (of 428)

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

+ BARR EQ 200MG BASE/5ML;EQ 600MG BASE/5ML A062759 001 May 20, 1988

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

AP HOSPIRA EQ 500MG BASE/VIAL A062638 001 Oct 31, 1986

AP + EQ 500MG BASE/VIAL N050609 001 Sep 24, 1986

AP + EQ 1GM BASE/VIAL A062638 002 Oct 31, 1986

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROCIN STEARATE

+ ARBOR PHARMS INC EQ 250MG BASE A060359 001

ESCITALOPRAM OXALATE

SOLUTION; ORAL

ESCITALOPRAM OXALATE

AA AMNEAL PHARMS EQ 5MG BASE/5ML A202227 001 Mar 14, 2012

AA AUROBINDO PHARMA LTD EQ 5MG BASE/5ML A079062 001 Apr 02, 2012

AA HETERO LABS LTD III EQ 5MG BASE/5ML A202221 001 Jun 12, 2012

AA TARO EQ 5MG BASE/5ML A079121 001 May 03, 2012

LEXAPRO

AA + FOREST LABS EQ 5MG BASE/5ML N021365 001 Nov 27, 2002

TABLET; ORAL

ESCITALOPRAM OXALATE

AB ACCORD HLTHCARE EQ 5MG BASE A202389 001 Sep 11, 2012

AB EQ 10MG BASE A202389 002 Sep 11, 2012

AB EQ 20MG BASE A202389 003 Sep 11, 2012

AB APOTEX INC EQ 5MG BASE A078777 001 Sep 11, 2012

AB EQ 10MG BASE A078777 002 Sep 11, 2012

AB EQ 20MG BASE A078777 003 Sep 11, 2012

AB AUROBINDO PHARMA LTD EQ 5MG BASE A090432 001 Sep 11, 2012

AB EQ 10MG BASE A090432 002 Sep 11, 2012

AB EQ 20MG BASE A090432 003 Sep 11, 2012

AB HIKMA PHARMS EQ 5MG BASE A078766 001 Sep 11, 2012

AB EQ 10MG BASE A078766 002 Sep 11, 2012

AB EQ 20MG BASE A078766 003 Sep 11, 2012

AB INVAGEN PHARMS EQ 5MG BASE A078604 001 Sep 11, 2012

AB EQ 10MG BASE A078604 002 Sep 11, 2012

AB EQ 20MG BASE A078604 003 Sep 11, 2012

AB IVAX SUB TEVA PHARMS EQ 5MG BASE A076765 001 Mar 14, 2012

AB EQ 10MG BASE A076765 002 Mar 14, 2012

AB EQ 20MG BASE A076765 003 Mar 14, 2012

AB JUBILANT ORGANOSYS EQ 5MG BASE A202280 001 Sep 12, 2012

AB EQ 10MG BASE A202280 002 Sep 12, 2012

AB EQ 20MG BASE A202280 003 Sep 12, 2012

AB LUPIN LTD EQ 5MG BASE A078169 001 Sep 11, 2012

AB EQ 10MG BASE A078169 002 Sep 11, 2012

AB EQ 20MG BASE A078169 003 Sep 11, 2012

AB MACLEODS PHARMS LTD EQ 5MG BASE A202210 001 Sep 11, 2012

AB EQ 10MG BASE A202210 002 Sep 11, 2012

AB EQ 20MG BASE A202210 003 Sep 11, 2012

AB STI PHARMA LLC EQ 5MG BASE A077512 001 Sep 12, 2012

AB EQ 10MG BASE A077512 002 Sep 12, 2012

AB EQ 20MG BASE A077512 003 Sep 12, 2012

AB TORRENT PHARMS LTD EQ 5MG BASE A090939 001 Sep 11, 2012

AB EQ 10MG BASE A090939 002 Sep 11, 2012

AB EQ 20MG BASE A090939 003 Sep 11, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 159 (of 428)

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 5MG BASE</u>	<u>A077734</u>	<u>001</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077734</u>	<u>002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077734</u>	<u>003</u>	Sep 11, 2012
<u>LEXAPRO</u>					
<u>AB</u>	FOREST LABS	<u>EQ 5MG BASE</u>	<u>N021323</u>	<u>001</u>	Aug 14, 2002
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>N021323</u>	<u>002</u>	Aug 14, 2002
<u>AB</u>	+	<u>EQ 20MG BASE</u>	<u>N021323</u>	<u>003</u>	Aug 14, 2002

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

<u>AP</u>	+	BAXTER HLTHCARE	<u>10MG/ML</u>	<u>N019386</u>	<u>006</u>	Feb 25, 2003
<u>ESMOLOL HYDROCHLORIDE</u>						
<u>AP</u>		BEDFORD LABS	<u>10MG/ML</u>	<u>A076323</u>	<u>001</u>	Aug 10, 2004
<u>AP</u>		BIONICHE PHARMA	<u>10MG/ML</u>	<u>A076474</u>	<u>001</u>	May 02, 2005
<u>AP</u>		FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A076573</u>	<u>001</u>	May 02, 2005
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER						
	+	BAXTER HLTHCARE	2GM/100ML	N019386	005	Jan 27, 2003
BREVIBLOC IN PLASTIC CONTAINER						
	+	BAXTER HLTHCARE	1GM/100ML	N019386	004	Feb 16, 2001

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

NEXIUM

		ASTRAZENECA	EQ 20MG BASE	N021153	001	Feb 20, 2001
	+		EQ 40MG BASE	N021153	002	Feb 20, 2001
FOR SUSPENSION, DELAYED RELEASE; ORAL						
<u>NEXIUM</u>						
		ASTRAZENECA	EQ 2.5MG BASE/PACKET	N021957	003	Dec 15, 2011
			EQ 5MG BASE/PACKET	N021957	004	Dec 15, 2011
			EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008
			EQ 20MG BASE/PACKET	N021957	001	Oct 20, 2006
	+		EQ 40MG BASE/PACKET	N021957	002	Oct 20, 2006

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL

VIMOVO

		ASTRAZENECA LP	EQ 20MG BASE;375MG	N022511	002	Apr 30, 2010
	+		EQ 20MG BASE;500MG	N022511	001	Apr 30, 2010

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

NEXIUM IV

	+	ASTRAZENECA	EQ 20MG BASE/VIAL	N021689	001	Mar 31, 2005
	+		EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005

ESTAZOLAM

TABLET; ORAL

ESTAZOLAM

<u>AB</u>	PAR PHARM	<u>1MG</u>	<u>A074826</u>	<u>001</u>	Jul 03, 1997
<u>AB</u>		<u>2MG</u>	<u>A074826</u>	<u>002</u>	Jul 03, 1997
<u>AB</u>	TEVA	<u>1MG</u>	<u>A074921</u>	<u>001</u>	Jul 10, 1997
<u>AB</u>	+	<u>2MG</u>	<u>A074921</u>	<u>002</u>	Jul 10, 1997
<u>AB</u>	WATSON LABS	<u>1MG</u>	<u>A074818</u>	<u>001</u>	Aug 19, 1997
<u>AB</u>		<u>2MG</u>	<u>A074818</u>	<u>002</u>	Aug 19, 1997

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 160 (of 428)

ESTRADIOL

CREAM; VAGINAL					
ESTRACE					
	+ WARNER CHILCOTT US	0.01%	A086069	001	Jan 31, 1984
FILM, EXTENDED RELEASE; TRANSDERMAL					
<u>CLIMARA</u>					
<u>AB</u>	BAYER HLTHCARE	<u>0.0375MG/24HR</u>	<u>N020375</u>	<u>005</u>	May 27, 2003
<u>AB</u>		<u>0.06MG/24HR</u>	<u>N020375</u>	<u>006</u>	May 27, 2003
<u>ESTRADIOL</u>					
<u>AB</u>	MYLAN TECHNOLOGIES	<u>0.0375MG/24HR</u>	<u>A075182</u>	<u>004</u>	Jul 20, 2006
<u>AB</u>		<u>0.06MG/24HR</u>	<u>A075182</u>	<u>005</u>	Jul 20, 2006
<u>VIVELLE</u>					
<u>AB1</u>	NOVARTIS	<u>0.05MG/24HR</u>	<u>N020323</u>	<u>002</u>	Oct 28, 1994
<u>AB1</u>		<u>0.1MG/24HR</u>	<u>N020323</u>	<u>004</u>	Oct 28, 1994
<u>VIVELLE-DOT</u>					
<u>AB1</u>	NOVARTIS	<u>0.05MG/24HR</u>	<u>N020538</u>	<u>006</u>	Jan 08, 1999
<u>AB1</u> +		<u>0.1MG/24HR</u>	<u>N020538</u>	<u>008</u>	Jan 08, 1999
<u>CLIMARA</u>					
<u>AB2</u>	BAYER HLTHCARE	<u>0.025MG/24HR</u>	<u>N020375</u>	<u>004</u>	Mar 05, 1999
<u>AB2</u>		<u>0.05MG/24HR</u>	<u>N020375</u>	<u>001</u>	Dec 22, 1994
<u>AB2</u>		<u>0.075MG/24HR</u>	<u>N020375</u>	<u>003</u>	Mar 23, 1998
<u>AB2</u> +		<u>0.1MG/24HR</u>	<u>N020375</u>	<u>002</u>	Dec 22, 1994
<u>ESTRADIOL</u>					
<u>AB2</u>	MYLAN TECHNOLOGIES	<u>0.025MG/24HR</u>	<u>A075182</u>	<u>003</u>	Jan 26, 2005
<u>AB2</u>		<u>0.05MG/24HR</u>	<u>A075182</u>	<u>006</u>	Feb 24, 2000
<u>AB2</u>		<u>0.075MG/24HR</u>	<u>A075182</u>	<u>002</u>	Jan 26, 2005
<u>AB2</u>		<u>0.1MG/24HR</u>	<u>A075182</u>	<u>001</u>	Feb 24, 2000
ALORA					
BX	WATSON LABS	0.025MG/24HR	N020655	004	Apr 05, 2002
BX		0.05MG/24HR	N020655	001	Dec 20, 1996
BX		0.075MG/24HR	N020655	002	Dec 20, 1996
BX		0.1MG/24HR	N020655	003	Dec 20, 1996
ESTRADERM					
BX	NOVARTIS	0.05MG/24HR	N019081	002	Sep 10, 1986
BX	+	0.1MG/24HR	N019081	003	Sep 10, 1986
<u>VIVELLE-DOT</u>					
BX	NOVARTIS	0.025MG/24HR	N020538	009	May 03, 2002
BX		0.0375MG/24HR	N020538	005	Jan 08, 1999
BX		0.075MG/24HR	N020538	007	Jan 08, 1999
MENOSTAR					
	+ BAYER HLTHCARE	0.014MG/24HR	N021674	001	Jun 08, 2004
MINIVELLE					
	NOVEN	0.0375MG/24HR	N203752	001	Oct 29, 2012
		0.05MG/24HR	N203752	003	Oct 29, 2012
		0.075MG/24HR	N203752	002	Oct 29, 2012
	+	0.1MG/24HR	N203752	004	Oct 29, 2012
GEL; TRANSDERMAL					
DIVIGEL					
	UPSHER SMITH	0.1% (0.5GM/PACKET)	N022038	002	Jun 04, 2007
	+	0.1% (1GM/PACKET)	N022038	003	Jun 04, 2007
		0.1% (0.25GM/PACKET)	N022038	001	Jun 04, 2007
GEL, METERED; TRANSDERMAL					
ELESTRIN					
	+ MEDA PHARMS	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006
ESTROGEL					
	+ ASCEND	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004
INSERT, EXTENDED RELEASE; VAGINAL					
ESTRING					
	+ PHARMACIA AND UPJOHN	0.0075MG/24HR	N020472	001	Apr 26, 1996
SPRAY; TRANSDERMAL					
EVAMIST					
	+ KV PHARM	1.53MG/SPRAY	N022014	001	Jul 27, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 161 (of 428)

ESTRADIOL

TABLET; ORAL

ESTRADIOL

<u>AB</u>	BARR LABS INC	<u>0.5MG</u>	<u>A040197</u>	<u>001</u>	Oct 22, 1997
<u>AB</u>		<u>1MG</u>	<u>A040197</u>	<u>002</u>	Oct 22, 1997
<u>AB</u>	+	<u>2MG</u>	<u>A040197</u>	<u>003</u>	Oct 22, 1997
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A040326</u>	<u>001</u>	Apr 21, 1999
<u>AB</u>		<u>1MG</u>	<u>A040326</u>	<u>002</u>	Apr 21, 1999
<u>AB</u>		<u>2MG</u>	<u>A040326</u>	<u>003</u>	Apr 21, 1999
<u>AB</u>	USL PHARMA	<u>0.5MG</u>	<u>A040297</u>	<u>001</u>	Apr 17, 2002
<u>AB</u>		<u>1MG</u>	<u>A040297</u>	<u>002</u>	Apr 17, 2002
<u>AB</u>		<u>2MG</u>	<u>A040297</u>	<u>003</u>	Apr 17, 2002
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A040114</u>	<u>003</u>	Mar 14, 1996
<u>AB</u>		<u>1MG</u>	<u>A040114</u>	<u>001</u>	Mar 14, 1996
<u>AB</u>		<u>2MG</u>	<u>A040114</u>	<u>002</u>	Mar 14, 1996

TABLET; VAGINAL

VAGIFEM

+	NOVO NORDISK INC	10MCG	N020908	002	Nov 25, 2009

ESTRADIOL ACETATEINSERT, EXTENDED RELEASE; VAGINAL
FEMRING

	WARNER IRELAND	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003
+		EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003

TABLET; ORAL

FEMTRACE

	WARNER CHILCOTT LLC	0.45MG	N021633	001	Aug 20, 2004
		0.9MG	N021633	002	Aug 20, 2004
+		1.8MG	N021633	003	Aug 20, 2004

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

DEPO-ESTRADIOL

<u>AO</u>	+	PHARMACIA AND UPJOHN	<u>5MG/ML</u>	<u>A085470</u>	<u>003</u>
<u>AO</u>		<u>ESTRADIOL CYPIONATE</u>			
<u>AO</u>		WATSON LABS	<u>5MG/ML</u>	<u>A085620</u>	<u>001</u>

ESTRADIOL HEMIHYDRATE

EMULSION; TOPICAL

ESTRASORB

+	MEDICIS	0.25%	N021371	001	Oct 09, 2003

ESTRADIOL VALERATE

INJECTABLE; INJECTION

DELESTROGEN

<u>AO</u>	+	JHP PHARMS	<u>10MG/ML</u>	<u>N009402</u>	<u>002</u>
<u>AO</u>	+		<u>20MG/ML</u>	<u>N009402</u>	<u>004</u>
<u>AO</u>	+		<u>40MG/ML</u>	<u>N009402</u>	<u>003</u>

ESTRADIOL VALERATE

<u>AO</u>		LUITPOLD	<u>20MG/ML</u>	<u>A090920</u>	<u>001</u>	Jan 19, 2010
<u>AO</u>			<u>40MG/ML</u>	<u>A090920</u>	<u>002</u>	Jan 19, 2010
<u>AO</u>		SANDOZ	<u>10MG/ML</u>	<u>A040628</u>	<u>001</u>	Oct 04, 2007
<u>AO</u>			<u>20MG/ML</u>	<u>A040628</u>	<u>002</u>	Oct 04, 2007
<u>AO</u>			<u>40MG/ML</u>	<u>A040628</u>	<u>003</u>	Oct 04, 2007
<u>AO</u>		WATSON LABS	<u>20MG/ML</u>	<u>A083547</u>	<u>001</u>	
<u>AO</u>			<u>40MG/ML</u>	<u>A083714</u>	<u>001</u>	

ESTRADIOL; LEVONORGESTRELFILM, EXTENDED RELEASE; TRANSDERMAL
CLIMARA PRO

+	BAYER HLTHCARE	0.045MG/24HR;0.015MG/24HR	N021258	001	Nov 21, 2003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 162 (of 428)

ESTRADIOL; NORETHINDRONE ACETATEFILM, EXTENDED RELEASE; TRANSDERMAL
COMBIPATCH

NOVARTIS	0.05MG/24HR;0.14MG/24HR	N020870	001	Aug 07, 1998
+	0.05MG/24HR;0.25MG/24HR	N020870	002	Aug 07, 1998

TABLET; ORAL

ACTIVELLA

<u>AB</u>	NOVO NORDISK INC	<u>0.5MG;0.1MG</u>	<u>N020907</u>	<u>002</u>	Dec 28, 2006
<u>AB</u>	+	<u>1MG;0.5MG</u>	<u>N020907</u>	<u>001</u>	Nov 18, 1998

ESTRADIOL AND NORETHINDRONE ACETATE

<u>AB</u>	BARR	<u>1MG;0.5MG</u>	<u>A079193</u>	<u>001</u>	May 11, 2010
<u>AB</u>	BRECKENRIDGE PHARM	<u>0.5MG;0.1MG</u>	<u>A078324</u>	<u>002</u>	Jun 09, 2011
<u>AB</u>		<u>1MG;0.5MG</u>	<u>A078324</u>	<u>001</u>	Apr 17, 2008
<u>AB</u>	TEVA PHARMS USA	<u>0.5MG;0.1MG</u>	<u>A200747</u>	<u>001</u>	Mar 08, 2012

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

ESTRADIOL AND NORGESTIMATE

<u>AB</u>	BARR	<u>1MG,1MG;N/A,0.09MG</u>	<u>A076812</u>	<u>001</u>	Apr 29, 2005

PREFEST

<u>AB</u>	+	TEVA WOMENS	<u>1MG,1MG;N/A,0.09MG</u>	<u>N021040</u>	<u>001</u>	Oct 22, 1999

ESTRAMUSTINE PHOSPHATE SODIUMCAPSULE; ORAL
EMCYT

+	PHARMACIA AND UPJOHN	EQ 140MG PHOSPHATE	N018045	001	

ESTROGENS, CONJUGATEDCREAM; TOPICAL, VAGINAL
PREMARIN

+	WYETH PHARMS INC	0.625MG/GM	N020216	001	

INJECTABLE; INJECTION
PREMARIN

+	WYETH PHARMS INC	25MG/VIAL	N010402	001	

TABLET; ORAL

PREMARIN

	WYETH PHARMS INC	0.3MG	N004782	003	
		0.45MG	N004782	006	Jul 16, 2003
+		0.625MG	N004782	004	
+		0.9MG	N004782	005	Jan 26, 1984
+		1.25MG	N004782	001	

ESTROGENS, CONJUGATED SYNTHETIC A

CREAM; VAGINAL

SYNTHETIC CONJUGATED ESTROGENS A

+	TEVA WOMENS	0.625MG/GM	N021788	001	Nov 28, 2008

TABLET; ORAL

CENESTIN

	TEVA BRANDED PHARM	0.3MG	N020992	001	Jun 21, 2002
		0.45MG	N020992	005	Feb 05, 2004
		0.625MG	N020992	002	Mar 24, 1999
		0.9MG	N020992	003	Mar 24, 1999
+		1.25MG	N020992	004	Mar 13, 2000

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

	TEVA WOMENS	0.3MG	N021443	001	Dec 20, 2004
		0.45MG	N021443	002	Dec 20, 2004
		0.625MG	N021443	003	May 10, 2004
		0.9MG	N021443	005	Apr 27, 2007
+		1.25MG	N021443	004	May 10, 2004

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 163 (of 428)

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE 14/14

+ WYETH PHARMS INC	0.625MG, 0.625MG; N/A, 5MG	N020527	002	Nov 17, 1995
PREMPRO				
+ WYETH PHARMS INC	0.3MG; 1.5MG	N020527	005	Jun 04, 2003
+	0.45MG; 1.5MG	N020527	004	Mar 12, 2003
+	0.625MG; 2.5MG	N020527	001	Nov 17, 1995
+	0.625MG; 5MG	N020527	003	Jan 09, 1998

ESTROGENS, ESTERIFIED

TABLET; ORAL

MENEST

MONARCH PHARMS

	0.3MG	A084951	001	
	0.625MG	A084948	001	
	1.25MG	A084950	001	
+	2.5MG	A084949	001	

ESTRONE

INJECTABLE; INJECTION

ESTRONE

+ WATSON LABS	5MG/ML	A085239	001	

ESTROPIPATE

TABLET; ORAL

ESTROPIPATE

<u>AB</u>	BARR	<u>0.75MG</u>	<u>A040135</u>	<u>001</u>	Nov 27, 1996
<u>AB</u>		<u>1.5MG</u>	<u>A040135</u>	<u>002</u>	Nov 27, 1996
<u>AB</u>		<u>3MG</u>	<u>A040135</u>	<u>003</u>	Nov 27, 1996
<u>AB</u>	MYLAN	<u>0.75MG</u>	<u>A040359</u>	<u>001</u>	Aug 26, 1999
<u>AB</u>		<u>1.5MG</u>	<u>A040359</u>	<u>002</u>	Aug 26, 1999
<u>AB</u>	WATSON LABS	<u>0.75MG</u>	<u>A081213</u>	<u>001</u>	Sep 23, 1993
<u>AB</u>		<u>1.5MG</u>	<u>A081214</u>	<u>001</u>	Sep 23, 1993
<u>AB</u>		<u>3MG</u>	<u>A081215</u>	<u>001</u>	Sep 23, 1993
<u>AB</u>		<u>6MG</u>	<u>A081216</u>	<u>001</u>	Sep 23, 1993
	<u>OGEN .625</u>				
<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.75MG</u>	<u>A083220</u>	<u>001</u>	
	<u>OGEN 1.25</u>				
<u>AB</u>	PHARMACIA AND UPJOHN	<u>1.5MG</u>	<u>A083220</u>	<u>002</u>	
	<u>OGEN 2.5</u>				
<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>3MG</u>	<u>A083220</u>	<u>003</u>	
	<u>OGEN 5</u>				
<u>AB</u>	PHARMACIA AND UPJOHN	<u>6MG</u>	<u>A083220</u>	<u>004</u>	
	<u>ORTHO-EST</u>				
<u>AB</u>	SUN PHARM INDS (IN)	<u>0.75MG</u>	<u>A089567</u>	<u>001</u>	Feb 27, 1991
<u>AB</u>		<u>1.5MG</u>	<u>A089582</u>	<u>001</u>	Jul 17, 1991

ESZOPICLONE

TABLET; ORAL

LUNESTA

SUNOVION PHARMS INC

	1MG	N021476	001	Dec 15, 2004
	2MG	N021476	002	Dec 15, 2004
+	3MG	N021476	003	Dec 15, 2004

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

EDECRIN

+ ATON	EQ 50MG BASE/VIAL	N016093	001	

PRESCRIPTION DRUG PRODUCT LIST

3 - 164 (of 428)

ETHACRYNIC ACID

TABLET; ORAL
EDECIN
+ ATON

25MG

N016092 001

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HYDROCHLORIDE

AB BARR **400MG**
AB LUPIN **100MG**
AB **400MG**
AB WEST WARD **100MG**
AB + **400MG**

A076057 001 Nov 26, 2001
A078939 001 Jun 17, 2009
A078939 002 Jun 17, 2009
A075095 001 Nov 30, 1999
A075095 002 Nov 30, 1999

MYAMBUTOL

AB STI PHARMA LLC **100MG**
AB **400MG**

N016320 001
N016320 003

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION
ETHAMOLIN

+ QOL MEDCL 50MG/ML

N019357 001 Dec 22, 1988

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

KELNOR

AB BARR **0.035MG;1MG**

A076785 001 May 23, 2005

ZOVIA 1/35E-28

AB WATSON LABS **0.035MG;1MG**

A072721 001 Dec 30, 1991

ZOVIA 1/50E-28

+ WATSON LABS 0.05MG;1MG

A072723 001 Dec 30, 1991

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL
NUVARING

+ ORGANON USA INC 0.015MG;0.12MG

N021187 001 Oct 03, 2001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

INTROVALE

AB SANDOZ **0.03MG;0.15MG**

A079064 001 Sep 27, 2010

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB LUPIN LTD **0.02MG,0.01MG;0.1MG,N/A**

A091674 001 Oct 26, 2011

AB **0.03MG;0.15MG**

A091440 001 Oct 23, 2012

AB WATSON LABS **0.02MG,0.01MG;0.1MG,N/A**

A200407 001 Oct 25, 2011

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

AB WATSON LABS **0.03MG,0.01MG;0.15MG,N/A**

A078834 001 May 31, 2011

LOSEASONIQUE

AB TEVA BRANDED PHARM **0.02MG,0.01MG;0.1MG,N/A**

N022262 001 Oct 24, 2008

QUASENSE

AB WATSON LABS **0.03MG;0.15MG**

A077101 001 Sep 06, 2006

SEASONALE

AB + TEVA BRANDED PHARM **0.03MG;0.15MG**

N021544 001 Sep 05, 2003

SEASONIQUE

AB + TEVA BRANDED PHARM **0.03MG,0.01MG;0.15MG,N/A**

N021840 001 May 25, 2006

LEVONORGESTREL AND ETHINYL ESTRADIOL

+ WATSON LABS 0.02MG;0.09MG

A079218 001 Jun 06, 2011

TABLET; ORAL-28

ALTAVERA

AB SANDOZ **0.03MG;0.15MG**

A079102 001 Aug 03, 2010

ENPRESSE-28

AB DURAMED PHARMS BARR **0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**

A075809 002 Jul 16, 2001

PRESCRIPTION DRUG PRODUCT LIST

3 - 165 (of 428)

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28					
<u>KURVELO</u>					
<u>AB</u>	LUPIN LTD	<u>0.03MG;0.15MG</u>	<u>A091408</u>	<u>001</u>	Oct 17, 2012
<u>LEVONEST</u>					
<u>AB</u>	NOVAST LABS LTD	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A090719</u>	<u>001</u>	Dec 29, 2010
<u>LEVONORGESTREL AND ETHINYL ESTRADIOL</u>					
<u>AB</u>	FAMY CARE LTD	<u>0.03MG;0.15MG</u>	<u>A091663</u>	<u>001</u>	Dec 21, 2012
<u>LEVORA 0.15/30-28</u>					
<u>AB</u>	WATSON LABS	<u>0.03MG;0.15MG</u>	<u>A073594</u>	<u>001</u>	Dec 13, 1993
<u>MARLISSA</u>					
<u>AB</u>	GLENMARK GENERICS	<u>0.03MG;0.15MG</u>	<u>A091452</u>	<u>001</u>	Feb 29, 2012
<u>MYZILRA</u>					
<u>AB</u>	VINTAGE PHARMS LLC	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A077502</u>	<u>001</u>	Nov 23, 2011
<u>NORDETTE-28</u>					
<u>AB</u>	+ TEVA BRANDED PHARM	<u>0.03MG;0.15MG</u>	<u>N018782</u>	<u>001</u>	Jul 21, 1982
<u>PORTIA-28</u>					
<u>AB</u>	BARR	<u>0.03MG;0.15MG</u>	<u>A075866</u>	<u>002</u>	May 23, 2002
<u>TRIVORA-28</u>					
<u>AB</u>	+ WATSON LABS	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A074538</u>	<u>002</u>	Dec 18, 1997
<u>AVIANE-28</u>					
<u>AB1</u>	DURAMED PHARMS BARR	<u>0.02MG;0.1MG</u>	<u>A075796</u>	<u>001</u>	Apr 30, 2001
<u>FALMINA</u>					
<u>AB1</u>	NOVAST LABS LTD	<u>0.02MG;0.1MG</u>	<u>A090721</u>	<u>001</u>	Mar 28, 2012
<u>LEVONORGESTREL AND ETHINYL ESTRADIOL</u>					
<u>AB1</u>	+ WATSON LABS	<u>0.02MG;0.1MG</u>	<u>A076625</u>	<u>001</u>	Nov 18, 2004
<u>ORSYTHIA</u>					
<u>AB1</u>	VINTAGE PHARMS LLC	<u>0.02MG;0.1MG</u>	<u>A077099</u>	<u>001</u>	May 11, 2011
<u>LESSINA-28</u>					
<u>AB2</u>	BARR	<u>0.02MG;0.1MG</u>	<u>A075803</u>	<u>002</u>	Mar 20, 2002
<u>LEVONORGESTREL AND ETHINYL ESTRADIOL</u>					
<u>AB2</u>	+ WATSON LABS	<u>0.02MG;0.1MG</u>	<u>A077681</u>	<u>001</u>	May 31, 2006

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL					
ORTHO EVRA					
	+ JANSSEN PHARMS	0.75MG;6MG	N021180	001	Nov 20, 2001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21					
<u>NORETHIN 1/35E-21</u>					
<u>AB</u>	WATSON LABS	<u>0.035MG;1MG</u>	<u>A071480</u>	<u>001</u>	Apr 12, 1988
<u>NORETHINDRONE AND ETHINYL ESTRADIOL</u>					
<u>AB</u>	WATSON LABS	<u>0.035MG;1MG</u>	<u>A070685</u>	<u>001</u>	Jan 29, 1987
<u>NORINYL 1+35 21-DAY</u>					
<u>AB</u>	WATSON LABS	<u>0.035MG;1MG</u>	<u>N017565</u>	<u>001</u>	
<u>NORTREL 1/35-21</u>					
<u>AB</u>	BARR	<u>0.035MG;1MG</u>	<u>A072693</u>	<u>001</u>	Feb 28, 1992
NORETHINDRONE AND ETHINYL ESTRADIOL					
	WATSON LABS	0.035MG;0.4MG	A078379	001	Feb 23, 2010
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)					
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071043	001	Apr 01, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)					
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071041	001	Sep 24, 1991
NORTREL 7/7/7					
	BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A075478	001	Aug 30, 2002

TABLET; ORAL-28					
<u>ALYACEN 1/35</u>					
<u>AB</u>	GLENMARK GENERICS	<u>0.035MG;1MG</u>	<u>A091634</u>	<u>001</u>	Jan 19, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 166 (of 428)

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28						
<u>ALYACEN 7/7/7</u>						
<u>AB</u>	GLENMARK GENERICS	<u>0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG</u>	<u>A091636</u>	<u>001</u>	Jan 19, 2012	
<u>ARANELLE</u>						
<u>AB</u>	BARR	<u>0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.5MG</u>	<u>A076783</u>	<u>001</u>	Sep 29, 2004	
<u>BALZIVA-28</u>						
<u>AB</u>	BARR	<u>0.035MG; 0.4MG</u>	<u>A076238</u>	<u>001</u>	Apr 22, 2004	
<u>BREVICON 28-DAY</u>						
<u>AB</u>	WATSON LABS	<u>0.035MG; 0.5MG</u>	<u>N017743</u>	<u>001</u>		
<u>BRIELLYN</u>						
<u>AB</u>	GLENMARK GENERICS	<u>0.035MG; 0.4MG</u>	<u>A090538</u>	<u>001</u>	Mar 22, 2011	
<u>CYCLAFEM 1/35</u>						
<u>AB</u>	VINTAGE PHARMS LLC	<u>0.035MG; 1MG</u>	<u>A076337</u>	<u>001</u>	Nov 12, 2010	
<u>CYCLAFEM 7/7/7</u>						
<u>AB</u>	VINTAGE PHARMS LLC	<u>0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG</u>	<u>A076338</u>	<u>001</u>	Nov 16, 2010	
<u>DASETTA 1/35</u>						
<u>AB</u>	NOVAST LABS LTD	<u>0.035MG; 1MG</u>	<u>A090948</u>	<u>001</u>	Dec 22, 2011	
<u>DASETTA 7/7/7</u>						
<u>AB</u>	NOVAST LABS LTD	<u>0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG</u>	<u>A090946</u>	<u>001</u>	Dec 22, 2011	
<u>GILDAGIA</u>						
<u>AB</u>	VINTAGE PHARMS	<u>0.035MG; 0.4MG</u>	<u>A078376</u>	<u>001</u>	Nov 06, 2012	
<u>MODICON 28</u>						
<u>AB</u> +	JANSSEN PHARMS	<u>0.035MG; 0.5MG</u>	<u>N017735</u>	<u>001</u>		
<u>NORETHIN 1/35E-28</u>						
<u>AB</u>	WATSON LABS	<u>0.035MG; 1MG</u>	<u>A071481</u>	<u>001</u>	Apr 12, 1988	
<u>NORETHINDRONE AND ETHINYL ESTRADIOL</u>						
<u>AB</u>	WATSON LABS	<u>0.035MG; 0.4MG</u>	<u>A078323</u>	<u>001</u>	Feb 04, 2010	
<u>AB</u>		<u>0.035MG; 0.5MG</u>	<u>A070686</u>	<u>001</u>	Jan 29, 1987	
<u>AB</u>		<u>0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG</u>	<u>A076393</u>	<u>001</u>	Feb 04, 2010	
<u>AB</u>		<u>0.035MG; 1MG</u>	<u>A070687</u>	<u>001</u>	Jan 29, 1987	
<u>NORINYL 1+35 28-DAY</u>						
<u>AB</u>	WATSON LABS	<u>0.035MG; 1MG</u>	<u>N017565</u>	<u>002</u>		
<u>NORTREL 0.5/35-28</u>						
<u>AB</u>	BARR	<u>0.035MG; 0.5MG</u>	<u>A072695</u>	<u>001</u>	Feb 28, 1992	
<u>NORTREL 1/35-28</u>						
<u>AB</u>	BARR	<u>0.035MG; 1MG</u>	<u>A072696</u>	<u>001</u>	Feb 28, 1992	
<u>NORTREL 7/7/7</u>						
<u>AB</u>	BARR	<u>0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG</u>	<u>A075478</u>	<u>002</u>	Aug 30, 2002	
<u>ORTHO-NOVUM 1/35-28</u>						
<u>AB</u> +	JANSSEN PHARMS	<u>0.035MG; 1MG</u>	<u>N017919</u>	<u>002</u>		
<u>ORTHO-NOVUM 7/7/7-28</u>						
<u>AB</u> +	JANSSEN PHARMS	<u>0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG</u>	<u>N018985</u>	<u>002</u>	Apr 04, 1984	
<u>OVCON-35</u>						
<u>AB</u> +	WARNER CHILCOTT LLC	<u>0.035MG; 0.4MG</u>	<u>N017716</u>	<u>001</u>		
<u>PHILITH</u>						
<u>AB</u>	NOVAST LABS LTD	<u>0.035MG; 0.4MG</u>	<u>A090947</u>	<u>001</u>	Dec 22, 2011	
<u>TRI-NORINYL 28-DAY</u>						
<u>AB</u> +	WATSON LABS	<u>0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.5MG</u>	<u>N018977</u>	<u>002</u>	Apr 13, 1984	
<u>WERA</u>						
<u>AB</u>	NOVAST LABS LTD	<u>0.035MG; 0.5MG</u>	<u>A091204</u>	<u>001</u>	Mar 27, 2012	
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)						
	WATSON LABS	0.035MG, 0.035MG; 0.5MG, 1MG	A071044	001	Apr 01, 1988	
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)						
	WATSON LABS	0.035MG, 0.035MG; 0.5MG, 1MG	A071042	001	Sep 24, 1991	
OVCON-50						
+	WARNER CHILCOTT LLC	0.05MG; 1MG	N017576	001		

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 167 (of 428)

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET, CHEWABLE; ORAL

FEMCON FE

<u>AB</u>	+	WARNER CHILCOTT LLC	<u>0.035MG;0.4MG</u>	<u>N021490</u>	<u>001</u>	Nov 14, 2003
			<u>NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>			
<u>AB</u>		BARR	<u>0.035MG;0.4MG</u>	<u>A078965</u>	<u>001</u>	Aug 05, 2010
<u>AB</u>		WATSON LABS	<u>0.035MG;0.4MG</u>	<u>A078892</u>	<u>001</u>	Sep 26, 2011
			<u>NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>			
	+	WATSON LABS INC	<u>0.025MG;0.8MG</u>	N022573	001	Dec 22, 2010

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

FEMHRT

<u>AB</u>	+	WARNER CHILCOTT LLC	<u>0.005MG;1MG</u>	<u>N021065</u>	<u>002</u>	Oct 15, 1999
			<u>LOESTRIN 24 FE</u>			
<u>AB</u>	+	WARNER CHILCOTT	<u>0.02MG;1MG</u>	<u>N021871</u>	<u>001</u>	Feb 17, 2006
			<u>NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL</u>			
<u>AB</u>		BARR	<u>0.005MG;1MG</u>	<u>A076221</u>	<u>001</u>	Nov 06, 2009
			<u>NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>			
<u>AB</u>		WATSON LABS	<u>0.02MG;1MG</u>	<u>A078267</u>	<u>001</u>	Sep 01, 2009
		FEMHRT				
		WARNER CHILCOTT LLC	0.0025MG;0.5MG	N021065	001	Jan 14, 2005
		LO LOESTRIN FE				
	+	WARNER CHILCOTT LLC	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010

TABLET; ORAL-21

JUNEL 1.5/30

<u>AB</u>		BARR	<u>0.03MG;1.5MG</u>	<u>A076381</u>	<u>001</u>	May 30, 2003
			<u>JUNEL 1/20</u>			
<u>AB</u>		BARR	<u>0.02MG;1MG</u>	<u>A076380</u>	<u>001</u>	May 30, 2003
			<u>LOESTRIN 21 1.5/30</u>			
<u>AB</u>		WARNER CHILCOTT LLC	<u>0.03MG;1.5MG</u>	<u>N017875</u>	<u>001</u>	
			<u>LOESTRIN 21 1/20</u>			
<u>AB</u>		WARNER CHILCOTT LLC	<u>0.02MG;1MG</u>	<u>N017876</u>	<u>001</u>	
			<u>MICROGESTIN 1.5/30</u>			
<u>AB</u>		WATSON LABS	<u>0.03MG;1.5MG</u>	<u>A075548</u>	<u>002</u>	Jul 30, 2003
			<u>MICROGESTIN 1/20</u>			
<u>AB</u>		WATSON LABS	<u>0.02MG;1MG</u>	<u>A075647</u>	<u>002</u>	Jul 30, 2003
		TRI-LEGEST 21				
		BARR	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A076405	001	Oct 26, 2007

TABLET; ORAL-28

ESTROSTEP FE

<u>AB</u>	+	WARNER CHILCOTT LLC	<u>0.02MG,0.03MG,0.035MG;1MG,1MG,1MG</u>	<u>N020130</u>	<u>002</u>	Oct 09, 1996
			<u>GILDESS FE 1.5/30</u>			
<u>AB</u>		VINTAGE PHARMS LLC	<u>0.03MG;1.5MG</u>	<u>A077075</u>	<u>001</u>	Apr 28, 2005
			<u>GILDESS FE 1/20</u>			
<u>AB</u>		VINTAGE PHARMS LLC	<u>0.02MG;1MG</u>	<u>A077077</u>	<u>001</u>	May 20, 2005
			<u>JUNEL FE 1.5/30</u>			
<u>AB</u>		BARR	<u>0.03MG;1.5MG</u>	<u>A076064</u>	<u>001</u>	Sep 18, 2003
			<u>JUNEL FE 1/20</u>			
<u>AB</u>		BARR	<u>0.02MG;1MG</u>	<u>A076081</u>	<u>001</u>	Sep 18, 2003
			<u>LOESTRIN FE 1.5/30</u>			
<u>AB</u>	+	WARNER CHILCOTT LLC	<u>0.03MG;1.5MG</u>	<u>N017355</u>	<u>001</u>	
			<u>LOESTRIN FE 1/20</u>			
<u>AB</u>		WARNER CHILCOTT	<u>0.02MG;1MG</u>	<u>N017354</u>	<u>001</u>	
			<u>MICROGESTIN FE 1.5/30</u>			
<u>AB</u>		WATSON LABS	<u>0.03MG;1.5MG</u>	<u>A075548</u>	<u>001</u>	Feb 05, 2001
			<u>MICROGESTIN FE 1/20</u>			
<u>AB</u>		WATSON LABS	<u>0.02MG;1MG</u>	<u>A075647</u>	<u>001</u>	Feb 05, 2001
			<u>NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL</u>			
<u>AB</u>		WATSON LABS	<u>0.02MG,0.03MG,0.035MG;1MG,1MG,1MG</u>	<u>A076629</u>	<u>001</u>	Mar 18, 2010
			<u>TRI-LEGEST FE</u>			
<u>AB</u>		BARR	<u>0.02MG,0.03MG,0.035MG;1MG,1MG,1MG</u>	<u>A076105</u>	<u>001</u>	Oct 26, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 168 (of 428)

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL

NORGESTIMATE AND ETHINYL ESTRADIOL

<u>AB</u>	GLENMARK GENERICS	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A200494</u>	<u>001</u>	Jun 17, 2011

TABLET; ORAL-28

MONO-LINYAH

<u>AB</u>	NOVAST LABS LTD	<u>0.035MG; 0.25MG</u>	<u>A090523</u>	<u>001</u>	May 23, 2012

NORGESTIMATE AND ETHINYL ESTRADIOL

<u>AB</u>	GLENMARK GENERICS	<u>0.035MG; 0.25MG</u>	<u>A200538</u>	<u>001</u>	Apr 05, 2012

<u>AB</u>	LUPIN PHARMS	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A200541</u>	<u>001</u>	Jun 25, 2012

<u>AB</u>	WATSON LABS	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A090479</u>	<u>001</u>	Mar 09, 2011

<u>AB</u>		<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A076626</u>	<u>001</u>	Aug 17, 2006

<u>AB</u>		<u>0.035MG; 0.25MG</u>	<u>A076627</u>	<u>001</u>	Aug 17, 2006

ORTHO CYCLEN-28

<u>AB</u>	+ JANSEN PHARMS	<u>0.035MG; 0.25MG</u>	<u>N019653</u>	<u>002</u>	Dec 29, 1989

ORTHO TRI-CYCLEN

<u>AB</u>	+ JANSEN PHARMS	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>N019697</u>	<u>001</u>	Jul 03, 1992

ORTHO TRI-CYCLEN LO

<u>AB</u>	+ JANSEN PHARMS	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>N021241</u>	<u>001</u>	Aug 22, 2002

PREVIFEM

<u>AB</u>	VINTAGE PHARMS LLC	<u>0.035MG; 0.25MG</u>	<u>A076334</u>	<u>001</u>	Jan 09, 2004

SPRINTEC

<u>AB</u>	BARR	<u>0.035MG; 0.25MG</u>	<u>A075804</u>	<u>001</u>	Sep 25, 2002

TRI LO SPRINTEC

<u>AB</u>	BARR	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A076784</u>	<u>001</u>	Jun 29, 2009

TRI-LINYAH

<u>AB</u>	NOVAST LABS LTD	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A090524</u>	<u>001</u>	May 30, 2012

TRI-PREVIFEM

<u>AB</u>	VINTAGE PHARMS LLC	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A076335</u>	<u>001</u>	Mar 26, 2004

TRI-SPRINTEC

<u>AB</u>	BARR	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A075808</u>	<u>001</u>	Dec 29, 2003

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

CRYSELLE

<u>AB</u>	DURAMED PHARMS BARR	<u>0.03MG; 0.3MG</u>	<u>A075840</u>	<u>001</u>	Nov 30, 2001

LOW-OGESTREL-21

<u>AB</u>	+ WATSON LABS	<u>0.03MG; 0.3MG</u>	<u>A075288</u>	<u>001</u>	Jul 28, 1999

TABLET; ORAL-28

CRYSELLE

<u>AB</u>	DURAMED PHARMS BARR	<u>0.03MG; 0.3MG</u>	<u>A075840</u>	<u>002</u>	Nov 30, 2001

ELINEST

<u>AB</u>	NOVAST LABS LTD	<u>0.03MG; 0.3MG</u>	<u>A091105</u>	<u>001</u>	Mar 28, 2012

LO/OVRAL-28

<u>AB</u>	WYETH PHARMS	<u>0.03MG; 0.3MG</u>	<u>N017802</u>	<u>001</u>	

LOW-OGESTREL-28

<u>AB</u>	WATSON LABS	<u>0.03MG; 0.3MG</u>	<u>A075288</u>	<u>002</u>	Jul 28, 1999

OGESTREL 0.5/50-28

	+ WATSON LABS	<u>0.05MG; 0.5MG</u>	<u>A075406</u>	<u>002</u>	Dec 15, 1999

PRESCRIPTION DRUG PRODUCT LIST

3 - 169 (of 428)

ETHIONAMIDE

TABLET; ORAL
TRECATOR

+ WYETH PHARMS INC	250MG	N013026	002	

ETHOSUXIMIDE

CAPSULE; ORAL
ETHOSUXIMIDE

<u>AB</u> BANNER PHARMACAPS	<u>250MG</u>	<u>A040430</u>	<u>001</u>	Oct 28, 2002
<u>AB</u> VERSAPHARM	<u>250MG</u>	<u>A040686</u>	<u>001</u>	May 28, 2008
<u>AB</u> ZYDUS PHARMS USA INC	<u>250MG</u>	<u>A200892</u>	<u>001</u>	Sep 25, 2012

ZARONTIN

+ PARKE DAVIS	<u>250MG</u>	<u>N012380</u>	<u>001</u>	

SYRUP; ORAL

ETHOSUXIMIDE

<u>AA</u> MIKART	<u>250MG/5ML</u>	<u>A040506</u>	<u>001</u>	Dec 22, 2003
<u>AA</u> PHARM ASSOC	<u>250MG/5ML</u>	<u>A040253</u>	<u>001</u>	Nov 22, 2000
<u>AA</u> TEVA PHARMS	<u>250MG/5ML</u>	<u>A081306</u>	<u>001</u>	Jul 30, 1993

ZARONTIN

+ PARKE DAVIS	<u>250MG/5ML</u>	<u>A080258</u>	<u>001</u>	

ETHOTOIN

TABLET; ORAL
PEGANONE

+ LUNDBECK LLC	250MG	N010841	001	

ETIDRONATE DISODIUM

TABLET; ORAL

DIDRONEL

<u>AB</u> PROCTER AND GAMBLE	<u>200MG</u>	<u>N017831</u>	<u>001</u>	
<u>AB</u> +	<u>400MG</u>	<u>N017831</u>	<u>002</u>	

ETIDRONATE DISODIUM

<u>AB</u> MYLAN	<u>200MG</u>	<u>A075800</u>	<u>001</u>	Jan 24, 2003
<u>AB</u>	<u>400MG</u>	<u>A075800</u>	<u>002</u>	Jan 24, 2003

ETODOLAC

CAPSULE; ORAL

ETODOLAC

<u>AB</u> APOTEX	<u>200MG</u>	<u>A075419</u>	<u>001</u>	Jul 28, 2000
<u>AB</u>	<u>300MG</u>	<u>A075419</u>	<u>002</u>	Jul 28, 2000
<u>AB</u> TARO	<u>200MG</u>	<u>A075078</u>	<u>001</u>	Apr 30, 1998
<u>AB</u> +	<u>300MG</u>	<u>A075078</u>	<u>002</u>	Apr 30, 1998
<u>AB</u> TEVA	<u>300MG</u>	<u>A075126</u>	<u>002</u>	Sep 16, 1999

TABLET; ORAL

ETODOLAC

<u>AB</u> APOTEX INC	<u>400MG</u>	<u>A076004</u>	<u>001</u>	Dec 03, 2002
<u>AB</u>	<u>500MG</u>	<u>A076004</u>	<u>002</u>	Dec 03, 2002
<u>AB</u> MYLAN	<u>400MG</u>	<u>A075104</u>	<u>001</u>	Feb 06, 1998
<u>AB</u>	<u>500MG</u>	<u>A075104</u>	<u>002</u>	Nov 20, 1998
<u>AB</u> PROSAM LABS	<u>400MG</u>	<u>A074819</u>	<u>001</u>	Feb 28, 1997
<u>AB</u>	<u>500MG</u>	<u>A074819</u>	<u>002</u>	Apr 28, 1998
<u>AB</u> SANDOZ	<u>400MG</u>	<u>A074903</u>	<u>001</u>	Apr 11, 1997
<u>AB</u>	<u>500MG</u>	<u>A074903</u>	<u>002</u>	Apr 19, 1999
<u>AB</u> TARO PHARM INDS	<u>400MG</u>	<u>A075074</u>	<u>001</u>	Mar 11, 1998
<u>AB</u> +	<u>500MG</u>	<u>A075074</u>	<u>002</u>	Apr 25, 2000
<u>AB</u> TEVA	<u>400MG</u>	<u>A075009</u>	<u>001</u>	Nov 26, 1997
<u>AB</u>	<u>500MG</u>	<u>A075009</u>	<u>002</u>	Dec 28, 1999

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

<u>AB</u> TARO	<u>400MG</u>	<u>A076174</u>	<u>001</u>	Mar 13, 2003
<u>AB</u>	<u>500MG</u>	<u>A076174</u>	<u>002</u>	Mar 13, 2003
<u>AB</u>	<u>600MG</u>	<u>A076174</u>	<u>003</u>	Mar 13, 2003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 170 (of 428)

ETODOLAC

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

<u>AB</u>	TEVA	<u>400MG</u>	<u>A075665</u>	<u>003</u>	Feb 05, 2001
<u>AB</u>		<u>500MG</u>	<u>A075665</u>	<u>002</u>	Jul 31, 2000
<u>AB</u>	+	<u>600MG</u>	<u>A075665</u>	<u>001</u>	Jul 31, 2000

ETOMIDATE

INJECTABLE; INJECTION

AMIDATE

<u>AP</u>	+	HOSPIRA	<u>2MG/ML</u>	<u>N018227</u>	<u>001</u>	Sep 07, 1982

ETOMIDATE

<u>AP</u>		BEDFORD	<u>2MG/ML</u>	<u>A074593</u>	<u>001</u>	Nov 04, 1996
<u>AP</u>		LUITPOLD	<u>2MG/ML</u>	<u>A078867</u>	<u>001</u>	Dec 22, 2009
<u>AP</u>		MYLAN INSTITUTIONAL	<u>2MG/ML</u>	<u>A091297</u>	<u>001</u>	Jun 20, 2012
<u>AP</u>		STRIDES ARCOLAB LTD	<u>2MG/ML</u>	<u>A078289</u>	<u>001</u>	Jan 02, 2009

ETONOGESTREL

IMPLANT; IMPLANTATION

IMPLANON

+	ORGANON USA INC	68MG/IMPLANT	N021529	001	Jul 17, 2006
	NEXPLANON				
+	ORGANON USA INC	68MG/IMPLANT	N021529	002	May 31, 2011

ETOPOSIDE

CAPSULE; ORAL

ETOPOSIDE

+	MYLAN	50MG	A075635	001	Sep 19, 2001

INJECTABLE; INJECTION

ETOPOSIDE

<u>AP</u>		ACCORD HLTHCARE INC	<u>20MG/ML</u>	<u>A074513</u>	<u>001</u>	Mar 14, 1996
<u>AP</u>		BEDFORD	<u>20MG/ML</u>	<u>A074290</u>	<u>001</u>	Jul 17, 1995
<u>AP</u>	+	FRESENIUS KABI USA	<u>20MG/ML</u>	<u>A074983</u>	<u>001</u>	Sep 30, 1998
<u>AP</u>		PHARMACHEMIE	<u>20MG/ML</u>	<u>A074227</u>	<u>001</u>	Feb 22, 1996
<u>AP</u>		TEVA PARENTERAL	<u>20MG/ML</u>	<u>A074284</u>	<u>001</u>	Feb 10, 1994
<u>AP</u>			<u>20MG/ML</u>	<u>A074529</u>	<u>001</u>	Jul 24, 1996

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS PRESERVATIVE FREE

+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N020457	001	May 17, 1996

ETRAVIRINE

TABLET; ORAL

INTELENCE

	JANSSEN R AND D	25MG	N022187	003	Mar 26, 2012
		100MG	N022187	001	Jan 18, 2008
+		200MG	N022187	002	Dec 22, 2010

EVEROLIMUS

TABLET; ORAL

AFINITOR

	NOVARTIS	2.5MG	N022334	003	Jul 09, 2010
		5MG	N022334	001	Mar 30, 2009
		7.5MG	N022334	004	Mar 30, 2012
+		10MG	N022334	002	Mar 30, 2009
	ZORTRESS				
	NOVARTIS	0.25MG	N021560	001	Apr 20, 2010
		0.5MG	N021560	002	Apr 20, 2010
+		0.75MG	N021560	003	Apr 20, 2010

PRESCRIPTION DRUG PRODUCT LIST

3 - 171 (of 428)

EVEROLIMUS

TABLET; FOR SUSPENSION; ORAL
AFINITOR DISPERZ

NOVARTIS PHARM	2MG	N203985	001	Aug 29, 2012
	3MG	N203985	002	Aug 29, 2012
+	5MG	N203985	003	Aug 29, 2012

EXEMESTANE

TABLET; ORAL

AROMASIN

<u>AB</u> + PHARMACIA AND UPJOHN	<u>25MG</u>	<u>N020753</u>	<u>001</u>	Oct 21, 1999

EXEMESTANE

<u>AB</u> ROXANE	<u>25MG</u>	<u>A077431</u>	<u>001</u>	Apr 01, 2011

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON

+ AMYLIN	2MG/VIAL	N022200	001	Jan 27, 2012

INJECTABLE; SUBCUTANEOUS

BYETTA

+ AMYLIN	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005

+	600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005

EZETIMIBE

TABLET; ORAL

ZETIA

+ MSD INTL GMBH	10MG	N021445	001	Oct 25, 2002

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

MSD INTL	10MG;10MG	N021687	001	Jul 23, 2004

	10MG;20MG	N021687	002	Jul 23, 2004

	10MG;40MG	N021687	003	Jul 23, 2004

+	10MG;80MG	N021687	004	Jul 23, 2004

EZOGBABINE

TABLET; ORAL

POTIGA

GLAXOSMITHKLINE	50MG	N022345	001	Jun 10, 2011

	200MG	N022345	002	Jun 10, 2011

	300MG	N022345	003	Jun 10, 2011

+	400MG	N022345	004	Jun 10, 2011

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

<u>AB</u> APOTEX	<u>125MG</u>	<u>A091480</u>	<u>001</u>	Jul 22, 2011

<u>AB</u>	<u>250MG</u>	<u>A091480</u>	<u>002</u>	Jul 22, 2011

<u>AB</u>	<u>500MG</u>	<u>A091480</u>	<u>003</u>	Jul 22, 2011

<u>AB</u> AUROBINDO PHARMA LTD	<u>125MG</u>	<u>A091114</u>	<u>001</u>	Mar 21, 2011

<u>AB</u>	<u>250MG</u>	<u>A091114</u>	<u>002</u>	Mar 21, 2011

<u>AB</u>	<u>500MG</u>	<u>A091114</u>	<u>003</u>	Mar 21, 2011

<u>AB</u> MACLEODS PHARMS LTD	<u>125MG</u>	<u>A201022</u>	<u>001</u>	Jan 12, 2012

<u>AB</u>	<u>250MG</u>	<u>A201022</u>	<u>002</u>	Jan 12, 2012

<u>AB</u>	<u>500MG</u>	<u>A201022</u>	<u>003</u>	Jan 12, 2012

<u>AB</u> MYLAN	<u>125MG</u>	<u>A201333</u>	<u>001</u>	Mar 24, 2011

<u>AB</u>	<u>250MG</u>	<u>A201333</u>	<u>002</u>	Mar 24, 2011

<u>AB</u>	<u>500MG</u>	<u>A201333</u>	<u>003</u>	Mar 24, 2011

<u>AB</u> ROXANE	<u>125MG</u>	<u>A090128</u>	<u>001</u>	Mar 21, 2011

<u>AB</u>	<u>250MG</u>	<u>A090128</u>	<u>002</u>	Mar 21, 2011

<u>AB</u>	<u>500MG</u>	<u>A090128</u>	<u>003</u>	Mar 21, 2011

PRESCRIPTION DRUG PRODUCT LIST

3 - 172 (of 428)

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

<u>AB</u>	TEVA PHARMS	<u>125MG</u>	<u>A077487</u>	<u>001</u>	Aug 24, 2007
<u>AB</u>		<u>250MG</u>	<u>A077487</u>	<u>002</u>	Aug 24, 2007
<u>AB</u>		<u>500MG</u>	<u>A077487</u>	<u>003</u>	Aug 24, 2007
<u>AB</u>	WATSON LABS	<u>125MG</u>	<u>A078278</u>	<u>001</u>	Mar 21, 2011
<u>AB</u>		<u>250MG</u>	<u>A078278</u>	<u>002</u>	Mar 21, 2011
<u>AB</u>		<u>500MG</u>	<u>A078278</u>	<u>003</u>	Mar 21, 2011
<u>FAMVIR</u>					
<u>AB</u>	NOVARTIS	<u>125MG</u>	<u>N020363</u>	<u>003</u>	Dec 11, 1995
<u>AB</u>		<u>250MG</u>	<u>N020363</u>	<u>001</u>	Apr 26, 1996
<u>AB</u>	+	<u>500MG</u>	<u>N020363</u>	<u>002</u>	Jun 29, 1994

FAMOTIDINE

FOR SUSPENSION; ORAL

FAMOTIDINE

<u>AB</u>	LUPIN LTD	<u>40MG/5ML</u>	<u>A090440</u>	<u>001</u>	Jun 29, 2010
<u>AB</u>	NAVINTA LLC	<u>40MG/5ML</u>	<u>A091020</u>	<u>001</u>	May 27, 2010

PEPCID

<u>AB</u>	+	<u>SALIX PHARMS</u>	<u>40MG/5ML</u>	<u>N019527</u>	<u>001</u>	Feb 02, 1987

INJECTABLE; INJECTION

FAMOTIDINE

AP	BEDFORD	10MG/ML	A075651	001	Apr 16, 2001
AP		10MG/ML	A075684	001	Apr 16, 2001
AP	FRESENIUS KABI USA	10MG/ML	A075709	001	Apr 16, 2001
AP	+ HIKMA MAPLE	10MG/ML	A075488	001	Apr 16, 2001
AP	+	10MG/ML	A075799	001	Apr 30, 2002
AP	PFIZER	10MG/ML	A078641	001	Jun 25, 2008

FAMOTIDINE PRESERVATIVE FREE

<u>AP</u>	BEDFORD	<u>10MG/ML</u>	<u>A075622</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>	BEN VENUE	<u>10MG/ML</u>	<u>A075825</u>	<u>001</u>	Apr 17, 2001
<u>AP</u>	CLARIS LIFESCIENCES	<u>10MG/ML</u>	<u>A076324</u>	<u>001</u>	Nov 27, 2002
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A075813</u>	<u>001</u>	Apr 16, 2001
<u>AP</u> +	HIKMA MAPLE	<u>10MG/ML</u>	<u>A075486</u>	<u>001</u>	Apr 16, 2001
<u>AP</u> +		<u>10MG/ML</u>	<u>A075789</u>	<u>001</u>	Apr 30, 2002
<u>AP</u>	PFIZER	<u>10MG/ML</u>	<u>A078642</u>	<u>001</u>	Jun 25, 2008

FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

<u>AP</u>	CLARIS LIFESCIENCES	<u>10MG/ML</u>	<u>A076322</u>	<u>001</u>	Nov 27, 2002

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

<u>AP</u>	+	<u>BAXTER HLTHCARE</u>	<u>0.4MG/ML</u>	<u>A075591</u>	<u>001</u>	May 10, 2001

SUSPENSION; ORAL

FAMOTIDINE

<u>AB</u>	NOVEL LABS INC	<u>40MG/5ML</u>	<u>A201695</u>	<u>001</u>	Dec 17, 2012

TABLET; ORAL

FAMOTIDINE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>20MG</u>	<u>A078916</u>	<u>001</u>	May 22, 2009
<u>AB</u>		<u>40MG</u>	<u>A078916</u>	<u>002</u>	May 22, 2009
<u>AB</u>	APOTEX	<u>20MG</u>	<u>A075611</u>	<u>001</u>	Jul 23, 2001
<u>AB</u>		<u>40MG</u>	<u>A075611</u>	<u>002</u>	Jul 23, 2001
<u>AB</u>	CARLSBAD	<u>20MG</u>	<u>A075805</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075805</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	DR REDDYS LABS LTD	<u>20MG</u>	<u>A075718</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075718</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>A075511</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075511</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A075704</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075704</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	PERRIGO	<u>20MG</u>	<u>A077352</u>	<u>002</u>	Jul 27, 2005
<u>AB</u>		<u>40MG</u>	<u>A077352</u>	<u>001</u>	Jul 27, 2005
<u>AB</u>	TEVA	<u>20MG</u>	<u>A075311</u>	<u>001</u>	Apr 16, 2001

PRESCRIPTION DRUG PRODUCT LIST

3 - 173 (of 428)

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

<u>AB</u>	TEVA	<u>40MG</u>	<u>A075311</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	WATSON LABS	<u>20MG</u>	<u>A075062</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075062</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>	WOCKHARDT	<u>20MG</u>	<u>A075786</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075786</u>	<u>002</u>	Apr 16, 2001
<u>PEPCID</u>					
<u>AB</u>	MARATHON PHARMS	<u>20MG</u>	<u>N019462</u>	<u>001</u>	Oct 15, 1986
<u>AB</u>	+	<u>40MG</u>	<u>N019462</u>	<u>002</u>	Oct 15, 1986

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

DUEXIS

+	HORIZON PHARMA	26.6MG;800MG	N022519	001	Apr 23, 2011

FEBUXOSTAT

TABLET; ORAL

ULORIC

	TAKEDA PHARMS USA	40MG	N021856	001	Feb 13, 2009
+		80MG	N021856	002	Feb 13, 2009

FELBAMATE

SUSPENSION; ORAL

FELBAMATE

<u>AB</u>	AMNEAL PHARMS	<u>600MG/5ML</u>	<u>A202385</u>	<u>001</u>	Dec 16, 2011

FELBATOL

<u>AB</u>	+	MEDA PHARMS	<u>600MG/5ML</u>	<u>N020189</u>	<u>003</u>	Jul 29, 1993

TABLET; ORAL

FELBAMATE

<u>AB</u>	AMNEAL PHARMS	<u>400MG</u>	<u>A201680</u>	<u>001</u>	Sep 13, 2011
<u>AB</u>		<u>600MG</u>	<u>A201680</u>	<u>002</u>	Sep 13, 2011

FELBATOL

<u>AB</u>	MEDA PHARMS	<u>400MG</u>	<u>N020189</u>	<u>001</u>	Jul 29, 1993
<u>AB</u>	+	<u>600MG</u>	<u>N020189</u>	<u>002</u>	Jul 29, 1993

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A203417</u>	<u>001</u>	Jan 17, 2013
<u>AB</u>		<u>5MG</u>	<u>A203417</u>	<u>002</u>	Jan 17, 2013
<u>AB</u>		<u>10MG</u>	<u>A203417</u>	<u>003</u>	Jan 17, 2013
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A090365</u>	<u>001</u>	Dec 17, 2010
<u>AB</u>		<u>5MG</u>	<u>A090365</u>	<u>002</u>	Dec 17, 2010
<u>AB</u>		<u>10MG</u>	<u>A090365</u>	<u>003</u>	Dec 17, 2010
<u>AB</u>	MUTUAL PHARM	<u>2.5MG</u>	<u>A075896</u>	<u>001</u>	Nov 02, 2004
<u>AB</u>		<u>5MG</u>	<u>A075896</u>	<u>002</u>	Nov 02, 2004
<u>AB</u>		<u>10MG</u>	<u>A075896</u>	<u>003</u>	Nov 02, 2004
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A078855</u>	<u>001</u>	Apr 17, 2008
<u>AB</u>		<u>5MG</u>	<u>A078855</u>	<u>002</u>	Apr 17, 2008
<u>AB</u>	+	<u>10MG</u>	<u>A078855</u>	<u>003</u>	Apr 17, 2008
<u>AB</u>	TORRENT PHARMS LTD	<u>2.5MG</u>	<u>A202170</u>	<u>001</u>	Nov 28, 2011
<u>AB</u>		<u>5MG</u>	<u>A202170</u>	<u>002</u>	Nov 28, 2011
<u>AB</u>		<u>10MG</u>	<u>A202170</u>	<u>003</u>	Nov 28, 2011
<u>AB</u>	VINTAGE PHARMS LLC	<u>2.5MG</u>	<u>A200815</u>	<u>001</u>	Oct 28, 2011
<u>AB</u>		<u>5MG</u>	<u>A200815</u>	<u>002</u>	Oct 28, 2011
<u>AB</u>		<u>10MG</u>	<u>A200815</u>	<u>003</u>	Oct 28, 2011
<u>AB</u>	WOCKHARDT LTD	<u>2.5MG</u>	<u>A091484</u>	<u>001</u>	Aug 15, 2012
<u>AB</u>		<u>5MG</u>	<u>A091484</u>	<u>002</u>	Aug 15, 2012
<u>AB</u>		<u>10MG</u>	<u>A091484</u>	<u>003</u>	Aug 15, 2012

PRESCRIPTION DRUG PRODUCT LIST

3 - 174 (of 428)

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

PLENDIL

<u>AB</u>	ASTRAZENECA	<u>2.5MG</u>	<u>N019834</u>	<u>004</u>	Sep 22, 1994
<u>AB</u>		<u>5MG</u>	<u>N019834</u>	<u>001</u>	Jul 25, 1991
<u>AB</u>		<u>10MG</u>	<u>N019834</u>	<u>002</u>	Jul 25, 1991

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

<u>AB</u>	LUPIN ATLANTIS	<u>43MG</u>	<u>N021695</u>	<u>001</u>	Nov 30, 2004
<u>AB</u>	+	<u>130MG</u>	<u>N021695</u>	<u>003</u>	Nov 30, 2004

FENOFIBRATE (MICRONIZED)

<u>AB</u>	DR REDDYS LABS SA	<u>43MG</u>	<u>A090859</u>	<u>001</u>	Mar 01, 2012
<u>AB</u>		<u>130MG</u>	<u>A090859</u>	<u>002</u>	Mar 01, 2012
<u>AB</u>	IMPAX LABS	<u>67MG</u>	<u>A075868</u>	<u>001</u>	Oct 27, 2003
<u>AB</u>		<u>134MG</u>	<u>A075868</u>	<u>002</u>	Oct 27, 2003
<u>AB</u>		<u>200MG</u>	<u>A075868</u>	<u>003</u>	Oct 27, 2003
<u>AB</u>	MYLAN PHARMS INC	<u>43MG</u>	<u>A202579</u>	<u>001</u>	Jan 10, 2013
<u>AB</u>		<u>67MG</u>	<u>A202676</u>	<u>001</u>	Oct 23, 2012
<u>AB</u>		<u>130MG</u>	<u>A202579</u>	<u>002</u>	Jan 10, 2013
<u>AB</u>		<u>134MG</u>	<u>A202676</u>	<u>002</u>	Oct 23, 2012
<u>AB</u>		<u>200MG</u>	<u>A202676</u>	<u>003</u>	Oct 23, 2012
<u>AB</u>	TEVA	<u>67MG</u>	<u>A075753</u>	<u>001</u>	Sep 03, 2002
<u>AB</u>		<u>134MG</u>	<u>A075753</u>	<u>002</u>	Apr 09, 2002
<u>AB</u>	+	<u>200MG</u>	<u>A075753</u>	<u>003</u>	Apr 09, 2002
	LIPOFEN				
	CIPHER PHARMS INC	50MG	N021612	001	Jan 11, 2006
	+	150MG	N021612	003	Jan 11, 2006

TABLET; ORAL

FENOFIBRATE

<u>AB</u>	IMPAX LABS	<u>54MG</u>	<u>A076509</u>	<u>001</u>	Mar 26, 2008
<u>AB</u>		<u>160MG</u>	<u>A076509</u>	<u>002</u>	Mar 26, 2008
<u>AB</u>	LUPIN LTD	<u>48MG</u>	<u>A090856</u>	<u>001</u>	Dec 23, 2011
<u>AB</u>		<u>145MG</u>	<u>A090856</u>	<u>002</u>	Dec 23, 2011
<u>AB</u>	MYLAN	<u>54MG</u>	<u>A076520</u>	<u>001</u>	Oct 25, 2007
<u>AB</u>		<u>160MG</u>	<u>A076520</u>	<u>003</u>	Oct 25, 2007
<u>AB</u>	MYLAN PHARMS INC	<u>48MG</u>	<u>A202856</u>	<u>001</u>	Dec 07, 2012
<u>AB</u>		<u>145MG</u>	<u>A202856</u>	<u>002</u>	Dec 07, 2012
<u>AB</u>	RANBAXY	<u>54MG</u>	<u>A076635</u>	<u>001</u>	Oct 31, 2005
<u>AB</u>		<u>160MG</u>	<u>A076635</u>	<u>003</u>	Oct 31, 2005
<u>AB</u>	TEVA	<u>54MG</u>	<u>A076433</u>	<u>001</u>	May 13, 2005
<u>AB</u>	+	<u>160MG</u>	<u>A076433</u>	<u>002</u>	May 13, 2005
<u>AB</u>	VALEANT INTL	<u>48MG</u>	<u>A090715</u>	<u>001</u>	Apr 05, 2012
<u>AB</u>		<u>145MG</u>	<u>A090715</u>	<u>002</u>	Apr 05, 2012

TRICOR

<u>AB</u>	ABBVIE	<u>48MG</u>	<u>N021656</u>	<u>001</u>	Nov 05, 2004
<u>AB</u>	+	<u>145MG</u>	<u>N021656</u>	<u>002</u>	Nov 05, 2004
	TRIGLIDE				
BX	+	SKYEPHARMA AG	N021350	002	May 07, 2005
	FENOFIBRATE				
	RANBAXY	107MG	A076635	002	Oct 31, 2005
	FENOGLIDE				
	SANTARUS	40MG	N022118	001	Aug 10, 2007
	+	120MG	N022118	002	Aug 10, 2007
	TRIGLIDE				
	SKYEPHARMA AG	50MG	N021350	001	May 07, 2005

PRESCRIPTION DRUG PRODUCT LIST

3 - 175 (of 428)

FENOFIBRIC ACID

TABLET; ORAL
FIBRICOR

AR HOLDING CO INC	35MG	N022418	001	Aug 14, 2009
+	105MG	N022418	002	Aug 14, 2009

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION
CORLOPAM

AP + HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>N019922</u>	<u>001</u>	Sep 23, 1997

AP FENOLDOPAM MESYLATE	<u>EQ 10MG BASE/ML</u>	<u>A076582</u>	<u>001</u>	Oct 12, 2004

AP BEDFORD LABS	<u>EQ 10MG BASE/ML</u>	<u>A077155</u>	<u>001</u>	Feb 15, 2005

FENOPROFEN CALCIUM

CAPSULE; ORAL
NALFON

+ XSPIRE	EQ 200MG BASE	N017604	003	
	EQ 400MG BASE	N017604	004	Jul 21, 2009

TABLET; ORAL

AB FENOPROFEN CALCIUM	<u>EQ 600MG BASE</u>	<u>A072557</u>	<u>001</u>	Aug 29, 1988

AB + MYLAN	<u>EQ 600MG BASE</u>	<u>A072267</u>	<u>001</u>	Aug 17, 1988

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

<u>DURAGESIC-100</u>				
AB JANSSEN PHARMS	<u>100MCG/HR</u>	<u>N019813</u>	<u>001</u>	Aug 07, 1990

<u>DURAGESIC-12</u>				
AB JANSSEN PHARMS	<u>12.5MCG/HR</u>	<u>N019813</u>	<u>005</u>	Feb 04, 2005

<u>DURAGESIC-25</u>				
AB + JANSSEN PHARMS	<u>25MCG/HR</u>	<u>N019813</u>	<u>004</u>	Aug 07, 1990

<u>DURAGESIC-50</u>				
AB JANSSEN PHARMS	<u>50MCG/HR</u>	<u>N019813</u>	<u>003</u>	Aug 07, 1990

<u>DURAGESIC-75</u>				
AB JANSSEN PHARMS	<u>75MCG/HR</u>	<u>N019813</u>	<u>002</u>	Aug 07, 1990

<u>FENTANYL-100</u>				
AB AVEVA	<u>100MCG/HR</u>	<u>A077449</u>	<u>004</u>	Oct 20, 2008

AB LAVIPHARM LABS	<u>100MCG/HR</u>	<u>A077051</u>	<u>004</u>	Aug 04, 2006

AB MALLINCKRODT INC	<u>100MCG/HR</u>	<u>A077154</u>	<u>004</u>	Feb 09, 2011

AB MYLAN TECHNOLOGIES	<u>100MCG/HR</u>	<u>A076258</u>	<u>004</u>	Jan 28, 2005

AB NOVEN	<u>100MCG/HR</u>	<u>A077775</u>	<u>004</u>	Oct 16, 2009

AB PAR PHARM INC	<u>100MCG/HR</u>	<u>A077062</u>	<u>004</u>	Aug 20, 2007

AB WATSON LABS	<u>100MCG/HR</u>	<u>A076709</u>	<u>004</u>	Aug 20, 2007

<u>FENTANYL-12</u>				
AB MYLAN TECHNOLOGIES	<u>12.5MCG/HR</u>	<u>A076258</u>	<u>005</u>	Jan 23, 2007

<u>FENTANYL-25</u>				
AB AVEVA	<u>25MCG/HR</u>	<u>A077449</u>	<u>001</u>	Oct 20, 2008

AB LAVIPHARM LABS	<u>25MCG/HR</u>	<u>A077051</u>	<u>001</u>	Aug 04, 2006

AB MALLINCKRODT INC	<u>25MCG/HR</u>	<u>A077154</u>	<u>001</u>	Feb 09, 2011

AB MYLAN TECHNOLOGIES	<u>25MCG/HR</u>	<u>A076258</u>	<u>001</u>	Jan 28, 2005

AB NOVEN	<u>25MCG/HR</u>	<u>A077775</u>	<u>001</u>	Oct 16, 2009

AB PAR PHARM INC	<u>25MCG/HR</u>	<u>A077062</u>	<u>001</u>	Aug 20, 2007

AB WATSON LABS	<u>25MCG/HR</u>	<u>A076709</u>	<u>001</u>	Aug 20, 2007

<u>FENTANYL-50</u>				
AB AVEVA	<u>50MCG/HR</u>	<u>A077449</u>	<u>002</u>	Oct 20, 2008

AB LAVIPHARM LABS	<u>50MCG/HR</u>	<u>A077051</u>	<u>002</u>	Aug 04, 2006

AB MALLINCKRODT INC	<u>50MCG/HR</u>	<u>A077154</u>	<u>002</u>	Feb 09, 2011

AB MYLAN TECHNOLOGIES	<u>50MCG/HR</u>	<u>A076258</u>	<u>002</u>	Jan 28, 2005

AB NOVEN	<u>50MCG/HR</u>	<u>A077775</u>	<u>002</u>	Oct 16, 2009

AB PAR PHARM INC	<u>50MCG/HR</u>	<u>A077062</u>	<u>002</u>	Aug 20, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 176 (of 428)

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL - 50

<u>AB</u>	WATSON LABS	<u>50MCG/HR</u>	<u>A076709</u>	<u>002</u>	Aug 20, 2007

FENTANYL - 75

<u>AB</u>	AVEVA	<u>75MCG/HR</u>	<u>A077449</u>	<u>003</u>	Oct 20, 2008
<u>AB</u>	LAVIPHARM LABS	<u>75MCG/HR</u>	<u>A077051</u>	<u>003</u>	Aug 04, 2006
<u>AB</u>	MALLINCKRODT INC	<u>75MCG/HR</u>	<u>A077154</u>	<u>003</u>	Feb 09, 2011
<u>AB</u>	MYLAN TECHNOLOGIES	<u>75MCG/HR</u>	<u>A076258</u>	<u>003</u>	Jan 28, 2005
<u>AB</u>	NOVEN	<u>75MCG/HR</u>	<u>A077775</u>	<u>003</u>	Oct 16, 2009
<u>AB</u>	PAR PHARM INC	<u>75MCG/HR</u>	<u>A077062</u>	<u>003</u>	Aug 20, 2007
<u>AB</u>	WATSON LABS	<u>75MCG/HR</u>	<u>A076709</u>	<u>003</u>	Aug 20, 2007

SPRAY; SUBLINGUAL
SUBSYS

	INSYS THERAP	0.1MG	N202788	001	Jan 04, 2012
		0.2MG	N202788	002	Jan 04, 2012
+		0.4MG	N202788	003	Jan 04, 2012
		0.6MG	N202788	004	Jan 04, 2012
		0.8MG	N202788	005	Jan 04, 2012

FENTANYL CITRATEFILM; BUCCAL
ONSOLIS

	MEDA PHARMS	EQ 0.2MG BASE	N022266	001	Jul 16, 2009
+		EQ 0.4MG BASE	N022266	002	Jul 16, 2009
		EQ 0.6MG BASE	N022266	003	Jul 16, 2009
		EQ 0.8MG BASE	N022266	004	Jul 16, 2009
		EQ 1.2MG BASE	N022266	005	Jul 16, 2009

INJECTABLE; INJECTION

FENTANYL CITRATE

<u>AP</u>	HOSPIRA	<u>EQ 0.05MG BASE/ML</u>	<u>N019115</u>	<u>001</u>	Jan 12, 1985
	<u>FENTANYL CITRATE PRESERVATIVE FREE</u>				
<u>AP</u> +	BAXTER HLTHCARE	<u>EQ 0.05MG BASE/ML</u>	<u>N019101</u>	<u>001</u>	Jul 11, 1984
<u>AP</u>	HOSPIRA	<u>EQ 0.05MG BASE/ML</u>	<u>A072786</u>	<u>001</u>	Sep 24, 1991

SUBLIMAZE PRESERVATIVE FREE

<u>AP</u> +	AKORN	<u>EQ 0.05MG BASE/ML</u>	<u>N016619</u>	<u>001</u>	
	SPRAY, METERED; NASAL				
	LAZANDA				
	ARCHIMEDES	EQ 0.1MG BASE	N022569	001	Jun 30, 2011
+		EQ 0.4MG BASE	N022569	002	Jun 30, 2011

TABLET; BUCCAL

FENTANYL CITRATE

<u>AB</u>	WATSON LABS	<u>EQ 0.1MG BASE</u>	<u>A079075</u>	<u>001</u>	Jan 07, 2011
<u>AB</u>		<u>EQ 0.2MG BASE</u>	<u>A079075</u>	<u>002</u>	Jan 07, 2011
<u>AB</u>		<u>EQ 0.4MG BASE</u>	<u>A079075</u>	<u>003</u>	Jan 07, 2011
<u>AB</u>		<u>EQ 0.6MG BASE</u>	<u>A079075</u>	<u>004</u>	Jan 07, 2011
<u>AB</u>		<u>EQ 0.8MG BASE</u>	<u>A079075</u>	<u>005</u>	Jan 07, 2011

FENTORA

<u>AB</u>	CEPHALON	<u>EQ 0.1MG BASE</u>	<u>N021947</u>	<u>001</u>	Sep 25, 2006
<u>AB</u>		<u>EQ 0.2MG BASE</u>	<u>N021947</u>	<u>002</u>	Sep 25, 2006
<u>AB</u> +		<u>EQ 0.4MG BASE</u>	<u>N021947</u>	<u>003</u>	Sep 25, 2006
<u>AB</u>		<u>EQ 0.6MG BASE</u>	<u>N021947</u>	<u>004</u>	Sep 25, 2006
<u>AB</u>		<u>EQ 0.8MG BASE</u>	<u>N021947</u>	<u>005</u>	Sep 25, 2006

TABLET; SUBLINGUAL
ABSTRAL

	PROSTRAKAN INC	EQ 0.1MG BASE	N022510	001	Jan 07, 2011
		EQ 0.2MG BASE	N022510	002	Jan 07, 2011
		EQ 0.3MG BASE	N022510	003	Jan 07, 2011
+		EQ 0.4MG BASE	N022510	004	Jan 07, 2011
		EQ 0.6MG BASE	N022510	005	Jan 07, 2011
		EQ 0.8MG BASE	N022510	006	Jan 07, 2011

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 177 (of 428)

FENTANYL CITRATE

TROCHE/LOZENGE; TRANSMUCOSAL

ACTIQ

<u>AB</u>	CEPHALON	<u>EQ 0.2MG BASE</u>	<u>N020747</u>	<u>001</u>	Nov 04, 1998
<u>AB</u>	+	<u>EQ 0.4MG BASE</u>	<u>N020747</u>	<u>002</u>	Nov 04, 1998
<u>AB</u>		<u>EQ 0.6MG BASE</u>	<u>N020747</u>	<u>003</u>	Nov 04, 1998
<u>AB</u>		<u>EQ 0.8MG BASE</u>	<u>N020747</u>	<u>004</u>	Nov 04, 1998
<u>AB</u>		<u>EQ 1.2MG BASE</u>	<u>N020747</u>	<u>005</u>	Nov 04, 1998
<u>AB</u>		<u>EQ 1.6MG BASE</u>	<u>N020747</u>	<u>006</u>	Nov 04, 1998

FENTANYL CITRATE

<u>AB</u>	MALLINCKRODT	<u>EQ 0.2MG BASE</u>	<u>A078907</u>	<u>001</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.4MG BASE</u>	<u>A078907</u>	<u>002</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.6MG BASE</u>	<u>A078907</u>	<u>003</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.8MG BASE</u>	<u>A078907</u>	<u>004</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 1.2MG BASE</u>	<u>A078907</u>	<u>005</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 1.6MG BASE</u>	<u>A078907</u>	<u>006</u>	Oct 30, 2009
<u>AB</u>	PAR PHARM	<u>EQ 0.2MG BASE</u>	<u>A077312</u>	<u>001</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.4MG BASE</u>	<u>A077312</u>	<u>002</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.6MG BASE</u>	<u>A077312</u>	<u>003</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.8MG BASE</u>	<u>A077312</u>	<u>004</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 1.2MG BASE</u>	<u>A077312</u>	<u>005</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 1.6MG BASE</u>	<u>A077312</u>	<u>006</u>	Oct 30, 2009

FERRIC HEXACYANOFERRATE(II)

CAPSULE; ORAL

RADIOGARDASE (PRUSSIAN BLUE)

+	HEYL CHEMISCH	500MG	N021626	001	Oct 02, 2003

FERUMOXASIL

SUSPENSION; ORAL

GASTROMARK

+	AMAG PHARMS INC	EQ 0.175MG IRON/ML	N020410	001	Dec 06, 1996

FERUMOXYTOL

SOLUTION; INTRAVENOUS

FERAHEME

+	AMAG PHARMS INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

TOVIAZ

	PFIZER	4MG	N022030	001	Oct 31, 2008
+		8MG	N022030	002	Oct 31, 2008

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

ALLEGRA

<u>AB</u>	+	SANOFI AVENTIS US	<u>30MG/5ML</u>	<u>N021963</u>	<u>001</u>	Oct 16, 2006

FEXOFENADINE HYDROCHLORIDE

<u>AB</u>		ACTAVIS MID ATLANTIC	<u>30MG/5ML</u>	<u>A201311</u>	<u>001</u>	Jul 25, 2012

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

<u>AB</u>		BARR	<u>30MG</u>	<u>A076191</u>	<u>001</u>	Aug 31, 2005
<u>AB</u>			<u>60MG</u>	<u>A076191</u>	<u>002</u>	Aug 31, 2005
<u>AB</u>			<u>180MG</u>	<u>A076191</u>	<u>003</u>	Aug 31, 2005
<u>AB</u>		DR REDDYS LABS LTD	<u>30MG</u>	<u>A076502</u>	<u>001</u>	Apr 11, 2006
<u>AB</u>			<u>60MG</u>	<u>A076502</u>	<u>002</u>	Apr 11, 2006
<u>AB</u>			<u>180MG</u>	<u>A076502</u>	<u>003</u>	Apr 11, 2006
<u>AB</u>		MYLAN	<u>30MG</u>	<u>A077081</u>	<u>002</u>	Apr 11, 2008
<u>AB</u>			<u>60MG</u>	<u>A077081</u>	<u>003</u>	Apr 11, 2008
<u>AB</u>			<u>180MG</u>	<u>A077081</u>	<u>001</u>	Apr 16, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 178 (of 428)

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

<u>AB</u>	TEVA	<u>30MG</u>	<u>A076447</u>	<u>001</u>	Sep 01, 2005
<u>AB</u>		<u>60MG</u>	<u>A076447</u>	<u>002</u>	Sep 01, 2005
<u>AB</u>		<u>180MG</u>	<u>A076447</u>	<u>003</u>	Sep 01, 2005

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>60MG;120MG</u>	<u>A076236</u>	<u>001</u>	Apr 14, 2005
<u>AB</u>	IMPAX PHARMS	<u>60MG;120MG</u>	<u>A076298</u>	<u>001</u>	Nov 12, 2010

FIDAXOMICIN

TABLET; ORAL

DIFICID

	+ OPTIMER PHARMS	200MG	N201699	001	May 27, 2011

FINASTERIDE

TABLET; ORAL

FINASTERIDE

<u>AB</u>	ACCORD HLTHCARE INC	<u>5MG</u>	<u>A090121</u>	<u>001</u>	Feb 23, 2010
<u>AB</u>	ACTAVIS TOTOWA	<u>5MG</u>	<u>A077914</u>	<u>001</u>	Mar 28, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078341</u>	<u>001</u>	Oct 30, 2007
<u>AB</u>	DR REDDYS LABS INC	<u>1MG</u>	<u>A076436</u>	<u>001</u>	Jul 28, 2006
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076437</u>	<u>001</u>	Feb 28, 2007
<u>AB</u>	GEDEON RICHTER USA	<u>5MG</u>	<u>A077251</u>	<u>001</u>	Dec 22, 2006
<u>AB</u>	HETERO DRUGS LTD	<u>5MG</u>	<u>A090061</u>	<u>001</u>	Jun 07, 2010
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A077578</u>	<u>001</u>	Dec 18, 2006
<u>AB</u>	SUN PHARMA GLOBAL	<u>5MG</u>	<u>A090507</u>	<u>001</u>	Aug 16, 2011
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076511</u>	<u>001</u>	Dec 15, 2006
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078900</u>	<u>001</u>	Dec 28, 2009

PROPECIA

<u>AB</u>	+ MERCK	<u>1MG</u>	<u>N020788</u>	<u>001</u>	Dec 19, 1997

PROSCAR

<u>AB</u>	+ MERCK	<u>5MG</u>	<u>N020180</u>	<u>001</u>	Jun 19, 1992

FINGOLIMOD

CAPSULE; ORAL

GILENYA

	+ NOVARTIS	0.5MG	N022527	001	Sep 21, 2010

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

<u>AB</u>	EPIC PHARMA	<u>100MG</u>	<u>A076835</u>	<u>001</u>	Nov 30, 2005
<u>AB</u>	IMPAX PHARMS	<u>100MG</u>	<u>A076234</u>	<u>001</u>	Aug 28, 2003
<u>AB</u>	+ PADDOCK LLC	<u>100MG</u>	<u>A076831</u>	<u>001</u>	Dec 16, 2004

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

<u>AB</u>	AMNEAL PHARM	<u>50MG</u>	<u>A075442</u>	<u>001</u>	Jul 31, 2001
<u>AB</u>		<u>100MG</u>	<u>A075442</u>	<u>002</u>	Jul 31, 2001
<u>AB</u>		<u>150MG</u>	<u>A075442</u>	<u>003</u>	Jul 31, 2001
<u>AB</u>	APOTEX INC	<u>50MG</u>	<u>A079164</u>	<u>001</u>	Jul 09, 2009
<u>AB</u>		<u>100MG</u>	<u>A079164</u>	<u>002</u>	Jul 09, 2009
<u>AB</u>		<u>150MG</u>	<u>A079164</u>	<u>003</u>	Jul 09, 2009
<u>AB</u>	BARR	<u>50MG</u>	<u>A075882</u>	<u>001</u>	Oct 28, 2002
<u>AB</u>		<u>100MG</u>	<u>A075882</u>	<u>002</u>	Oct 28, 2002
<u>AB</u>		<u>150MG</u>	<u>A075882</u>	<u>003</u>	Oct 28, 2002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 179 (of 428)

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

<u>AB</u>	RANBAXY	<u>50MG</u>	<u>A076421</u>	<u>001</u>	Mar 28, 2003
<u>AB</u>		<u>100MG</u>	<u>A076421</u>	<u>002</u>	Mar 28, 2003
<u>AB</u>		<u>150MG</u>	<u>A076421</u>	<u>003</u>	Mar 28, 2003
<u>AB</u>	ROXANE	<u>50MG</u>	<u>A076278</u>	<u>001</u>	Jan 14, 2003
<u>AB</u>		<u>100MG</u>	<u>A076278</u>	<u>002</u>	Jan 14, 2003
<u>AB</u>		<u>150MG</u>	<u>A076278</u>	<u>003</u>	Jan 14, 2003
	<u>TAMBOCOR</u>				
<u>AB</u>	MEDICIS	<u>50MG</u>	<u>N018830</u>	<u>004</u>	Aug 23, 1988
<u>AB</u>		<u>100MG</u>	<u>N018830</u>	<u>001</u>	Oct 31, 1985
<u>AB</u>	+	<u>150MG</u>	<u>N018830</u>	<u>003</u>	Jun 03, 1988

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

+	AVID RADIOPHARMS INC	10-50ML (13.5-51MCI/ML)	N202008	003	Apr 06, 2012
+		10-30ML (13.5-51MCI/ML)	N202008	002	Apr 06, 2012
+		10ML (13.5-51MCI/ML)	N202008	001	Apr 06, 2012

FLOXURIDINE

INJECTABLE; INJECTION

FLOXURIDINE

<u>AP</u>	+	BEDFORD	<u>500MG/VIAL</u>	<u>A075387</u>	<u>001</u>	Apr 16, 2000
<u>AP</u>		FRESENIUS KABI USA	<u>500MG/VIAL</u>	<u>A075837</u>	<u>001</u>	Feb 22, 2001

FLUCONAZOLE

FOR SUSPENSION; ORAL

DIFLUCAN

<u>AB</u>		PFIZER	<u>50MG/5ML</u>	<u>N020090</u>	<u>001</u>	Dec 23, 1993
<u>AB</u>	+		<u>200MG/5ML</u>	<u>N020090</u>	<u>002</u>	Dec 23, 1993

FLUCONAZOLE

<u>AB</u>		AUROBINDO PHARM	<u>50MG/5ML</u>	<u>A079150</u>	<u>001</u>	Sep 18, 2009
<u>AB</u>			<u>200MG/5ML</u>	<u>A079150</u>	<u>002</u>	Sep 18, 2009
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>50MG/5ML</u>	<u>A077523</u>	<u>001</u>	Sep 12, 2007
<u>AB</u>			<u>200MG/5ML</u>	<u>A077523</u>	<u>002</u>	Sep 12, 2007
<u>AB</u>		RANBAXY	<u>50MG/5ML</u>	<u>A076332</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>			<u>200MG/5ML</u>	<u>A076332</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		ROXANE	<u>50MG/5ML</u>	<u>A076246</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>			<u>200MG/5ML</u>	<u>A076246</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		TARO PHARM INDS	<u>50MG/5ML</u>	<u>A076918</u>	<u>001</u>	Dec 18, 2006
<u>AB</u>			<u>200MG/5ML</u>	<u>A076918</u>	<u>002</u>	Dec 18, 2006

INJECTABLE; INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	PFIZER	<u>200MG/100ML (2MG/ML)</u>	<u>N019950</u>	<u>003</u>	Sep 29, 1992
<u>AP</u>	+		<u>400MG/200ML (2MG/ML)</u>	<u>N019950</u>	<u>005</u>	Jul 08, 1994

DIFLUCAN IN SODIUM CHLORIDE 0.9%

<u>AP</u>	+	PFIZER	<u>200MG/100ML (2MG/ML)</u>	<u>N019950</u>	<u>001</u>	Jan 29, 1990
<u>AP</u>	+		<u>400MG/200ML (2MG/ML)</u>	<u>N019950</u>	<u>006</u>	Jan 29, 1990

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	+	PFIZER	<u>200MG/100ML (2MG/ML)</u>	<u>N019950</u>	<u>002</u>	Jan 29, 1990
<u>AP</u>	+		<u>400MG/200ML (2MG/ML)</u>	<u>N019950</u>	<u>004</u>	Jan 29, 1990

FLUCANAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>		ACS DOBFAR INFO SA	<u>200MG/100ML (2MG/ML)</u>	<u>A079104</u>	<u>001</u>	Jul 30, 2009
<u>AP</u>			<u>400MG/200ML (2MG/ML)</u>	<u>A079104</u>	<u>002</u>	Jul 30, 2009

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>		AGILA SPECLTS	<u>200MG/100ML (2MG/ML)</u>	<u>A076888</u>	<u>001</u>	Mar 25, 2005
<u>AP</u>			<u>400MG/200ML (2MG/ML)</u>	<u>A076888</u>	<u>002</u>	Mar 25, 2005
<u>AP</u>		HIKMA FARMACEUTICA	<u>200MG/100ML (2MG/ML)</u>	<u>A078764</u>	<u>001</u>	Jan 30, 2012
<u>AP</u>			<u>400MG/200ML (2MG/ML)</u>	<u>A078764</u>	<u>002</u>	Jan 30, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 180 (of 428)

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>200MG/100ML (2MG/ML)</u>	<u>A076304</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076304</u>	<u>002</u>	Jul 29, 2004

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

<u>AP</u>	BEDFORD	<u>200MG/100ML (2MG/ML)</u>	<u>A076087</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076087</u>	<u>003</u>	Jul 29, 2004
<u>AP</u>	CLARIS LIFESCIENCES	<u>200MG/100ML (2MG/ML)</u>	<u>A077947</u>	<u>001</u>	May 26, 2010
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A077947</u>	<u>002</u>	May 26, 2010
<u>AP</u>	FRESENIUS KABI USA	<u>200MG/100ML (2MG/ML)</u>	<u>A076145</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076145</u>	<u>002</u>	Jul 29, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>200MG/100ML (2MG/ML)</u>	<u>A076736</u>	<u>001</u>	Aug 23, 2005
<u>AP</u>	TEVA PARENTERAL	<u>200MG/100ML (2MG/ML)</u>	<u>A076653</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076653</u>	<u>002</u>	Jul 29, 2004

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>200MG/100ML (2MG/ML)</u>	<u>A076766</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076766</u>	<u>002</u>	Jul 29, 2004
<u>AP</u>	BEDFORD LABS	<u>200MG/100ML (2MG/ML)</u>	<u>A078107</u>	<u>001</u>	Jul 30, 2008
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A078107</u>	<u>002</u>	Jul 30, 2008
<u>AP</u>	CLARIS LIFESCIENCES	<u>200MG/100ML (2MG/ML)</u>	<u>A077909</u>	<u>001</u>	May 26, 2010
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A077909</u>	<u>002</u>	May 26, 2010
<u>AP</u>	HIKMA FARMACEUTICA	<u>200MG/100ML (2MG/ML)</u>	<u>A078698</u>	<u>001</u>	Jan 30, 2012
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A078698</u>	<u>002</u>	Jan 30, 2012
<u>AP</u>	HOSPIRA	<u>200MG/100ML (2MG/ML)</u>	<u>A076303</u>	<u>001</u>	Jul 29, 2004
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076303</u>	<u>002</u>	Jul 29, 2004
<u>AP</u>	TEVA PHARMS	<u>200MG/100ML (2MG/ML)</u>	<u>A076837</u>	<u>001</u>	Jan 13, 2005
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A076837</u>	<u>002</u>	Jan 13, 2005

FULCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	CLARIS LIFESCIENCES	<u>200MG/100ML (2MG/ML)</u>	<u>A077988</u>	<u>001</u>	May 26, 2010
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A077988</u>	<u>002</u>	May 26, 2010

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

	BEDFORD	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008

TABLET; ORAL

DIFLUCAN

<u>AB</u>	PFIZER	<u>50MG</u>	<u>N019949</u>	<u>001</u>	Jan 29, 1990
<u>AB</u>		<u>100MG</u>	<u>N019949</u>	<u>002</u>	Jan 29, 1990
<u>AB</u>		<u>150MG</u>	<u>N019949</u>	<u>004</u>	Jun 30, 1994
<u>AB</u>	+	<u>200MG</u>	<u>N019949</u>	<u>003</u>	Jan 29, 1990

FLUCONAZOLE

<u>AB</u>	APOTEX	<u>50MG</u>	<u>A076665</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076665</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076665</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076665</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	AUROBINDO PHARMA	<u>50MG</u>	<u>A077731</u>	<u>001</u>	Oct 07, 2008
<u>AB</u>		<u>100MG</u>	<u>A077731</u>	<u>002</u>	Oct 07, 2008
<u>AB</u>		<u>150MG</u>	<u>A077731</u>	<u>003</u>	Oct 07, 2008
<u>AB</u>		<u>200MG</u>	<u>A077731</u>	<u>004</u>	Oct 07, 2008
<u>AB</u>	GLENMARK GENERICS	<u>50MG</u>	<u>A077253</u>	<u>001</u>	Jan 25, 2006
<u>AB</u>		<u>100MG</u>	<u>A077253</u>	<u>002</u>	Jan 25, 2006
<u>AB</u>		<u>150MG</u>	<u>A077253</u>	<u>003</u>	Jan 25, 2006
<u>AB</u>		<u>200MG</u>	<u>A077253</u>	<u>004</u>	Jan 25, 2006
<u>AB</u>	HARRIS PHARM	<u>50MG</u>	<u>A078423</u>	<u>001</u>	Mar 07, 2011
<u>AB</u>		<u>100MG</u>	<u>A078423</u>	<u>002</u>	Mar 07, 2011
<u>AB</u>		<u>150MG</u>	<u>A078423</u>	<u>003</u>	Mar 07, 2011
<u>AB</u>		<u>200MG</u>	<u>A078423</u>	<u>004</u>	Mar 07, 2011
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>50MG</u>	<u>A076077</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076077</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076077</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076077</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A076351</u>	<u>001</u>	Jul 29, 2004

PRESCRIPTION DRUG PRODUCT LIST

3 - 181 (of 428)

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

<u>AB</u>	MYLAN	<u>100MG</u>	<u>A076351</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076351</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076351</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	TARO	<u>50MG</u>	<u>A076507</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076507</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076507</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076507</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	TEVA	<u>50MG</u>	<u>A074681</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A074681</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A074681</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A074681</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	UNIQUE PHARM LABS	<u>50MG</u>	<u>A076957</u>	<u>001</u>	Sep 28, 2005
<u>AB</u>		<u>100MG</u>	<u>A076957</u>	<u>002</u>	Sep 28, 2005
<u>AB</u>		<u>200MG</u>	<u>A076957</u>	<u>003</u>	Sep 28, 2005
	FLUCONAZOLE				
BX	DR REDDYS LABS INC	50MG	A076658	001	Jul 29, 2004
BX		100MG	A076658	002	Jul 29, 2004
BX		150MG	A076658	003	Jul 29, 2004
BX		200MG	A076658	004	Jul 29, 2004

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON

<u>AB</u>	VALEANT	<u>250MG</u>	<u>N017001</u>	<u>001</u>	
<u>AB</u>	+	<u>500MG</u>	<u>N017001</u>	<u>002</u>	
	<u>FLUCYTOSINE</u>				
<u>AB</u>	SIGMAPHARM LABS LLC	<u>250MG</u>	<u>A201566</u>	<u>001</u>	Jun 28, 2011
<u>AB</u>		<u>500MG</u>	<u>A201566</u>	<u>002</u>	Jun 28, 2011

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

<u>AP</u>	ACTAVIS TOTOWA	<u>50MG/VIAL</u>	<u>A078610</u>	<u>001</u>	Feb 11, 2009
<u>AP</u>	BIONICHE PHARMA USA	<u>50MG/2ML (25MG/ML)</u>	<u>A090724</u>	<u>001</u>	Sep 27, 2010
<u>AP</u>	FRESENIUS KABI USA	<u>50MG/2ML (25MG/ML)</u>	<u>A078393</u>	<u>001</u>	Oct 15, 2007
<u>AP</u>		<u>50MG/VIAL</u>	<u>A078544</u>	<u>001</u>	Oct 15, 2007
<u>AP</u>	+	<u>50MG/VIAL</u>	<u>A077790</u>	<u>001</u>	Apr 06, 2007
<u>AP</u>	ONCO THERAPIES LTD	<u>50MG/2ML (25MG/ML)</u>	<u>A200647</u>	<u>001</u>	Dec 21, 2011
<u>AP</u>		<u>50MG/VIAL</u>	<u>A200648</u>	<u>001</u>	Oct 16, 2012
<u>AP</u>	+	<u>50MG/2ML (25MG/ML)</u>	<u>N022137</u>	<u>001</u>	Sep 21, 2007
<u>AP</u>	TEVA PARENTERAL	<u>50MG/VIAL</u>	<u>A076349</u>	<u>001</u>	Aug 28, 2003
<u>AP</u>	+	<u>50MG/2ML (25MG/ML)</u>	<u>A076661</u>	<u>001</u>	Apr 28, 2004

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

<u>AP</u>	+	<u>FEINSTEIN</u>	<u>20-200mCi/ML</u>	<u>N021870</u>	<u>001</u>	Aug 19, 2005
<u>AP</u>		<u>PETNET</u>	<u>20-200mCi/ML</u>	<u>A079086</u>	<u>001</u>	Feb 25, 2011
		FLUDEOXYGLUCOSE F 18				
	+	WEILL MEDCL COLL	10-100mCi/ML	N021768	001	Aug 05, 2004
		FLUDEOXYGLUCOSE F18				
	+	FEINSTEIN	20-300mCi/ML	N021870	002	Nov 21, 2008

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

<u>AB</u>	BARR	<u>0.1MG</u>	<u>A040425</u>	<u>001</u>	Jan 21, 2003
<u>AB</u>	+	<u>IMPAX LABS</u>	<u>A040431</u>	<u>001</u>	Mar 18, 2002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 182 (of 428)

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

<u>AB</u>	WEST-WARD PHARM CORP	<u>0.1MG</u>	<u>A091302</u>	<u>001</u>	Jul 22, 2011

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

<u>AP</u>	BEDFORD LABS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076256</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076256</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	CLARIS LIFESCIENCES	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076755</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076755</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	FRESENIUS KABI USA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076955</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076955</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078527</u>	<u>001</u>	Mar 23, 2009
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A078527</u>	<u>002</u>	Mar 23, 2009
<u>AP</u>	HIKMA MAPLE	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076787</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076787</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	PFIZER	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078595</u>	<u>001</u>	May 13, 2008
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A078595</u>	<u>002</u>	May 13, 2008
<u>AP</u>	SAGENT PHARMS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A090584</u>	<u>001</u>	Aug 28, 2012
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A090584</u>	<u>002</u>	Aug 28, 2012
<u>AP</u>	SANDOZ	<u>1MG/10ML (0.1MG/ML)</u>	<u>A077071</u>	<u>002</u>	May 03, 2005
<u>AP</u>		<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A077071</u>	<u>001</u>	May 03, 2005
	<u>ROMAZICON</u>				
<u>AP</u>	+ HOFFMANN LA ROCHE	<u>1MG/10ML (0.1MG/ML)</u>	<u>N020073</u>	<u>001</u>	Dec 20, 1991
<u>AP</u>		<u>0.5MG/5ML (0.1MG/ML)</u>	<u>N020073</u>	<u>002</u>	Dec 20, 1991

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROBID

	+ ROCHE PALO	0.25MG/INH	N018340	001	Aug 17, 1984

AEROSPAN HFA

	+ ACTON PHARMS	EQ 78MG BASE/INH	N021247	001	Jan 27, 2006

SPRAY, METERED; NASAL

FLUNISOLIDE

<u>AB</u>	+ BAUSCH AND LOMB	<u>0.025MG/SPRAY</u>	<u>A074805</u>	<u>001</u>	Feb 20, 2002
<u>AB</u>	HI TECH PHARMA CO	<u>0.025MG/SPRAY</u>	<u>A077704</u>	<u>001</u>	Aug 03, 2006
	FLUNISOLIDE				
	+ APOTEX INC	0.029MG/SPRAY	A077436	001	Aug 09, 2007

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>0.01%</u>	<u>A088170</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>		<u>0.025%</u>	<u>A088169</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>	G AND W LABS	<u>0.01%</u>	<u>A089526</u>	<u>001</u>	Jul 26, 1988
<u>AT</u>		<u>0.025%</u>	<u>A089525</u>	<u>001</u>	Jul 26, 1988
<u>AT</u>	TARO	<u>0.025%</u>	<u>A087104</u>	<u>001</u>	Apr 27, 1982

SYNALAR

<u>AT</u>	+ MEDIMETRIKS PHARMS	<u>0.01%</u>	<u>N012787</u>	<u>004</u>	
<u>AT</u>	+	<u>0.025%</u>	<u>N012787</u>	<u>002</u>	
<u>AT</u>	+	<u>0.025%</u>	<u>N012787</u>	<u>005</u>	

IMPLANT; INTRAVITREAL
RETISERT

	+ BAUSCH AND LOMB	0.59MG	N021737	001	Apr 08, 2005

OIL; TOPICAL

DERMA-SMOOTHIE/FS

<u>AT</u>	+ HILL DERMAC	<u>0.01%</u>	<u>N019452</u>	<u>002</u>	Nov 09, 2005
<u>AT</u>	+	<u>0.01%</u>	<u>N019452</u>	<u>001</u>	Feb 03, 1988

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 183 (of 428)

FLUOCINOLONE ACETONIDE

OIL; TOPICAL					
<u>FLUOCINOLONE ACETONIDE</u>					
<u>AT</u>	IDENTI PHARMS INC	<u>0.01%</u>	<u>A201759</u>	<u>001</u>	Oct 17, 2011
<u>AT</u>		<u>0.01%</u>	<u>A201764</u>	<u>001</u>	Oct 17, 2011
OIL/DROPS; OTIC					
<u>DERMOTIC</u>					
<u>AT</u>	+ HILL DERMAC	<u>0.01%</u>	<u>N019452</u>	<u>003</u>	Nov 09, 2005
<u>FLUOCINOLONE ACETONIDE</u>					
<u>AT</u>	IDENTI PHARMS INC	<u>0.01%</u>	<u>A091306</u>	<u>001</u>	Oct 17, 2011
OINTMENT; TOPICAL					
<u>FLUOCINOLONE ACETONIDE</u>					
<u>AT</u>	FOUGERA	<u>0.025%</u>	<u>A088168</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>	G AND W LABS	<u>0.025%</u>	<u>A089524</u>	<u>001</u>	Jul 26, 1988
<u>AT</u>	TARO	<u>0.025%</u>	<u>A040041</u>	<u>001</u>	Sep 15, 1994
<u>SYNALAR</u>					
<u>AT</u>	+ MEDIMETRIKS PHARMS	<u>0.025%</u>	<u>N013960</u>	<u>001</u>	
SHAMPOO; TOPICAL					
CAPEX					
	+ GALDERMA LABS LP	0.01%	N020001	001	Aug 27, 1990
SOLUTION; TOPICAL					
<u>FLUOCINOLONE ACETONIDE</u>					
<u>AT</u>	FOUGERA	<u>0.01%</u>	<u>A088167</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>	TARO	<u>0.01%</u>	<u>A089124</u>	<u>001</u>	Sep 11, 1985
<u>SYNALAR</u>					
<u>AT</u>	+ MEDIMETRIKS PHARMS	<u>0.01%</u>	<u>N015296</u>	<u>001</u>	

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM; TOPICAL					
TRI-LUMA					
	+ GALDERMA LABS LP	0.01%;4%;0.05%	N021112	001	Jan 18, 2002

FLUOCINONIDE

CREAM; TOPICAL					
<u>FLUOCINONIDE</u>					
<u>AB1</u>	FOUGERA	<u>0.05%</u>	<u>A073030</u>	<u>001</u>	Oct 17, 1994
<u>AB1</u>	G AND W LABS INC	<u>0.05%</u>	<u>A073085</u>	<u>001</u>	Feb 14, 1992
<u>AB1</u>	+ TARO	<u>0.05%</u>	<u>N019117</u>	<u>001</u>	Jun 26, 1984
<u>AB1</u>	TEVA	<u>0.05%</u>	<u>A072488</u>	<u>001</u>	Feb 06, 1989
<u>FLUOCINONIDE EMULSIFIED BASE</u>					
<u>AB2</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A076586</u>	<u>001</u>	Jun 23, 2004
<u>AB2</u>	+ TARO	<u>0.05%</u>	<u>A072494</u>	<u>001</u>	Jan 19, 1989
<u>AB2</u>	TEVA	<u>0.05%</u>	<u>A072490</u>	<u>001</u>	Feb 07, 1989
VANOS					
	+ MEDICIS	0.1%	N021758	001	Feb 11, 2005
GEL; TOPICAL					
<u>FLUOCINONIDE</u>					
<u>AB</u>	FOUGERA	<u>0.05%</u>	<u>A072933</u>	<u>001</u>	Dec 30, 1994
<u>AB</u>	TARO	<u>0.05%</u>	<u>A074935</u>	<u>001</u>	Jul 29, 1997
<u>AB</u>	TEVA	<u>0.05%</u>	<u>A072537</u>	<u>001</u>	Feb 07, 1989
<u>LIDEX</u>					
<u>AB</u>	+ MEDICIS	<u>0.05%</u>	<u>N017373</u>	<u>001</u>	
OINTMENT; TOPICAL					
<u>FLUOCINONIDE</u>					
<u>AB</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A074905</u>	<u>001</u>	Aug 26, 1997
<u>AB</u>	TARO	<u>0.05%</u>	<u>A075008</u>	<u>001</u>	Jun 30, 1999
<u>AB</u>	TEVA	<u>0.05%</u>	<u>A073481</u>	<u>001</u>	Dec 27, 1991
<u>LIDEX</u>					
<u>AB</u>	+ MEDICIS	<u>0.05%</u>	<u>N016909</u>	<u>002</u>	
SOLUTION; TOPICAL					
<u>FLUOCINONIDE</u>					
<u>AT</u>	FOUGERA	<u>0.05%</u>	<u>A072934</u>	<u>001</u>	Feb 27, 1995

PRESCRIPTION DRUG PRODUCT LIST

3 - 184 (of 428)

FLUOCINONIDE

SOLUTION; TOPICAL

FLUOCINONIDE

<u>AT</u>	G AND W LABS INC	<u>0.05%</u>	<u>A071535</u>	<u>001</u>	Dec 02, 1988
<u>AT</u>	TARO	<u>0.05%</u>	<u>A074799</u>	<u>001</u>	Dec 31, 1996
<u>AT</u>	TEVA	<u>0.05%</u>	<u>A072511</u>	<u>001</u>	Feb 07, 1989
<u>LIDEX</u>					
<u>AT</u>	+ MEDICIS	<u>0.05%</u>	<u>N018849</u>	<u>001</u>	Apr 06, 1984

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS

AK-FLUOR 10%

<u>AP</u>	AKORN	<u>EQ 500MG BASE/5ML (EQ 100MG BASE/ML)</u>	<u>N022186</u>	<u>001</u>	Aug 08, 2008
<u>FLUORESCITE</u>					
<u>AP</u>	+ ALCON PHARMS LTD	<u>EQ 500MG BASE/5ML (EQ 100MG BASE/ML)</u>	<u>N021980</u>	<u>001</u>	Mar 28, 2006
	AK-FLUOR 25%				
	AKORN	<u>EQ 500MG BASE/2ML (EQ 250MG BASE/ML)</u>	<u>N022186</u>	<u>002</u>	Aug 08, 2008

FLUOROMETHOLONE

OINTMENT; OPHTHALMIC

FML

	+ ALLERGAN	0.1%	<u>N017760</u>	<u>001</u>	Sep 04, 1985

SUSPENSION/DROPS; OPHTHALMIC

FML

	+ ALLERGAN	0.1%	<u>N016851</u>	<u>002</u>	Jul 28, 1982

FML FORTE

	ALLERGAN	0.25%	<u>N019216</u>	<u>001</u>	Apr 23, 1986

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

	+ ALCON	0.1%	<u>N019079</u>	<u>001</u>	Feb 11, 1986

FLUOROURACIL

CREAM; TOPICAL

EFUDEX

<u>AB</u>	+ VALEANT PHARM INTL	<u>5%</u>	<u>N016831</u>	<u>003</u>	
<u>FLUOROURACIL</u>					
<u>AB</u>	SPEAR PHARMS	<u>5%</u>	<u>A077524</u>	<u>001</u>	Apr 11, 2008
<u>AB</u>	TARO	<u>5%</u>	<u>A090368</u>	<u>001</u>	Mar 05, 2010
	CARAC				
	+ VALEANT BERMUDA	0.5%	<u>N020985</u>	<u>001</u>	Oct 27, 2000
	FLUOROPLEX				
	+ AQUA PHARMS	1%	<u>N016988</u>	<u>001</u>	

INJECTABLE; INJECTION

FLUOROURACIL

<u>AP</u>	+ BIONICHE PHARMA	<u>500MG/10ML (50MG/ML)</u>	<u>A040743</u>	<u>002</u>	Apr 26, 2007
<u>AP</u>		<u>1GM/20ML (50MG/ML)</u>	<u>A040743</u>	<u>001</u>	Apr 26, 2007
<u>AP</u>		<u>2.5GM/50ML (50MG/ML)</u>	<u>A040798</u>	<u>002</u>	Apr 26, 2007
<u>AP</u>		<u>5GM/100ML (50MG/ML)</u>	<u>A040798</u>	<u>001</u>	Apr 26, 2007
<u>AP</u>	EBEWE PHARMA	<u>500MG/10ML (50MG/ML)</u>	<u>A040772</u>	<u>001</u>	Aug 11, 2008
<u>AP</u>	+ FRESENIUS KABI USA	<u>500MG/10ML (50MG/ML)</u>	<u>A040279</u>	<u>002</u>	Sep 30, 1998
<u>AP</u>		<u>1GM/20ML (50MG/ML)</u>	<u>A040279</u>	<u>001</u>	Sep 30, 1998
<u>AP</u>		<u>2.5GM/50ML (50MG/ML)</u>	<u>A040278</u>	<u>001</u>	Sep 30, 1998
<u>AP</u>		<u>5GM/100ML (50MG/ML)</u>	<u>A040278</u>	<u>002</u>	Sep 30, 1998
<u>AP</u>	ONCO THERAPIES LTD	<u>500MG/10ML (50MG/ML)</u>	<u>A202668</u>	<u>001</u>	Jul 17, 2012
<u>AP</u>		<u>1GM/20ML (50MG/ML)</u>	<u>A202668</u>	<u>002</u>	Jul 17, 2012
<u>AP</u>		<u>2.5GM/50ML (50MG/ML)</u>	<u>A202669</u>	<u>001</u>	Jul 17, 2012
<u>AP</u>		<u>5GM/100ML (50MG/ML)</u>	<u>A202669</u>	<u>002</u>	Jul 17, 2012
<u>AP</u>	SANDOZ	<u>2.5GM/50ML (50MG/ML)</u>	<u>A091299</u>	<u>001</u>	May 02, 2011
<u>AP</u>		<u>5GM/100ML (50MG/ML)</u>	<u>A091299</u>	<u>002</u>	May 02, 2011
<u>AP</u>	+ TEVA PARENTERAL	<u>500MG/10ML (50MG/ML)</u>	<u>A040333</u>	<u>001</u>	Jan 27, 2000

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 185 (of 428)

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

<u>AP</u>	+	TEVA PARENTERAL	<u>2.5GM/50ML (50MG/ML)</u>	<u>A040334</u>	<u>001</u>	Feb 25, 2000

<u>AP</u>	+		<u>5GM/100ML (50MG/ML)</u>	<u>A040334</u>	<u>002</u>	Feb 25, 2000

SOLUTION; TOPICAL

EFUDEX

<u>AT</u>	+	VALEANT PHARM INTL	<u>2%</u>	<u>N016831</u>	<u>001</u>	

<u>AT</u>	+		<u>5%</u>	<u>N016831</u>	<u>002</u>	

FLUOROURACIL

<u>AT</u>		TARO	<u>2%</u>	<u>A076526</u>	<u>001</u>	Nov 05, 2003

<u>AT</u>			<u>5%</u>	<u>A076526</u>	<u>002</u>	Nov 05, 2003

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>EQ 40MG BASE</u>	<u>A090223</u>	<u>003</u>	Mar 19, 2009

<u>AB</u>		AUROBINDO PHARMA	<u>EQ 40MG BASE</u>	<u>A078619</u>	<u>003</u>	Jan 31, 2008

<u>AB</u>		DR REDDYS LABS INC	<u>EQ 40MG BASE</u>	<u>A075465</u>	<u>003</u>	Aug 02, 2001

<u>AB</u>		HERITAGE PHARMS INC	<u>EQ 40MG BASE</u>	<u>A201336</u>	<u>003</u>	Oct 01, 2012

<u>AB</u>		IVAX SUB TEVA PHARMS	<u>EQ 40MG BASE</u>	<u>A075245</u>	<u>003</u>	Sep 28, 2004

<u>AB</u>		MYLAN	<u>EQ 40MG BASE</u>	<u>A075207</u>	<u>003</u>	May 25, 2007

<u>AB</u>		PAR PHARM	<u>EQ 40MG BASE</u>	<u>A076922</u>	<u>003</u>	Dec 16, 2004

<u>AB</u>		RANBAXY	<u>EQ 40MG BASE</u>	<u>A076990</u>	<u>001</u>	Dec 13, 2004

<u>AB</u>		SANDOZ	<u>EQ 40MG BASE</u>	<u>A075049</u>	<u>003</u>	Jan 29, 2002

<u>AB</u>		TEVA	<u>EQ 40MG BASE</u>	<u>A075452</u>	<u>003</u>	Jan 29, 2002

<u>AB</u>		WOCKHARDT	<u>EQ 40MG BASE</u>	<u>A078143</u>	<u>003</u>	Jan 16, 2008

PROZAC

<u>AB</u>	+	ELI LILLY AND CO	<u>EQ 40MG BASE</u>	<u>N018936</u>	<u>003</u>	Jun 15, 1999

FLUOXETINE HYDROCHLORIDE

<u>AB1</u>		ALEMBIC PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A090223</u>	<u>001</u>	Mar 19, 2009

<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A090223</u>	<u>002</u>	Mar 19, 2009

<u>AB1</u>		AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078619</u>	<u>001</u>	Jan 31, 2008

<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A078619</u>	<u>002</u>	Jan 31, 2008

<u>AB1</u>		BARR	<u>EQ 10MG BASE</u>	<u>A074803</u>	<u>002</u>	Jan 30, 2002

<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A074803</u>	<u>001</u>	Aug 02, 2001

<u>AB1</u>		BEIJING DOUBLE CRANE	<u>EQ 10MG BASE</u>	<u>A076165</u>	<u>001</u>	Feb 01, 2002

<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A076165</u>	<u>002</u>	Feb 01, 2002

<u>AB1</u>		CARLSBAD	<u>EQ 10MG BASE</u>	<u>A076022</u>	<u>001</u>	Jan 30, 2002

<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A076022</u>	<u>002</u>	Jan 30, 2002

<u>AB1</u>		DR REDDYS LABS INC	<u>EQ 10MG BASE</u>	<u>A075465</u>	<u>001</u>	Jan 29, 2002

<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A075465</u>	<u>002</u>	Jan 29, 2002

<u>AB1</u>		HERITAGE PHARMS INC	<u>EQ 10MG BASE</u>	<u>A201336</u>	<u>001</u>	Oct 01, 2012

<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A201336</u>	<u>002</u>	Oct 01, 2012

<u>AB1</u>		IVAX SUB TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A075245</u>	<u>002</u>	Jan 31, 2002

<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A075245</u>	<u>001</u>	Jan 31, 2002

<u>AB1</u>		LANDELA PHARM	<u>EQ 10MG BASE</u>	<u>A075464</u>	<u>001</u>	Jan 30, 2002

<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A075464</u>	<u>002</u>	Jan 30, 2002

<u>AB1</u>		MALLINCKRODT	<u>EQ 10MG BASE</u>	<u>A075658</u>	<u>001</u>	Jan 29, 2002

<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A075658</u>	<u>002</u>	Jan 29, 2002

<u>AB1</u>		MYLAN	<u>EQ 10MG BASE</u>	<u>A075207</u>	<u>001</u>	Jan 30, 2002

<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A075207</u>	<u>002</u>	Jan 30, 2002

<u>AB1</u>		MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A075577</u>	<u>001</u>	Jan 29, 2002

<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A075577</u>	<u>002</u>	Jan 29, 2002

<u>AB1</u>		PLIVA	<u>EQ 10MG BASE</u>	<u>A076001</u>	<u>001</u>	Jan 29, 2002

<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A076001</u>	<u>002</u>	Jan 29, 2002

<u>AB1</u>		SANDOZ	<u>EQ 10MG BASE</u>	<u>A075049</u>	<u>001</u>	Aug 02, 2001

<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A075049</u>	<u>002</u>	Jan 29, 2002

<u>AB1</u>		TEVA	<u>EQ 10MG BASE</u>	<u>A075452</u>	<u>001</u>	Jan 29, 2002

<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A075452</u>	<u>002</u>	Jan 29, 2002

<u>AB1</u>		WOCKHARDT	<u>EQ 10MG BASE</u>	<u>A078143</u>	<u>001</u>	Jan 16, 2008

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 186 (of 428)

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB1</u>	WOCKHARDT	<u>EQ 20MG BASE</u>	<u>A078143</u>	<u>002</u>	Jan 16, 2008
	<u>PROZAC</u>				
<u>AB1</u>	ELI LILLY AND CO	<u>EQ 10MG BASE</u>	<u>N018936</u>	<u>006</u>	Dec 23, 1992
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>N018936</u>	<u>001</u>	Dec 29, 1987
	<u>FLUOXETINE HYDROCHLORIDE</u>				
<u>AB2</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A078045</u>	<u>001</u>	Nov 17, 2008
<u>AB2</u>		<u>EQ 20MG BASE</u>	<u>A078045</u>	<u>002</u>	Nov 17, 2008
<u>AB2</u>	SANDOZ	<u>EQ 10MG BASE</u>	<u>A077469</u>	<u>001</u>	Nov 17, 2008
<u>AB2</u>		<u>EQ 20MG BASE</u>	<u>A077469</u>	<u>002</u>	Nov 17, 2008
<u>AB2</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A076287</u>	<u>001</u>	May 20, 2008
<u>AB2</u>		<u>EQ 20MG BASE</u>	<u>A076287</u>	<u>002</u>	May 20, 2008
	<u>SARAFEM</u>				
<u>AB2</u>	ELI LILLY AND CO	<u>EQ 10MG BASE</u>	<u>N018936</u>	<u>007</u>	Jul 06, 2000
<u>AB2</u> +		<u>EQ 20MG BASE</u>	<u>N018936</u>	<u>008</u>	Jul 06, 2000

CAPSULE, DELAYED REL PELLETS; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>EQ 90MG BASE</u>	<u>A076237</u>	<u>001</u>	Mar 24, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 90MG BASE</u>	<u>A078572</u>	<u>001</u>	Mar 22, 2010
	<u>PROZAC WEEKLY</u>				
<u>AB</u> +	LILLY	<u>EQ 90MG BASE</u>	<u>N021235</u>	<u>001</u>	Feb 26, 2001

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AA</u>	AUROBINDO PHARM	<u>EQ 20MG BASE/5ML</u>	<u>A079209</u>	<u>001</u>	Mar 20, 2009
<u>AA</u>	LANNETT	<u>EQ 20MG BASE/5ML</u>	<u>A076458</u>	<u>001</u>	May 14, 2004
<u>AA</u>	MALLINCKRODT	<u>EQ 20MG BASE/5ML</u>	<u>A075920</u>	<u>001</u>	Jan 29, 2002
<u>AA</u>	NOVEX	<u>EQ 20MG BASE/5ML</u>	<u>A075292</u>	<u>001</u>	Feb 07, 2002
<u>AA</u> +	PHARM ASSOC	<u>EQ 20MG BASE/5ML</u>	<u>A076015</u>	<u>001</u>	Jan 30, 2002
<u>AA</u>	SILARX	<u>EQ 20MG BASE/5ML</u>	<u>A077849</u>	<u>001</u>	Feb 09, 2007
<u>AA</u>	TEVA	<u>EQ 20MG BASE/5ML</u>	<u>A075506</u>	<u>001</u>	Aug 02, 2001
<u>AA</u>	WOCKHARDT	<u>EQ 20MG BASE/5ML</u>	<u>A075514</u>	<u>001</u>	Aug 29, 2002

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS INC	<u>EQ 10MG BASE</u>	<u>A076006</u>	<u>001</u>	Jan 30, 2002
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A075755</u>	<u>001</u>	Aug 02, 2001
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A075872</u>	<u>001</u>	Jan 29, 2002
	<u>FLUOXETINE HYDROCHLORIDE</u>				
	EDGEMONT PHARMS LLC	<u>EQ 60MG BASE</u>	N202133	001	Oct 06, 2011
+	MYLAN	<u>EQ 20MG BASE</u>	A075755	002	Aug 02, 2001
	<u>SARAFEM</u>				
	WARNER CHILCOTT LLC	<u>EQ 10MG BASE</u>	N021860	001	May 19, 2006
		<u>EQ 15MG BASE</u>	N021860	002	May 19, 2006
+		<u>EQ 20MG BASE</u>	N021860	003	May 19, 2006

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

<u>AB</u>	PAR PHARM	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A077742</u>	<u>001</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A077742</u>	<u>002</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A077742</u>	<u>003</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A077742</u>	<u>004</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A077742</u>	<u>005</u>	Nov 02, 2012
<u>AB</u>	SANDOZ	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A078901</u>	<u>005</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A078901</u>	<u>001</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A078901</u>	<u>003</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A078901</u>	<u>002</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A078901</u>	<u>004</u>	Nov 16, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A077528</u>	<u>001</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A077528</u>	<u>002</u>	Jun 19, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 187 (of 428)

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

<u>AB</u>	TEVA PHARMS	<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A077528</u>	<u>003</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A077528</u>	<u>004</u>	Jun 19, 2012
	<u>SYMBYAX</u>				
<u>AB</u>	LILLY	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>N021520</u>	<u>001</u>	Apr 09, 2007
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>N021520</u>	<u>002</u>	Dec 24, 2003
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>N021520</u>	<u>004</u>	Dec 24, 2003
<u>AB</u>	+	<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>N021520</u>	<u>003</u>	Dec 24, 2003
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>N021520</u>	<u>005</u>	Dec 24, 2003

FLUOXYMESTERONE

TABLET; ORAL

FLUOXYMESTERONE

+	USL PHARMA	10MG	A088342	001	Oct 21, 1983

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

<u>AO</u>	BEDFORD	<u>25MG/ML</u>	<u>A074531</u>	<u>001</u>	Aug 30, 1996
<u>AO</u>	CLARIS LIFESCIENCES	<u>25MG/ML</u>	<u>A075918</u>	<u>001</u>	Aug 17, 2001
<u>AO</u>	+	<u>FRESENIUS KABI USA</u>	<u>A071413</u>	<u>001</u>	Jul 14, 1987

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

+	PHARM ASSOC	5MG/ML	A074725	001	Sep 16, 1996

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

+	PHARM ASSOC	2.5MG/5ML	A040146	001	Aug 21, 1996

INJECTABLE; INJECTION

FLUPHENAZINE HYDROCHLORIDE

+	FRESENIUS KABI USA	2.5MG/ML	A089556	001	Apr 16, 1987

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

<u>AB</u>	LANNETT	<u>1MG</u>	<u>A089740</u>	<u>001</u>	Aug 25, 1988
<u>AB</u>		<u>2.5MG</u>	<u>A089741</u>	<u>001</u>	Aug 25, 1988
<u>AB</u>		<u>5MG</u>	<u>A089742</u>	<u>001</u>	Aug 25, 1988
<u>AB</u>		<u>10MG</u>	<u>A089743</u>	<u>001</u>	Aug 25, 1988
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A089804</u>	<u>002</u>	Aug 12, 1988
<u>AB</u>		<u>2.5MG</u>	<u>A089804</u>	<u>003</u>	Aug 12, 1988
<u>AB</u>		<u>5MG</u>	<u>A089804</u>	<u>004</u>	Aug 12, 1988
<u>AB</u>	+	<u>10MG</u>	<u>A089804</u>	<u>001</u>	Aug 12, 1988
<u>AB</u>	SANDOZ	<u>1MG</u>	<u>A089583</u>	<u>001</u>	Oct 16, 1987
<u>AB</u>		<u>2.5MG</u>	<u>A089584</u>	<u>001</u>	Oct 16, 1987
<u>AB</u>		<u>5MG</u>	<u>A089585</u>	<u>001</u>	Oct 16, 1987
<u>AB</u>		<u>10MG</u>	<u>A089586</u>	<u>001</u>	Oct 16, 1987

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

+	AQUA PHARMS	0.025%	N012806	003	

+		0.05%	N012806	002	

LOTION; TOPICAL

CORDRAN

+	AQUA PHARMS	0.05%	N013790	001	

TAPE; TOPICAL

CORDRAN

+	WATSON PHARMS	0.004MG/SQ CM	N016455	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 188 (of 428)

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

<u>AB</u>	MYLAN PHARMS INC	<u>15MG</u>	<u>A070345</u>	<u>002</u>	Nov 27, 1985
<u>AB</u>	+	<u>30MG</u>	<u>A070345</u>	<u>001</u>	Nov 27, 1985
<u>AB</u>	WATSON LABS	<u>15MG</u>	<u>A071205</u>	<u>001</u>	Nov 25, 1986
<u>AB</u>		<u>30MG</u>	<u>A071068</u>	<u>001</u>	Nov 25, 1986
<u>AB</u>		<u>30MG</u>	<u>A072369</u>	<u>001</u>	Mar 30, 1989
<u>AB</u>	WEST WARD	<u>15MG</u>	<u>A071107</u>	<u>001</u>	Dec 08, 1986
<u>AB</u>		<u>30MG</u>	<u>A071108</u>	<u>001</u>	Dec 08, 1986

FLURBIPROFEN

TABLET; ORAL

ANSAID

<u>AB</u>	PHARMACIA AND UPJOHN	<u>50MG</u>	<u>N018766</u>	<u>002</u>	Oct 31, 1988
<u>AB</u>	+	<u>100MG</u>	<u>N018766</u>	<u>003</u>	Oct 31, 1988
	<u>FLURBIPROFEN</u>				
<u>AB</u>	CARACO	<u>50MG</u>	<u>A075058</u>	<u>001</u>	Apr 27, 2001
<u>AB</u>		<u>100MG</u>	<u>A075058</u>	<u>002</u>	Apr 27, 2001
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A074358</u>	<u>001</u>	Jun 20, 1994
<u>AB</u>		<u>100MG</u>	<u>A074358</u>	<u>002</u>	Jun 20, 1994
<u>AB</u>	TEVA	<u>100MG</u>	<u>A074431</u>	<u>001</u>	May 31, 1995

FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

FLURBIPROFEN SODIUM

<u>AT</u>	BAUSCH AND LOMB	<u>0.03%</u>	<u>A074447</u>	<u>001</u>	Jan 04, 1995
	<u>OCUFEN</u>				
<u>AT</u>	+	<u>0.03%</u>	<u>N019404</u>	<u>001</u>	Dec 31, 1986

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

<u>AB</u>	+	IVAX SUB TEVA PHARMS	<u>125MG</u>	<u>A075780</u>	<u>001</u>	Sep 19, 2001
<u>AB</u>		MYLAN	<u>125MG</u>	<u>A076224</u>	<u>001</u>	May 09, 2003
<u>AB</u>		PAR PHARM	<u>125MG</u>	<u>A075298</u>	<u>001</u>	Sep 18, 2001
<u>AB</u>		WATSON LABS INC FL	<u>125MG</u>	<u>A075820</u>	<u>001</u>	Sep 18, 2001

FLUTICASONE FUROATE

SPRAY, METERED; NASAL

VERAMYST

+	GLAXOSMITHKLINE	0.0275MG/INH	N022051	001	Apr 27, 2007

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT HFA

+	GLAXO GRP LTD	0.044MG/INH	N021433	003	May 14, 2004
+		0.11MG/INH	N021433	002	May 14, 2004
+		0.22MG/INH	N021433	001	May 14, 2004

CREAM; TOPICAL

CUTIVATE

<u>AB</u>	+	FOUGERA PHARMS	<u>0.05%</u>	<u>N019958</u>	<u>001</u>	Dec 18, 1990
		<u>FLUTICASONE PROPIONATE</u>				
<u>AB</u>		FOUGERA PHARMS	<u>0.05%</u>	<u>A076451</u>	<u>001</u>	May 14, 2004
<u>AB</u>		G AND W LABS	<u>0.05%</u>	<u>A077055</u>	<u>001</u>	Jun 30, 2006
<u>AB</u>		PERRIGO NEW YORK	<u>0.05%</u>	<u>A076793</u>	<u>001</u>	May 14, 2004
<u>AB</u>		TOLMAR	<u>0.05%</u>	<u>A076633</u>	<u>001</u>	May 14, 2004

LOTION; TOPICAL

CUTIVATE

<u>AB</u>	+	FOUGERA PHARMS	<u>0.05%</u>	<u>N021152</u>	<u>001</u>	Mar 31, 2005
		<u>FLUTICASONE PROPIONATE</u>				
<u>AB</u>		GLENMARK GENERICS	<u>0.05%</u>	<u>A090759</u>	<u>001</u>	May 02, 2011

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 189 (of 428)

FLUTICASONE PROPIONATE

OINTMENT; TOPICAL

CUTIVATE

<u>AB</u>	+ FOUGERA PHARMS	<u>0.005%</u>	<u>N019957</u>	<u>001</u>	Dec 14, 1990
	<u>FLUTICASONE PROPIONATE</u>				
<u>AB</u>	FOUGERA PHARMS	<u>0.005%</u>	<u>A076300</u>	<u>001</u>	May 14, 2004
<u>AB</u>	G AND W LABS	<u>0.005%</u>	<u>A077168</u>	<u>001</u>	Mar 03, 2006
<u>AB</u>	PERRIGO NEW YORK	<u>0.005%</u>	<u>A076668</u>	<u>001</u>	May 14, 2004

POWDER; INHALATION

FLOVENT DISKUS 100

+ GLAXOSMITHKLINE	0.1MG/INH	N020833	002	Sep 29, 2000

FLOVENT DISKUS 250

+ GLAXOSMITHKLINE	0.25MG/INH	N020833	003	Sep 29, 2000

FLOVENT DISKUS 50

+ GLAXOSMITHKLINE	0.05MG/INH	N020833	001	Sep 29, 2000

SPRAY, METERED; NASAL

FLONASE

<u>AB</u>	+ GLAXOSMITHKLINE	<u>0.05MG/SPRAY</u>	<u>N020121</u>	<u>001</u>	Oct 19, 1994
	<u>FLUTICASONE PROPIONATE</u>				
<u>AB</u>	APOTEX INC	<u>0.05MG/SPRAY</u>	<u>A077538</u>	<u>001</u>	Sep 12, 2007
<u>AB</u>	HI TECH PHARMA	<u>0.05MG/SPRAY</u>	<u>A077570</u>	<u>001</u>	Jan 16, 2008
<u>AB</u>	ROXANE	<u>0.05MG/SPRAY</u>	<u>A076504</u>	<u>001</u>	Feb 22, 2006
<u>AB</u>	WOCKHARDT	<u>0.05MG/SPRAY</u>	<u>A078492</u>	<u>001</u>	Jan 09, 2012

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

ADVAIR HFA

+ GLAXOSMITHKLINE	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006

+	0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006

+	0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006

POWDER; INHALATION

ADVAIR DISKUS 100/50

+ GLAXOSMITHKLINE	0.1MG/INH;EQ 0.05MG BASE/INH	N021077	001	Aug 24, 2000

ADVAIR DISKUS 250/50

+ GLAXOSMITHKLINE	0.25MG/INH;EQ 0.05MG BASE/INH	N021077	002	Aug 24, 2000

ADVAIR DISKUS 500/50

+ GLAXOSMITHKLINE	0.5MG/INH;EQ 0.05MG BASE/INH	N021077	003	Aug 24, 2000

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUM

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A090595</u>	<u>001</u>	Apr 11, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090595</u>	<u>002</u>	Apr 11, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A078407</u>	<u>001</u>	Jun 12, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078407</u>	<u>002</u>	Jun 12, 2012

LESCOL

<u>AB</u>	NOVARTIS	<u>EQ 20MG BASE</u>	<u>N020261</u>	<u>001</u>	Dec 31, 1993
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020261</u>	<u>002</u>	Dec 31, 1993

TABLET, EXTENDED RELEASE; ORAL

LESCOL XL

+ NOVARTIS	80MG	N021192	001	Oct 06, 2000

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

LUVOX CR

JAZZ PHARMS	100MG	N022033	001	Feb 28, 2008

+	150MG	N022033	002	Feb 28, 2008

TABLET; ORAL

FLUVOXAMINE MALEATE

<u>AB</u>	APOTEX	<u>25MG</u>	<u>A075902</u>	<u>001</u>	May 07, 2001
<u>AB</u>		<u>50MG</u>	<u>A075902</u>	<u>002</u>	May 07, 2001
<u>AB</u>		<u>100MG</u>	<u>A075902</u>	<u>003</u>	May 07, 2001

PRESCRIPTION DRUG PRODUCT LIST

3 - 190 (of 428)

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

<u>AB</u>	BARR	<u>25MG</u>	<u>A075897</u>	<u>001</u>	Jan 25, 2001
<u>AB</u>		<u>50MG</u>	<u>A075897</u>	<u>002</u>	Jan 25, 2001
<u>AB</u>		<u>100MG</u>	<u>A075897</u>	<u>003</u>	Jan 25, 2001
<u>AB</u>	CARACO	<u>25MG</u>	<u>A075900</u>	<u>001</u>	Feb 23, 2006
<u>AB</u>		<u>50MG</u>	<u>A075900</u>	<u>002</u>	Feb 23, 2006
<u>AB</u>		<u>100MG</u>	<u>A075900</u>	<u>003</u>	Feb 23, 2006
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A075889</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>		<u>50MG</u>	<u>A075889</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>		<u>100MG</u>	<u>A075889</u>	<u>003</u>	Nov 29, 2000
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A075888</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>		<u>50MG</u>	<u>A075888</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>	+	<u>100MG</u>	<u>A075888</u>	<u>003</u>	Nov 29, 2000
<u>AB</u>	TEVA	<u>25MG</u>	<u>A075893</u>	<u>001</u>	Sep 10, 2002
<u>AB</u>		<u>50MG</u>	<u>A075893</u>	<u>002</u>	Sep 10, 2002
<u>AB</u>		<u>100MG</u>	<u>A075893</u>	<u>003</u>	Sep 10, 2002
	<u>LUVOX</u>				
<u>AB</u>	ANI PHARMS	<u>25MG</u>	<u>N021519</u>	<u>001</u>	Dec 20, 2007
<u>AB</u>		<u>50MG</u>	<u>N021519</u>	<u>002</u>	Dec 20, 2007
<u>AB</u>		<u>100MG</u>	<u>N021519</u>	<u>003</u>	Dec 20, 2007

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

+ FRESenius KABI USA 5MG/ML A089202 001 Feb 18, 1986

TABLET; ORAL

FOLIC ACID

<u>AA</u>	+	AMNEAL PHARM	<u>1MG</u>	<u>A040625</u>	<u>001</u>	Jul 21, 2005
<u>AA</u>		CONTRACT PHARMACAL	<u>1MG</u>	<u>A085061</u>	<u>001</u>	
<u>AA</u>		EXCELLIUM	<u>1MG</u>	<u>A040796</u>	<u>001</u>	Jan 12, 2009
<u>AA</u>		INVAGEN PHARMS	<u>1MG</u>	<u>A090035</u>	<u>001</u>	Jun 09, 2009
<u>AA</u>		JUBILANT CADISTA	<u>1MG</u>	<u>A040514</u>	<u>001</u>	Jun 14, 2005
<u>AA</u>		VINTAGE	<u>1MG</u>	<u>A040756</u>	<u>001</u>	Jun 04, 2010
<u>AA</u>	+	WATSON LABS	<u>1MG</u>	<u>A080680</u>	<u>001</u>	
<u>AA</u>		WEST WARD	<u>1MG</u>	<u>A080600</u>	<u>001</u>	

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

+ ORGANON USA INC 75 IU/0.5ML N021273 001 Aug 26, 2005

+ 150 IU/0.5ML N021273 002 Aug 26, 2005

+ 300 IU/0.36ML N021211 001 Mar 23, 2004

+ 600 IU/0.72ML N021211 002 Mar 23, 2004

+ 900 IU/1.08ML N021211 004 Feb 11, 2005

GONAL-F

+ EMD SERONO 450 IU/VIAL N020378 005 Mar 26, 2004

1,050 IU/VIAL N020378 004 Feb 28, 2001

GONAL-F RFF

+ EMD SERONO 75 IU/VIAL N021765 002 Mar 25, 2004

GONAL-F RFF PEN

+ EMD SERONO 300 IU/0.5ML N021684 001 May 25, 2004

+ 450 IU/0.75ML N021684 002 May 25, 2004

+ 900 IU/1.5ML N021684 003 May 25, 2004

FOMEPIZOLE

INJECTABLE; INJECTION

ANTIZOL

AP + PALADIN LABS 1.5GM/1.5ML (1GM/ML) N020696 001 Dec 04, 1997

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 191 (of 428)

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

<u>AP</u>	BIONICHE PHARMA USA	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A079033</u>	<u>001</u>	Apr 07, 2009
<u>AP</u>	LUITPOLD	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078368</u>	<u>001</u>	Dec 14, 2007
<u>AP</u>	MYLAN LLC	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078639</u>	<u>001</u>	Mar 03, 2008
<u>AP</u>	NAVINTA LLC	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078537</u>	<u>001</u>	Mar 06, 2008

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA

<u>AP</u>	+ GLAXOSMITHKLINE	<u>2.5MG/0.5ML</u>	<u>N021345</u>	<u>001</u>	Dec 07, 2001
<u>AP</u>	+	<u>5MG/0.4ML</u>	<u>N021345</u>	<u>002</u>	May 28, 2004
<u>AP</u>	+	<u>7.5MG/0.6ML</u>	<u>N021345</u>	<u>003</u>	May 28, 2004
<u>AP</u>	+	<u>10MG/0.8ML</u>	<u>N021345</u>	<u>004</u>	May 28, 2004

FONDAPARINUX SODIUM

<u>AP</u>	DR REDDYS LABS LTD	<u>2.5MG/0.5ML</u>	<u>A091316</u>	<u>001</u>	Jul 11, 2011
<u>AP</u>		<u>5MG/0.4ML</u>	<u>A091316</u>	<u>002</u>	Jul 11, 2011
<u>AP</u>		<u>7.5MG/0.6ML</u>	<u>A091316</u>	<u>003</u>	Jul 11, 2011
<u>AP</u>		<u>10MG/0.8ML</u>	<u>A091316</u>	<u>004</u>	Jul 11, 2011

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL

+	NOVARTIS	0.012MG/INH	N020831	001	Feb 16, 2001

SOLUTION; INHALATION

PERFOROMIST

+	MYLAN SPECLT	0.02MG/2ML	N022007	001	May 11, 2007

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

+	MERCK SHARP DOHME	0.005MG/INH;0.1MG/INH	N022518	001	Jun 22, 2010

+		0.005MG/INH;0.2MG/INH	N022518	002	Jun 22, 2010

FOSAMPRENAVIR CALCIUM

SUSPENSION; ORAL

LEXIVA

+	VIIIV HLTHCARE	EQ 50MG BASE/ML	N022116	001	Jun 14, 2007

TABLET; ORAL

LEXIVA

+	VIIIV HLTHCARE	EQ 700MG BASE	N021548	001	Oct 20, 2003

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

+	MERCK AND CO INC	EQ 115MG BASE/VIAL	N022023	001	Jan 25, 2008

+		EQ 150MG BASE/VIAL	N022023	002	Nov 12, 2010

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM

<u>AP</u>	HOSPIRA	<u>2.4GM/100ML</u>	<u>A077174</u>	<u>001</u>	May 31, 2005

FOSCAVIR

<u>AP</u>	+ CLINIGEN HLTHCARE	<u>2.4GM/100ML</u>	<u>N020068</u>	<u>001</u>	Sep 27, 1991

FOSFOMYCIN TROMETHAMINE

FOR SUSPENSION; ORAL

MONUROL

+	ZAMBON SPA	EQ 3GM BASE/PACKET	N050717	001	Dec 19, 1996

PRESCRIPTION DRUG PRODUCT LIST

3 - 192 (of 428)

FOSINOPRIL SODIUM

TABLET; ORAL

<u>FOSINOPRIL SODIUM</u>				
<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A076906</u>	<u>001</u> May 17, 2005
<u>AB</u>		<u>20MG</u>	<u>A076906</u>	<u>002</u> May 17, 2005
<u>AB</u>		<u>40MG</u>	<u>A076906</u>	<u>003</u> May 17, 2005
<u>AB</u>	AUROBINDO PHARMA LTD	<u>10MG</u>	<u>A091163</u>	<u>001</u> Mar 30, 2011
<u>AB</u>		<u>20MG</u>	<u>A091163</u>	<u>002</u> Mar 30, 2011
<u>AB</u>		<u>40MG</u>	<u>A091163</u>	<u>003</u> Mar 30, 2011
<u>AB</u>	INVAGEN PHARMS	<u>10MG</u>	<u>A077222</u>	<u>001</u> Apr 20, 2005
<u>AB</u>		<u>20MG</u>	<u>A077222</u>	<u>002</u> Apr 20, 2005
<u>AB</u>		<u>40MG</u>	<u>A077222</u>	<u>003</u> Apr 20, 2005
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A076483</u>	<u>001</u> Apr 23, 2004
<u>AB</u>		<u>20MG</u>	<u>A076483</u>	<u>002</u> Apr 23, 2004
<u>AB</u>		<u>40MG</u>	<u>A076483</u>	<u>003</u> Apr 23, 2004
<u>AB</u>	TEVA	<u>10MG</u>	<u>A076139</u>	<u>001</u> Nov 25, 2003
<u>AB</u>		<u>20MG</u>	<u>A076139</u>	<u>002</u> Nov 25, 2003
<u>AB</u>	+	<u>40MG</u>	<u>A076139</u>	<u>003</u> Nov 25, 2003
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A076987</u>	<u>001</u> Dec 23, 2004
<u>AB</u>		<u>10MG</u>	<u>A077531</u>	<u>001</u> Aug 31, 2006
<u>AB</u>		<u>20MG</u>	<u>A076987</u>	<u>002</u> Dec 23, 2004
<u>AB</u>		<u>20MG</u>	<u>A077531</u>	<u>002</u> Aug 31, 2006
<u>AB</u>		<u>40MG</u>	<u>A076987</u>	<u>003</u> Dec 23, 2004
<u>AB</u>		<u>40MG</u>	<u>A077531</u>	<u>003</u> Aug 31, 2006
<u>AB</u>	WATSON LABS FLORIDA	<u>10MG</u>	<u>A076620</u>	<u>001</u> Oct 15, 2004
<u>AB</u>		<u>20MG</u>	<u>A076620</u>	<u>002</u> Oct 15, 2004
<u>AB</u>		<u>40MG</u>	<u>A076620</u>	<u>003</u> Oct 15, 2004

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

<u>FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE</u>				
<u>AB</u>	AUROBINDO PHARMA	<u>10MG;12.5MG</u>	<u>A079245</u>	<u>001</u> Jul 09, 2009
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A079245</u>	<u>002</u> Jul 09, 2009
<u>AB</u>	INVAGEN PHARMS	<u>10MG;12.5MG</u>	<u>A090228</u>	<u>001</u> Jul 09, 2009
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A090228</u>	<u>002</u> Jul 09, 2009
<u>AB</u>	MYLAN	<u>10MG;12.5MG</u>	<u>A077705</u>	<u>001</u> Aug 14, 2006
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A077705</u>	<u>002</u> Aug 14, 2006
<u>AB</u>	RANBAXY	<u>10MG;12.5MG</u>	<u>A076739</u>	<u>001</u> Dec 17, 2004
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076739</u>	<u>002</u> Dec 17, 2004
<u>AB</u>	SANDOZ	<u>10MG;12.5MG</u>	<u>A076961</u>	<u>001</u> Sep 28, 2005
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076961</u>	<u>002</u> Sep 28, 2005
<u>AB</u>	WATSON LABS FLORIDA	<u>10MG;12.5MG</u>	<u>A076608</u>	<u>001</u> Dec 03, 2004
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076608</u>	<u>002</u> Dec 03, 2004

FOSINOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

<u>FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE</u>				
<u>AB</u>	EMCURE PHARMS INDIA	<u>10MG;12.5MG</u>	<u>A079025</u>	<u>001</u> Sep 17, 2010
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A079025</u>	<u>002</u> Sep 17, 2010

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

<u>FOSPHENYTOIN SODIUM</u>				
<u>AP</u>	APOTEX INC	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078126</u>	<u>001</u> Aug 06, 2007
<u>AP</u>	BEDFORD	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077481</u>	<u>001</u> Aug 06, 2007
<u>AP</u>	+	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078052</u>	<u>001</u> Aug 06, 2007
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078765</u>	<u>001</u> Dec 02, 2009
<u>AP</u>	HIKMA MAPLE	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077989</u>	<u>001</u> Aug 06, 2007
<u>AP</u>	HOSPIRA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078158</u>	<u>001</u> Aug 06, 2007
<u>AP</u>	LUITPOLD	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078277</u>	<u>001</u> Aug 06, 2007
<u>AP</u>		<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A090099</u>	<u>001</u> May 13, 2010

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 193 (of 428)

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

<u>AP</u>	PFIZER	<u>EQ 50MG PNEYTOIN NA/ML</u>	<u>A078476</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>	STRIDES ARCOLAB	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078736</u>	<u>001</u>	Jun 08, 2010
<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078417</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>	WOCKHARDT	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078137</u>	<u>001</u>	Aug 06, 2007

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA

+	ENDO PHARMS	EQ 2.5MG BASE	N021006	001	Nov 08, 2001

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FASLODEX

+	ASTRAZENECA	50MG/ML	N021344	001	Apr 25, 2002

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>N018902</u>	<u>001</u>	May 22, 1984
<u>AP</u>	HOSPIRA	<u>10MG/ML</u>	<u>A075241</u>	<u>001</u>	May 28, 1999
<u>AP</u>		<u>10MG/ML</u>	<u>N018667</u>	<u>001</u>	May 28, 1982
<u>AP</u>	INTL MEDICATION	<u>10MG/ML</u>	<u>N018025</u>	<u>001</u>	
<u>AP</u>	+ LUITPOLD	<u>10MG/ML</u>	<u>N018579</u>	<u>001</u>	Nov 30, 1983
<u>AP</u>	WOCKHARDT	<u>10MG/ML</u>	<u>A077941</u>	<u>001</u>	Mar 22, 2007

SOLUTION; ORAL

FUROSEMIDE

<u>AA</u>	+ ROXANE	<u>10MG/ML</u>	<u>A070434</u>	<u>001</u>	Apr 22, 1987
<u>AA</u>	WOCKHARDT	<u>10MG/ML</u>	<u>A070655</u>	<u>001</u>	Oct 02, 1987
	FUROSEMIDE				
	ROXANE	40MG/5ML	A070433	001	Apr 22, 1987

TABLET; ORAL

FUROSEMIDE

<u>AB</u>	DAVA PHARMS INC	<u>20MG</u>	<u>N018415</u>	<u>001</u>	Jul 27, 1982
<u>AB</u>		<u>40MG</u>	<u>N018415</u>	<u>002</u>	Jul 27, 1982
<u>AB</u>		<u>80MG</u>	<u>N018415</u>	<u>003</u>	Nov 26, 1984
<u>AB</u>	EXCELLIUM	<u>20MG</u>	<u>A077293</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>40MG</u>	<u>A077293</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>		<u>80MG</u>	<u>A077293</u>	<u>003</u>	Nov 09, 2005
<u>AB</u>	IPCA LABS LTD	<u>20MG</u>	<u>A078010</u>	<u>001</u>	Sep 18, 2006
<u>AB</u>		<u>40MG</u>	<u>A078010</u>	<u>002</u>	Sep 18, 2006
<u>AB</u>		<u>80MG</u>	<u>A078010</u>	<u>003</u>	Sep 18, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>N018413</u>	<u>001</u>	Nov 30, 1983
<u>AB</u>		<u>40MG</u>	<u>N018413</u>	<u>002</u>	Nov 30, 1983
<u>AB</u>	MYLAN	<u>20MG</u>	<u>N018487</u>	<u>001</u>	
<u>AB</u>		<u>40MG</u>	<u>N018487</u>	<u>002</u>	
<u>AB</u>		<u>80MG</u>	<u>A070082</u>	<u>001</u>	Oct 29, 1986
<u>AB</u>	ROXANE	<u>20MG</u>	<u>N018823</u>	<u>001</u>	Nov 10, 1983
<u>AB</u>		<u>40MG</u>	<u>N018823</u>	<u>002</u>	Nov 10, 1983
<u>AB</u>		<u>80MG</u>	<u>A070086</u>	<u>001</u>	Jan 24, 1986
<u>AB</u>	SANDOZ	<u>20MG</u>	<u>N018569</u>	<u>002</u>	
<u>AB</u>		<u>40MG</u>	<u>N018569</u>	<u>001</u>	
<u>AB</u>		<u>80MG</u>	<u>N018569</u>	<u>005</u>	Aug 14, 1984
<u>AB</u>	VINTAGE PHARMS	<u>20MG</u>	<u>A076796</u>	<u>001</u>	Mar 26, 2004
<u>AB</u>		<u>40MG</u>	<u>A076796</u>	<u>002</u>	Mar 26, 2004
<u>AB</u>		<u>80MG</u>	<u>A076796</u>	<u>003</u>	Mar 26, 2004
<u>AB</u>	WATSON LABS	<u>20MG</u>	<u>A070412</u>	<u>001</u>	Feb 26, 1986
<u>AB</u>		<u>20MG</u>	<u>A070449</u>	<u>001</u>	Nov 22, 1985
<u>AB</u>		<u>20MG</u>	<u>A071379</u>	<u>001</u>	Jan 02, 1987

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 194 (of 428)

FUROSEMIDE

TABLET; ORAL

FUROSEMIDE

<u>AB</u>	WATSON LABS	<u>40MG</u>	<u>A070450</u>	<u>001</u>	Nov 22, 1985
<u>AB</u>		<u>80MG</u>	<u>A070528</u>	<u>001</u>	Jan 07, 1986
<u>AB</u>		<u>80MG</u>	<u>A071594</u>	<u>001</u>	Feb 09, 1988
	<u>LASIX</u>				
<u>AB</u>	SANOFI AVENTIS US	<u>20MG</u>	<u>N016273</u>	<u>002</u>	
<u>AB</u>		<u>40MG</u>	<u>N016273</u>	<u>001</u>	
<u>AB</u>	+	<u>80MG</u>	<u>N016273</u>	<u>003</u>	

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A075350</u>	<u>001</u>	Sep 12, 2003
<u>AB</u>		<u>300MG</u>	<u>A075350</u>	<u>002</u>	Sep 12, 2003
<u>AB</u>		<u>400MG</u>	<u>A075350</u>	<u>003</u>	Sep 12, 2003
<u>AB</u>	ALKEM	<u>100MG</u>	<u>A090858</u>	<u>001</u>	Dec 17, 2010
<u>AB</u>		<u>300MG</u>	<u>A090858</u>	<u>002</u>	Dec 17, 2010
<u>AB</u>		<u>400MG</u>	<u>A090858</u>	<u>003</u>	Dec 17, 2010
<u>AB</u>	AMNEAL PHARMS NY	<u>100MG</u>	<u>A078428</u>	<u>001</u>	Jul 25, 2007
<u>AB</u>		<u>300MG</u>	<u>A078428</u>	<u>002</u>	Jul 25, 2007
<u>AB</u>		<u>400MG</u>	<u>A078428</u>	<u>003</u>	Jul 25, 2007
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A075360</u>	<u>001</u>	Apr 06, 2005
<u>AB</u>		<u>300MG</u>	<u>A075360</u>	<u>002</u>	Apr 06, 2005
<u>AB</u>		<u>400MG</u>	<u>A075360</u>	<u>003</u>	Apr 06, 2005
<u>AB</u>	AUROBINDO PHARM	<u>100MG</u>	<u>A078787</u>	<u>001</u>	Jan 31, 2008
<u>AB</u>		<u>300MG</u>	<u>A078787</u>	<u>002</u>	Jan 31, 2008
<u>AB</u>		<u>400MG</u>	<u>A078787</u>	<u>003</u>	Jan 31, 2008
<u>AB</u>	HIKMA	<u>100MG</u>	<u>A078150</u>	<u>001</u>	Sep 25, 2007
<u>AB</u>		<u>300MG</u>	<u>A078150</u>	<u>002</u>	Sep 25, 2007
<u>AB</u>		<u>400MG</u>	<u>A078150</u>	<u>003</u>	Sep 25, 2007
<u>AB</u>	INVAGEN PHARMS	<u>100MG</u>	<u>A090705</u>	<u>001</u>	Dec 30, 2009
<u>AB</u>		<u>300MG</u>	<u>A090705</u>	<u>002</u>	Dec 30, 2009
<u>AB</u>		<u>400MG</u>	<u>A090705</u>	<u>003</u>	Dec 30, 2009
<u>AB</u>	MARKSANS PHARMA	<u>100MG</u>	<u>A090007</u>	<u>001</u>	Jul 21, 2011
<u>AB</u>		<u>300MG</u>	<u>A090007</u>	<u>002</u>	Jul 21, 2011
<u>AB</u>		<u>400MG</u>	<u>A090007</u>	<u>003</u>	Jul 21, 2011
<u>AB</u>	MYLAN	<u>100MG</u>	<u>A090158</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>		<u>300MG</u>	<u>A090158</u>	<u>002</u>	Feb 14, 2011
<u>AB</u>		<u>400MG</u>	<u>A090158</u>	<u>003</u>	Feb 14, 2011
<u>AB</u>	RANBAXY	<u>100MG</u>	<u>A076606</u>	<u>001</u>	Oct 07, 2005
<u>AB</u>		<u>300MG</u>	<u>A076606</u>	<u>002</u>	Oct 07, 2005
<u>AB</u>		<u>400MG</u>	<u>A076606</u>	<u>003</u>	Oct 07, 2005
<u>AB</u>	SUN PHARM INDS LTD	<u>100MG</u>	<u>A077242</u>	<u>001</u>	Aug 24, 2006
<u>AB</u>		<u>300MG</u>	<u>A077242</u>	<u>002</u>	Aug 24, 2006
<u>AB</u>		<u>400MG</u>	<u>A077242</u>	<u>003</u>	Aug 24, 2006
<u>AB</u>	TEVA PHARMS	<u>100MG</u>	<u>A075435</u>	<u>001</u>	Oct 08, 2004
<u>AB</u>		<u>300MG</u>	<u>A075435</u>	<u>002</u>	Oct 08, 2004
<u>AB</u>		<u>400MG</u>	<u>A075435</u>	<u>003</u>	Oct 08, 2004
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>A075485</u>	<u>003</u>	May 11, 2007
<u>AB</u>		<u>300MG</u>	<u>A075485</u>	<u>002</u>	May 11, 2007
<u>AB</u>		<u>400MG</u>	<u>A075485</u>	<u>001</u>	May 11, 2007
	<u>NEURONTIN</u>				
<u>AB</u>	PFIZER PHARMS	<u>100MG</u>	<u>N020235</u>	<u>001</u>	Dec 30, 1993
<u>AB</u>		<u>300MG</u>	<u>N020235</u>	<u>002</u>	Dec 30, 1993
<u>AB</u>	+	<u>400MG</u>	<u>N020235</u>	<u>003</u>	Dec 30, 1993
	SOLUTION; ORAL				
	<u>GABAPENTIN</u>				
<u>AA</u>	ACELLA PHARMS LLC	<u>250MG/5ML</u>	<u>A076403</u>	<u>001</u>	May 01, 2012
<u>AA</u>	AMNEAL PHARMS	<u>250MG/5ML</u>	<u>A202024</u>	<u>001</u>	Mar 23, 2012

PRESCRIPTION DRUG PRODUCT LIST

3 - 195 (of 428)

GABAPENTIN

SOLUTION; ORAL					
<u>GABAPENTIN</u>					
<u>AA</u>	HI TECH PHARMA	<u>250MG/5ML</u>	<u>A078974</u>	<u>001</u>	Feb 18, 2011
<u>NEURONTIN</u>					
<u>AA</u>	+ PARKE DAVIS	<u>250MG/5ML</u>	<u>N021129</u>	<u>001</u>	Mar 02, 2000
TABLET; ORAL					
<u>GABAPENTIN</u>					
<u>AB</u>	ACTAVIS ELIZABETH	<u>600MG</u>	<u>A075694</u>	<u>001</u>	Oct 21, 2004
<u>AB</u>		<u>800MG</u>	<u>A075694</u>	<u>002</u>	Oct 21, 2004
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A077894</u>	<u>001</u>	Oct 10, 2006
<u>AB</u>		<u>300MG</u>	<u>A077894</u>	<u>002</u>	Oct 10, 2006
<u>AB</u>		<u>400MG</u>	<u>A077894</u>	<u>003</u>	Oct 10, 2006
<u>AB</u>		<u>600MG</u>	<u>A077661</u>	<u>004</u>	Sep 13, 2006
<u>AB</u>		<u>800MG</u>	<u>A077661</u>	<u>005</u>	Sep 13, 2006
<u>AB</u>	AUROBINDO PHARMA LTD	<u>600MG</u>	<u>A200651</u>	<u>001</u>	Oct 06, 2011
<u>AB</u>		<u>800MG</u>	<u>A200651</u>	<u>002</u>	Oct 06, 2011
<u>AB</u>	GLENMARK GENERICS	<u>600MG</u>	<u>A077662</u>	<u>001</u>	Aug 18, 2006
<u>AB</u>		<u>800MG</u>	<u>A077662</u>	<u>002</u>	Aug 18, 2006
<u>AB</u>	HIKMA PHARMS	<u>600MG</u>	<u>A078782</u>	<u>001</u>	Jul 21, 2011
<u>AB</u>		<u>800MG</u>	<u>A078782</u>	<u>002</u>	Jul 21, 2011
<u>AB</u>	INVAGEN PHARMS	<u>600MG</u>	<u>A202764</u>	<u>001</u>	Oct 16, 2012
<u>AB</u>		<u>800MG</u>	<u>A202764</u>	<u>002</u>	Oct 16, 2012
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>100MG</u>	<u>A076017</u>	<u>001</u>	Apr 28, 2004
<u>AB</u>		<u>300MG</u>	<u>A076017</u>	<u>002</u>	Apr 28, 2004
<u>AB</u>		<u>400MG</u>	<u>A076017</u>	<u>003</u>	Apr 28, 2004
<u>AB</u>		<u>600MG</u>	<u>A076017</u>	<u>004</u>	Apr 29, 2005
<u>AB</u>		<u>800MG</u>	<u>A076017</u>	<u>005</u>	Apr 29, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>600MG</u>	<u>A090335</u>	<u>001</u>	Jun 01, 2010
<u>AB</u>		<u>800MG</u>	<u>A090335</u>	<u>002</u>	Jun 01, 2010
<u>AB</u>	SUN PHARM INDS LTD	<u>600MG</u>	<u>A077525</u>	<u>001</u>	Aug 24, 2006
<u>AB</u>		<u>800MG</u>	<u>A077525</u>	<u>002</u>	Aug 24, 2006
<u>AB</u>	ZYDUS PHARMS USA INC	<u>600MG</u>	<u>A078926</u>	<u>001</u>	Feb 11, 2011
<u>AB</u>		<u>800MG</u>	<u>A078926</u>	<u>002</u>	Feb 11, 2011
<u>NEURONTIN</u>					
<u>AB</u>	PFIZER PHARMS	<u>600MG</u>	<u>N020882</u>	<u>001</u>	Oct 09, 1998
<u>AB</u>		<u>800MG</u>	<u>N020882</u>	<u>002</u>	Oct 09, 1998
GRALISE					
BX	+ DEPOMED INC	300MG	N022544	001	Jan 28, 2011
BX		600MG	N022544	002	Jan 28, 2011

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL					
HORIZANT					
	GLAXO GRP LTD	300MG	N022399	002	Dec 13, 2011
	+	600MG	N022399	001	Apr 06, 2011

GADOBENATE DIMEGLUMINE

INJECTABLE; INTRAVENOUS					
MULTIHANCE					
+	BRACCO	2.645GM/5ML (529MG/ML)	N021357	001	Nov 23, 2004
+		5.29GM/10ML (529MG/ML)	N021357	002	Nov 23, 2004
+		7.935GM/15ML (529MG/ML)	N021357	003	Nov 23, 2004
+		10.58GM/20ML (529MG/ML)	N021357	004	Nov 23, 2004
MULTIHANCE MULTIPACK					
+	BRACCO	26.45GM/50ML (529MG/ML)	N021358	001	Nov 23, 2004
+		52.9GM/100ML (529MG/ML)	N021358	002	Nov 23, 2004

PRESCRIPTION DRUG PRODUCT LIST

3 - 196 (of 428)

GADOBUTROL

SOLUTION; INTRAVENOUS
GADAVIST

+	BAYER HLTHCARE	4.5354GM/7.5ML (604.72MG/ML)	N201277	001	Mar 14, 2011
+		6.0472GM/10ML (604.72MG/ML)	N201277	002	Mar 14, 2011
+		9.0708GM/15ML (604.72MG/ML)	N201277	003	Mar 14, 2011
+		18.1416GM/30ML (604.72MG/ML)	N201277	004	Mar 14, 2011
+		39.3068GM/65ML (604.72MG/ML)	N201277	005	Mar 14, 2011

GADODIAMIDE

INJECTABLE; INJECTION
OMNISCAN

+	GE HEALTHCARE	287MG/ML	N020123	001	Jan 08, 1993
+		28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007

GADOFOSVESET TRISODIUM

SOLUTION; INTRAVENOUS
ABLAVAR

	LANTHEUS MEDCL	2440MG/10ML (244MG/ML)	N021711	001	Dec 22, 2008
+		3660MG/15ML (244MG/ML)	N021711	002	Dec 22, 2008

GADOPENTETATE DIMEGLUMINE

INJECTABLE; INJECTION
MAGNEVIST

+	BAYER HLTHCARE	469.01MG/ML	N019596	001	Jun 02, 1988
+		469.01MG/ML	N021037	001	Mar 10, 2000

GADOTERIDOL

INJECTABLE; INJECTION
PROHANCE

+	BRACCO	279.3MG/ML	N020131	001	Nov 16, 1992
	PROHANCE MULTIPACK				
+	BRACCO	279.3MG/ML	N021489	001	Oct 09, 2003

GADOVERSETAMIDE

INJECTABLE; INJECTION
OPTIMARK

+	MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999
+		3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999
+		4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999
+		6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999
+		16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999
	OPTIMARK IN PLASTIC CONTAINER				
+	MALLINCKRODT	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999
+		4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999
+		6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999
+		9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999

GADOXETATE DISODIUM

SOLUTION; INTRAVENOUS
EOVIST

+	BAYER HLTHCARE	1.8143GM/10ML (181.43MG/ML)	N022090	001	Jul 03, 2008

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

<u>AB</u>	BARR	<u>EQ 8MG BASE</u>	<u>A078189</u>	<u>001</u>	Sep 15, 2008
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A078189</u>	<u>002</u>	Sep 15, 2008
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A078189</u>	<u>003</u>	Sep 15, 2008
<u>AB</u>	IMPAX LABS	<u>EQ 8MG BASE</u>	<u>A078484</u>	<u>001</u>	May 27, 2009
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A078484</u>	<u>002</u>	May 27, 2009
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A078484</u>	<u>003</u>	May 27, 2009

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 197 (of 428)

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

<u>AB</u>	MYLAN	<u>EQ 8MG BASE</u>	<u>A090900</u>	<u>001</u>	Jan 24, 2011
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A090900</u>	<u>002</u>	Jan 24, 2011
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A090900</u>	<u>003</u>	Jan 24, 2011
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 8MG BASE</u>	<u>A090178</u>	<u>001</u>	Feb 02, 2011
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A090178</u>	<u>002</u>	Feb 02, 2011
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A090178</u>	<u>003</u>	Feb 02, 2011
<u>AB</u>	WATSON LABS	<u>EQ 8MG BASE</u>	<u>A079028</u>	<u>001</u>	Dec 15, 2008
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A079028</u>	<u>002</u>	Dec 15, 2008
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A079028</u>	<u>003</u>	Dec 15, 2008
	<u>RAZADYNE ER</u>				
<u>AB</u>	+ JANSSEN PHARMS	<u>EQ 8MG BASE</u>	<u>N021615</u>	<u>001</u>	Apr 01, 2005
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>N021615</u>	<u>002</u>	Apr 01, 2005
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>N021615</u>	<u>003</u>	Apr 01, 2005

SOLUTION; ORAL

GALANTAMINE HYDROBROMIDE

<u>AA</u>	ROXANE	<u>4MG/ML</u>	<u>A078185</u>	<u>001</u>	Jan 30, 2009
	<u>RAZADYNE</u>				
<u>AA</u>	+ JANSSEN PHARMS	<u>4MG/ML</u>	<u>N021224</u>	<u>001</u>	Jun 22, 2001

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

<u>AB</u>	APOTEX INC	<u>EQ 4MG BASE</u>	<u>A077781</u>	<u>001</u>	Sep 27, 2011
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077781</u>	<u>002</u>	Sep 27, 2011
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077781</u>	<u>003</u>	Sep 27, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A090957</u>	<u>001</u>	Mar 29, 2011
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090957</u>	<u>002</u>	Mar 29, 2011
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A090957</u>	<u>003</u>	Mar 29, 2011
<u>AB</u>	BARR	<u>EQ 4MG BASE</u>	<u>A077605</u>	<u>001</u>	Aug 28, 2008
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077605</u>	<u>002</u>	Aug 28, 2008
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077605</u>	<u>003</u>	Aug 28, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A077593</u>	<u>001</u>	Sep 11, 2008
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077593</u>	<u>002</u>	Sep 11, 2008
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077593</u>	<u>003</u>	Sep 11, 2008
<u>AB</u>	MYLAN	<u>EQ 4MG BASE</u>	<u>A077590</u>	<u>001</u>	May 29, 2009
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077603</u>	<u>001</u>	Aug 28, 2008
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077590</u>	<u>002</u>	May 29, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077603</u>	<u>002</u>	Aug 28, 2008
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077590</u>	<u>003</u>	May 29, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077603</u>	<u>003</u>	Aug 28, 2008
<u>AB</u>	ROXANE	<u>EQ 4MG BASE</u>	<u>A077608</u>	<u>001</u>	Feb 11, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077608</u>	<u>002</u>	Feb 11, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077608</u>	<u>003</u>	Feb 11, 2009
<u>AB</u>	SANDOZ	<u>EQ 4MG BASE</u>	<u>A077589</u>	<u>001</u>	Jun 22, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077589</u>	<u>002</u>	Jun 22, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077589</u>	<u>003</u>	Jun 22, 2009
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE</u>	<u>A077587</u>	<u>001</u>	Jul 09, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077587</u>	<u>002</u>	Jul 09, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077587</u>	<u>003</u>	Jul 09, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 4MG BASE</u>	<u>A078898</u>	<u>001</u>	Feb 17, 2011
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A078898</u>	<u>002</u>	Feb 17, 2011
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A078898</u>	<u>003</u>	Feb 17, 2011
	<u>RAZADYNE</u>				
<u>AB</u>	+ JANSSEN PHARMS	<u>EQ 4MG BASE</u>	<u>N021169</u>	<u>001</u>	Feb 28, 2001
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>N021169</u>	<u>002</u>	Feb 28, 2001
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>N021169</u>	<u>003</u>	Feb 28, 2001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 198 (of 428)

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION				
GALLIUM CITRATE GA 67				
BS	LANTHEUS MEDCL	2mCi/ML	N017478	001
BS	MALLINCKRODT	2mCi/ML	N018058	001

GALLIUM NITRATE

INJECTABLE; INJECTION				
GANITE				
	+ GENTA	25MG/ML	N019961	002 Jan 17, 1991

GANCICLOVIR

GEL; OPHTHALMIC				
ZIRGAN				
	+ BAUSCH AND LOMB	0.15%	N022211	001 Sep 15, 2009
IMPLANT; IMPLANTATION				
VITRASERT				
	+ BAUSCH AND LOMB	4.5MG	N020569	001 Mar 04, 1996

GANCICLOVIR SODIUM

INJECTABLE; INJECTION				
<u>CYTOVENE</u>				
<u>AP</u>	+ ROCHE PALO	<u>EQ 500MG BASE/VIAL</u>	<u>N019661</u>	<u>001</u> Jun 23, 1989
<u>GANCICLOVIR</u>				
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A090658</u>	<u>001</u> Jun 21, 2010

GANIRELIX ACETATE

INJECTABLE; INJECTION				
GANIRELIX ACETATE INJECTION				
	+ ORGANON USA INC	EQ 250MCG BASE/0.5ML	N021057	001 Jul 29, 1999

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC				
<u>GATIFLOXACIN</u>				
<u>AT</u>	APOTEX CORP	<u>0.3%</u>	<u>A079084</u>	<u>001</u> Aug 19, 2011
<u>ZYMAR</u>				
<u>AT</u>	+ ALLERGAN	<u>0.3%</u>	<u>N021493</u>	<u>001</u> Mar 28, 2003
ZYMAXID				
	+ ALLERGAN	0.5%	N022548	001 May 18, 2010

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION				
<u>GEMCITABINE HYDROCHLORIDE</u>				
<u>AP</u>	ACCORD HLTHCARE	<u>EQ 200MG BASE/VIAL</u>	<u>A091594</u>	<u>001</u> Jul 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A091594</u>	<u>002</u> Jul 25, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091594</u>	<u>003</u> Jul 25, 2011
<u>AP</u>	ACTAVIS TOTOWA	<u>EQ 200MG BASE/VIAL</u>	<u>A079160</u>	<u>001</u> Jul 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A079160</u>	<u>002</u> Jul 25, 2011
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 200MG BASE/VIAL</u>	<u>A091365</u>	<u>001</u> Jul 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A091365</u>	<u>002</u> Jul 25, 2011
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 200MG BASE/VIAL</u>	<u>A202063</u>	<u>001</u> Sep 11, 2012
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A202063</u>	<u>002</u> Sep 11, 2012
<u>AP</u>	FRESENIUS KABI ONCOL	<u>EQ 200MG BASE/VIAL</u>	<u>A090799</u>	<u>001</u> Jul 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090799</u>	<u>002</u> Jul 25, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090799</u>	<u>003</u> May 16, 2011
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2GM BASE/VIAL</u>	<u>A090242</u>	<u>003</u> May 16, 2011
<u>AP</u>	HAMELN RDS GMBH	<u>EQ 200MG BASE/VIAL</u>	<u>A090663</u>	<u>001</u> Sep 10, 2012
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090663</u>	<u>002</u> Sep 10, 2012
<u>AP</u>	HOSPIRA	<u>EQ 200MG BASE/VIAL</u>	<u>A078339</u>	<u>001</u> Jul 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A078339</u>	<u>002</u> Jul 25, 2011
<u>AP</u>	+ HOSPIRA INC	<u>EQ 2GM BASE/VIAL</u>	<u>A079183</u>	<u>001</u> Nov 15, 2010
<u>AP</u>	ONCO THERAPIES LTD	<u>EQ 200MG BASE/VIAL</u>	<u>A200145</u>	<u>001</u> Jul 25, 2011

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 199 (of 428)

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

<u>AP</u>	ONCO THERAPIES LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A200145</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A200145</u>	<u>003</u>	Jul 25, 2011
<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 200MG BASE/VIAL</u>	<u>A078433</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A078433</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>	TEVA PHARMS	<u>EQ 200MG BASE/VIAL</u>	<u>A077983</u>	<u>002</u>	Jan 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A077983</u>	<u>001</u>	Jan 25, 2011
<u>AP</u>	WATSON LABS	<u>EQ 200MG BASE/VIAL</u>	<u>A078759</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A078759</u>	<u>002</u>	Jul 25, 2011
	<u>GEMZAR</u>				
<u>AP</u>	+ LILLY	<u>EQ 200MG BASE/VIAL</u>	<u>N020509</u>	<u>001</u>	May 15, 1996
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>N020509</u>	<u>002</u>	May 15, 1996
	GEMCITABINE HYDROCHLORIDE				
	+ HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011
	+	1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011
	+	2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

<u>AB</u>	APOTEX	<u>600MG</u>	<u>A075034</u>	<u>001</u>	Jul 20, 1998
<u>AB</u>	BLU CARIBE	<u>600MG</u>	<u>A078012</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>	DAVA PHARMS INC	<u>600MG</u>	<u>A074270</u>	<u>001</u>	Sep 27, 1993
<u>AB</u>	HIKMA PHARMS	<u>600MG</u>	<u>A078599</u>	<u>001</u>	Aug 16, 2010
<u>AB</u>	IMPAX PHARMS	<u>600MG</u>	<u>A078207</u>	<u>001</u>	Jun 01, 2007
<u>AB</u>	INVAGEN PHARMS	<u>600MG</u>	<u>A077836</u>	<u>001</u>	Jul 27, 2006
<u>AB</u>	NORTHSTAR HLTHCARE	<u>600MG</u>	<u>A079072</u>	<u>001</u>	Sep 13, 2010
<u>AB</u>	SUN PHARM INDS INC	<u>600MG</u>	<u>A079239</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>	TEVA	<u>600MG</u>	<u>A074256</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>	WATSON LABS	<u>600MG</u>	<u>A074442</u>	<u>001</u>	Apr 28, 1995
	<u>LOPID</u>				
<u>AB</u>	+ PFIZER PHARMS	<u>600MG</u>	<u>N018422</u>	<u>003</u>	Nov 20, 1986

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

+	CORNERSTONE THERAP	EQ 320MG BASE	N021158	001	Apr 04, 2003

GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN SULFATE

<u>AT</u>	+ FOUGERA	<u>EQ 0.1% BASE</u>	<u>A062531</u>	<u>001</u>	Jul 05, 1984
<u>AT</u>	PERRIGO NEW YORK	<u>EQ 0.1% BASE</u>	<u>A062307</u>	<u>001</u>	
<u>AT</u>	TARO	<u>EQ 0.1% BASE</u>	<u>A062427</u>	<u>001</u>	May 26, 1983

INJECTABLE; INJECTION

GENTAMICIN SULFATE

<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 10MG BASE/ML</u>	<u>A062356</u>	<u>001</u>	Mar 04, 1982
<u>AP</u>	+	<u>EQ 40MG BASE/ML</u>	<u>A062356</u>	<u>002</u>	Mar 04, 1982
<u>AP</u>		<u>EQ 40MG BASE/ML</u>	<u>A062366</u>	<u>001</u>	Aug 04, 1983
<u>AP</u>	HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>A062420</u>	<u>001</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 10MG BASE/ML</u>	<u>A062612</u>	<u>004</u>	Feb 20, 1986
<u>AP</u>		<u>EQ 40MG BASE/ML</u>	<u>A062420</u>	<u>002</u>	Aug 15, 1983

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	+ B BRAUN	<u>EQ 0.8MG BASE/ML</u>	<u>A062814</u>	<u>001</u>	Aug 28, 1987
<u>AP</u>	+	<u>EQ 1.2MG BASE/ML</u>	<u>A062814</u>	<u>002</u>	Aug 28, 1987
<u>AP</u>	+	<u>EQ 1.4MG BASE/ML</u>	<u>A062814</u>	<u>003</u>	Aug 28, 1987
<u>AP</u>	+	<u>EQ 1.6MG BASE/ML</u>	<u>A062814</u>	<u>004</u>	Aug 28, 1987
<u>AP</u>	+	<u>EQ 1.8MG BASE/ML</u>	<u>A062814</u>	<u>005</u>	Aug 28, 1987
<u>AP</u>	+	<u>EQ 2MG BASE/ML</u>	<u>A062814</u>	<u>006</u>	Aug 28, 1987

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 200 (of 428)

GENTAMICIN SULFATEINJECTABLE; INJECTIONGENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	<u>+</u>	<u>B BRAUN</u>	<u>EQ 2.4MG BASE/ML</u>	<u>A062814</u>	<u>007</u>	Aug 28, 1987
<u>AP</u>	<u>+</u>		<u>EQ 40MG BASE/100ML</u>	<u>A062814</u>	<u>008</u>	Aug 28, 1987
<u>AP</u>	<u>+</u>		<u>EQ 60MG BASE/100ML</u>	<u>A062814</u>	<u>009</u>	Aug 28, 1987
<u>AP</u>	<u>+</u>		<u>EQ 70MG BASE/100ML</u>	<u>A062814</u>	<u>010</u>	Aug 28, 1987
<u>AP</u>	<u>+</u>		<u>EQ 80MG BASE/100ML</u>	<u>A062814</u>	<u>011</u>	Aug 28, 1987
<u>AP</u>	<u>+</u>		<u>EQ 90MG BASE/100ML</u>	<u>A062814</u>	<u>012</u>	Aug 28, 1987
<u>AP</u>	<u>+</u>		<u>EQ 100MG BASE/100ML</u>	<u>A062814</u>	<u>013</u>	Aug 28, 1987
<u>AP</u>	<u>+</u>		<u>EQ 120MG BASE/100ML</u>	<u>A062814</u>	<u>014</u>	Aug 28, 1987
<u>AP</u>		<u>HOSPIRA</u>	<u>EQ 1.2MG BASE/ML</u>	<u>A062414</u>	<u>001</u>	Aug 15, 1983
<u>AP</u>			<u>EQ 1.4MG BASE/ML</u>	<u>A062414</u>	<u>002</u>	Aug 15, 1983
<u>AP</u>			<u>EQ 1.6MG BASE/ML</u>	<u>A062414</u>	<u>003</u>	Aug 15, 1983
<u>AP</u>			<u>EQ 1.8MG BASE/ML</u>	<u>A062414</u>	<u>004</u>	Aug 15, 1983
<u>AP</u>			<u>EQ 2MG BASE/ML</u>	<u>A062414</u>	<u>005</u>	Aug 15, 1983
<u>AP</u>			<u>EQ 60MG BASE/100ML</u>	<u>A062414</u>	<u>006</u>	Aug 15, 1983
<u>AP</u>			<u>EQ 70MG BASE/100ML</u>	<u>A062414</u>	<u>007</u>	Aug 15, 1983
<u>AP</u>			<u>EQ 80MG BASE/100ML</u>	<u>A062414</u>	<u>008</u>	Aug 15, 1983
<u>AP</u>			<u>EQ 90MG BASE/100ML</u>	<u>A062414</u>	<u>009</u>	Aug 15, 1983
<u>AP</u>			<u>EQ 100MG BASE/100ML</u>	<u>A062414</u>	<u>010</u>	Aug 15, 1983

ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER

<u>AP</u>		<u>BAXTER HLTHCARE</u>	<u>EQ 0.8MG BASE/ML</u>	<u>A062373</u>	<u>001</u>	Sep 07, 1982
<u>AP</u>			<u>EQ 1.2MG BASE/ML</u>	<u>A062373</u>	<u>007</u>	Sep 07, 1982
<u>AP</u>			<u>EQ 1.6MG BASE/ML</u>	<u>A062373</u>	<u>008</u>	Sep 07, 1982
<u>AP</u>			<u>EQ 2MG BASE/ML</u>	<u>A062373</u>	<u>009</u>	Sep 07, 1982
<u>AP</u>			<u>EQ 2.4MG BASE/ML</u>	<u>A062373</u>	<u>010</u>	Sep 07, 1982
<u>AP</u>			<u>EQ 40MG BASE/100ML</u>	<u>A062373</u>	<u>003</u>	Sep 07, 1982
<u>AP</u>			<u>EQ 60MG BASE/100ML</u>	<u>A062373</u>	<u>004</u>	Sep 07, 1982
<u>AP</u>			<u>EQ 80MG BASE/100ML</u>	<u>A062373</u>	<u>002</u>	Sep 07, 1982
<u>AP</u>			<u>EQ 100MG BASE/100ML</u>	<u>A062373</u>	<u>005</u>	Sep 07, 1982
<u>AP</u>			<u>EQ 120MG BASE/100ML</u>	<u>A062373</u>	<u>006</u>	Sep 07, 1982

OINTMENT; OPHTHALMICGENTAMICIN SULFATE

<u>AT</u>	<u>+</u>	<u>AKORN</u>	<u>EQ 0.3% BASE</u>	<u>A064093</u>	<u>001</u>	Aug 31, 1995
<u>AT</u>		<u>FERA PHARMS</u>	<u>EQ 0.3% BASE</u>	<u>A065024</u>	<u>001</u>	Jul 30, 2004

OINTMENT; TOPICALGENTAMICIN SULFATE

<u>AT</u>		<u>FOUGERA</u>	<u>EQ 0.1% BASE</u>	<u>A062533</u>	<u>001</u>	Oct 05, 1984
<u>AT</u>	<u>+</u>	<u>PERRIGO NEW YORK</u>	<u>EQ 0.1% BASE</u>	<u>A062351</u>	<u>001</u>	Feb 18, 1982
<u>AT</u>		<u>TARO</u>	<u>EQ 0.1% BASE</u>	<u>A062477</u>	<u>001</u>	Dec 23, 1983

SOLUTION/DROPS; OPHTHALMICGENOPTIC

<u>AT</u>		<u>ALLERGAN</u>	<u>EQ 0.3% BASE</u>	<u>A062452</u>	<u>001</u>	Oct 10, 1984

GENTAK

<u>AT</u>		<u>AKORN</u>	<u>EQ 0.3% BASE</u>	<u>A064163</u>	<u>001</u>	Oct 12, 2001

GENTAMICIN SULFATE

<u>AT</u>		<u>AKORN</u>	<u>EQ 0.3% BASE</u>	<u>A062635</u>	<u>001</u>	Jan 08, 1987
<u>AT</u>	<u>+</u>	<u>BAUSCH AND LOMB</u>	<u>EQ 0.3% BASE</u>	<u>A064048</u>	<u>001</u>	May 11, 1994
<u>AT</u>		<u>FALCON PHARMS</u>	<u>EQ 0.3% BASE</u>	<u>A062196</u>	<u>001</u>	
<u>AT</u>		<u>FERA PHARMS</u>	<u>EQ 0.3% BASE</u>	<u>A065121</u>	<u>001</u>	Jan 30, 2004

GENTAMICIN SULFATE; PREDNISOLONE ACETATEOINTMENT; OPHTHALMICPRED-G

<u>+</u>	<u>ALLERGAN</u>	<u>EQ 0.3% BASE;0.6%</u>	<u>N050612</u>	<u>001</u>	Dec 01, 1989

SUSPENSION/DROPS; OPHTHALMIC

<u>+</u>	<u>ALLERGAN</u>	<u>EQ 0.3% BASE;1%</u>	<u>N050586</u>	<u>001</u>	Jun 10, 1988

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 201 (of 428)

GLATIRAMER ACETATEINJECTABLE; SUBCUTANEOUS
COPAXONE

+ TEVA

20MG/ML

N020622

002

Feb 12, 2002

GLIMEPIRIDE

TABLET; ORAL

AMARYLAB + SANOFI AVENTIS US1MGN020496001

Nov 30, 1995

AB2MGN020496002

Nov 30, 1995

AB4MGN020496003

Nov 30, 1995

GLIMEPIRIDEAB ACCORD HLTHCARE1MGA078181001

Aug 23, 2007

AB2MGA078181002

Aug 23, 2007

AB4MGA078181003

Aug 23, 2007

AB AUROBINDO PHARMA LTD1MGA202759001

Jun 29, 2012

AB2MGA202759002

Jun 29, 2012

AB4MGA202759003

Jun 29, 2012

AB CARLSBAD1MGA077911001

Sep 22, 2009

AB2MGA077911002

Sep 22, 2009

AB4MGA077911003

Sep 22, 2009

AB COREPHARMA1MGA077274001

Oct 06, 2005

AB2MGA077274002

Oct 06, 2005

AB4MGA077274003

Oct 06, 2005

AB DR REDDYS LABS LTD1MGA077091001

Oct 06, 2005

AB2MGA077091002

Oct 06, 2005

AB4MGA077091003

Oct 06, 2005

AB INVAGEN PHARMS1MGA077295001

Oct 06, 2005

AB2MGA077295002

Oct 06, 2005

AB4MGA077295003

Oct 06, 2005

AB MICRO LABS USA1MGA091220001

Jun 29, 2012

AB2MGA091220002

Jun 29, 2012

AB4MGA091220004

Jun 29, 2012

AB8MGA091220006

Jun 29, 2012

AB MYLAN1MGA077486001

Feb 10, 2006

AB1MGA077624001

Nov 28, 2005

AB2MGA077486002

Feb 10, 2006

AB2MGA077624002

Nov 28, 2005

AB4MGA077486003

Feb 10, 2006

AB4MGA077624003

Nov 28, 2005

AB TEVA1MGA076802001

Oct 06, 2005

AB2MGA076802002

Oct 06, 2005

AB4MGA076802003

Oct 06, 2005

AB VINTAGE1MGA077370001

Dec 23, 2005

AB2MGA077370002

Dec 23, 2005

AB4MGA077370003

Dec 23, 2005

AB8MGA077370004

Dec 23, 2005

AB WATSON LABS1MGA077280001

Feb 03, 2006

AB2MGA077280002

Feb 03, 2006

AB4MGA077280003

Feb 03, 2006

AB WATSON LABS FLORIDA1MGA076995001

Apr 27, 2010

AB2MGA076995002

Apr 27, 2010

AB4MGA076995003

Apr 27, 2010

GLIMEPIRIDE

MICRO LABS USA

3MG

A091220

003

Jun 29, 2012

6MG

A091220

005

Jun 29, 2012

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

DUETACTAB + TAKEDA PHARMS USA2MG; 30MGN021925001

Jul 28, 2006

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 202 (of 428)

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

DUETACT

<u>AB</u>	TAKEDA PHARMS USA	<u>4MG;30MG</u>	<u>N021925</u>	<u>002</u>	Jul 28, 2006
	<u>PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE</u>				
<u>AB</u>	SANDOZ	<u>2MG;30MG</u>	<u>A201049</u>	<u>001</u>	Jan 04, 2013
<u>AB</u>		<u>4MG;30MG</u>	<u>A201049</u>	<u>002</u>	Jan 04, 2013

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDARYL

	+ SB PHARMCO	1MG;4MG	N021700	001	Nov 23, 2005
		2MG;4MG	N021700	002	Nov 23, 2005
		2MG;8MG	N021700	004	Mar 30, 2007
		4MG;4MG	N021700	003	Nov 23, 2005
		4MG;8MG	N021700	005	Mar 30, 2007

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

<u>AB</u>	ACCORD HLTHCARE INC	<u>5MG</u>	<u>A074550</u>	<u>001</u>	Sep 11, 1997
<u>AB</u>		<u>10MG</u>	<u>A074550</u>	<u>002</u>	Sep 11, 1997
<u>AB</u>	APOTEX	<u>5MG</u>	<u>A075795</u>	<u>001</u>	Jun 13, 2001
<u>AB</u>		<u>10MG</u>	<u>A075795</u>	<u>002</u>	Jun 13, 2001
<u>AB</u>	CARACO	<u>5MG</u>	<u>A077820</u>	<u>001</u>	Jul 11, 2006
<u>AB</u>		<u>10MG</u>	<u>A077820</u>	<u>002</u>	Jul 11, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG</u>	<u>A074497</u>	<u>001</u>	Aug 31, 1995
<u>AB</u>		<u>10MG</u>	<u>A074497</u>	<u>002</u>	Aug 31, 1995
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A074226</u>	<u>001</u>	May 10, 1994
<u>AB</u>		<u>5MG</u>	<u>A074438</u>	<u>001</u>	Jun 20, 1995
<u>AB</u>		<u>10MG</u>	<u>A074226</u>	<u>002</u>	May 10, 1994
<u>AB</u>		<u>10MG</u>	<u>A074438</u>	<u>002</u>	Jun 20, 1995
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A074305</u>	<u>001</u>	Apr 07, 1995
<u>AB</u>		<u>10MG</u>	<u>A074305</u>	<u>002</u>	Apr 07, 1995
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A074223</u>	<u>001</u>	Feb 27, 1995
<u>AB</u>		<u>5MG</u>	<u>A074370</u>	<u>001</u>	Nov 22, 1994
<u>AB</u>		<u>10MG</u>	<u>A074223</u>	<u>002</u>	Feb 27, 1995
<u>AB</u>		<u>10MG</u>	<u>A074370</u>	<u>002</u>	Nov 22, 1994
	<u>GLUCOTROL</u>				
<u>AB</u>	PFIZER	<u>5MG</u>	<u>N017783</u>	<u>001</u>	May 08, 1984
<u>AB</u>	+	<u>10MG</u>	<u>N017783</u>	<u>002</u>	May 08, 1984

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A076467</u>	<u>003</u>	Mar 27, 2006
<u>AB</u>		<u>5MG</u>	<u>A076467</u>	<u>001</u>	Sep 08, 2003
<u>AB</u>		<u>10MG</u>	<u>A076467</u>	<u>002</u>	Nov 07, 2003

GLUCOTROL XL

<u>AB</u>	PFIZER	<u>2.5MG</u>	<u>N020329</u>	<u>003</u>	Aug 10, 1999
<u>AB</u>		<u>5MG</u>	<u>N020329</u>	<u>001</u>	Apr 26, 1994
<u>AB</u>	+	<u>10MG</u>	<u>N020329</u>	<u>002</u>	Apr 26, 1994

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>	CARACO	<u>2.5MG;250MG</u>	<u>A077620</u>	<u>001</u>	Jan 11, 2008
<u>AB</u>		<u>2.5MG;500MG</u>	<u>A077620</u>	<u>002</u>	Jan 11, 2008
<u>AB</u>		<u>5MG;500MG</u>	<u>A077620</u>	<u>003</u>	Jan 11, 2008
<u>AB</u>	COREPHARMA	<u>2.5MG;250MG</u>	<u>A077507</u>	<u>001</u>	Oct 27, 2005
<u>AB</u>		<u>2.5MG;500MG</u>	<u>A077507</u>	<u>002</u>	Oct 27, 2005
<u>AB</u>		<u>5MG;500MG</u>	<u>A077507</u>	<u>003</u>	Oct 27, 2005
<u>AB</u>	HERITAGE PHARMS INC	<u>2.5MG;250MG</u>	<u>A078728</u>	<u>001</u>	Jun 23, 2010

PRESCRIPTION DRUG PRODUCT LIST

3 - 203 (of 428)

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>	HERITAGE PHARMS INC	<u>2.5MG;500MG</u>	<u>A078728</u>	<u>002</u>	Jun 23, 2010
<u>AB</u>		<u>5MG;500MG</u>	<u>A078728</u>	<u>003</u>	Jun 23, 2010
<u>AB</u>	MYLAN	<u>2.5MG;250MG</u>	<u>A078083</u>	<u>001</u>	Apr 12, 2007
<u>AB</u>		<u>2.5MG;500MG</u>	<u>A078083</u>	<u>002</u>	Apr 12, 2007
<u>AB</u>		<u>5MG;500MG</u>	<u>A078083</u>	<u>003</u>	Apr 12, 2007
<u>AB</u>	TEVA PHARMS	<u>2.5MG;250MG</u>	<u>A077270</u>	<u>001</u>	Oct 28, 2005
<u>AB</u>		<u>2.5MG;500MG</u>	<u>A077270</u>	<u>002</u>	Oct 28, 2005
<u>AB</u>	+	<u>5MG;500MG</u>	<u>A077270</u>	<u>003</u>	Oct 28, 2005
<u>AB</u>	ZYDUS PHARMS USA INC	<u>2.5MG;250MG</u>	<u>A078905</u>	<u>001</u>	Jan 31, 2011
<u>AB</u>		<u>2.5MG;500MG</u>	<u>A078905</u>	<u>002</u>	Jan 31, 2011
<u>AB</u>		<u>5MG;500MG</u>	<u>A078905</u>	<u>003</u>	Jan 31, 2011

GLUCAGON HYDROCHLORIDE RECOMBINANT

INJECTABLE; INJECTION
GLUCAGON

+	NOVO NORDISK	EQ 1MG BASE/VIAL	N020918	001	Jun 22, 1998

GLUCAGON RECOMBINANT

INJECTABLE; INJECTION
GLUCAGON

+	LILLY	1MG/VIAL	N020928	001	Sep 11, 1998

GLUTAMINE

FOR SOLUTION; ORAL
NUTRESTORE

+	EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004

GLYBURIDE

TABLET; ORAL

GLYBURIDE

<u>AB</u>	AUROBINDO PHARMA	<u>1.25MG</u>	<u>A077537</u>	<u>001</u>	Oct 18, 2007
<u>AB</u>		<u>2.5MG</u>	<u>A077537</u>	<u>002</u>	Oct 18, 2007
<u>AB</u>		<u>5MG</u>	<u>A077537</u>	<u>003</u>	Oct 18, 2007
<u>AB</u>	COREPHARMA	<u>1.25MG</u>	<u>A076257</u>	<u>001</u>	Jun 27, 2002
<u>AB</u>		<u>2.5MG</u>	<u>A076257</u>	<u>002</u>	Jun 27, 2002
<u>AB</u>		<u>5MG</u>	<u>A076257</u>	<u>003</u>	Jun 27, 2002
<u>AB</u>	HERITAGE PHARMS INC	<u>1.25MG</u>	<u>A090937</u>	<u>001</u>	Feb 28, 2011
<u>AB</u>		<u>2.5MG</u>	<u>A090937</u>	<u>002</u>	Feb 28, 2011
<u>AB</u>		<u>5MG</u>	<u>A090937</u>	<u>003</u>	Feb 28, 2011
<u>AB</u>	TEVA	<u>1.25MG</u>	<u>A074388</u>	<u>001</u>	Aug 29, 1995
<u>AB</u>		<u>2.5MG</u>	<u>A074388</u>	<u>002</u>	Aug 29, 1995
<u>AB</u>	+	<u>5MG</u>	<u>A074388</u>	<u>003</u>	Aug 29, 1995
<u>GLYBURIDE (MICRONIZED)</u>					
<u>AB</u>	DAVA PHARMS INC	<u>1.5MG</u>	<u>A074591</u>	<u>001</u>	Dec 22, 1997
<u>AB</u>		<u>3MG</u>	<u>A074591</u>	<u>002</u>	Dec 22, 1997
<u>AB</u>		<u>4.5MG</u>	<u>A074591</u>	<u>003</u>	Dec 22, 1997
<u>AB</u>		<u>6MG</u>	<u>A074591</u>	<u>004</u>	Dec 22, 1997
<u>AB</u>	HIKMA	<u>1.5MG</u>	<u>A075890</u>	<u>001</u>	Jul 31, 2003
<u>AB</u>		<u>3MG</u>	<u>A075890</u>	<u>002</u>	Jul 31, 2003
<u>AB</u>		<u>6MG</u>	<u>A075890</u>	<u>003</u>	Jul 31, 2003
<u>AB</u>	MYLAN	<u>1.5MG</u>	<u>A074792</u>	<u>001</u>	Jun 26, 1998
<u>AB</u>		<u>3MG</u>	<u>A074792</u>	<u>002</u>	Jun 26, 1998
<u>AB</u>		<u>6MG</u>	<u>A074792</u>	<u>003</u>	Aug 17, 1999
<u>AB</u>	TEVA	<u>1.5MG</u>	<u>A074686</u>	<u>001</u>	Apr 20, 1999
<u>AB</u>		<u>3MG</u>	<u>A074686</u>	<u>002</u>	Apr 20, 1999
<u>AB</u>		<u>4.5MG</u>	<u>A074686</u>	<u>003</u>	Apr 20, 1999
<u>AB</u>		<u>6MG</u>	<u>A074686</u>	<u>004</u>	Apr 20, 1999

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 204 (of 428)

GLYBURIDE

TABLET; ORAL

GLYNASE

<u>AB</u>	PHARMACIA AND UPJOHN	<u>1.5MG</u>	<u>N020051</u>	<u>001</u>	Mar 04, 1992
<u>AB</u>		<u>3MG</u>	<u>N020051</u>	<u>002</u>	Mar 04, 1992
<u>AB</u>	+	<u>6MG</u>	<u>N020051</u>	<u>004</u>	Sep 24, 1993
	DIABETA				
BX	SANOFI AVENTIS US	1.25MG	N017532	001	May 01, 1984
BX		2.5MG	N017532	002	May 01, 1984
BX	+	5MG	N017532	003	May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>1.25MG;250MG</u>	<u>N021178</u>	<u>001</u>	Jul 31, 2000
<u>AB</u>	+	<u>2.5MG;500MG</u>	<u>N021178</u>	<u>002</u>	Jul 31, 2000
<u>AB</u>		<u>5MG;500MG</u>	<u>N021178</u>	<u>003</u>	Jul 31, 2000
	<u>GLYBURIDE AND METFORMIN HYDROCHLORIDE</u>				
<u>AB</u>	ACTAVIS ELIZABETH	<u>1.25MG;250MG</u>	<u>A076716</u>	<u>001</u>	Jun 28, 2005
<u>AB</u>		<u>2.5MG;500MG</u>	<u>A076716</u>	<u>002</u>	Jun 28, 2005
<u>AB</u>		<u>5MG;500MG</u>	<u>A076716</u>	<u>003</u>	Jun 28, 2005
<u>AB</u>	AUROBINDO PHARMA	<u>1.25MG;250MG</u>	<u>A077870</u>	<u>001</u>	Nov 14, 2007
<u>AB</u>		<u>2.5MG;500MG</u>	<u>A077870</u>	<u>002</u>	Nov 14, 2007
<u>AB</u>		<u>5MG;500MG</u>	<u>A077870</u>	<u>003</u>	Nov 14, 2007
<u>AB</u>	COREPHARMA	<u>1.25MG;250MG</u>	<u>A076731</u>	<u>001</u>	Nov 19, 2004
<u>AB</u>		<u>2.5MG;500MG</u>	<u>A076731</u>	<u>002</u>	Nov 19, 2004
<u>AB</u>		<u>5MG;500MG</u>	<u>A076731</u>	<u>003</u>	Nov 19, 2004
<u>AB</u>	HERITAGE PHARMS INC	<u>1.25MG;250MG</u>	<u>A079009</u>	<u>001</u>	Jun 03, 2009
<u>AB</u>		<u>2.5MG;500MG</u>	<u>A079009</u>	<u>002</u>	Jun 03, 2009
<u>AB</u>		<u>5MG;500MG</u>	<u>A079009</u>	<u>003</u>	Jun 03, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>1.25MG;250MG</u>	<u>A076345</u>	<u>001</u>	Feb 18, 2004
<u>AB</u>		<u>2.5MG;500MG</u>	<u>A076345</u>	<u>002</u>	Feb 18, 2004
<u>AB</u>		<u>5MG;500MG</u>	<u>A076345</u>	<u>003</u>	Feb 18, 2004

GLYCINE

SOLUTION; IRRIGATION

AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>1.5GM/100ML</u>	<u>N017865</u>	<u>001</u>	
	<u>GLYCINE 1.5% IN PLASTIC CONTAINER</u>				
<u>AT</u>	B BRAUN	<u>1.5GM/100ML</u>	<u>N016784</u>	<u>001</u>	
<u>AT</u>	HOSPIRA	<u>1.5GM/100ML</u>	<u>N018315</u>	<u>001</u>	

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

<u>AP</u>	HIKMA FARMACEUTICA	<u>0.2MG/ML</u>	<u>A090963</u>	<u>001</u>	Sep 21, 2011
<u>AP</u>	LUITPOLD	<u>0.2MG/ML</u>	<u>A089335</u>	<u>001</u>	Jul 23, 1986
	<u>ROBINUL</u>				
<u>AP</u>	+	<u>0.2MG/ML</u>	<u>N017558</u>	<u>001</u>	
	SOLUTION; ORAL				
	CUVPOSA				
	+	1MG/5ML	N022571	001	Jul 28, 2010

TABLET; ORAL

GLYCOPYRROLATE

<u>AA</u>	BOCA PHARMA	<u>1MG</u>	<u>A090020</u>	<u>001</u>	Oct 19, 2011
<u>AA</u>		<u>2MG</u>	<u>A090020</u>	<u>002</u>	Oct 19, 2011
<u>AA</u>	COREPHARMA	<u>1MG</u>	<u>A040568</u>	<u>001</u>	Dec 22, 2004
<u>AA</u>		<u>2MG</u>	<u>A040568</u>	<u>002</u>	Dec 22, 2004
<u>AA</u>	DR REDDYS LABS LTD	<u>1MG</u>	<u>A040847</u>	<u>001</u>	Mar 21, 2008
<u>AA</u>		<u>2MG</u>	<u>A040847</u>	<u>002</u>	Mar 21, 2008
<u>AA</u>	EXCELLIUM	<u>1MG</u>	<u>A090195</u>	<u>001</u>	Sep 21, 2012

PRESCRIPTION DRUG PRODUCT LIST

3 - 205 (of 428)

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

<u>AA</u>	EXCELLIUM	<u>2MG</u>	<u>A090195</u>	<u>002</u>	Sep 21, 2012
<u>AA</u>	NEXGEN PHARMA	<u>1.5MG</u>	<u>A091522</u>	<u>001</u>	Mar 12, 2012
<u>AA</u>	PAR PHARM	<u>1MG</u>	<u>A040653</u>	<u>001</u>	Aug 31, 2006
<u>AA</u>		<u>2MG</u>	<u>A040653</u>	<u>002</u>	Aug 31, 2006
<u>AA</u>	RANBAXY	<u>1MG</u>	<u>A040844</u>	<u>001</u>	Aug 18, 2009
<u>AA</u>		<u>2MG</u>	<u>A040844</u>	<u>002</u>	Aug 18, 2009
<u>AA</u>	VINTAGE	<u>1MG</u>	<u>A040821</u>	<u>001</u>	Dec 29, 2008
<u>AA</u>		<u>2MG</u>	<u>A040821</u>	<u>002</u>	Dec 29, 2008
<u>AA</u>	WEST WARD	<u>1MG</u>	<u>A040836</u>	<u>001</u>	Mar 05, 2009
<u>AA</u>		<u>2MG</u>	<u>A040836</u>	<u>002</u>	Mar 05, 2009

ROBINUL

<u>AA</u>	+ SHIONOGI INC	<u>1MG</u>	<u>N012827</u>	<u>001</u>	
<u>ROBINUL FORTE</u>					
<u>AA</u>	+ SHIONOGI INC	<u>2MG</u>	<u>N012827</u>	<u>002</u>	

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

CHORIONIC GONADOTROPIN

<u>AP</u>	+ FERRING	<u>10,000 UNITS/VIAL</u>	<u>N017016</u>	<u>007</u>	
<u>AP</u>	+ FRESENIUS KABI USA	<u>10,000 UNITS/VIAL</u>	<u>N017067</u>	<u>002</u>	
<u>PREGNYL</u>					
<u>AP</u>	+ ORGANON USA INC	<u>10,000 UNITS/VIAL</u>	<u>N017692</u>	<u>001</u>	

GOSERELIN ACETATE

IMPLANT; IMPLANTATION

ZOLADEX

	+ ASTRAZENECA	EQ 3.6MG BASE	N019726	001	Dec 29, 1989
		EQ 10.8MG BASE	N020578	001	Jan 11, 1996

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

<u>AT</u>	+ BAUSCH AND LOMB	<u>0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML</u>	<u>A064047</u>	<u>001</u>	Jan 31, 1996
<u>AT</u>	LUITPOLD	<u>0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML</u>	<u>A065187</u>	<u>001</u>	Oct 28, 2005
<u>NEOSPORIN</u>					
<u>AT</u>	+ MONARCH PHARMS	<u>0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML</u>	<u>A060582</u>	<u>001</u>	

GRANISETRON

FILM, EXTENDED RELEASE; TRANSDERMAL

SANCUSO

	+ PROSTRAKAN INC	3.1MG/24HR	N022198	001	Sep 12, 2008

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A079119</u>	<u>001</u>	Sep 10, 2009
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A079078</u>	<u>001</u>	Sep 14, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A079078</u>	<u>002</u>	Sep 14, 2009
<u>AP</u>	BEDFORD LABS	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A077913</u>	<u>001</u>	Jun 26, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077186</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077187</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	CIPLA LTD	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078262</u>	<u>001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078258</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078258</u>	<u>002</u>	Jun 30, 2008
<u>AP</u>	CLARIS LIFESCIENCES	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078197</u>	<u>001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078198</u>	<u>001</u>	Jun 30, 2008

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 206 (of 428)

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

<u>AP</u>	CLARIS LIFESCIENCES	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078198</u>	<u>002</u>	Jun 30, 2008
<u>AP</u>	DR REDDYS LABS INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078863</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078880</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	EBEWE PHARMA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078808</u>	<u>001</u>	Apr 29, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078835</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078835</u>	<u>002</u>	Jun 30, 2008
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078522</u>	<u>001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078090</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	HIKMA MAPLE	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077177</u>	<u>001</u>	Dec 31, 2007
<u>AP</u>	LUITPOLD	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A091274</u>	<u>001</u>	Sep 22, 2010
<u>AP</u>	SAGENT AGILA	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A091137</u>	<u>002</u>	Apr 09, 2010
<u>AP</u>	SAGENT STRIDES	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A091136</u>	<u>001</u>	Apr 09, 2010
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A091136</u>	<u>002</u>	Apr 09, 2010
<u>AP</u>	SANDOZ	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078534</u>	<u>001</u>	Apr 30, 2009
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078531</u>	<u>001</u>	Apr 30, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078531</u>	<u>002</u>	Apr 30, 2009
<u>AP</u> +	TEVA PARENTERAL	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078392</u>	<u>001</u>	Dec 31, 2007
<u>AP</u> +		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077963</u>	<u>001</u>	Jan 03, 2008
<u>AP</u> +		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077297</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	WOCKHARDT USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078566</u>	<u>001</u>	Feb 29, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078564</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078565</u>	<u>001</u>	Jun 30, 2008

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	DR REDDYS LABS INC	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078863</u>	<u>002</u>	Jun 30, 2008
<u>AP</u> +	FRESENIUS KABI USA	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078096</u>	<u>001</u>	Jun 30, 2008

GRANISTERON HYDROCHLORIDE

<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078629</u>	<u>001</u>	Dec 23, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078629</u>	<u>002</u>	Dec 23, 2009

SOLUTION; ORAL

GRANISETRON HYDROCHLORIDE

+	PEDIATRAX	EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>EQ 1MG BASE</u>	<u>A078843</u>	<u>001</u>	Feb 27, 2008
<u>AB</u>	CIPLA LTD	<u>EQ 1MG BASE</u>	<u>A078037</u>	<u>001</u>	Feb 27, 2008
<u>AB</u>	COREPHARMA	<u>EQ 1MG BASE</u>	<u>A078260</u>	<u>001</u>	Dec 31, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 1MG BASE</u>	<u>A078846</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A078725</u>	<u>001</u>	Jan 30, 2008
<u>AB</u>	NATCO PHARMA	<u>EQ 1MG BASE</u>	<u>A078969</u>	<u>001</u>	Jun 22, 2009
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1MG BASE</u>	<u>A078678</u>	<u>001</u>	Feb 13, 2008
<u>AB</u>	ROXANE	<u>EQ 1MG BASE</u>	<u>A077842</u>	<u>001</u>	Dec 31, 2007
<u>AB</u>	TARO	<u>EQ 1MG BASE</u>	<u>A090817</u>	<u>001</u>	May 28, 2010
<u>AB</u> +	TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A078080</u>	<u>001</u>	Dec 31, 2007

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRIFULVIN V

<u>AB</u> +	VALEANT PHARM NORTH	<u>125MG/5ML</u>	<u>A062483</u>	<u>001</u>	Jan 26, 1984
<u>AB</u>	ACTAVIS MID ATLANTIC	<u>125MG/5ML</u>	<u>A065394</u>	<u>001</u>	Jul 06, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>125MG/5ML</u>	<u>A065354</u>	<u>001</u>	Sep 10, 2007
<u>AB</u>	PERRIGO CO TENNESSEE	<u>125MG/5ML</u>	<u>A065200</u>	<u>001</u>	Mar 02, 2005
<u>AB</u>	VINTAGE PHARMS	<u>125MG/5ML</u>	<u>A065438</u>	<u>001</u>	Oct 08, 2010

TABLET; ORAL

GRIFULVIN V

<u>AB</u> +	VALEANT LUXEMBOURG	<u>500MG</u>	<u>A062279</u>	<u>003</u>	
<u>AB</u>	SIGMAPHARM LABS LLC	<u>500MG</u>	<u>A202482</u>	<u>001</u>	Oct 22, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 207 (of 428)

GRISEOFULVIN, ULTRAMICROSIZE

TABLET; ORAL

GRISEOFULVIN, ULTRAMICROSIZE

<u>AB</u>	SIGMAPHARM LABS LLC	<u>125MG</u>	<u>A202545</u>	<u>001</u>	Oct 22, 2012
<u>AB</u>		<u>250MG</u>	<u>A202545</u>	<u>002</u>	Oct 22, 2012
<u>GRIS-PEG</u>					
<u>AB</u>	PEDINOL	<u>125MG</u>	<u>N050475</u>	<u>001</u>	
<u>AB</u>	+	<u>250MG</u>	<u>N050475</u>	<u>002</u>	

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

	IVAX SUB TEVA PHARMS	EQ 4MG BASE	A074149	001	Apr 07, 1995
+		EQ 8MG BASE	A074149	002	Apr 07, 1995

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARM	<u>EQ 1MG BASE</u>	<u>A075109</u>	<u>001</u>	Nov 25, 1998
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075109</u>	<u>002</u>	Nov 25, 1998
<u>AB</u>	EPIC PHARMA	<u>EQ 1MG BASE</u>	<u>A074673</u>	<u>001</u>	Feb 28, 1997
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A074673</u>	<u>002</u>	Feb 28, 1997
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A074796</u>	<u>001</u>	Jan 27, 1997
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A074796</u>	<u>002</u>	Jan 27, 1997
<u>AB</u>	WATSON LABS	<u>EQ 1MG BASE</u>	<u>A074145</u>	<u>001</u>	Oct 17, 1995
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A074145</u>	<u>002</u>	Oct 17, 1995
<u>TENEX</u>					
<u>AB</u>	PROMIUS PHARMA	<u>EQ 1MG BASE</u>	<u>N019032</u>	<u>001</u>	Oct 27, 1986
<u>AB</u>	+	<u>EQ 2MG BASE</u>	<u>N019032</u>	<u>002</u>	Nov 07, 1988

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 1MG BASE</u>	<u>A200881</u>	<u>001</u>	Oct 05, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A200881</u>	<u>002</u>	Oct 05, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A200881</u>	<u>003</u>	Oct 05, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A200881</u>	<u>004</u>	Oct 05, 2012
<u>INTUNIV</u>					
<u>AB</u>	SHIRE	<u>EQ 1MG BASE</u>	<u>N022037</u>	<u>001</u>	Sep 02, 2009
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>N022037</u>	<u>002</u>	Sep 02, 2009
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>N022037</u>	<u>003</u>	Sep 02, 2009
<u>AB</u>	+	<u>EQ 4MG BASE</u>	<u>N022037</u>	<u>004</u>	Sep 02, 2009

GUANIDINE HYDROCHLORIDE

TABLET; ORAL

GUANIDINE HYDROCHLORIDE

MERCK SHARP DOHME	125MG	N001546	001	

HALCINONIDE

CREAM; TOPICAL

HALOG

+	RANBAXY	0.1%	N017556	001	

OINTMENT; TOPICAL

HALOG

+	RANBAXY	0.1%	N017824	001	

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

<u>AB</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A077001</u>	<u>001</u>	Dec 16, 2004
<u>AB</u>	G AND W LABS	<u>0.05%</u>	<u>A078162</u>	<u>001</u>	Apr 24, 2007
<u>AB</u>	PERRIGO ISRAEL	<u>0.05%</u>	<u>A077123</u>	<u>001</u>	Dec 16, 2004
<u>AB</u>	TARO	<u>0.05%</u>	<u>A077227</u>	<u>001</u>	Aug 04, 2005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 208 (of 428)

HALOBETASOL PROPIONATE

CREAM; TOPICAL

ULTRAVATE

<u>AB</u>	+ RANBAXY	<u>0.05%</u>	<u>N019967</u>	<u>001</u>	Dec 27, 1990

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

<u>AB</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A076903</u>	<u>001</u>	Dec 16, 2004

<u>AB</u>	G AND W LABS	<u>0.05%</u>	<u>A077721</u>	<u>001</u>	Sep 07, 2006

<u>AB</u>	PERRIGO	<u>0.05%</u>	<u>A076872</u>	<u>001</u>	Dec 16, 2004

<u>AB</u>	TARO	<u>0.05%</u>	<u>A076994</u>	<u>001</u>	Dec 16, 2004

ULTRAVATE

<u>AB</u>	+ RANBAXY	<u>0.05%</u>	<u>N019968</u>	<u>001</u>	Dec 17, 1990

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A070278</u>	<u>006</u>	Jun 10, 1986

<u>AB</u>		<u>1MG</u>	<u>A070278</u>	<u>004</u>	Jun 10, 1986

<u>AB</u>		<u>2MG</u>	<u>A070278</u>	<u>001</u>	Jun 10, 1986

<u>AB</u>		<u>5MG</u>	<u>A070278</u>	<u>005</u>	Jun 10, 1986

<u>AB</u>		<u>10MG</u>	<u>A070278</u>	<u>002</u>	Jul 16, 2009

<u>AB</u>		<u>20MG</u>	<u>A070278</u>	<u>003</u>	Jul 16, 2009

<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A071206</u>	<u>001</u>	Nov 17, 1986

<u>AB</u>		<u>1MG</u>	<u>A071207</u>	<u>001</u>	Nov 17, 1986

<u>AB</u>	+	<u>2MG</u>	<u>A071208</u>	<u>001</u>	Nov 17, 1986

<u>AB</u>		<u>5MG</u>	<u>A071209</u>	<u>001</u>	Nov 17, 1986

<u>AB</u>		<u>10MG</u>	<u>A071210</u>	<u>001</u>	Mar 11, 1988

<u>AB</u>		<u>20MG</u>	<u>A071211</u>	<u>001</u>	Mar 11, 1988

<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A077580</u>	<u>003</u>	Nov 29, 2007

<u>AB</u>		<u>10MG</u>	<u>A077580</u>	<u>004</u>	Nov 29, 2007

<u>AB</u>		<u>20MG</u>	<u>A077580</u>	<u>005</u>	Nov 29, 2007

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALDOL

<u>AO</u>	+ JANSSEN PHARMS	<u>EQ 50MG BASE/ML</u>	<u>N018701</u>	<u>001</u>	Jan 14, 1986

<u>AO</u>	+	<u>EQ 100MG BASE/ML</u>	<u>N018701</u>	<u>002</u>	Jan 31, 1997

HALOPERIDOL DECANOATE

<u>AO</u>	BEDFORD	<u>EQ 50MG BASE/ML</u>	<u>A074811</u>	<u>001</u>	Jan 30, 1998

<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A075305</u>	<u>001</u>	Sep 28, 1998

<u>AO</u>	CLARIS LIFESCIENCES	<u>EQ 50MG BASE/ML</u>	<u>A075440</u>	<u>001</u>	Feb 28, 2000

<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A075440</u>	<u>002</u>	Feb 28, 2000

<u>AO</u>	FRESENIUS KABI USA	<u>EQ 50MG BASE/ML</u>	<u>A074893</u>	<u>001</u>	Dec 19, 1997

<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A074893</u>	<u>002</u>	Dec 19, 1997

<u>AO</u>	TEVA PARENTERAL	<u>EQ 50MG BASE/ML</u>	<u>A075393</u>	<u>001</u>	May 11, 1999

<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A075393</u>	<u>002</u>	May 11, 1999

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

<u>AA</u>	PHARM ASSOC	<u>EQ 2MG BASE/ML</u>	<u>A073037</u>	<u>001</u>	Feb 26, 1993

<u>AA</u>	SILARX	<u>EQ 2MG BASE/ML</u>	<u>A073364</u>	<u>001</u>	Sep 28, 1993

<u>AA</u>	+ TEVA PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A071617</u>	<u>001</u>	Dec 01, 1988

INJECTABLE; INJECTION

HALDOL

<u>AP</u>	+ JANSSEN PHARMS	<u>EQ 5MG BASE/ML</u>	<u>N015923</u>	<u>001</u>	

HALOPERIDOL

<u>AP</u>	BEDFORD	<u>EQ 5MG BASE/ML</u>	<u>A075858</u>	<u>001</u>	Jun 18, 2001

<u>AP</u>	CLARIS LIFESCIENCES	<u>EQ 5MG BASE/ML</u>	<u>A076791</u>	<u>001</u>	Aug 25, 2004

<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A076828</u>	<u>001</u>	Aug 25, 2004

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 5MG BASE/ML</u>	<u>A075689</u>	<u>001</u>	Mar 09, 2001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 209 (of 428)

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

<u>AP</u>	GLAND PHARMA LTD	<u>EQ 5MG BASE/ML</u>	<u>A076774</u>	<u>001</u>	Aug 25, 2004
<u>AP</u>	PFIZER	<u>EQ 5MG BASE/ML</u>	<u>A078347</u>	<u>001</u>	Sep 14, 2009
<u>AP</u>	SAGENT PHARMS	<u>EQ 5MG BASE/ML</u>	<u>A091637</u>	<u>001</u>	Sep 02, 2011
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A200742</u>	<u>001</u>	Sep 02, 2011
<u>AP</u>	TEVA PARENTERAL	<u>EQ 5MG BASE/ML</u>	<u>A076035</u>	<u>001</u>	Aug 29, 2001

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

<u>AP</u>	+ BAXTER HLTHCARE	<u>1,000 UNITS/ML</u>	<u>N017037</u>	<u>001</u>	
<u>AP</u>	+	<u>5,000 UNITS/ML</u>	<u>N017037</u>	<u>002</u>	
<u>AP</u>	+	<u>10,000 UNITS/ML</u>	<u>N017037</u>	<u>003</u>	
<u>AP</u>	+ FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029</u>	<u>001</u>	
<u>AP</u>	+	<u>5,000 UNITS/ML</u>	<u>N017651</u>	<u>006</u>	
<u>AP</u>	+	<u>10,000 UNITS/ML</u>	<u>N017029</u>	<u>003</u>	
<u>AP</u>	+	<u>20,000 UNITS/ML</u>	<u>N017029</u>	<u>004</u>	
<u>AP</u>	HOSPIRA	<u>5,000 UNITS/ML</u>	<u>A088100</u>	<u>001</u>	Apr 28, 1983
<u>AP</u>	HOSPIRA INC	<u>1,000 UNITS/ML</u>	<u>A090571</u>	<u>001</u>	Aug 31, 2009
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A090571</u>	<u>002</u>	Aug 31, 2009
<u>AP</u>		<u>10,000 UNITS/ML</u>	<u>A090571</u>	<u>003</u>	Aug 31, 2009
<u>AP</u>	SAGENT PHARMS	<u>1,000 UNITS/ML</u>	<u>A090808</u>	<u>001</u>	Jun 30, 2010
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A090808</u>	<u>002</u>	Jun 30, 2010
<u>AP</u>		<u>10,000 UNITS/ML</u>	<u>A090808</u>	<u>003</u>	Jun 30, 2010
<u>AP</u>		<u>20,000 UNITS/ML</u>	<u>A090809</u>	<u>001</u>	Jun 30, 2010
<u>AP</u>	SANDOZ	<u>1,000 UNITS/ML</u>	<u>A091682</u>	<u>001</u>	Jun 08, 2011
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A091659</u>	<u>001</u>	Jun 08, 2011
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A091682</u>	<u>002</u>	Jun 08, 2011
<u>AP</u>		<u>10,000 UNITS/ML</u>	<u>A201002</u>	<u>001</u>	Jun 08, 2011
<u>HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	BAXTER HLTHCARE	<u>200 UNITS/100ML</u>	<u>N018609</u>	<u>001</u>	Apr 28, 1982
<u>HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	+ B BRAUN	<u>200 UNITS/100ML</u>	<u>N019953</u>	<u>001</u>	Jul 20, 1992
<u>AP</u>	HOSPIRA	<u>200 UNITS/100ML</u>	<u>N018916</u>	<u>010</u>	Jun 23, 1989
<u>HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
<u>AP</u>	HOSPIRA	<u>10,000 UNITS/100ML</u>	<u>N019339</u>	<u>003</u>	Mar 27, 1985
<u>HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	BAXTER HLTHCARE	<u>200 UNITS/100ML</u>	<u>N018609</u>	<u>002</u>	Apr 28, 1982
<u>HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	HOSPIRA	<u>200 UNITS/100ML</u>	<u>N018916</u>	<u>011</u>	Jun 23, 1989
<u>HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
<u>AP</u>	+ B BRAUN	<u>4,000 UNITS/100ML</u>	<u>N019952</u>	<u>001</u>	Jul 20, 1992
<u>AP</u>	HOSPIRA	<u>4,000 UNITS/100ML</u>	<u>N019805</u>	<u>001</u>	Jan 25, 1989
<u>HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
<u>AP</u>	+ B BRAUN	<u>5,000 UNITS/100ML</u>	<u>N019952</u>	<u>004</u>	Jul 20, 1992
<u>AP</u>	+	<u>10,000 UNITS/100ML</u>	<u>N019952</u>	<u>005</u>	Jul 20, 1992
<u>AP</u>	HOSPIRA	<u>5,000 UNITS/100ML</u>	<u>N019339</u>	<u>004</u>	Mar 27, 1985
<u>AP</u>		<u>5,000 UNITS/100ML</u>	<u>N019805</u>	<u>002</u>	Jan 25, 1989
<u>AP</u>		<u>10,000 UNITS/100ML</u>	<u>N019339</u>	<u>002</u>	Mar 27, 1985
<u>HEPARIN SODIUM IN PLASTIC CONTAINER</u>					
<u>AP</u>	+ FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029</u>	<u>013</u>	Dec 05, 1985
<u>AP</u>	+	<u>5,000 UNITS/ML</u>	<u>N017029</u>	<u>014</u>	Dec 05, 1985
<u>AP</u>	+	<u>10,000 UNITS/ML</u>	<u>N017029</u>	<u>015</u>	Dec 05, 1985
<u>AP</u>	+	<u>20,000 UNITS/ML</u>	<u>N017029</u>	<u>016</u>	Dec 05, 1985
<u>HEPARIN SODIUM PRESERVATIVE FREE</u>					
<u>AP</u>	+ FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029</u>	<u>010</u>	Apr 28, 1986
<u>AP</u>	+ HOSPIRA	<u>10,000 UNITS/ML</u>	<u>A089522</u>	<u>001</u>	May 04, 1987
<u>AP</u>	SAGENT PHARMS	<u>1,000 UNITS/ML</u>	<u>A090810</u>	<u>001</u>	Jun 30, 2010

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 210 (of 428)

HEPARIN SODIUMINJECTABLE; INJECTION
HEPARIN SODIUM

PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011
	5,000 UNITS/ML	N201370	002	Jul 21, 2011
	10,000 UNITS/ML	N201370	003	Jul 21, 2011
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
HOSPIRA	5,000 UNITS/100ML	N019339	001	Mar 27, 1985
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
HOSPIRA	5,000 UNITS/100ML	N018916	006	Jan 31, 1984
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
HOSPIRA	5,000 UNITS/100ML	N018916	007	Jan 31, 1984
	10,000 UNITS/100ML	N018916	008	Jan 31, 1984
HEPARIN SODIUM PRESERVATIVE FREE				
PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011

HEXACHLOROPHENEEMULSION; TOPICAL
PHISOHEX

+ SANOFI AVENTIS US 3% N006882 001

SPONGE; TOPICAL

PRE-OPAT + DAVIS AND GECK 480MG N017433 001PRE-OP IIAT DAVIS AND GECK 480MG N017433 002HEXAMINOLEVULINATE HYDROCHLORIDEFOR SOLUTION; INTRAVESICAL
CYSVIEW KIT

+ PHOTOCURE ASA 100MG/VIAL N022555 001 May 28, 2010

HISTRELIN ACETATEIMPLANT; SUBCUTANEOUS
SUPPRELIN LA

+ ENDO PHARM 50MG N022058 001 May 03, 2007

VANTAS

+ ENDO PHARM 50MG N021732 001 Oct 12, 2004

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDEAA ACTAVIS MID ATLANTIC 1.5MG/5ML; 5MG/5ML A088017 001 Jul 05, 1983AA + HI TECH PHARMA 1.5MG/5ML; 5MG/5ML A040613 001 Feb 08, 2008AA WOCKHARDT 1.5MG/5ML; 5MG/5ML A088008 001 Mar 03, 1983

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATEAB NOVEL LABS INC 1.5MG; 5MG A091528 001 Apr 20, 2011TUSSIGONAB + KING PHARMS 1.5MG; 5MG A088508 001 Jul 30, 1985HYALURONIDASEINJECTABLE; INJECTION
AMPHADASE

+ AMPHASTAR PHARM 150 UNITS/ML N021665 001 Oct 26, 2004

VITRASE

+ ISTA PHARMS 200 UNITS/VIAL N021640 002 Dec 02, 2004

HYALURONIDASE RECOMBINANT HUMANINJECTABLE; INJECTION
HYLENEX RECOMBINANT

+ HALOZYME THERAP 150 UNITS/ML N021859 001 Dec 02, 2005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 211 (of 428)

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

<u>AP</u>	AKORN	<u>20MG/ML</u>	<u>A040730</u>	<u>001</u>	Apr 21, 2009
<u>AP</u>	FRESENIUS KABI USA	<u>20MG/ML</u>	<u>A040388</u>	<u>001</u>	Mar 13, 2001
<u>AP</u>	+ LUITPOLD	<u>20MG/ML</u>	<u>A040136</u>	<u>001</u>	Jun 30, 1997

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

<u>AA</u>	GLENMARK PHARMS LTD	<u>10MG</u>	<u>A090527</u>	<u>001</u>	May 27, 2009
<u>AA</u>		<u>25MG</u>	<u>A090527</u>	<u>002</u>	May 27, 2009
<u>AA</u>		<u>50MG</u>	<u>A090527</u>	<u>003</u>	May 27, 2009
<u>AA</u>		<u>100MG</u>	<u>A090527</u>	<u>004</u>	May 27, 2009
<u>AA</u>	HERITAGE PHARMS INC	<u>10MG</u>	<u>A086242</u>	<u>001</u>	Feb 04, 2010
<u>AA</u>		<u>25MG</u>	<u>A086242</u>	<u>003</u>	
<u>AA</u>		<u>50MG</u>	<u>A086242</u>	<u>002</u>	
<u>AA</u>		<u>100MG</u>	<u>A086242</u>	<u>004</u>	Feb 04, 2010
<u>AA</u>	HETERO LABS UNIT III	<u>10MG</u>	<u>A040901</u>	<u>001</u>	Sep 12, 2008
<u>AA</u>		<u>25MG</u>	<u>A040901</u>	<u>002</u>	Sep 12, 2008
<u>AA</u>		<u>50MG</u>	<u>A040901</u>	<u>003</u>	Sep 12, 2008
<u>AA</u>		<u>100MG</u>	<u>A040901</u>	<u>004</u>	Sep 12, 2008
<u>AA</u>	INVAGEN PHARMS	<u>10MG</u>	<u>A090255</u>	<u>001</u>	Dec 15, 2008
<u>AA</u>		<u>25MG</u>	<u>A090255</u>	<u>002</u>	Dec 15, 2008
<u>AA</u>		<u>50MG</u>	<u>A090255</u>	<u>003</u>	Dec 15, 2008
<u>AA</u>		<u>100MG</u>	<u>A090255</u>	<u>004</u>	Dec 15, 2008
<u>AA</u>	MYLAN	<u>10MG</u>	<u>A090413</u>	<u>001</u>	Dec 08, 2010
<u>AA</u>		<u>25MG</u>	<u>A090413</u>	<u>002</u>	Dec 08, 2010
<u>AA</u>		<u>50MG</u>	<u>A090413</u>	<u>003</u>	Dec 08, 2010
<u>AA</u>		<u>100MG</u>	<u>A090413</u>	<u>004</u>	Dec 08, 2010
<u>AA</u>	PAR PHARM	<u>10MG</u>	<u>A087836</u>	<u>001</u>	Oct 05, 1982
<u>AA</u>		<u>25MG</u>	<u>A086961</u>	<u>002</u>	
<u>AA</u>		<u>50MG</u>	<u>A086962</u>	<u>001</u>	
<u>AA</u>		<u>100MG</u>	<u>A088391</u>	<u>001</u>	Sep 27, 1983
<u>AA</u>	+ PLIVA	<u>10MG</u>	<u>A089097</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>	+	<u>25MG</u>	<u>A088467</u>	<u>001</u>	May 01, 1984
<u>AA</u>	+	<u>50MG</u>	<u>A088468</u>	<u>001</u>	May 01, 1984
<u>AA</u>	+	<u>100MG</u>	<u>A089098</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>	WATSON LABS	<u>25MG</u>	<u>A084504</u>	<u>001</u>	
<u>AA</u>		<u>50MG</u>	<u>A084503</u>	<u>001</u>	
<u>AA</u>	ZYDUS PHARMS USA	<u>10MG</u>	<u>A040858</u>	<u>001</u>	Feb 26, 2010
<u>AA</u>		<u>25MG</u>	<u>A040858</u>	<u>002</u>	Feb 26, 2010
<u>AA</u>		<u>50MG</u>	<u>A040858</u>	<u>003</u>	Feb 26, 2010
<u>AA</u>		<u>100MG</u>	<u>A040858</u>	<u>004</u>	Feb 26, 2010
<u>HYDRALAZINE HYDROCHLORIDE</u>					
<u>AB</u>	ALKEM LABS LTD	<u>10MG</u>	<u>A200737</u>	<u>001</u>	Dec 07, 2012
<u>AB</u>		<u>25MG</u>	<u>A200737</u>	<u>002</u>	Dec 07, 2012
<u>AB</u>		<u>50MG</u>	<u>A200737</u>	<u>003</u>	Dec 07, 2012
<u>AB</u>		<u>100MG</u>	<u>A200737</u>	<u>004</u>	Dec 07, 2012

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRA-ZIDE

PAR PHARM	25MG; 25MG	A088957	001	Oct 21, 1985
+	50MG; 50MG	A088946	001	Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

BIDIL

+	ARBOR PHARMS INC	37.5MG; 20MG	N020727	001	Jun 23, 2005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 212 (of 428)

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>12.5MG</u>	<u>A200645</u>	<u>001</u>	Nov 30, 2010
<u>AB</u>	APOTEX	<u>12.5MG</u>	<u>A078389</u>	<u>001</u>	May 16, 2008
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG</u>	<u>A078164</u>	<u>001</u>	Sep 18, 2007
<u>AB</u>	IPCA LABS LTD	<u>12.5MG</u>	<u>A079237</u>	<u>001</u>	Apr 02, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>12.5MG</u>	<u>A077005</u>	<u>001</u>	Jul 13, 2005
<u>AB</u>	JUBILANT CADISTA	<u>12.5MG</u>	<u>A078391</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>	LANNETT HOLDINGS INC	<u>12.5MG</u>	<u>A091662</u>	<u>001</u>	Jan 27, 2012
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A075640</u>	<u>001</u>	Jan 28, 2000
<u>AB</u>	UNICHEM	<u>12.5MG</u>	<u>A090510</u>	<u>001</u>	Jan 19, 2010
<u>AB</u>	VINTAGE PHARMS	<u>12.5MG</u>	<u>A075907</u>	<u>001</u>	Sep 17, 2002
<u>AB</u>	WEST WARD	<u>12.5MG</u>	<u>A077885</u>	<u>001</u>	Nov 26, 2007

MICROZIDE

<u>AB</u>	+ WATSON LABS	<u>12.5MG</u>	<u>N020504</u>	<u>001</u>	Dec 27, 1996

TABLET; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	ACCORD HLTHCARE	<u>12.5MG</u>	<u>A202556</u>	<u>001</u>	Sep 24, 2012
<u>AB</u>		<u>25MG</u>	<u>A202556</u>	<u>002</u>	Sep 24, 2012
<u>AB</u>		<u>50MG</u>	<u>A202556</u>	<u>003</u>	Sep 24, 2012
<u>AB</u>	ACTAVIS ELIZABETH	<u>12.5MG</u>	<u>A040707</u>	<u>001</u>	Feb 27, 2007
<u>AB</u>	APOTEX	<u>25MG</u>	<u>A040774</u>	<u>001</u>	Oct 03, 2007
<u>AB</u>		<u>50MG</u>	<u>A040774</u>	<u>002</u>	Oct 03, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A040780</u>	<u>001</u>	Jul 20, 2007
<u>AB</u>		<u>50MG</u>	<u>A040780</u>	<u>002</u>	Jul 20, 2007
<u>AB</u>	CARACO	<u>12.5MG</u>	<u>A040857</u>	<u>001</u>	May 30, 2008
<u>AB</u>		<u>25MG</u>	<u>A040810</u>	<u>001</u>	Mar 27, 2007
<u>AB</u>		<u>50MG</u>	<u>A040810</u>	<u>002</u>	Mar 27, 2007
<u>AB</u>	DAVA PHARMS INC	<u>25MG</u>	<u>A087059</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A087068</u>	<u>001</u>	
<u>AB</u>	EXCELLIUM	<u>25MG</u>	<u>A040702</u>	<u>001</u>	Mar 16, 2007
<u>AB</u>		<u>50MG</u>	<u>A040702</u>	<u>002</u>	Mar 16, 2007
<u>AB</u>	HERITAGE PHARMS INC	<u>25MG</u>	<u>A085182</u>	<u>002</u>	
<u>AB</u>		<u>50MG</u>	<u>A085182</u>	<u>001</u>	
<u>AB</u>	IPCA LABS LTD	<u>12.5MG</u>	<u>A040807</u>	<u>001</u>	Jul 20, 2007
<u>AB</u>		<u>25MG</u>	<u>A040807</u>	<u>002</u>	Jul 20, 2007
<u>AB</u>		<u>50MG</u>	<u>A040807</u>	<u>003</u>	Jul 20, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A083177</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A083177</u>	<u>002</u>	
<u>AB</u>	+ JUBILANT CADISTA	<u>25MG</u>	<u>A040809</u>	<u>001</u>	Sep 04, 2007
<u>AB</u>		<u>50MG</u>	<u>A040809</u>	<u>002</u>	Sep 04, 2007
<u>AB</u>	LANNETT	<u>25MG</u>	<u>A084325</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A084324</u>	<u>001</u>	
<u>AB</u>	MYLAN PHARMS INC	<u>12.5MG</u>	<u>A040770</u>	<u>001</u>	Jan 23, 2007
<u>AB</u>		<u>25MG</u>	<u>A040735</u>	<u>002</u>	Jan 23, 2007
<u>AB</u>		<u>50MG</u>	<u>A040735</u>	<u>003</u>	Jan 23, 2007
<u>AB</u>	UNICHEM	<u>25MG</u>	<u>A040907</u>	<u>001</u>	Aug 15, 2008
<u>AB</u>		<u>50MG</u>	<u>A040907</u>	<u>002</u>	Aug 15, 2008
<u>AB</u>	VINTAGE PHARMS	<u>25MG</u>	<u>A040412</u>	<u>001</u>	Mar 29, 2002
<u>AB</u>		<u>50MG</u>	<u>A040412</u>	<u>002</u>	Mar 29, 2002
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A081189</u>	<u>001</u>	Jan 24, 1992
<u>AB</u>	WEST WARD	<u>25MG</u>	<u>A084878</u>	<u>002</u>	Jul 12, 2006
<u>AB</u>		<u>50MG</u>	<u>A084878</u>	<u>001</u>	

ORETIC

<u>AB</u>	ABBVIE	<u>50MG</u>	<u>N011971</u>	<u>002</u>	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

<u>AB</u>	+ SANOFI AVENTIS US	<u>12.5MG;150MG</u>	<u>N020758</u>	<u>002</u>	Sep 30, 1997

PRESCRIPTION DRUG PRODUCT LIST

3 - 213 (of 428)

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

<u>AVALIDE</u>				
<u>AB</u>	+ SANOFI AVENTIS US	<u>12.5MG;300MG</u>	<u>N020758</u>	<u>003</u> Aug 31, 1998
<u>IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>				
<u>AB</u>	ALEMBIC LTD	<u>12.5MG;150MG</u>	<u>A091370</u>	<u>001</u> Oct 15, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A091370</u>	<u>002</u> Oct 15, 2012
<u>AB</u>	APOTEX INC	<u>12.5MG;150MG</u>	<u>A201505</u>	<u>001</u> Oct 15, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A201505</u>	<u>002</u> Oct 15, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>12.5MG;150MG</u>	<u>A203500</u>	<u>001</u> Sep 27, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A203500</u>	<u>002</u> Sep 27, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>12.5MG;150MG</u>	<u>A202414</u>	<u>001</u> Sep 27, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A202414</u>	<u>002</u> Sep 27, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>12.5MG;150MG</u>	<u>A077969</u>	<u>001</u> Sep 27, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A077969</u>	<u>002</u> Sep 27, 2012
<u>AB</u>	ROXANE	<u>12.5MG;150MG</u>	<u>A090351</u>	<u>001</u> Oct 15, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A090351</u>	<u>002</u> Oct 15, 2012
<u>AB</u>	SANDOZ	<u>12.5MG;150MG</u>	<u>A077446</u>	<u>001</u> Sep 27, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A077446</u>	<u>002</u> Sep 27, 2012
<u>AB</u>	TEVA	<u>12.5MG;150MG</u>	<u>A077369</u>	<u>001</u> Mar 30, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A077369</u>	<u>002</u> Mar 30, 2012
<u>AB</u>	WATSON LABS INC	<u>12.5MG;150MG</u>	<u>A091539</u>	<u>001</u> Oct 22, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A091539</u>	<u>002</u> Oct 22, 2012

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

<u>LISINAPRIL AND HYDROCHLOROTHIAZIDE</u>				
<u>AB</u>	APOTEX INC	<u>12.5MG;10MG</u>	<u>A076674</u>	<u>001</u> Oct 05, 2004
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076674</u>	<u>002</u> Oct 05, 2004
<u>AB</u>		<u>25MG;20MG</u>	<u>A076674</u>	<u>003</u> Oct 05, 2004
<u>AB</u>	AUROBINDO	<u>12.5MG;10MG</u>	<u>A077606</u>	<u>001</u> Mar 14, 2006
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A077606</u>	<u>002</u> Mar 14, 2006
<u>AB</u>		<u>25MG;20MG</u>	<u>A077606</u>	<u>003</u> Mar 14, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>12.5MG;10MG</u>	<u>A075776</u>	<u>001</u> Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A075776</u>	<u>002</u> Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A075776</u>	<u>003</u> Jul 01, 2002
<u>AB</u>	LUPIN	<u>12.5MG;10MG</u>	<u>A077912</u>	<u>001</u> Sep 27, 2006
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A077912</u>	<u>002</u> Sep 27, 2006
<u>AB</u>		<u>25MG;20MG</u>	<u>A077912</u>	<u>003</u> Sep 27, 2006
<u>AB</u>	MYLAN	<u>12.5MG;10MG</u>	<u>A076113</u>	<u>001</u> Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076113</u>	<u>002</u> Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076113</u>	<u>003</u> Jul 01, 2002
<u>AB</u>	PRINSTON INC	<u>12.5MG;10MG</u>	<u>A076230</u>	<u>001</u> Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076230</u>	<u>002</u> Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076230</u>	<u>003</u> Jul 01, 2002
<u>AB</u>	RANBAXY	<u>12.5MG;10MG</u>	<u>A076007</u>	<u>001</u> Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076007</u>	<u>002</u> Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076007</u>	<u>003</u> Jul 01, 2002
<u>AB</u>	SANDOZ	<u>12.5MG;10MG</u>	<u>A076262</u>	<u>001</u> Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076262</u>	<u>002</u> Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076262</u>	<u>003</u> Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>12.5MG;10MG</u>	<u>A076194</u>	<u>003</u> Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076194</u>	<u>001</u> Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076194</u>	<u>002</u> Jul 01, 2002
<u>AB</u>	WEST WARD	<u>12.5MG;10MG</u>	<u>A076265</u>	<u>001</u> Jul 08, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076265</u>	<u>002</u> Jul 08, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076265</u>	<u>003</u> Jul 08, 2002
<u>PRINZIDE</u>				
<u>AB</u>	MERCK	<u>12.5MG;10MG</u>	<u>N019778</u>	<u>003</u> Nov 18, 1993
<u>AB</u>		<u>12.5MG;20MG</u>	<u>N019778</u>	<u>001</u> Feb 16, 1989

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 214 (of 428)

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

ZESTORETIC

<u>AB</u>	ASTRAZENECA	<u>12.5MG;10MG</u>	<u>N019888</u>	<u>003</u>	Nov 18, 1993
<u>AB</u>	+	<u>12.5MG;20MG</u>	<u>N019888</u>	<u>001</u>	Sep 20, 1990
<u>AB</u>	+	<u>25MG;20MG</u>	<u>N019888</u>	<u>002</u>	Jul 20, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

<u>AB</u>	MERCK	<u>12.5MG;50MG</u>	<u>N020387</u>	<u>001</u>	Apr 28, 1995
<u>AB</u>		<u>12.5MG;100MG</u>	<u>N020387</u>	<u>003</u>	Oct 20, 2005
<u>AB</u>	+	<u>25MG;100MG</u>	<u>N020387</u>	<u>002</u>	Nov 10, 1998

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>12.5MG;50MG</u>	<u>A091617</u>	<u>001</u>	Feb 17, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091617</u>	<u>002</u>	Feb 17, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A091617</u>	<u>003</u>	Feb 17, 2012
<u>AB</u>	APOTEX	<u>12.5MG;50MG</u>	<u>A090150</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A090150</u>	<u>002</u>	Aug 11, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A090150</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG;50MG</u>	<u>A091629</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091629</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A091629</u>	<u>003</u>	Jan 06, 2010
<u>AB</u>	CADISTA PHARMS	<u>12.5MG;50MG</u>	<u>A201845</u>	<u>001</u>	Sep 18, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A201845</u>	<u>002</u>	Sep 18, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A201845</u>	<u>003</u>	Sep 18, 2012
<u>AB</u>	LUPIN LTD	<u>12.5MG;50MG</u>	<u>A078245</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A078245</u>	<u>002</u>	May 21, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A078245</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>12.5MG;50MG</u>	<u>A202289</u>	<u>001</u>	Aug 09, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A202289</u>	<u>002</u>	Aug 09, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A202289</u>	<u>003</u>	Aug 09, 2012
<u>AB</u>	MYLAN	<u>12.5MG;50MG</u>	<u>A091652</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091652</u>	<u>002</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A091652</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	ROXANE	<u>12.5MG;50MG</u>	<u>A077732</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077732</u>	<u>001</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077732</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	SANDOZ	<u>12.5MG;50MG</u>	<u>A077948</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077948</u>	<u>003</u>	Aug 19, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077948</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>	TEVA PHARMS	<u>12.5MG;50MG</u>	<u>A077157</u>	<u>001</u>	Apr 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077157</u>	<u>002</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077157</u>	<u>003</u>	Apr 06, 2010
<u>AB</u>	TORRENT PHARMS	<u>12.5MG;50MG</u>	<u>A090528</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A090528</u>	<u>003</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A090528</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>	WATSON LABS	<u>12.5MG;50MG</u>	<u>A200180</u>	<u>001</u>	Jan 12, 2011
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A200180</u>	<u>002</u>	Jan 12, 2011
<u>AB</u>		<u>25MG;100MG</u>	<u>A200180</u>	<u>003</u>	Jan 12, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>12.5MG;50MG</u>	<u>A078385</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A078385</u>	<u>002</u>	Oct 06, 2010

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

	MYLAN	15MG;250MG	A070264	001	Jan 23, 1986
+		25MG;250MG	A070265	001	Jan 23, 1986

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 215 (of 428)

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATETABLET, EXTENDED RELEASE; ORAL
DUTOPROL

ASTRAZENECA	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006
	12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006
+	12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

<u>AB</u>	US PHARMS HOLDINGS I	<u>25MG;50MG</u>	<u>N018303</u>	<u>001</u>	Dec 31, 1984
<u>AB</u>	+	<u>25MG;100MG</u>	<u>N018303</u>	<u>002</u>	Dec 31, 1984

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	MYLAN	<u>25MG;50MG</u>	<u>A076792</u>	<u>001</u>	Aug 20, 2004
<u>AB</u>		<u>25MG;100MG</u>	<u>A076792</u>	<u>002</u>	Aug 20, 2004
<u>AB</u>		<u>50MG;100MG</u>	<u>A076792</u>	<u>003</u>	Aug 20, 2004
<u>AB</u>	SUN PHARM INDS	<u>25MG;50MG</u>	<u>A090654</u>	<u>001</u>	Jan 19, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A090654</u>	<u>002</u>	Jan 19, 2012
<u>AB</u>		<u>50MG;100MG</u>	<u>A090654</u>	<u>003</u>	Jan 19, 2012

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	GLENMARK PHARMS	<u>12.5MG;7.5MG</u>	<u>A090718</u>	<u>001</u>	Mar 17, 2010
<u>AB</u>		<u>12.5MG;15MG</u>	<u>A090718</u>	<u>002</u>	Mar 17, 2010
<u>AB</u>		<u>25MG;15MG</u>	<u>A090718</u>	<u>003</u>	Mar 17, 2010
<u>AB</u>	TEVA	<u>12.5MG;7.5MG</u>	<u>A076980</u>	<u>001</u>	Mar 07, 2007
<u>AB</u>		<u>12.5MG;15MG</u>	<u>A076980</u>	<u>003</u>	Mar 07, 2007
<u>AB</u>		<u>25MG;15MG</u>	<u>A076980</u>	<u>002</u>	Mar 07, 2007
<u>UNIRETIC</u>					
<u>AB</u>	UCB INC	<u>12.5MG;7.5MG</u>	<u>N020729</u>	<u>001</u>	Jun 27, 1997
<u>AB</u>		<u>12.5MG;15MG</u>	<u>N020729</u>	<u>003</u>	Feb 14, 2002
<u>AB</u>	+	<u>25MG;15MG</u>	<u>N020729</u>	<u>002</u>	Jun 27, 1997

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR HCT

DAIICHI SANKYO	12.5MG;20MG	N021532	002	Jun 05, 2003
	12.5MG;40MG	N021532	003	Jun 05, 2003
+	25MG;40MG	N021532	005	Jun 05, 2003

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERIDE-40/25

<u>AB</u>	+	AKRIMAX PHARMS	<u>25MG;40MG</u>	<u>N018031</u>	<u>001</u>	
<u>PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE</u>						
<u>AB</u>		MYLAN	<u>25MG;40MG</u>	<u>A070946</u>	<u>001</u>	Mar 04, 1987
<u>AB</u>	+		<u>25MG;80MG</u>	<u>A070947</u>	<u>001</u>	Apr 01, 1987
<u>AB</u>		PLIVA	<u>25MG;40MG</u>	<u>A072042</u>	<u>001</u>	Mar 14, 1988
<u>AB</u>			<u>25MG;80MG</u>	<u>A072043</u>	<u>001</u>	Mar 14, 1988
<u>AB</u>		WATSON LABS	<u>25MG;40MG</u>	<u>A070301</u>	<u>001</u>	Apr 18, 1986
<u>AB</u>			<u>25MG;80MG</u>	<u>A070305</u>	<u>001</u>	Apr 18, 1986

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC

<u>AB</u>	PFIZER PHARMS	<u>12.5MG;EQ 10MG BASE</u>	<u>N020125</u>	<u>001</u>	Dec 28, 1999
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>N020125</u>	<u>002</u>	Dec 28, 1999
<u>AB</u>	+	<u>25MG;EQ 20MG BASE</u>	<u>N020125</u>	<u>003</u>	Dec 28, 1999
<u>QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE</u>					
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG;EQ 10MG BASE</u>	<u>A078450</u>	<u>001</u>	Aug 24, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 216 (of 428)

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG;EQ 20MG BASE</u>	<u>A078450</u>	<u>002</u>	Aug 24, 2007
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A078450</u>	<u>003</u>	Aug 24, 2007
<u>AB</u>	INVAGEN PHARMS	<u>12.5MG;10MG</u>	<u>A201356</u>	<u>001</u>	Apr 20, 2011
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A201356</u>	<u>002</u>	Apr 20, 2011
<u>AB</u>		<u>25MG;20MG</u>	<u>A201356</u>	<u>003</u>	Apr 20, 2011
<u>AB</u>	MYLAN	<u>12.5MG;EQ 10MG BASE</u>	<u>A077093</u>	<u>001</u>	Mar 28, 2005
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A077093</u>	<u>002</u>	Mar 28, 2005
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A077093</u>	<u>003</u>	Mar 28, 2005
<u>AB</u>	RANBAXY	<u>12.5MG;EQ 10MG BASE</u>	<u>A078211</u>	<u>001</u>	Mar 04, 2009
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A078211</u>	<u>002</u>	Mar 04, 2009
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A078211</u>	<u>003</u>	Mar 04, 2009
<u>QUINARETIC</u>					
<u>AB</u>	GAVIS PHARMS	<u>12.5MG;EQ 10MG BASE</u>	<u>A076374</u>	<u>001</u>	Mar 31, 2004
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A076374</u>	<u>002</u>	Mar 31, 2004
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A076374</u>	<u>003</u>	Mar 31, 2004

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

ALDACTAZIDE

<u>AB</u>	GD SEARLE LLC	<u>25MG;25MG</u>	<u>N012616</u>	<u>004</u>	Dec 30, 1982
<u>SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE</u>					
<u>AB</u>	MUTUAL PHARM	<u>25MG;25MG</u>	<u>A089534</u>	<u>001</u>	Jul 02, 1987
<u>AB</u>	MYLAN	<u>25MG;25MG</u>	<u>A086513</u>	<u>001</u>	
<u>AB</u>	WATSON LABS	<u>25MG;25MG</u>	<u>A087398</u>	<u>001</u>	
<u>ALDACTAZIDE</u>					
	+ GD SEARLE LLC	50MG;50MG	N012616	005	Dec 30, 1982

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

	BOEHRINGER INGELHEIM	12.5MG;40MG	N021162	001	Nov 17, 2000
		12.5MG;80MG	N021162	002	Nov 17, 2000
	+	25MG;80MG	N021162	003	Apr 19, 2004

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

<u>AB</u>	+ GLAXOSMITHKLINE LLC	<u>25MG;37.5MG</u>	<u>N016042</u>	<u>003</u>	Mar 03, 1994
<u>TRIAMTERENE AND HYDROCHLOROTHIAZIDE</u>					
<u>AB</u>	DURAMED PHARMS BARR	<u>25MG;37.5MG</u>	<u>A075052</u>	<u>001</u>	Jun 18, 1999
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>25MG;50MG</u>	<u>A074259</u>	<u>001</u>	Mar 30, 1995
<u>AB</u>	LANNETT HOLDINGS INC	<u>25MG;37.5MG</u>	<u>A201407</u>	<u>001</u>	Dec 09, 2011
<u>AB</u>	MYLAN	<u>25MG;37.5MG</u>	<u>A074701</u>	<u>001</u>	Jun 07, 1996
<u>AB</u>	SANDOZ	<u>25MG;37.5MG</u>	<u>A074821</u>	<u>001</u>	Jun 05, 1997
<u>AB</u>	+	<u>25MG;50MG</u>	<u>A073191</u>	<u>001</u>	Jul 31, 1991

TABLET; ORAL

MAXZIDE

<u>AB</u>	+ MYLAN BERTEK	<u>50MG;75MG</u>	<u>N019129</u>	<u>001</u>	Oct 22, 1984
<u>MAXZIDE-25</u>					
<u>AB</u>	MYLAN BERTEK	<u>25MG;37.5MG</u>	<u>N019129</u>	<u>003</u>	May 13, 1988
<u>TRIAMTERENE AND HYDROCHLOROTHIAZIDE</u>					
<u>AB</u>	APOTEX INC	<u>25MG;37.5MG</u>	<u>A071251</u>	<u>002</u>	May 05, 1998
<u>AB</u>		<u>50MG;75MG</u>	<u>A071251</u>	<u>001</u>	Apr 17, 1988
<u>AB</u>	PLIVA	<u>25MG;37.5MG</u>	<u>A074026</u>	<u>001</u>	Apr 26, 1996
<u>AB</u>		<u>50MG;75MG</u>	<u>A073467</u>	<u>001</u>	Jan 31, 1996
<u>AB</u>	SANDOZ	<u>25MG;37.5MG</u>	<u>A073281</u>	<u>001</u>	Apr 30, 1992
<u>AB</u>		<u>50MG;75MG</u>	<u>A072011</u>	<u>001</u>	Jun 17, 1988
<u>AB</u>	WATSON LABS	<u>25MG;37.5MG</u>	<u>A073449</u>	<u>001</u>	Sep 23, 1993

PRESCRIPTION DRUG PRODUCT LIST

3 - 217 (of 428)

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	WATSON LABS	<u>50MG;75MG</u>	<u>A071851</u>	<u>001</u>	Nov 30, 1988
<u>AB</u>		<u>50MG;75MG</u>	<u>A071969</u>	<u>001</u>	Apr 17, 1988

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

<u>AB</u>	NOVARTIS	<u>12.5MG;80MG</u>	<u>N020818</u>	<u>001</u>	Mar 06, 1998
<u>AB</u>		<u>12.5MG;160MG</u>	<u>N020818</u>	<u>002</u>	Mar 06, 1998
<u>AB</u>		<u>12.5MG;320MG</u>	<u>N020818</u>	<u>004</u>	Apr 28, 2006
<u>AB</u>		<u>25MG;160MG</u>	<u>N020818</u>	<u>003</u>	Jan 17, 2002
<u>AB</u>	+	<u>25MG;320MG</u>	<u>N020818</u>	<u>005</u>	Apr 28, 2006

VALSARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>	MYLAN PHARMS INC	<u>12.5MG;80MG</u>	<u>A078020</u>	<u>001</u>	Sep 21, 2012
<u>AB</u>		<u>12.5MG;160MG</u>	<u>A078020</u>	<u>002</u>	Sep 21, 2012
<u>AB</u>		<u>12.5MG;320MG</u>	<u>A078020</u>	<u>004</u>	Sep 21, 2012
<u>AB</u>		<u>25MG;160MG</u>	<u>A078020</u>	<u>003</u>	Sep 21, 2012
<u>AB</u>		<u>25MG;320MG</u>	<u>A078020</u>	<u>005</u>	Sep 21, 2012

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

<u>AB</u>	AMNEAL PHARMS NY	<u>5MG;200MG</u>	<u>A076642</u>	<u>002</u>	Mar 18, 2004
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A076642</u>	<u>001</u>	Oct 12, 2004
<u>AB</u>	TEVA	<u>7.5MG;200MG</u>	<u>A076023</u>	<u>001</u>	Apr 11, 2003
<u>AB</u>	VINTAGE PHARMS	<u>5MG;200MG</u>	<u>A077727</u>	<u>001</u>	Nov 06, 2006
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A077723</u>	<u>001</u>	Nov 06, 2006
<u>AB</u>		<u>10MG;200MG</u>	<u>A077723</u>	<u>002</u>	Nov 06, 2006
<u>AB</u>	WATSON LABS FLORIDA	<u>5MG;200MG</u>	<u>A077454</u>	<u>001</u>	Jun 23, 2010
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A076604</u>	<u>001</u>	Dec 31, 2003
<u>VICOPROFEN</u>					
<u>AB</u>	+ ABBVIE	<u>7.5MG;200MG</u>	<u>N020716</u>	<u>001</u>	Sep 23, 1997
	REPREXAIN				
	AMNEAL PHARMS NY	2.5MG;200MG	A076642	003	Oct 19, 2007
		10MG;200MG	A076642	004	Oct 19, 2007

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

REZIRA

+	CYPRESS PHARM	5MG/5ML;60MG/5ML	N022442	001	Jun 08, 2011

HYDROCORTISONE

CREAM; TOPICAL

ALA-CORT

<u>AT</u>	CROWN LABS	<u>1%</u>	<u>A080706</u>	<u>006</u>	
<u>ANUSOL HC</u>					
<u>AT</u>	SALIX PHARMS	<u>2.5%</u>	<u>A088250</u>	<u>001</u>	Jun 06, 1984
<u>HYDROCORTISONE</u>					
<u>AT</u>	ACTAVIS MID ATLANTIC	<u>1%</u>	<u>A087795</u>	<u>001</u>	May 03, 1983
<u>AT</u>		<u>2.5%</u>	<u>A089682</u>	<u>001</u>	Mar 10, 1988
<u>AT</u>	+	<u>FOUGERA</u>	<u>1%</u>	<u>A080693</u>	<u>003</u>
<u>AT</u>	+	<u>2.5%</u>	<u>A089414</u>	<u>001</u>	Dec 16, 1986
<u>AT</u>	LYNE	<u>2.5%</u>	<u>A040879</u>	<u>001</u>	Aug 20, 2010
<u>AT</u>	PERRIGO NEW YORK	<u>2.5%</u>	<u>A085025</u>	<u>001</u>	
<u>AT</u>	TARO	<u>1%</u>	<u>A086155</u>	<u>001</u>	
<u>AT</u>		<u>2.5%</u>	<u>A088799</u>	<u>001</u>	Nov 09, 1984
<u>AT</u>	VINTAGE PHARMS	<u>2.5%</u>	<u>A040503</u>	<u>001</u>	Mar 12, 2004
<u>SYNACORT</u>					
<u>AT</u>	MEDICIS	<u>1%</u>	<u>A087458</u>	<u>001</u>	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 218 (of 428)

HYDROCORTISONE

CREAM; TOPICAL

SYNACORT

<u>AT</u>	MEDICIS	<u>2.5%</u>	<u>A087457</u>	<u>001</u>	

ENEMA; RECTAL

COLOCORT

<u>AB</u>	PADDOCK LLC	<u>100MG/60ML</u>	<u>A075172</u>	<u>001</u>	Dec 03, 1999

CORTENEMA

<u>AB</u>	+ ANI PHARMS	<u>100MG/60ML</u>	<u>N016199</u>	<u>001</u>	

HYDROCORTISONE

<u>AB</u>	TEVA PHARMS	<u>100MG/60ML</u>	<u>A074171</u>	<u>001</u>	May 27, 1994

LOTION; TOPICAL

ALA-CORT

<u>AT</u>	CROWN LABS	<u>1%</u>	<u>A083201</u>	<u>001</u>	

HYDROCORTISONE

<u>AT</u>	+ FOUGERA PHARMS	<u>2.5%</u>	<u>A040351</u>	<u>001</u>	Jul 25, 2000

<u>AT</u>	TARO	<u>2.5%</u>	<u>A040247</u>	<u>001</u>	Jul 23, 1999

<u>AT</u>	VINTAGE PHARMS	<u>2.5%</u>	<u>A040417</u>	<u>001</u>	Jul 30, 2003

NUTRACORT

<u>AT</u>	DOW PHARM	<u>1%</u>	<u>A080443</u>	<u>003</u>	

<u>AT</u>		<u>2.5%</u>	<u>A087644</u>	<u>001</u>	Aug 24, 1982

STIE-CORT

<u>AT</u>	PERRIGO	<u>1%</u>	<u>A089066</u>	<u>001</u>	Nov 25, 1985

<u>AT</u>		<u>2.5%</u>	<u>A089074</u>	<u>001</u>	Nov 26, 1985

ALA-SCALP

	CROWN LABS	2%	A083231	001	

OINTMENT; TOPICAL

HYDROCORTISONE

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>1%</u>	<u>A087796</u>	<u>001</u>	Oct 13, 1982

<u>AT</u>	+ FOUGERA	<u>2.5%</u>	<u>A081203</u>	<u>001</u>	May 28, 1993

<u>AT</u>	+ FOUGERA PHARMS	<u>1%</u>	<u>A080692</u>	<u>001</u>	

<u>AT</u>	PERRIGO NEW YORK	<u>2.5%</u>	<u>A085027</u>	<u>001</u>	

<u>AT</u>	TARO	<u>1%</u>	<u>A086257</u>	<u>001</u>	

<u>AT</u>		<u>2.5%</u>	<u>A040310</u>	<u>001</u>	Dec 29, 2000

HYDROCORTISONE IN ABSORBASE

<u>AT</u>	CAROLINA MEDCL	<u>1%</u>	<u>A088138</u>	<u>001</u>	Sep 06, 1985

POWDER; FOR RX COMPOUNDING

HYDRO-RX

	+ X GEN PHARMS	100%	A085982	001	

SOLUTION; TOPICAL

TEXACORT

	+ MISSION PHARMA	2.5%	A081271	001	Apr 17, 1992

TABLET; ORAL

CORTEF

<u>AB</u>	PHARMACIA AND UPJOHN	<u>5MG</u>	<u>N008697</u>	<u>003</u>	

<u>AB</u>		<u>10MG</u>	<u>N008697</u>	<u>001</u>	

<u>AB</u>	+	<u>20MG</u>	<u>N008697</u>	<u>002</u>	

HYDROCORTISONE

<u>AB</u>	AMEDRA PHARMS	<u>5MG</u>	<u>A040646</u>	<u>001</u>	Mar 30, 2007

<u>AB</u>		<u>10MG</u>	<u>A040646</u>	<u>002</u>	Mar 30, 2007

<u>AB</u>		<u>20MG</u>	<u>A040646</u>	<u>003</u>	Mar 30, 2007

<u>AB</u>	VINTAGE	<u>5MG</u>	<u>A040761</u>	<u>001</u>	Jul 16, 2007

<u>AB</u>		<u>10MG</u>	<u>A040761</u>	<u>002</u>	Jul 16, 2007

<u>AB</u>		<u>20MG</u>	<u>A040761</u>	<u>003</u>	Jul 16, 2007

HYDROCORTISONE

BP	WEST WARD	20MG	A083365	001	

HYDROCORTISONE ACETATE

AEROSOL, METERED; RECTAL

CORTIFOAM

	+ MEDA PHARMS	10%	N017351	001	Feb 10, 1982

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 219 (of 428)

HYDROCORTISONE ACETATE

CREAM; TOPICAL					
HYDROCORTISONE ACETATE					
+	FERNDAL E LABS	2.5%	A040259	001	Jul 29, 1999
MICORT-HC					
+	FERNDAL E LABS	2%	A040398	001	Mar 29, 2002
		2.5%	A040396	001	Feb 27, 2001
PASTE; TOPICAL					
ORABASE HCA					
	COLGATE	0.5%	A083205	001	
POWDER; FOR RX COMPOUNDING					
HYDROCORTISONE ACETATE					
	X GEN PHARMS	100%	A085981	001	

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL					
CORTISPORIN					
+	MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050218	001	Aug 09, 1985

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL					
EPIFOAM					
BX	MEDA PHARMS	1%;1%	A086457	001	
PROCTOFOAM HC					
BX	MEDA PHARMS	1%;1%	A086195	001	
CREAM; TOPICAL					
PRAMOSONE					
	FERNDAL E LABS	0.5%;1%	A083778	001	
		1%;1%	A085368	001	
LOTION; TOPICAL					
PRAMOSONE					
	FERNDAL E LABS	1%;1%	A085980	001	
		2.5%;1%	A085979	001	

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL					
<u>CARMOL HC</u>					
<u>AT</u>	FOUGERA PHARMS	<u>1%;10%</u>	<u>A080505</u>	<u>001</u>	
<u>U-CORT</u>					
<u>AT</u>	TARO	<u>1%;10%</u>	<u>A089472</u>	<u>001</u>	Jun 13, 1988

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL					
<u>HYDROCORTISONE BUTYRATE</u>					
<u>AB</u>	TARO PHARM INDS	<u>0.1%</u>	<u>A076654</u>	<u>001</u>	Aug 03, 2005
<u>LOCOID</u>					
<u>AB</u>	+ PRECISION DERMAT	<u>0.1%</u>	<u>N018514</u>	<u>001</u>	Mar 31, 1982
LOCOID LIPOCREAM					
	+ PRECISION DERMAT	0.1%	N020769	001	Sep 08, 1997
LOTION; TOPICAL					
LOCOID					
	+ PRECISION DERMAT	0.1%	N022076	001	May 18, 2007
OINTMENT; TOPICAL					
<u>HYDROCORTISONE BUTYRATE</u>					
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076842</u>	<u>001</u>	Dec 27, 2004
<u>LOCOID</u>					
<u>AB</u>	+ PRECISION DERMAT	<u>0.1%</u>	<u>N018652</u>	<u>001</u>	Oct 29, 1982
SOLUTION; TOPICAL					
<u>HYDROCORTISONE BUTYRATE</u>					
<u>AT</u>	TARO PHARM INDS	<u>0.1%</u>	<u>A076364</u>	<u>001</u>	Jan 14, 2004
<u>LOCOID</u>					
<u>AT</u>	+ PRECISION DERMAT	<u>0.1%</u>	<u>N019116</u>	<u>001</u>	Feb 25, 1987

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 220 (of 428)

HYDROCORTISONE PROBUTATECREAM; TOPICAL
PANDEL

+ FOUGERA PHARMS 0.1% N020453 001 Feb 28, 1997

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

AP HOSPIRA EQ 100MG BASE/VIAL A040666 001 Apr 06, 2006

SOLU-CORTEF

AP + PHARMACIA AND UPJOHN EQ 100MG BASE/VIAL N009866 001

AP + EQ 250MG BASE/VIAL N009866 002

AP + EQ 500MG BASE/VIAL N009866 003

AP + EQ 1GM BASE/VIAL N009866 004

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

AB PERRIGO NEW YORK 0.2% A075666 001 May 24, 2000

AB + TARO 0.2% A075042 001 Aug 25, 1998

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

AB FOUGERA PHARMS 0.2% A075085 001 Jul 31, 2001

AB TARO 0.2% A075043 001 Aug 25, 1998

WESTCORT

AB + RANBAXY 0.2% N018726 001 Aug 08, 1983

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

CORTISPORIN

AT + MONARCH PHARMS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML N050479 001

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT ALCON PHARMS LTD 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062423 001 Aug 25, 1983

AT BAUSCH AND LOMB 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A064053 001 Dec 29, 1995

AT LUITPOLD 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A065216 001 Oct 31, 2005

SUSPENSION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

+ ALCON PHARMS LTD 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062874 001 May 11, 1988

SUSPENSION/DROPS; OTIC

CORTISPORIN

AT + MONARCH PHARMS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A060613 001

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT ALCON PHARMS LTD 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062488 001 Nov 06, 1985

AT LUITPOLD 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A065219 001 May 01, 2006

OTICAIR

AT BAUSCH AND LOMB 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A064065 001 Aug 28, 1996

PEDIOTIC

AT MONARCH PHARMS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062822 001 Sep 29, 1987

HYDROFLUMETHIAZIDE

TABLET; ORAL

SALURON

AB + SHIRE LLC 50MG N011949 001

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID

AP + PURDUE PHARM PRODS 1MG/ML N019034 003 Apr 30, 2009

AP + 2MG/ML N019034 004 Apr 30, 2009

AP + 4MG/ML N019034 005 Apr 30, 2009

DILAUDID-HP

AP + PURDUE PHARM PRODS 10MG/ML N019034 001 Jan 11, 1984

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 221 (of 428)

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HYDROCHLORIDE

<u>AP</u>	AKORN	<u>10MG/ML</u>	<u>A078228</u>	<u>001</u>	Apr 14, 2010
<u>AP</u>		<u>10MG/ML</u>	<u>A078261</u>	<u>001</u>	Apr 14, 2010
<u>AP</u>	BARR	<u>10MG/ML</u>	<u>A076444</u>	<u>001</u>	Apr 25, 2003
<u>AP</u>	HOSPIRA	<u>10MG/ML</u>	<u>A074598</u>	<u>001</u>	Jun 19, 1997
<u>AP</u>	HOSPIRA INC	<u>1MG/ML</u>	<u>N200403</u>	<u>001</u>	Dec 01, 2011
<u>AP</u>		<u>2MG/ML</u>	<u>N200403</u>	<u>002</u>	Dec 01, 2011
<u>AP</u>		<u>4MG/ML</u>	<u>N200403</u>	<u>003</u>	Dec 01, 2011
<u>AP</u>		<u>10MG/ML</u>	<u>A078591</u>	<u>001</u>	Jun 17, 2008

DILAUDID-HP

+ PURDUE PHARM PRODS 250MG/VIAL N019034 002 Aug 04, 1994

SOLUTION; ORAL

DILAUDID

AA + PURDUE PHARM PRODS 5MG/5ML N019891 001 Dec 07, 1992

HYDROMORPHONE HYDROCHLORIDE

AA ROXANE 5MG/5ML A074653 001 Jul 29, 1998

TABLET; ORAL

DILAUDID

<u>AB</u>	PURDUE PHARM PRODS	<u>2MG</u>	<u>N019892</u>	<u>003</u>	Nov 09, 2007
<u>AB</u>		<u>4MG</u>	<u>N019892</u>	<u>002</u>	Nov 09, 2007
<u>AB</u>	+	<u>8MG</u>	<u>N019892</u>	<u>001</u>	Dec 07, 1992

HYDROMORPHONE HYDROCHLORIDE

<u>AB</u>	ELITE LABS	<u>8MG</u>	<u>A076723</u>	<u>001</u>	Oct 18, 2005
<u>AB</u>	LANNETT	<u>2MG</u>	<u>A078439</u>	<u>001</u>	Dec 09, 2009
<u>AB</u>		<u>4MG</u>	<u>A078439</u>	<u>002</u>	Dec 09, 2009
<u>AB</u>		<u>8MG</u>	<u>A077471</u>	<u>001</u>	Dec 09, 2009
<u>AB</u>	MALLINCKRODT	<u>8MG</u>	<u>A076855</u>	<u>001</u>	Dec 23, 2004
<u>AB</u>	MALLINCKRODT INC	<u>2MG</u>	<u>A078273</u>	<u>001</u>	Sep 19, 2007
<u>AB</u>		<u>4MG</u>	<u>A078273</u>	<u>002</u>	Sep 19, 2007
<u>AB</u>	ROXANE	<u>4MG</u>	<u>A074597</u>	<u>003</u>	May 29, 2009
<u>AB</u>		<u>8MG</u>	<u>A074597</u>	<u>001</u>	Jul 29, 1998

TABLET, EXTENDED RELEASE; ORAL
EXALGO

	MALLINCKRODT INC	8MG	N021217	001	Mar 01, 2010
		12MG	N021217	002	Mar 01, 2010
+		16MG	N021217	003	Mar 01, 2010
		32MG	N021217	004	Aug 24, 2012

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

CYANOKIT

+ MERCK SANTE SAS 5GM/VIAL (5GM/KIT) N022041 001 Apr 08, 2011

HYDROXOCOBALAMIN

+ WATSON LABS 1MG/ML A085998 001

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

+ AKORN 1%;0.25% N019261 001 Jan 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

<u>AB</u>	IPCA LABS LTD	<u>200MG</u>	<u>A040766</u>	<u>001</u>	Jun 14, 2007
<u>AB</u>	MYLAN	<u>200MG</u>	<u>A040274</u>	<u>001</u>	May 29, 1998
<u>AB</u>	SANDOZ	<u>200MG</u>	<u>A040104</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>	TEVA PHARMS	<u>200MG</u>	<u>A040081</u>	<u>001</u>	Sep 30, 1994
<u>AB</u>	WATSON LABS	<u>200MG</u>	<u>A040133</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>	WEST WARD	<u>200MG</u>	<u>A040760</u>	<u>001</u>	Aug 15, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 222 (of 428)

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

<u>AB</u>	ZYDUS PHARMS USA INC	<u>200MG</u>	<u>A040657</u>	<u>001</u>	Sep 21, 2007

PLAQUENIL

<u>AB</u>	+ SANOFI AVENTIS US	<u>200MG</u>	<u>N009768</u>	<u>001</u>	

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

MAKENA

	+ KV PHARM	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

LACRISERT

	+ ATON	5MG	N018771	001	

HYDROXYUREA

CAPSULE; ORAL

HYDREA

<u>AB</u>	+ BRISTOL MYERS SQUIBB	<u>500MG</u>	<u>N016295</u>	<u>001</u>	

HYDROXYUREA

<u>AB</u>	BARR	<u>500MG</u>	<u>A075143</u>	<u>001</u>	Oct 16, 1998

<u>AB</u>	PAR PHARM	<u>500MG</u>	<u>A075340</u>	<u>001</u>	Feb 24, 1999

DROXIA

	BRISTOL MYERS SQUIBB	200MG	N016295	002	Feb 25, 1998

		300MG	N016295	003	Feb 25, 1998

		400MG	N016295	004	Feb 25, 1998

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

<u>AP</u>	+ FRESENIUS KABI USA	<u>25MG/ML</u>	<u>A087329</u>	<u>001</u>	

<u>AP</u>	+	<u>50MG/ML</u>	<u>A087329</u>	<u>002</u>	

<u>AP</u>	LUITPOLD	<u>25MG/ML</u>	<u>A087408</u>	<u>001</u>	

<u>AP</u>		<u>50MG/ML</u>	<u>A087408</u>	<u>002</u>	

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

<u>AA</u>	+ HI TECH PHARMA	<u>10MG/5ML</u>	<u>A040010</u>	<u>001</u>	Oct 28, 1994

<u>AA</u>	+ VINTAGE PHARMS	<u>10MG/5ML</u>	<u>A040391</u>	<u>001</u>	Apr 10, 2002

<u>AA</u>	+ WOCKHARDT	<u>10MG/5ML</u>	<u>A087294</u>	<u>001</u>	Apr 12, 1982

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARM	<u>10MG</u>	<u>A040808</u>	<u>001</u>	Sep 24, 2008

<u>AB</u>		<u>25MG</u>	<u>A040808</u>	<u>002</u>	Sep 24, 2008

<u>AB</u>		<u>50MG</u>	<u>A040808</u>	<u>003</u>	Sep 24, 2008

<u>AB</u>	HERITAGE PHARMS INC	<u>10MG</u>	<u>A040804</u>	<u>001</u>	Jun 30, 2008

<u>AB</u>		<u>25MG</u>	<u>A040804</u>	<u>002</u>	Jun 30, 2008

<u>AB</u>		<u>50MG</u>	<u>A040804</u>	<u>003</u>	Jun 30, 2008

<u>AB</u>	HETERO LABS UNIT III	<u>10MG</u>	<u>A040805</u>	<u>001</u>	May 29, 2008

<u>AB</u>		<u>25MG</u>	<u>A040805</u>	<u>002</u>	May 29, 2008

<u>AB</u>		<u>50MG</u>	<u>A040805</u>	<u>003</u>	May 29, 2008

<u>AB</u>	INVAGEN PHARMS	<u>10MG</u>	<u>A040812</u>	<u>001</u>	Mar 12, 2008

<u>AB</u>		<u>25MG</u>	<u>A040812</u>	<u>002</u>	Mar 12, 2008

<u>AB</u>		<u>50MG</u>	<u>A040812</u>	<u>003</u>	Mar 12, 2008

<u>AB</u>	KVK TECH	<u>10MG</u>	<u>A040786</u>	<u>001</u>	Mar 20, 2007

<u>AB</u>		<u>25MG</u>	<u>A040787</u>	<u>001</u>	Mar 20, 2007

<u>AB</u>		<u>50MG</u>	<u>A040788</u>	<u>001</u>	Mar 20, 2007

<u>AB</u>	MUTUAL PHARM	<u>10MG</u>	<u>A089381</u>	<u>001</u>	May 19, 1986

<u>AB</u>		<u>25MG</u>	<u>A089382</u>	<u>001</u>	May 19, 1986

<u>AB</u>		<u>50MG</u>	<u>A089383</u>	<u>001</u>	May 19, 1986

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 223 (of 428)

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>10MG</u>	<u>A091176</u>	<u>001</u>	Jun 07, 2010
<u>AB</u>		<u>25MG</u>	<u>A091176</u>	<u>002</u>	Jun 07, 2010
<u>AB</u>		<u>50MG</u>	<u>A091176</u>	<u>003</u>	Jun 07, 2010
<u>AB</u>	NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A040841</u>	<u>001</u>	Mar 31, 2008
<u>AB</u>		<u>25MG</u>	<u>A040842</u>	<u>001</u>	Mar 31, 2008
<u>AB</u>		<u>50MG</u>	<u>A040840</u>	<u>001</u>	Mar 31, 2008
<u>AB</u>	+ PLIVA	<u>10MG</u>	<u>A088617</u>	<u>001</u>	Jan 10, 1986
<u>AB</u>	+	<u>25MG</u>	<u>A088618</u>	<u>001</u>	Jan 10, 1986
<u>AB</u>	+	<u>50MG</u>	<u>A088619</u>	<u>001</u>	Jan 10, 1986
<u>AB</u>	SUN PHARM INDS INC	<u>10MG</u>	<u>A040899</u>	<u>001</u>	Jun 10, 2008
<u>AB</u>		<u>25MG</u>	<u>A040899</u>	<u>002</u>	Jun 10, 2008
<u>AB</u>		<u>50MG</u>	<u>A040899</u>	<u>003</u>	Jun 10, 2008
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A040579</u>	<u>001</u>	May 27, 2005
<u>AB</u>		<u>25MG</u>	<u>A040574</u>	<u>001</u>	May 27, 2005
<u>AB</u>		<u>50MG</u>	<u>A040580</u>	<u>001</u>	May 27, 2005
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A081149</u>	<u>001</u>	Mar 18, 1994
<u>AB</u>		<u>10MG</u>	<u>A088348</u>	<u>001</u>	Sep 15, 1983
<u>AB</u>		<u>25MG</u>	<u>A081150</u>	<u>001</u>	Mar 18, 1994
<u>AB</u>		<u>25MG</u>	<u>A088349</u>	<u>001</u>	Sep 15, 1983
<u>AB</u>		<u>50MG</u>	<u>A081151</u>	<u>001</u>	Mar 18, 1994
<u>AB</u>		<u>50MG</u>	<u>A088350</u>	<u>001</u>	Sep 15, 1983

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

<u>AB</u>	BARR	<u>EQ 25MG HCL</u>	<u>A088496</u>	<u>001</u>	Jun 15, 1984
<u>AB</u>		<u>EQ 50MG HCL</u>	<u>A088487</u>	<u>001</u>	Jun 15, 1984
<u>AB</u>	SANDOZ	<u>EQ 25MG HCL</u>	<u>A087479</u>	<u>001</u>	
<u>AB</u>		<u>EQ 50MG HCL</u>	<u>A086183</u>	<u>001</u>	
<u>AB</u>	WATSON LABS	<u>EQ 25MG HCL</u>	<u>A040156</u>	<u>001</u>	Jul 15, 1996
<u>AB</u>		<u>EQ 25MG HCL</u>	<u>A081165</u>	<u>001</u>	Jul 31, 1991
<u>AB</u>		<u>EQ 50MG HCL</u>	<u>A040156</u>	<u>002</u>	Jul 15, 1996
	<u>VISTARIL</u>				
<u>AB</u>	PFIZER	<u>EQ 25MG HCL</u>	<u>N011459</u>	<u>002</u>	
<u>AB</u>	+	<u>EQ 50MG HCL</u>	<u>N011459</u>	<u>004</u>	
	HYDROXYZINE PAMOATE				
	BARR	EQ 100MG HCL	A088488	001	Jun 15, 1984

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

BONIVA

+ ROCHE

EQ 3MG BASE/3ML

N021858 001 Jan 06, 2006

TABLET; ORAL

BONIVA

<u>AB</u>	+ HOFFMANN LA ROCHE	<u>EQ 150MG BASE</u>	<u>N021455</u>	<u>002</u>	Mar 24, 2005
	<u>IBANDRONATE SODIUM</u>				
<u>AB</u>	APOTEX INC	<u>EQ 150MG BASE</u>	<u>A078948</u>	<u>001</u>	Mar 19, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 150MG BASE</u>	<u>A078997</u>	<u>001</u>	Apr 30, 2012
<u>AB</u>	MUTUAL PHARM CO INC	<u>EQ 150MG BASE</u>	<u>A078996</u>	<u>001</u>	Aug 15, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 150MG BASE</u>	<u>A078995</u>	<u>001</u>	Mar 19, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 150MG BASE</u>	<u>A078998</u>	<u>001</u>	Mar 19, 2012
<u>AB</u>	WATSON LABS INC	<u>EQ 150MG BASE</u>	<u>A079003</u>	<u>001</u>	Mar 20, 2012

IBUPROFEN

SOLUTION; INTRAVENOUS

CALDOLOR

CUMBERLAND PHARMS

400MG/4ML (100MG/ML)

N022348 001 Jun 11, 2009

+

800MG/8ML (100MG/ML)

N022348 002 Jun 11, 2009

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 224 (of 428)

IBUPROFEN

SUSPENSION; ORAL

IBUPROFEN

<u>AB</u>	+	ACTAVIS MID ATLANTIC	<u>100MG/5ML</u>	<u>A074978</u>	<u>001</u>	Mar 25, 1998
<u>AB</u>		PERRIGO R AND D	<u>100MG/5ML</u>	<u>A076925</u>	<u>001</u>	Sep 23, 2004

TABLET; ORAL

IBUPROFEN

<u>AB</u>		AMNEAL PHARMS NY	<u>400MG</u>	<u>A071334</u>	<u>001</u>	Nov 25, 1986
<u>AB</u>			<u>400MG</u>	<u>A078558</u>	<u>001</u>	Jun 18, 2007
<u>AB</u>			<u>600MG</u>	<u>A071335</u>	<u>001</u>	Nov 25, 1986
<u>AB</u>			<u>600MG</u>	<u>A078558</u>	<u>002</u>	Jun 18, 2007
<u>AB</u>			<u>800MG</u>	<u>A071935</u>	<u>001</u>	Oct 13, 1987
<u>AB</u>			<u>800MG</u>	<u>A078558</u>	<u>003</u>	Jun 18, 2007
<u>AB</u>		CONTRACT PHARMACAL	<u>400MG</u>	<u>A071267</u>	<u>001</u>	Oct 15, 1986
<u>AB</u>			<u>600MG</u>	<u>A071268</u>	<u>001</u>	Oct 15, 1986
<u>AB</u>			<u>800MG</u>	<u>A072300</u>	<u>001</u>	Jul 01, 1988
<u>AB</u>		DR REDDYS LA	<u>400MG</u>	<u>A075682</u>	<u>001</u>	Nov 14, 2001
<u>AB</u>			<u>600MG</u>	<u>A075682</u>	<u>002</u>	Nov 14, 2001
<u>AB</u>	+		<u>800MG</u>	<u>A075682</u>	<u>003</u>	Nov 14, 2001
<u>AB</u>		DR REDDYS LABS INC	<u>400MG</u>	<u>A076112</u>	<u>001</u>	Oct 31, 2001
<u>AB</u>			<u>600MG</u>	<u>A076112</u>	<u>002</u>	Oct 31, 2001
<u>AB</u>			<u>800MG</u>	<u>A076112</u>	<u>003</u>	Oct 31, 2001
<u>AB</u>		MARKSANS PHARMA	<u>400MG</u>	<u>A090796</u>	<u>001</u>	Dec 21, 2010
<u>AB</u>			<u>600MG</u>	<u>A090796</u>	<u>002</u>	Dec 21, 2010
<u>AB</u>			<u>800MG</u>	<u>A090796</u>	<u>003</u>	Dec 21, 2010
<u>AB</u>		PERRIGO R AND D	<u>400MG</u>	<u>A077114</u>	<u>001</u>	Jul 18, 2005
<u>AB</u>			<u>600MG</u>	<u>A077114</u>	<u>002</u>	Jul 18, 2005
<u>AB</u>			<u>800MG</u>	<u>A077114</u>	<u>003</u>	Jul 18, 2005
<u>AB</u>		SHASUN USA	<u>400MG</u>	<u>A078329</u>	<u>001</u>	Feb 05, 2009
<u>AB</u>			<u>600MG</u>	<u>A078329</u>	<u>002</u>	Feb 05, 2009
<u>AB</u>			<u>800MG</u>	<u>A078329</u>	<u>003</u>	Feb 05, 2009
<u>AB</u>		VINTAGE PHARMS	<u>300MG</u>	<u>A071230</u>	<u>001</u>	Oct 22, 1986
<u>AB</u>			<u>400MG</u>	<u>A071231</u>	<u>001</u>	Oct 22, 1986
<u>AB</u>			<u>400MG</u>	<u>A071644</u>	<u>001</u>	Feb 01, 1988
<u>AB</u>			<u>600MG</u>	<u>A071232</u>	<u>001</u>	Oct 22, 1986
<u>AB</u>			<u>800MG</u>	<u>A072004</u>	<u>001</u>	Nov 18, 1987
<u>AB</u>		WATSON LABS	<u>400MG</u>	<u>A070436</u>	<u>001</u>	Aug 21, 1985
<u>AB</u>			<u>600MG</u>	<u>A070437</u>	<u>001</u>	Aug 21, 1985
		<u>IBU - TAB</u>				
<u>AB</u>		ALRA	<u>400MG</u>	<u>A071058</u>	<u>001</u>	Aug 11, 1988
<u>AB</u>			<u>600MG</u>	<u>A071059</u>	<u>001</u>	Aug 11, 1988

IBUPROFEN LYSINEINJECTABLE; INTRAVENOUS
NEOPROFEN

+	LUNDBECK LLC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE AND IBUPROFEN

<u>AB</u>		ACTAVIS ELIZABETH	<u>400MG;5MG</u>	<u>A078769</u>	<u>001</u>	Jan 04, 2008
<u>AB</u>	+	BARR LABS INC	<u>400MG;5MG</u>	<u>A078316</u>	<u>001</u>	Nov 29, 2007
<u>AB</u>		WATSON LABS	<u>400MG;5MG</u>	<u>A078394</u>	<u>001</u>	Nov 26, 2007

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

CORVERT

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>0.1MG/ML</u>	<u>N020491</u>	<u>001</u>	Dec 28, 1995
		<u>IBUTILIDE FUMARATE</u>				
<u>AP</u>		BIONICHE PHARMA USA	<u>0.1MG/ML</u>	<u>A090643</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>			<u>0.1MG/ML</u>	<u>A090924</u>	<u>001</u>	Jan 11, 2010

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 225 (of 428)

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

IBUTILIDE FUMARATE

<u>AP</u>	LUITPOLD	<u>0.1MG/ML</u>	<u>A090240</u>	<u>001</u>	Jan 11, 2010

ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS

FIRAZYR

+	SHIRE ORPHAN THERAP	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N022150	001	Aug 25, 2011

ICODEXTRIN

SOLUTION; INTRAPERITONEAL

EXTRANEAL

+	BAXTER HLTHCARE	7.5GM/100ML	N021321	001	Dec 20, 2002

ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

+	AMARIN PHARMA INC	1GM	N202057	001	Jul 26, 2012

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN PFS

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>1MG/ML</u>	<u>N050734</u>	<u>001</u>	Feb 17, 1997

IDARUBICIN HYDROCHLORIDE

<u>AP</u>		BEDFORD LABS	<u>1MG/ML</u>	<u>A065275</u>	<u>001</u>	Dec 14, 2006

<u>AP</u>			<u>1MG/ML</u>	<u>A065288</u>	<u>001</u>	May 15, 2007

<u>AP</u>		FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A065440</u>	<u>001</u>	Aug 04, 2009

<u>AP</u>		ONCO THERAPIES LTD	<u>1MG/ML</u>	<u>A200144</u>	<u>001</u>	Oct 11, 2012

<u>AP</u>		SANDOZ	<u>1MG/ML</u>	<u>A091293</u>	<u>001</u>	Mar 29, 2011

IDARUBICIN HYDROCHLORIDE PFS

<u>AP</u>		TEVA PARENTERAL	<u>1MG/ML</u>	<u>A065036</u>	<u>001</u>	May 01, 2002

IDOXURIDINE

SOLUTION/DROPS; OPHTHALMIC

DENDRID

<u>AT</u>	+	ALCON	<u>0.1%</u>	<u>N014169</u>	<u>001</u>	

HERPLEX

<u>AT</u>	+	ALLERGAN	<u>0.1%</u>	<u>N013935</u>	<u>002</u>	

IFOSFAMIDE

INJECTABLE; INJECTION

IFEX

<u>AP</u>		BAXTER HLTHCARE	<u>1GM/VIAL</u>	<u>N019763</u>	<u>001</u>	Dec 30, 1988

<u>AP</u>			<u>3GM/VIAL</u>	<u>N019763</u>	<u>002</u>	Dec 30, 1988

IFOSFAMIDE

<u>AP</u>		BEDFORD LABS	<u>1GM/20ML (50MG/ML)</u>	<u>A076619</u>	<u>001</u>	Jun 29, 2011

<u>AP</u>			<u>3GM/60ML (50MG/ML)</u>	<u>A076619</u>	<u>002</u>	Jun 29, 2011

<u>AP</u>	+	FRESENIUS KABI USA	<u>1GM/VIAL</u>	<u>A076078</u>	<u>001</u>	May 28, 2002

<u>AP</u>			<u>1GM/20ML (50MG/ML)</u>	<u>A090181</u>	<u>001</u>	Sep 22, 2009

<u>AP</u>	+		<u>3GM/VIAL</u>	<u>A076078</u>	<u>002</u>	May 28, 2002

<u>AP</u>			<u>3GM/60ML (50MG/ML)</u>	<u>A090181</u>	<u>002</u>	Sep 22, 2009

<u>AP</u>		ONCO THERAPIES LTD	<u>1GM/20ML (50MG/ML)</u>	<u>A201689</u>	<u>001</u>	Nov 26, 2012

<u>AP</u>			<u>3GM/60ML (50MG/ML)</u>	<u>A201689</u>	<u>002</u>	Nov 26, 2012

<u>AP</u>	+	TEVA PARENTERAL	<u>1GM/20ML (50MG/ML)</u>	<u>A076657</u>	<u>001</u>	Apr 04, 2007

<u>AP</u>	+		<u>3GM/60ML (50MG/ML)</u>	<u>A076657</u>	<u>002</u>	Apr 04, 2007

IFOSFAMIDE; MESNA

INJECTABLE; INTRAVENOUS

IFOSFAMIDE/MESNA KIT

+	TEVA PARENTERAL	1GM/20ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	001	Feb 26, 2002

+		3GM/60ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	002	Feb 26, 2002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 226 (of 428)

ILOPERIDONETABLET; ORAL
FANAPT

+	NOVARTIS	1MG	N022192	001	May 06, 2009
		2MG	N022192	002	May 06, 2009
		4MG	N022192	003	May 06, 2009
		6MG	N022192	004	May 06, 2009
		8MG	N022192	005	May 06, 2009
		10MG	N022192	006	May 06, 2009
		12MG	N022192	007	May 06, 2009

ILOPROSTSOLUTION; INHALATION
VENTAVIS

+	ACTELION PHARMS LTD	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005
+		20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009

IMATINIB MESYLATETABLET; ORAL
GLEEVEC

	NOVARTIS	EQ 100MG BASE	N021588	001	Apr 18, 2003
+		EQ 400MG BASE	N021588	002	Apr 18, 2003

IMIGLUCERASEINJECTABLE; INJECTION
CEREZYME

	GENZYME	200 UNITS/VIAL	N020367	001	May 23, 1994
+		400 UNITS/VIAL	N020367	002	Sep 22, 1999

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

<u>AB</u>	EXCELLIUM	<u>10MG</u>	<u>A040903</u>	<u>001</u>	Oct 24, 2012
<u>AB</u>		<u>25MG</u>	<u>A040903</u>	<u>002</u>	Oct 24, 2012
<u>AB</u>		<u>50MG</u>	<u>A040903</u>	<u>003</u>	Oct 24, 2012
<u>AB</u>	LUPIN LTD	<u>10MG</u>	<u>A090443</u>	<u>001</u>	Mar 11, 2010
<u>AB</u>		<u>25MG</u>	<u>A090442</u>	<u>001</u>	Mar 11, 2010
<u>AB</u>		<u>50MG</u>	<u>A090441</u>	<u>001</u>	Mar 11, 2010
<u>AB</u>	MUTUAL PHARM	<u>10MG</u>	<u>A081048</u>	<u>001</u>	Jun 05, 1990
<u>AB</u>		<u>25MG</u>	<u>A081049</u>	<u>001</u>	Jun 05, 1990
<u>AB</u>		<u>50MG</u>	<u>A081050</u>	<u>001</u>	Jun 05, 1990
<u>AB</u>	PAR PHARM	<u>10MG</u>	<u>A088292</u>	<u>001</u>	Oct 21, 1983
<u>AB</u>		<u>10MG</u>	<u>A089422</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>25MG</u>	<u>A088262</u>	<u>001</u>	Oct 21, 1983
<u>AB</u>		<u>50MG</u>	<u>A088276</u>	<u>001</u>	Oct 21, 1983
<u>AB</u>	PROSAM LABS	<u>10MG</u>	<u>A040753</u>	<u>001</u>	Feb 28, 2008
<u>AB</u>		<u>25MG</u>	<u>A040752</u>	<u>001</u>	Feb 28, 2008
<u>AB</u>		<u>50MG</u>	<u>A040751</u>	<u>001</u>	Feb 28, 2008
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A084936</u>	<u>002</u>	
<u>AB</u>		<u>25MG</u>	<u>A083745</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A084937</u>	<u>001</u>	
	<u>TOFRANIL</u>				
<u>AB</u>	MALLINCKRODT INC	<u>10MG</u>	<u>A087844</u>	<u>001</u>	May 22, 1984
<u>AB</u>		<u>25MG</u>	<u>A087845</u>	<u>001</u>	May 22, 1984
<u>AB</u>	+	<u>50MG</u>	<u>A087846</u>	<u>001</u>	May 22, 1984

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

<u>AB</u>	LUPIN LTD	<u>EQ 75MG HCL</u>	<u>A090444</u>	<u>001</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 100MG HCL</u>	<u>A090444</u>	<u>002</u>	Apr 16, 2010

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 227 (of 428)

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

<u>AB</u>	LUPIN LTD	<u>EQ 125MG HCL</u>	<u>A090444</u>	<u>003</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 150MG HCL</u>	<u>A090444</u>	<u>004</u>	Apr 16, 2010
<u>AB</u>	ROXANE	<u>EQ 75MG HCL</u>	<u>A091099</u>	<u>001</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 100MG HCL</u>	<u>A091099</u>	<u>002</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 125MG HCL</u>	<u>A091099</u>	<u>003</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 150MG HCL</u>	<u>A091099</u>	<u>004</u>	Apr 16, 2010
<u>TOFRANIL - PM</u>					
<u>AB</u>	+ MALLINCKRODT INC	<u>EQ 75MG HCL</u>	<u>N017090</u>	<u>001</u>	
<u>AB</u>		<u>EQ 100MG HCL</u>	<u>N017090</u>	<u>004</u>	
<u>AB</u>		<u>EQ 125MG HCL</u>	<u>N017090</u>	<u>003</u>	
<u>AB</u>		<u>EQ 150MG HCL</u>	<u>N017090</u>	<u>002</u>	

IMIQUIMOD

CREAM; TOPICAL

ALDARA

<u>AB</u>	+ MEDICIS	<u>5%</u>	<u>N020723</u>	<u>001</u>	Feb 27, 1997
<u>IMIQUIMOD</u>					
<u>AB</u>	APOTEX INC	<u>5%</u>	<u>A091308</u>	<u>001</u>	Apr 06, 2012
<u>AB</u>	FOUGERA PHARMS	<u>5%</u>	<u>A078548</u>	<u>001</u>	Feb 25, 2010
<u>AB</u>	GLENMARK GENERICS	<u>5%</u>	<u>A201994</u>	<u>001</u>	Mar 06, 2012
<u>AB</u>	PERRIGO ISRAEL	<u>5%</u>	<u>A078837</u>	<u>001</u>	Sep 07, 2010
<u>AB</u>	TARO	<u>5%</u>	<u>A200173</u>	<u>001</u>	Apr 15, 2011
<u>AB</u>	TEVA PHARMS USA	<u>5%</u>	<u>A200481</u>	<u>001</u>	Apr 18, 2011
<u>AB</u>	TOLMAR	<u>5%</u>	<u>A091044</u>	<u>001</u>	Feb 28, 2011
<u>ZYCLARA</u>					
	+ MEDICIS	2.5%	N022483	002	Jul 15, 2011
	+	3.75%	N022483	001	Mar 25, 2010

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

	+ BEDFORD	EQ 5MG BASE/ML	A075513	001	May 09, 2000

INDACATEROL MALEATE

POWDER; INHALATION

ARCAPTA NEOHALER

	+ NOVARTIS	EQ 75MCG BASE	N022383	001	Jul 01, 2011

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>1.25MG</u>	<u>A074722</u>	<u>001</u>	Jun 17, 1996
<u>AB</u>		<u>2.5MG</u>	<u>A074722</u>	<u>002</u>	Jun 17, 1996
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>1.25MG</u>	<u>A074299</u>	<u>002</u>	Apr 29, 1996
<u>AB</u>		<u>2.5MG</u>	<u>A074299</u>	<u>001</u>	Jul 27, 1995
<u>AB</u>	MYLAN	<u>1.25MG</u>	<u>A074461</u>	<u>002</u>	Mar 26, 1997
<u>AB</u>	+	<u>2.5MG</u>	<u>A074461</u>	<u>001</u>	Mar 27, 1996
<u>AB</u>	MYLAN PHARMS INC	<u>1.25MG</u>	<u>A075105</u>	<u>001</u>	Jul 23, 1998
<u>AB</u>		<u>2.5MG</u>	<u>A075105</u>	<u>002</u>	Jul 23, 1998
<u>AB</u>	WATSON LABS	<u>1.25MG</u>	<u>A074585</u>	<u>001</u>	Sep 26, 1996
<u>AB</u>		<u>2.5MG</u>	<u>A074585</u>	<u>002</u>	Sep 26, 1996

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

	MERCK SHARP DOHME	EQ 100MG BASE	N020685	006	Apr 19, 2000
		EQ 200MG BASE	N020685	003	Mar 13, 1996
	+	EQ 400MG BASE	N020685	001	Mar 13, 1996

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 228 (of 428)

INDIUM IN-111 CHLORIDEINJECTABLE; INJECTION
INDICLOR

+ GE HEALTHCARE	2mCi/0.2ML	N019862	001	Dec 29, 1992
INDIUM IN 111 CHLORIDE				
+ MALLINCKRODT	5mCi/0.5ML	N019841	001	Sep 27, 1994

INDIUM IN-111 OXYQUINOLINEINJECTABLE; INJECTION
INDIUM IN-111 OXYQUINOLINE

+ GE HEALTHCARE	1mCi/ML	N019044	001	Dec 24, 1985

INDIUM IN-111 PENTETATE DISODIUMINJECTABLE; INTRATHECAL
MPI INDIUM DTPA IN 111

+ GE HEALTHCARE	1mCi/ML	N017707	001	Feb 18, 1982

INDIUM IN-111 PENTETREOTIDE KITINJECTABLE; INJECTION
OCTREOSCAN

+ MALLINCKRODT	3mCi/ML	N020314	001	Jun 02, 1994

INDOCYANINE GREENINJECTABLE; INJECTION
IC-GREEN

<u>AP</u> + AKORN	<u>25MG/VIAL</u>	<u>N011525</u>	<u>001</u>	

<u>AP</u> <u>INDOCYANINE GREEN</u>	<u>25MG/VIAL</u>	<u>A040811</u>	<u>001</u>	Nov 21, 2007

INDOMETHACINCAPSULE; ORAL
INDOMETHACIN

<u>AB</u> GLENMARK GENERICS	<u>25MG</u>	<u>A091276</u>	<u>001</u>	Dec 22, 2010
<u>AB</u>	<u>50MG</u>	<u>A091276</u>	<u>002</u>	Dec 22, 2010
<u>AB</u> HERITAGE PHARMS INC	<u>25MG</u>	<u>N018851</u>	<u>001</u>	May 18, 1984
<u>AB</u>	<u>50MG</u>	<u>N018851</u>	<u>002</u>	May 18, 1984
<u>AB</u> HETERO LABS UNIT III	<u>25MG</u>	<u>A091240</u>	<u>001</u>	Apr 12, 2011
<u>AB</u>	<u>50MG</u>	<u>A091240</u>	<u>002</u>	Apr 12, 2011
<u>AB</u> IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A070719</u>	<u>001</u>	Feb 12, 1986
<u>AB</u>	<u>50MG</u>	<u>A070756</u>	<u>001</u>	Feb 12, 1986
<u>AB</u> MYLAN	<u>25MG</u>	<u>N018858</u>	<u>001</u>	Apr 20, 1984
<u>AB</u> +	<u>50MG</u>	<u>A070624</u>	<u>001</u>	Sep 04, 1985
<u>AB</u> SANDOZ	<u>25MG</u>	<u>A070673</u>	<u>001</u>	Apr 29, 1987
<u>AB</u>	<u>50MG</u>	<u>A070674</u>	<u>001</u>	Apr 29, 1987
<u>AB</u> ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A090403</u>	<u>001</u>	Nov 15, 2010
<u>AB</u>	<u>50MG</u>	<u>A090403</u>	<u>002</u>	Nov 15, 2010

CAPSULE, EXTENDED RELEASE; ORAL
INDOMETHACIN

<u>AB</u> AMNEAL PHARMS	<u>75MG</u>	<u>A091549</u>	<u>001</u>	Dec 01, 2010
<u>AB</u> AVANTHI INC	<u>75MG</u>	<u>A079175</u>	<u>001</u>	Mar 06, 2009
<u>AB</u> HETERO LABS LTD III	<u>75MG</u>	<u>A201807</u>	<u>001</u>	Sep 28, 2012
<u>AB</u> PADDOCK LLC	<u>75MG</u>	<u>A200529</u>	<u>001</u>	Nov 30, 2010
<u>AB</u> + SANDOZ	<u>75MG</u>	<u>A074464</u>	<u>001</u>	May 28, 1998

INJECTABLE; INJECTION
INDOMETHACIN

+ FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N022536	001	Mar 17, 2010

SUPPOSITORY; RECTAL
INDOMETHACIN

+ G AND W LABS	50MG	A073314	001	Aug 31, 1992

SUSPENSION; ORAL
INDOCIN

+ IROKO PHARMS	25MG/5ML	N018332	001	Oct 10, 1985

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 229 (of 428)

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

<u>AP</u>	+	LUNDBECK LLC	<u>EQ 1MG BASE/VIAL</u>	<u>N018878</u>	<u>001</u>	Jan 30, 1985
<u>AP</u>		<u>INDOMETHACIN SODIUM</u>				
<u>AP</u>		BEDFORD	<u>EQ 1MG BASE/VIAL</u>	<u>A078713</u>	<u>001</u>	Jul 16, 2008

INGENOL MEBUTATE

GEL; TOPICAL

PICATO

		LEO PHARMA AS	0.015%	N202833	001	Jan 23, 2012
	+		0.05%	N202833	002	Jan 23, 2012

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG MIX 70/30

+	NOVO NORDISK INC	700 UNITS/10ML; 300 UNITS/10ML (70 UNITS/ML; 30 UNITS/ML)	N021172	001	Nov 01, 2001

NOVOLOG MIX 70/30 FLEXPEN

+	NOVO NORDISK INC	210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172	004	May 03, 2002

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG

+	NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N020986	001	Jun 07, 2000

NOVOLOG FLEXPEN

+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	003	Jan 19, 2001

NOVOLOG PENFILL

+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	002	Jun 07, 2000

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS

LEVEMIR

+	NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N021536	001	Jun 16, 2005

LEVEMIR FLEXPEN

+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	002	Jun 16, 2005

INSULIN GLARGINE RECOMBINANT

INJECTABLE; INJECTION

LANTUS

+	SANOFI AVENTIS US	100 UNITS/ML	N021081	001	Apr 20, 2000

INSULIN GLULISINE RECOMBINANT

INJECTABLE; IV (INFUSION)-SC

+	SANOFI AVENTIS US	1000 UNITS/10ML (100 UNITS/ML)	N021629	001	Apr 16, 2004

+		300 UNITS/3ML (100 UNITS/ML)	N021629	002	Dec 20, 2005

INJECTABLE; SUBCUTANEOUS

APIDRA SOLOSTAR

	SANOFI AVENTIS US	300 UNITS/3ML	N021629	003	Feb 24, 2009

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50

+	LILLY	50 UNITS/ML;50 UNITS/ML	N021018	001	Dec 22, 1999

HUMALOG MIX 50/50 KWIKPEN

+	LILLY	50 UNITS/ML;50 UNITS/ML	N021018	002	Sep 06, 2007

HUMALOG MIX 75/25

+	LILLY	75 UNITS/ML;25 UNITS/ML	N021017	001	Dec 22, 1999

HUMALOG MIX 75/25 KWIKPEN

+	LILLY	75 UNITS/ML;25 UNITS/ML	N021017	002	Sep 06, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 230 (of 428)

INSULIN LISPRO RECOMBINANTINJECTABLE; INJECTION
HUMALOG

+ LILLY 100 UNITS/ML N020563 001 Jun 14, 1996

HUMALOG KWIKPEN

+ LILLY 100 UNITS/ML N020563 003 Sep 06, 2007

INSULIN RECOMBINANT HUMANINJECTABLE; INJECTION
HUMULIN R

+ LILLY 500 UNITS/ML N018780 004 Mar 31, 1994

IOBENGUANE SULFATE I-123SOLUTION; INTRAVENOUS
ADREVIEW

+ GE HEALTHCARE 10MCI/5ML (2MCI/ML) N022290 001 Sep 19, 2008

IODIPAMIDE MEGLUMINEINJECTABLE; INJECTION
CHOLOGRAFIN MEGLUMINE

+ BRACCO 52% N009321 003

IODIXANOLINJECTABLE; INJECTION
VISIPAQUE 270

+ GE HEALTHCARE 55% N020351 001 Mar 22, 1996

55% N020808 001 Aug 29, 1997

VISIPAQUE 320

+ GE HEALTHCARE 65.2% N020351 002 Mar 22, 1996

65.2% N020808 002 Aug 29, 1997

IOFLUPANE I-123SOLUTION; INTRAVENOUS
DATSCAN

+ GE HLTHCARE INC 5MCI/2.5ML (2MCI/ML) N022454 001 Jan 14, 2011

IOHEXOLINJECTABLE; INJECTION
OMNIPAQUE 140

+ GE HEALTHCARE 30.2% N018956 005 Nov 30, 1988

SOLUTION; INJECTION, ORAL
OMNIPAQUE 350

+ GE HEALTHCARE 75.5% N018956 004 Dec 26, 1985

75.5% N020608 003 Oct 24, 1995

SOLUTION; INJECTION, ORAL, RECTAL
OMNIPAQUE 180

+ GE HEALTHCARE 38.8% N018956 001 Dec 26, 1985

OMNIPAQUE 240

+ GE HEALTHCARE 51.8% N018956 002 Dec 26, 1985

51.8% N020608 001 Oct 24, 1995

OMNIPAQUE 300

+ GE HEALTHCARE 64.7% N018956 003 Dec 26, 1985

64.7% N020608 002 Oct 24, 1995

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-250AP FRESENIUS KABI USA 51% A074679 001 Apr 02, 1997IOPAMIDOL-300AP FRESENIUS KABI USA 61% A074679 002 Apr 02, 1997IOPAMIDOL-370AP FRESENIUS KABI USA 76% A074679 003 Apr 02, 1997

PRESCRIPTION DRUG PRODUCT LIST

3 - 231 (of 428)

IOPAMIDOL

INJECTABLE; INJECTION

<u>ISOVUE-200</u>				
<u>AP</u>	+ BRACCO	<u>41%</u>	<u>N018735</u>	<u>006</u> Jul 07, 1987
<u>ISOVUE-250</u>				
<u>AP</u>	+ BRACCO	<u>51%</u>	<u>N018735</u>	<u>007</u> Jul 06, 1992
<u>AP</u>	+	<u>51%</u>	<u>N020327</u>	<u>002</u> Oct 12, 1994
<u>ISOVUE-300</u>				
<u>AP</u>	+ BRACCO	<u>61%</u>	<u>N018735</u>	<u>002</u> Dec 31, 1985
<u>AP</u>	+	<u>61%</u>	<u>N020327</u>	<u>003</u> Oct 12, 1994
<u>ISOVUE-370</u>				
<u>AP</u>	+ BRACCO	<u>76%</u>	<u>N018735</u>	<u>003</u> Dec 31, 1985
<u>AP</u>	+	<u>76%</u>	<u>N020327</u>	<u>004</u> Oct 12, 1994
<u>SCANLUX-300</u>				
<u>AP</u>	SANOCHEMIA CORP USA	<u>61%</u>	<u>A090394</u>	<u>001</u> Jun 18, 2010
<u>SCANLUX-370</u>				
<u>AP</u>	SANOCHEMIA CORP USA	<u>76%</u>	<u>A090394</u>	<u>002</u> Jun 18, 2010
ISOVUE-M 200				
	+ BRACCO	41%	N018735	001 Dec 31, 1985
ISOVUE-M 300				
	+ BRACCO	61%	N018735	004 Dec 31, 1985

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST (PHARMACY BULK)

	+ BAYER HLTHCARE	49.9%	N021425	003 Mar 12, 2004
	+	62.3%	N021425	001 Sep 20, 2002
	+	76.9%	N021425	002 Sep 20, 2002
ULTRAVIST 150				
	+ BAYER HLTHCARE	31.2%	N020220	004 May 10, 1995
ULTRAVIST 240				
	+ BAYER HLTHCARE	49.9%	N020220	003 May 10, 1995
ULTRAVIST 300				
	+ BAYER HLTHCARE	62.3%	N020220	002 May 10, 1995
ULTRAVIST 300 IN PLASTIC CONTAINER				
	+ BAYER HLTHCARE	62.3%	N020220	005 Nov 18, 2008
ULTRAVIST 370				
	+ BAYER HLTHCARE	76.9%	N020220	001 May 10, 1995

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION

CONRAY

	+ MALLINCKRODT	60%	N013295	001
CONRAY 30				
	+ MALLINCKRODT	30%	N016983	001
CONRAY 43				
	+ MALLINCKRODT	43%	N013295	002

SOLUTION; INTRAVESICAL

CYSTO-CONRAY II

	MALLINCKRODT	17.2%	N017057	002

IOTHALAMATE SODIUM I-125

INJECTABLE; INJECTION

GLOFIL-125

	ISOTEX	250-300uCi/ML	N017279	001

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 240

	+ MALLINCKRODT	51%	N019710	002 Dec 30, 1988
OPTIRAY 300				
	+ MALLINCKRODT	64%	N019710	004 Jan 22, 1992

PRESCRIPTION DRUG PRODUCT LIST

3 - 232 (of 428)

IOVERSOL

INJECTABLE; INJECTION
OPTIRAY 300

+ MALLINCKRODT	64%	N020923	004	May 13, 1999

OPTIRAY 320				
+ MALLINCKRODT	68%	N019710	001	Dec 30, 1988

OPTIRAY 350				
+ MALLINCKRODT	74%	N019710	005	Jan 22, 1992

+	74%	N020923	003	May 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE; INJECTION
HEXABRIX

+ GUERBET	39.3%;19.6%	N018905	002	Jul 26, 1985

IOXILAN

INJECTABLE; INJECTION
OXILAN-300

GUERBET	62%	N020316	001	Dec 21, 1995

OXILAN-350				
GUERBET	73%	N020316	002	Dec 21, 1995

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION
ATROVENT HFA

+ BOEHRINGER INGELHEIM	0.021MG/INH	N021527	001	Nov 27, 2004

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

<u>AN</u>	BAUSCH AND LOMB	0.02%	<u>A075835</u>	<u>001</u>	Oct 15, 2001

<u>AN</u>	+ DEY	0.02%	<u>A074755</u>	<u>001</u>	Jan 10, 1997

<u>AN</u>	LANDELA PHARM	0.02%	<u>A077072</u>	<u>001</u>	Jul 19, 2005

<u>AN</u>	NEPHRON	0.02%	<u>A075562</u>	<u>001</u>	Sep 27, 2001

<u>AN</u>	NOVEX	0.02%	<u>A075441</u>	<u>001</u>	Mar 28, 2001

<u>AN</u>	RITEDOSE CORP	0.02%	<u>A075693</u>	<u>001</u>	Jan 26, 2001

<u>AN</u>	TEVA PHARMS	0.02%	<u>A075313</u>	<u>001</u>	Feb 07, 2000

<u>AN</u>	WATSON LABS	0.02%	<u>A076291</u>	<u>001</u>	May 09, 2005

SPRAY, METERED; NASAL

ATROVENT

<u>AB</u>	+ BOEHRINGER INGELHEIM	0.021MG/SPRAY	<u>N020393</u>	<u>001</u>	Oct 20, 1995

<u>AB</u>	+	0.042MG/SPRAY	<u>N020394</u>	<u>001</u>	Oct 20, 1995

IPRATROPIUM BROMIDE

<u>AB</u>	BAUSCH AND LOMB	0.021MG/SPRAY	<u>A076025</u>	<u>001</u>	Mar 31, 2003

<u>AB</u>		0.042MG/SPRAY	<u>A076103</u>	<u>001</u>	Mar 31, 2003

<u>AB</u>	DEY	0.021MG/SPRAY	<u>A075552</u>	<u>001</u>	Mar 31, 2003

<u>AB</u>		0.042MG/SPRAY	<u>A075553</u>	<u>001</u>	Mar 31, 2003

<u>AB</u>	NOVEX	0.021MG/SPRAY	<u>A076156</u>	<u>001</u>	Apr 18, 2003

<u>AB</u>		0.042MG/SPRAY	<u>A076155</u>	<u>001</u>	Apr 18, 2003

<u>AB</u>	ROXANE	0.021MG/SPRAY	<u>A076664</u>	<u>001</u>	Nov 05, 2003

<u>AB</u>		0.042MG/SPRAY	<u>A076598</u>	<u>001</u>	Nov 05, 2003

IRBESARTAN

TABLET; ORAL

AVAPRO

<u>AB</u>	SANOFI AVENTIS US	75MG	<u>N020757</u>	<u>001</u>	Sep 30, 1997

<u>AB</u>		150MG	<u>N020757</u>	<u>002</u>	Sep 30, 1997

<u>AB</u>	+	300MG	<u>N020757</u>	<u>003</u>	Sep 30, 1997

IRBESARTAN

<u>AB</u>	ALEMBIC PHARMS LTD	75MG	<u>A091236</u>	<u>001</u>	Oct 15, 2012

<u>AB</u>		150MG	<u>A091236</u>	<u>002</u>	Oct 15, 2012

<u>AB</u>		300MG	<u>A091236</u>	<u>003</u>	Oct 15, 2012

<u>AB</u>	APOTEX INC	75MG	<u>A200832</u>	<u>001</u>	Oct 15, 2012

<u>AB</u>		150MG	<u>A200832</u>	<u>002</u>	Oct 15, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 233 (of 428)

IRBESARTAN

TABLET; ORAL

IRBESARTAN

<u>AB</u>	APOTEX INC	<u>300MG</u>	<u>A200832</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>75MG</u>	<u>A203081</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203081</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203081</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	CIPLA LTD	<u>75MG</u>	<u>A077205</u>	<u>001</u>	Nov 14, 2012
<u>AB</u>		<u>150MG</u>	<u>A077205</u>	<u>002</u>	Nov 14, 2012
<u>AB</u>		<u>300MG</u>	<u>A077205</u>	<u>003</u>	Nov 14, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>75MG</u>	<u>A203161</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203161</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203161</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	HETERO LABS LTD V	<u>75MG</u>	<u>A202910</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A202910</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A202910</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	LUPIN LTD	<u>75MG</u>	<u>A201531</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A201531</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A201531</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>75MG</u>	<u>A202254</u>	<u>001</u>	Oct 03, 2012
<u>AB</u>		<u>150MG</u>	<u>A202254</u>	<u>002</u>	Oct 03, 2012
<u>AB</u>		<u>300MG</u>	<u>A202254</u>	<u>003</u>	Oct 03, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>75MG</u>	<u>A200461</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A200461</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A200461</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	PRINSTON INC	<u>75MG</u>	<u>A203071</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203071</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203071</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	ROXANE	<u>75MG</u>	<u>A090201</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A090201</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A090201</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>	SANDOZ	<u>75MG</u>	<u>A077466</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A077466</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A077466</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	TEVA PHARMS	<u>75MG</u>	<u>A077159</u>	<u>001</u>	Mar 30, 2012
<u>AB</u>		<u>150MG</u>	<u>A077159</u>	<u>002</u>	Mar 30, 2012
<u>AB</u>		<u>300MG</u>	<u>A077159</u>	<u>003</u>	Mar 30, 2012
<u>AB</u>	WATSON LABS INC	<u>75MG</u>	<u>A090720</u>	<u>001</u>	Oct 12, 2012
<u>AB</u>		<u>150MG</u>	<u>A090720</u>	<u>002</u>	Oct 12, 2012
<u>AB</u>		<u>300MG</u>	<u>A090720</u>	<u>003</u>	Oct 12, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>75MG</u>	<u>A079213</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A079213</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A079213</u>	<u>003</u>	Sep 27, 2012

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

CAMPTOSAR

<u>AP</u>	+ PFIZER INC	<u>40MG/2ML (20MG/ML)</u>	<u>N020571</u>	<u>001</u>	Jun 14, 1996
<u>AP</u>	+	<u>100MG/5ML (20MG/ML)</u>	<u>N020571</u>	<u>002</u>	Jun 14, 1996
	<u>IRINOTECAN HYDROCHLORIDE</u>				
<u>AP</u>	ACCORD HLTHCARE	<u>40MG/2ML (20MG/ML)</u>	<u>A079068</u>	<u>001</u>	Nov 21, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A079068</u>	<u>002</u>	Nov 21, 2008
<u>AP</u>	ACTAVIS TOTOWA	<u>40MG/2ML (20MG/ML)</u>	<u>A078589</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078589</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>	AKORN	<u>40MG/2ML (20MG/ML)</u>	<u>A090726</u>	<u>001</u>	Sep 16, 2009
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090726</u>	<u>002</u>	Sep 16, 2009
<u>AP</u>	BEDFORD LABS	<u>40MG/2ML (20MG/ML)</u>	<u>A078753</u>	<u>001</u>	Dec 24, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078753</u>	<u>002</u>	Dec 24, 2008
<u>AP</u>	BIONICHE PHARMA	<u>40MG/2ML (20MG/ML)</u>	<u>A090393</u>	<u>002</u>	May 13, 2011
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090393</u>	<u>003</u>	May 13, 2011
<u>AP</u>	CIPLA LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A077219</u>	<u>001</u>	Feb 20, 2008

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 234 (of 428)

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

<u>AP</u>	CIPLA LTD	<u>100MG/5ML (20MG/ML)</u>	<u>A077219</u>	<u>002</u>	Feb 20, 2008
<u>AP</u>	DR REDDYS LABS LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A078953</u>	<u>001</u>	Apr 15, 2010
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078953</u>	<u>002</u>	Apr 15, 2010
<u>AP</u>	EBEWE PHARMA	<u>40MG/2ML (20MG/ML)</u>	<u>A090137</u>	<u>001</u>	Nov 12, 2009
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090137</u>	<u>002</u>	Nov 12, 2009
<u>AP</u>	EMCURE PHARMS LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A200771</u>	<u>001</u>	Feb 14, 2012
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A200771</u>	<u>002</u>	Feb 14, 2012
<u>AP</u>	FRESENIUS KABI ONCOL	<u>40MG/2ML (20MG/ML)</u>	<u>A078188</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078188</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>	FRESENIUS KABI USA	<u>40MG/2ML (20MG/ML)</u>	<u>A077776</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A077776</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>40MG/2ML (20MG/ML)</u>	<u>A091032</u>	<u>001</u>	Dec 20, 2010
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A091032</u>	<u>002</u>	Dec 20, 2010
<u>AP</u>	HISUN PHARM HANGZHOU	<u>40MG/2ML (20MG/ML)</u>	<u>A090016</u>	<u>001</u>	Jan 28, 2009
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090016</u>	<u>002</u>	Jan 28, 2009
<u>AP</u>	HOSPIRA	<u>40MG/2ML (20MG/ML)</u>	<u>A077915</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A077915</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>	+	<u>500MG/25ML (20MG/ML)</u>	<u>A078796</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>	JIANGSU HENGRUI MED	<u>40MG/2ML (20MG/ML)</u>	<u>A090675</u>	<u>002</u>	Dec 16, 2011
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090675</u>	<u>001</u>	Dec 16, 2011
<u>AP</u>	PLIVA LACHEMA	<u>40MG/2ML (20MG/ML)</u>	<u>A078122</u>	<u>001</u>	Oct 31, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078122</u>	<u>002</u>	Oct 31, 2008
<u>AP</u>	SUN PHARMA GLOBAL	<u>40MG/2ML (20MG/ML)</u>	<u>A078805</u>	<u>001</u>	Apr 21, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078805</u>	<u>002</u>	Apr 21, 2008
<u>AP</u>	TEVA PARENTERAL	<u>40MG/2ML (20MG/ML)</u>	<u>A090101</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090101</u>	<u>003</u>	Feb 27, 2008
<u>AP</u>		<u>500MG/25ML (20MG/ML)</u>	<u>A090101</u>	<u>001</u>	Nov 26, 2008
	CAMPTOSAR				
	+ PFIZER INC	300MG/15ML (20MG/ML)	N020571	003	Aug 05, 2010

IRON DEXTRAN

INJECTABLE; INJECTION

DEXFERRUM

BP	LUITPOLD	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996
	INFED				
BP	+ WATSON LABS (UTAH)	EQ 50MG IRON/ML	N017441	001	
	PROFERDEX				
BP	NEW RIVER	EQ 50MG IRON/ML	N017807	001	

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

	LUITPOLD	EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135	002	Mar 20, 2005
	+	EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N021135	001	Nov 06, 2000
		EQ 200MG BASE/10ML (EQ 20MG BASE/ML)	N021135	004	Feb 09, 2007

ISOCARBOXAZID

TABLET; ORAL

MARPLAN

	+ VALIDUS PHARMS INC	10MG	N011961	001	

ISOFLURANE

LIQUID; INHALATION

FORANE

<u>AN</u>	+ BAXTER HLTHCARE	<u>99.9%</u>	<u>N017624</u>	<u>001</u>	
	<u>ISOFLURANE</u>				
<u>AN</u>	HALOCARBON PRODS	<u>99.9%</u>	<u>A075225</u>	<u>001</u>	Oct 20, 1999
<u>AN</u>	HOSPIRA	<u>99.9%</u>	<u>A074097</u>	<u>001</u>	Jan 25, 1993

PRESCRIPTION DRUG PRODUCT LIST

3 - 235 (of 428)

ISOFLURANE

LIQUID; INHALATION

ISOFLURANE

<u>AN</u>	PIRAMAL CRITICAL	<u>99.9%</u>	<u>A074416</u>	<u>001</u>	Sep 30, 1994
<u>AN</u>	RHODIA	<u>99.9%</u>	<u>A074502</u>	<u>001</u>	Jun 27, 1995

ISONIAZID

INJECTABLE; INJECTION

ISONIAZID

	+ SANDOZ	100MG/ML	A040648	001	Jul 05, 2005

SYRUP; ORAL

ISONIAZID

	+ CAROLINA MEDCL	50MG/5ML	A088235	001	Nov 10, 1983

TABLET; ORAL

ISONIAZID

<u>AA</u>	BARR	<u>100MG</u>	<u>A080936</u>	<u>001</u>	
<u>AA</u>		<u>300MG</u>	<u>A080937</u>	<u>002</u>	
<u>AA</u>	MIKART	<u>100MG</u>	<u>A040090</u>	<u>001</u>	Jun 26, 1997
<u>AA</u>		<u>300MG</u>	<u>A040090</u>	<u>002</u>	Jun 26, 1997
<u>AA</u>	+ SANDOZ	<u>100MG</u>	<u>N008678</u>	<u>002</u>	
<u>AA</u>		<u>300MG</u>	<u>N008678</u>	<u>003</u>	
<u>AA</u>	WATSON LABS	<u>300MG</u>	<u>A080521</u>	<u>001</u>	
<u>AA</u>	WEST WARD	<u>100MG</u>	<u>A080212</u>	<u>001</u>	
<u>AA</u>		<u>300MG</u>	<u>A087425</u>	<u>001</u>	

ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET; ORAL

RIFATER

	+ SANOFI AVENTIS US	50MG;300MG;120MG	N050705	001	May 31, 1994

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMATE

<u>AB</u>	+ SANOFI AVENTIS US	<u>150MG;300MG</u>	<u>A061884</u>	<u>001</u>	
	<u>RIFAMPIN AND ISONIAZID</u>				
<u>AB</u>	WESTWARD	<u>150MG;300MG</u>	<u>A065221</u>	<u>001</u>	Jul 29, 2005

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

<u>AP</u>	INTL MEDICATION	<u>0.2MG/ML</u>	<u>A083724</u>	<u>001</u>	
	<u>ISUPREL</u>				
<u>AP</u>	+ HOSPIRA	<u>0.2MG/ML</u>	<u>N010515</u>	<u>001</u>	

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

DILATRATE-SR

	+ SCHWARZ PHARMA	40MG	N019790	001	Sep 02, 1988

TABLET; ORAL

ISORDIL

<u>AB</u>	VALEANT INTL	<u>5MG</u>	<u>N012093</u>	<u>007</u>	Jul 29, 1988
<u>AB</u>		<u>10MG</u>	<u>N012093</u>	<u>002</u>	Jul 29, 1988
<u>AB</u>		<u>20MG</u>	<u>N012093</u>	<u>006</u>	Jul 29, 1988
<u>AB</u>		<u>30MG</u>	<u>N012093</u>	<u>005</u>	Jul 29, 1988
	<u>ISOSORBIDE DINITRATE</u>				
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A086923</u>	<u>001</u>	Mar 12, 1987
<u>AB</u>		<u>10MG</u>	<u>A086925</u>	<u>001</u>	Mar 12, 1987
<u>AB</u>		<u>20MG</u>	<u>A087537</u>	<u>001</u>	Oct 02, 1987
<u>AB</u>		<u>30MG</u>	<u>A087946</u>	<u>001</u>	Jan 12, 1988
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A086221</u>	<u>001</u>	Jan 07, 1988
<u>AB</u>		<u>10MG</u>	<u>A086223</u>	<u>001</u>	Jan 07, 1988
<u>AB</u>		<u>20MG</u>	<u>A089367</u>	<u>001</u>	Apr 07, 1988

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 236 (of 428)

ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE

<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A086034</u>	<u>001</u>	Jan 06, 1988
<u>AB</u>		<u>10MG</u>	<u>A086032</u>	<u>001</u>	Jan 07, 1988
<u>AB</u>	WEST WARD	<u>5MG</u>	<u>A086067</u>	<u>001</u>	Oct 29, 1987
<u>AB</u>		<u>10MG</u>	<u>A086066</u>	<u>001</u>	Oct 29, 1987
<u>AB</u>		<u>20MG</u>	<u>A088088</u>	<u>001</u>	Nov 02, 1987
<u>AB</u>		<u>30MG</u>	<u>A040591</u>	<u>001</u>	Jan 10, 2007

ISORDIL

+	VALEANT INTL	40MG	N012093	001	Jul 29, 1988

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A086033</u>	<u>001</u>	Feb 26, 1988
<u>AB</u>	+	<u>5MG</u>	<u>A086031</u>	<u>001</u>	Sep 29, 1987
<u>AB</u>	WEST WARD	<u>2.5MG</u>	<u>A086054</u>	<u>001</u>	Oct 29, 1987
<u>AB</u>		<u>5MG</u>	<u>A086055</u>	<u>001</u>	Nov 02, 1987

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE DINITRATE

<u>AB</u>	+	CARACO	<u>40MG</u>	<u>A040009</u>	<u>001</u>	Dec 30, 1998
<u>AB</u>		COREPHARMA	<u>40MG</u>	<u>A040723</u>	<u>001</u>	Mar 17, 2008

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISOSORBIDE MONONITRATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A075037</u>	<u>002</u>	Oct 30, 1998
<u>AB</u>		<u>20MG</u>	<u>A075037</u>	<u>001</u>	Oct 30, 1998
<u>AB</u>	TEVA	<u>20MG</u>	<u>A075147</u>	<u>001</u>	Nov 27, 1998
<u>AB</u>	WEST WARD	<u>20MG</u>	<u>A075361</u>	<u>001</u>	Oct 05, 2000

MONOKET

<u>AB</u>	KREMERS URBAN PHARMS	<u>10MG</u>	<u>N020215</u>	<u>002</u>	Jun 30, 1993
<u>AB</u>	+	<u>20MG</u>	<u>N020215</u>	<u>001</u>	Jun 30, 1993

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>30MG</u>	<u>A075306</u>	<u>001</u>	Dec 31, 1998
<u>AB</u>		<u>60MG</u>	<u>A075306</u>	<u>002</u>	Dec 31, 1998
<u>AB</u>	DEXCEL LTD	<u>60MG</u>	<u>A075522</u>	<u>001</u>	Apr 17, 2000
<u>AB</u>	KREMERS URBAN PHARMS	<u>30MG</u>	<u>A075155</u>	<u>002</u>	Jan 13, 2000
<u>AB</u>		<u>60MG</u>	<u>A075155</u>	<u>001</u>	Oct 30, 1998
<u>AB</u>	+	<u>120MG</u>	<u>A075155</u>	<u>003</u>	Aug 04, 2000
<u>AB</u>	NESHER PHARMS	<u>30MG</u>	<u>A075395</u>	<u>001</u>	Mar 16, 2000
<u>AB</u>		<u>60MG</u>	<u>A075395</u>	<u>002</u>	Mar 16, 2000
<u>AB</u>		<u>120MG</u>	<u>A075395</u>	<u>003</u>	Mar 16, 2000
<u>AB</u>	TORRENT PHARMS	<u>30MG</u>	<u>A200270</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		<u>60MG</u>	<u>A200495</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		<u>120MG</u>	<u>A200495</u>	<u>002</u>	Jun 03, 2011
<u>AB</u>	VINTAGE PHARMS	<u>30MG</u>	<u>A090598</u>	<u>001</u>	Aug 11, 2010
<u>AB</u>		<u>60MG</u>	<u>A090598</u>	<u>002</u>	Aug 11, 2010
<u>AB</u>		<u>120MG</u>	<u>A090598</u>	<u>003</u>	Aug 11, 2010
<u>AB</u>	WEST WARD	<u>30MG</u>	<u>A076813</u>	<u>002</u>	Mar 30, 2006
<u>AB</u>		<u>60MG</u>	<u>A076813</u>	<u>001</u>	Jan 07, 2005

ISOSULFAN BLUE

INJECTABLE; INJECTION

ISOSULFAN BLUE

<u>AP</u>	MYLAN INSTITUTIONAL	<u>1%</u>	<u>A090874</u>	<u>001</u>	Jul 20, 2010
	<u>LYMPHAZURIN</u>				
<u>AP</u>	+	COVIDIEN	<u>1%</u>	<u>N018310</u>	<u>001</u>

PRESCRIPTION DRUG PRODUCT LIST

3 - 237 (of 428)

ISOTRETINOIN

CAPSULE; ORAL					
<u>AMNESTEEM</u>					
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A075945</u>	<u>001</u>	Nov 08, 2002
<u>AB</u>	+	<u>20MG</u>	<u>A075945</u>	<u>002</u>	Nov 08, 2002
<u>AB</u>	+	<u>40MG</u>	<u>A075945</u>	<u>003</u>	Nov 08, 2002
<u>CLARAVIS</u>					
<u>AB</u>	BARR	<u>10MG</u>	<u>A076356</u>	<u>001</u>	Apr 11, 2003
<u>AB</u>		<u>20MG</u>	<u>A076135</u>	<u>002</u>	Apr 11, 2003
<u>AB</u>		<u>30MG</u>	<u>A076135</u>	<u>003</u>	May 11, 2006
<u>AB</u>		<u>40MG</u>	<u>A076135</u>	<u>001</u>	Apr 11, 2003
<u>MYORISAN</u>					
<u>AB</u>	DOUGLAS PHARMS	<u>10MG</u>	<u>A076485</u>	<u>001</u>	Jan 19, 2012
<u>AB</u>		<u>20MG</u>	<u>A076485</u>	<u>002</u>	Jan 19, 2012
<u>AB</u>		<u>40MG</u>	<u>A076485</u>	<u>003</u>	Jan 19, 2012
<u>SOTRET</u>					
<u>AB</u>	RANBAXY	<u>10MG</u>	<u>A076041</u>	<u>001</u>	Dec 24, 2002
<u>AB</u>		<u>20MG</u>	<u>A076041</u>	<u>002</u>	Dec 24, 2002
<u>AB</u>		<u>30MG</u>	<u>A076503</u>	<u>001</u>	Jun 20, 2003
<u>AB</u>		<u>40MG</u>	<u>A076041</u>	<u>003</u>	Dec 24, 2002
ABSORICA					
BX	CIPHER	10MG	N021951	001	May 25, 2012
BX		20MG	N021951	002	May 25, 2012
BX		30MG	N021951	003	May 25, 2012
BX		40MG	N021951	004	May 25, 2012

ISRADIPINE

CAPSULE; ORAL					
<u>ISRADIPINE</u>					
<u>AB</u>	MIKAH PHARMA	<u>2.5MG</u>	<u>A077169</u>	<u>001</u>	Apr 24, 2006
<u>AB</u>		<u>5MG</u>	<u>A077169</u>	<u>002</u>	Apr 24, 2006
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A077317</u>	<u>001</u>	Jan 05, 2006
<u>AB</u>	+	<u>5MG</u>	<u>A077317</u>	<u>002</u>	Jan 05, 2006
TABLET, EXTENDED RELEASE; ORAL					
DYNACIRC CR					
	GLAXOSMITHKLINE LLC	5MG	N020336	001	Jun 01, 1994
	+	10MG	N020336	002	Jun 01, 1994

ITRACONAZOLE

CAPSULE; ORAL					
<u>ITRACONAZOLE</u>					
<u>AB</u>	MYLAN PHARMS INC	<u>100MG</u>	<u>A200463</u>	<u>001</u>	Jul 20, 2012
<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A076104</u>	<u>001</u>	May 28, 2004
<u>SPORANOX</u>					
<u>AB</u>	+ JANSSEN PHARMS	<u>100MG</u>	<u>N020083</u>	<u>001</u>	Sep 11, 1992
SOLUTION; ORAL					
SPORANOX					
	+ JANSSEN PHARMS	10MG/ML	N020657	001	Feb 21, 1997
TABLET; ORAL					
ONMEL					
	+ MERZ PHARMS	200MG	N022484	001	Apr 29, 2010

IVACAFTOR

TABLET; ORAL					
KALYDECO					
+	VERTEX PHARMS	150MG	N203188	001	Jan 31, 2012

IVERMECTIN

LOTION; TOPICAL						
SKLICE						
	+	SANOFI PASTEUR INC	0.5%	N202736	001	Feb 07, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 238 (of 428)

IVERMECTINTABLET; ORAL
STROMECTOL

+ MERCK SHARP DOHME 3MG N050742 002 Oct 08, 1998

IXABEPILONE

INJECTABLE; IV (INFUSION)

+ BRISTOL MYERS SQUIBB 15MG/VIAL N022065 001 Oct 16, 2007
+ 45MG/VIAL N022065 002 Oct 16, 2007KANAMYCIN SULFATEINJECTABLE; INJECTION
KANAMYCIN SULFATEFRESENIUS KABI USA EQ 500MG BASE/2ML A065111 001 Dec 17, 2002
+ EQ 1GM BASE/3ML A065111 002 Dec 17, 2002KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETALARAP + JHP PHARMS EQ 10MG BASE/ML N016812 001
AP + EQ 50MG BASE/ML N016812 002
AP + EQ 100MG BASE/ML N016812 003KETAMINE HYDROCHLORIDEAP BEDFORD EQ 50MG BASE/ML A074524 001 Mar 22, 1996
AP EQ 100MG BASE/ML A074524 002 Mar 22, 1996
AP BIONICHE PHARMA EQ 10MG BASE/ML A076092 001 Sep 30, 2008
AP EQ 50MG BASE/ML A076092 002 Dec 28, 2001
AP EQ 100MG BASE/ML A076092 003 Oct 25, 2002
AP HOSPIRA EQ 50MG BASE/ML A074549 001 Jun 27, 1996
AP EQ 100MG BASE/ML A074549 002 Jun 27, 1996KETOCONAZOLE

AEROSOL, FOAM; TOPICAL

EXTINA

AT + STIEFEL LABS INC 2% N021738 001 Jun 12, 2007

KETOCONAZOLE

AT PERRIGO ISRAEL 2% A091550 001 Aug 25, 2011

CREAM; TOPICAL

KETOCONAZOLEAB FOUGERA PHARMS 2% A076294 001 Apr 28, 2004
AB + TEVA 2% A075581 001 Apr 25, 2000KETOZOLE

AB TARO 2% A075638 001 Dec 18, 2002

GEL; TOPICAL

XOLEGEL

+ AQUA PHARMS 2% N021946 001 Jul 28, 2006

SHAMPOO; TOPICAL

KETOCONAZOLEAB PERRIGO NEW YORK 2% A076419 001 Jan 07, 2004
AB TOLMAR 2% A076942 001 Apr 11, 2005NIZORAL

AB + JANSSEN PHARMS 2% N019927 001 Aug 31, 1990

TABLET; ORAL

KETOCONAZOLEAB APOTEX 200MG A075912 001 Jan 10, 2002
AB MUTUAL PHARMA 200MG A075314 001 Jun 15, 1999
AB MYLAN 200MG A075597 001 Dec 23, 1999
AB PLIVA 200MG A075362 001 Jun 15, 1999
AB TARO 200MG A075319 001 Jun 15, 1999
AB TEVA 200MG A075273 001 Jun 15, 1999

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 239 (of 428)

KETOCONAZOLE

TABLET; ORAL

NIZORALAB + ORTHO MCNEIL JANSSEN 200MGN018533 001KETOPROFEN

CAPSULE; ORAL

KETOPROFENAB DORADO PHARMA 50MGA074014 002 Jan 29, 1993AB 75MGA074014 003 Jan 29, 1993AB MYLAN 50MGA074035 002 Dec 31, 1996AB 75MGA074035 003 Dec 31, 1996AB TEVA 50MGA073516 001 Dec 22, 1992AB + 75MGA073517 001 Dec 22, 1992

KETOPROFEN

DORADO PHARMA 25MG

A074014 001 Jan 29, 1993

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFENAB MYLAN 100MGA075679 003 Feb 20, 2002AB 150MGA075679 002 Feb 20, 2002AB + 200MGA075679 001 Feb 20, 2002AB WATSON LABS FLORIDA 100MGA075270 002 Mar 24, 1999AB 150MGA075270 003 Mar 24, 1999AB 200MGA075270 001 Mar 24, 1999KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINEAP + BEDFORD 15MG/MLA075222 001 Apr 26, 1999AP + 30MG/MLA075222 002 Apr 26, 1999AP + 30MG/MLA075228 001 Apr 26, 1999AP CLARIS LIFESCIENCES 15MG/MLA075631 002 Jun 29, 2001AP 30MG/MLA075631 001 Jun 29, 2001AP FRESENIUS KABI USA 15MG/MLA075784 001 Jan 11, 2002AP 30MG/MLA075784 002 Jan 11, 2002AP HIKMA MAPLE 15MG/MLA075299 001 Nov 03, 1999AP 15MG/MLA075772 001 Jul 21, 2004AP 30MG/MLA075299 002 Nov 03, 1999AP 30MG/MLA075772 002 Jul 21, 2004AP HOSPIRA 15MG/MLA074802 001 Jun 05, 1997AP 15MG/MLA074993 001 Jan 27, 1999AP 30MG/MLA074802 002 Jun 05, 1997AP 30MG/MLA074993 002 Jan 27, 1999AP LUITPOLD 15MG/MLA078145 001 Jan 14, 2008AP 30MG/MLA078145 002 Jan 14, 2008AP PFIZER 15MG/MLA078299 001 Jul 16, 2007AP 30MG/MLA078299 002 Jul 16, 2007AP SANDOZ 15MG/MLA076271 001 Oct 06, 2004AP 30MG/MLA076271 002 Oct 06, 2004AP SUN PHARMA GLOBAL 15MG/MLA078737 001 Oct 06, 2008AP 30MG/MLA078737 002 Oct 06, 2008AP WOCKHARDT 15MG/MLA077942 001 Mar 27, 2007AP 30MG/MLA077942 002 Mar 27, 2007AP 30MG/MLA077943 001 Mar 27, 2007

SOLUTION/DROPS; OPHTHALMIC

ACULARAT + ALLERGAN 0.5%N019700 001 Nov 09, 1992ACULAR LSAT + ALLERGAN 0.4%N021528 001 May 30, 2003KETOROLAC TROMETHAMINEAT AKORN 0.4%A078399 001 Nov 05, 2009

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 240 (of 428)

KETOROLAC TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC

KETOROLAC TROMETHAMINE

<u>AT</u>	AKORN	<u>0.5%</u>	<u>A078434</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>	ALCON PHARMS LTD	<u>0.4%</u>	<u>A078721</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A076583</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>	APOTEX INC	<u>0.4%</u>	<u>A077308</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A076109</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>	SUN PHARMA GLOBAL	<u>0.5%</u>	<u>A090017</u>	<u>001</u>	Nov 05, 2009
	ACULAR PRESERVATIVE FREE				
	+ ALLERGAN	0.5%	N020811	001	Nov 03, 1997
	ACUVAIL				
	+ ALLERGAN	0.45%	N022427	001	Jul 22, 2009
	SPRAY, METERED; NASAL				
	SPRIX				
	+ LUITPOLD	15.75MG/SPRAY	N022382	001	May 14, 2010
	TABLET; ORAL				
	<u>KETOROLAC TROMETHAMINE</u>				
<u>AB</u>	+ MYLAN	<u>10MG</u>	<u>A074761</u>	<u>001</u>	May 16, 1997
<u>AB</u>	PLIVA	<u>10MG</u>	<u>A075284</u>	<u>001</u>	Jun 23, 1999
<u>AB</u>	TEVA	<u>10MG</u>	<u>A074754</u>	<u>001</u>	May 16, 1997

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>5MG/ML</u>	<u>A075303</u>	<u>001</u>	May 28, 1999
<u>AP</u>	CLARIS LIFESCIENCES	<u>5MG/ML</u>	<u>A076051</u>	<u>001</u>	Jul 05, 2002
<u>AP</u>	GLAND PHARMA LTD	<u>5MG/ML</u>	<u>A090699</u>	<u>001</u>	Apr 03, 2012
<u>AP</u>	+ HOSPIRA	<u>5MG/ML</u>	<u>A075239</u>	<u>001</u>	Nov 29, 1999
<u>AP</u>	+	<u>5MG/ML</u>	<u>A075240</u>	<u>001</u>	Nov 29, 1999
<u>AP</u>	TAYLOR	<u>5MG/ML</u>	<u>A075431</u>	<u>001</u>	Nov 29, 1999
<u>AP</u>		<u>5MG/ML</u>	<u>A075524</u>	<u>001</u>	Nov 29, 1999
	<u>LABETALOL HYDROCHLORIDE</u>				
<u>AP</u>	SAGENT STRIDES	<u>5MG/ML</u>	<u>A079134</u>	<u>001</u>	Feb 03, 2010

TABLET; ORAL

LABETALOL HYDROCHLORIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>100MG</u>	<u>A074787</u>	<u>001</u>	Aug 03, 1998
<u>AB</u>		<u>200MG</u>	<u>A074787</u>	<u>002</u>	Aug 03, 1998
<u>AB</u>		<u>300MG</u>	<u>A074787</u>	<u>003</u>	Aug 03, 1998
<u>AB</u>	PAR FORM	<u>100MG</u>	<u>A200908</u>	<u>001</u>	Jul 10, 2012
<u>AB</u>		<u>200MG</u>	<u>A200908</u>	<u>002</u>	Jul 10, 2012
<u>AB</u>		<u>300MG</u>	<u>A200908</u>	<u>003</u>	Jul 10, 2012
<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A075113</u>	<u>001</u>	Aug 04, 1998
<u>AB</u>		<u>200MG</u>	<u>A075113</u>	<u>002</u>	Aug 04, 1998
<u>AB</u>		<u>300MG</u>	<u>A075113</u>	<u>003</u>	Aug 04, 1998
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>A075133</u>	<u>001</u>	Aug 03, 1998
<u>AB</u>		<u>200MG</u>	<u>A075133</u>	<u>002</u>	Aug 03, 1998
<u>AB</u>		<u>300MG</u>	<u>A075133</u>	<u>003</u>	Aug 03, 1998
	<u>TRANDATE</u>				
<u>AB</u>	PROMETHEUS LABS	<u>100MG</u>	<u>N018716</u>	<u>001</u>	May 24, 1985
<u>AB</u>	+	<u>200MG</u>	<u>N018716</u>	<u>002</u>	Aug 01, 1984

LACOSAMIDE

SOLUTION; INTRAVENOUS

VIMPAT

	+ UCB INC	200MG/20ML (10MG/ML)	N022254	001	Oct 28, 2008

SOLUTION; ORAL

VIMPAT

	+ UCB INC	10MG/ML	N022255	001	Apr 20, 2010

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 241 (of 428)

LACOSAMIDETABLET; ORAL
VIMPAT

UCB INC	50MG	N022253	001	Oct 28, 2008
	100MG	N022253	002	Oct 28, 2008
	150MG	N022253	003	Oct 28, 2008
+	200MG	N022253	004	Oct 28, 2008

LACTULOSEFOR SOLUTION; ORAL
LACTULOSE

+ CUMBERLAND PHARMS	10GM/PACKET	A074712	001	Dec 10, 1997
+	20GM/PACKET	A074712	002	Dec 10, 1997

SOLUTION; ORAL

CONSTILAC

<u>AA</u> ALRA	<u>10GM/15ML</u>	<u>A071054</u>	<u>001</u>	Jul 26, 1988

CONSTULOSE

<u>AA</u> + ACTAVIS MID ATLANTIC	<u>10GM/15ML</u>	<u>A070288</u>	<u>001</u>	Aug 15, 1988

LACTULOSE

<u>AA</u> ANI PHARMS	<u>10GM/15ML</u>	<u>A078430</u>	<u>001</u>	Nov 28, 2007
<u>AA</u> FRESENIUS KABI	<u>10GM/15ML</u>	<u>A090503</u>	<u>001</u>	Jan 25, 2012
<u>AA</u> HI TECH PHARMA	<u>10GM/15ML</u>	<u>A074076</u>	<u>001</u>	Jul 03, 1995
<u>AA</u> MORTON GROVE	<u>10GM/15ML</u>	<u>A074602</u>	<u>001</u>	Nov 14, 1996
<u>AA</u> NOVEX	<u>10GM/15ML</u>	<u>A075911</u>	<u>001</u>	Feb 21, 2002
<u>AA</u> PHARM ASSOC	<u>10GM/15ML</u>	<u>A074623</u>	<u>001</u>	Jul 30, 1996
<u>AA</u> ROXANE	<u>10GM/15ML</u>	<u>A073591</u>	<u>001</u>	May 29, 1992
<u>AA</u> VINTAGE PHARMS	<u>10GM/15ML</u>	<u>A075993</u>	<u>001</u>	Jul 26, 2001
<u>AA</u> VISTAPHARM	<u>10GM/15ML</u>	<u>A074138</u>	<u>001</u>	Sep 30, 1992

SOLUTION; ORAL, RECTAL

CHOLAC

<u>AA</u> ALRA	<u>10GM/15ML</u>	<u>A071331</u>	<u>001</u>	Jul 26, 1988

ENULOSE

<u>AA</u> + ACTAVIS MID ATLANTIC	<u>10GM/15ML</u>	<u>A071548</u>	<u>001</u>	Aug 15, 1988

GENERLAC

<u>AA</u> MORTON GROVE PHARMS	<u>10GM/15ML</u>	<u>A074603</u>	<u>001</u>	Oct 31, 1996

LACTULOSE

<u>AA</u> ANI PHARMS	<u>10GM/15ML</u>	<u>A090426</u>	<u>001</u>	Nov 21, 2008
<u>AA</u> FRESENIUS KABI	<u>10GM/15ML</u>	<u>A090502</u>	<u>001</u>	Jan 25, 2012
<u>AA</u> HI TECH PHARMA	<u>10GM/15ML</u>	<u>A074077</u>	<u>001</u>	Jul 03, 1995
<u>AA</u> NOVEX	<u>10GM/15ML</u>	<u>A076645</u>	<u>001</u>	Jul 28, 2003

LAMIVUDINE

SOLUTION; ORAL

EPIVIR

+ VIIV HLTHCARE	10MG/ML	N020596	001	Nov 17, 1995
EPIVIR-HBV				
+ GLAXOSMITHKLINE	5MG/ML	N021004	001	Dec 08, 1998

TABLET; ORAL

EPIVIR

<u>AB</u> VIIV HLTHCARE	<u>150MG</u>	<u>N020564</u>	<u>001</u>	Nov 17, 1995
<u>AB</u> +	<u>300MG</u>	<u>N020564</u>	<u>003</u>	Jun 24, 2002

LAMIVUDINE

<u>AB</u> APOTEX	<u>150MG</u>	<u>A091606</u>	<u>001</u>	Dec 02, 2011
<u>AB</u>	<u>300MG</u>	<u>A091606</u>	<u>002</u>	Dec 02, 2011
<u>AB</u> AUROBINDO PHARMA LTD	<u>150MG</u>	<u>A202032</u>	<u>001</u>	Nov 17, 2011
<u>AB</u>	<u>300MG</u>	<u>A202032</u>	<u>002</u>	Nov 17, 2011

EPIVIR-HBV

+ GLAXOSMITHKLINE	100MG	N021003	001	Dec 08, 1998

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 242 (of 428)

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

COMBIVIR

<u>AB</u>	+ VIIV HLTHCARE	<u>150MG;300MG</u>	<u>N020857</u>	<u>001</u>	Sep 26, 1997
<u>LAMIVUDINE AND ZIDOVUDINE</u>					
<u>AB</u>	AUROBINDO PHARMA LTD	<u>150MG;300MG</u>	<u>A202418</u>	<u>001</u>	May 15, 2012
<u>AB</u>	LUPIN LTD	<u>150MG;300MG</u>	<u>A090246</u>	<u>001</u>	May 15, 2012
<u>AB</u>	TEVA PHARMS	<u>150MG;300MG</u>	<u>A079081</u>	<u>001</u>	May 25, 2011

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

<u>AB</u>	+ GLAXOSMITHKLINE	<u>25MG</u>	<u>N020241</u>	<u>005</u>	Dec 27, 1994
<u>AB</u>		<u>100MG</u>	<u>N020241</u>	<u>001</u>	Dec 27, 1994
<u>AB</u>		<u>150MG</u>	<u>N020241</u>	<u>002</u>	Dec 27, 1994
<u>AB</u>		<u>200MG</u>	<u>N020241</u>	<u>003</u>	Dec 27, 1994

LAMOTRIGINE

<u>AB</u>	ACTAVIS TOTOWA	<u>25MG</u>	<u>A078669</u>	<u>001</u>	Apr 08, 2011
<u>AB</u>		<u>100MG</u>	<u>A078669</u>	<u>002</u>	Apr 08, 2011
<u>AB</u>		<u>150MG</u>	<u>A078669</u>	<u>003</u>	Apr 08, 2011
<u>AB</u>		<u>200MG</u>	<u>A078669</u>	<u>004</u>	Apr 08, 2011
<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A090607</u>	<u>001</u>	Jan 13, 2011
<u>AB</u>		<u>100MG</u>	<u>A090607</u>	<u>002</u>	Jan 13, 2011
<u>AB</u>		<u>150MG</u>	<u>A090607</u>	<u>003</u>	Jan 13, 2011
<u>AB</u>		<u>200MG</u>	<u>A090607</u>	<u>004</u>	Jan 13, 2011
<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A078625</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078625</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078625</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078625</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078956</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078956</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078956</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078956</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	CADISTA PHARMS	<u>25MG</u>	<u>A079132</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079132</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A079132</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079132</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>25MG</u>	<u>A076708</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076708</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A076708</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076708</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A090169</u>	<u>001</u>	May 12, 2012
<u>AB</u>		<u>100MG</u>	<u>A090169</u>	<u>002</u>	May 12, 2012
<u>AB</u>		<u>150MG</u>	<u>A090169</u>	<u>003</u>	May 12, 2012
<u>AB</u>		<u>200MG</u>	<u>A090169</u>	<u>004</u>	May 12, 2012
<u>AB</u>	HIKMA PHARMS	<u>25MG</u>	<u>A078134</u>	<u>001</u>	Apr 19, 2011
<u>AB</u>		<u>100MG</u>	<u>A078134</u>	<u>002</u>	Apr 19, 2011
<u>AB</u>		<u>150MG</u>	<u>A078134</u>	<u>003</u>	Apr 19, 2011
<u>AB</u>		<u>200MG</u>	<u>A078134</u>	<u>004</u>	Apr 19, 2011
<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A078691</u>	<u>001</u>	Jun 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A078691</u>	<u>002</u>	Jun 01, 2010
<u>AB</u>		<u>150MG</u>	<u>A078691</u>	<u>003</u>	Jun 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A078691</u>	<u>004</u>	Jun 01, 2010
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A077420</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077420</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077420</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077420</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A078645</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078645</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078645</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078645</u>	<u>004</u>	Jan 27, 2009

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 243 (of 428)

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

<u>AB</u>	TARO PHARM INDS	<u>25MG</u>	<u>A078525</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078525</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078525</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078525</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076388</u>	<u>001</u>	Aug 30, 2006
<u>AB</u>		<u>100MG</u>	<u>A076388</u>	<u>002</u>	Aug 30, 2006
<u>AB</u>		<u>150MG</u>	<u>A076388</u>	<u>003</u>	Aug 30, 2006
<u>AB</u>		<u>200MG</u>	<u>A076388</u>	<u>004</u>	Aug 30, 2006
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A078947</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078947</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078947</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078947</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A090170</u>	<u>001</u>	Oct 06, 2011
<u>AB</u>		<u>100MG</u>	<u>A090170</u>	<u>002</u>	Oct 06, 2011
<u>AB</u>		<u>150MG</u>	<u>A090170</u>	<u>003</u>	Oct 06, 2011
<u>AB</u>		<u>200MG</u>	<u>A090170</u>	<u>004</u>	Oct 06, 2011
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A077783</u>	<u>001</u>	Nov 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A077783</u>	<u>002</u>	Nov 01, 2010
<u>AB</u>		<u>150MG</u>	<u>A077783</u>	<u>003</u>	Nov 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A077783</u>	<u>004</u>	Nov 01, 2010
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077633</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077633</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077633</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077633</u>	<u>005</u>	Jan 27, 2009
	LAMOTRIGINE				
BX	UPSHER SMITH	25MG	A078310	001	Feb 04, 2009
BX		100MG	A078310	002	Feb 04, 2009
BX		150MG	A078310	003	Feb 04, 2009
BX		200MG	A078310	004	Feb 04, 2009
	LAMOTRIGINE				
	ZYDUS PHARMS USA	50MG	A077633	002	Jan 27, 2009
		250MG	A077633	006	Jan 27, 2009

TABLET, CHEWABLE; ORAL

LAMICTAL CD

<u>AB</u>	GLAXOSMITHKLINE	<u>2MG</u>	<u>N020764</u>	<u>004</u>	Sep 08, 2000
<u>AB</u>		<u>5MG</u>	<u>N020764</u>	<u>001</u>	Aug 24, 1998
<u>AB</u>	+	<u>25MG</u>	<u>N020764</u>	<u>002</u>	Aug 24, 1998
	<u>LAMOTRIGINE</u>				
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A090401</u>	<u>002</u>	Nov 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A090401</u>	<u>003</u>	Nov 04, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076701</u>	<u>001</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076701</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>	GLENMARK GENERICS	<u>5MG</u>	<u>A079099</u>	<u>001</u>	Feb 19, 2009
<u>AB</u>		<u>25MG</u>	<u>A079099</u>	<u>002</u>	Feb 19, 2009
<u>AB</u>	JUBILANT LIFE	<u>5MG</u>	<u>A200220</u>	<u>001</u>	Feb 28, 2011
<u>AB</u>		<u>25MG</u>	<u>A200220</u>	<u>002</u>	Feb 28, 2011
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076630</u>	<u>001</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076630</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>	TARO	<u>5MG</u>	<u>A079204</u>	<u>001</u>	Feb 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A079204</u>	<u>002</u>	Feb 04, 2009
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076420</u>	<u>001</u>	Jun 21, 2006
<u>AB</u>		<u>25MG</u>	<u>A076420</u>	<u>002</u>	Jun 21, 2006
<u>AB</u>	WATSON LABS	<u>2MG</u>	<u>A076928</u>	<u>001</u>	Jan 22, 2009
<u>AB</u>		<u>5MG</u>	<u>A076928</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076928</u>	<u>003</u>	Jan 22, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078009</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A078009</u>	<u>003</u>	Jan 22, 2009

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 244 (of 428)

LAMOTRIGINE

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

<u>AB</u>	SMITHKLINE BEECHAM	<u>25MG</u>	<u>N022115</u>	<u>001</u>	May 29, 2009
<u>AB</u>	+	<u>50MG</u>	<u>N022115</u>	<u>002</u>	May 29, 2009
<u>AB</u>		<u>100MG</u>	<u>N022115</u>	<u>003</u>	May 29, 2009
<u>AB</u>		<u>200MG</u>	<u>N022115</u>	<u>004</u>	May 29, 2009
<u>AB</u>		<u>250MG</u>	<u>N022115</u>	<u>006</u>	Jun 21, 2011
<u>AB</u>		<u>300MG</u>	<u>N022115</u>	<u>005</u>	Apr 14, 2010

LAMOTRIGINE

<u>AB</u>	ANCHEN PHARMS	<u>25MG</u>	<u>A201374</u>	<u>001</u>	Dec 26, 2012
<u>AB</u>		<u>50MG</u>	<u>A201374</u>	<u>002</u>	Dec 26, 2012
<u>AB</u>		<u>100MG</u>	<u>A201374</u>	<u>003</u>	Dec 26, 2012
<u>AB</u>		<u>200MG</u>	<u>A201374</u>	<u>004</u>	Dec 26, 2012
<u>AB</u>		<u>250MG</u>	<u>A201374</u>	<u>005</u>	Dec 26, 2012
<u>AB</u>		<u>300MG</u>	<u>A201374</u>	<u>006</u>	Dec 26, 2012
<u>AB</u>	WOCKHARDT LTD	<u>25MG</u>	<u>A202498</u>	<u>001</u>	Jan 04, 2013
<u>AB</u>		<u>50MG</u>	<u>A202498</u>	<u>002</u>	Jan 04, 2013
<u>AB</u>		<u>100MG</u>	<u>A202498</u>	<u>003</u>	Jan 04, 2013
<u>AB</u>		<u>200MG</u>	<u>A202498</u>	<u>004</u>	Jan 04, 2013
<u>AB</u>		<u>300MG</u>	<u>A202498</u>	<u>005</u>	Jan 04, 2013

TABLET, ORALLY DISINTEGRATING; ORAL

LAMICTAL ODT

	SMITHKLINE BEECHAM	25MG	N022251	001	May 08, 2009
+		50MG	N022251	002	May 08, 2009
		100MG	N022251	003	May 08, 2009
		200MG	N022251	004	May 08, 2009

LANREOTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SOMATULINE DEPOT

+	IPSEN PHARMA	EQ 60MG BASE	N022074	001	Aug 30, 2007
+		EQ 90MG BASE	N022074	002	Aug 30, 2007
+		EQ 120MG BASE	N022074	003	Aug 30, 2007

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

<u>AB</u>	DR REDDYS LABS LTD	<u>15MG</u>	<u>A091269</u>	<u>001</u>	Oct 15, 2010
<u>AB</u>		<u>30MG</u>	<u>A091269</u>	<u>002</u>	Oct 15, 2010
<u>AB</u>	MYLAN PHARMS INC	<u>15MG</u>	<u>A090763</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A090763</u>	<u>002</u>	Nov 10, 2009
<u>AB</u>	NATCO PHARMA LTD	<u>15MG</u>	<u>A201921</u>	<u>001</u>	Dec 18, 2012
<u>AB</u>		<u>30MG</u>	<u>A201921</u>	<u>002</u>	Dec 18, 2012
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A090331</u>	<u>001</u>	Apr 23, 2010
<u>AB</u>		<u>30MG</u>	<u>A090331</u>	<u>002</u>	Apr 23, 2010
<u>AB</u>	TEVA PHARMS	<u>15MG</u>	<u>A077255</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A077255</u>	<u>002</u>	Nov 10, 2009
<u>AB</u>	WOCKHARDT USA	<u>15MG</u>	<u>A202176</u>	<u>001</u>	Sep 14, 2012
<u>AB</u>		<u>30MG</u>	<u>A202176</u>	<u>002</u>	Sep 14, 2012

PREVACID

<u>AB</u>	TAKEDA PHARMS USA	<u>15MG</u>	<u>N020406</u>	<u>001</u>	May 10, 1995
<u>AB</u>	+	<u>30MG</u>	<u>N020406</u>	<u>002</u>	May 10, 1995

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL
PREVACID

	TAKEDA PHARMS USA	15MG	N021428	001	Aug 30, 2002
+		30MG	N021428	002	Aug 30, 2002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 245 (of 428)

LANTHANUM CARBONATETABLET, CHEWABLE; ORAL
FOSRENOL

SHIRE LLC	EQ 500MG BASE	N021468	002	Oct 26, 2004
	EQ 750MG BASE	N021468	003	Nov 23, 2005
+	EQ 1GM BASE	N021468	004	Nov 23, 2005

LAPATINIB DITOSYLATETABLET; ORAL
TYKERB

+ SMITHKLINE BEECHAM	EQ 250MG BASE	N022059	001	Mar 13, 2007

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

<u>AT</u>	AKORN	<u>0.005%</u>	<u>A090887</u>	<u>001</u>	Jul 19, 2011
<u>AT</u>	ALCON RES	<u>0.005%</u>	<u>A091449</u>	<u>001</u>	Mar 22, 2011
<u>AT</u>	APOTEX	<u>0.005%</u>	<u>A077697</u>	<u>001</u>	Mar 22, 2011
<u>AT</u>	BAUSCH AND LOMB	<u>0.005%</u>	<u>A201006</u>	<u>001</u>	Mar 22, 2011
<u>AT</u>	LUITPOLD	<u>0.005%</u>	<u>A200925</u>	<u>001</u>	Mar 22, 2011
<u>AT</u>	MYLAN	<u>0.005%</u>	<u>A201786</u>	<u>001</u>	Mar 22, 2011

XALATAN

<u>AT</u> + PHARMACIA AND UPJOHN	<u>0.005%</u>	<u>N020597</u>	<u>001</u>	Jun 05, 1996

LEFLUNOMIDE

TABLET; ORAL

ARAVA

<u>AB</u>	SANOFI AVENTIS US	<u>10MG</u>	<u>N020905</u>	<u>001</u>	Sep 10, 1998
<u>AB</u> +		<u>20MG</u>	<u>N020905</u>	<u>002</u>	Sep 10, 1998

LEFLUNOMIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>10MG</u>	<u>A091369</u>	<u>001</u>	Nov 21, 2011
<u>AB</u>		<u>20MG</u>	<u>A091369</u>	<u>002</u>	Nov 21, 2011
<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A077090</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>		<u>20MG</u>	<u>A077090</u>	<u>002</u>	Sep 13, 2005
<u>AB</u>	BARR	<u>10MG</u>	<u>A077083</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>		<u>20MG</u>	<u>A077083</u>	<u>002</u>	Sep 13, 2005
<u>AB</u>	HERITAGE PHARMS INC	<u>10MG</u>	<u>A077086</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>		<u>20MG</u>	<u>A077086</u>	<u>002</u>	Sep 13, 2005
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A077087</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>		<u>20MG</u>	<u>A077087</u>	<u>002</u>	Sep 13, 2005
<u>AB</u>	TEVA PHARMS	<u>10MG</u>	<u>A077084</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>		<u>20MG</u>	<u>A077084</u>	<u>002</u>	Sep 13, 2005

ARAVA

+ SANOFI AVENTIS US	100MG	N020905	003	Sep 10, 1998

LENALIDOMIDECAPSULE; ORAL
REVLIMID

CELGENE	2.5MG	N021880	005	Dec 21, 2011
	5MG	N021880	001	Dec 27, 2005
	10MG	N021880	002	Dec 27, 2005
	15MG	N021880	003	Jun 29, 2006
+	25MG	N021880	004	Jun 29, 2006

LEPIRUDIN RECOMBINANTINJECTABLE; INJECTION
REFLUDAN

+ BAYER HLTHCARE	50MG/VIAL	N020807	001	Mar 06, 1998

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 246 (of 428)

LETROZOLE

TABLET; ORAL

FEMARA

<u>AB</u>	+	NOVARTIS PHARMS	<u>2.5MG</u>	<u>N020726</u>	<u>001</u>	Jul 25, 1997
<u>LETROZOLE</u>						
<u>AB</u>		ACCORD HLTHCARE	<u>2.5MG</u>	<u>A090934</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		ACTAVIS TOTOWA	<u>2.5MG</u>	<u>A090292</u>	<u>001</u>	Jul 13, 2011
<u>AB</u>		APOTEX INC	<u>2.5MG</u>	<u>A091303</u>	<u>001</u>	Apr 19, 2012
<u>AB</u>		DR REDDYS LABS LTD	<u>2.5MG</u>	<u>A091191</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		FRESENIUS KABI ONCOL	<u>2.5MG</u>	<u>A090491</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		IMPAX LABS	<u>2.5MG</u>	<u>A091638</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		INDICUS PHARMA	<u>2.5MG</u>	<u>A201804</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		KUDCO IRELAND	<u>2.5MG</u>	<u>A091098</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		MYLAN	<u>2.5MG</u>	<u>A078190</u>	<u>001</u>	Dec 24, 2008
<u>AB</u>		NATCO PHARMA LTD	<u>2.5MG</u>	<u>A200161</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		ROXANE	<u>2.5MG</u>	<u>A090838</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		SUN PHARM INDS LTD	<u>2.5MG</u>	<u>A091466</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		TEVA PHARMS	<u>2.5MG</u>	<u>A090289</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		VINTAGE PHARMS LLC	<u>2.5MG</u>	<u>A090789</u>	<u>001</u>	Jun 03, 2011

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

<u>AP</u>	+	BEDFORD	<u>EQ 50MG BASE/VIAL</u>	<u>A089384</u>	<u>001</u>	Sep 14, 1987
<u>AP</u>	+		<u>EQ 100MG BASE/VIAL</u>	<u>A089717</u>	<u>001</u>	Mar 28, 1988
<u>AP</u>		TEVA PARENTERAL	<u>EQ 100MG BASE/VIAL</u>	<u>A081277</u>	<u>001</u>	Sep 28, 1993
<u>AP</u>			<u>EQ 350MG BASE/VIAL</u>	<u>A040174</u>	<u>001</u>	Jun 12, 1997

LEUCOVORIN CALCIUM PRESERVATIVE FREE

<u>AP</u>	+	BEDFORD	<u>EQ 200MG BASE/VIAL</u>	<u>A040056</u>	<u>001</u>	May 23, 1995
<u>AP</u>	+		<u>EQ 350MG BASE/VIAL</u>	<u>A040335</u>	<u>001</u>	Apr 20, 2000
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 200MG BASE/VIAL</u>	<u>A040258</u>	<u>001</u>	Feb 26, 1999
<u>AP</u>		LUITPOLD	<u>EQ 50MG BASE/VIAL</u>	<u>A040338</u>	<u>001</u>	Jan 31, 2001
<u>AP</u>		SAGENT PHARMS	<u>EQ 50MG BASE/VIAL</u>	<u>A200753</u>	<u>001</u>	Sep 06, 2012
<u>AP</u>			<u>EQ 100MG BASE/VIAL</u>	<u>A200753</u>	<u>002</u>	Sep 06, 2012
<u>AP</u>			<u>EQ 200MG BASE/VIAL</u>	<u>A200753</u>	<u>003</u>	Sep 06, 2012
<u>AP</u>			<u>EQ 350MG BASE/VIAL</u>	<u>A200855</u>	<u>001</u>	Sep 06, 2012

LEUCOVORIN CALCIUM PRESERVATIVE FREE

	+	BEDFORD	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000
	+	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A040286	001	Feb 26, 1999

TABLET; ORAL

LEUCOVORIN CALCIUM

<u>AB</u>		BARR	<u>EQ 5MG BASE</u>	<u>A071198</u>	<u>001</u>	Sep 24, 1987
<u>AB</u>			<u>EQ 25MG BASE</u>	<u>A071199</u>	<u>001</u>	Sep 24, 1987
<u>AB</u>		ROXANE	<u>EQ 5MG BASE</u>	<u>A072733</u>	<u>001</u>	Feb 22, 1993
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A072735</u>	<u>001</u>	Feb 22, 1993
<u>AB</u>	+		<u>EQ 25MG BASE</u>	<u>A072736</u>	<u>001</u>	Feb 22, 1993
		LEUCOVORIN CALCIUM				
		ROXANE	EQ 10MG BASE	A072734	001	Feb 22, 1993

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

<u>AP</u>	+	SANDOZ	<u>1MG/0.2ML</u>	<u>A074728</u>	<u>001</u>	Aug 04, 1998
<u>AP</u>		SUN PHARMA GLOBAL	<u>1MG/0.2ML</u>	<u>A078885</u>	<u>001</u>	Mar 09, 2009
<u>AP</u>		TEVA PARENTERAL	<u>1MG/0.2ML</u>	<u>A075471</u>	<u>001</u>	Oct 25, 2000
		LUPRON DEPOT				
	+	ABBOTT ENDOCRINE	3.75MG/VIAL	N020011	001	Oct 22, 1990
	+		7.5MG/VIAL	N019732	001	Jan 26, 1989
	+		11.25MG/VIAL	N020708	001	Mar 07, 1997
	+		22.5MG/VIAL	N020517	001	Dec 22, 1995
	+		30MG/VIAL	N020517	002	May 30, 1997

PRESCRIPTION DRUG PRODUCT LIST

3 - 247 (of 428)

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LUPRON DEPOT

ABBOTT ENDOCRINE	45MG/VIAL	N020517	003	Jun 17, 2011
LUPRON DEPOT-PED				
+ ABBOTT ENDOCRINE	7.5MG/VIAL	N020263	002	Apr 16, 1993
+	11.25MG/VIAL	N020263	005	Jan 21, 1994
+	11.25MG/VIAL	N020263	007	Aug 15, 2011
+	15MG/VIAL	N020263	006	Jan 21, 1994
+	30MG/VIAL	N020263	008	Aug 15, 2011

INJECTABLE; SUBCUTANEOUS
ELIGARD

+ TOLMAR THERAP	7.5MG/VIAL	N021343	001	Jan 23, 2002
+	22.5MG/VIAL	N021379	001	Jul 24, 2002
+	30MG/VIAL	N021488	001	Feb 13, 2003
+	45MG/VIAL	N021731	001	Dec 14, 2004

LEUPROLIDE ACETATE; NORETHINDRONE ACETATE

INJECTABLE, TABLET; INJECTION, ORAL
LUPANETA PACK

ABBVIE ENDOCRINE	3.75MG/VIAL, N/A; N/A, 5MG	N203696	001	Dec 14, 2012
+	11.25MG/VIAL, N/A; N/A, 5MG	N203696	002	Dec 14, 2012

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

<u>AN</u>	DEY	<u>EQ 0.25% BASE</u>	<u>A078309</u>	<u>001</u>	Mar 20, 2009
<u>AN</u>	WATSON LABS INC	<u>EQ 0.0103% BASE</u>	<u>A077756</u>	<u>003</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A077756</u>	<u>001</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A077756</u>	<u>002</u>	Apr 09, 2008
<u>XOPENEX</u>					
<u>AN</u>	+ SUNOVION	<u>EQ 0.0103% BASE</u>	<u>N020837</u>	<u>003</u>	Jan 30, 2002
<u>AN</u>	+	<u>EQ 0.021% BASE</u>	<u>N020837</u>	<u>001</u>	Mar 25, 1999
<u>AN</u>	+	<u>EQ 0.042% BASE</u>	<u>N020837</u>	<u>002</u>	Mar 25, 1999
<u>AN</u>	+	<u>EQ 0.25% BASE</u>	<u>N020837</u>	<u>004</u>	Jul 18, 2003

LEVALBUTEROL TARTRATE

AEROSOL, METERED; INHALATION
XOPENEX HFA

+ SUNOVION	EQ 0.045MG BASE/INH	N021730	001	Mar 11, 2005

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

KEPPRA

<u>AP</u>	+ UCB INC	<u>500MG/5ML (100MG/ML)</u>	<u>N021872</u>	<u>001</u>	Jul 31, 2006
<u>LEVETIRACETAM</u>					
<u>AP</u>	FRESENIUS KABI USA	<u>500MG/5ML (100MG/ML)</u>	<u>A090813</u>	<u>001</u>	May 26, 2010
<u>AP</u>	HIKMA FARMACEUTICA	<u>500MG/5ML (100MG/ML)</u>	<u>A090981</u>	<u>001</u>	Oct 13, 2011
<u>AP</u>	HOSPIRA INC	<u>500MG/ML (100MG/ML)</u>	<u>A202869</u>	<u>001</u>	Apr 06, 2012
<u>AP</u>	LUITPOLD	<u>500MG/5ML (100MG/ML)</u>	<u>A202143</u>	<u>001</u>	Jan 31, 2012
<u>AP</u>	SUN PHARM INDS LTD	<u>500MG/5ML (100MG/ML)</u>	<u>A090754</u>	<u>001</u>	Jun 16, 2010
<u>AP</u>	X GEN PHARMS	<u>500MG/5ML (100MG/ML)</u>	<u>A091485</u>	<u>001</u>	Aug 05, 2011
LEVETIRACETAM IN SODIUM CHLORIDE					
+	HQ SPECIALITY PHARMA	500MG/100ML (5MG/ML)	N202543	001	Nov 09, 2011
+		1000MG/100ML (10MG/ML)	N202543	002	Nov 09, 2011
+		1500MG/100ML (15MG/ML)	N202543	003	Nov 09, 2011

SOLUTION; ORAL

KEPPRA

<u>AA</u>	+ UCB INC	<u>100MG/ML</u>	<u>N021505</u>	<u>001</u>	Jul 15, 2003
<u>LEVETIRACETAM</u>					
<u>AA</u>	ACTAVIS MID ATLANTIC	<u>100MG/ML</u>	<u>A078976</u>	<u>001</u>	Jan 15, 2009
<u>AA</u>	AMNEAL PHARMS	<u>100MG/ML</u>	<u>A090992</u>	<u>001</u>	Oct 27, 2009

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 248 (of 428)

LEVETIRACETAM

SOLUTION; ORAL

LEVETIRACETAM

<u>AA</u>	APOTEX	<u>100MG/ML</u>	<u>A090187</u>	<u>001</u>	Aug 05, 2011
<u>AA</u>	AUROBINDO PHARM	<u>100MG/ML</u>	<u>A079063</u>	<u>001</u>	Jan 15, 2009
<u>AA</u>	CYPRESS PHARM	<u>100MG/ML</u>	<u>A079120</u>	<u>001</u>	Jan 16, 2009
<u>AA</u>	HI-TECH PHARMACAL	<u>100MG/ML</u>	<u>A090601</u>	<u>001</u>	Feb 28, 2012
<u>AA</u>	LUPIN LTD	<u>100MG/ML</u>	<u>A090893</u>	<u>001</u>	Oct 17, 2011
<u>AA</u>	ROXANE	<u>100MG/ML</u>	<u>A078582</u>	<u>001</u>	Jan 15, 2009
<u>AA</u>	SILARX	<u>100MG/ML</u>	<u>A090263</u>	<u>001</u>	Apr 03, 2009
<u>AA</u>	TARO	<u>100MG/ML</u>	<u>A078774</u>	<u>001</u>	Feb 10, 2009
<u>AA</u>	TOLMAR	<u>100MG/ML</u>	<u>A079107</u>	<u>001</u>	Jan 15, 2009
<u>AA</u>	TRIS PHARMA INC	<u>100MG/ML</u>	<u>A090461</u>	<u>001</u>	Sep 30, 2010
<u>AA</u>	VINTAGE PHARMS	<u>100MG/ML</u>	<u>A090079</u>	<u>001</u>	Apr 11, 2012
<u>AA</u>	WOCKHARDT	<u>100MG/ML</u>	<u>A090028</u>	<u>001</u>	Mar 03, 2010

TABLET; ORAL

KEPPRA

<u>AB</u>	UCB INC	<u>250MG</u>	<u>N021035</u>	<u>001</u>	Nov 30, 1999
<u>AB</u>		<u>500MG</u>	<u>N021035</u>	<u>002</u>	Nov 30, 1999
<u>AB</u>		<u>750MG</u>	<u>N021035</u>	<u>003</u>	Nov 30, 1999
<u>AB</u>	+	<u>1GM</u>	<u>N021035</u>	<u>004</u>	Jan 06, 2006

LEVETIRACETAM

<u>AB</u>	ACCORD HLTHCARE	<u>250MG</u>	<u>A090843</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>		<u>500MG</u>	<u>A090843</u>	<u>002</u>	Feb 14, 2011
<u>AB</u>		<u>750MG</u>	<u>A090843</u>	<u>003</u>	Feb 14, 2011
<u>AB</u>		<u>1GM</u>	<u>A090843</u>	<u>004</u>	Feb 14, 2011
<u>AB</u>	AJANTA PHARMA	<u>250MG</u>	<u>A201293</u>	<u>001</u>	Jun 14, 2011
<u>AB</u>		<u>500MG</u>	<u>A201293</u>	<u>002</u>	Jun 14, 2011
<u>AB</u>		<u>750MG</u>	<u>A201293</u>	<u>003</u>	Jun 14, 2011
<u>AB</u>		<u>1GM</u>	<u>A201293</u>	<u>004</u>	Jun 14, 2011
<u>AB</u>	APOTEX INC	<u>250MG</u>	<u>A078869</u>	<u>001</u>	Mar 13, 2009
<u>AB</u>		<u>500MG</u>	<u>A078869</u>	<u>002</u>	Mar 13, 2009
<u>AB</u>		<u>750MG</u>	<u>A078869</u>	<u>003</u>	Mar 13, 2009
<u>AB</u>		<u>1GM</u>	<u>A078869</u>	<u>004</u>	Mar 13, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>250MG</u>	<u>A078993</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078993</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078993</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078993</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	BOCA PHARMA	<u>250MG</u>	<u>A077319</u>	<u>001</u>	Mar 20, 2009
<u>AB</u>		<u>500MG</u>	<u>A077319</u>	<u>002</u>	Mar 20, 2009
<u>AB</u>		<u>750MG</u>	<u>A077319</u>	<u>003</u>	Mar 20, 2009
<u>AB</u>	BRECKENRIDGE PHARM	<u>250MG</u>	<u>A090511</u>	<u>001</u>	Aug 18, 2011
<u>AB</u>		<u>500MG</u>	<u>A090511</u>	<u>002</u>	Aug 18, 2011
<u>AB</u>		<u>750MG</u>	<u>A090511</u>	<u>003</u>	Aug 18, 2011
<u>AB</u>		<u>1GM</u>	<u>A090511</u>	<u>004</u>	Aug 18, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>250MG</u>	<u>A076920</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A076920</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A076920</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078904</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>	HETERO DRUGS LTD	<u>250MG</u>	<u>A090515</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>500MG</u>	<u>A090515</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>750MG</u>	<u>A090515</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>1GM</u>	<u>A090515</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>	INVAGEN PHARMS	<u>250MG</u>	<u>A078234</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078234</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078234</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	LOTUS PHARM CO LTD	<u>500MG</u>	<u>A090906</u>	<u>001</u>	Nov 05, 2010
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A078154</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078154</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078154</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A090025</u>	<u>001</u>	Jan 15, 2009

PRESCRIPTION DRUG PRODUCT LIST

3 - 249 (of 428)

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

<u>AB</u>	METHAPHARM	<u>250MG</u>	<u>A090767</u>	<u>001</u>	Jul 28, 2010
<u>AB</u>		<u>500MG</u>	<u>A090767</u>	<u>002</u>	Jul 28, 2010
<u>AB</u>		<u>750MG</u>	<u>A090767</u>	<u>003</u>	Jul 28, 2010
<u>AB</u>		<u>1GM</u>	<u>A090767</u>	<u>004</u>	Jul 28, 2010
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A076919</u>	<u>001</u>	Nov 04, 2008
<u>AB</u>		<u>500MG</u>	<u>A076919</u>	<u>002</u>	Nov 04, 2008
<u>AB</u>		<u>750MG</u>	<u>A076919</u>	<u>003</u>	Nov 04, 2008
<u>AB</u>		<u>1GM</u>	<u>A090261</u>	<u>001</u>	Dec 08, 2009
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A078526</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078526</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078526</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A090484</u>	<u>001</u>	Aug 05, 2010
<u>AB</u>	ROXANE	<u>250MG</u>	<u>A078042</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078042</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078042</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078042</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A077324</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A077324</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A077324</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A077324</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	SOLCO HLTHCARE	<u>250MG</u>	<u>A078106</u>	<u>001</u>	Feb 10, 2009
<u>AB</u>		<u>500MG</u>	<u>A078106</u>	<u>002</u>	Feb 10, 2009
<u>AB</u>		<u>750MG</u>	<u>A078106</u>	<u>003</u>	Feb 10, 2009
<u>AB</u>		<u>1GM</u>	<u>A078106</u>	<u>004</u>	Feb 10, 2009
<u>AB</u>	TARO	<u>250MG</u>	<u>A078960</u>	<u>004</u>	Feb 01, 2010
<u>AB</u>		<u>500MG</u>	<u>A078960</u>	<u>003</u>	Feb 01, 2010
<u>AB</u>		<u>750MG</u>	<u>A078960</u>	<u>002</u>	Feb 01, 2010
<u>AB</u>		<u>1GM</u>	<u>A078960</u>	<u>001</u>	Feb 01, 2010
<u>AB</u>	TEVA PHARMS	<u>250MG</u>	<u>A078101</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078101</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078101</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078101</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	TORRENT PHARMS	<u>250MG</u>	<u>A078858</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078858</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078858</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078858</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	VINTAGE PHARMS	<u>250MG</u>	<u>A091491</u>	<u>001</u>	Dec 14, 2010
<u>AB</u>		<u>500MG</u>	<u>A091491</u>	<u>002</u>	Dec 14, 2010
<u>AB</u>		<u>750MG</u>	<u>A091491</u>	<u>003</u>	Dec 14, 2010
<u>AB</u>		<u>1GM</u>	<u>A091491</u>	<u>004</u>	Dec 14, 2010
<u>AB</u>	WATSON LABS INC	<u>250MG</u>	<u>A078797</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078797</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078797</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078797</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A079042</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A079042</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A079042</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A079042</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>250MG</u>	<u>A078918</u>	<u>001</u>	Apr 29, 2009
<u>AB</u>		<u>1GM</u>	<u>A078918</u>	<u>002</u>	Apr 29, 2009

TABLET, EXTENDED RELEASE; ORAL

KEPPRA XR

<u>AB</u>	UCB INC	<u>500MG</u>	<u>N022285</u>	<u>001</u>	Sep 12, 2008
<u>AB</u>	+	<u>750MG</u>	<u>N022285</u>	<u>002</u>	Feb 12, 2009
	<u>LEVETIRACETAM</u>				
<u>AB</u>	ACTAVIS ELIZABETH	<u>500MG</u>	<u>A091557</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091557</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	ANCHEN PHARMS	<u>500MG</u>	<u>A091360</u>	<u>001</u>	Oct 04, 2011

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 250 (of 428)

LEVETIRACETAM

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

<u>AB</u>	ANCHEN PHARMS	<u>750MG</u>	<u>A091360</u>	<u>002</u>	Oct 04, 2011
<u>AB</u>	APOTEX INC	<u>500MG</u>	<u>A091261</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091261</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	BOCA PHARMA	<u>500MG</u>	<u>A201464</u>	<u>001</u>	May 25, 2012
<u>AB</u>		<u>750MG</u>	<u>A201464</u>	<u>002</u>	May 25, 2012
<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A091399</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091399</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	MUTUAL PHARM CO INC	<u>500MG</u>	<u>A091285</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091285</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>500MG</u>	<u>A200475</u>	<u>001</u>	Dec 19, 2011
<u>AB</u>		<u>750MG</u>	<u>A200475</u>	<u>002</u>	Dec 19, 2011
<u>AB</u>	PAR PHARM	<u>500MG</u>	<u>A091291</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091291</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	ROUSES POINT PHARMS	<u>500MG</u>	<u>A202524</u>	<u>001</u>	Aug 27, 2012
<u>AB</u>		<u>750MG</u>	<u>A202524</u>	<u>002</u>	Aug 27, 2012
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A091668</u>	<u>001</u>	Nov 01, 2012
<u>AB</u>		<u>750MG</u>	<u>A091668</u>	<u>002</u>	Nov 01, 2012
<u>AB</u>	TEVA PHARMS	<u>500MG</u>	<u>A091430</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091430</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	TORRENT PHARMS LTD	<u>500MG</u>	<u>A091338</u>	<u>001</u>	May 29, 2012
<u>AB</u>		<u>750MG</u>	<u>A091338</u>	<u>002</u>	May 29, 2012
<u>AB</u>	VINTAGE PHARMS LLC	<u>500MG</u>	<u>A202533</u>	<u>001</u>	Jul 20, 2012
<u>AB</u>		<u>750MG</u>	<u>A202533</u>	<u>002</u>	Jul 20, 2012
<u>AB</u>	WATSON LABS FLORIDA	<u>500MG</u>	<u>A091093</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091093</u>	<u>002</u>	Sep 12, 2011

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKBETA

<u>AT</u>	AKORN	<u>0.25%</u>	<u>A074779</u>	<u>001</u>	Oct 29, 1996
<u>AT</u>		<u>0.5%</u>	<u>A074780</u>	<u>001</u>	Oct 29, 1996

BETAGAN

<u>AT</u>	+ ALLERGAN	<u>0.25%</u>	<u>N019814</u>	<u>001</u>	Jun 28, 1989
<u>AT</u>	+	<u>0.5%</u>	<u>N019219</u>	<u>002</u>	Dec 19, 1985

LEVOBUNOLOL HYDROCHLORIDE

<u>AT</u>	BAUSCH AND LOMB	<u>0.25%</u>	<u>A074307</u>	<u>001</u>	Mar 04, 1994
<u>AT</u>		<u>0.5%</u>	<u>A074326</u>	<u>001</u>	Mar 04, 1994
<u>AT</u>	FALCON PHARMS	<u>0.25%</u>	<u>A074851</u>	<u>001</u>	Oct 28, 1996
<u>AT</u>		<u>0.5%</u>	<u>A074850</u>	<u>001</u>	Oct 28, 1996
<u>AT</u>	NOVEX	<u>0.25%</u>	<u>A075473</u>	<u>001</u>	Aug 03, 2000
<u>AT</u>		<u>0.5%</u>	<u>A075475</u>	<u>001</u>	Aug 03, 2000

LEVOCARNITINE

INJECTABLE; INJECTION

CARNITOR

<u>AP</u>	+ SIGMA TAU	<u>200MG/ML</u>	<u>N020182</u>	<u>001</u>	Dec 16, 1992

LEVOCARNITINE

<u>AP</u>	BEDFORD	<u>200MG/ML</u>	<u>A075567</u>	<u>001</u>	Mar 29, 2001
<u>AP</u>	LUITPOLD	<u>200MG/ML</u>	<u>A075861</u>	<u>001</u>	Jun 22, 2001
<u>AP</u>	TEVA PARENTERAL	<u>200MG/ML</u>	<u>A075881</u>	<u>001</u>	Mar 29, 2001

SOLUTION; ORAL

CARNITOR

<u>AA</u>	+ SIGMA TAU	<u>1GM/10ML</u>	<u>N019257</u>	<u>001</u>	Apr 10, 1986

CARNITOR SF

<u>AA</u>	SIGMA TAU	<u>1GM/10ML</u>	<u>N019257</u>	<u>002</u>	Mar 28, 2007

LEVOCARNITINE

<u>AA</u>	HI TECH PHARMA	<u>1GM/10ML</u>	<u>A077399</u>	<u>001</u>	Oct 25, 2007
<u>AA</u>	LYNE	<u>1GM/10ML</u>	<u>A076851</u>	<u>001</u>	Aug 10, 2004

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 251 (of 428)

LEVOCARNITINE

TABLET; ORAL

CARNITOR

<u>AB</u>	+	SIGMA TAU	<u>330MG</u>	<u>N018948</u>	<u>001</u>	Dec 27, 1985

LEVOCARNITINE

<u>AB</u>		COREPHARMA	<u>330MG</u>	<u>A076858</u>	<u>001</u>	Sep 20, 2004

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

<u>AA</u>		SYNTHON PHARMS	<u>2.5MG/5ML</u>	<u>A091263</u>	<u>001</u>	Nov 07, 2011

XYZAL

<u>AA</u>	+	UCB INC	<u>2.5MG/5ML</u>	<u>N022157</u>	<u>001</u>	Jan 28, 2008

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

<u>AB</u>		DR REDDYS LABS LTD	<u>5MG</u>	<u>A090392</u>	<u>001</u>	Feb 24, 2011

<u>AB</u>		GLENMARK GENERICS	<u>5MG</u>	<u>A090385</u>	<u>001</u>	Feb 24, 2011

<u>AB</u>		HETERO LABS LTD III	<u>5MG</u>	<u>A091264</u>	<u>001</u>	Jun 29, 2012

<u>AB</u>		SYNTHON PHARMS	<u>5MG</u>	<u>A090229</u>	<u>001</u>	Nov 26, 2010

<u>AB</u>		TEVA PHARMS	<u>5MG</u>	<u>A090199</u>	<u>001</u>	Aug 22, 2011

XYZAL

<u>AB</u>	+	UCB INC	<u>5MG</u>	<u>N022064</u>	<u>001</u>	May 25, 2007

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

<u>AP</u>	+	JANSSEN PHARMS	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>N020635</u>	<u>001</u>	Dec 20, 1996

<u>AP</u>	+		<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>N020635</u>	<u>004</u>	Dec 20, 1996

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	JANSSEN PHARMS	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>N020635</u>	<u>002</u>	Dec 20, 1996

<u>AP</u>	+		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>N020635</u>	<u>003</u>	Dec 20, 1996

<u>AP</u>	+		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>N020635</u>	<u>005</u>	Dec 20, 1996

LEVOFLOXACIN

<u>AP</u>		AKORN	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A091644</u>	<u>001</u>	Jun 20, 2011

<u>AP</u>			<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A091644</u>	<u>002</u>	Jun 20, 2011

<u>AP</u>		SAGENT PHARMS	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A200560</u>	<u>001</u>	Jun 20, 2011

<u>AP</u>			<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A200560</u>	<u>002</u>	Jun 20, 2011

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>		ACS DOBFAR INFO SA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A090343</u>	<u>001</u>	Jul 07, 2011

<u>AP</u>			<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A090343</u>	<u>002</u>	Jul 07, 2011

<u>AP</u>			<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A090343</u>	<u>003</u>	Jul 07, 2011

<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A091375</u>	<u>001</u>	Sep 16, 2011

<u>AP</u>			<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A091375</u>	<u>002</u>	Sep 16, 2011

<u>AP</u>			<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A091375</u>	<u>003</u>	Sep 16, 2011

SOLUTION; ORAL

LEVAQUIN

<u>AA</u>	+	JANSSEN PHARMS	<u>250MG/10ML</u>	<u>N021721</u>	<u>001</u>	Oct 21, 2004

LEVOFLOXACIN

<u>AA</u>		HI TECH PHARMA	<u>250MG/10ML</u>	<u>A091678</u>	<u>001</u>	Jun 20, 2011

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

<u>AT</u>		AKORN	<u>0.5%</u>	<u>A090268</u>	<u>001</u>	Dec 20, 2010

<u>AT</u>		APOTEX	<u>0.5%</u>	<u>A078282</u>	<u>001</u>	Dec 20, 2010

<u>AT</u>		HI TECH PHARMA	<u>0.5%</u>	<u>A076826</u>	<u>001</u>	Feb 10, 2011

<u>AT</u>		NEXUS PHARMS	<u>0.5%</u>	<u>A077700</u>	<u>001</u>	Dec 20, 2010

QUIXIN

<u>AT</u>	+	SANTEN	<u>0.5%</u>	<u>N021199</u>	<u>001</u>	Aug 18, 2000

IQUIX

	+	SANTEN	1.5%	N021571	001	Mar 01, 2004

TABLET; ORAL

LEVAQUIN

<u>AB</u>		JANSSEN PHARMS	<u>250MG</u>	<u>N020634</u>	<u>001</u>	Dec 20, 1996

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 252 (of 428)

LEVOFLOXACIN

TABLET; ORAL

LEVAQUIN

<u>AB</u>	JANSSEN PHARMS	<u>500MG</u>	<u>N020634</u>	<u>002</u>	Dec 20, 1996
<u>AB</u>	+	<u>750MG</u>	<u>N020634</u>	<u>003</u>	Sep 08, 2000
	<u>LEVOFLOXACIN</u>				
<u>AB</u>	APOTEX INC	<u>250MG</u>	<u>A090787</u>	<u>001</u>	Sep 29, 2011
<u>AB</u>		<u>500MG</u>	<u>A090787</u>	<u>002</u>	Sep 29, 2011
<u>AB</u>		<u>750MG</u>	<u>A090787</u>	<u>003</u>	Sep 29, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A201043</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A201043</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A201043</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	CIPLA LTD	<u>250MG</u>	<u>A076890</u>	<u>001</u>	Mar 30, 2012
<u>AB</u>		<u>500MG</u>	<u>A076890</u>	<u>002</u>	Mar 30, 2012
<u>AB</u>		<u>750MG</u>	<u>A076890</u>	<u>003</u>	Mar 30, 2012
<u>AB</u>	DR REDDYS LABS INC	<u>250MG</u>	<u>A076710</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A076710</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A076710</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	GLENMARK GENERICS	<u>250MG</u>	<u>A200250</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A200250</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A200250</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A078424</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A078424</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A078424</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	MACLEODS PHARMS LTD	<u>250MG</u>	<u>A200839</u>	<u>001</u>	Mar 22, 2012
<u>AB</u>		<u>500MG</u>	<u>A200839</u>	<u>002</u>	Mar 22, 2012
<u>AB</u>		<u>750MG</u>	<u>A200839</u>	<u>003</u>	Mar 22, 2012
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A076276</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A076276</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A077097</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A202200</u>	<u>001</u>	Jan 30, 2012
<u>AB</u>		<u>500MG</u>	<u>A202200</u>	<u>002</u>	Jan 30, 2012
<u>AB</u>		<u>750MG</u>	<u>A202200</u>	<u>003</u>	Jan 30, 2012
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A077438</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A077438</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A077438</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	TEVA	<u>250MG</u>	<u>A076361</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A076361</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A076361</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	TORRENT PHARMS	<u>250MG</u>	<u>A090722</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A090722</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A090722</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A090367</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A090367</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A090367</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>250MG</u>	<u>A077652</u>	<u>001</u>	Sep 07, 2012
<u>AB</u>		<u>500MG</u>	<u>A077652</u>	<u>002</u>	Sep 07, 2012
<u>AB</u>		<u>750MG</u>	<u>A077652</u>	<u>003</u>	Sep 07, 2012

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)

FUSILEV

+ SPECTRUM PHARMS EQ 50MG BASE/VIAL N020140 001 Mar 07, 2008

SOLUTION; IV (INFUSION)

FUSILEV

+ SPECTRUM PHARMS EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) N020140 002 Apr 29, 2011

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

<u>AP</u>	NOVOCOL	<u>0.05MG/ML; 2%</u>	<u>A084697</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

3 - 253 (of 428)

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

SCANDONEST L

<u>AP</u>	DEPROCO	<u>0.05MG/ML; 2%</u>	<u>A088388</u>	<u>001</u>	Oct 10, 1984

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

MIRENA

	+ BAYER HLTHCARE	52MG	N021225	001	Dec 06, 2000

TABLET; ORAL

LEVONORGESTREL

<u>AB</u>	PERRIGO R AND D	<u>0.75MG</u>	<u>A090740</u>	<u>001</u>	Dec 30, 2010

<u>AB</u>	+ WATSON LABS	<u>0.75MG</u>	<u>A078665</u>	<u>001</u>	Aug 28, 2009

<u>AB</u>		<u>0.75MG</u>	<u>A078666</u>	<u>001</u>	Jun 24, 2009

<u>AB</u>	WATSON LABS INC	<u>1.5MG</u>	<u>A200670</u>	<u>001</u>	Jul 12, 2012

PLAN B

<u>AB</u>	+ TEVA BRANDED PHARM	<u>0.75MG</u>	<u>N021045</u>	<u>002</u>	Aug 24, 2006

PLAN B ONE-STEP

<u>AB</u>	+ DURAMED	<u>1.5MG</u>	<u>N021998</u>	<u>001</u>	Jul 10, 2009

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

	ROXANE	2MG	A074278	001	Mar 31, 2000

LEVOTHYROXINE SODIUM**

Refer to Preface Section 1.8 Levothyroxine Sodium for amplifying information

CAPSULE; ORAL

TIROSINT

	INST BIOCHIMIQUE	0.013MG	N022121	001	Aug 01, 2007

	INSTITUT BIOCHIMIQUE	0.025MG	N021924	002	Oct 13, 2006

		0.05MG	N021924	003	Oct 13, 2006

		0.075MG	N021924	004	Oct 13, 2006

		0.088MG	N021924	010	Oct 02, 2009

		0.1MG	N021924	005	Oct 13, 2006

		0.112MG	N021924	008	Oct 02, 2009

		0.125MG	N021924	006	Oct 13, 2006

		0.137MG	N021924	009	Oct 02, 2009

+		0.15MG	N021924	007	Oct 13, 2006

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

	+ FRESENIUS KABI USA	100MCG/VIAL	N202231	001	Jun 24, 2011

	+	200MCG/VIAL	N202231	002	Jun 24, 2011

	+	500MCG/VIAL	N202231	003	Jun 24, 2011

TABLET; ORAL

LEVO-T

-->	ALARA PHARM	<u>--> AB1, AB2, AB3 0.025MG</u>	N021342	001	Mar 01, 2002

-->		<u>--> AB1, AB2, AB3 0.05MG</u>	N021342	002	Mar 01, 2002

-->		<u>--> AB1, AB2, AB3 0.075MG</u>	N021342	003	Mar 01, 2002

-->		<u>--> AB1, AB2, AB3 0.088MG</u>	N021342	004	Mar 01, 2002

-->		<u>--> AB1, AB2, AB3 0.1MG</u>	N021342	005	Mar 01, 2002

-->		<u>--> AB1, AB2, AB3 0.112MG</u>	N021342	006	Mar 01, 2002

-->		<u>--> AB1, AB2, AB3 0.125MG</u>	N021342	007	Mar 01, 2002

-->		<u>--> AB1, AB2, AB3 0.137MG</u>	N021342	012	Dec 08, 2003

-->		<u>--> AB1, AB2, AB3 0.15MG</u>	N021342	008	Mar 01, 2002

-->		<u>--> AB1, AB2, AB3 0.175MG</u>	N021342	009	Mar 01, 2002

-->		<u>--> AB1, AB2, AB3 0.2MG</u>	N021342	010	Mar 01, 2002

--> +		<u>--> AB1, AB2, AB3 0.3MG</u>	N021342	011	Mar 01, 2002

LEVOTHYROXINE SODIUM

-->	MERCK KGAA	<u>--> AB2, AB3 0.025MG</u>	A076752	001	Jun 16, 2005

-->		<u>--> AB2, AB3 0.05MG</u>	A076752	002	Jun 16, 2005

PRESCRIPTION DRUG PRODUCT LIST

3 - 254 (of 428)

LEVOTHYROXINE SODIUM**

Refer to Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL

LEVOTHYROXINE SODIUM

-->	MERCK KGAA	--> AB2,AB3 0.075MG	A076752	003	Jun 16, 2005
-->		--> AB2,AB3 0.088MG	A076752	004	Jun 16, 2005
-->		--> AB2,AB3 0.1MG	A076752	005	Jun 16, 2005
-->		--> AB2,AB3 0.112MG	A076752	006	Jun 16, 2005
-->		--> AB2,AB3 0.125MG	A076752	007	Jun 16, 2005
-->		--> AB2,AB3 0.15MG	A076752	008	Jun 16, 2005
-->		--> AB2,AB3 0.175MG	A076752	009	Jun 16, 2005
-->		--> AB2,AB3 0.2MG	A076752	010	Jun 16, 2005
-->		--> AB2,AB3 0.3MG	A076752	011	Jun 16, 2005
-->	MYLAN	--> AB1,AB2,AB3,AB4 0.025MG	A076187	001	Jun 05, 2002
-->		--> AB1,AB2,AB3,AB4 0.05MG	A076187	002	Jun 05, 2002
-->		--> AB1,AB2,AB3,AB4 0.075MG	A076187	003	Jun 05, 2002
-->		--> AB1,AB2,AB3,AB4 0.088MG	A076187	004	Jun 05, 2002
-->		--> AB1,AB2,AB3,AB4 0.1MG	A076187	005	Jun 05, 2002
-->		--> AB1,AB2,AB3,AB4 0.112MG	A076187	006	Jun 05, 2002
-->		--> AB1,AB2,AB3,AB4 0.125MG	A076187	007	Jun 05, 2002
-->		--> AB1,AB2,AB3,AB4 0.137MG	A076187	012	Dec 13, 2006
-->		--> AB1,AB2,AB3,AB4 0.15MG	A076187	008	Jun 05, 2002
-->		--> AB1,AB2,AB3,AB4 0.175MG	A076187	009	Jun 05, 2002
-->		--> AB1,AB2,AB3,AB4 0.2MG	A076187	010	Jun 05, 2002
-->		--> AB1,AB2,AB3,AB4 0.3MG	A076187	011	Jun 05, 2002
<u>LEVOXYL</u>					
-->	KING PHARMS	--> AB1,AB3 0.025MG	N021301	001	May 25, 2001
-->		--> AB1,AB3 0.05MG	N021301	002	May 25, 2001
-->		--> AB1,AB3 0.075MG	N021301	003	May 25, 2001
-->		--> AB1,AB3 0.088MG	N021301	004	May 25, 2001
-->		--> AB1,AB3 0.1MG	N021301	005	May 25, 2001
-->		--> AB1,AB3 0.112MG	N021301	006	May 25, 2001
-->		--> AB1,AB3 0.125MG	N021301	007	May 25, 2001
-->		--> AB1,AB3 0.137MG	N021301	008	May 25, 2001
-->		--> AB1,AB3 0.15MG	N021301	009	May 25, 2001
-->		--> AB1,AB3 0.175MG	N021301	010	May 25, 2001
--> +		--> AB1,AB3 0.2MG	N021301	011	May 25, 2001
<u>SYNTHROID</u>					
-->	ABBVIE	--> AB1,AB2 0.025MG	N021402	001	Jul 24, 2002
-->		--> AB1,AB2 0.05MG	N021402	002	Jul 24, 2002
-->		--> AB1,AB2 0.075MG	N021402	003	Jul 24, 2002
-->		--> AB1,AB2 0.088MG	N021402	004	Jul 24, 2002
-->		--> AB1,AB2 0.1MG	N021402	005	Jul 24, 2002
-->		--> AB1,AB2 0.112MG	N021402	006	Jul 24, 2002
-->		--> AB1,AB2 0.125MG	N021402	007	Jul 24, 2002
-->		--> AB1,AB2 0.137MG	N021402	008	Jul 24, 2002
-->		--> AB1,AB2 0.15MG	N021402	009	Jul 24, 2002
-->		--> AB1,AB2 0.175MG	N021402	010	Jul 24, 2002
-->		--> AB1,AB2 0.2MG	N021402	012	Jul 24, 2002
--> +		--> AB1,AB2 0.3MG	N021402	011	Jul 24, 2002
<u>UNITHROID</u>					
-->	STEVENS J	--> AB1,AB2,AB3 0.025MG	N021210	001	Aug 21, 2000
-->		--> AB1,AB2,AB3 0.05MG	N021210	002	Aug 21, 2000
-->		--> AB1,AB2,AB3 0.075MG	N021210	003	Aug 21, 2000
-->		--> AB1,AB2,AB3 0.088MG	N021210	004	Aug 21, 2000
-->		--> AB1,AB2,AB3 0.1MG	N021210	005	Aug 21, 2000
-->		--> AB1,AB2,AB3 0.112MG	N021210	006	Aug 21, 2000
-->		--> AB1,AB2,AB3 0.125MG	N021210	007	Aug 21, 2000
-->		--> AB1,AB2,AB3 0.137MG	N021210	012	Feb 08, 2008
-->		--> AB1,AB2,AB3 0.15MG	N021210	008	Aug 21, 2000
-->		--> AB1,AB2,AB3 0.175MG	N021210	009	Aug 21, 2000

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 255 (of 428)

LEVOTHYROXINE SODIUM**

Refer to Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL

UNITHROID

-->	STEVENS J	-->	AB1, AB2, AB3	0.2MG	N021210	010	Aug 21, 2000
--> +		-->	AB1, AB2, AB3	0.3MG	N021210	011	Aug 21, 2000

LEVOTHROID

<u>AB4</u>	LLOYD	<u>0.025MG</u>	<u>N021116</u>	<u>001</u>	Oct 24, 2002
<u>AB4</u>		<u>0.05MG</u>	<u>N021116</u>	<u>002</u>	Oct 24, 2002
<u>AB4</u>		<u>0.075MG</u>	<u>N021116</u>	<u>003</u>	Oct 24, 2002
<u>AB4</u>		<u>0.088MG</u>	<u>N021116</u>	<u>010</u>	Oct 24, 2002
<u>AB4</u>		<u>0.1MG</u>	<u>N021116</u>	<u>004</u>	Oct 24, 2002
<u>AB4</u>		<u>0.112MG</u>	<u>N021116</u>	<u>011</u>	Oct 24, 2002
<u>AB4</u>		<u>0.125MG</u>	<u>N021116</u>	<u>005</u>	Oct 24, 2002
<u>AB4</u>		<u>0.137MG</u>	<u>N021116</u>	<u>012</u>	Dec 07, 2004
<u>AB4</u>		<u>0.15MG</u>	<u>N021116</u>	<u>006</u>	Oct 24, 2002
<u>AB4</u>		<u>0.175MG</u>	<u>N021116</u>	<u>007</u>	Oct 24, 2002
<u>AB4</u>		<u>0.2MG</u>	<u>N021116</u>	<u>008</u>	Oct 24, 2002
<u>AB4</u> +		<u>0.3MG</u>	<u>N021116</u>	<u>009</u>	Oct 24, 2002

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

<u>AT</u>	+ FOUGERA	<u>5%</u>	<u>A080198</u>	<u>001</u>	
<u>AT</u>	NOVOCOL INC	<u>5%</u>	<u>A040911</u>	<u>001</u>	May 23, 2011
<u>AT</u>	TARO	<u>5%</u>	<u>A086724</u>	<u>001</u>	

PATCH; TOPICAL

LIDOCAINE

<u>AB</u>	WATSON LABS INC	<u>5%</u>	<u>A200675</u>	<u>001</u>	Aug 23, 2012

LIDODERM

<u>AB</u>	+ TEIKOKU PHARMA USA	<u>5%</u>	<u>N020612</u>	<u>001</u>	Mar 19, 1999

LIDOCAINE HYDROCHLORIDE

GEL; OPHTHALMIC

AKTEN

+	AKORN	3.5%	N022221	001	Oct 07, 2008

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>0.5%</u>	<u>A088328</u>	<u>001</u>	May 17, 1984
<u>AP</u>		<u>1%</u>	<u>A083158</u>	<u>001</u>	
<u>AP</u>		<u>1%</u>	<u>A088329</u>	<u>001</u>	May 17, 1984
<u>AP</u>		<u>2%</u>	<u>A040078</u>	<u>001</u>	Jun 23, 1995
<u>AP</u>		<u>2%</u>	<u>A083158</u>	<u>002</u>	
<u>AP</u>		<u>2%</u>	<u>A088294</u>	<u>001</u>	May 17, 1984
<u>AP</u>		<u>20%</u>	<u>A083158</u>	<u>003</u>	
<u>AP</u>	LUITPOLD	<u>1%</u>	<u>A080850</u>	<u>001</u>	
<u>AP</u>		<u>2%</u>	<u>A083198</u>	<u>001</u>	
<u>AP</u>	PFIZER	<u>0.5%</u>	<u>A091056</u>	<u>001</u>	Dec 08, 2010
<u>AP</u>		<u>0.5%</u>	<u>A091058</u>	<u>001</u>	Sep 30, 2010
<u>AP</u>		<u>1%</u>	<u>A091056</u>	<u>002</u>	Dec 08, 2010
<u>AP</u>		<u>1%</u>	<u>A091058</u>	<u>002</u>	Sep 30, 2010

LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>200MG/100ML</u>	<u>N019830</u>	<u>002</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>200MG/100ML</u>	<u>N018461</u>	<u>002</u>	

LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>400MG/100ML</u>	<u>N019830</u>	<u>003</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>400MG/100ML</u>	<u>N018461</u>	<u>003</u>	

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>400MG/100ML</u>	<u>N018388</u>	<u>002</u>	

LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>800MG/100ML</u>	<u>N019830</u>	<u>004</u>	Apr 08, 1992

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 256 (of 428)

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>800MG/100ML</u>	<u>N018461</u>	<u>004</u>	Feb 22, 1982

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>800MG/100ML</u>	<u>N018388</u>	<u>003</u>	Nov 05, 1982

LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER

<u>AP</u>	FRESENIUS KABI USA	<u>1%</u>	<u>A088586</u>	<u>001</u>	Jul 24, 1985

<u>AP</u>	HOSPIRA	<u>0.5%</u>	<u>A088325</u>	<u>001</u>	Jul 31, 1984

<u>AP</u>		<u>1%</u>	<u>A088299</u>	<u>001</u>	Jul 31, 1984

<u>AP</u>		<u>2%</u>	<u>A088327</u>	<u>001</u>	Jul 31, 1984

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	FRESENIUS KABI USA	<u>1%</u>	<u>A080404</u>	<u>002</u>	

<u>AP</u>		<u>2%</u>	<u>A080404</u>	<u>003</u>	

<u>AP</u>		<u>2%</u>	<u>N017584</u>	<u>001</u>	

<u>AP</u>		<u>4%</u>	<u>N017584</u>	<u>002</u>	

<u>AP</u>	HOSPIRA	<u>1%</u>	<u>A080408</u>	<u>001</u>	

<u>AP</u>		<u>1.5%</u>	<u>A080408</u>	<u>002</u>	

<u>AP</u>		<u>4%</u>	<u>A088295</u>	<u>001</u>	May 17, 1984

<u>AP</u>	INTL MEDICATION	<u>20%</u>	<u>N017702</u>	<u>001</u>	

<u>AP</u>	PFIZER	<u>2%</u>	<u>A090665</u>	<u>001</u>	Sep 27, 2010

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>1%</u>	<u>A040302</u>	<u>001</u>	Sep 28, 1998

<u>AP</u>		<u>2%</u>	<u>A040302</u>	<u>002</u>	Sep 28, 1998

LIDOPEN

<u>AP</u>	MERIDIAN MEDCL TECHN	<u>10%</u>	<u>N017549</u>	<u>001</u>	

XYLOCAINE

<u>AP</u>	+ FRESENIUS KABI USA	<u>0.5%</u>	<u>N006488</u>	<u>008</u>	

<u>AP</u>	+	<u>1%</u>	<u>N006488</u>	<u>007</u>	

<u>AP</u>	+	<u>1.5%</u>	<u>N006488</u>	<u>010</u>	

<u>AP</u>	+	<u>2%</u>	<u>N006488</u>	<u>002</u>	

XYLOCAINE 4% PRESERVATIVE FREE

<u>AP</u>	+ FRESENIUS KABI USA	<u>4%</u>	<u>N010417</u>	<u>001</u>	

XYLOCAINE PRESERVATIVE FREE

<u>AP</u>	+ FRESENIUS KABI USA	<u>1%</u>	<u>N016801</u>	<u>005</u>	Jan 19, 1988

<u>AP</u>	+	<u>2%</u>	<u>N016801</u>	<u>001</u>	

<u>AP</u>	+	<u>4%</u>	<u>N016801</u>	<u>002</u>	

<u>AP</u>	+	<u>10%</u>	<u>N016801</u>	<u>003</u>	

<u>AP</u>	+	<u>20%</u>	<u>N016801</u>	<u>004</u>	

INJECTABLE; SPINAL

LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%

	+ HOSPIRA	5%	A083914	001	

JELLY; TOPICAL

ANESTACON

<u>AT</u>	POLYMEDICA	<u>2%</u>	<u>A080429</u>	<u>001</u>	

LIDOCAINE HYDROCHLORIDE

<u>AT</u>	AKORN	<u>2%</u>	<u>A040433</u>	<u>001</u>	Feb 12, 2003

<u>AT</u>	HI TECH PHARMA	<u>2%</u>	<u>A040837</u>	<u>001</u>	Mar 23, 2011

<u>AT</u>	INTL MEDICATION	<u>2%</u>	<u>A086283</u>	<u>001</u>	

<u>AT</u>	TEVA PHARMS	<u>2%</u>	<u>A081318</u>	<u>001</u>	Apr 29, 1993

XYLOCAINE

<u>AT</u>	+ OAK PHARMS	<u>2%</u>	<u>N008816</u>	<u>001</u>	

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE

<u>AT</u>	HI TECH PHARMA	<u>2%</u>	<u>A040014</u>	<u>001</u>	Jul 10, 1995

<u>AT</u>	WOCKHARDT	<u>2%</u>	<u>A087872</u>	<u>001</u>	Nov 18, 1982

LIDOCAINE HYDROCHLORIDE VISCOUS

<u>AT</u>	VINTAGE	<u>2%</u>	<u>A040708</u>	<u>001</u>	Feb 27, 2007

LIDOCAINE VISCOUS

<u>AT</u>	ROXANE	<u>2%</u>	<u>A088802</u>	<u>001</u>	Apr 26, 1985

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 257 (of 428)

LIDOCAINE HYDROCHLORIDE

SOLUTION; ORAL			
<u>XYLOCAINE VISCOUS</u>			
<u>AT</u>	+ FRESenius KABI USA	<u>2%</u>	<u>N009470</u> <u>001</u>
SOLUTION; TOPICAL			
<u>LARYNG-O-JET KIT</u>			
<u>AT</u>	INTL MEDICATION	<u>4%</u>	<u>A086364</u> <u>001</u>
<u>LIDOCAINE HYDROCHLORIDE</u>			
<u>AT</u>	ROXANE	<u>4%</u>	<u>A088803</u> <u>001</u> Apr 03, 1985
<u>AT</u>	VINTAGE	<u>4%</u>	<u>A040710</u> <u>001</u> Feb 27, 2007
<u>AT</u>	WOCKHARDT	<u>4%</u>	<u>A087881</u> <u>001</u> Nov 18, 1982
<u>LTA II KIT</u>			
<u>AT</u>	HOSPIRA	<u>4%</u>	<u>A080409</u> <u>001</u>
<u>XYLOCAINE 4% PRESERVATIVE FREE</u>			
<u>AT</u>	+ FRESenius KABI USA	<u>4%</u>	<u>N010417</u> <u>002</u>

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL			
<u>EMLA</u>			
<u>AB</u>	+ OAK PHARMS	<u>2.5%;2.5%</u>	<u>N019941</u> <u>001</u> Dec 30, 1992
<u>LIDOCAINE AND PRILOCAINE</u>			
<u>AB</u>	FOUGERA PHARMS	<u>2.5%;2.5%</u>	<u>A076453</u> <u>001</u> Aug 18, 2003
<u>AB</u>	HI TECH PHARMA	<u>2.5%;2.5%</u>	<u>A076290</u> <u>001</u> Sep 25, 2003
<u>AB</u>	TOLMAR	<u>2.5%;2.5%</u>	<u>A076320</u> <u>001</u> Aug 27, 2003
GEL; PERIODONTAL			
ORAQIX			
	+ DENTSPLY PHARM	2.5%;2.5%	N021451 001 Dec 19, 2003

LIDOCAINE; TETRACAINE

CREAM; TOPICAL			
PLIAGLIS			
	+ GALDERMA LABS LP	7%;7%	N021717 001 Jun 29, 2006
PATCH; TOPICAL			
SYNERA			
	+ ZARS PHARM	70MG;70MG	N021623 001 Jun 23, 2005

LINACLOTIDE

CAPSULE; ORAL			
LINZESS			
	FOREST LABS INC	145MCG	N202811 001 Aug 30, 2012
	+	290MCG	N202811 002 Aug 30, 2012

LINAGLIPTIN

TABLET; ORAL			
TRADJENTA			
	+ BOEHRINGER INGELHEIM	5MG	N201280 001 May 02, 2011

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL			
JENTADUETO			
	BOEHRINGER INGELHEIM	2.5MG;500MG	N201281 001 Jan 30, 2012
		2.5MG;850MG	N201281 002 Jan 30, 2012
	+	2.5MG;1GM	N201281 003 Jan 30, 2012

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION			
LINCOCIN			
	+ PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N050317 001

PRESCRIPTION DRUG PRODUCT LIST

3 - 258 (of 428)

LINDANE

LOTION; TOPICAL

LINDANE

<u>AT</u>	OLTA PHARMS	<u>1%</u>	<u>A087313</u>	<u>001</u>	
<u>AT</u>	+ WOCHKHARDT	<u>1%</u>	<u>A088190</u>	<u>001</u>	Aug 16, 1984

SHAMPOO; TOPICAL

LINDANE

<u>AT</u>	OLTA PHARMS	<u>1%</u>	<u>A087266</u>	<u>001</u>	
<u>AT</u>	+ WOCHKHARDT	<u>1%</u>	<u>A088191</u>	<u>001</u>	Sep 18, 1984

LINEZOLID

FOR SUSPENSION; ORAL

ZYVOX

	+ PHARMACIA AND UPJOHN	100MG/5ML	N021132	001	Apr 18, 2000

INJECTABLE; INJECTION

LINEZOLID

<u>AP</u>	TEVA PHARMS	<u>200MG/100ML</u>	<u>A200222</u>	<u>001</u>	Jun 27, 2012

ZYVOX

<u>AP</u>	+ PHARMACIA AND UPJOHN	<u>200MG/100ML</u>	<u>N021131</u>	<u>001</u>	Apr 18, 2000

TABLET; ORAL

ZYVOX

	+ PHARMACIA AND UPJOHN	600MG	N021130	002	Apr 18, 2000

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION

LIOTHYRONINE SODIUM

<u>AP</u>	X GEN PHARMS	<u>EQ 0.01MG BASE/ML</u>	<u>A076923</u>	<u>001</u>	Aug 17, 2005

TRIOSTAT

<u>AP</u>	+ JHP PHARMS	<u>EQ 0.01MG BASE/ML</u>	<u>N020105</u>	<u>001</u>	Dec 31, 1991

TABLET; ORAL

CYTOMEL

<u>AB</u>	KING PHARMS	<u>EQ 0.005MG BASE</u>	<u>N010379</u>	<u>001</u>	

<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>N010379</u>	<u>002</u>	

<u>AB</u>	+	<u>EQ 0.05MG BASE</u>	<u>N010379</u>	<u>003</u>	

LIOTHYRONINE SODIUM

<u>AB</u>	COASTAL PHARMS	<u>EQ 0.005MG BASE</u>	<u>A090097</u>	<u>001</u>	Mar 20, 2009

<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>A090097</u>	<u>002</u>	Mar 20, 2009

<u>AB</u>		<u>EQ 0.05MG BASE</u>	<u>A090097</u>	<u>003</u>	Mar 20, 2009

<u>AB</u>	MYLAN	<u>EQ 0.005MG BASE</u>	<u>A090326</u>	<u>001</u>	Jul 14, 2009

<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>A090326</u>	<u>002</u>	Jul 14, 2009

<u>AB</u>		<u>EQ 0.05MG BASE</u>	<u>A090326</u>	<u>003</u>	Jul 14, 2009

<u>AB</u>	SIGMAPHARM LABS LLC	<u>EQ 0.005MG BASE</u>	<u>A200295</u>	<u>001</u>	Nov 29, 2012

<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>A200295</u>	<u>002</u>	Nov 29, 2012

<u>AB</u>		<u>EQ 0.05MG BASE</u>	<u>A200295</u>	<u>003</u>	Nov 29, 2012

LIOTRIX (T4;T3)

TABLET; ORAL

THYROLAR-0.25

	FOREST LABS	0.0125MG;0.0031MG	N016807	001	

THYROLAR-0.5

	FOREST LABS	0.025MG;0.0063MG	N016807	005	

THYROLAR-1

	FOREST LABS	0.05MG;0.0125MG	N016807	004	

THYROLAR-2

	FOREST LABS	0.1MG;0.025MG	N016807	002	

THYROLAR-3

	+ FOREST LABS	0.15MG;0.0375MG	N016807	003	

LIRAGLUTIDE RECOMBINANT

SOLUTION; SUBCUTANEOUS

VICTOZA

	+ NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 259 (of 428)

LISDEXAMFETAMINE DIMESYLATECAPSULE; ORAL
VYVANSE

SHIRE DEVELOPMENT

20MG

N021977

004

Dec 10, 2007

30MG

N021977

001

Feb 23, 2007

40MG

N021977

005

Dec 10, 2007

50MG

N021977

002

Feb 23, 2007

60MG

N021977

006

Dec 10, 2007

+

70MG

N021977

003

Feb 23, 2007

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB APOTEX INC

2.5MGA076102001

Sep 30, 2002

AB

5MGA076102002

Sep 30, 2002

AB

10MGA076102003

Sep 30, 2002

AB

20MGA076102004

Sep 30, 2002

AB

30MGA076102005

Sep 30, 2002

AB

40MGA076102006

Sep 30, 2002

AB

AUROBINDO

2.5MGA077622001

Feb 22, 2006

AB

5MGA077622002

Feb 22, 2006

AB

10MGA077622003

Feb 22, 2006

AB

20MGA077622004

Feb 22, 2006

AB

30MGA077622005

Feb 22, 2006

AB

40MGA077622006

Feb 22, 2006

AB

IVAX SUB TEVA PHARMS

2.5MGA075752001

Jul 01, 2002

AB

5MGA075752002

Jul 01, 2002

AB

10MGA075752003

Jul 01, 2002

AB

20MGA075752004

Jul 01, 2002

AB

30MGA075752005

Jul 01, 2002

AB

40MGA075752006

Jul 01, 2002

AB

LUPIN

2.5MGA077321001

Sep 09, 2005

AB

5MGA077321002

Sep 09, 2005

AB

10MGA077321003

Sep 09, 2005

AB

20MGA077321004

Sep 09, 2005

AB

30MGA077321005

Sep 09, 2005

AB

40MGA077321006

Sep 09, 2005

AB

MYLAN

2.5MGA076071001

Jul 01, 2002

AB

5MGA076071002

Jul 01, 2002

AB

10MGA076071003

Jul 01, 2002

AB

20MGA076071004

Jul 01, 2002

AB

30MGA076071005

Jul 01, 2002

AB

40MGA076071006

Jul 01, 2002

AB

PRINSTON INC

2.5MGA076180001

Jul 01, 2002

AB

5MGA076180002

Jul 01, 2002

AB

10MGA076180003

Jul 01, 2002

AB

20MGA076164001

Jul 01, 2002

AB

30MGA076164002

Jul 01, 2002

AB

40MGA076164003

Jul 01, 2002

AB

RANBAXY

2.5MGA075944001

Jul 01, 2002

AB

5MGA075944002

Jul 01, 2002

AB

10MGA075944003

Jul 01, 2002

AB

20MGA075944004

Jul 01, 2002

AB

30MGA075944006

Feb 11, 2003

AB

40MGA075944005

Jul 01, 2002

AB

SANDOZ

2.5MGA075903001

Jul 01, 2002

AB

2.5MGA075994001

Jul 01, 2002

AB

5MGA075903002

Jul 01, 2002

AB

5MGA075994002

Jul 01, 2002

AB

10MGA075903003

Jul 01, 2002

AB

10MGA075994003

Jul 01, 2002

PRESCRIPTION DRUG PRODUCT LIST

3 - 260 (of 428)

LISINOPRIL

TABLET; ORAL

LISINOPRIL

<u>AB</u>	<u>SANDOZ</u>	<u>20MG</u>	<u>A075903</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075994</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075903</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075994</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075903</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075994</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	<u>VINTAGE</u>	<u>2.5MG</u>	<u>A075743</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075743</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075743</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075743</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075743</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075743</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	<u>WATSON LABS</u>	<u>2.5MG</u>	<u>A076059</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076059</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076059</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076059</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076059</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076059</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	<u>WEST WARD</u>	<u>2.5MG</u>	<u>A076063</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076063</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076063</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076063</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076063</u>	<u>006</u>	Jun 27, 2003
<u>AB</u>		<u>40MG</u>	<u>A076063</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>	<u>WOCKHARDT</u>	<u>2.5MG</u>	<u>A078402</u>	<u>001</u>	Apr 19, 2007
<u>AB</u>		<u>5MG</u>	<u>A078402</u>	<u>002</u>	Apr 19, 2007
<u>AB</u>		<u>10MG</u>	<u>A078402</u>	<u>003</u>	Apr 19, 2007
<u>AB</u>		<u>20MG</u>	<u>A078402</u>	<u>004</u>	Apr 19, 2007
<u>AB</u>		<u>30MG</u>	<u>A078402</u>	<u>005</u>	Apr 19, 2007
<u>AB</u>		<u>40MG</u>	<u>A078402</u>	<u>006</u>	Apr 19, 2007
	<u>PRINIVIL</u>				
<u>AB</u>	<u>MERCK</u>	<u>5MG</u>	<u>N019558</u>	<u>001</u>	Dec 29, 1987
<u>AB</u>		<u>10MG</u>	<u>N019558</u>	<u>002</u>	Dec 29, 1987
<u>AB</u>		<u>20MG</u>	<u>N019558</u>	<u>003</u>	Dec 29, 1987
<u>AB</u>		<u>40MG</u>	<u>N019558</u>	<u>004</u>	Oct 25, 1988
	<u>ZESTRIL</u>				
<u>AB</u>	<u>ASTRAZENECA</u>	<u>2.5MG</u>	<u>N019777</u>	<u>005</u>	Apr 29, 1993
<u>AB</u>		<u>5MG</u>	<u>N019777</u>	<u>001</u>	May 19, 1988
<u>AB</u>		<u>10MG</u>	<u>N019777</u>	<u>002</u>	May 19, 1988
<u>AB</u>		<u>20MG</u>	<u>N019777</u>	<u>003</u>	May 19, 1988
<u>AB</u>		<u>30MG</u>	<u>N019777</u>	<u>006</u>	Jan 20, 1999
<u>AB</u>	<u>+</u>	<u>40MG</u>	<u>N019777</u>	<u>004</u>	May 19, 1988

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

<u>AB</u>	<u>ALEMBIC LTD</u>	<u>150MG</u>	<u>A079159</u>	<u>001</u>	Jan 12, 2009
<u>AB</u>		<u>300MG</u>	<u>A079159</u>	<u>002</u>	Jan 12, 2009
<u>AB</u>		<u>600MG</u>	<u>A079159</u>	<u>003</u>	Jan 12, 2009
<u>AB</u>	<u>APOTEX INC</u>	<u>300MG</u>	<u>A076795</u>	<u>001</u>	Nov 22, 2004
<u>AB</u>	<u>GLENMARK GENERICS</u>	<u>150MG</u>	<u>A079139</u>	<u>001</u>	Feb 03, 2009
<u>AB</u>		<u>300MG</u>	<u>A079139</u>	<u>002</u>	Feb 03, 2009
<u>AB</u>		<u>600MG</u>	<u>A079139</u>	<u>003</u>	Feb 03, 2009
<u>AB</u>	<u>HETERO DRUGS LTD</u>	<u>150MG</u>	<u>A090702</u>	<u>001</u>	Sep 25, 2009
<u>AB</u>		<u>300MG</u>	<u>A090702</u>	<u>002</u>	Sep 25, 2009
<u>AB</u>		<u>600MG</u>	<u>A090702</u>	<u>003</u>	Sep 25, 2009
<u>AB</u>	<u>ROXANE</u>	<u>150MG</u>	<u>N017812</u>	<u>002</u>	Jan 28, 1987
<u>AB</u>		<u>300MG</u>	<u>N017812</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

3 - 261 (of 428)

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

<u>AB</u>	+	ROXANE	<u>600MG</u>	<u>N017812</u>	<u>003</u>	Jan 28, 1987
<u>AB</u>		WEST WARD	<u>150MG</u>	<u>A076243</u>	<u>002</u>	Feb 24, 2003
<u>AB</u>			<u>300MG</u>	<u>A076243</u>	<u>001</u>	Jun 27, 2002
<u>AB</u>			<u>600MG</u>	<u>A078763</u>	<u>001</u>	Apr 15, 2008

TABLET; ORAL

LITHIUM CARBONATE

<u>AB</u>	+	ROXANE	<u>300MG</u>	<u>N018558</u>	<u>001</u>	Jan 29, 1982
<u>AB</u>		SUN PHARM INDS INC	<u>300MG</u>	<u>A091027</u>	<u>001</u>	Jun 24, 2010
<u>AB</u>		WEST WARD	<u>300MG</u>	<u>A078715</u>	<u>001</u>	Dec 28, 2010

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

<u>AB</u>		GLENMARK GENERICS	<u>300MG</u>	<u>A091544</u>	<u>001</u>	Dec 27, 2010
<u>AB</u>			<u>450MG</u>	<u>A091616</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>		MYLAN PHARMS INC	<u>300MG</u>	<u>A202288</u>	<u>001</u>	Jun 29, 2012
<u>AB</u>			<u>450MG</u>	<u>A202219</u>	<u>001</u>	Aug 08, 2012
<u>AB</u>		ROXANE	<u>300MG</u>	<u>A076832</u>	<u>001</u>	Oct 28, 2004
<u>AB</u>	+		<u>450MG</u>	<u>A076691</u>	<u>001</u>	Jan 05, 2004
<u>AB</u>		WEST WARD	<u>450MG</u>	<u>A076490</u>	<u>001</u>	Jun 17, 2003

LITHOBID

<u>AB</u>	+	NOVEN THERAP	<u>300MG</u>	<u>N018027</u>	<u>001</u>	

LITHIUM CITRATE

SYRUP; ORAL

LITHIUM CITRATE

<u>AA</u>	+	ROXANE	<u>EQ 300MG CARBONATE/5ML</u>	<u>N018421</u>	<u>001</u>	
<u>AA</u>		WOCKHARDT	<u>EQ 300MG CARBONATE/5ML</u>	<u>A070755</u>	<u>001</u>	May 21, 1986

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC

	+	ALCON	EQ 0.1% BASE	N020191	001	Sep 23, 1993

LOMITAPIDE MESYLATE

CAPSULE; ORAL

JUXTAPID

		AEGERION	EQ 5MG BASE	N203858	001	Dec 21, 2012
			EQ 10MG BASE	N203858	002	Dec 21, 2012
	+		EQ 20MG BASE	N203858	003	Dec 21, 2012

LOMUSTINE

CAPSULE; ORAL

CEENU

		BRISTOL MYERS SQUIBB	10MG	N017588	001	
			40MG	N017588	002	
	+		100MG	N017588	003	

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

IMODIUM

<u>AB</u>	+	MCNEIL CONS	<u>2MG</u>	<u>N017694</u>	<u>001</u>	

LOPERAMIDE HYDROCHLORIDE

<u>AB</u>		MYLAN	<u>2MG</u>	<u>A072741</u>	<u>001</u>	Sep 18, 1991
<u>AB</u>		TEVA	<u>2MG</u>	<u>A073192</u>	<u>001</u>	Apr 30, 1992

LOPINAVIR; RITONAVIR

CAPSULE; ORAL

KALETRA

	+	ABBVIE	133.3MG; 33.3MG	N021226	001	Sep 15, 2000

PRESCRIPTION DRUG PRODUCT LIST

3 - 262 (of 428)

LOPINAVIR; RITONAVIR

SOLUTION; ORAL
KALETRA

+ ABBVIE	80MG/ML;20MG/ML	N021251	001	Sep 15, 2000

TABLET; ORAL
KALETRA

ABBVIE	100MG;25MG	N021906	002	Nov 09, 2007
+	200MG;50MG	N021906	001	Oct 28, 2005

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA	AMNEAL PHARMS	2MG/ML	A091383	001	Dec 23, 2009
AA	HI-TECH PHARMA CO	2MG/ML	A200169	001	Jan 30, 2012
AA	PADDOCK LLC	2MG/ML	A079244	001	Apr 28, 2009
AA	PHARM ASSOC	2MG/ML	A090260	001	Jun 15, 2010

LORAZEPAM INTENSOL

AA	+ ROXANE	2MG/ML	A072755	001	Jun 28, 1991

INJECTABLE; INJECTION

ATIVAN

AP	+ BAXTER HLTHCARE CORP	2MG/ML	N018140	001	
AP	+	4MG/ML	N018140	002	

LORAZEPAM

AP	HOSPIRA	2MG/ML	A074243	001	Apr 12, 1994
AP		2MG/ML	A074282	001	May 27, 1994
AP		4MG/ML	A074243	002	Apr 12, 1994
AP		4MG/ML	A074282	002	May 27, 1994
AP	INTL MEDICATION SYS	2MG/ML	A076150	001	Nov 15, 2004
AP	TAYLOR	2MG/ML	A075025	001	Jul 23, 1998
AP	WATSON LABS	2MG/ML	A074276	001	Apr 15, 1994
AP		4MG/ML	A074276	002	Apr 15, 1994

LORAZEPAM PRESERVATIVE FREE

AP	BEDFORD LABS	2MG/ML	A077074	001	Jul 13, 2005
AP		4MG/ML	A077074	002	Jul 13, 2005

TABLET; ORAL

ATIVAN

AB	VALEANT INTL	0.5MG	N017794	001	
AB		1MG	N017794	002	
AB	+	2MG	N017794	003	

LORAZEPAM

AB	AMNEAL PHARMS	0.5MG	A078826	001	Jun 23, 2010
AB		1MG	A078826	002	Jun 23, 2010
AB		2MG	A078826	003	Jun 23, 2010
AB	EXCELLIUM	0.5MG	A078203	001	Jul 30, 2007
AB		1MG	A078203	002	Jul 30, 2007
AB		2MG	A078203	003	Jul 30, 2007
AB	IVAX SUB TEVA PHARMS	0.5MG	A077396	001	Dec 13, 2006
AB		1MG	A077396	002	Dec 13, 2006
AB		2MG	A077396	003	Dec 13, 2006
AB	MYLAN	0.5MG	A071589	001	Oct 13, 1987
AB		0.5MG	A077657	001	Mar 16, 2006
AB		1MG	A071590	001	Oct 13, 1987
AB		1MG	A077657	002	Mar 16, 2006
AB		2MG	A071591	001	Oct 13, 1987
AB		2MG	A077657	003	Mar 16, 2006
AB	RANBAXY	0.5MG	A076045	001	Aug 29, 2001
AB		1MG	A076045	002	Aug 29, 2001
AB		2MG	A076045	003	Aug 29, 2001
AB	SANDOZ	0.5MG	A071193	001	Apr 15, 1988
AB		0.5MG	A071403	001	Apr 21, 1987
AB		1MG	A071194	001	Apr 15, 1988

PRESCRIPTION DRUG PRODUCT LIST

3 - 263 (of 428)

LORAZEPAM

TABLET; ORAL				
<u>LORAZEPAM</u>				
<u>AB</u>	SANDOZ	<u>1MG</u>	<u>A071404</u>	<u>001</u> Apr 21, 1987
<u>AB</u>		<u>2MG</u>	<u>A071141</u>	<u>001</u> Apr 21, 1987
<u>AB</u>		<u>2MG</u>	<u>A071195</u>	<u>001</u> Apr 15, 1988
<u>AB</u>	VINTAGE PHARMS	<u>0.5MG</u>	<u>A077754</u>	<u>001</u> May 10, 2006
<u>AB</u>		<u>1MG</u>	<u>A077754</u>	<u>002</u> May 10, 2006
<u>AB</u>		<u>2MG</u>	<u>A077754</u>	<u>003</u> May 10, 2006
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A072926</u>	<u>001</u> Oct 31, 1991
<u>AB</u>		<u>1MG</u>	<u>A071118</u>	<u>001</u> Jul 24, 1986
<u>AB</u>		<u>1MG</u>	<u>A072927</u>	<u>001</u> Oct 31, 1991
<u>AB</u>		<u>2MG</u>	<u>A072928</u>	<u>001</u> Oct 31, 1991

LORCASERIN HYDROCHLORIDE

TABLET; ORAL				
BELVIQ				
	+ EISAI INC	10MG	N022529	001 Jun 27, 2012

LOSARTAN POTASSIUM

TABLET; ORAL				
<u>COZAAR</u>				
<u>AB</u>	MERCK	<u>25MG</u>	<u>N020386</u>	<u>001</u> Apr 14, 1995
<u>AB</u>		<u>50MG</u>	<u>N020386</u>	<u>002</u> Apr 14, 1995
<u>AB</u>	+	<u>100MG</u>	<u>N020386</u>	<u>003</u> Oct 13, 1998
<u>LOSARTAN POTASSIUM</u>				
<u>AB</u>	ACTAVIS INC	<u>25MG</u>	<u>A090382</u>	<u>001</u> Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090382</u>	<u>002</u> Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090382</u>	<u>003</u> Oct 06, 2010
<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A090428</u>	<u>001</u> Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090428</u>	<u>002</u> Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090428</u>	<u>003</u> Oct 06, 2010
<u>AB</u>	APOTEX CORP	<u>25MG</u>	<u>A090790</u>	<u>001</u> Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090790</u>	<u>002</u> Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090790</u>	<u>003</u> Oct 06, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A090083</u>	<u>001</u> Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090083</u>	<u>002</u> Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090083</u>	<u>003</u> Oct 06, 2010
<u>AB</u>	CADISTA PHARMS	<u>25MG</u>	<u>A201170</u>	<u>001</u> Sep 18, 2012
<u>AB</u>		<u>50MG</u>	<u>A201170</u>	<u>002</u> Sep 18, 2012
<u>AB</u>		<u>100MG</u>	<u>A201170</u>	<u>003</u> Sep 18, 2012
<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A078232</u>	<u>001</u> Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A078232</u>	<u>002</u> Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A078232</u>	<u>003</u> Oct 06, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>25MG</u>	<u>A202230</u>	<u>001</u> May 30, 2012
<u>AB</u>		<u>50MG</u>	<u>A202230</u>	<u>002</u> May 30, 2012
<u>AB</u>		<u>100MG</u>	<u>A202230</u>	<u>003</u> May 30, 2012
<u>AB</u>	MICRO LABS LTD INDIA	<u>25MG</u>	<u>A091541</u>	<u>001</u> Sep 24, 2012
<u>AB</u>		<u>50MG</u>	<u>A091541</u>	<u>002</u> Sep 24, 2012
<u>AB</u>		<u>100MG</u>	<u>A091541</u>	<u>003</u> Sep 24, 2012
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A091590</u>	<u>001</u> Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A091590</u>	<u>002</u> Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A091590</u>	<u>003</u> Oct 06, 2010
<u>AB</u>	PRINSTON INC	<u>25MG</u>	<u>A091497</u>	<u>001</u> Jun 06, 2011
<u>AB</u>		<u>50MG</u>	<u>A091497</u>	<u>002</u> Jun 06, 2011
<u>AB</u>		<u>100MG</u>	<u>A091497</u>	<u>003</u> Jun 06, 2011
<u>AB</u>	ROXANE	<u>25MG</u>	<u>A077459</u>	<u>001</u> Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A077459</u>	<u>002</u> Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A077459</u>	<u>003</u> Oct 06, 2010
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A077424</u>	<u>001</u> Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A077424</u>	<u>002</u> Oct 06, 2010

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 264 (of 428)

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A077424</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076958</u>	<u>001</u>	Apr 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A076958</u>	<u>002</u>	Apr 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A076958</u>	<u>003</u>	Apr 06, 2010
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A090467</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090467</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090467</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	UPSHER SMITH	<u>25MG</u>	<u>A090544</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090544</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090544</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A091129</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A091129</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A091129</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078243</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A078243</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A078243</u>	<u>003</u>	Oct 06, 2010

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC

LOTEMAX

+ BAUSCH AND LOMB 0.5% N202872 001 Sep 28, 2012

OINTMENT; OPHTHALMIC

LOTEMAX

+ BAUSCH AND LOMB 0.5% N200738 001 Apr 15, 2011

SUSPENSION/DROPS; OPHTHALMIC

ALREX

+ BAUSCH AND LOMB 0.2% N020803 001 Mar 09, 1998

LOTEMAX

+ BAUSCH AND LOMB 0.5% N020583 001 Mar 09, 1998

LOTEPREDNOL ETABONATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

+ BAUSCH AND LOMB 0.5%;0.3% N050804 001 Dec 14, 2004

LOVASTATIN

TABLET; ORAL

LOVASTATIN

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A075828</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075828</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075828</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A077748</u>	<u>001</u>	Feb 28, 2007
<u>AB</u>		<u>20MG</u>	<u>A077748</u>	<u>002</u>	Feb 28, 2007
<u>AB</u>		<u>40MG</u>	<u>A077748</u>	<u>003</u>	Feb 28, 2007
<u>AB</u>	CARLSBAD	<u>10MG</u>	<u>A075991</u>	<u>001</u>	Jun 05, 2002
<u>AB</u>		<u>20MG</u>	<u>A075991</u>	<u>002</u>	Jun 05, 2002
<u>AB</u>		<u>40MG</u>	<u>A075991</u>	<u>003</u>	Jun 05, 2002
<u>AB</u>	LUPIN	<u>10MG</u>	<u>A078296</u>	<u>001</u>	Mar 14, 2008
<u>AB</u>		<u>20MG</u>	<u>A078296</u>	<u>002</u>	Nov 01, 2007
<u>AB</u>		<u>40MG</u>	<u>A078296</u>	<u>003</u>	Nov 01, 2007
<u>AB</u>	MUTUAL PHARM	<u>10MG</u>	<u>A077520</u>	<u>001</u>	Apr 14, 2006
<u>AB</u>		<u>20MG</u>	<u>A077520</u>	<u>002</u>	Apr 14, 2006
<u>AB</u>		<u>40MG</u>	<u>A077520</u>	<u>003</u>	Apr 14, 2006
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A075451</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>10MG</u>	<u>A075935</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075451</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075935</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075451</u>	<u>003</u>	Dec 17, 2001

PRESCRIPTION DRUG PRODUCT LIST

3 - 265 (of 428)

LOVASTATIN

TABLET; ORAL					
<u>LOVASTATIN</u>					
<u>AB</u>	MYLAN	<u>40MG</u>	<u>A075935</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A075300</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>10MG</u>	<u>A075636</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075300</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075636</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075300</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075636</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>	TEVA	<u>10MG</u>	<u>A075551</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075551</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075551</u>	<u>001</u>	Dec 17, 2001
<u>MEVACOR</u>					
<u>AB</u>	MERCK	<u>20MG</u>	<u>N019643</u>	<u>003</u>	Aug 31, 1987
<u>AB</u>	+	<u>40MG</u>	<u>N019643</u>	<u>004</u>	Dec 14, 1988
TABLET, EXTENDED RELEASE; ORAL					
ALTOPREV					
	ANDRX LABS LLC	20MG	N021316	002	Jun 26, 2002
		40MG	N021316	003	Jun 26, 2002
	+	60MG	N021316	004	Jun 26, 2002

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL					
ADVICOR					
+	ABBVIE	20MG;500MG	N021249	001	Dec 17, 2001
+		20MG;750MG	N021249	002	Dec 17, 2001
+		20MG;1GM	N021249	003	Dec 17, 2001
+		40MG;1GM	N021249	004	Apr 27, 2006

LOXAPINE

POWDER; INHALATION					
ADASUVE					
+	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012

LOXAPINE SUCCINATE

CAPSULE; ORAL					
<u>LOXAPINE SUCCINATE</u>					
<u>AB</u>	LANNETT HOLDINGS INC	<u>EQ 5MG BASE</u>	<u>A090695</u>	<u>001</u>	Sep 26, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090695</u>	<u>002</u>	Sep 26, 2011
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A090695</u>	<u>003</u>	Sep 26, 2011
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090695</u>	<u>004</u>	Sep 26, 2011
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076762</u>	<u>001</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076762</u>	<u>002</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A076762</u>	<u>003</u>	Nov 01, 2004
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076762</u>	<u>004</u>	Nov 01, 2004
<u>AB</u>	WATSON LABS	<u>EQ 5MG BASE</u>	<u>A072204</u>	<u>001</u>	Jun 15, 1988
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A072205</u>	<u>001</u>	Jun 15, 1988
<u>AB</u>	+	<u>EQ 25MG BASE</u>	<u>A072206</u>	<u>001</u>	Jun 15, 1988
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A072062</u>	<u>001</u>	Jun 15, 1988

LUBIPROSTONE

CAPSULE; ORAL					
AMITIZA					
	SUCAMPO PHARMS	8MCG	N021908	002	Apr 29, 2008
+		24MCG	N021908	001	Jan 31, 2006

LUCINACTANT

SUSPENSION; INTRATRACHEAL					
SURFAXIN					
+	DISCOVERY LABS	8.5ML	N021746	001	Mar 06, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 266 (of 428)

LURASIDONE HYDROCHLORIDETABLET; ORAL
LATUDA

SUNOVION PHARMS INC	20MG	N200603	003	Dec 07, 2011
+	40MG	N200603	001	Oct 28, 2010
	80MG	N200603	002	Oct 28, 2010
	120MG	N200603	004	Apr 26, 2012

MAFENIDE ACETATECREAM; TOPICAL
SULFAMYLOX

+	MYLAN LLC	EQ 85MG BASE/GM	N016763	001	

FOR SOLUTION; TOPICAL
SULFAMYLOX

+	MYLAN LLC	5%	N019832	003	Jun 05, 1998

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

BAXTER HLTHCARE	32MG/100ML;128MG/100ML;234MG/100ML	N019047	001	Jun 15, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

+	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML	N019696	001	Sep 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML</u>	<u>N017378</u>	<u>001</u>	

PLASMA-LYTE A IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML</u>	<u>N017378</u>	<u>002</u>	Nov 22, 1982

ISOLYTE S IN PLASTIC CONTAINER

B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N019711	001	Sep 29, 1989

NORMOSOL-R IN PLASTIC CONTAINER

HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N017586	001	

SOLUTION; IRRIGATION

PHYSIOLYTE IN PLASTIC CONTAINER

B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N019024	001	Jun 08, 1984

PHYSIOSOL IN PLASTIC CONTAINER

HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N017637	002	Jul 08, 1982

MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SOLUTION; INJECTION

NORMOCARB HF 25

+	DIALYSIS SUPS	0.21GM/100ML;2.8GM/100ML;9.07GM/100ML	N021910	001	Jul 26, 2006

NORMOCARB HF 35

+	DIALYSIS SUPS	0.21GM/100ML;3.97GM/100ML;8.3GM/100ML	N021910	002	Jul 26, 2006

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE

<u>AP</u>	+	FRESENIUS KABI USA	<u>500MG/ML</u>	<u>N019316</u>	<u>001</u>	Sep 08, 1986
<u>AP</u>		HOSPIRA	<u>500MG/ML</u>	<u>A075151</u>	<u>001</u>	Apr 25, 2000

PRESCRIPTION DRUG PRODUCT LIST

3 - 267 (of 428)

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+	HOSPIRA	1GM/100ML	N020488	001	Jul 11, 1995
+		2GM/100ML	N020488	002	Jul 11, 1995

MAGNESIUM SULFATE IN PLASTIC CONTAINER

	HOSPIRA	2GM/50ML (40MG/ML)	N020309	003	Jan 26, 2007
+		4GM/50ML (80MG/ML)	N020309	002	Jun 24, 1994
+		4GM/100ML (40MG/ML)	N020309	001	Jun 24, 1994
		20GM/500ML (40MG/ML)	N020309	004	Jan 18, 1995
		40GM/1000ML (40MG/ML)	N020309	005	Jan 18, 1995

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION; ORAL

SUPREP BOWEL PREP KIT

+	BRAINTREE LABS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N022372	001	Aug 05, 2010

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

TIS-U-SOL

<u>AT</u>	BAXTER HLTHCARE	<u>20MG/100ML;40MG/100ML;6.25MG/100ML;800MG/100ML;8.75MG/100ML</u>	<u>N018508</u>	<u>001</u>	Feb 19, 1982

TIS-U-SOL IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>20MG/100ML;40MG/100ML;6.25MG/100ML;800MG/100ML;8.75MG/100ML</u>	<u>N018336</u>	<u>001</u>	

MALATHION

LOTION; TOPICAL

MALATHION

<u>AT</u>	MYLAN PHARMS INC	<u>0.5%</u>	<u>A078743</u>	<u>001</u>	Mar 06, 2009
<u>AT</u>	SUVEN LIFE	<u>0.5%</u>	<u>A091559</u>	<u>001</u>	May 23, 2012

OVIDE

<u>AT</u>	+ TARO PHARMS NORTH	<u>0.5%</u>	<u>N018613</u>	<u>001</u>	Aug 02, 1982

MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

	HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962	001	Jun 26, 1986

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

<u>AP</u>	B BRAUN	<u>10GM/100ML</u>	<u>N016080</u>	<u>002</u>	

MANNITOL 10% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>10GM/100ML</u>	<u>N020006</u>	<u>002</u>	Jul 26, 1993
<u>AP</u>	HOSPIRA	<u>10GM/100ML</u>	<u>N019603</u>	<u>002</u>	Jan 08, 1987

MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER

<u>AP</u>	B BRAUN	<u>10GM/100ML</u>	<u>N016080</u>	<u>006</u>	

MANNITOL 15%

<u>AP</u>	B BRAUN	<u>15GM/100ML</u>	<u>N016080</u>	<u>003</u>	

MANNITOL 15% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>15GM/100ML</u>	<u>N020006</u>	<u>003</u>	Jul 26, 1993
<u>AP</u>	HOSPIRA	<u>15GM/100ML</u>	<u>N019603</u>	<u>003</u>	Jan 08, 1990

MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%

<u>AP</u>	B BRAUN	<u>15GM/100ML</u>	<u>N016080</u>	<u>005</u>	

MANNITOL 20%

<u>AP</u>	B BRAUN	<u>20GM/100ML</u>	<u>N014738</u>	<u>001</u>	

<u>AP</u>		<u>20GM/100ML</u>	<u>N016080</u>	<u>004</u>	

MANNITOL 20% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>20GM/100ML</u>	<u>N020006</u>	<u>004</u>	Jul 26, 1993
<u>AP</u>	HOSPIRA	<u>20GM/100ML</u>	<u>N019603</u>	<u>004</u>	Jan 08, 1990

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 268 (of 428)

MANNITOL

INJECTABLE; INJECTION

MANNITOL 25%

AP	FRESENIUS KABI USA	12.5GM/50ML	A080677	001	
AP	HOSPIRA	12.5GM/50ML	N016269	006	Aug 25, 1994
AP	INTL MEDICATION	12.5GM/50ML	A083051	001	
AP	LUITPOLD	12.5GM/50ML	A087409	001	Jan 21, 1982

MANNITOL 5%

AP	B BRAUN	5GM/100ML	N016080	001	
<u>MANNITOL 5% IN PLASTIC CONTAINER</u>					
AP	B BRAUN	5GM/100ML	N020006	001	Jul 26, 1993
AP	HOSPIRA	5GM/100ML	N019603	001	Jan 08, 1987

MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%

AP	B BRAUN	5GM/100ML	N016080	007	
<u>OSMITROL 10% IN WATER</u>					
AP	BAXTER HLTHCARE	10GM/100ML	N013684	002	
<u>OSMITROL 10% IN WATER IN PLASTIC CONTAINER</u>					
AP	BAXTER HLTHCARE	10GM/100ML	N013684	006	
<u>OSMITROL 15% IN WATER</u>					
AP	BAXTER HLTHCARE	15GM/100ML	N013684	004	
<u>OSMITROL 15% IN WATER IN PLASTIC CONTAINER</u>					
AP	BAXTER HLTHCARE	15GM/100ML	N013684	008	
<u>OSMITROL 20% IN WATER</u>					
AP	BAXTER HLTHCARE	20GM/100ML	N013684	003	
<u>OSMITROL 20% IN WATER IN PLASTIC CONTAINER</u>					
AP	BAXTER HLTHCARE	20GM/100ML	N013684	007	
<u>OSMITROL 5% IN WATER</u>					
AP	BAXTER HLTHCARE	5GM/100ML	N013684	001	
<u>OSMITROL 5% IN WATER IN PLASTIC CONTAINER</u>					
AP	BAXTER HLTHCARE	5GM/100ML	N013684	005	

POWDER; INHALATION

ARIDOL KIT

+	PHARMAXIS LTD	N/A, 5MG, 10MG, 20MG, 40MG	N022368	001	Oct 05, 2010

SOLUTION; IRRIGATION

RESECTISOL IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML	N016772	002	

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

	HOSPIRA	540MG/100ML; 2.7GM/100ML	N018316	001	

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

MAPROTILINE HYDROCHLORIDE

	MYLAN	25MG	A072285	002	Oct 03, 1988
+		50MG	A072285	001	Oct 03, 1988
		75MG	A072285	003	Oct 03, 1988

MARAVIROC

TABLET; ORAL

SELZENTRY

	VIIV HLTHCARE	150MG	N022128	001	Aug 06, 2007
+		300MG	N022128	002	Aug 06, 2007

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

MEBENDAZOLE

+	TEVA PHARMS	100MG	A073580	001	Jan 04, 1995

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 269 (of 428)

MECASERMIN RECOMBINANTINJECTABLE; SUBCUTANEOUS
INCRELEX

+ IPSEN INC 40MG/4ML (10MG/ML) N021839 001 Aug 30, 2005

MECHLORETHAMINE HYDROCHLORIDEINJECTABLE; INJECTION
MUSTARGEN

+ LUNDBECK INC 10MG/VIAL N006695 001

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

<u>AA</u>	+	PFIZER	<u>12.5MG</u>	<u>N010721</u>	<u>006</u>	
<u>AA</u>	+		<u>25MG</u>	<u>N010721</u>	<u>004</u>	
<u>AA</u>	+		<u>50MG</u>	<u>N010721</u>	<u>001</u>	Jan 20, 1982

MECLIZINE HYDROCHLORIDE

<u>AA</u>		AMNEAL PHARMS	<u>12.5MG</u>	<u>A201451</u>	<u>001</u>	Feb 23, 2011
<u>AA</u>			<u>25MG</u>	<u>A201451</u>	<u>002</u>	Feb 23, 2011
<u>AA</u>			<u>50MG</u>	<u>A201451</u>	<u>003</u>	Feb 23, 2011
<u>AA</u>		EPIC PHARMA LLC	<u>12.5MG</u>	<u>A200294</u>	<u>001</u>	Apr 13, 2012
<u>AA</u>			<u>25MG</u>	<u>A200294</u>	<u>002</u>	Apr 13, 2012
<u>AA</u>		JUBILANT CADISTA	<u>12.5MG</u>	<u>A040659</u>	<u>001</u>	Jun 04, 2010
<u>AA</u>			<u>25MG</u>	<u>A040659</u>	<u>002</u>	Jun 04, 2010
<u>AA</u>		MYLAN PHARMS INC	<u>12.5MG</u>	<u>A202640</u>	<u>001</u>	Sep 17, 2012
<u>AA</u>			<u>25MG</u>	<u>A202640</u>	<u>002</u>	Sep 17, 2012
<u>AA</u>			<u>50MG</u>	<u>A202640</u>	<u>003</u>	Sep 17, 2012
<u>AA</u>		PAR PHARM	<u>12.5MG</u>	<u>A087127</u>	<u>001</u>	
<u>AA</u>			<u>25MG</u>	<u>A087128</u>	<u>001</u>	
<u>AA</u>			<u>50MG</u>	<u>A089674</u>	<u>001</u>	Mar 31, 1988
<u>AA</u>		SANDOZ	<u>12.5MG</u>	<u>A084843</u>	<u>002</u>	May 22, 1989
<u>AA</u>			<u>25MG</u>	<u>A084092</u>	<u>003</u>	May 22, 1989
<u>AA</u>		VINTAGE PHARMS	<u>12.5MG</u>	<u>A040179</u>	<u>001</u>	Jan 30, 1997
<u>AA</u>			<u>25MG</u>	<u>A040179</u>	<u>002</u>	Jan 30, 1997
<u>AA</u>		WATSON LABS	<u>25MG</u>	<u>A085740</u>	<u>001</u>	

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

<u>AB</u>		MYLAN	<u>EQ 50MG BASE</u>	<u>A071081</u>	<u>002</u>	Sep 03, 1986
<u>AB</u>	+		<u>EQ 100MG BASE</u>	<u>A071081</u>	<u>001</u>	Sep 03, 1986
<u>AB</u>		WATSON LABS	<u>EQ 50MG BASE</u>	<u>A071468</u>	<u>001</u>	Apr 15, 1987
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A071469</u>	<u>001</u>	Apr 15, 1987

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>150MG/ML</u>	<u>N020246</u>	<u>001</u>	Oct 29, 1992

MEDROXYPROGESTERONE ACETATE

<u>AB</u>		SANDOZ	<u>150MG/ML</u>	<u>A078711</u>	<u>001</u>	May 20, 2009
<u>AB</u>		TEVA PARENTERAL	<u>150MG/ML</u>	<u>A076553</u>	<u>001</u>	Jul 28, 2004

DEPO-PROVERA

+ PHARMACIA AND UPJOHN 400MG/ML N012541 003

INJECTABLE; SUBCUTANEOUS
DEPO-SUBQ PROVERA 104

+ PHARMACIA AND UPJOHN 104MG/0.65ML N021583 001 Dec 17, 2004

TABLET; ORAL

MEDROXYPROGESTERONE ACETATE

<u>AB</u>		BARR	<u>2.5MG</u>	<u>A040159</u>	<u>001</u>	Aug 09, 1996
<u>AB</u>			<u>5MG</u>	<u>A040159</u>	<u>002</u>	Aug 09, 1996
<u>AB</u>			<u>10MG</u>	<u>A040159</u>	<u>003</u>	Aug 09, 1996

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 270 (of 428)

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

PROVERAAB PHARMACIA AND UPJOHN 2.5MGN011839 001AB 5MGN011839 003AB + 10MGN011839 004

MEDROXYPROGESTERONE ACETATE

BP USL PHARMA 10MG

A088484 001 Jul 26, 1984

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACIDAB LUPIN LTD 250MGA091322 001 Jul 22, 2011AB MICRO LABS LTD 250MGA090562 001 Nov 19, 2010PONSTELAB + SHIONOGI INC 250MGN015034 003MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDEAB BARR 250MGA076392 001 Dec 29, 2003AB ROXANE 250MGA076523 001 Oct 01, 2004AB + SANDOZ 250MGA076175 001 Feb 20, 2002AB WEST WARD 250MGA077699 001 Apr 21, 2010MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACEAB + BRISTOL MYERS SQUIBB 40MG/MLN020264 001 Sep 10, 1993MEGESTROL ACETATEAB APOTEX INC 40MG/MLA077404 001 Feb 16, 2006AB PAR PHARM 40MG/MLA075671 001 Jul 25, 2001AB ROXANE 40MG/MLA075997 001 Feb 15, 2002AB TEVA PHARMS 40MG/MLA075681 001 May 05, 2003AB WOCKHARDT 40MG/MLA076721 001 Nov 01, 2004

MEGACE ES

+ PAR PHARM 125MG/ML

N021778 001 Jul 05, 2005

TABLET; ORAL

MEGESTROL ACETATEAB BARR 20MGA074621 002 Aug 16, 1996AB 40MGA074621 001 Nov 30, 1995AB PAR PHARM 20MGA072422 001 Aug 08, 1988AB + 40MGA072423 001 Aug 08, 1988AB ROXANE 20MGA074458 001 Sep 29, 1995AB 40MGA074458 002 Sep 29, 1995MELOXICAM

SUSPENSION; ORAL

MOBIC

+ BOEHRINGER INGELHEIM 7.5MG/5ML

N021530 001 Jun 01, 2004

TABLET; ORAL

MELOXICAMAB APOTEX INC 7.5MGA077882 001 Jul 20, 2006AB 15MGA077882 002 Jul 20, 2006AB AUROBINDO PHARMA 7.5MGA078008 001 Oct 02, 2006AB 15MGA078008 002 Oct 02, 2006AB BEIJING DOUBLE CRANE 7.5MGA078039 001 Dec 14, 2006AB 15MGA078039 002 Dec 14, 2006AB BRECKENRIDGE PHARM 7.5MGA077920 001 Jul 19, 2006AB 15MGA077920 002 Jul 19, 2006AB CARACO 7.5MGA077937 001 Jul 19, 2006

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 271 (of 428)

MELOXICAM

TABLET; ORAL

MELOXICAM

<u>AB</u>	CARACO	<u>15MG</u>	<u>A077937</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	CARLSBAD	<u>7.5MG</u>	<u>A077918</u>	<u>001</u>	Dec 07, 2006
<u>AB</u>		<u>15MG</u>	<u>A077918</u>	<u>002</u>	Dec 07, 2006
<u>AB</u>	COREPHARMA	<u>7.5MG</u>	<u>A077930</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077930</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	DR REDDYS LABS INC	<u>7.5MG</u>	<u>A077931</u>	<u>001</u>	Jul 25, 2006
<u>AB</u>		<u>15MG</u>	<u>A077931</u>	<u>002</u>	Jul 25, 2006
<u>AB</u>	GLENMARK GENERICS	<u>7.5MG</u>	<u>A077932</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077932</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	LUPIN PHARMS	<u>7.5MG</u>	<u>A077944</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077944</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	MYLAN	<u>7.5MG</u>	<u>A077923</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A077934</u>	<u>001</u>	Jul 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077923</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077934</u>	<u>002</u>	Jul 20, 2006
<u>AB</u>	PURACAP PHARM	<u>7.5MG</u>	<u>A077938</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077938</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	STRIDES ARCOLAB LTD	<u>7.5MG</u>	<u>A077928</u>	<u>001</u>	May 13, 2009
<u>AB</u>		<u>15MG</u>	<u>A077928</u>	<u>002</u>	May 13, 2009
<u>AB</u>	TARO	<u>7.5MG</u>	<u>A078102</u>	<u>001</u>	Nov 07, 2006
<u>AB</u>		<u>15MG</u>	<u>A078102</u>	<u>002</u>	Nov 07, 2006
<u>AB</u>	TEVA PHARMS	<u>7.5MG</u>	<u>A077936</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077936</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	UNICHEM	<u>7.5MG</u>	<u>A077927</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077927</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>	WATSON LABS	<u>7.5MG</u>	<u>A077929</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077929</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>7.5MG</u>	<u>A077921</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077921</u>	<u>002</u>	Jul 19, 2006
<u>MOBIC</u>					
<u>AB</u>	BOEHRINGER INGELHEIM	<u>7.5MG</u>	<u>N020938</u>	<u>001</u>	Apr 13, 2000
<u>AB</u>	+	<u>15MG</u>	<u>N020938</u>	<u>002</u>	Aug 23, 2000

MELPHALAN

TABLET; ORAL

ALKERAN

+ GLAXOSMITHKLINE 2MG

N014691 002

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

<u>AP</u>	+	GLAXOSMITHKLINE	<u>EQ 50MG BASE/VIAL</u>	<u>N020207</u>	<u>001</u>	Nov 18, 1992
<u>MELPHALAN HYDROCHLORIDE</u>						
<u>AP</u>		BEDFORD LABS	<u>EQ 50MG BASE/VIAL</u>	<u>A090303</u>	<u>001</u>	Oct 28, 2010
<u>AP</u>		BIONICHE PHARMA USA	<u>EQ 50MG BASE/VIAL</u>	<u>A090299</u>	<u>001</u>	Oct 27, 2009
<u>AP</u>		MYLAN INSTITUTIONAL	<u>EQ 50MG BASE/VIAL</u>	<u>A090270</u>	<u>001</u>	Jun 09, 2009

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NAMENDA XR

FOREST LABS 7MG

N022525 001 Jun 21, 2010

14MG

N022525 002 Jun 21, 2010

21MG

N022525 003 Jun 21, 2010

+ 28MG

N022525 004 Jun 21, 2010

SOLUTION; ORAL

NAMENDA

+ FOREST LABS 2MG/ML

N021627 001 Apr 18, 2005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 272 (of 428)

MEMANTINE HYDROCHLORIDETABLET; ORAL
NAMENDA

FOREST LABS	5MG	N021487	001	Oct 16, 2003
+	10MG	N021487	002	Oct 16, 2003

MENOTROPINS (FSH;LH)INJECTABLE; IM-SC
REPRONEX

+ FERRING	75 IU/VIAL;75 IU/VIAL	N021047	001	Aug 27, 1999

INJECTABLE; SUBCUTANEOUS
MENOPUR

+ FERRING	75 IU/VIAL;75 IU/VIAL	N021663	001	Oct 29, 2004

MEPENZOLATE BROMIDETABLET; ORAL
CANTIL

+ SANOFI AVENTIS US	25MG	N010679	003	

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

<u>AP</u>	<u>+</u>	<u>HOSPIRA</u>	<u>25MG/ML</u>	<u>N021171</u>	<u>001</u>	
<u>AP</u>	<u>+</u>		<u>50MG/ML</u>	<u>N021171</u>	<u>002</u>	
<u>AP</u>	<u>+</u>		<u>75MG/ML</u>	<u>N021171</u>	<u>003</u>	
<u>AP</u>	<u>+</u>		<u>100MG/ML</u>	<u>N021171</u>	<u>004</u>	

MEPERIDINE HYDROCHLORIDE

<u>AP</u>		<u>HIKMA MAPLE</u>	<u>25MG/ML</u>	<u>A080445</u>	<u>001</u>	
<u>AP</u>			<u>25MG/ML</u>	<u>A080455</u>	<u>007</u>	
<u>AP</u>			<u>50MG/ML</u>	<u>A080445</u>	<u>002</u>	
<u>AP</u>			<u>50MG/ML</u>	<u>A080455</u>	<u>008</u>	
<u>AP</u>			<u>75MG/ML</u>	<u>A080445</u>	<u>003</u>	
<u>AP</u>			<u>75MG/ML</u>	<u>A080455</u>	<u>009</u>	
<u>AP</u>			<u>100MG/ML</u>	<u>A080445</u>	<u>004</u>	
<u>AP</u>			<u>100MG/ML</u>	<u>A080455</u>	<u>010</u>	
<u>AP</u>		<u>WATSON LABS</u>	<u>50MG/ML</u>	<u>A073444</u>	<u>001</u>	Mar 17, 1992
<u>AP</u>			<u>100MG/ML</u>	<u>A073445</u>	<u>001</u>	Mar 17, 1992

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>		<u>HIKMA MAPLE</u>	<u>10MG/ML</u>	<u>A081002</u>	<u>001</u>	Jul 30, 1993
<u>AP</u>	<u>+</u>	<u>HOSPIRA</u>	<u>10MG/ML</u>	<u>A088432</u>	<u>001</u>	Aug 16, 1984
<u>AP</u>		<u>INTL MEDICATION</u>	<u>10MG/ML</u>	<u>A081309</u>	<u>001</u>	Aug 30, 1993
<u>AP</u>		<u>WATSON LABS</u>	<u>10MG/ML</u>	<u>A073443</u>	<u>001</u>	Mar 17, 1992

SYRUP; ORAL

MEPERIDINE HYDROCHLORIDE

+ ROXANE	50MG/5ML	A088744	001	Jan 30, 1985

TABLET; ORAL

DEMEROL

<u>AA</u>	<u>+</u>	<u>SANOFI AVENTIS US</u>	<u>50MG</u>	<u>N005010</u>	<u>001</u>	
<u>AA</u>	<u>+</u>		<u>100MG</u>	<u>N005010</u>	<u>004</u>	

MEPERIDINE HYDROCHLORIDE

<u>AA</u>		<u>BARR</u>	<u>50MG</u>	<u>A088639</u>	<u>001</u>	Jul 02, 1984
<u>AA</u>			<u>100MG</u>	<u>A088640</u>	<u>001</u>	Sep 19, 1984
<u>AA</u>		<u>CARACO</u>	<u>50MG</u>	<u>A040446</u>	<u>001</u>	Aug 08, 2002
<u>AA</u>			<u>100MG</u>	<u>A040446</u>	<u>002</u>	Aug 08, 2002
<u>AA</u>		<u>EPIC PHARMA</u>	<u>50MG</u>	<u>A040331</u>	<u>001</u>	May 28, 1999
<u>AA</u>			<u>100MG</u>	<u>A040331</u>	<u>002</u>	May 28, 1999
<u>AA</u>		<u>MALLINCKRODT</u>	<u>50MG</u>	<u>A040352</u>	<u>001</u>	Jun 13, 2000
<u>AA</u>			<u>100MG</u>	<u>A040352</u>	<u>002</u>	Jun 13, 2000
<u>AA</u>		<u>MIKART</u>	<u>50MG</u>	<u>A040893</u>	<u>001</u>	Jun 24, 2009
<u>AA</u>			<u>100MG</u>	<u>A040893</u>	<u>003</u>	Jun 24, 2009
<u>AA</u>		<u>ROXANE</u>	<u>50MG</u>	<u>A040110</u>	<u>001</u>	Mar 12, 1997

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 273 (of 428)

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

<u>AA</u>	ROXANE	<u>100MG</u>	<u>A040110</u>	<u>002</u>	Mar 12, 1997
<u>AA</u>	VINTAGE PHARMS	<u>50MG</u>	<u>A040191</u>	<u>001</u>	Dec 17, 1998
<u>AA</u>		<u>100MG</u>	<u>A040191</u>	<u>002</u>	Dec 17, 1998
<u>AA</u>	WATSON LABS	<u>50MG</u>	<u>A040186</u>	<u>001</u>	Jun 30, 1997
<u>AA</u>		<u>100MG</u>	<u>A040186</u>	<u>002</u>	Jun 30, 1997
<u>MEPERIDINE HYDROCHLORIDE</u>					
	MIKART	75MG	A040893	002	Jun 24, 2009
		150MG	A040893	004	Jun 24, 2009

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINE

<u>AP</u>	+	HOSPIRA	<u>1%</u>	<u>N012250</u>	<u>001</u>	
<u>AP</u>	+		<u>1.5%</u>	<u>N012250</u>	<u>005</u>	
<u>AP</u>	+		<u>2%</u>	<u>N012250</u>	<u>002</u>	

ISOCAINE HYDROCHLORIDE

<u>AP</u>	+	NOVOCOL	<u>3%</u>	<u>A080925</u>	<u>001</u>	

MEPIVACAINE HYDROCHLORIDE

<u>AP</u>		HOSPIRA INC	<u>3%</u>	<u>A040806</u>	<u>001</u>	Apr 28, 2008
<u>AP</u>		WATSON LABS	<u>1%</u>	<u>A088769</u>	<u>001</u>	Nov 20, 1984
<u>AP</u>			<u>2%</u>	<u>A088770</u>	<u>001</u>	Nov 20, 1984

POLOCAINE

<u>AP</u>		FRESENIUS KABI USA	<u>1%</u>	<u>A089407</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>			<u>2%</u>	<u>A089410</u>	<u>001</u>	Dec 01, 1986

POLOCAINE-MPF

<u>AP</u>		FRESENIUS KABI USA	<u>1%</u>	<u>A089406</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>			<u>1.5%</u>	<u>A089408</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>			<u>2%</u>	<u>A089409</u>	<u>001</u>	Dec 01, 1986

SCANDONEST PLAIN

<u>AP</u>	+	DEPROCO	<u>3%</u>	<u>A088387</u>	<u>001</u>	Oct 10, 1984

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

<u>AA</u>		ALEMBIC PHARMS LTD	<u>200MG</u>	<u>A090122</u>	<u>001</u>	Feb 18, 2009
<u>AA</u>			<u>400MG</u>	<u>A090122</u>	<u>002</u>	Feb 18, 2009
<u>AA</u>		INVAGEN PHARMS	<u>200MG</u>	<u>A040797</u>	<u>001</u>	Feb 27, 2008
<u>AA</u>			<u>400MG</u>	<u>A040797</u>	<u>002</u>	Feb 27, 2008
<u>AA</u>		TARO	<u>200MG</u>	<u>A200998</u>	<u>001</u>	May 23, 2011
<u>AA</u>			<u>400MG</u>	<u>A200998</u>	<u>002</u>	May 23, 2011
<u>AA</u>	+	WATSON LABS	<u>200MG</u>	<u>A083304</u>	<u>001</u>	
<u>AA</u>	+		<u>400MG</u>	<u>A083308</u>	<u>001</u>	

MERCAPTOPURINE

TABLET; ORAL

MERCAPTOPURINE

<u>AB</u>	MYLAN	<u>50MG</u>	<u>A040594</u>	<u>001</u>	Jul 01, 2005
<u>AB</u>	PROMETHEUS LABS	<u>50MG</u>	<u>A040461</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>	ROXANE	<u>50MG</u>	<u>A040528</u>	<u>001</u>	Feb 13, 2004
<u>PURINETHOL</u>					
AB +	TEVA	50MG	N009053	002	

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

<u>AP</u>		ACS DOBFAR	<u>500MG/VIAL</u>	<u>A091404</u>	<u>001</u>	Oct 26, 2011
<u>AP</u>			<u>1GM/VIAL</u>	<u>A091404</u>	<u>002</u>	Oct 26, 2011
<u>AP</u>		HOSPIRA INC	<u>500MG/VIAL</u>	<u>A090940</u>	<u>001</u>	Jun 22, 2010

PRESCRIPTION DRUG PRODUCT LIST

3 - 274 (of 428)

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

<u>AP</u>	HOSPIRA INC	<u>1GM/VIAL</u>	<u>A090940</u>	<u>002</u>	Jun 22, 2010
<u>AP</u>	SANDOZ	<u>500MG/VIAL</u>	<u>A091201</u>	<u>001</u>	Mar 29, 2011
<u>AP</u>		<u>1GM/VIAL</u>	<u>A091201</u>	<u>002</u>	Mar 29, 2011
<u>MERREM</u>					
<u>AP</u>	+ ASTRAZENECA	<u>500MG/VIAL</u>	<u>N050706</u>	<u>003</u>	Jun 21, 1996
<u>AP</u>	+	<u>1GM/VIAL</u>	<u>N050706</u>	<u>001</u>	Jun 21, 1996

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

APRISO

+	SALIX PHARMS	375MG	N022301	001	Oct 31, 2008
PENTASA					
	SHIRE	250MG	N020049	001	May 10, 1993
+		500MG	N020049	002	Jul 08, 2004

ENEMA; RECTAL

MESALAMINE

<u>AB</u>	PERRIGO ISRAEL	<u>4GM/60ML</u>	<u>A076751</u>	<u>001</u>	Sep 17, 2004
<u>AB</u>	TEVA	<u>4GM/60ML</u>	<u>A076841</u>	<u>001</u>	Sep 30, 2004
<u>ROWASA</u>					
<u>AB</u>	+ MEDA PHARMS	<u>4GM/60ML</u>	<u>N019618</u>	<u>001</u>	Dec 24, 1987
<u>SFLOWASA</u>					
<u>AB</u>	MEDA PHARMS	<u>4GM/60ML</u>	<u>N019618</u>	<u>002</u>	Jun 20, 2008
SUPPOSITORY; RECTAL					
CANASA					
	APTALIS PHARMA US	1GM	N021252	002	Nov 05, 2004
TABLET, DELAYED RELEASE; ORAL					
ASACOL					
+	WARNER CHILCOTT LLC	400MG	N019651	001	Jan 31, 1992
ASACOL HD					
+	WARNER CHILCOTT LLC	800MG	N021830	001	May 29, 2008
LIALDA					
+	SHIRE	1.2GM	N022000	001	Jan 16, 2007

MESNA

INJECTABLE; INTRAVENOUS

MESNA

<u>AP</u>	BEDFORD	<u>100MG/ML</u>	<u>A075739</u>	<u>001</u>	Jan 09, 2004
<u>AP</u>	FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A075811</u>	<u>001</u>	Apr 26, 2001
<u>AP</u>	MYLAN INSTITUTIONAL	<u>100MG/ML</u>	<u>A076488</u>	<u>001</u>	Mar 08, 2012
<u>AP</u>	SAGENT AGILA	<u>100MG/ML</u>	<u>A090913</u>	<u>001</u>	Apr 13, 2010
<u>AP</u>	TEVA PARENTERAL	<u>100MG/ML</u>	<u>A075764</u>	<u>001</u>	Apr 27, 2001

MESNEX

<u>AP</u>	+ BAXTER HLTHCARE	<u>100MG/ML</u>	<u>N019884</u>	<u>001</u>	Dec 30, 1988
TABLET; ORAL					
MESNEX					
+	BAXTER HLTHCARE	400MG	N020855	001	Mar 21, 2002

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28

NORINYL 1+50 28-DAY

+	WATSON LABS	0.05MG;1MG	N016659	001	

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

<u>AN</u>	+ DEY	<u>0.4%</u>	<u>A071786</u>	<u>001</u>	Aug 05, 1988
<u>AN</u>	+	<u>0.6%</u>	<u>A070804</u>	<u>001</u>	Aug 17, 1987
<u>AN</u>	NOVEX	<u>0.4%</u>	<u>A075402</u>	<u>001</u>	Feb 28, 2001
<u>AN</u>		<u>0.6%</u>	<u>A075403</u>	<u>001</u>	Feb 28, 2001

PRESCRIPTION DRUG PRODUCT LIST

3 - 275 (of 428)

METAPROTERENOL SULFATE

SOLUTION; INHALATION					
<u>METAPROTERENOL SULFATE</u>					
<u>AN</u>	WOCKHARDT	<u>0.4%</u>	<u>A075586</u>	<u>001</u>	May 30, 2002
<u>AN</u>		<u>0.6%</u>	<u>A075586</u>	<u>002</u>	May 30, 2002
SYRUP; ORAL					
<u>METAPROTERENOL SULFATE</u>					
<u>AA</u>	NOVEX	<u>10MG/5ML</u>	<u>A075235</u>	<u>001</u>	Jan 27, 2000
<u>AA</u>	+ SILARX	<u>10MG/5ML</u>	<u>A073632</u>	<u>001</u>	Jul 22, 1992
TABLET; ORAL					
<u>METAPROTERENOL SULFATE</u>					
<u>AB</u>	PAR PHARM	<u>10MG</u>	<u>A072024</u>	<u>001</u>	Jun 28, 1988
<u>AB</u>	+	<u>20MG</u>	<u>A072025</u>	<u>001</u>	Jun 28, 1988
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A073013</u>	<u>001</u>	Jan 31, 1991
<u>AB</u>		<u>20MG</u>	<u>A072795</u>	<u>001</u>	Jan 31, 1991

METARAMINOL BITARTRATE

INJECTABLE; INJECTION					
METARAMINOL BITARTRATE					
	+ FRESINIUS KABI USA	EQ 10MG BASE/ML	A080722	001	

METAXALONE

TABLET; ORAL					
<u>METAXALONE</u>					
<u>AB</u>	SANDOZ	<u>800MG</u>	<u>A040445</u>	<u>001</u>	Mar 31, 2010
<u>SKELAXIN</u>					
<u>AB</u>	+ KING PHARMS	<u>800MG</u>	<u>N013217</u>	<u>003</u>	Aug 30, 2002

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL					
RIOMET					
	+ RANBAXY	500MG/5ML	N021591	001	Sep 11, 2003
TABLET; ORAL					
<u>GLUCOPHAGE</u>					
<u>AB</u>	BRISTOL MYERS SQUIBB	<u>500MG</u>	<u>N020357</u>	<u>001</u>	Mar 03, 1995
<u>AB</u>		<u>850MG</u>	<u>N020357</u>	<u>002</u>	Mar 03, 1995
<u>AB</u>	+	<u>1GM</u>	<u>N020357</u>	<u>005</u>	Nov 05, 1998
<u>METFORMIN HYDROCHLORIDE</u>					
<u>AB</u>	ALKEM	<u>500MG</u>	<u>A091184</u>	<u>001</u>	Nov 01, 2010
<u>AB</u>		<u>850MG</u>	<u>A091184</u>	<u>002</u>	Nov 01, 2010
<u>AB</u>		<u>1GM</u>	<u>A091184</u>	<u>003</u>	Nov 01, 2010
<u>AB</u>	ALVOGEN	<u>500MG</u>	<u>A076033</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A076033</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A076033</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>	AMNEAL PHARMS NY	<u>500MG</u>	<u>A077880</u>	<u>001</u>	Jun 05, 2006
<u>AB</u>		<u>850MG</u>	<u>A077880</u>	<u>002</u>	Jun 05, 2006
<u>AB</u>		<u>1GM</u>	<u>A077880</u>	<u>003</u>	Jun 05, 2006
<u>AB</u>	APOTEX	<u>500MG</u>	<u>A075984</u>	<u>001</u>	Apr 23, 2002
<u>AB</u>		<u>500MG</u>	<u>A090666</u>	<u>001</u>	Dec 07, 2011
<u>AB</u>		<u>850MG</u>	<u>A075984</u>	<u>002</u>	Apr 23, 2002
<u>AB</u>		<u>850MG</u>	<u>A090666</u>	<u>002</u>	Dec 07, 2011
<u>AB</u>		<u>1GM</u>	<u>A075984</u>	<u>003</u>	Apr 23, 2002
<u>AB</u>		<u>1GM</u>	<u>A090666</u>	<u>003</u>	Dec 07, 2011
<u>AB</u>	AUROBINDO	<u>500MG</u>	<u>A077095</u>	<u>001</u>	Jan 14, 2005
<u>AB</u>		<u>850MG</u>	<u>A077095</u>	<u>002</u>	Jan 14, 2005
<u>AB</u>		<u>1GM</u>	<u>A077095</u>	<u>003</u>	Jan 14, 2005
<u>AB</u>	CARACO	<u>500MG</u>	<u>A075967</u>	<u>001</u>	Jan 29, 2002
<u>AB</u>		<u>850MG</u>	<u>A075967</u>	<u>002</u>	Jan 29, 2002
<u>AB</u>		<u>1GM</u>	<u>A075967</u>	<u>003</u>	Jan 29, 2002
<u>AB</u>	DR REDDYS LABS INC	<u>500MG</u>	<u>A077787</u>	<u>001</u>	Aug 23, 2006
<u>AB</u>		<u>850MG</u>	<u>A077787</u>	<u>002</u>	Aug 23, 2006

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 276 (of 428)

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS INC	<u>1GM</u>	<u>A077787</u>	<u>003</u>	Aug 23, 2006
<u>AB</u>	GLENMARK GENERICS	<u>500MG</u>	<u>A078170</u>	<u>001</u>	May 23, 2008
<u>AB</u>		<u>850MG</u>	<u>A078170</u>	<u>002</u>	May 23, 2008
<u>AB</u>		<u>1GM</u>	<u>A078170</u>	<u>003</u>	May 23, 2008
<u>AB</u>	GRANULES INDIA	<u>500MG</u>	<u>A090564</u>	<u>001</u>	Apr 22, 2010
<u>AB</u>		<u>850MG</u>	<u>A090564</u>	<u>002</u>	Apr 22, 2010
<u>AB</u>		<u>1GM</u>	<u>A090564</u>	<u>003</u>	Apr 22, 2010
<u>AB</u>	INDICUS PHARMA	<u>500MG</u>	<u>A079148</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>		<u>850MG</u>	<u>A079148</u>	<u>002</u>	Nov 25, 2008
<u>AB</u>		<u>1GM</u>	<u>A079148</u>	<u>003</u>	Nov 25, 2008
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>500MG</u>	<u>A075972</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A075972</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A075972</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>	MARKSANS PHARMA	<u>500MG</u>	<u>A090888</u>	<u>001</u>	Mar 12, 2012
<u>AB</u>		<u>850MG</u>	<u>A090888</u>	<u>002</u>	Mar 12, 2012
<u>AB</u>		<u>1GM</u>	<u>A090888</u>	<u>003</u>	Mar 12, 2012
<u>AB</u>	MUTUAL PHARMA	<u>500MG</u>	<u>A076038</u>	<u>001</u>	Feb 21, 2002
<u>AB</u>		<u>850MG</u>	<u>A076038</u>	<u>002</u>	Feb 21, 2002
<u>AB</u>		<u>1GM</u>	<u>A076038</u>	<u>003</u>	Feb 21, 2002
<u>AB</u>	MYLAN	<u>500MG</u>	<u>A075973</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>500MG</u>	<u>A075976</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A075973</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075976</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A075973</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075976</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>	MYLAN PHARMS INC	<u>500MG</u>	<u>A075969</u>	<u>001</u>	Jan 29, 2002
<u>AB</u>		<u>850MG</u>	<u>A075969</u>	<u>002</u>	Jan 29, 2002
<u>AB</u>		<u>1GM</u>	<u>A075969</u>	<u>003</u>	Jan 29, 2002
<u>AB</u>	PROVIDENT PHARM	<u>500MG</u>	<u>A077853</u>	<u>001</u>	Jul 28, 2006
<u>AB</u>		<u>850MG</u>	<u>A077853</u>	<u>002</u>	Jul 28, 2006
<u>AB</u>		<u>1GM</u>	<u>A077853</u>	<u>003</u>	Jul 28, 2006
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A075965</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>500MG</u>	<u>A075985</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075965</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075985</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075965</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075985</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>	TEVA	<u>500MG</u>	<u>A075978</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075978</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075978</u>	<u>003</u>	Nov 05, 2002
<u>AB</u>	TORRENT PHARMS	<u>500MG</u>	<u>A077711</u>	<u>001</u>	Jan 24, 2007
<u>AB</u>		<u>850MG</u>	<u>A077711</u>	<u>002</u>	Jan 24, 2007
<u>AB</u>		<u>1GM</u>	<u>A077711</u>	<u>003</u>	Jan 24, 2007
<u>AB</u>	WATSON LABS	<u>500MG</u>	<u>A075979</u>	<u>001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A075979</u>	<u>002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A075979</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>	WATSON LABS FLORIDA	<u>500MG</u>	<u>A075961</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075961</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075961</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>	ZYDUS PHARMS USA	<u>500MG</u>	<u>A077064</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>		<u>850MG</u>	<u>A077064</u>	<u>002</u>	Apr 18, 2005
<u>AB</u>		<u>1GM</u>	<u>A077064</u>	<u>003</u>	Apr 18, 2005
	METFORMIN HYDROCHLORIDE				
	IVAX SUB TEVA PHARMS	625MG	A075972	005	Jan 24, 2002
		750MG	A075972	004	Jan 24, 2002
	TABLET, EXTENDED RELEASE; ORAL				
	<u>FORTAMET</u>				
<u>AB</u>	+ ANDRX LABS LLC	<u>1GM</u>	<u>N021574</u>	<u>002</u>	Apr 27, 2004

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 277 (of 428)

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GLUCOPHAGE XR

<u>AB</u>	+ BRISTOL MYERS SQUIBB	<u>750MG</u>	<u>N021202</u>	<u>004</u>	Apr 11, 2003
	<u>METFORMIN HYDROCHLORIDE</u>				
<u>AB</u>	ALVOGEN	<u>750MG</u>	<u>A078321</u>	<u>002</u>	Apr 17, 2008
<u>AB</u>	AMNEAL PHARMS NY	<u>750MG</u>	<u>A078596</u>	<u>002</u>	Jan 03, 2008
<u>AB</u>	APOTEX	<u>750MG</u>	<u>A076706</u>	<u>002</u>	Dec 29, 2005
<u>AB</u>	AUROBINDO PHARMA LTD	<u>750MG</u>	<u>A079118</u>	<u>002</u>	Jul 20, 2012
<u>AB</u>	BARR	<u>750MG</u>	<u>A076863</u>	<u>001</u>	Oct 14, 2004
<u>AB</u>	IMPAX LABS	<u>750MG</u>	<u>A076985</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>	LUPIN LTD	<u>1GM</u>	<u>A090692</u>	<u>002</u>	Jun 29, 2011
<u>AB</u>	MYLAN	<u>750MG</u>	<u>A077113</u>	<u>001</u>	Sep 08, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>1GM</u>	<u>A200690</u>	<u>002</u>	Aug 01, 2012
<u>AB</u>	NOSTRUM PHARMS LLC	<u>750MG</u>	<u>A076756</u>	<u>002</u>	Dec 12, 2011
<u>AB</u>	SUN PHARM INDS (IN)	<u>750MG</u>	<u>A077336</u>	<u>002</u>	Feb 09, 2006
<u>AB</u>	TEVA	<u>750MG</u>	<u>A076864</u>	<u>001</u>	Apr 12, 2005
<u>AB</u>	TORRENT PHARMS	<u>750MG</u>	<u>A079226</u>	<u>001</u>	Feb 18, 2010
<u>AB</u>	WATSON LABS FLORIDA	<u>750MG</u>	<u>A076869</u>	<u>001</u>	Apr 12, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>750MG</u>	<u>A077078</u>	<u>001</u>	Apr 21, 2005

GLUCOPHAGE XR

<u>AB1</u>	BRISTOL MYERS SQUIBB	<u>500MG</u>	<u>N021202</u>	<u>001</u>	Oct 13, 2000
	<u>METFORMIN HYDROCHLORIDE</u>				
<u>AB1</u>	ALVOGEN	<u>500MG</u>	<u>A078321</u>	<u>001</u>	Apr 17, 2008
<u>AB1</u>	AMNEAL PHARMS NY	<u>500MG</u>	<u>A078596</u>	<u>001</u>	Jan 03, 2008
<u>AB1</u>	APOTEX	<u>500MG</u>	<u>A076706</u>	<u>001</u>	Dec 14, 2004
<u>AB1</u>	AUROBINDO PHARMA LTD	<u>500MG</u>	<u>A079118</u>	<u>001</u>	Jul 20, 2012
<u>AB1</u>	IMPAX LABS	<u>500MG</u>	<u>A076249</u>	<u>001</u>	Jul 30, 2004
<u>AB1</u>	INVENTIA HLTHCARE	<u>500MG</u>	<u>A201991</u>	<u>001</u>	Jan 18, 2012
<u>AB1</u>	MYLAN	<u>500MG</u>	<u>A076650</u>	<u>001</u>	Sep 13, 2005
<u>AB1</u>	NOSTRUM PHARMS LLC	<u>500MG</u>	<u>A076756</u>	<u>001</u>	Jul 26, 2006
<u>AB1</u>	SANDOZ	<u>500MG</u>	<u>A076873</u>	<u>001</u>	Dec 14, 2004
<u>AB1</u>	SUN PHARM INDS (IN)	<u>500MG</u>	<u>A077336</u>	<u>001</u>	Feb 09, 2006
<u>AB1</u>	TEVA	<u>500MG</u>	<u>A076269</u>	<u>001</u>	Jun 18, 2004
<u>AB1</u>	TORRENT PHARM	<u>500MG</u>	<u>A090014</u>	<u>001</u>	Dec 30, 2009
<u>AB1</u>	WATSON LABS FLORIDA	<u>500MG</u>	<u>A076172</u>	<u>001</u>	Jun 16, 2004
<u>AB1</u>	WATSON LABS INC	<u>500MG</u>	<u>A076818</u>	<u>001</u>	Dec 14, 2004
<u>AB1</u>	ZYDUS PHARMS USA	<u>500MG</u>	<u>A077060</u>	<u>001</u>	Apr 20, 2005

FORTAMET

<u>AB2</u>	ANDRX LABS LLC	<u>500MG</u>	<u>N021574</u>	<u>001</u>	Apr 27, 2004
	<u>METFORMIN HYDROCHLORIDE</u>				
<u>AB2</u>	LUPIN LTD	<u>500MG</u>	<u>A090692</u>	<u>001</u>	Jun 29, 2011
<u>AB2</u>	MYLAN PHARMS INC	<u>500MG</u>	<u>A200690</u>	<u>001</u>	Aug 01, 2012
	GLUMETZA				
BX	SANTARUS	500MG	N021748	001	Jun 03, 2005
BX	+	1GM	N021748	002	Jun 03, 2005

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

<u>AB</u>	TAKEDA PHARMS USA	<u>500MG;EQ 15MG BASE</u>	<u>N021842</u>	<u>001</u>	Aug 29, 2005
<u>AB</u>	+	<u>850MG;EQ 15MG BASE</u>	<u>N021842</u>	<u>002</u>	Aug 29, 2005
	<u>PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE</u>				
<u>AB</u>	MYLAN	<u>500MG;EQ 15MG BASE</u>	<u>A090406</u>	<u>001</u>	Feb 25, 2011
<u>AB</u>		<u>850MG;EQ 15MG BASE</u>	<u>A090406</u>	<u>002</u>	Feb 25, 2011

TABLET, EXTENDED RELEASE; ORAL

ACTOPLUS MET XR

	TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024	001	May 12, 2009
+		1GM;EQ 30MG BASE	N022024	002	May 12, 2009

PRESCRIPTION DRUG PRODUCT LIST

3 - 278 (of 428)

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET; ORAL
PRANDIMET

NOVO NORDISK INC	500MG;1MG	N022386	001	Jun 23, 2008
+	500MG;2MG	N022386	002	Jun 23, 2008

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL
AVANDAMET

SB PHARMC0	500MG;EQ 2MG BASE	N021410	002	Oct 10, 2002
	500MG;EQ 4MG BASE	N021410	003	Oct 10, 2002
	1GM;EQ 2MG BASE	N021410	004	Aug 25, 2003
+	1GM;EQ 4MG BASE	N021410	005	Aug 25, 2003

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
KOMBIGLYZE XR

BRISTOL MYERS SQUIBB	500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010
	1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010
+	1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL
JANUMET

MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044	001	Mar 30, 2007
+	1GM;EQ 50MG BASE	N022044	002	Mar 30, 2007

TABLET, EXTENDED RELEASE; ORAL
JANUMET XR

MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012
	1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012
+	1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012

METHACHOLINE CHLORIDE

FOR SOLUTION; INHALATION
PROVOCHOLINE

+ METHAPHARM	100MG/VIAL	N019193	001	Oct 31, 1986

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>	ROXANE	<u>10MG/ML</u>	<u>A040180</u>	<u>001</u>	Apr 30, 1998
<u>AA</u>	VISTAPHARM	<u>10MG/ML</u>	<u>A040088</u>	<u>001</u>	Nov 30, 1994

METHADONE HYDROCHLORIDE INTENSOL

<u>AA</u>	ROXANE	<u>10MG/ML</u>	<u>A089897</u>	<u>001</u>	Sep 06, 1988

METHADOSE

<u>AA</u>	+ MALLINCKRODT	<u>10MG/ML</u>	<u>N017116</u>	<u>002</u>	

INJECTABLE; INJECTION

DOLOPHINE HYDROCHLORIDE

+ MYLAN INSTITUTIONAL	10MG/ML	N021624	001	

POWDER; FOR RX COMPOUNDING

METHADONE HYDROCHLORIDE

MALLINCKRODT	50GM/BOT	N006383	002	
	100GM/BOT	N006383	003	
	500GM/BOT	N006383	004	

SOLUTION; ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>	+ ROXANE	<u>5MG/5ML</u>	<u>A087393</u>	<u>001</u>	
<u>AA</u>	+	<u>10MG/5ML</u>	<u>A087997</u>	<u>001</u>	Aug 30, 1982
<u>AA</u>	VISTAPHARM	<u>5MG/5ML</u>	<u>A090707</u>	<u>001</u>	Jun 30, 2010
<u>AA</u>		<u>10MG/5ML</u>	<u>A090707</u>	<u>002</u>	Jun 30, 2010

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 279 (of 428)

METHADONE HYDROCHLORIDE

TABLET; ORAL

DOLOPHINE HYDROCHLORIDE

<u>AA</u>	+	ROXANE	<u>5MG</u>
<u>AA</u>	+		<u>10MG</u>

<u>N006134</u>	<u>002</u>
<u>N006134</u>	<u>010</u>

METHADONE HYDROCHLORIDE

<u>AA</u>		MALLINCKRODT	<u>5MG</u>
<u>AA</u>			<u>10MG</u>
<u>AA</u>			<u>40MG</u>
<u>AA</u>	+	ROXANE	<u>40MG</u>
<u>AA</u>		SANDOZ	<u>10MG</u>
<u>AA</u>			<u>40MG</u>
<u>AA</u>		THE PHARMANETWORK	<u>10MG</u>

<u>A040517</u>	<u>001</u>	Apr 27, 2004
<u>A040517</u>	<u>002</u>	Apr 27, 2004
<u>A077142</u>	<u>001</u>	Jul 12, 2005
<u>N017058</u>	<u>001</u>	
<u>A040241</u>	<u>002</u>	May 29, 1998
<u>A075082</u>	<u>001</u>	Mar 25, 1998
<u>A090635</u>	<u>001</u>	Nov 25, 2009

METHADOSE

<u>AA</u>		MALLINCKRODT	<u>5MG</u>
<u>AA</u>			<u>10MG</u>
<u>AA</u>			<u>40MG</u>

<u>A040050</u>	<u>001</u>	Apr 15, 1993
<u>A040050</u>	<u>002</u>	Apr 15, 1993
<u>A074184</u>	<u>001</u>	Apr 29, 1993

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

<u>AA</u>	+	LUNDBECK INC	<u>5MG</u>
<u>AA</u>		COASTAL PHARMS	<u>5MG</u>

<u>N005378</u>	<u>002</u>	
<u>A091189</u>	<u>001</u>	Apr 21, 2010

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

<u>AB</u>		MIKART	<u>25MG</u>
<u>AB</u>	+		<u>50MG</u>
<u>AB</u>		SANDOZ	<u>25MG</u>
<u>AB</u>			<u>50MG</u>
<u>AB</u>		TEVA PHARMS	<u>25MG</u>
<u>AB</u>			<u>50MG</u>

<u>A040062</u>	<u>001</u>	Jan 27, 1994
<u>A040062</u>	<u>002</u>	Jan 27, 1994
<u>A040036</u>	<u>001</u>	Jun 30, 1993
<u>A040036</u>	<u>002</u>	Jun 30, 1993
<u>A040001</u>	<u>001</u>	Jun 30, 1993
<u>A040001</u>	<u>002</u>	Jun 30, 1993

METHENAMINE HIPPURATE

TABLET; ORAL

HIPREX

<u>AB</u>	+	SANOFI AVENTIS US	<u>1GM</u>

<u>N017681</u>	<u>001</u>

METHENAMINE HIPPURATE

<u>AB</u>		COREPHARMA	<u>1GM</u>

<u>A076411</u>	<u>001</u>	Jun 20, 2003

UREX

<u>AB</u>		CNTY LINE PHARMS	<u>1GM</u>

<u>N016151</u>	<u>001</u>

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

<u>AB</u>		BOCA PHARMA	<u>5MG</u>
<u>AB</u>			<u>10MG</u>
<u>AB</u>		CARACO	<u>5MG</u>
<u>AB</u>			<u>10MG</u>
<u>AB</u>		CEDAR PHARMS	<u>5MG</u>
<u>AB</u>			<u>10MG</u>
<u>AB</u>		EMCURE PHARMS USA	<u>5MG</u>
<u>AB</u>			<u>10MG</u>
<u>AB</u>		MYLAN	<u>5MG</u>
<u>AB</u>	+		<u>10MG</u>
<u>AB</u>		SANDOZ	<u>5MG</u>
<u>AB</u>			<u>10MG</u>

<u>A202068</u>	<u>001</u>	Mar 07, 2012
<u>A202068</u>	<u>002</u>	Mar 07, 2012
<u>A040870</u>	<u>001</u>	Sep 25, 2007
<u>A040870</u>	<u>002</u>	Sep 25, 2007
<u>A040547</u>	<u>001</u>	Feb 18, 2005
<u>A040547</u>	<u>002</u>	Feb 18, 2005
<u>A040734</u>	<u>001</u>	Dec 14, 2007
<u>A040734</u>	<u>002</u>	Dec 14, 2007
<u>A040350</u>	<u>001</u>	Mar 29, 2000
<u>A040350</u>	<u>002</u>	Mar 29, 2000
<u>A040411</u>	<u>001</u>	Mar 27, 2001
<u>A040411</u>	<u>002</u>	Mar 27, 2001

TAPAZOLE

<u>AB</u>		KING PHARMS	<u>5MG</u>

<u>A040320</u>	<u>001</u>	Mar 31, 2000

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 280 (of 428)

METHIMAZOLE

TABLET; ORAL

TAPAZOLE

<u>AB</u>	KING PHARMS	<u>10MG</u>	<u>A040320</u>	<u>002</u>	Mar 31, 2000

METHOCARBAMOL

INJECTABLE; INJECTION

METHOCARBAMOL

<u>AP</u>	WATSON LABS	<u>100MG/ML</u>	<u>A086459</u>	<u>001</u>	

ROBAXIN

<u>AP</u>	+ BAXTER HLTHCARE CORP	<u>100MG/ML</u>	<u>N011790</u>	<u>001</u>	

TABLET; ORAL

METHOCARBAMOL

<u>AA</u>	AUSTARPHARMA LLC	<u>500MG</u>	<u>A200958</u>	<u>001</u>	Oct 21, 2011

<u>AA</u>		<u>750MG</u>	<u>A200958</u>	<u>002</u>	Oct 21, 2011

<u>AA</u>	HETERO DRUGS	<u>500MG</u>	<u>A090200</u>	<u>001</u>	Nov 06, 2009

<u>AA</u>		<u>750MG</u>	<u>A090200</u>	<u>002</u>	Nov 06, 2009

<u>AA</u>	LANNETT HOLDINGS INC	<u>500MG</u>	<u>A084756</u>	<u>002</u>	Mar 31, 2003

<u>AA</u>		<u>750MG</u>	<u>A084756</u>	<u>001</u>	

<u>AA</u>	SANDOZ	<u>500MG</u>	<u>A084616</u>	<u>001</u>	

<u>AA</u>		<u>750MG</u>	<u>A084615</u>	<u>001</u>	

<u>AA</u>	SOLCO HLTHCARE	<u>500MG</u>	<u>A086989</u>	<u>001</u>	

<u>AA</u>		<u>750MG</u>	<u>A086988</u>	<u>001</u>	

<u>AA</u>	VINTAGE PHARMS	<u>500MG</u>	<u>A040489</u>	<u>001</u>	Jan 29, 2003

<u>AA</u>		<u>750MG</u>	<u>A040489</u>	<u>002</u>	Jan 29, 2003

<u>AA</u>	WATSON LABS	<u>500MG</u>	<u>A084277</u>	<u>001</u>	

<u>AA</u>		<u>500MG</u>	<u>A085180</u>	<u>001</u>	

<u>AA</u>		<u>750MG</u>	<u>A084276</u>	<u>002</u>	

<u>AA</u>		<u>750MG</u>	<u>A085192</u>	<u>001</u>	

<u>AA</u>	WEST WARD	<u>500MG</u>	<u>A085159</u>	<u>001</u>	

<u>AA</u>		<u>750MG</u>	<u>A085123</u>	<u>001</u>	

ROBAXIN

<u>AA</u>	+ ACTIENT PHARMS	<u>500MG</u>	<u>N011011</u>	<u>004</u>	

ROBAXIN-750

<u>AA</u>	+ ACTIENT PHARMS	<u>750MG</u>	<u>N011011</u>	<u>006</u>	

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

+	JHP PHARMS	200MG/VIAL	N011559	004	Dec 21, 2012

+		500MG/VIAL	N011559	001	

+		2.5GM/VIAL	N011559	002	

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1GM BASE/VIAL</u>	<u>A040266</u>	<u>001</u>	Feb 26, 1999

<u>AP</u>	PHARMACHEMIE BV	<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A200171</u>	<u>001</u>	Feb 27, 2012

METHOTREXATE SODIUM

<u>AP</u>	+ BEDFORD	<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A089341</u>	<u>001</u>	Sep 16, 1986

<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040263</u>	<u>001</u>	Feb 26, 1999

<u>AP</u>	+	<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040263</u>	<u>002</u>	Feb 26, 1999

<u>AP</u>	+ HOSPIRA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>N011719</u>	<u>010</u>	Dec 15, 2004

METHOTREXATE SODIUM PRESERVATIVE FREE

<u>AP</u>	+ BEDFORD	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A089340</u>	<u>001</u>	Sep 16, 1986

<u>AP</u>	+	<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A089343</u>	<u>001</u>	Sep 16, 1986

<u>AP</u>	EBEWE PHARMA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A090039</u>	<u>001</u>	Mar 31, 2009

<u>AP</u>		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A090039</u>	<u>002</u>	Mar 31, 2009

<u>AP</u>		<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A090029</u>	<u>001</u>	Mar 31, 2009

<u>AP</u>	+ HOSPIRA	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>N011719</u>	<u>012</u>	Apr 13, 2005

<u>AP</u>	+ MYLAN INSTITUTIONAL	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040767</u>	<u>001</u>	Apr 30, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 281 (of 428)

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

<u>AP</u>	+	MYLAN INSTITUTIONAL	<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040768</u>	<u>001</u>	Apr 30, 2007
<u>AP</u>	+		<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040716</u>	<u>001</u>	Apr 30, 2007
<u>AP</u>		ONCO THERAPIES LTD	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>001</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>002</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 200MG BASE/8ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>003</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>004</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A201530</u>	<u>001</u>	Mar 29, 2012
<u>AP</u>		PHARMACHEMIE BV	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040850</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>			<u>EQ 250MG/10ML (EQ 25MG BASE/ML)</u>	<u>A040853</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>			<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040843</u>	<u>001</u>	Jan 11, 2010
		METHOTREXATE SODIUM				
	+	BEDFORD	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986
		METHOTREXATE SODIUM PRESERVATIVE FREE				
	+	BEDFORD	EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005

TABLET; ORAL

METHOTREXATE SODIUM

<u>AB</u>		BARR	<u>EQ 2.5MG BASE</u>	<u>A081099</u>	<u>001</u>	Oct 15, 1990
<u>AB</u>	+	DAVA PHARMS INC	<u>EQ 2.5MG BASE</u>	<u>N008085</u>	<u>002</u>	
<u>AB</u>		MYLAN	<u>EQ 2.5MG BASE</u>	<u>A081235</u>	<u>001</u>	May 15, 1992
<u>AB</u>		ROXANE	<u>EQ 2.5MG BASE</u>	<u>A040054</u>	<u>001</u>	Aug 01, 1994
		TREXALL				
		BARR	EQ 5MG BASE	A040385	001	Mar 21, 2001
			EQ 7.5MG BASE	A040385	002	Mar 21, 2001
			EQ 10MG BASE	A040385	003	Mar 21, 2001
	+		EQ 15MG BASE	A040385	004	Mar 21, 2001

METHOXSALEN

CAPSULE; ORAL

8-MOP

	+	VALEANT PHARM INTL	10MG	N009048	001	
		OXSORALEN-ULTRA				
	+	VALEANT PHARM INTL	10MG	N019600	001	Oct 30, 1986

INJECTABLE; INJECTION

UVADEX

	+	THERAKOS	0.02MG/ML	N020969	001	Feb 25, 1999

LOTION; TOPICAL

OXSORALEN

	+	VALEANT PHARM INTL	1%	N009048	002	

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

<u>AA</u>		BAYSHORE PHARMS LLC	<u>2.5MG</u>	<u>A200602</u>	<u>001</u>	Sep 24, 2012
<u>AA</u>			<u>5MG</u>	<u>A200602</u>	<u>002</u>	Sep 24, 2012
<u>AA</u>		BOCA PHARMA	<u>2.5MG</u>	<u>A040624</u>	<u>001</u>	Dec 28, 2006
<u>AA</u>			<u>5MG</u>	<u>A040624</u>	<u>002</u>	Dec 28, 2006
<u>AA</u>		BRECKENRIDGE PHARM	<u>2.5MG</u>	<u>A040642</u>	<u>001</u>	Dec 06, 2011
<u>AA</u>			<u>5MG</u>	<u>A040642</u>	<u>002</u>	Dec 06, 2011
		<u>PAMINE</u>				
<u>AA</u>	+	FOUGERA PHARMS	<u>2.5MG</u>	<u>N008848</u>	<u>001</u>	
		<u>PAMINE FORTE</u>				
<u>AA</u>	+	FOUGERA PHARMS	<u>5MG</u>	<u>N008848</u>	<u>002</u>	Mar 25, 2003

METHSUXIMIDE

CAPSULE; ORAL

CELONTIN

		PARKE DAVIS	150MG	N010596	007	
	+		300MG	N010596	008	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 282 (of 428)

METHYCLOTHIAZIDE

TABLET; ORAL

METHYCLOTHIAZIDE

<u>AB</u>	+	MYLAN PHARMS INC	<u>5MG</u>	<u>A087672</u>	<u>001</u>	Aug 17, 1982
<u>AB</u>		WATSON LABS	<u>5MG</u>	<u>A088724</u>	<u>001</u>	Sep 06, 1984

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM; TOPICAL

METVIXIA

+	GALDERMA LABS LP	EQ 16.8% BASE	N021415	001	Jul 27, 2004

METHYLDOPA

TABLET; ORAL

METHYLDOPA

<u>AB</u>		ACCORD HLTH	<u>250MG</u>	<u>A070084</u>	<u>001</u>	Oct 15, 1985
<u>AB</u>			<u>500MG</u>	<u>A070085</u>	<u>001</u>	Oct 15, 1985
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>250MG</u>	<u>A070098</u>	<u>001</u>	Feb 20, 1986
<u>AB</u>			<u>500MG</u>	<u>A070343</u>	<u>001</u>	Feb 20, 1986
<u>AB</u>		MYLAN	<u>250MG</u>	<u>A070075</u>	<u>001</u>	Apr 18, 1985
<u>AB</u>	+		<u>500MG</u>	<u>A070076</u>	<u>001</u>	Apr 18, 1985
<u>AB</u>		WATSON LABS	<u>500MG</u>	<u>A070625</u>	<u>001</u>	Jun 06, 1986

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

<u>AP</u>	+	LUITPOLD	<u>50MG/ML</u>	<u>A071279</u>	<u>001</u>	Oct 02, 1987

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

METHERGINE

<u>AP</u>	+	US PHARMS HOLDINGS I	<u>0.2MG/ML</u>	<u>N006035</u>	<u>004</u>	
		<u>METHYLERGONOVINE MALEATE</u>				
<u>AP</u>		ERGOJECT	<u>0.2MG/ML</u>	<u>A040889</u>	<u>001</u>	Sep 13, 2010
<u>AP</u>		LUITPOLD	<u>0.2MG/ML</u>	<u>A090193</u>	<u>001</u>	Nov 24, 2008

TABLET; ORAL

METHERGINE

<u>AB</u>	+	US PHARMS HOLDINGS I	<u>0.2MG</u>	<u>N006035</u>	<u>003</u>	
		<u>METHYLERGONOVINE MALEATE</u>				
<u>AB</u>		NOVEL LABS INC	<u>0.2MG</u>	<u>A091577</u>	<u>001</u>	May 02, 2011

METHYLNALTREXONE BROMIDE

INJECTABLE; SUBCUTANEOUS

RELISTOR

	SALIX PHARMS	8MG/0.4ML	N021964	002	Sep 27, 2010
+		12MG/0.6ML (12MG/0.6ML)	N021964	003	Apr 24, 2008

SOLUTION; SUBCUTANEOUS

RELISTOR

+	SALIX PHARMS	12MG/0.6ML (12MG/0.6ML)	N021964	001	Apr 24, 2008

METHYLPHENIDATE

FILM, EXTENDED RELEASE; TRANSDERMAL

DAYTRANA

	NOVEN PHARMS INC	10MG/9HR (1.1MG/HR)	N021514	001	Apr 06, 2006
		15MG/9HR (1.6MG/HR)	N021514	002	Apr 06, 2006
		20MG/9HR (2.2MG/HR)	N021514	003	Apr 06, 2006
+		30MG/9HR (3.3MG/HR)	N021514	004	Apr 06, 2006

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

<u>AB</u>		UCB INC	<u>10MG</u>	<u>N021259</u>	<u>003</u>	May 27, 2003
<u>AB</u>			<u>50MG</u>	<u>N021259</u>	<u>005</u>	Feb 19, 2006

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 283 (of 428)

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

<u>AB</u>	+	UCB INC	60MG	<u>N021259</u>	<u>006</u>	Feb 19, 2006

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>		TEVA PHARMS	10MG	<u>A077707</u>	<u>001</u>	Jul 19, 2012

<u>AB</u>			50MG	<u>A078873</u>	<u>002</u>	Jul 19, 2012

<u>AB</u>			60MG	<u>A078873</u>	<u>003</u>	Jul 19, 2012

METHYLPHENIDATE HYDROCHLORIDE

<u>AB1</u>		ACTAVIS	20MG	<u>A078458</u>	<u>001</u>	Dec 01, 2011

<u>AB1</u>			30MG	<u>A078458</u>	<u>002</u>	Dec 01, 2011

<u>AB1</u>			40MG	<u>A078458</u>	<u>003</u>	Dec 01, 2011

<u>AB1</u>		BARR LABS INC	20MG	<u>A079031</u>	<u>001</u>	Jul 13, 2012

<u>AB1</u>			30MG	<u>A079031</u>	<u>002</u>	Jul 13, 2012

<u>AB1</u>			40MG	<u>A079031</u>	<u>003</u>	Jul 13, 2012

RITALIN LA

<u>AB1</u>		NOVARTIS	20MG	<u>N021284</u>	<u>001</u>	Jun 05, 2002

<u>AB1</u>			30MG	<u>N021284</u>	<u>002</u>	Jun 05, 2002

<u>AB1</u>	+		40MG	<u>N021284</u>	<u>003</u>	Jun 05, 2002

METADATE CD

<u>AB2</u>		UCB INC	20MG	<u>N021259</u>	<u>001</u>	Apr 03, 2001

<u>AB2</u>			30MG	<u>N021259</u>	<u>002</u>	Jun 19, 2003

<u>AB2</u>			40MG	<u>N021259</u>	<u>004</u>	Feb 19, 2006

METHYLPHENIDATE HYDROCHLORIDE

<u>AB2</u>		TEVA PHARMS	20MG	<u>A077707</u>	<u>002</u>	Jul 19, 2012

<u>AB2</u>			30MG	<u>A077707</u>	<u>003</u>	Jul 19, 2012

<u>AB2</u>			40MG	<u>A078873</u>	<u>001</u>	Jul 19, 2012

RITALIN LA

BX		NOVARTIS	10MG	N021284	004	Apr 10, 2004

FOR SUSPENSION, EXTENDED RELEASE; ORAL

QUILLIVANT XR

	+	NEXTWAVE PHARMS	5MG/ML	N202100	001	Sep 27, 2012

SOLUTION; ORAL

METHYLIN

<u>AA</u>	+	MALLINCKRODT	5MG/5ML	<u>N021419</u>	<u>001</u>	Dec 19, 2002

<u>AA</u>	+		10MG/5ML	<u>N021419</u>	<u>002</u>	Dec 19, 2002

METHYLPHENIDATE HYDROCHLORIDE

<u>AA</u>		TRIS PHARMA INC	5MG/5ML	<u>A091601</u>	<u>001</u>	Jul 23, 2010

<u>AA</u>			10MG/5ML	<u>A091601</u>	<u>002</u>	Jul 23, 2010

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>		MALLINCKRODT	5MG	<u>A040300</u>	<u>001</u>	Nov 27, 1998

<u>AB</u>			10MG	<u>A040300</u>	<u>002</u>	Nov 27, 1998

<u>AB</u>			20MG	<u>A040300</u>	<u>003</u>	Nov 27, 1998

<u>AB</u>		SUN PHARM INDS INC	5MG	<u>A090710</u>	<u>001</u>	Mar 15, 2012

<u>AB</u>			10MG	<u>A090710</u>	<u>002</u>	Mar 15, 2012

<u>AB</u>			20MG	<u>A090710</u>	<u>003</u>	Mar 15, 2012

<u>AB</u>		UCB INC	5MG	<u>A086429</u>	<u>001</u>	

<u>AB</u>			10MG	<u>A085799</u>	<u>001</u>	

<u>AB</u>			20MG	<u>A086428</u>	<u>001</u>	

<u>AB</u>		WATSON LABS	5MG	<u>A040220</u>	<u>001</u>	Aug 29, 1997

<u>AB</u>			10MG	<u>A040220</u>	<u>002</u>	Aug 29, 1997

<u>AB</u>			20MG	<u>A040220</u>	<u>003</u>	Aug 29, 1997

RITALIN

<u>AB</u>		NOVARTIS	5MG	<u>N010187</u>	<u>003</u>	

<u>AB</u>			10MG	<u>N010187</u>	<u>006</u>	

<u>AB</u>	+		20MG	<u>N010187</u>	<u>010</u>	

TABLET, CHEWABLE; ORAL

METHYLIN

		MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003

			5MG	N021475	002	Apr 15, 2003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 284 (of 428)

METHYLPHENIDATE HYDROCHLORIDE

TABLET, CHEWABLE; ORAL					
METHYLIN					
	+ MALLINCKRODT	10MG	N021475	003	Apr 15, 2003
TABLET, EXTENDED RELEASE; ORAL					
<u>CONCERTA</u>					
<u>AB</u>	JANSSEN PHARMS	<u>27MG</u>	<u>N021121</u>	<u>004</u>	Apr 01, 2002
<u>AB</u>		<u>36MG</u>	<u>N021121</u>	<u>002</u>	Aug 01, 2000
<u>AB</u>	+	<u>54MG</u>	<u>N021121</u>	<u>003</u>	Dec 08, 2000
<u>METADATE ER</u>					
<u>AB</u>	+ UCB INC	<u>20MG</u>	<u>A089601</u>	<u>001</u>	Jun 01, 1988
<u>METHYLIN ER</u>					
<u>AB</u>	MALLINCKRODT	<u>10MG</u>	<u>A075629</u>	<u>001</u>	May 09, 2000
<u>AB</u>		<u>20MG</u>	<u>A075629</u>	<u>002</u>	May 09, 2000
<u>METHYLPHENIDATE HYDROCHLORIDE</u>					
<u>AB</u>	MALLINCKRODT INC	<u>27MG</u>	<u>A202608</u>	<u>001</u>	Dec 28, 2012
<u>AB</u>		<u>36MG</u>	<u>A202608</u>	<u>002</u>	Dec 28, 2012
<u>AB</u>		<u>54MG</u>	<u>A202608</u>	<u>003</u>	Dec 28, 2012
<u>AB</u>	WATSON LABS	<u>20MG</u>	<u>A040410</u>	<u>001</u>	Feb 09, 2001
<u>RITALIN-SR</u>					
<u>AB</u>	NOVARTIS	<u>20MG</u>	<u>N018029</u>	<u>001</u>	Mar 30, 1982
CONCERTA					
	JANSSEN PHARMS	18MG	N021121	001	Aug 01, 2000

METHYLPREDNISOLONE

TABLET; ORAL					
<u>MEDROL</u>					
<u>AB</u>	PHARMACIA AND UPJOHN	<u>4MG</u>	<u>N011153</u>	<u>001</u>	
<u>AB</u>		<u>8MG</u>	<u>N011153</u>	<u>004</u>	
<u>AB</u>		<u>16MG</u>	<u>N011153</u>	<u>003</u>	
<u>AB</u>	+	<u>32MG</u>	<u>N011153</u>	<u>006</u>	
<u>METHYLPREDNISOLONE</u>					
<u>AB</u>	DURAMED PHARMS BARR	<u>4MG</u>	<u>A088497</u>	<u>001</u>	Feb 21, 1984
<u>AB</u>	JUBILANT CADISTA	<u>4MG</u>	<u>A040189</u>	<u>001</u>	Oct 31, 1997
<u>AB</u>		<u>8MG</u>	<u>A040189</u>	<u>002</u>	Oct 31, 1997
<u>AB</u>		<u>16MG</u>	<u>A040189</u>	<u>003</u>	Jul 20, 2007
<u>AB</u>		<u>32MG</u>	<u>A040189</u>	<u>004</u>	Jul 20, 2007
<u>AB</u>	SANDOZ	<u>4MG</u>	<u>A040194</u>	<u>001</u>	Oct 31, 1997
<u>AB</u>	VINTAGE PHARMS	<u>4MG</u>	<u>A040183</u>	<u>001</u>	Dec 22, 1998
<u>AB</u>	WATSON LABS	<u>4MG</u>	<u>A040232</u>	<u>001</u>	Oct 16, 1997

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION					
<u>DEPO-MEDROL</u>					
<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>40MG/ML</u>	<u>N011757</u>	<u>001</u>	
<u>AB</u>	+	<u>80MG/ML</u>	<u>N011757</u>	<u>004</u>	
<u>METHYLPREDNISOLONE ACETATE</u>					
<u>AB</u>	SANDOZ	<u>40MG/ML</u>	<u>A040719</u>	<u>001</u>	Jan 29, 2009
<u>AB</u>		<u>40MG/ML</u>	<u>A040794</u>	<u>001</u>	Mar 05, 2009
<u>AB</u>		<u>80MG/ML</u>	<u>A040719</u>	<u>002</u>	Jan 29, 2009
<u>AB</u>		<u>80MG/ML</u>	<u>A040794</u>	<u>002</u>	Mar 05, 2009
<u>AB</u>	TEVA PARENTERAL	<u>40MG/ML</u>	<u>A040557</u>	<u>001</u>	Feb 23, 2005
<u>AB</u>		<u>40MG/ML</u>	<u>A040620</u>	<u>001</u>	Oct 27, 2006
<u>AB</u>		<u>80MG/ML</u>	<u>A040557</u>	<u>002</u>	Feb 23, 2005
<u>AB</u>		<u>80MG/ML</u>	<u>A040620</u>	<u>002</u>	Oct 27, 2006
DEPO-MEDROL					
	+ PHARMACIA AND UPJOHN	20MG/ML	N011757	002	

PRESCRIPTION DRUG PRODUCT LIST

3 - 285 (of 428)

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

<u>AP</u>	HOSPIRA	<u>EQ 40MG BASE/VIAL</u>	<u>A040664</u>	<u>001</u>	Dec 20, 2005
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A040665</u>	<u>001</u>	Dec 20, 2005
<u>AP</u>	HOSPIRA INC	<u>EQ 40MG BASE/VIAL</u>	<u>A040793</u>	<u>001</u>	Nov 25, 2008
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A040827</u>	<u>001</u>	Nov 25, 2008

METHYLPREDNISOLONE SODIUM SUCCINATE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 40MG BASE/VIAL</u>	<u>A040583</u>	<u>001</u>	Jul 30, 2004
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A040583</u>	<u>002</u>	Jul 30, 2004
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A040612</u>	<u>001</u>	Aug 12, 2004
<u>AP</u>	MUSTAFA NEVSAT	<u>EQ 40MG BASE/VIAL</u>	<u>A040888</u>	<u>001</u>	Jul 18, 2011
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A040888</u>	<u>002</u>	Jul 18, 2011
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A040888</u>	<u>003</u>	Jul 18, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A040888</u>	<u>004</u>	Jul 18, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A040888</u>	<u>005</u>	Jul 18, 2011

SOLU-MEDROL

<u>AP</u>	+ PHARMACIA AND UPJOHN	<u>EQ 40MG BASE/VIAL</u>	<u>N011856</u>	<u>003</u>	
<u>AP</u>	+	<u>EQ 125MG BASE/VIAL</u>	<u>N011856</u>	<u>004</u>	
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>N011856</u>	<u>005</u>	
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>N011856</u>	<u>006</u>	
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>N011856</u>	<u>007</u>	Feb 27, 1985

METHYLTESTOSTERONE

CAPSULE; ORAL

TESTRED

	+ VALEANT PHARM INTL	10MG	A083976	001	

TABLET; ORAL

ANDROID 10

BP	VALEANT PHARM INTL	10MG	A086450	001	

ANDROID 25

BP	+ VALEANT PHARM INTL	25MG	A087147	001	

METHYLTESTOSTERONE

BP	IMPAX LABS	10MG	A080767	002	

BP		25MG	A084310	001	

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

METIPRANOLOL

<u>AT</u>	FALCON PHARMS	<u>0.3%</u>	<u>A075720</u>	<u>001</u>	Aug 06, 2001

OPTIPRANOLOL

<u>AT</u>	+ BAUSCH AND LOMB	<u>0.3%</u>	<u>N019907</u>	<u>001</u>	Dec 29, 1989

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>EQ 5MG BASE/ML</u>	<u>A073118</u>	<u>001</u>	Jan 17, 1991

<u>AP</u>	TEVA PARENTERAL	<u>EQ 5MG BASE/ML</u>	<u>A073135</u>	<u>001</u>	Nov 27, 1991

REGLAN

<u>AP</u>	+ BAXTER HLTHCARE CORP	<u>EQ 5MG BASE/ML</u>	<u>N017862</u>	<u>001</u>	

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

<u>AA</u>	ANI PHARMS	<u>EQ 5MG BASE/5ML</u>	<u>A071402</u>	<u>001</u>	Jun 25, 1993

<u>AA</u>	PHARM ASSOC	<u>EQ 5MG BASE/5ML</u>	<u>A072744</u>	<u>001</u>	May 28, 1991

<u>AA</u>	SILARX	<u>EQ 5MG BASE/5ML</u>	<u>A073680</u>	<u>001</u>	Oct 27, 1992

<u>AA</u>	VISTAPHARM	<u>EQ 5MG BASE/5ML</u>	<u>A075051</u>	<u>001</u>	Jan 26, 2001

<u>AA</u>	+ WOCKHARDT	<u>EQ 5MG BASE/5ML</u>	<u>A074703</u>	<u>001</u>	Oct 31, 1997

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

<u>AB</u>	IPCA LABS LTD	<u>EQ 5MG BASE</u>	<u>A078807</u>	<u>001</u>	Jun 12, 2008

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078807</u>	<u>002</u>	Jun 12, 2008

<u>AB</u>	MUTUAL PHARM	<u>EQ 5MG BASE</u>	<u>A071536</u>	<u>002</u>	Jan 16, 1997

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 286 (of 428)

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

<u>AB</u>	NORTHSTAR HLTHCARE	<u>EQ 5MG BASE</u>	<u>A078374</u>	<u>001</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078374</u>	<u>002</u>	Nov 30, 2007
<u>AB</u>	PAR PHARM INC	<u>EQ 10MG BASE</u>	<u>A070581</u>	<u>001</u>	Oct 17, 1985
<u>AB</u>	TEVA	<u>EQ 5MG BASE</u>	<u>A072801</u>	<u>001</u>	Jun 15, 1993
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A070184</u>	<u>001</u>	Jul 29, 1985
<u>AB</u>	VINTAGE PHARMS	<u>EQ 5MG BASE</u>	<u>A077878</u>	<u>001</u>	Aug 28, 2006
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077878</u>	<u>002</u>	Aug 28, 2006
<u>AB</u>	WATSON LABS	<u>EQ 5MG BASE</u>	<u>A072750</u>	<u>001</u>	Dec 28, 1995
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A071250</u>	<u>001</u>	Feb 03, 1988
<u>REGLAN</u>					
<u>AB</u>	ANI PHARMS	<u>EQ 5MG BASE</u>	<u>N017854</u>	<u>002</u>	May 05, 1987
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N017854</u>	<u>001</u>	
TABLET, ORALLY DISINTEGRATING; ORAL					
METOZOLV ODT					
	SALIX PHARMS	EQ 5MG BASE	N022246	001	Sep 04, 2009
	+	EQ 10MG BASE	N022246	002	Sep 04, 2009

METOLAZONE

TABLET; ORAL

METOLAZONE

<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076698</u>	<u>001</u>	Dec 23, 2003
<u>AB</u>		<u>5MG</u>	<u>A076698</u>	<u>002</u>	Oct 19, 2004
<u>AB</u>		<u>10MG</u>	<u>A076698</u>	<u>003</u>	Oct 19, 2004
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A076732</u>	<u>001</u>	Dec 19, 2003
<u>AB</u>		<u>5MG</u>	<u>A076466</u>	<u>001</u>	Dec 19, 2003
<u>AB</u>		<u>10MG</u>	<u>A076466</u>	<u>002</u>	Dec 19, 2003
<u>AB</u>	TEVA	<u>2.5MG</u>	<u>A076600</u>	<u>001</u>	Jan 06, 2004
<u>AB</u>		<u>5MG</u>	<u>A076833</u>	<u>001</u>	Mar 01, 2004
<u>AB</u>		<u>10MG</u>	<u>A075543</u>	<u>003</u>	Dec 24, 2003
<u>ZAROXOLYN</u>					
<u>AB</u>	UCB INC	<u>2.5MG</u>	<u>N017386</u>	<u>001</u>	
<u>AB</u>	+	<u>5MG</u>	<u>N017386</u>	<u>002</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N017386</u>	<u>003</u>	

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG TARTRATE</u>	<u>A090617</u>	<u>001</u>	Aug 01, 2012
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A090617</u>	<u>002</u>	Aug 01, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 25MG TARTRATE</u>	<u>A202033</u>	<u>001</u>	Dec 15, 2011
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A202033</u>	<u>002</u>	Dec 15, 2011
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A202033</u>	<u>003</u>	Dec 15, 2011
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A202033</u>	<u>004</u>	Dec 15, 2011
<u>AB</u>	NESHER PHARMS	<u>EQ 25MG TARTRATE</u>	<u>A077779</u>	<u>001</u>	Mar 20, 2008
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A077176</u>	<u>001</u>	May 14, 2008
<u>AB</u>	REDDYS	<u>EQ 100MG BASE</u>	<u>A078889</u>	<u>001</u>	Aug 15, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A078889</u>	<u>002</u>	Aug 15, 2012
<u>AB</u>	WATSON LABS FLORIDA	<u>EQ 25MG TARTRATE</u>	<u>A077118</u>	<u>001</u>	Aug 03, 2009
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A076862</u>	<u>001</u>	Aug 03, 2009
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A077298</u>	<u>001</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A077298</u>	<u>002</u>	Apr 15, 2010
<u>AB</u>	WOCKHARDT	<u>EQ 25MG TARTRATE</u>	<u>A090615</u>	<u>001</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A090615</u>	<u>002</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A090615</u>	<u>003</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A090615</u>	<u>004</u>	Jul 22, 2010
<u>TOPROL-XL</u>					
<u>AB</u>	ASTRAZENECA	<u>EQ 25MG TARTRATE</u>	<u>N019962</u>	<u>004</u>	Feb 05, 2001
<u>AB</u>	+	<u>EQ 50MG TARTRATE</u>	<u>N019962</u>	<u>001</u>	Jan 10, 1992

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 287 (of 428)

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

TOPROL-XL

<u>AB</u>	ASTRAZENECA	<u>EQ 100MG TARTRATE</u>	<u>N019962</u>	<u>002</u>	Jan 10, 1992
<u>AB</u>	+	<u>EQ 200MG TARTRATE</u>	<u>N019962</u>	<u>003</u>	Jan 10, 1992

METOPROLOL TARTRATE

INJECTABLE; INJECTION

LOPRESSOR

<u>AP</u>	+	NOVARTIS	<u>1MG/ML</u>	<u>N018704</u>	<u>001</u>	Mar 30, 1984

METOPROLOL TARTRATE

<u>AP</u>		BEDFORD LABS	<u>1MG/ML</u>	<u>A076495</u>	<u>001</u>	Jul 07, 2003
<u>AP</u>		FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A091045</u>	<u>001</u>	Oct 25, 2010
<u>AP</u>		HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A077761</u>	<u>001</u>	May 30, 2007
<u>AP</u>		HOSPIRA	<u>1MG/ML</u>	<u>A074133</u>	<u>001</u>	Dec 21, 1993
<u>AP</u>			<u>1MG/ML</u>	<u>A075160</u>	<u>001</u>	Jul 06, 1998
<u>AP</u>			<u>1MG/ML</u>	<u>A078085</u>	<u>001</u>	Apr 29, 2008
<u>AP</u>		LUITPOLD	<u>1MG/ML</u>	<u>A090386</u>	<u>001</u>	Sep 30, 2009
<u>AP</u>			<u>1MG/ML</u>	<u>A091307</u>	<u>001</u>	Dec 29, 2010
<u>AP</u>		SAGENT STRIDES	<u>1MG/ML</u>	<u>A090317</u>	<u>001</u>	Apr 19, 2010
<u>AP</u>		SANDOZ	<u>1MG/ML</u>	<u>A077360</u>	<u>001</u>	Oct 02, 2007
<u>AP</u>		WATSON LABS	<u>1MG/ML</u>	<u>A074032</u>	<u>001</u>	Dec 21, 1993

TABLET; ORAL

LOPRESSOR

<u>AB</u>		US PHARMS HOLDINGS I	<u>50MG</u>	<u>N017963</u>	<u>001</u>	
<u>AB</u>			<u>100MG</u>	<u>N017963</u>	<u>002</u>	
		<u>METOPROLOL TARTRATE</u>				
<u>AB</u>		AUROBINDO PHARMA	<u>25MG</u>	<u>A077739</u>	<u>001</u>	Sep 11, 2007
<u>AB</u>			<u>50MG</u>	<u>A077739</u>	<u>002</u>	Sep 11, 2007
<u>AB</u>			<u>100MG</u>	<u>A077739</u>	<u>003</u>	Sep 11, 2007
<u>AB</u>		CARACO	<u>25MG</u>	<u>A076670</u>	<u>001</u>	Jan 15, 2004
<u>AB</u>			<u>50MG</u>	<u>A074644</u>	<u>001</u>	Dec 10, 1996
<u>AB</u>			<u>100MG</u>	<u>A074644</u>	<u>002</u>	Dec 10, 1996
<u>AB</u>		IPCA LABS LTD	<u>25MG</u>	<u>A078459</u>	<u>001</u>	Jun 17, 2008
<u>AB</u>			<u>50MG</u>	<u>A078459</u>	<u>002</u>	Jun 17, 2008
<u>AB</u>			<u>100MG</u>	<u>A078459</u>	<u>003</u>	Jun 17, 2008
<u>AB</u>		MUTUAL PHARM	<u>25MG</u>	<u>A073654</u>	<u>002</u>	Jul 15, 2009
<u>AB</u>			<u>50MG</u>	<u>A073653</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>			<u>100MG</u>	<u>A073654</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>		MYLAN	<u>25MG</u>	<u>A076704</u>	<u>001</u>	Jan 16, 2004
<u>AB</u>			<u>50MG</u>	<u>A076704</u>	<u>002</u>	Jan 16, 2004
<u>AB</u>	+		<u>100MG</u>	<u>A076704</u>	<u>003</u>	Jan 16, 2004
<u>AB</u>		SANDOZ	<u>50MG</u>	<u>A073288</u>	<u>001</u>	Mar 25, 1994
<u>AB</u>			<u>100MG</u>	<u>A073289</u>	<u>001</u>	Mar 25, 1994
<u>AB</u>		TEVA	<u>50MG</u>	<u>A074141</u>	<u>001</u>	Jan 31, 1995
<u>AB</u>			<u>100MG</u>	<u>A074141</u>	<u>002</u>	Jan 31, 1995
<u>AB</u>		WATSON LABS	<u>50MG</u>	<u>A074217</u>	<u>001</u>	May 27, 1994
<u>AB</u>			<u>100MG</u>	<u>A074217</u>	<u>002</u>	May 27, 1994

METRONIDAZOLE

CAPSULE; ORAL

FLAGYL

<u>AB</u>	+	GD SEARLE LLC	<u>375MG</u>	<u>N020334</u>	<u>001</u>	May 03, 1995

METRONIDAZOLE

<u>AB</u>		ALEMBIC LTD	<u>375MG</u>	<u>A079065</u>	<u>001</u>	Jun 23, 2009
<u>AB</u>		PAR PHARM	<u>375MG</u>	<u>A076522</u>	<u>001</u>	Jan 29, 2004

CREAM; TOPICAL

METROCREAM

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N020531</u>	<u>001</u>	Sep 20, 1995

METRONIDAZOLE

<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A076408</u>	<u>001</u>	May 28, 2004

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 288 (of 428)

METRONIDAZOLE

CREAM; TOPICAL

METRONIDAZOLE

<u>AB</u>	G AND W LABS	<u>0.75%</u>	<u>A077549</u>	<u>001</u>	Dec 19, 2007
	NORITATE				
	+ VALEANT BERMUDA	1%	N020743	001	Sep 26, 1997

GEL; TOPICAL

METROGEL

<u>AB</u>	+ GALDERMA LABS LP	<u>0.75%</u>	<u>N019737</u>	<u>001</u>	Nov 22, 1988
<u>AB</u>	+	<u>1%</u>	<u>N021789</u>	<u>001</u>	Jun 30, 2005

METRONIDAZOLE

<u>AB</u>	FOUGERA PHARMS	<u>0.75%</u>	<u>A077018</u>	<u>001</u>	Jun 06, 2006
<u>AB</u>	G AND W LABS INC	<u>0.75%</u>	<u>A078178</u>	<u>001</u>	Jan 19, 2011
<u>AB</u>	TARO	<u>0.75%</u>	<u>A077819</u>	<u>001</u>	Jul 18, 2006
<u>AB</u>	TOLMAR	<u>0.75%</u>	<u>A077547</u>	<u>001</u>	Jul 13, 2006
<u>AB</u>		<u>1%</u>	<u>A090903</u>	<u>001</u>	Jul 22, 2011

GEL; VAGINAL

METROGEL - VAGINAL

<u>AB</u>	+ MEDICIS	<u>0.75%</u>	<u>N020208</u>	<u>001</u>	Aug 17, 1992

METRONIDAZOLE

<u>AB</u>	TOLMAR	<u>0.75%</u>	<u>A077264</u>	<u>001</u>	Oct 31, 2006
	VANDAZOLE				
BX	TEVA PHARMS	0.75%	N021806	001	May 20, 2005

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>500MG/100ML</u>	<u>N018657</u>	<u>001</u>	
<u>AP</u>	+ PFIZER	<u>500MG/100ML</u>	<u>N018353</u>	<u>002</u>	

METRO I.V. IN PLASTIC CONTAINER

<u>AP</u>	+ B BRAUN	<u>500MG/100ML</u>	<u>N018900</u>	<u>001</u>	Sep 29, 1983

METRONIDAZOLE IN PLASTIC CONTAINER

<u>AP</u>	CLARIS LIFESCIENCES	<u>500MG/100ML</u>	<u>A078084</u>	<u>001</u>	Mar 31, 2008
<u>AP</u>	+ HOSPIRA	<u>500MG/100ML</u>	<u>N018890</u>	<u>002</u>	Nov 18, 1983

LOTION; TOPICAL

METROLOTION

<u>AB</u>	+ GALDERMA LABS LP	<u>0.75%</u>	<u>N020901</u>	<u>001</u>	Nov 24, 1998

METRONIDAZOLE

<u>AB</u>	FOUGERA PHARMS	<u>0.75%</u>	<u>A077197</u>	<u>001</u>	May 24, 2006

TABLET; ORAL

FLAGYL

<u>AB</u>	GD SEARLE LLC	<u>250MG</u>	<u>N012623</u>	<u>001</u>	
<u>AB</u>	+	<u>500MG</u>	<u>N012623</u>	<u>003</u>	

METRONIDAZOLE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>250MG</u>	<u>A079067</u>	<u>001</u>	Mar 13, 2009
<u>AB</u>		<u>500MG</u>	<u>A079067</u>	<u>002</u>	Mar 13, 2009
<u>AB</u>	MUTUAL PHARM	<u>250MG</u>	<u>A070772</u>	<u>001</u>	Jul 16, 1986
<u>AB</u>		<u>500MG</u>	<u>A070773</u>	<u>001</u>	Jul 16, 1986
<u>AB</u>	PLIVA	<u>250MG</u>	<u>A070027</u>	<u>001</u>	Nov 06, 1984
<u>AB</u>		<u>500MG</u>	<u>A070033</u>	<u>001</u>	Dec 06, 1984
<u>AB</u>	TEVA	<u>500MG</u>	<u>A070044</u>	<u>001</u>	Feb 08, 1985
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A070035</u>	<u>001</u>	Dec 20, 1984
<u>AB</u>		<u>250MG</u>	<u>N018764</u>	<u>001</u>	Sep 17, 1982
<u>AB</u>		<u>500MG</u>	<u>N018764</u>	<u>002</u>	Dec 20, 1982

TABLET, EXTENDED RELEASE; ORAL

FLAGYL ER

<u>AB</u>	+ GD SEARLE LLC	<u>750MG</u>	<u>N020868</u>	<u>001</u>	Nov 26, 1997

METRONIDAZOLE

<u>AB</u>	ALEMBIC LTD	<u>750MG</u>	<u>A090222</u>	<u>001</u>	May 05, 2010

METYRAPONE

CAPSULE; ORAL

METOPIRONE

	+ HRA PHARMA	250MG	N012911	002	Aug 09, 1996

PRESCRIPTION DRUG PRODUCT LIST

3 - 289 (of 428)

METYROSINE

CAPSULE; ORAL
DEMSE

+ BIOVAIL TECHNOLOGIES 250MG	N017871	001

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

<u>AB</u>	TEVA	<u>150MG</u>	<u>A074377</u>	<u>001</u>	May 16, 1995
<u>AB</u>		<u>200MG</u>	<u>A074377</u>	<u>002</u>	May 16, 1995
<u>AB</u>	+	<u>250MG</u>	<u>A074377</u>	<u>003</u>	May 16, 1995
<u>AB</u>	WATSON LABS	<u>150MG</u>	<u>A074711</u>	<u>001</u>	Feb 26, 1997
<u>AB</u>		<u>150MG</u>	<u>A074865</u>	<u>001</u>	Apr 13, 1998
<u>AB</u>		<u>200MG</u>	<u>A074711</u>	<u>002</u>	Feb 26, 1997
<u>AB</u>		<u>200MG</u>	<u>A074865</u>	<u>002</u>	Apr 13, 1998
<u>AB</u>		<u>250MG</u>	<u>A074711</u>	<u>003</u>	Feb 26, 1997
<u>AB</u>		<u>250MG</u>	<u>A074865</u>	<u>003</u>	Apr 13, 1998

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)

+ ASTELLAS 50MG/VIAL	N021506	002	Mar 16, 2005
+ 100MG/VIAL	N021506	003	Jun 27, 2006

MICONAZOLE

TABLET; BUCCAL
ORAVIG

+ VESTIQ PHARMS 50MG	N022404	001	Apr 16, 2010

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>200MG</u>	<u>A073508</u>	<u>001</u>	Nov 19, 1993
	<u>MONISTAT 3</u>				
<u>AB</u>	+	<u>200MG</u>	<u>N018888</u>	<u>001</u>	Aug 15, 1984

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL
VUSION

+ STIEFEL LABS INC 0.25%;81.35%;15%	N021026	001	Feb 16, 2006

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>EQ 1MG BASE/ML</u>	<u>A075247</u>	<u>002</u>	Jun 23, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075247</u>	<u>001</u>	Jun 23, 2000
<u>AP</u>	BEN VENUE	<u>EQ 1MG BASE/ML</u>	<u>A075421</u>	<u>002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075421</u>	<u>001</u>	Jun 20, 2000
<u>AP</u>	CLARIS LIFESCIENCES	<u>EQ 1MG BASE/ML</u>	<u>A075637</u>	<u>001</u>	Oct 31, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075637</u>	<u>002</u>	Oct 31, 2000
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1MG BASE/ML</u>	<u>A075154</u>	<u>002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075154</u>	<u>001</u>	Jun 20, 2000
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 1MG BASE/ML</u>	<u>A090696</u>	<u>001</u>	Feb 29, 2012
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A090850</u>	<u>001</u>	Jan 25, 2012
<u>AP</u>	HIKMA MAPLE	<u>EQ 1MG BASE/ML</u>	<u>A075243</u>	<u>001</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075324</u>	<u>001</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075243</u>	<u>002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075324</u>	<u>002</u>	Jun 20, 2000
<u>AP</u>	+	<u>EQ 1MG BASE/ML</u>	<u>A075293</u>	<u>001</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075856</u>	<u>001</u>	Jun 13, 2002
<u>AP</u>	+	<u>EQ 5MG BASE/ML</u>	<u>A075293</u>	<u>002</u>	Jun 20, 2000

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 290 (of 428)

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>EQ 5MG BASE/ML</u>	<u>A075856</u>	<u>002</u>	Jun 13, 2002
<u>AP</u>	INTL MEDICATED	<u>EQ 1MG BASE/ML</u>	<u>A076144</u>	<u>001</u>	Jan 26, 2005
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A076144</u>	<u>002</u>	Jan 26, 2005
<u>AP</u>	INTL MEDICATION	<u>EQ 1MG BASE/ML</u>	<u>A076020</u>	<u>001</u>	Jul 16, 2004
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A076020</u>	<u>002</u>	Jul 16, 2004
<u>AP</u>	TAYLOR	<u>EQ 1MG BASE/ML</u>	<u>A075494</u>	<u>001</u>	Jun 30, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075481</u>	<u>001</u>	Jun 30, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075494</u>	<u>002</u>	Jun 30, 2000
<u>AP</u>	WOCKHARDT	<u>EQ 1MG BASE/ML</u>	<u>A078141</u>	<u>001</u>	May 30, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A078511</u>	<u>001</u>	Nov 10, 2008
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A078141</u>	<u>002</u>	May 30, 2008
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A078511</u>	<u>002</u>	Nov 10, 2008

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	+ HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>A075857</u>	<u>001</u>	Jul 22, 2002
<u>AP</u>	+	<u>EQ 5MG BASE/ML</u>	<u>A075857</u>	<u>002</u>	Jul 22, 2002
<u>AP</u>	SAGENT STRIDES	<u>EQ 1MG BASE/ML</u>	<u>A090315</u>	<u>001</u>	Nov 29, 2010
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A090315</u>	<u>002</u>	Nov 29, 2010

MIDOZALAM HYDROCHLORIDE

<u>AP</u>	SAGENT STRIDES	<u>EQ 1MG BASE/ML</u>	<u>A090316</u>	<u>001</u>	May 04, 2011
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A090316</u>	<u>002</u>	May 04, 2011

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

<u>AA</u>	APOTEX INC	<u>EQ 2MG BASE/ML</u>	<u>A077115</u>	<u>001</u>	Sep 09, 2005
<u>AA</u>	HI TECH PHARMA	<u>EQ 2MG BASE/ML</u>	<u>A075958</u>	<u>001</u>	Sep 04, 2003
<u>AA</u>	PADDOCK LLC	<u>EQ 2MG BASE/ML</u>	<u>A076379</u>	<u>001</u>	May 02, 2005
<u>AA</u>	RANBAXY	<u>EQ 2MG BASE/ML</u>	<u>A076058</u>	<u>001</u>	Mar 15, 2002
<u>AA</u>	+ ROXANE	<u>EQ 2MG BASE/ML</u>	<u>A075873</u>	<u>001</u>	Apr 30, 2002

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A077746</u>	<u>001</u>	Sep 12, 2006
<u>AB</u>		<u>5MG</u>	<u>A077746</u>	<u>002</u>	Sep 12, 2006
<u>AB</u>		<u>10MG</u>	<u>A077746</u>	<u>003</u>	Sep 12, 2006
<u>AB</u>	IMPAX PHARMS	<u>2.5MG</u>	<u>A076449</u>	<u>001</u>	May 27, 2004
<u>AB</u>		<u>5MG</u>	<u>A076449</u>	<u>002</u>	May 27, 2004
<u>AB</u>		<u>10MG</u>	<u>A076449</u>	<u>003</u>	Dec 16, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>2.5MG</u>	<u>A076577</u>	<u>001</u>	Sep 10, 2003
<u>AB</u>	+	<u>5MG</u>	<u>A076577</u>	<u>002</u>	Sep 10, 2003
<u>AB</u>		<u>10MG</u>	<u>A076577</u>	<u>003</u>	Sep 10, 2003
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A076514</u>	<u>001</u>	Sep 11, 2003
<u>AB</u>		<u>5MG</u>	<u>A076514</u>	<u>002</u>	Sep 11, 2003
<u>AB</u>		<u>10MG</u>	<u>A076514</u>	<u>003</u>	Jul 02, 2004
<u>ORVATEN</u>					
<u>AB</u>	UPSHER SMITH	<u>2.5MG</u>	<u>A076725</u>	<u>001</u>	Nov 03, 2004
<u>AB</u>		<u>5MG</u>	<u>A076725</u>	<u>002</u>	Nov 03, 2004
<u>AB</u>		<u>10MG</u>	<u>A076725</u>	<u>003</u>	Nov 03, 2004

MIFEPRISTONE

TABLET; ORAL

KORLYM

+	CORCEPT THERAP	300MG	N202107	001	Feb 17, 2012
MIFEPREX					
+	DANCO LABS LLC	200MG	N020687	001	Sep 28, 2000

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 291 (of 428)

MIGLITOLTABLET; ORAL
GLYSET

PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996
	50MG	N020682	002	Dec 18, 1996
+	100MG	N020682	003	Dec 18, 1996

MIGLUSTATCAPSULE; ORAL
ZAVESCA

+ ACTELION PHARMS LTD	100MG	N021348	001	Jul 31, 2003

MILNACIPRAN HYDROCHLORIDETABLET; ORAL
SAVELLA

CYPRESS BIOSCIENCE	12.5MG	N022256	001	Jan 14, 2009
	25MG	N022256	002	Jan 14, 2009
+	50MG	N022256	003	Jan 14, 2009
	100MG	N022256	004	Jan 14, 2009

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP + BEDFORD	EQ 1MG BASE/ML	A075660	001	May 28, 2002
AP CLARIS LIFESCIENCES	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004
AP FRESENIUS KABI USA	EQ 1MG BASE/ML	A075936	001	May 28, 2002
AP GLAND PHARMA LTD	EQ 1MG BASE/ML	A077190	001	Oct 31, 2006
AP HIKMA FARMACEUTICA	EQ 1MG BASE/ML	A077966	001	Dec 03, 2010
AP HIKMA MAPLE	EQ 1MG BASE/ML	A075530	001	May 28, 2002
AP INTL MEDICATED	EQ 1MG BASE/ML	A076013	001	Aug 02, 2002

MILRINONE LACTATE IN DEXTROSE 5%

AP CLARIS LIFESCIENCES	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP B BRAUN	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076414	001	Aug 18, 2004
AP + BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075834	001	May 28, 2002
AP +	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A075834	002	May 28, 2002
AP BEDFORD LABS	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008
AP	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008
AP CLARIS LIFESCIENCES	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005
AP HOSPIRA	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075885	001	May 28, 2002
AP	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A075885	002	May 28, 2002

MILRINONE LACTATE IN PLASTIC CONTAINER

AP HIKMA FARMACEUTICA	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A090038	001	Jan 21, 2010
AP	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A090038	002	Jan 21, 2010

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DYNACIN

AB MEDICIS	EQ 75MG BASE	A063067	002	Sep 15, 1999
AB	EQ 100MG BASE	A063067	001	Jul 31, 1990

MINOCIN

AB PRECISION DERMAT	EQ 50MG BASE	N050649	001	May 31, 1990
AB	EQ 100MG BASE	N050649	002	May 31, 1990

MINOCYCLINE HYDROCHLORIDE

AB AUROBINDO PHARMA	EQ 50MG BASE	A065470	001	Mar 11, 2008
AB	EQ 75MG BASE	A065470	002	Mar 11, 2008
AB	EQ 100MG BASE	A065470	003	Mar 11, 2008
AB IMPAX LABS	EQ 50MG BASE	A065005	001	Mar 23, 1999
AB	EQ 75MG BASE	A065005	003	Apr 18, 2001
AB	EQ 100MG BASE	A065005	002	Mar 23, 1999
AB RANBAXY	EQ 50MG BASE	A065062	001	Nov 30, 2000

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 292 (of 428)

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	RANBAXY	<u>EQ 75MG BASE</u>	<u>A065062</u>	<u>002</u>	Nov 30, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065062</u>	<u>003</u>	Nov 30, 2000
<u>AB</u>	TEVA	<u>EQ 50MG BASE</u>	<u>A063011</u>	<u>001</u>	Mar 02, 1992
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A063009</u>	<u>002</u>	Aug 12, 2003
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>A063009</u>	<u>001</u>	Mar 02, 1992
<u>AB</u>	WATSON LABS	<u>EQ 50MG BASE</u>	<u>A063181</u>	<u>001</u>	Dec 30, 1991
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A063065</u>	<u>002</u>	Jun 10, 1999
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A063065</u>	<u>001</u>	Dec 30, 1991

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

	RANBAXY LABS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012
		EQ 67.5MG BASE	N201922	002	Jul 11, 2012
		EQ 90MG BASE	N201922	003	Jul 11, 2012
		EQ 112.5MG BASE	N201922	004	Jul 11, 2012
	+	EQ 135MG BASE	N201922	005	Jul 11, 2012

INJECTABLE; INJECTION

MINOCIN

	+	REMPEX PHARMS INC	EQ 100MG BASE/VIAL	N050444	001

POWDER, EXTENDED RELEASE; DENTAL

ARESTIN

	+	ORAPHARMA	EQ 1MG BASE	N050781	001	Feb 16, 2001

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 50MG BASE</u>	<u>A065436</u>	<u>001</u>	Dec 26, 2007
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065436</u>	<u>002</u>	Dec 26, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065436</u>	<u>003</u>	Dec 26, 2007
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065131</u>	<u>001</u>	Apr 16, 2003
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065131</u>	<u>002</u>	Apr 16, 2003
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>A065131</u>	<u>003</u>	Apr 16, 2003
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE</u>	<u>A065156</u>	<u>001</u>	Jan 06, 2004
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065156</u>	<u>002</u>	Jan 06, 2004
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065156</u>	<u>003</u>	Jan 06, 2004

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 45MG BASE</u>	<u>A202261</u>	<u>001</u>	Nov 19, 2012
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A202261</u>	<u>003</u>	Nov 19, 2012
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A202261</u>	<u>005</u>	Nov 19, 2012
<u>AB</u>	BARR LABS INC	<u>EQ 45MG BASE</u>	<u>A065485</u>	<u>001</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 65MG BASE</u>	<u>A065485</u>	<u>004</u>	May 18, 2012
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A065485</u>	<u>002</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 115MG BASE</u>	<u>A065485</u>	<u>005</u>	May 18, 2012
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A065485</u>	<u>003</u>	Mar 17, 2009
<u>AB</u>	IMPAX LABS INC	<u>EQ 45MG BASE</u>	<u>A090024</u>	<u>001</u>	Feb 03, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090024</u>	<u>002</u>	Feb 03, 2009
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A090024</u>	<u>003</u>	Feb 03, 2009
<u>AB</u>	LUPIN LTD	<u>EQ 45MG BASE</u>	<u>A091424</u>	<u>001</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A091424</u>	<u>003</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A091424</u>	<u>004</u>	Nov 30, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 45MG BASE</u>	<u>A090911</u>	<u>001</u>	Jul 20, 2010
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090911</u>	<u>002</u>	Jul 20, 2010
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A090911</u>	<u>003</u>	Jul 20, 2010
<u>AB</u>	SANDOZ	<u>EQ 45MG BASE</u>	<u>A090422</u>	<u>001</u>	Aug 13, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090422</u>	<u>002</u>	Aug 13, 2009
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A090422</u>	<u>003</u>	Aug 13, 2009

SOLODYN

<u>AB</u>	MEDICIS	<u>EQ 45MG BASE</u>	<u>N050808</u>	<u>001</u>	May 08, 2006
<u>AB</u>		<u>EQ 65MG BASE</u>	<u>N050808</u>	<u>004</u>	Jul 23, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>N050808</u>	<u>002</u>	May 08, 2006

PRESCRIPTION DRUG PRODUCT LIST

3 - 293 (of 428)

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

SOLODYN

<u>AB</u>	MEDICIS	<u>EQ 115MG BASE</u>	<u>N050808</u>	<u>005</u>	Jul 23, 2009
<u>AB</u>	+	<u>EQ 135MG BASE</u>	<u>N050808</u>	<u>003</u>	May 08, 2006
	SOLODYN				
	MEDICIS	EQ 55MG BASE	N050808	008	Aug 27, 2010
		EQ 80MG BASE	N050808	007	Aug 27, 2010
		EQ 105MG BASE	N050808	006	Aug 27, 2010

MINOXIDIL

TABLET; ORAL

MINOXIDIL

<u>AB</u>	MUTUAL PHARM	<u>2.5MG</u>	<u>A072708</u>	<u>001</u>	Dec 14, 1995
<u>AB</u>		<u>10MG</u>	<u>A072709</u>	<u>001</u>	Dec 14, 1995
<u>AB</u>	PAR PHARM	<u>2.5MG</u>	<u>A071826</u>	<u>001</u>	Nov 14, 1988
<u>AB</u>		<u>10MG</u>	<u>A071839</u>	<u>001</u>	Nov 14, 1988
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A071344</u>	<u>001</u>	Mar 03, 1987
<u>AB</u>	+	<u>10MG</u>	<u>A071345</u>	<u>001</u>	Mar 03, 1987

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL

MYRBETRIQ

	APGDI	25MG	N202611	001	Jun 28, 2012
	+	50MG	N202611	002	Jun 28, 2012

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

<u>AB</u>	APOTEX INC	<u>15MG</u>	<u>A077666</u>	<u>001</u>	Aug 22, 2007
<u>AB</u>		<u>30MG</u>	<u>A077666</u>	<u>002</u>	Aug 22, 2007
<u>AB</u>		<u>45MG</u>	<u>A077666</u>	<u>003</u>	Aug 22, 2007
<u>AB</u>	AUROBINDO	<u>7.5MG</u>	<u>A076921</u>	<u>001</u>	Oct 22, 2004
<u>AB</u>		<u>15MG</u>	<u>A076921</u>	<u>002</u>	Oct 22, 2004
<u>AB</u>		<u>30MG</u>	<u>A076921</u>	<u>003</u>	Oct 22, 2004
<u>AB</u>		<u>45MG</u>	<u>A076921</u>	<u>004</u>	Oct 22, 2004
<u>AB</u>	CARACO	<u>7.5MG</u>	<u>A076541</u>	<u>004</u>	Apr 22, 2004
<u>AB</u>		<u>15MG</u>	<u>A076541</u>	<u>001</u>	Apr 22, 2004
<u>AB</u>		<u>30MG</u>	<u>A076541</u>	<u>002</u>	Apr 22, 2004
<u>AB</u>		<u>45MG</u>	<u>A076541</u>	<u>003</u>	Apr 22, 2004
<u>AB</u>	MYLAN	<u>15MG</u>	<u>A076122</u>	<u>001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076122</u>	<u>002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076122</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	MYLAN PHARMS INC	<u>15MG</u>	<u>A076176</u>	<u>001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076176</u>	<u>002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076176</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A076219</u>	<u>001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076219</u>	<u>002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076219</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	TEVA	<u>15MG</u>	<u>A076119</u>	<u>001</u>	Jan 24, 2003
<u>AB</u>		<u>30MG</u>	<u>A076119</u>	<u>002</u>	Jan 24, 2003
<u>AB</u>		<u>45MG</u>	<u>A076119</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	WATSON LABS	<u>15MG</u>	<u>A076312</u>	<u>001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076312</u>	<u>002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076312</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	WATSON LABS FLORIDA	<u>15MG</u>	<u>A076336</u>	<u>001</u>	Jun 20, 2003
<u>AB</u>		<u>30MG</u>	<u>A076336</u>	<u>002</u>	Jun 20, 2003
<u>AB</u>		<u>45MG</u>	<u>A076336</u>	<u>003</u>	Jun 20, 2003
	<u>REMERON</u>				
<u>AB</u>	+	<u>15MG</u>	<u>N020415</u>	<u>001</u>	Jun 14, 1996
<u>AB</u>		<u>30MG</u>	<u>N020415</u>	<u>002</u>	Jun 14, 1996

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 294 (of 428)

MIRTAZAPINE

TABLET; ORAL

REMERON

<u>AB</u>	ORGANON USA INC	<u>45MG</u>	<u>N020415</u>	<u>003</u>	Mar 17, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>15MG</u>	<u>A077959</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>		<u>30MG</u>	<u>A077959</u>	<u>002</u>	Feb 14, 2011
<u>AB</u>		<u>45MG</u>	<u>A077959</u>	<u>003</u>	Feb 14, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>15MG</u>	<u>A077376</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		<u>30MG</u>	<u>A077376</u>	<u>003</u>	Dec 08, 2005
<u>AB</u>		<u>45MG</u>	<u>A077376</u>	<u>004</u>	Feb 28, 2006
<u>AB</u>	TEVA	<u>15MG</u>	<u>A076901</u>	<u>001</u>	Jun 28, 2005
<u>AB</u>		<u>30MG</u>	<u>A076901</u>	<u>002</u>	Jun 28, 2005
<u>AB</u>		<u>45MG</u>	<u>A076901</u>	<u>003</u>	Jun 28, 2005
<u>AB</u>	WATSON LABS	<u>15MG</u>	<u>A076307</u>	<u>001</u>	Dec 17, 2003
<u>AB</u>		<u>30MG</u>	<u>A076307</u>	<u>002</u>	Dec 17, 2003
<u>AB</u>		<u>45MG</u>	<u>A076307</u>	<u>003</u>	Feb 28, 2006

<u>REMERON SOLTAB</u>					
<u>AB</u>	+ ORGANON USA INC	<u>15MG</u>	<u>N021208</u>	<u>001</u>	Jan 12, 2001
<u>AB</u>		<u>30MG</u>	<u>N021208</u>	<u>002</u>	Jan 12, 2001
<u>AB</u>		<u>45MG</u>	<u>N021208</u>	<u>003</u>	Jan 12, 2001

MISOPROSTOL

TABLET; ORAL

CYTOTEC

<u>AB</u>	GD SEARLE LLC	<u>0.1MG</u>	<u>N019268</u>	<u>003</u>	Sep 21, 1990
<u>AB</u>	+	<u>0.2MG</u>	<u>N019268</u>	<u>001</u>	Dec 27, 1988

<u>MISOPROSTOL</u>					
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>0.1MG</u>	<u>A076095</u>	<u>001</u>	Jul 10, 2002
<u>AB</u>		<u>0.2MG</u>	<u>A076095</u>	<u>002</u>	Jul 10, 2002
<u>AB</u>	NOVEL LABS INC	<u>0.1MG</u>	<u>A091667</u>	<u>001</u>	Jul 25, 2012
<u>AB</u>		<u>0.2MG</u>	<u>A091667</u>	<u>002</u>	Jul 25, 2012

MITOMYCIN

FOR SOLUTION; TOPICAL

MITOSOL

+	MOBIUS THERAP	0.2MG/VIAL	N022572	001	Feb 07, 2012

INJECTABLE; INJECTION

MITOMYCIN

<u>AP</u>	+	ACCORD HLTHCARE	<u>5MG/VIAL</u>	<u>A064144</u>	<u>001</u>	Apr 30, 1998
<u>AP</u>	+		<u>20MG/VIAL</u>	<u>A064144</u>	<u>002</u>	Apr 30, 1998
<u>AP</u>	+		<u>40MG/VIAL</u>	<u>A064144</u>	<u>003</u>	Aug 11, 2009
<u>AP</u>		BEDFORD	<u>5MG/VIAL</u>	<u>A064117</u>	<u>001</u>	Apr 19, 1995
<u>AP</u>			<u>20MG/VIAL</u>	<u>A064117</u>	<u>002</u>	Apr 19, 1995
<u>AP</u>		HIKMA MAPLE	<u>5MG/VIAL</u>	<u>A064180</u>	<u>001</u>	Dec 23, 1999
<u>AP</u>			<u>20MG/VIAL</u>	<u>A064180</u>	<u>002</u>	Dec 23, 1999

MITOTANE

TABLET; ORAL

LYSODREN

+	BRISTOL MYERS SQUIBB	500MG	N016885	001	

MITOXANTRONE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

<u>AP</u>	ONCO THERAPIES LTD	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A201014</u>	<u>001</u>	Dec 11, 2012

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A076611</u>	<u>001</u>	Apr 11, 2006

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 295 (of 428)

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A076611</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A076611</u>	<u>003</u>	Apr 11, 2006
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A077496</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A077496</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A077496</u>	<u>003</u>	Apr 11, 2006
<u>AP</u>	+ HOSPIRA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A076871</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>	+	<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A076871</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>	+	<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A076871</u>	<u>003</u>	Apr 11, 2006
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A078980</u>	<u>001</u>	Apr 13, 2009
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A078980</u>	<u>002</u>	Apr 13, 2009
<u>AP</u>	TEVA PARENTERAL	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A077356</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A077356</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A077356</u>	<u>003</u>	Apr 11, 2006

MODAFINIL

TABLET; ORAL

MODAFINIL

<u>AB</u>	ALEMBIC LTD	<u>100MG</u>	<u>A202700</u>	<u>001</u>	Oct 18, 2012
<u>AB</u>		<u>200MG</u>	<u>A202700</u>	<u>002</u>	Oct 18, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>100MG</u>	<u>A202566</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>200MG</u>	<u>A202566</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>	CARLSBAD	<u>100MG</u>	<u>A076715</u>	<u>001</u>	Nov 01, 2012
<u>AB</u>		<u>200MG</u>	<u>A076715</u>	<u>002</u>	Nov 01, 2012
<u>AB</u>	HIKMA PHARMS	<u>100MG</u>	<u>A090543</u>	<u>001</u>	Sep 26, 2012
<u>AB</u>		<u>200MG</u>	<u>A090543</u>	<u>002</u>	Sep 26, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>100MG</u>	<u>A076594</u>	<u>001</u>	Jul 16, 2012
<u>AB</u>		<u>200MG</u>	<u>A076594</u>	<u>002</u>	Jul 16, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>100MG</u>	<u>A078963</u>	<u>001</u>	Sep 26, 2012
<u>AB</u>		<u>200MG</u>	<u>A078963</u>	<u>002</u>	Sep 26, 2012
	<u>PROVIGIL</u>				
<u>AB</u>	CEPHALON	<u>100MG</u>	<u>N020717</u>	<u>001</u>	Dec 24, 1998
<u>AB</u>	+	<u>200MG</u>	<u>N020717</u>	<u>002</u>	Dec 24, 1998

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>7.5MG</u>	<u>A078454</u>	<u>001</u>	Jun 02, 2008
<u>AB</u>		<u>15MG</u>	<u>A078454</u>	<u>002</u>	Jun 02, 2008
<u>AB</u>	GLENMARK GENERICS	<u>7.5MG</u>	<u>A090416</u>	<u>001</u>	Mar 30, 2010
<u>AB</u>		<u>15MG</u>	<u>A090416</u>	<u>002</u>	Mar 30, 2010
<u>AB</u>	PADDOCK LLC	<u>7.5MG</u>	<u>A077536</u>	<u>001</u>	Nov 30, 2006
<u>AB</u>		<u>15MG</u>	<u>A077536</u>	<u>002</u>	Nov 30, 2006
<u>AB</u>	TEVA	<u>7.5MG</u>	<u>A076204</u>	<u>001</u>	May 08, 2003
<u>AB</u>		<u>15MG</u>	<u>A076204</u>	<u>002</u>	May 08, 2003
	<u>UNIVASC</u>				
<u>AB</u>	UCB INC	<u>7.5MG</u>	<u>N020312</u>	<u>001</u>	Apr 19, 1995
<u>AB</u>	+	<u>15MG</u>	<u>N020312</u>	<u>002</u>	Apr 19, 1995

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

<u>AB</u>	+ MERCK SHARP DOHME	<u>0.1%</u>	<u>N019625</u>	<u>001</u>	May 06, 1987
	<u>MOMETASONE FUROATE</u>				
<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A076171</u>	<u>001</u>	Apr 08, 2005
<u>AB</u>	G AND W LABS	<u>0.1%</u>	<u>A077447</u>	<u>001</u>	May 22, 2006
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A078541</u>	<u>001</u>	May 28, 2008
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076679</u>	<u>001</u>	Dec 21, 2004
<u>AB</u>	TOLMAR	<u>0.1%</u>	<u>A076591</u>	<u>001</u>	Apr 18, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 296 (of 428)

MOMETASONE FUROATE

LOTION; TOPICAL

ELOCON

<u>AB</u>	+ MERCK SHARP DOHME	<u>0.1%</u>	<u>N019796</u>	<u>001</u>	Mar 30, 1989
	<u>MOMETASONE FUROATE</u>				
<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A075919</u>	<u>001</u>	Nov 29, 2007
<u>AB</u>	G AND W LABS	<u>0.1%</u>	<u>A077678</u>	<u>001</u>	Nov 21, 2007
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A090506</u>	<u>001</u>	Aug 09, 2010
<u>AB</u>	PERRIGO	<u>0.1%</u>	<u>A077180</u>	<u>001</u>	Apr 06, 2005
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076788</u>	<u>001</u>	Mar 15, 2006
<u>AB</u>	TOLMAR	<u>0.1%</u>	<u>A076499</u>	<u>001</u>	Nov 21, 2007

OINTMENT; TOPICAL

ELOCON

<u>AB</u>	+ MERCK SHARP DOHME	<u>0.1%</u>	<u>N019543</u>	<u>001</u>	Apr 30, 1987
	<u>MOMETASONE FUROATE</u>				
<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A077061</u>	<u>001</u>	Mar 28, 2005
<u>AB</u>	G AND W LABS	<u>0.1%</u>	<u>A077401</u>	<u>001</u>	Jun 20, 2006
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A078571</u>	<u>001</u>	May 28, 2008
<u>AB</u>	PERRIGO NEW YORK	<u>0.1%</u>	<u>A076067</u>	<u>001</u>	Mar 18, 2002
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076624</u>	<u>001</u>	Dec 03, 2004
<u>AB</u>	TOLMAR	<u>0.1%</u>	<u>A076481</u>	<u>001</u>	Nov 14, 2003

POWDER; INHALATION

ASMANEX TWISTHALER

SCHERING

0.11MG/INH

N021067 002 Feb 01, 2008

+

0.22MG/INH

N021067 001 Mar 30, 2005

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL

NASONEX

+ SCHERING PLOUGH

EQ 0.05MG BASE/SPRAY

N020762 001 Oct 01, 1997

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/PACKET</u>	<u>A202906</u>	<u>001</u>	Sep 17, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 4MG BASE/PACKET</u>	<u>A202776</u>	<u>001</u>	Dec 18, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE/PACKET</u>	<u>A090955</u>	<u>001</u>	Aug 03, 2012
	<u>SINGULAIR</u>				
<u>AB</u>	+ MERCK	<u>EQ 4MG BASE/PACKET</u>	<u>N021409</u>	<u>001</u>	Jul 26, 2002

TABLET; ORAL

MONTELUKAST SODIUM

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 10MG BASE</u>	<u>A202717</u>	<u>001</u>	Sep 21, 2012
<u>AB</u>	APOTEX CORP	<u>EQ 10MG BASE</u>	<u>A201294</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 10MG BASE</u>	<u>A202468</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A201582</u>	<u>001</u>	Aug 06, 2012
<u>AB</u>	GLENMARK GENERICS	<u>EQ 10MG BASE</u>	<u>A090926</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	KUDCO IRELAND	<u>EQ 10MG BASE</u>	<u>A201522</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A079103</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	ROXANE	<u>EQ 10MG BASE</u>	<u>A090655</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 10MG BASE</u>	<u>A200889</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A078605</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A201515</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	VINTAGE PHARMS LLC	<u>EQ 10MG BASE</u>	<u>A091576</u>	<u>001</u>	Aug 03, 2012

SINGULAIR

<u>AB</u>	+ MERCK	<u>EQ 10MG BASE</u>	<u>N020829</u>	<u>002</u>	Feb 20, 1998

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

<u>AB</u>	APOTEX INC	<u>EQ 4MG BASE</u>	<u>A201508</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A201508</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A202096</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A202096</u>	<u>002</u>	Aug 03, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 297 (of 428)

MONTELUKAST SODIUM

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A201581</u>	<u>001</u>	Aug 06, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A201581</u>	<u>002</u>	Aug 06, 2012
<u>AB</u>	KUDCO IRELAND	<u>EQ 4MG BASE</u>	<u>A200405</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A200405</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 4MG BASE</u>	<u>A079142</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079142</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	ROXANE	<u>EQ 4MG BASE</u>	<u>A091128</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091128</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 4MG BASE</u>	<u>A091414</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091414</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE</u>	<u>A078723</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078723</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 4MG BASE</u>	<u>A090984</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090984</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	VINTAGE PHARMS LLC	<u>EQ 4MG BASE</u>	<u>A091588</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091588</u>	<u>002</u>	Aug 03, 2012
<u>SINGULAIR</u>					
<u>AB</u>	MERCK	<u>EQ 4MG BASE</u>	<u>N020830</u>	<u>002</u>	Mar 03, 2000
<u>AB</u>	+	<u>EQ 5MG BASE</u>	<u>N020830</u>	<u>001</u>	Feb 20, 1998

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

<u>AB</u>	PAR PHARM INC	<u>20MG</u>	<u>A200812</u>	<u>001</u>	Nov 10, 2011
<u>AB</u>		<u>30MG</u>	<u>A200812</u>	<u>002</u>	Nov 10, 2011
<u>AB</u>		<u>50MG</u>	<u>A200812</u>	<u>003</u>	Nov 10, 2011
<u>AB</u>		<u>60MG</u>	<u>A200812</u>	<u>004</u>	Nov 10, 2011
<u>AB</u>		<u>80MG</u>	<u>A200812</u>	<u>005</u>	Nov 10, 2011
<u>AB</u>		<u>100MG</u>	<u>A200812</u>	<u>006</u>	Nov 10, 2011
<u>KADIAN</u>					
<u>AB1</u>	ACTAVIS ELIZABETH	<u>20MG</u>	<u>N020616</u>	<u>001</u>	Jul 03, 1996
<u>AB1</u>		<u>30MG</u>	<u>N020616</u>	<u>004</u>	Mar 09, 2001
<u>AB1</u>		<u>50MG</u>	<u>N020616</u>	<u>002</u>	Jul 03, 1996
<u>AB1</u>		<u>60MG</u>	<u>N020616</u>	<u>005</u>	Mar 09, 2001
<u>AB1</u>		<u>80MG</u>	<u>N020616</u>	<u>006</u>	Oct 27, 2006
<u>AB1</u>	+	<u>100MG</u>	<u>N020616</u>	<u>003</u>	Jul 03, 1996
<u>AVINZA</u>					
<u>AB2</u>	KING PFIZER	<u>30MG</u>	<u>N021260</u>	<u>001</u>	Mar 20, 2002
<u>AB2</u>		<u>45MG</u>	<u>N021260</u>	<u>005</u>	Dec 18, 2008
<u>AB2</u>		<u>60MG</u>	<u>N021260</u>	<u>002</u>	Mar 20, 2002
<u>AB2</u>		<u>75MG</u>	<u>N021260</u>	<u>006</u>	Dec 18, 2008
<u>AB2</u>		<u>90MG</u>	<u>N021260</u>	<u>003</u>	Mar 20, 2002
<u>AB2</u>	+	<u>120MG</u>	<u>N021260</u>	<u>004</u>	Mar 20, 2002
<u>MORPHINE SULFATE</u>					
<u>AB2</u>	ACTAVIS ELIZABETH	<u>30MG</u>	<u>A079040</u>	<u>001</u>	Jan 16, 2013
<u>AB2</u>		<u>45MG</u>	<u>A079040</u>	<u>002</u>	Jan 16, 2013
<u>AB2</u>		<u>60MG</u>	<u>A079040</u>	<u>003</u>	Jan 16, 2013
<u>AB2</u>		<u>75MG</u>	<u>A079040</u>	<u>004</u>	Jan 16, 2013
<u>AB2</u>		<u>90MG</u>	<u>A079040</u>	<u>005</u>	Jan 16, 2013
<u>AB2</u>		<u>120MG</u>	<u>A079040</u>	<u>006</u>	Jan 16, 2013
<u>KADIAN</u>					
+	ACTAVIS ELIZABETH	10MG	N020616	008	Apr 20, 2007
		40MG	N020616	009	Jul 09, 2012
		70MG	N020616	010	Jul 09, 2012
		130MG	N020616	011	Jul 09, 2012
		150MG	N020616	012	Jul 09, 2012
+		200MG	N020616	007	Feb 27, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 298 (of 428)

MORPHINE SULFATE

INJECTABLE; INJECTION

ASTRAMORPH PF

<u>AP</u>	FRESENIUS KABI USA	<u>0.5MG/ML</u>	<u>A071050</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>		<u>0.5MG/ML</u>	<u>A071051</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>		<u>1MG/ML</u>	<u>A071052</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>		<u>1MG/ML</u>	<u>A071053</u>	<u>001</u>	Oct 07, 1986

DURAMORPH PF

<u>AP</u>	+ HIKMA MAPLE	<u>0.5MG/ML</u>	<u>N018565</u>	<u>001</u>	Sep 18, 1984
<u>AP</u>	+	<u>1MG/ML</u>	<u>N018565</u>	<u>002</u>	Sep 18, 1984

MORPHINE SULFATE

<u>AP</u>	HOSPIRA	<u>0.5MG/ML</u>	<u>A071849</u>	<u>001</u>	May 11, 1988
<u>AP</u>		<u>0.5MG/ML</u>	<u>A073509</u>	<u>001</u>	Sep 30, 1992
<u>AP</u>		<u>1MG/ML</u>	<u>A071850</u>	<u>001</u>	May 11, 1988
<u>AP</u>		<u>1MG/ML</u>	<u>A073510</u>	<u>001</u>	Sep 30, 1992
<u>AP</u>	+	<u>1MG/ML</u>	<u>N019916</u>	<u>001</u>	Oct 30, 1992
<u>AP</u>	WATSON LABS	<u>0.5MG/ML</u>	<u>A073373</u>	<u>001</u>	Sep 30, 1991
<u>AP</u>		<u>0.5MG/ML</u>	<u>A073375</u>	<u>001</u>	Sep 30, 1991
<u>AP</u>		<u>1MG/ML</u>	<u>A073374</u>	<u>001</u>	Sep 30, 1991
<u>AP</u>		<u>1MG/ML</u>	<u>A073376</u>	<u>001</u>	Sep 30, 1991

INFUMORPH

+	HIKMA MAPLE	10MG/ML	N018565	003	Jul 19, 1991
+		25MG/ML	N018565	004	Jul 19, 1991

MORPHINE SULFATE

+	HOSPIRA	5MG/ML	N019916	002	Oct 27, 2006
+	HOSPIRA INC	2MG/ML	N202515	001	Nov 14, 2011
+		4MG/ML	N202515	002	Nov 14, 2011
+		8MG/ML	N202515	003	Nov 14, 2011
+		10MG/ML	N202515	004	Nov 14, 2011
+		15MG/ML	N202515	005	Nov 14, 2011
+	MERIDIAN MEDCL TECHN	15MG/ML	N019999	001	Jul 12, 1990

SOLUTION; ORAL

MORPHINE SULFATE

<u>AA</u>	MALLINCKRODT INC	<u>100MG/5ML</u>	<u>A202348</u>	<u>001</u>	Jul 15, 2011
<u>AA</u>	PADDOCK LLC	<u>100MG/5ML</u>	<u>A201574</u>	<u>001</u>	Aug 06, 2012
<u>AA</u>	ROXANE	<u>10MG/5ML</u>	<u>N022195</u>	<u>001</u>	Mar 17, 2008
<u>AA</u>		<u>20MG/5ML</u>	<u>N022195</u>	<u>002</u>	Mar 17, 2008
<u>AA</u>	+	<u>100MG/5ML</u>	<u>N022195</u>	<u>003</u>	Jan 25, 2010
<u>AA</u>	VISTAPHARM	<u>10MG/5ML</u>	<u>A201947</u>	<u>001</u>	Jan 05, 2012
<u>AA</u>		<u>20MG/5ML</u>	<u>A201947</u>	<u>002</u>	Jan 05, 2012

MORPHINE SULFATE

	LANNETT HOLDINGS INC	20MG/ML	N201517	001	Jun 23, 2011

TABLET; ORAL

MORPHINE SULFATE

	ROXANE	15MG	N022207	001	Mar 17, 2008
+		30MG	N022207	002	Mar 17, 2008

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

<u>AB</u>	CLONMEL HLTHCARE	<u>15MG</u>	<u>A075407</u>	<u>001</u>	Jan 28, 2000
<u>AB</u>	MALLINCKRODT	<u>15MG</u>	<u>A076412</u>	<u>001</u>	Jul 31, 2003
<u>AB</u>		<u>30MG</u>	<u>A076412</u>	<u>002</u>	Jul 31, 2003
<u>AB</u>		<u>60MG</u>	<u>A076412</u>	<u>003</u>	Jul 31, 2003
<u>AB</u>		<u>100MG</u>	<u>A076438</u>	<u>001</u>	Jul 03, 2003
<u>AB</u>		<u>200MG</u>	<u>A076438</u>	<u>002</u>	Jul 03, 2003
<u>AB</u>	MYLAN PHARMS INC	<u>15MG</u>	<u>A200824</u>	<u>001</u>	Oct 18, 2011
<u>AB</u>		<u>30MG</u>	<u>A200824</u>	<u>002</u>	Oct 18, 2011
<u>AB</u>		<u>60MG</u>	<u>A200824</u>	<u>003</u>	Oct 18, 2011
<u>AB</u>		<u>100MG</u>	<u>A200824</u>	<u>004</u>	Oct 18, 2011
<u>AB</u>		<u>200MG</u>	<u>A200824</u>	<u>005</u>	Oct 18, 2011
<u>AB</u>	NESHER PHARMS	<u>15MG</u>	<u>A076733</u>	<u>001</u>	May 19, 2004
<u>AB</u>		<u>30MG</u>	<u>A076720</u>	<u>002</u>	Dec 23, 2005

PRESCRIPTION DRUG PRODUCT LIST

3 - 299 (of 428)

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

<u>MORPHINE SULFATE</u>					
<u>AB</u>	NESHER PHARMS	<u>60MG</u>	<u>A076720</u>	<u>001</u>	May 19, 2004
<u>AB</u>		<u>100MG</u>	<u>A077855</u>	<u>001</u>	Sep 27, 2007
<u>AB</u>		<u>200MG</u>	<u>A077855</u>	<u>002</u>	Sep 27, 2007
<u>AB</u>	RANBAXY LABS LTD	<u>15MG</u>	<u>A078761</u>	<u>001</u>	May 11, 2012
<u>AB</u>		<u>30MG</u>	<u>A078761</u>	<u>002</u>	May 11, 2012
<u>AB</u>		<u>60MG</u>	<u>A078761</u>	<u>003</u>	May 11, 2012
<u>AB</u>		<u>100MG</u>	<u>A078761</u>	<u>004</u>	May 11, 2012
<u>AB</u>		<u>200MG</u>	<u>A078761</u>	<u>005</u>	May 11, 2012
<u>AB</u>	RHODES PHARMS	<u>15MG</u>	<u>A074862</u>	<u>001</u>	Jul 07, 1998
<u>AB</u>		<u>30MG</u>	<u>A074862</u>	<u>002</u>	Jul 07, 1998
<u>AB</u>		<u>60MG</u>	<u>A074862</u>	<u>003</u>	Jul 07, 1998
<u>AB</u>		<u>100MG</u>	<u>A074769</u>	<u>001</u>	Jul 02, 1998
<u>AB</u>		<u>200MG</u>	<u>A074769</u>	<u>002</u>	Jul 02, 1998
<u>AB</u>	VINTAGE PHARMS LLC	<u>15MG</u>	<u>A075295</u>	<u>001</u>	Oct 28, 1998
<u>AB</u>		<u>30MG</u>	<u>A075295</u>	<u>002</u>	Oct 28, 1998
<u>AB</u>		<u>60MG</u>	<u>A075295</u>	<u>003</u>	Oct 28, 1998
<u>AB</u>		<u>100MG</u>	<u>A075295</u>	<u>004</u>	Sep 15, 2000
<u>AB</u>		<u>200MG</u>	<u>A075295</u>	<u>005</u>	Sep 15, 2000
<u>MS CONTIN</u>					
<u>AB</u>	PURDUE PHARMA LP	<u>15MG</u>	<u>N019516</u>	<u>003</u>	Sep 12, 1989
<u>AB</u>		<u>30MG</u>	<u>N019516</u>	<u>001</u>	May 29, 1987
<u>AB</u>		<u>60MG</u>	<u>N019516</u>	<u>002</u>	Apr 08, 1988
<u>AB</u>	+	<u>100MG</u>	<u>N019516</u>	<u>004</u>	Jan 16, 1990
<u>AB</u>		<u>200MG</u>	<u>N019516</u>	<u>005</u>	Nov 08, 1993

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
EMBEDA

ALPHARMA KING	20MG;0.8MG	N022321	001	Aug 13, 2009
	30MG;1.2MG	N022321	002	Aug 13, 2009
	50MG;2MG	N022321	003	Aug 13, 2009
	60MG;2.4MG	N022321	004	Aug 13, 2009
	80MG;3.2MG	N022321	005	Aug 13, 2009
+	100MG;4MG	N022321	006	Aug 13, 2009

MOXIFLOXACIN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER				
+ BAYER HLTHCARE	160MG/100ML	N021277	001	Nov 30, 2001

SOLUTION/DROPS; OPHTHALMIC

+ ALCON PHARMS LTD	EQ 0.5% BASE	N022428	001	Nov 19, 2010
VIGAMOX				
+ ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003

TABLET; ORAL

AVELOX				
+ BAYER HLTHCARE	EQ 400MG BASE	N021085	001	Dec 10, 1999

MUPIROICIN

OINTMENT; TOPICAL

<u>BACTROBAN</u>					
<u>AB</u>	+ GLAXOSMITHKLINE	<u>2%</u>	<u>N050591</u>	<u>001</u>	Dec 31, 1987
<u>MUPIROICIN</u>					
<u>AB</u>	FOUGERA PHARMS	<u>2%</u>	<u>A065192</u>	<u>001</u>	Nov 30, 2005
<u>AB</u>	GLENMARK PHARMS	<u>2%</u>	<u>A090480</u>	<u>001</u>	Jun 08, 2011
<u>AB</u>	PERRIGO NEW YORK	<u>2%</u>	<u>A065123</u>	<u>001</u>	Nov 07, 2003
<u>AB</u>	TARO	<u>2%</u>	<u>A065170</u>	<u>001</u>	Sep 23, 2005
<u>AB</u>	TEVA	<u>2%</u>	<u>A065085</u>	<u>001</u>	Nov 07, 2003

PRESCRIPTION DRUG PRODUCT LIST

3 - 300 (of 428)

MUPIROCIN

OINTMENT; TOPICAL					
CENTANY					
BX	PERRIGO NEW YORK	2%	N050788	001	Dec 04, 2002

MUPIROCIN CALCIUM

CREAM; TOPICAL					
BACTROBAN					
	+ GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997
OINTMENT; NASAL					
BACTROBAN					
	+ GLAXOSMITHKLINE	EQ 2% BASE	N050703	001	Sep 18, 1995

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL					
<u>CELLCEPT</u>					
<u>AB</u>	+ ROCHE PALO	<u>250MG</u>	<u>N050722</u>	<u>001</u>	May 03, 1995
<u>MYCOPHENOLATE MOFETIL</u>					
<u>AB</u>	ACCORD HLTHCARE INC	<u>250MG</u>	<u>A090253</u>	<u>001</u>	May 04, 2009
<u>AB</u>	APOTEX CORP	<u>250MG</u>	<u>A090419</u>	<u>001</u>	Apr 22, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>250MG</u>	<u>A091315</u>	<u>001</u>	Oct 27, 2011
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A065520</u>	<u>001</u>	May 04, 2009
<u>AB</u>	ROXANE	<u>250MG</u>	<u>A065410</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A065379</u>	<u>001</u>	Oct 15, 2008
<u>AB</u>	STRIDES ARCOLAB LTD	<u>250MG</u>	<u>A090055</u>	<u>001</u>	Jun 10, 2010
<u>AB</u>	TEVA PHARMS	<u>250MG</u>	<u>A065491</u>	<u>001</u>	May 06, 2009
<u>AB</u>	VINTAGE PHARMS LLC	<u>250MG</u>	<u>A090111</u>	<u>001</u>	Dec 22, 2009
SUSPENSION; ORAL					
CELLCEPT					
	+ ROCHE PALO	200MG/ML	N050759	001	Oct 01, 1998
TABLET; ORAL					
<u>CELLCEPT</u>					
<u>AB</u>	+ ROCHE PALO	<u>500MG</u>	<u>N050723</u>	<u>001</u>	Jun 19, 1997
<u>MYCOPHENOLATE MOFETIL</u>					
<u>AB</u>	ACCORD HLTHCARE	<u>500MG</u>	<u>A065416</u>	<u>001</u>	May 04, 2009
<u>AB</u>	ALKEM LABS LTD	<u>500MG</u>	<u>A091249</u>	<u>001</u>	Nov 04, 2011
<u>AB</u>	APOTEX	<u>500MG</u>	<u>A090499</u>	<u>001</u>	Apr 22, 2009
<u>AB</u>	MYLAN	<u>500MG</u>	<u>A065521</u>	<u>001</u>	May 04, 2009
<u>AB</u>	ROXANE	<u>500MG</u>	<u>A065413</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A065451</u>	<u>001</u>	Oct 15, 2008
<u>AB</u>	STRIDES ARCOLAB LTD	<u>500MG</u>	<u>A090456</u>	<u>001</u>	Jun 10, 2010
<u>AB</u>	TEVA PHARMS	<u>500MG</u>	<u>A065457</u>	<u>001</u>	May 04, 2009
<u>AB</u>	VINTAGE PHARMS LLC	<u>500MG</u>	<u>A090606</u>	<u>001</u>	Jul 16, 2010

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION					
CELLCEPT					
	+ ROCHE PALO	500MG/VIAL	N050758	001	Aug 12, 1998

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE; ORAL					
<u>MYCOPHENOLIC ACID</u>					
<u>AB</u>	APOTEX INC	<u>180MG</u>	<u>A091558</u>	<u>001</u>	Aug 21, 2012
<u>MYFORTIC</u>					
<u>AB</u>	NOVARTIS	<u>180MG</u>	<u>N050791</u>	<u>001</u>	Feb 27, 2004
MYFORTIC					
	+ NOVARTIS	360MG	N050791	002	Feb 27, 2004

NABILONE

CAPSULE; ORAL					
CESAMET					
	+ MEDA PHARMS	1MG	N018677	001	Dec 26, 1985

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 301 (of 428)

NABUMETONE

TABLET; ORAL

NABUMETONE

<u>AB</u>	APOTEX INC	<u>500MG</u>	<u>A090427</u>	<u>001</u>	Dec 30, 2011
<u>AB</u>		<u>750MG</u>	<u>A090427</u>	<u>002</u>	Dec 30, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>500MG</u>	<u>A078420</u>	<u>001</u>	Sep 24, 2008
<u>AB</u>		<u>750MG</u>	<u>A078420</u>	<u>002</u>	Sep 24, 2008
<u>AB</u>	INVAGEN PHARMS	<u>500MG</u>	<u>A078671</u>	<u>001</u>	Mar 07, 2008
<u>AB</u>		<u>750MG</u>	<u>A078671</u>	<u>002</u>	Mar 07, 2008
<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A090445</u>	<u>001</u>	Jan 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A090445</u>	<u>002</u>	Jan 12, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>500MG</u>	<u>A090516</u>	<u>001</u>	Jul 12, 2010
<u>AB</u>		<u>750MG</u>	<u>A090516</u>	<u>002</u>	Jul 12, 2010
<u>AB</u>	PAR PHARM	<u>500MG</u>	<u>A076009</u>	<u>001</u>	Jan 24, 2003
<u>AB</u>		<u>750MG</u>	<u>A076009</u>	<u>002</u>	Jan 24, 2003
<u>AB</u>	PROSAM LABS	<u>500MG</u>	<u>A079093</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>		<u>750MG</u>	<u>A079093</u>	<u>002</u>	Feb 27, 2009
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A075280</u>	<u>001</u>	Feb 25, 2002
<u>AB</u>		<u>750MG</u>	<u>A075280</u>	<u>002</u>	Feb 25, 2002
<u>AB</u>	TEVA	<u>500MG</u>	<u>A075189</u>	<u>001</u>	May 26, 2000
<u>AB</u>	+	<u>750MG</u>	<u>A075189</u>	<u>002</u>	Sep 24, 2001
<u>AB</u>	WATSON LABS	<u>500MG</u>	<u>A091083</u>	<u>001</u>	Jun 13, 2011
<u>AB</u>		<u>750MG</u>	<u>A091083</u>	<u>002</u>	Jun 13, 2011

NADOLOL

TABLET; ORAL

CORGARD

<u>AB</u>	KING PHARMS	<u>20MG</u>	<u>N018063</u>	<u>005</u>	Oct 28, 1986
<u>AB</u>		<u>40MG</u>	<u>N018063</u>	<u>001</u>	
<u>AB</u>	+	<u>80MG</u>	<u>N018063</u>	<u>002</u>	

NADOLOL

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>A074229</u>	<u>001</u>	Aug 30, 1996
<u>AB</u>		<u>40MG</u>	<u>A074229</u>	<u>002</u>	Aug 30, 1996
<u>AB</u>		<u>80MG</u>	<u>A074255</u>	<u>001</u>	Jan 24, 1996
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A074172</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>		<u>40MG</u>	<u>A074172</u>	<u>002</u>	Oct 31, 1993
<u>AB</u>		<u>80MG</u>	<u>A074172</u>	<u>003</u>	Oct 31, 1993
<u>AB</u>	SANDOZ	<u>20MG</u>	<u>A074501</u>	<u>001</u>	Nov 09, 1995
<u>AB</u>		<u>40MG</u>	<u>A074501</u>	<u>002</u>	Nov 09, 1995
<u>AB</u>		<u>80MG</u>	<u>A074501</u>	<u>003</u>	Nov 09, 1995

NAFARELIN ACETATESPRAY, METERED; NASAL
SYNAREL

+	GD SEARLE LLC	EQ 0.2MG BASE/SPRAY	N019886	001	Feb 13, 1990

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

<u>AP</u>	ANTIBIOTICE	<u>EQ 1GM BASE</u>	<u>A090560</u>	<u>001</u>	Oct 03, 2011
<u>AP</u>		<u>EQ 2GM BASE</u>	<u>A090560</u>	<u>002</u>	Oct 03, 2011
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A091613</u>	<u>001</u>	Dec 26, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091613</u>	<u>002</u>	Dec 26, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A091614</u>	<u>001</u>	Dec 26, 2012
<u>AP</u>	IBI	<u>EQ 1GM BASE/VIAL</u>	<u>A090002</u>	<u>001</u>	Jun 30, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090002</u>	<u>002</u>	Jun 30, 2011
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090005</u>	<u>001</u>	Apr 20, 2011
<u>AP</u>	SAGENT PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A090582</u>	<u>001</u>	Aug 24, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090582</u>	<u>002</u>	Aug 24, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090580</u>	<u>001</u>	Aug 24, 2012
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062527</u>	<u>002</u>	Aug 02, 1984

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 302 (of 428)

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

<u>AP</u>	+	SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A062732</u>	<u>001</u>	Dec 23, 1986
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>A062527</u>	<u>003</u>	Aug 02, 1984
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>A062732</u>	<u>002</u>	Dec 23, 1986
<u>AP</u>	+		<u>EQ 10GM BASE/VIAL</u>	<u>A062527</u>	<u>004</u>	Aug 02, 1984
		NALLPEN IN PLASTIC CONTAINER				
	+	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050655	001	Oct 31, 1989
	+		EQ 2GM BASE/100ML	N050655	002	Oct 31, 1989

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

	+	MERZ PHARMS	1%	N019599	001	Feb 29, 1988
	+		2%	N019599	002	Jan 13, 2012

GEL; TOPICAL

NAFTIN

	+	MERZ PHARMS	1%	N019356	001	Jun 18, 1990

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HYDROCHLORIDE

<u>AP</u>	+	HOSPIRA	<u>10MG/ML</u>	<u>A070914</u>	<u>001</u>	Feb 03, 1989
<u>AP</u>	+		<u>10MG/ML</u>	<u>A070915</u>	<u>001</u>	Feb 03, 1989
<u>AP</u>	+		<u>20MG/ML</u>	<u>A070916</u>	<u>001</u>	Feb 03, 1989
<u>AP</u>	+		<u>20MG/ML</u>	<u>A070918</u>	<u>001</u>	Feb 03, 1989

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HYDROCHLORIDE

<u>AP</u>	+	HOSPIRA	<u>0.4MG/ML</u>	<u>A070172</u>	<u>001</u>	Sep 24, 1986
<u>AP</u>	+		<u>0.4MG/ML</u>	<u>A070254</u>	<u>001</u>	Jan 07, 1987
<u>AP</u>	+		<u>0.4MG/ML</u>	<u>A070256</u>	<u>001</u>	Jan 07, 1987
<u>AP</u>	+		<u>0.4MG/ML</u>	<u>A070257</u>	<u>001</u>	Jan 07, 1987
<u>AP</u>		INTL MEDICATION	<u>0.4MG/ML</u>	<u>A070639</u>	<u>001</u>	Sep 24, 1986
<u>AP</u>	+		<u>1MG/ML</u>	<u>A072076</u>	<u>001</u>	Mar 24, 1988

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

PENTAZOCINE AND NALOXONE HYDROCHLORIDE

<u>AB</u>		GAVIS PHARMS	<u>EQ 0.5MG BASE;EQ 50MG BASE</u>	<u>A075735</u>	<u>001</u>	Jul 11, 2001
		<u>PENTAZOCINE AND NALOXONE HYDROCHLORIDES</u>				
<u>AB</u>		RANBAXY	<u>EQ 0.5MG BASE;EQ 50MG BASE</u>	<u>A075523</u>	<u>001</u>	Mar 17, 2000
<u>AB</u>	+	WATSON LABS	<u>EQ 0.5MG BASE;EQ 50MG BASE</u>	<u>A074736</u>	<u>001</u>	Jan 21, 1997

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

VIVITROL

	+	ALKERMES	380MG/VIAL	N021897	001	Apr 13, 2006

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

<u>AB</u>		ACCORD HLTHCARE	<u>50MG</u>	<u>A091205</u>	<u>001</u>	Aug 17, 2011
<u>AB</u>		BARR	<u>50MG</u>	<u>A074918</u>	<u>001</u>	May 08, 1998
<u>AB</u>		ELITE LABS	<u>50MG</u>	<u>A075274</u>	<u>001</u>	May 26, 1999
<u>AB</u>		MALLINCKRODT	<u>50MG</u>	<u>A076264</u>	<u>002</u>	Mar 22, 2002
<u>AB</u>		SANDOZ	<u>50MG</u>	<u>A075434</u>	<u>001</u>	Mar 08, 2000
<u>AB</u>		SUN PHARMA GLOBAL	<u>50MG</u>	<u>A090356</u>	<u>001</u>	Feb 24, 2012
		<u>REVIA</u>				
<u>AB</u>	+	DURAMED	<u>50MG</u>	<u>N018932</u>	<u>001</u>	Nov 20, 1984

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 303 (of 428)

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

MALLINCKRODT

25MG

A076264

001

Mar 22, 2002

100MG

A076264

003

Mar 22, 2002

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE

+ PHARMAFORCE

200MG/ML

A091252

001

Aug 30, 2010

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALBALONAT + ALLERGAN0.1%A080248001NAPHAZOLINE HYDROCHLORIDEAT TAYLOR0.1%A083590001NAPROXEN

SUSPENSION; ORAL

NAPROSYNAB + ROCHE PALO25MG/MLN018965001

Mar 23, 1987

NAPROXENAB ROXANE25MG/MLA074190001

Mar 30, 1994

TABLET; ORAL

NAPROSYNAB ROCHE PALO250MGN017581002AB375MGN017581003AB +500MGN017581004

Apr 15, 1982

NAPROXENAB AMNEAL PHARMS NY250MGA075927001

Dec 18, 2001

AB375MGA075927002

Dec 18, 2001

AB500MGA075927003

Dec 18, 2001

AB AUROBINDO PHARMA USA250MGA200429001

Nov 08, 2011

AB375MGA200429002

Nov 08, 2011

AB500MGA200429003

Nov 08, 2011

AB DAVA PHARMS INC250MGA074410001

Apr 28, 1995

AB375MGA074410002

Apr 28, 1995

AB500MGA074410003

Apr 28, 1995

AB GLENMARK GENERICS250MGA078250001

Mar 28, 2007

AB375MGA078250002

Mar 28, 2007

AB500MGA078250003

Mar 28, 2007

AB INVAGEN PHARMS250MGA091305001

Aug 24, 2011

AB375MGA091305002

Aug 24, 2011

AB500MGA091305003

Aug 24, 2011

AB MARKSANS PHARMA250MGA091416001

Feb 14, 2011

AB375MGA091416002

Feb 14, 2011

AB500MGA091416003

Feb 14, 2011

AB MYLAN250MGA074121001

Dec 21, 1993

AB375MGA074121002

Dec 21, 1993

AB500MGA074121003

Dec 21, 1993

AB PERRIGO R AND D250MGA077339001

Apr 27, 2005

AB375MGA077339002

Apr 27, 2005

AB500MGA077339003

Apr 27, 2005

AB SANDOZ250MGA074140001

Dec 21, 1993

AB375MGA074140002

Dec 21, 1993

AB500MGA074140003

Dec 21, 1993

AB TEVA250MGA074201001

Dec 21, 1993

AB375MGA074201002

Dec 21, 1993

AB500MGA074201003

Dec 21, 1993

AB WATSON LABS250MGA074457001

May 31, 1995

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 304 (of 428)

NAPROXEN

TABLET; ORAL

NAPROXEN

<u>AB</u>	WATSON LABS	<u>375MG</u>	<u>A074457</u>	<u>002</u>	May 31, 1995
<u>AB</u>		<u>500MG</u>	<u>A074457</u>	<u>003</u>	May 31, 1995
<u>AB</u>	WESTWARD	<u>250MG</u>	<u>A076494</u>	<u>001</u>	Jan 14, 2004
<u>AB</u>		<u>375MG</u>	<u>A076494</u>	<u>002</u>	Jan 14, 2004
<u>AB</u>		<u>500MG</u>	<u>A076494</u>	<u>003</u>	Jan 14, 2004
<u>AB</u>	ZYDUS PHARMS USA	<u>250MG</u>	<u>A078620</u>	<u>001</u>	Jun 07, 2007
<u>AB</u>		<u>375MG</u>	<u>A078620</u>	<u>002</u>	Jun 07, 2007
<u>AB</u>		<u>500MG</u>	<u>A078620</u>	<u>003</u>	Jun 07, 2007

TABLET, DELAYED RELEASE; ORAL

EC-NAPROSYN

<u>AB</u>	+ ROCHE PALO	<u>375MG</u>	<u>N020067</u>	<u>002</u>	Oct 14, 1994
<u>AB</u>	+	<u>500MG</u>	<u>N020067</u>	<u>003</u>	Oct 14, 1994

NAPROXEN

<u>AB</u>	INVAGEN PHARMS	<u>375MG</u>	<u>A091432</u>	<u>001</u>	Sep 19, 2011
<u>AB</u>		<u>500MG</u>	<u>A091432</u>	<u>002</u>	Sep 19, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>375MG</u>	<u>A075390</u>	<u>001</u>	Apr 19, 2001
<u>AB</u>		<u>500MG</u>	<u>A075390</u>	<u>002</u>	Apr 19, 2001
<u>AB</u>	PLIVA	<u>375MG</u>	<u>A075337</u>	<u>001</u>	May 26, 1999
<u>AB</u>		<u>500MG</u>	<u>A075337</u>	<u>002</u>	May 26, 1999
<u>AB</u>	SANDOZ	<u>375MG</u>	<u>A075061</u>	<u>001</u>	Feb 18, 1998
<u>AB</u>		<u>500MG</u>	<u>A075061</u>	<u>002</u>	Feb 18, 1998
<u>AB</u>	TEVA	<u>375MG</u>	<u>A075227</u>	<u>001</u>	Jun 30, 1998
<u>AB</u>		<u>500MG</u>	<u>A075227</u>	<u>002</u>	Jun 30, 1998

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

<u>AB</u>	HOFFMANN LA ROCHE	<u>EQ 250MG BASE</u>	<u>N018164</u>	<u>001</u>	
<u>AB</u>					
<u>AB</u>	<u>ANAPROX DS</u>				
<u>AB</u>	+ HOFFMANN LA ROCHE	<u>EQ 500MG BASE</u>	<u>N018164</u>	<u>003</u>	Sep 30, 1987

NAPROXEN SODIUM

<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 250MG BASE</u>	<u>A078432</u>	<u>001</u>	Apr 25, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078432</u>	<u>002</u>	Apr 25, 2007
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A200629</u>	<u>001</u>	Oct 31, 2011
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A200629</u>	<u>002</u>	Oct 31, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 250MG BASE</u>	<u>A078486</u>	<u>001</u>	Jul 26, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078486</u>	<u>002</u>	Jul 26, 2007
<u>AB</u>	GLENMARK GENERICS	<u>EQ 250MG BASE</u>	<u>A078314</u>	<u>001</u>	Apr 27, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078314</u>	<u>002</u>	Apr 27, 2007
<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A074480</u>	<u>002</u>	Feb 18, 1998
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A074480</u>	<u>001</u>	May 14, 1996
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A074198</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A074198</u>	<u>002</u>	Dec 21, 1993
<u>AB</u>	WATSON LABS	<u>EQ 250MG BASE</u>	<u>A074455</u>	<u>001</u>	May 31, 1995
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A074455</u>	<u>002</u>	May 31, 1995

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

	STAT TRADE	EQ 375MG BASE	N020353	001	Jan 05, 1996
		EQ 500MG BASE	N020353	002	Jan 05, 1996
	+	EQ 750MG BASE	N020353	003	Jan 05, 1996

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

	+ SMITHKLINE BEECHAM	500MG;EQ 85MG BASE	N021926	001	Apr 15, 2008

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 305 (of 428)

NARATRIPTAN

TABLET; ORAL

NARATRIPTAN

<u>AB</u>	APOTEX CORP	<u>EQ 1MG BASE</u>	<u>A091373</u>	<u>001</u>	Apr 22, 2011
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A091373</u>	<u>002</u>	Apr 22, 2011
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 2.5MG BASE</u>	<u>A091552</u>	<u>001</u>	Feb 14, 2011

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

AMERGE

<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 1MG BASE</u>	<u>N020763</u>	<u>002</u>	Feb 10, 1998
<u>AB</u>	+	<u>EQ 2.5MG BASE</u>	<u>N020763</u>	<u>001</u>	Feb 10, 1998

NARATRIPTAN

<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 1MG BASE</u>	<u>A200502</u>	<u>001</u>	Feb 28, 2011
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A200502</u>	<u>002</u>	Feb 28, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 1MG BASE</u>	<u>A202431</u>	<u>001</u>	May 31, 2012
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A202431</u>	<u>002</u>	May 31, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1MG BASE</u>	<u>A091441</u>	<u>001</u>	Apr 30, 2012
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A091441</u>	<u>002</u>	Apr 30, 2012
<u>AB</u>	PADDOCK LLC	<u>EQ 1MG BASE</u>	<u>A091326</u>	<u>001</u>	Jul 08, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A091326</u>	<u>002</u>	Jul 08, 2010
<u>AB</u>	ROXANE	<u>EQ 1MG BASE</u>	<u>A090381</u>	<u>001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A090381</u>	<u>002</u>	Jul 07, 2010
<u>AB</u>	SANDOZ	<u>EQ 1MG BASE</u>	<u>A090288</u>	<u>001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A090288</u>	<u>002</u>	Jul 07, 2010
<u>AB</u>	TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A078751</u>	<u>001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A078751</u>	<u>002</u>	Jul 07, 2010

NATAMYCIN

SUSPENSION; OPHTHALMIC

NATACYN

+	ALCON	5%	N050514	001	

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>60MG</u>	<u>A077461</u>	<u>001</u>	Sep 09, 2009
<u>AB</u>		<u>120MG</u>	<u>A077461</u>	<u>002</u>	Sep 09, 2009
<u>AB</u>	PAR PHARM	<u>60MG</u>	<u>A077463</u>	<u>001</u>	Sep 09, 2009
<u>AB</u>		<u>120MG</u>	<u>A077463</u>	<u>002</u>	Sep 09, 2009
<u>AB</u>	WATSON LABS	<u>60MG</u>	<u>A077462</u>	<u>001</u>	Mar 30, 2011
<u>AB</u>		<u>120MG</u>	<u>A077462</u>	<u>002</u>	Mar 30, 2011
	<u>STARLIX</u>				
<u>AB</u>	NOVARTIS	<u>60MG</u>	<u>N021204</u>	<u>001</u>	Dec 22, 2000
<u>AB</u>	+	<u>120MG</u>	<u>N021204</u>	<u>002</u>	Dec 22, 2000

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

BYSTOLIC

	FOREST LABS	EQ 2.5MG BASE	N021742	002	Dec 17, 2007
		EQ 5MG BASE	N021742	003	Dec 17, 2007
		EQ 10MG BASE	N021742	004	Dec 17, 2007
+		EQ 20MG BASE	N021742	005	Oct 08, 2008

NEDOCROMIL SODIUM

SOLUTION/DROPS; OPHTHALMIC

ALOCRIL

<u>AT</u>	+	ALLERGAN	<u>2%</u>	<u>N021009</u>	<u>001</u>	Dec 08, 1999
		<u>NEDOCROMIL SODIUM</u>				
<u>AT</u>		AKORN	<u>2%</u>	<u>A090638</u>	<u>001</u>	Aug 22, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 306 (of 428)

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

<u>AB</u>	RANBAXY	<u>50MG</u>	<u>A076409</u>	<u>001</u>	Sep 16, 2003
<u>AB</u>		<u>100MG</u>	<u>A076409</u>	<u>002</u>	Sep 16, 2003
<u>AB</u>		<u>150MG</u>	<u>A076409</u>	<u>003</u>	Sep 16, 2003
<u>AB</u>		<u>200MG</u>	<u>A076409</u>	<u>004</u>	Sep 16, 2003
<u>AB</u>		<u>250MG</u>	<u>A076409</u>	<u>005</u>	Sep 16, 2003
<u>AB</u>	TEVA	<u>50MG</u>	<u>A076037</u>	<u>001</u>	Sep 16, 2003
<u>AB</u>		<u>100MG</u>	<u>A076037</u>	<u>002</u>	Sep 16, 2003
<u>AB</u>		<u>150MG</u>	<u>A076037</u>	<u>003</u>	Sep 16, 2003
<u>AB</u>		<u>200MG</u>	<u>A076037</u>	<u>004</u>	Sep 16, 2003
<u>AB</u>	+	<u>250MG</u>	<u>A076037</u>	<u>005</u>	Sep 16, 2003
	<u>NEFAZODONE HYDROCHLORIDE</u>				
BX	DR REDDYS LABS INC	50MG	A076309	001	Sep 16, 2003
BX		100MG	A076309	002	Sep 16, 2003
BX		150MG	A076309	003	Sep 16, 2003
BX		200MG	A076309	004	Sep 16, 2003
BX		250MG	A076309	005	Sep 16, 2003

NELARABINE

INJECTABLE; IV (INFUSION)

ARRANON

+ SMITHKLINE BEECHAM 250MG/50ML (5MG/ML) N021877 001 Oct 28, 2005

NELFINAVIR MESYLATE

POWDER; ORAL

VIRACEPT

+ AGOURON EQ 50MG BASE/SC00PFUL N020778 001 Mar 14, 1997

TABLET; ORAL

VIRACEPT

+ AGOURON EQ 250MG BASE N020779 001 Mar 14, 1997

+ EQ 625MG BASE N021503 001 Apr 30, 2003

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING

NEO-RX

X GEN PHARMS 100% A061579 001

SOLUTION; ORAL

NEO-FRADIN

+ X GEN PHARMS EQ 87.5MG BASE/5ML A065010 001 May 23, 2002

TABLET; ORAL

NEOMYCIN SULFATE

<u>AA</u>	OMAN PHARM PRODUCTS	<u>500MG</u>	<u>A065468</u>	<u>001</u>	Mar 29, 2010
<u>AA</u>	+	<u>500MG</u>	<u>A060304</u>	<u>001</u>	
<u>AA</u>	X GEN PHARMS	<u>500MG</u>	<u>A065220</u>	<u>001</u>	Jul 28, 2006

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

<u>AT</u>	WATSON LABS	<u>EQ 40MG BASE/ML;200,000 UNITS/ML</u>	<u>A062664</u>	<u>001</u>	Apr 08, 1986
<u>AT</u>	X GEN PHARMS	<u>EQ 40MG BASE/ML;200,000 UNITS/ML</u>	<u>A065106</u>	<u>001</u>	Jan 31, 2006
<u>AT</u>		<u>EQ 40MG BASE/ML;200,000 UNITS/ML</u>	<u>A065108</u>	<u>001</u>	Jan 31, 2006

NEOSPORIN G.U. IRRIGANT

<u>AT</u>	+	MONARCH PHARMS	<u>EQ 40MG BASE/ML;200,000 UNITS/ML</u>	<u>A060707</u>	<u>001</u>

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

+ ALLERGAN EQ 0.35% BASE;10,000 UNITS/ML;0.5% N050081 002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 307 (of 428)

NEPAFENAC

SUSPENSION/DROPS; OPHTHALMIC

+	ALCON RES LTD	0.3%	N203491	001	Oct 16, 2012
	NEVANAC				
+	ALCON PHARMS LTD	0.1%	N021862	001	Aug 19, 2005

NESIRITIDE RECOMBINANTFOR SOLUTION; INTRAVENOUS
NATRECOR

+	SCIOS	1.5MG/VIAL	N020920	001	Aug 10, 2001

NEVIRAPINE

SUSPENSION; ORAL

NEVIRAPINE

<u>AA</u>	AUROBINDO	<u>50MG/5ML</u>	<u>A077702</u>	<u>001</u>	May 22, 2012

VIRAMUNE

<u>AA</u>	+ BOEHRINGER INGELHEIM	<u>50MG/5ML</u>	<u>N020933</u>	<u>001</u>	Sep 11, 1998

TABLET; ORAL

NEVIRAPINE

<u>AB</u>	APOTEX INC	<u>200MG</u>	<u>A203021</u>	<u>001</u>	May 22, 2012
<u>AB</u>	AUROBINDO	<u>200MG</u>	<u>A077521</u>	<u>001</u>	May 22, 2012
<u>AB</u>	CIPLA	<u>200MG</u>	<u>A077956</u>	<u>001</u>	May 22, 2012
<u>AB</u>	HETERO LABS LTD III	<u>200MG</u>	<u>A078584</u>	<u>001</u>	May 22, 2012
<u>AB</u>	MICRO LABS LTD	<u>200MG</u>	<u>A203080</u>	<u>001</u>	May 22, 2012
<u>AB</u>	MYLAN LABS	<u>200MG</u>	<u>A078864</u>	<u>001</u>	May 22, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>200MG</u>	<u>A202523</u>	<u>001</u>	May 22, 2012
<u>AB</u>	PRINSTON INC	<u>200MG</u>	<u>A078644</u>	<u>001</u>	May 22, 2012
<u>AB</u>	SCIEGEN PHARMS INC	<u>200MG</u>	<u>A203176</u>	<u>001</u>	May 22, 2012
<u>AB</u>	STRIDES	<u>200MG</u>	<u>A078195</u>	<u>001</u>	May 22, 2012

VIRAMUNE

<u>AB</u>	+ BOEHRINGER INGELHEIM	<u>200MG</u>	<u>N020636</u>	<u>001</u>	Jun 21, 1996

TABLET, EXTENDED RELEASE; ORAL
VIRAMUNE XR

	BOEHRINGER INGELHEIM	100MG	N201152	002	Nov 08, 2012
+		400MG	N201152	001	Mar 25, 2011

NIACIN

TABLET; ORAL

NIACIN

<u>AA</u>	WOCKHARDT	<u>500MG</u>	<u>A081134</u>	<u>001</u>	Apr 28, 1992

NIACOR

<u>AA</u>	+ UPSHER SMITH	<u>500MG</u>	<u>A040378</u>	<u>001</u>	May 03, 2000

TABLET, EXTENDED RELEASE; ORAL
NIASPAN

	ABBVIE	500MG	N020381	002	Jul 28, 1997
+		750MG	N020381	003	Jul 28, 1997
+		1GM	N020381	004	Jul 28, 1997

NIACIN; SIMVASTATINTABLET, EXTENDED RELEASE; ORAL
SIMCOR

+	ABBVIE	500MG; 20MG	N022078	001	Feb 15, 2008
+		500MG; 40MG	N022078	004	Jul 28, 2010
+		750MG; 20MG	N022078	002	Feb 15, 2008
+		1GM; 20MG	N022078	003	Feb 15, 2008
+		1GM; 40MG	N022078	005	Jul 28, 2010

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

CARDENE

<u>AB</u>	EKR THERAP	<u>20MG</u>	<u>N019488</u>	<u>001</u>	Dec 21, 1988

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 308 (of 428)

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

CARDENE

<u>AB</u>	+ EKR THERAP	<u>30MG</u>	<u>N019488</u>	<u>002</u>	Dec 21, 1988
	<u>NICARDIPINE HYDROCHLORIDE</u>				
<u>AB</u>	BARR	<u>20MG</u>	<u>A074439</u>	<u>001</u>	Dec 10, 1996
<u>AB</u>		<u>30MG</u>	<u>A074439</u>	<u>002</u>	Dec 10, 1996
<u>AB</u>	EPIC PHARMA	<u>20MG</u>	<u>A074928</u>	<u>001</u>	Mar 19, 1998
<u>AB</u>		<u>30MG</u>	<u>A074928</u>	<u>002</u>	Mar 19, 1998
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A074642</u>	<u>001</u>	Jul 18, 1996
<u>AB</u>		<u>30MG</u>	<u>A074642</u>	<u>002</u>	Jul 18, 1996
<u>AB</u>	TEVA	<u>20MG</u>	<u>A074540</u>	<u>001</u>	Oct 28, 1996
<u>AB</u>		<u>30MG</u>	<u>A074540</u>	<u>002</u>	Oct 28, 1996
<u>AB</u>	WATSON LABS	<u>20MG</u>	<u>A074670</u>	<u>001</u>	Oct 28, 1996
<u>AB</u>		<u>30MG</u>	<u>A074670</u>	<u>002</u>	Oct 28, 1996

CAPSULE, EXTENDED RELEASE; ORAL

CARDENE SR

	+ EKR THERAP	30MG	N020005	001	Feb 21, 1992
	+	60MG	N020005	003	Feb 21, 1992

INJECTABLE; INJECTION

CARDENE

<u>AP</u>	+ EKR THERAP	<u>25MG/10ML (2.5MG/ML)</u>	<u>N019734</u>	<u>001</u>	Jan 30, 1992
	<u>NICARDIPINE HYDROCHLORIDE</u>				
<u>AP</u>	BEDFORD	<u>25MG/10ML (2.5MG/ML)</u>	<u>A078714</u>	<u>001</u>	Dec 28, 2009
<u>AP</u>	BIONICHE PHARMA USA	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090664</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>	EXELA PHARMA SCIENCE	<u>25MG/10ML (2.5MG/ML)</u>	<u>N022276</u>	<u>001</u>	Jul 24, 2008
<u>AP</u>	NAVINTA LLC	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090125</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>	PHARMAFORCE	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090534</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>	SUN PHARMA GLOBAL	<u>25MG/10ML (2.5MG/ML)</u>	<u>N078405</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>	WOCKHARDT	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090671</u>	<u>001</u>	Nov 17, 2009

INJECTABLE; INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

	+ EKR THERAP	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008
	CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER				
	+ EKR THERAP	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008
	CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER				
	+ EKR THERAP	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008
	CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER				
	+ EKR THERAP	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008

NICOTINE

INHALANT; ORAL

NICOTROL

	+ PHARMACIA AND UPJOHN	4MG/CARTRIDGE	N020714	001	May 02, 1997

SPRAY, METERED; NASAL

NICOTROL

	+ PFIZER INC	0.5MG/SPRAY	N020385	001	Mar 22, 1996

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072579</u>	<u>001</u>	Jan 08, 1991
<u>AB</u>	CATALENT	<u>10MG</u>	<u>A073250</u>	<u>001</u>	Oct 08, 1991
<u>AB</u>	INTERGEL PHARM	<u>10MG</u>	<u>A072781</u>	<u>001</u>	Jul 30, 1993

PROCARDIA

<u>AB</u>	+ PFIZER	<u>10MG</u>	<u>N018482</u>	<u>001</u>	
	NIFEDIPINE				
	ACTAVIS ELIZABETH	20MG	A072556	001	Sep 20, 1990

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC

<u>AB1</u>	BAYER HLTHCARE	<u>30MG</u>	<u>N020198</u>	<u>001</u>	Apr 21, 1993
<u>AB1</u>	+	<u>60MG</u>	<u>N020198</u>	<u>002</u>	Apr 21, 1993

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 309 (of 428)

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC

<u>AB1</u> +	BAYER HLTHCARE	<u>90MG</u>	<u>N020198</u>	<u>003</u>	Apr 21, 1993

AFEDITAB CR

<u>AB1</u>	WATSON LABS	<u>30MG</u>	<u>A075128</u>	<u>001</u>	Mar 10, 2000

<u>AB1</u>		<u>60MG</u>	<u>A075659</u>	<u>001</u>	Oct 26, 2001

NIFEDIPINE

<u>AB1</u>	MYLAN	<u>30MG</u>	<u>A201071</u>	<u>001</u>	Dec 03, 2010

<u>AB1</u>		<u>60MG</u>	<u>A201071</u>	<u>002</u>	Dec 03, 2010

<u>AB1</u>		<u>90MG</u>	<u>A201071</u>	<u>003</u>	Dec 03, 2010

<u>AB1</u>	PAR PHARM	<u>30MG</u>	<u>A077899</u>	<u>001</u>	Dec 13, 2006

<u>AB1</u>		<u>60MG</u>	<u>A077899</u>	<u>002</u>	Dec 13, 2006

<u>AB1</u>		<u>90MG</u>	<u>A077899</u>	<u>003</u>	May 25, 2012

<u>AB1</u>	VALEANT INTL	<u>30MG</u>	<u>A075269</u>	<u>001</u>	Dec 04, 2000

<u>AB1</u>		<u>60MG</u>	<u>A075269</u>	<u>002</u>	Dec 04, 2000

<u>AB1</u>		<u>90MG</u>	<u>A076070</u>	<u>001</u>	Aug 16, 2002

NIFEDIPINE

<u>AB2</u>	MATRIX LABS LTD	<u>30MG</u>	<u>A090602</u>	<u>001</u>	Sep 13, 2010

<u>AB2</u>		<u>60MG</u>	<u>A090602</u>	<u>002</u>	Sep 13, 2010

<u>AB2</u>		<u>90MG</u>	<u>A090602</u>	<u>003</u>	Sep 13, 2010

<u>AB2</u>	MYLAN	<u>30MG</u>	<u>A090649</u>	<u>001</u>	Jun 21, 2010

<u>AB2</u>		<u>60MG</u>	<u>A090649</u>	<u>002</u>	Jun 21, 2010

<u>AB2</u>		<u>90MG</u>	<u>A090649</u>	<u>003</u>	Jun 21, 2010

<u>AB2</u>	OSMOTICA PHARM	<u>30MG</u>	<u>A077127</u>	<u>001</u>	Nov 21, 2005

<u>AB2</u>		<u>60MG</u>	<u>A077127</u>	<u>002</u>	Nov 21, 2005

<u>AB2</u>		<u>90MG</u>	<u>A077410</u>	<u>001</u>	Oct 03, 2007

<u>AB2</u>	VALEANT INTL	<u>30MG</u>	<u>A075289</u>	<u>002</u>	Feb 06, 2001

<u>AB2</u>		<u>60MG</u>	<u>A075289</u>	<u>001</u>	Sep 27, 2000

PROCARDIA XL

<u>AB2</u>	PFIZER	<u>30MG</u>	<u>N019684</u>	<u>001</u>	Sep 06, 1989

<u>AB2</u>		<u>60MG</u>	<u>N019684</u>	<u>002</u>	Sep 06, 1989

<u>AB2</u> +		<u>90MG</u>	<u>N019684</u>	<u>003</u>	Sep 06, 1989

NILOTINIB HYDROCHLORIDE MONOHYDRATE

CAPSULE; ORAL

TASIGNA

NOVARTIS

EQ 150MG BASE

<u>N022068</u>	<u>002</u>	Jun 17, 2010

+

EQ 200MG BASE

<u>N022068</u>	<u>001</u>	Oct 29, 2007

NILUTAMIDE

TABLET; ORAL

NILANDRON

+ SANOFI AVENTIS US

150MG

<u>N020169</u>	<u>002</u>	Apr 30, 1999

NIMODIPINE

CAPSULE; ORAL

NIMODIPINE

<u>AB</u>	BANNER PHARMACAPS	<u>30MG</u>	<u>A076740</u>	<u>001</u>	Jan 17, 2008

<u>AB</u>	BARR LABS INC	<u>30MG</u>	<u>A077811</u>	<u>001</u>	May 02, 2007

<u>AB</u> +	SUN PHARM INDS INC	<u>30MG</u>	<u>A077067</u>	<u>001</u>	Apr 17, 2007

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

NISOLDIPINE

<u>AB</u>	MYLAN	<u>8.5MG</u>	<u>A091001</u>	<u>001</u>	Jan 26, 2011

<u>AB</u>		<u>17MG</u>	<u>A091001</u>	<u>002</u>	Jan 26, 2011

<u>AB</u>		<u>25.5MG</u>	<u>A091001</u>	<u>003</u>	Jan 26, 2011

<u>AB</u>		<u>34MG</u>	<u>A091001</u>	<u>004</u>	Jan 26, 2011

SULAR

<u>AB</u> +	SHIONOGI INC	<u>8.5MG</u>	<u>N020356</u>	<u>008</u>	Jan 02, 2008

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 310 (of 428)

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

SULAR

<u>AB</u>	+	SHIONOGI INC	<u>17MG</u>	<u>N020356</u>	<u>007</u>	Jan 02, 2008
<u>AB</u>			<u>25.5MG</u>	<u>N020356</u>	<u>006</u>	Jan 02, 2008
<u>AB</u>	+		<u>34MG</u>	<u>N020356</u>	<u>005</u>	Jan 02, 2008
		NISOLDIPINE				
	+	MYLAN	20MG	A079051	001	Jul 25, 2008
	+		30MG	A079051	002	Jul 25, 2008
	+		40MG	A079051	003	Jul 25, 2008

NITAZOXANIDE

FOR SUSPENSION; ORAL

ALINIA

+	ROMARK	100MG/5ML	N021498	001	Nov 22, 2002

TABLET; ORAL

ALINIA

+	ROMARK	500MG	N021497	001	Jul 21, 2004

NITISINONE

CAPSULE; ORAL

ORFADINRARE DIS

		2MG	N021232	001	Jan 18, 2002
		5MG	N021232	002	Jan 18, 2002
+		10MG	N021232	003	Jan 18, 2002

NITRIC OXIDE

GAS; INHALATION

INOMAXINO

		100PPM	N020845	002	Dec 23, 1999
+		800PPM	N020845	003	Dec 23, 1999

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTIN

<u>AB</u>	+	SHIONOGI INC	<u>25MG/5ML</u>	<u>N009175</u>	<u>001</u>	

NITROFURANTOIN

<u>AB</u>		AMNEAL PHARMS	<u>25MG/5ML</u>	<u>A201679</u>	<u>001</u>	May 11, 2011

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACRODANTIN

<u>AB</u>		ALMATICA	<u>25MG</u>	<u>N016620</u>	<u>003</u>	
<u>AB</u>			<u>50MG</u>	<u>N016620</u>	<u>001</u>	
<u>AB</u>	+		<u>100MG</u>	<u>N016620</u>	<u>002</u>	
		<u>NITROFURANTOIN</u>				
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>50MG</u>	<u>A073671</u>	<u>001</u>	Jan 28, 1993
<u>AB</u>			<u>100MG</u>	<u>A073652</u>	<u>001</u>	Jan 28, 1993
<u>AB</u>		MYLAN	<u>50MG</u>	<u>A074967</u>	<u>001</u>	Jul 09, 1997
<u>AB</u>			<u>100MG</u>	<u>A077025</u>	<u>001</u>	Aug 18, 2004
<u>AB</u>		WATSON LABS	<u>25MG</u>	<u>A073696</u>	<u>001</u>	Dec 31, 1992
<u>AB</u>			<u>50MG</u>	<u>A073696</u>	<u>002</u>	Dec 31, 1992
<u>AB</u>			<u>100MG</u>	<u>A073696</u>	<u>003</u>	Dec 31, 1992

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

<u>AB</u>	+	ALMATICA	<u>75MG;25MG</u>	<u>N020064</u>	<u>001</u>	Dec 24, 1991

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

<u>AB</u>		MYLAN	<u>75MG;25MG</u>	<u>A076648</u>	<u>001</u>	Mar 22, 2004
<u>AB</u>		SANDOZ	<u>75MG;25MG</u>	<u>A077066</u>	<u>001</u>	Apr 05, 2005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 311 (of 428)

NITROGLYCERIN

AEROSOL, METERED; SUBLINGUAL

NITROMIST

+ NOVADEL 0.4MG/SPRAY

N021780 001 Nov 02, 2006

FILM, EXTENDED RELEASE; TRANSDERMAL

MINITRANAB1 MEDICIS0.1MG/HRA089771 001 Aug 30, 1996AB10.2MG/HRA089772 001 Aug 30, 1996AB10.4MG/HRA089773 001 Aug 30, 1996AB10.6MG/HRA089774 001 Aug 30, 1996NITRO-DURAB1 + KEY PHARMS0.1MG/HRN020145 001 Apr 04, 1995AB1 +0.2MG/HRN020145 002 Apr 04, 1995AB1 +0.4MG/HRN020145 004 Apr 04, 1995AB1 +0.6MG/HRN020145 005 Apr 04, 1995NITROGLYCERINAB1 KREMERS URBAN PHARMS0.2MG/HRA075115 001 Aug 10, 2004AB10.4MG/HRA075115 002 Aug 10, 2004NITROGLYCERINAB2 HERCON PHARM0.2MG/HRA089884 001 Oct 30, 1998AB20.4MG/HRA089885 001 Oct 30, 1998AB20.6MG/HRA089886 001 Oct 30, 1998AB2 + MYLAN TECHNOLOGIES0.2MG/HRA074559 003 Aug 30, 1996AB2 +0.4MG/HRA074559 002 Aug 30, 1996AB2 +0.6MG/HRA074559 001 Aug 30, 1996

NITRO-DUR

+ KEY PHARMS

0.3MG/HR

N020145 003 Apr 04, 1995

+

0.8MG/HR

N020145 006 Apr 04, 1995

NITROGLYCERIN

+ MYLAN TECHNOLOGIES

0.1MG/HR

A074559 004 Feb 06, 1998

INJECTABLE; INJECTION

NITROGLYCERINAP + HOSPIRA5MG/MLN018531 001AP +

LUITPOLD

5MG/MLA072034 001 May 24, 1988NITROGLYCERIN IN DEXTROSE 5%AP + BAXTER HLTHCARE10MG/100MLN019970 001 Dec 29, 1989AP +20MG/100MLN019970 002 Dec 29, 1989AP +40MG/100MLN019970 003 Dec 29, 1989AP

HOSPIRA

10MG/100MLA071846 001 Aug 31, 1990AP20MG/100MLA071847 001 Aug 31, 1990AP40MG/100MLA071848 001 Aug 31, 1990

OINTMENT; INTRA-ANAL

RECTIV

+ APTALIS PHARMA

0.4%

N021359 001 Jun 21, 2011

OINTMENT; TRANSDERMAL

NITROGLYCERIN

+ FOUGERA

2%

A087355 001 Jul 08, 1988

SPRAY, METERED; SUBLINGUAL

NITROLINGUAL PUMPSPRAY

+ POHL BOSKAMP

0.4MG/SPRAY

N018705 002 Jan 10, 1997

TABLET; SUBLINGUAL

NITROSTAT

PFIZER PHARMS

0.3MG

N021134 001 May 01, 2000

0.4MG

N021134 002 May 01, 2000

+

0.6MG

N021134 003 May 01, 2000

NIZATIDINE

CAPSULE; ORAL

NIZATIDINEAB APOTEX150MGA076383 001 Jan 23, 2003AB300MGA076383 002 Jan 23, 2003AB

DR REDDYS LABS LTD

150MGA077314 001 Sep 15, 2005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 312 (of 428)

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

<u>AB</u>	DR REDDYS LABS LTD	<u>300MG</u>	<u>A077314</u>	<u>002</u>	Sep 15, 2005
<u>AB</u>	GLENMARK GENERICS	<u>150MG</u>	<u>A090618</u>	<u>001</u>	Jul 15, 2011
<u>AB</u>		<u>300MG</u>	<u>A090618</u>	<u>002</u>	Jul 15, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>150MG</u>	<u>A075806</u>	<u>001</u>	Jul 05, 2002
<u>AB</u>	+	<u>300MG</u>	<u>A075806</u>	<u>002</u>	Jul 05, 2002
<u>AB</u>	SANDOZ	<u>150MG</u>	<u>A076178</u>	<u>001</u>	Jul 05, 2002
<u>AB</u>		<u>300MG</u>	<u>A076178</u>	<u>002</u>	Jul 05, 2002
<u>AB</u>	TEVA	<u>150MG</u>	<u>A075668</u>	<u>001</u>	Sep 12, 2002
<u>AB</u>		<u>300MG</u>	<u>A075668</u>	<u>002</u>	Sep 12, 2002
<u>AB</u>	WATSON LABS	<u>150MG</u>	<u>A075616</u>	<u>001</u>	Jul 09, 2002
<u>AB</u>		<u>300MG</u>	<u>A075616</u>	<u>002</u>	Jul 09, 2002

SOLUTION; ORAL

AXID

<u>AA</u>	+	BRAINTREE	<u>15MG/ML</u>	<u>N021494</u>	<u>001</u>	May 25, 2004

NIZATIDINE

<u>AA</u>		AMNEAL PHARMS	<u>15MG/ML</u>	<u>A090576</u>	<u>001</u>	Nov 18, 2009

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

LEVOPHED

<u>AP</u>	+	HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>N007513</u>	<u>001</u>	
		<u>NOREPINEPHRINE BITARTRATE</u>				
<u>AP</u>		BEDFORD	<u>EQ 1MG BASE/ML</u>	<u>A040462</u>	<u>001</u>	Oct 31, 2003
<u>AP</u>		CLARIS LIFESCIENCES	<u>EQ 1MG BASE/ML</u>	<u>A040859</u>	<u>001</u>	Mar 27, 2012
<u>AP</u>		TEVA PARENTERAL	<u>EQ 1MG BASE/ML</u>	<u>A040455</u>	<u>001</u>	Mar 03, 2003

NORETHINDRONE

TABLET; ORAL-28

CAMILA

<u>AB1</u>		BARR	<u>0.35MG</u>	<u>A076177</u>	<u>001</u>	Oct 21, 2002
		<u>HEATHER</u>				
<u>AB1</u>		GLENMARK GENERICS	<u>0.35MG</u>	<u>A090454</u>	<u>001</u>	Apr 23, 2010
		<u>NORETHINDRONE</u>				
<u>AB1</u>		LUPIN LTD	<u>0.35MG</u>	<u>A091325</u>	<u>001</u>	Sep 19, 2011
		<u>NOR-QD</u>				
<u>AB1</u>	+	WATSON LABS (UTAH)	<u>0.35MG</u>	<u>N017060</u>	<u>001</u>	
		<u>ERRIN</u>				
<u>AB2</u>		BARR	<u>0.35MG</u>	<u>A076225</u>	<u>001</u>	Oct 21, 2002
		<u>MICRONOR</u>				
<u>AB2</u>	+	JANSSEN PHARMS	<u>0.35MG</u>	<u>N016954</u>	<u>001</u>	
		<u>NORETHIDRONE</u>				
<u>AB2</u>		GLENMARK GENERICS	<u>0.35MG</u>	<u>A091209</u>	<u>001</u>	Jul 21, 2010

NORETHINDRONE ACETATE

TABLET; ORAL

AYGESTIN

<u>AB</u>	+	DURAMED RES	<u>5MG</u>	<u>N018405</u>	<u>001</u>	Apr 21, 1982
		<u>NORETHIDRONE ACETATE</u>				
<u>AB</u>		AMNEAL PHARMS	<u>5MG</u>	<u>A200275</u>	<u>001</u>	Jul 30, 2012
		<u>NORETHINDRONE ACETATE</u>				
<u>AB</u>		BARR	<u>5MG</u>	<u>A075951</u>	<u>001</u>	May 25, 2001
<u>AB</u>		GLENMARK GENERICS	<u>5MG</u>	<u>A091090</u>	<u>001</u>	Jul 21, 2010

NORFLOXACIN

TABLET; ORAL

NOROXIN

	+	MERCK	400MG	N019384	002	Oct 31, 1986

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 313 (of 428)

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A074234</u>	<u>001</u>	Jul 26, 1993
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A074234</u>	<u>002</u>	Jul 26, 1993
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A074234</u>	<u>003</u>	Jul 26, 1993
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A074234</u>	<u>004</u>	Jul 26, 1993
<u>AB</u>	TARO	<u>EQ 10MG BASE</u>	<u>A075520</u>	<u>004</u>	May 08, 2000
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A075520</u>	<u>003</u>	May 08, 2000
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A075520</u>	<u>001</u>	May 08, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A075520</u>	<u>002</u>	May 08, 2000
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A074132</u>	<u>001</u>	Mar 27, 1995
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A074132</u>	<u>002</u>	Mar 27, 1995
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A074132</u>	<u>003</u>	Mar 27, 1995
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A074132</u>	<u>004</u>	Mar 27, 1995
<u>AB</u>	WATSON LABS	<u>EQ 10MG BASE</u>	<u>A073553</u>	<u>001</u>	Mar 30, 1992
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A073554</u>	<u>001</u>	Mar 30, 1992
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A073555</u>	<u>001</u>	Mar 30, 1992
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A073556</u>	<u>001</u>	Mar 30, 1992
<u>PAMELOR</u>					
<u>AB</u>	MALLINCKRODT LLC	<u>EQ 10MG BASE</u>	<u>N018013</u>	<u>001</u>	
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>N018013</u>	<u>002</u>	
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N018013</u>	<u>004</u>	
<u>AB</u>	+	<u>EQ 75MG BASE</u>	<u>N018013</u>	<u>003</u>	

SOLUTION; ORAL

AVENTYL HYDROCHLORIDE

<u>AA</u>	+	RANBAXY	<u>EQ 10MG BASE/5ML</u>	<u>N014685</u>	<u>001</u>	
<u>NORTRIPTYLINE HYDROCHLORIDE</u>						
<u>AA</u>		PHARM ASSOC	<u>EQ 10MG BASE/5ML</u>	<u>A075606</u>	<u>001</u>	Aug 28, 2000
<u>AA</u>		TARO	<u>EQ 10MG BASE/5ML</u>	<u>A077965</u>	<u>001</u>	Jun 20, 2006

NYSTATIN

CREAM; TOPICAL

NYSTATIN

<u>AT</u>		ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM</u>	<u>A062949</u>	<u>001</u>	Jun 13, 1988
<u>AT</u>		FOUGERA PHARMS	<u>100,000 UNITS/GM</u>	<u>A062129</u>	<u>001</u>	
<u>AT</u>		PERRIGO NEW YORK	<u>100,000 UNITS/GM</u>	<u>A062225</u>	<u>001</u>	
<u>AT</u>	+	TARO	<u>100,000 UNITS/GM</u>	<u>A064022</u>	<u>001</u>	Jan 29, 1993
<u>AT</u>		VINTAGE	<u>100,000 UNITS/GM</u>	<u>A065315</u>	<u>001</u>	May 31, 2006

OINTMENT; TOPICAL

NYSTATIN

<u>AT</u>		ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM</u>	<u>A062840</u>	<u>001</u>	Nov 13, 1987
<u>AT</u>	+	FOUGERA PHARMS	<u>100,000 UNITS/GM</u>	<u>A062124</u>	<u>002</u>	Sep 23, 1982
<u>AT</u>		PERRIGO NEW YORK	<u>100,000 UNITS/GM</u>	<u>A062472</u>	<u>001</u>	Feb 13, 1984

POWDER; TOPICAL

NYSTATIN

<u>AT</u>	+	COASTAL PHARMS	<u>100,000 UNITS/GM</u>	<u>A065203</u>	<u>001</u>	Jul 15, 2004
<u>AT</u>		GAVIS PHARMS	<u>100,000 UNITS/GM</u>	<u>A065138</u>	<u>001</u>	Jul 23, 2004
<u>AT</u>		UPSHER SMITH	<u>100,000 UNITS/GM</u>	<u>A065183</u>	<u>001</u>	May 03, 2005
<u>AT</u>		X GEN PHARMS	<u>100,000 UNITS/GM</u>	<u>A065175</u>	<u>001</u>	Dec 17, 2004

NYSTOP

<u>AT</u>		PADDOCK LLC	<u>100,000 UNITS/GM</u>	<u>A064118</u>	<u>001</u>	Aug 16, 1996

SUSPENSION; ORAL

NILSTAT

<u>AA</u>	+	GLENMARK GENERICS	<u>100,000 UNITS/ML</u>	<u>N050299</u>	<u>001</u>	
<u>NYSTATIN</u>						
<u>AA</u>		ACTAVIS MID ATLANTIC	<u>100,000 UNITS/ML</u>	<u>A062349</u>	<u>001</u>	Jul 14, 1982
<u>AA</u>		FOUGERA	<u>100,000 UNITS/ML</u>	<u>A062517</u>	<u>001</u>	Jun 07, 1984
<u>AA</u>		HI TECH PHARMA	<u>100,000 UNITS/ML</u>	<u>A064042</u>	<u>001</u>	Feb 28, 1994
<u>AA</u>		TARO	<u>100,000 UNITS/ML</u>	<u>A062876</u>	<u>001</u>	Feb 29, 1988
<u>AA</u>		VINTAGE PHARMS	<u>100,000 UNITS/ML</u>	<u>A065148</u>	<u>001</u>	Jun 28, 2005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 314 (of 428)

NYSTATIN

SUSPENSION; ORAL

NYSTATIN

<u>AA</u>	VISTAPHARM	<u>100,000 UNITS/ML</u>	<u>A064142</u>	<u>001</u>	Jun 25, 1998
<u>AA</u>		<u>100,000 UNITS/ML</u>	<u>A065422</u>	<u>001</u>	Mar 07, 2011
<u>AA</u>	+ WOCHKHARDT	<u>100,000 UNITS/ML</u>	<u>A062512</u>	<u>001</u>	Oct 29, 1984

TABLET; ORAL

NYSTATIN

<u>AA</u>	HERITAGE PHARMS INC	<u>500,000 UNITS</u>	<u>A062474</u>	<u>001</u>	Dec 22, 1983
<u>AA</u>	MUTUAL PHARM	<u>500,000 UNITS</u>	<u>A062838</u>	<u>001</u>	Dec 22, 1988
<u>AA</u>	+ TEVA	<u>500,000 UNITS</u>	<u>A062506</u>	<u>001</u>	Jan 16, 1984

TABLET; VAGINAL

NYSTATIN

	+ ODYSSEY PHARMS	100,000 UNITS	A062615	001	Oct 17, 1985

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>100,000 UNITS/GM;0.1%</u>	<u>A062599</u>	<u>001</u>	Oct 08, 1985
<u>AT</u>	+ TARO	<u>100,000 UNITS/GM;0.1%</u>	<u>A062364</u>	<u>001</u>	Dec 22, 1987

OINTMENT; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>100,000 UNITS/GM;0.1%</u>	<u>A062602</u>	<u>001</u>	Oct 09, 1985
<u>AT</u>	+ TARO	<u>100,000 UNITS/GM;0.1%</u>	<u>A063305</u>	<u>001</u>	Mar 29, 1993

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

<u>AP</u>	+ BEDFORD	<u>EQ 0.2MG BASE/ML</u>	<u>A076330</u>	<u>001</u>	Apr 08, 2005
<u>AP</u>	+	<u>EQ 1MG BASE/ML</u>	<u>A076330</u>	<u>002</u>	Apr 08, 2005
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.2MG BASE/ML</u>	<u>A077450</u>	<u>001</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077450</u>	<u>002</u>	Feb 10, 2006
<u>AP</u>	SUN PHARM INDS	<u>EQ 0.05MG BASE/ML</u>	<u>A077329</u>	<u>001</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.05MG BASE/ML</u>	<u>A077372</u>	<u>001</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077329</u>	<u>002</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077372</u>	<u>002</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A077330</u>	<u>001</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A077373</u>	<u>001</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077329</u>	<u>003</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077372</u>	<u>003</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077331</u>	<u>001</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077373</u>	<u>002</u>	Aug 14, 2007
<u>AP</u>	TEVA PARENTERAL	<u>EQ 0.05MG BASE/ML</u>	<u>A075957</u>	<u>001</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A075957</u>	<u>002</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A075959</u>	<u>001</u>	Nov 21, 2005
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A075957</u>	<u>003</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075959</u>	<u>002</u>	Nov 21, 2005
<u>AP</u>	WOCHKHARDT USA	<u>EQ 0.2MG BASE/ML</u>	<u>A090986</u>	<u>001</u>	May 11, 2011
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A090986</u>	<u>002</u>	May 11, 2011

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

<u>AP</u>	+ BEDFORD	<u>EQ 0.05MG BASE/ML</u>	<u>A076313</u>	<u>001</u>	Mar 28, 2005
<u>AP</u>	+	<u>EQ 0.1MG BASE/ML</u>	<u>A076313</u>	<u>003</u>	Mar 28, 2005
<u>AP</u>	+	<u>EQ 0.5MG BASE/ML</u>	<u>A076313</u>	<u>002</u>	Mar 28, 2005
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.05MG BASE/ML</u>	<u>A077457</u>	<u>001</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077457</u>	<u>002</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077457</u>	<u>003</u>	Feb 10, 2006
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 0.05MG BASE/ML</u>	<u>A079198</u>	<u>001</u>	Feb 10, 2011
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A079198</u>	<u>002</u>	Feb 10, 2011
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A079198</u>	<u>003</u>	Feb 10, 2011
<u>AP</u>	WOCHKHARDT USA	<u>EQ 0.05MG BASE/ML</u>	<u>A090985</u>	<u>001</u>	May 11, 2011
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A090985</u>	<u>002</u>	May 11, 2011

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 315 (of 428)

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

<u>AP</u>	WOCKHARDT USA	<u>EQ 0.5MG BASE/ML</u>	<u>A090985</u>	<u>003</u>	May 11, 2011
	<u>SANDOSTATIN</u>				
<u>AP</u>	+ NOVARTIS	<u>EQ 0.05MG BASE/ML</u>	<u>N019667</u>	<u>001</u>	Oct 21, 1988
<u>AP</u>	+	<u>EQ 0.1MG BASE/ML</u>	<u>N019667</u>	<u>002</u>	Oct 21, 1988
<u>AP</u>	+	<u>EQ 0.2MG BASE/ML</u>	<u>N019667</u>	<u>004</u>	Jun 12, 1991
<u>AP</u>	+	<u>EQ 0.5MG BASE/ML</u>	<u>N019667</u>	<u>003</u>	Oct 21, 1988
<u>AP</u>	+	<u>EQ 1MG BASE/ML</u>	<u>N019667</u>	<u>005</u>	Jun 12, 1991
	SANDOSTATIN LAR				
	NOVARTIS	EQ 10MG BASE/VIAL	N021008	001	Nov 25, 1998
		EQ 20MG BASE/VIAL	N021008	002	Nov 25, 1998
	+	EQ 30MG BASE/VIAL	N021008	003	Nov 25, 1998

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OCUFLOX

<u>AT</u>	+ ALLERGAN	<u>0.3%</u>	<u>N019921</u>	<u>001</u>	Jul 30, 1993
	<u>OFLOXACIN</u>				
<u>AT</u>	AKORN	<u>0.3%</u>	<u>A076407</u>	<u>001</u>	Apr 15, 2008
<u>AT</u>	ALCON PHARMS LTD	<u>0.3%</u>	<u>A076231</u>	<u>001</u>	May 14, 2004
<u>AT</u>	BAUSCH AND LOMB	<u>0.3%</u>	<u>A076622</u>	<u>001</u>	May 14, 2004
<u>AT</u>	FDC LTD	<u>0.3%</u>	<u>A078559</u>	<u>001</u>	Feb 25, 2009
<u>AT</u>	FERA PHARMS	<u>0.3%</u>	<u>A076830</u>	<u>001</u>	Aug 31, 2004
<u>AT</u>	HI TECH PHARMA	<u>0.3%</u>	<u>A076615</u>	<u>001</u>	May 14, 2004
<u>AT</u>	NOVEX	<u>0.3%</u>	<u>A076513</u>	<u>001</u>	May 14, 2004

SOLUTION/DROPS; OTIC

FLOXIN OTIC

<u>AT</u>	+ DAIICHI	<u>0.3%</u>	<u>N020799</u>	<u>001</u>	Dec 16, 1997
	<u>OFLOXACIN</u>				
<u>AT</u>	ALCON PHARMS LTD	<u>0.3%</u>	<u>A078222</u>	<u>001</u>	Mar 17, 2008
<u>AT</u>	APOTEX INC	<u>0.3%</u>	<u>A076527</u>	<u>001</u>	Sep 28, 2007
<u>AT</u>	BAUSCH AND LOMB	<u>0.3%</u>	<u>A076128</u>	<u>001</u>	Mar 17, 2008
<u>AT</u>	FERA PHARMS	<u>0.3%</u>	<u>A090395</u>	<u>001</u>	Aug 11, 2009
<u>AT</u>	HI TECH PHARMA	<u>0.3%</u>	<u>A076616</u>	<u>001</u>	Mar 17, 2008

TABLET; ORAL

OFLOXACIN

<u>AB</u>	DR REDDYS LABS LTD	<u>200MG</u>	<u>A077098</u>	<u>001</u>	Feb 10, 2006
<u>AB</u>		<u>300MG</u>	<u>A077098</u>	<u>002</u>	Feb 10, 2006
<u>AB</u>		<u>400MG</u>	<u>A077098</u>	<u>003</u>	Feb 10, 2006
<u>AB</u>	TEVA	<u>200MG</u>	<u>A076182</u>	<u>001</u>	Sep 02, 2003
<u>AB</u>		<u>300MG</u>	<u>A076182</u>	<u>002</u>	Sep 02, 2003
<u>AB</u>	+	<u>400MG</u>	<u>A076182</u>	<u>003</u>	Sep 02, 2003

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

<u>AP</u>	LUITPOLD	<u>10MG/VIAL</u>	<u>A201741</u>	<u>001</u>	Mar 20, 2012
<u>AP</u>	SANDOZ INC	<u>10MG/VIAL</u>	<u>A201588</u>	<u>001</u>	Oct 24, 2011
	<u>ZYPREXA</u>				
<u>AP</u>	+ LILLY	<u>10MG/VIAL</u>	<u>N021253</u>	<u>001</u>	Mar 29, 2004

TABLET; ORAL

OLANZAPINE

<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A090798</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A090798</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A090798</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A090798</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A090798</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A090798</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A202050</u>	<u>001</u>	Apr 23, 2012

PRESCRIPTION DRUG PRODUCT LIST

3 - 316 (of 428)

OLANZAPINE

TABLET; ORAL

OLANZAPINE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A202050</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A202050</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A202050</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A202050</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A202050</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>2.5MG</u>	<u>A076255</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A076255</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A076255</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A076255</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A076133</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A076133</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076866</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A076866</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A076866</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A076866</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A076866</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A076866</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>2.5MG</u>	<u>A202287</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A202287</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A202287</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A202287</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A202287</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A202287</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	SUN PHARM INDS	<u>2.5MG</u>	<u>A091038</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A091038</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A091038</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A091038</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A091038</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A091038</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A076000</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>5MG</u>	<u>A076000</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>7.5MG</u>	<u>A076000</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A076000</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A076000</u>	<u>005</u>	Oct 24, 2011
<u>AB</u>	TORRENT PHARMS LTD	<u>2.5MG</u>	<u>A091434</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A091434</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A091434</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A091434</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A091434</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A091434</u>	<u>006</u>	Apr 23, 2012
<u>ZYPREXA</u>					
<u>AB</u>	LILLY	<u>2.5MG</u>	<u>N020592</u>	<u>001</u>	Sep 30, 1996
<u>AB</u>	+	<u>5MG</u>	<u>N020592</u>	<u>002</u>	Sep 30, 1996
<u>AB</u>		<u>7.5MG</u>	<u>N020592</u>	<u>003</u>	Sep 30, 1996
<u>AB</u>		<u>10MG</u>	<u>N020592</u>	<u>004</u>	Sep 30, 1996
<u>AB</u>		<u>15MG</u>	<u>N020592</u>	<u>005</u>	Sep 09, 1997
<u>AB</u>		<u>20MG</u>	<u>N020592</u>	<u>006</u>	Sep 09, 1997
TABLET, ORALLY DISINTEGRATING; ORAL					
<u>OLANZAPINE</u>					
<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A091265</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A091265</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A091265</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A091265</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	BARR LABS INC	<u>5MG</u>	<u>A077243</u>	<u>001</u>	Jan 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A077243</u>	<u>002</u>	Jan 30, 2012
<u>AB</u>		<u>15MG</u>	<u>A077243</u>	<u>003</u>	Jan 30, 2012
<u>AB</u>		<u>20MG</u>	<u>A077243</u>	<u>004</u>	Jan 30, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076534</u>	<u>001</u>	Oct 24, 2011

PRESCRIPTION DRUG PRODUCT LIST

3 - 317 (of 428)

OLANZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

<u>AB</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A076534</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A076534</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A076534</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	JUBILANT ORGANOSYS	<u>5MG</u>	<u>A200221</u>	<u>001</u>	Sep 12, 2012
<u>AB</u>		<u>10MG</u>	<u>A200221</u>	<u>002</u>	Sep 12, 2012
<u>AB</u>		<u>15MG</u>	<u>A200221</u>	<u>003</u>	Sep 12, 2012
<u>AB</u>		<u>20MG</u>	<u>A200221</u>	<u>004</u>	Sep 12, 2012
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A078109</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A078109</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A078109</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A078109</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A090881</u>	<u>001</u>	Feb 28, 2012
<u>AB</u>		<u>10MG</u>	<u>A090881</u>	<u>002</u>	Feb 28, 2012
<u>AB</u>		<u>15MG</u>	<u>A090881</u>	<u>003</u>	Feb 28, 2012
<u>AB</u>		<u>20MG</u>	<u>A090881</u>	<u>004</u>	Feb 28, 2012
<u>AB</u>	TORRENT PHARMS LLC	<u>5MG</u>	<u>A091415</u>	<u>001</u>	Oct 25, 2011
<u>AB</u>		<u>10MG</u>	<u>A091415</u>	<u>002</u>	Oct 25, 2011
<u>AB</u>		<u>15MG</u>	<u>A091415</u>	<u>003</u>	Oct 25, 2011
<u>AB</u>		<u>20MG</u>	<u>A091415</u>	<u>004</u>	Oct 25, 2011
<u>ZYPREXA ZYDIS</u>					
<u>AB</u>	+ LILLY	<u>5MG</u>	<u>N021086</u>	<u>001</u>	Apr 06, 2000
<u>AB</u>		<u>10MG</u>	<u>N021086</u>	<u>002</u>	Apr 06, 2000
<u>AB</u>		<u>15MG</u>	<u>N021086</u>	<u>003</u>	Apr 06, 2000
<u>AB</u>		<u>20MG</u>	<u>N021086</u>	<u>004</u>	Apr 06, 2000

OLANZAPINE PAMOATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
ZYPREXA RELPREVV

ELI LILLY CO	EQ 210MG BASE/VIAL	N022173	001	Dec 11, 2009
	EQ 300MG BASE/VIAL	N022173	002	Dec 11, 2009
+	EQ 405MG BASE/VIAL	N022173	003	Dec 11, 2009

OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR

DAIICHI SANKYO	5MG	N021286	001	Apr 25, 2002
	20MG	N021286	003	Apr 25, 2002
+	40MG	N021286	004	Apr 25, 2002

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

+ ALCON PHARMS LTD	EQ 0.2% BASE	N021545	001	Dec 22, 2004
PATANOL				
+ ALCON	EQ 0.1% BASE	N020688	001	Dec 18, 1996
SPRAY, METERED; NASAL				
PATANASE				
+ ALCON PHARMS LTD	0.665MG/SPRAY	N021861	001	Apr 15, 2008

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

+ MEDA PHARMS	250MG	N019715	001	Jul 31, 1990

OMACETAXINE MEPESUCCINATE

POWDER; SUBCUTANEOUS

SYNRIBO

+ IVAX INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012

PRESCRIPTION DRUG PRODUCT LIST

3 - 318 (of 428)

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL
LOVAZA

+ SMITHKLINE BEECHAM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

<u>AB</u>	APOTEX	<u>10MG</u>	<u>A076048</u>	<u>001</u>	Oct 22, 2007
<u>AB</u>		<u>20MG</u>	<u>A076048</u>	<u>002</u>	Oct 22, 2007
<u>AB</u>		<u>40MG</u>	<u>A076048</u>	<u>003</u>	Jan 21, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A075576</u>	<u>003</u>	Oct 22, 2007
<u>AB</u>		<u>10MG</u>	<u>A078490</u>	<u>002</u>	Mar 16, 2009
<u>AB</u>		<u>20MG</u>	<u>A075576</u>	<u>002</u>	Oct 22, 2007
<u>AB</u>		<u>20MG</u>	<u>A078490</u>	<u>003</u>	Mar 16, 2009
<u>AB</u>		<u>40MG</u>	<u>A075576</u>	<u>001</u>	Jan 21, 2009
<u>AB</u>		<u>40MG</u>	<u>A078490</u>	<u>001</u>	Apr 17, 2009
<u>AB</u>	IMPAX LABS	<u>10MG</u>	<u>A075785</u>	<u>001</u>	Oct 22, 2007
<u>AB</u>		<u>20MG</u>	<u>A075785</u>	<u>002</u>	Oct 22, 2007
<u>AB</u>		<u>40MG</u>	<u>A075785</u>	<u>003</u>	Jan 21, 2009
<u>AB</u>	KREMERS URBAN PHARMS	<u>10MG</u>	<u>A075410</u>	<u>001</u>	Nov 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075410</u>	<u>002</u>	Nov 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075410</u>	<u>003</u>	Jan 23, 2009
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A075876</u>	<u>001</u>	May 29, 2003
<u>AB</u>		<u>20MG</u>	<u>A075876</u>	<u>002</u>	May 29, 2003
<u>AB</u>		<u>40MG</u>	<u>A075876</u>	<u>003</u>	Jan 21, 2009
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A075757</u>	<u>001</u>	Jan 28, 2003
<u>AB</u>		<u>20MG</u>	<u>A075757</u>	<u>002</u>	Jan 28, 2003
<u>AB</u>		<u>40MG</u>	<u>A076515</u>	<u>001</u>	Jan 21, 2009
<u>AB</u>	WATSON LABS FLORIDA	<u>10MG</u>	<u>A075347</u>	<u>001</u>	May 30, 2008
<u>AB</u>		<u>20MG</u>	<u>A075347</u>	<u>002</u>	May 30, 2008
<u>AB</u>		<u>40MG</u>	<u>A075347</u>	<u>003</u>	May 30, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>10MG</u>	<u>A091352</u>	<u>001</u>	Nov 19, 2012
<u>AB</u>		<u>20MG</u>	<u>A091352</u>	<u>002</u>	Nov 19, 2012
<u>AB</u>		<u>40MG</u>	<u>A091352</u>	<u>003</u>	Nov 19, 2012
<u>PRILOSEC</u>					
<u>AB</u>	ASTRAZENECA	<u>10MG</u>	<u>N019810</u>	<u>003</u>	Oct 05, 1995
<u>AB</u>	+	<u>20MG</u>	<u>N019810</u>	<u>001</u>	Sep 14, 1989
<u>AB</u>	+	<u>40MG</u>	<u>N019810</u>	<u>002</u>	Jan 15, 1998

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL
PRILOSEC

ASTRAZENECA	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008
+	EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

<u>AB</u>	PAR PHARM	<u>20MG;1.1GM</u>	<u>A078966</u>	<u>001</u>	May 25, 2010
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A078966</u>	<u>002</u>	May 25, 2010
<u>ZEGERID</u>					
<u>AB</u>	SANTARUS	<u>20MG;1.1GM</u>	<u>N021849</u>	<u>001</u>	Feb 27, 2006
<u>AB</u>	+	<u>40MG;1.1GM</u>	<u>N021849</u>	<u>002</u>	Feb 27, 2006
FOR SUSPENSION; ORAL					
ZEGERID					
	SANTARUS	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004
+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 319 (of 428)

ONDANSETRON

FILM; ORAL

ZUPLENZ

VESTIQ PHARMS

4MG

N022524

001

Jul 02, 2010

+

8MG

N022524

002

Jul 02, 2010

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRONAB AUROBINDO PHARMA4MGA090469001

Apr 12, 2010

AB 8MGA090469002

Apr 12, 2010

AB BARR 4MGA076693001

Jun 25, 2007

AB 8MGA076693002

Jun 25, 2007

AB GLENMARK GENERICS 4MGA078152001

Jun 27, 2007

AB 8MGA078152002

Jun 27, 2007

AB MYLAN 4MGA078139001

Jun 25, 2007

AB 8MGA078139002

Jun 25, 2007

AB RANBAXY 4MGA078602001

Feb 24, 2011

AB 8MGA078602002

Feb 24, 2011

AB SANDOZ 4MGA078050001

Aug 13, 2007

AB 8MGA078050002

Aug 13, 2007

AB SUN PHARM INDS 4MGA077557001

Aug 02, 2007

AB 8MGA077557002

Aug 02, 2007

AB TEVA 4MGA076810001

Jun 25, 2007

AB 8MGA076810002

Jun 25, 2007

ZOFRAN ODTAB GLAXOSMITHKLINE 4MGN020781001

Jan 27, 1999

AB + 8MGN020781002

Jan 27, 1999

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDEAP APOTEX EQ 2MG BASE/MLA077368001

Dec 26, 2006

AP AUROBINDO PHARMA LTD EQ 2MG BASE/MLA202599001

Dec 21, 2012

AP BEDFORD EQ 2MG BASE/MLA076967001

Dec 26, 2006

AP EMCURE PHARMS EQ 2MG BASE/MLA090424001

Apr 16, 2010

AP FRESENIUS KABI USA EQ 2MG BASE/MLA076974001

Dec 26, 2006

AP GLAND PHARMA LTD EQ 2MG BASE/MLA079224001

Sep 25, 2009

AP EQ 2MG BASE/MLA090648001

Jun 15, 2012

AP HIKMA FARMACEUTICA EQ 2MG BASE/MLA076781001

Dec 26, 2006

AP HIKMA MAPLE EQ 2MG BASE/MLA077365001

Dec 26, 2006

AP HOSPIRA EQ 2MG BASE/MLA077473001

Dec 26, 2006

AP EQ 2MG BASE/MLA077840001

Jan 19, 2007

AP LANNETT EQ 2MG BASE/MLA090116001

Apr 14, 2010

AP EQ 2MG BASE/MLA090883001

Aug 05, 2010

AP LUITPOLD EQ 2MG BASE/MLA077582001

Dec 26, 2006

AP EQ 2MG BASE/MLA079039001

Nov 18, 2008

AP PFIZER EQ 2MG BASE/MLA078257001

Apr 23, 2008

AP PLIVA HRVATSKA DOO EQ 2MG BASE/MLA077544001

Dec 26, 2006

AP SANDOZ EQ 2MG BASE/MLA077430001

Jun 27, 2007

AP SUN PHARM INDS (IN) EQ 2MG BASE/MLA077172001

Dec 26, 2006

AP TEVA EQ 2MG BASE/MLA076876001

Nov 22, 2006

AP WOCKHARDT EQ 2MG BASE/MLA077577001

Dec 26, 2006

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINERAP BEDFORD LABS EQ 0.64MG BASE/MLA078291001

Apr 13, 2009

AP CLARIS LIFESCIENCES EQ 0.64MG BASE/MLA078308001

Mar 17, 2008

AP + HOSPIRA EQ 0.64MG BASE/MLA077348001

Feb 01, 2007

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREEAP APOTEX INC EQ 2MG BASE/MLA077343001

Dec 26, 2006

AP AUROBINDO PHARMA LTD EQ 2MG BASE/MLA202600001

Dec 21, 2012

AP BEDFORD LABS EQ 2MG BASE/MLA077011001

Dec 26, 2006

AP EMCURE PHARMS LTD EQ 2MG BASE/MLA078945001

Jan 03, 2013

AP FRESENIUS KABI USA EQ 2MG BASE/MLA076972001

Dec 26, 2006

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 320 (of 428)

ONDANSETRON HYDROCHLORIDEINJECTABLE; INJECTIONONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 2MG BASE/ML</u>	<u>A076780</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HIKMA MAPLE	<u>EQ 2MG BASE/ML</u>	<u>A077541</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077548</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	LUITPOLD	<u>EQ 2MG BASE/ML</u>	<u>A077387</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A079032</u>	<u>001</u>	Nov 18, 2008
<u>AP</u>	PFIZER	<u>EQ 2MG BASE/ML</u>	<u>A078244</u>	<u>001</u>	Apr 23, 2008
<u>AP</u>	SANDOZ	<u>EQ 2MG BASE/ML</u>	<u>A077551</u>	<u>001</u>	Jun 27, 2007
<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 2MG BASE/ML</u>	<u>A077173</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	TARO PHARMS IRELAND	<u>EQ 2MG BASE/ML</u>	<u>A078014</u>	<u>001</u>	Mar 21, 2008
<u>AP</u>	TEVA	<u>EQ 2MG BASE/ML</u>	<u>A076759</u>	<u>001</u>	Nov 22, 2006
<u>AP</u>	WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077716</u>	<u>001</u>	Dec 26, 2006

ZOFRAN

<u>AP</u>	+ GLAXOSMITHKLINE	<u>EQ 2MG BASE/ML</u>	<u>N020007</u>	<u>001</u>	Jan 04, 1991

ZOFRAN PRESERVATIVE FREE

<u>AP</u>	+ GLAXOSMITHKLINE	<u>EQ 2MG BASE/ML</u>	<u>N020007</u>	<u>003</u>	Dec 10, 1993

SOLUTION; ORALONDANSETRON HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>EQ 4MG BASE/5ML</u>	<u>A091483</u>	<u>001</u>	Jan 31, 2011
<u>AA</u>	APOTEX	<u>EQ 4MG BASE/5ML</u>	<u>A078127</u>	<u>001</u>	Jun 25, 2007
<u>AA</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE/5ML</u>	<u>A078776</u>	<u>001</u>	Nov 28, 2007
<u>AA</u>	ROXANE	<u>EQ 4MG BASE/5ML</u>	<u>A076960</u>	<u>001</u>	Dec 26, 2006
<u>AA</u>	SILARX	<u>EQ 4MG BASE/5ML</u>	<u>A091342</u>	<u>001</u>	Jan 27, 2011
<u>AA</u>	TARO	<u>EQ 4MG BASE/5ML</u>	<u>A077009</u>	<u>001</u>	Nov 30, 2007

ZOFRAN

<u>AA</u>	+ GLAXOSMITHKLINE	<u>EQ 4MG BASE/5ML</u>	<u>N020605</u>	<u>001</u>	Jan 24, 1997

TABLET; ORALONDANSETRON HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 4MG BASE</u>	<u>A077306</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077306</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE</u>	<u>A078539</u>	<u>001</u>	Jul 31, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A078539</u>	<u>002</u>	Jul 31, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A078539</u>	<u>003</u>	Jul 31, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A076183</u>	<u>003</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076183</u>	<u>002</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076183</u>	<u>001</u>	Dec 26, 2006
<u>AB</u>	GLENMARK GENERICS	<u>EQ 4MG BASE</u>	<u>A077535</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077535</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077535</u>	<u>003</u>	Jun 25, 2007
<u>AB</u>	MYLAN	<u>EQ 4MG BASE</u>	<u>A076930</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076930</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076930</u>	<u>004</u>	Jun 25, 2007
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A077851</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077851</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	PLIVA HRVATSKA DOO	<u>EQ 4MG BASE</u>	<u>A077112</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077112</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077112</u>	<u>003</u>	Jun 25, 2007
<u>AB</u>	SANDOZ	<u>EQ 4MG BASE</u>	<u>A077517</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077517</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077517</u>	<u>003</u>	Jun 25, 2007
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 4MG BASE</u>	<u>A077050</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077050</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	TARO	<u>EQ 4MG BASE</u>	<u>A077729</u>	<u>001</u>	Mar 28, 2011
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077729</u>	<u>002</u>	Mar 28, 2011
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077729</u>	<u>003</u>	Mar 28, 2011
<u>AB</u>	TEVA	<u>EQ 4MG BASE</u>	<u>A076252</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076252</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076252</u>	<u>003</u>	Jun 25, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 321 (of 428)

ONDANSETRON HYDROCHLORIDE

TABLET; ORAL

ZOFRAN

<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 4MG BASE</u>	<u>N020103</u>	<u>001</u>	Dec 31, 1992
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>N020103</u>	<u>002</u>	Dec 31, 1992
<u>AB</u>	+	<u>EQ 24MG BASE</u>	<u>N020103</u>	<u>003</u>	Aug 27, 1999
	ONDANSETRON HYDROCHLORIDE				
	DR REDDYS LABS LTD	EQ 16MG BASE	A076183	004	Dec 26, 2006

ORLISTAT

CAPSULE; ORAL

XENICAL

+	HOFFMANN LA ROCHE	120MG	N020766	001	Apr 23, 1999

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEX

<u>AP</u>	+	MEDICIS	<u>30MG/ML</u>	<u>N013055</u>	<u>001</u>	
		<u>ORPHENADRINE CITRATE</u>				
<u>AP</u>		AKORN	<u>30MG/ML</u>	<u>A040484</u>	<u>001</u>	May 24, 2006
<u>AP</u>		BEDFORD LABS	<u>30MG/ML</u>	<u>A040463</u>	<u>001</u>	Mar 04, 2003
<u>AP</u>		SAGENT PHARMS	<u>30MG/ML</u>	<u>A090585</u>	<u>001</u>	Aug 30, 2011
<u>AP</u>		WATSON LABS	<u>30MG/ML</u>	<u>A084779</u>	<u>001</u>	Mar 15, 1982
<u>AP</u>			<u>30MG/ML</u>	<u>A087062</u>	<u>001</u>	

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

<u>AB</u>		CNTY LINE PHARMS	<u>100MG</u>	<u>A040249</u>	<u>001</u>	Jan 29, 1999
<u>AB</u>		GAVIS PHARMS	<u>100MG</u>	<u>A040284</u>	<u>001</u>	Jun 19, 1998
<u>AB</u>		IMPAX PHARMS	<u>100MG</u>	<u>A040368</u>	<u>001</u>	Jun 23, 2000
<u>AB</u>		INVAGEN PHARMS	<u>100MG</u>	<u>A091158</u>	<u>001</u>	Jul 27, 2012
<u>AB</u>	+	SANDOZ	<u>100MG</u>	<u>A040327</u>	<u>001</u>	Feb 15, 2000

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

TAMIFLU

ROCHE

		EQ 30MG BASE	N021087	003	Jul 02, 2007
		EQ 45MG BASE	N021087	002	Jul 02, 2007
+		EQ 75MG BASE	N021087	001	Oct 27, 1999

FOR SUSPENSION; ORAL

TAMIFLU

+	ROCHE	EQ 6MG BASE/ML	N021246	002	Mar 21, 2011

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

<u>AP</u>		SAGENT PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A091246</u>	<u>001</u>	Mar 30, 2012
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A091246</u>	<u>002</u>	Mar 30, 2012
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A091245</u>	<u>001</u>	Mar 30, 2012
<u>AP</u>	+	SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A061490</u>	<u>003</u>	
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A062737</u>	<u>001</u>	Dec 23, 1986
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>A061490</u>	<u>004</u>	
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A062737</u>	<u>002</u>	Dec 23, 1986
<u>AP</u>	+		<u>EQ 10GM BASE/VIAL</u>	<u>A061490</u>	<u>006</u>	May 09, 1991
		BACTOCILL IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050640	001	Oct 26, 1989	
+		EQ 40MG BASE/ML	N050640	002	Oct 26, 1989	

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

<u>AP</u>	+	SANOFI AVENTIS US	<u>50MG/10ML (5MG/ML)</u>	<u>N021759</u>	<u>001</u>	Jan 31, 2005
<u>AP</u>	+		<u>100MG/20ML (5MG/ML)</u>	<u>N021759</u>	<u>002</u>	Jan 31, 2005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 322 (of 428)

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

<u>AP</u>	ACTAVIS TOTOWA	<u>50MG/VIAL</u>	<u>A078803</u>	<u>001</u>	Aug 08, 2012
<u>AP</u>		<u>100MG/VIAL</u>	<u>A078803</u>	<u>002</u>	Aug 08, 2012
<u>AP</u>	EBEWE PHARMA	<u>50MG/10ML (5MG/ML)</u>	<u>A078812</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078812</u>	<u>002</u>	Aug 07, 2009
<u>AP</u>	FRESENIUS KABI ONCOL	<u>100MG/20ML (5MG/ML)</u>	<u>A078811</u>	<u>002</u>	Jun 10, 2010
<u>AP</u>		<u>50MG/10ML (5MG/ML)</u>	<u>A078811</u>	<u>001</u>	Jun 10, 2010
<u>AP</u>		<u>50MG/VIAL</u>	<u>A078810</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/VIAL</u>	<u>A078810</u>	<u>002</u>	Aug 07, 2009
<u>AP</u>	FRESENIUS KABI USA	<u>50MG/VIAL</u>	<u>A078819</u>	<u>001</u>	Jun 02, 2010
<u>AP</u>		<u>100MG/VIAL</u>	<u>A078819</u>	<u>002</u>	Jun 02, 2010
<u>AP</u>	HOSPIRA INC	<u>50MG/VIAL</u>	<u>A078815</u>	<u>001</u>	Sep 30, 2009
<u>AP</u>		<u>100MG/VIAL</u>	<u>A078815</u>	<u>002</u>	Sep 30, 2009
<u>AP</u>	HOSPIRA WORLDWIDE	<u>50MG/10ML (5MG/ML)</u>	<u>A078813</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078813</u>	<u>002</u>	Aug 07, 2009
<u>AP</u>	ONCO THERAPIES LTD	<u>50MG/10ML (5MG/ML)</u>	<u>A091358</u>	<u>001</u>	Aug 07, 2012
<u>AP</u>		<u>50MG/VIAL</u>	<u>A200979</u>	<u>001</u>	Aug 08, 2012
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A091358</u>	<u>002</u>	Aug 07, 2012
<u>AP</u>		<u>100MG/VIAL</u>	<u>A200979</u>	<u>002</u>	Aug 08, 2012
<u>AP</u>	SANDOZ	<u>50MG/10ML (5MG/ML)</u>	<u>A078817</u>	<u>001</u>	Jan 24, 2011
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078817</u>	<u>002</u>	Jan 24, 2011
<u>AP</u>	+ SUN PHARMA GLOBAL	<u>50MG/VIAL</u>	<u>A078818</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>	+	<u>100MG/VIAL</u>	<u>A078818</u>	<u>002</u>	Aug 07, 2009
<u>AP</u>	+ TEVA PHARMS	<u>50MG/10ML (5MG/ML)</u>	<u>N022160</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>	+	<u>100MG/20ML (5MG/ML)</u>	<u>N022160</u>	<u>002</u>	Aug 07, 2009
	ELOXATIN				
	+ SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006

OXANDROLONE

TABLET; ORAL

OXANDRIN

<u>AB</u>	SAVIENT PHARMS	<u>2.5MG</u>	<u>N013718</u>	<u>001</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N013718</u>	<u>002</u>	Nov 05, 2001
	<u>OXANDROLONE</u>				
<u>AB</u>	PAR PHARM	<u>2.5MG</u>	<u>A077827</u>	<u>001</u>	Jun 22, 2007
<u>AB</u>		<u>10MG</u>	<u>A077827</u>	<u>002</u>	Jun 22, 2007
<u>AB</u>	UPSHER SMITH	<u>2.5MG</u>	<u>A076761</u>	<u>001</u>	Dec 01, 2006
<u>AB</u>		<u>10MG</u>	<u>A078033</u>	<u>001</u>	Mar 22, 2007

OXAPROZIN

TABLET; ORAL

DAYPRO

<u>AB</u>	+ GD SEARLE	<u>600MG</u>	<u>N018841</u>	<u>004</u>	Oct 29, 1992
	<u>OXAPROZIN</u>				
<u>AB</u>	APOTEX INC	<u>600MG</u>	<u>A075987</u>	<u>001</u>	Sep 02, 2004
<u>AB</u>	CARACO	<u>600MG</u>	<u>A075844</u>	<u>001</u>	Jan 03, 2002
<u>AB</u>	DR REDDYS LABS LTD	<u>600MG</u>	<u>A075855</u>	<u>001</u>	Jan 31, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>600MG</u>	<u>A075846</u>	<u>001</u>	May 13, 2002
<u>AB</u>	SANDOZ	<u>600MG</u>	<u>A075845</u>	<u>001</u>	Jan 31, 2001
<u>AB</u>	TEVA	<u>600MG</u>	<u>A075849</u>	<u>001</u>	Jul 03, 2002
<u>AB</u>	WATSON LABS	<u>600MG</u>	<u>A075848</u>	<u>001</u>	Feb 09, 2001

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072251</u>	<u>001</u>	Apr 14, 1988
<u>AB</u>		<u>15MG</u>	<u>A072252</u>	<u>001</u>	Apr 14, 1988
<u>AB</u>		<u>30MG</u>	<u>A072253</u>	<u>001</u>	Apr 14, 1988
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>10MG</u>	<u>A070943</u>	<u>001</u>	Aug 03, 1987

PRESCRIPTION DRUG PRODUCT LIST

3 - 323 (of 428)

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>15MG</u>	<u>A070944</u>	<u>001</u>	Aug 03, 1987
<u>AB</u>	+	<u>30MG</u>	<u>A070945</u>	<u>001</u>	Aug 03, 1987
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A071813</u>	<u>001</u>	Apr 19, 1988
<u>AB</u>		<u>15MG</u>	<u>A071756</u>	<u>001</u>	Apr 19, 1988
<u>AB</u>		<u>30MG</u>	<u>A071814</u>	<u>001</u>	Apr 19, 1988
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A072952</u>	<u>001</u>	Sep 28, 1990
<u>AB</u>		<u>15MG</u>	<u>A072953</u>	<u>001</u>	Sep 28, 1990
<u>AB</u>		<u>30MG</u>	<u>A072954</u>	<u>001</u>	Sep 28, 1990

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

<u>AB</u>	AMNEAL PHARMS	<u>300MG/5ML</u>	<u>A202961</u>	<u>001</u>	Sep 17, 2012
<u>AB</u>	RANBAXY	<u>300MG/5ML</u>	<u>A078734</u>	<u>001</u>	Jun 26, 2009
<u>AB</u>	ROXANE	<u>300MG/5ML</u>	<u>A201193</u>	<u>001</u>	Oct 03, 2012

TRILEPTAL

<u>AB</u>	+	NOVARTIS	<u>300MG/5ML</u>	<u>N021285</u>	<u>001</u>	May 25, 2001

TABLET; ORAL

OXCARBAZEPINE

<u>AB</u>	APOTEX INC	<u>150MG</u>	<u>A077747</u>	<u>001</u>	Apr 09, 2008
<u>AB</u>		<u>300MG</u>	<u>A077747</u>	<u>002</u>	Apr 09, 2008
<u>AB</u>		<u>600MG</u>	<u>A077747</u>	<u>003</u>	Apr 09, 2008
<u>AB</u>	BRECKENRIDGE PHARM	<u>150MG</u>	<u>A078069</u>	<u>001</u>	Jan 11, 2008
<u>AB</u>		<u>300MG</u>	<u>A078069</u>	<u>002</u>	Jan 11, 2008
<u>AB</u>		<u>600MG</u>	<u>A078069</u>	<u>003</u>	Jan 11, 2008
<u>AB</u>	CADISTA PHARMS	<u>150MG</u>	<u>A090239</u>	<u>001</u>	Jan 25, 2010
<u>AB</u>		<u>300MG</u>	<u>A090239</u>	<u>002</u>	Jan 25, 2010
<u>AB</u>		<u>600MG</u>	<u>A090239</u>	<u>003</u>	Jan 25, 2010
<u>AB</u>	GLENMARK GENERICS	<u>150MG</u>	<u>A077802</u>	<u>001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077802</u>	<u>002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077802</u>	<u>003</u>	Oct 09, 2007
<u>AB</u>	ROXANE	<u>150MG</u>	<u>A077795</u>	<u>001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077795</u>	<u>002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077795</u>	<u>003</u>	Oct 09, 2007
<u>AB</u>	SUN PHARM INDS	<u>150MG</u>	<u>A077794</u>	<u>001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077794</u>	<u>002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077794</u>	<u>003</u>	Oct 09, 2007
<u>AB</u>	TARO	<u>150MG</u>	<u>A077801</u>	<u>001</u>	Nov 15, 2007
<u>AB</u>		<u>300MG</u>	<u>A077801</u>	<u>002</u>	Nov 15, 2007
<u>AB</u>		<u>600MG</u>	<u>A077801</u>	<u>003</u>	Nov 15, 2007
<u>AB</u>	TEVA PHARMS	<u>150MG</u>	<u>A078005</u>	<u>001</u>	Dec 11, 2007
<u>AB</u>		<u>300MG</u>	<u>A078005</u>	<u>002</u>	Dec 11, 2007
<u>AB</u>		<u>600MG</u>	<u>A078005</u>	<u>003</u>	Dec 11, 2007

TRILEPTAL

<u>AB</u>	NOVARTIS	<u>150MG</u>	<u>N021014</u>	<u>001</u>	Jan 14, 2000
<u>AB</u>		<u>300MG</u>	<u>N021014</u>	<u>002</u>	Jan 14, 2000
<u>AB</u>	+	<u>600MG</u>	<u>N021014</u>	<u>003</u>	Jan 14, 2000

TABLET, EXTENDED RELEASE; ORAL

OXTELLAR XR

	SUPERNUS PHARMS	150MG	N202810	001	Oct 19, 2012
		300MG	N202810	002	Oct 19, 2012
+		600MG	N202810	003	Oct 19, 2012

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT

+	FOUGERA PHARMS	EQ 1% BASE	N019828	001	Dec 30, 1988

PRESCRIPTION DRUG PRODUCT LIST

3 - 324 (of 428)

OXICONAZOLE NITRATE

LOTION; TOPICAL
OXISTAT

+ FOUGERA PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL
CHOLEDYL SA

+ WARNER CHILCOTT LLC	400MG	A087863	001	May 24, 1983
+	600MG	A086742	001	

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL
OXYTROL

+ WATSON LABS (UTAH)	3.9MG/24HR	N021351	002	Feb 26, 2003

GEL, METERED; TRANSDERMAL
ANTUROL

+ WATSON LABS INC	3%	N202513	001	Dec 07, 2011

OXYBUTYNIN CHLORIDE

GEL; TRANSDERMAL
GELNIQUE

+ WATSON LABS	10%(100MG/PACKET)	N022204	001	Jan 27, 2009

SYRUP; ORAL

OXYBUTYNIN CHLORIDE

<u>AA</u>	MIKART	<u>5MG/5ML</u>	<u>A075039</u>	<u>001</u>	Jan 29, 1999
<u>AA</u>	NOVEX	<u>5MG/5ML</u>	<u>A074997</u>	<u>001</u>	Oct 15, 1997
<u>AA</u>	PHARM ASSOC	<u>5MG/5ML</u>	<u>A075137</u>	<u>001</u>	Dec 18, 1998
<u>AA</u>	SILARX	<u>5MG/5ML</u>	<u>A074520</u>	<u>001</u>	Mar 29, 1996
<u>AA</u>	VINTAGE PHARMS	<u>5MG/5ML</u>	<u>A076682</u>	<u>001</u>	Dec 28, 2004
<u>AA</u>	+ WOCHKHARDT	<u>5MG/5ML</u>	<u>A074868</u>	<u>001</u>	Feb 12, 1997

TABLET; ORAL

OXYBUTYNIN CHLORIDE

<u>AB</u>	PLIVA	<u>5MG</u>	<u>A071655</u>	<u>001</u>	Nov 14, 1988
<u>AB</u>	USL PHARMA	<u>5MG</u>	<u>A074625</u>	<u>001</u>	Jul 31, 1996
<u>AB</u>	+ VINTAGE PHARMS	<u>5MG</u>	<u>A075079</u>	<u>001</u>	Oct 31, 1997

TABLET, EXTENDED RELEASE; ORAL

DITROPAN XL

<u>AB</u>	JANSSEN PHARMS	<u>5MG</u>	<u>N020897</u>	<u>001</u>	Dec 16, 1998
<u>AB</u>		<u>10MG</u>	<u>N020897</u>	<u>002</u>	Dec 16, 1998
<u>AB</u>	+	<u>15MG</u>	<u>N020897</u>	<u>003</u>	Jun 22, 1999

OXYBUTYNIN CHLORIDE

<u>AB</u>	IMPAX PHARMS	<u>5MG</u>	<u>A076745</u>	<u>002</u>	May 09, 2007
<u>AB</u>		<u>10MG</u>	<u>A076745</u>	<u>003</u>	May 09, 2007
<u>AB</u>		<u>15MG</u>	<u>A076745</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076702</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A076644</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>		<u>15MG</u>	<u>A076644</u>	<u>002</u>	May 10, 2007
<u>AB</u>	OSMOTICA PHARM	<u>5MG</u>	<u>A078503</u>	<u>001</u>	Feb 04, 2009
<u>AB</u>		<u>10MG</u>	<u>A078503</u>	<u>002</u>	Feb 04, 2009
<u>AB</u>		<u>15MG</u>	<u>A078503</u>	<u>003</u>	Feb 04, 2009

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	COASTAL PHARMS	<u>5MG</u>	<u>A203107</u>	<u>001</u>	Jul 26, 2012
<u>AB</u>	+ LEHIGH VALLEY	<u>5MG</u>	<u>N200534</u>	<u>001</u>	Oct 20, 2010

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

<u>AA</u>	+ LEHIGH VALLEY	<u>100MG/5ML</u>	<u>N200535</u>	<u>001</u>	Oct 20, 2010
<u>AA</u>	VISTAPHARM	<u>100MG/5ML</u>	<u>A202537</u>	<u>001</u>	Jul 30, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 325 (of 428)

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

+ VISTAPHARM

5MG/5ML

N201194

001

Jan 12, 2012

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>15MG</u>	<u>A076636</u>	<u>001</u>	Feb 06, 2004
<u>AB</u>		<u>30MG</u>	<u>A076636</u>	<u>002</u>	Feb 06, 2004
<u>AB</u>	ALVOGEN INC	<u>5MG</u>	<u>A202116</u>	<u>001</u>	Dec 30, 2011
<u>AB</u>		<u>15MG</u>	<u>A202116</u>	<u>002</u>	Dec 30, 2011
<u>AB</u>		<u>30MG</u>	<u>A202116</u>	<u>003</u>	Dec 30, 2011
<u>AB</u>	AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A202160</u>	<u>001</u>	Nov 19, 2012
<u>AB</u>		<u>15MG</u>	<u>A202160</u>	<u>002</u>	Nov 19, 2012
<u>AB</u>		<u>30MG</u>	<u>A202160</u>	<u>003</u>	Nov 19, 2012
<u>AB</u>	AVANTHI INC	<u>5MG</u>	<u>A091393</u>	<u>001</u>	Aug 31, 2009
<u>AB</u>		<u>10MG</u>	<u>A091393</u>	<u>002</u>	Aug 31, 2009
<u>AB</u>		<u>15MG</u>	<u>A091393</u>	<u>003</u>	Aug 31, 2009
<u>AB</u>		<u>20MG</u>	<u>A091393</u>	<u>004</u>	Aug 31, 2009
<u>AB</u>		<u>30MG</u>	<u>A091393</u>	<u>005</u>	Aug 31, 2009
<u>AB</u>	COASTAL PHARMS	<u>5MG</u>	<u>A091313</u>	<u>001</u>	Feb 18, 2011
<u>AB</u>		<u>15MG</u>	<u>A091313</u>	<u>002</u>	Feb 18, 2011
<u>AB</u>		<u>30MG</u>	<u>A091313</u>	<u>003</u>	Feb 18, 2011
<u>AB</u>	COREPHARMA	<u>5MG</u>	<u>A090895</u>	<u>001</u>	Aug 24, 2009
<u>AB</u>		<u>15MG</u>	<u>A090895</u>	<u>002</u>	Aug 24, 2009
<u>AB</u>		<u>30MG</u>	<u>A090895</u>	<u>003</u>	Aug 24, 2009
<u>AB</u>	MALLINCKRODT INC	<u>5MG</u>	<u>A076758</u>	<u>003</u>	Mar 19, 2007
<u>AB</u>		<u>15MG</u>	<u>A076758</u>	<u>001</u>	Jun 30, 2004
<u>AB</u>		<u>30MG</u>	<u>A076758</u>	<u>002</u>	Jun 30, 2004
<u>AB</u>	NESHER PHARMS	<u>5MG</u>	<u>A077290</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>10MG</u>	<u>A077290</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		<u>15MG</u>	<u>A077290</u>	<u>003</u>	Dec 08, 2005
<u>AB</u>		<u>20MG</u>	<u>A077290</u>	<u>004</u>	Dec 08, 2005
<u>AB</u>		<u>30MG</u>	<u>A077290</u>	<u>005</u>	Dec 08, 2005
<u>AB</u>	RHODES PHARMS	<u>5MG</u>	<u>A091490</u>	<u>001</u>	Mar 09, 2011
<u>AB</u>		<u>10MG</u>	<u>A091490</u>	<u>002</u>	Mar 09, 2011
<u>AB</u>		<u>15MG</u>	<u>A091490</u>	<u>003</u>	Mar 09, 2011
<u>AB</u>		<u>20MG</u>	<u>A091490</u>	<u>004</u>	Mar 09, 2011
<u>AB</u>		<u>30MG</u>	<u>A091490</u>	<u>005</u>	Mar 09, 2011
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A090659</u>	<u>001</u>	Apr 10, 2009
<u>AB</u>		<u>10MG</u>	<u>A090659</u>	<u>005</u>	Nov 06, 2012
<u>AB</u>		<u>15MG</u>	<u>A090659</u>	<u>002</u>	Apr 10, 2009
<u>AB</u>		<u>20MG</u>	<u>A090659</u>	<u>004</u>	Nov 06, 2012
<u>AB</u>		<u>30MG</u>	<u>A090659</u>	<u>003</u>	Apr 10, 2009
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A077712</u>	<u>003</u>	Mar 02, 2009
<u>AB</u>		<u>15MG</u>	<u>A077712</u>	<u>001</u>	Jan 31, 2007
<u>AB</u>		<u>30MG</u>	<u>A077712</u>	<u>002</u>	Jan 31, 2007
	<u>ROXICODONE</u>				
<u>AB</u>	MALLINCKRODT INC	<u>5MG</u>	<u>N021011</u>	<u>003</u>	May 15, 2009
<u>AB</u>	+	<u>15MG</u>	<u>N021011</u>	<u>001</u>	Aug 31, 2000
<u>AB</u>		<u>30MG</u>	<u>N021011</u>	<u>002</u>	Aug 31, 2000
	OXECTA				
	KING PHARMS R AND D	5MG	N202080	001	Jun 17, 2011
		7.5MG	N202080	002	Jun 17, 2011
	TABLET, EXTENDED RELEASE; ORAL				
	OXYCONTIN				
	PURDUE PHARMA LP	10MG	N022272	001	Apr 05, 2010
		15MG	N022272	002	Apr 05, 2010
		20MG	N022272	003	Apr 05, 2010
		30MG	N022272	004	Apr 05, 2010
	+	40MG	N022272	005	Apr 05, 2010
		60MG	N022272	006	Apr 05, 2010

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 326 (of 428)

OXYCODONE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
OXYCONTIN

PURDUE PHARMA LP 80MG

N022272 007 Apr 05, 2010

OXYMETHOLONETABLET; ORAL
ANADROL-50

+ MEDA PHARMS 50MG

N016848 001

OXYMORPHONE HYDROCHLORIDEINJECTABLE; INJECTION
OPANA

+ ENDO PHARMS 1MG/ML

N011707 002

TABLET; ORAL

OPANAAB ENDO PHARMS 5MGN021611 001 Jun 22, 2006AB + 10MGN021611 002 Jun 22, 2006OXYMORPHONE HYDROCHLORIDEAB ROXANE 5MGA090964 001 Sep 27, 2010AB 10MGA090964 002 Sep 27, 2010AB TEVA 5MGA091443 002 Feb 15, 2011AB 10MGA091443 001 Feb 15, 2011

TABLET, EXTENDED RELEASE; ORAL

OXYMORPHONE HYDROCHLORIDEAB ACTAVIS 7.5MGA079046 001 Dec 13, 2010AB 15MGA079046 002 Dec 13, 2010AB IMPAX LABS 7.5MGA079087 002 Dec 21, 2010AB 15MGA079087 004 Dec 21, 2010

OPANA ER

ENDO PHARMS 5MG

N201655 001 Dec 09, 2011

7.5MG

N201655 002 Dec 09, 2011

10MG

N201655 003 Dec 09, 2011

15MG

N201655 004 Dec 09, 2011

20MG

N201655 005 Dec 09, 2011

30MG

N201655 006 Dec 09, 2011

+ 40MG

N201655 007 Dec 09, 2011

OXYMORPHONE HYDROCHLORIDE

IMPAX LABS 5MG

A079087 001 Jun 14, 2010

10MG

A079087 003 Jun 14, 2010

20MG

A079087 005 Jun 14, 2010

30MG

A079087 006 Jul 22, 2010

40MG

A079087 007 Jun 14, 2010

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

TERRAMYCIN W/ POLYMYXIN B SULFATE

+ PFIZER EQ 5MG BASE/GM;10,000 UNITS/GM

A061015 001

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCINAP + BAXTER HLTHCARE CORP 10USP UNITS/ML (10USP UNITS/ML)N018243 001AP + 100USP UNITS/10ML (10USP UNITS/ML)N018243 002 Jan 10, 2007AP + FRESENIUS KABI USA 10USP UNITS/ML (10USP UNITS/ML)N018248 001AP + 100USP UNITS/10ML (10USP UNITS/ML)N018248 002PITOCINAP + JHP PHARMS 10USP UNITS/ML (10USP UNITS/ML)N018261 001AP 100USP UNITS/10ML (10USP UNITS/ML)N018261 002 Jul 27, 2007

OXYTOCIN

+ FRESENIUS KABI USA 300USP UNITS/30ML (10USP UNITS/ML)

N018248 003 Jul 27, 2007

PRESCRIPTION DRUG PRODUCT LIST

3 - 327 (of 428)

OXYTOCIN

INJECTABLE; INJECTION
PITOCIN

JHP PHARMS	500USP UNITS/50ML (10USP UNITS/ML)	N018261	003	Sep 05, 2012

PACLITAXEL

FOR SUSPENSION; IV (INFUSION)

+ ABRAXIS BIOSCIENCE	100MG/VIAL	N021660	001	Jan 07, 2005

INJECTABLE; INJECTION

PACLITAXEL

<u>AP</u>	ACCORD HLTHCARE INC	6MG/ML	A075436	001	Nov 12, 2004
<u>AP</u>	ACTAVIS TOTOWA	6MG/ML	A090130	001	Dec 09, 2009
<u>AP</u>	BEDFORD	6MG/ML	A075190	001	Jan 28, 2002
<u>AP</u>	EBEWE PHARMA	6MG/ML	A078167	001	Dec 26, 2007
<u>AP</u>	FRESENIUS KABI ONCOL	6MG/ML	A077574	001	Nov 27, 2006
<u>AP</u>	+ HOSPIRA	6MG/ML	A076131	001	May 08, 2002
<u>AP</u>	MYLAN	6MG/ML	A075278	001	Jan 25, 2002
<u>AP</u>	ONCO THERAPIES LTD	6MG/ML	A091540	001	Sep 29, 2011
<u>AP</u>	TEVA PHARMS	6MG/ML	A075184	001	Jan 25, 2002

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL
INVEGA

JANSSEN PHARMS	1.5MG	N021999	006	Aug 26, 2008
	3MG	N021999	001	Dec 19, 2006
+	6MG	N021999	002	Dec 19, 2006
	9MG	N021999	003	Dec 19, 2006

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
INVEGA SUSTENNA

JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009
	78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009
+	117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009
	156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009
	234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS
ALOXI

+ HELSINN HLTHCARE	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N021372	002	Feb 29, 2008
+	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N021372	001	Jul 25, 2003

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

<u>AP</u>	AREVA PHARMS	30MG/VIAL	A077433	001	Nov 26, 2008
<u>AP</u>		60MG/VIAL	A077433	002	Nov 26, 2008
<u>AP</u>		90MG/VIAL	A077433	003	Nov 26, 2008
<u>AP</u>	BEDFORD	30MG/VIAL	A075290	001	Apr 30, 2001
<u>AP</u>	+	30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002
<u>AP</u>		90MG/VIAL	A075290	003	Apr 30, 2001
<u>AP</u>	+	90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002
<u>AP</u>	FRESENIUS KABI USA	30MG/VIAL	A075773	001	May 06, 2002
<u>AP</u>		30MG/10ML (3MG/ML)	A076207	001	May 17, 2002
<u>AP</u>		90MG/VIAL	A075773	002	May 06, 2002
<u>AP</u>		90MG/10ML (9MG/ML)	A076207	002	May 17, 2002
<u>AP</u>	+	30MG/10ML (3MG/ML)	A075841	001	Jun 27, 2002
<u>AP</u>	+	60MG/10ML (6MG/ML)	A075841	002	Jun 27, 2002
<u>AP</u>	+	90MG/10ML (9MG/ML)	A075841	003	Jun 27, 2002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 328 (of 428)

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

<u>AP</u>	LUITPOLD	<u>30MG/10ML (3MG/ML)</u>	<u>A078942</u>	<u>001</u>	Jul 25, 2008
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A078942</u>	<u>002</u>	Jul 25, 2008
<u>AP</u>	MN PHARMS	<u>30MG/VIAL</u>	<u>A078300</u>	<u>001</u>	Mar 10, 2009
<u>AP</u>		<u>90MG/VIAL</u>	<u>A078300</u>	<u>002</u>	Mar 10, 2009
<u>AP</u>	MUSTAFA NEVZAT	<u>30MG/10ML (3MG/ML)</u>	<u>A078373</u>	<u>001</u>	Dec 23, 2008
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A078373</u>	<u>002</u>	Dec 23, 2008
<u>AP</u>	PFIZER	<u>30MG/10ML (3MG/ML)</u>	<u>A078520</u>	<u>001</u>	Oct 31, 2008
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A078520</u>	<u>002</u>	Oct 31, 2008
<u>AP</u>	PLIVA LACHEMA	<u>30MG/10ML (3MG/ML)</u>	<u>A078156</u>	<u>001</u>	Aug 19, 2008
<u>AP</u>		<u>60MG/10ML (6MG/ML)</u>	<u>A078156</u>	<u>002</u>	Aug 19, 2008
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A078156</u>	<u>003</u>	Aug 19, 2008
<u>AP</u>	SUN PHARMA GLOBAL	<u>30MG/VIAL</u>	<u>A077703</u>	<u>001</u>	Dec 24, 2008
<u>AP</u>		<u>90MG/VIAL</u>	<u>A077703</u>	<u>002</u>	Dec 24, 2008
<u>AP</u>	TEVA PARENTERAL	<u>30MG/10ML (3MG/ML)</u>	<u>A076153</u>	<u>001</u>	Mar 27, 2002
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A076153</u>	<u>002</u>	Mar 27, 2002

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

	ABBVIE	15,000USP UNITS;3,000USP UNITS;9,500USP UNITS	N020725	004	Jul 12, 2011
		30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N020725	001	Apr 30, 2009
		60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N020725	002	Apr 30, 2009
+		120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N020725	003	Apr 30, 2009
	PANCREAZE				
	JANSSEN PHARMS	17,500USP/ UNITS;4,200USP/ UNITS;10,000USP/ UNITS	N022523	001	Apr 12, 2010
		43,750USP/ UNITS;10,500USP/ UNITS;25,000USP/ UNITS	N022523	002	Apr 12, 2010
		70,000USP/ UNITS;16,800USP/ UNITS;40,000USP/ UNITS	N022523	004	Apr 12, 2010
+		61,000USP/ UNITS;21,000USP/ UNITS;37,000USP/ UNITS	N022523	003	Apr 12, 2010
	PERTZYE				
	DIGESTIVE CARE INC	30,250USP/UNITS;8,000USP/UNITS;28,750USP/UNITS	N022175	001	May 17, 2012
+		60,500USP/UNITS;16,000USP/UNITS;57,500USP/UNITS	N022175	002	May 17, 2012
	ULTRESA				
	APTALIS PHARMA US	27,600USP UNITS;13,800USP UNITS;27,600USP UNITS	N022222	001	Mar 01, 2012
		41,400USP UNITS;20,700USP UNITS;41,400USP UNITS	N022222	002	Mar 01, 2012
+		46,000USP UNITS;23,000USP UNITS;46,000USP UNITS	N022222	003	Mar 01, 2012
	ZENPEP				
	APTALIS PHARMA US	16,000USP UNITS;3,000USP UNITS;10,000USP UNITS	N022210	005	Jun 15, 2011
		27,000USP UNITS;5,000USP UNITS;17,000USP UNITS	N022210	001	Aug 27, 2009
		55,000USP UNITS;10,000USP UNITS;34,000USP UNITS	N022210	002	Aug 27, 2009
		82,000USP UNITS;15,000USP UNITS;51,000USP UNITS	N022210	003	Aug 27, 2009
		109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210	004	Aug 27, 2009
+		136,000USP UNITS;25,000USP UNITS;85,000USP UNITS	N022210	006	Jul 13, 2011

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 329 (of 428)

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)TABLET; ORAL
VIOKACE

APTALIS PHARMA US	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012
+	78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012

PANCURONIUM BROMIDEINJECTABLE; INJECTION
PANCURONIUM BROMIDE

<u>AP</u>	HOSPIRA	<u>1MG/ML</u>	<u>A072320</u>	<u>001</u>	Jan 19, 1989
<u>AP</u>	+ TEVA PARENTERAL	<u>1MG/ML</u>	<u>A072759</u>	<u>001</u>	Jul 31, 1990
<u>AP</u>	+	<u>2MG/ML</u>	<u>A072760</u>	<u>001</u>	Jul 31, 1990

PANTOPRAZOLE SODIUMFOR SUSPENSION, DELAYED RELEASE; ORAL
PROTONIX

+	WYETH PHARMS INC	EQ 40MG BASE	N022020	001	Nov 14, 2007

INJECTABLE; IV (INFUSION)

PANTOPRAZOLE SODIUM

<u>AP</u>	AKORN INC	<u>EQ 40MG BASE/VIAL</u>	<u>A079197</u>	<u>001</u>	Nov 08, 2012
<u>AP</u>	+	<u>EQ 40MG BASE/VIAL</u>	<u>N020988</u>	<u>001</u>	Mar 22, 2001

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

<u>AB</u>	ACTAVIS TOTOWA	<u>EQ 20MG BASE</u>	<u>A090797</u>	<u>001</u>	Feb 07, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090797</u>	<u>002</u>	Feb 07, 2011
<u>AB</u>	APOTEX INC	<u>EQ 20MG BASE</u>	<u>A090807</u>	<u>001</u>	May 02, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090807</u>	<u>002</u>	May 02, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A202038</u>	<u>001</u>	Sep 28, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A202038</u>	<u>002</u>	Sep 28, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 20MG BASE</u>	<u>A077619</u>	<u>001</u>	Jan 19, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077619</u>	<u>002</u>	Jan 19, 2011
<u>AB</u>	JUBILANT ORGANOSYS	<u>EQ 20MG BASE</u>	<u>A090901</u>	<u>001</u>	Aug 30, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090901</u>	<u>002</u>	Aug 30, 2011
<u>AB</u>	KUDCO IRELAND	<u>EQ 20MG BASE</u>	<u>A078281</u>	<u>001</u>	Jan 20, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078281</u>	<u>002</u>	Jan 20, 2011
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A200821</u>	<u>001</u>	Feb 16, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A200821</u>	<u>002</u>	Feb 16, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A090970</u>	<u>001</u>	Jan 19, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090970</u>	<u>002</u>	Jan 19, 2011
<u>AB</u>	RANBAXY LABS LTD	<u>EQ 20MG BASE</u>	<u>A200794</u>	<u>001</u>	May 02, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A200794</u>	<u>002</u>	May 02, 2012
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 20MG BASE</u>	<u>A077058</u>	<u>001</u>	Sep 10, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077058</u>	<u>002</u>	Sep 10, 2007
<u>AB</u>	TEVA	<u>EQ 20MG BASE</u>	<u>A077056</u>	<u>001</u>	Aug 02, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077056</u>	<u>002</u>	Aug 02, 2007
<u>AB</u>	TORRENT PHARMS	<u>EQ 20MG BASE</u>	<u>A090074</u>	<u>001</u>	Jan 19, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090074</u>	<u>002</u>	Jan 19, 2011
<u>AB</u>	WOCKHARDT	<u>EQ 20MG BASE</u>	<u>A091231</u>	<u>001</u>	Jan 19, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091231</u>	<u>002</u>	Jan 19, 2011
	<u>PROTONIX</u>				
<u>AB</u>	WYETH PHARMS INC	<u>EQ 20MG BASE</u>	<u>N020987</u>	<u>002</u>	Jun 12, 2001
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020987</u>	<u>001</u>	Feb 02, 2000

PARICALCITOLCAPSULE; ORAL
ZEMPLAR

ABBVIE	1MCG	N021606	001	May 26, 2005
	2MCG	N021606	002	May 26, 2005
+	4MCG	N021606	003	May 26, 2005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 330 (of 428)

PARICALCITOL

INJECTABLE; INJECTION

PARICALCITOL

<u>AP</u>	SANDOZ CANADA INC	<u>0.002MG/ML</u>	<u>A091108</u>	<u>001</u>	Jul 27, 2011
<u>AP</u>		<u>0.005MG/ML</u>	<u>A091108</u>	<u>002</u>	Jul 27, 2011
<u>ZEMPLAR</u>					
<u>AP</u>	+ ABBVIE	<u>0.002MG/ML</u>	<u>N020819</u>	<u>002</u>	Feb 01, 2000
<u>AP</u>	+	<u>0.005MG/ML</u>	<u>N020819</u>	<u>001</u>	Apr 17, 1998

PAROMOMYCIN SULFATE

CAPSULE; ORAL

PAROMOMYCIN SULFATE

<u>AA</u>	+ CARACO	<u>EQ 250MG BASE</u>	<u>A064171</u>	<u>001</u>	Jun 30, 1997
<u>AA</u>	HERITAGE PHARMS INC	<u>EQ 250MG BASE</u>	<u>A065173</u>	<u>001</u>	Dec 14, 2007

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>EQ 10MG BASE/5ML</u>	<u>A077395</u>	<u>001</u>	Dec 05, 2006
<u>PAXIL</u>					
<u>AB</u>	+ GLAXOSMITHKLINE	<u>EQ 10MG BASE/5ML</u>	<u>N020710</u>	<u>001</u>	Jun 25, 1997

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 10MG BASE</u>	<u>A075356</u>	<u>001</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075356</u>	<u>002</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A075356</u>	<u>003</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075356</u>	<u>004</u>	Jul 30, 2003
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078406</u>	<u>001</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078406</u>	<u>002</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078406</u>	<u>003</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078406</u>	<u>004</u>	Jul 25, 2007
<u>AB</u>	CARACO	<u>EQ 10MG BASE</u>	<u>A078194</u>	<u>001</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078194</u>	<u>002</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078194</u>	<u>003</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078194</u>	<u>004</u>	Jun 29, 2007
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A078902</u>	<u>001</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078902</u>	<u>002</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078902</u>	<u>003</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078902</u>	<u>004</u>	Mar 13, 2008
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A075716</u>	<u>001</u>	Mar 08, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075716</u>	<u>002</u>	Mar 08, 2004
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A075716</u>	<u>003</u>	Mar 08, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075716</u>	<u>004</u>	Mar 08, 2004
<u>AB</u>	PROSAM LABS	<u>EQ 10MG BASE</u>	<u>A076968</u>	<u>001</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076968</u>	<u>002</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076968</u>	<u>003</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076968</u>	<u>004</u>	Jun 21, 2010
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A076618</u>	<u>001</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076618</u>	<u>002</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076618</u>	<u>003</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076618</u>	<u>004</u>	Aug 15, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 10MG BASE</u>	<u>A077584</u>	<u>001</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077584</u>	<u>002</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A077584</u>	<u>003</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077584</u>	<u>004</u>	Mar 07, 2007
<u>PAXIL</u>					
<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 10MG BASE</u>	<u>N020031</u>	<u>001</u>	Dec 29, 1992
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>N020031</u>	<u>002</u>	Dec 29, 1992
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>N020031</u>	<u>003</u>	Dec 29, 1992
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020031</u>	<u>005</u>	Dec 29, 1992

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 331 (of 428)

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>EQ 12.5MG BASE</u>	<u>A077873</u>	<u>001</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A077873</u>	<u>002</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A091427</u>	<u>001</u>	Apr 14, 2011
	<u>PAXIL CR</u>				
<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 12.5MG BASE</u>	<u>N020936</u>	<u>001</u>	Feb 16, 1999
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>N020936</u>	<u>002</u>	Feb 16, 1999
<u>AB</u>	+	<u>EQ 37.5MG BASE</u>	<u>N020936</u>	<u>003</u>	Dec 06, 2000

PAROXETINE MESYLATE

TABLET; ORAL

PEXEVA

NOVEN THERAP

		EQ 10MG BASE	N021299	001	Jul 03, 2003
		EQ 20MG BASE	N021299	002	Jul 03, 2003
		EQ 30MG BASE	N021299	003	Jul 03, 2003
	+	EQ 40MG BASE	N021299	004	Jul 03, 2003

PASIREOTIDE DIASPARTATE

SOLUTION; SUBCUTANEOUS

SIGNIFOR

NOVARTIS

		EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	N200677	001	Dec 14, 2012
		EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	N200677	002	Dec 14, 2012
	+	EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	N200677	003	Dec 14, 2012

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL

VOTRIENT

+	GLAXOSMITHKLINE	EQ 200MG BASE	N022465	001	Oct 19, 2009
		EQ 400MG BASE	N022465	002	Oct 19, 2009

PEGADEMASE BOVINE

INJECTABLE; INJECTION

ADAGEN

+	SIGMA TAU	250 UNITS/ML	N019818	001	Mar 21, 1990

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

+	VALEANT PHARMS LLC	EQ 0.3MG ACID/0.09ML	N021756	001	Dec 17, 2004

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

OMONTYS

+	AFFYMAX	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007	Mar 27, 2012
+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008	Mar 27, 2012
	OMONTYS PRESERVATIVE FREE				
+	AFFYMAX	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001	Mar 27, 2012
+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002	Mar 27, 2012
+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799	003	Mar 27, 2012
+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799	004	Mar 27, 2012
+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799	005	Mar 27, 2012
+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799	006	Mar 27, 2012

PEGVISOMANT

INJECTABLE; SUBCUTANEOUS

SOMAVERT

+	PHARMACIA AND UPJOHN	10MG/VIAL	N021106	001	Mar 25, 2003
+		15MG/VIAL	N021106	002	Mar 25, 2003
+		20MG/VIAL	N021106	003	Mar 25, 2003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 332 (of 428)

PEMETREXED DISODIUM

INJECTABLE; IV (INFUSION)

ALIMTA

+	LILLY	EQ 100MG BASE/VIAL	N021462	002	Sep 07, 2007
+		EQ 500MG BASE/VIAL	N021462	001	Feb 04, 2004

PEMIROLAST POTASSIUM

SOLUTION/DROPS; OPHTHALMIC

+	SANTEN	0.1%	N021079	001	Sep 24, 1999

PENBUTOLOL SULFATE

TABLET; ORAL

LEVATOL

+	ACTIENT PHARMS	20MG	N018976	004	Jan 05, 1989

PENCICLOVIR SODIUM

CREAM; TOPICAL

DENA VIR

+	DENCO ASSET	1%	N020629	001	Sep 24, 1996

PENICILLAMINE

CAPSULE; ORAL

CUPRIMINE

+	ATON	250MG	N019853	001	

TABLET; ORAL

DEPEN

+	MEDA PHARMS	250MG	N019854	001	

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A

BC	+	KING PHARMS	600,000 UNITS/ML	N050141	001

PERMAPEN

BC		PFIZER	600,000 UNITS/ML	A060014	001

BICILLIN L-A

+	KING PHARMS	300,000 UNITS/ML	N050141	003	

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION

BICILLIN C-R

+	KING PHARMS	150,000 UNITS/ML;150,000 UNITS/ML	N050138	002	

+		300,000 UNITS/ML;300,000 UNITS/ML	N050138	001	

BICILLIN C-R 900/300

+	KING PHARMS	900,000 UNITS/2ML;300,000 UNITS/2ML	N050138	003	

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

<u>AP</u>		<u>HANFORD GC</u>	<u>5,000,000 UNITS/VIAL</u>	<u>A065149</u>	<u>002</u>	Jul 23, 2009

<u>AP</u>			<u>20,000,000 UNITS/VIAL</u>	<u>A065149</u>	<u>003</u>	Jul 23, 2009

<u>AP</u>		<u>IBI</u>	<u>5,000,000 UNITS/VIAL</u>	<u>A065448</u>	<u>001</u>	Aug 18, 2009

<u>AP</u>			<u>20,000,000 UNITS/VIAL</u>	<u>A065448</u>	<u>002</u>	Aug 18, 2009

<u>AP</u>		<u>SANDOZ</u>	<u>5,000,000 UNITS/VIAL</u>	<u>A065079</u>	<u>002</u>	Aug 30, 2002

<u>AP</u>			<u>20,000,000 UNITS/VIAL</u>	<u>A065079</u>	<u>003</u>	Aug 30, 2002

PFIZERPEN

<u>AP</u>	+	<u>PFIZER</u>	<u>5,000,000 UNITS/VIAL</u>	<u>A060657</u>	<u>002</u>	

<u>AP</u>	+		<u>20,000,000 UNITS/VIAL</u>	<u>A060657</u>	<u>003</u>	

PENICILLIN G POTASSIUM

		HANFORD GC	1,000,000 UNITS/VIAL	A065149	001	Jul 23, 2009

PENICILLIN G POTASSIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	20,000 UNITS/ML	N050638	001	Jun 25, 1990

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 333 (of 428)

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION					
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	40,000 UNITS/ML	N050638	002	Jun 25, 1990
+		60,000 UNITS/ML	N050638	003	Jun 25, 1990

PENICILLIN G PROCAINE

INJECTABLE; INJECTION					
PENICILLIN G PROCAINE					
+	KING PHARMS	300,000 UNITS/ML	A060101	002	
+		600,000 UNITS/ML	A060101	001	

PENICILLIN G SODIUM

INJECTABLE; IM-IV					
PENICILLIN G SODIUM					
+	SANDOZ	5,000,000 UNITS/VIAL	A065068	001	Feb 26, 2001

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN V POTASSIUM

<u>AA</u>	DAVA PHARMS INC	<u>EQ 125MG BASE/5ML</u>	<u>A062981</u>	<u>001</u>	Feb 10, 1989
<u>AA</u>		<u>EQ 250MG BASE/5ML</u>	<u>A062981</u>	<u>002</u>	Feb 10, 1989

PENICILLIN-VK

<u>AA</u>	TEVA	<u>EQ 125MG BASE/5ML</u>	<u>A060456</u>	<u>001</u>	
<u>AA</u>	+	<u>EQ 250MG BASE/5ML</u>	<u>A060456</u>	<u>002</u>	

TABLET; ORAL

PENICILLIN V POTASSIUM

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A065435</u>	<u>001</u>	Apr 29, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065435</u>	<u>002</u>	Apr 29, 2008
<u>AB</u>	DAVA PHARMS INC	<u>EQ 250MG BASE</u>	<u>A062936</u>	<u>001</u>	Nov 25, 1988
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062935</u>	<u>001</u>	Nov 23, 1988
<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A064071</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A064071</u>	<u>002</u>	Nov 30, 1995

PENICILLIN-VK

<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A060711</u>	<u>002</u>	
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A060711</u>	<u>003</u>	

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

+	FRESENIUS KABI USA	300MG/VIAL	N019887	001	Jun 15, 1989

INJECTABLE; INJECTION

PENTAM

<u>AP</u>	+	FRESENIUS KABI USA	<u>300MG/VIAL</u>	<u>N019264</u>	<u>001</u>	Oct 16, 1984

PENTAMIDINE ISETHIONATE

<u>AP</u>		WATSON LABS	<u>300MG/VIAL</u>	<u>A074303</u>	<u>001</u>	Aug 17, 1995

PENTAZOCINE LACTATE

INJECTABLE; INJECTION

TALWIN

+	HOSPIRA	EQ 30MG BASE/ML	N016194	001	

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

+	OAK PHARMS	50MG/ML	A083246	001	

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON

+	JANSSEN PHARMS	100MG	N020193	001	Sep 26, 1996

PRESCRIPTION DRUG PRODUCT LIST

3 - 334 (of 428)

PENTOSTATIN

INJECTABLE; INJECTION

NIPENT

<u>AP</u>	+ HOSPIRA INC	<u>10MG/VIAL</u>	<u>N020122</u>	<u>001</u>	Oct 11, 1991

PENTOSTATIN

<u>AP</u>	BEDFORD LABS	<u>10MG/VIAL</u>	<u>A077841</u>	<u>001</u>	Aug 07, 2007

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

<u>AB</u>	APOTEX	<u>400MG</u>	<u>A075191</u>	<u>001</u>	Jun 09, 1999

<u>AB</u>	IMPAX LABS	<u>400MG</u>	<u>A075093</u>	<u>001</u>	Aug 10, 1999

<u>AB</u>	MYLAN	<u>400MG</u>	<u>A074425</u>	<u>001</u>	Jul 08, 1997

<u>AB</u>	PLIVA	<u>400MG</u>	<u>A074874</u>	<u>001</u>	May 25, 1999

<u>AB</u>	VALEANT INTL	<u>400MG</u>	<u>A075028</u>	<u>001</u>	Jul 20, 1998

<u>AB</u>	WATSON LABS	<u>400MG</u>	<u>A075107</u>	<u>001</u>	Sep 04, 1998

PENTOXIL

<u>AB</u>	UPSHER SMITH	<u>400MG</u>	<u>A074962</u>	<u>001</u>	Mar 31, 1999

TRENTAL

<u>AB</u>	+ SANOFI AVENTIS US	<u>400MG</u>	<u>N018631</u>	<u>001</u>	Aug 30, 1984

PERAMPANEL

TABLET; ORAL

FYCOMPA

EISAI INC

2MG

N202834 001 Oct 20, 2012

4MG

N202834 002 Oct 22, 2012

6MG

N202834 003 Oct 22, 2012

8MG

N202834 004 Oct 22, 2012

10MG

N202834 005 Oct 22, 2012

+

12MG

N202834 006 Oct 22, 2012

PERFLUTREN

INJECTABLE; INTRAVENOUS

DEFINITY

+ LANTHEUS MEDCL

6.52MG/ML

N021064 001 Jul 31, 2001

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

<u>AB</u>	XOMA	<u>2MG</u>	<u>N020184</u>	<u>001</u>	Dec 30, 1993

<u>AB</u>		<u>4MG</u>	<u>N020184</u>	<u>002</u>	Dec 30, 1993

<u>AB</u>	+	<u>8MG</u>	<u>N020184</u>	<u>003</u>	Dec 30, 1993

PERINDOPRIL ERBUMINE

<u>AB</u>	APOTEX	<u>2MG</u>	<u>A090463</u>	<u>001</u>	Aug 30, 2010

<u>AB</u>		<u>4MG</u>	<u>A090463</u>	<u>002</u>	Aug 30, 2010

<u>AB</u>		<u>8MG</u>	<u>A090463</u>	<u>003</u>	Aug 30, 2010

<u>AB</u>	AUROBINDO PHARMA	<u>2MG</u>	<u>A079070</u>	<u>001</u>	Nov 10, 2009

<u>AB</u>		<u>4MG</u>	<u>A079070</u>	<u>002</u>	Nov 10, 2009

<u>AB</u>		<u>8MG</u>	<u>A079070</u>	<u>003</u>	Nov 10, 2009

<u>AB</u>	IVAX PHARMS	<u>2MG</u>	<u>A078138</u>	<u>001</u>	Nov 10, 2009

<u>AB</u>		<u>4MG</u>	<u>A078138</u>	<u>002</u>	Nov 10, 2009

<u>AB</u>		<u>8MG</u>	<u>A078138</u>	<u>003</u>	Nov 10, 2009

<u>AB</u>	LUPIN LTD	<u>2MG</u>	<u>A078263</u>	<u>001</u>	Jan 27, 2010

<u>AB</u>		<u>4MG</u>	<u>A078263</u>	<u>002</u>	Jan 27, 2010

<u>AB</u>		<u>8MG</u>	<u>A078263</u>	<u>003</u>	Jan 27, 2010

<u>AB</u>	ROXANE	<u>2MG</u>	<u>A090072</u>	<u>001</u>	Nov 10, 2009

<u>AB</u>		<u>4MG</u>	<u>A090072</u>	<u>002</u>	Nov 10, 2009

<u>AB</u>		<u>8MG</u>	<u>A090072</u>	<u>003</u>	Nov 10, 2009

PRESCRIPTION DRUG PRODUCT LIST

3 - 335 (of 428)

PERMETHRIN

CREAM; TOPICAL

ELIMITE

<u>AB</u>	+ RENAISSANCE PHARMA	<u>5%</u>	<u>N019855</u>	<u>001</u>	Aug 25, 1989

PERMETHRIN

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>5%</u>	<u>A074806</u>	<u>001</u>	Jan 23, 1998

<u>AB</u>	PERRIGO NEW YORK	<u>5%</u>	<u>A076369</u>	<u>001</u>	Apr 21, 2003

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

<u>AB</u>	SANDOZ	<u>2MG</u>	<u>A089683</u>	<u>001</u>	Dec 08, 1988

<u>AB</u>		<u>4MG</u>	<u>A089684</u>	<u>001</u>	Dec 08, 1988

<u>AB</u>		<u>8MG</u>	<u>A089685</u>	<u>001</u>	Dec 08, 1988

<u>AB</u>	+	<u>16MG</u>	<u>A089686</u>	<u>001</u>	Dec 08, 1988

<u>AB</u>	VINTAGE PHARMS	<u>2MG</u>	<u>A040226</u>	<u>001</u>	Dec 31, 1998

<u>AB</u>		<u>4MG</u>	<u>A040226</u>	<u>002</u>	Dec 31, 1998

<u>AB</u>		<u>8MG</u>	<u>A040226</u>	<u>003</u>	Dec 31, 1998

<u>AB</u>		<u>16MG</u>	<u>A040226</u>	<u>004</u>	Dec 31, 1998

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

BONTRIL

BC	VALEANT	105MG	A088021	001	Sep 21, 1982

PHENDIMETRAZINE TARTRATE

BC	+ SANDOZ	105MG	N018074	001	

TABLET; ORAL

BONTRIL PDM

AA	+ VALEANT	<u>35MG</u>	<u>A085272</u>	<u>001</u>	

PHENDIMETRAZINE TARTRATE

AA	KVK TECH	<u>35MG</u>	<u>A091042</u>	<u>001</u>	Aug 31, 2010

AA	MIKAH PHARMA	<u>35MG</u>	<u>A040762</u>	<u>001</u>	Jan 28, 2008

AA	MIKART	<u>35MG</u>	<u>A089452</u>	<u>001</u>	Oct 30, 1991

AA	SANDOZ	<u>35MG</u>	<u>A085588</u>	<u>001</u>	

PHENELZINE SULFATE

TABLET; ORAL

NARDIL

<u>AB</u>	+ PARKE DAVIS	<u>EQ 15MG BASE</u>	<u>N011909</u>	<u>002</u>	

PHENELZINE SULFATE

<u>AB</u>	NOVEL LABS INC	<u>EQ 15MG BASE</u>	<u>A200181</u>	<u>001</u>	Dec 08, 2010

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

<u>AB</u>	+ WELLSRING PHARM	<u>10MG</u>	<u>N008708</u>	<u>001</u>	

PHENOXYBENZAMINE HYDROCHLORIDE

<u>AB</u>	ROXANE	<u>10MG</u>	<u>A201050</u>	<u>001</u>	Jul 16, 2012

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

ADIPEX-P

AA	+ TEVA	<u>37.5MG</u>	<u>A088023</u>	<u>001</u>	Aug 02, 1983

PHENTERMINE HYDROCHLORIDE

AA	BARR	<u>15MG</u>	<u>A090591</u>	<u>001</u>	Mar 18, 2010

AA		<u>30MG</u>	<u>A090591</u>	<u>002</u>	Mar 18, 2010

AA	ELITE LABS	<u>15MG</u>	<u>A202248</u>	<u>001</u>	Sep 28, 2012

AA		<u>30MG</u>	<u>A202248</u>	<u>002</u>	Sep 28, 2012

AA	KVK TECH	<u>15MG</u>	<u>A040886</u>	<u>002</u>	Mar 31, 2008

AA		<u>30MG</u>	<u>A040875</u>	<u>001</u>	Mar 21, 2008

AA		<u>30MG</u>	<u>A040886</u>	<u>001</u>	Mar 31, 2008

AA		<u>37.5MG</u>	<u>A040887</u>	<u>001</u>	Apr 24, 2008

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 336 (of 428)

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

<u>AA</u>	LANNETT	<u>15MG</u>	<u>A087022</u>	<u>002</u>	Jan 20, 2012
<u>AA</u>		<u>30MG</u>	<u>A087022</u>	<u>001</u>	Feb 03, 1983
<u>AA</u>		<u>30MG</u>	<u>A091359</u>	<u>001</u>	Jul 16, 2010
<u>AA</u>	LANNETT HOLDINGS INC	<u>37.5MG</u>	<u>A201961</u>	<u>001</u>	Jul 20, 2011
<u>AA</u>	MUTUAL PHARM	<u>30MG</u>	<u>A040525</u>	<u>001</u>	Oct 23, 2003
<u>AA</u>	+ SANDOZ	<u>15MG</u>	<u>A087190</u>	<u>002</u>	
<u>AA</u>	+	<u>30MG</u>	<u>A086945</u>	<u>001</u>	Jul 20, 1983
<u>AA</u>	+	<u>30MG</u>	<u>A087190</u>	<u>001</u>	

TABLET; ORAL

ADIPEX-P

<u>AA</u>	+ TEVA	<u>37.5MG</u>	<u>A085128</u>	<u>001</u>	
<u>PHENTERMINE HYDROCHLORIDE</u>					
<u>AA</u>	BARR	<u>37.5MG</u>	<u>A090470</u>	<u>001</u>	Aug 31, 2009
<u>AA</u>	CARACO	<u>37.5MG</u>	<u>A040790</u>	<u>001</u>	Aug 21, 2007
<u>AA</u>	ELITE LABS	<u>37.5MG</u>	<u>A200272</u>	<u>001</u>	Jan 31, 2011
<u>AA</u>	KVK TECH	<u>37.5MG</u>	<u>A040876</u>	<u>001</u>	Mar 31, 2008
<u>AA</u>	LANNETT	<u>37.5MG</u>	<u>A040555</u>	<u>001</u>	Apr 15, 2005
<u>AA</u>	MIRROR PHARMS	<u>37.5MG</u>	<u>A091451</u>	<u>001</u>	Sep 21, 2012
<u>AA</u>	MUTUAL PHARM	<u>37.5MG</u>	<u>A040526</u>	<u>001</u>	Oct 23, 2003
<u>AA</u>	VINTAGE PHARMS	<u>37.5MG</u>	<u>A040377</u>	<u>001</u>	Jan 04, 2002

TABLET, ORALLY DISINTEGRATING; ORAL
SUPRENZA

	CITIUS PHARMS	15MG	N202088	001	Jun 13, 2011
		30MG	N202088	002	Jun 13, 2011
+		37.5MG	N202088	003	Mar 27, 2012

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL

QSYMIA

	VIVUS	EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012
		EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012
		EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012
+		EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

+	LANNETT HOLDINGS INC	EQ 15MG BASE	A040872	001	Jul 28, 2011
+		EQ 30MG BASE	A040872	002	Jul 28, 2011

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

PHENTOLAMINE MESYLATE

<u>AP</u>	BEDFORD	<u>5MG/VIAL</u>	<u>A040235</u>	<u>001</u>	Mar 11, 1998
<u>REGITINE</u>					
<u>AP</u>	+ NOVARTIS	<u>5MG/VIAL</u>	<u>N008278</u>	<u>003</u>	
	ORAVerse				
+	SEPTODONT HOLDING	0.4MG/1.7ML	N022159	001	May 09, 2008

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IV (INFUSION)

+	WEST WARD PHARM CORP	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

<u>AA</u>	VINTAGE	<u>5MG/5ML;6.25MG/5ML</u>	<u>A040654</u>	<u>001</u>	Dec 07, 2006

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 337 (of 428)

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH VC PLAIN

<u>AA</u>	+	ACTAVIS MID ATLANTIC	<u>5MG/5ML;6.25MG/5ML</u>	<u>A088761</u>	<u>001</u>	Nov 08, 1984

PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE

<u>AA</u>		AMNEAL PHARMS	<u>5MG/5ML;6.25MG/5ML</u>	<u>A040902</u>	<u>001</u>	Aug 25, 2009

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-125

<u>AB</u>	+	PARKE DAVIS	<u>125MG/5ML</u>	<u>N008762</u>	<u>001</u>	

PHENYTOIN

<u>AB</u>		TARO	<u>125MG/5ML</u>	<u>A040521</u>	<u>001</u>	Mar 08, 2004

<u>AB</u>		VISTAPHARM	<u>125MG/5ML</u>	<u>A040342</u>	<u>001</u>	Jan 31, 2001

<u>AB</u>			<u>125MG/5ML</u>	<u>A040610</u>	<u>001</u>	Aug 18, 2005

<u>AB</u>		WOCKHARDT	<u>125MG/5ML</u>	<u>A040420</u>	<u>001</u>	Apr 19, 2002

TABLET, CHEWABLE; ORAL

DILANTIN

<u>AB</u>	+	PFIZER PHARMS	<u>50MG</u>	<u>A084427</u>	<u>001</u>	

PHENYTOIN

<u>AB</u>		MYLAN PHARMS INC	<u>50MG</u>	<u>A200691</u>	<u>001</u>	Dec 26, 2012

PHENYTOIN SODIUM

CAPSULE; ORAL

DILANTIN

<u>AB</u>	+	PARKE DAVIS	<u>30MG EXTENDED</u>	<u>A084349</u>	<u>001</u>	

<u>AB</u>	+		<u>100MG EXTENDED</u>	<u>A084349</u>	<u>002</u>	

EXTENDED PHENYTOIN SODIUM

<u>AB</u>		AMNEAL PHARMS NY	<u>100MG EXTENDED</u>	<u>A040765</u>	<u>001</u>	Nov 12, 2008

<u>AB</u>		MYLAN	<u>100MG EXTENDED</u>	<u>A040298</u>	<u>001</u>	Dec 28, 1998

<u>AB</u>		SUN PHARM INDS	<u>200MG EXTENDED</u>	<u>A040731</u>	<u>001</u>	Jun 30, 2008

<u>AB</u>			<u>300MG EXTENDED</u>	<u>A040731</u>	<u>002</u>	Jun 30, 2008

<u>AB</u>		SUN PHARM INDS (IN)	<u>100MG EXTENDED</u>	<u>A040621</u>	<u>001</u>	Dec 11, 2006

<u>AB</u>		TARO	<u>100MG EXTENDED</u>	<u>A040684</u>	<u>001</u>	Sep 05, 2006

<u>AB</u>		WOCKHARDT	<u>30MG EXTENDED</u>	<u>A040759</u>	<u>001</u>	Dec 18, 2007

<u>AB</u>		WOCKHARDT USA	<u>100MG EXTENDED</u>	<u>A040732</u>	<u>001</u>	Jan 30, 2008

PHENYTEK

<u>AB</u>		MYLAN	<u>200MG EXTENDED</u>	<u>A040298</u>	<u>002</u>	Dec 06, 2001

<u>AB</u>	+		<u>300MG EXTENDED</u>	<u>A040298</u>	<u>003</u>	Dec 06, 2001

INJECTABLE; INJECTION

PHENYTOIN SODIUM

<u>AP</u>	+	HIKMA MAPLE	<u>50MG/ML</u>	<u>A084307</u>	<u>001</u>	

<u>AP</u>		HOSPIRA	<u>50MG/ML</u>	<u>A089521</u>	<u>001</u>	Mar 17, 1987

<u>AP</u>			<u>50MG/ML</u>	<u>A089744</u>	<u>001</u>	Dec 18, 1987

<u>AP</u>		LUITPOLD	<u>50MG/ML</u>	<u>A040781</u>	<u>001</u>	Dec 04, 2007

<u>AP</u>		X-GEN PHARMS	<u>50MG/ML</u>	<u>A040573</u>	<u>001</u>	Sep 13, 2006

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

BP	+	INTL MEDICATION	1MG/0.5ML	A083722	001	

VITAMIN K1

BP	+	HOSPIRA	1MG/0.5ML	A087954	001	Jul 25, 1983

VITAMIN K1

	+	HOSPIRA	10MG/ML	A087955	001	Jul 25, 1983

TABLET; ORAL

MEPHYTON

	+	VALEANT PHARMS	5MG	N010104	003	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 338 (of 428)

PILOCARPINE HYDROCHLORIDE

GEL; OPHTHALMIC					
PILOPINE HS					
+	ALCON	4%	N018796	001	Oct 01, 1984
SOLUTION; OPHTHALMIC					
ISOPTO CARPINE					
	ALCON RES	1%	N200890	001	Jun 22, 2010
		2%	N200890	002	Jun 22, 2010
+		4%	N200890	003	Jun 22, 2010
TABLET; ORAL					
<u>PILOCARPINE HYDROCHLORIDE</u>					
<u>AB</u>	COREPHARMA	<u>5MG</u>	<u>A076746</u>	<u>001</u>	Nov 16, 2004
<u>AB</u>	IMPAX LABS	<u>5MG</u>	<u>A077248</u>	<u>001</u>	Mar 31, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A077248</u>	<u>002</u>	Mar 31, 2006
<u>AB</u>	LANNETT	<u>5MG</u>	<u>A077220</u>	<u>001</u>	Oct 14, 2005
<u>AB</u>		<u>7.5MG</u>	<u>A077220</u>	<u>002</u>	May 06, 2009
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A076963</u>	<u>001</u>	Dec 22, 2004
<u>AB</u>		<u>7.5MG</u>	<u>A076963</u>	<u>002</u>	Feb 27, 2007
<u>SALAGEN</u>					
<u>AB</u>	EISAI INC	<u>5MG</u>	<u>N020237</u>	<u>001</u>	Mar 22, 1994
<u>AB</u>	+	<u>7.5MG</u>	<u>N020237</u>	<u>002</u>	Apr 18, 2003

PIMECROLIMUS

CREAM; TOPICAL					
ELIDEL					
+	VALEANT BERMUDA	1%	N021302	001	Dec 13, 2001

PIMOZIDE

TABLET; ORAL					
ORAP					
	TEVA	1MG	N017473	003	Aug 27, 1997
+		2MG	N017473	001	Jul 31, 1984

PINDOLOL

TABLET; ORAL					
<u>PINDOLOL</u>					
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A074019</u>	<u>001</u>	Sep 03, 1992
<u>AB</u>	+	<u>10MG</u>	<u>A074019</u>	<u>002</u>	Sep 03, 1992
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A074437</u>	<u>001</u>	Feb 27, 1995
<u>AB</u>		<u>10MG</u>	<u>A074437</u>	<u>002</u>	Feb 27, 1995

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL					
<u>ACTOS</u>					
<u>AB</u>	TAKEDA PHARMS USA	<u>EQ 15MG BASE</u>	<u>N021073</u>	<u>001</u>	Jul 15, 1999
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>N021073</u>	<u>002</u>	Jul 15, 1999
<u>AB</u>	+	<u>EQ 45MG BASE</u>	<u>N021073</u>	<u>003</u>	Jul 15, 1999
<u>PIOGLITAZONE HYDROCHLORIDE</u>					
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 15MG BASE</u>	<u>A076801</u>	<u>001</u>	Aug 17, 2012
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076801</u>	<u>002</u>	Aug 17, 2012
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A076801</u>	<u>003</u>	Aug 17, 2012
<u>AB</u>	WATSON LABS	<u>EQ 15MG BASE</u>	<u>A076798</u>	<u>001</u>	Oct 26, 2012
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076798</u>	<u>002</u>	Oct 26, 2012
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A076798</u>	<u>003</u>	Oct 26, 2012

PIPERACILLIN SODIUM

INJECTABLE; INJECTION					
PIPERACILLIN					
+	IBI	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003
+		EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003
+		EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003
+		EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 339 (of 428)

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065498</u>	<u>001</u>	May 23, 2011
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065498</u>	<u>002</u>	May 23, 2011
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065498</u>	<u>003</u>	May 23, 2011
<u>AP</u>	HOSPIRA INC	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065386</u>	<u>001</u>	Sep 15, 2009
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065386</u>	<u>002</u>	Sep 15, 2009
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065386</u>	<u>003</u>	Sep 15, 2009
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A065446</u>	<u>001</u>	Sep 15, 2009
<u>AP</u>	IBI	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065523</u>	<u>001</u>	May 31, 2011
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065523</u>	<u>002</u>	May 31, 2011
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065523</u>	<u>003</u>	May 31, 2011
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A090498</u>	<u>001</u>	May 31, 2011
<u>AP</u>	SANDOZ	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065362</u>	<u>001</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065363</u>	<u>001</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065362</u>	<u>002</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065363</u>	<u>002</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065362</u>	<u>003</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065363</u>	<u>003</u>	Oct 21, 2010
<u>ZOSYN</u>					
<u>AP</u>	+ WYETH PHARMS INC	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>N050684</u>	<u>001</u>	Oct 22, 1993
<u>AP</u>	+	<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>N050684</u>	<u>002</u>	Oct 22, 1993
<u>AP</u>	+	<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050684</u>	<u>003</u>	Oct 22, 1993
<u>AP</u>	+	<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>N050684</u>	<u>004</u>	Oct 22, 1993
ZOSYN IN PLASTIC CONTAINER					
	+ WYETH PHARMS INC	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750	001	Feb 24, 1998
	+	EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750	002	Feb 24, 1998
	+	EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750	003	Feb 24, 1998

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

+	MEDICIS	EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992

PIROXICAM

CAPSULE; ORAL

FELDENE

<u>AB</u>	PFIZER	<u>10MG</u>	<u>N018147</u>	<u>002</u>	Apr 06, 1982
<u>AB</u>	+	<u>20MG</u>	<u>N018147</u>	<u>003</u>	Apr 06, 1982
<u>PIROXICAM</u>					
<u>AB</u>	MUTUAL PHARM	<u>10MG</u>	<u>A073535</u>	<u>001</u>	Mar 12, 1993
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A074102</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>		<u>20MG</u>	<u>A074102</u>	<u>002</u>	Jul 31, 1992
<u>AB</u>	NOSTRUM LABS	<u>10MG</u>	<u>A074116</u>	<u>001</u>	Jun 15, 1993
<u>AB</u>		<u>20MG</u>	<u>A074118</u>	<u>001</u>	Jun 15, 1993
<u>AB</u>	TEVA	<u>10MG</u>	<u>A074131</u>	<u>001</u>	Dec 11, 1992
<u>AB</u>		<u>20MG</u>	<u>A074131</u>	<u>002</u>	Dec 11, 1992
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A074287</u>	<u>001</u>	May 16, 1996
<u>AB</u>		<u>10MG</u>	<u>A074460</u>	<u>001</u>	Sep 29, 1995
<u>AB</u>		<u>20MG</u>	<u>A074287</u>	<u>002</u>	May 16, 1996
<u>AB</u>		<u>20MG</u>	<u>A074460</u>	<u>002</u>	Sep 29, 1995

PITAVASTATIN CALCIUM

TABLET; ORAL

LIVALO

	KOWA CO	EQ 1MG BASE	N022363	001	Aug 03, 2009
		EQ 2MG BASE	N022363	002	Aug 03, 2009
	+	EQ 4MG BASE	N022363	003	Aug 03, 2009

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 340 (of 428)

PLERIXAFORSOLUTION; SUBCUTANEOUS
MOZOBIL

+ GENZYME 24MG/1.2ML (20MG/ML) N022311 001 Dec 15, 2008

PODOFILOXGEL; TOPICAL
CONDYLOX

+ WATSON PHARMS 0.5% N020529 001 Mar 13, 1997

SOLUTION; TOPICAL

CONDYLOXAT + WATSON PHARMS 0.5% N019795 001 Dec 13, 1990PODOFILOXAT PADDOCK LLC 0.5% A075600 001 Jan 29, 2002AT PRECISION DERMAT 0.5% A090184 001 Jul 21, 2010POLIDOCANOLSOLUTION; INTRAVENOUS
ASCLERA

CHEMISCH FBRK KRSSLR 10MG/2ML (5MG/ML) N021201 001 Mar 30, 2010

+ 20MG/2ML (10MG/ML) N021201 002 Mar 30, 2010

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

GLYCOLAXAA KREMERS URBAN PHARMS 17GM/SC00PFUL A076652 001 Jul 02, 2004POLYETHYLENE GLYCOL 3350AA BRECKENRIDGE PHARM 17GM/SC00PFUL A077736 001 May 26, 2006AA NEXGEN PHARMA INC 17GM/SC00PFUL A077706 001 Sep 27, 2006AA PADDOCK LLC 17GM/SC00PFUL A077893 001 May 26, 2006POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

LAX-LYTE WITH FLAVOR PACKSAA PADDOCK LLC 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT A079232 001 Feb 25, 2010NULYTELYAA + BRAINTREE 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT N019797 001 Apr 22, 1991NULYTELY-FLAVOREDAA + BRAINTREE 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT N019797 002 Nov 18, 1994PEG-3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDEAA MYLAN 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT A090409 001 Apr 02, 2010AA NOVEL LABS INC 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT A090019 001 May 27, 2009TRILYTEAA MEDA PHARMS 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT A076491 001 Feb 05, 2004POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTEAA + MEDA PHARMS 227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT N018983 010 Jan 31, 1989AA + 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT N018983 007 Jun 12, 1987COLYTE WITH FLAVOR PACKSAA + MEDA PHARMS 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT N018983 012 Oct 08, 1998

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 341 (of 428)

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE-FLAVORED

<u>AA</u>	+	MEDA PHARMS	<u>227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT</u>	<u>N018983</u>	<u>008</u>	Nov 14, 1991

<u>AA</u>	+		<u>240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT</u>	<u>N018983</u>	<u>009</u>	Nov 14, 1991

GOLYTELY

<u>AA</u>	+	BRAINTREE	<u>236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT</u>	<u>N019011</u>	<u>001</u>	Jul 13, 1984

PEG 3350 AND ELECTROLYTES

<u>AA</u>		MYLAN	<u>236GM;2.97GM;6.74GM;5.86GM;22.74GM</u>	<u>A090928</u>	<u>001</u>	Jan 28, 2010

<u>AA</u>		NOVEL LABS INC	<u>236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT</u>	<u>A090231</u>	<u>001</u>	Jun 01, 2009

<u>AA</u>			<u>240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT</u>	<u>A090186</u>	<u>001</u>	Jun 01, 2009

GOLYTELY

	+	BRAINTREE	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N019011	002	Jun 02, 1992

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYCIN B SULFATE

<u>AP</u>		SAGENT STRIDES	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A090110</u>	<u>001</u>	Jun 29, 2011

POLYMYXIN B SULFATE

<u>AP</u>	+	BEDFORD	<u>EQ 500,000 U BASE/VIAL</u>	<u>A060716</u>	<u>001</u>	

<u>AP</u>		FRESENIUS KABI USA	<u>EQ 500,000 U BASE/VIAL</u>	<u>A065372</u>	<u>001</u>	Jan 10, 2008

<u>AP</u>		X GEN PHARMS	<u>EQ 500,000 U BASE/VIAL</u>	<u>A063000</u>	<u>001</u>	Sep 30, 1994

POWDER; FOR RX COMPOUNDING

POLY-RX

	+	X GEN PHARMS	100,000,000 UNITS/BOT	A061578	001	

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

POLYTRIM

<u>AT</u>	+	ALLERGAN	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	<u>N050567</u>	<u>001</u>	Oct 20, 1988

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

<u>AT</u>		BAUSCH AND LOMB	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	<u>A064120</u>	<u>001</u>	Feb 14, 1997

<u>AT</u>		FALCON PHARMS	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	<u>A064211</u>	<u>001</u>	Apr 13, 1998

<u>AT</u>		TAYLOR PHARMA	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	<u>A065006</u>	<u>001</u>	Dec 17, 1998

PONATINIB HYDROCHLORIDE

TABLET; ORAL

ICLUSIG

ARIAD

			EQ 15MG BASE	N203469	001	Dec 14, 2012

	+		EQ 45MG BASE	N203469	002	Dec 14, 2012

PORACTANT ALFA

SUSPENSION; INTRATRACHEAL

CUROSURF

	+	CORNERSTONE THERAP	80MG/ML	N020744	001	Nov 18, 1999

PORFIMER SODIUM

INJECTABLE; INJECTION

PHOTOFIN

PINNACLE BIOLGS

			75MG/VIAL	N020451	001	Dec 27, 1995

POSACONAZOLE

SUSPENSION; ORAL

NOXAFIL

	+	SCHERING	40MG/ML	N022003	001	Sep 15, 2006

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 342 (of 428)

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE IN PLASTIC CONTAINER

+	HOSPIRA	2MEQ/ML	N018896	001	Jul 20, 1984

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-K

<u>AB</u>	NESHER PHARMS	<u>8MEQ</u>	<u>N018238</u>	<u>001</u>	

MICRO-K 10

<u>AB</u>	NESHER PHARMS	<u>10MEQ</u>	<u>N018238</u>	<u>002</u>	May 14, 1984

POTASSIUM CHLORIDE

<u>AB</u>	PADDOCK LLC	<u>8MEQ</u>	<u>A200185</u>	<u>001</u>	May 18, 2011

<u>AB</u>		<u>10MEQ</u>	<u>A200185</u>	<u>002</u>	May 18, 2011

<u>AB</u>	WATSON LABS FLORIDA	<u>8MEQ</u>	<u>A077419</u>	<u>001</u>	Jun 02, 2008

<u>AB</u>	+	<u>10MEQ</u>	<u>A077419</u>	<u>002</u>	Jun 02, 2008

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

<u>AP</u>	B BRAUN	<u>2MEQ/ML</u>	<u>A085870</u>	<u>001</u>	

<u>AP</u>	BAXTER HLTHCARE	<u>2MEQ/ML</u>	<u>A085499</u>	<u>001</u>	

<u>AP</u>	FRESENIUS KABI USA	<u>2MEQ/ML</u>	<u>A080225</u>	<u>001</u>	

<u>AP</u>	+	<u>2MEQ/ML</u>	<u>A080205</u>	<u>001</u>	

<u>AP</u>	INTL MEDICATION	<u>2MEQ/ML</u>	<u>A083163</u>	<u>001</u>	

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

<u>AP</u>	+	<u>BAXTER HLTHCARE</u>	<u>14.9MG/ML</u>	<u>N019904</u>	<u>001</u>	Dec 26, 1989

<u>AP</u>	+		<u>746MG/100ML</u>	<u>N019904</u>	<u>005</u>	Dec 17, 1990

<u>AP</u>	HOSPIRA	<u>14.9MG/ML</u>	<u>N020161</u>	<u>005</u>	Nov 30, 1992

<u>AP</u>		<u>745MG/100ML</u>	<u>N020161</u>	<u>001</u>	Nov 30, 1992

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

<u>AP</u>	+	<u>BAXTER HLTHCARE</u>	<u>29.8MG/ML</u>	<u>N019904</u>	<u>002</u>	Dec 26, 1989

<u>AP</u>	+		<u>1.49GM/100ML</u>	<u>N019904</u>	<u>006</u>	Dec 17, 1990

<u>AP</u>	+	<u>HOSPIRA</u>	<u>29.8MG/ML</u>	<u>N020161</u>	<u>006</u>	Aug 11, 1998

<u>AP</u>		<u>1.49GM/100ML</u>	<u>N020161</u>	<u>002</u>	Nov 30, 1992

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

<u>AP</u>	+	<u>BAXTER HLTHCARE</u>	<u>2.24GM/100ML</u>	<u>N019904</u>	<u>003</u>	Dec 26, 1989

<u>AP</u>	+	<u>HOSPIRA</u>	<u>2.24GM/100ML</u>	<u>N020161</u>	<u>003</u>	Aug 11, 1998

POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

<u>AP</u>	+	<u>BAXTER HLTHCARE</u>	<u>2.98GM/100ML</u>	<u>N019904</u>	<u>004</u>	Dec 26, 1989

<u>AP</u>	+	<u>HOSPIRA</u>	<u>2.98GM/100ML</u>	<u>N020161</u>	<u>004</u>	Aug 11, 1998

POTASSIUM CHLORIDE IN PLASTIC CONTAINER

<u>AP</u>	FRESENIUS KABI USA	<u>2MEQ/ML</u>	<u>A088901</u>	<u>001</u>	Jan 25, 1985

<u>AP</u>		<u>2MEQ/ML</u>	<u>A088908</u>	<u>001</u>	Jan 25, 1985

POTASSIUM CHLORIDE

+	FRESENIUS KABI USA	3MEQ/ML	A080225	003	

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON M10

<u>AB</u>	UPSHER SMITH LABS	<u>10MEQ</u>	<u>A074726</u>	<u>002</u>	Aug 09, 2000

KLOR-CON M20

<u>AB</u>	+	UPSHER SMITH LABS	<u>20MEQ</u>	<u>A074726</u>	<u>001</u>	Nov 20, 1998

POTASSIUM CHLORIDE

<u>AB</u>	EURAND	<u>20MEQ</u>	<u>A076368</u>	<u>001</u>	Aug 18, 2004

<u>AB</u>	WATSON LABS FLORIDA	<u>10MEQ</u>	<u>A075604</u>	<u>001</u>	Apr 10, 2002

<u>AB</u>		<u>20MEQ</u>	<u>A075604</u>	<u>002</u>	Apr 10, 2002

KLOR-CON

BC	UPSHER-SMITH LABS	8MEQ	N019123	001	Apr 17, 1986

BC	+		10MEQ	N019123	002	Apr 17, 1986

K-TAB

BC	ABBVIE	10MEQ	N018279	001	

POTASSIUM CHLORIDE

BC	ABBVIE	8MEQ	N018279	002	Aug 01, 1988

KLOR-CON M15

	UPSHER SMITH LABS	15MEQ	A074726	003	Jun 06, 2003

PRESCRIPTION DRUG PRODUCT LIST

3 - 343 (of 428)

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

<u>POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
<u>AP</u>	HOSPIRA	<u>149MG/100ML;450MG/100ML</u>	<u>A078446</u>	<u>001</u>	Sep 10, 2008
<u>POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
<u>AP</u>	+ BAXTER HLTHCARE	<u>150MG/100ML;450MG/100ML</u>	<u>N017648</u>	<u>005</u>	Nov 26, 2002
<u>POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	B BRAUN	<u>150MG/100ML;900MG/100ML</u>	<u>N019708</u>	<u>004</u>	Sep 29, 1989
<u>AP</u>	BAXTER HLTHCARE	<u>150MG/100ML;900MG/100ML</u>	<u>N017648</u>	<u>001</u>	
<u>POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	BAXTER HLTHCARE	<u>300MG/100ML;900MG/100ML</u>	<u>N017648</u>	<u>002</u>	
<u>POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	HOSPIRA	<u>149MG/100ML;900MG/100ML</u>	<u>N019686</u>	<u>001</u>	Oct 17, 1988
<u>POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	HOSPIRA	<u>298MG/100ML;900MG/100ML</u>	<u>N019686</u>	<u>002</u>	Oct 17, 1988
	POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%				
	BAXTER HLTHCARE	224MG/100ML;900MG/100ML	N017648	003	

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

<u>POTASSIUM CITRATE</u>					
<u>AB</u>	COREPHARMA	<u>5MEQ</u>	<u>A077440</u>	<u>001</u>	Jun 09, 2006
<u>AB</u>		<u>10MEQ</u>	<u>A077440</u>	<u>002</u>	Jun 09, 2006
<u>UROCIT-K</u>					
<u>AB</u>	MISSION PHARMA	<u>5MEQ</u>	<u>N019071</u>	<u>001</u>	Aug 30, 1985
<u>AB</u>		<u>10MEQ</u>	<u>N019071</u>	<u>002</u>	Aug 31, 1992
	UROCIT-K				
	+ MISSION PHARMA	15MEQ	N019071	003	Dec 30, 2009

POVIDONE-IODINE

SOLUTION/DROPS; OPHTHALMIC

	+ ALCON PHARMS LTD	5%	N018634	001	Dec 17, 1986

PRALATREXATE

SOLUTION; INTRAVENOUS
FOLOTYN

	ALLOS	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009
	+	40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

<u>PRALIDOXIME CHLORIDE</u>					
	+ MERIDIAN MEDCL TECHN	300MG/ML	N018986	001	Apr 26, 1983
<u>PROTOPAM CHLORIDE</u>					
	+ BAXTER HLTHCARE CORP	1GM/VIAL	N014134	001	

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

<u>MIRAPEX</u>					
<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.125MG</u>	<u>N020667</u>	<u>001</u>	Jul 01, 1997
<u>AB</u>	+	<u>0.25MG</u>	<u>N020667</u>	<u>002</u>	Jul 01, 1997
<u>AB</u>		<u>0.5MG</u>	<u>N020667</u>	<u>006</u>	Feb 12, 1998
<u>AB</u>		<u>0.75MG</u>	<u>N020667</u>	<u>007</u>	Jul 30, 2007
<u>AB</u>		<u>1MG</u>	<u>N020667</u>	<u>003</u>	Jul 01, 1997
<u>AB</u>		<u>1.5MG</u>	<u>N020667</u>	<u>005</u>	Jul 01, 1997
<u>PRAMIPEXOLE DIHYDROCHLORIDE</u>					
<u>AB</u>	ACTAVIS PHARMA	<u>0.125MG</u>	<u>A091254</u>	<u>001</u>	Nov 30, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A091254</u>	<u>002</u>	Nov 30, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A091254</u>	<u>003</u>	Nov 30, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A091254</u>	<u>004</u>	Nov 30, 2010
<u>AB</u>		<u>1MG</u>	<u>A091254</u>	<u>005</u>	Nov 30, 2010

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 344 (of 428)

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>	ACTAVIS PHARMA	<u>1.5MG</u>	<u>A091254</u>	<u>006</u>	Nov 30, 2010
<u>AB</u>	ALEMBIC LTD	<u>0.125MG</u>	<u>A078894</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A078894</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078894</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A078894</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A078894</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>	APOTEX INC	<u>0.125MG</u>	<u>A090151</u>	<u>001</u>	Apr 30, 2012
<u>AB</u>		<u>0.25MG</u>	<u>A090151</u>	<u>002</u>	Apr 30, 2012
<u>AB</u>		<u>0.5MG</u>	<u>A090151</u>	<u>003</u>	Apr 30, 2012
<u>AB</u>		<u>0.75MG</u>	<u>A090151</u>	<u>006</u>	Apr 30, 2012
<u>AB</u>		<u>1MG</u>	<u>A090151</u>	<u>004</u>	Apr 30, 2012
<u>AB</u>		<u>1.5MG</u>	<u>A090151</u>	<u>005</u>	Apr 30, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.125MG</u>	<u>A202633</u>	<u>001</u>	Oct 26, 2012
<u>AB</u>		<u>0.25MG</u>	<u>A202633</u>	<u>002</u>	Oct 26, 2012
<u>AB</u>		<u>0.5MG</u>	<u>A202633</u>	<u>003</u>	Oct 26, 2012
<u>AB</u>		<u>0.75MG</u>	<u>A202633</u>	<u>004</u>	Oct 26, 2012
<u>AB</u>		<u>1MG</u>	<u>A202633</u>	<u>005</u>	Oct 26, 2012
<u>AB</u>		<u>1.5MG</u>	<u>A202633</u>	<u>006</u>	Oct 26, 2012
<u>AB</u>	BARR	<u>0.125MG</u>	<u>A077724</u>	<u>001</u>	Feb 19, 2008
<u>AB</u>		<u>0.25MG</u>	<u>A077724</u>	<u>002</u>	Feb 19, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077724</u>	<u>003</u>	Feb 19, 2008
<u>AB</u>		<u>1MG</u>	<u>A077724</u>	<u>004</u>	Feb 19, 2008
<u>AB</u>		<u>1.5MG</u>	<u>A077724</u>	<u>005</u>	Feb 19, 2008
<u>AB</u>	BRECKENRIDGE PHARM	<u>0.125MG</u>	<u>A091450</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A091450</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A091450</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A091450</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A091450</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>	GLENMARK GENERICS	<u>0.125MG</u>	<u>A090781</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090781</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090781</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090781</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090781</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>0.125MG</u>	<u>A202164</u>	<u>001</u>	Sep 20, 2012
<u>AB</u>		<u>0.25MG</u>	<u>A202164</u>	<u>002</u>	Sep 20, 2012
<u>AB</u>		<u>0.5MG</u>	<u>A202164</u>	<u>003</u>	Sep 20, 2012
<u>AB</u>		<u>1MG</u>	<u>A202164</u>	<u>004</u>	Sep 20, 2012
<u>AB</u>		<u>1.5MG</u>	<u>A202164</u>	<u>005</u>	Sep 20, 2012
<u>AB</u>	MYLAN	<u>0.125MG</u>	<u>A077854</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A077854</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A077854</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090764</u>	<u>001</u>	Apr 09, 2010
<u>AB</u>		<u>1MG</u>	<u>A077854</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A077854</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>	SANDOZ	<u>0.125MG</u>	<u>A090190</u>	<u>001</u>	Jul 06, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090190</u>	<u>002</u>	Jul 06, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090190</u>	<u>003</u>	Jul 06, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090190</u>	<u>006</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090190</u>	<u>004</u>	Jul 06, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090190</u>	<u>005</u>	Jul 06, 2010
<u>AB</u>	TEVA PHARMS	<u>0.125MG</u>	<u>A090241</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090241</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090241</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090241</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090241</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090241</u>	<u>006</u>	Oct 08, 2010
<u>AB</u>	TORRENT PHARMS	<u>0.125MG</u>	<u>A090865</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090865</u>	<u>002</u>	Oct 08, 2010

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 345 (of 428)

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>	TORRENT PHARMS	<u>0.5MG</u>	<u>A090865</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090865</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090865</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090865</u>	<u>006</u>	Oct 08, 2010
<u>AB</u>	WATSON LABS	<u>0.125MG</u>	<u>A078551</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A078551</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078551</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A078551</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A078551</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.125MG</u>	<u>A078920</u>	<u>001</u>	Jul 06, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A078920</u>	<u>002</u>	Jul 06, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078920</u>	<u>003</u>	Jul 06, 2010
<u>AB</u>		<u>1MG</u>	<u>A078920</u>	<u>004</u>	Jul 06, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A078920</u>	<u>005</u>	Jul 06, 2010

TABLET, EXTENDED RELEASE; ORAL

MIRAPEX ER

+	BOEHRINGER INGELHEIM	0.375MG	N022421	001	Feb 19, 2010
		0.75MG	N022421	002	Feb 19, 2010
		1.5MG	N022421	003	Feb 19, 2010
		2.25MG	N022421	006	Jun 17, 2011
		3MG	N022421	004	Feb 19, 2010
		3.75MG	N022421	007	Jun 17, 2011
		4.5MG	N022421	005	Feb 19, 2010

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

	AMYLIN	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007
		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007
+		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005

PRASUGREL HYDROCHLORIDE

TABLET; ORAL

EFFIENT

	ELI LILLY AND CO	EQ 5MG BASE	N022307	001	Jul 10, 2009
+		EQ 10MG BASE	N022307	002	Jul 10, 2009

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>10MG</u>	<u>N019898</u>	<u>002</u>	Oct 31, 1991
<u>AB</u>		<u>20MG</u>	<u>N019898</u>	<u>003</u>	Oct 31, 1991
<u>AB</u>		<u>40MG</u>	<u>N019898</u>	<u>004</u>	Mar 22, 1993
<u>AB</u>	+	<u>80MG</u>	<u>N019898</u>	<u>008</u>	Dec 18, 2001

PRAVASTATIN SODIUM

<u>AB</u>	APOTEX	<u>10MG</u>	<u>A076341</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076341</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076341</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076341</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	DR REDDYS LABS INC	<u>10MG</u>	<u>A076714</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076714</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076714</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076714</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	GLENMARK GENERICS	<u>10MG</u>	<u>A077987</u>	<u>001</u>	May 11, 2007
<u>AB</u>		<u>20MG</u>	<u>A077987</u>	<u>002</u>	May 11, 2007
<u>AB</u>		<u>40MG</u>	<u>A077987</u>	<u>003</u>	May 11, 2007
<u>AB</u>		<u>80MG</u>	<u>A077987</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	LUPIN PHARMS	<u>10MG</u>	<u>A077917</u>	<u>001</u>	Jan 08, 2008

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 346 (of 428)

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

<u>AB</u>	LUPIN PHARMS	<u>20MG</u>	<u>A077917</u>	<u>002</u>	Jan 08, 2008
<u>AB</u>		<u>40MG</u>	<u>A077917</u>	<u>003</u>	Jan 08, 2008
<u>AB</u>		<u>80MG</u>	<u>A077917</u>	<u>004</u>	Jan 08, 2008
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A077013</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A077013</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A077013</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077013</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A079187</u>	<u>001</u>	May 27, 2010
<u>AB</u>		<u>20MG</u>	<u>A079187</u>	<u>002</u>	May 27, 2010
<u>AB</u>		<u>40MG</u>	<u>A079187</u>	<u>003</u>	May 27, 2010
<u>AB</u>		<u>80MG</u>	<u>A079187</u>	<u>004</u>	May 27, 2010
<u>AB</u>	TEVA	<u>10MG</u>	<u>A076056</u>	<u>001</u>	Apr 24, 2006
<u>AB</u>		<u>20MG</u>	<u>A076056</u>	<u>002</u>	Apr 24, 2006
<u>AB</u>		<u>40MG</u>	<u>A076056</u>	<u>003</u>	Apr 24, 2006
<u>AB</u>	TEVA PHARMS	<u>80MG</u>	<u>A077793</u>	<u>001</u>	Jan 15, 2008
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A076939</u>	<u>004</u>	Oct 23, 2006
<u>AB</u>		<u>10MG</u>	<u>A077904</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076939</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A077904</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076939</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A077904</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076939</u>	<u>001</u>	Dec 28, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>10MG</u>	<u>A077751</u>	<u>001</u>	Apr 30, 2008
<u>AB</u>		<u>20MG</u>	<u>A077751</u>	<u>002</u>	Apr 30, 2008
<u>AB</u>		<u>40MG</u>	<u>A077751</u>	<u>003</u>	Apr 30, 2008
<u>AB</u>		<u>80MG</u>	<u>A077751</u>	<u>004</u>	Apr 30, 2008

PRAZQUANTEL

TABLET; ORAL

BILTRICIDE

+ BAYER PHARMA AG 600MG N018714 001 Dec 29, 1982

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIPRESS

<u>AB</u>	PFIZER	<u>EQ 1MG BASE</u>	<u>N017442</u>	<u>002</u>	
<u>AB</u>	+	<u>EQ 2MG BASE</u>	<u>N017442</u>	<u>003</u>	
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N017442</u>	<u>001</u>	
	<u>PRAZOSIN HYDROCHLORIDE</u>				
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A071994</u>	<u>001</u>	Sep 12, 1988
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A072575</u>	<u>003</u>	May 16, 1989
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A072575</u>	<u>002</u>	May 16, 1989
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A072575</u>	<u>001</u>	May 16, 1989
<u>AB</u>	TEVA PHARMS	<u>EQ 2MG BASE</u>	<u>A071995</u>	<u>001</u>	Sep 12, 1988
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A071745</u>	<u>001</u>	Sep 12, 1988

PREDNICARBATE

CREAM; TOPICAL

DERMATOP E EMOLLIENT

<u>AB</u>	+	VALEANT BERMUDA	<u>0.1%</u>	<u>N020279</u>	<u>001</u>	Oct 29, 1993
		<u>PREDNICARBATE</u>				
<u>AB</u>		FOUGERA PHARMS	<u>0.1%</u>	<u>A077287</u>	<u>001</u>	Sep 19, 2006
		OINTMENT; TOPICAL				
		<u>DERMATOP</u>				
<u>AB</u>	+	VALEANT BERMUDA	<u>0.1%</u>	<u>N019568</u>	<u>001</u>	Sep 23, 1991
		<u>PREDNICARBATE</u>				
<u>AB</u>		FOUGERA PHARMS	<u>0.1%</u>	<u>A077236</u>	<u>001</u>	Mar 09, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 347 (of 428)

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

<u>AA</u>	ALPHARMA	<u>15MG/5ML</u>	<u>A040323</u>	<u>001</u>	May 13, 1999
<u>AA</u>	APOTEX INC	<u>5MG/5ML</u>	<u>A040570</u>	<u>001</u>	Aug 25, 2005
<u>AA</u>		<u>15MG/5ML</u>	<u>A040571</u>	<u>001</u>	Aug 25, 2005
<u>AA</u>	+ HI TECH PHARMA CO	<u>15MG/5ML</u>	<u>A040401</u>	<u>001</u>	Feb 27, 2003
<u>AA</u>	PHARM ASSOC	<u>15MG/5ML</u>	<u>A040399</u>	<u>001</u>	Mar 05, 2003
<u>AA</u>	VINTAGE	<u>15MG/5ML</u>	<u>A040775</u>	<u>001</u>	Sep 21, 2007
<u>AA</u>	WOCKHARDT	<u>15MG/5ML</u>	<u>A040313</u>	<u>001</u>	Sep 10, 2003

PRELONE

<u>AA</u>	TEVA	<u>15MG/5ML</u>	<u>A089081</u>	<u>001</u>	Feb 04, 1986
	TABLET; ORAL				
	PREDNISOLONE				
	+ WATSON LABS	5MG	A080354	001	

PREDNISOLONE ACETATE

SUSPENSION; ORAL

FLO-PRED

	+ TARO	EQ 15MG BASE/5ML	N022067	002	Jan 17, 2008

SUSPENSION/DROPS; OPHTHALMIC

OMNIPRED

<u>AB</u>	ALCON	<u>1%</u>	<u>N017469</u>	<u>001</u>	
	<u>PRED FORTE</u>				
<u>AB</u>	+ ALLERGAN	<u>1%</u>	<u>N017011</u>	<u>001</u>	
	PRED MILD				
	+ ALLERGAN	0.12%	N017100	001	

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPHAMIDE S.O.P.

	+ ALLERGAN	0.2%;10%	A087748	001	Dec 03, 1986

SUSPENSION; OPHTHALMIC

BLEPHAMIDE

	+ ALLERGAN	0.2%;10%	N012813	002	

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

ORAPRED

<u>AA</u>	+ SHIONOGI INC	<u>EQ 15MG BASE/5ML</u>	<u>A075117</u>	<u>001</u>	Dec 14, 2000

PEDIAPRED

<u>AA</u>	+ SETON PHARM	<u>EQ 5MG BASE/5ML</u>	<u>N019157</u>	<u>001</u>	May 28, 1986

PREDNISOLONE SODIUM PHOSPHATE

<u>AA</u>	AMNEAL PHARMS	<u>EQ 15MG BASE/5ML</u>	<u>A078345</u>	<u>001</u>	Mar 10, 2009
<u>AA</u>	HI TECH PHARMA	<u>EQ 5MG BASE/5ML</u>	<u>A075183</u>	<u>001</u>	Mar 26, 2003
<u>AA</u>	NESHER PHARMS	<u>EQ 15MG BASE/5ML</u>	<u>A076988</u>	<u>001</u>	May 24, 2005
<u>AA</u>	PADDOCK LLC	<u>EQ 5MG BASE/5ML</u>	<u>A075988</u>	<u>001</u>	May 25, 2004
<u>AA</u>	PHARM ASSOC	<u>EQ 5MG BASE/5ML</u>	<u>A076123</u>	<u>001</u>	Dec 23, 2002
<u>AA</u>		<u>EQ 15MG BASE/5ML</u>	<u>A076913</u>	<u>001</u>	Apr 25, 2005
<u>AA</u>	VINTAGE	<u>EQ 15MG BASE/5ML</u>	<u>A079010</u>	<u>001</u>	May 26, 2009
<u>AA</u>	WE PHARMS	<u>EQ 15MG BASE/5ML</u>	<u>A075250</u>	<u>001</u>	Jul 12, 2002
<u>AA</u>	WOCKHARDT	<u>EQ 5MG BASE/5ML</u>	<u>A075099</u>	<u>001</u>	Jun 28, 2002
<u>AA</u>		<u>EQ 15MG BASE/5ML</u>	<u>A076895</u>	<u>001</u>	Oct 04, 2004

PREDNISOLONE SODIUM PHOSPHATE

	+ MISSION PHARMA	EQ 25MG BASE/5ML	A091396	001	Sep 13, 2010
	+ PHARM ASSOC	EQ 10MG BASE/5ML	A078465	001	Mar 07, 2008
	+	EQ 20MG BASE/5ML	A078988	001	Jun 09, 2008

SOLUTION/DROPS; OPHTHALMIC

	+ BAUSCH AND LOMB	EQ 0.9% PHOSPHATE	A040070	001	Jul 29, 1994

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 348 (of 428)

PREDNISOLONE SODIUM PHOSPHATETABLET, ORALLY DISINTEGRATING; ORAL
ORAPRED ODT

SHIONOGI INC	EQ 10MG BASE	N021959	001	Jun 01, 2006
	EQ 15MG BASE	N021959	002	Jun 01, 2006
+	EQ 30MG BASE	N021959	003	Jun 01, 2006

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

<u>AT</u>	ALCON PHARMS LTD	<u>EQ 0.23% PHOSPHATE;10%</u>	<u>A073630</u>	<u>001</u>	May 27, 1993
<u>AT</u>	BAUSCH AND LOMB	<u>EQ 0.23% PHOSPHATE;10%</u>	<u>A074449</u>	<u>001</u>	Dec 29, 1995
	<u>VASOCIDIN</u>				
<u>AT</u>	+ NOVARTIS	<u>EQ 0.23% PHOSPHATE;10%</u>	<u>N018988</u>	<u>001</u>	Aug 26, 1988

PREDNISONE

SOLUTION; ORAL

PREDNISONE

+	ROXANE	5MG/5ML	A088703	001	Nov 08, 1984
	PREDNISONE INTENSOL				
+	ROXANE	5MG/ML	A088810	001	Feb 20, 1985

TABLET; ORAL

PREDNISONE

<u>AB</u>	CONTRACT PHARMACAL	<u>5MG</u>	<u>A080209</u>	<u>001</u>	
<u>AB</u>	JUBILANT CADISTA	<u>1MG</u>	<u>A040611</u>	<u>001</u>	Jun 06, 2005
<u>AB</u>		<u>5MG</u>	<u>A040362</u>	<u>002</u>	Aug 29, 2001
<u>AB</u>		<u>10MG</u>	<u>A040362</u>	<u>001</u>	Aug 29, 2001
<u>AB</u>		<u>20MG</u>	<u>A040362</u>	<u>003</u>	Jun 29, 2005
<u>AB</u>	MUTUAL PHARM	<u>5MG</u>	<u>A089245</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>		<u>10MG</u>	<u>A089246</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>		<u>20MG</u>	<u>A089247</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>	+ ROXANE	<u>1MG</u>	<u>A087800</u>	<u>001</u>	Apr 22, 1982
<u>AB</u>	+	<u>2.5MG</u>	<u>A087801</u>	<u>001</u>	Apr 22, 1982
<u>AB</u>	+	<u>5MG</u>	<u>A080352</u>	<u>001</u>	
<u>AB</u>	+	<u>10MG</u>	<u>A084122</u>	<u>001</u>	
<u>AB</u>	+	<u>20MG</u>	<u>A087342</u>	<u>001</u>	
<u>AB</u>	+	<u>50MG</u>	<u>A084283</u>	<u>001</u>	
<u>AB</u>	VINTAGE PHARMS	<u>1MG</u>	<u>A040584</u>	<u>001</u>	Dec 21, 2004
<u>AB</u>		<u>2.5MG</u>	<u>A040581</u>	<u>001</u>	Dec 21, 2004
<u>AB</u>		<u>5MG</u>	<u>A040256</u>	<u>001</u>	Jul 12, 2002
<u>AB</u>		<u>10MG</u>	<u>A040256</u>	<u>002</u>	Jul 12, 2002
<u>AB</u>		<u>20MG</u>	<u>A040392</u>	<u>001</u>	Feb 12, 2003
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A080356</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>A085162</u>	<u>001</u>	
<u>AB</u>		<u>20MG</u>	<u>A085161</u>	<u>001</u>	
<u>AB</u>	WEST WARD	<u>2.5MG</u>	<u>A040538</u>	<u>001</u>	Jan 08, 2004
<u>AB</u>		<u>5MG</u>	<u>A080292</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>A088832</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>		<u>20MG</u>	<u>A083677</u>	<u>001</u>	
<u>AB</u>	WEST WARD PHARM CORP	<u>1MG</u>	<u>A040890</u>	<u>001</u>	Nov 01, 2010
<u>AB</u>		<u>50MG</u>	<u>A088465</u>	<u>001</u>	Jun 01, 1984

TABLET, DELAYED RELEASE; ORAL
RAYOS

HORIZON PHARMA	1MG	N202020	001	Jul 26, 2012
	2MG	N202020	002	Jul 26, 2012
+	5MG	N202020	003	Jul 26, 2012

PREGABALIN

CAPSULE; ORAL

LYRICA

<u>AB</u>	PF PRISM	<u>25MG</u>	<u>N021446</u>	<u>001</u>	Dec 30, 2004

PRESCRIPTION DRUG PRODUCT LIST

3 - 349 (of 428)

PREGABALIN

CAPSULE; ORAL

LYRICA

<u>AB</u>	PF PRISM	<u>50MG</u>	<u>N021446</u>	<u>002</u>	Dec 30, 2004
<u>AB</u>		<u>75MG</u>	<u>N021446</u>	<u>003</u>	Dec 30, 2004
<u>AB</u>		<u>100MG</u>	<u>N021446</u>	<u>004</u>	Dec 30, 2004
<u>AB</u>		<u>150MG</u>	<u>N021446</u>	<u>005</u>	Dec 30, 2004
<u>AB</u>		<u>200MG</u>	<u>N021446</u>	<u>006</u>	Dec 30, 2004
<u>AB</u>		<u>225MG</u>	<u>N021446</u>	<u>007</u>	Dec 30, 2004
<u>AB</u>	+	<u>300MG</u>	<u>N021446</u>	<u>008</u>	Dec 30, 2004

PREGABALIN

<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A091040</u>	<u>001</u>	Jul 03, 2012
<u>AB</u>		<u>50MG</u>	<u>A091040</u>	<u>002</u>	Jul 03, 2012
<u>AB</u>		<u>75MG</u>	<u>A091040</u>	<u>003</u>	Jul 03, 2012
<u>AB</u>		<u>100MG</u>	<u>A091040</u>	<u>004</u>	Jul 03, 2012
<u>AB</u>		<u>150MG</u>	<u>A091040</u>	<u>005</u>	Jul 03, 2012
<u>AB</u>		<u>200MG</u>	<u>A091040</u>	<u>006</u>	Jul 03, 2012
<u>AB</u>		<u>225MG</u>	<u>A091040</u>	<u>007</u>	Jul 03, 2012
<u>AB</u>		<u>300MG</u>	<u>A091040</u>	<u>008</u>	Jul 03, 2012
<u>AB</u>	TEVA PHARMS	<u>25MG</u>	<u>A091219</u>	<u>001</u>	Jul 03, 2012
<u>AB</u>		<u>50MG</u>	<u>A091219</u>	<u>002</u>	Jul 03, 2012
<u>AB</u>		<u>75MG</u>	<u>A091224</u>	<u>001</u>	Jul 03, 2012
<u>AB</u>		<u>100MG</u>	<u>A091224</u>	<u>002</u>	Jul 03, 2012
<u>AB</u>		<u>150MG</u>	<u>A091224</u>	<u>003</u>	Jul 03, 2012
<u>AB</u>		<u>200MG</u>	<u>A091224</u>	<u>004</u>	Jul 03, 2012
<u>AB</u>		<u>225MG</u>	<u>A091224</u>	<u>005</u>	Jul 03, 2012
<u>AB</u>		<u>300MG</u>	<u>A091224</u>	<u>006</u>	Jul 03, 2012
<u>AB</u>	WATSON LABS INC	<u>25MG</u>	<u>A091221</u>	<u>001</u>	Jul 03, 2012
<u>AB</u>		<u>50MG</u>	<u>A091221</u>	<u>002</u>	Jul 03, 2012
<u>AB</u>		<u>75MG</u>	<u>A091221</u>	<u>003</u>	Jul 03, 2012
<u>AB</u>		<u>100MG</u>	<u>A091221</u>	<u>004</u>	Jul 03, 2012
<u>AB</u>		<u>150MG</u>	<u>A091221</u>	<u>005</u>	Jul 03, 2012
<u>AB</u>		<u>200MG</u>	<u>A091221</u>	<u>006</u>	Jul 03, 2012
<u>AB</u>		<u>225MG</u>	<u>A091221</u>	<u>007</u>	Jul 03, 2012
<u>AB</u>		<u>300MG</u>	<u>A091221</u>	<u>008</u>	Jul 03, 2012

SOLUTION; ORAL

LYRICA

+	PF PRISM	20MG/ML	N022488	001	Jan 04, 2010

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRILOCAINE HYDROCHLORIDE

+	SEPTODONT INC	4%	A079235	001	Sep 29, 2010

PRIMAQUINE PHOSPHATE

TABLET; ORAL

PRIMAQUINE

+	SANOFI AVENTIS US	EQ 15MG BASE	N008316	001	

PRIMIDONE

TABLET; ORAL

MYSOLINE

<u>AB</u>	+	VALEANT	<u>50MG</u>	<u>N009170</u>	<u>003</u>
<u>AB</u>			<u>250MG</u>	<u>N009170</u>	<u>002</u>

PRIMIDONE

<u>AB</u>	AMNEAL PHARM	<u>50MG</u>	<u>A040866</u>	<u>001</u>	Apr 23, 2008
<u>AB</u>		<u>250MG</u>	<u>A040866</u>	<u>002</u>	Apr 23, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>50MG</u>	<u>A040862</u>	<u>001</u>	Oct 03, 2008
<u>AB</u>		<u>250MG</u>	<u>A040862</u>	<u>002</u>	Oct 03, 2008
<u>AB</u>	IMPAX LABS	<u>50MG</u>	<u>A040717</u>	<u>001</u>	Feb 12, 2008
<u>AB</u>		<u>250MG</u>	<u>A040717</u>	<u>002</u>	Feb 12, 2008

PRESCRIPTION DRUG PRODUCT LIST

3 - 350 (of 428)

PRIMIDONE

TABLET; ORAL

PRIMIDONE

<u>AB</u>	LANNETT	<u>50MG</u>	<u>A084903</u>	<u>002</u>	May 24, 2001
<u>AB</u>		<u>250MG</u>	<u>A084903</u>	<u>001</u>	
<u>AB</u>	MUTUAL PHARM	<u>50MG</u>	<u>A040626</u>	<u>001</u>	Sep 29, 2005
<u>AB</u>		<u>250MG</u>	<u>A040626</u>	<u>002</u>	Sep 29, 2005
<u>AB</u>	VINTAGE PHARMS	<u>50MG</u>	<u>A040586</u>	<u>001</u>	Feb 24, 2005
<u>AB</u>		<u>250MG</u>	<u>A040586</u>	<u>002</u>	Feb 24, 2005
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A083551</u>	<u>001</u>	
<u>AB</u>	WEST WARD	<u>50MG</u>	<u>A040667</u>	<u>001</u>	Jul 27, 2006
<u>AB</u>		<u>250MG</u>	<u>A040667</u>	<u>002</u>	Jul 27, 2006

PROBENECID

TABLET; ORAL

PROBALAN

<u>AB</u>	LANNETT	<u>500MG</u>	<u>A080966</u>	<u>001</u>	
	<u>PROBENECID</u>				
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>500MG</u>	<u>A083740</u>	<u>001</u>	May 09, 1984
<u>AB</u> +	MYLAN	<u>500MG</u>	<u>A084211</u>	<u>002</u>	
<u>AB</u>	WATSON LABS	<u>500MG</u>	<u>A084442</u>	<u>004</u>	Mar 29, 1983

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

<u>AP</u> +	HOSPIRA	<u>100MG/ML</u>	<u>A089069</u>	<u>001</u>	Feb 12, 1986
<u>AP</u> +		<u>500MG/ML</u>	<u>A089070</u>	<u>001</u>	Feb 12, 1986
<u>AP</u>	INTL MEDICATION	<u>100MG/ML</u>	<u>A088636</u>	<u>001</u>	Jul 31, 1984
<u>AP</u>		<u>500MG/ML</u>	<u>A088637</u>	<u>001</u>	Jul 31, 1984

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL

MATULANE

+ SIGMA TAU	EQ 50MG BASE	N016785	001	

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPRO

<u>AB</u>	PADDOCK LLC	<u>25MG</u>	<u>A040246</u>	<u>001</u>	Jun 28, 2000
	<u>PROCHLORPERAZINE</u>				
<u>AB</u> +	G AND W LABS	<u>25MG</u>	<u>A040058</u>	<u>001</u>	Nov 24, 1993

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

<u>AP</u>	BEDFORD	<u>EQ 5MG BASE/ML</u>	<u>A040540</u>	<u>001</u>	May 28, 2004
<u>AP</u> +	HIKMA MAPLE	<u>EQ 5MG BASE/ML</u>	<u>A089903</u>	<u>001</u>	Aug 29, 1989

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A040185</u>	<u>002</u>	Oct 28, 1996
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A040185</u>	<u>001</u>	Oct 28, 1996
<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A040101</u>	<u>001</u>	Jul 19, 1996
<u>AB</u> +		<u>EQ 10MG BASE</u>	<u>A040101</u>	<u>002</u>	Jul 19, 1996
<u>AB</u>	TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A040120</u>	<u>001</u>	Jul 11, 1996
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A040120</u>	<u>002</u>	Jul 11, 1996
	<u>PROCOMP</u>				
<u>AB</u>	JUBILANT CADISTA	<u>EQ 5MG BASE</u>	<u>A040268</u>	<u>001</u>	Feb 27, 1998
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A040268</u>	<u>002</u>	Feb 27, 1998

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 351 (of 428)

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

<u>AB</u>	SOFGEN PHARMS	<u>100MG</u>	<u>A200456</u>	<u>001</u>	Sep 28, 2012
<u>AB</u>		<u>200MG</u>	<u>A200456</u>	<u>002</u>	Sep 28, 2012
<u>AB</u>	TEVA PHARMS	<u>100MG</u>	<u>A202121</u>	<u>001</u>	Feb 29, 2012
<u>AB</u>		<u>200MG</u>	<u>A202121</u>	<u>002</u>	Feb 29, 2012

PROMETRIUM

<u>AB</u>	ABBOTT LABS	<u>100MG</u>	<u>N019781</u>	<u>001</u>	May 14, 1998
<u>AB</u>	+	<u>200MG</u>	<u>N019781</u>	<u>002</u>	Oct 15, 1999

GEL; VAGINAL

CRINONE

	WATSON LABS	4%	N020701	001	Jul 31, 1997
+		8%	N020701	002	Jul 31, 1997

INJECTABLE; INJECTION

PROGESTERONE

<u>AO</u>	FRESENIUS KABI USA	<u>50MG/ML</u>	<u>A075906</u>	<u>001</u>	Apr 25, 2001
<u>AO</u>	HIKMA FARMACEUTICA	<u>50MG/ML</u>	<u>A091033</u>	<u>001</u>	Oct 28, 2010
<u>AO</u>	LUITPOLD	<u>50MG/ML</u>	<u>A090845</u>	<u>001</u>	Jun 22, 2009
<u>AO</u>	+	<u>50MG/ML</u>	<u>N017362</u>	<u>002</u>	

INSERT; VAGINAL

ENDOMETRIN

+	FERRING	100MG	N022057	001	Jun 21, 2007

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

<u>AP</u>	HIKMA MAPLE	<u>25MG/ML</u>	<u>A083312</u>	<u>001</u>	
<u>AP</u>		<u>50MG/ML</u>	<u>A083312</u>	<u>002</u>	
<u>AP</u>	HOSPIRA	<u>25MG/ML</u>	<u>A040372</u>	<u>001</u>	Jun 08, 2000
<u>AP</u>	LUITPOLD	<u>25MG/ML</u>	<u>A040515</u>	<u>001</u>	Mar 19, 2003
<u>AP</u>	+	<u>25MG/ML</u>	<u>A040454</u>	<u>001</u>	Aug 22, 2002
<u>AP</u>	+	<u>50MG/ML</u>	<u>A040454</u>	<u>002</u>	Aug 22, 2002
<u>AP</u>	WOCKHARDT	<u>25MG/ML</u>	<u>A040785</u>	<u>001</u>	Sep 26, 2008
<u>AP</u>		<u>50MG/ML</u>	<u>A040785</u>	<u>002</u>	Sep 26, 2008
<u>AP</u>	X-GEN PHARMS	<u>25MG/ML</u>	<u>A040737</u>	<u>001</u>	Apr 24, 2008
<u>AP</u>		<u>50MG/ML</u>	<u>A040737</u>	<u>002</u>	Apr 24, 2008

SUPPOSITORY; RECTAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>	G AND W LABS	<u>12.5MG</u>	<u>A040428</u>	<u>002</u>	Mar 31, 2003
<u>AB</u>	+	<u>25MG</u>	<u>A040428</u>	<u>001</u>	Feb 05, 2002
<u>AB</u>	PERRIGO NEW YORK	<u>12.5MG</u>	<u>A040500</u>	<u>001</u>	Jun 30, 2003
<u>AB</u>		<u>25MG</u>	<u>A040500</u>	<u>002</u>	Jun 30, 2003
<u>AB</u>	TARO	<u>12.5MG</u>	<u>A040603</u>	<u>001</u>	Oct 26, 2006
<u>AB</u>		<u>25MG</u>	<u>A040603</u>	<u>002</u>	Oct 26, 2006
<u>AB</u>	WATSON LABS INC	<u>12.5MG</u>	<u>A040479</u>	<u>001</u>	Jun 24, 2003
<u>AB</u>		<u>25MG</u>	<u>A040479</u>	<u>002</u>	Jun 24, 2003

PROMETHEGAN

+	G AND W LABS	50MG	A087165	001	Aug 14, 1987

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>6.25MG/5ML</u>	<u>A040882</u>	<u>001</u>	Dec 30, 2009
<u>AA</u>	HI TECH PHARMA	<u>6.25MG/5ML</u>	<u>A040026</u>	<u>001</u>	Sep 25, 1998
<u>AA</u>	SUN PHARM INDS INC	<u>6.25MG/5ML</u>	<u>A040891</u>	<u>001</u>	Mar 13, 2009
<u>AA</u>	TARO	<u>6.25MG/5ML</u>	<u>A040718</u>	<u>001</u>	Apr 04, 2007
<u>AA</u>	TRIS PHARMA INC	<u>6.25MG/5ML</u>	<u>A091675</u>	<u>001</u>	Jun 28, 2012
<u>AA</u>	VINTAGE	<u>6.25MG/5ML</u>	<u>A040643</u>	<u>001</u>	Apr 26, 2006

PROMETHAZINE PLAIN

<u>AA</u>	+	<u>6.25MG/5ML</u>	<u>A087953</u>	<u>001</u>	Nov 15, 1982

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 352 (of 428)

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS NY	<u>12.5MG</u>	<u>A091179</u>	<u>001</u>	Dec 13, 2010
<u>AB</u>		<u>25MG</u>	<u>A091179</u>	<u>002</u>	Dec 13, 2010
<u>AB</u>		<u>50MG</u>	<u>A091179</u>	<u>003</u>	Dec 13, 2010
<u>AB</u>	EMCURE PHARMS USA	<u>12.5MG</u>	<u>A040673</u>	<u>001</u>	Mar 05, 2008
<u>AB</u>		<u>25MG</u>	<u>A040673</u>	<u>002</u>	Mar 05, 2008
<u>AB</u>		<u>50MG</u>	<u>A040673</u>	<u>003</u>	Mar 05, 2008
<u>AB</u>	IMPAX LABS	<u>12.5MG</u>	<u>A040724</u>	<u>001</u>	Feb 12, 2008
<u>AB</u>		<u>25MG</u>	<u>A040724</u>	<u>002</u>	Feb 12, 2008
<u>AB</u>		<u>50MG</u>	<u>A040791</u>	<u>001</u>	May 20, 2008
<u>AB</u>	KVK TECH	<u>12.5MG</u>	<u>A040712</u>	<u>002</u>	May 04, 2007
<u>AB</u>		<u>25MG</u>	<u>A040712</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>		<u>50MG</u>	<u>A040713</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A091054</u>	<u>001</u>	Aug 30, 2011
<u>AB</u>		<u>25MG</u>	<u>A091054</u>	<u>002</u>	Aug 30, 2011
<u>AB</u>		<u>50MG</u>	<u>A091054</u>	<u>003</u>	Aug 30, 2011
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A084234</u>	<u>001</u>	
<u>AB</u>	+	<u>50MG</u>	<u>A084176</u>	<u>001</u>	
<u>AB</u>	SUN PHARM INDS INC	<u>12.5MG</u>	<u>A040863</u>	<u>001</u>	Dec 30, 2008
<u>AB</u>		<u>25MG</u>	<u>A040863</u>	<u>002</u>	Dec 30, 2008
<u>AB</u>		<u>50MG</u>	<u>A040863</u>	<u>003</u>	Dec 30, 2008
<u>AB</u>	VINTAGE PHARMS	<u>12.5MG</u>	<u>A040622</u>	<u>001</u>	Jul 18, 2006
<u>AB</u>		<u>25MG</u>	<u>A040622</u>	<u>002</u>	Jul 18, 2006
<u>AB</u>		<u>50MG</u>	<u>A040622</u>	<u>003</u>	Jul 18, 2006
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A083426</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A083711</u>	<u>001</u>	
<u>AB</u>	ZYDUS PHARMS USA	<u>12.5MG</u>	<u>A040596</u>	<u>001</u>	Nov 18, 2005
<u>AB</u>		<u>25MG</u>	<u>A040596</u>	<u>002</u>	Nov 18, 2005
<u>AB</u>		<u>50MG</u>	<u>A040596</u>	<u>003</u>	Nov 18, 2005

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPAFENONE HYDROCHLORIDE

<u>AB</u>	PAR PHARM	<u>225MG</u>	<u>A078540</u>	<u>001</u>	Oct 18, 2010
<u>AB</u>		<u>325MG</u>	<u>A078540</u>	<u>002</u>	Oct 18, 2010
<u>AB</u>		<u>425MG</u>	<u>A078540</u>	<u>003</u>	Oct 18, 2010
	<u>RYTHMOL SR</u>				
<u>AB</u>	GLAXOSMITHKLINE LLC	<u>225MG</u>	<u>N021416</u>	<u>001</u>	Sep 04, 2003
<u>AB</u>		<u>325MG</u>	<u>N021416</u>	<u>002</u>	Sep 04, 2003
<u>AB</u>	+	<u>425MG</u>	<u>N021416</u>	<u>003</u>	Sep 04, 2003

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

<u>AB</u>	MUTUAL PHARM	<u>150MG</u>	<u>A075998</u>	<u>001</u>	Nov 29, 2001
<u>AB</u>		<u>225MG</u>	<u>A075998</u>	<u>002</u>	Nov 29, 2001
<u>AB</u>		<u>300MG</u>	<u>A075998</u>	<u>003</u>	Nov 29, 2001
<u>AB</u>	PLIVA	<u>150MG</u>	<u>A076550</u>	<u>001</u>	Apr 23, 2004
<u>AB</u>		<u>225MG</u>	<u>A076550</u>	<u>002</u>	Apr 23, 2004
<u>AB</u>		<u>300MG</u>	<u>A076550</u>	<u>003</u>	Apr 23, 2004
<u>AB</u>	VINTAGE PHARMS	<u>150MG</u>	<u>A075938</u>	<u>001</u>	Oct 17, 2002
<u>AB</u>		<u>225MG</u>	<u>A075938</u>	<u>002</u>	Oct 17, 2002
<u>AB</u>		<u>300MG</u>	<u>A075938</u>	<u>003</u>	Oct 17, 2002
<u>AB</u>	WATSON LABS	<u>150MG</u>	<u>A075203</u>	<u>001</u>	Oct 24, 2000
<u>AB</u>		<u>225MG</u>	<u>A075203</u>	<u>002</u>	Oct 24, 2000
	<u>RYTHMOL</u>				
<u>AB</u>	GLAXOSMITHKLINE LLC	<u>150MG</u>	<u>N019151</u>	<u>001</u>	Nov 27, 1989
<u>AB</u>		<u>225MG</u>	<u>N019151</u>	<u>003</u>	Nov 20, 1992
<u>AB</u>	+	<u>300MG</u>	<u>N019151</u>	<u>002</u>	Nov 27, 1989

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 353 (of 428)

PROPANTHELINE BROMIDE

TABLET; ORAL
 PROPANTHELINE BROMIDE
 + ROXANE 15MG

A080927 002

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALCAINE

AT ALCON 0.5%

A080027 001

OPHTHAINE

AT + APOTHECON 0.5%

N008883 001

OPHTHETIC

AT + ALLERGAN 0.5%

N012583 001

PROPARACAINE HYDROCHLORIDE

AT BAUSCH AND LOMB 0.5%

A040074 001 Sep 29, 1995

AT TAYLOR PHARMA 0.5%

A040277 001 Mar 16, 2000

PROPOFOL

INJECTABLE; INJECTION

DIPRIVAN

AB + FRESENIUS KABI USA 10MG/ML

N019627 002 Jun 11, 1996

PROPOFOL

AB HOSPIRA 10MG/ML

A077908 001 Mar 17, 2006

AB TEVA PARENTERAL 10MG/ML

A075102 001 Jan 04, 1999

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERAL LA

AB AKRIMAX PHARMS 60MG

N018553 004 Mar 18, 1987

AB 80MG

N018553 002 Apr 19, 1983

AB 120MG

N018553 003 Apr 19, 1983

AB + 160MG

N018553 001 Apr 19, 1983

PROPRANOLOL HYDROCHLORIDE

AB ACTAVIS ELIZABETH 60MG

A078494 001 Aug 10, 2007

AB 80MG

A078494 002 Aug 10, 2007

AB 120MG

A078494 003 Aug 10, 2007

AB 160MG

A078494 004 Aug 10, 2007

AB APTALIS PHARMATECH 60MG

A078703 001 Jul 15, 2011

AB 80MG

A078703 002 Jul 15, 2011

AB 120MG

A078703 003 Jul 15, 2011

AB 160MG

A078703 004 Jul 15, 2011

AB MYLAN 60MG

A078022 001 Feb 15, 2007

AB 80MG

A078022 002 Feb 15, 2007

AB 120MG

A078022 003 Feb 15, 2007

AB 160MG

A078022 004 Feb 15, 2007

AB PAR PHARM 60MG

A078065 001 Jan 26, 2007

AB 80MG

A078065 002 Jan 26, 2007

AB 120MG

A078065 003 Jan 26, 2007

AB 160MG

A078065 004 Jan 26, 2007

AB UPSHER SMITH 60MG

A078311 001 Mar 06, 2009

AB 80MG

A078311 002 Mar 06, 2009

AB 120MG

A078311 003 Mar 06, 2009

AB 160MG

A078311 004 Mar 06, 2009

AB ZYDUS PHARMS USA INC 60MG

A090321 001 Mar 25, 2011

AB 80MG

A090321 002 Mar 25, 2011

AB 120MG

A090321 003 Mar 25, 2011

AB 160MG

A090321 004 Mar 25, 2011

INNOPRAN XL

BX GLAXOSMITHKLINE LLC 80MG

N021438 001 Mar 12, 2003

BX 120MG

N021438 002 Mar 12, 2003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 354 (of 428)

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

<u>AP</u>	+	BAXTER HLTHCARE CORP	<u>1MG/ML</u>	<u>N016419</u>	<u>001</u>	
<u>AP</u>		BEDFORD	<u>1MG/ML</u>	<u>A075792</u>	<u>001</u>	Aug 29, 2000
<u>AP</u>		FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A075826</u>	<u>001</u>	Aug 31, 2001
<u>AP</u>		HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A077760</u>	<u>001</u>	Jan 31, 2008
<u>AP</u>		SANDOZ	<u>1MG/ML</u>	<u>A076400</u>	<u>001</u>	Feb 26, 2003

SOLUTION; ORAL

PROPRANOLOL HYDROCHLORIDE

+	ROXANE	20MG/5ML	A070979	001	May 15, 1987
+		40MG/5ML	A070690	001	May 15, 1987

TABLET; ORAL

INDERAL

<u>AB</u>		AKRIMAX PHARMS	<u>40MG</u>	<u>N016418</u>	<u>002</u>	
<u>AB</u>			<u>60MG</u>	<u>N016418</u>	<u>009</u>	Oct 18, 1982
<u>AB</u>	+		<u>80MG</u>	<u>N016418</u>	<u>004</u>	

PROPRANOLOL HYDROCHLORIDE

<u>AB</u>		IPCA LABS LTD	<u>10MG</u>	<u>A078955</u>	<u>001</u>	Jun 02, 2008
<u>AB</u>			<u>20MG</u>	<u>A078955</u>	<u>002</u>	Jun 02, 2008
<u>AB</u>			<u>40MG</u>	<u>A078955</u>	<u>003</u>	Jun 02, 2008
<u>AB</u>			<u>60MG</u>	<u>A078955</u>	<u>004</u>	Jun 02, 2008
<u>AB</u>			<u>80MG</u>	<u>A078955</u>	<u>005</u>	Jun 02, 2008
<u>AB</u>		MYLAN	<u>10MG</u>	<u>A070213</u>	<u>002</u>	Nov 19, 1985
<u>AB</u>			<u>20MG</u>	<u>A070213</u>	<u>003</u>	Nov 19, 1985
<u>AB</u>			<u>40MG</u>	<u>A070213</u>	<u>001</u>	Nov 19, 1985
<u>AB</u>			<u>60MG</u>	<u>A070213</u>	<u>005</u>	Apr 08, 2011
<u>AB</u>			<u>80MG</u>	<u>A070213</u>	<u>004</u>	Nov 19, 1985
<u>AB</u>		NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A078213</u>	<u>001</u>	Jan 10, 2008
<u>AB</u>			<u>20MG</u>	<u>A078213</u>	<u>002</u>	Jan 10, 2008
<u>AB</u>			<u>40MG</u>	<u>A078213</u>	<u>003</u>	Jan 10, 2008
<u>AB</u>			<u>60MG</u>	<u>A078213</u>	<u>004</u>	Jan 10, 2008
<u>AB</u>			<u>80MG</u>	<u>A078213</u>	<u>005</u>	Jan 10, 2008
<u>AB</u>		PLIVA	<u>10MG</u>	<u>A071972</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>			<u>20MG</u>	<u>A071973</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>			<u>40MG</u>	<u>A071974</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>			<u>60MG</u>	<u>A071975</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>	+		<u>80MG</u>	<u>A071976</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>		VINTAGE PHARMS	<u>10MG</u>	<u>A070217</u>	<u>001</u>	Aug 01, 1986
<u>AB</u>			<u>20MG</u>	<u>A070218</u>	<u>001</u>	Aug 01, 1986
<u>AB</u>			<u>40MG</u>	<u>A070219</u>	<u>001</u>	Aug 01, 1986
<u>AB</u>			<u>60MG</u>	<u>A070220</u>	<u>001</u>	Sep 24, 1986
<u>AB</u>			<u>80MG</u>	<u>A070221</u>	<u>001</u>	Apr 14, 1986
<u>AB</u>		WATSON LABS	<u>10MG</u>	<u>A070175</u>	<u>001</u>	May 13, 1986
<u>AB</u>			<u>20MG</u>	<u>A070176</u>	<u>001</u>	May 13, 1986
<u>AB</u>			<u>40MG</u>	<u>A070177</u>	<u>001</u>	May 13, 1986
<u>AB</u>			<u>80MG</u>	<u>A070178</u>	<u>001</u>	May 13, 1986

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

BD		ACTAVIS ELIZABETH	50MG	A080172	001	
BD	+	DAVA PHARMS INC	50MG	N006188	001	
BD		WEST WARD	50MG	A080154	001	

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

+	FRESENIUS KABI USA	10MG/ML	A089454	001	Apr 07, 1987

PRESCRIPTION DRUG PRODUCT LIST

3 - 355 (of 428)

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

PROTRIPTYLINE HYDROCHLORIDE

<u>AB</u>	EPIC PHARMA LLC	<u>5MG</u>	<u>A202220</u>	<u>001</u>	Nov 19, 2012
<u>AB</u>		<u>10MG</u>	<u>A202220</u>	<u>002</u>	Nov 19, 2012
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A078913</u>	<u>001</u>	Sep 16, 2008
<u>AB</u>		<u>10MG</u>	<u>A078913</u>	<u>002</u>	Sep 16, 2008
<u>AB</u>	SIGMAPHARM LABS LLC	<u>5MG</u>	<u>A090462</u>	<u>001</u>	May 03, 2010
<u>AB</u>		<u>10MG</u>	<u>A090462</u>	<u>002</u>	May 03, 2010
<u>VIVACTIL</u>					
<u>AB</u>	ODYSSEY PHARMS	<u>5MG</u>	<u>A073644</u>	<u>001</u>	Aug 24, 1995
<u>AB</u>	+	<u>10MG</u>	<u>A073645</u>	<u>001</u>	Aug 24, 1995

PYRAZINAMIDE

TABLET; ORAL

PYRAZINAMIDE

<u>AB</u>	+	DAVA PHARMS INC	<u>500MG</u>	<u>A080157</u>	<u>001</u>	
<u>AB</u>		MIKART	<u>500MG</u>	<u>A081319</u>	<u>001</u>	Jun 30, 1992

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

MESTINON

<u>AP</u>	+	VALEANT PHARM INTL	<u>5MG/ML</u>	<u>N009830</u>	<u>001</u>	

REGONOL

<u>AP</u>		SANDOZ	<u>5MG/ML</u>	<u>N017398</u>	<u>001</u>	

SYRUP; ORAL

MESTINON

	+	VALEANT PHARM INTL	60MG/5ML	N015193	001	

TABLET; ORAL

MESTINON

<u>AB</u>	+	VALEANT PHARMS LLC	<u>60MG</u>	<u>N009829</u>	<u>002</u>	

PYRIDOSTIGMINE BROMIDE

<u>AB</u>		COREPHARMA	<u>60MG</u>	<u>A040457</u>	<u>001</u>	Dec 26, 2002
<u>AB</u>		IMPAX LABS	<u>60MG</u>	<u>A040502</u>	<u>001</u>	Apr 24, 2003

TABLET, EXTENDED RELEASE; ORAL

MESTINON

	+	VALEANT PHARMS LLC	180MG	N011665	001	

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

PYRIDOXINE HYDROCHLORIDE

	+	FRESENIUS KABI USA	100MG/ML	A080618	001	

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

	+	COREPHARMA	25MG	N008578	001	

QUAZEPAM

TABLET; ORAL

DORAL

	+	QUESTCOR PHARMS	15MG	N018708	001	Dec 27, 1985

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

<u>AB</u>	ACCORD HLTHCARE INC	<u>EQ 25MG BASE</u>	<u>A202152</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A202152</u>	<u>002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A202152</u>	<u>003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A202152</u>	<u>004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202152</u>	<u>005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A202152</u>	<u>006</u>	Mar 27, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 356 (of 428)

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

<u>AB</u>	APOTEX INC	<u>EQ 25MG BASE</u>	<u>A090960</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090960</u>	<u>002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090960</u>	<u>003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090960</u>	<u>004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090960</u>	<u>005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090960</u>	<u>006</u>	Mar 27, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 25MG BASE</u>	<u>A091388</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A091388</u>	<u>002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A091388</u>	<u>003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091388</u>	<u>004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A091388</u>	<u>005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A091388</u>	<u>006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A091388</u>	<u>007</u>	Mar 27, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A077380</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077380</u>	<u>002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077380</u>	<u>003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A077380</u>	<u>004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A077380</u>	<u>005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077380</u>	<u>006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A077380</u>	<u>007</u>	Mar 27, 2012
<u>AB</u>	LUPIN LTD	<u>EQ 25MG BASE</u>	<u>A201109</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201109</u>	<u>002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201109</u>	<u>003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201109</u>	<u>004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201109</u>	<u>005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201109</u>	<u>006</u>	Mar 27, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 25MG BASE</u>	<u>A090323</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>	ROXANE	<u>EQ 25MG BASE</u>	<u>A090120</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090749</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090749</u>	<u>002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090749</u>	<u>003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090749</u>	<u>004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090749</u>	<u>005</u>	Mar 27, 2012
<u>AB</u>	SANDOZ	<u>EQ 25MG BASE</u>	<u>A078679</u>	<u>001</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078679</u>	<u>002</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078679</u>	<u>003</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078679</u>	<u>004</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A078679</u>	<u>005</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078679</u>	<u>006</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A078679</u>	<u>007</u>	Dec 14, 2012
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 25MG BASE</u>	<u>A201190</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201190</u>	<u>002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201190</u>	<u>003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201190</u>	<u>004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201190</u>	<u>005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201190</u>	<u>006</u>	Mar 27, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 25MG BASE</u>	<u>A077745</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077745</u>	<u>002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077745</u>	<u>003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A077745</u>	<u>004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A077745</u>	<u>005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077745</u>	<u>006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A077745</u>	<u>007</u>	Mar 27, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A200363</u>	<u>001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A200363</u>	<u>002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A200363</u>	<u>003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A200363</u>	<u>004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A200363</u>	<u>005</u>	Mar 27, 2012

PRESCRIPTION DRUG PRODUCT LIST

3 - 357 (of 428)

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 400MG BASE</u>	<u>A200363</u>	<u>006</u>	Mar 27, 2012
	<u>SEROQUEL</u>				
<u>AB</u>	+ ASTRAZENECA	<u>EQ 25MG BASE</u>	<u>N020639</u>	<u>001</u>	Sep 26, 1997
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N020639</u>	<u>007</u>	Oct 04, 2005
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>N020639</u>	<u>002</u>	Sep 26, 1997
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>N020639</u>	<u>003</u>	Sep 26, 1997
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N020639</u>	<u>005</u>	Jul 26, 2000
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>N020639</u>	<u>006</u>	Oct 04, 2005
	TABLET, EXTENDED RELEASE; ORAL				
	SEROQUEL XR				
	ASTRAZENECA	EQ 50MG BASE	N022047	001	May 17, 2007
		EQ 150MG BASE	N022047	005	Aug 11, 2008
	+	EQ 200MG BASE	N022047	002	May 17, 2007
		EQ 300MG BASE	N022047	003	May 17, 2007
		EQ 400MG BASE	N022047	004	May 17, 2007

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCUPRIL

<u>AB</u>	PFIZER PHARMS	<u>EQ 5MG BASE</u>	<u>N019885</u>	<u>001</u>	Nov 19, 1991
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>N019885</u>	<u>002</u>	Nov 19, 1991
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>N019885</u>	<u>003</u>	Nov 19, 1991
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N019885</u>	<u>004</u>	Nov 19, 1991
	<u>QUINAPRIL HYDROCHLORIDE</u>				
<u>AB</u>	APOTEX	<u>EQ 5MG BASE</u>	<u>A076240</u>	<u>001</u>	Jan 26, 2006
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076240</u>	<u>002</u>	Jan 26, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076240</u>	<u>003</u>	Jan 26, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076240</u>	<u>004</u>	Jan 26, 2006
<u>AB</u>	INVAGEN PHARMS	<u>EQ 5MG BASE</u>	<u>A078457</u>	<u>001</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078457</u>	<u>002</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078457</u>	<u>003</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078457</u>	<u>004</u>	Aug 24, 2007
<u>AB</u>	LUPIN	<u>EQ 5MG BASE</u>	<u>A077690</u>	<u>001</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077690</u>	<u>002</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077690</u>	<u>003</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077690</u>	<u>004</u>	Jun 20, 2006
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076036</u>	<u>001</u>	Jan 28, 2005
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076694</u>	<u>001</u>	Dec 23, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076036</u>	<u>002</u>	Jan 28, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076694</u>	<u>002</u>	Dec 23, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076036</u>	<u>003</u>	Jan 28, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076694</u>	<u>003</u>	Dec 23, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076036</u>	<u>004</u>	Jan 28, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076694</u>	<u>004</u>	Dec 23, 2004
<u>AB</u>	RANBAXY	<u>EQ 5MG BASE</u>	<u>A076607</u>	<u>001</u>	Dec 15, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076607</u>	<u>002</u>	Dec 15, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076607</u>	<u>003</u>	Dec 15, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076607</u>	<u>004</u>	Dec 15, 2004
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 5MG BASE</u>	<u>A090800</u>	<u>001</u>	Jun 18, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090800</u>	<u>002</u>	Jun 18, 2009
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090800</u>	<u>003</u>	Jun 18, 2009
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090800</u>	<u>004</u>	Jun 18, 2009
<u>AB</u>	TEVA	<u>EQ 5MG BASE</u>	<u>A075504</u>	<u>001</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075504</u>	<u>002</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075504</u>	<u>003</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075504</u>	<u>004</u>	Aug 24, 2007
<u>AB</u>	WATSON LABS FLORIDA	<u>EQ 5MG BASE</u>	<u>A076049</u>	<u>001</u>	Jan 14, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076049</u>	<u>002</u>	Jan 14, 2005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 358 (of 428)

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

<u>AB</u>	WATSON LABS FLORIDA	<u>EQ 20MG BASE</u>	<u>A076049</u>	<u>003</u>	Jan 14, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076049</u>	<u>004</u>	Jan 14, 2005

QUINIDINE GLUCONATE

INJECTABLE; INJECTION

QUINIDINE GLUCONATE

+	LILLY	80MG/ML	N007529	002	Feb 10, 1989

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

BX	+	MUTUAL PHARM	324MG	A089338	001	Feb 11, 1987
BX		WATSON LABS	324MG	A087810	001	Sep 29, 1982

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

<u>AB</u>	MUTUAL PHARM	<u>200MG</u>	<u>A081030</u>	<u>001</u>	Apr 14, 1989
<u>AB</u>		<u>300MG</u>	<u>A081031</u>	<u>001</u>	Apr 14, 1989
<u>AB</u>	SANDOZ	<u>200MG</u>	<u>A088072</u>	<u>002</u>	
<u>AB</u>		<u>300MG</u>	<u>A088072</u>	<u>001</u>	Sep 26, 1983
<u>AB</u>	+	WATSON LABS	<u>200MG</u>	<u>A083288</u>	<u>001</u>
<u>AB</u>	+		<u>300MG</u>	<u>A085583</u>	<u>001</u>

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE SULFATE

+	TEVA PHARMS	300MG	A040045	001	Jun 30, 1994

QUININE SULFATE

CAPSULE; ORAL

QUALAQUIN

<u>AB</u>	+	MUTUAL PHARM CO INC	<u>324MG</u>	<u>N021799</u>	<u>001</u>	Aug 12, 2005

QUININE SULFATE

<u>AB</u>	MYLAN PHARMS INC	<u>324MG</u>	<u>A202581</u>	<u>001</u>	Dec 14, 2012
<u>AB</u>	TEVA PHARMS	<u>324MG</u>	<u>A091661</u>	<u>001</u>	Sep 28, 2012

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

ACIPHEX

+	EISAI INC	20MG	N020973	002	Aug 19, 1999

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL

EVISTA

+	LILLY	60MG	N020815	001	Dec 09, 1997

RALTEGRAVIR POTASSIUM

TABLET; ORAL

ISENTRESS

+	MERCK SHARP DOHME	EQ 400MG BASE	N022145	001	Oct 12, 2007

TABLET, CHEWABLE; ORAL

ISENTRESS

	MERCK SHARP DOHME	EQ 25MG BASE	N203045	001	Dec 21, 2011
+		EQ 100MG BASE	N203045	002	Dec 21, 2011

RAMELTEON

TABLET; ORAL

ROZEREM

+	TAKEDA PHARMS USA	8MG	N021782	001	Jul 22, 2005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 359 (of 428)

RAMIPRIL

CAPSULE; ORAL

ALTACE

<u>AB</u>	KING PHARMS	<u>1.25MG</u>	<u>N019901</u>	<u>001</u>	Jan 28, 1991
<u>AB</u>		<u>2.5MG</u>	<u>N019901</u>	<u>002</u>	Jan 28, 1991
<u>AB</u>		<u>5MG</u>	<u>N019901</u>	<u>003</u>	Jan 28, 1991
<u>AB</u>	+	<u>10MG</u>	<u>N019901</u>	<u>004</u>	Jan 28, 1991

RAMIPRIL

<u>AB</u>	APOTEX	<u>1.25MG</u>	<u>A079116</u>	<u>001</u>	Jun 20, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A079116</u>	<u>002</u>	Jun 20, 2008
<u>AB</u>		<u>5MG</u>	<u>A079116</u>	<u>003</u>	Jun 20, 2008
<u>AB</u>		<u>10MG</u>	<u>A079116</u>	<u>004</u>	Jun 20, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>1.25MG</u>	<u>A091604</u>	<u>001</u>	Jun 08, 2011
<u>AB</u>		<u>2.5MG</u>	<u>A091604</u>	<u>002</u>	Jun 08, 2011
<u>AB</u>		<u>5MG</u>	<u>A091604</u>	<u>003</u>	Jun 08, 2011
<u>AB</u>		<u>10MG</u>	<u>A091604</u>	<u>004</u>	Jun 08, 2011
<u>AB</u>	CIPLA	<u>1.25MG</u>	<u>A077004</u>	<u>001</u>	Aug 07, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A077004</u>	<u>002</u>	Aug 07, 2008
<u>AB</u>		<u>5MG</u>	<u>A077004</u>	<u>003</u>	Aug 07, 2008
<u>AB</u>		<u>10MG</u>	<u>A077004</u>	<u>004</u>	Aug 07, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>1.25MG</u>	<u>A078191</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A078191</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>		<u>5MG</u>	<u>A078191</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A078191</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	INVAGEN PHARMS	<u>1.25MG</u>	<u>A078745</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A078745</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>		<u>5MG</u>	<u>A078745</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A078745</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	LUPIN	<u>1.25MG</u>	<u>A077626</u>	<u>001</u>	Jun 09, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A077626</u>	<u>002</u>	Jun 09, 2008
<u>AB</u>		<u>5MG</u>	<u>A077626</u>	<u>003</u>	Jun 09, 2008
<u>AB</u>		<u>10MG</u>	<u>A077626</u>	<u>004</u>	Jun 09, 2008
<u>AB</u>	ROXANE	<u>1.25MG</u>	<u>A077900</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A077900</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>		<u>5MG</u>	<u>A077900</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A077900</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	SANDOZ	<u>1.25MG</u>	<u>A077514</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A077514</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>		<u>5MG</u>	<u>A077514</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A077514</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	TEVA PHARMS	<u>1.25MG</u>	<u>A077470</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A077470</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>		<u>5MG</u>	<u>A077470</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A077470</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	WATSON LABS	<u>1.25MG</u>	<u>A076549</u>	<u>001</u>	Oct 24, 2005
<u>AB</u>		<u>2.5MG</u>	<u>A076549</u>	<u>002</u>	Oct 24, 2005
<u>AB</u>		<u>5MG</u>	<u>A076549</u>	<u>003</u>	Oct 24, 2005
<u>AB</u>		<u>10MG</u>	<u>A076549</u>	<u>004</u>	Oct 24, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>1.25MG</u>	<u>A078832</u>	<u>001</u>	Sep 02, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A078832</u>	<u>002</u>	Sep 02, 2008
<u>AB</u>		<u>5MG</u>	<u>A078832</u>	<u>003</u>	Sep 02, 2008
<u>AB</u>		<u>10MG</u>	<u>A078832</u>	<u>004</u>	Sep 02, 2008

TABLET; ORAL

RAMIPRIL

<u>AB</u>	MYLAN PHARMS INC	<u>1.25MG</u>	<u>A090650</u>	<u>001</u>	Jun 30, 2011
<u>AB</u>		<u>2.5MG</u>	<u>A090650</u>	<u>002</u>	Jun 30, 2011
<u>AB</u>		<u>5MG</u>	<u>A090650</u>	<u>003</u>	Jun 30, 2011
<u>AB</u>		<u>10MG</u>	<u>A090650</u>	<u>004</u>	Jun 30, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>1.25MG</u>	<u>A090697</u>	<u>001</u>	Sep 24, 2009
<u>AB</u>		<u>2.5MG</u>	<u>A090697</u>	<u>002</u>	Sep 24, 2009
<u>AB</u>		<u>5MG</u>	<u>A090697</u>	<u>003</u>	Sep 24, 2009

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 360 (of 428)

RAMIPRIL

TABLET; ORAL

RAMIPRIL

<u>AB</u>	ZYDUS PHARMS USA INC	<u>10MG</u>	<u>A090697</u>	<u>004</u>	Sep 24, 2009

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 150MG BASE</u>	<u>A075742</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075742</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074655</u>	<u>001</u>	Oct 22, 1997
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>A074655</u>	<u>002</u>	Oct 22, 1997

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>EQ 25MG BASE/ML</u>	<u>A077458</u>	<u>001</u>	Feb 16, 2006
<u>AP</u>	BEN VENUE	<u>EQ 25MG BASE/ML</u>	<u>A074777</u>	<u>001</u>	Mar 02, 2005
<u>ZANTAC</u>					
<u>AP</u>	+ COVIS PHARMA	<u>EQ 25MG BASE/ML</u>	<u>N019090</u>	<u>001</u>	Oct 19, 1984
ZANTAC IN PLASTIC CONTAINER					
	+ COVIS PHARMA	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>EQ 15MG BASE/ML</u>	<u>A076124</u>	<u>001</u>	Feb 21, 2007
<u>AA</u>	AMNEAL PHARMS	<u>EQ 15MG BASE/ML</u>	<u>A078312</u>	<u>001</u>	Sep 02, 2008
<u>AA</u>	APOTEX	<u>EQ 15MG BASE/ML</u>	<u>A077602</u>	<u>001</u>	Sep 17, 2007
<u>AA</u>	AUROBINDO PHARM	<u>EQ 15MG BASE/ML</u>	<u>A090623</u>	<u>001</u>	Jul 28, 2010
<u>AA</u>	CYPRESS PHARM	<u>EQ 15MG BASE/ML</u>	<u>A078684</u>	<u>001</u>	Aug 27, 2009
<u>AA</u>	DR REDDYS LABS LTD	<u>EQ 15MG BASE/ML</u>	<u>A090102</u>	<u>001</u>	May 26, 2009
<u>AA</u>	HI TECH PHARMA	<u>EQ 15MG BASE/ML</u>	<u>A091078</u>	<u>001</u>	Mar 22, 2011
<u>AA</u>	PHARM ASSOC	<u>EQ 15MG BASE/ML</u>	<u>A077405</u>	<u>001</u>	Sep 21, 2007
<u>AA</u>	SILARX	<u>EQ 15MG BASE/ML</u>	<u>A091288</u>	<u>001</u>	Dec 09, 2010
<u>AA</u>	SUN PHARM INDS INC	<u>EQ 15MG BASE/ML</u>	<u>A091091</u>	<u>001</u>	Sep 20, 2011
<u>AA</u>	TARO	<u>EQ 15MG BASE/ML</u>	<u>A077476</u>	<u>001</u>	Jun 13, 2011
<u>AA</u>	TOLMAR	<u>EQ 15MG BASE/ML</u>	<u>A090054</u>	<u>001</u>	Nov 15, 2010
<u>AA</u>	VINTAGE PHARMS	<u>EQ 15MG BASE/ML</u>	<u>A078890</u>	<u>001</u>	Jul 01, 2010
<u>AA</u>	WOCKHARDT	<u>EQ 15MG BASE/ML</u>	<u>A079211</u>	<u>001</u>	May 26, 2009
<u>AA</u>		<u>EQ 15MG BASE/ML</u>	<u>A079212</u>	<u>001</u>	Feb 23, 2009

ZANTAC

<u>AA</u>	+ GLAXOSMITHKLINE	<u>EQ 15MG BASE/ML</u>	<u>N019675</u>	<u>001</u>	Dec 30, 1988

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 150MG BASE</u>	<u>A077824</u>	<u>001</u>	Oct 13, 2006
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077824</u>	<u>002</u>	Oct 13, 2006
<u>AB</u>	APOTEX	<u>EQ 150MG BASE</u>	<u>A074680</u>	<u>001</u>	Sep 12, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074680</u>	<u>002</u>	Sep 12, 1997
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 150MG BASE</u>	<u>A076705</u>	<u>001</u>	Jul 27, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A076705</u>	<u>002</u>	Jul 27, 2005
<u>AB</u>	GLENMARK GENERICS	<u>EQ 150MG BASE</u>	<u>A078542</u>	<u>001</u>	Nov 19, 2008
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078542</u>	<u>002</u>	Nov 19, 2008
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 150MG BASE</u>	<u>A075165</u>	<u>001</u>	Sep 30, 1998
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075165</u>	<u>002</u>	Sep 30, 1998
<u>AB</u>	MYLAN	<u>EQ 150MG BASE</u>	<u>A074023</u>	<u>001</u>	Aug 22, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074023</u>	<u>002</u>	Aug 22, 1997
<u>AB</u>	PAR PHARM	<u>EQ 150MG BASE</u>	<u>A075180</u>	<u>001</u>	Jan 28, 1999
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075180</u>	<u>002</u>	Jan 28, 1999
<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074467</u>	<u>001</u>	Aug 29, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074467</u>	<u>002</u>	Aug 29, 1997
<u>AB</u>	TEVA	<u>EQ 150MG BASE</u>	<u>A074488</u>	<u>001</u>	Jul 31, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074488</u>	<u>002</u>	Jul 31, 1997
<u>AB</u>	WATSON LABS	<u>EQ 150MG BASE</u>	<u>A074864</u>	<u>001</u>	Oct 20, 1997
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A077426</u>	<u>001</u>	Dec 19, 2005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 361 (of 428)

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	WATSON LABS	<u>EQ 300MG BASE</u>	<u>A074864</u>	<u>002</u>	Oct 20, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077426</u>	<u>002</u>	Dec 19, 2005
<u>AB</u>	WOCKHARDT	<u>EQ 150MG BASE</u>	<u>A075208</u>	<u>001</u>	Dec 17, 1998
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078701</u>	<u>001</u>	Nov 12, 2009
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075208</u>	<u>002</u>	Dec 17, 1998
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078701</u>	<u>002</u>	Dec 11, 2009
	<u>ZANTAC 150</u>				
<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 150MG BASE</u>	<u>N018703</u>	<u>001</u>	Jun 09, 1983
	<u>ZANTAC 300</u>				
<u>AB</u> +	GLAXOSMITHKLINE	<u>EQ 300MG BASE</u>	<u>N018703</u>	<u>002</u>	Dec 09, 1985
	TABLET, EFFERVESCENT; ORAL				
	ZANTAC 25				
	+ GLAXOSMITHKLINE	EQ 25MG BASE	N020251	003	Apr 01, 2004

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANEXA

	GILEAD	500MG	N021526	002	Jan 27, 2006
+		1GM	N021526	001	Feb 12, 2007

RASAGILINE MESYLATE

TABLET; ORAL

AZILECT

	TEVA	EQ 0.5MG BASE	N021641	001	May 16, 2006
+		EQ 1MG BASE	N021641	002	May 16, 2006

REGADENOSON

SOLUTION; INTRAVENOUS

LEXISCAN

+	ASTELLAS	0.4MG/5ML (0.08MG/ML)	N022161	001	Apr 10, 2008

REGORAFENIB

TABLET; ORAL

STIVARGA

+	BAYER HLTHCARE	40MG	N203085	001	Sep 27, 2012

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ULTIVA

	MYLAN INSTITUTIONAL	EQ 1MG BASE/VIAL	N020630	001	Jul 12, 1996
		EQ 2MG BASE/VIAL	N020630	002	Jul 12, 1996
+		EQ 5MG BASE/VIAL	N020630	003	Jul 12, 1996

REPAGLINIDE

TABLET; ORAL

PRANDIN

	NOVO NORDISK INC	0.5MG	N020741	001	Dec 22, 1997
		1MG	N020741	002	Dec 22, 1997
+		2MG	N020741	003	Dec 22, 1997

RESERPINE

TABLET; ORAL

RESERPINE

BP	SANDOZ	0.1MG	N009838	001	
BP	+	0.25MG	N009838	002	
	SERPALAN				
BP	LANNETT	0.1MG	N010124	001	
BP		0.25MG	N010124	002	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 362 (of 428)

RETAPAMULINOINTMENT; TOPICAL
ALTABAX

+ GLAXO GRP LTD 1% N022055 001 Apr 12, 2007

RIBAVIRIN

CAPSULE; ORAL

REBETOLAB + MERCK SHARP DOHME 200MG N020903 002 Jul 25, 2001RIBASPHEREAB THREE RIVERS PHARMS 200MG A076203 001 Apr 06, 2004RIBAVARINAB AUROBINDO PHARMA 200MG A079117 001 Sep 17, 2009RIBAVIRINAB SANDOZ 200MG A076192 001 Apr 06, 2004AB TEVA 200MG A076277 001 Oct 04, 2004AB ZYDUS PHARMS USA 200MG A077224 001 Oct 28, 2005REBETOL

+ MERCK SHARP DOHME 200MG N020903 001 Jun 03, 1998

FOR SOLUTION; INHALATION

VIRAZOLE

+ VALEANT PHARM INTL 6GM/VIAL N018859 001 Dec 31, 1985

SOLUTION; ORAL

REBETOL

+ SCHERING 40MG/ML N021546 001 Jul 29, 2003

TABLET; ORAL

COPEGUSAB ROCHE 200MG N021511 001 Dec 03, 2002RIBAVIRINAB AUROBINDO PHARMA 200MG A079111 001 Sep 17, 2009AB SANDOZ 200MG A077743 001 Oct 03, 2006AB TEVA 200MG A077053 001 Dec 05, 2005AB THREE RIVERS PHARMS 200MG A077456 001 Dec 05, 2005AB 400MG A077456 002 Dec 05, 2005AB + 600MG A077456 003 Dec 05, 2005AB ZYDUS PHARMS USA 200MG A077094 001 Dec 05, 2005AB 400MG A077094 002 Mar 16, 2007AB 600MG A077094 003 Mar 16, 2007RIBAVIRIN

ZYDUS PHARMS USA 500MG A077094 004 Apr 18, 2008

RIFABUTIN

CAPSULE; ORAL

MYCOBUTIN

+ PHARMACIA AND UPJOHN 150MG N050689 001 Dec 23, 1992

RIFAMPIN

CAPSULE; ORAL

RIFADINAB SANOFI AVENTIS US 150MG A062303 001AB + 300MG N050420 001RIFAMPINAB LANNETT 150MG A065390 001 Mar 28, 2008AB 300MG A065390 002 Mar 28, 2008AB SANDOZ 150MG A064150 002 Jan 02, 1998AB 300MG A064150 001 May 28, 1997AB VERSAPHARM 150MG A065028 001 Mar 14, 2001AB 300MG A065028 002 Mar 14, 2001RIMACTANEAB PROSAM LABS 300MG N050429 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 363 (of 428)

RIFAMPIN

INJECTABLE; INJECTION

RIFADIN

<u>AP</u>	+	SANOFI AVENTIS US	<u>600MG/VIAL</u>	<u>N050627</u>	<u>001</u>	May 25, 1989

RIFAMPIN

<u>AP</u>		BEDFORD	<u>600MG/VIAL</u>	<u>A064217</u>	<u>001</u>	Oct 29, 1999

<u>AP</u>		PFIZER	<u>600MG/VIAL</u>	<u>A065421</u>	<u>001</u>	May 22, 2008

<u>AP</u>		VERSAPHARM INC	<u>600MG/VIAL</u>	<u>A065502</u>	<u>001</u>	Sep 21, 2010

RIFAPENTINE

TABLET; ORAL

PRIFTIN

	+	SANOFI AVENTIS US	150MG	N021024	001	Jun 22, 1998

RIFAXIMIN

TABLET; ORAL

XIFAXAN

	+	SALIX PHARMS	200MG	N021361	001	May 25, 2004

	+		550MG	N022554	001	Mar 24, 2010

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

	+	JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011

RILUZOLE

TABLET; ORAL

RILUTEK

<u>AB</u>	+	SANOFI AVENTIS US	<u>50MG</u>	<u>N020599</u>	<u>001</u>	Dec 12, 1995

RILUZOLE

<u>AB</u>		IMPAX LABS	<u>50MG</u>	<u>A076173</u>	<u>001</u>	Jan 29, 2003

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

FLUMADINE

<u>AB</u>	+	CARACO	<u>100MG</u>	<u>N019649</u>	<u>001</u>	Sep 17, 1993

RIMANTADINE HYDROCHLORIDE

<u>AB</u>		COREPHARMA	<u>100MG</u>	<u>A075916</u>	<u>001</u>	Nov 02, 2001

<u>AB</u>		IMPAX LABS	<u>100MG</u>	<u>A076132</u>	<u>001</u>	Aug 30, 2002

RIMEXOLONE

SUSPENSION/DROPS; OPHTHALMIC

	+	ALCON	1%	N020474	001	Dec 30, 1994

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

<u>AB</u>		WARNER CHILCOTT LLC	<u>5MG</u>	<u>N020835</u>	<u>002</u>	Apr 14, 2000

<u>AB</u>			<u>30MG</u>	<u>N020835</u>	<u>001</u>	Mar 27, 1998

<u>AB</u>	+		<u>35MG</u>	<u>N020835</u>	<u>003</u>	May 25, 2002

RISEDRONATE SODIUM

<u>AB</u>		TEVA PHARMS	<u>5MG</u>	<u>A077132</u>	<u>001</u>	Oct 05, 2007

<u>AB</u>			<u>30MG</u>	<u>A077132</u>	<u>002</u>	Oct 05, 2007

<u>AB</u>			<u>35MG</u>	<u>A077132</u>	<u>003</u>	Oct 05, 2007

ACTONEL

	+	WARNER CHILCOTT LLC	150MG	N020835	005	Apr 22, 2008

TABLET, DELAYED RELEASE; ORAL

ATELVIA

	+	WARNER CHILCOTT LLC	35MG	N022560	001	Oct 08, 2010

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 364 (of 428)

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

JANSSEN PHARMS

12.5MG/VIAL

N021346 004 Apr 12, 2007

+

25MG/VIAL

N021346 001 Oct 29, 2003

37.5MG/VIAL

N021346 002 Oct 29, 2003

50MG/VIAL

N021346 003 Oct 29, 2003

SOLUTION; ORAL

RISPERDALAA + JANSSEN PHARMS1MG/MLN020588 001 Jun 10, 1996RISPERIDONEAA AMNEAL PHARMS1MG/MLA091384 001 May 25, 2011AA APOTEX INC1MG/MLA077719 001 Jul 29, 2009AA AUROBINDO PHARMA1MG/MLA078452 001 Sep 04, 2009AA DR REDDYS LABS LTD1MG/MLA078909 001 Jul 29, 2009AA PRECISION DOSE1MG/MLA076797 001 Jun 28, 2010AA ROXANE1MG/MLA076904 001 Jul 29, 2009AA TARO1MG/MLA090347 001 Feb 07, 2011AA TEVA1MG/MLA076440 001 Jan 30, 2009AA TRIS PHARMA INC1MG/MLA079059 001 Dec 12, 2012AA VINTAGE1MG/MLA079158 001 Dec 03, 2010AA WOCKHARDT1MG/MLA078744 001 Oct 08, 2009

TABLET; ORAL

RISPERDALAB JANSSEN PHARMS0.25MGN020272 008 May 10, 1999AB0.5MGN020272 007 Jan 27, 1999AB +1MGN020272 001 Dec 29, 1993AB2MGN020272 002 Dec 29, 1993AB3MGN020272 003 Dec 29, 1993AB4MGN020272 004 Dec 29, 1993RISPERIDONEAB AJANTA PHARMA LTD0.25MGA201003 001 Aug 24, 2011AB0.5MGA201003 002 Aug 24, 2011AB1MGA201003 003 Aug 24, 2011AB2MGA201003 004 Aug 24, 2011AB3MGA201003 005 Aug 24, 2011AB4MGA201003 006 Aug 24, 2011AB APOTEX INC0.25MGA077953 001 Sep 15, 2008AB0.5MGA077953 002 Sep 15, 2008AB1MGA077953 003 Sep 15, 2008AB2MGA077953 004 Sep 15, 2008AB3MGA077953 005 Sep 15, 2008AB4MGA077953 006 Sep 15, 2008AB AUROBINDO PHARMA0.25MGA078269 001 Oct 08, 2008AB0.5MGA078269 002 Oct 08, 2008AB1MGA078269 003 Oct 08, 2008AB2MGA078269 004 Oct 08, 2008AB3MGA078269 005 Oct 08, 2008AB4MGA078269 006 Oct 08, 2008AB CIPLA0.25MGA077543 001 May 18, 2011AB0.5MGA077543 002 May 18, 2011AB1MGA077543 003 May 18, 2011AB2MGA077543 004 May 18, 2011AB3MGA077543 005 May 18, 2011AB4MGA077543 006 May 18, 2011AB DR REDDYS LABS LTD0.25MGA076879 001 Oct 24, 2008AB0.5MGA076879 002 Oct 24, 2008AB1MGA076879 003 Oct 24, 2008AB2MGA076879 004 Oct 24, 2008AB3MGA076879 005 Oct 24, 2008AB4MGA076879 006 Oct 24, 2008

PRESCRIPTION DRUG PRODUCT LIST

3 - 365 (of 428)

RISPERIDONE

TABLET; ORAL

RISPERIDONE

<u>AB</u>	MYLAN	<u>0.25MG</u>	<u>A076288</u>	<u>001</u>	Sep 15, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076288</u>	<u>002</u>	Sep 15, 2008
<u>AB</u>		<u>1MG</u>	<u>A076288</u>	<u>003</u>	Sep 15, 2008
<u>AB</u>		<u>2MG</u>	<u>A076288</u>	<u>004</u>	Sep 15, 2008
<u>AB</u>		<u>3MG</u>	<u>A076288</u>	<u>005</u>	Sep 15, 2008
<u>AB</u>		<u>4MG</u>	<u>A076288</u>	<u>006</u>	Sep 15, 2008
<u>AB</u>	PLIVA HRVATSKA DOO	<u>0.25MG</u>	<u>A077769</u>	<u>001</u>	Oct 16, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077769</u>	<u>002</u>	Oct 16, 2008
<u>AB</u>		<u>1MG</u>	<u>A077769</u>	<u>003</u>	Oct 16, 2008
<u>AB</u>		<u>2MG</u>	<u>A077769</u>	<u>004</u>	Oct 16, 2008
<u>AB</u>		<u>3MG</u>	<u>A077769</u>	<u>005</u>	Oct 16, 2008
<u>AB</u>		<u>4MG</u>	<u>A077769</u>	<u>006</u>	Oct 16, 2008
<u>AB</u>	PRINSTON INC	<u>0.25MG</u>	<u>A077493</u>	<u>001</u>	Nov 29, 2011
<u>AB</u>		<u>0.5MG</u>	<u>A077493</u>	<u>002</u>	Nov 29, 2011
<u>AB</u>		<u>1MG</u>	<u>A077493</u>	<u>003</u>	Nov 29, 2011
<u>AB</u>		<u>2MG</u>	<u>A077493</u>	<u>004</u>	Nov 29, 2011
<u>AB</u>		<u>3MG</u>	<u>A077493</u>	<u>005</u>	Nov 29, 2011
<u>AB</u>		<u>4MG</u>	<u>A077493</u>	<u>006</u>	Nov 29, 2011
<u>AB</u>	PROSAM LABS	<u>0.25MG</u>	<u>A078071</u>	<u>001</u>	Jun 17, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078071</u>	<u>002</u>	Jun 17, 2009
<u>AB</u>		<u>1MG</u>	<u>A078071</u>	<u>003</u>	Jun 17, 2009
<u>AB</u>		<u>2MG</u>	<u>A078071</u>	<u>004</u>	Jun 17, 2009
<u>AB</u>		<u>3MG</u>	<u>A078071</u>	<u>005</u>	Jun 17, 2009
<u>AB</u>		<u>4MG</u>	<u>A078071</u>	<u>006</u>	Jun 17, 2009
<u>AB</u>	SANDOZ	<u>0.25MG</u>	<u>A078528</u>	<u>001</u>	Oct 16, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078528</u>	<u>002</u>	Oct 16, 2009
<u>AB</u>		<u>1MG</u>	<u>A078528</u>	<u>003</u>	Oct 16, 2009
<u>AB</u>		<u>2MG</u>	<u>A078528</u>	<u>004</u>	Oct 16, 2009
<u>AB</u>		<u>3MG</u>	<u>A078528</u>	<u>005</u>	Oct 16, 2009
<u>AB</u>		<u>4MG</u>	<u>A078528</u>	<u>006</u>	Oct 16, 2009
<u>AB</u>	TEVA	<u>0.25MG</u>	<u>A076228</u>	<u>001</u>	Jun 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076228</u>	<u>002</u>	Jun 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A076228</u>	<u>003</u>	Jun 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A076228</u>	<u>004</u>	Jun 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A076228</u>	<u>005</u>	Jun 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A076228</u>	<u>006</u>	Jun 30, 2008
<u>AB</u>	TORRENT PHARMS	<u>0.25MG</u>	<u>A079088</u>	<u>001</u>	Oct 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A079088</u>	<u>002</u>	Oct 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A079088</u>	<u>003</u>	Oct 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A079088</u>	<u>004</u>	Oct 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A079088</u>	<u>005</u>	Oct 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A079088</u>	<u>006</u>	Oct 30, 2008
<u>AB</u>	VINTAGE	<u>0.25MG</u>	<u>A078707</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078707</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>		<u>1MG</u>	<u>A078707</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>2MG</u>	<u>A078707</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>		<u>3MG</u>	<u>A078707</u>	<u>005</u>	Dec 29, 2008
<u>AB</u>		<u>4MG</u>	<u>A078707</u>	<u>006</u>	Dec 29, 2008
<u>AB</u>	WATSON LABS	<u>0.25MG</u>	<u>A077860</u>	<u>001</u>	Dec 05, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077860</u>	<u>002</u>	Dec 05, 2008
<u>AB</u>		<u>1MG</u>	<u>A077860</u>	<u>003</u>	Dec 05, 2008
<u>AB</u>		<u>2MG</u>	<u>A077860</u>	<u>004</u>	Dec 05, 2008
<u>AB</u>		<u>3MG</u>	<u>A077860</u>	<u>005</u>	Dec 05, 2008
<u>AB</u>		<u>4MG</u>	<u>A077860</u>	<u>006</u>	Dec 05, 2008
<u>AB</u>	WEST WARD PHARMS	<u>0.25MG</u>	<u>A078740</u>	<u>001</u>	May 29, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078740</u>	<u>002</u>	May 29, 2009
<u>AB</u>		<u>1MG</u>	<u>A078740</u>	<u>003</u>	May 29, 2009
<u>AB</u>		<u>2MG</u>	<u>A078740</u>	<u>004</u>	May 29, 2009

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 366 (of 428)

RISPERIDONE

TABLET; ORAL

RISPERIDONE

<u>AB</u>	WEST WARD PHARMS	<u>3MG</u>	<u>A078740</u>	<u>005</u>	May 29, 2009
<u>AB</u>		<u>4MG</u>	<u>A078740</u>	<u>006</u>	May 29, 2009
<u>AB</u>	WOCKHARDT	<u>0.25MG</u>	<u>A078871</u>	<u>001</u>	Oct 09, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078871</u>	<u>002</u>	Oct 09, 2008
<u>AB</u>		<u>1MG</u>	<u>A078871</u>	<u>003</u>	Oct 09, 2008
<u>AB</u>		<u>2MG</u>	<u>A078871</u>	<u>004</u>	Oct 09, 2008
<u>AB</u>		<u>3MG</u>	<u>A078871</u>	<u>005</u>	Oct 09, 2008
<u>AB</u>		<u>4MG</u>	<u>A078871</u>	<u>006</u>	Oct 09, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.25MG</u>	<u>A078040</u>	<u>001</u>	Oct 16, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078040</u>	<u>002</u>	Oct 16, 2008
<u>AB</u>		<u>1MG</u>	<u>A078040</u>	<u>003</u>	Oct 16, 2008
<u>AB</u>		<u>2MG</u>	<u>A078040</u>	<u>004</u>	Oct 16, 2008
<u>AB</u>		<u>3MG</u>	<u>A078040</u>	<u>005</u>	Oct 16, 2008
<u>AB</u>		<u>4MG</u>	<u>A078040</u>	<u>006</u>	Oct 16, 2008

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

<u>AB</u>	JANSSEN PHARMS	<u>0.5MG</u>	<u>N021444</u>	<u>001</u>	Apr 02, 2003
<u>AB</u>	+	<u>1MG</u>	<u>N021444</u>	<u>002</u>	Apr 02, 2003
<u>AB</u>		<u>2MG</u>	<u>N021444</u>	<u>003</u>	Apr 02, 2003
<u>AB</u>		<u>3MG</u>	<u>N021444</u>	<u>004</u>	Dec 23, 2004
<u>AB</u>		<u>4MG</u>	<u>N021444</u>	<u>005</u>	Dec 23, 2004

RISPERIDONE

<u>AB</u>	DR REDDYS LABS LTD	<u>0.5MG</u>	<u>A077328</u>	<u>001</u>	Feb 24, 2009
<u>AB</u>		<u>1MG</u>	<u>A077328</u>	<u>002</u>	Oct 05, 2009
<u>AB</u>		<u>2MG</u>	<u>A077328</u>	<u>003</u>	Feb 24, 2009
<u>AB</u>	JUBILANT ORGANOSYS	<u>0.5MG</u>	<u>A090839</u>	<u>001</u>	Nov 04, 2011
<u>AB</u>		<u>1MG</u>	<u>A090839</u>	<u>002</u>	Nov 04, 2011
<u>AB</u>		<u>2MG</u>	<u>A090839</u>	<u>003</u>	Nov 04, 2011
<u>AB</u>		<u>3MG</u>	<u>A090839</u>	<u>004</u>	Nov 04, 2011
<u>AB</u>		<u>4MG</u>	<u>A090839</u>	<u>005</u>	Nov 04, 2011
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A091537</u>	<u>001</u>	Mar 30, 2011
<u>AB</u>		<u>1MG</u>	<u>A091537</u>	<u>002</u>	Mar 30, 2011
<u>AB</u>		<u>2MG</u>	<u>A091537</u>	<u>003</u>	Mar 30, 2011
<u>AB</u>		<u>3MG</u>	<u>A091537</u>	<u>004</u>	Mar 30, 2011
<u>AB</u>		<u>4MG</u>	<u>A091537</u>	<u>005</u>	Mar 30, 2011
<u>AB</u>	PAR PHARM	<u>0.5MG</u>	<u>A077494</u>	<u>002</u>	Apr 30, 2009
<u>AB</u>		<u>1MG</u>	<u>A077494</u>	<u>003</u>	Oct 26, 2009
<u>AB</u>		<u>2MG</u>	<u>A077494</u>	<u>004</u>	Apr 30, 2009
<u>AB</u>		<u>3MG</u>	<u>A077494</u>	<u>005</u>	Apr 30, 2009
<u>AB</u>		<u>4MG</u>	<u>A077494</u>	<u>006</u>	Apr 30, 2009
<u>AB</u>	RANBAXY	<u>0.5MG</u>	<u>A077542</u>	<u>001</u>	Aug 06, 2010
<u>AB</u>		<u>1MG</u>	<u>A077542</u>	<u>002</u>	Aug 06, 2010
<u>AB</u>		<u>2MG</u>	<u>A077542</u>	<u>003</u>	Aug 06, 2010
<u>AB</u>		<u>3MG</u>	<u>A078474</u>	<u>001</u>	Aug 06, 2010
<u>AB</u>		<u>4MG</u>	<u>A078474</u>	<u>002</u>	Aug 06, 2010
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A078116</u>	<u>001</u>	Dec 22, 2009
<u>AB</u>		<u>1MG</u>	<u>A078116</u>	<u>002</u>	Dec 22, 2009
<u>AB</u>		<u>2MG</u>	<u>A078116</u>	<u>003</u>	Dec 22, 2009
<u>AB</u>		<u>3MG</u>	<u>A078116</u>	<u>004</u>	Dec 22, 2009
<u>AB</u>		<u>4MG</u>	<u>A078116</u>	<u>005</u>	Dec 22, 2009
<u>AB</u>	TEVA	<u>0.5MG</u>	<u>A076908</u>	<u>001</u>	Mar 12, 2012
<u>AB</u>		<u>1MG</u>	<u>A076908</u>	<u>002</u>	Mar 12, 2012
<u>AB</u>		<u>2MG</u>	<u>A076908</u>	<u>003</u>	Mar 12, 2012
<u>AB</u>	WATSON LABS FLORIDA	<u>0.5MG</u>	<u>A076996</u>	<u>001</u>	Apr 19, 2011
<u>AB</u>		<u>1MG</u>	<u>A076996</u>	<u>002</u>	Apr 19, 2011
<u>AB</u>		<u>2MG</u>	<u>A076996</u>	<u>003</u>	Apr 19, 2011
<u>AB</u>		<u>3MG</u>	<u>A076996</u>	<u>004</u>	Apr 19, 2011
<u>AB</u>		<u>4MG</u>	<u>A076996</u>	<u>005</u>	Apr 19, 2011

PRESCRIPTION DRUG PRODUCT LIST

3 - 367 (of 428)

RISPERIDONE

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

<u>AB</u>	ZYDUS PHARMS USA	<u>0.5MG</u>	<u>A078516</u>	<u>001</u>	May 01, 2009
<u>AB</u>		<u>2MG</u>	<u>A078516</u>	<u>003</u>	May 01, 2009
	RISPERIDONE				
	PAR PHARM	0.25MG	A077494	001	Apr 30, 2009

RITONAVIR

CAPSULE; ORAL

NORVIR

+ ABBVIE	100MG	N020945	001	Jun 29, 1999

SOLUTION; ORAL

NORVIR

+ ABBVIE	80MG/ML	N020659	001	Mar 01, 1996

TABLET; ORAL

NORVIR

+ ABBVIE	100MG	N022417	001	Feb 10, 2010

RIVAROXABAN

TABLET; ORAL

XARELTO

+ JANSSEN PHARMS	10MG	N022406	001	Jul 01, 2011

	15MG	N022406	002	Nov 04, 2011

+	20MG	N022406	003	Nov 04, 2011

RIVASTIGMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EXELON

NOVARTIS	4.6MG/24HR	N022083	001	Jul 06, 2007

+	9.5MG/24HR	N022083	002	Jul 06, 2007

	13.3MG/24HR	N022083	005	Aug 31, 2012

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

EXELON

<u>AB</u>	+ NOVARTIS	<u>EQ 1.5MG BASE</u>	<u>N020823</u>	<u>003</u>	Apr 21, 2000
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>N020823</u>	<u>004</u>	Apr 21, 2000
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>N020823</u>	<u>005</u>	Apr 21, 2000
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>N020823</u>	<u>006</u>	Apr 21, 2000

RIVASTIGMINE TARTRATE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 1.5MG BASE</u>	<u>A091689</u>	<u>001</u>	Jun 12, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A091689</u>	<u>002</u>	Jun 12, 2012
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A091689</u>	<u>003</u>	Jun 12, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A091689</u>	<u>004</u>	Jun 12, 2012
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 1.5MG BASE</u>	<u>A077130</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077130</u>	<u>002</u>	Oct 31, 2007
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A077130</u>	<u>003</u>	Oct 31, 2007
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A077130</u>	<u>004</u>	Oct 31, 2007
<u>AB</u>	SUN PHARM INDS	<u>EQ 1.5MG BASE</u>	<u>A077131</u>	<u>001</u>	Oct 22, 2007
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077131</u>	<u>002</u>	Oct 22, 2007
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A077131</u>	<u>003</u>	Oct 22, 2007
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A077131</u>	<u>004</u>	Oct 22, 2007
<u>AB</u>	WATSON LABS	<u>EQ 1.5MG BASE</u>	<u>A077129</u>	<u>001</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077129</u>	<u>002</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A077129</u>	<u>003</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A077129</u>	<u>004</u>	Jan 08, 2008

SOLUTION; ORAL

EXELON

+ NOVARTIS	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 368 (of 428)

RIZATRIPTAN BENZOATE

TABLET; ORAL

MAXALT

<u>AB</u>	MERCK	<u>EQ 5MG BASE</u>	<u>N020864</u>	<u>001</u>	Jun 29, 1998
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N020864</u>	<u>002</u>	Jun 29, 1998
	<u>RIZATRIPTAN BENZOATE</u>				
<u>AB</u>	APOTEX INC	<u>EQ 5MG BASE</u>	<u>A202244</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202244</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A202490</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202490</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>	GLENMARK GENERICS	<u>EQ 5MG BASE</u>	<u>A201967</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201967</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 5MG BASE</u>	<u>A201993</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201993</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A200482</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A200482</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A079230</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A079230</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 5MG BASE</u>	<u>A202047</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202047</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A077263</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077263</u>	<u>002</u>	Dec 31, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

MAXALT-MLT

<u>AB</u>	MERCK	<u>EQ 5MG BASE</u>	<u>N020865</u>	<u>001</u>	Jun 29, 1998
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N020865</u>	<u>002</u>	Jun 29, 1998
	<u>RIZATRIPTAN BENZOATE</u>				
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 5MG BASE</u>	<u>A078173</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078173</u>	<u>002</u>	Dec 31, 2012

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

<u>AP</u>	BIONICHE PHARMA USA	<u>50MG/5ML (10MG/ML)</u>	<u>A079199</u>	<u>001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A079199</u>	<u>002</u>	Nov 26, 2008
<u>AP</u>	FRESENIUS KABI USA	<u>50MG/5ML (10MG/ML)</u>	<u>A078651</u>	<u>001</u>	Dec 29, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078651</u>	<u>002</u>	Dec 29, 2008
<u>AP</u>	HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A078519</u>	<u>001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078519</u>	<u>002</u>	Nov 26, 2008
<u>AP</u>	SAGENT STRIDES	<u>50MG/5ML (10MG/ML)</u>	<u>A091458</u>	<u>001</u>	Jul 28, 2010
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A091458</u>	<u>002</u>	Jul 28, 2010
<u>AP</u>	SANDOZ	<u>50MG/5ML (10MG/ML)</u>	<u>A079195</u>	<u>001</u>	Dec 05, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A079195</u>	<u>002</u>	Dec 05, 2008
<u>AP</u>	TAMARANG	<u>50MG/5ML (10MG/ML)</u>	<u>A091115</u>	<u>001</u>	Aug 27, 2012
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A091115</u>	<u>002</u>	Aug 27, 2012
<u>AP</u>	TEVA PHARMS	<u>50MG/5ML (10MG/ML)</u>	<u>A078717</u>	<u>001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078717</u>	<u>002</u>	Nov 26, 2008

ZEMURON

<u>AP</u>	+	SCHERING	<u>50MG/5ML (10MG/ML)</u>	<u>N020214</u>	<u>001</u>	Mar 17, 1994
<u>AP</u>	+		<u>100MG/10ML (10MG/ML)</u>	<u>N020214</u>	<u>003</u>	Mar 17, 1994

ROFLUMILAST

TABLET; ORAL

DALIRESP

+	FOREST RES INST INC	500MCG	N022522	001	Feb 28, 2011

ROMIDEPSIN

POWDER; IV (INFUSION)

+	CELGENE	10MG/VIAL	N022393	001	Nov 05, 2009

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 369 (of 428)

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP

<u>AB</u>	<u>+</u>	<u>GLAXOSMITHKLINE</u>	<u>EQ 0.25MG BASE</u>	<u>N020658</u>	<u>001</u>	Sep 19, 1997
<u>AB</u>			<u>EQ 0.5MG BASE</u>	<u>N020658</u>	<u>002</u>	Sep 19, 1997
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>N020658</u>	<u>003</u>	Sep 19, 1997
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>N020658</u>	<u>004</u>	Sep 19, 1997
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>N020658</u>	<u>006</u>	Jan 27, 1999
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>N020658</u>	<u>007</u>	Jan 27, 1999
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>N020658</u>	<u>005</u>	Sep 19, 1997

ROPINIROLE HYDROCHLORIDE

<u>AB</u>		<u>ALEMBIC LTD</u>	<u>EQ 0.25MG BASE</u>	<u>A090429</u>	<u>001</u>	Mar 24, 2010
<u>AB</u>			<u>EQ 0.5MG BASE</u>	<u>A090429</u>	<u>002</u>	Mar 24, 2010
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A090429</u>	<u>003</u>	Mar 24, 2010
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A090429</u>	<u>004</u>	Mar 24, 2010
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A090429</u>	<u>005</u>	Mar 24, 2010
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A090429</u>	<u>006</u>	Mar 24, 2010
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A090429</u>	<u>007</u>	Mar 24, 2010
<u>AB</u>		<u>APOTEX</u>	<u>EQ 0.25MG BASE</u>	<u>A079165</u>	<u>001</u>	Feb 07, 2012
<u>AB</u>			<u>EQ 0.5MG BASE</u>	<u>A079165</u>	<u>002</u>	Feb 07, 2012
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A079165</u>	<u>003</u>	Feb 07, 2012
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A079165</u>	<u>004</u>	Feb 07, 2012
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A079165</u>	<u>005</u>	Feb 07, 2012
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A079165</u>	<u>006</u>	Feb 07, 2012
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A079165</u>	<u>007</u>	Feb 07, 2012
<u>AB</u>		<u>COREPHARMA</u>	<u>EQ 0.25MG BASE</u>	<u>A078230</u>	<u>001</u>	May 20, 2008
<u>AB</u>			<u>EQ 0.5MG BASE</u>	<u>A078230</u>	<u>002</u>	May 20, 2008
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A078230</u>	<u>003</u>	May 20, 2008
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A078230</u>	<u>004</u>	May 20, 2008
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A078230</u>	<u>005</u>	May 20, 2008
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A078230</u>	<u>006</u>	May 20, 2008
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A078230</u>	<u>007</u>	May 20, 2008
<u>AB</u>		<u>GLENMARK GENERICS</u>	<u>EQ 0.25MG BASE</u>	<u>A090135</u>	<u>001</u>	Feb 25, 2010
<u>AB</u>			<u>EQ 0.5MG BASE</u>	<u>A090135</u>	<u>002</u>	Feb 25, 2010
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A090135</u>	<u>003</u>	Feb 25, 2010
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A090135</u>	<u>004</u>	Feb 25, 2010
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A090135</u>	<u>005</u>	Feb 25, 2010
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A090135</u>	<u>006</u>	Feb 25, 2010
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A090135</u>	<u>007</u>	Feb 25, 2010
<u>AB</u>		<u>MYLAN</u>	<u>EQ 0.25MG BASE</u>	<u>A078881</u>	<u>001</u>	May 05, 2008
<u>AB</u>			<u>EQ 0.5MG BASE</u>	<u>A078881</u>	<u>002</u>	May 05, 2008
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A078881</u>	<u>003</u>	May 05, 2008
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A078881</u>	<u>004</u>	May 05, 2008
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A078881</u>	<u>005</u>	May 05, 2008
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A078881</u>	<u>006</u>	May 05, 2008
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A078881</u>	<u>007</u>	May 19, 2008
<u>AB</u>		<u>ORCHID HLTHCARE</u>	<u>EQ 0.25MG BASE</u>	<u>A079229</u>	<u>001</u>	Nov 28, 2012
<u>AB</u>			<u>EQ 0.5MG BASE</u>	<u>A079229</u>	<u>002</u>	Nov 28, 2012
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A079229</u>	<u>003</u>	Nov 28, 2012
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A079229</u>	<u>004</u>	Nov 28, 2012
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A079229</u>	<u>005</u>	Nov 28, 2012
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A079229</u>	<u>006</u>	Nov 28, 2012
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A079229</u>	<u>007</u>	Nov 28, 2012
<u>AB</u>		<u>PRINSTON INC</u>	<u>EQ 0.25MG BASE</u>	<u>A078110</u>	<u>001</u>	May 05, 2008
<u>AB</u>			<u>EQ 0.5MG BASE</u>	<u>A078110</u>	<u>002</u>	May 05, 2008
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A078110</u>	<u>003</u>	May 05, 2008
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A078110</u>	<u>004</u>	May 05, 2008
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A078110</u>	<u>005</u>	May 05, 2008
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A078110</u>	<u>006</u>	May 05, 2008
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A078110</u>	<u>007</u>	Jul 11, 2008
<u>AB</u>		<u>ROXANE</u>	<u>EQ 0.25MG BASE</u>	<u>A077852</u>	<u>001</u>	May 05, 2008

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 370 (of 428)

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	ROXANE	EQ 0.5MG BASE	A077852	002	May 05, 2008
AB		EQ 1MG BASE	A077852	003	May 05, 2008
AB		EQ 2MG BASE	A077852	004	May 05, 2008
AB		EQ 3MG BASE	A077852	005	May 05, 2008
AB		EQ 4MG BASE	A077852	006	May 05, 2008
AB		EQ 5MG BASE	A077852	007	May 19, 2008
AB	TEVA	EQ 0.25MG BASE	A077460	001	May 05, 2008
AB		EQ 0.5MG BASE	A077460	002	May 05, 2008
AB		EQ 1MG BASE	A077460	003	May 05, 2008
AB		EQ 2MG BASE	A077460	004	May 05, 2008
AB		EQ 3MG BASE	A077460	005	May 05, 2008
AB		EQ 4MG BASE	A077460	006	May 05, 2008
AB		EQ 5MG BASE	A077460	007	May 19, 2008
AB	WOCKHARDT	EQ 0.25MG BASE	A079050	001	May 29, 2008
AB		EQ 0.5MG BASE	A079050	002	May 29, 2008
AB		EQ 1MG BASE	A079050	003	May 29, 2008
AB		EQ 2MG BASE	A079050	004	May 29, 2008
AB		EQ 3MG BASE	A079050	005	May 29, 2008
AB		EQ 4MG BASE	A079050	006	May 29, 2008
AB		EQ 5MG BASE	A079050	007	May 29, 2008
AB	ZYDUS PHARMS USA INC	EQ 0.25MG BASE	A090411	001	Jun 01, 2009
AB		EQ 0.5MG BASE	A090411	002	Jun 01, 2009
AB		EQ 1MG BASE	A090411	003	Jun 01, 2009
AB		EQ 2MG BASE	A090411	004	Jun 01, 2009
AB		EQ 3MG BASE	A090411	005	Jun 01, 2009
AB		EQ 4MG BASE	A090411	006	Jun 01, 2009
AB		EQ 5MG BASE	A090411	007	Jun 01, 2009

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

AB	+ SMITHKLINE BEECHAM	EQ 2MG BASE	N022008	001	Jun 13, 2008
AB		EQ 4MG BASE	N022008	003	Jun 13, 2008
AB		EQ 6MG BASE	N022008	006	Apr 10, 2009
AB		EQ 8MG BASE	N022008	004	Jun 13, 2008
AB		EQ 12MG BASE	N022008	005	Oct 31, 2008

ROPINIROLE HYDROCHLORIDE

AB	ACTAVIS	EQ 2MG BASE	A090869	001	May 17, 2012
AB		EQ 4MG BASE	A090869	002	May 17, 2012
AB		EQ 6MG BASE	A090869	003	May 17, 2012
AB		EQ 8MG BASE	A090869	004	May 17, 2012
AB		EQ 12MG BASE	A090869	005	May 17, 2012
AB	DR REDDYS LABS LTD	EQ 2MG BASE	A201576	001	Jun 06, 2012
AB		EQ 4MG BASE	A201576	002	Jun 06, 2012
AB		EQ 6MG BASE	A201576	003	Jun 06, 2012
AB		EQ 8MG BASE	A201576	004	Jun 06, 2012
AB		EQ 12MG BASE	A201576	005	Jun 06, 2012
AB	MYLAN PHARMS INC	EQ 2MG BASE	A200462	001	Oct 15, 2012
AB		EQ 4MG BASE	A200462	003	Oct 15, 2012
AB		EQ 6MG BASE	A200462	004	Oct 15, 2012
AB		EQ 8MG BASE	A200462	005	Oct 15, 2012
AB		EQ 12MG BASE	A200462	006	Oct 15, 2012
AB	SANDOZ INC	EQ 2MG BASE	A201047	001	Jun 06, 2012
AB		EQ 4MG BASE	A201047	003	Jun 06, 2012
AB		EQ 6MG BASE	A201047	004	Jun 06, 2012
AB		EQ 8MG BASE	A201047	005	Jun 06, 2012
AB		EQ 12MG BASE	A201047	006	Jun 06, 2012
AB	WATSON LABS INC	EQ 2MG BASE	A200431	001	Jun 06, 2012
AB		EQ 4MG BASE	A200431	002	Jun 06, 2012
AB		EQ 6MG BASE	A200431	003	Jun 06, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 371 (of 428)

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ROPINIROLE HYDROCHLORIDE

<u>AB</u>	WATSON LABS INC	<u>EQ 8MG BASE</u>	<u>A200431</u>	<u>004</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A200431</u>	<u>005</u>	Jun 06, 2012
<u>AB</u>	WOCKHARDT LTD	<u>EQ 2MG BASE</u>	<u>A091395</u>	<u>001</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A091395</u>	<u>002</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A091395</u>	<u>003</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A091395</u>	<u>004</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A091395</u>	<u>005</u>	Aug 27, 2012
	ROPINIROLE HYDROCHLORIDE				
	MYLAN PHARMS INC	EQ 3MG BASE	A200462	002	Oct 15, 2012

ROIIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NAROPIN

	FRESENIUS KABI USA	2MG/ML	N020533	001	Sep 24, 1996
		5MG/ML	N020533	003	Sep 24, 1996
		7.5MG/ML	N020533	004	Sep 24, 1996
+		10MG/ML	N020533	005	Sep 24, 1996

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

	SB PHARMC0	EQ 2MG BASE	N021071	002	May 25, 1999
		EQ 4MG BASE	N021071	003	May 25, 1999
+		EQ 8MG BASE	N021071	004	May 25, 1999

ROSUVASTATIN CALCIUM

TABLET; ORAL

CRESTOR

	IPR	5MG	N021366	002	Aug 12, 2003
		10MG	N021366	003	Aug 12, 2003
		20MG	N021366	004	Aug 12, 2003
+		40MG	N021366	005	Aug 12, 2003

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

	UCB INC	1MG/24HR	N021829	004	Apr 02, 2012
		2MG/24HR	N021829	001	May 09, 2007
		3MG/24HR	N021829	005	Apr 02, 2012
		4MG/24HR	N021829	002	May 09, 2007
		6MG/24HR	N021829	003	May 09, 2007
+		8MG/24HR	N021829	006	Apr 02, 2012

RUBIDIUM CHLORIDE RB-82

INJECTABLE; INJECTION

CARDIOGEN-82

	BRACCO	N/A	N019414	001	Dec 29, 1989

RUFINAMIDE

SUSPENSION; ORAL

BANZEL

+	EISAI INC	40MG/ML	N201367	001	Mar 03, 2011

TABLET; ORAL

BANZEL

	EISAI INC	200MG	N021911	002	Nov 14, 2008
+		400MG	N021911	003	Nov 14, 2008

PRESCRIPTION DRUG PRODUCT LIST

3 - 372 (of 428)

RUXOLITINIB PHOSPHATE

TABLET; ORAL
JAKAFI

INCYTE CORP	EQ 5MG BASE	N202192	001	Nov 16, 2011
	EQ 10MG BASE	N202192	002	Nov 16, 2011
	EQ 15MG BASE	N202192	003	Nov 16, 2011
	EQ 20MG BASE	N202192	004	Nov 16, 2011
+	EQ 25MG BASE	N202192	005	Nov 16, 2011

SACROSIDASE

SOLUTION; ORAL
SUCRAID

+ QOL MEDCL	8,500 IU/ML	N020772	001	Apr 09, 1998

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION
LIPOSYN II 10%

+ HOSPIRA	5%;5% (5GM/100ML)	N018997	001	Aug 27, 1984

+ HOSPIRA	10%;10% (10GM/100ML)	N018991	001	Aug 27, 1984

SALMETEROL XINAFOATE

POWDER; INHALATION
SEREVENT

+ GLAXO GRP LTD	EQ 0.05MG BASE/INH	N020692	001	Sep 19, 1997

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION
QUADRAMET

+ JAZZ EUSA PHARMA	50mCi/ML	N020570	001	Mar 28, 1997

SAPROPTERIN DIHYDROCHLORIDE

TABLET; ORAL
KUVAN

+ BIOMARIN PHARM	100MG	N022181	001	Dec 13, 2007

SAQUINAVIR MESYLATE

CAPSULE; ORAL
INVIRASE

+ HOFFMANN LA ROCHE	EQ 200MG BASE	N020628	001	Dec 06, 1995

TABLET; ORAL
INVIRASE

+ ROCHE	EQ 500MG BASE	N021785	001	Dec 17, 2004

SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL
ONGLYZA

BRISTOL MYERS SQUIBB	EQ 2.5MG BASE	N022350	001	Jul 31, 2009

+	EQ 5MG BASE	N022350	002	Jul 31, 2009

SCOPOLAMINE

FILM, EXTENDED RELEASE; TRANSDERMAL
TRANSDERM SCOP

+ NOVARTIS	1MG/72HR	N017874	001	

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECONAL SODIUM

+ MARATHON PHARMS	50MG	A086101	001	Oct 03, 1983

+	100MG	A086101	002	Oct 03, 1983

PRESCRIPTION DRUG PRODUCT LIST

3 - 373 (of 428)

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION; INTRAVENOUS
CHIRHOSTIM

+ CHIRHOCLIN	16MCG/VIAL	N021256	001	Apr 09, 2004
	40MCG/VIAL	N021256	002	Jun 21, 2007

SELEGILINE

FILM, EXTENDED RELEASE; TRANSDERMAL
EMSAM

+ SOMERSET	6MG/24HR	N021336	001	Feb 27, 2006
	9MG/24HR	N021336	002	Feb 27, 2006
	12MG/24HR	N021336	003	Feb 27, 2006

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

ELDEPRYL

<u>AB</u> + SOMERSET	<u>5MG</u>	<u>N020647</u>	<u>001</u>	May 15, 1996

SELEGILINE HYDROCHLORIDE

<u>AB</u> APOTEX	<u>5MG</u>	<u>A075321</u>	<u>001</u>	Dec 04, 1998
<u>AB</u> DAVA PHARMS INC	<u>5MG</u>	<u>A075352</u>	<u>001</u>	Nov 30, 1998

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

<u>AB</u> + APOTEX INC	<u>5MG</u>	<u>A074871</u>	<u>001</u>	Jun 06, 1997
<u>AB</u> DAVA PHARMS INC	<u>5MG</u>	<u>A074641</u>	<u>001</u>	Aug 02, 1996
<u>AB</u> MYLAN	<u>5MG</u>	<u>A074866</u>	<u>001</u>	Nov 26, 1997
<u>AB</u> STASON	<u>5MG</u>	<u>A074912</u>	<u>001</u>	Apr 30, 1998

TABLET, ORALLY DISINTEGRATING; ORAL
ZELAPAR

+ VALEANT PHARM INTL	1.25MG	N021479	001	Jun 14, 2006

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELENIUM SULFIDE

<u>AT</u> PERRIGO NEW YORK	<u>2.5%</u>	<u>A089996</u>	<u>001</u>	Jan 10, 1991
<u>AT</u> WOCKHARDT	<u>2.5%</u>	<u>A088228</u>	<u>001</u>	Sep 01, 1983

SELSUN

<u>AT</u> + CHATTEM	<u>2.5%</u>	<u>N007936</u>	<u>001</u>	

SERTACONAZOLE NITRATE

CREAM; TOPICAL
ERTACZO

+ VALEANT INTL	2%	N021385	001	Dec 10, 2003

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

<u>AA</u> AUROBINDO PHARMA	<u>EQ 20MG BASE/ML</u>	<u>A078861</u>	<u>001</u>	Oct 31, 2008

ZOLOFT

<u>AA</u> + PFIZER	<u>EQ 20MG BASE/ML</u>	<u>N020990</u>	<u>001</u>	Dec 07, 1999

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

<u>AB</u> APOTEX INC	<u>EQ 25MG BASE</u>	<u>A076882</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>	<u>EQ 50MG BASE</u>	<u>A076882</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>	<u>EQ 100MG BASE</u>	<u>A076882</u>	<u>003</u>	Feb 06, 2007
<u>AB</u> AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A077206</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>	<u>EQ 50MG BASE</u>	<u>A077206</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>	<u>EQ 100MG BASE</u>	<u>A077206</u>	<u>003</u>	Feb 06, 2007
<u>AB</u> AUSTARPHARMA LLC	<u>EQ 25MG BASE</u>	<u>A078677</u>	<u>001</u>	Mar 04, 2009
<u>AB</u>	<u>EQ 50MG BASE</u>	<u>A078677</u>	<u>002</u>	Mar 04, 2009
<u>AB</u>	<u>EQ 100MG BASE</u>	<u>A078677</u>	<u>003</u>	Mar 04, 2009
<u>AB</u> DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A076442</u>	<u>001</u>	Apr 30, 2007
<u>AB</u>	<u>EQ 50MG BASE</u>	<u>A076442</u>	<u>002</u>	Apr 30, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 374 (of 428)

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 100MG BASE</u>	<u>A076442</u>	<u>003</u>	Apr 30, 2007
<u>AB</u>	HIKMA PHARMS	<u>EQ 25MG BASE</u>	<u>A077864</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077864</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077864</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>	INVAGEN PHARMS	<u>EQ 25MG BASE</u>	<u>A077397</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077397</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077397</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	LUPIN	<u>EQ 25MG BASE</u>	<u>A077670</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077670</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077670</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A076671</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076671</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076671</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 25MG BASE</u>	<u>A078626</u>	<u>001</u>	Jan 31, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078626</u>	<u>002</u>	Jan 31, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078626</u>	<u>003</u>	Jan 31, 2008
<u>AB</u>	PROSAM LABS	<u>EQ 25MG BASE</u>	<u>A078175</u>	<u>001</u>	Jul 21, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078175</u>	<u>002</u>	Jul 21, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078175</u>	<u>003</u>	Jul 21, 2010
<u>AB</u>	RANBAXY	<u>EQ 25MG BASE</u>	<u>A077977</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077977</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077977</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 25MG BASE</u>	<u>A078108</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078108</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078108</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076465</u>	<u>001</u>	Aug 11, 2006
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076465</u>	<u>002</u>	Aug 11, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076465</u>	<u>003</u>	Aug 11, 2006
<u>AB</u>	TORRENT PHARMS	<u>EQ 25MG BASE</u>	<u>A077765</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077765</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077765</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	WATSON LABS	<u>EQ 25MG BASE</u>	<u>A077663</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077663</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077663</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	WOCKHARDT	<u>EQ 25MG BASE</u>	<u>A078403</u>	<u>001</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078403</u>	<u>002</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078403</u>	<u>003</u>	Jan 08, 2008
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 25MG BASE</u>	<u>A077106</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077106</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077106</u>	<u>003</u>	Feb 06, 2007
	<u>ZOLOFT</u>				
<u>AB</u>	PFIZER	<u>EQ 25MG BASE</u>	<u>N019839</u>	<u>005</u>	Mar 06, 1996
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N019839</u>	<u>001</u>	Dec 30, 1991
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N019839</u>	<u>002</u>	Dec 30, 1991
	SERTRALINE HYDROCHLORIDE				
	RANBAXY	EQ 150MG BASE	A077977	004	Feb 06, 2007
		EQ 200MG BASE	A077977	005	Feb 06, 2007

SEVELAMER CARBONATE

FOR SUSPENSION; ORAL

RENVELA

GENZYME

800MG/PACKET

N022318

001

Aug 12, 2009

+

2.4GM/PACKET

N022318

002

Feb 18, 2009

TABLET; ORAL

RENVELA

+ GENZYME

800MG

N022127

001

Oct 19, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 375 (of 428)

SEVELAMER HYDROCHLORIDETABLET; ORAL
RENAGEL

GENZYME	400MG	N021179	001	Jul 12, 2000
+	800MG	N021179	002	Jul 12, 2000

SEVOFLURANE

LIQUID; INHALATION

SEVOFLURANE

<u>AN</u>	BAXTER HLTHCARE	<u>100%</u>	<u>A075895</u>	<u>001</u>	Jul 02, 2002
<u>AN</u>	HALOCARBON PRODS	<u>100%</u>	<u>A078650</u>	<u>001</u>	Nov 19, 2007

SOJOURN

<u>AN</u>	PIRAMAL CRITICAL	<u>100%</u>	<u>A077867</u>	<u>001</u>	May 02, 2007

ULTANE

<u>AN</u>	+ ABBVIE	<u>100%</u>	<u>N020478</u>	<u>001</u>	Jun 07, 1995

SILDENAFIL CITRATEFOR SUSPENSION; ORAL
REVATIO

+	PFIZER	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012

SOLUTION; INTRAVENOUS
REVATIO

+	PFIZER	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009

TABLET; ORAL

REVATIO

<u>AB</u>	+	PFIZER	<u>EQ 20MG BASE</u>	<u>N021845</u>	<u>001</u>	Jun 03, 2005

SILDENAFIL CITRATE

<u>AB</u>	APOTEX CORP	<u>EQ 20MG BASE</u>	<u>A091379</u>	<u>001</u>	Nov 06, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 20MG BASE</u>	<u>A202598</u>	<u>001</u>	Nov 06, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A201150</u>	<u>001</u>	Nov 09, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A078380</u>	<u>001</u>	Jan 07, 2013
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A091479</u>	<u>001</u>	Nov 06, 2012
<u>AB</u>	WATSON LABS INC	<u>EQ 20MG BASE</u>	<u>A202503</u>	<u>001</u>	Nov 06, 2012

VIAGRA

PFIZER IRELAND	EQ 25MG BASE	N020895	001	Mar 27, 1998
	EQ 50MG BASE	N020895	002	Mar 27, 1998
+	EQ 100MG BASE	N020895	003	Mar 27, 1998

SILODOSINCAPSULE; ORAL
RAPAFLO

+	WATSON LABS	4MG	N022206	001	Oct 08, 2008
		8MG	N022206	002	Oct 08, 2008

SILVER SULFADIAZINE

CREAM; TOPICAL

SILVADENE

<u>AB</u>	+	KING PHARMS	<u>1%</u>	<u>N017381</u>	<u>001</u>

SSD

<u>AB</u>	DR REDDYS LA	<u>1%</u>	<u>N018578</u>	<u>001</u>	Feb 25, 1982

THERMAZENE

<u>AB</u>	THEPHARMANETWORK LLC	<u>1%</u>	<u>N018810</u>	<u>001</u>	Dec 23, 1985

SSD AF

BX	DR REDDYS LA	1%	N018578	003	Jul 11, 1990

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

<u>AB</u>	ACCORD HLTHCARE	<u>10MG</u>	<u>A078155</u>	<u>002</u>	Feb 26, 2008
<u>AB</u>		<u>20MG</u>	<u>A078155</u>	<u>003</u>	Feb 26, 2008
<u>AB</u>		<u>40MG</u>	<u>A078155</u>	<u>004</u>	Feb 26, 2008
<u>AB</u>		<u>80MG</u>	<u>A078155</u>	<u>001</u>	Feb 26, 2008

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 376 (of 428)

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A077691</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A077691</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077691</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077691</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077691</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	BLU CARIBE	<u>5MG</u>	<u>A078034</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A078034</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A078034</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A078034</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A078034</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	DR REDDYS LABS INC	<u>5MG</u>	<u>A077752</u>	<u>005</u>	Jan 23, 2008
<u>AB</u>		<u>10MG</u>	<u>A077752</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077752</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077752</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077752</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG</u>	<u>A076052</u>	<u>001</u>	Jun 23, 2006
<u>AB</u>		<u>10MG</u>	<u>A076052</u>	<u>002</u>	Jun 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076052</u>	<u>003</u>	Jun 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076052</u>	<u>004</u>	Jun 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076052</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	LUPIN	<u>5MG</u>	<u>A078103</u>	<u>005</u>	Apr 14, 2009
<u>AB</u>		<u>10MG</u>	<u>A078103</u>	<u>001</u>	May 11, 2007
<u>AB</u>		<u>20MG</u>	<u>A078103</u>	<u>002</u>	May 11, 2007
<u>AB</u>		<u>40MG</u>	<u>A078103</u>	<u>003</u>	May 11, 2007
<u>AB</u>		<u>80MG</u>	<u>A078103</u>	<u>004</u>	May 11, 2007
<u>AB</u>	MICRO LABS LTD	<u>5MG</u>	<u>A090383</u>	<u>001</u>	Sep 16, 2011
<u>AB</u>		<u>10MG</u>	<u>A090383</u>	<u>002</u>	Sep 16, 2011
<u>AB</u>		<u>20MG</u>	<u>A090383</u>	<u>003</u>	Sep 16, 2011
<u>AB</u>		<u>40MG</u>	<u>A090383</u>	<u>004</u>	Sep 16, 2011
<u>AB</u>		<u>80MG</u>	<u>A090383</u>	<u>005</u>	Sep 16, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A090868</u>	<u>001</u>	Jun 08, 2010
<u>AB</u>		<u>10MG</u>	<u>A090868</u>	<u>002</u>	Jun 08, 2010
<u>AB</u>		<u>20MG</u>	<u>A090868</u>	<u>003</u>	Jun 08, 2010
<u>AB</u>		<u>40MG</u>	<u>A090868</u>	<u>004</u>	Jun 08, 2010
<u>AB</u>		<u>80MG</u>	<u>A090868</u>	<u>005</u>	Jun 08, 2010
<u>AB</u>	PROSAM LABS	<u>5MG</u>	<u>A078735</u>	<u>001</u>	Aug 30, 2010
<u>AB</u>		<u>10MG</u>	<u>A078735</u>	<u>002</u>	Aug 30, 2010
<u>AB</u>		<u>20MG</u>	<u>A078735</u>	<u>003</u>	Aug 30, 2010
<u>AB</u>		<u>40MG</u>	<u>A078735</u>	<u>004</u>	Aug 30, 2010
<u>AB</u>		<u>80MG</u>	<u>A078735</u>	<u>005</u>	Aug 30, 2010
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A076285</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A076285</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A076285</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A076285</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A076285</u>	<u>005</u>	Jun 23, 2006
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A076685</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A076685</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A076685</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A076685</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A076685</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A077837</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A077837</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077837</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077837</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077837</u>	<u>005</u>	Dec 20, 2006
<u>ZOCOR</u>					
<u>AB</u>	MERCK	<u>5MG</u>	<u>N019766</u>	<u>001</u>	Dec 23, 1991
<u>AB</u>		<u>10MG</u>	<u>N019766</u>	<u>002</u>	Dec 23, 1991

PRESCRIPTION DRUG PRODUCT LIST

3 - 377 (of 428)

SIMVASTATIN

TABLET; ORAL					
ZOCOR					
<u>AB</u>	MERCK	<u>20MG</u>	<u>N019766</u>	<u>003</u>	Dec 23, 1991
<u>AB</u>		<u>40MG</u>	<u>N019766</u>	<u>004</u>	Dec 23, 1991
<u>AB</u>	+	<u>80MG</u>	<u>N019766</u>	<u>005</u>	Jul 10, 1998

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL					
JUVISYNC					
	MERCK SHARP DOHME	10MG;EQ 50MG BASE	N202343	004	Sep 18, 2012
		10MG;EQ 100MG BASE	N202343	001	Oct 07, 2011
		20MG;EQ 50MG BASE	N202343	005	Sep 18, 2012
		20MG;EQ 100MG BASE	N202343	002	Oct 07, 2011
		40MG;EQ 50MG BASE	N202343	006	Sep 18, 2012
	+	40MG;EQ 100MG BASE	N202343	003	Oct 07, 2011

SINCALIDE

INJECTABLE; INJECTION					
KINEVAC					
	+ BRACCO	0.005MG/VIAL	N017697	001	

SINECATECHINS

OINTMENT; TOPICAL					
VEREGEN					
	+ MEDIGENE AG	15%	N021902	001	Oct 31, 2006

SIROLIMUS

SOLUTION; ORAL					
RAPAMUNE					
	+ WYETH PHARMS INC	1MG/ML	N021083	001	Sep 15, 1999
TABLET; ORAL					
RAPAMUNE					
	WYETH PHARMS INC	0.5MG	N021110	004	Jan 25, 2010
		1MG	N021110	001	Aug 25, 2000
	+	2MG	N021110	002	Aug 22, 2002

SITAGLIPTIN PHOSPHATE

TABLET; ORAL					
JANUVIA					
	MERCK SHARP DOHME	EQ 25MG BASE	N021995	001	Oct 16, 2006
		EQ 50MG BASE	N021995	002	Oct 16, 2006
	+	EQ 100MG BASE	N021995	003	Oct 16, 2006

SODIUM ACETATE ANHYDROUS

INJECTABLE; INJECTION					
SODIUM ACETATE IN PLASTIC CONTAINER					
	+ HOSPIRA	2MEQ/ML	N018893	001	May 04, 1983

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; IV (INFUSION)					
	+ UCYCLYD	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005

SODIUM BICARBONATE

INJECTABLE; INJECTION					
SODIUM BICARBONATE					
	+ HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09, 2005
	+	1MEQ/ML	A077394	002	Nov 09, 2005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 378 (of 428)

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	FRESENIUS KABI USA	<u>9MG/ML</u>	<u>A088911</u>	<u>001</u>	Feb 07, 1985

<u>AP</u>	+	HOSPIRA	<u>9MG/ML</u>	<u>N018800</u>	<u>001</u>	Oct 29, 1982

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>450MG/100ML</u>	<u>N019635</u>	<u>001</u>	Mar 09, 1988

<u>AP</u>	BAXTER HLTHCARE	<u>450MG/100ML</u>	<u>N018016</u>	<u>001</u>	

<u>AP</u>	HOSPIRA	<u>450MG/100ML</u>	<u>N018090</u>	<u>001</u>	

<u>AP</u>		<u>450MG/100ML</u>	<u>N019759</u>	<u>001</u>	Jun 08, 1988

SODIUM CHLORIDE 0.9%

<u>AP</u>	HIKMA (MAPLE)	<u>9MG/ML</u>	<u>A201850</u>	<u>001</u>	Jan 20, 2012

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>900MG/100ML</u>	<u>N017464</u>	<u>001</u>	

<u>AP</u>	+		<u>900MG/100ML</u>	<u>N019635</u>	<u>002</u>	Mar 09, 1988

<u>AP</u>	+	BAXTER HLTHCARE	<u>9MG/ML</u>	<u>N016677</u>	<u>004</u>	Oct 30, 1985

<u>AP</u>			<u>9MG/ML</u>	<u>N020178</u>	<u>002</u>	Dec 07, 1992

<u>AP</u>	+		<u>900MG/100ML</u>	<u>N016677</u>	<u>001</u>	

<u>AP</u>	+		<u>900MG/100ML</u>	<u>N020178</u>	<u>001</u>	Dec 07, 1992

<u>AP</u>	+	FRESENIUS KABI USA	<u>9MG/ML</u>	<u>A088912</u>	<u>001</u>	Jan 10, 1985

<u>AP</u>		FRESENIUS MEDCL	<u>900MG/100ML</u>	<u>A078177</u>	<u>001</u>	Apr 12, 2007

<u>AP</u>		HAEMONETICS	<u>900MG/100ML</u>	<u>A076316</u>	<u>001</u>	Oct 27, 2004

<u>AP</u>	+	HOSPIRA	<u>9MG/ML</u>	<u>N018803</u>	<u>001</u>	Oct 29, 1982

<u>AP</u>	+		<u>9MG/ML</u>	<u>N019217</u>	<u>001</u>	Jul 13, 1984

<u>AP</u>			<u>9MG/ML</u>	<u>N019465</u>	<u>002</u>	Jul 15, 1985

<u>AP</u>	+		<u>900MG/100ML</u>	<u>N016366</u>	<u>001</u>	

<u>AP</u>	+		<u>900MG/100ML</u>	<u>N019465</u>	<u>001</u>	Jul 15, 1985

<u>AP</u>	+		<u>900MG/100ML</u>	<u>N019480</u>	<u>001</u>	Sep 17, 1985

<u>AP</u>	+	TARO PHARMS IRELAND	<u>9MG/ML</u>	<u>A077407</u>	<u>001</u>	Aug 11, 2006

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	+	MALLINCKRODT	45MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006

			112.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006

		MEDEFIL	9MG/ML	N202832	001	Jan 06, 2012

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

		BAXTER HLTHCARE	3GM/100ML	N019022	001	Nov 01, 1983

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

		BAXTER HLTHCARE	5GM/100ML	N019022	002	Nov 01, 1983

SODIUM CHLORIDE IN PLASTIC CONTAINER

		HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984

SOLUTION FOR SLUSH; IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

		BAXTER HLTHCARE	900MG/100ML	N019319	002	May 17, 1985

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AT</u>		BAXTER HLTHCARE	<u>450MG/100ML</u>	<u>N017864</u>	<u>001</u>	

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AT</u>		B BRAUN	<u>900MG/100ML</u>	<u>N016733</u>	<u>001</u>	

<u>AT</u>		BAXTER HLTHCARE	<u>900MG/100ML</u>	<u>N017427</u>	<u>001</u>	

<u>AT</u>			<u>900MG/100ML</u>	<u>N017867</u>	<u>001</u>	

<u>AT</u>		HOSPIRA	<u>900MG/100ML</u>	<u>N017514</u>	<u>001</u>	

<u>AT</u>			<u>900MG/100ML</u>	<u>N018314</u>	<u>001</u>	

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

<u>AB</u>	+	SANOFI AVENTIS US	<u>62.5MG/5ML</u>	<u>N020955</u>	<u>001</u>	Feb 18, 1999

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

<u>AB</u>		HIKMA PHARMS	<u>62.5MG/5ML</u>	<u>A078215</u>	<u>001</u>	Mar 31, 2011

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 379 (of 428)

SODIUM FLUORIDE F-18INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F-18

+ HOUSTON CYCLOTRON 10-200mCi/ML A203544 001 Dec 26, 2012

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123AA + CARDINAL HLTH 414 100uCi N018671 001 May 27, 1982AA + 200uCi N018671 002 May 27, 1982AA MALLINCKRODT 100uCi A071909 001 Feb 28, 1989AA 200uCi A071910 001 Feb 28, 1989

SODIUM IODIDE I 123

+ CARDINAL HLTH 414 400uCi N018671 003 May 27, 1982

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I 131

+ MALLINCKRODT 0.8-100mCi N016517 001

SODIUM IODIDE I-131

JUBILANT DRAXIMAGE 9-100mCi N021305 006 May 19, 2005

SOLUTION; ORAL

HICON

+ JUBILANT DRAXIMAGE 250-1000mCi N021305 007 Dec 05, 2011

SODIUM IODIDE I 131

+ MALLINCKRODT 3.5-150mCi/VIAL N016515 001

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINERAP BAXTER HLTHCARE 1.87GM/100ML N016692 001SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINERAP B BRAUN 1.87GM/100ML N020004 001 Apr 21, 1992

SODIUM LACTATE IN PLASTIC CONTAINER

+ HOSPIRA 5MEQ/ML N018947 001 Sep 05, 1984

SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+ HOPE PHARMS 300MG/10ML (30MG/ML) N203922 001 Feb 14, 2012

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS

NITHIODOTE

+ HOPE PHARMS 300MG/10ML (30MG/ML), N/A; N/A, 12.5GM/50ML (250MG/ML) N201444 001 Jan 14, 2011

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NITROPRESS

+ HOSPIRA 25MG/ML A071961 001 Aug 01, 1988

SODIUM OXYBATE

SOLUTION; ORAL

XYREM

+ JAZZ PHARMS 500MG/ML N021196 001 Jul 17, 2002

SODIUM PHENYLBUTYRATE

POWDER; ORAL

BUPHENYL

+ MEDICIS 3GM/TEASPOONFUL N020573 001 Apr 30, 1996

PRESCRIPTION DRUG PRODUCT LIST

3 - 380 (of 428)

SODIUM PHENYLBUTYRATE

TABLET; ORAL					
<u>BUPHENYL</u>					
<u>AB</u>	+	MEDICIS	<u>500MG</u>	<u>N020572</u>	<u>001</u> May 13, 1996
<u>SODIUM PHENYLBUTYRATE</u>					
<u>AB</u>		AMPOLGEN	<u>500MG</u>	<u>A090910</u>	<u>001</u> Nov 18, 2011

SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL					
VISICOL					
	+	SALIX PHARMS	0.398GM;1.102GM	N021097	001 Sep 21, 2000

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL					
<u>MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE</u>					
<u>AB</u>		NOVEL LABS INC	<u>0.398GM;1.102GM</u>	<u>A079247</u>	<u>001</u> Dec 30, 2011
<u>OSMOPREP</u>					
<u>AB</u>	+	SALIX PHARMS	<u>0.398GM;1.102GM</u>	<u>N021892</u>	<u>001</u> Mar 16, 2006

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION					
SODIUM PHOSPHATES IN PLASTIC CONTAINER					
		HOSPIRA	142MG/ML;276MG/ML	N018892	001 May 10, 1983

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL					
<u>KALEXATE</u>					
<u>AA</u>		KVK TECH	<u>454GM/BOT</u>	<u>A040905</u>	<u>001</u> Mar 30, 2009
<u>KAYEXALATE</u>					
<u>AA</u>	+	SANOFI AVENTIS US	<u>453.6GM/BOT</u>	<u>N011287</u>	<u>001</u>
<u>KIONEX</u>					
<u>AA</u>		PADDOCK LLC	<u>454GM/BOT</u>	<u>A040029</u>	<u>001</u> Feb 06, 1998
<u>SODIUM POLYSTYRENE SULFONATE</u>					
<u>AA</u>		CAROLINA MEDCL	<u>454GM/BOT</u>	<u>A089910</u>	<u>001</u> Jan 19, 1989
<u>AA</u>		CEDAR PHARMS	<u>453.6GM/BOT</u>	<u>A090313</u>	<u>001</u> Dec 21, 2011
SUSPENSION; ORAL, RECTAL					
<u>KIONEX</u>					
<u>AA</u>		PADDOCK LLC	<u>15GM/60ML</u>	<u>A040028</u>	<u>001</u> Sep 17, 2007
<u>SODIUM POLYSTYRENE SULFONATE</u>					
<u>AA</u>		PADDOCK LLC	<u>15GM/60ML</u>	<u>A090590</u>	<u>001</u> May 13, 2011
<u>AA</u>		ROXANE	<u>15GM/60ML</u>	<u>A089049</u>	<u>001</u> Nov 17, 1986
<u>SPS</u>					
<u>AA</u>	+	CAROLINA MEDCL	<u>15GM/60ML</u>	<u>A087859</u>	<u>001</u> Dec 08, 1982

SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION					
SOTRADECOL					
		BIONICHE PHARMA	20MG/2ML (10MG/ML)	A040541	001 Nov 12, 2004
	+		60MG/2ML (30MG/ML)	A040541	002 Nov 12, 2004

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS					
SODIUM THIOSULFATE					
	+	HOPE PHARMS	12.5GM/50ML (250MG/ML)	N203923	001 Feb 14, 2012

SOLIFENACIN SUCCINATE

TABLET; ORAL					
VESICARE					
		ASTELLAS	5MG	N021518	001 Nov 19, 2004
	+		10MG	N021518	002 Nov 19, 2004

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 381 (of 428)

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION					
GENOTROPIN					
BX	+ PHARMACIA AND UPJOHN	5.8MG/VIAL	N020280	006	Aug 24, 1995
GENOTROPIN PRESERVATIVE FREE					
BX	PHARMACIA AND UPJOHN	1.5MG/VIAL	N020280	004	Aug 24, 1995
HUMATROPE					
BX	+ LILLY	5MG/VIAL	N019640	004	Mar 08, 1987
BX		6MG/VIAL	N019640	005	Feb 04, 1999
NORDITROPIN FLEXPRO					
BX	NOVO NORDISK INC	5MG/1.5ML	N021148	008	Mar 01, 2010
BX		10MG/1.5ML	N021148	009	Mar 01, 2010
NUTROPIN					
BX	GENENTECH	5MG/VIAL	N020168	001	Nov 17, 1993
OMNITROPE					
BX	SANDOZ	1.5MG/VIAL	N021426	002	May 30, 2006
BX		5MG/1.5ML	N021426	003	Jan 16, 2008
BX		5.8MG/VIAL	N021426	001	May 30, 2006
BX		10MG/1.5ML	N021426	004	Aug 25, 2008
SAIZEN					
BX	EMD SERONO	5MG/VIAL	N019764	002	Oct 08, 1996
SEROSTIM					
BX	EMD SERONO	4MG/VIAL	N020604	003	Jul 25, 1997
BX		5MG/VIAL	N020604	002	Aug 23, 1996
BX		6MG/VIAL	N020604	001	Aug 23, 1996
TEV-TROPIN					
BX	+ FERRING	5MG/VIAL	N019774	002	Jan 04, 2002
VALTROPIN					
BX	LG LIFE	5MG/VIAL	N021905	001	Apr 19, 2007
GENOTROPIN					
	+ PHARMACIA AND UPJOHN	13.8MG/VIAL	N020280	007	Oct 23, 1996
GENOTROPIN PRESERVATIVE FREE					
	PHARMACIA AND UPJOHN	0.2MG/VIAL	N020280	001	Jan 27, 1998
		0.4MG/VIAL	N020280	002	Jan 27, 1998
		0.6MG/VIAL	N020280	003	Jan 27, 1998
		0.8MG/VIAL	N020280	005	Jan 27, 1998
		1MG/VIAL	N020280	008	Jan 27, 1998
		1.2MG/VIAL	N020280	009	Jan 27, 1998
		1.4MG/VIAL	N020280	010	Jan 27, 1998
		1.6MG/VIAL	N020280	011	Jan 27, 1998
		1.8MG/VIAL	N020280	012	Jan 27, 1998
		2MG/VIAL	N020280	013	Jan 27, 1998
HUMATROPE					
	+ LILLY	12MG/VIAL	N019640	006	Feb 04, 1999
	+	24MG/VIAL	N019640	007	Feb 04, 1999
NORDITROPIN FLEXPRO					
	NOVO NORDISK INC	15MG/1.5ML	N021148	010	Mar 01, 2010
NORDITROPIN NORDIFLEX					
	NOVO NORDISK INC	30MG/3ML	N021148	007	Mar 10, 2009
NUTROPIN					
	+ GENENTECH	10MG/VIAL	N020168	002	Nov 17, 1993
NUTROPIN AQ					
	+ GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008
	+	10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995
	+	20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008
NUTROPIN AQ PEN					
	+ GENENTECH	10MG/2ML (5MG/ML)	N020522	002	Apr 22, 2002
SAIZEN					
	+ EMD SERONO	8.8MG/VIAL	N019764	003	Aug 29, 2000
ZORBTIVE					
	+ EMD SERONO	8.8MG/VIAL	N021597	004	Dec 01, 2003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 382 (of 428)

SORAFENIB TOSYLATETABLET; ORAL
NEXAVAR

+ BAYER HLTHCARE EQ 200MG BASE N021923 001 Dec 20, 2005

SORBITOL

SOLUTION; IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE 3GM/100ML N017863 001

SORBITOL 3.3% IN PLASTIC CONTAINER

B BRAUN 3.3GM/100ML N016741 001

SOTALOL HYDROCHLORIDE

SOLUTION; INTRAVENOUS

SOTALOL HYDROCHLORIDE

+ ACADEMIC PHARMS 150MG/10ML (15MG/ML) N022306 001 Jul 02, 2009

TABLET; ORAL

BETAPACEAB1 BAYER HLTHCARE 80MG N019865 001 Oct 30, 1992AB1 120MG N019865 005 Apr 20, 1994AB1 + 160MG N019865 002 Oct 30, 1992AB1 240MG N019865 003 Oct 30, 1992SORINEAB1 UPSHER SMITH 80MG A075500 001 Apr 27, 2001AB1 120MG A075500 004 Apr 27, 2001AB1 160MG A075500 002 Apr 27, 2001AB1 240MG A075500 003 Apr 27, 2001SOTALOL HYDROCHLORIDEAB1 APOTEX INC 80MG A076140 001 Sep 26, 2002AB1 120MG A076140 002 Sep 26, 2002AB1 160MG A076140 003 Sep 26, 2002AB1 240MG A076140 004 Sep 26, 2002AB1 IMPAX PHARMS 80MG A075663 001 Nov 07, 2000AB1 120MG A075663 002 Nov 07, 2000AB1 160MG A075663 003 Nov 07, 2000AB1 240MG A075663 004 Nov 07, 2000AB1 MYLAN 80MG A075237 001 May 01, 2000AB1 80MG A075725 001 Dec 19, 2000AB1 120MG A075237 002 May 01, 2000AB1 120MG A075725 002 Dec 19, 2000AB1 160MG A075237 003 May 01, 2000AB1 160MG A075725 003 Dec 19, 2000AB1 240MG A075237 004 May 01, 2000AB1 240MG A075725 004 Dec 19, 2000AB1 SANDOZ 80MG A075366 001 May 01, 2000AB1 120MG A075366 002 May 01, 2000AB1 160MG A075366 003 May 01, 2000AB1 240MG A075366 004 May 01, 2000AB1 TEVA 80MG A075429 001 May 01, 2000AB1 120MG A075429 002 May 01, 2000AB1 160MG A075429 003 May 01, 2000AB1 240MG A075429 004 May 01, 2000AB1 VINTAGE PHARMS 80MG A075563 001 Nov 07, 2003AB1 120MG A075563 002 Nov 07, 2003AB1 160MG A075563 003 Nov 07, 2003AB1 240MG A075563 004 Nov 07, 2003BETAPACE AFAB2 BAYER HLTHCARE 80MG N021151 001 Feb 22, 2000AB2 120MG N021151 002 Feb 22, 2000AB2 + 160MG N021151 003 Feb 22, 2000

PRESCRIPTION DRUG PRODUCT LIST

3 - 383 (of 428)

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

<u>AB2</u>	APOTEX	<u>80MG</u>	<u>A076214</u>	<u>001</u>	Aug 27, 2003
<u>AB2</u>		<u>120MG</u>	<u>A076214</u>	<u>002</u>	Aug 27, 2003
<u>AB2</u>		<u>160MG</u>	<u>A076214</u>	<u>003</u>	Aug 27, 2003
<u>AB2</u>	EPIC PHARMA INC	<u>80MG</u>	<u>A077070</u>	<u>001</u>	Nov 04, 2005
<u>AB2</u>		<u>120MG</u>	<u>A077070</u>	<u>002</u>	Nov 04, 2005
<u>AB2</u>		<u>160MG</u>	<u>A077070</u>	<u>003</u>	Nov 04, 2005
<u>AB2</u>	MYLAN	<u>80MG</u>	<u>A077616</u>	<u>001</u>	Feb 07, 2007
<u>AB2</u>		<u>120MG</u>	<u>A077616</u>	<u>002</u>	Feb 07, 2007
<u>AB2</u>		<u>160MG</u>	<u>A077616</u>	<u>003</u>	Feb 07, 2007
<u>AB2</u>	TEVA	<u>80MG</u>	<u>A076883</u>	<u>001</u>	Jul 26, 2004
<u>AB2</u>		<u>120MG</u>	<u>A076883</u>	<u>002</u>	Jul 26, 2004
<u>AB2</u>		<u>160MG</u>	<u>A076883</u>	<u>003</u>	Jul 26, 2004

SOYBEAN OIL

INJECTABLE; INJECTION

INTRALIPID 10%

<u>AP</u>	+ FRESENIUS	<u>10%</u>	<u>N017643</u>	<u>001</u>	
	<u>INTRALIPID 20%</u>				
<u>AP</u>	+ FRESENIUS	<u>20%</u>	<u>N018449</u>	<u>001</u>	
<u>AP</u>		<u>20%</u>	<u>N020248</u>	<u>001</u>	Aug 07, 1996
	<u>INTRALIPID 30%</u>				
<u>AP</u>	+ FRESENIUS	<u>30%</u>	<u>N019942</u>	<u>001</u>	Dec 30, 1993
	<u>LIPOSYN III 10%</u>				
<u>AP</u>	+ HOSPIRA	<u>10%</u>	<u>N018969</u>	<u>001</u>	Sep 24, 1984
	<u>LIPOSYN III 20%</u>				
<u>AP</u>	+ HOSPIRA	<u>20%</u>	<u>N018970</u>	<u>001</u>	Sep 25, 1984
	<u>LIPOSYN III 30%</u>				
<u>AP</u>	+ HOSPIRA	<u>30%</u>	<u>N020181</u>	<u>001</u>	Jan 13, 1998
	<u>NUTRILIPID 10%</u>				
<u>AP</u>	+ B BRAUN	<u>10%</u>	<u>N019531</u>	<u>001</u>	May 28, 1993
	<u>NUTRILIPID 20%</u>				
<u>AP</u>	+ B BRAUN	<u>20%</u>	<u>N019531</u>	<u>002</u>	May 28, 1993

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+ PARAPRO LLC	0.9%	N022408	001	Jan 18, 2011

SPIRONOLACTONE

TABLET; ORAL

ALDACTONE

<u>AB</u>	GD SEARLE LLC	<u>25MG</u>	<u>N012151</u>	<u>009</u>	Dec 30, 1983
<u>AB</u>		<u>50MG</u>	<u>N012151</u>	<u>008</u>	Dec 30, 1982
<u>AB</u>		<u>100MG</u>	<u>N012151</u>	<u>010</u>	Dec 30, 1983
	<u>SPIRONOLACTONE</u>				
<u>AB</u>	ACTAVIS ELIZABETH	<u>25MG</u>	<u>A040353</u>	<u>003</u>	Mar 15, 2006
<u>AB</u>		<u>50MG</u>	<u>A040353</u>	<u>001</u>	Jul 29, 1999
<u>AB</u>		<u>100MG</u>	<u>A040353</u>	<u>002</u>	Jul 29, 1999
<u>AB</u>	AMNEAL PHARMS	<u>25MG</u>	<u>A091426</u>	<u>001</u>	Jun 08, 2010
<u>AB</u>		<u>50MG</u>	<u>A091426</u>	<u>002</u>	Jun 08, 2010
<u>AB</u>		<u>100MG</u>	<u>A091426</u>	<u>003</u>	Jun 08, 2010
<u>AB</u>	MUTUAL PHARM	<u>25MG</u>	<u>A089424</u>	<u>001</u>	Jul 23, 1986
<u>AB</u>		<u>50MG</u>	<u>A089424</u>	<u>002</u>	Aug 11, 1999
<u>AB</u>		<u>100MG</u>	<u>A089424</u>	<u>003</u>	Aug 11, 1999
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A040424</u>	<u>001</u>	Aug 20, 2001
<u>AB</u>		<u>50MG</u>	<u>A040424</u>	<u>002</u>	Aug 20, 2001
<u>AB</u>		<u>100MG</u>	<u>A040424</u>	<u>003</u>	Aug 20, 2001
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A086809</u>	<u>001</u>	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 384 (of 428)

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

<u>AB</u>	VINTAGE	<u>25MG</u>	<u>A040750</u>	<u>001</u>	Aug 29, 2006
<u>AB</u>		<u>50MG</u>	<u>A040750</u>	<u>002</u>	Aug 29, 2006
<u>AB</u>		<u>100MG</u>	<u>A040750</u>	<u>003</u>	Aug 29, 2006

STAVUDINE

CAPSULE; ORAL

STAVUDINE

<u>AB</u>	AUROBINDO PHARMA	<u>15MG</u>	<u>A077672</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>20MG</u>	<u>A077672</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>		<u>30MG</u>	<u>A077672</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>40MG</u>	<u>A077672</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>	HETERO DRUGS	<u>15MG</u>	<u>A078957</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>20MG</u>	<u>A078957</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>		<u>30MG</u>	<u>A078957</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>40MG</u>	<u>A078957</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>	MATRIX LABS LTD	<u>30MG</u>	<u>A078775</u>	<u>001</u>	Jan 05, 2009
<u>AB</u>		<u>40MG</u>	<u>A078775</u>	<u>002</u>	Jan 05, 2009
<u>AB</u>	MYLAN	<u>15MG</u>	<u>A079069</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>20MG</u>	<u>A079069</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>		<u>30MG</u>	<u>A079069</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>40MG</u>	<u>A079069</u>	<u>004</u>	Dec 29, 2008

ZERIT

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>15MG</u>	<u>N020412</u>	<u>002</u>	Jun 24, 1994
<u>AB</u>		<u>20MG</u>	<u>N020412</u>	<u>003</u>	Jun 24, 1994
<u>AB</u>		<u>30MG</u>	<u>N020412</u>	<u>004</u>	Jun 24, 1994
<u>AB</u>	+	<u>40MG</u>	<u>N020412</u>	<u>005</u>	Jun 24, 1994

FOR SOLUTION; ORAL

STAVUDINE

<u>AA</u>	AUROBINDO PHARMA	<u>1MG/ML</u>	<u>A077774</u>	<u>001</u>	Dec 29, 2008
<u>AA</u>	CIPLA LTD	<u>1MG/ML</u>	<u>A078030</u>	<u>001</u>	Mar 20, 2009

ZERIT

<u>AA</u>	+	BRISTOL MYERS SQUIBB	<u>1MG/ML</u>	<u>N020413</u>	<u>001</u>	Sep 06, 1996

STERILE WATER FOR INJECTION

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

<u>AP</u>	+	HOSPIRA	<u>100%</u>	<u>N018802</u>	<u>001</u>	Oct 27, 1982

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>100%</u>	<u>N019633</u>	<u>001</u>	Feb 29, 1988
<u>AP</u>	+	BAXTER HLTHCARE	<u>100%</u>	<u>N018632</u>	<u>002</u>	Apr 19, 1988
<u>AP</u>	+		<u>100%</u>	<u>N018632</u>	<u>001</u>	Jun 30, 1982
<u>AP</u>		FRESENIUS KABI USA	<u>100%</u>	<u>A088400</u>	<u>001</u>	Jan 16, 1984
<u>AP</u>	+	HOSPIRA	<u>100%</u>	<u>N018233</u>	<u>001</u>	
<u>AP</u>	+		<u>100%</u>	<u>N018801</u>	<u>001</u>	Oct 27, 1982
<u>AP</u>	+		<u>100%</u>	<u>N019869</u>	<u>001</u>	Dec 26, 1989
<u>AP</u>		TARO PHARMS IRELAND	<u>100%</u>	<u>A077393</u>	<u>001</u>	Aug 11, 2006

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER

<u>AT</u>	BAXTER HLTHCARE	<u>100%</u>	<u>N017428</u>	<u>001</u>	

STERILE WATER IN PLASTIC CONTAINER

<u>AT</u>	B BRAUN	<u>100%</u>	<u>N016734</u>	<u>001</u>	
<u>AT</u>	BAXTER HLTHCARE	<u>100%</u>	<u>N017866</u>	<u>001</u>	
<u>AT</u>	HOSPIRA	<u>100%</u>	<u>N017513</u>	<u>001</u>	
<u>AT</u>		<u>100%</u>	<u>N018313</u>	<u>001</u>	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 385 (of 428)

STREPTOMYCIN SULFATEINJECTABLE; INJECTION
STREPTOMYCIN SULFATE

+ X GEN PHARMS EQ 1GM BASE/VIAL A064210 001 Jun 30, 1998

STREPTOZOCININJECTABLE; INJECTION
ZANOSAR

+ TEVA PARENTERAL 1GM/VIAL N050577 001 May 07, 1982

STRONTIUM CHLORIDE SR-89

INJECTABLE; INJECTION

METASTRON

AP + GE HEALTHCARE 1mCi/ML N020134 001 Jun 18, 1993

STRONTIUM CHLORIDE SR-89

AP BIO NUCLEONICS 1mCi/ML A075941 001 Jan 06, 2003

SUCCIMERCAPSULE; ORAL
CHEMET

+ LUNDBECK LLC 100MG N019998 002 Jan 30, 1991

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

AP + SANDOZ 20MG/ML N008453 002

QUELICIN

AP + HOSPIRA 20MG/ML N008845 006

QUELICIN PRESERVATIVE FREE

AP + HOSPIRA 20MG/ML N008845 001

QUELICIN PRESERVATIVE FREE

+ HOSPIRA 100MG/ML N008845 004

SUCRALFATE

SUSPENSION; ORAL

CARAFATE

+ APTALIS PHARMA US 1GM/10ML N019183 001 Dec 16, 1993

TABLET; ORAL

CARAFATE

AB + APTALIS PHARMA US 1GM N018333 001

SUCRALFATE

AB NOSTRUM LABS 1GM A074415 001 Jun 08, 1998

AB TEVA 1GM A070848 001 Mar 29, 1996

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTA PRESERVATIVE FREE

AP + AKORN EQ 0.05MG BASE/ML N019050 001 May 04, 1984

SUFENTANIL CITRATE

AP HIKMA MAPLE EQ 0.05MG BASE/ML A074413 001 Dec 15, 1995

AP HOSPIRA EQ 0.05MG BASE/ML A074534 001 Dec 11, 1996

SULCONAZOLE NITRATE

CREAM; TOPICAL

EXELDERM

+ RANBAXY 1% N018737 001 Feb 28, 1989

SOLUTION; TOPICAL

EXELDERM

+ RANBAXY 1% N018738 001 Aug 30, 1985

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 386 (of 428)

SULFACETAMIDE SODIUM

LOTION; TOPICAL

KLARON

<u>AB</u>	+ SANOFI AVENTIS US	<u>10%</u>	<u>N019931</u>	<u>001</u>	Dec 23, 1996
	<u>SULFACETAMIDE SODIUM</u>				
<u>AB</u>	FOUGERA PHARMS	<u>10%</u>	<u>A077015</u>	<u>001</u>	Nov 17, 2006
<u>AB</u>	PERRIGO CO TENNESSEE	<u>10%</u>	<u>A078649</u>	<u>001</u>	Mar 23, 2009
<u>AB</u>	TARO	<u>10%</u>	<u>A078668</u>	<u>001</u>	May 20, 2009

OINTMENT; OPHTHALMIC

CETAMIDE

<u>AT</u>	+ ALCON	<u>10%</u>	<u>A080021</u>	<u>001</u>	
	<u>SULFACETAMIDE SODIUM</u>				
<u>AT</u>	FERA PHARMS	<u>10%</u>	<u>A080029</u>	<u>001</u>	

SOLUTION/DROPS; OPHTHALMIC

BLEPH-10

<u>AT</u>	+ ALLERGAN	<u>10%</u>	<u>A080028</u>	<u>001</u>	
	<u>SULFACETAMIDE SODIUM</u>				
<u>AT</u>	ALCON PHARMS LTD	<u>10%</u>	<u>A089560</u>	<u>001</u>	Oct 18, 1988
<u>AT</u>	BAUSCH AND LOMB	<u>10%</u>	<u>A040066</u>	<u>001</u>	Dec 28, 1994

SULFADIAZINETABLET; ORAL
SULFADIAZINE

	+ SANDOZ	500MG	A040091	001	Jul 29, 1994

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

	+ TEVA PARENTERAL	80MG/ML;16MG/ML	A073303	001	Oct 31, 1991

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

<u>AB</u>	AUROBINDO PHARMA	<u>200MG/5ML;40MG/5ML</u>	<u>A091348</u>	<u>001</u>	Jun 08, 2010
<u>AB</u>	+ HI TECH PHARMA	<u>200MG/5ML;40MG/5ML</u>	<u>A074650</u>	<u>001</u>	Dec 29, 1997
<u>AB</u>	VINTAGE	<u>200MG/5ML;40MG/5ML</u>	<u>A077785</u>	<u>001</u>	Jan 24, 2007
	<u>SULFATRIM PEDIATRIC</u>				
<u>AB</u>	STI PHARMA LLC	<u>200MG/5ML;40MG/5ML</u>	<u>N018615</u>	<u>001</u>	Jan 07, 1983

TABLET; ORAL

BACTRIM

<u>AB</u>	MUTUAL PHARM	<u>400MG;80MG</u>	<u>N017377</u>	<u>001</u>	

BACTRIM DS

<u>AB</u>	+ MUTUAL PHARM	<u>800MG;160MG</u>	<u>N017377</u>	<u>002</u>	

SEPTRA

<u>AB</u>	MONARCH PHARMS	<u>400MG;80MG</u>	<u>N017376</u>	<u>001</u>	

SEPTRA DS

<u>AB</u>	MONARCH PHARMS	<u>800MG;160MG</u>	<u>N017376</u>	<u>002</u>	

SULFAMETHOPRIM

<u>AB</u>	NOVEL LABS INC	<u>400MG;80MG</u>	<u>A070022</u>	<u>001</u>	Feb 15, 1985

SULFAMETHOPRIM-DS

<u>AB</u>	NOVEL LABS INC	<u>800MG;160MG</u>	<u>A070032</u>	<u>001</u>	Feb 15, 1985

SULFAMETHOXAZOLE AND TRIMETHOPRIM

<u>AB</u>	AMNEAL PHARMS NY	<u>400MG;80MG</u>	<u>A076899</u>	<u>001</u>	Jan 27, 2005
<u>AB</u>		<u>800MG;160MG</u>	<u>A076899</u>	<u>002</u>	Jan 27, 2005
<u>AB</u>	AUROBINDO PHARMA	<u>400MG;80MG</u>	<u>A090624</u>	<u>001</u>	Feb 16, 2010
<u>AB</u>		<u>800MG;160MG</u>	<u>A090624</u>	<u>002</u>	Feb 16, 2010
<u>AB</u>	GLENMARK GENERICS	<u>400MG;80MG</u>	<u>A090828</u>	<u>002</u>	Dec 22, 2010
<u>AB</u>		<u>800MG;160MG</u>	<u>A090828</u>	<u>001</u>	Dec 22, 2010
<u>AB</u>	MUTUAL PHARM	<u>800MG;160MG</u>	<u>A071017</u>	<u>001</u>	Aug 25, 1986
<u>AB</u>	VINTAGE	<u>400MG;80MG</u>	<u>A078060</u>	<u>002</u>	Jan 25, 2007
<u>AB</u>		<u>800MG;160MG</u>	<u>A078060</u>	<u>001</u>	Jan 25, 2007
<u>AB</u>	VISTA PHARMS	<u>400MG;80MG</u>	<u>A076817</u>	<u>001</u>	Oct 07, 2005
<u>AB</u>		<u>800MG;160MG</u>	<u>A076817</u>	<u>002</u>	Oct 07, 2005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 387 (of 428)

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

<u>AB</u>	SANDOZ	<u>800MG;160MG</u>	<u>N018598</u>	<u>004</u>	May 19, 1982

<u>AB</u>	TEVA	<u>800MG;160MG</u>	<u>A070037</u>	<u>001</u>	Jun 02, 1987

SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH

<u>AB</u>	TEVA PHARMS	<u>400MG;80MG</u>	<u>A070030</u>	<u>001</u>	Jun 02, 1987

SULFANILAMIDE

CREAM; VAGINAL

AVC

+	MEDA PHARMS	15%	N006530	003	Jan 27, 1987

SULFASALAZINE

SUSPENSION; ORAL

AZULFIDINE

+	PHARMACIA AND UPJOHN	250MG/5ML	A086983	001	

TABLET; ORAL

AZULFIDINE

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>500MG</u>	<u>N007073</u>	<u>001</u>

SULFASALAZINE

<u>AB</u>	VINTAGE PHARMS	<u>500MG</u>	<u>A040349</u>	<u>001</u>	Jan 11, 2002

<u>AB</u>	WATSON LABS	<u>500MG</u>	<u>A085828</u>	<u>001</u>	

<u>AB</u>		<u>500MG</u>	<u>A087197</u>	<u>001</u>	

TABLET, DELAYED RELEASE; ORAL

AZULFIDINE EN-TABS

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>500MG</u>	<u>N007073</u>	<u>002</u>	Apr 06, 1983

SULFASALAZINE

<u>AB</u>	VINTAGE PHARMS	<u>500MG</u>	<u>A075339</u>	<u>001</u>	Jan 11, 2002

SULINDAC

TABLET; ORAL

CLINORIL

<u>AB</u>	+	MERCK	<u>200MG</u>	<u>N017911</u>	<u>002</u>

SULINDAC

<u>AB</u>	EPIC PHARMA	<u>150MG</u>	<u>A072710</u>	<u>001</u>	Mar 25, 1991

<u>AB</u>		<u>200MG</u>	<u>A072711</u>	<u>001</u>	Mar 25, 1991

<u>AB</u>	MUTUAL PHARM	<u>150MG</u>	<u>A072050</u>	<u>001</u>	Apr 17, 1991

<u>AB</u>		<u>200MG</u>	<u>A072051</u>	<u>001</u>	Apr 17, 1991

<u>AB</u>	MYLAN	<u>150MG</u>	<u>A073039</u>	<u>002</u>	Jun 22, 1993

<u>AB</u>		<u>200MG</u>	<u>A073039</u>	<u>001</u>	Jun 22, 1993

<u>AB</u>	WATSON LABS	<u>150MG</u>	<u>A071891</u>	<u>001</u>	Apr 03, 1990

<u>AB</u>		<u>200MG</u>	<u>A071795</u>	<u>001</u>	Apr 03, 1990

SUMATRIPTAN

SPRAY; NASAL

IMITREX

+	GLAXOSMITHKLINE	5MG/SPRAY	N020626	001	Aug 26, 1997

+		20MG/SPRAY	N020626	003	Aug 26, 1997

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX STATDOSE

<u>AB</u>	+	GLAXOSMITHKLINE	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>N020080</u>	<u>003</u>	Dec 23, 1996

SUMATRIPTAN SUCCINATE

<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090358</u>	<u>001</u>	Jun 21, 2011

IMITREX

<u>AP</u>	+	GLAXOSMITHKLINE	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>N020080</u>	<u>001</u>	Dec 28, 1992

SUMATRIPTAN SUCCINATE

<u>AP</u>	BEDFORD	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079123</u>	<u>001</u>	Feb 06, 2009

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079242</u>	<u>001</u>	Mar 02, 2009

<u>AP</u>		<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079240</u>	<u>002</u>	Sep 18, 2009

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 388 (of 428)

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)</u>	<u>A079240</u>	<u>001</u>	Sep 18, 2009
<u>AP</u>	INJECTALIA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090310</u>	<u>001</u>	Aug 11, 2010
<u>AP</u>	JHP PHARMS	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077871</u>	<u>001</u>	Jul 09, 2009
<u>AP</u>	PAR PHARM	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077332</u>	<u>001</u>	Oct 09, 2009
<u>AP</u>	SAGENT STRIDES	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090314</u>	<u>001</u>	Jun 10, 2010
<u>AP</u>		<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090641</u>	<u>001</u>	Jul 28, 2010
<u>AP</u>	SANDOZ	<u>EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)</u>	<u>A078067</u>	<u>002</u>	Feb 06, 2009
<u>AP</u>		<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A078067</u>	<u>001</u>	Feb 06, 2009
<u>AP</u>	TEVA PARENTERAL	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077907</u>	<u>001</u>	Feb 06, 2009
<u>AP</u>	WOCKHARDT	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A078593</u>	<u>001</u>	Feb 06, 2009
	ALSUMA				
BX	MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377	001	Jun 29, 2010
	SUMAVEL DOSEPRO				
BX +	ZOGENIX INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009
	IMITREX STATDOSE				
	+ GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N020080	002	Feb 01, 2006
	TABLET; ORAL				
	<u>IMITREX</u>				
<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 25MG BASE</u>	<u>N020132</u>	<u>002</u>	Jun 01, 1995
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N020132</u>	<u>003</u>	Jun 01, 1995
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N020132</u>	<u>001</u>	Jun 01, 1995
	<u>SUMATRIPTAN SUCCINATE</u>				
<u>AB</u>	APOTEX INC	<u>EQ 25MG BASE</u>	<u>A200263</u>	<u>001</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A200263</u>	<u>002</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A200263</u>	<u>003</u>	Jun 19, 2012
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A078327</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078327</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078327</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 25MG BASE</u>	<u>A076847</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076847</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076847</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A077163</u>	<u>001</u>	Nov 02, 2009
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A077744</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077163</u>	<u>002</u>	Nov 02, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077744</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077163</u>	<u>003</u>	Nov 02, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077744</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 25MG BASE</u>	<u>A078284</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078284</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078284</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>	RANBAXY	<u>EQ 25MG BASE</u>	<u>A076554</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076554</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076572</u>	<u>001</u>	Feb 09, 2009
<u>AB</u>	SANDOZ	<u>EQ 25MG BASE</u>	<u>A076976</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076976</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076976</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>	SUN PHARM INDS	<u>EQ 25MG BASE</u>	<u>A078295</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078295</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078295</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076840</u>	<u>001</u>	Feb 09, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076840</u>	<u>002</u>	Feb 09, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076840</u>	<u>003</u>	Feb 09, 2009
<u>AB</u>	WATSON LABS	<u>EQ 25MG BASE</u>	<u>A076933</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076933</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076933</u>	<u>003</u>	Aug 10, 2009

PRESCRIPTION DRUG PRODUCT LIST

3 - 389 (of 428)

SUNITINIB MALATE

CAPSULE; ORAL
SUTENT

CPPI CV	EQ 12.5MG BASE	N021938	001	Jan 26, 2006
	EQ 25MG BASE	N021938	002	Jan 26, 2006
	EQ 37.5MG BASE	N021938	004	Mar 31, 2009
+	EQ 50MG BASE	N021938	003	Jan 26, 2006

TACROLIMUS

CAPSULE; ORAL

PROGRAF

AB ASTELLAS	EQ 0.5MG BASE	N050708	003	Aug 24, 1998
AB	EQ 1MG BASE	N050708	001	Apr 08, 1994
AB +	EQ 5MG BASE	N050708	002	Apr 08, 1994

TACROLIMUS

AB ACCORD HLTHCARE	EQ 0.5MG BASE	A091195	001	Aug 31, 2011
AB	EQ 1MG BASE	A091195	002	Aug 31, 2011
AB	EQ 5MG BASE	A091195	003	Aug 31, 2011
AB DR REDDYS LABS LTD	EQ 0.5MG BASE	A090509	001	May 12, 2010
AB	EQ 1MG BASE	A090509	002	May 12, 2010
AB	EQ 5MG BASE	A090509	003	May 12, 2010
AB MYLAN	EQ 0.5MG BASE	A090596	001	Sep 17, 2010
AB	EQ 1MG BASE	A090596	002	Sep 17, 2010
AB	EQ 5MG BASE	A090596	003	Sep 17, 2010
AB PANACEA BIOTEC LTD	EQ 0.5MG BASE	A090802	001	Sep 28, 2012
AB	EQ 1MG BASE	A090802	002	Sep 28, 2012
AB	EQ 5MG BASE	A090802	003	Sep 28, 2012
AB SANDOZ	EQ 0.5MG BASE	A065461	001	Aug 10, 2009
AB	EQ 1MG BASE	A065461	002	Aug 10, 2009
AB	EQ 5MG BASE	A065461	003	Aug 10, 2009
AB WATSON LABS	EQ 5MG BASE	A090402	001	Jul 01, 2010

INJECTABLE; INJECTION

PROGRAF

+ ASTELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994

OINTMENT; TOPICAL
PROTOPIC

ASTELLAS	0.03%	N050777	001	Dec 08, 2000
+	0.1%	N050777	002	Dec 08, 2000

TADALAFIL

TABLET; ORAL

ADCIRCA

+ ELI LILLY CO	20MG	N022332	001	May 22, 2009
CIALIS				
LILLY	2.5MG	N021368	004	Jan 07, 2008
	5MG	N021368	001	Nov 21, 2003
	10MG	N021368	002	Nov 21, 2003
+	20MG	N021368	003	Nov 21, 2003

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

+ MERCK SHARP DOHME	0.0015%	N202514	001	Feb 10, 2012

TALC

AEROSOL, METERED; INTRAPLEURAL
SCLEROSOL

+ BRYAN	400MG/SPRAY	N020587	001	Dec 24, 1997

POWDER; INTRAPLEURAL
TALC

+ BRYAN	5GM/BOT	N021388	001	Dec 15, 2003

PRESCRIPTION DRUG PRODUCT LIST

3 - 390 (of 428)

TALIGLUCERASE ALFA

POWDER; IV (INFUSION)

+ PFIZER	200 UNITS/VIAL	N022458	001	May 01, 2012

TAMOXIFEN CITRATE

SOLUTION; ORAL

SOLTAMOX

DARA BIOSCIENCES	EQ 10MG BASE/5ML	N021807	001	Oct 29, 2005

TABLET; ORAL

TAMOXIFEN CITRATE

<u>AB</u> APOTEX	<u>EQ 10MG BASE</u>	<u>A090878</u>	<u>001</u>	Sep 23, 2011
<u>AB</u>	<u>EQ 20MG BASE</u>	<u>A090878</u>	<u>002</u>	Sep 23, 2011
<u>AB</u> MYLAN	<u>EQ 10MG BASE</u>	<u>A074732</u>	<u>002</u>	Feb 20, 2003
<u>AB</u>	<u>EQ 20MG BASE</u>	<u>A074732</u>	<u>001</u>	Feb 20, 2003
<u>AB</u> TEVA	<u>EQ 10MG BASE</u>	<u>A075797</u>	<u>001</u>	Feb 20, 2003
<u>AB</u> + TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A074858</u>	<u>001</u>	Feb 20, 2003
<u>AB</u> WATSON LABS	<u>EQ 10MG BASE</u>	<u>A070929</u>	<u>001</u>	Feb 20, 2003
<u>AB</u>	<u>EQ 20MG BASE</u>	<u>A070929</u>	<u>002</u>	Feb 20, 2003
<u>AB</u> WATSON LABS FLORIDA	<u>EQ 10MG BASE</u>	<u>A076179</u>	<u>001</u>	Feb 20, 2003
<u>AB</u>	<u>EQ 20MG BASE</u>	<u>A076179</u>	<u>002</u>	Feb 20, 2003

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

FLOMAX

<u>AB</u> + BOEHRINGER INGELHEIM	<u>0.4MG</u>	<u>N020579</u>	<u>001</u>	Apr 15, 1997

TAMSULOSIN HYDROCHLORIDE

<u>AB</u> ANCHEN PHARMS	<u>0.4MG</u>	<u>A202010</u>	<u>001</u>	Jan 04, 2013
<u>AB</u> IMPAX LABS	<u>0.4MG</u>	<u>A090377</u>	<u>001</u>	Mar 02, 2010
<u>AB</u> MYLAN	<u>0.4MG</u>	<u>A090408</u>	<u>001</u>	Apr 27, 2010
<u>AB</u> SANDOZ	<u>0.4MG</u>	<u>A078015</u>	<u>001</u>	Apr 27, 2010
<u>AB</u> SUN PHARM INDS LTD	<u>0.4MG</u>	<u>A090931</u>	<u>001</u>	Jul 15, 2010
<u>AB</u> SYNTHON PHARMS	<u>0.4MG</u>	<u>A078801</u>	<u>001</u>	Apr 27, 2010
<u>AB</u> TEVA PHARMS	<u>0.4MG</u>	<u>A077630</u>	<u>001</u>	Apr 27, 2010
<u>AB</u> WOCKHARDT	<u>0.4MG</u>	<u>A078938</u>	<u>001</u>	Apr 27, 2010
<u>AB</u> ZYDUS PHARMS USA INC	<u>0.4MG</u>	<u>A078225</u>	<u>001</u>	Apr 27, 2010

TAPENTADOL HYDROCHLORIDE

SOLUTION; ORAL

NUCYNTA

+ JANSSEN PHARMS	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012

TABLET; ORAL

NUCYNTA

JANSSEN PHARMS	EQ 50MG BASE	N022304	001	Nov 20, 2008
	EQ 75MG BASE	N022304	002	Nov 20, 2008
+	EQ 100MG BASE	N022304	003	Nov 20, 2008

TABLET, EXTENDED RELEASE; ORAL

NUCYNTA ER

JANSSEN PHARMS	EQ 50MG BASE	N200533	001	Aug 25, 2011
	EQ 100MG BASE	N200533	002	Aug 25, 2011
	EQ 150MG BASE	N200533	003	Aug 25, 2011
	EQ 200MG BASE	N200533	004	Aug 25, 2011
+	EQ 250MG BASE	N200533	005	Aug 25, 2011

TAZAROTENE

AEROSOL, FOAM; TOPICAL

FABIOR

+ STIEFEL LABS INC	0.1%	N202428	001	May 11, 2012

CREAM; TOPICAL

AVAGE

+ ALLERGAN	0.1%	N021184	003	Sep 30, 2002

PRESCRIPTION DRUG PRODUCT LIST

3 - 391 (of 428)

TAZAROTENE

CREAM; TOPICAL
TAZORAC

+ ALLERGAN	0.05%	N021184	001	Sep 29, 2000
+	0.1%	N021184	002	Sep 29, 2000

GEL; TOPICAL
TAZORAC

+ ALLERGAN	0.05%	N020600	001	Jun 13, 1997
+	0.1%	N020600	002	Jun 13, 1997

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
PULMOLITE

BS PHARMALUCENCE	N/A	N017776	001	
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT				
BS DRAXIMAGE	N/A	N017881	001	Dec 30, 1987

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE; INJECTION
NEUROLITE

LANTHEUS MEDCL	N/A	N020256	001	Nov 23, 1994

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION
HEPATOLITE

PHARMALUCENCE	N/A	N018467	001	Mar 16, 1982

TECHNETIUM TC-99M EXAMETAZIME KIT

INJECTABLE; INJECTION
CERETEC

+ GE HEALTHCARE	N/A	N019829	001	Dec 30, 1988

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE; INJECTION

CHOLETEC

<u>AP</u> + BRACCO	N/A	<u>N018963</u>	<u>001</u>	Jan 21, 1987

TECHNETIUM TC-99M MEBROFENIN

<u>AP</u> PHARMALUCENCE	N/A	<u>A078242</u>	<u>001</u>	Jan 29, 2008

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION
DRAXIMAGE MDP-25

+ JUBILANT DRAXIMAGE	N/A	N018035	002	Feb 27, 2004

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

CIS-MDP

<u>AP</u> PHARMALUCENCE	N/A	<u>N018124</u>	<u>001</u>	

MDP-BRACCO

<u>AP</u> BRACCO	N/A	<u>N018107</u>	<u>001</u>	

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE; INJECTION
TECHNESCAN MAG3

+ MALLINCKRODT	N/A	N019882	001	Jun 15, 1990

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION
TECHNESCAN

+ MALLINCKRODT	N/A	N018321	001	

PRESCRIPTION DRUG PRODUCT LIST

3 - 392 (of 428)

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

AN-DTPA

AP	PHARMALUCENCE	N/A	N017714	001	

DTPA

AP	DRAXIMAGE	N/A	N018511	001	Dec 29, 1989

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

CIS-PYRO

AP	PHARMALUCENCE	N/A	N019039	001	Jun 30, 1987

TECHNISCAN PYP KIT

AP	MALLINCKRODT	N/A	N017538	001	

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

ULTRATAG

	MALLINCKRODT	N/A	N019981	001	Jun 10, 1991

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

CARDIOLITE

AP	+ LANTHEUS MEDCL	N/A	N019785	001	Dec 21, 1990

TECHNETIUM TC 99M SESTAMIBI

AP	CARDINAL HEALTH 414	N/A	A078809	001	Apr 28, 2009

AP	DRAXIMAGE	N/A	A078806	001	Apr 29, 2009

AP	PHARMALUCENCE	10-30mCi	A079157	001	Jul 10, 2009

TECHNETIUM TC-99 SESTAMIBI

AP	MALLINCKRODT	N/A	A078098	001	Sep 22, 2008

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL

TECHNELITE

	+ LANTHEUS MEDCL	0.0083-2.7 CI/GENERATOR	N017771	001	

ULTRA-TECHNEKOW FM

	+ MALLINCKRODT	0.25-3 CI/GENERATOR	N017243	002	

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE; INJECTION

MPI DMSA KIDNEY REAGENT

	GE HEALTHCARE	N/A	N017944	001	May 18, 1982

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

AN-SULFUR COLLOID

	+ PHARMALUCENCE	N/A	N017858	001	

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVUE

	+ GE HEALTHCARE	N/A	N020372	001	Feb 09, 1996

MYOVUE 30ML

	+ GE HEALTHCARE	N/A	N020372	002	Jul 07, 2005

TEDUGLUTIDE RECOMBINANT

POWDER; SUBCUTANEOUS

GATTEX KIT

	+ NPS PHARMS INC	5MG/VIAL	N203441	001	Dec 21, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 393 (of 428)

TELAPREVIRTABLET; ORAL
INCIVEK

+ VERTEX PHARMS 375MG N0201917 001 May 23, 2011

TELAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)

THERAVANCE INC EQ 250MG BASE/VIAL N022110 001 Sep 11, 2009
+ EQ 750MG BASE/VIAL N022110 002 Sep 11, 2009TELBIVUDINETABLET; ORAL
TYZEKA

+ NOVARTIS 600MG N022011 001 Oct 25, 2006

TELITHROMYCINTABLET; ORAL
KetekSANOFI AVENTIS US 300MG N021144 002 Feb 09, 2005
+ 400MG N021144 001 Apr 01, 2004TELMISARTANTABLET; ORAL
MICARDISBOEHRINGER INGELHEIM 20MG N020850 003 Apr 04, 2000
40MG N020850 001 Nov 10, 1998
+ 80MG N020850 002 Nov 10, 1998TEMAZEPAM

CAPSULE; ORAL

RESTORILAB MALLINCKRODT INC 7.5MG N018163 003 Oct 25, 1991
AB 15MG N018163 001
AB 22.5MG N018163 004 Nov 02, 2004
AB + 30MG N018163 002TEMAZEPAMAB ACTAVIS ELIZABETH 15MG A071638 001 Aug 07, 1987
AB 30MG A071620 001 Aug 07, 1987
AB MUTUAL PHARM 7.5MG A078581 001 Sep 08, 2009
AB 22.5MG A071175 002 Sep 14, 2009
AB MYLAN 7.5MG A070920 002 May 21, 2010
AB 15MG A070920 004 Jul 07, 1986
AB 22.5MG A070920 003 Jun 12, 2009
AB 30MG A070920 001 Jul 10, 1986
AB NOVEL LABS INC 7.5MG A071457 002 Jun 22, 2012
AB 15MG A071456 001 Apr 21, 1987
AB 22.5MG A071457 003 Jun 22, 2012
AB 30MG A071457 001 Apr 21, 1987
AB SANDOZ 15MG A071427 001 Jan 12, 1988
AB 30MG A071428 001 Jan 12, 1988
AB WATSON LABS 15MG A071446 001 May 21, 1993
AB 30MG A071447 001 May 21, 1993TEMOZOLOMIDE

CAPSULE; ORAL

TEMODARAB MERCK SHARP DOHME 5MG N021029 001 Aug 11, 1999
AB 20MG N021029 002 Aug 11, 1999
AB 100MG N021029 003 Aug 11, 1999
AB 140MG N021029 005 Oct 19, 2006

PRESCRIPTION DRUG PRODUCT LIST

3 - 394 (of 428)

TEMOZOLOMIDE

CAPSULE; ORAL					
<u>TEMODAR</u>					
<u>AB</u>	MERCK SHARP DOHME	<u>180MG</u>	<u>N021029</u>	<u>006</u>	Oct 19, 2006
<u>AB</u>	+	<u>250MG</u>	<u>N021029</u>	<u>004</u>	Aug 11, 1999
<u>TEMOZOLOMIDE</u>					
<u>AB</u>	BARR	<u>5MG</u>	<u>A078879</u>	<u>001</u>	Mar 01, 2010
<u>AB</u>		<u>20MG</u>	<u>A078879</u>	<u>002</u>	Mar 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A078879</u>	<u>003</u>	Mar 01, 2010
<u>AB</u>		<u>140MG</u>	<u>A078879</u>	<u>005</u>	Mar 01, 2010
<u>AB</u>		<u>180MG</u>	<u>A078879</u>	<u>006</u>	Mar 01, 2010
<u>AB</u>		<u>250MG</u>	<u>A078879</u>	<u>004</u>	Mar 01, 2010
POWDER; INTRAVENOUS					
TEMODAR					
	+ MERCK SHARP DOHME	100MG/VIAL	N022277	001	Feb 27, 2009

TEMSIROLIMUS

SOLUTION; INTRAVENOUS					
TORISEL					
	+ WYETH PHARMS INC	25MG/ML (25MG/ML)	N022088	001	May 30, 2007

TENIPOSIDE

INJECTABLE; INJECTION					
VUMON					
	+ BRISTOL MYERS SQUIBB	10MG/ML	N020119	001	Jul 14, 1992

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL					
VIREAD					
	+ GILEAD SCIENCES INC	40MG/SC00PFUL	N022577	001	Jan 18, 2012
TABLET; ORAL					
VIREAD					
	GILEAD SCIENCES INC	150MG	N021356	002	Jan 18, 2012
		200MG	N021356	003	Jan 18, 2012
		250MG	N021356	004	Jan 18, 2012
	+	300MG	N021356	001	Oct 26, 2001

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL					
<u>HYTRIN</u>					
<u>AB</u>	ABBOTT	<u>EQ 1MG BASE</u>	<u>N020347</u>	<u>001</u>	Dec 14, 1994
<u>AB</u>	+	<u>EQ 2MG BASE</u>	<u>N020347</u>	<u>002</u>	Dec 14, 1994
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N020347</u>	<u>003</u>	Dec 14, 1994
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>N020347</u>	<u>004</u>	Dec 14, 1994
<u>TERAZOSIN HYDROCHLORIDE</u>					
<u>AB</u>	APOTEX	<u>EQ 1MG BASE</u>	<u>A075498</u>	<u>001</u>	Apr 12, 2001
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075498</u>	<u>002</u>	Apr 12, 2001
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075498</u>	<u>003</u>	Apr 12, 2001
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075498</u>	<u>004</u>	Apr 12, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A075614</u>	<u>002</u>	Jan 30, 2001
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075614</u>	<u>001</u>	Jan 30, 2001
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075614</u>	<u>003</u>	Jan 30, 2001
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075614</u>	<u>004</u>	Jan 30, 2001
<u>AB</u>	JUBILANT CADISTA	<u>EQ 1MG BASE</u>	<u>A075317</u>	<u>001</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075317</u>	<u>002</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075317</u>	<u>003</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075317</u>	<u>004</u>	Dec 20, 2004
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A075140</u>	<u>002</u>	Feb 11, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075140</u>	<u>003</u>	Feb 11, 2000
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075140</u>	<u>001</u>	Feb 11, 2000
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075140</u>	<u>004</u>	Feb 11, 2000

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 395 (of 428)

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

<u>AB</u>	SANDOZ	<u>EQ 1MG BASE</u>	<u>A074823</u>	<u>001</u>	Mar 30, 1998
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A074823</u>	<u>002</u>	Mar 30, 1998
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A074823</u>	<u>003</u>	Mar 30, 1998
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A074823</u>	<u>004</u>	Mar 30, 1998

TABLET; ORAL

HYTRIN

ABBOTT

+

EQ 1MG BASE

N019057 001 Aug 07, 1987

EQ 2MG BASE

N019057 002 Aug 07, 1987

EQ 5MG BASE

N019057 003 Aug 07, 1987

EQ 10MG BASE

N019057 004 Aug 07, 1987

TERBINAFINE HYDROCHLORIDE

GRANULE; ORAL

LAMISIL

NOVARTIS

EQ 125MG BASE/PACKET

N022071 001 Sep 28, 2007

+

EQ 187.5MG BASE/PACKET

N022071 002 Sep 28, 2007

TABLET; ORAL

LAMISIL

<u>AB</u>	+	NOVARTIS	<u>EQ 250MG BASE</u>	<u>N020539</u>	<u>001</u>	May 10, 1996

TERBINAFINE HYDROCHLORIDE

<u>AB</u>		APOTEX	<u>EQ 250MG BASE</u>	<u>A078199</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A078297</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		BRECKENRIDGE PHARM	<u>EQ 250MG BASE</u>	<u>A077714</u>	<u>001</u>	Jun 04, 2010
<u>AB</u>		DR REDDYS LABS INC	<u>EQ 250MG BASE</u>	<u>A076390</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		GLENMARK GENERICS	<u>EQ 250MG BASE</u>	<u>A078157</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		HARRIS PHARM	<u>EQ 250MG BASE</u>	<u>A077919</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		INVAGEN PHARMS	<u>EQ 250MG BASE</u>	<u>A077533</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		MYLAN	<u>EQ 250MG BASE</u>	<u>A077136</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A077195</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 250MG BASE</u>	<u>A078163</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		TEVA	<u>EQ 250MG BASE</u>	<u>A076377</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		WATSON LABS	<u>EQ 250MG BASE</u>	<u>A077137</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		WOCKHARDT	<u>EQ 250MG BASE</u>	<u>A078229</u>	<u>001</u>	Jul 02, 2007

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

<u>AP</u>		AKORN	<u>1MG/ML</u>	<u>A078151</u>	<u>001</u>	Jan 07, 2008
<u>AP</u>	+	BEDFORD	<u>1MG/ML</u>	<u>A076770</u>	<u>001</u>	Apr 23, 2004
<u>AP</u>		FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A076887</u>	<u>001</u>	May 26, 2004
<u>AP</u>		HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A078630</u>	<u>001</u>	May 20, 2009

TABLET; ORAL

TERBUTALINE SULFATE

<u>AB</u>		IMPAX LABS	<u>2.5MG</u>	<u>A075877</u>	<u>001</u>	Jun 26, 2001
<u>AB</u>	+		<u>5MG</u>	<u>A075877</u>	<u>002</u>	Jun 26, 2001
<u>AB</u>		LANNETT	<u>2.5MG</u>	<u>A077152</u>	<u>001</u>	Mar 25, 2005
<u>AB</u>			<u>5MG</u>	<u>A077152</u>	<u>002</u>	Mar 25, 2005

TERCONAZOLE

CREAM; VAGINAL

TERAZOL 3

<u>AB</u>	+	JANSSEN PHARMS	<u>0.8%</u>	<u>N019964</u>	<u>001</u>	Feb 21, 1991

TERAZOL 7

<u>AB</u>	+	JANSSEN PHARMS	<u>0.4%</u>	<u>N019579</u>	<u>001</u>	Dec 31, 1987

TERCONAZOLE

<u>AB</u>		FOUGERA PHARMS	<u>0.4%</u>	<u>A076712</u>	<u>001</u>	Feb 18, 2005
<u>AB</u>		TARO	<u>0.4%</u>	<u>A076043</u>	<u>001</u>	Jan 19, 2005
<u>AB</u>			<u>0.8%</u>	<u>A075953</u>	<u>001</u>	Apr 06, 2004

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 396 (of 428)

TERCONAZOLE

CREAM; VAGINAL					
TERCONAZOLE					
BX	+	NYCOMED US	0.8%	N021735	001 Oct 01, 2004
SUPPOSITORY; VAGINAL					
<u>TERAZOL 3</u>					
<u>AB</u>	+	JANSSEN PHARMS	<u>80MG</u>	<u>N019641</u>	<u>001</u> May 24, 1988
<u>TERCONAZOLE</u>					
<u>AB</u>		FOUGERA PHARMS	<u>80MG</u>	<u>A076850</u>	<u>001</u> Jul 12, 2006
<u>AB</u>		PERRIGO NEW YORK	<u>80MG</u>	<u>A077149</u>	<u>001</u> Mar 17, 2006
<u>AB</u>		TARO	<u>80MG</u>	<u>A077553</u>	<u>001</u> Mar 09, 2007

TERIFLUNOMIDE

TABLET; ORAL					
AUBAGIO					
		SANOFI AVENTIS US	7MG	N202992	001 Sep 12, 2012
	+		14MG	N202992	002 Sep 12, 2012

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS					
FORTEO					
	+	LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318	002 Jun 25, 2008

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS					
EGRIFTA					
	+	EMD SERONO	EQ 2MG BASE/VIAL	N022505	002 Nov 29, 2011

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL					
ANDRODERM					
	+	WATSON LABS	2MG/24HR	N020489	003 Oct 20, 2011
	+		4MG/24HR	N020489	004 Oct 20, 2011
GEL; TRANSDERMAL					
ANDROGEL					
BX	+	ABBVIE	1% (50MG/5GM PACKET)	N021015	002 Feb 28, 2000
TESTIM					
BX	+	AUXILIUM PHARMS	1% (50MG/5GM PACKET)	N021454	001 Oct 31, 2002
ANDROGEL					
		ABBVIE	1% (25MG/2.5GM PACKET)	N021015	001 Feb 28, 2000
			1.62% (20.25MG/1.25GM PACKET)	N022309	002 Sep 07, 2012
	+		1.62% (40.5MG/2.5GM PACKET)	N022309	003 Sep 07, 2012
TESTOSTERONE					
		TEVA PHARMS	25MG/2.5GM PACKET	N202763	001 Feb 14, 2012
			50MG/5GM PACKET	N202763	002 Feb 14, 2012
GEL, METERED; TRANSDERMAL					
ANDROGEL					
	+	ABBVIE	1% (1.25GM/ACTUATION)	N021015	003 Sep 26, 2003
	+		1.62% (20.25MG/1.25GM ACTIVATION)	N022309	001 Apr 29, 2011
FORTESTA					
	+	ENDO PHARMS	10MG/0.5GM ACTUATION	N021463	001 Dec 29, 2010
PELLET; IMPLANTATION					
TESTOPEL					
	+	ACTIENT PHARMS	75MG	A080911	001
SOLUTION, METERED; TRANSDERMAL					
AXIRON					
	+	ELI LILLY AND CO	30MG/1.5ML ACTUATION	N022504	001 Nov 23, 2010
TABLET, EXTENDED RELEASE; BUCCAL					
STRIANT					
	+	ACTIENT PHARMS	30MG	N021543	001 Jun 19, 2003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 397 (of 428)

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTOSTERONE

<u>AO</u>	+	PHARMACIA AND UPJOHN	<u>100MG/ML</u>	<u>A085635</u>	<u>002</u>	
<u>AO</u>	+		<u>200MG/ML</u>	<u>A085635</u>	<u>003</u>	
<u>TESTOSTERONE CYPIONATE</u>						
<u>AO</u>		BEDFORD	<u>100MG/ML</u>	<u>A090387</u>	<u>001</u>	Jul 15, 2010
<u>AO</u>			<u>200MG/ML</u>	<u>A090387</u>	<u>002</u>	Jul 15, 2010
<u>AO</u>		HIKMA FARMACEUTICA	<u>200MG/ML</u>	<u>A091244</u>	<u>001</u>	May 01, 2012
<u>AO</u>		MYLAN INSTITUTIONAL	<u>200MG/ML</u>	<u>A040652</u>	<u>001</u>	Dec 11, 2006
<u>AO</u>		PADDOCK LLC	<u>200MG/ML</u>	<u>A040530</u>	<u>001</u>	Jan 31, 2005
<u>AO</u>		SANDOZ	<u>100MG/ML</u>	<u>A040615</u>	<u>001</u>	Aug 10, 2006
<u>AO</u>			<u>200MG/ML</u>	<u>A040615</u>	<u>002</u>	Aug 10, 2006
<u>AO</u>		WATSON LABS	<u>200MG/ML</u>	<u>A086030</u>	<u>001</u>	

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

<u>AO</u>	+	ENDO PHARM	<u>200MG/ML</u>	<u>N009165</u>	<u>003</u>	
<u>TESTOSTERONE ENANTHATE</u>						
<u>AO</u>		HIKMA FARMACEUTICA	<u>200MG/ML</u>	<u>A091120</u>	<u>001</u>	Sep 18, 2012
<u>AO</u>		MYLAN INSTITUTIONAL	<u>200MG/ML</u>	<u>A040647</u>	<u>001</u>	Oct 05, 2009
<u>AO</u>		PADDOCK LLC	<u>200MG/ML</u>	<u>A040575</u>	<u>001</u>	Jun 14, 2006
<u>AO</u>		WATSON LABS	<u>200MG/ML</u>	<u>A085598</u>	<u>001</u>	

TETRABENAZINE

TABLET; ORAL

XENAZINE

		VALEANT BERMUDA	12.5MG	N021894	001	Aug 15, 2008
	+		25MG	N021894	002	Aug 15, 2008

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACYCLINE HYDROCHLORIDE

<u>AB</u>		IMPAX LABS	<u>250MG</u>	<u>A060469</u>	<u>001</u>	
<u>AB</u>			<u>500MG</u>	<u>A060469</u>	<u>003</u>	
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>250MG</u>	<u>A060704</u>	<u>001</u>	
<u>AB</u>	+		<u>500MG</u>	<u>A060704</u>	<u>002</u>	
<u>AB</u>		WATSON LABS	<u>250MG</u>	<u>A061837</u>	<u>001</u>	
<u>AB</u>			<u>500MG</u>	<u>A061837</u>	<u>002</u>	
<u>TETRACYCLINE HYDROCHLORIDE</u>						
		IMPAX LABS	100MG	A060469	002	

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

	+	FOUGERA PHARMS	0.05%	A086576	002	
			0.1%	A086576	001	

SPRAY; NASAL

TYZINE

	+	FOUGERA PHARMS	0.1%	A086576	003	

THALIDOMIDE

CAPSULE; ORAL

THALOMID

		CELGENE	50MG	N020785	001	Jul 16, 1998
			100MG	N020785	002	Jan 17, 2003
			150MG	N020785	004	Jan 10, 2007
	+		200MG	N020785	003	Jan 17, 2003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 398 (of 428)

THALLOUS CHLORIDE TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

<u>AP</u>	+	GE HEALTHCARE	<u>1mCi/ML</u>	<u>N018110</u>	<u>002</u>	Feb 27, 1996
<u>AP</u>	+	LANTHEUS MEDCL	<u>1mCi/ML</u>	<u>N017806</u>	<u>001</u>	
<u>AP</u>	+	MALLINCKRODT	<u>1mCi/ML</u>	<u>N018150</u>	<u>001</u>	

INJECTABLE; INTRAVENOUS

THALLOUS CHLORIDE TL 201

<u>AP</u>	+	LANTHEUS MEDCL	<u>2mCi/ML</u>	<u>N017806</u>	<u>002</u>	Oct 09, 1998
<u>AP</u>		MALLINCKRODT	<u>2mCi/ML</u>	<u>A077698</u>	<u>001</u>	Nov 09, 2006

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

		ACTIENT PHARMS	100MG	A087942	001	Aug 22, 1983
			200MG	A087943	001	Aug 22, 1983
			300MG	A087944	001	Aug 22, 1983
	+		400MG	A081034	001	Feb 28, 1992

ELIXIR; ORAL

ELIXOPHYLLIN

	+	CARACO	80MG/15ML	A085186	001	

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>40MG/100ML</u>	<u>N019826</u>	<u>001</u>	Aug 14, 1992

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>80MG/100ML</u>	<u>N019826</u>	<u>002</u>	Aug 14, 1992

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>160MG/100ML</u>	<u>N019826</u>	<u>003</u>	Aug 14, 1992

THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>320MG/100ML</u>	<u>N019826</u>	<u>006</u>	Aug 14, 1992

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	HOSPIRA INC	<u>4MG/ML</u>	<u>N019211</u>	<u>007</u>	Dec 14, 1984
<u>AP</u>	+		<u>40MG/100ML</u>	<u>N019211</u>	<u>001</u>	Dec 14, 1984
<u>AP</u>	+		<u>160MG/100ML</u>	<u>N019211</u>	<u>003</u>	Dec 14, 1984
<u>AP</u>	+		<u>320MG/100ML</u>	<u>N019211</u>	<u>006</u>	Jan 20, 1988

SOLUTION; ORAL

THEOPHYLLINE

<u>AA</u>	+	SILARX	<u>80MG/15ML</u>	<u>A091156</u>	<u>001</u>	Apr 13, 2011
<u>AA</u>		TRIS PHARMA INC	<u>80MG/15ML</u>	<u>A091586</u>	<u>001</u>	Jun 15, 2012

TABLET; ORAL

THEOLAIR

	+	MEDICIS	125MG	A086399	001	
	+		250MG	A086399	002	

TABLET, EXTENDED RELEASE; ORAL

THEOCHRON

<u>AB</u>		CARACO	<u>100MG</u>	<u>A088320</u>	<u>001</u>	Feb 21, 1985
<u>AB</u>			<u>200MG</u>	<u>A088321</u>	<u>001</u>	Feb 21, 1985
<u>AB</u>			<u>300MG</u>	<u>A087400</u>	<u>002</u>	Jan 11, 1983

THEOPHYLLINE

<u>AB</u>		ALEMBIC LTD	<u>300MG</u>	<u>A090430</u>	<u>001</u>	Oct 27, 2010
<u>AB</u>			<u>450MG</u>	<u>A090430</u>	<u>002</u>	Oct 27, 2010
<u>AB</u>		GLENMARK GENERICS	<u>400MG</u>	<u>A090355</u>	<u>001</u>	Jul 13, 2010
<u>AB</u>			<u>600MG</u>	<u>A090355</u>	<u>002</u>	Jul 13, 2010
<u>AB</u>		NOSTRUM	<u>400MG</u>	<u>A040595</u>	<u>001</u>	Apr 21, 2006
<u>AB</u>	+		<u>600MG</u>	<u>A040560</u>	<u>002</u>	Apr 21, 2006
<u>AB</u>	+	PLIVA	<u>100MG</u>	<u>A089807</u>	<u>001</u>	Apr 30, 1990
<u>AB</u>	+		<u>200MG</u>	<u>A089808</u>	<u>001</u>	Apr 30, 1990
<u>AB</u>			<u>300MG</u>	<u>A089763</u>	<u>001</u>	Apr 30, 1990
<u>AB</u>	+		<u>450MG</u>	<u>A081236</u>	<u>001</u>	Nov 09, 1992

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 399 (of 428)

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

<u>AP</u>	+	FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A080556</u>	<u>001</u>	
<u>AP</u>		MYLAN INSTITUTIONAL	<u>100MG/ML</u>	<u>A091623</u>	<u>001</u>	Jun 25, 2012
<u>AP</u>		WATSON LABS	<u>100MG/ML</u>	<u>A080571</u>	<u>001</u>	
		THIAMINE HYDROCHLORIDE				
	+	WATSON LABS	200MG/ML	A080571	002	

THIOGUANINE

TABLET; ORAL

THIOGUANINE

	+	GLAXOSMITHKLINE	40MG	N012429	001	

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

<u>AB</u>		MUTUAL PHARM	<u>10MG</u>	<u>A089953</u>	<u>004</u>	Aug 01, 1986
<u>AB</u>			<u>25MG</u>	<u>A089953</u>	<u>003</u>	Aug 01, 1986
<u>AB</u>			<u>50MG</u>	<u>A089953</u>	<u>002</u>	Aug 01, 1986
<u>AB</u>			<u>100MG</u>	<u>A089953</u>	<u>001</u>	Oct 07, 1988
<u>AB</u>		MYLAN	<u>10MG</u>	<u>A088004</u>	<u>002</u>	Mar 15, 1983
<u>AB</u>			<u>25MG</u>	<u>A088004</u>	<u>003</u>	Mar 15, 1983
<u>AB</u>			<u>50MG</u>	<u>A088004</u>	<u>004</u>	Mar 15, 1983
<u>AB</u>	+		<u>100MG</u>	<u>A088004</u>	<u>001</u>	Nov 18, 1983

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

		BEDFORD	15MG/VIAL	A075547	001	Apr 02, 2001

THIOTHIXENE

CAPSULE; ORAL

NAVANE

<u>AB</u>		PFIZER	<u>1MG</u>	<u>N016584</u>	<u>001</u>	
<u>AB</u>			<u>2MG</u>	<u>N016584</u>	<u>002</u>	
<u>AB</u>	+		<u>5MG</u>	<u>N016584</u>	<u>003</u>	
<u>AB</u>			<u>10MG</u>	<u>N016584</u>	<u>004</u>	

THIOTHIXENE

<u>AB</u>		MYLAN	<u>1MG</u>	<u>A071093</u>	<u>002</u>	Jun 23, 1987
<u>AB</u>			<u>2MG</u>	<u>A071093</u>	<u>003</u>	Jun 23, 1987
<u>AB</u>			<u>5MG</u>	<u>A071093</u>	<u>004</u>	Jun 23, 1987
<u>AB</u>			<u>10MG</u>	<u>A071093</u>	<u>001</u>	Jun 23, 1987
<u>AB</u>		SANDOZ	<u>1MG</u>	<u>A071610</u>	<u>001</u>	Jun 24, 1987
<u>AB</u>			<u>2MG</u>	<u>A071570</u>	<u>001</u>	Jun 24, 1987
<u>AB</u>			<u>5MG</u>	<u>A071529</u>	<u>001</u>	Jun 24, 1987
<u>AB</u>			<u>10MG</u>	<u>A071530</u>	<u>001</u>	Jun 24, 1987
<u>AB</u>		WATSON LABS	<u>2MG</u>	<u>A070601</u>	<u>001</u>	Jun 05, 1987
<u>AB</u>			<u>5MG</u>	<u>A070602</u>	<u>001</u>	Jun 05, 1987

THYROTROPIN ALFA

INJECTABLE; INJECTION

THYROGEN

	+	GENZYME	1.1MG/VIAL	N020898	001	Nov 30, 1998

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

<u>AB</u>		CEPHALON	<u>2MG</u>	<u>N020646</u>	<u>005</u>	Apr 16, 1999
<u>AB</u>	+		<u>4MG</u>	<u>N020646</u>	<u>001</u>	Sep 30, 1997
		TIAGABINE HYDROCHLORIDE				
<u>AB</u>		SUN PHARM INDS	<u>2MG</u>	<u>A077555</u>	<u>001</u>	Nov 04, 2011

PRESCRIPTION DRUG PRODUCT LIST

3 - 400 (of 428)

TIAGABINE HYDROCHLORIDE

TABLET; ORAL					
<u>TIAGABINE HYDROCHLORIDE</u>					
<u>AB</u>	SUN PHARM INDS	<u>4MG</u>	<u>A077555</u>	<u>002</u>	Nov 04, 2011
	GABITRIL				
	CEPHALON	12MG	N020646	002	Sep 30, 1997
		16MG	N020646	003	Sep 30, 1997

TICAGRELOR

TABLET; ORAL					
BRILINTA					
	+ ASTRAZENECA LP	90MG	N022433	001	Jul 20, 2011

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL					
<u>TICLOPIDINE HYDROCHLORIDE</u>					
<u>AB</u>	APOTEX	<u>250MG</u>	<u>A075089</u>	<u>001</u>	Jul 01, 1999
<u>AB</u>	CARACO	<u>250MG</u>	<u>A075526</u>	<u>001</u>	Sep 26, 2002
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A075161</u>	<u>001</u>	Sep 13, 1999
<u>AB</u>	+ TEVA	<u>250MG</u>	<u>A075149</u>	<u>001</u>	Aug 20, 1999

TIGECYCLINE

INJECTABLE; IV (INFUSION)					
TYGACIL					
	+ WYETH PHARMS INC	50MG/VIAL	N021821	001	Jun 15, 2005

TILUDRONATE DISODIUM

TABLET; ORAL					
SKELID					
	+ SANOFI AVENTIS US	EQ 200MG BASE	N020707	001	Mar 07, 1997

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC					
	+ SANTEN OY	EQ 0.25% BASE	N020439	001	Mar 31, 1995
	+	EQ 0.5% BASE	N020439	002	Mar 31, 1995

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC					
<u>TIMOLOL MALEATE</u>					
<u>AB</u>	FALCON PHARMS	<u>EQ 0.25% BASE</u>	<u>N020963</u>	<u>001</u>	Oct 21, 1998
<u>AB</u>		<u>EQ 0.5% BASE</u>	<u>N020963</u>	<u>002</u>	Oct 21, 1998
<u>TIMOPTIC-XE</u>					
<u>AB</u>	+ ATON	<u>EQ 0.25% BASE</u>	<u>N020330</u>	<u>001</u>	Nov 04, 1993
<u>AB</u>	+	<u>EQ 0.5% BASE</u>	<u>N020330</u>	<u>002</u>	Nov 04, 1993
SOLUTION/DROPS; OPHTHALMIC					
<u>TIMOLOL MALEATE</u>					
<u>AT</u>	AKORN	<u>EQ 0.25% BASE</u>	<u>A074515</u>	<u>001</u>	Mar 25, 1997
<u>AT</u>		<u>EQ 0.5% BASE</u>	<u>A074466</u>	<u>001</u>	Mar 25, 1997
<u>AT</u>		<u>EQ 0.5% BASE</u>	<u>A074516</u>	<u>001</u>	Mar 25, 1997
<u>AT</u>	APOTEX INC	<u>EQ 0.25% BASE</u>	<u>A075411</u>	<u>001</u>	Sep 08, 2000
<u>AT</u>		<u>EQ 0.5% BASE</u>	<u>A075412</u>	<u>001</u>	Sep 08, 2000
<u>AT</u>	BAUSCH AND LOMB	<u>EQ 0.25% BASE</u>	<u>A074778</u>	<u>001</u>	Mar 25, 1997
<u>AT</u>		<u>EQ 0.5% BASE</u>	<u>A074776</u>	<u>001</u>	Mar 25, 1997
<u>AT</u>	FALCON PHARMS	<u>EQ 0.25% BASE</u>	<u>A074261</u>	<u>001</u>	Apr 28, 1995
<u>AT</u>		<u>EQ 0.5% BASE</u>	<u>A074262</u>	<u>001</u>	Apr 28, 1995
<u>AT</u>	FDC LTD	<u>EQ 0.25% BASE</u>	<u>A077259</u>	<u>001</u>	Apr 30, 2008
<u>AT</u>		<u>EQ 0.5% BASE</u>	<u>A077259</u>	<u>002</u>	Apr 30, 2008
<u>AT</u>	HI TECH PHARMA	<u>EQ 0.5% BASE</u>	<u>A075163</u>	<u>001</u>	Sep 10, 2002
<u>AT</u>	PACIFIC PHARMA	<u>EQ 0.25% BASE</u>	<u>A074746</u>	<u>001</u>	Mar 25, 1997
<u>AT</u>		<u>EQ 0.5% BASE</u>	<u>A074747</u>	<u>001</u>	Mar 25, 1997
<u>AT</u>	WOCKHARDT	<u>EQ 0.25% BASE</u>	<u>A078771</u>	<u>001</u>	Sep 28, 2009

PRESCRIPTION DRUG PRODUCT LIST

3 - 401 (of 428)

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

<u>TIMOLOL MALEATE</u>					
<u>AT</u>	WOCKHARDT	<u>EQ 0.5% BASE</u>	<u>A078771</u>	<u>002</u>	Sep 28, 2009
<u>TIMOPTIC</u>					
<u>AT</u>	+ ATON	<u>EQ 0.25% BASE</u>	<u>N018086</u>	<u>001</u>	
<u>AT</u>	+	<u>EQ 0.5% BASE</u>	<u>N018086</u>	<u>002</u>	
	ISTALOL				
BT	+ ISTA PHARMS	EQ 0.5% BASE	N021516	001	Jun 04, 2004
	TIMOPTIC IN OCUDOSE				
	+ ATON	EQ 0.25% BASE	N019463	001	Nov 05, 1986
	+	EQ 0.5% BASE	N019463	002	Nov 05, 1986
TABLET; ORAL					
<u>TIMOLOL MALEATE</u>					
	MYLAN	5MG	A072668	002	Jun 08, 1990
		10MG	A072668	003	Jun 08, 1990
	+	20MG	A072668	001	Jun 08, 1990

TINIDAZOLE

TABLET; ORAL

<u>TINDAMAX</u>					
<u>AB</u>	MISSION PHARMA	<u>250MG</u>	<u>N021618</u>	<u>001</u>	May 17, 2004
<u>AB</u>	+	<u>500MG</u>	<u>N021618</u>	<u>002</u>	May 17, 2004
<u>TINIDAZOLE</u>					
<u>AB</u>	NOVEL LABS INC	<u>250MG</u>	<u>A202044</u>	<u>001</u>	Apr 30, 2012
<u>AB</u>		<u>500MG</u>	<u>A202044</u>	<u>002</u>	Apr 30, 2012
<u>AB</u>	ROXANE	<u>250MG</u>	<u>A201172</u>	<u>001</u>	Apr 30, 2012
<u>AB</u>		<u>500MG</u>	<u>A201172</u>	<u>002</u>	Apr 30, 2012

TIOPRONIN

TABLET; ORAL

<u>TIOPRONIN</u>					
	+ MISSION PHARMA	100MG	N019569	001	Aug 11, 1988

TIOTROPIUM BROMIDE MONOHYDRATE

POWDER; INHALATION

<u>SPIRIVA</u>					
	+ BOEHRINGER INGELHEIM	EQ 0.018MG BASE/INH	N021395	001	Jan 30, 2004

TIPRANA VIR

CAPSULE; ORAL

<u>APTIVUS</u>					
	+ BOEHRINGER INGELHEIM	250MG	N021814	001	Jun 22, 2005
SOLUTION; ORAL					
<u>APTIVUS</u>					
	+ BOEHRINGER INGELHEIM	100MG/ML	N022292	001	Jun 23, 2008

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

<u>AGGRASTAT</u>					
	MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002
	+	EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	N020913	003	Apr 20, 2000

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

<u>TIZANIDINE HYDROCHLORIDE</u>					
<u>AB</u>	APOTEX INC	<u>EQ 2MG BASE</u>	<u>A078868</u>	<u>001</u>	Feb 03, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078868</u>	<u>002</u>	Feb 03, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A078868</u>	<u>003</u>	Feb 03, 2012
<u>AB</u>	MYLAN LABS	<u>EQ 2MG BASE</u>	<u>A091502</u>	<u>001</u>	Nov 09, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A091502</u>	<u>002</u>	Nov 09, 2012

PRESCRIPTION DRUG PRODUCT LIST

3 - 402 (of 428)

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

<u>AB</u>	MYLAN LABS	<u>EQ 6MG BASE</u>	<u>A091502</u>	<u>003</u>	Nov 09, 2012
	<u>ZANAFLEX</u>				
<u>AB</u>	ACORDA	<u>EQ 2MG BASE</u>	<u>N021447</u>	<u>001</u>	Aug 29, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>N021447</u>	<u>002</u>	Aug 29, 2002
<u>AB</u>	+	<u>EQ 6MG BASE</u>	<u>N021447</u>	<u>003</u>	Aug 29, 2002

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 2MG BASE</u>	<u>A076533</u>	<u>001</u>	Jan 16, 2004
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076533</u>	<u>002</u>	Jan 16, 2004
<u>AB</u>	CARACO	<u>EQ 2MG BASE</u>	<u>A076416</u>	<u>001</u>	Sep 29, 2003
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076416</u>	<u>002</u>	Sep 29, 2003
<u>AB</u>	COREPHARMA	<u>EQ 2MG BASE</u>	<u>A076347</u>	<u>001</u>	Oct 11, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076347</u>	<u>002</u>	Oct 11, 2002
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 2MG BASE</u>	<u>A076286</u>	<u>001</u>	Jul 03, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076286</u>	<u>002</u>	Jul 03, 2002
<u>AB</u>	MYLAN	<u>EQ 2MG BASE</u>	<u>A076354</u>	<u>001</u>	Mar 28, 2003
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076354</u>	<u>002</u>	Mar 28, 2003
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2MG BASE</u>	<u>A076282</u>	<u>001</u>	Dec 16, 2003
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076282</u>	<u>002</u>	Dec 16, 2003
<u>AB</u>	PROSAM LABS	<u>EQ 2MG BASE</u>	<u>A076281</u>	<u>001</u>	Oct 20, 2003
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076281</u>	<u>002</u>	Oct 20, 2003
<u>AB</u>	SANDOZ INC	<u>EQ 2MG BASE</u>	<u>A076280</u>	<u>001</u>	Nov 26, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076280</u>	<u>002</u>	Jun 27, 2002
<u>AB</u>	TEVA	<u>EQ 2MG BASE</u>	<u>A076284</u>	<u>001</u>	Jul 03, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076284</u>	<u>002</u>	Jul 03, 2002
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 2MG BASE</u>	<u>A091283</u>	<u>001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A091283</u>	<u>002</u>	Nov 28, 2012
	<u>ZANAFLEX</u>				
<u>AB</u>	+	<u>EQ 4MG BASE</u>	<u>N020397</u>	<u>001</u>	Nov 27, 1996

TOBRAMYCIN

OINTMENT; OPHTHALMIC

TOBREX

+	ALCON	0.3%	N050555	001	

SOLUTION; INHALATION

BETHKIS

	CORNERSTONE THERAP	300MG/4ML	N201820	001	Oct 12, 2012

TOBI

+	NOVARTIS PHARMS	300MG/5ML	N050753	001	Dec 22, 1997

SOLUTION/DROPS; OPHTHALMIC

AKTOB

<u>AT</u>	AKORN	<u>0.3%</u>	<u>A064096</u>	<u>001</u>	Jan 31, 1996
	<u>TOBRAMYCIN</u>				
<u>AT</u>	BAUSCH AND LOMB	<u>0.3%</u>	<u>A064052</u>	<u>001</u>	Nov 29, 1993
<u>AT</u>	FERA PHARMS	<u>0.3%</u>	<u>A065026</u>	<u>001</u>	Sep 11, 2001
<u>AT</u>	NOVEX	<u>0.3%</u>	<u>A065087</u>	<u>001</u>	Feb 25, 2002

TOBREX

<u>AT</u>	ALCON	<u>0.3%</u>	<u>A062535</u>	<u>001</u>	Dec 13, 1984
<u>AT</u>	+	<u>0.3%</u>	<u>N050541</u>	<u>001</u>	

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 10MG BASE/ML</u>	<u>A065122</u>	<u>001</u>	Nov 29, 2002
<u>AP</u>	+	<u>EQ 40MG BASE/ML</u>	<u>A065122</u>	<u>002</u>	Nov 29, 2002
<u>AP</u>		<u>EQ 1.2GM BASE/VIAL</u>	<u>N050789</u>	<u>001</u>	Jul 13, 2004
<u>AP</u>	HIKMA MAPLE	<u>EQ 40MG BASE/ML</u>	<u>A063117</u>	<u>001</u>	Apr 26, 1991
<u>AP</u>	+	<u>EQ 10MG BASE/ML</u>	<u>A063112</u>	<u>001</u>	Apr 30, 1991

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 403 (of 428)

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

<u>AP</u>	HOSPIRA	<u>EQ 40MG BASE/ML</u>	<u>A063111</u>	<u>001</u>	Apr 30, 1991
<u>AP</u>	+	<u>EQ 40MG BASE/ML</u>	<u>A063116</u>	<u>001</u>	May 18, 1992
<u>AP</u>	MARSAM PHARMS LLC	<u>EQ 10MG BASE/ML</u>	<u>A062945</u>	<u>001</u>	Aug 09, 1989
<u>AP</u>	PFIZER	<u>EQ 40MG BASE/ML</u>	<u>A065407</u>	<u>001</u>	Mar 11, 2008
<u>AP</u>	TEVA PARENTERAL	<u>EQ 40MG BASE/ML</u>	<u>A063100</u>	<u>001</u>	Jan 30, 1992
<u>AP</u>	+	<u>EQ 1.2GM BASE/VIAL</u>	<u>A065013</u>	<u>001</u>	Aug 17, 2001
<u>TOBRAMYCIN SULFATE (PHARMACY BULK)</u>					
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 40MG BASE/ML</u>	<u>A065120</u>	<u>001</u>	Nov 29, 2002
	TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	+	EQ 1.2MG BASE/ML	A063081	003	Jul 31, 1990
	+	EQ 1.6MG BASE/ML	A063081	006	Jun 02, 1993
	+	EQ 80MG BASE/100ML	A063081	001	Jul 31, 1990

TOFACITINIB CITRATE

TABLET; ORAL

XELJANZ

+	PFIZER	EQ 5MG BASE	N203214	001	Nov 06, 2012

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

<u>AB</u>	MYLAN	<u>250MG</u>	<u>A070259</u>	<u>001</u>	Jan 02, 1986
<u>AB</u>	+	<u>500MG</u>	<u>A070259</u>	<u>003</u>	Mar 17, 1986
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A070514</u>	<u>001</u>	Jan 09, 1986
<u>AB</u>		<u>500MG</u>	<u>A070515</u>	<u>001</u>	Jan 09, 1986

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

+	MYLAN PHARMS INC	500MG	A086445	001	

TOLCAPONE

TABLET; ORAL

TASMAR

+	VALEANT PHARMS LLC	100MG	N020697	001	Jan 29, 1998

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

<u>AB</u>	MYLAN	<u>EQ 400MG BASE</u>	<u>A073393</u>	<u>001</u>	May 27, 1993
<u>AB</u>	+	<u>EQ 400MG BASE</u>	<u>A073290</u>	<u>001</u>	Nov 27, 1991
TABLET; ORAL					
<u>TOLMETIN SODIUM</u>					
<u>AB</u>	MUTUAL PHARM	<u>EQ 200MG BASE</u>	<u>A073310</u>	<u>001</u>	Nov 27, 1991
<u>AB</u>	+	<u>EQ 600MG BASE</u>	<u>A074473</u>	<u>001</u>	Aug 30, 1994

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

DETROL LA

	PHARMACIA AND UPJOHN	2MG	N021228	001	Dec 22, 2000
+		4MG	N021228	002	Dec 22, 2000

TABLET; ORAL

DETROL

<u>AB</u>	PHARMACIA AND UPJOHN	<u>1MG</u>	<u>N020771</u>	<u>001</u>	Mar 25, 1998
<u>AB</u>	+	<u>2MG</u>	<u>N020771</u>	<u>002</u>	Mar 25, 1998
<u>TOLTERODINE TARTRATE</u>					
<u>AB</u>	APOTEX CORP	<u>1MG</u>	<u>A200164</u>	<u>001</u>	Sep 25, 2012
<u>AB</u>		<u>2MG</u>	<u>A200164</u>	<u>002</u>	Sep 25, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>1MG</u>	<u>A202641</u>	<u>001</u>	Nov 27, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 404 (of 428)

TOLTERODINE TARTRATE

TABLET; ORAL

TOLTERODINE TARTRATE

<u>AB</u>	MYLAN PHARMS INC	<u>2MG</u>	<u>A202641</u>	<u>002</u>	Nov 27, 2012

TOLVAPTAN

TABLET; ORAL

SAMSCA

	OTSUKA AMERICA PHARM	15MG	N022275	001	May 19, 2009
+		30MG	N022275	002	May 19, 2009

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX

<u>AB</u>	JANSSEN PHARMS	<u>15MG</u>	<u>N020844</u>	<u>001</u>	Oct 26, 1998

<u>AB</u>	+	<u>25MG</u>	<u>N020844</u>	<u>002</u>	Oct 26, 1998

TOPIRAMATE

<u>AB</u>	MYLAN	<u>15MG</u>	<u>A078418</u>	<u>001</u>	Oct 14, 2009

<u>AB</u>		<u>25MG</u>	<u>A078418</u>	<u>002</u>	Oct 14, 2009

<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A079206</u>	<u>001</u>	Oct 14, 2009

<u>AB</u>		<u>25MG</u>	<u>A079206</u>	<u>002</u>	Oct 14, 2009

<u>AB</u>	TEVA	<u>15MG</u>	<u>A076575</u>	<u>001</u>	Apr 17, 2009

<u>AB</u>		<u>25MG</u>	<u>A076575</u>	<u>002</u>	Apr 17, 2009

<u>AB</u>	WATSON LABS	<u>15MG</u>	<u>A077868</u>	<u>001</u>	Apr 15, 2009

<u>AB</u>		<u>25MG</u>	<u>A077868</u>	<u>002</u>	Apr 15, 2009

<u>AB</u>	ZYDUS PHARMS USA INC	<u>15MG</u>	<u>A078877</u>	<u>001</u>	Oct 14, 2009

<u>AB</u>		<u>25MG</u>	<u>A078877</u>	<u>002</u>	Oct 14, 2009

TABLET; ORAL

TOPAMAX

<u>AB</u>	+	JANSSEN PHARMS	<u>25MG</u>	<u>N020505</u>	<u>004</u>	Dec 24, 1996

<u>AB</u>		<u>50MG</u>	<u>N020505</u>	<u>005</u>	Dec 24, 1996

<u>AB</u>		<u>100MG</u>	<u>N020505</u>	<u>001</u>	Dec 24, 1996

<u>AB</u>		<u>200MG</u>	<u>N020505</u>	<u>002</u>	Dec 24, 1996

TOPIRAMATE

<u>AB</u>	ACCORD HLTHCARE	<u>25MG</u>	<u>A076311</u>	<u>001</u>	Mar 27, 2009

<u>AB</u>		<u>50MG</u>	<u>A076311</u>	<u>002</u>	Mar 27, 2009

<u>AB</u>		<u>100MG</u>	<u>A076311</u>	<u>003</u>	Mar 27, 2009

<u>AB</u>		<u>200MG</u>	<u>A076311</u>	<u>004</u>	Mar 27, 2009

<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A077733</u>	<u>001</u>	Mar 27, 2009

<u>AB</u>		<u>50MG</u>	<u>A077733</u>	<u>002</u>	Mar 27, 2009

<u>AB</u>		<u>100MG</u>	<u>A077733</u>	<u>003</u>	Mar 27, 2009

<u>AB</u>		<u>200MG</u>	<u>A077733</u>	<u>004</u>	Mar 27, 2009

<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078462</u>	<u>001</u>	Mar 27, 2009

<u>AB</u>		<u>50MG</u>	<u>A078462</u>	<u>002</u>	Mar 27, 2009

<u>AB</u>		<u>100MG</u>	<u>A078462</u>	<u>003</u>	Mar 27, 2009

<u>AB</u>		<u>200MG</u>	<u>A078462</u>	<u>004</u>	Mar 27, 2009

<u>AB</u>	CIPLA LTD	<u>25MG</u>	<u>A076343</u>	<u>001</u>	Mar 27, 2009

<u>AB</u>		<u>50MG</u>	<u>A076343</u>	<u>002</u>	Mar 27, 2009

<u>AB</u>		<u>100MG</u>	<u>A076343</u>	<u>003</u>	Mar 27, 2009

<u>AB</u>		<u>200MG</u>	<u>A076343</u>	<u>004</u>	Mar 27, 2009

<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A077627</u>	<u>001</u>	Mar 27, 2009

<u>AB</u>		<u>50MG</u>	<u>A077627</u>	<u>002</u>	Mar 27, 2009

<u>AB</u>		<u>100MG</u>	<u>A077627</u>	<u>003</u>	Mar 27, 2009

<u>AB</u>		<u>200MG</u>	<u>A077627</u>	<u>004</u>	Mar 27, 2009

<u>AB</u>	INVAGEN PHARMS	<u>25MG</u>	<u>A079162</u>	<u>001</u>	Mar 27, 2009

<u>AB</u>		<u>50MG</u>	<u>A079162</u>	<u>002</u>	Mar 27, 2009

<u>AB</u>		<u>100MG</u>	<u>A079162</u>	<u>003</u>	Mar 27, 2009

<u>AB</u>		<u>200MG</u>	<u>A079162</u>	<u>004</u>	Mar 27, 2009

<u>AB</u>	MYLAN	<u>25MG</u>	<u>A076314</u>	<u>001</u>	Mar 27, 2009

<u>AB</u>		<u>50MG</u>	<u>A076314</u>	<u>002</u>	Mar 27, 2009

<u>AB</u>		<u>100MG</u>	<u>A076314</u>	<u>003</u>	Mar 27, 2009

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 405 (of 428)

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

<u>AB</u>	MYLAN	<u>200MG</u>	<u>A076314</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	RANBAXY	<u>25MG</u>	<u>A076327</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076327</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076327</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>	SUN PHARM INDS LTD	<u>25MG</u>	<u>A090278</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090278</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090278</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A090278</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076317</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076317</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076317</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076317</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A079153</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A079153</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079153</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079153</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	UNICHEM	<u>25MG</u>	<u>A090162</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090162</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090162</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>	UPSHER SMITH	<u>25MG</u>	<u>A078499</u>	<u>001</u>	Jan 07, 2010
<u>AB</u>		<u>50MG</u>	<u>A078499</u>	<u>002</u>	Jan 07, 2010
<u>AB</u>		<u>100MG</u>	<u>A078499</u>	<u>003</u>	Jan 07, 2010
<u>AB</u>		<u>200MG</u>	<u>A078499</u>	<u>004</u>	Jan 07, 2010
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A077643</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A077643</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077643</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077643</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	WOCKHARDT USA	<u>25MG</u>	<u>A090353</u>	<u>001</u>	Sep 01, 2010
<u>AB</u>		<u>50MG</u>	<u>A090353</u>	<u>002</u>	Sep 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A090353</u>	<u>003</u>	Sep 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A090353</u>	<u>004</u>	Sep 01, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078235</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A078235</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078235</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078235</u>	<u>004</u>	Mar 27, 2009

TOPOTECAN HYDROCHLORIDE

CAPSULE; ORAL

HYCAMTIN

SMITHKLINE BEECHAM

EQ 0.25MG BASE

N020981 001 Oct 11, 2007

+

EQ 1MG BASE

N020981 002 Oct 11, 2007

INJECTABLE; INJECTION

HYCAMTIN

<u>AP</u>	+ GLAXOSMITHKLINE	<u>EQ 4MG BASE/VIAL</u>	<u>N020671</u>	<u>001</u>	May 28, 1996
	<u>TOPOTECAN HYDROCHLORIDE</u>				
<u>AP</u>	ACTAVIS TOTOWA	<u>EQ 4MG BASE/VIAL</u>	<u>A090620</u>	<u>001</u>	Dec 02, 2010
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A201191</u>	<u>001</u>	Mar 09, 2011
<u>AP</u>	FRESENIUS KABI ONCOL	<u>EQ 4MG BASE/VIAL</u>	<u>A091376</u>	<u>001</u>	Nov 29, 2010
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 4MG BASE/VIAL</u>	<u>A091089</u>	<u>001</u>	Nov 29, 2010
<u>AP</u>	MYLAN LLC	<u>EQ 4MG BASE/VIAL</u>	<u>A201166</u>	<u>001</u>	Aug 08, 2012
<u>AP</u>	ONCO THERAPIES LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A091542</u>	<u>001</u>	Aug 28, 2012
<u>AP</u>	SAGENT PHARMS	<u>EQ 4MG BASE/VIAL</u>	<u>A091284</u>	<u>001</u>	Jan 26, 2011
<u>AP</u>	THREE RIVERS PHARMS	<u>EQ 4MG BASE/VIAL</u>	<u>A091199</u>	<u>001</u>	Dec 01, 2010

SOLUTION; INTRAVENOUS

TOPOTECAN

<u>AP</u>	+ HOSPIRA INC	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>N200582</u>	<u>001</u>	Feb 02, 2011
<u>AP</u>	TEVA PHARMS	<u>EQ 4MG BASE/4ML (1MG/ML)</u>	<u>N022453</u>	<u>001</u>	Dec 20, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 406 (of 428)

TOREMIFENE CITRATE

TABLET; ORAL

FARESTON

+ GTX INC

EQ 60MG BASE

N020497

001

May 29, 1997

TORSEMIDE

INJECTABLE; INJECTION

TORSEMIDEAP + BEDFORD LABS20MG/2ML (10MG/ML)A078007001

Jun 11, 2008

AP +50MG/5ML (10MG/ML)A078007002

Jun 11, 2008

AP LUITPOLD50MG/5ML (10MG/ML)A090656002

Apr 21, 2010

AP20MG/2ML (10MG/ML)A090656001

Apr 21, 2010

TABLET; ORAL

DEMADEXAB MEDA PHARMS5MGN020136001

Aug 23, 1993

AB10MGN020136002

Aug 23, 1993

AB +20MGN020136003

Aug 23, 1993

AB100MGN020136004

Aug 23, 1993

TORSEMIDEAB APOTEX INC5MGA076894001

May 31, 2005

AB10MGA076894002

May 31, 2005

AB20MGA076894003

May 31, 2005

AB100MGA076894004

May 31, 2005

AB AUROBINDO PHARMA5MGA078249001

Oct 17, 2007

AB10MGA078249002

Oct 17, 2007

AB20MGA078249003

Oct 17, 2007

AB100MGA078249004

Oct 17, 2007

AB HETERO DRUGS5MGA079234001

Jan 27, 2009

AB10MGA079234002

Jan 27, 2009

AB20MGA079234003

Jan 27, 2009

AB100MGA079234004

Jan 27, 2009

AB PAR PHARM5MGA076226001

May 27, 2003

AB10MGA076226002

May 27, 2003

AB20MGA076226003

May 27, 2003

AB100MGA076226004

May 27, 2003

AB PLIVA PHARM IND5MGA076346001

May 30, 2003

AB10MGA076346002

May 30, 2003

AB20MGA076346003

May 30, 2003

AB100MGA076346004

Oct 19, 2004

AB ROXANE5MGA076943001

Mar 01, 2005

AB10MGA076943002

Mar 01, 2005

AB20MGA076943003

Mar 01, 2005

AB SUN PHARM INDS5MGA078478001

Feb 26, 2008

AB10MGA078478002

Feb 26, 2008

AB20MGA078478003

Feb 26, 2008

AB100MGA078478004

Feb 26, 2008

AB TEVA5MGA076110001

May 14, 2002

AB10MGA076110002

May 14, 2002

AB20MGA076110003

May 14, 2002

AB100MGA076110004

May 14, 2002

AB VINTAGE PHARMS5MGA090613001

Mar 22, 2011

AB10MGA090613002

Mar 22, 2011

AB20MGA090613003

Mar 22, 2011

AB100MGA090613004

Mar 22, 2011

TRAMADOL HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
CONZIP

+ CIPHER PHARMS INC

100MG

N022370

001

May 07, 2010

150MG

N022370

004

Aug 01, 2011

200MG

N022370

002

May 07, 2010

PRESCRIPTION DRUG PRODUCT LIST

3 - 407 (of 428)

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CONZIP

CIPHER PHARMS INC 300MG

N022370 003 May 07, 2010

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB</u>	ALVOGEN	<u>50MG</u>	<u>A202075</u>	<u>001</u>	Nov 28, 2011
<u>AB</u>	AMNEAL PHARMS	<u>50MG</u>	<u>A076003</u>	<u>001</u>	Jun 20, 2002
<u>AB</u>	APOTEX	<u>50MG</u>	<u>A075981</u>	<u>001</u>	Jul 10, 2002
<u>AB</u>	CARACO	<u>50MG</u>	<u>A075964</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	IPCA LABS LTD	<u>50MG</u>	<u>A201973</u>	<u>001</u>	Nov 16, 2012
<u>AB</u>	MALLINCKRODT	<u>50MG</u>	<u>A075983</u>	<u>001</u>	Jun 25, 2002
<u>AB</u>	MUTUAL PHARM	<u>50MG</u>	<u>A076100</u>	<u>001</u>	Jun 20, 2002
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A075986</u>	<u>001</u>	Jun 21, 2002
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A075980</u>	<u>001</u>	Nov 21, 2002
<u>AB</u>	NORTHSTAR HLTHCARE	<u>50MG</u>	<u>A078935</u>	<u>001</u>	May 26, 2010
<u>AB</u>	PLIVA	<u>50MG</u>	<u>A075982</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>	TEVA	<u>50MG</u>	<u>A075977</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	WATSON LABS	<u>50MG</u>	<u>A075962</u>	<u>001</u>	Jun 24, 2002
<u>AB</u>	ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A090404</u>	<u>001</u>	Jan 31, 2011

ULTRAM

AB + JANSSEN PHARMS 50MG

N020281 002 Mar 03, 1995

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB1</u>	LUPIN LTD	<u>100MG</u>	<u>A200503</u>	<u>001</u>	Aug 29, 2011
<u>AB1</u>		<u>200MG</u>	<u>A200503</u>	<u>002</u>	Aug 29, 2011
<u>AB1</u>		<u>300MG</u>	<u>A200503</u>	<u>003</u>	Aug 29, 2011
<u>AB1</u>	PAR PHARM	<u>100MG</u>	<u>A078783</u>	<u>001</u>	Nov 13, 2009
<u>AB1</u>		<u>200MG</u>	<u>A078783</u>	<u>002</u>	Nov 13, 2009
<u>AB1</u>		<u>300MG</u>	<u>A078783</u>	<u>003</u>	Sep 20, 2011
<u>AB1</u>	SUN PHARMA GLOBAL	<u>100MG</u>	<u>A201384</u>	<u>001</u>	Dec 07, 2011
<u>AB1</u>		<u>200MG</u>	<u>A201384</u>	<u>002</u>	Dec 07, 2011
<u>AB1</u>		<u>300MG</u>	<u>A201384</u>	<u>003</u>	Dec 07, 2011

ULTRAM ER

AB1 + VALEANT INTL 100MG

N021692 001 Sep 08, 2005

AB1 200MG

N021692 002 Sep 08, 2005

AB1 300MG

N021692 003 Sep 08, 2005

RYZOLT

AB2 + PURDUE PHARMA 100MG

N021745 001 Dec 30, 2008

AB2 200MG

N021745 002 Dec 30, 2008

AB2 300MG

N021745 003 Dec 30, 2008

TRAMADOL HYDROCHLORIDE

<u>AB2</u>	ACTAVIS	<u>100MG</u>	<u>A091609</u>	<u>001</u>	Jun 27, 2012
<u>AB2</u>		<u>200MG</u>	<u>A091609</u>	<u>002</u>	Jun 27, 2012
<u>AB2</u>		<u>300MG</u>	<u>A091609</u>	<u>003</u>	Jun 27, 2012
<u>AB2</u>	ANCHEN PHARMS	<u>100MG</u>	<u>A200491</u>	<u>001</u>	Jun 27, 2012
<u>AB2</u>		<u>200MG</u>	<u>A200491</u>	<u>002</u>	Jun 27, 2012
<u>AB2</u>		<u>300MG</u>	<u>A200491</u>	<u>003</u>	Jun 27, 2012
<u>AB2</u>	SUN PHARMA GLOBAL	<u>100MG</u>	<u>A091607</u>	<u>001</u>	Dec 30, 2011
<u>AB2</u>		<u>200MG</u>	<u>A091607</u>	<u>002</u>	Dec 30, 2011
<u>AB2</u>		<u>300MG</u>	<u>A091607</u>	<u>003</u>	Dec 30, 2011

TABLET, ORALLY DISINTEGRATING; ORAL

RYBIX ODT

+ SHIONOGI INC 50MG

N021693 001 May 05, 2005

TRANSDOLAPRIL

TABLET; ORAL

MAVIK

<u>AB</u>	ABBVIE	<u>1MG</u>	<u>N020528</u>	<u>001</u>	Apr 26, 1996
<u>AB</u>		<u>2MG</u>	<u>N020528</u>	<u>002</u>	Apr 26, 1996
<u>AB</u>	+	<u>4MG</u>	<u>N020528</u>	<u>003</u>	Apr 26, 1996

PRESCRIPTION DRUG PRODUCT LIST

3 - 408 (of 428)

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

<u>AB</u>	AUROBINDO PHARMA	<u>1MG</u>	<u>A078438</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A078438</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A078438</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	CIPLA	<u>1MG</u>	<u>A077307</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077307</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077307</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	COREPHARMA	<u>1MG</u>	<u>A077256</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077256</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077256</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>1MG</u>	<u>A078493</u>	<u>001</u>	Aug 25, 2008
<u>AB</u>		<u>2MG</u>	<u>A078493</u>	<u>002</u>	Aug 25, 2008
<u>AB</u>		<u>4MG</u>	<u>A078493</u>	<u>003</u>	Aug 25, 2008
<u>AB</u>	EPIC PHARMA	<u>1MG</u>	<u>A078508</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>2MG</u>	<u>A078508</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>4MG</u>	<u>A078508</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A078320</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A078320</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A078320</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	LUPIN	<u>1MG</u>	<u>A077522</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077522</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077522</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A078346</u>	<u>001</u>	Apr 28, 2008
<u>AB</u>		<u>2MG</u>	<u>A078346</u>	<u>002</u>	Apr 28, 2008
<u>AB</u>		<u>4MG</u>	<u>A078346</u>	<u>003</u>	Apr 28, 2008
<u>AB</u>	TEVA PHARMS	<u>1MG</u>	<u>A077489</u>	<u>001</u>	Dec 12, 2006
<u>AB</u>		<u>2MG</u>	<u>A077489</u>	<u>002</u>	Dec 12, 2006
<u>AB</u>		<u>4MG</u>	<u>A077489</u>	<u>003</u>	Dec 12, 2006
<u>AB</u>	WATSON LABS	<u>1MG</u>	<u>A077805</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077805</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077805</u>	<u>003</u>	Jun 12, 2007

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TARKA

<u>AB</u>	ABBVIE	<u>1MG;240MG</u>	<u>N020591</u>	<u>003</u>	Oct 22, 1996
<u>AB</u>		<u>2MG;180MG</u>	<u>N020591</u>	<u>001</u>	Oct 22, 1996
<u>AB</u>		<u>2MG;240MG</u>	<u>N020591</u>	<u>004</u>	Oct 22, 1996
<u>AB</u>	+	<u>4MG;240MG</u>	<u>N020591</u>	<u>002</u>	Oct 22, 1996
<u>TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE</u>					
<u>AB</u>	GLENMARK GENERICS	<u>1MG;240MG</u>	<u>A079135</u>	<u>004</u>	Aug 30, 2010
<u>AB</u>		<u>2MG;180MG</u>	<u>A079135</u>	<u>001</u>	May 26, 2010
<u>AB</u>		<u>2MG;240MG</u>	<u>A079135</u>	<u>002</u>	May 26, 2010
<u>AB</u>		<u>4MG;240MG</u>	<u>A079135</u>	<u>003</u>	May 05, 2010

TRANEXAMIC ACID

INJECTABLE; INJECTION

CYKLOKAPRON

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>100MG/ML</u>	<u>N019281</u>	<u>001</u>	Dec 30, 1986
<u>TRANEXAMIC ACID</u>						
<u>AP</u>		FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A091596</u>	<u>001</u>	Mar 02, 2012
<u>AP</u>		LUITPOLD	<u>100MG/ML</u>	<u>A201885</u>	<u>001</u>	Aug 10, 2011
<u>AP</u>		MYLAN INSTITUTIONAL	<u>100MG/ML</u>	<u>A091657</u>	<u>001</u>	Nov 03, 2011
<u>AP</u>		VERSAPHARM INC	<u>100MG/ML</u>	<u>A202373</u>	<u>001</u>	Nov 17, 2011

TABLET; ORAL

LYSTEDA

<u>AB</u>	+	FERRING PHARMS AS	<u>650MG</u>	<u>N022430</u>	<u>001</u>	Nov 13, 2009
<u>TRANEXAMIC ACID</u>						
<u>AB</u>		WATSON LABS INC FL	<u>650MG</u>	<u>A202093</u>	<u>001</u>	Dec 27, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 409 (of 428)

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

<u>AB</u>	+	COVIS PHARMA	<u>EQ 10MG BASE</u>	<u>N012342</u>	<u>003</u>	Aug 16, 1985

TRANLYCYPROMINE SULFATE

<u>AB</u>		PAR PHARM	<u>EQ 10MG BASE</u>	<u>A040640</u>	<u>001</u>	Jun 29, 2006

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN Z

+	ALCON PHARMS LTD	0.004%	N021994	001	Sep 21, 2006

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

<u>AB</u>		ALVOGEN	<u>50MG</u>	<u>A071636</u>	<u>001</u>	Apr 18, 1988

<u>AB</u>			<u>100MG</u>	<u>A071514</u>	<u>001</u>	Apr 18, 1988

<u>AB</u>		APOTEX	<u>50MG</u>	<u>A071258</u>	<u>001</u>	Mar 25, 1987

<u>AB</u>	+	APOTEX INC	<u>100MG</u>	<u>A071196</u>	<u>001</u>	Mar 25, 1987

<u>AB</u>			<u>150MG</u>	<u>A071196</u>	<u>002</u>	Apr 26, 1999

<u>AB</u>			<u>300MG</u>	<u>A071196</u>	<u>003</u>	Apr 26, 1999

<u>AB</u>		MUTUAL PHARM	<u>50MG</u>	<u>A073137</u>	<u>002</u>	Mar 24, 1993

<u>AB</u>			<u>100MG</u>	<u>A073137</u>	<u>001</u>	Mar 24, 1993

<u>AB</u>			<u>150MG</u>	<u>A073137</u>	<u>003</u>	Dec 22, 1995

<u>AB</u>		MYLAN PHARMS INC	<u>50MG</u>	<u>A090514</u>	<u>001</u>	Jun 02, 2009

<u>AB</u>			<u>100MG</u>	<u>A090514</u>	<u>002</u>	Jun 02, 2009

<u>AB</u>			<u>150MG</u>	<u>A090514</u>	<u>003</u>	Jun 02, 2009

<u>AB</u>			<u>300MG</u>	<u>A090514</u>	<u>004</u>	Jun 02, 2009

<u>AB</u>		PLIVA	<u>50MG</u>	<u>A071523</u>	<u>001</u>	Dec 11, 1987

<u>AB</u>			<u>100MG</u>	<u>A071524</u>	<u>001</u>	Dec 11, 1987

<u>AB</u>			<u>150MG</u>	<u>A071525</u>	<u>001</u>	Mar 09, 1988

<u>AB</u>		VINTAGE	<u>50MG</u>	<u>A072192</u>	<u>001</u>	Feb 02, 1989

<u>AB</u>			<u>100MG</u>	<u>A072193</u>	<u>001</u>	Feb 02, 1989

<u>AB</u>		WATSON LABS	<u>50MG</u>	<u>A070857</u>	<u>001</u>	Oct 10, 1986

<u>AB</u>			<u>100MG</u>	<u>A070858</u>	<u>001</u>	Oct 10, 1986

TABLET, EXTENDED RELEASE; ORAL

OLEPTRO

+	ANGELINI LLC	150MG	N022411	001	Feb 02, 2010

		300MG	N022411	002	Feb 02, 2010

TREPROSTINIL SODIUM

INJECTABLE; IV (INFUSION)-SC

UNITED THERAP	1MG/ML	N021272	001	May 21, 2002

	2.5MG/ML	N021272	002	May 21, 2002

	5MG/ML	N021272	003	May 21, 2002

+	10MG/ML	N021272	004	May 21, 2002

SOLUTION; INHALATION

TYVASO

+	UNITED THERAP	EQ 0.6MG BASE/ML	N022387	001	Jul 30, 2009

TRETINOIN

CAPSULE; ORAL

TRETINOIN

<u>AB</u>		ANCHEN PHARMS	<u>10MG</u>	<u>A201687</u>	<u>001</u>	Oct 24, 2012

<u>AB</u>	+	BARR LABS INC	<u>10MG</u>	<u>A077684</u>	<u>001</u>	Jun 22, 2007

CREAM; TOPICAL

AVITA

<u>AB</u>		MYLAN PHARMS INC	<u>0.025%</u>	<u>N020404</u>	<u>003</u>	Jan 14, 1997

RETIN-A

<u>AB</u>	+	VALEANT INTL	<u>0.025%</u>	<u>N019049</u>	<u>001</u>	Sep 16, 1988

PRESCRIPTION DRUG PRODUCT LIST

3 - 410 (of 428)

TRETINOIN

CREAM; TOPICAL				
RETIN-A				
<u>AB</u>	+ VALEANT INTL	<u>0.1%</u>	<u>N017340</u>	<u>001</u>
TRETINOIN				
<u>AB</u>	PRECISION DERMAT	<u>0.025%</u>	<u>A075264</u>	<u>001</u> Dec 24, 1998
<u>AB</u>		<u>0.1%</u>	<u>A075213</u>	<u>001</u> Dec 24, 1998
RETIN-A				
<u>AB1</u>	+ VALEANT INTL	<u>0.05%</u>	<u>N017522</u>	<u>001</u>
TRETINOIN				
<u>AB1</u>	PRECISION DERMAT	<u>0.05%</u>	<u>A075265</u>	<u>001</u> Dec 24, 1998
RENOVA				
<u>AB2</u>	+ VALEANT INTL	<u>0.05%</u>	<u>N019963</u>	<u>001</u> Dec 29, 1995
TRETINOIN				
<u>AB2</u>	SUNEVA MEDCL	<u>0.05%</u>	<u>A076498</u>	<u>001</u> Sep 15, 2005
RENOVA				
	+ VALEANT INTL	0.02%	N021108	001 Aug 31, 2000
TRETINOIN				
	+ PRECISION DERMAT	0.0375%	A090098	001 Mar 22, 2010
		0.075%	A202209	001 Oct 11, 2012
GEL; TOPICAL				
RETIN-A				
<u>AB</u>	+ VALEANT INTL	<u>0.01%</u>	<u>N017955</u>	<u>001</u>
<u>AB</u>		<u>0.025%</u>	<u>N017579</u>	<u>002</u>
TRETINOIN				
<u>AB</u>	PRECISION DERMAT	<u>0.01%</u>	<u>A075589</u>	<u>001</u> Jun 11, 2002
<u>AB</u>		<u>0.025%</u>	<u>A075529</u>	<u>001</u> Feb 22, 2000
AVITA				
BT	MYLAN	0.025%	N020400	001 Jan 29, 1998
ATRALIN				
	+ DOW PHARM SCIENCES	0.05%	N022070	001 Jul 26, 2007
RETIN-A MICRO				
	+ VALEANT INTL	0.04%	N020475	002 May 10, 2002
		0.1%	N020475	001 Feb 07, 1997
SOLUTION; TOPICAL				
RETIN-A				
<u>AT</u>	+ VALEANT INTL	<u>0.05%</u>	<u>N016921</u>	<u>001</u>
TRETINOIN				
<u>AT</u>	WOCKHARDT	<u>0.05%</u>	<u>A075260</u>	<u>001</u> Jan 25, 1999

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL				
KENALOG				
<u>AT</u>	+ APOTHECON	<u>0.025%</u>	<u>N011601</u>	<u>003</u>
<u>AT</u>		<u>0.1%</u>	<u>N011601</u>	<u>006</u>
TRIACET				
<u>AT</u>	TEVA	<u>0.025%</u>	<u>A084908</u>	<u>001</u>
<u>AT</u>		<u>0.5%</u>	<u>A084908</u>	<u>003</u>
TRIAMCINOLONE ACETONIDE				
<u>AT</u>	FOUGERA PHARMS	<u>0.025%</u>	<u>A085692</u>	<u>001</u>
<u>AT</u>		<u>0.1%</u>	<u>A085692</u>	<u>003</u>
<u>AT</u>		<u>0.5%</u>	<u>A085692</u>	<u>002</u>
<u>AT</u>	G AND W LABS	<u>0.025%</u>	<u>A089797</u>	<u>001</u> May 31, 1991
<u>AT</u>	PERRIGO NEW YORK	<u>0.025%</u>	<u>A086415</u>	<u>001</u>
<u>AT</u>		<u>0.1%</u>	<u>A086414</u>	<u>001</u>
<u>AT</u>		<u>0.5%</u>	<u>A086413</u>	<u>001</u>
<u>AT</u>	TARO	<u>0.025%</u>	<u>A086277</u>	<u>001</u>
<u>AT</u>		<u>0.1%</u>	<u>A040039</u>	<u>001</u> Nov 26, 1997
<u>AT</u>		<u>0.1%</u>	<u>A086276</u>	<u>001</u>
<u>AT</u>		<u>0.5%</u>	<u>A086275</u>	<u>001</u>
<u>AT</u>	VINTAGE	<u>0.025%</u>	<u>A040671</u>	<u>001</u> Jun 09, 2006
<u>AT</u>		<u>0.1%</u>	<u>A040671</u>	<u>002</u> Jun 09, 2006

PRESCRIPTION DRUG PRODUCT LIST

3 - 411 (of 428)

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL				
<u>TRIDERM</u>				
<u>AT</u>	CROWN LABS	<u>0.1%</u>	<u>A088042</u>	<u>001</u> Mar 19, 1984
INJECTABLE; INJECTION				
<u>KENALOG-10</u>				
<u>AB</u>	APOTHECON	<u>10MG/ML</u>	<u>N012041</u>	<u>001</u>
<u>KENALOG-40</u>				
<u>AB</u>	+ APOTHECON	<u>40MG/ML</u>	<u>N014901</u>	<u>001</u>
<u>TRIAMCINOLONE ACETONIDE</u>				
<u>AB</u>	SANDOZ	<u>10MG/ML</u>	<u>A090166</u>	<u>001</u> May 27, 2009
<u>AB</u>		<u>40MG/ML</u>	<u>A090164</u>	<u>001</u> May 27, 2009
INJECTABLE; INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL				
TRIVARIS				
	+ ALLERGAN	8MG/0.1ML (8MG/0.1ML)	N022220	001 Jun 16, 2008
INJECTABLE; INTRAVITREAL				
TRIESENCE				
	+ ALCON	40MG/ML (40MG/ML)	N022048	001 Nov 29, 2007
LOTION; TOPICAL				
<u>TRIAMCINOLONE ACETONIDE</u>				
<u>AT</u>	FOUGERA PHARMS	<u>0.025%</u>	<u>A040467</u>	<u>001</u> Apr 21, 2003
<u>AT</u>		<u>0.1%</u>	<u>A040467</u>	<u>002</u> Apr 21, 2003
<u>AT</u>	+ MORTON GROVE	<u>0.025%</u>	<u>A088450</u>	<u>001</u> Apr 01, 1985
<u>AT</u>	TARO	<u>0.1%</u>	<u>A089129</u>	<u>001</u> Aug 14, 1986
<u>AT</u>	VINTAGE	<u>0.1%</u>	<u>A040672</u>	<u>002</u> Dec 13, 2006
<u>AT</u>	+ WOCKHARDT	<u>0.1%</u>	<u>A088451</u>	<u>001</u> Apr 03, 1985
OINTMENT; TOPICAL				
<u>KENALOG</u>				
<u>AT</u>	APOTHECON	<u>0.025%</u>	<u>N011600</u>	<u>003</u>
<u>AT</u>		<u>0.1%</u>	<u>N011600</u>	<u>001</u>
<u>TRIAMCINOLONE ACETONIDE</u>				
<u>AT</u>	FOUGERA PHARMS	<u>0.025%</u>	<u>A085691</u>	<u>001</u>
<u>AT</u>		<u>0.1%</u>	<u>A085691</u>	<u>003</u>
<u>AT</u>		<u>0.5%</u>	<u>A085691</u>	<u>002</u>
<u>AT</u>	+ PERRIGO NEW YORK	<u>0.025%</u>	<u>A087356</u>	<u>001</u>
<u>AT</u>	+	<u>0.1%</u>	<u>A087357</u>	<u>001</u>
<u>AT</u>	+	<u>0.5%</u>	<u>A087385</u>	<u>001</u>
<u>AT</u>	TARO	<u>0.025%</u>	<u>A040040</u>	<u>001</u> Sep 30, 1994
<u>AT</u>		<u>0.025%</u>	<u>A040374</u>	<u>001</u> Jun 05, 2001
<u>AT</u>		<u>0.1%</u>	<u>A040037</u>	<u>001</u> Sep 30, 1994
<u>AT</u>		<u>0.1%</u>	<u>A087902</u>	<u>001</u> Dec 27, 1982
<u>AT</u>		<u>0.5%</u>	<u>A040386</u>	<u>001</u> Jun 05, 2001
TRIAMCINOLONE ACETONIDE IN ABSORBASE				
	+ CAROLINA MEDCL	0.05%	A089595	001 Mar 23, 1995
PASTE; DENTAL				
<u>TRIAMCINOLONE ACETONIDE</u>				
<u>AT</u>	LYNE	<u>0.1%</u>	<u>A040771</u>	<u>001</u> Jul 01, 2010
<u>AT</u>	+ TARO	<u>0.1%</u>	<u>A070730</u>	<u>001</u> Oct 01, 1986
SPRAY; TOPICAL				
KENALOG				
	+ RANBAXY	0.147MG/GM	N012104	001
SPRAY, METERED; NASAL				
<u>NASACORT AQ</u>				
<u>AB</u>	+ SANOFI AVENTIS US	<u>0.055MG/SPRAY</u>	<u>N020468</u>	<u>001</u> May 20, 1996
<u>TRIAMCINOLONE ACETONIDE</u>				
<u>AB</u>	TEVA PHARMS	<u>0.055MG/SPRAY</u>	<u>A078104</u>	<u>001</u> Jul 30, 2009
<u>TRIAMCINOLONE HEXACETONIDE</u>				
INJECTABLE; INJECTION				
ARISTOSPAN				
	+ SANDOZ	5MG/ML	N016466	001
	+	20MG/ML	N016466	002

PRESCRIPTION DRUG PRODUCT LIST

3 - 412 (of 428)

TRIAMTERENE

CAPSULE; ORAL
DYRENIUM

WELLSPRING PHARM	50MG	N013174	001
+	100MG	N013174	002

TRIAZOLAM

TABLET; ORAL

HALCION

<u>AB</u> PHARMACIA AND UPJOHN	<u>0.125MG</u>	<u>N017892</u>	<u>003</u>	Apr 26, 1985
<u>AB</u> +	<u>0.25MG</u>	<u>N017892</u>	<u>001</u>	Nov 15, 1982

TRIAZOLAM

<u>AB</u> MYLAN PHARMS INC	<u>0.125MG</u>	<u>A074031</u>	<u>001</u>	Mar 25, 1994
<u>AB</u>	<u>0.25MG</u>	<u>A074031</u>	<u>002</u>	Mar 25, 1994
<u>AB</u> ROXANE	<u>0.125MG</u>	<u>A074224</u>	<u>001</u>	Jun 01, 1994
<u>AB</u>	<u>0.25MG</u>	<u>A074224</u>	<u>002</u>	Jun 01, 1994
<u>AB</u> WATSON LABS	<u>0.125MG</u>	<u>A074445</u>	<u>001</u>	Oct 20, 1995
<u>AB</u>	<u>0.25MG</u>	<u>A074445</u>	<u>002</u>	Oct 20, 1995

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL
SYPRINE

+ ATON	250MG	N019194	001	Nov 08, 1985

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

<u>AB</u> MYLAN	<u>EQ 1MG BASE</u>	<u>A040209</u>	<u>001</u>	Jul 07, 1997
<u>AB</u>	<u>EQ 2MG BASE</u>	<u>A040209</u>	<u>002</u>	Jul 07, 1997
<u>AB</u>	<u>EQ 5MG BASE</u>	<u>A040209</u>	<u>003</u>	Jul 07, 1997
<u>AB</u> +	<u>EQ 10MG BASE</u>	<u>A040209</u>	<u>004</u>	Jul 07, 1997
<u>AB</u> SANDOZ	<u>EQ 1MG BASE</u>	<u>A085785</u>	<u>001</u>	
<u>AB</u>	<u>EQ 2MG BASE</u>	<u>A085786</u>	<u>001</u>	
<u>AB</u>	<u>EQ 5MG BASE</u>	<u>A085789</u>	<u>001</u>	
<u>AB</u>	<u>EQ 10MG BASE</u>	<u>A085788</u>	<u>001</u>	

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

TRIFLURIDINE

<u>AT</u> ALCON PHARMS LTD	<u>1%</u>	<u>A074311</u>	<u>001</u>	Oct 06, 1995
<u>VIROPTIC</u>				
<u>AT</u> + MONARCH PHARMS	<u>1%</u>	<u>N018299</u>	<u>001</u>	

TRIHXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

TRIHXYPHENIDYL HYDROCHLORIDE

<u>AA</u> MIKART	<u>2MG/5ML</u>	<u>A040251</u>	<u>001</u>	Sep 27, 1999
<u>AA</u> + PHARM ASSOC	<u>2MG/5ML</u>	<u>A040177</u>	<u>001</u>	Apr 17, 1997

TABLET; ORAL

TRIHXYPHENIDYL HYDROCHLORIDE

<u>AA</u> NATCO PHARMA LTD	<u>2MG</u>	<u>A091630</u>	<u>001</u>	Nov 17, 2010
<u>AA</u>	<u>5MG</u>	<u>A091630</u>	<u>002</u>	Nov 17, 2010
<u>AA</u> VINTAGE PHARMS	<u>2MG</u>	<u>A040254</u>	<u>001</u>	Dec 24, 1998
<u>AA</u>	<u>5MG</u>	<u>A040254</u>	<u>002</u>	Dec 24, 1998
<u>AA</u> WATSON LABS	<u>2MG</u>	<u>A040184</u>	<u>001</u>	Feb 06, 1998
<u>AA</u> +	<u>2MG</u>	<u>A084363</u>	<u>001</u>	
<u>AA</u>	<u>5MG</u>	<u>A040184</u>	<u>002</u>	Feb 06, 1998
<u>AA</u> +	<u>5MG</u>	<u>A084364</u>	<u>001</u>	
<u>AA</u> WEST WARD	<u>2MG</u>	<u>A040337</u>	<u>002</u>	Feb 16, 2000
<u>AA</u>	<u>5MG</u>	<u>A040337</u>	<u>001</u>	Feb 16, 2000

PRESCRIPTION DRUG PRODUCT LIST

3 - 413 (of 428)

TRIMETHADIONE

TABLET; ORAL

TRIDIONE

+ ABBVIE 150MG

N005856 009

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TIGAN

AB + KING PHARMS 300MG

N017531 006 Dec 13, 2001

TRIMETHOBENZAMIDE HYDROCHLORIDE

AB GAVIS PHARMS 300MG

A076546 001 Aug 20, 2003

AB MUTUAL PHARMA 300MG

A076570 001 Aug 28, 2003

INJECTABLE; INJECTION

TIGAN

AP + JHP PHARMS 100MG/ML

N017530 001

TRIMETHOBENZAMIDE HYDROCHLORIDE

AP LUITPOLD 100MG/ML

A091330 001 Mar 08, 2011

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

AP LUITPOLD 100MG/ML

A091329 001 Mar 08, 2011

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

AB NOVEL LABS INC 100MG

A091437 001 Jun 15, 2011

AB TEVA 100MG

N018679 001 Jul 30, 1982

AB WATSON LABS 100MG

A070049 001 Jun 06, 1985

TRIMETHOPRIM

+ TEVA 200MG

A071259 001 Jun 18, 1987

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

+ FSC EQ 50MG BASE/5ML

N074973 001 Jan 24, 2000

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

AB ODYSSEY PHARMS EQ 25MG BASE

N016792 001

AB EQ 50MG BASE

N016792 002

AB + EQ 100MG BASE

N016792 003 Sep 15, 1982

TRIMIPRAMINE MALEATE

AB MIKAH PHARMA EQ 25MG BASE

A077361 001 Aug 02, 2006

AB EQ 50MG BASE

A077361 002 Aug 02, 2006

AB EQ 100MG BASE

A077361 003 Aug 02, 2006

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR

+ WATSON LABS EQ 3.75MG BASE/VIAL

N020715 001 Jun 15, 2000

+ EQ 11.25MG BASE/VIAL

N021288 001 Jun 29, 2001

+ EQ 22.5MG BASE/VIAL

N022437 001 Mar 10, 2010

TROMETHAMINE

INJECTABLE; INJECTION

THAM

+ HOSPIRA 3.6GM/100ML

N013025 002

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

MYDRIACYL

AT + ALCON 0.5%

A084305 001

AT + 1%

A084306 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 414 (of 428)

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

TROPICACYL

<u>AT</u>	AKORN	<u>0.5%</u>	<u>A040314</u>	<u>001</u>	Sep 29, 2000

<u>AT</u>		<u>1%</u>	<u>A040315</u>	<u>001</u>	Sep 29, 2000

TROPICAMIDE

<u>AT</u>	BAUSCH AND LOMB	<u>0.5%</u>	<u>A040067</u>	<u>001</u>	Jul 27, 1994

<u>AT</u>		<u>1%</u>	<u>A040064</u>	<u>001</u>	Jul 27, 1994

TROSPIMUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

SANCTURA XR

<u>AB</u>	+ ALLERGAN	<u>60MG</u>	<u>N022103</u>	<u>001</u>	Aug 03, 2007

TROSPIMUM CHLORIDE

<u>AB</u>	WATSON LABS INC FL	<u>60MG</u>	<u>A091289</u>	<u>001</u>	Oct 12, 2012

TABLET; ORAL

SANCTURA

<u>AB</u>	+ ALLERGAN	<u>20MG</u>	<u>N021595</u>	<u>001</u>	May 28, 2004

TROSPIMUM CHLORIDE

<u>AB</u>	APOTEX	<u>20MG</u>	<u>A091513</u>	<u>001</u>	Dec 06, 2011

<u>AB</u>	GLENMARK GENERICS	<u>20MG</u>	<u>A091575</u>	<u>001</u>	Aug 13, 2010

<u>AB</u>	PADDOCK LLC	<u>20MG</u>	<u>A091573</u>	<u>001</u>	Nov 17, 2010

TRYPAN BLUE

SOLUTION; OPHTHALMIC

MEMBRANEBLUE

+	DORC	0.15%	N022278	001	Feb 20, 2009

VISIONBLUE

+	DORC	0.06%	N021670	001	Dec 16, 2004

ULIPRISTAL ACETATE

TABLET; ORAL

ELLA

+	LAB HRA PHARMA	30MG	N022474	001	Aug 13, 2010

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC

	SUCAMPO PHARMS	0.15%	N021214	001	Aug 03, 2000

UREA C-13

FOR SOLUTION; ORAL

BREATHTEK UBT FOR H-PYLORI

+	OTSUKA AMERICA	EQ 75MG /POUCH	N020586	002	May 10, 2001

UREA, C-14

CAPSULE; ORAL

PYTEST

+	AVENT	1uCi	N020617	001	May 09, 1997

PYTEST KIT

+	AVENT	1uCi	N020617	002	May 09, 1997

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

BRAVELLE

+	FERRING	75 IU/VIAL	N021289	001	May 06, 2002

URSODIOL

CAPSULE; ORAL

ACTIGALL

<u>AB</u>	+ WATSON PHARMS	<u>300MG</u>	<u>N019594</u>	<u>002</u>	Dec 31, 1987

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 415 (of 428)

URSODIOL

CAPSULE; ORAL

URSODIOL

<u>AB</u>	COREPHARMA	<u>300MG</u>	<u>A077895</u>	<u>001</u>	Jul 27, 2006
<u>AB</u>	EPIC PHARMA	<u>300MG</u>	<u>A075517</u>	<u>001</u>	Mar 14, 2000
<u>AB</u>	LANNETT	<u>300MG</u>	<u>A079082</u>	<u>001</u>	Dec 15, 2008
<u>AB</u>	MYLAN	<u>300MG</u>	<u>A090530</u>	<u>001</u>	Feb 17, 2010
<u>AB</u>	TEVA PHARMS	<u>300MG</u>	<u>A075592</u>	<u>001</u>	May 25, 2000

TABLET; ORAL

URSO 250

<u>AB</u>	APTALIS PHARMA US	<u>250MG</u>	<u>N020675</u>	<u>001</u>	Dec 10, 1997

URSO FORTE

<u>AB</u>	+ APTALIS PHARMA US	<u>500MG</u>	<u>N020675</u>	<u>002</u>	Jul 21, 2004

URSODIOL

<u>AB</u>	GLENMARK GENERICS	<u>250MG</u>	<u>A090801</u>	<u>001</u>	Jul 12, 2011
<u>AB</u>		<u>500MG</u>	<u>A090801</u>	<u>002</u>	Jul 12, 2011
<u>AB</u>	TEVA PHARMS	<u>250MG</u>	<u>A079184</u>	<u>001</u>	May 13, 2009
<u>AB</u>		<u>500MG</u>	<u>A079184</u>	<u>002</u>	May 13, 2009
<u>AB</u>	WATSON LABS INC	<u>250MG</u>	<u>A200826</u>	<u>001</u>	Dec 23, 2011
<u>AB</u>		<u>500MG</u>	<u>A200826</u>	<u>002</u>	Dec 23, 2011

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

<u>AB</u>	ACTAVIS PHARMA	<u>EQ 500MG BASE</u>	<u>A090370</u>	<u>001</u>	Mar 16, 2011
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A090370</u>	<u>002</u>	Mar 16, 2011
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 500MG BASE</u>	<u>A090682</u>	<u>001</u>	May 24, 2010
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A090682</u>	<u>002</u>	May 24, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 500MG BASE</u>	<u>A079012</u>	<u>001</u>	May 24, 2010
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A079012</u>	<u>002</u>	May 24, 2010
<u>AB</u>	JUBILANT ORGANOSYS	<u>EQ 500MG BASE</u>	<u>A201506</u>	<u>001</u>	Apr 03, 2012
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A201506</u>	<u>002</u>	Apr 03, 2012
<u>AB</u>	MYLAN	<u>EQ 500MG BASE</u>	<u>A078070</u>	<u>001</u>	May 24, 2010
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A078070</u>	<u>002</u>	May 24, 2010
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 500MG BASE</u>	<u>A078518</u>	<u>001</u>	May 24, 2010
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A078518</u>	<u>002</u>	May 24, 2010
<u>AB</u>	RANBAXY	<u>EQ 500MG BASE</u>	<u>A076588</u>	<u>001</u>	Jan 31, 2007
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A076588</u>	<u>002</u>	Jan 31, 2007
<u>AB</u>	ROXANE	<u>EQ 500MG BASE</u>	<u>A078656</u>	<u>001</u>	May 24, 2010
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A078656</u>	<u>002</u>	May 24, 2010
<u>AB</u>	SANDOZ	<u>EQ 500MG BASE</u>	<u>A077478</u>	<u>001</u>	May 24, 2010
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A077478</u>	<u>002</u>	May 24, 2010
<u>AB</u>	TEVA PHARMS	<u>EQ 500MG BASE</u>	<u>A077655</u>	<u>001</u>	May 24, 2010
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A077655</u>	<u>002</u>	May 24, 2010
<u>AB</u>	WATSON LABS	<u>EQ 500MG BASE</u>	<u>A077135</u>	<u>001</u>	May 24, 2010
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A077135</u>	<u>002</u>	May 24, 2010
<u>AB</u>	WOCKHARDT	<u>EQ 500MG BASE</u>	<u>A090216</u>	<u>001</u>	May 24, 2010
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A090216</u>	<u>002</u>	May 24, 2010
<u>VALTREX</u>					
<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 500MG BASE</u>	<u>N020487</u>	<u>001</u>	Jun 23, 1995
<u>AB</u>	+	<u>EQ 1GM BASE</u>	<u>N020487</u>	<u>002</u>	Jun 23, 1995

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

+	HOFFMANN LA ROCHE	50MG/ML	N022257	001	Aug 28, 2009

TABLET; ORAL

VALCYTE

+	HOFFMANN LA ROCHE	EQ 450MG BASE	N021304	001	Mar 29, 2001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 416 (of 428)

VALPROATE SODIUM

INJECTABLE; INJECTION

DEPACON

<u>AP</u>	+	ABBVIE	<u>EQ 100MG BASE/ML</u>	<u>N020593</u>	<u>001</u>	Dec 30, 1996
<u>AP</u>		<u>VALPROATE SODIUM</u>				
<u>AP</u>		BEDFORD	<u>EQ 100MG BASE/ML</u>	<u>A076295</u>	<u>001</u>	Nov 14, 2002
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 100MG BASE/ML</u>	<u>A076539</u>	<u>001</u>	Jun 26, 2003
<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 100MG BASE/ML</u>	<u>A078523</u>	<u>001</u>	Feb 17, 2010

VALPROIC ACID

CAPSULE; ORAL

DEPAKENE

<u>AB</u>	+	ABBVIE	<u>250MG</u>	<u>N018081</u>	<u>001</u>	
<u>AB</u>		<u>VALPROIC ACID</u>				
<u>AB</u>		BANNER PHARMACAPS	<u>250MG</u>	<u>A073484</u>	<u>001</u>	Jun 29, 1993
<u>AB</u>		CATALENT	<u>250MG</u>	<u>A073229</u>	<u>001</u>	Oct 29, 1991
		CAPSULE, DELAYED RELEASE; ORAL				
		STAVZOR				
		BANNER PHARMACAPS	125MG	N022152	001	Jul 29, 2008
			250MG	N022152	002	Jul 29, 2008
		+	500MG	N022152	003	Jul 29, 2008

SYRUP; ORAL

DEPAKENE

<u>AA</u>	+	ABBVIE	<u>250MG/5ML</u>	<u>N018082</u>	<u>001</u>	
<u>AA</u>		<u>VALPROIC ACID</u>				
<u>AA</u>		ALPHARMA	<u>250MG/5ML</u>	<u>A075782</u>	<u>001</u>	Dec 22, 2000
<u>AA</u>		HIGH TECH PHARMA	<u>250MG/5ML</u>	<u>A074060</u>	<u>001</u>	Jan 13, 1995
<u>AA</u>		PHARM ASSOC	<u>250MG/5ML</u>	<u>A075379</u>	<u>001</u>	Dec 15, 2000
<u>AA</u>		SUN PHARM INDS INC	<u>250MG/5ML</u>	<u>A090517</u>	<u>001</u>	May 28, 2010
<u>AA</u>		TEVA PHARMS	<u>250MG/5ML</u>	<u>A073178</u>	<u>001</u>	Aug 25, 1992
<u>AA</u>		VINTAGE	<u>250MG/5ML</u>	<u>A077960</u>	<u>001</u>	Oct 13, 2006
<u>AA</u>		WOCKHARDT	<u>250MG/5ML</u>	<u>A070868</u>	<u>001</u>	Jul 01, 1986

VALRUBICIN

SOLUTION; INTRAVESICAL

VALSTAR PRESERVATIVE FREE

+	ENDO PHARM	40MG/ML	N020892	001	Sep 25, 1998

VALSARTAN

TABLET; ORAL

DIOVAN

		NOVARTIS	40MG	N021283	004	Aug 14, 2002
			80MG	N021283	001	Jul 18, 2001
			160MG	N021283	002	Jul 18, 2001
		+	320MG	N021283	003	Jul 18, 2001

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

<u>AB</u>		VIROPHARMA	<u>EQ 125MG BASE</u>	<u>N050606</u>	<u>001</u>	Apr 15, 1986
<u>AB</u>	+		<u>EQ 250MG BASE</u>	<u>N050606</u>	<u>002</u>	Apr 15, 1986
<u>AB</u>		<u>VANCOMYCIN HYDROCHLORIDE</u>				
<u>AB</u>		AKORN	<u>EQ 125MG BASE</u>	<u>A065478</u>	<u>001</u>	Apr 09, 2012
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065478</u>	<u>002</u>	Apr 09, 2012
<u>AB</u>		FRESENIUS KABI USA	<u>EQ 125MG BASE</u>	<u>A065453</u>	<u>001</u>	Jun 18, 2012
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065453</u>	<u>002</u>	Jun 18, 2012
<u>AB</u>		STRIDES ARCOLAB LTD	<u>EQ 125MG BASE</u>	<u>A065490</u>	<u>001</u>	Apr 09, 2012
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065490</u>	<u>002</u>	Apr 09, 2012
<u>AB</u>		WATSON LABS	<u>EQ 125MG BASE</u>	<u>A065510</u>	<u>001</u>	Apr 09, 2012
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065510</u>	<u>002</u>	Apr 09, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 417 (of 428)

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

<u>AP</u>	BIONICHE PHARMA USA	<u>EQ 500MG BASE/VIAL</u>	<u>A065401</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065401</u>	<u>002</u>	Jun 30, 2008
<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A062663</u>	<u>001</u>	Mar 17, 1987
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062663</u>	<u>002</u>	Jul 31, 1987
<u>AP</u>	+	<u>EQ 5GM BASE/VIAL</u>	<u>A062663</u>	<u>003</u>	Jun 03, 1988
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A062663</u>	<u>004</u>	Nov 28, 1997
<u>AP</u>	+ HOSPIRA	<u>EQ 500MG BASE/VIAL</u>	<u>A062911</u>	<u>001</u>	Aug 04, 1988
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A062931</u>	<u>001</u>	Oct 29, 1992
<u>AP</u>		<u>EQ 750MG BASE/VIAL</u>	<u>A062912</u>	<u>002</u>	Jan 07, 2009
<u>AP</u>		<u>EQ 750MG BASE/VIAL</u>	<u>A062933</u>	<u>002</u>	May 27, 2009
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062912</u>	<u>001</u>	Aug 04, 1988
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062933</u>	<u>001</u>	Oct 29, 1992
<u>AP</u>	+	<u>EQ 5GM BASE/VIAL</u>	<u>A063076</u>	<u>001</u>	Dec 21, 1990
<u>AP</u>	HOSPIRA INC	<u>EQ 10GM BASE/VIAL</u>	<u>A065455</u>	<u>001</u>	Apr 29, 2009
<u>AP</u>	PFIZER	<u>EQ 500MG BASE/VIAL</u>	<u>A065397</u>	<u>001</u>	Dec 30, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065397</u>	<u>002</u>	Dec 30, 2008
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	<u>A065432</u>	<u>001</u>	Dec 30, 2008
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A091469</u>	<u>001</u>	Jul 01, 2011
<u>AP</u>	SAGENT PHARMS	<u>EQ 5GM BASE/VIAL</u>	<u>A200837</u>	<u>001</u>	Aug 10, 2012
<u>AP</u>	SANDOZ	<u>EQ 500MG BASE/VIAL</u>	<u>A090250</u>	<u>001</u>	Apr 27, 2010
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090250</u>	<u>002</u>	Apr 27, 2010
<u>AP</u>	SANDOZ INC	<u>EQ 5GM BASE/VIAL</u>	<u>A201048</u>	<u>001</u>	Aug 10, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A201048</u>	<u>002</u>	Aug 10, 2012
<u>AP</u>	STRIDES ARCOLAB LTD	<u>EQ 10GM BASE/VIAL</u>	<u>A091554</u>	<u>001</u>	Sep 19, 2011
	VANCOCIN HYDROCHLORIDE	IN PLASTIC CONTAINER			
	+ BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993
	+	EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010

VANDETANIB

TABLET; ORAL

CAPRELSA

	IPR PHARMS INC	100MG	N022405	001	Apr 06, 2011
	+	300MG	N022405	002	Apr 06, 2011

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

<u>AB</u>	BAYER HLTHCARE	<u>2.5MG</u>	<u>N021400</u>	<u>003</u>	Aug 19, 2003
<u>AB</u>		<u>5MG</u>	<u>N021400</u>	<u>001</u>	Aug 19, 2003
<u>AB</u>		<u>10MG</u>	<u>N021400</u>	<u>002</u>	Aug 19, 2003
<u>AB</u>	+	<u>20MG</u>	<u>N021400</u>	<u>004</u>	Aug 19, 2003
	<u>VARDENAFIL HYDROCHLORIDE</u>				
<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A091347</u>	<u>001</u>	May 03, 2012
<u>AB</u>		<u>5MG</u>	<u>A091347</u>	<u>002</u>	May 03, 2012
<u>AB</u>		<u>10MG</u>	<u>A091347</u>	<u>003</u>	May 03, 2012
<u>AB</u>		<u>20MG</u>	<u>A091347</u>	<u>004</u>	May 03, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

STAXYN

	+ BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010

VARENICLINE TARTRATE

TABLET; ORAL

CHANTIX

	PFIZER INC	EQ 0.5MG BASE	N021928	001	May 10, 2006
	+	EQ 1MG BASE	N021928	002	May 10, 2006

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 418 (of 428)

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

<u>AP</u>	BEDFORD	<u>10MG/VIAL</u>	<u>A075549</u>	<u>001</u>	Jun 13, 2000
<u>AP</u>		<u>20MG/VIAL</u>	<u>A075549</u>	<u>002</u>	Jun 13, 2000
<u>AP</u>	HOSPIRA	<u>10MG/VIAL</u>	<u>A075164</u>	<u>001</u>	Oct 21, 1999
<u>AP</u>		<u>20MG/VIAL</u>	<u>A075164</u>	<u>002</u>	Oct 21, 1999
<u>AP</u>	MUSTAFA NEVZAT	<u>10MG/VIAL</u>	<u>A078274</u>	<u>001</u>	Dec 29, 2008
<u>AP</u>		<u>20MG/VIAL</u>	<u>A078274</u>	<u>002</u>	Dec 29, 2008
<u>AP</u>	PFIZER	<u>10MG/VIAL</u>	<u>A090243</u>	<u>001</u>	May 11, 2010
<u>AP</u>		<u>20MG/VIAL</u>	<u>A090243</u>	<u>002</u>	May 11, 2010
<u>AP</u>	+ SUN PHARMA GLOBAL	<u>10MG/VIAL</u>	<u>A079001</u>	<u>001</u>	Jun 17, 2009
<u>AP</u>	+	<u>20MG/VIAL</u>	<u>A079001</u>	<u>002</u>	Jun 17, 2009
<u>AP</u>	TEVA PARENTERAL	<u>10MG/VIAL</u>	<u>A074688</u>	<u>001</u>	Aug 25, 1999
<u>AP</u>		<u>20MG/VIAL</u>	<u>A074688</u>	<u>002</u>	Aug 25, 1999
<u>AP</u>	WATSON LABS	<u>10MG/VIAL</u>	<u>A074334</u>	<u>001</u>	Aug 31, 1995
<u>AP</u>		<u>20MG/VIAL</u>	<u>A074334</u>	<u>002</u>	Aug 31, 1995

VELAGLUCERASE ALFA

INJECTABLE; IV (INFUSION)

SHIRE HUMAN GENETIC	400 UNITS/VIAL	N022575	001	Feb 26, 2010

VEMURAFENIB

TABLET; ORAL

ZELBORAF

+ HOFFMANN LA ROCHE	240MG	N202429	001	Aug 17, 2011

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

<u>AB</u>	WYETH PHARMS INC	<u>EQ 37.5MG BASE</u>	<u>N020699</u>	<u>001</u>	Oct 20, 1997
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>N020699</u>	<u>002</u>	Oct 20, 1997
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>N020699</u>	<u>004</u>	Oct 20, 1997

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	ANCHEN PHARMS	<u>EQ 37.5MG BASE</u>	<u>A078087</u>	<u>001</u>	Mar 16, 2012
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078087</u>	<u>002</u>	Mar 16, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078087</u>	<u>003</u>	Mar 16, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 37.5MG BASE</u>	<u>A200834</u>	<u>001</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A200834</u>	<u>002</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A200834</u>	<u>003</u>	Apr 14, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 37.5MG BASE</u>	<u>A078421</u>	<u>001</u>	May 06, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078421</u>	<u>002</u>	May 06, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078421</u>	<u>003</u>	May 06, 2011
<u>AB</u>	MYLAN	<u>EQ 37.5MG BASE</u>	<u>A078789</u>	<u>001</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078789</u>	<u>002</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078789</u>	<u>003</u>	Jun 01, 2011
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 37.5MG BASE</u>	<u>A091123</u>	<u>001</u>	Jul 11, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091123</u>	<u>002</u>	Jul 11, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091123</u>	<u>003</u>	Jul 11, 2011
<u>AB</u>	TEVA	<u>EQ 37.5MG BASE</u>	<u>A076565</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A076565</u>	<u>002</u>	Jun 28, 2010
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A076565</u>	<u>003</u>	Jun 28, 2010
<u>AB</u>	TORRENT PHARMS LLC	<u>EQ 37.5MG BASE</u>	<u>A090899</u>	<u>001</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090899</u>	<u>002</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090899</u>	<u>003</u>	Jun 01, 2011
<u>AB</u>	VALEANT INTL	<u>EQ 37.5MG BASE</u>	<u>A090071</u>	<u>001</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090071</u>	<u>002</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090071</u>	<u>003</u>	Apr 15, 2011
<u>AB</u>	WOCKHARDT	<u>EQ 37.5MG BASE</u>	<u>A078865</u>	<u>001</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078865</u>	<u>002</u>	Apr 14, 2011

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 419 (of 428)

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	WOCKHARDT	<u>EQ 150MG BASE</u>	<u>A078865</u>	<u>003</u>	Apr 14, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 37.5MG BASE</u>	<u>A090174</u>	<u>001</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090174</u>	<u>002</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090174</u>	<u>003</u>	Apr 14, 2011

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A078932</u>	<u>001</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078932</u>	<u>002</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078932</u>	<u>003</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078932</u>	<u>004</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078932</u>	<u>005</u>	Dec 14, 2010
<u>AB</u>	AMNEAL PHARMS	<u>EQ 25MG BASE</u>	<u>A079098</u>	<u>001</u>	May 11, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A079098</u>	<u>002</u>	May 11, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A079098</u>	<u>003</u>	May 11, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A079098</u>	<u>004</u>	May 11, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A079098</u>	<u>005</u>	May 11, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A090555</u>	<u>001</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A090555</u>	<u>002</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090555</u>	<u>003</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090555</u>	<u>004</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090555</u>	<u>005</u>	Apr 07, 2010
<u>AB</u>	CARACO	<u>EQ 25MG BASE</u>	<u>A078627</u>	<u>001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078627</u>	<u>002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078627</u>	<u>003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078627</u>	<u>004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078627</u>	<u>005</u>	Jun 13, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A078301</u>	<u>001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078301</u>	<u>002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078301</u>	<u>003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078301</u>	<u>004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078301</u>	<u>005</u>	Jun 13, 2008
<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 25MG BASE</u>	<u>A078554</u>	<u>001</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078554</u>	<u>002</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078554</u>	<u>003</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078554</u>	<u>004</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078554</u>	<u>005</u>	Jan 09, 2009
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A077166</u>	<u>001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A077166</u>	<u>002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077166</u>	<u>003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A077166</u>	<u>004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077166</u>	<u>005</u>	Jun 13, 2008
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076690</u>	<u>001</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A076690</u>	<u>002</u>	Aug 03, 2006
<u>AB</u>	+	<u>EQ 50MG BASE</u>	<u>A076690</u>	<u>003</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A076690</u>	<u>004</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076690</u>	<u>005</u>	Aug 03, 2006
<u>AB</u>	VINTAGE	<u>EQ 25MG BASE</u>	<u>A090027</u>	<u>001</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A090027</u>	<u>002</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090027</u>	<u>003</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090027</u>	<u>004</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090027</u>	<u>005</u>	Aug 04, 2010
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 25MG BASE</u>	<u>A077653</u>	<u>001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A077653</u>	<u>002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077653</u>	<u>003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A077653</u>	<u>004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077653</u>	<u>005</u>	Jun 13, 2008

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 420 (of 428)

VENLAFAXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	OSMOTICA PHARM	<u>EQ 37.5MG BASE</u>	<u>N022104</u>	<u>001</u>	May 20, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>N022104</u>	<u>002</u>	May 20, 2008
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>N022104</u>	<u>003</u>	May 20, 2008
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 37.5MG BASE</u>	<u>A091272</u>	<u>001</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091272</u>	<u>002</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091272</u>	<u>003</u>	Aug 18, 2010
<u>VENLAFAXINE HYDROCHLORIDE</u>					
	OSMOTICA PHARM	EQ 225MG BASE	N022104	004	May 20, 2008

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>100MG</u>	<u>A078306</u>	<u>001</u>	Aug 09, 2007
<u>AB</u>		<u>120MG</u>	<u>A075138</u>	<u>001</u>	Apr 20, 1999
<u>AB</u>		<u>180MG</u>	<u>A075138</u>	<u>002</u>	Apr 20, 1999
<u>AB</u>		<u>200MG</u>	<u>A078306</u>	<u>002</u>	Aug 09, 2007
<u>AB</u>		<u>240MG</u>	<u>A075138</u>	<u>003</u>	Apr 20, 1999
<u>AB</u>		<u>300MG</u>	<u>A078306</u>	<u>003</u>	Aug 09, 2007
<u>VERELAN</u>					
<u>AB</u>	ALKERMES GAINESVILLE	<u>120MG</u>	<u>N019614</u>	<u>001</u>	May 29, 1990
<u>AB</u>		<u>180MG</u>	<u>N019614</u>	<u>003</u>	Jan 09, 1992
<u>AB</u>		<u>240MG</u>	<u>N019614</u>	<u>002</u>	May 29, 1990
<u>VERELAN PM</u>					
<u>AB</u>	ELAN DRUG	<u>100MG</u>	<u>N020943</u>	<u>001</u>	Nov 25, 1998
<u>AB</u>		<u>200MG</u>	<u>N020943</u>	<u>002</u>	Nov 25, 1998
<u>AB</u>	+	<u>300MG</u>	<u>N020943</u>	<u>003</u>	Nov 25, 1998
	VERELAN				
	+ ALKERMES GAINESVILLE	360MG	N019614	004	May 10, 1996
<u>INJECTABLE; INJECTION</u>					
<u>VERAPAMIL HYDROCHLORIDE</u>					
<u>AP</u>	HOSPIRA	<u>2.5MG/ML</u>	<u>A070737</u>	<u>001</u>	May 06, 1987
<u>AP</u>		<u>2.5MG/ML</u>	<u>A070738</u>	<u>001</u>	May 06, 1987
<u>AP</u>		<u>2.5MG/ML</u>	<u>A075136</u>	<u>001</u>	Oct 20, 1998
<u>AP</u>	INTL MEDICATION	<u>2.5MG/ML</u>	<u>A070451</u>	<u>001</u>	Dec 16, 1985
<u>TABLET; ORAL</u>					
<u>CALAN</u>					
<u>AB</u>	GD SEARLE LLC	<u>40MG</u>	<u>N018817</u>	<u>003</u>	Feb 23, 1988
<u>AB</u>		<u>80MG</u>	<u>N018817</u>	<u>001</u>	Sep 10, 1984
<u>AB</u>	+	<u>120MG</u>	<u>N018817</u>	<u>002</u>	Sep 10, 1984
<u>VERAPAMIL HYDROCHLORIDE</u>					
<u>AB</u>	MYLAN	<u>80MG</u>	<u>A071482</u>	<u>001</u>	Feb 15, 1989
<u>AB</u>		<u>120MG</u>	<u>A071483</u>	<u>001</u>	Feb 15, 1989
<u>AB</u>	WATSON LABS	<u>40MG</u>	<u>A072923</u>	<u>001</u>	Jun 29, 1993
<u>AB</u>		<u>40MG</u>	<u>A072924</u>	<u>001</u>	Jun 29, 1993
<u>AB</u>		<u>80MG</u>	<u>A070855</u>	<u>001</u>	Sep 24, 1986
<u>AB</u>		<u>80MG</u>	<u>A070995</u>	<u>001</u>	Oct 01, 1986
<u>AB</u>		<u>80MG</u>	<u>A071366</u>	<u>001</u>	Oct 01, 1986
<u>AB</u>		<u>120MG</u>	<u>A070856</u>	<u>001</u>	Sep 24, 1986
<u>AB</u>		<u>120MG</u>	<u>A070994</u>	<u>001</u>	Oct 01, 1986
<u>AB</u>		<u>120MG</u>	<u>A071367</u>	<u>001</u>	Oct 01, 1986
<u>TABLET, EXTENDED RELEASE; ORAL</u>					
<u>CALAN SR</u>					
<u>AB</u>	+ PFIZER	<u>120MG</u>	<u>N019152</u>	<u>003</u>	Mar 06, 1991
<u>AB</u>	+	<u>180MG</u>	<u>N019152</u>	<u>002</u>	Dec 15, 1989
<u>AB</u>	+	<u>240MG</u>	<u>N019152</u>	<u>001</u>	Dec 16, 1986
<u>VERAPAMIL HYDROCHLORIDE</u>					
<u>AB</u>	APOTEX CORP	<u>120MG</u>	<u>A200878</u>	<u>001</u>	Apr 20, 2012
<u>AB</u>		<u>180MG</u>	<u>A200878</u>	<u>002</u>	Apr 20, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 421 (of 428)

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	APOTEX CORP	<u>240MG</u>	<u>A200878</u>	<u>003</u>	Apr 20, 2012
<u>AB</u>	GLENMARK GENERICS	<u>120MG</u>	<u>A090700</u>	<u>001</u>	Aug 03, 2011
<u>AB</u>		<u>180MG</u>	<u>A090700</u>	<u>002</u>	Aug 03, 2011
<u>AB</u>		<u>240MG</u>	<u>A078906</u>	<u>001</u>	Sep 17, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>120MG</u>	<u>A073568</u>	<u>002</u>	Oct 10, 1997
<u>AB</u>		<u>180MG</u>	<u>A074330</u>	<u>001</u>	Jan 31, 1994
<u>AB</u>		<u>240MG</u>	<u>A073568</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>	MYLAN	<u>120MG</u>	<u>A074587</u>	<u>002</u>	Feb 21, 1997
<u>AB</u>		<u>180MG</u>	<u>A074587</u>	<u>003</u>	Sep 09, 1997
<u>AB</u>		<u>240MG</u>	<u>A074587</u>	<u>001</u>	Mar 23, 1996
<u>AB</u>	PAR PHARM	<u>120MG</u>	<u>A075072</u>	<u>001</u>	May 25, 1999
<u>AB</u>		<u>240MG</u>	<u>A075072</u>	<u>003</u>	May 25, 1999
<u>AB</u>	SUN PHARM INDS INC	<u>120MG</u>	<u>A090529</u>	<u>001</u>	Dec 30, 2011
<u>AB</u>		<u>180MG</u>	<u>A090529</u>	<u>002</u>	Dec 30, 2011
<u>AB</u>		<u>240MG</u>	<u>A090529</u>	<u>003</u>	Dec 30, 2011
	COVERA-HS				
BC +	GD SEARLE LLC	180MG	N020552	001	Feb 26, 1996
BC +		240MG	N020552	002	Feb 26, 1996

VERTEPORFININJECTABLE; INJECTION
VISUDYNE

+ QLT 15MG/VIAL N021119 001 Apr 12, 2000

VIGABATRINFOR SOLUTION; ORAL
SABRIL

+ LUNDBECK LLC 500MG/PACKET N022006 001 Aug 21, 2009

TABLET; ORAL
SABRIL

+ LUNDBECK LLC 500MG N020427 001 Aug 21, 2009

VILAZODONE HYDROCHLORIDETABLET; ORAL
VIIBRYD

+ FOREST LABS INC	10MG	N022567	001	Jan 21, 2011
	20MG	N022567	002	Jan 21, 2011
	40MG	N022567	003	Jan 21, 2011

VINBLASTINE SULFATEINJECTABLE; INJECTION
VINBLASTINE SULFATE

+ BEDFORD	10MG/VIAL	A089395	001	Apr 09, 1987
+ FRESenius KABI USA	1MG/ML	A089515	001	Apr 29, 1987

VINCRIStINE SULFATEINJECTABLE; INJECTION
VINCRIStINE SULFATE PFS

<u>AP</u> + HOSPIRA	<u>1MG/ML</u>	<u>A071484</u>	<u>001</u>	Apr 19, 1988
<u>AP</u> TEVA PARENTERAL	<u>1MG/ML</u>	<u>A075493</u>	<u>001</u>	Sep 01, 1999

INJECTABLE, LIPOSOMAL; INTRAVENOUS
MARQIBO KIT

+ TALON THERAP 5MG/5ML (1MG/ML) N202497 001 Aug 09, 2012

VINOReLBINEINJECTABLE; INJECTION
VINOReLBINE

<u>AP</u> ONCO THERAPIES LTD	<u>EQ 10MG BASE/ML</u>	<u>A200148</u>	<u>001</u>	Aug 31, 2012

PRESCRIPTION DRUG PRODUCT LIST

3 - 422 (of 428)

VINORELBINE TARTRATE

INJECTABLE; INJECTION

NAVELBINE

<u>AP</u>	+	PIERRE FABRE	<u>EQ 10MG BASE/ML</u>	<u>N020388</u>	<u>001</u>	Dec 23, 1994
<u>VINORELBINE TARTRATE</u>						
<u>AP</u>		ACTAVIS TOTOWA	<u>EQ 10MG BASE/ML</u>	<u>A078011</u>	<u>001</u>	Jul 22, 2009
<u>AP</u>		BEDFORD	<u>EQ 10MG BASE/ML</u>	<u>A076461</u>	<u>001</u>	Dec 11, 2003
<u>AP</u>		EBEWE PHARMA	<u>EQ 10MG BASE/ML</u>	<u>A078408</u>	<u>001</u>	Feb 13, 2008
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 10MG BASE/ML</u>	<u>A076849</u>	<u>001</u>	Apr 18, 2005
<u>AP</u>		HIKMA MAPLE	<u>EQ 10MG BASE/ML</u>	<u>A075992</u>	<u>001</u>	Jun 10, 2003
<u>AP</u>		HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>A076827</u>	<u>001</u>	Jun 02, 2005
<u>AP</u>		JIANGSU HANSON PHARM	<u>EQ 10MG BASE/ML</u>	<u>A091106</u>	<u>001</u>	Sep 26, 2012
<u>AP</u>		TEVA PARENTERAL	<u>EQ 10MG BASE/ML</u>	<u>A076028</u>	<u>001</u>	Feb 03, 2003

VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

+	GENENTECH	150MG	N203388	001	Jan 30, 2012

VITAMIN A PALMITATE

INJECTABLE; INJECTION

AQUASOL A

+	HOSPIRA	EQ 50,000 UNITS BASE/ML	N006823	001	

VORICONAZOLE

FOR SUSPENSION; ORAL

VFEND

+	PFIZER	200MG/5ML	N021630	001	Dec 19, 2003

INJECTABLE; IV (INFUSION)

VFEND

<u>AP</u>	+	PFIZER	<u>200MG/VIAL</u>	<u>N021267</u>	<u>001</u>	May 24, 2002
<u>VORICONAZOLE</u>						
<u>AP</u>		SANDOZ INC	<u>200MG/VIAL</u>	<u>A090862</u>	<u>001</u>	May 30, 2012

TABLET; ORAL

VFEND

<u>AB</u>		PFIZER	<u>50MG</u>	<u>N021266</u>	<u>001</u>	May 24, 2002
<u>AB</u>	+		<u>200MG</u>	<u>N021266</u>	<u>002</u>	May 24, 2002
<u>VORICONAZOLE</u>						
<u>AB</u>		MYLAN PHARMS INC	<u>50MG</u>	<u>A090547</u>	<u>001</u>	Apr 22, 2010
<u>AB</u>			<u>200MG</u>	<u>A090547</u>	<u>002</u>	Apr 22, 2010
<u>AB</u>		SANDOZ INC	<u>50MG</u>	<u>A200265</u>	<u>001</u>	Dec 12, 2011
<u>AB</u>			<u>200MG</u>	<u>A200265</u>	<u>002</u>	Dec 12, 2011
<u>AB</u>		TEVA PHARMS	<u>50MG</u>	<u>A091658</u>	<u>001</u>	Apr 06, 2012
<u>AB</u>			<u>200MG</u>	<u>A091658</u>	<u>002</u>	Apr 06, 2012

VORINOSTAT

CAPSULE; ORAL

ZOLINZA

+	MERCK	100MG	N021991	001	Oct 06, 2006

WARFARIN SODIUM

INJECTABLE; INJECTION

COUMADIN

+	BRISTOL MYERS SQUIBB	5MG/VIAL	N009218	024	Feb 07, 1995

TABLET; ORAL

COUMADIN

<u>AB</u>		BRISTOL MYERS SQUIBB	<u>1MG</u>	<u>N009218</u>	<u>022</u>	Mar 01, 1990
<u>AB</u>			<u>2MG</u>	<u>N009218</u>	<u>013</u>	
<u>AB</u>			<u>2.5MG</u>	<u>N009218</u>	<u>018</u>	
<u>AB</u>			<u>3MG</u>	<u>N009218</u>	<u>025</u>	Nov 18, 1996
<u>AB</u>			<u>4MG</u>	<u>N009218</u>	<u>023</u>	Aug 24, 1993
<u>AB</u>			<u>5MG</u>	<u>N009218</u>	<u>007</u>	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 423 (of 428)

WARFARIN SODIUM

TABLET; ORAL

COUMADIN

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>6MG</u>	<u>N009218</u>	<u>026</u>	Nov 18, 1996
<u>AB</u>		<u>7.5MG</u>	<u>N009218</u>	<u>016</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N009218</u>	<u>005</u>	

JANTOVEN

<u>AB</u>	USL PHARMA	<u>1MG</u>	<u>A040416</u>	<u>001</u>	Oct 02, 2003
<u>AB</u>		<u>2MG</u>	<u>A040416</u>	<u>002</u>	Oct 02, 2003
<u>AB</u>		<u>2.5MG</u>	<u>A040416</u>	<u>003</u>	Oct 02, 2003
<u>AB</u>		<u>3MG</u>	<u>A040416</u>	<u>004</u>	Oct 02, 2003
<u>AB</u>		<u>4MG</u>	<u>A040416</u>	<u>005</u>	Oct 02, 2003
<u>AB</u>		<u>5MG</u>	<u>A040416</u>	<u>006</u>	Oct 02, 2003
<u>AB</u>		<u>6MG</u>	<u>A040416</u>	<u>007</u>	Oct 02, 2003
<u>AB</u>		<u>7.5MG</u>	<u>A040416</u>	<u>008</u>	Oct 02, 2003
<u>AB</u>		<u>10MG</u>	<u>A040416</u>	<u>009</u>	Oct 02, 2003

WARFARIN SODIUM

<u>AB</u>	BARR	<u>1MG</u>	<u>A040145</u>	<u>001</u>	Mar 26, 1997
<u>AB</u>		<u>2MG</u>	<u>A040145</u>	<u>002</u>	Mar 26, 1997
<u>AB</u>		<u>2.5MG</u>	<u>A040145</u>	<u>003</u>	Mar 26, 1997
<u>AB</u>		<u>3MG</u>	<u>A040145</u>	<u>008</u>	Nov 05, 1998
<u>AB</u>		<u>4MG</u>	<u>A040145</u>	<u>004</u>	Mar 26, 1997
<u>AB</u>		<u>5MG</u>	<u>A040145</u>	<u>005</u>	Mar 26, 1997
<u>AB</u>		<u>6MG</u>	<u>A040145</u>	<u>009</u>	Nov 05, 1998
<u>AB</u>		<u>7.5MG</u>	<u>A040145</u>	<u>006</u>	Mar 26, 1997
<u>AB</u>		<u>10MG</u>	<u>A040145</u>	<u>007</u>	Mar 26, 1997
<u>AB</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A090935</u>	<u>001</u>	May 25, 2011
<u>AB</u>		<u>2MG</u>	<u>A090935</u>	<u>002</u>	May 25, 2011
<u>AB</u>		<u>2.5MG</u>	<u>A090935</u>	<u>003</u>	May 25, 2011
<u>AB</u>		<u>3MG</u>	<u>A090935</u>	<u>004</u>	May 25, 2011
<u>AB</u>		<u>4MG</u>	<u>A090935</u>	<u>005</u>	May 25, 2011
<u>AB</u>		<u>5MG</u>	<u>A090935</u>	<u>006</u>	May 25, 2011
<u>AB</u>		<u>6MG</u>	<u>A090935</u>	<u>007</u>	May 25, 2011
<u>AB</u>		<u>7.5MG</u>	<u>A090935</u>	<u>008</u>	May 25, 2011
<u>AB</u>		<u>10MG</u>	<u>A090935</u>	<u>009</u>	May 25, 2011
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A040415</u>	<u>001</u>	Sep 27, 2004
<u>AB</u>		<u>2MG</u>	<u>A040415</u>	<u>002</u>	Sep 27, 2004
<u>AB</u>		<u>2.5MG</u>	<u>A040415</u>	<u>003</u>	Sep 29, 2004
<u>AB</u>		<u>3MG</u>	<u>A040415</u>	<u>004</u>	Sep 27, 2004
<u>AB</u>		<u>4MG</u>	<u>A040415</u>	<u>005</u>	Sep 27, 2004
<u>AB</u>		<u>5MG</u>	<u>A040415</u>	<u>006</u>	Sep 27, 2004
<u>AB</u>		<u>6MG</u>	<u>A040415</u>	<u>007</u>	Sep 27, 2004
<u>AB</u>		<u>7.5MG</u>	<u>A040415</u>	<u>008</u>	Sep 27, 2004
<u>AB</u>		<u>10MG</u>	<u>A040415</u>	<u>009</u>	Sep 27, 2004
<u>AB</u>	PLIVA	<u>1MG</u>	<u>A040616</u>	<u>009</u>	Jul 05, 2006
<u>AB</u>		<u>2MG</u>	<u>A040616</u>	<u>001</u>	Jul 05, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040616</u>	<u>002</u>	Jul 05, 2006
<u>AB</u>		<u>3MG</u>	<u>A040616</u>	<u>003</u>	Jul 05, 2006
<u>AB</u>		<u>4MG</u>	<u>A040616</u>	<u>004</u>	Jul 05, 2006
<u>AB</u>		<u>5MG</u>	<u>A040616</u>	<u>005</u>	Jul 05, 2006
<u>AB</u>		<u>6MG</u>	<u>A040616</u>	<u>006</u>	Jul 05, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040616</u>	<u>007</u>	Jul 05, 2006
<u>AB</u>		<u>10MG</u>	<u>A040616</u>	<u>008</u>	Jul 05, 2006
<u>AB</u>	TARO	<u>1MG</u>	<u>A040301</u>	<u>002</u>	Jul 15, 1999
<u>AB</u>		<u>2MG</u>	<u>A040301</u>	<u>003</u>	Jul 15, 1999
<u>AB</u>		<u>2.5MG</u>	<u>A040301</u>	<u>004</u>	Jul 15, 1999
<u>AB</u>		<u>3MG</u>	<u>A040301</u>	<u>005</u>	Jul 15, 1999
<u>AB</u>		<u>4MG</u>	<u>A040301</u>	<u>006</u>	Jul 15, 1999
<u>AB</u>		<u>5MG</u>	<u>A040301</u>	<u>007</u>	Jul 15, 1999
<u>AB</u>		<u>6MG</u>	<u>A040301</u>	<u>008</u>	Jul 15, 1999
<u>AB</u>		<u>7.5MG</u>	<u>A040301</u>	<u>009</u>	Jul 15, 1999

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 424 (of 428)

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

<u>AB</u>	TARO	<u>10MG</u>	<u>A040301</u>	<u>001</u>	Jul 15, 1999
<u>AB</u>	ZYDUS PHARMS USA	<u>1MG</u>	<u>A040663</u>	<u>001</u>	May 30, 2006
<u>AB</u>		<u>2MG</u>	<u>A040663</u>	<u>002</u>	May 30, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040663</u>	<u>003</u>	May 30, 2006
<u>AB</u>		<u>3MG</u>	<u>A040663</u>	<u>004</u>	May 30, 2006
<u>AB</u>		<u>4MG</u>	<u>A040663</u>	<u>005</u>	May 30, 2006
<u>AB</u>		<u>5MG</u>	<u>A040663</u>	<u>006</u>	May 30, 2006
<u>AB</u>		<u>6MG</u>	<u>A040663</u>	<u>007</u>	May 30, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040663</u>	<u>008</u>	May 30, 2006
<u>AB</u>		<u>10MG</u>	<u>A040663</u>	<u>009</u>	May 30, 2006

XENON XE-133

GAS; INHALATION

XENON XE 133

<u>AA</u>	LANTHEUS MEDCL	<u>20mCi/VIAL</u>	<u>N017284</u>	<u>002</u>	
	XENON XE 133				
	LANTHEUS MEDCL	10mCi/VIAL	N017284	001	

ZAFIRLUKAST

TABLET; ORAL

ACCOLATE

<u>AB</u>	ASTRAZENECA	<u>10MG</u>	<u>N020547</u>	<u>003</u>	Sep 17, 1999
<u>AB</u>	+	<u>20MG</u>	<u>N020547</u>	<u>001</u>	Sep 26, 1996
	<u>ZAFIRLUKAST</u>				
<u>AB</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A090372</u>	<u>001</u>	Nov 18, 2010
<u>AB</u>		<u>20MG</u>	<u>A090372</u>	<u>002</u>	Nov 18, 2010

ZALEPLON

CAPSULE; ORAL

SONATA

<u>AB</u>	KING PHARMS	<u>5MG</u>	<u>N020859</u>	<u>001</u>	Aug 13, 1999
<u>AB</u>	+	<u>10MG</u>	<u>N020859</u>	<u>002</u>	Aug 13, 1999
	<u>ZALEPLON</u>				
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078829</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078829</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	CIPLA LTD	<u>5MG</u>	<u>A077505</u>	<u>001</u>	Jun 20, 2008
<u>AB</u>		<u>10MG</u>	<u>A077505</u>	<u>002</u>	Jun 20, 2008
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A077238</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077238</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>5MG</u>	<u>A090374</u>	<u>001</u>	Sep 17, 2009
<u>AB</u>		<u>10MG</u>	<u>A090374</u>	<u>002</u>	Sep 17, 2009
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A077237</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077237</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A077239</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077239</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	UNICHEM	<u>5MG</u>	<u>A078989</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078989</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	UPSHER SMITH	<u>5MG</u>	<u>A078706</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078706</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	WEST WARD	<u>5MG</u>	<u>A078147</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>		<u>10MG</u>	<u>A078147</u>	<u>002</u>	Nov 25, 2008

ZANAMIVIR

POWDER; INHALATION

RELENZA

	+	GLAXOSMITHKLINE	5MG	N021036	001	Jul 26, 1999

PRESCRIPTION DRUG PRODUCT LIST

3 - 425 (of 428)

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL
PRIALT

+ JAZZ PHARMS INTL	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004
+	500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004
+	500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004

ZIDOVUDINE

CAPSULE; ORAL

RETROVIR

AB + VIIIV HLTHCARE	100MG	N019655	001	Mar 19, 1987

ZIDOVUDINE

AB AUROBINDO PHARMA LTD	100MG	A078128	001	Mar 27, 2006
AB CIPLA LTD	100MG	A078349	001	May 23, 2007

INJECTABLE; INJECTION

RETROVIR

AP + VIIIV HLTHCARE	10MG/ML	N019951	001	Feb 02, 1990

ZIDOVUDINE

AP LUITPOLD	10MG/ML	A091457	001	May 06, 2010

SYRUP; ORAL

RETROVIR

AA + VIIIV HLTHCARE	50MG/5ML	N019910	001	Sep 28, 1989

ZIDOVUDINE

AA AUROBINDO	50MG/5ML	A077268	001	Sep 19, 2005
AA CIPLA LTD	50MG/5ML	A077981	001	Jun 26, 2008

TABLET; ORAL

RETROVIR

AB + VIIIV HLTHCARE	300MG	N020518	002	Oct 04, 1996

ZIDOVUDINE

AB AUROBINDO	300MG	A077267	001	Sep 19, 2005
AB CIPLA	300MG	A090561	001	Oct 27, 2010
AB HEC PHARM USA INC	300MG	A202058	001	Oct 07, 2011
AB HETERO DRUGS LTD	300MG	A090092	001	Apr 25, 2008
AB MYLAN PHARMS INC	300MG	A078922	001	Feb 14, 2008
AB ROXANE	300MG	A076844	001	Sep 19, 2005

ZILEUTON

TABLET; ORAL

ZYFLO

+ CORNERSTONE THERAP	600MG	N020471	003	Dec 09, 1996

TABLET, EXTENDED RELEASE; ORAL

ZYFLO CR

+ CORNERSTONE THERAP	600MG	N022052	001	May 30, 2007

ZINC ACETATE

CAPSULE; ORAL

GALZIN

TEVA	EQ 25MG ZINC	N020458	001	Jan 28, 1997
+	EQ 50MG ZINC	N020458	002	Jan 28, 1997

ZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA	EQ 1MG ZINC/ML	N018959	001	Jun 26, 1986

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

AB + PFIZER	EQ 20MG BASE	N020825	001	Feb 05, 2001
AB	EQ 40MG BASE	N020825	002	Feb 05, 2001
AB	EQ 60MG BASE	N020825	003	Feb 05, 2001
AB	EQ 80MG BASE	N020825	004	Feb 05, 2001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 426 (of 428)

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

ZIPRASIDONE HYDROCHLORIDE

<u>AB</u>	APOTEX CORP	<u>EQ 20MG BASE</u>	<u>A077561</u>	<u>001</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077561</u>	<u>002</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A077561</u>	<u>003</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077561</u>	<u>004</u>	Mar 02, 2012
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 20MG BASE</u>	<u>A077565</u>	<u>001</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077565</u>	<u>002</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A077565</u>	<u>003</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077565</u>	<u>004</u>	Mar 02, 2012
<u>AB</u>	LUPIN PHARMS	<u>EQ 20MG BASE</u>	<u>A077560</u>	<u>001</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077560</u>	<u>002</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A077560</u>	<u>003</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077560</u>	<u>004</u>	Mar 02, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 20MG BASE</u>	<u>A077562</u>	<u>001</u>	Jun 01, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077562</u>	<u>002</u>	Jun 01, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A077562</u>	<u>003</u>	Jun 01, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077562</u>	<u>004</u>	Jun 01, 2012
<u>AB</u>	WOCKHARDT LTD	<u>EQ 20MG BASE</u>	<u>A090348</u>	<u>001</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090348</u>	<u>002</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090348</u>	<u>003</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A090348</u>	<u>004</u>	Sep 05, 2012

SUSPENSION; ORAL

GEODON

+ PFIZER INC

EQ 10MG BASE/ML

N021483 001 Mar 29, 2006

ZIPRASIDONE MESYLATE

INJECTABLE; INTRAMUSCULAR

GEODON

+ PFIZER

EQ 20MG BASE/ML

N020919 001 Jun 21, 2002

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

+ NOVARTIS

EQ 5MG BASE/100ML

N021817 001 Apr 16, 2007

ZOMETA

+ NOVARTIS

EQ 4MG BASE/5ML

N021223 002 Mar 07, 2003

+

EQ 4MG BASE/100ML

N021223 003 Jun 17, 2011

ZOLMITRIPTAN

SPRAY; NASAL

ZOMIG

+ ASTRAZENECA

5MG/SPRAY

N021450 004 Sep 30, 2003

TABLET; ORAL

ZOMIG

IPR

2.5MG

N020768 001 Nov 25, 1997

+

5MG

N020768 002 Nov 25, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

ZOMIG-ZMT

ASTRAZENECA

2.5MG

N021231 001 Feb 13, 2001

+

5MG

N021231 002 Sep 17, 2001

ZOLPIDEM TARTRATE

SPRAY, METERED; ORAL

ZOLPIMIST

+ NOVADEL

5MG/SPRAY

N022196 001 Dec 19, 2008

TABLET; ORAL

AMBIENAB SANOFI AVENTIS US5MGN019908 001 Dec 16, 1992AB +10MGN019908 002 Dec 16, 1992

PRESCRIPTION DRUG PRODUCT LIST

3 - 427 (of 428)

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A077884</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077884</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078413</u>	<u>001</u>	May 04, 2007
<u>AB</u>		<u>10MG</u>	<u>A078413</u>	<u>002</u>	May 04, 2007
<u>AB</u>	CARACO	<u>5MG</u>	<u>A077359</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077359</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	CARLSBAD	<u>5MG</u>	<u>A077990</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077990</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	CIPLA LTD	<u>5MG</u>	<u>A077388</u>	<u>001</u>	Jul 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A077388</u>	<u>002</u>	Jul 30, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A077985</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077985</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	HIKMA	<u>5MG</u>	<u>A078129</u>	<u>001</u>	Apr 30, 2008
<u>AB</u>		<u>10MG</u>	<u>A078129</u>	<u>002</u>	Apr 30, 2008
<u>AB</u>	INVAGEN PHARMS	<u>5MG</u>	<u>A078184</u>	<u>001</u>	Sep 07, 2007
<u>AB</u>		<u>10MG</u>	<u>A078184</u>	<u>002</u>	Sep 07, 2007
<u>AB</u>	LEK PHARMS DD	<u>5MG</u>	<u>A077322</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077322</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076578</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A076578</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A078055</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A078055</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A077214</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077214</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076410</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A076410</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	TORRENT PHARMS	<u>5MG</u>	<u>A077903</u>	<u>001</u>	Aug 17, 2007
<u>AB</u>		<u>10MG</u>	<u>A077903</u>	<u>002</u>	Aug 17, 2007
<u>AB</u>	VINTAGE	<u>5MG</u>	<u>A078616</u>	<u>001</u>	Nov 21, 2008
<u>AB</u>		<u>10MG</u>	<u>A078616</u>	<u>002</u>	Nov 21, 2008
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A077773</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077773</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	WOCKHARDT	<u>5MG</u>	<u>A078426</u>	<u>001</u>	May 15, 2007
<u>AB</u>		<u>10MG</u>	<u>A078426</u>	<u>002</u>	May 15, 2007

TABLET; SUBLINGUAL
EDLUAR

	MEDA PHARMS	5MG	N021997	001	Mar 13, 2009
+		10MG	N021997	002	Mar 13, 2009
	INTERMEZZO				
	PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011
+		3.5MG	N022328	002	Nov 23, 2011

TABLET, EXTENDED RELEASE; ORAL

AMBIEN CR

<u>AB</u>	SANOFI AVENTIS US	<u>6.25MG</u>	<u>N021774</u>	<u>002</u>	Sep 02, 2005
<u>AB</u>	+	<u>12.5MG</u>	<u>N021774</u>	<u>001</u>	Sep 02, 2005

ZOLPIDEM TARTRATE

<u>AB</u>	ACTAVIS S ATLANTIC	<u>6.25MG</u>	<u>A078179</u>	<u>002</u>	Oct 13, 2010
<u>AB</u>		<u>12.5MG</u>	<u>A078179</u>	<u>001</u>	Jun 06, 2011
<u>AB</u>	ANCHEN PHARMS	<u>6.25MG</u>	<u>A078148</u>	<u>002</u>	Apr 14, 2011
<u>AB</u>		<u>12.5MG</u>	<u>A078148</u>	<u>001</u>	Dec 03, 2010
<u>AB</u>	SANDOZ	<u>6.25MG</u>	<u>A090107</u>	<u>001</u>	Jul 01, 2011
<u>AB</u>		<u>12.5MG</u>	<u>A090107</u>	<u>002</u>	Jul 01, 2011
<u>AB</u>	SYNTHON PHARMS	<u>6.25MG</u>	<u>A078483</u>	<u>001</u>	Apr 12, 2011
<u>AB</u>		<u>12.5MG</u>	<u>A078483</u>	<u>002</u>	Jun 06, 2011

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

PRESCRIPTION DRUG PRODUCT LIST

3 - 428 (of 428)

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN

<u>AB</u>	EISAI INC	<u>25MG</u>	<u>N020789</u>	<u>003</u>	Aug 22, 2003
<u>AB</u>		<u>50MG</u>	<u>N020789</u>	<u>002</u>	Aug 22, 2003
<u>AB</u>	+	<u>100MG</u>	<u>N020789</u>	<u>001</u>	Mar 27, 2000
	<u>ZONISAMIDE</u>				
<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A077642</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077642</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077642</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	BANNER PHARMACAPS	<u>25MG</u>	<u>A077813</u>	<u>001</u>	Aug 16, 2006
<u>AB</u>		<u>50MG</u>	<u>A077813</u>	<u>002</u>	Aug 16, 2006
<u>AB</u>		<u>100MG</u>	<u>A077813</u>	<u>003</u>	Aug 16, 2006
<u>AB</u>	BARR	<u>25MG</u>	<u>A077639</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077639</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077639</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	COREPHARMA	<u>25MG</u>	<u>A077876</u>	<u>001</u>	Feb 21, 2007
<u>AB</u>		<u>50MG</u>	<u>A077876</u>	<u>002</u>	Feb 21, 2007
<u>AB</u>		<u>100MG</u>	<u>A077876</u>	<u>003</u>	Feb 21, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>25MG</u>	<u>A077645</u>	<u>002</u>	Sep 29, 2006
<u>AB</u>		<u>50MG</u>	<u>A077645</u>	<u>003</u>	Sep 29, 2006
<u>AB</u>		<u>100MG</u>	<u>A077645</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A077651</u>	<u>001</u>	Jan 30, 2006
<u>AB</u>		<u>50MG</u>	<u>A077651</u>	<u>002</u>	Jan 30, 2006
<u>AB</u>		<u>100MG</u>	<u>A077651</u>	<u>003</u>	Jan 30, 2006
<u>AB</u>	INVAGEN PHARMS	<u>25MG</u>	<u>A077869</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>50MG</u>	<u>A077869</u>	<u>002</u>	May 31, 2006
<u>AB</u>		<u>100MG</u>	<u>A077869</u>	<u>003</u>	May 31, 2006
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A077637</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077637</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077637</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>25MG</u>	<u>A077647</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077647</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077647</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A077644</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077644</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077644</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	SUN PHARM INDS (IN)	<u>25MG</u>	<u>A077634</u>	<u>001</u>	Mar 17, 2006
<u>AB</u>		<u>50MG</u>	<u>A077634</u>	<u>002</u>	Mar 17, 2006
<u>AB</u>		<u>100MG</u>	<u>A077634</u>	<u>003</u>	Mar 17, 2006
<u>AB</u>	WOCKHARDT	<u>25MG</u>	<u>A077636</u>	<u>003</u>	Jul 27, 2006
<u>AB</u>		<u>50MG</u>	<u>A077636</u>	<u>002</u>	Jul 27, 2006
<u>AB</u>		<u>100MG</u>	<u>A077636</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077625</u>	<u>001</u>	Oct 16, 2006
<u>AB</u>		<u>50MG</u>	<u>A077625</u>	<u>002</u>	Oct 16, 2006
<u>AB</u>		<u>100MG</u>	<u>A077625</u>	<u>003</u>	Oct 16, 2006

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 1 (of 20)

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACEPHEN

G AND W LABS

120MG

N018060 001

325MG

A072344 001

Mar 27, 1992

325MG

N018060 003

Dec 18, 1986

650MG

A072237 001

Mar 27, 1992

650MG

N018060 002

ACETAMINOPHEN

ACTAVIS MID ATLANTIC

120MG

N018337 003

Sep 12, 1983

325MG

N018337 002

+

650MG

N018337 001

PERRIGO NEW YORK

120MG

A070607 001

Apr 06, 1987

650MG

A070608 001

Dec 01, 1986

INFANTS' FEVERALL

ACTAVIS MID ATLANTIC

80MG

N018337 004

Aug 26, 1992

NEOPAP

POLYMEDICA

120MG

N016401 001

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

OHM LABS

650MG

A076200 001

Mar 19, 2002

PERRIGO

650MG

A075077 001

Feb 25, 2000

RANBAXY LABS LTD

650MG

A078569 001

Dec 14, 2011

TYLENOL (CAPLET)

+

MCNEIL CONS

650MG

N019872 001

Jun 08, 1994

TYLENOL (GELTAB)

+

MCNEIL CONS

650MG

N019872 002

Jan 11, 2001

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

PERRIGO

250MG;250MG;65MG

A075794 001

Nov 26, 2001

EXCEDRIN (MIGRAINE)

+

NOVARTIS

250MG;250MG;65MG

N020802 001

Jan 14, 1998

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

TAVIST ALLERGY/SINUS/HEADACHE

+

NOVARTIS

500MG;EQ 0.25MG BASE;30MG

N021082 001

Mar 01, 2001

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DRIXORAL PLUS

+

SCHERING PLOUGH

500MG;3MG;60MG

N019453 001

May 22, 1987

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

AVAGARD

+

3M

61%;1%

N021074 001

Jun 07, 2001

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

FOAMCOAT

GUARDIAN DRUG

80MG;20MG

A071793 001

Sep 04, 1987

GAVISCON

SANOFI AVENTIS US

80MG;20MG

N018685 001

Dec 09, 1983

+

160MG;40MG

N018685 002

Dec 09, 1983

AVOBENZONE; ECAMSULE; OCTOCRYLENE

CREAM; TOPICAL

ANTHELIOS SX

+

LOREAL USA

2%;2%;10%

N021502 001

Jul 21, 2006

CAPITAL SOLEIL 15

+

LOREAL USA

2%;3%;10%

N021501 001

Oct 02, 2006

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 2 (of 20)

AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE

CREAM; TOPICAL					
ANTHELIOS 20					
+ LOREAL USA	2%; 2%; 10%; 2%	N021471	001	Oct 05, 2006	
ANTHELIOS 40					
+ LOREAL USA	2%; 3%; 10%; 5%	N022009	001	Mar 31, 2008	
+	2%; 3%; 10%; 5%	N022009	002	Oct 29, 2009	

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION; TOPICAL					
SHADE UVAGUARD					
+ SCHERING PLOUGH	3%; 7.5%; 3%	N020045	001	Dec 07, 1992	

BENTOQUATAM

LOTION; TOPICAL					
IVY BLOCK					
+ STAND HOMEOPATH	5%	N020532	001	Aug 26, 1996	

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL					
LOTRIMIN ULTRA					
+ SCHERING PLOUGH	1%	N021307	001	Dec 07, 2001	

BUTOCONAZOLE NITRATE

CREAM; VAGINAL					
FEMSTAT 3					
+ BAYER	2%	N020421	001	Dec 21, 1995	

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL					
CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE					
PERRIGO R AND D	800MG; 10MG; 165MG	A077355	001	Feb 06, 2008	
PEPCID COMPLETE					
+ MCNEIL CONS	800MG; 10MG; 165MG	N020958	001	Oct 16, 2000	

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL					
CETIRIZINE HYDROCHLORIDE ALLERGY					
BANNER PHARMACAPS	5MG	N022429	001	Jul 23, 2009	
+	10MG	N022429	004	Jul 23, 2009	
CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
BANNER PHARMACAPS	5MG	N022429	003	Jul 23, 2009	
+	10MG	N022429	002	Jul 23, 2009	

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
AMNEAL PHARMS	5MG/5ML	A090765	002	Oct 07, 2009	
APOTEX	5MG/5ML	A090188	002	Apr 22, 2008	
AUROBINDO PHARMA	5MG/5ML	A090750	002	Feb 02, 2010	
CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008	
DR REDDYS LABS LTD	5MG/5ML	A090474	002	Mar 30, 2009	
PERRIGO R AND D	5MG/5ML	A090254	002	Apr 09, 2008	
SILARX	5MG/5ML	A091130	001	Apr 22, 2011	
SUN PHARM INDS INC	5MG/5ML	A091327	001	Oct 17, 2011	
TARO	5MG/5ML	A090182	002	Apr 22, 2008	
	5MG/5ML	A201546	001	May 20, 2011	
TRIS PHARMA INC	5MG/5ML	A090572	001	Nov 16, 2012	
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
AMNEAL PHARMS	5MG/5ML	A090765	001	Oct 07, 2009	
APOTEX	5MG/5ML	A090188	001	Apr 22, 2008	
AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb 02, 2010	
CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008	
DR REDDYS LABS LTD	5MG/5ML	A090474	001	Mar 30, 2009	
PERRIGO R AND D	5MG/5ML	A090254	001	Apr 09, 2008	
SILARX	5MG/5ML	A091130	002	Apr 22, 2011	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 3 (of 20)

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SUN PHARM INDS INC	5MG/5ML	A091327	002	Oct 17, 2011
TARO	5MG/5ML	A090182	001	Apr 22, 2008
	5MG/5ML	A201546	002	May 20, 2011
TRIS PHARMA INC	5MG/5ML	A090572	002	Nov 16, 2012

CHILDREN'S ZYRTEC ALLERGY

+ MCNEIL CONSUMER	5MG/5ML	N022155	002	Nov 16, 2007
CHILDREN'S ZYRTEC HIVES RELIEF				
+ MCNEIL CONSUMER	5MG/5ML	N022155	001	Nov 16, 2007

TABLET, CHEWABLE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

CARACO	5MG	A077631	004	Jan 11, 2008
	10MG	A077631	003	Jan 11, 2008
SANDOZ	5MG	A078692	001	Feb 14, 2008
	10MG	A078692	002	Feb 14, 2008

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

CARACO	5MG	A077631	001	Jan 11, 2008
	10MG	A077631	002	Jan 11, 2008

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARMA GLOBAL	5MG	A090142	001	Aug 30, 2011
	10MG	A090142	002	Aug 30, 2011

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SUN PHARMA GLOBAL	5MG	A090142	003	Aug 30, 2011
	10MG	A090142	004	Aug 30, 2011

CHILDREN'S ZYRTEC ALLERGY

MCNEIL CONS	5MG	N021621	003	Nov 16, 2007
	10MG	N021621	004	Nov 16, 2007
+ CHILDREN'S ZYRTEC HIVES RELIEF				
MCNEIL CONS	5MG	N021621	005	Nov 16, 2007
	10MG	N021621	006	Nov 16, 2007

TABLET, ORALLY DISINTEGRATING; ORAL
ZYRTEC ALLERGY

+ MCNEIL CONSUMER	10MG	N022578	001	Sep 03, 2010

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS NY	5MG	A078780	001	Jan 21, 2010
	10MG	A078780	004	Jan 21, 2010
APOTEX INC	5MG	A078317	001	Dec 27, 2007
	10MG	A078317	002	Dec 27, 2007
CADISTA PHARMS	5MG	A078933	001	Jun 15, 2010
	10MG	A078933	002	Jun 15, 2010
CARACO	5MG	A077499	001	Dec 27, 2007
	10MG	A077499	002	Dec 27, 2007
CONTRACT PHARMA	5MG	A076047	001	Dec 27, 2007
	10MG	A076047	002	Dec 27, 2007
DR REDDYS LABS LTD	5MG	A078343	004	Jan 15, 2008
	10MG	A078343	003	Jan 15, 2008
MYLAN	5MG	A076677	001	Dec 27, 2007
	10MG	A076677	002	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	001	Feb 19, 2009
	10MG	A078862	002	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	001	Dec 27, 2007
	10MG	A078336	002	Dec 27, 2007
RANBAXY	5MG	A077498	001	Dec 27, 2007
	10MG	A077498	002	Dec 27, 2007
SANDOZ	5MG	A077946	001	Dec 27, 2007
	10MG	A077946	002	Dec 27, 2007
TARO	5MG	A078072	001	Jul 22, 2009
	5MG	A078072	003	Jul 22, 2009
TORRENT PHARMS LLC	5MG	A079191	001	Apr 15, 2010
	10MG	A079191	004	Apr 15, 2010
UNICHEM	5MG	A078680	003	Jun 26, 2009
	10MG	A078680	004	Jun 26, 2009

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 4 (of 20)

CETIRIZINE HYDROCHLORIDE

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

UNIQUE PHARM LABS	5MG	A077829	001	Aug 26, 2009
	10MG	A077829	004	Aug 26, 2009
WOCKHARDT	5MG	A078427	003	Dec 28, 2007
	10MG	A078427	004	Dec 28, 2007

CETIRIZINE HYDROCHLORIDE HIVES

CADISTA PHARMS	5MG	A078933	003	Jun 15, 2010
	10MG	A078933	004	Jun 15, 2010
CARACO	5MG	A077499	003	Dec 27, 2007
	10MG	A077499	004	Dec 27, 2007
DR REDDYS LABS LTD	5MG	A078343	001	Jan 15, 2008
	10MG	A078343	002	Jan 15, 2008
MYLAN	5MG	A076677	004	Dec 27, 2007
	10MG	A076677	003	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	003	Feb 19, 2009
	10MG	A078862	004	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	003	Dec 27, 2007
	10MG	A078336	004	Dec 27, 2007
RANBAXY	5MG	A077498	003	Dec 27, 2007
	10MG	A077498	004	Dec 27, 2007
UNICHEM	5MG	A078680	001	Jun 26, 2009
	10MG	A078680	002	Jun 26, 2009
UNIQUE PHARM LABS	5MG	A077829	003	Aug 26, 2009
	10MG	A077829	002	Aug 26, 2009

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS NY	5MG	A078780	003	Jan 21, 2010
	10MG	A078780	002	Jan 21, 2010
TARO	10MG	A078072	002	Jul 22, 2009
	10MG	A078072	004	Jul 22, 2009
TORRENT PHARMS LLC	5MG	A079191	003	Apr 15, 2010
	10MG	A079191	002	Apr 15, 2010

ZYRTEC ALLERGY

MCNEIL CONSUMER	5MG	N019835	003	Nov 16, 2007
	10MG	N019835	004	Nov 16, 2007

+

ZYRTEC HIVES RELIEF

MCNEIL CONSUMER	5MG	N019835	005	Nov 16, 2007
	10MG	N019835	006	Nov 16, 2007

+

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	5MG;120MG	A077170	001	Feb 25, 2008
SANDOZ	5MG;120MG	A077991	001	Mar 05, 2008
SUN PHARM INDS LTD	5MG;120MG	A090922	001	Sep 28, 2012
ZYRTEC-D 12 HOUR				
+ MCNEIL	5MG;120MG	N021150	002	Nov 09, 2007

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED; TOPICAL

EXIDINE

+ XTTRIUM	4%	N019127	001	Dec 24, 1984

CLOTH; TOPICAL

CHLORHEXIDINE GLUCONATE

+ SAGE PRODS	2%	N021669	001	Apr 25, 2005

SOLUTION; TOPICAL

BRIAN CARE

SOAPCO	4%	A071419	001	Dec 17, 1987

CHG SCRUB

ECOLAB	4%	N019258	002	Jul 22, 1986

CIDA-STAT

ECOLAB	2%	N019258	001	Jul 22, 1986

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 5 (of 20)

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

DYNA-HEX

XTTRIUM

0.75%

N020111 001 Sep 11, 1997

EXIDINE

+ XTTRIUM

2%

N019422 001 Dec 17, 1985

4%

N019125 001 Dec 24, 1984

HIBICLENS

+ MOLNLYCKE HLTH

4%

N017768 001

HIBISTAT

+ MOLNLYCKE HLTH

0.5%

N018300 001

SPONGE; TOPICAL

BIOSCRUB

GRIFFEN

4%

N019822 001 Mar 31, 1989

CHLORHEXIDINE GLUCONATE

BECTON DICKINSON

4%

A072525 001 Oct 24, 1989

PHARMASEAL SCRUB CARE

+ CAREFUSION

4%

N019793 001 Dec 02, 1988

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP ONE-STEP

+ CAREFUSION

2%;70% (3ML)

N020832 001 Jul 14, 2000

+

2%;70% (10.5ML)

N020832 004 Aug 20, 2003

+

2%;70% (26ML)

N020832 006 Nov 21, 2006

CHLORAPREP ONE-STEP FREPP

+ CAREFUSION

2%;70% (1.5ML)

N020832 003 Apr 26, 2002

CHLORAPREP WITH TINT

+ CAREFUSION

2%;70% (26ML)

N020832 002 May 03, 2005

+

2%;70% (10.5ML)

N020832 005 Apr 03, 2006

+

2%;70% (3ML)

N020832 007 Oct 10, 2006

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+ CAREFUSION

2%;70% (0.67ML)

N021555 001 Oct 07, 2002

CHLORAPREP SINGLE SWABSTICK

+ CAREFUSION

2%;70% (1.75ML)

N021555 002 May 10, 2005

CHLORAPREP TRIPLE SWABSTICK

+ CAREFUSION

2%;70% (5.25ML)

N021555 003 Jun 10, 2009

CHLORASCRUB MAXI SWABSTICK

+ PROF DSPLS

3.15%;70% (5.1ML)

N021524 003 Jun 03, 2005

CHLORASCRUB SWAB

+ PROF DSPLS

3.15%;70% (1ML)

N021524 001 Jun 03, 2005

CHLORASCRUB SWABSTICK

+ PROF DSPLS

3.15%;70% (1.6ML)

N021524 002 Jun 03, 2005

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

AVANTHI INC

12MG

A040829 001 May 13, 2009

CHLOR-TRIMETON

+ SCHERING PLOUGH

12MG

N007638 002

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL ALLERGY AND CONGESTION RELIEF

+ PFIZER

4MG;200MG;10MG

N022113 001 Dec 21, 2011

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ADVIL ALLERGY SINUS

+ PFIZER

1MG/5ML;100MG/5ML;15MG/5ML

N021587 001 Feb 24, 2004

TABLET; ORAL

ADVIL ALLERGY SINUS

+ PFIZER

2MG;200MG;30MG

N021441 001 Dec 19, 2002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 6 (of 20)

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

+ SCHERING PLOUGH 8MG;120MG N018397 001

CIMETIDINE

TABLET; ORAL

CIMETIDINE

APOTEX

100MG

A074948 001 Jun 19, 1998

200MG

A074948 002 Jul 26, 2002

CONTRACT PHARMACAL

200MG

A074961 001 Jun 19, 1998

200MG

A074963 001 Jun 19, 1998

IVAX SUB TEVA PHARMS

200MG

A075345 001 Jun 16, 1999

PERRIGO

200MG

A075285 001 Oct 29, 1998

WATSON LABS

200MG

A075425 001 Jul 29, 1999

TAGAMET HB

+ GLAXOSMITHKLINE 200MG

N020238 002 Aug 21, 1996

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

PERRIGO

1.34MG

A074512 001 Nov 22, 1995

SANDOZ

1.34MG

A073458 001 Oct 31, 1993

TAVIST-1

+ NOVARTIS 1.34MG

N020925 001 Aug 21, 1992

CLOTRIMAZOLE

CREAM, TABLET; TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK

+ SCHERING PLOUGH 1%,200MG

N020526 002 Jul 29, 1996

GYNE-LOTRIMIN COMBINATION PACK

+ SCHERING PLOUGH 1%,100MG

N020289 002 Apr 26, 1993

MYCELEX-7 COMBINATION PACK

BAYER PHARMS 1%,100MG

N020389 002 Jun 23, 1994

CREAM; VAGINAL

CLOTRIMAZOLE

ACTAVIS MID ATLANTIC 1%

A074165 001 Jul 16, 1993

TARO 1%

A072641 001 Dec 04, 1995

GYNE-LOTRIMIN

+ SCHERING PLOUGH 1%

N018052 002 Nov 30, 1990

GYNE-LOTRIMIN 3

+ SCHERING PLOUGH 2%

N020574 001 Nov 24, 1998

MYCELEX-7

BAYER PHARMS 1%

N018230 002 Dec 26, 1991

TRIVAGIZOLE 3

TARO 2%

N021143 001 Apr 12, 2000

TABLET; VAGINAL

GYNE-LOTRIMIN

+ SCHERING PLOUGH 100MG

N017717 002 Nov 30, 1990

GYNE-LOTRIMIN 3

+ SCHERING PLOUGH 200MG

N020525 001 Jul 29, 1996

MYCELEX-7

BAYER PHARMS 100MG

N018182 002 Dec 26, 1991

CROMOLYN SODIUM

SPRAY, METERED; NASAL

CROMOLYN SODIUM

+ BAUSCH AND LOMB 5.2MG/SPRAY

A075702 001 Jul 03, 2001

PERRIGO 5.2MG/SPRAY

A075427 001 Dec 12, 2001

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DISOPHROL

SCHERING PLOUGH 6MG;120MG

N013483 004 Sep 13, 1982

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 7 (of 20)

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DRIXORAL

+	SCHERING PLOUGH	6MG;120MG	N013483	003	Sep 13, 1982

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX DM

	RECKITT BENCKISER	30MG;600MG	N021620	002	Apr 29, 2004
+		60MG;1.2GM	N021620	001	Apr 29, 2004

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DELSYM

+	RECKITT BENCKISER	EQ 30MG HBR/5ML	N018658	001	Oct 08, 1982
	DEXTROMETHORPHAN POLISTIREX				
	TRIS PHARMA INC	EQ 30MG HBR/5ML	A091135	001	May 25, 2012

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET; ORAL

ADVIL PM

+	PFIZER	38MG;200MG	N021394	001	Dec 21, 2005
	IBUPROFEN AND DIPHENHYDRAMINE CITRATE				
	DR REDDYS LABS LTD	38MG;200MG	A090619	001	Jul 08, 2009
	PERRIGO R AND D	38MG;200MG	A079113	001	Dec 22, 2008

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

ADVIL PM

+	PFIZER	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	N021393	001	Dec 21, 2005
	IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE				
	BANNER PHARMACAPS	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010
	STRIDES ARCOLAB LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888	001	Mar 05, 2012

DOCOSANOL

CREAM; TOPICAL

ABREVA

+	GLAXOSMITHKLINE	10%	N020941	001	Jul 25, 2000

DOXYLAMINE SUCCINATE

TABLET; ORAL

DOXYLAMINE SUCCINATE

	LNK	25MG	A040564	001	Aug 27, 2004
	PERRIGO	25MG	A040167	001	Sep 18, 1996
	UNISOM				
+	CHATTEM	25MG	N018066	001	

EPINEPHRINE

AEROSOL, METERED; INHALATION

EPINEPHRINE

	ARMSTRONG PHARMS	0.2MG/INH	A087907	001	May 23, 1984

FAMOTIDINE

TABLET, CHEWABLE; ORAL

FAMOTIDINE

	PERRIGO	10MG	A075715	001	Aug 22, 2003
	PEPCID AC				
+	MCNEIL CONS	20MG	N020801	002	Dec 17, 2007
	FAMOTIDINE				
	DR REDDYS LABS LTD	10MG	A075758	001	Aug 17, 2001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 8 (of 20)

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

DR REDDYS LABS LTD	20MG	A077367	001	Sep 25, 2006
IVAX SUB TEVA PHARMS	10MG	A075512	001	Jul 26, 2001
MYLAN	10MG	A075674	001	Dec 21, 2001
PERRIGO	10MG	A075400	001	Mar 18, 2005
	20MG	A077351	001	Sep 25, 2006
RANBAXY	10MG	A090283	001	Nov 17, 2009
	20MG	A090283	002	Nov 17, 2009
TEVA	10MG	A075312	001	May 31, 2001
WATSON LABS	10MG	A075404	001	Nov 28, 2001
WOCKHARDT	10MG	A077146	001	Mar 07, 2005
	20MG	A090837	001	Aug 04, 2010
PEPCID AC				
MCNEIL CONS	10MG	N020325	001	Apr 28, 1995
+	20MG	N020325	002	Sep 23, 2003
PEPCID AC (GELTAB)				
MCNEIL CONS	10MG	N020902	001	Aug 05, 1999

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ALLEGRA ALLERGY

+	SANOFI AVENTIS US	30MG/5ML	N201373	001	Jan 24, 2011
	CHILDREN'S ALLEGRA HIVES				
+	SANOFI AVENTIS US	30MG/5ML	N201373	002	Jan 24, 2011
	TABLET, ORALLY DISINTEGRATING; ORAL				
	CHILDREN'S ALLEGRA ALLERGY				
+	SANOFI AVENTIS US	30MG	N021909	002	Jan 24, 2011
	CHILDREN'S ALLEGRA HIVES				
+	SANOFI AVENTIS US	30MG	N021909	003	Jan 24, 2011
	TABLET; ORAL				
	ALLEGRA ALLERGY				
	SANOFI AVENTIS US	60MG	N020872	007	Jan 24, 2011
+		180MG	N020872	010	Jan 24, 2011
	ALLEGRA HIVES				
	SANOFI AVENTIS US	60MG	N020872	008	Jan 24, 2011
+		180MG	N020872	009	Jan 24, 2011
	CHILDREN'S ALLEGRA ALLERGY				
	SANOFI AVENTIS US	30MG	N020872	005	Jan 24, 2011
	CHILDREN'S ALLEGRA HIVES				
	SANOFI AVENTIS US	30MG	N020872	006	Jan 24, 2011
	CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY				
	DR REDDYS LABS LTD	30MG	A076502	004	Apr 12, 2011
	MYLAN	30MG	A077081	004	Jul 21, 2011
	SUN PHARM INDS	30MG	A091567	002	Feb 06, 2012
	TEVA	30MG	A076447	004	Apr 13, 2011
	WOCKHARDT LTD	30MG	A079112	002	Feb 08, 2012
	CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES				
	DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011
	MYLAN	30MG	A077081	005	Jul 21, 2011
	SUN PHARM INDS	30MG	A091567	001	Feb 06, 2012
	TEVA	30MG	A076447	005	Apr 13, 2011
	WOCKHARDT LTD	30MG	A079112	001	Feb 08, 2012
	FEXOFENADINE HYDROCHLORIDE ALLERGY				
	DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011
		180MG	A076502	008	Apr 12, 2011
	MYLAN	60MG	A077081	006	Jul 21, 2011
		180MG	A077081	008	Jul 21, 2011
	SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012
		180MG	A091567	006	Feb 06, 2012
	TEVA	60MG	A076447	006	Apr 13, 2011
		180MG	A076447	008	Apr 13, 2011
	WOCKHARDT LTD	60MG	A079112	004	Feb 08, 2012

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 9 (of 20)

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE ALLERGY

WOCKHARDT LTD	180MG	A079112	006	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	60MG	A076502	007	Apr 12, 2011

	180MG	A076502	009	Apr 12, 2011

MYLAN	60MG	A077081	007	Jul 21, 2011

	180MG	A077081	009	Jul 21, 2011

SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012

	180MG	A091567	005	Feb 06, 2012

TEVA	60MG	A076447	007	Apr 13, 2011

	180MG	A076447	009	Apr 13, 2011

WOCKHARDT LTD	60MG	A079112	003	Feb 08, 2012

	180MG	A079112	005	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US	60MG;120MG	N020786	002	Jan 24, 2011

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US	180MG;240MG	N021704	002	Jan 24, 2011

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS LTD	180MG;240MG	A079043	002	Jun 22, 2011

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN

PERRIGO R AND D	600MG	A078912	001	Nov 23, 2011

MUCINEX

RECKITT BENCKISER	600MG	N021282	001	Jul 12, 2002

+	1.2GM	N021282	002	Dec 18, 2002

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MUCINEX D

RECKITT BENCKISER	600MG;60MG	N021585	001	Jun 22, 2004

+	1.2GM;120MG	N021585	002	Jun 22, 2004

IBUPROFEN

CAPSULE; ORAL

ADVIL LIQUI-GELS

+ PFIZER	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	001	Apr 20, 1995

ADVIL MIGRAINE LIQUI-GELS

+ PFIZER	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	002	Mar 16, 2000

IBUPROFEN

AMNEAL PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A202300	001	Dec 23, 2011

BANNER PHARMACAPS	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009

+ CONTRACT PHARMACAL	200MG	A074782	001	Jul 06, 1998

MARKSANS PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A079205	001	Jun 26, 2009

PLD ACQUISITIONS	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338	001	Jul 10, 2009

MIDOL LIQUID GELS

+ BANNER PHARMACAPS	200MG	N021472	001	Oct 18, 2002

SUSPENSION/DROPS; ORAL

CHILDREN'S MOTRIN

+ MCNEIL CONS	40MG/ML	N020603	001	Jun 10, 1996

IBUPROFEN

PERRIGO	40MG/ML	A075217	001	Dec 16, 1998

TRIS PHARMA INC	40MG/ML	A079058	001	Aug 31, 2009

PEDIATRIC ADVIL

+ PFIZER	100MG/2.5ML	N020812	001	Jan 30, 1998

SUSPENSION; ORAL

CHILDREN'S ADVIL

PFIZER	100MG/5ML	N020589	001	Jun 27, 1996

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 10 (of 20)

IBUPROFEN

SUSPENSION; ORAL

CHILDREN'S ADVIL-FLAVORED

PFIZER	100MG/5ML	N020589	002	Nov 07, 1997

CHILDREN'S ELIXSURE

ALTERNA TCHP LLC	100MG/5ML	N021604	001	Jan 07, 2004

CHILDREN'S IBUPROFEN

PERRIGO	100MG/5ML	A074937	001	Dec 22, 1998

CHILDREN'S MOTRIN

+ MCNEIL	100MG/5ML	N020516	001	Jun 16, 1995

IBUPROFEN

ACTAVIS MID ATLANTIC	100MG/5ML	A074916	001	Apr 30, 1999

AMNEAL PHARMS	100MG/5ML	A200457	001	Aug 18, 2011

TABLET, CHEWABLE; ORAL

CHILDREN'S ADVIL

PFIZER	50MG	N020944	001	Dec 18, 1998

CHILDREN'S MOTRIN

MCNEIL CONS	50MG	N020601	001	Nov 15, 1996

IBUPROFEN

PERRIGO	50MG	A076359	001	Jan 16, 2004

	100MG	A076359	002	Jan 16, 2004

JUNIOR STRENGTH ADVIL

PFIZER	100MG	N020944	002	Dec 18, 1998

JUNIOR STRENGTH MOTRIN

+ MCNEIL CONS	100MG	N020601	003	Nov 15, 1996

TABLET; ORAL

ADVIL

PFIZER	200MG	N018989	001	May 18, 1984

IBUPROFEN

AMNEAL PHARMS NY	200MG	A071333	001	Feb 17, 1987

	200MG	A072199	001	May 23, 1988

AVEMA PHARMA	200MG	A076460	001	Nov 26, 2003

CONTRACT PHARMACAL	200MG	A071732	001	Sep 10, 1987

	200MG	A071735	001	Sep 10, 1987

	200MG	A072299	001	Jul 01, 1988

	200MG	A074931	001	Jul 20, 1998

DR REDDYS LA	200MG	A075661	001	Dec 12, 2001

DR REDDYS LABS INC	100MG	A076117	001	Nov 20, 2001

GRANULES INDIA	200MG	A079174	001	Dec 10, 2010

LNK	100MG	A076741	001	Jun 17, 2004

	200MG	A075010	001	Mar 01, 1999

	200MG	A075139	001	Mar 01, 1999

MARKSANS PHARMA	200MG	A091237	001	Feb 08, 2011

	200MG	A091239	001	Feb 01, 2011

MCNEIL	200MG	A073019	001	Mar 30, 1994

MERRO PHARM	200MG	A070985	001	Oct 02, 1987

OHM	200MG	A071163	001	Jul 15, 1986

PAR PHARM	200MG	A070481	001	Sep 24, 1986

PERRIGO	200MG	A072096	001	Dec 08, 1987

	200MG	A075995	001	Mar 14, 2002

PERRIGO R AND D	200MG	A077349	001	Jun 21, 2005

SVADS HOLDINGS SA	200MG	A079129	001	Mar 28, 2011

	200MG	A091355	001	Apr 04, 2011

VINTAGE PHARMS	200MG	A071229	001	Apr 01, 1987

	200MG	A071639	001	Feb 02, 1988

WATSON LABS	200MG	A070435	001	Mar 05, 1986

IBUPROHM

OHM LABS	200MG	A071214	001	Dec 01, 1986

IBU-TAB 200

ALRA	200MG	A071057	001	Aug 11, 1988

JUNIOR STRENGTH ADVIL

PFIZER	100MG	N020267	002	Dec 13, 1996

JUNIOR STRENGTH IBUPROFEN

PERRIGO	100MG	A075367	001	Apr 22, 1999

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 11 (of 20)

IBUPROFEN

TABLET; ORAL				
JUNIOR STRENGTH MOTRIN				
MCNEIL CONS	100MG	N020602	001	Jun 10, 1996
MOTRIN IB				
+ MCNEIL	200MG	N019012	003	Dec 17, 1990
MOTRIN MIGRAINE PAIN				
+ MCNEIL	200MG	N019012	004	Feb 25, 2000
PROFEN				
CONTRACT PHARMACAL	200MG	A071265	001	Oct 15, 1986
TAB-PROFEN				
PERRIGO	200MG	A072095	001	Dec 08, 1987

IBUPROFEN SODIUM

TABLET; ORAL				
ADVIL				
+ PFIZER CONS HLTHCARE	EQ 200MG BASE	N201803	001	Jun 12, 2012

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET; ORAL				
ADVIL CONGESTION RELIEF				
+ PFIZER	200MG;10MG	N022565	001	May 27, 2010

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL				
ADVIL COLD AND SINUS				
+ PFIZER	EQ 200MG FREE ACID AND POTASSIUM SALT;30MG	N021374	001	May 30, 2002
SUSPENSION; ORAL				
CHILDREN'S ADVIL COLD				
PFIZER	100MG/5ML;15MG/5ML	N021373	001	Apr 18, 2002
CHILDREN'S MOTRIN COLD				
+ MCNEIL CONS	100MG/5ML;15MG/5ML	N021128	001	Aug 01, 2000
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE				
PERRIGO	100MG/5ML;15MG/5ML	A076478	001	Nov 05, 2003
TABLET; ORAL				
ADVIL COLD AND SINUS				
+ PFIZER	200MG;30MG	N019771	001	Sep 19, 1989
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE				
CONTRACT PHARMACAL	200MG;30MG	A075588	001	Apr 08, 2002
DR REDDYS LABS LTD	200MG;30MG	A077628	001	Aug 14, 2006
IBUPROHM COLD AND SINUS				
OHM LABS	200MG;30MG	A074567	001	Apr 17, 2001
SINE-AID IB				
MCNEIL CONS	200MG;30MG	N019899	001	Dec 31, 1992

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION				
HUMULIN R				
+ LILLY	100 UNITS/ML	N018780	001	Oct 28, 1982
HUMULIN R PEN				
+ LILLY	100 UNITS/ML	N018780	005	Aug 06, 1998
NOVOLIN R				
+ NOVO NORDISK INC	100 UNITS/ML	N019938	001	Jun 25, 1991

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION				
HUMULIN 70/30				
+ LILLY	30 UNITS/ML;70 UNITS/ML	N019717	001	Apr 25, 1989
HUMULIN 70/30 PEN				
+ LILLY	30 UNITS/ML;70 UNITS/ML	N019717	002	Aug 06, 1998
NOVOLIN 70/30				
+ NOVO NORDISK INC	30 UNITS/ML;70 UNITS/ML	N019991	001	Jun 25, 1991

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 12 (of 20)

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN N

+ LILLY 100 UNITS/ML N018781 001 Oct 28, 1982

NOVOLIN N

+ NOVO NORDISK INC 100 UNITS/ML N019959 001 Jul 01, 1991

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

DURAPREP

+ 3M EQ 0.7% IODINE;74% (6ML) N021586 001 Sep 29, 2006

+ EQ 0.7% IODINE;74% (26ML) N021586 002 Sep 29, 2006

KETOCONAZOLE

SHAMPOO; TOPICAL

NIZORAL A-D

+ MCNEIL CONS 1% N020310 001 Oct 10, 1997

KETOPROFEN

FILM; ORAL

NEXCEDE

+ NOVARTIS 12.5MG N022470 001 Nov 25, 2009

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ALAWAY

+ BAUSCH AND LOMB EQ 0.025% BASE N021996 001 Dec 01, 2006

KETOTIFEN FUMARATE

AKORN EQ 0.025% BASE A077958 001 Jul 26, 2007

ALCON PHARMS LTD EQ 0.025% BASE A077200 001 Sep 02, 2008

APOTEX INC EQ 0.025% BASE A077354 001 May 09, 2006

ZADITOR

+ ALCON PHARMA EQ 0.025% BASE N021066 002 Oct 19, 2006

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

DR REDDYS LABS LTD 15MG A202194 001 May 18, 2012

PERRIGO R AND D 15MG A202319 001 May 18, 2012

WOCKHARDT LTD 15MG A202727 001 May 18, 2012

PREVACID 24 HR

+ NOVARTIS 15MG N022327 001 May 18, 2009

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

PERRIGO R AND D 0.75MG A090740 001 Dec 30, 2010

+ WATSON LABS 0.75MG A078665 001 Aug 28, 2009

WATSON LABS INC 1.5MG A200670 001 Jul 12, 2012

PLAN B

+ TEVA BRANDED PHARM 0.75MG N021045 002 Aug 24, 2006

PLAN B ONE-STEP

+ DURAMED 1.5MG N021998 001 Jul 10, 2009

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

LOPERAMIDE HYDROCHLORIDE

BANNER PHARMACAPS 1MG N021855 001 Aug 04, 2005

+ 2MG N021855 002 Aug 04, 2005

SOLUTION; ORAL

IMODIUM A-D

+ MCNEIL CONS 1MG/5ML N019487 001 Mar 01, 1988

LOPERAMIDE HYDROCHLORIDE

HI TECH PHARMA 1MG/5ML A074352 001 Nov 17, 1995

OTC DRUG PRODUCT LIST

4 - 13 (of 20)

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

LOPERAMIDE HYDROCHLORIDE

PERRIGO	1MG/5ML	A073243	001	Jan 21, 1992
ROXANE	1MG/5ML	A073079	001	Apr 30, 1992
WOCKHARDT	1MG/5ML	A074730	001	Aug 28, 1997

SUSPENSION; ORAL

IMODIUM A-D

+ MCNEIL CONS	1MG/7.5ML	N019487	002	Jul 08, 2004

LOPERAMIDE HYDROCHLORIDE

PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011

TABLET, CHEWABLE; ORAL

IMODIUM A-D EZ CHEWS

+ MCNEIL	2MG	N020448	001	Jul 24, 1997

TABLET; ORAL

IMODIUM A-D

+ MCNEIL CONS	2MG	N019860	001	Nov 22, 1989

LOPERAMIDE HYDROCHLORIDE

CONTRACT PHARMACAL	2MG	A073254	001	Jul 30, 1993

LNK	2MG	A076497	001	Jun 10, 2003

OHM LABS	2MG	A074091	001	Dec 10, 1992

PERRIGO	2MG	A075232	001	Jan 06, 2000

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE; ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ MCNEIL	2MG;125MG	N020606	001	Jun 26, 1996

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

PERRIGO	2MG;125MG	A076029	001	Aug 30, 2002

TABLET; ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ MCNEIL CONS	2MG;125MG	N021140	001	Nov 30, 2000

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

RANBAXY	2MG;125MG	A077500	001	Sep 06, 2006

LORATADINE

CAPSULE; ORAL

CLARITIN

+ SCHERING PLOUGH	10MG	N021952	001	Jun 16, 2008

SUSPENSION; ORAL

LORATADINE

+ TARO	1MG/ML	N021734	001	Oct 04, 2005

SYRUP; ORAL

CLARITIN

+ SCHERING PLOUGH	1MG/ML	N020641	002	Nov 27, 2002

LORATADINE

APOTEX INC	1MG/ML	A075565	001	Oct 05, 2004

PERRIGO	1MG/ML	A075728	001	Aug 20, 2004

SILARX	1MG/ML	A077421	001	Jun 29, 2006

TARO	1MG/ML	A076805	001	Aug 20, 2004

TEVA	1MG/ML	A075505	001	Nov 07, 2003

WOCKHARDT	1MG/ML	A075815	001	Aug 20, 2004

TABLET, CHEWABLE; ORAL

CHILDREN'S CLARITIN

+ SCHERING PLOUGH	5MG	N021891	001	Aug 23, 2006

TABLET, ORALLY DISINTEGRATING; ORAL

ALAVERT

PFIZER	10MG	N021375	001	Dec 19, 2002

CLARITIN HIVES RELIEF REDITAB

+ SCHERING PLOUGH	10MG	N020704	003	Nov 19, 2003

CLARITIN REDITABS

+ SCHERING PLOUGH	5MG	N021993	001	Dec 12, 2006

+	10MG	N020704	002	Nov 27, 2002

LORATADINE

IMPAX LABS	10MG	A076011	001	Sep 29, 2003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 14 (of 20)

LORATADINETABLET, ORALLY DISINTEGRATING; ORAL
LORATADINE

PFIZER 10MG A075822 001 Feb 10, 2003

WATSON LABS FLORIDA 10MG A075990 001 Nov 03, 2003

LORATADINE REDIDOSE

RANBAXY 10MG A077153 001 Apr 11, 2007

TABLET; ORAL

CLARITIN

+ SCHERING PLOUGH 10MG N019658 002 Nov 27, 2002

CLARITIN HIVES RELIEF

+ SCHERING PLOUGH 10MG N019658 003 Nov 19, 2003

LORATADINE

APOTEX INC 10MG A076471 001 Feb 14, 2006

MYLAN 10MG A075790 001 Nov 07, 2008

10MG A076154 001 Aug 20, 2003

10MG A078447 001 Aug 12, 2011

PERRIGO 10MG A076301 001 Jun 25, 2004

RANBAXY 10MG A076134 001 Aug 18, 2003

SANDOZ 10MG A075209 001 Jan 21, 2003

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D

+ SCHERING PLOUGH 5MG;120MG N019670 002 Nov 27, 2002

CLARITIN-D 24 HOUR

+ SCHERING PLOUGH 10MG;240MG N020470 002 Nov 27, 2002

LORATADINE AND PSEUDOEPHEDRINE SULFATE

IMPAX LABS 5MG;120MG A076050 001 Jan 30, 2003

10MG;240MG A075989 001 Mar 04, 2004

RANBAXY 10MG;240MG A076557 001 Sep 22, 2004

WATSON LABS FLORIDA 5MG;120MG A076208 001 Jan 28, 2004

10MG;240MG A075706 001 Feb 21, 2003

MENTHOL; METHYL SALICYLATE

PATCH; TOPICAL

SALONPAS

+ HISAMITSU PHARM CO 3%;10% N022029 001 Feb 20, 2008

3%;10% N022029 002 Nov 05, 2012

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

MICONAZOLE 7 COMBINATION PACK

G AND W LABS 2%,100MG A076585 001 Mar 26, 2004

MICONAZOLE NITRATE

PERRIGO R AND D 2%,1.2GM A079114 001 Jun 02, 2010

MICONAZOLE NITRATE COMBINATION PACK

PERRIGO 2%,200MG A075329 001 Apr 20, 1999

MONISTAT 1 COMBINATION PACK

+ INSIGHT PHARMS 2%,1.2GM N021308 001 Jun 29, 2001

MONISTAT 7 COMBINATION PACK

+ INSIGHT PHARMS 2%,100MG N020288 002 Apr 26, 1993

MONISTAT-3 COMBINATION PACK

+ INSIGHT PHARMS 2%,200MG N020670 002 Apr 16, 1996

M-ZOLE 3 COMBINATION PACK

ACTAVIS MID ATLANTIC 2%,200MG A074926 001 Apr 16, 1999

CREAM; TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK

PERRIGO 2%,4% A076357 001 Mar 30, 2004

MONISTAT 3 COMBINATION PACK

INSIGHT PHARMS 2%,4% N021261 003 Jun 17, 2003

MONISTAT 3 COMBINATION PACK (PREFILLED)

+ INSIGHT PHARMS 2%,4% N021261 001 Feb 02, 2001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 15 (of 20)

MICONAZOLE NITRATE

CREAM; VAGINAL

MICONAZOLE 3

TARO 4%

A076773 001 Mar 02, 2005

MICONAZOLE 7

ACTAVIS MID ATLANTIC 2%

A074164 001 Mar 29, 1996

MICONAZOLE NITRATE

G AND W LABS 2%

A074366 001 Feb 22, 1996

PERRIGO 2%

A074760 001 May 15, 1997

PERRIGO R AND D 4%

A091366 001 Jan 15, 2010

TARO 2%

A074444 001 Jan 13, 1997

MONISTAT 3

+ INSIGHT PHARMS 4%

N020827 001 Mar 30, 1998

MONISTAT 7

+ INSIGHT PHARMS 2%

N017450 002 Feb 15, 1991

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE

ACTAVIS MID ATLANTIC 100MG

A073507 001 Nov 19, 1993

G AND W LABS 100MG

A074414 001 Apr 30, 1997

+ PERRIGO 100MG

A074395 001 Mar 20, 1997

MONISTAT 7

+ INSIGHT PHARMS 100MG

N018520 002 Feb 15, 1991

MINOXIDIL

AEROSOL, FOAM; TOPICAL

MEN'S ROGAINE

+ JOHNSON AND JOHNSON 5%

N021812 001 Jan 20, 2006

MINOXIDIL

PERRIGO ISRAEL 5%

A091344 001 Apr 28, 2011

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)

ACTAVIS MID ATLANTIC 2%

A074588 001 Apr 05, 1996

HI TECH PHARMA 2%

A074731 001 Dec 24, 1996

NOVEX 2%

A074924 001 Apr 29, 1998

PERRIGO 2%

A075357 001 Jul 30, 1999

WOCKHARDT 2%

A074767 001 Feb 28, 1997

MINOXIDIL (FOR WOMEN)

HI TECH PHARMA 2%

A074731 002 May 11, 2005

NOVEX 2%

A074924 002 Apr 29, 1998

PERRIGO 2%

A075357 002 Jul 30, 1999

MINOXIDIL EXTRA STRENGTH (FOR MEN)

ACTAVIS MID ATLANTIC 5%

A075518 001 Nov 17, 2000

AVACOR PRODS 5%

A075619 001 Nov 17, 2000

NOVEX 5%

A075839 001 Oct 01, 2001

PERRIGO 5%

A075598 001 Jun 13, 2001

PERRIGO NEW YORK 5%

A075737 001 Mar 15, 2002

WOCKHARDT 5%

A075438 001 Feb 27, 2003

ROGAINE (FOR MEN)

+ JOHNSON AND JOHNSON 2%

N019501 002 Feb 09, 1996

ROGAINE (FOR WOMEN)

+ JOHNSON AND JOHNSON 2%

N019501 003 Feb 09, 1996

ROGAINE EXTRA STRENGTH (FOR MEN)

+ JOHNSON AND JOHNSON 5%

N020834 001 Nov 14, 1997

THEROXIDIL

EI INC 2%

A078176 001 Nov 09, 2007

5%

A076239 001 Aug 24, 2004

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

ALTAIRE PHARMS INC 0.02675%;0.315%

A078208 001 Sep 27, 2010

NAPHCON-A

+ ALCON 0.025%;0.3%

N020226 001 Jun 08, 1994

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 16 (of 20)

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

OPCON-A

+ BAUSCH AND LOMB 0.02675%;0.315% N020065 001 Jun 08, 1994

VISINE-A

+ JOHNSON AND JOHNSON 0.025%;0.3% N020485 001 Jan 31, 1996

NAPROXEN SODIUM

CAPSULE; ORAL

NAPROXEN SODIUM

+ BANNER PHARMACAPS EQ 200MG BASE N021920 001 Feb 17, 2006

TABLET; ORAL

ALEVE

+ BAYER EQ 200MG BASE N020204 002 Jan 11, 1994

NAPROXEN SODIUM

AMNEAL PHARMS NY EQ 200MG BASE A079096 001 Dec 16, 2008

CONTRACT PHARMACAL EQ 200MG BASE A074635 001 Jan 13, 1997

EQ 200MG BASE A074789 001 Feb 27, 1997

DR REDDYS LABS INC EQ 200MG BASE A075168 001 Jul 28, 1998

GRANULES INDIA EQ 200MG BASE A091353 001 Sep 20, 2011

MARKSANS PHARMA EQ 200MG BASE A090545 001 Mar 16, 2011

PERRIGO EQ 200MG BASE A074661 001 Jan 13, 1997

RANBAXY LABS LTD EQ 200MG BASE A091183 001 May 20, 2011

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALEVE-D SINUS & COLD

+ BAYER 200MG;120MG N021076 001 Nov 29, 1999

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS INC EQ 220MG BASE;120MG A077381 001 Sep 27, 2006

PERRIGO EQ 200MG BASE;120MG A076518 001 Mar 17, 2004

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

HABITROL

+ NOVARTIS 7MG/24HR N020076 004 Nov 12, 1999

+ 14MG/24HR N020076 005 Nov 12, 1999

+ 21MG/24HR N020076 006 Nov 12, 1999

NICODERM CQ

+ SANOFI AVENTIS US 7MG/24HR N020165 006 Aug 02, 1996

+ 14MG/24HR N020165 005 Aug 02, 1996

+ 21MG/24HR N020165 004 Aug 02, 1996

NICOTINE

AVEVA 7MG/24HR A074612 002 Jul 28, 2003

14MG/24HR A074612 003 Oct 20, 1997

21MG/24HR A074612 001 Oct 20, 1997

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICORETTE

+ GLAXOSMITHKLINE EQ 2MG BASE N018612 002 Feb 09, 1996

EQ 2MG BASE N018612 004 Sep 25, 2000

+ EQ 4MG BASE N020066 002 Feb 09, 1996

EQ 4MG BASE N020066 004 Sep 25, 2000

NICORETTE (MINT)

GLAXOSMITHKLINE EQ 2MG BASE N018612 003 Dec 23, 1998

EQ 4MG BASE N020066 003 Dec 23, 1998

NICOTINE POLACRILEX

IVAX SUB TEVA PHARMS EQ 2MG BASE A076880 001 Feb 18, 2009

EQ 4MG BASE A077850 001 Feb 18, 2009

PERRIGO EQ 2MG BASE A076775 001 Sep 16, 2004

EQ 2MG BASE A076777 001 Sep 16, 2004

EQ 2MG BASE A076777 001 Sep 16, 2004

EQ 4MG BASE A076778 001 Sep 16, 2004

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 17 (of 20)

NICOTINE POLACRILEXGUM, CHEWING; BUCCAL
NICOTINE POLACRILEX

PERRIGO

EQ 4MG BASE

A076779 001 Sep 16, 2004

EQ 4MG BASE

A076789 001 Sep 16, 2004

PERRIGO R AND D

EQ 2MG BASE

A078325 001 Oct 30, 2006

EQ 2MG BASE

A078547 001 May 24, 2007

EQ 2MG BASE

A078967 001 Apr 23, 2008

EQ 2MG BASE

A091349 001 Jul 20, 2011

EQ 4MG BASE

A078326 001 Oct 30, 2006

EQ 4MG BASE

A078546 001 May 24, 2007

EQ 4MG BASE

A078968 001 Apr 23, 2008

EQ 4MG BASE

A091354 001 Jul 20, 2011

WATSON LABS

EQ 2MG BASE

A074507 001 Mar 15, 1999

EQ 2MG BASE

A076569 001 Jul 29, 2004

EQ 2MG BASE

A078699 001 Dec 29, 2008

EQ 2MG BASE

A079044 001 Jul 08, 2009

EQ 2MG BASE

A079216 001 Jul 08, 2009

EQ 4MG BASE

A074707 001 Mar 19, 1999

EQ 4MG BASE

A076568 002 Jul 29, 2004

EQ 4MG BASE

A078697 001 Dec 29, 2008

EQ 4MG BASE

A079038 001 Jul 08, 2009

EQ 4MG BASE

A079219 001 Jul 08, 2009

THRIVE

NOVARTIS

EQ 2MG BASE

A077658 001 Jun 19, 2007

EQ 4MG BASE

A077656 001 Jun 19, 2007

TROCHE/LOZENGE; ORAL
COMMIT

GLAXOSMITHKLINE CONS

EQ 2MG BASE

N021330 001 Oct 31, 2002

+

EQ 4MG BASE

N021330 002 Oct 31, 2002

NICORETTE

GLAXOSMITHKLINE CONS

EQ 2MG BASE

N022360 001 May 18, 2009

+

EQ 4MG BASE

N022360 002 May 18, 2009

NICOTINE POLACRILEX

PERRIGO R AND D

EQ 2MG BASE

A077007 001 Jan 31, 2006

EQ 2MG BASE

A090711 001 Jul 10, 2009

EQ 2MG BASE

A090821 001 Jul 10, 2009

EQ 2MG BASE

A203690 001 Oct 09, 2012

EQ 4MG BASE

A077007 002 Jan 31, 2006

EQ 4MG BASE

A090711 002 Jul 10, 2009

EQ 4MG BASE

A090821 002 Jul 10, 2009

EQ 4MG BASE

A203690 002 Oct 09, 2012

NIZATIDINETABLET; ORAL
AXID AR

+ PFIZER

75MG

N020555 001 May 09, 1996

NONOXYNOL-9SPONGE; VAGINAL
TODAY

+ AZTIQ PHARMA

1GM

N018683 001 Apr 01, 1983

OMEPRAZOLETABLET, DELAYED RELEASE; ORAL
OMEPRAZOLE

+ DEXCEL PHARMA

20MG

N022032 001 Dec 04, 2007

OMEPRAZOLE MAGNESIUMCAPSULE, DELAYED RELEASE; ORAL
OMEPRAZOLE MAGNESIUM

+ DR REDDYS LABS LTD

EQ 20MG BASE

A078878 001 Jun 05, 2009

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 18 (of 20)

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE; ORAL					
PRILOSEC OTC					
+	ASTRAZENECA	EQ 20MG BASE	N021229	001	Jun 20, 2003

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL					
ZEGERID OTC					
+	MSD CONSUMER	20MG;1.1GM	N022281	001	Dec 01, 2009

ORLISTAT

CAPSULE; ORAL					
ALLI					
+	GLAXOSMITHKLINE CONS	60MG	N021887	001	Feb 07, 2007

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC					
OCUCLEAR					
	SCHERING PLOUGH	0.025%	N018471	001	May 30, 1986
VISINE L.R.					
+	JOHNSON AND JOHNSON	0.025%	N019407	001	Mar 31, 1989

PERMETHRIN

LOTION; TOPICAL					
NIX					
+	INSIGHT PHARMS	1%	N019918	001	May 02, 1990
PERMETHRIN					
	ACTAVIS MID ATLANTIC	1%	A075014	001	Mar 28, 2000
	PERRIGO NEW YORK	1%	A076090	001	Dec 20, 2001

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL					
RID MOUSSE					
+	BAYER HLTHCARE	4%;EQ 0.33% BASE	N021043	001	Mar 07, 2000

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL					
GLYCOLAX					
	KREMERS URBAN PHARMS	17GM/PACKET	A090600	001	Oct 06, 2009
		17GM/SCOOPFUL	A090600	002	Oct 06, 2009
MIRALAX					
+	SCHERING PLOUGH	17GM/SCOOPFUL	N022015	001	Oct 06, 2006
POLYETHYLENE GLYCOL 3350					
	EMCURE PHARMS USA	17GM/SCOOPFUL	A202071	001	Dec 28, 2012
	MYLAN	17GM/PACKET	A078915	001	Oct 06, 2009
		17GM/SCOOPFUL	A078915	002	Oct 06, 2009
	NEXGEN PHARMA	17GM/SCOOPFUL	A090812	001	Oct 07, 2009
	NOVEL LABS INC	17GM/SCOOPFUL	A091077	001	Oct 06, 2009
	PERRIGO R AND D	17GM/PACKET	A090685	001	Oct 06, 2009
		17GM/SCOOPFUL	A090685	002	Oct 06, 2009

POTASSIUM IODIDE

SOLUTION; ORAL					
THYROSHIELD					
+	ARCO PHARMS LLC	65MG/ML	A077218	001	Jan 12, 2005
TABLET; ORAL					
IOSAT					
	ANBEX	65MG	N018664	002	May 12, 2011
+		130MG	N018664	001	Oct 14, 1982
THYROSAFE					
+	RECIP	65MG	A076350	001	Sep 10, 2002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

OTC DRUG PRODUCT LIST

4 - 19 (of 20)

POVIDONE- IODINE

SOLUTION; TOPICAL

POVIDONE IODINE

+ ALLEGIANCE HLTHCARE	1%	N019522	001	Mar 31, 1989

SPONGE; TOPICAL

E-Z SCRUB 201

+ BECTON DICKINSON	20%	N019240	001	Nov 29, 1985

E-Z SCRUB 241

+ BECTON DICKINSON	10%	N019476	001	Jan 07, 1987

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE

PERRIGO 120MG

A075153 001 Feb 26, 1999

RANBAXY 120MG

A077442 001 Sep 28, 2005

SUDAFED 12 HOUR

+ MCNEIL CONS	120MG	A073585	001	Oct 31, 1991

SUDAFED 24 HOUR

+ MCNEIL CONS	240MG	N020021	002	Dec 15, 1992

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

AFRINOL

+ SCHERING PLOUGH	120MG	N018191	001	

PURIFIED WATER

SOLUTION; OPHTHALMIC

PUR-WASH

+ NIAGARA PHARMS	98.3%	N022305	001	Sep 01, 2011

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

APOTEX INC EQ 150MG BASE

A200172 001 May 31, 2012

CONTRACT PHARMACAL EQ 75MG BASE

A075094 001 Jun 21, 1999

DR REDDYS LABS LTD EQ 75MG BASE

A075294 001 Mar 28, 2000

EQ 150MG BASE

A078192 001 Aug 31, 2007

IVAX SUB TEVA PHARMS EQ 75MG BASE

A075296 001 Jan 14, 2000

MYLAN EQ 75MG BASE

A075497 001 Jan 14, 2000

PERRIGO EQ 75MG BASE

A076195 001 Aug 30, 2002

PERRIGO R AND D EQ 150MG BASE

A091429 001 May 11, 2011

EQ 150MG BASE

A091429 002 May 11, 2011

SHASUN CHEMS EQ 75MG BASE

A201745 001 Feb 29, 2012

SVADS HOLDINGS SA EQ 150MG BASE

A200536 001 Jun 28, 2011

TORPHARM EQ 75MG BASE

A075167 001 May 04, 2000

WATSON LABS EQ 75MG BASE

A075212 001 Jan 14, 2000

WOCKHARDT EQ 75MG BASE

A076760 001 Feb 24, 2006

EQ 75MG BASE

A078884 001 Jul 31, 2008

EQ 150MG BASE

A078653 001 Nov 26, 2007

ZANTAC 150

+ BOEHRINGER INGELHEIM	EQ 150MG BASE	N021698	001	Aug 31, 2004

	EQ 150MG BASE	N021698	002	Mar 13, 2007

ZANTAC 75

BOEHRINGER INGELHEIM	EQ 75MG BASE	N020520	001	Dec 19, 1995

SODIUM CHLORIDE

AEROSOL, METERED; INHALATION

BRONCHO SALINE

+ BLAIREX	0.9%	N019912	001	Sep 03, 1992

SODIUM FLUORIDE; TRICLOSAN

PASTE; DENTAL

COLGATE TOTAL

+ COLGATE PALMOLIVE	0.24%;0.3%	N020231	001	Jul 11, 1997

OTC DRUG PRODUCT LIST

4 - 20 (of 20)

TERBINAFINE

GEL; TOPICAL LAMISIL AT + NOVARTIS	1%	N021958 001	Jul 24, 2006

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL LAMISIL + NOVARTIS	1%	N020980 001	Mar 09, 1999
TERBINAFINE HYDROCHLORIDE TARO	1%	A077511 001	Jul 02, 2007
SOLUTION; TOPICAL LAMISIL AT + NOVARTIS	1%	N021124 001	Mar 17, 2000
SPRAY; TOPICAL LAMISIL AT + NOVARTIS	1%	N021124 002	Mar 17, 2000

TIOCONAZOLE

OINTMENT; VAGINAL TIOCONAZOLE PERRIGO	6.5%	A075915 001	Nov 21, 2001
VAGISTAT-1 + NOVARTIS	6.5%	N020676 001	Feb 11, 1997

33RD EDITION - 2013- APPROVED DRUG PRODUCT LIST

5 - 1 of 5

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

HAEMONETICS

N760305

Jun 30, 1978

MANUFACTURING INC

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION

CITRA LABS LLC

N020037

Aug 26, 2003

ACD-A SOLUTION

GAMBRO BCT INC

A010228

ANDA

Feb 25, 2002

ADSOL WITH ACD-A

FENWAL INC

N000922

Aug 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A

HAEMONETICS CORP

A980728

ANDA

Feb 06, 2002

AS3 SOLUTION/ACD-A

GAMBRO BCT INC

N001214

May 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N100855

Jun 03, 1959

N160918

Mar 17, 1978

FRESENIUS MEDICAL

N110912

Sep 02, 1959

CARE NORTH AMERICA

MEDSEP CORPORATION

A710497

ANDA

MILES INC

N100102

Dec 14, 1961

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD-A)

INJECTABLE; INJECTION

NONE

ARTERIOCYTE MEDICAL

A110057

May 11, 2012

SYSTEMS, INC

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

INJECTABLE; INJECTION

CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3

HAEMONETICS CORP

N000127

Jan 18, 2002

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION

NONE

FRESENIUS MEDICAL

N780519

Apr 23, 1980

CARE NORTH AMERICA

TERUMO MEDICAL CORP

N820528

Nov 03, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION (CPDA)

INJECTABLE; INJECTION

CPDA-1 BLOOD-PACK UNIT (PL 146 PLASTIC) 250, 450, 500 ML BLOOD PACK UNITS

FENWAL INC

N770420

May 12, 1978

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION

BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER

FENWAL INC

N940404

Jul 28, 1994

33RD EDITION - 2013- APPROVED DRUG PRODUCT LIST

5 - 2 of 5

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS
MANUFACTURING INC

N800077

Nov 06, 1980

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION

ADSOL IN PLASTIC CONTAINER

FENWAL INC

N900223

Dec 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

INJECTABLE; INJECTION

MACOPRODUCTIONS SAS CPD/AS-1: MACOPHARMA LEUCOFLEX MTL1 LEUKOREDUCTION SYSTEM FOR BLOOD
COMPONENTS KNOWN AS MTL1-WB

MACOPRODUCTIONS SAS

N040083

Nov 21, 2005

NONE

GAMBRO BCT INC

A070025

Jan 06, 2008

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N170401

Dec 06, 1977

N811012

Jun 28, 1983

FRESENIUS MEDICAL
CARE NORTH AMERICA

N160907

May 16, 1973

HAEMONETICS
MANUFACTURING INC

N800222

Aug 23, 1982

MILES INC

N160527

Jun 22, 1970

TERUMO MEDICAL CORP

N781211

Jun 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1:
DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION

FENWAL INC

N811104

May 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5:
DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION

TERUMO MEDICAL CORP

N880217

Oct 07, 1988

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:
AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-3 NUTRICEL ADDITIVE SYSTEM

HAEMONETICS 0.042GM/100ML;0.276GM/100ML;
MANUFACTURING INC 0.410GM/100ML;0.30GM/100ML;
1.10GM/100ML;0.588GM/100ML

N820915

Oct 19, 1984

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:
AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-2 NUTRICEL ADDITIVE SYSTEM

MEDSEP CORP 0.042GM/100ML;0.285GM/100ML;
0.718GM/100ML;0.017GM/100ML;
0.396GM/100ML;0.588GM/100ML

N820915

Sep 22, 1983

33RD EDITION - 2013- APPROVED DRUG PRODUCT LIST

5 - 3 of 5

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT ETHYLENEDIAMINE TETRAACETIC ACID (EDTA)

INJECTABLE; INJECTION

NONE

FENWAL INC

N090480

Mar 07, 1955

ANTICOAGULANT HEPARIN SOLUTION USP

INJECTABLE; INJECTION

NONE

FRESENIUS MEDICAL
CARE NORTH AMERICA

N770822

May 17, 1978

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS
CORPORATION

N980123

Mar 03, 2000

ANTICOAGULANT SODIUM CITRATE SOLUTION

INJECTABLE; INJECTION

TRICITRASOL

CYTOSOL
LABORATORIES INC

N010409

Jul 10, 2003

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC
FRESENIUS MEDICAL
CARE NORTH AMERICA
TERUMO MEDICAL CORP

N770923

Jan 20, 1978

N160702

Dec 28, 1970

N781214

Feb 08, 1980

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION

PROMIT

MEDA AB

N830715

Oct 30, 1984

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION

GENTRAN 40

BAXTER HLTHCARE CORP 10GM/100ML;5GM/100ML

N840619

Feb 22, 1985

LMD IN PLASTIC CONTAINER

HOSPIRA INC 10GM/100ML;5GM/100ML

A720563

ANDA

Oct 30, 1992

NONE

B BRAUN MEDICAL INC 10GM/100ML;5GM/100ML

N160767

Apr 06, 1970

HOSPIRA INC 10GM/100ML;5GM/100ML

N160375

Jul 25, 1967

MILES INC 10GM/100ML;5GM/100ML

N160653

Sep 23, 1969

PHARMACHEM CORP 10GM/100ML;5GM/100ML

N160836

Nov 14, 1972

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

GENTRAN 40

BAXTER HLTHCARE CORP 10GM/100ML;0.9GM/100ML

N840620

Feb 22, 1985

LMD IN PLASTIC CONTAINER

HOSPIRA INC 10GM/100ML;0.9GM/100ML

A720562

ANDA

Oct 30, 1992

NONE

B BRAUN MEDICAL INC 10GM/100ML;0.9GM/100ML

N160767

Apr 06, 1970

HOSPIRA INC 10GM/100ML;0.9GM/100ML

N160375

Jul 25, 1967

MILES INC 10GM/100ML;0.9GM/100ML

N160653

Sep 23, 1969

PHARMACHEM CORP 10GM/100ML;0.9GM/100ML

N160836

Nov 14, 1972

33RD EDITION - 2013- APPROVED DRUG PRODUCT LIST

5 - 4 of 5

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

GENTRAIN 70

BAXTER HLTHCARE CORP

N160607

Jan 26, 1970

NONE

B BRAUN MEDICAL INC 6GM/100ML;0.9 GM/100ML

N090024

Aug 18, 1969

MILES INC 6GM/100ML;0.9 GM/100ML

N080716

Mar 13, 1953

DEXTRAN 75, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

NONE

PHARMACHEM CORP 6GM/100ML;0.9GM/100ML

N080564

Sep 19, 1952

6GM/100ML;0.9GM/100ML

N160759

Aug 19, 1970

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION

HEXTEND

BIOTIME INC

6GM/100ML

N200952

Mar 31, 1999

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA INC 6GM/100ML;0.9GM/100ML

A740193

ANDA

Jan 30, 1995

HESPAN

B BRAUN MEDICAL INC 6GM/100ML;0.9GM/100ML

N160889

Jul 17, 1972

HESPAN IN PLASTIC CONTAINER

B BRAUN MEDICAL INC 6GM/100ML;0.9GM/100ML

N890105

Apr 04, 1991

NONE

B BRAUN MEDICAL INC 6GM/100ML;0.9GM/100ML

A740283

ANDA

Oct 21, 1998

TEVA PARENTERAL 6GM/100ML;0.9GM/100ML

A740592

ANDA

Nov 12, 1998

MEDICINES INC

HETASTARCH 6% IN SODIUM CHLORIDE 0.9% NACL 500 ML GLASS BOTTLES

INJECTABLE; INJECTION

NONE

HOSPIRA INC 6GM/100ML;0.9 GM/100ML

A720746

ANDA

Feb 07, 1996

HYDROXYETHYL STARCH 130/0.4 IN 6% SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

VOLUVEN

FRESENIUS KABI 6GM/100ML;0.9GM/100ML
DEUTSCHLAND GMBH

N070012

NDA

Dec 27, 2007

PENTASTARCH 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

PENTASPAN

B BRAUN MEDICAL INC 10GM/100ML;0.9GM/100ML

N841207

May 19, 1987

PENTASPAN IN PLASTIC CONTAINER

B BRAUN MEDICAL INC 10GM/100ML;0.9GM/100ML

N890104

Apr 04, 1991

PERFLUORODECALIN; PERFLUOROTRI-N-PROPYLAMINE

INJECTABLE; INJECTION

FLUOSOL

ALPHA THERAPEUTIC 17.5GM/100ML;7.5GM/100ML
CORP

N860909

Dec 26, 1989

33RD EDITION - 2013- APPROVED DRUG PRODUCT LIST

5 - 5 of 5

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

RED BLOOD CELL PROCESSING SOLUTION

INJECTABLE; INJECTION

REJUVESOL

CITRA LABS LLC

N950522

Feb 26, 1997

SODIUM CHLORIDE; SODIUM ACETATE; SODIUM CITRATE DIHYDRATE; SODIUM PHOSPHATE,
DIABASIC ANHYDROUS; SODIUM PHOSPHATE MONOBASIC, MONOHYDRATE

INJECTABLE; INJECTION

INTERSOL SOLUTION

FENWAL INC.

2.26G/500ML; 2.21G/500ML; 1.59G/500ML;
1.53G/500ML; 0.465G/500ML

N080041

NDA

Dec 09, 2009

DISCONTINUED DRUG PRODUCT LIST

6 - 1 (of 360)

ABARELIX

INJECTABLE; INTRAMUSCULAR PLENAXIS				
SPECIALITY EUROPEAN	100MG/VIAL	N021320	001	Nov 25, 2003

ACETAMINOPHEN

INJECTABLE; INJECTION INJECTAPAP				
ORTHO MCNEIL PHARM	100MG/ML	N017785	001	Mar 07, 1986
SUPPOSITORY; RECTAL ACEPHEN				
G AND W LABS	120MG	A072218	001	Mar 27, 1992
ACETAMINOPHEN ABLE	120MG	A073106	001	Feb 27, 1995
	325MG	A073107	001	Feb 27, 1995
	650MG	A073108	001	Feb 27, 1995
ROXANE	120MG	A071010	001	May 12, 1987
	650MG	A071011	001	May 12, 1987
TYLENOL MCNEIL CONS	120MG	N017756	002	
	650MG	N017756	001	
TABLET, EXTENDED RELEASE; ORAL ACETAMINOPHEN				
RANBAXY	650MG	A090205	001	Nov 18, 2009

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE				
MIKART	150MG;180MG;15MG	A081095	001	Oct 26, 1990
	150MG;180MG;30MG	A081096	001	Oct 26, 1990
	150MG;180MG;60MG	A081097	001	Oct 26, 1990
CODEINE, ASPIRIN, APAP FORMULA NO. 2 SCHERER LABS	150MG;180MG;15MG	A085640	001	
CODEINE, ASPIRIN, APAP FORMULA NO. 3 SCHERER LABS	150MG;180MG;30MG	A085639	001	
CODEINE, ASPIRIN, APAP FORMULA NO. 4 SCHERER LABS	150MG;180MG;60MG	A085638	001	

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL BANCAP				
FOREST PHARMS	325MG;50MG	A088889	001	Jan 16, 1986
BUCET MALLINCKRODT	650MG;50MG	A088991	001	Jun 28, 1985
TENCON MALLINCKRODT	650MG;50MG	A089405	001	May 15, 1990
TRIAPRIN DUNHALL	325MG;50MG	A089268	001	Jul 02, 1987
TABLET; ORAL BUTALBITAL AND ACETAMINOPHEN				
HALSEY	325MG;50MG	A089568	001	Oct 05, 1988
WATSON LABS	325MG;50MG	A087550	001	Oct 19, 1984
PHRENILIN VALEANT	325MG;50MG	A087811	001	Jun 19, 1985
SEDAPAP MAYRAND	650MG;50MG	A088944	001	Oct 17, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL ANOQUAN				
SHIRE	325MG;50MG;40MG	A087628	001	Oct 01, 1986
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE GRAHAM DM	325MG;50MG;40MG	A088743	001	Jul 18, 1985

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 2 (of 360)

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

GRAHAM DM 325MG;50MG;40MG

A088765 001 Mar 27, 1985

325MG;50MG;40MG

A089067 001 Apr 19, 1985

MALLINCKRODT 325MG;50MG;40MG

A088758 001 Mar 27, 1985

BUTALIBITAL, ACETAMINOPHEN AND CAFFEINE

GILBERT LABS 325MG;50MG;40MG

A088825 001 Dec 05, 1984

FEMCET

MALLINCKRODT 325MG;50MG;40MG

A089102 001 Jun 19, 1985

MEDIGESIC PLUS

US CHEM 325MG;50MG;40MG

A089115 001 Jan 14, 1986

TRIAD

MALLINCKRODT 325MG;50MG;40MG

A089023 001 Jun 19, 1985

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

ABLE 325MG;50MG;40MG

A040390 001 Jul 23, 2001

500MG;50MG;40MG

A040394 001 Jul 23, 2001

GILBERT LABS 325MG;50MG;40MG

A087629 001 Nov 13, 1984

MUTUAL PHARM 325MG;50MG;40MG

A040601 001 Jul 29, 2005

WATSON LABS 325MG;50MG;40MG

A089536 001 Feb 16, 1988

ESGIC

FOREST PHARMS 325MG;50MG;40MG

A089660 001 Dec 23, 1988

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

ABLE 325MG;50MG;40MG;30MG

A076528 001 Aug 21, 2003

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

DHC PLUS

PHARM RES ASSOC 356.4MG;30MG;16MG

A088584 001 Mar 04, 1986

SYNALGOS-DC-A

LEITNER PHARMS 356.4MG;30MG;16MG

A089166 001 May 14, 1986

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

WEST-WARD PHARM CORP 712.8MG;60MG;32MG

A040637 001 Sep 22, 2006

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

TEVA 300MG;15MG

A088537 001 Jun 04, 1984

300MG;30MG

A088324 001 Dec 29, 1983

300MG;60MG

A088599 001 Jun 01, 1984

PHENAPHEN W/ CODEINE NO. 2

ROBINS AH 325MG;15MG

A084444 001

PHENAPHEN W/ CODEINE NO. 3

ROBINS AH 325MG;30MG

A084445 001

PHENAPHEN W/ CODEINE NO. 4

ROBINS AH 325MG;60MG

A084446 001

PROVAL #3

SOLVAY 325MG;30MG

A085685 001

TYLENOL W/ CODEINE NO. 3

ORTHO MCNEIL PHARM 300MG;30MG

A087422 001

TYLENOL W/ CODEINE NO. 4

ORTHO MCNEIL PHARM 300MG;60MG

A087421 001

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ACTAVIS MID ATLANTIC 120MG/5ML;12MG/5ML

A085861 001

CLONMEL 120MG/5ML;12MG/5ML

A040098 001 Sep 20, 1996

ROXANE 120MG/5ML;12MG/5ML

A086366 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 3 (of 360)

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL					
TYLENOL W/ CODEINE					
ORTHO MCNEIL PHARM	120MG/5ML;12MG/5ML	A085057	001		
SUSPENSION; ORAL					
CAPITAL AND CODEINE					
ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085883	001		
TABLET; ORAL					
ACETAMINOPHEN AND CODEINE PHOSPHATE					
ABLE	300MG;30MG	A040452	001	Aug 01, 2002	
	300MG;60MG	A040459	001	Aug 01, 2002	
AM THERAP	300MG;15MG	A089478	001	Mar 03, 1987	
	300MG;15MG	A089481	001	Mar 03, 1987	
	300MG;30MG	A089479	001	Mar 03, 1987	
	300MG;30MG	A089482	001	Mar 03, 1987	
	300MG;60MG	A089480	001	Mar 03, 1987	
	300MG;60MG	A089483	001	Mar 03, 1987	
DURAMED PHARMS BARR	300MG;15MG	A040223	001	Nov 18, 1997	
	300MG;15MG	A088353	001	Feb 06, 1984	
	300MG;30MG	A040223	002	Nov 18, 1997	
	300MG;30MG	A088354	001	Feb 06, 1984	
	300MG;60MG	A040223	003	Nov 18, 1997	
	300MG;60MG	A088355	001	Feb 06, 1984	
EVERYLIFE	325MG;30MG	A085217	001		
	300MG;15MG	A083871	001		
HALSEY	300MG;30MG	A083872	001		
	300MG;60MG	A086549	001		
KV PHARM	300MG;30MG	A085288	001		
	300MG;60MG	A085365	001		
	325MG;15MG	A085364	001		
	325MG;45MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A085363	001		
LEDERLE	300MG;30MG	A087141	001		
MIKART	300MG;60MG	A089244	001	Feb 25, 1986	
MUTUAL PHARM	300MG;15MG	A085795	001		
	300MG;15MG	A089671	001	Feb 10, 1988	
	300MG;30MG	A085794	001		
	300MG;30MG	A089672	001	Feb 10, 1988	
	300MG;60MG	A087653	001	Apr 13, 1982	
	300MG;60MG	A089673	001	Feb 10, 1988	
PURACAP PHARM	300MG;30MG	A087762	001	Dec 10, 1982	
PUREPAC PHARM	300MG;30MG	A086681	001		
	300MG;30MG	A089080	001	Jul 17, 1986	
ROXANE	300MG;60MG	A086683	001		
	300MG;15MG	A084659	001		
	300MG;30MG	A084656	001		
	300MG;60MG	A084667	001		
	500MG;15MG	A089511	001	Apr 25, 1989	
	500MG;30MG	A089512	001	Apr 25, 1989	
SANDOZ	500MG;60MG	A089513	001	Apr 25, 1989	
	300MG;15MG	A087433	001		
	300MG;30MG	A081250	001	Jul 16, 1992	
	300MG;30MG	A085291	002		
	300MG;30MG	A085917	001		
	300MG;60MG	A081249	001	Jul 16, 1992	
SUPERPHARM	300MG;60MG	A085964	001		
	300MG;60MG	A087423	001		
	300MG;15MG	A089183	001	Oct 18, 1985	
	300MG;30MG	A089184	001	Oct 18, 1985	
	300MG;30MG	A089253	001	May 19, 1986	
	300MG;60MG	A089185	001	Oct 18, 1985	
	300MG;60MG	A089254	001	May 19, 1986	

DISCONTINUED DRUG PRODUCT LIST

6 - 4 (of 360)

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

USL PHARMA	300MG;30MG	A087919	001	Jun 22, 1982
	300MG;60MG	A087920	001	Jun 22, 1982
VALEANT PHARM INTL	300MG;30MG	A085896	001	
VITARINE	300MG;30MG	A085676	001	
WARNER CHILCOTT	300MG;15MG	A085992	001	
	300MG;30MG	A085218	002	
	300MG;60MG	A087306	001	
WATSON LABS	300MG;15MG	A087277	001	May 26, 1982
	300MG;15MG	A089997	001	Dec 28, 1994
	300MG;30MG	A087276	001	May 26, 1982
	300MG;30MG	A089998	001	Dec 28, 1994
	300MG;60MG	A087275	001	May 26, 1982
	300MG;60MG	A089999	001	Dec 28, 1994
WATSON LABS FLORIDA	300MG;15MG	A040443	001	Jan 22, 2003
	300MG;30MG	A040443	002	Jan 22, 2003
	300MG;60MG	A040443	003	Jan 22, 2003
WHITEWORTH TOWN PLSN	300MG;30MG	A084360	001	
	300MG;60MG	A085607	001	
CAPITAL AND CODEINE				
CARNRICK	325MG;30MG	A083643	001	
CODRIX				
WATSON LABS FLORIDA	500MG;15MG	A040447	001	Feb 26, 2003
	500MG;30MG	A040441	001	Mar 27, 2003
	500MG;60MG	A040488	001	Mar 28, 2003
EMPRACET W/ CODEINE PHOSPHATE #3				
GLAXOSMITHKLINE	300MG;30MG	A083951	001	
EMPRACET W/ CODEINE PHOSPHATE #4				
GLAXOSMITHKLINE	300MG;60MG	A083951	002	
PAPA-DEINE #3				
VANGARD	300MG;30MG	A088037	001	Mar 20, 1984
PAPA-DEINE #4				
VANGARD	300MG;60MG	A088715	001	Mar 20, 1984
PHENAPHEN-650 W/ CODEINE				
ROBINS AH	650MG;30MG	A085856	001	
TYLENOL W/ CODEINE				
ORTHO MCNEIL PHARM	325MG;7.5MG	A085056	001	
	325MG;15MG	A085056	002	
	325MG;30MG	A085056	003	
	325MG;60MG	A085056	004	
TYLENOL W/ CODEINE NO. 1				
JANSSEN PHARMS	300MG;7.5MG	A085055	001	
TYLENOL W/ CODEINE NO. 2				
JANSSEN PHARMS	300MG;15MG	A085055	002	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

CENT PHARMS	500MG;5MG	A088898	001	Mar 27, 1985
ALLAY				
IVAX PHARMS	500MG;5MG	A089907	001	Jan 13, 1989
BANCAP HC				
FOREST PHARMS	500MG;5MG	A087961	001	Mar 17, 1983
CO-GESIC				
CENT PHARMS	500MG;5MG	A089360	001	Mar 02, 1988
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
MALLINCKRODT	500MG;5MG	A088956	001	Jul 19, 1985
	500MG;5MG	A089006	001	Aug 09, 1985
MIKART	500MG;5MG	A081068	001	Nov 30, 1989
	500MG;5MG	A081069	001	Nov 30, 1989
	500MG;5MG	A081070	001	Nov 30, 1989

DISCONTINUED DRUG PRODUCT LIST

6 - 5 (of 360)

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL				
LORCET-HD				
MALLINCKRODT	500MG;5MG	A087336	001	Jul 08, 1982
SOLUTION; ORAL				
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
MALLINCKRODT INC	500MG/15ML;10MG/15ML	A040508	001	Aug 29, 2003
MIKART	500MG/15ML;5MG/15ML	A081226	001	Oct 27, 1992
	500MG/15ML;5MG/15ML	A089557	001	Apr 29, 1992
NESHER PHARMS	500MG/15ML;7.5MG/15ML	A040366	001	Jan 23, 2002
TABLET; ORAL				
DURADYNE DHC				
FOREST PHARMS	500MG;5MG	A087809	001	Mar 17, 1983
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
ABLE	325MG;5MG	A040478	001	Nov 08, 2002
	325MG;7.5MG	A040464	001	Oct 23, 2002
	325MG;10MG	A040464	002	Oct 23, 2002
	500MG;5MG	A040477	001	Nov 06, 2002
	500MG;7.5MG	A040490	001	May 21, 2003
	500MG;10MG	A040473	001	Nov 06, 2002
	650MG;7.5MG	A040474	001	Jan 02, 2003
	650MG;10MG	A040476	001	Oct 23, 2002
	750MG;7.5MG	A040469	001	Oct 25, 2002
	500MG;2.5MG	A040307	001	Jul 26, 2000
	500MG;5MG	A040308	001	Jul 26, 2000
	500MG;5MG	A088577	001	Dec 21, 1984
	500MG;7.5MG	A040307	002	Jul 26, 2000
	500MG;10MG	A040309	001	Jul 26, 2000
BARR	650MG;7.5MG	A040307	003	Jul 26, 2000
	650MG;10MG	A040307	004	Jul 26, 2000
	750MG;7.5MG	A040308	002	Jul 26, 2000
	500MG;5MG	A089554	001	Jun 12, 1987
	500MG;5MG	A089696	001	Apr 21, 1988
	500MG;5MG	A089271	001	Jul 16, 1986
	500MG;5MG	A089697	001	Jan 28, 1992
	500MG;5MG	A040236	001	Sep 25, 1997
	650MG;7.5MG	A040240	002	Nov 26, 1997
	650MG;10MG	A040240	001	Nov 26, 1997
	750MG;7.5MG	A040236	002	Sep 25, 1997
	500MG;5MG	A040825	001	Aug 16, 2007
	500MG;10MG	A040824	001	Aug 16, 2007
	325MG;10MG	A040826	001	Aug 16, 2007
RANBAXY	750MG;7.5MG	A040822	001	Aug 16, 2007
	500MG;5MG	A040149	001	Jan 27, 1997
SANDOZ	750MG;7.5MG	A040149	002	Jan 27, 1997
	500MG;10MG	A040210	001	Aug 13, 1997
UCB INC	650MG;7.5MG	A040134	001	Nov 21, 1996
	500MG;5MG	A089290	001	May 29, 1987
USL PHARMA	500MG;5MG	A089291	001	May 29, 1987
	500MG;5MG	A089831	001	Sep 07, 1988
VINTAGE PHARMS	500MG;5MG	A040281	001	Sep 30, 1998
VINTAGE PHARMS LLC	500MG;5MG	A040280	001	Sep 30, 1998
	650MG;7.5MG	A040280	002	Sep 30, 1998
	650MG;10MG	A040280	003	Sep 30, 1998
	750MG;7.5MG	A040281	002	Sep 30, 1998
	325MG;7.5MG	A040248	001	Apr 28, 2000
WATSON LABS	325MG;10MG	A040248	002	Apr 28, 2000
	500MG;2.5MG	A040123	003	Mar 04, 1996
	500MG;5MG	A040122	001	Mar 04, 1996
	500MG;7.5MG	A040123	004	Mar 04, 1996
	650MG;7.5MG	A040123	001	Mar 04, 1996
	650MG;10MG	A040123	002	Mar 04, 1996
	750MG;7.5MG	A040122	002	Mar 04, 1996
	500MG;5MG	A040493	001	May 28, 2003
WATSON LABS FLORIDA	500MG;5MG	A040493	001	May 28, 2003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 6 (of 360)

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

WATSON LABS FLORIDA	750MG;7.5MG	A040494	001	May 28, 2003
HY-PHEN				
ASCHER	500MG;5MG	A087677	001	May 03, 1982
NORCET				
ABANA	500MG;5MG	A088871	001	May 15, 1986
TYCOLET				
ORTHO MCNEIL PHARM	500MG;5MG	A089385	001	Aug 27, 1986
VICODIN				
ABBOTT	500MG;5MG	A085667	001	
ABBVIE	500MG;5MG	A088058	001	Jan 07, 1983
VICODIN ES				
ABBVIE	750MG;7.5MG	A089736	001	Dec 09, 1988
VICODIN HP				
ABBVIE	660MG;10MG	A040117	001	Sep 23, 1996

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

ACTAVIS TOTOWA	500MG;5MG	A040199	001	Dec 30, 1998
BARR	500MG;5MG	A040304	001	Oct 02, 2000
HALSEY	500MG;5MG	A089994	001	May 04, 1989
MUTUAL PHARM	500MG;5MG	A040219	001	Jan 22, 1998
VINTAGE PHARMS LLC	500MG;5MG	A040303	001	Dec 30, 1999
TYLOX-325				
ORTHO MCNEIL PHARM	325MG;5MG	A088246	001	Nov 08, 1984

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

MALLINCKRODT INC	325MG/5ML;5MG/5ML	A040680	001	Sep 29, 2006

TABLET; ORAL

OXYCODONE 2.5/APAP 500

BRISTOL MYERS SQUIBB	500MG;2.5MG	A085910	001	

OXYCODONE 5/APAP 500

BRISTOL MYERS SQUIBB	500MG;5MG	A085911	001	

OXYCODONE AND ACETAMINOPHEN

ACTAVIS TOTOWA	325MG;5MG	A040203	001	Mar 15, 1999
BARR	325MG;5MG	A087406	001	
DURAMED PHARMS BARR	325MG;5MG	A040272	001	Jun 30, 1998

PERCOCET

VINTAGE PHARMS LLC	325MG;5MG	A085106	002	

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

CAPSULE; ORAL

TYLOX

ORTHO MCNEIL PHARM	500MG;4.5MG;0.38MG	A085375	001	

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALACEN

SANOFI AVENTIS US	650MG;EQ 25MG BASE	N018458	001	Sep 23, 1982

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

DARVOCET

AAIPHARMA LLC	325MG;32.5MG	N016844	001	

DOLENE AP-65

LEDERLE	650MG;65MG	A085100	001	

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

MYLAN	325MG;32MG	A083689	001	
	650MG;65MG	A083978	001	
SANDOZ	650MG;65MG	A089959	001	Jul 18, 1989

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 7 (of 360)

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

VINTAGE PHARMS	650MG;65MG	A040507	001	Jul 30, 2003
WATSON LABS	650MG;65MG	A040139	001	Dec 16, 1996
WYGESIC				
CARACO	650MG;65MG	A084999	001	

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET A500

XANODYNE PHARM	500MG;100MG	A076429	001	Sep 10, 2003

DARVOCET-N 100

XANODYNE PHARM	650MG;100MG	N017122	002	

DARVOCET-N 50

XANODYNE PHARM	325MG;50MG	N017122	001	

PROPACET 100

TEVA	650MG;100MG	A070107	001	Jun 12, 1985

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

ABLE	650MG;100MG	A075838	001	Jul 11, 2001

ACTAVIS ELIZABETH	650MG;100MG	A070910	001	Jan 02, 1987

CORNERSTONE	325MG;100MG	A076743	001	May 07, 2004

	500MG;100MG	A076750	001	Jun 28, 2004

HALSEY	325MG;50MG	A072105	001	May 13, 1988

	650MG;100MG	A072106	001	May 13, 1988

IVAX SUB TEVA PHARMS	650MG;100MG	A070146	001	Aug 02, 1985

MALLINCKRODT	650MG;100MG	A075738	001	Feb 02, 2001

MIRROR PHARMS	650MG;100MG	A077821	001	Feb 11, 2008

MUTUAL PHARM	325MG;50MG	A070115	001	Jun 12, 1985

	650MG;100MG	A070116	001	Jun 12, 1985

	650MG;100MG	A070615	001	Mar 21, 1986

	650MG;100MG	A070771	001	Mar 21, 1986

	650MG;100MG	A070775	001	Mar 21, 1986

MYLAN	650MG;100MG	A072195	001	Feb 16, 1988

MYLAN PHARMS INC	650MG;100MG	A070145	001	Jun 12, 1985

SANDOZ	650MG;100MG	A070443	001	Jan 23, 1986

SUPERPHARM	650MG;100MG	A071319	001	Jan 06, 1987

TEVA	650MG;100MG	A070732	001	Jan 03, 1986

	650MG;100MG	A074119	001	Dec 19, 1994

VINTAGE PHARMS	325MG;50MG	A074843	002	Feb 15, 2001

	650MG;100MG	A074843	001	Feb 12, 1997

WATSON LABS	325MG;50MG	A070398	001	Dec 18, 1986

	650MG;100MG	A070399	001	Dec 18, 1986

WATSON LABS FLORIDA	500MG;100MG	A077196	001	Jun 28, 2005

	650MG;100MG	A076609	001	Nov 16, 2004

WOCKHARDT LTD	325MG;50MG	A077677	001	Mar 16, 2007

	650MG;100MG	A077677	002	Mar 16, 2007

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

ALRA	250MG	A083320	001	

ASCOT	250MG	A087686	001	Oct 20, 1982

MUTUAL PHARM	250MG	A089753	001	Jun 22, 1988

VANGARD	250MG	A087654	001	Feb 05, 1982

WATSON LABS	250MG	A084498	002	

DIAMOX

DURAMED PHARMS BARR	125MG	N008943	001	

	250MG	N008943	002	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 8 (of 360)

ACETAZOLAMIDE SODIUMINJECTABLE; INJECTION
ACETAZOLAMIDE SODIUM

HOSPIRA	EQ 500MG BASE/VIAL	A040108	001	Oct 30, 1995
DIAMOX				
TEVA WOMENS	EQ 500MG BASE/VIAL	N009388	001	Dec 05, 1990

ACETIC ACID, GLACIALSOLUTION/DROPS; OTIC
ACETASOL

ACTAVIS MID ATLANTIC	2%	A087146	001	
ACETIC ACID				
KV PHARM	2%	A085493	001	
ORLEX				
WARNER CHILCOTT	2%	A086845	001	

ACETIC ACID, GLACIAL; ALUMINUM ACETATESOLUTION/DROPS; OTIC
BOROFAIR

PHARMAFAIR	2%;0.79%	A088606	001	Aug 21, 1985
DOMEBORO				
BAYER PHARMS	2%;0.79%	A084476	001	

ACETIC ACID, GLACIAL; DESONIDESOLUTION/DROPS; OTIC
TRIDESILON

BAYER PHARMS	2%;0.05%	N017914	001	

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

ACETIC ACID W/ HYDROCORTISONE

KV PHARM	2%;1%	A085492	001	

HYDROCORTISONE AND ACETIC ACID

BAUSCH AND LOMB	2%;1%	A040097	001	Oct 31, 1994
WOCKHARDT	2%;1%	A040168	001	Aug 30, 1996

ORLEX HC				
WARNER CHILCOTT	2%;1%	A086844	001	

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS; OTIC

NEO-CORT-DOME

BAYER PHARMS	2%;1%;EQ 0.35% BASE	N050238	001	

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

BARR	250MG	A070869	001	Feb 09, 1987
	500MG	A070870	001	Feb 09, 1987
USL PHARMA	250MG	A070753	001	Nov 03, 1986
	500MG	A070754	001	Nov 03, 1986

DYMELOR

LILLY	250MG	N013378	002	
	500MG	N013378	001	

ACETOPHENAZINE MALEATE

TABLET; ORAL

TINDAL

SCHERING	20MG	N012254	002	

ACETRIZOATE SODIUM

SOLUTION; INTRAUTERINE

SALPIX

ORTHO MCNEIL PHARM	53%	N009008	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 9 (of 360)

ACETYLCHOLINE CHLORIDEFOR SOLUTION; OPHTHALMIC
MIOCHOL

NOVARTIS

20MG/VIAL

N016211 001

ACETYLCYSTEINESOLUTION; INHALATION, ORAL
ACETYLCYSTEINE

HOSPIRA

10%

A071364 001 May 01, 1989

ROXANE

20%

A071365 001 May 01, 1989

10%

A072621 001 Sep 30, 1992

20%

A072622 001 Sep 30, 1992

MUCOMYST

APOTHECON

10%

N013601 002

20%

N013601 001

MUCOSIL-10

DEY

10%

A070575 001 Oct 14, 1986

MUCOSIL-20

DEY

20%

A070576 001 Oct 14, 1986

ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

MUCOMYST W/ ISOPROTERENOL

MEAD JOHNSON

10%;0.05%

N017366 001

ACETYLDIGITOXIN

TABLET; ORAL

ACYLANID

NOVARTIS

0.1MG

N009436 001

ACRISORCIN

CREAM; TOPICAL

AKRINOL

SCHERING

2MG/GM

N012470 001

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

ACTAVIS ELIZABETH

200MG

A074906 001 Aug 26, 1997

DAVA PHARMS INC

200MG

A074872 001 Apr 22, 1997

HERITAGE PHARMS INC

200MG

A074889 001 Oct 31, 1997

IVAX SUB TEVA PHARMS

200MG

A074674 001 Apr 22, 1997

LEK PHARM

200MG

A074750 001 Apr 22, 1997

ROXANE

200MG

A074570 002 Apr 22, 1997

TEVA

200MG

A074828 001 Apr 22, 1997

TEVA PHARMS

200MG

A074914 001 Nov 26, 1997

TABLET; ORAL

ACYCLOVIR

ACTAVIS ELIZABETH

400MG

A074870 001 Jun 05, 1997

800MG

A074870 002 Jun 05, 1997

DAVA PHARMS INC

400MG

A074834 001 Apr 24, 1997

800MG

A074834 002 Apr 24, 1997

HERITAGE PHARMS INC

400MG

A074891 001 Oct 31, 1997

800MG

A074891 002 Oct 31, 1997

IVAX SUB TEVA PHARMS

400MG

A074836 001 Apr 22, 1997

800MG

A074836 002 Apr 22, 1997

LEK PHARM

400MG

A074658 001 Apr 22, 1997

800MG

A074658 002 Apr 22, 1997

TEVA

200MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

A074556 001 Apr 22, 1997

TEVA PHARMS

400MG

A075021 001 Mar 18, 1998

800MG

A075021 002 Mar 18, 1998

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 10 (of 360)

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

ABBVIE

EQ 50MG BASE/ML

A075114 001 Jul 26, 1999

ACYCLOVIR SODIUM

APOTHECON

EQ 500MG BASE/VIAL

A074897 001 Feb 27, 1998

EQ 1GM BASE/VIAL

A074897 002 Feb 27, 1998

HOSPIRA

EQ 25MG BASE/ML

A074720 001 Apr 22, 1997

EQ 50MG BASE/ML

A075065 001 Feb 25, 1999

EQ 500MG BASE/VIAL

A074663 001 Apr 22, 1997

EQ 500MG BASE/VIAL

A074758 001 Apr 22, 1997

EQ 1GM BASE/VIAL

A074663 002 Apr 22, 1997

EQ 1GM BASE/VIAL

A074758 002 Apr 22, 1997

TEVA PARENTERAL

EQ 50MG BASE/ML

A075627 001 Mar 28, 2001

EQ 500MG BASE/VIAL

A074969 001 Aug 26, 1997

EQ 1GM BASE/VIAL

A074969 002 Aug 26, 1997

ZOVIRAX

GLAXOSMITHKLINE

EQ 250MG BASE/VIAL

N018603 003 Aug 30, 1983

EQ 500MG BASE/VIAL

N018603 001 Oct 22, 1982

EQ 1GM BASE/VIAL

N018603 002 Jun 29, 1989

ADAPALENE

SOLUTION; TOPICAL

DIFFERIN

GALDERMA LABS LP

0.1%

N020338 001 May 31, 1996

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

HIKMA MAPLE

3MG/ML

A076501 001 Jun 16, 2004

TEVA PARENTERAL

3MG/ML

A076564 001 Jun 16, 2004

3MG/ML

A078676 001 Jul 31, 2008

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION

TROVAN PRESERVATIVE FREE

PFIZER

EQ 200MG BASE/VIAL

N020760 001 Dec 18, 1997

EQ 300MG BASE/VIAL

N020760 002 Dec 18, 1997

ALBUMIN CHROMATED CR-51 SERUM

INJECTABLE; INJECTION

CHROMALBIN

ISO TEX

100uCi/VIAL

N017835 001

250uCi/VIAL

N017835 002

500uCi/VIAL

N017835 003

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN)

BAYER PHARMS

2.5uCi/AMP

N017846 001

RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125

MALLINCKRODT

6.67uCi/ML

N017844 003

10uCi/ML

N017844 001

100uCi/ML

N017844 002

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION

MEGATOPE

ISO TEX

2mCi/VIAL

N017837 003

5uCi/AMP

N017837 004

20uCi/AMP

N017837 005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 11 (of 360)

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

ARMSTRONG PHARMS	0.09MG/INH	A072273	001	Aug 14, 1996
GENPHARM	0.09MG/INH	A073045	001	Aug 19, 1997
IVAX SUB TEVA PHARMS	0.09MG/INH	A073272	001	Dec 28, 1995
PLIVA	0.09MG/INH	A074072	001	Aug 01, 1996
PROVENTIL				
SCHERING	0.09MG/INH	N017559	001	
VENTOLIN				
GLAXOSMITHKLINE	0.09MG/INH	N018473	001	

ALBUTEROL SULFATE

CAPSULE; INHALATION

VENTOLIN ROTACAPS

GLAXOSMITHKLINE	EQ 0.2MG BASE	N019489	001	May 04, 1988

SOLUTION; INHALATION

ALBUTEROL SULFATE

ACTAVIS MID ATLANTIC	EQ 0.083% BASE	A073533	001	Sep 26, 1995
BAUSCH AND LOMB	EQ 0.083% BASE	A075358	001	Mar 29, 2000
COPLEY PHARM	EQ 0.083% BASE	A073495	001	May 28, 1993
	EQ 0.5% BASE	A073307	001	Nov 27, 1991
ROXANE	EQ 0.083% BASE	A075129	001	Feb 13, 2001
PROVENTIL				
SCHERING	EQ 0.083% BASE	N019243	002	Jan 14, 1987
	EQ 0.5% BASE	N019243	001	Jan 14, 1987
VENTOLIN				
GLAXOSMITHKLINE	EQ 0.083% BASE	N019773	001	Apr 23, 1992
	EQ 0.5% BASE	N019269	002	Jan 16, 1987

SYRUP; ORAL

ALBUTEROL SULFATE

ACTAVIS MID ATLANTIC	EQ 2MG BASE/5ML	A075262	001	Mar 30, 1999
MOVA	EQ 2MG BASE/5ML	A074302	001	Sep 30, 1994
WATSON LABS	EQ 2MG BASE/5ML	A073165	001	Apr 29, 1993
PROVENTIL				
SCHERING	EQ 2MG BASE/5ML	N018062	001	Jan 19, 1983
VENTOLIN				
GLAXOSMITHKLINE	EQ 2MG BASE/5ML	N019621	001	Jun 10, 1987

TABLET; ORAL

ALBUTEROL SULFATE

AM THERAP	EQ 2MG BASE	A072449	001	Dec 05, 1989
	EQ 4MG BASE	A072450	001	Dec 05, 1989
COPLEY PHARM	EQ 2MG BASE	A072966	001	Nov 22, 1991
	EQ 4MG BASE	A072967	001	Nov 22, 1991
DAVA PHARMS INC	EQ 2MG BASE	A072859	001	Dec 20, 1989
	EQ 4MG BASE	A072860	001	Dec 20, 1989
PLIVA	EQ 2MG BASE	A072316	001	Dec 05, 1989
	EQ 4MG BASE	A072317	001	Dec 05, 1989
SANDOZ	EQ 2MG BASE	A072151	001	Dec 05, 1989
	EQ 4MG BASE	A072152	001	Dec 05, 1989
TEVA	EQ 2MG BASE	A072619	001	Dec 05, 1989
	EQ 2MG BASE	A072779	001	Jun 25, 1993
	EQ 2MG BASE	A072938	001	Mar 30, 1990
	EQ 4MG BASE	A072620	001	Dec 05, 1989
	EQ 4MG BASE	A072780	001	Jun 25, 1993
	EQ 4MG BASE	A072939	001	Mar 30, 1990
UCB INC	EQ 2MG BASE	A073120	001	Sep 29, 1992
	EQ 4MG BASE	A073121	001	Sep 29, 1992
WARNER CHILCOTT	EQ 2MG BASE	A072817	001	Jan 09, 1990
	EQ 4MG BASE	A072818	001	Jan 09, 1990
WATSON LABS	EQ 2MG BASE	A072629	001	Jan 31, 1991
	EQ 4MG BASE	A072630	001	Jan 31, 1991
	EQ 4MG BASE	A072765	001	Aug 28, 1991

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 12 (of 360)

ALBUTEROL SULFATETABLET; ORAL
PROVENTIL

SCHERING

EQ 2MG BASE

N017853 001 May 07, 1982

EQ 4MG BASE

N017853 002 May 07, 1982

VENTOLIN

GLAXOSMITHKLINE

EQ 2MG BASE

N019112 001 Jul 10, 1986

EQ 4MG BASE

N019112 002 Jul 10, 1986

TABLET, EXTENDED RELEASE; ORAL
PROVENTIL

SCHERING

EQ 4MG BASE

N019383 001 Jul 13, 1987

VOLMAX

MURO

EQ 4MG BASE

N019604 002 Dec 23, 1992

EQ 8MG BASE

N019604 001 Dec 23, 1992

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

SANDOZ INC

EQ 0.083% BASE;0.017%

A076867 001 Dec 21, 2006

ALCOHOL

INJECTABLE; INJECTION

ALCOHOL 5% IN DEXTROSE 5%

MILES

5ML/100ML

A083483 001

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 5% IN D5-W

HOSPIRA

5ML/100ML;5GM/100ML

A083263 001

ALCOHOL 5% IN DEXTROSE 5% IN WATER

BAXTER HLTHCARE

5ML/100ML;5GM/100ML

A083256 001

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

SANDOZ

EQ 5MG BASE

A075871 001 Apr 22, 2009

EQ 10MG BASE

A075871 002 Apr 22, 2009

EQ 35MG BASE

A075871 004 Apr 22, 2009

EQ 40MG BASE

A075871 003 Apr 22, 2009

EQ 70MG BASE

A075871 005 Apr 22, 2009

TEVA PHARMS

EQ 35MG BASE

A076184 002 Aug 04, 2008

EQ 70MG BASE

A076184 001 Feb 06, 2008

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

GENZYME

10 UNITS/ML

N020057 004 May 08, 1992

80 UNITS/ML

N020057 003 Apr 05, 1991

ALKAVERVIR

TABLET; ORAL

VERILOID

3M

2MG

N007336 002

3MG

N007336 003

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

MUTUAL PHARM

100MG

A070466 001 Dec 24, 1985

300MG

A070467 001 Dec 24, 1985

PURACAP PHARM

100MG

A070150 001 Dec 10, 1985

300MG

A070147 001 Dec 10, 1985

PUREPAC PHARM

100MG

A070579 001 Apr 14, 1986

DISCONTINUED DRUG PRODUCT LIST

6 - 13 (of 360)

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL

PUREPAC PHARM	300MG	A070580	001	Apr 14, 1986
SANDOZ	100MG	A070268	001	Dec 31, 1985
	300MG	A070269	001	Dec 31, 1985
SUPERPHARM	100MG	A070950	001	Nov 30, 1988
	300MG	A070951	001	Nov 30, 1988
WATSON LABS	100MG	N018241	001	Nov 16, 1984
	100MG	N018785	001	Sep 28, 1984
	300MG	N018241	002	Nov 16, 1984
	300MG	N018785	002	Sep 28, 1984
LOPURIN				
ABBOTT	100MG	N018297	001	
	300MG	N018297	002	

ALPRAZOLAM

SOLUTION; ORAL
ALPRAZOLAM

ROXANE	0.5MG/5ML	A074314	001	Oct 31, 1993

TABLET; ORAL
ALPRAZOLAM

IVAX SUB TEVA PHARMS	0.25MG	A074294	001	Jul 29, 1994
	0.5MG	A074294	002	Jul 29, 1994
	1MG	A074294	003	Jul 29, 1994
	2MG	A074294	004	Jul 29, 1994
ROXANE	0.25MG	A074199	001	Oct 19, 1993
	0.5MG	A074199	002	Oct 19, 1993
	1MG	A074199	003	Oct 19, 1993
TEVA	0.25MG	A074085	001	Feb 16, 1994
	0.5MG	A074085	002	Feb 16, 1994
	1MG	A074085	003	Feb 16, 1994
	2MG	A074085	004	Feb 26, 1996
WATSON LABS	0.25MG	A074456	001	Aug 31, 1995
	0.25MG	A074479	001	Jan 21, 1997
	0.5MG	A074456	002	Aug 31, 1995
	0.5MG	A074479	002	Jan 21, 1997
	1MG	A074456	003	Aug 31, 1995
	1MG	A074479	003	Jan 21, 1997

TABLET, EXTENDED RELEASE; ORAL
ALPRAZOLAM

SANDOZ INC	0.5MG	A077777	001	Jun 30, 2006
	1MG	A077777	002	Jun 30, 2006
	2MG	A077777	003	Jun 30, 2006
	3MG	A077777	004	Jun 30, 2006
VINTAGE PHARMS	0.5MG	A078442	001	Oct 15, 2007
	1MG	A078442	002	Oct 15, 2007
	2MG	A078442	003	Oct 15, 2007
	3MG	A078442	004	Oct 15, 2007

ALPROSTADIL

INJECTABLE; INJECTION
CAVERJECT

PFIZER	0.005MG/ML	N020755	001	Oct 31, 1997
	0.01MG/ML	N020755	002	Oct 01, 1997
	0.02MG/ML	N020755	003	Oct 01, 1997

EDEX

ACTIENT PHARMS	0.005MG/VIAL	N020649	001	Jun 12, 1997

ALSEROXYLON

TABLET; ORAL
RAUTENSIN

NOVARTIS	2MG	N009215	001	

DISCONTINUED DRUG PRODUCT LIST

6 - 14 (of 360)

ALSEROXYLON

TABLET; ORAL
RAUWILLOID
3M

2MG

N008867 001

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL
ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE
PENNEX
FOAMICON
NOVARTIS

80MG;20MG

A089449 001 Nov 27, 1987

80MG;20MG

A072687 001 Jun 28, 1989

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
AMANTADINE HYDROCHLORIDE

ACTAVIS TOTOWA
WATSON LABS

100MG

A077659 001 Feb 23, 2006

100MG

A071382 001 Jan 21, 1987

SYMADINE

SOLVAY

100MG

A071000 001 Sep 04, 1986

SYMMETREL

ENDO PHARMS

100MG

N016020 001

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

50MG/5ML

A072655 001 Oct 30, 1990

TEVA PHARMS

50MG/5ML

A073115 001 Aug 23, 1991

SYMMETREL

ENDO PHARMS

50MG/5ML

N016023 002

TABLET; ORAL

SYMMETREL

ENDO PHARMS

100MG

N018101 001

AMCINONIDE

CREAM; TOPICAL
CYCLOCORT

ASTELLAS
0.025%
0.1%

N018116 001

N018116 002

LOTION; TOPICAL
CYCLOCORT

ASTELLAS
0.1%

N019729 001 Jun 13, 1988

OINTMENT; TOPICAL
CYCLOCORT

ASTELLAS
0.1%

N018498 001

AMDINOCILLIN

INJECTABLE; INJECTION
COACTIN

ROCHE
250MG/VIAL
500MG/VIAL
1GM/VIAL

N050565 001 Dec 21, 1984

N050565 002 Dec 21, 1984

N050565 003 Dec 21, 1984

AMIFOSTINE

INJECTABLE; INJECTION
ETHYOL

MEDIMMUNE
375MG/VIAL

N020221 002 Sep 10, 1999

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN SULFATE

ABBOTT
EQ 250MG BASE/ML
EQ 250MG BASE/ML
ASTRAZENECA
EQ 50MG BASE/ML
EQ 250MG BASE/ML
HIKMA MAPLE
EQ 50MG BASE/ML

A063265 001 Nov 30, 1994

A063266 001 Oct 31, 1994

A063167 001 Dec 14, 1995

A063169 001 Dec 14, 1995

A063274 001 May 18, 1992

DISCONTINUED DRUG PRODUCT LIST

6 - 15 (of 360)

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

HIKMA MAPLE	EQ 250MG BASE/ML	A063275	001	May 18, 1992
HOSPIRA	EQ 50MG BASE/ML	A063263	001	Nov 30, 1994
	EQ 50MG BASE/ML	A063350	001	Jul 30, 1993
	EQ 62.5MG BASE/ML	A063283	001	Oct 31, 1994
	EQ 250MG BASE/ML	A063350	002	Jul 30, 1993
	EQ 250MG BASE/ML	A064098	001	Jun 26, 1995
	EQ 250MG BASE/ML	A064099	001	Jun 20, 1995
TEVA PARENTERAL	EQ 50MG BASE/ML	A064045	001	Sep 28, 1993
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
HOSPIRA	EQ 500MG BASE/100ML	A064146	001	Apr 02, 1997
AMIKIN				
APOTHECON	EQ 50MG BASE/ML	A062311	001	
	EQ 50MG BASE/ML	A062562	001	Sep 20, 1984
	EQ 50MG BASE/ML	N050495	001	
	EQ 250MG BASE/ML	A062311	002	
	EQ 250MG BASE/ML	A062562	002	Sep 20, 1984
	EQ 250MG BASE/ML	N050495	002	
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
APOTHECON	EQ 5MG BASE/ML	N050618	002	Nov 30, 1987
	EQ 10MG BASE/ML	N050618	001	Nov 30, 1987

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SANDOZ	EQ 5MG ANHYDROUS;50MG	A073357	001	Nov 27, 1991
TEVA	EQ 5MG ANHYDROUS;50MG	A070795	001	Apr 17, 1988
WATSON LABS	EQ 5MG ANHYDROUS;50MG	A073334	001	Jul 19, 1991
HYDRO-RIDE				
PAR PHARM	EQ 5MG ANHYDROUS;50MG	A070347	001	Dec 25, 1990
MODURETIC 5-50				
MERCK	EQ 5MG ANHYDROUS;50MG	N018201	001	

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE

HOSPIRA	5.2% (5.2GM/100ML)	N018901	001	Apr 06, 1984
AMINOSYN 3.5% IN PLASTIC CONTAINER				
ABBOTT	3.5% (3.5GM/100ML)	N018804	001	May 15, 1984
	3.5% (3.5GM/100ML)	N018875	001	Aug 08, 1984
AMINOSYN II 3.5%				
HOSPIRA	3.5% (3.5GM/100ML)	N019438	001	Apr 03, 1986
AMINOSYN II 3.5% IN PLASTIC CONTAINER				
ABBOTT	3.5% (3.5GM/100ML)	N019491	001	Oct 10, 1986
AMINOSYN II 5%				
HOSPIRA	5% (5GM/100ML)	N019438	002	Apr 03, 1986
AMINOSYN-HBC 7% IN PLASTIC CONTAINER				
ABBOTT	7% (7GM/100ML)	N019400	001	Jul 23, 1986
BRANCHAMIN 4%				
BAXTER HLTHCARE	4% (4GM/100ML)	N018678	001	Sep 28, 1984
FREAMINE 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	001	
FREAMINE II 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	002	
NEOPHAM 6.4%				
HOSPIRA	6.4% (6.4GM/100ML)	N018792	001	Jan 17, 1984
NOVAMINE 11.4%				
HOSPIRA INC	11.4% (11.4GM/100ML)	N017957	003	Aug 09, 1982
NOVAMINE 15%				
HOSPIRA INC	15% (75GM/500ML)	N017957	004	Nov 28, 1986

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 16 (of 360)

AMINO ACIDSINJECTABLE; INJECTION

NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER

BAXTER HLTHCARE 15% (15GM/100ML)

N020107 001 Feb 05, 1993

NOVAMINE 8.5%

HOSPIRA INC 8.5% (8.5GM/100ML)

N017957 002 Aug 09, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDEINJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT 3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML N019714 001 Sep 12, 1988
;22.4MG/100ML;261MG/100ML;205MG/100MLHOSPIRA INC 3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML N019683 001 Nov 07, 1988
;22.4MG/100ML;261MG/100ML;205MG/100ML

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT 4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML N019714 002 Sep 12, 1988
L;22.4MG/100ML;261MG/100ML;205MG/100MLHOSPIRA INC 4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML N019683 002 Nov 07, 1988
L;22.4MG/100ML;261MG/100ML;205MG/100ML

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT 4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML N019714 004 Sep 12, 1988
L;22.4MG/100ML;261MG/100ML;205MG/100MLHOSPIRA INC 4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML N019683 003 Nov 07, 1988
L;22.4MG/100ML;261MG/100ML;205MG/100ML

AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT 5%;36.8MG/100ML;25GM/100ML;51MG/100ML;2 N019714 003 Sep 12, 1988
2.4MG/100ML;261MG/100ML;205MG/100MLHOSPIRA INC 5%;36.8MG/100ML;25GM/100ML;51MG/100ML;2 N019683 004 Nov 07, 1988
2.4MG/100ML;261MG/100ML;205MG/100MLAMINO ACIDS; DEXTROSEINJECTABLE; INJECTION

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT 3.5%;25GM/100ML N019118 001 Oct 11, 1984

AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT 3.5%;5GM/100ML N019120 001 Oct 11, 1984

AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT 4.25%;25GM/100ML N019119 001 Oct 11, 1984

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT 3.5%;25GM/100ML N019505 002 Nov 07, 1986

3.5%;25GM/100ML N019713 006 Sep 09, 1988

HOSPIRA 3.5%;25GM/100ML N019681 001 Nov 01, 1988

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT 3.5%;5GM/100ML N019506 001 Nov 07, 1986

3.5%;5GM/100ML N019713 002 Sep 09, 1988

HOSPIRA 3.5%;5GM/100ML N019681 002 Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT 4.25%;10GM/100ML N019713 001 Sep 09, 1988

HOSPIRA 4.25%;10GM/100ML N019681 004 Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

ABBOTT 4.25%;20GM/100ML N019713 004 Sep 09, 1988

HOSPIRA 4.25%;20GM/100ML N019681 005 Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT 4.25%;25GM/100ML N019504 002 Nov 07, 1986

4.25%;25GM/100ML N019713 005 Sep 09, 1988

HOSPIRA 4.25%;25GM/100ML N019681 003 Nov 01, 1988

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT 5%;25GM/100ML N019565 001 Dec 17, 1986

5%;25GM/100ML N019713 003 Sep 09, 1988

HOSPIRA 5%;25GM/100ML N019681 006 Nov 01, 1988

TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE 2.75%;10GM/100ML N019520 002 Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE 2.75%;15GM/100ML N019520 003 Sep 23, 1988

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 17 (of 360)

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE 2.75%;20GM/100ML	N019520	004	Sep 23, 1988	
TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE 2.75%;25GM/100ML	N019520	005	Sep 23, 1988	
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE 2.75%;5GM/100ML	N019520	001	Sep 23, 1988	
TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE 4.25%;10GM/100ML	N019520	007	Sep 23, 1988	
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER				
BAXTER HLTHCARE 4.25%;15GM/100ML	N019520	008	Sep 23, 1988	
TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE 4.25%;20GM/100ML	N019520	009	Sep 23, 1988	
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE 4.25%;25GM/100ML	N019520	010	Sep 23, 1988	
TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE 4.25%;5GM/100ML	N019520	006	Sep 23, 1988	

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER				
ABBOTT 4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N019712	002	Sep 08, 1988	
HOSPIRA INC 4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N019682	003	Nov 01, 1988	

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT 3.5%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564	002	Dec 16, 1986	
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT 4.25%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564	004	Dec 16, 1986	

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT 3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019564	001	Dec 16, 1986	
	N019712	001	Sep 08, 1988	
HOSPIRA INC 3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682	001	Nov 01, 1988	
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER				
ABBOTT 4.25%;10GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019564	003	Dec 16, 1986	
HOSPIRA INC 4.25%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682	002	Nov 01, 1988	

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE 2.75%;10GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147	002	Oct 23, 1995	
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER				
BAXTER HLTHCARE 2.75%;15GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147	003	Oct 23, 1995	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 18 (of 360)

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDEINJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE	FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;20GM/100ML;51MG/100ML;261MG/100ML	N020147 004	Oct 23, 1995		
	;216MG/100ML;112MG/100ML				
TRAVASOL 2.75% SULFITE	FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;25GM/100ML;51MG/100ML;261MG/100ML	N020147 005	Oct 23, 1995		
	;216MG/100ML;112MG/100ML				
TRAVASOL 2.75% SULFITE	FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;5GM/100ML;51MG/100ML;261MG/100ML;	N020147 001	Oct 23, 1995		
	216MG/100ML;112MG/100ML				
TRAVASOL 4.25% SULFITE	FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;10GM/100ML;51MG/100ML;261MG/100ML	N020147 007	Oct 23, 1995		
	;297MG/100ML;77MG/100ML				
TRAVASOL 4.25% SULFITE	FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;15GM/100ML;51MG/100ML;261MG/100ML	N020147 008	Oct 23, 1995		
	;297MG/100ML;77MG/100ML				
TRAVASOL 4.25% SULFITE	FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;20GM/100ML;51MG/100ML;261MG/100ML	N020147 009	Oct 23, 1995		
	;297MG/100ML;77MG/100ML				
TRAVASOL 4.25% SULFITE	FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;25GM/100ML;51MG/100ML;261MG/100ML	N020147 010	Oct 23, 1995		
	;297MG/100ML;77MG/100ML				
TRAVASOL 4.25% SULFITE	FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;5GM/100ML;51MG/100ML;261MG/100ML;	N020147 006	Oct 23, 1995		
	297MG/100ML;77MG/100ML				

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDEINJECTABLE; INJECTION

AMINOSYN 3.5% M IN PLASTIC CONTAINER					
ABBOTT	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;	N018804 002	May 15, 1984		
	234MG/100ML				
	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;	N018875 002	Aug 08, 1984		
	234MG/100ML				

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDEINJECTABLE; INJECTION

AMINOSYN 3.5% M					
HOSPIRA	3.5%;21MG/100ML;128MG/100ML;234MG/100ML	N017789 005			

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATEINJECTABLE; INJECTION

AMINOSYN II 3.5% M IN PLASTIC CONTAINER					
ABBOTT	3.5%;32MG/100ML;128MG/100ML;222MG/100ML	N019493 001	Oct 16, 1986		
	;49MG/100ML				

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATEINJECTABLE; INJECTION

VEINAMINE 8%					
HOSPIRA INC	8%;61MG/100ML;211MG/100ML;56MG/100ML;38	N017957 001			
	8MG/100ML				

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDEINJECTABLE; INJECTION

AMINOSYN II 7% W/ ELECTROLYTES					
HOSPIRA	7%;102MG/100ML;45MG/100ML;522MG/100ML;4	N019437 006	Apr 03, 1986		
	10MG/100ML				

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 19 (of 360)

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M

HOSPIRA

3.5%;30MG/100ML;97MG/100ML;120MG/100ML; N019437 007 Apr 03, 1986
49MG/100MLAMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

CLOVER PHARMS

250MG/ML

N015229 002

AMINOCAPROIC ACID

ABRAXIS PHARM

250MG/ML

A070522 001 Jun 17, 1986

BAXTER HLTHCARE

250MG/ML

N018590 001 Oct 29, 1982

HOSPIRA

250MG/ML

A070888 001 Jun 16, 1988

AMINOGLUTETHIMIDE

TABLET; ORAL

CYTADREN

NOVARTIS

250MG

N018202 001

AMINOPHYLLINE

ENEMA; RECTAL

SOMOPHYLLIN

FISONS

300MG/5ML

N018232 001 Apr 02, 1982

INJECTABLE; INJECTION

AMINOPHYLLIN

GD SEARLE LLC

25MG/ML

A087243 001 May 24, 1982

25MG/ML

A087621 001 May 24, 1982

AMINOPHYLLINE

ABRAXIS PHARM

25MG/ML

A084568 001

25MG/ML

A087200 001

25MG/ML

A087250 001 Jan 06, 1982

25MG/ML

A087886 001 Aug 30, 1983

25MG/ML

A088407 001 Jan 25, 1984

ELKINS SINN

25MG/ML

A087239 001

HOSPIRA

25MG/ML

A087601 001 Jul 23, 1982

INTL MEDICATION

25MG/ML

A087867 001 Nov 10, 1983

25MG/ML

A087868 001 Nov 10, 1983

KING PHARMS

25MG/ML

A086606 001

LUITPOLD

25MG/ML

A087240 001

LYPHOMED

25MG/ML

A087431 001

PHARMA SERVE NY

25MG/ML

A087387 001 Jun 03, 1983

SMITH AND NEPHEW

25MG/ML

A088429 001 May 30, 1985

25MG/ML

A088749 001 May 30, 1985

TEVA PARENTERAL

25MG/ML

A081142 001 Sep 25, 1991

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

HOSPIRA

100MG/100ML

A088147 002 May 03, 1983

200MG/100ML

A088147 003 May 03, 1983

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

HOSPIRA

100MG/100ML

N018924 001 Dec 12, 1984

200MG/100ML

N018924 002 Dec 12, 1984

400MG/100ML

N018924 003 Dec 12, 1984

500MG/100ML

N018924 004 Dec 12, 1984

SOLUTION; ORAL

AMINOPHYLLINE

MORTON GROVE

105MG/5ML

A088156 001 Dec 05, 1983

ROXANE

105MG/5ML

A088126 001 Aug 19, 1983

AMINOPHYLLINE DYE FREE

ACTAVIS MID ATLANTIC

105MG/5ML

A087727 001 Apr 16, 1982

SOMOPHYLLIN

FISONS

105MG/5ML

A086466 001

SOMOPHYLLIN-DF

FISONS

105MG/5ML

A087045 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 20 (of 360)

AMINOPHYLLINESUPPOSITORY; RECTAL
TRUPHYLLINE

G AND W LABS	250MG	A085498	001	Mar 23, 1983
	500MG	A085498	002	Jan 03, 1983

TABLET; ORAL

AMINOPHYLLIN

GD SEARLE LLC	100MG	N002386	002	
	200MG	N002386	003	

AMINOPHYLLINE

ASCOT	100MG	A087522	001	Feb 12, 1982
	200MG	A087523	001	Feb 12, 1982

BARR	100MG	A088297	001	Aug 19, 1983
	200MG	A088298	001	Aug 19, 1983

DURAMED PHARMS BARR	100MG	A088182	001	Mar 31, 1983
	200MG	A088183	001	Mar 31, 1983

HALSEY	100MG	A084674	001	

IMPAX LABS	100MG	A084574	001	
	200MG	A084576	001	

KV PHARM	100MG	A085284	001	
	200MG	A085289	001	

LANNETT	100MG	A084588	001	
	200MG	A084588	002	

PAL PAK	100MG	A084533	001	

PANRAY	100MG	A084552	001	

	200MG	A084552	002	
PUREPAC PHARM	100MG	A084699	001	

	200MG	A085333	001	

ROXANE	100MG	A087500	001	Feb 09, 1982

	200MG	A087501	001	Feb 09, 1982

SANDOZ	100MG	A085261	003	

	100MG	A085262	002	

	200MG	A085261	002	

VALEANT PHARM INTL	200MG	A084563	001	

VANGARD	100MG	A088314	001	Oct 03, 1983

	200MG	A088319	001	Oct 03, 1983

VINTAGE PHARMS	100MG	A085409	001	

	200MG	A085410	001	

WATSON LABS	100MG	A085567	001	

	200MG	A085564	001	

TABLET, DELAYED RELEASE; ORAL

AMINOPHYLLINE

IMPAX LABS	100MG	A084577	001	
	200MG	A084575	001	

TABLICAPS	100MG	A084632	002	

VALE	100MG	A084531	001	

	200MG	A084530	001	

TABLET, EXTENDED RELEASE; ORAL

PHYLLLOCONTIN

PHARM RES ASSOC	225MG	A086760	001	

AMINOSALICYLATE SODIUM

POWDER; ORAL

P.A.S. SODIUM

CENTURY PHARMS	4GM/PACKET	A080947	001	

SODIUM AMINOSALICYLATE

HEXCEL	100%	A080097	001	

TABLET; ORAL

PARASAL SODIUM

PANRAY	500MG	N006811	006	
	1GM	N006811	011	

SODIUM P.A.S.

LANNETT	500MG	A080138	002	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 21 (of 360)

AMINOSALICYLATE SODIUMTABLET; ORAL
TEEBACIN

CONSOLIDATED MIDLAND 500MG

N007320 002

AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACIDTABLET; ORAL
NEOPASALATE

MEDPOINTE PHARM HLC 846MG;112MG

A080059 002

AMINOSALICYLIC ACIDTABLET; ORAL
PARASALPANRAY 500MG
1GM

N006811 001

N006811 002

AMINOSALICYLIC ACID RESIN COMPLEXPOWDER; ORAL
REZIPAS

BRISTOL MYERS SQUIBB EQ 500MG BASE/GM

N009052 001

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

BEDFORD 50MG/ML

A076018 001 Oct 15, 2002

BEDFORD LABS 50MG/ML

A076299 001 Oct 24, 2002

BEN VENUE 50MG/ML

A076088 001 Oct 15, 2002

HOSPIRA 50MG/ML

A076108 001 Oct 15, 2002

INTL MEDICATION SYS 50MG/ML

N021594 001 Feb 04, 2004

TEVA PARENTERAL 50MG/ML

A076163 001 Sep 05, 2003

CORDARONE

WYETH PHARMS INC 50MG/ML

N020377 001 Aug 03, 1995

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

TEVA 200MG

A074895 001 Apr 16, 1999

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE; ORAL

ENDEP

ROCHE 40MG/ML

A085749 001

INJECTABLE; INJECTION

AMITRIPTYLINE HYDROCHLORIDE

WATSON LABS 10MG/ML

A085594 001

ELAVIL

ASTRAZENECA 10MG/ML

N012704 001

TABLET; ORAL

AMITID

BRISTOL MYERS SQUIBB 10MG

A086454 001

25MG

A086454 002

50MG

A086454 003

75MG

A086454 004

100MG

A086454 005

AMITRIL

WARNER CHILCOTT 10MG

A083939 001

25MG

A083937 001

50MG

A083938 002

75MG

A084957 001

100MG

A085093 001

150MG

A086295 001

AMITRIPTYLINE HYDROCHLORIDE

AM THERAP 25MG

A088672 001 Nov 20, 1984

50MG

A088673 001 Nov 20, 1984

75MG

A088674 001 Nov 20, 1984

DISCONTINUED DRUG PRODUCT LIST

6 - 22 (of 360)

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AM THERAP	100MG	A088675	001	Nov 20, 1984
COPLEY PHARM	10MG	A088421	001	Apr 30, 1984
	25MG	A088422	001	Apr 30, 1984
	50MG	A088423	001	Apr 30, 1984
	75MG	A088424	001	Apr 30, 1984
	100MG	A088425	001	Apr 30, 1984
	150MG	A088426	001	Apr 30, 1984
HALSEY	10MG	A085923	001	
	25MG	A085922	001	
	50MG	A085925	001	
	50MG	A087557	001	Mar 05, 1982
	75MG	A085926	001	May 20, 1983
	100MG	A085927	001	May 20, 1983
LEDERLE	10MG	A086744	001	
	10MG	A087366	001	Jan 04, 1982
	25MG	A086746	001	
	25MG	A087367	001	May 03, 1982
	50MG	A086743	001	
	50MG	A087181	001	Jan 04, 1982
	75MG	A086745	001	
	75MG	A087369	001	Jan 04, 1982
	100MG	A086747	001	
	100MG	A087368	001	May 03, 1982
	150MG	A087370	001	Jan 04, 1982
MUTUAL PHARM	10MG	A085744	001	
	25MG	A085627	001	
	50MG	A085745	001	
	75MG	A085743	001	
	100MG	A085742	002	May 11, 1982
	150MG	A089423	001	Feb 17, 1987
PAR PHARM	10MG	A088697	001	Sep 25, 1984
	25MG	A088698	001	Sep 25, 1984
	50MG	A088699	001	Sep 25, 1984
	75MG	A088700	001	Sep 25, 1984
	100MG	A088701	001	Sep 25, 1984
	150MG	A088702	001	Sep 25, 1984
PLIVA	10MG	A088883	001	Sep 26, 1984
	25MG	A088884	001	Sep 26, 1984
	50MG	A088885	001	Sep 26, 1984
	75MG	A088886	001	Sep 26, 1984
	100MG	A088887	001	Sep 26, 1984
	150MG	A088888	001	Sep 26, 1984
PUREPAC PHARM	10MG	A088075	001	Sep 16, 1983
	10MG	A088084	001	Jul 18, 1983
	25MG	A088076	001	May 20, 1983
	25MG	A088085	001	Jul 18, 1983
	50MG	A088077	001	Sep 16, 1983
	50MG	A088105	001	Jul 18, 1983
	75MG	A088078	001	Sep 16, 1983
	75MG	A088106	001	Jul 18, 1983
	100MG	A088079	001	Sep 16, 1983
	100MG	A088107	001	Jul 18, 1983
ROXANE	10MG	A086002	001	
	10MG	A086144	001	
	25MG	A085944	001	
	25MG	A086145	001	
	50MG	A085945	001	
	50MG	A086143	001	
	75MG	A086004	001	
	75MG	A086147	001	

DISCONTINUED DRUG PRODUCT LIST

6 - 23 (of 360)

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

ROXANE	100MG	A086003	001	
	100MG	A086146	001	
	150MG	A086090	001	
	150MG	A086148	001	
SUPERPHARM	10MG	A088853	001	Nov 13, 1984
	25MG	A088854	001	Nov 13, 1984
	50MG	A088855	001	Nov 13, 1984
	75MG	A088856	001	Nov 13, 1984
	100MG	A088857	001	Nov 13, 1984
TEVA	10MG	A084910	003	
	10MG	A086610	001	
	25MG	A085031	001	
	25MG	A086859	001	
	50MG	A085032	001	
	50MG	A086857	001	
	75MG	A085030	001	
	75MG	A086860	001	
	100MG	A085836	001	
	100MG	A086854	001	
	150MG	A086853	001	
UCB INC	10MG	A085864	001	
	25MG	A085935	001	
	50MG	A085936	001	
	75MG	A086337	001	
	100MG	A086336	001	
	150MG	A086335	001	
USL PHARMA	25MG	A087775	001	Feb 10, 1982
VANGARD	10MG	A087632	001	Feb 01, 1982
	50MG	A087616	001	Feb 08, 1982
	75MG	A087617	001	Feb 05, 1982
	100MG	A087639	001	Feb 08, 1982
WATSON LABS	10MG	A085816	001	
	10MG	A088620	001	Mar 02, 1984
	25MG	A085817	001	
	25MG	A088621	001	Mar 02, 1984
	50MG	A085815	001	
	50MG	A088622	001	Mar 02, 1984
	75MG	A085819	001	
	75MG	A088633	001	Mar 02, 1984
	100MG	A085820	001	
	100MG	A088634	001	Mar 02, 1984
	150MG	A085821	001	
	150MG	A088635	001	Mar 02, 1984
WEST WARD	10MG	A087647	001	Mar 05, 1982
	25MG	A087278	001	
ELAVIL				
ASTRAZENECA	10MG	N012703	001	
	25MG	N012703	003	
	50MG	N012703	004	
	75MG	N012703	005	
	100MG	N012703	006	
	150MG	N012703	007	
ENDEP				
ROCHE	10MG	A083639	001	
	25MG	A083639	002	
	50MG	A083639	003	
	75MG	A083639	004	
	100MG	A083639	005	
	150MG	A085303	001	

DISCONTINUED DRUG PRODUCT LIST

6 - 24 (of 360)

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

MUTUAL PHARM	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986
	EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986
PAR PHARM	EQ 12.5MG BASE;5MG	A072277	001	May 09, 1988
	EQ 25MG BASE;10MG	A072278	001	May 09, 1988
USL PHARMA	EQ 12.5MG BASE;5MG	A070477	001	Jan 12, 1988
	EQ 25MG BASE;10MG	A070478	001	Jan 12, 1988
WATSON LABS	EQ 12.5MG BASE;5MG	A072052	001	Dec 16, 1988
	EQ 25MG BASE;10MG	A072053	001	Dec 16, 1988
LIMBITROL				
VALEANT PHARM INTL	EQ 12.5MG BASE;5MG	N016949	001	
LIMBITROL DS				
VALEANT PHARM INTL	EQ 25MG BASE;10MG	N016949	002	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

ETRAFON 2-10

SCHERING	10MG;2MG	N014713	007	

ETRAFON 2-25

SCHERING	25MG;2MG	N014713	004	

ETRAFON-A

SCHERING	10MG;4MG	N014713	002	

ETRAFON-FORTE

SCHERING	25MG;4MG	N014713	006	

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	10MG;2MG	A070935	001	Sep 11, 1986
	10MG;4MG	A070937	001	Sep 11, 1986
	25MG;2MG	A070936	001	Sep 11, 1986
	25MG;4MG	A070938	001	Sep 11, 1986
	50MG;4MG	A070939	001	Sep 12, 1986
MUTUAL PHARM	10MG;2MG	A071077	001	Nov 12, 1986
	10MG;4MG	A071078	001	Nov 12, 1986
	25MG;2MG	A070297	001	Nov 12, 1986
	25MG;4MG	A071079	001	Nov 12, 1986
	10MG;2MG	A070565	001	Sep 11, 1986
PAR PHARM	10MG;4MG	A070620	001	Sep 11, 1986
	25MG;2MG	A070621	001	Sep 11, 1986
	25MG;4MG	A070595	001	Sep 11, 1986
	50MG;4MG	A070574	001	Sep 11, 1986
	10MG;2MG	A071062	001	Nov 27, 1987
SANDOZ	10MG;4MG	A071862	001	Dec 21, 1987
	25MG;2MG	A071063	001	Nov 27, 1987
	25MG;4MG	A071064	001	Nov 27, 1987
	50MG;4MG	A071863	001	Dec 21, 1987
	10MG;2MG	A070373	001	Aug 25, 1986
WATSON LABS	10MG;2MG	A072539	001	Feb 15, 1989
	10MG;2MG	A073007	001	Oct 17, 1991
	10MG;4MG	A070375	001	Aug 25, 1986
	10MG;4MG	A072540	001	Feb 15, 1989
	10MG;4MG	A073009	001	Oct 17, 1991
	25MG;2MG	A070374	001	Aug 25, 1986
	25MG;2MG	A072541	001	Feb 15, 1989
	25MG;2MG	A073008	001	Oct 17, 1991
	25MG;4MG	A070376	001	Aug 25, 1986
	25MG;4MG	A072134	001	Feb 15, 1989
	25MG;4MG	A073010	001	Oct 17, 1991
	50MG;4MG	A070377	001	Nov 04, 1986
	50MG;4MG	A071558	001	Mar 02, 1987
	50MG;4MG	A072135	001	Feb 15, 1989

TRIAVIL 2-10

NEW RIVER	10MG;2MG	N014715	004	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 25 (of 360)

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

TRIAVIL 2-25

NEW RIVER

25MG;2MG

N014715 002

TRIAVIL 4-10

NEW RIVER

10MG;4MG

N014715 003

TRIAVIL 4-25

NEW RIVER

25MG;4MG

N014715 005

TRIAVIL 4-50

NEW RIVER

50MG;4MG

N014715 006

AMLEXANOX

PATCH; TOPICAL

AMLEXANOX

ULURU

2MG

N021727 001 Sep 29, 2004

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

GEDEON RICHTER USA

EQ 2.5MG BASE

A077333 001 Jul 17, 2007

EQ 5MG BASE

A077333 002 Jul 17, 2007

EQ 10MG BASE

A077333 003 Jul 17, 2007

GENPHARM

EQ 2.5MG BASE

A077362 001 Jul 09, 2007

EQ 5MG BASE

A077362 002 Jul 09, 2007

EQ 10MG BASE

A077362 003 Jul 09, 2007

MUTUAL PHARMA

EQ 2.5MG BASE

A078081 001 Jan 31, 2008

EQ 5MG BASE

A078081 002 Jan 31, 2008

EQ 10MG BASE

A078081 003 Jan 31, 2008

SANDOZ

EQ 2.5MG BASE

A076859 001 Sep 10, 2007

EQ 5MG BASE

A076859 002 Sep 10, 2007

EQ 10MG BASE

A076859 003 Sep 10, 2007

SYNTHON PHARMS

EQ 2.5MG BASE

A077080 001 Jun 27, 2007

EQ 5MG BASE

A077080 002 Jun 27, 2007

EQ 10MG BASE

A077080 003 Jun 27, 2007

TABLET, ORALLY DISINTEGRATING; ORAL

AMLODIPINE BESYLATE

SYNTHON PHARMS

EQ 2.5MG BASE

N022026 001 Sep 27, 2007

EQ 5MG BASE

N022026 002 Sep 27, 2007

EQ 10MG BASE

N022026 003 Sep 27, 2007

AMLODIPINE MALEATE

TABLET; ORAL

AMVAZ

DR REDDYS LABS INC

2.5MG

N021435 001 Oct 31, 2003

5MG

N021435 002 Oct 31, 2003

10MG

N021435 003 Oct 31, 2003

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE

ABBOTT

5MEQ/ML

A083130 001

GD SEARLE LLC

3MEQ/ML

A086205 001

AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE

MCGAW

900MG/100ML

N006580 001

AMMONIUM CHLORIDE 2.14%

B BRAUN

40MEQ/100ML

A085734 001

AMODIAQUINE HYDROCHLORIDE

TABLET; ORAL

CAMOQUIN HYDROCHLORIDE

PARKE DAVIS

EQ 200MG BASE

N006441 001

DISCONTINUED DRUG PRODUCT LIST

6 - 26 (of 360)

AMOXAPINE

TABLET; ORAL
AMOXAPINE

SANDOZ	25MG	A072943	001	Jun 28, 1991
	50MG	A072944	001	Jun 28, 1991
	100MG	A072878	001	Jun 28, 1991
	150MG	A072879	001	Jun 28, 1991
	25MG	A072418	001	May 11, 1989
WATSON LABS	50MG	A072419	001	May 11, 1989
	100MG	A072420	001	May 11, 1989
	150MG	A072421	001	May 11, 1989
	25MG	N018021	001	
LEDERLE	50MG	N018021	002	
	100MG	N018021	003	
	150MG	N018021	004	

AMOXICILLIN

CAPSULE; ORAL
AMOXICILLIN

LABS ATRAL	250MG	A062528	001	Aug 07, 1985
	500MG	A062528	002	Aug 07, 1985
MYLAN	250MG	A062067	001	
	500MG	A062067	002	
TEVA	250MG	A062853	001	Dec 22, 1987
	250MG	A063030	001	Feb 28, 1989
	500MG	A062854	001	Dec 22, 1987
	500MG	A063031	001	Feb 28, 1989
AMOXIL GLAXOSMITHKLINE	250MG	N050459	001	
	500MG	N050459	002	
TRIMOX APOTHECON	250MG	A061885	001	
	250MG	A062098	001	
	250MG	A062152	001	
	250MG	A063099	001	Mar 20, 1992
	500MG	A061885	002	
	500MG	A062098	002	
	500MG	A062152	002	
	500MG	A063099	002	Mar 20, 1992
UTIMOX PARKE DAVIS	250MG	A062107	001	
	500MG	A062107	002	
WYMOX WYETH AYERST	250MG	A062120	001	
	500MG	A062120	002	
FOR SUSPENSION; ORAL AMOXICILLIN AM ANTIBIOTICS	125MG/5ML	A062059	001	
	250MG/5ML	A062059	002	
	125MG/5ML	A062090	001	
	250MG/5ML	A062090	002	
	125MG/5ML	A062946	001	Nov 01, 1988
	250MG/5ML	A063001	001	Jan 06, 1989
	50MG/ML	N050460	005	
	125MG/5ML	N050460	001	
LAROTID GLAXOSMITHKLINE	250MG/5ML	N050460	002	
	50MG/ML	N050460	006	
POLYMOX APOTHECON	125MG/5ML	A061851	001	
	125MG/5ML	A062323	001	

DISCONTINUED DRUG PRODUCT LIST

6 - 27 (of 360)

AMOXICILLIN

FOR SUSPENSION; ORAL
POLYMOX

APOTHECON	250MG/5ML	A061851	002	
	250MG/5ML	A062323	002	

TRIMOX

APOTHECON	50MG/ML	A061886	001	
	125MG/5ML	A061886	002	
	125MG/5ML	A062099	001	
	125MG/5ML	A062154	001	
	125MG/5ML	A062885	001	Mar 08, 1988
	250MG/5ML	A061886	003	
	250MG/5ML	A062099	002	
	250MG/5ML	A062154	002	
	250MG/5ML	A062885	002	Mar 08, 1988

UTIMOX

PARKE DAVIS	125MG/5ML	A062127	001	
	250MG/5ML	A062127	002	

WYMOX

WYETH AYERST	125MG/5ML	A062131	001	
	250MG/5ML	A062131	002	

TABLET, CHEWABLE; ORAL

AMOXICILLIN

APOTHECON	125MG	A064131	001	May 06, 1996
	250MG	A064131	002	May 06, 1996
TEVA	125MG	A064031	001	Dec 19, 1996
	250MG	A064031	002	Dec 19, 1996

TABLET, FOR SUSPENSION; ORAL

DISPERMOX

RANBAXY LABS LTD	200MG	A065080	002	Aug 11, 2003
	400MG	A065080	001	Aug 11, 2003
	600MG	A065159	001	Dec 04, 2003

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE;
DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL

DELCOBESE

TEVA	1.25MG;1.25MG;1.25MG;1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A083564	001	
	2.5MG;2.5MG;2.5MG;2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A083564	002	
	3.75MG;3.75MG;3.75MG;3.75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A083564	003	
	5MG;5MG;5MG;5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A083564	004	

TABLET; ORAL

DELCOBESE

TEVA	1.25MG;1.25MG;1.25MG;1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A083563	004	
	2.5MG;2.5MG;2.5MG;2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A083563	003	
	3.75MG;3.75MG;3.75MG;3.75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A083563	002	

DISCONTINUED DRUG PRODUCT LIST

6 - 28 (of 360)

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DELCOBESE

TEVA	5MG;5MG;5MG;5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A083563	001	

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

ADDERALL 10

TEVA WOMENS	2.5MG;2.5MG;2.5MG;2.5MG	N011522	007	Feb 13, 1996

ADDERALL 12.5

TEVA WOMENS	3.125MG;3.125MG;3.125MG;3.125MG	N011522	012	Aug 31, 2000

ADDERALL 15

TEVA WOMENS	3.75MG;3.75MG;3.75MG;3.75MG	N011522	013	Aug 31, 2000

ADDERALL 20

TEVA WOMENS	5MG;5MG;5MG;5MG	N011522	008	Feb 13, 1996

ADDERALL 30

TEVA WOMENS	7.5MG;7.5MG;7.5MG;7.5MG	N011522	010	May 12, 1997

ADDERALL 5

TEVA WOMENS	1.25MG;1.25MG;1.25MG;1.25MG	N011522	009	May 12, 1997

ADDERALL 7.5

TEVA WOMENS	1.875MG;1.875MG;1.875MG;1.875MG	N011522	011	Aug 31, 2000

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

MALLINCKRODT INC	1.25MG;1.25MG;1.25MG;1.25MG	A040440	001	Oct 07, 2003

	1.875MG;1.875MG;1.875MG;1.875MG	A040440	002	Oct 07, 2003

	2.5MG;2.5MG;2.5MG;2.5MG	A040440	003	Oct 07, 2003

	3.125MG;3.125MG;3.125MG;3.125MG	A040440	004	Oct 07, 2003

	3.75MG;3.75MG;3.75MG;3.75MG	A040440	005	Oct 07, 2003

	5MG;5MG;5MG;5MG	A040440	006	Oct 07, 2003

	7.5MG;7.5MG;7.5MG;7.5MG	A040440	007	Oct 07, 2003

MUTUAL PHARM	1.25MG;1.25MG;1.25MG;1.25MG	A040480	001	Sep 09, 2003

	1.875MG;1.875MG;1.875MG;1.875MG	A040480	002	Sep 09, 2003

	2.5MG;2.5MG;2.5MG;2.5MG	A040480	003	Sep 09, 2003

	3.125MG;3.125MG;3.125MG;3.125MG	A040480	004	Sep 09, 2003

	3.75MG;3.75MG;3.75MG;3.75MG	A040480	005	Sep 09, 2003

	5MG;5MG;5MG;5MG	A040480	006	Sep 09, 2003

	7.5MG;7.5MG;7.5MG;7.5MG	A040480	007	Sep 09, 2003

WATSON LABS	1.25MG;1.25MG;1.25MG;1.25MG	A040456	001	May 06, 2003

	2.5MG;2.5MG;2.5MG;2.5MG	A040456	002	May 06, 2003

	5MG;5MG;5MG;5MG	A040456	003	May 06, 2003

	7.5MG;7.5MG;7.5MG;7.5MG	A040456	004	May 06, 2003

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

BIPHETAMINE 12.5

UCB INC	EQ 6.25MG BASE;EQ 6.25MG BASE	N010093	007	

BIPHETAMINE 20

UCB INC	EQ 10MG BASE;EQ 10MG BASE	N010093	003	

BIPHETAMINE 7.5

UCB INC	EQ 3.75MG BASE;EQ 3.75MG BASE	N010093	009	

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

LANNETT	5MG	A083901	001	Aug 31, 1984

	10MG	A083901	002	Aug 31, 1984

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 29 (of 360)

AMPHOTERICIN BCREAM; TOPICAL
FUNGIZONE

APOTHECON 3% N050314 001

INJECTABLE; INJECTION
AMPHOTERICIN B

ABBOTT 50MG/VIAL A064141 001 Dec 23, 1996

ABRAXIS PHARM 50MG/VIAL A062728 001 Apr 13, 1987

TEVA PARENTERAL 50MG/VIAL A064062 001 Mar 31, 1995

FUNGIZONE

APOTHECON 50MG/VIAL A060517 001

LOTION; TOPICAL

FUNGIZONE

APOTHECON 3% A060570 001

OINTMENT; TOPICAL

FUNGIZONE

APOTHECON 3% N050313 001

SUSPENSION; ORAL

FUNGIZONE

BRISTOL MYERS SQUIBB 100MG/ML N050341 003

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

APOTHECON EQ 125MG BASE/VIAL A062860 001 Feb 05, 1988

EQ 250MG BASE/VIAL A062860 002 Feb 05, 1988

EQ 500MG BASE/VIAL A062860 003 Feb 05, 1988

EQ 1GM BASE/VIAL A062860 004 Feb 05, 1988

EQ 2GM BASE/VIAL A062860 005 Feb 05, 1988

CONSOLIDATED PHARM EQ 125MG BASE/VIAL A061936 005

EQ 250MG BASE/VIAL A061936 001

EQ 500MG BASE/VIAL A061936 002

EQ 1GM BASE/VIAL A061936 003

EQ 2GM BASE/VIAL A061936 004

HANFORD GC EQ 125MG BASE/VIAL A063143 001 Apr 15, 1993

EQ 500MG BASE/VIAL A063147 001 Apr 15, 1993

EQ 1GM BASE/VIAL A063139 001 Apr 15, 1993

EQ 2GM BASE/VIAL A063141 001 Apr 15, 1993

HIKMA MAPLE EQ 125MG BASE/VIAL A062692 001 Jun 24, 1986

EQ 250MG BASE/VIAL A062692 002 Jun 24, 1986

EQ 500MG BASE/VIAL A062692 003 Jun 24, 1986

EQ 1GM BASE/VIAL A062692 004 Jun 24, 1986

EQ 2GM BASE/VIAL A062692 005 Jun 24, 1986

EQ 10GM BASE/VIAL A062692 006 Jun 24, 1986

INTL MEDICATION EQ 1GM BASE/VIAL A062634 002 Jan 09, 1987

EQ 2GM BASE/VIAL A062634 003 Jan 09, 1987

LILLY EQ 500MG BASE/VIAL A062565 001 Apr 04, 1985

EQ 1GM BASE/VIAL A062565 002 Apr 04, 1985

EQ 2GM BASE/VIAL A062565 003 Jun 24, 1986

MARSAM PHARMS LLC EQ 125MG BASE/VIAL A062816 001 Oct 24, 1988

EQ 250MG BASE/VIAL A062816 002 Oct 24, 1988

EQ 500MG BASE/VIAL A062816 003 Oct 24, 1988

EQ 1GM BASE/VIAL A062816 004 Oct 24, 1988

EQ 2GM BASE/VIAL A062816 005 Oct 24, 1988

EQ 10GM BASE/VIAL A062994 001 Sep 15, 1988

OMNIPEN-N

WYETH AYERST EQ 125MG BASE/VIAL A060626 001

EQ 125MG BASE/VIAL A062718 001 Dec 16, 1986

EQ 250MG BASE/VIAL A060626 002

EQ 250MG BASE/VIAL A062718 002 Dec 16, 1986

EQ 500MG BASE/VIAL A060626 003

EQ 500MG BASE/VIAL A062718 003 Dec 16, 1986

EQ 1GM BASE/VIAL A060626 004

EQ 1GM BASE/VIAL A062718 004 Dec 16, 1986

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 30 (of 360)

AMPICILLIN SODIUM

INJECTABLE; INJECTION

OMNIPEN-N

WYETH AYERST

EQ 2GM BASE/VIAL

A060626 005

EQ 2GM BASE/VIAL

A062718 005

Dec 16, 1986

PENBRITIN-S

WYETH AYERST

EQ 125MG BASE/VIAL

N050072 001

EQ 250MG BASE/VIAL

N050072 002

EQ 500MG BASE/VIAL

N050072 003

EQ 1GM BASE/VIAL

N050072 004

EQ 2GM BASE/VIAL

N050072 005

EQ 4GM BASE/VIAL

N050072 006

POLYCILLIN-N

BRISTOL

EQ 125MG BASE/VIAL

N050309 001

EQ 250MG BASE/VIAL

N050309 002

EQ 500MG BASE/VIAL

N050309 003

EQ 1GM BASE/VIAL

N050309 004

EQ 2GM BASE/VIAL

N050309 005

TOTACILLIN-N

GLAXOSMITHKLINE

EQ 125MG BASE/VIAL

A060677 001

EQ 250MG BASE/VIAL

A060677 002

EQ 500MG BASE/VIAL

A060677 003

EQ 1GM BASE/VIAL

A060677 004

EQ 1GM BASE/VIAL

A062727 001

Dec 19, 1986

EQ 2GM BASE/VIAL

A060677 005

EQ 2GM BASE/VIAL

A062727 002

Dec 19, 1986

EQ 10GM BASE/VIAL

A060677 006

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

UNASYN

PFIZER

EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL

N050608 003

Dec 31, 1986

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMCILL

PARKE DAVIS

EQ 250MG BASE

A062041 001

EQ 500MG BASE

A062041 002

AMPICILLIN TRIHYDRATE

AM ANTIBIOTICS

EQ 250MG BASE

A061602 001

EQ 500MG BASE

A061602 002

IVAX SUB TEVA PHARMS

EQ 250MG BASE

A060765 001

EQ 500MG BASE

A060765 002

LEDERLE

EQ 250MG BASE

A062208 001

EQ 500MG BASE

A062208 002

MYLAN

EQ 250MG BASE

A061755 001

EQ 500MG BASE

A061755 002

PUREPAC PHARM

EQ 250MG BASE

A061853 001

EQ 500MG BASE

A061853 002

TEVA

EQ 250MG BASE

A061502 001

EQ 500MG BASE

A061502 002

VITARINE

EQ 250MG BASE

A061387 001

EQ 500MG BASE

A061387 003

OMNIPEN (AMPICILLIN)

WYETH AYERST

250MG

A060624 001

500MG

A060624 002

PENBRITIN

WYETH AYERST

EQ 250MG BASE

A060908 001

EQ 500MG BASE

A060908 002

PFIZERPEN-A

PFIZER

EQ 250MG BASE

A062050 001

EQ 500MG BASE

A062050 002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 31 (of 360)

AMPICILLIN/AMPICILLIN TRIHYDRATECAPSULE; ORAL
POLYCILLIN

BRISTOL	EQ 250MG BASE	N050310	001
	EQ 500MG BASE	N050310	002

PRINCIPEN

APOTHECON	EQ 250MG BASE	A062888	001	Mar 04, 1988
	EQ 500MG BASE	A062888	002	
BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061392	001	
	EQ 500MG BASE	A061392	002	

PRINCIPEN '250'

APOTHECON	EQ 250MG BASE	A062157	002
	EQ 250MG BASE	N050056	001

PRINCIPEN '500'

APOTHECON	EQ 500MG BASE	A062157	001
	EQ 500MG BASE	N050056	002

TOTACILLIN

GLAXOSMITHKLINE	EQ 250MG BASE	A060060	001
	EQ 250MG BASE	A062212	001
	EQ 500MG BASE	A060060	002
	EQ 500MG BASE	A062212	002

FOR SUSPENSION; ORAL

AMCILL

PARKE DAVIS	EQ 125MG BASE/5ML	A062030	001
	EQ 250MG BASE/5ML	A062030	002

AMPICILLIN TRIHYDRATE

AM ANTIBIOTICS	EQ 125MG BASE/5ML	A061601	001
	EQ 250MG BASE/5ML	A061601	002
MYLAN	EQ 125MG BASE/5ML	A061829	002
	EQ 250MG BASE/5ML	A061829	001
PUREPAC PHARM	EQ 125MG BASE/5ML	A061980	001
	EQ 250MG BASE/5ML	A061980	002
TEVA	EQ 125MG BASE/5ML	A061370	001
	EQ 250MG BASE/5ML	A061370	002

OMNIPEN (AMPICILLIN)

WYETH AYERST	100MG/ML	A060625	001
	125MG/5ML	A060625	002
	250MG/5ML	A060625	003
	500MG/5ML	A060625	004

PENBRITIN

WYETH AYERST	EQ 100MG BASE/ML	N050019	001
	EQ 125MG BASE/5ML	N050019	002
	EQ 250MG BASE/5ML	N050019	003

PFIZERPEN-A

PFIZER	EQ 125MG BASE/5ML	A062049	001
	EQ 250MG BASE/5ML	A062049	002

POLYCILLIN

APOTHECON	EQ 125MG BASE/5ML	A062297	001
	EQ 250MG BASE/5ML	A062297	002
BRISTOL	EQ 100MG BASE/ML	N050308	004
	EQ 125MG BASE/5ML	N050308	001
	EQ 250MG BASE/5ML	N050308	002
	EQ 500MG BASE/5ML	N050308	003

PRINCIPEN

APOTHECON	EQ 100MG BASE/ML	A061394	001
	EQ 125MG BASE/5ML	A061394	002
	EQ 250MG BASE/5ML	A061394	003

PRINCIPEN '125'

APOTHECON	EQ 125MG BASE/5ML	A060127	002
	EQ 125MG BASE/5ML	A062151	001

PRINCIPEN '250'

APOTHECON	EQ 250MG BASE/5ML	A060127	001
	EQ 250MG BASE/5ML	A062151	002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 32 (of 360)

AMPICILLIN/AMPICILLIN TRIHYDRATEFOR SUSPENSION; ORAL
TOTACILLIN

GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A060666	001
	EQ 125MG BASE/5ML	A062223	001
	EQ 250MG BASE/5ML	A060666	002
	EQ 250MG BASE/5ML	A062223	002

TABLET, CHEWABLE; ORAL
POLYCILLIN

BRISTOL	EQ 125MG BASE	N050093	001

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECIDCAPSULE; ORAL
PRINCIPEN W/ PROBENECID

APOTHECON	EQ 389MG BASE;111MG	A062150	001
	EQ 389MG BASE;111MG	N050488	001

FOR SUSPENSION; ORAL
POLYCILLIN-PRB

APOTHECON	EQ 3.5GM BASE/BOT;1GM/BOT	A061898	001
BRISTOL	EQ 3.5GM BASE/BOT;1GM/BOT	N050457	001

PROBAMPACIN

TEVA	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001

AMPRENAVIRCAPSULE; ORAL
AGENERASE

GLAXOSMITHKLINE	50MG	N021007	001	Apr 15, 1999
	150MG	N021007	002	Apr 15, 1999

SOLUTION; ORAL
AGENERASE

GLAXOSMITHKLINE	15MG/ML **Federal Register notice determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021039	001	Apr 15, 1999

ANAGRELIDE HYDROCHLORIDECAPSULE; ORAL
AGRYLIN

SHIRE LLC	EQ 1MG BASE	N020333	002	Mar 14, 1997

ANAGRELIDE HYDROCHLORIDE

ROXANE	EQ 0.5MG BASE	A076489	001	Apr 18, 2005
	EQ 1MG BASE	A076489	002	Apr 18, 2005
SANDOZ INC	EQ 0.5MG BASE	A076683	001	Apr 18, 2005
	EQ 1MG BASE	A076683	002	Apr 18, 2005

ANASTROZOLETABLET; ORAL
ANASTROZOLE

SYNTHON PHARMS	1MG	A078322	001	Jun 28, 2010

ANILERIDINE HYDROCHLORIDETABLET; ORAL
LERITINE

MERCK	EQ 25MG BASE	N010585	002

ANILERIDINE PHOSPHATE

INJECTABLE; INJECTION

LERITINE

MERCK	25MG/ML	N010520	003

ANISINDIONETABLET; ORAL
MIRADON

SCHERING	50MG	N010909	003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 33 (of 360)

ANISOTROPINE METHYLBROMIDE

TABLET; ORAL

ANISOTROPINE METHYLBROMIDE

WATSON LABS

50MG

A086046 001

VALPIN 50

ENDO PHARMS

50MG

N013428 001

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A

NOVARTIS

0.5%;0.05%

N018746 002 Jul 11, 1994

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

US WORLDMEDS

20MG/2ML (10MG/ML)

N021264 001 Apr 20, 2004

APROTININ

INJECTABLE; INJECTION

TRASYLOL

BAYER HLTHCARE

10,000KIU/ML

N020304 001 Dec 29, 1993

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

GENESA

GENSIA AUTOMEDICS

0.05MG/ML

N020420 001 Sep 12, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION

NORMIFLO

PHARMACIA AND UPJOHN

5,000 UNITS/0.5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020227 002 May 23, 1997

10,000 UNITS/0.5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020227 001 May 23, 1997

ARGATROBAN

SOLUTION; IV (INFUSION)

ARGATROBAN IN DEXTROSE

SANDOZ

125MG/125ML (1MG/ML)

N201743 001 May 09, 2011

ARIPIRAZOLE

TABLET, ORALLY DISINTEGRATING; ORAL

ABILIFY

OTSUKA

20MG **Federal Register determination that the product was not discontinued or withdrawn for safety or efficacy reasons**

N021729 004 Jun 07, 2006

30MG **Federal Register determination that the product was not discontinued or withdrawn for safety or efficacy reasons**

N021729 005 Jun 07, 2006

ARMODAFINIL

TABLET; ORAL

NUVIGIL

CEPHALON

100MG

N021875 002 Mar 26, 2009

200MG

N021875 005 Mar 26, 2009

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 34 (of 360)

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

BEROCCA PN

ROCHE

50MG/ML;0.03MG/ML;0.0025MG/ML;7.5MG/ML; N006071 003 Oct 10, 1985
100
IU/ML;0.2MG/ML;20MG/ML;2MG/ML;1.8MG/ML;
1.5MG/ML;1,650 IU/ML;5 IU/ML

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.C. 9+3

ABRAXIS PHARM

10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2 N018440 002 Aug 08, 1985
0
IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/
ML;0.3MG/ML;330 UNITS/ML;1 IU/ML

M.V.I. -12

HOSPIRA

10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2 N008809 004 Aug 08, 1985
0
IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/
ML;0.3MG/ML;330 UNITS/ML;1 IU/ML

MVC PLUS

WATSON LABS

10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2 N018439 002 Aug 08, 1985
0
IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/
ML;0.3MG/ML;330 UNITS/ML;1 IU/ML

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I. -12

HOSPIRA

20MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2 N008809 005 Apr 22, 2004
0
IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0.36MG/M
L;0.6MG/ML;330 UNITS/ML;1 IU/ML

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I. -12 LYOPHILIZED

ASTRAZENECA

100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15M N018933 002 Aug 08, 1985
G/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4
MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10
MG/VIAL

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

VITAPED

HOSPIRA

N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A,0.001 N020176 001 Dec 29, 1993
MG/VIAL;400
IU/10ML,N/A;N/A,0.14MG/VIAL;N/A,17MG/VI
AL;N/A,5MG/VIAL;0.2MG/10ML,N/A;N/A,1MG/
VIAL;N/A,1.4MG/VIAL;N/A,1.2MG/VIAL;EQ
2,300 UNITS BASE/10ML,N/A;7 IU/10ML,N/A

ASPIRIN

TABLET; ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

BAYER

500MG

N021317 001 Oct 18, 2001

TABLET, EXTENDED RELEASE; ORAL

8-HOUR BAYER

BAYER

650MG

N016030 001

DISCONTINUED DRUG PRODUCT LIST

6 - 35 (of 360)

ASPIRIN

TABLET, EXTENDED RELEASE; ORAL
MEASURIN

BAYER	650MG	N016030	002

ASPIRIN; BUTALBITAL

TABLET; ORAL
AXOTAL

SAVAGE LABS	650MG;50MG	A088305	001	Oct 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

MUTUAL PHARM	325MG;50MG;40MG	A078149	001	Jun 13, 2007

WATSON LABS	325MG;50MG;40MG	A086231	002	Feb 12, 1985

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

ACTAVIS ELIZABETH	325MG;50MG;40MG	A086710	002	Aug 23, 1983

HALSEY	325MG;50MG;40MG	A089448	001	Dec 01, 1986

IVAX PHARMS	325MG;50MG;40MG	A085441	002	Oct 31, 1984

PURACAP PHARM	325MG;50MG;40MG	A087048	002	Dec 09, 1983

QUANTUM PHARMICS	325MG;50MG;40MG	A088972	001	Jun 18, 1985

SANDOZ	325MG;50MG;40MG	A086398	002	Apr 06, 1984

WATSON LABS	325MG;50MG;40MG	A086237	002	Mar 23, 1984

FIORINAL

WATSON LABS INC	325MG;50MG;40MG	N017534	003	Apr 16, 1986

LANORINAL

LANNETT	325MG;50MG;40MG	A086986	002	Oct 18, 1985

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

VINTAGE PHARMS LLC	325MG;50MG;40MG;30MG	A075351	001	Mar 05, 1999

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

INVAGESIC

SANDOZ	385MG;30MG;25MG	A074817	001	Nov 27, 1996

INVAGESIC FORTE

SANDOZ	770MG;60MG;50MG	A074817	002	Nov 27, 1996

ORPHENGESIC

SOLCO HLTHCARE	385MG;30MG;25MG	A075141	001	May 29, 1998

ORPHENGESIC FORTE

SOLCO HLTHCARE	770MG;60MG;50MG	A075141	002	May 29, 1998

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

COMPOUND 65

ALRA	389MG;32.4MG;65MG	A084553	002	Aug 17, 1983

DARVON COMPOUND

XANODYNE PHARM	389MG;32.4MG;32MG	N010996	006	Mar 08, 1983

DARVON COMPOUND-65

XANODYNE PHARM	389MG;32.4MG;65MG	N010996	007	Mar 08, 1983

PROPOXYPHENE COMPOUND 65

IVAX SUB TEVA PHARMS	389MG;32.4MG;65MG	A083077	002	Dec 07, 1984

SANDOZ	389MG;32.4MG;65MG	A080044	002	Sep 16, 1983

TEVA	389MG;32.4MG;65MG	A089025	001	Mar 29, 1985

PROPOXYPHENE COMPOUND-65

SANDOZ	389MG;32.4MG;65MG	A083101	002	Jun 24, 1985

PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE

WATSON LABS	389MG;32.4MG;65MG	A085732	002	Sep 03, 1984

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 36 (of 360)

ASPIRIN; CARISOPRODOL

TABLET; ORAL				
CARISOPRODOL COMPOUND				
WATSON LABS	325MG;200MG	A088809	001	Oct 03, 1985

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL				
AZDONE				
SCHWARZ PHARMA	500MG;5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A089420	001	Jan 25, 1988
VICOPRIN				
ABBOTT	500MG;5MG	A086333	001	Sep 14, 1983

ASPIRIN; MEPROBAMATE

TABLET; ORAL				
EQUAGESIC				
CARACO	325MG;200MG	N011702	003	Dec 29, 1983
MEPRO-ASPIRIN				
SANDOZ	325MG;200MG	A089127	001	Mar 02, 1987
MEPROBAMATE AND ASPIRIN				
PAR PHARM	325MG;200MG	A089126	001	Aug 19, 1986
MICRAININ				
MEDPOINTE PHARM HLC	325MG;200MG	A084978	001	
Q-GESIC				
QUANTUM PHARMICS	325MG;200MG	A088740	001	Jun 01, 1984

ASPIRIN; METHOCARBAMOL

TABLET; ORAL				
METHOCARBAMOL AND ASPIRIN				
IVAX SUB TEVA PHARMS	325MG;400MG	A087211	001	Dec 22, 1982
MCNEIL	325MG;400MG	A089193	001	Feb 12, 1986
PAR PHARM	325MG;400MG	A089657	001	Nov 04, 1988
ROBAXISAL				
ROBINS AH	325MG;400MG	N012281	001	

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL				
CODOXY				
HALSEY	325MG;4.5MG;0.38MG	A087464	001	Jul 01, 1982
OXYCODONE AND ASPIRIN				
MUTUAL PHARM	325MG;4.5MG;0.38MG	A040260	001	Jul 17, 1998
	325MG;4.5MG;0.38MG	A087794	001	May 26, 1982
OXYCODONE AND ASPIRIN (HALF-STRENGTH)				
ROXANE	325MG;2.25MG;0.19MG	A087742	001	Jun 04, 1982
PERCODAN				
ENDO PHARMS	325MG;4.5MG;0.38MG	N007337	006	
PERCODAN-DEMI				
ENDO PHARMS	325MG;2.25MG;0.19MG	N007337	005	
ROXIPRIN				
ROXANE	325MG;4.5MG;0.38MG	A087743	001	Jun 04, 1982

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL				
TALWIN COMPOUND				
SANOFI AVENTIS US	325MG;EQ 12.5MG BASE	N016891	001	

ASPIRIN; PRAVASTATIN SODIUM

TABLET, TABLET; ORAL				
PRAVIGARD PAC (COPACKAGED)				
BRISTOL MYERS SQUIBB	325MG,N/A;N/A,80MG	N021387	006	Jun 24, 2003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 37 (of 360)

ASPIRIN; PRAVASTATIN SODIUMTABLET, TABLET, TABLET; ORAL
PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB	81MG, N/A; N/A, 20MG	N021387	001	Jun 24, 2003
	81MG, N/A; N/A, 40MG	N021387	002	Jun 24, 2003
	81MG, N/A; N/A, 80MG	N021387	003	Jun 24, 2003
	325MG, N/A; N/A, 20MG	N021387	004	Jun 24, 2003
	325MG, N/A; N/A, 40MG	N021387	005	Jun 24, 2003

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON W/ ASA

XANODYNE PHARM	325MG; 65MG	N010996	005	

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC	325MG; 100MG	N016829	001	

TABLET; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC	325MG; 100MG	N016863	001	

ATENOLOL

INJECTABLE; INJECTION

TENORMIN

ASTRAZENECA	0.5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019058	001	Sep 13, 1989

TABLET; ORAL

ATENOLOL

ABLE	25MG	A076907	001	Jul 30, 2004
	50MG	A076907	002	Jul 30, 2004
	100MG	A076907	003	Jul 30, 2004
APOTHECON	50MG	A073317	001	Mar 20, 1992
	100MG	A073318	001	Mar 20, 1992
NOSTRUM LABS	50MG	A074127	001	Feb 21, 1995
	100MG	A074127	002	Feb 21, 1995
PLIVA	25MG	A074101	001	Jul 17, 1997
	50MG	A074101	002	Jul 17, 1997
	100MG	A074101	003	Jul 17, 1997
SANDOZ	25MG	A074265	001	Feb 28, 1994
	50MG	A074265	002	Feb 28, 1994
	100MG	A074265	003	Feb 28, 1994
SCS	50MG	A073676	001	Oct 30, 1992
	100MG	A073676	002	Oct 30, 1992
TEVA	50MG	A073315	001	May 28, 1993
	100MG	A073316	001	May 28, 1993
TEVA PHARMS	50MG	A074120	001	Feb 24, 1995
	100MG	A074120	002	Feb 24, 1995

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

NOSTRUM LABS	50MG; 25MG	A074404	001	May 14, 1998
	100MG; 25MG	A074404	002	May 14, 1998
PLIVA	50MG; 25MG	A074107	001	Sep 24, 1997
	100MG; 25MG	A074107	002	Sep 24, 1997

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

ZYDUS PHARMS USA INC	18MG	A079017	001	Sep 17, 2010
	25MG	A079017	002	Sep 17, 2010

DISCONTINUED DRUG PRODUCT LIST

6 - 38 (of 360)

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

ZYDUS PHARMS USA INC	40MG	A079017	003	Sep 17, 2010
	60MG	A079017	004	Sep 17, 2010
	80MG	A079017	005	Sep 17, 2010
	100MG	A079017	006	Sep 17, 2010

STRATTERA

LILLY	5MG	N021411	001	Nov 26, 2002

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

TEVA PHARMS	EQ 10MG BASE	A078773	001	May 29, 2012
	EQ 20MG BASE	A078773	002	May 29, 2012
	EQ 40MG BASE	A078773	003	May 29, 2012
	EQ 80MG BASE	A078773	004	May 29, 2012

ATOVAQUONE

TABLET; ORAL

MEPRON

GLAXOSMITHKLINE LLC	250MG **Federal Register determination that product was not discontinued or withdrawn for safety of efficacy reasons**	N020259	001	Nov 25, 1992

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

BAXTER HLTHCARE	10MG/ML	A074824	001	Sep 30, 1997
BAXTER HLTHCARE CORP	10MG/ML	A074753	001	Jan 23, 1997
HOSPIRA	10MG/ML	A074632	001	Dec 23, 1996
	10MG/ML	A074740	001	Mar 28, 1997
MARSAM PHARMS LLC	10MG/ML	A074945	001	Jul 28, 1998
TEVA PARENTERAL	10MG/ML	A074784	001	Jun 11, 1997

ATRACURIUM BESYLATE PRESERVATIVE FREE

BAXTER HLTHCARE	10MG/ML	A074825	001	Sep 30, 1997
BAXTER HLTHCARE CORP	10MG/ML	A074768	001	Jan 23, 1997
HOSPIRA	10MG/ML	A074633	001	Dec 23, 1996
	10MG/ML	A074639	001	Mar 25, 1997
	10MG/ML	A074741	001	Mar 28, 1997
MARSAM PHARMS LLC	10MG/ML	A074944	001	Jul 28, 1998

TRACRIUM

HOSPIRA	10MG/ML	N018831	002	Jun 20, 1985

TRACRIUM PRESERVATIVE FREE

HOSPIRA	10MG/ML	N018831	001	Nov 23, 1983

ATROPINE

INJECTABLE; INJECTION

ATROPINE

ABBVIE	EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987

ATROPINE SULFATE

AEROSOL, METERED; INHALATION

ATROPINE SULFATE

US ARMY	EQ 0.36MG BASE/INH	N020056	001	Sep 19, 1990

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN HALF-STRENGTH

VALEANT	0.025MG;0.5MG	N017744	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 39 (of 360)

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

CAPSULE; ORAL				
DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE				
SCHERER RP	0.025MG;2.5MG	A086440	001	
SOLUTION; ORAL				
COLONAIID				
MEDPOINTE PHARM HLC	0.025MG/5ML;2.5MG/5ML	A085735	001	
LOMANATE				
ALPHARMA US PHARMS	0.025MG/5ML;2.5MG/5ML	A085746	001	
LOMOTIL				
GD SEARLE LLC	0.025MG/5ML;2.5MG/5ML	N012699	001	
TABLET; ORAL				
COLONAIID				
MEDPOINTE PHARM HLC	0.025MG;2.5MG	A085737	001	
DI-ATRO				
MD PHARM	0.025MG;2.5MG	A085266	001	
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE				
ABLE	0.025MG;2.5MG	A040395	001	Nov 27, 2000
ASCOT	0.025MG;2.5MG	A087934	001	Jul 19, 1983
HEATHER	0.025MG;2.5MG	A086798	001	
INWOOD LABS	0.025MG;2.5MG	A085509	001	
IVAX PHARMS	0.025MG;2.5MG	A086727	001	
KV PHARM	0.025MG;2.5MG	A085659	001	
LEDERLE	0.025MG;2.5MG	A086950	001	
MUTUAL PHARM	0.025MG;2.5MG	A085506	001	
PARKE DAVIS	0.025MG;2.5MG	A087131	001	
PVT FORM	0.025MG;2.5MG	A085766	001	
R AND S PHARMA	0.025MG;2.5MG	A085035	001	
ROXANE	0.025MG;2.5MG	A086057	001	
SANDOZ	0.025MG;2.5MG	A086173	001	
USL PHARMA	0.025MG;2.5MG	A087842	001	Mar 29, 1982
VALEANT PHARM INTL	0.025MG;2.5MG	A087195	001	Feb 16, 1982
WATSON LABS	0.025MG;2.5MG	A085876	001	
WEST WARD	0.025MG;2.5MG	A087765	001	Mar 15, 1982
LOGEN				
SUPERPHARM	0.025MG;2.5MG	A088962	001	May 10, 1985
LO-TROL				
VANGARD	0.025MG;2.5MG	A088009	001	Mar 25, 1983
LOW-QUEL				
HALSEY	0.025MG;2.5MG	A085211	001	

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION				
ENLON-PLUS				
MYLAN INSTITUTIONAL	0.14MG/ML;10MG/ML	N019677	001	Nov 06, 1991

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION				
ATROPINE AND DEMEROL				
ABBVIE	0.4MG/ML;50MG/ML	A087853	001	Nov 26, 1982
	0.4MG/ML;75MG/ML	A087847	001	Nov 26, 1982
	0.4MG/ML;100MG/ML	A087848	001	Nov 26, 1982
MEPERIDINE AND ATROPINE SULFATE				
WYETH AYERST	0.4MG/ML;50MG/ML	A085121	001	
	0.4MG/ML;75MG/ML	A085121	002	
	0.4MG/ML;100MG/ML	A085121	003	

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR				
ATNAA				
US ARMY	2.1MG/0.7ML;600MG/0.7ML	N021175	001	Jan 17, 2002

DISCONTINUED DRUG PRODUCT LIST

6 - 40 (of 360)

AZATADINE MALEATE

TABLET; ORAL OPTIMINE				
SCHERING	1MG	N017601	001	

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL TRINALIN				
SCHERING	1MG;120MG	N018506	001	Mar 23, 1982

AZATHIOPRINE

TABLET; ORAL IMURAN				
PROMETHEUS LABS	25MG	N016324	002	

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION IMURAN				
PROMETHEUS LABS	EQ 100MG BASE/VIAL	N017391	001	

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL ASTEPRO				
MEDA PHARMS	EQ 0.125MG BASE/SPRAY	N022203	001	Oct 15, 2008

AZITHROMYCIN

CAPSULE; ORAL ZITHROMAX				
PFIZER	EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050670	001	Nov 01, 1991
FOR SUSPENSION; ORAL AZITHROMYCIN				
SANDOZ	EQ 100MG BASE/5ML	A065297	001	Sep 18, 2006
	EQ 200MG BASE/5ML	A065297	002	Sep 18, 2006
INJECTABLE; INJECTION AZITHROMYCIN				
PLIVA HRVATSKA DOO	EQ 500MG BASE/VIAL	A065265	001	Jan 18, 2007
TEVA PARENTERAL	EQ 500MG BASE/VIAL	N050809	001	Dec 19, 2006
	EQ 2.5GM BASE/VIAL	N050809	002	Dec 19, 2006

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

FOR SUSPENSION, TABLET; ORAL TROVAN/ZITHROMAX COMPLIANCE PAK				
PFIZER	EQ 1GM BASE,N/A;N/A,EQ 100MG BASE	N050762	001	Dec 18, 1998

AZLOCILLIN SODIUM

INJECTABLE; INJECTION AZLIN				
BAYER PHARMS	EQ 2GM BASE/VIAL	A062388	001	Sep 08, 1982
	EQ 2GM BASE/VIAL	A062417	001	Oct 12, 1982
	EQ 2GM BASE/VIAL	N050562	001	Sep 03, 1982
	EQ 3GM BASE/VIAL	A062388	002	Sep 08, 1982
	EQ 3GM BASE/VIAL	A062417	002	Oct 12, 1982
	EQ 3GM BASE/VIAL	N050562	002	Sep 03, 1982
	EQ 4GM BASE/VIAL	A062388	003	Sep 08, 1982
	EQ 4GM BASE/VIAL	A062417	003	Oct 12, 1982
	EQ 4GM BASE/VIAL	N050562	003	Sep 03, 1982

AZTREONAM

INJECTABLE; INJECTION AZACTAM				
BRISTOL MYERS SQUIBB	500MG/VIAL	N050580	001	Dec 31, 1986

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 41 (of 360)

AZTREONAM

INJECTABLE; INJECTION				
AZACTAM IN PLASTIC CONTAINER				
BRISTOL MYERS SQUIBB	10MG/ML	N050632	003	May 24, 1989

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION; ORAL				
SPECTROBID				
PFIZER	125MG/5ML	N050556	001	Mar 23, 1982
TABLET; ORAL				
SPECTROBID				
PFIZER	400MG	N050520	001	
	800MG	N050520	002	Sep 12, 1983

BACITRACIN

INJECTABLE; INJECTION				
BACITRACIN				
PFIZER	50,000 UNITS/VIAL	A060282	001	
OINTMENT; OPHTHALMIC				
BACIGUENT				
PHARMACIA AND UPJOHN	500 UNITS/GM	A060734	001	
BACITRACIN				
LILLY	500 UNITS/GM	A060687	001	
PHARMADERM	500 UNITS/GM	A062158	001	
PHARMAFAIR	500 UNITS/GM	A062453	001	Mar 28, 1984
OINTMENT; TOPICAL				
BACITRACIN				
COMBE	500 UNITS/GM	A062799	001	May 14, 1987
NASKA	500 UNITS/GM	A062857	001	Nov 13, 1987
POWDER; FOR RX COMPOUNDING				
BACITRACIN				
APOTHEKERNES	5,000,000 UNITS/BOT	A061699	001	
PADDOCK LLC	5,000,000 UNITS/BOT	A062456	001	Jul 27, 1983

BACITRACIN ZINC

POWDER; FOR RX COMPOUNDING				
ZIBA-RX				
X GEN PHARMS	500,000 UNITS/BOT	A061737	001	

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC				
CORTISPORIN				
MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050416	002	
ZINC BACITRACIN, NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE				
PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062389	001	Jul 02, 1982
OINTMENT; TOPICAL				
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE				
PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062381	001	Sep 06, 1985

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL				
LANABIOTIC				
COMBE	400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM;5,000 UNITS/GM	A062499	001	Jun 03, 1985

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC				
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE				
PHARMAFAIR	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062386	001	Sep 09, 1982

DISCONTINUED DRUG PRODUCT LIST

6 - 42 (of 360)

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC				
BACITRACIN-NEOMYCIN-POLYMYXIN				
PHARMADERM	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062167	001	
NEO-POLYCIN				
DOW PHARM	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060647	001	
NEOSPORIN				
MONARCH PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050417	001	
OINTMENT; TOPICAL				
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE				
NASKA	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062833	001	Nov 09, 1987

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL; TOPICAL				
POLYSPORIN				
GLAXOSMITHKLINE	10,000 UNITS/GM;2,000,000 UNITS/GM	N050167	002	Mar 01, 1985
OINTMENT; OPHTHALMIC				
OCUMYCIN				
PHARMAFAIR	500 UNITS/GM;10,000 UNITS/GM	A062430	001	Apr 08, 1983
POLYSPORIN				
MONARCH PHARMS	500 UNITS/GM;10,000 UNITS/GM	A061229	001	
OINTMENT; TOPICAL				
BACITRACIN ZINC-POLYMYXIN B SULFATE				
NASKA	500 UNITS/GM;10,000 UNITS/GM	A062849	001	Nov 13, 1987

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC				
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE				
ALTANA	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060731	002	

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC				
MYCITRACIN				
PHARMACIA AND UPJOHN	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A061048	001	

BACITRACIN; POLYMYXIN B SULFATE

DISC; TOPICAL				
LANABIOTIC				
COMBE	500 UNITS/GM;5,000 UNITS/GM	N050598	001	Sep 22, 1986

BACLOFEN

TABLET; ORAL				
BACLOFEN				
TEVA	10MG	A073043	001	Feb 27, 1992
	20MG	A073044	001	Feb 27, 1992
USL PHARMA	10MG	A071260	001	May 06, 1988
	20MG	A071261	001	May 06, 1988
WATSON LABS	10MG	A073092	001	Jan 28, 1994
	10MG	A074698	001	Aug 20, 1996
	20MG	A073093	001	Jan 28, 1994
	20MG	A074698	002	Aug 20, 1996
LIORESAL				
NOVARTIS	10MG	N017851	001	
	20MG	N017851	003	Jan 20, 1982
TABLET, ORALLY DISINTEGRATING; ORAL				
KEMSTRO				
UCB INC	10MG	N021589	001	Oct 30, 2003
	20MG	N021589	002	Oct 30, 2003

DISCONTINUED DRUG PRODUCT LIST

6 - 43 (of 360)

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

BECLOVENT

GLAXOSMITHKLINE 0.042MG/INH

N018153 001

VANCERIL

SCHERING 0.042MG/INH

N017573 001

VANCERIL DOUBLE STRENGTH

SCHERING 0.084MG/INH

N020486 001 Dec 24, 1996

AEROSOL, METERED; NASAL

BECONASE

GLAXOSMITHKLINE 0.042MG/INH

N018584 001

VANCENASE

SCHERING 0.042MG/INH

N018521 001

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

VANCENASE AQ

SCHERING EQ 0.042MG DIPROP/SPRAY

N019589 001 Dec 23, 1987

EQ 0.084MG DIPROP/SPRAY

N020469 001 Jun 26, 1996

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

GENPHARM 5MG

A076476 001 Feb 11, 2004

10MG

A076476 002 Feb 11, 2004

20MG

A076476 003 Feb 11, 2004

40MG

A076476 004 Feb 11, 2004

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

MYLAN PHARMS INC 5MG;6.25MG

A076612 001 Feb 11, 2004

10MG;12.5MG

A076612 002 Feb 11, 2004

20MG;12.5MG

A076612 003 Feb 11, 2004

20MG;25MG

A076612 004 Feb 11, 2004

BENDROFLUMETHIAZIDE

TABLET; ORAL

NATURETIN-10

APOTHECON 10MG

N012164 003

NATURETIN-2.5

APOTHECON 2.5MG

N012164 001

NATURETIN-5

APOTHECON 5MG

N012164 002

BENOXINATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BENOXINATE HYDROCHLORIDE

SOLA BARNES HIND 0.4%

A084149 001

BENTIROMIDE

SOLUTION; ORAL

CHYMEX

SAVAGE LABS 500MG/7.5ML

N018366 001 Dec 29, 1983

BENZONATATE

CAPSULE; ORAL

BENZONATATE

NESHER PHARMS 100MG

A040795 001 Oct 31, 2007

200MG

A040795 002 Oct 31, 2007

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 44 (of 360)

BENZPHETAMINE HYDROCHLORIDETABLET; ORAL
DIDREX

PHARMACIA AND UPJOHN 25MG

N012427 003

BENZQUINAMIDE HYDROCHLORIDEINJECTABLE; INJECTION
EMETE-CON

PFIZER

EQ 50MG BASE/VIAL

N016820 001

SUPPOSITORY; RECTAL
EMETE-CON

ROERIG

EQ 100MG BASE

N016818 006

BENZTHIAZIDETABLET; ORAL
AQUATAG

SOLVAY

25MG

N016001 001

50MG

N016001 002

BENZTHIAZIDE

PVT FORM

50MG

A083206 001

EXNA

AH ROBINS INC

50MG

N012489 001

FOVANE

PFIZER

50MG

N012128 002

URESE

PFIZER

25MG

N012128 003

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

LANNETT HOLDINGS INC

0.5MG

A088877 001 Apr 11, 1985

1MG

A088894 001 Apr 11, 1985

2MG

A088895 001 Apr 11, 1985

MUTUAL PHARM

1MG

A081264 001 Jan 23, 1992

2MG

A081265 001 Jan 23, 1992

QUANTUM PHARMICS

0.5MG

A088514 001 Jan 31, 1984

1MG

A088510 001 Jan 31, 1984

2MG

A088511 001 Jan 31, 1984

USL PHARMA

0.5MG

A089211 001 Jun 14, 1988

1MG

A089212 001 Jun 14, 1988

2MG

A089213 001 Jun 14, 1988

COGENTIN

MERCK

0.5MG

N009193 004

1MG

N009193 003

2MG

N009193 002

BENZYL BENZOATEEMULSION; TOPICAL
BENZYL BENZOATE

LANNETT

50%

A084535 001

BEPRIDIL HYDROCHLORIDETABLET; ORAL
BEPADIN

MEDPOINTE PHARM HLC

200MG

N019001 001 Dec 28, 1990

300MG

N019001 002 Dec 28, 1990

400MG

N019001 003 Dec 28, 1990

VASCOR

JOHNSON AND JOHNSON

200MG

N019002 001 Dec 28, 1990

300MG

N019002 002 Dec 28, 1990

400MG

N019002 003 Dec 28, 1990

DISCONTINUED DRUG PRODUCT LIST

6 - 45 (of 360)

BETA CAROTENE

CAPSULE; ORAL SOLATENE ROCHE	30MG	N017589	001	

BETAMETHASONE

CREAM; TOPICAL CELESTONE SCHERING	0.2%	N014762	001	
SYRUP; ORAL CELESTONE SCHERING	0.6MG/5ML	N014215	002	
TABLET; ORAL CELESTONE SCHERING	0.6MG	N012657	003	

BETAMETHASONE BENZOATE

CREAM; TOPICAL UTICORT PARKE DAVIS	0.025%	N016998	002	
GEL; TOPICAL UTICORT PARKE DAVIS	0.025%	N017244	001	
LOTION; TOPICAL UTICORT PARKE DAVIS	0.025%	N017528	001	
OINTMENT; TOPICAL UTICORT PARKE DAVIS	0.025%	N018089	001	

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL ALPHATREX SAVAGE LABS	EQ 0.05% BASE	N019138	001	Jun 26, 1984
BETAMETHASONE DIPROPIONATE PERRIGO NEW YORK	EQ 0.05% BASE	A072536	001	Jan 31, 1990
	EQ 0.05% BASE	A074579	001	Nov 26, 1997
PHARMADERM	EQ 0.05% BASE	N019136	001	Jun 26, 1984
TARO	EQ 0.05% BASE	A071143	001	Jun 17, 1987
TEVA	EQ 0.05% BASE	A071476	001	Aug 10, 1987
DIPROSONE SCHERING	EQ 0.05% BASE	N017536	001	
CREAM, AUGMENTED; TOPICAL DIPROLENE SCHERING	EQ 0.05% BASE	N019408	001	Jan 31, 1986
DISC; TOPICAL DIPROSONE SCHERING	EQ 0.1% BASE	N017829	001	
GEL, AUGMENTED; TOPICAL DIPROLENE SCHERING	EQ 0.05% BASE	N019408	002	Nov 22, 1991
LOTION; TOPICAL ALPHATREX SAVAGE LABS	EQ 0.05% BASE	A070273	001	Aug 12, 1985
BETAMETHASONE DIPROPIONATE ALPHARMA US PHARMS	EQ 0.05% BASE	A071085	001	Feb 03, 1987
PHARMADERM	EQ 0.05% BASE	A070274	001	Aug 12, 1985
TARO	EQ 0.05% BASE	A072276	001	Aug 24, 1988
	EQ 0.05% BASE	A074272	001	Sep 30, 1994
TEVA PHARMS	EQ 0.05% BASE	A071882	001	Jun 06, 1988
DIPROSONE SCHERING	EQ 0.05% BASE	N017781	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 46 (of 360)

BETAMETHASONE DIPROPIONATE

OINTMENT; TOPICAL

ALPHATREX

SAVAGE LABS EQ 0.05% BASE

N019143 001 Sep 04, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK EQ 0.05% BASE

A072526 001 Jan 31, 1990

PHARMADERM EQ 0.05% BASE

N019140 001 Sep 04, 1984

TEVA EQ 0.05% BASE

A071477 001 Aug 10, 1987

DIPROSONE

SCHERING EQ 0.05% BASE

N017691 001

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE SODIUM PHOSPHATE

WATSON LABS EQ 3MG BASE/ML

A085738 001

CELESTONE

SCHERING EQ 3MG BASE/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

N017561 001

BETAMETHASONE VALERATE

CREAM; TOPICAL

BETADERM

ROACO EQ 0.1% BASE

N018839 001 Jun 30, 1983

BETAMETHASONE VALERATE

PERRIGO NEW YORK EQ 0.1% BASE

A070053 001 Jun 10, 1986

PHARMADERM EQ 0.1% BASE

N018860 002 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE

A070485 001 May 29, 1987

TARO EQ 0.1% BASE

A070062 001 May 14, 1985

BETATREX

SAVAGE LABS EQ 0.1% BASE

N018862 001 Aug 31, 1983

VALISONE

SCHERING EQ 0.01% BASE

N016322 002

EQ 0.1% BASE

N016322 001

LOTION; TOPICAL

BETAMETHASONE VALERATE

PHARMADERM EQ 0.1% BASE

N018870 001 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE

A070484 001 May 29, 1987

TEVA PHARMS EQ 0.1% BASE

A071883 001 Apr 22, 1988

BETATREX

SAVAGE LABS EQ 0.1% BASE

N018867 001 Aug 31, 1983

VALISONE

SCHERING EQ 0.1% BASE

N016932 001

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

PERRIGO NEW YORK EQ 0.1% BASE

A071478 001 Dec 23, 1987

PHARMADERM EQ 0.1% BASE

N018864 001 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE

A070486 001 May 29, 1987

BETATREX

SAVAGE LABS EQ 0.1% BASE

N018863 001 Aug 31, 1983

BETA-VAL

TEVA EQ 0.1% BASE

A070069 001 Dec 19, 1985

VALISONE

SCHERING EQ 0.1% BASE

N016740 001

BETAXOLOL HYDROCHLORIDE

TABLET; ORAL

KERLONE

SANOFI AVENTIS US 10MG

N019507 001 Oct 27, 1989

20MG

N019507 002 Oct 27, 1989

DISCONTINUED DRUG PRODUCT LIST

6 - 47 (of 360)

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET; ORAL
KERLEDEX

SANOFI AVENTIS US	5MG;12.5MG	N019807	001	Oct 30, 1992
	10MG;12.5MG	N019807	002	Oct 30, 1992

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
BETOPTIC PILO

ALCON	EQ 0.25% BASE;1.75%	N020619	001	Apr 17, 1997

BETAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION
HISTALOG
LILLY

50MG/ML	N009344	001

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION
URECHOLINE

ODYSSEY PHARMS	5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006536	001

TABLET; ORAL

BETHANECHOL CHLORIDE

ABLE	5MG	A040492	001	Jul 27, 2004
	10MG	A040483	001	Jul 27, 2004
	25MG	A040485	001	Jul 27, 2004
	50MG	A040509	001	Jul 27, 2004
ACTAVIS TOTOWA	5MG	A040552	001	Oct 28, 2004
	10MG	A040553	001	Oct 28, 2004
	25MG	A040554	001	Oct 28, 2004
	50MG	A040551	001	Oct 28, 2004
ASCOT	10MG	A088288	001	Jun 08, 1983
	25MG	A088289	001	Jun 08, 1983
IVAX SUB TEVA PHARMS	25MG	A084689	001	
LANNETT	5MG	A084702	001	
	10MG	A084712	001	
	25MG	A084074	001	
SANDOZ	5MG	A084353	001	
	10MG	A084378	001	
	10MG	A084379	001	
	25MG	A084383	001	
	25MG	A084384	001	
WATSON LABS	5MG	A084402	001	
	5MG	A085230	002	
	5MG	A085841	001	
	10MG	A084408	001	
	10MG	A085228	001	
	10MG	A085842	001	
	25MG	A084441	001	
	25MG	A085229	001	
	25MG	A085839	001	
	50MG	A087397	001	
	50MG	A087444	001	
MYOTONACHOL				
GLENWOOD	5MG	A084188	001	
	10MG	A084188	003	
	25MG	A084188	004	
URECHOLINE				
ODYSSEY PHARMS	5MG	N006536	003	
	10MG	N006536	002	
	25MG	N006536	004	
	50MG	N006536	005	

DISCONTINUED DRUG PRODUCT LIST

6 - 48 (of 360)

BETHANIDINE SULFATE

TABLET; ORAL
TENATHAN

ROBINS AH	10MG	N017675	001
	25MG	N017675	002

BIPERIDEN LACTATE

INJECTABLE; INJECTION

AKINETON

ABBVIE	5MG/ML	N012418	002

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE; ORAL
HALFLYTELY

BRAINTREE	5MG, N/A; N/A, 210GM; N/A, 0.74GM; N/A, 2.86GM ; N/A, 5.6GM	N021551	002	Sep 24, 2007

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

MUTUAL PHARM	5MG	A075474	001	Oct 25, 2002
	10MG	A075474	002	Oct 25, 2002

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

ACTAVIS ELIZABETH	2.5MG; 6.25MG	A075672	001	Sep 25, 2000
	5MG; 6.25MG	A075672	002	Sep 25, 2000
	10MG; 6.25MG	A075672	003	Sep 25, 2000
APOTHECON	2.5MG; 6.25MG	A075642	002	Dec 27, 2000
	5MG; 6.25MG	A075642	001	Dec 27, 2000
	10MG; 6.25MG	A075642	003	Dec 27, 2000
IVAX SUB TEVA PHARMS	2.5MG; 6.25MG	A075632	001	Sep 27, 2000
	5MG; 6.25MG	A075632	002	Sep 27, 2000
	10MG; 6.25MG	A075632	003	Sep 27, 2000
SANDOZ	2.5MG; 6.25MG	A075527	001	Sep 25, 2000
	5MG; 6.25MG	A075527	003	Sep 25, 2000
	10MG; 6.25MG	A075527	002	Sep 25, 2000
TEVA	2.5MG; 6.25MG	A075686	001	Jan 19, 2001
	5MG; 6.25MG	A075686	002	Jan 19, 2001
	10MG; 6.25MG	A075686	003	Jan 19, 2001

BITOLTEROL MESYLATE

AEROSOL, METERED; INHALATION

TORNALATE

SANOFI AVENTIS US	0.37MG/INH	N018770	001	Dec 28, 1984

SOLUTION; INHALATION

TORNALATE

SANOFI AVENTIS US	0.2%	N019548	001	Feb 19, 1992

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLENOXANE

BRISTOL MYERS SQUIBB	EQ 15 UNITS BASE/VIAL	N050443	001	
	EQ 30 UNITS BASE/VIAL	N050443	002	Sep 07, 1995

BLEOMYCIN SULFATE

TEVA PARENTERAL	EQ 15 UNITS BASE/VIAL	A064084	001	Jun 01, 1996
	EQ 30 UNITS BASE/VIAL	A064084	002	Jun 01, 1996

DISCONTINUED DRUG PRODUCT LIST

6 - 49 (of 360)

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

ABRAXIS PHARM	50MG/ML	A070134	001	Apr 29, 1986
	100MG/ML	A071298	001	Feb 13, 1987
ASTRAZENECA	50MG/ML	A071151	001	Aug 10, 1987
	50MG/ML	A071152	001	Aug 10, 1987
	50MG/ML	A071153	001	Aug 10, 1987
HIKMA MAPLE	50MG/ML	A070545	001	May 14, 1986
	50MG/ML	A070546	001	May 14, 1986
HOSPIRA	50MG/ML	N019030	001	Apr 29, 1986
	50MG/ML	N019033	001	Apr 29, 1986
INTL MEDICATION	50MG/ML	A070119	001	Apr 29, 1986
LUITPOLD	50MG/ML	A070891	001	Jul 26, 1988
BRETYLIUM TOSYLATE IN DEXTROSE 5%				
ABBOTT	200MG/100ML	N019005	002	Apr 29, 1986
	400MG/100ML	N019005	003	Apr 29, 1986
	800MG/100ML	N019005	001	Apr 29, 1986
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	200MG/100ML	N019837	002	Apr 12, 1989
	400MG/100ML	N019837	001	Apr 12, 1989
HOSPIRA INC	200MG/100ML	N019008	002	Apr 29, 1986
	400MG/100ML	N019008	003	Apr 29, 1986
	800MG/100ML	N019008	001	Apr 29, 1986
BRETYLOL				
HOSPIRA	50MG/ML	N017954	001	

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN

ALLERGAN	0.2%	N020613	001	Sep 06, 1996
	0.5%	N020490	001	Mar 13, 1997
BRIMONIDINE TARTRATE				
TEVA PARENTERAL	0.2%	A076372	001	Sep 10, 2004

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

XIBROM

ISTA PHARMS INC	0.09%	N021664	001	Mar 24, 2005

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

BROMOCRIPTINE MESYLATE

LEK PHARM	EQ 5MG BASE	A075100	001	Dec 10, 1998

BROMODIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

AMBODRYL

PARKE DAVIS	25MG	N007984	001	

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL

AMBENYL

FOREST LABS	12.5MG/5ML;10MG/5ML	N009319	006	Jan 10, 1984

BROMANYL

ALPHARMA US PHARMS	12.5MG/5ML;10MG/5ML	A088343	001	Aug 15, 1984

BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE

WOCKHARDT	12.5MG/5ML;10MG/5ML	A088626	001	Oct 12, 1984

BROMPHENIRAMINE MALEATE

ELIXIR; ORAL

BROMPHENIRAMINE MALEATE

ALPHARMA US PHARMS	2MG/5ML	A086936	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 50 (of 360)

BROMPHENIRAMINE MALEATE

ELIXIR; ORAL

BROMPHENIRAMINE MALEATE

KV PHARM 2MG/5ML A085466 001

PHARM ASSOC 2MG/5ML A087517 001

USL PHARMA 2MG/5ML A087964 001 Jan 25, 1983

INJECTABLE; INJECTION

BROMPHENIRAMINE MALEATE

WATSON LABS 10MG/ML A083821 001

100MG/ML A083820 001

DIMETANE-TEN

WYETH AYERST 10MG/ML N011418 002

TABLET; ORAL

BROMPHENIRAMINE MALEATE

BARR 4MG A084468 001

IVAX SUB TEVA PHARMS 4MG A084351 001

NEWTRON PHARMS 4MG A086987 001

NEXGEN PHARMA INC 4MG A086187 001

PAR PHARM 4MG A087009 001

PIONEER PHARMS 4MG A088604 001 Jul 13, 1984

SANDOZ 4MG A083215 001

VITARINE 4MG A085850 001

WATSON LABS 4MG A083123 001

4MG A085769 001

DIMETANE

WYETH CONS 4MG N010799 003

TABLET, EXTENDED RELEASE; ORAL

DIMETANE

WYETH CONS 8MG N010799 010 Jun 10, 1983

12MG N010799 011 Jun 10, 1983

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

BROMANATE DC

ALPHARMA US PHARMS 2MG/5ML;10MG/5ML;12.5MG/5ML A088723 001 Feb 25, 1985

DIMETANE-DC

ROBINS AH 2MG/5ML;10MG/5ML;12.5MG/5ML N011694 006 Mar 29, 1984

MYPHETANE DC

WOCKHARDT 2MG/5ML;10MG/5ML;12.5MG/5ML A088904 001 Feb 21, 1985

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMANATE DM

ALPHARMA US PHARMS 2MG/5ML;10MG/5ML;30MG/5ML A088722 001 Mar 07, 1985

BROMFED-DM

WOCKHARDT 2MG/5ML;10MG/5ML;30MG/5ML A089681 001 Dec 22, 1988

DIMETANE-DX

ROBINS AH 2MG/5ML;10MG/5ML;30MG/5ML N019279 001 Aug 24, 1984

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR; ORAL

BIPHETAP

MORTON GROVE 4MG/5ML;25MG/5ML A088687 001 Sep 26, 1984

BROMANATE

ALPHARMA US PHARMS 4MG/5ML;25MG/5ML A088688 001 Feb 06, 1985

DIMETAPP

WYETH CONS 2MG/5ML;12.5MG/5ML N013087 003 Mar 29, 1984

TABLET, EXTENDED RELEASE; ORAL

BROMATAPP

COPLEY PHARM 12MG;75MG A071099 001 Jul 02, 1987

DIMETAPP

WYETH CONS 12MG;75MG N012436 003 May 14, 1985

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 51 (of 360)

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL				
EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE				
ALZA	16MG;240MG	N019672	001	Mar 29, 1996

BUCLIZINE HYDROCHLORIDE

TABLET; ORAL				
BUCLADIN-S				
STUART PHARMS	50MG	N010911	006	

BUDESONIDE

AEROSOL, METERED; NASAL				
RHINOCORT				
ASTRAZENECA	0.032MG/INH	N020233	001	Feb 14, 1994
POWDER, METERED; INHALATION				
PULMICORT				
ASTRAZENECA	0.16MG/INH	N020441	002	Jun 24, 1997
	0.32MG/INH	N020441	003	Jun 24, 1997
SPRAY, METERED; NASAL				
RHINOCORT				
ASTRAZENECA	0.064MG/INH	N020746	002	Oct 01, 1999

BUMETANIDE

INJECTABLE; INJECTION				
BUMETANIDE				
HOSPIRA	0.25MG/ML	A074160	001	Oct 30, 1997
TEVA PARENTERAL	0.25MG/ML	A074613	001	Nov 18, 1997
BUMEX				
VALIDUS PHARMS INC	0.25MG/ML	N018226	001	Feb 28, 1983
TABLET; ORAL				
BUMEX				
VALIDUS PHARMS INC	0.5MG	N018225	002	Feb 28, 1983
	1MG	N018225	001	Feb 28, 1983
	2MG	N018225	003	Jun 14, 1985

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION				
EXPAREL				
PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION				
BUPIVACAINE HYDROCHLORIDE KIT				
HOSPIRA	0.075%	N019978	001	Sep 03, 1992
	0.114%	N019978	002	Sep 03, 1992
	0.23%	N019978	003	Sep 03, 1992

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION				
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE				
HOSPIRA	0.25%;0.005MG/ML	A071166	001	Jun 16, 1988
	0.5%;0.005MG/ML	A071169	001	Jun 16, 1988
	0.75%;0.005MG/ML	A071171	001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION				
DUOCAINE				
AMPHASTAR PHARMS INC	EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML)	N021496	001	May 23, 2003

DISCONTINUED DRUG PRODUCT LIST

6 - 52 (of 360)

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL
SUBUTEX

RECKITT BENCKISER	EQ 2MG BASE	N020732	002	Oct 08, 2002
	EQ 8MG BASE	N020732	003	Oct 08, 2002

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

SANDOZ	75MG	A075613	002	Oct 10, 2000
	100MG	A075613	001	Oct 10, 2000

WELLBUTRIN

GLAXOSMITHKLINE	50MG	N018644	001	Dec 30, 1985

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

SANDOZ	100MG	A076845	001	Jul 14, 2005
	150MG	A076834	001	Jul 14, 2005
	150MG	A076845	002	Jul 14, 2005

WELLBUTRIN SR

GLAXOSMITHKLINE	50MG	N020358	001	Oct 04, 1996

ZYBAN

GLAXOSMITHKLINE	100MG	N020711	002	May 14, 1997

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL

BUSPAR

BRISTOL MYERS SQUIBB	5MG	N021190	001	Dec 20, 2000
	7.5MG	N021190	002	Dec 20, 2000
	10MG	N021190	003	Dec 20, 2000
	15MG	N021190	004	Dec 20, 2000

TABLET; ORAL

BUSPAR

BRISTOL MYERS SQUIBB	5MG	N018731	001	Sep 29, 1986
	10MG	N018731	002	Sep 29, 1986
	15MG	N018731	003	Apr 22, 1996
	30MG	N018731	004	Apr 22, 1996

BUSPIRONE HYDROCHLORIDE

APOTEX	5MG	A075521	001	Apr 05, 2002
	10MG	A075521	002	Apr 05, 2002
	15MG	A075521	003	Apr 05, 2002
EGIS	5MG	A075119	001	Mar 14, 2002
	10MG	A075119	002	Mar 14, 2002
	15MG	A075119	003	Jan 23, 2003
IVAX SUB TEVA PHARMS	5MG	A075385	001	Mar 01, 2002
	10MG	A075385	002	Mar 01, 2002
	15MG	A075385	003	Mar 01, 2002
NESHER PHARMS	5MG	A075572	001	Feb 27, 2002
	10MG	A075572	002	Feb 27, 2002
	15MG	A075572	003	Feb 27, 2002
PROSAM LABS	5MG	A075388	001	May 09, 2002
	10MG	A075388	002	May 09, 2002
	15MG	A075388	003	May 09, 2002
SANDOZ	5MG	A075413	001	Mar 19, 2002
	10MG	A075413	002	Mar 19, 2002
	15MG	A075413	003	Mar 19, 2002

BUTABARBITAL SODIUM

CAPSULE; ORAL

BUTICAPS

MEDPOINTE PHARM HLC	15MG	A085381	001	
	30MG	A085381	002	
	50MG	A085381	003	
	100MG	A085381	004	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 53 (of 360)

BUTABARBITAL SODIUM

ELIXIR; ORAL

BUTABARB

ALPHARMA US PHARMS

30MG/5ML

A085873 001

BUTABARBITAL SODIUM

WOCKHARDT

30MG/5ML

A085383 001

BUTALAN

LANNETT

33.3MG/5ML

A085880 001

SARISOL

HALSEY

30MG/5ML

A084723 001

TABLET; ORAL

BUTABARBITAL

BUNDY

30MG

A085550 001

BUTABARBITAL SODIUM

SANDOZ

15MG

A084292 003

Feb 09, 1982

15MG

A085938 001

30MG

A084272 002

30MG

A085934 001

SOLVAY

16.2MG

A083606 001

32.4MG

A083898 001

48.6MG

A083897 001

97.2MG

A083896 001

TEVA

15MG

A088632 001

May 18, 1985

30MG

A088631 001

May 01, 1985

WATSON LABS

15MG

A085764 001

30MG

A085772 001

WHITEWORTH TOWN PLSN

15MG

A083325 002

30MG

A083337 001

BUTISOL SODIUM

MEDA PHARMS

15MG

N000793 002

100MG

N000793 005

SARISOL NO. 1

HALSEY

15MG

A084719 001

SARISOL NO. 2

HALSEY

30MG

A084719 002

SODIUM BUTABARBITAL

IVAX SUB TEVA PHARMS

15MG

A083484 001

30MG

A084040 001

LANNETT

15MG

A085849 001

30MG

A085866 001

100MG

A085881 001

MARSHALL PHARMA

16.2MG

A083524 001

32.4MG

A083858 001

WEST WARD

15MG

A085418 001

30MG

A085432 001

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT

ROCHE PALO

2%

N019215 001

Nov 25, 1985

SUPPOSITORY; VAGINAL

FEMSTAT

ROCHE PALO

100MG

N019359 001

Nov 25, 1985

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

HOSPIRA

1MG/ML

A075342 001

Nov 04, 1999

1MG/ML

A075559 001

Mar 20, 2000

2MG/ML

A075342 002

Nov 04, 1999

2MG/ML

A075559 002

Mar 20, 2000

BUTORPHANOL TARTRATE PRESERVATIVE FREE

HOSPIRA

1MG/ML

A074620 001

Jan 22, 1997

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 54 (of 360)

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE PRESERVATIVE FREE

HOSPIRA	1MG/ML	A075170	001	Sep 28, 1998
	2MG/ML	A074620	002	Jan 22, 1997
	2MG/ML	A075170	002	Sep 28, 1998

SPRAY, METERED; NASAL

STADOL

BRISTOL MYERS SQUIBB	1MG/SPRAY	N019890	001	Dec 12, 1991

CABERGOLINE

TABLET; ORAL

DOSTINEX

PHARMACIA AND UPJOHN	0.5MG	N020664	001	Dec 23, 1996

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

CAFERGOT

NOVARTIS	100MG;2MG	N009000	002	

TABLET; ORAL

CAFERGOT

NOVARTIS	100MG;1MG	N006620	001	

WIGRAINE

ORGANON USA INC	100MG;1MG	A086562	001	

CALCIFEDIOL

CAPSULE; ORAL

CALDEROL

ORGANON USA INC	0.02MG	N018312	001	
	0.05MG	N018312	002	

CALCIPOTRIENE

OINTMENT; TOPICAL

DOVONEX

LEO PHARM	0.005%	N020273	001	Dec 29, 1993

CALCITONIN HUMAN

INJECTABLE; INJECTION

CIBACALCIN

NOVARTIS	0.5MG/VIAL	N018470	001	Oct 31, 1986

CALCITONIN SALMON

INJECTABLE; INJECTION

CALCIMAR

SANOFI AVENTIS US	200 IU/ML	N017769	001	
	400 IU/VIAL	N017497	001	

CALCITONIN-SALMON

ASTRAZENECA	200 IU/ML	A073690	001	Apr 14, 1995

MIACALCIN

NOVARTIS	100 IU/ML	N017808	001	Jul 03, 1986

CALCITRIOL

INJECTABLE; INJECTION

CALCITRIOL

HOSPIRA	0.001MG/ML	A075816	001	Jan 16, 2004
	0.002MG/ML	A075816	002	Jan 16, 2004
TEVA PARENTERAL	0.001MG/ML	A075823	001	Mar 31, 2003

CALCIUM ACETATE

CAPSULE; ORAL

PHOSLO

FRESENIUS MEDCL	EQ 84.5MG CALCIUM	N021160	001	Apr 02, 2001
	EQ 169MG CALCIUM	N021160	002	Apr 02, 2001

DISCONTINUED DRUG PRODUCT LIST

6 - 55 (of 360)

CALCIUM ACETATE

TABLET; ORAL
CALCIUM ACETATE

ROXANE	EQ 169MG CALCIUM	A077693	001	Jan 30, 2008
PHOSLO				
FRESENIUS MEDCL	EQ 169MG CALCIUM	N019976	001	Dec 10, 1990

CALCIUM CARBONATE; RISEDRONATE SODIUM

TABLET, TABLET; ORAL
ACTONEL WITH CALCIUM (COPACKAGED)

WARNER CHILCOTT	EQ 500MG BASE,N/A;N/A,35MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021823	001	Aug 12, 2005

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML	N021703	012	Oct 10, 2008

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML	N021703	005	Oct 25, 2006

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML	N021703	008	Oct 25, 2006

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML	N021703	007	Oct 25, 2006

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML	N021703	009	Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML	N018271	001	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N018269	002	Jan 17, 1983

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML;2.5GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460	006	Jan 29, 1986

DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML;1.5GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460	001	

DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML;4.25GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460	003	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 56 (of 360)

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML;1.5GM/100ML;15MG/100ML;560MG /100ML;390MG/100ML	N018460	002	

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML;5GM/100ML;5MG/100ML;530MG/10 0ML;450MG/100ML	N018460	008	Jan 29, 1986

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML;4.25GM/100ML;15MG/100ML;560M G/100ML;390MG/100ML	N018460	004	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML;860MG/1 00ML	N018256	001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	4MG/100ML;4GM/100ML;6MG/100ML;120MG/100 ML;62MG/100ML	N019634	002	Feb 24, 1988

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML;600MG/1 00ML;310MG/100ML	N017510	001	

MILES	20MG/100ML;5GM/100ML;30MG/100ML;600MG/1 00ML;310MG/100ML	N018499	001	

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA	20MG/100ML;5GM/100ML;104MG/100ML;600MG/ 100ML;310MG/100ML	N019685	005	Oct 17, 1988

	20MG/100ML;5GM/100ML;179MG/100ML;600MG/ 100ML;310MG/100ML	N019685	006	Oct 17, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA	20MG/100ML;5GM/100ML;254MG/100ML;600MG/ 100ML;310MG/100ML	N019685	007	Oct 17, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA	20MG/100ML;5GM/100ML;254MG/100ML;600MG/ 100ML;310MG/100ML	N019685	003	Oct 17, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA	20MG/100ML;5GM/100ML;104MG/100ML;600MG/ 100ML;310MG/100ML	N019685	001	Oct 17, 1988

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;538MG/100ML;44 8MG/100ML	N019395	001	Mar 26, 1986

INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;538MG/100ML;44 8MG/100ML	N019395	002	Mar 26, 1986

INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;538MG/100ML;4 48MG/100ML	N019395	003	Mar 26, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

ABBOTT	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML; 16.1MG/ML	N019399	001	Jun 16, 1986

DISCONTINUED DRUG PRODUCT LIST

6 - 57 (of 360)

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

B BRAUN	35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N018899	001	Oct 31, 1983

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ACETATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	20MG/100ML;30MG/100ML;380MG/100ML;600MG/100ML	N018725	001	Nov 29, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

B BRAUN	33MG/100ML;30MG/100ML;860MG/100ML	N018721	001	Nov 09, 1982

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

ABBOTT	33MG/100ML;30MG/100ML;860MG/100ML	N018462	001	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

ABBOTT	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N019485	001	Oct 24, 1985

B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N018023	001	

MILES	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N018417	001	

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION

CALCIUM GLUCEPTATE

ABBOTT	EQ 90MG CALCIUM/5ML	A080001	001	
	EQ 90MG CALCIUM/5ML	A083159	001	
ABRAXIS PHARM	EQ 90MG CALCIUM/5ML	A089373	001	Apr 30, 1987
LILLY	EQ 90MG CALCIUM/5ML	N006470	001	

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE; INJECTION

ISOPAQUE 440

GE HEALTHCARE	0.78MG/ML;75.9MG/ML;0.15MG/ML;16.6MG/ML	N016847	001	

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE; INJECTION

ISOPAQUE 280

GE HEALTHCARE	0.35MG/ML;140.1MG/ML;461.8MG/ML	N017506	001	

CANDICIDIN

OINTMENT; VAGINAL

VANOBI

SANOFI AVENTIS US	0.6MG/GM	A061596	001	

TABLET; VAGINAL

VANOBI

SANOFI AVENTIS US	3MG	A061613	001	

CAPTOPRIL

TABLET; ORAL

CAPOTEN

PAR PHARM	37.5MG	N018343	006	Sep 17, 1986
	75MG	N018343	007	Jun 13, 1995
	150MG	N018343	004	Jun 13, 1995

DISCONTINUED DRUG PRODUCT LIST

6 - 58 (of 360)

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

APOTHECON	12.5MG	A074472	001	Mar 31, 1995
	25MG	A074472	002	Mar 31, 1995
	50MG	A074472	003	Mar 31, 1995
	100MG	A074472	004	Mar 31, 1995
CLONMEL HLTHCARE	12.5MG	A074423	001	Feb 13, 1996
	25MG	A074423	002	Feb 13, 1996
	50MG	A074423	003	Feb 13, 1996
	100MG	A074423	004	Feb 13, 1996
EGIS PHARMS	12.5MG	A074748	004	May 29, 1997
	25MG	A074748	002	May 29, 1997
	50MG	A074748	001	May 29, 1997
	100MG	A074748	003	May 29, 1997
IVAX SUB TEVA PHARMS	12.5MG	A074590	004	Aug 30, 1996
	25MG	A074590	002	Aug 30, 1996
	50MG	A074590	001	Aug 30, 1996
	100MG	A074590	003	Aug 30, 1996
PAR PHARM	12.5MG	A074493	001	Feb 13, 1996
	25MG	A074493	002	Feb 13, 1996
	50MG	A074493	003	Feb 13, 1996
	100MG	A074493	004	Feb 13, 1996
PUREPAC PHARM	12.5MG	A074640	001	Mar 31, 1997
	25MG	A074640	002	Mar 31, 1997
	50MG	A074640	003	Mar 31, 1997
	100MG	A074640	004	Mar 31, 1997
SANDOZ	12.5MG	A074481	001	Feb 13, 1996
	12.5MG	A074519	001	Feb 13, 1996
	25MG	A074481	002	Feb 13, 1996
	25MG	A074519	002	Feb 13, 1996
	50MG	A074481	003	Feb 13, 1996
	50MG	A074519	003	Feb 13, 1996
	100MG	A074481	004	Feb 13, 1996
	100MG	A074519	004	Feb 13, 1996
TEVA	12.5MG	A074433	001	Feb 13, 1996
	25MG	A074433	002	Feb 13, 1996
	50MG	A074433	003	Feb 13, 1996
	100MG	A074433	004	Feb 13, 1996
TEVA PHARMS	12.5MG	A074462	001	Feb 13, 1996
	25MG	A074462	002	Feb 13, 1996
	50MG	A074462	003	Feb 13, 1996
	100MG	A074462	004	Feb 13, 1996
VINTAGE PHARMS LLC	12.5MG	A074418	001	Feb 13, 1996
	25MG	A074418	002	Feb 13, 1996
	50MG	A074418	003	Feb 13, 1996
	100MG	A074418	004	Feb 13, 1996
WATSON LABS	12.5MG	A074576	001	Apr 23, 1996
	25MG	A074576	002	Apr 23, 1996
	50MG	A074576	003	Apr 23, 1996
	100MG	A074576	004	Apr 23, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

IVAX SUB TEVA PHARMS	25MG;15MG	A075055	001	Jun 18, 1998
	25MG;25MG	A075055	002	Jun 18, 1998
	50MG;15MG	A075055	004	Jun 18, 1998
	50MG;25MG	A075055	003	Jun 18, 1998
VINTAGE PHARMS LLC	25MG;15MG	A074788	001	Dec 29, 1997
	25MG;25MG	A074788	002	Dec 29, 1997
	50MG;15MG	A074788	004	Dec 29, 1997
	50MG;25MG	A074788	003	Dec 29, 1997

DISCONTINUED DRUG PRODUCT LIST

6 - 59 (of 360)

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL				
CAPTOPRIL AND HYDROCHLOROTHIAZIDE				
WATSON LABS	50MG;25MG	A074832	001	Dec 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR				
CARBACHOL				
PHARMAFAIR	0.01%	A070292	001	May 21, 1986
CARBASTAT				
NOVARTIS	0.01%	A073677	001	Apr 28, 1995

CARBAMAZEPINE

SUSPENSION; ORAL				
CARBAMAZEPINE				
TARO	100MG/5ML	A075875	001	Dec 21, 2000
TABLET; ORAL				
CARBAMAZEPINE				
ACTAVIS ELIZABETH	200MG	A071696	001	Nov 09, 1987
INWOOD LABS	200MG	A070231	001	Aug 14, 1986
PLIVA	200MG	A071479	001	Jul 24, 1987
USL PHARMA	200MG	A070300	001	May 15, 1986
WARNER CHILCOTT	200MG	A070429	001	Jan 02, 1987
TERIL				
TARO	200MG	A076525	001	Sep 26, 2003
TABLET, CHEWABLE; ORAL				
CARBAMAZEPINE				
JUBILANT CADISTA	100MG	A071940	001	Feb 01, 1988

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION				
GEOPEN				
ROERIG	EQ 1GM BASE/VIAL	N050306	001	
	EQ 2GM BASE/VIAL	N050306	004	
	EQ 5GM BASE/VIAL	N050306	002	
	EQ 10GM BASE/VIAL	N050306	006	
	EQ 30GM BASE/VIAL	N050306	007	
PYOPEN				
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050298	001	
	EQ 2GM BASE/VIAL	N050298	002	
	EQ 5GM BASE/VIAL	N050298	003	
	EQ 10GM BASE/VIAL	N050298	006	
	EQ 20GM BASE/VIAL	N050298	007	

CARBENICILLIN INDANYL SODIUM

TABLET; ORAL				
GEOCILLIN				
PFIZER	EQ 382MG BASE	N050435	001	

CARBIDOPA; LEVODOPA

TABLET; ORAL				
CARBIDOPA AND LEVODOPA				
SANDOZ	10MG;100MG	A073586	001	Jun 29, 1995
	25MG;100MG	A073587	001	Jun 29, 1995
	25MG;250MG	A073620	001	Jun 29, 1995
SCS	10MG;100MG	A074080	001	Mar 25, 1994
	25MG;100MG	A074080	002	Mar 25, 1994
	25MG;250MG	A074080	003	Mar 25, 1994
WATSON LABS	10MG;100MG	A073381	001	Sep 28, 1993
	25MG;100MG	A073382	001	Sep 28, 1993
	25MG;250MG	A073383	001	Sep 28, 1993

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 60 (of 360)

CARBIDOPA; LEVODOPATABLET, EXTENDED RELEASE; ORAL
CARBIDOPA AND LEVODOPA

KV PHARM 50MG;200MG

A076663 001 Jun 24, 2004

TABLET, FOR SUSPENSION; ORAL
CARBILEV

RANBAXY 10MG;100MG

A076643 001 Jun 10, 2005

25MG;100MG

A076643 002 Jun 10, 2005

25MG;250MG

A076643 003 Jun 10, 2005

CARBINOXAMINE MALEATEELIXIR; ORAL
CLISTINMCNEIL 4MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

N008955 001

TABLET; ORAL
CLISTIN

ORTHO MCNEIL PHARM 4MG

N008915 001

CARBOPLATININJECTABLE; INJECTION
CARBOPLATIN
HOSPIRA

50MG/VIAL

A076473 001 Oct 27, 2004

150MG/VIAL

A076473 002 Oct 27, 2004

450MG/VIAL

A076473 003 Oct 27, 2004

PARAPLATIN

CORDEN PHARMA

50MG/VIAL

N019880 001 Mar 03, 1989

150MG/VIAL

N019880 002 Mar 03, 1989

450MG/VIAL

N019880 003 Mar 03, 1989

INJECTABLE; IV (INFUSION)
CARBOPLATIN

FRESENIUS KABI USA

50MG/5ML (10MG/ML)

A077247 001 Oct 21, 2004

150MG/15ML (10MG/ML)

A077247 002 Oct 21, 2004

SAGENT PHARMS

50MG/5ML (10MG/ML)

A077096 001 Jun 14, 2005

150MG/15ML (10MG/ML)

A077096 002 Jun 14, 2005

450MG/45ML (10MG/ML)

A077096 003 Jun 14, 2005

TEVA PARENTERAL

50MG/5ML (10MG/ML)

A077389 001 Mar 30, 2007

150MG/15ML (10MG/ML)

A077389 002 Mar 30, 2007

450MG/45ML (10MG/ML)

A077389 003 Mar 30, 2007

PARAPLATIN

BRISTOL MYERS SQUIBB

50MG/5ML (10MG/ML)

N020452 001 Jul 14, 2003

150MG/15ML (10MG/ML)

N020452 002 Jul 14, 2003

450MG/45ML (10MG/ML)

N020452 003 Jul 14, 2003

600MG/60ML (10MG/ML)

N020452 004 Jan 15, 2004

CARISOPRODOLCAPSULE; ORAL
SOMA

MEDA PHARMS

250MG

N011792 003

TABLET; ORAL
CARISOPRODOL

ABLE

350MG

A040421 001 Jun 21, 2001

PIONEER PHARMS

350MG

A089390 001 Oct 13, 1988

SANDOZ

350MG

A081025 001 Apr 13, 1989

350MG

A089566 001 Aug 30, 1988

WATSON LABS

350MG

A040152 001 Dec 03, 1996

350MG

A085433 001

350MG

A086179 001

RELA

SCHERING

350MG

N012155 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 61 (of 360)

CARPHENAZINE MALEATECONCENTRATE; ORAL
PROKETAZINE

WYETH AYERST

50MG/ML

N014173 001

TABLET; ORAL
PROKETAZINE

WYETH AYERST

12.5MG

N012768 001

25MG

N012768 002

50MG

N012768 004

CARPROFENTABLET; ORAL
RIMADYL

ROCHE

100MG

N018550 002 Dec 31, 1987

150MG

N018550 003 Dec 31, 1987

CARTEOLOL HYDROCHLORIDETABLET; ORAL
CARTROL

ABBVIE

2.5MG

N019204 001 Dec 28, 1988

5MG

N019204 002 Dec 28, 1988

10MG

N019204 003 Dec 28, 1988

CEFACLORCAPSULE; ORAL
CECLOR

LILLY

EQ 250MG BASE

N050521 001

EQ 500MG BASE

N050521 002

CEFACLOR

CEPH INTL

EQ 250MG BASE

A062205 001

EQ 500MG BASE

A062205 002

CLONMEL HLTHCARE

EQ 250MG BASE

A064107 001 Apr 27, 1995

EQ 500MG BASE

A064107 002 Apr 27, 1995

IVAX SUB TEVA PHARMS

EQ 250MG BASE

A064061 001 Apr 27, 1995

EQ 500MG BASE

A064061 002 Apr 27, 1995

MARSAM PHARMS LLC

EQ 250MG BASE

A064148 001 May 23, 1996

EQ 500MG BASE

A064148 002 May 23, 1996

RANBAXY

EQ 250MG BASE

A064156 001 Aug 28, 1997

EQ 500MG BASE

A064156 002 Aug 28, 1997

TEVA

EQ 250MG BASE

A064081 001 Sep 16, 1996

EQ 250MG BASE

A064145 001 Jun 24, 1996

EQ 500MG BASE

A064081 002 Sep 16, 1996

EQ 500MG BASE

A064145 002 Jun 24, 1996

FOR SUSPENSION; ORAL
CECLOR

LILLY

EQ 125MG BASE/5ML

N050522 001

EQ 250MG BASE/5ML

N050522 002

CEFACLOR

CLONMEL HLTHCARE

EQ 125MG BASE/5ML

A064114 001 Apr 28, 1995

EQ 187MG BASE/5ML

A064115 001 Apr 28, 1995

EQ 250MG BASE/5ML

A064116 001 Apr 28, 1995

EQ 375MG BASE/5ML

A064110 001 Apr 28, 1995

FACTA FARMA

EQ 125MG BASE/5ML

A062206 001

EQ 187MG BASE/5ML

A062206 003 Apr 20, 1988

EQ 250MG BASE/5ML

A062206 002

EQ 375MG BASE/5ML

A062206 004 Apr 20, 1988

IVAX SUB TEVA PHARMS

EQ 125MG BASE/5ML

A064087 001 Apr 28, 1995

EQ 187MG BASE/5ML

A064086 001 Apr 28, 1995

EQ 250MG BASE/5ML

A064085 001 Apr 28, 1995

EQ 375MG BASE/5ML

A064070 001 Apr 28, 1995

MARSAM PHARMS LLC

EQ 125MG BASE/5ML

A064204 001 Feb 18, 1998

EQ 187MG BASE/5ML

A064205 001 Feb 18, 1998

EQ 250MG BASE/5ML

A064206 001 Feb 18, 1998

DISCONTINUED DRUG PRODUCT LIST

6 - 62 (of 360)

CEFACLOR

FOR SUSPENSION; ORAL

CEFACLOR

MARSAM PHARMS LLC	EQ 375MG BASE/5ML	A064207	001	Feb 18, 1998
RANBAXY	EQ 125MG BASE/5ML	A064166	001	Oct 02, 1997
	EQ 187MG BASE/5ML	A064165	001	Oct 02, 1997
	EQ 250MG BASE/5ML	A064164	001	Oct 02, 1997
	EQ 375MG BASE/5ML	A064155	001	Oct 02, 1997

TABLET, CHEWABLE; ORAL

RANICLOR

RANBAXY LABS LTD	EQ 125MG BASE	A065092	001	Dec 22, 2003
	EQ 187MG BASE	A065092	002	Dec 22, 2003
	EQ 250MG BASE	A065092	003	Dec 22, 2003
	EQ 375MG BASE	A065092	004	Dec 22, 2003

TABLET, EXTENDED RELEASE; ORAL

CECLOR CD

LILLY	EQ 375MG BASE	N050673	001	Jun 28, 1996
	EQ 500MG BASE	N050673	002	Jun 28, 1996

CEFACLOR

WORLD GEN	EQ 500MG BASE	A065057	001	Jan 05, 2001

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

IVAX SUB TEVA PHARMS	EQ 500MG BASE	A062766	001	Mar 03, 1987
PUREPAC PHARM	EQ 500MG BASE	A063017	001	Jan 05, 1989
RANBAXY LABS LTD	EQ 500MG BASE	A065015	001	Jun 22, 1999
TEVA	EQ 500MG BASE	A062695	001	Feb 10, 1989

DURICEF

WARNER CHILCOTT	EQ 250MG BASE	N050512	002	
	EQ 500MG BASE	N050512	001	

ULTRACEF

BRISTOL	EQ 500MG BASE	A062378	001	Mar 16, 1982

FOR SUSPENSION; ORAL

CEFADROXIL

APOTHECON	EQ 125MG BASE/5ML	A062334	001	
	EQ 250MG BASE/5ML	A062334	002	
	EQ 500MG BASE/5ML	A062334	003	
TEVA	EQ 125MG BASE/5ML	A062698	001	Mar 01, 1989
	EQ 250MG BASE/5ML	A062698	002	Mar 01, 1989
	EQ 500MG BASE/5ML	A062698	003	Mar 01, 1989

DURICEF

WARNER CHILCOTT	EQ 125MG BASE/5ML	N050527	002	
	EQ 250MG BASE/5ML	N050527	003	
	EQ 500MG BASE/5ML	N050527	001	

ULTRACEF

BRISTOL	EQ 125MG BASE/5ML	A062376	001	Mar 16, 1982
	EQ 250MG BASE/5ML	A062376	002	Mar 16, 1982
	EQ 500MG BASE/5ML	A062376	003	Mar 16, 1982

TABLET; ORAL

CEFADROXIL

RANBAXY	EQ 1GM BASE	A065018	001	Apr 23, 1999

DURICEF

WARNER CHILCOTT	EQ 1GM BASE	N050528	001	

ULTRACEF

APOTHECON	EQ 1GM BASE	A062390	001	Jun 10, 1982
BRISTOL	EQ 1GM BASE	A062408	001	Aug 31, 1982

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

MANDOL

LILLY	EQ 500MG BASE/VIAL	N050504	001	
	EQ 1GM BASE/VIAL	A062560	001	Sep 10, 1985
	EQ 1GM BASE/VIAL	N050504	002	

DISCONTINUED DRUG PRODUCT LIST

6 - 63 (of 360)

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION
MANDOL

LILLY	EQ 2GM BASE/VIAL	A062560	002	Sep 10, 1985
	EQ 2GM BASE/VIAL	N050504	003	
	EQ 10GM BASE/VIAL	N050504	004	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
ANCEF

GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050461	001	
	EQ 500MG BASE/VIAL	N050461	002	
	EQ 1GM BASE/VIAL	N050461	003	
	EQ 5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050461	004	
	EQ 10GM BASE/VIAL	N050461	005	
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566	003	Jun 08, 1983
	EQ 20MG BASE/ML	N050566	004	Jun 08, 1983
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566	001	Jun 08, 1983
	EQ 20MG BASE/ML	N050566	002	Jun 08, 1983
CEFAZOLIN AND DEXTROSE B BRAUN	EQ 500MG BASE/VIAL	N050779	001	Jul 27, 2000
CEFAZOLIN SODIUM ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062688	002	Nov 17, 1986
	EQ 1GM BASE/VIAL	A062688	003	Nov 17, 1986
	EQ 10GM BASE/VIAL	A062688	004	Nov 17, 1986
	EQ 20GM BASE/VIAL	A062688	005	Aug 03, 1987
BEDFORD	EQ 250MG BASE/VIAL	A062894	001	Jul 21, 1988
	EQ 500MG BASE/VIAL	A062894	002	Jul 21, 1988
	EQ 1GM BASE/VIAL	A062894	003	Jul 21, 1988
	EQ 5GM BASE/VIAL	A062894	004	Jul 21, 1988
	EQ 10GM BASE/VIAL	A062894	005	Jul 21, 1988
CEPHAZONE PHARMA	EQ 500MG BASE/VIAL	A065280	001	Mar 18, 2009
	EQ 1GM BASE/VIAL	A065280	002	Mar 18, 2009
	EQ 10GM BASE/VIAL	A065295	001	Mar 18, 2009
	EQ 20GM BASE/VIAL	A065296	001	Mar 18, 2009
FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A064169	001	Aug 14, 1998
	EQ 1GM BASE/VIAL	A064169	002	Aug 14, 1998
	EQ 10GM BASE/VIAL	A064170	001	Mar 18, 1998
	EQ 20GM BASE/VIAL	A064170	002	Mar 18, 1998
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A064033	001	Oct 31, 1993
HIKMA MAPLE	EQ 250MG BASE/VIAL	A062807	001	Jan 12, 1988
	EQ 500MG BASE/VIAL	A062807	002	Jan 12, 1988
	EQ 1GM BASE/VIAL	A062807	003	Jan 12, 1988
	EQ 5GM BASE/VIAL	A062807	004	Jan 12, 1988
	EQ 10GM BASE/VIAL	A062807	005	Jan 12, 1988
	EQ 20GM BASE/VIAL	A062807	006	Jan 12, 1988
MARSAM PHARMS LLC	EQ 250MG BASE/VIAL	A062988	001	Dec 29, 1989
	EQ 500MG BASE/VIAL	A062988	002	Dec 29, 1989
	EQ 1GM BASE/VIAL	A062988	003	Dec 29, 1989
	EQ 5GM BASE/VIAL	A062989	001	Dec 29, 1989
	EQ 10GM BASE/VIAL	A062989	002	Dec 29, 1989
	EQ 20GM BASE/VIAL	A062989	003	Dec 29, 1989
TEVA PHARMS	EQ 250MG BASE/VIAL	A063016	001	Mar 14, 1989
	EQ 500MG BASE/VIAL	A063016	002	Mar 14, 1989
	EQ 1GM BASE/VIAL	A063016	003	Mar 14, 1989
	EQ 5GM BASE/VIAL	A063018	001	Mar 05, 1990

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 64 (of 360)

CEFAZOLIN SODIUMINJECTABLE; INJECTION
CEFAZOLIN SODIUM

TEVA PHARMS	EQ 10GM BASE/VIAL	A063018	002	Mar 05, 1990
KEFZOL				
ACS DOBFAR	EQ 250MG BASE/VIAL	A061773	001	
	EQ 20GM BASE/VIAL	A061773	005	Sep 08, 1987
LILLY	EQ 500MG BASE/VIAL	A062557	001	Sep 10, 1985
	EQ 1GM BASE/VIAL	A062557	002	Sep 10, 1985

CEFDINIRCAPSULE; ORAL
OMNICEF

ABBVIE	300MG	N050739	001	Dec 04, 1997

FOR SUSPENSION; ORAL
OMNICEF

ABBVIE	125MG/5ML	N050749	001	Dec 04, 1997
	250MG/5ML	N050749	002	Jul 29, 2004

CEFIXIMEFOR SUSPENSION; ORAL
SUPRAX

LEDERLE	100MG/5ML	N050622	001	Apr 28, 1989

TABLET; ORAL
SUPRAX

LEDERLE	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050621	001	Apr 28, 1989
	400MG	N050621	002	Apr 28, 1989

CEFMENOXIME HYDROCHLORIDEINJECTABLE; INJECTION
CEFMAX

TAP PHARM	EQ 500MG BASE/VIAL	N050571	001	Dec 30, 1987
	EQ 1GM BASE/VIAL	N050571	002	Dec 30, 1987
	EQ 2GM BASE/VIAL	N050571	003	Dec 30, 1987

CEFMETAZOLE SODIUMINJECTABLE; INJECTION
ZEFAZONE

PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N050637	001	Dec 11, 1989
	EQ 2GM BASE/VIAL	N050637	002	Dec 11, 1989

ZEFAZONE IN PLASTIC CONTAINER

PHARMACIA AND UPJOHN	EQ 20MG BASE/ML	N050683	001	Dec 29, 1992
	EQ 40MG BASE/ML	N050683	002	Dec 29, 1992

CEFONICID SODIUMINJECTABLE; INJECTION
MONOCID

GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	N050579	001	May 23, 1984
	EQ 1GM BASE/VIAL	A063295	001	Jul 26, 1993
	EQ 1GM BASE/VIAL	N050579	002	May 23, 1984
	EQ 2GM BASE/VIAL	N050579	003	May 23, 1984
	EQ 10GM BASE/VIAL	N050579	004	May 23, 1984

CEFOPERAZONE SODIUMINJECTABLE; INJECTION
CEFOBID

PFIZER	EQ 1GM BASE/VIAL	A063333	001	Mar 31, 1995
	EQ 1GM BASE/VIAL	N050551	001	Nov 18, 1982
	EQ 2GM BASE/VIAL	A063333	002	Mar 31, 1995
	EQ 2GM BASE/VIAL	N050551	002	Nov 18, 1982
	EQ 10GM BASE/VIAL	N050551	003	Mar 05, 1990

DISCONTINUED DRUG PRODUCT LIST

6 - 65 (of 360)

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION
CEFOBID IN PLASTIC CONTAINER

PFIZER	EQ 20MG BASE/ML	N050613	002	Jul 31, 1987
	EQ 40MG BASE/ML	N050613	001	Jul 23, 1986

CEFORANIDE

INJECTABLE; INJECTION
PRECEF

APOTHECON	500MG/VIAL	A062579	001	Nov 26, 1984
	1GM/VIAL	A062579	002	Nov 26, 1984
	2GM/VIAL	A062579	003	Nov 26, 1984
	10GM/VIAL	A062579	004	Nov 26, 1984
	20GM/VIAL	A062579	005	Nov 26, 1984
BRISTOL	500MG/VIAL	N050554	001	May 24, 1984
	1GM/VIAL	N050554	002	May 24, 1984
	2GM/VIAL	N050554	003	May 24, 1984
	10GM/VIAL	N050554	004	May 24, 1984
	20GM/VIAL	N050554	005	May 24, 1984

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CEFOTAXIME

FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A064200	001	Mar 24, 2000
	EQ 1GM BASE/VIAL	A064200	002	Mar 24, 2000
	EQ 2GM BASE/VIAL	A064200	003	Mar 24, 2000
	EQ 10GM BASE/VIAL	A064201	001	Mar 24, 2000
	EQ 20GM BASE/VIAL	A064201	002	Mar 24, 2000
CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER				
B BRAUN	EQ 2GM BASE	N050792	001	Jul 29, 2004
CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER				
B BRAUN	EQ 1GM BASE	N050792	002	Jul 29, 2004
CEFOTAXIME SODIUM				
CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A065348	001	Jan 25, 2010
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
SANOFI AVENTIS US	EQ 20MG BASE/ML	N050596	001	May 20, 1985
	EQ 40MG BASE/ML	N050596	003	May 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION
CEFOTAN

ASTRAZENECA	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993
	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985
	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993
	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985
	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988
CEFOTAN IN PLASTIC CONTAINER				
ASTRAZENECA	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993
	EQ 40MG BASE/ML	N050694	001	Jul 30, 1993

CEFOTIAM HYDROCHLORIDE

INJECTABLE; INJECTION
CERADON

TAKEDA	EQ 1GM BASE/VIAL	N050601	001	Dec 30, 1988

CEFOXITIN SODIUM

INJECTABLE; INJECTION
CEFOXITIN

FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A065012	001	Jul 03, 2000
	EQ 2GM BASE/VIAL	A065012	002	Jul 03, 2000
	EQ 10GM BASE/VIAL	A065011	001	Jul 03, 2000
MEFOXIN				
BIONICHE PHARMA	EQ 1GM BASE/VIAL	A062757	001	Jan 08, 1987

DISCONTINUED DRUG PRODUCT LIST

6 - 66 (of 360)

CEFOXITIN SODIUM

INJECTABLE; INJECTION
MEFOXIN

BIONICHE PHARMA	EQ 2GM BASE/VIAL	A062757	002	Jan 08, 1987
MYLAN INSTITUTIONAL	EQ 1GM BASE/VIAL	N050517	001	
	EQ 2GM BASE/VIAL	N050517	002	
	EQ 10GM BASE/VIAL	N050517	003	
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
MERCK	EQ 20MG BASE/ML	N050581	003	Sep 20, 1984
	EQ 40MG BASE/ML	N050581	004	Sep 20, 1984
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
MERCK	EQ 20MG BASE/ML	N050581	002	Sep 20, 1984
	EQ 40MG BASE/ML	N050581	001	Sep 20, 1984

CEFPIRAMIDE SODIUM

INJECTABLE; INJECTION
CEFPIRAMIDE SODIUM

WYETH AYERST	EQ 1GM BASE/VIAL	N050633	002	Jan 31, 1989
	EQ 2GM BASE/VIAL	N050633	003	Jan 31, 1989
	EQ 10GM BASE/VIAL	N050633	005	Jan 31, 1989

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL
BANAN

SANKYO	EQ 50MG BASE/5ML	N050688	002	Aug 07, 1992
	EQ 100MG BASE/5ML	N050688	001	Aug 07, 1992
VANTIN				
PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML	N050675	001	Aug 07, 1992
	EQ 100MG BASE/5ML	N050675	002	Aug 07, 1992

TABLET; ORAL
BANAN

SANKYO	EQ 100MG BASE	N050687	001	Aug 07, 1992
	EQ 200MG BASE	N050687	002	Aug 07, 1992
VANTIN				
PHARMACIA AND UPJOHN	EQ 100MG BASE	N050674	001	Aug 07, 1992
	EQ 200MG BASE	N050674	002	Aug 07, 1992

CEFPROZIL

FOR SUSPENSION; ORAL
CEFPROZIL

RANBAXY LABS LTD	125MG/5ML	A065202	001	Jun 30, 2006
	250MG/5ML	A065202	002	Jun 30, 2006
CEFZIL				
CORDEN PHARMA	125MG/5ML	N050665	001	Dec 23, 1991
	250MG/5ML	N050665	002	Dec 23, 1991

TABLET; ORAL
CEFPROZIL

RANBAXY LABS LTD	250MG	A065198	001	Dec 13, 2006
	500MG	A065198	002	Dec 13, 2006
CEFZIL				
CORDEN PHARMA	250MG	N050664	001	Dec 23, 1991
	500MG	N050664	002	Dec 23, 1991

CEFTAZIDIME

INJECTABLE; INJECTION
CEPTAZ

GLAXOSMITHKLINE	500MG/VIAL	N050646	001	Sep 27, 1990
	1GM/VIAL	N050646	002	Sep 27, 1990
	2GM/VIAL	N050646	003	Sep 27, 1990
	10GM/VIAL	N050646	004	Sep 27, 1990
PENTACEF				
GLAXOSMITHKLINE	1GM/VIAL	A063322	001	Nov 07, 1995
	1GM/VIAL	A064006	001	Mar 31, 1992

DISCONTINUED DRUG PRODUCT LIST

6 - 67 (of 360)

CEFTAZIDIME

INJECTABLE; INJECTION
PENTACEF

GLAXOSMITHKLINE	2GM/VIAL	A063322	002	Nov 07, 1995
	2GM/VIAL	A064006	002	Mar 31, 1992
	6GM/VIAL	A064008	001	Mar 31, 1992
	10GM/VIAL	A064008	002	Mar 31, 1992

TAZIDIME

LILLY	1GM/VIAL	A062655	001	Nov 20, 1985
	2GM/VIAL	A062655	002	Nov 20, 1985

TAZIDIME IN PLASTIC CONTAINER

LILLY	1GM/VIAL	A062739	001	Jul 10, 1986
	2GM/VIAL	A062739	002	Jul 10, 1986

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	A063221	001	Apr 29, 1993
	EQ 20MG BASE/ML	A063221	002	Apr 29, 1993
	EQ 40MG BASE/ML	A063221	003	Apr 29, 1993

FORTAZ IN PLASTIC CONTAINER

COVIS PHARMA	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989

CEFTIBUTEN DIHYDRATE

FOR SUSPENSION; ORAL

CEDAX

PERNIX THERAP	EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

ASTELLAS	EQ 500MG BASE/VIAL	N050560	001	Sep 15, 1983
	EQ 1GM BASE/VIAL	A063294	002	Mar 31, 1994
	EQ 1GM BASE/VIAL	N050560	002	Sep 15, 1983
	EQ 2GM BASE/VIAL	A063294	003	Mar 31, 1994
	EQ 2GM BASE/VIAL	N050560	003	Sep 15, 1983
	EQ 10GM BASE/VIAL	N050560	005	Mar 19, 1993

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

ASTELLAS	EQ 20MG BASE/ML	N050589	001	Oct 03, 1984
	EQ 40MG BASE/ML	N050589	002	Oct 03, 1984

CEFIZOX IN PLASTIC CONTAINER

ASTELLAS	EQ 20MG BASE/ML	N050589	003	Apr 13, 1995
	EQ 40MG BASE/ML	N050589	004	Apr 13, 1995

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAXONE

CEPHAZONE PHARMA	EQ 250MG BASE/VIAL	A065294	001	Mar 26, 2007
	EQ 500MG BASE/VIAL	A065294	002	Mar 26, 2007
	EQ 1GM BASE/VIAL	A065294	003	Mar 26, 2007
	EQ 2GM BASE/VIAL	A065294	004	Mar 26, 2007
FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A065245	002	Feb 15, 2006
	EQ 1GM BASE/VIAL	A065245	003	Feb 15, 2006
	EQ 2GM BASE/VIAL	A065245	004	Feb 15, 2006

ROCEPHIN

HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL	N050585	001	Dec 21, 1984
	EQ 500MG BASE/VIAL	N050585	002	Dec 21, 1984
	EQ 1GM BASE/VIAL	N050585	003	Dec 21, 1984
	EQ 2GM BASE/VIAL	N050585	004	Dec 21, 1984

INJECTABLE; INJECTION

CEFTRIAXONE

FRESENIUS KABI USA	EQ 10GM BASE/VIAL	A065252	001	Feb 15, 2006

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 68 (of 360)

CEFTRIAXONE SODIUMINJECTABLE; INJECTION
ROCEPHIN

HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL	A063239	001	Aug 13, 1993
	EQ 500MG BASE/VIAL	A062654	001	Apr 30, 1987
	EQ 1GM BASE/VIAL	A062654	002	Apr 30, 1987
	EQ 2GM BASE/VIAL	A062654	003	Apr 30, 1987
	EQ 10GM BASE/VIAL	N050585	005	Dec 21, 1984
ROCHE	EQ 250MG BASE/VIAL	A062510	001	Mar 12, 1985
	EQ 500MG BASE/VIAL	A062510	002	Mar 12, 1985
	EQ 1GM BASE/VIAL	A062510	003	Mar 12, 1985
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER				
HOFFMANN LA ROCHE	EQ 10MG BASE/ML	N050624	001	Feb 11, 1987
	EQ 20MG BASE/ML	N050624	002	Feb 11, 1987
	EQ 40MG BASE/ML	N050624	003	Feb 11, 1987

CEFTRIAXONE SODIUM; LIDOCAINEINJECTABLE; INJECTION
ROCEPHIN KIT

HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL, N/A; N/A, 1%	N050585	007	May 08, 1996
	EQ 1GM BASE/VIAL, N/A; N/A, 1%	N050585	006	May 08, 1996

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

RANBAXY LABS LTD	EQ 125MG BASE	A065043	003	Feb 15, 2002
	EQ 250MG BASE	A065043	002	Feb 15, 2002
	EQ 500MG BASE	A065043	001	Feb 15, 2002
SANDOZ	EQ 250MG BASE	A065126	001	Oct 28, 2003
	EQ 500MG BASE	A065126	002	Oct 28, 2003

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A065001	001	May 30, 2001
MARSAM PHARMS LLC	EQ 750MG BASE/VIAL	A064035	001	Feb 26, 1993
KEFUROX				
ACS DOBFAR	EQ 750MG BASE/VIAL	A062591	001	Jan 10, 1986
INJECTABLE; INJECTION				
CEFUROXIME SODIUM				
FRESENIUS KABI USA	EQ 1.5GM BASE/VIAL	A065001	002	May 30, 2001
	EQ 7.5GM BASE/VIAL	A065002	001	Sep 28, 1998
MARSAM PHARMS LLC	EQ 1.5GM BASE/VIAL	A064035	002	Feb 26, 1993
	EQ 7.5GM BASE/VIAL	A064036	001	Feb 26, 1993
KEFUROX				
ACS DOBFAR	EQ 1.5GM BASE/VIAL	A062591	002	Jan 10, 1986
	EQ 7.5GM BASE/VIAL	A062591	003	Dec 17, 1987
LILLY	EQ 1.5GM BASE/VIAL	A062592	002	Jan 10, 1986
KEFUROX IN PLASTIC CONTAINER				
LILLY	EQ 1.5GM BASE/VIAL	A062590	002	Jan 10, 1986
INJECTABLE; INTRAVENOUS				
KEFUROX				
LILLY	EQ 750MG BASE/VIAL	A062592	001	Jan 10, 1986
KEFUROX IN PLASTIC CONTAINER				
LILLY	EQ 750MG BASE/VIAL	A062590	001	Jan 10, 1986

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL

CALCIBIND

MISSION PHARMA	2.5GM/PACKET	N018757	002	Dec 28, 1982
	300GM/BOT	N018757	003	Oct 16, 1984

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 69 (of 360)

CEPHALEXINCAPSULE; ORAL
CEPHALEXIN

APOTHECON	EQ 250MG BASE	A062973	001	Nov 08, 1988
	EQ 250MG BASE	A063063	001	Sep 29, 1989
	EQ 250MG BASE	A063186	001	Dec 30, 1994
	EQ 500MG BASE	A062974	001	Nov 23, 1988
	EQ 500MG BASE	A063063	002	Sep 29, 1989
	EQ 500MG BASE	A063186	002	Dec 30, 1994
BARR	EQ 250MG BASE	A062773	001	Jun 26, 1987
	EQ 500MG BASE	A062775	001	Apr 22, 1987
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A061969	001	
	EQ 500MG BASE	A061969	002	
PUREPAC PHARM	EQ 250MG BASE	A062809	001	Apr 22, 1987
	EQ 500MG BASE	A062809	002	Apr 22, 1987
STEVENS J	EQ 500MG BASE	A062869	001	Mar 17, 1988
	EQ 250MG BASE	A062760	001	Apr 24, 1987
TEVA	EQ 250MG BASE	A062821	001	Feb 05, 1988
	EQ 500MG BASE	A062761	001	Apr 24, 1987
	EQ 500MG BASE	A062823	001	Feb 05, 1988
	EQ 250MG BASE	A062872	001	Jun 20, 1988
YOSHITOMI	EQ 250MG BASE	A062871	001	Jul 05, 1988
	EQ 500MG BASE			
KEFLEX				
SHIONOGI INC	EQ 333MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050405	004	May 12, 2006

FOR SUSPENSION; ORAL
CEPHALEXIN

APOTHECON	EQ 125MG BASE/5ML	A062986	001	Apr 18, 1991
	EQ 250MG BASE/5ML	A062987	001	Jul 25, 1989
BARR	EQ 125MG BASE/5ML	A062778	001	Aug 06, 1987
	EQ 250MG BASE/5ML	A062777	001	Aug 06, 1987
FACTA FARMA	EQ 100MG BASE/ML	A062117	001	
	EQ 125MG BASE/5ML	A062767	001	Jun 16, 1987
TEVA	EQ 125MG BASE/5ML	A062873	001	May 23, 1988
	EQ 250MG BASE/5ML	A062768	001	Jun 16, 1987
	EQ 250MG BASE/5ML	A062867	001	Apr 15, 1988
	EQ 125MG BASE/5ML	A062779	001	Dec 22, 1987
VITARINE	EQ 125MG BASE/5ML	A062781	001	Dec 22, 1987
	EQ 250MG BASE/5ML			
KEFLEX				
SHIONOGI INC	EQ 100MG BASE/ML	N050406	003	
	EQ 125MG BASE/5ML	N050406	001	
	EQ 250MG BASE/5ML	N050406	002	

TABLET; ORAL
CEPHALEXIN

BARR	EQ 250MG BASE	A062826	001	Aug 17, 1987
	EQ 500MG BASE	A062827	001	Aug 17, 1987
VITARINE	EQ 250MG BASE	A062863	001	Aug 11, 1988
	EQ 500MG BASE	A062863	002	Aug 11, 1988
	EQ 1GM BASE	A062863	003	Aug 11, 1988
KEFLET				
LILLY	EQ 250MG BASE	A062745	001	Dec 01, 1986
	EQ 250MG BASE	N050440	003	Feb 26, 1987
	EQ 500MG BASE	A062745	002	Dec 01, 1986
	EQ 500MG BASE	N050440	001	
	EQ 1GM BASE	N050440	002	

TABLET, FOR SUSPENSION; ORAL

PANIXINE DISPERDOSE

RANBAXY LABS LTD	EQ 125MG BASE	A065100	002	Sep 11, 2003
	EQ 250MG BASE	A065100	001	Sep 11, 2003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 70 (of 360)

CEPHALEXIN HYDROCHLORIDETABLET; ORAL
KEFTAB

LILLY

EQ 250MG BASE

N050614 001 Oct 29, 1987

EQ 333MG BASE

N050614 003 May 16, 1988

EQ 500MG BASE

N050614 002 Oct 29, 1987

CEPHALOGLYCINCAPSULE; ORAL
KAFOCIN

LILLY

250MG

N050219 001

CEPHALOTHIN SODIUMINJECTABLE; INJECTION
CEPHALOTHIN

INTL MEDICATION

EQ 500MG BASE/VIAL

A062426 001 May 03, 1985

EQ 1GM BASE/VIAL

A062426 002 May 03, 1985

EQ 2GM BASE/VIAL

A062426 003 May 03, 1985

EQ 4GM BASE/VIAL

A062426 004 May 03, 1985

CEPHALOTHIN SODIUM

ABBOTT

EQ 1GM BASE/VIAL

A062547 001 Sep 11, 1985

EQ 1GM BASE/VIAL

A062548 001 Sep 11, 1985

EQ 2GM BASE/VIAL

A062547 002 Sep 11, 1985

EQ 2GM BASE/VIAL

A062548 002 Sep 11, 1985

ABRAXIS PHARM

EQ 1GM BASE/VIAL

A062666 002 Jun 10, 1987

EQ 2GM BASE/VIAL

A062666 001 Jun 10, 1987

BRISTOL

EQ 1GM BASE/VIAL

A062464 001 May 07, 1984

EQ 2GM BASE/VIAL

A062464 002 May 07, 1984

EQ 4GM BASE/VIAL

A062464 003 May 07, 1984

CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 20MG BASE/ML

A062422 003 Jan 31, 1984

EQ 20MG BASE/ML

A062422 005 Jul 16, 1991

EQ 20MG BASE/ML

A062730 001 Mar 05, 1987

EQ 40MG BASE/ML

A062422 004 Jan 31, 1984

EQ 40MG BASE/ML

A062422 006 Jul 16, 1991

EQ 40MG BASE/ML

A062730 002 Mar 05, 1987

CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 20MG BASE/ML

A062422 001 Jan 31, 1984

EQ 40MG BASE/ML

A062422 002 Jan 31, 1984

KEFLIN

LILLY

EQ 1GM BASE/VIAL

N050482 001

EQ 2GM BASE/VIAL

N050482 002

EQ 4GM BASE/VIAL

N050482 003

EQ 20GM BASE/VIAL

N050482 007

KEFLIN IN PLASTIC CONTAINER

LILLY

EQ 1GM BASE/VIAL

A062549 001 Sep 10, 1985

EQ 2GM BASE/VIAL

A062549 002 Sep 10, 1985

SEFFIN

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A062435 001 Nov 15, 1983

EQ 2GM BASE/VIAL

A062435 002 Nov 15, 1983

EQ 10GM BASE/VIAL

A062435 003 Nov 15, 1983

CEPHAPIRIN SODIUMINJECTABLE; INJECTION
CEFADYL

APOTHECON

EQ 500MG BASE/VIAL

A062961 001 Sep 20, 1988

EQ 500MG BASE/VIAL

N050446 005

EQ 1GM BASE/VIAL

A061769 001

EQ 1GM BASE/VIAL

A062724 001 Dec 23, 1986

EQ 1GM BASE/VIAL

A062961 002 Sep 20, 1988

EQ 1GM BASE/VIAL

N050446 001

EQ 2GM BASE/VIAL

A061769 002

EQ 2GM BASE/VIAL

A062724 002 Dec 23, 1986

DISCONTINUED DRUG PRODUCT LIST

6 - 71 (of 360)

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION CEFADYL

APOTHECON	EQ 2GM BASE/VIAL	A062961	003	Sep 20, 1988
	EQ 2GM BASE/VIAL	N050446	002	
	EQ 4GM BASE/VIAL	A061769	003	
	EQ 4GM BASE/VIAL	A062961	004	Sep 20, 1988
	EQ 4GM BASE/VIAL	N050446	003	
	EQ 20GM BASE/VIAL	N050446	004	

CEPHAPIRIN SODIUM

ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062723	001	Nov 17, 1986
	EQ 1GM BASE/VIAL	A062723	002	Nov 17, 1986
	EQ 2GM BASE/VIAL	A062723	003	Nov 17, 1986
	EQ 4GM BASE/VIAL	A062723	004	Nov 17, 1986
	EQ 20GM BASE/VIAL	A062723	005	Nov 17, 1986
HIKMA MAPLE	EQ 500MG BASE/VIAL	A062720	001	Jul 02, 1987
	EQ 1GM BASE/VIAL	A062720	002	Jul 02, 1987
	EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987
	EQ 20GM BASE/VIAL	A062720	004	Jul 02, 1987

CEPHRADINE

CAPSULE; ORAL

ANSPOR

GLAXOSMITHKLINE	250MG	A061859	001	
	500MG	A061859	002	

CEPHRADINE

BARR	250MG	A062850	001	Apr 22, 1988
	500MG	A062851	001	Apr 22, 1988
IVAX SUB TEVA PHARMS	250MG	A062762	001	Mar 06, 1987
	500MG	A062762	002	Mar 06, 1987
TEVA	250MG	A062683	001	Jan 09, 1987
	500MG	A062683	002	Jan 09, 1987
VITARINE	250MG	A062813	001	Feb 25, 1988
	500MG	A062813	002	Feb 25, 1988

VELOSEF

APOTHECON	250MG	A061764	001	
	500MG	A061764	002	

VELOSEF '250'

ERSANA	250MG	N050548	001	

VELOSEF '500'

ERSANA	500MG	N050548	002	

FOR SUSPENSION; ORAL

ANSPOR

GLAXOSMITHKLINE	125MG/5ML	A061866	001	
	250MG/5ML	A061866	002	

CEPHRADINE

BARR	125MG/5ML	A062858	001	May 19, 1988
	250MG/5ML	A062859	001	May 19, 1988
TEVA	125MG/5ML	A062693	001	Jan 09, 1987
	250MG/5ML	A062693	002	Jan 09, 1987

VELOSEF '125'

APOTHECON	125MG/5ML	A061763	001	

VELOSEF '250'

APOTHECON	250MG/5ML	A061763	002	

INJECTABLE; INJECTION

VELOSEF

APOTHECON	250MG/VIAL	A061976	001	
	500MG/VIAL	A061976	002	
	1GM/VIAL	A061976	004	
	2GM/VIAL	A061976	003	
	4GM/VIAL	A061976	005	

TABLET; ORAL

VELOSEF

BRISTOL MYERS SQUIBB	1GM	N050530	001	

DISCONTINUED DRUG PRODUCT LIST

6 - 72 (of 360)

CERIVASTATIN SODIUM

TABLET; ORAL

BAYCOL

BAYER PHARMS

0.05MG

N020740 001 Jun 26, 1997

0.1MG

N020740 002 Jun 26, 1997

0.2MG

N020740 003 Jun 26, 1997

0.3MG

N020740 004 Jun 26, 1997

0.4MG

N020740 005 May 24, 1999

0.8MG

N020740 006 Jul 24, 2000

CERULETIDE DIETHYLAMINE

INJECTABLE; INJECTION

TYMTRAN

PHARMACIA AND UPJOHN

0.02MG/ML

N018296 001

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC 5MG/5ML

A078617 001 Feb 02, 2010

RANBAXY LABS LTD 5MG/5ML

A077472 001 Jun 18, 2008

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS MID ATLANTIC 5MG/5ML

A090378 002 May 09, 2008

RANBAXY LABS LTD 5MG/5ML

A090183 002 Apr 24, 2008

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

ACTAVIS MID ATLANTIC 5MG/5ML

A090378 001 May 09, 2008

RANBAXY LABS LTD 5MG/5ML

A090183 001 Apr 24, 2008

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS ELIZABETH 5MG

A078615 003 Dec 28, 2007

10MG

A078615 004 Dec 28, 2007

CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

FOR SUSPENSION; INTRATRACHEAL

EXOSURF NEONATAL

GLAXOSMITHKLINE 12MG/VIAL;108MG/VIAL;8MG/VIAL

N020044 001 Aug 02, 1990

CHENODIOL

TABLET; ORAL

CHENIX

SIGMA TAU

250MG

N018513 002 Jul 28, 1983

CHLOPHEDIANOL HYDROCHLORIDE

SYRUP; ORAL

ULO

3M

25MG/5ML

N012126 001

CHLORAMPHENICOL

CAPSULE; ORAL

AMPHICOL

FERRANTE 100MG

A060058 001

CHLOROMYCETIN

PARKEDALE 50MG

A060591 001

100MG

A060591 003

CREAM; TOPICAL

CHLOROMYCETIN

PARKE DAVIS 1%

N050183 001

FOR SOLUTION; OPHTHALMIC

CHLOROMYCETIN

PARKEDALE 25MG/VIAL

N050143 001

INJECTABLE; INJECTION

CHLOROMYCETIN

PARKE DAVIS 250MG/ML

N050153 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 73 (of 360)

CHLORAMPHENICOLOINTMENT; OPHTHALMIC
CHLORAMPHENICOL

ALTANA 1% A060133 001

CHLOROFAIR

PHARMAFAIR 1% A062439 001 Apr 21, 1983

CHLOROMYCETIN

PARKEDALE 1% N050156 001

CHLOROPTIC S.O.P.

ALLERGAN 1% A061187 001

ECONOCHLOR

ALCON 1% A061648 001

SOLUTION/DROPS; OPHTHALMIC
CHLORAMPHENICOL

AKORN 0.5% A062042 001

ALCON 0.5% A062628 001 Sep 25, 1985

CHLOROFAIR

PHARMAFAIR 0.5% A062437 001 Apr 14, 1983

CHLOROPTIC

ALLERGAN 0.5% N050091 001

ECONOCHLOR

ALCON 0.5% A061645 001

OPHTHOCHLOR

PARKEDALE 0.5% A061220 001

OPTOMYCIN

OPTOPICS 0.5% A062171 001 Mar 31, 1982

SOLUTION/DROPS; OTIC
CHLOROMYCETIN

PARKEDALE 0.5% N050205 001

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL

CHLOROMYCETIN PALMITATE

PARKE DAVIS EQ 150MG BASE/5ML A062301 001

EQ 150MG BASE/5ML N050152 001

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL

ELKINS SINN EQ 1GM BASE/VIAL A062406 001 Nov 09, 1982

CHLORAMPHENICOL SODIUM SUCCINATE

GRUPPO LEPETIT EQ 1GM BASE/VIAL A062278 001

CHLOROMYCETIN

PARKEDALE EQ 1GM BASE/VIAL N050155 001

MYCHEL-S

ANGUS EQ 1GM BASE/VIAL A060132 001

CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

OINTMENT; TOPICAL

ELASE-CHLOROMYCETIN

PARKE DAVIS 10MG/GM;666 UNITS/GM;1 UNITS/GM N050294 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION; OPHTHALMIC

CHLOROMYCETIN HYDROCORTISONE

PARKEDALE 12.5MG/VIAL;25MG/VIAL N050202 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

OPHTHOCORT

PARKEDALE 10MG/GM;5MG/GM;10,000 UNITS/GM N050201 002

DISCONTINUED DRUG PRODUCT LIST

6 - 74 (of 360)

CHLORAMPHENICOL; POLYMYXIN B SULFATE

 OINTMENT; OPHTHALMIC
 CHLOROMYXIN

PARKE DAVIS	1%;10,000 UNITS/GM	N050203	002

CHLORAMPHENICOL; PREDNISOLONE

 OINTMENT; OPHTHALMIC
 CHLOROPTIC-P S.O.P.

ALLERGAN	1%;0.5%	A061188	001

CHLORDIAZEPOXIDE

 CAPSULE, EXTENDED RELEASE; ORAL
 LIBRELEASE

VALEANT PHARM INTL	30MG	N017813	001	Sep 12, 1983

 TABLET; ORAL
 LIBRITABS

VALEANT PHARM INTL	5MG	A085482	001
	10MG	A085481	001
	25MG	A085488	001

CHLORDIAZEPOXIDE HYDROCHLORIDE

 CAPSULE; ORAL
 A-POXIDE

ABBOTT	5MG	A085447	001
	5MG	A085517	001
	10MG	A085447	002
	10MG	A085518	001
	25MG	A085447	003
	25MG	A085513	001

 CHLORDIAZACHEL

RACHELLE	5MG	A085086	001
	10MG	A084639	001
	25MG	A085087	001

 CHLORDIAZEPOXIDE HYDROCHLORIDE

ASCOT	5MG	A087525	001	Jan 07, 1982
	10MG	A087524	001	Jan 07, 1982
	25MG	A087512	001	Jan 07, 1982
FERRANTE	5MG	A085118	001	
	10MG	A085119	001	
	25MG	A085120	001	
HALSEY	5MG	A085340	001	
	10MG	A085339	001	
	25MG	A084685	001	
IMPAX LABS	5MG	A086213	001	
	10MG	A085113	001	
	25MG	A086212	001	
IVAX SUB TEVA PHARMS	5MG	A083741	001	
	10MG	A083742	001	
	25MG	A083570	001	
LEDERLE	5MG	A086892	001	
	5MG	A087234	001	
	10MG	A086876	001	
	10MG	A087037	001	
	25MG	A086893	001	
	25MG	A087231	001	
MAST MM	10MG	A086217	001	
MYLAN	5MG	A084886	001	
	10MG	A084601	001	
	25MG	A084887	001	
PARKE DAVIS	5MG	A085163	001	
	10MG	A084598	001	
	25MG	A085164	001	
PIONEER PHARMS	10MG	A089533	001	Jul 15, 1988

DISCONTINUED DRUG PRODUCT LIST

6 - 75 (of 360)

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

PIONEER PHARMS	25MG	A089558	001	Jul 15, 1988
PUREPAC PHARM	5MG	A085155	001	
	10MG	A084939	002	
	25MG	A085144	001	
ROXANE	5MG	A084706	001	
	10MG	A084700	001	
	25MG	A084705	001	
SANDOZ	5MG	A084678	001	
	5MG	A084919	001	
	10MG	A084041	001	
	10MG	A084920	001	
	25MG	A084679	002	
	25MG	A084823	001	
SUPERPHARM	5MG	A088987	001	Apr 25, 1985
	10MG	A088986	001	Apr 25, 1985
	25MG	A088988	001	Apr 25, 1985
TEVA	5MG	A088705	001	Jan 18, 1985
	10MG	A088706	001	Jan 18, 1985
	25MG	A086494	001	
	25MG	A088707	001	Jan 18, 1985
USL PHARMA	5MG	A084644	001	
	25MG	A084645	001	
VANGARD	5MG	A088129	001	Mar 28, 1983
	10MG	A088010	001	Mar 28, 1983
	25MG	A088130	001	Mar 28, 1983
WEST WARD	5MG	A085014	001	
	10MG	A085000	001	
	25MG	A085294	001	
LIBRIUM				
VALEANT PHARM INTL	5MG	N012249	002	
	10MG	N012249	001	
	25MG	N012249	003	
LYGEN				
ALRA	5MG	A085107	001	
	10MG	A085009	001	
	25MG	A085108	001	
INJECTABLE; INJECTION				
LIBRIUM				
VALEANT PHARM INTL	100MG/AMP	N012301	001	

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET; ORAL

MENRIUM 10-4

ROCHE	10MG;0.4MG	N014740	006

MENRIUM 5-2

ROCHE	5MG;0.2MG	N014740	002

MENRIUM 5-4

ROCHE	5MG;0.4MG	N014740	004

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

EXIDINE

XTTRIUM	2.5%	N019421	001	Dec 17, 1985

MICRODERM

J AND J	4%	A072255	001	Apr 15, 1991

PREVACARE R

J AND J	0.5%	A072292	001	Jan 28, 1992

STERI-STAT

MATRIX MEDCL	4%	A070104	001	Jul 24, 1986

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 76 (of 360)

CHLORHEXIDINE GLUCONATE

SPONGE; TOPICAL					
CHLORHEXIDINE GLUCONATE					
KENDALL IL	4%	N019490	001	Mar 27, 1987	
E-Z SCRUB					
BECTON DICKINSON	4%	A073416	001	Mar 14, 2000	
HIBICLENS					
MOLNLYCKE HLTH	4% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018423	001		
MICRODERM					
J AND J	4%	A072295	001	Feb 28, 1991	

CHLORMERODRIN HG-197

INJECTABLE; INJECTION					
CHLORMERODRIN HG 197					
BRACCO	0.6-1.4mCi/ML	N017269	001		

CHLORMEZANONE

TABLET; ORAL					
TRANCOPAL					
SANOFI AVENTIS US	100MG	N011467	003		
	200MG	N011467	005		

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION					
NESACAINE-MPF					
FRESENIUS KABI USA	2%	N009435	003		
	3%	N009435	004		

CHLOROQUINE HYDROCHLORIDE

INJECTABLE; INJECTION					
ARALEN HYDROCHLORIDE					
SANOFI AVENTIS US	EQ 40MG BASE/ML	N006002	002		

CHLOROQUINE PHOSPHATE

TABLET; ORAL					
CHLOROQUINE PHOSPHATE					
MD PHARM	EQ 150MG BASE	A087228	001		
PUREPAC PHARM	EQ 150MG BASE	A080886	001		
TEVA	EQ 150MG BASE	A087504	001	Jan 13, 1982	
WATSON LABS	EQ 150MG BASE	A087979	001	Dec 21, 1982	
	EQ 300MG BASE	A088030	001	Dec 21, 1982	

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

TABLET; ORAL					
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE					
SANOFI AVENTIS US	EQ 300MG BASE;EQ 45MG BASE	N014860	002		

CHLOROTHIAZIDE

TABLET; ORAL					
CHLOROTHIAZIDE					
ABC HOLDING	250MG	A085569	001		
LEDERLE	250MG	A086940	001		
	500MG	A086938	001		
SANDOZ	250MG	A085485	001		
WATSON LABS	250MG	A085165	001		
	250MG	A085173	001		
	250MG	A086795	001	Aug 15, 1983	
	500MG	A084026	001	Sep 01, 1982	
	500MG	A086796	001	Aug 15, 1983	

DISCONTINUED DRUG PRODUCT LIST

6 - 77 (of 360)

CHLOROTHIAZIDE

TABLET; ORAL
DIURIL

LUNDBECK INC	250MG	N011145	004
OAK PHARMS AKORN	500MG	N011145	002

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDOCLOR-150			
MERCK	150MG;250MG	N016016	001
ALDOCLOR-250			
MERCK	250MG;250MG	N016016	002
METHYLDOPA AND CHLOROTHIAZIDE			
PAR PHARM	150MG;250MG	A070783	001 Nov 06, 1987
	250MG;250MG	A070654	001 Nov 06, 1987

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CHLOROTHIAZIDE AND RESERPINE			
WEST WARD	250MG;0.125MG	A088557	001 Dec 22, 1983
	500MG;0.125MG	A088365	001 Dec 22, 1983
CHLOROTHIAZIDE W/ RESERPINE			
WATSON LABS	250MG;0.125MG	A084853	001
	500MG;0.125MG	A088151	001 Jun 09, 1983
CHLOROTHIAZIDE-RESERPINE			
MYLAN	250MG;0.125MG	A087744	001 May 06, 1982
	500MG;0.125MG	A087745	001 May 06, 1982
DIUPRES-250			
MERCK	250MG;0.125MG	N011635	003 Aug 26, 1987
DIUPRES-500			
MERCK	500MG;0.125MG	N011635	006 Aug 26, 1987

CHLOROTRIANISENE

CAPSULE; ORAL

CHLOROTRIANISENE			
BANNER PHARMACAPS	12MG	A084652	001
TACE			
SANOFI AVENTIS US	12MG	N008102	004
	25MG	N011444	001
	72MG	N016235	001

CHLOROXINE

SHAMPOO; TOPICAL

CAPITROL			
WESTWOOD SQUIBB	2%	N017594	001

CHLORPHENESIN CARBAMATE

TABLET; ORAL

MAOLATE			
PHARMACIA AND UPJOHN	400MG	N014217	002

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE			
SANDOZ	12MG	A070797	001 Aug 12, 1988
TELDRIN			
GLAXOSMITHKLINE	8MG	N017369	001
	12MG	N017369	002

INJECTABLE; INJECTION

CHLORPHENIRAMINE MALEATE			
BEL MAR	10MG/ML	A080821	001
ELKINS SINN	10MG/ML	A080797	001
WATSON LABS	10MG/ML	A083593	001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 78 (of 360)

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION

CHLORPHENIRAMINE MALEATE

WATSON LABS	10MG/ML	A086096	001
	100MG/ML	A086095	001

CHLOR-TRIMETON

SCHERING PLOUGH	10MG/ML	N008826	001
	100MG/ML	N008794	001

PYRIDAMAL 100

BEL MAR	100MG/ML	A083733	001

SYRUP; ORAL

CHLORPHENIRAMINE MALEATE

PHARM ASSOC	2MG/5ML	A087520	001	Feb 10, 1982

CHLOR-TRIMETON

SCHERING	2MG/5ML	N006921	006

TABLET; ORAL

ANTAGONATE

BAYER PHARMS	4MG	A083381	001

CHLORPHENIRAMINE MALEATE

ANABOLIC	4MG	A083078	001
BELL PHARMA	4MG	A083062	001
ELKINS SINN	4MG	A080938	001
IMPAX LABS	4MG	A080809	001
IVAX SUB TEVA PHARMS	4MG	A080779	001
KV PHARM	4MG	A087164	001
LEDERLE	4MG	A086941	001
MUTUAL PHARM	4MG	A080700	001
NEWTRON PHARMS	4MG	A086519	001
PANRAY	4MG	A083243	001
PHARMAVITE	4MG	A085104	001
PHARMERAL	4MG	A083753	001
PIONEER PHARMS	4MG	A088556	001
PUREPAC PHARM	4MG	A086306	001
PVT FORM	4MG	A080786	001
ROXANE	4MG	A080626	001
SANDOZ	4MG	A080961	001
VITARINE	4MG	A085837	001
WATSON LABS	4MG	A080696	001
	4MG	A080791	001
	4MG	A085139	001
	4MG	A083787	001

Jul 13, 1984

CHLOR-TRIMETON

SCHERING	4MG	N006921	002

KLOROMIN

HALSEY	4MG	A083629	001

PHENETRON

LANNETT	4MG	A080846	001

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

SCHERING PLOUGH	8MG	N007638	001

EFIDAC 24 CHLORPHENIRAMINE MALEATE

ALZA	16MG	N019746	002	Nov 18, 1994

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HYDROCHLORIDE

WATSON LABS	12MG;75MG	A088681	001	Sep 29, 1987

CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HYDROCHLORIDE

SANDOZ	12MG;75MG	A088940	001	Jan 26, 1989

COLD CAPSULE IV

GRAHAM DM	12MG;75MG	N018793	001	Apr 25, 1985

COLD CAPSULE V

GRAHAM DM	8MG;75MG	N018794	001	Apr 23, 1985

DISCONTINUED DRUG PRODUCT LIST

6 - 79 (of 360)

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL				
CONTAC 12 HOUR				
GLAXOSMITHKLINE	8MG;75MG	N018099	001	
DRIZE				
ASCHER	12MG;75MG	A088359	001	Feb 13, 1986
ORNADE				
GLAXOSMITHKLINE	12MG;75MG	N012152	004	
PHENYLPROPANOLAMINE HYDROCHLORIDE W/ CHLORPHENIRAMINE MALEATE				
CENT PHARMS	8MG;75MG	N018809	001	May 07, 1984
TABLET, EXTENDED RELEASE; ORAL				
CONTAC				
NOVARTIS	12MG;75MG	N019613	001	Jun 13, 1986
DEMAZIN				
SCHERING PLOUGH	4MG;25MG	N018556	001	May 14, 1984
TRIAMINIC-12				
NOVARTIS	12MG;75MG	N018115	001	

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL				
CODIMAL-L.A. 12				
SCHWARZ PHARMA	12MG;120MG	N018935	001	Apr 15, 1985
ISOCLOR				
FISONS	8MG;120MG	N018747	001	Mar 06, 1986
PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE				
CENT PHARMS	8MG;120MG	N019428	001	Aug 02, 1988
GRAHAM DM	8MG;120MG	N018844	001	Mar 20, 1985
	12MG;120MG	N018843	001	Mar 18, 1985
KV PHARM	12MG;120MG	A071455	001	Mar 01, 1989

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL				
CODEPREX				
UCB INC	EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N021369	001	Jun 21, 2004
PENNTUSS				
FISONS	EQ 4MG MALEATE/5ML;EQ 10MG BASE/5ML	N018928	001	Aug 14, 1985

CHLORPHENIRAMINE POLISTIREX; PHENYLPROPANOLAMINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL				
CORSYM				
UCB INC	EQ 4MG MALEATE/5ML;EQ 37.5MG HCL/5ML	N018050	001	Jan 04, 1984

CHLORPHENTERMINE HYDROCHLORIDE

TABLET; ORAL				
PRE-SATE				
PARKE DAVIS	EQ 65MG BASE	N014696	001	

CHLORPROMAZINE

SUPPOSITORY; RECTAL				
THORAZINE				
GLAXOSMITHKLINE	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149	024	
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149	033	

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL				
THORAZINE				
GLAXOSMITHKLINE	30MG	N011120	016	
	75MG	N011120	017	

DISCONTINUED DRUG PRODUCT LIST

6 - 80 (of 360)

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
THORAZINE

GLAXOSMITHKLINE	150MG	N011120	018	
	200MG	N011120	019	
	300MG	N011120	020	

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	100MG/ML	A086863	001	
PHARM ASSOC	30MG/ML	A040231	001	Dec 30, 1999
	100MG/ML	A040224	001	Jan 26, 1999
WOCKHARDT	30MG/ML	A087032	001	Jul 08, 1982
	100MG/ML	A087053	001	

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

ROXANE	30MG/ML	A088157	001	Apr 27, 1983
	100MG/ML	A088158	001	Apr 27, 1983

SONAZINE

SANDOZ	30MG/ML	A080983	004	
	100MG/ML	A080983	005	

THORAZINE

GLAXOSMITHKLINE	30MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149	032	
	100MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149	043	

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

ABRAXIS PHARM	25MG/ML	A084911	001	
MARSAM PHARMS LLC	25MG/ML	A089563	001	Apr 15, 1988
WATSON LABS	25MG/ML	A080365	001	
	25MG/ML	A085591	001	
WYETH AYERST	25MG/ML	A080370	001	

THORAZINE

GLAXOSMITHKLINE	25MG/ML	N009149	011	

SYRUP; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ALPHARMA US PHARMS	10MG/5ML	A086712	001	

SONAZINE

SANDOZ	10MG/5ML	A083040	001	

THORAZINE

GLAXOSMITHKLINE	10MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149	022	

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ABBOTT	10MG	A084414	001	
	25MG	A084415	001	
	50MG	A084411	001	
	100MG	A084412	001	
	200MG	A084413	001	
IVAX SUB TEVA PHARMS	10MG	A083549	001	
	25MG	A083549	002	
	50MG	A083549	003	
	100MG	A083574	001	
	200MG	A083575	001	

KV PHARM	10MG	A085750	002	Jan 04, 1982
	25MG	A085751	001	
	50MG	A085484	001	
	100MG	A085752	001	
	200MG	A085748	002	Jan 04, 1982
LEDERLE	10MG	A084803	001	

DISCONTINUED DRUG PRODUCT LIST

6 - 81 (of 360)

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

LEDERLE	25MG	A084801	001	
	50MG	A084800	001	
	100MG	A084789	001	
	200MG	A084802	001	
PUREPAC PHARM	10MG	A080403	004	
	25MG	A080403	001	
	50MG	A080403	002	
	100MG	A080403	003	
	200MG	A080403	005	
PVT FORM	25MG	A080340	001	
	50MG	A080340	002	
	200MG	A080340	003	
ROXANE	10MG	A085331	001	
	25MG	A085331	002	
	50MG	A085331	003	
	100MG	A085331	004	
	200MG	A085331	005	
VANGARD	10MG	A088038	001	Aug 16, 1982
	25MG	A087645	001	
	50MG	A087646	001	
WATSON LABS	10MG	A085959	001	
	25MG	A085956	001	
	50MG	A085960	001	
	100MG	A085957	001	
	200MG	A085958	001	
WEST WARD	10MG	A087783	001	Sep 16, 1982
	25MG	A087865	001	Sep 16, 1982
	50MG	A087878	001	Sep 15, 1982
	100MG	A087884	001	Sep 15, 1982
	200MG	A087880	001	Sep 16, 1982
PROMAPAR				
PARKE DAVIS	10MG	A086886	001	
	25MG	A084423	001	
	50MG	A086887	001	
	100MG	A086888	001	
	200MG	A086885	001	
THORAZINE				
GLAXOSMITHKLINE	10MG	N009149	002	
	25MG	N009149	007	
	50MG	N009149	013	
	100MG	N009149	018	
	200MG	N009149	020	

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

BARR	100MG	A088812	001	Oct 19, 1984
	100MG	A089446	001	Nov 17, 1986
	250MG	A088813	001	Oct 19, 1984
	250MG	A089447	001	Nov 17, 1986
CLONMEL HLTHCARE	100MG	A089561	001	Sep 04, 1987
	250MG	A089562	001	Sep 04, 1987
DURAMED PHARMS BARR	100MG	A088918	001	Oct 16, 1984
	250MG	A088919	001	Oct 16, 1984
HALSEY	100MG	A089321	001	Jan 16, 1986
	250MG	A088662	001	Jan 09, 1986
IVAX PHARMS	100MG	A088840	001	Oct 25, 1984
	250MG	A087353	001	
PAR PHARM	100MG	A088175	001	Feb 27, 1984
	250MG	A088176	001	Feb 27, 1984

DISCONTINUED DRUG PRODUCT LIST

6 - 82 (of 360)

CHLORPROPAMIDE

TABLET; ORAL
CHLORPROPAMIDE

SANDOZ	100MG	A088725	001	Aug 31, 1984
	250MG	A084669	001	
	250MG	A088726	001	Aug 31, 1984
SUPERPHARM	100MG	A088694	001	Sep 17, 1984
	250MG	A088695	001	Sep 17, 1984
TEVA	100MG	A088768	001	Oct 11, 1984
USL PHARMA	100MG	A088708	001	Aug 30, 1984
	250MG	A088709	001	Aug 30, 1984
WATSON LABS	100MG	A088685	001	Sep 24, 1984
	100MG	A088608	001	Apr 12, 1984
	250MG	A088686	001	
	250MG	A088568	001	Apr 12, 1984
GLUCAMIDE				
TEVA	250MG	A088641	001	Oct 11, 1984

CHLORPROTHIXENE

CONCENTRATE; ORAL
TARACTAN

ROCHE	100MG/5ML	N016149	002	

INJECTABLE; INJECTION
TARACTAN

ROCHE	12.5MG/ML	N012487	001	

TABLET; ORAL
TARACTAN

ROCHE	10MG	N012486	005	
	25MG	N012486	004	
	50MG	N012486	003	
	100MG	N012486	001	

CHLORTETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC
AUREOMYCIN

LEDERLE	1%	N050404	001	

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE

ABBOTT	25MG	A087364	001	
	50MG	A087384	001	
ASCOT	25MG	A087698	001	Oct 20, 1982
	50MG	A087699	001	Oct 20, 1982
DAVA PHARMS INC	25MG	A087451	001	
	50MG	A087450	001	
IVAX PHARMS	25MG	A087555	001	
	25MG	A088164	001	Jan 09, 1984
	50MG	A087176	001	
	50MG	A087947	001	Feb 27, 1984
KV PHARM	25MG	A087311	001	
	50MG	A087312	001	
MUTUAL PHARM	25MG	A087292	001	
	25MG	A089285	001	Jul 21, 1986
	25MG	A089738	001	Sep 19, 1988
	50MG	A087293	001	
	50MG	A089286	001	Jul 21, 1986
	50MG	A089739	001	Sep 19, 1988
PIONEER PHARMS	50MG	A089591	001	Jul 21, 1988
PUREPAC PHARM	25MG	A088139	001	Jul 16, 1986
	50MG	A088140	001	Aug 11, 1983
SANDOZ	25MG	A087380	001	
	50MG	A087118	001	

DISCONTINUED DRUG PRODUCT LIST

6 - 83 (of 360)

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE

SANDOZ	50MG	A087381	001	
SUPERPHARM	25MG	A087473	001	Feb 09, 1983
	50MG	A087247	001	Feb 09, 1983
TEVA	50MG	A088651	001	May 30, 1985
USL PHARMA	25MG	A089051	001	Jun 01, 1987
	50MG	A089052	001	Jun 01, 1987
VANGARD	25MG	A088012	001	Jul 14, 1982
	50MG	A088073	001	Mar 25, 1983
WARNER CHILCOTT	25MG	A087515	001	Jan 24, 1983
	50MG	A087516	001	Feb 09, 1983
WATSON LABS	25MG	A087050	001	
	25MG	A087100	001	
	25MG	A087296	001	
	25MG	A087706	001	
	50MG	A087029	001	
	50MG	A087082	001	
	50MG	A087521	001	
	50MG	A087689	001	
HYGROTON				
SANOFI AVENTIS US	25MG	N012283	004	
	50MG	N012283	003	
THALITONE				
MONARCH PHARMS	25MG	A088051	001	Nov 12, 1982
	25MG	N019574	002	Feb 12, 1992

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

PAR PHARM	15MG;0.1MG	A071179	001	Dec 16, 1987
	15MG;0.2MG	A071178	001	Dec 16, 1987
	15MG;0.3MG	A071142	001	Dec 16, 1987
COMBIPRES				
BOEHRINGER INGELHEIM	15MG;0.1MG	N017503	001	
	15MG;0.2MG	N017503	002	
	15MG;0.3MG	N017503	003	Apr 10, 1984

CHLORTHALIDONE; METOPROLOL TARTRATE

CAPSULE; ORAL

LOPRESSIDONE

NOVARTIS	25MG;100MG	N019451	001	Dec 31, 1987
	25MG;200MG	N019451	002	Dec 31, 1987

CHLORTHALIDONE; RESERPINE

TABLET; ORAL

DEMI-REGROTON

SANOFI AVENTIS US	25MG;0.125MG	N015103	002	
REGROTON				
SANOFI AVENTIS US	50MG;0.25MG	N015103	001	

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

ACTAVIS TOTOWA	250MG	A088928	001	May 08, 1987
	500MG	A040113	001	Sep 29, 1995
MUTUAL PHARM	500MG	A089970	001	Sep 27, 1990
OHM LABS	250MG	A081298	001	Dec 29, 1993
	500MG	A081299	001	Dec 29, 1993
PAR PHARM	250MG	A087981	001	Sep 20, 1983
PIONEER PHARMS	250MG	A089592	001	Jan 06, 1989
	500MG	A089948	001	Jan 06, 1989

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 84 (of 360)

CHLORZOXAZONETABLET; ORAL
CHLORZOXAZONE

SANDOZ	250MG	A089852	001	May 04, 1988
	500MG	A089853	001	May 04, 1988
WATSON LABS	250MG	A086901	001	
	250MG	A086948	001	Aug 09, 1982
	500MG	A081019	001	Jul 29, 1991
PARAFLEX				
ORTHO MCNEIL PHARM	250MG	N011300	003	
STRIFON FORTE DSC				
FERNDAL LABS	500MG	A081008	001	Dec 23, 1988

CHOLESTYRAMINEBAR, CHEWABLE; ORAL
CHOLYBAR

PARKE DAVIS	EQ 4GM RESIN/BAR	A071621	001	May 26, 1988
	EQ 4GM RESIN/BAR	A071739	001	May 26, 1988

POWDER; ORAL
CHOLESTYRAMINE

IVAX SUB TEVA PHARMS	EQ 4GM RESIN/PACKET	A074771	001	Jul 09, 1997
	EQ 4GM RESIN/SCOOPFUL	A074771	002	Jul 09, 1997
TEVA	EQ 4GM RESIN/PACKET	A074347	001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074347	002	May 28, 1998
TEVA PHARMS	EQ 4GM RESIN/PACKET	A074554	001	Oct 02, 1996
	EQ 4GM RESIN/SCOOPFUL	A074554	002	Oct 02, 1996
CHOLESTYRAMINE LIGHT				
TEVA	EQ 4GM RESIN/PACKET	A074348	001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074348	002	May 28, 1998
TEVA PHARMS	EQ 4GM RESIN/PACKET	A074555	001	Sep 30, 1998
	EQ 4GM RESIN/SCOOPFUL	A074555	002	Sep 30, 1998

LOCHOLEST

SANDOZ	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996
	EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996

LOCHOLEST LIGHT

SANDOZ	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996
	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996

QUESTRAN

BRISTOL MYERS	EQ 4GM RESIN/PACKET	N016640	001	
	EQ 4GM RESIN/SCOOPFUL	N016640	003	

QUESTRAN LIGHT

BRISTOL MYERS	EQ 4GM RESIN/PACKET	N019669	001	Dec 05, 1988
	EQ 4GM RESIN/SCOOPFUL	N019669	003	Dec 05, 1988

TABLET; ORAL

QUESTRAN

APOTHECON	EQ 800MG RESIN	A073403	002	Dec 27, 1999
	EQ 1GM RESIN	A073403	001	Apr 28, 1994

CHORIOGONADOTROPIN ALFAINJECTABLE; INJECTION
OVIDREL

EMD SERONO	0.25MG/VIAL	N021149	001	Sep 20, 2000

CHROMIC CHLORIDEINJECTABLE; INJECTION
CHROMIC CHLORIDE

ABRAXIS PHARM	EQ 0.004MG CHROMIUM/ML	N019271	001	May 05, 1987

CHROMIC PHOSPHATE P-32INJECTABLE; INJECTION
PHOSPHOCOL P32

MALLINCKRODT	5mCi/ML	N017084	001	

DISCONTINUED DRUG PRODUCT LIST

6 - 85 (of 360)

CHYMOPAPAIN

INJECTABLE; INJECTION
CHYMODIACTIN

CHART MEDCL	4,000 UNITS/VIAL	N018663	002	Aug 21, 1984
	10,000 UNITS/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018663	001	Nov 10, 1982

DISCAGE ABBOTT	12,500 UNITS/VIAL	N018625	001	Jan 18, 1984

CHYMOTRYPSIN

FOR SOLUTION; OPHTHALMIC
ALPHA CHYMAR

SOLA BARNES HIND	750 UNITS/VIAL	N011837	001	
CATARASE				
CIBA	300 UNITS/VIAL	N016938	001	
NOVARTIS	150 UNITS/VIAL	N018121	001	
ZOLYSE				
ALCON	750 UNITS/VIAL	N011903	001	

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION
PRIMAXIN

MERCK	EQ 750MG BASE/VIAL;750MG/VIAL	N050630	002	Dec 14, 1990

CILOSTAZOL

TABLET; ORAL
CILOSTAZOL

ACTAVIS TOTOWA	100MG	A077028	002	Nov 26, 2004
IVAX SUB TEVA PHARMS	100MG	A077020	002	Mar 01, 2005
MUTUAL PHARM	50MG	A077208	002	Mar 29, 2006
	100MG	A077208	001	Mar 29, 2006

CIMETIDINE

SUSPENSION; ORAL
TAGAMET HB 200

GLAXOSMITHKLINE	200MG/20ML	N020951	001	Jul 09, 1999

TABLET; ORAL
CIMETIDINE

IVAX SUB TEVA PHARMS	200MG	A074401	001	May 30, 1995
	300MG	A074401	002	May 30, 1995
	400MG	A074401	003	May 30, 1995
	800MG	A074402	001	May 30, 1995
LEK PHARMS	100MG	A075122	001	Jun 19, 1998
	200MG	A074250	001	Jun 29, 1995
	200MG	A075122	002	Jun 19, 1998
	300MG	A074250	002	Jun 29, 1995
	400MG	A074250	003	Jun 29, 1995
	800MG	A074250	004	Jun 29, 1995
PERRIGO	100MG	A074972	001	Jun 19, 1998
ROXANE	300MG	A074361	001	Dec 23, 1994
	400MG	A074361	002	Dec 23, 1994
	800MG	A074371	001	Dec 23, 1994
SANDOZ	200MG	A074100	001	Jan 31, 1995
	200MG	A074506	001	Jan 24, 1996
	300MG	A074100	002	Jan 31, 1995
	300MG	A074506	002	Jan 24, 1996
	400MG	A074100	003	Jan 31, 1995
	400MG	A074506	003	Jan 24, 1996
	800MG	A074100	004	Jan 31, 1995
	800MG	A074506	004	Jan 24, 1996
TEVA	200MG	A074365	001	Feb 28, 1995
	300MG	A074365	002	Feb 28, 1995

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 86 (of 360)

CIMETIDINETABLET; ORAL
CIMETIDINE

TEVA	400MG	A074365	003	Feb 28, 1995
	800MG	A074365	004	Feb 28, 1995
VINTAGE PHARMS LLC	200MG	A074281	001	May 17, 1994
	300MG	A074281	002	May 17, 1994
	400MG	A074281	003	May 17, 1994
	800MG	A074329	001	May 17, 1994
TAGAMET HB				
GLAXOSMITHKLINE	100MG	N020238	001	Jun 19, 1995

CIMETIDINE HYDROCHLORIDEINJECTABLE; INJECTION
CIMETIDINE HYDROCHLORIDE

HOSPIRA	EQ 300MG BASE/2ML	A074296	001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074344	001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074345	001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074412	001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074422	001	Jan 31, 1995
LUITPOLD	EQ 300MG BASE/2ML	A074353	001	Dec 20, 1994
TEVA PARENTERAL	EQ 300MG BASE/2ML	A074252	001	Nov 26, 1997
VINTAGE PHARMS LLC	EQ 300MG BASE/2ML	A074005	001	Aug 31, 1994
CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
HOSPIRA	EQ 6MG BASE/ML	A074269	001	Dec 27, 1994
	EQ 90MG BASE/100ML	A074468	005	Dec 29, 1994
	EQ 120MG BASE/100ML	A074468	006	Dec 29, 1994
	EQ 180MG BASE/100ML	A074468	003	Dec 29, 1994
	EQ 240MG BASE/100ML	A074468	004	Dec 29, 1994
	EQ 360MG BASE/100ML	A074468	001	Dec 29, 1994
	EQ 480MG BASE/100ML	A074468	002	Dec 29, 1994
TAGAMET				
GLAXOSMITHKLINE	EQ 300MG BASE/2ML	N017939	002	
TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
GLAXOSMITHKLINE	EQ 6MG BASE/ML	N019434	001	Oct 31, 1985
SOLUTION; ORAL				
CIMETIDINE HYDROCHLORIDE				
ACTAVIS MID ATLANTIC	EQ 300MG BASE/5ML	A074176	001	Jun 01, 1994
DURAMED PHARMS BARR	EQ 300MG BASE/5ML	A075110	001	Jun 18, 1998
ROXANE	EQ 300MG BASE/5ML	A074541	001	Aug 05, 1997
TEVA PHARMS	EQ 300MG BASE/5ML	A074859	001	Jul 09, 1998
VINTAGE PHARMS LLC	EQ 300MG BASE/5ML	A074251	001	Dec 22, 1994
TAGAMET				
GLAXOSMITHKLINE	EQ 300MG BASE/5ML	N017924	001	

CINOXACINCAPSULE; ORAL
CINOXACIN

LILLY	250MG	N018067	001	
	500MG	N018067	002	
CINOXACIN				
TEVA	250MG	A073005	001	Feb 28, 1992
	500MG	A073006	001	Feb 28, 1992

CIPROFLOXACININJECTABLE; INJECTION
CIPRO

BAYER HLTHCARE	1200MG/120ML (10MG/ML)	N019847	003	Dec 26, 1990
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
BAYER PHARMS	200MG/100ML	N019858	001	Dec 26, 1990
CIPROFLOXACIN				
BEDFORD LABS	200MG/20ML (10MG/ML)	A076992	001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A076992	002	Aug 28, 2006

DISCONTINUED DRUG PRODUCT LIST

6 - 87 (of 360)

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

BEDFORD LABS	1200MG/120ML (10MG/ML)	A076993	001	Aug 28, 2006
FRESENIUS KABI USA	200MG/20ML (10MG/ML)	A076484	001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A076484	002	Aug 28, 2006
TEVA PARENTERAL	200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A077782	002	Aug 28, 2006
CIPROFLOXACIN IN DEXTROSE 5%				
HIKMA FARMACEUTICA	200MG/100ML	A076757	001	Apr 21, 2008
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	200MG/100ML	A077888	001	Mar 18, 2008
	400MG/200ML	A077888	002	Mar 18, 2008
BEDFORD	200MG/100ML	A078114	001	Mar 18, 2008
	400MG/200ML	A078114	002	Mar 18, 2008
TEVA PHARMS	200MG/100ML	A077138	001	Mar 18, 2008
	400MG/200ML	A077138	002	Mar 18, 2008

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

BARR	EQ 250MG BASE	A074124	001	Jun 09, 2004
	EQ 500MG BASE	A074124	002	Jun 09, 2004
	EQ 750MG BASE	A074124	003	Jun 09, 2004
NOSTRUM LABS	EQ 250MG BASE	A076138	001	Jun 09, 2004
	EQ 500MG BASE	A076138	002	Jun 09, 2004
	EQ 750MG BASE	A076138	003	Jun 09, 2004
PLIVA	EQ 100MG BASE	A076426	001	Jun 15, 2005
	EQ 250MG BASE	A076426	002	Jun 15, 2005
	EQ 500MG BASE	A076426	003	Jun 15, 2005
	EQ 750MG BASE	A076426	004	Jun 15, 2005
SANDOZ	EQ 100MG BASE	A075939	001	Mar 03, 2005
	EQ 250MG BASE	A075939	002	Jun 09, 2004
	EQ 250MG BASE	A076593	002	Jun 09, 2004
	EQ 500MG BASE	A075939	003	Jun 09, 2004
	EQ 500MG BASE	A076593	003	Jun 09, 2004
	EQ 750MG BASE	A075939	004	Jun 09, 2004
	EQ 750MG BASE	A076593	004	Jun 09, 2004
	EQ 750MG BASE	A076593	004	Jun 09, 2004
TEVA	EQ 250MG BASE	A076136	001	Jun 09, 2004
	EQ 500MG BASE	A076136	002	Jun 09, 2004
	EQ 750MG BASE	A076136	003	Jun 09, 2004
TABLET, EXTENDED RELEASE; ORAL				
PROQUIN XR				
DEPOMED INC	EQ 500MG BASE	N021744	001	May 19, 2005

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

SANDOZ	212.6MG;EQ 287.5MG BASE	A078712	001	Dec 11, 2007

CISAPRIDE MONOHYDRATE

SUSPENSION; ORAL

PROPULSID

JANSSEN PHARMS	EQ 1MG BASE/ML	N020398	001	Sep 15, 1995

TABLET; ORAL

PROPULSID

JANSSEN PHARMS	EQ 10MG BASE	N020210	001	Jul 29, 1993
	EQ 20MG BASE	N020210	002	Dec 23, 1993

TABLET, ORALLY DISINTEGRATING; ORAL

PROPULSID QUICKSOLV

JANSSEN PHARMA	EQ 20MG BASE	N020767	001	Nov 07, 1997

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 88 (of 360)

CISPLATININJECTABLE; INJECTION
CISPLATIN

BEDFORD	10MG/VIAL	A074713	001	Nov 14, 2000
	50MG/VIAL	A074713	002	Nov 14, 2000
TEVA PARENTERAL	1MG/ML	A074814	001	May 16, 2000
PLATINOL				
CORDEN PHARMA	10MG/VIAL	N018057	001	
	50MG/VIAL	N018057	002	
PLATINOL-AQ				
CORDEN PHARMA	0.5MG/ML	N018057	003	Jul 18, 1984
	1MG/ML	N018057	004	Nov 08, 1988

CITALOPRAM HYDROBROMIDESOLUTION; ORAL
CITALOPRAM HYDROBROMIDE

APOTEX INC	EQ 10MG BASE/5ML	A077601	001	Nov 15, 2005

TABLET; ORAL
CELEXA

FOREST LABS	EQ 60MG BASE	N020822	004	Jul 17, 1998

CITALOPRAM HYDROBROMIDE

ACTAVIS ELIZABETH	EQ 10MG BASE	A077033	001	Oct 28, 2004
	EQ 20MG BASE	A077033	002	Oct 28, 2004
	EQ 40MG BASE	A077033	003	Oct 28, 2004
MUTUAL PHARM	EQ 10MG BASE	A077052	001	Jul 03, 2006
	EQ 20MG BASE	A077052	002	Jul 03, 2006
	EQ 40MG BASE	A077052	003	Jul 03, 2006
ROXANE	EQ 10MG BASE	A077041	001	Nov 23, 2004
	EQ 20MG BASE	A077041	002	Nov 23, 2004
	EQ 40MG BASE	A077041	003	Nov 23, 2004
SANDOZ	EQ 10MG BASE	A077035	001	Oct 28, 2004
	EQ 10MG BASE	A077040	001	Aug 17, 2005
	EQ 20MG BASE	A077035	002	Oct 28, 2004
	EQ 20MG BASE	A077040	002	Aug 17, 2005
	EQ 40MG BASE	A077035	003	Oct 28, 2004
	EQ 40MG BASE	A077040	003	Aug 17, 2005
TARO	EQ 10MG BASE	A077278	001	Mar 22, 2006
	EQ 20MG BASE	A077278	002	Mar 22, 2006
	EQ 40MG BASE	A077278	003	Mar 22, 2006
TEVA PHARMS	EQ 10MG BASE	A077213	001	Mar 31, 2006
	EQ 20MG BASE	A077213	002	Mar 31, 2006
	EQ 40MG BASE	A077213	003	Mar 31, 2006

TABLET, ORALLY DISINTEGRATING; ORAL
CITALOPRAM HYDROBROMIDE

BIOVAIL LABS INTL	EQ 10MG BASE	N021763	001	Dec 20, 2005
	EQ 20MG BASE	N021763	002	Dec 20, 2005
	EQ 40MG BASE	N021763	003	Dec 20, 2005

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION

IRRIGATING SOLUTION G IN PLASTIC CONTAINER

BAXTER HLTHCARE	3.24GM/100ML;380MG/100ML;430MG/100ML	N018519	001	Jun 22, 1982

UROLOGIC G IN PLASTIC CONTAINER

HOSPIRA	3.24GM/100ML;380MG/100ML;430MG/100ML	N018904	001	May 27, 1983

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

ABBVIE	187MG/5ML	N050698	003	Sep 30, 1998

TABLET; ORAL

CLARITHROMYCIN

IVAX SUB TEVA PHARMS	250MG	A065137	001	May 31, 2005
	500MG	A065137	002	May 31, 2005

DISCONTINUED DRUG PRODUCT LIST

6 - 89 (of 360)

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL
CLARITHROMYCIN

RANBAXY	1GM	A065210	001	Jan 26, 2005
SANDOZ	500MG	A065250	001	Aug 25, 2005

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

ACTAVIS MID ATLANTIC	EQ 0.5MG BASE/5ML	A074075	001	Oct 31, 1993
TEVA PHARMS	EQ 0.5MG BASE/5ML	A073095	001	Apr 21, 1992

TAVIST

NOVARTIS	EQ 0.5MG BASE/5ML	N018675	001	Jun 28, 1985

TABLET; ORAL

CLEMASTINE FUMARATE

TEVA	1.34MG	A073282	001	Jan 31, 1992
	1.34MG	A073282	002	Dec 03, 1992

TAVIST

NOVARTIS	2.68MG	N017661	001	

TAVIST-1

NOVARTIS	1.34MG	N017661	002	
	1.34MG	N017661	003	Aug 21, 1992

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TAVIST-D

NOVARTIS	EQ 1MG BASE;75MG	N018298	001	Dec 15, 1982
	1.34MG;75MG	N018298	002	Aug 21, 1992
	1.34MG;75MG	N020640	001	Aug 09, 1996

CLIDINIUM BROMIDE

CAPSULE; ORAL

QUARZAN

ROCHE	2.5MG	N010355	001	
	5MG	N010355	002	

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN

PHARMACIA AND UPJOHN	EQ 75MG BASE	A061809	001	
	EQ 150MG BASE	A061809	002	

CLINDAMYCIN HYDROCHLORIDE

TEVA	EQ 75MG BASE	A063027	001	Sep 20, 1989
WATSON LABS	EQ 75MG BASE	A063082	001	Jul 31, 1991

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML	A061827	001	

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLEOCIN

PHARMACIA AND UPJOHN	EQ 2% BASE	N050680	001	Aug 11, 1992

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE

PHARMACIA AND UPJOHN	EQ 150MG BASE/ML	A061839	001	

CLINDAMYCIN PHOSPHATE

ABRAXIS PHARM	EQ 150MG BASE/ML	A062747	001	Jun 03, 1988
ASTRAZENECA	EQ 150MG BASE/ML	A062928	001	Feb 13, 1989
BEDFORD	EQ 150MG BASE/ML	A063163	001	Jun 30, 1994
BRISTOL MYERS SQUIBB	EQ 150MG BASE/ML	A062908	001	Feb 01, 1989
HIKMA MAPLE	EQ 150MG BASE/ML	A062806	001	Oct 15, 1987

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 90 (of 360)

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

HIKMA MAPLE	EQ 150MG BASE/ML	A062953	001	Apr 21, 1988
	EQ 150MG BASE/ML	A063068	001	Aug 28, 1989
LOCH	EQ 150MG BASE/ML	A062905	001	May 09, 1988
MARSAM PHARMS LLC	EQ 150MG BASE/ML	A062913	001	Oct 20, 1988
SOLOPAK	EQ 150MG BASE/ML	A062819	001	Mar 15, 1988
	EQ 150MG BASE/ML	A062852	001	Mar 17, 1988
TEVA PARENTERAL	EQ 150MG BASE/ML	A063041	001	Dec 29, 1989
	EQ 150MG BASE/ML	A063282	001	May 29, 1992
WATSON LABS	EQ 150MG BASE/ML	A062900	001	Jun 08, 1988
	EQ 150MG BASE/ML	A063079	001	Mar 05, 1990

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

ABRAXIS PHARM	EQ 12MG BASE/ML	N050636	001	Dec 22, 1989

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBVIE	EQ 6MG BASE/ML	A065027	001	Jun 29, 2001
	EQ 12MG BASE/ML	A065027	002	Jun 29, 2001
	EQ 18MG BASE/ML	A065027	003	Jun 29, 2001
BAXTER HLTHCARE	EQ 6MG BASE/ML	N050648	001	Dec 29, 1989
	EQ 12MG BASE/ML	N050648	002	Dec 29, 1989
	EQ 900MG BASE/100ML	N050648	003	Dec 29, 1989

SOLUTION; TOPICAL

CLEOCIN T

PHARMACIA AND UPJOHN	EQ 1% BASE	A062363	001	Feb 08, 1982

CLINDAMYCIN PHOSPHATE

BOCA PHARMA	EQ 1% BASE	A062930	001	Jun 28, 1989
COPLEY PHARM	EQ 1% BASE	A062944	001	Jan 11, 1989
G AND W LABS INC	EQ 1% BASE	A062811	001	Sep 01, 1988
RENAISSANCE PHARMA	EQ 1% BASE	A064108	001	Sep 27, 1996

CLIOQUINOL; NYSTATIN

OINTMENT; TOPICAL

NYSTAFORM

BAYER PHARMS	10MG/GM;100,000 UNITS/GM	N050235	001	

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

G AND W LABS INC	0.05%	A074139	001	Aug 03, 1994
RENAISSANCE PHARMA	0.05%	A075338	001	Feb 09, 2001
CLOBETASOL PROPIONATE (EMOLLIENT)				
RENAISSANCE PHARMA	0.05%	A075733	001	Aug 22, 2001

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

ACTAVIS MID ATLANTIC	0.05%	A074128	001	Aug 03, 1994
RENAISSANCE PHARMA	0.05%	A075057	001	Aug 12, 1998

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

G AND W LABS INC	0.05%	A074331	001	Dec 15, 1995

CLOFAZIMINE

CAPSULE; ORAL

LAMPRENE

NOVARTIS	100MG	N019500	001	Dec 15, 1986

CLOFIBRATE

CAPSULE; ORAL

ATROMID-S

WYETH AYERST	500MG	N016099	002	

CLOFIBRATE

BANNER PHARMACAPS	500MG	A073396	001	Mar 20, 1992
SANDOZ	500MG	A072191	001	May 02, 1988

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 91 (of 360)

CLOFIBRATECAPSULE; ORAL
CLOFIBRATE

TEVA	500MG	A072600	001	Jul 25, 1991
USL PHARMA	500MG	A070531	001	Jun 16, 1986
WATSON LABS	500MG	A071603	001	Sep 18, 1987

CLOMIPHENE CITRATETABLET; ORAL
MILOPHENE

MILEX	50MG	A072196	001	Dec 20, 1988

CLOMIPRAMINE HYDROCHLORIDECAPSULE; ORAL
CLOMIPRAMINE HYDROCHLORIDE

SANDOZ	25MG	A074953	001	Jun 25, 1997
	50MG	A074953	002	Jun 25, 1997
	75MG	A074953	003	Jun 25, 1997
TEVA	25MG	A074849	001	Apr 04, 1997
	50MG	A074849	002	Apr 04, 1997
	75MG	A074849	003	Apr 04, 1997
WATSON LABS	25MG	A074600	001	Nov 27, 1996
	25MG	A074751	001	Sep 30, 1998
	50MG	A074600	002	Nov 27, 1996
	50MG	A074751	002	Sep 30, 1998
	75MG	A074600	003	Nov 27, 1996
	75MG	A074751	003	Sep 30, 1998

CLONAZEPAMTABLET; ORAL
CLONAZEPAM

SANDOZ	0.5MG	A074925	001	Sep 30, 1997
	1MG	A074925	002	Sep 30, 1997
	2MG	A074925	003	Sep 30, 1997
TEVA	0.5MG	A074920	001	Aug 04, 1998
	1MG	A074920	002	Aug 04, 1998
	2MG	A074920	003	Aug 04, 1998

KLONOPIN

ROCHE	0.125MG	N017533	005	Apr 09, 1997
	0.25MG	N017533	006	Apr 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL
KLONOPIN RAPIDLY DISINTEGRATING

ROCHE	0.125MG	N020813	001	Dec 23, 1997
	0.25MG	N020813	002	Dec 23, 1997
	0.5MG	N020813	003	Dec 23, 1997
	1MG	N020813	004	Dec 23, 1997
	2MG	N020813	005	Dec 23, 1997

CLONIDINESUSPENSION, EXTENDED RELEASE; ORAL
CLONIDINE

TRIS PHARMA INC	EQ 0.09MG BASE/ML	N022499	001	Dec 03, 2009

TABLET, EXTENDED RELEASE; ORAL
CLONIDINE

TRIS PHARMA INC	EQ 0.17MG BASE	N022500	001	Dec 03, 2009
	EQ 0.26MG BASE	N022500	002	Dec 03, 2009

CLONIDINE HYDROCHLORIDETABLET; ORAL
CLONIDINE HYDROCHLORIDE

AM THERAP	0.1MG	A070881	001	Jul 08, 1986
	0.2MG	A070882	001	Jul 08, 1986
	0.3MG	A070883	001	Jul 08, 1986

DISCONTINUED DRUG PRODUCT LIST

6 - 92 (of 360)

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

DURAMED PHARMS BARR	0.1MG	A071103	001	Aug 14, 1986
	0.2MG	A071102	001	Aug 14, 1986
	0.3MG	A071101	001	Aug 14, 1986
INTERPHARM	0.1MG	A071252	001	Oct 01, 1986
	0.2MG	A071253	001	Oct 01, 1986
	0.3MG	A071254	001	Oct 01, 1986
PAR PHARM	0.1MG	A070461	001	Jul 08, 1986
	0.2MG	A070460	001	Jul 08, 1986
	0.3MG	A070459	001	Jul 08, 1986
SANDOZ	0.1MG	A070887	001	Aug 31, 1988
	0.2MG	A070886	001	Aug 31, 1988
	0.3MG	A071294	001	Aug 31, 1988
TEVA	0.1MG	A070747	001	Jul 08, 1986
	0.2MG	A070702	001	Jul 08, 1986
	0.3MG	A070659	001	Jul 08, 1986
WARNER CHILCOTT	0.1MG	A072138	001	Jun 13, 1988
	0.2MG	A072139	001	Jun 13, 1988
	0.3MG	A072140	001	Jun 13, 1988
WATSON LABS	0.1MG	A070395	001	Mar 23, 1987
	0.1MG	A070965	001	Jul 08, 1986
	0.2MG	A070396	001	Mar 23, 1987
	0.2MG	A070964	001	Jul 08, 1986
	0.3MG	A070397	001	Mar 23, 1987
TABLET, EXTENDED RELEASE; ORAL				
JENLOGA				
SHIONOGI INC	0.1MG	N022331	001	Sep 30, 2009
	0.2MG	N022331	002	May 25, 2010

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071777	001	Jul 14, 1987
	7.5MG	A071778	001	Jul 14, 1987
	15MG	A071779	001	Jul 14, 1987
AM THERAP	3.75MG	A071429	001	Jun 23, 1987
	7.5MG	A071430	001	Jun 23, 1987
	15MG	A071431	001	Jun 23, 1987
CLONMEL HLTHCARE	3.75MG	A071742	001	Dec 14, 1987
	7.5MG	A071743	001	Dec 14, 1987
	15MG	A071744	001	Dec 14, 1987
GD SEARLE LLC	3.75MG	A071727	001	Dec 18, 1987
	7.5MG	A071728	001	Dec 18, 1987
	15MG	A071729	001	Dec 18, 1987
MYLAN	3.75MG	A071509	001	Oct 19, 1987
	7.5MG	A071510	001	Oct 19, 1987
	15MG	A071511	001	Oct 19, 1987
PUREPAC PHARM	3.75MG	A071924	001	Apr 25, 1988
	7.5MG	A071925	001	Apr 25, 1988
	15MG	A071926	001	Apr 25, 1988
QUANTUM PHARMICS	3.75MG	A071549	001	Sep 12, 1988
	7.5MG	A071550	001	Sep 12, 1988
	15MG	A071522	001	Sep 12, 1988
SANDOZ	3.75MG	A072219	001	Aug 26, 1988
	7.5MG	A072220	001	Aug 26, 1988
	15MG	A072112	001	Aug 26, 1988
USL PHARMA	3.75MG	A071242	001	Jun 23, 1987
	7.5MG	A071243	001	Jun 23, 1987
	15MG	A071244	001	Jun 23, 1987
WARNER CHILCOTT	3.75MG	A071774	001	Mar 01, 1988
	7.5MG	A071775	001	Mar 01, 1988

DISCONTINUED DRUG PRODUCT LIST

6 - 93 (of 360)

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

WARNER CHILCOTT	15MG	A071776	001	Mar 01, 1988
WATSON LABS	3.75MG	A071878	001	Mar 15, 1988
	7.5MG	A071879	001	Mar 15, 1988
	15MG	A071860	001	Mar 15, 1988

TRANXENE

LUNDBECK LLC	3.75MG	N017105	001	
	7.5MG	N017105	002	
	15MG	N017105	003	

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071780	001	Jun 26, 1987
	7.5MG	A071781	001	Jun 26, 1987
	15MG	A071782	001	Jun 26, 1987
AM THERAP	3.75MG	A071747	001	Jun 23, 1987
	7.5MG	A071748	001	Jun 23, 1987
	15MG	A071749	001	Jun 23, 1987
LEDERLE	3.75MG	A072013	001	Dec 15, 1987
	7.5MG	A072014	001	Dec 15, 1987
	15MG	A072015	001	Dec 15, 1987
PUREPAC PHARM	3.75MG	A072330	001	Aug 08, 1988
	7.5MG	A072331	001	Aug 08, 1988
	15MG	A072332	001	Aug 08, 1988
QUANTUM PHARMICS	3.75MG	A071730	001	Oct 26, 1987
	7.5MG	A071731	001	Oct 26, 1987
	15MG	A071702	001	Oct 26, 1987
SANDOZ	3.75MG	A072512	001	May 11, 1990
	7.5MG	A072513	001	May 11, 1990
	15MG	A072514	001	May 11, 1990
WARNER CHILCOTT	3.75MG	A071828	001	Mar 03, 1988
	7.5MG	A071829	001	Mar 03, 1988
	15MG	A071830	001	Mar 03, 1988
TRANXENE SD				
LUNDBECK LLC	11.25MG	N017105	005	
	22.5MG	N017105	004	

CLOTRIMAZOLE

CREAM; TOPICAL

LOTTRIMIN

SCHERING PLOUGH	1%	N017619	001	

MYCELEX

BAYER PHARMS	1%	N018183	001	

LOTION; TOPICAL

LOTTRIMIN

SCHERING	1%	N018813	001	Feb 17, 1984

SOLUTION; TOPICAL

LOTTRIMIN

SCHERING PLOUGH	1%	N017613	001	

TABLET; VAGINAL

GYNIX

TEVA PHARMS	100MG	A073249	001	Feb 13, 1998

MYCELEX-G

BAYER PHARMS	500MG	N019069	001	Apr 19, 1985

TROCHE/LOZENGE; ORAL

MYCELEX

BAYER HLTHCARE	10MG	N018713	001	Jun 17, 1983

CLOXACILLIN SODIUM

CAPSULE; ORAL

CLOXACILLIN SODIUM

APOTHECON	EQ 250MG BASE	A061452	001	
	EQ 500MG BASE	A061452	002	

DISCONTINUED DRUG PRODUCT LIST

6 - 94 (of 360)

CLOXACILLIN SODIUM

CAPSULE; ORAL				
CLOXACILLIN SODIUM				
TEVA	EQ 250MG BASE	A062240	001	
	EQ 500MG BASE	A062240	002	
CLOXAPEN				
GLAXOSMITHKLINE	EQ 250MG BASE	A061806	001	
	EQ 250MG BASE	A062233	001	
	EQ 500MG BASE	A061806	002	
	EQ 500MG BASE	A062233	002	
FOR SOLUTION; ORAL				
CLOXACILLIN SODIUM				
TEVA	EQ 125MG BASE/5ML	A062268	001	
	EQ 125MG BASE/5ML	A062978	001	Apr 06, 1989
TEGOPEN				
APOTHECON	EQ 125MG BASE/5ML	A061453	001	
	EQ 125MG BASE/5ML	N050192	001	

CLOZAPINE

TABLET; ORAL				
CLOZAPINE				
PAR PHARM	25MG	A075162	001	Apr 26, 2005
	100MG	A075162	002	Apr 26, 2005
	25MG	A074546	001	Aug 30, 1996
SANDOZ	100MG	A074546	002	Aug 30, 1996
TABLET, ORALLY DISINTEGRATING; ORAL				
FAZACLO ODT				
JAZZ PHARMS III	50MG	N021590	003	Jun 03, 2005

COBALT CHLORIDE CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A; N/A				
RUBRATOPE-57 KIT				
BRACCO	N/A;N/A;N/A;N/A	N016089	001	

COBALT CHLORIDE CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN CO-60; INTRINSIC FACTOR

N/A; N/A				
RUBRATOPE-60 KIT				
BRACCO	N/A;N/A;N/A;N/A	N016090	001	

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL				
PHENERGAN VC W/ CODEINE				
ANI PHARMS	10MG/5ML;5MG/5ML;6.25MG/5ML	N008306	005	Apr 02, 1984
PHERAZINE VC W/ CODEINE				
HALSEY	10MG/5ML;5MG/5ML;6.25MG/5ML	A088870	001	Mar 02, 1987
PROMETHAZINE VC W/ CODEINE				
CENCI	10MG/5ML;5MG/5ML;6.25MG/5ML	A088816	001	Nov 22, 1985
WOCKHARDT	10MG/5ML;5MG/5ML;6.25MG/5ML	A088896	001	Jan 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL				
PHENERGAN W/ CODEINE				
ANI PHARMS	10MG/5ML;6.25MG/5ML	N008306	004	Apr 02, 1984
PHERAZINE W/ CODEINE				
HALSEY	10MG/5ML;6.25MG/5ML	A088739	001	Dec 23, 1988
PROMETHAZINE W/ CODEINE				
CENCI	10MG/5ML;6.25MG/5ML	A088814	001	Nov 22, 1985

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL				
ACTIFED W/ CODEINE				
GLAXOSMITHKLINE	10MG/5ML;30MG/5ML;1.25MG/5ML	N012575	003	Apr 04, 1984

DISCONTINUED DRUG PRODUCT LIST

6 - 95 (of 360)

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL		
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE		
CENCI	10MG/5ML;30MG/5ML;1.25MG/5ML	A089018 001 Jul 23, 1986
TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE		
WOCKHARDT	10MG/5ML;30MG/5ML;1.25MG/5ML	A088833 001 Nov 16, 1984

COLCHICINE; PROBENECID

TABLET; ORAL		
COLBENEMID		
MERCK	0.5MG;500MG	N012383 001
PROBEN-C		
WATSON LABS	0.5MG;500MG	A085552 001
PROBENECID AND COLCHICINE		
BEECHAM	0.5MG;500MG	A084321 001
IMPAX LABS	0.5MG;500MG	A083720 002
IVAX SUB TEVA PHARMS	0.5MG;500MG	A083734 001
SANDOZ	0.5MG;500MG	A086130 001
PROBENECID W/ COLCHICINE		
LEDERLE	0.5MG;500MG	A086954 001
WATSON LABS	0.5MG;500MG	A083221 001

COLESEVELAM HYDROCHLORIDE

CAPSULE; ORAL		
WELCHOL		
DAIICHI SANKYO	375MG	N021141 001 May 26, 2000

COLISTIN SULFATE

SUSPENSION; ORAL		
COLY-MYCIN S		
PARKE DAVIS	EQ 25MG BASE/5ML	N050355 001

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)		
VAPRISOL		
ASTELLAS	20MG/4ML (5MG/ML)	N021697 001 Dec 29, 2005

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE		
CU-7		
GD SEARLE LLC	89MG	N017408 001
TATUM-T		
GD SEARLE LLC	120MG	N018205 001

CORTICOTROPIN

INJECTABLE; INJECTION		
ACTH		
PARKEDALE	25 UNITS/VIAL	N008317 002
	40 UNITS/VIAL	N008317 004
ACTHAR		
SANOFI AVENTIS US	25 UNITS/VIAL	N007504 002
	40 UNITS/VIAL	N007504 003
CORTICOTROPIN		
ORGANICS LAGRANGE	40 UNITS/ML	N010831 001
	80 UNITS/ML	N010831 002
WATSON LABS	40 UNITS/VIAL	A088772 001 Nov 21, 1984
H.P. ACTHAR GEL		
QUESTCOR PHARMS	40 UNITS/ML	N008372 006
PURIFIED CORTROPHIN GEL		
ORGANON USA INC	40 UNITS/ML	N008975 001
	80 UNITS/ML	N008975 002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 96 (of 360)

CORTICOTROPIN-ZINC HYDROXIDEINJECTABLE; INJECTION
CORTROPHIN-ZINC

ORGANON USA INC 40 UNITS/ML N009854 001

CORTISONE ACETATEINJECTABLE; INJECTION
CORTISONE ACETATE

PHARMACIA AND UPJOHN	25MG/ML	N008126	002
WATSON LABS	25MG/ML	A083147	003
	25MG/ML	A085677	001
	50MG/ML	A083147	004
	50MG/ML	A085677	002

CORTONE

MERCK	25MG/ML	N007110	002
	50MG/ML	N007110	003

TABLET; ORAL

CORTISONE ACETATE

BARR	25MG	A083471	001
ELKINS SINN	25MG	A080836	001
EVERYLIFE	25MG	A084246	001
HEATHER	25MG	A085736	001
IMPAX LABS	25MG	N009458	001
INWOOD LABS	25MG	A080731	001
IVAX SUB TEVA PHARMS	25MG	A080630	001
	25MG	A083536	001
LANNETT	25MG	A080694	001
PANRAY	5MG	N008284	002
	25MG	N008284	001
PHARMACIA AND UPJOHN	5MG	N008126	003
	10MG	N008126	004
	25MG	N008126	001
PUREPAC PHARM	25MG	A080493	001
VITARINE	25MG	A080333	001
WATSON LABS	25MG	A085884	001
WHITEWORTH TOWN PLSN	25MG	A080341	001
CORTONE			
MERCK	25MG	N007750	003

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

KING PFIZER 0.8MG/INH N018887 001 Dec 05, 1985

CAPSULE; INHALATION

INTAL

SANOFI AVENTIS US 20MG N016990 001

CAPSULE; ORAL

GASTROCROM

UCB INC 100MG N019188 001 Dec 22, 1989

CONCENTRATE; ORAL

CROMOLYN SODIUM

GENERA PHARMS 100MG/5ML A090954 001 Dec 18, 2009

SOLUTION; INHALATION

CROMOLYN SODIUM

ACTAVIS MID ATLANTIC	10MG/ML	A075067	001	Jul 19, 1999
PHARMASCIENCE INC	10MG/ML	A075437	001	Apr 21, 2000
ROXANE	10MG/ML	A075175	001	Sep 30, 1999

INTAL

KING PHARMS 10MG/ML N018596 001 May 28, 1982

SOLUTION/DROPS; OPHTHALMIC

CROMOPTIC

KING PHARMS 4% A075088 001 Apr 27, 1999

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 97 (of 360)

CROMOLYN SODIUMSPRAY, METERED; NASAL
CROMOLYN SODIUM

ACTAVIS MID ATLANTIC	5.2MG/SPRAY	A074800	001	Jul 26, 2001
HH AND P	5.2MG/SPRAY	A077976	001	Sep 07, 2007
NASALCROM				
BLACKSMITH BRANDS	5.2MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020463	001	Jan 03, 1997

CRYPTENAMINE ACETATESINJECTABLE; INJECTION
UNITENSEN

MEDPOINTE PHARM HLC	260CSR UNIT/ML	N008814	001	

CRYPTENAMINE TANNATESTABLET; ORAL
UNITENSEN

MEDPOINTE PHARM HLC	260CSR UNIT	N009217	001	

CUPRIC SULFATEINJECTABLE; INJECTION
CUPRIC SULFATE

ABRAXIS PHARM	EQ 0.4MG COPPER/ML	N019350	001	May 05, 1987

CYANOCOBALAMINGEL, METERED; NASAL
NASCOBAL

PAR PHARM	0.5MG/INH	N019722	001	Nov 05, 1996

INJECTABLE; INJECTION
BERUBIGEN

PHARMACIA AND UPJOHN	1MG/ML	N006798	001	

BETALIN 12

LILLY	0.1MG/ML	A080855	001	
	1MG/ML	A080855	002	

COBAVITE

WATSON LABS	0.1MG/ML	A083013	001	
	1MG/ML	A083064	001	

CYANOCOBALAMIN

ABRAXIS PHARM	0.03MG/ML	A080510	003	
	0.1MG/ML	A080510	001	
	1MG/ML	A080510	002	

AKORN	1MG/ML	A087969	001	Nov 10, 1983

BIONICHE PHARMA	1MG/ML	A040451	001	Sep 23, 2003

DELL LABS	0.03MG/ML	A080689	001	

	0.1MG/ML	A080689	002	

	1MG/ML	A080689	003	

FRESENIUS KABI USA	0.1MG/ML	A080557	002	

HIKMA MAPLE	1MG/ML	A080515	002	

LUITPOLD	0.03MG/ML	A080668	001	

LYPHOMED	1MG/ML	A083075	001	

SANOFI AVENTIS US	1MG/ML	A080564	001	

SOLOPAK	1MG/ML	A087551	001	Feb 29, 1984

WARNER CHILCOTT	1MG/ML	N007085	002	

WATSON LABS	0.1MG/ML	A080573	002	

	0.1MG/ML	A083120	001	

	1MG/ML	A080573	001	

	1MG/ML	A083120	002	

WYETH AYERST	0.1MG/ML	A080554	001	

	1MG/ML	A080554	002	

REDISOL

MERCK	1MG/ML	N006668	010	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 98 (of 360)

CYANOCOBALAMIN

INJECTABLE; INJECTION

RUBIVITE

BEL MAR

0.03MG/ML

N010791 004

0.05MG/ML

N010791 001

0.1MG/ML

N010791 002

0.12MG/ML

N010791 005

1MG/ML

N010791 003

RUBRAMIN PC

BRISTOL MYERS SQUIBB

0.1MG/ML

N006799 002

1MG/ML

N006799 004

1MG/ML

N006799 010 Apr 28, 1988

RUVITE

SAVAGE LABS

1MG/ML

A080570 002

VI-TWEL

BAYER HLTHCARE

1MG/ML

N007012 002

SPRAY, METERED; NASAL

CALOMIST

PAR PHARM

25MCG/SPRAY

N022102 001 Jul 27, 2007

TABLET; ORAL

CYANOCOBALAMIN

WEST WARD

1MG

A084264 001

CYANOCOBALAMIN CO-57

CAPSULE; ORAL

RUBRATOPE-57

BRACCO

0.5-1uCi

N016089 002

CYANOCOBALAMIN CO-60

CAPSULE; ORAL

RUBRATOPE-60

BRACCO

0.5-1uCi

N016090 002

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; CYANOCOBALAMIN CO-58

N/A; N/A

DICOPAC KIT

GE HEALTHCARE

N/A;N/A;N/A

N017406 001

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A; N/A

CYANOCOBALAMIN CO 57 SCHILLING TEST KIT

MALLINCKRODT

0.1MG;0.5uCi;60MG

N016635 001

CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

INJECTABLE; INJECTION

DEPINAR

ARMOUR PHARM

0.5MG/ML;2.3MG/ML;1MG/ML

N011208 001

CYCLACILLIN

FOR SUSPENSION; ORAL

CYCLAPEN-W

WYETH AYERST

125MG/5ML

N050508 001

250MG/5ML

N050508 002

500MG/5ML

N050508 003

TABLET; ORAL

CYCLACILLIN

TEVA

250MG

A062895 001 Aug 04, 1988

500MG

A062895 002 Aug 04, 1988

CYCLAPEN-W

WYETH AYERST

250MG

N050509 001

500MG

N050509 002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 99 (of 360)

CYCLIZINE LACTATEINJECTABLE; INJECTION
MAREZINE

GLAXOSMITHKLINE 50MG/ML N009495 001

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

SANDOZ 10MG A073683 001 Feb 26, 1993

WATSON LABS 10MG A073143 001 Nov 27, 1991

10MG A074436 001 Nov 30, 1994

FLEXERIL

JANSSEN RES AND DEV 5MG N017821 001

10MG N017821 002

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AK-PENTOLATE

AKORN 1% A085555 001

CYCLOPENTOLATE HYDROCHLORIDE

ALCON PHARMS LTD 1% A089162 001 Jan 24, 1991

SOLA BARNES HIND 1% A084150 001

1% A084863 001

PENTOLAIR

PHARMAFAIR 0.5% A088643 001 Feb 09, 1987

1% A088150 001 Feb 25, 1983

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

BAXTER HLTHCARE 100MG/VIAL A088371 001 Jul 03, 1986

200MG/VIAL A088372 001 Jul 03, 1986

500MG/VIAL A088373 001 Jul 03, 1986

1GM/VIAL A088374 001 Sep 24, 1986

CYTOXAN

BAXTER HLTHCARE 100MG/VIAL N012142 001

200MG/VIAL N012142 002

LYOPHILIZED CYTOXAN

BAXTER HLTHCARE 100MG/VIAL N012142 006 Dec 05, 1985

200MG/VIAL N012142 007 Dec 10, 1985

500MG/VIAL N012142 008 Jan 04, 1984

1GM/VIAL N012142 010 Sep 24, 1985

2GM/VIAL N012142 009 Dec 10, 1985

NEOSAR

TEVA PARENTERAL 100MG/VIAL A040015 001 Apr 29, 1993

100MG/VIAL A087442 001 Feb 16, 1982

200MG/VIAL A040015 002 Apr 29, 1993

200MG/VIAL A087442 002 Feb 16, 1982

500MG/VIAL A040015 003 Apr 29, 1993

500MG/VIAL A087442 003 Feb 16, 1982

1GM/VIAL A040015 004 Apr 29, 1993

1GM/VIAL A087442 004 Jul 08, 1983

2GM/VIAL A040015 005 Apr 29, 1993

2GM/VIAL A087442 005 Mar 30, 1989

TABLET; ORAL

CYTOXAN

BAXTER HLTHCARE 25MG N012141 002

50MG N012141 001

CYCLOSPORINE

CAPSULE; ORAL

NEORAL

NOVARTIS 50MG N050715 003 Jul 14, 1995

DISCONTINUED DRUG PRODUCT LIST

6 - 100 (of 360)

CYCLOTHIAZIDE

TABLET; ORAL
ANHYDRON

LILLY	2MG	N013157	002	
FLUIDIL				
PHARMACIA AND UPJOHN	2MG	N018173	001	

CYCRIMINE HYDROCHLORIDE

TABLET; ORAL
PAGITANE

LILLY	1.25MG	N008951	001	
	2.5MG	N008951	002	

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	2MG/5ML	A086833	001	
HALSEY	2MG/5ML	A089199	001	Jul 03, 1986
MORTON GROVE	2MG/5ML	A087001	001	Nov 04, 1982
NASKA	2MG/5ML	A089021	001	Dec 21, 1987
PERIACTIN				
MERCK	2MG/5ML	N013220	002	

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AM THERAP	4MG	A088798	001	Feb 15, 1985
ASCOT	4MG	A087685	001	Oct 25, 1982
DURAMED PHARMS BARR	4MG	A088232	001	Oct 25, 1983
HALSEY	4MG	A089057	001	Jul 03, 1986
KV PHARM	4MG	A086737	001	
MD PHARM	4MG	A087566	001	Nov 10, 1982
MYLAN	4MG	A086678	001	
PIIONEER PHARMS	4MG	A087839	001	Feb 08, 1984
PLIVA	4MG	A088205	001	Jul 26, 1983
SANDOZ	4MG	A086808	001	
SUPERPHARM	4MG	A087405	001	
TG UNITED LABS	4MG	A088212	001	May 26, 1983
VITARINE	4MG	A087284	001	
WATSON LABS	4MG	A085245	001	
	4MG	A086165	001	
	4MG	A086580	001	
PERIACTIN				
MERCK	4MG	N012649	001	

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION

CYSTEINE HYDROCHLORIDE

HOSPIRA	7.25% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019523	001	Oct 22, 1986

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

TEVA PARENTERAL	100MG/VIAL	N016793	001	
	500MG/VIAL	N016793	002	
	1GM/VIAL	N016793	003	Dec 21, 1987
	2GM/VIAL	N016793	004	Dec 21, 1987

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

ABRAXIS PHARM	100MG/VIAL	A070962	001	Aug 28, 1986
	200MG/VIAL	A070990	001	Aug 28, 1986

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 101 (of 360)

DALFOPRISTIN; QUINUPRISTININJECTABLE; IV (INFUSION)
SYNERCID

KING PHARMS

420MG/VIAL;180MG/VIAL

N050748 002 Aug 24, 2000

DALTEPARIN SODIUMINJECTABLE; INJECTION
FRAGMIN

EISAI INC

7,500 IU/0.75ML

N020287 008 Apr 04, 2002

DANAPAROID SODIUMINJECTABLE; INJECTION
ORGARAN

ORGANON USA INC

750 UNITS/0.6ML

N020430 001 Dec 24, 1996

DANAZOLCAPSULE; ORAL
DANAZOL

AM THERAP

200MG

A071569 001 Dec 30, 1987

DANOCRINE

SANOFI AVENTIS US

50MG

N017557 003

100MG

N017557 004

200MG

N017557 002

DANTROLENE SODIUMCAPSULE; ORAL
DANTROLENE SODIUM

MIKAH PHARMA

25MG

A076686 001 Oct 24, 2005

50MG

A076686 002 Oct 24, 2005

100MG

A076686 003 Oct 24, 2005

DAPIPRAZOLE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
DAPIPRAZOLE HYDROCHLORIDE

FERA PHARMS

0.5%

N019849 001 Dec 31, 1990

DAPTOMYCININJECTABLE; IV (INFUSION)
CUBICIN

CUBIST

250MG/VIAL

N021572 001 Sep 12, 2003

DARUNAVIR ETHANOLATETABLET; ORAL
PREZISTA

JANSSEN PRODS

EQ 300MG BASE

N021976 001 Jun 23, 2006

DAUNORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
CERUBIDINE

SANOFI AVENTIS US

EQ 20MG BASE/VIAL

A061876 001

WYETH AYERST

EQ 20MG BASE/VIAL

N050484 001

DAUNORUBICIN HYDROCHLORIDE

TEVA PARENTERAL

EQ 20MG BASE/VIAL

A064212 001 Jun 23, 1998

EQ 50MG BASE/VIAL

A064212 002 May 03, 1999

DECAMETHONIUM BROMIDEINJECTABLE; INJECTION
SYNCURINE

GLAXOSMITHKLINE

1MG/ML

N006931 002

DISCONTINUED DRUG PRODUCT LIST

6 - 102 (of 360)

DEMECARIUM BROMIDE

SOLUTION/DROPS; OPHTHALMIC
HUMORSOL

MERCK	0.125%	N011860	002
	0.25%	N011860	001

DEMECLOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DECLOMYCIN

LEDERLE	150MG	N050262	001

SYRUP; ORAL

DECLOMYCIN

LEDERLE	75MG/5ML	N050257	001

TABLET; ORAL

DECLOMYCIN

COREPHARMA	75MG	N050261	001
	150MG	N050261	002
	300MG	N050261	003

DESERPIDINE

TABLET; ORAL

HARMONYL

ABBVIE	0.1MG	N010796	001
	0.25MG	N010796	002

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ORETICYL 25

ABBVIE	0.125MG; 25MG	N012148	001

ORETICYL 50

ABBVIE	0.125MG; 50MG	N012148	003

ORETICYL FORTE

ABBVIE	0.25MG; 25MG	N012148	002

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL

ENDURONYL

ABBOTT	0.25MG; 5MG	N012775	001

ENDURONYL FORTE

ABBOTT	0.5MG; 5MG	N012775	002

METHYCLOTHIAZIDE AND DESERPIDINE

WATSON LABS	0.25MG; 5MG	A088486	001	Aug 10, 1984
	0.5MG; 5MG	A088452	001	Aug 10, 1984

DESIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

PERTOFRANE

SANOFI AVENTIS US	25MG	N013621	001
	50MG	N013621	002

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

PLIVA	25MG	A071800	001	Dec 08, 1987
	50MG	A071801	001	Dec 08, 1987
	75MG	A071802	001	Dec 08, 1987
	100MG	A071803	001	May 29, 1997
	150MG	A071804	001	May 29, 1997
USL PHARMA	25MG	A071864	001	Sep 09, 1987
	50MG	A071865	001	Sep 09, 1987
	75MG	A071866	001	Sep 09, 1987
	100MG	A071867	001	Sep 09, 1987

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 103 (of 360)

DESLANOSIDE

INJECTABLE; INJECTION

CEDILANID-D

NOVARTIS

0.2MG/ML

N009282 002

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

SANOFI AVENTIS US

0.015MG/ML

N018938 002 Apr 25, 1995

DESMOPRESSIN ACETATE

BEDFORD

0.004MG/ML

A074575 001 Feb 18, 2000

DESMOPRESSIN ACETATE PRESERVATIVE FREE

BEDFORD

0.004MG/ML

A074574 001 Feb 18, 2000

SOLUTION; NASAL

CONCENTRAID

FERRING

0.01%

N019776 001 Dec 26, 1990

SPRAY, METERED; NASAL

DDAVP

SANOFI AVENTIS US

0.01MG/SPRAY

N017922 002 Feb 06, 1989

STIMATE

CSL BEHRING

0.15MG/SPRAY

N020355 001 Mar 07, 1994

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

DESOGEN

ORGANON USA INC

0.15MG;0.03MG

N020071 001 Dec 10, 1992

DESOGESTREL AND ETHINYL ESTRADIOL

DURAMED PHARMS BARR

0.15MG;0.03MG

A075256 001 Aug 12, 1999

ORTHO-CEPT

JANSSEN PHARMS

0.15MG;0.03MG

N020301 001 Dec 14, 1992

DESONIDE

CREAM; TOPICAL

DESONIDE

TEVA PHARMS

0.05%

A074027 001 Sep 28, 1992

DESOXIMETASONE

CREAM; TOPICAL

TOPICORT

TARO PHARMS NORTH

0.25%

N017856 001

TOPICORT LP

TARO PHARMS NORTH

0.05%

N018309 001

GEL; TOPICAL

TOPICORT

TARO PHARMS NORTH

0.05%

N018586 001 Mar 29, 1982

OINTMENT; TOPICAL

DESOXIMETASONE

ALTANA

0.25%

A073440 001 Apr 01, 1998

TOPICORT

TARO PHARMS NORTH

0.25%

N018763 001 Sep 30, 1983

DESOXYCORTICOSTERONE ACETATE

INJECTABLE; INJECTION

DOCA

ORGANON USA INC

5MG/ML

N001104 001

PELLET; IMPLANTATION

PERCORTEN

NOVARTIS

125MG

N005151 001

DESOXYCORTICOSTERONE PIVALATE

INJECTABLE; INJECTION

PERCORTEN

NOVARTIS

25MG/ML

N008822 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 104 (of 360)

DEXAMETHASONE

AEROSOL; TOPICAL

AEROSEB-DEX

ALLERGAN HERBERT

0.01% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

A083296 002

DECASPRAY

MERCK

0.04% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N012731 002

ELIXIR; ORAL

DECADRON

MERCK

0.5MG/5ML

N012376 002

DEXAMETHASONE

ALPHARMA US PHARMS

0.5MG/5ML

A088997 001

Oct 10, 1986

HEXADROL

ORGANON USA INC

0.5MG/5ML

N012674 001

GEL; TOPICAL

DECADERM

MERCK

0.1%

N013538 001

SUSPENSION/DROPS; OPHTHALMIC

DEXAMETHASONE

WATSON LABS

0.1%

A089170 001

May 09, 1989

TABLET; ORAL

DECADRON

MERCK

0.25MG **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

N011664 004

0.5MG

N011664 001

0.75MG

N011664 002

1.5MG

N011664 003

4MG

N011664 005

6MG

N011664 006

Jul 30, 1982

DEXAMETHASONE

IMPAX LABS

0.75MG

A085376 001

MUTUAL PHARM

0.25MG

A084013 001

0.25MG

A084764 001

0.5MG

A084084 001

0.5MG

A084766 001

0.75MG

A084081 001

0.75MG

A084765 001

1.5MG

A084086 001

1.5MG

A084763 001

PAR PHARM

0.25MG

A088149 001

Apr 28, 1983

PHOENIX LABS NY

0.75MG

A083806 001

PVT FORM

0.75MG

A083420 001

ROXANE

0.25MG

A084614 001

SANDOZ

0.75MG

A080399 001

UPSHER SMITH

0.75MG

A087534 001

1.5MG

A087533 001

WATSON LABS

0.25MG

A085455 001

0.5MG

A085458 001

0.75MG

A080968 001

0.75MG

A084457 001

0.75MG

A085818 001

1.5MG

A085456 001

1.5MG

A085840 001

WHITEWORTH TOWN PLSN

0.75MG

A084327 001

DEXONE 0.5

SOLVAY

0.5MG

A084991 001

DEXONE 0.75

SOLVAY

0.75MG

A084993 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 105 (of 360)

DEXAMETHASONE

TABLET; ORAL

DEXONE 1.5

SOLVAY

1.5MG

A084990 001

DEXONE 4

SOLVAY

4MG

A084992 001

HEXADROL

ORGANON USA INC

0.5MG

N012675 004

0.75MG

N012675 007

1.5MG

N012675 009

4MG

N012675 010

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION

DECADRON-LA

MERCK

EQ 8MG BASE/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

N016675 001

DEXAMETHASONE ACETATE

WATSON LABS

EQ 8MG BASE/ML

A084315 001

EQ 16MG BASE/ML

A087711 001

May 24, 1982

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL; NASAL

DEXACORT

UCB INC

EQ 0.1MG PHOSPHATE/INH

N014242 001

AEROSOL, METERED; INHALATION

DEXACORT

UCB INC

EQ 0.1MG PHOSPHATE/INH

N013413 001

CREAM; TOPICAL

DECADRON

MERCK

EQ 0.1% PHOSPHATE

N011983 002

INJECTABLE; INJECTION

DECADRON

MERCK

EQ 4MG PHOSPHATE/ML

N012071 002

EQ 24MG PHOSPHATE/ML **Federal
Register determination that product
was not discontinued or withdrawn for
safety or efficacy reasons**

N012071 004

DEXACEN-4

CENT PHARMS

EQ 4MG PHOSPHATE/ML

A084342 001

DEXAMETHASONE

ABRAXIS PHARM

EQ 4MG PHOSPHATE/ML

A088448 001

Jan 25, 1984

FRESENIUS KABI USA

EQ 10MG PHOSPHATE/ML

A088469 001

Jan 25, 1984

DEXAMETHASONE SODIUM PHOSPHATE

AKORN

EQ 4MG PHOSPHATE/ML

A084493 001

BEL MAR

EQ 4MG PHOSPHATE/ML

A084752 001

DELL LABS

EQ 4MG PHOSPHATE/ML

A083161 001

HIKMA MAPLE

EQ 4MG PHOSPHATE/ML

A084282 001

INTL MEDICATION

EQ 20MG PHOSPHATE/ML

A088522 001

Feb 17, 1984

LYPHOMED

EQ 4MG PHOSPHATE/ML

A087065 001

TEVA PARENTERAL

EQ 4MG PHOSPHATE/ML

A081125 001

Aug 31, 1990

EQ 10MG PHOSPHATE/ML

A081126 001

Aug 31, 1990

WATSON LABS

EQ 4MG PHOSPHATE/ML

A083702 001

EQ 4MG PHOSPHATE/ML

A084355 001

EQ 4MG PHOSPHATE/ML

A089169 001

Apr 09, 1986

EQ 10MG PHOSPHATE/ML

A087668 001

Jul 01, 1982

EQ 24MG PHOSPHATE/ML

A085606 001

WYETH AYERST

EQ 4MG PHOSPHATE/ML

A085641 001

HEXADROL

ORGANON USA INC

EQ 4MG PHOSPHATE/ML

N014694 002

EQ 10MG PHOSPHATE/ML

N014694 003

EQ 20MG PHOSPHATE/ML

N014694 004

DISCONTINUED DRUG PRODUCT LIST

6 - 106 (of 360)

DEXAMETHASONE SODIUM PHOSPHATE

OINTMENT; OPHTHALMIC				
DECADRON				
MERCK	EQ 0.05% PHOSPHATE	N011977	001	
DEXAIR				
PHARMAFAIR	EQ 0.05% PHOSPHATE	A088071	001	Dec 28, 1982
MAXIDEX				
ALCON	EQ 0.05% PHOSPHATE	A083342	001	
SOLUTION/DROPS; OPHTHALMIC				
DEXAIR				
PHARMAFAIR	EQ 0.1% PHOSPHATE	A088433	001	Dec 15, 1983
DEXAMETHASONE SODIUM PHOSPHATE				
SOLA BARNES HIND	EQ 0.1% PHOSPHATE	A084170	001	
	EQ 0.1% PHOSPHATE	A084173	001	
SOLUTION/DROPS; OPHTHALMIC, OTIC				
DECADRON				
MERCK	EQ 0.1% PHOSPHATE	N011984	001	
SOLUTION/DROPS; OTIC				
DEXAMETHASONE SODIUM PHOSPHATE				
AKORN	EQ 0.1% PHOSPHATE	A084855	001	

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION				
DECADRON W/ XYLOCAINE				
MERCK	EQ 4MG PHOSPHATE/ML;10MG/ML	N013334	002	

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

OINTMENT; OPHTHALMIC				
NEODECADRON				
MERCK	EQ 0.05% PHOSPHATE;EQ 3.5MG BASE/GM	N050324	001	
SOLUTION/DROPS; OPHTHALMIC				
NEODECADRON				
MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N050322	001	
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE				
BAUSCH AND LOMB	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A064055	001	Oct 30, 1995
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE				
ALCON PHARMS LTD	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A062714	001	Jul 21, 1986
PHARMAFAIR	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A062539	001	Jan 10, 1985

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC				
DEXACIDIN				
NOVARTIS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062566	001	Feb 22, 1985
DEXASPORIN				
PHARMAFAIR	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062411	001	May 16, 1983
SUSPENSION/DROPS; OPHTHALMIC				
DEXACIDIN				
NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062544	001	Oct 29, 1984
DEXASPORIN				
PHARMAFAIR	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062428	001	May 18, 1983

DEXBROMPHENIRAMINE MALEATE

SYRUP; ORAL				
DISOMER				
SCHERING	2MG/5ML	N011814	002	
TABLET; ORAL				
DISOMER				
SCHERING	2MG	N011814	001	

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET; ORAL				
DISOPHROL				
SCHERING	2MG;60MG	N012394	002	

DISCONTINUED DRUG PRODUCT LIST

6 - 107 (of 360)

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

BROMPHERIL

COPLEY PHARM	6MG;120MG	A089116	001	Jan 22, 1987

DISOBROM

SANDOZ	6MG;120MG	A070770	001	Sep 30, 1991

RESPORAL

PIONEER PHARMS	6MG;120MG	A089139	001	Jun 16, 1988

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

POLARAMINE

SCHERING	2MG/5ML	A086837	001	Jul 19, 1982

TABLET; ORAL

DEXCHLORPHENIRAMINE MALEATE

PLIVA	2MG	A088682	001	Jan 17, 1986

POLARAMINE

SCHERING	2MG	A086835	001	

DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL

DEXAMPEX

TEVA	15MG	A085355	001	

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMPHETAMINE SULFATE

ABLE	5MG	A076814	001	Aug 25, 2004

	10MG	A076814	002	Aug 25, 2004

	15MG	A076814	003	Aug 25, 2004

ELIXIR; ORAL

DEXEDRINE

GLAXOSMITHKLINE	5MG/5ML **Federal Register	A083902	001	

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

TABLET; ORAL

DEXAMPEX

TEVA	5MG	A083735	001	

	10MG	A083735	002	

DEXEDRINE

GLAXOSMITHKLINE	5MG	A084935	001	

DEXTROAMPHETAMINE SULFATE

HALSEY	10MG	A083930	001	

LANNETT	5MG	A083903	001	

	10MG	A083903	003	

	15MG **Federal Register determination	A085652	001	

that product was not discontinued or withdrawn for safety or efficacy reasons**

MAST MM	5MG	A086521	001	

NESHER PHARMS	5MG	A040365	001	Oct 31, 2002

	10MG	A040367	001	Oct 31, 2002

PUREPAC PHARM	5MG	A084125	001	

SANDOZ	5MG	A085370	001	

	10MG	A085371	001	

VINTAGE PHARMS LLC	5MG	A040299	001	May 13, 1999

VITARINE	5MG	A084986	001	

	10MG	A085892	001	

DEXTROSTAT

SHIRE	5MG	A084051	001	

	10MG	A084051	002	

FERNDEX

FERNDAL LABS	5MG	A084001	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 108 (of 360)

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL		
PHERAZINE DM		
HALSEY	15MG/5ML;6.25MG/5ML	A088913 001 Mar 02, 1987
PROMETHAZINE HYDROCHLORIDE AND DESTROMETHORPHAN HYDROBROMIDE		
ANI PHARMS	15MG/5ML;6.25MG/5ML	N011265 002 Apr 02, 1984

DEXTROSE

INJECTABLE; INJECTION		
DEXTROSE 10% IN PLASTIC CONTAINER		
B BRAUN	10GM/100ML	N018046 001
MILES	10GM/100ML	N018504 001
DEXTROSE 2.5% IN PLASTIC CONTAINER		
B BRAUN	2.5GM/100ML	N018358 001
	2.5GM/100ML	N019626 001 Feb 02, 1988
DEXTROSE 38.5% IN PLASTIC CONTAINER		
ABBOTT	38.5GM/100ML	N018923 001 Sep 19, 1984
DEXTROSE 5% IN PLASTIC CONTAINER		
DHL	5GM/100ML	N019971 001 Sep 28, 1995
DEXTROSE 60%		
B BRAUN	60GM/100ML	N017995 002 Sep 22, 1982
DEXTROSE 60% IN PLASTIC CONTAINER		
B BRAUN	60GM/100ML	N017995 001
BAXTER HLTHCARE	60GM/100ML	N020047 002 Jul 02, 1991
HOSPIRA	60GM/100ML	N019346 001 Jan 25, 1985
DEXTROSE 7.7% IN PLASTIC CONTAINER		
B BRAUN	7.7GM/100ML	N019626 003 Feb 02, 1988

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION		
ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML;26MG/100ML;320MG/100ML	N019025 001 Dec 27, 1984

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION		
ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;220MG/100ML;140MG/100ML	N018273 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION		
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N018274 001

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION		
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML;37MG/100ML	N019699 001 Sep 29, 1989
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML;75MG/100ML	N019699 002 Sep 29, 1989
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML;110MG/100ML	N019699 003 Sep 29, 1989
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML;220MG/100ML	N019699 005 Sep 29, 1989

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION		
IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER		
HOSPIRA	5GM/100ML;111MG/100ML;256MG/100ML;146MG/100ML;207MG/100ML	N019514 001 May 08, 1986

DISCONTINUED DRUG PRODUCT LIST

6 - 109 (of 360)

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;280MG/100ML;91MG/100ML	N018270	001

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML;75MG/100ML;200MG/100ML	N018268	009

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;200MG/100ML	N018268	004

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML;200MG/100ML	N018268	005

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML;200MG/100ML	N018268	006

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;75MG/100ML;330MG/100ML	N018268	011 Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;330MG/100ML	N018268	012 Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML;330MG/100ML	N018268	013 Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML;330MG/100ML	N018268	014 Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML;75MG/100ML;450MG/100ML	N018268	010

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;450MG/100ML	N018268	001

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML;450MG/100ML	N018268	002

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML;450MG/100ML	N018268	003

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;224MG/100ML;450MG/100ML	N018008	003

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008	001

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;75MG/100ML;450MG/100ML	N018008	002

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;200MG/100ML	N018386	001

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;450MG/100ML	N018229	001

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;900MG/100ML	N018047	001

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML;450MG/100ML	N018030	001

HOSPIRA	2.5GM/100ML;450MG/100ML	N018096	001

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML;900MG/100ML	N018376	001

DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT	3.3GM/100ML;300MG/100ML	N018055	001

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;110MG/100ML	N018030	005

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;200MG/100ML	N018030	004

MILES	5GM/100ML;200MG/100ML	N018399	001

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML;225MG/100ML	N019482	001 Oct 04, 1985

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML;300MG/100ML	N019486	001 Oct 04, 1985

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 110 (of 360)

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
MILES	5GM/100ML;300MG/100ML	N018501	001
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;330MG/100ML	N018030	003
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;450MG/100ML	N019484	001
B BRAUN	5GM/100ML;450MG/100ML	N018030	002
MILES	5GM/100ML;450MG/100ML	N018400	001
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;900MG/100ML	N019483	001
B BRAUN	5GM/100ML;900MG/100ML	N018026	001
MILES	5GM/100ML;900MG/100ML	N018500	001

DEXTROTHYROXINE SODIUM

TABLET; ORAL

CHOLOXIN

ABBVIE	1MG	N012302	005
	2MG	N012302	002
	4MG	N012302	004
	6MG	N012302	006

DEZOCINE

INJECTABLE; INJECTION

DALGAN

ASTRAZENECA	5MG/ML	N019082	001
	10MG/ML	N019082	002
	15MG/ML	N019082	003

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

ANGIOVIST 282

BAYER HLTHCARE	60%	A087726	001

CARDIOGRAFIN

BRACCO	85%	N011620	002

DIATRIZOATE MEGLUMINE

BRACCO	76%	N010040	017

HYPAQUE

GE HEALTHCARE	30%	N016403	002

	60%	N016403	001

RENO-60

BRACCO	60%	N010040	016

RENO-DIP

BRACCO	30%	N010040	012

UROVIST MEGLUMINE DIU/CT

BAYER HLTHCARE	30%	A087739	001

SOLUTION; URETERAL

RENO-30

BRACCO	30%	N010040	021

UROVIST CYSTO

BAYER HLTHCARE	30%	A087729	001

UROVIST CYSTO PEDIATRIC

BAYER HLTHCARE	30%	A087731	001

SOLUTION; URETHRAL

HYPAQUE-CYSTO

GE HEALTHCARE	30%	N016403	003

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

ANGIOVIST 292

BAYER HLTHCARE	52%;8%	A087724	001

DISCONTINUED DRUG PRODUCT LIST

6 - 111 (of 360)

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

ANGIOVIST 370

BAYER HLTHCARE	66%;10%	A087723	001	Sep 23, 1982

DIATRIZOATE-60

INTL MEDICATION	52%;8%	A088166	001	Jun 17, 1983

HYPAQUE-76

GE HEALTHCARE	66%;10%	A086505	001	

HYPAQUE-M, 75%

GE HEALTHCARE	50%;25%	N010220	003	

HYPAQUE-M, 90%

GE HEALTHCARE	60%;30%	N010220	002	

MD-60

MALLINCKRODT	52%;8%	A087074	001	

MD-76

MALLINCKRODT	66%;10%	A087073	001	

RENOCAL-76

BRACCO	66%;10%	A089347	001	Jun 01, 1988

RENOGRAFIN-60

BRACCO	52%;8%	N010040	006	

RENOVIST

BRACCO	34.3%;35%	N010040	020	

RENOVIST II

BRACCO	28.5%;29.1%	N010040	019	

SOLUTION; ORAL, RECTAL

GASTROVIST

BAYER HLTHCARE	66%;10%	A087728	001	Sep 23, 1982

DIATRIZOATE SODIUM

FOR SOLUTION; ORAL, RECTAL

HYPAQUE

GE HEALTHCARE	100%	N011386	001	

INJECTABLE; INJECTION

HYPAQUE

GE HEALTHCARE	25%	N009561	003	

	50%	N009561	001	

MD-50

MALLINCKRODT	50%	A087075	001	

UROVIST SODIUM 300

BAYER HLTHCARE	50%	A087725	001	Sep 23, 1982

SOLUTION; ORAL, RECTAL

HYPAQUE

GE HEALTHCARE	40%	N011386	003	

SOLUTION; URETERAL

HYPAQUE SODIUM 20%

GE HEALTHCARE	20%	N009561	002	

DIAZEPAM

CAPSULE, EXTENDED RELEASE; ORAL

VALRELEASE

ROCHE	15MG	N018179	001	

GEL; RECTAL

DIASTAT

VALEANT	5MG/ML (5MG/ML) **Federal Register	N020648	002	Jul 29, 1997

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

	10MG/2ML (5MG/ML)	N020648	003	Jul 29, 1997

	15MG/3ML (5MG/ML)	N020648	004	Jul 29, 1997

	20MG/4ML (5MG/ML)	N020648	005	Jul 29, 1997

INJECTABLE; INJECTION

DIAZEPAM

ABRAXIS PHARM	5MG/ML	A070662	001	Jun 25, 1986

HIKMA MAPLE	5MG/ML	A070311	001	Dec 16, 1985

	5MG/ML	A070312	001	Dec 16, 1985

DISCONTINUED DRUG PRODUCT LIST

6 - 112 (of 360)

DIAZEPAM

INJECTABLE; INJECTION DIAZEPAM

HIKMA MAPLE	5MG/ML	A070313	001	Dec 16, 1985
	5MG/ML	A071308	001	Jul 17, 1987
	5MG/ML	A071309	001	Jul 17, 1987
	5MG/ML	A071310	001	Jul 17, 1987
HOSPIRA	5MG/ML	A071584	001	Oct 13, 1987
MARSAM PHARMS LLC	5MG/ML	A072370	001	Jan 29, 1993
	5MG/ML	A072371	001	Jan 29, 1993
	5MG/ML	A072397	001	Jan 29, 1993
PARENTA PHARMS	5MG/ML	A076815	001	Apr 15, 2004
US ARMY	5MG/ML	N020124	001	Dec 05, 1990
WARNER CHILCOTT	5MG/ML	A071613	001	Oct 22, 1987
	5MG/ML	A071614	001	Oct 22, 1987
WATSON LABS	5MG/ML	A070911	001	Aug 28, 1986
	5MG/ML	A070912	001	Aug 28, 1986
	5MG/ML	A070930	001	Dec 01, 1986

DIZAC

PHARMACIA AND UPJOHN	5MG/ML	N019287	001	Jun 18, 1993

VALIUM

ROCHE	5MG/ML	N016087	001	

TABLET; ORAL

DIAZEPAM

ACTAVIS ELIZABETH	2MG	A070781	001	Mar 19, 1986
	5MG	A070706	001	Mar 19, 1986
	10MG	A070707	001	Mar 19, 1986
DAVA PHARMS INC	5MG	A070227	001	Sep 26, 1985
	10MG	A070228	001	Sep 26, 1985
DURAMED PHARMS BARR	2MG	A070894	001	Aug 27, 1986
	5MG	A070895	001	Aug 27, 1986
	10MG	A070896	001	Aug 27, 1986
FERNDAL LABS	2MG	A070903	001	Apr 01, 1987
	5MG	A070904	001	Apr 01, 1987
	10MG	A070905	001	Apr 01, 1987
HALSEY	2MG	A070987	001	Aug 15, 1986
	5MG	A070996	001	Aug 15, 1986
	10MG	A070956	001	Aug 15, 1986
IVAX SUB TEVA PHARMS	2MG	A070360	001	Sep 04, 1985
	5MG	A070361	001	Sep 04, 1985
	10MG	A070362	001	Sep 04, 1985
MARTEC USA LLC	10MG	A072402	001	Apr 25, 1989
PAR PHARM	2MG	A070462	001	Feb 25, 1986
	5MG	A070463	001	Feb 25, 1986
	10MG	A070464	001	Feb 25, 1986
PIIONEER PHARMS	2MG	A070787	001	Aug 02, 1988
	5MG	A070788	001	Aug 02, 1988
	10MG	A070776	001	Aug 02, 1988
ROXANE	2MG	A070356	001	Jun 17, 1986
	5MG	A070357	001	Jun 17, 1986
	10MG	A070358	001	Jun 17, 1986
SANDOZ	2MG	A070302	001	Dec 20, 1985
	5MG	A070303	001	Dec 20, 1985
	10MG	A070304	001	Dec 20, 1985
TEVA PHARMS	5MG	A070153	001	Nov 01, 1985
WARNER CHILCOTT	2MG	A070209	001	Sep 04, 1985
	5MG	A070210	001	Sep 04, 1985
	10MG	A070222	001	Sep 04, 1985
WATSON LABS	2MG	A070456	001	Nov 01, 1985
	5MG	A070457	001	Nov 01, 1985
	10MG	A070458	001	Nov 01, 1985

Q-PAM

QUANTUM PHARMICS	2MG	A070423	001	Dec 12, 1985

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 113 (of 360)

DIAZEPAMTABLET; ORAL
Q-PAM

QUANTUM PHARMICS	2MG	A072431	001	Apr 29, 1988
	5MG	A070424	001	Dec 12, 1985
	5MG	A072432	001	Apr 29, 1988
	10MG	A070425	001	Dec 12, 1985
	10MG	A072433	001	Apr 29, 1988

DIAZOXIDECAPSULE; ORAL
PROGLYCEM

TEVA BRANDED PHARM	50MG	N017425	001	
	100MG	N017425	002	

INJECTABLE; INJECTION
DIAZOXIDE

ABRAXIS PHARM	15MG/ML	A071519	001	Aug 26, 1987
HYPERSTAT				
SCHERING	15MG/ML	N016996	001	

DIBUCAINE HYDROCHLORIDEINJECTABLE; INJECTION
HEAVY SOLUTION NUPERCAINE

NOVARTIS	2.5MG/ML	N006203	001	

DICHLORPHENAMIDETABLET; ORAL
DARANIDE

TARO	50MG **Federal Register determination that product was not discontinued or withdrawn for safety of efficacy reasons**	N011366	001	

DICLOFENAC POTASSIUMTABLET; ORAL
CATAFLAM

NOVARTIS	25MG **Federal Register determination that product was not discontinued or withdrawn for safety of efficacy reasons**	N020142	001	Nov 24, 1993

DICLOFENAC POTASSIUM

MUTUAL PHARM	50MG	A075470	001	Feb 21, 2002
SANDOZ	50MG	A075582	001	Feb 23, 2001
WATSON LABS	50MG	A075152	001	Nov 27, 1998

DICLOFENAC SODIUMSOLUTION/DROPS; OPHTHALMIC
DICLOFENAC SODIUM

FALCON PHARMS	0.1%	N020809	001	May 04, 1998

TABLET, DELAYED RELEASE; ORAL
DICLOFENAC SODIUM

NOSTRUM LABS	50MG	A074986	001	Feb 26, 1999
	75MG	A074986	002	Feb 26, 1999
PLIVA	50MG	A074432	002	Jul 29, 1999
	75MG	A074432	003	Jul 29, 1999
ROXANE	25MG	A074391	001	Jun 29, 1995
	50MG	A074391	002	Jun 29, 1995
	75MG	A074391	003	Jun 29, 1995
TEVA	50MG	A074723	001	Mar 30, 1999
	75MG	A074390	001	Aug 15, 1996
TEVA PHARMS	25MG	A074459	001	Jun 25, 1997
	50MG	A074459	002	Jun 25, 1997
	75MG	A074459	003	Jun 25, 1997

DISCONTINUED DRUG PRODUCT LIST

6 - 114 (of 360)

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL
VOLTAREN

NOVARTIS	25MG	N019201	001	Jul 28, 1988
	50MG	N019201	002	Jul 28, 1988
	75MG	N019201	003	Jul 28, 1988

DICLOXACILLIN SODIUM

CAPSULE; ORAL
DYCILL

GLAXOSMITHKLINE	EQ 250MG BASE	A060254	002	
	EQ 250MG BASE	A062238	001	
	EQ 500MG BASE	A060254	003	
	EQ 500MG BASE	A062238	002	

PATHOCIL

WYETH AYERST	EQ 250MG BASE	N050011	002	
	EQ 500MG BASE	N050011	003	Mar 28, 1983

FOR SUSPENSION; ORAL
DICLOXACILLIN SODIUM

APOTHECON	EQ 62.5MG BASE/5ML	A061455	001	
DYNAPEN				
APOTHECON	EQ 62.5MG BASE/5ML	N050337	002	
PATHOCIL				
WYETH AYERST	EQ 62.5MG BASE/5ML	N050092	001	

DICUMAROL

CAPSULE; ORAL
DICUMAROL

LILLY	25MG	N005509	003	
	50MG	N005509	001	

TABLET; ORAL
DICUMAROL

ABBVIE	25MG	N005545	003	
	50MG	N005545	004	
	100MG	N005545	005	

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL
DICYCLOMINE HYDROCHLORIDE

MUTUAL PHARM	10MG	A084505	001	Oct 21, 1986
PIONEER PHARMS	10MG	A089361	001	Jan 10, 1989
WATSON LABS	10MG	A083179	001	Feb 12, 1986

INJECTABLE; INJECTION

DICYCLOMINE HYDROCHLORIDE

WATSON LABS	10MG/ML	A080614	001	Feb 11, 1986

SYRUP; ORAL

DICYCLOMINE HYDROCHLORIDE

ALPHARMA US PHARMS	10MG/5ML	A084479	001	

TABLET; ORAL

DICYCLOMINE HYDROCHLORIDE

MUTUAL PHARM	20MG	A084600	001	Jul 29, 1985
PIONEER PHARMS	20MG	A088585	001	Aug 20, 1986
WATSON LABS	20MG	A084361	001	Feb 06, 1986

DIDANOSINE

FOR SOLUTION; ORAL
VIDEX

BRISTOL MYERS SQUIBB	100MG/PACKET	N020155	003	Oct 09, 1991
	167MG/PACKET	N020155	004	Oct 09, 1991
	250MG/PACKET	N020155	005	Oct 09, 1991
	375MG/PACKET	N020155	006	Oct 09, 1991

TABLET, CHEWABLE; ORAL
VIDEX

BRISTOL MYERS SQUIBB	25MG	N020154	002	Oct 09, 1991

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 115 (of 360)

DIDANOSINETABLET, CHEWABLE; ORAL
VIDEX

BRISTOL MYERS SQUIBB	50MG	N020154	003	Oct 09, 1991
	100MG	N020154	004	Oct 09, 1991
	150MG	N020154	005	Oct 09, 1991
	200MG	N020154	006	Oct 28, 1999

DIENESTROLCREAM; VAGINAL
DIENESTROL

ORTHO MCNEIL PHARM	0.01%	N006110	005	

DV

SANOFI AVENTIS US	0.01%	A083518	001	

ESTRAGUARD

SOLVAY	0.01%	A084436	001	

SUPPOSITORY; VAGINAL
DV

SANOFI AVENTIS US	0.7MG	A083517	001	

DIETHYLCARBAMAZINE CITRATETABLET; ORAL
HETRAZAN

LEDERLE	50MG	N006459	001	

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

SANDOZ	25MG	A085916	001	
TEVA	25MG	A088642	001	Sep 20, 1984
TG UNITED LABS	25MG	A088267	001	Aug 25, 1983
	25MG	A088268	001	Aug 25, 1983
UCB INC	25MG	A085544	001	
WATSON LABS	25MG	A085741	001	

TENUATE

SANOFI AVENTIS US	25MG	N017668	001	

TEPANIL

3M	25MG	N011673	001	

TABLET, EXTENDED RELEASE; ORAL
TENUATE

SANOFI AVENTIS US	75MG	N017669	001	

TEPANIL TEN-TAB

3M	75MG	N017956	001	

DIETHYLSTILBESTROLINJECTABLE; INJECTION
STILBESTROL

BRISTOL MYERS SQUIBB	0.2MG/ML	N004056	003	
	0.5MG/ML	N004056	004	
	1MG/ML	N004056	005	
	5MG/ML	N004056	006	

SUPPOSITORY; VAGINAL
DIETHYLSTILBESTROL

LILLY	0.1MG	N004040	001	
	0.5MG	N004040	002	

STILBESTROL

BRISTOL MYERS SQUIBB	0.1MG	N004056	001	
	0.5MG	N004056	002	

TABLET; ORAL

DIETHYLSTILBESTROL

LILLY	0.1MG	N004041	002	
	0.5MG	N004041	003	
	1MG	N004041	004	
	5MG	N004041	005	

DISCONTINUED DRUG PRODUCT LIST

6 - 116 (of 360)

DIETHYLSTILBESTROL

TABLET; ORAL			
STILBESTROL			
TABLICAPS	0.5MG	A083004	001
	1MG	A083002	001
	5MG	A083006	001
STILBETIN			
BRISTOL MYERS SQUIBB	0.1MG	N004056	007
	0.25MG	N004056	017
	0.5MG	N004056	008
	1MG	N004056	009
	5MG	N004056	010
TABLET, DELAYED RELEASE; ORAL			
DIETHYLSTILBESTROL			
LILLY	0.1MG	N004039	002
	0.25MG	N004039	005
	0.5MG	N004039	003
	1MG	N004039	004
	5MG	N004039	006
STILBESTROL			
TABLICAPS	0.5MG	A083003	001
	1MG	A083005	001
	5MG	A083007	001
STILBETIN			
BRISTOL MYERS SQUIBB	0.1MG	N004056	011
	0.5MG	N004056	012
	1MG	N004056	013
	5MG	N004056	014

DIETHYLSTILBESTROL DIPHOSPHATE

INJECTABLE; INJECTION			
STILPHOSTROL			
BAYER PHARMS	250MG/5ML	N010010	001
TABLET; ORAL			
STILPHOSTROL			
BAYER PHARMS	50MG	N010010	002

DIFLORASONE DIACETATE

CREAM; TOPICAL			
FLORONE			
PHARMACIA AND UPJOHN	0.05%	N017741	001
FLORONE E			
PHARMACIA AND UPJOHN	0.05%	N019259	001 Aug 28, 1985
PSORCON			
TARO	0.05%	N020205	001 Nov 20, 1992
OINTMENT; TOPICAL			
PSORCON			
PHARMACIA AND UPJOHN	0.05%	N019260	001 Aug 28, 1985
PSORCON E			
PHARMACIA AND UPJOHN	0.05%	N017994	001

DIFLUNISAL

TABLET; ORAL			
DIFLUNISAL			
PUREPAC PHARM	250MG	A074285	001 May 07, 1996
	500MG	A074285	002 May 07, 1996
ROXANE	250MG	A073562	001 Nov 27, 1992
	500MG	A073563	001 Nov 27, 1992
SANDOZ	500MG	A074604	001 Jun 10, 1996
TEVA	250MG	A073679	001 Jul 31, 1992
WATSON LABS	250MG	A074400	001 Jul 17, 1997
	500MG	A074400	002 Jul 17, 1997

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 117 (of 360)

DIFLUNISAL

TABLET; ORAL
DOLOBID
MERCK

250MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**
500MG

N018445 001 Apr 19, 1982
N018445 002 Apr 19, 1982

DIGITOXIN

INJECTABLE; INJECTION
CRYSTODIGIN
LILLY

0.2MG/ML

A084100 005

DIGOXIN

CAPSULE; ORAL
LANOXICAPS

GLAXOSMITHKLINE LLC

0.05MG
0.1MG
0.15MG
0.2MG

N018118 002 Jul 26, 1982
N018118 003 Jul 26, 1982
N018118 004 Sep 24, 1984
N018118 001 Jul 26, 1982

INJECTABLE; INJECTION
DIGOXIN

ABRAXIS PHARM
HOSPIRA

0.25MG/ML
0.25MG/ML
0.25MG/ML
0.25MG/ML

A083217 001
A040093 001 May 16, 1996
A040206 001 Aug 28, 1998
A084386 001

DIGOXIN PEDIATRIC

HOSPIRA

0.1MG/ML

A040092 001 Apr 25, 1996

TABLET; ORAL
DIGOXIN

MYLAN PHARMS INC

0.125MG
0.25MG

A040282 001 Dec 23, 1999
A040282 002 Dec 23, 1999

LANOXIN

COVIS PHARMA

0.0625MG
0.1875MG
0.375MG
0.5MG

N020405 001 Sep 30, 1997
N020405 003 Sep 30, 1997
N020405 005 Sep 30, 1997
N020405 006 Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
EMBOLEX

NOVARTIS

0.5MG/0.5ML; 2,500
UNITS/0.5ML; 5.33MG/0.5ML
0.5MG/0.7ML; 5,000
UNITS/0.7ML; 7.46MG/0.7ML

N018885 001 Nov 30, 1984
N018885 002 Nov 30, 1984

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARDIZEM SR

BIOVAIL

60MG
90MG
120MG
180MG

N019471 001 Jan 23, 1989
N019471 002 Jan 23, 1989
N019471 003 Jan 23, 1989
N019471 004 Jan 23, 1989

DILTIAZEM HYDROCHLORIDE

BIOVAIL

60MG
90MG
120MG
120MG
180MG
240MG
300MG
360MG
420MG

A074845 001 Sep 15, 1999
A074845 002 Sep 15, 1999
A074845 003 Sep 15, 1999
N020939 001 Jan 28, 2000
N020939 002 Jan 28, 2000
N020939 003 Jan 28, 2000
N020939 004 Jan 28, 2000
N020939 005 Sep 14, 2001
N020939 006 Sep 14, 2001

DISCONTINUED DRUG PRODUCT LIST

6 - 118 (of 360)

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HYDROCHLORIDE

TEVA	60MG	A074079	001	Nov 30, 1993
	90MG	A074079	002	Nov 30, 1993
	120MG	A074079	003	Nov 30, 1993

INJECTABLE; INJECTION
CARDIZEM

BIOVAIL	100MG/VIAL	N020792	001	Sep 05, 1997
BIOVAIL LABS INTL	5MG/ML	N020027	001	Oct 24, 1991
	25MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020027	003	Aug 18, 1995

DILTIAZEM HYDROCHLORIDE

HOSPIRA	5MG/ML	A075004	001	Feb 16, 2000
	5MG/ML	A075106	001	Apr 29, 1999
TEVA PARENTERAL	5MG/ML	A074894	001	Aug 26, 1997

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

APOTHECON	30MG	A074051	001	Mar 31, 1993
	60MG	A074051	002	Mar 31, 1993
	90MG	A074051	003	Mar 31, 1993
	120MG	A074051	004	Mar 31, 1993
IVAX SUB TEVA PHARMS	30MG	A074168	001	Mar 03, 1995
	60MG	A074168	002	Mar 03, 1995
	90MG	A074168	003	Mar 03, 1995
	120MG	A074168	004	Mar 03, 1995
TEVA	30MG	A074084	001	Feb 25, 1994
	60MG	A074084	002	Feb 25, 1994
TEVA PHARMS	30MG	A074067	001	Nov 05, 1992
	60MG	A074067	002	Nov 05, 1992
	90MG	A074067	003	Nov 05, 1992
	120MG	A074067	004	Nov 05, 1992

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL
TIAMATE

MERCK	EQ 120MG HCL	N020506	001	Oct 04, 1996
	EQ 180MG HCL	N020506	002	Oct 04, 1996
	EQ 240MG HCL	N020506	003	Oct 04, 1996

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE; ORAL
TECZEM

BIOVAIL	EQ 180MG HCL;5MG	N020507	001	Oct 04, 1996

DIMENHYDRINATE

INJECTABLE; INJECTION
DIMENHYDRINATE

BAXTER HLTHCARE	50MG/ML	A084767	001	
WATSON LABS	50MG/ML	A083531	001	
WYETH AYERST	50MG/ML	A084316	001	

LIQUID; ORAL

DIMENHYDRINATE

ALRA	12.5MG/4ML	A080715	001	

TABLET; ORAL

DIMENHYDRINATE

HEATHER	50MG	A080841	001	
NEXGEN PHARMA INC	50MG	A085985	001	
WATSON LABS	50MG	A085166	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 119 (of 360)

DIMYRISTOYL LECITHIN; PERFLEXANEINJECTABLE; INTRAVENOUS
IMAGENT

IMCOR PHARMS CO 0.92MG/VIAL;0.092MG/VIAL N021191 001 May 31, 2002

DINOPROST TROMETHAMINEINJECTABLE; INJECTION
PROSTIN F2 ALPHA

PHARMACIA AND UPJOHN EQ 5MG BASE/ML N017434 001

DIPHEMANIL METHYLSULFATETABLET; ORAL
PRANTAL

SCHERING 100MG N008114 004

DIPHENHYDRAMINE HYDROCHLORIDECAPSULE; ORAL
BENADRYLMCNEIL CONS 25MG N005845 007
50MG N005845 001DIPHENHYDRAMINE HYDROCHLORIDEALRA 25MG A080519 004
50MG A080519 003

ANABOLIC 50MG A083275 001

ELKINS SINN 25MG A085701 001

50MG A085701 002

HALSEY 50MG A087914 001 Jun 04, 1984

HEATHER 25MG A084524 001

50MG A083953 001

IMPAX LABS 25MG A080807 001

50MG A080807 002

IVAX SUB TEVA PHARMS 25MG A080762 001

50MG A080762 002

LANNETT 25MG A080868 001

50MG A080868 002

LEDERLE 25MG A086874 001

50MG A086875 001

LNK 25MG A087977 001 Jan 27, 1983

50MG A087978 001 Jan 27, 1983

MK LABS 25MG A083087 001

50MG A083087 002

MUTUAL PHARM 25MG A084506 001

25MG A089488 001 Jan 02, 1987

50MG A089489 001 Jan 02, 1987

NEWTRON PHARMS 25MG A086543 001

50MG A086544 001

NEXGEN PHARMA INC 25MG A083634 001

PERRIGO 25MG A083061 001

50MG A083061 002

PIONEER PHARMS 25MG A089101 001 Dec 20, 1985

50MG A088880 001 Dec 20, 1985

PUREPAC PHARM 25MG A085156 001

50MG A085150 001

PVT FORM 25MG A083027 001

50MG A083027 002

ROXANE 50MG A080635 001

SANDOZ 25MG A080832 001

25MG A080845 002

50MG A080832 002

50MG A080845 001

SUPERPHARM 25MG A089040 001 May 15, 1985

50MG A089041 001 May 15, 1985

TEVA 25MG A085874 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 120 (of 360)

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

TEVA	50MG	A085874	002	
VALEANT PHARM INTL	25MG	A080596	001	
	50MG	A080592	001	
VANGARD	25MG	A088034	001	Oct 27, 1982
	50MG	A087630	001	
WATSON LABS	25MG	A080728	001	
	25MG	A083797	001	
	25MG	A085138	001	
	50MG	A080727	001	
	50MG	A083797	002	
	50MG	A085083	001	
WEST WARD	50MG	A083567	001	
WHITEWORTH TOWN PLSN	25MG	A083441	001	
	50MG	A080800	001	

ELIXIR; ORAL

BELIX

HALSEY	12.5MG/5ML	A086586	001	Oct 03, 1983

BENADRYL

MCNEIL CONS	12.5MG/5ML	N005845	004	

DIBENIL

CENCI	12.5MG/5ML	A088304	001	Dec 16, 1983

DIPHEN

USL PHARMA	12.5MG/5ML	A084640	001	

DIPHENHYDRAMINE HYDROCHLORIDE

BUNDY	12.5MG/5ML	A083674	001	
CENCI	12.5MG/5ML	A087941	001	Dec 17, 1982
KV PHARM	12.5MG/5ML	A085621	001	
LANNETT	12.5MG/5ML	A080939	002	
LEDERLE	12.5MG/5ML	A086937	001	
MK LABS	12.5MG/5ML	A083088	002	
NASKA	12.5MG/5ML	A088680	001	May 31, 1985
PERRIGO	12.5MG/5ML	A083063	001	
PUREPAC PHARM	12.5MG/5ML	A083237	001	Jan 25, 1982
PVT FORM	12.5MG/5ML	A085287	001	
ROXANE	12.5MG/5ML	A080643	001	

HYDRAMINE

ALPHARMA US PHARMS	12.5MG/5ML	A080763	002	

INJECTABLE; INJECTION

BENADRYL

MCNEIL CONS	10MG/ML	N006146	001	
	50MG/ML	N006146	002	

BENADRYL PRESERVATIVE FREE

MCNEIL CONS	50MG/ML	N009486	001	

DIPHENHYDRAMINE HYDROCHLORIDE

BEL MAR	10MG/ML	A080822	001	
HIKMA MAPLE	50MG/ML	A083183	001	
LYPHOMED	10MG/ML	A087066	001	
WATSON LABS	10MG/ML	A083533	001	
WYETH AYERST	50MG/ML	A080577	001	

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

ABRAXIS PHARM	50MG/ML	A080586	002	

SYRUP; ORAL

ANTITUSSIVE

PERRIGO	12.5MG/5ML	A071292	001	Apr 10, 1987

BELDIN

HALSEY	12.5MG/5ML	A089179	001	Jun 05, 1986

BENYLIN

PARKE DAVIS	12.5MG/5ML	N006514	004	

DIPHEN

MORTON GROVE	12.5MG/5ML	A070118	001	Oct 01, 1985

DISCONTINUED DRUG PRODUCT LIST

6 - 121 (of 360)

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

ALPHARMA US PHARMS	12.5MG/5ML	A070497	001	Apr 25, 1989

CUMBERLAND SWAN	12.5MG/5ML	A073611	001	Aug 20, 1992

HI TECH PHARMA	12.5MG/5ML	A072416	001	Sep 28, 1990

HYDRAMINE

ALPHARMA US PHARMS	12.5MG/5ML	A070205	001	Jan 28, 1986

SILPHEN

SILARX	12.5MG/5ML	A072646	001	Feb 27, 1992

VICKS FORMULA 44

WARNER CHILCOTT	12.5MG/5ML	A070524	001	Jan 14, 1987

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

BENYLIN

PARKE DAVIS	12.5MG/5ML;30MG/5ML	N019014	001	Jun 11, 1985

DIPHENIDOL HYDROCHLORIDE

TABLET; ORAL

VONTROL

GLAXOSMITHKLINE	EQ 25MG BASE	N016033	001	

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

HISPRIL

GLAXOSMITHKLINE	5MG	N011945	001	

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DIPIVEFRIN HYDROCHLORIDE

BAUSCH AND LOMB	0.1%	A074188	001	May 19, 1995

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

HOSPIRA	5MG/ML	A074601	001	Dec 19, 1997

TEVA PARENTERAL	5MG/ML	A074952	001	Nov 26, 1997

IV PERSANTINE

BOEHRINGER INGELHEIM	5MG/ML	N019817	001	Dec 13, 1990

TABLET; ORAL

DIPYRIDAMOLE

PUREPAC PHARM	50MG	A089426	001	Jul 12, 1990

	75MG	A089427	001	Jul 12, 1990

SANDOZ	25MG	A086944	002	Apr 16, 1991

	50MG	A087562	001	Feb 25, 1992

	75MG	A087561	001	Feb 25, 1992

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

DYNABAC

LILLY RES LABS	250MG	N050678	001	Jun 19, 1995

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

INTERPHARM	EQ 100MG BASE	A071190	001	Jan 15, 1987

	EQ 150MG BASE	A071191	001	Jan 15, 1987

IVAX SUB TEVA PHARMS	EQ 100MG BASE	A070186	001	Nov 18, 1985

	EQ 150MG BASE	A070187	001	Nov 18, 1985

MUTUAL PHARM	EQ 100MG BASE	A070351	001	Dec 17, 1985

	EQ 150MG BASE	A070352	001	Dec 17, 1985

MYLAN	EQ 100MG BASE	A070138	001	Jun 14, 1985

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 122 (of 360)

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

MYLAN	EQ 150MG BASE	A070139	001	Jun 14, 1985
SANDOZ	EQ 100MG BASE	A070470	001	Dec 10, 1985
	EQ 150MG BASE	A070471	001	Dec 10, 1985
SUPERPHARM	EQ 100MG BASE	A070940	001	Feb 09, 1987
	EQ 150MG BASE	A070941	001	Feb 09, 1987
WATSON LABS	EQ 100MG BASE	A070240	001	Feb 02, 1986
	EQ 150MG BASE	A070241	001	Feb 02, 1986

CAPSULE, EXTENDED RELEASE; ORAL

DISOPYRAMIDE PHOSPHATE

NESHER PHARMS	EQ 150MG BASE	A071200	001	Dec 15, 1987

DISULFIRAM

TABLET; ORAL

ANTABUSE

TEVA WOMENS	250MG	N007883	003	
	500MG	N007883	002	

DISULFIRAM

PAR PHARM	250MG	A088792	001	Aug 14, 1984
	500MG	A088793	001	Aug 14, 1984
WATSON LABS	250MG	A086889	001	
	250MG	A087973	001	Aug 05, 1983
	500MG	A086890	001	
	500MG	A087974	001	Aug 05, 1983

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE CP

ABBOTT	EQ 250MG BASE	N019794	001	Jul 11, 1990
	EQ 500MG BASE	N019794	002	Jul 11, 1990

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

ASTRAZENECA	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995
BAXTER HLTHCARE	EQ 12.5MG BASE/ML	A074381	001	Sep 26, 1996
HOSPIRA	EQ 1.25GM BASE/100ML	A074634	001	Sep 27, 1996
LUITPOLD	EQ 12.5MG BASE/ML	A074545	001	Jun 25, 1998
MARSAM PHARMS LLC	EQ 12.5MG BASE/ML	A074279	001	Feb 18, 1998
	EQ 12.5MG BASE/ML	A074995	001	Mar 31, 1998
TEVA PARENTERAL	EQ 12.5MG BASE/ML	A074206	001	Oct 19, 1993
DOBUTREX				
LILLY	EQ 12.5MG BASE/ML	N017820	002	

DOCETAXEL

INJECTABLE; INJECTION

TAXOTERE

SANOFI AVENTIS US	40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020449	001	May 14, 1996

DONEPEZIL HYDROCHLORIDE

SOLUTION; ORAL

ARICEPT

EISAI INC	5MG/5ML	N021719	001	Oct 18, 2004

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

MUTUAL PHARM	5MG	A077975	002	Dec 11, 2009
	10MG	A077975	001	Dec 11, 2009

DISCONTINUED DRUG PRODUCT LIST

6 - 123 (of 360)

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HYDROCHLORIDE

ABBOTT	40MG/ML	A070656	001	Jan 24, 1989
	80MG/ML	A070657	001	Jan 24, 1989
ABRAXIS PHARM	40MG/ML	A070012	001	Jun 12, 1985
	40MG/ML	A070058	001	Mar 20, 1985
	80MG/ML	A070013	001	Jun 12, 1985
	80MG/ML	A070059	001	Mar 20, 1985
	160MG/ML	A070364	001	Dec 04, 1985
ASTRAZENECA	40MG/ML	A070087	001	Oct 23, 1985
	40MG/ML	N018656	001	Jun 28, 1983
	80MG/ML	A070089	001	Oct 23, 1985
	80MG/ML	A070090	001	Oct 23, 1985
	80MG/ML	A070091	001	Oct 23, 1985
	160MG/ML	A070092	001	Oct 23, 1985
	160MG/ML	A070093	001	Oct 23, 1985
	160MG/ML	A070094	001	Oct 23, 1985
	40MG/ML	N018398	001	
	80MG/ML	N018398	002	Mar 22, 1982
HOSPIRA	40MG/ML	A074403	001	May 23, 1996
INTL MEDICATION	40MG/ML	N018014	001	
LYPHOMED	40MG/ML	N018549	001	Mar 11, 1983
SMITH AND NEPHEW	40MG/ML	A070011	001	Aug 29, 1985
	40MG/ML	A070046	001	Aug 29, 1985
	80MG/ML	A070047	001	Aug 29, 1985
TEVA PARENTERAL	40MG/ML	A072999	001	Oct 23, 1991
	80MG/ML	A073000	001	Oct 23, 1991
WARNER CHILCOTT	40MG/ML	A070558	001	Sep 20, 1985
	40MG/ML	N018138	001	
	80MG/ML	A070559	001	Sep 20, 1985
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%				
HOSPIRA	1.6MG/ML	N020542	001	Aug 30, 1995
INTROPIN				
HOSPIRA	40MG/ML	N017395	001	
	80MG/ML	N017395	002	
	160MG/ML	N017395	003	

DOXACURIUM CHLORIDE

INJECTABLE; INJECTION
NUROMAX

ABBVIE	EQ 1MG BASE/ML	N019946	001	Mar 07, 1991

DOXAZOSIN MESYLATE

TABLET; ORAL
DOXAZOSIN MESYLATE

ACTAVIS ELIZABETH	EQ 1MG BASE	A075574	001	Oct 18, 2000
	EQ 2MG BASE	A075574	002	Oct 18, 2000
	EQ 4MG BASE	A075574	003	Oct 18, 2000
	EQ 8MG BASE	A075574	004	Oct 18, 2000
GENPHARM	EQ 1MG BASE	A075466	001	Oct 18, 2000
	EQ 2MG BASE	A075466	002	Oct 18, 2000
	EQ 4MG BASE	A075466	003	Oct 18, 2000
	EQ 8MG BASE	A075466	004	Oct 18, 2000
IVAX SUB TEVA PHARMS	EQ 1MG BASE	A075453	001	Oct 18, 2000
	EQ 2MG BASE	A075453	002	Oct 18, 2000
	EQ 4MG BASE	A075453	003	Oct 18, 2000
	EQ 8MG BASE	A075453	004	Oct 18, 2000
NESHER PHARMS	EQ 1MG BASE	A075609	001	Oct 18, 2000
	EQ 2MG BASE	A075609	002	Oct 18, 2000
	EQ 4MG BASE	A075609	003	Oct 18, 2000
	EQ 8MG BASE	A075609	004	Oct 18, 2000
SANDOZ	EQ 1MG BASE	A075432	001	Oct 18, 2000

DISCONTINUED DRUG PRODUCT LIST

6 - 124 (of 360)

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

SANDOZ

EQ 1MG BASE	A075646	001	Oct 18, 2000
EQ 2MG BASE	A075432	002	Oct 18, 2000
EQ 2MG BASE	A075646	002	Oct 18, 2000
EQ 4MG BASE	A075432	003	Oct 18, 2000
EQ 4MG BASE	A075646	003	Oct 18, 2000
EQ 8MG BASE	A075432	004	Oct 18, 2000
EQ 8MG BASE	A075646	004	Oct 18, 2000
TEVA	A075353	001	Jan 12, 2001
EQ 2MG BASE	A075353	002	Jan 12, 2001
EQ 4MG BASE	A075353	003	Jan 12, 2001
EQ 8MG BASE	A075353	004	Jan 12, 2001

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

DAVA PHARMS INC

EQ 10MG BASE	A071685	001	Jan 05, 1988	
EQ 25MG BASE	A071686	001	Jan 05, 1988	
EQ 50MG BASE	A071673	001	Jan 05, 1988	
EQ 75MG BASE	A071674	001	Jan 05, 1988	
EQ 100MG BASE	A071675	001	Jan 05, 1988	
EQ 150MG BASE	A071676	001	Jan 05, 1988	
MUTUAL PHARM	EQ 25MG BASE	A071502	001	Feb 18, 1988
	EQ 50MG BASE	A071653	001	Feb 18, 1988
	EQ 75MG BASE	A071654	001	Feb 18, 1988
	EQ 100MG BASE	A071521	001	Feb 18, 1988
NEW RIVER	EQ 10MG BASE	N016987	001	
	EQ 25MG BASE	N016987	002	
	EQ 50MG BASE	N016987	003	
	EQ 75MG BASE	N016987	006	
	EQ 100MG BASE	N016987	004	
	EQ 150MG BASE	N016987	007	Apr 13, 1987
PUREPAC PHARM	EQ 10MG BASE	A073054	001	Dec 28, 1990
	EQ 25MG BASE	A072109	001	Dec 28, 1990
	EQ 50MG BASE	A073055	001	Dec 28, 1990
	EQ 75MG BASE	A072386	001	Sep 08, 1988
	EQ 100MG BASE	A072110	001	Sep 08, 1988
	EQ 150MG BASE	A072387	001	Sep 08, 1988
QUANTUM PHARMICS	EQ 10MG BASE	A070972	001	Sep 29, 1987
	EQ 25MG BASE	A070973	001	Sep 29, 1987
	EQ 50MG BASE	A070931	001	Sep 29, 1987
	EQ 75MG BASE	A070932	001	Sep 29, 1987
	EQ 100MG BASE	A072375	001	Mar 15, 1989
	EQ 150MG BASE	A072376	001	Mar 15, 1989
SANDOZ	EQ 10MG BASE	A071487	001	Mar 02, 1987
	EQ 25MG BASE	A070827	001	May 15, 1986
	EQ 50MG BASE	A070828	001	May 15, 1986
	EQ 75MG BASE	A070825	001	May 15, 1986
	EQ 100MG BASE	A071562	001	Mar 02, 1987
WATSON LABS	EQ 10MG BASE	A070952	001	Mar 04, 1987
	EQ 10MG BASE	A072985	001	Mar 29, 1991
	EQ 25MG BASE	A070953	001	May 15, 1986
	EQ 25MG BASE	A072986	001	Mar 29, 1991
	EQ 50MG BASE	A070954	001	May 15, 1986
	EQ 50MG BASE	A072987	001	Mar 29, 1991
	EQ 75MG BASE	A071763	001	Feb 09, 1988
	EQ 100MG BASE	A070955	001	May 15, 1986
	EQ 150MG BASE	A071764	001	Feb 09, 1988

SINEQUAN

PFIZER

EQ 10MG BASE	N016798	003	
EQ 25MG BASE	N016798	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 125 (of 360)

DOXEPIN HYDROCHLORIDECAPSULE; ORAL
SINEQUAN

PFIZER

EQ 50MG BASE

N016798 002

EQ 75MG BASE

N016798 006

EQ 100MG BASE

N016798 005

EQ 150MG BASE **Federal Register
notice determination that product was
not discontinued or withdrawn for
safety or efficacy reasons**

N016798 007

CONCENTRATE; ORAL
SINEQUAN

PFIZER

EQ 10MG BASE/ML

N017516 001

DOXORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
ADRIAMYCIN PFS

PHARMACIA AND UPJOHN

2MG/ML

A063165 001 Jan 30, 1991

2MG/ML

N050629 001 Dec 23, 1987

200MG/100ML

A063165 002 Jan 30, 1991

200MG/100ML

N050629 002 May 03, 1988

ADRIAMYCIN RDF

PHARMACIA AND UPJOHN

10MG/VIAL

N050467 001

20MG/VIAL

N050467 003 May 20, 1985

50MG/VIAL

N050467 002

150MG/VIAL

N050467 004 Jul 22, 1987

RUBEX

BRISTOL MYERS SQUIBB

10MG/VIAL

A062926 001 Apr 13, 1989

50MG/VIAL

A062926 002 Apr 13, 1989

100MG/VIAL

A062926 003 Apr 13, 1989

DOXYCYCLINECAPSULE; ORAL
DOXYCYCLINE

PAR PHARM

EQ 75MG BASE

A065055 004 Apr 18, 2005

SANDOZ INC

EQ 50MG BASE

A065032 001 Jun 30, 2000

EQ 100MG BASE

A065032 002 Jun 30, 2000

FOR SUSPENSION; ORAL
DOXYCHEL

RACHELLE

EQ 25MG BASE/5ML

A061720 001

TABLET; ORAL
DOXYCYCLINE

MUTUAL PHARM

EQ 50MG BASE

A065471 001 Apr 17, 2009

EQ 75MG BASE

A065471 002 Apr 17, 2009

EQ 100MG BASE

A065471 003 Apr 17, 2009

SANDOZ INC

EQ 50MG BASE

A065353 001 Nov 27, 2006

EQ 75MG BASE

A065353 002 Nov 27, 2006

EQ 100MG BASE

A065353 003 Nov 27, 2006

DOXYCYCLINE HYCLATECAPSULE; ORAL
DOXYCYCLINE HYCLATE

HALSEY

EQ 50MG BASE

A062119 002 May 24, 1985

EQ 100MG BASE

A062119 001 May 24, 1985

HEATHER

EQ 50MG BASE

A062463 001 Dec 07, 1983

EQ 100MG BASE

A062463 002 Dec 07, 1983

INTERPHARM

EQ 50MG BASE

A062763 001 Sep 02, 1988

EQ 100MG BASE

A062763 002 Sep 02, 1988

MUTUAL PHARM

EQ 50MG BASE

A062418 001 Jan 28, 1983

EQ 100MG BASE

A062418 002 Jan 28, 1983

MYLAN

EQ 50MG BASE

A062337 001 Mar 29, 1982

EQ 100MG BASE

A062337 002 Mar 29, 1982

PAR PHARM

EQ 50MG BASE

A062434 001 Oct 19, 1984

EQ 100MG BASE

A062442 001 Dec 22, 1983

DISCONTINUED DRUG PRODUCT LIST

6 - 126 (of 360)

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

PVT FORM

EQ 50MG BASE	A062631	001	Jul 24, 1986
EQ 100MG BASE	A062631	002	Jul 24, 1986
RANBAXY	EQ 50MG BASE	A062479	001 Dec 23, 1983
	EQ 100MG BASE	A062479	002 Dec 23, 1983
SUPERPHARM	EQ 50MG BASE	A062469	001 Oct 31, 1984
	EQ 100MG BASE	A062469	002 Oct 31, 1984
WARNER CHILCOTT	EQ 50MG BASE	A062594	001 Dec 05, 1985
	EQ 100MG BASE	A062594	002 Dec 05, 1985
WATSON LABS	EQ 50MG BASE	A061717	001
	EQ 50MG BASE	A062142	001
	EQ 100MG BASE	A061717	002
	EQ 100MG BASE	A062142	002

DOXY-LEMMON

TEVA

EQ 50MG BASE	A062497	001	Aug 23, 1984
EQ 100MG BASE	A062497	002	Jun 15, 1984

PERIOSTAT

COLLAGENEX

EQ 20MG BASE	N050744	001	Sep 30, 1998

CAPSULE, COATED PELLETS; ORAL

DOXYCYCLINE HYCLATE

PLIVA

EQ 100MG BASE	A063187	001	Jun 30, 1992

CAPSULE, DELAYED RELEASE; ORAL

DORYX

MAYNE PHARMA INTL

EQ 75MG BASE	N050582	002	Aug 13, 2001
EQ 100MG BASE	N050582	001	Jul 22, 1985
WARNER CHILCOTT	EQ 100MG BASE	A062653	001 Oct 30, 1985

INJECTABLE; INJECTION

DOXYCHEL HYCLATE

RACHELLE

EQ 100MG BASE/VIAL	A061953	001	

DOXYCYCLINE

BEDFORD

EQ 200MG BASE/VIAL	A062569	002	Mar 09, 1988

HIKMA MAPLE

EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983
EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983

DOXYCYCLINE HYCLATE

HIKMA MAPLE

EQ 100MG BASE/VIAL	A062992	001	Feb 16, 1989
EQ 200MG BASE/VIAL	A062992	002	Feb 16, 1989

VIBRAMYCIN

PFIZER

EQ 100MG BASE/VIAL	N050442	002	
EQ 200MG BASE/VIAL	N050442	001	

TABLET; ORAL

DOXYCYCLINE HYCLATE

HEATHER

EQ 100MG BASE	A062462	001	May 11, 1983

INTERPHARM

EQ 100MG BASE	A062764	001	Sep 02, 1988

MUTUAL PHARM

EQ 100MG BASE	A062391	001	Sep 30, 1982

MYLAN

EQ 100MG BASE	A062432	001	Feb 15, 1983

SUPERPHARM

EQ 100MG BASE	A062494	001	Feb 20, 1985

TRUXTON INC

EQ 50MG BASE	A062269	003	

EQ 100MG BASE	A062269	002	Nov 08, 1982

WARNER CHILCOTT

EQ 100MG BASE	A062593	001	Aug 28, 1985

WATSON LABS

EQ 50MG BASE	A062392	001	Mar 31, 1983
EQ 100MG BASE	A062392	002	Mar 31, 1983

DOXY-LEMMON

TEVA

EQ 100MG BASE	A062581	001	Mar 15, 1985

VIBRA-TABS

PFIZER

EQ 100MG BASE	N050533	001	

DOXYLAMINE SUCCINATE

CAPSULE; ORAL

UNISOM

PFIZER

25MG	N019440	001	Feb 05, 1986

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 127 (of 360)

DOXYLAMINE SUCCINATETABLET; ORAL
DECAPRYNSANOFI AVENTIS US 12.5MG
25MGN006412 015
N006412 014

DOXYLAMINE SUCCINATE

COPLEY PHARM 25MG
QUANTUM PHARMICS 25MGA088900 002 Feb 12, 1988
A088603 001 Aug 07, 1984

DOXY-SLEEP-AID

PAR PHARM 25MG

A070156 001 Jul 02, 1987

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
BENDECTINSANOFI AVENTIS US 10MG;10MG **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

N010598 002

DROMOSTANOLONE PROPIONATEINJECTABLE; INJECTION
DROLBAN

LILLY 50MG/ML

N012936 001

DROPERIDOLINJECTABLE; INJECTION
DROPERIDOLABRAXIS PHARM 2.5MG/ML
2.5MG/MLA070992 001 Nov 17, 1986
A070993 001 Nov 17, 1986ASTRAZENECA 2.5MG/ML
2.5MG/ML
2.5MG/ML
2.5MG/ML
2.5MG/MLA072018 001 Oct 20, 1988
A072019 001 Oct 19, 1988
A072020 001 Oct 19, 1988
A072021 001 Oct 19, 1988HOSPIRA 2.5MG/ML
2.5MG/MLA071645 001 Apr 07, 1988
A072272 001 Aug 31, 1995LUITPOLD 2.5MG/ML
SMITH AND NEPHEW 2.5MG/ML
SOLOPAK 2.5MG/MLA072335 001 Oct 24, 1988
A071750 001 Sep 06, 1988
A071754 001 Sep 06, 19882.5MG/ML
WATSON LABS 2.5MG/ML
2.5MG/ML
2.5MG/MLA071755 001 Sep 06, 1988
A073520 001 Nov 27, 1991
A073521 001 Nov 27, 1991
A073523 001 Nov 27, 1991DROPERIDOL; FENTANYL CITRATEINJECTABLE; INJECTION
FENTANYL CITRATE AND DROPERIDOLASTRAZENECA 2.5MG/ML;EQ 0.05MG BASE/ML
2.5MG/ML;EQ 0.05MG BASE/ML
2.5MG/ML;EQ 0.05MG BASE/MLA072026 001 Apr 13, 1989
A072027 001 Apr 13, 1989
A072028 001 Apr 13, 1989

HOSPIRA 2.5MG/ML;EQ 0.05MG BASE/ML

A071982 001 May 04, 1988

INNOVAR

AKORN MFG 2.5MG/ML;EQ 0.05MG BASE/ML

N016049 001

DYCLONINE HYDROCHLORIDESOLUTION; TOPICAL
DYCLONEASTRAZENECA 0.5% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N009925 002

1% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N009925 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 128 (of 360)

DYDROGESTERONE

TABLET; ORAL
GYNOREST
SOLVAY

5MG
10MG

N017388 001
N017388 002

DYPHYLLINE

ELIXIR; ORAL
NEOTHYLLINE

TEVA

160MG/15ML

N007794 003

INJECTABLE; INJECTION
NEOTHYLLINE

TEVA

250MG/ML

N009088 001

TABLET; ORAL
DILOR

SAVAGE LABS

200MG

A084514 001

DILOR-400

SAVAGE LABS

400MG

A084751 001

NEOTHYLLINE

TEVA

200MG

N007794 001

400MG

N007794 002

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC
PHOSPHOLINE IODIDE

WYETH PHARMS INC

0.03%

N011963 002

0.06%

N011963 004

0.25%

N011963 003

ECONAZOLE NITRATE

CREAM; TOPICAL
SPECTAZOLE

ORTHO JANSSEN

1%

N018751 001 Dec 23, 1982

EDETATE CALCIUM DISODIUM

TABLET; ORAL
CALCIUM DISODIUM VERSENATE
MEDICIS

500MG

N008922 002

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
EDROPHONIUM CHLORIDE

HOSPIRA

10MG/ML

A040131 001 Feb 24, 1998

WATSON LABS

10MG/ML

A040044 001 Mar 20, 1996

EDROPHONIUM CHLORIDE PRESERVATIVE FREE

WATSON LABS

10MG/ML

A040043 001 Mar 20, 1996

REVERSOL

ORGANON USA INC

10MG/ML

A089624 001 May 13, 1988

EFAVIRENZ

CAPSULE; ORAL
SUSTIVA

BRISTOL MYERS SQUIBB

100MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020972 002 Sep 17, 1998

TABLET; ORAL
SUSTIVA

BRISTOL MYERS SQUIBB

300MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021360 001 Feb 01, 2002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 129 (of 360)

EFLORNITHINE HYDROCHLORIDEINJECTABLE; INJECTION
ORNIDYL

SANOFI AVENTIS US	200MG/ML	N019879	002	Nov 28, 1990

ENALAPRIL MALEATETABLET; ORAL
ENALAPRIL MALEATE

APOTHECON	2.5MG	A075583	001	Aug 22, 2000
	5MG	A075583	002	Aug 22, 2000
	10MG	A075583	003	Aug 22, 2000
	20MG	A075583	004	Aug 22, 2000
IVAX SUB TEVA PHARMS	2.5MG	A075482	001	Aug 22, 2000
	5MG	A075482	002	Aug 22, 2000
	10MG	A075482	003	Aug 22, 2000
	20MG	A075482	004	Aug 22, 2000
KRKA DD NOVO MESTO	2.5MG	A075370	001	Aug 22, 2000
	5MG	A075370	002	Aug 22, 2000
	10MG	A075369	001	Aug 22, 2000
	20MG	A075369	002	Aug 22, 2000
RANBAXY	2.5MG	A075556	001	Aug 22, 2000
	5MG	A075556	002	Aug 22, 2000
	10MG	A075556	003	Aug 22, 2000
	20MG	A075556	004	Aug 22, 2000
SANDOZ	2.5MG	A075048	001	Aug 22, 2000
	5MG	A075048	002	Aug 22, 2000
	10MG	A075048	003	Aug 22, 2000
	20MG	A075048	004	Aug 22, 2000
SANDOZ INC	2.5MG	A075496	001	Aug 22, 2000
	2.5MG	A075621	001	Aug 22, 2000
	5MG	A075496	002	Aug 22, 2000
	5MG	A075621	002	Aug 22, 2000
	10MG	A075459	001	Aug 22, 2000
	10MG	A075621	003	Aug 22, 2000
	20MG	A075459	002	Aug 22, 2000
	20MG	A075621	004	Aug 22, 2000

ENALAPRIL MALEATE; FELODIPINETABLET, EXTENDED RELEASE; ORAL
LEXXEL

ASTRAZENECA	5MG; 2.5MG	N020668	002	Oct 28, 1998
	5MG; 5MG	N020668	001	Dec 27, 1996

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDETABLET; ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

IVAX SUB TEVA PHARMS	5MG; 12.5MG	A075736	001	Mar 25, 2003
	10MG; 25MG	A075736	002	Mar 25, 2003
SANDOZ INC	5MG; 12.5MG	A076116	001	Sep 19, 2001
	10MG; 25MG	A076116	002	Sep 19, 2001

ENALAPRILATINJECTABLE; INJECTION
ENALAPRILAT

HOSPIRA	1.25MG/ML	A075456	001	Aug 22, 2000
	1.25MG/ML	A075571	001	Aug 22, 2000
VASOTEC				
BIOVAIL LABS INTL	1.25MG/ML	N019309	001	Feb 09, 1988

ENFLURANELIQUID; INHALATION
ENFLURANE

ABBOTT	99.9%	A070803	001	Sep 08, 1987

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 130 (of 360)

ENOXACINTABLET; ORAL
PENETREX

SANOFI AVENTIS US	200MG	N019616	004	Dec 31, 1991
	400MG	N019616	005	Dec 31, 1991

ENOXAPARIN SODIUMINJECTABLE; SUBCUTANEOUS
LOVENOX (PRESERVATIVE FREE)

SANOFI AVENTIS US	90MG/0.6ML (150MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020164	006	Jun 02, 2000

EPINEPHRINEAEROSOL, METERED; INHALATION
BRONKAID MIST

STERLING	0.25MG/INH	N016803	001	

PRIMATENE MIST

WYETH CONS	0.2MG/INH	N016126	001	

INJECTABLE; INJECTION

SUS-PHRINE SULFITE-FREE

FOREST LABS	1.5MG/AMP	N007942	003	Feb 05, 1999
	5MG/ML	N007942	001	

INJECTABLE; INTRAMUSCULAR

EPI E Z PEN JR

MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N019430	004	Aug 03, 1995

EPIPEN E Z PEN

MERIDIAN MEDCL TECHN	0.3MG/DELIVERY	N019430	003	Aug 03, 1995

EPINEPHRINE BITARTRATEAEROSOL, METERED; INHALATION
BRONITIN MIST

WYETH CONS	0.3MG/INH	N016126	002	

MEDIHALER-EPI

3M	0.3MG/INH	N010374	003	

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTION
DURANEST

ASTRAZENECA	0.005MG/ML;1%	N017751	006	
	0.005MG/ML;1.5%	N017751	007	
DENTSPLY PHARM	0.005MG/ML;1.5%	N021384	001	

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDEINJECTABLE; INJECTION
CITANEST FORTE

ASTRAZENECA	0.005MG/ML;4%	N014763	008	

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTION
DURANEST

ASTRAZENECA	0.005MG/ML;0.5%	N017751	004	

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE

CARLISLE	0.01MG/ML;2%	A084720	001	
	0.02MG/ML;2%	A084732	001	

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

GRAHAM CHEM	0.01MG/ML;2%	A080504	004	Oct 19, 1983
	0.02MG/ML;2%	A080504	005	Oct 19, 1983
HIKMA MAPLE	0.01MG/ML;1%	A080406	001	
	0.01MG/ML;2%	A080406	002	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 131 (of 360)

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

HOSPIRA	0.005MG/ML;1%	A089649	001	Jun 21, 1988
	0.005MG/ML;1.5%	A089650	001	Jun 21, 1988

LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE

ABBOTT	0.01MG/ML;1%	A083154	001	
BEL MAR	0.01MG/ML;1%	A080820	001	
	0.01MG/ML;2%	A080757	001	
DELL LABS	0.01MG/ML;1%	A083389	001	
	0.01MG/ML;2%	A083390	001	
INTL MEDICATION	0.01MG/ML;1%	A086402	001	
WATSON LABS	0.01MG/ML;1%	A080377	003	
	0.01MG/ML;1%	A085463	001	
	0.01MG/ML;2%	A080377	004	

LIDOCATON

PHARMATON	0.01MG/ML;2%	A084729	001	Aug 17, 1983
	0.02MG/ML;2%	A084728	001	Aug 17, 1983

XYLOCAINE DENTAL WITH EPINEPHRINE

DENTSPLY PHARM	0.01MG/ML;2%	N021381	001	
	0.02MG/ML;2%	N021381	002	

XYLOCAINE W/ EPINEPHRINE

ASTRAZENECA	0.005MG/ML;1%	N010418	006	
	0.005MG/ML;1.5%	N010418	010	
	0.005MG/ML;2%	N010418	008	
FRESENIUS KABI USA	0.01MG/ML;2%	N006488	003	

PATCH; IONTOPHORESIS, TOPICAL

LIDOSITE TOPICAL SYSTEM KIT

VYTERIS	1.05MG/PATCH;100MG/PATCH	N021504	001	May 06, 2004

SOLUTION; IONTOPHORESIS

IONTOCAINE

IOMED	0.01MG/ML;2%	N020530	001	Dec 21, 1995

SOLUTION; IONTOPHORESIS, TOPICAL

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

EMPI	0.01MG/ML;2%	N021486	001	Oct 26, 2004

EPINEPHRINE; PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HYDROCHLORIDE W/ EPINEPHRINE

BEL MAR	0.02MG/ML;1%	A080758	001	
	0.02MG/ML;2%	A080759	001	

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

EPIRUBICIN HYDROCHLORIDE

HOSPIRA	200MG/VIAL	N050807	002	Sep 15, 2006

EPLERENONE

TABLET; ORAL

INSPIRA

GD SEARLE LLC	100MG	N021437	003	Sep 27, 2002

EPROSARTAN MESYLATE

TABLET; ORAL

TEVETEN

ABBVIE	EQ 300MG BASE	N020738	004	Dec 22, 1997

ERGOCALCIFEROL

CAPSULE; ORAL

DELTALIN

LILLY	50,000 IU	A080884	001	

VITAMIN D

CHASE CHEM	50,000 IU	A080747	001	

DISCONTINUED DRUG PRODUCT LIST

6 - 132 (of 360)

ERGOCALCIFEROL

CAPSULE; ORAL
VITAMIN D

EVERYLIFE	50,000 IU	A080956	001
IMPAX LABS	50,000 IU	A080951	001
LANNETT	50,000 IU	A080825	001
VITARINE	50,000 IU	A084053	001
WEST WARD	50,000 IU	A083102	001

ERGOLOID MESYLATES

CAPSULE; ORAL
HYDERGINE LC

NOVARTIS	1MG	N018706	001	Jan 18, 1983

SOLUTION; ORAL
HYDERGINE

NOVARTIS	1MG/ML	N018418	001

TABLET; ORAL
ERGOLOID MESYLATES

MUTUAL PHARM	1MG	A088891	001	Nov 01, 1985
WATSON LABS	1MG	A086433	001	May 27, 1982
	1MG	A087244	001	Aug 16, 1982

GERIMAL

WATSON LABS	1MG	A088207	001	Mar 22, 1984

HYDERGINE

NOVARTIS	0.5MG	N017993	003

TABLET; SUBLINGUAL
ALKERGOT

SANDOZ	0.5MG	A085153	001
	1MG	A087417	001

CIRCANOL

3M	0.5MG	A084868	001
	1MG	A085809	001

DEAPRIL-ST

BRISTOL MYERS SQUIBB	1MG	A085020	002

ERGOLOID MESYLATES

KV PHARM	0.5MG	A085899	001
	0.5MG	A086265	001
	1MG	A085900	001
	1MG	A086264	001

LEDERLE	0.5MG	A086984	001
	1MG	A086985	001

MUTUAL PHARM	0.5MG	A087407	001
	1MG	A087552	001

SUPERPHARM	0.5MG	A089233	001	Sep 23, 1986

	1MG	A089234	001	Sep 23, 1986

VANGARD	0.5MG	A088013	001	Sep 20, 1982

	1MG	A088014	001	Sep 20, 1982

WATSON LABS	0.5MG	A084930	001

	1MG	A085177	001

	1MG	A087183	001

GERIMAL

WATSON LABS	0.5MG	A086189	001
	1MG	A086188	001

HYDERGINE

NOVARTIS	0.5MG	N009087	002
	1MG	N009087	001

HYDROGENATED ERGOT ALKALOIDS

IVAX PHARMS	0.5MG	A087186	001
	1MG	A087185	001

ERGOTAMINE TARTRATE

AEROSOL, METERED; INHALATION
MEDIHALER ERGOTAMINE

3M	0.36MG/INH	N012102	001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 133 (of 360)

ERGOTAMINE TARTRATETABLET; SUBLINGUAL
ERGOSTAT

PARKE DAVIS 2MG A088337 001 Jun 08, 1984

WIGRETTES

ORGANON USA INC 2MG A086750 001 Jul 29, 1982

ERYTHROMYCINCAPSULE, DELAYED REL PELLETS; ORAL
ERYC

PARKE DAVIS 250MG A062546 001 Jul 25, 1985

250MG A062618 001 Sep 25, 1985

ERYC 125

PARKE DAVIS 125MG A062648 001 Oct 24, 1985

ERYC SPRINKLES

HOSPIRA 125MG N050593 001 Jul 22, 1985

ERYTHROMYCIN

BARR 250MG A063098 001 May 04, 1989

GEL; TOPICAL

E-GLADES

RENAISSANCE PHARMA 2% A065009 001 Mar 18, 2002

EMGEL

ALTANA 2% A063107 001 Aug 23, 1991

LOTION; TOPICAL

E-SOLVE 2

SYOSSET 2% A062467 001 Jul 03, 1985

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

PHARMADERM 5MG/GM A062446 001 Sep 26, 1983

PHARMAFAIR 5MG/GM A062481 001 Apr 05, 1984

ILOTYCIN

DISTA 0.5% N050368 001

POWDER; FOR RX COMPOUNDING

ERYTHROMYCIN

PADDOCK LLC 100% N050610 001 Nov 07, 1986

SOLUTION; TOPICAL

A/T/S

TARO PHARMS NORTH 2% A062405 001 Nov 18, 1982

ERYDERM

ARBOR PHARMS INC 2% A062290 001

ERYMAX

MERZ PHARMS 2% A062508 002 Jul 11, 1985

ERYTHROMYCIN

ALPHARMA US PHARMS 1.5% A062328 001 Apr 19, 1982

2% A062326 001 Apr 19, 1982

2% A062327 001 Apr 19, 1982

2% A062342 001 Feb 25, 1982

2% A062957 001 Jul 21, 1988

BAUSCH AND LOMB 2% A064039 001 Jan 27, 1994

LILLY 2% N050532 001

PHARMAFAIR 1.5% A062485 001 Jul 11, 1984

2% A062616 001 Jul 25, 1985

RENAISSANCE PHARMA 2% A064127 001 Feb 14, 1997

SANSAC

DOW PHARM SCIENCES 2% A062522 001 Jan 24, 1985

STATICIN

WESTWOOD SQUIBB 1.5% N050526 001

T-STAT

WESTWOOD SQUIBB 2% A062436 001 Mar 09, 1983

SWAB; TOPICAL

C-SOLVE-2

IVAX SUB TEVA PHARMS 2% A062751 001 Jul 30, 1993

ERYCETTE

JOHNSON AND JOHNSON 2% N050594 001 Feb 15, 1985

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 134 (of 360)

ERYTHROMYCIN

SWAB; TOPICAL				
ERYTHROMYCIN				
RENAISSANCE PHARMA	2%	A064128	001	Jul 03, 1996
T-STAT				
WESTWOOD SQUIBB	2%	A062748	001	Jul 23, 1987
TABLET, DELAYED RELEASE; ORAL				
E-BASE				
BARR	333MG	A063028	001	May 15, 1990
	333MG	A063086	001	May 15, 1990
	500MG	A062999	001	Nov 25, 1988
E-MYCIN				
ARBOR PHARMS INC	250MG	A060272	001	
	333MG	A060272	002	
ILOTYCIN				
DISTA	250MG	A061910	001	
ROBIMYCIN				
ROBINS AH	250MG	A061633	001	
R-P MYCIN				
SOLVAY	250MG	A061659	001	

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL				
ERYTHROMYCIN ESTOLATE				
BARR	EQ 125MG BASE	A062162	001	
	EQ 250MG BASE	A062162	002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A062237	001	
WATSON LABS	EQ 250MG BASE	A062087	001	
ILOSONE				
LILLY	EQ 125MG BASE	A061897	001	
	EQ 250MG BASE	A061897	002	
FOR SUSPENSION; ORAL				
ILOSONE				
DISTA	EQ 125MG BASE/5ML	A061893	001	
SUSPENSION; ORAL				
ERYTHROMYCIN ESTOLATE				
ALPHARMA US PHARMS	EQ 125MG BASE/5ML	A062353	001	Nov 18, 1982
	EQ 250MG BASE/5ML	A062409	001	Dec 16, 1982
BARR	EQ 125MG BASE/5ML	A062169	001	Oct 17, 1990
	EQ 250MG BASE/5ML	A062169	002	Oct 17, 1990
LIFE LABS	EQ 250MG BASE/5ML	A062362	001	Dec 17, 1982
ILOSONE				
LILLY	EQ 125MG BASE/5ML	A061894	001	
	EQ 125MG BASE/5ML	N050010	001	
	EQ 250MG BASE/5ML	A061894	002	
	EQ 250MG BASE/5ML	N050010	002	
SUSPENSION/DROPS; ORAL				
ILOSONE				
LILLY	EQ 100MG BASE/ML	A061894	003	
TABLET; ORAL				
ILOSONE				
LILLY	EQ 500MG BASE	A061896	001	
TABLET, CHEWABLE; ORAL				
ILOSONE				
DISTA	EQ 125MG BASE	A061895	001	
	EQ 250MG BASE	A061895	002	

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION; ORAL				
ILOSONE SULFA				
LILLY	EQ 125MG BASE/5ML; EQ 600MG BASE/5ML	N050599	001	Sep 29, 1989

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 135 (of 360)

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

ERYTHROMYCIN ETHYLSUCCINATE

BARR EQ 200MG BASE/5ML A062055 001

PEDIAMYCIN

ROSS LABS EQ 200MG BASE/5ML A062305 001

SUSPENSION; ORAL

E-MYCIN E

PHARMACIA AND UPJOHN EQ 200MG BASE/5ML A062198 001

EQ 400MG BASE/5ML A062198 002

ERYTHROMYCIN ETHYLSUCCINATE

ALPHARMA US PHARMS EQ 200MG BASE/5ML A062200 001

EQ 400MG BASE/5ML A062200 002

DISTA EQ 200MG BASE/5ML A062177 001

EQ 400MG BASE/5ML A062177 002

NASKA EQ 400MG BASE/5ML A062674 001 Mar 10, 1987

PARKE DAVIS EQ 200MG BASE/5ML A062231 001

EQ 400MG BASE/5ML A062231 002

PHARMAFAIR EQ 200MG BASE/5ML A062559 001 Mar 15, 1985

EQ 400MG BASE/5ML A062558 001 Mar 15, 1985

WYAMYCIN E

WYETH AYERST EQ 200MG BASE/5ML A062123 002

EQ 400MG BASE/5ML A062123 001

SUSPENSION/DROPS; ORAL

PEDIAMYCIN

ROSS LABS EQ 100MG BASE/2.5ML A062305 002

TABLET; ORAL

E.E.S. 400

ARBOR PHARMS INC EQ 400MG BASE A061905 001

ERYTHROMYCIN ETHYLSUCCINATE

BARR EQ 400MG BASE A062256 001

MYLAN EQ 400MG BASE A062847 001 Sep 14, 1988

TABLET, CHEWABLE; ORAL

E.E.S.

ARBOR PHARMS INC EQ 200MG BASE N050297 002

ERYPED

ARBOR PHARMS INC EQ 200MG BASE N050297 003 Jul 05, 1988

PEDIAMYCIN

ROSS LABS EQ 200MG BASE A062306 001

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

ERYZOLE

ALRA EQ 200MG BASE/5ML;EQ 600MG BASE/5ML A062758 001 Jun 15, 1988

PEDIAZOLE

ROSS LABS EQ 200MG BASE/5ML;EQ 600MG BASE/5ML N050529 001

ERYTHROMYCIN GLUCEPTATE

INJECTABLE; INJECTION

ILOTYCIN GLUCEPTATE

DISTA EQ 250MG BASE/VIAL N050370 001

EQ 500MG BASE/VIAL N050370 002

EQ 1GM BASE/VIAL N050370 003

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

ABBOTT EQ 500MG BASE/VIAL A062586 001 Jan 04, 1988

EQ 1GM BASE/VIAL A062586 002 Jan 04, 1988

HOSPIRA EQ 500MG BASE/VIAL N050182 002

EQ 1GM BASE/VIAL N050182 003

EQ 1GM BASE/VIAL N050609 002 Sep 24, 1986

ERYTHROMYCIN

ELKINS SINN EQ 500MG BASE/VIAL A062563 001 Mar 28, 1985

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 136 (of 360)

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROMYCIN

ELKINS SINN EQ 1GM BASE/VIAL

A062563 002 Mar 28, 1985

ERYTHROMYCIN LACTOBIONATE

ABRAXIS PHARM EQ 500MG BASE/VIAL

A062604 001 Nov 24, 1986

EQ 1GM BASE/VIAL

A062604 002 Nov 24, 1986

BAXTER HLTHCARE EQ 500MG BASE/VIAL

A062993 001 May 09, 1989

EQ 1GM BASE/VIAL

A062993 002 May 09, 1989

TEVA PARENTERAL EQ 500MG BASE/VIAL

A063253 001 Jul 30, 1993

EQ 1GM BASE/VIAL

A063253 002 Jul 30, 1993

ERYTHROMYCIN STEARATE

TABLET; ORAL

BRISTAMYCIN

BRISTOL EQ 250MG BASE

A061304 001

EQ 250MG BASE

A061887 001

ERYPAR

PARKE DAVIS EQ 250MG BASE

A062032 001

EQ 500MG BASE

A062032 002

WARNER CHILCOTT EQ 250MG BASE

A062322 001

ERYTHROCIN STEARATE

ARBOR PHARMS INC EQ 125MG BASE

A060359 002

EQ 500MG BASE

A060359 003

ERYTHROMYCIN STEARATE

BARR EQ 250MG BASE

A061591 001

EQ 500MG BASE

A063179 001 May 15, 1990

IVAX SUB TEVA PHARMS EQ 250MG BASE

A061461 001

EQ 500MG BASE

A061461 002

LEDERLE EQ 250MG BASE

A062089 001

EQ 500MG BASE

A062089 002

MYLAN EQ 250MG BASE

A061505 001

EQ 500MG BASE

A061505 002

PUREPAC PHARM EQ 250MG BASE

A061743 001

WATSON LABS EQ 250MG BASE

A062121 002

EQ 500MG BASE

A062121 001

ETHRIL 250

BRISTOL MYERS SQUIBB EQ 250MG BASE

A061605 001

ETHRIL 500

BRISTOL MYERS SQUIBB EQ 500MG BASE

A061605 002

PFIZER-E

PFIZER EQ 250MG BASE

A061791 001

EQ 500MG BASE

A061791 002

WYAMYCIN S

WYETH AYERST EQ 250MG BASE

A061675 001

EQ 500MG BASE

A061675 002

ESCITALOPRAM OXALATE

CAPSULE; ORAL

ESCITALOPRAM OXALATE

MYLAN PHARMS INC EQ 5MG BASE

A077660 001 Jul 31, 2007

EQ 10MG BASE

A077660 002 Jul 31, 2007

EQ 20MG BASE

A077660 003 Jul 31, 2007

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

BAXTER HLTHCARE 10MG/ML

N019386 003 Aug 15, 1988

20MG/ML

N019386 007 May 28, 2003

DISCONTINUED DRUG PRODUCT LIST

6 - 137 (of 360)

ESTAZOLAM

TABLET; ORAL
PROSOM

ABBOTT	1MG	N019080	001	Dec 26, 1990
	2MG	N019080	002	Dec 26, 1990

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
ESCLIM

WOMEN FIRST HLTHCARE	0.025MG/24HR	N020847	001	Aug 04, 1998
	0.0375MG/24HR	N020847	002	Aug 04, 1998
	0.05MG/24HR	N020847	003	Aug 04, 1998
	0.075MG/24HR	N020847	004	Aug 04, 1998
	0.1MG/24HR	N020847	005	Aug 04, 1998

ESTRADIOL

ORTHO MCNEIL PHARM	0.05MG/24HR	N021048	001	Sep 20, 1999
	0.075MG/24HR	N021048	002	Sep 20, 1999
	0.1MG/24HR	N021048	003	Sep 20, 1999

FEMPATCH

PARKE DAVIS	0.025MG/24HR	N020417	001	Dec 03, 1996

VIVELLE

NOVARTIS	0.025MG/24HR	N020323	005	Aug 16, 2000
	0.0375MG/24HR	N020323	001	Oct 28, 1994
	0.075MG/24HR	N020323	003	Oct 28, 1994

GEL; TOPICAL

ESTROGEL

ASCEND	0.06%	N021166	001	Feb 09, 2004

TABLET; ORAL

ESTRACE

BRISTOL MYERS SQUIBB	0.5MG	A081295	001	Jun 30, 1993
	1MG	A084499	001	
	2MG	A084500	001	

ESTRADIOL

AAI PHARMA INC	0.5MG	A040138	001	Jan 30, 1998
	1MG	A040138	002	Jan 30, 1998
	2MG	A040138	003	Jan 30, 1998
HERITAGE PHARMS INC	0.5MG	A040275	001	Dec 29, 1998
	1MG	A040275	002	Dec 29, 1998
	2MG	A040275	003	Dec 29, 1998

GYNODIOL

DURAMED PHARMS BARR	0.5MG	A040212	001	Dec 29, 1997
	1MG	A040212	002	Dec 29, 1997
	1.5MG	A040212	003	Dec 29, 1997
	2MG	A040212	004	Dec 29, 1997

INNOFEM

NOVO NORDISK INC	0.5MG	A040312	001	Nov 19, 1999
	1MG	A040312	002	Nov 19, 1999
	2MG	A040312	003	Nov 19, 1999

TABLET; VAGINAL

VAGIFEM

NOVO NORDISK INC	25MCG	N020908	001	Mar 26, 1999

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

DEPO-ESTRADIOL

PHARMACIA AND UPJOHN	1MG/ML	A085470	001	
	3MG/ML	A085470	002	

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE; INTRAMUSCULAR

LUNELLE

PHARMACIA AND UPJOHN	5MG/0.5ML; 25MG/0.5ML	N020874	001	Oct 05, 2000

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 138 (of 360)

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATEINJECTABLE; INJECTION
DEPO-TESTADIOL

PHARMACIA AND UPJOHN 2MG/ML;50MG/ML

N017968 001

TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE

WATSON LABS 2MG/ML;50MG/ML

A085603 001 Mar 13, 1986

ESTRADIOL VALERATEINJECTABLE; INJECTION
ESTRADIOL VALERATE

WATSON LABS 10MG/ML

A083546 001

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATEINJECTABLE; INJECTION
DITATE-DS

SAVAGE LABS 8MG/ML;180MG/ML

A086423 001

TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE

WATSON LABS 4MG/ML;90MG/ML

A085865 001

8MG/ML;180MG/ML

A085860 001

ESTROGENS, CONJUGATEDTABLET; ORAL
PREMARIN

WYETH PHARMS INC 2.5MG

N004782 002

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE (PREMARIN;CYCRIN 14/14)

WYETH PHARMS INC 0.625MG,0.625MG;N/A,5MG

N020303 002 Dec 30, 1994

PREMPRO (PREMARIN;CYCRIN)

WYETH PHARMS INC 0.625MG,0.625MG;2.5MG,2.5MG

N020303 001 Dec 30, 1994

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL

MILPREM-200

MEDPOINTE PHARM HLC 0.45MG;200MG

N011045 002

MILPREM-400

MEDPOINTE PHARM HLC 0.45MG;400MG

N011045 001

PMB 200

WYETH AYERST 0.45MG;200MG

N010971 005

PMB 400

WYETH AYERST 0.45MG;400MG

N010971 003

ESTROGENS, ESTERIFIED

TABLET; ORAL

AMNESTROGEN

BRISTOL MYERS SQUIBB 0.3MG

A083266 001

0.625MG

A083266 002

1.25MG

A083266 003

2.5MG

A083266 004

ESTERIFIED ESTROGENS

PVT FORM 0.625MG

A083414 001

1.25MG

A083765 001

2.5MG

A085907 001

SANDOZ

1.25MG

A085302 001

ESTRATAB

SOLVAY 0.3MG

A086715 001

0.625MG

A083209 001

1.25MG

A083856 001

2.5MG

A083857 001

EVEX

ROCHE PALO 0.625MG

A084215 001

1.25MG

A083376 002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 139 (of 360)

ESTROGENS, ESTERIFIEDTABLET; ORAL
FEMOGEN

PVT FORM	0.625MG	A085076	001
	1.25MG	A085008	001
	2.5MG	A085007	001

ESTRONEINJECTABLE; INJECTION
ESTROGENIC SUBSTANCE

WYETH AYERST	2MG/ML	A083488	001

ESTRONE

WATSON LABS	2MG/ML	A083397	001

NATURAL ESTROGENIC SUBSTANCE-ESTRONE

WATSON LABS	2MG/ML	A085237	001	Nov 23, 1982

THEELIN

PARKEDALE	1MG/ML	N003977	001
	2MG/ML	N003977	002
	5MG/ML	N003977	003

ESTROPIPATECREAM; VAGINAL
OGEN

PHARMACIA AND UPJOHN	1.5MG/GM	A084710	001

TABLET; ORAL
ESTROPIPATE

DURAMED PHARMS BARR	0.75MG	A040296	001	Nov 01, 1999
	1.5MG	A040296	002	Nov 01, 1999
	3MG	A040296	003	Nov 01, 1999
MYLAN	3MG	A040359	003	Aug 26, 1999

ESZOPICLONETABLET; ORAL
ESZOPICLONE

LUPIN LTD	1MG	A091124	001	Sep 13, 2011
	2MG	A091124	002	Sep 13, 2011
	3MG	A091124	003	Sep 13, 2011
TEVA	1MG	A091169	001	May 23, 2011
	2MG	A091169	002	May 23, 2011
	3MG	A091169	003	May 23, 2011
WOCKHARDT LTD	1MG	A091165	001	Jul 14, 2011
	2MG	A091165	002	Jul 14, 2011
	3MG	A091165	003	Jul 14, 2011

ETHACRYNIC ACIDTABLET; ORAL
EDECRIN
ATON

50MG	N016092	002

ETHAMBUTOL HYDROCHLORIDETABLET; ORAL
MYAMBUTOL

STI PHARMA LLC	200MG	N016320	002
	500MG	N016320	004

ETHCHLORVYNOLCAPSULE; ORAL
ETHCHLORVYNOL

BANNER PHARMACAPS	100MG	A084463	001
	200MG	A084463	002
	500MG	A084463	003
	750MG	A084463	004

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 140 (of 360)

ETHCHLORVYNOLCAPSULE; ORAL
PLACIDYL

ABBVIE

100MG

N010021 004

200MG

N010021 007

500MG

N010021 002

750MG

N010021 010

ETHINAMATECAPSULE; ORAL
VALMID

DISTA

500MG

N009750 001

ETHINYL ESTRADIOLTABLET; ORAL
ESTINYL

SCHERING

0.02MG

N005292 001

0.05MG

N005292 002

0.5MG

N005292 003

FEMINONE

PHARMACIA AND UPJOHN 0.05MG

N016649 001

LYNORAL

ORGANON USA INC 0.01MG

N005490 003

0.05MG

N005490 002

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21

DEMULEN 1/35-21

GD SEARLE LLC

0.035MG;1MG **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

N018168 001

DEMULEN 1/50-21

GD SEARLE LLC

0.05MG;1MG

N016927 001

ZOVIA 1/35E-21

WATSON LABS

0.035MG;1MG

A072720 001

Dec 30, 1991

ZOVIA 1/50E-21

WATSON LABS

0.05MG;1MG

A072722 001

Dec 30, 1991

TABLET; ORAL-28

DEMULEN 1/35-28

GD SEARLE LLC

0.035MG;1MG

N018160 001

DEMULEN 1/50-28

GD SEARLE LLC

0.05MG;1MG

N016936 001

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET; ORAL-28

NORQUEST FE

GD SEARLE LLC

0.035MG;75MG;1MG

N018926 001

Jul 18, 1986

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

TABLET; ORAL-28

NORLESTRIN FE 1/50

PARKE DAVIS

0.05MG;75MG;1MG

N016766 001

NORLESTRIN FE 2.5/50

PARKE DAVIS

0.05MG;75MG;2.5MG

N016854 001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LYBREL

WYETH PHARMS INC

0.02MG;0.09MG

N021864 001

May 22, 2007

PREVEN EMERGENCY CONTRACEPTIVE KIT

TEVA BRANDED PHARM

0.05MG;0.25MG

N020946 001

Sep 01, 1998

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 141 (of 360)

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

ALESSE

WYETH PHARMS	0.02MG;0.1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020683	001	Mar 27, 1997

AVIANE-21

DURAMED PHARMS BARR	0.02MG;0.1MG	A075796	002	Apr 30, 2001

ENPRESSE-21

DURAMED PHARMS BARR	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A075809	001	Jul 16, 2001

LESSINA-21

BARR	0.02MG;0.1MG	A075803	001	Mar 20, 2002

LEVLITE

BAYER HLTHCARE	0.02MG;0.1MG	N020860	001	Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR	0.02MG;0.1MG	A075862	001	Apr 29, 2003

LEVORA 0.15/30-21

WATSON LABS	0.03MG;0.15MG	A073592	001	Dec 13, 1993

NORDETTE-21

TEVA BRANDED PHARM	0.03MG;0.15MG	N018668	001	May 10, 1982

PORTIA-21

BARR	0.03MG;0.15MG	A075866	001	May 23, 2002

TRIPHASIL-21

WYETH PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019192	001	Nov 01, 1984

TRIVORA-21

WATSON LABS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A074538	001	Dec 18, 1997

TABLET; ORAL-28

ALESSE

WYETH PHARMS	0.02MG;0.1MG	N020683	002	Mar 27, 1997

LEVLITE

BAYER HLTHCARE	0.02MG;0.1MG	N020860	002	Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR	0.02MG;0.1MG	A075862	002	Apr 29, 2003

TRIPHASIL-28

WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N019190	001	Nov 01, 1984

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BALZIVA-21

BARR	0.035MG;0.4MG	A076198	001	Apr 22, 2004

BREVICON 21-DAY

WATSON LABS	0.035MG;0.5MG	N017566	001	

GENCEPT 10/11-21

BARR	0.035MG,0.035MG;0.5MG,1MG	A072694	001	Feb 28, 1992

MODICON 21

ORTHO MCNEIL PHARM	0.035MG;0.5MG	N017488	001	

N.E.E. 1/35 21

LPI	0.035MG;1MG	A071541	001	Dec 14, 1987

NORCEPT-E 1/35 21

ORTHO MCNEIL PHARM	0.035MG;1MG	A071545	001	Feb 09, 1989

NORETHINDRONE AND ETHINYL ESTRADIOL

WATSON LABS	0.035MG;0.5MG	A070684	001	Jan 29, 1987

NORTREL 0.5/35-21

BARR	0.035MG;0.5MG	A072692	001	Feb 28, 1992

ORTHO-NOVUM 1/35-21

ORTHO MCNEIL PHARM	0.035MG;1MG	N017489	002	

DISCONTINUED DRUG PRODUCT LIST

6 - 142 (of 360)

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21						
ORTHO-NOVUM 10/11-21						
ORTHO MCNEIL JANSSEN	0.035MG, 0.035MG; 0.5MG, 1MG	N018354	001	Jan 11, 1982		
ORTHO-NOVUM 7/14-21						
ORTHO MCNEIL PHARM	0.035MG, 0.035MG; 0.5MG, 1MG	N019004	001	Apr 04, 1984		
ORTHO-NOVUM 7/7/7-21						
JANSSEN PHARMS	0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG	N018985	001	Apr 04, 1984		
OVCON-35						
WARNER CHILCOTT	0.035MG; 0.4MG	N018127	001			
OVCON-50						
WARNER CHILCOTT	0.05MG; 1MG	N018128	001			
TRI-NORINYL 21-DAY						
WATSON LABS	0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.5MG	N018977	001	Apr 13, 1984		
TABLET; ORAL-28						
GENCEPT 10/11-28						
BARR	0.035MG, 0.035MG; 0.5MG, 1MG	A072697	001	Feb 28, 1992		
N.E.E. 1/35 28						
LPI	0.035MG; 1MG	A071542	001	Dec 14, 1987		
NORCEPT-E 1/35 28						
ORTHO MCNEIL PHARM	0.035MG; 1MG	A071546	001	Feb 09, 1989		
ORTHO-NOVUM 10/11-28						
ORTHO MCNEIL JANSSEN	0.035MG, 0.035MG; 0.5MG, 1MG	N018354	002	Jan 11, 1982		
ORTHO-NOVUM 7/14-28						
ORTHO MCNEIL PHARM	0.035MG, 0.035MG; 0.5MG, 1MG	N019004	002	Apr 04, 1984		

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21						
ESTROSTEP 21						
WARNER CHILCOTT LLC	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG	N020130	001	Oct 09, 1996		
NORLESTRIN 21 1/50						
PARKE DAVIS	0.05MG; 1MG	N016749	001			
NORLESTRIN 21 2.5/50						
PARKE DAVIS	0.05MG; 2.5MG	N016852	001			
TABLET; ORAL-28						
NORLESTRIN 28 1/50						
PARKE DAVIS	0.05MG; 1MG	N016723	001			

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-21						
ORTHO CYCLEN-21						
JANSSEN PHARMS	0.035MG; 0.25MG	N019653	001	Dec 29, 1989		
ORTHO TRI-CYCLEN						
JANSSEN PHARMS	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG	N019697	002	Jul 03, 1992		

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21						
LO/OVRAL						
WYETH PHARMS INC	0.03MG; 0.3MG	N017612	001			
OGESTREL 0.5/50-21						
WATSON LABS	0.05MG; 0.5MG	A075406	001	Dec 15, 1999		
OVRAL						
WYETH PHARMS	0.05MG; 0.5MG	N016672	001			
TABLET; ORAL-28						
OVRAL-28						
WYETH PHARMS	0.05MG; 0.5MG	N016806	001			

ETHIODIZED OIL

OIL; INTRALYMPHATIC						
ETHIODOL						
GUERBET	99%	N009190	001			

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 143 (of 360)

ETHOPROPAZINE HYDROCHLORIDETABLET; ORAL
PARSIDOL

PARKE DAVIS

10MG

N009078 003

50MG

N009078 006

100MG

N009078 008

ETHOTOINTABLET; ORAL
PEGANONE

LUNDBECK LLC

500MG

N010841 003

ETHOXZOLAMIDETABLET; ORAL
CARDRASE

PHARMACIA AND UPJOHN

62.5MG

N011047 002

125MG

N011047 001

ETHAMIDE

ALLERGAN

125MG

N016144 001

ETHYLESTRENOLELIXIR; ORAL
MAXIBOLIN

ORGANON USA INC

2MG/5ML

N014006 002

TABLET; ORAL
MAXIBOLIN

ORGANON USA INC

2MG

N014005 002

ETHYNODIOL DIACETATE; MESTRANOLTABLET; ORAL-20
OVULEN

GD SEARLE LLC

1MG;0.1MG

N016029 002

TABLET; ORAL-21
OVULEN-21

GD SEARLE LLC

1MG;0.1MG

N016029 003

TABLET; ORAL-28
OVULEN-28

GD SEARLE LLC

1MG;0.1MG

N016705 001

ETIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTION
DURANEST

ASTRAZENECA

0.5%

N017751 003

1%

N017751 005

ETIDRONATE DISODIUMINJECTABLE; INJECTION
DIDRONEL

MGI PHARMA INC

50MG/ML

N019545 001 Apr 20, 1987

ETODOLACCAPSULE; ORAL
ETODOLAC

AAIPHARMA LLC

300MG

A074929 001 Jan 30, 1998

IVAX SUB TEVA PHARMS

200MG

A074899 001 Jul 08, 1997

300MG

A074899 002 Jul 08, 1997

MYLAN

200MG

A074932 001 May 16, 1997

200MG

A075071 001 Sep 30, 1998

300MG

A074932 002 May 16, 1997

300MG

A075071 002 Sep 30, 1998

SANDOZ

200MG

A074840 001 Aug 29, 1997

200MG

A074942 001 Sep 30, 1997

300MG

A074840 002 Aug 29, 1997

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 144 (of 360)

ETODOLAC

CAPSULE; ORAL

ETODOLAC

SANDOZ	300MG	A074942	002	Sep 30, 1997
TEVA	200MG	A075126	001	Sep 16, 1999
VINTAGE PHARMS LLC	200MG	A074842	001	Jul 17, 1997
	300MG	A074842	002	Jul 17, 1997
WATSON LABS	200MG	A074844	001	Dec 23, 1997
	300MG	A074844	002	Dec 23, 1997

LODINE

WYETH PHARMS INC	200MG	N018922	002	Jan 31, 1991
	300MG	N018922	003	Jan 31, 1991

TABLET; ORAL

ETODOLAC

AAIPHARMA LLC	400MG	A074927	001	Oct 30, 1997
IVAX SUB TEVA PHARMS	400MG	A074883	001	Feb 28, 1997
	500MG	A074883	002	Nov 20, 1998
MYLAN	400MG	A075012	001	Sep 30, 1998
	500MG	A075012	002	Sep 30, 1998
RANBAXY LABS LTD	400MG	A075226	001	Nov 24, 1998
	500MG	A075226	002	Nov 24, 1998
SANDOZ	400MG	A074839	001	Jul 11, 1997
	400MG	A074846	001	Feb 28, 1997
TEVA	400MG	A074847	001	Apr 23, 1999
	500MG	A074847	002	Apr 23, 1999
VINTAGE PHARMS LLC	400MG	A074841	001	Jun 27, 1997
WATSON LABS	400MG	A074892	001	Apr 16, 1997
	400MG	A075069	001	Apr 16, 1998
	500MG	A074892	002	Oct 29, 1998

LODINE

WYETH PHARMS INC	400MG	N018922	004	Jul 29, 1993
	500MG	N018922	005	Jun 28, 1996

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

ACTAVIS ELIZABETH	400MG	A075696	001	Jul 31, 2000
SANDOZ	400MG	A075943	001	Jul 26, 2002
	500MG	A075943	002	Jul 26, 2002
	600MG	A075943	003	Jul 26, 2002
WATSON LABS FLORIDA	400MG	A075829	001	Nov 30, 2001
	500MG	A075829	002	Nov 30, 2001

LODINE XL

WYETH PHARMS INC	400MG	N020584	001	Oct 25, 1996
	500MG	N020584	003	Jan 20, 1998
	600MG	N020584	002	Oct 25, 1996

ETOPOSIDE

CAPSULE; ORAL

VEPESID

CORDEN PHARMA	50MG	N019557	001	Dec 30, 1986
	100MG	N019557	002	Dec 30, 1986

INJECTABLE; INJECTION

ETOPOSIDE

HOSPIRA	20MG/ML	A074320	001	Aug 30, 1995
	20MG/ML	A074351	001	Aug 30, 1995
MARSAM PHARMS LLC	20MG/ML	A074968	001	Jan 09, 1998
PIERRE FABRE	20MG/ML	A074813	001	Jul 09, 1997
TEVA PARENTERAL	20MG/ML	A074510	001	Jun 29, 1995
WATSON LABS	20MG/ML	A074228	001	Oct 15, 1996

TOPOSAR

TEVA PARENTERAL	20MG/ML	A074166	001	Feb 27, 1995

VEPESID

CORDEN PHARMA	20MG/ML	N018768	001	Nov 10, 1983

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 145 (of 360)

ETOPOSIDE PHOSPHATEINJECTABLE; INJECTION
ETOPOPHOS PRESERVATIVE FREE

BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N020906	001	Feb 27, 1998
	EQ 1GM BASE/VIAL	N020906	002	Feb 27, 1998

ETRETINATE

CAPSULE; ORAL

TEGISON

ROCHE

10MG

N019369 001 Sep 30, 1986

25MG

N019369 002 Sep 30, 1986

EVANS BLUE

INJECTABLE; INJECTION

EVANS BLUE

PARKE DAVIS

0.5% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N008041 001

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

APOTEX INC

10MG/ML

A075942 001 Aug 02, 2002

APOTHECON

10MG/ML

A075707 001 Apr 16, 2001

HOSPIRA

10MG/ML

A075705 001 Apr 16, 2001

10MG/ML

A075870 001 Nov 23, 2001

10MG/ML

A075905 001 Nov 23, 2001

FAMOTIDINE PRESERVATIVE FREE

APOTHECON

10MG/ML

A075708 001 Apr 16, 2001

HOSPIRA

10MG/ML

A075669 001 Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

ABBVIE

0.4MG/ML

A075729 001 Dec 17, 2001

PEPCID

MERCK

10MG/ML

N019510 001 Nov 04, 1986

PEPCID PRESERVATIVE FREE

MERCK

10MG/ML

N019510 004 Nov 04, 1986

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

MERCK

0.4MG/ML

N020249 001 Feb 18, 1994

TABLET; ORAL

FAMOTIDINE

ACTAVIS ELIZABETH

20MG

A075650 001 Sep 14, 2001

40MG

A075650 002 Sep 14, 2001

APOTEX

10MG

A075610 001 Mar 12, 2002

MUTUAL PHARM

20MG

A075639 002 Dec 12, 2001

40MG

A075639 001 Dec 12, 2001

MYLAN PHARMS INC

20MG

A075457 001 Apr 18, 2001

40MG

A075457 002 Apr 18, 2001

SANDOZ

10MG

A076101 001 Oct 21, 2002

20MG

A075302 001 Apr 16, 2001

20MG

A075607 001 May 10, 2001

20MG

A075793 001 Apr 16, 2001

40MG

A075302 002 Apr 16, 2001

40MG

A075607 002 May 10, 2001

40MG

A075793 002 Apr 16, 2001

TABLET, CHEWABLE; ORAL

PEPCID AC

MCNEIL CONS

10MG

N020801 001 Sep 24, 1998

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

UCB INC

20MG

N021712 001 Sep 24, 2004

40MG

N021712 002 Sep 24, 2004

PEPCID RPD

MERCK

20MG

N020752 001 May 28, 1998

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 146 (of 360)

FAMOTIDINETABLET, ORALLY DISINTEGRATING; ORAL
PEPCID RPD

MERCK	40MG	N020752	002	May 28, 1998

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

LUPIN ATLANTIS	87MG	N021695	002	Nov 30, 2004

LIPIDIL

ABBVIE	100MG	N019304	001	Dec 31, 1993

LIPOFEN

CIPHER PHARMS INC	100MG	N021612	002	Jan 11, 2006

TRICOR (MICRONIZED)

ABBVIE	67MG	N019304	002	Feb 09, 1998

	134MG	N019304	003	Jun 30, 1999

	200MG	N019304	004	Jun 30, 1999

TABLET; ORAL

FENOFIBRATE

MYLAN	107MG	A076520	002	Dec 29, 2005

TRICOR

ABBOTT	54MG	N021203	001	Sep 04, 2001

	160MG	N021203	003	Sep 04, 2001

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

FENOLDOPAM MESYLATE

LUITPOLD	EQ 10MG BASE/ML	A076656	001	Dec 01, 2003

TEVA PARENTERAL	EQ 10MG BASE/ML	A077826	001	Mar 07, 2007

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

AM THERAP	EQ 200MG BASE	A072307	001	Aug 22, 1988

	EQ 300MG BASE	A072308	001	Aug 22, 1988

HALSEY	EQ 200MG BASE	A072355	001	Aug 17, 1988

	EQ 300MG BASE	A072356	001	Aug 17, 1988

PAR PHARM	EQ 200MG BASE	A072437	001	Aug 22, 1988

	EQ 300MG BASE	A072438	001	Aug 22, 1988

QUANTUM PHARMICS	EQ 200MG BASE	A072214	001	Aug 17, 1988

	EQ 300MG BASE	A071738	001	Aug 17, 1988

SANDOZ	EQ 200MG BASE	A072394	001	Oct 17, 1988

	EQ 300MG BASE	A072395	001	Oct 17, 1988

WARNER CHILCOTT	EQ 200MG BASE	A072946	001	Apr 30, 1991

	EQ 300MG BASE	A072472	001	Apr 30, 1991

WATSON LABS	EQ 200MG BASE	A072294	001	Aug 17, 1988

	EQ 200MG BASE	A072981	001	Aug 19, 1991

	EQ 300MG BASE	A072293	001	Aug 17, 1988

	EQ 300MG BASE	A072982	001	Aug 19, 1991

NALFON

XSPIRE	EQ 300MG BASE	N017604	002	

TABLET; ORAL

FENOPROFEN CALCIUM

ACTAVIS ELIZABETH	EQ 600MG BASE	A072274	001	May 02, 1988

AM THERAP	EQ 600MG BASE	A072309	001	Aug 17, 1988

CLONMEL HLTHCARE	EQ 600MG BASE	A072326	001	Aug 17, 1988

HALSEY	EQ 600MG BASE	A072357	001	Aug 17, 1988

MUTUAL PHARM	EQ 600MG BASE	A072902	001	Dec 21, 1990

PAR PHARM	EQ 600MG BASE	A072429	001	Aug 17, 1988

QUANTUM PHARMICS	EQ 600MG BASE	A072194	001	Aug 17, 1988

SANDOZ	EQ 600MG BASE	A072396	001	Oct 17, 1988

USL PHARMA	EQ 600MG BASE	A072362	001	Aug 17, 1988

WATSON LABS	EQ 600MG BASE	A072165	001	Aug 17, 1988

DISCONTINUED DRUG PRODUCT LIST

6 - 147 (of 360)

FENOPROFEN CALCIUM

TABLET; ORAL		
FENOPROFEN CALCIUM		
WATSON LABS	EQ 600MG BASE	A072407 001 Aug 17, 1988
	EQ 600MG BASE	A072602 001 Oct 11, 1988
NALFON		
DISTA	EQ 600MG BASE	N017710 001

FENTANYL CITRATE

INJECTABLE; INJECTION		
FENTANYL CITRATE		
ABBOTT	EQ 0.05MG BASE/ML	A070636 001 Apr 30, 1990
	EQ 0.05MG BASE/ML	A070637 001 Apr 30, 1990
WATSON LABS	EQ 0.05MG BASE/ML	A073488 001 Jun 30, 1992
FENTANYL CITRATE PRESERVATIVE FREE		
MARSAM PHARMS LLC	EQ 0.05MG BASE/ML	A074917 001 Feb 03, 1998
TABLET; BUCCAL		
FENTORA		
CEPHALON	EQ 0.3MG BASE	N021947 006 Mar 02, 2007
TROCHE/LOZENGE; ORAL		
FENTANYL		
CEPHALON	EQ 0.1MG BASE	N020195 007 Oct 30, 1995
	EQ 0.2MG BASE	N020195 001 Oct 04, 1993
	EQ 0.3MG BASE	N020195 002 Oct 04, 1993
	EQ 0.4MG BASE	N020195 003 Oct 04, 1993

FENTANYL HYDROCHLORIDE

SYSTEM; IONTOPHORESIS, TRANSDERMAL		
IONSYS		
INCLINE THERAP	10.8MCG	N021338 001 May 22, 2006

FERRIC AMMONIUM CITRATE

FOR SOLUTION; ORAL		
FERRISELTZ		
OTSUKA	600MG/PACKET	N020292 001 Oct 14, 1997

FERROUS CITRATE, FE-59

INJECTABLE; INJECTION		
FERROUS CITRATE FE 59		
MALLINCKRODT	25uCi/ML	N016729 001

FERROUS SULFATE; FOLIC ACID

CAPSULE; ORAL		
FOLVRON		
LEDERLE	182MG;0.33MG	N006012 003

FERUMOXIDES

INJECTABLE; INJECTION		
FERIDEX I.V.		
AMAG PHARMS INC	EQ 11.2MG IRON/ML	N020416 001 Aug 30, 1996

FEXOFENADINE HYDROCHLORIDE

CAPSULE; ORAL		
ALLEGRA		
SANOFI AVENTIS US	60MG	N020625 001 Jul 25, 1996
FEXOFENADINE HYDROCHLORIDE		
BARR	60MG	A076169 001 Jul 13, 2005

FIBRINOGEN, I-125

INJECTABLE; INJECTION		
IBRIN		
GE HEALTHCARE	154uCi/VIAL	N017879 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 148 (of 360)

FIBRINOGEN, I-125

INJECTABLE; INJECTION				
RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR				
ABBOTT	140uCi/ML	N017787	001	

FINASTERIDE

TABLET; ORAL				
FINASTERIDE				
IVAX SUB TEVA PHARMS	5MG	A076340	001	Jun 19, 2006

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL				
URISPAS				
ORTHO MCNEIL JANSSEN	100MG	N016769	001	

FLECAINIDE ACETATE

TABLET; ORAL				
FLECAINIDE ACETATE				
SANDOZ	50MG	A076030	001	Oct 28, 2002
	100MG	A076030	002	Oct 28, 2002
	150MG	A076030	003	Oct 28, 2002
TAMBOCOR				
MEDICIS	200MG	N018830	002	Oct 31, 1985

FLOXURIDINE

INJECTABLE; INJECTION				
FUDR				
HOSPIRA	500MG/VIAL	N016929	001	

FLUCONAZOLE

INJECTABLE; INJECTION				
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AGILA SPECLTS	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005
	400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005
HOSPIRA	200MG/100ML (2MG/ML)	A076617	001	Jul 29, 2004
	400MG/200ML (2MG/ML)	A076617	002	Jul 29, 2004
TABLET; ORAL				
FLUCONAZOLE				
GEDEON RICHTER USA	50MG	A076432	001	Jul 29, 2004
	100MG	A076432	002	Jul 29, 2004
	150MG	A076432	003	Jul 29, 2004
	200MG	A076432	004	Jul 29, 2004
MYLAN PHARMS INC	50MG	A076042	001	Jul 29, 2004
	100MG	A076042	002	Jul 29, 2004
	150MG	A076042	003	Jul 29, 2004
	200MG	A076042	004	Jul 29, 2004
PLIVA	50MG	A076424	001	Jul 29, 2004
	100MG	A076424	002	Jul 29, 2004
	150MG	A076424	003	Jul 29, 2004
	200MG	A076424	004	Jul 29, 2004
RANBAXY LABS LTD	50MG	A076386	001	Jul 29, 2004
	100MG	A076386	002	Jul 29, 2004
	150MG	A076386	003	Jul 29, 2004
	200MG	A076386	004	Jul 29, 2004
ROXANE	50MG	A076213	001	Jul 29, 2004
	100MG	A076213	002	Jul 29, 2004
	150MG	A076213	003	Jul 29, 2004
	200MG	A076213	004	Jul 29, 2004
SANDOZ	50MG	A076086	001	Jul 29, 2004
	100MG	A076086	002	Jul 29, 2004
	150MG	A076086	003	Jul 29, 2004
	200MG	A076086	004	Jul 29, 2004

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 149 (of 360)

FLUDARABINE PHOSPHATEINJECTABLE; INJECTION
FLUDARA

GENZYME CORP

50MG/VIAL

N020038 001 Apr 18, 1991

TABLET; ORAL
OFORTA

SANOFI AVENTIS US

10MG

N022273 001 Dec 18, 2008

FLUDEOXYGLUCOSE F-18INJECTABLE; INJECTION
FLUDEOXYGLUCOSE F 18

DOWNSIDE CLINCL

4-40mCi/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

N020306 001 Aug 19, 1994

4-90mCi/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

N020306 002 Sep 25, 2001

FLUDROCORTISONE ACETATETABLET; ORAL
FLORINEF

KING PHARMS

0.1MG

N010060 001

FLUMAZENILINJECTABLE; INJECTION
FLUMAZENIL

TEVA PARENTERAL

0.5MG/5ML (0.1MG/ML)

A076589 002 Oct 12, 2004

1MG/10ML (0.1MG/ML)

A076589 001 Oct 12, 2004

FLUMETHASONE PIVALATECREAM; TOPICAL
LOCORTEN

NOVARTIS

0.03%

N016379 001

FLUNISOLIDESPRAY, METERED; NASAL
NASALIDE

IVAX RES

0.025MG/SPRAY

N018148 001

NASAREL

TEVA BRANDED PHARM

0.029MG/SPRAY

N020409 001 Mar 08, 1995

FLUOCINOLONE ACETONIDECREAM; TOPICAL
FLUOCET

ALPHARMA US PHARMS

0.025%

A088360 001 Jan 16, 1984

FLUOCINOLONE ACETONIDE

ALPHARMA US PHARMS

0.01%

A088361 001 Jan 16, 1984

PERRIGO NEW YORK

0.01%

A086810 001 Mar 04, 1982

0.025%

A086811 001 Mar 04, 1982

PHARMADERM

0.01%

A088047 001 Dec 16, 1982

0.025%

A088045 001 Dec 16, 1982

PHARMAFAIR

0.01%

A088499 001 Aug 02, 1984

0.025%

A088506 001 Aug 02, 1984

TARO

0.01%

A040035 001 Oct 31, 1994

0.01%

A087102 001 Apr 27, 1982

0.025%

A040042 001 Oct 31, 1994

USL PHARMA

0.01%

A088757 001 Feb 11, 1985

0.025%

A088756 001 Mar 28, 1985

FLUONID

ALLERGAN HERBERT

0.025%

A087156 002 Sep 06, 1984

FLUOTREX

SAVAGE LABS

0.01%

A088174 001 May 06, 1983

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 150 (of 360)

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL					
FLUOTREX					
SAVAGE LABS	0.025%	A088173	001	Mar 09, 1983	
SYNALAR-HP					
MEDIMETRIKS PHARMS	0.2%	N016161	002		
GEL; TOPICAL					
FLUONID					
ALLERGAN HERBERT	0.025%	A087300	001	May 27, 1982	
OINTMENT; TOPICAL					
FLUOCINOLONE ACETONIDE					
PHARMADERM	0.025%	A088046	001	Dec 16, 1982	
PHARMAFAIR	0.025%	A088507	001	Feb 27, 1984	
USL PHARMA	0.025%	A088742	001	Feb 08, 1985	
FLUONID					
ALLERGAN HERBERT	0.025%	A087157	001	Sep 06, 1984	
FLUOTREX					
SAVAGE LABS	0.025%	A088172	001	Mar 09, 1983	
SOLUTION; TOPICAL					
FLUOCINOLONE ACETONIDE					
ALPHARMA US PHARMS	0.01%	A087159	001	Jun 16, 1982	
BAUSCH AND LOMB	0.01%	A040059	001	Dec 20, 1993	
MORTON GROVE	0.01%	A088312	001	Jan 27, 1984	
PHARMADERM	0.01%	A088048	001	Dec 16, 1982	
PHARMAFAIR	0.01%	A088449	001	Feb 08, 1984	
FLUONID					
ALLERGAN HERBERT	0.01%	A087158	001	Mar 17, 1983	
FLUOTREX					
SAVAGE LABS	0.01%	A088171	001	Mar 09, 1983	

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL					
NEO-SYNALAR					
MEDIMETRIKS PHARMS	0.025%;EQ 3.5MG BASE/GM	A060700	001		

FLUOCINONIDE

CREAM; TOPICAL					
FLUOCINONIDE					
PERRIGO NEW YORK	0.05%	A071790	001	Jul 13, 1988	
TARO	0.05%	A071500	001	Jun 10, 1987	
FLUOCINONIDE EMULSIFIED BASE					
G AND W LABS INC	0.05%	A074204	001	Jun 13, 1995	
LIDEX					
MEDICIS	0.05%	N016908	002		
LIDEX-E					
MEDICIS	0.05%	N016908	003		
SOLUTION; TOPICAL					
FLUOCINONIDE					
TARO	0.05%	A072857	001	Aug 02, 1989	
TEVA PHARMS	0.05%	A072522	001	Sep 28, 1990	

FLUORESCEIN SODIUM

INJECTABLE; INJECTION					
FUNDUSCEIN-25					
NOVARTIS	25%	N017869	001		

FLUOROMETHOLONE

CREAM; TOPICAL					
OXYLONE					
PHARMACIA AND UPJOHN	0.025%	N011748	001		
SUSPENSION/DROPS; OPHTHALMIC					
FLUOR-OP					
NOVARTIS	0.1%	A070185	001	Feb 27, 1986	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 151 (of 360)

FLUOROMETHOLONE ACETATE; TOBRAMYCINSUSPENSION/DROPS; OPHTHALMIC
TOBRASONE

ALCON	0.1%;0.3%	N050628	001	Jul 21, 1989

FLUOROMETHOLONE; SULFACETAMIDE SODIUMSUSPENSION/DROPS; OPHTHALMIC
FML-S

ALLERGAN	0.1%;10%	N019525	001	Sep 29, 1989

FLUOROURACILINJECTABLE; INJECTION
ADRUCIL

PHARMACIA AND UPJOHN	50MG/ML	A081222	001	Jun 28, 1991
	50MG/ML	N017959	001	
TEVA PARENTERAL	50MG/ML	A040023	001	Oct 18, 1991
	50MG/ML	A081225	001	Aug 28, 1991

FLUOROURACIL

ABIC	50MG/ML	A088929	001	Mar 04, 1986
ABRAXIS PHARM	50MG/ML	A089152	001	Mar 21, 1986
	50MG/ML	A089428	001	Jan 12, 1987
	50MG/ML	A089519	001	Mar 12, 1987
BEDFORD	50MG/ML	A089508	001	Jan 26, 1988
FRESENIUS KABI USA	50MG/ML	A040291	001	Mar 24, 1999
	50MG/ML	A040379	001	Nov 15, 2000
MARCHAR	50MG/ML	A087791	001	Jan 18, 1983
SMITH AND NEPHEW	50MG/ML	A088766	001	Dec 28, 1984
	50MG/ML	A088767	001	Dec 28, 1984
	50MG/ML	A089434	001	Mar 26, 1987
SPECTRUM PHARMS	50MG/ML	A087792	001	Oct 13, 1982
VALEANT	500MG/10ML (50MG/ML)	N012209	001	

SOLUTION; TOPICAL

FLUOROPLEX

ELORAC	1%	N016765	001	

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE

MUTUAL PHARMA	EQ 10MG BASE	A075787	001	Jan 29, 2002
	EQ 20MG BASE	A075787	002	Jan 29, 2002
WATSON LABS	EQ 10MG BASE	A075662	001	Jan 29, 2002
	EQ 20MG BASE	A075662	002	Jan 29, 2002

FLUOXETINE HYDROCHLORIDE

BARR	EQ 40MG BASE	A076251	001	May 18, 2005
PAR PHARM	EQ 10MG BASE	A076922	001	Dec 16, 2004
	EQ 20MG BASE	A076922	002	Dec 16, 2004
SANDOZ	EQ 10MG BASE	A075807	001	Jan 29, 2002
	EQ 20MG BASE	A075807	002	Jan 29, 2002

PROZAC

ELI LILLY AND CO	EQ 60MG BASE	N018936	004	Jun 15, 1999

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 20MG BASE/5ML	A075690	001	Jan 31, 2002
HI TECH PHARMA	EQ 20MG BASE/5ML	A075525	001	Jun 27, 2002

PROZAC

LILLY	EQ 20MG BASE/5ML	N020101	001	Apr 24, 1991

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

BARR	EQ 10MG BASE	A075810	001	Feb 01, 2002
IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075865	001	Feb 28, 2002
	EQ 40MG BASE	A075865	003	Aug 30, 2004
SANDOZ	EQ 10MG BASE	A076024	001	Jan 29, 2002

DISCONTINUED DRUG PRODUCT LIST

6 - 152 (of 360)

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL
PROZAC

LILLY	EQ 10MG BASE	N020974	001	Mar 09, 1999
	EQ 20MG BASE	N020974	002	Mar 09, 1999

FLUOXYMESTERONE

TABLET; ORAL
ANDROID-F

VALEANT PHARM INTL	10MG	A087196	001	
FLUOXYMESTERONE				
VALEANT PHARM INTL	10MG	A088221	001	May 05, 1983
WATSON LABS	2MG	A088260	001	Dec 06, 1983
	5MG	A088265	001	Dec 06, 1983
	10MG	A088309	001	Dec 06, 1983

HALOTESTIN

PHARMACIA AND UPJOHN	2MG	N010611	002	
	5MG	N010611	006	
	10MG	N010611	010	

ORA-TESTRYL

BRISTOL MYERS SQUIBB	2MG	N011359	001	
	5MG	N011359	002	

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION
FLUPHENAZINE DECANOATE

HOSPIRA	25MG/ML	A074966	001	Apr 16, 1998
TEVA PARENTERAL	25MG/ML	A074795	001	Sep 10, 1996
PROLIXIN DECANOATE				
BRISTOL MYERS SQUIBB	25MG/ML	N016727	001	

FLUPHENAZINE ENANTHATE

INJECTABLE; INJECTION
PROLIXIN ENANTHATE

APOTHECON	25MG/ML	N016110	001	

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
FLUPHENAZINE HYDROCHLORIDE

TEVA PHARMS	5MG/ML	A073058	001	Aug 30, 1991

PERMITIL

SCHERING	5MG/ML	N016008	001	

PROLIXIN

APOTHECON	5MG/ML	A070533	001	Nov 07, 1985

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

TEVA PHARMS	2.5MG/5ML	A081310	001	Apr 29, 1993

PROLIXIN

APOTHECON	2.5MG/5ML	N012145	003	

INJECTABLE; INJECTION

PROLIXIN

APOTHECON	2.5MG/ML	N011751	005	

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

WATSON LABS	1MG	A088555	001	Dec 18, 1987
	2.5MG	A088544	001	Dec 18, 1987
	5MG	A088527	001	Dec 18, 1987
	10MG	A088550	001	Dec 18, 1987

PERMITIL

SCHERING	0.25MG	N012034	001	
	2.5MG	N012034	004	
	5MG	N012034	005	
	10MG	N012034	006	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 153 (of 360)

FLUPHENAZINE HYDROCHLORIDETABLET; ORAL
PROLIXIN

APOTHECON

1MG

N011751 004

2.5MG

N011751 001

5MG

N011751 003

10MG

N011751 002

TABLET, EXTENDED RELEASE; ORAL
PERMITIL

SCHERING

1MG

N012419 004

FLUPREDNISOLONE

TABLET; ORAL

ALPHADROL

PHARMACIA AND UPJOHN 1.5MG

N012259 002

FLURANDRENOLIDE

LOTION; TOPICAL

FLURANDRENOLIDE

ALPHARMA US PHARMS 0.05%

A087203 001 Apr 29, 1982

OINTMENT; TOPICAL

CORDRAN

AQUA PHARMS 0.025%

N012806 004

0.05%

N012806 001

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

CORDRAN-N

LILLY

0.05%;EQ 3.5MG BASE/GM

N050346 001

OINTMENT; TOPICAL

CORDRAN-N

LILLY

0.05%;EQ 3.5MG BASE/GM

N050345 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

DALMANE

VALEANT PHARM INTL

15MG

N016721 001

30MG

N016721 002

FLURAZEPAM HYDROCHLORIDE

HALSEY

15MG

A071808 001 Jan 07, 1988

30MG

A071809 001 Jan 07, 1988

MUTUAL PHARM

15MG

A070454 001 Aug 04, 1986

30MG

A070455 001 Aug 04, 1986

PAR PHARM

15MG

A070444 001 Mar 20, 1986

30MG

A070445 001 Mar 20, 1986

PUREPAC PHARM

15MG

A071927 001 Sep 09, 1987

30MG

A071551 001 Sep 09, 1987

SANDOZ

15MG

A071716 001 Jul 31, 1991

30MG

A071717 001 Jul 31, 1991

SUPERPHARM

15MG

A071659 001 Aug 04, 1988

30MG

A071660 001 Aug 04, 1988

USL PHARMA

15MG

A070562 001 Jul 09, 1987

30MG

A070563 001 Jul 09, 1987

WARNER CHILCOTT

15MG

A071767 001 Dec 04, 1987

30MG

A071768 001 Dec 04, 1987

WATSON LABS

15MG

A072368 001 Mar 30, 1989

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

IVAX SUB TEVA PHARMS

50MG

A074411 001 May 31, 1995

100MG

A074411 002 May 31, 1995

PLIVA

50MG

A074647 001 Apr 01, 1997

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 154 (of 360)

FLURBIPROFENTABLET; ORAL
FLURBIPROFEN

PLIVA	100MG	A074647	002	Apr 01, 1997
SANDOZ	50MG	A074448	001	Jul 28, 1995
	100MG	A074448	002	Jul 28, 1995
TEVA	50MG	A074405	002	May 24, 1995
	100MG	A074405	001	May 24, 1995
THERAGEN	100MG	A074560	002	May 16, 1997

FLUTAMIDECAPSULE; ORAL
EULEXIN

SCHERING	125MG	N018554	001	Jan 27, 1989
FLUTAMIDE				
SANDOZ	125MG	A075818	001	Sep 18, 2001

FLUTICASONE PROPIONATEAEROSOL, METERED; INHALATION
FLOVENT

GLAXOSMITHKLINE	0.044MG/INH	N020548	001	Mar 27, 1996
	0.11MG/INH	N020548	002	Mar 27, 1996
	0.22MG/INH	N020548	003	Mar 27, 1996

CREAM; TOPICAL

FLUTICASONE PROPIONATE

NESHER PHARMS	0.05%	A076865	001	Sep 10, 2004

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

TARO PHARM INDS	0.005%	A077145	001	Jun 14, 2005

POWDER; INHALATION

FLOVENT

GLAXOSMITHKLINE	0.044MG/INH	N020549	001	Nov 07, 1997
	0.088MG/INH	N020549	002	Nov 07, 1997
	0.22MG/INH	N020549	003	Nov 07, 1997

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

ACTAVIS ELIZABETH	25MG	A075901	001	Dec 28, 2000
	50MG	A075901	002	Dec 28, 2000
	100MG	A075901	003	Dec 28, 2000
IVAX SUB TEVA PHARMS	25MG	A075898	001	Mar 12, 2001
	50MG	A075898	002	Mar 12, 2001
	100MG	A075898	003	Mar 12, 2001
MUTUAL PHARM	25MG	A076125	001	Apr 29, 2002
	50MG	A076125	002	Apr 29, 2002
	100MG	A076125	003	Apr 29, 2002
MYLAN	50MG	A075950	001	Oct 15, 2001
	100MG	A075950	002	Oct 15, 2001
SANDOZ	25MG	A075887	001	Jan 05, 2001
	50MG	A075887	002	Jan 05, 2001
	100MG	A075887	003	Jan 05, 2001
SYNTHON PHARMS	25MG	A075899	001	Jan 17, 2001
	50MG	A075899	002	Jan 17, 2001
	100MG	A075899	003	Jan 17, 2001
WATSON LABS	25MG	A075894	001	Apr 18, 2001
	50MG	A075894	002	Apr 18, 2001
	100MG	A075894	003	Apr 18, 2001

LUVOX

SOLVAY

25MG	N020243	001	Dec 05, 1994
50MG	N020243	002	Dec 05, 1994
100MG	N020243	003	Dec 05, 1994
150MG	N020243	004	Dec 05, 1994

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 155 (of 360)

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

BEN VENUE	5MG/ML	A081066	001	Dec 29, 1993

FOLVITE

HIKMA (MAPLE)	5MG/ML	N005897	008	

TABLET; ORAL

FOLIC ACID

BARR	1MG	A089177	001	Jan 08, 1986

EVERYLIFE	1MG	A080755	001	

HALSEY	1MG	A083598	001	

IMPAX LABS	1MG	A080686	001	

IVAX SUB TEVA PHARMS	1MG	A083000	001	

LANNETT	1MG	A080816	001	

LILLY	1MG	N006135	003	

MK LABS	1MG	A083526	001	

MUTUAL PHARM	1MG	A040582	001	Jul 18, 2005

NEXGEN PHARMA INC	1MG	A084915	001	

PHARMERAL	1MG	A084158	001	

PIONEER PHARMS	1MG	A088949	001	Sep 13, 1985

PUREPAC PHARM	1MG	A080784	001	

SANDOZ	1MG	A084472	001	

TABLICAPS	1MG	A083133	002	

UDL	1MG	A088199	001	Mar 29, 1983

USL PHARMA	1MG	A087828	001	May 13, 1982

VALEANT PHARM INTL	1MG	A080903	001	

VANGARD	1MG	A088730	001	Mar 23, 1984

VINTAGE PHARMS	1MG	A086296	001	

WATSON LABS	1MG	A083141	001	

	1MG	A085141	002	

WHITEWORTH TOWN PLSN	1MG	A080691	002	

FOLICET

MISSION PHARMA	1MG	A087438	001	

FOLVITE

HIKMA (MAPLE)	1MG	N005897	004	

FOLLITROPIN ALFA/BETA

INJECTABLE; IM-SC

FOLLISTIM

ORGANON USA INC	75 IU/VIAL	N020582	001	Sep 29, 1997

	150 IU/VIAL	N020582	002	Sep 29, 1997

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

ORGANON USA INC	150 IU/0.18ML	N021211	003	Feb 11, 2004

GONAL-F

EMD SERONO	37.5 IU/VIAL	N020378	003	May 25, 2000

	37.5 IU/VIAL	N021765	001	Mar 25, 2004

	75 IU/VIAL	N020378	001	Sep 29, 1997

	150 IU/VIAL	N020378	002	Sep 29, 1997

	150 IU/VIAL	N021765	003	Mar 25, 2004

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION

VITRAVENE PRESERVATIVE FREE

NOVARTIS	6.6MG/ML	N020961	001	Aug 26, 1998

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL CERTIHALER

NOVARTIS	0.0085MG/INH	N021592	001	Dec 15, 2006

DISCONTINUED DRUG PRODUCT LIST

6 - 156 (of 360)

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

RANBAXY LABS LTD	10MG	A076580	001	Apr 23, 2004
	20MG	A076580	002	Apr 23, 2004
	40MG	A076580	003	Apr 23, 2004
SANDOZ	10MG	A076188	001	Oct 08, 2004
	20MG	A076188	002	Oct 08, 2004
	40MG	A076188	003	Oct 08, 2004
MONOPRIL				
BRISTOL MYERS SQUIBB	10MG	N019915	002	May 16, 1991
	20MG	N019915	003	May 16, 1991
	40MG	N019915	004	Mar 28, 1995

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

TEVA	10MG;12.5MG	A076945	001	Jul 05, 2006
	20MG;12.5MG	A076945	002	Jul 05, 2006
WATSON LABS	10MG;12.5MG	A077144	001	Aug 16, 2005
	20MG;12.5MG	A077144	002	Aug 16, 2005
MONOPRIL-HCT				
BRISTOL MYERS SQUIBB	10MG;12.5MG	N020286	002	Nov 30, 1994
	20MG;12.5MG	N020286	001	Nov 30, 1994

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX

PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N020450	001	Aug 05, 1996
FOSPHENYTOIN SODIUM				
TEVA PARENTERAL	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007

FOSPROPOFOL DISODIUM

SOLUTION; INTRAVENOUS

LUSEDRA

EISAI INC	1050MG/30ML (35MG/ML)	N022244	001	Dec 12, 2008

FURAZOLIDONE

SUSPENSION; ORAL

FUROXONE

SHIRE	50MG/15ML	N011323	002	

TABLET; ORAL

FUROXONE

SHIRE	100MG	N011270	002	

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

ABRAXIS PHARM	10MG/ML	N018507	001	Jul 30, 1982
	10MG/ML	N019036	001	Aug 13, 1984
ASTRAZENECA	10MG/ML	A070014	001	Sep 09, 1985
	10MG/ML	A070095	001	Sep 09, 1985
	10MG/ML	A070096	001	Sep 09, 1985
	10MG/ML	A071439	001	Sep 14, 1990
HIKMA MAPLE	10MG/ML	N018267	001	
	10MG/ML	A070578	001	Jul 08, 1987
	10MG/ML	A072080	001	Aug 13, 1991
HOSPIRA	10MG/ML	A074337	001	Oct 31, 1994
	10MG/ML	A074017	001	Jun 30, 1994
	10MG/ML	A070017	001	Dec 15, 1986
MARSAM PHARMS LLC	10MG/ML	A070023	001	Feb 05, 1986
ORGANON USA INC	10MG/ML	A070078	001	Feb 05, 1986
SMITH AND NEPHEW	10MG/ML	N018420	001	Feb 26, 1982
WARNER CHILCOTT	10MG/ML			

DISCONTINUED DRUG PRODUCT LIST

6 - 157 (of 360)

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

WATSON LABS	10MG/ML	A070019	001	Sep 22, 1986
	10MG/ML	A070604	001	Jan 02, 1987
WYETH AYERST	10MG/ML	N018670	001	Jul 20, 1982

LASIX

SANOFI AVENTIS US	10MG/ML	N016363	001	

SOLUTION; ORAL
LASIX

SANOFI AVENTIS US	10MG/ML	N017688	001	

TABLET; ORAL
FUROSEMIDE

INTL MEDICATION	20MG	N018753	001	Feb 28, 1984
	40MG	N018753	002	Feb 28, 1984
KALAPHARM	20MG	N018868	001	Jun 28, 1983
	40MG	N018868	002	Jun 28, 1983
MUTUAL PHARM	20MG	A070043	001	Sep 26, 1985
	40MG	N018790	001	Nov 29, 1983
	80MG	A070100	001	Jan 26, 1988
SANDOZ	40MG	N018750	002	Jul 30, 1984
SUPERPHARM	20MG	N018370	002	Jun 26, 1984
	40MG	N018370	001	Feb 10, 1983
WARNER CHILCOTT	20MG	N018419	001	Jan 31, 1983
	40MG	N018419	002	Jan 31, 1983
	80MG	N018419	003	Nov 13, 1984
WATSON LABS	20MG	N018369	001	May 14, 1982
	40MG	A070413	001	Feb 26, 1986
	40MG	N018369	002	May 14, 1982

GABAPENTIN

CAPSULE; ORAL
GABAPENTIN

IVAX SUB TEVA PHARMS	100MG	A075477	001	Mar 23, 2005
	300MG	A075477	002	Mar 23, 2005
	400MG	A075477	003	Mar 23, 2005
MUTUAL PHARM	100MG	A076537	001	Jun 30, 2005
	300MG	A076537	002	Jun 30, 2005
	400MG	A076537	003	Jun 30, 2005
SANDOZ	100MG	A075428	001	Jan 24, 2006
	100MG	A075539	001	Apr 06, 2005
	300MG	A075428	002	Jan 24, 2006
	300MG	A075539	002	Apr 06, 2005
	400MG	A075428	003	Jan 24, 2006
	400MG	A075539	003	Apr 06, 2005

TABLET; ORAL
GABAPENTIN

RANBAXY	600MG	A076605	001	Sep 14, 2005
	800MG	A076605	002	Sep 14, 2005
SANDOZ	600MG	A076120	001	Jan 27, 2006
	600MG	A076877	001	Jul 06, 2006
	800MG	A076120	002	Jan 27, 2006
	800MG	A076877	002	Jul 06, 2006
TEVA	600MG	A075827	001	Dec 15, 2004
	800MG	A075827	002	Dec 15, 2004

GADODIAMIDE

INJECTABLE; INJECTION
OMNISCAN

GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066	001	Sep 05, 2007

DISCONTINUED DRUG PRODUCT LIST

6 - 158 (of 360)

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

ACTAVIS ELIZABETH	EQ 4MG BASE	A077585	001	Sep 15, 2009
	EQ 8MG BASE	A077585	002	Sep 15, 2009
	EQ 12MG BASE	A077585	003	Sep 15, 2009
YABAO BIOPHARMS	EQ 4MG BASE	A077604	001	Feb 06, 2009
	EQ 8MG BASE	A077604	002	Feb 06, 2009
	EQ 12MG BASE	A077604	003	Feb 06, 2009

GALLAMINE TRIETHIODIDE

INJECTABLE; INJECTION

FLAXEDIL

DAVIS AND GECK	20MG/ML	N007842	001	
	100MG/ML	N007842	002	

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

GE HEALTHCARE	1mCi/ML	N017700	001	
NEOSCAN				
GE HEALTHCARE	2mCi/ML	N017655	001	

GANCICLOVIR

CAPSULE; ORAL

CYTOVENE

ROCHE PALO	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020460	001	Dec 22, 1994
	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020460	002	Dec 12, 1997
GANCICLOVIR				
RANBAXY LABS LTD	250MG	A076457	001	Jun 27, 2003
	500MG	A076457	002	Jun 27, 2003

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

GANCICLOVIR SODIUM

BEDFORD	EQ 500MG BASE/VIAL	A076222	001	Jul 16, 2003

GEFITINIB

TABLET; ORAL

IRESSA

ASTRAZENECA	250MG	N021399	001	May 05, 2003

GEMFIBROZIL

CAPSULE; ORAL

GEMFIBROZIL

MYLAN	300MG	A073466	001	Jan 25, 1993
PUREPAC PHARM	300MG	A072929	001	Jan 29, 1993
LOPID				
PFIZER PHARMS	200MG	N018422	001	
	300MG	N018422	002	

TABLET; ORAL

GEMFIBROZIL

MYLAN	600MG	A074452	001	Feb 16, 1995
PUREPAC PHARM	600MG	A074360	001	Aug 31, 1994
SANDOZ	600MG	A074615	001	Sep 29, 1995
WATSON LABS	600MG	A074156	001	Oct 24, 1994

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 159 (of 360)

GEMTUZUMAB OZOGAMICININJECTABLE; INJECTION
MYLOTARG

WYETH PHARMS INC

5MG/VIAL

N021174 001

May 17, 2000

GENTAMICIN SULFATE

CREAM; TOPICAL

GARAMYCIN

SCHERING

EQ 0.1% BASE

A060462 001

GENTAFAIR

PHARMAFAIR

EQ 0.1% BASE

A062458 001

Sep 01, 1983

GENTAMICIN SULFATE

ALPHARMA US PHARMS

EQ 0.1% BASE

A062471 001

Sep 27, 1983

BAUSCH AND LOMB

EQ 0.1% BASE

A064056 001

Apr 29, 1994

PHARMADERM

EQ 1MG BASE/GM

A062530 001

Jul 05, 1984

INJECTABLE; INJECTION

APOGEN

KING PHARMS

EQ 10MG BASE/ML

A062289 001

EQ 40MG BASE/ML

A062289 002

BRISTAGEN

BRISTOL

EQ 40MG BASE/ML

A062288 001

GARAMYCIN

SCHERING

EQ 1MG BASE/ML

A061716 002

EQ 10MG BASE/ML

A061739 001

EQ 40MG BASE/ML

A061716 001

GENTAFAIR

PHARMAFAIR

EQ 40MG BASE/ML

A062493 001

Aug 28, 1985

GENTAMICIN

INTL MEDICATION

EQ 1MG BASE/ML

A062325 003

Jun 23, 1982

EQ 40MG BASE/ML

A062325 001

EQ 100MG BASE/100ML

A062325 004

Jun 23, 1982

GENTAMICIN SULFATE

ABBOTT

EQ 1.2MG BASE/ML

A062413 001

Aug 11, 1983

EQ 1.4MG BASE/ML

A062413 002

Aug 11, 1983

EQ 1.6MG BASE/ML

A062413 003

Aug 11, 1983

EQ 1.8MG BASE/ML

A062413 004

Aug 11, 1983

EQ 2MG BASE/ML

A062413 005

Aug 11, 1983

EQ 60MG BASE/100ML

A062413 006

Aug 11, 1983

EQ 70MG BASE/100ML

A062413 007

Aug 11, 1983

EQ 80MG BASE/100ML

A062413 008

Aug 11, 1983

EQ 90MG BASE/100ML

A062413 009

Aug 11, 1983

EQ 100MG BASE/100ML

A062413 010

Aug 11, 1983

HIKMA MAPLE

EQ 10MG BASE/ML

A062251 002

EQ 40MG BASE/ML

A062251 001

KALAPHARM

EQ 40MG BASE/ML

A062354 001

Apr 05, 1982

PHARM SPEC

EQ 40MG BASE/ML

A062340 001

Mar 28, 1983

SOLOPAK

EQ 10MG BASE/ML

A062507 001

Jun 06, 1985

EQ 40MG BASE/ML

A062507 002

Jun 06, 1985

TEVA PARENTERAL

EQ 10MG BASE/ML

A063149 001

Nov 21, 1991

EQ 40MG BASE/ML

A063106 002

Nov 21, 1991

WATSON LABS

EQ 10MG BASE/ML

A062318 002

EQ 40MG BASE/ML

A062318 001

WYETH AYERST

EQ 10MG BASE/ML

A062264 001

EQ 40MG BASE/ML

A062264 002

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA

EQ 1.2MG BASE/ML

A062588 001

Jan 06, 1986

EQ 1.4MG BASE/ML

A062588 002

Jan 06, 1986

EQ 1.6MG BASE/ML

A062588 003

Jan 06, 1986

EQ 1.8MG BASE/ML

A062588 004

Jan 06, 1986

EQ 2MG BASE/ML

A062588 005

Jan 06, 1986

EQ 60MG BASE/100ML

A062588 006

Jan 06, 1986

EQ 70MG BASE/100ML

A062588 007

Jan 06, 1986

EQ 80MG BASE/100ML

A062588 008

Jan 06, 1986

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 160 (of 360)

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA	EQ 90MG BASE/100ML	A062588	009	Jan 06, 1986
	EQ 100MG BASE/100ML	A062588	010	Jan 06, 1986

U-GENCIN

PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	A062248	001	
	EQ 40MG BASE/ML	A062248	002	

INJECTABLE; INTRATHECAL

GARAMYCIN

SCHERING	EQ 2MG BASE/ML	N050505	001	

OINTMENT; OPHTHALMIC

GARAMYCIN

SCHERING	EQ 0.3% BASE	N050425	001	

GENTACIDIN

NOVARTIS	EQ 0.3% BASE	A062501	001	Jul 26, 1984

GENTAFAIR

PHARMAFAIR	EQ 3MG BASE/GM	A062443	001	May 26, 1983

OINTMENT; TOPICAL

GARAMYCIN

SCHERING	EQ 0.1% BASE	A060463	001	

GENTAFAIR

PHARMAFAIR	EQ 0.1% BASE	A062444	001	May 26, 1983

GENTAMICIN SULFATE

ALPHARMA US PHARMS	EQ 0.1% BASE	A062496	001	Mar 14, 1984

BAUSCH AND LOMB	EQ 0.1% BASE	A064054	001	Apr 29, 1994

PHARMADERM	EQ 0.1% BASE	A062534	001	Oct 10, 1984

SOLUTION/DROPS; OPHTHALMIC

GARAMYCIN

SCHERING	EQ 0.3% BASE	N050039	002	

GENTACIDIN

NOVARTIS	EQ 0.3% BASE	A062480	001	Mar 30, 1984

GENTAFAIR

PHARMAFAIR	EQ 0.3% BASE	A062440	001	May 03, 1983

GENTAMICIN SULFATE

ALCON PHARMS LTD	EQ 0.3% BASE	A062523	001	Nov 25, 1985

PACO	EQ 3MG BASE/ML	A062932	001	Nov 07, 1988

GENTIAN VIOLET

SUPPOSITORY; VAGINAL

GVS

SAVAGE LABS	0.4%	A083513	001	

TAMPON; VAGINAL

GENAPAX

KEY PHARMS	5MG	A085017	001	

GLATIRAMER ACETATE

FOR SOLUTION; SUBCUTANEOUS

COPAXONE

TEVA	20MG/VIAL	N020622	001	Dec 20, 1996

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

RANBAXY	3MG	A077366	001	Oct 06, 2005

	6MG	A077366	002	Oct 06, 2005

RANBAXY LABS LTD	1MG	A076875	001	Oct 06, 2005

	2MG	A076875	002	Oct 06, 2005

	4MG	A076875	003	Oct 06, 2005

	8MG	A076875	004	Oct 06, 2005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 161 (of 360)

GLIPIZIDETABLET; ORAL
GLIPIZIDE

PLIVA	5MG	A074619	001	Apr 04, 1997
	10MG	A074619	002	Apr 04, 1997
SANDOZ	5MG	A074542	001	Jun 20, 1995
	10MG	A074542	002	Jun 20, 1995
TEVA	5MG	A074387	001	Mar 04, 1996
	10MG	A074387	002	Mar 04, 1996
VINTAGE PHARMS LLC	5MG	A074378	001	Nov 28, 1994
	10MG	A074378	002	Nov 28, 1994
GLUCOTROL				
PFIZER	2.5MG	N017783	003	May 11, 1993

GLIPIZIDE; METFORMIN HYDROCHLORIDETABLET; ORAL
METAGLIP

BRISTOL MYERS SQUIBB	2.5MG;250MG	N021460	001	Oct 21, 2002
	2.5MG;500MG	N021460	002	Oct 21, 2002
	5MG;500MG	N021460	003	Oct 21, 2002

GLUCAGON HYDROCHLORIDEINJECTABLE; INJECTION
GLUCAGON

LILLY	EQ 1MG BASE/VIAL	N012122	001	
	EQ 10MG BASE/VIAL	N012122	002	

GLUTETHIMIDECAPSULE; ORAL
DORIDEN

SANOFI AVENTIS US	500MG	N009519	008	

TABLET; ORAL
DORIDEN

SANOFI AVENTIS US	250MG	N009519	002	
	500MG	N009519	005	

GLUTETHIMIDE

HALSEY	250MG	A089458	001	Oct 10, 1986
	500MG	A089459	001	Oct 10, 1986
LANNETT	250MG	A083475	001	
	500MG	A085571	001	
SANDOZ	500MG	A083234	002	
UCB INC	500MG	A085171	001	
VITARINE	500MG	A087297	001	
WATSON LABS	500MG	A084362	001	
	500MG	A085763	001	

GLYBURIDETABLET; ORAL
GLYBURIDE

ACTAVIS TOTOWA	1.5MG	A075947	001	Nov 14, 2002
	3MG	A075947	002	Nov 14, 2002
	6MG	A075947	003	Nov 14, 2002

GLYBURIDE (MICRONIZED)

SANDOZ	1.5MG	A075174	001	Jun 22, 1998
	3MG	A075174	002	Jun 22, 1998
SANOFI AVENTIS US	1.5MG	N020055	001	Apr 17, 1992
	3MG	N020055	002	Apr 17, 1992
	6MG	N020055	003	Mar 08, 2000

GLYNASE

PHARMACIA AND UPJOHN	4.5MG	N020051	003	Sep 24, 1993

MICRONASE

PHARMACIA AND UPJOHN	1.25MG	N017498	001	May 01, 1984
	2.5MG	N017498	002	May 01, 1984

DISCONTINUED DRUG PRODUCT LIST

6 - 162 (of 360)

GLYBURIDE

TABLET; ORAL
MICRONASE

PHARMACIA AND UPJOHN 5MG	N017498	003	May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

TEVA 1.25MG;250MG	A076821	001	Jan 27, 2005
2.5MG;500MG	A076821	002	Jan 27, 2005
5MG;500MG	A076821	003	Jan 27, 2005

GLYCINE

SOLUTION; IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 1.5GM/100ML	N018522	001	Feb 19, 1982
HOSPIRA 1.5GM/100ML	N017633	001	

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

ABRAXIS PHARM 0.2MG/ML	A088475	001	Jun 12, 1984
HOSPIRA 0.2MG/ML	A089393	001	Jun 15, 1988
TEVA PARENTERAL 0.2MG/ML	A081169	001	Sep 10, 1991
WATSON LABS 0.2MG/ML	A086947	001	Jun 24, 1983
ROBINUL			
ROBINS AH 0.2MG/ML	N014764	001	

TABLET; ORAL

GLYCOPYRROLATE

WATSON LABS 1MG	A085562	001	
1MG	A086902	001	
2MG	A085563	001	
2MG	A086178	001	
2MG	A086900	001	

GONADORELIN ACETATE

INJECTABLE; INJECTION

LUTREPULSE KIT

FERRING 0.8MG/VIAL	N019687	001	Oct 10, 1989
3.2MG/VIAL	N019687	002	Oct 10, 1989

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

HIKMA (MAPLE) EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982
EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982
EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

A.P.L.

FERRING 5,000 UNITS/VIAL	N017055	001	
10,000 UNITS/VIAL	N017055	002	
20,000 UNITS/VIAL	N017055	003	

CHORIONIC GONADOTROPIN

BEL MAR 5,000 UNITS/VIAL	N017054	001	
10,000 UNITS/VIAL	N017054	002	
FERRING 2,000 UNITS/VIAL	N017016	009	Dec 27, 1984
2,000 UNITS/VIAL	N017016	011	Feb 16, 1990
5,000 UNITS/VIAL	N017016	006	
15,000 UNITS/VIAL	N017016	010	Feb 15, 1985
20,000 UNITS/VIAL	N017016	004	
FRESENIUS KABI USA 5,000 UNITS/VIAL	N017067	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 163 (of 360)

GONADOTROPIN, CHORIONICINJECTABLE; INJECTION
CHORIONIC GONADOTROPIN

FRESENIUS KABI USA	15,000 UNITS/VIAL	N017067	004
	20,000 UNITS/VIAL	N017067	003

FOLLUTEIN

BRISTOL MYERS SQUIBB	10,000 UNITS/VIAL	N017056	001

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

IPHARM	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062818	001	Oct 11, 1988

WATSON LABS	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062788	001	Jun 11, 1987

NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN

PHARMAFAIR	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062383	001	Aug 31, 1982

NEO-POLYCIN

DOW PHARM	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A060427	001

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

TEVA PARENTERAL	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007

KYTRIL

ROCHE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020239	003	Sep 17, 2004

	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N020239	004	Mar 11, 1994

	EQ 3MG BASE/ML	N020239	001	Dec 29, 1993

	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N020239	002	Mar 11, 1994

SOLUTION; ORAL

KYTRIL

ROCHE	EQ 2MG BASE/10ML	N021238	001	Jun 27, 2001

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

BARR	EQ 1MG BASE	A078221	001	Dec 31, 2007

KYTRIL

ROCHE	EQ 1MG BASE	N020305	001	Mar 16, 1995

	EQ 2MG BASE	N020305	002	Jun 15, 1998

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL

RAXAR

OTSUKA	EQ 200MG BASE	N020695	001	Nov 06, 1997

	EQ 400MG BASE	N020695	002	May 14, 1998

	EQ 600MG BASE	N020695	003	May 14, 1998

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE; ORAL

GRISACTIN

WYETH AYERST	125MG	N050051	002

	250MG	N050051	001

SUSPENSION; ORAL

GRIFULVIN V

JOHNSON AND JOHNSON	125MG/5ML	N050448	001

TABLET; ORAL

FULVICIN-U/F

ELORAC	250MG	A060569	002

	500MG	A060569	001

GRIFULVIN V

J AND J	125MG	A060618	001

	250MG	A060618	002

	500MG	A060618	003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 164 (of 360)

GRISEOFULVIN, MICROCRYSTALLINETABLET; ORAL
GRIFULVIN V

VALEANT LUXEMBOURG	125MG	A062279	001	
	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A062279	002	

GRISACTIN

WYETH AYERST	500MG	A060212	001	

GRISEOFULVIN, ULTRAMICROCRYSTALLINETABLET; ORAL
FULVICIN P/G

ELORAC	125MG	A061996	001	
	250MG	A061996	002	

FULVICIN P/G 165

ELORAC	165MG	A061996	003	Apr 06, 1982

FULVICIN P/G 330

ELORAC	330MG	A061996	004	Apr 06, 1982

GRISACTIN ULTRA

WYETH AYERST	125MG	A062178	001	
	165MG	A062438	001	Nov 17, 1983
	250MG	A062178	002	
	330MG	A062438	002	Nov 17, 1983

ULTRAGRIS-165

PLIVA	165MG	A062645	001	Jun 30, 1992

ULTRAGRIS-330

PLIVA	330MG	A062646	001	Jun 30, 1992

GUANABENZ ACETATETABLET; ORAL
GUANABENZ ACETATE

SANDOZ	EQ 4MG BASE	A074517	001	Sep 30, 1998
	EQ 8MG BASE	A074517	002	Sep 30, 1998
TEVA PHARMS	EQ 4MG BASE	A074267	001	Jun 01, 1994
	EQ 8MG BASE	A074267	002	Jun 01, 1994
WATSON LABS	EQ 4MG BASE	A074025	001	Feb 28, 1994
	EQ 8MG BASE	A074025	002	Feb 28, 1994

WYTENSIN

WYETH AYERST	EQ 4MG BASE	N018587	001	Sep 07, 1982
	EQ 8MG BASE	N018587	002	Sep 07, 1982
	EQ 16MG BASE	N018587	003	Sep 07, 1982

GUANADREL SULFATETABLET; ORAL
HYLOREL

PHARMACIA AND UPJOHN	10MG	N018104	001	Dec 29, 1982
	25MG	N018104	002	Dec 29, 1982

GUANETHIDINE MONOSULFATETABLET; ORAL
GUANETHIDINE MONOSULFATE

WATSON LABS	EQ 10MG SULFATE	A086113	001	Mar 26, 1985
	EQ 25MG SULFATE	A086114	001	Mar 26, 1985

ISMELIN

NOVARTIS	EQ 10MG SULFATE	N012329	001	
	EQ 25MG SULFATE	N012329	002	

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDETABLET; ORAL
ESIMIL

NOVARTIS	10MG;25MG	N013553	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 165 (of 360)

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

WATSON LABS

EQ 1MG BASE

A074762 001 Jun 25, 1997

EQ 2MG BASE

A074762 002 Jun 25, 1997

TENEX

PROMIUS PHARMA

EQ 3MG BASE

N019032 003 Nov 07, 1988

HALAZEPAM

TABLET; ORAL

PAXIPAM

SCHERING

20MG

N017736 003

40MG

N017736 004

HALCINONIDE

CREAM; TOPICAL

HALOG

WESTWOOD SQUIBB

0.025%

N017818 001

HALOG-E

RANBAXY

0.1%

N018234 001

OINTMENT; TOPICAL

HALOG

BRISTOL MYERS SQUIBB 0.025%

N018125 001

SOLUTION; TOPICAL

HALOG

RANBAXY

0.1%

N017823 001

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

VENUS PHARMS

0.05%

A077109 001 Jun 14, 2005

HALOFANTRINE HYDROCHLORIDE

TABLET; ORAL

HALFAN

GLAXOSMITHKLINE

250MG

N020250 001 Jul 24, 1992

HALOPERIDOL

TABLET; ORAL

HALDOL

ORTHO MCNEIL

0.5MG

N015921 001

1MG

N015921 002

2MG

N015921 003

5MG

N015921 004

10MG

N015921 005

20MG

N015921 006 Feb 02, 1982

HALDOL SOLUTAB

ORTHO MCNEIL PHARM

1MG

N017079 001

HALOPERIDOL

DURAMED PHARMS BARR

0.5MG

A071216 001 Dec 04, 1986

1MG

A071217 001 Dec 04, 1986

2MG

A071218 001 Dec 04, 1986

5MG

A071219 001 Dec 04, 1986

10MG

A071220 001 Jul 07, 1987

20MG

A071221 001 Jul 07, 1987

LEDERLE

0.5MG

A072727 001 Sep 19, 1989

1MG

A072728 001 Sep 19, 1989

2MG

A072729 001 Sep 19, 1989

5MG

A072730 001 Sep 19, 1989

10MG

A072731 001 Sep 19, 1989

20MG

A072732 001 Sep 19, 1989

MUTUAL PHARM

0.5MG

A071156 001 Jan 02, 1987

1MG

A071157 001 Jan 02, 1987

DISCONTINUED DRUG PRODUCT LIST

6 - 166 (of 360)

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

MUTUAL PHARM	2MG	A071172	001	Jan 02, 1987
	5MG	A071212	001	Jan 07, 1988
	10MG	A071173	001	Jan 07, 1988
	20MG	A071177	001	Jan 07, 1988
PAR PHARM	20MG	A071328	001	Jul 20, 1987
PUREPAC PHARM	0.5MG	A071071	001	Nov 03, 1986
	1MG	A071072	001	Nov 03, 1986
	2MG	A071073	001	Nov 03, 1986
	5MG	A071074	001	Nov 03, 1986
	10MG	A071075	001	Aug 04, 1987
	20MG	A071076	001	Aug 04, 1987
QUANTUM PHARMICS	0.5MG	A071255	001	Feb 17, 1987
	1MG	A071269	001	Feb 17, 1987
	2MG	A071256	001	Feb 17, 1987
	5MG	A071257	001	Feb 17, 1987
ROXANE	0.5MG	A071128	001	Feb 17, 1987
	1MG	A071129	001	Feb 17, 1987
	2MG	A071130	001	Feb 17, 1987
	5MG	A071131	001	Feb 17, 1987
	10MG	A071132	001	May 12, 1987
	20MG	A071133	001	May 12, 1987
ROYCE LABS	0.5MG	A071722	001	Dec 24, 1987
	1MG	A071723	001	Dec 24, 1987
	2MG	A071724	001	Dec 24, 1987
	5MG	A071725	001	Dec 24, 1987
	10MG	A072121	001	Dec 24, 1987
	20MG	A072122	001	Dec 24, 1987
SCS	0.5MG	A070720	001	Jun 10, 1986
	1MG	A070721	001	Jun 10, 1986
	2MG	A070722	001	Jun 10, 1986
	5MG	A070723	001	Jun 10, 1986
	10MG	A070724	001	Jun 10, 1986
	20MG	A070725	001	Sep 24, 1986
VINTAGE	0.5MG	A071233	001	Nov 03, 1986
	1MG	A071234	001	Nov 03, 1986
	2MG	A071235	001	Nov 03, 1986
	5MG	A071236	001	Nov 03, 1986
	10MG	A071237	001	Jul 20, 1987
WATSON LABS	0.5MG	A070981	001	Mar 06, 1987
	0.5MG	A071571	001	Jun 03, 1988
	1MG	A070982	001	Mar 06, 1987
	1MG	A071572	001	Jun 03, 1988
	2MG	A070983	001	Mar 06, 1987
	2MG	A071573	001	Jun 03, 1988
	5MG	A070984	001	Mar 06, 1987
	5MG	A071374	001	Jun 03, 1988
	10MG	A071375	001	Jun 03, 1988
	10MG	A072113	001	Aug 27, 1991
	20MG	A071376	001	Jun 03, 1988
	20MG	A072353	001	Aug 27, 1991

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

HOSPIRA	EQ 50MG BASE/ML	A075176	001	Feb 09, 2000
	EQ 100MG BASE/ML	A075176	002	Feb 09, 2000
SANDOZ	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005
	EQ 100MG BASE/ML	A076463	002	Jun 24, 2005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 167 (of 360)

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALDOL

ORTHO MCNEIL

EQ 2MG BASE/ML

N015922 001

HALOPERIDOL

ALPHARMA

EQ 2MG BASE/ML

A070318 001 Apr 11, 1986

MORTON GROVE

EQ 2MG BASE/ML

A070710 001 Mar 07, 1986

SCS

EQ 2MG BASE/ML

A070726 001 Jun 10, 1986

TEVA

EQ 2MG BASE/ML

A071015 001 Aug 25, 1987

HALOPERIDOL INTENSOL

ROXANE

EQ 2MG BASE/ML

A072045 001 Apr 12, 1988

INJECTABLE; INJECTION

HALOPERIDOL

ABRAXIS PHARM

EQ 5MG BASE/ML

A071187 001 Jan 20, 1987

MARSAM PHARMS LLC

EQ 5MG BASE/ML

A072516 001 Feb 25, 1993

EQ 5MG BASE/ML

A072517 001 Feb 25, 1993

SANDOZ

EQ 5MG BASE/ML

A076464 001 Sep 29, 2004

SMITH AND NEPHEW

EQ 5MG BASE/ML

A070802 001 Dec 14, 1987

SOLOPAK

EQ 5MG BASE/ML

A070800 001 Dec 14, 1987

EQ 5MG BASE/ML

A070801 001 Dec 14, 1987

EQ 5MG BASE/ML

A070864 001 Dec 14, 1987

WATSON LABS

EQ 5MG BASE/ML

A070713 001 May 17, 1988

EQ 5MG BASE/ML

A070714 001 May 17, 1988

EQ 5MG BASE/ML

A070744 001 May 17, 1988

SOLUTION; ORAL

HALOPERIDOL LACTATE

ACTAVIS MID ATLANTIC

EQ 1MG BASE/ML

A074536 001 Nov 02, 1995

HALOPROGIN

CREAM; TOPICAL

HALOTEX

WESTWOOD SQUIBB

1%

N016942 001

SOLUTION; TOPICAL

HALOTEX

WESTWOOD SQUIBB

1%

N016943 001

HALOTHANE

LIQUID; INHALATION

FLUOTHANE

WYETH AYERST

99.99%

N011338 001

HALOTHANE

BH

99.99%

A084977 001

HALOCARBON

99.99%

A080810 001

HOSPIRA

99.99%

A083254 001

HEPARIN CALCIUM

INJECTABLE; INJECTION

CALCIPARINE

SANOFI AVENTIS US

25,000 UNITS/ML

N018237 001

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

HOSPIRA

100 UNITS/ML

N005264 010

INTL MEDICATION

10 UNITS/ML

A086357 001

500 UNITS/ML

A086357 002

LUITPOLD

10 UNITS/ML

A089063 001 Oct 09, 1985

100 UNITS/ML

A089064 001 Oct 09, 1985

PARKE DAVIS

10 UNITS/ML

N017346 006

SMITH AND NEPHEW

10 UNITS/ML

A087904 001 Apr 20, 1983

10 UNITS/ML

A087958 001 Apr 20, 1983

10 UNITS/ML

A088458 001 Jul 26, 1984

10 UNITS/ML

A088580 001 Oct 25, 1984

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 168 (of 360)

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

SMITH AND NEPHEW

100 UNITS/ML

A087906 001 Apr 20, 1983

100 UNITS/ML

A087959 001 Apr 20, 1983

100 UNITS/ML

A088460 001 Jul 26, 1984

100 UNITS/ML

A088581 001 Oct 25, 1984

SOLOPAK

10 UNITS/ML

A087903 001 Apr 20, 1983

10 UNITS/ML

A088457 001 Oct 25, 1984

100 UNITS/ML

A087905 001 Apr 20, 1983

100 UNITS/ML

A088459 001 Jul 26, 1984

HEPARIN SODIUM

ABRAXIS PHARM

1,000 UNITS/ML

N017033 001

1,000 UNITS/ML

N017979 001

5,000 UNITS/ML

N017979 003

10,000 UNITS/ML

N017979 002

AKORN

1,000 UNITS/ML

N017486 001

5,000 UNITS/ML

N017486 002

10,000 UNITS/ML

N017486 003

20,000 UNITS/ML

N017486 004

40,000 UNITS/ML

N017486 005

BAXTER HLTHCARE

5,000 UNITS/0.5ML

N017037 013 Apr 07, 1986

BAXTER HLTHCARE CORP

1,000 UNITS/ML

N017007 001

2,500 UNITS/ML

N017007 007

5,000 UNITS/ML

N017007 002

5,000 UNITS/0.5ML

N017007 010

7,500 UNITS/ML

N017007 003

10,000 UNITS/ML

N017007 004

15,000 UNITS/ML

N017007 005

20,000 UNITS/ML

N017007 006

CHAMBERLIN PARENTERL

1,000 UNITS/ML

N017130 001

5,000 UNITS/ML

N017130 002

10,000 UNITS/ML

N017130 003

20,000 UNITS/ML

N017130 004

DELL LABS

1,000 UNITS/ML

N017540 001

5,000 UNITS/ML

N017540 002

10,000 UNITS/ML

N017540 003

20,000 UNITS/ML

N017540 004

40,000 UNITS/ML

N017540 005

FRESENIUS KABI USA

1,000 UNITS/ML

N017651 005

5,000 UNITS/ML

N017029 002

10,000 UNITS/ML

N017651 003

20,000 UNITS/ML

N017651 008

HOSPIRA

2,500 UNITS/ML

A088099 001 Apr 28, 1983

10,000 UNITS/ML

A040095 001 Jul 26, 1996

LILLY

1,000 UNITS/ML

N005521 001

10,000 UNITS/ML

N005521 002

20,000 UNITS/ML

N005521 004

LUITPOLD

1,000 UNITS/ML

A087452 001 Oct 31, 1983

MARSAM PHARMS LLC

1,000 UNITS/ML

A040007 001 Jun 07, 1996

1,000 UNITS/ML

A040008 001 Oct 10, 1995

ORGANON USA INC

1,000 UNITS/ML

N000552 008

5,000 UNITS/ML

N000552 009

10,000 UNITS/ML

N000552 010

PARKE DAVIS

1,000 UNITS/ML

N017346 001

5,000 UNITS/ML

N017346 002

7,500 UNITS/ML

N017346 003

10,000 UNITS/ML

N017346 004

20,000 UNITS/ML

N017346 005

PHARM SPEC

1,000 UNITS/ML

N017780 001

5,000 UNITS/ML

N017780 002

10,000 UNITS/ML

N017780 003

20,000 UNITS/ML

N017780 004

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 169 (of 360)

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

PHARM SPEC	40,000 UNITS/ML	N017780	005	
PHARMACIA AND UPJOHN	1,000 UNITS/ML	N004570	001	
	5,000 UNITS/ML	N004570	002	
	10,000 UNITS/ML	N004570	003	
SMITH AND NEPHEW	1,000 UNITS/ML	A088239	001	Jul 26, 1984
SOLOPAK	1,000 UNITS/ML	A087043	001	
	5,000 UNITS/ML	A087077	001	
	5,000 UNITS/0.5ML	A087395	001	
	10,000 UNITS/ML	A087107	001	
	10,000 UNITS/0.5ML	A087363	001	
WATSON LABS	1,000 UNITS/ML	N017064	002	
	2,500 UNITS/ML	N017064	015	
	3,000 UNITS/ML	N017064	016	
	4,000 UNITS/ML	N017064	017	
	5,000 UNITS/ML	N017064	003	
	6,000 UNITS/ML	N017064	018	
	7,500 UNITS/ML	N017064	019	
	10,000 UNITS/ML	N017064	004	
	20,000 UNITS/ML	N017064	005	
	40,000 UNITS/ML	N017064	006	
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	200 UNITS/100ML	N019130	001	Dec 31, 1984
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	200 UNITS/100ML	N019042	001	Mar 29, 1985
HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2,000 UNITS/100ML	N018814	002	Jul 09, 1985
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%				
HOSPIRA	10,000 UNITS/100ML	N018911	006	Jan 30, 1985
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%				
HOSPIRA	10,000 UNITS/100ML	N018911	001	Jan 30, 1985
	10,000 UNITS/100ML	N018916	005	Jan 31, 1984
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	10,000 UNITS/100ML	N018911	003	Jan 30, 1985
	10,000 UNITS/100ML	N018916	002	Jan 31, 1984
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%				
HOSPIRA	5,000 UNITS/100ML	N018911	007	Jan 30, 1985
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019802	001	Jul 20, 1992
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	5,000 UNITS/100ML	N018911	005	Jan 30, 1985
	5,000 UNITS/100ML	N018916	003	Jan 31, 1984
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	200 UNITS/100ML	N019130	003	Dec 31, 1984
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	200 UNITS/100ML	N019042	002	Mar 29, 1985
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4,000 UNITS/100ML	N018814	001	Oct 31, 1983
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5,000 UNITS/100ML	N018814	003	Jul 09, 1985
	10,000 UNITS/100ML	N018814	004	Jul 02, 1987
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%				
HOSPIRA	5,000 UNITS/100ML	N018911	009	Jan 30, 1985
	10,000 UNITS/100ML	N018911	008	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019134	001	Mar 29, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019802	005	Jul 20, 1992
	10,000 UNITS/100ML	N019802	002	Jul 20, 1992
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	5,000 UNITS/100ML	N018911	004	Jan 30, 1985

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 170 (of 360)

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN 5,000 UNITS/100ML N019135 001 Mar 29, 1985

5,000 UNITS/100ML N019802 003 Jul 20, 1992

HOSPIRA 5,000 UNITS/100ML N018916 009 Jan 31, 1984

HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAXTER HLTHCARE 500 UNITS/100ML N018609 003 Apr 28, 1982

HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

MCGAW 1,000 UNITS/100ML N019130 002 Dec 31, 1984

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%

HOSPIRA 100 UNITS/ML N018911 002 Jan 30, 1985

100 UNITS/ML N018916 004 Jan 31, 1984

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%

HOSPIRA 1,000 UNITS/100ML N018916 001 Jan 31, 1984

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN 1,000 UNITS/100ML N019042 004 Mar 29, 1985

HEPARIN SODIUM PRESERVATIVE FREE

HOSPIRA 2,000 UNITS/ML N005264 013 Apr 07, 1986

2,500 UNITS/ML N005264 014 Apr 07, 1986

MARSAM PHARMS LLC 1,000 UNITS/ML A089464 001 Jun 03, 1986

PHARMA SERVE NY 1,000 UNITS/ML A086129 001

LIPO-HEPIN

3M 1,000 UNITS/0.5ML N017027 001

1,000 UNITS/ML N017027 006

5,000 UNITS/0.5ML N017027 002

5,000 UNITS/ML N017027 008

7,500 UNITS/0.5ML N017027 010

10,000 UNITS/0.5ML N017027 003

10,000 UNITS/ML N017027 009

15,000 UNITS/0.5ML N017027 011

20,000 UNITS/0.5ML N017027 004

20,000 UNITS/ML N017027 007

40,000 UNITS/ML N017027 005

LIQUAEMIN LOCK FLUSH

ORGANON USA INC 100 UNITS/ML N000552 007

LIQUAEMIN SODIUM

ORGANON USA INC 1,000 UNITS/ML N000552 004

5,000 UNITS/ML N000552 003

10,000 UNITS/ML N000552 005

20,000 UNITS/ML N000552 001

40,000 UNITS/ML N000552 002

LIQUAEMIN SODIUM PRESERVATIVE FREE

ORGANON USA INC 1,000 UNITS/ML N000552 011 Apr 11, 1986

5,000 UNITS/ML N000552 012 Apr 11, 1986

10,000 UNITS/ML N000552 013 Apr 11, 1986

PANHEPRIN

HOSPIRA 1,000 UNITS/ML N005264 004

5,000 UNITS/ML N005264 006

10,000 UNITS/ML N005264 007

20,000 UNITS/ML N005264 008

40,000 UNITS/ML N005264 009

SODIUM HEPARIN

ABRAXIS PHARM 5,000 UNITS/ML N017033 002

10,000 UNITS/ML N017033 003

20,000 UNITS/ML N017033 004

BAXTER HLTHCARE 1,000 UNITS/ML N017036 001 Mar 04, 1988

HETACILLIN

FOR SUSPENSION; ORAL

VERSAPEN

BRISTOL EQ 112.5MG AMPICIL/ML A061398 001

EQ 112.5MG AMPICIL/5ML N050060 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 171 (of 360)

HETACILLINFOR SUSPENSION; ORAL
VERSAPEN

BRISTOL

EQ 112.5MG AMPICIL/ML

N050060 003

EQ 225MG AMPICIL/5ML

A061398 002

HETACILLIN POTASSIUMCAPSULE; ORAL
VERSAPEN-K

BRISTOL

EQ 225MG AMPICIL

A061396 001

EQ 450MG AMPICIL

A061396 002

HEXACHLOROPHENEAEROSOL; TOPICAL
SEPTISOL

VESTAL LABS

0.23%

N017424 001

TURGEX

XTTRIUM

3%

N018375 001

EMULSION; TOPICAL
HEXA-GERM

HUNTINGTON LABS

3%

N017411 001

PHISOHEX

SANOFI AVENTIS US

3%

N008402 001

SOY-DOME

BAYER PHARMS

3%

N017405 001

TURGEX

XTTRIUM

3%

N019055 001 Nov 30, 1984

SOAP; TOPICAL
GAMOPHEN

ARBROOK

2%

N006270 003

SOLUTION; TOPICAL
DIAL

DIAL

0.25%

N017421 002

GERMA-MEDICA

HUNTINGTON LABS

1%

N017412 001

GERMA-MEDICA "MG"

HUNTINGTON LABS

0.25%

N017412 002

SEPTI-SOFT

CALGON

0.25%

N017460 001

SEPTISOL

VESTAL LABS

0.25%

N017423 001

SPONGE; TOPICAL

E-Z SCRUB

BECTON DICKINSON

450MG

N017452 001

HEXASCRUB

PROF DSPLS

3%

N018363 001

PHISO-SCRUB

SANOFI AVENTIS US

3%

N017446 001

SCRUBTEAM SURGICAL SPONGEBRUSH

3M

330MG

N017413 001

HEXAFLUORENIUM BROMIDEINJECTABLE; INJECTION
MYLAXEN

MEDPOINTE PHARM HLC

20MG/ML

N009789 003

HEXOCYCLIUM METHYLSULFATETABLET; ORAL
TRAL

ABBVIE

25MG

N010599 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 172 (of 360)

HEXYLCAINE HYDROCHLORIDESOLUTION; TOPICAL
CYCLAINA
MERCK

5%

N008472 001

HISTAMINE PHOSPHATEINJECTABLE; INJECTION
HISTAMINE PHOSPHATE
LILLYEQ 0.1MG BASE/ML
EQ 0.2MG BASE/ML
EQ 1MG BASE/MLN000734 003
N000734 002
N000734 001HISTRELIN ACETATEINJECTABLE; INJECTION
SUPPRELIN
SHIREEQ 0.2MG BASE/ML
EQ 0.5MG BASE/ML
EQ 1MG BASE/MLN019836 001 Dec 24, 1991
N019836 002 Dec 24, 1991
N019836 003 Dec 24, 1991HOMATROPINE METHYLBROMIDETABLET; ORAL
HOMAPIN-10

MISSION PHARMA

10MG

A086308 001

HOMAPIN-5

MISSION PHARMA

5MG

A086309 001

TABLET, CHEWABLE; ORAL
EQUIPIN

MISSION PHARMA

3MG

A086310 001

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATESYRUP; ORAL
HYCODAN

ENDO PHARMS

1.5MG/5ML;5MG/5ML

N005213 002 Jul 26, 1988

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

IVAX SUB TEVA PHARMS 1.5MG/5ML;5MG/5ML

A040285 001 Jul 19, 1999

HYDROPANE

HALSEY

1.5MG/5ML;5MG/5ML

A088066 001 Jun 28, 1985

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

ACTAVIS TOTOWA

1.5MG;5MG

A040295 001 Dec 01, 2000

HYCODAN

ENDO PHARMS

1.5MG;5MG

N005213 001 Jul 26, 1988

HYALURONIDASEINJECTABLE; INJECTION
HYDASE

AKORN INC

150 UNITS/ML

N021716 001 Oct 25, 2005

VITRASE

ISTA PHARMS

6,200 UNITS/VIAL

N021640 001 May 05, 2004

WYDASE

BAXTER HLTHCARE

150 UNITS/ML

N006343 002

150 UNITS/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

N006343 006

1,500 UNITS/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

N006343 005

HYDRALAZINE HYDROCHLORIDEINJECTABLE; INJECTION
APRESOLINE
NOVARTIS

20MG/ML

N008303 003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 173 (of 360)

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

ABRAXIS PHARM	20MG/ML	A089532	001	Aug 11, 1987
SMITH AND NEPHEW	20MG/ML	A088518	001	Apr 20, 1984
SOLOPAK	20MG/ML	A088517	001	Aug 22, 1985
TEVA PARENTERAL	20MG/ML	A040373	001	Feb 23, 2000

TABLET; ORAL

APRESOLINE

NOVARTIS	10MG	N008303	004	
	25MG	N008303	001	
	50MG	N008303	002	
	100MG	N008303	005	

DRALZINE

TEVA	25MG	A084301	001	

HYDRALAZINE HYDROCHLORIDE

ACTAVIS TOTOWA	25MG	A088560	001	Oct 04, 1984
	50MG	A088649	001	Oct 18, 1984
ASCOT	25MG	A088310	001	Dec 19, 1984
	50MG	A088311	001	Dec 19, 1984
HALSEY	10MG	A089218	001	Jan 22, 1986
	25MG	A089130	001	Jan 15, 1986
	50MG	A089222	001	Jan 22, 1986
	100MG	A089178	001	Jan 15, 1986
IMPAX LABS	25MG	A084922	001	
	50MG	A084923	001	
IVAX SUB TEVA PHARMS	10MG	A084443	001	
	25MG	A084437	001	
	50MG	A084469	002	
	100MG	A084581	001	
MUTUAL PHARM	10MG	A088728	001	Apr 11, 1985
	10MG	A089359	001	Jul 25, 1986
	25MG	A084106	002	
	25MG	A089258	001	May 05, 1986
	50MG	A084107	002	
	50MG	A089259	001	May 05, 1986
	100MG	A088729	001	Apr 11, 1985
PUREPAC PHARM	25MG	A088177	001	Jul 29, 1983
	50MG	A088178	001	Aug 15, 1983
QUANTUM PHARMICS	10MG	A088671	001	May 01, 1984
	25MG	A088657	001	Jun 15, 1984
	50MG	A088652	001	May 08, 1984
	100MG	A088686	001	May 01, 1984
SANDOZ	10MG	A083241	001	
	25MG	A083560	001	
	50MG	A083561	001	
	50MG	A085088	001	
SUPERPHARM	10MG	A088787	001	Aug 28, 1984
	25MG	A088788	001	Aug 28, 1984
	50MG	A088789	001	Aug 28, 1984
TG UNITED LABS	10MG	A088846	001	Feb 26, 1985
	25MG	A088847	001	Feb 26, 1985
	50MG	A088848	001	Feb 26, 1985
	100MG	A088849	001	Feb 26, 1985
USL PHARMA	25MG	A087780	001	Mar 29, 1982
	50MG	A087751	001	Mar 29, 1982
VANGARD	25MG	A087712	001	
	50MG	A087908	001	May 07, 1982
VITARINE	25MG	A086088	001	
WATSON LABS	25MG	A085532	002	May 24, 1982
	50MG	A085533	002	May 25, 1982
WEST WARD	25MG	A088240	001	May 27, 1983
	50MG	A088241	001	May 27, 1983

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 174 (of 360)

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

APRESAZIDE

NOVARTIS

25MG;25MG

A084735 001

50MG;50MG

A084810 001

100MG;50MG

A084811 001

HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SOLVAY

25MG;25MG

A087608 001 Feb 08, 1982

50MG;50MG

A087213 001 Feb 08, 1982

100MG;50MG

A087609 001 Feb 08, 1982

SUPERPHARM

25MG;25MG

A089200 001 Feb 09, 1987

50MG;50MG

A089201 001 Feb 09, 1987

WATSON LABS

25MG;25MG

A085457 001 Mar 04, 1982

50MG;50MG

A085446 001 Mar 04, 1982

100MG;50MG

A085440 001 Mar 04, 1982

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50

IVAX PHARMS

100MG;50MG

A088358 001 Apr 10, 1984

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25

IVAX PHARMS

25MG;25MG

A088356 001 Apr 10, 1984

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50

IVAX PHARMS

50MG;50MG

A088357 001 Apr 10, 1984

HYDRA-ZIDE

PAR PHARM

100MG;50MG

A088961 001 Oct 21, 1985

TABLET; ORAL

APRESOLINE-ESIDRIX

NOVARTIS

25MG;15MG

N012026 002

HYDRALAZINE AND HYDROCHLOROTHIAZIDE

WATSON LABS

25MG;15MG

A085827 001

HYDROCHLOROTHIAZIDE W/ HYDRALAZINE

WATSON LABS

25MG;15MG

A085373 001

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CAM-AP-ES

TG UNITED LABS

25MG;15MG;0.1MG

A084897 001

HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE

IVAX SUB TEVA PHARMS

25MG;15MG;0.1MG

A084291 001

HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE

MYLAN

25MG;15MG;0.1MG

A087085 001

HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE

WATSON LABS

25MG;15MG;0.1MG

A085771 001

HYDRAP-ES

SANDOZ

25MG;15MG;0.1MG

A084876 001

HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE

WATSON LABS

25MG;15MG;0.1MG

A083770 001

HYDROSERPINE PLUS (R-H-H)

IVAX SUB TEVA PHARMS

25MG;15MG;0.1MG

A083877 001

RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

MUTUAL PHARM

25MG;15MG;0.1MG

A088570 001 Apr 10, 1984

SOLVAY

25MG;15MG;0.1MG

A088376 001 Oct 28, 1983

WATSON LABS

25MG;15MG;0.1MG

A085549 001

25MG;15MG;0.1MG

A087556 001

RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE

LEDERLE

25MG;15MG;0.1MG

A087709 001 May 13, 1982

SER-A-GEN

SOLVAY

25MG;15MG;0.1MG

A087210 001

SER-AP-ES

NOVARTIS

25MG;15MG;0.1MG

N012193 005

UNIPRES

SOLVAY

25MG;15MG;0.1MG

A085893 001

25MG;15MG;0.1MG

A086298 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 175 (of 360)

HYDRALAZINE HYDROCHLORIDE; RESERPINETABLET; ORAL
DRALSERP

SANDOZ 25MG;0.1MG A084617 001

SERPASIL - APRESOLINE 25MG;0.1MG N009296 004

NOVARTIS 25MG;0.1MG N009296 002
50MG;0.2MGHYDROCHLOROTHIAZIDESOLUTION; ORAL
HYDROCHLOROTHIAZIDE

MORTON GROVE 50MG/5ML A089661 001 Jun 20, 1988

ROXANE 50MG/5ML A088587 001 Jul 02, 1984

HYDROCHLOROTHIAZIDE INTENSOL
ROXANE 100MG/ML A088588 001 Jul 02, 1984

TABLET; ORAL

ESIDRIX
NOVARTIS 25MG N011793 005

50MG N011793 008

100MG N011793 009

HYDROCHLOROTHIAZIDE

ABC HOLDING 50MG A085672 001

ACTAVIS ELIZABETH 25MG A085054 002

50MG A085208 001

ALRA 25MG A086369 001

50MG A083554 001

ASCOT 25MG A087539 001 Feb 03, 1982

50MG A087540 001 Feb 03, 1982

BARR 50MG A084771 001

DAVA PHARMS INC 100MG A087060 001

ELKINS SINN 50MG A085152 002

HEATHER 50MG A084135 001

IMPAX LABS 25MG A084029 001

50MG A083607 002

100MG A085098 001

INWOOD LABS 25MG A084776 001

25MG A085067 001

50MG A084776 002

IVAX SUB TEVA PHARMS 50MG A084658 001

100MG A085022 001

MAST MM 25MG A086192 001

50MG A086192 002

MUTUAL PHARM 25MG A083972 001

50MG A083972 002

100MG A083972 003

MYLAN 25MG A084880 001

50MG A085112 001

PVT FORM 50MG A086597 001

ROXANE 25MG A085004 001

50MG A084536 002

50MG A085005 001

SANDOZ 25MG A083899 001

25MG A087565 001 Mar 09, 1982

50MG A084912 001

50MG A085219 001

SOLVAY 25MG A085323 001

SUPERPHARM 25MG A088827 001 Dec 28, 1984

50MG A088828 001 Dec 28, 1984

100MG A088829 001 Dec 28, 1984

TEVA 25MG A088924 001 Feb 07, 1985

50MG A088923 001 Feb 07, 1985

TG UNITED LABS 25MG A085683 001

50MG A083965 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 176 (of 360)

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

USL PHARMA	25MG	A087827	001	Apr 19, 1982
	50MG	A087752	001	Apr 19, 1982
VANGARD	25MG	A087638	001	
	50MG	A087610	001	
WARNER CHILCOTT	25MG	A087586	001	May 03, 1982
	50MG	A087587	001	May 03, 1982
WATSON LABS	25MG	A083458	001	
	25MG	A085232	002	
	50MG	A083232	001	
	50MG	A083456	001	
	50MG	A085233	001	
	50MG	A086087	001	
	50MG	A086594	001	
	100MG	A081190	001	Jan 24, 1992
	100MG	A085099	001	
	100MG	A087002	001	
WEST WARD	25MG	A084899	001	
WHITEWORTH TOWN PLSN	25MG	A083809	002	
	50MG	A083809	001	
	100MG	A085347	001	
HYDRO-D				
HALSEY	25MG	A086504	001	
	50MG	A083891	002	
HYDRODIURIL				
MERCK	25MG	N011835	003	
	50MG	N011835	006	
	100MG	N011835	007	
ORETIC				
ABBVIE	25MG	N011971	001	
ZIDE				
SOLVAY	50MG	A083925	001	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

SANOFI AVENTIS US	12.5MG;75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020758	001	Sep 30, 1997
	25MG;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020758	004	Mar 15, 2005
IRBESARTAN AND HYDROCHLOROTHIAZIDE				
TEVA	25MG;300MG	A077369	003	Mar 30, 2012

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

NORMOZIDE

SCHERING	25MG;100MG	N019046	001	Apr 06, 1987
	25MG;200MG	N019046	002	Apr 06, 1987
	25MG;300MG	N019046	003	Apr 06, 1987
	25MG;400MG	N019046	004	Apr 06, 1987
TRANDATE HCT				
GLAXOSMITHKLINE	25MG;100MG	N019174	001	Apr 10, 1987
	25MG;200MG	N019174	002	Apr 10, 1987
	25MG;300MG	N019174	003	Apr 10, 1987
	25MG;400MG	N019174	004	Apr 10, 1987

DISCONTINUED DRUG PRODUCT LIST

6 - 177 (of 360)

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

SANDOZ	12.5MG;10MG	A075926	001	Jul 01, 2002
	12.5MG;20MG	A075926	002	Jul 01, 2002
	25MG;20MG	A075926	003	Jul 01, 2002
TEVA	12.5MG;10MG	A075869	001	Jul 01, 2002
	12.5MG;20MG	A075869	002	Jul 01, 2002
	25MG;20MG	A075869	003	Jul 01, 2002
<u>PRINZIDE</u>				
MERCK	25MG;20MG	N019778	002	Feb 16, 1989

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDORIL 15

MERCK	15MG;250MG	N013402	001	

ALDORIL 25

MERCK	25MG;250MG	N013402	002	

ALDORIL D30

MERCK	30MG;500MG	N013402	003	

ALDORIL D50

MERCK	50MG;500MG	N013402	004	

METHYLDOPA AND HYDROCHLOROTHIAZIDE

CLONMEL HLTHCARE	15MG;250MG	A072507	001	Jun 02, 1989
	25MG;250MG	A072508	001	Jun 02, 1989
	30MG;500MG	A072509	001	Jun 02, 1989
	50MG;500MG	A072510	001	Jun 02, 1989
IVAX SUB TEVA PHARMS	15MG;250MG	A071458	001	Mar 08, 1988
	25MG;250MG	A071459	001	Mar 08, 1988
	30MG;500MG	A071460	001	Mar 08, 1988
	50MG;500MG	A071461	001	Mar 08, 1988
PAR PHARM	15MG;250MG	A070616	001	Feb 02, 1987
	25MG;250MG	A070612	001	Feb 02, 1987
	30MG;500MG	A070613	001	Feb 02, 1987
	50MG;500MG	A070614	001	Feb 02, 1987
PARKE DAVIS	15MG;250MG	A071897	001	Nov 23, 1987
	25MG;250MG	A071898	001	Nov 23, 1987
	30MG;500MG	A071899	001	Nov 23, 1987
	50MG;500MG	A071900	001	Nov 23, 1987
PUREPAC PHARM	15MG;250MG	A070853	001	Oct 08, 1986
	25MG;250MG	A070688	001	Apr 24, 1986
	30MG;500MG	A070854	001	Oct 08, 1986
	50MG;500MG	A070689	001	Apr 24, 1986
SANDOZ	15MG;250MG	A070182	001	Jan 15, 1986
	15MG;250MG	A070829	001	Mar 09, 1987
	25MG;250MG	A070183	001	Jan 15, 1986
	25MG;250MG	A070830	001	Mar 09, 1987
	30MG;500MG	A070543	001	Jan 15, 1986
	50MG;500MG	A070544	001	Jan 15, 1986
TEVA	15MG;250MG	A071819	001	Apr 08, 1988
	25MG;250MG	A071820	001	Apr 08, 1988
	30MG;500MG	A071821	001	Apr 08, 1988
	50MG;500MG	A071822	001	Apr 08, 1988
WATSON LABS	15MG;250MG	A070365	001	Mar 19, 1986
	15MG;250MG	A070958	001	Feb 06, 1989
	15MG;250MG	A071920	001	Aug 29, 1988
	25MG;250MG	A070366	001	Apr 16, 1986
	25MG;250MG	A070959	001	Jan 19, 1989
	25MG;250MG	A071921	001	Aug 29, 1988
	30MG;500MG	A070367	001	Mar 19, 1986
	30MG;500MG	A071069	001	Jan 19, 1989
	30MG;500MG	A071922	001	Aug 29, 1988
	50MG;500MG	A070368	001	Apr 16, 1986

DISCONTINUED DRUG PRODUCT LIST

6 - 178 (of 360)

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL		
METHYLDOPA AND HYDROCHLOROTHIAZIDE		
WATSON LABS	50MG;500MG	A070960 001 Feb 06, 1989
	50MG;500MG	A071923 001 Aug 29, 1988

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL		
LOPRESSOR HCT		
US PHARMS HOLDINGS I	50MG;100MG	N018303 003 Dec 31, 1984

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL		
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE		
PADDOCK LLC	12.5MG;7.5MG	A090096 001 Sep 25, 2008
	12.5MG;15MG	A090096 002 Sep 25, 2008
	25MG;15MG	A090096 003 Sep 25, 2008

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET; ORAL		
VISKAZIDE		
NOVARTIS	25MG;5MG	N018872 001 Jul 22, 1987
	25MG;10MG	N018872 002 Jul 22, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL		
INDERIDE LA 120/50		
WYETH AYERST	50MG;120MG	N019059 002 Jul 03, 1985
INDERIDE LA 160/50		
WYETH AYERST	50MG;160MG	N019059 003 Jul 03, 1985
INDERIDE LA 80/50		
WYETH AYERST	50MG;80MG	N019059 001 Jul 03, 1985
TABLET; ORAL		
INDERIDE-80/25		
AKRIMAX PHARMS	25MG;80MG	N018031 002
PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE		
DURAMED PHARMS BARR	25MG;40MG	A071126 001 Mar 02, 1987
	25MG;80MG	A071127 001 Mar 02, 1987
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE		
ACTAVIS ELIZABETH	25MG;40MG	A070851 001 May 15, 1986
	25MG;80MG	A070852 001 May 15, 1986
BARR	25MG;40MG	A070704 001 Oct 01, 1986
	25MG;80MG	A070705 001 Oct 01, 1986
IVAX SUB TEVA PHARMS	25MG;40MG	A071552 001 Dec 01, 1988
	25MG;80MG	A071553 001 Dec 01, 1988
SANDOZ	25MG;40MG	A071060 001 Aug 26, 1987
	25MG;80MG	A071061 001 Aug 26, 1987
WARNER CHILCOTT	25MG;40MG	A071771 001 Jan 26, 1988
	25MG;80MG	A071772 001 Jan 26, 1988
WATSON LABS	25MG;40MG	A071498 001 Dec 18, 1991
	25MG;80MG	A071501 001 Dec 18, 1991

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL		
H.R.-50		
WHITEWORTH TOWN PLSN	50MG;0.125MG	A085338 001
HYDROCHLOROTHIAZIDE W/ RESERPINE		
IVAX SUB TEVA PHARMS	25MG;0.1MG	A083572 001
	25MG;0.125MG	A083571 001
	50MG;0.1MG	A083568 001
	50MG;0.125MG	A083573 001
PHARMERAL	25MG;0.125MG	A085421 001
	50MG;0.125MG	A085420 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 179 (of 360)

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDROCHLOROTHIAZIDE W/ RESERPINE

ROXANE	50MG;0.125MG	A084603	001	
WATSON LABS	25MG;0.125MG	A084466	001	
	25MG;0.125MG	A085317	001	
	25MG;0.125MG	A086330	002	
	50MG;0.125MG	A083666	001	
	50MG;0.125MG	A084467	001	
	50MG;0.125MG	A086331	001	
HYDROPRES 25				
MERCK	25MG;0.125MG	N011958	002	
HYDROPRES 50				
MERCK	50MG;0.125MG	N011958	003	
HYDRO-RESERP				
ABC HOLDING	50MG;0.125MG	A084714	002	Jun 29, 1982
HYDRO-SERP "25"				
SANDOZ	25MG;0.125MG	A084827	001	
HYDRO-SERP "50"				
SANDOZ	50MG;0.125MG	A085213	001	
RESERPINE AND HYDROCHLOROTHIAZIDE				
BARR	25MG;0.125MG	A084580	001	
	50MG;0.125MG	A084579	001	
SANDOZ	50MG;0.125MG	A088200	001	Jan 31, 1984
RESERPINE AND HYDROCHLOROTHIAZIDE-50				
WEST WARD	50MG;0.125MG	A088189	001	May 10, 1984
SERPASIL-ESIDRIX #1				
NOVARTIS	25MG;0.1MG	N011878	003	
SERPASIL-ESIDRIX #2				
NOVARTIS	50MG;0.1MG	N011878	005	

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

ASCOT	25MG;25MG	A088025	001	Nov 23, 1984
MUTUAL PHARM	25MG;25MG	A087267	001	
PUREPAC PHARM	25MG;25MG	A087999	001	Nov 06, 1985
SANDOZ	25MG;25MG	A086881	001	
SUPERPHARM	25MG;25MG	A089137	001	Aug 26, 1985
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE				
IVAX PHARMS	25MG;25MG	A087004	002	May 24, 1982
LEDERLE	25MG;25MG	A087511	001	
PARKE DAVIS	25MG;25MG	A087948	001	Feb 22, 1983
PUREPAC PHARM	25MG;25MG	A088054	001	Aug 18, 1983
UPSHER SMITH	25MG;25MG	A087553	001	
USL PHARMA	25MG;25MG	A087651	001	
VANGARD	25MG;25MG	A087655	001	
WATSON LABS	25MG;25MG	A085974	001	
	25MG;25MG	A086026	001	

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL

TIMOLIDE 10-25

MERCK	25MG;10MG	N018061	001	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DIAZIDE

GLAXOSMITHKLINE LLC	25MG;50MG	N016042	002	
TRIAMTERENE AND HYDROCHLOROTHIAZIDE				
BARR	25MG;37.5MG	A074970	001	Jan 06, 1998
NOVARTIS	25MG;37.5MG	A074857	001	Sep 09, 1997
VITARINE	25MG;50MG	A071737	001	Feb 12, 1988

DISCONTINUED DRUG PRODUCT LIST

6 - 180 (of 360)

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AM THERAP 50MG;75MG

A072022 001 Apr 17, 1988

QUANTUM PHARMICS 50MG;75MG

A071980 001 Apr 17, 1988

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

CODAMINE

ALPHARMA US PHARMS 5MG/5ML;25MG/5ML

A075103 001 Sep 29, 2000

HYCOMINE

ENDO PHARMS 5MG/5ML;25MG/5ML

N019410 001 Aug 17, 1990

HYCOMINE PEDIATRIC

ENDO PHARMS 2.5MG/5ML;12.5MG/5ML

N019411 001 Aug 17, 1990

HYDROCORTAMATE HYDROCHLORIDE

OINTMENT; TOPICAL

MAGNACORT

PFIZER 0.5%

N010554 001

HYDROCORTISONE

AEROSOL; TOPICAL

AEROSEB-HC

ALLERGAN HERBERT 0.5%

A085805 001

CREAM; TOPICAL

CORT-DOME

BAYER PHARMS 0.5%

N009585 003

1%

N009585 001

DERMACORT

MONARCH PHARMS 1%

A083011 002

ELDECORT

VALEANT PHARM INTL 1%

A080459 001

2.5%

A084055 001

FLEXICORT

WESTWOOD SQUIBB 0.5%

A087136 003 Apr 08, 1982

1%

A087136 002 Apr 08, 1982

2.5%

A087136 001 Apr 08, 1982

HC #1

BAYER PHARMS 0.5%

A080438 001

HC #4

BAYER PHARMS 1%

A080438 002

HC (HYDROCORTISONE)

C AND M PHARMA 0.5%

A080482 003

1%

A080482 004

H-CORT

PHARM ASSOC 0.5%

A086823 001

HI-COR

C AND M PHARMA 2.5%

A080483 001

HYDROCORTISONE

ALPHARMA US PHARMS 2.5%

A089754 001 Feb 01, 1989

ALTANA 0.5%

A080848 002

1%

A080848 003

AMBIX 1%

A086080 001

2.5%

A086271 001

EVERYLIFE 0.5%

A080452 001

1%

A080452 002

G AND W LABS 1%

A084059 001

INGRAM PHARM 0.5%

A080456 002

1%

A080456 003

IVAX PHARMS 1%

A085733 001

NASKA 1%

A089706 001 Mar 10, 1988

PERRIGO NEW YORK 0.5%

A084970 002

1%

A085026 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 181 (of 360)

HYDROCORTISONECREAM; TOPICAL
HYDROCORTISONE

PHARMADERM	1%	A088845	001	Feb 27, 1986
	2.5%	A089413	001	Dec 16, 1986
PHARMAFAIR	1%	A087838	001	Jul 28, 1982
STIEFEL	1%	A086170	001	
SYOSSET	0.5%	A085527	001	
TARO	0.5%	A086154	001	
TEVA	0.5%	A080400	002	
	1%	A080400	003	
	1%	A085191	001	
	2.5%	A080400	004	
TOPIDERM	1%	A089273	001	Feb 17, 1989
USL PHARMA	1%	A088027	001	Sep 27, 1983
	2.5%	A088029	001	Sep 27, 1983
WHITEWORTH TOWN PLSN	1%	A080496	002	

HYTONE

VALEANT INTL	1%	A080472	003	
	2.5%	A080472	004	

NOGENIC HC

IVAX PHARMS	1%	A087427	001	Apr 04, 1988

NUTRACORT

DOW PHARM	0.5%	A080442	002	
	1%	A080442	003	

PENECORT

ALLERGAN HERBERT	1%	A088216	001	Jun 06, 1984

PROCTOCORT

MONARCH PHARMS	1%	A083011	001	

SYNACORT

MEDICIS	0.5%	A087459	001	

GEL; TOPICAL

NUTRACORT

HEALTHPOINT	1%	A084698	001	

PENECORT

ALLERGAN HERBERT	1%	A088215	001	Jun 06, 1984

INJECTABLE; INJECTION

CORTEF

PHARMACIA AND UPJOHN	50MG/ML	N009864	001	

LOTION; TOPICAL

ACTICORT

BAKER NORTON	1%	A086535	001	

BALNEOL-HC

SOLVAY	1%	A088041	001	Dec 03, 1982

BETA-HC

BETA DERMAC	1%	A089495	001	Jan 25, 1988

CETACORT

DOW PHARM	0.5%	A080426	002	
	1%	A080426	001	

CORT-DOME

BAYER PHARMS	0.5%	N009895	003	
	1%	N009895	001	

DERMACORT

SOLVAY	0.5%	A084573	002	
	1%	A086462	001	

EPICORT

BLULINE	0.5%	A083219	002	

GLYCORT

HERAN	1%	A087489	001	Oct 03, 1983

H-CORT

PHARM ASSOC	0.5%	A086824	001	

HYDROCORTISONE

ALPHARMA US PHARMS	0.5%	A087317	001	Jun 07, 1982
	1%	A087315	001	Jun 07, 1982

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 182 (of 360)

HYDROCORTISONELOTION; TOPICAL
HYDROCORTISONE

MERICON	0.5%	A085282	001	
	1%	A085282	002	Feb 26, 1987
NASKA	1%	A089705	001	Apr 25, 1988
PERRIGO NEW YORK	0.5%	A085662	001	
	1%	A085663	001	
TARO	1%	A089024	001	Feb 12, 1986

HYTONE

VALEANT INTL	1%	A080473	003	
	2.5%	A080473	004	Nov 30, 1982

NUTRACORT

DOW PHARM	0.5%	A080443	002	

OINTMENT; TOPICAL

CORTRIL

PFIZER GLOBAL	1%	N009176	001	
	2.5%	N009176	002	

HC (HYDROCORTISONE)

C AND M PHARMA	0.5%	A080481	001	
	1%	A080481	002	

HYDROCORTISONE

ALTANA	0.5%	A080489	002	
	1%	A080489	003	
AMBIX	1%	A086079	001	
	2.5%	A086272	001	
NASKA	1%	A089704	001	Mar 10, 1988
PERRIGO NEW YORK	0.5%	A084969	003	
	1%	A085028	001	
PHARMADERM	1%	A088842	001	Feb 09, 1987
TARO	0.5%	A086256	001	
USL PHARMA	1%	A088061	001	Sep 27, 1983
	2.5%	A088039	001	Sep 27, 1983

HYTONE

DERMIK LABS	1%	A080474	003	
	2.5%	A080474	004	

PENECORT

ALLERGAN HERBERT	2.5%	A088217	001	Jun 06, 1984

POWDER; FOR RX COMPOUNDING

H-CORT

TORCH	100%	A087834	001	Mar 29, 1982

HYDROCORTISONE

PADDOCK LLC	100%	A088082	001	Apr 08, 1983

SOLUTION; TOPICAL

PENECORT

ALLERGAN HERBERT	1%	A088214	001	Jun 06, 1984

TEXACORT

MISSION PHARMA	1%	A080425	001	

TABLET; ORAL

CORTRIL

PFIZER	10MG	N009127	005	
	20MG	N009127	003	

HYDROCORTISONE

BARR	20MG	A083999	001	
ELKINS SINN	20MG	A080624	001	
FERRANTE	10MG	A080568	001	
	20MG	A080568	002	
IMPAX LABS	20MG	A080781	001	
INWOOD LABS	20MG	A080732	001	
LANNETT	20MG	A085070	001	
NEXGEN PHARMA INC	20MG	A083140	001	
PANRAY	10MG	N009659	001	
	20MG	N009659	002	
PARKE DAVIS	20MG	A084243	001	

DISCONTINUED DRUG PRODUCT LIST

6 - 183 (of 360)

HYDROCORTISONE

TABLET; ORAL

HYDROCORTISONE

PUREPAC PHARM	10MG	A084247	003	Aug 31, 1982
	20MG	A080395	001	
	20MG	A084247	002	
ROXANE	10MG	A088539	001	Mar 21, 1984
SANDOZ	20MG	A080642	002	
WATSON LABS	20MG	A080355	001	
WHITEWORTH TOWN PLSN	10MG	A080344	001	
	20MG	A080344	002	

HYDROCORTONE

MERCK

10MG	N008506	007
20MG	N008506	011

TABLET; VAGINAL

CORTRIL

PFIPHARMECS	10MG	N009796	001

HYDROCORTISONE ACETATE

CREAM; TOPICAL

HEMSOL-HC

ABLE	1%	A081274	001	Jun 19, 1992

HYDROCORTISONE ACETATE

CENCI	1%	A080419	001	Jan 25, 1982
PARKE DAVIS	1%	A089914	001	Jan 03, 1989
PUREPAC PHARM	0.5%	A086050	001	
	1%	A086052	001	

INJECTABLE; INJECTION

CORTEF ACETATE

PHARMACIA AND UPJOHN	50MG/ML	N009378	002

CORTRIL

PFIZER	25MG/ML	N009164	001

HYDROCORTISONE ACETATE

AKORN	25MG/ML	N009637	001
	50MG/ML	N009637	002
BEL MAR	25MG/ML	A083739	001
	50MG/ML	A083739	002
WATSON LABS	25MG/ML	A083128	001
	25MG/ML	A083759	001
	50MG/ML	A083759	002
	50MG/ML	A085214	001

HYDROCORTONE

MERCK

25MG/ML	N008228	001
50MG/ML	N008228	004

LOTION; TOPICAL

DRICORT

INGRAM PHARM	0.5%	A086207	001

OINTMENT; OPHTHALMIC

HYDROCORTISONE ACETATE

FERA PHARMS	0.5%	A080828	001

OINTMENT; OPHTHALMIC, OTIC

HYDROCORTONE

MERCK	1.5%	N009018	003

OINTMENT; TOPICAL

CORTEF ACETATE

PHARMACIA AND UPJOHN	1%	N008917	002
	2.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008917	001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORTEF

PHARMACIA AND UPJOHN	1%;EQ 3.5MG BASE/GM	A061049	001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 184 (of 360)

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL				
NEO-CORTEF				
PHARMACIA AND UPJOHN	2.5%;EQ 3.5MG BASE/GM	A061049	002	
OINTMENT; OPHTHALMIC				
NEO-CORTEF				
PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060610	001	
	1.5%;EQ 3.5MG BASE/GM	A060610	002	
OINTMENT; TOPICAL				
NEO-CORTEF				
PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060751	001	
	1%;EQ 3.5MG BASE/GM	A060751	002	
	2.5%;EQ 3.5MG BASE/GM	A060751	003	
SUSPENSION/DROPS; OPHTHALMIC				
COR-OTICIN				
AKORN	1.5%;EQ 3.5MG BASE/ML	A060188	001	
NEO-CORTEF				
PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/ML	A060612	002	
	1.5%;EQ 3.5MG BASE/ML	A060612	001	

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION; OPHTHALMIC				
TERRA-CORTRIL				
PFIZER	1.5%;EQ 5MG BASE/ML	A061016	001	

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL				
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%				
BOCA PHARMA	1%;1%	A089440	001	May 17, 1988
LOTION; TOPICAL				
PRAMOSONE				
FERNDAL LABS	0.5%;1%	A083213	002	

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL				
LOCOID				
YAMANOUCHI	0.1%	N018795	001	Jan 07, 1983
OINTMENT; TOPICAL				
LOCOID				
YAMANOUCHI	0.1%	N019106	001	Jul 03, 1984
SOLUTION; TOPICAL				
LOCOID				
YAMANOUCHI	0.1%	N019819	001	Sep 15, 1988

HYDROCORTISONE CYPIONATE

SUSPENSION; ORAL				
CORTEF				
PHARMACIA AND UPJOHN	EQ 10MG BASE/5ML	N009900	001	

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION				
HYDROCORTONE				
MERCK	EQ 50MG BASE/ML	N012052	001	

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION				
A-HYDROCORT				
ABBOTT	EQ 100MG BASE/VIAL	A085928	001	
	EQ 100MG BASE/VIAL	A089577	001	Apr 11, 1989
	EQ 250MG BASE/VIAL	A089578	001	Apr 11, 1989
	EQ 500MG BASE/VIAL	A089579	001	Apr 11, 1989
	EQ 1GM BASE/VIAL	A089580	001	Apr 11, 1989
HOSPIRA	EQ 100MG BASE/VIAL	A085929	001	
	EQ 250MG BASE/VIAL	A085930	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 185 (of 360)

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

HOSPIRA

EQ 500MG BASE/VIAL

A085931 001

EQ 1GM BASE/VIAL

A085932 001

HYDROCORTISONE SODIUM SUCCINATE

ABRAXIS PHARM

EQ 100MG BASE/VIAL

A088667 001 Jun 08, 1984

EQ 100MG BASE/VIAL

A088712 001 Jun 08, 1984

EQ 250MG BASE/VIAL

A088668 001 Jun 08, 1984

EQ 500MG BASE/VIAL

A088669 001 Jun 08, 1984

EQ 1GM BASE/VIAL

A088670 001 Jun 08, 1984

BAXTER HLTHCARE

EQ 100MG BASE/VIAL

A088619 001

EQ 250MG BASE/VIAL

A087567 001

EQ 500MG BASE/VIAL

A087568 001

EQ 1GM BASE/VIAL

A087569 001

INTL MEDICATION

EQ 100MG BASE/VIAL

A087532 001 Mar 19, 1982

WATSON LABS

EQ 100MG BASE/VIAL

A084737 002

EQ 100MG BASE/VIAL

A084738 001

EQ 250MG BASE/VIAL

A084737 001

EQ 500MG BASE/VIAL

A084747 001

EQ 1GM BASE/VIAL

A084748 001

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

TEVA PHARMS

0.2%

A074489 001 Aug 12, 1998

WESTCORT

RANBAXY

0.2%

N017950 001

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORT-DOME

BAYER PHARMS

0.5%;EQ 3.5MG BASE/GM

N050237 006 Jun 05, 1984

1%;EQ 3.5MG BASE/GM

N050237 005 Jun 05, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A062394 001 Sep 29, 1982

OTOCORT

WATSON LABS

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A060730 002

SUSPENSION/DROPS; OPHTHALMIC

CORTISPORIN

MONARCH PHARMS

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

N050169 001

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A062623 001 Sep 24, 1985

SUSPENSION/DROPS; OTIC

NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE

PHARMAFAIR

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A062617 001 Sep 18, 1985

OTICAIR

PHARMAFAIR

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A062399 001 Nov 18, 1982

OTOBIONE

SCHERING

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A061816 001

OTOCORT

WATSON LABS

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A062521 001 Jul 11, 1985

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

OTOBIOIC

SCHERING

5MG/ML;EQ 10,000 UNITS BASE/ML

A062302 001

PYOCIDIN

FOREST LABS

5MG/ML;EQ 10,000 UNITS BASE/ML

A061606 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 186 (of 360)

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC				
ACHROMYCIN				
LEDERLE	1.5%;1%	N050272	001	

HYDROCORTISONE; UREA

CREAM; TOPICAL				
ALPHADERM				
BIOGLAN	1%;10%	A086008	001	
CALMURID HC				
PHARMACIA AND UPJOHN	1%;10%	A083947	001	

HYDROFLUMETHIAZIDE

TABLET; ORAL				
DIUCARDIN				
WYETH AYERST	50MG	A083383	001	
HYDROFLUMETHIAZIDE				
PAR PHARM	50MG	A088850	001	May 31, 1985
WATSON LABS	50MG	A088031	001	Apr 06, 1983
	50MG	A088528	001	Aug 15, 1984

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL				
HYDROFLUMETHIAZIDE AND RESERPINE				
USL PHARMA	50MG;0.125MG	A088195	001	Oct 26, 1983
WATSON LABS	25MG;0.125MG	A088127	001	Mar 22, 1983
	50MG;0.125MG	A088110	001	Mar 22, 1983
RESERPINE AND HYDROFLUMETHIAZIDE				
IVAX PHARMS	50MG;0.125MG	A088932	001	Jan 11, 1985
PAR PHARM	50MG;0.125MG	A088907	001	Sep 20, 1985
SALUTENSIN				
SHIRE	50MG;0.125MG	N012359	003	
SALUTENSIN-DEMI				
SHIRE	25MG;0.125MG	N012359	004	

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL				
PALLADONE				
PURDUE PHARMA LP	12MG	N021044	001	Sep 24, 2004
	16MG	N021044	002	Sep 24, 2004
	24MG	N021044	003	Sep 24, 2004
	32MG	N021044	004	Sep 24, 2004
INJECTABLE; INJECTION				
HYDROMORPHONE HYDROCHLORIDE				
WATSON LABS	10MG/ML	A074317	001	Aug 23, 1995
TABLET; ORAL				
HYDROMORPHONE HYDROCHLORIDE				
NESHER PHARMS	2MG	A077311	001	Nov 09, 2005
	4MG	A077311	002	Nov 09, 2005
	8MG	A077311	003	Nov 09, 2005

HYDROXOCOBALAMIN

INJECTABLE; INJECTION				
ALPHAREDISOL				
MERCK	1MG/ML	A080778	001	
CYANOKIT				
MERCK SANTE SAS	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006
HYDROXOCOBALAMIN				
ABRAXIS PHARM	1MG/ML	A084921	001	
WATSON LABS	1MG/ML	A085528	001	
HYDROXOMIN				
BEL MAR	1MG/ML	A084629	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 187 (of 360)

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRIINE

PHARMICS

1%

N000004 004

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

SANDOZ

200MG

A040150 001 Jan 27, 1996

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

DELALUTIN

BRISTOL MYERS SQUIBB

125MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

N010347 004

125MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

N016911 001

250MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

N010347 002

250MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

N016911 002

HYDROXYPROGESTERONE CAPROATE

AKORN

125MG/ML

N018004 001

WATSON LABS

125MG/ML

N017439 001

250MG/ML

N017439 002

HYDROXYSTILBAMIDINE ISETHIONATE

INJECTABLE; INJECTION

HYDROXYSTILBAMIDINE ISETHIONATE

SANOFI AVENTIS US

225MG/AMP

N009166 001

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

BARR

250MG

A075143 002 Sep 21, 2000

DURAMED PHARMS BARR

250MG

A075020 002 Jun 26, 2000

500MG

A075020 001 Jul 30, 1998

ROXANE

500MG

A074476 001 Aug 18, 1995

TABLET; ORAL

HYDROXYUREA

BARR

1GM

A075734 001 Aug 29, 2000

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE

BAXTER HLTHCARE

50MG/ML

A085551 002

HYDROXYZINE HYDROCHLORIDE

ALTANA

25MG/ML

A087273 001 Apr 20, 1982

50MG/ML

A087273 002 Apr 20, 1982

BAXTER HLTHCARE

25MG/ML

A085551 001

FRESENIUS KABI USA

25MG/ML

A088184 001 Mar 31, 1983

50MG/ML

A088185 001 Mar 31, 1983

HOSPIRA

25MG/ML

A087416 001

50MG/ML

A086821 001

50MG/ML

A087546 001

PHARMAFAIR

25MG/ML

A088862 001 Feb 14, 1986

25MG/ML

A089106 001 Feb 14, 1986

DISCONTINUED DRUG PRODUCT LIST

6 - 188 (of 360)

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

PHARMAFAIR	50MG/ML	A088881	001	Feb 14, 1986
	50MG/ML	A089107	001	Feb 14, 1986
SMITH AND NEPHEW	25MG/ML	A087592	001	
SOLOPAK	25MG/ML	A086822	001	
	25MG/ML	A087591	001	
	50MG/ML	A087310	001	
	50MG/ML	A087593	001	
	50MG/ML	A087595	001	
	50MG/ML	A087596	001	
WATSON LABS	25MG/ML	A085778	001	
	25MG/ML	A087274	001	
	50MG/ML	A085779	001	
	50MG/ML	A087274	002	
WYETH AYERST	25MG/ML	A086258	001	
	50MG/ML	A086258	002	

ORGATRAX

ORGANON USA INC	25MG/ML	A087014	001	
	50MG/ML	A087014	002	

VISTARIL

PFIZER	25MG/ML	N011111	001	
	50MG/ML	N011111	002	

SYRUP; ORAL

ATARAX

ROERIG	10MG/5ML	N010485	001	

HYDROXYZINE HYDROCHLORIDE

ALPHARMA US PHARMS	10MG/5ML	A088785	001	Feb 03, 1988
KV PHARM	10MG/5ML	A087730	001	Jul 01, 1982
STI PHARMA LLC	10MG/5ML	A086880	001	

TABLET; ORAL

ATARAX

PFIZER	10MG	N010392	001	
	25MG	N010392	004	
	50MG	N010392	006	
	100MG	N010392	005	

HYDROXYZINE HYDROCHLORIDE

ABLE	10MG	A040559	001	Jul 22, 2004
	25MG	A040562	001	Jul 22, 2004
	50MG	A040563	001	Jul 22, 2004
ACTAVIS TOTOWA	10MG	A089071	001	Jul 22, 1986
	25MG	A089072	001	Jul 22, 1986
	50MG	A089073	001	Jul 22, 1986
HALSEY	10MG	A089366	001	May 02, 1988
	25MG	A089117	001	May 02, 1988
	50MG	A089396	001	May 02, 1988
IVAX PHARMS	10MG	A087216	001	
	25MG	A087410	001	
	50MG	A087411	001	
KV PHARM	10MG	A087819	001	Jun 23, 1982
	25MG	A087820	001	Jun 23, 1982
	50MG	A087821	001	Jun 23, 1982
	100MG	A087822	001	Jun 23, 1982
MIKAH PHARMA	10MG	A040600	001	Dec 28, 2004
	25MG	A040602	001	Dec 28, 2004
	50MG	A040604	001	Dec 28, 2004
MUTUAL PHARM	10MG	A088409	001	Nov 15, 1983
	25MG	A087857	001	Apr 18, 1983
	50MG	A087860	001	Apr 18, 1983
	100MG	A087862	001	Apr 18, 1983
PLIVA	100MG	A081054	001	Sep 25, 1995
PUREPAC PHARM	10MG	A088120	001	Sep 25, 1984
	25MG	A088121	001	Sep 25, 1984

DISCONTINUED DRUG PRODUCT LIST

6 - 189 (of 360)

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

PUREPAC PHARM	50MG	A088122	001	Sep 25, 1984
QUANTUM PHARMICS	10MG	A088540	001	Oct 22, 1985
	25MG	A088551	001	Oct 22, 1985
	50MG	A088529	001	Oct 22, 1985
SANDOZ	10MG	A087246	002	
	10MG	A087869	001	Dec 20, 1982
	25MG	A085247	001	
	25MG	A087870	001	Dec 20, 1982
	50MG	A087245	001	
	50MG	A087871	001	Dec 20, 1982
SUPERPHARM	10MG	A088794	001	Dec 05, 1984
	25MG	A088795	001	Dec 05, 1984
	50MG	A088796	001	Dec 05, 1984
USL PHARMA	10MG	A089121	001	Mar 20, 1986
	25MG	A089122	001	Mar 20, 1986
	50MG	A089123	001	Mar 20, 1986
VINTAGE	10MG	A087602	001	Jan 22, 1982
	25MG	A087603	001	Jan 22, 1982
	50MG	A087604	001	Jan 22, 1982
WATSON LABS	10MG	A086827	001	
	25MG	A086829	001	
	50MG	A086836	001	

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

DURAMED PHARMS BARR	EQ 25MG HCL	A088593	001	Feb 29, 1984
	EQ 50MG HCL	A088594	001	Feb 29, 1984
	EQ 100MG HCL	A088595	001	Feb 29, 1984
IVAX SUB TEVA PHARMS	EQ 25MG HCL	A087761	001	Mar 05, 1982
	EQ 50MG HCL	A087760	001	Mar 05, 1982
PAR PHARM	EQ 25MG HCL	A087656	001	Jun 11, 1982
	EQ 25MG HCL	A089145	001	Mar 17, 1986
	EQ 50MG HCL	A087657	001	Jun 11, 1982
	EQ 50MG HCL	A089146	001	Mar 17, 1986
	EQ 100MG HCL	A087658	001	Jun 11, 1982
SANDOZ	EQ 25MG HCL	A081127	001	Jun 28, 1991
	EQ 50MG HCL	A081128	001	Jun 28, 1991
	EQ 100MG HCL	A081129	001	Jun 28, 1991
SUPERPHARM	EQ 25MG HCL	A089031	001	Jan 02, 1987
	EQ 50MG HCL	A089032	001	Jan 02, 1987
	EQ 100MG HCL	A089033	001	Jan 02, 1987
VANGARD	EQ 25MG HCL	A088392	001	Sep 19, 1983
	EQ 50MG HCL	A088393	001	Sep 19, 1983
WATSON LABS	EQ 25MG HCL	A086698	001	
	EQ 25MG HCL	A086840	001	Jul 01, 1982
	EQ 50MG HCL	A086695	001	
	EQ 50MG HCL	A086705	001	Jul 01, 1982
	EQ 50MG HCL	A087767	001	Aug 16, 1982
	EQ 100MG HCL	A086697	001	
	EQ 100MG HCL	A086728	001	Oct 05, 1982
	EQ 100MG HCL	A087790	001	Aug 16, 1982
HY-PAM "25"				
TEVA	EQ 25MG HCL	A088713	001	Mar 04, 1985
VISTARIL				
PFIZER	EQ 100MG HCL	N011459	006	
SUSPENSION; ORAL				
VISTARIL				
PFIZER	EQ 25MG HCL/5ML	N011795	001	

DISCONTINUED DRUG PRODUCT LIST

6 - 190 (of 360)

IBANDRONATE SODIUM

TABLET; ORAL
BONIVA

HOFFMANN LA ROCHE

EQ 2.5MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

N021455 001 May 16, 2003

IBUPROFEN

CAPSULE; ORAL
MIDOL

BAYER

200MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

A070626 001 Sep 02, 1987

200MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

A071002 001 Sep 02, 1987

SUSPENSION; ORAL
CHILDREN'S ADVIL

WYETH CONS

100MG/5ML

N019833 002 Sep 19, 1989

IBU

ABBOTT

100MG/5ML

N019784 001 Dec 18, 1989

MOTRIN

MCNEIL CONSUMER

100MG/5ML

N019842 001 Sep 19, 1989

SUSPENSION/DROPS; ORAL

MOTRIN

MCNEIL

40MG/ML

N020476 001 May 25, 1995

TABLET; ORAL

ACHES-N-PAIN

LEDERLE

200MG

A071065 001 May 28, 1987

CAP-PROFEN

PERRIGO

200MG

A072097 001 Dec 08, 1987

IBU

BASF

400MG

A070083 001 Feb 22, 1985

400MG

N018197 001

600MG

A070088 001 Feb 08, 1985

600MG

A070099 001 Mar 29, 1985

800MG

A070745 001 Jul 23, 1986

IBUPRIN

PLIVA

200MG

A071773 001 Jul 16, 1987

IBUPROFEN

ABBOTT

600MG

A070556 001 Jun 14, 1985

800MG

A071264 001 Jul 25, 1986

CONTRACT PHARMACAL

200MG

A073691 001 Feb 25, 1994

HALSEY

200MG

A071027 001 Sep 29, 1987

300MG

A071028 001 Mar 23, 1987

400MG

A071029 001 Mar 23, 1987

600MG

A071030 001 Mar 23, 1987

800MG

A072137 001 Feb 05, 1988

IVAX SUB TEVA PHARMS

200MG

A071144 001 Jan 20, 1987

200MG

A071154 001 Oct 27, 1987

200MG

A072040 001 Apr 29, 1988

200MG

A072901 001 Dec 19, 1991

200MG

A072903 001 Dec 19, 1991

400MG

A071145 001 Sep 23, 1986

600MG

A071146 001 Sep 23, 1986

800MG

A071769 001 May 08, 1987

LEDERLE

400MG

A070629 001 Sep 19, 1986

600MG

A070630 001 Sep 19, 1986

LEINER

300MG

A071266 001 Oct 15, 1986

MCNEIL

400MG

A070081 001 Jun 16, 1986

600MG

A070476 001 Jun 16, 1986

MUTUAL PHARM

200MG

A070493 001 Dec 24, 1985

DISCONTINUED DRUG PRODUCT LIST

6 - 191 (of 360)

IBUPROFEN

TABLET; ORAL
IBUPROFEN

MUTUAL PHARM	200MG	A070908	001	Sep 26, 1986
	200MG	A071462	001	Oct 02, 1986
	400MG	A070079	001	Jul 24, 1985
	600MG	A070080	001	Jul 24, 1985
	800MG	A071448	001	Feb 18, 1987
MYLAN	200MG	A071870	001	May 05, 1988
	400MG	A070045	001	Sep 24, 1985
	600MG	A070057	001	Sep 24, 1985
	800MG	A071999	001	Dec 03, 1987
NORTHSTAR HLTHCARE	400MG	A078132	001	Sep 10, 2007
	600MG	A078132	002	Sep 10, 2007
	800MG	A078132	003	Sep 10, 2007
OHM LABS	400MG	A070818	001	Dec 26, 1985
PAR PHARM	200MG	A071575	001	May 08, 1987
	300MG	A070328	001	Aug 06, 1985
	400MG	A070329	001	Aug 06, 1985
	600MG	A070330	001	Aug 06, 1985
	800MG	A070986	001	Jul 25, 1986
PERRIGO	200MG	A072098	001	Dec 08, 1987
PLIVA	400MG	A071666	001	Jun 18, 1987
	600MG	A071667	001	Jun 18, 1987
	800MG	A071668	001	Jun 18, 1987
PUREPAC PHARM	200MG	A071122	001	Oct 03, 1986
	200MG	A071664	001	Feb 03, 1987
	300MG	A071123	001	Sep 19, 1986
	400MG	A071124	001	Sep 19, 1986
	600MG	A071125	001	Sep 19, 1986
SANDOZ	800MG	A071964	001	Feb 01, 1988
	200MG	A070733	001	Sep 19, 1986
	200MG	A071807	001	Feb 25, 1988
	200MG	A074525	001	Dec 15, 1995
	200MG	A074533	001	Dec 15, 1995
	300MG	A070734	001	Jun 12, 1986
	400MG	A070735	001	Jun 12, 1986
	400MG	A072064	001	Jan 14, 1988
	600MG	A070736	001	Jun 12, 1986
	600MG	A072065	001	Jan 14, 1988
	800MG	A071938	001	Jan 14, 1988
	800MG	A072169	001	Dec 11, 1987
	600MG	A070709	001	Apr 25, 1986
	200MG	A073141	001	May 29, 1992
	400MG	A073343	001	Jun 30, 1992
TEVA	600MG	A073344	001	Jun 30, 1992
	800MG	A073345	001	Jun 30, 1992
VINTAGE PHARMS	200MG	A072249	001	Jan 10, 1989
WATSON LABS	200MG	A071765	001	Sep 04, 1987
	200MG	A071905	001	Mar 08, 1988
	300MG	A071338	001	Dec 01, 1986
	400MG	A070038	001	Sep 06, 1985
	600MG	A070041	001	Sep 06, 1985
	800MG	A071547	001	Jul 02, 1987
	800MG	A071911	001	Oct 13, 1987
IBUPROHM				
OHM LABS	400MG	A070469	001	Aug 29, 1985
IBU-TAB				
ALRA	800MG	A071965	001	Aug 11, 1988
MEDIPREN				
MCNEIL	200MG	A070475	001	Feb 06, 1986
	200MG	A071215	001	Jun 26, 1986

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 192 (of 360)

IBUPROFENTABLET; ORAL
MIDOL

BAYER	200MG	A070591	001	Sep 02, 1987
	200MG	A071001	001	Sep 02, 1987

MOTRIN

MCNEIL CONSUMER	300MG	N017463	003	
	400MG	N017463	002	
	600MG	N017463	004	
	800MG	N017463	005	May 22, 1985
MCNEIL PED	100MG	N020418	001	Nov 16, 1994

NUPRIN

BRISTOL MYERS	200MG	A072035	001	Feb 16, 1988
	200MG	A072036	001	Feb 16, 1988
MCNEIL	200MG	N019012	001	May 18, 1984
	200MG	N019012	002	Jul 29, 1987

RUFEN

BASF	600MG	N018197	002	Mar 05, 1984

TABLET, CHEWABLE; ORAL
MOTRIN

MCNEIL PED	50MG	N020135	001	Nov 16, 1994
	100MG	N020135	002	Nov 16, 1994

IBUPROFEN; OXYCODONE HYDROCHLORIDETABLET; ORAL
COMBUNOX

FOREST LABS	400MG; 5MG	N021378	001	Nov 26, 2004

IDARUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
IDAMYCIN

PHARMACIA AND UPJOHN	5MG/VIAL	N050661	002	Sep 27, 1990
	10MG/VIAL	N050661	001	Sep 27, 1990
	20MG/VIAL	N050661	003	Apr 25, 1995

IDARUBICIN HYDROCHLORIDE

TEVA PARENTERAL	5MG/VIAL	A065037	003	May 01, 2002
	10MG/VIAL	A065037	002	May 01, 2002
	20MG/VIAL	A065037	001	May 01, 2002

IDOXURIDINEOINTMENT; OPHTHALMIC
STOXIL

GLAXOSMITHKLINE	0.5%	N015868	001	

SOLUTION/DROPS; OPHTHALMIC
STOXIL

GLAXOSMITHKLINE	0.1%	N013934	001	

IFOSFAMIDE; MESNAINJECTABLE; INJECTION
IFEX/MESNEX KIT

BAXTER HLTHCARE	1GM/VIAL; 100MG/ML	N019763	003	Oct 10, 1992
	3GM/VIAL; 100MG/ML	N019763	004	Oct 10, 1992

ILOPROSTSOLUTION; INHALATION
VENTAVIS

ACTELION PHARMS LTD	20MCG/2ML (10MCG/ML)	N021779	001	Dec 29, 2004

IMATINIB MESYLATECAPSULE; ORAL
GLEEVEC

NOVARTIS	EQ 50MG BASE	N021335	001	May 10, 2001
	EQ 100MG BASE	N021335	002	May 10, 2001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 193 (of 360)

IMIPRAMINE HYDROCHLORIDE

CONCENTRATE; ORAL

IMIPRAMINE HYDROCHLORIDE

NOVARTIS

25MG/ML

A086765 001

INJECTABLE; INJECTION

TOFRANIL

NOVARTIS

12.5MG/ML

N011838 002

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

LEDERLE

10MG

A086269 001

25MG

A086267 001

50MG

A086268 001

PAR PHARM

25MG

A089497 001

Jul 14, 1987

ROXANE

10MG

A083799 001

25MG

A083799 002

50MG

A083799 003

SANDOZ

10MG

A085200 001

25MG

A084869 002

50MG

A085133 001

TEVA

10MG

A083729 001

25MG

A083729 004

50MG

A083729 003

USL PHARMA

25MG

A087776 001

Feb 10, 1982

VANGARD

10MG

A088036 001

Nov 03, 1982

25MG

A087619 001

Feb 09, 1982

50MG

A087631 001

Jan 04, 1982

WATSON LABS

10MG

A085220 001

10MG

A085875 001

25MG

A084252 002

25MG

A085878 001

50MG

A085221 001

50MG

A085877 001

WEST WARD

25MG

A088222 001

May 26, 1983

50MG

A088223 001

May 26, 1983

JANIMINE

ABBOTT

10MG

N017895 001

25MG

N017895 002

50MG

N017895 003

PRAMINE

ALRA

10MG

A083827 001

25MG

A083827 002

50MG

A083827 003

PRESAMINE

SANOFI AVENTIS US

10MG

N011836 006

25MG

N011836 003

50MG

N011836 007

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

BAXTER HLTHCARE CORP

EQ 5MG BASE/ML

A075542 001

May 10, 2000

HOSPIRA

EQ 5MG BASE/ML

A074616 001

Aug 03, 1998

INOCOR

SANOFI AVENTIS US

EQ 5MG BASE/ML

N018700 001

Jul 31, 1984

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

CADISTA PHARMS

1.25MG

A075201 001

Dec 04, 1998

2.5MG

A075201 002

Dec 04, 1998

SANDOZ

1.25MG

A074594 001

May 23, 1996

2.5MG

A074594 002

May 23, 1996

TEVA

1.25MG

A074498 002

Feb 12, 1998

DISCONTINUED DRUG PRODUCT LIST

6 - 194 (of 360)

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE

TEVA	1.25MG	A074665	001	Apr 04, 1997
	2.5MG	A074498	001	Oct 31, 1996
	2.5MG	A074665	002	Apr 04, 1997

LOZOL

SANOFI AVENTIS US	1.25MG	N018538	002	Apr 29, 1993
	2.5MG	N018538	001	Jul 06, 1983

INDECAINIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
DECABID

LILLY	EQ 50MG BASE	N019693	001	Dec 29, 1989
	EQ 75MG BASE	N019693	002	Dec 29, 1989
	EQ 100MG BASE	N019693	003	Dec 29, 1989

INDINAVIR SULFATE

CAPSULE; ORAL
CRIXIVAN

MERCK SHARP DOHME	EQ 333MG BASE	N020685	005	Dec 17, 1998

INDOCYANINE GREEN

INJECTABLE; INJECTION
IC-GREEN

AKORN	10MG/VIAL	N011525	003	
	40MG/VIAL	N011525	004	
	50MG/VIAL	N011525	002	

INDOMETHACIN

CAPSULE; ORAL
INDOCIN

IROKO PHARMS	25MG	N016059	001	
	50MG	N016059	002	

INDO-LEMMON

TEVA	25MG	A070266	001	Nov 07, 1985
	50MG	A070267	001	Nov 07, 1985

INDOMETHACIN

ABLE	25MG	A076666	001	Dec 17, 2003
	50MG	A076666	002	Dec 17, 2003
DURAMED PHARMS BARR	25MG	A070326	001	Oct 18, 1985
	50MG	A070327	001	Oct 18, 1985
HALSEY	25MG	A070782	001	Jun 03, 1987
	50MG	A070635	001	Jun 03, 1987
IVAX SUB TEVA PHARMS	25MG	N018730	001	May 04, 1984
	50MG	N018730	002	May 04, 1984
MUTUAL PHARM	25MG	A070067	001	Oct 03, 1986
	25MG	A070899	001	Feb 09, 1987
	50MG	A070068	001	Oct 03, 1986
	50MG	A070900	001	Feb 09, 1987
MYLAN	50MG	N018858	002	Apr 20, 1984
PARKE DAVIS	25MG	N018806	001	Nov 23, 1984
	50MG	N018806	002	Nov 23, 1984
PIONEER PHARMS	25MG	A070813	001	Aug 11, 1986
	50MG	A070592	001	Aug 11, 1986
PLIVA	25MG	A071148	001	Mar 18, 1987
	50MG	A071149	001	Mar 18, 1987
ROXANE	25MG	A070353	001	Jun 18, 1985
	50MG	A070354	001	Jun 18, 1985
SUPERPHARM	25MG	A070487	001	Oct 10, 1986
	50MG	A070488	001	Oct 10, 1986
TEVA	25MG	A071342	001	Apr 18, 1988
	50MG	A071343	001	Apr 18, 1988

DISCONTINUED DRUG PRODUCT LIST

6 - 195 (of 360)

INDOMETHACIN

CAPSULE; ORAL					
INDOMETHACIN					
VINTAGE	25MG	N018829	002	Aug 06, 1984	
	50MG	A070651	001	Mar 05, 1986	
	50MG	N018829	001	Aug 06, 1984	
	25MG	A070529	001	Oct 18, 1985	
	25MG	A070784	001	Aug 20, 1986	
	25MG	A072996	001	Jul 31, 1991	
	25MG	N018690	001	Jul 31, 1984	
	50MG	A070530	001	Oct 18, 1985	
	50MG	A070785	001	Aug 20, 1986	
	50MG	A071635	001	May 18, 1987	
	50MG	A072997	001	Jul 31, 1991	
	50MG	N018690	002	Jul 31, 1984	
CAPSULE, EXTENDED RELEASE; ORAL					
INDOCIN SR					
IROKO PHARMS	75MG	N018185	001	Feb 23, 1982	
INDOMETHACIN					
ABLE	75MG	A076114	001	Feb 06, 2002	
INWOOD LABS	75MG	A072410	001	Mar 15, 1989	
SUPPOSITORY; RECTAL					
INDOCIN					
IROKO PHARMS	50MG	N017814	001	Aug 13, 1984	
SUSPENSION; ORAL					
INDOMETHACIN					
ROXANE	25MG/5ML	A071412	001	Mar 18, 1987	

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS					
NOVOLOG MIX 50/50					
NOVO NORDISK INC	50 UNITS/ML;50 UNITS/ML	N021810	001	Aug 26, 2008	
NOVOLOG MIX 70/30 PENFILL					
NOVO NORDISK INC	210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172	002	Nov 01, 2001	
	210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172	003	Nov 01, 2001	

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS					
NOVOLOG INNOLET					
NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	004	Apr 23, 2004	

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS					
LEVEMIR INNOLET					
NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	003	Jun 16, 2005	
LEVEMIR PENFILL					
NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	004	Jun 16, 2005	

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION					
HUMALOG MIX 50/50 PEN					
LILLY	50 UNITS/ML;50 UNITS/ML	N021018	003	Dec 22, 1999	
HUMALOG MIX 75/25 PEN					
LILLY	75 UNITS/ML;25 UNITS/ML	N021017	003	Dec 22, 1999	

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION					
HUMALOG PEN					
LILLY	100 UNITS/ML	N020563	002	Aug 06, 1998	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 196 (of 360)

INSULIN PORKINJECTABLE; INJECTION
Iletin I

LILLY 500 UNITS/ML N017931 001

INSULIN

NOVO NORDISK INC 40 UNITS/ML N017926 001

REGULAR INSULIN

NOVO NORDISK INC 100 UNITS/ML N017926 003

INSULIN PURIFIED BEEFINJECTABLE; INJECTION
REGULAR Iletin II

LILLY 100 UNITS/ML N018478 001

INSULIN PURIFIED PORKINJECTABLE; INJECTION
Iletin II

LILLY 500 UNITS/ML N018344 002

REGULAR Iletin II (PORK)

LILLY 100 UNITS/ML N018344 001

REGULAR PURIFIED PORK INSULIN

NOVO NORDISK INC 100 UNITS/ML N018381 001

VELOSULIN

NOVO NORDISK INC 100 UNITS/ML N018193 001

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORKINJECTABLE; INJECTION
INSULIN NORDISK MIXTARD (PORK)

NOVO NORDISK INC 30 UNITS/ML;70 UNITS/ML N018195 001

INSULIN RECOMBINANT HUMANINJECTABLE; INJECTION
HUMULIN BR

LILLY 100 UNITS/ML N019529 001 Apr 28, 1986

VELOSULIN BR

NOVO NORDISK INC 100 UNITS/ML N021028 001 Jul 19, 1999

POWDER; INHALATION

EXUBERA

PFIZER 1MG/INH N021868 001 Jan 27, 2006

3MG/INH N021868 002 Jan 27, 2006

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMANINJECTABLE; INJECTION
HUMULIN 50/50

LILLY 50 UNITS/ML;50 UNITS/ML N020100 001 Apr 29, 1992

INSULIN RECOMBINANT PURIFIED HUMANINJECTABLE; INJECTION
NOVOLIN R

NOVO NORDISK INC 100 UNITS/ML N018778 001 Aug 30, 1983

VELOSULIN BR HUMAN

NOVO NORDISK INC 100 UNITS/ML N019450 001 May 30, 1986

INSULIN RECOMBINANT PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMANINJECTABLE; INJECTION
MIXTARD HUMAN 70/30

BAYER PHARMS 30 UNITS/ML;70 UNITS/ML N019585 001 Mar 11, 1988

NOVOLIN 70/30

NOVO NORDISK INC 30 UNITS/ML;70 UNITS/ML N019441 001 Jul 11, 1986

DISCONTINUED DRUG PRODUCT LIST

6 - 197 (of 360)

INSULIN SUSP ISOPHANE BEEF

INJECTABLE; INJECTION
NPH INSULIN

NOVO NORDISK INC	40 UNITS/ML	N017929	001
	100 UNITS/ML	N017929	003

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE; INJECTION
NPH ILETIN I (BEEF-PORK)

LILLY	40 UNITS/ML	N017936	001
	100 UNITS/ML	N017936	002

INSULIN SUSP ISOPHANE PURIFIED BEEF

INJECTABLE; INJECTION
NPH ILETIN II

LILLY	100 UNITS/ML	N018479	001

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION
INSULIN INSULATARD NPH NORDISK

NOVO NORDISK INC	100 UNITS/ML	N018194	001

NPH ILETIN II (PORK)

LILLY	100 UNITS/ML	N018345	001

NPH PURIFIED PORK ISOPHANE INSULIN

NOVO NORDISK INC	100 UNITS/ML	N018623	001

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION
INSULATARD NPH HUMAN

NOVO NORDISK INC	100 UNITS/ML	N019449	001	May 30, 1986

NOVOLIN N

NOVO NORDISK INC	100 UNITS/ML	N019065	001	Jan 23, 1985

INSULIN SUSP PROTAMINE ZINC BEEF/PORK

INJECTABLE; INJECTION
PROTAMINE ZINC & ILETIN I (BEEF-PORK)

LILLY	40 UNITS/ML	N017932	001
	100 UNITS/ML	N017932	002

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION
PROTAMINE ZINC AND ILETIN II

LILLY	100 UNITS/ML	N018476	001

PROTAMINE ZINC INSULIN

BRISTOL MYERS SQUIBB	40 UNITS/ML	N017928	001

	100 UNITS/ML	N017928	003

INSULIN SUSP PROTAMINE ZINC PURIFIED PORK

INJECTABLE; INJECTION
PROTAMINE ZINC AND ILETIN II (PORK)

LILLY	100 UNITS/ML	N018346	001

INSULIN ZINC SUSP BEEF

INJECTABLE; INJECTION
LENTE INSULIN

NOVO NORDISK INC	40 UNITS/ML	N017998	001

	100 UNITS/ML	N017998	003

INSULIN ZINC SUSP EXTENDED BEEF

INJECTABLE; INJECTION
ULTRALENTE INSULIN

NOVO NORDISK INC	100 UNITS/ML	N017997	003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 198 (of 360)

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF

INJECTABLE; INJECTION			
ULTRALENTE			
NOVO NORDISK INC	100 UNITS/ML	N018385	001

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

INJECTABLE; INJECTION			
HUMULIN U			
LILLY	40 UNITS/ML	N019571	001 Jun 10, 1987
	100 UNITS/ML	N019571	002 Jun 10, 1987

INSULIN ZINC SUSP PROMPT BEEF

INJECTABLE; INJECTION			
SEMILENTE INSULIN			
NOVO NORDISK INC	100 UNITS/ML	N017996	003

INSULIN ZINC SUSP PROMPT PURIFIED PORK

INJECTABLE; INJECTION			
SEMILENTE			
NOVO NORDISK INC	100 UNITS/ML	N018382	001

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE; INJECTION			
LENTE ILETIN II			
LILLY	100 UNITS/ML	N018477	001

INSULIN ZINC SUSP PURIFIED BEEF/PORK

INJECTABLE; INJECTION			
LENTARD			
NOVO NORDISK INC	100 UNITS/ML	N018384	001

INSULIN ZINC SUSP PURIFIED PORK

INJECTABLE; INJECTION			
LENTE			
NOVO NORDISK INC	100 UNITS/ML	N018383	001
LENTE ILETIN II (PORK)			
LILLY	100 UNITS/ML	N018347	001

INSULIN ZINC SUSP RECOMBINANT HUMAN

INJECTABLE; INJECTION			
HUMULIN L			
LILLY	100 UNITS/ML	N019377	002 Sep 30, 1985
NOVOLIN L			
NOVO NORDISK INC	100 UNITS/ML	N019965	001 Jun 25, 1991

INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION			
NOVOLIN L			
NOVO NORDISK INC	100 UNITS/ML	N018777	001 Aug 30, 1983

INULIN

INJECTABLE; INJECTION			
INULIN AND SODIUM CHLORIDE			
ISO TEX	100MG/ML	N002282	001

INVERT SUGAR

INJECTABLE; INJECTION			
TRAVERT 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	10GM/100ML	N016717	001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 199 (of 360)

IOBENGUANE SULFATE I-131INJECTABLE; INJECTION
IOBENGUANE SULFATE I 131

PHARMALUCENCE 2.3mCi/ML

N020084 001 Mar 25, 1994

IOCETAMIC ACIDTABLET; ORAL
CHOLEBRINE

MALLINCKRODT 750MG

N017129 001

IODAMIDE MEGLUMINEINJECTABLE; INJECTION
RENOVUE-65

BRACCO 65%

N017902 001

RENOVUE-DIP

BRACCO 24%

N017903 001

IODIPAMIDE MEGLUMINEINJECTABLE; INJECTION
CHOLOGRAFIN MEGLUMINE

BRACCO 10.3%

N009321 007

IODIPAMIDE SODIUMINJECTABLE; INJECTION
CHOLOGRAFIN SODIUM

BRACCO 20%

N009321 001

IODOHIPPURATE SODIUM I-123INJECTABLE; INJECTION
NEPHROFLOW

GE HEALTHCARE 1mCi/ML

N018289 001 Dec 28, 1984

IODOHIPPURATE SODIUM I-131INJECTABLE; INJECTION
HIPURAN I 131

MALLINCKRODT 0.25mCi/ML

N016666 001

HIPPUTOPE

BRACCO 1-2mCi/VIAL

N015419 002

IODOHIPPURATE SODIUM I 131

PHARMALUCENCE 0.2mCi/ML

N017313 001

IODOXAMATE MEGLUMINEINJECTABLE; INJECTION
CHOLOVUE

BRACCO 9.9%

N018077 001

40.3%

N018076 001

IOFETAMINE HYDROCHLORIDE I-123INJECTABLE; INJECTION
SPECTAMINE

IMP 1mCi/ML

N019432 001 Dec 24, 1987

IOHEXOLINJECTABLE; INJECTION
OMNIPAQUE 210

GE HEALTHCARE 45.3%

N018956 006 Jun 30, 1989

SOLUTION; URETHRAL
OMNIPAQUE 70

GE HEALTHCARE 15.1%

N018956 007 Jun 01, 1994

DISCONTINUED DRUG PRODUCT LIST

6 - 200 (of 360)

IOPAMIDOL

INJECTABLE; INJECTION IOPAMIDOL

BAXTER HLTHCARE	41%	A074629	001	Nov 06, 1996
	51%	A074629	004	Mar 31, 1998
	61%	A074629	002	Nov 06, 1996
	76%	A074629	003	Nov 06, 1996
HOSPIRA	61%	A074734	001	Dec 10, 1996
	76%	A074734	002	Dec 10, 1996
IOPAMIDOL-200				
COOK IMAGING	41%	A074881	001	Jul 28, 2000
HOSPIRA	41%	A074898	001	Dec 30, 1997
IOPAMIDOL-200 IN PLASTIC CONTAINER				
HOSPIRA	41%	A074636	001	Dec 30, 1997
IOPAMIDOL-250				
COOK IMAGING	51%	A074881	002	Jul 28, 2000
HOSPIRA	51%	A074898	002	Dec 30, 1997
	51%	A075005	001	Feb 24, 1998
IOPAMIDOL-250 IN PLASTIC CONTAINER				
HOSPIRA	51%	A074636	002	Dec 30, 1997
IOPAMIDOL-300				
ABBVIE	61%	A074638	001	Apr 30, 1997
COOK IMAGING	61%	A074881	003	Jul 28, 2000
HOSPIRA	61%	A074898	003	Dec 30, 1997
	61%	A075005	002	Feb 24, 1998
IOPAMIDOL-300 IN PLASTIC CONTAINER				
HOSPIRA	61%	A074636	003	Dec 30, 1997
	61%	A074637	001	Apr 03, 1997
IOPAMIDOL-370				
COOK IMAGING	76%	A074881	004	Jul 28, 2000
HOSPIRA	76%	A074898	004	Dec 30, 1997
	76%	A075005	003	Feb 24, 1998
IOPAMIDOL-370 IN PLASTIC CONTAINER				
HOSPIRA	76%	A074636	004	Dec 30, 1997
ISOVUE-128				
BRACCO	26%	N018735	005	Oct 21, 1986
ISOVUE-200				
BRACCO	41%	N020327	001	Oct 12, 1994

IOPANOIC ACID

TABLET; ORAL TELEPAQUE

GE HEALTHCARE	500MG	N008032	001

IOPHENDYLATE

INJECTABLE; INJECTION PANTOPAQUE ALCON

100%	N005319	001

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION VASCORAY

MALLINCKRODT	52%;26%	N016783	001

IOTHALAMATE SODIUM

INJECTABLE; INJECTION ANGIO-CONRAY

MALLINCKRODT	80%	N013319	001
CONRAY 325			
MALLINCKRODT	54.3%	N017685	001
CONRAY 400			
MALLINCKRODT	66.8%	N014295	001

DISCONTINUED DRUG PRODUCT LIST

6 - 201 (of 360)

IOTROLAN

INJECTABLE; INTRATHECAL
OSMOVIST 190

BAYER HLTHCARE	40.6%	N019580	001	Dec 07, 1989

OSMOVIST 240

BAYER HLTHCARE	51.3%	N019580	002	Dec 07, 1989

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 160

MALLINCKRODT	34%	N019710	003	Dec 30, 1988

OPTIRAY 240

MALLINCKRODT	51%	N020923	001	May 28, 1998

OPTIRAY 320

MALLINCKRODT	68%	N020923	002	May 29, 1998

IPODATE CALCIUM

GRANULE; ORAL
ORAGRAFIN CALCIUM

BRACCO	3GM/PACKET	N012968	001	

IPODATE SODIUM

CAPSULE; ORAL

BILIVIST

BAYER HLTHCARE	500MG	A087768	001	Aug 11, 1982

ORAGRAFIN SODIUM

BRACCO	500MG	N012967	001	

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT

BOEHRINGER INGELHEIM	0.018MG/INH	N019085	001	Dec 29, 1986

SOLUTION; INHALATION

ATROVENT

BOEHRINGER INGELHEIM	0.02%	N020228	001	Sep 29, 1993

IPRATROPIUM BROMIDE

ACTAVIS MID ATLANTIC	0.02%	A075111	001	Apr 22, 1999

PHARMASCIENCE INC	0.02%	A075507	001	Jan 19, 2001

ROXANE	0.02%	A075867	001	Jul 22, 2002

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

SANDOZ	40MG/2ML (20MG/ML)	A077994	001	Feb 27, 2008

	100MG/5ML (20MG/ML)	A077994	002	Feb 27, 2008

IRON DEXTRAN

INJECTABLE; INJECTION

IRON DEXTRAN

SANOFI AVENTIS US	EQ 50MG IRON/ML	N010787	002	

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

LUITPOLD	EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)	N021135	003	Mar 29, 2005

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

BETA-2

NEPHRON	1%	A086711	001	

BRONKOSOL

SANOFI AVENTIS US	0.25%	N012339	009	

	1%	N012339	008	

DISCONTINUED DRUG PRODUCT LIST

6 - 202 (of 360)

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

ISOETHARINE HYDROCHLORIDE

ALPHARMA US PHARMS	1%	A087101	001	
ASTRAZENECA	0.062%	A087937	001	Nov 15, 1982
	0.062%	A089614	001	Jun 13, 1991
	0.125%	A087938	001	Nov 15, 1982
	0.125%	A089615	001	Jun 13, 1991
	0.167%	A088470	001	Mar 14, 1984
	0.167%	A089616	001	Jun 13, 1991
	0.2%	A088471	001	Mar 14, 1984
	0.2%	A089617	001	Jun 13, 1991
	0.25%	A088472	001	Mar 14, 1984
	0.25%	A089618	001	Jun 13, 1991
BAXTER HLTHCARE	0.08%	A088144	001	Jul 29, 1983
	0.14%	A088145	001	Mar 26, 1984
	0.25%	A088146	001	Aug 01, 1983
DEY	0.08%	A088187	001	Dec 03, 1982
	0.1%	A087389	001	
	0.17%	A087390	001	
	0.25%	A088188	001	Dec 03, 1982
	1%	A086763	001	
INTL MEDICATION	0.077%	A086651	001	
	0.08%	A086651	002	
	0.1%	A086651	003	
	0.143%	A086651	004	
	0.167%	A086651	005	
	0.2%	A086651	006	
	0.25%	A086651	007	
	1%	A086651	008	
PARKE DAVIS	0.5%	A085997	001	
	1%	A085889	001	
ROXANE	0.1%	A087396	001	
	0.125%	A087025	001	
	0.167%	A088226	001	Sep 16, 1983
	0.2%	A087324	001	
	0.25%	A088275	001	Jun 03, 1983
	1%	A086899	001	
ISOETHARINE HYDROCHLORIDE S/F				
DEY	0.08%	A089817	001	Nov 22, 1988
	0.1%	A089818	001	Nov 22, 1988
	0.17%	A089819	001	Nov 22, 1988
	0.25%	A089820	001	Nov 22, 1988
	1%	A089252	001	Sep 15, 1986

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION BRONKOMETER

SANOFI AVENTIS US	0.34MG/INH	N012339	007	
ISOETHARINE MESYLATE				
ALPHARMA US PHARMS	0.34MG/INH	A087858	001	Aug 21, 1984

ISOFLURANE

LIQUID; INHALATION ISOFLURANE

MARSAM PHARMS LLC	99.9%	A074393	001	May 12, 1995

ISOFLUROPHATE

OINTMENT; OPHTHALMIC FLOROPRYL

MERCK	0.025%	N010656	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 203 (of 360)

ISONIAZID

INJECTABLE; INJECTION

NYDRAZID

SANDOZ

100MG/ML

N008662 001

RIMIFON

ROCHE

25MG/ML

N008420 002

100MG/ML

N008420 003

SYRUP; ORAL

ISONIAZID

MIKART

50MG/5ML

A081118 001

Jul 21, 1997

LANIAZID

LANNETT

50MG/5ML

A089243 001

Feb 03, 1986

RIMIFON

ROCHE

50MG/5ML

N008420 001

TABLET; ORAL

DOW-ISONIAZID

DOW PHARM

300MG

A080330 002

HYZYD

MEDPOINTE PHARM HLC

100MG

A080134 003

300MG

A080134 004

INH

NOVARTIS

300MG

A080935 001

ISONIAZID

DURAMED PHARMS BARR

100MG

A088231 001

Mar 17, 1983

300MG

A088119 001

Mar 17, 1983

HALSEY

50MG

A083632 001

IMPAX LABS

100MG

A080153 001

IVAX SUB TEVA PHARMS

100MG

A080270 001

300MG

A083610 001

LILLY

100MG

N008499 002

300MG

N008499 003

MK LABS

100MG

A080941 001

MUTUAL PHARM

100MG

A080136 001

300MG

A083633 001

NEXGEN PHARMA INC

100MG

A084050 001

PANRAY

50MG

N008428 001

100MG

N008428 002

300MG

N008428 003

PERRIGO

100MG

A083060 001

PHARMAVITE

100MG

A085091 001

PHOENIX LABS NY

50MG

A080368 001

100MG

A080368 002

PUREPAC PHARM

50MG

A080132 003

Jul 14, 1982

100MG

A080132 004

Jul 14, 1982

WATSON LABS

50MG

A080522 001

100MG

A080401 001

100MG

A080523 001

100MG

A085790 001

300MG

A083178 001

300MG

A085784 001

WHITEWORTH TOWN PLSN

100MG

A080120 002

LANIAZID

LANNETT

50MG

A080140 001

100MG

A080140 002

300MG

A089776 001

Jun 13, 1988

NYDRAZID

BRISTOL MYERS SQUIBB

100MG

N008392 003

STANOZIDE

EVERYLIFE

100MG

A080126 001

300MG

A080126 002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 204 (of 360)

ISOPROPAMIDE IODIDETABLET; ORAL
DARBID

GLAXOSMITHKLINE EQ 5MG BASE N010744 001

ISOPROTERENOL HYDROCHLORIDEAEROSOL, METERED; INHALATION
ISOPROTERENOL HYDROCHLORIDE

3M 0.12MG/INH N010375 004

ALPHARMA US PHARMS 0.12MG/INH A085904 001

ISUPREL

SANOFI AVENTIS US 0.103MG/INH N011178 001

DISC; INHALATION

NORISODRINE AEROTROL

ABBOTT 0.25% N016814 001

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

ABRAXIS PHARM 0.2MG/ML A083431 001

BAXTER HLTHCARE 0.2MG/ML A083486 001

HOSPIRA 0.02MG/ML A083283 001

0.2MG/ML A083346 001

SOLUTION; INHALATION

AEROLONE

LILLY 0.25% N007245 001

ISOPROTERENOL HYDROCHLORIDE

ARMOUR PHARM 0.031% A087935 001 Nov 18, 1982

0.062% A087936 001 Nov 18, 1982

DEY 0.5% A086764 001 Jan 04, 1982

PARKE DAVIS 0.25% A085994 001

0.5% A085540 001

ISUPREL

SANOFI AVENTIS US 0.5% N006327 002

1% N006327 003

VAPO-ISO

FISONS 0.5% N016813 001

TABLET; RECTAL, SUBLINGUAL

ISUPREL

SANOFI AVENTIS US 10MG N006328 001

15MG N006328 002

ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

DUO-MEDIAHALER

3M 0.16MG/INH;0.24MG/INH N013296 001

ISOPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

MEDIAHALER-ISO

3M 0.08MG/INH N010375 003

POWDER; INHALATION

NORISODRINE

ABBVIE 10% N006905 003

25% N006905 002

ISOSORBIDE

SOLUTION; ORAL

ISMOTIC

ALCON 100GM/220ML N017063 001

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

ISORDIL

WYETH AYERST 40MG N012882 002 Jul 29, 1988

DISCONTINUED DRUG PRODUCT LIST

6 - 205 (of 360)

ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE

MUTUAL PHARM

5MG	A086166	002	Sep 19, 1986
10MG	A086169	001	Sep 19, 1986
20MG	A086167	001	Sep 19, 1986
30MG	A087564	001	Sep 18, 1986
5MG	A089190	001	Feb 17, 1987
10MG	A089191	001	Feb 17, 1987
20MG	A089192	001	Feb 17, 1987

SORBITRATE

ASTRAZENECA

5MG	N016192	001	Apr 01, 1996
10MG	N016192	002	Apr 01, 1996
20MG	A086405	002	Aug 21, 1990
30MG	A088124	001	Aug 21, 1990
40MG	A088125	001	Aug 21, 1990

TABLET; SUBLINGUAL

ISORDIL

BIOVAIL

2.5MG	N012940	004	Jul 29, 1988
5MG	N012940	003	Jul 29, 1988
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012940	005	Jul 29, 1988

ISOSORBIDE DINITRATE

MUTUAL PHARM

2.5MG	A084204	001	Sep 18, 1986
5MG	A086168	001	Sep 18, 1986
10MG	A087545	001	Sep 18, 1986
2.5MG	A086225	001	Feb 19, 1988
5MG	A086222	001	Feb 19, 1988

SANDOZ

SORBITRATE

ASTRAZENECA

2.5MG	N016191	002	Apr 01, 1996
5MG	N016191	001	Apr 01, 1996

TABLET, CHEWABLE; ORAL

SORBITRATE

ASTRAZENECA

5MG	N016776	002	Apr 01, 1996
10MG	N016776	003	Apr 01, 1996

TABLET, EXTENDED RELEASE; ORAL

ISORDIL

WYETH AYERST

40MG	N012882	001	Jul 29, 1988

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISMO

PROMIUS PHARMA

20MG	N019091	001	Dec 30, 1991

TABLET, EXTENDED RELEASE; ORAL

IMDUR

SCHERING PLOUGH

30MG	N020225	001	Aug 12, 1993
60MG	N020225	002	Aug 12, 1993
120MG	N020225	003	Mar 30, 1995

ISOSORBIDE MONONITRATE

ALKERMES GAINESVILLE

60MG	A075041	001	Sep 22, 1998

IVAX SUB TEVA PHARMS

30MG	A075448	002	Aug 07, 2001

60MG	A075448	001	Jun 19, 2000

120MG	A075448	003	Aug 07, 2001

SKYEPHARMA AG

60MG	A075166	001	Oct 07, 1999

ISOTRETINOIN

CAPSULE; ORAL

ACCUTANE

HOFFMANN LA ROCHE

10MG	N018662	002	May 07, 1982
20MG	N018662	004	Mar 28, 1983
40MG	N018662	003	May 07, 1982

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 206 (of 360)

ISRADIPINECAPSULE; ORAL
DYNACIRCSMITHKLINE BEECHAM 2.5MG
5MGN019546 001 Dec 20, 1990
N019546 002 Dec 20, 1990ITRACONAZOLEINJECTABLE; INJECTION
SPORANOX

JANSSEN PHARMS 10MG/ML

N020966 001 Mar 30, 1999

IVERMECTINTABLET; ORAL
STROMEKTOL

MERCK SHARP DOHME 6MG

N050742 001 Nov 22, 1996

KANAMYCIN SULFATECAPSULE; ORAL
KANTREXAPOTHECON EQ 500MG BASE
EQ 500MG BASE
EQ 500MG BASEA060516 001
A061911 001
A062726 001 Mar 06, 1987INJECTABLE; INJECTION
KANAMYCINHIKMA MAPLE EQ 75MG BASE/2ML
EQ 500MG BASE/2ML
EQ 1GM BASE/3MLA062324 001
A062324 002
A062324 003

KANAMYCIN SULFATE

ABRAXIS PHARM EQ 75MG BASE/2ML
EQ 500MG BASE/2ML
EQ 1GM BASE/3MLA062504 001 Apr 05, 1984
A062504 002 Apr 05, 1984
A062504 003 Apr 05, 1984INTL MEDICATION EQ 500MG BASE/2ML
EQ 1GM BASE/3MLA062466 001 Sep 30, 1983
A062466 002 Sep 30, 1983LOCH EQ 75MG BASE/2ML
EQ 500MG BASE/2ML
EQ 1GM BASE/3MLA063021 001 Jul 31, 1992
A063022 001 Jul 31, 1992
A063025 001 Jul 31, 1992PHARMAFAIR EQ 75MG BASE/2ML
EQ 500MG BASE/2ML
EQ 1GM BASE/3MLA062668 001 May 07, 1987
A062672 001 May 07, 1987
A062669 001 May 07, 1987SOLOPAK EQ 75MG BASE/2ML
EQ 500MG BASE/2ML
EQ 1GM BASE/3MLA062605 003 Feb 26, 1986
A062605 001 Feb 26, 1986
A062605 002 Feb 26, 1986WARNER CHILCOTT EQ 1GM BASE/3ML
WATSON LABS EQ 1GM BASE/3MLA063092 001 Oct 11, 1989
A062520 003 May 09, 1985

KANTREX

APOTHECON EQ 75MG BASE/2ML
EQ 75MG BASE/2ML
EQ 75MG BASE/2ML
EQ 500MG BASE/2ML
EQ 500MG BASE/2ML
EQ 500MG BASE/2ML
EQ 1GM BASE/3ML
EQ 1GM BASE/3ML
EQ 1GM BASE/3MLA061655 003
A061901 003
A062564 001 Sep 21, 1984
A061655 001
A061901 001
A062564 002 Sep 21, 1984
A061655 002
A061901 002
A062564 003 Sep 21, 1984

KLEBCIL

KING PHARMS EQ 75MG BASE/2ML
EQ 500MG BASE/2ML
EQ 1GM BASE/3MLA062170 001
A062170 002
A062170 003KETOCONAZOLECREAM; TOPICAL
NIZORAL

JANSSEN PHARMA 2%

N019084 001 Dec 31, 1985

DISCONTINUED DRUG PRODUCT LIST

6 - 207 (of 360)

KETOCONAZOLE

SUSPENSION; ORAL
NIZORAL

JANSSEN PHARMA	100MG/5ML	A070767	001	Nov 07, 1986

TABLET; ORAL
KETOCONAZOLE

AAIPHARMA LLC	200MG	A075341	001	Jul 27, 1999
TEVA	200MG	A074971	001	Jun 15, 1999

KETOPROFEN

CAPSULE; ORAL
KETOPROFEN

SANDOZ	50MG	A074024	001	Dec 29, 1995
	75MG	A074024	002	Dec 29, 1995
TEVA	25MG	A073515	001	Dec 22, 1992

ORUDIS

WYETH AYERST	25MG	N018754	001	Jul 31, 1987
	50MG	N018754	002	Jan 09, 1986
	75MG	N018754	003	Jan 09, 1986

CAPSULE, EXTENDED RELEASE; ORAL
KETOPROFEN

ALKERMES GAINESVILLE	200MG	A074879	001	Dec 10, 1997
ORUVAIL				
WYETH PHARMS INC	100MG	N019816	003	Feb 08, 1995
	150MG	N019816	002	Feb 08, 1995
	200MG	N019816	001	Sep 24, 1993

TABLET; ORAL

ACTRON

BAYER	12.5MG	N020499	001	Oct 06, 1995

KETOPROFEN

PERRIGO	12.5MG	A075364	001	Feb 07, 2002

ORUDIS KT

WYETH CONS	12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020429	001	Oct 06, 1995

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

AMPHASTAR PHARM	15MG/ML	A076209	001	Jul 21, 2004
	30MG/ML	A076209	002	Jul 21, 2004
APOTEX INC	30MG/ML	A075626	001	Jul 24, 2001
	30MG/ML	A077201	001	Oct 14, 2005
APOTHECON	15MG/ML	A075348	001	Nov 28, 2000
	30MG/ML	A075348	002	Nov 28, 2000
BEDFORD	15MG/ML	A075230	002	Oct 25, 1999
	30MG/ML	A075230	001	Oct 25, 1999
GLAND PHARMA LTD	15MG/ML	A076722	001	Jul 27, 2004
	30MG/ML	A076722	002	Jul 27, 2004
HOSPIRA	15MG/ML	A074801	001	Jun 05, 1997
	30MG/ML	A074801	002	Jun 05, 1997

TORADOL

ROCHE PALO	15MG/ML	N019698	001	Nov 30, 1989
	30MG/ML	N019698	002	Nov 30, 1989

TABLET; ORAL

KETOROLAC TROMETHAMINE

ROXANE	10MG	A074790	001	Jun 26, 1997
WATSON LABS	10MG	A074955	001	Sep 19, 1997

TORADOL

ROCHE PALO	10MG	N019645	001	Dec 20, 1991

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 208 (of 360)

KRYPTON, KR-81M

GAS; INHALATION

MPI KRYPTON 81M GENERATOR

GE HEALTHCARE

N/A

N018088 001

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

APOTHECON

5MG/ML

A075355 001 Nov 29, 1999

HOSPIRA

5MG/ML

A075242 001 Sep 30, 1999

NORMODYNE

SCHERING

5MG/ML

N018686 001 Aug 01, 1984

TRANDATE

PROMETHEUS LABS

5MG/ML

N019425 001 Dec 31, 1985

TABLET; ORAL

LABETALOL HYDROCHLORIDE

APOTHECON

100MG

A075223 001 Nov 20, 1998

200MG

A075223 002 Nov 20, 1998

300MG

A075223 003 Nov 20, 1998

MUTUAL PHARM

100MG

A075215 001 Jul 29, 1999

200MG

A075215 002 Jul 29, 1999

300MG

A075215 003 Jul 29, 1999

TEVA

100MG

A074989 001 Sep 30, 1998

200MG

A074989 002 Sep 30, 1998

300MG

A074989 003 Sep 30, 1998

NORMODYNE

SCHERING

100MG

N018687 001 Aug 31, 1987

200MG

N018687 002 Aug 01, 1984

300MG

N018687 003 Aug 01, 1984

400MG

N018687 004 Aug 01, 1984

TRANDATE

PROMETHEUS LABS

300MG

N018716 003 Aug 01, 1984

400MG

N018716 004 Aug 01, 1984

LACTULOSE

SOLUTION; ORAL

CHRONULAC

SANOFI AVENTIS US

10GM/15ML

N017884 001

DUPHALAC

SOLVAY

10GM/15ML

A072372 001 Mar 22, 1989

EVALOSE

TEVA PHARMS

10GM/15ML

A073497 001 May 28, 1993

LACTULOSE

MORTON GROVE

10GM/15ML

A071841 001 Sep 22, 1988

PACO

10GM/15ML

A073160 001 Aug 25, 1992

LAXILOSE

NOSTRUM LABS

10GM/15ML

A073686 001 May 28, 1993

SOLUTION; ORAL, RECTAL

ACILAC

NOSTRUM LABS

10GM/15ML

A073685 001 May 28, 1993

CEPHULAC

SANOFI AVENTIS US

10GM/15ML

N017657 001

GENERLAC

MORTON GROVE

10GM/15ML

A071842 001 Sep 27, 1988

HEPTALAC

TEVA PHARMS

10GM/15ML

A073504 001 May 28, 1993

LACTULOSE

PACO

10GM/15ML

A072029 001 Aug 25, 1992

ROXANE

10GM/15ML

A073590 001 May 29, 1992

SOLVAY

10GM/15ML

N017906 001

PORTALAC

SOLVAY

10GM/15ML

A072374 001 Mar 22, 1989

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 209 (of 360)

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

GLAXOSMITHKLINE

50MG

N020241

006

Dec 27, 1994

250MG

N020241

004

Dec 27, 1994

LAMOTRIGINE

MATRIX LABS LTD

25MG

A078443

001

Feb 11, 2009

100MG

A078443

002

Feb 11, 2009

150MG

A078443

003

Feb 11, 2009

200MG

A078443

004

Feb 11, 2009

MYLAN

25MG

A077428

001

Jan 27, 2009

100MG

A077428

002

Jan 27, 2009

150MG

A077428

003

Jan 27, 2009

200MG

A077428

004

Jan 27, 2009

ROXANE

25MG

A077392

001

Jan 27, 2009

100MG

A077392

002

Jan 27, 2009

150MG

A077392

003

Jan 27, 2009

200MG

A077392

004

Jan 27, 2009

WOCKHARDT

25MG

A078982

001

Jan 27, 2009

100MG

A078982

002

Jan 27, 2009

150MG

A078982

003

Jan 27, 2009

200MG

A078982

004

Jan 27, 2009

TABLET, CHEWABLE; ORAL

LAMICTAL CD

GLAXOSMITHKLINE

100MG

N020764

003

Aug 24, 1998

LAMOTRIGINE

SANDOZ

5MG

A078409

002

Jan 22, 2009

25MG

A078409

003

Jan 22, 2009

LANSOPRAZOLE

FOR SUSPENSION, DELAYED RELEASE; ORAL

PREVACID

TAKEDA PHARMS NA

15MG/PACKET

N021281

001

May 03, 2001

30MG/PACKET

N021281

002

May 03, 2001

INJECTABLE; INTRAVENOUS

PREVACID IV

TAKEDA PHARMS NA

30MG/VIAL

N021566

001

May 27, 2004

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

LANSOPRAZOLE

TEVA PHARMS

15MG

A078730

001

Oct 15, 2010

30MG

A078730

002

Oct 15, 2010

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

PREVACID NAPRAPAC 250 (COPACKAGED)

TAKEDA PHARMS NA

15MG,N/A;N/A,250MG **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

N021507

002

Nov 14, 2003

PREVACID NAPRAPAC 375 (COPACKAGED)

TAKEDA PHARMS NA

15MG,N/A;N/A,375MG

N021507

003

Nov 14, 2003

PREVACID NAPRAPAC 500 (COPACKAGED)

TAKEDA PHARMS NA

15MG,N/A;N/A,500MG

N021507

004

Nov 14, 2003

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

SHIRE LLC

EQ 250MG BASE

N021468

001

Oct 26, 2004

LAPYRIUM CHLORIDE; UNDECOYLIUM CHLORIDE IODINE COMPLEX

SOLUTION; TOPICAL

VIRAC REX

CHESEBROUGH PONDS

0.5%;1.8%

N011914

001

DISCONTINUED DRUG PRODUCT LIST

6 - 210 (of 360)

LEFLUNOMIDE

TABLET; ORAL
LEFLUNOMIDE

SANDOZ	10MG	A077085	001	Sep 13, 2005
	20MG	A077085	002	Sep 13, 2005

LETROZOLE

TABLET; ORAL
LETROZOLE

SYNTHON PHARMS	2.5MG	A090196	001	Jun 03, 2011

LEUCOVORIN CALCIUM

FOR SOLUTION; ORAL
LEUCOVORIN CALCIUM

HOSPIRA	EQ 60MG BASE/VIAL	N008107	003	Jan 30, 1987

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

ABIC	EQ 3MG BASE/ML	A089352	001	Jun 01, 1988
	EQ 50MG BASE/VIAL	A089353	001	Jun 01, 1988
ABRAXIS PHARM	EQ 50MG BASE/VIAL	A088939	001	Dec 01, 1986
ELKINS SINN	EQ 50MG BASE/VIAL	A070480	001	Jan 02, 1987
	EQ 100MG BASE/VIAL	A081224	001	Jun 03, 1994
HOSPIRA	EQ 3MG BASE/ML	N008107	001	
	EQ 50MG BASE/VIAL	N008107	002	
	EQ 100MG BASE/VIAL	N008107	004	May 23, 1988
	EQ 350MG BASE/VIAL	N008107	005	Apr 05, 1989
PHARMACHEMIE	EQ 350MG BASE/VIAL	A040262	001	Dec 15, 1999
PHARMACHEMIE USA	EQ 50MG BASE/VIAL	A089628	001	Apr 17, 1997
	EQ 100MG BASE/VIAL	A089915	001	Apr 17, 1997
TEVA PARENTERAL	EQ 50MG BASE/VIAL	A081278	001	Sep 28, 1993

LEUCOVORIN CALCIUM PRESERVATIVE FREE

HOSPIRA	EQ 10MG BASE/ML	A040147	001	Jun 25, 1997
TEVA PARENTERAL	EQ 10MG BASE/ML	A040332	001	Jun 28, 1999

WELLCOVORIN

GLAXOSMITHKLINE	EQ 5MG BASE/ML	A087439	001	Oct 19, 1982
	EQ 25MG BASE/VIAL	A089833	001	Jan 23, 1989
	EQ 50MG BASE/VIAL	A089465	001	Jan 23, 1989
	EQ 100MG BASE/VIAL	A089834	001	Jan 23, 1989

TABLET; ORAL

LEUCOVORIN CALCIUM

COREPHARMA	EQ 5MG BASE	A074544	001	Aug 28, 1997
	EQ 25MG BASE	A074544	002	Aug 28, 1997
PAR PHARM	EQ 5MG BASE	A071600	001	Oct 14, 1987
	EQ 25MG BASE	A071598	001	Oct 14, 1987
PHARMACHEMIE	EQ 5MG BASE	A073099	001	Mar 28, 1997
	EQ 25MG BASE	A073101	001	Mar 28, 1997
SANDOZ	EQ 15MG BASE	A075327	001	Mar 24, 1999
XANODYNE PHARM	EQ 5MG BASE	N018459	001	Jan 30, 1986
	EQ 10MG BASE	A071962	001	Nov 19, 1987
	EQ 15MG BASE	A071104	001	Mar 04, 1987

WELLCOVORIN

GLAXOSMITHKLINE	EQ 5MG BASE	N018342	001	Jul 08, 1983
	EQ 25MG BASE	N018342	002	Jul 08, 1983

LEUPROLIDE ACETATE

IMPLANT; IMPLANTATION
VIADUR

ORTHO MCNEIL JANSSEN	EQ 65MG BASE	N021088	001	Mar 03, 2000

INJECTABLE; INJECTION
LEUPROLIDE ACETATE

GENZYME	1MG/0.2ML	A075721	001	Nov 29, 2001

LUPRON

ABBOTT LABS	1MG/0.2ML	N019010	001	Apr 09, 1985

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 211 (of 360)

LEUPROLIDE ACETATEINJECTABLE; INJECTION
LUPRON DEPOT-PED

ABBOTT ENDOCRINE

3.75MG/VIAL, 7.5MG/VIAL
7.5MG/VIAL, 7.5MG/VIALN020263 003 Apr 16, 1993
N020263 004 Apr 16, 1993LEVALLORPHAN TARTRATEINJECTABLE; INJECTION
LORFAN

ROCHE

1MG/ML

N010423 001

LEVAMISOLE HYDROCHLORIDETABLET; ORAL
ERGAMISOL

JANSSEN PHARMA

EQ 50MG BASE

N020035 001 Jun 18, 1990

LEVETIRACETAMTABLET; ORAL
LEVETIRACETAM

MYLAN

250MG
500MG
750MG
1GM
250MG
500MG
750MGA078731 001 Feb 10, 2009
A078731 002 Feb 10, 2009
A078731 003 Feb 10, 2009
A078731 004 Feb 10, 2009
A077408 001 Mar 02, 2009
A077408 002 Mar 02, 2009
A077408 003 Mar 02, 2009

WATSON LABS FLORIDA

LEVOBETAXOLOL HYDROCHLORIDESUSPENSION/DROPS; OPHTHALMIC
BETAXON

ALCON PHARMS LTD

EQ 0.5% BASE

N021114 001 Feb 23, 2000

LEVOBUPIVACAINE HYDROCHLORIDEINJECTABLE; INJECTION
CHIROCAINE

PURDUE PHARMA LP

EQ 2.5MG BASE/ML
EQ 5MG BASE/ML
EQ 7.5MG BASE/MLN020997 001 Aug 05, 1999
N020997 002 Aug 05, 1999
N020997 003 Aug 05, 1999LEVOCABASTINE HYDROCHLORIDESUSPENSION/DROPS; OPHTHALMIC
LIVOSTIN

NOVARTIS

EQ 0.05% BASE

N020219 001 Nov 10, 1993

LEVOCARNITINESOLUTION; ORAL
CARNITOR

SIGMA TAU

1GM/10ML

N018948 002 Apr 27, 1988

LEVODOPACAPSULE; ORAL
BENDOPA

VALEANT PHARM INTL

100MG
250MG
500MGN016948 003
N016948 001
N016948 002

DOPAR

SHIRE

100MG
250MG
500MGN016913 003
N016913 001
N016913 002

LARODOPA

ROCHE

100MG
250MG
500MGN016912 002
N016912 001
N016912 006

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 212 (of 360)

LEVODOPATABLET; ORAL
DOPAR

SHIRE	250MG	N016913	004
	500MG	N016913	005

LARODOPA

ROCHE	100MG	N016912	005
	250MG	N016912	003
	500MG	N016912	004

LEVOLEUCOVORIN CALCIUM

SOLUTION; IV (INFUSION)

FUSILEV

SPECTRUM PHARMS	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 29, 2011

LEVOMEPRMAZINE

INJECTABLE; INJECTION

LEVOPROME

IMMUNEX	20MG/ML	N015865	001

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL

ORLAAM

ROXANE	10MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020315	001	Jul 09, 1993

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

SOLVAY	0.05MG/ML;2%	A085010	001

CARBOCAINE W/ NEO-COBEFRIN

EASTMAN KODAK	0.05MG/ML;2%	N012125	002

MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFIN

GRAHAM CHEM	0.05MG/ML;2%	A084850	002	Oct 21, 1983

POLOCAINE W/ LEVONORDEFIN

DENTSPLY PHARM	0.05MG/ML;2%	A089517	001	Apr 14, 1988

LEVONORDEFIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN

EASTMAN KODAK	0.05MG/ML;2%;0.4%	N008592	007

LEVONORGESTREL

IMPLANT; IMPLANTATION

LEVONORGESTREL

WYETH PHARMS INC	75MG/IMPLANT	N020627	001	Aug 15, 1996

NORPLANT

POPULATION COUNCIL	36MG/IMPLANT	N019897	001	Dec 10, 1990

NORPLANT II

POPULATION COUNCIL	75MG/IMPLANT	N020544	001	Nov 01, 1996

NORPLANT SYSTEM IN PLASTIC CONTAINER

WYETH PHARMS INC	36MG/IMPLANT	N020088	001	Dec 10, 1990

TABLET; ORAL

PLAN B

TEVA BRANDED PHARM	0.75MG	N021045	001	Jul 28, 1999

LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS

CAPSULE; ORAL

NOVRAD

LILLY	EQ 50MG BASE	N012928	006
	EQ 100MG BASE	N012928	004

DISCONTINUED DRUG PRODUCT LIST

6 - 213 (of 360)

LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS

SUSPENSION; ORAL
NOVRAD

LILLY

EQ 50MG BASE/5ML

N012928 002

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION
LEVO-DROMORAN

VALEANT PHARM INTL

2MG/ML

N008719 001 Dec 19, 1991

TABLET; ORAL
LEVO-DROMORAN

VALEANT PHARM INTL

2MG

N008720 001 Dec 19, 1991

LEVOTHYROXINE SODIUM**

TABLET; ORAL
LEVOLET

VINTAGE

0.025MG

N021137 001 Jun 06, 2003

0.05MG

N021137 002 Jun 06, 2003

0.075MG

N021137 003 Jun 06, 2003

0.088MG

N021137 004 Jun 06, 2003

0.1MG

N021137 005 Jun 06, 2003

0.112MG

N021137 006 Jun 06, 2003

0.125MG

N021137 007 Jun 06, 2003

0.137MG

N021137 008 Jun 06, 2003

0.15MG

N021137 009 Jun 06, 2003

0.175MG

N021137 010 Jun 06, 2003

0.2MG

N021137 011 Jun 06, 2003

0.3MG

N021137 012 Jun 06, 2003

LEVOXYL

--> KING PHARMS

--> 0.3MG

N021301 012 May 25, 2001

NOVOTHYROX

MERCK KGAA

0.025MG

N021292 001 May 31, 2002

0.05MG

N021292 002 May 31, 2002

0.075MG

N021292 003 May 31, 2002

0.088MG

N021292 004 May 31, 2002

0.1MG

N021292 005 May 31, 2002

0.112MG

N021292 006 May 31, 2002

0.125MG

N021292 007 May 31, 2002

0.137MG

N021292 008 May 31, 2002

0.15MG

N021292 009 May 31, 2002

0.175MG

N021292 010 May 31, 2002

0.2MG

N021292 011 May 31, 2002

0.3MG

N021292 012 May 31, 2002

LIDOCAINE

AEROSOL; ORAL
XYLOCAINE

ASTRAZENECA

10%

N014394 001

FILM, EXTENDED RELEASE; BUCCAL

DENTIPATCH

NOVEN

23MG/PATCH

N020575 001 May 21, 1996

OINTMENT; TOPICAL

ALPHACAINE

CARLISLE

5%

A084944 001

5%

A084946 001

5%

A084947 001

LIDOCAINE

GRAHAM CHEM

5%

A080210 001

XYLOCAINE

ASTRAZENECA

5%

N008048 001

PATCH; TOPICAL

DENTIPATCH

NOVEN

46.1MG/PATCH

N020575 002 May 21, 1996

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 214 (of 360)

LIDOCAINESOLUTION; TOPICAL
XYLOCAINE

ASTRAZENECA 5%

N014127 001

SUPPOSITORY; RECTAL
XYLOCAINE

ASTRAZENECA 100MG

N013077 001

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HYDROCHLORIDE

CARLISLE 2%

A084721 001

LIDOCAINE HYDROCHLORIDE

ABBOTT 10%

A087980 001

Feb 02, 1983

20%

A089362 001

May 25, 1988

ABRAXIS PHARM

1%

A080420 001

1%

A086761 001

1.5%

A080420 005

2%

A080420 002

2%

A080420 004

2%

A086761 002

2%

N017508 001

4%

N017508 002

20%

N017508 004

AKORN

1%

A085037 001

2%

A085037 002

BEL MAR

1%

A080710 001

2%

A080760 001

DELL LABS

1%

A083387 001

2%

A083388 001

ELKINS SINN

0.5%

A085131 001

4%

A084626 001

GD SEARLE LLC

1%

A083135 001

2%

A083135 002

GRAHAM CHEM

2%

A080504 001

HIKMA MAPLE

1%

A080407 001

2%

A080407 002

HOSPIRA

1%

A040013 001

Jun 23, 1995

1.5%

A088330 001

May 17, 1984

2%

A088331 001

May 17, 1984

INTL MEDICATION

1%

A083173 001

1%

N017701 002

2%

A083173 002

2%

N017701 001

1GM/VIAL

N018543 001

2GM/VIAL

N018543 002

LYPHOMED

1%

A080390 001

2%

A080390 002

MILES

1%

A080414 001

2%

A080414 002

WATSON LABS

1%

A080377 001

1%

A083627 001

2%

A080377 002

2%

A083627 002

WYETH AYERST

1%

A083083 001

2%

A083083 002

LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE

100MG/100ML

N018461 001

LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN

200MG/100ML

N018967 001

Mar 30, 1984

LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%

HOSPIRA

200MG/100ML

A083158 005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 215 (of 360)

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT 200MG/100ML

N018954 001 Jul 09, 1985

HOSPIRA 200MG/100ML

N018388 001

LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 400MG/100ML

N018967 002 Mar 30, 1984

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5%

HOSPIRA 400MG/100ML

A083158 006

LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 800MG/100ML

N018967 003 Mar 30, 1984

LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER

HOSPIRA 1.5%

A088326 001 Jul 31, 1984

10%

A088367 001 Jul 31, 1984

20%

A088368 001 Jul 31, 1984

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

HIKMA MAPLE 1%

A084625 001

2%

A084625 002

INTL MEDICATION 4%

N017702 002

LIDOCATON

PHARMATON 2%

A084727 001 Aug 17, 1983

XYLOCAINE

ASTRAZENECA 1%

N010418 005

1.5%

N010418 009

2%

N010418 007

XYLOCAINE DENTAL

DENTSPLY PHARM 2%

N021380 001

INJECTABLE; SPINAL

XYLOCAINE 1.5% W/ DEXTROSE 7.5%

FRESENIUS KABI USA 1.5%

N016297 001

XYLOCAINE 5% W/ GLUCOSE 7.5%

ASTRAZENECA 5%

N010496 002 Jul 07, 1982

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

ACTAVIS MID ATLANTIC 2%

A086578 001

INTL MEDICATION 2%

A086389 001 Feb 02, 1982

SOLUTION; TOPICAL

LARYNGOTRACHEAL ANESTHESIA KIT

KENDALL IL 4%

A087931 001 Jun 10, 1983

LIDOCAINE HYDROCHLORIDE

PACO 4%

A089688 001 Jun 30, 1989

LTA II KIT

HOSPIRA 4%

A088542 001 Jul 31, 1984

PEDIATRIC LTA KIT

ABBOTT 2%

A088572 001 Jul 31, 1984

HOSPIRA 2%

A085995 001

SYSTEM; INTRADERMAL

ZINGO

POWDER PHARMS 0.5MG

N022114 001 Aug 16, 2007

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE; INJECTION

TERRAMYCIN

PFIZER 2%; 50MG/ML

A060567 001

2%; 125MG/ML

A060567 002

LIDOCAINE; PRILOCAINE

DISC; TOPICAL

EMLA

ASTRAZENECA 2.5%; 2.5%

N020962 001 Feb 04, 1998

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 216 (of 360)

LINCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

LINCOCIN

PHARMACIA AND UPJOHN EQ 250MG BASE

N050316 001

EQ 500MG BASE

N050316 002

INJECTABLE; INJECTION

LINCOMYCIN HYDROCHLORIDE

WATSON LABS EQ 300MG BASE/ML

A063180 001 Apr 16, 1991

LINDANE

CREAM; TOPICAL

K WELL

REED AND CARNRICK 1%

A084218 001

1%

N006309 001

LOTION; TOPICAL

GAMENE

SOLA BARNES HIND 1%

A084989 001

K WELL

REED AND CARNRICK 1%

A084218 002

1%

N006309 003

SCABENE

STIEFEL 1%

A086769 001

SHAMPOO; TOPICAL

GAMENE

SOLA BARNES HIND 1%

A084988 001

K WELL

REED AND CARNRICK 1%

A084219 001

1%

N010718 001

SCABENE

STIEFEL 1%

A087940 001 Apr 08, 1983

LINEZOLID

TABLET; ORAL

ZYVOX

PHARMACIA AND UPJOHN 400MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021130 001 Apr 18, 2000

LIOTHYRONINE SODIUM

TABLET; ORAL

LIOTHYRONINE SODIUM

WATSON LABS EQ 0.025MG BASE

A085755 001 Jan 25, 1982

EQ 0.05MG BASE

A085753 001 Feb 03, 1982

LIOTRIX (T4;T3)

TABLET; ORAL

EUTHROID-0.5

PARKE DAVIS 0.03MG;0.0075MG

N016680 001

EUTHROID-1

PARKE DAVIS 0.06MG;0.015MG

N016680 002

EUTHROID-2

PARKE DAVIS 0.12MG;0.03MG

N016680 003

EUTHROID-3

PARKE DAVIS 0.18MG;0.045MG

N016680 004

THYROLAR-5

FOREST LABS 0.25MG;0.0625MG

N016807 006

LISINAPRIL

TABLET; ORAL

LISINAPRIL

LEK PHARMS 2.5MG

A075999 001 Jul 01, 2002

5MG

A075999 002 Jul 01, 2002

10MG

A075999 003 Jul 01, 2002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 217 (of 360)

LISINOPRILTABLET; ORAL
LISINOPRIL

LEK PHARMS

20MG

A075999 004 Jul 01, 2002

30MG

A075999 005 Jul 01, 2002

40MG

A075999 006 Jul 01, 2002

TEVA

2.5MG

A075783 001 Jul 01, 2002

5MG

A075783 002 Jul 01, 2002

10MG

A075783 003 Jul 01, 2002

20MG

A075783 004 Jul 01, 2002

30MG

A075783 005 Jul 01, 2002

40MG

A075783 006 Jul 01, 2002

PRINIVIL

MERCK

2.5MG

N019558 006 Jan 28, 1994

LITHIUM CARBONATE

CAPSULE; ORAL

ESKALITH

NOVEN THERAP

300MG

N016860 001

LITHIUM CARBONATE

ABLE

150MG

A076823 001 Jun 29, 2004

300MG

A076121 001 Sep 27, 2001

300MG

A076823 002 Jun 29, 2004

600MG

A076823 003 Jun 29, 2004

USL PHARMA

300MG

A072542 001 Feb 01, 1989

WATSON LABS

300MG

A070407 001 Mar 19, 1987

LITHONATE

SOLVAY

300MG

N016782 001

TABLET; ORAL

ESKALITH

JDS PHARMS

300MG

N017971 001

LITHANE

BAYER PHARMS

300MG

N018833 001 Jul 18, 1985

LITHIUM CARBONATE

PFIZER

300MG

N016834 001

LITHOTABS

SOLVAY

300MG

N016980 001

TABLET, EXTENDED RELEASE; ORAL

ESKALITH CR

JDS PHARMS

450MG

N018152 001 Mar 29, 1982

LITHIUM CARBONATE

ABLE

300MG

A076382 001 Apr 21, 2003

BARR

300MG

A076170 001 Jun 10, 2002

450MG

A076366 001 Aug 21, 2003

LITHIUM CITRATE

SYRUP; ORAL

LITHONATE

SOLVAY

EQ 300MG CARBONATE/5ML

N017672 001

LOMEFLOXACIN HYDROCHLORIDE

TABLET; ORAL

MAXAQUIN

PHARMACIA

EQ 400MG BASE

N020013 001 Feb 21, 1992

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

IMODIUM

MCNEIL PED

2MG

N017690 001

LOPERAMIDE HYDROCHLORIDE

ROXANE

2MG

A073080 001 Nov 27, 1991

SANDOZ

2MG

A072993 001 Aug 28, 1992

TEVA

2MG

A073122 001 Aug 30, 1991

DISCONTINUED DRUG PRODUCT LIST

6 - 218 (of 360)

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL IMODIUM

JANSSEN PHARMA	1MG/5ML	N019037	001	Jul 31, 1984

LOPERAMIDE HYDROCHLORIDE

ALPHARMA US PHARMS	1MG/5ML	A073187	001	Sep 15, 1992
DURAMED PHARMS BARR	1MG/5ML	A074991	001	Dec 29, 1997
TEVA	1MG/5ML	A073478	001	Jun 23, 1995
WATSON LABS	1MG/5ML	A073062	001	May 28, 1993

TABLET; ORAL

LOPERAMIDE HYDROCHLORIDE

ABLE	2MG	A073528	001	Nov 30, 1993
PERRIGO	2MG	A074194	001	Oct 30, 1992

LORACARBEF

CAPSULE; ORAL LORABID

KING PHARMS	200MG	N050668	001	Dec 31, 1991
	400MG	N050668	002	Apr 05, 1996

FOR SUSPENSION; ORAL

LORABID

KING PHARMS	100MG/5ML	N050667	001	Dec 31, 1991
	200MG/5ML	N050667	002	Dec 31, 1991

LORATADINE

SYRUP; ORAL

CLARITIN HIVES RELIEF

SCHERING PLOUGH	1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020641	003	Nov 19, 2003

LORATADINE

RANBAXY LABS LTD	1MG/ML	A076529	001	Aug 20, 2004

TABLET; ORAL

LORATADINE

PERRIGO	10MG	N021512	001	Jun 24, 2004

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

AKORN	2MG/ML	A074974	001	Jul 23, 1998
BEDFORD	2MG/ML	A077076	001	Jul 13, 2005
	4MG/ML	A077076	002	Jul 13, 2005
DAVA PHARMS INC	2MG/ML	A074793	001	Mar 16, 2000
	4MG/ML	A074793	002	Mar 16, 2000
HIKMA MAPLE	2MG/ML	A074496	001	Sep 28, 1998
	4MG/ML	A074496	002	Sep 28, 1998
HOSPIRA	2MG/ML	A074280	001	May 27, 1994
	2MG/ML	A074300	001	Apr 12, 1994
	4MG/ML	A074280	002	May 27, 1994
	4MG/ML	A074300	003	Mar 19, 1997
MARSAM PHARMS LLC	1MG/0.5ML	A074551	003	Sep 12, 1996
	2MG/ML	A074535	001	Sep 12, 1996
	2MG/ML	A074551	001	Sep 12, 1996
	4MG/ML	A074535	002	Sep 12, 1996
	4MG/ML	A074551	002	Sep 12, 1996

SOLUTION; ORAL

LORAZEPAM

ROXANE	0.5MG/5ML	A074648	001	Mar 18, 1997

TABLET; ORAL

LORAZ

QUANTUM PHARMICS	0.5MG	A070200	001	Aug 09, 1985
	1MG	A070201	001	Aug 09, 1985
	2MG	A070202	001	Aug 09, 1985

DISCONTINUED DRUG PRODUCT LIST

6 - 219 (of 360)

LORAZEPAM

TABLET; ORAL
LORAZEPAM

AM THERAP	0.5MG	A070727	001	Mar 07, 1986
	1MG	A070728	001	Mar 07, 1986
	2MG	A070729	001	Mar 07, 1986
HALSEY	0.5MG	A071434	001	Sep 01, 1987
	1MG	A071435	001	Sep 01, 1987
	2MG	A071436	001	Sep 01, 1987
MUTUAL PHARM	0.5MG	A070472	001	Dec 10, 1985
	0.5MG	A072553	001	Mar 29, 1991
	1MG	A070473	001	Dec 10, 1985
	1MG	A072554	001	Mar 29, 1991
	2MG	A070474	001	Dec 10, 1985
	2MG	A072555	001	Mar 29, 1991
PAR PHARM	0.5MG	A070675	001	Dec 01, 1986
	1MG	A070676	001	Dec 01, 1986
	2MG	A070677	001	Dec 01, 1986
SUPERPHARM	0.5MG	A071245	001	Feb 09, 1987
	1MG	A071246	001	Feb 09, 1987
	2MG	A071247	001	Feb 09, 1987
USL PHARMA	1MG	A070539	001	Dec 22, 1986
	2MG	A070540	001	Dec 22, 1986
WARNER CHILCOTT	1MG	A071038	001	Jan 12, 1988
	2MG	A071039	001	Jan 12, 1988
WATSON LABS	0.5MG	A071086	001	Mar 23, 1987
	0.5MG	A071117	001	Jul 24, 1986
	1MG	A071087	001	Mar 23, 1987
	2MG	A071088	001	Mar 23, 1987
	2MG	A071110	001	Jul 24, 1986

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

LOTEMAX

PHARMOS	0.5%	N020841	001	Mar 09, 1998

LOVASTATIN

TABLET; ORAL
MEVACOR

MERCK	10MG	N019643	002	Mar 28, 1991

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

ANDRX LABS LLC	10MG	N021316	001	Jun 26, 2002

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

LOXITANE C

WATSON LABS	EQ 25MG BASE/ML	N017658	001	

INJECTABLE; INJECTION

LOXITANE IM

WATSON LABS	EQ 50MG BASE/ML	N018039	001	

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

MIKAH PHARMA	EQ 5MG BASE	A076868	001	Aug 04, 2005
	EQ 10MG BASE	A076868	002	Aug 04, 2005
	EQ 25MG BASE	A076868	003	Aug 04, 2005
	EQ 50MG BASE	A076868	004	Aug 04, 2005

LOXITANE

WATSON LABS	EQ 5MG BASE	N017525	001	
	EQ 10MG BASE	N017525	002	
	EQ 25MG BASE	N017525	003	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 220 (of 360)

LOXAPINE SUCCINATE

CAPSULE; ORAL				
LOXITANE				
WATSON LABS	EQ 50MG BASE	N017525	004	
TABLET; ORAL				
LOXITANE				
WATSON LABS	EQ 10MG BASE	N017525	006	
	EQ 25MG BASE	N017525	007	
	EQ 50MG BASE	N017525	008	

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS				
LUVERIS				
EMD SERONO	75 IU/VIAL	N021322	001	Oct 08, 2004

LYPRESSIN

SOLUTION; NASAL				
DIAPID				
NOVARTIS	0.185MG/ML	N016755	001	

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION				
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER				
B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML	N019006	001	Apr 04, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION				
ISOLYTE S IN PLASTIC CONTAINER				
B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N018252	001	
SOLUTION; IRRIGATION				
PHYSIOSOL IN PLASTIC CONTAINER				
HOSPIRA INC	14MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N018406	001	
PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER				
HOSPIRA INC	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N018406	002	Jul 08, 1982
SYNOVALYTE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N019326	001	Jan 25, 1985

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET; ORAL				
MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE				
SANTARUS	343MG;20MG;750MG	N022456	001	Dec 04, 2009
	343MG;40MG;750MG	N022456	002	Dec 04, 2009
TABLET, CHEWABLE; ORAL				
ZEGERID				
SANTARUS	700MG;20MG;600MG	N021850	001	Mar 24, 2006
	700MG;40MG;600MG	N021850	002	Mar 24, 2006

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION				
TESLASCAN				
GE HEALTHCARE	37.9MG/ML	N020652	001	Nov 26, 1997

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION; ORAL				
LUMENHANCE				
BRACCO	3.49MG/GM	N020686	001	Dec 19, 1997

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 221 (of 360)

MANGANESE SULFATEINJECTABLE; INJECTION
MANGANESE SULFATE

ABRAXIS PHARM EQ 0.1MG MANGANESE/ML N019228 001 May 05, 1987

MANNITOLINJECTABLE; INJECTION
MANNITOL 10%

HOSPIRA 10GM/100ML N016269 002

MILES 10GM/100ML N016472 002

MANNITOL 15%

HOSPIRA 15GM/100ML N016269 003

MILES 15GM/100ML N016472 005

MANNITOL 20%

HOSPIRA 20GM/100ML N016269 004

MILES 20GM/100ML N016472 004

MANNITOL 25%

ABRAXIS PHARM 12.5GM/50ML A086754 001

ASTRAZENECA 12.5GM/50ML A089239 001 May 06, 1987

12.5GM/50ML A089240 001 May 06, 1987

HOSPIRA 12.5GM/50ML N016269 005

MERCK 12.5GM/50ML N005620 001

WATSON LABS 12.5GM/50ML A087460 001 Jun 27, 1983

MANNITOL 5%

HOSPIRA 5GM/100ML N016269 001

SOLUTION; IRRIGATION
RESECTISOL

B BRAUN 5GM/100ML N016704 002

MANNITOL; SORBITOLSOLUTION; IRRIGATION
SORBITOL-MANNITOL

HOSPIRA 540MG/100ML; 2.7GM/100ML A080224 001

SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA 540MG/100ML; 2.7GM/100ML N017636 001

MAPROTILINE HYDROCHLORIDETABLET; ORAL
LUDIOMIL

NOVARTIS 25MG N017543 001

50MG N017543 002

75MG N017543 003 Sep 30, 1982

MAPROTILINE HYDROCHLORIDE

AM THERAP 25MG A072129 001 Jan 14, 1988

50MG A072130 001 Jan 14, 1988

75MG A072131 001 Jan 14, 1988

WATSON LABS 25MG A071943 001 Dec 30, 1987

25MG A072162 001 Jun 01, 1988

50MG A071944 001 Dec 30, 1987

50MG A072163 001 Jun 01, 1988

75MG A071945 001 Dec 30, 1987

75MG A072164 001 Jun 01, 1988

MASOPROCOLCREAM; TOPICAL
ACTINEX

UNIV AZ CANCER CTR 10% N019940 001 Sep 04, 1992

MAZINDOLTABLET; ORAL
MAZANOR

WYETH AYERST 1MG N017980 002

2MG N017980 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 222 (of 360)

MAZINDOL

TABLET; ORAL
 SANOREX
 NOVARTIS

1MG **Federal Register determination
 that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

N017247 001

2MG **Federal Register determination
 that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

N017247 002

MEBENDAZOLE

TABLET, CHEWABLE; ORAL
 VERMOX
 JANSSEN PHARMS

100MG

N017481 001

MEBUTAMATE

TABLET; ORAL
 DORMATE

MEDPOINTE PHARM HLC 600MG

N017374 001

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL
 INVERSINE

TARGACEPT

2.5MG **Federal Register notice
 determination that product was not
 discontinued or withdrawn for safety
 or efficacy reasons**

N010251 001

MECASERMIN RINFABATE RECOMBINANT

INJECTABLE; SUBCUTANEOUS
 IPLEX

INSMED

36MG/0.6ML

N021884 001 Dec 12, 2005

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
 MECLIZINE HYDROCHLORIDE

ABC HOLDING

12.5MG

A085253 001

25MG

A085252 001

ANABOLIC

25MG

A085891 001

BUNDY

12.5MG

A084382 001

25MG

A084872 001

IVAX SUB TEVA PHARMS

12.5MG

A083784 001

12.5MG

A084975 001

25MG

A084657 001

KV PHARM

12.5MG

A085524 001

25MG

A085523 001

PLIVA

12.5MG

A088732 001 Dec 11, 1985

25MG

A088734 001 Dec 11, 1985

SUPERPHARM

12.5MG

A089113 001 Aug 20, 1985

25MG

A089114 001 Aug 20, 1985

UDL

12.5MG

A088256 001 Jun 13, 1983

25MG

A088257 001 Jun 13, 1983

VANGARD

12.5MG

A087877 001 Apr 20, 1982

25MG

A087620 001 Jan 04, 1982

WATSON LABS

12.5MG

A085195 001

12.5MG

A085269 001

TABLET, CHEWABLE; ORAL
 ANTIVERT

PFIZER

25MG

N010721 005

MECLIZINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS

25MG

A084976 001

NEXGEN PHARMA INC

25MG

A086392 001

PLIVA

25MG

A088733 001 Dec 11, 1985

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 223 (of 360)

MECLOCYCLINE SULFOSALICYLATECREAM; TOPICAL
MECLAN

JOHNSON AND JOHNSON 1%

N050518 001

MECLOFENAMATE SODIUMCAPSULE; ORAL
MECLODIUM

QUANTUM PHARMICS

EQ 50MG BASE
EQ 100MG BASEA071380 001 Jul 14, 1987
A071381 001 Jul 14, 1987

MECLOFENAMATE SODIUM

AM THERAP

EQ 50MG BASE
EQ 100MG BASEA071362 001 Feb 10, 1987
A071363 001 Feb 10, 1987

BARR

EQ 50MG BASE
EQ 100MG BASEA072848 001 Mar 20, 1989
A072809 001 Mar 20, 1989

PAR PHARM

EQ 50MG BASE
EQ 100MG BASEA072077 001 Mar 10, 1988
A072078 001 Mar 10, 1988

SANDOZ

EQ 50MG BASE
EQ 100MG BASEA072262 001 Nov 29, 1988
A072263 001 Nov 29, 1988

USL PHARMA

EQ 50MG BASE
EQ 100MG BASEA071007 001 Mar 25, 1988
A071008 001 Mar 25, 1988

VITARINE

EQ 50MG BASE
EQ 100MG BASEA071710 001 Jun 15, 1988
A071684 001 Jun 15, 1988

WATSON LABS

EQ 50MG BASE
EQ 50MG BASE
EQ 100MG BASE
EQ 100MG BASEA070400 001 Nov 25, 1986
A071640 001 Aug 11, 1987
A070401 001 Nov 25, 1986
A071641 001 Aug 11, 1987

MECLOMEN

PARKE DAVIS

EQ 50MG BASE
EQ 100MG BASEN018006 001
N018006 002MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

PHARMACIA AND UPJOHN

100MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

N012541 002

MEDROXYPROGESTERONE ACETATE

TEVA PARENTERAL

150MG/ML

A076552 001 Oct 27, 2004

TABLET; ORAL

AMEN

AMARIN PHARMS

10MG

A083242 001

CURRETAB

SOLVAY

10MG

A085686 001

CYCRIN

ESI

2.5MG
5MG
10MGA081239 001 Oct 30, 1992
A081240 001 Oct 30, 1992
A089386 001 Sep 09, 1987

MEDROXYPROGESTERONE ACETATE

DURAMED PHARMS BARR

2.5MG
5MG
10MGA040311 001 Dec 01, 1999
A040311 002 Dec 01, 1999
A040311 003 Dec 01, 1999MEDRYSONESUSPENSION; OPHTHALMIC
HMS

ALLERGAN

1%

N016624 003

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

LARIAM

ROCHE

250MG

N019591 001 May 02, 1989

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 224 (of 360)

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

US ARMY WALTER REED 250MG

N019578 001 May 02, 1989

MEGESTROL ACETATE

TABLET; ORAL

MEGACE

BRISTOL MYERS SQUIBB 20MG

N016979 001

40MG

N016979 002

MEGESTROL ACETATE

TEVA 40MG

A074745 001 Feb 27, 1998

USL PHARMA 20MG

A070646 001 Oct 02, 1987

40MG

A070647 001 Oct 02, 1987

MELOXICAM

TABLET; ORAL

MELOXICAM

MUTUAL PHARM 7.5MG

A077935 001 Jul 19, 2006

15MG

A077935 002 Jul 19, 2006

ROXANE 7.5MG

A077925 001 Jul 19, 2006

15MG

A077925 002 Jul 19, 2006

YABAO BIOPHARMS 7.5MG

A077933 001 Jul 19, 2006

15MG

A077933 002 Jul 19, 2006

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE

SUN PHARMA GLOBAL 5MG

A090058 001 May 05, 2010

10MG

A090058 002 May 05, 2010

MEMANTINE HYDROCHLORIDE

DR REDDYS LABS LTD 5MG

A090048 001 Apr 14, 2010

10MG

A090048 002 Apr 14, 2010

ORCHID HLTHCARE 5MG

A090044 001 Mar 12, 2012

10MG

A090044 002 Mar 12, 2012

TEVA PHARMS 5MG

A090052 001 Oct 25, 2011

10MG

A090052 002 Oct 25, 2011

MENADIOL SODIUM DIPHOSPHATE

INJECTABLE; INJECTION

KAPPADIONE

LILLY 10MG/ML

N005725 001

SYNKAYVITE

ROCHE 5MG/ML

N003718 004

10MG/ML

N003718 006

37.5MG/ML

N003718 008

TABLET; ORAL

SYNKAYVITE

ROCHE 5MG

N003718 010

MENADIONE

TABLET; ORAL

MENADIONE

LILLY 5MG

N002139 003

MENOTROPINS (FSH; LH)

INJECTABLE; INJECTION

HUMEGON

ORGANON USA INC 75 IU/VIAL; 75 IU/VIAL
150 IU/VIAL; 150 IU/VIAL

N020328 001 Sep 01, 1994

N020328 002 Sep 01, 1994

MENOTROPINS

FERRING 75 IU/VIAL; 75 IU/VIAL
150 IU/VIAL; 150 IU/VIAL

A073598 001 Jan 30, 1997

A073599 001 Jan 30, 1997

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 225 (of 360)

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

PERGONAL

SERONO

75 IU/AMP;75 IU/AMP
150 IU/AMP;150 IU/AMP

N017646 001

N017646 002 May 20, 1985

REPRONEX

FERRING

150 IU/VIAL;150 IU/VIAL

N021047 002

Aug 27, 1999

MEPENZOLATE BROMIDE

SOLUTION; ORAL

CANTIL

SANOFI AVENTIS US

25MG/5ML

N010679 004

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

SANOFI AVENTIS US

25MG/ML
50MG/ML
75MG/ML
100MG/ML

N005010 007

N005010 002

N005010 009

N005010 003

MEPERIDINE HYDROCHLORIDE

ABBOTT

25MG/ML
50MG/ML
50MG/ML
75MG/ML
100MG/ML

A080388 001

A080385 001

A080387 001

A080389 001

A080386 001

ASTRAZENECA

25MG/ML
50MG/ML
50MG/ML
50MG/ML
75MG/ML
100MG/ML
100MG/ML
100MG/ML

A089781 001

Mar 31, 1989

A089782 001

Mar 31, 1989

A089783 001

Mar 31, 1989

A089784 001

Mar 31, 1989

A089785 001

Mar 31, 1989

A089786 001

Mar 31, 1989

A089787 001

Mar 31, 1989

A089788 001

Mar 31, 1989

BAXTER HLTHCARE

25MG/ML
50MG/ML
75MG/ML
100MG/ML

A088279 001

Jun 15, 1984

A088280 001

Jun 15, 1984

A088281 001

Jun 15, 1984

A088282 001

Jun 15, 1984

INTL MEDICATION

10MG/ML

A086332 001

PARKE DAVIS

50MG/ML

A080364 002

75MG/ML

A080364 003

100MG/ML

A080364 001

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

HOSPIRA

10MG/ML

A040305 001

Mar 10, 1999

MALLINCKRODT

10MG/ML

A040163 001

May 12, 1997

SYRUP; ORAL

DEMEROL

SANOFI AVENTIS US

50MG/5ML

N005010 005

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

DURAMED PHARMS BARR

50MG
100MG

A040318 001

Oct 05, 1999

A040318 002

Oct 05, 1999

MUTUAL PHARM

50MG

A080448 001

100MG

A080448 002

WYETH AYERST

50MG

A080454 001

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

BAXTER HLTHCARE CORP

25MG/ML;25MG/ML

N011730 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 226 (of 360)

MEPHENTERMINE SULFATEINJECTABLE; INJECTION
WYAMINE SULFATE

BAXTER HLTHCARE CORP	EQ 15MG BASE/ML	N008248	002
	EQ 30MG BASE/ML	N008248	001

MEPHENYTOINTABLET; ORAL
MESANTOIN
NOVARTIS

100MG **Federal Register determination that the product was not discontinued or withdrawn for safety or efficacy reasons**	N006008	001

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE

SOLVAY	3%	A084777	002	Apr 18, 1982

CARBOCAINE

EASTMAN KODAK	3%	N012125	003

MEPIVACAINE HYDROCHLORIDE

GRAHAM CHEM	3%	A083559	001

INTL MEDICATION	1%	A087509	001	Oct 05, 1982

POLOCAINE

DENTSPLY PHARM	3%	A088653	001	Aug 21, 1984

MEPREDNISONETABLET; ORAL
BETAPAR

SCHERING	4MG	N016053	002

MEPROBAMATECAPSULE; ORAL
EQUANIL

WYETH AYERST	400MG	N012455	002

CAPSULE, EXTENDED RELEASE; ORAL

MEPROSPAN

MEDPOINTE PHARM HLC	200MG	N011284	001

	400MG	N011284	002

TABLET; ORAL

AMOSENE

FERNDAL LABS	400MG	A084030	001

BAMATE

ALRA	200MG	A080380	001

	400MG	A080380	002

EQUANIL

WYETH AYERST	200MG	N010028	005

	400MG	N010028	004

MEPRIAM

TEVA	400MG	N016069	001

MEPROBAMATE

BARR	600MG	A084230	001

ELKINS SINN	200MG	N015426	002

	400MG	N015426	001

HEATHER	400MG	N016928	003

	600MG	A084329	001

IMPAX LABS	200MG	N014322	002

	400MG	N014322	001

IVAX SUB TEVA PHARMS	200MG	N015438	001

	400MG	N015438	002

	600MG	A084181	001

IVC INDS	400MG	A084153	001

LANNETT	200MG	N014882	002

	400MG	N014882	001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 227 (of 360)

MEPROBAMATETABLET; ORAL
MEPROBAMATE

LEDERLE	400MG	A086299	001	
LEE KM	400MG	A089538	001	Nov 25, 1987
MALLARD	400MG	N015072	002	
MK LABS	200MG	N014368	004	
	400MG	N014368	002	
MUTUAL PHARM	200MG	A080699	001	
	400MG	A080699	002	
MYLAN	400MG	A083618	001	
NEXGEN PHARMA INC	200MG	A084220	001	
	400MG	A084589	001	
PARKE DAVIS	200MG	A084744	001	
	400MG	A084744	002	
PERRIGO	200MG	A084546	001	
	400MG	A084547	001	
PHARMAVITE	400MG	A084438	001	
PUREPAC PHARM	200MG	A084804	001	
	400MG	A084804	002	
PVT FORM	400MG	N014601	001	
ROXANE	600MG	A084332	001	
SANDOZ	200MG	N014547	002	
	400MG	A080655	001	
	400MG	N014547	001	
SCHERER LABS	400MG	A083343	001	
SOLVAY	200MG	A084435	001	
STANLABS PHARM	200MG	N014474	002	
	400MG	N014474	004	
TABLICAPS	400MG	A083494	001	
USL PHARMA	200MG	A087825	001	Mar 18, 1982
	400MG	A087826	001	Mar 18, 1982
VALEANT PHARM INTL	200MG	N015139	006	
	400MG	N015139	005	
VANGARD	400MG	A088011	001	Jul 14, 1982
WATSON LABS	200MG	A085720	001	
	400MG	A085721	001	
	600MG	A084274	001	
	600MG	A085719	001	
WEST WARD	200MG	N015417	003	
	400MG	N015417	002	
WHITEWORTH TOWN PLSN	200MG	A083830	001	
	400MG	A083442	001	
MILTOWN				
MEDPOINTE PHARM HLC	200MG	N009698	004	
	400MG	N009698	002	
	600MG	A083919	001	
NEURAMATE				
HALSEY	200MG	N014359	002	
	400MG	N014359	001	
TRANMEP				
SOLVAY	400MG	A084369	001	
	400MG	N016249	001	

MEQUINOL; TRETINOINSOLUTION; TOPICAL
SOLAGE

AQUA PHARMS	2%;0.01%	N020922	001	Dec 10, 1999

MERSALYL SODIUM; THEOPHYLLINEINJECTABLE; INJECTION
MERSALYL-THEOPHYLLINE

WATSON LABS	100MG/ML;50MG/ML	A084875	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 228 (of 360)

MESALAMINESUPPOSITORY; RECTAL
CANASA

APTALIS PHARMA US 500MG N021252 001 Jan 05, 2001

ROWASA

MEDA PHARMS 500MG N019919 001 Dec 18, 1990

MESORIDAZINE BESYLATECONCENTRATE; ORAL
SERENTIL

NOVARTIS EQ 25MG BASE/ML N016997 001

INJECTABLE; INJECTION
SERENTIL

NOVARTIS EQ 25MG BASE/ML N016775 001

TABLET; ORAL
SERENTIL

NOVARTIS EQ 10MG BASE N016774 001

EQ 25MG BASE N016774 002

EQ 50MG BASE N016774 003

EQ 100MG BASE N016774 004

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20

NORINYL

WATSON LABS 0.1MG;2MG N013625 004

TABLET; ORAL-21

NORETHIN 1/50M-21

WATSON LABS 0.05MG;1MG A071539 001 Apr 12, 1988

NORETHINDRONE AND MESTRANOL

WATSON LABS 0.05MG;1MG A070758 001 Jul 01, 1988

NORINYL 1+50 21-DAY

WATSON LABS 0.05MG;1MG N013625 002

NORINYL 1+80 21-DAY

GD SEARLE LLC 0.08MG;1MG N016724 001

ORTHO-NOVUM 1/50 21

ORTHO MCNEIL PHARM 0.05MG;1MG N012728 004

ORTHO-NOVUM 1/80 21

ORTHO MCNEIL PHARM 0.08MG;1MG N016715 001

ORTHO-NOVUM 10-21

ORTHO MCNEIL PHARM 0.06MG;10MG N012728 001

ORTHO-NOVUM 2-21

ORTHO MCNEIL PHARM 0.1MG;2MG N012728 005

TABLET; ORAL-28

NORETHIN 1/50M-28

WATSON LABS 0.05MG;1MG A071540 001 Apr 12, 1988

NORETHINDRONE AND MESTRANOL

WATSON LABS 0.05MG;1MG A070759 001 Jul 01, 1988

NORINYL 1+80 28-DAY

GD SEARLE LLC 0.08MG;1MG N016725 001

ORTHO-NOVUM 1/50 28

ORTHO MCNEIL JANSSEN 0.05MG;1MG N016709 001

ORTHO-NOVUM 1/80 28

ORTHO MCNEIL PHARM 0.08MG;1MG N016715 002

MESTRANOL; NORETHYNODRELTABLET; ORAL
ENOVID

GD SEARLE LLC 0.075MG;5MG N010976 008

0.15MG;9.85MG N010976 005

TABLET; ORAL-20

ENOVID

GD SEARLE LLC 0.075MG;5MG N010976 004

ENOVID-E

GD SEARLE LLC 0.1MG;2.5MG N010976 006

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 229 (of 360)

MESTRANOL; NORETHYNODREL

TABLET; ORAL-21

ENOVID-E 21

GD SEARLE LLC

0.1MG;2.5MG

N010976 007

METAPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

ALUPENT

BOEHRINGER INGELHEIM

0.65MG/INH

N016402 001

SOLUTION; INHALATION

ALUPENT

BOEHRINGER INGELHEIM

0.4%

N018761 002

Oct 10, 1986

0.6%

N018761 001

Jun 30, 1983

5%

N017659 001

METAPROTERENOL SULFATE

ASTRAZENECA

0.4%

A071275 001

Jul 27, 1988

0.6%

A071018 001

Jul 27, 1988

DEY

0.33%

A071806 001

Aug 05, 1988

0.5%

A071805 001

Aug 05, 1988

5%

A070805 001

Aug 17, 1987

NEPHRON

0.4%

A071855 001

Jul 14, 1988

0.6%

A071726 001

Jul 14, 1988

WOCKHARDT

5%

A072190 001

Jun 07, 1988

PROMETA

MURO

5%

A073340 001

Mar 30, 1992

SYRUP; ORAL

ALUPENT

BOEHRINGER INGELHEIM

10MG/5ML

N017571 001

METAPROTERENOL SULFATE

MORTON GROVE

10MG/5ML

A071656 001

Oct 13, 1987

TEVA

10MG/5ML

A072761 001

Feb 27, 1992

TEVA PHARMS

10MG/5ML

A073034 001

Aug 30, 1991

WOCKHARDT

10MG/5ML

A074702 001

Mar 24, 1997

PROMETA

MURO

10MG/5ML

A072023 001

Sep 15, 1988

TABLET; ORAL

ALUPENT

BOEHRINGER INGELHEIM

10MG

N015874 002

20MG

N015874 001

METAPROTERENOL SULFATE

AM THERAP

10MG

A072054 001

Jun 23, 1988

20MG

A072055 001

Jun 23, 1988

TEVA

10MG

A072519 001

Mar 30, 1990

20MG

A072520 001

Mar 30, 1990

USL PHARMA

10MG

A071013 001

Jan 25, 1988

20MG

A071014 001

Jan 25, 1988

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

ARAMINE

MERCK

EQ 10MG BASE/ML

N009509 002

Dec 22, 1987

METARAMINOL BITARTRATE

ABRAXIS PHARM

EQ 10MG BASE/ML

A080431 001

ELKINS SINN

EQ 10MG BASE/ML

A083363 001

GD SEARLE LLC

EQ 10MG BASE/ML

A086418 001

EQ 20MG BASE/ML

A086418 002

METAXALONE

TABLET; ORAL

SKELAXIN

KING PHARMS

400MG

N013217 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 230 (of 360)

METFORMIN HYDROCHLORIDETABLET; ORAL
GLUCOPHAGE

BRISTOL MYERS SQUIBB	625MG	N020357	003	Nov 05, 1998
	750MG	N020357	004	Nov 05, 1998

METFORMIN HYDROCHLORIDE

BARR	500MG	A075971	001	Jan 25, 2002
	850MG	A075971	002	Jan 25, 2002
	1GM	A075971	003	Jan 25, 2002
IPCA LABS LTD	500MG	A078422	001	Aug 06, 2007
	850MG	A078422	002	Aug 06, 2007
	1GM	A078422	003	Aug 06, 2007
IVAX SUB TEVA PHARMS	500MG	A075975	001	Jan 24, 2002
	625MG	A075975	004	Jan 24, 2002
	750MG	A075975	005	Jan 24, 2002
	850MG	A075975	002	Jan 24, 2002
	1GM	A075975	003	Jan 24, 2002
TEVA	500MG	A076328	001	Dec 16, 2002
	850MG	A076328	002	Dec 16, 2002
	1GM	A076328	003	Dec 16, 2002

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

ACTAVIS ELIZABETH	500MG	A076450	001	Oct 01, 2004
	750MG	A076878	001	Apr 13, 2005
BARR	500MG	A076496	001	Nov 25, 2005
IVAX SUB TEVA PHARMS	500MG	A076545	001	Dec 01, 2003
MUTUAL PHARM	500MG	A077124	001	Dec 21, 2005
RANBAXY LABS LTD	500MG	A076413	001	Jun 18, 2004
	750MG	A077211	001	Jun 29, 2005
SANDOZ	500MG	A076223	001	Dec 14, 2004

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

SB PHARMCO	500MG;EQ 1MG BASE	N021410	001	Oct 10, 2002

METHACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

RONDOMYCIN

MEDPOINTE PHARM HLC	EQ 140MG BASE	A060641	001
	EQ 280MG BASE	A060641	002

SYRUP; ORAL

RONDOMYCIN

MEDPOINTE PHARM HLC	EQ 70MG BASE/5ML	A060641	003

METHADONE HYDROCHLORIDE

SYRUP; ORAL

DOLOPHINE HYDROCHLORIDE

ROXANE	10MG/30ML	N006134	004

TABLET; ORAL

METHADONE HYDROCHLORIDE

ROXANE	5MG	A088108	001	Mar 08, 1983
	10MG	A088109	001	Mar 08, 1983
	40MG	A074081	001	Apr 28, 1995
SANDOZ	5MG	A040241	001	May 29, 1998

TABLET, DISPERSIBLE; ORAL

WESTADONE

SANDOZ	2.5MG	N017108	001

TABLET, EFFERVESCENT; ORAL

WESTADONE

SANDOZ	5MG	N017108	002
	10MG	N017108	003
	40MG	N017108	004

DISCONTINUED DRUG PRODUCT LIST

6 - 231 (of 360)

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL			
METHAMPEX			
TEVA	10MG	A083889	001
METHAMPHETAMINE HYDROCHLORIDE			
ABLE	5MG	A040529	001
REXAR	5MG	A084931	001
	10MG	A084931	002
TEVA	5MG	A086359	001
TABLET, EXTENDED RELEASE; ORAL			
DESOXYN			
LUNDBECK INC	5MG	N005378	004
	10MG	N005378	003
	15MG	N005378	005

Feb 25, 2004

METHANTHELINE BROMIDE

TABLET; ORAL			
BANTHINE			
SHIRE	50MG	N007390	001

METHARBITAL

TABLET; ORAL			
GEMONIL			
ABBVIE	100MG	N008322	001

METHAZOLAMIDE

TABLET; ORAL			
METHAZOLAMIDE			
APPLIED ANAL	25MG	A040011	001
	50MG	A040011	002
SANDOZ	25MG	A040102	001
	50MG	A040102	002
NEPTAZANE			
LEDERLE	25MG	N011721	002
	50MG	N011721	001

Jul 17, 1997

Jul 17, 1997

Aug 28, 1996

Aug 28, 1996

Nov 25, 1991

METHDILAZINE

TABLET, CHEWABLE; ORAL			
TACARYL			
WESTWOOD SQUIBB	3.6MG	N011950	009

METHDILAZINE HYDROCHLORIDE

SYRUP; ORAL			
METHDILAZINE HYDROCHLORIDE			
ALPHARMA US PHARMS	4MG/5ML	A087122	001
TACARYL			
WESTWOOD SQUIBB	4MG/5ML	N011950	007
TABLET; ORAL			
TACARYL			
WESTWOOD SQUIBB	8MG	N011950	006

METHICILLIN SODIUM

INJECTABLE; INJECTION			
STAPHICILLIN			
APOTHECON	EQ 900MG BASE/VIAL	A061449	001
	EQ 900MG BASE/VIAL	N050117	001
	EQ 3.6GM BASE/VIAL	A061449	002
	EQ 3.6GM BASE/VIAL	N050117	002
	EQ 5.4GM BASE/VIAL	A061449	003
	EQ 5.4GM BASE/VIAL	N050117	003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 232 (of 360)

METHIMAZOLETABLET; ORAL
METHIMAZOLE

CEDAR PHARMS	15MG	A040619	003	Jul 12, 2005
	20MG	A040547	004	Feb 18, 2005
MYLAN	20MG	A040350	003	Jun 07, 2001
TAPAZOLE				
KING PHARMS	5MG	N007517	002	
	10MG	N007517	004	

METHIXENE HYDROCHLORIDETABLET; ORAL
TREST

NOVARTIS	1MG	N013420	001	

METHOCARBAMOLINJECTABLE; INJECTION
METHOCARBAMOL

MARSAM PHARMS LLC	100MG/ML	A089849	001	Dec 27, 1991

TABLET; ORAL
DELAXIN

FERNDAL LABS	500MG	A085454	001	

FORBAXIN

FOREST LABS	750MG	A085136	001	

METHOCARBAMOL

ABLE	500MG	A040413	001	Mar 17, 2003

	750MG	A040413	002	Mar 17, 2003

AM THERAP	500MG	A089417	001	Feb 11, 1987

	750MG	A089418	001	Feb 11, 1987

ASCOT	500MG	A087660	001	Oct 27, 1982

	750MG	A087661	001	Oct 27, 1982

CLONMEL HLTHCARE	500MG	A085961	001	

	750MG	A085963	001	

HEATHER	500MG	A084675	001	

	750MG	A084924	001	

IMPAX LABS	500MG	A084927	001	

	750MG	A084928	001	

INWOOD LABS	500MG	A085137	001	

IVAX SUB TEVA PHARMS	500MG	A084648	001	

	750MG	A084649	001	

KV PHARM	500MG	A085660	001	

	750MG	A085658	001	

MUTUAL PHARM	500MG	A084488	001	

	750MG	A084486	001	

MYLAN	500MG	A084259	001	

	750MG	A084323	001	

NYLOS	750MG	A085033	001	

PIONEER PHARMS	500MG	A088731	001	Dec 13, 1985

	750MG	A089082	001	Dec 13, 1985

PURACAP PHARM	500MG	A084231	002	

	750MG	A084471	001	

PUREPAC PHARM	500MG	A085718	001	

	750MG	A085718	002	

ROXANE	500MG	A088646	001	Feb 29, 1984

	750MG	A088647	001	Feb 29, 1984

SANDOZ	500MG	A087283	001	

	750MG	A087282	001	

SOLVAY	500MG	A084448	001	

	750MG	A084449	001	

SUPERPHARM	500MG	A087589	001	Jan 22, 1982

	750MG	A087590	001	Jan 22, 1982

TABLICAPS	500MG	A084846	001	

UPSHER SMITH	500MG	A087453	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 233 (of 360)

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

UPSHER SMITH

750MG

A087454 001

WATSON LABS

500MG

A083605 001

750MG

A083605 002

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

JHP PHARMS

5GM/VIAL

N011559 003

METHOTREXATE SODIUM

INJECTABLE; INJECTION

ABITREXATE

ABIC

EQ 25MG BASE/ML

A089161 001 Mar 10, 1987

EQ 50MG BASE/VIAL

A089354 001 Jul 17, 1987

EQ 100MG BASE/VIAL

A089355 001 Jul 17, 1987

EQ 250MG BASE/VIAL

A089356 001 Jul 17, 1987

FOLEX

PHARMACIA AND UPJOHN

EQ 25MG BASE/VIAL

A087695 001 Apr 08, 1983

EQ 50MG BASE/VIAL

A087695 002 Apr 08, 1983

EQ 100MG BASE/VIAL

A087695 003 Apr 08, 1983

EQ 250MG BASE/VIAL

A088954 001 Oct 24, 1985

FOLEX PFS

PHARMACIA AND UPJOHN

EQ 25MG BASE/ML

A081242 001 Aug 23, 1991

EQ 25MG BASE/ML

A089180 001 Jan 03, 1986

METHOTREXATE LPF

HOSPIRA

EQ 25MG BASE/ML

N011719 007 Mar 31, 1982

METHOTREXATE PRESERVATIVE FREE

FRESENIUS KABI USA

EQ 25MG BASE/ML

A040265 001 Feb 26, 1999

HOSPIRA

EQ 20MG BASE/2ML (EQ 10MG BASE/ML)

N011719 014 Apr 13, 2005

EQ 500MG BASE/20ML (EQ 25MG BASE/ML)

N011719 013 Apr 13, 2005

**Federal Register determination that
product was not discontinued or
withdrawn for safety or efficacy
reasons**

EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)

N011719 011 Apr 13, 2005

METHOTREXATE SODIUM

ABRAXIS PHARM

EQ 2.5MG BASE/ML

A089323 001 Jun 13, 1986

EQ 20MG BASE/VIAL

A088935 001 Oct 11, 1985

EQ 25MG BASE/ML

A089263 001 Jun 13, 1986

EQ 25MG BASE/ML

A089322 001 Jun 13, 1986

EQ 50MG BASE/VIAL

A088936 001 Oct 11, 1985

EQ 100MG BASE/VIAL

A088937 001 Oct 11, 1985

HOSPIRA

EQ 2.5MG BASE/ML

N011719 004

EQ 20MG BASE/VIAL

N011719 001

EQ 25MG BASE/ML

N011719 005

EQ 50MG BASE/VIAL

N011719 003

EQ 100MG BASE/VIAL

N011719 006

NORBROOK

EQ 25MG BASE/ML

A088648 001 May 09, 1986

PHARMACHEMIE USA

EQ 25MG BASE/ML

A089158 001 Jul 08, 1988

METHOTREXATE SODIUM PRESERVATIVE FREE

HOSPIRA

EQ 1GM BASE/VIAL

N011719 009 Apr 07, 1988

MEXATE

BRISTOL

EQ 20MG BASE/VIAL

A086358 001

EQ 50MG BASE/VIAL

A086358 002

EQ 100MG BASE/VIAL

A086358 003

EQ 250MG BASE/VIAL

A086358 004

MEXATE-AQ

BRISTOL MYERS

EQ 25MG BASE/ML

A088760 001 Feb 14, 1985

MEXATE-AQ PRESERVED

BRISTOL MYERS SQUIBB

EQ 25MG BASE/ML

A089887 001 Apr 14, 1989

DISCONTINUED DRUG PRODUCT LIST

6 - 234 (of 360)

METHOTREXATE SODIUM

TABLET; ORAL				
METHOTREXATE SODIUM				
DURAMED PHARMS BARR	EQ 2.5MG BASE	A040233	001	Jun 17, 1999

METHOXAMINE HYDROCHLORIDE

INJECTABLE; INJECTION				
VASOXYL				
GLAXOSMITHKLINE	10MG/ML	N006772	002	
	20MG/ML	N006772	001	

METHOXSALEN

CAPSULE; ORAL				
METHOXSALEN				
SANDOZ	10MG	A087781	001	Jun 08, 1982

METHSCOPOLAMINE BROMIDE

TABLET; ORAL				
METHSCOPOLAMINE BROMIDE				
PVT FORM	2.5MG	A080970	001	

METHYCLOTHIAZIDE

TABLET; ORAL				
AQUATENSEN				
MEDPOINTE PHARM HLC	5MG	N017364	001	
ENDURON				
ABBVIE	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012524	001	
	5MG	N012524	004	
METHYCLOTHIAZIDE				
IVAX PHARMS	2.5MG	A087913	001	Jun 03, 1982
	5MG	A087786	001	May 18, 1982
MYLAN	2.5MG	A087671	001	Aug 17, 1982
PAR PHARM	2.5MG	A089135	001	Feb 12, 1986
	5MG	A089136	001	Feb 12, 1986
SANDOZ	2.5MG	A089835	001	Aug 18, 1988
	5MG	A089837	001	Aug 18, 1988
USL PHARMA	5MG	A088745	001	Mar 21, 1985
WATSON LABS	2.5MG	A085487	001	Mar 11, 1982
	2.5MG	A088750	001	Sep 06, 1984
	5MG	A085476	001	Mar 11, 1982

METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE

TABLET; ORAL				
EUTRON				
ABBOTT	5MG;25MG	N016047	001	

METHYCLOTHIAZIDE; RESERPINE

TABLET; ORAL				
DIUTENSEN-R				
MEDPOINTE PHARM HLC	2.5MG;0.1MG	N012708	005	

METHYLDOPA

SUSPENSION; ORAL				
ALDOMET				
MERCK	250MG/5ML	N018389	001	
TABLET; ORAL				
ALDOMET				
MERCK	125MG	N013400	003	
	250MG	N013400	001	
	500MG	N013400	002	

DISCONTINUED DRUG PRODUCT LIST

6 - 235 (of 360)

METHYLDOPA

TABLET; ORAL
METHYLDOPA

ACCORD HLTH	125MG	A070070	003	Oct 15, 1985
DURAMED PHARMS BARR	250MG	A071006	001	Dec 16, 1986
	500MG	A071009	001	Dec 16, 1986
HALSEY	125MG	A071751	001	Mar 28, 1988
	250MG	A071752	001	Mar 28, 1988
	500MG	A071753	001	Mar 28, 1988
MUTUAL PHARM	125MG	A070073	001	Oct 09, 1986
	250MG	A070060	001	Oct 09, 1986
	500MG	A070074	001	Oct 09, 1986
PAR PHARM	125MG	A070535	001	Jan 02, 1987
	250MG	A070536	001	Jan 02, 1987
	500MG	A070537	001	Jan 02, 1987
PARKE DAVIS	125MG	A070331	001	Apr 15, 1986
	250MG	A070332	001	Apr 15, 1986
	500MG	A070333	001	Apr 15, 1986
PLIVA	125MG	A072126	001	Jul 07, 1988
	250MG	A072127	001	Jul 07, 1988
	500MG	A072128	001	Jul 07, 1988
PUREPAC PHARM	125MG	A070749	001	Feb 07, 1986
	250MG	A070750	001	Feb 07, 1986
	500MG	A070452	001	Feb 07, 1986
ROXANE	125MG	A070192	001	Apr 25, 1986
	250MG	A070193	001	Apr 25, 1986
	500MG	A070194	001	Apr 25, 1986
SANDOZ	125MG	A071700	001	Mar 02, 1988
	250MG	N018934	001	Jun 29, 1984
	500MG	N018934	002	Jun 29, 1984
SUPERPHARM	250MG	A070669	001	Jun 23, 1989
	500MG	A070670	001	Jun 23, 1989
TEVA	125MG	A071105	001	Dec 05, 1986
	250MG	A071106	001	Dec 05, 1986
	500MG	A071067	001	Dec 05, 1986
WATSON LABS	125MG	A070245	001	Feb 25, 1986
	125MG	A070260	001	Jun 24, 1985
	250MG	A070246	001	Feb 25, 1986
	250MG	A070261	001	Jun 24, 1985
	250MG	A070703	001	Jun 06, 1986
	500MG	A070247	001	Feb 25, 1986
	500MG	A070262	001	Jun 24, 1985

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION
ALDOMET

MERCK	50MG/ML	N013401	001	
METHYLDOPATE HYDROCHLORIDE				
ABRAXIS PHARM	50MG/ML	A070652	001	Jun 03, 1986
BAXTER HLTHCARE	50MG/ML	A070291	001	Jul 01, 1986
HOSPIRA	50MG/ML	A070691	001	Jun 19, 1987
	50MG/ML	A070698	001	Jun 15, 1987
	50MG/ML	A070699	001	Jun 15, 1987
	50MG/ML	A070849	001	Jun 19, 1987
MARSAM PHARMS LLC	50MG/ML	A071812	001	Dec 22, 1987
SMITH AND NEPHEW	50MG/ML	A070841	001	Jan 02, 1987
TEVA PARENTERAL	50MG/ML	A072974	001	Nov 22, 1991

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL
METHYLPHENIDATE HYDROCHLORIDE

ABLE	5MG	A040404	001	Mar 29, 2001
	10MG	A040404	002	Mar 29, 2001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 236 (of 360)

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

ABLE	20MG	A040404	003	Mar 29, 2001
ACTAVIS ELIZABETH	5MG	A040321	001	Feb 05, 2002
	10MG	A040321	002	Feb 05, 2002
	20MG	A040321	003	Feb 05, 2002

TABLET, EXTENDED RELEASE; ORAL

METADATE ER

UCB INC	10MG	A040306	001	Oct 20, 1999

METHYLPHENIDATE HYDROCHLORIDE

ABLE	20MG	A076032	001	May 09, 2001
ACTAVIS ELIZABETH	20MG	A075450	001	Dec 21, 2001

METHYLPREDNISOLONE

TABLET; ORAL

MEDROL

PHARMACIA AND UPJOHN	2MG	N011153	002	
	24MG	N011153	005	

METHYLPREDNISOLONE

HEATHER	4MG	A085650	001	
PAR PHARM	16MG	A089207	001	Apr 25, 1988
	24MG	A089208	001	Apr 25, 1988
	32MG	A089209	001	Apr 25, 1988
SANDOZ	4MG	A087341	001	
WATSON LABS	4MG	A086161	001	Feb 09, 1982
	16MG	A086159	001	Feb 09, 1982

METHYLPREDNISOLONE ACETATE

ENEMA; RECTAL

MEDROL

PHARMACIA AND UPJOHN	40MG/BOT	N018102	001	

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

AKORN	40MG/ML	A086903	001	Oct 20, 1982
	80MG/ML	A086903	002	Oct 20, 1982
WATSON LABS	20MG/ML	A085597	001	
	20MG/ML	A087248	001	
	40MG/ML	A085374	001	
	40MG/ML	A085600	001	
	80MG/ML	A085595	001	
	80MG/ML	A086507	001	

M-PREDROL

BEL MAR	40MG/ML	A086666	001	
	80MG/ML	A087135	001	

OINTMENT; TOPICAL

MEDROL ACETATE

PHARMACIA AND UPJOHN	0.25%	N012421	001	
	1%	N012421	002	

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-MEDROL ACETATE

PHARMACIA AND UPJOHN	0.25%;EQ 3.5MG BASE/GM	A060611	002	
	1%;EQ 3.5MG BASE/GM	A060611	001	

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

ABBOTT	EQ 40MG BASE/VIAL	A089573	001	Feb 22, 1991
	EQ 125MG BASE/VIAL	A089574	001	Feb 22, 1991
	EQ 500MG BASE/VIAL	A089575	001	Feb 22, 1991
	EQ 1GM BASE/VIAL	A089576	001	Feb 22, 1991

DISCONTINUED DRUG PRODUCT LIST

6 - 237 (of 360)

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

HOSPIRA	EQ 40MG BASE/VIAL	A085853	001	
	EQ 125MG BASE/VIAL	A085855	001	
	EQ 500MG BASE/VIAL	A085854	001	
	EQ 500MG BASE/VIAL	A089173	001	Aug 18, 1987
	EQ 1GM BASE/VIAL	A085852	001	
	EQ 1GM BASE/VIAL	A089174	001	Aug 18, 1987

METHYLPREDNISOLONE

ELKINS SINN	EQ 125MG BASE/VIAL	A086906	002	
	EQ 500MG BASE/VIAL	A086906	003	
	EQ 1GM BASE/VIAL	A086906	004	
ORGANON USA INC	EQ 500MG BASE/VIAL	A087535	001	Jun 25, 1982
	EQ 1GM BASE/VIAL	A087535	002	Jun 25, 1982

METHYLPREDNISOLONE SODIUM SUCCINATE

ABRAXIS PHARM	EQ 40MG BASE/VIAL	A088676	001	Jun 08, 1984
	EQ 40MG BASE/VIAL	A089143	001	Mar 28, 1986
	EQ 125MG BASE/VIAL	A088677	001	Jun 08, 1984
	EQ 125MG BASE/VIAL	A089144	001	Mar 28, 1986
	EQ 500MG BASE/VIAL	A088678	001	Jun 08, 1984
	EQ 500MG BASE/VIAL	A089186	001	Mar 28, 1986
	EQ 500MG BASE/VIAL	A089187	001	Mar 28, 1986
	EQ 1GM BASE/VIAL	A088679	001	Jun 08, 1984
	EQ 1GM BASE/VIAL	A089188	001	Mar 28, 1986
	EQ 1GM BASE/VIAL	A089189	001	Mar 28, 1986
BEDFORD LABS	EQ 40MG BASE/VIAL	A040662	001	Feb 21, 2007
	EQ 125MG BASE/VIAL	A040641	002	Feb 21, 2007
	EQ 500MG BASE/VIAL	A040641	003	Feb 21, 2007
	EQ 500MG BASE/VIAL	A040709	001	Feb 21, 2007
	EQ 1GM BASE/VIAL	A040641	004	Feb 21, 2007
	EQ 1GM BASE/VIAL	A040709	002	Feb 21, 2007
ELKINS SINN	EQ 40MG BASE/VIAL	A086906	001	
INTL MEDICATION	EQ 40MG BASE/VIAL	A087812	001	Feb 09, 1983
	EQ 125MG BASE/VIAL	A087813	001	Feb 09, 1983
	EQ 500MG BASE/VIAL	A087851	001	Feb 09, 1983
	EQ 1GM BASE/VIAL	A087852	001	Feb 09, 1983
TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266	001	Nov 30, 1992
	EQ 500MG BASE/VIAL	A081267	001	Nov 30, 1992
	EQ 1GM BASE/VIAL	A081268	001	Nov 30, 1992
WATSON LABS	EQ 40MG BASE/VIAL	A086953	001	Jul 22, 1982
	EQ 125MG BASE/VIAL	A087030	001	Jul 22, 1982
	EQ 500MG BASE/VIAL	A088523	001	Jul 24, 1984
	EQ 1GM BASE/VIAL	A088524	001	Jul 24, 1984

METHYLPREDNISOLONE; NEOMYCIN SULFATE

OINTMENT; OPHTHALMIC

NEO-MEDROL

PHARMACIA AND UPJOHN	0.1%;EQ 3.5MG BASE/GM	A060645	001	

METHYLTESTOSTERONE

CAPSULE; ORAL

METHYLTESTOSTERONE

HEATHER	10MG	A084967	001	
VIRILON				
STAR PHARMS FL	10MG	A087750	001	Nov 24, 1982

TABLET; BUCCAL

ANDROID 5

VALEANT PHARM INTL	5MG	A087222	001	

ORETON

SCHERING	10MG	A080281	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 238 (of 360)

METHYLTESTOSTERONE

TABLET; BUCCAL/SUBLINGUAL

METANDREN

NOVARTIS

5MG

N003240 004

10MG

N003240 005

METHYLTESTOSTERONE

IMPAX LABS

10MG

A084287 001

LILLY

10MG

A080256 001

PUREPAC PHARM

10MG

A080308 001

10MG

A080475 001

PVT FORM

5MG

A083836 001

TABLICAPS

10MG

A085125 001

USL PHARMA

10MG

A080271 001

TABLET; ORAL

METANDREN

NOVARTIS

10MG

N003240 001

25MG

N003240 003

METHYLTESTOSTERONE

INWOOD LABS

10MG

A080839 001

25MG

A080973 001

KV PHARM

10MG

A084312 001

LANNETT

10MG

A087092 001

25MG

A087111 001

Nov 05, 1982

Jan 27, 1983

LILLY

25MG

A080256 002

PARKE DAVIS

10MG

A084244 001

25MG

A084241 001

PUREPAC PHARM

10MG

A080309 001

10MG

A080475 002

25MG

A080310 001

25MG

A080475 003

PVT FORM

5MG

A080214 001

10MG

A080214 002

25MG

A080214 003

TABLICAPS

10MG

A080313 001

25MG

A085270 001

WATSON LABS

10MG

A080933 001

25MG

A080931 001

WEST WARD

10MG

A084331 001

25MG

A084331 002

25MG

A084642 001

ORETON METHYL

SCHERING

10MG

N003158 001

25MG

N003158 002

METHYPRYLON

CAPSULE; ORAL

NOLUDAR

ROCHE

300MG

N009660 008

ELIXIR; ORAL

NOLUDAR

ROCHE

50MG/5ML

N009660 007

TABLET; ORAL

NOLUDAR

ROCHE

50MG

N009660 002

200MG

N009660 004

METHYSERGIDE MALEATE

TABLET; ORAL

SANSERT

NOVARTIS

2MG

N012516 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 239 (of 360)

METOCLOPRAMIDE HYDROCHLORIDE

CONCENTRATE; ORAL

METOCLOPRAMIDE INTENSOL

ROXANE EQ 10MG BASE/ML

A072995 001 Jan 30, 1992

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

BEDFORD EQ 5MG BASE/ML

A072155 001 Mar 30, 1992

EQ 5MG BASE/ML

A072244 001 Mar 30, 1992

EQ 5MG BASE/ML

A072247 001 May 18, 1992

HOSPIRA EQ 5MG BASE/ML

A070505 001 Jun 23, 1989

EQ 5MG BASE/ML

A070506 001 Jun 22, 1989

EQ 5MG BASE/ML

A070847 001 Nov 07, 1988

EQ 5MG BASE/ML

A071291 001 Mar 03, 1989

EQ 5MG BASE/ML

A071990 001 Jan 18, 1989

EQ 5MG BASE/ML

A073117 001 Jan 17, 1991

EQ 5MG BASE/ML

A074147 001 Aug 02, 1996

LYPHOMED EQ 10MG BASE/2ML

A070293 001 Jan 24, 1986

NORBROOK EQ 10MG BASE/2ML

A070892 001 Aug 26, 1988

SMITH AND NEPHEW EQ 5MG BASE/ML

A070623 001 Mar 02, 1987

EQ 10MG BASE/2ML

A070622 001 Mar 02, 1987

REGLAN

BAXTER HLTHCARE CORP EQ 10MG BASE/ML

N017862 004 May 28, 1987

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

ACTAVIS MID ATLANTIC EQ 5MG BASE/5ML

A071340 001 Aug 18, 1988

MORTON GROVE EQ 5MG BASE/5ML

A070949 001 Mar 06, 1987

PACO EQ 5MG BASE/5ML

A071665 001 Dec 05, 1988

ROXANE EQ 5MG BASE/5ML

A072038 001 Dec 05, 1988

TEVA EQ 5MG BASE/5ML

A070819 001 Jul 10, 1987

EQ 5MG BASE/5ML

A071315 001 Jun 30, 1993

REGLAN

ROBINS AH EQ 5MG BASE/5ML

N018821 001 Mar 25, 1983

TABLET; ORAL

CLOPRA

QUANTUM PHARMICS EQ 5MG BASE

A072384 001 Jun 02, 1988

EQ 10MG BASE

A070294 001 Jul 29, 1985

CLOPRA-"YELLOW"

QUANTUM PHARMICS EQ 10MG BASE

A070632 001 Oct 28, 1985

MAXOLON

KING PHARMS EQ 10MG BASE

A070106 001 Mar 04, 1986

METOCLOPRAMIDE HYDROCHLORIDE

CLONMEL HLTHCARE EQ 10MG BASE

A072639 001 May 09, 1991

HALSEY EQ 10MG BASE

A070906 001 Oct 28, 1986

INTERPHARM EQ 10MG BASE

A071213 001 Sep 24, 1986

MUTUAL PHARM EQ 10MG BASE

A070660 001 Feb 10, 1987

EQ 10MG BASE

A071536 001 Apr 28, 1993

PAR PHARM EQ 10MG BASE

A070342 001 Mar 25, 1986

SANDOZ EQ 5MG BASE

A072436 001 Jun 22, 1989

EQ 5MG BASE

A074478 001 Oct 05, 1995

EQ 10MG BASE

A070850 001 Feb 03, 1987

EQ 10MG BASE

A072215 001 Jan 30, 1990

EQ 10MG BASE

A074478 002 Oct 05, 1995

SCHERING EQ 10MG BASE

A070598 001 Feb 02, 1987

SUPERPHARM EQ 10MG BASE

A070926 001 Jun 26, 1987

USL PHARMA EQ 10MG BASE

A070339 001 Jul 29, 1985

WATSON LABS EQ 10MG BASE

A070363 001 Mar 02, 1987

EQ 10MG BASE

A070453 001 Jun 06, 1986

EQ 10MG BASE

A070511 001 Jan 22, 1986

EQ 10MG BASE

A070645 001 May 11, 1987

TABLET, ORALLY DISINTEGRATING; ORAL

REGLAN ODT

MEDA PHARMS EQ 5MG BASE

N021793 001 Jun 10, 2005

EQ 10MG BASE

N021793 002 Jun 10, 2005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 240 (of 360)

METOCURINE IODIDEINJECTABLE; INJECTION
METUBINE IODIDE

LILLY

2MG/ML

N006632 003

METOLAZONETABLET; ORAL
DIULO

GD SEARLE LLC

2.5MG

N018535 001

5MG

N018535 002

10MG

N018535 003

METOLAZONE

ROXANE

10MG

A076482 002 Apr 29, 2004

WATSON LABS

10MG

A076891 001 Jul 21, 2004

MYKROX

UCB INC

0.5MG

N019532 001 Oct 30, 1987

METOPROLOL FUMARATETABLET, EXTENDED RELEASE; ORAL
LOPRESSOR

NOVARTIS

EQ 100MG TARTRATE

N019786 001 Dec 27, 1989

EQ 200MG TARTRATE

N019786 002 Dec 27, 1989

EQ 300MG TARTRATE

N019786 003 Dec 27, 1989

EQ 400MG TARTRATE

N019786 004 Dec 27, 1989

METOPROLOL SUCCINATETABLET, EXTENDED RELEASE; ORAL
METOPROLOL SUCCINATE

NESHER PHARMS

EQ 100MG TARTRATE

A076640 002 May 18, 2007

EQ 200MG TARTRATE

A076640 001 May 18, 2007

SANDOZ

EQ 25MG TARTRATE

A076969 001 Jul 31, 2006

EQ 50MG TARTRATE

A076969 002 May 18, 2007

EQ 100MG TARTRATE

A076969 003 Mar 20, 2008

EQ 200MG TARTRATE

A076969 004 Mar 20, 2008

METOPROLOL TARTRATETABLET; ORAL
METOPROLOL TARTRATE

APOTHECON

50MG

A074258 001 Jan 27, 1994

100MG

A074258 002 Jan 27, 1994

MYLAN

50MG

A073666 001 Dec 21, 1993

100MG

A073666 002 Dec 21, 1993

PUREPAC PHARM

50MG

A074380 001 Jul 29, 1994

100MG

A074380 002 Jul 29, 1994

SOLCO HLTHCARE

50MG

A074453 001 Apr 27, 1995

100MG

A074453 002 Apr 27, 1995

TEVA

50MG

A074143 001 Sep 30, 1994

100MG

A074143 002 Sep 30, 1994

TEVA PHARMS

50MG

A074333 001 Jan 27, 1994

100MG

A074333 002 Jan 27, 1994

METRIZAMIDEINJECTABLE; INJECTION
AMIPAQUE

GE HEALTHCARE

2.5GM/VIAL

N017982 003 Sep 12, 1983

3.75GM/VIAL

N017982 001

6.75GM/VIAL

N017982 002

13.5GM/VIAL

N017982 004 Sep 12, 1983

METRONIDAZOLECAPSULE; ORAL
METRONIDAZOLE

ABLE

375MG

A076505 001 Nov 13, 2003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 241 (of 360)

METRONIDAZOLE

INJECTABLE; INJECTION

METRO I.V.

B BRAUN

500MG/100ML

N018674 001 Aug 31, 1982

METRONIDAZOLE

ABBOTT

500MG/100ML

N018889 001 Nov 18, 1983

ABRAXIS PHARM

500MG/100ML

A070071 001 Dec 03, 1984

HIKMA MAPLE

500MG/100ML

N018907 001 Mar 30, 1984

INTL MEDICATION

500MG/100ML

A070004 001 May 08, 1985

WATSON LABS

500MG/100ML

A070042 001 Dec 20, 1984

500MG/100ML

A070170 001 Apr 01, 1986

TABLET; ORAL

METROMIDOL

LABS AF

250MG

A074523 001 Oct 24, 1996

500MG

A074523 002 Oct 24, 1996

METRONIDAZOLE

ABLE

250MG

A076519 001 Jun 27, 2003

500MG

A076519 002 Jun 27, 2003

HALSEY

250MG

A070021 001 Apr 02, 1985

500MG

A070593 001 Feb 27, 1986

IVAX SUB TEVA PHARMS

250MG

N018517 001

500MG

N018517 002 May 05, 1982

LNK

250MG

N019029 001 Apr 10, 1984

MUTUAL PHARM

250MG

N018818 001 Feb 16, 1983

500MG

N018818 002 Feb 16, 1983

PAR PHARM

250MG

N018845 001 Aug 18, 1983

500MG

N018930 001 Aug 18, 1983

SANDOZ

250MG

N018620 001 Mar 04, 1982

250MG

N018740 001 Oct 22, 1982

500MG

N018620 002 Jun 02, 1983

500MG

N018740 002 Oct 22, 1982

SUPERPHARM

250MG

A070008 001 Dec 11, 1984

500MG

A070009 001 Dec 11, 1984

WATSON LABS

250MG

N018599 001 Sep 17, 1982

500MG

N018599 002 Feb 13, 1984

WORLD GEN

250MG

A070040 001 Jan 29, 1985

500MG

A070039 001 Jan 29, 1985

PROTOSTAT

ORTHO MCNEIL PHARM

250MG

N018871 001 Mar 02, 1983

500MG

N018871 002 Mar 02, 1983

SATRIC

SAVAGE LABS

250MG

A070029 001 Mar 19, 1985

500MG

A070731 001 Jun 08, 1987

TABLET, EXTENDED RELEASE; ORAL

METRONIDAZOLE

ABLE

750MG

A076462 001 Jun 25, 2003

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

FLAGYL I.V.

PFIZER

EQ 500MG BASE/VIAL

N018353 001

METRONIDAZOLE HYDROCHLORIDE

ABRAXIS PHARM

EQ 500MG BASE/VIAL

A070295 001 Oct 15, 1985

METYRAPONE

TABLET; ORAL

METOPIRONE

HRA PHARMA

250MG

N012911 001

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

SANDOZ

150MG

A074450 001 May 16, 1996

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 242 (of 360)

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

SANDOZ	200MG	A074450	002	May 16, 1996
	250MG	A074450	003	May 16, 1996
MEXITIL				
BOEHRINGER INGELHEIM	150MG	N018873	002	Dec 30, 1985
	200MG	N018873	003	Dec 30, 1985
	250MG	N018873	004	Dec 30, 1985

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

MEZLIN

BAYER PHARMS	EQ 1GM BASE/VIAL	A062333	001	
	EQ 1GM BASE/VIAL	A062372	005	Jan 13, 1983
	EQ 1GM BASE/VIAL	N050549	001	
	EQ 2GM BASE/VIAL	A062333	002	
	EQ 2GM BASE/VIAL	A062372	001	May 13, 1982
	EQ 2GM BASE/VIAL	N050549	002	
	EQ 3GM BASE/VIAL	A062333	003	
	EQ 3GM BASE/VIAL	A062372	002	May 13, 1982
	EQ 3GM BASE/VIAL	A062697	001	Jan 22, 1987
	EQ 3GM BASE/VIAL	N050549	003	
	EQ 4GM BASE/VIAL	A062333	004	
	EQ 4GM BASE/VIAL	A062372	003	May 13, 1982
	EQ 4GM BASE/VIAL	A062697	002	Jan 22, 1987
	EQ 4GM BASE/VIAL	N050549	004	
	EQ 20GM BASE/VIAL	A062372	004	Mar 02, 1988
	EQ 20GM BASE/VIAL	N050549	005	Mar 02, 1988

MICONAZOLE

INJECTABLE; INJECTION

MONISTAT

JANSSEN PHARMA	10MG/ML	N018040	001	

MICONAZOLE NITRATE

CREAM; TOPICAL

MONISTAT-DERM

INSIGHT PHARMS	2%	N017494	001	

CREAM; VAGINAL

MICONAZOLE NITRATE

TEVA	2%	A074136	001	Jan 04, 1995
TEVA PHARMS	2%	A074030	001	Oct 30, 1992

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 7 DUAL PACK

ACTAVIS MID ATLANTIC	2%,100MG	A074586	001	Jul 17, 1997

LOTION; TOPICAL

MONISTAT-DERM

INSIGHT PHARMS	2%	N017739	001	

TAMPON; VAGINAL

MONISTAT 5

PERSONAL PRODS	100MG	N018592	001	Oct 27, 1989

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

APOTHECON	EQ 1MG BASE/ML	A075620	001	Nov 01, 2000
	EQ 5MG BASE/ML	A075620	002	Nov 01, 2000
	EQ 5MG BASE/ML	A075641	001	Oct 19, 2000
ASTRAZENECA	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000
BEDFORD	EQ 5MG BASE/ML	A075249	001	Jun 23, 2000
BEN VENUE	EQ 5MG BASE/ML	A075455	001	Jun 20, 2000
HOSPIRA	EQ 1MG BASE/ML	A075396	001	Jun 20, 2000
	EQ 5MG BASE/ML	A075396	002	Jun 20, 2000

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 243 (of 360)

MIDAZOLAM HYDROCHLORIDEINJECTABLE; INJECTION
MIDAZOLAM HYDROCHLORIDE

HOSPIRA	EQ 5MG BASE/ML	A075484	001	Jun 20, 2000
HOSPIRA INC	EQ 1MG BASE/ML	A075409	002	Jun 20, 2000
	EQ 5MG BASE/ML	A075409	001	Jun 20, 2000

VERSED

HLR	EQ 1MG BASE/ML	N018654	002	May 26, 1987
	EQ 5MG BASE/ML	N018654	001	Dec 20, 1985

SYRUP; ORAL

VERSED

ROCHE	EQ 2MG BASE/ML	N020942	001	Oct 15, 1998

MIDODRINE HYDROCHLORIDETABLET; ORAL
PROAMATINE

SHIRE LLC	2.5MG	N019815	001	Sep 06, 1996
	5MG	N019815	002	Sep 06, 1996
	10MG	N019815	003	Mar 20, 2002

MILRINONE LACTATEINJECTABLE; INJECTION
MILRINONE LACTATE

BIONICHE PHARMA	EQ 1MG BASE/ML	A076428	001	Jun 16, 2003
HIKMA MAPLE	EQ 1MG BASE/ML	A075852	001	May 28, 2002
HOSPIRA	EQ 1MG BASE/ML	A075830	001	May 28, 2002
	EQ 1MG BASE/ML	A075884	001	May 28, 2002

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076259	001	Aug 08, 2002
HIKMA MAPLE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510	001	May 28, 2002

PRIMACOR

SANOFI AVENTIS US	EQ 1MG BASE/ML	N019436	001	Dec 31, 1987

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

SANOFI AVENTIS US	EQ 10MG BASE/100ML	N020343	001	Aug 09, 1994
	EQ 15MG BASE/100ML	N020343	002	Aug 09, 1994
	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343	003	Aug 09, 1994
	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343	004	Aug 09, 1994

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DYNACIN

MEDICIS	EQ 50MG BASE	A063066	001	Aug 14, 1990

MINOCIN

PRECISION DERMAT	EQ 75MG BASE	N050649	003	Feb 12, 2001
TRIAx PHARMS	EQ 50MG BASE	N050315	002	
	EQ 100MG BASE	N050315	001	

INJECTABLE; INJECTION

MINOCIN

LEDERLE	EQ 100MG BASE/VIAL	A062139	001	

SUSPENSION; ORAL

MINOCIN

PRECISION DERMAT	EQ 50MG BASE/5ML	N050445	001	

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

TRIAx PHARMS	EQ 50MG BASE	N050451	003	Aug 10, 1982
	EQ 100MG BASE	N050451	002	Aug 10, 1982

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

LUPIN LTD	EQ 55MG BASE	A091424	002	Nov 30, 2011

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)

BAUSCH AND LOMB	2%	A074643	001	Apr 09, 1996

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 244 (of 360)

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)

COPLEY PHARM	2%	A074500	001	May 23, 1996

SIGHT PHARMS	2%	A074743	002	Oct 18, 1996

TEVA	2%	A074589	001	Apr 05, 1996

MINOXIDIL (FOR WOMEN)

SIGHT PHARMS	2%	A074743	001	Oct 18, 1996

TABLET; ORAL

LONITEN

PHARMACIA AND UPJOHN	2.5MG	N018154	001	

10MG	N018154	003		

MINODYL

QUANTUM PHARMICS	2.5MG	A072153	001	Jul 13, 1988

10MG	A071534	001	Mar 19, 1987	

MINOXIDIL

ROYCE LABS	2.5MG	A071799	001	Nov 10, 1987

10MG	A071796	001	Nov 10, 1987	

USL PHARMA	2.5MG	A071537	001	Dec 16, 1988

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A076308	001	Jun 20, 2003

30MG	A076308	002	Jun 20, 2003	

45MG	A076308	003	Jun 20, 2003	

ACTAVIS TOTOWA	15MG	A076241	001	Jun 25, 2003

30MG	A076241	002	Jun 25, 2003	

45MG	A076241	003	Jun 25, 2003	

IVAX SUB TEVA PHARMS	15MG	A076244	001	Dec 22, 2003

30MG	A076244	002	Dec 22, 2003	

45MG	A076244	003	Dec 22, 2003	

ROXANE	15MG	A076270	001	Jun 19, 2003

30MG	A076270	002	Jun 19, 2003	

45MG	A076270	003	Jun 19, 2003	

SANDOZ	15MG	A076189	001	Jun 19, 2003

30MG	A076189	002	Jun 19, 2003	

45MG	A076189	003	Jun 19, 2003	

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

ACTAVIS TOTOWA	15MG	A076689	001	Aug 31, 2005

30MG	A076689	002	Aug 31, 2005	

45MG	A076689	003	Aug 31, 2005	

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

HOSPIRA	20MG/VIAL	A064106	001	Nov 29, 1995

MITOZYTREX

SUPERGEN	5MG/VIAL	N050763	001	Nov 14, 2002

MUTAMYCIN

BRISTOL	5MG/VIAL	N050450	001	

20MG/VIAL	N050450	002		

BRISTOL MYERS	5MG/VIAL	A062336	001	

20MG/VIAL	A062336	002		

40MG/VIAL	A062336	003	Mar 10, 1988	

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606	001	May 14, 2008

	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606	002	May 14, 2008

	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606	003	May 14, 2008

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 245 (of 360)

MITOXANTRONE HYDROCHLORIDEINJECTABLE; INJECTION
NOVANTRONE

EMD SERONO

EQ 20MG BASE/10ML (EQ 2MG BASE/ML)
EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)
EQ 30MG BASE/15ML (EQ 2MG BASE/ML)N019297 001 Dec 23, 1987
N019297 002 Dec 23, 1987
N019297 003 Dec 23, 1987MIVACURIUM CHLORIDEINJECTABLE; INJECTION
MIVACRON

ABBVIE

EQ 2MG BASE/ML

N020098 001 Jan 22, 1992

MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBVIE

EQ 0.5MG BASE/ML
EQ 50MG BASE/100MLN020098 002 Jan 22, 1992
N020098 003 Jan 22, 1992

MIVACURIUM CHLORIDE

STRIDES ARCOLAB LTD

EQ 2MG BASE/ML

A078562 001 Apr 30, 2009

MOLINDONE HYDROCHLORIDECAPSULE; ORAL
MOBAN

ENDO PHARMS

5MG
10MG
25MGN017111 001
N017111 002
N017111 003

CONCENTRATE; ORAL

MOBAN

ENDO PHARMS

20MG/ML

N017938 001

TABLET; ORAL

MOBAN

ENDO PHARMS

5MG
10MG
25MG
50MG
100MGN017111 004
N017111 005
N017111 006
N017111 007
N017111 008MONOBENZONECREAM; TOPICAL
BENOQUIN

VALEANT PHARM INTL

20%

N008173 003

MONOCTANOINLIQUID; PERFUSION, BILIARY
MOCTANIN

ETHITEK

100%

N019368 001 Oct 29, 1985

MORICIZINE HYDROCHLORIDETABLET; ORAL
ETHMOZINE

SHIRE

200MG
250MG
300MGN019753 001 Jun 19, 1990
N019753 002 Jun 19, 1990
N019753 003 Jun 19, 1990MORPHINE SULFATEINJECTABLE; INJECTION
MORPHINE SULFATE

HOSPIRA

0.5MG/ML

N019917 001 Oct 30, 1992

MALLINCKRODT

1MG/ML
2MG/MLN020631 001 Jul 03, 1996
N020631 002 Jul 03, 1996INJECTABLE, LIPOSOMAL; EPIDURAL
DEPODUR

PACIRA PHARMS INC

10MG/ML (10MG/ML)
15MG/1.5ML (10MG/ML)
20MG/2ML (10MG/ML)N021671 001 May 18, 2004
N021671 002 May 18, 2004
N021671 003 May 18, 2004

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 246 (of 360)

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

WATSON LABS	100MG	A075656	001	Jan 30, 2001
ORAMORPH SR				
XANODYNE PHARMS INC	15MG	N019977	004	Nov 23, 1994
	30MG	N019977	001	Aug 15, 1991
	60MG	N019977	002	Aug 15, 1991
	100MG	N019977	003	Aug 15, 1991

MOXALACTAM DISODIUM

INJECTABLE; INJECTION

MOXAM

LILLY

EQ 250MG BASE/VIAL	N050550	001
EQ 500MG BASE/VIAL	N050550	002
EQ 1GM BASE/VIAL	N050550	003
EQ 2GM BASE/VIAL	N050550	004
EQ 10GM BASE/VIAL	N050550	008

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

ZYDUS PHARMS USA INC 250MG

A065433 001 May 04, 2009

TABLET; ORAL

MYCOPHENOLATE MOFETIL

DR REDDYS LABS LTD 500MG

A090464 001 Sep 13, 2010

ZYDUS PHARMS USA INC 500MG

A065477 001 May 04, 2009

NABUMETONE

TABLET; ORAL

NABUMETONE

COPLEY PHARM 750MG

A075179 001 Jun 06, 2000

SANDOZ 500MG

A075590 001 Feb 25, 2002

750MG

A075590 002 Feb 25, 2002

RELAFEN

SMITHKLINE BEECHAM 500MG

N019583 001 Dec 24, 1991

750MG

N019583 002 Dec 24, 1991

NADOLOL

TABLET; ORAL

CORCARD

KING PHARMS 120MG

N018063 003

160MG

N018063 004

NADOLOL

IVAX SUB TEVA PHARMS 120MG

A074255 002 Jan 24, 1996

160MG

A074255 003 Jan 24, 1996

TEVA PHARMS 80MG

A074368 001 Aug 31, 1994

120MG

A074368 002 Aug 31, 1994

160MG

A074368 003 Aug 31, 1994

NAFCILLIN SODIUM

CAPSULE; ORAL

UNIPEN

WYETH AYERST EQ 250MG BASE

N050111 001

FOR SOLUTION; ORAL

UNIPEN

WYETH AYERST EQ 250MG BASE/5ML

N050199 001

INJECTABLE; INJECTION

NAFCILLIN SODIUM

APOTHECON EQ 500MG BASE/VIAL

A061984 001

EQ 1GM BASE/VIAL

A061984 002

EQ 2GM BASE/VIAL

A061984 003

EQ 4GM BASE/VIAL

A061984 005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 247 (of 360)

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

MARSAM PHARMS LLC

EQ 500MG BASE/VIAL

A062844 001 Oct 26, 1988

EQ 1GM BASE/VIAL

A062844 002 Oct 26, 1988

EQ 1.5GM BASE/VIAL

A062844 003 Oct 26, 1988

EQ 2GM BASE/VIAL

A062844 004 Oct 26, 1988

EQ 4GM BASE/VIAL

A062844 005 Oct 26, 1988

EQ 10GM BASE/VIAL

A063008 001 Sep 29, 1988

EQ 500MG BASE/VIAL

A062527 001 Aug 02, 1984

SANDOZ

NALLPEN

GLAXOSMITHKLINE

EQ 500MG BASE/VIAL

A061999 001

EQ 1GM BASE/VIAL

A061999 002

EQ 1GM BASE/VIAL

A062755 001 Dec 19, 1986

EQ 2GM BASE/VIAL

A061999 003

EQ 2GM BASE/VIAL

A062755 002 Dec 19, 1986

EQ 10GM BASE/VIAL

A061999 004

UNIPEN

WYETH AYERST

EQ 500MG BASE/VIAL

A062717 001 Dec 16, 1986

EQ 500MG BASE/VIAL

N050320 001

EQ 1GM BASE/VIAL

A062717 002 Dec 16, 1986

EQ 2GM BASE/VIAL

A062717 004 Dec 16, 1986

EQ 2GM BASE/VIAL

N050320 003

EQ 4GM BASE/VIAL

N050320 004

EQ 10GM BASE/VIAL

N050320 005

EQ 20GM BASE/VIAL

N050320 006

UNIPEN IN PLASTIC CONTAINER

WYETH AYERST

EQ 1GM BASE/VIAL

N050320 002

TABLET; ORAL

UNIPEN

WYETH AYERST

EQ 500MG BASE

N050462 001

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE

ABRAXIS PHARM

10MG/ML

A070751 001 Jul 02, 1986

20MG/ML

A070752 001 Sep 24, 1986

NALBUPHINE HYDROCHLORIDE

ABBOTT

20MG/ML

A070917 001 Feb 03, 1989

ABBVIE

1.5MG/ML

N020200 001 Mar 12, 1993

ASTRAZENECA

10MG/ML

A072070 001 Apr 10, 1989

10MG/ML

A072071 001 Apr 10, 1989

10MG/ML

A072072 001 Apr 10, 1989

20MG/ML

A072073 001 Apr 10, 1989

20MG/ML

A072074 001 Apr 10, 1989

20MG/ML

A072075 001 Apr 10, 1989

BARR

10MG/ML

A074471 001 Mar 19, 1998

20MG/ML

A074471 002 Mar 19, 1998

NUBAIN

ENDO PHARMS

10MG/ML

N018024 001

20MG/ML

N018024 002 May 27, 1982

NALIDIXIC ACID

SUSPENSION; ORAL

NEGGRAM

SANOFI AVENTIS US

250MG/5ML

N017430 001

TABLET; ORAL

NALIDIXIC ACID

MUTUAL PHARM

250MG

A070270 001 Jun 29, 1988

500MG

A070271 001 Jun 29, 1988

1GM

A070272 001 Jun 29, 1988

WATSON LABS

250MG

A071936 001 Jun 29, 1988

500MG

A072061 001 Jun 29, 1988

DISCONTINUED DRUG PRODUCT LIST

6 - 248 (of 360)

NALIDIXIC ACID

TABLET; ORAL
NALIDIXIC ACID

WATSON LABS	1GM	A071919	001	Jun 29, 1988
NEGGRAM				
SANOFI AVENTIS US	250MG	N014214	002	
	500MG	N014214	004	
	1GM	N014214	005	

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION
REVEX

BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995
	EQ 1MG BASE/ML	N020459	002	Apr 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE

HIKMA MAPLE	0.4MG/ML	A070298	001	Sep 24, 1986
	0.4MG/ML	A070299	001	Sep 24, 1986
	0.4MG/ML	A070496	001	Sep 24, 1986
WYETH AYERST	0.02MG/ML	A070188	001	Sep 24, 1986
	0.02MG/ML	A070189	001	Sep 24, 1986
	0.4MG/ML	A070190	001	Sep 24, 1986
	0.4MG/ML	A070191	001	Sep 24, 1986
NALOXONE HYDROCHLORIDE				
ABRAXIS PHARM	0.02MG/ML	A070648	001	Nov 17, 1986
	0.02MG/ML	A070661	001	Nov 17, 1986
	0.4MG/ML	A070649	001	Nov 17, 1986
	1MG/ML	A071604	001	Dec 16, 1988
ASTRAZENECA	0.02MG/ML	A072081	001	Apr 11, 1989
	0.02MG/ML	A072082	001	Apr 11, 1989
	0.02MG/ML	A072083	001	Apr 11, 1989
	0.02MG/ML	A072084	001	Apr 11, 1989
	0.02MG/ML	A072085	001	Apr 11, 1989
	0.4MG/ML	A072086	001	Apr 11, 1989
	0.4MG/ML	A072087	001	Apr 11, 1989
	0.4MG/ML	A072088	001	Apr 11, 1989
	0.4MG/ML	A072089	001	Apr 11, 1989
	0.4MG/ML	A072090	001	Apr 11, 1989
	1MG/ML	A072091	001	Apr 11, 1989
	1MG/ML	A072092	001	Apr 11, 1989
	1MG/ML	A072093	001	Apr 11, 1989
HIKMA MAPLE	0.02MG/ML	A071272	001	May 24, 1988
	1MG/ML	A071273	001	May 24, 1988
	1MG/ML	A071274	001	May 24, 1988
	1MG/ML	A071287	001	May 24, 1988
HOSPIRA	0.02MG/ML	A070171	001	Sep 24, 1986
	0.02MG/ML	A070252	001	Jan 16, 1987
	0.02MG/ML	A070253	001	Jan 16, 1987
	0.4MG/ML	A070255	001	Jan 07, 1987
INTL MEDICATION	0.4MG/ML	A070417	001	Sep 24, 1986
	1MG/ML	A072115	001	Apr 27, 1988
MARSAM PHARMS LLC	0.4MG/ML	A071811	001	Jul 19, 1988
SMITH AND NEPHEW	0.02MG/ML	A071671	001	Nov 17, 1987
	0.4MG/ML	A071681	001	Nov 17, 1987
	0.4MG/ML	A071682	001	Nov 17, 1987
SOLOPAK	0.02MG/ML	A071672	001	Nov 17, 1987
	0.4MG/ML	A071683	001	Nov 17, 1987
WATSON LABS	0.4MG/ML	A071339	001	Nov 18, 1987
NARCAN				
BRISTOL MYERS SQUIBB	0.4MG/ML	A071083	001	Jul 28, 1988
	1MG/ML	A071084	001	Jul 28, 1988

DISCONTINUED DRUG PRODUCT LIST

6 - 249 (of 360)

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NARCAN

BRISTOL MYERS SQUIBB	1MG/ML	A071311	001	Jul 28, 1988
ENDO PHARMS	0.02MG/ML	N016636	002	
	0.4MG/ML	N016636	001	
	1MG/ML	N016636	003	Jun 14, 1982

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
TALWIN NX

SANOFI AVENTIS US	EQ 0.5MG BASE;EQ 50MG BASE	N018733	001	Dec 16, 1982

NANDROLONE DECANOATE

INJECTABLE; INJECTION
DECA-DURABOLIN

ORGANON USA INC	50MG/ML	N013132	001	Jun 12, 1986
	100MG/ML	N013132	002	Jun 12, 1986
	200MG/ML	N013132	003	Jun 12, 1986

NANDROLONE DECANOATE

ABRAXIS PHARM	100MG/ML	A088290	001	Oct 03, 1983
	200MG/ML	A088317	001	Oct 14, 1983
AKORN	100MG/ML	A087519	001	Sep 28, 1983
WATSON LABS	50MG/ML	A086385	001	Jan 13, 1984
	50MG/ML	A087598	001	Oct 06, 1983
	50MG/ML	A088554	001	Feb 10, 1986
	100MG/ML	A086598	001	Jan 13, 1984
	100MG/ML	A087599	001	Oct 06, 1983
	200MG/ML	A088128	001	Dec 05, 1983

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION
DURABOLIN

ORGANON USA INC	25MG/ML	N011891	001	
	50MG/ML	N011891	002	

NANDROLONE PHENPROPIONATE

WATSON LABS	25MG/ML	A086386	001	Jun 17, 1983
	50MG/ML	A087488	001	Jun 17, 1983

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
NAFAZAIR

BAUSCH AND LOMB	0.1%	A040073	001	May 25, 1994
PHARMAFAIR	0.1%	A088101	001	Apr 15, 1983
NAPHCN FORTE				
ALCON	0.1%	A080229	001	
OPCON				
BAUSCH AND LOMB	0.1%	A087506	001	
VASOCON				
NOVARTIS	0.1%	A080235	002	Mar 24, 1983

NAPROXEN

TABLET; ORAL
NAPROXEN

DAVA PHARMS INC	250MG	A074105	001	Dec 21, 1993
	375MG	A074105	002	Dec 21, 1993
	500MG	A074105	003	Dec 21, 1993
HAMILTON PHARMS	250MG	A074110	001	Oct 30, 1992
	375MG	A074110	002	Oct 30, 1992
	500MG	A074110	003	Oct 30, 1992
IVAX SUB TEVA PHARMS	250MG	A074111	001	Feb 28, 1995
	375MG	A074111	002	Feb 28, 1995
	500MG	A074111	003	Feb 28, 1995

DISCONTINUED DRUG PRODUCT LIST

6 - 250 (of 360)

NAPROXEN

TABLET; ORAL NAPROXEN

PLIVA	250MG	A074182	001	Jun 27, 1996
	375MG	A074182	002	Jun 27, 1996
	500MG	A074182	003	Jun 27, 1996
PUREPAC PHARM	250MG	A074263	001	Dec 21, 1993
	375MG	A074263	002	Dec 21, 1993
	500MG	A074263	003	Dec 21, 1993
ROXANE	250MG	A074211	001	Feb 28, 1994
	375MG	A074211	002	Feb 28, 1994
	500MG	A074211	003	Feb 28, 1994
TEVA	250MG	A074129	001	Dec 21, 1993
	250MG	A074216	001	Apr 11, 1996
	375MG	A074129	002	Dec 21, 1993
	375MG	A074216	002	Apr 11, 1996
	500MG	A074129	003	Dec 21, 1993
	500MG	A074216	003	Apr 11, 1996
TEVA PHARMS	250MG	A074207	001	Dec 21, 1993
	375MG	A074207	002	Dec 21, 1993
	500MG	A074207	003	Dec 21, 1993
WATSON LABS	250MG	A074163	001	Feb 10, 1995
	375MG	A074163	002	Feb 10, 1995
	500MG	A074163	003	Feb 10, 1995

TABLET, DELAYED RELEASE; ORAL NAPROXEN

ACTAVIS ELIZABETH	375MG	A074936	001	Feb 24, 1998
	500MG	A074936	002	Feb 24, 1998

NAPROXEN SODIUM

TABLET; ORAL NAPROXEN SODIUM

ABLE	EQ 250MG BASE	A076544	001	Aug 22, 2003
	EQ 500MG BASE	A076544	002	Aug 22, 2003
HAMILTON PHARMS	EQ 250MG BASE	A074106	001	Aug 31, 1993
	EQ 500MG BASE	A074106	002	Aug 31, 1993
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A074230	001	Mar 14, 1995
	EQ 500MG BASE	A074230	002	Mar 14, 1995
MYLAN	EQ 250MG BASE	A074367	001	Aug 31, 1994
	EQ 500MG BASE	A074367	002	Aug 31, 1994
PLIVA	EQ 250MG BASE	A074242	001	Jun 20, 1996
	EQ 500MG BASE	A074242	002	Jun 20, 1996
PUREPAC PHARM	EQ 250MG BASE	A074319	001	Mar 20, 1995
	EQ 500MG BASE	A074319	002	Mar 20, 1995
ROXANE	EQ 250MG BASE	A074257	001	Dec 21, 1993
	EQ 500MG BASE	A074257	002	Dec 21, 1993
SANDOZ	EQ 200MG BASE	A074646	001	Jan 13, 1997
	EQ 250MG BASE	A074162	001	Dec 21, 1993
	EQ 250MG BASE	A074495	001	Dec 05, 1994
	EQ 500MG BASE	A074162	002	Dec 21, 1993
	EQ 500MG BASE	A074495	002	Dec 05, 1994
TEVA	EQ 250MG BASE	A074142	001	Dec 21, 1993
	EQ 500MG BASE	A074142	002	Dec 21, 1993
TEVA PHARMS	EQ 250MG BASE	A074289	001	Jan 27, 1994
	EQ 500MG BASE	A074289	002	Jan 27, 1994
WATSON LABS	EQ 250MG BASE	A074195	001	Dec 21, 1993
	EQ 500MG BASE	A074195	002	Dec 21, 1993

TABLET, EXTENDED RELEASE; ORAL NAPROXEN SODIUM

WATSON LABS FLORIDA	EQ 375MG BASE	A075416	002	Apr 23, 2003
	EQ 500MG BASE	A075416	001	Aug 27, 2002

DISCONTINUED DRUG PRODUCT LIST

6 - 251 (of 360)

NATEGLINIDE

TABLET; ORAL
NATEGLINIDE

TEVA PHARMS	60MG	A077467	001	Sep 09, 2009
	120MG	A077467	002	Sep 09, 2009

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION
TILADE

KING PHARMS	1.75MG/INH	N019660	001	Dec 30, 1992

SOLUTION; INHALATION
TILADE

SANOFI AVENTIS US	0.5%	N020750	001	Oct 01, 1997

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL
NEFAZODONE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	50MG	A075763	001	Sep 16, 2003
	100MG	A075763	002	Sep 16, 2003
	150MG	A075763	003	Sep 16, 2003
	200MG	A075763	004	Sep 16, 2003
	250MG	A075763	005	Sep 16, 2003
MYLAN	100MG	A076129	002	Sep 16, 2003
	150MG	A076129	003	Sep 16, 2003
	200MG	A076129	004	Sep 16, 2003
	250MG	A076129	005	Sep 16, 2003
ROXANE	50MG	A076196	001	Sep 16, 2003
	100MG	A076196	002	Sep 16, 2003
	150MG	A076196	003	Sep 16, 2003
	200MG	A076196	004	Sep 16, 2003
	250MG	A076196	005	Sep 16, 2003
SANDOZ	50MG	A076072	001	Sep 16, 2003
	50MG	A076302	001	Sep 16, 2003
	100MG	A076072	002	Sep 16, 2003
	100MG	A076302	002	Sep 16, 2003
	150MG	A076072	003	Sep 16, 2003
	150MG	A076302	003	Sep 16, 2003
	200MG	A076072	004	Sep 16, 2003
	200MG	A076302	004	Sep 16, 2003
	250MG	A076072	005	Sep 16, 2003
	250MG	A076302	005	Sep 16, 2003
WATSON LABS	100MG	A076073	002	Sep 16, 2003
	150MG	A076073	003	Sep 16, 2003
	200MG	A076073	004	Sep 16, 2003
	250MG	A076073	005	Sep 16, 2003

SERZONE

BRISTOL MYERS SQUIBB	50MG	N020152	001	Dec 22, 1994
	100MG	N020152	002	Dec 22, 1994
	150MG	N020152	003	Dec 22, 1994
	200MG	N020152	004	Dec 22, 1994
	250MG	N020152	005	Dec 22, 1994
	300MG	N020152	006	Dec 22, 1994

NEOMYCIN SULFATE

SOLUTION; ORAL
MYCIFRADIN

PHARMACIA AND UPJOHN	EQ 87.5MG BASE/5ML	N050285	001	

TABLET; ORAL
MYCIFRADIN

PHARMACIA AND UPJOHN	EQ 350MG BASE	A060520	001	

NEOBIOTIC

PFIZER	EQ 350MG BASE	A060475	001	

DISCONTINUED DRUG PRODUCT LIST

6 - 252 (of 360)

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

BRISTOL MYERS SQUIBB	500MG	A060365	001
LANNETT	500MG	A060607	001
LILLY	500MG	A060385	001
ROXANE	500MG	A062173	001
SANDOZ	500MG	A061586	001

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

NEOSPORIN

GLAXOSMITHKLINE	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050176	002	Jan 14, 1985

OINTMENT; OPHTHALMIC

STATROL

ALCON	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050344	002

SOLUTION/DROPS; OPHTHALMIC

STATROL

ALCON	EQ 3.5MG BASE/ML;16,250 UNITS/ML	A062339	001	Nov 30, 1984
	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N050456	001	

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN	EQ 3.5MG BASE/GM;0.25%	A061039	002
	EQ 3.5MG BASE/GM;0.5%	A061039	001

SUSPENSION/DROPS; OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN	EQ 3.5MG BASE/ML;0.25%	A061037	001

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

OINTMENT; OPHTHALMIC

NEO-HYDELTRASOL

MERCK	EQ 3.5MG BASE/GM;EQ 0.25% PHOSPHATE	N050378	001

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYTREX A

SAVAGE LABS	EQ 3.5MG BASE/GM;0.1%	A062598	001	Jul 21, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA	EQ 3.5MG BASE/GM;0.1%	A062600	001	Jul 21, 1986
PHARMADERM	EQ 3.5MG BASE/GM;0.1%	A062595	001	Jul 21, 1986

OINTMENT; TOPICAL

MYTREX A

SAVAGE LABS	EQ 3.5MG BASE/GM;0.1%	A062609	001	May 23, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA	EQ 3.5MG BASE/GM;0.1%	A062608	001	May 23, 1986
PHARMADERM	EQ 3.5MG BASE/GM;0.1%	A062607	001	May 23, 1986

NETILMICIN SULFATE

INJECTABLE; INJECTION

NETROMYCIN

SCHERING	EQ 10MG BASE/ML	N050544	001	Feb 28, 1983
	EQ 25MG BASE/ML	N050544	002	Feb 28, 1983
	EQ 100MG BASE/ML	N050544	003	Feb 28, 1983

NIACIN

CAPSULE; ORAL

WAMPOCAP

MEDPOINTE PHARM HLC	500MG	N011073	003

TABLET; ORAL

NIACIN

EVERYLIFE	500MG	A083203	001
HALSEY	500MG	A083453	001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 253 (of 360)

NIACIN

TABLET; ORAL

NIACIN

IMPAX LABS 500MG A083115 001

IVAX SUB TEVA PHARMS 500MG A083180 001

MK LABS 500MG A083525 001

PUREPAC PHARM 500MG A083271 001

SANDOZ 500MG A083306 001

TABLICAPS 500MG A084237 001

WATSON LABS 500MG A083136 001

500MG A083305 001

500MG A085172 001

WEST WARD 500MG A083718 001

NICOLAR

SANOFI AVENTIS US 500MG A083823 001

TABLET, EXTENDED RELEASE; ORAL

NIACIN

BARR 500MG A076378 001 Apr 26, 2005

750MG A076378 002 Apr 26, 2005

1GM A076250 001 Apr 14, 2005

NIASPAN

ABBVIE 375MG N020381 001 Jul 28, 1997

NIASPAN TITRATION STARTER PACK

ABBVIE 375MG;500MG;750MG N020381 005 Jul 28, 1997

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION; ORAL

TPN

INTL MINERALS 15MG/5ML;3.75MG/5ML;600MG/5ML N008378 003

NICARDIPINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDENE SR

EKR THERAP 45MG N020005 002 Feb 21, 1992

NICLOSAMIDE

TABLET, CHEWABLE; ORAL

NICLOCIDE

BAYER PHARMS 500MG N018669 001 May 14, 1982

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTROL

MCNEIL CONS 15MG/16HR N020536 001 Jul 03, 1996

PROSTEP

AVEVA 11MG/24HR N019983 003 Dec 23, 1998

22MG/24HR N019983 004 Dec 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

WATSON LABS EQ 2MG BASE A076568 001 Jul 29, 2004

EQ 4MG BASE A076569 002 Jul 29, 2004

NIFEDIPINE

CAPSULE; ORAL

ADALAT

BAYER PHARMS 10MG N019478 001 Nov 27, 1985

20MG N019478 002 Sep 17, 1986

NIFEDIPINE

CATALENT 20MG A074045 001 Apr 30, 1992

CHASE LABS NJ 10MG A072409 001 Jul 04, 1990

20MG A073421 001 Jun 19, 1991

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 254 (of 360)

NIFEDIPINE

CAPSULE; ORAL				
NIFEDIPINE				
TEVA	10MG	A072651	001	Feb 19, 1992
PROCARDIA				
PFIZER	20MG	N018482	002	Jul 24, 1986
TABLET, EXTENDED RELEASE; ORAL				
NIFEDIPINE				
MARTEC USA LLC	90MG	A075414	003	Mar 23, 2004
MYLAN	30MG	A075108	001	Dec 17, 1999

NILUTAMIDE

TABLET; ORAL				
NILANDRON				
SANOFI AVENTIS US	50MG	N020169	001	Sep 19, 1996

NIMODIPINE

CAPSULE; ORAL				
NIMOTOP				
BAYER PHARMS	30MG	N018869	001	Dec 28, 1988

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL				
SULAR				
SHIONOGI INC	10MG	N020356	001	Feb 02, 1995
	20MG	N020356	002	Feb 02, 1995
	30MG	N020356	003	Feb 02, 1995
	40MG	N020356	004	Feb 02, 1995

NITROFURANTOIN

CAPSULE; ORAL				
NITROFURANTOIN				
WATSON LABS	50MG	A084326	001	
	100MG	A084326	002	
TABLET; ORAL				
FURADANTIN				
PROCTER AND GAMBLE	50MG	N008693	001	
	100MG	N008693	002	
FURALAN				
LANNETT	50MG	A080017	001	
	100MG	A080017	002	
NITROFURANTOIN				
ELKINS SINN	50MG	A080003	001	
	100MG	A080003	002	
IVAX SUB TEVA PHARMS	50MG	A080078	002	
	100MG	A080078	001	
SANDOZ	50MG	A080043	001	
	100MG	A080043	002	
WATSON LABS	50MG	A080447	001	
	50MG	A085797	001	
	100MG	A080447	002	
	100MG	A085796	001	
WHITEWORTH TOWN PLSN	100MG	A084085	002	

NITROFURANTOIN SODIUM

INJECTABLE; INJECTION				
IVADANTIN				
PROCTER AND GAMBLE	EQ 180MG BASE/VIAL	N012402	001	

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL				
NITROFURANTOIN				
MYLAN	100MG	A074967	002	Jul 09, 1997

DISCONTINUED DRUG PRODUCT LIST

6 - 255 (of 360)

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL					
NITROFURANTOIN					
SANDOZ	25MG	A074336	001	Jan 25, 1995	
	50MG	A074336	002	Jan 25, 1995	
	100MG	A074336	003	Jan 25, 1995	
NITROFURANTOIN MACROCRYSTALLINE					
WATSON LABS	50MG	A070248	001	Jun 24, 1988	
	100MG	A070249	001	Jun 24, 1988	

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL					
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)					
RANBAXY LABS LTD	75MG;25MG	A076951	001	Mar 30, 2005	

NITROFURAZONE

CREAM; TOPICAL					
FURACIN					
SHIRE	0.2%	A083789	001		
DRESSING; TOPICAL					
ACTIN-N					
SHERWOOD MEDCL	0.2%	N017343	001		
OINTMENT; TOPICAL					
FURACIN					
SHIRE	0.2%	N005795	001		
NITROFURAZONE					
AMBIX	0.2%	A086077	001		
LANNETT	0.2%	A084393	001		
PERRIGO NEW YORK	0.2%	A084968	001		
TARO	0.2%	A086156	001		
WENDT	0.2%	A086766	001		
POWDER; TOPICAL					
FURACIN					
SHIRE	0.2%	A083791	001		
SOLUTION; TOPICAL					
NITROFURAZONE					
PERRIGO NEW YORK	0.2%	A085130	001		
WENDT	0.2%	A087081	001		

NITROGLYCERIN

AEROSOL; SUBLINGUAL					
NITROLINGUAL					
POHL BOSKAMP	0.4MG/SPRAY	N018705	001	Oct 31, 1985	
FILM, EXTENDED RELEASE; TRANSDERMAL					
NITROGLYCERIN					
MYLAN TECHNOLOGIES	0.1MG/HR	A074992	004	Nov 12, 1999	
	0.2MG/HR	A074992	003	Nov 12, 1999	
	0.4MG/HR	A074992	002	Nov 12, 1999	
	0.6MG/HR	A074992	001	Nov 12, 1999	
TRANSDERM-NITRO					
NOVARTIS	0.1MG/HR	N020144	001	Feb 27, 1996	
	0.2MG/HR	N020144	002	Feb 27, 1996	
	0.4MG/HR	N020144	003	Feb 27, 1996	
	0.6MG/HR	N020144	004	Feb 27, 1996	
	0.8MG/HR	N020144	005	Feb 27, 1996	
INJECTABLE; INJECTION					
NITRO IV					
POHL BOSKAMP	5MG/ML	N018672	002	Aug 30, 1983	
NITRO-BID					
SANOFI AVENTIS US	5MG/ML	N018621	001	Jan 05, 1982	
	10MG/ML	A071159	001	Feb 28, 1990	
NITROGLYCERIN					
ABRAXIS PHARM	5MG/ML	A070077	001	Dec 13, 1985	
	5MG/ML	A071203	001	May 08, 1987	

DISCONTINUED DRUG PRODUCT LIST

6 - 256 (of 360)

NITROGLYCERIN

INJECTABLE; INJECTION NITROGLYCERIN

INTL MEDICATION	5MG/ML	A070026	001	Sep 10, 1985
LUITPOLD	5MG/ML	A071492	001	May 24, 1988
SMITH AND NEPHEW	5MG/ML	A070633	001	Jun 19, 1986
	5MG/ML	A070634	001	Jun 19, 1986
NITROGLYCERIN IN DEXTROSE 5%				
HOSPIRA	0.1MG/ML	A074083	001	Oct 26, 1994
NITROL				
RORER	0.8MG/ML	N018774	001	Jan 19, 1983
NITRONAL				
POHL BOSKAMP	1MG/ML	N018672	001	Aug 30, 1983
NITROSTAT				
PARKE DAVIS	0.8MG/ML	N018588	001	
	5MG/ML	A070863	001	Jan 08, 1987
	5MG/ML	N018588	002	Dec 23, 1983
	10MG/ML	A070871	001	Jan 08, 1987
	10MG/ML	A070872	001	Jan 08, 1987
TRIDIL				
HOSPIRA	0.5MG/ML	N018537	002	Jun 16, 1983
	5MG/ML	N018537	001	

NIZATIDINE

CAPSULE; ORAL AXID

SMITHKLINE BEECHAM	150MG	N019508	001	Apr 12, 1988
	300MG	N019508	002	Apr 12, 1988
NIZATIDINE				
IVAX SUB TEVA PHARMS	150MG	A075461	001	Jul 08, 2002
	300MG	A075461	002	Jul 08, 2002
MYLAN PHARMS INC	150MG	A075934	001	Jul 09, 2002
	300MG	A075934	002	Jul 09, 2002

NONOXYNOL-9

AEROSOL; VAGINAL Delfen

PERSONAL PRODS	12.5%	N014349	002	

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION NOREPINEPHRINE BITARTRATE

METRICS PHARM	EQ 1MG BASE/ML	A040522	001	Sep 30, 2004

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ LEVOPHED				
EASTMAN KODAK	EQ 0.033MG BASE/ML ; 2%; 0.4%	N008592	003	

NORETHINDRONE

TABLET; ORAL NORLUTIN

PARKE DAVIS	5MG	N010895	002	

NORETHINDRONE ACETATE

TABLET; ORAL NORLUTATE

PARKE DAVIS	5MG	N012184	002	

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC CHIBROXIN

MERCK	0.3%	N019757	001	Jun 17, 1991

DISCONTINUED DRUG PRODUCT LIST

6 - 257 (of 360)

NORGESTREL

TABLET; ORAL
OVRETTE

WYETH PHARMS	0.075MG	N017031	001

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

AVENTYL HYDROCHLORIDE

LILLY	EQ 10MG BASE	N014684	001
	EQ 25MG BASE	N014684	002

NORTRIPTYLINE HYDROCHLORIDE

SANDOZ	EQ 10MG BASE	A074054	001	Dec 31, 1992
	EQ 10MG BASE	A074835	001	Jun 30, 1997
	EQ 25MG BASE	A074054	002	Dec 31, 1992
	EQ 25MG BASE	A074835	002	Jun 30, 1997
	EQ 50MG BASE	A074054	003	Dec 31, 1992
	EQ 50MG BASE	A074835	003	Jun 30, 1997
	EQ 75MG BASE	A074054	004	Dec 31, 1992
	EQ 75MG BASE	A074835	004	Jun 30, 1997
TEVA	EQ 10MG BASE	A073667	001	Apr 11, 1996
	EQ 25MG BASE	A073667	002	Apr 11, 1996
	EQ 50MG BASE	A073667	003	Apr 11, 1996
	EQ 75MG BASE	A073667	004	Apr 11, 1996

SOLUTION; ORAL

PAMELOR

MALLINCKRODT INC	EQ 10MG BASE/5ML	N018012	001

NYSTATIN

CREAM; TOPICAL

CANDEX

BAYER PHARMS	100,000 UNITS/GM	A061810	001

MYCOSTATIN

BRISTOL MYERS SQUIBB	100,000 UNITS/GM	A060575	001

MYKINAC

ALPHARMA US PHARMS	100,000 UNITS/GM	A062387	001	Jul 29, 1982

NILSTAT

LEDERLE	100,000 UNITS/GM	A061445	001

NYSTATIN

TARO	100,000 UNITS/GM	A062457	001	Jul 28, 1983

TEVA	100,000 UNITS/GM	A061966	001

LOTION; TOPICAL

CANDEX

BAYER PHARMS	100,000 UNITS/ML	N050233	001

OINTMENT; TOPICAL

MYCOSTATIN

WESTWOOD SQUIBB	100,000 UNITS/GM	A060571	001

MYKINAC

ALPHARMA US PHARMS	100,000 UNITS/GM	A062731	001	Sep 22, 1986

NILSTAT

LEDERLE	100,000 UNITS/GM	A061444	001

PASTILLE; ORAL

MYCOSTATIN

BRISTOL MYERS SQUIBB	200,000 UNITS	N050619	001	Apr 09, 1987

POWDER; ORAL

BARSTATIN 100

BARLAN	100%	A062489	001	Apr 27, 1988

NILSTAT

DAVA PHARMS INC	100%	N050576	001	Dec 22, 1983

NYSTATIN

PADDOCK LLC	100%	A062613	001	Nov 26, 1985

POWDER; TOPICAL

MYCOSTATIN

BRISTOL MYERS SQUIBB	100,000 UNITS/GM	A060578	001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 258 (of 360)

NYSTATIN

POWDER; TOPICAL

NYSTATIN

NESHER PHARMS

100,000 UNITS/GM

A065321 001

Aug 18, 2006

SUPPOSITORY; VAGINAL

NYSERT

WARNER CHILCOTT

100,000 UNITS

N050478 001

SUSPENSION; ORAL

MYCOSTATIN

APOTHECON

100,000 UNITS/ML

A061533 001

NYSTATIN

ALPHARMA US PHARMS

100,000 UNITS/ML

A062571 001

Oct 29, 1985

MORTON GROVE

100,000 UNITS/ML

A062835 001

Nov 19, 1987

PHARMADERM

100,000 UNITS/ML

A062518 001

Jul 06, 1984

PHARMAFAIR

100,000 UNITS/ML

A062541 001

Jan 16, 1985

ROXANE

100,000 UNITS/ML

A062832 001

Dec 27, 1991

TEVA

100,000 UNITS/ML

A062670 001

Jun 18, 1987

100,000 UNITS/ML

A062776 001

Dec 17, 1987

NYSTEX

SAVAGE LABS

100,000 UNITS/ML

A062519 001

Jul 06, 1984

TABLET; ORAL

MYCOSTATIN

BRISTOL MYERS SQUIBB

500,000 UNITS

A060574 001

NILSTAT

LEDERLE

500,000 UNITS

A061151 001

NYSTATIN

QUANTUM PHARMICS

500,000 UNITS

A062525 001

Oct 29, 1984

SANDOZ

500,000 UNITS

A062065 001

USL PHARMA

500,000 UNITS

A062524 001

Nov 26, 1985

WATSON LABS

500,000 UNITS

A062402 001

Dec 16, 1982

TABLET; VAGINAL

KOROSTATIN

HOLLAND RANTOS

100,000 UNITS

A061718 001

MYCOSTATIN

BRISTOL MYERS SQUIBB

100,000 UNITS

A060577 001

NILSTAT

LEDERLE

100,000 UNITS

A061325 001

NYSTATIN

FOUGERA

100,000 UNITS

A062459 001

Nov 09, 1983

PHARMADERM

100,000 UNITS

A062460 001

Nov 09, 1983

QUANTUM PHARMICS

100,000 UNITS

A062509 001

Apr 03, 1984

SANDOZ

100,000 UNITS

A061965 001

TEVA

100,000 UNITS

A062502 001

Dec 23, 1983

WATSON LABS

100,000 UNITS

A062176 001

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYCOLOG-II

APOTHECON

100,000 UNITS/GM;0.1%

A060576 002

May 01, 1985

100,000 UNITS/GM;0.1%

A062606 001

May 15, 1985

MYCO-TRIACET II

TEVA

100,000 UNITS/GM;0.1%

A061954 002

Sep 20, 1985

MYKACET

G AND W LABS INC

100,000 UNITS/GM;0.1%

A062367 001

May 28, 1985

MYTrex F

SAVAGE LABS

100,000 UNITS/GM;0.1%

A062597 001

Oct 08, 1985

NYSTATIN AND TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS

100,000 UNITS/GM;0.1%

A063010 001

Dec 20, 1988

PERRIGO NEW YORK

100,000 UNITS/GM;0.1%

A062186 002

Jun 06, 1985

PHARMAFAIR

100,000 UNITS/GM;0.1%

A062657 001

Jul 30, 1986

TARO

100,000 UNITS/GM;0.1%

A062347 001

Mar 30, 1987

NYSTATIN-TRIAMCINOLONE ACETONIDE

PHARMADERM

100,000 UNITS/GM;0.1%

A062596 001

Oct 08, 1985

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 259 (of 360)

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

MYCOLOG-II

APOTHECON	100,000 UNITS/GM;0.1%	A060572	001	Jun 28, 1985

MYCO-TRIACET II

TEVA	100,000 UNITS/GM;0.1%	A062045	002	Nov 26, 1985

MYKACET

G AND W LABS INC	100,000 UNITS/GM;0.1%	A062733	001	Mar 09, 1987

MYTREX F

SAVAGE LABS	100,000 UNITS/GM;0.1%	A062601	001	Oct 09, 1985

NYSTATIN AND TRIAMCINOLONE ACETONIDE

PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062280	002	Oct 10, 1985

PHARMAFAIR	100,000 UNITS/GM;0.1%	A062656	001	Jul 30, 1986

NYSTATIN-TRIAMCINOLONE ACETONIDE

PHARMADERM	100,000 UNITS/GM;0.1%	A062603	001	Oct 09, 1985

OFLOXACIN

INJECTABLE; INJECTION

FLOXIN

ORTHO MCNEIL PHARM	20MG/ML	N020087	002	Mar 31, 1992

40MG/ML	N020087	003	Mar 31, 1992

FLOXIN IN DEXTROSE 5%

ORTHO MCNEIL PHARM	400MG/100ML	N020087	001	Mar 31, 1992

FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

ORTHO MCNEIL PHARM	4MG/ML	N020087	004	Mar 31, 1992

400MG/100ML	N020087	005	Mar 31, 1992

OFLOXACIN

BEDFORD	40MG/ML	A075762	001	Jan 16, 2002

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

SANDOZ	0.3%	A076848	001	Nov 25, 2008

TABLET; ORAL

FLOXIN

JANSSEN PHARMS	200MG	N019735	001	Dec 28, 1990

300MG	N019735	002	Dec 28, 1990

400MG	N019735	003	Dec 28, 1990

OFLOXACIN

LARKEN LABS	200MG	A076093	001	Sep 02, 2003

300MG	A076093	002	Sep 02, 2003

400MG	A076093	003	Sep 02, 2003

RANBAXY LABS LTD	200MG	A076220	001	Sep 02, 2003

300MG	A076220	002	Sep 02, 2003

400MG	A076220	003	Sep 02, 2003

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

NESHER PHARMS	4MG	A077717	001	Jun 25, 2007

8MG	A077717	002	Jun 25, 2007

PAR PHARM	4MG	A076506	001	Dec 26, 2006

8MG	A076506	002	Dec 26, 2006

16MG	A077406	001	Dec 26, 2006

24MG	A077406	002	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

HOSPIRA	EQ 2MG BASE/ML	A076695	001	Dec 26, 2006

SAGENT PHARMS	EQ 2MG BASE/ML	A078180	001	Mar 26, 2007

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

HOSPIRA	EQ 0.64MG BASE/ML	A076978	001	Feb 26, 2007

TEVA PHARMS	EQ 0.64MG BASE/ML	A077480	001	Nov 22, 2006

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 260 (of 360)

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE AND SODIUM CHLORIDE IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 0.64MG BASE/ML	N021915	002	Dec 27, 2006

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

HOSPIRA	EQ 2MG BASE/ML	A076696	001	Dec 26, 2006

ZOFTRAN AND DEXTROSE IN PLASTIC CONTAINER

GLAXOSMITHKLINE	EQ 0.64MG BASE/ML	N020403	001	Jan 31, 1995

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

PAR PHARM	EQ 4MG BASE	A077303	001	Jun 25, 2007

	EQ 8MG BASE	A077303	002	Jun 25, 2007

	EQ 24MG BASE	A077303	004	Jun 25, 2007

WEST WARD PHARM CORP	EQ 4MG BASE	A077545	001	Sep 06, 2007

	EQ 8MG BASE	A077545	002	Sep 06, 2007

	EQ 24MG BASE	A077545	003	Sep 06, 2007

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

NORFLEX

MEDICIS	100MG	N012157	001	

ORPHENADRINE CITRATE

ASCOT	100MG	A088067	001	Apr 06, 1983

SANDOZ	100MG	A085046	001	

WATSON LABS	100MG	A084303	001	

ORPHENADRINE HYDROCHLORIDE

TABLET; ORAL

DISIPAL

3M	50MG	N010653	001	

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

ROCHE	EQ 12MG BASE/ML	N021246	001	Dec 14, 2000

OXACILLIN SODIUM

CAPSULE; ORAL

BACTOCILL

GLAXOSMITHKLINE	EQ 250MG BASE	A061336	001	

	EQ 250MG BASE	A062241	001	

	EQ 500MG BASE	A061336	002	

	EQ 500MG BASE	A062241	002	

OXACILLIN SODIUM

APOTHECON	EQ 250MG BASE	A061450	002	

	EQ 500MG BASE	A061450	001	

TEVA	EQ 250MG BASE	A062222	001	

	EQ 500MG BASE	A062222	002	

PROSTAPHLIN

APOTHECON	EQ 500MG BASE	N050118	002	

FOR SOLUTION; ORAL

BACTOCILL

GLAXOSMITHKLINE	EQ 250MG BASE/5ML	A062321	001	

OXACILLIN SODIUM

APOTHECON	EQ 250MG BASE/5ML	A061457	001	

TEVA	EQ 250MG BASE/5ML	A062252	001	

PROSTAPHLIN

APOTHECON	EQ 250MG BASE/5ML	N050194	001	

INJECTABLE; INJECTION

BACTOCILL

GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	A061334	009	Mar 26, 1982

	EQ 1GM BASE/VIAL	A061334	006	Mar 26, 1982

	EQ 1GM BASE/VIAL	A062736	001	Dec 19, 1986

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 261 (of 360)

OXACILLIN SODIUMINJECTABLE; INJECTION
BACTOCILL

GLAXOSMITHKLINE	EQ 2GM BASE/VIAL	A061334	007	Mar 26, 1982
	EQ 2GM BASE/VIAL	A062736	002	Dec 19, 1986
	EQ 4GM BASE/VIAL	A061334	008	Mar 26, 1982
	EQ 10GM BASE/VIAL	A061334	010	

OXACILLIN SODIUM

APOTHECON

EQ 250MG BASE/VIAL	N050195	001	
EQ 500MG BASE/VIAL	N050195	002	
EQ 1GM BASE/VIAL	N050195	003	
EQ 2GM BASE/VIAL	N050195	004	
EQ 4GM BASE/VIAL	N050195	005	

ELKINS SINN

EQ 250MG BASE/VIAL	A062711	001	Feb 03, 1989
EQ 500MG BASE/VIAL	A062711	002	Feb 03, 1989
EQ 1GM BASE/VIAL	A062711	003	Feb 03, 1989
EQ 2GM BASE/VIAL	A062711	004	Feb 03, 1989
EQ 4GM BASE/VIAL	A062711	005	Feb 03, 1989
EQ 10GM BASE/VIAL	A062711	006	Feb 03, 1989

IBI

EQ 125MG BASE/VIAL	A062798	003	Dec 11, 1995
EQ 250MG BASE/VIAL	A062798	004	Dec 11, 1995
EQ 500MG BASE/VIAL	A062798	005	Dec 11, 1995
EQ 1GM BASE/VIAL	A062798	001	Dec 11, 1995
EQ 2GM BASE/VIAL	A062798	002	Dec 11, 1995

MARSAM PHARMS LLC

SANDOZ

EQ 10GM BASE/VIAL	A062984	001	Sep 29, 1988
EQ 250MG BASE/VIAL	A061490	001	

WATSON LABS

EQ 500MG BASE/VIAL	A061490	002	
EQ 250MG BASE/VIAL	A062856	001	Oct 26, 1988
EQ 500MG BASE/VIAL	A062856	002	Oct 26, 1988
EQ 1GM BASE/VIAL	A062856	003	Oct 26, 1988
EQ 2GM BASE/VIAL	A062856	004	Oct 26, 1988
EQ 4GM BASE/VIAL	A062856	005	Oct 26, 1988

OXALIPLATININJECTABLE; IV (INFUSION)
ELOXATIN

SANOFI AVENTIS US	50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021492	001	Aug 09, 2002
	100MG/VIAL	N021492	002	Aug 09, 2002

OXALIPLATIN

SANDOZ

50MG/VIAL	A090849	001	Apr 28, 2011
100MG/VIAL	A090849	002	Apr 28, 2011

OXAMNIQUINECAPSULE; ORAL
VANSIL

PFIZER	250MG	N018069	001	

OXANDROLONETABLET; ORAL
OXANDROLONE

ROXANE	2.5MG	A077249	001	Jul 10, 2007
	10MG	A077249	002	Jul 10, 2007
SANDOZ	2.5MG	A076897	001	Dec 01, 2006
	10MG	A076897	002	Dec 01, 2006

OXAPROZINTABLET; ORAL
OXAPROZIN

ACTAVIS ELIZABETH	600MG	A075843	001	Oct 03, 2001
MYLAN	600MG	A075851	001	Aug 17, 2001
MYLAN PHARMS INC	600MG	A075847	001	Feb 28, 2001

DISCONTINUED DRUG PRODUCT LIST

6 - 262 (of 360)

OXAPROZIN

TABLET; ORAL
OXAPROZIN

SANDOZ	600MG	A075842	001	Apr 12, 2001
	600MG	A075850	001	Apr 27, 2001

OXAPROZIN POTASSIUM

TABLET; ORAL
DAYPRO ALTA
GD SEARLE

GD SEARLE	600MG	N020776	001	Oct 17, 2002

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM

AM THERAP	10MG	A071955	001	Mar 03, 1988
	15MG	A071956	001	Mar 03, 1988
	30MG	A071957	001	Mar 03, 1988
MUTUAL PHARM	10MG	A071026	002	Aug 10, 1987
	15MG	A071026	003	Aug 10, 1987
	30MG	A071026	001	Aug 10, 1987
MYLAN	10MG	A071713	001	Oct 20, 1987
	15MG	A071714	001	Oct 20, 1987
	30MG	A071715	001	Oct 20, 1987

SERAX

ALPHARMA US PHARMS	10MG	N015539	002	
	15MG	N015539	004	
	30MG	N015539	006	

ZAXOPAM

QUANTUM PHARMICS	10MG	A070650	001	Mar 01, 1988
	15MG	A070640	001	Mar 01, 1988
	30MG	A070641	001	Mar 01, 1988

TABLET; ORAL
OXAZEPAM

MUTUAL PHARM	15MG	A070683	001	Jan 16, 1987
PARKE DAVIS	15MG	A071508	001	Feb 02, 1987
WATSON LABS	15MG	A071494	001	Apr 21, 1987

SERAX

ALPHARMA US PHARMS	15MG	N015539	008	

OXPRENOLOL HYDROCHLORIDE

CAPSULE; ORAL
TRASICOR

NOVARTIS	20MG	N018166	001	Dec 28, 1983
	40MG	N018166	002	Dec 28, 1983
	80MG	N018166	003	Dec 28, 1983
	160MG	N018166	004	Dec 28, 1983

OXTRIPHYLLINE

SOLUTION; ORAL
CHOLEDYL

PARKE DAVIS	100MG/5ML	N009268	012	Nov 27, 1984
OXTRIPHYLLINE				
MORTON GROVE	100MG/5ML	A088243	001	Dec 05, 1983

SYRUP; ORAL
CHOLEDYL

PARKE DAVIS	50MG/5ML	N009268	011	
OXTRIPHYLLINE PEDIATRIC				
MORTON GROVE	50MG/5ML	A088242	001	Dec 05, 1983

TABLET, DELAYED RELEASE; ORAL
CHOLEDYL

PARKE DAVIS	100MG	N009268	003	
	200MG	N009268	007	

DISCONTINUED DRUG PRODUCT LIST

6 - 263 (of 360)

OXTRIPHYLLINE

TABLET, DELAYED RELEASE; ORAL
OXTRIPHYLLINE

WATSON LABS	100MG	A087866	001	Aug 25, 1983
	200MG	A087835	001	Aug 25, 1983

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

DITROPAN

ORTHO MCNEIL JANSSEN	5MG/5ML	N018211	001	

TABLET; ORAL

DITROPAN

JANSSEN PHARMS	5MG	N017577	001	

OXYBUTYNIN CHLORIDE

QUANTUM PHARMICS	5MG	A072296	001	Dec 08, 1988
USL PHARMA	5MG	A070746	001	Mar 10, 1988
WATSON LABS	5MG	A072485	001	Apr 19, 1989

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN

PURDUE PHARMA LP	10MG	N020553	001	Dec 12, 1995
	15MG	N020553	006	Sep 18, 2006
	20MG	N020553	002	Dec 12, 1995
	30MG	N020553	007	Sep 18, 2006
	40MG	N020553	003	Dec 12, 1995
	60MG	N020553	008	Sep 18, 2006
	80MG	N020553	004	Jan 06, 1997
	160MG	N020553	005	Mar 15, 2000

ROXICODONE

ROXANE	10MG	N020932	001	Oct 26, 1998
	30MG	N020932	002	Oct 26, 1998

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

OPANA

ENDO PHARMS	1.5MG/ML	N011707	001	

SUPPOSITORY; RECTAL

NUMORPHAN

ENDO PHARMS	5MG	N011738	004	

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

ENDO PHARMS	5MG	N021610	001	Jun 22, 2006
	7.5MG	N021610	005	Feb 29, 2008
	10MG	N021610	002	Jun 22, 2006
	15MG	N021610	006	Feb 29, 2008
	20MG	N021610	003	Jun 22, 2006
	30MG	N021610	007	Feb 29, 2008
	40MG	N021610	004	Jun 22, 2006

OXYPHENBUTAZONE

TABLET; ORAL

OXYPHENBUTAZONE

WATSON LABS	100MG	A088399	001	Sep 17, 1984

TANDEARIL

NOVARTIS	100MG	N012542	004	Sep 03, 1982

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET; ORAL

DARICON

PFIZER	10MG	N011612	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 264 (of 360)

OXYPHENONIUM BROMIDE

TABLET; ORAL ANTRENYL NOVARTIS	5MG	N008492	002

OXYTETRACYCLINE

TABLET; ORAL TERRAMYCIN PFIZER	250MG	N050287	001

OXYTETRACYCLINE CALCIUM

SYRUP; ORAL TERRAMYCIN PFIZER	EQ 125MG BASE/5ML	A060595	001

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL OXY-KESSO-TETRA FERRANTE	EQ 250MG BASE	A060179	001
OXYTETRACYCLINE HYDROCHLORIDE IMPAX LABS	EQ 250MG BASE	A060760	001
PROTER	EQ 250MG BASE	A060869	001
PUREPAC PHARM	EQ 250MG BASE	A060634	001
WEST WARD	EQ 250MG BASE	A060770	001
TERRAMYCIN PFIZER	EQ 125MG BASE EQ 250MG BASE	N050286 N050286	001 002
INJECTABLE; INJECTION TERRAMYCIN PFIZER	EQ 250MG BASE/VIAL EQ 500MG BASE/VIAL	A060586 A060586	001 002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OTIC TERRAMYCIN W/ POLYMYXIN PFIZER	EQ 5MG BASE/GM;10,000 UNITS/GM	A061841	001
TABLET; VAGINAL TERRAMYCIN-POLYMYXIN PFIZER	EQ 100MG BASE;100,000 UNITS	A061009	001

OXYTOCIN

INJECTABLE; INJECTION OXYTOCIN TEVA PARENTERAL	10USP UNITS/ML (10USP UNITS/ML) 100USP UNITS/10ML (10USP UNITS/ML)	A077453 A077453	001 002	Jan 24, 2008 Jan 24, 2008
OXYTOCIN 10 USP UNITS IN DEXTROSE 5% ABBOTT	1USP UNITS/100ML 2USP UNITS/100ML	N019185 N019185	004 003	Mar 29, 1985 Mar 29, 1985
OXYTOCIN 20 USP UNITS IN DEXTROSE 5% ABBOTT	2USP UNITS/100ML	N019185	002	Mar 29, 1985
OXYTOCIN 5 USP UNITS IN DEXTROSE 5% ABBOTT	1USP UNITS/100ML	N019185	001	Mar 29, 1985
SYNTOCINON NOVARTIS	10USP UNITS/ML	N018245	001	
SOLUTION; NASAL SYNTOCINON NOVARTIS	40USP UNITS/ML	N012285	001	

PACLITAXEL

INJECTABLE; INJECTION PACLITAXEL HOSPIRA	6MG/ML	A076233	001	Aug 01, 2002
PLIVA LACHEMA	6MG/ML	A077413	001	Mar 12, 2008

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 265 (of 360)

PACLITAXELINJECTABLE; INJECTION
PACLITAXEL

TEVA PARENTERAL 6MG/ML A075297 001 Jan 25, 2002

TAXOL

CORDEN PHARMA 6MG/ML N020262 001 Dec 29, 1992

PALIPERIDONETABLET, EXTENDED RELEASE; ORAL
INVEGA

JANSSEN PHARMS 12MG N021999 004 Dec 19, 2006

PALONOSETRON HYDROCHLORIDECAPSULE; ORAL
ALOXIHELSINN HLTHCARE EQ 0.5MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons** N022233 001 Aug 22, 2008PAMIDRONATE DISODIUMINJECTABLE; INJECTION
AREDIA

NOVARTIS 30MG/VIAL N020036 001 Oct 31, 1991

60MG/VIAL N020036 003 May 06, 1993

90MG/VIAL N020036 004 May 06, 1993

PAMIDRONATE DISODIUM

AESGEN 30MG/VIAL A075594 001 May 06, 2002

90MG/VIAL A075594 002 May 06, 2002

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)CAPSULE; ORAL
COTAZYMORGANON USA INC 30,000USP UNITS;8,000USP
UNITS;30,000USP UNITS N020580 001 Dec 09, 1996PANCURONIUM BROMIDEINJECTABLE; INJECTION
PANCURONIUM BROMIDE

ASTRAZENECA 1MG/ML A072210 001 Mar 31, 1988

2MG/ML A072211 001 Mar 31, 1988

2MG/ML A072212 001 Mar 31, 1988

2MG/ML A072213 001 Mar 31, 1988

ELKINS SINN 1MG/ML A072058 001 Mar 23, 1988

2MG/ML A072059 001 Mar 23, 1988

2MG/ML A072060 001 Mar 23, 1988

HOSPIRA 2MG/ML A072321 001 Jan 19, 1989

PAVULON

ORGANON USA INC 1MG/ML N017015 002

2MG/ML N017015 001

PARAMETHADIONECAPSULE; ORAL
PARADIONE

ABBVIE 150MG N006800 003

300MG N006800 001

SOLUTION; ORAL

PARADIONE

ABBVIE 300MG/ML N006800 002

PARAMETHASONE ACETATETABLET; ORAL
HALDRONE

LILLY 1MG N012772 005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 266 (of 360)

PARAMETHASONE ACETATE

TABLET; ORAL				
HALDRONE				
LILLY	2MG	N012772	006	

PARGYLINE HYDROCHLORIDE

TABLET; ORAL				
EUTONYL				
ABBOTT	10MG	N013448	002	
	25MG	N013448	003	
	50MG	N013448	004	

PAROMOMYCIN SULFATE

CAPSULE; ORAL				
HUMATIN				
KING PFIZER	EQ 250MG BASE	A062310	001	
PARKEDALE	EQ 250MG BASE	A060521	001	
SYRUP; ORAL				
HUMATIN				
PARKE DAVIS	EQ 125MG BASE/5ML	A060522	001	

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL				
PAXIL				
GLAXOSMITHKLINE	EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020885	001	Oct 09, 1998
	EQ 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020885	002	Oct 09, 1998
	EQ 30MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020885	003	Oct 09, 1998
	EQ 40MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020885	004	Oct 09, 1998
TABLET; ORAL				
PAROXETINE HYDROCHLORIDE				
ROXANE	EQ 10MG BASE	A078026	001	Jun 29, 2007
	EQ 20MG BASE	A078026	002	Jun 29, 2007
	EQ 30MG BASE	A078026	003	Jun 29, 2007
	EQ 40MG BASE	A078026	004	Jun 29, 2007
SANDOZ	EQ 10MG BASE	A075566	001	Mar 08, 2004
	EQ 20MG BASE	A075566	002	Mar 08, 2004
	EQ 30MG BASE	A075566	003	Mar 08, 2004
	EQ 40MG BASE	A075566	004	Mar 08, 2004
TEVA PHARMS	EQ 10MG BASE	A077082	001	Jun 29, 2007
	EQ 20MG BASE	A077082	002	Jun 29, 2007
	EQ 30MG BASE	A077082	003	Jun 29, 2007
	EQ 40MG BASE	A077082	004	Jun 29, 2007
PAXIL				
GLAXOSMITHKLINE	EQ 50MG BASE	N020031	004	Dec 29, 1992

PEMOLINE

TABLET; ORAL				
CYLERT				
ABBOTT	18.75MG	N016832	001	
	37.5MG	N016832	002	
	75MG	N016832	003	
PEMOLINE				
ACTAVIS TOTOWA	18.75MG	A075595	001	Feb 28, 2000

DISCONTINUED DRUG PRODUCT LIST

6 - 267 (of 360)

PEMOLINE

TABLET; ORAL
PEMOLINE

ACTAVIS TOTOWA	37.5MG	A075595	002	Feb 28, 2000
	75MG	A075595	003	Feb 28, 2000
MALLINCKRODT	18.75MG	A075726	003	Mar 30, 2001
	37.5MG	A075726	002	Mar 30, 2001
	75MG	A075726	001	Mar 30, 2001
SANDOZ	18.75MG	A075286	001	Dec 27, 1999
	37.5MG	A075286	002	Jun 30, 1999
	75MG	A075286	003	Jun 30, 1999
TEVA PHARMS	18.75MG	A075030	003	Feb 22, 2000
	37.5MG	A075030	001	Jan 29, 1999
	75MG	A075030	002	Jan 29, 1999
VINTAGE PHARMS	18.75MG	A075328	001	Apr 19, 2000
	37.5MG	A075328	002	Apr 19, 2000
	75MG	A075328	003	Apr 19, 2000
WATSON LABS	18.75MG	A075287	001	Jun 13, 2001
	37.5MG	A075287	002	Sep 18, 2000
	75MG	A075287	003	Sep 18, 2000

TABLET, CHEWABLE; ORAL
CYLERT

ABBOTT	37.5MG	N017703	001	
PEMOLINE				
ACTAVIS TOTOWA	37.5MG	A075678	001	Jul 26, 2000
TEVA PHARMS	37.5MG	A075555	001	Feb 18, 2000

PENBUTOLOL SULFATE

TABLET; ORAL
LEVATOL

ACTIENT PHARMS	10MG	N018976	001	Dec 30, 1987

PENICILLAMINE

CAPSULE; ORAL
CUPRIMINE

ATON	125MG	N019853	002	

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION
BICILLIN L-A

WYETH AYERST	300,000 UNITS/ML	N050131	001	

SUSPENSION; ORAL
BICILLIN

WYETH AYERST	300,000 UNITS/5ML	N050126	002	

TABLET; ORAL
BICILLIN

WYETH AYERST	200,000 UNITS	N050128	001	

PENICILLIN G POTASSIUM

FOR SOLUTION; ORAL
PENICILLIN

TEVA	200,000 UNITS/5ML	A060307	002	
	400,000 UNITS/5ML	A060307	004	

PENICILLIN G POTASSIUM

MYLAN	200,000 UNITS/5ML	A060752	003	
	250,000 UNITS/5ML	A060752	002	
	400,000 UNITS/5ML	A060752	001	
PUREPAC PHARM	250,000 UNITS/5ML	A061740	001	
	400,000 UNITS/5ML	A061740	002	

PENICILLIN-2

TEVA	250,000 UNITS/5ML	A060307	003	

PENTIDS '200'

APOTHECON	200,000 UNITS/5ML	A062149	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 268 (of 360)

PENICILLIN G POTASSIUM

FOR SOLUTION; ORAL

PENTIDS '400'

APOTHECON

400,000 UNITS/5ML

A062149 002

PFIZERPEN G

PFIZER

400,000 UNITS/5ML

A060587 001

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

APOTHECON

1,000,000 UNITS/VIAL

A060362 001

5,000,000 UNITS/VIAL

A060362 003

10,000,000 UNITS/VIAL

A060362 004

20,000,000 UNITS/VIAL

A060362 002

CONSOLIDATED PHARM

500,000 UNITS/VIAL

A060806 001

1,000,000 UNITS/VIAL

A060806 002

5,000,000 UNITS/VIAL

A060806 003

10,000,000 UNITS/VIAL

A060806 004

LILLY

200,000 UNITS/VIAL

A060384 004

500,000 UNITS/VIAL

A060384 003

1,000,000 UNITS/VIAL

A060384 002

5,000,000 UNITS/VIAL

A060384 001

20,000,000 UNITS/VIAL

A060384 005

20,000,000 UNITS/VIAL

A060601 001

MARSAM PHARMS LLC

1,000,000 UNITS/VIAL

A062991 001

Sep 13, 1988

5,000,000 UNITS/VIAL

A062991 002

Sep 13, 1988

10,000,000 UNITS/VIAL

A062991 003

Sep 13, 1988

20,000,000 UNITS/VIAL

A062991 004

Sep 13, 1988

PARKE DAVIS

1,000,000 UNITS/VIAL

A062003 001

5,000,000 UNITS/VIAL

A062003 002

PFIZER

20,000,000 UNITS/VIAL

A060074 003

SANDOZ

1,000,000 UNITS/VIAL

A065079 001

Aug 30, 2002

PFIZERPEN

PFIZER

1,000,000 UNITS/VIAL

A060657 001

TABLET; ORAL

PENICILLIN G POTASSIUM

APOTHECON

250,000 UNITS

A060392 003

IVAX SUB TEVA PHARMS

400,000 UNITS

A060073 004

LILLY

250,000 UNITS

A060403 001

MYLAN

200,000 UNITS

A060781 001

250,000 UNITS

A060781 002

400,000 UNITS

A060781 003

500,000 UNITS

A060781 005

800,000 UNITS

A060781 004

PUREPAC PHARM

200,000 UNITS

A061588 001

250,000 UNITS

A061588 002

400,000 UNITS

A061588 003

TEVA

200,000 UNITS

A060306 001

250,000 UNITS

A060306 002

400,000 UNITS

A060306 003

500,000 UNITS

A060306 004

WYETH AYERST

200,000 UNITS

A060413 001

250,000 UNITS

A060413 002

400,000 UNITS

A060413 003

PENTIDS '200'

APOTHECON

200,000 UNITS

A062155 001

PENTIDS '250'

APOTHECON

250,000 UNITS

A062155 002

PENTIDS '400'

APOTHECON

400,000 UNITS

A060392 004

400,000 UNITS

A062155 003

PENTIDS '800'

APOTHECON

800,000 UNITS

A060392 005

800,000 UNITS

A062155 004

PFIZERPEN G

PFIZER

50,000 UNITS

A060075 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 269 (of 360)

PENICILLIN G POTASSIUM

TABLET; ORAL

PFIZERPEN G

PFIZER

100,000 UNITS

A060075 002

200,000 UNITS

A060075 003

250,000 UNITS

A060075 004

400,000 UNITS

A060075 005

800,000 UNITS

A060075 006

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

DURACILLIN A.S.

LILLY

300,000 UNITS/ML

A060093 001

PENICILLIN G PROCAINE

CONSOLIDATED PHARM

300,000 UNITS/ML

A060800 001

600,000 UNITS/1.2ML

A060800 002

PARKE DAVIS

300,000 UNITS/ML

A062029 001

PFIZER

300,000 UNITS/VIAL

A060099 001

1,500,000 UNITS/VIAL

A060099 002

PFIZERPEN-AS

PFIZER

300,000 UNITS/ML

A060286 001

600,000 UNITS/ML

A060286 002

PENICILLIN G SODIUM

INJECTABLE; IM-IV

PENICILLIN G SODIUM

MARSAM PHARMS LLC

5,000,000 UNITS/VIAL

A063014 001

Sep 13, 1988

INJECTABLE; INJECTION

PENICILLIN G SODIUM

BRISTOL MYERS SQUIBB

5,000,000 UNITS/VIAL

A061935 001

COPANOS

5,000,000 UNITS/VIAL

A061051 001

PHARMACIA AND UPJOHN

1,000,000 UNITS/VIAL

A061046 001

PENICILLIN V

FOR SUSPENSION; ORAL

V-CILLIN

LILLY

125MG/0.6ML

A060002 001

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

BEEPEN-VK

GLAXOSMITHKLINE

EQ 125MG BASE/5ML

A062270 001

EQ 250MG BASE/5ML

A062270 002

BETAPEN-VK

APOTHECON

EQ 125MG BASE/5ML

A061149 001

EQ 250MG BASE/5ML

A061149 002

LEDERCILLIN VK

LEDERLE

EQ 125MG BASE/5ML

A060136 001

EQ 250MG BASE/5ML

A060136 002

PENAPAR-VK

PARKE DAVIS

EQ 125MG BASE/5ML

A062002 001

EQ 250MG BASE/5ML

A062002 002

PENICILLIN V POTASSIUM

AM ANTIBIOTICS

EQ 125MG BASE/5ML

A061529 001

EQ 250MG BASE/5ML

A061529 002

MYLAN

EQ 125MG BASE/5ML

A061624 002

EQ 250MG BASE/5ML

A061624 001

PUREPAC PHARM

EQ 125MG BASE/5ML

A061758 001

EQ 250MG BASE/5ML

A061758 002

PEN-VEE K

WYETH AYERST

EQ 125MG BASE/5ML

A060007 001

EQ 250MG BASE/5ML

A060007 002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 270 (of 360)

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PFIZERPEN VK

PFIZER

EQ 125MG BASE/5ML

A061815 001

EQ 250MG BASE/5ML

A061815 002

V-CILLIN K

LILLY

EQ 125MG BASE/5ML

A060004 001

EQ 250MG BASE/5ML

A060004 002

VEETIDS

APOTHECON

EQ 125MG BASE/5ML

A061410 001

EQ 250MG BASE/5ML

A061410 002

VEETIDS '125'

APOTHECON

EQ 125MG BASE/5ML

A061206 001

EQ 125MG BASE/5ML

A062153 001

VEETIDS '250'

APOTHECON

EQ 250MG BASE/5ML

A061206 002

EQ 250MG BASE/5ML

A062153 002

TABLET; ORAL

BEEPEN-VK

GLAXOSMITHKLINE

EQ 250MG BASE

A062273 001

EQ 500MG BASE

A062273 002

BETAPEN-VK

BRISTOL

EQ 250MG BASE

A061150 001

EQ 500MG BASE

A061150 002

LEDERCILLIN VK

LEDERLE

EQ 250MG BASE

A060134 001

EQ 500MG BASE

A060134 002

PENAPAR-VK

PARKE DAVIS

EQ 250MG BASE

A062001 001

EQ 500MG BASE

A062001 002

PENICILLIN V POTASSIUM

AM ANTIBIOTICS

EQ 250MG BASE

A061528 001

EQ 500MG BASE

A061528 002

IVAX SUB TEVA PHARMS

EQ 125MG BASE

A060518 001

EQ 250MG BASE

A060518 002

EQ 500MG BASE

A060518 003

MYLAN

EQ 250MG BASE

A061530 001

EQ 500MG BASE

A061530 002

PUREPAC PHARM

EQ 125MG BASE

A061571 001

EQ 250MG BASE

A061571 002

EQ 500MG BASE

A061571 003

PEN-VEE K

WYETH AYERST

EQ 125MG BASE

A060006 001

EQ 250MG BASE

A060006 002

EQ 500MG BASE

A060006 003

PFIZERPEN VK

PFIZER

EQ 250MG BASE

A061836 001

EQ 500MG BASE

A061836 002

UTICILLIN VK

PHARMACIA AND UPJOHN

EQ 250MG BASE

A061651 001

EQ 500MG BASE

A061651 002

V-CILLIN K

LILLY

EQ 125MG BASE

A060003 001

EQ 250MG BASE

A060003 002

EQ 500MG BASE

A060003 003

VEETIDS

APOTHECON

EQ 250MG BASE

A061411 001

EQ 500MG BASE

A061411 002

VEETIDS '250'

APOTHECON

EQ 250MG BASE

A061164 001

EQ 250MG BASE

A062156 002

VEETIDS '500'

APOTHECON

EQ 500MG BASE

A061164 002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 271 (of 360)

PENICILLIN V POTASSIUM

TABLET; ORAL			
VEETIDS '500'			
APOTHECON	EQ 500MG BASE	A062156	001

PENTAGASTRIN

INJECTABLE; INJECTION			
PEPTAVLON			
WYETH AYERST	0.25MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017048	001

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION			
NEBUPENT			
FRESENIUS KABI USA	600MG/VIAL	N019887	002 Mar 22, 1996
INJECTABLE; INJECTION			
PENTACARINAT			
ARMOUR PHARM	300MG/VIAL	A073447	001 Apr 28, 1994
PENTAMIDINE ISETHIONATE			
BAXTER HLTHCARE	300MG/VIAL	A073617	001 Dec 18, 1995
HOSPIRA	300MG/VIAL	A073479	001 Jun 30, 1992

PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL			
TALWIN 50			
SANOFI AVENTIS US	EQ 50MG BASE	N016732	001

PENTETATE CALCIUM TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS			
PENTETATE CALCIUM TRISODIUM			
HAMELN PHARMS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021749	001 Aug 11, 2004

PENTETATE CALCIUM TRISODIUM YB-169

INJECTABLE; INJECTION			
YTTERBIUM YB 169 DTPA			
3M	2mCi/ML	N017518	001

PENTETATE ZINC TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS			
PENTETATE ZINC TRISODIUM			
HAMELN PHARMS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021751	001 Aug 11, 2004

PENTOBARBITAL

ELIXIR; ORAL			
NEMBUTAL			
OAK PHARMS	18.2MG/5ML	A083244	001

PENTOBARBITAL SODIUM

CAPSULE; ORAL			
NEMBUTAL SODIUM			
OAK PHARMS	30MG	A084095	001
	50MG	A084093	001
	100MG	A083245	001
PENTOBARBITAL SODIUM			
LANNETT	50MG	A085937	001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 272 (of 360)

PENTOBARBITAL SODIUM

CAPSULE; ORAL

PENTOBARBITAL SODIUM

LANNETT 100MG A085915 001

VITARINE 100MG A083284 001

WHITEWORTH TOWN PLSN 100MG A083338 001

SODIUM PENTOBARBITAL

ANABOLIC 100MG A084590 001

ELKINS SINN 100MG A083368 001

EVERYLIFE 100MG A083259 001

HALSEY 100MG A084677 001

IVAX SUB TEVA PHARMS 50MG A083461 001

100MG A083461 002

PARKE DAVIS 100MG A084156 001

PERRIGO 100MG A084560 001

PUREPAC PHARM 100MG A083301 001

VALEANT PHARM INTL 100MG A083264 001

WATSON LABS 100MG A085791 001

WYETH AYERST 100MG A083239 001

INJECTABLE; INJECTION

PENTOBARBITAL SODIUM

ELKINS SINN 50MG/ML A083270 001

SODIUM PENTOBARBITAL

WYETH AYERST 50MG/ML A083261 001

SUPPOSITORY; RECTAL

NEMBUTAL

OAK PHARMS 30MG A083247 001 Jan 25, 1982

60MG A083247 002 Jan 25, 1982

120MG A083247 003 Jan 25, 1982

200MG A083247 004 Jan 25, 1982

TABLET; ORAL

PENTOBARBITAL SODIUM

VITARINE 100MG A083285 001

SODIUM PENTOBARBITAL

NEXGEN PHARMA INC 100MG A084238 001

PENTOLINIUM TARTRATE

INJECTABLE; INJECTION

ANSOLYSEN

WYETH AYERST 10MG/ML N009372 001

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

ACTAVIS ELIZABETH 400MG A074878 001 Jul 09, 1997

HERITAGE PHARMS INC 400MG A074877 001 Jul 08, 1997

TEVA 400MG A075199 001 Sep 03, 1999

PERFLUBRON

LIQUID; ORAL

IMAGENT

ALLIANCE PHARM 100% N020091 001 Aug 13, 1993

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

PASTE; TOPICAL

SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS

US ARMY 50%;50% N021084 001 Feb 17, 2000

PERGOLIDE MESYLATE

TABLET; ORAL

PERGOLIDE MESYLATE

IVAX SUB TEVA PHARMS EQ 0.05MG BASE A076094 001 Sep 04, 2003

EQ 0.25MG BASE A076094 002 Sep 04, 2003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 273 (of 360)

PERGOLIDE MESYLATE

TABLET; ORAL

PERGOLIDE MESYLATE

IVAX SUB TEVA PHARMS	EQ 1MG BASE	A076094	003	Sep 04, 2003
PAR PHARM	EQ 0.05MG BASE	A076061	001	Nov 27, 2002
	EQ 0.25MG BASE	A076061	002	Nov 27, 2002
	EQ 1MG BASE	A076061	003	Nov 27, 2002
PERMAX				
VALEANT PHARM INTL	EQ 0.05MG BASE	N019385	001	Dec 30, 1988
	EQ 0.25MG BASE	N019385	002	Dec 30, 1988
	EQ 1MG BASE	N019385	003	Dec 30, 1988

PERMETHRIN

LOTION; TOPICAL

NIX

GLAXOSMITHKLINE	1%	N019435	001	Mar 31, 1986

PERPHENAZINE

CONCENTRATE; ORAL

PERPHENAZINE

PHARM ASSOC	16MG/5ML	A040360	001	May 25, 2001

TRILAFON

SCHERING	16MG/5ML	N011557	001	

INJECTABLE; INJECTION

TRILAFON

SCHERING	5MG/ML	N011213	002	

SYRUP; ORAL

TRILAFON

SCHERING	2MG/5ML	N011294	002	

TABLET; ORAL

PERPHENAZINE

IVAX PHARMS	2MG	A089707	001	Sep 10, 1987
	4MG	A089708	001	Sep 10, 1987
	8MG	A089456	001	Sep 10, 1987
	16MG	A089457	001	Sep 10, 1987

TRILAFON

SCHERING	2MG	N010775	001	
	4MG	N010775	002	
	8MG	N010775	003	
	16MG	N010775	004	

TABLET, EXTENDED RELEASE; ORAL

TRILAFON

SCHERING	8MG	N011361	002	

PHENACEMIDE

TABLET; ORAL

PHENURONE

ABBVIE	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007707	001	

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET; ORAL

AZO GANTANOL

ROCHE	100MG;500MG	N013294	001	Sep 10, 1987

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HYDROCHLORIDE

ABLE	200MG, N/A, N/A; N/A, 800MG, 160MG	N021105	001	Jun 26, 2001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 274 (of 360)

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL
AZO GANTRISIN
ROCHE

50MG;500MG

N019358 001 Aug 31, 1990

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL
PHENAZINE

MAST MM

35MG

A086523 001

35MG

A086524 001

35MG

A086525 001

PHENDIMETRAZINE TARTRATE

SANDOZ

35MG

A085633 001

35MG

A085694 001

35MG

A085695 001

35MG

A085702 001

VITARINE

35MG

A085634 001

35MG

A085645 001

35MG

A085670 001

35MG

A086403 001

35MG

A086408 001

35MG

A086410 001

35MG

A087424 001

SPRX-3

SOLVAY

35MG

A085897 001

STATOBEX

TEVA

35MG

A085507 001

X-TROZINE

SHIRE RICHWOOD

35MG

A087394 001 Sep 22, 1982

CAPSULE, EXTENDED RELEASE; ORAL
MELFIAT-105

NUMARK

105MG

A087487 001 Oct 13, 1982

PHENDIMETRAZINE TARTRATE

GRAHAM DM

105MG

A087214 001 May 26, 1982

105MG

A088020 001 Aug 16, 1982

105MG

A088028 001 Aug 16, 1982

105MG

A088062 001 Sep 13, 1982

105MG

A088063 001 Sep 10, 1982

105MG

A088111 001 Oct 18, 1982

SANDOZ

105MG

A087378 001

SPRX-105

NUMARK

105MG

A088024 001 Dec 22, 1982

X-TROZINE L.A.

SHIRE RICHWOOD

105MG

A087371 001 Aug 24, 1982

TABLET; ORAL

ADPHEN

FERNDAL LABS

35MG

A083655 001

ALPHAZINE

SANDOZ

35MG

A085034 001

CAM-METRAZINE

ABC HOLDING

35MG

A085511 001

CAMALL

35MG

A085756 001

TG UNITED LABS

35MG

A083922 001

35MG

A085318 001

35MG

A085320 001

35MG

A085321 001

DI-METREX

PVT FORM

35MG

A085698 001

MELFIAT

NUMARK

35MG

A083790 002

METRA

FOREST PHARMS

35MG

A083754 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 275 (of 360)

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENAZINE

MAST MM

35MG

A087305 001

PHENAZINE-35

ABC HOLDING

35MG

A085512 001

PHENDIMETRAZINE TARTRATE

BARR

35MG

A083644 001

35MG

A083684 001

35MG

A083686 001

35MG

A083687 001

35MG

A084831 001

35MG

A084834 001

35MG

A084835 001

FERNDAL LABS

35MG

A086834 001

Sep 15, 1983

INWOOD LABS

35MG

A084740 001

35MG

A084741 001

35MG

A084742 001

35MG

A084743 001

IVAX PHARMS

35MG

A085611 001

35MG

A085612 001

IVAX SUB TEVA PHARMS

35MG

A083682 001

KV PHARM

35MG

A084138 001

35MG

A084141 001

35MG

A085525 001

MFG CHEMISTS

35MG

A085914 001

NEXGEN PHARMA INC

35MG

A086020 001

NUMARK

35MG

A083790 001

PVT FORM

35MG

A085199 001

35MG

A085697 001

SANDOZ

35MG

A085402 001

35MG

A085497 001

35MG

A085830 001

35MG

A086365 001

35MG

A086370 001

SOLVAY

35MG

A083993 001

TG UNITED LABS

35MG

A085761 001

35MG

A085941 001

Jun 27, 1983

USL PHARMA

35MG

A083805 001

35MG

A084398 001

35MG

A084399 001

VITARINE

35MG

A085519 001

35MG

A086005 001

35MG

A086106 001

WATSON LABS

35MG

A085767 001

35MG

A085768 001

35MG

A085770 001

35MG

A085773 001

PLEGINE

WYETH AYERST

35MG

N012248 001

STATOBEX

TEVA

35MG

A086013 001

STATOBEX-G

TEVA

35MG

A085095 001

X-TROZINE

SHIRE RICHWOOD

35MG

A086550 001

35MG

A086551 001

35MG

A086552 001

35MG

A086553 001

35MG

A086554 001

DISCONTINUED DRUG PRODUCT LIST

6 - 276 (of 360)

PHENINDIONE

TABLET; ORAL
HEDULIN

SANOFI AVENTIS US	50MG	N008767	002

PHENMETRAZINE HYDROCHLORIDE

TABLET; ORAL
PRELUDIN

BOEHRINGER INGELHEIM	25MG	N010460	005

TABLET, EXTENDED RELEASE; ORAL
PRELUDIN

BOEHRINGER INGELHEIM	50MG	N011752	004
	75MG	N011752	003

PHENPROCOUMON

TABLET; ORAL
LIQUAMAR

ORGANON USA INC	3MG	N011228	001

PHENSUXIMIDE

CAPSULE; ORAL
MILONTIN

PARKE DAVIS	500MG	N008855	004

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
FASTIN

GLAXOSMITHKLINE	30MG	N017352	001

OBESTIN-30

FERNDAL LABS	30MG	A087144	001

OBY-TRIM

SHIRE RICHWOOD	30MG	A087764	001	Mar 18, 1982

ONA-MAST

MAST MM	30MG	A086511	001

	30MG	A086516	001

PHENTERMINE HYDROCHLORIDE

ABC HOLDING	30MG	A085411	001

ABLE	15MG	A040497	001	Mar 13, 2003

	30MG	A040403	001	Aug 30, 2001

	30MG	A040427	001	Aug 30, 2001

CAMALL	15MG	A086735	001

	30MG	A087226	001

DURAMED PHARMS BARR	30MG	A088948	001	Apr 25, 1986

IVAX PHARMS	30MG	A086329	001

MIKAH PHARMA	15MG	A040460	001	Jan 14, 2003

	30MG	A040227	001	Jun 18, 1997

	30MG	A040448	001	Jan 22, 2003

	37.5MG	A040228	001	Jun 19, 1997

MUTUAL PHARM	37.5MG	A040527	001	Oct 23, 2003

SANDOZ	30MG	A087208	001

	30MG	A087223	001

	37.5MG	A088414	001	Oct 19, 1983

TEVA	30MG	A086911	001

	30MG	A087126	001

	30MG	A087777	001	Nov 01, 1985

	30MG	A088612	001	Apr 04, 1984

	30MG	A088613	001	Apr 09, 1984

	30MG	A088614	001	Apr 09, 1984

TG UNITED INC	30MG	A040083	001	Mar 07, 1997

TG UNITED LABS	18.75MG	A088576	001	May 23, 1984

	30MG	A085417	001

	30MG	A086732	002

	30MG	A087215	001

DISCONTINUED DRUG PRODUCT LIST

6 - 277 (of 360)

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

TG UNITED LABS	37.5MG	A087915	001	Dec 22, 1983
	37.5MG	A087918	001	Dec 22, 1983
	37.5MG	A087930	001	Oct 14, 1983
	37.5MG	A088610	001	Jun 04, 1984
	37.5MG	A088611	001	Jun 04, 1984
	37.5MG	A088625	001	Aug 23, 1984
USL PHARMA	30MG	A084487	001	Apr 09, 1982
	30MG	A088430	001	Mar 27, 1984
	30MG	A088797	001	Dec 10, 1984
VITARINE	30MG	A087202	001	
	30MG	A087235	001	
WATSON LABS	30MG	A086740	001	Mar 21, 1985

TABLET; ORAL

ONA-MAST

MAST MM	8MG	A086260	001	

PHENTERMINE HYDROCHLORIDE

ABLE	37.5MG	A040402	001	Aug 30, 2001
ACTAVIS ELIZABETH	37.5MG	A040276	001	Nov 25, 1998
IVAX PHARMS	8MG	A085553	001	
MIKAH PHARMA	37.5MG	A040190	001	May 30, 1997
SANDOZ	8MG	A085671	001	
	8MG	A085689	001	
SANDOZ INC	30MG	A088605	001	Sep 28, 1987
TG UNITED LABS	8MG	A083923	001	
	8MG	A085319	001	
	37.5MG	A087805	001	Dec 06, 1982
	37.5MG	A088596	001	Apr 04, 1984
USL PHARMA	8MG	A083804	001	
	37.5MG	A088910	001	Jul 17, 1985
	37.5MG	A088917	001	Jul 17, 1985
VITARINE	8MG	A086453	001	
	8MG	A086456	001	
WATSON LABS	8MG	A085739	001	
TORA				
SOLVAY	8MG	A084035	001	
WILPO				
SANDOZ	8MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012737	001	

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

IONAMIN

UCB INC	EQ 15MG BASE	N011613	004	
	EQ 30MG BASE	N011613	002	

PHENTERMINE RESIN 30

QUANTUM PHARMICS	EQ 30MG BASE	A089120	001	Feb 04, 1988

PHENYL AMINOSALICYLATE

POWDER; ORAL

PHENY-PAS-TEBAMIN

PHARM RES ASSOC	50%	N011695	002	

TABLET; ORAL

PHENY-PAS-TEBAMIN

PHARM RES ASSOC	500MG	N011695	003	

PHENYLBUTAZONE

CAPSULE; ORAL

AZOLID

SANOFI AVENTIS US	100MG	A087260	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 278 (of 360)

PHENYLBUTAZONE

CAPSULE; ORAL

BUTAZOLIDIN

NOVARTIS

100MG

N008319 009

PHENYLBUTAZONE

IVAX PHARMS

100MG

A088218 001 Jun 24, 1983

MUTUAL PHARM

100MG

A088994 001 Dec 04, 1985

SANDOZ

100MG

A087774 001 Jun 16, 1982

WATSON LABS

100MG

A087756 001 Dec 17, 1982

TABLET; ORAL

AZOLID

SANOFI AVENTIS US

100MG

A087091 001

BUTAZOLIDIN

NOVARTIS

100MG

N008319 008

PHENYLBUTAZONE

MUTUAL PHARM

100MG

A088863 001 Dec 04, 1985

SANDOZ

100MG

A084339 001

WATSON LABS

100MG

A086151 001

100MG

A087674 001 Apr 21, 1982

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN VC

ANI PHARMS

5MG/5ML;6.25MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

N008604 003 Apr 02, 1984

PHERAZINE VC

HALSEY

5MG/5ML;6.25MG/5ML

A088868 001 Mar 02, 1987

PROMETHAZINE VC PLAIN

CENCI

5MG/5ML;6.25MG/5ML

A088815 001 Nov 22, 1985

WOCKHARDT

5MG/5ML;6.25MG/5ML

A088897 001 Jan 04, 1985

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

PREFRIN-A

ALLERGAN

0.12%;0.1%

N007953 001

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-30

PARKE DAVIS

30MG/5ML

N008762 002

PHENYTOIN

ACTAVIS MID ATLANTIC

125MG/5ML

A089892 001 Sep 25, 1992

PHENYTOIN SODIUM

CAPSULE; ORAL

DIPHENYLAN SODIUM

LANNETT

30MG PROMPT

A080857 001

100MG PROMPT

A080857 002

EXTENDED PHENYTOIN SODIUM

BARR

100MG EXTENDED

A040435 001 Jun 20, 2003

PLIVA

100MG EXTENDED

A089441 001 Dec 18, 1986

PHENYTEX

WATSON LABS

100MG EXTENDED

A088711 001 Dec 21, 1984

PHENYTOIN SODIUM

PHARMERAL

100MG PROMPT

A085435 001

WATSON LABS

100MG PROMPT

A085894 001

PROMPT PHENYTOIN SODIUM

IVAX SUB TEVA PHARMS

100MG PROMPT

A080259 001

WATSON LABS

100MG PROMPT

A080905 001

INJECTABLE; INJECTION

DILANTIN

PARKE DAVIS

50MG/ML

N010151 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 279 (of 360)

PHENYTOIN SODIUMINJECTABLE; INJECTION
PHENYTOIN SODIUM

FRESENIUS KABI USA	50MG/ML	A089003	001	May 31, 1985
MARSAM PHARMS LLC	50MG/ML	A089501	001	Oct 13, 1987
	50MG/ML	A089779	001	Nov 27, 1992
SMITH AND NEPHEW	50MG/ML	A088519	001	Dec 19, 1984
	50MG/ML	A088521	001	Dec 18, 1984
SOLOPAK	50MG/ML	A088520	001	Dec 17, 1984
WARNER CHILCOTT	50MG/ML	A089900	001	Mar 30, 1990
WATSON LABS	50MG/ML	A085434	001	

PHYTONADIONEINJECTABLE; INJECTION
AQUAMEPHYTON

BIOVAIL TECHNOLOGIES	1MG/0.5ML	N012223	002	
	10MG/ML	N012223	001	
KONAKION				
ROCHE	1MG/0.5ML	N011745	001	
	10MG/ML	N011745	003	
PHYTONADIONE				
GLAXOSMITHKLINE	1MG/0.5ML	A084060	001	
	10MG/ML	A084060	002	
VITAMIN K1				
HOSPIRA	10MG/ML	A087956	001	Jul 25, 1983

PILOCARPINEINSERT, EXTENDED RELEASE; OPHTHALMIC
OCUSERT PILO-20

AKORN	5MG	N017431	001	
OCUSERT PILO-40				
AKORN	11MG	N017548	001	

PINACIDILCAPSULE, EXTENDED RELEASE; ORAL
PINDAC

LEO PHARM	12.5MG	N019456	001	Dec 28, 1989
	25MG	N019456	002	Dec 28, 1989

PINDOLOLTABLET; ORAL
PINDOLOL

IVAX SUB TEVA PHARMS	5MG	A073687	001	Feb 26, 1993
	10MG	A073687	002	Feb 26, 1993
MUTUAL PHARM	5MG	A074063	001	Jan 27, 1994
	10MG	A074063	002	Jan 27, 1994
MYLAN PHARMS INC	5MG	A074013	001	Sep 24, 1992
	10MG	A074018	001	Sep 24, 1992
NOSTRUM LABS	5MG	A074474	001	Oct 28, 1996
	10MG	A074474	002	Oct 28, 1996
PUREPAC PHARM	5MG	A074125	001	Apr 28, 1993
	10MG	A074125	002	Apr 28, 1993
SANDOZ	5MG	A073608	001	Mar 29, 1993
	10MG	A073609	001	Mar 29, 1993
TEVA	5MG	A073661	001	Oct 31, 1993
	5MG	A074123	001	Apr 17, 1997
	10MG	A073661	002	Oct 31, 1993
	10MG	A074123	002	Apr 17, 1997
VISKEN				
NOVARTIS	5MG	N018285	001	Sep 03, 1982
	10MG	N018285	002	Sep 03, 1982

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 280 (of 360)

PIPECURONIUM BROMIDEINJECTABLE; INJECTION
ARDUAN

ORGANON USA INC	10MG/VIAL	N019638	001	Jun 26, 1990

PIPERACETAZINETABLET; ORAL
GUIDE

DOW PHARM	10MG	N013615	001	
	25MG	N013615	002	

PIPERACILLIN SODIUMINJECTABLE; INJECTION
PIPRACIL

WYETH PHARMS INC	EQ 2GM BASE/VIAL	A062750	001	Oct 13, 1987
	EQ 2GM BASE/VIAL	N050545	002	
	EQ 3GM BASE/VIAL	A062750	002	Oct 13, 1987
	EQ 3GM BASE/VIAL	N050545	003	
	EQ 4GM BASE/VIAL	A062750	003	Oct 13, 1987
	EQ 4GM BASE/VIAL	N050545	004	
	EQ 40GM BASE/VIAL	N050545	006	Sep 30, 1985

PIPERAZINE CITRATESYRUP; ORAL
ANTEPAR

GLAXOSMITHKLINE	EQ 500MG BASE/5ML	N009102	001	

BRYREL				
SANOFI AVENTIS US	EQ 500MG BASE/5ML	N017796	001	

MULTIFUGE				
BLULINE	EQ 500MG BASE/5ML	N009452	001	

PIPERAZINE CITRATE				
ALPHARMA US PHARMS	EQ 500MG BASE/5ML	A080774	001	
LANNETT	EQ 500MG BASE/5ML	A080963	001	
LUITPOLD	EQ 500MG BASE/5ML	A080671	001	

VERMIDOL				
SOLVAY	EQ 500MG BASE/5ML	A080992	001	

TABLET; ORAL
ANTEPAR

GLAXOSMITHKLINE	EQ 500MG BASE	N009102	003	

PIPERAZINE CITRATE				
IMPAX LABS	EQ 250MG BASE	A080874	001	

PIPOBROMANTABLET; ORAL
VERCYTE

ABBOTT	10MG	N016245	001	
	25MG	N016245	002	

PIRBUTEROL ACETATEAEROSOL, METERED; INHALATION
MAXAIR

MEDICIS	EQ 0.2MG BASE/INH	N019009	001	Dec 30, 1986

PIROXICAMCAPSULE; ORAL
PIROXICAM

EGIS	10MG	A074808	001	Jul 08, 1997
	20MG	A074808	002	Jul 08, 1997
IVAX SUB TEVA PHARMS	10MG	A074148	001	Jun 03, 1996
	20MG	A074148	002	Jun 03, 1996
MUTUAL PHARM	20MG	A073536	001	Mar 12, 1993
MYLAN	10MG	A074043	001	Sep 22, 1992
	20MG	A074043	002	Sep 22, 1992

DISCONTINUED DRUG PRODUCT LIST

6 - 281 (of 360)

PIROXICAM

CAPSULE; ORAL
PIROXICAM

ROXANE	10MG	A073651	001	Feb 26, 1993
	20MG	A073651	002	Feb 26, 1993
SCS	10MG	A074036	001	May 29, 1992
	20MG	A074036	002	May 29, 1992
TEVA	10MG	A073637	001	Jan 28, 1994
	20MG	A073638	001	Jan 28, 1994
TEVA PHARMS	10MG	A074103	001	Aug 28, 1992
	20MG	A074103	002	Aug 28, 1992

PLICAMYCIN

INJECTABLE; INJECTION
MITHRACIN

PFIZER	2.5MG/VIAL	N050109	001	

POLYESTRADIOL PHOSPHATE

INJECTABLE; INJECTION
ESTRADURIN

WYETH AYERST	40MG/AMP	N010753	001	

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL
POLYETHYLENE GLYCOL 3350

PADDOCK LLC	17GM/SC00PFUL	A090567	001	Oct 15, 2009
TEVA PHARMS	17GM/SC00PFUL	A077445	001	May 04, 2006

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL
CLENZ-LYTE

PADDOCK LLC	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090769	001	Jun 07, 2010

SOLUTION; ORAL
OCL

HOSPIRA	6GM/100ML;75MG/100ML;168MG/100ML;146MG/100ML;1.29GM/100ML	N019284	001	Apr 30, 1986

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL
COLYTE

MEDA PHARMS	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984
	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984
	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

PADDOCK LLC	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A090712	001	Feb 25, 2010

FOR SUSPENSION; ORAL
CO-LAV

BOCA PHARMA	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A073428	001	Jan 28, 1992

COLOVAGE

DYNAPHARM	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	A071320	001	Apr 20, 1988

E-Z-EM PREP LYTE

E Z EM	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A071278	001	Nov 21, 1988

GLYCOPREP

GOLDLINE	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A072319	001	Dec 23, 1988

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 282 (of 360)

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SUSPENSION; ORAL

GO-EVAC

BOCA PHARMA

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

A073433 001

Apr 28, 1992

PEG-LYTE

SANDOZ

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

A073098 001

Aug 31, 1993

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

AEROSPORIN

GLAXOSMITHKLINE

EQ 500,000 U BASE/VIAL

A062036 001

POWDER; FOR RX COMPOUNDING

POLYMYXIN B SULFATE

PADDOCK LLC

100,000,000 UNITS/BOT

A062455 001

Jul 27, 1983

POLYTHIAZIDE

TABLET; ORAL

RENESE

PFIZER

1MG

N012845 001

2MG

N012845 002

4MG

N012845 003

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIZIDE

PFIZER

0.5MG;EQ 1MG BASE

N017986 001

0.5MG;EQ 2MG BASE

N017986 002

0.5MG;EQ 5MG BASE

N017986 003

POLYTHIAZIDE; RESERPINE

TABLET; ORAL

RENESE-R

PFIZER

2MG;0.25MG

N013636 001

POTASSIUM AMINOSALICYLATE

CAPSULE; ORAL

PASKALIUM

GLENWOOD

500MG

N009395 004

POWDER; ORAL

POTASSIUM AMINOSALICYLATE

HEXCEL

100%

A080098 001

TABLET; ORAL

PASKALIUM

GLENWOOD

1GM

N009395 003

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

K-LEASE

SAVAGE LABS

8MEQ

A073398 001

Jan 28, 1992

10MEQ

A072427 001

Mar 28, 1990

POTASSIUM CHLORIDE

NESHER PHARMS

10MEQ

A070980 001

Feb 17, 1987

TEVA

8MEQ

A073531 001

Apr 26, 1996

10MEQ

A073532 001

Apr 26, 1996

FOR SUSPENSION, EXTENDED RELEASE; ORAL

MICRO-K LS

KV PHARM

20MEQ/PACKET

N019561 003

Aug 26, 1988

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

ABRAXIS PHARM

2MEQ/ML

A080204 001

2MEQ/ML

A084290 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 283 (of 360)

POTASSIUM CHLORIDEINJECTABLE; INJECTION
POTASSIUM CHLORIDE

ABRAXIS PHARM	2MEQ/ML	A086713	001	
	2MEQ/ML	A086714	001	
	2MEQ/ML	A087787	001	Apr 20, 1982
	2MEQ/ML	A087885	001	Feb 03, 1983
AKORN	2MEQ/ML	A088286	001	Sep 05, 1985
BAXTER HLTHCARE	2MEQ/ML	A080203	001	
FRESENIUS KABI USA	2MEQ/ML	A087817	001	Oct 20, 1982
GD SEARLE LLC	1MEQ/ML	A086219	001	
	2MEQ/ML	A086219	002	
	2MEQ/ML	A086220	002	
	3MEQ/ML	A086219	003	
	3MEQ/ML	A086220	001	
	4MEQ/ML	A086219	004	
HOSPIRA	1MEQ/ML	A080205	003	
	1MEQ/ML	A083345	003	
	1.5MEQ/ML	A083345	001	
	2MEQ/ML	A083345	002	
	2.4MEQ/ML	A080205	004	
	3.2MEQ/ML	A080205	005	
LILLY	2MEQ/ML	N007865	002	
LUITPOLD	2MEQ/ML	A080221	001	
	2MEQ/ML	A080736	001	
	2MEQ/ML	A087584	001	
	2MEQ/ML	A087585	001	
MILES	1MEQ/ML	A080195	002	
	2MEQ/ML	A080195	001	
	3MEQ/ML	A080195	003	
	4MEQ/ML	A080195	004	
PHARMA SERVE NY	2MEQ/ML	A086297	001	
	2MEQ/ML	A087362	001	Mar 08, 1983
WATSON LABS	2MEQ/ML	A086208	001	
	2MEQ/ML	A089163	001	Mar 10, 1988
	2MEQ/ML	A089421	001	Jan 02, 1987
	3MEQ/ML	A086210	001	

TABLET, EXTENDED RELEASE; ORAL

K+10				
FUTURE PAK	10MEQ	A070999	001	Oct 22, 1987
K+8				
FUTURE PAK	8MEQ	A070998	001	Jan 25, 1993
KAON CL				
SAVAGE LABS	6.7MEQ	N017046	001	
KAON CL-10				
SAVAGE LABS	10MEQ	N017046	002	
KLOTRIX				
APOTHECON	10MEQ	N017850	001	
POTASSIUM CHLORIDE				
COPLEY PHARM	8MEQ	A070618	001	Sep 09, 1987
NESHER PHARMS	20MEQ	A076044	001	Apr 05, 2002
SCHERING	10MEQ	N019439	002	Jun 13, 1986
	20MEQ	N019439	001	Jun 13, 1986
SLOW-K				
NOVARTIS	8MEQ	N017476	002	
TEN-K				
NOVARTIS	10MEQ	N019381	001	Apr 16, 1986

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	37MG/100ML;900MG/100ML	N019708	001	Sep 29, 1989

DISCONTINUED DRUG PRODUCT LIST

6 - 284 (of 360)

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
B BRAUN	75MG/100ML;900MG/100ML	N019708	002	Sep 29, 1989	
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
B BRAUN	110MG/100ML;900MG/100ML	N019708	003	Sep 29, 1989	
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
B BRAUN	220MG/100ML;900MG/100ML	N019708	005	Sep 29, 1989	
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
B BRAUN	300MG/100ML;900MG/100ML	N019708	006	Sep 29, 1989	
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER					
B BRAUN	75MG/100ML;900MG/100ML	N018722	001	Nov 09, 1982	
BAXTER HLTHCARE	75MG/100ML;900MG/100ML	N017648	004		
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER					
B BRAUN	150MG/100ML;900MG/100ML	N018722	002	Nov 09, 1982	
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER					
B BRAUN	220MG/100ML;900MG/100ML	N018722	003	Nov 09, 1982	
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
B BRAUN	300MG/100ML;900MG/100ML	N018722	004	Nov 09, 1982	

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION

THAM-E					
HOSPIRA	370MG/VIAL;1.75GM/VIAL;36GM/VIAL	N013025	001		

POTASSIUM CITRATE

FOR SOLUTION; ORAL POTASSIUM CITRATE

NOVA K	10MEQ/PACKET	N019647	002	Oct 13, 1988	
	20MEQ/PACKET	N019647	001	Oct 13, 1988	

POTASSIUM IODIDE

SOLUTION; ORAL POTASSIUM IODIDE

ROXANE	1GM/ML	N018551	001	Feb 19, 1982	

TABLET; ORAL THYRO-BLOCK

MEDPOINTE PHARM HLC	130MG	N018307	001		

POTASSIUM PERCHLORATE

CAPSULE; ORAL PERCHLORACAP MALLINCKRODT

200MG	N017551	001		

POVIDONE- IODINE

SOLUTION; TOPICAL E-Z PREP

CLINIPAD	10%	N019382	001	Jul 25, 1989	

SPONGE; TOPICAL E-Z PREP

CLINIPAD	5%	N019382	002	Jul 25, 1989	

E-Z PREP 220

CLINIPAD	5%	N019382	003	Jul 25, 1989	

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION PRALIDOXIME CHLORIDE

BAXTER HLTHCARE CORP	300MG/ML	N018799	001	Dec 13, 1982	

TABLET; ORAL PROTOPAM CHLORIDE

WYETH AYERST	500MG	N014122	002		

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 285 (of 360)

PRAMIPEXOLE DIHYDROCHLORIDETABLET; ORAL
MIRAPEX

BOEHRINGER INGELHEIM 1.25MG

N020667 004 Jul 01, 1997

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

PLIVA HRVATSKA DOO

10MG

A077730 001 Nov 21, 2006

20MG

A077730 002 Nov 21, 2006

30MG

A077730 003 Nov 21, 2006

40MG

A077730 005 Nov 21, 2006

RANBAXY LABS LTD

10MG

A076445 001 Apr 23, 2007

20MG

A076445 002 Apr 23, 2007

40MG

A076445 003 Apr 23, 2007

80MG

A076445 004 Apr 23, 2007

SANDOZ

10MG

A076397 003 Oct 23, 2006

20MG

A076397 002 Oct 23, 2006

40MG

A076397 001 Oct 23, 2006

80MG

A077491 001 Feb 11, 2008

PRAZEPAMCAPSULE; ORAL
CENTRAX

PARKE DAVIS

5MG

N018144 001

10MG

N018144 002

20MG

N018144 003 May 10, 1982

PRAZEPAM

USL PHARMA

5MG

A070427 001 Nov 06, 1987

10MG

A070428 001 Nov 06, 1987

TABLET; ORAL

CENTRAX

PARKE DAVIS

10MG

N017415 001

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

AM THERAP

EQ 1MG BASE

A072782 001 May 16, 1989

EQ 2MG BASE

A072783 001 May 16, 1989

EQ 5MG BASE

A072784 001 May 16, 1989

CLONMEL HLTHCARE

EQ 1MG BASE

A072705 001 May 16, 1989

EQ 2MG BASE

A072706 001 May 16, 1989

EQ 5MG BASE

A072707 001 May 16, 1989

PUREPAC PHARM

EQ 1MG BASE

A072991 001 May 16, 1989

EQ 2MG BASE

A072921 001 May 16, 1989

EQ 5MG BASE

A072992 001 May 16, 1989

SANDOZ

EQ 1MG BASE

A072576 001 May 16, 1989

EQ 2MG BASE

A072577 001 May 16, 1989

EQ 5MG BASE

A072578 001 May 16, 1989

WATSON LABS

EQ 1MG BASE

A072352 001 May 16, 1989

EQ 2MG BASE

A072333 001 May 16, 1989

EQ 5MG BASE

A072609 001 May 16, 1989

TABLET, EXTENDED RELEASE; ORAL

MINIPRESS XL

PFIZER

2.5MG

N019775 001 Jan 29, 1992

5MG

N019775 002 Jan 29, 1992

PREDNISOLONECREAM; TOPICAL
METI-DERM

SCHERING

0.5%

N010209 002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 286 (of 360)

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

IVAX SUB TEVA PHARMS 15MG/5ML

A040287 001 May 28, 1999

NESHER PHARMS 5MG/5ML

A040423 001 Oct 22, 2001

15MG/5ML

A040364 001 Apr 10, 2002

TEVA PHARMS 15MG/5ML

A040322 001 Jan 19, 2000

WE PHARMS 15MG/5ML

A040192 001 May 28, 1998

PRELONE

MURO 5MG/5ML

A089654 001 Jan 17, 1989

TABLET; ORAL

CORTALONE

HALSEY 1MG

A080304 003

2.5MG

A080304 002

5MG

A080304 001

DELTA-CORTEF

PHARMACIA AND UPJOHN 5MG

N009987 004

FERNISOLONE-P

FERNDAL LABS 5MG

A083941 001

PREDNISOLONE

BARR 5MG

A084426 002

BUNDY 5MG

A083675 001

ELKINS SINN 5MG

A080625 001

EVERYLIFE 1MG

A084439 001

2.5MG

A084439 002

5MG

A084439 003

FERRANTE 2.5MG

A080562 001

5MG

A080562 002

HEATHER 5MG

A080326 001

IMPAX LABS 5MG

A080780 001

INWOOD LABS 5MG

A080748 001

IVAX SUB TEVA PHARMS 5MG

A080378 001

LANNETT 5MG

A080531 002

MARSHALL PHARMA 5MG

A080307 001

PANRAY 1MG

A080351 001

5MG

A080351 002

PERRIGO 5MG

A084542 001

PHOENIX LABS NY 5MG

A080322 001

PUREPAC PHARM 5MG

A080325 001

PVT FORM 5MG

A080211 001

ROXANE 5MG

A080327 002

SANDOZ 5MG

A080339 001

5MG

A084773 001

SPERTI 1MG

A080358 001

2.5MG

A080358 002

5MG

A080358 003

SUPERPHARM 5MG

A088892 001 Feb 26, 1985

TABLICAPS 5MG

A085170 001

TEVA 5MG

A080398 001

UDL 5MG

A087987 001 Jan 18, 1983

VALEANT PHARM INTL 5MG

A080236 001

VITARINE 5MG

A080534 001

WATSON LABS 5MG

A085085 002

5MG

A085415 001

5MG

A085416 001

WEST WARD 5MG

A080324 001

WHITEWORTH TOWN PLSN 5MG

A080342 001

STERANE

PFIZER 5MG

N009996 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 287 (of 360)

PREDNISOLONE ACETATEINJECTABLE; INJECTION
METICORTEZONE

SCHERING 25MG/ML N010255 002

PREDNISOLONE ACETATE

AKORN 25MG/ML A083032 001

50MG/ML A084492 001

BEL MAR 25MG/ML A083738 001

50MG/ML A083738 002

CENT PHARMS 25MG/ML A084717 001

50MG/ML A084717 002

WATSON LABS 25MG/ML A083398 001

25MG/ML A083654 001

40MG/ML A083767 001

50MG/ML A083764 001

50MG/ML A085781 001

STERANE

PFIZER 25MG/ML N011446 001

SUSPENSION; ORAL

FLO-PRED

TARO EQ 5MG BASE/5ML N022067 001 Jan 17, 2008

SUSPENSION/DROPS; OPHTHALMIC

ECONOPRED

ALCON 0.125% N017468 001

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

CETAPRED

ALCON 0.25%;10% A087771 001 Aug 06, 1993

METIMYD

SCHERING 0.5%;10% N010210 002 Sep 09, 1984

PREDSULFAIR

PHARMAFAIR 0.5%;10% A088032 001 Apr 15, 1983

VASOCIDIN

NOVARTIS 0.5%;10% A088791 001 Oct 05, 1984

SUSPENSION; OPHTHALMIC

ISOPTO CETAPRED

ALCON 0.25%;10% A087547 001

SUSPENSION/DROPS; OPHTHALMIC

METIMYD

SCHERING 0.5%;10% N010210 001

PREDAMIDE

AKORN 0.5%;10% A088059 001 Jul 29, 1983

PREDSULFAIR

PHARMAFAIR 0.5%;10% A088007 001 Apr 19, 1983

PREDSULFAIR II

PHARMAFAIR 0.2%;10% A088837 001 Dec 24, 1985

SULPHRIN

BAUSCH AND LOMB 0.5%;10% A088089 001 Dec 28, 1982

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDELTRASOL

MERCK EQ 20MG PHOSPHATE/ML N011583 002

PREDNISOLONE SODIUM PHOSPHATE

WATSON LABS EQ 20MG PHOSPHATE/ML A080517 001

OINTMENT; OPHTHALMIC, OTIC

HYDELTRASOL

MERCK EQ 0.25% PHOSPHATE N011028 001

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

NESHER PHARMS EQ 5MG BASE/5ML A076982 001 May 24, 2005

VINTAGE PHARMS EQ 5MG BASE/5ML A078416 001 Oct 31, 2007

WE PHARMS EQ 5MG BASE/5ML A075181 001 Dec 23, 2002

DISCONTINUED DRUG PRODUCT LIST

6 - 288 (of 360)

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC
INFLAMASE FORTE

NOVARTIS EQ 0.9% PHOSPHATE A080751 002

INFLAMASE MILD
NOVARTIS EQ 0.11% PHOSPHATE A080751 001

METRETON
SCHERING EQ 0.5% PHOSPHATE A083834 001

PREDAIR
PHARMAFAIR EQ 0.11% PHOSPHATE A088415 001 Feb 29, 1984

PREDAIR FORTE
PHARMAFAIR EQ 0.9% PHOSPHATE A088165 001 Mar 28, 1983

PREDNISOLONE SODIUM PHOSPHATE
AKORN EQ 0.11% PHOSPHATE A083358 001

EQ 0.9% PHOSPHATE A083358 002

ALCON PHARMS LTD EQ 0.11% PHOSPHATE A081043 001 Oct 24, 1991

EQ 0.9% PHOSPHATE A081044 001 Oct 24, 1991

BAUSCH AND LOMB EQ 0.11% PHOSPHATE A040065 001 Jul 29, 1994

SOLA BARNES HIND EQ 0.11% PHOSPHATE A084171 001

EQ 0.9% PHOSPHATE A084168 001

EQ 0.9% PHOSPHATE A084169 001

EQ 0.9% PHOSPHATE A084172 001

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULSTER

AKORN EQ 0.23% PHOSPHATE;10% A074511 001 Jul 30, 1996

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION
HYDELTRA-TBA

MERCK 20MG/ML N010562 001

PREDNISOLONE TEBUTATE
WATSON LABS 20MG/ML A083362 001 Feb 17, 1984

PREDNISONE

SOLUTION; ORAL
PREDNISONE

WOCKHARDT 5MG/5ML A089726 001 Aug 02, 1988

SYRUP; ORAL
LIQUID PRED

MURO 5MG/5ML A087611 002 Sep 07, 1982

TABLET; ORAL
CORTAN

HALSEY 20MG A087480 001

DELTA-DOME

BAYER PHARMS 5MG A080293 001

DELTASONE

PHARMACIA AND UPJOHN 2.5MG N009986 005

5MG N009986 002

10MG N009986 006

20MG N009986 007

50MG N009986 008

FERNISONE

FERNDAL LABS 5MG A083364 001

METICORTEN

SCHERING 1MG N009766 002

5MG N009766 001

ORASONE

SOLVAY 1MG A083009 001

5MG A083009 002

10MG A083009 003

20MG A083009 004

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 289 (of 360)

PREDNISONETABLET; ORAL
ORASONE

SOLVAY 50MG A085999 001

PARACORT

PARKE DAVIS 5MG N010962 002

PREDNICEN-M

SCHWARZ PHARMA 5MG A084655 001

PREDNISONE

AM THERAP 5MG A089387 001 Nov 06, 1986

10MG A089388 001 Nov 06, 1986

20MG A089389 001 Nov 06, 1986

AMNEAL PHARMS NY 5MG A089597 001 Oct 05, 1987

10MG A089598 001 Oct 05, 1987

20MG A089599 001 Oct 05, 1987

BUNDY

5MG A083676 001

DURAMED PHARMS BARR

5MG A088394 001 Oct 04, 1983

10MG A088395 001 Oct 04, 1983

20MG A088396 001 Oct 04, 1983

ELKINS SINN

5MG A080491 001

20MG A085811 001

EVERYLIFE

1MG A084440 001

2.5MG A084440 002

5MG A084440 003

FERRANTE

2.5MG A080563 001

5MG A080563 002

HALSEY

5MG A080300 001

HEATHER

5MG A080320 001

10MG A084341 001

20MG A084417 001

20MG A085543 001

50MG A086946 001

IMPAX LABS

5MG A080782 001

INWOOD LABS

1MG A080328 001

2.5MG A080306 001

5MG A080279 001

IVAX SUB TEVA PHARMS

5MG A080283 001

10MG A084133 001

20MG A084134 001

KV PHARM

5MG A084236 001

LANNETT

5MG A080514 001

20MG A084275 001

LEDERLE

5MG A086968 001

MARSHALL PHARMA

5MG A080301 001

MUTUAL PHARM

5MG A080701 001

10MG A086595 001

20MG A084634 001

50MG A086596 001

NYLOS

5MG A085115 001

PANRAY

1MG A080350 001

2.5MG A080350 002

5MG A080350 003

PERRIGO

5MG A083059 001

PHARMAVITE

5MG A084662 002

PHOENIX LABS NY

5MG A080321 001

20MG A083807 001

PUREPAC PHARM

5MG A080353 001

10MG A086062 001

20MG A086061 001

PVT FORM

20MG A085151 001

REXALL

5MG A080232 001

ROXANE

20MG N017109 001

25MG A087833 001 May 04, 1982

DISCONTINUED DRUG PRODUCT LIST

6 - 290 (of 360)

PREDNISONE

TABLET; ORAL
PREDNISONE

SANDOZ	5MG	A080336	002	
	5MG	A084774	001	
	10MG	A089983	001	Jan 12, 1989
	20MG	A085813	001	
	50MG	A089984	001	Jan 12, 1989
SCHERER LABS SPERTI	5MG	A080371	001	
	1MG	A080359	001	
	2.5MG	A080359	002	
SUPERPHARM	5MG	A080359	003	
	5MG	A088865	001	Oct 25, 1984
	10MG	A088866	001	Oct 25, 1984
	20MG	A088867	001	Oct 25, 1984
TEVA	5MG	A080397	001	
UDL	5MG	A087984	001	Jan 18, 1983
	10MG	A087985	001	Jan 18, 1983
	20MG	A087986	001	Jan 18, 1983
UPSHER SMITH	5MG	A087471	001	
	20MG	A087470	001	
VALEANT PHARM INTL	5MG	A080237	001	
VANGARD	5MG	A087682	001	Jan 15, 1982
	20MG	A087701	001	Jan 15, 1982
VITARINE	5MG	A080334	001	
	5MG	A080506	001	
WATSON LABS	5MG	A085084	002	
	10MG	A087773	001	Jul 13, 1982
	20MG	A086813	001	
	50MG	A086867	001	
	50MG	A087772	001	Jul 13, 1982
WHITEWORTH TOWN PLSN	2.5MG	A084913	001	
	5MG	A080343	001	
	10MG	A089028	001	Jul 24, 1986
	20MG	A084913	002	
SERVISONE				
LEDERLE	5MG	A080223	001	

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CITANEST

ASTRAZENECA	1%	N014763	004	
	2%	N014763	005	
	3%	N014763	003	
CITANEST PLAIN				
ASTRAZENECA	4%	N014763	007	
CITANEST PLAIN DENTAL				
DENTSPLY PHARM	4%	N021382	001	

PRIMIDONE

SUSPENSION; ORAL
MYSOLINE

NURO PHARMA	250MG/5ML	N010401	001	
TABLET; ORAL				
PRIMIDONE				
WATSON LABS	250MG	A085052	001	

PROBENECID

TABLET; ORAL
BENEMID

MERCK	500MG	N007898	004	
PROBENECID				
LEDERLE	500MG	A086917	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 291 (of 360)

PROBENECIDTABLET; ORAL
PROBENECID

WATSON LABS	500MG	A086150	002	Apr 23, 1982

PROBUCOLTABLET; ORAL
LORELCO

SANOFI AVENTIS US	250MG	N017535	001	
	500MG	N017535	002	Jul 06, 1988

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HYDROCHLORIDE

ASCOT	250MG	A087542	001	Jan 08, 1982
	375MG	A087697	001	Mar 01, 1983
	500MG	A087543	001	Jan 08, 1982
IVAX SUB TEVA PHARMS	250MG	A084604	001	
	375MG	A084595	001	
	500MG	A084606	001	
LANNETT	250MG	A083693	001	
	500MG	A084696	001	
LEDERLE	250MG	A086942	001	
	375MG	A086952	001	
	500MG	A086943	001	
ROXANE	250MG	A088989	001	Apr 26, 1985
	500MG	A088990	001	Apr 26, 1985
SANDOZ	250MG	A089219	001	Jul 01, 1986
	375MG	A089220	001	Jul 01, 1986
	500MG	A089221	001	Jul 01, 1986
VANGARD	250MG	A087643	001	Jun 01, 1982
	500MG	A087875	001	Jun 01, 1982
WATSON LABS	250MG	A083287	001	
	250MG	A083795	001	
	250MG	A085167	001	
	375MG	A084403	001	
	375MG	A087020	001	
	500MG	A084280	001	
	500MG	A084357	001	
	500MG	A087021	001	
PROCAN				
PARKE DAVIS	250MG	A085804	001	
	375MG	A087502	001	
	500MG	A085079	001	
PROCAPAN				
PANRAY	250MG	A083553	002	
PRONESTYL				
APOTHECON	250MG	N007335	001	
	375MG	N007335	004	
	500MG	N007335	003	

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

ABRAXIS PHARM	100MG/ML	A089415	001	Nov 17, 1986
	500MG/ML	A089416	001	Nov 17, 1986
HIKMA MAPLE	100MG/ML	A089029	001	Apr 17, 1986
	500MG/ML	A089030	001	Apr 17, 1986
HOSPIRA	500MG/ML	A089537	001	Aug 25, 1987
PHARMAFAIR	100MG/ML	A088824	001	Nov 20, 1985
	500MG/ML	A088830	001	Nov 20, 1985
SMITH AND NEPHEW	100MG/ML	A088530	001	Mar 04, 1985
	500MG/ML	A088531	001	Mar 04, 1985
SOLOPAK	500MG/ML	A088532	001	Mar 04, 1985
WARNER CHILCOTT	100MG/ML	A089528	001	May 03, 1988

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 292 (of 360)

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

WARNER CHILCOTT	500MG/ML	A089529	001	May 03, 1988
WATSON LABS	100MG/ML	A087079	001	
	500MG/ML	A087080	001	

PRONESTYL

APOTHECON	100MG/ML	N007335	002	
	500MG/ML	N007335	005	

TABLET; ORAL

PRONESTYL

APOTHECON	250MG	N017371	001	
	375MG	N017371	002	
	500MG	N017371	003	

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HYDROCHLORIDE

COPLEY PHARM	500MG	A088974	001	Jul 22, 1985
	750MG	A089438	001	Mar 23, 1987
	1GM	A040111	001	Dec 13, 1996
INWOOD LABS	500MG	A089840	001	Mar 06, 1989
PLIVA	250MG	A088958	001	Dec 02, 1985
	500MG	A088959	001	Dec 02, 1985
SANDOZ	250MG	A089369	001	Aug 14, 1987
	500MG	A089284	001	Jun 23, 1986
	500MG	A089370	001	Jan 09, 1987
	750MG	A089371	001	Aug 14, 1987
WATSON LABS	250MG	A088533	001	Dec 03, 1984
	250MG	A089026	001	Oct 22, 1985
	500MG	A088534	001	Dec 03, 1984
	500MG	A089027	001	Oct 22, 1985
	750MG	A088535	001	Nov 03, 1984
	750MG	A089042	001	Oct 22, 1985
	1GM	A089520	001	Jan 15, 1987

PROCAN SR

PARKE DAVIS	250MG	A086468	001	
PARKEDALE	500MG	A086065	001	
	750MG	A087510	001	Apr 01, 1982
	1GM	A088489	001	Jan 16, 1985

PROCANBID

KING PHARMS	500MG	N020545	001	Jan 31, 1996
	1GM	N020545	002	Jan 31, 1996

PRONESTYL-SR

APOTHECON	500MG	A087361	001	

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NOVOCAIN

HOSPIRA	1%	A085362	003	
	2%	A085362	004	
	10%	A086797	001	

PROCAINE HYDROCHLORIDE

ABRAXIS PHARM	1%	A080384	002	
	1%	A080421	001	
	2%	A080384	003	
	2%	A080421	002	
BEL MAR	1%	A080711	001	
	2%	A080756	001	
ELKINS SINN	1%	A083315	001	
	2%	A083315	002	
GD SEARLE LLC	1%	A086202	001	
	2%	A086202	002	
HOSPIRA	1%	A080416	001	
	2%	A080416	002	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 293 (of 360)

PROCAINE HYDROCHLORIDEINJECTABLE; INJECTION
PROCAINE HYDROCHLORIDE

MILES	1%	A080415	001
	2%	A080415	002
WATSON LABS	1%	A080658	001
	1%	A083535	001
	2%	A080658	002
	2%	A083535	002

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDEINJECTABLE; INJECTION
ACHROMYCIN

LEDERLE	40MG/VIAL;100MG/VIAL	N050276	001
	40MG/VIAL;250MG/VIAL	N050276	003

TETRACYN

PFIZER	40MG/VIAL;100MG/VIAL	A060285	002
	40MG/VIAL;250MG/VIAL	A060285	003

PROCAINE MERETHOXYLLINE; THEOPHYLLINE

INJECTABLE; INJECTION

DICURIN PROCAINE

LILLY	100MG/ML;50MG/ML	N008869	001

PROCHLORPERAZINESUPPOSITORY; RECTAL
COMPAZINE

GLAXOSMITHKLINE	2.5MG	N011127	003
	5MG	N011127	001
	25MG	N011127	002

PROCHLORPERAZINE

ABLE	2.5MG	A040407	001	Jul 11, 2001
	5MG	A040407	002	Jul 11, 2001
	25MG	A040407	003	Jul 11, 2001

PROCHLORPERAZINE EDISYLATECONCENTRATE; ORAL
COMPAZINE

GLAXOSMITHKLINE	EQ 10MG BASE/ML	N011276	001

PROCHLORPERAZINE

ALPHARMA US PHARMS	EQ 10MG BASE/ML	A087153	001	Jun 08, 1982

PROCHLORPERAZINE EDISYLATE

MORTON GROVE	EQ 10MG BASE/ML	A088598	001	Oct 25, 1984

INJECTABLE; INJECTION
COMPAZINE

GLAXOSMITHKLINE	EQ 5MG BASE/ML	N010742	002

PROCHLORPERAZINE

BAXTER HLTHCARE	EQ 5MG BASE/ML	A087759	001	Oct 01, 1982

PROCHLORPERAZINE EDISYLATE

HIKMA MAPLE	EQ 5MG BASE/ML	A089523	001	May 03, 1988

HOSPIRA	EQ 5MG BASE/ML	A089703	001	Apr 07, 1988

MARSAM PHARMS LLC	EQ 5MG BASE/ML	A089675	001	Dec 05, 1988

SMITH AND NEPHEW	EQ 5MG BASE/ML	A089251	001	Dec 04, 1986

TEVA PARENTERAL	EQ 5MG BASE/ML	A040505	001	May 30, 2003

WATSON LABS	EQ 5MG BASE/ML	A089530	001	Jul 08, 1987

	EQ 5MG BASE/ML	A089605	001	Jul 08, 1987

	EQ 5MG BASE/ML	A089606	001	Jul 08, 1987

WYETH AYERST	EQ 5MG BASE/ML	A086348	001

SYRUP; ORAL
COMPAZINE

GLAXOSMITHKLINE	EQ 5MG BASE/5ML	N011188	001

PROCHLORPERAZINE EDISYLATE

ALPHARMA US PHARMS	EQ 5MG BASE/5ML	A087154	001	Sep 01, 1982

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 294 (of 360)

PROCHLORPERAZINE EDISYLATE

SYRUP; ORAL

PROCHLORPERAZINE EDISYLATE

MORTON GROVE

EQ 5MG BASE/5ML

A088597 001

Oct 25, 1984

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 10MG BASE

N011000 001

EQ 10MG BASE

N021019 001

Oct 06, 1999

EQ 15MG BASE

N011000 002

EQ 15MG BASE

N021019 002

Oct 06, 1999

EQ 30MG BASE

N011000 003

EQ 75MG BASE

N011000 004

TABLET; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 5MG BASE

N010571 001

EQ 10MG BASE

N010571 002

EQ 25MG BASE

N010571 003

PROCHLORPERAZINE

WATSON LABS

EQ 5MG BASE

A085580 001

EQ 10MG BASE

A085178 001

EQ 25MG BASE

A085579 001

PROCHLORPERAZINE MALEATE

DURAMED PHARMS BARR

EQ 5MG BASE

A040207 001

May 01, 1997

EQ 5MG BASE

A089484 001

Jan 20, 1987

EQ 10MG BASE

A040207 002

May 01, 1997

EQ 10MG BASE

A089485 001

Jan 20, 1987

EQ 25MG BASE

A089486 001

Jan 20, 1987

IVAX SUB TEVA PHARMS

EQ 5MG BASE

A040162 001

Jan 20, 1998

EQ 10MG BASE

A040162 002

Jan 20, 1998

SANDOZ

EQ 25MG BASE

A040101 003

Jul 19, 1996

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL

KEMADRIN

MONARCH PHARMS

2MG

N009818 005

5MG

N009818 003

PROGESTERONE

CAPSULE; ORAL

PROMETRIUM

ABBOTT LABS

300MG

N019781 003

Oct 15, 1999

INJECTABLE; INJECTION

PROGESTERONE

LILLY

25MG/ML

N009238 002

50MG/ML

N009238 001

INSERT, EXTENDED RELEASE; INTRAUTERINE

PROGESTASERT

ALZA

38MG

N017553 001

PROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

SPARINE

WYETH AYERST

30MG/ML

N010942 001

100MG/ML

N010942 004

INJECTABLE; INJECTION

PROMAZINE HYDROCHLORIDE

WATSON LABS

25MG/ML

A084510 001

50MG/ML

A084517 001

SPARINE

BAXTER HLTHCARE CORP

25MG/ML

N010349 008

50MG/ML

N010349 006

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 295 (of 360)

PROMAZINE HYDROCHLORIDE

SYRUP; ORAL SPARINE			
WYETH AYERST	10MG/5ML	N010942	003
TABLET; ORAL SPARINE			
WYETH AYERST	10MG	N010348	006
	25MG	N010348	001
	50MG	N010348	002
	100MG	N010348	003
	200MG	N010348	004

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION PHENERGAN			
WYETH AYERST	25MG/ML	N008857	002
	50MG/ML	N008857	003
PROMETHAZINE HYDROCHLORIDE			
ABBOTT	25MG/ML	A084223	001
	50MG/ML	A084222	001
AKORN	25MG/ML	A083955	002
	50MG/ML	A083955	001
BEDFORD LABS	25MG/ML	A040524	001 Mar 17, 2004
	50MG/ML	A040524	002 Mar 17, 2004
BIONICHE PHARMA	25MG/ML	A040471	001 Nov 21, 2002
HOSPIRA	50MG/ML	A040372	002 Jun 08, 2000
	50MG/ML	A083838	002
MARSAM PHARMS LLC	25MG/ML	A089463	001 May 02, 1988
	50MG/ML	A089477	001 May 02, 1988
SANDOZ	25MG/ML	A040593	001 Nov 08, 2006
	50MG/ML	A040593	002 Nov 08, 2006
WATSON LABS	25MG/ML	A083532	001
	25MG/ML	A084591	001
	50MG/ML	A080629	002
	50MG/ML	A083532	002
ZIPAN-25			
ALTANA	25MG/ML	A083997	001
ZIPAN-50			
ALTANA	50MG/ML	A083997	002
SUPPOSITORY; RECTAL PHENERGAN			
SHIONOGI INC	12.5MG	N010926	002
	25MG	N010926	001
	50MG	N011689	001
PROMETHACON			
POLYMEDICA	25MG	A084901	001
	50MG	A084902	001
PROMETHAZINE HYDROCHLORIDE			
ABLE	12.5MG	A040504	001 Apr 11, 2003
	25MG	A040504	002 Apr 11, 2003
	50MG	A040449	001 Feb 27, 2003
SYRUP; ORAL MYMETHAZINE FORTIS			
USL PHARMA	25MG/5ML	A087996	001 Jan 18, 1983
PROMETH FORTIS			
ALPHARMA US PHARMS	25MG/5ML	A084772	001
PROMETH PLAIN			
ACTAVIS MID ATLANTIC	6.25MG/5ML	A085953	001
PROMETHAZINE			
CENCI	6.25MG/5ML	A089013	001 Sep 20, 1985
PROMETHAZINE HYDROCHLORIDE			
KV PHARM	6.25MG/5ML	A085388	001
	25MG/5ML	A085385	001
PHARM ASSOC	6.25MG/5ML	A087518	001

DISCONTINUED DRUG PRODUCT LIST

6 - 296 (of 360)

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

WHITEWORTH TOWN PLSN 6.25MG/5ML

A086395 001

PROMETHAZINE HYDROCHLORIDE PLAIN

ANI PHARMS 6.25MG/5ML

N008381 004 Apr 18, 1984

25MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

N008381 003

TABLET; ORAL

PHENERGAN

WYETH PHARMS INC 12.5MG

N007935 002

25MG

N007935 003

50MG

N007935 004

PROMETHAZINE HYDROCHLORIDE

ABBOTT 12.5MG

A084160 001

25MG

A084166 001

50MG

A084539 001

ABLE 12.5MG

A040558 001 Jul 01, 2004

25MG

A040558 002 Jul 01, 2004

50MG

A040558 003 Jul 01, 2004

IMPAX LABS 25MG

A084214 002 Jul 07, 1982

IVAX SUB TEVA PHARMS 12.5MG

A083604 001

25MG

A083603 001

50MG

A083613 001

LANNETT 12.5MG

A080949 001

25MG

A080949 002

50MG

A080949 003

MUTUAL PHARM 12.5MG

A084555 001

25MG

A084554 001

50MG

A084557 001

PVT FORM 12.5MG

A083214 001

25MG

A083658 001

SANDOZ 12.5MG

A084176 002 May 22, 2009

12.5MG

A084233 001

25MG

A085146 001

50MG

A085146 002

TABLICAPS 12.5MG

A084080 001

25MG

A084027 001

TEVA 25MG

A089109 001 Sep 10, 1985

WATSON LABS 12.5MG

A083401 001

12.5MG

A083712 001

12.5MG

A085986 001

25MG

A083204 001

25MG

A085684 001

50MG

A083403 001

50MG

A085664 001

REMSD

BRISTOL MYERS SQUIBB 25MG

A083176 002

50MG

A083176 001

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

NESHER PHARMS 150MG

A076193 001 Feb 07, 2002

225MG

A076193 002 Feb 07, 2002

300MG

A076193 003 Feb 07, 2002

PROPANTHELINE BROMIDE

INJECTABLE; INJECTION

PRO-BANTHINE

GD SEARLE LLC 30MG/VIAL

N008843 001

DISCONTINUED DRUG PRODUCT LIST

6 - 297 (of 360)

PROPANTHELINE BROMIDE

TABLET; ORAL				
PRO-BANTHINE				
SHIRE	7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008732	003	
	15MG	N008732	002	
PROPANTHELINE BROMIDE				
ASCOT	15MG	A087663	001	Oct 25, 1982
HEATHER	15MG	A085780	001	
IMPAX LABS	15MG	A084541	002	
MYLAN	15MG	A083706	001	
PAR PHARM	15MG	A088377	001	Dec 08, 1983
PVT FORM	15MG	A080977	001	
ROXANE	7.5MG	A080927	001	
SANDOZ	15MG	A080928	001	
TABLICAPS	15MG	A084428	001	
WATSON LABS	15MG	A083029	002	
	15MG	A083151	001	

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC				
KAINAIR				
PHARMAFAIR	0.5%	A088087	001	Jun 07, 1983
PARACAINE				
OPTOPICS	0.5%	A087681	001	Aug 05, 1982
PROPARACAINE HYDROCHLORIDE				
SOLA BARNES HIND	0.5%	A084144	001	
	0.5%	A084151	001	

PROPIOLACTONE

SOLUTION; IRRIGATION				
BETAPRONE				
FOREST LABS	N/A	N011657	001	

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION				
LARGON				
BAXTER HLTHCARE CORP	20MG/ML	N012382	002	

PROPOFOL

INJECTABLE; INJECTION				
DIPRIVAN				
FRESENIUS KABI USA	10MG/ML	N019627	001	Oct 02, 1989
PROPOFOL				
BEDFORD	10MG/ML	A074848	001	Apr 19, 2005
TEVA PARENTERAL	10MG/ML	A075392	001	Sep 19, 2000

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL				
DARVON				
XANODYNE PHARM	32MG	N010997	001	
	65MG	N010997	003	
DOLENE				
HERITAGE PHARMS INC	65MG	A080530	001	
KESSO-GESIC				
MK LABS	65MG	A083544	001	
PROPHENE 65				
HALSEY	65MG	A083538	002	
PROPOXYPHENE HYDROCHLORIDE				
ALRA	65MG	A083184	001	
IMPAX LABS	65MG	A083317	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 298 (of 360)

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	32MG	A083597	001	
MUTUAL PHARM	65MG	A083186	001	
MYLAN	32MG	A083528	001	
	65MG	A040569	001	Dec 16, 2004
	65MG	A083299	001	
NEXGEN PHARMA INC	65MG	A083185	001	
PAR PHARM	65MG	A080269	001	
PUREPAC PHARM	65MG	A083278	001	
PVT FORM	32MG	A083464	001	
	65MG	A083113	001	
ROXANE	32MG	A083089	001	
	65MG	A083089	002	
SANDOZ	32MG	A084014	001	
	65MG	A083125	002	
	65MG	A083688	001	
	65MG	A083870	002	
	65MG	A086495	001	
TEVA	65MG	A088615	001	Oct 22, 1984
VALEANT PHARM INTL	65MG	A080783	001	
VINTAGE PHARMS	65MG	A040908	001	Jul 17, 2009
WATSON LABS	65MG	A080908	002	
	65MG	A085190	001	
WEST WARD	65MG	A083501	001	
WHITEWORTH TOWN PLSN	65MG	A084551	001	
PROPOXYPHENE HYDROCHLORIDE 65				
WARNER CHILCOTT	65MG	A083786	001	

PROPOXYPHENE NAPSYLATE

SUSPENSION; ORAL

DARVON-N

AAIPHARMA LLC	50MG/5ML	N016861	001	

TABLET; ORAL

DARVON-N

XANODYNE PHARM	100MG	N016862	002	

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

INWOOD LABS	60MG	A072499	001	Apr 11, 1989
	80MG	A072500	001	Apr 11, 1989
	120MG	A072501	001	Apr 11, 1989
	160MG	A072502	001	Apr 11, 1989

CONCENTRATE; ORAL

PROPRANOLOL HYDROCHLORIDE INTENSOL

ROXANE	80MG/ML	A071388	001	May 15, 1987

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

SMITH AND NEPHEW	1MG/ML	A070135	001	Apr 15, 1986
	1MG/ML	A070137	001	Apr 15, 1986
SOLOPAK	1MG/ML	A070136	001	Apr 15, 1986

SOLUTION; ORAL

PROPRANOLOL HYDROCHLORIDE

MORTON GROVE	20MG/5ML	A071984	001	Mar 03, 1989
	40MG/5ML	A071985	001	Mar 03, 1989

SUSPENSION; ORAL

INDERAL

WYETH AYERST	10MG/ML	N019536	001	Dec 12, 1986

TABLET; ORAL

INDERAL

AKRIMAX PHARMS	10MG	N016418	001	
	20MG	N016418	003	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 299 (of 360)

PROPRANOLOL HYDROCHLORIDETABLET; ORAL
INDERAL

AKRIMAX PHARMS	90MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016418	010	Oct 18, 1982

PROPRANOLOL HYDROCHLORIDE

CLONMEL HLTHCARE	10MG	A070125	001	Jul 30, 1985
	20MG	A070126	001	Jul 30, 1985
	40MG	A070127	001	Jul 30, 1985
	60MG	A071495	001	Dec 31, 1987
	80MG	A070128	001	Jul 30, 1985
DURAMED PHARMS BARR	90MG	A071496	001	Dec 31, 1987
	10MG	A070306	001	Sep 09, 1985
	20MG	A070307	001	Sep 09, 1985
	40MG	A070308	001	Sep 09, 1985
	60MG	A070309	001	Oct 01, 1986
INTERPHARM	80MG	A070310	001	Sep 09, 1985
	90MG	A071327	001	Oct 01, 1986
	10MG	A071368	001	May 05, 1987
	20MG	A071369	001	May 05, 1987
	40MG	A071370	001	May 05, 1987
IVAX SUB TEVA PHARMS	80MG	A071371	001	May 05, 1987
	10MG	A072063	001	Jul 29, 1988
	20MG	A072066	001	Jul 29, 1988
	40MG	A072067	001	Jul 29, 1988
	60MG	A072068	001	Jul 29, 1988
LEDERLE	80MG	A072069	001	Jul 29, 1988
	10MG	A072117	001	Jun 23, 1988
	20MG	A072118	001	Jun 23, 1988
	40MG	A072119	001	Jun 23, 1988
	80MG	A072120	001	Jun 23, 1988
MUTUAL PHARM	10MG	A070319	001	Oct 22, 1985
	20MG	A070320	001	Oct 22, 1985
	40MG	A070103	001	Oct 22, 1985
	60MG	A070321	001	Sep 24, 1986
	80MG	A070322	001	Aug 04, 1986
MYLAN	60MG	A072275	001	Jun 09, 1989
PAR PHARM	90MG	A071288	001	Oct 22, 1986
PLIVA	90MG	A071977	001	Apr 06, 1988
PUREPAC PHARM	10MG	A070814	001	Nov 03, 1986
	20MG	A070815	001	Nov 03, 1986
	40MG	A070816	001	Nov 03, 1986
	60MG	A070817	001	Nov 03, 1986
	80MG	A070757	001	Nov 03, 1986
ROXANE	10MG	A070516	001	Jul 07, 1986
	20MG	A070517	001	Jul 07, 1986
	40MG	A070518	001	Jul 07, 1986
	60MG	A070519	001	Sep 24, 1986
	80MG	A070520	001	Jul 07, 1986
SANDOZ	90MG	A070521	001	Sep 24, 1986
	10MG	A070663	001	Jun 13, 1986
	10MG	A071658	001	Jul 05, 1988
	20MG	A070664	001	Jun 13, 1986
	20MG	A071687	001	Jul 05, 1988
SCHERING	40MG	A070665	001	Jun 13, 1986
	40MG	A071688	001	Jul 05, 1988
	60MG	A070666	001	Oct 10, 1986
	60MG	A072197	001	Jul 05, 1988
	80MG	A070667	001	Jun 13, 1986
	80MG	A071689	001	Jul 05, 1988
	90MG	A072198	001	Jul 05, 1988
	10MG	A070120	001	Aug 06, 1985

DISCONTINUED DRUG PRODUCT LIST

6 - 300 (of 360)

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

SCHERING	20MG	A070121	001	Aug 06, 1985
	40MG	A070122	001	Aug 06, 1985
	60MG	A070123	001	Oct 29, 1986
	80MG	A070124	001	Aug 06, 1985
SUPERPHARM	10MG	A071515	001	Jun 08, 1988
	20MG	A071516	001	Jun 08, 1988
	40MG	A071517	001	Jun 08, 1988
	80MG	A071518	001	Jun 08, 1988
TEVA	10MG	A070232	001	Oct 07, 1987
	20MG	A070233	001	Jun 23, 1986
	40MG	A070234	001	Jun 23, 1986
WARNER CHILCOTT	10MG	A070438	001	Sep 15, 1986
	20MG	A070439	001	Sep 15, 1986
	40MG	A070440	001	Sep 15, 1986
	60MG	A070441	001	Sep 24, 1986
	80MG	A070442	001	Sep 15, 1986
WATSON LABS	10MG	A070140	001	Jul 30, 1985
	10MG	A070378	001	Mar 19, 1987
	10MG	A070548	001	Jul 10, 1986
	20MG	A070141	001	Jul 30, 1985
	20MG	A070379	001	Mar 19, 1987
	20MG	A070549	001	Apr 11, 1986
	40MG	A070142	001	Jul 30, 1985
	40MG	A070380	001	Mar 19, 1987
	40MG	A070550	001	Apr 11, 1986
	60MG	A070143	001	Jan 15, 1987
	60MG	A070381	001	Mar 19, 1987
	60MG	A071098	001	Oct 06, 1986
	60MG	A071791	001	Jul 15, 1987
	80MG	A070144	001	Jul 30, 1985
	80MG	A070382	001	Mar 19, 1987
	80MG	A070551	001	Jul 10, 1986
	90MG	A071183	001	Oct 06, 1986
	90MG	A071792	001	Jul 15, 1987

PROPYLIODONE

SUSPENSION; INTRATRACHEAL

DIONOSIL AQUEOUS

GLAXOSMITHKLINE	50%	N009309	001

DIONOSIL OILY

GLAXOSMITHKLINE	60%	N009309	002

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

ABBOTT	50MG	A084075	001
ANABOLIC	50MG	A080285	001
HALSEY	50MG	A080015	001
IMPAX LABS	50MG	A080159	001
IVAX SUB TEVA PHARMS	50MG	A080215	001
LANNETT	50MG	A080016	001
LILLY	50MG	N006213	001
MUTUAL PHARM	50MG	A083982	001
PERRIGO	50MG	A084543	001
TABLICAPS	50MG	A080840	001
WATSON LABS	50MG	A080932	001
	50MG	A085201	001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 301 (of 360)

PROTAMINE SULFATEINJECTABLE; INJECTION
PROTAMINE SULFATE

HIKMA MAPLE	10MG/ML	A089474	001	Nov 05, 1986
	10MG/ML	A089475	001	Nov 05, 1986
LILLY	10MG/ML	N006460	002	
PHARMACIA AND UPJOHN	50MG/VIAL	N007413	001	
	250MG/VIAL	N007413	002	Aug 02, 1984

PROTEIN HYDROLYSATEINJECTABLE; INJECTION
AMINOSOL 5%

ABBVIE	5%	N005932	012	Jan 31, 1985
HYPROTIGEN 5%				
B BRAUN	5%	N006170	003	Jan 10, 1984

PROTIRELININJECTABLE; INJECTION
THYPINONE

ABBOTT	0.5MG/ML	N017638	001	
THYREL TRH				
FERRING	0.5MG/ML	N018087	001	

PROTOKYLOL HYDROCHLORIDETABLET; ORAL
VENTAIRE

SANOFI AVENTIS US	2MG	A083459	001	

PROTRIPTYLINE HYDROCHLORIDETABLET; ORAL
VIVACTIL

TEVA WOMENS R AND D	5MG	N016012	001	
	10MG	N016012	002	

PSEUDOEPHEDRINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
NOVAFED

SANOFI AVENTIS US	120MG	N017603	001	

SUDAFED 12 HOUR

GLAXOSMITHKLINE	120MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017941	002	

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
ACTIFED

GLAXOSMITHKLINE	120MG;5MG	N018996	001	Jun 17, 1985

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM	120MG;5MG	A071798	001	Mar 16, 1989

SYRUP; ORAL

ACTAHIST

CENCI	30MG/5ML;1.25MG/5ML	A088344	001	Feb 09, 1984

HISTAFED

CENCI	30MG/5ML;1.25MG/5ML	A088283	001	Apr 20, 1984

MYFED

USL PHARMA	30MG/5ML;1.25MG/5ML	A088116	001	Mar 04, 1983

TRILITRON

NEWTRON PHARMS	30MG/5ML;1.25MG/5ML	A088474	001	Feb 12, 1985

TABLET; ORAL

ALLERFED

PVT FORM	60MG;2.5MG	A088860	001	Jan 31, 1985

CORPHED

SANDOZ	60MG;2.5MG	A088602	001	Apr 11, 1985

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 302 (of 360)

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE

SANDOZ 60MG;2.5MG

A088193 001 May 17, 1983

TRILITRON

NEWTRON PHARMS 60MG;2.5MG

A088515 001 Jan 09, 1985

TRIPHED

TEVA 60MG;2.5MG

A088630 001 May 17, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE

WATSON LABS 60MG;2.5MG

A088318 002 Jan 13, 1984

WEST WARD 60MG;2.5MG

A088117 001 Apr 19, 1983

TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS 60MG;2.5MG

A085273 001 Dec 12, 1984

SUPERPHARM 60MG;2.5MG

A088578 001 Feb 21, 1985

TABLET, EXTENDED RELEASE; ORAL

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM 120MG;5MG

A072758 001 Nov 25, 1991

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

PSEUDO-12

UCB INC EQ 60MG HCL/5ML

N019401 001 Jun 19, 1987

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

PYRIDOSTIGMINE BROMIDE

BARR 30MG

A040512 002 Jul 20, 2005

60MG

A040512 001 Oct 08, 2003

SOLVAY 30MG

A089572 001 Nov 27, 1990

US ARMY 30MG

N020414 001 Feb 05, 2003

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

HEXA-BETALIN

LILLY 100MG/ML

A080854 001

PYRIDOXINE HYDROCHLORIDE

AKORN 100MG/ML

A087967 001 Oct 01, 1982

BEL MAR 100MG/ML

A080761 001

DELL LABS 50MG/ML

A083771 001

100MG/ML

A083772 001

ELKINS SINN 100MG/ML

A080581 001

LUITPOLD 100MG/ML

A080669 001

WATSON LABS 100MG/ML

A080572 001

100MG/ML

A083760 001

PYRILAMINE MALEATE

TABLET; ORAL

PYRILAMINE MALEATE

IMPAX LABS 25MG

A080808 001

WATSON LABS 25MG

A085231 001

PYRIMETHAMINE; SULFADOXINE

TABLET; ORAL

FANSIDAR

ROCHE 25MG;500MG

N018557 001

PYRITHIONE ZINC

LOTION; TOPICAL

HEAD & SHOULDERS CONDITIONER

WARNER CHILCOTT 0.3%

N019412 002 Mar 10, 1986

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 303 (of 360)

PYRVINIUM PAMOATESUSPENSION; ORAL
POVAN

PARKE DAVIS

EQ 50MG BASE/5ML

N011964 001

TABLET; ORAL
POVAN

PARKE DAVIS

EQ 50MG BASE

N012485 002

QUAZEPAMTABLET; ORAL
DORAL

QUESTCOR PHARMS

7.5MG

N018708 003 Feb 26, 1987

QUETIAPINE FUMARATETABLET; ORAL
SEROQUEL

ASTRAZENECA

EQ 150MG BASE

N020639 004 Dec 20, 1998

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

ACTAVIS TOTOWA

EQ 5MG BASE

A076459 001 Dec 22, 2004

EQ 10MG BASE

A076459 002 Dec 22, 2004

EQ 20MG BASE

A076459 003 Dec 22, 2004

EQ 40MG BASE

A076459 004 Dec 22, 2004

SANDOZ

EQ 5MG BASE

A076803 001 Mar 02, 2005

EQ 10MG BASE

A076803 002 Mar 02, 2005

EQ 20MG BASE

A076803 003 Mar 02, 2005

EQ 40MG BASE

A076803 004 Mar 02, 2005

QUINESTROLTABLET; ORAL
ESTROVIS

PARKE DAVIS

0.1MG

N016768 002

0.2MG

N016768 003

QUINETHAZONETABLET; ORAL
HYDROMOX

LEDERLE

50MG

N013264 001

QUINETHAZONE; RESERPINETABLET; ORAL
HYDROMOX R

LEDERLE

50MG;0.125MG

N013927 001

QUINIDINE GLUCONATETABLET; ORAL
QUINACT

BAYER HLTHCARE

266MG

A085978 001

400MG

A086099 001

TABLET, EXTENDED RELEASE; ORAL
DURAQUIN

WARNER CHILCOTT

330MG

N017917 001

QUINAGLUTE

BAYER HLTHCARE

324MG

N016647 001

QUINALAN

LANNETT

324MG

A088081 001 Feb 10, 1986

QUINATIME

WATSON LABS

324MG

A087448 001

QUINIDINE GLUCONATE

ASCOT

324MG

A088582 001 Jun 17, 1985

HALSEY

324MG

A089476 001 Apr 10, 1987

DISCONTINUED DRUG PRODUCT LIST

6 - 304 (of 360)

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL
QUINIDINE GLUCONATE

ROXANE	324MG	A088431	001	Jan 06, 1984
SANDOZ	324MG	A089894	001	Dec 15, 1988
SUPERPHARM	324MG	A089164	001	Nov 21, 1985
WATSON LABS	324MG	A087785	001	Jan 24, 1983

QUINIDINE POLYGALACTURONATE

TABLET; ORAL
CARDIOQUIN

PHARM RES ASSOC	275MG	N011642	002	

QUINIDINE SULFATE

CAPSULE; ORAL
CIN-QUIN

SOLVAY	200MG	A085296	001	
	300MG	A085297	001	

QUINIDINE SULFATE

LILLY	200MG	A085103	001	

TABLET; ORAL

CIN-QUIN

SOLVAY	100MG	A085299	001	
	200MG	A084932	001	
	300MG	A085298	001	

QUINIDINE SULFATE

BARR	200MG	A084177	001	
CLONMEL HLTHCARE	200MG	A087011	001	
CONTRACT PHARMACAL	200MG	A083808	001	
ELKINS SINN	200MG	A083622	001	
EVERYLIFE	200MG	A083439	001	
HALSEY	200MG	A083583	001	
IMPAX LABS	200MG	A083347	001	
IVAX SUB TEVA PHARMS	200MG	A084549	001	
KING PHARMS	200MG	A085175	001	
KV PHARM	200MG	A085276	001	
LANNETT	200MG	A083743	001	
LEDERLE	200MG	A086176	001	
LILLY	200MG	A085038	001	
MUTUAL PHARM	100MG	A081029	001	Apr 14, 1989
PERRIGO	200MG	A085322	001	
PHARMAVITE	200MG	A084627	001	
PUREPAC PHARM	200MG	A084003	001	
ROXANE	200MG	A083640	001	

	300MG	A085632	001	
SANDOZ	200MG	A084631	001	
	200MG	A084914	001	
	300MG	A089839	001	Sep 29, 1988

SCHERER LABS	200MG	A085068	001	
SUPERPHARM	200MG	A088973	001	Apr 10, 1985
USL PHARMA	200MG	A087837	001	Apr 14, 1982
VALEANT PHARM INTL	200MG	A083393	001	
VANGARD	200MG	A087909	001	Jul 13, 1982
VINTAGE PHARMS	200MG	A083963	001	
WARNER CHILCOTT	200MG	A083879	001	
WATSON LABS	100MG	A085584	001	
	200MG	A085140	002	
WEST WARD	200MG	A083862	001	
WHITEWORTH TOWN PLSN	200MG	A085444	001	

QUINORA

KEY PHARMS	200MG	A083576	001	
SCHERING	300MG	A085222	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 305 (of 360)

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
QUINIDEX

WYETH PHARMS INC 300MG N012796 002

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL
ACIPHEX

EISAI INC 10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons** N020973 001 May 29, 2002

RAMIPRIL

CAPSULE; ORAL
RAMIPRIL

ACTAVIS ELIZABETH 1.25MG A077513 001 Jun 18, 2008
2.5MG A077513 002 Jun 18, 2008
5MG A077513 003 Jun 18, 2008
10MG A077513 004 Jun 18, 2008
RANBAXY LABS LTD 5MG A078849 001 Mar 06, 2009
10MG A078849 002 Mar 06, 2009

TABLET; ORAL
ALTACE

KING PFIZER 1.25MG N022021 001 Feb 27, 2007
2.5MG N022021 002 Feb 27, 2007
5MG N022021 003 Feb 27, 2007
10MG N022021 004 Feb 27, 2007

RANITIDINE BISMUTH CITRATE

TABLET; ORAL
TRITEC

GLAXOSMITHKLINE 400MG N020559 001 Aug 08, 1996

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

MYLAN EQ 150MG BASE A075564 001 Oct 27, 2000
EQ 300MG BASE A075564 002 Oct 27, 2000
TEVA EQ 150MG BASE A075557 001 Oct 31, 2003
EQ 300MG BASE A075557 002 Oct 31, 2003

ZANTAC 150

GLAXOSMITHKLINE EQ 150MG BASE N020095 001 Mar 08, 1994

ZANTAC 300

GLAXOSMITHKLINE EQ 300MG BASE N020095 002 Mar 08, 1994

GRANULE, EFFERVESCENT; ORAL

ZANTAC 150

GLAXOSMITHKLINE EQ 150MG BASE/PACKET N020251 002 Mar 31, 1994

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

BEDFORD EQ 25MG BASE/ML A074764 001 Nov 19, 2004

ZANTAC IN PLASTIC CONTAINER

COVIS PHARMA EQ 50MG BASE/100ML N019593 001 Dec 17, 1986

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

RANBAXY EQ 15MG BASE/ML A078448 001 Dec 13, 2007

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

BOEHRINGER INGELHEIM EQ 150MG BASE A074662 001 Aug 29, 1997

EQ 300MG BASE A074662 002 Aug 29, 1997

MYLAN EQ 150MG BASE A074552 001 Jul 30, 1998

EQ 300MG BASE A074552 002 Jul 30, 1998

RANBAXY EQ 75MG BASE A075132 001 Jan 14, 2000

EQ 75MG BASE A075254 001 Jan 14, 2000

DISCONTINUED DRUG PRODUCT LIST

6 - 306 (of 360)

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

RANBAXY	EQ 150MG BASE	A075000	001	Jan 30, 1998
	EQ 150MG BASE	A075439	001	Apr 19, 2000
	EQ 300MG BASE	A075000	002	Jan 30, 1998
	EQ 300MG BASE	A075439	002	Apr 19, 2000
SANDOZ	EQ 75MG BASE	A075519	001	Sep 26, 2002

TABLET, EFFERVESCENT; ORAL

ZANTAC 150

GLAXOSMITHKLINE	EQ 150MG BASE	N020251	001	Mar 31, 1994

ZANTAC 75

BOEHRINGER INGELHEIM	EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020745	001	Feb 26, 1998

RAPACURONIUM BROMIDE

INJECTABLE; INJECTION

RAPLON

ORGANON USA INC	100MG/VIAL	N020984	001	Aug 18, 1999
	200MG/VIAL	N020984	002	Aug 18, 1999

RAUWOLFIA SERPENTINA ROOT

TABLET; ORAL

HIWOLFIA

BOWMAN PHARMS	50MG	N009276	003
	50MG	N009276	005
	100MG	N009276	004

HYSERPIN

PHYS PRODS VA	50MG	N010581	001

KOGLUCOID

PANRAY	50MG	N009278	001
	100MG	N009278	002

RAUDIXIN

APOTHECON	50MG	N008842	001
	100MG	N008842	002

RAUSERPIN

FERNDAL LABS	50MG	N009926	002
	100MG	N009926	004

RAUVAL

PAL PAK	50MG	N009108	002
	100MG	N009108	004

RAUWOLFIA SERPENTINA

BUNDY	50MG	N009477	001
	100MG	N009477	002

HALSEY	50MG	A080498	001
	100MG	A080498	002

IMPAX LABS	50MG	N009273	001
	100MG	N009273	002

IVAX SUB TEVA PHARMS	50MG	N011521	001
	100MG	N011521	002

PUREPAC PHARM	50MG	A080842	001
	100MG	A080842	002

PVT FORM	50MG	A080583	001
	100MG	A080583	002

SOLVAY	50MG	A080500	001
	100MG	A080500	002

TABLICAPS	50MG	A083867	001
	100MG	A083444	001

VALEANT PHARM INTL	50MG	N009668	001
	100MG	N009668	002

WATSON LABS	50MG	A080907	001
	100MG	A080914	001

DISCONTINUED DRUG PRODUCT LIST

6 - 307 (of 360)

RAUWOLFIA SERPENTINA ROOT

TABLET; ORAL
WOLFINA

FOREST PHARMS	50MG	N009255	008
	100MG	N009255	006

RESCINNAMINE

CAPSULE; ORAL
CINNASIL

PANRAY	0.5MG	A084736	001

TABLET; ORAL
MODERIL

PFIZER	0.25MG	N010686	003
	0.5MG	N010686	006

RESERPINE

ELIXIR; ORAL
SERPASIL

NOVARTIS	0.2MG/4ML	N009115	005

INJECTABLE; INJECTION
SANDRIL

LILLY	2.5MG/ML	N010012	001

SERPASIL

NOVARTIS	2.5MG/ML	N009434	002

TABLET; ORAL
HISERPIA

BOWMAN PHARMS	0.1MG	N009631	002
	0.25MG	N009631	004

RAU-SED

BRISTOL MYERS SQUIBB	0.1MG	N009357	001
	0.25MG	N009357	004
	0.5MG	N009357	006
	1MG	N009357	008

RESERPINE

BARR	0.25MG	A080721	002

BELL PHARMA	0.1MG	A083058	001

	0.25MG	A083058	002

BUNDY	0.1MG	N009663	001

	0.25MG	N009663	003

ELKINS SINN	0.1MG	A083145	001

	0.25MG	A083145	002

EVERYLIFE	0.1MG	N010441	001

	0.25MG	N010441	002

	0.5MG	N010441	003

	1MG	N010441	004

HALSEY	0.1MG	A080457	002

	0.25MG	A080457	001

	1MG	A080457	003

IMPAX LABS	0.1MG	N009627	001

	0.25MG	N009627	002

IVAX SUB TEVA PHARMS	0.1MG	N011185	001

	0.25MG	N011185	002

MARSHALL PHARMA	0.1MG	A080492	001

	0.25MG	A080492	002

MK LABS	0.1MG	A080525	002

	0.25MG	A080525	001

MYLAN	1MG	A084974	001

PHARMAVITE	0.25MG	A084663	001

PUREPAC PHARM	0.1MG	A080753	002

	0.25MG	A080753	001

PVT FORM	0.1MG	A086117	001

	0.25MG	A080582	001

	0.25MG	A085775	001

	1MG	A080582	002

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 308 (of 360)

RESERPINETABLET; ORAL
RESERPINE

REXALL	0.25MG	A080637	001	
ROXANE	0.1MG	N009859	001	
	0.25MG	N009859	002	
SOLVAY	0.25MG	A080446	001	
TABLICAPS	0.25MG	A085207	001	
TEVA	0.1MG	A089020	001	Mar 07, 1985
	0.25MG	A089019	001	Mar 07, 1985
VALEANT PHARM INTL	0.1MG	N009667	001	
	0.25MG	N009667	002	
WATSON LABS	0.1MG	A080679	001	
	0.25MG	A080393	001	
	0.25MG	A085401	001	
	1MG	A080749	001	
WEST WARD	0.1MG	A080975	001	
	0.25MG	A080975	002	
	1MG	A080975	003	
WHITEWORTH TOWN PLSN	0.1MG	A080723	001	
	0.25MG	A080723	002	
	1MG	A080723	003	
SANDRIL				
LILLY	0.1MG	N009376	004	
	0.25MG	N009376	001	
SERPANRAY				
PANRAY	0.1MG	N009391	001	
	0.25MG	N009391	002	
	1MG	N009391	004	
SERPASIL				
NOVARTIS	0.1MG	N009115	001	
	0.25MG	N009115	003	
	1MG	N009115	004	
SERPATE				
VALE	0.1MG	N009453	001	
	0.25MG	N009453	002	
SERPIVITE				
VITARINE	0.25MG	N009645	002	

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL

METATENSIN #2				
SANOFI AVENTIS US	0.1MG;2MG	N012972	001	
METATENSIN #4				
SANOFI AVENTIS US	0.1MG;4MG	N012972	002	
NAQUIVAL				
SCHERING	0.1MG;4MG	N012265	003	
TRICHLORMETHIAZIDE W/ RESERPINE				
WATSON LABS	0.1MG;4MG	A085248	001	

RIBAVIRINTABLET; ORAL
COPEGUS

ROCHE	400MG	N021511	002	Jun 21, 2005

RIMANTADINE HYDROCHLORIDESYRUP; ORAL
FLUMADINE

FOREST LABS	50MG/5ML	N019650	001	Sep 17, 1993

TABLET; ORAL

RIMANTADINE HYDROCHLORIDE

ACTAVIS TOTOWA	100MG	A076375	001	Jan 14, 2003

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 309 (of 360)

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

WARNER CHILCOTT LLC

75MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020835 004

Apr 16, 2007

RISPERIDONE

TABLET; ORAL

RISPERDAL

JANSSEN PHARMS

5MG

N020272 005

Dec 29, 1993

RISPERIDONE

CADISTA PHARMS

0.25MG

A078828 001

Mar 23, 2009

0.5MG

A078828 002

Mar 23, 2009

1MG

A078828 003

Mar 23, 2009

2MG

A078828 004

Mar 23, 2009

3MG

A078828 005

Mar 23, 2009

4MG

A078828 006

Mar 23, 2009

RATIOPHARM

0.25MG

A077784 001

Jun 08, 2010

0.5MG

A077784 002

Jun 08, 2010

1MG

A077784 003

Jun 08, 2010

2MG

A077784 004

Jun 08, 2010

3MG

A077784 005

Jun 08, 2010

4MG

A077784 006

Jun 08, 2010

SYNTHON PHARMS

0.25MG

A078187 001

Oct 22, 2009

0.5MG

A078187 002

Oct 22, 2009

1MG

A078187 003

Oct 22, 2009

2MG

A078187 004

Oct 22, 2009

3MG

A078187 005

Oct 22, 2009

4MG

A078187 006

Oct 22, 2009

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

RITODRINE HYDROCHLORIDE

ABRAXIS PHARM

10MG/ML

A071188 001

Jul 23, 1987

15MG/ML

A071189 001

Jul 23, 1987

HOSPIRA

10MG/ML

A071618 001

Feb 28, 1991

15MG/ML

A071619 001

Feb 28, 1991

RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA

30MG/100ML

A071438 001

Jan 22, 1991

YUTOPAR

ASTRAZENECA

10MG/ML

N018580 001

15MG/ML

N018580 002

TABLET; ORAL

YUTOPAR

ASTRAZENECA

10MG

N018555 001

RITONAVIR

CAPSULE; ORAL

NORVIR

ABBOTT

100MG

N020680 001

Mar 01, 1996

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ZEMURON

SCHERING

10MG/ML (10MG/ML)

N020214 002

Mar 17, 1994

ROFECOXIB

SUSPENSION; ORAL

VIOXX

MERCK

12.5MG/5ML

N021052 001

May 20, 1999

25MG/5ML

N021052 002

May 20, 1999

DISCONTINUED DRUG PRODUCT LIST

6 - 310 (of 360)

ROFECOXIB

TABLET; ORAL
VIOXX

MERCK	12.5MG	N021042	001	May 20, 1999
	25MG	N021042	002	May 20, 1999
	50MG	N021042	003	Feb 25, 2000

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
REQUIP XL

SMITHKLINE BEECHAM	EQ 3MG BASE	N022008	002	Jun 13, 2008

ROSE BENGAL SODIUM I-131

INJECTABLE; INJECTION
ROBENGATOPE

BRACCO	0.5mCi/VIAL	N016224	001	
	1mCi/VIAL	N016224	002	
	2mCi/VIAL	N016224	003	

SODIUM ROSE BENGAL I 131				
SORIN	0.5mCi/ML	N017318	001	

RUFINAMIDE

TABLET; ORAL
BANZEL

EISAI INC	100MG	N021911	001	Nov 14, 2008

SAFFLOWER OIL

INJECTABLE; INJECTION
LIPOSYN 10%

ABBOTT	10% (10GM/100ML)	N018203	001	

LIPOSYN 20%				
ABBOTT	20% (20GM/100ML)	N018614	001	

SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION
SEREVENT

GLAXOSMITHKLINE	EQ 0.021MG BASE/INH	N020236	001	Feb 04, 1994

SAQUINAVIR

CAPSULE; ORAL
FORTOVASE

HOFFMANN LA ROCHE	200MG	N020828	001	Nov 07, 1997

SARALASIN ACETATE

INJECTABLE; INJECTION
SARENIN

PROCTER AND GAMBLE	EQ 0.6MG BASE/ML	N018009	001	

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECOBARBITAL SODIUM

ANABOLIC	100MG	A084422	001	
BARR	100MG	A084225	001	
EVERYLIFE	100MG	A085895	001	
HALSEY	100MG	A084676	001	
IVAX PHARMS	100MG	A085869	001	
KV PHARM	100MG	A085285	001	
LANNETT	50MG	A085909	001	
	100MG	A085903	001	
PARKE DAVIS	100MG	A084762	001	
PERRIGO	100MG	A084561	001	
PUREPAC PHARM	100MG	A085867	001	
VALEANT PHARM INTL	100MG	A085477	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 311 (of 360)

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECOBARBITAL SODIUM

VITARINE

100MG

A085898 001

100MG

A086273 001

WATSON LABS

100MG

A085792 001

WEST WARD

100MG

A084926 001

WHITEWORTH TOWN PLSN

100MG

A085798 001

WYETH AYERST

100MG

A086390 001

INJECTABLE; INJECTION

SECOBARBITAL SODIUM

ELKINS SINN

100MG/VIAL

A083281 001

WYETH AYERST

50MG/ML

A083262 001

SECONAL SODIUM

LILLY

50MG/ML

N007392 002

SUPPOSITORY; RECTAL

SECONAL SODIUM

LILLY

30MG

A086530 001

60MG

A086530 002

120MG

A086530 003

200MG

A086530 004

SECRETIN

INJECTABLE; INJECTION

SECRETIN-FERRING

FERRING

75CU/VIAL

N018290 001

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION; INTRAVENOUS

SECREFO

CHIRHOCLIN

16MCG/VIAL

N021136 001 Apr 04, 2002

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

SELEGILINE HYDROCHLORIDE

AAIPHARMA LLC

5MG

A075145 001 Sep 15, 2003

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS

5MG

A074756 001 Nov 25, 1998

SIEGFRIED

5MG

A074672 001 Apr 01, 1997

SOMERSET

5MG

N019334 001 Jun 05, 1989

TEVA

5MG

A074537 001 Aug 02, 1996

5MG

A074744 001 Jan 27, 1997

VINTAGE PHARMS LLC

5MG

A074565 001 Aug 02, 1996

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

EXSEL

ALLERGAN HERBERT

2.5%

A083892 001

SELENIUM SULFIDE

ACTAVIS MID ATLANTIC

2.5%

A084394 001

IVAX PHARMS

2.5%

A085777 001

TARO

2.5%

A086209 001

SELENOMETHIONINE SE-75

INJECTABLE; INJECTION

SELENOMETHIONINE SE 75

GE HEALTHCARE

250uCi/ML

N017257 001

MALLINCKRODT

100uCi/ML

N017098 001

PHARMALUCENCE

500uCi/ML

N017322 001

SETHOTOPE

BRACCO

85-550uCi/ML

N017047 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 312 (of 360)

SERACTIDE ACETATEINJECTABLE; INJECTION
ACTHAR GEL-SYNTHETIC

ARMOUR PHARM

40 UNITS/ML

N017861 001

80 UNITS/ML

N017861 002

SERMORELIN ACETATEINJECTABLE; INJECTION
GEREF

EMD SERONO

EQ 0.05MG BASE/AMP

N019863 001 Dec 28, 1990

EQ 0.5MG BASE/VIAL

N020443 001 Sep 26, 1997

EQ 1MG BASE/VIAL

N020443 002 Sep 26, 1997

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

RANBAXY LABS LTD

EQ 20MG BASE/ML

A078053 001 Feb 05, 2007

ROXANE

EQ 20MG BASE/ML

A076934 001 Jun 30, 2006

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

ACTAVIS ELIZABETH

EQ 25MG BASE

A077345 001 Feb 06, 2007

EQ 50MG BASE

A077345 002 Feb 06, 2007

EQ 100MG BASE

A077345 003 Feb 06, 2007

IVAX SUB TEVA PHARMS

EQ 25MG BASE

A075719 003 Jun 30, 2006

EQ 50MG BASE

A075719 001 Jun 30, 2006

EQ 100MG BASE

A075719 002 Jun 30, 2006

MUTUAL PHARM

EQ 25MG BASE

A077818 001 Feb 06, 2007

EQ 50MG BASE

A077818 002 Feb 06, 2007

EQ 100MG BASE

A077818 003 Feb 06, 2007

MYLAN PHARMS INC

EQ 25MG BASE

A076540 001 Mar 20, 2007

EQ 50MG BASE

A076540 002 Mar 20, 2007

EQ 100MG BASE

A076540 003 Mar 20, 2007

PLIVA HRVATSKA DOO

EQ 25MG BASE

A077299 001 Feb 06, 2007

EQ 50MG BASE

A077299 002 Feb 06, 2007

EQ 100MG BASE

A077299 003 Feb 06, 2007

ROXANE

EQ 25MG BASE

A076881 001 Feb 06, 2007

EQ 50MG BASE

A076881 002 Feb 06, 2007

EQ 100MG BASE

A076881 003 Feb 06, 2007

SANDOZ

EQ 25MG BASE

A077713 001 Feb 06, 2007

EQ 50MG BASE

A077713 002 Feb 06, 2007

EQ 100MG BASE

A077713 003 Feb 06, 2007

WATSON LABS

EQ 25MG BASE

A077162 001 Feb 06, 2007

EQ 50MG BASE

A077162 002 Feb 06, 2007

EQ 100MG BASE

A077162 003 Feb 06, 2007

ZOLOFT

PFIZER

EQ 150MG BASE

N019839 003 Dec 30, 1991

EQ 200MG BASE

N019839 004 Dec 30, 1991

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL

RENAGEL

GENZYME

403MG

N020926 001 Oct 30, 1998

SIBUTRAMINE HYDROCHLORIDE

CAPSULE; ORAL

MERIDIA

ABBOTT

5MG

N020632 001 Nov 22, 1997

10MG

N020632 002 Nov 22, 1997

15MG

N020632 003 Nov 22, 1997

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 313 (of 360)

SILVER SULFADIAZINEDRESSING; TOPICAL
SILDAFLO

FRANKLIN PHARMS 1% N019608 001 Nov 30, 1989

SIMETHICONE-CELLULOSESUSPENSION; ORAL
SONORX

BRACCO 7.5MG/ML N020773 001 Oct 29, 1998

SIMVASTATINTABLET; ORAL
SIMVASTATIN

SANDOZ INC	5MG	A077766	001	Dec 20, 2006
	10MG	A077766	002	Dec 20, 2006
	20MG	A077766	003	Dec 20, 2006
	40MG	A077766	004	Dec 20, 2006
	80MG	A077766	005	Dec 20, 2006

TABLET, ORALLY DISINTEGRATING; ORAL
SIMVASTATIN

SYNTHON PHARMS	10MG	N021961	001	Oct 09, 2007
	20MG	N021961	002	Oct 09, 2007
	40MG	N021961	003	Oct 09, 2007
	80MG	N021961	004	Oct 09, 2007

SIROLIMUSTABLET; ORAL
RAPAMUNE

WYETH PHARMS INC	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021110	003	Feb 23, 2004

SODIUM BENZOATE; SODIUM PHENYLACETATESOLUTION; ORAL
UCEPHAN

B BRAUN 100MG/ML;100MG/ML N019530 001 Dec 23, 1987

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE IN PLASTIC CONTAINER

ABBOTT	0.9MEQ/ML	N019443	001	Jun 03, 1986
	1MEQ/ML	N019443	002	Jun 03, 1986

SODIUM BICARBONATE; TARTARIC ACIDGRANULE, EFFERVESCENT; ORAL
BAROS

MALLINCKRODT INC 460MG/GM;420MG/GM N018509 001 Aug 07, 1985

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABRAXIS PHARM 9MG/ML A088909 001 Feb 07, 1985

SODIUM CHLORIDE

ABBOTT	20GM/100ML	N017013	001	
B BRAUN	20GM/100ML	N017038	001	

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	450MG/100ML	N018184	001	
MILES	450MG/100ML	N018503	001	

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT	9MG/ML	N019218	001	Jul 13, 1984
MILES	900MG/100ML	N018502	001	

DISCONTINUED DRUG PRODUCT LIST

6 - 314 (of 360)

SODIUM CHLORIDE

INJECTABLE; INJECTION		
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER		
ABRAXIS PHARM	234MG/ML	N019329 001 Apr 22, 1987
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER		
B BRAUN	3GM/100ML	N019635 003 Mar 09, 1988
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER		
B BRAUN	5GM/100ML	N019635 004 Mar 09, 1988
SOLUTION; IRRIGATION		
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	450MG/100ML	N018497 001 Feb 19, 1982
HOSPIRA	450MG/100ML	N017670 001
	450MG/100ML	N018380 001
SODIUM CHLORIDE IN PLASTIC CONTAINER		
MILES	900MG/100ML	N018247 001

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION		
CHROMITOPES SODIUM		
BRACCO	2mCi/VIAL	N013993 002
	200uCi/ML	N013993 001
SODIUM CHROMATE CR 51		
MALLINCKRODT	100uCi/ML	N016708 001

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS		
FLUORINE F-18		
GE HEALTHCARE	2mCi/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017042 001
SODIUM FLUORIDE F 18		
NIH NCI DCTD	10-200mCi/ML	N022494 001 Jan 26, 2011

SODIUM IODIDE I-123

CAPSULE; ORAL		
SODIUM IODIDE I 123		
GE HEALTHCARE	100uCi	N017630 001
SOLUTION; ORAL		
SODIUM IODIDE I 123		
GE HEALTHCARE	2mCi/ML	N017630 002

SODIUM IODIDE I-131

CAPSULE; ORAL		
IODOTOPE		
BRACCO	1-130mCi	N010929 001
	1-150mCi	N010929 003
SODIUM IODIDE I 131		
CIS	50uCi	N017316 001
	100uCi	N017316 002
MALLINCKRODT	0.8-100mCi	N016515 002
	15-100uCi	N016517 002
SODIUM IODIDE I-131		
JUBILANT DRAXIMAGE	2-200mCi	N021305 004 Nov 18, 2004
SOLUTION; ORAL		
HICON		
JUBILANT DRAXIMAGE	1-250mCi/0.25ML	N021305 002 Jan 24, 2003
	1-500mCi/0.5ML	N021305 003 Jan 24, 2003
	1-1000mCi/ML	N021305 005 Apr 04, 2006
IODOTOPE		
BRACCO	7-106mCi/BOT	N010929 002
SODIUM IODIDE I 131		
CIS	50mCi/ML	N017315 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 315 (of 360)

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

B BRAUN 1.87GM/100ML

N018186 001

HOSPIRA 1.87GM/100ML

N018249 001

SODIUM MONOFLUOROPHOSPHATE

GEL; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH POND'S 1.2%

N019518 002 Aug 06, 1986

PASTE; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH POND'S 1.2%

N019518 001 Jun 03, 1987

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NIPRIDE

ROCHE 50MG/VIAL

N017546 001

NITROPRESS

ABBOTT 50MG/VIAL

A071555 001 Nov 16, 1987

ABBVIE 50MG/VIAL

N018450 001

HOSPIRA 50MG/VIAL

A070566 001 Jun 09, 1986

SODIUM NITROPRUSSIDE

ABRAXIS PHARM 50MG/VIAL

A070031 001 Jan 17, 1985

BAXTER HLTHCARE 50MG/VIAL

N018581 001 Jul 28, 1982

TEVA PARENTERAL 25MG/ML

A073465 001 Mar 30, 1992

SODIUM PHOSPHATE P-32

SOLUTION; INJECTION, ORAL

PHOSPHOTOPE

BRACCO 1-8mCi/VIAL

N010927 001

SODIUM PHOSPHATE P 32

MALLINCKRODT 0.67mCi/ML

N011777 001

1.5mCi/VIAL

N011777 002

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

CITRUSPHARMA 454GM/BOT

A040909 001 Dec 03, 2008

WOCKHARDT 453.6GM/BOT

A088786 001 Sep 11, 1984

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

MORTON GROVE 15GM/60ML

A088717 001 Sep 11, 1984

ROXANE 15GM/60ML

A088453 001 Nov 17, 1983

SODIUM SUCCINATE

INJECTABLE; INJECTION

SODIUM SUCCINATE

ELKINS SINN 30%

A080516 001

SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

SOTRADECOL

ELKINS SINN 1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N005970 004

3% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N005970 005

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 316 (of 360)

SODIUM THIOSULFATE

INJECTABLE; INJECTION
SODIUM THIOSULFATE
US ARMY

250MG/ML

N020166 001 Feb 14, 1992

SOMATREM

INJECTABLE; INJECTION
PROTROPIN
GENENTECH

5MG/VIAL
10MG/VIAL

N019107 001 Oct 17, 1985
N019107 002 Oct 24, 1989

SOMATROPIN

INJECTABLE; INJECTION
ASELLACRIN 10
SERONO
ASELLACRIN 2
SERONO
CRESCORMON
GENENTECH

10 IU/VIAL

2 IU/VIAL

4 IU/VIAL

N017726 001

N017726 002 Jul 21, 1983

N017992 001

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
ACCRETROPIN
CANGENE
BIO-TROPIN
FERRING
HUMATROPE
LILLY
NORDITROPIN
NOVO NORDISK INC

5MG/ML (5MG/ML)

4.8MG/VIAL

2MG/VIAL

4MG/VIAL
5MG/1.5ML
8MG/VIAL
10MG/1.5ML
15MG/1.5ML

N021538 001 Jan 23, 2008

N019774 001 May 25, 1995

N019640 001 Jun 23, 1987

N019721 001 May 08, 1995
N021148 001 Jun 20, 2000
N019721 002 May 08, 1995
N021148 002 Jun 20, 2000
N021148 003 Jun 20, 2000

NORDITROPIN NORDIFLEX
NOVO NORDISK INC

5MG/1.5ML
10MG/1.5ML
15MG/1.5ML

N021148 004 Oct 01, 2004
N021148 005 Oct 01, 2004
N021148 006 Oct 01, 2004

NUTROPIN DEPOT
GENENTECH

13.5MG/VIAL
18MG/VIAL
22.5MG/VIAL

N021075 001 Dec 22, 1999
N021075 002 Dec 22, 1999
N021075 003 Dec 22, 1999

SAIZEN

EMD SERONO
6MG/VIAL

N019764 005 Jan 16, 2007
N019764 001 Oct 08, 1996

SEROSTIM

EMD SERONO

8.8MG/VIAL

N020604 004 Sep 06, 2001

ZORBTIVE

EMD SERONO

4MG/VIAL
5MG/VIAL
6MG/VIAL

N021597 001 Dec 01, 2003
N021597 002 Dec 01, 2003
N021597 003 Dec 01, 2003

INJECTABLE; SUBCUTANEOUS
SEROSTIM LQ

EMD SERONO

6MG/0.5ML (6MG/0.5ML)

N020604 005 Feb 11, 2005

SORBITOL

SOLUTION; IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER
BAXTER HLTHCARE

3GM/100ML

N018512 001 May 27, 1982

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 317 (of 360)

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE

BAYER HLTHCARE

320MG

N019865

004

Oct 30, 1992

BETAPACE AF

BAYER HLTHCARE

40MG

N021151

006

Apr 02, 2003

60MG

N021151

007

Apr 02, 2003

100MG

N021151

005

Mar 14, 2003

SOTALOL HYDROCHLORIDE

MUTUAL PHARM

80MG

A075515

001

Oct 15, 2001

80MG

A076576

001

Apr 08, 2004

120MG

A075515

004

Oct 15, 2001

120MG

A076576

002

Apr 08, 2004

160MG

A075515

002

Oct 15, 2001

160MG

A076576

003

Apr 08, 2004

240MG

A075515

003

Oct 15, 2001

WATSON LABS

80MG

A075238

001

Jul 13, 2000

120MG

A075238

002

Jul 13, 2000

160MG

A075238

003

Jul 13, 2000

240MG

A075238

004

Jul 13, 2000

SOYBEAN OIL

INJECTABLE; INJECTION

SOYACAL 10%

ALPHA THERA

10%

N018465

001

Jun 29, 1983

SOYACAL 20%

ALPHA THERA

20%

N018786

001

Jun 29, 1983

TRAVAMULSION 10%

BAXTER HLTHCARE

10%

N018660

001

Feb 26, 1982

TRAVAMULSION 20%

BAXTER HLTHCARE

20%

N018758

001

Feb 15, 1983

SPARFLOXACIN

TABLET; ORAL

ZAGAM

MYLAN

200MG

N020677

001

Dec 19, 1996

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

PFIZER

EQ 2GM BASE/VIAL

N050347

001

EQ 4GM BASE/VIAL

N050347

002

SPIRAPRIL HYDROCHLORIDE

TABLET; ORAL

RENORMAX

SCHERING

3MG

N020240

001

Dec 29, 1994

6MG

N020240

002

Dec 29, 1994

12MG

N020240

003

Dec 29, 1994

24MG

N020240

004

Dec 29, 1994

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

ASCOT

25MG

A087687

001

Oct 20, 1982

IVAX PHARMS

25MG

A087108

001

LEDERLE

25MG

A087634

001

MUTUAL PHARM

25MG

A087265

001

MYLAN

25MG

A087086

001

PUREPAC PHARM

25MG

A087998

001

Oct 14, 1983

25MG

A088053

001

Aug 25, 1983

SUPERPHARM

25MG

A089364

001

Nov 07, 1986

UPSHER SMITH

25MG

A087554

001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 318 (of 360)

SPIRONOLACTONETABLET; ORAL
SPIRONOLACTONE

VANGARD	25MG	A087648	001	Feb 01, 1982
WARNER CHILCOTT	25MG	A087952	001	Nov 18, 1982
WATSON LABS	25MG	A086898	002	Mar 02, 1982
	25MG	A087078	001	

STANOZOLOLTABLET; ORAL
WINSTROL

LUNDBECK INC	2MG	N012885	001	May 14, 1984

STAVUDINECAPSULE; ORAL
ZERIT

BRISTOL MYERS SQUIBB	5MG	N020412	001	Jun 24, 1994
CAPSULE, EXTENDED RELEASE; ORAL ZERIT XR				
BRISTOL MYERS SQUIBB	37.5MG	N021453	001	Dec 31, 2002
	50MG	N021453	002	Dec 31, 2002
	75MG	N021453	003	Dec 31, 2002
	100MG	N021453	004	Dec 31, 2002

STERILE WATER FOR INJECTION

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

ABRAXIS PHARM	100%	A089099	001	Dec 29, 1987
	100%	A089100	001	Dec 29, 1987

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

B BRAUN	100%	N019077	001	Mar 02, 1984

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

MILES	100%	N018246	001	

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

COPANOS	EQ 500MG BASE/ML	A060684	001	
LILLY	EQ 1GM BASE/VIAL	A060107	001	
	EQ 1GM BASE/2ML	A060404	001	
	EQ 5GM BASE/VIAL	A060107	002	
PFIZER	EQ 1GM BASE/VIAL	A060076	001	
	EQ 1GM BASE/2.5ML	A060111	001	
	EQ 5GM BASE/VIAL	A060076	002	

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

SANDOZ	50MG/ML	N008453	003	
	500MG/VIAL	N008453	001	
	1GM/VIAL	N008453	004	

QUELICIN PRESERVATIVE FREE

HOSPIRA	50MG/ML	N008845	002	

SUCCINYLCHOLINE CHLORIDE

INTL MEDICATION	100MG/VIAL	A085400	001	Feb 04, 1982
ORGANON USA INC	20MG/ML	A080997	001	

SUCOSTRIN

APOTHECON	20MG/ML	N008847	001	
	100MG/ML	N008847	003	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 319 (of 360)

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

WATSON LABS

EQ 0.05MG BASE/ML

A074406 001

Dec 15, 1995

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPH-10

ALLERGAN

10%

A084015 001

SODIUM SULAMYD

SCHERING

10%

N005963 002

SULFAIR 10

PHARMAFAIR

10%

A088000 001

Dec 22, 1982

SOLUTION/DROPS; OPHTHALMIC

BLEPH-30

ALLERGAN

30%

A080028 002

ISOPTO CETAMIDE

ALCON

15%

A080020 002

OCUSULF-10

MIZA PHARMS USA

10%

A080660 001

OCUSULF-30

MIZA PHARMS USA

30%

A080660 002

SODIUM SULAMYD

SCHERING

10%

N005963 001

30%

N005963 003

SODIUM SULFACETAMIDE

AKORN

10%

A083021 001

15%

A083021 002

30%

A083021 003

SOLA BARNES HIND

10%

A084143 001

10%

A084145 001

30%

A084146 001

30%

A084147 001

SULF-10

NOVARTIS

10%

A080025 001

SULF-15

NOVARTIS

15%

A089047 001

Oct 31, 1995

SULFACEL-15

OPTOPICS

15%

A080024 001

SULFACETAMIDE SODIUM

AKORN

10%

A040215 001

May 25, 1999

30%

A040216 001

May 25, 1999

ALCON PHARMS LTD

30%

A089068 001

May 05, 1987

PHARMAFAIR

10%

A088947 001

May 17, 1985

SULFAIR 10

PHARMAFAIR

10%

A087949 001

Dec 13, 1982

SULFAIR FORTE

PHARMAFAIR

30%

A088385 001

Oct 13, 1983

SULFAIR-15

PHARMAFAIR

15%

A088186 001

May 25, 1983

SULTEN-10

BAUSCH AND LOMB

10%

A087818 001

Feb 03, 1983

SULFACYTINE

TABLET; ORAL

RENOQUID

GLENWOOD

250MG

N017569 001

SULFADIAZINE

TABLET; ORAL

SULFADIAZINE

ABBVIE

300MG

N004125 005

EVERYLIFE

500MG

A080088 001

DISCONTINUED DRUG PRODUCT LIST

6 - 320 (of 360)

SULFADIAZINE

TABLET; ORAL
SULFADIAZINE

IMPAX LABS	500MG	A080081	001	
LANNETT	500MG	A080084	001	
LEDERLE	500MG	N004054	001	
LILLY	500MG	N004122	002	

SULFADIAZINE SODIUM

INJECTABLE; INJECTION
SULFADIAZINE SODIUM

LEDERLE	250MG/ML	N004054	002	

SULFADIAZINE; SULFAMERAZINE

SUSPENSION; ORAL
SULFONAMIDES DUPLEX

LILLY	250MG/5ML; 250MG/5ML	N006317	007	

SULFAMETER

TABLET; ORAL
SULLA

BAYER HLTHCARE	500MG	N016000	002	

SULFAMETHIZOLE

TABLET; ORAL
MICROSUL

FOREST PHARMS	1GM	A086012	001	
PROKLAR				
FOREST PHARMS	500MG	A080273	001	
THIOSULFIL				
WYETH AYERST	250MG	N008565	001	
	500MG	N008565	004	

SULFAMETHOXAZOLE

SUSPENSION; ORAL
GANTANOL

ROCHE	500MG/5ML	N013664	002	

TABLET; ORAL
GANTANOL

ROCHE	500MG	N012715	002	

GANTANOL - DS

ROCHE	1GM	N012715	003	

SULFAMETHOXAZOLE

ASCOT	500MG	A087662	001	Oct 20, 1982
BARR	500MG	A087189	001	Jul 25, 1983
HEATHER	500MG	A086163	001	
SANDOZ	500MG	A085844	001	
WATSON LABS	500MG	A085053	001	
	1GM	A086000	001	

UROBAK

SHIONOGI	500MG	A087307	001	

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION
BACTRIM

MUTUAL PHARM	80MG/ML; 16MG/ML	N018374	001	

SEPTRA

MONARCH PHARMS	80MG/ML; 16MG/ML	N018452	001	

SULFAMETHOXAZOLE AND TRIMETHOPRIM

ABRAXIS PHARM	80MG/ML; 16MG/ML	A070223	001	Dec 29, 1987
BEDFORD	80MG/ML; 16MG/ML	A072383	001	Apr 29, 1992
HIKMA MAPLE	80MG/ML; 16MG/ML	A070627	001	Dec 29, 1987
	80MG/ML; 16MG/ML	A070628	001	Dec 29, 1987

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 321 (of 360)

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

HOSPIRA 80MG/ML;16MG/ML A073199 001 Sep 11, 1992

WATSON LABS 80MG/ML;16MG/ML A071556 001 Dec 29, 1987

SUSPENSION; ORAL

BACTRIM

MUTUAL PHARM 200MG/5ML;40MG/5ML N017560 001

BACTRIM PEDIATRIC

MUTUAL PHARM 200MG/5ML;40MG/5ML N017560 002

SEPTRA

MONARCH PHARMS 200MG/5ML;40MG/5ML N017598 001

SEPTRA GRAPE

MONARCH PHARMS 200MG/5ML;40MG/5ML N017598 002 Feb 12, 1986

SULFAMETHOXAZOLE AND TRIMETHOPRIM

TEVA 200MG/5ML;40MG/5ML A070028 001 Jun 02, 1987

200MG/5ML;40MG/5ML N018812 001 Jan 28, 1983

200MG/5ML;40MG/5ML N018812 002 Jun 10, 1983

TEVA PHARMS 200MG/5ML;40MG/5ML A077612 001 Nov 13, 2006

SULFATRIM

STI PHARMA LLC 200MG/5ML;40MG/5ML N018615 002 Jan 07, 1983

SULMEPRIM

USL PHARMA 200MG/5ML;40MG/5ML A070063 001 Aug 01, 1986

SULMEPRIM PEDIATRIC

USL PHARMA 200MG/5ML;40MG/5ML A070064 001 Aug 01, 1986

TRIMETH/SULFA

ALPHARMA US PHARMS 200MG/5ML;40MG/5ML A072289 001 May 23, 1988

200MG/5ML;40MG/5ML A072398 001 May 23, 1988

NASKA 200MG/5ML;40MG/5ML A072399 001 May 23, 1988

TABLET; ORAL

COTRIM

TEVA 400MG;80MG A070034 001 May 16, 1985

COTRIM D.S.

TEVA 800MG;160MG A070048 001 Mar 18, 1985

SULFAMETHOXAZOLE AND TRIMETHOPRIM

HEATHER 400MG;80MG N018946 001 Aug 10, 1984

800MG;160MG N018946 002 Aug 10, 1984

INTERPHARM 400MG;80MG A071299 001 Oct 27, 1987

800MG;160MG A071300 001 Oct 27, 1987

MARTEC USA LLC 400MG;80MG A072408 001 Dec 07, 1988

MUTUAL PHARM 400MG;80MG A070006 001 Nov 14, 1984

400MG;80MG A071016 001 Aug 25, 1986

PLIVA 400MG;80MG A070215 001 Sep 10, 1985

800MG;160MG A070216 001 Sep 10, 1985

ROXANE 400MG;80MG A072768 001 Aug 30, 1991

SANDOZ 400MG;80MG A070889 001 Nov 13, 1986

400MG;80MG N018598 003 May 19, 1982

800MG;160MG A070890 001 Nov 13, 1986

TEVA 400MG;80MG N018242 001

800MG;160MG N018242 002

USL PHARMA 400MG;80MG A070203 001 Nov 08, 1985

800MG;160MG A070204 001 Nov 08, 1985

WATSON LABS 400MG;80MG A070002 001 Nov 07, 1984

400MG;80MG N018852 001 May 09, 1983

800MG;160MG A070000 001 Nov 07, 1984

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

MARTEC USA LLC 800MG;160MG A072417 001 Dec 07, 1988

MUTUAL PHARM 800MG;160MG A070007 001 Nov 14, 1984

ROXANE 800MG;160MG A072769 001 Aug 30, 1991

WATSON LABS 800MG;160MG N018854 001 May 09, 1983

SULFATRIM-DS

SUPERPHARM 800MG;160MG A070066 001 Jun 24, 1985

SULFATRIM-SS

SUPERPHARM 400MG;80MG A070065 002 Jun 24, 1985

DISCONTINUED DRUG PRODUCT LIST

6 - 322 (of 360)

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL				
UROPLUS DS				
SHIONOGI	800MG;160MG	A071816	001	Sep 28, 1987
UROPLUS SS				
SHIONOGI	400MG;80MG	A071815	001	Sep 28, 1987

SULFANILAMIDE

CREAM; VAGINAL				
SULFANILAMIDE				
TEVA	15%	A088718	001	Sep 19, 1985
SUPPOSITORY; VAGINAL				
AVC				
MEDA PHARMS	1.05GM	N006530	004	Jan 27, 1987

SULFAPHENAZOLE

SUSPENSION; ORAL				
SULFABID				
PHARM RES ASSOC	500MG/5ML	N013093	001	
TABLET; ORAL				
SULFABID				
PURDUE FREDERICK	500MG	N013092	002	

SULFAPYRIDINE

TABLET; ORAL				
SULFAPYRIDINE				
LILLY	500MG	N000159	001	

SULFASALAZINE

SUSPENSION; ORAL				
AZULFIDINE				
PHARMACIA AND UPJOHN	250MG/5ML	N018605	001	
TABLET; ORAL				
S.A.S. -500				
SOLVAY	500MG	A083450	001	
SULFASALAZINE				
HERITAGE PHARMS INC	500MG	A080197	001	
MUTUAL PHARM	500MG	A089590	001	Oct 19, 1987
SANDOZ	500MG	A086184	001	
SUPERPHARM	500MG	A089339	001	Oct 26, 1987
WATSON LABS	500MG	A084964	001	
TABLET, DELAYED RELEASE; ORAL				
SULFASALAZINE				
WATSON LABS	500MG	A088052	001	May 24, 1983

SULFINPYRAZONE

CAPSULE; ORAL				
ANTURANE				
NOVARTIS	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011556	004	
SULFINPYRAZONE				
BARR	200MG	A087666	001	Sep 17, 1982
IVAX PHARMS	200MG	A087770	001	Nov 19, 1982
PAR PHARM	200MG	A088934	001	Sep 06, 1985
VANGARD	200MG	A088666	001	Feb 17, 1984
TABLET; ORAL				
ANTURANE				
NOVARTIS	100MG *Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011556	003	
SULFINPYRAZONE				
BARR	100MG	A087665	001	Sep 17, 1982

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 323 (of 360)

SULFINPYRAZONETABLET; ORAL
SULFINPYRAZONE

IVAX PHARMS	100MG	A087769	001	Jun 01, 1982
PAR PHARM	100MG	A088933	001	Sep 06, 1985
WATSON LABS	100MG	A087667	001	May 26, 1982

SULFISOXAZOLE

TABLET; ORAL

GANTRISIN

ROCHE	500MG	N006525	001	

SOSOL

MK LABS	500MG	A080036	001	

SOXAZOLE

ALRA	500MG	A080366	001	

SULFALAR

PARKE DAVIS	500MG	A084955	001	

SULFISOXAZOLE

BARR	500MG	A084031	001	

HEATHER	500MG	A080189	001	

IMPAX LABS	500MG	A080109	001	

IVAX SUB TEVA PHARMS	500MG	A080142	001	

LANNETT	500MG	A080085	001	

LEDERLE	500MG	A087649	001	

PHARMERAL	500MG	A084385	001	

PUREPAC PHARM	500MG	A080087	001	

ROXANE	500MG	A080082	001	

SANDOZ	500MG	A085628	001	

VALEANT PHARM INTL	500MG	A080268	002	

VITARINE	500MG	A087332	001	

WATSON LABS	500MG	A085534	001	

WEST WARD	500MG	A080379	001	

SULSOXIN

SOLVAY	500MG	A080040	001	

SULFISOXAZOLE ACETYL

EMULSION; ORAL

LIPO GANTRISIN

ROCHE	EQ 1GM BASE/5ML	N009182	009	

SUSPENSION; ORAL

GANTRISIN PEDIATRIC

ROCHE	EQ 500MG BASE/5ML	N009182	004	

SYRUP; ORAL

GANTRISIN

ROCHE	EQ 500MG BASE/5ML	N009182	002	

SULFISOXAZOLE DIOLAMINE

INJECTABLE; INJECTION

GANTRISIN

ROCHE	EQ 400MG BASE/ML	N006917	001	

OINTMENT; OPHTHALMIC

GANTRISIN

ROCHE	EQ 4% BASE	N008414	002	

SOLUTION/DROPS; OPHTHALMIC

GANTRISIN

ROCHE	EQ 4% BASE	N007757	002	

SULFISOXAZOLE DIOLAMINE

SOLA BARNES HIND	EQ 4% BASE	A084148	001	

SULFOXONE SODIUM

TABLET, DELAYED RELEASE; ORAL

DIASONE SODIUM

ABBVIE	165MG	N006044	003	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 324 (of 360)

SULFUR

POWDER; TOPICAL BENSULFOID POYTHRESS	33.32%	N002918	001	

SULINDAC

TABLET; ORAL CLINORIL MERCK	150MG	N017911	001	
SULINDAC HERITAGE PHARMS INC	150MG	A073262	002	Sep 06, 1991
	200MG	A073262	001	Sep 06, 1991
SANDOZ	150MG	A072712	001	Aug 30, 1991
	200MG	A072713	001	Aug 30, 1991
TEVA	150MG	A072972	001	Feb 28, 1992
	200MG	A072973	001	Feb 28, 1992

SUMATRIPTAN

SPRAY; NASAL IMITREX GLAXOSMITHKLINE	10MG/SPRAY	N020626	002	Aug 26, 1997

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS SUMATRIPTAN SUCCINATE TEVA PARENTERAL	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078318	001	Feb 06, 2009
		A078318	002	Feb 06, 2009
TABLET; ORAL SUMATRIPTAN SUCCINATE ROXANE	EQ 25MG BASE EQ 50MG BASE EQ 100MG BASE	A078241	001	Aug 10, 2009
		A078241	002	Aug 10, 2009
		A078241	003	Aug 10, 2009

SUPROFEN

SOLUTION/DROPS; OPHTHALMIC PROFENAL ALCON	1%	N019387	001	Dec 23, 1988

SUTILAINS

OINTMENT; TOPICAL TRAVASE ABBOTT	82,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012828	001	

TACRINE HYDROCHLORIDE

CAPSULE; ORAL COGNEX SHIONOGI INC	EQ 10MG BASE EQ 20MG BASE EQ 30MG BASE EQ 40MG BASE	N020070	001	Sep 09, 1993
		N020070	002	Sep 09, 1993
		N020070	003	Sep 09, 1993
		N020070	004	Sep 09, 1993

TALBUTAL

TABLET; ORAL LOTUSATE SANOFI AVENTIS US	120MG	N009410	005	

TAMOXIFEN CITRATE

TABLET; ORAL NOLVADEX ASTRAZENECA	EQ 10MG BASE	N017970	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 325 (of 360)

TAMOXIFEN CITRATETABLET; ORAL
NOLVADEX

ASTRAZENECA	EQ 20MG BASE	N017970	002	Mar 21, 1994
TAMOXIFEN CITRATE				
AEGIS PHARMS	EQ 10MG BASE	A076398	001	Mar 31, 2003
	EQ 20MG BASE	A076398	002	Mar 31, 2003
IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075740	001	Feb 20, 2003
	EQ 20MG BASE	A075740	002	Feb 20, 2003
PHARMACHEMIE	EQ 10MG BASE	A074539	001	Mar 31, 2003
ROXANE	EQ 10MG BASE	A076027	001	Feb 20, 2003
	EQ 20MG BASE	A076027	002	Feb 20, 2003
TEVA	EQ 10MG BASE	A074504	001	Apr 28, 2003
	EQ 20MG BASE	A074504	002	Apr 28, 2003

TECHNETIUM TC-99M ALBUMIN AGGREGATEDINJECTABLE; INJECTION
TC 99M-LUNGAGGREGATE

GE HEALTHCARE	5mCi/ML	N017848	001

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

A-N STANNOUS AGGREGATED ALBUMIN			
SYNCOR PHARMS	N/A	N017916	001
AN-MAA			
PHARMALUCENCE	N/A	N017792	001
LUNGAGGREGATE REAGENT			
GE HEALTHCARE	N/A	N017838	001
MACROTEC			
BRACCO	N/A	N017833	001
TECHNESCAN MAA			
MALLINCKRODT	N/A	N017842	001
TECHNETIUM TC 99M MAA			
GE HEALTHCARE	N/A	N017773	001

TECHNETIUM TC-99M ALBUMIN COLLOID KITINJECTABLE; INJECTION
MICROLITE

PHARMALUCENCE	N/A	N018263	001	Mar 25, 1983

TECHNETIUM TC-99M ALBUMIN KITINJECTABLE; INJECTION
TECHNETIUM TC 99M HSA

GE HEALTHCARE	N/A	N017775	001

TECHNETIUM TC-99M ALBUMIN MICROSPHERES KITINJECTABLE; INJECTION
INSTANT MICROSPHERES

3M	N/A	N017832	001

TECHNETIUM TC-99M APCITIDEINJECTABLE; INJECTION
ACUTECT

CIS BIO INTL SA	N/A	N020887	001	Sep 14, 1998

TECHNETIUM TC-99M DEPREOTIDEINJECTABLE; INJECTION
NEO TECT KIT

CIS BIO INTL SA	N/A	N021012	001	Aug 03, 1999

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 326 (of 360)

TECHNETIUM TC-99M ETIDRONATE KIT

INJECTABLE; INJECTION		
CINTICHEM TECHNETIUM 99M HEDSPA		
GE HEALTHCARE	N/A	N017653 001
MPI STANNOUS DIPHOSPHONATE		
GE HEALTHCARE	N/A	N017667 001
OSTEOSCAN		
MALLINCKRODT	N/A	N017454 001
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT		
GE HEALTHCARE	N/A	N017562 001

TECHNETIUM TC-99M FERPENTETATE KIT

INJECTABLE; INJECTION		
RENOTEC		
BRACCO	N/A	N017045 001

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION		
GLUCOSCAN		
BRISTOL MYERS SQUIBB	N/A	N017907 001
TECHNISCAN GLUCEPTATE		
DRAXIMAGE	N/A	N018272 001 Jan 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION		
TECHNISCAN HIDA		
DRAXIMAGE	N/A	N018489 001 Oct 31, 1986

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION		
DRAXIMAGE MDP-10		
JUBILANT DRAXIMAGE	N/A	N018035 001

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION		
AMERSCAN MDP KIT		
GE HEALTHCARE	N/A	N018335 001 Aug 05, 1982
OSTEOLITE		
PHARMALUCENCE	N/A	N017972 001
TECHNETIUM TC 99M MPI MDP		
GE HEALTHCARE	N/A	N018141 001
	N/A	N018141 002 Jun 12, 1989

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION		
MPI DTPA KIT - CHELATE		
GE HEALTHCARE	N/A	N017255 001
TECHNETIUM TC-99M PENTETATE KIT		
GE HEALTHCARE	N/A	N017264 002

TECHNETIUM TC-99M POLYPHOSPHATE KIT

INJECTABLE; INJECTION		
SODIUM POLYPHOSPHATE-TIN KIT		
GE HEALTHCARE	N/A	N017664 001

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION		
PYROLITE		
PHARMALUCENCE	N/A	N017684 001

DISCONTINUED DRUG PRODUCT LIST

6 - 327 (of 360)

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION
PHOSPHOTEC

BRACCO N/A

N017680 001

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION
RBC-SCAN

CADEMA N/A

N020063 001 Jun 11, 1992

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION
MIRALUMA

LANTHEUS MEDCL N/A

N019785 003 May 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL
SODIUM PERTECHNETATE TC 99M

GE HEALTHCARE 2-100mCi/ML

N017471 001

MALLINCKRODT 10-60mCi/ML

N017725 001

PHARMALUCENCE 12mCi/ML

N017321 001

24mCi/ML

N017321 002

48mCi/ML

N017321 003

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL
MINITEC

BRACCO 0.22-2.22 CI/GENERATOR

N017339 001

TECHNETIUM TC 99M GENERATOR

GE HEALTHCARE 830-16600mCi/GENERATOR

N017693 001

TECHNETIUM TC-99M SULFUR COLLOID

SOLUTION; INJECTION, ORAL

TECHNETIUM TC 99M SULFUR COLLOID

GE HEALTHCARE 4mCi/ML

N017456 001

SOLUTION; ORAL

TECHNETIUM TC 99M SULFUR COLLOID

MALLINCKRODT 3mCi/ML

N017724 001

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

TECHNECOLL

MALLINCKRODT N/A

N017059 001

TECHNETIUM TC 99M TSC

GE HEALTHCARE N/A

N017784 001

TESULOID

BRACCO N/A

N016923 001

TECHNETIUM TC-99M TEBOROXIME KIT

INJECTABLE; INJECTION
CARDIOTEC

BRACCO N/A

N019928 001 Dec 19, 1990

TEGASEROD MALEATE

TABLET; ORAL
ZELNORM

NOVARTIS EQ 2MG BASE

N021200 001 Jul 24, 2002

EQ 6MG BASE

N021200 002 Jul 24, 2002

TELBIVUDINE

SOLUTION; ORAL
TYZEKA

NOVARTIS 100MG/5ML

N022154 001 Apr 28, 2009

DISCONTINUED DRUG PRODUCT LIST

6 - 328 (of 360)

TEMAZEPAM

CAPSULE; ORAL

TEMAZ

QUANTUM PHARMICS	15MG	A070564	001	Oct 15, 1985
	30MG	A070547	001	Oct 15, 1985
TEMAZEPAM				
DURAMED PHARMS BARR	15MG	A071708	001	Sep 29, 1988
	30MG	A071709	001	Sep 29, 1988
MUTUAL PHARM	15MG	A071174	001	Jul 10, 1986
	30MG	A071175	001	Jul 10, 1986
USL PHARMA	15MG	A070489	001	Jul 07, 1986
	30MG	A070490	001	Jul 07, 1986
WATSON LABS	15MG	A070383	001	Mar 23, 1987
	30MG	A070384	001	Mar 23, 1987

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

MYLAN TECHNOLOGIES	EQ 1MG BASE	A075384	001	Dec 01, 2000
	EQ 2MG BASE	A075384	002	Dec 01, 2000
	EQ 5MG BASE	A075384	003	Dec 01, 2000
	EQ 10MG BASE	A075384	004	Dec 01, 2000
RANBAXY LABS LTD	EQ 1MG BASE	A076021	001	Aug 22, 2002
	EQ 2MG BASE	A076021	002	Aug 22, 2002
	EQ 5MG BASE	A076021	003	Aug 22, 2002
	EQ 10MG BASE	A076021	004	Aug 22, 2002
SANDOZ	EQ 1MG BASE	A075667	001	Jul 28, 2000
	EQ 2MG BASE	A075667	002	Jul 28, 2000
	EQ 5MG BASE	A075667	003	Jul 28, 2000
	EQ 10MG BASE	A075667	004	Jul 28, 2000

TABLET; ORAL

TERAZOSIN HYDROCHLORIDE

IVAX SUB TEVA PHARMS	EQ 1MG BASE	A074530	001	Apr 21, 2000
	EQ 2MG BASE	A074530	002	Apr 21, 2000
	EQ 5MG BASE	A074530	003	Apr 21, 2000
	EQ 10MG BASE	A074530	004	Apr 21, 2000
SANDOZ	EQ 1MG BASE	A074315	001	Dec 31, 1998
	EQ 1MG BASE	A074657	001	Apr 28, 2000
	EQ 2MG BASE	A074315	002	Dec 31, 1998
	EQ 2MG BASE	A074657	002	Apr 28, 2000
	EQ 5MG BASE	A074315	003	Dec 31, 1998
	EQ 5MG BASE	A074657	003	Apr 28, 2000
	EQ 10MG BASE	A074315	004	Dec 31, 1998
	EQ 10MG BASE	A074657	004	Apr 28, 2000
TEVA	EQ 1MG BASE	A074446	001	May 18, 2000
	EQ 2MG BASE	A074446	002	May 18, 2000
	EQ 5MG BASE	A074446	003	May 18, 2000
	EQ 10MG BASE	A074446	004	May 18, 2000

TERBINAFINE

GEL; TOPICAL

LAMISIL

NOVARTIS	1%	N020846	001	Apr 29, 1998

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL

NOVARTIS	1%	N020192	001	Dec 30, 1992

SOLUTION; TOPICAL

LAMISIL

NOVARTIS	1%	N020749	001	Oct 17, 1997

DISCONTINUED DRUG PRODUCT LIST

6 - 329 (of 360)

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

GEDEON RICHTER USA EQ 250MG BASE

A077065 001 Jul 02, 2007

ROXANE EQ 250MG BASE

A077223 001 Jul 02, 2007

TERBUTALINE SULFATE

AEROSOL, METERED; INHALATION

BRETHAIRE

NOVARTIS 0.2MG/INH

N018762 001 Aug 17, 1984

BRICANYL

SANOFI AVENTIS US 0.2MG/INH

N018000 001 Mar 19, 1985

INJECTABLE; INJECTION

BRETHINE

AAIPHARMA LLC 1MG/ML

N018571 001

BRICANYL

SANOFI AVENTIS US 1MG/ML

N017466 001

TERBUTALINE SULFATE

TEVA PARENTERAL 1MG/ML

A076853 001 Jul 20, 2004

TABLET; ORAL

BRETHINE

LEHIGH VALLEY 2.5MG

N017849 001

5MG

N017849 002

BRICANYL

SANOFI AVENTIS US 2.5MG

N017618 001

5MG

N017618 002

TERIPARATIDE ACETATE

INJECTABLE; INJECTION

PARATHAR

SANOFI AVENTIS US 200 UNITS/VIAL

N019498 001 Dec 23, 1987

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

LILLY 0.75MG/3ML (0.25MG/ML)

N021318 001 Nov 26, 2002

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

EMD SERONO EQ 1MG BASE/VIAL

N022505 001 Nov 10, 2010

TESTOLACTONE

INJECTABLE; INJECTION

TESLAC

BRISTOL MYERS SQUIBB 100MG/ML

N016119 001

TABLET; ORAL

TESLAC

BRISTOL MYERS SQUIBB 50MG

N016118 001

250MG

N016118 002

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

WATSON LABS 2.5MG/24HR

N020489 001 Sep 29, 1995

5MG/24HR

N020489 002 May 02, 1997

TESTODERM

ALZA 4MG/24HR

N019762 001 Oct 12, 1993

6MG/24HR

N019762 002 Oct 12, 1993

TESTODERM TTS

ALZA 5MG/24HR

N020791 001 Dec 18, 1997

DISCONTINUED DRUG PRODUCT LIST

6 - 330 (of 360)

TESTOSTERONE

GEL; TRANSDERMAL
TESTOSTERONE

PAR PHARM	1% (2.5GM/PACKET)	A076744	001	May 23, 2007
	1% (5GM/PACKET)	A076744	002	May 23, 2007
WATSON LABS	1% (2.5GM/PACKET)	A076737	001	Jan 27, 2006
	1% (5GM/PACKET)	A076737	002	Jan 27, 2006

INJECTABLE; INJECTION
TESTOSTERONE

WATSON LABS	25MG/ML	A086420	001	May 10, 1983
	50MG/ML	A086419	001	Aug 23, 1983
	100MG/ML	A086417	001	Jul 07, 1983

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION
DEPO-TESTOSTERONE

PHARMACIA AND UPJOHN	50MG/ML	A085635	001	
TESTOSTERONE CYPIONATE				
WATSON LABS	100MG/ML	A084401	001	
	100MG/ML	A086029	001	
	200MG/ML	A084401	002	

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
DELATESTYL

ENDO PHARM	200MG/ML	N009165	001	
TESTOSTERONE ENANTHATE				
WATSON LABS	100MG/ML	A083667	001	
	100MG/ML	A085599	001	
	200MG/ML	A083667	002	

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION
TESTOSTERONE PROPIONATE

BEL MAR	25MG/ML	A080741	001	
	50MG/ML	A080742	001	
	100MG/ML	A080743	001	
ELKINS SINN	25MG/ML	A080276	001	
LILLY	50MG/ML	A080254	002	
WATSON LABS	25MG/ML	A080188	001	
	25MG/ML	A085490	001	
	50MG/ML	A080188	002	
	50MG/ML	A085490	002	
	100MG/ML	A080188	003	
	100MG/ML	A083595	003	

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
ACHROMYCIN V

HERITAGE PHARMS INC	250MG	N050278	003	
	500MG	N050278	001	

BRISTACYCLINE
BRISTOL

250MG	A061658	001	
250MG	A061888	001	
500MG	A061658	002	
500MG	A061888	002	

CYCLOPAR

WARNER CHILCOTT	250MG	A061725	001	
	250MG	A062175	001	
	250MG	A062332	001	
	500MG	A061725	002	
	500MG	A062332	002	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 331 (of 360)

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

PANMYCIN

PHARMACIA AND UPJOHN 250MG

A060347 001

RETET

SOLVAY 250MG

A061443 001

500MG

A061443 002

ROBITET

WYETH AYERST 250MG

A061734 001

500MG

A061734 002

SUMYCIN

APOTHECON 100MG

A060429 002

125MG

A060429 004

250MG

A060429 001

500MG

A060429 003

TETRACHEL

ANGUS 250MG

A060343 001

500MG

A060343 003

TETRACYCLINE HYDROCHLORIDE

ABBOTT 250MG

A061802 001

500MG

A061802 002

ELKINS SINN 250MG

A060059 001

FERRANTE 125MG

A060173 001

250MG

A060173 002

HEATHER 250MG

A061148 001

500MG

A061148 002

LABS ATRAL 250MG

A062752 001

Aug 12, 1988

500MG

A062752 002

Aug 12, 1988

MAST MM 250MG

A062085 001

MUTUAL PHARM 250MG

A060736 001

500MG

A060736 002

MYLAN 250MG

A060783 001

500MG

A060783 002

PUREPAC PHARM 250MG

A060290 001

500MG

A060290 002

PVT FORM 250MG

A062686 001

Jul 24, 1986

500MG

A062686 002

Jul 24, 1986

ROXANE 500MG

A061214 002

SANDOZ 250MG

A061471 001

SUPERPHARM 250MG

A062540 001

Mar 21, 1985

500MG

A062540 002

Mar 21, 1985

VALEANT PHARM INTL 250MG

A060471 001

500MG

A060471 002

WARNER CHILCOTT 250MG

A062300 001

500MG

A062300 002

WATSON LABS 250MG

A062103 001

250MG

A062343 001

500MG

A062103 002

500MG

A062343 002

WEST WARD 250MG

A060768 001

500MG

A060768 002

WYETH AYERST 250MG

A061685 001

500MG

A061685 002

TETRACYN

PFIPHARMECS 250MG

A060082 003

500MG

A060082 004

FIBER, EXTENDED RELEASE; PERIODONTAL

ACTISITE

SCHIFF AND CO 12.7MG/FIBER

N050653 001

Mar 25, 1994

FOR SOLUTION; TOPICAL

TOPICYCLINE

SHIRE 2.2MG/ML

N050493 001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 332 (of 360)

TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ACHROMYCIN

LEDERLE

250MG/VIAL

N050273 002

500MG/VIAL

N050273 003

TETRACYN

PFIZER

250MG/VIAL

A060096 001

500MG/VIAL

A060096 002

OINTMENT; OPHTHALMIC

ACHROMYCIN

STORZ

10MG/GM

N050266 001

SUSPENSION; ORAL

ACHROMYCIN V

LEDERLE

125MG/5ML

N050263 002

SUMYCIN

PAR PHARM

125MG/5ML

A060400 001

TETRACYCLINE HYDROCHLORIDE

ALPHARMA US PHARMS

125MG/5ML

A060633 001

FERRANTE

125MG/5ML

A060174 001

PROTER

125MG/5ML

A060446 001

PUREPAC PHARM

125MG/5ML

A060291 001

TETRACYN

PFIPHARMECS

125MG/5ML

A060095 001

TETRAMED

IVAX SUB TEVA PHARMS

125MG/5ML

A061468 001

SUSPENSION/DROPS; OPHTHALMIC

ACHROMYCIN

STORZ

1%

N050268 001

TABLET; ORAL

PANMYCIN

PHARMACIA AND UPJOHN

250MG

A061705 001

500MG

A061705 002

SUMYCIN

PAR PHARM

50MG

A061147 003

100MG

A061147 002

250MG

A061147 001

500MG

A061147 004

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE; ORAL

TETREX

BRISTOL

EQ 100MG HCL

A061653 001

EQ 250MG HCL

A061653 002

EQ 250MG HCL

A061889 002

EQ 250MG HCL

N050212 002

EQ 500MG HCL

A061653 003

EQ 500MG HCL

A061889 001

EQ 500MG HCL

N050212 003

THALLOUS CHLORIDE TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

BRACCO

1mCi/ML

N018548 001

TRACE LIFE

1mCi/ML

A075569 001

Dec 30, 1982

Nov 21, 2001

THEOPHYLLINE

CAPSULE; ORAL

BRONKODYL

SANOFI AVENTIS US

100MG

A085264 001

200MG

A085264 002

ELIXOPHYLLIN

FOREST LABS

100MG

A085545 001

Jul 31, 1984

200MG

A083921 001

Jul 31, 1984

DISCONTINUED DRUG PRODUCT LIST

6 - 333 (of 360)

THEOPHYLLINE

CAPSULE; ORAL
SOMOPHYLLIN-T

FISONS	100MG	A087155	001	Feb 25, 1985
	200MG	A087155	002	Feb 25, 1985
	250MG	A087155	003	Feb 25, 1985

THEOPHYLLINE

KV PHARM	100MG	A085263	001	
	200MG	A085263	002	
SCHERER RP	100MG	A084731	002	Nov 07, 1986
	200MG	A084731	001	Nov 07, 1986
	250MG	A084731	003	Nov 07, 1986

CAPSULE, EXTENDED RELEASE; ORAL

AEROLATE III

FLEMING PHARMS	65MG	A085075	003	Nov 24, 1986

AEROLATE JR

FLEMING PHARMS	130MG	A085075	002	Nov 24, 1986

AEROLATE SR

FLEMING PHARMS	260MG	A085075	001	Nov 24, 1986

ELIXOPHYLLIN SR

FOREST LABS	125MG	A086826	001	Jan 29, 1985
	250MG	A086826	002	Jan 29, 1985

SLO-BID

SANOFI AVENTIS US	50MG	A088269	001	Jan 31, 1985
	75MG	A089539	001	May 10, 1989
	100MG	A087892	001	Jan 31, 1985
	125MG	A089540	001	May 10, 1989
	200MG	A087893	001	Jan 31, 1985
	300MG	A087894	001	Jan 31, 1985

SLO-PHYLLIN

SANOFI AVENTIS US	60MG	A085206	001	May 24, 1982
	125MG	A085203	001	May 24, 1982
	250MG	A085205	001	May 24, 1982

SOMOPHYLLIN-CRT

GRAHAM DM	50MG	A087763	001	Feb 27, 1985
	100MG	A087194	001	
	200MG	A088382	001	Feb 27, 1985
	250MG	A087193	001	
	300MG	A088383	001	Feb 27, 1985

THEOBID

WHITBY	260MG	A085983	001	Mar 20, 1985

THEOBID JR.

WHITBY	130MG	A087854	001	Mar 20, 1985

THEOCLEAR L.A.-130

SCHWARZ PHARMA	130MG	A086569	001	May 27, 1982

THEOCLEAR L.A.-260

SCHWARZ PHARMA	260MG	A086569	002	May 27, 1982

THEO-DUR

SCHERING	50MG	A088022	001	Sep 10, 1985
	75MG	A088015	001	Sep 10, 1985
	125MG	A088016	001	Sep 10, 1985
	200MG	A087995	001	Sep 10, 1985

THEOPHYLLINE

CENT PHARMS	125MG	A088654	001	Feb 12, 1985
	250MG	A088689	001	Feb 12, 1985

HOSPIRA	100MG	A089976	001	Jan 04, 1995
	200MG	A089977	001	Jan 04, 1995
	300MG	A089932	001	Jan 04, 1995

INWOOD LABS	100MG	A040052	001	Feb 14, 1994
	125MG	A040052	002	Feb 14, 1994
	200MG	A040052	003	Feb 14, 1994
	300MG	A040052	004	Feb 14, 1994

SANDOZ	260MG	A087462	001	May 11, 1982

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 334 (of 360)

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEOPHYLLINE-SR

SCHERER RP	300MG	A088255	001	Jun 12, 1986

THEOPHYL-SR

ORTHO MCNEIL PHARM	125MG	A086480	001	Feb 08, 1985

	250MG	A086471	001	Feb 08, 1985

THEOVENT

SCHERING	125MG	A087010	001	Jan 31, 1985

	250MG	A087910	001	Jan 31, 1985

ELIXIR; ORAL

ELIXOMIN

CENCI	80MG/15ML	A088303	001	Jan 25, 1984

LANOPHYLLIN

LANNETT	80MG/15ML	A084578	001	

THEOLIXIR

PANRAY	80MG/15ML	A084559	001	

THEOPHYL-225

ORTHO MCNEIL PHARM	112.5MG/15ML	A086485	001	

THEOPHYLLINE

ALPHARMA US PHARMS	80MG/15ML	A089223	001	May 27, 1988

CENCI	80MG/15ML	A087679	001	Apr 15, 1982

HALSEY	80MG/15ML	A085169	001	

PERRIGO	80MG/15ML	A085952	001	

PHARM ASSOC	80MG/15ML	A086720	001	

PRECISION DOSE	80MG/15ML	A085863	001	

ROXANE	80MG/15ML	A084739	001	

TARO	80MG/15ML	A089626	001	Oct 28, 1988

WOCKHARDT	80MG/15ML	A086748	001	

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	40MG/100ML	N019083	001	Nov 07, 1984

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	80MG/100ML	N019083	002	Nov 07, 1984

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	160MG/100ML	N019083	003	Nov 07, 1984

THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	200MG/100ML	N019212	001	Nov 07, 1984

	200MG/100ML	N019826	004	Aug 14, 1992

THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	4MG/ML	N019212	003	Nov 07, 1984

	400MG/100ML	N019212	002	Nov 07, 1984

	400MG/100ML	N019826	005	Aug 14, 1992

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4MG/ML	N018649	007	Jul 26, 1982

	40MG/100ML	N018649	001	Jul 26, 1982

	80MG/100ML	N018649	002	Jul 26, 1982

	160MG/100ML	N018649	003	Jul 26, 1982

	200MG/100ML	N018649	004	Jul 26, 1982

	320MG/100ML	N018649	006	Nov 13, 1985

	400MG/100ML	N018649	005	Jul 26, 1982

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA INC	80MG/100ML	N019211	002	Dec 14, 1984

	200MG/100ML	N019211	004	Dec 14, 1984

	400MG/100ML	N019211	005	Dec 14, 1984

SOLUTION; ORAL

AEROLATE

FLEMING PHARMS	150MG/15ML	A089141	001	Dec 03, 1986

THEOLAIR

3M	80MG/15ML	A086107	001	

THEOPHYLLINE

ROXANE	80MG/15ML	A087449	001	Sep 15, 1983

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 335 (of 360)

THEOPHYLLINESUSPENSION; ORAL
ELIXICON

FOREST LABS 100MG/5ML

A085502 001

SYRUP; ORAL
ACCURBRON

SANOFI AVENTIS US 150MG/15ML

A088746 001 Nov 22, 1985

AQUAPHYLLIN

FERNDAL LABS 80MG/15ML

A087917 001 Jan 18, 1983

SLO-PHYLLIN

SANOFI AVENTIS US 80MG/15ML

A085187 001

THEOCLEAR-80

CENT PHARMS 80MG/15ML

A087095 001 Mar 01, 1982

THEOPHYLLINE

ALPHARMA US PHARMS 80MG/15ML

A086001 001

150MG/15ML

A086545 001

TABLET; ORAL

QUIBRON-T

MONARCH PHARMS 300MG

A088656 001 Aug 22, 1985

SLO-PHYLLIN

SANOFI AVENTIS US 100MG

A085202 001

200MG

A085204 001

THEOCLEAR-100

CENT PHARMS 100MG

A085353 002

THEOCLEAR-200

CENT PHARMS 200MG

A085353 001

THEOPHYL-225

ORTHO MCNEIL PHARM 225MG

A084726 001

TABLET, CHEWABLE; ORAL

THEOPHYL

ORTHO MCNEIL PHARM 100MG

A086506 001 Sep 12, 1985

TABLET, EXTENDED RELEASE; ORAL

DURAPHYL

FOREST LABS 100MG

A088503 001 Apr 03, 1985

200MG

A088504 001 Apr 03, 1985

300MG

A088505 001 Apr 03, 1985

LABID

WARNER CHILCOTT 250MG

A087225 001

QUIBRON-T/SR

MONARCH PHARMS 300MG

A087563 001 Jun 21, 1983

SUSTAIRE

ROERIG 100MG

A085665 001

300MG

A085665 002

THEO-DUR

SCHERING 100MG

A085328 001

200MG

A086998 001

300MG

A085328 002

450MG

A089131 001 Jun 25, 1986

THEOLAIR-SR

3M 200MG

A088369 001 Jul 16, 1987

250MG

A086363 002 Jul 16, 1987

300MG

A088364 001 Jul 16, 1987

500MG

A089132 001 Jul 16, 1987

THEOPHYLLINE

ABLE 300MG

A040548 001 Apr 30, 2004

400MG

A040543 001 Apr 27, 2004

450MG

A040546 001 Apr 30, 2004

600MG

A040539 001 Apr 27, 2004

INWOOD LABS 450MG

A040034 001 Apr 28, 1995

T-PHYL

PHARM RES ASSOC 200MG

A088253 001 Aug 17, 1983

UNI-DUR

SCHERING 400MG

A089822 001 Jan 04, 1995

600MG

A089823 001 Jan 04, 1995

DISCONTINUED DRUG PRODUCT LIST

6 - 336 (of 360)

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL
UNIPHYL

RHODES PHARMS	400MG	A087571	001	Sep 01, 1982
	600MG	A040086	001	Apr 15, 1996

THEOPHYLLINE SODIUM GLYCINATE

ELIXIR; ORAL
SYNOHYLATE

CENT PHARMS	EQ 165MG BASE/15ML	N006333	008

TABLET; ORAL
ASBRON

NOVARTIS	EQ 150MG BASE	A085148	001

THIABENDAZOLE

SUSPENSION; ORAL
MINTEZOL

MERCK	500MG/5ML	N016097	001

TABLET, CHEWABLE; ORAL
MINTEZOL

MERCK	500MG	N016096	001

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
BETALIN S

LILLY	100MG/ML	A080853	001

THIAMINE HYDROCHLORIDE

ABRAXIS PHARM	100MG/ML	A080509	001

AKORN	100MG/ML	A087968	001

BEL MAR	100MG/ML	A080718	001

	200MG/ML	A080712	001

DELL LABS	100MG/ML	A083775	001

HIKMA MAPLE	100MG/ML	A080575	001

HOSPIRA	100MG/ML	A040079	001

LUITPOLD	100MG/ML	A080667	001

PARKE DAVIS	100MG/ML	A080770	001

WATSON LABS	100MG/ML	A083534	001

	200MG/ML	A083534	002

WYETH AYERST	100MG/ML	A080553	001

THIAMYLAL SODIUM

INJECTABLE; INJECTION
SURITAL

PARKEDALE	1GM/VIAL	N007600	003

	5GM/VIAL	N007600	005

	10GM/VIAL	N007600	009

THIETHYLPERAZINE MALATE

INJECTABLE; INJECTION
TORECAN

NOVARTIS	5MG/ML	N012754	002

THIETHYLPERAZINE MALEATE

SUPPOSITORY; RECTAL
TORECAN

NOVARTIS	10MG	N013247	001

TABLET; ORAL
TORECAN

NOVARTIS	10MG	N012753	001

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 337 (of 360)

THIOPENTAL SODIUM

SUSPENSION; RECTAL
PENTOTHAL
ABBOTT

400MG/GM

N011679 001

THIORIDAZINE

SUSPENSION; ORAL
MELLARIL-S
NOVARTIS

EQ 25MG HCL/5ML
EQ 100MG HCL/5ML

N017923 001
N017923 002

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
MELLARIL

NOVARTIS

30MG/ML
100MG/ML

N011808 012
N011808 018

THIORIDAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

100MG/ML

A088229 001 Aug 23, 1983

ALPHARMA US PHARMS

30MG/ML

A087766 001 Apr 26, 1983

HI TECH PHARMA

30MG/ML

A040125 001 Aug 16, 1996

100MG/ML

A040126 001 Aug 16, 1996

PHARM ASSOC

30MG/ML

A040187 001 Aug 28, 1997

100MG/ML

A040213 001 May 29, 1998

SANDOZ

30MG/ML

A088307 001 Nov 23, 1983

100MG/ML

A088308 001 Nov 23, 1983

TEVA PHARMS

30MG/ML

A089602 001 Nov 09, 1987

100MG/ML

A089603 001 Nov 09, 1987

WOCKHARDT

30MG/ML

A088258 001 Jul 25, 1983

100MG/ML

A088227 001 Jul 05, 1983

THIORIDAZINE HYDROCHLORIDE INTENSOL

ROXANE

30MG/ML

A088941 001 Dec 16, 1985

100MG/ML

A088942 001 Dec 16, 1985

TABLET; ORAL

MELLARIL

NOVARTIS

10MG

N011808 003

15MG

N011808 016

25MG

N011808 006

50MG

N011808 011

100MG

N011808 009

150MG

N011808 017

200MG

N011808 015

THIORIDAZINE HYDROCHLORIDE

IVAX PHARMS

10MG

A088270 001 Apr 14, 1983

15MG

A088271 001 Apr 14, 1983

25MG

A088272 001 Apr 14, 1983

50MG

A088194 001 Apr 14, 1983

100MG

A088273 001 Oct 03, 1983

MUTUAL PHARM

10MG

A088375 001 Nov 18, 1983

15MG

A088461 001 Nov 18, 1983

25MG

A087264 001 Nov 18, 1983

50MG

A088370 001 Nov 18, 1983

100MG

A088379 001 Nov 16, 1983

150MG

A088737 001 Sep 26, 1984

200MG

A088738 001 Oct 16, 1984

MYLAN

10MG

A088332 001 Jun 27, 1983

25MG

A088333 001 Jun 27, 1983

50MG

A088334 001 Jun 27, 1983

100MG

A088335 001 Nov 18, 1983

PAR PHARM

10MG

A088351 001 Dec 05, 1983

15MG

A088352 001 Dec 05, 1983

25MG

A088336 001 Dec 05, 1983

50MG

A088322 001 Dec 05, 1983

100MG

A088480 001 Dec 29, 1983

DISCONTINUED DRUG PRODUCT LIST

6 - 338 (of 360)

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

PAR PHARM	150MG	A089764	001	Feb 09, 1988
	200MG	A089765	001	Feb 09, 1988
ROXANE	10MG	A088663	001	Mar 15, 1984
	25MG	A088664	001	Mar 15, 1984
	50MG	A088665	001	Mar 15, 1984
	100MG	A089048	001	Feb 26, 1985
SANDOZ	10MG	A088131	001	Aug 30, 1983
	15MG	A088132	001	Aug 30, 1983
	25MG	A088133	001	Aug 30, 1983
	50MG	A088134	001	Aug 30, 1983
	100MG	A088135	001	Nov 20, 1984
	150MG	A088136	001	Sep 17, 1986
	200MG	A088137	001	Sep 17, 1986
	10MG	A089103	001	Jul 02, 1985
SUPERPHARM	25MG	A089104	001	Jul 02, 1985
	50MG	A089105	001	Jul 02, 1985
	10MG	A088493	001	May 17, 1985
TEVA	100MG	A088456	001	May 17, 1985
	10MG	A088412	001	Sep 12, 1983
WATSON LABS	10MG	A088476	001	Nov 08, 1983
	10MG	A088561	001	May 11, 1984
	15MG	A088345	001	Jul 28, 1983
	15MG	A088477	001	Nov 08, 1983
	15MG	A088562	001	May 11, 1984
	25MG	A088296	001	Jul 28, 1983
	25MG	A088478	001	Nov 08, 1983
	25MG	A088567	001	May 11, 1984
	25MG	A088755	001	Jul 24, 1984
	50MG	A088323	001	Jul 28, 1983
	50MG	A088479	001	Nov 08, 1983
	50MG	A088563	001	May 11, 1984
	100MG	A088284	001	Aug 25, 1983
	100MG	A088564	001	May 11, 1984
	100MG	A088736	001	Jul 24, 1984
	150MG	A088410	001	Mar 05, 1984
	150MG	A088869	001	Jun 28, 1985
	200MG	A088381	001	Mar 14, 1984
	200MG	A088872	001	Apr 26, 1985
	10MG	A088658	001	Mar 26, 1984
WEST WARD	15MG	A088659	001	Mar 26, 1984
	25MG	A088660	001	Mar 26, 1984
	50MG	A088661	001	Mar 26, 1984

THIOTEPA

INJECTABLE; INJECTION

THIOPLEX

IMMUNEX	15MG/VIAL	N020058	001	Dec 22, 1994

THIOTEPA

FRESENIUS KABI USA	15MG/VIAL	A075698	001	Sep 20, 2001
IMMUNEX	15MG/VIAL	N011683	001	
TEVA PARENTERAL	15MG/VIAL	A075730	001	Apr 20, 2001
	30MG/VIAL	A075730	002	Apr 20, 2001

THIOTHIXENE

CAPSULE; ORAL

NAVANE

PFIZER	20MG	N016584	005	

THIOTHIXENE

AM THERAP	1MG	A071884	001	Aug 12, 1987
	2MG	A071885	001	Aug 12, 1987

DISCONTINUED DRUG PRODUCT LIST

6 - 339 (of 360)

THIOTHIXENE

CAPSULE; ORAL
THIOTHIXENE

AM THERAP	5MG	A071886	001	Aug 12, 1987
	10MG	A071887	001	Aug 12, 1987
	20MG	A072200	001	Dec 17, 1987
WATSON LABS	1MG	A070600	001	Jun 05, 1987
	2MG	A071626	001	Jun 25, 1987
	5MG	A071627	001	Jun 25, 1987
	10MG	A070603	001	Jun 05, 1987
	10MG	A071628	001	Jun 25, 1987

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

NAVANE

PFIZER	EQ 5MG BASE/ML	N016758	001	

THIOTHIXENE HYDROCHLORIDE

ALPHARMA US PHARMS	EQ 5MG BASE/ML	A070969	001	Oct 16, 1987
PACO	EQ 1MG BASE/ML	A071917	001	Sep 20, 1989
	EQ 5MG BASE/ML	A071939	001	Dec 16, 1988
TEVA	EQ 5MG BASE/ML	A071184	001	Jun 22, 1987
TEVA PHARMS	EQ 5MG BASE/ML	A071554	001	Oct 16, 1987

THIOTHIXENE HYDROCHLORIDE INTENSOL

ROXANE	EQ 5MG BASE/ML	A073494	001	Jun 30, 1992

INJECTABLE; INJECTION

NAVANE

PFIZER	EQ 2MG BASE/ML	N016904	001	
	EQ 10MG BASE/VIAL	N016904	002	

THYROGLOBULIN

TABLET; ORAL

PROLOID

PARKE DAVIS	16MG	N002245	009	
	32MG	N002245	005	
	65MG	N002245	002	
	100MG	N002245	008	
	130MG	N002245	010	
	200MG	N002245	007	
	325MG	N002245	004	

THYROGLOBULIN

IMPAX LABS	64.8MG	A080151	001	

THYROTROPIN

INJECTABLE; INJECTION

THYTROPAR

SANOFI AVENTIS US	10 IU/VIAL	N008682	001	

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

CEPHALON	6MG	N020646	006	Nov 29, 2005
	8MG	N020646	007	Nov 29, 2005
	10MG	N020646	008	Nov 29, 2005
	20MG	N020646	004	Sep 30, 1997

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TICAR

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050497	001	
	EQ 3GM BASE/VIAL	A062690	001	Dec 19, 1986
	EQ 3GM BASE/VIAL	N050497	002	
	EQ 6GM BASE/VIAL	N050497	003	
	EQ 20GM BASE/VIAL	N050497	004	

DISCONTINUED DRUG PRODUCT LIST

6 - 340 (of 360)

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TICAR

GLAXOSMITHKLINE	EQ 30GM BASE/VIAL	N050497	005	Apr 04, 1984

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLID

ROCHE PALO	125MG	N019979	001	Mar 24, 1993
	250MG	N019979	002	Oct 31, 1991

TICLOPIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH	250MG	A075253	001	Aug 20, 1999
MYLAN	250MG	A075316	001	Nov 02, 1999
SANDOZ	250MG	A075318	001	Aug 20, 1999
	250MG	A075326	001	Aug 20, 1999
WATSON LABS	250MG	A075309	001	Apr 26, 2000

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AKORN	EQ 0.25% BASE	A074465	001	Mar 25, 1997
FOUGERA	EQ 0.25% BASE	A074667	001	Mar 25, 1997
	EQ 0.5% BASE	A074668	001	Mar 25, 1997

TABLET; ORAL

BLOCADREN

MERCK	5MG	N018017	001	
	10MG	N018017	002	
	20MG	N018017	004	

TIMOLOL MALEATE

QUANTUM PHARMICS	5MG	A072466	001	May 19, 1989
	10MG	A072467	001	May 19, 1989
	20MG	A072468	001	May 19, 1989
SANDOZ	5MG	A072550	001	Apr 13, 1989
	10MG	A072551	001	Apr 13, 1989
	20MG	A072552	001	Apr 13, 1989
TEVA	5MG	A072648	001	Jun 16, 1993
	10MG	A072649	001	Jun 16, 1993
	20MG	A072650	001	Jun 16, 1993
USL PHARMA	5MG	A072001	001	Apr 11, 1989
	10MG	A072002	001	Apr 11, 1989
	20MG	A072003	001	Apr 11, 1989
WATSON LABS	5MG	A072269	001	Apr 11, 1989
	5MG	A072917	001	Jul 31, 1991
	10MG	A072270	001	Apr 11, 1989
	10MG	A072918	001	Jul 31, 1991
	20MG	A072271	001	Apr 11, 1989
	20MG	A072919	001	Jul 31, 1991

TINZAPARIN SODIUM

INJECTABLE; INJECTION

INNOHEP

LEO PHARMA AS	20,000 IU/ML	N020484	001	Jul 14, 2000

TIOCONAZOLE

CREAM; TOPICAL

TZ-3

PFIZER	1%	N018682	001	Feb 18, 1983

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

MEDICURE	EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)	N020912	001	May 14, 1998
	EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)	N020913	001	May 14, 1998

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 341 (of 360)

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH	EQ 2MG BASE	A076283	001	Jul 12, 2002
	EQ 4MG BASE	A076283	002	Jul 12, 2002
BARR	EQ 2MG BASE	A076371	001	Apr 09, 2003
	EQ 4MG BASE	A076371	002	Apr 09, 2003
IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076321	001	Sep 30, 2004
	EQ 4MG BASE	A076321	002	Sep 30, 2004
ZANAFLEX				
ACORDA	EQ 2MG BASE	N020397	002	Feb 04, 2000

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

ALCON PHARMS LTD	0.3%	A063176	001	May 25, 1994

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

NEBCIN

LILLY	EQ 10MG BASE/ML	A062008	004	
	EQ 10MG BASE/ML	A062707	001	Apr 29, 1987
	EQ 10MG BASE/ML	N050477	005	
	EQ 40MG BASE/ML	A062008	001	
	EQ 1.2GM BASE/VIAL	N050519	001	
TOBRAMYCIN SULFATE				
APOTHECON	EQ 10MG BASE/ML	A064021	001	May 31, 1994
	EQ 40MG BASE/ML	A064021	002	May 31, 1994
	EQ 40MG BASE/ML	A064026	001	May 31, 1994
ASTRAZENECA	EQ 10MG BASE/ML	A063119	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063120	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063121	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063122	001	Oct 31, 1994
HIKMA MAPLE	EQ 10MG BASE/ML	A063113	001	Apr 26, 1991
	EQ 10MG BASE/ML	A063128	001	Nov 27, 1991
	EQ 40MG BASE/ML	A063118	001	Jul 29, 1991
	EQ 40MG BASE/ML	A063127	001	Nov 27, 1991
HOSPIRA	EQ 10MG BASE/ML	A063080	001	Apr 30, 1991
	EQ 40MG BASE/ML	A063161	001	May 29, 1991
MARSAM PHARMS LLC	EQ 40MG BASE/ML	A062945	002	Aug 09, 1989

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL

TONOCARD

ASTRAZENECA	400MG	N018257	001	Nov 09, 1984
	600MG	N018257	002	Nov 09, 1984

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

BARR	100MG	A070162	001	Jan 14, 1986
	250MG	A070163	001	Jan 14, 1986
	500MG	A070164	001	Jan 14, 1986
DURAMED PHARMS BARR	100MG	A070165	001	Jan 10, 1986
	250MG	A070166	001	Jan 10, 1986
	500MG	A070167	001	Jan 10, 1986
INTERPHARM	250MG	A071270	001	Sep 23, 1986
	500MG	A071271	001	Sep 23, 1986
IVAX SUB TEVA PHARMS	100MG	N018894	001	Nov 02, 1984
	250MG	N018894	002	Nov 02, 1984
	500MG	N018894	003	Nov 02, 1984
MUTUAL PHARM	100MG	A071357	001	Jul 16, 1987
	250MG	A071358	001	Jul 16, 1987

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 342 (of 360)

TOLAZAMIDETABLET; ORAL
TOLAZAMIDE

MUTUAL PHARM	500MG	A071359	001	Jul 16, 1987
PAR PHARM	100MG	A070159	001	Jan 06, 1986
	250MG	A070160	001	Jan 06, 1986
	500MG	A070161	001	Jan 06, 1986
SANDOZ	100MG	A071633	001	Dec 09, 1987
	250MG	A070289	001	Mar 13, 1986
	500MG	A070290	001	Mar 13, 1986
SUPERPHARM	250MG	A070763	001	Jun 16, 1986
	500MG	A070764	001	Jun 16, 1986
USL PHARMA	100MG	A071355	001	Jan 11, 1988
	250MG	A070168	001	Apr 02, 1986
	500MG	A070169	001	Apr 02, 1986
WATSON LABS	100MG	A070242	001	Aug 01, 1986
	100MG	A070513	001	Jan 09, 1986
	250MG	A070243	001	Aug 01, 1986
	500MG	A070244	001	Aug 01, 1986

TOLINASE

PHARMACIA AND UPJOHN	100MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N015500	002	
	250MG		N015500	004	
	500MG		N015500	005	

TOLAZOLINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRISCOLINE

NOVARTIS	25MG/ML	N006403	005	Feb 22, 1985

TOLBUTAMIDE

TABLET; ORAL

ORINASE

PHARMACIA AND UPJOHN	250MG	N010670	002	
	500MG	N010670	001	

TOLBUTAMIDE

ALRA	500MG	A086141	001	
ASCOT	500MG	A087541	001	Mar 01, 1983
BARR	500MG	A087121	001	
CLONMEL HLTHCARE	500MG	A086926	001	
IVAX PHARMS	500MG	A087093	001	
PARKE DAVIS	500MG	A086047	001	
PUREPAC PHARM	500MG	A088950	001	Jun 17, 1985
SANDOZ	500MG	A086574	001	
	500MG	N012678	001	
SUPERPHARM	500MG	A088893	001	Nov 19, 1984
VANGARD	500MG	A087876	001	Apr 20, 1982
WATSON LABS	250MG	A089110	001	May 29, 1987
	500MG	A086109	001	
	500MG	A087318	001	
	500MG	A089111	001	May 29, 1987

TOLBUTAMIDE SODIUM

INJECTABLE; INJECTION

ORINASE DIAGNOSTIC

PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N012095	001	

TOLCAPONE

TABLET; ORAL

TASMAR

VALEANT PHARMS LLC	200MG	N020697	002	Jan 29, 1998

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 343 (of 360)

TOLMETIN SODIUM

CAPSULE; ORAL

TOLECTIN DS

ORTHO MCNEIL JANSSEN EQ 400MG BASE

N018084 001

TOLMETIN SODIUM

ACTAVIS ELIZABETH EQ 400MG BASE

A073308 001 Jan 24, 1992

IVAX SUB TEVA PHARMS EQ 400MG BASE

A073392 001 Jan 24, 1992

MUTUAL PHARM EQ 400MG BASE

A073311 001 Nov 27, 1991

SANDOZ EQ 400MG BASE

A073462 001 Apr 30, 1992

TEVA EQ 400MG BASE

A073519 001 May 29, 1992

TABLET; ORAL

TOLECTIN

ORTHO MCNEIL JANSSEN EQ 200MG BASE

N017628 001

TOLECTIN 600

ORTHO MCNEIL JANSSEN EQ 600MG BASE

N017628 002 Mar 08, 1989

TOLMETIN SODIUM

ACTAVIS ELIZABETH EQ 600MG BASE

A073527 001 Jun 30, 1992

IVAX SUB TEVA PHARMS EQ 600MG BASE

A074399 001 Mar 28, 1996

SANDOZ EQ 200MG BASE

A073588 001 Jul 31, 1992

EQ 600MG BASE

A074002 001 Sep 27, 1993

TEVA EQ 600MG BASE

A074729 001 Feb 27, 1997

TOLVAPTAN

TABLET; ORAL

SAMSCA

OTSUKA AMERICA PHARM 60MG

N022275 003 May 19, 2009

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX SPRINKLE

JANSSEN PHARMS 50MG

N020844 003 Oct 26, 1998

TOPIRAMATE

BARR 15MG

A076448 001 Apr 15, 2009

25MG

A076448 002 Apr 15, 2009

TABLET; ORAL

TOPAMAX

JANSSEN PHARMS 300MG

N020505 003 Dec 24, 1996

400MG

N020505 006 Dec 24, 1996

TOPIRAMATE

BARR 25MG

A076315 001 Mar 27, 2009

100MG

A076315 002 Mar 27, 2009

200MG

A076315 003 Mar 27, 2009

PLIVA HRVATSKA DOO 25MG

A077905 001 Mar 30, 2009

50MG

A077905 002 Mar 30, 2009

100MG

A077905 003 Mar 30, 2009

200MG

A077905 004 Mar 30, 2009

ROXANE 25MG

A076306 001 Mar 27, 2009

50MG

A076306 002 Mar 27, 2009

100MG

A076306 003 Mar 27, 2009

200MG

A076306 004 Mar 27, 2009

TOPOTECAN HYDROCHLORIDE

SOLUTION; INTRAVENOUS

TOPOTECAN

SANDOZ INC EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N200199 001 Feb 25, 2011

EQ 3MG BASE/3ML (EQ 1MG BASE/ML)

N200199 002 Feb 25, 2011

EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

N200199 003 Feb 25, 2011

TORSEMIDE

INJECTABLE; INJECTION

DEMADEX

ROCHE 50MG/5ML (10MG/ML)

N020137 002 Aug 23, 1993

20MG/2ML (10MG/ML)

N020137 001 Aug 23, 1993

DISCONTINUED DRUG PRODUCT LIST

6 - 344 (of 360)

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

ACTAVIS ELIZABETH	50MG	A075960	001	Jun 19, 2002
ASTA	50MG	A075974	001	Jul 12, 2002
IVAX SUB TEVA PHARMS	50MG	A075963	001	Jul 03, 2002
SANDOZ	50MG	A075968	001	Jun 25, 2002
ULTRAM				
JANSSEN PHARMS	100MG	N020281	001	Mar 03, 1995

TRANEXAMIC ACID

TABLET; ORAL

CYKLOKAPRON

PHARMACIA AND UPJOHN	500MG	N019280	001	Dec 30, 1986

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN

ALCON PHARMS LTD	0.004%	N021257	001	Mar 16, 2001

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

DESYREL

APOTHECON	50MG	N018207	001	
	100MG	N018207	002	
	150MG	N018207	003	Mar 25, 1985
	300MG	N018207	004	Nov 07, 1988

TRAZODONE HYDROCHLORIDE

AM THERAP	50MG	A071139	001	Oct 29, 1986
	100MG	A071140	001	Oct 29, 1986
MYLAN	50MG	A071405	001	Feb 27, 1991
	100MG	A071406	001	Feb 27, 1991
QUANTUM PHARMICS	100MG	A070921	001	Dec 01, 1986
SANDOZ	50MG	A072484	001	Apr 30, 1990
	100MG	A072483	001	Apr 30, 1990
TEVA	150MG	A074357	001	Apr 30, 1997
USL PHARMA	50MG	A070491	001	Apr 29, 1987
	100MG	A070492	001	Apr 29, 1987
WATSON LABS	50MG	A071112	001	Nov 17, 1986
	100MG	A071113	001	Nov 17, 1986

TRIALODINE

QUANTUM PHARMICS	50MG	A070942	001	Dec 01, 1986

TRETINOIN

CAPSULE; ORAL

VESANOID

ROCHE	10MG	N020438	001	Nov 22, 1995

SOLUTION; TOPICAL

TRETINOIN

TEVA PHARMS	0.05%	A074873	001	Jun 19, 1998

SWAB; TOPICAL

RETIN-A

VALEANT INTL	0.05%	N016921	002	

TRIAMCINOLONE

TABLET; ORAL

ARISTOCORT

ASTELLAS	1MG	N011161	009	
	2MG	N011161	004	
	4MG	N011161	007	
	8MG	N011161	011	
	16MG	N011161	010	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 345 (of 360)

TRIAMCINOLONETABLET; ORAL
KENACORT

BRISTOL MYERS SQUIBB	1MG	N011283	003
	2MG	N011283	008
	4MG	N011283	006
	8MG	N011283	010

TRIAMCINOLONE

BARR	2MG	A084286	001
	2MG	A084318	001
	4MG	A084267	001
	4MG	A084319	001
	8MG	A084268	001
	8MG	A084320	001
IMPAX LABS	4MG	A084340	001
IVAX SUB TEVA PHARMS	4MG	A083750	001
MYLAN	2MG	A084406	001
PUREPAC PHARM	2MG	A084020	002
	4MG	A084020	003
ROXANE	2MG	A084708	001
	4MG	A084709	001
	8MG	A084707	001
SANDOZ	4MG	A085601	001
TEVA	4MG	A084775	001
WATSON LABS	4MG	A084270	001
	4MG	A085834	001

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT

ABBVIE	0.1MG/INH	N018117	001	Apr 23, 1982

AEROSOL, METERED; NASAL

NASACORT

SANOFI AVENTIS US	0.055MG/INH	N019798	001	Jul 11, 1991

CREAM; TOPICAL

ARISTOCORT

ASTELLAS	0.025%	A083017	003
	0.1%	A083016	004
	0.5%	A083015	002

ARISTOCORT A

ASTELLAS	0.025%	A083017	004	
	0.025%	A088818	001	Oct 16, 1984
	0.1%	A083016	005	
	0.1%	A088819	001	Oct 16, 1984
	0.5%	A083015	003	
	0.5%	A088820	001	Oct 16, 1984

FLUTEX

IVAX PHARMS	0.025%	A085539	001
	0.1%	A085539	002
	0.5%	A085539	003

KENALOG

APOTHECON	0.5%	A083943	001

KENALOG-H

APOTHECON	0.1%	A086240	001

TRACET

TEVA	0.1%	A084908	002

TRIACORT

SOLVAY	0.1%	A087113	001

TRIAMCINOLONE ACETONIDE

ACTAVIS MID ATLANTIC	0.1%	A087798	001	Jun 04, 1982
ALPHARMA US PHARMS	0.025%	A087797	001	Jun 07, 1982
AMBIX	0.025%	A087932	001	May 09, 1983
G AND W LABS	0.1%	A089798	001	May 31, 1991

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 346 (of 360)

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

MORTON GROVE	0.025%	A088094	001	Sep 01, 1983
	0.1%	A088095	001	Sep 01, 1983
	0.5%	A088096	001	Sep 01, 1983
PHARMADERM	0.025%	A087990	001	Jul 07, 1983
	0.1%	A087991	001	Jul 07, 1983
	0.5%	A087992	001	Jul 07, 1983
PHARMAFAIR	0.025%	A087921	001	Aug 10, 1982
	0.1%	A087912	001	Aug 10, 1982
	0.5%	A087922	001	Aug 10, 1982
TARO	0.025%	A040038	001	Oct 26, 1994
TOPIDERM	0.025%	A089274	001	Feb 21, 1989
	0.1%	A089275	001	Feb 21, 1989
	0.5%	A089276	001	Feb 21, 1989
TRIALEX				
IVAX PHARMS	0.025%	A087430	001	Nov 01, 1988
	0.1%	A087429	001	Nov 01, 1988
	0.5%	A087428	001	Nov 01, 1988
TRYMEX				
SAVAGE LABS	0.025%	A088196	001	Mar 25, 1983
	0.1%	A088197	001	Mar 25, 1983
	0.5%	A088198	001	Mar 25, 1983

GEL; TOPICAL

ARISTOGEL

ASTELLAS	0.1%	A083380	001	

INJECTABLE; INJECTION

TRIAMCINOLONE ACETONIDE

PARNELL	3MG/ML	N019503	001	Oct 16, 1987
WATSON LABS	40MG/ML	A085825	001	

LOTION; TOPICAL

KENALOG

APOTHECON	0.025%	A084343	001	
	0.1%	A084343	002	
BRISTOL MYERS SQUIBB	0.025%	N011602	003	
	0.1%	N011602	001	

TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS	0.025%	A087191	001	Sep 08, 1982
	0.1%	A087192	001	Sep 08, 1982

OINTMENT; TOPICAL

ARISTOCORT

ASTELLAS	0.1%	A080750	004	
	0.5%	A080745	002	

ARISTOCORT A

ASTELLAS	0.1%	A080750	003	
	0.1%	A088780	001	Oct 01, 1984
	0.5%	A080745	003	
	0.5%	A088781	001	Oct 05, 1984

FLUTEX

IVAX PHARMS	0.025%	A087375	001	Nov 01, 1988
	0.1%	A087377	001	Nov 01, 1988
	0.5%	A087376	001	Nov 01, 1988

KENALOG

APOTHECON	0.5%	A083944	001	

TRIAMCINOLONE ACETONIDE

ACTAVIS MID ATLANTIC	0.1%	A087799	001	Jun 07, 1982
ALPHARMA US PHARMS	0.5%	A089913	001	Dec 23, 1988
G AND W LABS	0.025%	A089795	001	Dec 23, 1988
	0.1%	A089796	001	Dec 23, 1988
MORTON GROVE	0.025%	A088090	001	Sep 01, 1983
	0.1%	A088091	001	Sep 01, 1983
	0.5%	A088092	001	Sep 01, 1983
PHARMADERM	0.025%	A088692	001	Aug 02, 1984

DISCONTINUED DRUG PRODUCT LIST

6 - 347 (of 360)

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

PHARMADERM	0.1%	A088690	001	Aug 02, 1984

TRYMEX

SAVAGE LABS	0.025%	A088693	001	Aug 02, 1984

	0.1%	A088691	001	Aug 02, 1984

PASTE; DENTAL

KENALOG IN ORABASE

APOTHECON	0.1%	N012097	001	

ORALONE

TARO	0.1%	A071383	001	Jul 06, 1987

SPRAY, METERED; NASAL

ALLERNAZE

LUPIN ATLANTIS	0.05MG/SPRAY	N020120	001	Feb 04, 2000

NASACORT HFA

SANOFI AVENTIS US	0.055MG/SPRAY	N020784	001	Apr 07, 2004

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

SANDOZ	25MG/ML	N011685	003	

	40MG/ML **Federal Register	N012802	001	

determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

TRIAMCINOLONE DIACETATE

AKORN	25MG/ML	A085122	001	

	40MG/ML	A086394	001	

WATSON LABS	40MG/ML	A084072	001	

	40MG/ML	A085529	001	

SYRUP; ORAL

ARISTOCORT

ASTELLAS	2MG/5ML	N011960	004	

KENACORT

BRISTOL MYERS SQUIBB	EQ 4MG BASE/5ML	N012515	001	

TRIAZOLAM

TABLET; ORAL

HALCION

PHARMACIA AND UPJOHN	0.5MG	N017892	002	Nov 15, 1982

TRICHLORMETHIAZIDE

TABLET; ORAL

METAHYDRIN

SANOFI AVENTIS US	2MG	N012594	001	Jun 16, 1988

	4MG	N012594	002	Jun 16, 1988

NAQUA

SCHERING	2MG	N012265	001	

	4MG	N012265	002	

TRICHLOREX

LANNETT	4MG	A083436	001	

	4MG	A085630	001	

TRICHLORMAS

MAST MM	4MG	A086259	001	

TRICHLORMETHIAZIDE

IMPAX LABS	4MG	A083967	001	

PAR PHARM	2MG	A087007	001	

	4MG	A087005	001	

SANDOZ	4MG	A086171	001	

TG UNITED LABS	4MG	A085568	001	

WATSON LABS	2MG	A083847	001	

	2MG	A086458	001	

	4MG	A083462	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 348 (of 360)

TRICHLORMETHIAZIDE

TABLET; ORAL				
TRICHLORMETHIAZIDE				
WATSON LABS	4MG	A083855	001	
	4MG	A085962	001	

TRICLOFOS SODIUM

SOLUTION; ORAL				
TRICLOS				
SANOFI AVENTIS US	1.5GM/15ML	N016830	001	
TABLET; ORAL				
TRICLOS				
SANOFI AVENTIS US	750MG	N016809	002	

TRIDIHEXETHYL CHLORIDE

INJECTABLE; INJECTION				
PATHILON				
LEDERLE	10MG/ML	N009729	001	
TABLET; ORAL				
PATHILON				
LEDERLE	25MG	N009489	005	

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL				
STELAZINE				
GLAXOSMITHKLINE	EQ 10MG BASE/ML	N011552	006	
TRIFLUOPERAZINE HYDROCHLORIDE				
SANDOZ	EQ 10MG BASE/ML	A085787	001	Apr 15, 1982
WOCKHARDT	EQ 10MG BASE/ML	A088143	001	Jul 26, 1983
INJECTABLE; INJECTION				
STELAZINE				
GLAXOSMITHKLINE	EQ 2MG BASE/ML	N011552	005	
TABLET; ORAL				
STELAZINE				
GLAXOSMITHKLINE	EQ 1MG BASE	N011552	001	
	EQ 2MG BASE	N011552	002	
	EQ 5MG BASE	N011552	003	
	EQ 10MG BASE	N011552	004	
TRIFLUOPERAZINE HYDROCHLORIDE				
DURAMED PHARMS BARR	EQ 1MG BASE	A088967	001	Apr 23, 1985
	EQ 2MG BASE	A088968	001	Apr 23, 1985
	EQ 5MG BASE	A088969	001	Apr 23, 1985
	EQ 10MG BASE	A088970	001	Apr 23, 1985
IVAX PHARMS	EQ 1MG BASE	A087612	001	Nov 19, 1982
	EQ 2MG BASE	A087613	001	Nov 19, 1982
	EQ 5MG BASE	A087328	001	Nov 19, 1982
	EQ 10MG BASE	A087614	001	Nov 19, 1982
SANDOZ	EQ 1MG BASE	A040153	001	Oct 25, 1996
	EQ 2MG BASE	A040153	002	Oct 25, 1996
	EQ 5MG BASE	A040153	003	Oct 25, 1996
	EQ 10MG BASE	A040153	004	Oct 25, 1996
WATSON LABS	EQ 1MG BASE	A085975	001	Jun 23, 1988
	EQ 2MG BASE	A085976	001	Jun 23, 1988
	EQ 5MG BASE	A085973	001	Jun 23, 1988
	EQ 10MG BASE	A088710	001	Jun 23, 1988

TRIFLUPROMAZINE

SUSPENSION; ORAL				
VESPRIN				
APOTHECON	EQ 50MG HCL/5ML	N011491	004	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 349 (of 360)

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

VESPRIN

APOTHECON

3MG/ML

N011325 005

10MG/ML

N011325 004

20MG/ML

N011325 001

TABLET; ORAL

VESPRIN

BRISTOL MYERS SQUIBB

10MG

N011123 001

25MG

N011123 002

50MG

N011123 003

TRIHENXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

ARTANE

LEDERLE

5MG

N006773 010

5MG

N012947 001

ELIXIR; ORAL

ARTANE

LEDERLE

2MG/5ML

N006773 009

TRIHENXYPHENIDYL HYDROCHLORIDE

PHARM VENTURES

2MG/5ML

A089514 001

Apr 07, 1989

TABLET; ORAL

ARTANE

LEDERLE

2MG

N006773 005

5MG

N006773 003

TREMIN

SCHERING

2MG

A080381 001

5MG

A080381 003

TRIHENXYPHENIDYL HYDROCHLORIDE

NYLOS

5MG

A085622 001

VANGARD

2MG

A088035 001

Jul 30, 1982

WATSON LABS

2MG

A085117 001

5MG

A085105 001

TRILOSTANE

CAPSULE; ORAL

MODRASTANE

BIOENVISION

30MG

N018719 002

Dec 31, 1984

60MG

N018719 001

Dec 31, 1984

TRIMEPAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

TEMARIL

ALLERGAN HERBERT

EQ 5MG BASE

N011316 004

SYRUP; ORAL

TEMARIL

ALLERGAN HERBERT

EQ 2.5MG BASE/5ML

N011316 003

TRIMEPAZINE TARTRATE

ALPHARMA US PHARMS

EQ 2.5MG BASE/5ML

A085015 001

Feb 18, 1982

MORTON GROVE

EQ 2.5MG BASE/5ML

A088285 001

Apr 11, 1985

TABLET; ORAL

TEMARIL

ALLERGAN HERBERT

EQ 2.5MG BASE

N011316 001

TRIMETHADIONE

CAPSULE; ORAL

TRIDIONE

ABBVIE

300MG

N005856 005

SOLUTION; ORAL

TRIDIONE

ABBVIE

200MG/5ML

N005856 002

DISCONTINUED DRUG PRODUCT LIST

6 - 350 (of 360)

TRIMETHAPHAN CAMSYLATE

INJECTABLE; INJECTION
ARFONAD

ROCHE	50MG/ML	N008983	001

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

HOSPIRA	100MG/ML	A088804	001	Apr 03, 1987
SMITH AND NEPHEW	100MG/ML	A088960	001	Apr 04, 1986
	100MG/ML	A089043	001	Apr 04, 1986
SOLOPAK	100MG/ML	A089094	001	Apr 04, 1986
WATSON LABS	100MG/ML	A086577	001	Oct 19, 1982
	100MG/ML	A087939	001	Dec 28, 1982

TRIMETHOPRIM

TABLET; ORAL

PROLOPRIM

MONARCH PHARMS	100MG	N017943	001	
	200MG	N017943	003	Jul 14, 1982

TRIMETHOPRIM

MUTUAL PHARM	100MG	A070494	001	Jan 22, 1986
	200MG	A070495	001	Sep 24, 1986

TRIMPEX

ROCHE	100MG	N017952	001	

TRIMPEX 200

ROCHE	200MG	N017952	002	Nov 09, 1982

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

FSC	EQ 25MG BASE/5ML	A074374	001	Jun 23, 1995

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION

NEUTREXIN

MEDIMMUNE ONCOLOGY	EQ 25MG BASE/VIAL	N020326	001	Dec 17, 1993
	EQ 200MG BASE/VIAL	N020326	002	Jul 31, 1998

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

USL PHARMA	EQ 25MG BASE	A071283	001	Dec 08, 1987
	EQ 50MG BASE	A071284	001	Dec 08, 1987
	EQ 100MG BASE	A071285	001	Dec 08, 1987

TRIOXSALEN

TABLET; ORAL

TRISORALEN

VALEANT PHARM INTL	5MG	N012697	001	

TRIPLENNAMINE CITRATE

ELIXIR; ORAL

PBZ

NOVARTIS	EQ 25MG HCL/5ML	N005914	004	

TRIPLENNAMINE HYDROCHLORIDE

TABLET; ORAL

PBZ

NOVARTIS	25MG	A083149	001	
	50MG	N005914	002	
TRIPLENNAMINE HYDROCHLORIDE				
ANABOLIC	50MG	A083037	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 351 (of 360)

TRIPLENNAMINE HYDROCHLORIDE

TABLET; ORAL

TRIPLENNAMINE HYDROCHLORIDE

BARR	50MG	A080744	001
HEATHER	50MG	A083989	001
IMPAX LABS	50MG	A080785	001
LANNETT	50MG	A083557	001
NYLOS	50MG	A085412	001
PARKE DAVIS	25MG	A083625	001
	50MG	A083626	001
WATSON LABS	50MG	A080713	001
	50MG	A080790	001
	50MG	A085188	001

TABLET, EXTENDED RELEASE; ORAL

PBZ-SR

NOVARTIS	50MG	N010533	002
	100MG	N010533	001

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL

GYNE-SULF

G AND W LABS	3.7%;2.86%;3.42%	A088607	001	Jun 09, 1986

SULTRIN

ORTHO MCNEIL PHARM	3.7%;2.86%;3.42%	N005794	001	

TRIPLE SULFA

ALPHARMA US PHARMS	3.7%;2.86%;3.42%	A087864	001	Sep 01, 1982

FOUGERA	3.7%;2.86%;3.42%	A086424	001	

PERRIGO NEW YORK	3.7%;2.86%;3.42%	A087285	001	Nov 15, 1982

TRYSL

SAVAGE LABS	3.7%;2.86%;3.42%	A087887	001	Jul 23, 1982

VAGILIA

TEVA	3.7%;2.86%;3.42%	A088821	001	Nov 09, 1987

TABLET; VAGINAL

SULTRIN

ORTHO MCNEIL PHARM	184MG;143.75MG;172.5MG	N005794	002	

TRIPLE SULFA

FOUGERA	184MG;143.75MG;172.5MG	A088463	001	Jan 03, 1985

PHARMADERM	184MG;143.75MG;172.5MG	A088462	001	Jan 03, 1985

TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

ACTIDIL

GLAXOSMITHKLINE	1.25MG/5ML	N011496	002	Jul 01, 1983

MYIDYL

USL PHARMA	1.25MG/5ML	A087963	001	Jan 18, 1983

TRIPROLIDINE HYDROCHLORIDE

ALPHARMA US PHARMS	1.25MG/5ML	A085940	001	

HALSEY	1.25MG/5ML	A088735	001	Jan 17, 1985

PHARM ASSOC	1.25MG/5ML	A087514	001	Feb 10, 1982

TABLET; ORAL

ACTIDIL

GLAXOSMITHKLINE	2.5MG	N011110	002	Jul 01, 1983

TRIPROLIDINE HYDROCHLORIDE

VITARINE	2.5MG	A085610	001	

WATSON LABS	2.5MG	A085094	001	

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION; ORAL

LANTRISUL

LANNETT	167MG/5ML;167MG/5ML;167MG/5ML	A080123	002	

NEOTRIZINE

LILLY	167MG/5ML;167MG/5ML;167MG/5ML	N006317	012	

DISCONTINUED DRUG PRODUCT LIST

6 - 352 (of 360)

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION; ORAL				
SULFALOID				
FOREST PHARMS	167MG/5ML;167MG/5ML;167MG/5ML	A080100	001	
SULFOSE				
WYETH AYERST	167MG/5ML;167MG/5ML;167MG/5ML	A080013	002	
TERFONYL				
BRISTOL MYERS SQUIBB	167MG/5ML;167MG/5ML;167MG/5ML	N006904	002	
TRIPLE SULFA				
ALPHARMA US PHARMS	167MG/5ML;167MG/5ML;167MG/5ML	A080280	001	
TRIPLE SULFAS				
LEDERLE	167MG/5ML;167MG/5ML;167MG/5ML	N006920	003	
TABLET; ORAL				
NEOTRIZINE				
LILLY	167MG;167MG;167MG	N006317	011	
SULFALOID				
FOREST PHARMS	167MG;167MG;167MG	A080099	001	
SULFA-TRIPLE #2				
IMPAX LABS	167MG;167MG;167MG	A080079	001	
SULFOSE				
WYETH AYERST	167MG;167MG;167MG	A080013	001	
TERFONYL				
BRISTOL MYERS SQUIBB	167MG;167MG;167MG	N006904	001	
TRIPLE SULFA				
PUREPAC PHARM	167MG;167MG;167MG	A080086	001	
TRIPLE SULFAS				
LEDERLE	167MG;167MG;167MG	N006920	002	
TRIPLE SULFOID				
PAL PAK	167MG;167MG;167MG	A080094	001	

TROGLITAZONE

TABLET; ORAL				
PRELAY				
SANKYO	200MG	N020719	001	Jan 29, 1997
	300MG	N020719	003	Aug 04, 1997
	400MG	N020719	002	Jan 29, 1997
REZULIN				
PFIZER PHARMS	200MG	N020720	001	Jan 29, 1997
	300MG	N020720	003	Aug 04, 1997
	400MG	N020720	002	Jan 29, 1997

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS; OTIC				
CERUMENEX				
PHARM RES ASSOC	10%	N011340	002	

TROLEANDOMYCIN

CAPSULE; ORAL				
TAO				
PFIZER	EQ 250MG BASE	N050336	002	
SUSPENSION; ORAL				
TAO				
PFIZER	EQ 125MG BASE/5ML	N050332	001	

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC				
MYDRIACYL				
ALCON	0.5%	N012111	002	
	1%	N012111	004	
MYDRIAFAIR				
PHARMAFAIR	0.5%	A088274	001	Sep 16, 1983
	1%	A088230	001	Sep 16, 1983

DISCONTINUED DRUG PRODUCT LIST

6 - 353 (of 360)

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
TROPICAMIDE

AKORN	1%	A088447	001	Aug 28, 1985
ALCON PHARMS LTD	1%	A089172	001	Dec 28, 1990
MIZA PHARMS USA	0.5%	A087636	001	Jul 30, 1982
	1%	A087637	001	Aug 09, 1982
WATSON LABS	0.5%	A089171	001	Dec 28, 1990

TROVAFLOXACIN MESYLATE

TABLET; ORAL
TROVAN

PFIZER	EQ 100MG BASE	N020759	001	Dec 18, 1997
	EQ 200MG BASE	N020759	002	Dec 18, 1997

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE

BRISTOL MYERS SQUIBB	3MG/ML	N005657	001	
HOSPIRA	3MG/ML	N006095	001	
LILLY	3MG/ML	N006325	001	

TYROPANOATE SODIUM

CAPSULE; ORAL
BILOPAQUE

GE HEALTHCARE	750MG	N013731	001	

URACIL MUSTARD

CAPSULE; ORAL
URACIL MUSTARD
SHIRE

1MG	N012892	001	

UREA

INJECTABLE; INJECTION
STERILE UREA

HOSPIRA	40GM/VIAL	N017698	001	
UREAPHIL				
HOSPIRA	40GM/VIAL	N012154	001	

UREA C-13

FOR SOLUTION; ORAL
HELICOSOL

METABOLIC SOLUTIONS	125MG/VIAL	N021092	001	Dec 17, 1999
MERETEK UBT KIT (W/ PRANACTIN)				
OTSUKA AMERICA	125MG/VIAL	N020586	001	Sep 17, 1996
PYLORI-CHEK BREATH TEST				
DXS DEVICES	100MG/VIAL	N020900	001	Feb 04, 1999

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR
METRODIN

SERONO	75 IU/AMP	N019415	002	Sep 18, 1986
	150 IU/AMP	N019415	003	Sep 18, 1986

INJECTABLE; SUBCUTANEOUS
FERTINEX

SERONO	75 IU/AMP	N019415	005	Aug 23, 1996
	150 IU/AMP	N019415	004	Aug 23, 1996

UROKINASE

INJECTABLE; INJECTION
KINLYTIC

MICROBIX BIOSYSTEMS	5,000 IU/VIAL	N021846	003	
	9,000 IU/VIAL	N021846	002	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 354 (of 360)

UROKINASEINJECTABLE; INJECTION
KINLYTIC

MICROBIX BIOSYSTEMS 250,000 IU/VIAL N021846 001

URSODIOLCAPSULE; ORAL
ACTIGALL

WATSON PHARMS 150MG N019594 001 Dec 31, 1987

VALDECOXIBTABLET; ORAL
BEXTRAGD SEARLE 10MG N021341 002 Nov 16, 2001
20MG N021341 003 Nov 16, 2001VALPROIC ACIDCAPSULE; ORAL
VALPROIC ACID

PAR PHARM 250MG A070431 001 Feb 28, 1986

SCHERER RP 250MG A070195 001 Jul 02, 1987

USL PHARMA 250MG A070631 001 Jun 11, 1987

SYRUP; ORAL
VALPROIC ACID

APOTEX INC 250MG/5ML A077105 001 Jul 29, 2005

VALSARTANCAPSULE; ORAL
DIOVAN

NOVARTIS 80MG N020665 001 Dec 23, 1996

160MG N020665 002 Dec 23, 1996

VANCOMYCIN HYDROCHLORIDEFOR SOLUTION; ORAL
VANCOCIN HYDROCHLORIDE

VIROPHARMA EQ 250MG BASE/5ML A061667 002 Jul 13, 1983

EQ 500MG BASE/6ML A061667 001

VANCOLED

LEDERLE EQ 250MG BASE/5ML A063321 002 Oct 15, 1993

EQ 500MG BASE/6ML A063321 003 Oct 15, 1993

INJECTABLE; INJECTION
VANCOCIN HYDROCHLORIDE

VIROPHARMA EQ 500MG BASE/VIAL A060180 001

EQ 500MG BASE/VIAL A062476 001 Mar 15, 1984

EQ 500MG BASE/VIAL A062716 001 Mar 13, 1987

EQ 500MG BASE/VIAL A062812 001 Nov 17, 1987

EQ 1GM BASE/VIAL A060180 002 Mar 21, 1986

EQ 1GM BASE/VIAL A062476 002 Mar 21, 1986

EQ 1GM BASE/VIAL A062716 002 Mar 13, 1987

EQ 1GM BASE/VIAL A062812 002 Nov 17, 1987

EQ 10GM BASE/VIAL A062812 003 Nov 17, 1987

VANCOLED

HIKMA MAPLE EQ 500MG BASE/VIAL A062682 001 Jul 22, 1986

EQ 1GM BASE/VIAL A062682 002 Mar 30, 1988

EQ 2GM BASE/VIAL A062682 003 May 11, 1988

EQ 5GM BASE/VIAL A062682 004 May 11, 1988

EQ 10GM BASE/VIAL A062682 005 May 11, 1988

VANCOMYCIN HYDROCHLORIDE

HIKMA MAPLE EQ 500MG BASE/VIAL A062879 001 Aug 02, 1988

EQ 1GM BASE/VIAL A062879 002 Aug 02, 1988

VANCOR

PHARMACIA AND UPJOHN EQ 500MG BASE/VIAL A062956 001 Aug 01, 1988

EQ 1GM BASE/VIAL A062956 002 Aug 01, 1988

DISCONTINUED DRUG PRODUCT LIST

6 - 355 (of 360)

VASOPRESSIN TANNATE

INJECTABLE; INJECTION
PITRESSIN TANNATE

PARKE DAVIS

5PRESSOR UNITS/ML

N003402 001

VECURONIUM BROMIDE

INJECTABLE; INJECTION
NORCURON

ORGANON USA INC

10MG/VIAL

N018776 002 Apr 30, 1984

20MG/VIAL

N018776 003 Jan 03, 1992

VECURONIUM BROMIDE

HIKMA MAPLE

10MG/VIAL

A075218 001 Aug 23, 1999

20MG/VIAL

A075218 002 Aug 23, 1999

HOSPIRA

4MG/VIAL

A075558 001 Sep 11, 2001

VELAGLUCERASE ALFA

POWDER; IV (INFUSION)
VPRIV

SHIRE HUMAN GENETIC

200 UNITS/VIAL

N022575 002 Feb 26, 2010

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
EFFEXOR XR

WYETH PHARMS INC

EQ 100MG BASE

N020699 003 Oct 20, 1997

TABLET; ORAL

EFFEXOR

WYETH PHARMS INC

EQ 12.5MG BASE

N020151 001 Dec 28, 1993

EQ 25MG BASE

N020151 002 Dec 28, 1993

EQ 37.5MG BASE

N020151 006 Dec 28, 1993

EQ 50MG BASE

N020151 003 Dec 28, 1993

EQ 75MG BASE

N020151 004 Dec 28, 1993

EQ 100MG BASE

N020151 005 Dec 28, 1993

VENLAFAXINE HYDROCHLORIDE

PLIVA HRVATSKA DOO

EQ 25MG BASE

A078517 001 Jun 13, 2008

EQ 37.5MG BASE

A078517 002 Jun 13, 2008

EQ 50MG BASE

A078517 003 Jun 13, 2008

EQ 75MG BASE

A078517 004 Jun 13, 2008

EQ 100MG BASE

A078517 005 Jun 13, 2008

SANDOZ

EQ 25MG BASE

A077515 001 Jun 13, 2008

EQ 37.5MG BASE

A077515 002 Jun 13, 2008

EQ 50MG BASE

A077515 003 Jun 13, 2008

EQ 75MG BASE

A077515 004 Jun 13, 2008

EQ 100MG BASE

A077515 005 Jun 13, 2008

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
CALAN

GD SEARLE LLC

2.5MG/ML

N018925 001 Mar 30, 1984

2.5MG/ML

N019038 001 Mar 30, 1984

ISOPTIN

FSC

2.5MG/ML

N018485 001

VERAPAMIL HYDROCHLORIDE

ABRAXIS PHARM

2.5MG/ML

A070348 001 May 01, 1986

BEDFORD

2.5MG/ML

A072888 001 Jul 28, 1995

HOSPIRA

2.5MG/ML

A070577 001 Feb 02, 1987

2.5MG/ML

A070739 001 May 06, 1987

2.5MG/ML

A070740 001 May 06, 1987

LUITPOLD

2.5MG/ML

A070225 001 Nov 12, 1985

2.5MG/ML

A070617 001 Nov 12, 1985

MARSAM PHARMS LLC

2.5MG/ML

A072233 001 Feb 26, 1993

2.5MG/ML

A073485 001 Sep 27, 1993

SMITH AND NEPHEW

2.5MG/ML

A070696 001 Jul 31, 1987

2.5MG/ML

A070697 001 Jul 31, 1987

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 356 (of 360)

VERAPAMIL HYDROCHLORIDEINJECTABLE; INJECTION
VERAPAMIL HYDROCHLORIDE

SOLOPAK 2.5MG/ML

A070695 001 Jul 31, 1987

TABLET; ORAL

CALAN

GD SEARLE LLC 160MG

N018817 004 Feb 23, 1988

ISOPTIN

FSC 40MG
80MG
120MG

N018593 003 Nov 23, 1987

N018593 001 Mar 08, 1982

N018593 002 Mar 08, 1982

VERAPAMIL HYDROCHLORIDE

ACTAVIS ELIZABETH 80MG
120MG

A071019 001 Sep 24, 1986

A070468 001 Sep 24, 1986

HERITAGE PHARMS INC 80MG
120MG

A071880 001 Apr 05, 1988

A071881 001 Apr 05, 1988

MUTUAL PHARM 80MG
80MG
120MG
120MG

A070482 001 Sep 24, 1986

A071489 002 Jan 13, 1988

A070483 001 Sep 24, 1986

A071489 001 Jan 13, 1988

PLIVA 40MG
80MG
120MG

A072751 001 Feb 23, 1996

A072124 001 Jan 26, 1989

A072125 001 Jan 26, 1989

SANDOZ 40MG
80MG
120MG

A073168 001 Jul 31, 1992

A071423 001 May 24, 1988

A071424 001 May 25, 1988

WARNER CHILCOTT 80MG
120MG

A070340 001 Sep 24, 1986

A070341 001 Sep 24, 1986

WATSON LABS 40MG

A072799 001 Apr 28, 1989

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE
PLIVA 240MG

A072922 001 Mar 01, 1996

VERATRUM VIRIDE ROOT

TABLET; ORAL

VERTAVIS

MEDPOINTE PHARM HLC 130CSR UNIT

N005691 002

VIDARABINE

INJECTABLE; INJECTION

VIRA-A

PARKEDALE EQ 187.4MG BASE/ML

N050523 001

OINTMENT; OPHTHALMIC

VIRA-A

PARKEDALE 3%

N050486 001

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VELBAN

LILLY 10MG/VIAL

N012665 001

VINBLASTINE SULFATE

ABRAXIS PHARM 10MG/VIAL

A089011 001 Nov 18, 1985

HOSPIRA 10MG/VIAL

A089565 001 Aug 18, 1987

VINCRIStINE SULFATE

INJECTABLE; INJECTION

ONCOVIN

LILLY 1MG/VIAL
1MG/ML
5MG/VIAL

N014103 001

N014103 003 Mar 07, 1984

N014103 002

VINCASAR PFS

TEVA PARENTERAL 1MG/ML

A071426 001 Jul 17, 1987

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 357 (of 360)

VINCRIStINE SULFATEINJECTABLE; INJECTION
VINCREX

BRISTOL MYERS SQUIBB	5MG/VIAL	A070867	001	Jul 12, 1988
VINCRIStINE SULFATE				
ABIC	1MG/ML	A070873	001	Feb 19, 1987
ABRAXIS PHARM	1MG/ML	A070411	001	Sep 10, 1986
FRESENIUS KABI USA	1MG/ML	A076296	001	Dec 20, 2002
	1MG/ML	A076401	001	Oct 28, 2003
HOSPIRA	1MG/VIAL	A071559	001	Apr 11, 1988
	2MG/VIAL	A071560	001	Apr 11, 1988
	5MG/VIAL	A071561	001	Apr 11, 1988

VIOMYCIN SULFATEINJECTABLE; INJECTION
VIOCIN SULFATE

PFIZER	EQ 1GM BASE/VIAL	A061086	001	
	EQ 5GM BASE/VIAL	A061086	002	

VITAMIN A

CAPSULE; ORAL

AQUASOL A

ASTRAZENECA	25,000USP UNITS	A083080	002	
	50,000USP UNITS	A083080	001	

VITAMIN A

BANNER PHARMACAPS	50,000USP UNITS	A083973	001	
CHASE CHEM	50,000 IU	A083351	001	
EVERYLIFE	50,000 IU	A083134	001	
IMPAX LABS	50,000USP UNITS	A080952	001	
WEST WARD	50,000USP UNITS	A080985	001	

VITAMIN A PALMITATE

CAPSULE; ORAL

AFAXIN

STERLING WINTHROP	EQ 50,000 UNITS BASE	A083187	001	

ALPHALIN

LILLY	EQ 50,000 UNITS BASE	A080883	001	

DEL-VI-A

DEL RAY LABS	EQ 50,000 UNITS BASE	A080830	001	

VI-DOM-A

BAYER PHARMS	EQ 50,000 UNITS BASE	A080972	001	

VITAMIN A

BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A080702	001	
BRISTOL MYERS SQUIBB	EQ 50,000 UNITS BASE	A080860	001	
CHASE CHEM	EQ 50,000 UNITS BASE	A080746	001	
	EQ 50,000 UNITS BASE	A083207	001	
ELKINS SINN	EQ 50,000 UNITS BASE	A085479	001	
EVERYLIFE	EQ 50,000 UNITS BASE	A080943	001	
	EQ 50,000 UNITS BASE	A083114	001	
IMPAX LABS	EQ 50,000 UNITS BASE	A080953	001	
	EQ 50,000 UNITS BASE	A080955	001	
IVAX SUB TEVA PHARMS	EQ 50,000 UNITS BASE	A083035	001	
	EQ 50,000 UNITS BASE	A083190	001	
MK LABS	EQ 25,000 UNITS BASE	A083457	002	
	EQ 50,000 UNITS BASE	A083457	001	
WEST WARD	EQ 50,000 UNITS BASE	A080967	001	
WHARTON LABS	EQ 50,000 UNITS BASE	A083665	001	

VITAMIN A PALMITATE

ARCUM	EQ 50,000 UNITS BASE	A083311	001	
	EQ 50,000 UNITS BASE	A083321	001	
BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A083948	001	
	EQ 50,000 UNITS BASE	A083981	001	

33RD EDITION - 2013 - APPROVED DRUG PRODUCTS LIST

DISCONTINUED DRUG PRODUCT LIST

6 - 358 (of 360)

VITAMIN A PALMITATE

CAPSULE; ORAL				
VITAMIN A SOLUBILIZED				
TEVA	EQ 50,000 UNITS BASE	A080921	001	
INJECTABLE; INJECTION				
VITAMIN A PALMITATE				
BEL MAR	EQ 50,000 UNITS BASE/ML	A080819	001	

WARFARIN POTASSIUM

TABLET; ORAL				
ATHROMBIN-K				
PHARM RES ASSOC	2MG	N011771	007	
	5MG	N011771	004	
	10MG	N011771	005	
	25MG	N011771	006	

WARFARIN SODIUM

INJECTABLE; INJECTION				
COUMADIN				
BRISTOL MYERS SQUIBB	50MG/VIAL	N009218	020	
	75MG/VIAL	N009218	012	
TABLET; ORAL				
ATHROMBIN				
PHARM RES ASSOC	5MG	N011771	003	
	10MG	N011771	002	
	25MG	N011771	001	
PANWARFIN				
ABBOTT	2MG	N017020	001	
	2.5MG	N017020	002	
	5MG	N017020	003	
	7.5MG	N017020	004	
	10MG	N017020	005	
WARFARIN SODIUM				
SANDOZ	1MG	A040196	001	Sep 30, 1997
	2MG	A040196	002	Sep 30, 1997
	2.5MG	A040196	003	Sep 30, 1997
	3MG	A040196	008	Jul 26, 2000
	4MG	A040196	004	Sep 30, 1997
	5MG	A040196	005	Sep 30, 1997
	6MG	A040196	009	Jul 26, 2000
	7.5MG	A040196	006	Sep 30, 1997
	10MG	A040196	007	Sep 30, 1997
USL PHARMA	2MG	A088719	001	Jun 27, 1985
	2.5MG	A088720	001	Aug 06, 1985
	5MG	A088721	001	Jul 02, 1985
WATSON LABS	2MG	A086123	001	Aug 17, 1982
	2.5MG	A086120	001	Aug 17, 1982
	5MG	A086119	001	Aug 17, 1982
	7.5MG	A086118	001	Aug 17, 1982
	10MG	A086122	001	Aug 17, 1982

XENON XE-127

GAS; INHALATION				
XENON XE 127				
MALLINCKRODT	5mCi/VIAL	N018536	001	Oct 01, 1982
	10mCi/VIAL	N018536	002	Oct 01, 1982

XENON XE-133

GAS; INHALATION				
XENON XE 133				
GE HEALTHCARE	1 CI/AMP	N017256	002	
	10mCi/VIAL	N017687	002	
	20mCi/VIAL	N017687	003	

DISCONTINUED DRUG PRODUCT LIST

6 - 359 (of 360)

XENON XE-133

GAS; INHALATION				
XENON XE 133				
GEN ELECTRIC	5-100 CI/CYLINDER	N017550	001	
	0.25-5 CI/AMP	N017550	003	
MALLINCKRODT	10mCi/VIAL	N018327	001	Mar 09, 1982
	20mCi/VIAL	N018327	002	Mar 09, 1982
XENON XE 133-V.S.S.				
GE HEALTHCARE	10mCi/VIAL	N017687	001	
INJECTABLE; INJECTION				
XENON XE 133				
GE HEALTHCARE	1.3-1.7 CI/AMP	N017256	001	
LANTHEUS MEDCL	6.3mCi/ML	N017283	001	
SOLUTION; INHALATION, INJECTION				
XENEISOL				
MALLINCKRODT	18-25mCi/AMP	N017262	002	

XYLOSE

POWDER; ORAL				
XYLO-PFAN				
SAVAGE LABS	25GM/BOT	N017605	001	
XYLOSE				
LYNE	25GM/BOT	N018856	001	Mar 26, 1987

ZALCITABINE

TABLET; ORAL				
HIVID				
ROCHE	0.375MG	N020199	001	Jun 19, 1992
	0.75MG	N020199	002	Jun 19, 1992

ZALEPLON

CAPSULE; ORAL				
ZALEPLON				
SANDOZ	5MG	A078095	001	Jun 06, 2008
	10MG	A078095	002	Jun 06, 2008

ZICONOTIDE

INJECTABLE; INTRATHECAL				
PRIALT				
JAZZ PHARMS INTL	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004

ZIDOVUDINE

TABLET; ORAL				
RETROVIR				
VIIV HLTHCARE	200MG	N020518	001	Dec 19, 1995
ZIDOVUDINE				
AUROBINDO PHARMA	60MG	N022294	001	Jul 23, 2009
MATRIX LABS LTD	100MG	N200732	001	Feb 23, 2011
RANBAXY LABS LTD	300MG	A077327	001	Sep 19, 2005

ZILEUTON

TABLET; ORAL				
ZYFLO				
CORNERSTONE THERAP	300MG	N020471	001	Dec 09, 1996

ZINC SULFATE

INJECTABLE; INJECTION				
ZINC SULFATE				
ABRAXIS PHARM	EQ 1MG ZINC/ML	N019229	002	May 05, 1987

DISCONTINUED DRUG PRODUCT LIST

6 - 360 (of 360)

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOMETA

NOVARTIS

EQ 4MG BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety
or efficacy reasons**

N021223 001 Aug 20, 2001

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

MUTUAL PHARMA

5MG

A077288 001 Apr 23, 2007

10MG

A077288 002 Apr 23, 2007

MYLAN PHARMS INC

5MG

A078016 001 Apr 23, 2007

10MG

A078016 002 Apr 23, 2007

SYNTHON PHARMS

5MG

A077540 001 Apr 23, 2007

10MG

A077540 002 Apr 23, 2007

WORLD GEN

5MG

A076062 001 Apr 23, 2007

10MG

A076062 002 Apr 23, 2007

TABLET, ORALLY DISINTEGRATING; ORAL

TOVALT ODT

BIOVAIL LABS INTL

5MG

N021412 001 Apr 25, 2007

10MG

N021412 002 Apr 25, 2007

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

MUTUAL PHARM

25MG

A077635 001 Dec 22, 2005

50MG

A077635 002 Dec 22, 2005

100MG

A077635 003 Dec 22, 2005

ROXANE

25MG

A077648 001 Dec 22, 2005

50MG

A077648 002 Dec 22, 2005

100MG

A077648 003 Dec 22, 2005

TEVA PHARMS

25MG

A077641 003 Dec 22, 2005

50MG

A077641 002 Dec 22, 2005

100MG

A077641 001 Dec 22, 2005

WATSON LABS

25MG

A077650 001 Apr 20, 2006

50MG

A077650 002 Apr 20, 2006

100MG

A077650 003 Apr 20, 2006

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:
<http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

ACETAMINOPHEN;ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG
325MG;325MG;50MG

ASPIRIN;CAFFEINE;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
160MG;32MG;200MG;16MG

ACETAMINOPHEN;ASPIRIN;BUTALBITAL;
CAFFEINE
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG;40MG
325MG;325MG;50MG;40MG

ASPIRIN;CARISOPRODOL
TABLET; ORAL
325MG;200MG

ACETAMINOPHEN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG

ASPIRIN;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
325MG;200MG;16MG

ACETAMINOPHEN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG

ASPIRIN;MEPROBAMATE
TABLET; ORAL
325MG;200MG

AMINOPHYLLINE
TABLET; ORAL
100MG;200MG

ASPIRIN;METHOCARBAMOL
TABLET; ORAL
325MG;400MG

ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG
650MG;50MG

CHLOROTHIAZIDE
TABLET; ORAL
250MG

ASPIRIN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG
650MG;50MG;40MG

HYDROXYZINE HYDROCHLORIDE
TABLET; ORAL
10MG;25MG;
50MG;100MG

ASPIRIN;CAFFEINE;CARISOPRODOL
TABLET; ORAL
160MG;32MG;200MG

PREDNISONE
TABLET; ORAL
1MG;2.5MG;5MG;10MG;
20MG;25MG;50MG

APPENDIX A - PRODUCT NAME INDEX

A - 1

**** 8 ****

8-MOP, METHOXSALEN

**** A ****

ABACAVIR SULFATE, ABACAVIR SULFATE
ABELCET, AMPHOTERICIN B
ABILIFY, ARIPIPRAZOLE
ABLAVAR, GADOFOSVESET TRISODIUM
ABRAXANE, PACLITAXEL
ABREVA, DOCOSANOL (OTC)
ABSORICA, ISOTRETINOIN
ABSTRAL, FENTANYL CITRATE
ACANYA, BENZOYL PEROXIDE
ACARBOSE, ACARBOSE
ACCOLATE, ZAFIRLUKAST
ACCUNEB, ALBUTEROL SULFATE
ACUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ACEON, PERINDOPRIL ERBUMINE
ACEPHEN, ACETAMINOPHEN (OTC)
ACETADOTE, ACETYLCYSTEINE
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE, ACETAMINOPHEN
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ACETASOL HC, ACETIC ACID, GLACIAL
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL
ACETIC ACID, ACETIC ACID, GLACIAL
ACETOHEXAMIDE, ACETOHEXAMIDE
ACETYLCYSTEINE, ACETYLCYSTEINE
ACIPHEX, RABEPRAZOLE SODIUM
ACLOVATE, ALCLOMETASONE DIPROPIONATE
ACOVA, ARGATROBAN
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
ACTIGALL, URSODIOL
ACTIQ, FENTANYL CITRATE
ACTIVELLA, ESTRADIOL
ACTONEL, RISEDRONATE SODIUM
ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ACULAR LS, KETOROLAC TROMETHAMINE
ACULAR PRESERVATIVE FREE, KETOROLAC TROMETHAMINE
ACULAR, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, ACYCLOVIR SODIUM
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
ACZONE, DAPSONE
ADAGEN, PEGADEMASE BOVINE
ADALAT CC, NIFEDIPINE
ADAPALENE, ADAPALENE
ADASUVE, LOXAPINE
ADCIRCA, TADALAFIL
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE

APPENDIX A - PRODUCT NAME INDEX

A - 2

**** A ****

ADDERALL XR 5, AMPHETAMINE ASPARTATE
ADENOCARD, ADENOSINE
ADENOSCAN, ADENOSINE
ADENOSINE, ADENOSINE
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ADRENALICK, EPINEPHRINE
ADRENALIN, EPINEPHRINE
ADREVIEW, IOBENGUANE SULFATE I-123
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
ADVICOR, LOVASTATIN
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADVIL, IBUPROFEN (OTC)
ADVIL, IBUPROFEN SODIUM (OTC)
AEROBID, FLUNISOLIDE
AEROSPAN HFA, FLUNISOLIDE
AFEDITAB CR, NIFEDIPINE
AFINITOR DISPERZ, EVEROLIMUS
AFINITOR, EVEROLIMUS
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
AGGRENOLX, ASPIRIN
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AK-FLUOR 10%, FLUORESCEIN SODIUM
AK-FLUOR 25%, FLUORESCEIN SODIUM
AKINETON, BIPERIDEN HYDROCHLORIDE
AKNE-MYCIN, ERYTHROMYCIN
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKPRO, DIPIVEFRIN HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
ALA-CORT, HYDROCORTISONE
ALAMAST, PEMIROLAST POTASSIUM
ALA-SCALP, HYDROCORTISONE
ALAVERT, LORATADINE (OTC)
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALBALON, NAPHAZOLINE HYDROCHLORIDE
ALBENZA, ALBENDAZOLE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALCOHOL 10% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% AND DEXTROSE 5%, ALCOHOL
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ALDARA, IMIQUIMOD
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALEVE, NAPROXEN SODIUM (OTC)
ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)
ALFENTA, ALFENTANIL HYDROCHLORIDE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 3

**** A ****

ALIMTA, PEMETREXED DISODIUM
ALINIA, NITAZOXANIDE
ALKERAN, MELPHALAN
ALKERAN, MELPHALAN HYDROCHLORIDE
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLI, ORLISTAT (OTC)
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
ALLOPURINOL, ALLOPURINOL
ALOCRIL, NEDOCROMIL SODIUM
ALOMIDE, LODOXAMIDE TROMETHAMINE
ALOPRIM, ALLOPURINOL SODIUM
ALORA, ESTRADIOL
ALOXI, PALONOSETRON HYDROCHLORIDE
ALPHAGAN P, BRIMONIDINE TARTRATE
ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
ALREX, LOTEPREDNOL ETABONATE
ALSUMA, SUMATRIPTAN SUCCINATE
ALTABAX, RETAPAMULIN
ALTACE, RAMIPRIL
ALTAVERA, ETHINYL ESTRADIOL
ALTOPREV, LOVASTATIN
ALVESCO, CICLESONIDE
ALYACEN 1/35, ETHINYL ESTRADIOL
ALYACEN 7/7/7, ETHINYL ESTRADIOL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMARYL, GLIMEPIRIDE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBIEN, ZOLPIDEM TARTRATE
AMBISOME, AMPHOTERICIN B
AMCINONIDE, AMCINONIDE
AMERGE, NARATRIPTAN HYDROCHLORIDE
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
AMICAR, AMINOCAPROIC ACID
AMIDATE, ETOMIDATE
AMIFOSTINE, AMIFOSTINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMINO ACIDS, AMINO ACIDS
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC, AMINOCAPROIC ACID
AMINOHIPPURATE SODIUM, AMINOHIPPURATE SODIUM
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN 10% (PH6), AMINO ACIDS
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 3.5%, AMINO ACIDS
AMINOSYN 5%, AMINO ACIDS
AMINOSYN 7% (PH6), AMINO ACIDS
AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 7%, AMINO ACIDS
AMINOSYN 8.5% (PH6), AMINO ACIDS
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 10%, AMINO ACIDS

APPENDIX A - PRODUCT NAME INDEX

A - 4

**** A ****

AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 7%, AMINO ACIDS
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 8.5%, AMINO ACIDS
AMINOSYN-HBC 7%, AMINO ACIDS
AMINOSYN-HF 8%, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
AMINOSYN-RF 5.2%, AMINO ACIDS
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITIZA, LUBIPROSTONE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE
AMMONIA N 13, AMMONIA N-13
AMMONIA N 13, AMMONIA, N-13
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMMONIUM LACTATE, AMMONIUM LACTATE
AMMONUL, SODIUM BENZOATE
AMNESTEEM, ISOTRETINOIN
AMOXAPINE, AMOXAPINE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
AMOXIL, AMOXICILLIN
AMPHADASE, HYALURONIDASE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AMPHOTEC, AMPHOTERICIN B
AMPHOTERICIN B, AMPHOTERICIN B
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMPYRA, DALFAMPRIDINE
AMRINONE LACTATE, INAMRINONE LACTATE
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
AMTURNIDE, ALISKIREN HEMIFUMARATE
AMYVID, FLORBETAPIR F-18
ANADROL-50, OXYMETHOLONE
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ANAPROX DS, NAPROXEN SODIUM
ANAPROX, NAPROXEN SODIUM
ANASTROZOLE, ANASTROZOLE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCOBON, FLUCYTOSINE
ANDRODERM, TESTOSTERONE
ANDROGEL, TESTOSTERONE
ANDROID 10, METHYLTESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANESTACON, LIDOCAINE HYDROCHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
ANEXSIA 7.5/650, ACETAMINOPHEN
ANEXSIA, ACETAMINOPHEN
ANGELIQ, DROSPIRENONE
ANGIOMAX, BIVALIRUDIN
ANSAID, FLURBIPROFEN
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
ANTABUSE, DISULFIRAM
ANTARA (MICRONIZED), FENOFIBRATE
ANTHELIOS 20, AVOBENZONE (OTC)

APPENDIX A - PRODUCT NAME INDEX

A - 5

**** A ****

ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
ANTIVERT, MECLIZINE HYDROCHLORIDE
ANTIZOL, FOMEPIZOLE
ANTUROL, OXYBUTYNIN
ANUSOL HC, HYDROCORTISONE
ANZEMET, DOLASETRON MESYLATE
APHTHASOL, AMLEXANOX
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
APIDRA, INSULIN GLULISINE RECOMBINANT
APLENZIN, BUPROPION HYDROBROMIDE
APOKYN, APOMORPHINE HYDROCHLORIDE
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
APREPITANT, APREPITANT
APRISO, MESALAMINE
APTIVUS, TIPRANAVIR
AQUASOL A, VITAMIN A PALMITATE
ARALEN, CHLOROQUINE PHOSPHATE
ARANELLE, ETHINYL ESTRADIOL
ARAVA, LEFLUNOMIDE
ARCAPTA NEOHALER, INDACATEROL MALEATE
ARESTIN, MINOCYCLINE HYDROCHLORIDE
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARGATROBAN, ARGATROBAN
ARICEPT ODT, DONEPEZIL HYDROCHLORIDE
ARICEPT, DONEPEZIL HYDROCHLORIDE
ARIDOL KIT, MANNITOL
ARIMIDEX, ANASTROZOLE
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
ARIXTRA, FONDAPARINUX SODIUM
ARMODAFINIL, ARMODAFINIL
AROMASIN, EXEMESTANE
ARRANON, NELARABINE
ARTHROTEC, DICLOFENAC SODIUM
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAINE HYDROCHLORIDE
ARTICAINE HYDROCHLORIDE WITH EPINEPHRINE, ARTICAINE HYDROCHLORIDE
ASACOL HD, MESALAMINE
ASACOL, MESALAMINE
ASCLERA, POLIDOCANOL
ASMANEX TWISTHALER, MOMETASONE FUROATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ASPIRIN, ASPIRIN (OTC)
ASTELIN, AZELASTINE HYDROCHLORIDE
ASTEPRO, AZELASTINE HYDROCHLORIDE
ASTRAMORPH PF, MORPHINE SULFATE
ATACAND HCT, CANDESARTAN CILEXETIL
ATACAND, CANDESARTAN CILEXETIL
ATELVIA, RISEDRONATE SODIUM
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
ATIVAN, LORAZEPAM
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATRALIN, TRETINOIN
ATRIDOX, DOXYCYCLINE HYCLATE
ATRIPLA, EFAVIRENZ
ATROPEN, ATROPINE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
ATROVENT HFA, IPRATROPIUM BROMIDE
ATROVENT, IPRATROPIUM BROMIDE
AUBAGIO, TERIFLUNOMIDE
AUGMENTIN '125', AMOXICILLIN

APPENDIX A - PRODUCT NAME INDEX

A - 6

**** A ****

AUGMENTIN '200', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '400', AMOXICILLIN
AUGMENTIN '500', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN
AUVI-Q, EPINEPHRINE
AVAGARD, ALCOHOL (OTC)
AVAGE, TAZAROTENE
AVALIDE, HYDROCHLOROTHIAZIDE
AVANDAMET, METFORMIN HYDROCHLORIDE
AVANDARYL, GLIMEPIRIDE
AVANDIA, ROSIGLITAZONE MALEATE
AVAPRO, IRBESARTAN
AVC, SULFANILAMIDE
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
AVENTYL HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
AVIANE-28, ETHINYL ESTRADIOL
AVINZA, MORPHINE SULFATE
AVITA, TRETINOIN
AVODART, DUTASTERIDE
AXERT, ALMOTRIPTAN MALATE
AXID AR, NIZATIDINE (OTC)
AXID, NIZATIDINE
AXIRON, TESTOSTERONE
AYGESTIN, NORETHINDRONE ACETATE
AZACTAM IN PLASTIC CONTAINER, AZTREONAM
AZACTAM, AZTREONAM
AZASAN, AZATHIOPRINE
AZASITE, AZITHROMYCIN
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZATHIOPRINE, AZATHIOPRINE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZELEX, AZELAIC ACID
AZILECT, RASAGILINE MESYLATE
AZITHROMYCIN, AZITHROMYCIN
AZITHROMYCIN, AZITHROMYCIN, UNSPECIFIED FORM
AZOPT, BRINZOLAMIDE
AZOR, AMLODIPINE BESYLATE
AZTREONAM, AZTREONAM
AZULFIDINE EN-TABS, SULFASALAZINE
AZULFIDINE, SULFASALAZINE

**** B ****

BACIIM, BACITRACIN
BACI-RX, BACITRACIN
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
BACLOFEN, BACLOFEN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BACTRIM DS, SULFAMETHOXAZOLE
BACTRIM, SULFAMETHOXAZOLE
BACTROBAN, MUPIROCIN
BACTROBAN, MUPIROCIN CALCIUM
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BALZIVA-28, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

A - 7

**** B ****

BANZEL, RUFINAMIDE
BARACLUDE, ENTECAVIR
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
BELVIQ, LORCaserin HYDROCHLORIDE
BENZAEPRIl HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENZAEPRIl HYDROCHLORIDE
BENZAEPRIl HYDROCHLORIDE, BENZAEPRIl HYDROCHLORIDE
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENICAR, OLMESARTAN MEDOXOMIL
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BENZACLIN, BENZOYL PEROXIDE
BENZAMYCIN PAK, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE
BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BEPREVE, BEPOTASTINE BESILATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
BETADINE, POVIDONE-IODINE
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAPACE, SOTALOL HYDROCHLORIDE
BETA-VAL, BETAMETHASONE VALERATE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BETHKIS, TOBRAMYCIN
BETIMOL, TIMOLOL
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BEYAZ, DROSPIRENONE
BIAXIN XL, CLARITHROMYCIN
BIAXIN, CLARITHROMYCIN
BICALUTAMIDE, BICALUTAMIDE
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICNU, CARMUSTINE
BIDIL, HYDRALAZINE HYDROCHLORIDE
BILTRICIDE, PRAZIQUANTEL
BINOSTO, ALENDRONATE SODIUM
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BLEPH-10, SULFACETAMIDE SODIUM
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLEPHAMIDE, PREDNISOLONE ACETATE
BONIVA, IBANDRONATE SODIUM
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BONTRIL, PHENDIMETRAZINE TARTRATE
BOSULIF, BOSUTINIB MONOHYDRATE
BRANCHAMIN 4% IN PLASTIC CONTAINER, AMINO ACIDS
BRAVELLE, UROFOLLITROPIN
BREATHTEK UBT FOR H-PYLORI, UREA C-13
BRETILIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETILIUM TOSYLATE
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
BREVICON 28-DAY, ETHINYL ESTRADIOL
BREVITAL SODIUM, METHOHEXITAL SODIUM
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)

APPENDIX A - PRODUCT NAME INDEX

A - 8

**** B ****

BRIELLYN, ETHINYL ESTRADIOL
BRILINTA, TICAGRELOR
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BROMDAY, BROMFENAC SODIUM
BROMFED-DM, BROMPHENIRAMINE MALEATE
BROMFENAC SODIUM, BROMFENAC SODIUM
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BRONCHO SALINE, SODIUM CHLORIDE (OTC)
BROVANA, ARFORMOTEROL TARTRATE
BSS PLUS, CALCIUM CHLORIDE
BSS, CALCIUM CHLORIDE
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUPHENYL, SODIUM PHENYLBUTYRATE
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUSULFEX, BUSULFAN
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
BUTAPAP, ACETAMINOPHEN
BUTISOL SODIUM, BUTABARBITAL SODIUM
BUTOCONAZOLE NITRATE, BUTOCONAZOLE NITRATE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
BUTRANS, BUPRENORPHINE
BYDUREON, EXENATIDE SYNTHETIC
BYETTA, EXENATIDE SYNTHETIC
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE

**** C ****

CABERGOLINE, CABERGOLINE
CADUET, AMLODIPINE BESYLATE
CAFCIT, CAFFEINE CITRATE
CAFERGOT, CAFFEINE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALAN SR, VERAPAMIL HYDROCHLORIDE
CALAN, VERAPAMIL HYDROCHLORIDE
CALCIJEX, CALCITRIOL
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CALCITONIN-SALMON, CALCITONIN SALMON
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
CALDOLOR, IBUPROFEN
CAMBIA, DICLOFENAC POTASSIUM
CAMILA, NORETHINDRONE
CAMPRAL, ACAMPROSATE CALCIUM
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CANASA, MESALAMINE
CANCIDAS, CASPOFUNGIN ACETATE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL

APPENDIX A - PRODUCT NAME INDEX

A - 9

**** C ****

CANTIL, MEPENZOLATE BROMIDE
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CAPEX, FLUOCINOLONE ACETONIDE
CAPITAL AND CODEINE, ACETAMINOPHEN
CAPITAL SOLEIL 15, AVOBENZONE (OTC)
CAPOTEN, CAPTOPRIL
CAPOZIDE 25/15, CAPTOPRIL
CAPOZIDE 25/25, CAPTOPRIL
CAPOZIDE 50/15, CAPTOPRIL
CAPOZIDE 50/25, CAPTOPRIL
CAPRELSA, VANDETANIB
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CARAC, FLUOROURACIL
CARAFATE, SUCRALFATE
CARBAGLU, CARGLUMIC ACID
CARBAMAZEPINE, CARBAMAZEPINE
CARBATROL, CARBAMAZEPINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE SR, NICARDIPINE HYDROCHLORIDE
CARDENE, NICARDIPINE HYDROCHLORIDE
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CARDURA XL, DOXAZOSIN MESYLATE
CARDURA, DOXAZOSIN MESYLATE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CARMOL HC, HYDROCORTISONE ACETATE
CARNITOR SF, LEVOCARNITINE
CARNITOR, LEVOCARNITINE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CASODEX, BICALUTAMIDE
CATAFLAM, DICLOFENAC POTASSIUM
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
CAVERJECT IMPULSE, ALPROSTADIL
CAVERJECT, ALPROSTADIL
CAYSTON, AZTREONAM
CEDAX, CEFTIBUTEN DIHYDRATE
CEENU, LOMUSTINE
CEFACLOL, CEFACLOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN AND DEXTROSE, CEFZOLIN SODIUM
CEFAZOLIN SODIUM, CEFZOLIN SODIUM
CEFDINIR, CEFdinir
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 10

**** C ****

CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFOTAXIME, CEFOTAXIME SODIUM
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOTETAN, CEFOTETAN DISODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFOXITIN, CEFOTAXIME SODIUM
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
CEFTAZIDIME, CEFTAZIDIME
CEFTIN, CEFUROXIME AXETIL
CEFTRIAZONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAZONE SODIUM
CEFTRIAZONE IN PLASTIC CONTAINER, CEFTRIAZONE SODIUM
CEFTRIAZONE, CEFTRIAZONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEFUROXIME SODIUM IN PLASTIC CONTAINER, CEFUROXIME SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CELEBREX, CELECOXIB
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELEXA, CITALOPRAM HYDROBROMIDE
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A
CENTANY, MUPIROCIN
CEPHALEXIN, CEPHALEXIN
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CEREZYME, IMIGLUCERASE
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CERVIDIL, DINOPROSTONE
CESAMET, NABILONE
CETAMIDE, SULFACETAMIDE SODIUM
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE
CETROTIDE, CETRORELIX
CEVIMELINE, CEVIMELINE HYDROCHLORIDE
CHANTIX, VARENICLINE TARTRATE
CHEMET, SUCCIMER
CHENODIOL, CHENODIOL
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CLARITIN, LORATADINE (OTC)
CHILDREN'S ELIXSURE, IBUPROFEN (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN

APPENDIX A - PRODUCT NAME INDEX

A - 11

**** C ****

CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)
CHLORASCRUB MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORASCRUB SWAB, CHLORHEXIDINE GLUCONATE (OTC)
CHLORASCRUB SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
CHLORZOXAZONE, CHLORZOXAZONE
CHOLAC, LACTULOSE
CHOLEDYL SA, OXTRIPHYLLINE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLINE C-11, CHOLINE C-11
CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIALIS, TADALAFIL
CICLOPIROX, CICLOPIROX
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)
CIDOFOVIR, CIDOFOVIR
CILOSTAZOL, CILOSTAZOL
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRO XR, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CISATRAURIUM BESYLATE PRESERVATIVE FREE, CISATRAURIUM BESYLATE
CISATRAURIUM BESYLATE, CISATRAURIUM BESYLATE
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CISPLATIN, CISPLATIN
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
CLADRIBINE, CLADRIBINE
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN, CEFOTAXIME SODIUM
CLARAVIS, ISOTRETINOIN
CLARINEX D 24 HOUR, DESLORATADINE

APPENDIX A - PRODUCT NAME INDEX

A - 12

**** C ****

CLARINEX, DESLORATADINE
CLARINEX-D 12 HOUR, DESLORATADINE
CLARITHROMYCIN, CLARITHROMYCIN
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
CLEVIPREX, CLEVIDIPINE BUTYRATE
CLIMARA PRO, ESTRADIOL
CLIMARA, ESTRADIOL
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDESSE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS

APPENDIX A - PRODUCT NAME INDEX

A - 13

**** C ****

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CLINORIL, SULINDAC
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOBEX, CLOBETASOL PROPIONATE
CLODERM, CLOCORTOLONE PIVALATE
CLOLAR, CLOFARABINE
CLOMID, CLOMIPHENE CITRATE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLONIDINE, CLONIDINE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLORPRES, CHLORTHALIDONE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
CLOZAPINE, CLOZAPINE
CLOZARIL, CLOZAPINE
COARTEM, ARTEMETHER
CODEINE SULFATE, CODEINE SULFATE
COGENTIN, BENZTROPINE MESYLATE
CO-GESIC, ACETAMINOPHEN
COLAZAL, BALSALAZIDE DISODIUM
COLCRYS, COLCHICINE
COLESTID, COLESTIPOL HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COL-PROBENECID, COLCHICINE
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COLYTE, POLYETHYLENE GLYCOL 3350
COLYTE-FLAVORED, POLYETHYLENE GLYCOL 3350
COMBIGAN, BRIMONIDINE TARTRATE
COMBIPATCH, ESTRADIOL
COMBIVENT RESPIMAT, ALBUTEROL SULFATE
COMBIVENT, ALBUTEROL SULFATE
COMBIVIR, LAMIVUDINE
COMETRIQ, CABOZANTINIB S-MALATE
COMMIT, NICOTINE POLACRILEX (OTC)
COMPLERA, EMTRICITABINE
COMPRO, PROCHLORPERAZINE
COMTAN, ENTACAPONE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
CONDYLOX, PODOFILOX
CONRAY 30, IOTHALAMATE MEGLUMINE
CONRAY 43, IOTHALAMATE MEGLUMINE
CONRAY, IOTHALAMATE MEGLUMINE
CONSTILAC, LACTULOSE
CONSTULOSE, LACTULOSE
CONZIP, TRAMADOL HYDROCHLORIDE
COPAXONE, GLATIRAMER ACETATE
COPEGUS, RIBAVIRIN
CORDARONE, AMIODARONE HYDROCHLORIDE
CORDRAN SP, FLURANDRENOLIDE
CORDRAN, FLURANDRENOLIDE
COREG CR, CARVEDILOL PHOSPHATE
COREG, CARVEDILOL
CORGARD, NADOLOL

APPENDIX A - PRODUCT NAME INDEX

A - 14

**** C ****

CORLOPAM, FENOLDOPAM MESYLATE
CORMAX, CLOBETASOL PROPIONATE
CORTEF, HYDROCORTISONE
CORTENEMA, HYDROCORTISONE
CORTIFOAM, HYDROCORTISONE ACETATE
CORTISONE ACETATE, CORTISONE ACETATE
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE
CORTISPORIN, HYDROCORTISONE ACETATE
CORTROSYN, COSYNTROPIN
CORVERT, IBUTILIDE FUMARATE
CORZIDE, BENDROFLUMETHIAZIDE
COSMEGEN, DACTINOMYCIN
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COSYNTROPIN, COSYNTROPIN
COUMADIN, WARFARIN SODIUM
COVERA-HS, VERAPAMIL HYDROCHLORIDE
COZAAR, LOSARTAN POTASSIUM
CREON, LIPASE
CRESTOR, ROSUVASTATIN CALCIUM
CRINONE, PROGESTERONE
CRIXIVAN, INDINAVIR SULFATE
CROLOM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
CROTAN, CROTAMITON
CRYSELLE, ETHINYL ESTRADIOL
C-SOLVE-2, ERYTHROMYCIN
CUBICIN, DAPTOMYCIN
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CUPRIMINE, PENICILLAMINE
CUROSURF, PORACTANT ALFA
CUTIVATE, FLUTICASONE PROPIONATE
CUVPOSA, GLYCOPYRROLATE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYANOKIT, HYDROXOCOBALAMIN
CYCLAFEM 1/35, ETHINYL ESTRADIOL
CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
CYCLESSA, DESOGESTREL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSET, BROMOCRIPTINE MESYLATE
CYCLOSPORINE, CYCLOSPORINE
CYKLOKAPRON, TRANEXAMIC ACID
CYMBALTA, DULOXETINE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
CYSTADANE, BETAINE HYDROCHLORIDE
CYSTAGON, CYSTEAMINE BITARTRATE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE
CYTARABINE, CYTARABINE
CYTOMEL, LIOTHYRONINE SODIUM
CYTOSAR-U, CYTARABINE
CYTOTEC, MISOPROSTOL
CYTOVENE, GANCICLOVIR SODIUM
CYTOXAN, CYCLOPHOSPHAMIDE

APPENDIX A - PRODUCT NAME INDEX

A - 15

**** D ****

D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DACARBAZINE, DACARBAZINE
DACOGEN, DECITABINE
DACTINOMYCIN, DACTINOMYCIN
DALIRESP, ROFLUMILAST
DANAZOL, DANAZOL
DANTRIUM, DANTROLENE SODIUM
DANTROLENE SODIUM, DANTROLENE SODIUM
DAPSONE, DAPSONE
DARAPRIM, PYRIMETHAMINE
DASETTA 1/35, ETHINYL ESTRADIOL
DASETTA 7/7/7, ETHINYL ESTRADIOL
DATSCAN, IOFLUPANE I-123
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DAUNOXOME, DAUNORUBICIN CITRATE
DAYPRO, OXAPROZIN
DAYTRANA, METHYLPHENIDATE
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DDAVP, DESMOPRESSIN ACETATE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEFINITY, PERFLUTREN
DELATESTRYL, TESTOSTERONE ENANTHATE
DELESTROGEN, ESTRADIOL VALERATE
Delflex W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
Delflex-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
DEMADEX, TORSEMIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEMSE, METYROSINE
DENAVID, PENCICLOVIR SODIUM
DENDRID, IDOXURIDINE
DEPAON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
DEPEN, PENICILLAMINE
DEPOCYT, CYTARABINE
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DERMABET, BETAMETHASONE VALERATE
DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE
DERMATOP E EMOLLIENT, PREDNICARBATE
DERMATOP, PREDNICARBATE
DERMOTIC, FLUOCINOLONE ACETONIDE
DESFERAL, DEFEROXAMINE MESYLATE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
DESLORATADINE, DESLORATADINE

APPENDIX A - PRODUCT NAME INDEX

A - 16

**** D ****

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESOGEN, DESOGESTREL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DESONATE, DESONIDE
DESONIDE, DESONIDE
DESOWEN, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
DETROL LA, TOLTERODINE TARTRATE
DETROL, TOLTERODINE TARTRATE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE, DEXAMETHASONE
DEXASPORIN, DEXAMETHASONE
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DEXFERRUM, IRON DEXTRAN
DEXILANT, DEXLANSOPRAZOLE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE ASPARTATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 25%, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX A - PRODUCT NAME INDEX

A - 17

**** D ****

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER,
DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIABETA, GLYBURIDE
DIABINESE, CHLORPROPAMIDE
DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIAMOX, ACETAZOLAMIDE
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIASTAT ACUDIAL, DIAZEPAM
DIASTAT, DIAZEPAM
DIAZEPAM INTENSOL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DIBENZYLIN, PHENOXYBENZAMINE HYDROCHLORIDE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE), DICYCLOMINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIDANOSINE, DIDANOSINE
DIDREX, BENZPHETAMINE HYDROCHLORIDE
DIDRONEL, ETIDRONATE DISODIUM
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DIFFERIN, ADAPALENE
DIFICID, FIDAXOMICIN
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
DIFLUCAN, FLUCONAZOLE

APPENDIX A - PRODUCT NAME INDEX

A - 18

**** D ****

DIFLUNISAL, DIFLUNISAL
DIGOXIN, DIGOXIN
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DILACOR XR, DILTIAZEM HYDROCHLORIDE
DILANTIN, PHENYTOIN
DILANTIN, PHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN
DILATRATE-SR, ISOSORBIDE DINITRATE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE
DILT-CD, DILTIAZEM HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DILTZAC, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
DIPENTUM, OLSALAZINE SODIUM
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPIVEFRIN HYDROCHLORIDE, DIPIVEFRIN HYDROCHLORIDE
DIPRIVAN, PROPOFOL
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOPHROL, DEXBROMPHENIRAMINE MALEATE (OTC)
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISULFIRAM, DISULFIRAM
DITROPAN XL, OXYBUTYNIN CHLORIDE
DIURIL, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DIVIGEL, ESTRADIOL
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOCEFREZ, DOCETAXEL
DOCETAXEL, DOCETAXEL
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DOPRAM, DOXAPRAM HYDROCHLORIDE
DORAL, QUAZEPAM
DORIBAX, DORIPENEM
DORYX, DOXYCYCLINE HYCLATE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOVONEX, CALCIPOTRIENE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXIL, DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)

APPENDIX A - PRODUCT NAME INDEX

A - 19

**** D ****

DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
DRISDOL, ERGOCALCIFEROL
DRIXORAL PLUS, ACETAMINOPHEN (OTC)
DRIXORAL, DEXBROMPHENIRAMINE MALEATE (OTC)
DRONABINOL, DRONABINOL
DROPERIDOL, DROPERIDOL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DROXIA, HYDROXYUREA
DTIC-DOME, DACARBAZINE
DTPA, TECHNETIUM TC-99M PENTETATE KIT
DUAC, BENZOYL PEROXIDE
DUETACT, GLIMEPIRIDE
DUEXIS, FAMOTIDINE
DULERA, FORMOTEROL FUMARATE
DUODOTE, ATROPINE
DUONEB, ALBUTEROL SULFATE
DURACLON, CLONIDINE HYDROCHLORIDE
DURAGESIC-100, FENTANYL
DURAGESIC-12, FENTANYL
DURAGESIC-25, FENTANYL
DURAGESIC-50, FENTANYL
DURAGESIC-75, FENTANYL
DURAMORPH PF, MORPHINE SULFATE
DURAPREP, IODINE POVACRYLEX (OTC)
DUREZOL, DIFLUPREDNATE
DUTASTERIDE, DUTASTERIDE
DUTOPROL, HYDROCHLOROTHIAZIDE
DUVOID, BETHANECHOL CHLORIDE
DYAZIDE, HYDROCHLOROTHIAZIDE
DYMISTA, AZELASTINE HYDROCHLORIDE
DYNACIN, MINOCYCLINE HYDROCHLORIDE
DYNACIRC CR, ISRADIPINE
DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)
DYRENIUM, TRIAMTERENE

**** E ****

E.E.S. 200, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
EC-NAPROSYN, NAPROXEN
ECONAZOLE NITRATE, ECONAZOLE NITRATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EDEX, ALPROSTADIL
EDLUAR, ZOLPIDEM TARTRATE
EDURANT, RILPIVIRINE HYDROCHLORIDE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFIENT, PRASUGREL HYDROCHLORIDE
EFUDEX, FLUOROURACIL
EGRIFTA, TESAMORELIN ACETATE
ELDEPRYL, SELEGILINE HYDROCHLORIDE
ELELYSO, TALIGLUCERASE ALFA
ELESTAT, EPINASTINE HYDROCHLORIDE
ELESTRIN, ESTRADIOL
ELIDEL, PIMECROLIMUS
ELIGARD, LEUPROLIDE ACETATE
ELIMITE, PERMETHRIN
ELINEST, ETHINYL ESTRADIOL
ELIPHOS, CALCIUM ACETATE
ELIQUIS, APIXABAN
ELIXOPHYLLIN, THEOPHYLLINE

APPENDIX A - PRODUCT NAME INDEX

A - 20

**** E ****

ELLA, ULIPRISTAL ACETATE
ELLENC, EPIRUBICIN HYDROCHLORIDE
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
ELOCON, MOMETASONE FUROATE
ELOXATIN, OXALIPLATIN
EMADINE, EMEDASTINE DIFUMARATE
EMBEDA, MORPHINE SULFATE
EMBELINE E, CLOBETASOL PROPIONATE
EMBELINE, CLOBETASOL PROPIONATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
EMEND, APREPITANT
EMEND, FOSAPREPITANT DIMEGLUMINE
EMLA, LIDOCAINE
EMOQUETTE, DESOGESTREL
EMSAM, SELEGILINE
EMTRIVA, EMTRICITABINE
ENABLEX, DARIFENACIN HYDROBROMIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENALAPRILAT, ENALAPRILAT
ENDOMETRIN, PROGESTERONE
ENDOSOL EXTRA, CALCIUM CHLORIDE
ENFLURANE, ENFLURANE
ENJUVIA, ESTROGENS, CONJUGATED SYNTHETIC B
ENLON, EDROPHONIUM CHLORIDE
ENLON-PLUS, ATROPINE SULFATE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
ENPRESSE-28, ETHINYL ESTRADIOL
ENTACAPONE, ENTACAPONE
ENTEREG, ALVIMOPAN
ENTOCORT EC, BUDESONIDE
ENULOSE, LACTULOSE
EOVIST, GADOXETATE DISODIUM
EPIDUO, ADAPALENE
EPIFOAM, HYDROCORTISONE ACETATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPINEPHRINE, EPINEPHRINE (OTC)
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
EPITOL, CARBAMAZEPINE
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
EPLERENONE, EPLERENONE
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPROSARTAN MESYLATE, EPROSARTAN MESYLATE
EPZICOM, ABACAVIR SULFATE
EQUETRO, CARBAMAZEPINE
ERAXIS, ANIDULAFUNGIN
ERGOCALCIFEROL, ERGOCALCIFEROL
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERGOMAR, ERGOTAMINE TARTRATE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ERIVEDGE, VISMODEGIB
ERRIN, NORETHINDRONE
ERTACZO, SERTACONAZOLE NITRATE
ERYC, ERYTHROMYCIN
ERYGEL, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERY-TAB, ERYTHROMYCIN
ERYTHRA-DERM, ERYTHROMYCIN
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE

APPENDIX A - PRODUCT NAME INDEX

A - 21

**** E ****

ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN, ERYTHROMYCIN
ERYTHRO-STATIN, ERYTHROMYCIN
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESGIC-PLUS, ACETAMINOPHEN
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESTARYLLA, ETHINYL ESTRADIOL
ESTAZOLAM, ESTAZOLAM
ESTRACE, ESTRADIOL
ESTRADERM, ESTRADIOL
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL AND NORGESTIMATE, ESTRADIOL
ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRADIOL, ESTRADIOL
ESTRASORB, ESTRADIOL HEMIHYDRATE
ESTRING, ESTRADIOL
ESTROGEL, ESTRADIOL
ESTRONE, ESTRONE
ESTROPIPATE, ESTROPIPATE
ESTROSTEP FE, ETHINYL ESTRADIOL
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHAMOLIN, ETHANOLAMINE OLEATE
ETHOSUXIMIDE, ETHOSUXIMIDE
ETHRANE, ENFLURANE
ETHYOL, AMIFOSTINE
ETIDRONATE DISODIUM, ETIDRONATE DISODIUM
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
ETOPOSIDE, ETOPOSIDE
EURAX, CROTAMITON
EVAMIST, ESTRADIOL
EVISTA, RALOXIFENE HYDROCHLORIDE
EVOCLIN, CLINDAMYCIN PHOSPHATE
EVOXAC, CEVIMELINE HYDROCHLORIDE
EXALGO, HYDROMORPHONE HYDROCHLORIDE
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
EXELDERM, SULCONAZOLE NITRATE
EXELON, RIVASTIGMINE
EXELON, RIVASTIGMINE TARTRATE
EXEMESTANE, EXEMESTANE
EXFORGE HCT, AMLODIPINE BESYLATE
EXFORGE, AMLODIPINE BESYLATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
EXJADE, DEFERASIROX
EXPAREL, BUPIVACAINE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
EXTINA, KETOCONAZOLE
EXTRANEAL, ICODextrin
E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)

**** F ****

FABIOR, TAZAROTENE
FACTIVE, GEMIFLOXACIN MESYLATE
FALMINA, ETHINYL ESTRADIOL
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK), FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE

APPENDIX A - PRODUCT NAME INDEX

A - 22

**** F ****

FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FAMVIR, FAMCICLOVIR
FANAPT, ILOPERIDONE
FARESTON, TOREMIFENE CITRATE
FASLODEX, FULVESTRANT
FAZACLO ODT, CLOZAPINE
FELBAMATE, FELBAMATE
FELBATOL, FELBAMATE
FELDENE, PIROXICAM
FELODIPINE, FELODIPINE
FEMARA, LETROZOLE
FEMCON FE, ETHINYL ESTRADIOL
FEMHRT, ETHINYL ESTRADIOL
FEMRING, ESTRADIOL ACETATE
FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)
FEMTRACE, ESTRADIOL ACETATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FENOGLIDE, FENOFIBRATE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
FENTORA, FENTANYL CITRATE
FERAHEME, FERUMOXYTOL
FERRIPROX, DEFERIPRONE
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FIBRICOR, FENOFIBRIC ACID
FINACEA, AZELAIC ACID
FINASTERIDE, FINASTERIDE
FIORICET W/ CODEINE, ACETAMINOPHEN
FIORICET, ACETAMINOPHEN
FIORINAL W/CODEINE, ASPIRIN
FIORINAL, ASPIRIN
FIRAZYR, ICATIBANT ACETATE
FIRMAGON, DEGARELIX ACETATE
FLAGYL ER, METRONIDAZOLE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAGYL, METRONIDAZOLE
FLAREX, FLUOROMETHOLONE ACETATE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLECTOR, DICLOFENAC EPOLAMINE
FLOLAN, EPOPROSTENOL SODIUM
FLOMAX, TAMSULOSIN HYDROCHLORIDE
FLONASE, FLUTICASONE PROPIONATE
FLO-PRED, PREDNISOLONE ACETATE
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
FLOVENT HFA, FLUTICASONE PROPIONATE

APPENDIX A - PRODUCT NAME INDEX

A - 23

**** F ****

FLOXIN OTIC, OFLOXACIN
FLOXURIDINE, FLOXURIDINE
FLUCANAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUCONAZOLE, FLUCONAZOLE
FLUCYTOSINE, FLUCYTOSINE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUDEOXYGLUCOSE F 18, FLUDEOXYGLUCOSE F-18
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLUMAZENIL, FLUMAZENIL
FLUNISOLIDE, FLUNISOLIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUORESCITE, FLUORESCIN SODIUM
FLUOROPLEX, FLUOROURACIL
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUOXYMESTERONE, FLUOXYMESTERONE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
FLURBIPROFEN, FLURBIPROFEN
FLUTAMIDE, FLUTAMIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FML FORTE, FLUROMETHOLONE
FML, FLUROMETHOLONE
FOAMCOAT, ALUMINUM HYDROXIDE (OTC)
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
FOLOTYN, PRALATREXATE
FOMEPIZOLE, FOMEPIZOLE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
FORADIL, FORMOTEROL FUMARATE
FORANE, ISOFLURANE
FORFIVO XL, BUPROPION HYDROCHLORIDE
FORTAMET, METFORMIN HYDROCHLORIDE
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
FORTAZ, CEFTAZIDIME
FORTEO, TERIPARATIDE RECOMBINANT HUMAN
FORTESTA, TESTOSTERONE
FORTICAL, CALCITONIN SALMON RECOMBINANT
FOSAMAX PLUS D, ALENDRONATE SODIUM
FOSAMAX, ALENDRONATE SODIUM
FOSCARNET SODIUM, FOSCARNET SODIUM
FOSCAVIR, FOSCARNET SODIUM
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FOSRENOL, LANTHANUM CARBONATE
FRAGMIN, DALTEPARIN SODIUM
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS

APPENDIX A - PRODUCT NAME INDEX

A - 24

**** F ****

FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
 FREAMINE III 8.5%, AMINO ACIDS
 FROVA, FROVATRIPTAN SUCCINATE
 FULCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 FULYZAQ, CROFELEMER
 FURADANTIN, NITROFURANTOIN
 FUROSEMIDE, FUROSEMIDE
 FUSILEV, LEVOLEUCOVORIN CALCIUM
 FUZEON, ENFUVIRTIDE
 FYCOMPA, PERAMPANEL

**** G ****

GABAPENTIN, GABAPENTIN
 GABITRIL, TIAGABINE HYDROCHLORIDE
 GABLOFEN, BACLOFEN
 GADAVIST, GADOBUTROL
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
 GALZIN, ZINC ACETATE
 GANCICLOVIR, GANCICLOVIR SODIUM
 GANIRELIX ACETATE INJECTION, GANIRELIX ACETATE
 GANITE, GALLIUM NITRATE
 GASTROCROM, CROMOLYN SODIUM
 GASTROGRAFIN, DIATRIZOATE MEGLUMINE
 GASTROMARK, FERUMOXASIL
 GATIFLOXACIN, GATIFLOXACIN
 GATTEX KIT, TEDUGLUTIDE
 GAVISCON, ALUMINUM HYDROXIDE (OTC)
 GELNIQUE, OXYBUTYNIN CHLORIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GEMFIBROZIL, GEMFIBROZIL
 GEMZAR, GEMCITABINE HYDROCHLORIDE
 GENERLAC, LACTULOSE
 GENGRAF, CYCLOSPORINE
 GENOPTIC, GENTAMICIN SULFATE
 GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
 GENOTROPIN, SOMATROPIN RECOMBINANT
 GENTAK, GENTAMICIN SULFATE
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 GEN-XENE, CLORAZEPATE DIPOTASSIUM
 GEODON, ZIPRASIDONE HYDROCHLORIDE
 GEODON, ZIPRASIDONE MESYLATE
 GIAZO, BALSALAZIDE DISODIUM
 GILDAGIA, ETHINYL ESTRADIOL
 GILDESS FE 1.5/30, ETHINYL ESTRADIOL
 GILDESS FE 1/20, ETHINYL ESTRADIOL
 GILENYA, FINGOLIMOD
 GLEEVEC, IMATINIB MESYLATE
 GLIADEL, CARMUSTINE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GLIPIZIDE, GLIPIZIDE
 GLOFIL-125, IOTHALAMATE SODIUM I-125
 GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT
 GLUCAGON, GLUCAGON RECOMBINANT
 GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
 GLUCOPHAGE, METFORMIN HYDROCHLORIDE
 GLUCOTROL XL, GLIPIZIDE
 GLUCOTROL, GLIPIZIDE
 GLUCOVANCE, GLYBURIDE
 GLUMETZA, METFORMIN HYDROCHLORIDE
 GLYBURIDE (MICRONIZED), GLYBURIDE

APPENDIX A - PRODUCT NAME INDEX

A - 25

**** G ****

GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GLYBURIDE, GLYBURIDE
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
 GLYCOLAX, POLYETHYLENE GLYCOL 3350
 GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GLYNASE, GLYBURIDE
 GLYSET, MIGLITOL
 GOLYTELY, POLYETHYLENE GLYCOL 3350
 GONAL-F RFF PEN, FOLLITROPIN ALFA/BETA
 GONAL-F RFF, FOLLITROPIN ALFA/BETA
 GONAL-F, FOLLITROPIN ALFA/BETA
 GRALISE, GABAPENTIN
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GRANISTERON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GRIFULVIN V, GRISEOFULVIN, MICROSIZE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
 GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
 GUAIFENESIN, GUAIFENESIN (OTC)
 GUANABENZ ACETATE, GUANABENZ ACETATE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
 GYNAZOLE-1, BUTOCONAZOLE NITRATE
 GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)
 GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)
 GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)
 GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)

**** H ****

H.P. ACTHAR GEL, CORTICOTROPIN
 HABITROL, NICOTINE (OTC)
 HALAVEN, ERIBULIN MESYLATE
 HALCION, TRIAZOLAM
 HALDOL, HALOPERIDOL DECANOATE
 HALDOL, HALOPERIDOL LACTATE
 HALFLYTELY, BISACODYL
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HALOG, HALCINONIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEATHER, NORETHINDRONE
 HECTOROL, DOXERCALCIFEROL
 HELIDAC, BISMUTH SUBSALICYLATE
 HEMABATE, CARBOPROST TROMETHAMINE
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM
 HEPATAMINE 8%, AMINO ACIDS
 HEPATASOL 8%, AMINO ACIDS
 HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT

APPENDIX A - PRODUCT NAME INDEX

A - 26

**** H ****

HEPSERA, ADEFOVIR DIPIVOXIL
 HERPLEX, IDOXURIDINE
 HEXABRIX, IOXAGLATE MEGLUMINE
 HEXALEN, ALTRETAMINE
 HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
 HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)
 HICON, SODIUM IODIDE I-131
 HIPREX, METHENAMINE HIPPURATE
 HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
 HORIZANT, GABAPENTIN ENACARBIL
 HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
 HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG, INSULIN LISPRO RECOMBINANT
 HUMATROPE, SOMATROPIN RECOMBINANT
 HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
 HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN R, INSULIN RECOMBINANT HUMAN
 HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
 Hycamtin, Topotecan Hydrochloride
 HYDERGINE, ERGOLOID MESYLATES
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
 HYDREA, HYDROXYUREA
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
 HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
 HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 HYDROCORTISONE, HYDROCORTISONE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 HYDRO-RX, HYDROCORTISONE
 HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 HYDROXYUREA, HYDROXYUREA
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN
 HYTRIN, TERAZOSIN HYDROCHLORIDE
 HYZAAR, HYDROCHLOROTHIAZIDE

**** I ****

IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
 IBUPROHM, IBUPROFEN (OTC)
 IBU-TAB 200, IBUPROFEN (OTC)
 IBU-TAB, IBUPROFEN
 IBUTILIDE FUMARATE, IBUTILIDE FUMARATE

APPENDIX A - PRODUCT NAME INDEX

A - 27

**** I ****

IC-GREEN, INDOCYANINE GREEN
ICLUSIG, PONATINIB HYDROCHLORIDE
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IDKIT:HP, UREA C-13
IFEX, IFOSFAMIDE
IFOSFAMIDE, IFOSFAMIDE
IFOSFAMIDE/MESNA KIT, IFOSFAMIDE
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IMIQUIMOD, IMIQUIMOD
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
IMODIUM A-D EZ CHEWS, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM, LOPERAMIDE HYDROCHLORIDE
IMPLANON, ETONOGESTREL
IMURAN, AZATHIOPRINE
INAPSINE, DROPERIDOL
INCIVEK, TELAPREVIR
INCRELEX, MECASERMIN RECOMBINANT
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDERAL, PROPRANOLOL HYDROCHLORIDE
INDERIDE-40/25, HYDROCHLOROTHIAZIDE
INDICLOR, INDIUM IN-111 CHLORIDE
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
INDOCIN, INDOMETHACIN
INDOCIN, INDOMETHACIN SODIUM
INDOCYANINE GREEN, INDOCYANINE GREEN
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
INDOMETHACIN, INDOMETHACIN
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
INFASURF PRESERVATIVE FREE, CALFACTANT
INFED, IRON DEXTRAN
INFUMORPH, MORPHINE SULFATE
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INFUVITE PEDIATRIC, ASCORBIC ACID
INLYTA, AXITINIB
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
INOMAX, NITRIC OXIDE
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INSpra, EPLERENONE
INTEGRILIN, EPTIFIBATIDE
INTELENCE, ETRAVIRINE
INTERMEZZO, ZOLPIDEM TARTRATE
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
INTROVALE, ETHINYL ESTRADIOL
INTUNIV, GUANFACINE HYDROCHLORIDE
INVANZ, ERTAPENEM SODIUM
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVEGA, PALIPERIDONE
INVIRASE, SAQUINAVIR MESYLATE

APPENDIX A - PRODUCT NAME INDEX

A - 28

**** I ****

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 IOPAMIDOL-250, IOPAMIDOL
 IOPAMIDOL-300, IOPAMIDOL
 IOPAMIDOL-370, IOPAMIDOL
 IOPIDINE, APRACLOINIDINE HYDROCHLORIDE
 IOSAT, POTASSIUM IODIDE (OTC)
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 IPRIVASK, DESIRUDIN RECOMBINANT
 IQUIX, LEVOFLOXACIN
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 ISENTRESS, RALTEGRAVIR POTASSIUM
 ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN, LEVONORDEFIN
 ISOCAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
 ISOFLURANE, ISOFLURANE
 ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 ISOLYTE E IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 ISONIAZID, ISONIAZID
 ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
 ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
 ISORDIL, ISOSORBIDE DINITRATE
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 ISOSULFAN BLUE, ISOSULFAN BLUE
 ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 ISOVUE-200, IOPAMIDOL
 ISOVUE-250, IOPAMIDOL
 ISOVUE-300, IOPAMIDOL
 ISOVUE-370, IOPAMIDOL
 ISOVUE-M 200, IOPAMIDOL
 ISOVUE-M 300, IOPAMIDOL
 ISRADIPINE, ISRADIPINE
 ISTALOL, TIMOLOL MALEATE
 ISTODAX, ROMIDEPSIN
 ISUPREL, ISOPROTERENOL HYDROCHLORIDE
 ITRACONAZOLE, ITRACONAZOLE
 IVY BLOCK, BENTOQUATAM (OTC)
 IXEMPRA KIT, IXABEPILONE

**** J ****

JAKAFI, RUXOLITINIB PHOSPHATE
 JALYN, DUTASTERIDE
 JANTOVEN, WARFARIN SODIUM
 JANUMET XR, METFORMIN HYDROCHLORIDE
 JANUMET, METFORMIN HYDROCHLORIDE
 JANUVIA, SITAGLIPTIN PHOSPHATE
 JEANATOPE, ALBUMIN IODINATED I-125 SERUM
 JENTADUETO, LINAGLIPTIN
 JEVTANA KIT, CABAZITAXEL
 JUNEL 1.5/30, ETHINYL ESTRADIOL
 JUNEL 1/20, ETHINYL ESTRADIOL
 JUNEL FE 1.5/30, ETHINYL ESTRADIOL
 JUNEL FE 1/20, ETHINYL ESTRADIOL
 JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)

APPENDIX A - PRODUCT NAME INDEX

A - 29

**** J ****

JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
JUVISYNC, SIMVASTATIN
JUXTAPID, LOMITAPIDE MESYLATE

**** K ****

KADIAN, MORPHINE SULFATE
KALETRA, LOPINAVIR
KALEXATE, SODIUM POLYSTYRENE SULFONATE
KALYDECO, IVACAFTOR
KANAMYCIN SULFATE, KANAMYCIN SULFATE
KAPVAY, CLONIDINE HYDROCHLORIDE
KARIVA, DESOGESTREL
KAYEXALATE, SODIUM POLYSTYRENE SULFONATE
KAZANO, ALOGLIPTIN BENZOATE
KEFLEX, CEPHALEXIN
KEFZOL, CEFAZOLIN SODIUM
KELNOR, ETHINYL ESTRADIOL
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KEPPRA XR, LEVETIRACETAM
KEPPRA, LEVETIRACETAM
KETALAR, KETAMINE HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETEK, TELITHROMYCIN
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
KETOZOLE, KETOCONAZOLE
KINEVAC, SINCALIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
KLARON, SULFACETAMIDE SODIUM
KLONOPIN, CLONAZEPAM
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOR-CON, POTASSIUM CHLORIDE
KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
KORLYM, MIFEPRISTONE
K-TAB, POTASSIUM CHLORIDE
KURVELO, ETHINYL ESTRADIOL
KUVAN, SAPROPTERIN DIHYDROCHLORIDE
KYPROLIS, CARFILZOMIB

**** L ****

LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAC-HYDRIN, AMMONIUM LACTATE
LACRISERT, HYDROXYPROPYL CELLULOSE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTULOSE, LACTULOSE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE
LAMICTAL, LAMOTRIGINE
LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFINE HYDROCHLORIDE
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE

APPENDIX A - PRODUCT NAME INDEX

A - 30

**** L ****

LAMIVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LAMPRENE, CLOFAZIMINE
LANORINAL, ASPIRIN
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LANTUS, INSULIN GLARGINE RECOMBINANT
LAROTID, AMOXICILLIN
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LASIX, FUROSEMIDE
LASTACAF, ALCAFTADINE
LATANOPROST, LATANOPROST
LATISSE, BIMATOPROST
LATUDA, LURASIDONE HYDROCHLORIDE
LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
LAZANDA, FENTANYL CITRATE
LEFLUNOMIDE, LEFLUNOMIDE
LESCOL XL, FLUVASTATIN SODIUM
LESCOL, FLUVASTATIN SODIUM
LESSINA-28, ETHINYL ESTRADIOL
LETAIRIS, AMBRISENTAN
LETROZOLE, LETROZOLE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUKERAN, CHLORAMBUCIL
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEUSTATIN, CLADRIBINE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVAQUIN, LEVOFLOXACIN
LEVATOL, PENBUTOLOL SULFATE
LEVEMIR FLEXPEN, INSULIN DETEMIR RECOMBINANT
LEVEMIR, INSULIN DETEMIR RECOMBINANT
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVETIRACETAM, LEVETIRACETAM
LEVITRA, VARDENAFIL HYDROCHLORIDE
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
LEVOCARNITINE, LEVOCARNITINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOFLOXACIN, LEVOFLOXACIN
LEVONEST, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LEVOPHED, NOREPINEPHRINE BITARTRATE
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LEVO-T, LEVOTHYROXINE SODIUM
LEVOTHROID, LEVOTHYROXINE SODIUM
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LEVOXYL, LEVOTHYROXINE SODIUM
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
LEXAPRO, ESCITALOPRAM OXALATE
LEXISCAN, REGADENOSON
LEXIVA, FOSAMPRENAVIR CALCIUM
LIALDA, MESALAMINE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 31

**** L ****

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
LIDODERM, LIDOCAINE
LIDOPEN, LIDOCAINE HYDROCHLORIDE
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LINDANE, LINDANE
LINEZOLID, LINEZOLID
LINZESS, LINACLOTIDE
LIORESAL, BACLOFEN
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LIPITOR, ATORVASTATIN CALCIUM
LIPOFEN, FENOFIBRATE
LIPOSYN II 10%, SAFFLOWER OIL
LIPOSYN II 20%, SAFFLOWER OIL
LIPOSYN III 10%, SOYBEAN OIL
LIPOSYN III 20%, SOYBEAN OIL
LIPOSYN III 30%, SOYBEAN OIL
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LITHOBID, LITHIUM CARBONATE
LITHOSTAT, ACETOHYDROXAMIC ACID
LIVALO, PITAVASTATIN CALCIUM
LO LOESTRIN FE, ETHINYL ESTRADIOL
LO/OVRAL-28, ETHINYL ESTRADIOL
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LOCOID, HYDROCORTISONE BUTYRATE
LODOSYN, CARBIDOPA
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN 24 FE, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
LOMOTIL, ATROPINE SULFATE
LONOX, ATROPINE SULFATE
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPID, GEMFIBROZIL
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL TARTRATE
LOPROX, CICLOPIROX
LOPURIN, ALLOPURINOL
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE REDIDOSE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
LORAZEPAM INTENSOL, LORAZEPAM
LORAZEPAM PRESERVATIVE FREE, LORAZEPAM
LORAZEPAM, LORAZEPAM
LORTAB, ACETAMINOPHEN
LORYNA, DROSPIRENONE

APPENDIX A - PRODUCT NAME INDEX

A - 32

**** L ****

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOSEASONIQUE, ETHINYL ESTRADIOL
 LOTEMAX, LOTEPREDNOL ETABONATE
 LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
 LOTENSIN, BENAZEPRIL HYDROCHLORIDE
 LOTREL, AMLODIPINE BESYLATE
 LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
 LOTRISONE, BETAMETHASONE DIPROPIONATE
 LOTRONEX, ALOSETRON HYDROCHLORIDE
 LOVASTATIN, LOVASTATIN
 LOVAZA, OMEGA-3-ACID ETHYL ESTERS
 LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 LOVENOX, ENOXAPARIN SODIUM
 LOW-OGESTREL-21, ETHINYL ESTRADIOL
 LOW-OGESTREL-28, ETHINYL ESTRADIOL
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 LTA II KIT, LIDOCAINE HYDROCHLORIDE
 LUFYLLIN, DYPHYLLINE
 LUMIGAN, BIMATOPROST
 LUNESTA, ESZOPICLONE
 LUPANETA PACK, LEUPROLIDE ACETATE
 LUPRON DEPOT, LEUPROLIDE ACETATE
 LUPRON DEPOT-PED, LEUPROLIDE ACETATE
 LUVOX CR, FLUVOXAMINE MALEATE
 LUVOX, FLUVOXAMINE MALEATE
 LUXIQ, BETAMETHASONE VALERATE
 LYMPHAZURIN, ISOSULFAN BLUE
 LYRICA, PREGABALIN
 LYSODREN, MITOTANE
 LYSTEDA, TRANEXAMIC ACID

**** M ****

M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
 M.V.I. ADULT, ASCORBIC ACID
 M.V.I. PEDIATRIC, ASCORBIC ACID
 M.V.I.-12 (WITHOUT VITAMIN K), ASCORBIC ACID
 MACROBID, NITROFURANTOIN
 MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
 MACUGEN, PEGAPTANIB SODIUM
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MAGNEVIST, GADOPENTETATE DIMEGLUMINE
 MAKENA, HYDROXYPROGESTERONE CAPROATE
 MALARONE PEDIATRIC, ATOVAQUONE
 MALARONE, ATOVAQUONE
 MALATHION, MALATHION
 MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, MANNITOL
 MANNITOL 10%, MANNITOL
 MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%, MANNITOL
 MANNITOL 15%, MANNITOL
 MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 20%, MANNITOL
 MANNITOL 25%, MANNITOL
 MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%, MANNITOL
 MANNITOL 5%, MANNITOL
 MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 33

**** M ****

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
MARINOL, DRONABINOL
MARLISSA, ETHINYL ESTRADIOL
MARPLAN, ISOCARBOXAZID
MARQIBO KIT, VINCRISTINE SULFATE
MATULANE, PROCARBAZINE HYDROCHLORIDE
MAVIK, TRANDOLAPRIL
MAXAIR, PIRBUTEROL ACETATE
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MAXIDEX, DEXAMETHASONE
MAXIPIME, CEFEPIME HYDROCHLORIDE
MAXITROL, DEXAMETHASONE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MD-76R, DIATRIZOATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
MEBENDAZOLE, MEBENDAZOLE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROL, METHYLPREDNISOLONE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFENAMIC ACID, MEFENAMIC ACID
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEGACE ES, MEGESTROL ACETATE
MEGACE, MEGESTROL ACETATE
MEGATOPE, ALBUMIN IODINATED I-131 SERUM
MEGESTROL ACETATE, MEGESTROL ACETATE
MELOXICAM, MELOXICAM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMBRANEBLUE, TRYPAN BLUE
MENEST, ESTROGENS, ESTERIFIED
MENOPUR, LUTEINIZING HORMONE
MENOSTAR, ESTRADIOL
MEN'S ROGAINE, MINOXIDIL (OTC)
MENTAX, BUTENAFINE HYDROCHLORIDE
MENTAX-TC, BUTENAFINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MEPHYTON, PHYTONADIONE
MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
MEPRON, ATOVAQUONE
MERCAPTOPYRINE, MERCAPTOPYRINE
MEROPENEM, MEROPENEM
MERREM, MEROPENEM
MESALAMINE, MESALAMINE
MESNA, MESNA
MESNEX, MESNA
MESTINON, PYRIDOSTIGMINE BROMIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METASTRON, STRONTIUM CHLORIDE SR-89
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 34

**** M ****

METHADOSE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHERGINE, METHYLERGONOVINE MALEATE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYLCLOTHIAZIDE, METHYLCLOTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOLAZONE, METOLAZONE
METOPIRONE, METYRAPONE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROGEL-VAGINAL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
METRONIDAZOLE, METRONIDAZOLE
METVIXIA, METHYL AMINOLEVULINATE HYDROCHLORIDE
MEVACOR, LOVASTATIN
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIACALCIN, CALCITONIN SALMON
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICARDIS, TELMISARTAN
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MICORT-HC, HYDROCORTISONE ACETATE
MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN 1/20, ETHINYL ESTRADIOL
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
MICRO-K 10, POTASSIUM CHLORIDE
MICRO-K, POTASSIUM CHLORIDE
MICRONOR, NORETHINDRONE
MICROZIDE, HYDROCHLOROTHIAZIDE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 35

**** M ****

MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MIDOL LIQUID GELS, IBUPROFEN (OTC)
MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIFEPREX, MIFEPRISTONE
MIGERGOT, CAFFEINE
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MINIRIN, DESMOPRESSIN ACETATE
MINITRAN, NITROGLYCERIN
MINIVELLE, ESTRADIOL
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL, MINOXIDIL
MINOXIDIL, MINOXIDIL (OTC)
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
MIOSTAT, CARBACHOL
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
MIRCETTE, DESOGESTREL
MIRENA, LEVONORGESTREL
MIRTAZAPINE, MIRTAZAPINE
MISOPROSTOL, MISOPROSTOL
MITOMYCIN, MITOMYCIN
MITOSOL, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MOBIC, MELOXICAM
MODAFINIL, MODAFINIL
MODICON 28, ETHINYL ESTRADIOL
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
MONODOX, DOXYCYCLINE
MONOKET, ISOSORBIDE MONONITRATE
MONO-LINYAH, ETHINYL ESTRADIOL
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MONUROL, FOSFOMYCIN TROMETHAMINE
MORPHINE SULFATE, MORPHINE SULFATE
MOTOFEN, ATROPINE SULFATE
MOTRIN IB, IBUPROFEN (OTC)
MOTRIN MIGRAINE PAIN, IBUPROFEN (OTC)
MOVIPREP, ASCORBIC ACID
MOXATAG, AMOXICILLIN
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
MOZOBIL, PLERIXAFOR
MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM

APPENDIX A - PRODUCT NAME INDEX

A - 36

**** M ****

MS CONTIN, MORPHINE SULFATE
 MUCINEX D, GUAIFENESIN (OTC)
 MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 MUCINEX, GUAIFENESIN (OTC)
 MULTAQ, DRONEDARONE HYDROCHLORIDE
 MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
 MULTIHANCE, GADOBENATE DIMEGLUMINE
 MUPIROCIN, MUPIROCIN
 MUPIROCIN, MUPIROCIN CALCIUM
 MUSE, ALPROSTADIL
 MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
 MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
 MYCAMINE, MICAFUNGIN SODIUM
 MYCELEX, CLOTRIMAZOLE
 MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
 MYCELEX-7, CLOTRIMAZOLE (OTC)
 MYCOBUTIN, RIFABUTIN
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
 MYDRIACYL, TROPICAMIDE
 MYFORTIC, MYCOPHENOLIC ACID
 MYLERAN, BUSULFAN
 MYORISAN, ISOTRETINOIN
 MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
 MYOVIEW, TECHNETIUM TC-99M TETROFOSMIN KIT
 MYRBETRIQ, MIRABEGRON
 MYSOLINE, PRIMIDONE
 MYTELASE, AMBENONIUM CHLORIDE
 MYZILRA, ETHINYL ESTRADIOL
 M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)

**** N ****

NABUMETONE, NABUMETONE
 NADOLOL AND BENDROFLUMETHAZIDE, BENDROFLUMETHIAZIDE
 NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
 NADOLOL, NADOLOL
 NAFCILLIN SODIUM, NAFCILLIN SODIUM
 NAFTIN, NAFTIFINE HYDROCHLORIDE
 NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
 NALFON, FENOPROFEN CALCIUM
 NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NAMENDA XR, MEMANTINE HYDROCHLORIDE
 NAMENDA, MEMANTINE HYDROCHLORIDE
 NANDROLONE DECANOATE, NANDROLONE DECANOATE
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
 NAPHAZOLINE HYDROCHLORIDE, NAPHAZOLINE HYDROCHLORIDE
 NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
 NAPRELAN, NAPROXEN SODIUM
 NAPROSYN, NAPROXEN
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NAPROXEN, NAPROXEN
 NARATRIPTAN, NARATRIPTAN
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 NARDIL, PHENELZINE SULFATE
 NAROPIN, ROPIVACAINE HYDROCHLORIDE
 NASACORT AQ, TRIAMCINOLONE ACETONIDE
 NASCOBAL, CYANOCOBALAMIN
 NASONEX, MOMETASONE FUROATE MONOHYDRATE
 NATACYN, NATAMYCIN

APPENDIX A - PRODUCT NAME INDEX

A - 37

**** N ****

NATAZIA, ESTRADIOL VALERATE
NATEGLINIDE, NATEGLINIDE
NATRECOR, NESIRITIDE RECOMBINANT
NATROBA, SPINOSAD
NAVANE, THIOTHIXENE
NAVELBINE, VINORELBINE TARTRATE
NAVSTEL, CALCIUM CHLORIDE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NEO-FRADIN, NEOMYCIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOPAP, ACETAMINOPHEN (OTC)
NEOPROFEN, IBUPROFEN LYSINE
NEORAL, CYCLOSPORINE
NEO-RX, NEOMYCIN SULFATE
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, GRAMICIDIN
NEPAFENAC, NEPAFENAC
NEPHRAMINE 5.4%, AMINO ACIDS
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NESINA, ALOGLIPTIN
NEUPRO, ROTIGOTINE
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
NEURONTIN, GABAPENTIN
NEVANAC, NEPAFENAC
NEVIRAPINE, NEVIRAPINE
NEXAVAR, SORAFENIB TOSYLATE
NEXCEDE, KETOPROFEN (OTC)
NEXIUM IV, ESOMEPRAZOLE SODIUM
NEXIUM, ESOMEPRAZOLE MAGNESIUM
NEXPLANON, ETONOGESTREL
NEXTERONE, AMIODARONE HYDROCHLORIDE
NIACIN, NIACIN
NIACOR, NIACIN
NIASPAN, NIACIN
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NICODERM CQ, NICOTINE (OTC)
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NICOTINE, NICOTINE (OTC)
NICOTROL, NICOTINE
NIFEDIPINE, NIFEDIPINE
NILANDRON, NILUTAMIDE
NILSTAT, NYSTATIN
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NIMODIPINE, NIMODIPINE
NIPENT, PENTOSTATIN
NIRAVAM, ALPRAZOLAM
NISOLDIPINE, NISOLDIPINE
NITHIODOTE, SODIUM NITRITE
NITRO-DUR, NITROGLYCERIN
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN

APPENDIX A - PRODUCT NAME INDEX

A - 38

**** N ****

NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROGLYCERIN, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROMIST, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
NITROSTAT, NITROGLYCERIN
NIX, PERMETHRIN (OTC)
NIZATIDINE, NIZATIDINE
NIZORAL A-D, KETOCONAZOLE (OTC)
NIZORAL, KETOCONAZOLE
NORCO, ACETAMINOPHEN
NORDETTE-28, ETHINYL ESTRADIOL
NORDITROPIN FLEXPOR, SOMATROPIN RECOMBINANT
NORDITROPIN NORDIFLEX, SOMATROPIN RECOMBINANT
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
NORETHIDRONE ACETATE, NORETHINDRONE ACETATE
NORETHIDRONE, NORETHINDRONE
NORETHIN 1/35E-21, ETHINYL ESTRADIOL
NORETHIN 1/35E-28, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORFLEX, ORPHENADRINE CITRATE
NORGESIC FORTE, ASPIRIN
NORGESIC, ASPIRIN
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
NORINYL 1+50 28-DAY, MESTRANOL
NORITATE, METRONIDAZOLE
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
NOROXIN, NORFLOXACIN
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
NOR-QD, NORETHINDRONE
NORTREL 0.5/35-28, ETHINYL ESTRADIOL
NORTREL 1/35-21, ETHINYL ESTRADIOL
NORTREL 1/35-28, ETHINYL ESTRADIOL
NORTREL 7/7/7, ETHINYL ESTRADIOL
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NORVASC, AMLODIPINE BESYLATE
NORVIR, RITONAVIR
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT
NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT
NOVOLOG, INSULIN ASPART RECOMBINANT
NOXAFIL, POSACONAZOLE
NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
NUCYNTA, TAPENTADOL HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 39

**** N ****

NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE
 NULYTELY, POLYETHYLENE GLYCOL 3350
 NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
 NUTRACORT, HYDROCORTISONE
 NUTRESTORE, GLUTAMINE
 NUTRILIPID 10%, SOYBEAN OIL
 NUTRILIPID 20%, SOYBEAN OIL
 NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT
 NUTROPIN AQ, SOMATROPIN RECOMBINANT
 NUTROPIN, SOMATROPIN RECOMBINANT
 NUVARING, ETHINYL ESTRADIOL
 NUVIGIL, ARMODAFINIL
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTATIN, NYSTATIN
 NYSTOP, NYSTATIN

**** O ****

OCTOCAINE, EPINEPHRINE
 OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)
 OCUFEN, FLURBIPROFEN SODIUM
 OCUFLOX, OFLOXACIN
 OCUPRESS, CARTEOLOL HYDROCHLORIDE
 OFIRMEV, ACETAMINOPHEN
 OFLOXACIN, OFLOXACIN
 OGEN .625, ESTROPIRATE
 OGEN 1.25, ESTROPIRATE
 OGEN 2.5, ESTROPIRATE
 OGEN 5, ESTROPIRATE
 OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 OLANZAPINE, OLANZAPINE
 OLEPTRO, TRAZODONE HYDROCHLORIDE
 OLUX E, CLOBETASOL PROPIONATE
 OLUX, CLOBETASOL PROPIONATE
 OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
 OMEPRAZOLE, OMEPRAZOLE
 OMEPRAZOLE, OMEPRAZOLE (OTC)
 OMNARIS, CICLESONIDE
 OMNIPAQUE 140, IOHEXOL
 OMNIPAQUE 180, IOHEXOL
 OMNIPAQUE 240, IOHEXOL
 OMNIPAQUE 300, IOHEXOL
 OMNIPAQUE 350, IOHEXOL
 OMNIPRED, PREDNISOLONE ACETATE
 OMNISCAN, GADODIAMIDE
 OMNITROPE, SOMATROPIN RECOMBINANT
 OMONTYS PRESERVATIVE FREE, PEGINESATIDE ACETATE
 OMONTYS, PEGINESATIDE ACETATE
 ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 ONFI, CLOBAZAM
 ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
 ONMEL, ITRACONAZOLE
 ONSOLIS, FENTANYL CITRATE
 OPANA ER, OXYMORPHONE HYDROCHLORIDE
 OPANA, OXYMORPHONE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 40

**** 0 ****

OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
OPHTHAINE, PROPARACAINE HYDROCHLORIDE
OPHTHETIC, PROPARACAINE HYDROCHLORIDE
OPTICROM, CROMOLYN SODIUM
OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
OPTIMARK, GADOVERSETAMIDE
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
OPTISON, ALBUMIN HUMAN
OPTIVAR, AZELASTINE HYDROCHLORIDE
ORABASE HCA, HYDROCORTISONE ACETATE
ORACEA, DOXYCYCLINE
ORAP, PIMOZIDE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
ORAPRED, PREDNISOLONE SODIUM PHOSPHATE
ORAQIX, LIDOCAINE
ORAVERSE, PHENTOLAMINE MESYLATE
ORAVIG, MICONAZOLE
ORETIC, HYDROCHLOROTHIAZIDE
ORFADIN, NITISINONE
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
ORSYTHIA, ETHINYL ESTRADIOL
ORTHO CYCLEN-28, ETHINYL ESTRADIOL
ORTHO EVRA, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
ORTHO-CEPT, DESOGESTREL
ORTHO-EST, ESTROPIPATE
ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
ORVATEN, MIDODRINE HYDROCHLORIDE
OSEN, ALOGLIPTIN
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
OTICAIR, HYDROCORTISONE
OVCON-35, ETHINYL ESTRADIOL
OVCON-50, ETHINYL ESTRADIOL
OVIDE, MALATHION
OVIDREL, CHORIOGONADOTROPIN ALFA
OXACILLIN SODIUM, OXACILLIN SODIUM
OXALIPLATIN, OXALIPLATIN
OXANDRIN, OXANDROLONE
OXANDROLONE, OXANDROLONE
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
OXCARBAZEPINE, OXCARBAZEPINE
OXYCTA, OXYCODONE HYDROCHLORIDE
OXILAN-300, IOXILAN
OXILAN-350, IOXILAN
OXISTAT, OXICONAZOLE NITRATE
OXSORALEN, METHOXSALEN
OXSORALEN-ULTRA, METHOXSALEN
OXTELLAR XR, OXCARBAZEPINE

APPENDIX A - PRODUCT NAME INDEX

A - 41

**** O ****

OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYCONTIN, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
OXYTOCIN, OXYTOCIN
OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
OXYTROL, OXYBUTYNIN
OZURDEX, DEXAMETHASONE

**** P ****

PACERONE, AMIODARONE HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PAMINE FORTE, METHSCOPOLAMINE BROMIDE
PAMINE, METHSCOPOLAMINE BROMIDE
PANCREAZE, LIPASE
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PANDEL, HYDROCORTISONE PROBUTATE
PANRETIN, ALITRETINOIN
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARAFON FORTE DSC, CHLORZOXAZONE
PARAGARD T 380A, COPPER
PARCOPA, CARBIDOPA
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
PARICALCITOL, PARICALCITOL
PARLODEL, BROMOCRIPTINE MESYLATE
PARNATE, TRANYLCPROMINE SULFATE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PASER, AMINOSALICYLIC ACID
PATADAY, OLOPATADINE HYDROCHLORIDE
PATANASE, OLOPATADINE HYDROCHLORIDE
PATANOL, OLOPATADINE HYDROCHLORIDE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PCE, ERYTHROMYCIN
PEDIAMYCIN 400, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAMYCIN, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
PEDIATRIC ADVIL, IBUPROFEN (OTC)
PEDIOTIC, HYDROCORTISONE
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE, POLYETHYLENE GLYCOL 3350
PEGANONE, ETHOTOIN
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENICILLIN-VK, PENICILLIN V POTASSIUM
PENLAC, CICLOPIROX
PENNSAID, DICLOFENAC SODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PENTASA, MESALAMINE
PENTAZOCINE AND NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
PENTAZOCINE AND NALOXONE HYDROCHLORIDES, NALOXONE HYDROCHLORIDE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 42

**** P ****

PENTOSTATIN, PENTOSTATIN
PENTOXIFYLLINE, PENTOXIFYLLINE
PENTOXIL, PENTOXIFYLLINE
PEPCID AC (GELTAB), FAMOTIDINE (OTC)
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
PEPCID, FAMOTIDINE
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERFOROMIST, FORMOTEROL FUMARATE
PERIDEX, CHLORHEXIDINE GLUCONATE
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PERIOCHIP, CHLORHEXIDINE GLUCONATE
PERIOGARD, CHLORHEXIDINE GLUCONATE
PERIOSTAT, DOXYCYCLINE HYCLATE
PERMAPEN, PENICILLIN G BENZATHINE
PERMETHRIN, PERMETHRIN
PERMETHRIN, PERMETHRIN (OTC)
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PERSANTINE, DIPYRIDAMOLE
PERTZE, PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)
PEXEVA, PAROXETINE MESYLATE
PFIZERPEN, PENICILLIN G POTASSIUM
PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENELZINE SULFATE, PHENELZINE SULFATE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PHENTERMINE RESIN COMPLEX, PHENTERMINE RESIN COMPLEX
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHENYTOIN, PHENYTOIN
PHILITH, ETHINYL ESTRADIOL
PHISOHEX, HEXACHLOROPHENE
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSLYRA, CALCIUM ACETATE
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PHOTOFRIN, PORFIMER SODIUM
PHRENILIN FORTE, ACETAMINOPHEN
PHRENILIN WITH CAFFEINE AND CODEINE, ACETAMINOPHEN
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYTONADIONE, PHYTONADIONE
PICATO, INGENOL MEBUTATE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PILOPINE HS, PILOCARPINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIPERACILLIN, PIPERACILLIN SODIUM
PIROXICAM, PIROXICAM
PITOCIN, OXYTOCIN
PLAN B ONE-STEP, LEVONORGESTREL
PLAN B ONE-STEP, LEVONORGESTREL (OTC)
PLAN B, LEVONORGESTREL
PLAN B, LEVONORGESTREL (OTC)
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX A - PRODUCT NAME INDEX

A - 43

**** P ****

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE 56 IN PLASTIC CONTAINER, MAGNESIUM ACETATE TETRAHYDRATE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLASMA-LYTE R IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLAVIX, CLOPIDOGREL BISULFATE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLENDIL, FELODIPINE
PLETAL, CILOSTAZOL
PLIAGLIS, LIDOCAINE
PODOFILOX, PODOFILOX
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POLMYCIN B SULFATE, POLYMYXIN B SULFATE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POLY-PRED, NEOMYCIN SULFATE
POLY-RX, POLYMYXIN B SULFATE
POLYTRIM, POLYMYXIN B SULFATE
PONSTEL, MEFENAMIC ACID
PORTIA-28, ETHINYL ESTRADIOL
POTASSIUM ACETATE IN PLASTIC CONTAINER, POTASSIUM ACETATE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

A - 44

**** p ****

[illegible]

APPENDIX A - PRODUCT NAME INDEX

A - 45

**** P ****

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
POTIGA, EZOGABINE
POVIDONE IODINE, POVIDONE-IODINE (OTC)
PRADAXA, DABIGATRAN ETEXILATE MESYLATE
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAMOSONE, HYDROCORTISONE ACETATE
PRANDIMET, METFORMIN HYDROCHLORIDE
PRANDIN, REPAGLINIDE
PRAVACHOL, PRAVASTATIN SODIUM
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
PRECOSE, ACARBOSE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE
PREDNICARBATE, PREDNICARBATE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE INTENSOL, PREDNISONE
PREDNISONE, PREDNISONE
PREFEST, ESTRADIOL
PREGABALIN, PREGABALIN
PREGNYL, GONADOTROPIN, CHORIONIC
PRELONE, PREDNISOLONE
PREMARIN, ESTROGENS, CONJUGATED
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE
PRE-PEN, BENZYL PENICILLOYL POLYLYSINE
PREPIDIL, DINOPROSTONE
PREPOPIK, CITRIC ACID
PREVACID 24 HR, LANSOPRAZOLE (OTC)
PREVACID, LANSOPRAZOLE
PREVALITE, CHOLESTYRAMINE
PREVIFEM, ETHINYL ESTRADIOL
PREVPAC, AMOXICILLIN
PREZISTA, DARUNAVIR ETHANOLATE
PRIALT, ZICONOTIDE ACETATE
PRIFTIN, RIFAPENTINE
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PRILOSEC, OMEPRAZOLE
PRILOSEC, OMEPRAZOLE MAGNESIUM
PRIMAQUINE, PRIMAQUINE PHOSPHATE
PRIMAXIN, CILASTATIN SODIUM
PRIMIDONE, PRIMIDONE
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE
PRINIVIL, LISINAPRIL
PRINZIDE, HYDROCHLOROTHIAZIDE
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 46

**** P ****

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISTIQ, DESVENLAFAXINE SUCCINATE
PROAIR HFA, ALBUTEROL SULFATE
PROBALAN, PROBENECID
PROBENECID AND COLCHICINE, COLCHICINE
PROBENECID, PROBENECID
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROCALAMINE, AMINO ACIDS
PROCARDIA XL, NIFEDIPINE
PROCARDIA, NIFEDIPINE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROCOMP, PROCHLORPERAZINE MALEATE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
PROFEN, IBUPROFEN (OTC)
PROFERDEX, IRON DEXTRAN
PROGESTERONE, PROGESTERONE
PROGLYCEM, DIAZOXIDE
PROGRAF, TACROLIMUS
PROHANCE MULTIPACK, GADOTERIDOL
PROHANCE, GADOTERIDOL
PROMACTA, ELTROMBOPAG OLAMINE
PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
PROMETRIUM, PROGESTERONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
PROPECIA, FINASTERIDE
PROPINE, DIPIVEFRIN HYDROCHLORIDE
PROPOFOL, PROPOFOL
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROSCAR, FINASTERIDE
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
PROSTIN E2, DINOPROSTONE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTONIX, PANTOPRAZOLE SODIUM
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
PROTOPIC, TACROLIMUS
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 47

**** P ****

PROVENTIL-HFA, ALBUTEROL SULFATE
PROVERA, MEDROXYPROGESTERONE ACETATE
PROVIGIL, MODAFINIL
PROVOCHOLINE, METHACHOLINE CHLORIDE
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
PULMICORT FLEXHALER, BUDESONIDE
PULMICORT RESPULES, BUDESONIDE
PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
PURINETHOL, MERCAPTOPURINE
PUR-WASH, PURIFIED WATER (OTC)
PYLERA, BISMUTH SUBCITRATE POTASSIUM
PYRAZINAMIDE, PYRAZINAMIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

**** Q ****

QNASL, BECLOMETHASONE DIPROPIONATE
QSYMIA, PHENTERMINE HYDROCHLORIDE
QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
QUALAQUIN, QUININE SULFATE
QUASENSE, ETHINYL ESTRADIOL
QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
QUELICIN, SUCCINYLCHOLINE CHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
QUINARETIC, HYDROCHLOROTHIAZIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
QUININE SULFATE, QUININE SULFATE
QUIXIN, LEVOFLOXACIN
QUTENZA, CAPSAICIN
QVAR 40, BECLOMETHASONE DIPROPIONATE
QVAR 80, BECLOMETHASONE DIPROPIONATE

**** R ****

RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)
RAMIPRIL, RAMIPRIL
RANEXA, RANOLAZINE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RAPAFLO, SILODOSIN
RAPAMUNE, SIROLIMUS
RAYOS, PREDNISONE
RAZADYNE ER, GALANTAMINE HYDROBROMIDE
RAZADYNE, GALANTAMINE HYDROBROMIDE
REBETOL, RIBAVIRIN
RECLAST, ZOLEDRONIC ACID
RECTIV, NITROGLYCERIN
REFLUDAN, LEPIRUDIN RECOMBINANT
REGITINE, PHENTOLAMINE MESYLATE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
REGONOL, PYRIDOSTIGMINE BROMIDE
RELENZA, ZANAMIVIR
RELISTOR, METHYLNALTREXONE BROMIDE
RELPAK, ELETRIPTAN HYDROBROMIDE
REMERON SOLTAB, MIRTAZAPINE
REMERON, MIRTAZAPINE

APPENDIX A - PRODUCT NAME INDEX

A - 48

**** R ****

REMODULIN, TREPROSTINIL SODIUM
RENACIDIN, CITRIC ACID
RENAGEL, SEVELAMER HYDROCHLORIDE
RENAMIN W/O ELECTROLYTES, AMINO ACIDS
RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
RENOVA, TRETINOIN
RENVELA, SEVELAMER CARBONATE
REPREXAIN, HYDROCODONE BITARTRATE
REPRONEX, LUTEINIZING HORMONE
REQUIP XL, ROPINIROLE HYDROCHLORIDE
REQUIP, ROPINIROLE HYDROCHLORIDE
RESCRIPTOR, DELAVIRDINE MESYLATE
RESCULA, UNOPROSTONE ISOPROPYL
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RESERPINE, RESERPINE
RESTASIS, CYCLOSPORINE
RESTORIL, TEMAZEPAM
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
RETISERT, FLUOCINOLONE ACETONIDE
RETROVIR, ZIDOVUDINE
REVATIO, SILDENAFIL CITRATE
REVIA, NALTREXONE HYDROCHLORIDE
REVLIMID, LENALIDOMIDE
REYATAZ, ATAZANAVIR SULFATE
REZIRA, HYDROCODONE BITARTRATE
R-GENE 10, ARGININE HYDROCHLORIDE
RHINOCORT, BUDESONIDE
RIBASPHERE, RIBAVIRIN
RIBAVARIN, RIBAVIRIN
RIBAVIRIN, RIBAVIRIN
RID MOUSSE, PIPERONYL BUTOXIDE (OTC)
RIDAURA, AURANOFIN
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFAMPIN AND ISONIAZID, ISONIAZID
RIFAMPIN, RIFAMPIN
RIFATER, ISONIAZID
RILUTEK, RILUZOLE
RILUZOLE, RILUZOLE
RIMACTANE, RIFAMPIN
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
RIMSO-50, DIMETHYL SULFOXIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RIOMET, METFORMIN HYDROCHLORIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERDAL CONSTA, RISPERIDONE
RISPERDAL, RISPERIDONE
RISPERIDONE, RISPERIDONE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
ROBINUL FORTE, GLYCOPYRROLATE
ROBINUL, GLYCOPYRROLATE
ROCALTROL, CALCITRIOL
ROCEPHIN, CEFTRIAXONE SODIUM
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

APPENDIX A - PRODUCT NAME INDEX

A - 49

**** R ****

ROMAZICON, FLUMAZENIL
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROSIGLITAZONE MALEATE, ROSIGLITAZONE MALEATE
ROWASA, MESALAMINE
ROXICET 5/500, ACETAMINOPHEN
ROXICET, ACETAMINOPHEN
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROXILOX, ACETAMINOPHEN
ROZEREM, RAMELTEON
RYBIX ODT, TRAMADOL HYDROCHLORIDE
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE
RYTHMOL, PROPAFENONE HYDROCHLORIDE

**** S ****

SABRIL, VIGABATRIN
SAFYRAL, DROSPIRENONE
SAIZEN, SOMATROPIN RECOMBINANT
SALAGEN, PILOCARPINE HYDROCHLORIDE
SALONPAS, MENTHOL (OTC)
SALURON, HYDROFLUMETHIAZIDE
SAMSCA, TOLVAPTAN
SANCTURA XR, TROSPIMUM CHLORIDE
SANCTURA, TROSPIMUM CHLORIDE
SANCUSO, GRANISETRON
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SANDOSTATIN, OCTREOTIDE ACETATE
SAPHRIS, ASENAPINE MALEATE
SARAFEM, FLUOXETINE HYDROCHLORIDE
SAVELLA, MILNACIPRAN HYDROCHLORIDE
SCANDONEST L, LEVONORDEFIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SCANLUX-300, IOPAMIDOL
SCANLUX-370, IOPAMIDOL
SCLEROSOL, TALC
SEASONALE, ETHINYL ESTRADIOL
SEASONIQUE, ETHINYL ESTRADIOL
SECONAL SODIUM, SECOBARBITAL SODIUM
SECTRAL, ACEBUTOLOL HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
SELSUN, SELENIUM SULFIDE
SELZENTRY, MARAVIROC
SEMPREX-D, ACRIVASTINE
SENSIPAR, CINACALCET HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAIN HYDROCHLORIDE
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
SEREVENT, SALMETEROL XINAFOATE
SEROMYCIN, CYCLOSERINE
SEROPHENE, CLOMIPHENE CITRATE
SEROQUEL XR, QUETIAPINE FUMARATE
SEROQUEL, QUETIAPINE FUMARATE
SEROSTIM, SOMATROPIN RECOMBINANT
SERPALAN, RESERPINE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SEVOFLURANE, SEVOFLURANE
SFROWASA, MESALAMINE
SHADE UVAGUARD, AVOBENZONE (OTC)
SIGNIFOR, PASIREOTIDE DIASPARTATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILENOR, DOXEPIN HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 50

**** S ****

SILVADENE, SILVER SULFADIAZINE
SIMCOR, NIACIN
SIMVASTATIN, SIMVASTATIN
SINE-AID IB, IBUPROFEN (OTC)
SINEMET CR, CARBIDOPA
SINEMET, CARBIDOPA
SINGULAIR, MONTELUKAST SODIUM
SINOGRAPHIN, DIATRIZOATE MEGLUMINE
SIRTURO, BEDAQUILINE FUMARATE
SKELAXIN, METAXALONE
SKELID, TILUDRONATE DISODIUM
SKLICE, IVERMECTIN
SKYLA, LEVONORGESTREL
SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE ANHYDROUS
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
SODIUM IODIDE I 123, SODIUM IODIDE I-123
SODIUM IODIDE I 131, SODIUM IODIDE I-131
SODIUM IODIDE I-131, SODIUM IODIDE I-131
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM NITRITE, SODIUM NITRITE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SODIUM THIOSULFATE, SODIUM THIOSULFATE
SOJOURN, SEVOFLURANE
SOLARAZE, DICLOFENAC SODIUM
SOLODYN, MINOCYCLINE HYDROCHLORIDE
SOLTAMOX, TAMOXIFEN CITRATE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOMA COMPOUND W/ CODEINE, ASPIRIN
SOMA COMPOUND, ASPIRIN
SOMA, CARISOPRODOL
SOMATULINE DEPOT, LANREOTIDE ACETATE
SOMAVERT, PEGVISOMANT
SONATA, ZALEPLON
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORIATANE, ACITRETIN
SORILUX, CALCIPOTRIENE
SORINE, SOTALOL HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SOTRET, ISOTRETINOIN
SPECTRACEF, CEFDITOREN PIVOXIL
SPIRIVA, TIOTROPIUM BROMIDE MONOHYDRATE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SPORANOX, ITRACONAZOLE
SPRINTEC, ETHINYL ESTRADIOL
SPRIX, KETOROLAC TROMETHAMINE
SPRYCEL, DASATINIB

APPENDIX A - PRODUCT NAME INDEX

A - 51

**** S ****

SPS, SODIUM POLYSTYRENE SULFONATE
SSD AF, SILVER SULFADIAZINE
SSD, SILVER SULFADIAZINE
STADOL PRESERVATIVE FREE, BUTORPHANOL TARTRATE
STADOL, BUTORPHANOL TARTRATE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA
STARLIX, NATEGLINIDE
STAVUDINE, STAVUDINE
STAVZOR, VALPROIC ACID
STAXYN, VARDENAFIL HYDROCHLORIDE
STENDRA, AVANAFIL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STERILE WATER, STERILE WATER FOR IRRIGATION
STIE-CORT, HYDROCORTISONE
STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
STIVARGA, REGORAFENIB
STRATTERA, ATOMOXETINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
STRIANT, TESTOSTERONE
STRIBILD, COBICISTAT
STROMEKTOL, IVERMECTIN
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
SUBSYS, FENTANYL
SUCRAID, SACROSIDASE
SUCRALFATE, SUCRALFATE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULAR, NISOLDIPINE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFADIAZINE, SULFADIAZINE
SULFAMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOPRIM-DS, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMYLON, MAFENIDE ACETATE
SULFASALAZINE, SULFASALAZINE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE
SUPPRELIN LA, HISTRELIN ACETATE
SUPRANE, DESFLURANE
SUPRAX, CEFIXIME
SUPRENZA, PHENTERMINE HYDROCHLORIDE
SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE ANHYDROUS
SURFAXIN, LUCINACTANT
SURMONTIL, TRIMIPRAMINE MALEATE
SURVANTA, BERACTANT
SUSTIVA, EFAVIRENZ
SUTENT, SUNITINIB MALATE
SYEDA, DROSPIRENONE
SYMBICORT, BUDESONIDE

APPENDIX A - PRODUCT NAME INDEX

A - 52

**** S ****

SYMBYAX, FLUOXETINE HYDROCHLORIDE
SYMLIN, PRAMLINTIDE ACETATE
SYNACORT, HYDROCORTISONE
SYNALAR, FLUOCINOLONE ACETONIDE
SYNALGOS-DC, ASPIRIN
SYNAREL, NAFARELIN ACETATE
SYNERA, LIDOCAINE
SYNERCID, DALFOPRISTIN
SYNRIBO, OMACETAXINE MEPESUCCINATE
SYNTHETIC CONJUGATED ESTROGENS A, ESTROGENS, CONJUGATED SYNTHETIC A
SYNTHROID, LEVOTHYROXINE SODIUM
SYPRINE, TRIENTINE HYDROCHLORIDE

**** T ****

TAB-PROFEN, IBUPROFEN (OTC)
TACLONEX, BETAMETHASONE DIPROPIONATE
TACROLIMUS, TACROLIMUS
TAGAMET HB, CIMETIDINE (OTC)
TAGAMET, CIMETIDINE
TALC, TALC
TALWIN, PENTAZOCINE LACTATE
TAMBOCOR, FLECAINIDE ACETATE
TAMIFLU, OSELTAMIVIR PHOSPHATE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TAPAZOLE, METHIMAZOLE
TARCEVA, ERLOTINIB HYDROCHLORIDE
TARGRETIN, BEXAROTENE
TARKA, TRANDOLAPRIL
TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE
TASMAR, TOLCAPONE
TAVIST ALLERGY/SINUS/HEADACHE, ACETAMINOPHEN (OTC)
TAVIST-1, CLEMASTINE FUMARATE (OTC)
TAXOTERE, DOCETAXEL
TAZICEF, CEFTAZIDIME
TAZORAC, TAZAROTENE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNISCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNISCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNISCAN, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99 SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
TEFLARO, CEFTAROLINE FOSAMIL
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TEKAMLO, ALISKIREN HEMIFUMARATE
TEKTRNA HCT, ALISKIREN HEMIFUMARATE
TEKTRNA, ALISKIREN HEMIFUMARATE
TEMAZEPAM, TEMAZEPAM
TEMODAR, TEMOZOLOMIDE
TEMOVATE E, CLOBETASOL PROPIONATE
TEMOVATE, CLOBETASOL PROPIONATE
TEMOZOLOMIDE, TEMOZOLOMIDE
TENEX, GUANFACINE HYDROCHLORIDE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TENSILON PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
TENSILON, EDROPHONIUM CHLORIDE
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 53

**** T ****

TENUATE, DIETHYLPROPION HYDROCHLORIDE
TERAZOL 3, TERCONAZOLE
TERAZOL 7, TERCONAZOLE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TERCONAZOLE, TERCONAZOLE
TERIL, CARBAMAZEPINE
TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
TESSALON, BENZONATATE
TESTIM, TESTOSTERONE
TESTOPEL, TESTOSTERONE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TESTOSTERONE, TESTOSTERONE
TESTRED, METHYLTESTOSTERONE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TEVETEN HCT, EPROSARTAN MESYLATE
TEVETEN, EPROSARTAN MESYLATE
TEV-TROPIN, SOMATROPIN RECOMBINANT
TEXACORT, HYDROCORTISONE
THALITONE, CHLORTHALIDONE
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
THALOMID, THALIDOMIDE
THAM, TROMETHAMINE
THEO-24, THEOPHYLLINE
THEOCHRON, THEOPHYLLINE
THEOLAIR, THEOPHYLLINE
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE
THERMAZENE, SILVER SULFADIAZINE
THEROXIDIL, MINOXIDIL (OTC)
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
THIOGUANINE, THIOGUANINE
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
THIOTEPA, THIOTEPA
THIOTHIXENE, THIOTHIXENE
THRIVE, NICOTINE POLACRILEX (OTC)
THYROGEN, THYROTROPIN ALFA
THYROLAR-0.25, LIOTHYRONINE SODIUM
THYROLAR-0.5, LIOTHYRONINE SODIUM
THYROLAR-1, LIOTHYRONINE SODIUM
THYROLAR-2, LIOTHYRONINE SODIUM
THYROLAR-3, LIOTHYRONINE SODIUM
THYROSAFE, POTASSIUM IODIDE (OTC)
THYROSHIELD, POTASSIUM IODIDE (OTC)
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
TIAZAC, DILTIAZEM HYDROCHLORIDE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TIKOSYN, DOFETILIDE
TIMENTIN IN PLASTIC CONTAINER, CLAVULANATE POTASSIUM
TIMENTIN, CLAVULANATE POTASSIUM
TIMOLOL MALEATE, TIMOLOL MALEATE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
TINDAMAX, TINIDAZOLE
TINIDAZOLE, TINIDAZOLE

APPENDIX A - PRODUCT NAME INDEX

A - 54

**** T ****

TIOCONAZOLE, TIOCONAZOLE (OTC)
TIOPRONIN, TIOPRONIN
TIROSINT, LEVOTHYROXINE SODIUM
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIS-U-SOL, MAGNESIUM SULFATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOBI, TOBRAMYCIN
TOBRADEX ST, DEXAMETHASONE
TOBRADEX, DEXAMETHASONE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN
TOBREX, TOBRAMYCIN
TODAY, NONOXYNOL-9 (OTC)
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOFRANIL-PM, IMIPRAMINE PAMOATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOPAMAX, TOPIRAMATE
TOPICORT, DESOXIMETASONE
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TOPOTECAN, TOPOTECAN HYDROCHLORIDE
TOPROL-XL, METOPROLOL SUCCINATE
TORISEL, TEMSIROLIMUS
TORSEMIDE, TORSEMIDE
TOTECT, DEXRAZOXANE HYDROCHLORIDE
TOVIAZ, FESOTERODINE FUMARATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TRACLEER, BOSENTAN
TRADJENTA, LINAGLIPTIN
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TRANDOLAPRIL, TRANDOLAPRIL
TRANEXAMIC ACID, TRANEXAMIC ACID
TRANSDERM SCOP, SCOPOLAMINE
TRANXENE, CLORAZEPATE DIPOTASSIUM
TRANLYCYPROMINE SULFATE, TRANLYCYPROMINE SULFATE
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 10% W/O ELECTROLYTES, AMINO ACIDS
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 3.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 5.5% W/O ELECTROLYTES, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 8.5% W/O ELECTROLYTES, AMINO ACIDS
TRAVATAN Z, TRAVOPROST
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TREANDA, BENDAMUSTINE HYDROCHLORIDE
TRECATOR, ETHIONAMIDE
TRELSTAR, TRIPTORELIN PAMOATE
TRENTAL, PENTOXIFYLLINE
TRETINOIN, TRETINOIN
TREXALL, METHOTREXATE SODIUM
TREXIMET, NAPROXEN SODIUM

APPENDIX A - PRODUCT NAME INDEX

A - 55

**** T ****

TRI LO SPRINTEC, ETHINYL ESTRADIOL
TRIACET, TRIAMCINOLONE ACETONIDE
TRIACIN-C, CODEINE PHOSPHATE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAZOLAM, TRIAZOLAM
TRIBENZOR, AMLODIPINE BESYLATE
TRICOR, FENOFIBRATE
TRIDERM, TRIAMCINOLONE ACETONIDE
TRIDIONE, TRIMETHADIONE
TRIESENCE, TRIAMCINOLONE ACETONIDE
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
TRIFLURIDINE, TRIFLURIDINE
TRIGLIDE, FENOFIBRATE
TRIHXYPHENIDYL HYDROCHLORIDE, TRIHXYPHENIDYL HYDROCHLORIDE
TRI-LEGEST 21, ETHINYL ESTRADIOL
TRI-LEGEST FE, ETHINYL ESTRADIOL
TRILEPTAL, OXCARBAZEPINE
TRI-LINYAH, ETHINYL ESTRADIOL
TRILIPIX, CHOLINE FENOFIBRATE
TRI-LUMA, FLUOCINOLONE ACETONIDE
TRILYTE, POLYETHYLENE GLYCOL 3350
TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TRIMETHOPRIM, TRIMETHOPRIM
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRIOSTAT, LIOTHYRONINE SODIUM
TRI-PREVIFEM, ETHINYL ESTRADIOL
TRISENOX, ARSENIC TRIOXIDE
TRI-SPRINTEC, ETHINYL ESTRADIOL
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
TRIVARIS, TRIAMCINOLONE ACETONIDE
TRIVORA-28, ETHINYL ESTRADIOL
TRIZIVIR, ABACAVIR SULFATE
TROPHAMINE 10%, AMINO ACIDS
TROPHAMINE, AMINO ACIDS
TROPICACYL, TROPICAMIDE
TROPICAMIDE, TROPICAMIDE
TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
TRUVADA, EMTRICITABINE
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
TUSSICAPS, CHLORPHENIRAMINE POLISTIREX
TUSSIGON, HOMATROPINE METHYLBROMIDE
TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLISTIREX
TWINJECT 0.15, EPINEPHRINE
TWINJECT 0.3, EPINEPHRINE
TWYNSTA, AMLODIPINE BESYLATE
TYGACIL, TIGECYCLINE
TYKERB, LAPATINIB DITOSYLATE
TYLENOL (CAPLET), ACETAMINOPHEN (OTC)
TYLENOL (GELTAB), ACETAMINOPHEN (OTC)
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
TYLOX, ACETAMINOPHEN
TYVASO, TREPROSTINIL SODIUM
TYZEKA, TELBIVUDINE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 56

**** U ****

UCERIS, BUDESONIDE
U-CORT, HYDROCORTISONE ACETATE
ULESFIA, BENZYL ALCOHOL
ULORIC, FEBUXOSTAT
ULTANE, SEVOFLURANE
ULTIVA, REMIFENTANIL HYDROCHLORIDE
ULTRACET, ACETAMINOPHEN
ULTRAM ER, TRAMADOL HYDROCHLORIDE
ULTRAM, TRAMADOL HYDROCHLORIDE
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRAVATE, HALOBETASOL PROPIONATE
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 150, IOPROMIDE
ULTRAVIST 240, IOPROMIDE
ULTRAVIST 300 IN PLASTIC CONTAINER, IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
ULTRESA, LIPASE
UNASYN, AMPICILLIN SODIUM
UNIRETIC, HYDROCHLOROTHIAZIDE
UNISOM, DOXYLAMINE SUCCINATE (OTC)
UNITHROID, LEVOTHYROXINE SODIUM
UNIVASC, MOEXIPRIL HYDROCHLORIDE
URECHOLINE, BETHANECHOL CHLORIDE
UREX, METHENAMINE HIPPURATE
UROCIT-K, POTASSIUM CITRATE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE
URSO 250, URSODIOL
URSO FORTE, URSODIOL
URSODIOL, URSODIOL
UVADEX, METHOXSALEN

**** V ****

VAGIFEM, ESTRADIOL
VAGISTAT-1, TIOCONAZOLE (OTC)
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
VALIUM, DIAZEPAM
VALNAC, BETAMETHASONE VALERATE
VALPROATE SODIUM, VALPROATE SODIUM
VALPROIC ACID, VALPROIC ACID
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VALTROPIN, SOMATROPIN RECOMBINANT
VALTURNA, ALISKIREN HEMIFUMARATE
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANDAZOLE, METRONIDAZOLE
VANIQA, EFLORNITHINE HYDROCHLORIDE
VANOS, FLUOCINONIDE
VANTAS, HISTRELIN ACETATE
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VASCEPA, ICOSAPENT ETHYL
VASERETIC, ENALAPRIL MALEATE
VASOCIDIN, PREDNISOLONE SODIUM PHOSPHATE
VASOTEC, ENALAPRIL MALEATE
VECTICAL, CALCITRIOL
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VELCADE, BORTEZOMIB

APPENDIX A - PRODUCT NAME INDEX

A - 57

**** V ****

VELETRI, EPOPROSTENOL SODIUM
VELIVET, DESOGESTREL
VELTIN, CLINDAMYCIN PHOSPHATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VENOFER, IRON SUCROSE
VENTAVIS, ILOPROST
VENTOLIN HFA, ALBUTEROL SULFATE
VERAMYST, FLUTICASONE FUROATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VERDESO, DESONIDE
VEREGEN, SINECATECHINS
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERELAN, VERAPAMIL HYDROCHLORIDE
VESICARE, SOLIFENACIN SUCCINATE
VEXOL, RIMEXOLONE
VFEND, VORICONAZOLE
VIAGRA, SILDENAFIL CITRATE
VIBATIV, TELAVANCIN HYDROCHLORIDE
VIBISONE, CYANOCOBALAMIN
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VICOPROFEN, HYDROCODONE BITARTRATE
VICTOZA, LIRAGLUTIDE RECOMBINANT
VICTRELIS, BOCEPREVIR
VIDAZA, AZACITIDINE
VIDEX EC, DIDANOSINE
VIDEX, DIDANOSINE
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
VIIBRYD, VILAZODONE HYDROCHLORIDE
VIMOVO, ESOMEPRAZOLE MAGNESIUM
VIMPAT, LACOSAMIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
VINORELBINE, VINORELBINE
VIOKACE, LIPASE
VIORELE, DESOGESTREL
VIRACEPT, NELFINAVIR MESYLATE
VIRAMUNE XR, NEVIRAPINE
VIRAMUNE, NEVIRAPINE
VIRAZOLE, RIBAVIRIN
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VIROPTIC, TRIFLURIDINE
VISICOL, SODIUM PHOSPHATE, DIBASIC ANHYDROUS
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
VISIONBLUE, TRYPAN BLUE
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VISTARIL, HYDROXYZINE PAMOATE
VISTIDE, CIDOFOVIR
VISUDYNE, VERTEPORFIN
VITAMIN D, ERGOCALCIFEROL
VITAMIN K1, PHYTONADIONE
VITRASE, HYALURONIDASE
VITRASERT, GANCICLOVIR
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE
VIVELLE, ESTRADIOL
VIVELLE-DOT, ESTRADIOL
VIVITROL, NALTREXONE
VOLTAREN, DICLOFENAC SODIUM
VOLTAREN-XR, DICLOFENAC SODIUM
VORICONAZOLE, VORICONAZOLE

APPENDIX A - PRODUCT NAME INDEX

A - 58

**** V ****

VOSOL HC, ACETIC ACID, GLACIAL
 VOSOL, ACETIC ACID, GLACIAL
 VOSPIRE ER, ALBUTEROL SULFATE
 VOTRIENT, PAZOPANIB HYDROCHLORIDE
 VPRIV, VELAGLUCERASE ALFA
 VUMON, TENIPOSIDE
 VUSION, MICONAZOLE NITRATE
 VYTORIN, EZETIMIBE
 VYVANSE, LISDEXAMFETAMINE DIMESYLATE

**** W ****

WARFARIN SODIUM, WARFARIN SODIUM
 WELCHOL, COLESEVELAM HYDROCHLORIDE
 WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
 WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
 WELLBUTRIN, BUPROPION HYDROCHLORIDE
 WERA, ETHINYL ESTRADIOL
 WESTCORT, HYDROCORTISONE VALERATE

**** X ****

XALATAN, LATANOPROST
 XALKORI, CRIZOTINIB
 XANAX XR, ALPRAZOLAM
 XANAX, ALPRAZOLAM
 XARELTO, RIVAROXABAN
 XELJANZ, TOFACITINIB CITRATE
 XELODA, CAPECITABINE
 XENAZINE, TETRABENAZINE
 XENICAL, ORLISTAT
 XENON XE 133, XENON XE-133
 XERESE, ACYCLOVIR
 XIFAXAN, RIFAXIMIN
 XIMINO, MINOCYCLINE HYDROCHLORIDE
 XOLEGEL, KETOCONAZOLE
 XOPENEX HFA, LEVALBUTEROL TARTRATE
 XOPENEX, LEVALBUTEROL HYDROCHLORIDE
 XTANDI, ENZALUTAMIDE
 XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE
 XYREM, SODIUM OXYBATE
 XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE

**** Y ****

YASMIN, DROSPIRENONE
 YAZ, DROSPIRENONE

**** Z ****

ZADITOR, KETOTIFEN FUMARATE (OTC)
 ZAFIRLUKAST, ZAFIRLUKAST
 ZALEPLON, ZALEPLON
 ZANAFLEX, TIZANIDINE HYDROCHLORIDE
 ZANOSAR, STREPTOZOCIN
 ZANTAC 150, RANITIDINE HYDROCHLORIDE
 ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
 ZANTAC 25, RANITIDINE HYDROCHLORIDE
 ZANTAC 300, RANITIDINE HYDROCHLORIDE
 ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
 ZANTAC IN PLASTIC CONTAINER, RANITIDINE HYDROCHLORIDE
 ZANTAC, RANITIDINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

A - 59

**** Z ****

ZARONTIN, ETHOSUXIMIDE
ZAROXOLYN, METOLAZONE
ZAVESCA, MIGLUSTAT
ZEBETA, BISOPROLOL FUMARATE
ZECUITY, SUMATRIPTAN SUCCINATE
ZEGERID OTC, OMEPRAZOLE (OTC)
ZEGERID, OMEPRAZOLE
ZELAPAR, SELEGILINE HYDROCHLORIDE
ZELBORAF, VEMURAFENIB
ZEMPLAR, PARICALCITOL
ZEMURON, ROCURONIUM BROMIDE
ZENPEP, LIPASE
ZERIT, STAVUDINE
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINAPRIL
ZETIA, EZETIMIBE
ZETONNA, CICLESONIDE
ZIAC, BISOPROLOL FUMARATE
ZIAGEN, ABACAVIR SULFATE
ZIANA, CLINDAMYCIN PHOSPHATE
ZIDOVUDINE, ZIDOVUDINE
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
ZINACEF, CEFUROXIME SODIUM
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZIOPTAN, TAFLUPROST
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZIPSOR, DICLOFENAC POTASSIUM
ZIRGAN, GANCICLOVIR
ZITHROMAX, AZITHROMYCIN
ZMAX, AZITHROMYCIN
ZOCOR, SIMVASTATIN
ZOFRAN ODT, ONDANSETRON
ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOLADEX, GOSERELIN ACETATE
ZOLINZA, VORINOSTAT
ZOLOFT, SERTRALINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZOLPIMIST, ZOLPIDEM TARTRATE
ZOMETA, ZOLEDRONIC ACID
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
ZONALON, DOXEPIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE
ZONISAMIDE, ZONISAMIDE
ZORBTIVE, SOMATROPIN RECOMBINANT
ZORTRESS, EVEROLIMUS
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOSYN, PIPERACILLIN SODIUM
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
ZOVIRAX, ACYCLOVIR
ZUPLENZ, ONDANSETRON
ZUTRIPRO, CHLORPHENIRAMINE MALEATE
ZYBAN, BUPROPION HYDROCHLORIDE
ZYCLARA, IMIQUIMOD
ZYDONE, ACETAMINOPHEN
ZYFLO CR, ZILEUTON
ZYFLO, ZILEUTON
ZYLET, LOTEPREDNOL ETABONATE
ZYLOPRIM, ALLOPURINOL
ZYMAR, GATIFLOXACIN
ZYMAXID, GATIFLOXACIN

APPENDIX A - PRODUCT NAME INDEX

A - 60

**** Z ****

ZYPREXA RELPREVV, OLANZAPINE PAMOATE
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE
ZYTREC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYTREC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ZYTREC, CETIRIZINE HYDROCHLORIDE
ZYTREC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)
ZYTIGA, ABIRATERONE ACETATE
ZYVOX, LINEZOLID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** 3 ****

3M

- * 3M CO
PERIDEX, CHLORHEXIDINE GLUCONATE
- * 3M HEALTH CARE INC
AVAGARD, ALCOHOL (OTC)
DURAPREP, IODINE POVACRYLEX (OTC)
- * 3M PHARMACEUTICALS INC
PROVENTIL-HFA, ALBUTEROL SULFATE

AAIPHARMA LLC

- * AAIPHARMA LLC
AZASAN, AZATHIOPRINE

ABBOTT

- * ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS DIV
HYTRIN, TERAZOSIN HYDROCHLORIDE

ABBOTT ENDOCRINE

- * ABBOTT ENDOCRINE INC
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE

ABBOTT LABS

- * ABBOTT LABORATORIES
PROMETRIUM, PROGESTERONE

ABBVIE

- * ABBVIE INC
ADVICOR, LOVASTATIN
AKINETON, BIPERIDEN HYDROCHLORIDE
ANDROGEL, TESTOSTERONE
BIAXIN XL, CLARITHROMYCIN
BIAXIN, CLARITHROMYCIN
CALCIJEX, CALCITRIOL
CREON, LIPASE
CYCLOSPORINE, CYCLOSPORINE
DEPACON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
GENGRAF, CYCLOSPORINE
KALETRA, LOPINAVIR
K-TAB, POTASSIUM CHLORIDE
MARINOL, DRONABINOL
MAVIK, TRANDOLAPRIL
NIASPAN, NIACIN
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NORVIR, RITONAVIR
ORETIC, HYDROCHLOROTHIAZIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
SIMCOR, NIACIN
SURVANTA, BERACTANT
SYNTHROID, LEVOTHYROXINE SODIUM
TARKA, TRANDOLAPRIL
TEVETEN HCT, EPROSARTAN MESYLATE
TEVETEN, EPROSARTAN MESYLATE
TRICOR, FENOFIBRATE
TRIDIONE, TRIMETHADIONE
TRILIPIX, CHOLINE FENOFIBRATE
ULTANE, SEVOFLURANE
VICOPROFEN, HYDROCODONE BITARTRATE
ZEMPLAR, PARICALCITOL

ABBVIE ENDOCRINE

- * ABBVIE ENDOCRINE INC
LUPANETA PACK, LEUPROLIDE ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

ABRAXIS BIOSCIENCE

* ABRAXIS BIOSCIENCE LLC
ABRAXANE, PACLITAXEL

ABRAXIS PHARM

* ABRAXIS PHARMACEUTICAL PRODUCTS
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE

ACADEMIC PHARMS

* ACADEMIC PHARMACEUTICALS INC
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

ACCORD HLTH

* ACCORD HEALTH CARE INC
METHYLDOPA, METHYLDOPA

ACCORD HLTHCARE

* ACCORD HEALTHCARE INC
DOCETAXEL, DOCETAXEL
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
MITOMYCIN, MITOMYCIN
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
TACROLIMUS, TACROLIMUS
TOPIRAMATE, TOPIRAMATE

ACCORD HLTHCARE INC

* ACCORD HEALTHCARE INC USA
ANASTROZOLE, ANASTROZOLE
BICALUTAMIDE, BICALUTAMIDE
CLONAZEPAM, CLONAZEPAM
ETOPOSIDE, ETOPOSIDE
FINASTERIDE, FINASTERIDE
GLIPIZIDE, GLIPIZIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
PACLITAXEL, PACLITAXEL
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

ACELLA PHARMS LLC

* ACELLA PHARMACEUTICALS LLC
GABAPENTIN, GABAPENTIN

ACORDA

* ACORDA THERAPEUTICS INC
AMPYRA, DALFAMPRIDINE
ZANAFLEX, TIZANIDINE HYDROCHLORIDE

ACS DOBFAR

* ACS DOBFAR SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
CEFAZOLIN SODIUM, CEFZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFOXITIN, CEFOTAXIME SODIUM
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
KEFZOL, CEFZOLIN SODIUM
MEROPENEM, MEROPENEM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

ACS DOBFAR INFO SA

- * ACS DOBFAR INFO SA
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
FLUCANAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN

ACTAVIS

- * ACTAVIS SOUTH ATLANTIC LLC
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
- * ACTAVIS SOUTHATLANTIC LLC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

ACTAVIS ELIZABETH

- * ACTAVIS ELIZABETH LLC
ALPRAZOLAM, ALPRAZOLAM
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
ASPARTATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
GABAPENTIN, GABAPENTIN
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDAPAMIDE, INDAPAMIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
KADIAN, MORPHINE SULFATE
LEVETIRACETAM, LEVETIRACETAM
LOVASTATIN, LOVASTATIN
MIRTAZAPINE, MIRTAZAPINE
MORPHINE SULFATE, MORPHINE SULFATE
NIFEDIPINE, NIFEDIPINE
OXAZEPAM, OXAZEPAM
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
SPIRONOLACTONE, SPIRONOLACTONE
TEMAZEPAM, TEMAZEPAM

ACTAVIS INC

- * ACTAVIS INC
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM

ACTAVIS MID ATLANTIC

- * ACTAVIS MID ATLANTIC LLC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETASOL HC, ACETIC ACID, GLACIAL
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CICLOPIROX, CICLOPIROX
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
CONSTULOSE, LACTULOSE
ENULOSE, LACTULOSE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ACTAVIS MID ATLANTIC LLC
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCORTISONE, HYDROCORTISONE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
LEVETIRACETAM, LEVETIRACETAM
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
NYSTATIN, NYSTATIN
PERMETHRIN, PERMETHRIN
PERMETHRIN, PERMETHRIN (OTC)
PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
VALNAC, BETAMETHASONE VALERATE

ACTAVIS PHARMA

* ACTAVIS PHARMA MANUFACTURING PRIVATE LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

ACTAVIS S ATLANTIC

* ACTAVIS SOUTH ATLANTIC LLC
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

ACTAVIS TOTOWA

* ACTAVIS TOTOWA LLC
BICALUTAMIDE, BICALUTAMIDE
CARBOPLATIN, CARBOPLATIN
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LETROZOLE, LETROZOLE
OXALIPLATIN, OXALIPLATIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

ACTELION PHARMS LTD

* ACTELION PHARMACEUTICALS LTD
TRACLEER, BOSENTAN
VELETRI, EPOPROSTENOL SODIUM
VENTAVIS, ILOPROST
ZAVESCA, MIGLUSTAT

ACTIENT PHARMS

* ACTIENT PHARMACEUTICALS LLC
EDEX, ALPROSTADIL
LEVATOL, PENBUTOLOL SULFATE
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
STRIANT, TESTOSTERONE
TESTOPEL, TESTOSTERONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ACTIENT PHARMACEUTICALS LLC
THEO-24, THEOPHYLLINE

ACTON PHARMS

* ACTON PHARMACEUTICALS INC
AEROSPAN HFA, FLUNISOLIDE

ADVENT PHARMS

* ADVENT PHARMACEUTICALS INC
CARISOPRODOL, CARISOPRODOL

AEGERION

* AEGERION PHARMACEUTICALS INC
JUXTAPID, LOMITAPIDE MESYLATE

AFFYMAX

* AFFYMAX INC
OMONTYS PRESERVATIVE FREE, PEGINESATIDE ACETATE
OMONTYS, PEGINESATIDE ACETATE

AGILA SPECCLTS

* AGILA SPECIALTIES PRIVATE LTD
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE

AGOURON

* AGOURON PHARMACEUTICALS INC
VIRACEPT, NELFINAVIR MESYLATE

AJANTA PHARMA

* AJANTA PHARMA LTD
LEVETIRACETAM, LEVETIRACETAM

AJANTA PHARMA LTD

* AJANTA PHARMA LTD
RISPERIDONE, RISPERIDONE

AKORN

* AKORN INC
ADENOSINE, ADENOSINE
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AK-FLUOR 10%, FLUORESCCEIN SODIUM
AK-FLUOR 25%, FLUORESCCEIN SODIUM
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKPRO, DIPIVEFRIN HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
ALFENTA, ALFENTANIL HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CALCITRIOL, CALCITRIOL
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CARBOPLATIN, CARBOPLATIN
CROMOLYN SODIUM, CROMOLYN SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ENDOSOL EXTRA, CALCIUM CHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IC-GREEN, INDOCYANINE GREEN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
LATANOPROST, LATANOPROST

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AKORN INC
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
OFLOXACIN, OFLOXACIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TIMOLOL MALEATE, TIMOLOL MALEATE
TROPICACYL, TROPICAMIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

AKORN INC

* AKORN INC
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
CEFTRIAXONE, CEFTRIAXONE SODIUM
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
INAPSINE, DROPERIDOL
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM

AKRIMAX PHARMS

* AKRIMAX PHARMACEUTICALS LLC
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDERAL, PROPRANOLOL HYDROCHLORIDE
INDERIDE-40/25, HYDROCHLOROTHIAZIDE

ALARA PHARM

* ALARA PHARMACEUTICAL CORPORATION
LEVO-T, LEVOTHYROXINE SODIUM

ALCON

* ALCON INC
TRIESENCE, TRIAMCINOLONE ACETONIDE
* ALCON LABORATORIES INC
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALOMIDE, LODOXAMIDE TROMETHAMINE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BSS PLUS, CALCIUM CHLORIDE
BSS, CALCIUM CHLORIDE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CETAMIDE, SULFACETAMIDE SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
DENDRID, IDOXURIDINE
EMADINE, EMEDASTINE DIFUMARATE
FLAREX, FLUOROMETHOLONE ACETATE
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
MAXIDEX, DEXAMETHASONE
MAXITROL, DEXAMETHASONE
MIOSTAT, CARBACHOL
MYDRIACYL, TROPICAMIDE
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
NATACYN, NATAMYCIN
OMNIPRED, PREDNISOLONE ACETATE
PATANOL, OLOPATADINE HYDROCHLORIDE
PILOPINE HS, PILOCARPINE HYDROCHLORIDE
TOBRADEX, DEXAMETHASONE
TOBREX, TOBRAMYCIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALCON LABORATORIES INC
VEXOL, RIMEXOLONE

ALCON PHARMA

* ALCON RESEARCH LTD
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
ZADITOR, KETOTIFEN FUMARATE (OTC)

ALCON PHARMS LTD

* ALCON PHARMACEUTICALS LTD
AZOPT, BRINZOLAMIDE
BETADINE, POVIDONE-IODINE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DUREZOL, DIFLUPREDNATE
FLUORESCITE, FLUORESCIN SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
NAVSTEL, CALCIUM CHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEVANAC, NEPAFENAC
OFLOXACIN, OFLOXACIN
PATADAY, OLOPATADINE HYDROCHLORIDE
PATANASE, OLOPATADINE HYDROCHLORIDE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TOBRADEX ST, DEXAMETHASONE
TRAVATAN Z, TRAVOPROST
TRIFLURIDINE, TRIFLURIDINE
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE

ALCON RES

* ALCON RESEARCH LTD
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
LATANOPROST, LATANOPROST

ALCON RES LTD

* ALCON RESEARCH LTD
NEPAFENAC, NEPAFENAC

ALEMBIC LTD

* ALEMBIC LTD
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
METRONIDAZOLE, METRONIDAZOLE
MODAFINIL, MODAFINIL
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE

ALEMBIC PHARMS LTD

* ALEMBIC PHARMACEUTICALS LTD
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
FAMOTIDINE, FAMOTIDINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEFLUNOMIDE, LEFLUNOMIDE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ALEMBIC PHARMACEUTICALS LTD
MEPROBAMATE, MEPROBAMATE
METRONIDAZOLE, METRONIDAZOLE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ALEXZA PHARMS

* ALEXZA PHARMACEUTICALS INC
ADASUVE, LOXAPINE

ALKEM

* ALKEM LABORATORIES LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CEPHALEXIN, CEPHALEXIN
GABAPENTIN, GABAPENTIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ALKEM LABS LTD

* ALKEM LABORATORIES LTD
CEFUROXIME AXETIL, CEFUROXIME AXETIL
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

ALKERMES

* ALKERMES INC
VIVITROL, NALTREXONE

ALKERMES GAINESVILLE

* ALKERMES GAINESVILLE LLC
VERELAN, VERAPAMIL HYDROCHLORIDE

ALKOPHARMA USA

* ALKOPHARMA USA INC
AMPHOTEC, AMPHOTERICIN B

ALLEGIANCE HLTHCARE

* ALLEGIANCE HEALTHCARE CORP
POVIDONE IODINE, POVIDONE-IODINE (OTC)

ALLERGAN

* ALLERGAN
ACULAR LS, KETOROLAC TROMETHAMINE
ALPHAGAN P, BRIMONIDINE TARTRATE
BLEPH-10, SULFACETAMIDE SODIUM
GENOPTIC, GENTAMICIN SULFATE
Zymaxid, GATIFLOXACIN
* ALLERGAN INC
ACULAR PRESERVATIVE FREE, KETOROLAC TROMETHAMINE
ACULAR, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACZONE, DAPSONE
ALBALON, NAPHAZOLINE HYDROCHLORIDE
ALOCRIL, NEDOCROMIL SODIUM
ALPHAGAN P, BRIMONIDINE TARTRATE
AVAGE, TAZAROTENE
AZELEX, AZELAIC ACID
COMBIGAN, BRIMONIDINE TARTRATE
ELESTAT, EPINASTINE HYDROCHLORIDE
LASTACFT, ALCAFTADINE
LATISSE, BIMATOPROST
LUMIGAN, BIMATOPROST
OCUFLOX, OFLOXACIN
OPTICROM, CROMOLYN SODIUM
OZURDEX, DEXAMETHASONE
POLYTRIM, POLYMYXIN B SULFATE
RESTASIS, CYCLOSPORINE
SANCTURA XR, TROSPIUM CHLORIDE
SANCTURA, TROSPIUM CHLORIDE
TAZORAC, TAZAROTENE
TRIVARIS, TRIAMCINOLONE ACETONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALLERGAN INC
ZYMAR, GATIFLOXACIN
* ALLERGAN PHARMACEUTICAL
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLEPHAMIDE, PREDNISOLONE ACETATE
FML FORTE, FLUOROMETHOLONE
FML, FLUOROMETHOLONE
HERPLEX, IDOXURIDINE
OCUFEN, FLURBIPROFEN SODIUM
OPHTHETIC, PROPARACAINE HYDROCHLORIDE
POLY-PRED, NEOMYCIN SULFATE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE
PROPINE, DIPIVEFRIN HYDROCHLORIDE

ALLERQUEST

* ALLERQUEST LLC
PRE-PEN, BENZYL PENICILLOYL POLYLYSINE

ALLOS

* ALLOS THERAPEUTICS INC
FOLOTYN, PRALATREXATE

ALMATICA

* ALMATICA PHARMA INC
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE

ALPHARMA

* ALPHARMA USPD INC
PREDNISOLONE, PREDNISOLONE
VALPROIC ACID, VALPROIC ACID

ALPHARMA KING

* ALPHARMA PHARMACEUTICALS LLC KING PHARMACEUTICALS
EMBEDA, MORPHINE SULFATE

ALRA

* ALRA LABORATORIES INC
CHOLAC, LACTULOSE
CONSTILAC, LACTULOSE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
IBU-TAB 200, IBUPROFEN (OTC)
IBU-TAB, IBUPROFEN

ALTAIRE PHARMS INC

* ALTAIRE PHARMACEUTICALS INC
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)

ALTERNA TCHP LLC

* ALTERNA TCHP LLC
CHILDREN'S ELIXSURE, IBUPROFEN (OTC)

ALVOGEN

* ALVOGEN INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

ALVOGEN INC

* ALVOGEN INC
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

AM ANTIBIOTICS

* AMERICAN ANTIBIOTICS INC
AMOXICILLIN, AMOXICILLIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

AMAG PHARMS INC

- * AMAG PHARMACEUTICALS INC
FERAHEME, FERUMOXYTOL
GASTROMARK, FERUMOXSYL

AMARIN PHARMA INC

- * AMARIN PHARMA INC
VASCEPA, ICOSAPENT ETHYL

AMEDRA PHARMS

- * AMEDRA PHARMACEUTICALS LLC
ADRENALIN, EPINEPHRINE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
HYDROCORTISONE, HYDROCORTISONE
TWINJECT 0.15, EPINEPHRINE
TWINJECT 0.3, EPINEPHRINE

AMGEN

- * AMGEN INC
SENSIPAR, CINACALCET HYDROCHLORIDE

AMNEAL PHARM

- * AMNEAL PHARMACEUTICAL
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FOLIC ACID, FOLIC ACID
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE

AMNEAL PHARMS

- * AMNEAL PHARMACEUTICALS
ALBUTEROL SULFATE, ALBUTEROL SULFATE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FELBAMATE, FELBAMATE
GABAPENTIN, GABAPENTIN
IBUPROFEN, IBUPROFEN (OTC)
INDOMETHACIN, INDOMETHACIN
LEVETIRACETAM, LEVETIRACETAM
LORAZEPAM, LORAZEPAM
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN
NIZATIDINE, NIZATIDINE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SPIRONOLACTONE, SPIRONOLACTONE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
- * AMNEAL PHARMACEUTICALS LLC
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

AMNEAL PHARMS NY

- * AMNEAL PHARMACEUTICALS NY LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALPRAZOLAM, ALPRAZOLAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* AMNEAL PHARMACEUTICALS NY LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
REPREXAIN, HYDROCODONE BITARTRATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

AMPHASTAR PHARM

* AMPHASTAR PHARMACEUTICAL INC
AMPHADASE, HYALURONIDASE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM

AMPHASTAR PHARMS INC

* AMPHASTAR PHARMACEUTICALS INC
CORTROSYN, COSYNTROPIN

AMPOLGEN

* AMPOLGEN PHARMACEUTICALS LLC
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE

AMYLIN

* AMYLIN PHARMACEUTICALS INC
BYDUREON, EXENATIDE SYNTHETIC
BYETTA, EXENATIDE SYNTHETIC
SYMLIN, PRAMLINTIDE ACETATE

ANBEX

* ANBEX INC
IOSAT, POTASSIUM IODIDE (OTC)

ANCHEN PHARMS

* ANCHEN PHARMACEUTICALS INC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRETINOIN, TRETINOIN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
* ANCHEN PHARMACEUTICALS TAIWAN INC
DIVALPROEX SODIUM, DIVALPROEX SODIUM
* ANCHEN PHARMACEUTICALS, INC
ALPRAZOLAM, ALPRAZOLAM
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ANDRX LABS LLC

* ANDRX LABS LLC
ALTOPREV, LOVASTATIN
FORTAMET, METFORMIN HYDROCHLORIDE

ANGELINI LLC

* ANGELINI LABOPHARM LLC
OLEPTRO, TRAZODONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******ANI PHARMS**

- * ANI PHARMACEUTICALS INC
CORTENEMA, HYDROCORTISONE
LACTULOSE, LACTULOSE
LUVOX, FLUVOXAMINE MALEATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE

ANTIBIOTICE

- * ANTIBIOTICE SA
AMPICILLIN SODIUM, AMPICILLIN SODIUM
NAFCILLIN SODIUM, NAFCILLIN SODIUM

ANTIBIOTICOS BRASIL

- * ANTIBIOTICOS DO BRASIL LTDA
CEFOXITIN, CEFOXITIN SODIUM

APGDI

- * ASTELLAS PHARMA GLOBAL DEVELOPMENT INC
MYRBETRIQ, MIRABEGRON

APHENA PHARMA MD

- * APHENA PHARMA SOLUTIONS MARYLAND LLC
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)

APOPHARMA INC

- * APOPHARMA INC
FERRIPROX, DEFERIPRONE

APOTEX

- * APOTEX CORP
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
- * APOTEX INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
BUDESONIDE, BUDESONIDE
CAPTOPRIL, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CYCLOSPORINE, CYCLOSPORINE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DILT-CD, DILTIAZEM HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPLERENONE, EPLERENONE
ETODOLAC, ETODOLAC
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FLUCONAZOLE, FLUCONAZOLE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
KETOCONAZOLE, KETOCONAZOLE
LAMIVUDINE, LAMIVUDINE
LATANOPROST, LATANOPROST

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* APOTEX INC
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NIZATIDINE, NIZATIDINE
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PENTOXIFYLLINE, PENTOXIFYLLINE
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RAMIPRIL, RAMIPRIL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE

APOTEX CORP

* APOTEX CORP
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AZITHROMYCIN, AZITHROMYCIN
 CICLOPIROX, CICLOPIROX
 CLARITHROMYCIN, CLARITHROMYCIN
 GATIFLOXACIN, GATIFLOXACIN
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NARATRIPTAN, NARATRIPTAN
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

APOTEX INC

* APOTEX INC
 ABACAVIR SULFATE, ABACAVIR SULFATE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALPRAZOLAM, ALPRAZOLAM
 ANASTROZOLE, ANASTROZOLE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 CALCITONIN-SALMON, CALCITONIN SALMON
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CARBAMAZEPINE, CARBAMAZEPINE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CEFPROZIL, CEFPROZIL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CEVIMELINE, CEVIMELINE HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DOCETAXEL, DOCETAXEL
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* APOTEX INC
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMIQUIMOD, IMIQUIMOD
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LOVASTATIN, LOVASTATIN
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
NABUMETONE, NABUMETONE
NEVIRAPINE, NEVIRAPINE
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
OXCARBAZEPINE, OXCARBAZEPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISPERIDONE, RISPERIDONE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* APOTEX INC ETOBICOKE SITE
ACYCLOVIR, ACYCLOVIR
ALLOPURINOL, ALLOPURINOL
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
CARVEDILOL, CARVEDILOL
CILOSTAZOL, CILOSTAZOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DILTIZAC, DILTIAZEM HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
LEFLUNOMIDE, LEFLUNOMIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LITHIUM CARBONATE, LITHIUM CARBONATE
LORATADINE, LORATADINE (OTC)
MELOXICAM, MELOXICAM
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
OXAPROZIN, OXAPROZIN
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TORSEMIDE, TORSEMIDE
ZONISAMIDE, ZONISAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

- * APOTEX INC RICHMOND HILL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FLUNISOLIDE, FLUNISOLIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LORATADINE, LORATADINE (OTC)
MEGESTROL ACETATE, MEGESTROL ACETATE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
RISPERIDONE, RISPERIDONE
- * APOTEX INC.
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

APOTHECON

- * APOTHECON INC DIV BRISTOL MYERS SQUIBB
CAPOZIDE 25/15, CAPTOPRIL
CAPOZIDE 25/25, CAPTOPRIL
CAPOZIDE 50/15, CAPTOPRIL
CAPOZIDE 50/25, CAPTOPRIL
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
OPHTHAINE, PROPARACAINE HYDROCHLORIDE
STADOL PRESERVATIVE FREE, BUTORPHANOL TARTRATE
STADOL, BUTORPHANOL TARTRATE

APP PHARMS

- * APP PHARMACEUTICALS LLC
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

APRICUS PHARMS

- * APRICUS PHARMACEUTICALS USA INC
TOTECT, DEXRAZOXANE HYDROCHLORIDE

APTALIS PHARMA

- * APTALIS PHARMA LTD
RECTIV, NITROGLYCERIN

APTALIS PHARMA US

- * APTALIS PHARMA US INC
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
CANASA, MESALAMINE
CARAFATE, SUCRALFATE
PYLERA, BISMUTH SUBCITRATE POTASSIUM
ULTRESA, LIPASE
URSO 250, URSODIOL
URSO FORTE, URSODIOL
VIOKACE, LIPASE
ZENPEP, LIPASE

APTALIS PHARMATECH

- * APTALIS PHARMATECH INC
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

AQUA PHARMS

- * AQUA PHARMACEUTICALS
CORDRAN SP, FLURANDRENOLIDE
CORDRAN, FLURANDRENOLIDE
MONODOX, DOXYCYCLINE
- * AQUA PHARMACEUTICALS LLC
FLUOROPLEX, FLUOROURACIL
XOLEGEL, KETOCONAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

AR HOLDING CO INC

* AR HOLDING CO INC
FIBRICOR, FENOFIBRIC ACID

ARBOR PHARMS INC

* ARBOR PHARMACEUTICALS INC
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
BIDIL, HYDRALAZINE HYDROCHLORIDE
E.E.S. 200, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERY-TAB, ERYTHROMYCIN
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN, ERYTHROMYCIN
GLIADEL, CARMUSTINE
PCE, ERYTHROMYCIN
PEDIAMYCIN 400, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAMYCIN, ERYTHROMYCIN ETHYLSUCCINATE

ARCHIMEDES

* ARCHIMEDES DEVELOPMENT LTD
LAZANDA, FENTANYL CITRATE

ARCO PHARMS LLC

* ARCO PHARMACEUTICALS LLC
THYROSHIELD, POTASSIUM IODIDE (OTC)

AREVA PHARMS

* AREVA PHARMACEUTICALS INC
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

ARIAD

* ARIAD PHARMACEUTICALS INC
ICLUSIG, PONATINIB HYDROCHLORIDE

ARMSTRONG PHARMS

* ARMSTRONG PHARMACEUTICALS INC
EPINEPHRINE, EPINEPHRINE (OTC)

ASCEND

* ASCEND THERAPEUTICS INC
ESTROGEL, ESTRADIOL

ASPEN GLOBAL

* ASPEN GLOBAL INC
MYLERAN, BUSULFAN

ASPEN GLOBAL INC

* ASPEN GLOBAL INC
LEUKERAN, CHLORAMBUCIL

ASTELLAS

* ASTELLAS PHARMA US INC
ADENOCARD, ADENOSINE
ADENOSCAN, ADENOSINE
AMBISOME, AMPHOTERICIN B
LEXISCAN, REGADENOSON
MYCAMINE, MICAfungin sodium
PROGRAF, TACROLIMUS
PROTOPIC, TACROLIMUS
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VESICARE, SOLIFENACIN SUCCINATE
XTANDI, ENZALUTAMIDE

ASTRAZENECA

* ASTRAZENECA LP
DUTOPROL, HYDROCHLOROTHIAZIDE
ENTOCORT EC, BUDESONIDE
NEXIUM IV, ESOMEPRazole sodium

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

- * ASTRAZENECA LP
 - NEXIUM, ESOMEPRAZOLE MAGNESIUM
 - PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
 - PRILOSEC, OMEPRAZOLE
 - PRILOSEC, OMEPRAZOLE MAGNESIUM
 - PULMICORT FLEXHALER, BUDESONIDE
 - PULMICORT RESPULES, BUDESONIDE
 - RHINOCORT, BUDESONIDE
 - SEROQUEL, QUETIAPINE FUMARATE
 - SYMBICORT, BUDESONIDE
 - TENORMIN, ATENOLOL
 - TOPROL-XL, METOPROLOL SUCCINATE
- * ASTRAZENECA PHARMACEUTICALS LP
 - ATACAND HCT, CANDESARTAN CILEXETIL
 - ATACAND, CANDESARTAN CILEXETIL
 - FASLODEX, FULVESTRANT
 - PLENDIL, FELODIPINE
 - SEROQUEL XR, QUETIAPINE FUMARATE
 - TENORETIC 100, ATENOLOL
 - TENORETIC 50, ATENOLOL
 - ZOMIG, ZOLMITRIPTAN
 - ZOMIG-ZMT, ZOLMITRIPTAN
- * ASTRAZENECA UK LTD
 - ACCOLATE, ZAFIRLUKAST
 - ARIMIDEX, ANASTROZOLE
 - CASODEX, BICALUTAMIDE
 - MERREM, MEROPENEM
 - ZESTORETIC, HYDROCHLOROTHIAZIDE
 - ZESTRIL, LISINOPRIL
 - ZOLADEX, GOSERELIN ACETATE

ASTRAZENECA LP

- * ASTRAZENECA LP
 - BRILINTA, TICAGRELOR
 - VIMOVO, ESOMEPRAZOLE MAGNESIUM

ATON

- * ATON PHARMA INC
 - CUPRIMINE, PENICILLAMINE
 - EDECIN, ETHACRYNATE SODIUM
 - EDECIN, ETHACRYNIC ACID
 - LACRISERT, HYDROXYPROPYL CELLULOSE
 - LODOSYN, CARBIDOPA
 - SYPRINE, TRIENTINE HYDROCHLORIDE
 - TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
 - TIMOPTIC, TIMOLOL MALEATE

AUROBINDO

- * AUROBINDO PHARMA LTD
 - AMOXICILLIN, AMOXICILLIN
 - CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 - CLARITHROMYCIN, CLARITHROMYCIN
 - DIDANOSINE, DIDANOSINE
 - DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 - LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - LISINOPRIL, LISINOPRIL
 - METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 - MIRTAZAPINE, MIRTAZAPINE
 - NEVIRAPINE, NEVIRAPINE
 - ZIDOVUDINE, ZIDOVUDINE

AUROBINDO PHARM

- * AUROBINDO PHARMA USA INC
 - FLUCONAZOLE, FLUCONAZOLE
 - FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 - GABAPENTIN, GABAPENTIN
 - LEVETIRACETAM, LEVETIRACETAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* AUROBINDO PHARMA USA INC
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

AUROBINDO PHARMA

* AUROBINDO PHARMA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM

* AUROBINDO PHARMA LTD
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ATENOLOL, ATENOLOL
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CARISOPRODOL, CARISOPRODOL
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFDINIR, CEFDINIR
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DIDANOSINE, DIDANOSINE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MELOXICAM, MELOXICAM
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RIBAVARIN, RIBAVIRIN
RIBAVIRIN, RIBAVIRIN
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
STAVUDINE, STAVUDINE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFFINE HYDROCHLORIDE, TERBINAFFINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TORSEMIDE, TORSEMIDE
TRANDOLAPRIL, TRANDOLAPRIL
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZALEPLON, ZALEPLON

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

AUROBINDO PHARMA LTD

* AUROBINDO PHARMA LIMITED
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
LEVOFLOXACIN, LEVOFLOXACIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

* AUROBINDO PHARMA LTD
ABACAVIR SULFATE, ABACAVIR SULFATE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FAMCICLOVIR, FAMCICLOVIR
FELODIPINE, FELODIPINE
GABAPENTIN, GABAPENTIN
GLIMEPIRIDE, GLIMEPIRIDE
IRBESARTAN, IRBESARTAN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LEVOFLOXACIN, LEVOFLOXACIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MODAFINIL, MODAFINIL
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM
OLANZAPINE, OLANZAPINE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE

* AUROBINDO PHARMA LTD INC
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
MIRTAZAPINE, MIRTAZAPINE
ZIDOVUDINE, ZIDOVUDINE

AUROBINDO PHARMA USA

* AUROBINDO PHARMA USA INC
ALPRAZOLAM, ALPRAZOLAM
NAPROXEN, NAPROXEN

AUROLIFE PHARMA LLC

* AUROLIFE PHARMA LLC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

AUSTARPHARMA LLC

* AUSTARPHARMA LLC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
METHOCARBAMOL, METHOCARBAMOL
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

AUXILIUM PHARMS

* AUXILIUM PHARMACEUTICALS INC
TESTIM, TESTOSTERONE

AVACOR PRODS

* AVACOR PRODUCTS LLC
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

AVANIR PHARMS

* AVANIR PHARMACEUTICALS INC
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE

AVANTHI INC

* AVANTHI INC
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

AVEMA PHARMA

* AVEMA PHARMA SOLUTIONS
IBUPROFEN, IBUPROFEN (OTC)

AVENT

* AVENT INC
PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

AVEVA

* AVEVA DRUG DELIVERY SYSTEMS INC
CLONIDINE, CLONIDINE
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
NICOTINE, NICOTINE (OTC)

AVID RADIOPHARMS INC

* AVID RADIOPHARMACEUTICALS INC
AMYVID, FLORBETAPIR F-18

AZTIQ PHARMA

* AZTIQ PHARMA INC
TODAY, NONOXYNOL-9 (OTC)

B BRAUN

* B BRAUN MEDICAL INC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ALCOHOL 10% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% AND DEXTROSE 5%, ALCOHOL
AMINO ACIDS, AMINO ACIDS
BALANCED SALT, CALCIUM CHLORIDE
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
CEFAZOLIN AND DEXTROSE, CEFZOLIN SODIUM
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETIN SODIUM
CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
CEFTRIAZONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAZONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* B BRAUN MEDICAL INC

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE

FREAMINE HBC 6.9%, AMINO ACIDS

FREAMINE III 10%, AMINO ACIDS

FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS

FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS

FREAMINE III 8.5%, AMINO ACIDS

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE

GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM

HEPATAMINE 8%, AMINO ACIDS

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

ISOLYTE E IN PLASTIC CONTAINER, CALCIUM CHLORIDE

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE

LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE

LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE

LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE

MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL

MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, MANNITOL

MANNITOL 10%, MANNITOL

MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL

MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%, MANNITOL

MANNITOL 15%, MANNITOL

MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL

MANNITOL 20%, MANNITOL

MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL

MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%, MANNITOL

MANNITOL 5%, MANNITOL

METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE

NEPHRAMINE 5.4%, AMINO ACIDS

NUTRILIPID 10%, SOYBEAN OIL

NUTRILIPID 20%, SOYBEAN OIL

PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* B BRAUN MEDICAL INC
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* B BRAUN MEDICAL INC
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROCALAMINE, AMINO ACIDS
 RESECTISOL IN PLASTIC CONTAINER, MANNITOL
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
 SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 TROPHAMINE 10%, AMINO ACIDS
 TROPHAMINE, AMINO ACIDS

BANNER PHARMACAPS

* BANNER PHARMACAPS INC
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 BENZONATATE, BENZONATATE
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 ETHOSUXIMIDE, ETHOSUXIMIDE
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BANNER PHARMACAPS INC
MIDOL LIQUID GELS, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NIMODIPINE, NIMODIPINE
STAVZOR, VALPROIC ACID
VALPROIC ACID, VALPROIC ACID
VITAMIN D, ERGOCALCIFEROL
ZONISAMIDE, ZONISAMIDE

BARR

* BARR LABORATORIES INC
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ARANELLE, ETHINYL ESTRADIOL
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BALZIVA-28, ETHINYL ESTRADIOL
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CAMILA, NORETHINDRONE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORZOXAZONE, CHLORZOXAZONE
CLARAVIS, ISOTRETINOIN
CLONAZEPAM, CLONAZEPAM
CLONIDINE, CLONIDINE
DANAZOL, DANAZOL
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
ASPARTATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DIDANOSINE, DIDANOSINE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DUTASTERIDE, DUTASTERIDE
ERRIN, NORETHINDRONE
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL AND NORGESTIMATE, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
ISONIAZID, ISONIAZID
JUNEL 1.5/30, ETHINYL ESTRADIOL
JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL
JUNEL FE 1/20, ETHINYL ESTRADIOL
KARIVA, DESOGESTREL
KELNOR, ETHINYL ESTRADIOL
LEFLUNOMIDE, LEFLUNOMIDE
LESSINA-28, ETHINYL ESTRADIOL
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

- * BARR LABORATORIES INC
 - MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 - METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 - METHOTREXATE SODIUM, METHOTREXATE SODIUM
 - NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 - NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 - NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 - NORTREL 0.5/35-28, ETHINYL ESTRADIOL
 - NORTREL 1/35-21, ETHINYL ESTRADIOL
 - NORTREL 1/35-28, ETHINYL ESTRADIOL
 - NORTREL 7/7/7, ETHINYL ESTRADIOL
 - ONDANSETRON, ONDANSETRON
 - PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 - PORTIA-28, ETHINYL ESTRADIOL
 - PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 - SPRINTEC, ETHINYL ESTRADIOL
 - TEMOZOLOMIDE, TEMOZOLOMIDE
 - TREXALL, METHOTREXATE SODIUM
 - TRI LO SPRINTEC, ETHINYL ESTRADIOL
 - TRI-LEGEST 21, ETHINYL ESTRADIOL
 - TRI-LEGEST FE, ETHINYL ESTRADIOL
 - TRI-SPRINTEC, ETHINYL ESTRADIOL
 - WARFARIN SODIUM, WARFARIN SODIUM
 - ZONISAMIDE, ZONISAMIDE
- * BARR PHARMACEUTICALS
 - LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

BARR LABS INC

- * BARR LABORATORIES INC
 - ESTRADIOL, ESTRADIOL
 - METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 - MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 - NIMODIPINE, NIMODIPINE
 - OLANZAPINE, OLANZAPINE
 - OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
 - TRETINOIN, TRETINOIN

BAUSCH AND LOMB

- * BAUSCH AND LOMB INC
 - ALAWAY, KETOTIFEN FUMARATE (OTC)
 - ALBUTEROL SULFATE, ALBUTEROL SULFATE
 - ALREX, LOTEPREDNOL ETABONATE
 - BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
 - CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
 - DICLOFENAC SODIUM, DICLOFENAC SODIUM
 - DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 - DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 - FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
 - IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 - LATANOPROST, LATANOPROST
 - LOTEMAX, LOTEPREDNOL ETABONATE
 - MIOCHOL-E, ACETYLCHOLINE CHLORIDE
 - OFLOXACIN, OFLOXACIN
 - OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
 - RETISERT, FLUOCINOLONE ACETONIDE
 - TIMOLOL MALEATE, TIMOLOL MALEATE
 - VITRASERT, GANCICLOVIR
 - ZIRGAN, GANCICLOVIR
 - ZYLET, LOTEPREDNOL ETABONATE
- * BAUSCH AND LOMB PHARMACEUTICALS INC
 - ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL
 - BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
 - BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 - BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAUSCH AND LOMB PHARMACEUTICALS INC
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CROLOM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
ERYTHROMYCIN, ERYTHROMYCIN
FLUNISOLIDE, FLUNISOLIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
OFLOXACIN, OFLOXACIN
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
OTICAIR, HYDROCORTISONE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TROPICAMIDE, TROPICAMIDE

BAXTER HLTHCARE

* BAXTER HEALTHCARE CORP
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BRANCHAMIN 4% IN PLASTIC CONTAINER, AMINO ACIDS
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BAXTER HEALTHCARE CORP

CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS

CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS

CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS

CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS

CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS

CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS

CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS

CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE

CYTOXAN, CYCLOPHOSPHAMIDE

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE

DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE

DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BAXTER HEALTHCARE CORP
 DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 ETHRANE, ENFLURANE
 EXTRANEAL, ICODextrin
 FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
 FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FORANE, ISOFLURANE
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPATASOL 8%, AMINO ACIDS
 IFEX, IFOSFAMIDE
 ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 HYDROCHLORIDE
 MESNEX, MESNA
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
 NEXTERONE, AMIODARONE HYDROCHLORIDE
 NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
 OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 10% IN WATER, MANNITOL
 OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 15% IN WATER, MANNITOL
 OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 20% IN WATER, MANNITOL
 OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 5% IN WATER, MANNITOL
 PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
 PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 PLASMA-LYTE 56 IN PLASTIC CONTAINER, MAGNESIUM ACETATE TETRAHYDRATE
 PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PLASMA-LYTE R IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
 CHLORIDE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 CALCIUM CHLORIDE
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 DEXTROSE
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 DEXTROSE
 POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BAXTER HEALTHCARE CORP
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
 RENAMIN W/O ELECTROLYTES, AMINO ACIDS
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 SEVOFLURANE, SEVOFLURANE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
 SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 STERILE WATER, STERILE WATER FOR IRRIGATION
 SUPRANE, DESFLURANE
 TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 TIS-U-SOL, MAGNESIUM SULFATE
 TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 10% W/O ELECTROLYTES, AMINO ACIDS
 TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 3.5% W/ ELECTROLYTES, AMINO ACIDS
 TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 5.5% W/ ELECTROLYTES, AMINO ACIDS
 TRAVASOL 5.5% W/O ELECTROLYTES, AMINO ACIDS
 TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 8.5% W/ ELECTROLYTES, AMINO ACIDS
 TRAVASOL 8.5% W/O ELECTROLYTES, AMINO ACIDS
 VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

* BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE
 DOPRAM, DOXAPRAM HYDROCHLORIDE
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 HEPARIN SODIUM, HEPARIN SODIUM
 ROBINUL, GLYCOPYRROLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

- * BAXTER HEALTHCARE INTERNATIONAL SPECIALTY THERAPIES DIV
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

BAXTER HLTHCARE CORP

- * BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
- * BAXTER HEALTHCARE CORP ANESTHESIA CRITICAL CARE
ATIVAN, LORAZEPAM
OXYTOCIN, OXYTOCIN
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
ROBAXIN, METHOCARBAMOL

BAYER

- * BAYER HEALTHCARE LLC
ALEVE, NAPROXEN SODIUM (OTC)
ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)
FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)

BAYER HLTHCARE

- * BAYER HEALTHCARE CONSUMER CARE
RID MOUSSE, PIPERONYL BUTOXIDE (OTC)
- * BAYER HEALTHCARE PHARMACEUTICALS INC
ADALAT CC, NIFEDIPINE
ANGELIQ, DROSPIRENONE
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAPACE, SOTALOL HYDROCHLORIDE
BEYAZ, DROSPIRENONE
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRO XR, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CLIMARA PRO, ESTRADIOL
CLIMARA, ESTRADIOL
DTIC-DOME, DACARBAZINE
EOVIST, GADOXETATE DISODIUM
GADAVIST, GADOBUTROL
LEVITRA, VARDENAFIL HYDROCHLORIDE
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
MENOSTAR, ESTRADIOL
MIRENA, LEVONORGESTREL
MYCELEX, CLOTRIMAZOLE
NATAZIA, ESTRADIOL VALERATE
NEXAVAR, SORAFENIB TOSYLATE
PRECOSE, ACARBOSE
REFLUDAN, LEPIRUDIN RECOMBINANT
SAFYRAL, DROSPIRENONE
SKYLA, LEVONORGESTREL
STAXYN, VARDENAFIL HYDROCHLORIDE
STIVARGA, REGORAFENIB
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 150, IOPROMIDE
ULTRAVIST 240, IOPROMIDE
ULTRAVIST 300 IN PLASTIC CONTAINER, IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
YASMIN, DROSPIRENONE
YAZ, DROSPIRENONE

BAYER PHARMA AG

- * BAYER PHARMA AG
BILTRICIDE, PRAZIQUANTEL

BAYER PHARMS

- * BAYER PHARMACEUTICALS CORP
MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAYER PHARMACEUTICALS CORP
MYCELEX-7, CLOTRIMAZOLE (OTC)

BAYSHORE PHARMS LLC

* BAYSHORE PHARMACEUTICALS LLC
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE

BECTON DICKINSON

* BECTON DICKINSON AND CO
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)

BEDFORD

* BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ADENOSINE, ADENOSINE
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMRINONE LACTATE, INAMRINONE LACTATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZTREONAM, AZTREONAM
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUMETANIDE, BUMETANIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CARBOPLATIN, CARBOPLATIN
CEFTRIAXONE, CEFTRIAXONE SODIUM
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYCLOSPORINE, CYCLOSPORINE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DACTINOMYCIN, DACTINOMYCIN
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE), DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
ENALAPRILAT, ENALAPRILAT
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ETOMIDATE, ETOMIDATE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLOXURIDINE, FLOXURIDINE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEVOCARNITINE, LEVOCARNITINE
 MESNA, MESNA
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE, MILRINONE LACTATE
 MITOMYCIN, MITOMYCIN
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PACLITAXEL, PACLITAXEL
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIFAMPIN, RIFAMPIN
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 THIOTEPA, THIOTEPA
 VALPROATE SODIUM, VALPROATE SODIUM
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VINBLASTINE SULFATE, VINBLASTINE SULFATE
 VINOELBINE TARTRATE, VINOELBINE TARTRATE

BEDFORD LABS

* BEDFORD LABORATORIES
 ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
 CAFCIT, CAFFEINE CITRATE
 CARBOPLATIN, CARBOPLATIN
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUMAZENIL, FLUMAZENIL
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LORAZEPAM PRESERVATIVE FREE, LORAZEPAM
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 PENTOSTATIN, PENTOSTATIN
 TORSEMIDE, TORSEMIDE

BEIJING DOUBLE CRANE

* BEIJING DOUBLE CRANE PHARMACEUTICAL CO LTD
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 MELOXICAM, MELOXICAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

BELCHER PHARMS

- * BELCHER PHARMACEUTICALS LLC
CEPHALEXIN, CEPHALEXIN
DESLOTRADINE, DESLOTRADINE

BEN VENUE

- * BEN VENUE LABORATORIES INC
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

BEXIMCO USA

- * BEXIMCO PHARMACEUTICALS USA INC
CARVEDILOL, CARVEDILOL

BHP DERMATOLOGY

- * BAYER HEALTHCARE PHARMACEUTICALS INC DERMATOLOGY
DESONATE, DESONIDE
FINACEA, AZELAIC ACID

BIO NUCLEONICS

- * BIO NUCLEONICS INC
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89

BIOKEY

- * BIOKEY INC
BENZAEPRIIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
CILOSTAZOL, CILOSTAZOL

BIOMARIN PHARM

- * BIOMARIN PHARMACEUTICAL INC
KUVAN, SAPROPTERIN DIHYDROCHLORIDE

BIONICHE PHARMA

- * BIONICHE PHARMA USA LLC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
COSYNTROPIN, COSYNTROPIN
DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
ENLON, EDROPHONIUM CHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
FLUOROURACIL, FLUOROURACIL
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
RIMSO-50, DIMETHYL SULFOXIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE

BIONICHE PHARMA USA

- * BIONICHE PHARMA USA LLC
CARBOPLATIN, CARBOPLATIN
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FOMEPIZOLE, FOMEPIZOLE
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
ROCURIUM BROMIDE, ROCURIUM BROMIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

BIOVAIL TECHNOLOGIES

- * BIOVAIL TECHNOLOGIES LTD
DEMSER, METYROSINE

BLAIREX

- * BLAIREX LABORATORIES INC
BRONCHO SALINE, SODIUM CHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

BLU CARIBE

* BLU CARIBE INC
GEMFIBROZIL, GEMFIBROZIL
SIMVASTATIN, SIMVASTATIN

BOCA PHARMA

* BOCA PHARMACAL INC
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ALPRAZOLAM, ALPRAZOLAM
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LEVETIRACETAM, LEVETIRACETAM
METHIMAZOLE, METHIMAZOLE
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE

BOEHRINGER INGELHEIM

* BOEHRINGER INGELHEIM
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICARDIS, TELMISARTAN
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
* BOEHRINGER INGELHEIM PHARMACEUTICALS INC
AGGRENOX, ASPIRIN
APTIVUS, TIPRANAVIR
ATROVENT HFA, IPRATROPIUM BROMIDE
ATROVENT, IPRATROPIUM BROMIDE
COMBIVENT RESPIMAT, ALBUTEROL SULFATE
COMBIVENT, ALBUTEROL SULFATE
FLOMAX, TAMSULOSIN HYDROCHLORIDE
JENTADUETO, LINAGLIPTIN
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
MOBIC, MELOXICAM
PERSANTINE, DIPYRIDAMOLE
PRADAXA, DABIGATRAN ETEXILATE MESYLATE
SPIRIVA, TIOTROPIUM BROMIDE MONOHYDRATE
TRADJENTA, LINAGLIPTIN
TWINSTA, AMLODIPINE BESYLATE
VIRAMUNE XR, NEVIRAPINE
VIRAMUNE, NEVIRAPINE

BRACCO

* BRACCO DIAGNOSTICS INC
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
KINEVAC, SINCALIDE
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MULTIHANCE, GADOBENATE DIMEGLUMINE
PROHANCE MULTIPACK, GADOTERIDOL
PROHANCE, GADOTERIDOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

- * BRACCO DIAGNOSTICS INC
RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
SINOGRAFIN, DIATRIZOATE MEGLUMINE

BRAINTREE

- * BRAINTREE LABORATORIES INC
AXID, NIZATIDINE
GOLYTELY, POLYETHYLENE GLYCOL 3350
HALFLYTELY, BISACODYL
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350

BRAINTREE LABS

- * BRAINTREE LABORATORIES INC
SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE ANHYDROUS

BRECKENRIDGE PHARM

- * BRECKENRIDGE PHARMACEUTICAL INC
CILOSTAZOL, CILOSTAZOL
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
LEVETIRACETAM, LEVETIRACETAM
MELOXICAM, MELOXICAM
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
OXCARBAZEPINE, OXCARBAZEPINE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

BRISTOL MYERS SQUIBB

- * BRISTOL MYERS SQUIBB
AZACTAM, AZTREONAM
BARACLUDE, ENTECAVIR
GLUCOVANCE, GLYBURIDE
KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
LYSODREN, MITOTANE
MEGACE, MEGESTROL ACETATE
PRAVACHOL, PRAVASTATIN SODIUM
- * BRISTOL MYERS SQUIBB CO
AZACTAM IN PLASTIC CONTAINER, AZTREONAM
CEENU, LOMUSTINE
DROXIA, HYDROXYUREA
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
HYDREA, HYDROXYUREA
IXEMPRA KIT, IXABEPILONE
ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
REYATAZ, ATAZANAVIR SULFATE
SPRYCEL, DASATINIB
SUSTIVA, EFAVIRENZ
VIDEX EC, DIDANOSINE
- * BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
ELIQUIS, APIXABAN
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
GLUCOPHAGE, METFORMIN HYDROCHLORIDE
VIDEX, DIDANOSINE
VUMON, TENIPOSIDE
ZERIT, STAVUDINE
- * BRISTOL MYERS SQUIBB PHARMA CO
COUMADIN, WARFARIN SODIUM
SUSTIVA, EFAVIRENZ

BRYAN

- * BRYAN CORP
SCLEROSOL, TALC
TALC, TALC

CADENCE PHARMS

- * CADENCE PHARMACEUTICALS INC
OFIRMEV, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** C **

CADISTA PHARMS

* CADISTA PHARMACEUTICALS INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
LAMOTRIGINE, LAMOTRIGINE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
OXCARBAZEPINE, OXCARBAZEPINE

CANYON

* CANYON PHARMACEUTICALS INC
IPRIVASK, DESIRUDIN RECOMBINANT

CARACO

* CARACO PHARMACEUTICAL LABORATORIES LTD
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLONAZEPAM, CLONAZEPAM
CLOZAPINE, CLOZAPINE
DIGOXIN, DIGOXIN
ELIXOPHYLLIN, THEOPHYLLINE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLIPIZIDE, GLIPIZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
MELOXICAM, MELOXICAM
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIRTAZAPINE, MIRTAZAPINE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
SYNALGOS-DC, ASPIRIN
THEOCHRON, THEOPHYLLINE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CARDINAL HEALTH 414

* CARDINAL HEALTH 414 LLC
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

CARDINAL HLTH 414

* CARDINAL HEALTH 414
SODIUM IODIDE I 123, SODIUM IODIDE I-123

CAREFUSION

* CAREFUSION 213 LLC
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** C **

- * CAREFUSION 213 LLC
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)
PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)

CARLSBAD

- * CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FAMOTIDINE, FAMOTIDINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
LOVASTATIN, LOVASTATIN
MELOXICAM, MELOXICAM
MODAFINIL, MODAFINIL
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CAROLINA MEDCL

- * CAROLINA MEDICAL PRODUCTS CO
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
ISONIAZID, ISONIAZID
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SPS, SODIUM POLYSTYRENE SULFONATE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE

CATALENT

- * CATALENT PHARMA SOLUTIONS LLC
NIFEDIPINE, NIFEDIPINE
VALPROIC ACID, VALPROIC ACID

CEDAR PHARMS

- * CEDAR PHARMACEUTICALS LLC
METHIMAZOLE, METHIMAZOLE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

CELGENE

- * CELGENE CORP
ISTODAX, ROMIDEPSIN
REVLIMID, LENALIDOMIDE
THALOMID, THALIDOMIDE
VIDAZA, AZACITIDINE

CEPHALON

- * CEPHALON INC
ACTIQ, FENTANYL CITRATE
FENTORA, FENTANYL CITRATE
GABITRIL, TIAGABINE HYDROCHLORIDE
NUVIGIL, ARMODAFINIL
PROVIGIL, MODAFINIL
TREANDA, BENDAMUSTINE HYDROCHLORIDE
TRISENOX, ARSENIC TRIOXIDE

CEREXA

- * CEREXA INC
TEFLARO, CEFTAROLINE FOSAMIL

CHATTEM

- * CHATTEM INC
SELSUN, SELENIUM SULFIDE
UNISOM, DOXYLAMINE SUCCINATE (OTC)

CHEMISCH FBRK KRSSLR

- * CHEMISCHE FABRIK KREUSSLER & CO. GMBH
ASCLERA, POLIDOCANOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

CHIRHOCLIN

* CHIRHOCLIN INC
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN

CIPHER

* CIPHER PHARMACEUTICALS LTD
ABSORICA, ISOTRETINOIN

CIPHER PHARMS INC

* CIPHER PHARMACEUTICALS INC
CONZIP, TRAMADOL HYDROCHLORIDE
LIPOFEN, FENOFIBRATE

CIPLA

* CIPLA LTD
NEVIRAPINE, NEVIRAPINE
RAMIPRIL, RAMIPRIL
RISPERIDONE, RISPERIDONE
TRANOLAPRIL, TRANOLAPRIL
ZIDOVUDINE, ZIDOVUDINE

CIPLA LTD

* CIPLA LTD
CARBOPLATIN, CARBOPLATIN
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IRBESARTAN, IRBESARTAN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
STAVUDINE, STAVUDINE
TOPIRAMATE, TOPIRAMATE
ZALEPLON, ZALEPLON
ZIDOVUDINE, ZIDOVUDINE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CITIUS PHARMS

* CITIUS PHARMACEUTICALS LLC
SUPRENZA, PHENTERMINE HYDROCHLORIDE

CLARIS LIFESCIENCES

* CLARIS LIFESCIENCES LTD
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
DIPYRIDAMOLE, DIPYRIDAMOLE
FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK), FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUMAZENIL, FLUMAZENIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FULCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** C **

CLINIGEN HLTHCARE

- * CLINIGEN HEALTHCARE LTD
FOSCAVIR, FOSCARNET SODIUM

CLONMEL HLTHCARE

- * CLONMEL HEALTHCARE LTD
MORPHINE SULFATE, MORPHINE SULFATE

CLOVER PHARMS

- * CLOVER PHARMACEUTICALS CORP
AMICAR, AMINOCAPROIC ACID

CNS THERAPS INC

- * CNS THERAPEUTICS INC
GABLOFEN, BACLOFEN

CNTY LINE PHARMS

- * COUNTY LINE PHARMACEUTICALS LLC
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
UREX, METHENAMINE HIPPURATE

COASTAL PHARMS

- * COASTAL PHARMACEUTICALS
BROMFENAC SODIUM, BROMFENAC SODIUM
LIOETHYRONINE SODIUM, LIOETHYRONINE SODIUM
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

COLGATE

- * COLGATE ORAL PHARMACEUTICALS INC
ORABASE HCA, HYDROCORTISONE ACETATE
PERIOGARD, CHLORHEXIDINE GLUCONATE

COLGATE PALMOLIVE

- * COLGATE PALMOLIVE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)

CONTRACT PHARMA

- * CONTRACT PHARMACAL CORP
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)

CONTRACT PHARMACAL

- * CONTRACT PHARMACAL CORP
CIMETIDINE, CIMETIDINE (OTC)
FOLIC ACID, FOLIC ACID
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PREDNISONE, PREDNISONE
PROFEN, IBUPROFEN (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

CORCEPT THERAP

- * CORCEPT THERAPEUTICS INC
KORLYM, MIFEPRISTONE

COREPHARMA

- * COREPHARMA LLC
ALBENZA, ALBENDAZOLE
ALPRAZOLAM, ALPRAZOLAM
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARISOPRODOL, CARISOPRODOL
CILOSTAZOL, CILOSTAZOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* COREPHARMA LLC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DARAPRIM, PYRIMETHAMINE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
ASPARTATE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LEVOCARNITINE, LEVOCARNITINE
MELOXICAM, MELOXICAM
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRANDOLAPRIL, TRANDOLAPRIL
URSODIOL, URSODIOL
ZONISAMIDE, ZONISAMIDE

CORNERSTONE THERAP

* CORNERSTONE THERAPEUTICS INC
BETHKIS, TOBRAMYCIN
CUROSURF, PORACTANT ALFA
FACTIVE, GEMIFLOXACIN MESYLATE
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
ZYFLO CR, ZILEUTON
ZYFLO, ZILEUTON

COVIDIEN

* COVIDIEN
LYMPHAZURIN, ISOSULFAN BLUE

COVIS PHARMA

* COVIS PHARMA SARL
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
FORTAZ, CEFTAZIDIME
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
PARNATE, TRANLYCYPROMINE SULFATE
ZANTAC IN PLASTIC CONTAINER, RANITIDINE HYDROCHLORIDE
ZANTAC, RANITIDINE HYDROCHLORIDE
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
ZINACEF, CEFUROXIME SODIUM

CPPI CV

* CP PHARMACEUTICALS INTERNATIONAL CV
SUTENT, SUNITINIB MALATE

CROWN LABS

* CROWN LABORATORIES INC
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
TRIDERM, TRIAMCINOLONE ACETONIDE

CSL BEHRING

* CSL BEHRING LLC
STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

CUBIST

* CUBIST PHARMACEUTICALS INC
CUBICIN, DAPTOMYCIN

CUBIST PHARMS

* CUBIST PHARMACEUTICALS INC
ENTEREG, ALVIMOPAN

CUMBERLAND PHARMS

* CUMBERLAND PHARMACEUTICALS INC
ACETADOTE, ACETYLCYSTEINE
CALDOLOR, IBUPROFEN
LACTULOSE, LACTULOSE

CYPRESS BIOSCIENCE

* CYPRESS BIOSCIENCE INC
SAVELLA, MILNACIPRAN HYDROCHLORIDE

CYPRESS PHARM

* CYPRESS PHARMACEUTICAL INC
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ELIPHOS, CALCIUM ACETATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
REZIRA, HYDROCODONE BITARTRATE
ZUTRIPRO, CHLORPHENIRAMINE MALEATE

DAIICHI

* DAIICHI PHARMACEUTICAL CORP
FLOXIN OTIC, OFLOXACIN

DAIICHI SANKYO

* DAIICHI SANKYO INC
AZOR, AMLODIPINE BESYLATE
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENICAR, OLMESARTAN MEDOXOMIL
TRIBENZOR, AMLODIPINE BESYLATE
WELCHOL, COLESEVELAM HYDROCHLORIDE

DAIICHI SANKYO CO

* DAIICHI SANKYO CO LTD
EVOXAC, CEVIMELINE HYDROCHLORIDE

DANCO LABS LLC

* DANCO LABORATORIES LLC
MIFEPREX, MIFEPRISTONE

DARA BIOSCIENCES

* DARA BIOSCIENCES INC
SOLTAMOX, TAMOXIFEN CITRATE

DAVA INTL INC

* DAVA INTERNATIONAL INC
ALPRAZOLAM, ALPRAZOLAM

DAVA PHARMS INC

* DAVA PHARMACEUTICALS INC
ACYCLOVIR, ACYCLOVIR
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ATENOLOL, ATENOLOL
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
FUROSEMIDE, FUROSEMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DAVA PHARMACEUTICALS INC
GEMFIBROZIL, GEMFIBROZIL
GLYBURIDE (MICRONIZED), GLYBURIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
NAPROXEN, NAPROXEN
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRAZINAMIDE, PYRAZINAMIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
VOSPIRE ER, ALBUTEROL SULFATE

DAVIS AND GECK

* DAVIS AND GECK DIV AMERICAN CYANAMID CO
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE

DENCO ASSET

* DENCO ASSET LLC
DENA VIR, PENCICLOVIR SODIUM

DENTSPLY PHARM

* DENTSPLY PHARMACEUTICAL INC
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
ORAQIX, LIDOCAINE

DEPOMED INC

* DEPOMED INC
GRALISE, GABAPENTIN
ZIPSOR, DICLOFENAC POTASSIUM

DEPROCO

* DEPROCO INC
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
SCANDONEST L, LEVONORDEFIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE

DEXCEL LTD

* DEXCEL LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

DEXCEL PHARMA

* DEXCEL PHARMA TECHNOLOGIES LTD
OMEPRazole, OMEPRazole (OTC)
PERIOCHIP, CHLORHEXIDINE GLUCONATE

DEY

* DEY LP
ACCUNEB, ALBUTEROL SULFATE
CROMOLYN SODIUM, CROMOLYN SODIUM
DUONEB, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE

DIALYSIS SUPS

* DIALYSIS SUPPLIES INC
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE

DIGESTIVE CARE INC

* DIGESTIVE CARE INC
PERTZY, PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

DISCOVERY LABS

* DISCOVERY LABORATORIES INC
SURFAXIN, LUCINACTANT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

DORADO PHARMA

* DORADO PHARMA LLC
KETOPROFEN, KETOPROFEN

DORC

* DORC INTERNATIONAL BV
MEMBRANEBLUE, TRYPAN BLUE
VISIONBLUE, TRYPAN BLUE

DOUGLAS PHARMS

* DOUGLAS PHARMACEUTICALS AMERICA LTD
MYORISAN, ISOTRETINOIN

DOW PHARM

* DOW PHARMACEUTICAL SCIENCES
NUTRACORT, HYDROCORTISONE

DOW PHARM SCI

* DOW PHARMACEUTICAL SCIENCES
ACANYA, BENZOYL PEROXIDE

DOW PHARM SCIENCES

* DOW PHARMACEUTICAL SCIENCES INC
AKNE-MYCIN, ERYTHROMYCIN
ATRALIN, TRETINOIN

DR REDDYS LA

* DR REDDYS LABORATORIES LOUISIANA LLC
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LOPURIN, ALLOPURINOL
SSD AF, SILVER SULFADIAZINE
SSD, SILVER SULFADIAZINE

DR REDDYS LABS INC

* DR REDDYS LABORATORIES INC
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMOXIL, AMOXICILLIN
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '200', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '400', AMOXICILLIN
AUGMENTIN '500', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LAROTID, AMOXICILLIN
LEVOFLOXACIN, LEVOFLOXACIN
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SIMVASTATIN, SIMVASTATIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** D **

* DR REDDYS LABORATORIES INC
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

DR REDDYS LABS LTD

* DR REDDYS LABORATORIES LIMITED
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

* DR REDDYS LABORATORIES LTD
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NABUMETONE, NABUMETONE
NAPROXEN SODIUM, NAPROXEN SODIUM
NATEGLINIDE, NATEGLINIDE
NIZATIDINE, NIZATIDINE
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
OMEPRazole MAGNESIUM, OMEPRazole MAGNESIUM (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES LTD
OMEPRazole, OMEPRazole
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PRIMIDONE, PRIMIDONE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TACROLIMUS, TACROLIMUS
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRANDOLAPRIL, TRANDOLAPRIL
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZAFIRLUKAST, ZAFIRLUKAST
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONISAMIDE, ZONISAMIDE

DR REDDYS LABS SA

* DR REDDYS LABORATORIES SA
FENOFIBRATE (MICRONIZED), FENOFIBRATE

DRAXIMAGE

* DRAXIMAGE INC
DTPA, TECHNETIUM TC-99M PENTETATE KIT
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

DURAMED

* DURAMED PHARMACEUTICALS INC
PLAN B ONE-STEP, LEVONORGESTREL
PLAN B ONE-STEP, LEVONORGESTREL (OTC)
REVIA, NALTREXONE HYDROCHLORIDE

DURAMED PHARMS BARR

* DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC
AVIANE-28, ETHINYL ESTRADIOL
CRYSSELLE, ETHINYL ESTRADIOL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DIAMOX, ACETAZOLAMIDE
ENPRESSE-28, ETHINYL ESTRADIOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VELIVET, DESOGESTREL

DURAMED RES

* DURAMED RESEARCH INC
AYGESTIN, NORETHINDRONE ACETATE

DUSA

* DUSA PHARMACEUTICALS INC
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

EAGLE PHARMS

* EAGLE PHARMACEUTICALS INC
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN

EASTMAN KODAK

* EASTMAN KODAK CO
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE

EBEWE PHARMA

* EBEWE PHARMA
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EBEWE PHARMA GES MBH NFG KG
CARBOPLATIN, CARBOPLATIN
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FLUOROURACIL, FLUOROURACIL
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
VINORELBINE TARTRATE, VINORELBINE TARTRATE

ECOLAB

* ECOLAB INC
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

ECR

* ECR PHARMACEUTICALS
DEXAMETHASONE, DEXAMETHASONE

EDGEMONT PHARMS LLC

* EDGEMONT PHARMACEUTICALS LLC
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FORFIVO XL, BUPROPION HYDROCHLORIDE

EI INC

* EI INC
THEROXIDIL, MINOXIDIL (OTC)

EISAI INC

* EISAI INC
ACIPHEX, RABEPRAZOLE SODIUM
ARICEPT ODT, DONEPEZIL HYDROCHLORIDE
ARICEPT, DONEPEZIL HYDROCHLORIDE
BANZEL, RUFINAMIDE
BELVIQ, LORCASERIN HYDROCHLORIDE
DACOGEN, DECITABINE
FRAGMIN, DALTEPARIN SODIUM
FYCOMPA, PERAMPANEL
HALAVEN, ERIBULIN MESYLATE
HEXALEN, ALTRETAMINE
PANRETIN, ALITRETINOIN
SALAGEN, PILOCARPINE HYDROCHLORIDE
TARGRETIN, BEXAROTENE
ZONEGRAN, ZONISAMIDE

EKR THERAP

* EKR THERAPEUTICS INC
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE SR, NICARDIPINE HYDROCHLORIDE
CARDENE, NICARDIPINE HYDROCHLORIDE

ELAN DRUG

* ELAN DRUG DELIVERY INC
VERELAN PM, VERAPAMIL HYDROCHLORIDE

ELI LILLY AND CO

* ELI LILLY AND CO
AXIRON, TESTOSTERONE
EFFIENT, PRASUGREL HYDROCHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
SARAFEM, FLUOXETINE HYDROCHLORIDE

ELI LILLY CO

* ELI LILLY CO
ADCIRCA, TADALAFIL
ZYPREXA RELPREVV, OLANZAPINE PAMOATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** E **

ELITE LABS

- * ELITE LABORATORIES INC
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

EMCURE PHARMS

- * EMCURE PHARMACEUTICALS LTD
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

EMCURE PHARMS INDIA

- * EMCURE PHARMACEUTICALS LTD INDIA
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL

EMCURE PHARMS LTD

- * EMCURE PHARMACEUTICALS LTD
ACARBOSE, ACARBOSE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BICNU, CARMUSTINE
CIDOFOVIR, CIDOFOVIR
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE

EMCURE PHARMS USA

- * EMCURE PHARMACEUTICALS USA INC
DIFLUNISAL, DIFLUNISAL
METHIMAZOLE, METHIMAZOLE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

EMCURE USA

- * EMCURE PHARMACEUTICALS USA INC
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE

EMD SERONO

- * EMD SERONO INC
CETROTIDE, CETRORELIX
EGRIFTA, TESAMORELIN ACETATE
GONAL-F RFF PEN, FOLLITROPIN ALFA/BETA
GONAL-F RFF, FOLLITROPIN ALFA/BETA
GONAL-F, FOLLITROPIN ALFA/BETA
OVIDREL, CHORIOGONADOTROPIN ALFA
SAIZEN, SOMATROPIN RECOMBINANT
SEROPHENE, CLOMIPHENE CITRATE
SEROSTIM, SOMATROPIN RECOMBINANT
ZORBTIVE, SOMATROPIN RECOMBINANT

EMMAUS MEDCL

- * EMMAUS MEDICAL INC
NUTRESTORE, GLUTAMINE

ENDO PHARM

- * ENDO PHARMACEUTICAL SOLUTIONS INC
SUPPRELIN LA, HISTRELIN ACETATE
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VANTAS, HISTRELIN ACETATE

ENDO PHARMS

- * ENDO PHARMACEUTICALS INC
DELATESTRYL, TESTOSTERONE ENANTHATE
FORTESTA, TESTOSTERONE
FROVA, FROVATRIPTAN SUCCINATE
OPANA ER, OXYMORPHONE HYDROCHLORIDE
OPANA, OXYMORPHONE HYDROCHLORIDE
PERCODAN, ASPIRIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** E **

EPIC PHARMA

- * EPIC PHARMA INC
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
- * EPIC PHARMA LLC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
SULINDAC, SULINDAC
TRANDOLAPRIL, TRANDOLAPRIL
URSODIOL, URSODIOL

EPIC PHARMA INC

- * EPIC PHARMA INC
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

EPIC PHARMA LLC

- * EPIC PHARMA LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE

ERGOJECT

- * ERGOJECT LLC
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE

ETHYPHARM

- * ETHYPHARM
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

EURAND

- * EURAND AMERICA INC
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

EXALENZ BIOSCIENCE

- * EXALENZ BIOSCIENCE LTD
IDKIT:HP, UREA C-13

EXCELLIUM

- * EXCELLIUM PHARMACEUTICAL INC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM

EXELA PHARMA SCIENCE

- * EXELA PHARMA SCIENCES
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

EXELIXIS

- * EXELIXIS INC
COMETRIQ, CABOZANTINIB S-MALATE

FACTA FARMA

- * FACTA FARMACEUTICI SPA
CEPHALEXIN, CEPHALEXIN

FALCON PHARMS

- * FALCON PHARMACEUTICALS INC
TIMOLOL MALEATE, TIMOLOL MALEATE
- * FALCON PHARMACEUTICALS LTD
DIPIVEFRIN HYDROCHLORIDE, DIPIVEFRIN HYDROCHLORIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
MAXITROL, DEXAMETHASONE
METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

* FALCON PHARMACEUTICALS LTD
TOBREX, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

FAMY CARE LTD

* FAMY CARE LTD
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

FDC LTD

* FDC LTD
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
OFLOXACIN, OFLOXACIN
TIMOLOL MALEATE, TIMOLOL MALEATE

FEINSTEIN

* FEINSTEIN INSTITUTE MEDICAL RESEARCH
AMMONIA N 13, AMMONIA, N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

FERA PHARMS

* FERA PHARMACEUTICALS LLC
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
ERYTHROMYCIN, ERYTHROMYCIN
GENTAMICIN SULFATE, GENTAMICIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
OFLOXACIN, OFLOXACIN
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TOBRAMYCIN, TOBRAMYCIN

FERNDALE LABS

* FERNDALE LABORATORIES INC
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
MICORT-HC, HYDROCORTISONE ACETATE
PRAMOSONE, HYDROCORTISONE ACETATE

FERRING

* FERRING PHARMACEUTICALS INC
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
BRAVELLE, UROFOLLITROPIN
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
ENDOMETRIN, PROGESTERONE
FIRMAGON, DEGARELIX ACETATE
MENOPUR, LUTEINIZING HORMONE
MINIRIN, DESMOPRESSIN ACETATE
REPRONEX, LUTEINIZING HORMONE
TEV-TROPIN, SOMATROPIN RECOMBINANT

FERRING CONTROLLED

* FERRING CONTROLLED THERAPEUTICS LTD
CERVIDIL, DINOPROSTONE

FERRING PHARMS AS

* FERRING PHARMACEUTICALS AS
LYSTEDA, TRANEXAMIC ACID
PREPOPIK, CITRIC ACID

FOREST LABS

* FOREST LABORATORIES INC
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE
CAMPRAL, ACAMPROSATE CALCIUM
CELEXA, CITALOPRAM HYDROBROMIDE
LEXAPRO, ESCITALOPRAM OXALATE
NAMENDA XR, MEMANTINE HYDROCHLORIDE
NAMENDA, MEMANTINE HYDROCHLORIDE
THYROLAR-0.25, LIOTHYRONINE SODIUM
THYROLAR-0.5, LIOTHYRONINE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FOREST LABORATORIES INC
THYROLAR-1, LIOTHYRONINE SODIUM
THYROLAR-2, LIOTHYRONINE SODIUM
THYROLAR-3, LIOTHYRONINE SODIUM

FOREST LABS INC

* FOREST LABORATORIES INC
LINZESS, LINACLOTIDE
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
VIIBRYD, VILAZODONE HYDROCHLORIDE

FOREST RES INST INC

* FOREST RESEARCH INSTITUTE INC
DALIRESP, ROFLUMILAST

FOUGERA

* E FOUGERA DIV ALTANA INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE, LIDOCAINE
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN

FOUGERA PHARMS

* FOUGERA PHARMACEUTICALS INC
ACLOVATE, ALCLOMETASONE DIPROPIONATE
ADAPALENE, ADAPALENE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
AMCINONIDE, AMCINONIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CARMOL HC, HYDROCORTISONE ACETATE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
C-SOLVE-2, ERYTHROMYCIN
CUTIVATE, FLUTICASONE PROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NYSTATIN, NYSTATIN
OXISTAT, OXICONAZOLE NITRATE
PAMINE FORTE, METHSCOPOLAMINE BROMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FOUGERA PHARMACEUTICALS INC
 PAMINE, METHSCOPOLAMINE BROMIDE
 PANDEL, HYDROCORTISONE PROBUTATE
 PREDNICARBATE, PREDNICARBATE
 SOLARAZE, DICLOFENAC SODIUM
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TEMOVATE E, CLOBETASOL PROPIONATE
 TEMOVATE, CLOBETASOL PROPIONATE
 TERCONAZOLE, TERCONAZOLE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE
 ZONALON, DOXEPIN HYDROCHLORIDE

FRESENIUS

* FRESENIUS KABI DEUTSCHLAND GMBH
 INTRALIPID 10%, SOYBEAN OIL
 INTRALIPID 20%, SOYBEAN OIL
 INTRALIPID 30%, SOYBEAN OIL

* FRESENIUS USA INC
 INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

FRESENIUS KABI

* FRESENIUS KABI AUSTRIA GMBH
 LACTULOSE, LACTULOSE

FRESENIUS KABI ONCOL

* FRESENIUS KABI ONCOLOGY PLC
 ANASTROZOLE, ANASTROZOLE
 BICALUTAMIDE, BICALUTAMIDE
 CARBOPLATIN, CARBOPLATIN
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LETROZOLE, LETROZOLE
 OXALIPLATIN, OXALIPLATIN
 PACLITAXEL, PACLITAXEL
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

FRESENIUS KABI USA

* FRESENIUS KABI USA LLC
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 ADENOSINE, ADENOSINE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ASTRAMORPH PF, MORPHINE SULFATE
 AZITHROMYCIN, AZITHROMYCIN, UNSPECIFIED FORM
 AZTREONAM, AZTREONAM
 BACITRACIN, BACITRACIN
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CALCITRIOL, CALCITRIOL
 CARBOPLATIN, CARBOPLATIN
 CEFOTETAN, CEFOTETAN DISODIUM
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
 CISPLATIN, CISPLATIN
 CLADRIBINE, CLADRIBINE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 CYTARABINE, CYTARABINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FRESSENIUS KABI USA LLC
 DACARBAZINE, DACARBAZINE
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DIMENHYDRINATE, DIMENHYDRINATE
 DIPRIVAN, PROPOFOL
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXY 100, DOXYCYCLINE HYCLATE
 DOXY 200, DOXYCYCLINE HYCLATE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ETOPOSIDE, ETOPOSIDE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FLOXURIDINE, FLOXURIDINE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUMAZENIL, FLUMAZENIL
 FLUOROURACIL, FLUOROURACIL
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FUROSEMIDE, FUROSEMIDE
 GANCICLOVIR, GANCICLOVIR SODIUM
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 INDOMETHACIN, INDOMETHACIN
 IOPAMIDOL-250, IOPAMIDOL
 IOPAMIDOL-300, IOPAMIDOL
 IOPAMIDOL-370, IOPAMIDOL
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 KANAMYCIN SULFATE, KANAMYCIN SULFATE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEVETIRACETAM, LEVETIRACETAM
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MANNITOL 25%, MANNITOL
 MESNA, MESNA
 METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
 METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE, MILRINONE LACTATE
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 NAROPIN, ROPIVACAINE HYDROCHLORIDE
 NEBUPENT, PENTAMIDINE ISETHIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FRESENIUS KABI USA LLC
 NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
 NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 OXYTOCIN, OXYTOCIN
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PENTAM, PENTAMIDINE ISETHIONATE
 POLOCAINE, MEPIVACAINE HYDROCHLORIDE
 POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROGESTERONE, PROGESTERONE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PROTAMINE SULFATE, PROTAMINE SULFATE
 PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 VALPROATE SODIUM, VALPROATE SODIUM
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VIBISONE, CYANOCOBALAMIN
 VINBLASTINE SULFATE, VINBLASTINE SULFATE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE
 XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE

FRESENIUS MEDCL

* FRESENIUS MEDICAL CARE NORTH AMERICA
 CALCITRIOL, CALCITRIOL
 DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PHOSLO GELCAPS, CALCIUM ACETATE
 PHOSLYRA, CALCIUM ACETATE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

FSC

- * FSC LABORATORIES INC
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE

G AND W LABS

- * G AND W LABORATORIES INC
ACEPHEN, ACETAMINOPHEN (OTC)
CICLOPIROX, CICLOPIROX
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
INDOMETHACIN, INDOMETHACIN
METRONIDAZOLE, METRONIDAZOLE
MICONAZOLE 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MIGERGOT, CAFFEINE
MOMETASONE FUROATE, MOMETASONE FUROATE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

G AND W LABS INC

- * G AND W LABORATORIES INC
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
FLUOCINONIDE, FLUOCINONIDE
METRONIDAZOLE, METRONIDAZOLE

GALDERMA LABS

- * GALDERMA LABORATORIES INC
CLOBEX, CLOBETASOL PROPIONATE

GALDERMA LABS LP

- * GALDERMA LABORATORIES L P
CLOBEX, CLOBETASOL PROPIONATE
- * GALDERMA LABORATORIES LP
CAPEX, FLUOCINOLONE ACETONIDE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
CLOBEX, CLOBETASOL PROPIONATE
DESOWEN, DESONIDE
DIFFERIN, ADAPALENE
EPIDUO, ADAPALENE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
METVIXIA, METHYL AMINOLEVULINATE HYDROCHLORIDE
ORACEA, DOXYCYCLINE
PERIOSTAT, DOXYCYCLINE HYCLATE
PLIAGLIS, LIDOCAINE
TRI-LUMA, FLUOCINOLONE ACETONIDE
VECTICAL, CALCITRIOL

GALEN (UK)

- * GALEN LTD
DAUNOXOME, DAUNORUBICIN CITRATE

GAMBRO RENAL PRODS

- * GAMBRO RENAL PRODUCTS
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** G **

* GAMBRO RENAL PRODUCTS
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE

GASTROENTERO

* GASTROENTERO LOGIC LLC
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN

GATE PHARMS

* GATE PHARMACEUTICALS
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE

GAVIS PHARMS

* GAVIS PHARMACEUTICALS LLC
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE, ACETAMINOPHEN
NYSTATIN, NYSTATIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PENTAZOCINE AND NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
QUINARETIC, HYDROCHLOROTHIAZIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

GD SEARLE

* GD SEARLE LLC
CELEBREX, CELECOXIB
DAYPRO, OXAPROZIN

GD SEARLE LLC

* GD SEARLE LLC
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ARTHROTEC, DICLOFENAC SODIUM
CALAN, VERAPAMIL HYDROCHLORIDE
COVERA-HS, VERAPAMIL HYDROCHLORIDE
CYTOTEC, MISOPROSTOL
FLAGYL ER, METRONIDAZOLE
FLAGYL, METRONIDAZOLE
INSPRA, EPLERENONE
LOMOTIL, ATROPINE SULFATE
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
SYNAREL, NAFARELIN ACETATE

GE HEALTHCARE

* GE HEALTHCARE
ADREVIEW, IOBENGUANE SULFATE I-123
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
INDICLOR, INDIUM IN-111 CHLORIDE
INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
METASTRON, STRONTIUM CHLORIDE SR-89
MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MYOVUE 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
MYOVUE, TECHNETIUM TC-99M TETROFOSMIN KIT
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNISCAN, GADODIAMIDE
OPTISON, ALBUMIN HUMAN
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL

GE HLTHCARE INC

* GE HEALTHCARE INC
DATSCAN, IOFLUPANE I-123

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** G **

GEDEON RICHTER USA

* GEDEON RICHTER USA INC
FINASTERIDE, FINASTERIDE

GENENTECH

* GENENTECH INC
ERIVEDGE, VISMODEGIB
NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT
NUTROPIN AQ, SOMATROPIN RECOMBINANT
NUTROPIN, SOMATROPIN RECOMBINANT

GENTA

* GENTA INC
GANITE, GALLIUM NITRATE

GENZYME

* GENZYME CORP
CEREZYME, IMIGLUCERASE
CLOLAR, CLOFARABINE
MOZOBIL, PLERIXAFOR
RENAGEL, SEVELAMER HYDROCHLORIDE
REVELA, SEVELAMER CARBONATE
THYROGEN, THYROTROPIN ALFA

GENZYME CORP

* GENZYME CORP
HECTOROL, DOXERCALCIFEROL
* GENZYME CORPORATION
HECTOROL, DOXERCALCIFEROL

GILEAD

* GILEAD SCIENCES INC
ATRIPLA, EFAVIRENZ
CAYSTON, AZTREONAM
EMTRIVA, EMTRICITABINE
HEPSERA, ADEFOVIR DIPIVOXIL
LETAIRIS, AMBRISENTAN
RANEXA, RANOLAZINE
TRUVADA, EMTRICITABINE

GILEAD SCIENCES INC

* GILEAD SCIENCES INC
COMPLERA, EMTRICITABINE
STRIBILD, COBICISTAT
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VISTIDE, CIDOFOVIR

GLAND PHARMA LTD

* GLAND PHARMA LTD
ADENOSINE, ADENOSINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
HALOPERIDOL, HALOPERIDOL LACTATE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

GLAXO GRP LTD

* GLAXO GROUP LTD
HORIZANT, GABAPENTIN ENACARBIL
* GLAXO GROUP LTD DBA GLAXOSMITHKLINE
ALTABAX, RETAPAMULIN
FLOVENT HFA, FLUTICASONE PROPIONATE
SEREVENT, SALMETEROL XINAFOATE

GLAXOSMITHKLINE

* GLAXOSMITHKLINE
ABREVA, DOCOSANOL (OTC)
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** G **

* GLAXOSMITHKLINE
 ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
 ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
 ADVAIR HFA, FLUTICASONE PROPIONATE
 ALKERAN, MELPHALAN
 ALKERAN, MELPHALAN HYDROCHLORIDE
 AMERGE, NARATRIPTAN HYDROCHLORIDE
 ARIXTRA, FONDAPARINUX SODIUM
 AVODART, DUTASTERIDE
 BACTROBAN, MUPIROCI
 BACTROBAN, MUPIROCI
 BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
 CEFTIN, CEFUROXIME AXETIL
 EPIVIR-HBV, LAMIVUDINE
 FLONASE, FLUTICASONE PROPIONATE
 FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
 FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
 FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
 Hycamtin, Topotecan Hydrochloride
 IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
 IMITREX, SUMATRIPTAN
 IMITREX, SUMATRIPTAN SUCCINATE
 JALYN, DUTASTERIDE
 LAMICTAL CD, LAMOTRIGINE
 LAMICTAL, LAMOTRIGINE
 MALARONE PEDIATRIC, ATOVAQUONE
 MALARONE, ATOVAQUONE
 NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
 NICORETTE, NICOTINE POLACRILEX (OTC)
 PAXIL CR, PAROXETINE HYDROCHLORIDE
 PAXIL, PAROXETINE HYDROCHLORIDE
 POTIGA, EZOGABINE
 PROMACTA, ELTROMBOPAG OLAMINE
 RELENZA, ZANAMIVIR
 REQUIP, ROPINIROLE HYDROCHLORIDE
 TAGAMET HB, CIMETIDINE (OTC)
 TAGAMET, CIMETIDINE
 THIOGUANINE, THIOGUANINE
 Timentin in Plastic Container, Clavulanate Potassium
 Timentin, Clavulanate Potassium
 VALTREX, VALACYCLOVIR HYDROCHLORIDE
 VENTOLIN HFA, ALBUTEROL SULFATE
 VERAMYST, FLUTICASONE FUROATE
 VOTRIENT, PAZOPANIB HYDROCHLORIDE
 WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
 WELLBUTRIN, BUPROPION HYDROCHLORIDE
 ZANTAC 150, RANITIDINE HYDROCHLORIDE
 ZANTAC 25, RANITIDINE HYDROCHLORIDE
 ZANTAC 300, RANITIDINE HYDROCHLORIDE
 ZANTAC, RANITIDINE HYDROCHLORIDE
 ZOFRAN ODT, ONDANSETRON
 ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ZOFRAN, ONDANSETRON HYDROCHLORIDE
 ZOVIRAX, ACYCLOVIR
 ZYBAN, BUPROPION HYDROCHLORIDE

GLAXOSMITHKLINE CONS

* GLAXOSMITHKLINE CONSUMER HEALTHCARE
 ALLI, ORLISTAT (OTC)
 COMMIT, NICOTINE POLACRILEX (OTC)
 NICORETTE, NICOTINE POLACRILEX (OTC)

GLAXOSMITHKLINE LLC

* GLAXOSMITHKLINE LLC
 DYAIDE, HYDROCHLOROTHIAZIDE
 DYNACIRC CR, ISRADIPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** G **

* GLAXOSMITHKLINE LLC
 FLOLAN, EPOPROSTENOL SODIUM
 INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
 MEPRON, ATOVAQUONE
 RYTHMOL SR, PROPAFENONE HYDROCHLORIDE
 RYTHMOL, PROPAFENONE HYDROCHLORIDE

GLENMARK GENERICS

* GLENMARK GENERICS INC USA
 ADAPALENE, ADAPALENE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CALCIPOTRIENE, CALCIPOTRIENE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 IMIQUIMOD, IMIQUIMOD
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MUPIROCIN, MUPIROCIN CALCIUM
 NILSTAT, NYSTATIN
 NIZATIDINE, NIZATIDINE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 ZONISAMIDE, ZONISAMIDE

* GLENMARK GENERICS LIMITED
 BRIELLYN, ETHINYL ESTRADIOL
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

* GLENMARK GENERICS LTD
 ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
 ALYACEN 1/35, ETHINYL ESTRADIOL
 ALYACEN 7/7/7, ETHINYL ESTRADIOL
 ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
 CARVEDILOL, CARVEDILOL
 CICLOPIROX, CICLOPIROX
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 FELODIPINE, FELODIPINE
 FLUCONAZOLE, FLUCONAZOLE
 GABAPENTIN, GABAPENTIN
 HEATHER, NORETHINDRONE
 LAMOTRIGINE, LAMOTRIGINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LITHIUM CARBONATE, LITHIUM CARBONATE
 MARLISSA, ETHINYL ESTRADIOL
 MELOXICAM, MELOXICAM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN, NAPROXEN
 NORETHIDRONE, NORETHINDRONE
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 OXCARBAZEPINE, OXCARBAZEPINE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 THEOPHYLLINE, THEOPHYLLINE
 TOPIRAMATE, TOPIRAMATE
 TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
 URSODIOL, URSODIOL
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 VIORELE, DESOGESTREL

* GLENMARK GENERICS LTD INDIA
 INDOMETHACIN, INDOMETHACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** G **

- * GLENMARK GENERICS LTD INDIA
LITHIUM CARBONATE, LITHIUM CARBONATE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

GLENMARK PHARMS

- * GLENMARK PHARMACEUTICALS INC USA
CICLOPIROX, CICLOPIROX
CLOTRIMAZOLE, CLOTRIMAZOLE
MUPIROCIN, MUPIROCIN
- * GLENMARK PHARMACEUTICALS LTD
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

GLENMARK PHARMS LTD

- * GLENMARK PHARMACEUTICALS LTD
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE

GRANULES INDIA

- * GRANULES INDIA LTD
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

GRIFFEN

- * KW GRIFFEN CO
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

GTX INC

- * GTX INC
FARESTON, TOREMIFENE CITRATE

GUARDIAN DRUG

- * GUARDIAN DRUG CO INC
FOAMCOAT, ALUMINUM HYDROXIDE (OTC)

GUERBET

- * GUERBET LLC
HEXABRIX, IOXAGLATE MEGLUMINE
OXILAN-300, IOXILAN
OXILAN-350, IOXILAN

HAEMONETICS

- * HAEMONETICS CORP
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

HALOCARBON PRODS

- * HALOCARBON PRODUCTS CORP
ISOFLURANE, ISOFLURANE
SEVOFLURANE, SEVOFLURANE

HALOZYME THERAP

- * HALOZYME THERAPEUTICS INC
HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN

HAMELN RDS GMBH

- * HAMELN RDS GMBH
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE

HANFORD GC

- * GC HANFORD MANUFACTURING CO
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

HARRIS PHARM

- * HARRIS PHARMACEUTICAL INC
FLUCONAZOLE, FLUCONAZOLE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

HEC PHARM USA INC

- * HEC PHARM USA INC
ZIDOVUDINE, ZIDOVUDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

HELSINN HLTHCARE

* HELSINN HEALTHCARE SA
ALOXI, PALONOSETRON HYDROCHLORIDE

HERCON PHARM

* HERCON PHARMACEUTICAL LLC
NITROGLYCERIN, NITROGLYCERIN

HERITAGE PHARMS INC

* HERITAGE PHARMACEUTICALS INC
ACETAZOLAMIDE, ACETAZOLAMIDE
CARISOPRODOL AND ASPIRIN, ASPIRIN
DOXYCYCLINE, DOXYCYCLINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
LEFLUNOMIDE, LEFLUNOMIDE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NYSTATIN, NYSTATIN
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

HETERO DRUGS

* HETERO DRUGS LTD
METHOCARBAMOL, METHOCARBAMOL
STAVUDINE, STAVUDINE
TORSEMIDE, TORSEMIDE

HETERO DRUGS LTD

* HETERO DRUGS LTD UNIT III
FINASTERIDE, FINASTERIDE
LEVETIRACETAM, LEVETIRACETAM
LITHIUM CARBONATE, LITHIUM CARBONATE
ZIDOVUDINE, ZIDOVUDINE

HETERO LABS LTD III

* HETERO LABS LTD UNIT III
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
INDOMETHACIN, INDOMETHACIN
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE

HETERO LABS LTD V

* HETERO LABS LTD UNIT V
IRBESARTAN, IRBESARTAN

HETERO LABS UNIT III

* HETERO LABS LTD UNIT III
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN

HEYL CHEMISCH

* HEYL CHEMISCH PHARMAZEUTISCHE FABRIK
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)

HI TECH PHARMA

* HI TECH PHARMACAL CO INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
CALCIPOTRIENE, CALCIPOTRIENE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CICLOPIROX, CICLOPIROX

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HI TECH PHARMACAL CO INC
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 CORMAX, CLOBETASOL PROPIONATE
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 EMBELINE E, CLOBETASOL PROPIONATE
 EMBELINE, CLOBETASOL PROPIONATE
 ERYTHRO-STATIN, ERYTHROMYCIN
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LACTULOSE, LACTULOSE
 LEVOCARNITINE, LEVOCARNITINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
 NYSTATIN, NYSTATIN
 OFLOXACIN, OFLOXACIN
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
 HYDROBROMIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 VOSOL HC, ACETIC ACID, GLACIAL
 VOSOL, ACETIC ACID, GLACIAL

HI TECH PHARMA CO

* HI TECH PHARMACAL CO INC
 FLUNISOLIDE, FLUNISOLIDE
 PREDNISOLONE, PREDNISOLONE
 TUSSICAPS, CHLORPHENIRAMINE POLISTIREX

HIGH TECH PHARMA

* HIGH TECHNOLOGY PHARMACAL CO INC
 VALPROIC ACID, VALPROIC ACID

HIKMA

* HIKMA FARMACEUTICA LDA
 CEFOTAXIME, CEFOTAXIME SODIUM

* HIKMA PHARMACEUTICALS
 AMOXICILLIN, AMOXICILLIN
 CARVEDILOL, CARVEDILOL
 CEFACLOL, CEFACLOL
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEPHALEXIN, CEPHALEXIN
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 GLYBURIDE (MICRONIZED), GLYBURIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

HIKMA (MAPLE)

* HIKMA (MAPLE) LTD
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

HIKMA FARMACEUTICA

* HIKMA FARMACEUTICA (PORTUGAL) SA
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

- * HIKMA FARMACEUTICA (PORTUGAL) SA
 - CEFOXITIN, CEFOXITIN SODIUM
 - CEFTRIAZONE, CEFTRIAZONE SODIUM
 - CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 - CIPROFLOXACIN, CIPROFLOXACIN
 - CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 - ENALAPRILAT, ENALAPRILAT
 - FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 - FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 - FLUMAZENIL, FLUMAZENIL
 - FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 - GLYCOPYRROLATE, GLYCOPYRROLATE
 - GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 - IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 - LEVETIRACETAM, LEVETIRACETAM
 - LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 - METOPROLOL TARTRATE, METOPROLOL TARTRATE
 - MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
 - MILRINONE LACTATE, MILRINONE LACTATE
 - ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 - ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 - PROGESTERONE, PROGESTERONE
 - PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 - TERBUTALINE SULFATE, TERBUTALINE SULFATE
 - TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 - VALPROATE SODIUM, VALPROATE SODIUM
- * HIKMA FARMACEUTICA PORTUGAL LDA
 - CEFAZOLIN SODIUM, CEFZOLIN SODIUM
 - CEFUROXIME SODIUM, CEFUROXIME SODIUM
 - FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
- * HIKMA FARMACEUTICA PORTUGAL SA
 - DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 - TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
- * HIKMA FARMACEUTICA SA
 - BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE

HIKMA MAPLE

- * HIKMA MAPLE LTD
 - ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, ACYCLOVIR SODIUM
 - ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 - ADENOSINE, ADENOSINE
 - AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 - BUMETANIDE, BUMETANIDE
 - CEFOXITIN, CEFOXITIN SODIUM
 - CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 - CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 - DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 - DIGOXIN, DIGOXIN
 - DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 - DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 - DIPYRIDAMOLE, DIPYRIDAMOLE
 - DURAMORPH PF, MORPHINE SULFATE
 - FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 - FAMOTIDINE, FAMOTIDINE
 - FLUMAZENIL, FLUMAZENIL
 - FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 - GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 - INFUMORPH, MORPHINE SULFATE
 - KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 - MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
 - MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 - MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 - MILRINONE LACTATE, MILRINONE LACTATE
 - MITOMYCIN, MITOMYCIN
 - ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 - ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HIKMA MAPLE LTD
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

HIKMA PHARM CO LTD

* HIKMA PHARM CO LTD
ARGATROBAN, ARGATROBAN

HIKMA PHARMS

* HIKMA PHARMACEUTICALS
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEPHALEXIN, CEPHALEXIN
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
GABAPENTIN, GABAPENTIN
GEMFIBROZIL, GEMFIBROZIL
LAMOTRIGINE, LAMOTRIGINE
MODAFINIL, MODAFINIL
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
* HIKMA PHARMACEUTICALS LLC
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX

HILL DERMAC

* HILL DERMACEUTICALS INC
DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE
DERMOTIC, FLUOCINOLONE ACETONIDE

HISAMITSU PHARM CO

* HISAMITSU PHARMACEUTICAL CO INC
SALONPAS, MENTHOL (OTC)

HISUN PHARM HANGZHOU

* HISUN PHARMACEUTICAL (HANGZHOU) CO LTD
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

HITECH PHARMA

* HITECH PHARMACAL CORP
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE

HI-TECH PHARMA CO

* HI-TECH PHARMACAL CO INC
LORAZEPAM, LORAZEPAM

HI-TECH PHARMACAL

* HI-TECH PHARMACAL CO INC
LEVETIRACETAM, LEVETIRACETAM

HOFFMANN LA ROCHE

* HOFFMANN LA ROCHE INC
ANAPROX DS, NAPROXEN SODIUM
ANAPROX, NAPROXEN SODIUM
BONIVA, IBANDRONATE SODIUM
INVIRASE, SAQUINAVIR MESYLATE
ROCEPHIN, CEFTRIAXONE SODIUM
ROMAZICON, FLUMAZENIL
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
XELODA, CAPECITABINE
XENICAL, ORLISTAT
ZELBORAF, VEMURAFENIB

HOPE PHARMS

* HOPE PHARMACEUTICALS
NITHIODOTE, SODIUM NITRITE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HOPE PHARMACEUTICALS
 SODIUM NITRITE, SODIUM NITRITE
 SODIUM THIOSULFATE, SODIUM THIOSULFATE

HORIZON PHARMA

* HORIZON PHARMA INC
 DUEXIS, FAMOTIDINE
 RAYOS, PREDNISONE

HOSPIRA

* HOSPIRA INC
 ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
 ACETYLCYSTEINE, ACETYLCYSTEINE
 A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
 ALFENTANIL, ALFENTANIL HYDROCHLORIDE
 A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
 AMIDATE, ETOMIDATE
 AMIKACIN SULFATE, AMIKACIN SULFATE
 AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
 AMINOPHYLLINE, AMINOPHYLLINE
 AMINOSYN 10% (PH6), AMINO ACIDS
 AMINOSYN 10%, AMINO ACIDS
 AMINOSYN 3.5% M, AMINO ACIDS
 AMINOSYN 3.5%, AMINO ACIDS
 AMINOSYN 5%, AMINO ACIDS
 AMINOSYN 7% (PH6), AMINO ACIDS
 AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
 AMINOSYN 7%, AMINO ACIDS
 AMINOSYN 8.5% (PH6), AMINO ACIDS
 AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
 AMINOSYN 8.5%, AMINO ACIDS
 AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
 AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
 AMINOSYN II 10%, AMINO ACIDS
 AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
 AMINOSYN II 7%, AMINO ACIDS
 AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
 AMINOSYN II 8.5%, AMINO ACIDS
 AMINOSYN-HBC 7%, AMINO ACIDS
 AMINOSYN-HF 8%, AMINO ACIDS
 AMINOSYN-PF 10%, AMINO ACIDS
 AMINOSYN-PF 7%, AMINO ACIDS
 AMINOSYN-RF 5.2%, AMINO ACIDS
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
 AQUASOL A, VITAMIN A PALMITATE
 ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAINE HYDROCHLORIDE
 ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
 AZITHROMYCIN, AZITHROMYCIN
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BUMETANIDE, BUMETANIDE
 BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
 CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
 CARBOPLATIN, CARBOPLATIN
 CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
 CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 CIPROFLOXACIN, CIPROFLOXACIN
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HOSPIRA INC
CORLOPAM, FENOLDOPAM MESYLATE
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 25%, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIAZEPAM, DIAZEPAM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
ENALAPRILAT, ENALAPRILAT
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ERYC, ERYTHROMYCIN
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL CITRATE, FENTANYL CITRATE
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FOSCARNET SODIUM, FOSCARNET SODIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISOFLURANE, ISOFLURANE
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HOSPIRA INC

LEVOPHED, NOREPINEPHRINE BITARTRATE

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE

LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE

LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE

LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

LIPOSYN II 10%, SAFFLOWER OIL

LIPOSYN II 20%, SAFFLOWER OIL

LIPOSYN III 10%, SOYBEAN OIL

LIPOSYN III 20%, SOYBEAN OIL

LIPOSYN III 30%, SOYBEAN OIL

LORAZEPAM, LORAZEPAM

LTA II KIT, LIDOCAINE HYDROCHLORIDE

M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID

M.V.I. ADULT, ASCORBIC ACID

M.V.I. PEDIATRIC, ASCORBIC ACID

M.V.I.-12 (WITHOUT VITAMIN K), ASCORBIC ACID

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE

MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE

MAGNESIUM SULFATE, MAGNESIUM SULFATE

MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE

MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL

MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL

MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL

MANNITOL 25%, MANNITOL

MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL

MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE

MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE

MARCAINE, BUPIVACAINE HYDROCHLORIDE

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE

METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

METHOTREXATE SODIUM, METHOTREXATE SODIUM

METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE

METOPROLOL TARTRATE, METOPROLOL TARTRATE

METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE

MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE

MORPHINE SULFATE, MORPHINE SULFATE

NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE

NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE

NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN

NITROGLYCERIN, NITROGLYCERIN

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE

ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

PACLITAXEL, PACLITAXEL

PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

PANCURONIUM BROMIDE, PANCURONIUM BROMIDE

PHENYTOIN SODIUM, PHENYTOIN SODIUM

PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE

PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE

POTASSIUM ACETATE IN PLASTIC CONTAINER, POTASSIUM ACETATE

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HOSPIRA INC

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE

PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE

PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

PROPOFOL, PROPOFOL

QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE

QUELICIN, SUCCINYLCHOLINE CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

- * HOSPIRA INC
 - RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 - SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE ANHYDROUS
 - SODIUM BICARBONATE, SODIUM BICARBONATE
 - SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 - SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 - SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
 - SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
 - SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
 - SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
 - STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 - STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 - SUFENTANIL CITRATE, SUFENTANIL CITRATE
 - TALWIN, PENTAZOCINE LACTATE
 - TAZICEF, CEFTAZIDIME
 - THAM, TROMETHAMINE
 - TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
 - TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 - TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 - VECURONIUM BROMIDE, VECURONIUM BROMIDE
 - VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 - VINORELBINE TARTRATE, VINORELBINE TARTRATE
 - VITAMIN K1, PHYTONADIONE
 - ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
- * HOSPIRA WORLDWIDE, INC
 - DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 - FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 - GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 - MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 - NITROPRESS, SODIUM NITROPRUSSIDE
 - TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 - VINCRIStINE SULFATE PFS, VINCRIStINE SULFATE

HOSPIRA INC

- * HOSPIRA INC
 - A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
 - AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 - ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 - ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 - CEFAZOLIN SODIUM, CEFZOLIN SODIUM
 - CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
 - CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
 - CEFOXITIN, CEFOTAXIME SODIUM
 - CEFTRIAXONE, CEFTRIAXONE SODIUM
 - CEFUROXIME SODIUM, CEFUROXIME SODIUM
 - DOCETAXEL, DOCETAXEL
 - GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 - HEPARIN SODIUM, HEPARIN SODIUM
 - HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 - IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
 - LEVETIRACETAM, LEVETIRACETAM
 - MAXIPIME, CEFEPIME HYDROCHLORIDE
 - MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
 - MEROPENEM, MEROPENEM
 - MORPHINE SULFATE, MORPHINE SULFATE
 - NIPENT, PENTOSTATIN
 - OXALIPLATIN, OXALIPLATIN
 - PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 - THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 - TOPOTECAN, TOPOTECAN HYDROCHLORIDE
 - VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

HOSPIRA WORLDWIDE

* HOSPIRA WORLDWIDE PTY
OXALIPLATIN, OXALIPLATIN

HOUSTON CYCLOTRON

* HOUSTON CYCLOTRON PARTNERS LP
AMMONIA N 13, AMMONIA N-13
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

HQ SPECIALITY PHARMA

* HQ SPECIALITY PHARMA LLC
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM

HRA PHARMA

* HRA PHARMA LLC
METOPIRONE, METYRAPONE

IBI

* ISTITUTO BIOCHIMICO ITALIANO SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
NAFCILLIN SODIUM, NAFCILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIPERACILLIN, PIPERACILLIN SODIUM

IDENTI PHARMS INC

* IDENTI PHARMACEUTICALS INC
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

IMPAX LABS

* IMPAX LABORATORIES INC
ACARBOSE, ACARBOSE
ALPRAZOLAM, ALPRAZOLAM
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
DANTROLENE SODIUM, DANTROLENE SODIUM
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DIGOXIN, DIGOXIN
DIPYRIDAMOLE, DIPYRIDAMOLE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
LETROZOLE, LETROZOLE
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
OMEPRazole, OMEPRazole
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RILUZOLE, RILUZOLE
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* IMPAX LABORATORIES INC
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

IMPAX LABS INC

* IMPAX LABORATORIES INC
ANASTROZOLE, ANASTROZOLE
CABERGOLINE, CABERGOLINE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

IMPAX PHARMS

* IMPAX PHARMACEUTICALS
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
GEMFIBROZIL, GEMFIBROZIL
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

INCYTE CORP

* INCYTE CORP
JAKAFI, RUXOLITINIB PHOSPHATE

INDICUS PHARMA

* INDICUS PHARMA LLC
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LETROZOLE, LETROZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

INJECTALIA

* INJECTALIA SRL
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

INNOPHARMA INC

* INNOPHARMA INC
ACETYLCYSTEINE, ACETYLCYSTEINE

INO

* INO THERAPEUTICS INC
INOMAX, NITRIC OXIDE

INSIGHT PHARMS

* INSIGHT PHARMACEUTICALS CORP
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
NIX, PERMETHRIN (OTC)

INSPIRE

* INSPIRE PHARMACEUTICALS INC
AZASITE, AZITHROMYCIN

INST BIOCHEM

* INSTITUT BIOCHEMIQUE SA
FLECTOR, DICLOFENAC EPOLAMINE

INST BIOCHIMIQUE

* INSTITUT BIOCHIMIQUE SA (IBSA)
TIROSINT, LEVOTHYROXINE SODIUM

INSTITUT BIOCHIMIQUE

* INSTITUT BIOCHIMIQUE SA IBSA
TIROSINT, LEVOTHYROXINE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** I **

INSYS THERAP

- * INSYS THERAPEUTICS INC
DRONABINOL, DRONABINOL
SUBSYS, FENTANYL

INTERGEL PHARM

- * INTERGEL PHARMACEUTICAL INC
NIFEDIPINE, NIFEDIPINE

INTL MEDICATED

- * INTERNATIONAL MEDICATED SYSTEMS LTD
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE

INTL MEDICATION

- * INTERNATIONAL MEDICATION SYSTEM
AMINOPHYLLINE, AMINOPHYLLINE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
- * INTERNATIONAL MEDICATION SYSTEMS LTD
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE

INTL MEDICATION SYS

- * INTERNATIONAL MEDICATION SYSTEMS LTD
LORAZEPAM, LORAZEPAM

INVAGEN PHARMS

- * INVAGEN PHARMACEUTICALS INC
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FOLIC ACID, FOLIC ACID
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
MEPROBAMATE, MEPROBAMATE
NABUMETONE, NABUMETONE
NAPROXEN, NAPROXEN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRANDOLAPRIL, TRANDOLAPRIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* INVAGEN PHARMACEUTICALS INC
WARFARIN SODIUM, WARFARIN SODIUM
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONISAMIDE, ZONISAMIDE

INVENTIA HLTHCARE

* INVENTIA HEALTHCARE PRIVATE LTD
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

IPCA LABS LTD

* IPCA LABORATORIES LTD
ALLOPURINOL, ALLOPURINOL
ATENOLOL, ATENOLOL
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
FUROSEMIDE, FUROSEMIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

IPR

* IPR PHARMACEUTICALS INC
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
CRESTOR, ROSUVASTATIN CALCIUM
ZOMIG, ZOLMITRIPTAN

IPR PHARMS INC

* IPR PHARMACEUTICALS INC
CAPRELSA, VANDETANIB

IPSEN INC

* IPSEN BIOPHARMACEUTICALS INC
INCRELEX, MECASERMIN RECOMBINANT

IPSEN PHARMA

* IPSEN PHARMA BIOTECH SAS
SOMATULINE DEPOT, LANREOTIDE ACETATE

IROKO PHARMS

* IROKO PHARMACEUTICALS LLC
INDOCIN, INDOMETHACIN

ISO TEX

* ISO TEX DIAGNOSTICS INC
JEANATOPE, ALBUMIN IODINATED I-125 SERUM
MEGATOPE, ALBUMIN IODINATED I-131 SERUM

ISOTEX

* ISOTEX DIAGNOSTICS
GLOFIL-125, IOTHALAMATE SODIUM I-125

ISTA PHARMS

* ISTA PHARMACEUTICALS
BEPREVE, BEPOTASTINE BESILATE
ISTALOL, TIMOLOL MALEATE
VITRASE, HYALURONIDASE

ISTA PHARMS INC

* ISTA PHARMACEUTICALS INC
BROMDAY, BROMFENAC SODIUM

IVAX INTL

* IVAX INTERNATIONAL GMBH
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
SYNRIBO, OMACETAXINE MEPESUCCINATE

IVAX PHARMS

* IVAX PHARMACEUTICALS INC
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

IVAX SUB TEVA PHARMS

* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUMETANIDE, BUMETANIDE
CABERGOLINE, CABERGOLINE
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE (OTC)
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOZAPINE, CLOZAPINE
CYCLOSPORINE, CYCLOSPORINE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUTAMIDE, FLUTAMIDE
FUROSEMIDE, FUROSEMIDE
GABAPENTIN, GABAPENTIN
GLIPIZIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GUANABENZ ACETATE, GUANABENZ ACETATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LORAZEPAM, LORAZEPAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYLDOPA, METHYLDOPA
MISOPROSTOL, MISOPROSTOL
NADOLOL, NADOLOL
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PROBENECID, PROBENECID
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
SIMVASTATIN, SIMVASTATIN
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

JACOBUS

* JACOBUS PHARMACEUTICAL CO
DAPSONE, DAPSONE
PASER, AMINOSALICYLIC ACID

JANSSEN BIOTECH

* JANSSEN BIOTECH INC
ZYTIGA, ABIRATERONE ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

JANSSEN PHARMS

* JANSSEN PHARMACEUTICALS INC
AXERT, ALMOTRIPTAN MALATE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
DITROPAN XL, OXYBUTYNIN CHLORIDE
DORIBAX, DORIPENEM
DURAGESIC-100, FENTANYL
DURAGESIC-12, FENTANYL
DURAGESIC-25, FENTANYL
DURAGESIC-50, FENTANYL
DURAGESIC-75, FENTANYL
ELMIRON, PENTOSAN POLYSULFATE SODIUM
HALDOL, HALOPERIDOL DECANOATE
HALDOL, HALOPERIDOL LACTATE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVEGA, PALIPERIDONE
LEUSTATIN, CLADRIBINE
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVAQUIN, LEVOFLOXACIN
MICRONOR, NORETHINDRONE
MODICON 28, ETHINYL ESTRADIOL
NIZORAL, KETOCONAZOLE
NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
NUCYNTA, TAPENTADOL HYDROCHLORIDE
ORTHO CYCLEN-28, ETHINYL ESTRADIOL
ORTHO EVRA, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
ORTHO-CEPT, DESOGESTREL
ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
PANCREAZE, LIPASE
RAZADYNE ER, GALANTAMINE HYDROBROMIDE
RAZADYNE, GALANTAMINE HYDROBROMIDE
RISPERDAL CONSTA, RISPERIDONE
RISPERDAL, RISPERIDONE
SPORANOX, ITRACONAZOLE
TERAZOL 3, TERCONAZOLE
TERAZOL 7, TERCONAZOLE
TOPAMAX, TOPIRAMATE
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
TYLOX, ACETAMINOPHEN
ULTRACET, ACETAMINOPHEN
ULTRAM, TRAMADOL HYDROCHLORIDE
XARELTO, RIVAROXABAN

JANSSEN PRODS

* JANSSEN PRODUCTS LP
EDURANT, RILPIVIRINE HYDROCHLORIDE
PREZISTA, DARUNAVIR ETHANOLATE

JANSSEN R AND D

* JANSSEN RESEARCH AND DEVELOPMENT LLC
INTELENCE, ETRAVIRINE
PARAFON FORTE DSC, CHLORZOXAZONE

JANSSEN RES AND DEV

* JANSSEN RESEARCH AND DEVELOPMENT LLC
DOXIL, DOXORUBICIN HYDROCHLORIDE

JANSSEN THERAP

* JANSSEN THERAPEUTICS DIV JANSSEN PRODUCTS LP
SIRTURO, BEDAQUILINE FUMARATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

JAZZ EUSA PHARMA

- * JAZZ PHARMACEUTICALS EUSA PHARMA USA INC
QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

JAZZ PHARMS

- * JAZZ PHARMACEUTICALS INC
LUVOX CR, FLUVOXAMINE MALEATE
XYREM, SODIUM OXYBATE

JAZZ PHARMS III

- * JAZZ PHARMACEUTICALS III INTERNATIONAL LTD
FAZACLO ODT, CLOZAPINE

JAZZ PHARMS INTL

- * JAZZ PHARMACEUTICALS INTERNATIONAL LTD
PRIALT, ZICONOTIDE ACETATE

JHP PHARMS

- * JHP PHARMACEUTICALS LLC
ADRENALIN, EPINEPHRINE
BREVITAL SODIUM, METHOHEXITAL SODIUM
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
DANTRIUM, DANTROLENE SODIUM
DELESTROGEN, ESTRADIOL VALERATE
KETALAR, KETAMINE HYDROCHLORIDE
PITOCIN, OXYTOCIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIOSTAT, LIOTHYRONINE SODIUM

JIANGSU HANSON PHARM

- * JIANGSU HANSON PHARMACEUTICAL CO LTD
VINOELBINE TARTRATE, VINOELBINE TARTRATE

JIANGSU HENGRUI MED

- * JIANGSU HENGRUI MEDICINE CO LTD
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

JOHN O BUTLER CO

- * JOHN O BUTLER CO
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE

JOHNSON AND JOHNSON

- * JOHNSON AND JOHNSON GROUP CONSUMER COMPANIES
MEN'S ROGAINE, MINOXIDIL (OTC)
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)

JUBILANT CADISTA

- * JUBILANT CADISTA PHARMACEUTICALS INC
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
PREDNISONE, PREDNISONE
PROCOMP, PROCHLORPERAZINE MALEATE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

JUBILANT DRAXIMAGE

- * JUBILANT DRAXIMAGE INC
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
HICON, SODIUM IODIDE I-131
SODIUM IODIDE I-131, SODIUM IODIDE I-131

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

JUBILANT LIFE

- * JUBILANT LIFE SCIENCES LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE

JUBILANT ORGANOSYS

- * JUBILANT ORGANOSYS LTD
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
OLANZAPINE, OLANZAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
RISPERIDONE, RISPERIDONE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

KEY PHARMS

- * KEY PHARMACEUTICALS INC SUB SCHERING PLOUGH CORP
NITRO-DUR, NITROGLYCERIN

KING PFIZER

- * KING PHARMACEUTICALS INC SUB PFIZER INC
AVINZA, MORPHINE SULFATE

KING PHARMS

- * KING PHARMACEUTICALS INC
ALTACE, RAMIPRIL
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
CORCARD, NADOLOL
CORZIDE, BENDROFLUMETHIAZIDE
CYTOMEL, LIOTHYRONINE SODIUM
LEVOXYL, LEVOTHYROXINE SODIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
SILVADENE, SILVER SULFADIAZINE
SKELAXIN, METAXALONE
SYNERCID, DALFOPRISTIN
TIGAN, TRIMETHO BENZAMIDE HYDROCHLORIDE
- * KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC SUB KING PHARMACEUTICALS INC
SONATA, ZALEPLON
TAPAZOLE, METHIMAZOLE
TUSSIGON, HOMATROPINE METHYLBROMIDE

KING PHARMS R AND D

- * KING PHARMACEUTICALS RESEARCH DEVELOPMENT INC
OXYCTA, OXYCODONE HYDROCHLORIDE

KOWA CO

- * KOWA CO LTD
LIVALO, PITAVASTATIN CALCIUM

KREMERS URBAN PHARMS

- * KREMERS URBAN PHARMACEUTICALS INC
GLYCOLAX, POLYETHYLENE GLYCOL 3350
GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
MONOKET, ISOSORBIDE MONONITRATE
NITROGLYCERIN, NITROGLYCERIN
OMEPRAZOLE, OMEPRAZOLE

KUDCO IRELAND

- * KUDCO IRELAND LTD
ANASTROZOLE, ANASTROZOLE
BICALUTAMIDE, BICALUTAMIDE
LETROZOLE, LETROZOLE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM

KV PHARM

- * KV PHARMACEUTICAL CO
CLINDESSE, CLINDAMYCIN PHOSPHATE
EVAMIST, ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** K ****

* KV PHARMACEUTICAL CO
GYNAZOLE-1, BUTOCONAZOLE NITRATE
MAKENA, HYDROXYPROGESTERONE CAPROATE

KVK TECH

* KVK TECH INC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
KALEXATE, SODIUM POLYSTYRENE SULFONATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

LAB HRA PHARMA

* LABORATOIRE HRA PHARMA
ELLA, ULIPRISTAL ACETATE

LANDELA PHARM

* LANDELA PHARMACEUTICAL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

LANNETT

* LANNETT CO INC
ACETAZOLAMIDE, ACETAZOLAMIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
LANORINAL, ASPIRIN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
PROBALAN, PROBENECID
SERPALAN, RESERPINE
* LANNETT HOLDINGS INC
BACLOFEN, BACLOFEN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
DANAZOL, DANAZOL
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
TERBUTALINE SULFATE, TERBUTALINE SULFATE
URSODIOL, URSODIOL

LANNETT HOLDINGS INC

* LANNETT HOLDINGS INC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
METHOCARBAMOL, METHOCARBAMOL
MORPHINE SULFATE, MORPHINE SULFATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PHENTERMINE RESIN COMPLEX, PHENTERMINE RESIN COMPLEX
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

LANTHEUS MEDCL

* LANTHEUS MEDICAL IMAGING INC
ABLAVAR, GADOFOSVESET TRISODIUM
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
DEFINITY, PERFLUTREN
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
XENON XE 133, XENON XE-133

LARKEN LABS

* LARKEN LABORATORIES INC
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

LAVIPHARM LABS

* LAVIPHARM LABORATORIES INC
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL

LEHIGH VALLEY

* LEHIGH VALLEY TECHNOLOGIES INC
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

LEK PHARMS

* LEK PHARMACEUTICALS D D
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE

LEK PHARMS DD

* LEK PHARMACEUTICALS DD
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

LEO PHARM

* LEO PHARMACEUTICAL PRODUCTS LTD
DOVONEX, CALCIPOTRIENE
TACLONEX, BETAMETHASONE DIPROPIONATE

LEO PHARMA AS

* LEO PHARMA AS
DOVONEX, CALCIPOTRIENE
PICATO, INGENOL MEBUTATE
TACLONEX, BETAMETHASONE DIPROPIONATE

LG LIFE

* LG LIFE SCIENCES LTD
VALTROPIN, SOMATROPIN RECOMBINANT

LILLY

* ELI LILLY AND CO
ALIMTA, PEMETREXED DISODIUM
CIALIS, TADALAFIL
CYMBALTA, DULOXETINE HYDROCHLORIDE
EVISTA, RALOXIFENE HYDROCHLORIDE
FORTEO, TERIPARATIDE RECOMBINANT HUMAN
GEMZAR, GEMCITABINE HYDROCHLORIDE
GLUCAGON, GLUCAGON RECOMBINANT
HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG, INSULIN LISPRO RECOMBINANT
HUMATROPE, SOMATROPIN RECOMBINANT
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN RECOMBINANT HUMAN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* ELI LILLY AND CO
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
STRATTERA, ATOMOXETINE HYDROCHLORIDE
SYMBYAX, FLUOXETINE HYDROCHLORIDE
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE

LLOYD

* LLOYD INC
LEVOTHROID, LEVOTHYROXINE SODIUM

LNK

* LNK INTERNATIONAL INC
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

LOREAL USA

* LOREAL USA PRODUCTS INC
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
CAPITAL SOLEIL 15, AVOBENZONE (OTC)

LOTUS PHARM CO LTD

* LOTUS PHARMACEUTICAL CO LTD
LEVETIRACETAM, LEVETIRACETAM

LUITPOLD

* LUITPOLD PHARMACEUTICALS INC
ACETYLCYSTEINE, ACETYLCYSTEINE
ADENOSINE, ADENOSINE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCITRIOL, CALCITRIOL
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLOSPORINE, CYCLOSPORINE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXFERRUM, IRON DEXTRAN
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ETOMIDATE, ETOMIDATE
FOMEPIZOLE, FOMEPIZOLE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LATANOPROST, LATANOPROST
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOCARNITINE, LEVOCARNITINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LUITPOLD PHARMACEUTICALS INC
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NITROGLYCERIN, NITROGLYCERIN
OLANZAPINE, OLANZAPINE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROGESTERONE, PROGESTERONE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
SPRIX, KETOROLAC TROMETHAMINE
TORSEMIDE, TORSEMIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
VENOFER, IRON SUCROSE
ZIDOVUDINE, ZIDOVUDINE

LUNDBECK INC

* LUNDBECK INC
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE

LUNDBECK LLC

* LUNDBECK LLC
CHEMET, SUCCIMER
COSMEGEN, DACTINOMYCIN
INDOCIN, INDOMETHACIN SODIUM
NEOPROFEN, IBUPROFEN LYSINE
ONFI, CLOBAZAM
PEGANONE, ETHOTOIN
SABRIL, VIGABATRIN
TRANXENE, CLORAZEPATE DIPOTASSIUM

LUPIN

* LUPIN LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFPROZIL, CEFPROZIL
CEFTRIAZONE, CEFTRIAZONE SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINAPRIL, LISINAPRIL
LOVASTATIN, LOVASTATIN
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
TRANDOLAPRIL, TRANDOLAPRIL

LUPIN ATLANTIS

* LUPIN ATLANTIS HOLDINGS SA
ANTARA (MICRONIZED), FENOFIBRATE

LUPIN LTD

* LUPIN LIMITED
LEVETIRACETAM, LEVETIRACETAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

* LUPIN LIMITED
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

* LUPIN LTD
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FAMOTIDINE, FAMOTIDINE
FENOFIBRATE, FENOFIBRATE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IRBESARTAN, IRBESARTAN
KURVELO, ETHINYL ESTRADIOL
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEFENAMIC ACID, MEFENAMIC ACID
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
NABUMETONE, NABUMETONE
NORETHINDRONE, NORETHINDRONE
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PREGABALIN, PREGABALIN
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
SUPRAX, CEFIXIME
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

LUPIN PHARMS

* LUPIN PHARMACEUTICALS INC
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
DESLOMATADINE, DESLOMATADINE
MELOXICAM, MELOXICAM
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
SUPRAX, CEFIXIME
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

LYNE

* LYNE LABORATORIES INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
HYDROCORTISONE, HYDROCORTISONE
LEVOCARNITINE, LEVOCARNITINE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

LYNROSE LABS

* LYNROSE LABS LLC
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE

MACLEODS PHARMS LTD

* MACLEODS PHARMACEUTICALS LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FAMCICLOVIR, FAMCICLOVIR
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LEVOFLOXACIN, LEVOFLOXACIN
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

MALLINCKRODT

- * MALLINCKRODT CHEMICAL INC
 - ANEXSIA 7.5/650, ACETAMINOPHEN
 - ANEXSIA, ACETAMINOPHEN
 - BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 - HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 - METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 - METHADOSE, METHADONE HYDROCHLORIDE
 - OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
- * MALLINCKRODT INC
 - ANEXSIA 5/325, ACETAMINOPHEN
 - ANEXSIA 7.5/325, ACETAMINOPHEN
 - ANEXSIA, ACETAMINOPHEN
 - DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 - FENTANYL CITRATE, FENTANYL CITRATE
 - FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 - HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 - HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 - MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 - METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 - METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
 - METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
 - METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 - MORPHINE SULFATE, MORPHINE SULFATE
 - NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 - OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
 - OPTIMARK, GADOVERSETAMIDE
 - OXYCET, ACETAMINOPHEN
 - OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 - PENNSAID, DICLOFENAC SODIUM
 - SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 - TECHNETIUM TC-99 SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
 - THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
 - TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
- * MALLINCKRODT MEDICAL INC
 - CONRAY 30, IOTHALAMATE MEGLUMINE
 - CONRAY 43, IOTHALAMATE MEGLUMINE
 - CONRAY, IOTHALAMATE MEGLUMINE
 - CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
 - GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
 - INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
 - MD-76R, DIATRIZOATE MEGLUMINE
 - MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
 - OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
 - OPTIRAY 240, IOVERSOL
 - OPTIRAY 300, IOVERSOL
 - OPTIRAY 320, IOVERSOL
 - OPTIRAY 350, IOVERSOL
 - SODIUM IODIDE I 123, SODIUM IODIDE I-123
 - SODIUM IODIDE I 131, SODIUM IODIDE I-131
 - TECHNISCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
 - TECHNISCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
 - TECHNISCAN, TECHNETIUM TC-99M OXIDRONATE KIT
 - THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
 - ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
 - ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

MALLINCKRODT INC

- * MALLINCKRODT INC
 - ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 - BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 - EXALGO, HYDROMORPHONE HYDROCHLORIDE
 - FENTANYL-100, FENTANYL
 - FENTANYL-25, FENTANYL
 - FENTANYL-50, FENTANYL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MALLINCKRODT INC
FENTANYL-75, FENTANYL
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
RESTORIL, TEMAZEPAM
ROXICODONE, OXYCODONE HYDROCHLORIDE
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOFRANIL-PM, IMIPRAMINE PAMOATE

MALLINCKRODT LLC

* MALLINCKRODT LLC
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE

MARATHON PHARMS

* MARATHON PHARMACEUTICALS LLC
PEPCID, FAMOTIDINE
SECONAL SODIUM, SECOBARBITAL SODIUM

MARKSANS PHARMA

* MARKSANS PHARMA LTD
GABAPENTIN, GABAPENTIN
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN

MARSAM PHARMS LLC

* MARSAM PHARMACEUTICALS LLC
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

MATRIX LABS LTD

* MATRIX LABORATORIES LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
NIFEDIPINE, NIFEDIPINE
STAVUDINE, STAVUDINE

MAYNE PHARMA

* MAYNE PHARMA INTERNATIONAL PTY LTD
DORYX, DOXYCYCLINE HYCLATE

MCNEIL

* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
IMODIUM A-D EZ CHEWS, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
MOTRIN IB, IBUPROFEN (OTC)
MOTRIN MIGRAINE PAIN, IBUPROFEN (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

MCNEIL CONS

* MCNEIL CONSUMER HEALTHCARE
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM, LOPERAMIDE HYDROCHLORIDE
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
NIZORAL A-D, KETOCONAZOLE (OTC)
PEPCID AC (GELTAB), FAMOTIDINE (OTC)
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
SINE-AID IB, IBUPROFEN (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MCNEIL CONSUMER HEALTHCARE
 SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 TYLENOL (CAPLET), ACETAMINOPHEN (OTC)
 TYLENOL (GELTAB), ACETAMINOPHEN (OTC)

MCNEIL CONSUMER

* MCNEIL CONSUMER HEALTHCARE DIV MCNEIL PPC INC
 CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 ZYRTEC, CETIRIZINE HYDROCHLORIDE

MCPRE

* MAYO CLINIC PET RADIOCHEMISTRY FACILITY
 CHOLINE C-11, CHOLINE C-11

MEDA PHARMS

* MEDA PHARMACEUTICALS
 DYMISTA, AZELASTINE HYDROCHLORIDE
 EDLUAR, ZOLPIDEM TARTRATE

* MEDA PHARMACEUTICALS INC
 ANADROL-50, OXYMETHOLONE
 ASTELIN, AZELASTINE HYDROCHLORIDE
 ASTEPRO, AZELASTINE HYDROCHLORIDE
 AVC, SULFANILAMIDE
 BUTISOL SODIUM, BUTABARBITAL SODIUM
 CESAMET, NABILONE
 COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
 COLYTE, POLYETHYLENE GLYCOL 3350
 COLYTE-FLAVORED, POLYETHYLENE GLYCOL 3350
 CORTIFOAM, HYDROCORTISONE ACETATE
 DEMADEX, TORSEMIDE
 DEPEN, PENICILLAMINE
 DIPENTUM, OLSALAZINE SODIUM
 ELESTRIN, ESTRADIOL
 EPIFOAM, HYDROCORTISONE ACETATE
 FELBATOL, FELBAMATE
 GASTROCROM, CROMOLYN SODIUM
 LUFYLLIN, DYPHYLLINE
 MUSE, ALPROSTADIL
 ONSOLIS, FENTANYL CITRATE
 OPTIVAR, AZELASTINE HYDROCHLORIDE
 PROCTOFOAM HC, HYDROCORTISONE ACETATE
 ROWASA, MESALAMINE
 SFROWASA, MESALAMINE
 TRILYTE, POLYETHYLENE GLYCOL 3350

* MEDA PHARMACEUTICALS MEDA PHARMACEUTICALS INC
 SOMA COMPOUND W/ CODEINE, ASPIRIN
 SOMA COMPOUND, ASPIRIN
 SOMA, CARISOPRODOL

MEDEFIL

* MEDEFIL INC
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

MEDICINES CO

* THE MEDICINES CO
 ANGIOMAX, BIVALIRUDIN
 CLEVIPREX, CLEVIDIPINE BUTYRATE

MEDICIS

* MEDICIS PHARMACEUTICAL CORP
 ALDARA, IMIQUIMOD
 BUPHENYL, SODIUM PHENYLBUTYRATE
 CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DYNACIN, MINOCYCLINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MEDICIS PHARMACEUTICAL CORP
ESTRASORB, ESTRADIOL HEMIHYDRATE
LOPROX, CICLOPIROX
MAXAIR, PIRBUTEROL ACETATE
METROGEL-VAGINAL, METRONIDAZOLE
MINITRAN, NITROGLYCERIN
NORFLEX, ORPHENADRINE CITRATE
NORGESIC FORTE, ASPIRIN
NORGESIC, ASPIRIN
SOLODYN, MINOCYCLINE HYDROCHLORIDE
SYNACORT, HYDROCORTISONE
TAMBOCOR, FLECAINIDE ACETATE
THEOLAIR, THEOPHYLLINE
VANOS, FLUOCINONIDE
ZIANA, CLINDAMYCIN PHOSPHATE
ZYCLARA, IMIQUIMOD

MEDICURE

* MEDICURE INTERNATIONAL INC
AGGRASTAT, TIROFIBAN HYDROCHLORIDE

MEDIGENE AG

* MEDIGENE AG
VEREGEN, SINECATECHINS

MEDIMETRIKS PHARMS

* MEDIMETRIKS PHARMACEUTICALS INC
SYNALAR, FLUOCINOLONE ACETONIDE

MEDIMMUNE

* MEDIMMUNE
ETHYOL, AMIFOSTINE

MEDTRONIC

* MEDTRONIC INC
LIORESAL, BACLOFEN

MERCK

* MERCK AND CO INC
AMINOHIPPURATE SODIUM, AMINOHIPPURATE SODIUM
CANCIDAS, CASPOFUNGIN ACETATE
EMEND, APREPITANT
FOSAMAX PLUS D, ALENDRONATE SODIUM
FOSAMAX, ALENDRONATE SODIUM
HYZAAR, HYDROCHLOROTHIAZIDE
INVANZ, ERTAPENEM SODIUM
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
PRIMAXIN, CILASTATIN SODIUM
PROSCAR, FINASTERIDE
SINGULAIR, MONTELUKAST SODIUM
ZOLINZA, VORINOSTAT

* MERCK RESEARCH LABORATORIES DIV MERCK CO INC
CLINORIL, SULINDAC
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COZAAR, LOSARTAN POTASSIUM
MEVACOR, LOVASTATIN
NOROXIN, NORFLOXACIN
PRINIVIL, LISINOPRIL
PRINZIDE, HYDROCHLOROTHIAZIDE
PROPECIA, FINASTERIDE
SINGULAIR, MONTELUKAST SODIUM
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
ZOCOR, SIMVASTATIN

MERCK AND CO INC

* MERCK AND CO INC
EMEND, FOSAPREPITANT DIMEGLUMINE
FOSAMAX, ALENDRONATE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

MERCK KGAA

- * MERCK KGAA
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM

MERCK SANTE SAS

- * MERCK SANTE SAS
CYANOKIT, HYDROXOCOBALAMIN

MERCK SHARP DOHME

- * MERCK SHARP AND DOHME CORP
CLARINEX D 24 HOUR, DESLORATADINE
CLARINEX, DESLORATADINE
CLARINEX-D 12 HOUR, DESLORATADINE
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
CRIXIVAN, INDINAVIR SULFATE
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
DIPROLENE, BETAMETHASONE DIPROPIONATE
DULERA, FORMOTEROL FUMARATE
ELOCON, MOMETASONE FUROATE
GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
ISENTRESS, RALTEGRAVIR POTASSIUM
JANUMET XR, METFORMIN HYDROCHLORIDE
JANUMET, METFORMIN HYDROCHLORIDE
JANUVIA, SITAGLIPTIN PHOSPHATE
JUVISYNC, SIMVASTATIN
LOTRISONE, BETAMETHASONE DIPROPIONATE
REBETOL, RIBAVIRIN
SINEMET CR, CARBIDOPA
SINEMET, CARBIDOPA
STROMECTOL, IVERMECTIN
TEMODAR, TEMOZOLOMIDE
VICTRELIS, BOCEPREVIR
ZIOPTAN, TAFLUPROST

MERIDIAN MEDCL

- * MERIDIAN MEDICAL TECHNOLOGIES INC
DUODOTE, ATROPINE
- * MERIDIAN MEDICAL TECHNOLOGIES INC SUB KING PHARMACEUTICALS INC
ALSUMA, SUMATRIPTAN SUCCINATE

MERIDIAN MEDCL TECHN

- * MERIDIAN MEDICAL TECHNOLOGIES INC
ATROPEN, ATROPINE
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
LIDOPEN, LIDOCAINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE

MERRO PHARM

- * MERRO PHARMACEUTICAL CO LTD
IBUPROFEN, IBUPROFEN (OTC)

MERZ PHARMS

- * MERZ PHARMACEUTICALS LLC
CUVPOSA, GLYCOPYRROLATE
ERYGEL, ERYTHROMYCIN
NAFTIN, NAFTIFINE HYDROCHLORIDE
ONMEL, ITRACONAZOLE

METHAPHARM

- * METHAPHARM INC
LEVETIRACETAM, LEVETIRACETAM
PROVOCHOLINE, METHACHOLINE CHLORIDE

MICRO LABS LTD

- * MICRO LABS LTD
MEFENAMIC ACID, MEFENAMIC ACID
NEVIRAPINE, NEVIRAPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MICRO LABS LTD
SIMVASTATIN, SIMVASTATIN

MICRO LABS LTD INDIA

* MICRO LABS LTD INDIA
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

MICRO LABS USA

* MICRO LABS USA INC
GLIMEPIRIDE, GLIMEPIRIDE

MIKAH PHARMA

* MIKAH PHARMA LLC
ISRADIPINE, ISRADIPINE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

MIKART

* MIKART INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC, AMINOCAPROIC ACID
BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTAPAP, ACETAMINOPHEN
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CHLORZOXAZONE, CHLORZOXAZONE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
ESGIC-PLUS, ACETAMINOPHEN
ETHOSUXIMIDE, ETHOSUXIMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
ISONIAZID, ISONIAZID
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PYRAZINAMIDE, PYRAZINAMIDE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

MILLENNIUM PHARMS

* MILLENNIUM PHARMACEUTICALS INC
VELCADE, BORTEZOMIB

MIRROR PHARMS

* MIRROR PHARMACEUTICALS LLC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PROBENECID AND COLCHICINE, COLCHICINE

MISSION PHARMA

* MISSION PHARMACAL CO
BINOSTO, ALENDRONATE SODIUM
LITHOSTAT, ACETOHYDROXAMIC ACID
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TEXACORT, HYDROCORTISONE
TINDAMAX, TINIDAZOLE
TIOPRONIN, TIOPRONIN
UROCIT-K, POTASSIUM CITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

MN PHARMS

* MN PHARMACEUTICALS
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

MOBIUS THERAP

* MOBIUS THERAPEUTICS LLC
MITOSOL, MITOMYCIN

MOLNLYCKE HLTH

* MOLNLYCKE HEALTH CARE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

MONARCH PHARMS

* MONARCH PHARMACEUTICALS INC
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE
CORTISPORIN, HYDROCORTISONE ACETATE
MENEST, ESTROGENS, ESTERIFIED
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, GRAMICIDIN
PEDIOTIC, HYDROCORTISONE
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
THALITONE, CHLORTHALIDONE
VIROPTIC, TRIFLURIDINE

MORTON GROVE

* MORTON GROVE PHARMACEUTICALS INC
LACTULOSE, LACTULOSE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

MORTON GROVE PHARMS

* MORTON GROVE PHARMACEUTICALS INC
GENERLAC, LACTULOSE

MSD CONSUMER

* MSD CONSUMER CARE INC
OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
ZEGERID OTC, OMEPRAZOLE (OTC)

MSD INTL

* MSD INTERNATIONAL GMBH
VYTORIN, EZETIMIBE

MSD INTL GMBH

* MSD INTERNATIONAL GMBH
ZETIA, EZETIMIBE

MURTY PHARMS

* MURTY PHARMACEUTICALS INC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE

MUSTAFA NEVSAT

* MUSTAFA NEVSAT ILAC SANAYII AS
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE

MUSTAFA NEVZAT

* MUSTAFA NEVZAT ILAC SANAYII AS
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
VECURIUM BROMIDE, VECURIUM BROMIDE

MUTUAL PHARM

* MUTUAL PHARMACEUTICAL CO INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MUTUAL PHARMACEUTICAL CO INC
 ATENOLOL, ATENOLOL
 BACTRIM DS, SULFAMETHOXAZOLE
 BACTRIM, SULFAMETHOXAZOLE
 CARISOPRODOL, CARISOPRODOL
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 ERGOLOID MESYLATES, ERGOLOID MESYLATES
 FELODIPINE, FELODIPINE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 LOVASTATIN, LOVASTATIN
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE, METRONIDAZOLE
 MINOXIDIL, MINOXIDIL
 NYSTATIN, NYSTATIN
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PIROXICAM, PIROXICAM
 PREDNISONE, PREDNISONE
 PRIMIDONE, PRIMIDONE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
 QUINIDINE SULFATE, QUINIDINE SULFATE
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 SPIRONOLACTONE, SPIRONOLACTONE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SULINDAC, SULINDAC
 TEMAZEPAM, TEMAZEPAM
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
 TOLMETIN SODIUM, TOLMETIN SODIUM
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

MUTUAL PHARM CO INC

* MUTUAL PHARMACEUTICAL CO INC
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 LEVETIRACETAM, LEVETIRACETAM
 QUALAQUIN, QUININE SULFATE

MUTUAL PHARMA

* MUTUAL PHARMACAL CO
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 KETOCONAZOLE, KETOCONAZOLE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

MYLAN

* MYLAN LABORATORIES INC
 ACYCLOVIR, ACYCLOVIR
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 CAPTOPRIL, CAPTOPRIL
 ETODOLAC, ETODOLAC
 OLANZAPINE, OLANZAPINE
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
* MYLAN PHARMACEUTICALS
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
* MYLAN PHARMACEUTICALS INC
 ACARBOSE, ACARBOSE
 ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
 ACYCLOVIR, ACYCLOVIR
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALLOPURINOL, ALLOPURINOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN PHARMACEUTICALS INC
 ALPRAZOLAM, ALPRAZOLAM
 AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMNESTEEM, ISOTRETINOIN
 ANASTROZOLE, ANASTROZOLE
 ATENOLOL AND CHLORTHALIDONE, ATENOLOL
 ATENOLOL, ATENOLOL
 AVITA, TRETINOIN
 AZATHIOPRINE, AZATHIOPRINE
 AZITHROMYCIN, AZITHROMYCIN
 BACLOFEN, BACLOFEN
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 BUDESONIDE, BUDESONIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CARVEDILOL, CARVEDILOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHLOROTHIAZIDE, CHLOROTHIAZIDE
 CHLORPROPAMIDE, CHLORPROPAMIDE
 CHLORTHALIDONE, CHLORTHALIDONE
 CILOSTAZOL, CILOSTAZOL
 CIMETIDINE, CIMETIDINE
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 CLORPRES, CHLORTHALIDONE
 CLOZAPINE, CLOZAPINE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 CYSTAGON, CYSTEAMINE BITARTRATE
 DIAZEPAM, DIAZEPAM
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 ESTRADIOL, ESTRADIOL
 ESTROPIPATE, ESTROPIPATE
 ETIDRONATE DISODIUM, ETIDRONATE DISODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN PHARMACEUTICALS INC
 ETOPOSIDE, ETOPOSIDE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 FAMCICLOVIR, FAMCICLOVIR
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FELODIPINE, FELODIPINE
 FENOFIBRATE, FENOFIBRATE
 FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FINASTERIDE, FINASTERIDE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FLURBIPROFEN, FLURBIPROFEN
 FLUTAMIDE, FLUTAMIDE
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 FUROSEMIDE, FUROSEMIDE
 GABAPENTIN, GABAPENTIN
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GLIPIZIDE, GLIPIZIDE
 GLYBURIDE (MICRONIZED), GLYBURIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 INDAPAMIDE, INDAPAMIDE
 INDOMETHACIN, INDOMETHACIN
 KETOCONAZOLE, KETOCONAZOLE
 KETOPROFEN, KETOPROFEN
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LAMOTRIGINE, LAMOTRIGINE
 LATANOPROST, LATANOPROST
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
 LIOETHYRONINE SODIUM, LIOETHYRONINE SODIUM
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINOPRIL, LISINOPRIL
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
 LORATADINE, LORATADINE (OTC)
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOVASTATIN, LOVASTATIN
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
 MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
 MELOXICAM, MELOXICAM
 MENTAX, BUTENAFINE HYDROCHLORIDE
 MENTAX-TC, BUTENAFINE HYDROCHLORIDE
 MERCAPTOPYRINE, MERCAPTOPYRINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHIMAZOLE, METHIMAZOLE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN PHARMACEUTICALS INC
 METHYLDOPA, METHYLDOPA
 METOLAZONE, METOLAZONE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIRTAZAPINE, MIRTAZAPINE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NADOLOL AND BENDROFLUMETHAZIDE, BENDROFLUMETHIAZIDE
 NADOLOL, NADOLOL
 NAPROXEN, NAPROXEN
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NIFEDIPINE, NIFEDIPINE
 NISOLDIPINE, NISOLDIPINE
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PACLITAXEL, PACLITAXEL
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
 PEG-3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE, POLYETHYLENE GLYCOL 3350
 PENTOXIFYLLINE, PENTOXIFYLLINE
 PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 PHENYTEK, PHENYTOIN SODIUM
 PINDOLOL, PINDOLOL
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIROXICAM, PIROXICAM
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 PROBENECID, PROBENECID
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 SPIRONOLACTONE, SPIRONOLACTONE
 STAVUDINE, STAVUDINE
 SULINDAC, SULINDAC
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TACROLIMUS, TACROLIMUS
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TEMAZEPAM, TEMAZEPAM
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
 THIOTHIXENE, THIOTHIXENE
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLAZAMIDE, TOLAZAMIDE
 TOLMETIN SODIUM, TOLMETIN SODIUM
 TOPIRAMATE, TOPIRAMATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN PHARMACEUTICALS INC
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRANDOLAPRIL, TRANDOLAPRIL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
URSODIOL, URSODIOL
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
ZALEPLON, ZALEPLON
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONISAMIDE, ZONISAMIDE

MYLAN BERTEK

* MYLAN BERTEK PHARMACEUTICALS INC
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE

MYLAN INSTITUTIONAL

* MYLAN INSTITUTIONAL LLC
ALOPRIM, ALLOPURINOL SODIUM
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
DURACLON, CLONIDINE HYDROCHLORIDE
ENLON-PLUS, ATROPINE SULFATE
ETOMIDATE, ETOMIDATE
ISOSULFAN BLUE, ISOSULFAN BLUE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MESNA, MESNA
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
ULTIVA, REMIFENTANIL HYDROCHLORIDE

MYLAN LABS

* MYLAN LABORATORIES LTD
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
NEVIRAPINE, NEVIRAPINE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

MYLAN LLC

* MYLAN INSTITUTIONAL LLC
CIDOFOVIR, CIDOFOVIR
FOMEPIZOLE, FOMEPIZOLE
SULFAMYLOX, MAFENIDE ACETATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

MYLAN PHARMS INC

* MYLAN PHARMACEUTICALS INC
ABACAVIR SULFATE, ABACAVIR SULFATE
ALPRAZOLAM, ALPRAZOLAM
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ARMODAFINIL, ARMODAFINIL
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AVITA, TRETINOIN
BACLOFEN, BACLOFEN
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CICLOPIROX, CICLOPIROX
CILOSTAZOL, CILOSTAZOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN PHARMACEUTICALS INC
 CLONAZEPAM, CLONAZEPAM
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DESLORATADINE, DESLORATADINE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIDANOSINE, DIDANOSINE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 EPROSARTAN MESYLATE, EPROSARTAN MESYLATE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 INDAPAMIDE, INDAPAMIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 ITRACONAZOLE, ITRACONAZOLE
 LANSOPRAZOLE, LANSOPRAZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LITHIUM CARBONATE, LITHIUM CARBONATE
 MALATHION, MALATHION
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHYLCLOTHIAZIDE, METHYLCLOTHIAZIDE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MODAFINIL, MODAFINIL
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MORPHINE SULFATE, MORPHINE SULFATE
 NABUMETONE, NABUMETONE
 NAPROXEN, NAPROXEN
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 NEVIRAPINE, NEVIRAPINE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PHENYTOIN, PHENYTOIN
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUININE SULFATE, QUININE SULFATE
 RAMIPRIL, RAMIPRIL
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SIMVASTATIN, SIMVASTATIN
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLBUTAMIDE, TOLBUTAMIDE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRIAZOLAM, TRIAZOLAM
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VORICONAZOLE, VORICONAZOLE
 ZIDOVUDINE, ZIDOVUDINE
 ZONISAMIDE, ZONISAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN PHARMACEUTICALS INC.
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
NIZATIDINE, NIZATIDINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

MYLAN SPECLT

* MYLAN SPECIALTY LP
ALBUTEROL SULFATE, ALBUTEROL SULFATE
PERFORMIST, FORMOTEROL FUMARATE

MYLAN TECHNOLOGIES

* MYLAN TECHNOLOGIES INC
CLONIDINE, CLONIDINE
ESTRADIOL, ESTRADIOL
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
NITROGLYCERIN, NITROGLYCERIN

NATCO PHARMA

* NATCO PHARMA LTD
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

NATCO PHARMA LTD

* NATCO PHARMA LIMITED
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
* NATCO PHARMA LTD
ANASTROZOLE, ANASTROZOLE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
LANSOPRAZOLE, LANSOPRAZOLE
LETROZOLE, LETROZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

NAUTILUS NEUROSCIENC

* NAUTILUS NEUROSCIENCES INC
CAMBIA, DICLOFENAC POTASSIUM

NAVINTA LLC

* NAVINTA LLC
FAMOTIDINE, FAMOTIDINE
FOMEPIZOLE, FOMEPIZOLE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

NEPHRON

* NEPHRON CORP
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
* NEPHRON PHARMACEUTICALS CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE

NESHER PHARMS

* NESHER PHARMACEUTICALS USA LLC
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MICRO-K 10, POTASSIUM CHLORIDE
MICRO-K, POTASSIUM CHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE

NEUROGESX

* NEUROGESX INC
QUTENZA, CAPSAICIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** N **

NEW RIVER

- * NEW RIVER PHARMACEUTICALS INC
PROFERDEX, IRON DEXTRAN

NEXGEN PHARMA

- * NEXGEN PHARMA INC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHENODIOL, CHENODIOL
GLYCOPYRROLATE, GLYCOPYRROLATE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

NEXGEN PHARMA INC

- * NEXGEN PHARMA INC
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350

NEXTWAVE PHARMS

- * NEXTWAVE PHARMACEUTICALS INC
QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE

NEXUS PHARMS

- * NEXUS PHARMACEUTICALS INC
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
LEVOFLOXACIN, LEVOFLOXACIN

NIAGARA PHARMS

- * NIAGARA PHARMACEUTICALS INC
PUR-WASH, PURIFIED WATER (OTC)

NORTHSTAR HLTHCARE

- * NORTHSTAR HEALTHCARE HOLDINGS LTD
ALLOPURINOL, ALLOPURINOL
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
GEMFIBROZIL, GEMFIBROZIL
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

NOSTRUM

- * NOSTRUM PHARMACEUTICALS INC
CARBAMAZEPINE, CARBAMAZEPINE
THEOPHYLLINE, THEOPHYLLINE

NOSTRUM LABS

- * NOSTRUM LABORATORIES INC
PIROXICAM, PIROXICAM
SUCRALFATE, SUCRALFATE

NOSTRUM PHARMS LLC

- * NOSTRUM PHARMACEUTICALS LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

NOVADEL

- * NOVADEL PHARMA INC
NITROMIST, NITROGLYCERIN
ZOLPIMIST, ZOLPIDEM TARTRATE

NOVARTIS

- * NOVARTIS CONSUMER HEALTH INC
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
HABITROL, NICOTINE (OTC)
LAMISIL AT, TERBINAFAINE (OTC)
LAMISIL AT, TERBINAFAINE HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFAINE HYDROCHLORIDE (OTC)
NEXCEDE, KETOPROFEN (OTC)
PREVACID 24 HR, LANSOPRAZOLE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** N **

* NOVARTIS CONSUMER HEALTH INC
TAVIST ALLERGY/SINUS/HEADACHE, ACETAMINOPHEN (OTC)
THRIVE, NICOTINE POLACRILEX (OTC)
TRANSDERM SCOP, SCOPOLAMINE
VAGISTAT-1, TIOCONAZOLE (OTC)
VOLTAREN, DICLOFENAC SODIUM

* NOVARTIS PHARMACEUTICALS CORP
AFINITOR, EVEROLIMUS
AMTURNIDE, ALISKIREN HEMIFUMARATE
ARCAPTA NEOHALER, INDACATEROL MALEATE
CATAFLAM, DICLOFENAC POTASSIUM
CLOZARIL, CLOZAPINE
COARTEM, ARTEMETHER
COMBIPATCH, ESTRADIOL
DESFERAL, DEFEROXAMINE MESYLATE
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
ESTRADERM, ESTRADIOL
EXELON, RIVASTIGMINE
EXELON, RIVASTIGMINE TARTRATE
EXFORGE HCT, AMLODIPINE BESYLATE
EXFORGE, AMLODIPINE BESYLATE
EXJADE, DEFERASIROX
FAMVIR, FAMCICLOVIR
FANAPT, ILOPERIDONE
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FORADIL, FORMOTEROL FUMARATE
GILENYA, FINGOLIMOD
GLEEVEC, IMATINIB MESYLATE
HYDERGINE, ERGOLOID MESYLATES
LAMISIL, TERBINAFINE HYDROCHLORIDE
LAMPRENE, CLOFAZIMINE
LESCOL XL, FLUVASTATIN SODIUM
LESCOL, FLUVASTATIN SODIUM
LOPRESSOR, METOPROLOL TARTRATE
LOTREL, AMLODIPINE BESYLATE
MIACALCIN, CALCITONIN SALMON
MYFORTIC, MYCOPHENOLIC ACID
NEORAL, CYCLOSPORINE
OCUPRESS, CARTEOLOL HYDROCHLORIDE
RECLAST, ZOLEDRONIC ACID
REGITINE, PHENTOLAMINE MESYLATE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SANDOSTATIN, OCTREOTIDE ACETATE
SIGNIFOR, PASIREOTIDE DIASPARTATE
STARLIX, NATEGLINIDE
TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE
TAVIST-1, CLEMASTINE FUMARATE (OTC)
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TEKAMLO, ALISKIREN HEMIFUMARATE
TEKTURN HCT, ALISKIREN HEMIFUMARATE
TEKTURN, ALISKIREN HEMIFUMARATE
TRILEPTAL, OXCARBAZEPINE
TYZEKA, TELBIVUDINE
VALTURN, ALISKIREN HEMIFUMARATE
VASOCIDIN, PREDNISOLONE SODIUM PHOSPHATE
VIVELLE, ESTRADIOL
VIVELLE-DOT, ESTRADIOL
VOLTAREN, DICLOFENAC SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVARTIS PHARMACEUTICALS CORP
VOLTAREN-XR, DICLOFENAC SODIUM
ZOMETA, ZOLEDRONIC ACID
ZORTRESS, EVEROLIMUS

NOVARTIS PHARM

* NOVARTIS PHARMACEUTICAL CORP
AFINITOR DISPERZ, EVEROLIMUS

NOVARTIS PHARMS

* NOVARTIS PHARMACEUTICALS CORP
FEMARA, LETROZOLE
TOBI, TOBRAMYCIN

NOVAST LABS LTD

* NOVAST LABORATORIES LTD
DASETTA 1/35, ETHINYL ESTRADIOL
DASETTA 7/7/7, ETHINYL ESTRADIOL
ELINEST, ETHINYL ESTRADIOL
FALMINA, ETHINYL ESTRADIOL
LEVONEST, ETHINYL ESTRADIOL
MONO-LINYAH, ETHINYL ESTRADIOL
PHILITH, ETHINYL ESTRADIOL
TRI-LINYAH, ETHINYL ESTRADIOL
WERA, ETHINYL ESTRADIOL

NOVEL LABS INC

* NOVEL LABORATORIES INC
FAMOTIDINE, FAMOTIDINE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
MISOPROSTOL, MISOPROSTOL
MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE, SODIUM PHOSPHATE, DIBASIC,
ANHYDROUS
MOVIPREP, ASCORBIC ACID
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE, POLYETHYLENE GLYCOL 3350
PHENELZINE SULFATE, PHENELZINE SULFATE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
SULFAMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOPRIM-DS, SULFAMETHOXAZOLE
TEMAZEPAM, TEMAZEPAM
TINIDAZOLE, TINIDAZOLE
TRIMETHOPRIM, TRIMETHOPRIM

NOVEN

* NOVEN PHARMACEUTICALS INC
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
MINIVELLE, ESTRADIOL

NOVEN PHARMS INC

* NOVEN PHARMACEUTICALS INC
DAYTRANA, METHYLPHENIDATE

NOVEN THERAP

* NOVEN THERAPEUTICS LLC
LITHOBID, LITHIUM CARBONATE
PEXEVA, PAROXETINE MESYLATE

NOVEX

* NOVEX PHARMA
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

*** NOVEX PHARMA**

CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOSPORINE, CYCLOSPORINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LACTULOSE, LACTULOSE
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
OFLOXACIN, OFLOXACIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
TOBRAMYCIN, TOBRAMYCIN

NOVO NORDISK

* NOVO NORDISK PHARMACEUTICALS INC
GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT

NOVO NORDISK INC

* NOVO NORDISK INC
ACTIVELLA, ESTRADIOL
LEVEMIR FLEXPEN, INSULIN DETEMIR RECOMBINANT
LEVEMIR, INSULIN DETEMIR RECOMBINANT
NORDITROPIN FLEXPEN, SOMATROPIN RECOMBINANT
NORDITROPIN NORDIFLEX, SOMATROPIN RECOMBINANT
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT
NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT
NOVOLOG, INSULIN ASPART RECOMBINANT
PRANDIMET, METFORMIN HYDROCHLORIDE
PRANDIN, REPAGLINIDE
VAGIFEM, ESTRADIOL
VICTOZA, LIRAGLUTIDE RECOMBINANT

NOVOCOL

* NOVOCOL PHARMACEUTICAL INC
ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN, LEVONORDEFIN
ISOCAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE

NOVOCOL INC

* NOVOCOL INC
LIDOCAINE, LIDOCAINE

NPS PHARMS INC

* NPS PHARMACEUTICALS INC
GATTEX KIT, TEDUGLUTIDE

NU PHARM

* NU PHARM INC
DIVALPROEX SODIUM, DIVALPROEX SODIUM

NUPATHE

* NUPATHE INC
ZECUITY, SUMATRIPTAN SUCCINATE

NYCOMED US

* NYCOMED US INC
TERCONAZOLE, TERCONAZOLE

OAK PHARMS

* OAK PHARMACEUTICALS INC
EMLA, LIDOCAINE
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
XYLOCAINE, LIDOCAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** 0 ****

OAK PHARMS AKORN

* OAK PHARMACEUTICALS INC SUB AKORN INC
COGENTIN, BENZTROPINE MESYLATE
DIURIL, CHLOROTHIAZIDE SODIUM

ODYSSEY PHARMS

* ODYSSEY PHARMACEUTICALS INC
ANTABUSE, DISULFIRAM
NYSTATIN, NYSTATIN
SURMONTIL, TRIMIPRAMINE MALEATE
URECHOLINE, BETHANECHOL CHLORIDE
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE

OHM

* OHM CORP
IBUPROFEN, IBUPROFEN (OTC)

OHM LABS

* OHM LABORATORIES INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUPROHM, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

OLTA PHARMS

* OLTA PHARMACEUTICALS CORP
LINDANE, LINDANE

OMAN PHARM PRODUCTS

* OMAN PHARMACEUTICAL PRODUCTS CO LLC
NEOMYCIN SULFATE, NEOMYCIN SULFATE

ONCO THERAPIES LTD

* ONCO THERAPIES LTD
CARBOPLATIN, CARBOPLATIN
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE
CYTARABINE, CYTARABINE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUOROURACIL, FLUOROURACIL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VINORELBINE, VINORELBINE

ONY

* ONY INC
INFASURF PRESERVATIVE FREE, CALFACTANT

ONYX PHARMS

* ONYX PHARMACEUTICALS INC
KYPROLIS, CARFILZOMIB

OPTIMER PHARMS

* OPTIMER PHARMACEUTICALS INC
DIFICID, FIDAXOMICIN

ORAPHARMA

* ORAPHARMA INC
ARESTIN, MINOCYCLINE HYDROCHLORIDE

ORCHID HLTHCARE

* ORCHID HEALTHCARE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** 0 **

- * ORCHID HEALTHCARE
 - CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 - CEFDINIR, CEFDINIR
 - CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 - CEFPROZIL, CEFPROZIL
 - CEFUROXIME AXETIL, CEFUROXIME AXETIL
 - CEPHALEXIN, CEPHALEXIN
 - CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 - CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 - DESLORATADINE, DESLORATADINE
 - DIVALPROEX SODIUM, DIVALPROEX SODIUM
 - GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 - IBANDRONATE SODIUM, IBANDRONATE SODIUM
 - LEVETIRACETAM, LEVETIRACETAM
 - MODAFINIL, MODAFINIL
 - NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 - OLANZAPINE, OLANZAPINE
 - ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 - SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 - TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 - VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
- * ORCHID HEALTHCARE DIV ORCHID CHEMICALS AND PHARMACEUTICALS LTD
 - LEVOFLOXACIN, LEVOFLOXACIN
 - ZALEPLON, ZALEPLON

ORGANON SUB MERCK

- * ORGANON USA INC SUB MERCK AND CO INC
 - SAPHRIS, ASENAPINE MALEATE

ORGANON USA INC

- * ORGANON USA INC
 - CYCLESSA, DESOGESTREL
 - DESOGEN, DESOGESTREL
 - FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
 - GANIRELIX ACETATE INJECTION, GANIRELIX ACETATE
 - IMPLANON, ETONOGESTREL
 - NEXPLANON, ETONOGESTREL
 - NUVARING, ETHINYL ESTRADIOL
 - PREGNYL, GONADOTROPIN, CHORIONIC
 - REMERON SOLTAB, MIRTAZAPINE
 - REMERON, MIRTAZAPINE

ORION PHARMA

- * ORION PHARMA
 - COMTAN, ENTACAPONE
 - STALEVO 100, CARBIDOPA
 - STALEVO 125, CARBIDOPA
 - STALEVO 150, CARBIDOPA
 - STALEVO 200, CARBIDOPA
 - STALEVO 50, CARBIDOPA
 - STALEVO 75, CARBIDOPA

ORIT LABS LLC

- * ORIT LABORATORIES LLC
 - BENZONATATE, BENZONATATE
 - CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 - ERGOCALCIFEROL, ERGOCALCIFEROL

ORPHAN EUROPE

- * ORPHAN EUROPE
 - CARBAGLU, CARGLUMIC ACID

ORTHO MCNEIL JANSSEN

- * ORTHO MCNEIL JANSSEN PHARMACEUTICALS INC
 - NIZORAL, KETOCONAZOLE

OSI PHARMS

- * OSI PHARMACEUTICALS INC
 - TARCEVA, ERLOTINIB HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** 0 **

OSMOTICA PHARM

- * OSMOTICA PHARMACEUTICAL CORP
NIFEDIPINE, NIFEDIPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

OTSUKA

- * OTSUKA PHARMACEUTICAL CO LTD
ABILIFY, ARIPIPRAZOLE
PLETAL, CILOSTAZOL
- * OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC
ABILIFY, ARIPIPRAZOLE

OTSUKA AMERICA

- * OTSUKA AMERICA PHARMACEUTICALS INC
BREATHTEK UBT FOR H-PYLORI, UREA C-13

OTSUKA AMERICA PHARM

- * OTSUKA AMERICA PHARMACEUTICAL INC
SAMSCA, TOLVAPTAN

OTSUKA PHARM

- * OTSUKA PHARMACEUTICAL CO LTD
BUSULFEX, BUSULFAN

OUTLOOK PHARMS

- * OUTLOOK PHARMACEUTICALS INC
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

PACIFIC PHARMA

- * PACIFIC PHARMA
TIMOLOL MALEATE, TIMOLOL MALEATE
- * PACIFIC PHARMA INC
TIMOLOL MALEATE, TIMOLOL MALEATE

PACIRA PHARMS INC

- * PACIRA PHARMACEUTICALS INC
DEPOCYT, CYTARABINE
EXPAREL, BUPIVACAINE

PACK PHARMS LLC

- * PACK PHARMACEUTICALS LLC
CROMOLYN SODIUM, CROMOLYN SODIUM

PADDOCK

- * PADDOCK LABORATORIES INC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

PADDOCK LABS

- * PADDOCK LABORATORIES INC
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE

PADDOCK LLC

- * PADDOCK LABORATORIES LLC
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCIUM ACETATE, CALCIUM ACETATE
CICLOPIROX, CICLOPIROX
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COMPRO, PROCHLORPERAZINE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
ERYTHRA-DERM, ERYTHROMYCIN
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
KIONEX, SODIUM POLYSTYRENE SULFONATE
LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
LORAZEPAM, LORAZEPAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PADDOCK LABORATORIES LLC
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NYSTOP, NYSTATIN
PODOFILOX, PODOFILOX
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE

PALADIN LABS

* PALADIN LABS USA INC
ANTIZOL, FOMEPIZOLE

PANACEA BIOTEC LTD

* PANACEA BIOTEC LTD
TACROLIMUS, TACROLIMUS

PAR FORM

* PAR FORMULATIONS PRIVATE LTD
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE

PAR PHARM

* PAR PHARMACEUTICAL
NABUMETONE, NABUMETONE
OMEPRazole AND SODIUM BICARBONATE, OMEPRazole
PROPafenONE HYDROCHLORIDE, PROPafenONE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

* PAR PHARMACEUTICAL INC
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLDIPINE BESYLATE
CABERGOLINE, CABERGOLINE
CALCITONIN-SALMON, CALCITONIN SALMON
CAPOTEN, CAPTOPRIL
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLONAZEPAM, CLONAZEPAM
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
ESTAZOLAM, ESTAZOLAM
FENTANYL CITRATE, FENTANYL CITRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUTAMIDE, FLUTAMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYUREA, HYDROXYUREA
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEGACE ES, MEGESTROL ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PAR PHARMACEUTICAL INC
 MEGESTROL ACETATE, MEGESTROL ACETATE
 METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
 METRONIDAZOLE, METRONIDAZOLE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MINOXIDIL, MINOXIDIL
 NASCOBAL, CYANOCOBALAMIN
 NATEGLINIDE, NATEGLINIDE
 NIFEDIPINE, NIFEDIPINE
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 OLANZAPINE, OLANZAPINE
 OXANDROLONE, OXANDROLONE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TORSEMIDE, TORSEMIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRANLYCYPROMINE SULFATE, TRANLYCYPROMINE SULFATE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

PAR PHARM INC

* PAR PHARMACEUTICAL INC
 FENTANYL-100, FENTANYL
 FENTANYL-25, FENTANYL
 FENTANYL-50, FENTANYL
 FENTANYL-75, FENTANYL
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE

PARAPRO LLC

* PARAPRO LLC
 NATROBA, SPINOSAD

PARKE DAVIS

* PARKE DAVIS DIV WARNER LAMBERT CO
 CELONTIN, METHSUXIMIDE
 DILANTIN, PHENYTOIN SODIUM
 DILANTIN-125, PHENYTOIN
 NARDIL, PHENELZINE SULFATE
 NEURONTIN, GABAPENTIN
 ZARONTIN, ETHOSUXIMIDE
 * PARKE DAVIS PHARMACEUTICAL RESEARCH DIV WARNER LAMBERT CO
 ZARONTIN, ETHOSUXIMIDE

PEDIATRX

* PEDIATRX INC
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

PEDINOL

* PEDINOL PHARMACAL INC
 GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE

PERNIX THERAP

* PERNIX THERAPEUTICS LLC
 CEDAX, CEFTIBUTEN DIHYDRATE

PERRIGO

* L PERRIGO CO
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
 CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
 CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
 DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
 FAMOTIDINE, FAMOTIDINE (OTC)
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

- * L PERRIGO CO
 - LORATADINE, LORATADINE (OTC)
 - MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 - MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 - MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 - NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
 - NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 - TAB-PROFEN, IBUPROFEN (OTC)
 - TIOCONAZOLE, TIOCONAZOLE (OTC)
- * PERRIGO CO
 - BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 - CICLOPIROX, CICLOPIROX
 - CIMETIDINE, CIMETIDINE (OTC)
 - CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
 - CLINDETS, CLINDAMYCIN PHOSPHATE
 - CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 - ERYTHROMYCIN, ERYTHROMYCIN
 - FAMOTIDINE, FAMOTIDINE
 - FAMOTIDINE, FAMOTIDINE (OTC)
 - HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 - IBUPROFEN, IBUPROFEN (OTC)
 - JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
 - LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 - MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 - MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 - MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
 - MOMETASONE FUROATE, MOMETASONE FUROATE
 - NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 - PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 - STIE-CORT, HYDROCORTISONE

PERRIGO CO TENNESSEE

- * PERRIGO CO TENNESSEE INC
 - GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 - SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM

PERRIGO ISRAEL

- * PERRIGO ISRAEL PHARMACEUTICALS LTD
 - BUTOCONAZOLE NITRATE, BUTOCONAZOLE NITRATE
 - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 - CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 - HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 - IMIQUIMOD, IMIQUIMOD
 - KETOCONAZOLE, KETOCONAZOLE
 - MESALAMINE, MESALAMINE
 - MINOXIDIL, MINOXIDIL (OTC)
 - TESTOSTERONE, TESTOSTERONE

PERRIGO NEW YORK

- * PERRIGO NEW YORK INC
 - ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 - AMMONIUM LACTATE, AMMONIUM LACTATE
 - BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 - CENTANY, MUPIROCIN
 - CICLOPIROX, CICLOPIROX
 - CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 - DESONIDE, DESONIDE
 - DESOXIMETASONE, DESOXIMETASONE
 - ECONAZOLE NITRATE, ECONAZOLE NITRATE
 - ERYTHROMYCIN, ERYTHROMYCIN
 - FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 - GENTAMICIN SULFATE, GENTAMICIN SULFATE
 - HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 - HYDROCORTISONE, HYDROCORTISONE
 - KETOCONAZOLE, KETOCONAZOLE
 - MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PERRIGO NEW YORK INC
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MUPIROCIN, MUPIROCIN
 NYSTATIN, NYSTATIN
 PERMETHRIN, PERMETHRIN
 PERMETHRIN, PERMETHRIN (OTC)
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 SELENIUM SULFIDE, SELENIUM SULFIDE
 TERCONAZOLE, TERCONAZOLE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERRIGO R AND D

* PERRIGO R AND D CO
 CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 DESLORATADINE, DESLORATADINE
 GUAIFENESIN, GUAIFENESIN (OTC)
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LEVONORGESTREL, LEVONORGESTREL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 NAPROXEN, NAPROXEN
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

PERRIGO UK FINCO

* PERRIGO UK FINCO LTD PARTNERSHIP
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE

PETNET

* PETNET SOLUTIONS INC
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

PF PRISM

* PF PRISM CV
 LYRICA, PREGABALIN

PFIZER

* PFIZER CENTRAL RESEARCH
 DIFLUCAN, FLUCONAZOLE
 ZITHROMAX, AZITHROMYCIN

* PFIZER CHEMICALS DIV PFIZER INC
 DIFLUCAN, FLUCONAZOLE
 ZITHROMAX, AZITHROMYCIN

* PFIZER INC
 ACOVA, ARGATROBAN
 ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
 ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
 ADVIL COLD AND SINUS, IBUPROFEN (OTC)
 ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
 ADVIL LIQUI-GELS, IBUPROFEN (OTC)
 ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
 ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
 ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 ADVIL, IBUPROFEN (OTC)
 ALAVERT, LORATADINE (OTC)
 ANTIVERT, MECLIZINE HYDROCHLORIDE
 AXID AR, NIZATIDINE (OTC)
 CADUET, AMLODIPINE BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PFIZER INC
CALAN SR, VERAPAMIL HYDROCHLORIDE
CARDURA XL, DOXAZOSIN MESYLATE
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
ELELYSO, TALIGLUCERASE ALFA
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLUMAZENIL, FLUMAZENIL
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GLUCOTROL XL, GLIPIZIDE
GLUCOTROL, GLIPIZIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
INLYTA, AXITINIB
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIPITOR, ATORVASTATIN CALCIUM
LORATADINE, LORATADINE (OTC)
NAVANE, THIOTHIXENE
NORVASC, AMLODIPINE BESYLATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PEDIATRIC ADVIL, IBUPROFEN (OTC)
PROCARDIA, NIFEDIPINE
REVATIO, SILDENAFIL CITRATE
RIFAMPIN, RIFAMPIN
TESSALON, BENZONATATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOVIAZ, FESOTERODINE FUMARATE
UNASYN, AMPICILLIN SODIUM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VFEND, VORICONAZOLE
XALKORI, CRIZOTINIB
XELJANZ, TOFACITINIB CITRATE
ZITHROMAX, AZITHROMYCIN
* PFIZER LABORATORIES DIV PFIZER INC
CARDURA, DOXAZOSIN MESYLATE
DIABINESE, CHLORPROPAMIDE
FELDENE, PIROXICAM
MINIPRESS, PRAZOSIN HYDROCHLORIDE
PERMAPEN, PENICILLIN G BENZATHINE
PFIZERPEN, PENICILLIN G POTASSIUM
PROCARDIA XL, NIFEDIPINE
TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
UNASYN, AMPICILLIN SODIUM
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VISTARIL, HYDROXYZINE PAMOATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

- * PFIZER PHARMACEUTICALS INC
ZOLOFT, SERTRALINE HYDROCHLORIDE
- * PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
TIKOSYN, DOFETILIDE

PFIZER CONS HLTHCARE

- * PFIZER CONSUMER HEALTHCARE
ADVIL, IBUPROFEN SODIUM (OTC)

PFIZER GLOBAL

- * PFIZER GLOBAL RESEARCH DEVELOPMENT
ZMAX, AZITHROMYCIN

PFIZER INC

- * PFIZER INC
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CHANTIX, VARENICLINE TARTRATE
ELLEENCE, EPIRUBICIN HYDROCHLORIDE
GEODON, ZIPRASIDONE HYDROCHLORIDE
NICOTROL, NICOTINE

PFIZER IRELAND

- * PFIZER IRELAND PHARMACEUTICALS
RELPAX, ELETRIPTAN HYDROBROMIDE
VIAGRA, SILDENAFIL CITRATE

PFIZER PHARMS

- * PFIZER PHARMACEUTICALS LTD
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
DILANTIN, PHENYTOIN
LOPID, GEMFIBROZIL
NEURONTIN, GABAPENTIN
NITROSTAT, NITROGLYCERIN

PHARM ASSOC

- * PHARMACEUTICAL ASSOC INC
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LORAZEPAM, LORAZEPAM
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
- * PHARMACEUTICAL ASSOC INC DIV BEACH PRODUCTS
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PREDNISOLONE, PREDNISOLONE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID
- * PHARMACEUTICAL ASSOCIATES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN

PHARMA SERVE NY

- * PHARMA SERVE INC SUB TORIGIAN LABORATORIES
AMINOPHYLLINE, AMINOPHYLLINE

PHARMACHEMIE

- * PHARMACHEMIE BV
CARBOPLATIN, CARBOPLATIN
CISPLATIN, CISPLATIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PHARMACHEMIE BV
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
ETOPOSIDE, ETOPOSIDE

PHARMACHEMIE BV

* PHARMACHEMIE BV
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
CARBOPLATIN, CARBOPLATIN
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

PHARMACIA AND UPJOHN

* PHARMACIA AND UPJOHN
XANAX XR, ALPRAZOLAM

* PHARMACIA AND UPJOHN CO
ANSAID, FLURBIPROFEN
AROMASIN, EXEMESTANE
AZULFIDINE EN-TABS, SULFASALAZINE
AZULFIDINE, SULFASALAZINE
BACITRACIN, BACITRACIN
CAVERJECT IMPULSE, ALPROSTADIL
CAVERJECT, ALPROSTADIL
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
COLESTID, COLESTIPOL HYDROCHLORIDE
CORTEF, HYDROCORTISONE
CORVERT, IBUTILIDE FUMARATE
CYKLOKAPRON, TRANEXAMIC ACID
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DETROL LA, TOLTERODINE TARTRATE
DETROL, TOLTERODINE TARTRATE
DIDREX, BENZPHETAMINE HYDROCHLORIDE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
ESTRING, ESTRADIOL
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
GENOTROPIN, SOMATROPIN RECOMBINANT
GLYNASE, GLYBURIDE
GLYSET, MIGLITOL
HALCION, TRIAZOLAM
HEMABATE, CARBOPROST TROMETHAMINE
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
MEDROL, METHYLPREDNISOLONE
MYCOBUTIN, RIFABUTIN
NICOTROL, NICOTINE
OGEN .625, ESTROPIPATE
OGEN 1.25, ESTROPIPATE
OGEN 2.5, ESTROPIPATE
OGEN 5, ESTROPIPATE
PREPIDIL, DINOPROSTONE
PROSTIN E2, DINOPROSTONE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROVERA, MEDROXYPROGESTERONE ACETATE
R-GENE 10, ARGININE HYDROCHLORIDE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOMAVERT, PEGVISOMANT
XALATAN, LATANOPROST

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

- * PHARMACIA AND UPJOHN CO
XANAX, ALPRAZOLAM
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZYVOX, LINEZOLID
- * PHARMACIA AND UPJOHN SUB PFIZER INC
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE

PHARMAFORCE

- * PHARMAFORCE INC
BROMFENAC SODIUM, BROMFENAC SODIUM
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

PHARMALUCENCE

- * PHARMALUCENCE INC
AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT

PHARMAX

- * PHARMAX GROUP INC
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE

PHARMAXIS LTD

- * PHARMAXIS LTD
ARIDOL KIT, MANNITOL

PHOTOCURE ASA

- * PHOTOCURE ASA
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE

PIERRE FABRE

- * PIERRE FABRE MEDICAMENT
NAVELBINE, VINORELBINE TARTRATE

PIERREL

- * PIERREL S.P.A.
ARTICAINE HYDROCHLORIDE WITH EPINEPHRINE, ARTICAINE HYDROCHLORIDE

PINNACLE BIOLGS

- * PINNACLE BIOLOGICS INC
PHOTOFRIN, PORFIMER SODIUM

PIRAMAL CRITICAL

- * PIRAMAL CRITICAL CARE INC
ENFLURANE, ENFLURANE
ISOFLURANE, ISOFLURANE
SOJOURN, SEVOFLURANE

PLD ACQUISITIONS

- * PLD ACQUISITIONS LLC
IBUPROFEN, IBUPROFEN (OTC)

PLIVA

- * PLIVA INC
AZITHROMYCIN, AZITHROMYCIN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARBOPLATIN, CARBOPLATIN
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CIMETIDINE, CIMETIDINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PLIVA INC
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
METRONIDAZOLE, METRONIDAZOLE
NAPROXEN, NAPROXEN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
WARFARIN SODIUM, WARFARIN SODIUM

PLIVA HRVATSKA DOO

* PLIVA HRVATSKA DOO
ADAPALENE, ADAPALENE
CARVEDILOL, CARVEDILOL
CILOSTAZOL, CILOSTAZOL
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
RISPERIDONE, RISPERIDONE

PLIVA LACHEMA

* PLIVA LACHEMA AS
CARBOPLATIN, CARBOPLATIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

PLIVA PHARM IND

* PLIVA PHARMACEUTICAL INDUSTRY INC
TORSEMIDE, TORSEMIDE

PLX PHARMA

* PLX PHARMA INC
ASPIRIN, ASPIRIN (OTC)

POHL BOSKAMP

* POHL BOSKAMP
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN

POLYMEDICA

* POLYMEDICA INDUSTRIES INC
ANESTACON, LIDOCAINE HYDROCHLORIDE
NEOPAP, ACETAMINOPHEN (OTC)

PRASCO

* PRASCO LLC DBA PRASCO LABORATORIES
ECONAZOLE NITRATE, ECONAZOLE NITRATE

PRECISION DERMAT

* PRECISION DERMATOLOGY INC
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LOCOID, HYDROCORTISONE BUTYRATE
MINOCIN, MINOCYCLINE HYDROCHLORIDE
PODOFILOX, PODOFILOX
TRETINOIN, TRETINOIN

PRECISION DOSE

* PRECISION DOSE INC
RISPERIDONE, RISPERIDONE

PRINSTON INC

* PRINSTON PHARMACEUTICAL INC
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
CAPTOPRIL, CAPTOPRIL
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PRINSTON PHARMACEUTICAL INC
IRBESARTAN, IRBESARTAN
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
NEVIRAPINE, NEVIRAPINE
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

PROCTER AND GAMBLE

* PROCTER AND GAMBLE PHARMACEUTICALS INC SUB PROCTER AND GAMBLE CO
DIDRONEL, ETIDRONATE DISODIUM

PROF DSPLS

* PROFESSIONAL DISPOSABLES INC
CHLORASCRUB MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORASCRUB SWAB, CHLORHEXIDINE GLUCONATE (OTC)
CHLORASCRUB SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)

PROMETHEUS LABS

* PROMETHEUS LABORATORIES INC
HELIDAC, BISMUTH SUBSALICYLATE
IMURAN, AZATHIOPRINE
LOTRONEX, ALOSETRON HYDROCHLORIDE
MERCAPTOPYRINE, MERCAPTOPYRINE
RIDAURA, AURANOFIN
ZYLOPRIM, ALLOPURINOL

PROMIUS PHARMA

* PROMIUS PHARMA LLC
SECTRAL, ACEBUTOLOL HYDROCHLORIDE
TENEX, GUANFACINE HYDROCHLORIDE

PROMIUS PHARMA LLC

* PROMIUS PHARMA LLC
CLODERM, CLOCORTOLONE PIVALATE

PROSAM LABS

* PROSAM LABS LLC
BACLOFEN, BACLOFEN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
ETODOLAC, ETODOLAC
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
NABUMETONE, NABUMETONE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
RIMACTANE, RIFAMPIN
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

PROSTRAKAN INC

* PROSTRAKAN INC
ABSTRAL, FENTANYL CITRATE
SANCUSO, GRANISETRON

PROVIDENT PHARM

* PROVIDENT PHARMACEUTICAL INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

PULSION MEDCL

* PULSION MEDICAL SYSTEMS AG
INDOCYANINE GREEN, INDOCYANINE GREEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

PURACAP PHARM

- * PURACAP PHARMACEUTICAL LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
MELOXICAM, MELOXICAM

PURDUE GMP

- * PURDUE GMP CENTER LLC DBA THE CHAO CENTER INDUSTRIAL PHARMACY
SEROMYCIN, CYCLOSERINE

PURDUE PHARM PRODS

- * PURDUE PHARMACEUTICAL PRODUCTS LP
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE

PURDUE PHARMA

- * PURDUE PHARMA PRODUCTS LP
INTERMEZZO, ZOLPIDEM TARTRATE

PURDUE PHARMA LP

- * PURDUE PHARMA LP
BUTRANS, BUPRENORPHINE
MS CONTIN, MORPHINE SULFATE
OXYCONTIN, OXYCODONE HYDROCHLORIDE

PUREPAC PHARM

- * PUREPAC PHARMACEUTICAL CO
DIPYRIDAMOLE, DIPYRIDAMOLE

QOL MEDCL

- * QOL MEDICAL LLC
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
ETHAMOLIN, ETHANOLAMINE OLEATE
SUCRAID, SACROSIDASE

QUESTCOR PHARMS

- * QUESTCOR PHARMACEUTICALS INC
DORAL, QUAZEPAM
H.P. ACTHAR GEL, CORTICOTROPIN

RANBAXY

- * RANBAXY INC
GLYCOPYRROLATE, GLYCOPYRROLATE
- * RANBAXY LABORATORIES INC
EURAX, CROTAMITON
EXELDERM, SULCONAZOLE NITRATE
FAMOTIDINE, FAMOTIDINE (OTC)
HALOG, HALCINONIDE
KENALOG, TRIAMCINOLONE ACETONIDE
LAC-HYDRIN, AMMONIUM LACTATE
RISPERIDONE, RISPERIDONE
ULTRAVATE, HALOBETASOL PROPIONATE
WESTCORT, HYDROCORTISONE VALERATE
- * RANBAXY LABORATORIES LTD
ACYCLOVIR, ACYCLOVIR
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CLARITHROMYCIN, CLARITHROMYCIN
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

- * RANBAXY LABORATORIES LTD
 - CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 - DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 - DOXYCYCLINE, DOXYCYCLINE
 - FENOFIBRATE, FENOFIBRATE
 - FLECAINIDE ACETATE, FLECAINIDE ACETATE
 - FLUCONAZOLE, FLUCONAZOLE
 - FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 - FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 - GABAPENTIN, GABAPENTIN
 - LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 - LORATADINE REDIDOSE, LORATADINE (OTC)
 - LORATADINE, LORATADINE (OTC)
 - LORAZEPAM, LORAZEPAM
 - MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 - MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 - NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
 - ONDANSETRON, ONDANSETRON
 - OXCARBAZEPINE, OXCARBAZEPINE
 - PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 - QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 - RISPERIDONE, RISPERIDONE
 - SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 - SIMVASTATIN, SIMVASTATIN
 - SOTRET, ISOTRETINOIN
 - SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 - TOPIRAMATE, TOPIRAMATE
 - VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 - ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- * RANBAXY PHARMACEUTICALS INC
 - ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 - AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 - AMOXICILLIN, AMOXICILLIN
 - AVENTYL HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 - CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 - LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - LISINOPRIL, LISINOPRIL
 - LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 - PENTAZOCINE AND NALOXONE HYDROCHLORIDES, NALOXONE HYDROCHLORIDE
 - RIOMET, METFORMIN HYDROCHLORIDE
 - SOTRET, ISOTRETINOIN

RANBAXY LABS LTD

- * RANBAXY LABORATORIES LIMITED
 - NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
- * RANBAXY LABORATORIES LTD
 - ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 - ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 - MORPHINE SULFATE, MORPHINE SULFATE
 - PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 - XIMINO, MINOCYCLINE HYDROCHLORIDE

RARE DIS

- * RARE DISEASE THERAPEUTICS INC
 - ORFADIN, NITISINONE

RARE DIS THERAP

- * RARE DISEASE THERAPEUTICS INC
 - CYSTADANE, BETAINES HYDROCHLORIDE

RECIP

- * RECIP AB
 - THYROSAFE, POTASSIUM IODIDE (OTC)

RECKITT BENCKISER

- * RECKITT BENCKISER LLC
 - DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

- * RECKITT BENCKISER LLC
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MUCINEX, GUAIFENESIN (OTC)
- * RECKITT BENCKISER PHARMACEUTICALS INC
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE

REDDYS

- * DOCTOR REDDYS LABORATORIES LTD
DESLOMATADINE, DESLOMATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

REMPEX PHARMS INC

- * REMPEX PHARMACEUTICALS INC
MINOCIN, MINOCYCLINE HYDROCHLORIDE

RENAISSANCE PHARMA

- * RENAISSANCE PHARMA US HOLDINGS INC
ELIMITE, PERMETHRIN

RHODES PHARMS

- * RHODES PHARMACEUTICALS LP
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

RHODIA

- * RHODIA LTD
ISOFLURANE, ISOFLURANE

RITEDOSE CORP

- * THE RITEDOSE CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

ROCHE

- * HOFFMANN LA ROCHE INC
BONIVA, IBANDRONATE SODIUM
COPEGUS, RIBAVIRIN
FUZEON, ENFUVIRTIDE
INVIRASE, SAQUINAVIR MESYLATE
KLONOPIN, CLONAZEPAM
TAMIFLU, OSELTAMIVIR PHOSPHATE
VALIUM, DIAZEPAM

ROCHE PALO

- * ROCHE PALO ALTO LLC
AEROBID, FLUNISOLIDE
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CYTOVENE, GANCICLOVIR SODIUM
EC-NAPROSYN, NAPROXEN
NAPROSYN, NAPROXEN

ROCKWELL MEDCL

- * ROCKWELL MEDICAL TECHNOLOGIES INC
CALCITRIOL, CALCITRIOL

ROMARK

- * ROMARK LABORATORIES
ALINIA, NITAZOXANIDE

ROSEDALE THERAPEUTIC

- * ROSEDALE THERAPEUTICS
ERGOMAR, ERGOTAMINE TARTRATE

ROUSES POINT PHARMS

- * ROUSES POINT PHARMACEUTICALS LLC
LEVETIRACETAM, LEVETIRACETAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

ROXANE

* ROXANE LABORATORIES INC
ACARBOSE, ACARBOSE
ALPRAZOLAM, ALPRAZOLAM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
AZATHIOPRINE, AZATHIOPRINE
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BICALUTAMIDE, BICALUTAMIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CILOSTAZOL, CILOSTAZOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLARITHROMYCIN, CLARITHROMYCIN
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CODEINE SULFATE, CODEINE SULFATE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM INTENSOL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DIGOXIN, DIGOXIN
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
EXEMESTANE, EXEMESTANE
FAMCICLOVIR, FAMCICLOVIR
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUCONAZOLE, FLUCONAZOLE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FUROSEMIDE, FUROSEMIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LACTULOSE, LACTULOSE
LETROZOLE, LETROZOLE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORAZEPAM INTENSOL, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MERCAPTOPYRINE, MERCAPTOPYRINE
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** R ****

* ROXANE LABORATORIES INC
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NAPROXEN, NAPROXEN
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PREDNISONE INTENSOL, PREDNISONE
PREDNISONE, PREDNISONE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROXICET 5/500, ACETAMINOPHEN
ROXICET, ACETAMINOPHEN
ROXILOX, ACETAMINOPHEN
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
TINIDAZOLE, TINIDAZOLE
TORSEMIDE, TORSEMIDE
TRIAZOLAM, TRIAZOLAM
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
ZALEPLON, ZALEPLON
ZIDOVUDINE, ZIDOVUDINE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SAGE PRODS

* SAGE PRODUCTS INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

SAGENT AGILA

* SAGENT AGILA LLC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
MESNA, MESNA

SAGENT PHARMS

* SAGENT PHARMACEUTICALS INC
ATRAURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRAURIUM BESYLATE, ATRACURIUM BESYLATE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCITRIOL, CALCITRIOL
FLUMAZENIL, FLUMAZENIL
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVOFLOXACIN, LEVOFLOXACIN
NAFCILLIN SODIUM, NAFCILLIN SODIUM
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXACILLIN SODIUM, OXACILLIN SODIUM
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

SAGENT STRIDES

* SAGENT STRIDES LLC
AZITHROMYCIN, AZITHROMYCIN
BACITRACIN, BACITRACIN
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SAGENT STRIDES LLC
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
 MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 POLYMYCIN B SULFATE, POLYMYXIN B SULFATE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

SALIX PHARMS

* SALIX PHARMACEUTICALS INC
 ANUSOL HC, HYDROCORTISONE
 APRISO, MESALAMINE
 COLAZAL, BALSALAZIDE DISODIUM
 DIURIL, CHLOROTHIAZIDE
 FULYZAQ, CROFELEMER
 GIAZO, BALSALAZIDE DISODIUM
 METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE
 MOVIPREP, ASCORBIC ACID
 OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
 PEPCID, FAMOTIDINE
 RELISTOR, METHYLNALTREXONE BROMIDE
 VISICOL, SODIUM PHOSPHATE, DIBASIC ANHYDROUS
 XIFAXAN, RIFAXIMIN

SAMSON MEDCL

* SAMSON MEDICAL TECHNOLOGIES LLC
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFUROXIME SODIUM IN PLASTIC CONTAINER, CEFUROXIME SODIUM

SANDOZ

* SANDOZ
 DOCETAXEL, DOCETAXEL

* SANDOZ CANADA INC
 ANECTINE, SUCCINYLCHOLINE CHLORIDE
 ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 COSYNTROPIN, COSYNTROPIN
 DIGOXIN, DIGOXIN
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 ESTRADIOL VALERATE, ESTRADIOL VALERATE
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
 FLUMAZENIL, FLUMAZENIL
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
 INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
 INFUVITE PEDIATRIC, ASCORBIC ACID
 ISONIAZID, ISONIAZID
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 REGONOL, PYRIDOSTIGMINE BROMIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

* SANDOZ INC
 ALPRAZOLAM, ALPRAZOLAM
 ALTAVERA, ETHINYL ESTRADIOL
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SANDOZ INC

AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN

AMOXICILLIN, AMOXICILLIN

AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM

AMPICILLIN SODIUM, AMPICILLIN SODIUM

AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE

ANASTROZOLE, ANASTROZOLE

APREPITANT, APREPITANT

ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN

ATENOLOL, ATENOLOL

AZITHROMYCIN, AZITHROMYCIN

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE

BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE

BICALUTAMIDE, BICALUTAMIDE

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE

BISOPROLOL FUMARATE, BISOPROLOL FUMARATE

BUMETANIDE, BUMETANIDE

BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE

CAFERGOT, CAFFEINE

CAPTOPRIL, CAPTOPRIL

CARBOPLATIN, CARBOPLATIN

CARISOPRODOL AND ASPIRIN, ASPIRIN

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN

CARVEDILOL, CARVEDILOL

CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE

CEFAZOLIN SODIUM, CEFZOLIN SODIUM

CEFDINIR, CEFdinIR

CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE

CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL

CEFPROZIL, CEFPROZIL

CEFTRIAXONE, CEFTRIAXONE SODIUM

CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE (OTC)

CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE

CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE

CHOLESTYRAMINE, CHOLESTYRAMINE

CILOSTAZOL, CILOSTAZOL

CLARITHROMYCIN, CLARITHROMYCIN

CLEMASTINE FUMARATE, CLEMASTINE FUMARATE

CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)

CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE

CLONAZEPAM, CLONAZEPAM

COSYNTROPIN, COSYNTROPIN

CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE

CYCLOSPORINE, CYCLOSPORINE

DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE

DESLOMATADINE, DESLOMATADINE

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE ASPARTATE

DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM

DICLOFENAC SODIUM, DICLOFENAC SODIUM

DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM

DIVALPROEX SODIUM, DIVALPROEX SODIUM

DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE

ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM

EPLERENONE, EPLERENONE

ESTARYLLA, ETHINYL ESTRADIOL

ETODOLAC, ETODOLAC

FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE

FLUOROURACIL, FLUOROURACIL

FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE

FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE

FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FUROSEMIDE, FUROSEMIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE, GLIPIZIDE
HALOPERIDOL, HALOPERIDOL
HEPARIN SODIUM, HEPARIN SODIUM
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
INTROVALE, ETHINYL ESTRADIOL
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ITRACONAZOLE, ITRACONAZOLE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LEFLUNOMIDE, LEFLUNOMIDE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LONOX, ATROPINE SULFATE
LORATADINE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LORYNA, DROSPIRENONE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOVASTATIN, LOVASTATIN
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEROPENEM, MEROPENEM
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NAPROXEN, NAPROXEN
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NIZATIDINE, NIZATIDINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OMEPRazole, OMEPRazole
OMNITROPE, SOMATROPIN RECOMBINANT
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SANDOZ INC
 ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
 OXACILLIN SODIUM, OXACILLIN SODIUM
 OXALIPLATIN, OXALIPLATIN
 OXAPROZIN, OXAPROZIN
 OXAZEPAM, OXAZEPAM
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
 PENICILLIN G SODIUM, PENICILLIN G SODIUM
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PERPHENAZINE, PERPHENAZINE
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUINIDINE SULFATE, QUINIDINE SULFATE
 RAMIPRIL, RAMIPRIL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RESERPINE, RESERPINE
 RIBAVIRIN, RIBAVIRIN
 RIFAMPIN, RIFAMPIN
 RISPERIDONE, RISPERIDONE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SPIRONOLACTONE, SPIRONOLACTONE
 SULFADIAZINE, SULFADIAZINE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 SYEDA, DROSPIRENONE
 TACROLIMUS, TACROLIMUS
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TEMAZEPAM, TEMAZEPAM
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
 THIOTHIXENE, THIOTHIXENE
 TOPIRAMATE, TOPIRAMATE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRI-ESTARYLLA, ETHINYL ESTRADIOL
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
 ZONISAMIDE, ZONISAMIDE

SANDOZ CANADA INC

* SANDOZ CANADA INC
 PARICALCITOL, PARICALCITOL

SANDOZ INC

* SANDOZ INC
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 OLANZAPINE, OLANZAPINE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

SANOCHEMIA CORP USA

* SANOCHEMIA CORP USA
SCANLUX-300, IOPAMIDOL
SCANLUX-370, IOPAMIDOL

SANOFI AVENTIS US

* SANOFI AVENTIS US INC
JEVTANA KIT, CABAZITAXEL

* SANOFI AVENTIS US LLC
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
AMARYL, GLIMEPIRIDE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBIEN, ZOLPIDEM TARTRATE
ANZEMET, DOLASETRON MESYLATE
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
APIDRA, INSULIN GLULISINE RECOMBINANT
ARALEN, CHLOROQUINE PHOSPHATE
ARAVA, LEFLUNOMIDE
AUBAGIO, TERIFLUNOMIDE
AUVI-Q, EPINEPHRINE
AVALIDE, HYDROCHLOROTHIAZIDE
AVAPRO, IRBESARTAN
CANTIL, MEPENZOLATE BROMIDE
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN, CEFOTAXIME SODIUM
CLOMID, CLOMIPHENE CITRATE
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DDAVP, DESMOPRESSIN ACETATE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DIABETA, GLYBURIDE
DRISDOL, ERGOCALCIFEROL
ELOXATIN, OXALIPLATIN
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
GAVISCON, ALUMINUM HYDROXIDE (OTC)
HIPREX, METHENAMINE HIPPURATE
KAYEXALATE, SODIUM POLYSTYRENE SULFONATE
KETEK, TELITHROMYCIN
KLARON, SULFACETAMIDE SODIUM
LANTUS, INSULIN GLARGINE RECOMBINANT
LASIX, FUROSEMIDE
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOVENOX, ENOXAPARIN SODIUM
MULTAQ, DRONEDARONE HYDROCHLORIDE
MYTELASE, AMBENONIUM CHLORIDE
NASACORT AQ, TRIAMCINOLONE ACETONIDE
NICODERM CQ, NICOTINE (OTC)
NILANDRON, NILUTAMIDE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
PENLAC, CICLOPIROX
PHISOHEX, HEXACHLOROPHENE
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLAVIX, CLOPIDOGREL BISULFATE
PRIFTIN, RIFAPENTINE
PRIMAQUINE, PRIMAQUINE PHOSPHATE
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFATER, ISONIAZID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANOFI AVENTIS US LLC
RILUTEK, RILUZOLE
SKELID, TILUDRONATE DISODIUM
TAXOTERE, DOCETAXEL
TRENTAL, PENTOXIFYLLINE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE

SANOFI PASTEUR INC

* SANOFI PASTEUR INC
SKLICE, IVERMECTIN

SANTARUS

* SANTARUS INC
FENOGLIDE, FENOFIBRATE
GLUMETZA, METFORMIN HYDROCHLORIDE
UCERIS, BUDESONIDE
ZEGERID, OMEPRAZOLE

SANTEN

* SANTEN INC
ALAMAST, PEMIROLAST POTASSIUM
IQUIX, LEVOFLOXACIN
QUIXIN, LEVOFLOXACIN

SANTEN OY

* SANTEN OY
BETIMOL, TIMOLOL

SANTOS BIOTECH

* SANTOS BIOTECH INDUSTRIES INC
ANASTROZOLE, ANASTROZOLE

SAVIENT PHARMS

* SAVIENT PHARMACEUTICALS INC
OXANDRIN, OXANDROLONE

SB PHARMCO

* SB PHARMCO PUERTO RICO INC
AVANDAMET, METFORMIN HYDROCHLORIDE
AVANDARYL, GLIMEPIRIDE
AVANDIA, ROSIGLITAZONE MALEATE
COREG CR, CARVEDILOL PHOSPHATE

SCHERING

* SCHERING CORP
ASMANEX TWISTHALER, MOMETASONE FUROATE
INTEGRILIN, EPTIFIBATIDE
NOXAFIL, POSACONAZOLE
REBETOL, RIBAVIRIN
ZEMURON, ROCURONIUM BROMIDE
* SCHERING CORP SUB SCHERING PLOUGH CORP
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE

SCHERING CORP

* SCHERING CORP
LOTRISONE, BETAMETHASONE DIPROPIONATE

SCHERING PLOUGH

* SCHERING PLOUGH HEALTHCARE PRODUCTS INC
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)
CHILDREN'S CLARITIN, LORATADINE (OTC)
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
DISOPHROL, DEXBROMPHENIRAMINE MALEATE (OTC)
DRIXORAL PLUS, ACETAMINOPHEN (OTC)
DRIXORAL, DEXBROMPHENIRAMINE MALEATE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SCHERING PLOUGH HEALTHCARE PRODUCTS INC
GYNE-LOTTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTTRIMIN 3, CLOTRIMAZOLE (OTC)
GYNE-LOTTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTTRIMIN, CLOTRIMAZOLE (OTC)
LOTTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
NASONEX, MOMETASONE FUROATE MONOHYDRATE
OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)
SHADE UVAGUARD, AVOBENZONE (OTC)

SCHWARZ PHARMA

* SCHWARZ PHARMA INC
DILATRATE-SR, ISOSORBIDE DINITRATE

SCIEGEN PHARMS INC

* SCIEGEN PHARMACEUTICALS INC
NEVIRAPINE, NEVIRAPINE

SCIOS

* SCIOS INC
NATRECOR, NESIRITIDE RECOMBINANT

SECAN PHARMS

* SECAN PHARMACEUTICALS INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

SEPTODONT

* SEPTODONT INC
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
OCTOCAINE, EPINEPHRINE

SEPTODONT HOLDING

* SEPTODONT HOLDING SAS
ORAVERSE, PHENTOLAMINE MESYLATE

SEPTODONT INC

* SEPTODONT INC
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE

SETON PHARM

* SETON PHARMACEUTICAL LLC
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE

SHASUN CHEMS

* SHASUN CHEMICALS AND DRUGS LTD
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

SHASUN USA

* SHASUN USA INC
IBUPROFEN, IBUPROFEN

SHIONOGI INC

* SHIONOGI INC
FURADANTIN, NITROFURANTOIN
KAPVAY, CLONIDINE HYDROCHLORIDE
KEFLEX, CEPHALEXIN
MOXATAG, AMOXICILLIN
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
ORAPRED, PREDNISOLONE SODIUM PHOSPHATE
PONSTEL, MEFENAMIC ACID
ROBINUL FORTE, GLYCOPYRROLATE
ROBINUL, GLYCOPYRROLATE
RYBIX ODT, TRAMADOL HYDROCHLORIDE
SULAR, NISOLDIPINE
ULESFIA, BENZYL ALCOHOL

SHIRE

* SHIRE DEVELOPMENT INC
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SHIRE DEVELOPMENT INC
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
CARBATROL, CARBAMAZEPINE
INTUNIV, GUANFACINE HYDROCHLORIDE
LIALDA, MESALAMINE
PENTASA, MESALAMINE

SHIRE DEVELOPMENT

* SHIRE DEVELOPMENT INC
VYVANSE, LISDEXAMFETAMINE DIMESYLATE

SHIRE HUMAN GENETIC

* SHIRE HUMAN GENETIC THERAPIES INC
VPRIV, VELAGLUCERASE ALFA

SHIRE LLC

* SHIRE DEVELOPMENT LLC
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
FOSRENOL, LANTHANUM CARBONATE
SALURON, HYDROFLUMETHIAZIDE

SHIRE ORPHAN THERAP

* SHIRE ORPHAN THERAPIES INC
FIRAZYR, ICATIBANT ACETATE

SIGMA TAU

* SIGMA TAU PHARMACEUTICALS INC
ABELCET, AMPHOTERICIN B
ADAGEN, PEGADEMASE BOVINE
CARNITOR SF, LEVOCARNITINE
CARNITOR, LEVOCARNITINE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
MATULANE, PROCARBAZINE HYDROCHLORIDE

SIGMAPHARM LABS LLC

* SIGMAPHARM LABORATORIES LLC
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
DISULFIRAM, DISULFIRAM
ERGOCALCIFEROL, ERGOCALCIFEROL
FLUCYTOSINE, FLUCYTOSINE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE

SILARX

* SILARX PHARMACEUTICALS INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
LEVETIRACETAM, LEVETIRACETAM
LORATADINE, LORATADINE (OTC)
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

SKINMEDICA

- * SKINMEDICA INC
VANIQA, EFLORNITHINE HYDROCHLORIDE

SKYEPHARMA AG

- * SKYEPHARMA AG
TRIGLIDE, FENOFIBRATE

SMITHKLINE BEECHAM

- * SMITHKLINE BEECHAM
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
- * SMITHKLINE BEECHAM CORP
LAMICTAL XR, LAMOTRIGINE
- * SMITHKLINE BEECHAM CORP DBA GLAXOSMITHKLINE
ARRANON, NELARABINE
COREG, CARVEDILOL
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
LAMICTAL ODT, LAMOTRIGINE
REQUIP XL, ROPINIROLE HYDROCHLORIDE
TREXIMET, NAPROXEN SODIUM
TYKERB, LAPATINIB DITOSYLATE

SOAPCO

- * SOAPCO INC
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)

SOFGEN PHARMS

- * SOFGEN PHARMACEUTICALS LLC
PROGESTERONE, PROGESTERONE

SOLCO HLTHCARE

- * SOLCO HEALTHCARE US LLC
LEVETIRACETAM, LEVETIRACETAM
METHOCARBAMOL, METHOCARBAMOL

SOMAXON

- * SOMAXON PHARMACEUTICALS INC
SILENOR, DOXEPIN HYDROCHLORIDE

SOMERSET

- * SOMERSET PHARMACEUTICALS INC
ELDEPRYL, SELEGILINE HYDROCHLORIDE
EMSAM, SELEGILINE

SPEAR PHARMS

- * SPEAR PHARMACEUTICALS INC
FLUOROURACIL, FLUOROURACIL

SPECTRUM PHARMS

- * SPECTRUM PHARMACEUTICALS INC
FUSILEV, LEVOLEUCOVORIN CALCIUM

STAND HOMEOPATH

- * STANDARD HOMEOPATHIC CO
IVY BLOCK, BENTOQUATAM (OTC)

STASON

- * STASON INDUSTRIAL CORP
ACYCLOVIR, ACYCLOVIR
CAPTOPRIL, CAPTOPRIL
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

STASON PHARMS

- * STASON PHARMACEUTICALS INC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

STAT TRADE

- * STAT TRADE INC
NAPRELAN, NAPROXEN SODIUM

STERI PHARMA

- * STERI PHARMA LLC
CEFAZOLIN SODIUM, CEFZOLIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* STERI PHARMA LLC
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM

STEVENS J

* JEROME STEVENS PHARMACEUTICALS INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CEPHALEXIN, CEPHALEXIN
DIGOXIN, DIGOXIN
METHOCARBAMOL AND ASPIRIN, ASPIRIN
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
UNITHROID, LEVOTHYROXINE SODIUM

STI PHARMA LLC

* STI PHARMA LLC
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
DEXAMETHASONE, DEXAMETHASONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
TRIACIN-C, CODEINE PHOSPHATE

STIEFEL

* STIEFEL LABORATORIES INC
DUAC, BENZOYL PEROXIDE
LUXIQ, BETAMETHASONE VALERATE

STIEFEL GSK

* STIEFEL A GSK CO
VELTIN, CLINDAMYCIN PHOSPHATE

STIEFEL LABS INC

* STIEFEL LABORATORIES INC
EVOCLIN, CLINDAMYCIN PHOSPHATE
EXTINA, KETOCONAZOLE
FABIOR, TAZAROTENE
OLUX E, CLOBETASOL PROPIONATE
OLUX, CLOBETASOL PROPIONATE
SORIATANE, ACITRETIN
SORILUX, CALCIPOTRIENE
VERDESO, DESONIDE
VUSION, MICONAZOLE NITRATE

STRIDES

* STRIDES INC
NEVIRAPINE, NEVIRAPINE

STRIDES ARCOLAB

* STRIDES ARCOLAB LIMITED
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM

STRIDES ARCOLAB LTD

* STRIDES ARCOLAB LTD
ACARBOSE, ACARBOSE
ADENOSINE, ADENOSINE
CEFTRIAXONE, CEFTRIAXONE SODIUM
ERGOCALCIFEROL, ERGOCALCIFEROL
ETOMIDATE, ETOMIDATE
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
MELOXICAM, MELOXICAM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

SUCAMPO PHARMS

* SUCAMPO PHARMACEUTICALS INC
AMITIZA, LUBIPROSTONE
RESCULA, UNOPROSTONE ISOPROPYL

SUMMERS

* SUMMERS LABORATORIES INC
CROTAN, CROTAMITON

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

SUN PHARM INDS

* SUN PHARMACEUTICAL INDUSTRIES LTD
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 DESLORATADINE, DESLORATADINE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 OLANZAPINE, OLANZAPINE
 ONDANSETRON, ONDANSETRON
 OXCARBAZEPINE, OXCARBAZEPINE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
 TORSEMIDE, TORSEMIDE

SUN PHARM INDS (IN)

* SUN PHARMACEUTICAL INDUSTRIES LTD
 CEPHALEXIN, CEPHALEXIN
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ORTHO-EST, ESTROPIRATE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 ZONISAMIDE, ZONISAMIDE

SUN PHARM INDS INC

* SUN PHARMACEUTICAL INDUSTRIES INC
 BENZONATATE, BENZONATATE
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 ERGOCALCIFEROL, ERGOCALCIFEROL
 GEMFIBROZIL, GEMFIBROZIL
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 NIMODIPINE, NIMODIPINE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 VALPROIC ACID, VALPROIC ACID
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

SUN PHARM INDS LTD

* SUN PHARMACEUTICAL INDUSTRIES LTD
 CARISOPRODOL, CARISOPRODOL
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE (OTC)
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 GABAPENTIN, GABAPENTIN
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 NARATRIPTAN, NARATRIPTAN
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

- * SUN PHARMACEUTICAL INDUSTRIES LTD
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
- * SUN PHARMACEUTICAL INDUSTRIES LTD.
 ANASTROZOLE, ANASTROZOLE

SUN PHARMA GLOBAL

- * SUN PHARMA GLOBAL FZE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DOCEFREZ, DOCETAXEL
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 ENTACAPONE, ENTACAPONE
 FINASTERIDE, FINASTERIDE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
- * SUN PHARMA GLOBAL INC
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALPRAZOLAM, ALPRAZOLAM
 AMIFOSTINE, AMIFOSTINE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 CARBOPLATIN, CARBOPLATIN
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 VECURONIUM BROMIDE, VECURONIUM BROMIDE

SUNEVA MEDCL

- * SUNEVA MEDICAL INC
 TRETINOIN, TRETINOIN

SUNOVION

- * SUNOVION PHARMACEUTICALS INC
 BROVANA, ARFORMOTEROL TARTRATE
 XOPENEX HFA, LEVALBUTEROL TARTRATE
 XOPENEX, LEVALBUTEROL HYDROCHLORIDE

SUNOVION PHARMS INC

- * SUNOVION PHARMACEUTICALS INC
 LATUDA, LURASIDONE HYDROCHLORIDE
 LUNESTA, ESZOPICLONE

SUPERNUS PHARMS

- * SUPERNUS PHARMACEUTICALS INC
 OXTELLAR XR, OXCARBAZEPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

SUVEN LIFE

* SUVEN LIFE SCIENCES LTD
MALATHION, MALATHION

SVADS HOLDINGS SA

* SVADS HOLDINGS SA
IBUPROFEN, IBUPROFEN (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

SVC PHARMA

* SVC PHARMA LP
DRONABINOL, DRONABINOL

SYNTHON PHARMS

* SYNTHON PHARMACEUTICALS INC
BICALUTAMIDE, BICALUTAMIDE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TAKEDA GLOBAL

* TAKEDA GLOBAL RESEARCH DEVELOPMENT CENTER INC
KAZANO, ALOGLIPTIN BENZOATE
NESINA, ALOGLIPTIN
OSEN, ALOGLIPTIN

TAKEDA GMBH

* TAKEDA GMBH
ALVESCO, CICLESONIDE
OMNARIS, CICLESONIDE
ZETONNA, CICLESONIDE

TAKEDA PHARMS

* TAKEDA PHARMACEUTICALS NORTH AMERICA INC
DEXILANT, DEXLANSOPRAZOLE

TAKEDA PHARMS USA

* TAKEDA PHARMACEUTICALS USA INC
ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
COLCRYS, COLCHICINE
DUETACT, GLIMEPIRIDE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
PREVACID, LANSOPRAZOLE
PREVPAC, AMOXICILLIN
ROZEREM, RAMELTEON
ULORIC, FEBUXOSTAT

TALON THERAP

* TALON THERAPEUTICS INC
MARQIBO KIT, VINCRISTINE SULFATE

TAMARANG

* TAMARANG SA
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

TARO

* TARO PHARMACEUTICAL INDUSTRIES LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
CARBAMAZEPINE, CARBAMAZEPINE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

- * TARO PHARMACEUTICAL INDUSTRIES LTD
 - ETODOLAC, ETODOLAC
 - EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 - FLUCONAZOLE, FLUCONAZOLE
 - FLUOROURACIL, FLUOROURACIL
 - HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 - IMIQUIMOD, IMIQUIMOD
 - KETOCONAZOLE, KETOCONAZOLE
 - LAMOTRIGINE, LAMOTRIGINE
 - LEVETIRACETAM, LEVETIRACETAM
 - LORATADINE, LORATADINE (OTC)
 - MELOXICAM, MELOXICAM
 - MEPROBAMATE, MEPROBAMATE
 - METRONIDAZOLE, METRONIDAZOLE
 - NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 - ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 - OXCARBAZEPINE, OXCARBAZEPINE
 - PHENYTOIN, PHENYTOIN
- * TARO PHARMACEUTICALS INC
 - BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 - CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 - CLOTRIMAZOLE, CLOTRIMAZOLE
 - CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
 - DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 - FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 - FLUOCINONIDE, FLUOCINONIDE
 - HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 - MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 - NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 - TOPICORT, DESOXIMETASONE
 - TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 - WARFARIN SODIUM, WARFARIN SODIUM
- * TARO PHARMACEUTICALS USA INC
 - ACETIC ACID, ACETIC ACID, GLACIAL
 - ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
 - AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 - AMMONIUM LACTATE, AMMONIUM LACTATE
 - BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 - CICLOPIROX, CICLOPIROX
 - CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 - CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
 - CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 - CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 - CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 - CLOTRIMAZOLE, CLOTRIMAZOLE
 - DERMABET, BETAMETHASONE VALERATE
 - DESONIDE, DESONIDE
 - DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 - ECONAZOLE NITRATE, ECONAZOLE NITRATE
 - ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 - FLO-PRED, PREDNISOLONE ACETATE
 - FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 - FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 - FLUOCINONIDE, FLUOCINONIDE
 - FLUOROURACIL, FLUOROURACIL
 - GENTAMICIN SULFATE, GENTAMICIN SULFATE
 - GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 - HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 - HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
 - HYDROCORTISONE, HYDROCORTISONE
 - KETOZOLE, KETOCONAZOLE
 - LIDOCAINE, LIDOCAINE
 - LORATADINE, LORATADINE (OTC)
 - MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
 - MOMETASONE FUROATE, MOMETASONE FUROATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

- * TARO PHARMACEUTICALS USA INC
 - MUPIROCIN, MUPIROCIN
 - NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 - NYSTATIN, NYSTATIN
 - PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 - RISPERIDONE, RISPERIDONE
 - SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 - TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
 - TERCONAZOLE, TERCONAZOLE
 - TERIL, CARBAMAZEPINE
 - TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 - TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
 - U-CORT, HYDROCORTISONE ACETATE
- * TARO PHARMACEUTICALS, INC.
 - HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 - TOPICORT, DESOXIMETASONE

TARO PHARM INDS

- * TARO PHARMACEUTICAL INDUSTRIES LTD
 - AMCINONIDE, AMCINONIDE
 - CARBAMAZEPINE, CARBAMAZEPINE
 - CICLOPIROX, CICLOPIROX
 - CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 - ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 - ETODOLAC, ETODOLAC
 - FLUCONAZOLE, FLUCONAZOLE
 - HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 - LAMOTRIGINE, LAMOTRIGINE

TARO PHARMS IRELAND

- * TARO PHARMACEUTICALS IRELAND LTD
 - ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 - SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 - STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION

TARO PHARMS NORTH

- * TARO PHARMACEUTICALS NORTH AMERICA INC
 - OVIDE, MALATHION
 - TOPICORT, DESOXIMETASONE

TAYLOR

- * TAYLOR PHARMACEUTICALS
 - LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 - LORAZEPAM, LORAZEPAM
 - MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 - NAPHAZOLINE HYDROCHLORIDE, NAPHAZOLINE HYDROCHLORIDE

TAYLOR PHARMA

- * TAYLOR PHARMACAL CO
 - DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 - PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
 - TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

TEDOR PHARM

- * TEDOR PHARMA INC
 - BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

TEIKOKU PHARMA USA

- * TEIKOKU PHARMA USA INC
 - LIDODERM, LIDOCAINE

TEVA

- * TEVA NEUROSCIENCE INC
 - AZILECT, RASAGILINE MESYLATE
 - COPAXONE, GLATIRAMER ACETATE
- * TEVA PHARMACEUTICALS USA INC
 - ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 - ACYCLOVIR, ACYCLOVIR
 - ADIPEX-P, PHENTERMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TEVA PHARMACEUTICALS USA INC
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN PEDIATRIC, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 ATENOLOL, ATENOLOL
 AZITHROMYCIN, AZITHROMYCIN
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 BETA-VAL, BETAMETHASONE VALERATE
 BICALUTAMIDE, BICALUTAMIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CALCITRIOL, CALCITRIOL
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
 CAPTOPRIL, CAPTOPRIL
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CARVEDILOL, CARVEDILOL
 CEFACLOL, CEFACLOL
 CEFPROZIL, CEFPROZIL
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CEPHALEXIN, CEPHALEXIN
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CILOSTAZOL, CILOSTAZOL
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 CIMETIDINE, CIMETIDINE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
 DIFLUNISAL, DIFLUNISAL
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 EPITOL, CARBAMAZEPINE
 ESTAZOLAM, ESTAZOLAM
 ETODOLAC, ETODOLAC
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FINASTERIDE, FINASTERIDE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 FLUOCINONIDE, FLUOCINONIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLURBIPROFEN, FLURBIPROFEN
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TEVA PHARMACEUTICALS USA INC
 GALZIN, ZINC ACETATE
 GEMFIBROZIL, GEMFIBROZIL
 GLIMEPIRIDE, GLIMEPIRIDE
 GLYBURIDE (MICRONIZED), GLYBURIDE
 GLYBURIDE, GLYBURIDE
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 KETOCONAZOLE, KETOCONAZOLE
 KETOPROFEN, KETOPROFEN
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LAMOTRIGINE, LAMOTRIGINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
 LORATADINE, LORATADINE (OTC)
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOVASTATIN, LOVASTATIN
 MESALAMINE, MESALAMINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOLAZONE, METOLAZONE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE, METRONIDAZOLE
 MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
 MUPIROCIN, MUPIROCIN
 NABUMETONE, NABUMETONE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN, NAPROXEN
 NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
 NEOMYCIN SULFATE, NEOMYCIN SULFATE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NIZATIDINE, NIZATIDINE
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 OFLOXACIN, OFLOXACIN
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 ORAP, PIMOZIDE
 OXAPROZIN, OXAPROZIN
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PENICILLIN-VK, PENICILLIN V POTASSIUM
 PIROXICAM, PIROXICAM
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRELONE, PREDNISOLONE
 PURINETHOL, MERCAPTOPYRINE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIBAVIRIN, RIBAVIRIN
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROSIGLITAZONE MALEATE, ROSIGLITAZONE MALEATE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SUCRALFATE, SUCRALFATE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TEVA PHARMACEUTICALS USA INC
 TERBINAFFINE HYDROCHLORIDE, TERBINAFFINE HYDROCHLORIDE
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLMETIN SODIUM, TOLMETIN SODIUM
 TOPIRAMATE, TOPIRAMATE
 TORSEMIDE, TORSEMIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRIACET, TRIAMCINOLONE ACETONIDE
 TRIMETHOPRIM, TRIMETHOPRIM
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TEVA BRANDED PHARM

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC
 CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A
 LOSEASONIQUE, ETHINYL ESTRADIOL
 MIRCETTE, DESOGESTREL
 NORDETTE-28, ETHINYL ESTRADIOL
 PLAN B, LEVONORGESTREL
 PLAN B, LEVONORGESTREL (OTC)
 QNASL, BECLOMETHASONE DIPROPIONATE
 QVAR 40, BECLOMETHASONE DIPROPIONATE
 QVAR 80, BECLOMETHASONE DIPROPIONATE
 SEASONALE, ETHINYL ESTRADIOL
 SEASONIQUE, ETHINYL ESTRADIOL

TEVA GLOBAL

* TEVA GLOBAL RESPIRATORY RESEARCH LLC
 PROAIR HFA, ALBUTEROL SULFATE
 PROGLYCEM, DIAZOXIDE

TEVA PARENTERAL

* TEVA PARENTERAL MEDICINES INC
 ALPROSTADIL, ALPROSTADIL
 AMIKACIN SULFATE, AMIKACIN SULFATE
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 CALCITRIOL, CALCITRIOL
 CARBOPLATIN, CARBOPLATIN
 CYTOSAR-U, CYTARABINE
 DACARBAZINE, DACARBAZINE
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 ENALAPRILAT, ENALAPRILAT
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
 ETOPOSIDE, ETOPOSIDE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUOROURACIL, FLUOROURACIL
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 IFOSFAMIDE/MESNA KIT, IFOSFAMIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVOCARNITINE, LEVOCARNITINE
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 MESNA, MESNA
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TEVA PARENTERAL MEDICINES INC
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPOFOL, PROPOFOL
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE
 ZANOSAR, STREPTOZOCIN

TEVA PHARMS

* TEVA PHARMACEUTICALS USA
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALPRAZOLAM, ALPRAZOLAM
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE
 ANASTROZOLE, ANASTROZOLE
 AZITHROMYCIN, AZITHROMYCIN
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 BUDESONIDE, BUDESONIDE
 CARBAMAZEPINE, CARBAMAZEPINE
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEFDINIR, CEFDINIR
 CEFPROZIL, CEFPROZIL
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CEFUROXIME SODIUM, CEFUROXIME SODIUM
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 ETHOSUXIMIDE, ETHOSUXIMIDE
 FAMCICLOVIR, FAMCICLOVIR
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
 GABAPENTIN, GABAPENTIN
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HYDROCORTISONE, HYDROCORTISONE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 IRBESARTAN, IRBESARTAN
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LANSOPRAZOLE, LANSOPRAZOLE
 LEFLUNOMIDE, LEFLUNOMIDE
 LETROZOLE, LETROZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TEVA PHARMACEUTICALS USA
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LINEZOLID, LINEZOLID
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 MEBENDAZOLE, MEBENDAZOLE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 MELOXICAM, MELOXICAM
 METHAZOLAMIDE, METHAZOLAMIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 OLANZAPINE, OLANZAPINE
 OXALIPLATIN, OXALIPLATIN
 OXCARBAZEPINE, OXCARBAZEPINE
 PACLITAXEL, PACLITAXEL
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 PREGABALIN, PREGABALIN
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
 PROGESTERONE, PROGESTERONE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUINIDINE SULFATE, QUINIDINE SULFATE
 QUININE SULFATE, QUININE SULFATE
 RAMIPRIL, RAMIPRIL
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TESTOSTERONE, TESTOSTERONE
 TOPOTECAN, TOPOTECAN HYDROCHLORIDE
 TRANDOLAPRIL, TRANDOLAPRIL
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 URSODIOL, URSODIOL
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALPROIC ACID, VALPROIC ACID
 VANDAZOLE, METRONIDAZOLE
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 ZALEPLON, ZALEPLON

TEVA PHARMS USA

* TEVA PHARMACEUTICALS USA INC
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 IMIQUIMOD, IMIQUIMOD

TEVA WOMENS

* TEVA WOMENS HEALTH INC
 ENJUVIA, ESTROGENS, CONJUGATED SYNTHETIC B
 PARAGARD T 380A, COPPER
 PREFEST, ESTRADIOL
 SYNTHETIC CONJUGATED ESTROGENS A, ESTROGENS, CONJUGATED SYNTHETIC A
 ZEBETA, BISOPROLOL FUMARATE
 ZIAC, BISOPROLOL FUMARATE

THE PHARMA NETWORK

* THE PHARMA NETWORK LLC
 BENZONATATE, BENZONATATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

THE PHARMANETWORK

* THE PHARMANETWORK LLC
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE

THEPHARMANETWORK LLC

* THEPHARMANETWORK LLC
THERMAZENE, SILVER SULFADIAZINE

THERAKOS

* THERAKOS INC
UVADEX, METHOXSALEN

THERAVANCE INC

* THERAVANCE INC
VIBATIV, TELAVANCIN HYDROCHLORIDE

THREE RIVERS PHARMS

* THREE RIVERS PHARMACEUTICALS LLC
ANASTROZOLE, ANASTROZOLE
RIBASPHERE, RIBAVIRIN
RIBAVIRIN, RIBAVIRIN
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

TOLMAR

* TOLMAR INC
ADAPALENE, ADAPALENE
ATRIDOX, DOXYCYCLINE HYCLATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE AND PRILOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MOMETASONE FUROATE, MOMETASONE FUROATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

TOLMAR THERAP

* TOLMAR THERAPEUTICS INC
ELIGARD, LEUPROLIDE ACETATE

TORPHARM

* TORPHARM INC
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

TORRENT PHARM

* TORRENT PHARMA INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

TORRENT PHARMS

* TORRENT PHARMACEUTICALS LIMITED
LEVOFLOXACIN, LEVOFLOXACIN
* TORRENT PHARMACEUTICALS LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARBAMAZEPINE, CARBAMAZEPINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

- * TORRENT PHARMACEUTICALS LTD
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- * TORRENT PHARMACEUTICALS LTD.
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE

TORRENT PHARMS LLC

- * TORRENT PHARMACEUTICALS LLC
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
OLANZAPINE, OLANZAPINE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

TORRENT PHARMS LTD

- * TORRENT PHARMACEUTICALS LTD
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FELODIPINE, FELODIPINE
LEVETIRACETAM, LEVETIRACETAM
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OLANZAPINE, OLANZAPINE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE

TRIS PHARMA INC

- * TRIS PHARMA INC
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
IBUPROFEN, IBUPROFEN (OTC)
LEVETIRACETAM, LEVETIRACETAM
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
THEOPHYLLINE, THEOPHYLLINE

TWI PHARMS INC

- * TWI PHARMACEUTICALS INC
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE

UCB INC

- * UCB INC
CO-GESIC, ACETAMINOPHEN
KEPPRA XR, LEVETIRACETAM
KEPPRA, LEVETIRACETAM
LORTAB, ACETAMINOPHEN
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NEUPRO, ROTIGOTINE
NIRAVAM, ALPRAZOLAM
PARCOPA, CARBIDOPA
SEMPREX-D, ACRIVASTINE
TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLISTIREX
UNIRETIC, HYDROCHLOROTHIAZIDE
UNIVASC, MOEXIPRIL HYDROCHLORIDE
VIMPAT, LACOSAMIDE
XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE
ZAROXOLYN, METOLAZONE

UCYCLYD

- * UCYCLYD PHARMA INC
AMMONUL, SODIUM BENZOATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** U **

ULURU

- * ULURU INC
APHTHASOL, AMLEXANOX

UNICHEM

- * UNICHEM LABORATORIES LTD
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MELOXICAM, MELOXICAM
TOPIRAMATE, TOPIRAMATE
ZALEPLON, ZALEPLON

UNICHEM LABS LTD

- * UNICHEM LABORATORIES LIMITED
DIVALPROEX SODIUM, DIVALPROEX SODIUM
- * UNICHEM LABORATORIES LTD
LAMOTRIGINE, LAMOTRIGINE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

UNICHEM PHARMS (USA)

- * UNICHEM PHARMACEUTICALS (USA) INC
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE

UNIQUE PHARM LABS

- * UNIQUE PHARMACEUTICAL LABORATORIES
ATENOLOL, ATENOLOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FLUCONAZOLE, FLUCONAZOLE

UNITED GUARDIAN

- * UNITED GUARDIAN INC
RENACIDIN, CITRIC ACID

UNITED THERAP

- * UNITED THERAPEUTICS CORP
REMODULIN, TREPROSTINIL SODIUM
TYVASO, TREPROSTINIL SODIUM

UPSHER SMITH

- * UPSHER SMITH LABORATORIES INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DIVIGEL, ESTRADIOL
FORTICAL, CALCITONIN SALMON RECOMBINANT
LAMOTRIGINE, LAMOTRIGINE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
NIACOR, NIACIN
NYSTATIN, NYSTATIN
ORVATEN, MIDODRINE HYDROCHLORIDE
OXANDROLONE, OXANDROLONE
PACERONE, AMIODARONE HYDROCHLORIDE
PENTOXIL, PENTOXIFYLLINE
PREVALITE, CHOLESTYRAMINE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
SORINE, SOTALOL HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
ZALEPLON, ZALEPLON

UPSHER SMITH LABS

- * UPSHER SMITH LABORATORIES INC
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

* UPSHER SMITH LABORATORIES INC
KLOR-CON M20, POTASSIUM CHLORIDE

UPSHER-SMITH LABS

* UPSHER-SMITH LABORATORIES INC
KLOR-CON, POTASSIUM CHLORIDE

US PHARMS HOLDINGS I

* US PHARMACEUTICALS HOLDINGS I LLC
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL TARTRATE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
METHERGINE, METHYLERGONOVINE MALEATE
PARLODEL, BROMOCRIPTINE MESYLATE

US WORLDMEDS

* US WORLDMEDS LLC
APOKYN, APOMORPHINE HYDROCHLORIDE
DANTROLENE SODIUM, DANTROLENE SODIUM

USL PHARMA

* USL PHARMA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
ESTRADIOL, ESTRADIOL
FLUOXYMESTERONE, FLUOXYMESTERONE
JANTOVEN, WARFARIN SODIUM
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

VALEANT

* VALEANT PHARMACEUTICALS INTERNATIONAL
ANCOBON, FLUCYTOSINE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BONTRIL, PHENDIMETRAZINE TARTRATE
D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DIASTAT ACUDIAL, DIAZEPAM
DIASTAT, DIAZEPAM
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MOTOFEN, ATROPINE SULFATE
MYSOLINE, PRIMIDONE
PHRENILIN FORTE, ACETAMINOPHEN
PHRENILIN WITH CAFFEINE AND CODEINE, ACETAMINOPHEN

VALEANT BERMUDA

* VALEANT INTERNATIONAL BERMUDA
CARAC, FLUOROURACIL
DERMATOP E EMOLLIENT, PREDNICARBATE
DERMATOP, PREDNICARBATE
ELIDEL, PIMECROLIMUS
NORITATE, METRONIDAZOLE
XENAZINE, TETRABENAZINE

VALEANT INTL

* VALEANT INTERNATIONAL BARBADOS SRL
ATIVAN, LORAZEPAM
BENZAMYCIN PAK, BENZOYL PEROXIDE
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
ERTACZO, SERTACONAZOLE NITRATE
FENOFIBRATE, FENOFIBRATE
ISORDIL, ISOSORBIDE DINITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** V ****

- * VALEANT INTERNATIONAL BARBADOS SRL
NIFEDIPINE, NIFEDIPINE
PENTOXIFYLLINE, PENTOXIFYLLINE
RENOVA, TRETINOIN
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
TIAZAC, DILTIAZEM HYDROCHLORIDE
ULTRAM ER, TRAMADOL HYDROCHLORIDE
VASERETIC, ENALAPRIL MALEATE
VASOTEC, ENALAPRIL MALEATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
XERESE, ACYCLOVIR
ZOVIRAX, ACYCLOVIR
- * VALEANT INTERNATIONAL SRL
APLENZIN, BUPROPION HYDROBROMIDE
BENZACLIN, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE

VALEANT LUXEMBOURG

- * VALEANT PHARMACEUTICALS LUXEMBOURG SARL
GRIFULVIN V, GRISEOFULVIN, MICROSIZE

VALEANT PHARM INTL

- * VALEANT PHARMACEUTICALS INTERNATIONAL
8-MOP, METHOXSALEN
ANDROID 10, METHYLTESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
EFUDEX, FLUOROURACIL
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
MESTINON, PYRIDOSTIGMINE BROMIDE
OXSORALEN, METHOXSALEN
OXSORALEN-ULTRA, METHOXSALEN
TENSILON PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
TENSILON, EDROPHONIUM CHLORIDE
TESTRED, METHYLTESTOSTERONE
VIRAZOLE, RIBAVIRIN
ZELAPAR, SELEGILINE HYDROCHLORIDE

VALEANT PHARM NORTH

- * VALEANT PHARMACEUTICAL NORTH AMERICA LLC
GRIFULVIN V, GRISEOFULVIN, MICROSIZE

VALEANT PHARMS

- * VALEANT PHARMACEUTICALS NORTH AMERICA
MEPHYTON, PHYTONADIONE

VALEANT PHARMS INC

- * VALEANT PHARMACEUTICALS INTERNATIONAL INC
VISUDYNE, VERTEPORFIN

VALEANT PHARMS LLC

- * VALEANT PHARMACEUTICALS NORTH AMERICA LLC
CAPITAL AND CODEINE, ACETAMINOPHEN
MACUGEN, PEGAPTANIB SODIUM
MESTINON, PYRIDOSTIGMINE BROMIDE
TASMAR, TOLCAPONE
TIMOPTIC-XE, TIMOLOL MALEATE

VALIDUS PHARMS

- * VALIDUS PHARMACEUTICALS LLC
ROCALTROL, CALCITRIOL

VALIDUS PHARMS INC

- * VALIDUS PHARMACEUTICALS INC
EQUETRO, CARBAMAZEPINE
MARPLAN, ISOCARBOXAZID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

VANSEN PHARMA

* VANSEN PHARMA
SPECTRACEF, CEFEDITOREN PIVOXIL

VEROSCIENCE

* VEROSCIENCE LLC
CYCLOSET, BROMOCRIPTINE MESYLATE

VERSAPHARM

* VERSAPHARM INC
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DESOXIMETASONE, DESOXIMETASONE
ERYTHROMYCIN, ERYTHROMYCIN
ETHOSUXIMIDE, ETHOSUXIMIDE
RIFAMPIN, RIFAMPIN

VERSAPHARM INC

* VERSAPHARM INC
RIFAMPIN, RIFAMPIN
* VERSAPHARM INCORPORATED
TRANEXAMIC ACID, TRANEXAMIC ACID

VERTEX PHARMS

* VERTEX PHARMACEUTICALS INC
INCIVEK, TELAPREVIR
KALYDECO, IVACAFTOR

VESTIQ PHARMS

* VESTIQ PHARMACEUTICALS INC
ORAVIG, MICONAZOLE
ZUPLENZ, ONDANSETRON

VICURON

* VICURON PHARMACEUTICALS INC
ERAXIS, ANIDULAFUNGIN

VIIV HLTHCARE

* VIIV HEALTHCARE CO
COMBIVIR, LAMIVUDINE
EPIVIR, LAMIVUDINE
EPZICOM, ABACAVIR SULFATE
LEXIVA, FOSAMPRENAVIR CALCIUM
RESCRIPTOR, DELAVIRDINE MESYLATE
RETROVIR, ZIDOVUDINE
SELZENTRY, MARAVIROC
TRIZIVIR, ABACAVIR SULFATE
ZIAGEN, ABACAVIR SULFATE

VINTAGE

* VINTAGE PHARMACEUTICALS LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETIC ACID, ACETIC ACID, GLACIAL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPRAZOLAM, ALPRAZOLAM
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FOLIC ACID, FOLIC ACID
GLIMEPIRIDE, GLIMEPIRIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

* VINTAGE PHARMACEUTICALS LLC
 LISINOPRIL, LISINOPRIL
 NYSTATIN, NYSTATIN
 PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PREDNISOLONE, PREDNISOLONE
 PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
 RISPERIDONE, RISPERIDONE
 SPIRONOLACTONE, SPIRONOLACTONE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VALPROIC ACID, VALPROIC ACID
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

VINTAGE PHARMS

* VINTAGE PHARMACEUTICALS
 DISULFIRAM, DISULFIRAM
 GILDAGIA, ETHINYL ESTRADIOL
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 LEVETIRACETAM, LEVETIRACETAM
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

* VINTAGE PHARMACEUTICALS INC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ALLOPURINOL, ALLOPURINOL
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 BACLOFEN, BACLOFEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
 CARISOPRODOL, CARISOPRODOL
 CLONAZEPAM, CLONAZEPAM
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DEXAMETHASONE, DEXAMETHASONE
 DIAZEPAM, DIAZEPAM
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 FUROSEMIDE, FUROSEMIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 HYDROCORTISONE, HYDROCORTISONE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LACTULOSE, LACTULOSE
 LEVETIRACETAM, LEVETIRACETAM
 LORAZEPAM, LORAZEPAM
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 METHOCARBAMOL, METHOCARBAMOL
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PERPHENAZINE, PERPHENAZINE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PREDNISONE, PREDNISONE
 PRIMIDONE, PRIMIDONE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** V ****

* VINTAGE PHARMACEUTICALS INC
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SULFASALAZINE, SULFASALAZINE
TORSEMIDE, TORSEMIDE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

VINTAGE PHARMS LLC

* VINTAGE PHARMACEUTICALS LLC
CYCLAFEM 1/35, ETHINYL ESTRADIOL
CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
EMOQUETTE, DESOGESTREL
FELODIPINE, FELODIPINE
GILDESS FE 1.5/30, ETHINYL ESTRADIOL
GILDESS FE 1/20, ETHINYL ESTRADIOL
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYZILRA, ETHINYL ESTRADIOL
ORSYTHIA, ETHINYL ESTRADIOL
PERCOCET, ACETAMINOPHEN
PREVIFEM, ETHINYL ESTRADIOL
TRI-PREVIFEM, ETHINYL ESTRADIOL
ZYDONE, ACETAMINOPHEN

VIROPHARMA

* VIROPHARMA INC
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

VISTA PHARMS

* VISTA PHARMACEUTICALS INC
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

VISTAPHARM

* VISTAPHARM INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NYSTATIN, NYSTATIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN

VIVUS

* VIVUS INC
QSYMIA, PHENTERMINE HYDROCHLORIDE
STENDRA, AVANAFIL

WARNER CHILCOTT

* WARNER CHILCOTT INC
LOESTRIN 24 FE, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL

WARNER CHILCOTT LLC

* WARNER CHILCOTT CO LLC
ACTONEL, RISEDRONATE SODIUM
ASACOL HD, MESALAMINE
ASACOL, MESALAMINE
ATELVIA, RISEDRONATE SODIUM
CHOLEDYL SA, OXTRIPHYLLINE
ENABLEX, DARIFENACIN HYDROBROMIDE
ERYC, ERYTHROMYCIN
ESTROSTEP FE, ETHINYL ESTRADIOL
FEMCON FE, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WARNER CHILCOTT CO LLC
 FEMHRT, ETHINYL ESTRADIOL
 FEMTRACE, ESTRADIOL ACETATE
 LO LOESTRIN FE, ETHINYL ESTRADIOL
 LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
 LOESTRIN 21 1/20, ETHINYL ESTRADIOL
 LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
 OVCON-35, ETHINYL ESTRADIOL
 OVCON-50, ETHINYL ESTRADIOL
 SARAFEM, FLUOXETINE HYDROCHLORIDE

WARNER CHILCOTT US

* WARNER CHILCOTT US LLC
 ESTRACE, ESTRADIOL

WARNER IRELAND

* WARNER CHILCOTT IRELAND LTD
 FEMRING, ESTRADIOL ACETATE

WATSON LABS

* WATSON LABORATORIES
 ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE, ACETAMINOPHEN
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 ANASTROZOLE, ANASTROZOLE
 CARVEDILOL, CARVEDILOL
 FOLIC ACID, FOLIC ACID
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
 MICROGESTIN 1/20, ETHINYL ESTRADIOL
 MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
 MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
 NORCO, ACETAMINOPHEN
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 OXAPROZIN, OXAPROZIN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

* WATSON LABORATORIES INC
 ACARBOSE, ACARBOSE
 ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
 ACETOHEXAMIDE, ACETOHEXAMIDE
 ACYCLOVIR, ACYCLOVIR
 AFEDITAB CR, NIFEDIPINE
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALLOPURINOL, ALLOPURINOL
 ALORA, ESTRADIOL
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AMOXAPINE, AMOXAPINE
 ANDRODERM, TESTOSTERONE
 ATENOLOL AND CHLORTHALIDONE, ATENOLOL
 ATENOLOL, ATENOLOL
 BACLOFEN, BACLOFEN
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
 BREVICON 28-DAY, ETHINYL ESTRADIOL
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
 CABERGOLINE, CABERGOLINE
 CAPTOPRIL, CAPTOPRIL
 CARBOPLATIN, CARBOPLATIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WATSON LABORATORIES INC
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORZOXAZONE, CHLORZOXAZONE
CICLOPIROX, CICLOPIROX
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
COL-PROBENECID, COLCHICINE
CRINONE, PROGESTERONE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOSPORINE, CYCLOSPORINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DIAZEPAM, DIAZEPAM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILACOR XR, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ESTAZOLAM, ESTAZOLAM
ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRADIOL, ESTRADIOL
ESTRONE, ESTRONE
ESTROPIRATE, ESTROPIRATE
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FUROSEMIDE, FUROSEMIDE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GELNIQUE, OXYBUTYNIN CHLORIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WATSON LABORATORIES INC
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 INDAPAMIDE, INDAPAMIDE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 ISONIAZID, ISONIAZID
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 ISRADIPINE, ISRADIPINE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LAMOTRIGINE, LAMOTRIGINE
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL, LEVONORGESTREL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LEVORA 0.15/30-28, ETHINYL ESTRADIOL
 LISINAPRIL, LISINAPRIL
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOW-OGESTREL-21, ETHINYL ESTRADIOL
 LOW-OGESTREL-28, ETHINYL ESTRADIOL
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
 MELOXICAM, MELOXICAM
 MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
 MEPROBAMATE, MEPROBAMATE
 METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
 METHOCARBAMOL, METHOCARBAMOL
 METHYLDOPA, METHYLDOPA
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE, METRONIDAZOLE
 MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
 MICROZIDE, HYDROCHLOROTHIAZIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MINOXIDIL, MINOXIDIL
 MIRTAZAPINE, MIRTAZAPINE
 MORPHINE SULFATE, MORPHINE SULFATE
 NABUMETONE, NABUMETONE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN, NAPROXEN
 NATEGLINIDE, NATEGLINIDE
 NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 NIZATIDINE, NIZATIDINE
 NORCO, ACETAMINOPHEN
 NORETHIN 1/35E-21, ETHINYL ESTRADIOL
 NORETHIN 1/35E-28, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL (7/14), ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WATSON LABORATORIES INC
 NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
 NORINYL 1+50 28-DAY, MESTRANOL
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXAZEPAM, OXAZEPAM
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE AND ASPIRIN, ASPIRIN
 OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
 PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
 PENTAZOCINE AND NALOXONE HYDROCHLORIDES, NALOXONE HYDROCHLORIDE
 PENTOXIFYLLINE, PENTOXIFYLLINE
 PINDOLOL, PINDOLOL
 PIROXICAM, PIROXICAM
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PREDNISOLONE, PREDNISOLONE
 PREDNISON, PREDNISON
 PRIMIDONE, PRIMIDONE
 PROBENECID, PROBENECID
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 QUASENSE, ETHINYL ESTRADIOL
 QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
 QUINIDINE SULFATE, QUINIDINE SULFATE
 RAMIPRIL, RAMIPRIL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 RAPAFLO, SILODOSIN
 RISPERIDONE, RISPERIDONE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SIMVASTATIN, SIMVASTATIN
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 SULFASALAZINE, SULFASALAZINE
 SULINDAC, SULINDAC
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TACROLIMUS, TACROLIMUS
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TEMAZEPAM, TEMAZEPAM
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 THIOTHIXENE, THIOTHIXENE
 TOLAZAMIDE, TOLAZAMIDE
 TOPIRAMATE, TOPIRAMATE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRANDOLAPRIL, TRANDOLAPRIL
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRELSTAR, TRIPTORELIN PAMOATE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIAZOLAM, TRIAZOLAM
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
 TRIMETHOPRIM, TRIMETHOPRIM
 TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
 TRIVORA-28, ETHINYL ESTRADIOL
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

- * WATSON LABORATORIES INC
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
- * WATSON LABS INC
LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

WATSON LABS (UTAH)

- * WATSON LABORATORIES INC
INFED, IRON DEXTRAN
NOR-QD, NORETHINDRONE
OXYTROL, OXYBUTYNIN
PROGESTERONE, PROGESTERONE

WATSON LABS FLORIDA

- * WATSON LABORATORIES INC FLORIDA
ALPRAZOLAM, ALPRAZOLAM
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CLARITHROMYCIN, CLARITHROMYCIN
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GLIMEPIRIDE, GLIMEPIRIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
KETOPROFEN, KETOPROFEN
LEVETIRACETAM, LEVETIRACETAM
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MIRTAZAPINE, MIRTAZAPINE
OMEPRazole, OMEPRazole
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE

WATSON LABS INC

- * WATSON LABORATORIES INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMMONIUM LACTATE, AMMONIUM LACTATE
ANTUROL, OXYBUTYNIN
ARMODAFINIL, ARMODAFINIL
BUDESONIDE, BUDESONIDE
CICLOPIROX, CICLOPIROX
CYCLOSPORINE, CYCLOSPORINE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
FIORICET W/ CODEINE, ACETAMINOPHEN
FIORINAL W/CODEINE, ASPIRIN
FIORINAL, ASPIRIN
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LIDOCAINE, LIDOCAINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

- * WATSON LABORATORIES INC
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
PREGABALIN, PREGABALIN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
URSODIOL, URSODIOL

WATSON LABS INC FL

- * WATSON LABORATORIES INC FLORIDA
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FLUTAMIDE, FLUTAMIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE

WATSON PHARMS

- * WATSON PHARMACEUTICALS
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
TENUATE, DIETHYLPROPION HYDROCHLORIDE
- * WATSON PHARMACEUTICALS INC
ACTIGALL, URSODIOL
CONDYLOX, PODOFILOX
CORDRAN, FLURANDRENOLIDE
FIORICET, ACETAMINOPHEN

WE PHARMS

- * WE PHARMACEUTICALS INC
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE

WEILL MEDCL COLL

- * WEILL MEDICAL COLLEGE CORNELL UNIV
FLUDEOXYGLUCOSE F 18, FLUDEOXYGLUCOSE F-18

WELLSPRING PHARM

- * WELLSPRING PHARMACEUTICAL CORP
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DUVOID, BETHANECHOL CHLORIDE
DYRENIUM, TRIAMTERENE

WEST WARD

- * WEST WARD INC
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
- * WEST WARD PHARMACEUTICAL CORP
AMINOPHYLLINE, AMINOPHYLLINE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL, CARISOPRODOL
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CORTISONE ACETATE, CORTISONE ACETATE
DICYCLIMINE HYDROCHLORIDE, DICYCLIMINE HYDROCHLORIDE
DIGOXIN, DIGOXIN
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LITHIUM CARBONATE, LITHIUM CARBONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WEST WARD PHARMACEUTICAL CORP
 MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
 METHOCARBAMOL, METHOCARBAMOL
 PREDNISONE, PREDNISONE
 PRIMIDONE, PRIMIDONE
 PROPYLTHIOURACIL, PROPYLTHIOURACIL
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
 ZALEPLON, ZALEPLON

WEST WARD PHARM CORP

* WEST WARD PHARMACEUTICAL CORP
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PREDNISONE, PREDNISONE

WEST WARD PHARMS

* WEST WARD PHARMACEUTICALS CORP
 RISPERIDONE, RISPERIDONE

WESTWARD

* WESTWARD PHARMACEUTICAL CORP
 NAPROXEN, NAPROXEN
 RIFAMPIN AND ISONIAZID, ISONIAZID

WEST-WARD PHARM CORP

* WEST-WARD PHARMACEUTICAL CORP
 CEFOTETAN, CEFOTETAN DISODIUM
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE

WOCKHARDT

* WOCKHARDT AMERICAS INC
 CAPTOPRIL, CAPTOPRIL
 FAMOTIDINE, FAMOTIDINE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

* WOCKHARDT EU OPERATIONS (SWISS) AG
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACETIC ACID, ACETIC ACID, GLACIAL
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 BROMFED-DM, BROMPHENIRAMINE MALEATE
 CARBAMAZEPINE, CARBAMAZEPINE
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 CYCLOSPORINE, CYCLOSPORINE
 DEXAMETHASONE, DEXAMETHASONE
 DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 FUROSEMIDE, FUROSEMIDE
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LINDANE, LINDANE
 LITHIUM CITRATE, LITHIUM CITRATE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORATADINE, LORATADINE (OTC)
 MEGESTROL ACETATE, MEGESTROL ACETATE
 METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

- * WOCKHARDT EU OPERATIONS (SWISS) AG
 - MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 - MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 - NYSTATIN, NYSTATIN
 - OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 - PHENYTOIN, PHENYTOIN
 - PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 - PREDNISOLONE, PREDNISOLONE
 - PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 - PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
 - PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
 - SELENIUM SULFIDE, SELENIUM SULFIDE
 - TRETINOIN, TRETINOIN
 - TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 - VALPROIC ACID, VALPROIC ACID
- * WOCKHARDT LTD
 - ADENOSINE, ADENOSINE
 - AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 - AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 - AZITHROMYCIN, AZITHROMYCIN
 - BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 - BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 - CARVEDILOL, CARVEDILOL
 - CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
 - CEFOTAXIME, CEFOTAXIME SODIUM
 - CEFPROZIL, CEFPROZIL
 - CEFTAZIDIME, CEFTAZIDIME
 - CEFTRIAZONE, CEFTRIAZONE SODIUM
 - CEFUROXIME AXETIL, CEFUROXIME AXETIL
 - CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 - CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 - CLARITHROMYCIN, CLARITHROMYCIN
 - DIVALPROEX SODIUM, DIVALPROEX SODIUM
 - DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 - EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 - FAMOTIDINE, FAMOTIDINE (OTC)
 - FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 - FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 - FUROSEMIDE, FUROSEMIDE
 - KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 - LEVETIRACETAM, LEVETIRACETAM
 - LEVOFLOXACIN, LEVOFLOXACIN
 - LISINAPRIL, LISINAPRIL
 - METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 - MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 - NIACIN, NIACIN
 - NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 - ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 - ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 - PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 - PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 - RISPERIDONE, RISPERIDONE
 - ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 - SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 - SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 - TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 - TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 - TIMOLOL MALEATE, TIMOLOL MALEATE
 - VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 - VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 - ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
 - ZONISAMIDE, ZONISAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

WOCKHARDT LTD

- * WOCKHARDT LTD
 - ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 - BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 - CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
 - CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 - CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 - CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 - ENTACAPONE, ENTACAPONE
 - FELODIPINE, FELODIPINE
 - FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 - FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 - LAMOTRIGINE, LAMOTRIGINE
 - LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 - ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 - ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

WOCKHARDT USA

- * WOCKHARDT USA INC
 - EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 - GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 - OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 - OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
- * WOCKHARDT USA LLC
 - ENALAPRIL MALEATE, ENALAPRIL MALEATE
 - LANSOPRAZOLE, LANSOPRAZOLE
 - TOPIRAMATE, TOPIRAMATE

WORLD GEN

- * WORLD GEN LLC
 - AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

WRASER PHARMS

- * WRASER PHARMACEUTICALS LLC
 - CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE

WRASER PHARMS LLC

- * WRASER PHARMACEUTICALS LLC
 - ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN

WYETH PHARMS

- * WYETH PHARMACEUTICALS INC SUB PFIZER INC
 - LO/OVRAL-28, ETHINYL ESTRADIOL

WYETH PHARMS INC

- * WYETH PHARMACEUTICALS INC
 - BOSULIF, BOSUTINIB MONOHYDRATE
 - CORDARONE, AMIODARONE HYDROCHLORIDE
 - EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
 - PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
 - PREMARIN, ESTROGENS, CONJUGATED
 - PREMPHASE 14/14, ESTROGENS, CONJUGATED
 - PREMPRO, ESTROGENS, CONJUGATED
 - PRISTIQ, DESVENLAFAXINE SUCCINATE
 - PROTONIX IV, PANTOPRAZOLE SODIUM
 - PROTONIX, PANTOPRAZOLE SODIUM
 - RAPAMUNE, SIROLIMUS
 - TORISEL, TEMSIROLIMUS
 - TRECTOR, ETHIONAMIDE
 - TYGACIL, TIGECYCLINE
 - ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
 - ZOSYN, PIPERACILLIN SODIUM

X GEN PHARMS

- * X GEN PHARMACEUTICALS INC
 - ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
 - AMPHOTERICIN B, AMPHOTERICIN B
 - BACIIM, BACITRACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** X ****

* X GEN PHARMACEUTICALS INC
BACI-RX, BACITRACIN
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDRO-RX, HYDROCORTISONE
LEVETIRACETAM, LEVETIRACETAM
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
NEO-FRADIN, NEOMYCIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEO-RX, NEOMYCIN SULFATE
NYSTATIN, NYSTATIN
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POLY-RX, POLYMYXIN B SULFATE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

X-GEN PHARMS

* X-GEN PHARMACEUTICALS INC
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

XOMA

* XOMA (US) LLC
ACEON, PERINDOPRIL ERBUMINE

XSPIRE

* XSPIRE LLC
NALFON, FENOPROFEN CALCIUM

XTTRIUM

* XTTRIUM LABORATORIES INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)

YUNG SHIN PHARM

* YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO LTD
CEFACLOL, CEFACLOL
CEPHALEXIN, CEPHALEXIN

ZAMBON SPA

* ZAMBON SPA ITALY
MONUROL, FOSFOMYCIN TROMETHAMINE

ZARS PHARM

* ZARS PHARMA INC
SYNERA, LIDOCAINE

ZOGENIX INC

* ZOGENIX INC
SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE

ZYDUS PHARMS USA

* ZYDUS PHARMACEUTICALS USA INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
AZATHIOPRINE, AZATHIOPRINE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENZONATATE, BENZONATATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN, NAPROXEN
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
RAMIPRIL, RAMIPRIL
RIBAVIRIN, RIBAVIRIN
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
ZONISAMIDE, ZONISAMIDE

ZYDUS PHARMS USA INC

* ZYDUS PHARMACEUTICALS USA INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALPRAZOLAM, ALPRAZOLAM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ANASTROZOLE, ANASTROZOLE
BICALUTAMIDE, BICALUTAMIDE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
CARVEDILOL, CARVEDILOL
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ETHOSUXIMIDE, ETHOSUXIMIDE
FINASTERIDE, FINASTERIDE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
INDOMETHACIN, INDOMETHACIN
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
OMEPRazole, OMEPRazole
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

APPENDIX C**UNIFORM TERMS*****DOSAGE FORMS***

AEROSOL	LOTION/SHAMPOO
AEROSOL, FOAM	OIL
AEROSOL, METERED	OIL/DROPS
CAPSULE	OINTMENT
CAPSULE, DELAYED REL PELLETS	OINTMENT, AUGMENTED
CAPSULE, DELAYED RELEASE	PASTE
CAPSULE, EXTENDED RELEASE	PATCH
CLOTH	PELLET
CONCENTRATE	POWDER
CREAM	POWDER, EXTENDED RELEASE
CREAM, AUGMENTED	POWDER, METERED
ELIXIR	RING
EMULSION	SHAMPOO
ENEMA	SOLUTION
FILM	SOLUTION FOR SLUSH
FILM, EXTENDED RELEASE	SOLUTION, GEL FORMING/DROPS
FOR SOLUTION	SOLUTION, METERED
FOR SUSPENSION	SOLUTION/DROPS
FOR SUSPENSION, DELAYED RELEASE	SPONGE
FOR SUSPENSION, EXTENDED RELEASE	SPRAY
GAS	SPRAY, METERED
GEL	SUPPOSITORY
GEL, AUGMENTED	SUSPENSION
GEL, METERED	SUSPENSION, EXTENDED RELEASE
GRANULE	SUSPENSION/DROPS
GRANULE, DELAYED RELEASE	SWAB
GUM, CHEWING	SYRUP
IMPLANT	SYSTEM, EXTENDED RELEASE
INHALANT	TABLET
INJECTABLE	TABLET, CHEWABLE
INJECTABLE, LIPID COMPLEX	TABLET, COATED PARTICLES
INJECTABLE, LIPOSOMAL	TABLET, DELAYED RELEASE
INJECTABLE, TABLET	TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING
INSERT	TABLET, EFFERVESCENT
INSERT, EXTENDED RELEASE	TABLET, EXTENDED RELEASE
INTRAUTERINE DEVICE	TABLET, FOR SUSPENSION
JELLY	TABLET, ORALLY DISINTEGRATING
LIQUID	TAPE
LOTION	TROCHE/LOZENGE
LOTION, AUGMENTED	

Note: Terms comprise currently marketed products

APPENDIX C**UNIFORM TERMS*****ROUTES OF ADMINISTRATION***

BUCCAL	IRRIGATION
DENTAL	IV (INFUSION)
ENDOCERVICAL	N/A
FOR RX COMPOUNDING	NASAL
IMPLANTATION	OPHTHALMIC
INHALATION	ORAL
INJECTION	ORAL-21
INTRA-ANAL	ORAL-28
INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL	OTIC
INTRACRANIAL	PERFUSION, CARDIAC
INTRAMUSCULAR	PERIODONTAL
INTRAOCULAR	RECTAL
INTRAPERITONEAL	SPINAL
INTRAPLEURAL	SUBCUTANEOUS
INTRATHECAL	SUBLINGUAL
INTRATRACHEAL	TOPICAL
INTRAUTERINE	TRANSDERMAL
INTRAVENOUS	TRANSMUCOSAL
INTRAVESICAL	URETHRAL
INTRAVITREAL	VAGINAL

Note: Terms comprise currently marketed products

APPENDIX C**UNIFORM TERMS*****ABBREVIATIONS***

AMP	AMPULE
AMPICIL	AMPICILLIN
APPROX	APPROXIMATELY
BOT	BOTTLE
CI	CURIE
CSR	CAROTID SINUS REFLEX
CU	CLINICAL UNITS
DIPROP	DIPROPIONATE
ELECT	ELECTROLYTE
EQ	EQUIVALENT TO
ER	EXTENDED RELEASE
GM	GRAM
HBR	HYDROBROMIDE
HCL	HYDROCHLORIDE
HR	HOURLY
IM	INTRAMUSCULAR
INH	INHALATION
IU	INTERNATIONAL UNITS
IV	INTRAVENOUS
KIU	KALLIKREIN INHIBITOR UNITS
MCG	MICROGRAM
MCI	MILLICURIE
MEQ	MILLIEQUIVALENT
MG	MILLIGRAM
ML	MILLILITER
N/A	NOT APPLICABLE
PPM	PARTS PER MILLION
REL	RELEASE
SC	SUBCUTANEOUS
SQ CM	SQUARE CENTIMETER
U	UNITS
UCI	MICROCURIE
UMOLAR	MICROMOLAR
USP	UNITED STATES PHARMACOPEIA

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Drug Price Competition and Patent Term Restoration Act (1984 Amendments) for periods of exclusivity, during which abbreviated new drug applications (ANDAs) and applications described in Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (the Act) for those drug products may, in some instances, not be submitted or made effective as described below, and provides patent information concerning the listed drug products. Those drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the Act and those drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A are also included in this *Addendum*. This section is arranged in alphabetical order by active ingredient name followed the trade name. Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* Section. Exclusivity prevents the submission or effective approval of ANDAs or applications described in Section 505(b)(2) of the Act. It does not prevent the submission or approval of a second 505(b)(1) application except in the case of Orphan Drug exclusivity. Applications qualifying for periods of exclusivity are:

- (1) A new drug application approved after September 24, 1984, for a drug product all active ingredients (including any ester or salt of the active ingredient) of which had never been approved in any other new drug application under Section 505 (b) of the Act. No subsequent ANDA or application described in Section 505(b)(2) of the Act for the same drug may be *submitted* for a period of *five years* from the date of approval of the original application, except that such an application may be *submitted* after *four years* if it contains a certification that a patent claiming the drug is invalid or will not be infringed by the product for which approval is sought.
- (2) A new drug application approved after September 24, 1984, for a drug product containing an active ingredient (including any ester or salt of that active ingredient) that has been approved in an earlier new drug application and that includes reports of new clinical investigations (other than bioavailability studies). Such investigations must have been conducted or sponsored by the applicant and must have been essential to approval of the application. If these requirements are met, the approval of a subsequent ANDA or an application described in Section 505(b)(2) of the Act may not be *made effective* for the same drug or use, if for a new indication, before the expiration of *three years* from the date of approval of the original application. If an applicant has exclusivity for a new application or 505(b)(2) application for the drug product with indications or use, this does not preclude the approval of an ANDA or 505(b)(2) application not covered by the exclusivity.
- (3) A supplement to a new drug application for a drug containing a previously approved active ingredient including (any ester or salt of the active ingredient) approved after September 24, 1984, that contains reports of new clinical investigations (other than bioavailability studies) essential to the approval of the supplement and conducted or sponsored by the applicant. The approval of a subsequent ANDA or 505(b)(2) application for a change approved in the supplement may not be

made effective for three years from the date of approval of the original supplement.

The Act requires that patent information be filed with all newly submitted Section 505(b) drug applications. No NDA may be approved after September 24, 1984, without the submission of patent information to the Agency. Effective August 18, 2003, this information must be filed using FDA Form 3524a "Patent Information Submitted with the Filing of an NDA, Amendment or Supplement".

Effective August 18, 2003, upon approval of an application, patent information for purposes of listing in the Orange Book must be submitted to the agency within 30 days of approval on FDA Form 3542 "Patent Information Submitted Upon and After Approval of an NDA or Supplement". Patent information on unapproved applications or on patents beyond the scope of the Act (i.e., process or manufacturing patents) will not be published. FDA form 3542 will be the only form used for the purposes of this publication.

The patents that FDA regards as covered by the statutory provisions for submission of patent information are: patents that claim the active ingredient(s); drug product patents which include formulation/composition patents; use patents for a particular approved indication or method of using the product; and certain other patents as detailed on FDA Form 3542. This information, as provided by the sponsor on FDA form 3542, will be published as described above.

A requirement for submission of patent information to FDA for certain old antibiotics became effective October 7, 2008 under section 4(b)(1) of the Q1 Act. A guidance for industry on this subject is available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM080576.pdf>

Upon approval, patent numbers and expiration dates, in addition to certain other information on appropriate patents claiming drug products that are the subject of approved applications, will be published daily in the [Electronic Orange Book Query](#). The Addendum lists patent and exclusivity information up to January of the Edition year. The monthly Cumulative Supplements to the annual edition list patent and exclusivity information changes since the Annual Edition Addendum. Since all parts of this publication are subject to changes, additions, or deletions, the Electronic Orange Book, updated daily, should be consulted for the most recent patent and exclusivity information.

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ABACAVIR SULFATE</u>						
A091294	001				PC	Dec 16, 2012
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N020977	001	6294540	May 14, 2018	DS DP	U-65	
		6294540*PED	Nov 14, 2018		U-65	
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N020978	001	6294540	May 14, 2018	DS DP	U-65	
		6294540*PED	Nov 14, 2018		U-65	
		6641843	Feb 04, 2019	DP		
		6641843*PED	Aug 04, 2019			
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N021652	001	5905082	May 18, 2016	DS DP		
		5905082*PED	Nov 18, 2016			
		6294540	May 14, 2018	DS DP	U-257	
		6294540*PED	Nov 14, 2018			
		6417191	Mar 28, 2016	DP	U-257	
<u>ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE - TRIZIVIR</u>						
N021205	001	5905082	May 18, 2016	DS DP	U-248	
		5905082*PED	Nov 18, 2016			
		6294540	May 14, 2018	DS DP	U-65	
		6294540*PED	Nov 14, 2018		U-65	
		6417191	Mar 28, 2016	DP	U-248	
<u>ABARELIX - PLENAXIS</u>						
N021320	001	5843901	Dec 01, 2015	DS DP		
		5968895	Dec 11, 2016		DP	
		6180608	Dec 11, 2016		DP	U-549
		6423686	Jun 07, 2015	DS		
		6455499	Jun 07, 2015		U-549	
		6699833	Dec 11, 2016	DP		
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N202379	001	5604213	Feb 18, 2014	DS DP	U-1126	I-663 Dec 10, 2015
		5604213	Feb 18, 2014	DS DP	U-1314	NCE Apr 28, 2016
<u>ACETAMINOPHEN - OFIRMEV</u>						
N022450	001	6028222	Aug 05, 2017	DP		
		6992218	Jun 06, 2021	DP		
<u>ACETAMINOPHEN; ASPIRIN; CAFFEINE - EXCEDRIN (MIGRAINE)</u>						
N020802	001	5972916	Jul 14, 2017		U-296	
<u>ACETYLCHOLINE CHLORIDE - MIOCHOL-E</u>						
N020213	001	6261546	Apr 29, 2019		U-506	
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N021539	001	8148356	May 21, 2026	DP		
<u>ACETYLCYSTEINE - ACETYLCYSTEINE</u>						
A200644	001				PC	May 29, 2013
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N202450	001	5840279	Jun 21, 2016	DP		
		6071498	Jun 21, 2016	DP		
		6681768	Aug 07, 2022	DP		
		6750226	Sep 05, 2020	DS DP	U-1264	
		7078412	Jul 16, 2020	DS DP	U-1263	
		8051851	Apr 22, 2027	DP		
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N022436	001	6514980	Jan 24, 2017	DP	U-1006	
		7223387	Feb 28, 2021	DP	U-1006	
		RE39264	Feb 02, 2016	DP	U-1006	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAPALENE - DIFFERIN</u>						
N021753 001	7579377	Feb 23, 2025				
	7737181	Aug 29, 2024	DP			
	7834060	Mar 12, 2023				
	7838558	Mar 12, 2023	DP			
	7868044	Mar 12, 2023				
<u>ADAPALENE - DIFFERIN</u>						
N022502 001	7998467	May 31, 2028	DP	U-1078	NDF	Mar 17, 2013
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	7820186	Nov 23, 2025	DP			
	7964202	Sep 01, 2024	DP	U-1078		
	8071644	Jul 18, 2027	DP	U-1078		
	8080537	Jul 18, 2027		U-1078		
	8105618	Dec 23, 2022		U-1078		
	8129362	Jul 18, 2027		U-1078		
	8241649	Dec 23, 2022	DP			
<u>ADEFOVIR DIPIVOXIL - HEPSERA</u>						
N021449 001	5663159	Sep 02, 2014	DS DP			
	6451340	Jul 23, 2018	DS DP	U-470		
<u>ADENOSINE - ADENOSCAN</u>						
N020059 001	5731296	Mar 24, 2015		U-221		
<u>ALATROFLOXACIN MESYLATE - TROVAN PRESERVATIVE FREE</u>						
N020760 001	5763454	Jun 15, 2015		U-282		
	6080756	Jul 05, 2016				
	6194429	Jul 23, 2018				
<u>ALATROFLOXACIN MESYLATE - TROVAN PRESERVATIVE FREE</u>						
N020760 002	5763454	Jun 15, 2015		U-282		
	6080756	Jul 05, 2016				
	6194429	Jul 23, 2018				
<u>ALBUMIN HUMAN - OPTISON</u>						
N020899 001	5529766	Jun 25, 2013		U-505	M-120	Aug 17, 2015
	6723303	Apr 20, 2021	DP			
<u>ALBUTEROL SULFATE - ACCUNEB</u>						
N020949 001	6702997	Dec 28, 2021		U-558		
<u>ALBUTEROL SULFATE - ACCUNEB</u>						
N020949 002	6702997	Dec 28, 2021		U-558		
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N021457 001	5605674	Feb 25, 2014	DP			
	6446627	Dec 18, 2017	DP			
	7105152	Sep 12, 2023	DP			
	7566445	Jun 04, 2017	DP			
	8132712	Sep 07, 2028	DP			
<u>ALBUTEROL SULFATE - PROVENTIL-HFA</u>						
N020503 001	5605674	Feb 25, 2014				
	5766573	Jun 16, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N020983 001	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6558651	Dec 19, 2016	DP	U-716		
	6558651*PED	Jun 19, 2017				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021		U-716		
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 06, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT</u>						
N020291 001	5603918	Jun 09, 2015				
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N021747 001	5472143	Sep 29, 2013	DP		NP	Oct 07, 2014
	5497944	Mar 12, 2013	DP			
	5662271	Sep 02, 2014	DP			
	5911851	Sep 29, 2013	DP			
	5964416	Oct 04, 2016	DP			
	6007676	Sep 29, 2013	DP			
	6149054	Dec 19, 2016	DP			
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6503362	Sep 29, 2013	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7104470	Oct 04, 2016	DP			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - DUONEB</u>						
N020950 001	6632842	Dec 28, 2021		U-532		
<u>ALCAFTADINE - LASTACFT</u>						
N022134 001	5468743	Nov 21, 2013	DS DP		NCE	Jul 28, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALCOHOL; CHLORHEXIDINE GLUCONATE - AVAGARD</u>						
N021074 001	5897031	Jun 21, 2016				
	6090395	Jun 22, 2015	DP			
	6534069	Jun 22, 2015	DP			
	6623744	Jun 23, 2015			U-1008	
	7081246	Aug 03, 2016	DP			
	7566460	Jun 22, 2015	DP		U-1008	
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N202344 001	7488496	Aug 11, 2023	DS	DP		
	7964212	Mar 06, 2023	DS	DP		
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N020560 001	5358941	Dec 02, 2012				
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012				
	5681590*PED	Jun 02, 2013				
	6090410	Dec 02, 2012				
	6090410*PED	Jun 02, 2013				
	6194004	Dec 02, 2012				
	6194004*PED	Jun 02, 2013				
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N020560 002	5358941	Dec 02, 2012				
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012				
	5681590*PED	Jun 02, 2013				
	6090410	Dec 02, 2012				
	6090410*PED	Jun 02, 2013				
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N020560 003	5358941	Dec 02, 2012				
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012				
	5681590*PED	Jun 02, 2013				
	6090410	Dec 02, 2012				
	6090410*PED	Jun 02, 2013				
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N020560 004	5358941	Dec 02, 2012				
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012				
	5681590*PED	Jun 02, 2013				
	6090410	Dec 02, 2012				
	6090410*PED	Jun 02, 2013				
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N020560 005	5358941	Dec 02, 2012				
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012				
	5681590*PED	Jun 02, 2013				
	6090410	Dec 02, 2012				
	6090410*PED	Jun 02, 2013				
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N021575 001	5462932	May 17, 2014				
	5462932*PED	Nov 17, 2014				
	5994329	Jul 17, 2018			Y	
	5994329*PED	Jan 17, 2019				
	6015801	Jul 17, 2018			Y	
	6015801*PED	Jan 17, 2019				
	6225294	Jul 17, 2018			Y	
	6225294*PED	Jan 17, 2019				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D</u>						
N021762 001	5358941	Dec 02, 2012	DP			
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012	DP			
	5681590*PED	Jun 02, 2013				
	5994329	Jul 17, 2018		U-647	Y	
	5994329*PED	Jan 17, 2019				
	6090410	Dec 02, 2012	DP			
	6090410*PED	Jun 02, 2013	DP			
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D</u>						
N021762 002	5358941	Dec 02, 2012	DP			
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012	DP			
	5681590*PED	Jun 02, 2013				
	6090410	Dec 02, 2012	DP			
	6090410*PED	Jun 02, 2013	DP			
<u>ALFUZOSIN HYDROCHLORIDE - UROXATRAL</u>						
N021287 001	6149940	Aug 22, 2017			M-97	Dec 15, 2013
	6149940*PED	Feb 22, 2018			PED	Jun 15, 2014
<u>ALISKIREN HEMIFUMARATE - TEKTRINA</u>						
N021985 001	5559111	Jul 21, 2018	DS DP U-3			
<u>ALISKIREN HEMIFUMARATE - TEKTRINA</u>						
N021985 002	5559111	Jul 21, 2018	DS DP U-3			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 001	5559111	Jul 21, 2018	DS DP U-3		NC	Aug 26, 2013
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 002	5559111	Jul 21, 2018	DS DP U-3		NC	Aug 26, 2013
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 003	5559111	Jul 21, 2018	DS DP U-3		NC	Aug 26, 2013
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 004	5559111	Jul 21, 2018	DS DP U-3		NC	Aug 26, 2013
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 001	5559111	Jul 21, 2018	DS DP U-3		NC	Dec 21, 2013
	8183295	May 16, 2023	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 002	5559111	Jul 21, 2018	DS DP U-3		NC	Dec 21, 2013
	8183295	May 16, 2023	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 003	5559111	Jul 21, 2018	DS DP U-3		NC	Dec 21, 2013
	8183295	May 16, 2023	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 004	5559111	Jul 21, 2018	DS DP U-3		NC	Dec 21, 2013
	8183295	May 16, 2023	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 005	5559111	Jul 21, 2018	DS DP U-3		NC	Dec 21, 2013
	8183295	May 16, 2023	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRINA HCT</u>						
N022107 001	5559111	Jul 21, 2018	DS DP U-3		I-600	Jul 16, 2012
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRINA HCT</u>						
N022107 002	5559111	Jul 21, 2018	DS DP U-3		I-600	Jul 16, 2012
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRINA HCT</u>						
N022107 003	5559111	Jul 21, 2018	DS DP U-3		I-600	Jul 16, 2012

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRONA HCT</u>						
N022107 004	5559111	Jul 21, 2018	DS DP U-3		I-600	Jul 16, 2012
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTRONA</u>						
N022217 001	5559111	Jul 21, 2018	DS DP U-3		NC	Sep 16, 2012
	8168616	Jul 05, 2025	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTRONA</u>						
N022217 002	5559111	Jul 21, 2018	DS DP U-3		NC	Sep 16, 2012
	8168616	Jul 05, 2025	DP			
<u>ALITRETINOIN - PANRETIN</u>						
N020886 001	5932622	Aug 03, 2016	U-562			
<u>ALMOTRIPTAN MALATE - AXERT</u>						
N021001 001	5565447	May 07, 2015	DS DP U-969			
	5565447*PED	Nov 07, 2015				
<u>ALMOTRIPTAN MALATE - AXERT</u>						
N021001 002	5565447	May 07, 2015	DS DP U-969			
	5565447*PED	Nov 07, 2015				
<u>ALOSETRON HYDROCHLORIDE - LOTRONEX</u>						
N021107 001	5360800	Jan 13, 2013	DS DP U-405			
	6284770	Oct 05, 2018	U-405			
<u>ALOSETRON HYDROCHLORIDE - LOTRONEX</u>						
N021107 002	5360800	Jan 13, 2013	DS DP U-405			
	6284770	Oct 05, 2018	U-405			
<u>ALPRAZOLAM - NIRAVAM</u>						
N021726 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N021726 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N021726 003	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N021726 004	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPROSTADIL - CAVERJECT</u>						
N020379 001	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT</u>						
N020379 002	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT</u>						
N020379 003	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT</u>						
N020379 004	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT IMPULSE</u>						
N021212 001	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
<u>ALPROSTADIL - CAVERJECT IMPULSE</u>						
N021212 002	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
<u>ALPROSTADIL - MUSE</u>						
N020700 001	5474535	Dec 12, 2012	U-155			
	5886039	Mar 23, 2016	DP U-155			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALPROSTADIL - MUSE</u>						
N020700 002	5474535	Dec 12, 2012	U-155			
	5886039	Mar 23, 2016	DP U-155			
<u>ALPROSTADIL - MUSE</u>						
N020700 003	5474535	Dec 12, 2012	U-155			
	5886039	Mar 23, 2016	DP U-155			
<u>ALPROSTADIL - MUSE</u>						
N020700 004	5474535	Dec 12, 2012	U-155			
	5886039	Mar 23, 2016	DP U-155			
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	5250542	Mar 29, 2016	DS DP U-878		NCE	May 20, 2013
	5434171	Dec 08, 2013	DS DP U-878			
	6469030	Nov 29, 2020	U-879			
	8112290	Jul 31, 2030	U-1225			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 001	5703017	Dec 30, 2014	DS		ODE	Jun 15, 2014
	5840722	Nov 24, 2015		U-1297		
	5840722	Nov 24, 2015		U-821		
	7109205	Oct 07, 2015	DS DP			
	7601730	Oct 07, 2015		U-1080		
	RE42462	Jul 29, 2018	DS			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 002	5703017	Dec 30, 2014	DS		ODE	Jun 15, 2014
	5840722	Nov 24, 2015		U-1297		
	5840722	Nov 24, 2015		U-821		
	7109205	Oct 07, 2015	DS DP			
	7601730	Oct 07, 2015		U-1080		
	RE42462	Jul 29, 2018	DS			
<u>AMIFOSTINE - ETHYOL</u>						
N020221 001	5424471	Jul 31, 2012				
	5591731	Jul 31, 2012				
	5994409	Dec 08, 2017	U-305			
<u>AMIFOSTINE - ETHYOL</u>						
N020221 002	5424471	Jul 31, 2012				
	5591731	Jul 31, 2012				
	5994409	Dec 08, 2017	U-305			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N020965 001	5079262	Sep 30, 2013	U-289		M-82	Mar 12, 2013
	5954703	Oct 31, 2017	U-289			
	6709446	May 01, 2018	U-289			
	7723910	Jun 17, 2019	U-289			
	8216289	May 01, 2018	U-289			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N022325 001	6869939	May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N022325 002	6869939	May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N022325 003	6869939	May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N022026 001	6828339	Nov 20, 2022	DS			
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N022026 002	6828339	Nov 20, 2022	DS			
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N022026 003	6828339	Nov 20, 2022	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 001	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 002	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 003	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 004	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 005	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 006	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 007	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018	U-552			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 008	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 009	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 010	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N021540 011	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N020364 002	6162802	Dec 19, 2017	U-367			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N020364 003	6162802	Dec 19, 2017	U-367			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N020364 004	6162802	Dec 19, 2017	U-367			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N020364 005	6162802	Dec 19, 2017	U-367			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N020364 006	6162802	Dec 19, 2017	DS DP U-185			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N020364 007	6162802	Dec 19, 2017	DS DP U-185			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N200175 001	5616599	Apr 25, 2016	DS DP U-3		NC	Jul 23, 2013
	5616599*PED	Oct 25, 2016				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N200175 002	5616599	Apr 25, 2016	DS DP U-3		NC	Jul 23, 2013
	5616599*PED	Oct 25, 2016				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N200175 003	5616599	Apr 25, 2016	DS DP U-3		NC	Jul 23, 2013
	5616599*PED	Oct 25, 2016				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N200175 004	5616599	Apr 25, 2016	DS DP U-3		NC	Jul 23, 2013
	5616599*PED	Oct 25, 2016				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N200175 005	5616599	Apr 25, 2016	DS DP U-3		NC	Jul 23, 2013
	5616599*PED	Oct 25, 2016				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 001	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 002	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 003	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 004	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 005	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N022100 001	5616599	Apr 25, 2016	DS DP U-3			
	5616599*PED	Oct 25, 2016				
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N022100 002	5616599	Apr 25, 2016	DS DP U-3			
	5616599*PED	Oct 25, 2016				
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N022100 003	5616599	Apr 25, 2016	DS DP U-3			
	5616599*PED	Oct 25, 2016				
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N022100 004	5616599	Apr 25, 2016	DS DP U-3			
	5616599*PED	Oct 25, 2016				
<u>AMLODIPINE BESYLATE; TELMISARTAN - TWYNSTA</u>						
N022401 001	5591762	Jan 07, 2014	DS DP U-3		NC	Oct 16, 2012
<u>AMLODIPINE BESYLATE; TELMISARTAN - TWYNSTA</u>						
N022401 002	5591762	Jan 07, 2014	DS DP U-3		NC	Oct 16, 2012
<u>AMLODIPINE BESYLATE; TELMISARTAN - TWYNSTA</u>						
N022401 003	5591762	Jan 07, 2014	DS DP U-3		NC	Oct 16, 2012
<u>AMLODIPINE BESYLATE; TELMISARTAN - TWYNSTA</u>						
N022401 004	5591762	Jan 07, 2014	DS DP U-3		NC	Oct 16, 2012
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N021990 002	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
	6395728	Jul 08, 2019	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N021990 003	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N021990 004	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N021990 005	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
	6395728	Jul 08, 2019	DP			
<u>AMMONIA, N-13 - AMMONIA N 13</u>						
N022119 001					NCE W	Aug 23, 2012 Aug 23, 2012
<u>AMOXICILLIN - MOXATAG</u>						
N050813 001	6544555	Oct 13, 2020	DS DP U-897			
	6669948	Oct 13, 2020	DS DP U-897			
	6723341	Oct 13, 2020	DS DP U-897			
	8299052	May 07, 2027	U-1304			
<u>AMOXICILLIN; CLAVULANATE POTASSIUM - AUGMENTIN XR</u>						
N050785 001	6746692	Apr 04, 2020	DP			
	6783773	Apr 04, 2020	DP			
	6878386	Apr 04, 2020			U-926	
	7217430	Apr 04, 2020	DP U-926			
	7250176	Apr 04, 2020	U-926			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 10</u>						
N011522 007	6384020	Jul 06, 2020				
	6384020*PED	Jan 06, 2021				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 12.5</u>						
N011522 012	6384020	Jul 06, 2020				
	6384020*PED	Jan 06, 2021				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 15</u>						
N011522 013	6384020	Jul 06, 2020				
	6384020*PED	Jan 06, 2021				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 20</u>						
N011522 008	6384020	Jul 06, 2020				
	6384020*PED	Jan 06, 2021				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 30</u>						
N011522 010	6384020	Jul 06, 2020				
	6384020*PED	Jan 06, 2021				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 5</u>						
N011522 009	6384020	Jul 06, 2020				
	6384020*PED	Jan 06, 2021				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 7.5</u>						
N011522 011	6384020	Jul 06, 2020				
	6384020*PED	Jan 06, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10</u>						
N021303 001	6322819	Oct 21, 2018				
	6322819*PED	Apr 21, 2019				
	6605300	Oct 21, 2018				
	6605300*PED	Apr 21, 2019				
	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u>						
N021303 006	6322819	Oct 21, 2018				
	6322819*PED	Apr 21, 2019				
	6605300	Oct 21, 2018				
	6605300*PED	Apr 21, 2019				
	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20</u>						
N021303 002	6322819	Oct 21, 2018				
	6322819*PED	Apr 21, 2019				
	6605300	Oct 21, 2018				
	6605300*PED	Apr 21, 2019				
	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25</u>						
N021303 004	6322819	Oct 21, 2018				
	6322819*PED	Apr 21, 2019				
	6605300	Oct 21, 2018				
	6605300*PED	Apr 21, 2019				
	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u>						
N021303 003	6322819	Oct 21, 2018				
	6322819*PED	Apr 21, 2019				
	6605300	Oct 21, 2018				
	6605300*PED	Apr 21, 2019				
	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5</u>						
N021303 005	6322819	Oct 21, 2018				
	6322819*PED	Apr 21, 2019				
	6605300	Oct 21, 2018				
	6605300*PED	Apr 21, 2019				
	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHOTERICIN B - ABELCET</u>						
N050724 001	5616334	Apr 01, 2014	DS			
	6406713	Jun 18, 2019	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
AMPHOTERICIN B - AMBISOME									
N050740	001	5874104	Feb 23, 2016	DP	U-922				
		5965156	Oct 12, 2016	DP	U-922				
AMPRENAVIR - AGENERASE									
N021007	001	5585397	Dec 17, 2013						
		5646180	Jul 08, 2014		U-257				
		5723490	Mar 03, 2015		U-257				
		6730679	Nov 11, 2017	DP					
AMPRENAVIR - AGENERASE									
N021007	002	5585397	Dec 17, 2013						
		5646180	Jul 08, 2014		U-257				
		5723490	Mar 03, 2015		U-257				
		6730679	Nov 11, 2017	DP					
AMPRENAVIR - AGENERASE									
N021039	001	5585397	Dec 17, 2013						
		5646180	Jul 08, 2014		U-257				
		5723490	Mar 03, 2015		U-257				
ANIDULAFUNGIN - ERAXIS									
N021632	001	5965525	Feb 17, 2020	DS	DP	U-540			
		6960564	Apr 12, 2021		DP	U-540			
		7709444	Apr 12, 2021		DP	U-540			
ANIDULAFUNGIN - ERAXIS									
N021632	002	5965525	Feb 17, 2020	DS	DP	U-540			
		6960564	Apr 12, 2021		DP	U-540			
		7709444	Apr 12, 2021		DP	U-540			
APIXABAN - ELIQUIS									
N202155	001						NCE	Dec 28, 2017	
APIXABAN - ELIQUIS									
N202155	002						NCE	Dec 28, 2017	
APREPITANT - EMEND									
N021549	001	5538982	Jul 23, 2013			U-745			
		5719147	Apr 17, 2015	DS	DP	U-853			
		6096742	Jul 01, 2018	DS	DP	U-745			
		7214692	Sep 18, 2012			U-853			
		8258132	Sep 26, 2027		DP	U-1282			
		8258132	Sep 26, 2027		DP	U-901			
APREPITANT - EMEND									
N021549	002	5538982	Jul 23, 2013			U-745			
		5719147	Apr 17, 2015	DS	DP	U-853			
		6096742	Jul 01, 2018	DS	DP	U-745			
		7214692	Sep 18, 2012			U-853			
		8258132	Sep 26, 2027		DP	U-1282			
		8258132	Sep 26, 2027		DP	U-901			
APREPITANT - EMEND									
N021549	003	5538982	Jul 23, 2013			U-745			
		5719147	Apr 17, 2015	DS	DP	U-853			
		6096742	Jul 01, 2018	DS	DP	U-745			
		7214692	Sep 18, 2012			U-853			
		8258132	Sep 26, 2027		DP	U-1282			
		8258132	Sep 26, 2027		DP	U-901			
ARFORMOTEROL TARTRATE - BROVANA									
N021912	001	6040344	Nov 12, 2016	DS					
		6472563	Nov 09, 2021	DS					
		6589508	Apr 03, 2013			U-793			
		6667344	Jun 22, 2021		DP				
		6720453	Nov 09, 2021	DS					
		6814953	Jun 22, 2021			U-793			
		7145036	Nov 09, 2021	DS					
		8110706	Nov 09, 2021		DP				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARGATROBAN - ACOVA</u>						
N020883 001	5214052	Jun 30, 2014				
<u>ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE</u>						
N022434 001	7589106	Sep 26, 2027	DP U-1163			
	7687516	Sep 26, 2027	DP U-1164			
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 001	5006528	Oct 20, 2014	DS DP U-761		I-633	Feb 16, 2014
	5006528*PED	Apr 20, 2015			I-616	Nov 19, 2012
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 002	5006528	Oct 20, 2014	DS DP U-761		I-633	Feb 16, 2014
	5006528*PED	Apr 20, 2015			I-616	Nov 19, 2012
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 003	5006528	Oct 20, 2014	DS DP U-761		I-633	Feb 16, 2014
	5006528*PED	Apr 20, 2015			I-616	Nov 19, 2012
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 004	5006528	Oct 20, 2014	DS DP U-761		I-633	Feb 16, 2014
	5006528*PED	Apr 20, 2015			I-616	Nov 19, 2012
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 005	5006528	Oct 20, 2014	DS DP U-761		I-633	Feb 16, 2014
	5006528*PED	Apr 20, 2015			I-616	Nov 19, 2012
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 006	5006528	Oct 20, 2014	DS DP U-761		I-633	Feb 16, 2014
	5006528*PED	Apr 20, 2015			I-616	Nov 19, 2012
<u>ARIPIRAZOLE - ABILIFY</u>						
N021713 001	5006528	Oct 20, 2014	DS DP U-761		I-633	Feb 16, 2014
	5006528*PED	Apr 20, 2015				
	6977257	Apr 24, 2022	DS DP			
	6977257*PED	Oct 24, 2022				
<u>ARIPIRAZOLE - ABILIFY</u>						
N021729 002	5006528	Oct 20, 2014	DS DP U-761		I-633	Feb 16, 2014
	5006528*PED	Apr 20, 2015				
<u>ARIPIRAZOLE - ABILIFY</u>						
N021729 003	5006528	Oct 20, 2014	DS DP U-761		I-633	Feb 16, 2014
	5006528*PED	Apr 20, 2015				
<u>ARIPIRAZOLE - ABILIFY</u>						
N021729 004	5006528	Oct 20, 2014	DS DP U-761			
	5006528*PED	Apr 20, 2015				
<u>ARIPIRAZOLE - ABILIFY</u>						
N021729 005	5006528	Oct 20, 2014	DS DP U-761			
	5006528*PED	Apr 20, 2015				
<u>ARIPIRAZOLE - ABILIFY</u>						
N021866 001	5006528	Oct 20, 2014	DS DP U-763		I-633	Feb 16, 2014
	5006528*PED	Apr 20, 2015				
	7115587	Jul 21, 2024	DS DP U-764			
	7115587*PED	Jan 21, 2025				
	7550445	Jul 21, 2024	DP			
	7550445*PED	Jan 21, 2025				
<u>ARMODAFINIL - NUVIGIL</u>						
N021875 001	7132570	Dec 18, 2023	DS DP			
	7132570*PED	Jun 18, 2024				
	7297346	Nov 29, 2023	DP			
	7297346*PED	May 29, 2024				
	RE37516	Oct 06, 2014	DP U-820			
	RE37516*PED	Apr 06, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARMODAFINIL - NUVIGIL</u>						
N021875 002	7132570	Dec 18, 2023	DS DP			
	7132570*PED	Jun 18, 2024				
	7297346	Nov 29, 2023	DP			
	7297346*PED	May 29, 2024				
	RE37516	Oct 06, 2014	DP U-820			
	RE37516*PED	Apr 06, 2015				
<u>ARMODAFINIL - NUVIGIL</u>						
N021875 003	7132570	Dec 18, 2023	DS DP			
	7132570*PED	Jun 18, 2024				
	7297346	Nov 29, 2023	DP			
	7297346*PED	May 29, 2024				
	RE37516	Oct 06, 2014	DP U-820			
	RE37516*PED	Apr 06, 2015				
<u>ARMODAFINIL - NUVIGIL</u>						
N021875 004	7132570	Dec 18, 2023	DS DP			
	7132570*PED	Jun 18, 2024				
	7297346	Nov 29, 2023	DP			
	7297346*PED	May 29, 2024				
	RE37516	Oct 06, 2014	DP U-820			
	RE37516*PED	Apr 06, 2015				
<u>ARMODAFINIL - NUVIGIL</u>						
N021875 005	7132570	Dec 18, 2023	DS DP			
	7132570*PED	Jun 18, 2024				
	7297346	Nov 29, 2023	DP			
	7297346*PED	May 29, 2024				
	RE37516	Oct 06, 2014	DP U-820			
	RE37516*PED	Apr 06, 2015				
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N021248 001	6723351	Nov 10, 2018			U-573	
	6855339	Nov 10, 2018			U-617	
	6861076	Nov 10, 2018			U-617	
	6884439	Nov 10, 2018			U-651	
	6982096	Nov 10, 2018			U-651	
	8273379	Nov 10, 2018			U-1291	
<u>ARTEMETHER; LUMEFANTRINE - COARTEM</u>						
N022268 001	5677331	Oct 14, 2014	DP U-977		NCE	Apr 07, 2014
					ODE	Apr 07, 2016
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP</u>						
N021881 001	7169381	Sep 01, 2024	DS DP			
	7658914	Sep 01, 2024	DS DP			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N022117 001	5763476	Jun 09, 2015	DP U-326		I-629	Sep 03, 2013
	7741358	Apr 06, 2026	DS DP U-1064		I-628	Sep 03, 2013
					NCE	Aug 13, 2014
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N022117 002	5763476	Jun 09, 2015	DP U-326		I-629	Sep 03, 2013
	7741358	Apr 06, 2026	DS DP U-1064		I-628	Sep 03, 2013
					NCE	Aug 13, 2014
<u>ASPIRIN; DIPYRIDAMOLE - AGGRENOL</u>						
N020884 001	6015577	Jan 18, 2017	U-302			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N021387 001	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N021387 002	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N021387 003	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N021387 004	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N021387 005	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>ASPIRIN; PRAVASTATIN SODIUM - PRAVIGARD PAC (COPACKAGED)</u>						
N021387 006	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 001	5849911	Jun 20, 2017	DS DP U-167		D-130	Feb 04, 2014
	6087383	Dec 21, 2018	DS DP			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 002	5849911	Jun 20, 2017	DS DP U-167		D-130	Feb 04, 2014
	6087383	Dec 21, 2018	DS DP			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 003	5849911	Jun 20, 2017	DS DP U-167		D-130	Feb 04, 2014
	6087383	Dec 21, 2018	DS DP			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 004	5849911	Jun 20, 2017	DS DP U-167		D-130	Feb 04, 2014
	6087383	Dec 21, 2018	DS DP			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 001	5658590	Nov 26, 2016	U-494			
	5658590*PED	May 26, 2017	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 002	5658590	Nov 26, 2016	U-494			
	5658590*PED	May 26, 2017	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 003	5658590	Nov 26, 2016	U-494			
	5658590*PED	May 26, 2017	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 004	5658590	Nov 26, 2016	U-494			
	5658590*PED	May 26, 2017	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 005	5658590	Nov 26, 2016	U-494			
	5658590*PED	May 26, 2017	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 006	5658590	Nov 26, 2016	U-494			
	5658590*PED	May 26, 2017	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 007	5658590	Nov 26, 2016	U-494			
	5658590*PED	May 26, 2017	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N021411 008	5658590	Nov 26, 2016	U-494			
	5658590*PED	May 26, 2017	U-494			
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N020702 001	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015	U-213			
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N020702 002	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015	U-213			
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N020702 003	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015	U-213			
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N020702 004	5686104	Nov 11, 2014	DP U-213			
	5686104*PED	May 11, 2015	U-213			
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	6126971	Jan 19, 2013	DP			
	6126971*PED	Jul 19, 2013				
<u>ATOVAQUONE - MEPRON</u>						
N020500 001	6649659	Jul 10, 2016	DS DP U-69			
	6649659*PED	Jan 10, 2017				
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - MALARONE</u>						
N021078 001	5998449	Nov 25, 2013	U-990			
	5998449*PED	May 25, 2014				
	6166046	Nov 25, 2013	U-406			
	6166046*PED	May 25, 2014				
	6291488	Nov 25, 2013	U-406			
	6291488*PED	May 25, 2014				
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - MALARONE PEDIATRIC</u>						
N021078 002	5998449	Nov 25, 2013	U-990			
	5998449*PED	May 25, 2014				
	6166046	Nov 25, 2013				
	6166046*PED	May 25, 2014				
	6291488	Nov 25, 2013	U-406			
	6291488*PED	May 25, 2014				
<u>AVANAFIL - STENDRA</u>						
N202276 001	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
	7501409	May 05, 2023	DP			
<u>AVANAFIL - STENDRA</u>						
N202276 002	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
	7501409	May 05, 2023	DP			
<u>AVANAFIL - STENDRA</u>						
N202276 003	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
	7501409	May 05, 2023	DP			
<u>AVOBENZONE; ECAMSULE; OCTOCRYLENE - ANTHELIOS SX</u>						
N021502 001	5587150	Dec 24, 2013	DP U-752			
<u>AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE - ANTHELIOS 40</u>						
N022009 002					NP	Oct 29, 2012
<u>AXITINIB - INLYTA</u>						
N202324 001	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AXITINIB - INLYTA</u>						
N202324 002	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZELAIC ACID - FINACEA</u>						
N021470 001	6534070	Nov 18, 2018				
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N022203 001	8071073	Jun 04, 2028	DP			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N022371 001	8071073	Jun 04, 2028	DP		NP	Aug 31, 2012
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N202236 001	8163723	Aug 29, 2023	U-707		NC	May 01, 2015
	8163723	Aug 29, 2023	U-77			
	8163723	Aug 29, 2023	U-644			
	8163723	Aug 29, 2023	U-81			
	8168620	Feb 24, 2026	DP			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N200796 001	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N200796 002	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 001	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	7157584	May 22, 2025	DS		NC	Dec 20, 2014
	7572920	Jan 07, 2025	DP U-3			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 002	5583141	Dec 10, 2013	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZITHROMYCIN - AZASITE</u>						
N050810 001	6159458	Nov 04, 2017	DP U-709			
	6239113	Mar 31, 2019	U-709			
	6569443	Mar 31, 2019	DP U-709			
	6861411	Nov 25, 2018	U-709			
	7056893	Mar 31, 2019	DP U-709			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050693 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050710 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050710 002	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050711 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050730 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050733 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N050784 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZMAX</u>						
N050797 001	6068859	May 30, 2017	DP			
	6268489	Jul 31, 2018	DS			
	6984403	Feb 14, 2024	DP U-282			
	7887844	Feb 14, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZTREONAM - CAYSTON</u>						
N050814 001	7208141	Dec 20, 2021	DP U-1031		ODE	Feb 22, 2017
	7214364	Dec 20, 2021	DP			
	7427633	Dec 20, 2021	DP U-1031			
<u>BACLOFEN - KEMSTRO</u>						
N021589 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>BACLOFEN - KEMSTRO</u>						
N021589 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>BALSALAZIDE DISODIUM - COLAZAL</u>						
N020610 001	7452872	Aug 24, 2026	U-141		ODE	Dec 20, 2013
	7452872*PED	Feb 24, 2027			PED	Jun 20, 2014
	7625884	Aug 24, 2026	U-141			
	7625884*PED	Feb 24, 2027				
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N022205 001	6197341	Mar 13, 2018	DP U-1229		NDF	Feb 03, 2015
	7452872	Aug 24, 2026	U-1229			
	7625884	Aug 24, 2026	U-1229			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N202813 001	5605674	Feb 25, 2014	DP		NP	Mar 23, 2015
	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP			
	7780038	Jan 24, 2027	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N020911 002	5605674	Feb 25, 2014				
	5683677	Nov 04, 2014				
	5776432	Jul 07, 2015				
<u>BECLOMETHASONE DIPROPIONATE - QVAR 80</u>						
N020911 001	5605674	Feb 25, 2014				
	5683677	Nov 04, 2014				
	5776432	Jul 07, 2015				
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N204384 001					NCE	Dec 28, 2017
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 001					NCE	Mar 20, 2013
					ODE	Mar 20, 2015
					PED	Sep 20, 2013
					PED	Sep 20, 2015
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 002					NCE	Mar 20, 2013
					ODE	Mar 20, 2015
					PED	Sep 20, 2013
					PED	Sep 20, 2015
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N050819 001	5733886	Mar 31, 2015	DP U-124			
	8288434	Aug 05, 2029	DP U-124			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - DUAC</u>						
N050741 001	5466446	Feb 16, 2014	DS DP			
<u>BENZYL ALCOHOL - ULESFIA</u>						
N022129 001	5858383	Aug 11, 2017	U-970		NCE	Apr 09, 2014
	6139859	Aug 11, 2017	U-970			
	6793931	Jul 11, 2022	DP U-970			
	7294342	May 19, 2024	U-970			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N022288 001	6780877	Dec 25, 2017	DS DP		NCE	Sep 08, 2014
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N022308 001	5447926	Apr 13, 2016	DS DP U-80		NCE	May 28, 2014
	6685958	Jun 29, 2021	DP U-80			
	6699492	Mar 31, 2019	DP U-80			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N021852 001	5763426	Jun 09, 2015	DS DP			
	6753013	Jan 27, 2020	DP U-193			
	6753013	Jan 27, 2020	DP U-88			
	RE39706	Jun 09, 2015	DS DP			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N022185 001	6753013	Jan 27, 2020	DP U-88		I-659	Oct 17, 2015
	6753013	Jan 27, 2020	DP U-193			
	6787529	Jan 27, 2020	DP U-193			
	6787529	Jan 27, 2020	DP U-88			
	RE39706	Jun 09, 2015	DS DP			
<u>BETAMETHASONE VALERATE - LUXIQ</u>						
N020934 001	6126920	Mar 01, 2016		U-484		
	7078058	May 24, 2017	DP			
<u>BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE - BETOPTIC PILO</u>						
N020619 001	5635172	Jun 03, 2014		U-191		
<u>BEXAROTENE - TARGRETIN</u>						
N021055 001	5780676	Jul 14, 2015		U-509		
	5962731	Oct 05, 2016		U-475		
<u>BEXAROTENE - TARGRETIN</u>						
N021056 001	5780676	Jul 14, 2015		U-510		
	5962731	Oct 05, 2016				
<u>BIMATOPROST - LATISSE</u>						
N022369 001	6403649	Sep 21, 2012	DS			
	7351404	May 25, 2024		U-939		
	7388029	Jan 21, 2022		U-938		
	8017655	Nov 27, 2012	DS DP			
	8038988	Aug 25, 2023	DS DP	U-1208		
	8101161	May 25, 2024		U-1218		
	8101161	May 25, 2024		U-1217		
	8263054	Aug 25, 2023		U-1277		
<u>BIMATOPROST - LUMIGAN</u>						
N021275 001	5688819	Aug 19, 2014		U-446		
	6403649	Sep 21, 2012	DS DP	U-446		
	8017655	Nov 27, 2012	DS DP			
<u>BIMATOPROST - LUMIGAN</u>						
N022184 001	5688819	Aug 19, 2014		U-1081	NP	Aug 31, 2013
	6403649	Sep 21, 2012	DS	U-1081		
	7851504	Jun 13, 2027	DS DP			
	8017655	Nov 27, 2012	DS DP			
	8278353	Mar 16, 2025	DP			
	8299118	Mar 16, 2025		U-1295		
	8309605	Mar 16, 2025		U-1293		
	8309605	Mar 16, 2025		U-1294		
	8338479	Mar 16, 2025	DP	U-1295		
<u>BISACODYL - HALFLYTELY</u>						
N021551 003	7291324	Oct 22, 2022		U-837	NP	Jul 16, 2013
<u>BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - HALFLYTELY</u>						
N021551 002	7291324	Oct 22, 2022		U-837		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE - PYLERA</u>						
N050786 001	6350468	Dec 14, 2018	U-932			
	6350468	Dec 14, 2018	U-956			
<u>BIVALIRUDIN - ANGIOMAX</u>						
N020873 001	5196404	Dec 15, 2014	DS DP U-1040			
	5196404	Dec 15, 2014	DS DP U-1232			
	5196404*PED	Jun 15, 2015				
	7582727	Jul 27, 2028	DP			
	7582727*PED	Jan 27, 2029				
	7598343	Jul 27, 2028	DP			
	7598343*PED	Jan 27, 2029				
<u>BOCEPREVIR - VICTRELIS</u>						
N202258 001	7772178	Nov 11, 2027	DP U-1128		NCE	May 13, 2016
	8119602	Mar 17, 2027	U-1233			
	RE43298	Feb 22, 2022	DS DP U-1128			
<u>BORTEZOMIB - VELCADE</u>						
N021602 001	5780454	May 03, 2017	DP		NR	Jan 23, 2015
	6083903	Oct 28, 2014	DP U-515			
	6297217	Oct 28, 2014	U-885			
	6297217	Oct 28, 2014	U-884			
	6297217	Oct 28, 2014	U-515			
	6617317	Oct 28, 2014	DS DP			
	6713446	Jan 25, 2022	DP			
	6747150	Oct 28, 2014	DP			
	6958319	Jan 25, 2022	DP			
	7119080	Oct 28, 2014	DP			
<u>BOSENTAN - TRACLEER</u>						
N021290 001	5292740	Nov 20, 2015			I-607	Aug 07, 2012
<u>BOSENTAN - TRACLEER</u>						
N021290 002	5292740	Nov 20, 2015			I-607	Aug 07, 2012
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N203341 001	6002008	Mar 27, 2018	DS DP U-1284		NCE	Sep 04, 2017
	7417148	Jan 23, 2026	U-1283		ODE	Sep 04, 2019
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Sep 24, 2019	DS			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N203341 002	6002008	Mar 27, 2018	DS DP U-1284		NCE	Sep 04, 2017
	7417148	Jan 23, 2026	U-1283		ODE	Sep 04, 2019
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Sep 24, 2019	DS			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N021262 001	5424078*PED	Dec 13, 2012				
	6562873	Jul 10, 2021				
	6562873*PED	Jan 10, 2022				
	6627210	Jul 18, 2021	DP			
	6627210*PED	Jan 18, 2022				
	6641834	Jul 28, 2021	DP			
	6641834*PED	Jan 28, 2022				
	6673337	Jul 26, 2021	DP			
	6673337*PED	Jan 26, 2022				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N021770 001	5424078*PED	Dec 13, 2012				
	6562873	Jul 10, 2021	DP			
	6562873*PED	Jan 10, 2022				
	6627210	Jul 18, 2021	DP			
	6627210*PED	Jan 18, 2022				
	6641834	Jul 28, 2021	DP			
	6641834*PED	Jan 28, 2022				
	6673337	Jul 26, 2021	DP			
	6673337*PED	Jan 26, 2022				
<u>BRIMONIDINE TARTRATE - BRIMONIDINE TARTRATE</u>						
N021764 001	7265117	Aug 19, 2025	DP			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N021398 001	7030149	Apr 19, 2022			U-849	
	7320976	Apr 19, 2022			U-849	
	7323463	Jan 19, 2023				
	7642258	Apr 19, 2022	DS DP		U-1024	
	8133890	Apr 19, 2022			U-1235	
<u>BRINZOLAMIDE - AZOPT</u>						
N020816 001	5378703*PED	Oct 01, 2012				
	5461081	Oct 24, 2012	DP		U-225	
	5461081*PED	Apr 24, 2013				
<u>BROMFENAC SODIUM - BROMDAY</u>						
N021664 002					NP	Oct 16, 2013
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N020866 001	5468755	Nov 21, 2012			U-976	
	5679685	Oct 21, 2014	DP			
	5716957	Feb 10, 2015			U-976	
	5756513	Nov 21, 2012			U-976	
	5866584	Nov 21, 2012			U-976	
	7888310	Jul 25, 2023			U-976	
<u>BUDESONIDE - ENTOCORT EC</u>						
N021324 001	5643602	Jul 01, 2014			U-655	
	5643602*PED	Jan 01, 2015	DP			
<u>BUDESONIDE - PULMICORT FLEXHALER</u>						
N021949 001	6027714	Jan 09, 2018	DP		U-787	
	6142145	May 08, 2018	DP			
	6287540	Jan 09, 2018	DP			
	7143764	Mar 13, 2018	DP			
<u>BUDESONIDE - PULMICORT FLEXHALER</u>						
N021949 002	6027714	Jan 09, 2018	DP		U-787	
	6142145	May 08, 2018	DP			
	6287540	Jan 09, 2018	DP			
	7143764	Mar 13, 2018	DP			
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N020929 001	6598603	Dec 23, 2018			U-529	
	6598603*PED	Jun 23, 2019				
	6899099	Dec 23, 2018			U-529	
	6899099*PED	Jun 23, 2019				
	7524834	Nov 11, 2018	DP		U-966	
	7524834*PED	May 11, 2019				
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N020929 002	6598603	Dec 23, 2018			U-529	
	6598603*PED	Jun 23, 2019				
	6899099	Dec 23, 2018			U-529	
	6899099*PED	Jun 23, 2019				
	7524834	Nov 11, 2018	DP		U-966	
	7524834*PED	May 11, 2019				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N020929 003	6598603	Dec 23, 2018	U-529			
	6598603*PED	Jun 23, 2019				
	6899099	Dec 23, 2018	U-529			
	6899099*PED	Jun 23, 2019				
	7524834	Nov 11, 2018	DP U-966			
	7524834*PED	May 11, 2019				
<u>BUDESONIDE - RHINOCORT</u>						
N020746 001	6291445	Apr 29, 2017		Y		
	6291445*PED	Oct 29, 2017				
	6686346	Apr 29, 2017	DP U-557	Y		
	6686346*PED	Oct 29, 2017				
	6986904	Apr 29, 2017	DP U-699	Y		
	6986904*PED	Oct 29, 2017				
<u>BUDESONIDE - RHINOCORT</u>						
N020746 002	6291445	Apr 29, 2017				
	6291445*PED	Oct 29, 2017				
	6686346	Apr 29, 2017	DP U-557			
	6686346*PED	Oct 29, 2017				
	6986904	Apr 29, 2017	DP U-699			
	6986904*PED	Oct 29, 2017				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	5674860	Oct 07, 2014	DP U-1075			
	5972919	Dec 17, 2012	DP U-1075			
	6123924	Sep 26, 2017	DP			
	6641800	Sep 23, 2012	DP			
	7367333	Nov 11, 2018	DP			
	7587988	Apr 10, 2026	DP			
	7759328	Jan 29, 2023	DP U-1073			
	7967011	Aug 11, 2021	DP			
	8143239	Jan 29, 2023	DP U-1073			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	5674860	Oct 07, 2014	DP U-1075			
	5972919	Dec 17, 2012	DP U-1075			
	6123924	Sep 26, 2017	DP			
	6641800	Sep 23, 2012	DP			
	7367333	Nov 11, 2018	DP			
	7587988	Apr 10, 2026	DP			
	7759328	Jan 29, 2023	DP U-1073			
	7897646	Sep 09, 2018	U-1118			
	7967011	Aug 11, 2021	DP			
	8143239	Jan 29, 2023	DP U-1073			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 001	6132766	Nov 16, 2013	DP		NP	Oct 28, 2014
	8182835	Sep 18, 2018	DP U-1246			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 002	6132766	Nov 16, 2013	DP		NP	Oct 28, 2014
	8182835	Sep 18, 2018	DP U-1246			
<u>BUPRENORPHINE - BUTRANS</u>						
N021306 001	6264980	Dec 18, 2015	DP		NDF	Jun 30, 2013
	6344211	Dec 18, 2015	U-1072			
	RE41408	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1072			
<u>BUPRENORPHINE - BUTRANS</u>						
N021306 002	6264980	Dec 18, 2015	DP		NDF	Jun 30, 2013
	6344211	Dec 18, 2015	U-1072			
	RE41408	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1072			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - BUTRANS</u>						
N021306 003	6264980	Dec 18, 2015	DP		NDF	Jun 30, 2013
	6344211	Dec 18, 2015	U-1072			
	RE41408	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1072			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 001	8017150	Feb 13, 2023	DP		NDF	Aug 30, 2013
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 002	8017150	Feb 13, 2023	DP		NDF	Aug 30, 2013
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 003	8017150	Feb 13, 2023	DP		NDF	Aug 30, 2013
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 004	8017150	Feb 13, 2023	DP		NDF	Aug 30, 2013
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N022108 001	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N022108 002	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N022108 003	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROCHLORIDE - FORFIVO XL</u>						
N022497 001	7674479	Jun 25, 2027	DP			
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN SR</u>						
N020358 001	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN SR</u>						
N020358 002	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN SR</u>						
N020358 003	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN SR</u>						
N020358 004	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN XL</u>						
N021515 001	6096341	Oct 30, 2018				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN XL</u>						
N021515 002	6096341	Oct 30, 2018				
<u>BUPROPION HYDROCHLORIDE - ZYBAN</u>						
N020711 002	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUPROPION HYDROCHLORIDE - ZYBAN</u>						
N020711 003	5358970	Aug 12, 2013				
	5427798	Aug 12, 2013				
	5731000	Aug 12, 2013				
	5763493	Aug 12, 2013				
<u>BUSULFAN - BUSULFEX</u>						
N020954 001	5430057	Sep 30, 2013		U-263		
	5430057*PED	Mar 30, 2014		U-263		
	5559148	Sep 30, 2013		U-264		
	5559148*PED	Mar 30, 2014		U-264		
<u>BUTOCONAZOLE NITRATE - BUTOCONAZOLE NITRATE</u>						
A200923 001					PC	May 14, 2013
<u>BUTOCONAZOLE NITRATE - GYNAZOLE-1</u>						
N019881 001	5993856	Nov 17, 2017	DP	U-457		
<u>CABAZITAXEL - JEVTANA KIT</u>						
N201023 001	5438072	Nov 22, 2013	DP		NCE	Jun 17, 2015
	5698582	Jul 03, 2012	DP			
	5847170	Mar 26, 2016	DS	DP		
	6331635	Mar 26, 2016	DS	DP		
	6372780	Mar 26, 2016		U-1067		
	6387946	Mar 26, 2016		U-1067		
	7241907	Dec 10, 2025	DS			
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N203756 001	7579473	Sep 24, 2024	DS	DP	NCE	Nov 29, 2017
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N203756 002	7579473	Sep 24, 2024	DS	DP	NCE	Nov 29, 2017
<u>CALCIPOTRIENE - DOVONEX</u>						
N020554 001	5763426	Jun 09, 2015	DS	DP		
	RE39706	Jun 09, 2015	DS	DP		
<u>CALCIPOTRIENE - DOVONEX</u>						
N020611 001	5763426	Jun 09, 2015	DS	DP		
	RE39706	Jun 09, 2015	DS	DP		
<u>CALCIPOTRIENE - SORILUX</u>						
N022563 001	8263580	May 26, 2026	DP	U-1280	I-657 NDF	Sep 27, 2015 Oct 06, 2013
<u>CALCITONIN SALMON - MIACALCIN</u>						
N020313 002	5733569	Mar 31, 2015		U-227		
	5759565	Mar 31, 2015				
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N021406 001	6440392	Feb 02, 2021	DP	U-227		
	RE40812	Feb 02, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCITRIOL - CALCIJEX</u>						
N018874 001	6051567	Aug 02, 2019				
	6051567*PED	Feb 02, 2020				
	6265392	Aug 02, 2019				
	6265392*PED	Feb 02, 2020				
	6274169	Aug 02, 2019				
	6274169*PED	Feb 02, 2020				
<u>CALCITRIOL - CALCIJEX</u>						
N018874 002	6051567	Aug 02, 2019				
	6051567*PED	Feb 02, 2020				
	6265392	Aug 02, 2019				
	6265392*PED	Feb 02, 2020				
	6274169	Aug 02, 2019				
	6274169*PED	Feb 02, 2020				
<u>CALCIUM ACETATE - PHOSLO</u>						
N021160 002	6576665	Apr 03, 2021				
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N021160 003	6576665	Apr 03, 2021				
<u>CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPICID COMPLETE</u>						
N020958 001	5229137*PED	Nov 16, 2012				
	5989588	Sep 30, 2015			U-349	
	5989588*PED	Mar 30, 2016			U-349	
	6814978	Aug 26, 2021	DP			
	6814978*PED	Feb 26, 2022				
<u>CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)</u>						
N021823 001	5583122	Dec 10, 2013	DS DP		U-353	
	5583122*PED	Jun 10, 2014				
	5994329	Jul 17, 2018			U-353	
	5994329*PED	Jan 17, 2019				
	6015801	Jul 17, 2018			U-353	
	6015801*PED	Jan 17, 2019				
	6165513	Jun 10, 2018		DP		
	6165513*PED	Dec 10, 2018				
	6432932	Jul 17, 2018			U-595	
	6432932*PED	Jan 17, 2019				
	6465443	Aug 14, 2018	DP			
	6465443*PED	Feb 14, 2019				
<u>CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - NAVSTEL</u>						
N022193 001	7084130	Nov 29, 2021		DP	U-891	
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
N020838 001	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013		DP		
	5534534*PED	Jan 09, 2014				
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
N020838 002	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013		DP		
	5534534*PED	Jan 09, 2014				
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
N020838 003	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013		DP		
	5534534*PED	Jan 09, 2014				
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
N020838 004	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013		DP		
	5534534*PED	Jan 09, 2014				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
N021093 001	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013	DP			
	5534534*PED	Jan 09, 2014				
	5721263	Feb 24, 2015	DP U-3			
	5958961	Jun 06, 2014	DP U-3			
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
N021093 002	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013	DP			
	5534534*PED	Jan 09, 2014				
	5721263	Feb 24, 2015	DP U-3			
	5958961	Jun 06, 2014	DP U-3			
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
N021093 003	5196444*PED	Dec 04, 2012				
	5534534	Jul 09, 2013	DP			
	5534534*PED	Jan 09, 2014				
	5721263	Feb 24, 2015	DP U-3			
	5958961	Jun 06, 2014	DP U-3			
<u>CAPECITABINE - XELODA</u>						
N020896 001	5472949	Dec 14, 2013				
					U-271	
<u>CAPECITABINE - XELODA</u>						
N020896 002	5472949	Dec 14, 2013				
					U-271	
<u>CAPSAICIN - QUTENZA</u>						
N022395 001	6239180	Nov 06, 2016	DP		NCE	Nov 16, 2014
					ODE	Nov 16, 2016
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 001	5912013	Jun 15, 2016				
					U-277	
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 002	5912013	Jun 15, 2016				
					U-277	
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 003	5912013	Jun 15, 2016				
					U-277	
<u>CARBAMAZEPINE - EQUETRO</u>						
N021710 001	5912013	Jun 15, 2016	DP			
	6977253	May 19, 2024			U-693	
<u>CARBAMAZEPINE - EQUETRO</u>						
N021710 002	5912013	Jun 15, 2016	DP			
	6977253	May 19, 2024			U-693	
<u>CARBAMAZEPINE - EQUETRO</u>						
N021710 003	5912013	Jun 15, 2016	DP			
	6977253	May 19, 2024			U-693	
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100</u>						
N021485 002	5446194	Oct 19, 2013	DS			
	6500867	Jun 29, 2020	DP		U-219	
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 125</u>						
N021485 006	5446194	Oct 19, 2013	DS			
	6500867	Jun 29, 2020	DP		U-219	
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150</u>						
N021485 003	5446194	Oct 19, 2013	DS			
	6500867	Jun 29, 2020	DP		U-219	
	6797732	Jun 29, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 200</u>						
N021485 004	5446194	Oct 19, 2013	DS			
	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50</u>						
N021485 001	5446194	Oct 19, 2013	DS			
	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 75</u>						
N021485 005	5446194	Oct 19, 2013	DS			
	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N202714 001	7232818	Apr 14, 2025	DS DP		NCE	Jul 20, 2017
	7417042	Jun 07, 2026	DS DP		ODE	Jul 20, 2019
	7491704	Apr 14, 2025		U-1260		
	7737112	Dec 07, 2027	DP			
	8129346	Dec 25, 2026		U-1260		
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025		U-1260		
	8207297	Apr 14, 2025	DS DP			
<u>CARGLUMIC ACID - CARBAGLU</u>						
N022562 001					NCE	Mar 18, 2015
					ODE	Mar 18, 2017
<u>CARVEDILOL - COREG</u>						
N020297 001	RE40000	Jun 07, 2015		U-233		
	RE40000*PED	Dec 07, 2015				
<u>CARVEDILOL - COREG</u>						
N020297 002	RE40000	Jun 07, 2015		U-233		
	RE40000*PED	Dec 07, 2015				
<u>CARVEDILOL - COREG</u>						
N020297 003	RE40000	Jun 07, 2015		U-233		
	RE40000*PED	Dec 07, 2015				
<u>CARVEDILOL - COREG</u>						
N020297 004	RE40000	Jun 07, 2015		U-233		
	RE40000*PED	Dec 07, 2015				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 001	6022562	Oct 17, 2015	DP		Y	
	6022562*PED	Apr 17, 2016				
	7268156	Jun 27, 2023	DS DP U-313			
	7268156	Jun 27, 2023	DS DP U-3			
	7268156*PED	Dec 27, 2023				
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
	RE40000	Jun 07, 2015		U-777		
	RE40000*PED	Dec 07, 2015				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 002	6022562	Oct 17, 2015	DP		Y	
	6022562*PED	Apr 17, 2016				
	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	7268156*PED	Dec 27, 2023				
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
	RE40000	Jun 07, 2015		U-777		
	RE40000*PED	Dec 07, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 003	6022562	Oct 17, 2015	DP	Y		
	6022562*PED	Apr 17, 2016				
	7268156	Jun 27, 2023	DS DP U-313			
	7268156	Jun 27, 2023	DS DP U-3			
	7268156*PED	Dec 27, 2023				
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
	RE40000	Jun 07, 2015	U-777			
	RE40000*PED	Dec 07, 2015				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 004	6022562	Oct 17, 2015	DP	Y		
	6022562*PED	Apr 17, 2016				
	7268156	Jun 27, 2023	DS DP U-313			
	7268156	Jun 27, 2023	DS DP U-3			
	7268156*PED	Dec 27, 2023				
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
	RE40000	Jun 07, 2015	U-777			
	RE40000*PED	Dec 07, 2015				
<u>CASPOFUNGIN ACETATE - CANCIDAS</u>						
N021227 001	5378804	Mar 16, 2013	DS			
	5378804*PED	Sep 16, 2013				
	5514650	Jan 26, 2015	DP U-607			
	5514650*PED	Jul 26, 2015				
	5792746	Mar 16, 2013	DS DP U-607			
	5792746*PED	Sep 16, 2013				
	5952300	Mar 28, 2017	DP			
	5952300*PED	Sep 28, 2017				
	6136783	Mar 28, 2017	U-607			
	6136783*PED	Sep 28, 2017				
<u>CASPOFUNGIN ACETATE - CANCIDAS</u>						
N021227 002	5378804	Mar 16, 2013	DS			
	5378804*PED	Sep 16, 2013				
	5514650	Jan 26, 2015	DP U-607			
	5514650*PED	Jul 26, 2015				
	5792746	Mar 16, 2013	DS DP U-607			
	5792746*PED	Sep 16, 2013				
	5952300	Mar 28, 2017	DP			
	5952300*PED	Sep 28, 2017				
	6136783	Mar 28, 2017	U-607			
	6136783*PED	Sep 28, 2017				
<u>CEFditoren Pivoxil - Spectracef</u>						
N021222 001	5958915	Oct 14, 2016				
<u>CEFditoren Pivoxil - Spectracef</u>						
N021222 002	5958915	Oct 14, 2016	DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N200327 001	6417175	Dec 17, 2018	DS DP U-282		NCE	Oct 29, 2015
	6906055	Dec 15, 2021	DS DP			
	7419973	Dec 15, 2021	DP			
	8247400	Feb 10, 2031	DP U-282			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N200327 002	6417175	Dec 17, 2018	DS DP U-282		NCE	Oct 29, 2015
	6906055	Dec 15, 2021	DS DP			
	7419973	Dec 15, 2021	DP			
	8247400	Feb 10, 2031	DP U-282			
<u>CEFTIBUTEN DIHYDRATE - CEDAX</u>						
N050685 002	5599557	Apr 30, 2013	DP			
<u>CEFTIBUTEN DIHYDRATE - CEDAX</u>						
N050686 001	5599557	Feb 04, 2014	DP U-282			
	5599557	Feb 04, 2014	DP U-578			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CEFTIBUTEN DIHYDRATE - CEDAX</u>						
N050686 002	5599557	Feb 04, 2014	DP U-578			
	5599557	Feb 04, 2014	DP U-282			
<u>CELECOXIB - CELEBREX</u>						
N020998 001	5466823	Nov 30, 2013	DS			
	5466823*PED	May 30, 2014				
	5563165	Nov 30, 2013	DP			
	5563165*PED	May 30, 2014				
	5760068	Jun 02, 2015			U-672	
	5760068*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N020998 002	5466823	Nov 30, 2013	DS			
	5466823*PED	May 30, 2014				
	5563165	Nov 30, 2013	DP			
	5563165*PED	May 30, 2014				
	5760068	Jun 02, 2015			U-672	
	5760068*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N020998 003	5466823	Nov 30, 2013	DS			
	5466823*PED	May 30, 2014				
	5563165	Nov 30, 2013	DP			
	5563165*PED	May 30, 2014				
	5760068	Jun 02, 2015			U-672	
	5760068*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N020998 004	5466823	Nov 30, 2013	DS			
	5466823*PED	May 30, 2014				
	5563165	Nov 30, 2013	DP			
	5563165*PED	May 30, 2014				
	5760068	Jun 02, 2015			U-672	
	5760068*PED	Dec 02, 2015				
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC ALLERGY</u>						
N021621 003	6455533	Jul 02, 2018	DP U-295			
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC ALLERGY</u>						
N021621 004	6455533	Jul 02, 2018	DP U-295			
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC HIVES RELIEF</u>						
N021621 005	6455533	Jul 02, 2018	DP U-295			
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC HIVES RELIEF</u>						
N021621 006	6455533	Jul 02, 2018	DP U-295			
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR</u>						
N021150 002	6469009	Jul 13, 2019	DP U-295			
	6489329	Apr 08, 2016	DP			
	7014867	Jun 10, 2022	DP			
	7226614	Jun 10, 2022			U-295	
<u>CETRORELIX - CETROTIDE</u>						
N021197 001	6319192	Apr 23, 2019			U-426	
	6863891	Feb 22, 2014			U-426	
	7605121	Feb 22, 2014	DP			
<u>CETRORELIX - CETROTIDE</u>						
N021197 002	6319192	Apr 23, 2019			U-426	
	6863891	Feb 22, 2014			U-426	
	7605121	Feb 22, 2014	DP			
<u>CEVIMELINE HYDROCHLORIDE - CEVIMELINE</u>						
A091260 001					PC	Apr 06, 2013
<u>CEVIMELINE HYDROCHLORIDE - EVOXAC</u>						
N020989 002	5340821	Jul 07, 2013	U-309			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N021669 001	7066916	Feb 17, 2024			U-737	
	7427574	Apr 25, 2026	DP			
	7595021	May 12, 2023	DP		U-1022	
	7717889	Feb 27, 2025	DP		U-1022	
	7935093	Oct 02, 2027	DP		U-1022	
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N020832 001	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N020832 004	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N020832 006	5690958	Sep 30, 2016	DP			
	6991394	Jan 31, 2024	DP			
	7182536	Dec 30, 2023	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP FREPP</u>						
N020832 003	5538353	Aug 25, 2015	DP			
	5690958	Sep 30, 2016	DP			
	5752363	Apr 22, 2017	DP			
	5772346	Apr 22, 2017	DP			
	D396911	Aug 11, 2012	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP SEPP</u>						
N021555 001	5690958	Sep 30, 2016	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N020832 002	5690958	Sep 30, 2016	DP			
	6729786	Mar 14, 2023	DP			
	6991393	Mar 14, 2023	DP			
	6991394	Jan 31, 2024	DP			
	7182536	Dec 30, 2023	DP			
	7241065	Mar 14, 2023	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N020832 005	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
	6729786	Mar 14, 2023	DP			
	6991393	Jan 31, 2024	DP			
	7241065	Mar 14, 2023	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N020832 007	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
	6729786	Mar 14, 2023	DP			
	6991393	Mar 14, 2023	DP			
	7241065	Mar 14, 2023	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORASCUB MAXI SWABSTICK</u>						
N021524 003	D468424	Jan 07, 2017				
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS</u>						
N021441 001	7863287	Feb 28, 2027	DP			
<u>CHOLINE C-11 - CHOLINE C-11</u>						
N203155 001					NCE W	Sep 12, 2017 Sep 12, 2017
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N022224 001	7259186	Jan 07, 2025	DS			
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N022224 002	7259186	Jan 07, 2025	DS			
<u>CHORIOGONADOTROPIN ALFA - OVIDREL</u>						
N021149 001	5767251	Jun 16, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CHORIOGONADOTROPIN ALFA - OVIDREL</u>						
N021149 002	5767251	Jun 16, 2015	DS			
	6706681	Mar 16, 2021	DP			
<u>CICLESONIDE - ALVESCO</u>						
N021658 002	5482934	Oct 24, 2017	DS DP		U-1002	
	5605674	Feb 25, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6036942	Apr 30, 2013	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
<u>CICLESONIDE - ALVESCO</u>						
N021658 003	5482934	Oct 24, 2017	DS DP		U-1002	
	5605674	Feb 25, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6036942	Apr 30, 2013	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
<u>CICLESONIDE - OMNARIS</u>						
N022004 001	5482934	Oct 24, 2017	DS DP		U-557	
	6767901	Oct 21, 2020	DP			
	6939559	Apr 21, 2019	DP			
	7235247	Apr 21, 2019	DP			
<u>CICLESONIDE - ZETONNA</u>						
N202129 001	5482934	Oct 24, 2017	DS DP		U-1002	
	5605674	Feb 25, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6036942	Apr 30, 2013	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
<u>CICLOPIROX - LOPROX</u>						
N020519 001	7018656	Sep 05, 2018	DP			
	7026337	Nov 21, 2016			U-714	
<u>CICLOPIROX - LOPROX</u>						
N021159 001	7981909	Sep 16, 2017			U-1162	
	8227490	Sep 16, 2017			U-1256	
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 001	6011068	Mar 08, 2018	DS DP		I-634	Feb 25, 2014
	6031003	Dec 14, 2016			U-559	
	6211244	Oct 23, 2015	DS DP		M-101	Feb 25, 2014
	6313146	Dec 14, 2016	DS DP		ODE	Feb 25, 2018
	7829595	Sep 22, 2026	DP		U-1098	
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 002	6011068	Mar 08, 2018	DS DP		I-634	Feb 25, 2014
	6031003	Dec 14, 2016			M-101	Feb 25, 2014
	6211244	Oct 23, 2015	DS DP		U-560	
	6313146	Dec 14, 2016	DS DP		ODE	Feb 25, 2018
	7829595	Sep 22, 2026	DP		U-1098	
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 003	6011068	Mar 08, 2018	DS DP		I-634	Feb 25, 2014
	6031003	Dec 14, 2016			U-559	
	6211244	Oct 23, 2015	DS DP		M-101	Feb 25, 2014
	6313146	Dec 14, 2016	DS DP		ODE	Feb 25, 2018
	7829595	Sep 22, 2026	DP		U-1098	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CIPROFLOXACIN - CIPRO</u>						
N020780 001	5695784	Dec 09, 2014				
	5695784*PED	Jun 09, 2015				
	6136347	Jan 06, 2013	U-362			
	6136347*PED	Jul 06, 2013				
<u>CIPROFLOXACIN - CIPRO</u>						
N020780 002	5695784	Dec 09, 2014				
	5695784*PED	Jun 09, 2015				
	6136347	Jan 06, 2013	U-362			
	6136347*PED	Jul 06, 2013				
<u>CIPROFLOXACIN HYDROCHLORIDE - PROQUIN XR</u>						
N021744 001	5972389	Sep 19, 2016	DP	U-663		
	6340475	Sep 19, 2016	DP	U-663		
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP	U-663		
<u>CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE - CIPRO HC</u>						
N020805 001	5843930	Jun 06, 2015			U-646	
	5965549	Jun 06, 2015	DP			
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N021473 001	7709022	Jun 23, 2021	DP			
	7709022*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N021473 002	7709022	Jun 23, 2021	DP			
	7709022*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N021537 001	6284804	Aug 10, 2020				
	6359016	Aug 10, 2020				
<u>CISAPRIDE MONOHYDRATE - PROPULSID QUICKSOLV</u>						
N020767 001	5648093	Jul 15, 2014				
<u>CISATRACURIUM BESYLATE - NIMBEX</u>						
N020551 001	5453510	Sep 26, 2012		U-127		
<u>CISATRACURIUM BESYLATE - NIMBEX PRESERVATIVE FREE</u>						
N020551 002	5453510	Sep 26, 2012		U-127		
<u>CISATRACURIUM BESYLATE - NIMBEX PRESERVATIVE FREE</u>						
N020551 003	5453510	Sep 26, 2012		U-127		
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N202535 001					NP	Jul 16, 2015
<u>CLARITHROMYCIN - BIAVIN XL</u>						
N050775 001	6010718	Apr 11, 2017	DP	U-924		
	6551616	Jul 15, 2017		U-924		
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 001	5739152	Apr 14, 2015	DP	U-893	NCE	Aug 01, 2013
	5856346	Jan 05, 2021	DS DP	U-893		
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 002	5739152	Apr 14, 2015	DP	U-893	NCE	Aug 01, 2013
	5856346	Jan 05, 2021	DS DP	U-893		
<u>CLINDAMYCIN PHOSPHATE - CLEOCIN</u>						
N050767 001	6495157	Jul 20, 2020	DP			
<u>CLINDAMYCIN PHOSPHATE - CLINDAGEL</u>						
N050782 001	6387383	Aug 03, 2020	DP	U-818		
<u>CLINDAMYCIN PHOSPHATE - CLINDESSE</u>						
N050793 001	5993856	Nov 17, 2017	DP	U-137		
	6899890	Apr 27, 2023	DP	U-137		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLINDAMYCIN PHOSPHATE - EVOCLIN</u>						
N050801 001	7141237	Jan 23, 2024	DS DP			
	7374747	Aug 09, 2026	DS DP U-921			
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - VELTIN</u>						
N050803 001	5690923	Nov 25, 2014	DP			
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - ZIANA</u>						
N050802 001	6387383	Aug 03, 2020	DP U-916			
	RE41134	Feb 24, 2015	DP U-1033			
<u>CLOBAZAM - ONFI</u>						
N202067 001					NCE ODE	Oct 21, 2016 Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N202067 002					NCE ODE	Oct 21, 2016 Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N202067 003					NCE ODE	Oct 21, 2016 Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N203993 001					NCE	Oct 21, 2016
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N021535 001	6106848	Sep 22, 2017				
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N021644 001	7316810	Jun 17, 2019	DP			
	7700081	Jan 03, 2022	U-1044			
	8066975	Jun 17, 2019	DP			
	8066976	Jun 17, 2019	DP			
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N021835 001	5972920	Feb 12, 2018	DP			
	5990100	Mar 24, 2018	DP U-742			
<u>CLOBETASOL PROPIONATE - OLUX</u>						
N021142 001	6126920	Mar 01, 2016			U-484	
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N022013 001	6730288	Sep 08, 2019	DP			
	7029659	Sep 08, 2019	DP			
<u>CLOFARABINE - CLOLAR</u>						
N021673 001	5661136	Jan 14, 2018	U-626			
	5661136*PED	Jul 14, 2018				
<u>CLONIDINE HYDROCHLORIDE - JENLOGA</u>						
N022331 001	5869100	Oct 13, 2013	DP		NP	Sep 29, 2012
<u>CLONIDINE HYDROCHLORIDE - JENLOGA</u>						
N022331 002	5869100	Oct 13, 2013	DP			
<u>CLONIDINE HYDROCHLORIDE - KAPVAY</u>						
N022331 003	5869100	Oct 13, 2013	DP		NP	Sep 28, 2013
<u>CLONIDINE HYDROCHLORIDE - KAPVAY</u>						
N022331 004	5869100	Oct 13, 2013	DP		NP	Sep 28, 2013
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A077665 002					PC	Nov 13, 2012
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A091023 001					PC	Nov 13, 2012

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N020839 001	6429210	Jun 10, 2019	DS DP		M-61	May 06, 2014
	6429210*PED	Dec 10, 2019			PED	Nov 06, 2014
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N020839 002	6429210	Jun 10, 2019	DS DP		M-61	May 06, 2014
	6429210*PED	Dec 10, 2019			PED	Nov 06, 2014
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
<u>CLOZAPINE - FAZACLO ODT</u>						
N021590 001	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N021590 002	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N021590 003	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N021590 004	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N021590 005	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>CLOZAPINE - FAZACLO ODT</u>						
N021590 006	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N203100 001	5814639	Sep 29, 2015	DS DP			
	5914331	Jul 02, 2017	DS			
	5922695	Jul 25, 2017	DS	U-257		
	5935946	Jul 25, 2017	DS DP	U-257		
	5977089	Jul 25, 2017	DS DP	U-257		
	6043230	Jul 25, 2017		U-257		
	6642245	Nov 04, 2020		U-257		
	6703396	Mar 09, 2021	DS DP			
	7176220	Nov 20, 2023	DS DP	U-257		
	7635704	Jan 12, 2026	DS DP	U-257		
	8148374	Sep 03, 2029	DS DP	U-1279		
<u>COLCHICINE - COLCRYS</u>						
N022352 001	7601758	Feb 10, 2029	U-1007		I-603	Jul 30, 2012
	7619004	Dec 03, 2028	U-1020		ODE	Jul 29, 2016
	7820681	Feb 17, 2029	U-1020			
	7906519	Feb 17, 2029	U-1116			
	7915269	Feb 17, 2029	U-1007			
	7935731	Dec 03, 2028	U-1116			
	7964647	Oct 06, 2028	U-1007			
	7964648	Oct 06, 2028	U-1161			
	7981938	Oct 06, 2028	U-1166			
	8093296	Oct 06, 2028	U-1007			
	8093297	Oct 06, 2028	U-1161			
	8093298	Oct 06, 2028	U-1116			
	8097655	Oct 06, 2028	U-1020			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N021141 001	5607669	Jun 10, 2014	U-323			
	5607669*PED	Dec 10, 2014				
	5679717	Apr 29, 2014	U-323			
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014				
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	U-323			
	5917007*PED	Oct 29, 2014				
	5919832	Jun 10, 2014				
	5919832*PED	Dec 10, 2014				
	6066678	Jun 10, 2014	U-323			
	6066678*PED	Dec 10, 2014				
	6433026	Jun 10, 2014				
	6433026*PED	Dec 10, 2014				
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N021176 001	5607669	Jun 10, 2014	U-323		I-608	Oct 02, 2012
	5607669*PED	Dec 10, 2014			PED	Apr 02, 2013
	5679717	Apr 29, 2014	U-323			
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014	DS			
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	DS	U-323		
	5917007*PED	Oct 29, 2014				
	5919832	Apr 29, 2014	DS			
	5919832*PED	Oct 29, 2014				
	6066678	Apr 29, 2014	DS	U-323		
	6066678*PED	Oct 29, 2014				
	6433026	Apr 29, 2014	DS			
	6433026*PED	Oct 29, 2014				
	6784254	Apr 29, 2014	DS DP			
	6784254*PED	Oct 29, 2014				
	7101960	Apr 29, 2014	DS DP	U-757		
	7101960*PED	Oct 29, 2014				
	7229613	Apr 17, 2022	U-851			
	7229613*PED	Oct 17, 2022				
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N022362 001	5607669	Jun 10, 2014	U-757		I-608	Oct 02, 2012
	5607669*PED	Dec 10, 2014			PED	Apr 02, 2013
	5679717	Apr 29, 2014	U-757			
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014	DS			
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	DS	U-757		
	5917007*PED	Oct 29, 2014				
	5919832	Apr 29, 2014	DS			
	5919832*PED	Oct 29, 2014				
	6066678	Apr 29, 2014	DS	U-757		
	6066678*PED	Oct 29, 2014				
	6433026	Apr 29, 2014	DS			
	6433026*PED	Oct 29, 2014				
	6784254	Apr 29, 2014	DS DP			
	6784254*PED	Oct 29, 2014				
	7101960	Apr 29, 2014	DS DP	U-757		
	7101960*PED	Oct 29, 2014				
	7229613	Apr 17, 2022	U-493			
	7229613*PED	Oct 17, 2022				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N022362 002	5607669	Jun 10, 2014	U-757		I-608	Oct 02, 2012
	5607669*PED	Dec 10, 2014			PED	Apr 02, 2013
	5679717	Apr 29, 2014	U-757			
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014	DS			
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	DS	U-757		
	5917007*PED	Oct 29, 2014				
	5919832	Apr 29, 2014	DS			
	5919832*PED	Oct 29, 2014				
	6066678	Apr 29, 2014	DS	U-757		
	6066678*PED	Oct 29, 2014				
	6433026	Apr 29, 2014	DS			
	6433026*PED	Oct 29, 2014				
	6784254	Apr 29, 2014	DS DP			
	6784254*PED	Oct 29, 2014				
	7101960	Apr 29, 2014	DS DP	U-757		
	7101960*PED	Oct 29, 2014				
	7229613	Apr 17, 2022		U-493		
	7229613*PED	Oct 17, 2022				
<u>COLESTIPOL HYDROCHLORIDE - COLESTID</u>						
N020222 001	5490987	Feb 13, 2013	DP			
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL</u>						
N021697 001	5723606	Dec 15, 2019	DS DP	U-868		
	5723606	Dec 15, 2019	DS DP	U-698		
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER</u>						
N021697 002	5723606	Dec 15, 2019	DS DP	U-698		
	5723606	Dec 15, 2019	DS DP	U-868		
<u>CORTICOTROPIN - H.P. ACTHAR GEL</u>						
N008372 008					ODE	Oct 15, 2017
<u>CRIZOTINIB - XALKORI</u>						
N202570 001	7230098	Mar 01, 2025	DS		NCE	Aug 26, 2016
	7825137	May 12, 2027		U-1179	ODE	Aug 26, 2018
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS DP			
<u>CRIZOTINIB - XALKORI</u>						
N202570 002	7230098	Mar 01, 2025	DS		NCE	Aug 26, 2016
	7825137	May 12, 2027		U-1179	ODE	Aug 26, 2018
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS DP			
<u>CROFELEMER - FULYZAQ</u>						
N202292 001	7323195	Jun 07, 2018	DP		NCE	Dec 31, 2017
	7341744	Jun 16, 2018		U-1319		
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N021642 001	7229636	Jun 11, 2024	DP	U-817		
	7404489	Mar 12, 2024	DP			
	7879349	Jun 01, 2024	DP	U-1152		
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N021777 001	7387793	Feb 26, 2025	DP			
	7544372	Nov 14, 2023		U-979		
	7790199	Nov 14, 2023	DP			
	7820203	Nov 14, 2023	DP			
	7829121	Nov 14, 2023		U-1088		
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N021777 002	7387793	Feb 26, 2025	DP			
	7544372	Nov 14, 2023		U-979		
	7790199	Nov 14, 2023	DP			
	7820203	Nov 14, 2023	DP			
	7829121	Nov 14, 2023		U-1088		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOSPORINE - NEORAL</u>						
N050715 001	5985321	Sep 26, 2014	DP			
<u>CYCLOSPORINE - NEORAL</u>						
N050715 002	5985321	Sep 26, 2014	DP			
<u>CYCLOSPORINE - NEORAL</u>						
N050715 003	5985321	Sep 26, 2014	DP			
<u>CYCLOSPORINE - NEORAL</u>						
N050716 001	5985321	Sep 26, 2014	DP			
<u>CYCLOSPORINE - RESTASIS</u>						
N050790 001	5474979	May 17, 2014	DP			
<u>CYSTEAMINE HYDROCHLORIDE - CYSTARAN</u>						
N200740 001					NP ODE	Oct 02, 2015 Oct 02, 2019
<u>CYTARABINE - DEPOCYT</u>						
N021041 001	5455044	May 14, 2013	U-806			
	5723147	Mar 03, 2015	DP U-806			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N022512 001	6087380	Feb 18, 2018	DS DP U-1089		NCE	Oct 19, 2015
	7866474	Aug 31, 2027	DP			
	7932273	Sep 07, 2025	DS DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N022512 002	6087380	Feb 18, 2018	DS DP U-1089		NCE	Oct 19, 2015
	7866474	Aug 31, 2027	DP			
	7932273	Sep 07, 2025	DS DP			
<u>DALFAMPRIDINE - AMPYRA</u>						
N022250 001	5540938	Jul 30, 2013	U-1030		NCE	Jan 22, 2015
	8007826	May 26, 2027	U-1030		ODE	Jan 22, 2017
<u>DAPSONE - ACZONE</u>						
N021794 001	5863560	Sep 11, 2016	DP			
	6060085	Sep 11, 2016	U-124			
	6620435	Sep 11, 2016	DP			
<u>DAPTOMYCIN - CUBICIN</u>						
N021572 001	6468967	Sep 24, 2019	U-282			
	6852689	Sep 24, 2019	U-282			
	8058238	Nov 28, 2020	DS DP			
<u>DAPTOMYCIN - CUBICIN</u>						
N021572 002	6468967	Sep 24, 2019	U-282			
	6852689	Sep 24, 2019	U-282			
	8003673	Sep 04, 2028	U-1180			
	8058238	Nov 28, 2020	DS DP			
	8129342	Nov 28, 2020	DS DP			
	RE39071	Jun 15, 2016	DS DP U-728			
<u>DARIFENACIN HYDROBROMIDE - ENABLEX</u>						
N021513 001	5096890	Mar 13, 2015	DS DP U-631			
	6106864	Aug 21, 2016	DP U-630			
<u>DARIFENACIN HYDROBROMIDE - ENABLEX</u>						
N021513 002	5096890	Mar 13, 2015	DS DP U-631			
	6106864	Aug 21, 2016	DP U-630			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-1209		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-935		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-744		PED	Jun 13, 2014
	5843946	Dec 01, 2015	DP U-1305			
	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1305			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015	U-1305			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1305			
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1305			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1305			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1305			
	RE43802*PED	Apr 19, 2017				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	5843946	Dec 01, 2015	DP U-1209		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-903		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-1305		PED	Jun 13, 2014
	5843946	Dec 01, 2015	DP U-744			
	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015				
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1305			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1305			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1305			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1305			
	RE43802*PED	Apr 19, 2017				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-1305		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-935		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-1209		PED	Jun 13, 2014
	5843946*PED	Jun 01, 2016	DP U-744			
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1305			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015				
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1305			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1305			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1305			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1305			
	RE43802*PED	Apr 19, 2017				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-1209		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-744		PED	Jun 13, 2014
	5843946	Dec 01, 2015	DP U-1305			
	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015				
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1305			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-1305			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1305			
	RE43802*PED	Apr 19, 2017				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-1209		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-744		PED	Jun 13, 2014
	5843946	Dec 01, 2015	DP U-1305			
	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1305			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015				
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1305			
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1305			
	RE43802*PED	Apr 19, 2017				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 006	5843946	Dec 01, 2015	DP U-744		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-1209		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-935		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-1305		PED	Jun 13, 2014
	5843946	Dec 01, 2015	DP U-903			
	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015	U-1305			
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-1305			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1305			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1305			
	RE43802*PED	Apr 19, 2017				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N202895 001	5843946	Dec 01, 2015	DP U-1209		NDF	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-1305		PED	Jun 16, 2015
	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1305			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015				
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-1305			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-1305			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017	U-1305			
	RE43802	Oct 19, 2016	U-1305			
	RE43802*PED	Apr 19, 2017				
<u>DASATINIB - SPRYCEL</u>						
N021986 001	6596746	Jun 28, 2020	DS DP U-780		M-94	Oct 28, 2013
	6596746	Jun 28, 2020	DS DP U-748		ODE	Jun 28, 2013
	7125875	Apr 13, 2020	U-780		ODE	Jun 28, 2013
	7125875	Apr 13, 2020	U-779			
	7153856	Apr 28, 2020	U-780			
	7491725	Mar 28, 2026	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
N021986 002	6596746	Jun 28, 2020	DS DP U-780		M-94	Oct 28, 2013
	6596746	Jun 28, 2020	DS DP U-748		ODE	Jun 28, 2013
	7125875	Apr 13, 2020	U-779		ODE	Jun 28, 2013
	7125875	Apr 13, 2020	U-780			
	7153856	Apr 28, 2020	U-780			
	7491725	Mar 28, 2026	DS DP			
<u>DASATINIB - SPRYCEL</u>						
N021986 003	6596746	Jun 28, 2020	DS DP U-780		M-94	Oct 28, 2013
	6596746	Jun 28, 2020	DS DP U-748		ODE	Jun 28, 2013
	7125875	Apr 13, 2020	U-779		ODE	Jun 28, 2013
	7125875	Apr 13, 2020	U-780			
	7153856	Apr 28, 2020	U-780			
	7491725	Mar 28, 2026	DS DP			
<u>DASATINIB - SPRYCEL</u>						
N021986 004	6596746	Jun 28, 2020	DS DP U-780		M-94	Oct 28, 2013
	6596746	Jun 28, 2020	DS DP U-748		ODE	Jun 28, 2013
	7125875	Apr 13, 2020	U-780		ODE	Jun 28, 2013
	7125875	Apr 13, 2020	U-779			
	7153856	Apr 28, 2020	U-780			
	7491725	Mar 28, 2026	DS DP			
<u>DASATINIB - SPRYCEL</u>						
N021986 005	6596746	Jun 28, 2020	DS DP U-780		M-94	Oct 28, 2013
	6596746	Jun 28, 2020	DS DP U-748		ODE	Jun 28, 2013
	7125875	Apr 13, 2020	U-780		ODE	Jun 28, 2013
	7125875	Apr 13, 2020	U-779			
	7153856	Apr 28, 2020	U-780			
	7491725	Mar 28, 2026	DS DP			
<u>DASATINIB - SPRYCEL</u>						
N021986 006	6596746	Jun 28, 2020	DS DP U-748		M-94	Oct 28, 2013
	6596746	Jun 28, 2020	DS DP U-780		ODE	Jun 28, 2013
	7125875	Apr 13, 2020	U-779		ODE	Jun 28, 2013
	7125875	Apr 13, 2020	U-780			
	7153856	Apr 28, 2020	U-780			
	7491725	Mar 28, 2026	DS DP			
<u>DECITABINE - DACOGEN</u>						
N021790 001					D-123	Mar 11, 2013
					ODE	May 02, 2013
<u>DEFERASIROX - EXJADE</u>						
N021882 001	6465504	Apr 05, 2019	DS DP		ODE	Nov 02, 2012
	6596750	Jun 24, 2017	DS	U-735		
<u>DEFERASIROX - EXJADE</u>						
N021882 002	6465504	Apr 05, 2019	DS DP		ODE	Nov 02, 2012
	6596750	Jun 24, 2017	DS	U-735		
<u>DEFERASIROX - EXJADE</u>						
N021882 003	6465504	Apr 05, 2019	DS DP		ODE	Nov 02, 2012
	6596750	Jun 24, 2017	DS	U-735		
<u>DEFERIPRONE - FERRIPROX</u>						
N021825 001					NCE	Oct 14, 2016
					ODE	Oct 14, 2018
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 001	5925730	May 18, 2021	DS DP U-943		NCE	Dec 24, 2013
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 002	5925730	May 18, 2021	DS DP U-943		NCE	Dec 24, 2013
<u>DELAVIDINE MESYLATE - RESCRIPTOR</u>						
N020705 001	5563142	Oct 08, 2013				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DELAVIDINE MESYLATE - RESCRIPTOR</u>						
N020705 002	5563142	Oct 08, 2013				
	6177101	Jun 07, 2019				
<u>DESFLURANE - SUPRANE</u>						
N020118 001	5617906	Apr 08, 2014	DP			
	5617906*PED	Oct 08, 2014				
<u>DESIRUDIN RECOMBINANT - IPRIVASK</u>						
N021271 001	5733874	Mar 31, 2015				
<u>DESLOMATADINE - CLARINEX</u>						
N021165 001	6100274	Jul 07, 2019				
	6100274*PED	Jan 07, 2020				
	7211582	Dec 30, 2014	U-809			
	7211582*PED	Jun 30, 2015				
	7214683	Dec 30, 2014	DP			
	7214683*PED	Jun 30, 2015				
	7214684	Dec 30, 2014	U-138			
	7214684*PED	Jun 30, 2015				
	7405223	Jul 07, 2019	U-886			
	7405223*PED	Jan 07, 2020				
<u>DESLOMATADINE - CLARINEX</u>						
N021300 001	6514520	Jun 01, 2018	DP			
	6514520*PED	Dec 01, 2018				
	7211582	Dec 30, 2014	U-809			
	7211582*PED	Jun 30, 2015				
	7214683	Dec 30, 2014	DP			
	7214683*PED	Jun 30, 2015				
	7214684	Dec 30, 2014	U-138			
	7214684*PED	Jun 30, 2015				
<u>DESLOMATADINE - CLARINEX</u>						
N021312 001	5607697	Jun 07, 2015	DP			
	5607697*PED	Dec 07, 2015				
	6100274	Jul 07, 2019	DP			
	6100274*PED	Jan 07, 2020				
	7211582	Dec 30, 2014	U-809			
	7211582*PED	Jun 30, 2015				
	7214683	Dec 30, 2014	DP			
	7214683*PED	Jun 30, 2015				
	7214684	Dec 30, 2014	U-138			
	7214684*PED	Jun 30, 2015				
	7618649	Dec 19, 2020	DP U-1017			
	7618649*PED	Jun 19, 2021				
<u>DESLOMATADINE - CLARINEX</u>						
N021312 002	5607697	Jun 07, 2015	DP			
	5607697*PED	Dec 07, 2015				
	6100274	Jul 07, 2019	DP			
	6100274*PED	Jan 07, 2020				
	7211582	Dec 30, 2014	U-809			
	7211582*PED	Jun 30, 2015				
	7214683	Dec 30, 2014	DP			
	7214683*PED	Jun 30, 2015				
	7214684	Dec 30, 2014	U-138			
	7214684*PED	Jun 30, 2015				
	7618649	Dec 19, 2020	DP U-1017			
	7618649*PED	Jun 19, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DES Loratadine; Pseudoephedrine Sulfate - Clarinex-D 24 Hour</u>						
N021605 001	6100274	Jul 07, 2019	DP			
	6100274*PED	Jan 07, 2020				
	6979463	Mar 28, 2022	DP			
	7214683	Dec 30, 2014	DP			
	7214683*PED	Jun 30, 2015				
	7214684	Dec 30, 2014			U-138	
	7214684*PED	Jun 30, 2015				
	7618649	Dec 19, 2020	DP		U-1017	
	7618649*PED	Jun 19, 2021				
	7820199	Mar 28, 2022	DP			
	7820199*PED	Sep 28, 2022				
<u>DES Loratadine; Pseudoephedrine Sulfate - Clarinex-D 12 Hour</u>						
N021313 001	6100274	Jul 07, 2019	DP			
	6100274*PED	Jan 07, 2020				
	6709676	Feb 18, 2021	DP		U-707	
	7214683	Dec 30, 2014	DP			
	7214683*PED	Jun 30, 2015				
	7214684	Dec 30, 2014			U-138	
	7214684*PED	Jun 30, 2015				
	7618649	Dec 19, 2020	DP		U-1017	
	7618649*PED	Jun 19, 2021				
	8187630	Dec 19, 2020	DP		U-1017	
<u>Desmopressin Acetate - DDAVP</u>						
N017922 001	5500413	Jun 29, 2013				
	5674850	Dec 23, 2013				
	5763407	Jun 29, 2013				
<u>Desmopressin Acetate - DDAVP</u>						
N017922 002	5500413	Jun 29, 2013				
	5674850	Dec 23, 2013				
	5763407	Jun 29, 2013				
<u>Desmopressin Acetate - DDAVP</u>						
N018938 001	5500413	Jun 29, 2013				
	5763407	Jun 29, 2013				
<u>Desmopressin Acetate - DDAVP</u>						
N018938 002	5500413	Jun 29, 2013				
	5763407	Jun 29, 2013				
<u>Desmopressin Acetate - DDAVP</u>						
N019955 001	5500413	Jun 29, 2013				
	5674850	Dec 23, 2013				
	5763407	Jun 29, 2013				
	7022340	Apr 30, 2023	DP			
<u>Desmopressin Acetate - DDAVP</u>						
N019955 002	5500413	Jun 29, 2013				
	5674850	Dec 23, 2013				
	5763407	Jun 29, 2013				
	7022340	Apr 30, 2023	DP			
<u>Desmopressin Acetate - DDAVP (NEEDS NO REFRIGERATION)</u>						
N017922 003	5482931	Jun 29, 2013				
	5500413	Jun 29, 2013				
	5674850	Dec 23, 2013				
	5763407	Jun 29, 2013				
<u>Desmopressin Acetate - Desmopressin Acetate</u>						
N021795 001	7022340	Apr 30, 2023	DP			
<u>Desmopressin Acetate - Desmopressin Acetate</u>						
N021795 002	7022340	Apr 30, 2023	DP			
<u>Desonide - Desonate</u>						
N021844 001	6387383	Aug 03, 2020	DS DP		U-783	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES			PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
DESONIDE - VERDESO										
N021978 001	6730288	Sep 08,	2019	DP						
	7029659	Sep 08,	2019	DP						
DESVENLAFAXINE SUCCINATE - PRISTIQ										
N021992 001	6673838	Feb 11,	2022	DS	DP	U-860		NCE	Mar 01,	2013
	8269040	Jul 05,	2027	DS						
DESVENLAFAXINE SUCCINATE - PRISTIQ										
N021992 002	6673838	Feb 11,	2022	DS	DP	U-860		NCE	Mar 01,	2013
	8269040	Jul 05,	2027	DS						
DEXAMETHASONE - OZURDEX										
N022315 001	6726918	Oct 20,	2020	DP	U-1204			ODE	Sep 24,	2017
	6726918	Oct 20,	2020	DP	U-1205					
	6899717	Nov 01,	2023		U-1206					
	7033605	Oct 20,	2020	DP						
	7767223	Nov 28,	2021	DP						
	8034366	Jan 09,	2023	DP	U-1204					
	8034366	Jan 09,	2023	DP	U-1205					
	8034370	Jan 09,	2023	DP						
	8043628	Oct 20,	2020	DP	U-1205					
	8063031	Oct 20,	2020	DP						
	8088407	Oct 20,	2020	DP	U-1205					
DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST										
N050818 001	7795316	Aug 03,	2028	DP	U-1082					
	8101582	Dec 19,	2027	DP	U-1082					
DEXLANSOPRAZOLE - DEXILANT										
N022287 001	6462058	Jun 15,	2020	DS	DP	U-949		PED	Jul 30,	2012
	6462058	Jun 15,	2020	DS	DP	U-950				
	6462058	Jun 15,	2020	DS	DP	U-951				
	6462058*PED	Dec 15,	2020							
	6664276	Jun 15,	2020	DS	DP	U-951				
	6664276	Jun 15,	2020	DS	DP	U-949				
	6664276	Jun 15,	2020	DS	DP	U-950				
	6664276*PED	Dec 15,	2020							
	6939971	Jun 15,	2020			U-950				
	6939971	Jun 15,	2020			U-949				
	6939971	Jun 15,	2020			U-951				
	6939971*PED	Dec 15,	2020							
	7285668	Jun 15,	2020	DS						
	7285668*PED	Dec 15,	2020							
	7790755	Aug 02,	2026		DP					
	7790755*PED	Feb 02,	2027							
	8105626	Sep 27,	2026		DP					
	8105626*PED	Mar 27,	2027							
	8173158	Mar 17,	2030			U-950				
	8173158	Mar 17,	2030			U-951				
	8173158	Mar 17,	2030			U-949				
	8173158*PED	Sep 17,	2030							

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 002	6462058	Jun 15, 2020	DS DP U-950		PED	Jul 30, 2012
	6462058	Jun 15, 2020	DS DP U-949			
	6462058	Jun 15, 2020	DS DP U-951			
	6462058*PED	Dec 15, 2020				
	6664276	Jun 15, 2020	DS DP U-951			
	6664276	Jun 15, 2020	DS DP U-950			
	6664276	Jun 15, 2020	DS DP U-949			
	6664276*PED	Dec 15, 2020				
	6939971	Jun 15, 2020			U-951	
	6939971	Jun 15, 2020			U-949	
	6939971	Jun 15, 2020			U-950	
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
	7790755	Aug 02, 2026		DP		
	7790755*PED	Feb 02, 2027				
	8105626	Sep 27, 2026		DP		
	8105626*PED	Mar 27, 2027				
	8173158	Mar 17, 2030			U-950	
	8173158	Mar 17, 2030			U-951	
	8173158	Mar 17, 2030			U-949	
	8173158*PED	Sep 17, 2030				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N021038 001	4910214	Jul 15, 2013	DS DP U-421			
	6716867	Mar 31, 2019			U-572	
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N021278 001	5908850	Dec 04, 2015			U-422	
	6355656	Dec 04, 2015				
	6528530	Dec 04, 2015	DS DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N021278 002	5908850	Dec 04, 2015			U-422	
	6355656	Dec 04, 2015				
	6528530	Dec 04, 2015	DS DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N021278 003	5908850	Dec 04, 2015			U-422	
	6355656	Dec 04, 2015				
	6528530	Dec 04, 2015	DS DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 001	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015			U-678	
	6228398	Nov 01, 2019	DP		U-676	
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP		U-677	
	6730325	Nov 01, 2019	DP		U-676	
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 002	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015			U-678	
	6228398	Nov 01, 2019	DP		U-676	
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP		U-677	
	6730325	Nov 01, 2019	DP		U-676	
	7431944	Dec 04, 2015	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 003	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	U-678			
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 004	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	U-678			
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 005	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	DP	U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 006	5837284	Dec 04, 2015	DP	U-677	D-121	Oct 23, 2012
	5908850	Dec 04, 2015	DP	U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 007	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	DP	U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 008	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	DP	U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXRAZOXANE HYDROCHLORIDE - TOTECT</u>						
N022025 001	6727253	Mar 13, 2020	U-829		ODE	Sep 06, 2014
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N021620 001	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP	U-685		
	7838032	Apr 28, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N021620 002	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP	U-685		
	7838032	Apr 28, 2020	DP			
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N021879 001	7659282	Aug 13, 2026		U-1093	NC	Oct 29, 2013
	8227484	Jul 17, 2023		U-1093		
	RE38115	Jan 26, 2016	DP			
<u>DEXTROMETHORPHAN POLISTIREX - DELSYM</u>						
N018658 001	5980882	Apr 16, 2017	DP			
<u>DIAZEPAM - DIASTAT</u>						
N020648 001	5462740	Sep 17, 2013	DP			
<u>DIAZEPAM - DIASTAT</u>						
N020648 002	5462740	Sep 17, 2013	DP			
<u>DIAZEPAM - DIASTAT</u>						
N020648 003	5462740	Sep 17, 2013	DP			
<u>DIAZEPAM - DIASTAT</u>						
N020648 004	5462740	Sep 17, 2013	DP			
<u>DIAZEPAM - DIASTAT</u>						
N020648 005	5462740	Sep 17, 2013	DP			
<u>DIAZEPAM - DIASTAT ACUDIAL</u>						
N020648 006	5462740	Sep 17, 2013	DP			
<u>DIAZEPAM - DIASTAT ACUDIAL</u>						
N020648 007	5462740	Sep 17, 2013	DP			
<u>DICLOFENAC EPOLAMINE - FLECTOR</u>						
N021234 001	5607690	Apr 13, 2014	DP			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N022165 001	6974595	May 15, 2017		U-436		
	7482377	May 15, 2017	DS DP	U-436		
	7759394	Jun 16, 2026	DS DP	U-436		
	8097651	Jun 16, 2026	DS DP	U-436		
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	6365180	Jul 15, 2019	DP	U-980		
	7662858	Feb 24, 2029		U-1035		
	7884095	Feb 24, 2029		U-1111		
	7939518	Feb 24, 2029		U-980		
	8110606	Feb 24, 2029		U-980		
<u>DICLOFENAC SODIUM - DICLOFENAC SODIUM</u>						
N020809 001	5603929	Nov 16, 2014		U-239		
	5653972	Nov 16, 2014		U-239		
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N020947 001	8217078	Jul 10, 2029		U-1248	NDF	Nov 04, 2012
<u>DICLOFENAC SODIUM - SOLARAZE</u>						
N021005 001	5639738	Jun 17, 2014		U-402		
	5792753	Aug 11, 2015				
	5852002	Jun 17, 2014		U-402		
	5914322	Aug 11, 2015				
	5929048	Jun 17, 2014		U-402		
	5985850	Aug 11, 2015	DP			
<u>DICLOFENAC SODIUM; MISOPROSTOL - ARTHROTEC</u>						
N020607 001	5601843	Feb 11, 2014				
<u>DICLOFENAC SODIUM; MISOPROSTOL - ARTHROTEC</u>						
N020607 002	5601843	Feb 11, 2014				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	6133251	Oct 25, 2016	DP U-112	Y	I-648	Mar 14, 2015
	6133251	Oct 25, 2016	DP U-828	Y	NP	May 06, 2013
	6133251	Oct 25, 2016	DP U-1	Y		
	6884793	Oct 25, 2016	DP	Y		
	8071577	May 13, 2026	DP U-1			
	8153616	Jan 30, 2028	U-1240			
<u>DIFLUPREDNATE - DUREZOL</u>						
N022212 001	6114319	May 18, 2019	DP		I-653	Jun 13, 2015
					NCE	Jun 23, 2013
					ODE	Jun 13, 2019
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM CD</u>						
N020062 001	5439689	Aug 08, 2012	U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM CD</u>						
N020062 002	5439689	Aug 08, 2012	U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM CD</u>						
N020062 003	5439689	Aug 08, 2012	U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM CD</u>						
N020062 004	5439689	Aug 08, 2012	U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM CD</u>						
N020062 005	5439689	Aug 08, 2012	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N021392 001	5529791	Jun 25, 2013				
	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N021392 002	5529791	Jun 25, 2013				
	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N021392 003	5529791	Jun 25, 2013				
	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N021392 004	5529791	Jun 25, 2013				
	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N021392 005	5529791	Jun 25, 2013				
	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N021392 006	5529791	Jun 25, 2013				
	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
N020939 001	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
N020939 002	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
N020939 003	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
N020939 004	5529791	Jun 25, 2013				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DILTIAZEM HYDROCHLORIDE - TIAZAC</u>						
N020401 001	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - TIAZAC</u>						
N020401 002	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - TIAZAC</u>						
N020401 003	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - TIAZAC</u>						
N020401 004	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - TIAZAC</u>						
N020401 005	5529791	Jun 25, 2013				
<u>DILTIAZEM HYDROCHLORIDE - TIAZAC</u>						
N020401 006	5529791	Jun 25, 2013				
<u>DIMYRISTOYL LECITHIN; PERFLEXANE - IMAGENT</u>						
N021191 001	5605673	Feb 25, 2014				
	5626833	May 16, 2014			U-458	
	5639443	Jun 17, 2014				
	5695741	Dec 09, 2014			U-458	
	5720938	Feb 24, 2015				
	5798091	Aug 25, 2015			U-458	
	6280704	Jul 30, 2013				
	6280705	Jul 30, 2013				
	6287539	Jul 30, 2013				
<u>DINOPROSTONE - CERVIDIL</u>						
N020411 001	5269321	Jul 14, 2012	DP		U-110	
<u>DIPHENHYDRAMINE CITRATE; IBUPROFEN - ADVIL PM</u>						
N021394 001	8263647	May 30, 2022	DP			
<u>DIVALPROEX SODIUM - DEPAKOTE ER</u>						
N021168 001	6419953	Dec 18, 2018				
	6419953*PED	Jun 18, 2019				
	6511678	Dec 18, 2018				
	6511678*PED	Jun 18, 2019				
	6528090	Dec 18, 2018			DP	
	6528090*PED	Jun 18, 2019				
	6528091	Dec 18, 2018			U-106	
	6528091*PED	Jun 18, 2019				
	6713086	Dec 18, 2018			DP	U-579
	6713086*PED	Jun 18, 2019				
	6720004	Dec 18, 2018			DP	
	6720004*PED	Jun 18, 2019				
<u>DIVALPROEX SODIUM - DEPAKOTE ER</u>						
N021168 002	6511678	Dec 18, 2018				
	6511678*PED	Jun 18, 2019				
	6528090	Dec 18, 2018			DP	
	6528090*PED	Jun 18, 2019				
	6713086	Dec 18, 2018			DP	U-579
	6713086*PED	Jun 18, 2019				
	6720004	Dec 18, 2018			DP	
	6720004*PED	Jun 18, 2019				
<u>DOCETAXEL - TAXOTERE</u>						
N020449 001	5438072	Nov 22, 2013	DP		M-61	May 13, 2013
	5438072*PED	May 22, 2014			PED	Nov 13, 2013
	5698582	Jul 03, 2012	DP			
	5698582*PED	Jan 03, 2013				
	5714512	Jul 03, 2012	DP			
	5714512*PED	Jan 03, 2013				
	5750561	Jul 03, 2012	DP			
	5750561*PED	Jan 03, 2013				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DOCETAXEL - TAXOTERE</u>						
N020449 003	5698582	Jul 03, 2012	DP		M-61	May 13, 2013
	5698582*PED	Jan 03, 2013			PED	Nov 13, 2013
	5714512	Jul 03, 2012	DP			
	5714512*PED	Jan 03, 2013				
	5750561	Jul 03, 2012	DP			
	5750561*PED	Jan 03, 2013				
<u>DOCETAXEL - TAXOTERE</u>						
N020449 004	5698582	Jul 03, 2012	DP		M-61	May 13, 2013
	5698582*PED	Jan 03, 2013			PED	Nov 13, 2013
	5714512	Jul 03, 2012	DP			
	5714512*PED	Jan 03, 2013				
	5750561	Jul 03, 2012	DP			
	5750561*PED	Jan 03, 2013				
<u>DOCOSANOL - ABREVA</u>						
N020941 001	4874794	Apr 28, 2014		U-815		
	5534554	Dec 13, 2013	DP	U-815		
<u>DOFETILIDE - TIKOSYN</u>						
N020931 001	4959366	Sep 25, 2012	DS DP	U-652		
	6124363	Oct 09, 2018				
<u>DOFETILIDE - TIKOSYN</u>						
N020931 002	4959366	Sep 25, 2012	DS DP	U-652		
	6124363	Oct 09, 2018				
<u>DOFETILIDE - TIKOSYN</u>						
N020931 003	4959366	Sep 25, 2012	DS DP	U-652		
	6124363	Oct 09, 2018				
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N020690 001	5985864	Dec 30, 2016				
	6140321	Dec 30, 2016				
	6245911	Dec 01, 2018				
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N020690 002	5985864	Dec 30, 2016				
	6140321	Dec 30, 2016				
	6245911	Dec 01, 2018				
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N022568 001					NP	Jul 23, 2013
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>						
N021720 001	7727548	Jun 23, 2022	DP	U-1062		
	7727552	Mar 26, 2018	DP			
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>						
N021720 002	7727548	Jun 23, 2022	DP	U-1062		
	7727552	Mar 26, 2018	DP			
<u>DORIPENEM - DORIBAX</u>						
N022106 001	5317016	Jun 05, 2015	DS DP	U-282	NCE	Oct 12, 2012
	8247402	Mar 30, 2021	DS DP			
<u>DORIPENEM - DORIBAX</u>						
N022106 002	5317016	Jun 05, 2015	DS DP	U-282	NCE	Oct 12, 2012
	8247402	Mar 30, 2021	DS DP			
<u>DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT PF</u>						
N202667 001					NP	Feb 01, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 001	5502047	Mar 26, 2013	U-620		NP	Mar 17, 2013
	5585115	Jan 09, 2015	DP			
	5725884	Jan 09, 2015	DP			
	5866166	Jan 09, 2015	DP			
	5948438	Jan 09, 2015	DP			
	6103219	Jan 09, 2015	DP			
	6211229	Feb 17, 2020	U-620			
	6217909	Jan 09, 2015	DP			
	7915307	Aug 24, 2027	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 002	5502047	Mar 26, 2013	U-620		NP	Mar 17, 2013
	5585115	Jan 09, 2015	DP			
	5725884	Jan 09, 2015	DP			
	5866166	Jan 09, 2015	DP			
	5948438	Jan 09, 2015	DP			
	6103219	Jan 09, 2015	DP			
	6211229	Feb 17, 2020	U-620			
	6217909	Jan 09, 2015	DP			
	7915307	Aug 24, 2027	U-620			
<u>DOXERCALCIFEROL - HECTOROL</u>						
N020862 001	5602116	Feb 11, 2014	U-278			
	5602116	Feb 11, 2014	U-987			
	6903083	Jul 18, 2021	DS DP	Y		
<u>DOXERCALCIFEROL - HECTOROL</u>						
N020862 002	5602116	Feb 11, 2014	U-987			
	5602116	Feb 11, 2014	U-278			
	6903083	Jul 18, 2021	DS DP	Y		
<u>DOXERCALCIFEROL - HECTOROL</u>						
N020862 003	5602116	Feb 11, 2014	U-987			
<u>DOXERCALCIFEROL - HECTOROL</u>						
N021027 001	5602116	Feb 11, 2014	U-321			
	6903083	Jul 18, 2021	DS DP	Y		
	7148211	Sep 14, 2023	DP	Y		
<u>DOXERCALCIFEROL - HECTOROL</u>						
N021027 002	5602116	Feb 11, 2014	U-321			
	7148211	Sep 14, 2023	DP	Y		
<u>DOXORUBICIN HYDROCHLORIDE - DOXIL</u>						
N050718 001					ODE	May 17, 2014
<u>DOXORUBICIN HYDROCHLORIDE - DOXIL</u>						
N050718 002					ODE	May 17, 2014
<u>DOXYCYCLINE - ORACEA</u>						
N050805 001	5789395	Aug 30, 2016	U-925			
	5919775	Aug 30, 2016	U-925			
	7211267	Apr 05, 2022	U-925			
	7232572	Apr 05, 2022	U-925			
	7749532	Dec 19, 2027	DP U-1063			
	8206740	Dec 24, 2025	DP U-925			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N050795 001	6958161	Dec 15, 2022	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N050795 002	6958161	Dec 15, 2022	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N050795 003	6958161	Dec 15, 2022	DP U-918			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N022425 001	5223510	Jul 26, 2013	DS DP U-1261		NCE	Jul 01, 2014
	5223510	Jul 26, 2013	DS DP U-992			
	7323493	Jun 19, 2018	DP			
	8318800	Jun 19, 2018	DP			
<u>DROSPIRENONE; ESTRADIOL - ANGELIQ</u>						
N021355 001					NS	Mar 01, 2015
<u>DROSPIRENONE; ESTRADIOL - ANGELIQ</u>						
N021355 002	6933395	Aug 11, 2017	DS			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YASMIN</u>						
N021098 001	5569652	Oct 29, 2013		U-1		
	6787531	Aug 31, 2020	DP			
	6933395	Aug 11, 2017	DS			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N021676 001	5569652	Oct 29, 2013		U-1		
	5798338	Jul 10, 2015	DP			
	6787531	Aug 31, 2020	DP			
	6933395	Aug 11, 2017	DP			
	6958326	Dec 20, 2021	DP			
	6987101	Dec 22, 2017		U-758		
	7163931	Dec 20, 2021		U-1		
	RE37564	Jun 30, 2014	DP			
	RE37838	Jun 30, 2014	DP			
	RE38253	Jun 30, 2014	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N022532 001	5798338	Jul 10, 2015	DP		NC	Sep 24, 2013
	6441168	Apr 17, 2020	DS		NP	Sep 24, 2013
	6958326	Dec 30, 2021	DP			
	7163931	Mar 03, 2022		U-1		
	RE37564	Jun 30, 2014	DP			
	RE37838	Jun 30, 2014	DP			
	RE38253	Jun 30, 2014	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N022574 001	5798338	Jul 10, 2015	DP		NP	Dec 16, 2013
	6441168	Apr 17, 2020	DS			
	6958326	Dec 20, 2021	DP			
	7163931	Mar 03, 2022		U-1		
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 001	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-799		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-839		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-398		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-797			
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019		U-882		
	6596756*PED	Mar 10, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 002	5023269	Jun 11, 2013	DS DP U-398		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-797		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799			
	5023269	Jun 11, 2013	DS DP U-796		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-795		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269	Jun 11, 2013	DS DP U-839			
	5023269	Jun 11, 2013	DS DP U-882			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 004	5023269	Jun 11, 2013	DS DP U-795		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-605		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-882		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-398		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269	Jun 11, 2013	DS DP U-797			
	5023269	Jun 11, 2013	DS DP U-799			
	5023269	Jun 11, 2013	DS DP U-839			
	5023269	Jun 11, 2013	DS DP U-796			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				
<u>DUTASTERIDE - AVODART</u>						
N021319 001	5565467	Nov 20, 2015	DS DP			
	5846976	Sep 17, 2013	U-476			
	5998427	Sep 17, 2013	DS DP U-477			
<u>DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE - JALYN</u>						
N022460 001	5565467	Nov 20, 2015	DS DP			
	5846976	Sep 17, 2013	U-1065			
	5998427	Sep 17, 2013	DS DP U-1066			
<u>EFAVIRENZ - SUSTIVA</u>						
N020972 001	5519021	May 21, 2013	DS DP			
	5663169	Sep 02, 2014	U-257			
	5811423	Aug 07, 2012	DS DP U-256			
	6238695	Apr 06, 2019	DP			
	6555133	Apr 06, 2019	U-248			
	6639071	Feb 14, 2018	DS			
	6939964	Jan 20, 2018	DS			
<u>EFAVIRENZ - SUSTIVA</u>						
N020972 002	5519021	May 21, 2013	DS DP			
	5663169	Sep 02, 2014	U-257			
	5811423	Aug 07, 2012	DS DP U-256			
	6238695	Apr 06, 2019	DP			
	6555133	Apr 06, 2019	U-248			
	6639071	Feb 14, 2018	DS			
	6939964	Jan 20, 2018	DS			
<u>EFAVIRENZ - SUSTIVA</u>						
N020972 003	5519021	May 21, 2013	DS DP			
	5663169	Sep 02, 2014	U-257			
	5811423	Aug 07, 2012	DS DP U-256			
	6238695	Apr 06, 2019	DP			
	6555133	Apr 06, 2019	U-248			
	6639071	Feb 14, 2018	DS			
	6939964	Jan 20, 2018	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ - SUSTIVA</u>						
N021360 001	5519021	May 21, 2013				
	5663169	Sep 02, 2014				
	5811423	Aug 07, 2012			U-256	
	6639071	Feb 14, 2018	DS			
	6939964	Jan 20, 2018	DS			
<u>EFAVIRENZ - SUSTIVA</u>						
N021360 002	5519021	May 21, 2013	DS DP			
	5663169	Sep 02, 2014			U-248	
	5811423	Aug 07, 2012			U-256	
	6639071	Feb 14, 2018	DS			
	6939964	Jan 20, 2018	DS			
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N021937 001	5519021	May 21, 2013	DS DP			
	5663169	Sep 02, 2014			U-750	
	5663169	Sep 02, 2014			U-1170	
	5811423	Aug 07, 2012			U-750	
	5811423	Aug 07, 2012			U-1170	
	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	5922695	Jul 25, 2017	DS		U-1170	
	5922695	Jul 25, 2017	DS		U-750	
	5922695*PED	Jan 25, 2018				
	5935946	Jul 25, 2017	DS DP		U-750	
	5935946	Jul 25, 2017	DS DP		U-1170	
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP		U-1170	
	5977089	Jul 25, 2017	DS DP		U-750	
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017			U-750	
	6043230	Jul 25, 2017			U-1170	
	6043230*PED	Jan 25, 2018				
	6639071	Feb 14, 2018	DS			
	6642245	Nov 04, 2020			U-1170	
	6642245	Nov 04, 2020			U-750	
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	6939964	Jan 20, 2018	DS			
<u>EFLORNITHINE HYDROCHLORIDE - VANIQA</u>						
N021145 001	5648394	Jul 15, 2014			U-334	
<u>ELETRIPTAN HYDROBROMIDE - RELPAX</u>						
N021016 001	5545644	Dec 26, 2016	DS DP		U-876	
	6110940	Aug 29, 2017				
<u>ELETRIPTAN HYDROBROMIDE - RELPAX</u>						
N021016 002	5545644	Dec 26, 2016	DS DP		U-876	
	6110940	Aug 29, 2017				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 001	6280959	Oct 30, 2018	DS DP U-1306		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-930		NCE	Nov 20, 2013
	7160870	Nov 20, 2022	DS DP U-1306		ODE	Nov 20, 2015
	7160870	Nov 20, 2022	DS DP U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-930			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-930			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-930			
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 002	6280959	Oct 30, 2018	DS DP U-1306		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-930		NCE	Nov 20, 2013
	7160870	Nov 20, 2022	DS DP U-1306		ODE	Nov 20, 2015
	7160870	Nov 20, 2022	DS DP U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-930			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-930			
	8052994	Aug 01, 2027	DP U-930			
	8052994	Aug 01, 2027	DP U-1306			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 003	6280959	Oct 30, 2018	DS DP U-1306		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-930		NCE	Nov 20, 2013
	7160870	Nov 20, 2022	DS DP U-1306		ODE	Nov 20, 2015
	7160870	Nov 20, 2022	DS DP U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-930			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-930			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	8062665	Aug 01, 2027	DP U-930			
	8062665	Aug 01, 2027	DP U-1306			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 004	6280959	Oct 30, 2018	DS DP	U-930	I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP	U-1306	NCE	Nov 20, 2013
	7160870	Nov 20, 2022	DS DP	U-930	ODE	Nov 20, 2015
	7160870	Nov 20, 2022	DS DP	U-1306		
	7332481	May 24, 2021		U-930		
	7332481	May 24, 2021		U-1306		
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP	U-930		
	7473686	May 24, 2021	DS DP	U-1306		
	7547719	Jul 13, 2025	DS DP	U-1306		
	7547719	Jul 13, 2025	DS DP	U-930		
	7790704	May 24, 2021		U-1306		
	7790704	May 24, 2021		U-930		
	7795293	May 21, 2023		U-1306		
	7795293	May 21, 2023		U-930		
	8071129	Aug 01, 2027	DP	U-1306		
	8071129	Aug 01, 2027	DP	U-930		
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 005	6280959	Oct 30, 2018	DS DP	U-930	I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP	U-1306	NCE	Nov 20, 2013
	7160870	Nov 20, 2022	DS DP	U-930	ODE	Nov 20, 2015
	7160870	Nov 20, 2022	DS DP	U-1306		
	7332481	May 24, 2021		U-1306		
	7332481	May 24, 2021		U-930		
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP	U-930		
	7473686	May 24, 2021	DS DP	U-1306		
	7547719	Jul 13, 2025	DS DP	U-930		
	7547719	Jul 13, 2025	DS DP	U-1306		
	7790704	May 24, 2021		U-1306		
	7790704	May 24, 2021		U-930		
	7795293	May 21, 2023		U-930		
	7795293	May 21, 2023		U-1306		
	8052995	Aug 01, 2027	DP	U-1306		
<u>EMEDASTINE DIFUMARATE - EMADINE</u>						
N020706 001	5441958	Dec 08, 2013		U-404		
<u>EMTRICITABINE - EMTRIVA</u>						
N021500 001	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020		U-257		
	6642245	Nov 04, 2020		U-541		
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE - EMTRIVA</u>						
N021896 001	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020		U-257		
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N202123 001	5814639	Sep 29, 2015	DS DP		NCE	May 20, 2016
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018		U-257		
	5922695	Jul 25, 2017	DS	U-257		
	5922695*PED	Jan 25, 2018				
	5935946	Jul 25, 2017	DS DP	U-257		
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP	U-257		
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017		U-257		
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020		U-257		
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 14, 2023	DS DP	U-257		
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N021752 001	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS DP	U-248		
	5914331*PED	Jan 02, 2018	DS			
	5922695	Jul 25, 2017	DS	U-248		
	5922695	Jul 25, 2017	DS	U-1259		
	5922695	Jul 25, 2017	DS	U-1170		
	5922695	Jul 25, 2017	DS	U-541		
	5922695*PED	Jan 25, 2018				
	5935946	Jul 25, 2017	DS DP	U-248		
	5935946	Jul 25, 2017	DS DP	U-541		
	5935946	Jul 25, 2017	DS DP	U-1170		
	5935946	Jul 25, 2017	DS DP	U-1259		
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP	U-541		
	5977089	Jul 25, 2017	DS DP	U-1259		
	5977089	Jul 25, 2017	DS DP	U-248		
	5977089	Jul 25, 2017	DS DP	U-1170		
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	DP	U-541		
	6043230	Jul 25, 2017	DP	U-1170		
	6043230	Jul 25, 2017	DP	U-248		
	6043230	Jul 25, 2017	DP	U-1259		
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020		U-248		
	6642245	Nov 04, 2020		U-541		
	6642245	Nov 04, 2020		U-1170		
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>ENFUVIRTIDE - FUZEON</u>						
N021481 001	5464933	Jun 07, 2013				
	6133418	Nov 17, 2014	DS DP			
	6475491	Jun 07, 2015		U-248		
<u>ENTACAPONE - COMTAN</u>						
N020796 001	5446194	Oct 19, 2013	DS			
	6599530	Sep 14, 2018		DP	U-219	
<u>ENTECAVIR - BARACLUDE</u>						
N021797 001	5206244	Feb 21, 2015	DS		D-127	Oct 15, 2013
					NPP	Oct 12, 2015
					NPP	Oct 12, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ENTECAVIR - BARACLUDE</u>						
N021797 002	5206244	Feb 21, 2015	DS		D-127 NPP NPP	Oct 15, 2013 Oct 12, 2015 Oct 12, 2015
<u>ENTECAVIR - BARACLUDE</u>						
N021798 001	5206244	Feb 21, 2015	DS		D-127 NPP NPP	Oct 15, 2013 Oct 12, 2015 Oct 12, 2015
<u>ENZALUTAMIDE - XTANDI</u>						
N203415 001	7709517 8183274	Aug 13, 2027 May 15, 2026	DS DP	U-1281	NCE	Aug 31, 2017
<u>EPINEPHRINE - ADRENACLICK</u>						
N020800 003	5665071	May 27, 2013	DP			
<u>EPINEPHRINE - ADRENACLICK</u>						
N020800 004	5665071	May 27, 2013	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N201739 001	8226610 8231573 8313466	Apr 10, 2029 Nov 25, 2028 Nov 23, 2024	DP DP DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N201739 002	8226610 8231573 8313466	Apr 10, 2029 Nov 25, 2028 Nov 23, 2024	DP DP DP			
<u>EPINEPHRINE - EPIPEN</u>						
N019430 001	7449012 7794432 8048035	Sep 11, 2025 Sep 11, 2025 Sep 11, 2025	DP DP DP			
<u>EPINEPHRINE - EPIPEN JR.</u>						
N019430 002	7449012 7794432 8048035	Sep 11, 2025 Sep 11, 2025 Sep 11, 2025	DP DP DP			
<u>EPINEPHRINE - TWINJECT 0.15</u>						
N020800 002	7297136 7621891	Jan 18, 2025 Feb 04, 2025	DP DP			
<u>EPINEPHRINE - TWINJECT 0.3</u>						
N020800 001	7297136 7621891	Jan 18, 2025 Feb 04, 2025	DP DP			
<u>EPINEPHRINE; LIDOCAINE HYDROCHLORIDE - LIDOSITE TOPICAL SYSTEM KIT</u>						
N021504 001	5246418 5873850 6377847 6385488 6629968 6635045 6862473	Sep 30, 2013 Sep 30, 2013 Sep 30, 2013 Sep 30, 2013 Jun 30, 2020 Jun 29, 2021 Sep 30, 2013	DS DP DS DP DS DP DS DP DS DP DS DP DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPLERENONE - INSPRA</u>						
N021437 001	6410054	Dec 08, 2019				U-3
	6410054	Dec 08, 2019				U-537
	6410054*PED	Jun 08, 2020				
	6410524	Nov 05, 2019				U-467
	6410524*PED	May 05, 2020				
	6495165	Dec 08, 2019				U-537
	6495165	Dec 08, 2019				U-3
	6495165*PED	Jun 08, 2020				
	6534093	Dec 08, 2019				U-537
	6534093	Dec 08, 2019				U-3
	6534093*PED	Jun 08, 2020				
	6558707	Dec 08, 2019	DP			U-537
	6558707*PED	Jun 08, 2020				
	6747020	Nov 05, 2019				U-587
	6747020*PED	May 05, 2020				
	6863902	Apr 10, 2020	DP			U-664
	6863902*PED	Oct 10, 2020				
	7157101	Dec 08, 2019	DP			U-664
	7157101*PED	Jun 08, 2020				
<u>EPLERENONE - INSPRA</u>						
N021437 002	6410054	Dec 08, 2019				U-537
	6410054	Dec 08, 2019				U-3
	6410054*PED	Jun 08, 2020				
	6410524	Nov 05, 2019				U-467
	6410524*PED	May 05, 2020				
	6495165	Dec 08, 2019				U-537
	6495165	Dec 08, 2019				U-3
	6495165*PED	Jun 08, 2020				
	6534093	Dec 08, 2019				U-3
	6534093	Dec 08, 2019				U-537
	6534093*PED	Jun 08, 2020				
	6558707	Dec 08, 2019	DP			U-537
	6558707*PED	Jun 08, 2020				
	6747020	Nov 05, 2019				U-587
	6747020*PED	May 05, 2020				
	6863902	Apr 10, 2020	DP			U-664
	6863902*PED	Oct 10, 2020				
	7157101	Dec 08, 2019	DP			U-664
	7157101*PED	Jun 08, 2020				
<u>EPLERENONE - INSPRA</u>						
N021437 003	6410054	Dec 08, 2019				U-537
	6410054	Dec 08, 2019				U-3
	6410054*PED	Jun 08, 2020				
	6410524	Nov 05, 2019				U-467
	6410524*PED	May 05, 2020				
	6495165	Dec 08, 2019				U-3
	6495165	Dec 08, 2019				U-537
	6495165*PED	Jun 08, 2020				
	6534093	Dec 08, 2019				U-3
	6534093	Dec 08, 2019				U-537
	6534093*PED	Jun 08, 2020				
	6558707	Dec 08, 2019	DP			U-537
	6558707*PED	Jun 08, 2020				
	6747020	Nov 05, 2019				U-587
	6747020*PED	May 05, 2020				
	6863902	Apr 10, 2020	DP			U-664
	6863902*PED	Oct 10, 2020				
	7157101	Dec 08, 2019	DP			U-664
	7157101*PED	Jun 08, 2020				
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N022260 001	8318802	Feb 09, 2027	DP			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N022260 002	8318802	Feb 09, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPROSARTAN MESYLATE - TEVETEN</u>						
N020738 004	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE - TEVETEN</u>						
N020738 005	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE - TEVETEN</u>						
N020738 006	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE - TEVETEN HCT</u>						
N021268 001	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE - TEVETEN HCT</u>						
N021268 002	5656650	Aug 12, 2014	U-3			
<u>EPTIFIBATIDE - INTEGRILIN</u>						
N020718 001	5686570	Nov 11, 2014				
	5747447	May 05, 2015				
	5756451	Nov 11, 2014				
	5807825	Sep 15, 2015	U-244			
	5968902	Jun 02, 2015	U-453			
<u>EPTIFIBATIDE - INTEGRILIN</u>						
N020718 002	5686570	Nov 11, 2014				
	5747447	May 05, 2015				
	5756451	Nov 11, 2014				
	5807825	Sep 15, 2015	U-244			
	5968902	Jun 02, 2015	U-453			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N201532 001	6214865	Jun 16, 2019	DS		NCE	Nov 15, 2015
	6469182	Jun 16, 2019		U-1096		
	7470720	Jun 16, 2019	DP			
	8097648	Jan 22, 2021		U-1096		
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 001	5747498	Nov 08, 2018	DS DP	U-659	I-624	Apr 16, 2013
	6900221	Nov 09, 2020	DS DP	U-875		
	6900221	Nov 09, 2020	DS DP	U-659		
	6900221	Nov 09, 2020	DS DP	U-1046		
	7087613	Nov 09, 2020		U-1045		
	7087613	Nov 09, 2020		U-659		
	RE41065	Nov 08, 2018	DS DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 002	5747498	Nov 08, 2018	DS DP	U-659	I-624	Apr 16, 2013
	6900221	Nov 09, 2020	DS DP	U-875		
	6900221	Nov 09, 2020	DS DP	U-1046		
	6900221	Nov 09, 2020	DS DP	U-659		
	7087613	Nov 09, 2020		U-659		
	7087613	Nov 09, 2020		U-1045		
	RE41065	Nov 08, 2018	DS DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 003	5747498	Nov 08, 2018	DS DP	U-659	I-624	Apr 16, 2013
	6900221	Nov 09, 2020	DS DP	U-1046		
	6900221	Nov 09, 2020	DS DP	U-659		
	6900221	Nov 09, 2020	DS DP	U-875		
	7087613	Nov 09, 2020		U-1045		
	7087613	Nov 09, 2020		U-659		
	RE41065	Nov 08, 2018	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ERTAPENEM SODIUM - INVANZ</u>						
N021337 001	5478820	Nov 21, 2015	DS DP U-160			
	5478820*PED	May 21, 2016				
	5652233	Feb 02, 2013	DS DP U-160			
	5652233*PED	Aug 02, 2013				
	5952323	May 15, 2017	DP			
	5952323*PED	Nov 15, 2017				
	7342005	Feb 02, 2013	DP			
	7342005*PED	Aug 02, 2013				
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 001					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 002					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 003					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N021323 001	6916941	Aug 12, 2022	DS DP			
	6916941*PED	Feb 12, 2023	DS DP			
	7420069	Aug 12, 2022	DP			
	7420069*PED	Feb 12, 2023				
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N021323 002	6916941	Aug 12, 2022	DS DP			
	6916941*PED	Feb 12, 2023	DS DP			
	7420069	Aug 12, 2022	DP			
	7420069*PED	Feb 12, 2023				
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N021323 003	6916941	Aug 12, 2022	DS DP			
	6916941*PED	Feb 12, 2023	DS DP			
	7420069	Aug 12, 2022	DP			
	7420069*PED	Feb 12, 2023				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N019386 006	6310094	Jan 12, 2021				
	6310094*PED	Jul 12, 2021				
	6528540	Jan 12, 2021				
	6528540*PED	Jul 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N019386 007	6310094	Jan 12, 2021				
	6310094*PED	Jul 12, 2021				
	6528540	Jan 12, 2021				
	6528540*PED	Jul 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N019386 005	6310094	Jan 12, 2021				
	6310094*PED	Jul 12, 2021				
	6528540	Jan 12, 2021				
	6528540*PED	Jul 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC IN PLASTIC CONTAINER</u>						
N019386 004	6310094	Jan 12, 2021				
	6310094*PED	Jul 12, 2021				
	6528540	Jan 12, 2021				
	6528540*PED	Jul 12, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021153 001	5690960	Nov 25, 2014	DP U-770			
	5690960	Nov 25, 2014	DP U-373			
	5690960	Nov 25, 2014	DP U-729			
	5690960*PED	May 25, 2015	U-373			
	5714504	Feb 03, 2015	DP U-770			
	5714504	Feb 03, 2015	DP U-373			
	5714504	Feb 03, 2015	DP U-729			
	5714504*PED	Aug 03, 2015	U-373			
	5877192	May 27, 2014	DP U-770			
	5877192	May 27, 2014	DP U-729			
	5877192	May 27, 2014	DP U-373			
	5877192*PED	Nov 27, 2014	U-373			
	5900424	May 04, 2016	DS U-729			
	5900424	May 04, 2016	DS U-373			
	5900424	May 04, 2016	DS U-770			
	5900424*PED	Nov 04, 2016	U-373			
	6147103	Oct 09, 2018				
	6147103*PED	Apr 09, 2019				
	6166213	Oct 09, 2018				
	6166213*PED	Apr 09, 2019				
	6191148	Oct 09, 2018				
	6191148*PED	Apr 09, 2019				
	6369085	May 25, 2018	DS DP U-770			
	6369085	May 25, 2018	DS DP U-729			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-469			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-770			
	6428810*PED	May 03, 2020	U-469			
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021153 002	5690960	Nov 25, 2014	DP U-373			
	5690960	Nov 25, 2014	DP U-770			
	5690960	Nov 25, 2014	DP U-729			
	5690960*PED	May 25, 2015	U-373			
	5714504	Feb 03, 2015	DP U-729			
	5714504	Feb 03, 2015	DP U-373			
	5714504	Feb 03, 2015	DP U-770			
	5714504*PED	Aug 03, 2015	U-373			
	5877192	May 27, 2014	DP U-729			
	5877192	May 27, 2014	DP U-373			
	5877192	May 27, 2014	DP U-770			
	5877192*PED	Nov 27, 2014	U-373			
	5900424	May 04, 2016	DS U-373			
	5900424	May 04, 2016	DS U-770			
	5900424	May 04, 2016	DS U-729			
	5900424*PED	Nov 04, 2016	U-373			
	6147103	Oct 09, 2018				
	6147103*PED	Apr 09, 2019				
	6166213	Oct 09, 2018				
	6166213*PED	Apr 09, 2019				
	6191148	Oct 09, 2018				
	6191148*PED	Apr 09, 2019				
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-770			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-770			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-469			
	6428810*PED	May 03, 2020	U-469			
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
ESOMEPRAZOLE MAGNESIUM - NEXIUM									
N021957 001	5690960	Nov 25, 2014	DP	U-773			PED	Dec 18, 2012	
	5690960	Nov 25, 2014	DP	U-729					
	5690960	Nov 25, 2014	DP	U-1207					
	5690960*PED	May 25, 2015							
	5714504	Feb 03, 2015	DP	U-729					
	5714504	Feb 03, 2015	DP	U-773					
	5714504	Feb 03, 2015	DP	U-1207					
	5714504*PED	Aug 03, 2015							
	5877192	May 27, 2014		U-1207					
	5877192	May 27, 2014		U-729					
	5877192	May 27, 2014		U-773					
	5877192*PED	Nov 27, 2014							
	5900424	May 04, 2016	DS	U-1207					
	5900424	May 04, 2016	DS	U-729					
	5900424	May 04, 2016	DS	U-773					
	5900424*PED	Nov 04, 2016							
	6369085	May 25, 2018	DS	DP	U-1207				
	6369085	May 25, 2018	DS	DP	U-729				
	6369085	May 25, 2018	DS	DP	U-773				
	6369085*PED	Nov 25, 2018							
	6428810	Nov 03, 2019		DP	U-1207				
	6428810	Nov 03, 2019		DP	U-773				
	6428810	Nov 03, 2019		DP	U-729				
	6428810*PED	May 03, 2020							
	6875872	May 27, 2014	DS						
	6875872*PED	Nov 27, 2014							
	7411070	May 25, 2018	DS						
	7411070*PED	Nov 25, 2018							
ESOMEPRAZOLE MAGNESIUM - NEXIUM									
N021957 002	5690960	Nov 25, 2014	DP	U-773			PED	Dec 18, 2012	
	5690960	Nov 25, 2014	DP	U-729					
	5690960	Nov 25, 2014	DP	U-1207					
	5690960*PED	May 25, 2015							
	5714504	Feb 03, 2015	DP	U-773					
	5714504	Feb 03, 2015	DP	U-729					
	5714504	Feb 03, 2015	DP	U-1207					
	5714504*PED	Aug 03, 2015							
	5877192	May 27, 2014		U-1207					
	5877192	May 27, 2014		U-729					
	5877192	May 27, 2014		U-773					
	5877192*PED	Nov 27, 2014							
	5900424	May 04, 2016	DS	U-1207					
	5900424	May 04, 2016	DS	U-773					
	5900424	May 04, 2016	DS	U-729					
	5900424*PED	Nov 04, 2016							
	6369085	May 25, 2018	DS	DP	U-773				
	6369085	May 25, 2018	DS	DP	U-1207				
	6369085	May 25, 2018	DS	DP	U-729				
	6369085*PED	Nov 25, 2018							
	6428810	Nov 03, 2019		DP	U-729				
	6428810	Nov 03, 2019		DP	U-773				
	6428810	Nov 03, 2019		DP	U-1207				
	6428810*PED	May 03, 2020							
	6875872	May 27, 2014	DS						
	6875872*PED	Nov 27, 2014							
	7411070	May 25, 2018	DS						
	7411070*PED	Nov 25, 2018							

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 003	5690960	Nov 25, 2014	DP U-1207			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1207			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1207			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1207			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1207			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 004	5690960	Nov 25, 2014	DP U-1207			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1207			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1207			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1207			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1207			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N022101 001	5690960	Nov 25, 2014	DP U-858		PED	Dec 18, 2012
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-858			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014	U-858			
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-858			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-858			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-858			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 001	5714504	Feb 03, 2015	DP U-1053		NC	Apr 30, 2013
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS U-1053			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1053			
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	6926907	Feb 28, 2023	DP U-1052			
	7411070	May 25, 2018	DS U-1053			
	7411070*PED	Nov 25, 2018				
	7745466	Oct 13, 2018	DP U-1053			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 002	5714504	Feb 03, 2015	DP U-1053		NC	Apr 30, 2013
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS U-1053			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1053			
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	6926907	Feb 28, 2023	DP U-1052			
	7411070	May 25, 2018	DS U-1053			
	7411070*PED	Nov 25, 2018				
	7745466	Oct 13, 2018	DP U-1053			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N021689 001	5877192	May 27, 2014	U-643			
	5877192*PED	Nov 27, 2014				
	6143771	May 27, 2014	DP U-643			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N021689 002	5877192	May 27, 2014	U-643			
	5877192*PED	Nov 27, 2014				
	6143771	May 27, 2014	DP U-643			
<u>ESTRADIOL - ELESTRIN</u>						
N021813 001	7198801	Jun 25, 2022	DP			
	7470433	Aug 03, 2021	DP			
<u>ESTRADIOL - EVAMIST</u>						
N022014 001	6299900	Feb 19, 2017	DP U-889			
	6299900	Feb 19, 2017	DP U-888			
	6818226	Feb 19, 2017	DP U-888			
	6818226	Feb 19, 2017	DP U-889			
	6923983	Feb 19, 2017	DP U-889			
	6923983	Feb 19, 2017	DP U-888			
	6978945	Nov 30, 2021	DP			
<u>ESTRADIOL - MENOSTAR</u>						
N021674 001	5891868	Nov 21, 2017	DP U-594			
	6692763	Nov 21, 2017	DP U-594			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 001	6841716	Apr 27, 2020	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 002	6841716	Apr 27, 2020	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 003	6841716	Apr 27, 2020	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 004	6841716	Apr 27, 2020	DP			
<u>ESTRADIOL - VAGIFEM</u>						
N020908 002	5860946	Jul 01, 2017	DP		D-122	Nov 25, 2012
	7018992	Sep 17, 2022	U-1023			
<u>ESTRADIOL - VIVELLE-DOT</u>						
N020538 005	5474783	Dec 12, 2012				
	5656286	Aug 12, 2014				
	5958446	Dec 12, 2012				
	6024976	Jan 07, 2014				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N020538 006	5474783	Dec 12, 2012				
	5656286	Aug 12, 2014				
	5958446	Dec 12, 2012				
	6024976	Jan 07, 2014				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - VIVELLE-DOT</u>						
N020538	007	5474783	Dec 12, 2012			
		5656286	Aug 12, 2014			
		5958446	Dec 12, 2012			
		6024976	Jan 07, 2014			
<u>ESTRADIOL - VIVELLE-DOT</u>						
N020538	008	5474783	Dec 12, 2012			
		5656286	Aug 12, 2014			
		5958446	Dec 12, 2012			
		6024976	Jan 07, 2014			
<u>ESTRADIOL - VIVELLE-DOT</u>						
N020538	009	5474783	Dec 12, 2012	DP		
		5656286	Aug 12, 2014	DP		
		5958446	Dec 12, 2012	DP		
		6024976	Jan 07, 2014	DP		
<u>ESTRADIOL ACETATE - FEMRING</u>						
N021367	001	5855906	Dec 19, 2015		U-508	
<u>ESTRADIOL ACETATE - FEMRING</u>						
N021367	002	5855906	Dec 19, 2015		U-508	
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N021633	001	6962908	Dec 21, 2021	DP		
		7572779	Oct 02, 2025		U-904	
		7799771	Dec 21, 2021	DP		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N021633	002	6962908	Dec 21, 2021	DP		
		7572779	Oct 02, 2025		U-904	
		7799771	Dec 21, 2021	DP		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N021633	003	6962908	Dec 21, 2021	DP		
		7572779	Oct 02, 2025		U-904	
		7799771	Dec 21, 2021	DP		
<u>ESTRADIOL HEMIHYDRATE - ESTRASORB</u>						
N021371	001	5629021	Jan 31, 2015	DP		
<u>ESTRADIOL; LEVONORGESTREL - CLIMARA PRO</u>						
N021258	001	5676968	Oct 14, 2014	DP		
<u>ESTRADIOL; NORETHINDRONE ACETATE - COMBIPATCH</u>						
N020870	001	5474783	Dec 12, 2012			
		5656286	Aug 12, 2014			
		5958446	Dec 12, 2012			
		6024976	Jan 07, 2014			
<u>ESTRADIOL; NORETHINDRONE ACETATE - COMBIPATCH</u>						
N020870	002	5474783	Dec 12, 2012			
		5656286	Aug 12, 2014			
		5958446	Dec 12, 2012			
		6024976	Jan 07, 2014			
<u>ESTRADIOL; NORGESTIMATE - PREFEST</u>						
N021040	001	6747019	Mar 20, 2020		U-311	
		7320970	Mar 30, 2020	DP	U-844	
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N020992	001	5908638	Jul 26, 2015	DP		
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N020992	002	5908638	Jul 26, 2015			
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N020992	003	5908638	Jul 26, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N020992 004	5908638	Jul 26, 2015				
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N020992 005	5908638	Jul 26, 2015				
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N021443 001	6660726	Mar 08, 2021	DS DP		U-905	
	6660726	Mar 08, 2021	DS DP		U-904	
	6855703	Feb 12, 2021	DS DP		U-904	
	6855703	Feb 12, 2021	DS DP		U-905	
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N021443 002	6660726	Mar 08, 2021	DS DP		U-905	
	6660726	Mar 08, 2021	DS DP		U-904	
	6855703	Feb 12, 2021	DS DP		U-905	
	6855703	Feb 12, 2021	DS DP		U-904	
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N021443 003	6660726	Mar 08, 2021	DS DP		U-905	
	6660726	Mar 08, 2021	DS DP		U-904	
	6855703	Feb 12, 2021	DS DP		U-904	
	6855703	Feb 12, 2021	DS DP		U-905	
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N021443 004	6660726	Mar 08, 2021	DS DP		U-905	
	6660726	Mar 08, 2021	DS DP		U-904	
	6855703	Feb 12, 2021	DS DP		U-905	
	6855703	Feb 12, 2021	DS DP		U-904	
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N021443 005	6660726	Mar 08, 2021	DS DP		U-905	
	6660726	Mar 08, 2021	DS DP		U-904	
	6855703	Feb 12, 2021	DS DP		U-904	
	6855703	Feb 12, 2021	DS DP		U-905	
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPHASE 14/14</u>						
N020527 002	5547948	Jan 17, 2015				
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N020527 001	5547948	Jan 17, 2015				
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N020527 003	5547948	Jan 17, 2015				
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N020527 004	5547948	Jan 17, 2015				
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N020527 005	5547948	Jan 17, 2015				
<u>ESZOPICLONE - LUNESTA</u>						
N021476 001	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012			U-629	
	6864257*PED	Mar 02, 2013				
	7381724*PED	Jul 16, 2012				
<u>ESZOPICLONE - LUNESTA</u>						
N021476 002	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012			U-629	
	6864257*PED	Mar 02, 2013				
	7381724*PED	Jul 16, 2012				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
ESZOPICLONE - LUNESTA									
N021476 003	6319926*PED	Jul	16,	2012	DS DP	U-629			
	6444673	Feb	14,	2014					
	6444673*PED	Aug	14,	2014					
	6864257	Aug	30,	2012					
	6864257*PED	Mar	02,	2013					
	7381724*PED	Jul	16,	2012					
ETHINYL ESTRADIOL; ETONOGESTREL - NUVARING									
N021187 001	5989581	Apr	08,	2018					
ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE									
N022262 001	7615545	Jun	15,	2023		U-1			
	7855190	Dec	05,	2028		U-1			
	7858605	Jun	23,	2023	DP				
ETHINYL ESTRADIOL; LEVONORGESTREL - LYBREL									
N021864 001	6500814	Sep	03,	2018		U-1			
ETHINYL ESTRADIOL; LEVONORGESTREL - PREVEN EMERGENCY CONTRACEPTIVE KIT									
N020946 001	6156742	Dec	05,	2020		U-374			
ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONALE									
N021544 001	5898032	Jun	23,	2017		U-1			
	RE39861	Jun	23,	2017		U-828			
ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE									
N021840 001	7320969	Jan	30,	2024		U-828			
	7615545	Jun	15,	2023		U-1			
	7855190	Dec	05,	2028		U-1			
	7858605	Jun	23,	2023	DP				
ETHINYL ESTRADIOL; NORELGESTROMIN - ORTHO EVRA									
N021180 001	5876746	Nov	20,	2015	DP	U-514			
	5972377	Jun	07,	2015		U-514			
ETHINYL ESTRADIOL; NORETHINDRONE - FEMCON FE									
N021490 001	6667050	Apr	06,	2019	DP	U-1			
ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE									
N022573 001	5552394	Jul	22,	2014		U-828	NP	Dec	22, 2013
	6667050	Apr	06,	2019	DP	U-828			
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO LOESTRIN FE									
N022501 001	5552394	Jul	22,	2014		U-1090	NP	Oct	21, 2013
	7704984	Feb	02,	2029		U-1090			
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LOESTRIN 24 FE									
N021871 001	5552394	Jul	22,	2014		U-1			
ETHINYL ESTRADIOL; NORGESTIMATE - ORTHO TRI-CYCLEN LO									
N021241 001	6214815	Jun	09,	2019		U-112			
	6214815*PED	Dec	09,	2019					
ETONOGESTREL - NEXPLANON									
N021529 002							NP	May	31, 2014
ETRAVIRINE - INTELENCE									
N022187 001	6878717	Nov	05,	2019		U-1237	NPP	Mar	26, 2015
	6878717	Nov	05,	2019		U-1016	NCE	Jan	18, 2013
	6878717	Nov	05,	2019		U-256			
	7037917	Dec	13,	2020	DS DP	U-1237			
	7037917	Dec	13,	2020	DS DP	U-256			
	7037917	Dec	13,	2020	DS DP	U-1016			
	7887845	Mar	25,	2019	DP				
	8003789	Nov	01,	2019	DS DP				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETRAVIRINE - INTELENCE</u>						
N022187 002	6878717	Nov 05, 2019		U-1237	NPP	Mar 26, 2015
	6878717	Nov 05, 2019		U-1016	NCE	Jan 18, 2013
	6878717	Nov 05, 2019		U-256		
	7037917	Dec 13, 2020	DS DP	U-1237		
	7037917	Dec 13, 2020	DS DP	U-1016		
	7037917	Dec 13, 2020	DS DP	U-256		
	7887845	Mar 25, 2019		DP		
	8003789	Nov 01, 2019	DS DP			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 003	6878717	Nov 05, 2019		U-1016	NCE	Jan 18, 2013
	6878717	Nov 05, 2019		U-1237	NPP	Mar 26, 2015
	6878717	Nov 05, 2019		U-256		
	7037917	Dec 13, 2020	DS DP	U-1237		
	7887845	Mar 25, 2019		DP		
	8003789	Nov 01, 2019	DS DP			
<u>EVEROLIMUS - AFINITOR</u>						
N022334 001	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016		DP	I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019		DP	NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Apr 29, 2014
					PED	Sep 30, 2014
					PED	Nov 05, 2014
					PED	Oct 26, 2015
					PED	Apr 29, 2018
					PED	Nov 05, 2018
					PED	Oct 26, 2019
<u>EVEROLIMUS - AFINITOR</u>						
N022334 002	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016		DP	I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019		DP	NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Apr 29, 2014
					PED	Sep 30, 2014
					PED	Nov 05, 2014
					PED	Oct 26, 2015
					PED	Apr 29, 2018
					PED	Nov 05, 2018
					PED	Oct 26, 2019

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N022334 003	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Apr 29, 2014
					PED	Sep 30, 2014
					PED	Nov 05, 2014
					PED	Oct 26, 2015
					PED	Apr 29, 2018
					PED	Nov 05, 2018
					PED	Oct 26, 2019
<u>EVEROLIMUS - AFINITOR</u>						
N022334 004	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-638	May 05, 2014
	6004973	Jul 12, 2016	DP		I-630	Oct 29, 2013
	6004973*PED	Jan 12, 2017			I-650	Apr 26, 2015
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Apr 29, 2014
					PED	Sep 30, 2014
					PED	Nov 05, 2014
					PED	Oct 26, 2015
					PED	Apr 29, 2018
					PED	Nov 05, 2018
					PED	Oct 26, 2019
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 001	5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	6004973*PED	Jan 12, 2017			PED	Apr 29, 2018
	7297703	Dec 06, 2019	DP		PED	Apr 29, 2014
	7297703*PED	Jun 06, 2020			PED	Sep 30, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 002	5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	6004973*PED	Jan 12, 2017			PED	Apr 29, 2018
	7297703	Dec 06, 2019	DP		PED	Apr 29, 2014
	7297703*PED	Jun 06, 2020			PED	Sep 30, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 003	5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	6004973*PED	Jan 12, 2017			PED	Apr 29, 2018
	7297703	Dec 06, 2019	DP		PED	Apr 29, 2014
	7297703*PED	Jun 06, 2020			PED	Sep 30, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 001	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Oct 20, 2013
	6004973*PED	Jan 12, 2017			PED	Sep 30, 2014
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Oct 20, 2013
	6004973*PED	Jan 12, 2017			PED	Sep 30, 2014
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Oct 20, 2013
	6004973*PED	Jan 12, 2017			PED	Sep 30, 2014
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N022200 001	5424286	Dec 01, 2016	U-1108		NP	Jan 27, 2015
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
	8329648	Aug 18, 2026	U-1313			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 001	5424286	Dec 01, 2016	U-653		M-113	Oct 19, 2014
	5424286	Dec 01, 2016	U-1108		M-111	Oct 19, 2014
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6902744	Jan 14, 2020	DP			
	6956026	Jan 07, 2018	U-687			
	7297761	Oct 15, 2017	DP			
	7521423	Oct 15, 2017	DP			
	7741269	Jan 07, 2018	U-1074			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 002	5424286	Dec 01, 2016	U-1108		M-113	Oct 19, 2014
	5424286	Dec 01, 2016	U-653		M-111	Oct 19, 2014
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6902744	Jan 14, 2020	DP			
	6956026	Jan 07, 2018	U-687			
	7297761	Oct 15, 2017	DP			
	7521423	Oct 15, 2017	DP			
	7741269	Jan 07, 2018	U-1074			
<u>EZETIMIBE - ZETIA</u>						
N021445 001	5846966	Sep 21, 2013	U-474		M-109	Jan 24, 2015
	5846966	Sep 21, 2013	U-1172			
	5846966	Sep 21, 2013	U-473			
	5846966*PED	Mar 21, 2014				
	7030106	Jan 25, 2022	DP			
	7030106*PED	Jul 25, 2022				
	7612058	Jan 25, 2022	U-1173			
	7612058	Jan 25, 2022	U-1027			
	7612058*PED	Jul 25, 2022				
	RE37721	Oct 25, 2016	DS DP U-473			
	RE37721*PED	Apr 25, 2017				
	RE42461	Oct 25, 2016	DS DP U-1173			
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 001	5846966	Sep 21, 2013	DP U-593		M-109	Jan 24, 2015
	5846966	Sep 21, 2013	DP U-473			
	5846966*PED	Mar 21, 2014				
	RE37721	Oct 25, 2016	DS DP U-473			
	RE37721*PED	Apr 25, 2017				
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 002	5846966	Sep 21, 2013	DP U-593		M-109	Jan 24, 2015
	5846966	Sep 21, 2013	DP U-473			
	5846966*PED	Mar 21, 2014				
	RE37721	Oct 25, 2016	DS DP U-473			
	RE37721*PED	Apr 25, 2017				
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 003	5846966	Sep 21, 2013	DP U-593		M-109	Jan 24, 2015
	5846966	Sep 21, 2013	DP U-473			
	5846966*PED	Mar 21, 2014				
	RE37721	Oct 25, 2016	DS DP U-473			
	RE37721*PED	Apr 25, 2017				
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 004	5846966	Sep 21, 2013	DP U-473		M-109	Jan 24, 2015
	5846966	Sep 21, 2013	DP U-593			
	5846966*PED	Mar 21, 2014				
	RE37721	Oct 25, 2016	DS DP U-473			
	RE37721*PED	Apr 25, 2017				
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZOGABINE - POTIGA</u>						
N022345 001					NCE	Jun 10, 2016
<u>EZOGABINE - POTIGA</u>						
N022345 002					NCE	Jun 10, 2016
<u>EZOGABINE - POTIGA</u>						
N022345 003					NCE	Jun 10, 2016

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EZOGABINE - POTIGA</u>						
N022345	004				NCE	Jun 10, 2016
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	001	5840763	Sep 01, 2015	U-96	M-112	Feb 09, 2015
		5840763*PED	Mar 01, 2016		M-98	Jan 31, 2014
		5866581	Oct 04, 2014	U-96	M-54	Dec 24, 2012
		5866581*PED	Apr 04, 2015		PED	Jun 24, 2013
		5916893	Sep 01, 2015	U-96		
		5916893*PED	Mar 01, 2016			
		6124304	Oct 04, 2014	U-96		
		6124304*PED	Apr 04, 2015			
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	002	5840763	Sep 01, 2015	U-96	M-112	Feb 09, 2015
		5840763*PED	Mar 01, 2016		M-98	Jan 31, 2014
		5866581	Oct 04, 2014	U-96	M-54	Dec 24, 2012
		5866581*PED	Apr 04, 2015		PED	Jun 24, 2013
		5916893	Sep 01, 2015	U-96		
		5916893*PED	Mar 01, 2016			
		6124304	Oct 04, 2014	U-96		
		6124304*PED	Apr 04, 2015			
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	003	5840763	Sep 01, 2015	U-96	M-112	Feb 09, 2015
		5840763*PED	Mar 01, 2016		M-98	Jan 31, 2014
		5866581	Oct 04, 2014	U-96	M-54	Dec 24, 2012
		5866581*PED	Apr 04, 2015		PED	Jun 24, 2013
		5916893	Sep 01, 2015	U-96		
		5916893*PED	Mar 01, 2016			
		6124304	Oct 04, 2014	U-96		
		6124304*PED	Apr 04, 2015			
<u>FAMOTIDINE - FLUXID</u>						
N021712	001	6024981	Apr 09, 2018	DP		
		6221392	Apr 09, 2018	DP		
<u>FAMOTIDINE - FLUXID</u>						
N021712	002	6024981	Apr 09, 2018	DP		
		6221392	Apr 09, 2018	DP		
<u>FAMOTIDINE - PEPCID AC</u>						
N020325	001	5854267	Dec 29, 2015	U-267		
		5854267*PED	Jun 29, 2016	U-267		
<u>FAMOTIDINE - PEPCID AC</u>						
N020801	001	5667794	May 02, 2015		Y	
		5667794*PED	Nov 02, 2015			
		5854267	Dec 29, 2015	U-267		
		5854267*PED	Jun 29, 2016			
<u>FAMOTIDINE - PEPCID AC</u>						
N020801	002	6814978	Aug 26, 2021	DP		
		6814978*PED	Feb 26, 2022			
<u>FAMOTIDINE - PEPCID AC (GELTAB)</u>						
N020902	001	5854267	Dec 29, 2015	U-368		
		5854267*PED	Jun 29, 2016	U-368		
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N022519	001	8067033	Jul 18, 2026	DP	NC	Apr 23, 2014
		8067451	Jul 18, 2026	DP	U-1196	
		8309127	Jul 18, 2026	DP		
		8318202	Jul 18, 2026	DP		
<u>FEBUXOSTAT - ULORIC</u>						
N021856	001	5614520	Mar 25, 2014	DS DP	NCE	Feb 13, 2014
		6225474	Jun 18, 2019	DS		
		7361676	Mar 08, 2024	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES			PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
<u>FEBUXOSTAT - ULORIC</u>										
N021856	002	5614520	Mar 25, 2014	DS	DP	U-954		NCE	Feb 13, 2014	
		6225474	Jun 18, 2019	DS						
		7361676	Mar 08, 2024		DP					
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>										
N021695	001	7101574	Aug 20, 2020	DS	DP					
		7863331	Aug 08, 2020			U-1107				
		7863331	Aug 08, 2020			U-1106				
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>										
N021695	003	7101574	Aug 20, 2020	DS	DP					
		7863331	Aug 08, 2020			U-1106				
		7863331	Aug 08, 2020			U-1107				
<u>FENOFIBRATE - FENOGLIDE</u>										
N022118	001	7658944	Dec 09, 2024		DP					
		8124125	Oct 01, 2024		DP	U-1234				
<u>FENOFIBRATE - FENOGLIDE</u>										
N022118	002	7658944	Dec 09, 2024		DP					
		8124125	Oct 01, 2024		DP	U-1234				
<u>FENOFIBRATE - LIPOFEN</u>										
N021612	001	5545628	Jan 10, 2015		DP	U-701				
<u>FENOFIBRATE - LIPOFEN</u>										
N021612	002	5545628	Jan 10, 2015		DP	U-701				
<u>FENOFIBRATE - LIPOFEN</u>										
N021612	003	5545628	Jan 10, 2015		DP	U-701				
<u>FENOFIBRATE - TRICOR</u>										
N021203	001	6074670	Jan 09, 2018							
		6277405	Jan 09, 2018							
		6589552	Jan 09, 2018							
		6652881	Jan 09, 2018		DP					
		7037529	Jan 09, 2018		DP					
		7041319	Jan 09, 2018		DP					
<u>FENOFIBRATE - TRICOR</u>										
N021203	003	6074670	Jan 09, 2018							
		6277405	Jan 09, 2018							
		6589552	Jan 09, 2018							
		6652881	Jan 09, 2018		DP					
		7037529	Jan 09, 2018		DP					
		7041319	Jan 09, 2018		DP					
<u>FENOFIBRATE - TRICOR</u>										
N021656	001	6277405	Jan 09, 2018	DS						
		6375986	Sep 21, 2020		DP	U-615				
		6652881	Jan 09, 2018	DS						
		7037529	Jan 09, 2018		DP					
		7041319	Jan 09, 2018		DP					
		7276249	Feb 21, 2023		DP					
		7320802	Feb 21, 2023			U-847				
<u>FENOFIBRATE - TRICOR</u>										
N021656	002	6277405	Jan 09, 2018	DS						
		6375986	Sep 21, 2020		DP	U-615				
		6652881	Jan 09, 2018	DS						
		7037529	Jan 09, 2018		DP					
		7041319	Jan 09, 2018		DP					
		7276249	Feb 21, 2023		DP					
		7320802	Feb 21, 2023			U-847				
<u>FENOFIBRATE - TRIGLIDE</u>										
N021350	001	6696084	Sep 11, 2021	DS	DP	U-680				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRATE - TRIGLIDE</u>						
N021350 002	6696084	Sep 11, 2021	DS DP U-680			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418 001	7569612	Aug 20, 2027	U-1000			
	7741373	Aug 20, 2027	U-1059			
	7741374	Aug 20, 2027	U-1060			
	7741374	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1000			
	7915247	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1059			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418 002	7569612	Aug 20, 2027	U-1000			
	7741373	Aug 20, 2027	U-1059			
	7741374	Aug 20, 2027	U-1061			
	7741374	Aug 20, 2027	U-1060			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1000			
	7915247	Aug 20, 2027	U-1061			
<u>FENTANYL - SUBSYS</u>						
N202788 001					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 002					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 003					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 004					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 005					NP	Jan 04, 2015
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 001	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 002	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 003	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 004	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 005	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 006	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 001	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 002	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 003	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 004	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 005	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 006	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 001	6432440	Apr 20, 2018	DP U-1169		NDF	Jun 30, 2014
	8216604	Oct 03, 2024	U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 002	6432440	Apr 20, 2018	DP U-1169		NDF	Jun 30, 2014
	8216604	Oct 03, 2024	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 001	6159498	Oct 18, 2016	DP		NP	Jul 16, 2012
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 002	6159498	Oct 18, 2016	DP		NP	Jul 16, 2012
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 003	6159498	Oct 18, 2016	DP		NP	Jul 16, 2012
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 004	6159498	Oct 18, 2016	DP		NP	Jul 16, 2012
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 005	6159498	Oct 18, 2016	DP		NP	Jul 16, 2012
	7579019	Jan 22, 2020	U-767			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N021338 001	5697896	Dec 16, 2014	DP			
	5843014	Dec 01, 2015	DP			
	6169920	Jan 02, 2018	DP			
	6171294	Jun 05, 2015		U-736		
	6181963	Nov 02, 2019	DP			
	6195582	Jan 28, 2019	DP	U-736		
	6216033	Jun 05, 2015	DP			
	6425892	Jun 05, 2015		U-736		
	6842640	Jun 02, 2015	DP			
	6881208	Apr 19, 2022		U-736		
	6975902	Apr 01, 2024	DP			
	7018370	Jun 05, 2015		U-736		
	7027859	Sep 26, 2014	DP			
	7302293	Jun 05, 2015	DP			
<u>FERUMOXYTOL - FERAHEME</u>						
N022180 001	6599498	Mar 08, 2020	DS DP			
	7553479	Mar 08, 2020	DS DP			
	7871597	Mar 08, 2020	DS DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	6858650	Jul 03, 2022	DS	U-913	NCE	Oct 31, 2013
	7384980	May 11, 2019	DS DP	U-913		
	7807715	Jun 07, 2027		DP U-913		
	7855230	May 11, 2019		U-913		
	7985772	May 11, 2019	DS DP	U-913		
	8088398	Jun 07, 2027	DP	U-913		
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	6858650	Jul 03, 2022	DS	U-913	NCE	Oct 31, 2013
	7384980	May 11, 2019	DS DP	U-913		
	7807715	Jun 07, 2027		DP U-913		
	7855230	May 11, 2019		U-913		
	7985772	May 11, 2019	DS DP	U-913		
	8088398	Jun 07, 2027	DP	U-913		
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N020625 001	5578610	Nov 26, 2013		U-192		
	5578610*PED	May 26, 2014		U-192		
	5738872	Feb 28, 2015				
	5738872*PED	Aug 28, 2015				
	5855912	Feb 28, 2015				
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015				
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017		U-138		
	6037353*PED	Sep 14, 2017		U-138		
	6113942	Feb 28, 2015				
	6113942*PED	Aug 28, 2015				
	6187791*PED	Nov 11, 2012		U-138		
	6399632*PED	Nov 11, 2012		U-468		
	7135571	May 18, 2014	DS			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N021963 001	5578610	Nov 26, 2013	DS DP	U-772		
	6037353	Mar 14, 2017		U-772		
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY							
N020872 007	5578610	Nov 26, 2013	DS DP	U-1160			
	5578610*PED	May 26, 2014					
	5855912	Feb 28, 2015					
	5855912*PED	Aug 28, 2015					
	5932247	Feb 28, 2015					
	5932247*PED	Aug 28, 2015					
	6037353	Mar 14, 2017					
	6037353*PED	Sep 14, 2017					
	6113942	Feb 28, 2015					
	6113942*PED	Aug 28, 2015					
	6187791*PED	Nov 11, 2012					
	6399632*PED	Nov 11, 2012					
	7135571	May 18, 2014					
	7135571*PED	Nov 18, 2014					
7138524	May 18, 2014	DS					
7138524*PED	Nov 18, 2014	DS					
FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY							
N020872 010	5578610	Nov 26, 2013	DS DP	U-1160			
	5578610*PED	May 26, 2014					
	5855912	Feb 28, 2015					
	5855912*PED	Aug 28, 2015					
	5932247	Feb 28, 2015					
	5932247*PED	Aug 28, 2015					
	6037353	Mar 14, 2017					
	6037353*PED	Sep 14, 2017					
	6113942	Feb 28, 2015					
	6113942*PED	Aug 28, 2015					
	6187791*PED	Nov 11, 2012					
	6399632*PED	Nov 11, 2012					
	7135571	May 18, 2014					
	7135571*PED	Nov 18, 2014					
7138524	May 18, 2014	DS					
7138524*PED	Nov 18, 2014	DS					
FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES							
N020872 008	5578610	Nov 26, 2013	DS DP	U-1160			
	5578610*PED	May 26, 2014					
	5855912	Feb 28, 2015					
	5855912*PED	Aug 28, 2015					
	5932247	Feb 28, 2015					
	5932247*PED	Aug 28, 2015					
	6037353	Mar 14, 2017					
	6037353*PED	Sep 14, 2017					
	6113942	Feb 28, 2015					
	6113942*PED	Aug 28, 2015					
	6187791*PED	Nov 11, 2012					
	6399632*PED	Nov 11, 2012					
	7135571	May 18, 2014					
	7135571*PED	Nov 18, 2014					
7138524	May 18, 2014	DS					
7138524*PED	Nov 18, 2014	DS					

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N020872 009	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017			U-1160	
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791*PED	Nov 11, 2012				
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS		U-1160	
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N020872 005	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017			U-1160	
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791*PED	Nov 11, 2012				
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS		U-1160	
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N021909 002	5578610	Nov 26, 2013	DS DP U-1158			
	5738872	Feb 28, 2015	DP			
	6037353	Mar 14, 2017			U-1158	
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N201373 001	5578610	Nov 26, 2013	DS DP U-1157			
	5578610*PED	May 26, 2014				
	6037353	Mar 14, 2017			U-1157	
	6037353*PED	Sep 14, 2017				
	6187791*PED	Nov 11, 2012				
	6399632*PED	Nov 11, 2012				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N020872 006	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017			U-1160	
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791*PED	Nov 11, 2012				
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS		U-1160	
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N021909 003	5578610	Nov 26, 2013	DS DP			U-1158
	5738872	Feb 28, 2015	DP			
	6037353	Mar 14, 2017				U-1158
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N201373 002	5578610	Nov 26, 2013	DS DP			U-1157
	5578610*PED	May 26, 2014				
	6037353	Mar 14, 2017				U-1157
	6037353*PED	Sep 14, 2017				
	6187791*PED	Nov 11, 2012				
	6399632*PED	Nov 11, 2012				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION</u>						
N020786 002	5578610	Nov 26, 2013	DS DP			U-1159
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015		DP		
	5855912*PED	Aug 28, 2015				
	6037353	Mar 14, 2017				U-1159
	6037353*PED	Sep 14, 2017				U-138
	6039974	Jul 31, 2018		DP		
	6113942	Feb 28, 2015		DP		
	6113942*PED	Aug 28, 2015				
	6187791*PED	Nov 11, 2012				U-138
	6399632*PED	Nov 11, 2012				U-468
	7135571	May 18, 2014	DS			U-1159
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION</u>						
N021704 002	5578610	Nov 26, 2013	DS DP			U-1159
	5578610*PED	May 26, 2014				
	6037353	Mar 14, 2017				U-1159
	6037353*PED	Sep 14, 2017				
	6187791*PED	Nov 11, 2012				
	6399632*PED	Nov 11, 2012				
	6613357	Dec 25, 2020		DP		U-1159
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
	RE39069	May 29, 2018		DP		
<u>FIDAXOMICIN - DIFICID</u>						
N201699 001	7378508	Jul 31, 2027	DS DP		NCE	May 27, 2016
	7863249	Jul 31, 2027	DS DP			
	7906489	Mar 04, 2027				U-319
<u>FINASTERIDE - FINASTERIDE</u>						
A076436 001					PC	Jul 01, 2013
<u>FINASTERIDE - PROPECIA</u>						
N020788 001	5547957	Oct 15, 2013				U-236
	5571817	Nov 05, 2013				U-259
	5886184	Nov 19, 2012				
<u>FINASTERIDE - PROSCAR</u>						
N020180 001	5886184	Nov 19, 2012	DS			
	5942519	Oct 23, 2018				U-280
<u>FINGOLIMOD - GILENYA</u>						
N022527 001	5604229	Feb 18, 2014	DS		M-106	Jul 20, 2014
	6004565	Sep 23, 2017				
	8324283	Mar 29, 2026			NCE	Sep 21, 2015
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 001	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 002	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 003	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLUDARABINE PHOSPHATE - OFORTA</u>						
N022273 001	7148207	Dec 20, 2022	DP U-944		ODE	Dec 18, 2015
	7547776	Dec 10, 2018	DS			
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N021247 001	5776433	Jul 07, 2015	DP			
	5980867	Jul 06, 2018	DP			
<u>FLUOCINOLONE ACETONIDE - RETISERT</u>						
N021737 001	6217895	Mar 22, 2019	DP U-708			
	6548078	Mar 22, 2019	DP U-708			
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N021112 001	7915243	Mar 22, 2026	DP			
	7939516	May 04, 2025	DP			
	8247395	Oct 22, 2022	DP			
<u>FLUOCINONIDE - VANOS</u>						
N021758 001	6765001	Dec 21, 2021	DP			
	7220424	Jan 07, 2023			U-861	
	7794738	Sep 11, 2022			U-1084	
	8232264	Mar 09, 2023	DP			
<u>FLUOROURACIL - CARAC</u>						
N020985 001	6670335	Jun 02, 2021	DP U-68			
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N018936 001	6960577	Nov 01, 2017			U-963	
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N018936 003	6960577	Nov 01, 2017			U-963	
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N018936 006	6960577	Nov 01, 2017			U-963	
<u>FLUOXETINE HYDROCHLORIDE - PROZAC WEEKLY</u>						
N021235 001	5910319	May 29, 2017			U-396	
	5985322	May 29, 2017			U-397	
	RE39030	May 29, 2017	DP U-396			
	RE39030	May 29, 2017	DP U-397			
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N021520 001	6960577	Nov 01, 2017			U-962	
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N021520 002	5945416	Mar 24, 2017	DS DP			Y
	6960577	Nov 01, 2017			U-962	
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N021520 003	5945416	Mar 24, 2017	DS DP			Y
	6960577	Nov 01, 2017			U-962	
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N021520 004	5945416	Mar 24, 2017	DS DP			Y
	6960577	Nov 01, 2017			U-962	
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N021520 005	5945416	Mar 24, 2017	DS DP			Y
	6960577	Nov 01, 2017			U-962	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
FLUTICASONE FUROATE - VERAMYST							
N022051 001	6858596	Aug 03, 2021	DS	DP	U-808		
	7101866	Aug 03, 2021		DP	U-808		
	7541350	Aug 03, 2021		DP	U-988		
	8062264	Apr 05, 2026		DP			
	8147461	Mar 10, 2025		DP			
FLUTICASONE PROPIONATE - CUTIVATE							
N021152 001	7300669	Oct 20, 2019	DP	U-835			
FLUTICASONE PROPIONATE - FLOVENT DISKUS 100							
N020833 002	5873360	Feb 23, 2016	DP				
	5873360*PED	Aug 23, 2016					
FLUTICASONE PROPIONATE - FLOVENT DISKUS 250							
N020833 003	5873360	Feb 23, 2016	DP				
	5873360*PED	Aug 23, 2016					
FLUTICASONE PROPIONATE - FLOVENT DISKUS 50							
N020833 001	5873360	Feb 23, 2016	DP				
	5873360*PED	Aug 23, 2016					
FLUTICASONE PROPIONATE - FLOVENT HFA							
N021433 001	5658549	Aug 19, 2014		DP	U-710		
	5658549*PED	Feb 19, 2015					
	5674472	Oct 07, 2014		DP			
	5674472*PED	Apr 07, 2015					
	6161724	Jan 16, 2018		DP			
	6161724*PED	Jul 16, 2018					
	6170717	Dec 23, 2017		DP			
	6170717*PED	Jun 23, 2018					
	6251368	Dec 04, 2012		DP			
	6251368*PED	Jun 04, 2013					
	6315173	Dec 23, 2017		DP			
	6315173*PED	Jun 23, 2018					
	6431168	Jun 08, 2018		DP			
	6431168*PED	Dec 08, 2018					
	6435372	Jan 16, 2018		DP			
	6435372*PED	Jul 16, 2018					
	6510969	Dec 23, 2017		DP			
	6510969*PED	Jun 23, 2018					
	6596260	Aug 10, 2014		DP			
	6596260*PED	Feb 10, 2015					
	6743413	Jun 01, 2021			U-581		
	6743413*PED	Dec 01, 2021					
	6938796	Jan 16, 2018		DP			
	6938796*PED	Jul 16, 2018					
	6966467	Dec 23, 2017		DP			
	6966467*PED	Jun 23, 2018					
	6997349	Jan 16, 2018		DP			
	6997349*PED	Jul 16, 2018					
	7107986	Jun 08, 2018		DP			
	7107986*PED	Dec 08, 2019					
	7143908	Jan 16, 2018		DP			
	7143908*PED	Jul 16, 2018					
	7350676	Aug 24, 2018		DP			
	7350676*PED	Feb 24, 2019					
	7500444	Jan 04, 2025		DP			
	7500444*PED	Jul 04, 2025					
	7832351	Jun 19, 2023		DP			
	7832351*PED	Dec 19, 2023					

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 002	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015				
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 003	5658549	Aug 19, 2014	DP	U-710		
	5658549*PED	Feb 19, 2015		U-710		
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021		U-581		
	6743413*PED	Dec 01, 2021		U-581		
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>						
N021077 001	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>						
N021077 002	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>						
N021077 003	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA						
N021254 001	5658549	Aug 19, 2014	DP			U-738
	5658549*PED	Feb 19, 2015				U-738
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017				
	6510969*PED	Jun 23, 2018				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021				U-841
	6743413*PED	Dec 01, 2021				U-841
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA						
N021254 002	5658549	Aug 19, 2014	DP			U-738
	5658549*PED	Feb 19, 2015	DP			U-738
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015	DP			
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013	DP			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021				U-841
	6743413*PED	Dec 01, 2021				U-841
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 003	5658549	Aug 19, 2014	DP U-738			
	5658549*PED	Feb 19, 2015	DP U-738			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015	DP			
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013	DP			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021		U-841		
	6743413*PED	Dec 01, 2021		U-841		
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUVASTATIN SODIUM - LESCOL XL</u>						
N021192 001	6242003	Apr 13, 2020				
	6242003*PED	Oct 13, 2020				
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N022033 001	7465462	May 10, 2020	DP U-929			
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N022033 002	7465462	May 10, 2020	DP U-929			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM</u>						
N020582 001	5767251	Jun 16, 2015				
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM</u>						
N020582 002	5767251	Jun 16, 2015				
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 001	5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	5929028	Jan 14, 2018	DP U-567		I-306	Jun 28, 2013
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019		U-1183		
	7563763	Aug 23, 2019		U-993		
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 002	5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	5929028	Jan 14, 2018	DP U-567		I-306	Jun 28, 2013
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019		U-993		
	7563763	Aug 23, 2019		U-1183		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 003	5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	5929028	Jan 14, 2018	DP	U-567		
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019		U-993		
	7563763	Aug 23, 2019		U-1183		
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 004	5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	5929028	Jan 14, 2018	DP	U-567	I-306	Jun 28, 2013
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019		U-1183		
	7563763	Aug 23, 2019		U-993		
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021273 001					I-306	Jun 28, 2013
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021273 002					I-306	Jun 28, 2013
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N020378 001	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N020378 002	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N020378 003	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N020378 004	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7563763	Aug 23, 2019		DP		
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N020378 005	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7563763	Aug 23, 2019		DP		
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N021765 001	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N021765 003	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF</u>						
N021765 002	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF PEN</u>						
N021684 001	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7446090	Aug 23, 2019		DP		
	7741268	Apr 02, 2024		DP		
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF PEN</u>						
N021684 002	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7446090	Aug 23, 2019		DP		
	7741268	Apr 02, 2024		DP		
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF PEN</u>						
N021684 003	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7446090	Aug 23, 2019		DP		
	7741268	Apr 02, 2024		DP		
<u>FOMEPIZOLE - ANTIZOL</u>						
N020696 001	7553863	Jun 30, 2027	DS	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOMIVIRSEN SODIUM - VITRAVENE PRESERVATIVE FREE</u>						
N020961 001	5442049	Aug 15, 2012				
	5595978	Aug 15, 2012	U-522			
<u>FORMOTEROL FUMARATE - FORADIL</u>						
N020831 001	6488027	Mar 08, 2019				
	6887459	Nov 28, 2020	U-762			
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N022007 001	6667344	Jun 22, 2021	DP			
	6814953	Jun 22, 2021	DP	U-813		
	7348362	Jun 22, 2021	DP			
	7462645	Jun 22, 2021	DP	U-813		
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N022518 001	5889015	Jan 27, 2014	U-1068		NC	Jun 22, 2013
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP	U-1068		
	6057307*PED	Jul 27, 2014				
	6068832	Aug 27, 2017	DP	U-1068		
	6677323	Jan 27, 2014		U-1068		
	7067502	May 21, 2020	DP	U-1068		
	7566705	May 08, 2020	DP	U-1068		
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N022518 002	5889015	Jan 27, 2014	U-1068		NC	Jun 22, 2013
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP	U-1068		
	6057307*PED	Jul 27, 2014				
	6068832	Aug 27, 2017	DP	U-1068		
	6677323	Jan 27, 2014		U-1068		
	7067502	May 21, 2020	DP	U-1068		
	7566705	May 08, 2020	DP	U-1068		
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N021548 001	6436989	Dec 24, 2017	DS DP	U-257	NPP	Apr 27, 2015
	6436989*PED	Jun 24, 2018			PED	Oct 27, 2015
	6514953	Jul 15, 2019	DS DP	U-257		
	6514953*PED	Jan 15, 2020				
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N022116 001	6436989	Dec 24, 2017	DS DP	U-257	NPP	Apr 27, 2015
	6436989*PED	Jun 24, 2018			PED	Oct 27, 2015
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N022023 001	5512570	Mar 04, 2014		U-850	NCE	Jan 25, 2013
	5538982	Jul 23, 2013		U-850		
	5691336	Mar 04, 2019	DS DP			
	5716942	Feb 10, 2015		U-850		
	7214692	Sep 18, 2012		U-850		
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N022023 002	5512570	Mar 04, 2014		U-850	D-128	Nov 12, 2013
	5538982	Jul 23, 2013		U-850	NCE	Jan 25, 2013
	5691336	Mar 04, 2019	DS DP			
	5716942	Feb 10, 2015		U-850		
	7214692	Sep 18, 2012		U-850		
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N022244 001	6204257	Jul 01, 2022	DS DP	U-945	NCE	Dec 12, 2013
	6872838	Aug 07, 2018	DS			
<u>FROVATRIPTAN SUCCINATE - FROVA</u>						
N021006 001	5464864	Nov 07, 2015		U-436		
	5616603	Apr 01, 2014		U-436		
	5637611	Jun 10, 2014		U-436		
	5827871	Oct 27, 2015		U-436		
	5962501	Dec 16, 2013		U-436		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FULVESTRANT - FASLODEX</u>						
N021344 001	6774122	Jan 09, 2021	U-596		D-126	Sep 09, 2013
	6774122*PED	Jul 09, 2021			M-123	Nov 09, 2015
	7456160	Jan 09, 2021	U-596		M-103	May 17, 2014
	7456160*PED	Jul 09, 2021			PED	Nov 17, 2014
	8329680	Jan 09, 2021	U-596		PED	Mar 09, 2014
	8329680*PED	Jul 09, 2021				
<u>GABAPENTIN - GRALISE</u>						
N022544 001	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
	8192756	Oct 25, 2022	DP	U-1114		
	8252332	Oct 25, 2022	DP	U-1114		
<u>GABAPENTIN - GRALISE</u>						
N022544 002	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
	8192756	Oct 25, 2022	DP	U-1114		
	8252332	Oct 25, 2022	DP	U-1114		
<u>GABAPENTIN - NEURONTIN</u>						
N020235 001	6054482	Apr 25, 2017				
	6054482*PED	Oct 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N020235 002	6054482	Apr 25, 2017				
	6054482*PED	Oct 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N020235 003	6054482	Apr 25, 2017				
	6054482*PED	Oct 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N020882 001	6054482	Apr 25, 2017				
	6054482*PED	Oct 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N020882 002	6054482	Apr 25, 2017				
	6054482*PED	Oct 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N021129 001	6054482	Apr 25, 2017				
	6054482*PED	Oct 25, 2017				
	7256216	May 28, 2022	DP			
	7256216*PED	Nov 28, 2022				
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 001	6818787	Nov 06, 2022	DS DP		I-652	Jun 06, 2015
	8026279	Nov 10, 2026	DS DP		NCE	Apr 06, 2016
	8048917	Nov 06, 2022	DS DP	U-1247		
	8114909	Apr 11, 2026		U-1231		
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 002	6818787	Nov 06, 2022	DS DP		I-652	Jun 06, 2015
	8026279	Nov 10, 2026	DS DP		NCE	Apr 06, 2016
	8048917	Nov 06, 2022	DS DP	U-1247		
	8114909	Apr 11, 2026		U-1231		
<u>GADOBENATE DIMEGLUMINE - MULTIANCE</u>						
N021357 001					I-654	Jul 06, 2015
					NPP	Mar 17, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE</u>						
N021357 002					I-654 NPP	Jul 06, 2015 Mar 17, 2013
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE</u>						
N021357 003					I-654 NPP	Jul 06, 2015 Mar 17, 2013
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE</u>						
N021357 004					I-654 NPP	Jul 06, 2015 Mar 17, 2013
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE MULTIPACK</u>						
N021358 001					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE MULTIPACK</u>						
N021358 002					I-654	Jul 06, 2015
<u>GADOBUTROL - GADAVIST</u>						
N201277 001 5980864		Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 002 5980864		Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 003 5980864		Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 004 5980864		Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 005 5980864		Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADODIAMIDE - OMNISCAN</u>						
N020123 001 5560903		Oct 01, 2013	DP			
<u>GADODIAMIDE - OMNISCAN</u>						
N022066 001 5560903		Oct 01, 2013	DP			
<u>GADODIAMIDE - OMNISCAN</u>						
N022066 002 5560903		Oct 01, 2013	DP			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001 6676929		May 04, 2020	DP		NCE	Dec 22, 2013
7011815		Feb 01, 2015		U-1112		
7060250		May 26, 2015	DS			
7229606		May 26, 2015		U-1112		
8017105		May 26, 2015	DS			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002 6676929		May 04, 2020	DP		NCE	Dec 22, 2013
7011815		Feb 01, 2015		U-1112		
7060250		May 26, 2015	DS			
7229606		May 26, 2015		U-1112		
8017105		May 26, 2015	DS			
<u>GADOTERIDOL - PROHANCE</u>						
N020131 001 5474756		Dec 12, 2012		U-480		
5846519		Dec 08, 2015				
6143274		Dec 12, 2012		U-480		
<u>GADOTERIDOL - PROHANCE MULTIPACK</u>						
N021489 001 5474756		Dec 12, 2012		U-536		
5846519		Dec 08, 2015				
6143274		Dec 12, 2012		U-536		
<u>GADOXETATE DISODIUM - EOVIIST</u>						
N022090 001 5798092		Aug 25, 2015	DS DP		NCE	Jul 03, 2013
6039931		Nov 13, 2021		U-1239		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GALANTAMINE HYDROBROMIDE - RAZADYNE						
N021169 001	6099863	Jun 06, 2017	DP U-322			
	6358527	Jun 06, 2017				
GALANTAMINE HYDROBROMIDE - RAZADYNE						
N021169 002	6099863	Jun 06, 2017	DP U-322			
	6358527	Jun 06, 2017				
GALANTAMINE HYDROBROMIDE - RAZADYNE						
N021169 003	6099863	Jun 06, 2017	DP U-322			
	6358527	Jun 06, 2017				
GALANTAMINE HYDROBROMIDE - RAZADYNE ER						
N021615 001	7160559	Dec 20, 2019	DP			
GALANTAMINE HYDROBROMIDE - RAZADYNE ER						
N021615 002	7160559	Dec 20, 2019	DP			
GALANTAMINE HYDROBROMIDE - RAZADYNE ER						
N021615 003	7160559	Dec 20, 2019	DP			
GANCICLOVIR - ZIRGAN						
N022211 001					NDF ODE	Sep 15, 2012 Sep 15, 2016
GANIRELIX ACETATE - GANIRELIX ACETATE INJECTION						
N021057 001	5767082	Jun 16, 2015				
GATIFLOXACIN - ZYMAR						
N021493 001	5880283	Dec 05, 2015	DP			
	5880283*PED	Jun 05, 2016				
	6333045	Aug 20, 2019				
	6333045*PED	Feb 20, 2020				
GATIFLOXACIN - ZYMAXID						
N022548 001	5880283	Dec 05, 2015	DS		NP	May 18, 2013
	5880283*PED	Jun 05, 2016	DS DP			
	6333045	Aug 20, 2019				
	6333045*PED	Feb 20, 2020				
GEFITINIB - IRESSA						
N021399 001	5457105	Jan 19, 2013	DS DP U-881			
	5616582	Jan 19, 2013				
	5770599	May 05, 2017				
GEMCITABINE HYDROCHLORIDE - GEMZAR						
N020509 001	5464826	Nov 07, 2012	U-146			
	5464826*PED	May 07, 2013				
GEMCITABINE HYDROCHLORIDE - GEMZAR						
N020509 002	5464826	Nov 07, 2012	U-146			
	5464826*PED	May 07, 2013				
GEMIFLOXACIN MESYLATE - FACTIVE						
N021158 001	5633262	Jun 15, 2015	DS DP			
	5776944	Apr 04, 2017				
	5962468	Jun 15, 2015			U-282	
	6262071	Sep 21, 2019			U-513	
	6331550	Sep 21, 2019			U-511	
	6340689	Sep 14, 2019			U-512	
	6455540	Sep 21, 2019			U-511	
	6723734	Mar 20, 2018	DS DP			
	6803376	Sep 21, 2019	DS DP		U-609	
	6803376	Sep 21, 2019	DS DP		U-608	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GEMTUZUMAB OZOGAMICIN - MYLOTARG</u>						
N021174 001	5585089	Dec 17, 2013				
	5606040	Feb 25, 2014				
	5693762	Dec 02, 2014				
	5739116	Apr 14, 2015				
	5767285	Jun 16, 2015				
	5773001	Jun 30, 2015			U-320	
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N020622 001	5981589	May 24, 2014				
	6054430	May 24, 2014				
	6342476	May 24, 2014			U-441	
	6362161	May 24, 2014			U-441	
	6620847	May 24, 2014	DS			
	6939539	May 24, 2014	DS			
	7199098	May 24, 2014	DS			
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N020622 002	5981589	May 24, 2014				
	6054430	May 24, 2014				
	6342476	May 24, 2014			U-441	
	6362161	May 24, 2014			U-441	
	6620847	May 24, 2014	DS			
	6939539	May 24, 2014	DS			
	7199098	May 24, 2014	DS			
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N021925 001	6150383	Jun 19, 2016			U-753	
	6211205	Jun 19, 2016			U-753	
	6303640	Aug 09, 2016			U-753	
	6329404	Jun 19, 2016	DP		U-753	
	7538125	Jun 19, 2016	DP			
	7700128	Jan 30, 2027	DP			
	8071130	Jun 08, 2028	DP			
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N021925 002	6150383	Jun 19, 2016			U-753	
	6211205	Jun 19, 2016			U-753	
	6303640	Aug 09, 2016			U-753	
	6329404	Jun 19, 2016	DP		U-753	
	7538125	Jun 19, 2016	DP			
	7700128	Jan 30, 2027	DP			
	8071130	Jun 08, 2028	DP			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N021700 001	5741803	Apr 21, 2015	DS	DP	U-781	
	5741803	Apr 21, 2015	DS	DP	U-690	
	5741803*PED	Oct 21, 2015				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N021700 002	5741803	Apr 21, 2015	DS	DP	U-690	
	5741803	Apr 21, 2015	DS	DP	U-781	
	5741803*PED	Oct 21, 2015				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N021700 003	5741803	Apr 21, 2015	DS	DP	U-690	
	5741803	Apr 21, 2015	DS	DP	U-781	
	5741803*PED	Oct 21, 2015				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N021700 004	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL								
N021700 005	7358366	Apr	19, 2020	DS				
	7358366*PED	Oct	19, 2020					
GLIPIZIDE - GLUCOTROL XL								
N020329 001	5591454	Jan	07, 2014		U-150			
GLIPIZIDE - GLUCOTROL XL								
N020329 002	5591454	Jan	07, 2014		U-150			
GLIPIZIDE - GLUCOTROL XL								
N020329 003	5591454	Jan	07, 2014		U-111			
GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE								
N021178 001	6303146	Jul	14, 2019		U-412			
	6303146*PED	Jan	14, 2020		U-412			
GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE								
N021178 002	6303146	Jul	14, 2019		U-412			
	6303146*PED	Jan	14, 2020		U-412			
GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE								
N021178 003	6303146	Jul	14, 2019		U-412			
	6303146*PED	Jan	14, 2020		U-412			
GLYCOPYRROLATE - CUVPOSA								
N022571 001	7638552	Aug	20, 2023		U-1076	NP	Jul	28, 2013
	7816396	Aug	20, 2023		U-1076	ODE	Jul	28, 2017
GLYCOPYRROLATE - ROBINUL								
N012827 001	7091236	Apr	24, 2024		U-877			
GLYCOPYRROLATE - ROBINUL FORTE								
N012827 002	7091236	Apr	24, 2024		U-877			
GOSERELIN ACETATE - ZOLADEX								
N019726 001	7118552	Apr	13, 2022	DP				
	7220247	Apr	09, 2022	DP				
	7500964	Feb	26, 2021	DP				
GOSERELIN ACETATE - ZOLADEX								
N020578 001	7118552	Apr	13, 2022	DP				
	7220247	Apr	09, 2022	DP				
	7500964	Feb	26, 2021	DP				
GRANISETRON - SANCUSO								
N022198 001	7608282	Oct	22, 2024	DP	U-1011			
GRANISETRON HYDROCHLORIDE - KYTRIL								
N020239 001	5952340	Sep	14, 2016		U-519	M-102	Apr	29, 2014
GRANISETRON HYDROCHLORIDE - KYTRIL								
N020239 002	5952340	Sep	14, 2016		U-519	M-102	Apr	29, 2014
GRANISETRON HYDROCHLORIDE - KYTRIL								
N020239 003						M-102	Apr	29, 2014
GRANISETRON HYDROCHLORIDE - KYTRIL								
N020239 004	5952340	Sep	14, 2016		U-519	M-102	Apr	29, 2014
GREPAFLOXACIN HYDROCHLORIDE - RAXAR								
N020695 001	5563138	Oct	08, 2013					
GUAIFENESIN - MUCINEX								
N021282 001	6372252	Apr	28, 2020		U-489			
	6955821	Apr	28, 2020	DP	U-489			
	7838032	Apr	28, 2020	DP				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GUAIFENESIN - MUCINEX</u>						
N021282 002	6372252	Apr 28, 2020		U-489		
	6955821	Apr 28, 2020	DP	U-489		
	7838032	Apr 28, 2020	DP			
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N021585 001	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP	U-686		
	7838032	Apr 28, 2020	DP			
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N021585 002	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP	U-686		
	7838032	Apr 28, 2020	DP			
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 001	5854290	Sep 21, 2015		U-494	Y	I-635 Feb 25, 2014
	6287599	Dec 20, 2020	DP			NP Sep 02, 2012
	6811794	Jul 04, 2022	DP	U-494		
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 002	5854290	Sep 21, 2015		U-494	Y	I-635 Feb 25, 2014
	6287599	Dec 20, 2020	DP			NP Sep 02, 2012
	6811794	Jul 04, 2022	DP	U-494		
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 003	5854290	Sep 21, 2015		U-494	Y	I-635 Feb 25, 2014
	6287599	Dec 20, 2020	DP			NP Sep 02, 2012
	6811794	Jul 04, 2022	DP	U-494		
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 004	5854290	Sep 21, 2015		U-494	Y	I-635 Feb 25, 2014
	6287599	Dec 20, 2020	DP			NP Sep 02, 2012
	6811794	Jul 04, 2022	DP	U-494		
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N022555 001	6034267	Mar 08, 2016		U-1087		NP May 28, 2013
	7247655	Mar 08, 2016	DP	U-1087		
	7348361	Apr 22, 2019	DP	U-1087		
	7530461	Jan 11, 2017	DP	U-1087		
<u>HISTRELIN ACETATE - SUPPRELIN LA</u>						
N022058 001	8062652	Jun 16, 2026		U-1197		ODE May 03, 2014
<u>HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT</u>						
N021859 001	7767429	Sep 23, 2027	DS DP			
<u>HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - BIDIL</u>						
N020727 001	6465463	Sep 08, 2020		U-71		
	6784177	Sep 08, 2020		U-71		
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N020758 001	5994348	Jun 07, 2015				
	5994348*PED	Dec 07, 2015				
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N020758 002	5994348	Jun 07, 2015				
	5994348*PED	Dec 07, 2015				
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N020758 003	5994348	Jun 07, 2015				
	5994348*PED	Dec 07, 2015				
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N020758 004	5994348	Jun 07, 2015	DP			
	5994348*PED	Dec 07, 2015				
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369 001					PC	Sep 26, 2012

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369	002				PC	Sep 26, 2012
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N021532	002	5616599	Apr 25, 2016	DS DP	U-500	
		5616599*PED	Oct 25, 2016			
		6878703	Nov 19, 2021		U-3	Y
		6878703*PED	May 19, 2022			
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N021532	003	5616599	Apr 25, 2016	DS DP	U-500	
		5616599*PED	Oct 25, 2016			
		6878703	Nov 19, 2021		U-3	Y
		6878703*PED	May 19, 2022			
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N021532	005	5616599	Apr 25, 2016	DS DP	U-500	
		5616599*PED	Oct 25, 2016			
		6878703	Nov 19, 2021		U-3	Y
		6878703*PED	May 19, 2022			
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N021162	001	5591762	Jan 07, 2014	DS DP	U-3	
		6358986	Jan 10, 2020			
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N021162	002	5591762	Jan 07, 2014	DS DP	U-3	
		6358986	Jan 10, 2020			
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N021162	003	5591762	Jan 07, 2014	DS DP	U-3	
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N020818	001	5399578*PED	Sep 21, 2012			
		6294197	Jun 18, 2017		U-3	
		6294197*PED	Dec 18, 2017			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N020818	002	5399578*PED	Sep 21, 2012			
		6294197	Jun 18, 2017		U-3	
		6294197*PED	Dec 18, 2017			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N020818	003	5399578*PED	Sep 21, 2012			
		6294197	Jun 18, 2017		U-3	
		6294197*PED	Dec 18, 2017			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N020818	004	5399578*PED	Sep 21, 2012			
		6294197	Jun 18, 2017		U-3	
		6294197*PED	Dec 18, 2017			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N020818	005	5399578*PED	Sep 21, 2012			
		6294197	Jun 18, 2017		U-3	
		6294197*PED	Dec 18, 2017			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020	001				PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020	002				PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020	003				PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020	004				PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020	005				PC	Mar 20, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE; IBUPROFEN - VICOPROFEN</u>						
N020716 001	6348216	Jun 10, 2017				
	6599531	Jun 10, 2017				
<u>HYDROCORTISONE BUTYRATE - LOCOID</u>						
N022076 001	7378405	Dec 19, 2026	DP			
	7981877	Jan 23, 2025	DP			
<u>HYDROCORTISONE BUTYRATE - LOCOID LIPOCREAM</u>						
N020769 001	5635497	Jun 03, 2014			I-613	Oct 19, 2012
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019034 003	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019034 004	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019034 005	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019891 001	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019892 001	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019892 002	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N019892 003	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N019034 001	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N019034 002	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N021217 001	5702725	Jul 07, 2014	DP U-1043		NDF	Mar 01, 2013
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N021217 002	5702725	Jul 07, 2014	DP U-1043		NDF	Mar 01, 2013
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N021217 003	5702725	Jul 07, 2014	DP U-1043		NDF	Mar 01, 2013
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N021217 004	5702725	Jul 07, 2014	DP U-1043		NDF	Mar 01, 2013
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N021044 001	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP U-616			
	6335033	Nov 04, 2014	DP U-616			
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP U-616			
	6743442	Nov 04, 2014	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N021044 002	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP U-616			
	6335033	Nov 04, 2014	DP U-616			
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP U-616			
	6743442	Nov 04, 2014	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N021044 003	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP U-616			
	6335033	Nov 04, 2014	DP U-616			
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP U-616			
	6743442	Nov 04, 2014	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N021044 004	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP U-616			
	6335033	Nov 04, 2014	DP U-616			
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP U-616			
	6743442	Nov 04, 2014	DP			
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N022041 001	5834448	Nov 14, 2016	DP		ODE	Dec 15, 2013
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N022041 002	5834448	Nov 14, 2016	DP U-789		ODE	Dec 15, 2013
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA</u>						
N021945 001					ODE	Feb 03, 2018
<u>IBANDRONATE SODIUM - BONIVA</u>						
N021455 001	6143326	Apr 21, 2017	U-642			
	6294196	Oct 07, 2019	DP			
<u>IBANDRONATE SODIUM - BONIVA</u>						
N021455 002	6294196	Oct 07, 2019	DP			
	7192938	May 06, 2023	U-798			
	7410957	May 06, 2023	U-887			
	7718634	May 06, 2023	U-642			
<u>IBANDRONATE SODIUM - BONIVA</u>						
N021858 001	5662918	Sep 02, 2014	DP			
<u>IBUPROFEN - CALDOLOR</u>						
N022348 001	6727286	Nov 27, 2021	DP U-981			
<u>IBUPROFEN - CALDOLOR</u>						
N022348 002	6727286	Nov 27, 2021	DP U-981			
<u>IBUPROFEN - MIDOL LIQUID GELS</u>						
N021472 001	6251426	Jun 25, 2018				
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N021903 001	6342530	Nov 14, 2020	DP U-1127		ODE	Apr 13, 2013
	6342530	Nov 14, 2020	DP U-794			
	6344479	Mar 20, 2021	DS DP U-794	Y		
<u>IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S MOTRIN COLD</u>						
N021128 001	6211246	Jun 10, 2019				
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N022150 001	5648333	Jul 15, 2014	DS DP U-1187		NCE	Aug 25, 2016
					ODE	Aug 25, 2018
<u>ICODEXTRIN - EXTRANEAL</u>						
N021321 001	6077836	Jun 20, 2017	U-495			
	6248726	Jun 19, 2018	U-495			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N202057 001	8188146	Jan 27, 2020	DS DP			
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N022192 001	RE39198	Nov 15, 2016	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N022192 002	RE39198	Nov 15, 2016	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N022192 003	RE39198	Nov 15, 2016	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N022192 004	RE39198	Nov 15, 2016	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N022192 005	RE39198	Nov 15, 2016	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N022192 006	RE39198	Nov 15, 2016	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
N022192 007	RE39198	Nov 15, 2016	DS DP U-971		NCE	May 06, 2014
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021335 001	5521184	Jan 04, 2015	DS DP			
	5521184*PED	Jul 04, 2015				
	6894051	May 23, 2019	DS DP U-649			
	6894051*PED	Nov 23, 2019				
	6958335	Dec 19, 2021			U-791	
	6958335*PED	Jun 19, 2022				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021335 002	5521184	Jan 04, 2015	DS DP U-649			
	5521184*PED	Jul 04, 2015				
	6894051	May 23, 2019	DS DP U-649			
	6894051*PED	Nov 23, 2019				
	6958335	Dec 19, 2021			U-791	
	6958335*PED	Jun 19, 2022				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 001	5521184	Jan 04, 2015	DS DP		ODE	Dec 19, 2015
	5521184*PED	Jul 04, 2015			ODE	Oct 19, 2013
	6894051	May 23, 2019	DS DP U-649		ODE	Oct 19, 2013
	6894051*PED	Nov 23, 2019			ODE	Oct 19, 2013
	6958335	Dec 19, 2021			ODE	Oct 19, 2013
	6958335*PED	Jun 19, 2022			ODE	Oct 19, 2013
	7544799	Jan 16, 2019	DS DP		ODE	Oct 19, 2013
	7544799*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 002	5521184	Jan 04, 2015			ODE	Dec 19, 2015
	5521184*PED	Jul 04, 2015			ODE	Oct 19, 2013
	6894051	May 23, 2019	DS DP U-649		ODE	Oct 19, 2013
	6894051*PED	Nov 23, 2019			ODE	Oct 19, 2013
	6958335	Dec 19, 2021			ODE	Oct 19, 2013
	6958335*PED	Jun 19, 2022			ODE	Oct 19, 2013
	7544799	Jan 16, 2019	DS DP		ODE	Oct 19, 2013
	7544799*PED	Jul 16, 2019				
<u>IMIGLUCERASE - CEREZYME</u>						
N020367 001	5549892	Aug 27, 2013		U-252		
<u>IMIGLUCERASE - CEREZYME</u>						
N020367 002	5549892	Aug 27, 2013		U-252		
<u>IMIQUIMOD - ALDARA</u>						
N020723 001	7696159	Apr 01, 2024	DS	U-1047		
	7696159	Apr 01, 2024	DS	U-1048		
	7696159*PED	Oct 01, 2024				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 001	8236816	Dec 11, 2029	U-68		I-636	Mar 24, 2014
	8299109	Dec 11, 2029	U-68		NP	Mar 25, 2013
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 002	8222270	Dec 11, 2029	U-68		NS	Jul 15, 2014
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N022383 001	6878721	Oct 10, 2020	DS DP U-1168		NCE	Jul 01, 2016
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N020685 001	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N020685 003	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N020685 005	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N020685 006	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN</u>						
N020314 001	5753627	May 19, 2015			U-1125	
	5776894	Jul 07, 2015	DS DP			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 001	6432452	Aug 19, 2018	DS	U-68	NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP	U-1221		
	7410656	Aug 19, 2018	DS	U-1222		
	8278292	Feb 20, 2027	DS DP			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 002	6432452	Aug 19, 2018	DS	U-68	NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP	U-1221		
	7410656	Aug 19, 2018	DS	U-1222		
	8278292	Feb 20, 2027	DS DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 50/50</u>						
N021810 001	5547930	Sep 28, 2013	DS DP			
	5618913	Jun 07, 2014	DS DP			
	5618913*PED	Dec 07, 2014				
	5834422	Sep 28, 2013		DP U-471		
	5840680	Sep 28, 2013	DS DP	U-471		
	5866538	Jun 20, 2017	DP			
	5866538*PED	Dec 20, 2017				
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30</u>						
N021172 001	5547930	Sep 28, 2013	DS DP			
	5618913	Jun 07, 2014	DS DP			
	5618913*PED	Dec 07, 2014				
	5834422	Sep 28, 2013		DP U-471		
	5840680	Sep 28, 2013	DS DP	U-471		
	5866538	Jun 19, 2017	DP			
	5866538*PED	Dec 19, 2017				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N021172 004	5547930	Sep 28, 2013	DS DP			
	5618913	Jun 07, 2014	DS DP			
	5618913*PED	Dec 07, 2014				
	5834422	Sep 28, 2013		DP	U-471	
	5840680	Sep 28, 2013	DS DP	DP	U-471	
	5866538	Jun 19, 2017		DP		
	5866538*PED	Dec 19, 2017				
	6004297	Jan 28, 2019		DP		
	RE41956	Jan 21, 2021		DP		
	RE43834	Jan 28, 2019		DP		
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 PENFILL</u>						
N021172 002	5547930	Sep 28, 2013	DS DP			
	5618913	Jun 07, 2014	DS DP			
	5618913*PED	Dec 07, 2014				
	5834422	Sep 28, 2013		DP	U-471	
	5840680	Sep 28, 2013	DS DP	DP	U-471	
	5866538	Jun 19, 2017		DP		
	5866538*PED	Dec 19, 2017				
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 PENFILL</u>						
N021172 003	5547930	Sep 28, 2013	DS DP			
	5618913	Jun 07, 2014	DS DP			
	5618913*PED	Dec 07, 2014				
	5834422	Sep 28, 2013		DP	U-471	
	5840680	Sep 28, 2013	DS DP	DP	U-471	
	5866538	Jun 19, 2017		DP		
	5866538*PED	Dec 19, 2017				
<u>INSULIN ASPART RECOMBINANT - NOVOLOG</u>						
N020986 001	5618913	Jun 07, 2014	DS DP			
	5618913*PED	Dec 07, 2014				
	5866538	Jun 20, 2017		DP		
	5866538*PED	Dec 20, 2017				
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N020986 003	5618913	Jun 07, 2014	DS DP			
	5618913*PED	Dec 07, 2014				
	5866538	Jun 20, 2017		DP		
	5866538*PED	Dec 20, 2017				
	6004297	Jan 28, 2019		DP		
	6004297*PED	Jul 28, 2019				
	RE41956	Jan 21, 2021		DP		
	RE41956*PED	Jul 21, 2021				
	RE43834	Jan 28, 2019		DP		
<u>INSULIN ASPART RECOMBINANT - NOVOLOG INNOLET</u>						
N020986 004	5618913	Jun 07, 2014	DS DP			
	5618913*PED	Dec 07, 2014				
	5866538	Jun 20, 2017		DP		
	5866538*PED	Dec 20, 2017				
	RE41956	Jan 21, 2021		DP		
	RE41956*PED	Jul 21, 2021				
<u>INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL</u>						
N020986 002	5618913	Jun 07, 2014	DS DP			
	5618913*PED	Dec 07, 2014				
	5626566	May 06, 2014		DP		
	5626566*PED	Nov 06, 2014				
	5693027	Dec 02, 2014		DP		
	5693027*PED	Jun 02, 2015				
	5866538	Jun 20, 2017		DP		
	5866538*PED	Dec 20, 2017				
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N021536 001	5750497	Jun 16, 2019	DS DP	U-668	M-117	May 18, 2015
	5866538	Jun 20, 2017	DS DP		M-115	Apr 06, 2015
	6011007	Feb 02, 2014	DS DP	U-668		
	6869930	Feb 02, 2014	DS DP	U-668		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N021536 002	5750497	Jun 16, 2019	DS DP		U-668	
	5866538	Jun 20, 2017	DS	DP		
	6004297	Jan 28, 2019		DP		
	6011007	Feb 02, 2014	DS	DP	U-668	
	6869930	Feb 02, 2014	DS	DP	U-668	
	RE41956	Jan 21, 2021		DP		
	RE43834	Jan 28, 2019		DP		
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR INNOLET</u>						
N021536 003	5750497	Jun 16, 2019	DS	DP	U-668	
	5866538	Jun 20, 2017	DS	DP		
	6011007	Feb 02, 2014	DS	DP	U-668	
	6869930	Feb 02, 2014	DS	DP	U-668	
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR PENFILL</u>						
N021536 004	5750497	Jun 16, 2019	DS	DP	U-668	
	5866538	Jun 20, 2017	DS	DP		
	6011007	Feb 02, 2014	DS	DP	U-668	
	6869930	Feb 02, 2014	DS	DP	U-668	
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
N021081 001	5656722	Aug 12, 2014	DS	DP	U-948	
	5656722*PED	Feb 12, 2015				
	7476652	Jul 23, 2023		DP		
	7476652*PED	Jan 23, 2024				
	7713930	Jun 13, 2023		DP		
	7713930*PED	Dec 13, 2023				
	7918833	Sep 23, 2027		DP		
	7918833*PED	Mar 23, 2028				
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N021629 001	6221633	Jun 18, 2018	DS	DP	U-471	
	6960561	Jan 25, 2023		DP	U-471	
	7452860	Mar 22, 2022		DP		
	7696162	Mar 22, 2022		DP	U-471	
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N021629 002	6221633	Jun 18, 2018	DS	DP	U-471	
	6960561	Jan 25, 2023		DP	U-471	
	7452860	Mar 22, 2022		DP		
	7696162	Mar 22, 2022		DP	U-471	
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N021629 003	6221633	Jun 18, 2018	DS	DP	U-471	
	6960561	Jan 25, 2023		DP	U-471	
	7452860	Mar 22, 2022		DP		
	7696162	Mar 22, 2022		DP	U-471	
	7918833	Sep 23, 2027		DP		
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50</u>						
N021018 001	5461031	Jun 16, 2014		DP	U-948	
	5474978	Jun 16, 2014	DS	DP	U-948	
	5514646	May 07, 2013	DS	DP	U-1312	
	5747642	Jun 16, 2014		DP		
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50 KWIKPEN</u>						
N021018 002	5461031	Jun 16, 2014		DP	U-948	
	5474978	Jun 16, 2014	DS	DP	U-948	
	5514646	May 07, 2013	DS	DP	U-1312	
	5747642	Jun 16, 2014		DP		
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25</u>						
N021017 001	5461031	Jun 16, 2014		DP	U-948	
	5474978	Jun 16, 2014	DS	DP	U-948	
	5514646	May 07, 2013	DS	DP	U-1312	
	5747642	Jun 16, 2014		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25 KWIKPEN</u>						
N021017 002	5461031	Jun 16, 2014	DP U-948			
	5474978	Jun 16, 2014	DS DP U-948			
	5514646	May 07, 2013	DS DP U-1312			
	5747642	Jun 16, 2014	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG</u>						
N020563 001	5474978	Jun 16, 2014	DS DP U-948		NR	Oct 12, 2015
	5474978	Jun 16, 2014	DS DP U-534			
	5514646	May 07, 2013	DS DP U-1312			
	5514646	May 07, 2013	DS DP U-534			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N020563 003	5474978	Jun 16, 2014	DS DP U-948			
	5514646	May 07, 2013	DS DP U-1312			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG PEN</u>						
N020563 002	5474978	Jun 16, 2014		U-534	NR	Oct 12, 2015
	5514646	May 07, 2013		U-534		
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N021868 001	5740794	Apr 21, 2015	DP			
	5997848	Mar 07, 2014		U-704		
	6051256	Mar 07, 2014	DP			
	6257233	May 14, 2019		U-704		
	6423344	Mar 07, 2014	DP			
	6543448	Sep 21, 2014	DP			
	6546929	May 14, 2019		U-704		
	6582728	Jun 24, 2020	DP			
	6592904	Mar 07, 2014	DP			
	6685967	Sep 11, 2018	DP			
	6737045	Mar 07, 2014		U-704		
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N021868 002	5740794	Apr 21, 2015	DP			
	5997848	Mar 07, 2014		U-704		
	6051256	Mar 07, 2014	DP			
	6257233	May 14, 2019		U-704		
	6423344	Mar 07, 2014	DP			
	6543448	Sep 21, 2014	DP			
	6546929	May 14, 2019		U-704		
	6582728	Jun 24, 2020	DP			
	6592904	Mar 07, 2014	DP			
	6685967	Sep 11, 2018	DP			
	6737045	Mar 07, 2014		U-704		
<u>INSULIN RECOMBINANT HUMAN - HUMULIN R</u>						
N018780 001					NR	Mar 25, 2014
<u>INSULIN RECOMBINANT HUMAN - HUMULIN R PEN</u>						
N018780 005					NR	Mar 25, 2014
<u>IOBENGUANE SULFATE I-123 - ADREVIEW</u>						
N022290 001					NCE	Sep 19, 2013
					ODE	Sep 19, 2015
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454 001	5310912	Feb 25, 2013	DS		NCE	Jan 14, 2016
<u>IOPROMIDE - ULTRAVIST (PHARMACY BULK)</u>						
N021425 002					I-619	Dec 30, 2012
<u>IOPROMIDE - ULTRAVIST 370</u>						
N020220 001					I-619	Dec 30, 2012
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N021527 001	5676930	Oct 14, 2014	DP			
	5683677	Nov 04, 2014	DP			
	6739333	May 26, 2020	DP			
	6983743	May 26, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IRBESARTAN - AVAPRO</u>						
N020757 001	6342247	Jun 07, 2015				
	6342247*PED	Dec 07, 2015				
<u>IRBESARTAN - AVAPRO</u>						
N020757 002	6342247	Jun 07, 2015				
	6342247*PED	Dec 07, 2015				
<u>IRBESARTAN - AVAPRO</u>						
N020757 003	6342247	Jun 07, 2015				
	6342247*PED	Dec 07, 2015				
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 001					PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 002					PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 003					PC	Sep 26, 2012
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N020571 001	6403569	Apr 28, 2020	U-449			
	6403569*PED	Oct 28, 2020				
	6794370	May 01, 2020	U-606			
	6794370*PED	Nov 01, 2020				
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N020571 002	6403569	Apr 28, 2020	U-449			
	6403569*PED	Oct 28, 2020				
	6794370	May 01, 2020	U-606			
	6794370*PED	Nov 01, 2020				
<u>IRON DEXTRAN - DEXFERRUM</u>						
A040024 001	5624668	Sep 29, 2015				
<u>IRON SUCROSE - VENOFER</u>						
N021135 001					NPP	Sep 21, 2015
<u>IRON SUCROSE - VENOFER</u>						
N021135 002					NPP	Sep 21, 2015
<u>IRON SUCROSE - VENOFER</u>						
N021135 004					NPP	Sep 21, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 001	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 002	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 003	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 004	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ITRACONAZOLE - ONMEL</u>						
N022484 001	6509038	May 12, 2017	DP U-1054		NP	Apr 29, 2013
	7081255	May 12, 2017	DP U-1054			
<u>ITRACONAZOLE - SPORANOX</u>						
N020083 001	5633015	May 27, 2014				
<u>ITRACONAZOLE - SPORANOX</u>						
N020657 001	5707975	Jan 13, 2015				
	6407079	Jun 18, 2019				
<u>ITRACONAZOLE - SPORANOX</u>						
N020966 001	6407079	Jun 18, 2019				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N203188 001	7495103	May 20, 2027	DS DP		NCE	Jan 31, 2017
	8324242	Apr 18, 2027	U-1311		ODE	Jan 31, 2019
<u>IVERMECTIN - SKLICE</u>						
N202736 001	6103248	May 22, 2018	DP		NP	Feb 07, 2015
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	6670384	Jan 23, 2022	DP	U-959	M-61	Oct 18, 2014
	6670384	Jan 23, 2022	DP	U-960	NCE	Oct 16, 2012
	6670384*PED	Jul 23, 2022			PED	Apr 18, 2015
	7022330	Jan 23, 2022	DP	U-958	PED	Apr 16, 2013
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP	U-957		
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024		U-965		
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022		U-961		
	RE41393*PED	Aug 08, 2022				
	RE41911	Sep 28, 2020	DS DP	U-961		
	RE41911*PED	Mar 28, 2021				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	6670384	Jan 23, 2022	DP	U-960	M-61	Oct 18, 2014
	6670384	Jan 23, 2022	DP	U-959	NCE	Oct 16, 2012
	6670384*PED	Jul 23, 2022			PED	Apr 18, 2015
	7022330	Jan 23, 2022	DP	U-958	PED	Apr 16, 2013
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP	U-957		
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024		U-965		
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022		U-961		
	RE41393*PED	Aug 08, 2022				
	RE41911	Sep 28, 2020	DS DP	U-961		
	RE41911*PED	Mar 28, 2021				
<u>KETOCONAZOLE - EXTINA</u>						
N021738 001	7553835	Oct 19, 2018	DP	U-245		
	8026238	Oct 19, 2018	DP	U-1213		
<u>KETOCONAZOLE - NIZORAL A-D</u>						
N020310 001	5456851	Apr 07, 2014				
<u>KETOCONAZOLE - XOLEGEL</u>						
N021946 001	7179475	Dec 04, 2018	DP	U-792		
	8232276	Nov 24, 2020	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N021528 001	8008338	May 24, 2027	DS DP	U-1181		
	8008338*PED	Nov 24, 2027				
	8207215	May 28, 2024		U-1251		
	8207215*PED	Nov 28, 2024				
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N022427 001	7842714	Aug 15, 2029	DS DP		NP	Jul 22, 2012
<u>KETOROLAC TROMETHAMINE - SPRIX</u>						
N022382 001	6333044	Dec 25, 2018	DP	U-1057	NDF	May 14, 2013
	7476689	Oct 11, 2012	DP	U-1056		
<u>LACOSAMIDE - VIMPAT</u>						
N022253 001	5654301	Aug 05, 2014	DS DP	U-914	NCE	Oct 28, 2013
	RE38551	Mar 17, 2022	DS DP	U-914		
<u>LACOSAMIDE - VIMPAT</u>						
N022253 002	5654301	Aug 05, 2014	DS DP	U-914	NCE	Oct 28, 2013
	RE38551	Mar 17, 2022	DS DP	U-914		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES			PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
<u>LACOSAMIDE - VIMPAT</u>										
N022253	003	5654301 RE38551	Aug 05, 2014 Mar 17, 2022	DS DS	DP DP	U-914 U-914		NCE	Oct 28, 2013	
<u>LACOSAMIDE - VIMPAT</u>										
N022253	004	5654301 RE38551	Aug 05, 2014 Mar 17, 2022	DS DS	DP DP	U-914 U-914		NCE	Oct 28, 2013	
<u>LACOSAMIDE - VIMPAT</u>										
N022254	001	5654301 RE38551	Aug 05, 2014 Mar 17, 2022	DS DS	DP DP	U-911 U-911		NCE	Oct 28, 2013	
<u>LACOSAMIDE - VIMPAT</u>										
N022255	001	5654301 RE38551	Aug 05, 2014 Mar 17, 2022	DS DS	DP DP	U-914 U-914		NCE	Oct 28, 2013	
<u>LAMIVUDINE - EPIVIR</u>										
N020564	001	5905082 5905082*PED	May 18, 2016 Nov 18, 2016	DS	DP	U-248				
<u>LAMIVUDINE - EPIVIR</u>										
N020564	003	5905082 5905082*PED	May 18, 2016 Nov 18, 2016							
<u>LAMIVUDINE - EPIVIR</u>										
N020596	001	6004968 6004968*PED	Mar 20, 2018 Sep 20, 2018							
<u>LAMIVUDINE - EPIVIR-HBV</u>										
N021003	001	5905082 5905082*PED RE39155 RE39155*PED	May 18, 2016 Nov 18, 2016 Jul 02, 2013 Jan 02, 2014			U-250				
<u>LAMIVUDINE - EPIVIR-HBV</u>										
N021004	001	6004968 6004968*PED RE39155 RE39155*PED	Mar 20, 2018 Sep 20, 2018 Jul 02, 2013 Jan 02, 2014			U-250				
<u>LAMIVUDINE; ZIDOVUDINE - COMBIVIR</u>										
N020857	001	5905082 5905082*PED	May 18, 2016 Nov 18, 2016	DS	DP	U-248 U-248				
<u>LAMOTRIGINE - LAMICTAL CD</u>										
N020764	001	5698226*PED	Jul 29, 2012							
<u>LAMOTRIGINE - LAMICTAL CD</u>										
N020764	002	5698226*PED	Jul 29, 2012							
<u>LAMOTRIGINE - LAMICTAL CD</u>										
N020764	003	5698226*PED	Jul 29, 2012							
<u>LAMOTRIGINE - LAMICTAL CD</u>										
N020764	004	5698226*PED	Jul 29, 2012							
<u>LAMOTRIGINE - LAMICTAL ODT</u>										
N022251	001	7919115	Jan 04, 2029	DS	DP					
<u>LAMOTRIGINE - LAMICTAL ODT</u>										
N022251	002	7919115	Jan 04, 2029	DS	DP					
<u>LAMOTRIGINE - LAMICTAL ODT</u>										
N022251	003	7919115	Jan 04, 2029	DS	DP					
<u>LAMOTRIGINE - LAMICTAL ODT</u>										
N022251	004	7919115	Jan 04, 2029	DS	DP					

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115	001				I-644 I-622 PED	Apr 25, 2014 Jan 29, 2013 Nov 29, 2012
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115	002				I-644 I-622 PED	Apr 15, 2014 Jan 29, 2013 Nov 29, 2012
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115	003				I-644 I-622 PED	Apr 25, 2014 Jan 29, 2013 Nov 29, 2012
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115	004				I-644 I-622 PED	Apr 25, 2014 Jan 29, 2013 Nov 29, 2012
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115	005				I-644 I-622 PED	Apr 25, 2014 Jan 29, 2013 Nov 29, 2012
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115	006				I-622 I-644 PED	Jan 29, 2013 Apr 25, 2014 Nov 29, 2012
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074	001	5595760	Mar 08, 2020	DP U-831	D-131 NCE ODE	Mar 04, 2014 Aug 30, 2012 Aug 30, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074	002	5595760	Mar 08, 2020	DP U-831	D-131 NCE ODE	Mar 04, 2014 Aug 30, 2012 Aug 30, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074	003	5595760	Mar 08, 2020	DP U-831	D-131 NCE ODE	Mar 04, 2014 Aug 30, 2012 Aug 30, 2014
<u>LANSOPRAZOLE - PREVACID</u>						
N021428	001	5464632	Nov 07, 2012			
		5464632*PED	May 07, 2013			
		6328994	May 17, 2019			
		6328994*PED	Nov 17, 2019			
		7399485	May 26, 2018	DP		
		7399485*PED	Nov 26, 2018			
		7431942	May 17, 2019	DP		
		7431942*PED	Nov 17, 2019			
		7875292	May 17, 2019	DP		
		7875292*PED	Nov 17, 2019			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 002	5464632	Nov 07, 2012				
	5464632*PED	May 07, 2013				
	6328994	May 17, 2019				
	6328994*PED	Nov 17, 2019				
	7399485	May 26, 2018	DP			
	7399485*PED	Nov 26, 2018				
	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				
	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
<u>LANSOPRAZOLE - PREVACID IV</u>						
N021566 001	7396841	Aug 17, 2021	DP	U-947		
	7396841*PED	Feb 17, 2022				
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N021468 001	5968976	Oct 26, 2018	DP	U-613		
	7381428	Aug 26, 2024		U-890		
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N021468 002	5968976	Oct 26, 2018	DP	U-613		
	7381428	Aug 26, 2024		U-890		
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N021468 003	5968976	Oct 26, 2018	DP	U-613		
	7381428	Aug 26, 2024		U-890		
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N021468 004	5968976	Oct 26, 2018	DP	U-613		
	7381428	Aug 26, 2024		U-890		
	7465465	Aug 26, 2024	DP			
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N022059 001	6391874	Jul 11, 2017	DS DP	U-800	I-620	Jan 29, 2013
	6713485	Sep 29, 2020	DS DP	U-800		
	6727256	Jan 08, 2019	DS DP	U-800		
	6828320	Jul 11, 2017		U-800		
	7157466	Nov 19, 2021	DS DP			
<u>LENALIDOMIDE - REVLMID</u>						
N021880 001	5635517	Oct 04, 2019	DS	U-1211	ODE	Jun 29, 2013
	6045501	Aug 28, 2018		U-1210	ODE	Dec 27, 2012
	6281230	Jul 24, 2016		U-1212		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLMID</u>						
N021880 002	5635517	Oct 04, 2019	DS	U-1211	ODE	Jun 29, 2013
	6045501	Aug 28, 2018		U-1210	ODE	Dec 27, 2012
	6281230	Jul 24, 2016		U-1212		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
<u>LENALIDOMIDE - REVLMID</u>						
N021880 003	5635517	Oct 04, 2019	DS	U-1211	ODE	Jun 29, 2013
	6045501	Aug 28, 2018		U-1210		
	6281230	Jul 24, 2016		U-1212		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
<u>LENALIDOMIDE - REVLMID</u>						
N021880 004	5635517	Oct 04, 2019	DS	U-1211	ODE	Jun 29, 2013
	6045501	Aug 28, 2018		U-1210		
	6281230	Jul 24, 2016		U-1212		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLMID</u>						
N021880 005	5635517	Oct 04, 2019	DS	U-1211	ODE	Dec 27, 2012
	6045501	Aug 28, 2018		U-1210	ODE	Jun 29, 2013
	6281230	Jul 24, 2016		U-1212		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N021343 001	5599552	Feb 04, 2014				
	6395293	Sep 28, 2013	DP	U-801		
	6565874	Oct 28, 2018	DP	U-801		
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	DP	U-801		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N021379 001	5599552	Feb 04, 2014				
	6395293	Sep 28, 2013	DP			
	6565874	Oct 28, 2018	DP	U-801		
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	DP	U-801		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N021488 001	5599552	Feb 04, 2014				
	6395293	Sep 28, 2013	DP			
	6565874	Oct 28, 2018	DP	U-801		
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	DP	U-801		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N021731 001	5599552	Feb 04, 2014	DP	U-621		
	6395293	Sep 28, 2013	DP			
	6565874	Oct 28, 2018	DP	U-621		
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018		U-621		
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N019732 001	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N020011 001	5575987	Sep 02, 2013				
	5631021	May 20, 2014				
	5716640	Sep 02, 2013				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N020517 001	5480656	Jan 02, 2013				
	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5643607	Jan 02, 2013				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N020517 002	5480656	Jan 02, 2013				
	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5643607	Jan 02, 2013				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N020517 003	6036976	Dec 13, 2016	DP		D-132	Jun 17, 2014
	7429559	Dec 13, 2016	DP		NS	Jun 17, 2014
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N020708 001	5480656	Jan 02, 2013				
	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5643607	Jan 02, 2013				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 002	5575987	Sep 02, 2013			M-107	Oct 08, 2014
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 003	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2013				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 004	5575987	Sep 02, 2013				
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2013				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 005	5575987	Sep 02, 2013			M-107	Oct 08, 2014
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 006	5575987	Sep 02, 2013			M-107	Oct 08, 2014
	5631020	May 20, 2014				
	5716640	Sep 02, 2013				
	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 007	5575987	Sep 02, 2013	DP		NP	Aug 15, 2014
	5631020	May 20, 2014	DP			
	5716640	Sep 02, 2013	DP			
	6036976	Dec 13, 2016	DP			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 008	5480656	Jan 02, 2013	DP		NP	Aug 15, 2014
	5575987	Sep 02, 2013	DP			
	5631020	May 20, 2014	DP			
	5643607	Jan 02, 2013	DP			
	5716640	Sep 02, 2013	DP			
	6036976	Dec 13, 2016	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - VIADUR</u>						
N021088 001	5728396	Jan 30, 2017	U-316			
	5932547	Jun 13, 2017				
	5985305	Jan 30, 2017				
	6113938	Jul 24, 2018				
	6124261	Jun 13, 2017				
	6132420	Jan 30, 2017				
	6156331	Jan 30, 2017				
	6235712	Jun 13, 2017				
	6375978	Dec 17, 2018				
	6395292	Jan 30, 2017				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N020837 001	5362755	Mar 25, 2013	U-332			
	5547994	Aug 20, 2013	U-332			
	6451289	Mar 21, 2021				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N020837 002	5362755	Mar 25, 2013	U-332			
	5547994	Aug 20, 2013	U-332			
	6451289	Mar 21, 2021				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N020837 003	5362755	Mar 25, 2013	U-332			
	5547994	Aug 20, 2013	U-332			
	6451289	Mar 21, 2021				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N020837 004	5362755	Mar 25, 2013	U-332			
	5547994	Aug 20, 2013	U-332			
	6451289	Mar 21, 2021	DP			
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N021730 001	5362755	Mar 25, 2013	U-636			
	5547994	Aug 20, 2013	U-636			
	5605674	Feb 25, 2014	DP			
	5836299	Nov 17, 2015	DP			
	7256310	Oct 08, 2024	DS DP			
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 001					NPP	Dec 16, 2014
					PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 002					NPP	Dec 16, 2014
					PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 003					NPP	Dec 16, 2014
					PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 004					NPP	Dec 16, 2014
					PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N021505 001					NPP	Dec 16, 2014
					PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA XR</u>						
N022285 001	7858122	Sep 17, 2028	DP			
<u>LEVETIRACETAM - KEPPRA XR</u>						
N022285 002	7858122	Sep 17, 2028	DP			
<u>LEVOBETAXOLOL HYDROCHLORIDE - BETAXON</u>						
N021114 001	5540918	Jul 30, 2013	DP			
	5540918*PED	Jan 30, 2014				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOBUPIVACAINE HYDROCHLORIDE - CHIROCAINE</u>						
N020997 001	5708011	Oct 13, 2014	U-276			
<u>LEVOBUPIVACAINE HYDROCHLORIDE - CHIROCAINE</u>						
N020997 002	5708011	Oct 13, 2014	U-276			
<u>LEVOBUPIVACAINE HYDROCHLORIDE - CHIROCAINE</u>						
N020997 003	5708011	Oct 13, 2014	U-276			
<u>LEVOCARNITINE - CARNITOR</u>						
N020182 001	6335369	Jan 18, 2021	U-433			
	6429230	Jan 18, 2021	U-433			
	6696493	Jan 18, 2021	U-433			
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL</u>						
N022064 001	5698558	Jul 26, 2013	U-812		NPP	Aug 21, 2012
	5698558*PED	Jan 26, 2014			PED	Feb 21, 2013
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL</u>						
N022157 001	5698558	Jul 26, 2013	U-852		NPP	Aug 21, 2012
	5698558*PED	Jan 26, 2014			PED	Feb 21, 2013
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N021721 001	6806256	Feb 26, 2022	DP			
	6806256*PED	Aug 26, 2022				
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 001	6500829	Dec 31, 2019	DS DP		I-637 ODE ODE	Apr 29, 2014 Apr 29, 2018 Mar 07, 2015
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 002	6500829	Dec 31, 2019	DS DP		I-637 ODE ODE	Apr 29, 2014 Apr 29, 2018 Mar 07, 2015
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 003	6500829	Dec 31, 2019	DS DP		I-637 ODE ODE	Apr 29, 2014 Apr 29, 2018 Mar 07, 2015
<u>LEVONORGESTREL - MIRENA</u>						
N021225 001	5785053	Dec 05, 2015	DP		I-610	Oct 01, 2012
<u>LEVONORGESTREL - PLAN B ONE-STEP</u>						
N021998 001					NP	Jul 10, 2012
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 001	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 002	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 003	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 004	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 005	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 006	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N021342 007	6399101	Mar 30, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>							
N021342 008	6399101	Mar	30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>							
N021342 009	6399101	Mar	30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>							
N021342 010	6399101	Mar	30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>							
N021342 011	6399101	Mar	30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>							
N021301 001	6555581	Feb	15, 2022	DP		U-759	
	7067148	Feb	15, 2022				
	7101569	Aug	14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>							
N021301 002	6555581	Feb	15, 2022	DP		U-759	
	7067148	Feb	15, 2022				
	7101569	Aug	14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>							
N021301 003	6555581	Feb	15, 2022	DP		U-759	
	7067148	Feb	15, 2022				
	7101569	Aug	14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>							
N021301 004	6555581	Feb	15, 2022	DP		U-759	
	7067148	Feb	15, 2022				
	7101569	Aug	14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>							
N021301 005	6555581	Feb	15, 2022	DP		U-759	
	7067148	Feb	15, 2022				
	7101569	Aug	14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>							
N021301 006	6555581	Feb	15, 2022	DP		U-759	
	7067148	Feb	15, 2022				
	7101569	Aug	14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>							
N021301 007	6555581	Feb	15, 2022	DP		U-759	
	7067148	Feb	15, 2022				
	7101569	Aug	14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>							
N021301 008	6555581	Feb	15, 2022	DP		U-759	
	7067148	Feb	15, 2022				
	7101569	Aug	14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>							
N021301 009	6555581	Feb	15, 2022	DP		U-759	
	7067148	Feb	15, 2022				
	7101569	Aug	14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>							
N021301 010	6555581	Feb	15, 2022	DP		U-759	
	7067148	Feb	15, 2022				
	7101569	Aug	14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>							
N021301 011	6555581	Feb	15, 2022	DP		U-759	
	7067148	Feb	15, 2022				
	7101569	Aug	14, 2022				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>							
N021301 012	6555581	Feb	15, 2022	DP		U-759	
	7067148	Feb	15, 2022				
	7101569	Aug	14, 2022				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 002	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 003	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 004	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 005	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 006	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 007	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 008	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 009	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 010	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N022121 001	7723390	Mar 14, 2024	DP			
<u>LIDOCAINE - LIDODERM</u>						
N020612 001	5741510	Mar 30, 2014	DP			
	5827529	Oct 27, 2015		U-486		
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N022114 001	5630796	May 20, 2014				
	5899880	May 04, 2016	DP			
	6004286	Mar 17, 2017	DP			
	6881200	Jun 11, 2016	DP			
<u>LIDOCAINE; PRILOCAINE - ORAQIX</u>						
N021451 001	6031007	Apr 01, 2017	DP	U-553		
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u>						
N021717 001	5919479	Jul 28, 2015	DP			
	6528086	Sep 28, 2019	DP			
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
N021623 001	5658583	Jul 28, 2015	DP			
	5919479	Jul 28, 2015	DP			
	6306431	Jul 28, 2015	DP			
	6465006	Jul 28, 2015	DP			
	6465709	Jul 07, 2020	DP			
	6546281	Jul 28, 2015	DP			
	6780426	Jul 28, 2015	DP			
<u>LINACLOTIDE - LINZESS</u>						
N202811 001	7304036	Jan 28, 2024	DS DP	U-1278	NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024		U-1278		
<u>LINACLOTIDE - LINZESS</u>						
N202811 002	7304036	Jan 28, 2024	DS DP	U-1278	NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024		U-1278		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN - TRADJENTA</u>						
N201280 001	6303661	Apr 24, 2017	U-1270		M-121	Aug 13, 2015
	6303661	Apr 24, 2017	U-774		M-118	Aug 13, 2015
	6890898	Feb 02, 2019	U-1270		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-493			
	7078381	Feb 02, 2019	U-493			
	7078381	Feb 02, 2019	U-1270			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1270			
	7459428	Feb 02, 2019	U-493			
	8119648	Aug 12, 2023	U-774			
	8119648	Aug 12, 2023	U-1270			
	8178541	Aug 12, 2023	U-1245			
	8178541	Aug 12, 2023	U-775			
	8178541	Aug 12, 2023	U-1244			
	8178541	Aug 12, 2023	U-1270			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 001	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 002	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 003	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LINEZOLID - ZYVOX</u>						
N021130 001	5688792	Nov 18, 2014	DS		U-319	
	5688792*PED	May 18, 2015				
	6514529	Mar 15, 2021	DP			
	6514529*PED	Sep 15, 2021				
	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LINEZOLID - ZYVOX</u>						
N021130 002	5688792	Nov 18, 2014	DS		U-319	
	5688792*PED	May 18, 2015				
	6514529	Mar 15, 2021	DP			
	6514529*PED	Sep 15, 2021				
	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LINEZOLID - ZYVOX</u>						
N021131 001	5688792	Nov 18, 2014			U-319	
	5688792*PED	May 18, 2015				
	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINEZOLID - ZYVOX</u>						
N021132 001	5688792	Nov 18, 2014	DS	U-319		
	5688792*PED	May 18, 2015				
	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N022341 001	6004297	Jan 28, 2019		DP	M-115	Apr 06, 2015
	6268343	Aug 22, 2017	DS DP	U-968	NCE	Jan 25, 2015
	6458924	Aug 22, 2017	DS DP	U-968		
	7235627	Aug 22, 2017	DS	DP		
	8114833	Aug 13, 2025		DP		
	RE41956	Jan 21, 2021		DP		
	RE43834	Jan 28, 2019		DP		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 001	7105486	Jun 29, 2023		U-727	I-645	Jan 31, 2015
	7223735	Jun 29, 2023		DP	M-82	Apr 05, 2013
	7655630	Feb 24, 2023	DS		NPP	Nov 10, 2013
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023		DP U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023		DP U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023		DP U-842		
	7687466	Feb 24, 2023		DP		
	7687467	Apr 08, 2023		DP U-842		
	7700561	Jun 29, 2023		DP		
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023		DP U-842		
	7723305	Feb 24, 2023		DP U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 002	7105486	Jun 29, 2023		U-727	I-645	Jan 31, 2015
	7223735	Jun 29, 2023		DP	M-82	Apr 05, 2013
	7655630	Feb 24, 2023	DS		NPP	Nov 10, 2013
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023		DP U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023		DP U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023		DP U-842		
	7687466	Feb 24, 2023		DP		
	7687467	Apr 08, 2023		DP U-842		
	7700561	Jun 29, 2023		DP		
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023		DP U-842		
	7723305	Feb 24, 2023		DP U-842		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 003	7105486	Jun 29, 2023		U-727	I-645	Jan 31, 2015
	7223735	Jun 29, 2023	DP		M-82	Apr 05, 2013
	7655630	Feb 24, 2023	DS		NPP	Nov 10, 2013
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023	DP	U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP	U-842		
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 004	7105486	Jun 29, 2023		U-842	I-645	Jan 31, 2015
	7223735	Jun 29, 2023	DP		M-82	Apr 05, 2013
	7655630	Feb 24, 2023	DS		NPP	Nov 10, 2013
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023	DP	U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP	U-842		
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 005	7105486	Jun 29, 2023		U-842	I-645	Jan 31, 2015
	7223735	Jun 29, 2023	DP		M-82	Apr 05, 2013
	7655630	Feb 24, 2023	DS		NPP	Nov 10, 2013
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023	DP	U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP	U-842		
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 006	7105486	Jun 29, 2023	U-842		I-645	Jan 31, 2015
	7223735	Jun 29, 2023	DP		M-82	Apr 05, 2013
	7655630	Feb 24, 2023	DS		NPP	Nov 10, 2013
	7659253	Feb 24, 2023	DS DP			
	7659254	Feb 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023				
	7671030	Feb 24, 2023	DP			
	7671031	Feb 28, 2023				
	7674774	Mar 18, 2023	DP			
	7678770	Mar 25, 2023				
	7678771	Mar 25, 2023	DP			
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP			
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023				
	7718619	Feb 24, 2023	DP			
	7723305	Feb 24, 2023	DP			
<u>LODOXAMIDE TROMETHAMINE - ALOMIDE</u>						
N020191 001	5457126	Oct 10, 2012	U-117			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N203858 001	5712279	Feb 21, 2015	DS		NCE	Dec 21, 2017
	5739135	Apr 14, 2015	DS			
	6492365	Dec 10, 2019				
	7932268	Aug 19, 2027				
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N203858 002	5712279	Feb 21, 2015	DS		NCE	Dec 21, 2017
	5739135	Apr 14, 2015	DS			
	6492365	Dec 10, 2019				
	7932268	Aug 19, 2027				
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N203858 003	5712279	Feb 21, 2015	DS		NCE	Dec 21, 2017
	5739135	Apr 14, 2015	DS			
	6492365	Dec 10, 2019				
	7932268	Aug 19, 2027				
<u>LOPERAMIDE HYDROCHLORIDE - IMODIUM A-D EZ CHEWS</u>						
N020448 001	5489436	Feb 06, 2013	DP			
	6814978	Aug 26, 2021	DP			
<u>LOPERAMIDE HYDROCHLORIDE; SIMETHICONE - IMODIUM MULTI-SYMP TOM RELIEF</u>						
N020606 001	5489436	Feb 06, 2013				
	5679376	Oct 21, 2014				Y
<u>LOPERAMIDE HYDROCHLORIDE; SIMETHICONE - IMODIUM MULTI-SYMP TOM RELIEF</u>						
N021140 001	6103260	Jul 17, 2017	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021226 001	5541206	Jul 30, 2013	DS	U-348		
	5541206*PED	Jan 30, 2014				
	5648497	Jul 15, 2014				
	5648497*PED	Jan 15, 2015				
	5886036	Nov 19, 2013	DS DP			
	5886036*PED	May 19, 2014				
	5914332	Dec 13, 2015		U-351		
	5914332*PED	Jun 13, 2016				
	5948436	Sep 13, 2013	DP			
	5948436*PED	Mar 13, 2014				
	6037157	Jun 26, 2016		U-346		
	6037157*PED	Dec 26, 2016				
	6232333	Nov 07, 2017				
	6232333*PED	May 07, 2018				
	6284767	Feb 15, 2016	DP	U-688		
	6284767	Feb 15, 2016	DP	U-401		
	6284767*PED	Aug 15, 2016				
	6458818	Nov 07, 2017				
	6458818*PED	May 07, 2018				
	6521651	Nov 07, 2017	DP			
	6521651*PED	May 07, 2018				
	6703403	Jun 26, 2016		U-257		
	6703403*PED	Dec 26, 2016				
	7141593	May 22, 2020	DP			
	7141593*PED	Nov 22, 2020				
	7432294	May 22, 2020	DP			
	7432294*PED	Nov 22, 2020				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021251 001	5484801	Jan 28, 2014	DP		D-124	Apr 27, 2013
	5484801*PED	Jul 28, 2014				
	5541206	Jul 30, 2013	DS DP	U-348		
	5541206	Jul 30, 2013	DS DP	U-895		
	5541206*PED	Jan 30, 2014				
	5648497	Jul 15, 2014	DS			
	5648497*PED	Jan 15, 2015				
	5886036	Nov 19, 2013	DS DP	U-895		
	5886036*PED	May 19, 2014				
	5914332	Dec 13, 2015	DS DP	U-351		
	5914332	Dec 13, 2015	DS DP	U-895		
	5914332*PED	Jun 13, 2016				
	5948436	Sep 13, 2013	DP			
	5948436*PED	Mar 13, 2014				
	6037157	Jun 26, 2016		U-895		
	6037157	Jun 26, 2016		U-346		
	6037157*PED	Dec 26, 2016				
	6284767	Feb 15, 2016	DP	U-895		
	6284767	Feb 15, 2016	DP	U-401		
	6284767*PED	Aug 15, 2016				
	6703403	Jun 26, 2016		U-257		
	6703403	Jun 26, 2016		U-895		
	6703403*PED	Dec 26, 2016				
	6911214	Nov 28, 2021	DP	U-895		
	6911214*PED	May 28, 2022				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 001	5541206	Jul 30, 2013	DS DP U-688		D-124	Apr 27, 2013
	5541206*PED	Jan 30, 2014				
	5648497	Jul 15, 2014	DS DP			
	5648497*PED	Jan 15, 2015				
	5886036	Nov 19, 2013	DS DP U-895			
	5886036*PED	May 19, 2014				
	5914332	Dec 13, 2015	DS DP U-688			
	5914332*PED	Jun 13, 2016				
	6037157	Jun 26, 2016			U-688	
	6037157*PED	Dec 26, 2016				
	6284767	Feb 15, 2016	DP U-688			
	6284767*PED	Aug 15, 2016				
	6703403	Jun 26, 2016			U-688	
	6703403*PED	Dec 26, 2016				
	7148359	Jul 19, 2019	DP			
	7148359*PED	Jan 19, 2020				
	7364752	Nov 10, 2020	DP U-688			
	7364752*PED	May 10, 2021				
	8025899	Sep 26, 2027	DP			
	8025899*PED	Mar 26, 2028				
	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				
	8309613	Dec 24, 2024			U-688	
	8309613*PED	Jun 24, 2025				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 002	5541206	Jul 30, 2013	DS DP U-688		D-124	Apr 27, 2013
	5541206*PED	Jan 30, 2014				
	5648497	Jul 15, 2014	DS DP			
	5648497*PED	Jan 15, 2015				
	5886036	Nov 19, 2013	DS DP U-895			
	5886036*PED	May 19, 2014				
	5914332	Dec 13, 2015	DS DP U-688			
	5914332*PED	Jun 13, 2016				
	6037157	Jun 26, 2016			U-688	
	6037157*PED	Dec 26, 2016				
	6284767	Feb 15, 2016	DP U-688			
	6284767*PED	Aug 15, 2016				
	6703403	Jun 26, 2016			U-688	
	6703403*PED	Dec 26, 2016				
	7148359	Jul 19, 2019	DP			
	7148359*PED	Jan 19, 2020				
	7364752	Nov 10, 2020	DP U-688			
	7364752*PED	May 10, 2021				
	8025899	Sep 26, 2027	DP			
	8025899*PED	Mar 26, 2028				
	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				
	8309613	Dec 24, 2024			U-688	
	8309613*PED	Jun 24, 2025				
<u>LORATADINE - CLARITIN</u>						
N020641 002	6132758	Jun 01, 2018				
<u>LORATADINE; PSEUDOEPHEDRINE SULFATE - CLARITIN-D 24 HOUR</u>						
N020470 002	5314697	Oct 23, 2012				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIQ</u>						
N022529 001	6953787	Apr 10, 2023	DS DP	U-1254	NCE	Jun 27, 2017
	6953787	Apr 10, 2023	DS DP	U-1255		
	6953787	Apr 10, 2023	DS DP	U-1252		
	6953787	Apr 10, 2023	DS DP	U-1253		
	7514422	Apr 10, 2023		U-1255		
	7514422	Apr 10, 2023		U-1254		
	7514422	Apr 10, 2023		U-1252		
	7514422	Apr 10, 2023		U-1253		
	7977329	Apr 10, 2023	DS DP	U-1252		
	7977329	Apr 10, 2023	DS DP	U-1255		
	7977329	Apr 10, 2023	DS DP	U-1253		
	7977329	Apr 10, 2023	DS DP	U-1254		
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023		U-1254		
	8207158	Apr 10, 2023		U-1253		
	8207158	Apr 10, 2023		U-1252		
	8207158	Apr 10, 2023		U-1255		
	8273734	Apr 10, 2023		U-1254		
	8273734	Apr 10, 2023		U-1255		
<u>LOTEPREDNOL ETABONATE - ALREX</u>						
N020803 001	4996335*PED	Sep 09, 2012				
	5540930	Oct 25, 2013				
	5540930*PED	Apr 25, 2014				
	5747061	Oct 25, 2013	DP	U-576		
	5747061*PED	Apr 25, 2014				
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N020583 001	4996335*PED	Sep 09, 2012				
	5540930	Oct 25, 2013				
	5540930*PED	Apr 25, 2014				
	5747061	Oct 25, 2013	DP	U-575		
	5747061*PED	Apr 25, 2014				
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N020841 001	5540930	Oct 25, 2013				
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N200738 001					NDF	Apr 15, 2014
					PED	Oct 15, 2014
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N202872 001					NDF	Sep 28, 2015
<u>LOTEPREDNOL ETABONATE; TOBRAMYCIN - ZYLET</u>						
N050804 001	4996335*PED	Sep 09, 2012				
	5540930	Oct 25, 2013	DP			
	5540930*PED	Apr 25, 2014				
	5747061	Oct 25, 2013	DP	U-920		
	5747061*PED	Apr 25, 2014				
<u>LOVASTATIN - ALTOPREV</u>						
N021316 001	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018			U-456	
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N021316 002	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018			U-456	
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N021316 003	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018			U-456	
	6485748	Dec 12, 2017	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOVASTATIN - ALTOPREV</u>						
N021316 004	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018				
	6485748	Dec 12, 2017	DP	U-456		
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 001	6080428	May 27, 2017			U-447	
	6080428	May 27, 2017			U-1134	
	6080428	May 27, 2017			U-1133	
	6080428	May 27, 2017			U-1132	
	6129930	Sep 20, 2013	DP		U-448	
	6129930	Sep 20, 2013	DP		U-1133	
	6129930	Sep 20, 2013	DP		U-1132	
	6129930	Sep 20, 2013	DP		U-1134	
	6406715	Sep 20, 2013	DP		U-450	
	6469035	Mar 15, 2018			U-1131	
	6469035	Mar 15, 2018			U-1129	
	6469035	Mar 15, 2018			U-1130	
	6469035	Mar 15, 2018			U-768	
	6676967	Sep 20, 2013			U-548	
	6676967	Sep 20, 2013			U-1132	
	6676967	Sep 20, 2013			U-1134	
	6676967	Sep 20, 2013			U-1133	
	6746691	Sep 20, 2013	DP		U-586	
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013			U-712	
	7011848	Sep 20, 2013			U-1137	
	7011848	Sep 20, 2013			U-1135	
	7011848	Sep 20, 2013			U-1136	
	7998506	Sep 20, 2013			U-1137	
	7998506	Sep 20, 2013			U-1135	
	7998506	Sep 20, 2013			U-1136	
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 002	6080428	May 27, 2017			U-447	
	6080428	May 27, 2017			U-1134	
	6080428	May 27, 2017			U-1133	
	6080428	May 27, 2017			U-1132	
	6129930	Sep 20, 2013	DP		U-448	
	6129930	Sep 20, 2013	DP		U-1134	
	6129930	Sep 20, 2013	DP		U-1132	
	6129930	Sep 20, 2013	DP		U-1133	
	6406715	Sep 20, 2013	DP		U-450	
	6469035	Mar 15, 2018			U-1130	
	6469035	Mar 15, 2018			U-1129	
	6469035	Mar 15, 2018			U-1131	
	6469035	Mar 15, 2018			U-768	
	6676967	Sep 20, 2013			U-548	
	6676967	Sep 20, 2013			U-1132	
	6676967	Sep 20, 2013			U-1133	
	6676967	Sep 20, 2013			U-1134	
	6746691	Sep 20, 2013	DP		U-586	
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013			U-712	
	7011848	Sep 20, 2013			U-1137	
	7011848	Sep 20, 2013			U-1135	
	7011848	Sep 20, 2013			U-1136	
	7998506	Sep 20, 2013			U-1136	
	7998506	Sep 20, 2013			U-1137	
	7998506	Sep 20, 2013			U-1135	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 003	6080428	May 27, 2017			U-1134	
	6080428	May 27, 2017			U-447	
	6080428	May 27, 2017			U-1132	
	6080428	May 27, 2017			U-1133	
	6129930	Sep 20, 2013	DP		U-1132	
	6129930	Sep 20, 2013	DP		U-1134	
	6129930	Sep 20, 2013	DP		U-1133	
	6129930	Sep 20, 2013	DP		U-448	
	6406715	Sep 20, 2013	DP		U-450	
	6469035	Mar 15, 2018			U-768	
	6469035	Mar 15, 2018			U-1131	
	6469035	Mar 15, 2018			U-1130	
	6469035	Mar 15, 2018			U-1129	
	6676967	Sep 20, 2013			U-1132	
	6676967	Sep 20, 2013			U-1133	
	6676967	Sep 20, 2013			U-1134	
	6676967	Sep 20, 2013			U-548	
	6746691	Sep 20, 2013	DP		U-586	
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013			U-712	
	7011848	Sep 20, 2013			U-1136	
	7011848	Sep 20, 2013			U-1135	
	7011848	Sep 20, 2013			U-1137	
	7998506	Sep 20, 2013			U-1137	
	7998506	Sep 20, 2013			U-1136	
	7998506	Sep 20, 2013			U-1135	
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 004	6080428	May 27, 2017			U-1134	
	6080428	May 27, 2017			U-1132	
	6080428	May 27, 2017			U-447	
	6080428	May 27, 2017			U-1133	
	6129930	Sep 20, 2013	DP		U-448	
	6129930	Sep 20, 2013	DP		U-1133	
	6129930	Sep 20, 2013	DP		U-1134	
	6129930	Sep 20, 2013	DP		U-1132	
	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018			U-1129	
	6469035	Mar 15, 2018			U-768	
	6469035	Mar 15, 2018			U-1131	
	6469035	Mar 15, 2018			U-1130	
	6676967	Sep 20, 2013			U-548	
	6676967	Sep 20, 2013			U-1132	
	6676967	Sep 20, 2013			U-1134	
	6676967	Sep 20, 2013			U-1133	
	6746691	Sep 20, 2013	DP		U-586	
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013			U-1136	
	7011848	Sep 20, 2013			U-1135	
	7011848	Sep 20, 2013			U-1137	
	7011848	Sep 20, 2013			U-712	
	7998506	Sep 20, 2013			U-1137	
	7998506	Sep 20, 2013			U-1136	
	7998506	Sep 20, 2013			U-1135	
<u>LOXAPINE - ADASUVE</u>						
N022549 001						

NDF Dec 21, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 001	5284858	Jul 14, 2014	DS			
	6414016	Sep 05, 2020		U-717		
	6583174	Oct 16, 2020	DP			
	7064148	Aug 30, 2022		U-739		
	7417067	Oct 16, 2020	DP			
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020		U-1203		
	8088934	May 18, 2021	DS			
	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022		U-1214		
	8114890	Sep 05, 2020	DP			
	8338639	Jan 23, 2027	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 002	5284858	Jul 14, 2014	DS			
	6414016	Sep 05, 2020		U-874		
	6583174	Oct 16, 2020	DP			
	7064148	Aug 30, 2022		U-739		
	7064148	Aug 30, 2022		U-873		
	7417067	Oct 16, 2020	DP			
	7795312	Sep 17, 2024		U-1085		
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020		U-1202		
	8088934	May 18, 2021	DS			
	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
	8338639	Jan 23, 2027	DP			
<u>LUCINACTANT - SURFAXIN</u>						
N021746 001	5407914	Nov 17, 2013	DS DP	U-1242		
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 001	5532372	Jul 02, 2013	DS		D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 002	5532372	Jul 02, 2013	DS		D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 003	5532372	Jul 02, 2013	DS		D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 004	5532372	Jul 02, 2013	DS		D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>LUTROPIN ALFA - LUVERIS</u>						
N021322 001	5767251	Jun 16, 2015	DS			
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 25</u>						
N021910 001	5945449	Oct 31, 2017	DP	U-785	ODE	Jul 26, 2013
	7300674	Mar 04, 2023	DP	U-785		
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 35</u>						
N021910 002	5945449	Oct 31, 2017	DP	U-785	ODE	Jul 26, 2013
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE</u>						
N022456 001	6489346	Jul 16, 2016	DP	U-588		
	6489346	Jul 16, 2016	DP	U-1021		
	6645988	Jul 16, 2016	DP			
	6699885	Jul 16, 2016	DP	U-1021		
	6699885	Jul 16, 2016	DP	U-588		
	7399772	Jul 16, 2016	DP	U-588		
	7399772	Jul 16, 2016	DP	U-1021		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE</u>						
N022456 002	6489346	Jul 16, 2016	DP U-1021			
	6489346	Jul 16, 2016	DP U-588			
	6645988	Jul 16, 2016	DP			
	6699885	Jul 16, 2016	DP U-588			
	6699885	Jul 16, 2016	DP U-1021			
	7399772	Jul 16, 2016	DP U-1021			
	7399772	Jul 16, 2016	DP U-588			
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N021850 001	6489346	Jul 16, 2016	DS DP U-588			
	6645988	Jul 16, 2016	DS DP U-588			
	6699885	Jul 16, 2016	U-588			
	7399772	Jul 16, 2016	U-588			
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N021850 002	6489346	Jul 16, 2016	DS DP U-623			
	6645988	Jul 16, 2016	DS DP U-623			
	6699885	Jul 16, 2016	U-623			
	7399772	Jul 16, 2016	U-623			
<u>MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT</u>						
N022372 001	6946149	Mar 07, 2023	DP U-837		NC	Aug 05, 2013
<u>MALATHION - OVIDE</u>						
N018613 001	7560445	Feb 01, 2027	DS DP U-986			
	7977324	Aug 14, 2026	DP			
<u>MANNITOL - ARIDOL KIT</u>						
N022368 001	5817028	Feb 23, 2015	U-1091		NP	Oct 05, 2013
<u>MARAVIROC - SELZENTRY</u>						
N022128 001	6586430	Dec 01, 2019	DS DP U-824		NPP	May 28, 2013
	6667314	Aug 06, 2021	DS DP U-824		NCE	Aug 06, 2012
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N022128 002	6586430	Dec 01, 2019	DS DP U-824		NPP	May 28, 2013
	6667314	Aug 06, 2021	DS DP U-824		NCE	Aug 06, 2012
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MECASERMIN RECOMBINANT - INCRELEX</u>						
N021839 001	5681814	Sep 18, 2017	DP		ODE	Aug 30, 2012
	5824642	Jul 08, 2014	U-681			
	6207640	Apr 07, 2014	U-681			
<u>MECASERMIN RINFABATE RECOMBINANT - IPLEX</u>						
N021884 001	5681818	Oct 28, 2014	U-697		ODE	Dec 12, 2012
<u>MEDROXYPROGESTERONE ACETATE - DEPO-SUBQ PROVERA 104</u>						
N021583 001	6495534	May 15, 2020	DP			
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N021778 001	6592903	Sep 21, 2020	DP			
	7101576	Apr 22, 2024	U-755			
<u>MELOXICAM - MOBIC</u>						
N020938 001					ODE	Aug 11, 2012
					PED	Feb 11, 2013
<u>MELOXICAM - MOBIC</u>						
N020938 002					ODE	Aug 11, 2012
					PED	Feb 11, 2013
<u>MELOXICAM - MOBIC</u>						
N021530 001	6184220	Mar 25, 2019	DP		ODE	Aug 11, 2012
	6184220*PED	Sep 25, 2019			PED	Feb 11, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N021487 001	5061703	Apr 11, 2015	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N021487 002	5061703	Apr 11, 2015	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N021627 001	5061703	Apr 11, 2015	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525 001	5061703	Apr 11, 2015	U-539		NDF	Jun 21, 2013
	8039009	Mar 24, 2029	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525 002	5061703	Apr 11, 2015	U-539		NDF	Jun 21, 2013
	8039009	Mar 24, 2029	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525 003	5061703	Apr 11, 2015	U-539		NDF	Jun 21, 2013
	8039009	Mar 24, 2029	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525 004	5061703	Apr 11, 2015	U-539		NDF	Jun 21, 2013
	8039009	Mar 24, 2029	U-539			
<u>MEQUINOL; TRETINOIN - SOLAGE</u>						
N020922 001	5194247	Dec 10, 2013	DP U-294			
	6353029	Aug 24, 2020				
<u>MESALAMINE - APRISO</u>						
N022301 001	6551620	Apr 20, 2018	DS DP U-907			
	8337886	Apr 20, 2018	DP U-1310			
<u>MESALAMINE - ASACOL</u>						
N019651 001	5541170	Jul 30, 2013	U-141			
	5541171	Jul 30, 2013	U-141			
<u>MESALAMINE - ASACOL HD</u>						
N021830 001	5541170	Jul 30, 2013	DP U-141			
	5541171	Jul 30, 2013	DP U-141			
	6893662	Nov 15, 2021	DP U-141			
<u>MESALAMINE - LIALDA</u>						
N022000 001	6773720	Jun 08, 2020	DP		I-640	Jul 14, 2014
<u>MESALAMINE - SFROWASA</u>						
N019618 002	7645801	Jul 24, 2027	DS DP			
<u>METAXALONE - SKELAXIN</u>						
N013217 003	7122566	Feb 06, 2026	U-915			
	7714006	Dec 03, 2021	U-1050			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 001	6099859	Mar 20, 2018	DP			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-604			
	6866866	Mar 17, 2021	DP			
	7919116	Mar 20, 2018	DP			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 002	6099859	Mar 20, 2018	DP			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-604			
	6866866	Mar 17, 2021	DP			
	7919116	Mar 20, 2018	DP			
<u>METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR</u>						
N021202 001	6475521	Mar 19, 2018				
	6660300	Mar 19, 2018	U-542			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR</u>						
N021202 004	6475521	Mar 19, 2018				
	6660300	Mar 19, 2018	U-542			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N021748 001	6340475	Sep 19, 2016	DS DP	U-669		
	6488962	Jun 20, 2020	DS DP			
	6635280	Sep 19, 2016	DS DP			
	6723340	Oct 25, 2021	DS DP			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N021748 002	6488962	Jun 20, 2020	DS DP			
	7780987	Mar 23, 2025	DS DP			
	8323692	Mar 23, 2025	DP			
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N021591 001	6890957	Sep 14, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842 001	5965584	Jun 19, 2016	DP	U-1055	M-116	May 17, 2015
	6166042	Jun 19, 2016		U-679		
	6166043	Jun 19, 2016		U-679		
	6172090	Jun 19, 2016		U-679		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842 002	5965584	Jun 19, 2016	DP	U-1055	M-116	May 17, 2015
	6166042	Jun 19, 2016		U-679		
	6166043	Jun 19, 2016		U-679		
	6172090	Jun 19, 2016		U-679		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024 001	5965584	Jun 19, 2016	DP	U-973		
	6099859	Mar 20, 2018	DP			
	6166042	Jun 19, 2016		U-973		
	6166043	Jun 19, 2016		U-973		
	6172090	Jun 19, 2016		U-973		
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021		U-974		
	6866866	Mar 17, 2021	DP			
	7785627	Jul 31, 2026	DP			
	7919116	Mar 20, 2018		U-973		
	7919116	Mar 20, 2018		U-1120		
	7959946	Jul 31, 2026	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024 002	5965584	Jun 19, 2016	DP	U-973		
	6099859	Mar 20, 2018	DP			
	6166042	Jun 19, 2016		U-973		
	6166043	Jun 19, 2016		U-973		
	6172090	Jun 19, 2016		U-973		
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021		U-974		
	6866866	Mar 17, 2021	DP			
	7785627	Jul 31, 2026	DP			
	7919116	Mar 20, 2018		U-973		
	7919116	Mar 20, 2018		U-1120		
	7959946	Jul 31, 2026	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE</u>						
A090406 001					PC	Feb 13, 2013
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE</u>						
A090406 002					PC	Feb 13, 2013
<u>METFORMIN HYDROCHLORIDE; REPAGLINIDE - PRANDIMET</u>						
N022386 001	6677358	Jun 12, 2018	DP	U-546		
<u>METFORMIN HYDROCHLORIDE; REPAGLINIDE - PRANDIMET</u>						
N022386 002	6677358	Jun 12, 2018	DP	U-546		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 001	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	5741803*PED	Oct 21, 2015				
	5965584	Jun 19, 2016	U-493	Y		
	6166042	Jun 19, 2016	U-493	Y		
	6288095	Feb 11, 2017	U-493	Y		
	6288095*PED	Aug 11, 2017				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 002	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	5741803*PED	Oct 21, 2015				
	5965584	Jun 19, 2016	U-493	Y		
	6166042	Jun 19, 2016	U-493	Y		
	6288095	Feb 11, 2017	U-493	Y		
	6288095*PED	Aug 11, 2017				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 003	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	5741803*PED	Oct 21, 2015				
	5965584	Jun 19, 2016	U-493	Y		
	6166042	Jun 19, 2016	U-493	Y		
	6288095	Feb 11, 2017	U-493	Y		
	6288095*PED	Aug 11, 2017				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 004	5741803	Apr 21, 2015	DS DP U-734	Y		
	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803*PED	Oct 21, 2015				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 005	5741803	Apr 21, 2015	DS DP U-734	Y		
	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803*PED	Oct 21, 2015				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N200678 001	6395767	Feb 16, 2021	DS DP U-1097		NCE	Jul 31, 2014
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N200678 002	6395767	Feb 16, 2021	DS DP U-1097		NCE	Jul 31, 2014
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N200678 003	6395767	Feb 16, 2021	DS DP U-1097		NCE	Jul 31, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N022044 001	6303661	Apr 24, 2017				U-802
	6699871	Jul 26, 2022	DS DP			U-802
	6890898	Feb 02, 2019				U-1036
	6890898	Feb 02, 2019				U-1038
	6890898	Feb 02, 2019				U-803
	7078381	Feb 02, 2019				U-1036
	7078381	Feb 02, 2019				U-1038
	7078381	Feb 02, 2019				U-803
	7125873	Jul 26, 2022	DP			U-803
	7125873	Jul 26, 2022	DP			U-1038
	7125873	Jul 26, 2022	DP			U-1036
	7326708	Apr 11, 2026	DS DP			U-802
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N022044 002	6303661	Apr 24, 2017				U-802
	6699871	Jul 26, 2022	DS DP			U-802
	6890898	Feb 02, 2019				U-1038
	6890898	Feb 02, 2019				U-1036
	6890898	Feb 02, 2019				U-803
	7078381	Feb 02, 2019				U-803
	7078381	Feb 02, 2019				U-1038
	7078381	Feb 02, 2019				U-1036
	7125873	Jul 26, 2022	DP			U-1036
	7125873	Jul 26, 2022	DP			U-1038
	7125873	Jul 26, 2022	DP			U-803
	7326708	Apr 11, 2026	DS DP			U-802
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 001	6303661	Apr 24, 2017				U-1227
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP			U-1227
	6890898	Feb 02, 2019				U-1228
	7078381	Feb 02, 2019				U-1227
	7125873	Jul 26, 2022	DP			U-1227
	7326708	Apr 11, 2026	DS DP			U-1227
	7459428	Feb 02, 2019				U-1227
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 002	6303661	Apr 24, 2017				U-1227
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP			U-1227
	6890898	Feb 02, 2019				U-1228
	7078381	Feb 02, 2019				U-1227
	7125873	Jul 26, 2022	DP			U-1227
	7326708	Apr 11, 2026	DS DP			U-1227
	7459428	Feb 02, 2019				U-1227
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 003	6303661	Apr 24, 2017				U-1227
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP			U-1227
	6890898	Feb 02, 2019				U-1228
	7078381	Feb 02, 2019				U-1227
	7125873	Jul 26, 2022	DP			U-1227
	7326708	Apr 11, 2026	DS DP			U-1227
	7459428	Feb 02, 2019				U-1227
<u>METHYL AMINOLEVULINATE HYDROCHLORIDE - METVIXIA</u>						
N021415 001	6034267	Mar 08, 2016				U-804
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 001	6559158	Nov 03, 2017				U-1185
	8247425	Dec 31, 2030			NCE	Apr 24, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 002	6559158 8247425	Nov 03, 2017 Dec 31, 2030	U-1185 U-1185		NCE	Apr 24, 2013
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 003	8247425	Dec 31, 2030	U-1185			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N021514 001	5958446 6210705 6348211	Dec 12, 2012 Sep 30, 2018 Sep 30, 2018	DP DP U-727 DP U-727		NPP	Jun 29, 2013
<u>METHYLPHENIDATE - DAYTRANA</u>						
N021514 002	5958446 6210705 6348211	Dec 12, 2012 Sep 30, 2018 Sep 30, 2018	DP DP U-727 DP U-727		NPP	Jun 29, 2013
<u>METHYLPHENIDATE - DAYTRANA</u>						
N021514 003	5958446 6210705 6348211	Dec 12, 2012 Sep 30, 2018 Sep 30, 2018	DP DP U-727 DP U-727		NPP	Jun 29, 2013
<u>METHYLPHENIDATE - DAYTRANA</u>						
N021514 004	5958446 6210705 6348211	Dec 12, 2012 Sep 30, 2018 Sep 30, 2018	DP DP U-727 DP U-727		NPP	Jun 29, 2013
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 001	6919373 6919373*PED 6930129 6930129*PED 8163798 8163798*PED	Jul 31, 2017 Jan 31, 2018 Jul 31, 2017 Jan 31, 2018 Jul 31, 2017 Jan 31, 2018	U-666 U-666 DP		M-88	Nov 04, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 002	6919373 6919373*PED 6930129 6930129*PED 8163798 8163798*PED	Jul 31, 2017 Jan 31, 2018 Jul 31, 2017 Jan 31, 2018 Jul 31, 2017 Jan 31, 2018	U-666 U-666 DP		M-88	Nov 04, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 003	6919373 6919373*PED 6930129 6930129*PED 8163798 8163798*PED	Jul 31, 2017 Jan 31, 2018 Jul 31, 2017 Jan 31, 2018 Jul 31, 2017 Jan 31, 2018	U-666 U-666 DP		M-88	Nov 04, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 004	6919373 6919373*PED 6930129 6930129*PED 8163798 8163798*PED	Jul 31, 2017 Jan 31, 2018 Jul 31, 2017 Jan 31, 2018 Jul 31, 2017 Jan 31, 2018	U-666 U-666 DP		M-88	Nov 04, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N021259 001	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N021259 002	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N021259 003	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N021259 004	6344215	Oct 27, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N021419 001	7691880	Oct 07, 2024	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N021419 002	7691880	Oct 07, 2024	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 001					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 002					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 003					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N202100 001					NDF	Sep 27, 2015
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N021284 001	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP	U-472		
	6635284	Dec 04, 2015	DP	U-591		
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N021284 002	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP	U-472		
	6635284	Dec 04, 2015	DP	U-591		
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N021284 003	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP	U-472		
	6635284	Dec 04, 2015	DP	U-591		
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N021284 004	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP	U-472		
	6635284	Dec 04, 2015	DP	U-591		
	7431944	Dec 04, 2015	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT</u>						
N022246 001	6413549	Jul 11, 2017	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT</u>						
N022246 002	6413549	Jul 11, 2017	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT</u>						
N021793 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT</u>						
N021793 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>METRONIDAZOLE - FLAGYL ER</u>						
N020868 001	6103262	Aug 15, 2017	DP	U-137		
<u>METRONIDAZOLE - METROGEL</u>						
N021789 001	6881726	Feb 21, 2022	DP	U-743		
	7348317	Feb 21, 2022	DP	U-743		
<u>METRONIDAZOLE - METROGEL-VAGINAL</u>						
N020208 001	5536743	Jul 16, 2013		U-137		
<u>METRONIDAZOLE - VANDAZOLE</u>						
N021806 001	7456207	Sep 22, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N021506 002	6107458	Mar 16, 2019	DS DP U-650			
	6107458	Mar 16, 2019	DS DP U-845			
	6265536	Sep 29, 2015	DS DP U-650			
	6265536	Sep 29, 2015	DS DP U-845			
	6774104	Jan 08, 2021	DP U-650			
	6774104	Jan 08, 2021	DP U-845			
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N021506 003	6107458	Mar 16, 2019	DS DP U-650			
	6107458	Mar 16, 2019	DS DP U-845			
	6265536	Sep 29, 2015	DS DP U-650			
	6265536	Sep 29, 2015	DS DP U-845			
	6774104	Jan 08, 2021	DP U-650			
	6774104	Jan 08, 2021	DP U-845			
<u>MICONAZOLE - ORAVIG</u>						
N022404 001	6916485	Sep 11, 2022	DP U-1051		NDF	Apr 16, 2013
	7651698	Sep 11, 2022	U-1051			
<u>MICONAZOLE NITRATE - MONISTAT 1 COMBINATION PACK</u>						
N021308 001	5514698	Mar 21, 2014		Y		
	6153635	Nov 28, 2020		Y		
<u>MIFEPRISTONE - KORLYM</u>						
N202107 001					NP	Feb 17, 2015
					ODE	Feb 17, 2019
<u>MIGLUSTAT - ZAVESCA</u>						
N021348 001	5472969	May 13, 2013				
	5525616	Jun 11, 2013				
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 001	6602911	Jan 14, 2023	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 002	6602911	Jan 14, 2023	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 003	6602911	Jan 14, 2023	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 004	6602911	Jan 14, 2023	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N050781 001	6682348	Mar 29, 2022	DP			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 001	5908838	Feb 19, 2018	U-917			
	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 002	5908838	Feb 19, 2018	DP			
	7541347	Apr 02, 2027				
	7544373	Apr 02, 2027				
	7790705	Jun 24, 2025				
	7919483	Mar 07, 2027				
	8252776	Jun 24, 2025				
	8268804	Jun 24, 2025				
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 003	5908838	Feb 19, 2018				
	7790705	Jun 24, 2025				
	7919483	Mar 07, 2027				
	8252776	Jun 24, 2025				
	8268804	Jun 24, 2025				
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 004	5908838	Feb 19, 2018				
	7790705	Jun 24, 2025				
	7919483	Mar 07, 2027				
	8252776	Jun 24, 2025				
	8268804	Jun 24, 2025				
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 005	5908838	Feb 19, 2018				
	7790705	Jun 24, 2025				
	7919483	Mar 07, 2027				
	8252776	Jun 24, 2025				
	8268804	Jun 24, 2025				
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 006	5908838	Feb 19, 2018				
	7790705	Jun 24, 2025				
	7919483	Mar 07, 2027				
	8252776	Jun 24, 2025				
	8268804	Jun 24, 2025				
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 007	5908838	Feb 19, 2018				
	7790705	Jun 24, 2025				
	7919483	Mar 07, 2027				
	8252776	Jun 24, 2025				
	8268804	Jun 24, 2025				
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 008	5908838	Feb 19, 2018				
	7790705	Jun 24, 2025				
	7919483	Mar 07, 2027				
	8252776	Jun 24, 2025				
	8268804	Jun 24, 2025				
MINOXIDIL - MEN'S ROGAINE						
N021812 001	6946120	Apr 20, 2019	DP			
MIRABEGRON - MYRBETRIQ						
N202611 001	6346532	Oct 15, 2018	DS	DP	NCE	Jun 28, 2017
	6562375	Aug 01, 2020		DP		
	6699503	Sep 10, 2013	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023				
	7982049	Nov 04, 2023		DP		
MIRABEGRON - MYRBETRIQ						
N202611 002	6346532	Oct 15, 2018	DS	DP	NCE	Jun 28, 2017
	6562375	Aug 01, 2020		DP		
	6699503	Sep 10, 2013	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023				
	7982049	Nov 04, 2023		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MITOMYCIN - MITOSOL</u>						
N022572 001	7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
	8186511	Jul 19, 2026	DP			
<u>MODAFINIL - PROVIGIL</u>						
N020717 001	7297346	Nov 29, 2023	DP			
	7297346*PED	May 29, 2024				
	RE37516	Oct 06, 2014		U-255		
	RE37516*PED	Apr 06, 2015				
<u>MODAFINIL - PROVIGIL</u>						
N020717 002	7297346	Nov 29, 2023	DP			
	7297346*PED	May 29, 2024				
	RE37516	Oct 06, 2014		U-255		
	RE37516*PED	Apr 06, 2015				
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 001	5394868*PED	Dec 25, 2012				
	5687710	Nov 18, 2014	DP			
	5687710*PED	May 18, 2015				
	5829434	Nov 03, 2015	DP			
	5829434*PED	May 03, 2016				
	5889015	Jan 27, 2014		U-645		
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP	U-645		
	6057307*PED	Jul 27, 2014				
	6240918	Feb 20, 2017	DP			
	6240918*PED	Aug 20, 2017				
	6365581	Jan 27, 2014		U-645		
	6365581*PED	Jul 27, 2014				
	6503537	Mar 17, 2018	DP			
	6503537*PED	Sep 17, 2018				
	6677322	Jan 27, 2014		U-645		
	6677322*PED	Jul 27, 2014				
	6949532	Jan 27, 2014		U-645		
	6949532*PED	Jul 27, 2014				
	8173172	Mar 17, 2018	DP			
	8173172*PED	Sep 17, 2018				
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 002	5394868*PED	Dec 25, 2012				
	5687710	Nov 18, 2014	DP			
	5687710*PED	May 18, 2015				
	5829434	Nov 03, 2015	DP			
	5829434*PED	May 03, 2016				
	5889015	Jan 27, 2014		U-645		
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP	U-645		
	6057307*PED	Jul 27, 2014				
	6240918	Feb 20, 2017	DP			
	6240918*PED	Aug 20, 2017				
	6365581	Jan 27, 2014		U-645		
	6365581*PED	Jul 27, 2014				
	6503537	Mar 17, 2018	DP			
	6503537*PED	Sep 17, 2018				
	6677322	Jan 27, 2014		U-645		
	6677322*PED	Jul 27, 2014				
	6949532	Jan 27, 2014		U-645		
	6949532*PED	Jul 27, 2014				
	8173172	Mar 17, 2018	DP			
	8173172*PED	Sep 17, 2018				
<u>MOMETASONE FUROATE MONOHYDRATE - NASONEX</u>						
N020762 001	5837699	Jan 27, 2014	DP	U-625	I-626	May 26, 2013
	5837699*PED	Jul 27, 2014			M-99	Jan 19, 2014
	6127353	Oct 03, 2017	DS	DP		
	6127353*PED	Apr 03, 2018				
	6723713	Jan 27, 2014		U-625		
	6723713*PED	Jul 27, 2014				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020829 002	5565473*PED	Aug 03, 2012	U-228		NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 001	5565473*PED	Aug 03, 2012	U-228		NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 002	5565473*PED	Aug 03, 2012	U-228		NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N021409 001	5565473*PED	Aug 03, 2012			NPP	Mar 26, 2015
	8007830	Oct 24, 2022	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N021260 001	6066339	Nov 25, 2017				
<u>MORPHINE SULFATE - AVINZA</u>						
N021260 002	6066339	Nov 25, 2017				
<u>MORPHINE SULFATE - AVINZA</u>						
N021260 003	6066339	Nov 25, 2017				
<u>MORPHINE SULFATE - AVINZA</u>						
N021260 004	6066339	Nov 25, 2017				
<u>MORPHINE SULFATE - AVINZA</u>						
N021260 005	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N021260 006	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - DEPODUR</u>						
N021671 001	5723147	Mar 03, 2015	DP	U-584		
	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931809	Jul 14, 2015		U-584		
	5962016	Jan 31, 2017	DP	U-584		
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
<u>MORPHINE SULFATE - DEPODUR</u>						
N021671 002	5723147	Mar 03, 2015	DP	U-584		
	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931809	Jul 14, 2015		U-584		
	5962016	Jan 31, 2017	DP	U-584		
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
<u>MORPHINE SULFATE - DEPODUR</u>						
N021671 003	5723147	Mar 03, 2015	DP	U-584		
	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931809	Jul 14, 2015		U-584		
	5962016	Jan 31, 2017	DP	U-584		
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 001	7682633	Jun 19, 2027		U-1241	NC	Aug 13, 2012
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027		U-1241		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 002	7682633	Jun 19, 2027	U-1241		NC	Aug 13, 2012
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 003	7682633	Jun 19, 2027	U-1241		NC	Aug 13, 2012
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 004	7682633	Jun 19, 2027	U-1241		NC	Aug 13, 2012
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 005	7682633	Jun 19, 2027	U-1241		NC	Aug 13, 2012
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 006	7682633	Jun 19, 2027	U-1241		NC	Aug 13, 2012
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1241			
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX</u>						
N021085 001	5607942	Mar 04, 2014	U-298			
	5849752	Dec 05, 2016	U-298			
	6610327	Oct 29, 2019	DP U-298			
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>						
N021277 001	5607942	Mar 04, 2014	U-298			
	5849752	Dec 05, 2016	U-298			
	6548079	Jul 25, 2020	DP U-298			
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N022428 001	5607942	Mar 04, 2014	DS DP U-709		NP	Nov 19, 2013
	5607942*PED	Sep 04, 2014			PED	May 19, 2014
	6716830	Sep 29, 2019	DP			
	6716830*PED	Mar 29, 2020				
	7671070	Sep 29, 2019	DP U-709			
	7671070*PED	Mar 29, 2020				
<u>MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX</u>						
N021598 001	5607942	Mar 04, 2014	DS DP U-709			
	5607942*PED	Sep 04, 2014				
	6716830	Sep 29, 2019	DP			
	6716830*PED	Mar 29, 2020				
	7671070	Sep 29, 2019	U-709			
	7671070*PED	Mar 29, 2020				
<u>MUPIROICIN - CENTANY</u>						
N050788 001	6013657	Jul 08, 2018	DP			
<u>MUPIROICIN CALCIUM - BACTROBAN</u>						
N050746 001	6025389	Oct 20, 2014	DP U-1122			
<u>MYCOPHENOLATE MOFETIL - CELLCEPT</u>						
N050759 001	5688529	Nov 18, 2014	DP			
<u>MYCOPHENOLATE MOFETIL HYDROCHLORIDE - CELLCEPT</u>						
N050758 001	5543408	Sep 15, 2013	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N050791 001	6025391	Apr 10, 2017	DP U-908			
	6172107	Apr 10, 2017	DP U-908			
	6306900	Apr 10, 2017	DP			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N050791 002	6025391	Apr 10, 2017	DP U-908			
	6172107	Apr 10, 2017	DP U-908			
	6306900	Apr 10, 2017	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N019599 002					NS	Jan 13, 2015
<u>NALTREXONE - VIVITROL</u>						
N021897 001	5792477	May 02, 2017	DP		I-631	Oct 12, 2013
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6264987	May 19, 2020	DP			
	6331317	Nov 12, 2019	DP			
	6379703	Dec 30, 2018	DP			
	6379704	May 19, 2020	DP			
	6395304	Nov 12, 2019	DP			
	6403114	May 02, 2017	DP			
	6495164	May 25, 2020	DP			
	6495166	Nov 12, 2019	DP			
	6534092	May 19, 2020	DP			
	6537586	Nov 12, 2019	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
	6713090	Nov 12, 2019	DP			
	6939033	Nov 12, 2019	DP			
	7799345	May 25, 2020	DP			
	7919499	Oct 15, 2029	U-1123			
	7919499	Oct 15, 2029	U-1124			
<u>NAPROXEN SODIUM - NAPRELAN</u>						
N020353 001	5637320	Jun 10, 2014				
<u>NAPROXEN SODIUM - NAPRELAN</u>						
N020353 002	5637320	Jun 10, 2014				
<u>NAPROXEN SODIUM - NAPRELAN</u>						
N020353 003	5637320	Jun 10, 2014				
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N021926 001	6060499	Aug 14, 2017	DP U-867			
	6586458	Aug 14, 2017	DP U-867			
	7332183	Oct 02, 2025	DP U-867			
	8022095	Aug 14, 2017	DP U-867			
<u>NATEGLINIDE - STARLIX</u>						
N021204 001	5463116	Oct 21, 2012				
	5488150	Jan 30, 2013				
	6559188	Sep 15, 2020	DP U-827			
	6641841	Nov 14, 2017	DP U-214			
	6844008	Nov 14, 2017	DP U-214			
	6878749	Sep 15, 2020	DP			
<u>NATEGLINIDE - STARLIX</u>						
N021204 002	5463116	Oct 21, 2012				
	5488150	Jan 30, 2013				
	6559188	Sep 15, 2020	DP U-827			
	6641841	Nov 14, 2017	DP U-214			
	6844008	Nov 14, 2017	DP U-214			
	6878749	Sep 15, 2020	DP			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 002	5759580	Jun 02, 2015	DP		NCE	Dec 17, 2012
	6545040	Dec 17, 2021	DP U-3			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 003	5759580	Jun 02, 2015	DP		NCE	Dec 17, 2012
	6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 004	5759580	Jun 02, 2015	DP		NCE	Dec 17, 2012
	6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 005	5759580	Jun 02, 2015	DP		NCE	Dec 17, 2012
	6545040	Dec 17, 2021	DP U-3			
<u>NEDOCROMIL SODIUM - ALOCRIIL</u>						
N021009 001	RE38628	Aug 22, 2012		U-304		
<u>NELARABINE - ARRANON</u>						
N021877 001	5424295	Jun 13, 2017	DS DP		ODE	Oct 28, 2012
	5492897	Feb 20, 2013		U-689		
	5747472	Feb 20, 2013		U-689		
	5747472	Feb 20, 2013		U-696		
	5747472	Feb 20, 2013		U-695		
	5821236	Feb 20, 2013		U-695		
<u>NELFINAVIR MESYLATE - VIRACEPT</u>						
N020778 001	5484926	Oct 07, 2013				
	5484926*PED	Apr 07, 2014				
	5952343	Oct 07, 2013		U-257		
	5952343*PED	Apr 07, 2014		U-257		
	6162812	Oct 07, 2013		U-248		
	6162812*PED	Apr 07, 2014		U-248		
<u>NELFINAVIR MESYLATE - VIRACEPT</u>						
N020779 001	5484926	Oct 07, 2013				
	5484926*PED	Apr 07, 2014				
	5952343	Oct 07, 2013		U-257		
	5952343*PED	Apr 07, 2014		U-257		
	6162812	Oct 07, 2013		U-248		
	6162812*PED	Apr 07, 2014		U-248		
<u>NELFINAVIR MESYLATE - VIRACEPT</u>						
N021503 001	5484926	Oct 07, 2013				
	5484926*PED	Apr 07, 2014				
	5952343	Oct 07, 2013		U-257		
	5952343*PED	Apr 07, 2014		U-257		
	6162812	Oct 07, 2013		U-248		
	6162812*PED	Apr 07, 2014		U-248		
<u>NEPAFENAC - NEPAFENAC</u>						
N203491 001					NP	Oct 16, 2015
<u>NEPAFENAC - NEVANAC</u>						
N021862 001	5475034	Jun 06, 2014		U-100		
	7834059	Jan 31, 2027		U-1095		
	8071648	Dec 02, 2025	DP			
	8324281	Dec 02, 2025	DP			
<u>NESIRITIDE RECOMBINANT - NATRECOR</u>						
N020920 001	5114923	May 19, 2014	DS DP	U-855		
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N201152 001					NPP	Nov 08, 2015
					NDF	Mar 25, 2014
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N201152 002					NPP	Nov 08, 2015
					NDF	Mar 25, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N020381 001	6080428	May 27, 2017				U-331
	6129930	Sep 20, 2013				U-354
	6406715	Sep 20, 2013				U-450
	6746691	Sep 20, 2013				U-586
	6818229	Feb 15, 2014				
	7011848	Sep 20, 2013	DP			U-712
<u>NIACIN - NIASPAN</u>						
N020381 002	6080428	May 27, 2017				U-1138
	6080428	May 27, 2017				U-331
	6080428	May 27, 2017				U-1141
	6080428	May 27, 2017				U-1140
	6080428	May 27, 2017				U-1139
	6129930	Sep 20, 2013	DP			U-1141
	6129930	Sep 20, 2013	DP			U-1138
	6129930	Sep 20, 2013	DP			U-1140
	6129930	Sep 20, 2013	DP			U-1139
	6129930	Sep 20, 2013	DP			U-354
	6406715	Sep 20, 2013	DP			U-450
	6469035	Mar 15, 2018				U-1144
	6469035	Mar 15, 2018				U-1142
	6469035	Mar 15, 2018				U-1145
	6469035	Mar 15, 2018				U-768
	6469035	Mar 15, 2018				U-1143
	6676967	Sep 20, 2013				U-1146
	6676967	Sep 20, 2013				U-1139
	6676967	Sep 20, 2013				U-548
	6676967	Sep 20, 2013				U-1140
	6676967	Sep 20, 2013				U-1138
	6746691	Sep 20, 2013	DP			U-586
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013				U-712
	7011848	Sep 20, 2013				U-1140
	7011848	Sep 20, 2013				U-1141
	7011848	Sep 20, 2013				U-1147
	7011848	Sep 20, 2013				U-1148
	7998506	Sep 20, 2013				U-1140
	7998506	Sep 20, 2013				U-1138
	7998506	Sep 20, 2013				U-1141
	7998506	Sep 20, 2013				U-1139

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N020381 003	6080428	May 27, 2017			U-331	
	6080428	May 27, 2017			U-1139	
	6080428	May 27, 2017			U-1140	
	6080428	May 27, 2017			U-1138	
	6080428	May 27, 2017			U-1141	
	6129930	Sep 20, 2013	DP		U-1141	
	6129930	Sep 20, 2013	DP		U-1139	
	6129930	Sep 20, 2013	DP		U-1138	
	6129930	Sep 20, 2013	DP		U-1140	
	6129930	Sep 20, 2013	DP		U-354	
	6406715	Sep 20, 2013	DP		U-450	
	6469035	Mar 15, 2018			U-1142	
	6469035	Mar 15, 2018			U-768	
	6469035	Mar 15, 2018			U-1145	
	6469035	Mar 15, 2018			U-1144	
	6469035	Mar 15, 2018			U-1143	
	6676967	Sep 20, 2013			U-1138	
	6676967	Sep 20, 2013			U-1139	
	6676967	Sep 20, 2013			U-1140	
	6676967	Sep 20, 2013			U-1146	
	6676967	Sep 20, 2013			U-1141	
	6676967	Sep 20, 2013			U-548	
	6746691	Sep 20, 2013	DP		U-586	
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013			U-1141	
	7011848	Sep 20, 2013			U-1140	
	7011848	Sep 20, 2013			U-1148	
	7011848	Sep 20, 2013			U-1147	
	7011848	Sep 20, 2013			U-712	
	7998506	Sep 20, 2013			U-1140	
	7998506	Sep 20, 2013			U-1138	
	7998506	Sep 20, 2013			U-1141	
	7998506	Sep 20, 2013			U-1139	
<u>NIACIN - NIASPAN</u>						
N020381 004	6080428	May 27, 2017			U-331	
	6080428	May 27, 2017			U-1138	
	6080428	May 27, 2017			U-1139	
	6080428	May 27, 2017			U-1141	
	6080428	May 27, 2017			U-1140	
	6129930	Sep 20, 2013	DP		U-1139	
	6129930	Sep 20, 2013	DP		U-1138	
	6129930	Sep 20, 2013	DP		U-1141	
	6129930	Sep 20, 2013	DP		U-1140	
	6129930	Sep 20, 2013	DP		U-354	
	6406715	Sep 20, 2013	DP		U-450	
	6469035	Mar 15, 2018			U-768	
	6469035	Mar 15, 2018			U-1145	
	6469035	Mar 15, 2018			U-1143	
	6469035	Mar 15, 2018			U-1144	
	6469035	Mar 15, 2018			U-1142	
	6676967	Sep 20, 2013			U-1138	
	6676967	Sep 20, 2013			U-1139	
	6676967	Sep 20, 2013			U-548	
	6676967	Sep 20, 2013			U-1140	
	6676967	Sep 20, 2013			U-1141	
	6676967	Sep 20, 2013			U-1146	
	6746691	Sep 20, 2013	DP		U-586	
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013			U-1141	
	7011848	Sep 20, 2013			U-1147	
	7011848	Sep 20, 2013			U-1148	
	7011848	Sep 20, 2013			U-1140	
	7011848	Sep 20, 2013			U-712	
	7998506	Sep 20, 2013			U-1139	
	7998506	Sep 20, 2013			U-1138	
	7998506	Sep 20, 2013			U-1140	
	7998506	Sep 20, 2013			U-1141	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN TITRATION STARTER PACK</u>						
N020381 005	6080428	May 27, 2017				U-331
	6129930	Sep 20, 2013				U-354
	6406715	Sep 20, 2013				U-450
	6746691	Sep 20, 2013				U-586
	7011848	Sep 20, 2013				U-712
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 001	6080428	May 27, 2017				U-1132
	6080428	May 27, 2017				U-862
	6080428	May 27, 2017				U-1134
	6129930	Sep 20, 2013	DP			U-1132
	6129930	Sep 20, 2013	DP			U-1134
	6129930	Sep 20, 2013	DP			U-862
	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018				U-1129
	6469035	Mar 15, 2018				U-1149
	6469035	Mar 15, 2018				U-863
	6676967	Sep 20, 2013				U-1132
	6676967	Sep 20, 2013				U-1134
	6676967	Sep 20, 2013				U-862
	6746691	Sep 20, 2013	DP			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013				U-862
	7011848	Sep 20, 2013				U-1151
	7011848	Sep 20, 2013				U-1150
	7998506	Sep 20, 2013				U-1151
	7998506	Sep 20, 2013				U-1150
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 002	6080428	May 27, 2017				U-862
	6080428	May 27, 2017				U-1132
	6080428	May 27, 2017				U-1134
	6129930	Sep 20, 2013	DP			U-1132
	6129930	Sep 20, 2013	DP			U-1134
	6129930	Sep 20, 2013	DP			U-862
	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018				U-1149
	6469035	Mar 15, 2018				U-863
	6469035	Mar 15, 2018				U-1129
	6676967	Sep 20, 2013				U-1134
	6676967	Sep 20, 2013				U-862
	6676967	Sep 20, 2013				U-1132
	6746691	Sep 20, 2013	DP			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013				U-1151
	7011848	Sep 20, 2013				U-862
	7011848	Sep 20, 2013				U-1150
	7998506	Sep 20, 2013				U-1150
	7998506	Sep 20, 2013				U-1151

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 003	6080428	May 27, 2017			U-1134	
	6080428	May 27, 2017			U-1132	
	6080428	May 27, 2017			U-862	
	6129930	Sep 20, 2013	DP		U-1132	
	6129930	Sep 20, 2013	DP		U-862	
	6129930	Sep 20, 2013	DP		U-1134	
	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018			U-863	
	6469035	Mar 15, 2018			U-1129	
	6469035	Mar 15, 2018			U-1149	
	6676967	Sep 20, 2013			U-1132	
	6676967	Sep 20, 2013			U-1134	
	6676967	Sep 20, 2013			U-862	
	6746691	Sep 20, 2013	DP			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013			U-1151	
	7011848	Sep 20, 2013			U-862	
	7011848	Sep 20, 2013			U-1150	
	7998506	Sep 20, 2013			U-1151	
	7998506	Sep 20, 2013			U-1150	
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 004	6080428	May 27, 2017			U-1132	
	6080428	May 27, 2017			U-1134	
	6080428	May 27, 2017			U-862	
	6129930	Sep 20, 2013	DP		U-862	
	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018			U-1149	
	6469035	Mar 15, 2018			U-863	
	6469035	Mar 15, 2018			U-1129	
	6676967	Sep 20, 2013			U-1134	
	6676967	Sep 20, 2013			U-1132	
	6676967	Sep 20, 2013			U-862	
	6746691	Sep 20, 2013	DP			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013			U-1150	
	7011848	Sep 20, 2013			U-1151	
	7011848	Sep 20, 2013			U-862	
	7998506	Sep 20, 2013			U-1151	
	7998506	Sep 20, 2013			U-1150	
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 005	6080428	May 27, 2017			U-1134	
	6080428	May 27, 2017			U-862	
	6080428	May 27, 2017			U-1132	
	6129930	Sep 20, 2013	DP		U-862	
	6406715	Sep 20, 2013	DP			
	6469035	Mar 15, 2018			U-1129	
	6469035	Mar 15, 2018			U-863	
	6469035	Mar 15, 2018			U-1149	
	6676967	Sep 20, 2013			U-862	
	6676967	Sep 20, 2013			U-1134	
	6676967	Sep 20, 2013			U-1132	
	6746691	Sep 20, 2013	DP			
	6818229	Sep 20, 2013	DP			
	7011848	Sep 20, 2013			U-1150	
	7011848	Sep 20, 2013			U-862	
	7011848	Sep 20, 2013			U-1151	
	7998506	Sep 20, 2013			U-1151	
	7998506	Sep 20, 2013			U-1150	
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N019734 004	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027			U-1029	
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N019734 003	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027			U-1029	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N019734 002	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027		U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N019734 005	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027		U-1029		
<u>NICOTINE - NICODERM CQ</u>						
N020165 004	5508038	Apr 16, 2013				
	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CQ</u>						
N020165 005	5508038	Apr 16, 2013				
	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CQ</u>						
N020165 006	5508038	Apr 16, 2013				
	8075911	May 22, 2021	DP			
<u>NICOTINE - NICOTROL</u>						
N020385 001	5656255	Aug 12, 2014				
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N018612 002	8323683	Apr 30, 2028				
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N020066 002	8323683	Apr 30, 2028	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 001	7169791	Jul 04, 2023	DS DP	U-836	I-627	Jun 17, 2013
	8163904	Aug 23, 2028	DS DP		NCE	Oct 29, 2012
					ODE	Oct 29, 2014
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 002	7169791	Jul 04, 2023	DS DP	U-836	I-627	Jun 17, 2014
	8163904	Aug 23, 2028	DS DP		NCE	Oct 29, 2012
					ODE	Oct 29, 2014
<u>NISOLDIPINE - SULAR</u>						
N020356 005	5626874	Nov 30, 2014	DP			
<u>NISOLDIPINE - SULAR</u>						
N020356 006	5626874	Nov 30, 2014	DP			
<u>NISOLDIPINE - SULAR</u>						
N020356 007	5626874	Nov 30, 2014	DP			
<u>NISOLDIPINE - SULAR</u>						
N020356 008	5626874	Nov 30, 2014	DP			
<u>NITAZOXANIDE - ALINIA</u>						
N021497 001	5578621	Nov 26, 2013	DP	U-525		
	5968961	May 07, 2017	DP			
	6020353	Sep 18, 2014	DS DP			
<u>NITAZOXANIDE - ALINIA</u>						
N021498 001	5578621	Sep 08, 2014		U-525		
	5965590	Jul 03, 2017		U-523		
	5968961	May 07, 2017				
	6020353	Sep 08, 2014				
	6117894	May 07, 2017				
<u>NITISINONE - ORFADIN</u>						
N021232 001	5550165	Aug 27, 2013				
<u>NITISINONE - ORFADIN</u>						
N021232 002	5550165	Aug 27, 2013				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NITISINONE - ORFADIN</u>						
N021232 003	5550165	Aug 27, 2013				
<u>NITRIC OXIDE - INOMAX</u>						
N020845 002	5485827	Jan 23, 2013		U-297		
	5485827*PED	Jul 23, 2013				
	5558083	Nov 22, 2013	DP	U-1226		
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP	U-1230		
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP	U-1230		
	5752504*PED	Jun 13, 2017				
	5873359	Jan 23, 2013		U-297		
	5873359*PED	Jul 23, 2013				
	8282966	Jun 30, 2029		U-1286		
	8282966*PED	Dec 30, 2029				
	8291904	Jan 06, 2031	DP	U-1226		
	8291904*PED	Jul 06, 2031				
	8293284	Jun 30, 2029		U-1286		
	8293284*PED	Dec 30, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N020845 003	5485827	Jan 23, 2013		U-297		
	5485827*PED	Jul 23, 2013				
	5558083	Nov 22, 2013	DP	U-1226		
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP	U-1230		
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP	U-1230		
	5752504*PED	Jun 13, 2017				
	5873359	Jan 23, 2013		U-297		
	5873359*PED	Jul 23, 2013				
	8282966	Jun 30, 2029		U-1286		
	8282966*PED	Dec 30, 2029				
	8291904	Jan 06, 2031	DP	U-1226		
	8291904*PED	Jul 06, 2031				
	8293284	Jun 30, 2029		U-1286		
	8293284*PED	Dec 30, 2029				
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N018705 002	7872049	Mar 14, 2028	DP	U-39		
<u>NITROGLYCERIN - NITROMIST</u>						
N021780 001	5869082	Apr 16, 2016	DP			
<u>NITROGLYCERIN - NITROSTAT</u>						
N021134 001	6500456	Sep 16, 2018				
<u>NITROGLYCERIN - NITROSTAT</u>						
N021134 002	6500456	Sep 16, 2018				
<u>NITROGLYCERIN - NITROSTAT</u>						
N021134 003	6500456	Sep 16, 2018				
<u>NITROGLYCERIN - RECTIV</u>						
N021359 001	7189761	May 27, 2014	DP	U-1198	NP	Jun 21, 2014
<u>NIZATIDINE - AXID</u>						
N021494 001	6930119	Jul 17, 2022	DP			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N019667 001	5753618	May 19, 2015				
	5753618*PED	Nov 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N019667 002	5753618	May 19, 2015				
	5753618*PED	Nov 19, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OCTREOTIDE ACETATE - SANDOSTATIN						
N019667 003	5753618	May 19, 2015				
	5753618*PED	Nov 19, 2015				
OCTREOTIDE ACETATE - SANDOSTATIN						
N019667 004	5753618	May 19, 2015				
	5753618*PED	Nov 19, 2015				
OCTREOTIDE ACETATE - SANDOSTATIN						
N019667 005	5753618	May 19, 2015				
	5753618*PED	Nov 19, 2015				
OCTREOTIDE ACETATE - SANDOSTATIN LAR						
N021008 001	5538739	Jul 23, 2013	DP			
	5538739*PED	Jan 23, 2014				
	5639480	Jun 17, 2014	DP			
	5639480*PED	Dec 17, 2014				
	5688530	Nov 18, 2014		U-268		
	5688530*PED	May 18, 2015				
	5922338	Jul 13, 2016	DP			
	5922338*PED	Jan 13, 2017				
	5922682	Jul 13, 2016	DP			
	5922682*PED	Jan 13, 2017				
OCTREOTIDE ACETATE - SANDOSTATIN LAR						
N021008 002	5538739	Jul 23, 2013				
	5538739*PED	Jan 23, 2014				
	5639480	Jun 17, 2014	DP			
	5639480*PED	Dec 17, 2014				
	5688530	Nov 18, 2014		U-268		
	5688530*PED	May 18, 2015				
	5922338	Jul 13, 2016	DP			
	5922338*PED	Jan 13, 2017				
	5922682	Jul 13, 2016	DP			
	5922682*PED	Jan 13, 2017				
OCTREOTIDE ACETATE - SANDOSTATIN LAR						
N021008 003	5538739	Jul 23, 2013				
	5538739*PED	Jan 23, 2014				
	5639480	Jun 17, 2014	DP			
	5639480*PED	Dec 17, 2014				
	5688530	Nov 18, 2014		U-268		
	5688530*PED	May 18, 2015				
	5922338	Jul 13, 2016	DP			
	5922338*PED	Jan 13, 2017				
	5922682	Jul 13, 2016	DP			
	5922682*PED	Jan 13, 2017				
OLANZAPINE - ZYPREXA						
N020592 001	6960577	Nov 01, 2017	U-963		NPP	Dec 04, 2012
					NPP	Dec 04, 2012
					PED	Jun 04, 2013
					PED	Jun 04, 2013
OLANZAPINE - ZYPREXA						
N020592 002	6960577	Nov 01, 2017	U-963		NPP	Dec 04, 2012
					NPP	Dec 04, 2012
					PED	Jun 04, 2013
					PED	Jun 04, 2013
OLANZAPINE - ZYPREXA						
N020592 003	6960577	Nov 01, 2017	U-963		NPP	Dec 04, 2012
					NPP	Dec 04, 2012
					PED	Jun 04, 2013
					PED	Jun 04, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE - ZYPREXA</u>						
N020592 004	6960577	Nov 01, 2017	U-963		NPP	Dec 04, 2012
					NPP	Dec 04, 2012
					PED	Jun 04, 2013
					PED	Jun 04, 2013
<u>OLANZAPINE - ZYPREXA</u>						
N020592 005	6960577	Nov 01, 2017	U-963		NPP	Dec 04, 2012
					NPP	Dec 04, 2012
					PED	Jun 04, 2013
					PED	Jun 04, 2013
<u>OLANZAPINE - ZYPREXA</u>						
N020592 006	6960577	Nov 01, 2017	U-963		NPP	Dec 04, 2012
					NPP	Dec 04, 2012
					PED	Jun 04, 2013
					PED	Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 001	6960577	Nov 01, 2017	U-964		NPP	Dec 04, 2012
					NPP	Dec 04, 2012
					PED	Jun 04, 2013
					PED	Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 002	6960577	Nov 01, 2017	U-964		NPP	Dec 04, 2012
					NPP	Dec 04, 2012
					PED	Jun 04, 2013
					PED	Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 003	6960577	Nov 01, 2017	U-964		NPP	Dec 04, 2012
					NPP	Dec 04, 2012
					PED	Jun 04, 2013
					PED	Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 004	6960577	Nov 01, 2017	U-964		NPP	Dec 04, 2012
					NPP	Dec 04, 2012
					PED	Jun 04, 2013
					PED	Jun 04, 2013
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N022173 001	6169084	Sep 30, 2018	DS DP U-1026		NP	Dec 11, 2012
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N022173 002	6169084	Sep 30, 2018	DS DP U-1026		NP	Dec 11, 2012
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N022173 003	6169084	Sep 30, 2018	DS DP U-1026		NP	Dec 11, 2012
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N021286 001	5616599	Apr 25, 2016	DS DP U-500		NPP	Feb 04, 2013
	5616599*PED	Oct 25, 2016			PED	Aug 04, 2013
	6878703	Nov 19, 2021	U-3	Y		
	6878703*PED	May 19, 2022				
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N021286 003	5616599	Apr 25, 2016	DS DP U-500		NPP	Feb 04, 2013
	5616599*PED	Oct 25, 2016			PED	Aug 04, 2013
	6878703	Nov 19, 2021	U-3	Y		
	6878703*PED	May 19, 2022				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N021286 004	5616599	Apr 25, 2016	DS DP U-500		NPP	Feb 04, 2013
	5616599*PED	Oct 25, 2016			PED	Aug 04, 2013
	6878703	Nov 19, 2021	U-3	Y		
	6878703*PED	May 19, 2022				
<u>OLOPATADINE HYDROCHLORIDE - PATADAY</u>						
N021545 001	5641805	Jun 06, 2015	U-765			
	5641805*PED	Dec 06, 2015				
	6995186	Nov 12, 2023	DP U-765			
	6995186*PED	May 12, 2024				
	7402609	Jun 19, 2022	DP			
	7402609*PED	Dec 19, 2022				
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N021861 001	7977376	Feb 02, 2023	DP		NPP	Dec 01, 2012
	7977376*PED	Aug 02, 2023	DP		PED	Jun 01, 2013
<u>OLOPATADINE HYDROCHLORIDE - PATANOL</u>						
N020688 001	5641805	Jun 06, 2015	U-184			
	5641805*PED	Dec 06, 2015				
<u>OMACETAXINE MEPEUSUCCINATE - SYNRIBO</u>						
N203585 001	6987103	Jun 28, 2023		U-1300	NCE	Oct 26, 2017
	7842687	Mar 16, 2019	DS DP U-1299		ODE	Oct 26, 2019
<u>OMEGA-3-ACID ETHYL ESTERS - LOVAZA</u>						
N021654 001	5502077	Mar 26, 2013	DS	U-822	M-87	Sep 16, 2012
	5656667	Apr 10, 2017	DS DP U-822			
	7732488	Jan 30, 2025	DS DP			
<u>OMEPRAZOLE - PRILOSEC</u>						
N019810 001	6147103	Oct 09, 2018				
	6147103*PED	Apr 09, 2019				
	6150380	Nov 10, 2018				
	6150380*PED	May 10, 2019				
	6166213	Oct 09, 2018				
	6166213*PED	Apr 09, 2019				
	6191148	Oct 09, 2018				
	6191148*PED	Apr 09, 2019				
<u>OMEPRAZOLE - PRILOSEC</u>						
N019810 002	6147103	Oct 09, 2018				
	6147103*PED	Apr 09, 2019				
	6150380	Nov 10, 2018				
	6150380*PED	May 10, 2019				
	6166213	Oct 09, 2018				
	6166213*PED	Apr 09, 2019				
	6191148	Oct 09, 2018				
	6191148*PED	Apr 09, 2019				
<u>OMEPRAZOLE - PRILOSEC</u>						
N019810 003	6147103	Oct 09, 2018				
	6147103*PED	Apr 09, 2019				
	6150380	Nov 10, 2018				
	6150380*PED	May 10, 2019				
	6166213	Oct 09, 2018				
	6166213*PED	Apr 09, 2019				
	6191148	Oct 09, 2018				
	6191148*PED	Apr 09, 2019				
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N022056 001	5690960	Nov 25, 2014	DP U-864			
	5900424	May 04, 2016	DS U-864			
	6428810	Nov 03, 2019	DP U-864			
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N022056 002	5690960	Nov 25, 2014	DP U-864			
	5900424	May 04, 2016	DS U-864			
	6428810	Nov 03, 2019	DP U-864			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC OTC</u>						
N021229 001	5690960	Nov 25, 2014				
	5753265	Jun 07, 2015				
	5817338	Oct 06, 2015				
	5900424	May 04, 2016				
	6403616	Nov 15, 2019				
	6428810	Nov 03, 2019				
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N021636 001	5840737	Jul 16, 2016			U-588	
	6489346	Jul 16, 2016	DS DP		U-588	
	6645988	Jul 16, 2016	DS DP			
	6699885	Jul 16, 2016			U-588	
	6780882	Jul 16, 2016	DS DP			
	7399772	Jul 16, 2016			U-588	
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N021636 002	5840737	Jul 16, 2016			U-623	
	5840737	Jul 16, 2016			U-624	
	6489346	Jul 16, 2016	DS DP		U-624	
	6489346	Jul 16, 2016	DS DP		U-623	
	6645988	Jul 16, 2016	DS DP			
	6699885	Jul 16, 2016			U-623	
	6699885	Jul 16, 2016			U-624	
	6780882	Jul 16, 2016	DS DP			
	7399772	Jul 16, 2016			U-624	
	7399772	Jul 16, 2016			U-623	
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N021849 001	6489346	Jul 16, 2016	DS DP		U-588	
	6645988	Jul 16, 2016	DS DP			
	6699885	Jul 16, 2016			U-588	
	7399772	Jul 16, 2016			U-588	
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N021849 002	6489346	Jul 16, 2016	DS DP		U-623	
	6645988	Jul 16, 2016	DS DP			
	6699885	Jul 16, 2016			U-623	
	7399772	Jul 16, 2016			U-623	
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N022281 001	6489346	Jul 15, 2016		DP	U-1025	
	6645988	Jul 15, 2016		DP		
	6699885	Jul 15, 2016		DP		
	7399772	Jul 15, 2016			U-1025	
<u>ONDANSETRON - ZOFTRAN ODT</u>						
N020781 001	5955488	Nov 14, 2015				
	5955488*PED	May 14, 2016				
	6063802	Nov 14, 2015				
	6063802*PED	May 14, 2016				
<u>ONDANSETRON - ZOFTRAN ODT</u>						
N020781 002	5955488	Nov 14, 2015				
	5955488*PED	May 14, 2016				
	6063802	Nov 14, 2015				
	6063802*PED	May 14, 2016				
<u>ONDANSETRON HYDROCHLORIDE - ZOFTRAN</u>						
N020605 001	5854270	Nov 20, 2015		DP	U-44	
	5854270*PED	May 20, 2016				
<u>ORLISTAT - ALLI</u>						
N021887 001	6004996	Jan 06, 2018		DP		
<u>ORLISTAT - XENICAL</u>						
N020766 001	6004996	Jan 06, 2018				
	6004996*PED	Jul 06, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 001	5763483	Dec 27, 2016	DS	U-1113	M-90	Feb 22, 2013
	5763483*PED	Jun 27, 2017				
	5866601	Feb 02, 2016	DS	DP		
	5866601*PED	Aug 02, 2016				
	5952375	Feb 27, 2015	DS	DP		
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 002	5763483	Dec 27, 2016	DS	U-1113	M-90	Feb 22, 2013
	5763483*PED	Jun 27, 2017				
	5866601	Feb 02, 2016	DS	DP		
	5866601*PED	Aug 02, 2016				
	5952375	Feb 27, 2015	DS	DP		
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 003	5763483	Dec 27, 2016	DS	U-1113		
	5763483*PED	Jun 27, 2017				
	5866601	Feb 02, 2016	DS	DP		
	5866601*PED	Aug 02, 2016				
	5952375	Feb 27, 2015	DS	DP		
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246 001	5763483	Dec 27, 2016	DS	U-376	M-90	Feb 22, 2013
	5763483	Dec 27, 2016	DS	U-1113		
	5763483*PED	Jun 27, 2017				
	5866601	Feb 02, 2016	DS	DP		
	5866601*PED	Aug 02, 2016				
	5952375	Feb 27, 2015	DS	DP		
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246 002	5763483	Dec 27, 2016	DS	DP	U-1113	
	5763483*PED	Jun 27, 2017				
	5866601	Feb 02, 2016	DS	DP		
	5866601*PED	Aug 02, 2016				
	5952375	Feb 27, 2015	DS	DP		
	5952375*PED	Aug 27, 2015				
<u>OXALIPLATIN - ELOXATIN</u>						
N021492 001	5290961	Jan 12, 2013	DS			
	5290961*PED	Jul 12, 2013				
	5338874	Apr 07, 2013	DS			
	5338874*PED	Oct 07, 2013				
	5420319	Aug 09, 2016	DS			
	5420319*PED	Feb 09, 2017				
<u>OXALIPLATIN - ELOXATIN</u>						
N021492 002	5290961	Jan 12, 2013	DS			
	5290961*PED	Jul 12, 2013				
	5338874	Apr 07, 2013	DS			
	5338874*PED	Oct 07, 2013				
	5420319	Aug 09, 2016	DS			
	5420319*PED	Feb 09, 2017				
<u>OXALIPLATIN - ELOXATIN</u>						
N021759 001	5290961	Jan 12, 2013	DS			
	5290961*PED	Jul 12, 2013				
	5338874	Apr 07, 2013	DS			
	5338874*PED	Oct 07, 2013				
	5420319	Aug 09, 2016	DS			
	5420319*PED	Feb 09, 2017				
	5716988	Aug 07, 2015		DP		
	5716988*PED	Feb 07, 2016				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXALIPLATIN - ELOXATIN</u>						
N021759 002	5290961	Jan 12, 2013	DS			
	5290961*PED	Jul 12, 2013				
	5338874	Apr 07, 2013	DS			
	5338874*PED	Oct 07, 2013				
	5420319	Aug 09, 2016	DS			
	5420319*PED	Feb 09, 2017				
	5716988	Aug 07, 2015	DP			
	5716988*PED	Feb 07, 2016				
<u>OXALIPLATIN - ELOXATIN</u>						
N021759 003	5290961	Jan 12, 2013	DS			
	5290961*PED	Jul 12, 2013				
	5338874	Apr 07, 2013	DS			
	5338874*PED	Oct 07, 2013				
	5420319	Aug 09, 2016	DS			
	5420319*PED	Feb 09, 2017				
	5716988	Aug 07, 2015	DP			
	5716988*PED	Feb 07, 2016				
<u>OXANDROLONE - OXANDRIN</u>						
N013718 001	5872147	Dec 05, 2017		U-585		
	6090799	Jul 18, 2017		U-585		
	6576659	Dec 05, 2017		U-585		
	6670351	Oct 20, 2012		U-585		
	6828313	Dec 05, 2017		U-585		
<u>OXANDROLONE - OXANDRIN</u>						
N013718 002	5872147	Dec 05, 2017		U-585		
	6090799	Jul 18, 2017		U-585		
	6576659	Dec 05, 2017		U-585		
	6670351	Oct 20, 2012		U-585		
	6828313	Dec 05, 2017		U-585		
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N202810 001	7722898	Apr 13, 2027	DP		NDF	Oct 19, 2015
	7910131	Apr 13, 2027	U-1298			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N202810 002	7722898	Apr 13, 2027	DP		NDF	Oct 19, 2015
	7910131	Apr 13, 2027	U-1298			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N202810 003	7722898	Apr 13, 2027	DP		NDF	Oct 19, 2015
	7910131	Apr 13, 2027	U-1298			
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021014 001	7037525	Feb 12, 2018		U-724		
	7037525*PED	Aug 12, 2018				
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021014 002	7037525	Feb 12, 2018		U-724		
	7037525*PED	Aug 12, 2018				
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021014 003	7037525	Feb 12, 2018		U-724		
	7037525*PED	Aug 12, 2018				
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021285 001	7037525	Feb 12, 2018		U-724		
	7037525*PED	Aug 12, 2018				
	8119148	Dec 19, 2020	DP	U-724		
	8119148*PED	Jun 19, 2021				
<u>OXYBUTYNIN - ANTUROL</u>						
N202513 001	7029694	Apr 26, 2020	DP	U-318	NP	Dec 07, 2014
	7179483	Apr 26, 2020		U-318		
	7198801	Jun 25, 2022	DP			
	8241662	Apr 26, 2020		U-318		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYBUTYNIN - OXYTROL</u>						
N021351 002	5601839	Apr 26, 2015				
	5834010	Apr 26, 2015				
	6743441	Apr 26, 2020	DP		U-318	
	7081249	Apr 26, 2020	DP		U-318	
	7081250	Apr 26, 2020	DP		U-318	
	7081251	Apr 26, 2020	DP		U-318	
	7081252	Apr 26, 2020	DP		U-318	
	7179483	Apr 26, 2020	DS DP		U-318	
<u>OXYBUTYNIN CHLORIDE - DITROPAN XL</u>						
N020897 001	5674895	May 22, 2015				
	5674895*PED	Nov 22, 2015				
	5840754	May 22, 2015				
	5840754*PED	Nov 22, 2015				
	5912268	May 22, 2015				
	5912268*PED	Nov 22, 2015				
	6262115	May 22, 2015			U-393	
	6262115*PED	Nov 22, 2015			U-393	
<u>OXYBUTYNIN CHLORIDE - DITROPAN XL</u>						
N020897 002	5674895	May 22, 2015				
	5674895*PED	Nov 22, 2015				
	5840754	May 22, 2015				
	5840754*PED	Nov 22, 2015				
	5912268	May 22, 2015				
	5912268*PED	Nov 22, 2015				
	6262115	May 22, 2015			U-393	
	6262115*PED	Nov 22, 2015			U-393	
<u>OXYBUTYNIN CHLORIDE - DITROPAN XL</u>						
N020897 003	5674895	May 22, 2015				
	5674895*PED	Nov 22, 2015				
	5840754	May 22, 2015				
	5840754*PED	Nov 22, 2015				
	5912268	May 22, 2015				
	5912268*PED	Nov 22, 2015				
	6262115	May 22, 2015			U-393	
	6262115*PED	Nov 22, 2015			U-393	
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N022204 001	7029694	Apr 26, 2020	DP		U-318	
	7179483	Apr 26, 2020			U-318	
	8241662	Apr 26, 2020			U-318	
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N202080 001	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N202080 002	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 001	5508042	Apr 16, 2013			U-443	
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 002	5508042	Apr 16, 2013			U-443	
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 003	5508042	Apr 16, 2013				U-443
	7674799	Mar 30, 2025		DP		
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 004	5508042	Apr 16, 2013				U-443
	7674799	Mar 30, 2025		DP		
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 005	5508042	Apr 16, 2013				U-443
	7674799	Mar 30, 2025		DP		
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 006	5508042	Apr 16, 2013				U-443
	7674799	Mar 30, 2025		DP		
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 007	5508042	Apr 16, 2013				U-443
	7674799	Mar 30, 2025		DP		
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553 008	5508042	Apr 16, 2013				U-443
	7674799	Mar 30, 2025		DP		
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 001	5508042	Apr 16, 2013				U-443
	6488963	Jun 24, 2017		DP		
	7674799	Mar 30, 2025		DP		
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025		DP		
	8114383	Oct 10, 2024		DP		
	8309060	Nov 20, 2023		DP		U-443
	8337888	Aug 06, 2022		DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 002	5508042	Apr 16, 2013				U-443
	6488963	Jun 24, 2017		DP		
	7674799	Mar 30, 2025		DP		
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025		DP		
	8114383	Oct 10, 2024		DP		
	8309060	Nov 20, 2023		DP		U-443
	8337888	Aug 06, 2022		DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 003	5508042	Apr 16, 2013				U-443
	6488963	Jun 24, 2017		DP		
	7674799	Mar 30, 2025		DP		
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025		DP		
	8114383	Oct 10, 2024		DP		
	8309060	Nov 20, 2023		DP		U-443
	8337888	Aug 06, 2022		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 004	5508042	Apr 16, 2013				U-443
	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP			
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP			U-443
	8337888	Aug 06, 2022	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 005	5508042	Apr 16, 2013				U-443
	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP			
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP			U-443
	8337888	Aug 06, 2022	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 006	5508042	Apr 16, 2013				U-443
	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP			
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP			U-443
	8337888	Aug 06, 2022	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 007	5508042	Apr 16, 2013				U-443
	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP			
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP			U-443
	8337888	Aug 06, 2022	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 001	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP			U-826
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 002	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP			U-826
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 003	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP			U-826
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 004	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP			U-826
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 005	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP			U-826

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 006	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP	U-826		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 007	5662933	Sep 09, 2013	DP			
	5958456	Sep 09, 2013	DP			
	7276250	Feb 04, 2023	DP	U-826		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 001	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 002	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 003	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 004	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 005	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 006	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 007	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A079087 001					PC	Jul 07, 2013
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A079087 003					PC	Jul 07, 2013
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A079087 005					PC	Jul 02, 2013
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A079087 007					PC	Jul 07, 2013
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	5439686	Feb 22, 2013	DP U-1290		I-658	Oct 11, 2015
	5439686	Feb 22, 2013	DP U-1092			
	5498421	Mar 12, 2013	DP U-634			
	5498421	Mar 12, 2013	DP U-1092			
	5498421	Mar 12, 2013	DP U-1290			
	6096331	Feb 22, 2013	DP U-1290			
	6096331	Feb 22, 2013	DP U-1092			
	6096331	Feb 22, 2013	DP U-633			
	6506405	Feb 22, 2013	DP U-633			
	6506405	Feb 22, 2013	DP U-1092			
	6506405	Feb 22, 2013	DP U-1290			
	6537579	Feb 22, 2013	U-1290			
	6537579	Feb 22, 2013	U-632			
	6537579	Feb 22, 2013	U-1092			
	6749868	Feb 22, 2013	DP			
	6753006	Feb 22, 2013	DP			
	7820788	Mar 03, 2024	DP U-1290			
	7820788	Mar 03, 2024	DP U-1092			
	7923536	Dec 09, 2023	U-1117			
	7923536	Dec 09, 2023	U-1290			
	8034375	Aug 13, 2026	U-1290			
	8138229	Dec 09, 2023	DP U-1092			
	8138229	Dec 09, 2023	DP U-1290			
	8268348	Feb 21, 2026	U-1290			
	8314156	Dec 09, 2023	U-1290			
	RE41884	Aug 14, 2016	U-1290			
	RE41884	Aug 14, 2016	U-1117			
<u>PALIPERIDONE - INVEGA</u>						
N021999 001					I-605	Jul 31, 2012
					I-606	Jul 31, 2012
					NPP	Apr 06, 2014
					PED	Oct 06, 2014
					PED	Jan 31, 2013
					PED	Jan 31, 2013
<u>PALIPERIDONE - INVEGA</u>						
N021999 002					I-605	Jul 31, 2012
					I-606	Jul 31, 2012
					NPP	Apr 06, 2014
					PED	Oct 06, 2014
					PED	Jan 31, 2013
					PED	Jan 31, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE - INVEGA</u>						
N021999 003					I-605	Jul 31, 2012
					I-606	Jul 31, 2012
					NPP	Apr 06, 2014
					PED	Oct 06, 2014
					PED	Jan 31, 2013
					PED	Jan 31, 2013
<u>PALIPERIDONE - INVEGA</u>						
N021999 004					NPP	Apr 06, 2014
					PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 006					I-605	Jul 31, 2012
					I-606	Jul 31, 2012
					NPP	Apr 06, 2014
					PED	Oct 06, 2014
					PED	Jan 31, 2013
					PED	Jan 31, 2013
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 001	5254556	Oct 15, 2013	DS DP U-543		M-119	Aug 29, 2015
	5254556*PED	Apr 15, 2014			NDF	Jul 31, 2012
	5352459	Dec 16, 2012	DP		PED	Jan 31, 2013
	5352459*PED	Jun 16, 2013				
	6077843	May 12, 2017	DP U-543			
	6077843*PED	Nov 12, 2017				
	6555544	Nov 10, 2018	DP U-543			
	6555544*PED	May 10, 2019				
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 002	5254556	Oct 15, 2013	DS DP U-543		M-119	Aug 29, 2015
	5254556*PED	Apr 15, 2014			NDF	Jul 31, 2012
	5352459	Dec 16, 2012	DP		PED	Jan 31, 2013
	5352459*PED	Jun 16, 2013				
	6077843	May 12, 2017	DP U-543			
	6077843*PED	Nov 12, 2017				
	6555544	Nov 10, 2018	DP U-543			
	6555544*PED	May 10, 2019				
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 003	5254556	Oct 15, 2013	DS DP U-543		M-119	Aug 29, 2015
	5254556*PED	Apr 15, 2014			NDF	Jul 31, 2012
	5352459	Dec 16, 2012	DP		PED	Jan 31, 2013
	5352459*PED	Jun 16, 2013				
	6077843	May 12, 2017	DP U-543			
	6077843*PED	Nov 12, 2017				
	6555544	Nov 10, 2018	DP U-543			
	6555544*PED	May 10, 2019				
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 004	5254556	Oct 15, 2013	DS DP U-543		M-119	Aug 29, 2015
	5254556*PED	Apr 15, 2014			NDF	Jul 31, 2012
	5352459	Dec 16, 2012	DP		PED	Jan 31, 2013
	5352459*PED	Jun 16, 2013				
	6077843	May 12, 2017	DP U-543			
	6077843*PED	Nov 12, 2017				
	6555544	Nov 10, 2018	DP U-543			
	6555544*PED	May 10, 2019				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 005	5254556	Oct 15, 2013	DS DP U-543		M-119	Aug 29, 2015
	5254556*PED	Apr 15, 2014			NDF	Jul 31, 2012
	5352459	Dec 16, 2012	DP			
	5352459*PED	Jun 16, 2013			PED	Jan 31, 2013
	6077843	May 12, 2017	DP U-543			
	6077843*PED	Nov 12, 2017				
	6555544	Nov 10, 2018	DP U-543			
	6555544*PED	May 10, 2019				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N021372 001	5202333	Apr 13, 2015	DS DP U-528			
	7947724	Jan 30, 2024	DP			
	7947725	Jan 30, 2024	DP			
	7960424	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N021372 002	5202333	Apr 13, 2015	DS DP U-901			
	7947724	Jan 30, 2024	DP			
	7947725	Jan 30, 2024	DP			
	7960424	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N022233 001	5202333	Apr 13, 2015	DS DP U-528			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 001					I-625	Apr 30, 2013
					M-93	Jul 29, 2013
					NCE	Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 002					I-625	Apr 30, 2013
					M-93	Jul 29, 2013
					NCE	Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 003					I-625	Apr 30, 2013
					M-93	Jul 29, 2013
					NCE	Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 004					I-625	Apr 30, 2013
					M-93	Jul 29, 2019
					NCE	Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N022523 001					NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N022523 002					NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N022523 003					NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N022523 004					NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175 001					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175 002					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 002					NCE	Mar 01, 2017

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 003					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 001	7658918	Feb 20, 2028	DP		NCE	Aug 27, 2014
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 002	7658918	Feb 20, 2028	DP		NCE	Aug 27, 2014
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 003	7658918	Feb 20, 2028	DP		NCE	Aug 27, 2014
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 004	7658918	Feb 20, 2028	DP		NCE	Aug 27, 2014
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 005	8221747	Feb 20, 2028	DP		NCE	Aug 27, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 006	8221747	Feb 20, 2028	DP		NCE	Aug 27, 2014
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N020987 001	5997903	Dec 07, 2016			I-614	Nov 12, 2012
	5997903*PED	Jun 07, 2017			M-54	Nov 12, 2012
					PED	May 12, 2013
					PED	May 12, 2013
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N020987 002	5997903	Dec 07, 2016			I-614	Nov 12, 2012
	5997903*PED	Jun 07, 2017			M-54	Nov 12, 2012
					PED	May 12, 2013
					PED	May 12, 2013
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N022020 001	7544370	Jun 07, 2026	DP		I-614	Nov 12, 2012
	7544370*PED	Dec 07, 2026			M-54	Nov 12, 2012
	7550153	Sep 30, 2024		U-859	PED	May 12, 2013
	7550153*PED	Mar 30, 2025			PED	May 12, 2013
	7553498	Sep 30, 2024		U-859		
	7553498*PED	Mar 30, 2025				
	7838027	Sep 30, 2024	DP	U-859		
	7838027*PED	Mar 30, 2025				
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N020988 001	6780881	Nov 17, 2021	DP			
	6780881*PED	May 17, 2022				
	7351723	Nov 17, 2021	DP			
	7351723*PED	May 17, 2022				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
PARICALCITOL - ZEMPLAR							
N020819 001	5246925*PED	Oct 17, 2012	U-1195	DP			
	5587497	Dec 24, 2013					
	5587497*PED	Jun 24, 2014					
	5597815	Jul 13, 2015					
	5597815*PED	Jan 13, 2016					
	6136799	Apr 08, 2018					
	6136799*PED	Oct 08, 2018					
	6361758	Apr 08, 2018					
	6361758*PED	Oct 08, 2018					
PARICALCITOL - ZEMPLAR							
N020819 002	5246925*PED	Oct 17, 2012	U-1195	DP			
	5587497	Dec 24, 2013					
	5587497*PED	Jun 24, 2014					
	5597815	Jul 13, 2015					
	5597815*PED	Jan 13, 2016					
	6136799	Apr 08, 2018					
	6136799*PED	Oct 08, 2018					
	6361758	Apr 08, 2018					
	6361758*PED	Oct 08, 2018					
PARICALCITOL - ZEMPLAR							
N021606 001	5246925*PED	Oct 17, 2012	DS		U-1195		
	5587497	Dec 24, 2013					
	5587497*PED	Jun 24, 2014					
	5597815	Jul 13, 2015					
	5597815*PED	Jan 13, 2016					
PARICALCITOL - ZEMPLAR							
N021606 002	5246925*PED	Oct 17, 2012	DS		U-1195		
	5587497	Dec 24, 2013					
	5587497*PED	Jun 24, 2014					
	5597815	Jul 13, 2015					
	5597815*PED	Jan 13, 2016					
PARICALCITOL - ZEMPLAR							
N021606 003	5246925*PED	Oct 17, 2012	DS		U-1195		
	5587497	Dec 24, 2013					
	5587497*PED	Jun 24, 2014					
	5597815	Jul 13, 2015					
	5597815*PED	Jan 13, 2016					
PAROXETINE HYDROCHLORIDE - PAXIL							
N020031 001	5872132	May 19, 2015					
	5872132*PED	Nov 19, 2015					
	5900423	May 19, 2015					
	5900423*PED	Nov 19, 2015					
	6113944	Dec 14, 2014					
	6113944*PED	Jun 14, 2015					
	6121291	Mar 17, 2017					U-286
	6121291	Mar 17, 2017					U-431
	6121291*PED	Sep 17, 2017					U-431
	6121291*PED	Sep 17, 2017					U-286
	6133289	May 19, 2015					U-358
	6133289*PED	Nov 19, 2015					U-358
	PAROXETINE HYDROCHLORIDE - PAXIL						
N020031 002	5872132	May 19, 2015					
	5872132*PED	Nov 19, 2015					
	5900423	May 19, 2015					
	5900423*PED	Nov 19, 2015					
	6113944	Dec 14, 2014					
	6113944*PED	Jun 14, 2015					
	6121291	Mar 17, 2017					U-286
	6121291	Mar 17, 2017					U-431
	6121291*PED	Sep 17, 2017					U-286
	6121291*PED	Sep 17, 2017					U-431
	6133289	May 19, 2015					U-358
	6133289*PED	Nov 19, 2015					U-358

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020031 003	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6113944	Dec 14, 2014				
	6113944*PED	Jun 14, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020031 004	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6113944	Dec 14, 2014				
	6113944*PED	Jun 14, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020031 005	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6113944	Dec 14, 2014				
	6113944*PED	Jun 14, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-286		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020710 001	5811436	Sep 22, 2015				
	5811436*PED	Mar 22, 2016				
	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-431		
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020885 001	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6063927	Apr 23, 2019				
	6063927*PED	Oct 23, 2019				
	6080759	May 19, 2015				
	6080759*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-431		
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
	6172233	Jan 15, 2018				
	6172233*PED	Jul 15, 2018				
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020885 002	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6063927	Apr 23, 2019				
	6063927*PED	Oct 23, 2019				
	6080759	May 19, 2015				
	6080759*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-431		
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-286		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
	6172233	Jan 15, 2018				
	6172233*PED	Jul 15, 2018				
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020885 003	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6063927	Apr 23, 2019				
	6063927*PED	Oct 23, 2019				
	6080759	May 19, 2015				
	6080759*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-286		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
	6172233	Jan 15, 2018				
	6172233*PED	Jul 15, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N020885 004	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6063927	Apr 23, 2019				
	6063927*PED	Oct 23, 2019				
	6080759	May 19, 2015				
	6080759*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6121291*PED	Sep 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6133289*PED	Nov 19, 2015		U-358		
	6172233	Jan 15, 2018				
	6172233*PED	Jul 15, 2018				
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N020936 001	5422123*PED	Dec 06, 2012				
	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-286		
	6133289	May 19, 2015		U-286		
	6133289*PED	Nov 19, 2015		U-286		
	6548084	Jul 19, 2016				
	6548084*PED	Jan 19, 2017				
	7229640	Jul 19, 2016	DP	U-816		
	7229640*PED	Jan 19, 2017				
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N020936 002	5422123*PED	Dec 06, 2012				
	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-286		
	6133289	May 19, 2015		U-286		
	6133289*PED	Nov 19, 2015		U-286		
	6548084	Jul 19, 2016				
	6548084*PED	Jan 19, 2017				
	7229640	Jul 19, 2016	DP	U-816		
	7229640*PED	Jan 19, 2017				
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N020936 003	5422123*PED	Dec 06, 2012				
	5872132	May 19, 2015				
	5872132*PED	Nov 19, 2015				
	5900423	May 19, 2015				
	5900423*PED	Nov 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291*PED	Sep 17, 2017		U-286		
	6133289	May 19, 2015		U-286		
	6133289*PED	Nov 19, 2015		U-286		
	6548084	Jul 19, 2016				
	6548084*PED	Jan 19, 2017				
	7229640	Jul 19, 2016	DP	U-816		
	7229640*PED	Jan 19, 2017				
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N021299 001	5874447	Jun 10, 2017		U-46		
	5874447	Jun 10, 2017		U-518		
	5874447	Jun 10, 2017		U-286		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE MESYLATE - PEKEVA</u>						
N021299 002	5874447	Jun 10, 2017	U-518			
	5874447	Jun 10, 2017	U-46			
	5874447	Jun 10, 2017	U-286			
<u>PAROXETINE MESYLATE - PEKEVA</u>						
N021299 003	5874447	Jun 10, 2017	U-286			
	5874447	Jun 10, 2017	U-46			
	5874447	Jun 10, 2017	U-518			
<u>PAROXETINE MESYLATE - PEKEVA</u>						
N021299 004	5874447	Jun 10, 2017	U-46			
	5874447	Jun 10, 2017	U-286			
	5874447	Jun 10, 2017	U-518			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N200677 001	6225284	Jun 28, 2016	DS DP		NCE	Dec 14, 2017
	7473761	Jul 29, 2025	DS DP		ODE	Dec 14, 2019
	8299209	Dec 27, 2025	DS DP			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N200677 002	6225284	Jun 28, 2016	DS DP		NCE	Dec 14, 2017
	7473761	Jul 29, 2025	DS DP		ODE	Dec 14, 2019
	8299209	Dec 27, 2025	DS DP			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N200677 003	6225284	Jun 28, 2016	DS DP		NCE	Dec 14, 2017
	7473761	Jul 29, 2025	DS DP		ODE	Dec 14, 2019
	8299209	Dec 27, 2025	DS DP			
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 001	7105530	Oct 19, 2023	DS DP		I-649	Apr 26, 2015
	7262203	Dec 19, 2021	DS DP		NCE	Oct 19, 2014
	8114885	Dec 19, 2021	DS DP		ODE	Apr 26, 2019
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 002	7105530	Oct 19, 2023	DS DP		I-649	Apr 26, 2015
	7262203	Dec 19, 2021	DS DP		NCE	Oct 19, 2014
	8114885	Dec 19, 2021	DS DP		ODE	Apr 26, 2019
<u>PEGAPTANIB SODIUM - MACUGEN</u>						
N021756 001	5919455	Oct 27, 2013	DS			
	5932462	Aug 03, 2016	DS			
	6011020	Jan 04, 2017	DS			
	6051698	May 19, 2015	DS	U-622		
	6113906	Oct 27, 2013	DS			
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 007	7084245	May 12, 2024	DS DP	U-1238		
	7414105	May 12, 2024	DS DP	U-1238		
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 008	7084245	May 12, 2024	DS DP	U-1238		
	7414105	May 12, 2024	DS DP	U-1238		
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 001	7084245	May 12, 2024	DS DP	U-1238	NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP	U-1238		
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 002	7084245	May 12, 2024	DS DP	U-1238	NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP	U-1238		
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 003	7084245	May 12, 2024	DS DP	U-1238	NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP	U-1238		
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 004	7084245	May 12, 2024	DS DP	U-1238	NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP	U-1238		
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 005	7084245	May 12, 2024	DS DP	U-1238	NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP	U-1238		
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 006	7084245	May 12, 2024	DS DP	U-1238	NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP	U-1238		
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		
<u>PEGVISOMANT - SOMAVER</u>						
N021106 001	5849535	Mar 25, 2017	DS			
	6057292	Sep 21, 2015		U-507		
<u>PEGVISOMANT - SOMAVER</u>						
N021106 002	5849535	Mar 25, 2017	DS			
	6057292	Sep 21, 2015		U-507		
<u>PEGVISOMANT - SOMAVER</u>						
N021106 003	5849535	Mar 25, 2017	DS			
	6057292	Sep 21, 2015		U-507		
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 001	5344932	Jul 24, 2016	DS DP		I-601	Jul 02, 2012
	5344932*PED	Jan 24, 2017			M-122	Oct 17, 2015
	7772209	Nov 24, 2021		U-1296	M-61	Mar 17, 2014
	7772209	Nov 24, 2021		U-1077	PED	Sep 17, 2014
	7772209*PED	May 24, 2022			PED	Jan 02, 2013
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 002	5344932	Jul 24, 2016	DS DP		I-601	Jul 02, 2012
	5344932*PED	Jan 24, 2017			M-122	Oct 17, 2015
	7772209	Nov 24, 2021		U-1296	M-61	Mar 17, 2014
	7772209*PED	May 24, 2022			PED	Sep 17, 2014
					PED	Jan 02, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PENCICLOVIR SODIUM - DENAVIR</u>						
N020629 001	5840763	Sep 01, 2015	U-501			
	5866581	Oct 04, 2014	U-501			
	5916893	Sep 01, 2015	U-501			
	6124304	Oct 04, 2014	U-501			
	6469015	Oct 22, 2019	U-501			
	6579981	Jun 17, 2020	U-501			
<u>PERAMPANEL - FYCOMPA</u>						
N202834 001	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N202834 002	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N202834 003	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N202834 004	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N202834 005	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N202834 006	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE - SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS</u>						
N021084 001	5607979	May 30, 2015				
<u>PERFLUTREN - DEFINITY</u>						
N021064 001	5527521	Feb 22, 2015	DP U-665			
	5585112	Dec 17, 2013	DP			
	6033645	Jun 19, 2016	U-665			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 001	6149938	Jul 23, 2018	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 002	6149938	Jul 23, 2018	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 003	6149938	Jul 23, 2018	DP U-1243			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 001	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 002	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 003	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 004	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N022159 001	6764678	May 11, 2021			U-967	
	6872390	May 11, 2021	DP			
	7229630	Jun 20, 2023	DP			
	7569230	Oct 17, 2023			U-967	
	7575757	Apr 21, 2025	DP			
<u>PIMECROLIMUS - ELIDEL</u>						
N021302 001	5912238	Jun 15, 2016				
	5912238*PED	Dec 15, 2016				
	6352998	Oct 26, 2015				
	6352998*PED	Apr 26, 2016				
	6423722	Jun 26, 2018				
	6423722*PED	Dec 26, 2018				
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N021073 001	5965584	Jun 19, 2016			U-753	
	6150383	Jun 19, 2016			U-418	
	6150384	Jun 19, 2016			U-419	
	6166042	Jun 19, 2016			U-414	
	6166043	Jun 19, 2016			U-415	
	6172090	Jun 19, 2016			U-416	
	6211205	Jun 19, 2016			U-410	
	6271243	Jun 19, 2016			U-411	
	6303640	Aug 09, 2016			U-425	
	6329404	Jun 19, 2016			U-753	
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N021073 002	5965584	Jun 19, 2016			U-753	
	6150383	Jun 19, 2016			U-418	
	6150384	Jun 19, 2016			U-419	
	6166042	Jun 19, 2016			U-414	
	6166043	Jun 19, 2016			U-415	
	6172090	Jun 19, 2016			U-416	
	6211205	Jun 19, 2016			U-410	
	6271243	Jun 19, 2016			U-411	
	6303640	Aug 09, 2016			U-425	
	6329404	Jun 19, 2016			U-753	
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N021073 003	5965584	Jun 19, 2016			U-753	
	6150383	Jun 19, 2016			U-418	
	6150384	Jun 19, 2016			U-419	
	6166042	Jun 19, 2016			U-414	
	6166043	Jun 19, 2016			U-415	
	6172090	Jun 19, 2016			U-416	
	6211205	Jun 19, 2016			U-410	
	6271243	Jun 19, 2016			U-411	
	6303640	Aug 09, 2016			U-425	
	6329404	Jun 19, 2016			U-753	
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 001					PC	Feb 13, 2013
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 002					PC	Feb 13, 2013
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 003					PC	Feb 13, 2013
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 001	6900184	Apr 14, 2023	DP		U-282	
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP		U-282	
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	6900184	Apr 14, 2023	DP		U-282	
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP		U-282	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N022363 001	5753675	May 19, 2015	DS DP U-998		NCE	Aug 03, 2014
	5854259	Dec 29, 2015	DP			
	5856336	Jan 05, 2016	DS U-998			
	6465477	Dec 20, 2016	DP			
	7022713	Feb 19, 2024	U-998			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N022363 002	5753675	May 19, 2015	DS DP U-998		NCE	Aug 03, 2014
	5854259	Dec 29, 2015	DP			
	5856336	Jan 05, 2016	DS U-998			
	6465477	Dec 20, 2016	DP			
	7022713	Feb 19, 2024	U-998			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N022363 003	5753675	May 19, 2015	DS DP U-998		NCE	Aug 03, 2014
	5854259	Dec 29, 2015	DP			
	5856336	Jan 05, 2016	DS U-998			
	6465477	Dec 20, 2016	DP			
	7022713	Feb 19, 2024	U-998			
<u>PLERIXAFOR - MOZOBIL</u>						
N022311 001	6987102	Jul 22, 2023	U-936		NCE	Dec 15, 2013
	7897590	Jul 22, 2023	U-936		ODE	Dec 15, 2015
	RE42152	Dec 10, 2013	DP			
<u>POLIDOCANOL - ASCLERA</u>						
N021201 001					NCE	Mar 30, 2015
<u>POLIDOCANOL - ASCLERA</u>						
N021201 002					NCE	Mar 30, 2015
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N203469 001	8114874	Dec 22, 2026	DS DP		NCE	Dec 14, 2017
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N203469 002	8114874	Dec 22, 2026	DS DP		NCE	Dec 14, 2017
<u>PORFIMER SODIUM - PHOTOFRIN</u>						
N020451 001	5438071	Aug 01, 2012				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>POSACONAZOLE - NOXAFIL</u>						
N022003 001	5661151	Jul 19, 2019	DS DP U-760			
	5703079	Aug 26, 2014	DS DP U-760			
	6958337	Oct 05, 2018	DS DP U-760			
	8263600	Apr 01, 2022	DP			
<u>PRALATREXATE - FOLOTYN</u>						
N022468 001	6028071	Jul 16, 2017	DS DP U-1004		NCE	Sep 24, 2014
	7622470	May 31, 2025	U-1015		ODE	Sep 24, 2016
	8299078	May 31, 2025	U-1004			
<u>PRALATREXATE - FOLOTYN</u>						
N022468 002	6028071	Jul 16, 2017	DS DP U-1004		NCE	Sep 24, 2014
	7622470	May 31, 2025	U-1015		ODE	Sep 24, 2016
	8299078	May 31, 2025	U-1004			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 001	6001861	Jan 16, 2018	U-784		M-104	May 13, 2014
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 002	6001861	Jan 16, 2018	U-784		M-104	May 13, 2014
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 003	6001861	Jan 16, 2018	U-784		M-104	May 13, 2014
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 005	6001861	Jan 16, 2018	U-784		M-104	May 13, 2014
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 006	6001861	Jan 16, 2018	U-784		M-104	May 13, 2014
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 007	6001861	Jan 16, 2018	U-784		M-104	May 13, 2014
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 001	7695734	Apr 26, 2028	DP		I-623 NDF	Mar 19, 2013 Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 002	7695734	Apr 26, 2028	DP		I-623 NDF	Mar 19, 2013 Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 003	7695734	Apr 26, 2028	DP		I-623 NDF	Mar 19, 2013 Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 004	7695734	Apr 26, 2028	DP		I-623 NDF	Mar 19, 2013 Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 005	7695734	Apr 26, 2028	DP		I-623 NDF	Mar 19, 2013 Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 006	7695734	Apr 26, 2028	DP		I-623 NDF	Mar 19, 2013 Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 007	7695734	Apr 26, 2028	DP		I-623 NDF	Mar 19, 2013 Feb 19, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N021332 001	5686411	Mar 16, 2019	DS DP U-638			
	5814600	Sep 29, 2015	U-639			
	6114304	Sep 05, 2017	U-640			
	6608029	Sep 07, 2013	U-641			
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N021332 002	5686411	Mar 16, 2019	DS DP U-638			
	5814600	Sep 29, 2015	U-639			
	5814600	Sep 29, 2015	U-638			
	5814600	Sep 29, 2015	U-637			
	6114304	Sep 05, 2017	U-637			
	6114304	Sep 05, 2017	U-640			
	6608029	Sep 07, 2013	U-637			
	6608029	Sep 07, 2013	U-640			
	6608029	Sep 07, 2013	U-641			
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N021332 003	5686411	Mar 16, 2019	DS DP U-638			
	5814600	Sep 29, 2015	U-639			
	5814600	Sep 29, 2015	U-638			
	5814600	Sep 29, 2015	U-637			
	6114304	Sep 05, 2017	U-640			
	6114304	Sep 05, 2017	U-637			
	6608029	Sep 07, 2013	U-637			
	6608029	Sep 07, 2013	U-641			
	6608029	Sep 07, 2013	U-640			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N022307 001	5288726	Apr 14, 2017	DS DP U-991		NCE	Jul 10, 2014
	6693115	Jul 03, 2021	DS DP U-991			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N022307 002	5288726	Apr 14, 2017	DS DP U-991		NCE	Jul 10, 2014
	6693115	Jul 03, 2021	DS DP U-991			
<u>PRAVASTATIN SODIUM - PRAVACHOL</u>						
N019898 002	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>PRAVASTATIN SODIUM - PRAVACHOL</u>						
N019898 003	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>PRAVASTATIN SODIUM - PRAVACHOL</u>						
N019898 004	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>PRAVASTATIN SODIUM - PRAVACHOL</u>						
N019898 008	5622985	Apr 22, 2014	U-335			
	5622985*PED	Oct 22, 2014	U-335			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 001	5881926	Mar 16, 2016	DP			
	6071523	Jun 03, 2018	DP			
	6102254	Mar 11, 2013	DP			
	6399079	Jun 03, 2018	DP			
	6656482	Jun 03, 2018	DP			
	7799331	Oct 11, 2028	DP U-1068			
	7799331	Oct 11, 2028	DP U-139			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 002	5881926	Mar 16, 2016	DP			
	6071523	Jun 03, 2018	DP			
	6102254	Mar 11, 2013	DP			
	6399079	Jun 03, 2018	DP			
	6656482	Jun 03, 2018	DP			
	7799331	Oct 11, 2028	DP U-1068			
	7799331	Oct 11, 2028	DP U-139			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N021959 001	6024981	Apr 09, 2018	DP	Y		
	6221392	Apr 09, 2018	DP	Y		
	6740341	Nov 24, 2019	DP			
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N021959 002	6024981	Apr 09, 2018	DP	Y		
	6221392	Apr 09, 2018	DP	Y		
	6740341	Nov 24, 2019	DP			
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N021959 003	6024981	Apr 09, 2018	DP	Y		
	6221392	Apr 09, 2018	DP	Y		
	6740341	Nov 24, 2019	DP			
<u>PREDNISONE - RAYOS</u>						
N202020 001	6488960	Mar 14, 2020	DP U-1267			
	6677326	Mar 14, 2020	DP U-1268			
	8309124	Apr 23, 2024	U-1292			
<u>PREDNISONE - RAYOS</u>						
N202020 002	6488960	Mar 14, 2020	DP U-1267			
	6677326	Mar 14, 2020	DP U-1268			
	8309124	Apr 23, 2024				
<u>PREDNISONE - RAYOS</u>						
N202020 003	8168218	Jan 07, 2028	DP U-1269			
	8309124	Apr 23, 2024	U-1292			
<u>PREGABALIN - LYRICA</u>						
N021446 001	5563175	Oct 08, 2013	U-661		I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 002	5563175	Oct 08, 2013	U-661		I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-819	Y		
	6001876	Dec 30, 2018	U-55	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 003	5563175	Oct 08, 2013	U-661		I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 004	5563175	Oct 08, 2013	U-661		I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-819	Y		
	6001876	Dec 30, 2018	U-55	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 005	5563175	Oct 08, 2013	U-661		I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 006	5563175	Oct 08, 2013	U-661		I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N021446 007	5563175	Oct 08, 2013	U-661		I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-819	Y		
	6001876	Dec 30, 2018	U-55	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 008	5563175	Oct 08, 2013	U-661		I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-819	Y		
	6001876	Dec 30, 2018	U-55	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N022488 001	5563175	Oct 08, 2013	U-661			
	6001876	Dec 30, 2018	U-819	Y		
	6001876	Dec 30, 2018	U-55	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PROCAINAMIDE HYDROCHLORIDE - PROCANBID</u>						
N020545 001	5656296	Aug 12, 2014				
<u>PROCAINAMIDE HYDROCHLORIDE - PROCANBID</u>						
N020545 002	5656296	Aug 12, 2014				
<u>PROGESTERONE - CRINONE</u>						
N020701 001	5543150	Sep 15, 2013	U-209			
<u>PROGESTERONE - CRINONE</u>						
N020701 002	5543150	Sep 15, 2013	U-209			
<u>PROGESTERONE - ENDOMETRIN</u>						
N022057 001	7300664	Nov 17, 2019	U-856			
	7320800	Nov 17, 2019	U-856			
	7393543	Nov 17, 2019	DP U-880			
<u>PROPAFENONE HYDROCHLORIDE - RYTHMOL SR</u>						
N021416 001	5681588	Oct 28, 2014				
<u>PROPAFENONE HYDROCHLORIDE - RYTHMOL SR</u>						
N021416 002	5681588	Oct 28, 2014				
<u>PROPAFENONE HYDROCHLORIDE - RYTHMOL SR</u>						
N021416 003	5681588	Oct 28, 2014				
<u>PROPOFOL - DIPRIVAN</u>						
N019627 002	5714520	Mar 22, 2015				
	5714520*PED	Sep 22, 2015				
	5731355	Mar 22, 2015	U-217			
	5731355*PED	Sep 22, 2015	U-217			
	5731356	Mar 22, 2015	U-218			
	5731356*PED	Sep 22, 2015	U-218			
	5908869	Mar 22, 2015	U-270			
	5908869*PED	Sep 22, 2015	U-270			
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N021438 001	6500454	Oct 04, 2021	DP			
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N021438 002	6500454	Oct 04, 2021	DP			
<u>QUAZEPAM - DORAL</u>						
N018708 001	7608616	Jun 03, 2028	U-1012			
<u>QUAZEPAM - DORAL</u>						
N018708 003	7608616	Jun 03, 2028	U-1012			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
<u>QUETIAPINE FUMARATE - SEROQUEL</u>								
N020639 001						NPP	Dec 02, 2012	
						NPP	Dec 02, 2012	
						PED	Jun 02, 2013	
						PED	Jun 02, 2013	
<u>QUETIAPINE FUMARATE - SEROQUEL</u>								
N020639 002						NPP	Dec 02, 2012	
						NPP	Dec 02, 2012	
						PED	Jun 02, 2013	
						PED	Jun 02, 2013	
<u>QUETIAPINE FUMARATE - SEROQUEL</u>								
N020639 003						NPP	Dec 02, 2012	
						NPP	Dec 02, 2012	
						PED	Jun 02, 2013	
						PED	Jun 02, 2013	
<u>QUETIAPINE FUMARATE - SEROQUEL</u>								
N020639 004						NPP	Dec 02, 2012	
						NPP	Dec 02, 2012	
						PED	Jun 02, 2013	
						PED	Jun 02, 2013	
<u>QUETIAPINE FUMARATE - SEROQUEL</u>								
N020639 005						NPP	Dec 02, 2012	
						NPP	Dec 02, 2012	
						PED	Jun 02, 2013	
						PED	Jun 02, 2013	
<u>QUETIAPINE FUMARATE - SEROQUEL</u>								
N020639 006						NPP	Dec 02, 2012	
						NPP	Dec 02, 2012	
						PED	Jun 02, 2013	
						PED	Jun 02, 2013	
<u>QUETIAPINE FUMARATE - SEROQUEL</u>								
N020639 007						NPP	Dec 02, 2012	
						NPP	Dec 02, 2012	
						PED	Jun 02, 2013	
						PED	Jun 02, 2013	
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>								
N022047 001	5948437	May 28, 2017	DP U-814 DP U-601 DP U-839			I-618	Dec 02, 2012	
	5948437	May 28, 2017						
	5948437	May 28, 2017						
	5948437*PED	Nov 28, 2017						
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>								
N022047 002	5948437	May 28, 2017	DP U-839 DP U-601 DP U-814			I-618	Dec 02, 2012	
	5948437	May 28, 2017						
	5948437	May 28, 2017						
	5948437*PED	Nov 28, 2017						
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>								
N022047 003	5948437	May 28, 2017	DP U-814 DP U-601 DP U-839			I-618	Dec 02, 2012	
	5948437	May 28, 2017						
	5948437	May 28, 2017						
	5948437*PED	Nov 28, 2017						
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>								
N022047 004	5948437	May 28, 2017	DP U-601 DP U-814 DP U-839			I-618	Dec 02, 2012	
	5948437	May 28, 2017						
	5948437	May 28, 2017						
	5948437*PED	Nov 28, 2017						

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N022047 005	5948437	May 28, 2017	DP U-814		I-618	Dec 02, 2012
	5948437	May 28, 2017	DP U-839			
	5948437	May 28, 2017	DP U-601			
	5948437*PED	Nov 28, 2017				
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N019885 001	5684016	Nov 04, 2014	U-210			
	5684016*PED	May 04, 2015	U-210			
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N019885 002	5684016	Nov 04, 2014	U-210			
	5684016*PED	May 04, 2015	U-210			
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N019885 003	5684016	Nov 04, 2014	U-210			
	5684016*PED	May 04, 2015	U-210			
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N019885 004	5684016	Nov 04, 2014	U-210			
	5684016*PED	May 04, 2015	U-210			
<u>QUININE SULFATE - QALAAQUIN</u>						
N021799 001					ODE	Aug 12, 2012
<u>RABEPRAZOLE SODIUM - ACIPHEX</u>						
N020973 001	5045552	May 08, 2013	U-385			
	5045552*PED	Nov 08, 2013				
<u>RABEPRAZOLE SODIUM - ACIPHEX</u>						
N020973 002	5045552	May 08, 2013	U-385			
	5045552*PED	Nov 08, 2013				
<u>RALOXIFENE HYDROCHLORIDE - EVISTA</u>						
N020815 001	5393763	Jul 28, 2012	U-114	Y	ODE	Sep 13, 2014
	5457117	Jul 28, 2012	U-114	Y		
	5478847	Mar 02, 2014	U-114	Y		
	5811120	Mar 02, 2014				
	5972383	Mar 02, 2014	U-287			
	6458811	Mar 10, 2017	DS DP U-825			
	6797719	Mar 10, 2017	DP			
	6894064	Mar 10, 2017	DP			
	6906086	Jul 28, 2012	U-657			
	6906086	Jul 28, 2012	U-657			
	6906086	Jul 28, 2012	U-662			
	8030330	Mar 10, 2017	DP			
	RE38968	Jul 28, 2012	U-657			
	RE38968	Jul 28, 2012	U-662			
	RE39049	Jul 28, 2012	U-662			
	RE39049	Jul 28, 2012	U-657			
	RE39050	Mar 02, 2014	U-662			
	RE39050	Mar 02, 2014	U-657			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145 001	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257		NPP	Dec 21, 2014
	7435734	Oct 21, 2022	U-257		NCE	Oct 12, 2012
	7435734	Oct 21, 2022	U-900			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 001	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257		NDF	Dec 21, 2014
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 002	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257		NDF	Dec 21, 2014
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RAMELTEON - ROZEREM</u>						
N021782 001	6034239	Jul 22, 2019	DS DP U-674			
<u>RAMIPRIL - ALTACE</u>						
N019901 001	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N019901 002	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N019901 003	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N019901 004	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N022021 001	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N022021 002	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N022021 003	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N022021 004	7368469	Aug 30, 2020	U-871			
<u>RANITIDINE BISMUTH CITRATE - TRITEC</u>						
N020559 001	5456925	Oct 10, 2012				
	5601848	Feb 11, 2014	U-202			
	5629297	May 13, 2014	U-186			
<u>RANOLAZINE - RANEXA</u>						
N021526 001	6303607	May 27, 2019	U-705			
	6369062	May 27, 2019	DP			Y
	6479496	May 27, 2019	U-705			
	6503911	May 27, 2019	DP			
	6525057	May 27, 2019	U-705			
	6562826	May 27, 2019	U-705			
	6617328	May 27, 2019	DP			
	6620814	May 27, 2019	U-705			
	6852724	May 27, 2019	U-705			
	6864258	May 27, 2019	U-705			
<u>RANOLAZINE - RANEXA</u>						
N021526 002	6303607	May 27, 2019	U-705			
	6369062	May 27, 2019	DP			
	6479496	May 27, 2019	U-705			
	6503911	May 27, 2019	DP			
	6525057	May 27, 2019	U-705			
	6562826	May 27, 2019	U-705			
	6617328	May 27, 2019	DP			
	6620814	May 27, 2019	U-705			
	6852724	May 27, 2019	U-705			
	6864258	May 27, 2019	U-705			
<u>RAPACURONIUM BROMIDE - RAPLON</u>						
N020984 001	5418226	Apr 14, 2013				
<u>RAPACURONIUM BROMIDE - RAPLON</u>						
N020984 002	5418226	Apr 14, 2013				
<u>RASAGILINE MESYLATE - AZILECT</u>						
N021641 001	5453446	Feb 07, 2017	U-219			
	5532415	Jul 02, 2013	DS			
	6126968	Sep 18, 2016	DP			
	7572834	Dec 05, 2026	DP			
	7815942	Aug 27, 2027	DS DP U-219			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RASAGILINE MESYLATE - AZILECT</u>						
N021641 002	5453446	Feb 07, 2017			U-219	
	5532415	Jul 02, 2013	DS			
	6126968	Sep 18, 2016		DP		
	7572834	Dec 05, 2026		DP		
	7815942	Aug 27, 2027	DS DP		U-219	
<u>REGADENOSON - LEXISCAN</u>						
N022161 001	6403567	Apr 10, 2022	DS DP		U-869	NCE Apr 10, 2013
	6642210	Jun 22, 2019	DS DP		U-869	
	7144872	Jun 22, 2019	DS DP		U-116	
	7144872	Jun 22, 2019	DS DP		U-870	
	7144872	Jun 22, 2019	DS DP		U-869	
	7183264	Jun 22, 2019		DP	U-870	
	7183264	Jun 22, 2019		DP	U-869	
	7183264	Jun 22, 2019		DP	U-116	
	7582617	Jun 22, 2019			U-1003	
	7655636	Jun 22, 2019			U-869	
	7655637	Jun 22, 2019	DS DP		U-869	
	7683037	Jun 22, 2019			U-1042	
	8106029	Jun 22, 2019			U-1042	
	8106183	Feb 02, 2027	DS			
	8133879	Jun 22, 2019		DP		
	8183226	Jun 22, 2019			U-116	
<u>REGORAFENIB - STIVARGA</u>						
N203085 001	7351834	Jan 12, 2020	DS			NCE Sep 27, 2017
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N020630 001	5866591	Sep 10, 2017		DP		
	5866591*PED	Mar 10, 2018				
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N020630 002	5866591	Sep 10, 2017		DP		
	5866591*PED	Mar 10, 2018				
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N020630 003	5866591	Sep 10, 2017		DP		
	5866591*PED	Mar 10, 2018				
<u>REPAGLINIDE - PRANDIN</u>						
N020741 001	6677358	Jun 12, 2018	DS DP		U-1265	
<u>REPAGLINIDE - PRANDIN</u>						
N020741 002	6677358	Jun 12, 2018	DS DP		U-1265	
<u>REPAGLINIDE - PRANDIN</u>						
N020741 003	6677358	Jun 12, 2018	DS DP		U-1265	
<u>RETAPAMULIN - ALTABAX</u>						
N022055 001	7875630	Feb 14, 2027	DS			
	RE39128	Apr 12, 2021	DS DP		U-805	
	RE43390	Apr 12, 2021	DS DP		U-805	
<u>RIBAVIRIN - COPEGUS</u>						
N021511 001					NPP	Aug 09, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIBAVIRIN - REBETOL</u>						
N020903 001	6172046	Sep 21, 2017	U-377			
	6172046	Sep 21, 2017	U-1014			
	6172046*PED	Mar 21, 2018	U-377			
	6177074	Nov 01, 2016	U-454			
	6177074	Nov 01, 2016	U-1013			
	6177074*PED	May 01, 2017	U-454			
	6461605	Nov 01, 2016	U-478			
	6461605	Nov 01, 2016	U-1013			
	6461605*PED	May 01, 2017	U-478			
	6472373	Sep 21, 2017	U-1014			
	6472373	Sep 21, 2017	U-479			
	6472373*PED	Mar 21, 2018	U-479			
	6524570	Nov 01, 2016	U-1013			
	6524570	Nov 01, 2016	U-499			
	6524570*PED	May 01, 2017	U-499			
<u>RIBAVIRIN - REBETOL</u>						
N020903 002	6172046	Sep 21, 2017	U-1014			
	6172046	Sep 21, 2017	U-377			
	6172046*PED	Mar 21, 2018	U-377			
	6177074	Nov 01, 2016	U-454			
	6177074	Nov 01, 2016	U-1013			
	6177074*PED	May 01, 2017	U-454			
	6461605	Nov 01, 2016	U-1013			
	6461605	Nov 01, 2016	U-478			
	6461605*PED	May 01, 2017	U-478			
	6472373	Sep 21, 2017	U-479			
	6472373	Sep 21, 2017	U-1014			
	6472373*PED	Mar 21, 2018	U-479			
	6524570	Nov 01, 2016	U-1013			
	6524570	Nov 01, 2016	U-499			
	6524570*PED	May 01, 2017	U-499			
<u>RIBAVIRIN - REBETOL</u>						
N021546 001	6172046	Sep 21, 2017	U-1014			
	6172046	Sep 21, 2017	U-521			
	6172046*PED	Mar 21, 2018	U-521			
	6177074	Nov 01, 2016	U-1013			
	6177074*PED	May 01, 2017				
	6461605	Nov 01, 2016	U-521			
	6461605	Nov 01, 2016	U-1013			
	6461605*PED	May 01, 2017	U-521			
	6472373	Sep 21, 2017	U-521			
	6472373*PED	Mar 21, 2018	U-521			
	6524570	Nov 01, 2016	U-1013			
	6524570*PED	May 01, 2017				
	6790837	Apr 05, 2023	DP			
	6790837*PED	Oct 05, 2023	U-1014			
<u>RIBAVIRIN - VIRAZOLE</u>						
N018859 001	6150337	Nov 21, 2017	U-400			
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	7045620	Jun 19, 2024	DS DP			
	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7928115	Jul 24, 2029			U-1121	
	8158644	Jun 19, 2024		DP		
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	7045620	Jun 19, 2024	DS		NP	Mar 24, 2013
	7612199	Jun 19, 2024	DS DP		ODE	Mar 24, 2017
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N202022 001	6838464	Feb 26, 2021	DS DP		NCE	May 20, 2016
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 14, 2023	DS DP	U-1153		
	7125879	Apr 14, 2023	DS DP	U-1307		
	7638522	Apr 14, 2023	DP			
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
<u>RILUZOLE - RILUTEK</u>						
N020599 001	5527814	Jun 18, 2013				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N020835 001	5583122	Dec 10, 2013		U-222	M-61	Jul 23, 2012
	5583122*PED	Jun 10, 2014			PED	Jan 23, 2013
	6165513	Jun 10, 2018				
	6165513*PED	Dec 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N020835 002	5583122	Dec 10, 2013		U-222	M-61	Jul 23, 2012
	5583122*PED	Jun 10, 2014			PED	Jan 23, 2013
	6165513	Jun 10, 2018				
	6165513*PED	Dec 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N020835 003	5583122	Dec 10, 2013	DS DP	U-222	M-61	Jul 23, 2012
	5583122	Dec 10, 2013	DS DP	U-756	PED	Jan 23, 2013
	5583122*PED	Jun 10, 2014				
	5994329	Jul 17, 2018		U-353		
	5994329*PED	Jan 17, 2019				
	6015801	Jul 17, 2018		U-353		
	6015801*PED	Jan 17, 2019				
	6165513	Jun 10, 2018	DP			
	6165513*PED	Dec 10, 2018				
	6432932	Jul 17, 2018		U-595		
	6432932*PED	Jan 17, 2019				
	6465443	Aug 14, 2018	DP			
	6465443*PED	Feb 14, 2019				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N020835 004	5583122	Dec 10, 2013	DS DP	U-353	M-61	Jul 23, 2012
	5583122*PED	Jun 10, 2014			PED	Jan 23, 2013
	6165513	Jun 10, 2018	DP			
	6165513*PED	Dec 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N020835 005	5583122	Dec 10, 2013	DS DP	U-353	M-61	Jul 23, 2012
	5583122*PED	Jun 10, 2014			PED	Jan 23, 2013
	6165513	Jun 10, 2018	DP			
	6165513*PED	Dec 10, 2018				
	7192938	May 06, 2023		U-353		
	7192938*PED	Nov 06, 2023				
	7718634	May 06, 2023		U-662		
	7718634*PED	Nov 06, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISEDRONATE SODIUM - ATELVIA</u>						
N022560 001	5583122	Dec 10, 2013	DS DP U-662		NDF	Oct 08, 2013
	5583122*PED	Jun 10, 2014				
	5622721	Apr 21, 2014	DP U-662			
	7645459	Jan 09, 2028	DP U-662			
	7645460	Jan 09, 2028	DP U-662			
	8246989	Jan 16, 2026	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N020588 001	5453425	Jul 11, 2014	DP			
	5453425*PED	Jan 11, 2015				
	RE39181	Jul 11, 2014	DP			
	RE39181*PED	Jan 11, 2015				
<u>RISPERIDONE - RISPERDAL</u>						
N021444 001	5648093	Jul 15, 2014	DP			
	5648093*PED	Jan 15, 2015				
	6224905	Jun 10, 2017	DP			
	6224905*PED	Dec 10, 2017				
<u>RISPERIDONE - RISPERDAL</u>						
N021444 002	5648093	Jul 15, 2014	DP			
	5648093*PED	Jan 15, 2015				
	6224905	Jun 10, 2017	DP			
	6224905*PED	Dec 10, 2017				
<u>RISPERIDONE - RISPERDAL</u>						
N021444 003	5648093	Jul 15, 2014	DP			
	5648093*PED	Jan 15, 2015				
	6224905	Jun 10, 2017	DP			
	6224905*PED	Dec 10, 2017				
<u>RISPERIDONE - RISPERDAL</u>						
N021444 004	5648093	Jul 15, 2014	DP			
	5648093*PED	Jan 15, 2015				
	6224905	Jun 10, 2017	DP			
	6224905*PED	Dec 10, 2017				
<u>RISPERIDONE - RISPERDAL</u>						
N021444 005	5648093	Jul 15, 2014	DP			
	5648093*PED	Jan 15, 2015				
	6224905	Jun 10, 2017	DP			
	6224905*PED	Dec 10, 2017				
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N021346 001	5688801	Nov 18, 2014		U-972		
	5688801	Nov 18, 2014		U-543		
	5688801*PED	May 18, 2015				
	5792477	May 02, 2017	DP			
	5792477*PED	Nov 02, 2017				
	5916598	May 02, 2017	DP			
	5916598*PED	Nov 02, 2017				
	5965168	Nov 19, 2013	DP			
	5965168*PED	May 19, 2014				
	6110921	Nov 19, 2013		U-543		
	6110921*PED	May 19, 2014				
	6194006	Dec 30, 2018	DP			
	6194006*PED	Jun 30, 2019				
	6368632	Nov 19, 2013		U-543		
	6368632*PED	May 19, 2014				
	6379703	Dec 30, 2018	DP			
	6379703*PED	Jun 30, 2019				
	6403114	May 02, 2017	DP			
	6403114*PED	Nov 02, 2017				
	6596316	Dec 30, 2018	DP			
	6596316*PED	Jun 30, 2019				
	6667061	May 25, 2020	DP			
	6667061*PED	Nov 25, 2020				
	7547452	Nov 19, 2013	DP			
	7547452*PED	May 19, 2014				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N021346 002	5688801	Nov 18, 2014			U-543	
	5688801	Nov 18, 2014			U-972	
	5688801*PED	May 18, 2015				
	5792477	May 02, 2017	DP			
	5792477*PED	Nov 02, 2017				
	5916598	May 02, 2017	DP			
	5916598*PED	Nov 02, 2017				
	5965168	Nov 19, 2013	DP			
	5965168*PED	May 19, 2014				
	6110921	Nov 19, 2013			U-543	
	6110921*PED	May 19, 2014				
	6194006	Dec 30, 2018	DP			
	6194006*PED	Jun 30, 2019				
	6368632	Nov 19, 2013			U-543	
	6368632*PED	May 19, 2014				
	6379703	Dec 30, 2018	DP			
	6379703*PED	Jun 30, 2019				
	6403114	May 02, 2017	DP			
	6403114*PED	Nov 02, 2017				
	6596316	Dec 30, 2018	DP			
	6596316*PED	Jun 30, 2019				
	6667061	May 25, 2020	DP			
	6667061*PED	Nov 25, 2020				
	7547452	Nov 19, 2013	DP			
	7547452*PED	May 19, 2014				
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N021346 003	5688801	Nov 18, 2014			U-543	
	5688801	Nov 18, 2014			U-972	
	5688801*PED	May 18, 2015				
	5792477	May 02, 2017	DP			
	5792477*PED	Nov 02, 2017				
	5916598	May 02, 2017	DP			
	5916598*PED	Nov 02, 2017				
	5965168	Nov 19, 2013	DP			
	5965168*PED	May 19, 2014				
	6110921	Nov 19, 2013			U-543	
	6110921*PED	May 19, 2014				
	6194006	Dec 30, 2018	DP			
	6194006*PED	Jun 30, 2019				
	6368632	Nov 19, 2013			U-543	
	6368632*PED	May 19, 2014				
	6379703	Dec 30, 2018	DP			
	6379703*PED	Jun 30, 2019				
	6403114	May 02, 2017	DP			
	6403114*PED	Nov 02, 2017				
	6596316	Dec 30, 2018	DP			
	6596316*PED	Jun 30, 2019				
	6667061	May 25, 2020	DP			
	6667061*PED	Nov 25, 2020				
	7547452	Nov 19, 2013	DP			
	7547452*PED	May 19, 2014				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N021346 004	5688801	Nov 18, 2014				
	5688801	Nov 18, 2014				
	5688801*PED	May 18, 2015				
	5792477	May 02, 2017	DP			
	5792477*PED	Nov 02, 2017				
	5916598	May 02, 2017	DP			
	5916598*PED	Nov 02, 2017				
	5965168	Nov 19, 2013	DP			
	5965168*PED	May 19, 2014				
	6110921	Nov 19, 2013			U-543	
	6110921*PED	May 19, 2014				
	6194006	Dec 30, 2018	DP			
	6194006*PED	Jun 30, 2019				
	6368632	Nov 19, 2013			U-543	
	6368632*PED	May 19, 2014				
	6379703	Dec 30, 2018	DP			
	6379703*PED	Jun 30, 2019				
	6403114	May 02, 2017	DP			
	6403114*PED	Nov 02, 2017				
	6596316	Dec 30, 2018	DP			
	6596316*PED	Jun 30, 2019				
	7547452	Nov 19, 2013	DP			
	7547452*PED	May 19, 2014				
<u>RITONAVIR - NORVIR</u>						
N020659 001	5484801	Jan 28, 2014				
	5484801*PED	Jul 28, 2014				
	5541206	Jul 30, 2013			U-140	
	5541206*PED	Jan 30, 2014				
	5635523	Jul 30, 2013			U-190	
	5635523*PED	Jan 30, 2014				
	5648497	Jul 15, 2014				
	5648497*PED	Jan 15, 2015				
	5674882	Jul 30, 2013			U-688	
	5674882*PED	Jan 30, 2014				
	5948436	Sep 13, 2013	DP			
	5948436*PED	Mar 13, 2014				
	6037157	Jun 26, 2016				
	6037157*PED	Dec 26, 2016				
	6703403	Jun 26, 2016			U-564	
	6703403*PED	Dec 26, 2016				
<u>RITONAVIR - NORVIR</u>						
N020680 001	5541206	Jul 30, 2013			U-140	
	5541206*PED	Jan 30, 2014				
	5635523	Jun 03, 2014			U-190	
	5635523*PED	Dec 03, 2014				
	5648497	Jul 15, 2014				
	5648497*PED	Jan 15, 2015				
	5948436	Sep 13, 2013				
	5948436*PED	Mar 13, 2014				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RITONAVIR - NORVIR</u>						
N020945 001	5541206	Jul 30, 2013	U-348			
	5541206*PED	Jan 30, 2014				
	5635523	Jul 30, 2013	U-347			
	5635523*PED	Jan 30, 2014				
	5648497	Jul 15, 2014				
	5648497*PED	Jan 15, 2015				
	5674882	Jul 30, 2013	U-895			
	5674882*PED	Jan 30, 2014				
	5948436	Sep 13, 2013	DP			
	5948436*PED	Mar 13, 2014				
	6037157	Jun 26, 2016	U-895			
	6037157*PED	Dec 26, 2016				
	6232333	Nov 07, 2017				
	6232333*PED	May 07, 2018				
	6703403	Jun 26, 2016	U-564			
	6703403*PED	Dec 26, 2016				
	7141593	May 22, 2020	DP			
	7141593*PED	Nov 22, 2020				
	7432294	May 22, 2020	DP			
	7432294*PED	Nov 22, 2020				
<u>RITONAVIR - NORVIR</u>						
N022417 001	5541206	Jul 30, 2013	DS DP U-688			
	5541206*PED	Jan 30, 2014				
	5635523	Jul 30, 2013	U-688			
	5635523*PED	Jan 30, 2014				
	5648497	Jul 15, 2014	DS			
	5648497*PED	Jan 15, 2015				
	5674882	Jul 30, 2013	U-688			
	5674882*PED	Jan 30, 2014				
	6037157	Jun 26, 2016	U-688			
	6037157*PED	Dec 26, 2016				
	6703403	Jun 26, 2016	U-688			
	6703403*PED	Dec 26, 2016				
	7148359	Jul 19, 2019	DP			
	7148359*PED	Jan 19, 2020				
	7364752	Nov 10, 2020	DP U-688			
	7364752*PED	May 10, 2021				
	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				
<u>RIVAROXABAN - XARELTO</u>						
N022406 001	7157456	Feb 08, 2021	DS DP U-1302		I-662	Nov 02, 2015
	7157456	Feb 08, 2021	DS DP U-1301		I-661	Nov 02, 2015
	7585860	Dec 11, 2020	DS U-1303		I-660	Nov 02, 2015
	7592339	Dec 11, 2020	U-1302		NCE	Jul 01, 2016
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1167			
	7592339	Dec 11, 2020	U-1303			
	7592339	Dec 11, 2020				
<u>RIVAROXABAN - XARELTO</u>						
N022406 002	7157456	Feb 08, 2021	DS DP U-1302		I-662	Nov 02, 2015
	7157456	Feb 08, 2021	DS DP U-1301		I-661	Nov 02, 2015
	7585860	Dec 11, 2020	DS U-1303		I-660	Nov 02, 2015
	7592339	Dec 11, 2020	U-1303		I-643	Nov 04, 2014
	7592339	Dec 11, 2020	U-1302		NCE	Jul 01, 2016
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1167			
	7592339	Dec 11, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N022406 003	7157456	Feb 08, 2021	DS DP U-1302		I-662	Nov 02, 2015
	7157456	Feb 08, 2021	DS DP U-1301		I-661	Nov 02, 2015
	7585860	Dec 11, 2020	DS U-1303		I-660	Nov 02, 2015
	7592339	Dec 11, 2020	U-1302		I-643	Nov 04, 2014
	7592339	Dec 11, 2020	U-1303			
	7592339	Dec 11, 2020	U-1167		NCE	Jul 01, 2016
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1200			
<u>RIVASTIGMINE - EXELON</u>						
N022083 001	4948807	Aug 14, 2012	DS U-322			
	5602176	Feb 11, 2014	DS DP U-322			
	6316023	Jan 08, 2019	DP			
	6335031	Jan 08, 2019	DP			
<u>RIVASTIGMINE - EXELON</u>						
N022083 002	4948807	Aug 14, 2012	DS U-322			
	5602176	Feb 11, 2014	DS DP U-322			
	6316023	Jan 08, 2019	DP			
	6335031	Jan 08, 2019	DP			
<u>RIVASTIGMINE - EXELON</u>						
N022083 005	5602176	Feb 11, 2014	DS DP U-322		NS	Aug 31, 2015
	6316023	Jan 08, 2019	DP			
	6335031	Jan 08, 2019	DP			
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
N020823 003	4948807	Aug 14, 2012	DS U-322			
	5602176	Feb 11, 2014	U-322			
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
N020823 004	4948807	Aug 14, 2012	DS U-322			
	5602176	Feb 11, 2014	U-322			
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
N020823 005	4948807	Aug 14, 2012	DS U-322			
	5602176	Feb 11, 2014	U-322			
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
N020823 006	4948807	Aug 14, 2012	DS U-322			
	5602176	Feb 11, 2014	U-322			
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
N021025 001	4948807	Aug 14, 2012	DS U-322			
	5602176	Feb 11, 2014	U-322			
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 001	5298520*PED	Dec 29, 2012			NPP	Dec 15, 2014
	5602162*PED	Jul 28, 2012			PED	Jun 15, 2015
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 002	5298520*PED	Dec 29, 2012			NPP	Dec 15, 2014
	5602162*PED	Jul 28, 2012			PED	Jun 15, 2015
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 001	5298520*PED	Dec 29, 2012			NPP	Dec 15, 2014
	5457895	Oct 01, 2013	DP		PED	Jun 15, 2015
	5457895*PED	Apr 01, 2014				
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 002	5298520*PED	Dec 29, 2012			NPP	Dec 15, 2014
	5457895	Oct 01, 2013	DP		PED	Jun 15, 2015
	5457895*PED	Apr 01, 2014				
	5602162*PED	Jul 28, 2012				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES			PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE		
ROFECOXIB - VIOXX											
N021042 001	5474995	Jun	24,	2013	DS	DP	U-602				
	5474995*PED	Dec	24,	2013							
	5691374	May	18,	2015			U-602				
	5691374*PED	Nov	18,	2015							
	6063811	May	06,	2017	DS	DP	U-602				
	6063811*PED	Nov	06,	2017							
	6239173	Jun	24,	2013							
	6239173*PED	Dec	24,	2013							
ROFECOXIB - VIOXX											
N021042 002	5474995	Jun	24,	2013	DS	DP	U-602				
	5474995*PED	Dec	24,	2013							
	5691374	May	18,	2015			U-602				
	5691374*PED	Nov	18,	2015							
	6063811	May	06,	2017	DS	DP	U-602				
	6063811*PED	Nov	06,	2017							
	6239173	Jun	24,	2013							
	6239173*PED	Dec	24,	2013							
ROFECOXIB - VIOXX											
N021042 003	5474995	Jun	24,	2013	DS	DP	U-602				
	5474995*PED	Dec	24,	2013							
	5691374	May	18,	2015			U-602				
	5691374*PED	Nov	18,	2015							
	6063811	May	06,	2017	DS	DP	U-602				
	6063811*PED	Nov	06,	2017							
	6239173	Jun	24,	2013							
	6239173*PED	Dec	24,	2013							
ROFECOXIB - VIOXX											
N021052 001	5474995	Jun	24,	2013			U-266				
	5474995*PED	Dec	24,	2013							
	5691374	May	18,	2015			U-266				
	5691374*PED	Nov	18,	2015							
	6063811	May	06,	2017			U-266				
	6063811*PED	Nov	06,	2017							
	6239173	Jun	24,	2013							
	6239173*PED	Dec	24,	2013							
ROFECOXIB - VIOXX											
N021052 002	5474995	Jun	24,	2013			U-266				
	5474995*PED	Dec	24,	2013							
	5691374	May	18,	2015			U-266				
	5691374*PED	Nov	18,	2015							
	6063811	May	06,	2017			U-266				
	6063811*PED	Nov	06,	2017							
	6239173	Jun	24,	2013							
	6239173*PED	Dec	24,	2013							
ROFLUMILAST - DALIRESP											
N022522 001	5712298	Jan	27,	2015	DS	DP	U-1115	NCE	Feb	28,	2016
ROMIDEPSIN - ISTODAX											
N022393 001	4977138	Aug	22,	2013	DS	DP		NCE	Nov	05,	2014
	7608280	Aug	22,	2021	DS			ODE	Jun	16,	2018
	7611724	Aug	22,	2021	DS			ODE	Nov	05,	2016
ROPINIROLE HYDROCHLORIDE - REQUIP XL											
N022008 001	7927624	Dec	02,	2021		DP	U-20				
	8303986	Apr	12,	2021		DP					
ROPINIROLE HYDROCHLORIDE - REQUIP XL											
N022008 002	7927624	Dec	02,	2021		DP	U-20				
	8303986	Apr	12,	2021		DP					
ROPINIROLE HYDROCHLORIDE - REQUIP XL											
N022008 003	7927624	Dec	02,	2021		DP	U-20				
	8303986	Apr	12,	2021		DP					

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 004	7927624	Dec 02, 2021	DP U-20			
	8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 005	7927624	Dec 02, 2021	DP U-20			
	8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 006	7927624	Dec 02, 2021	DP U-20			
	8303986	Apr 12, 2021	DP			
<u>ROIIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N020533 001	5670524	May 26, 2014	DS DP U-833			
	5834489	May 26, 2014	DS DP U-838			
<u>ROIIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N020533 003	5670524	May 26, 2014	DS DP U-833			
	5834489	May 26, 2014	DS DP U-838			
<u>ROIIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N020533 004	5670524	May 26, 2014	DS DP U-833			
	5834489	May 26, 2014	DS DP U-838			
<u>ROIIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N020533 005	5670524	May 26, 2014	DS DP U-833			
	5834489	May 26, 2014	DS DP U-838			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N021071 002	5741803	Apr 21, 2015	DS DP U-628		Y	
	5741803	Apr 21, 2015	DS DP U-329		Y	
	5741803*PED	Oct 21, 2015				
	6288095	Feb 11, 2017			U-420	Y
	6288095*PED	Aug 11, 2017				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N021071 003	5741803	Apr 21, 2015	DS DP U-329		Y	
	5741803	Apr 21, 2015	DS DP U-628		Y	
	5741803*PED	Oct 21, 2015				
	6288095	Feb 11, 2017			U-420	Y
	6288095*PED	Aug 11, 2017				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N021071 004	5741803	Apr 21, 2015	DS DP U-329		Y	
	5741803	Apr 21, 2015	DS DP U-628		Y	
	5741803*PED	Oct 21, 2015				
	6288095	Feb 11, 2017			U-420	Y
	6288095*PED	Aug 11, 2017				
	7358366	Apr 19, 2020	DS			
	7358366*PED	Oct 19, 2020				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 002	6316460	Aug 04, 2020	DP		I-621	Feb 08, 2013
	6316460*PED	Feb 04, 2021			I-611	Oct 16, 2012
	6858618	Dec 17, 2021			PED	Apr 16, 2013
	6858618*PED	Jun 17, 2022				
	7030152	Apr 02, 2018			U-1032	
	7030152*PED	Oct 02, 2018				
	7964614	Apr 02, 2018			U-1032	
	7964614*PED	Oct 02, 2018				
	RE37314	Jan 08, 2016	DS			
	RE37314*PED	Jul 08, 2016				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 003	6316460	Aug 04, 2020	DP		I-621	Feb 08, 2013
	6316460*PED	Feb 04, 2021			I-611	Oct 16, 2012
	6858618	Dec 17, 2021	U-618		PED	Apr 16, 2013
	6858618*PED	Jun 17, 2022				
	7030152	Apr 02, 2018	U-1032			
	7030152*PED	Oct 02, 2018				
	7964614	Apr 02, 2018	U-1032			
	7964614*PED	Oct 02, 2018				
	RE37314	Jan 08, 2016	DS			
	RE37314*PED	Jul 08, 2016				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 004	6316460	Aug 04, 2020	DP		I-621	Feb 08, 2013
	6316460*PED	Feb 04, 2021			I-611	Oct 16, 2012
	6858618	Dec 17, 2021	U-618		PED	Apr 16, 2013
	6858618*PED	Jun 17, 2022				
	7030152	Apr 02, 2018	U-1032			
	7030152*PED	Oct 02, 2018				
	7964614	Apr 02, 2018	U-1032			
	7964614*PED	Oct 02, 2018				
	RE37314	Jan 08, 2016	DS			
	RE37314*PED	Jul 08, 2016				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 005	6316460	Aug 04, 2020	DP		I-621	Feb 08, 2013
	6316460*PED	Feb 04, 2021			I-611	Oct 16, 2012
	6858618	Dec 17, 2021	U-618		PED	Apr 16, 2013
	6858618*PED	Jun 17, 2022				
	7030152	Apr 02, 2018	U-1032			
	7030152*PED	Oct 02, 2018				
	7964614	Apr 02, 2018	U-1032			
	7964614*PED	Oct 02, 2018				
	RE37314	Jan 08, 2016	DS			
	RE37314*PED	Jul 08, 2016				
<u>ROTIGOTINE - NEUPRO</u>						
N021829 001	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1273			
	8246979	Sep 01, 2027	DP U-1272			
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 002	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 003	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1273			
	8246979	Sep 01, 2027	DP U-1272			
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 004	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1273			
	8246979	Sep 01, 2027	DP U-1272			
	8246980	Nov 27, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N021829 005	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP	U-1272		
	8246979	Sep 01, 2027	DP	U-1273		
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 006	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP	U-1273		
	8246979	Sep 01, 2027	DP	U-1272		
	8246980	Nov 27, 2025	DP			
<u>RUFINAMIDE - BANZEL</u>						
N021911 001	6740669	Nov 14, 2022	DS DP		NCE	Nov 14, 2013
	7750028	Oct 19, 2018		U-106	ODE	Nov 14, 2015
	8076362	Jun 08, 2018	DP			
<u>RUFINAMIDE - BANZEL</u>						
N021911 002	6740669	Nov 14, 2022	DS DP		NCE	Nov 14, 2013
	7750028	Oct 19, 2018		U-106	ODE	Nov 14, 2015
	8076362	Jun 08, 2018	DP			
<u>RUFINAMIDE - BANZEL</u>						
N021911 003	6740669	Nov 14, 2022	DS DP		NCE	Nov 14, 2013
	7750028	Oct 19, 2018		U-106	ODE	Nov 14, 2015
	8076362	Jun 08, 2018	DP			
<u>RUFINAMIDE - BANZEL</u>						
N201367 001	6740669	Nov 14, 2022	DS DP		NCE	Nov 14, 2013
	7750028	Oct 19, 2018		U-106	ODE	Nov 14, 2015
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 001	7598257	Dec 24, 2027	DS DP	U-1201	NCE	Nov 16, 2016
					ODE	Nov 16, 2018
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 002	7598257	Dec 24, 2027	DS DP	U-1201	NCE	Nov 16, 2016
					ODE	Nov 16, 2018
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 003	7598257	Dec 24, 2027	DS DP	U-1201	NCE	Nov 16, 2016
					ODE	Nov 16, 2018
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 004	7598257	Dec 24, 2027	DS DP	U-1201	NCE	Nov 16, 2016
					ODE	Nov 16, 2018
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 005	7598257	Dec 24, 2027	DS DP	U-1201	NCE	Nov 16, 2016
					ODE	Nov 16, 2018
<u>SALMETEROL XINAFOATE - SEREVENT</u>						
N020692 001	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N022181 001	7566462	Nov 16, 2025	DP		NCE	Dec 13, 2012
	7566714	Nov 17, 2024		U-989	ODE	Dec 13, 2014
	7612073	Nov 17, 2024		U-1010		
	7727987	Nov 17, 2024	DP			
	7947681	Nov 17, 2024		U-1156		
	8003126	Nov 16, 2025				
	8067416	Nov 17, 2024		U-989		
	RE43797	Nov 17, 2024		U-1156		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SAQUINAVIR - FORTOVASE</u>						
N020828 001	6008228	Jun 06, 2015				
	6008228*PED	Dec 06, 2015				
	6352717	Nov 16, 2019				
	6352717*PED	May 16, 2020				
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N022350 001	6395767	Feb 16, 2021	DS DP U-995		M-108	Dec 16, 2014
	7951400	Nov 30, 2028	DP		NCE	Jul 31, 2014
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N022350 002	6395767	Feb 16, 2021	DS DP U-995		M-108	Dec 16, 2014
	7951400	Nov 30, 2028	DP		NCE	Jul 31, 2014
<u>SELEGILINE - EMSAM</u>						
N021336 001	7070808	May 10, 2018	DS DP			
	7150881	Jun 12, 2018	DS DP			
	7638140	May 10, 2018	DP			
<u>SELEGILINE - EMSAM</u>						
N021336 002	7070808	May 10, 2018	DS DP			
	7150881	Jun 12, 2018	DS DP			
	7638140	May 10, 2018	DP			
<u>SELEGILINE - EMSAM</u>						
N021336 003	7070808	May 10, 2018	DS DP			
	7150881	Jun 12, 2018	DS DP			
	7638140	May 10, 2018	DP			
<u>SELEGILINE HYDROCHLORIDE - ZELAPAR</u>						
N021479 001	5648093	Jul 15, 2014	DP			
	6423342	Mar 01, 2016	DP			
<u>SERTACONAZOLE NITRATE - ERTACZO</u>						
N021385 001	5135943	May 31, 2014	DS DP U-786			
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N019839 001	5248699	Aug 13, 2012				
	5248699*PED	Feb 13, 2013				
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N019839 002	5248699	Aug 13, 2012				
	5248699*PED	Feb 13, 2013				
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N019839 003	5248699	Aug 13, 2012				
	5248699*PED	Feb 13, 2013				
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N019839 004	5248699	Aug 13, 2012				
	5248699*PED	Feb 13, 2013				
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N019839 005	5248699	Aug 13, 2012				
	5248699*PED	Feb 13, 2013				
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N020990 001	5248699	Aug 13, 2012				
	5248699*PED	Feb 13, 2013				
	6727283	Oct 11, 2019	DP U-580			
	6727283*PED	Apr 11, 2020				
	7067555	Nov 10, 2019	DP			
	7067555*PED	May 10, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SEVELAMER CARBONATE - RENVELA</u>						
N022127 001	5496545	Aug 11, 2013	DP U-246			
	5667775	Sep 16, 2014	U-246			
	6509013	Aug 11, 2013	DP			
	6858203	Aug 11, 2013	DP U-246			
	7014846	Aug 11, 2013	DP U-246			
	7459151	Aug 11, 2013	U-246			
	7985418	Oct 27, 2025	DP			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N022318 001	5496545	Aug 11, 2013	DP U-246		NDF	Aug 12, 2012
	5667775	Sep 16, 2014	U-246			
	6509013	Aug 11, 2013	DP			
	6858203	Aug 11, 2013	DP U-246			
	7014846	Aug 11, 2013	DP U-246			
	7459151	Aug 11, 2013	U-246			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N022318 002	5496545	Aug 11, 2013	DP U-246		NDF	Aug 12, 2012
	5667775	Sep 16, 2014	U-246			
	6509013	Aug 11, 2013	DP			
	6858203	Aug 11, 2013	DP U-246			
	7014846	Aug 11, 2013	DP U-246			
	7459151	Aug 11, 2013	U-246			
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N020926 001	5496545	Aug 11, 2013	U-246			
	5667775	Sep 16, 2014	U-246			
	6509013	Aug 11, 2013				
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N021179 001	5496545	Aug 11, 2013	U-246			
	5667775	Sep 16, 2014	U-246			
	6509013	Aug 11, 2013				
	6733780	Oct 18, 2020	DP			
	7014846	Aug 11, 2013	DP U-246			
	7459151	Aug 11, 2013	U-246			
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N021179 002	5496545	Aug 11, 2013	U-246			
	5667775	Sep 16, 2014	U-246			
	6509013	Aug 11, 2013				
	6733780	Oct 18, 2020	DP			
	7014846	Aug 11, 2013	DP U-246			
	7459151	Aug 11, 2013	U-246			
<u>SEVOFLURANE - ULTANE</u>						
N020478 001	5990176	Jan 27, 2017				
	5990176*PED	Jul 27, 2017				
	6074668	Jan 09, 2018				
	6074668*PED	Jul 09, 2018				
	6288127	Jan 27, 2017				
	6288127*PED	Jul 27, 2017				
	6444859	Jan 27, 2017				
	6444859*PED	Jul 27, 2017				
<u>SIBUTRAMINE HYDROCHLORIDE - MERIDIA</u>						
N020632 001	5436272	Jul 25, 2012	U-439			
	5436272*PED	Jan 25, 2013				
<u>SIBUTRAMINE HYDROCHLORIDE - MERIDIA</u>						
N020632 002	5436272	Jul 25, 2012	U-439			
	5436272*PED	Jan 25, 2013				
<u>SIBUTRAMINE HYDROCHLORIDE - MERIDIA</u>						
N020632 003	5436272	Jul 25, 2012	U-439			
	5436272*PED	Jan 25, 2013				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SILDENAFIL CITRATE - REVATIO</u>						
N021845 001	5250534*PED	Sep 27, 2012			M-61 PED PED	Aug 30, 2015 Mar 01, 2016 Nov 07, 2012
<u>SILDENAFIL CITRATE - REVATIO</u>						
N022473 001	5250534*PED	Sep 27, 2012			M-61 NDF PED PED	Aug 30, 2015 Nov 20, 2012 Mar 01, 2016 May 20, 2013
<u>SILDENAFIL CITRATE - REVATIO</u>						
N203109 001					NDF PED	Aug 30, 2015 Mar 01, 2016
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 001	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019		U-155		
	6469012*PED	Apr 22, 2020				
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 002	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019		U-155		
	6469012*PED	Apr 22, 2020				
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 003	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019		U-155		
	6469012*PED	Apr 22, 2020				
<u>SILODOSIN - RAPAFLO</u>						
N022206 001	5387603	Dec 01, 2018	DS DP		NCE	Oct 08, 2013
	5403847	Nov 13, 2012		U-902		
	5780485	Nov 13, 2012		U-902		
	6015819	Nov 13, 2012		U-902		
<u>SILODOSIN - RAPAFLO</u>						
N022206 002	5387603	Dec 01, 2018	DS DP		NCE	Oct 08, 2013
	5403847	Nov 13, 2012		U-902		
	5780485	Nov 13, 2012		U-902		
	6015819	Nov 13, 2012		U-902		
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 001	6303661	Apr 24, 2017		U-1188		
	6699871	Jul 26, 2022	DS DP	U-1188		
	6890898	Feb 02, 2019		U-1189		
	6890898	Feb 02, 2019		U-1191		
	6890898	Feb 02, 2019		U-1190		
	7078381	Feb 02, 2019		U-1188		
	7125873	Jul 26, 2022	DP	U-1193		
	7125873	Jul 26, 2022	DP	U-1189		
	7125873	Jul 26, 2022	DP	U-1192		
	7125873	Jul 26, 2022	DP	U-1190		
	7326708	Apr 11, 2026	DS DP	U-1188		
	7459428	Feb 02, 2019		U-1189		
	8168637	Jun 26, 2022	DP	U-1188		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 002	6303661	Apr 24, 2017				U-1188
	6699871	Jul 26, 2022	DS DP			U-1188
	6890898	Feb 02, 2019				U-1191
	6890898	Feb 02, 2019				U-1190
	6890898	Feb 02, 2019				U-1189
	7078381	Feb 02, 2019				U-1188
	7125873	Jul 26, 2022	DP			U-1190
	7125873	Jul 26, 2022	DP			U-1192
	7125873	Jul 26, 2022	DP			U-1193
	7125873	Jul 26, 2022	DP			U-1189
	7326708	Apr 11, 2026	DS DP			U-1188
	7459428	Feb 02, 2019				U-1189
	8168637	Jun 26, 2022	DP			U-1188
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 003	6303661	Apr 24, 2017				U-1188
	6699871	Jul 26, 2022	DS DP			U-1188
	6890898	Feb 02, 2019				U-1189
	6890898	Feb 02, 2019				U-1190
	6890898	Feb 02, 2019				U-1191
	7078381	Feb 02, 2019				U-1188
	7125873	Jul 26, 2022	DP			U-1193
	7125873	Jul 26, 2022	DP			U-1192
	7125873	Jul 26, 2022	DP			U-1190
	7125873	Jul 26, 2022	DP			U-1189
	7326708	Apr 11, 2026	DS DP			U-1188
	7459428	Feb 02, 2019				U-1189
	8168637	Jun 26, 2022	DP			U-1188
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 004	6303661	Apr 24, 2017				U-1188
	6699871	Jul 26, 2022	DS DP			U-1188
	6890898	Feb 02, 2019				U-1190
	6890898	Feb 02, 2019				U-1191
	6890898	Feb 02, 2019				U-1189
	7078381	Feb 02, 2019				U-1188
	7125873	Jul 26, 2022	DP			U-1190
	7125873	Jul 26, 2022	DP			U-1192
	7125873	Jul 26, 2022	DP			U-1193
	7125873	Jul 26, 2022	DP			U-1189
	7326708	Apr 11, 2026	DS DP			U-1188
	7459428	Feb 02, 2019				U-1189
	8168637	Jun 26, 2022	DP			U-1188
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 005	6303661	Apr 24, 2017				U-1188
	6699871	Jul 26, 2022	DS DP			U-1188
	6890898	Feb 02, 2019				U-1189
	6890898	Feb 02, 2019				U-1191
	6890898	Feb 02, 2019				U-1190
	7078381	Feb 02, 2019				U-1188
	7125873	Jul 26, 2022	DP			U-1190
	7125873	Jul 26, 2022	DP			U-1192
	7125873	Jul 26, 2022	DP			U-1193
	7125873	Jul 26, 2022	DP			U-1189
	7326708	Apr 11, 2026	DS DP			U-1188
	7459428	Feb 02, 2019				U-1189
	8168637	Jun 26, 2022	DP			U-1188

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 006	6303661	Apr 24, 2017				U-1188
	6699871	Jul 26, 2022	DS DP			U-1188
	6890898	Feb 02, 2019				U-1189
	6890898	Feb 02, 2019				U-1190
	6890898	Feb 02, 2019				U-1191
	7078381	Feb 02, 2019				U-1188
	7125873	Jul 26, 2022	DP			U-1189
	7125873	Jul 26, 2022	DP			U-1193
	7125873	Jul 26, 2022	DP			U-1192
	7125873	Jul 26, 2022	DP			U-1190
	7326708	Apr 11, 2026	DS DP			U-1188
	7459428	Feb 02, 2019				U-1189
	8168637	Jun 26, 2022	DP			U-1188
<u>SINCALIDE - KINEVAC</u>						
N017697 001	6803046	Aug 16, 2022	DP			
<u>SINECATECHINS - VEREGEN</u>						
N021902 001	5795911	Oct 31, 2020				U-172
	5968973	Apr 10, 2017				U-172
	7858662	Oct 02, 2026	DP			U-172
<u>SIROLIMUS - RAPAMUNE</u>						
N021083 001	5100899	Jul 07, 2013				U-290
	5100899*PED	Jan 07, 2014				
	5403833*PED	Oct 04, 2012				
	5536729	Sep 30, 2013	DP			
	5536729*PED	Mar 30, 2014				
<u>SIROLIMUS - RAPAMUNE</u>						
N021110 001	5100899	Jul 07, 2013				U-290
	5100899*PED	Jan 07, 2014				
	5403833*PED	Oct 04, 2012				
	5989591	Mar 11, 2018	DP			
	5989591*PED	Sep 11, 2018				
<u>SIROLIMUS - RAPAMUNE</u>						
N021110 002	5100899	Jul 07, 2013				U-290
	5100899*PED	Jan 07, 2014				
	5403833*PED	Oct 04, 2012				
	5989591	Mar 11, 2018	DP			
	5989591*PED	Sep 11, 2018				
<u>SIROLIMUS - RAPAMUNE</u>						
N021110 003	5100899	Jul 07, 2013				U-290
	5100899*PED	Jan 07, 2014				
	5403833*PED	Oct 04, 2012				
	5989591	Mar 11, 2018	DP			
	5989591*PED	Sep 11, 2018				
<u>SIROLIMUS - RAPAMUNE</u>						
N021110 004	5100899	Jul 07, 2013				U-290
	5100899*PED	Jan 07, 2014				
	5403833*PED	Oct 04, 2012				
	5989591	Mar 11, 2018	DP			
	5989591*PED	Sep 11, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
SITAGLIPTIN PHOSPHATE - JANUVIA									
N021995 001	6303661	Apr	24,	2017	DS DP		U-774		
	6699871	Jul	26,	2022			U-774		
	6890898	Feb	02,	2019			U-1039		
	6890898	Feb	02,	2019			U-775		
	6890898	Feb	02,	2019			U-1036		
	7078381	Feb	02,	2019			U-775		
	7078381	Feb	02,	2019			U-1037		
	7078381	Feb	02,	2019			U-1036		
	7078381	Feb	02,	2019			U-1038		
	7125873	Jul	26,	2022			U-1037		
	7125873	Jul	26,	2022			U-1036		
	7125873	Jul	26,	2022			U-775		
	7125873	Jul	26,	2022			U-1038		
	7326708	Apr	11,	2026			U-802		
	SITAGLIPTIN PHOSPHATE - JANUVIA								
N021995 002	6303661	Apr	24,	2017	DS DP		U-774		
	6699871	Jul	26,	2022			U-774		
	6890898	Feb	02,	2019			U-1036		
	6890898	Feb	02,	2019			U-775		
	6890898	Feb	02,	2019			U-1039		
	7078381	Feb	02,	2019			U-775		
	7078381	Feb	02,	2019			U-1037		
	7078381	Feb	02,	2019			U-1038		
	7078381	Feb	02,	2019			U-1036		
	7125873	Jul	26,	2022			U-775		
	7125873	Jul	26,	2022			U-1038		
	7125873	Jul	26,	2022			U-1037		
	7125873	Jul	26,	2022			U-1036		
	7326708	Apr	11,	2026			U-802		
	SITAGLIPTIN PHOSPHATE - JANUVIA								
N021995 003	6303661	Apr	24,	2017	DS DP		U-774		
	6699871	Jul	26,	2022			U-774		
	6890898	Feb	02,	2019			U-775		
	6890898	Feb	02,	2019			U-1036		
	6890898	Feb	02,	2019			U-1039		
	7078381	Feb	02,	2019			U-1038		
	7078381	Feb	02,	2019			U-1036		
	7078381	Feb	02,	2019			U-1037		
	7078381	Feb	02,	2019			U-775		
	7125873	Jul	26,	2022			U-1038		
	7125873	Jul	26,	2022			U-1036		
	7125873	Jul	26,	2022			U-775		
	7125873	Jul	26,	2022			U-1037		
	7326708	Apr	11,	2026			U-802		
	SODIUM NITRITE - SODIUM NITRITE								
N203922 001							ODE	Jan	14, 2018
SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE									
N201444 001							ODE	Jan	14, 2018
SODIUM OXYBATE - XYREM									
N021196 001	6780889	Jul	04,	2020	DP DP		ODE	Nov	18, 2012
	7262219	Jul	04,	2020					
	7668730	Jun	16,	2024			U-1110		
	7765106	Jun	16,	2024			U-1069		
	7765107	Jun	16,	2024			U-1070		
	7851506	Dec	22,	2019			U-1102		
	7851506	Dec	22,	2019			U-1101		
	7895059	Dec	17,	2022			U-1110		
	8263650	Dec	22,	2019			U-1102		
	8263650	Dec	22,	2019			U-1101		
	8324275	Dec	22,	2019			U-1102		
	8324275	Dec	22,	2019			U-1101		
	SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - VISICOL								
N021097 001	5616346	May	18,	2013			U-359		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u>						
N021892 001	5616346	May 18, 2013	DP	U-715		
	7687075	Jun 22, 2028	DS DP			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N203923 001					ODE	Jan 14, 2018
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N021518 001	6017927	Nov 19, 2018	DS DP			
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N021518 002	6017927	Nov 19, 2018	DS DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 001	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 002	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 003	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 005	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 008	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 009	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 010	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 011	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 012	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N020280 013	5435076	Apr 16, 2013	DP			
	5501673	Apr 16, 2013	DP			
	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
N019640 001					ODE	Nov 01, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
N019640	004				ODE	Nov 01, 2013
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
N019640	005				ODE	Nov 01, 2013
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
N019640	006				ODE	Nov 01, 2013
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
N019640	007				ODE	Nov 01, 2013
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N021148	001	5849700	Dec 15, 2015	U-340	ODE	May 31, 2014
		5849704	Dec 15, 2015			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N021148	002	5849700	Dec 15, 2015	U-340	ODE	May 31, 2014
		5849704	Dec 15, 2015			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N021148	003	5633352	May 27, 2014		ODE	May 31, 2014
		5849700	Dec 15, 2015	U-340		
		5849704	Dec 15, 2015			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXP</u>						
N021148	008	5849700	Dec 15, 2015	U-1041	ODE	May 31, 2014
		5849704	Dec 15, 2015	DP U-1041		
		6716198	Jun 05, 2021	DP		
		6899699	Jan 02, 2022	DP		
		7686786	Aug 03, 2026	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXP</u>						
N021148	009	5849700	Dec 15, 2015	U-1041	ODE	May 31, 2014
		5849704	Dec 15, 2015	DP U-1041		
		6716198	Jun 05, 2021	DP		
		6899699	Jan 02, 2022	DP		
		7686786	Aug 03, 2026	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXP</u>						
N021148	010	5849700	Dec 15, 2015	U-1041	ODE	May 31, 2014
		5849704	Dec 15, 2015	DP U-1041		
		6716198	Jun 05, 2021	DP		
		6899699	Jan 02, 2022	DP		
		7686786	Aug 03, 2026	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N021148	004	5849700	Dec 15, 2015	U-340	ODE	May 31, 2014
		5849704	Dec 15, 2015	DP U-340		
		6004297	Jan 28, 2019	DP		
		6235004	Jan 28, 2019	DP		
		RE41956	Jan 21, 2021	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N021148	005	5849700	Dec 15, 2015	U-340	ODE	May 31, 2014
		5849704	Dec 15, 2015	DP U-340		
		6004297	Jan 28, 2019	DP		
		6235004	Jan 28, 2019	DP		
		RE41956	Jan 21, 2021	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N021148	006	5849700	Dec 15, 2015	U-340	ODE	May 31, 2014
		5849704	Dec 15, 2015	DP U-340		
		6004297	Jan 28, 2019	DP		
		6235004	Jan 28, 2019	DP		
		RE41956	Jan 21, 2021	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N021148 007	5849700	Dec 15, 2015		U-340	ODE	May 31, 2014
	5849704	Dec 15, 2015	DP	U-340		
	6004297	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>SOMATROPIN RECOMBINANT - NUTROPIN AQ</u>						
N020522 001	5763394	Jun 09, 2015	DP			
<u>SOMATROPIN RECOMBINANT - NUTROPIN AQ PEN</u>						
N020522 002	5763394	Jun 09, 2015	DP			
<u>SOMATROPIN RECOMBINANT - NUTROPIN DEPOT</u>						
N021075 001	5654010	Aug 05, 2014				
	5656297	Jul 25, 2014				
	6051259	Dec 02, 2012		U-340		
<u>SOMATROPIN RECOMBINANT - NUTROPIN DEPOT</u>						
N021075 002	5654010	Aug 05, 2014				
	5656297	Jul 25, 2014				
	6051259	Dec 02, 2012		U-340		
<u>SOMATROPIN RECOMBINANT - NUTROPIN DEPOT</u>						
N021075 003	5654010	Aug 05, 2014				
	5656297	Jul 25, 2014				
	6051259	Dec 02, 2012		U-340		
<u>SOMATROPIN RECOMBINANT - SAIZEN</u>						
N019764 002	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SAIZEN</u>						
N019764 003	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N020604 001	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N020604 002	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N020604 003	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N020604 004	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - ZORBTIVE</u>						
N021597 004	5898030	Apr 27, 2016	DP			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N021923 001	7235576	Jan 12, 2020	DS DP		ODE	Nov 16, 2014
	7351834	Jan 12, 2020	DS		ODE	Dec 20, 2012
	7897623	Jan 12, 2020	DP			
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N022306 001					ODE	Jul 02, 2016
<u>SPINOSAD - NATROBA</u>						
N022408 001	5496931	Mar 05, 2013	DS	U-1105	NCE	Jan 18, 2016
	6063771	Jun 22, 2019	DP	U-1105		
	6342482	Jun 22, 2019	DP	U-1105		
	7030095	Jul 02, 2021	DP	U-1105		
<u>STAVUDINE - ZERIT XR</u>						
N021453 001	7135465	Feb 18, 2023	DP	U-167		
	7135465*PED	Aug 18, 2023				
<u>STAVUDINE - ZERIT XR</u>						
N021453 002	7135465	Feb 18, 2023	DP	U-167		
	7135465*PED	Aug 18, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>STAVUDINE - ZERIT XR</u>						
N021453 003	7135465	Feb 18, 2023	DP U-167			
	7135465*PED	Aug 18, 2023				
<u>STAVUDINE - ZERIT XR</u>						
N021453 004	7135465	Feb 18, 2023	DP U-167			
	7135465*PED	Aug 18, 2023				
<u>SUMATRIPTAN - IMITREX</u>						
N020626 001	5307953	Dec 02, 2012				
	5307953*PED	Jun 02, 2013				
	5554639	Sep 10, 2013	U-232			
	5554639*PED	Mar 10, 2014				
<u>SUMATRIPTAN - IMITREX</u>						
N020626 002	5307953	Dec 02, 2012				
	5307953*PED	Jun 02, 2013				
	5554639	Sep 10, 2013	U-232			
	5554639*PED	Mar 10, 2014				
<u>SUMATRIPTAN - IMITREX</u>						
N020626 003	5307953	Dec 02, 2012				
	5307953*PED	Jun 02, 2013				
	5554639	Sep 10, 2013	U-232			
	5554639*PED	Mar 10, 2014				
<u>SUMATRIPTAN SUCCINATE - ALSUMA</u>						
N022377 001	7811254	Aug 26, 2027	DP U-1083			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	5891086	Jul 27, 2014	DP			
	5957886	Mar 08, 2016	DP			
	6135979	Mar 21, 2017	DP			
	7776007	Nov 22, 2026	DP			
	7901385	Jul 31, 2026	DP			
	8118771	Aug 10, 2023	DP			
	8241243	Dec 25, 2025	DP			
	8241244	Nov 21, 2022	DP			
	8267903	Mar 18, 2023	DP			
	8287489	Dec 06, 2024	DP			
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 001	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 002	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 003	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 004	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>TACROLIMUS - PROGRAF</u>						
N050708 001					ODE	Mar 29, 2013
<u>TACROLIMUS - PROGRAF</u>						
N050708 002					ODE	Mar 29, 2013
<u>TACROLIMUS - PROGRAF</u>						
N050708 003					ODE	Mar 29, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - PROGRAF</u>						
N050709	001				ODE	Mar 29, 2013
<u>TACROLIMUS - PROTOPIC</u>						
N050777	001 5665727	Sep 09, 2014	U-919			
<u>TACROLIMUS - PROTOPIC</u>						
N050777	002 5665727	Sep 09, 2014	U-919			
<u>TADALAFIL - ADCIRCA</u>						
N022332	001 5859006	Nov 21, 2017	DS DP U-975		ODE	May 22, 2016
	6821975	Nov 19, 2020	DS DP			
	7182958	Apr 26, 2020	DP			
<u>TADALAFIL - CIALIS</u>						
N021368	001 5859006	Nov 21, 2017	DS DP		I-642	Oct 06, 2014
	6140329	Jul 11, 2016	DP U-1184		I-641	Oct 06, 2014
	6140329	Jul 11, 2016	DP U-155			
	6821975	Nov 19, 2020	DS DP U-1184			
	6821975	Nov 19, 2020	DS DP U-614			
	6821975	Nov 19, 2020	DS DP U-533			
	6943166	Apr 26, 2020	U-614			
	6943166	Apr 26, 2020	U-1184			
	6943166	Apr 26, 2020	U-155			
	7182958	Apr 26, 2020	DP U-1184			
	7182958	Apr 26, 2020	DP U-155			
<u>TADALAFIL - CIALIS</u>						
N021368	002 5859006	Nov 21, 2017	DS DP		I-642	Oct 06, 2014
	6140329	Jul 11, 2016	DP U-155		I-641	Oct 06, 2014
	6821975	Nov 19, 2020	DS DP U-614			
	6821975	Nov 19, 2020	DS DP U-533			
	6943166	Apr 26, 2020	U-155			
	6943166	Apr 26, 2020	U-614			
	7182958	Apr 26, 2020	DP U-155			
<u>TADALAFIL - CIALIS</u>						
N021368	003 5859006	Nov 21, 2017	DS DP		I-642	Oct 06, 2014
	6140329	Jul 11, 2016	DP U-155		I-641	Oct 06, 2014
	6821975	Nov 19, 2020	DS DP U-614			
	6821975	Nov 19, 2020	DS DP U-533			
	6943166	Apr 26, 2020	U-614			
	7182958	Apr 26, 2020	DP U-155			
<u>TADALAFIL - CIALIS</u>						
N021368	004 5859006	Nov 21, 2017	DS DP		I-642	Oct 06, 2014
	6140329	Jul 11, 2016	DP U-155		I-641	Oct 06, 2014
	6821975	Nov 19, 2020	DS DP U-614			
	6821975	Nov 19, 2020	DS DP U-533			
	6943166	Apr 26, 2020	U-155			
	7182958	Apr 26, 2020	DP U-155			
<u>TAFLUPROST - ZIOPTAN</u>						
N202514	001 5886035	Dec 18, 2017	DS DP U-778		NCE	Feb 10, 2017
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N022458	001 8227230	Feb 24, 2024	DS DP		NCE	May 01, 2017
<u>TAMOXIFEN CITRATE - SOLTAMOX</u>						
N021807	001 6127425	Jun 26, 2018	DP			
<u>TAMSULOSIN HYDROCHLORIDE - FLOMAX</u>						
N020579	001				M-54 PED	Dec 22, 2012 Jun 22, 2013
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304	001 6071970	Jun 06, 2017	U-931		NCE	Nov 20, 2013
	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304 002	6071970	Jun 06, 2017		U-931	NCE	Nov 20, 2013
	7994364	Jun 27, 2025	DS DP	U-931		
	RE39593	Aug 05, 2022	DS DP	U-931		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304 003	6071970	Jun 06, 2017		U-931	NCE	Nov 20, 2013
	7994364	Jun 27, 2025	DS DP	U-931		
	RE39593	Aug 05, 2022	DS DP	U-931		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N203794 001	6071970	Jun 06, 2017		U-1289	NCE	Nov 20, 2013
	7994364	Jun 27, 2025	DS DP	U-1289		
	RE39593	Aug 05, 2022	DS DP	U-1289		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 001	6071970	Jun 06, 2017		U-1276	I-656	Aug 28, 2015
	6071970	Jun 06, 2017		U-1178	NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP	U-1178	NCE	Nov 20, 2013
	7994364	Jun 27, 2025	DS DP	U-1276		
	8075872	Nov 20, 2023		DP		
	8114383	Oct 10, 2024		DP		
	8309060	Nov 20, 2023		DP U-1178		
	8309060	Nov 20, 2023		DP U-1276		
	RE39593	Aug 05, 2022	DS DP	U-1178		
	RE39593	Aug 05, 2022	DS DP	U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 002	6071970	Jun 06, 2017		U-1178	I-656	Aug 28, 2015
	6071970	Jun 06, 2017		U-1276	NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP	U-1178	NCE	Nov 20, 2013
	7994364	Jun 27, 2025	DS DP	U-1276		
	8075872	Nov 20, 2023		DP		
	8114383	Oct 10, 2024		DP		
	8309060	Nov 20, 2023		DP U-1276		
	8309060	Nov 20, 2023		DP U-1178		
	RE39593	Aug 05, 2022	DS DP	U-1276		
	RE39593	Aug 05, 2022	DS DP	U-1178		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 003	6071970	Jun 06, 2017		U-1276	I-656	Aug 28, 2015
	6071970	Jun 06, 2017		U-1178	NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP	U-1276	NCE	Nov 20, 2013
	7994364	Jun 27, 2025	DS DP	U-1178		
	8075872	Nov 20, 2023		DP		
	8114383	Oct 10, 2024		DP		
	8309060	Nov 20, 2023		DP U-1178		
	8309060	Nov 20, 2023		DP U-1276		
	RE39593	Aug 05, 2022	DS DP	U-1276		
	RE39593	Aug 05, 2022	DS DP	U-1178		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 004	6071970	Jun 06, 2017		U-1276	I-656	Aug 28, 2015
	6071970	Jun 06, 2017		U-1178	NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP	U-1178	NCE	Nov 20, 2013
	7994364	Jun 27, 2025	DS DP	U-1276		
	8075872	Nov 20, 2023		DP		
	8114383	Oct 10, 2024		DP		
	8309060	Nov 20, 2023		DP U-1276		
	8309060	Nov 20, 2023		DP U-1178		
	RE39593	Aug 05, 2022	DS DP	U-1178		
	RE39593	Aug 05, 2022	DS DP	U-1276		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533	005	6071970			I-656	Aug 28, 2015
		6071970			NDF	Aug 25, 2014
		7994364	DS DP	U-1178	NCE	Nov 20, 2013
		7994364	DS DP	U-1276		
		8075872		DP		
		8114383		DP		
		8309060		DP	U-1276	
		8309060		DP	U-1178	
		RE39593	DS DP	U-1178		
		RE39593	DS DP	U-1276		
<u>TAZAROTENE - FABIOR</u>						
N202428	001				NDF	May 11, 2015
<u>TAZAROTENE - TAZORAC</u>						
N020600	001	5914334		U-517		
		6258830		U-517		
<u>TAZAROTENE - TAZORAC</u>						
N020600	002	5914334		U-517		
		6258830		U-517		
<u>TECHNETIUM TC-99M APCITIDE - ACUTECT</u>						
N020887	001	5443815				
		5508020				
		5645815				
<u>TECHNETIUM TC-99M BICISATE KIT - NEUROLITE</u>						
N020256	001	5431900		U-336		
<u>TECHNETIUM TC-99M MERTIATIDE KIT - TECHNISCAN MAG3</u>						
N019882	001	5573748		DP		
<u>TECHNETIUM TC-99M SULFUR COLLOID KIT - AN-SULFUR COLLOID</u>						
N017858	001				ODE	Aug 13, 2019
<u>TECHNETIUM TC-99M TEBOROXIME KIT - CARDIOTEC</u>						
N019928	001	6056941		DP		
<u>TEDUGLUTIDE - GATTEX KIT</u>						
N203441	001				NCE	Dec 21, 2017
<u>TEGASEROD MALEATE - ZELNORM</u>						
N021200	001	5510353		U-466		
<u>TEGASEROD MALEATE - ZELNORM</u>						
N021200	002	5510353		U-466		
<u>TELAPREVIR - INCIVEK</u>						
N201917	001	7820671	DS DP		NCE	May 23, 2016
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110	001	6635618	DS DP	U-728	NCE	Sep 11, 2014
		6858584		DP		
		6872701		DP		
		7008923		U-1005		
		7208471	DS DP			
		7351691	DS DP	U-728		
		7531623	DS			
		7544364		DP		
		7700550		U-282		
		8101575		DP		
		8158580		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 002	6635618	Sep 22, 2021	DS DP U-728		NCE	Sep 11, 2014
	6858584	Aug 24, 2022	DP			
	6872701	Jun 05, 2021	DP			
	7008923	May 06, 2021			U-1005	
	7208471	May 01, 2021	DS DP			
	7351691	May 01, 2021	DS DP U-728			
	7531623	Jan 01, 2027	DS			
	7544364	May 01, 2021	DP			
	7700550	May 01, 2021			U-282	
	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELBIVUDINE - TYZEKA</u>						
N022011 001	6395716	Aug 10, 2019			U-782	
	6444652	Aug 10, 2019			U-782	
	6566344	Aug 10, 2019			U-782	
	6569837	Oct 25, 2020			U-782	
	6569837	Oct 25, 2020			U-999	
	7589079	Sep 11, 2023	DS DP U-999			
	7795238	Aug 10, 2019			U-999	
	7858594	Sep 11, 2023	DS DP U-999			
<u>TELBIVUDINE - TYZEKA</u>						
N022154 001	6395716	Aug 10, 2019			U-999	
	6444652	Aug 10, 2019			U-999	
	6566344	Aug 10, 2019			U-999	
	6569837	Oct 25, 2020			U-999	
	7795238	Aug 10, 2019			U-999	
	7858594	Sep 11, 2023	DS DP U-999			
<u>TELITHROMYCIN - KETEK</u>						
N021144 001	5635485	Apr 01, 2018	DS DP U-578			
	D459798	Sep 24, 2015	DP			
<u>TELITHROMYCIN - KETEK</u>						
N021144 002	5635485	Apr 01, 2018	DS DP U-578			
	D459798	Sep 24, 2015	DP			
<u>TELMISARTAN - MICARDIS</u>						
N020850 001	5591762	Jan 07, 2014			U-3	
	6358986	Jan 10, 2020				
<u>TELMISARTAN - MICARDIS</u>						
N020850 002	5591762	Jan 07, 2014	DS DP U-3		I-612	Oct 16, 2012
	6358986	Jan 10, 2020				
	7998953	Jun 06, 2020			U-1177	
	8003679	Oct 06, 2022			U-1176	
<u>TELMISARTAN - MICARDIS</u>						
N020850 003	5591762	Jan 07, 2014			U-3	
	6358986	Jan 10, 2020				
<u>TEMOZOLOMIDE - TEMODAR</u>						
N021029 001	5260291	Aug 11, 2013	DS DP U-619			
	5260291*PED	Feb 11, 2014				
<u>TEMOZOLOMIDE - TEMODAR</u>						
N021029 002	5260291	Aug 11, 2013	DS DP U-619			
	5260291*PED	Feb 11, 2014				
<u>TEMOZOLOMIDE - TEMODAR</u>						
N021029 003	5260291	Aug 11, 2013	DS DP U-619			
	5260291*PED	Feb 11, 2014				
<u>TEMOZOLOMIDE - TEMODAR</u>						
N021029 004	5260291	Aug 11, 2013	DS DP U-619			
	5260291*PED	Feb 11, 2014				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES			PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE							
TEMOZOLOMIDE - TEMODAR																
N021029 005	5260291	Aug	11,	2013	DS	DP	U-619									
	5260291*PED	Feb	11,	2014												
TEMOZOLOMIDE - TEMODAR																
N021029 006	5260291	Aug	11,	2013	DS	DP	U-619									
	5260291*PED	Feb	11,	2014												
TEMOZOLOMIDE - TEMODAR																
N022277 001	5260291	Aug	11,	2013	DS	DP	U-619									
	5260291*PED	Feb	11,	2014												
	6987108	Sep	08,	2023							DP					
	7786118	Feb	21,	2023							DP					
TEMSIROLIMUS - TORISEL																
N022088 001	5362718	Apr	18,	2014	DS	DP		M-61	May	30,	2015					
	5362718*PED	Oct	18,	2014								M-92	Jul	09,	2013	
	8026276	Jan	20,	2026								DP	M-91	Apr	26,	2013
	8026276*PED	Jul	20,	2026								ODE	May	30,	2014	
	8299116	Jul	25,	2023								DP	PED	Nov	30,	2015
	8299116*PED	Jan	25,	2024								PED	Nov	30,	2014	
												PED	Jan	09,	2014	
												PED	Oct	26,	2013	
TENOFVIR DISOPROXIL FUMARATE - VIREAD																
N021356 001	5922695	Jul	25,	2017	DS		U-999	M-95	Oct	01,	2013					
	5922695	Jul	25,	2017								DS	U-256	NPP	Aug	16,
	5922695	Jul	25,	2017	DS		U-248	NPP	Jan	18,	2015					
	5922695	Jul	25,	2017	DS		U-250	NPP	Mar	24,	2013					
	5922695	Jul	25,	2017	DS		U-1275	NPP	Mar	24,	2017					
	5922695*PED	Jan	25,	2018				ODE	Mar	24,	2017					
	5935946	Jul	25,	2017	DS	DP	U-999	PED	Jul	18,	2015					
	5935946	Jul	25,	2017	DS	DP	U-256	PED	Apr	01,	2014					
	5935946	Jul	25,	2017	DS	DP	U-248	PED	Sep	24,	2013					
	5935946	Jul	25,	2017	DS	DP	U-250	PED	Sep	24,	2017					
	5935946*PED	Jan	25,	2018												
	5977089	Jul	25,	2017	DS	DP	U-1275									
	5977089	Jul	25,	2017	DS	DP	U-256									
	5977089	Jul	25,	2017	DS	DP	U-250									
	5977089	Jul	25,	2017	DS	DP	U-999									
	5977089	Jul	25,	2017	DS	DP	U-248									
	5977089*PED	Jan	25,	2018												
	6043230	Jul	25,	2017			U-1275									
	6043230	Jul	25,	2017			U-999									
	6043230	Jul	25,	2017			U-248									
	6043230	Jul	25,	2017			U-250									
	6043230	Jul	25,	2017			U-256									
	6043230*PED	Jan	25,	2018												

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 002	5922695	Jul 25, 2017	DS	U-248	M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS	U-999	NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS	U-256	NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS	U-1275	NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS	U-250	ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP	U-248	PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP	U-256	PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP	U-999	PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP	U-250		
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP	U-256		
	5977089	Jul 25, 2017	DS DP	U-1275		
	5977089	Jul 25, 2017	DS DP	U-999		
	5977089	Jul 25, 2017	DS DP	U-248		
	5977089	Jul 25, 2017	DS DP	U-250		
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017		U-250		
	6043230	Jul 25, 2017		U-999		
	6043230	Jul 25, 2017		U-248		
	6043230	Jul 25, 2017		U-256		
	6043230	Jul 25, 2017		U-1275		
	6043230*PED	Jan 25, 2018				
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 003	5922695	Jul 25, 2017	DS	U-248	M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS	U-250	NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS	U-256	NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS	U-1275	NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS	U-999	ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP	U-999	PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP	U-250	PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP	U-248	PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP	U-256		
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP	U-250		
	5977089	Jul 25, 2017	DS DP	U-1275		
	5977089	Jul 25, 2017	DS DP	U-256		
	5977089	Jul 25, 2017	DS DP	U-248		
	5977089	Jul 25, 2017	DS DP	U-999		
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017		U-256		
	6043230	Jul 25, 2017		U-248		
	6043230	Jul 25, 2017		U-250		
	6043230	Jul 25, 2017		U-999		
	6043230	Jul 25, 2017		U-1275		
	6043230*PED	Jan 25, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 004	5922695	Jul 25, 2017	DS	U-999	M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS	U-248	NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS	U-250	NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS	U-1275	NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS	U-256	NPP	Mar 24, 2013
	5922695*PED	Jan 25, 2018			ODE	Mar 24, 2017
	5935946	Jul 25, 2017	DS DP	U-999	PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP	U-248	PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP	U-256	PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP	U-250	PED	Sep 24, 2013
	5935946*PED	Jan 25, 2018			PED	Sep 24, 2013
	5977089	Jul 25, 2017	DS DP	U-248		
	5977089	Jul 25, 2017	DS DP	U-1275		
	5977089	Jul 25, 2017	DS DP	U-250		
	5977089	Jul 25, 2017	DS DP	U-256		
	5977089	Jul 25, 2017	DS DP	U-999		
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017		U-256		
	6043230	Jul 25, 2017		U-999		
	6043230	Jul 25, 2017		U-250		
	6043230	Jul 25, 2017		U-248		
	6043230	Jul 25, 2017		U-1275		
	6043230*PED	Jan 25, 2018				
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N022577 001	5922695	Jul 25, 2017	DS	U-256	M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS	U-248	NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS	U-250	NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS	U-999	NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS	U-1275	NDF	Jan 18, 2015
	5922695*PED	Jan 25, 2018			ODE	Mar 24, 2017
	5935946	Jul 25, 2017	DS DP	U-999	PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP	U-256	PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP	U-250	PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP	U-248	PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP	U-1275	PED	Jul 18, 2015
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP	U-248		
	5977089	Jul 25, 2017	DS DP	U-999		
	5977089	Jul 25, 2017	DS DP	U-256		
	5977089	Jul 25, 2017	DS DP	U-1275		
	5977089	Jul 25, 2017	DS DP	U-250		
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017		U-256		
	6043230	Jul 25, 2017		U-250		
	6043230	Jul 25, 2017		U-1275		
	6043230	Jul 25, 2017		U-999		
	6043230	Jul 25, 2017		U-248		
	6043230*PED	Jan 25, 2018				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N019057 001	5294615	Apr 29, 2013		U-165		
	5294615	Apr 29, 2013		U-3		
	5412095	Apr 29, 2013				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N019057 002	5294615	Apr 29, 2013		U-3		
	5294615	Apr 29, 2013		U-165		
	5412095	Apr 29, 2013				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N019057 003	5294615	Apr 29, 2013		U-165		
	5294615	Apr 29, 2013		U-3		
	5412095	Apr 29, 2013				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N019057 004	5294615	Apr 29, 2013		U-3		
	5294615	Apr 29, 2013		U-165		
	5412095	Apr 29, 2013				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N020347 001	5294615	Apr 29, 2013	U-165			
	5294615	Apr 29, 2013	U-3			
	5412095	Apr 29, 2013				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N020347 002	5294615	Apr 29, 2013	U-3			
	5294615	Apr 29, 2013	U-165			
	5412095	Apr 29, 2013				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N020347 003	5294615	Apr 29, 2013	U-3			
	5294615	Apr 29, 2013	U-165			
	5412095	Apr 29, 2013				
<u>TERAZOSIN HYDROCHLORIDE - HYTRIN</u>						
N020347 004	5294615	Apr 29, 2013	U-165			
	5294615	Apr 29, 2013	U-3			
	5412095	Apr 29, 2013				
<u>TERBINAFINE - LAMISIL</u>						
N020846 001	5681849	Oct 28, 2014	DP			
	5681849*PED	Apr 28, 2015				
	5856355*PED	Nov 18, 2012				
	6005001*PED	Nov 18, 2012				
<u>TERBINAFINE - LAMISIL AT</u>						
N021958 001	5681849	Oct 28, 2014	DP			
	5681849*PED	Apr 28, 2015				
	5856355*PED	Nov 18, 2012				
<u>TERBINAFINE HYDROCHLORIDE - LAMISIL AT</u>						
N021124 001	5681849	Oct 28, 2014				
	5681849*PED	Apr 28, 2015				
<u>TERBINAFINE HYDROCHLORIDE - LAMISIL AT</u>						
N021124 002	5681849	Oct 28, 2014				
	5681849*PED	Apr 28, 2015				
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N202992 001	5459163	Oct 17, 2012	DP		NCE	Sep 12, 2017
	5679709	Oct 21, 2014	DP U-1285			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N202992 002	5459163	Oct 17, 2012	DP		NCE	Sep 12, 2017
	5679709	Oct 21, 2014	DP U-1285			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N021318 001	6770623	Dec 08, 2018	DP U-597		I-602	Jul 22, 2012
	6977077	Aug 19, 2019	U-597			
	7144861	Dec 08, 2018	DP			
	7163684	Aug 19, 2019	U-790			
	7351414	Aug 19, 2019	U-865			
	7550434	Dec 08, 2018	DP U-982			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N021318 002	6770623	Dec 08, 2018	DP U-982		I-602	Jul 22, 2012
	6977077	Aug 19, 2019	U-994			
	6977077	Aug 19, 2019	U-982			
	7144861	Dec 08, 2018	DP			
	7163684	Aug 19, 2019	U-983			
	7163684	Aug 19, 2019	U-994			
	7351414	Aug 19, 2019	U-994			
	7351414	Aug 19, 2019	U-984			
	7550434	Dec 08, 2018	DP U-982			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE			PATENT CODES			PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
<u>TESAMORELIN ACETATE - EGRIFTA</u>											
N022505 001	5861379	May	26,	2015	DS	DP	U-1100		NCE	Nov	10, 2015
	6020311	May	26,	2015	DS	DP	U-1100				
	7144577	Jul	14,	2020			U-1100				
	7316997	Aug	14,	2023			U-1100				
<u>TESAMORELIN ACETATE - EGRIFTA</u>											
N022505 002	5861379	May	26,	2015	DS	DP	U-1100		NCE	Nov	10, 2015
	6020311	May	26,	2015	DS	DP	U-1100				
	7144577	Jul	14,	2020			U-1100				
	7316997	Aug	14,	2023			U-1100				
<u>TESTOSTERONE - ANDRODERM</u>											
N020489 003									NS	Oct	20, 2014
<u>TESTOSTERONE - ANDRODERM</u>											
N020489 004									NS	Oct	20, 2014
<u>TESTOSTERONE - ANDROGEL</u>											
N021015 001	6503894	Aug	30,	2020			U-490				
	6503894*PED	Mar	01,	2021							
<u>TESTOSTERONE - ANDROGEL</u>											
N021015 002	6503894	Aug	30,	2020			U-490				
	6503894*PED	Mar	01,	2021							
<u>TESTOSTERONE - ANDROGEL</u>											
N021015 003	6503894	Aug	30,	2020			U-490				
	6503894*PED	Mar	01,	2021							
<u>TESTOSTERONE - ANDROGEL</u>											
N022309 001	6503894	Aug	30,	2020			U-1103		NP	Apr	29, 2014
<u>TESTOSTERONE - ANDROGEL</u>											
N022309 002									NP	Apr	29, 2014
<u>TESTOSTERONE - ANDROGEL</u>											
N022309 003									NP	Apr	29, 2014
<u>TESTOSTERONE - AXIRON</u>											
N022504 001	6299900	Feb	19,	2017		DP	U-1103		NP	Nov	23, 2013
	6818226	Feb	19,	2017		DP	U-1103				
	6923983	Feb	19,	2017		DP	U-1103				
	8071075	Feb	19,	2017		DP	U-1103				
<u>TESTOSTERONE - FORTESTA</u>											
N021463 001	6319913	Nov	09,	2018			U-490		NP	Dec	29, 2013
	6579865	Nov	09,	2018		DP					
<u>TESTOSTERONE - STRIANT</u>											
N021543 001	6248358	Aug	23,	2019			U-527				
<u>TESTOSTERONE - TESTIM</u>											
N021454 001	7320968	Jan	18,	2025			U-843				
	7608605	Apr	21,	2023			U-1009				
	7608606	Apr	21,	2023			U-1009				
	7608607	Apr	21,	2023			U-1009				
	7608608	Apr	21,	2023			U-1009				
	7608609	Apr	21,	2023			U-1009				
	7608610	Apr	21,	2023			U-1009				
	7935690	Apr	21,	2023			U-1009				
	8063029	Apr	21,	2023			U-843				
	8178518	Apr	21,	2023		DP					
<u>TESTOSTERONE - TESTODERM</u>											
N019762 001	5840327	Aug	15,	2016							
<u>TESTOSTERONE - TESTODERM</u>											
N019762 002	5840327	Aug	15,	2016							

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - TESTODERM TTS</u>						
N020791 001	6348210	Nov 10, 2019	U-440			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N202763 001					NP	Feb 14, 2015
<u>TETRABENAZINE - XENAZINE</u>						
N021894 001					NCE ODE	Aug 15, 2013 Aug 15, 2015
<u>TETRABENAZINE - XENAZINE</u>						
N021894 002					NCE ODE	Aug 15, 2013 Aug 15, 2015
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	5629327	May 13, 2014	U-731		ODE	May 25, 2013
	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6235756	Mar 01, 2013	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-731			
	6561977	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-733			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-731			
	6908432	Aug 28, 2018	U-731			
	6908432	Aug 28, 2018	U-371			
	7141018	Oct 23, 2020	U-733			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7230012	Dec 09, 2023		DP		
	7435745	Nov 03, 2017	U-899			
	7723361	Mar 01, 2013	U-1058			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-1109			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-733			
	7959566	Oct 23, 2020	U-1155			
	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	5629327	May 13, 2014	U-731		ODE	May 25, 2013
	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6235756	Mar 01, 2013	U-731			
	6315720	Oct 23, 2020	U-731			
	6315720	Oct 23, 2020	U-442			
	6561976	Aug 28, 2018	U-731			
	6561976	Aug 28, 2018	U-371			
	6561977	Oct 23, 2020	U-731			
	6561977	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-733			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6908432	Aug 28, 2018	U-731			
	6908432	Aug 28, 2018	U-371			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-733			
	7141018	Oct 23, 2020	U-732			
	7230012	Dec 09, 2023	DP			
	7435745	Nov 03, 2017	U-899			
	7723361	Mar 01, 2013	U-1058			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	5629327	May 13, 2014	U-731		ODE	May 25, 2013
	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6235756	Mar 01, 2013	U-731			
	6315720	Oct 23, 2020	U-731			
	6315720	Oct 23, 2020	U-442			
	6561976	Aug 28, 2018	U-731			
	6561976	Aug 28, 2018	U-371			
	6561977	Oct 23, 2020	U-731			
	6561977	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-733			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-371			
	6908432	Aug 28, 2018	U-731			
	6908432	Aug 28, 2018	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-733			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-732			
	7230012	Dec 09, 2023	DP			
	7435745	Nov 03, 2017	U-899			
	7723361	Mar 01, 2013	U-1058			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-1109			
	7874984	Aug 28, 2018	U-732			
	7959566	Oct 23, 2020	U-1155			
	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	5629327	May 13, 2014	U-731		ODE	May 23, 2013
	6045501	Aug 28, 2018	U-731			
	6235756	Mar 01, 2013	U-731			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-731			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-731			
	7435745	Nov 03, 2017	U-899			
	7723361	Mar 01, 2013	U-1058			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7959566	Oct 23, 2020	U-1155			
	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
<u>THYROTROPIN ALFA - THYROGEN</u>						
N020898 001	5840566	Nov 24, 2015			ODE	Dec 14, 2014
	6365127	Nov 24, 2015	DS DP U-556			
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N020646 001	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N020646 002	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N020646 003	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N020646 004	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N020646 005	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TICAGRELOR - BRILINTA</u>						
N022433 001	6251910	Jul 15, 2018	DS		NCE	Jul 20, 2016
	6525060	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1171			
<u>TIGECYCLINE - TYGACIL</u>						
N021821 001	7879828	Feb 05, 2029	DP			
	RE40086	Jun 25, 2013		U-282		
	RE40183	Apr 09, 2016	DS DP			
<u>TIMOLOL MALEATE - ISTALOL</u>						
N021516 001	6335335	Nov 02, 2018	DP			
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
N020963 001	6174524	Mar 26, 2019	DP			
	6174524*PED	Sep 26, 2019				
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
N020963 002	6174524	Mar 26, 2019	DP			
	6174524*PED	Sep 26, 2019				
<u>TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA</u>						
N021395 001	5478578	Dec 26, 2012	DP		M-89	Dec 17, 2012
	6777423	Sep 24, 2021	DS DP			
	6908928	Sep 24, 2021	DS DP U-762			
	6908928	Sep 24, 2021	DS DP U-566			
	7070800	Jan 22, 2022	DP U-566			
	7309707	Sep 24, 2021	DS DP			
	7642268	Sep 24, 2021	DS DP			
	7694676	Mar 12, 2027	DP			
	8022082	Jan 19, 2026	DP U-1186			
	RE38912	Oct 11, 2021	DP			
	RE39820	Jan 30, 2018	DS DP U-566			
<u>TIPRANAVIR - APTIVUS</u>						
N021814 001	5852195	Jun 22, 2019	DS			
	5852195*PED	Dec 22, 2019				
	6147095	Oct 29, 2019		U-670		
	6147095*PED	Apr 29, 2020				
	6169181	May 06, 2014	DS			
	6169181*PED	Nov 06, 2014				
	6231887	Jul 27, 2018	DP			
	6231887*PED	Jan 27, 2019				
<u>TIPRANAVIR - APTIVUS</u>						
N022292 001	5852195	Jun 22, 2019	DS			
	5852195*PED	Dec 22, 2019				
	6147095	Oct 29, 2019		U-670		
	6147095*PED	Apr 29, 2020				
	6169181	May 06, 2014	DS			
	6169181*PED	Nov 06, 2014				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N020912 001	5733919	Oct 23, 2016				
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N020913 001	5733919	Oct 23, 2016				
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N020913 002	5733919	Oct 23, 2016				
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N020913 003	5733919	Oct 23, 2016				
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
<u>TOBRAMYCIN - TOBI</u>						
N050753 001	5508269	Oct 19, 2014	DP	U-909		
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N203214 001	6956041	Dec 08, 2020	DP		NCE	Nov 06, 2017
	6965027	Mar 25, 2023	DS			
	7091208	Dec 08, 2020		U-247		
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	RE41783	Dec 08, 2020	DS			
<u>TOLCAPONE - TASMAR</u>						
N020697 001	5476875	Dec 19, 2012		U-219		
<u>TOLCAPONE - TASMAR</u>						
N020697 002	5476875	Dec 19, 2012		U-219		
<u>TOLTERODINE TARTRATE - DETROL</u>						
N020771 001	5382600*PED	Sep 25, 2012				
<u>TOLTERODINE TARTRATE - DETROL</u>						
N020771 002	5382600*PED	Sep 25, 2012				
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N021228 001	5382600*PED	Sep 25, 2012				
	6630162	Nov 11, 2019	DP	U-544		
	6630162*PED	May 11, 2020				
	6770295	Aug 26, 2019	DP	U-544		
	6770295*PED	Feb 26, 2020				
	6911217	Aug 26, 2019	DP	U-544		
	6911217*PED	Feb 26, 2020	DP	U-544		
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N021228 002	5382600*PED	Sep 25, 2012				
	6630162	Nov 11, 2019	DP	U-544		
	6630162*PED	May 11, 2020				
	6770295	Aug 26, 2019	DP	U-544		
	6770295*PED	Feb 26, 2020				
	6911217	Aug 26, 2019	DP	U-544		
	6911217*PED	Feb 26, 2020	DP	U-544		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
TOLVAPTAN - SAMSCA									
N022275 001	5258510 5753677	Nov May	02, 2012 19, 2015	DS	DP U-978		NCE	May	19, 2014
TOLVAPTAN - SAMSCA									
N022275 002	5258510 5753677	Nov May	02, 2012 19, 2015	DS	DP U-978		NCE	May	19, 2014
TOLVAPTAN - SAMSCA									
N022275 003	5258510 5753677	Nov May	02, 2012 19, 2015	DS	DP U-978		NCE	May	19, 2014
TOPIRAMATE - TOPAMAX									
N020505 001	5998380 5998380*PED 6503884 6503884*PED 7018983 7018983*PED 7498311 7498311*PED	Oct Apr Oct Apr Oct Apr Oct Apr	13, 2015 13, 2016 13, 2015 13, 2016 13, 2015 13, 2016 13, 2015 13, 2016		U-598 U-598 U-723 U-955		M-54 NPP PED	Dec Jul Jun	22, 2012 15, 2014 22, 2013
TOPIRAMATE - TOPAMAX									
N020505 002	5998380 5998380*PED 6503884 6503884*PED 7018983 7018983*PED 7498311 7498311*PED	Oct Apr Oct Apr Oct Apr Oct Apr	13, 2015 13, 2016 13, 2015 13, 2016 13, 2015 13, 2016 13, 2015 13, 2016		U-598 U-598 U-723 U-955		M-54 NPP PED	Dec Jul Jun	22, 2012 15, 2014 22, 2013
TOPIRAMATE - TOPAMAX									
N020505 003	5998380 5998380*PED 6503884 6503884*PED 7018983 7018983*PED 7498311 7498311*PED	Oct Apr Oct Apr Oct Apr Oct Apr	13, 2015 13, 2016 13, 2015 13, 2016 13, 2015 13, 2016 13, 2015 13, 2016		U-598 U-598 U-723 U-955		M-54 PED	Dec Jun	22, 2012 22, 2013
TOPIRAMATE - TOPAMAX									
N020505 004	5998380 5998380*PED 6503884 6503884*PED 7018983 7018983*PED 7498311 7498311*PED	Oct Apr Oct Apr Oct Apr Oct Apr	13, 2015 13, 2016 13, 2015 13, 2016 13, 2015 13, 2016 13, 2015 13, 2016		U-598 U-598 U-723 U-955		M-54 NPP PED	Dec Jul Jun	22, 2012 15, 2014 22, 2013
TOPIRAMATE - TOPAMAX									
N020505 005	5998380 5998380*PED 6503884 6503884*PED 7018983 7018983*PED 7498311 7498311*PED	Oct Apr Oct Apr Oct Apr Oct Apr	13, 2015 13, 2016 13, 2015 13, 2016 13, 2015 13, 2016 13, 2015 13, 2016		U-598 U-598 U-723 U-955		M-54 NPP PED	Dec Jul Jun	22, 2012 15, 2014 22, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 006	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			PED	Jun 22, 2013
	6503884	Oct 13, 2015	U-598			
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 001	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			NPP	Jul 15, 2014
	6503884	Oct 13, 2015	U-598		PED	Jun 22, 2013
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7125560	Mar 01, 2019	U-766			
	7125560*PED	Sep 01, 2019				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 002	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			NPP	Jul 15, 2014
	6503884	Oct 13, 2015	U-598		PED	Jun 22, 2013
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7125560	Mar 01, 2019	U-766			
	7125560*PED	Sep 01, 2019				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
N020844 003	5998380	Oct 13, 2015	U-598		M-54	Dec 22, 2012
	5998380*PED	Apr 13, 2016			PED	Jun 22, 2013
	6503884	Oct 13, 2015	U-598			
	6503884*PED	Apr 13, 2016				
	7018983	Oct 13, 2015	U-723			
	7018983*PED	Apr 13, 2016				
	7125560	Mar 01, 2019	U-766			
	7125560*PED	Sep 01, 2019				
	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020671 001	5674872	Oct 07, 2014	U-910			
	5674872*PED	Apr 07, 2015				
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 001	8158645	Dec 10, 2024	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 002	8158645	Dec 10, 2024	DP			
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N022370 001	7858118	Apr 11, 2022	DP	U-1104		
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N022370 002	7858118	Apr 11, 2022	DP	U-1104		
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N022370 003	7858118	Apr 11, 2022	DP	U-1104		
<u>TRAMADOL HYDROCHLORIDE - RYBIX ODT</u>						
N021693 001	5464632	Mar 22, 2013	DP			
	6106861	Dec 05, 2017	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N021745 001	5591452	May 10, 2014	DP			
	6254887	May 10, 2014	DP			
	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N021745 002	5591452	May 10, 2014	DP			
	6254887	May 10, 2014	DP			
	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N021745 003	5591452	May 10, 2014	DP			
	6254887	May 10, 2014	DP			
	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - ULTRAM</u>						
N020281 001	6339105	Oct 12, 2019		U-435		
	6339105*PED	Apr 12, 2020		U-435		
<u>TRAMADOL HYDROCHLORIDE - ULTRAM</u>						
N020281 002	6339105	Oct 12, 2019		U-435		
	6339105*PED	Apr 12, 2020		U-435		
<u>TRANDOLAPRIL - MAVIK</u>						
N020528 001	5744496	Apr 28, 2015		U-229		
<u>TRANDOLAPRIL - MAVIK</u>						
N020528 002	5744496	Apr 28, 2015		U-229		
<u>TRANDOLAPRIL - MAVIK</u>						
N020528 003	5744496	Apr 28, 2015		U-229		
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N020591 001	5721244	Feb 24, 2015				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N020591 002	5721244	Feb 24, 2015				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N020591 003	5721244	Feb 24, 2015				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N020591 004	5721244	Feb 24, 2015				
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N022430 001	7947739	Mar 04, 2025	DP		NDF	Nov 13, 2012
	8022106	Mar 04, 2025		U-1182		
	8273795	Mar 04, 2025		U-1182		
<u>TRAVOPROST - TRAVATAN</u>						
N021257 001	5510383	Aug 03, 2013	DP	U-383		
	5631287	Dec 22, 2014		U-382		
	5849792	Dec 22, 2014	DP	U-383		
	5889052	Dec 02, 2014	DP	U-383		
	6011062	Dec 22, 2014	DP			
<u>TRAVOPROST - TRAVATAN Z</u>						
N021994 001	5510383	Aug 03, 2013	DP	U-383		
	5889052	Dec 02, 2014	DP	U-383		
	8268299	Oct 13, 2029	DP			
	8323630	Sep 20, 2027	DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 001	6607748	Jun 29, 2020	DP		NDF	Feb 02, 2013
	7829120	Mar 27, 2027	DP	U-796		
	8133893	Mar 13, 2029	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 002	6607748	Jun 29, 2020	DP		NDF	Feb 02, 2013
	7829120	Mar 27, 2027	DP U-796			
	8133893	Mar 13, 2029	DS DP			
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 001	5153222	Oct 06, 2014			U-455	
	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029	DP U-1174			
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 002	5153222	Oct 06, 2014			U-455	
	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029	DP U-1174			
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 003	5153222	Oct 06, 2014			U-455	
	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029	DP U-1174			
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 004	5153222	Oct 06, 2014			U-455	
	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029	DP U-1174			
<u>TREPROSTINIL SODIUM - TYVASO</u>						
N022387 001	5153222	Oct 16, 2014			U-1019	NDF Jul 30, 2012
	6521212	Nov 13, 2018			U-1018	ODE Jul 30, 2016
	6756033	Nov 13, 2018			U-1018	
	6765117	Oct 24, 2017	DS			
<u>TRETINOIN - ATRALIN</u>						
N022070 001	5670547	Sep 23, 2014	DP			
<u>TRETINOIN - RENOVA</u>						
N021108 001	6531141	Mar 07, 2020				
<u>TRETINOIN - RETIN-A MICRO</u>						
N020475 001	5955109	Sep 21, 2016	DP U-134			
<u>TRETINOIN - RETIN-A MICRO</u>						
N020475 002	5955109	Sep 21, 2016			U-134	
<u>TRIAMCINOLONE ACETONIDE - NASACORT AQ</u>						
N020468 001	5976573	Jul 03, 2016	DP U-896			
	5976573	Jul 03, 2016	DP U-295			
	6143329	Jul 03, 2016	DP U-896			
	7977045	Jul 03, 2016	DP U-896			
<u>TRIAMCINOLONE ACETONIDE - TRIESENCE</u>						
N022048 001	6395294	Jan 13, 2020	DP U-846			
	8128960	Dec 17, 2029	DP			
	8211880	Mar 10, 2029			U-1257	
	8211880	Mar 10, 2029			U-1258	
<u>TRIMETHOPRIM HYDROCHLORIDE - PRIMSO</u>						
A074973 001	5763449	Aug 07, 2016				
	5962461	Aug 07, 2016				
<u>TRIMETREXATE GLUCURONATE - NEUTREXIN</u>						
N020326 001	6017922	May 18, 2018				
<u>TRIMETREXATE GLUCURONATE - NEUTREXIN</u>						
N020326 002	6017922	May 18, 2018				
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N020715 001	5776885	Jul 07, 2015				
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N021288 001	5776885	Jul 07, 2015	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N022437 001	5776885	Jul 07, 2015	DP		NP	Mar 10, 2013
<u>TROGLITAZONE - PRELAY</u>						
N020719 001	5602133	Sep 15, 2013	U-173			
	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
	6046202	Sep 15, 2013	U-317			
<u>TROGLITAZONE - PRELAY</u>						
N020719 002	5602133	Sep 15, 2013	U-173			
	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
	6046202	Sep 15, 2013	U-317			
<u>TROGLITAZONE - PRELAY</u>						
N020719 003	5602133	Sep 15, 2013	U-173			
	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
	6046202	Sep 15, 2013	U-317			
<u>TROGLITAZONE - REZULIN</u>						
N020720 001	5602133	Sep 15, 2013	U-173			
	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
	6046202	Sep 15, 2013	U-317			
<u>TROGLITAZONE - REZULIN</u>						
N020720 002	5602133	Sep 15, 2013	U-173			
	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
	6046202	Sep 15, 2013	U-317			
<u>TROGLITAZONE - REZULIN</u>						
N020720 003	5602133	Sep 15, 2013	U-173			
	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
	6046202	Sep 15, 2013	U-317			
<u>TROSPIUM CHLORIDE - SANCTURA XR</u>						
N022103 001	7410978	Feb 01, 2025	DP			
	7759359	Nov 04, 2024	U-1071			
	7763635	Nov 04, 2024	U-1071			
	7781448	Nov 04, 2024	U-1071			
	7781449	Nov 04, 2024	U-1071			
<u>TROVAFLOXACIN MESYLATE - TROVAN</u>						
N020759 001	5763454	Jun 15, 2015	U-282			
	6187341	Jan 20, 2019				
<u>TROVAFLOXACIN MESYLATE - TROVAN</u>						
N020759 002	5763454	Jun 15, 2015	U-282			
	6187341	Jan 20, 2019				
<u>TRYPAN BLUE - MEMBRANEBLUE</u>						
N022278 001					ODE	Feb 20, 2016
<u>ULIPRISTAL ACETATE - ELLA</u>						
N022474 001					NCE	Aug 13, 2015
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N021214 001	5221763	Jul 15, 2012	DS			
	6458836	Jul 09, 2021	U-333			
	6458836	Jul 09, 2021	U-1315			
<u>UROFOLLITROPIN - FERTINEX</u>						
N019415 004	5767067	Jun 16, 2015				
<u>UROFOLLITROPIN - FERTINEX</u>						
N019415 005	5767067	Jun 16, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VALACYCLOVIR HYDROCHLORIDE - VALTREX</u>						
N020487 001	5879706	Jan 19, 2016	DP U-894			
	5879706	Jan 19, 2016	DP U-530			
	5879706*PED	Jul 19, 2016				
	6107302	Jan 19, 2016	DS U-894			
	6107302	Jan 19, 2016	DS U-530			
	6107302*PED	Jul 19, 2016				
<u>VALACYCLOVIR HYDROCHLORIDE - VALTREX</u>						
N020487 002	5879706	Jan 19, 2016	DP U-894			
	5879706	Jan 19, 2016	DP U-530			
	5879706*PED	Jul 19, 2016				
	6107302	Jan 19, 2016	DS U-530			
	6107302	Jan 19, 2016	DS U-894			
	6107302*PED	Jul 19, 2016				
<u>VALDECOXIB - BEXTRA</u>						
N021341 002	5633272	Feb 13, 2015	U-462			
<u>VALDECOXIB - BEXTRA</u>						
N021341 003	5633272	Feb 13, 2015	U-462			
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N021304 001	6083953	Mar 29, 2015	DS DP U-854		D-125	Aug 05, 2013
	6083953	Mar 29, 2015	DS DP U-384		I-604	Aug 28, 2012
	6083953*PED	Sep 29, 2015			PED	Feb 28, 2013
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N022257 001	6083953	Mar 29, 2015	DS DP U-854		NDF	Aug 28, 2012
	6083953	Mar 29, 2015	DS DP U-384		PED	Feb 28, 2013
<u>VALSARTAN - DIOVAN</u>						
N020665 001	5399578*PED	Sep 21, 2012				
<u>VALSARTAN - DIOVAN</u>						
N020665 002	5399578*PED	Sep 21, 2012				
<u>VALSARTAN - DIOVAN</u>						
N021283 001	5399578*PED	Sep 21, 2012				
	5972990	Oct 26, 2016	U-692			
	5972990*PED	Apr 26, 2017				
	6294197	Jun 18, 2017	U-3			
	6294197*PED	Dec 18, 2017				
<u>VALSARTAN - DIOVAN</u>						
N021283 002	5399578*PED	Sep 21, 2012				
	5972990	Oct 26, 2016	U-692			
	5972990*PED	Apr 26, 2017				
	6294197	Jun 18, 2017	U-3			
	6294197*PED	Dec 18, 2017				
<u>VALSARTAN - DIOVAN</u>						
N021283 003	5399578*PED	Sep 21, 2012				
	5972990	Oct 26, 2016	U-692			
	5972990*PED	Apr 26, 2017				
	6294197	Jun 18, 2017	U-3			
	6294197*PED	Dec 18, 2017				
<u>VALSARTAN - DIOVAN</u>						
N021283 004	5399578*PED	Sep 21, 2012				
	5972990	Oct 26, 2016	U-692			
	5972990*PED	Apr 26, 2017				
	6294197	Jun 18, 2017	U-3			
	6294197*PED	Dec 18, 2017				
<u>VANDETANIB - CAPRELSA</u>						
N022405 001	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	8067427	Aug 08, 2028	DP		ODE	Apr 06, 2018
	RE42353	Sep 23, 2017	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES			PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
VANDETANIB - CAPRELSA										
N022405 002	7173038	Aug	14, 2021	DS	DP			NCE	Apr	06, 2016
	8067427	Aug	08, 2028		DP			ODE	Apr	06, 2018
	RE42353	Sep	23, 2017	DS	DP					
VARDENAFIL HYDROCHLORIDE - LEVITRA										
N021400 001	6362178	Oct	31, 2018	DS	DP	U-533				
	7696206	Oct	31, 2018	DS	DP	U-533				
	8273876	Jul	23, 2027			U-1288				
VARDENAFIL HYDROCHLORIDE - LEVITRA										
N021400 002	6362178	Oct	31, 2018	DS	DP	U-533				
	7696206	Oct	31, 2018	DS	DP	U-533				
	8273876	Jul	23, 2027			U-1288				
VARDENAFIL HYDROCHLORIDE - LEVITRA										
N021400 003	6362178	Oct	31, 2018	DS	DP	U-533				
	7696206	Oct	31, 2018	DS	DP	U-533				
	8273876	Jul	23, 2027			U-1288				
VARDENAFIL HYDROCHLORIDE - LEVITRA										
N021400 004	6362178	Oct	31, 2018	DS	DP	U-533				
	7696206	Oct	31, 2018	DS	DP	U-533				
	8273876	Jul	23, 2027			U-1288				
VARDENAFIL HYDROCHLORIDE - STAXYN										
N200179 001	6362178	Oct	31, 2018			U-155		NDF	Jun	17, 2013
	7696206	Oct	31, 2018			U-155				
VARENICLINE TARTRATE - CHANTIX										
N021928 001	6410550	May	10, 2020	DS	DP	U-56		M-105	Jul	22, 2014
	6890927	May	06, 2022	DS	DP	U-56				
	7265119	Aug	03, 2022	DS	DP	U-56				
VARENICLINE TARTRATE - CHANTIX										
N021928 002	6410550	May	10, 2020	DS	DP	U-56		M-105	Jul	22, 2014
	6890927	May	06, 2022	DS	DP	U-56				
	7265119	Aug	03, 2022	DS	DP	U-56				
VELAGLUCERASE ALFA - VPRIV										
N022575 001								NCE	Feb	26, 2015
VELAGLUCERASE ALFA - VPRIV										
N022575 002								NCE	Feb	26, 2015
VEMURAFENIB - ZELBORAF										
N202429 001	7504509	Oct	22, 2026	DS	DP			NCE	Aug	17, 2016
	7863288	Jun	20, 2029	DS	DP			ODE	Aug	17, 2018
	8143271	Jun	21, 2026	DS	DP					
VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR										
N020699 001	5916923	Jun	28, 2013			U-398				
	5916923*PED	Dec	28, 2013			U-398				
	6274171	Mar	20, 2017							
	6274171*PED	Sep	20, 2017							
	6310101	Jun	28, 2013			U-46				
	6403120	Mar	20, 2017			U-535				
	6403120	Mar	20, 2017			U-451				
	6403120*PED	Sep	20, 2017			U-535				
	6403120*PED	Sep	20, 2017			U-451				
	6419958	Mar	20, 2017			U-535				
	6419958	Mar	20, 2017			U-459				
	6419958*PED	Sep	20, 2017			U-535				
	6419958*PED	Sep	20, 2017			U-459				
	6444708	Jun	28, 2013			U-398				
	6444708*PED	Dec	28, 2013			U-398				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N020699 002	5916923	Jun 28, 2013	U-398			
	5916923*PED	Dec 28, 2013	U-398			
	6274171	Mar 20, 2017				
	6274171*PED	Sep 20, 2017				
	6310101	Jun 28, 2013	U-46			
	6403120	Mar 20, 2017	U-451			
	6403120	Mar 20, 2017	U-535			
	6403120*PED	Sep 20, 2017	U-451			
	6403120*PED	Sep 20, 2017	U-535			
	6419958	Mar 20, 2017	U-459			
	6419958	Mar 20, 2017	U-535			
	6419958*PED	Sep 20, 2017	U-535			
	6419958*PED	Sep 20, 2017	U-459			
	6444708	Jun 28, 2013	U-398			
	6444708*PED	Dec 28, 2013	U-398			
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N020699 003	5916923	Jun 28, 2013	U-398			
	5916923*PED	Dec 28, 2013	U-398			
	6274171	Mar 20, 2017				
	6274171*PED	Sep 20, 2017				
	6403120	Mar 20, 2017	U-535			
	6403120	Mar 20, 2017	U-451			
	6403120*PED	Sep 20, 2017	U-451			
	6403120*PED	Sep 20, 2017	U-535			
	6419958	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-459			
	6419958*PED	Sep 20, 2017	U-459			
	6419958*PED	Sep 20, 2017	U-535			
	6444708	Jun 28, 2013	U-398			
	6444708*PED	Dec 28, 2013	U-398			
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N020699 004	5916923	Jun 28, 2013	U-398			
	5916923*PED	Dec 28, 2013	U-398			
	6274171	Mar 20, 2017				
	6274171*PED	Sep 20, 2017				
	6310101	Jun 28, 2013	U-46			
	6403120	Mar 20, 2017	U-535			
	6403120	Mar 20, 2017	U-451			
	6403120*PED	Sep 20, 2017	U-451			
	6403120*PED	Sep 20, 2017	U-535			
	6419958	Mar 20, 2017	U-459			
	6419958	Mar 20, 2017	U-535			
	6419958*PED	Sep 20, 2017	U-459			
	6419958*PED	Sep 20, 2017	U-535			
	6444708	Jun 28, 2013	U-398			
	6444708*PED	Dec 28, 2013	U-398			
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N022104 001	6403120	Mar 20, 2017	U-535			
	6403120	Mar 20, 2017	U-839			
	6419958	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-839			
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N022104 002	6403120	Mar 20, 2017	U-839			
	6403120	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-839			
	6419958	Mar 20, 2017	U-535			
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N022104 003	6403120	Mar 20, 2017	U-839			
	6403120	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-839			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N022104 004	6403120	Mar 20, 2017	U-839			
	6403120	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-839			
	6419958	Mar 20, 2017	U-535			
<u>VERAPAMIL HYDROCHLORIDE - COVERA-HS</u>						
N020552 001	6096339	Apr 04, 2017	U-365			
<u>VERAPAMIL HYDROCHLORIDE - COVERA-HS</u>						
N020552 002	6096339	Apr 04, 2017	U-365			
<u>VERTEPORFIN - VISUDYNE</u>						
N021119 001	5707608	Aug 02, 2015				
	5756541	Mar 11, 2016	U-357			
	5770619	Jan 06, 2015	U-357			
	5798349	Aug 25, 2015	U-357			
<u>VIGABATRIN - SABRIL</u>						
N020427 001					NCE	Aug 21, 2014
<u>VIGABATRIN - SABRIL</u>						
N022006 001					NCE	Aug 21, 2014
					ODE	Aug 21, 2016
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 001	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 002	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 003	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VINCRIStINE SULFATE - MARQIBO KIT</u>						
N202497 001	5543152	Jun 20, 2014	DP		NP	Aug 09, 2015
	5741516	Jun 20, 2014	DP		ODE	Aug 09, 2019
	5814335	Jun 20, 2014	DP			
	6723338	Mar 31, 2020	U-1271			
	7247316	Sep 25, 2020	DP			
	7887836	Mar 31, 2020	U-1271			
<u>VISMODEGIB - ERIVEDGE</u>						
N203388 001	7888364	Nov 11, 2028	DS DP		NCE	Jan 30, 2017
<u>VORICONAZOLE - VFEND</u>						
N021266 001	5567817	May 24, 2016	DS DP U-540			
<u>VORICONAZOLE - VFEND</u>						
N021266 002	5567817	May 24, 2016	DS DP U-540			
<u>VORICONAZOLE - VFEND</u>						
N021267 001	5567817	May 24, 2016	DS DP U-540			
	6632803	Jun 02, 2018	DP			
<u>VORICONAZOLE - VFEND</u>						
N021630 001	5567817	May 24, 2016	DS DP U-540			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
VORINOSTAT - ZOLINZA									
N021991 001	7399787	Feb	09, 2025	DS	U-892		ODE	Oct	06, 2013
	7456219	Mar	11, 2027						
	7652069	Mar	04, 2023	DP					
	7732490	Mar	04, 2023		U-892				
	7851509	Feb	21, 2024	DP	U-892				
	8067472	Mar	04, 2023		U-892				
	8093295	May	16, 2026	DP					
	8101663	Mar	04, 2023		U-892				
	RE38506	Nov	29, 2013	DS	DP				
ZAFIRLUKAST - ACCOLATE									
N020547 001	5482963	Jan	09, 2013						
	5612367	Mar	18, 2014		U-189				
ZAFIRLUKAST - ACCOLATE									
N020547 003	5482963	Jan	09, 2013						
	5612367	Mar	18, 2014		U-189				
ZANAMIVIR - RELENZA									
N021036 001	5360817	Jul	26, 2013	DS	DP				
	5648379	Jul	15, 2014		U-721				
	5648379	Jul	15, 2014		U-274				
	5648379	Jul	15, 2014		U-722				
	6294572	Dec	15, 2014	DS	DP				
ZICONOTIDE - PRIALT									
N021060 003	5364842	Dec	30, 2016		U-48				
	5364842	Dec	30, 2016		U-55				
	5795864	Jun	27, 2015		DP				
ZICONOTIDE ACETATE - PRIALT									
N021060 001	5364842	Dec	30, 2016		U-55				
	5364842	Dec	30, 2016		U-48				
	5795864	Jun	27, 2015		DP				
ZICONOTIDE ACETATE - PRIALT									
N021060 002	5364842	Dec	30, 2016		U-55				
	5364842	Dec	30, 2016		U-48				
	5795864	Jun	27, 2015		DP				
ZICONOTIDE ACETATE - PRIALT									
N021060 004	5364842	Dec	30, 2016		U-55				
	5364842	Dec	30, 2016		U-48				
	5795864	Jun	27, 2015		DP				
ZILEUTON - ZYFLO CR									
N022052 001	6183778	Sep	21, 2013		DP				
ZIPRASIDONE HYDROCHLORIDE - GEODON									
N020825 001	5312925	Sep	01, 2012	DS	DP		I-615	Nov	20, 2012
	6150366	May	27, 2019		DP				
	6245766	Dec	18, 2018		U-601				
ZIPRASIDONE HYDROCHLORIDE - GEODON									
N020825 002	5312925	Sep	01, 2012	DS	DP		I-615	Nov	20, 2012
	6150366	May	27, 2019		DP				
	6245766	Dec	18, 2018		U-601				
ZIPRASIDONE HYDROCHLORIDE - GEODON									
N020825 003	5312925	Sep	01, 2012	DS	DP		I-615	Nov	20, 2012
	6150366	May	27, 2019		DP				
	6245766	Dec	18, 2018		U-601				
ZIPRASIDONE HYDROCHLORIDE - GEODON									
N020825 004	5312925	Sep	01, 2012	DS	DP		I-615	Nov	20, 2012
	6150366	May	27, 2019		DP				
	6245766	Dec	18, 2018		U-601				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N021483 001	5312925	Sep 01, 2012	DS DP		U-720	
	6150366	May 27, 2019		DP	U-719	
	6245766	Dec 18, 2018			U-601	
	7175855	May 18, 2020	DP			
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 001					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 002					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 003					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 004					PC	Aug 29, 2012
<u>ZIPRASIDONE MESYLATE - GEODON</u>						
N020919 001	6110918	Mar 26, 2017				
	6232304	Apr 01, 2017				
	6399777	Apr 01, 2017				
<u>ZOLEDRONIC ACID - RECLAST</u>						
N021817 001	4939130	Sep 02, 2012	DS DP		U-662	
	4939130*PED	Mar 02, 2013				
	7932241	Feb 05, 2028		DP		
	7932241*PED	Aug 05, 2028				
	8052987	Mar 19, 2024			U-1199	
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N021223 001	4939130	Sep 02, 2012	DS DP		U-53	
	4939130*PED	Mar 02, 2013				
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N021223 002	4939130	Sep 02, 2012	DS DP		U-53	
	4939130*PED	Mar 02, 2013				
	8324189	May 29, 2025			U-53	
	8324189	May 29, 2025			U-1308	
	8324189	May 29, 2025			U-1309	
	8324189*PED	Nov 29, 2025				
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N021223 003	4939130	Sep 02, 2012	DS DP		U-53	
	4939130*PED	Mar 02, 2013				
	7932241	Feb 05, 2028		DP		
	8324189	May 29, 2025			U-53	
	8324189	May 29, 2025			U-1308	
	8324189	May 29, 2025			U-1309	
	8324189*PED	Nov 29, 2025				
<u>ZOLMITRIPTAN - ZOMIG</u>						
N020768 001	5466699	Nov 14, 2012				
	5466699*PED	May 14, 2013				
	5863935	Nov 14, 2012				
	5863935*PED	May 14, 2013				
<u>ZOLMITRIPTAN - ZOMIG</u>						
N020768 002	5466699	Nov 14, 2012				
	5466699*PED	May 14, 2013				
	5863935	Nov 14, 2012				
	5863935*PED	May 14, 2013				
<u>ZOLMITRIPTAN - ZOMIG</u>						
N021450 004	5466699	Nov 14, 2012			U-436	
	5466699*PED	May 14, 2013				
	6750237	Nov 28, 2020		DP		
	6750237*PED	May 28, 2021				
	7220767	Nov 28, 2020		DP		
	7220767*PED	May 28, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZOLMITRIPTAN - ZOMIG-ZMT</u>						
N021231 001	5466699	Nov 14, 2012				
	5466699*PED	May 14, 2013				
<u>ZOLMITRIPTAN - ZOMIG-ZMT</u>						
N021231 002	5466699	Nov 14, 2012				
	5466699*PED	May 14, 2013				
<u>ZOLPIDEM TARTRATE - AMBIEN CR</u>						
N021774 001	6514531	Dec 01, 2019	DP			
	6514531*PED	Jun 01, 2020				
<u>ZOLPIDEM TARTRATE - AMBIEN CR</u>						
N021774 002	6514531	Dec 01, 2019	DP			
	6514531*PED	Jun 01, 2020				
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N021997 001	6761910	Sep 24, 2019	DP U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N021997 002	6761910	Sep 24, 2019	DP U-674			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N022328 001	7658945	Apr 15, 2027	DP U-1194		NP	Nov 23, 2014
	7682628	Feb 16, 2025	U-1194			
	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N022328 002	7658945	Apr 15, 2027	DP U-1194		NP	Nov 23, 2014
	7682628	Feb 16, 2025	U-1194			
	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			
<u>ZOLPIDEM TARTRATE - ZOLPIMIST</u>						
N022196 001	7632517	Oct 01, 2017	U-70			

Footnote:

- Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
- Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

ADB 1 of 55

PATENT & EXCLUSIVITY ABBREVIATIONS

D	NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES)
I	NEW INDICATION (SEE INDIVIDUAL REFERENCES)
M	MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY
PC	PATENT CHALLENGE
PED	PEDIATRIC EXCLUSIVITY
RTO	RX TO OTC SWITCH OR OTC USE
U	PATENT USE CODE (SEE INDIVIDUAL REFERENCES)
W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN
D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY
D-28	USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
D-29	INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS
D-30	5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS
D-31	CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
D-32	REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS
D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS
D-34	EVERY FOUR MONTHS DOSAGE REGIMEN
D-35	FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS
D-36	FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY

PATENT AND EXCLUSIVITY TERMS

ADB 2 of 55

EXCLUSIVITY DOSING SCHEDULE

- D-37 DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)
- D-38 CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
- D-39 CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "...1/2 TO 1 HOUR BEFORE EATING" TO "... RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..."
- D-40 ONCE-A-DAY DOSING REGIMEN
- D-41 DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
- D-42 TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
- D-43 INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
- D-44 IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
- D-45 ONCE DAILY DOSING FOR MAINTENANCE ONLY
- D-46 NEW DOSING REGIMEN OF 80MG DAILY
- D-47 PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
- D-48 ADMINISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL
- D-49 PEDIATRIC DOSING GUIDELINES
- D-50 INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
- D-51 OPTIONAL STARTING DOSE OF 40MG/DAY
- D-52 ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
- D-53 USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
- D-54 USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
- D-55 ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
- D-56 ADDITION OF POSTPRANDIAL DOSING
- D-57 3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
- D-58 CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
- D-59 REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY
- D-60 ADDITION OF A POST-OPERATIVE DOSING REGIMEN
- D-61 ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-62 ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-63 TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
- D-64 INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML
- D-65 CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
- D-66 DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
- D-67 SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
- D-68 CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
- D-69 SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
- D-70 80MG ONCE DAILY DOSING REGIMEN
- D-71 EIGHT WEEK DOSING REGIMEN
- D-72 INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
- D-73 ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-74 ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-75 INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
- D-76 FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
- D-77 ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)
- D-78 USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
- D-79 NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE

PATENT AND EXCLUSIVITY TERMS

ADB 3 of 55

EXCLUSIVITY DOSING SCHEDULE

- D-80 CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
- D-81 NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-82 USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-83 750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
- D-84 ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS
- D-85 LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
- D-86 FOR USE IN SELECT EXTERNAL INSULIN PUMPS
- D-87 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- D-88 NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES
- D-89 USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
- D-90 ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
- D-91 ALTERNATE INTERMITTENT DOSING REGIMEN
- D-92 ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME
- D-93 ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS
- D-94 NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD)
- D-95 BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE
- D-96 ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS
- D-97 PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFPRE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE
- D-98 DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE
- D-99 ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS
- D-100 750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
- D-101 ONCE DAILY IN CHRONIC IDIOPATHIC UTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- D-102 NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER
- D-103 NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.
- D-104 0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS
- D-105 USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-106 FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA
- D-107 PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- D-108 TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS
- D-109 PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE
- D-110 TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17
- D-111 PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREATMENT OF ERECTILE DYSFUNCTION
- D-112 PROVIDES FOR PEDIATRIC PUMP USE
- D-113 ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN
- D-114 NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS
- D-115 STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
- D-116 ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS

PATENT AND EXCLUSIVITY TERMS

ADB 4 of 55

EXCLUSIVITY DOSING SCHEDULE

- D-117 50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER
- D-118 TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR
- D-119 DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE
- D-120 DOSING REGIMEN ADJUSTMENTS
- D-121 CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION
- D-122 USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
- D-123 ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS
- D-124 ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
- D-125 EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.
- D-126 CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG
- D-127 DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DISEASE
- D-128 SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO
- D-129 800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT -EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNIVIR RESISTANCE ASSOCIATED SUBSTITUTIONS
- D-130 DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN
- D-131 EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG
- D-132 45MG FOR 6 MONTH ADMINISTRATION
- D-133 NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE
- D-134 INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY

EXCLUSIVITY INDICATION

- I-1 DYSMENORRHEA
- I-2 CHOLANGIOPANCREATOGRAPHY
- I-3 INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
- I-4 PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)
- I-5 HYSTEROSALPINGOGRAPHY
- I-6 TREATMENT OF JUVENILE ARTHRITIS
- I-7 BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN
- I-8 ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY
- I-9 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
- I-10 PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY
- I-11 RELIEF OF MILD TO MODERATE PAIN
- I-12 TREATMENT OF CUTANEOUS CANDIDIASIS
- I-13 URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI
- I-14 SEBORRHEIC DERMATITIS
- I-15 PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
- I-16 STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM
- I-17 MANAGEMENT OF CONGESTIVE HEART FAILURE
- I-18 ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
- I-19 HERNIOGRAPHY
- I-20 KNEE ARTHROGRAPHY
- I-21 HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
- I-22 RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
- I-23 SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
- I-24 TREATMENT OF RHEUMATOID ARTHRITIS

PATENT AND EXCLUSIVITY TERMS

ADB 5 of 55

EXCLUSIVITY INDICATION

I-25 ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS
I-26 TREATMENT OF LIVER FLUKES
I-27 ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE
I-28 SELECTIVE ADULT VISCERAL ARTERIOGRAPHY
I-29 METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION
I-30 TREATMENT OF TINEA PEDIS
I-31 CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES
I-32 PEDIATRIC MYELOGRAPHY
I-33 ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN
I-34 ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT
I-35 PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING
I-36 ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS
I-37 RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS
I-38 CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)
I-39 TREATMENT OF ACUTE MYOCARDIAL INFARCTION
I-40 PRIMARY NOCTURNAL ENURESIS
I-41 MIGRAINE HEADACHE PROPHYLAXIS
I-42 HERPES ZOSTER
I-43 HERPES SIMPLEX ENCEPHALITIS
I-44 MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY
I-45 ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS
I-46 USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING
I-47 TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
I-48 PEDIATRIC ANGIOCARDIOGRAPHY
I-49 TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI
I-50 FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER
I-51 TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS
I-52 PEDIATRIC EXCRETORY UROGRAPHY
I-53 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-54 RENAL CONCENTRATION CAPACITY TEST
I-55 HYPERTENSION
I-56 EROSIIVE GASTROESOPHAGEAL REFLUX DISEASE
I-57 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER
I-58 INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS
I-59 ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE
I-60 SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE
I-61 FEMALE ANDROGENETIC ALOPECIA
I-62 PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-63 ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION
I-64 PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS
I-65 PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
I-66 UNCOMPLICATED GONORRHEA
I-67 TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
I-68 CENTRAL PRECOCIOUS PUBERTY
I-69 SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
I-70 USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
I-71 VARICELLA INFECTIONS (CHICKENPOX)
I-72 PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE
I-73 INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
I-74 INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY

PATENT AND EXCLUSIVITY TERMS

ADB 6 of 55

EXCLUSIVITY INDICATION

I-75	TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSION ESOPHAGITIS
I-76	PREVENTION OF OSTEOPOROSIS
I-77	DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM
I-78	CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY
I-79	MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM
I-80	DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE
I-81	PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS
I-82	TREATMENT OF TRAVELERS' DIARRHEA
I-83	ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN
I-84	INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION
I-85	TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
I-86	TREATMENT OF SECONDARY CARNITINE DEFICIENCY
I-87	RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88	MANAGEMENT OF ENDOMETRIOSIS
I-89	EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90	INTENSIVE CARE UNIT SEDATION
I-91	MONOTHERAPY USE FOR HYPERTENSION
I-92	ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94	USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
I-95	TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-96	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
I-97	ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT
I-98	TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY
I-99	PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100	TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102	TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
I-103	PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104	TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105	TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106	TREATMENT OF ACROMEGALY
I-107	VAGINAL CANDIDIASIS
I-108	EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
I-109	TYPHOID FEVER
I-110	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
I-111	TREATMENT OF PAGET'S DISEASE OF BONE
I-112	MANAGEMENT OF MODERATE TO SEVERE PAIN
I-113	TREATMENT OF PROSTATITIS
I-114	USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE
I-115	USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK
I-116	MAINTENANCE OF HEALING OF EROSION ESOPHAGITIS
I-117	TO SLOW THE PROGRESSION FO CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118	PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY
I-119	TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
I-120	MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
I-121	EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS
I-122	PSORIASIS OF THE SCALP
I-123	RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER

PATENT AND EXCLUSIVITY TERMS

ADB 7 of 55

EXCLUSIVITY INDICATION

- I-124 LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
- I-125 EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
- I-126 ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
- I-127 TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
- I-128 IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...
- I-129 TREATMENT OF ALCOHOL DEPENDENCE
- I-130 MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
- I-131 PERIPHERAL ARTERIOGRAPHY
- I-132 TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
- I-133 MANAGEMENT OF CHRONIC STABLE ANGINA
- I-134 HEART FAILURE POST MYOCARDIAL INFARCTION
- I-135 BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
- I-136 IDIOPATHIC CHRONIC URTICARIA
- I-137 PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
- I-138 TREATMENT OF ACUTE RECURRENT GENITAL HERPES
- I-139 PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN
- I-140 PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE
- I-141 TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
- I-142 LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
- I-143 EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
- I-144 ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
- I-145 0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
- I-146 CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS
- I-147 PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
- I-148 TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO₂) IS LESS THAN OR EQUAL TO 55 TORR
- I-149 TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
- I-150 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
- I-151 PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
- I-152 SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS
- I-153 MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN]
- I-154 PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
- I-155 TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT
- I-156 ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
- I-157 TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES
- I-158 TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER
- I-159 FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES
- I-160 TREATMENT OF BACTERIAL CORNEAL ULCERS
- I-161 TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY
- I-162 FOR USE IN PATIENTS 6-11 YEARS OF AGE
- I-163 TREATMENT OF PHOTOPHOBIA
- I-164 CHRONIC BACTERIAL PROSTATITIS
- I-165 MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
- I-166 TREATMENT OF BULIMIA
- I-167 COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS
- I-168 MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)
- I-169 USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER

PATENT AND EXCLUSIVITY TERMS

ADB 8 of 55

EXCLUSIVITY INDICATION

- I-170 PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS
- I-171 RELIEF OF SYMPTOMS OF THE COMMON COLD
- I-172 TREATMENT OF INITIAL EPISODE OF GENITAL HERPES
- I-173 PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY
- I-174 PELVIC INFLAMMATORY DISEASE
- I-175 TREATMENT OF TINEA CORPORIS AND TINEA CRURIS
- I-176 TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
- I-177 TX OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
- I-178 TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
- I-179 NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
- I-180 TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
- I-181 TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
- I-182 TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
- I-183 MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
- I-184 TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG)
- I-185 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- I-186 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
- I-187 PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- I-188 TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
- I-189 TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
- I-190 PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
- I-191 ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
- I-192 THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
- I-193 TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
- I-194 CONGESTIVE HEART FAILURE
- I-195 FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER
- I-196 ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
- I-197 MAINTENANCE OF HEALING OF DUODENAL ULCER
- I-198 FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER
- I-199 MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES
- I-200 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
- I-201 EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
- I-202 SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
- I-203 MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
- I-204 USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- I-205 INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS
- I-206 TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
- I-207 FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
- I-208 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
- I-209 PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
- I-210 TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
- I-211 FOR USE IN PEDIATRIC POPULATION
- I-212 TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME

PATENT AND EXCLUSIVITY TERMS

ADB 9 of 55

EXCLUSIVITY INDICATION

- I-213 TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
- I-214 TREATMENT OF OSTEOPOROSIS
- I-215 PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
- I-216 FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- I-217 PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
- I-218 USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)
- I-219 USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
- I-220 TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
- I-221 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
- I-222 PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
- I-223 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
- I-224 FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- I-225 USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
- I-226 FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
- I-227 SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)
- I-228 PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL
- I-229 PRILOSEC (OMEPRazole), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
- I-230 IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
- I-231 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
- I-232 TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
- I-233 PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
- I-234 FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER
- I-235 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
- I-236 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- I-237 MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- I-238 ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS
- I-239 TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- I-240 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS
- I-241 USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER
- I-242 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS
- I-243 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS
- I-244 REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
- I-245 TREATMENT OF ACUTE SINUSITIS
- I-246 TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
- I-247 USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG

PATENT AND EXCLUSIVITY TERMS

ADB 10 of 55

EXCLUSIVITY INDICATION

- I-248 INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM
- I-249 TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY
- I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C
- I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER
- I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN
- I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN
- I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)
- I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)
- I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY
- I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION
- I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE
- I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
- I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)
- I-261 TREATMENT OF SOCIAL ANXIETY DISORDER
- I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12
- I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY
- I-264 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION
- I-265 TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER
- I-266 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES
- I-267 USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES
- I-268 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE
- I-269 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
- I-270 ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
- I-271 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- I-272 TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOID IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
- I-273 ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
- I-274 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
- I-275 USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES
- I-276 USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
- I-277 TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA
- I-278 TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)
- I-279 TREATMENT OF POST-TRAUMATIC STRESS DISORDER
- I-280 USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
- I-281 INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
- I-282 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
- I-283 TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS
- I-284 TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE

PATENT AND EXCLUSIVITY TERMS

ADB 11 of 55

EXCLUSIVITY INDICATION

- I-285 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER
- I-286 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III
- I-287 USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH
- I-288 CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINAPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE
- I-289 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL
- I-290 PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
- I-291 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- I-292 TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- I-293 TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
- I-294 TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS
- I-295 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS
- I-296 LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY
- I-297 SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-298 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA
- I-299 USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM
- I-300 PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE
- I-301 TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS
- I-302 TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME
- I-303 INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS
- I-304 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV
- I-305 TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
- I-306 INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE
- I-307 NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES
- I-308 TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS
- I-309 USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- I-310 REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES
- I-311 ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS
- I-312 FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
- I-313 EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE
- I-314 TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES
- I-315 THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
- I-316 TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID
- I-317 PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER
- I-318 FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
- I-319 USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS
- I-320 TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)
- I-321 JUVENILE RHEUMATOID ARTHRITIS
- I-322 USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
- I-323 COLORECTAL CANCER
- I-324 REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
- I-325 PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION

PATENT AND EXCLUSIVITY TERMS

ADB 12 of 55

EXCLUSIVITY INDICATION

- I-326 GENERALIZED ANXIETY DISORDER
- I-327 SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
- I-328 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
- I-329 UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
- I-330 MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTEMS IN PATIENTS WITH GERD
- I-331 TREATMENT OF MODERATE ACNE VULGARIS
- I-332 EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN)
- I-333 TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
- I-334 LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
- I-335 ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
- I-336 EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
- I-337 PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME
- I-338 MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
- I-339 TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
- I-340 ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
- I-341 BREAST CANCER COMBINATION THERAPY
- I-342 USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- I-343 USE OF COREG FOR SEVERE HEART FAILURE
- I-344 ACNE VULGARIS
- I-345 TREATMENT OF POSTTRAUMATIC STRESS DISORDER
- I-346 TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
- I-347 TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE
- I-348 LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
- I-349 ACUTE CORONARY SYNDROME
- I-350 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
- I-351 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
- I-352 ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
- I-353 TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
- I-354 MANAGEMENT OF POST HERPETIC NEURALGIA
- I-355 PREMENSTRUAL DYSPHORIC DISORDER
- I-356 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
- I-357 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
- I-358 TREATMENT OF PANIC DISORDER
- I-359 TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE
- I-360 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE
- I-361 TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
- I-362 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
- I-363 ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
- I-364 TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
- I-365 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
- I-366 PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
- I-367 COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS: METFORMIN, SULFONYLUREAS, REPAGLINIDE, OR THIAZOLIDINEDIONES
- I-368 USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE

PATENT AND EXCLUSIVITY TERMS

ADB 13 of 55

EXCLUSIVITY INDICATION

- I-369 PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
- I-370 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
- I-371 HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- I-372 NOSOCOMIAL PNEUMONIA
- I-373 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
- I-374 SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS
- I-375 FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- I-376 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
- I-377 USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
- I-378 RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
- I-379 USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION
- I-380 TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
- I-381 TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
- I-382 FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
- I-383 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
- I-384 USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
- I-385 MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD"INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML TO STREPTOCOCCUS PNEUMONIAE
- I-386 RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
- I-387 ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE
- I-388 TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
- I-389 SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
- I-390 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE,DIABETES,PERIPHERAL VESSEL DISEASE,STROKE HISTORY,OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH,REDUCE NONFATAL MI & STROKE.....
- I-391 ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY
- I-392 TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL
- I-393 CHRONIC BACTERIAL PROSTATITIS
- I-394 USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES
- I-395 TO IMPROVE PHYSICAL FUNCTION
- I-396 EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
- I-397 EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
- I-398 IDIOPATHIC SHORT STATURE
- I-399 TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESES, PERITONITIS AND PLEURAL SPACE INFECTIONS
- I-400 USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-401 LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
- I-402 DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
- I-403 USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESSIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE
- I-404 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY

PATENT AND EXCLUSIVITY TERMS

ADB 14 of 55

EXCLUSIVITY INDICATION

- I-405 TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN
- I-406 PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
- I-407 IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION
- I-408 STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE IDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP)
- I-409 ESOPHAGEAL CANDIDIASIS
- I-410 USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS
- I-411 EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS
- I-412 MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-413 ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-414 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
- I-415 SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY
- I-416 THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
- I-417 USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
- I-418 ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
- I-419 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-420 TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
- I-421 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
- I-422 INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
- I-423 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
- I-424 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
- I-425 FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
- I-426 TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-427 TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-428 FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
- I-429 FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
- I-430 FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
- I-431 NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS
- I-432 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
- I-433 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
- I-434 PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA
- I-435 CHRONIC IDIOPATHIC CONSTIPATION
- I-436 FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
- I-437 TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-438 EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS
- I-439 USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY
- I-440 FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY

PATENT AND EXCLUSIVITY TERMS

ADB 15 of 55

EXCLUSIVITY INDICATION

- I-441 USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS
- I-442 USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS
- I-443 TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER
- I-444 USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIIVE ESOPHAGITIS
- I-445 TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)
- I-446 EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS
- I-447 USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A)
- I-448 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE
- I-449 TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER
- I-450 TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT
- I-451 MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN
- I-452 EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
- I-453 USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)
- I-454 MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CHRON'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS
- I-455 MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%
- I-456 TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR
- I-457 TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SUREGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLIATIONS
- I-458 USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
- I-459 NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN
- I-460 TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER
- I-461 USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED
- I-462 LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE
- I-463 TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION
- I-464 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME
- I-465 PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER
- I-466 FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS
- I-467 USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES
- I-468 USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUSE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFARCTION
- I-469 RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
- I-470 DIABETIC PERIPHERAL NEUROPATHIC PAIN
- I-471 INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE
- I-472 USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE
- I-473 USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER
- I-474 TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECIEIVING AN ERYTHROPOIETIN

PATENT AND EXCLUSIVITY TERMS

ADB 16 of 55

EXCLUSIVITY INDICATION

- I-475 PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
- I-476 TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS
- I-477 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE
- I-478 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS
- I-479 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES
- I-480 PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE
- I-481 INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
- I-482 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES
- I-483 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- I-484 FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS
- I-485 TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
- I-486 ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI
- I-487 INDICATED FOR THE RELIEF OF THE INFAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER
- I-488 MAINTENANCE THERAPY IN BIPOLAR I DISORDER
- I-489 FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES
- I-490 FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE
- I-491 INFLUENZA PROPHYLAXIS
- I-492 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES
- I-493 ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA
- I-494 CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE
- I-495 ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY
- I-496 LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES
- I-497 PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER
- I-498 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
- I-499 USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY
- I-500 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- I-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.
- I-502 FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY
- I-503 TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-504 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME
- I-505 TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES
- I-506 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
- I-507 ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- I-508 PREMENSTRUAL DYSPHONIC DISORDER
- I-509 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER

PATENT AND EXCLUSIVITY TERMS

ADB 17 of 55

EXCLUSIVITY INDICATION

- I-510 ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP)
- I-511 ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP)
- I-512 ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY
- I-513 ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)
- I-514 ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL)
- I-515 PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY
- I-516 PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
- I-517 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS)
- I-518 TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED
- I-519 USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
- I-520 USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL
- I-521 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY
- I-522 TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.
- I-523 USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE
- I-524 GENERALIZED ANXIETY DISORDER (GAD)
- I-525 USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS
- I-526 TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS
- I-527 ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
- I-528 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE
- I-529 TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE
- I-530 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER
- I-531 MAINTENANCE TREATMENT OF SCHIZOPHRENIA
- I-532 TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES
- I-533 ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)
- I-534 EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECCURENCE OF VTE IN PATIENTS WITH CANCER
- I-535 MANAGEMENT OF FIBROMYALGIA
- I-536 FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME
- I-537 LONG TERM TREATMENT OF PANIC DISORDER
- I-538 SHORT TERM TREATMENT OF PANIC DISORDER
- I-539 REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER
- I-540 TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17
- I-541 TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17
- I-542 EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM "INOPERABLE" PATIENTS TO ALL PATIENTS
- I-543 USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
- I-544 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
- I-545 ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- I-546 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
- I-547 ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS
- I-548 SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE
- I-549 USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
- I-550 TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE
- I-551 TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME
- I-552 ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER

PATENT AND EXCLUSIVITY TERMS

ADB 18 of 55

EXCLUSIVITY INDICATION

- I-553 FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- I-554 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONIS AND ABSCESES
- I-555 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS
- I-556 PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY
- I-557 USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD
- I-558 MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- I-559 ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
- I-560 MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX
- I-561 LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER
- I-562 MAINTENANCE TREATMENT OF ATTENTION-DEFICIT DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
- I-563 ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
- I-564 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
- I-565 USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)
- I-566 MANAGEMENT OF FIBROMYALGIA
- I-567 INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
- I-568 USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR
- I-569 TREATMENT OF CHRONIC HEPATITIS B
- I-570 TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE
- I-571 NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQUAMOUS NON-SMALL CELL LUNG CANCER
- I-572 TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.
- I-573 TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET
- I-574 MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION
- I-575 MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA
- I-576 ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA
- I-577 SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCUDURES
- I-578 EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS
- I-579 TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION
- I-580 INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
- I-581 TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- I-582 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- I-583 ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTROINTESTINAL STROMAL TUMORS (GIST)
- I-584 TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOIDES FOR AT LEAST 12 MONTHS
- I-585 TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS
- I-586 COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
- I-587 ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION
- I-588 ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION
- I-589 TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE
- I-590 ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE)
- I-591 TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE
- I-592 ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE)
- I-593 TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD)
- I-594 INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS
- I-595 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

PATENT AND EXCLUSIVITY TERMS

ADB 19 of 55

EXCLUSIVITY INDICATION

- I-596 USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
- I-597 MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
- I-598 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING
- I-599 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
- I-600 FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
- I-601 MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY
- I-602 TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE
- I-603 GOUT FLARES
- I-604 PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK
- I-605 ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER
- I-606 TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY
- I-607 INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS
- I-608 REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY
- I-610 TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION
- I-611 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY
- I-612 MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS
- I-613 MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE
- I-614 SHORT TERM TREATMENT OF EROSIIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER
- I-615 MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
- I-616 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE
- I-617 MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD)
- I-618 ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
- I-619 INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY
- I-620 FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED
- I-621 PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)
- I-622 ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER
- I-623 TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE
- I-624 MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY
- I-625 PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY
- I-626 RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATENTS 2 YEARS OF AGE AND OLDER
- I-627 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.
- I-628 MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS
- I-629 ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-630 TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.
- I-631 PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION
- I-632 MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN

PATENT AND EXCLUSIVITY TERMS

ADB 20 of 55

EXCLUSIVITY INDICATION

- I-633 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
- I-634 TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
- I-635 ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
- I-636 TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER
- I-637 USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER
- I-638 FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.
- I-639 TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE
- I-640 MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
- I-641 TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
- I-642 TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
- I-643 REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.
- I-644 MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED)
- I-645 MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
- I-646 SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD)
- I-647 SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
- I-648 TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
- I-649 TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
- I-650 TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY
- I-651 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY
- I-652 MANAGEMENT OF POSTHERPETIC NEURALGIA
- I-653 TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
- I-654 MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE
- I-655 TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE,HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
- I-656 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
- I-657 PLAQUE PSORIASIS OF THE SCALP
- I-658 FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY
- I-659 PLAQUE PSORIASIS OF THE BODY
- I-660 TREATMENT OF DEEP VEIN THROMBOSIS
- I-661 TREATMENT OF PULMONARY EMBOLISM
- I-662 REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR PULMONARY EMBOLISM
- I-663 IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- I-664 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY

EXCLUSIVITY MISCELLANEOUS

- M-1 INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
- M-2 APPROVAL FOR ADDITION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
- M-3 ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN
- M-4 CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD

PATENT AND EXCLUSIVITY TERMS

ADB 21 of 55

EXCLUSIVITY MISCELLANEOUS

- M-5 INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION
- M-6 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION
- M-7 CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
- M-8 ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
- M-9 ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
- M-10 INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
- M-11 USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
- M-12 NEW LANGUAGE FOR PEDIATRIC USE
- M-13 INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
- M-14 ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
- M-15 LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
- M-16 CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
- M-17 INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
- M-18 INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
- M-19 INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
- M-20 LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
- M-21 COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
- M-22 CHANGE IN TIME TO ONSET OF ACTION
- M-23 INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
- M-24 INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
- M-25 ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT
- M-26 INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
- M-27 INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY
- M-28 INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION
- M-29 LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS
- M-30 CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
- M-31 INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
- M-32 ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
- M-33 INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
- M-34 EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-35 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
- M-36 ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE
- M-37 INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS
- M-38 SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL
- M-39 FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST
- M-40 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS
- M-41 REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED "THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENSITY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA"
- M-42 ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION

PATENT AND EXCLUSIVITY TERMS

ADB 22 of 55

EXCLUSIVITY MISCELLANEOUS

- M-43 INCLUSION OF RESULTS OF STUDY-"PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION
- M-44 CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18
- M-45 INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING - EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY
- M-46 PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY
- M-47 PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS
- M-48 CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES
- M-49 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGLAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN
- M-50 NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION
- M-51 INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY
- M-52 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- M-53 FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT
- M-54 INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
- M-55 INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.
- M-56 INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON "GEMINI" TRIAL
- M-57 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS
- M-58 CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS
- M-59 RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATED EXPERIENCED PEDIATRIC SUBJECTS AND ADOLSCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS
- M-60 CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WITH HYPERCHOLESTEROLEMIA
- M-61 REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-62 CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES
- M-63 DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY
- M-64 CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS
- M-65 ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS)
- M-66 USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER
- M-67 INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS
- M-68 DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL
- M-69 RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY
- M-70 PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY
- M-71 REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- M-72 INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS
- M-73 NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH - SECRETING PITUITARY ADENOMAS
- M-74 REVISIONS TO CLINICAL STUDIES - CHILDREN AND ADOLSCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS
- M-75 PROVISION FOR USE OF ARGAGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS)
- M-76 REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA

PATENT AND EXCLUSIVITY TERMS

ADB 23 of 55

EXCLUSIVITY MISCELLANEOUS

- M-77 USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS
- M-78 CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY
- M-79 LABELING REVISIONS RELATED TO SMOKING AND ERLOTIMB EXPOSURE
- M-80 ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
- M-81 ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOXICOSIS)
- M-82 LABELING REVISIONS RELATED TO CLINICAL STUDIES
- M-83 ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL
- M-84 STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY
- M-85 INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD
- M-86 LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION
- M-87 INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION
- M-88 ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE
- M-89 PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM
- M-90 LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12
- M-91 UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS
- M-92 UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED "A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION
- M-93 EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS
- M-94 INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE
- M-95 INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108
- M-96 UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION
- M-97 LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES - NOT INDICATED FOR USE IN PEDIATRIC POPULATION
- M-98 NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.
- M-99 ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.
- M-100 INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS
- M-101 INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL
- M-102 INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, "INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY."
- M-103 SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING
- M-104 INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY
- M-105 NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE
- M-106 ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT

PATENT AND EXCLUSIVITY TERMS

ADB 24 of 55

EXCLUSIVITY MISCELLANEOUS

- M-107 INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED,1-MONTH,BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516, ENTITLED "STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY".
- M-108 CHANGES ARE BASED ON RESULTS FROM STUDY CV181057
- M-109 CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
- M-110 CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
- M-111 LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS
- M-112 REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS
- M-113 LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS
- M-114 CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR)
- M-115 REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES
- M-116 LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008
- M-117 ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL
- M-118 LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36
- M-119 LABELING CHANGES REGARDING MISSED DOSES
- M-120 CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS
- M-121 LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43
- M-122 LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL
- M-123 UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY

PATENT USE

- U-1 PREVENTION OF PREGNANCY
- U-2 TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
- U-3 TREATMENT OF HYPERTENSION
- U-4 PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS
- U-5 METHOD OF PRODUCING BRONCHODILATION
- U-6 METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS
- U-7 INCREASING CARDIAC CONTRACTILITY
- U-8 ACUTE MYOCARDIAL INFARCTION
- U-9 CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT
- U-10 DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS
- U-11 TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS
- U-12 METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION
- U-13 A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT
- U-14 ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES
- U-15 METHOD OF LOWERING INTRAOCULAR PRESSURE
- U-16 USE IN LUNG SCANNING PROCEDURES
- U-17 TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
- U-18 METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
- U-19 TREATMENT OF INFLAMMATION
- U-20 A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
- U-21 TREATMENT OF HUMANS SUFFERING UNDESIRE UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS
- U-22 METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS
- U-23 METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE
- U-24 METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST
- U-25 REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS

PATENT AND EXCLUSIVITY TERMS

ADB 25 of 55

PATENT USE

U-26 REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-27 DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-28 CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY
U-29 CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY
U-30 CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY
U-31 INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY
U-32 PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN
U-33 TREATING VIRAL INFECTIONS IN A MAMMAL
U-34 TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL
U-35 TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION
U-36 METHODS OF TREATING BACTERIAL ILLNESSES
U-37 METHOD OF TREATING GASTROINTESTINAL DISEASE
U-38 TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
U-39 ANGINA PECTORIS
U-40 METHOD OF TREATMENT OF BURNS
U-41 METHOD OF TREATING CARDIAC ARRHYTHMIAS
U-42 ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER
U-43 MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-44 RELIEF OF NAUSEA AND VOMITING
U-45 TREATMENT OF INFLAMMATION AND ANALGESIA
U-46 TREATMENT OF PANIC DISORDER
U-47 STIMULATION OF THE RELEASE OF GROWTH HORMONE
U-48 ANALGESIA
U-49 SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
U-50 USE IN TREATING INFLAMMATORY DERMATOSES
U-51 BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
U-52 TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-53 HYPERCALCEMIA OF MALIGNANCY
U-54 REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS
U-55 TREATMENT OF PAIN
U-56 AID TO SMOKING CESSATION
U-57 OPHTHALMIC USE OF NORFLOXACIN
U-58 METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
U-59 METHOD OF TREATING HYPERCHOLESTEROLEMIA
U-60 NASAL ADMINISTRATION OF BUTORPHANOL
U-61 CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD
U-62 CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY
U-63 ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE
U-64 TREATMENT OF VIRAL INFECTIONS
U-65 METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
U-66 TRIPHASIC REGIMEN
U-67 METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL
U-68 TREATMENT OF ACTINIC KERATOSIS
U-69 TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS
U-70 TREATMENT OF TRANSIENT INSOMNIA
U-71 METHOD OF TREATMENT OF HEART FAILURE
U-72 TREATMENT OF MIGRAINE
U-73 METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES
U-74 METHOD OF PROVIDING HYPNOTIC EFFECT
U-75 RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
U-76 USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
U-77 TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-78 ULCERATIVE COLITIS
U-79 SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD
U-80 METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
U-81 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS

PATENT AND EXCLUSIVITY TERMS

ADB 26 of 55

PATENT USE

U-82 TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE

U-83 TREATMENT OF SEIZURES

U-84 A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS

U-85 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

U-86 METHOD OF TREATING CERTAIN FORMS OF EPILEPSY

U-87 METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS

U-88 TREATMENT OF MODERATE PLAQUE PSORIASIS

U-89 TREATMENT OR PROPHYLAXIS OF EMESIS

U-90 TREATMENT OF PSYCHOTIC DISORDERS

U-91 ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS

U-92 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY

U-93 USE AS AN ANTIHISTAMINE/DECONGESTANT

U-94 TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED

U-95 SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS

U-96 METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS

U-97 A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT

U-98 A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL

U-99 METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM

U-100 METHOD OF TREATING OCULAR INFLAMMATION

U-101 ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED

U-102 METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN

U-103 TREATMENT OF OCULAR HYPERTENSION

U-104 TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE

U-105 EMESIS

U-106 TREATMENT OF EPILEPSY

U-107 TREATMENT OF HYPERTENSION AND ANGINA PECTORIS

U-108 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGICAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIIVE ESOPHAGITIS

U-109 ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE

U-110 USE AS A RETRIEVABLE PERSSARY

U-111 DIABETES

U-112 CONTRACEPTION

U-113 METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE

U-114 USE FOR INHIBITING BONE RESORPTION

U-115 USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS

U-116 METHOD OF MYOCARDIAL IMAGING

U-117 TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES

U-118 METHOD OF LOWERING BLOOD SUGAR LEVEL

U-119 TREATMENT OF NASAL HYPERSECRETION

U-120 CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES

U-121 METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS

U-122 A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS

U-123 METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS

U-124 TREATMENT OF ACNE

U-125 TREATMENT NEUROGENERATIVE DISEASES

U-126 TREATMENT OF GASTRITIS

U-127 METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE

U-128 METHOD FOR TREATMENT OF TUMORS

U-129 METHOD TO DESTROY OR IMPAIR TARGET CELLS

U-130 MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS

U-131 PHOTODAMAGED SKIN

PATENT AND EXCLUSIVITY TERMS

ADB 27 of 55

PATENT USE

U-132 INHIBITING HIV PROTEASE
U-133 MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET
U-134 TREATMENT OF ACNE VULGARIS
U-135 ANTITUMOR AGENT
U-136 PROCESS FOR WASTE NITROGEN REMOVAL
U-137 METHOD OF TREATING BACTERIAL VAGINOSIS
U-138 TREATMENT OF ALLERGIC RHINITIS
U-139 TREATMENT OF ALLERGIC REACTIONS
U-140 USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION
U-141 TREATMENT OF ULCERATIVE COLITIS
U-142 METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE
U-143 BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING
U-144 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS
U-145 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS
U-146 METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS
U-147 DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF $^{13}\text{CO}_2$
U-148 DEVICE FOR COLLECTING A BREATH SAMPLE
U-149 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES
U-150 METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE
U-151 RELIEF OF SYMPTOMS OF THE COMMON COLD
U-152 METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER
U-153 TREATMENT OF INITIAL EPISODE GENITAL HERPES
U-154 METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER
U-155 TREATMENT OF ERECTILE DYSFUNCTION
U-156 METHOD OF PROVIDING ANESTHESIA
U-157 TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY
U-158 ANGINA
U-159 TREATMENT OF INTERSTITIAL CYSTITIS
U-160 TREATMENT OF BACTERIAL INFECTIOUS DISEASE
U-161 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
U-162 METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
U-163 METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
U-164 METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
U-165 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
U-166 TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER
U-167 METHOD FOR TREATING HIV-1 INFECTION
U-168 METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
U-169 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
U-170 METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
U-171 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
U-172 TREATMENT OF GENITAL WARTS
U-173 ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
U-174 USE AS AN ANTIHISTAMINE AGENT
U-175 METHOD OF TREATING MALIGNANT TUMORS
U-176 METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES
U-177 FUNGICIDE
U-178 FACILITATED ADHERENCE OF AGENTS TO SKIN
U-179 ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
U-180 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-181 PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
U-182 USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION

PATENT AND EXCLUSIVITY TERMS

ADB 28 of 55

PATENT USE

U-183 TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
U-184 TREATING ALLERGIC EYE DISEASES IN HUMANS
U-185 METHOD OF TREATING HYPERTENSION
U-186 METHOD FOR TREATING GI DISORDERS CAUSED BY H.PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
U-187 THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
U-188 TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER
U-189 ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
U-190 USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
U-191 METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
U-192 USE IN TREATING ALLERGIC REACTIONS
U-193 PSORIASIS
U-194 TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE
U-195 METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON
U-196 TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
U-197 USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
U-198 TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA
U-199 METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT
U-200 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-201 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-202 METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
U-203 TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-204 USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-205 METHOD FOR TREATING HEARTBURN
U-206 METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION
U-207 USE AS NASAL SPRAY
U-208 VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
U-209 VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION
U-210 METHOD OF TREATING CONGESTIVE HEART FAILURE
U-211 USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-212 METHOD OF TREATMENT OF PARKINSON'S DISEASE
U-213 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
U-214 USE AS A BLOOD GLUCOSE-LOWERING AGENT
U-215 TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
U-216 TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE
U-217 METHOD OF PRODUCING ANESTHESIA
U-218 METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
U-219 TREATMENT OF PARKINSON'S DISEASE
U-220 METHOD OF DIAGNOSIS
U-221 SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
U-222 METHOD OF TREATING PAGET'S DISEASE USING ACTONEL
U-223 TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
U-224 CONTROLLING INTRAOCULAR PRESSURE
U-225 METHOD FOR DELIVERY
U-226 METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
U-227 NASAL ADMINISTRATION
U-228 ASTHMA
U-229 CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
U-230 PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS

PATENT AND EXCLUSIVITY TERMS

ADB 29 of 55

PATENT USE

U-231 USE IN PARKINSON'S DISEASE
U-232 METHOD OF TREATING MIGRAINE
U-233 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-234 METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
U-235 METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
U-236 TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY
U-237 METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
U-238 IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IS ENHANCED....
U-239 TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
U-240 TREATMENT OF ACUTE MIGRAINE ATTACKS
U-241 FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-242 USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
U-243 TOPICAL ADMINISTRATION
U-244 PLATELET AGGREGATION INHIBITORS
U-245 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-246 PHOSPHATE BINDING
U-247 TREATMENT OF RHEUMATOID ARTHRITIS
U-248 TREATMENT OF HIV
U-249 METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE
U-250 TREATMENT OF HEPATITIS B INFECTION
U-251 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
U-252 METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE
U-253 ORAL TRANSMUCOSAL USE
U-254 USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
U-255 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
U-256 TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
U-257 TREATMENT OF HIV INFECTION
U-258 TREATMENT OF NEURODEGENERATIVE DISEASES
U-259 TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE
U-260 REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
U-261 TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
U-262 TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
U-263 METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN
U-264 METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN
U-265 USE AS LAXATIVE
U-266 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS
U-267 PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
U-268 ACROMEGALY
U-269 EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
U-270 METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
U-271 METHOD OF TREATING TUMORS
U-272 METHOD OF TREATING CARCINOMA

PATENT AND EXCLUSIVITY TERMS

ADB 30 of 55

PATENT USE

U-273 CUTANEOUS T-CELL LYMPHOMA
U-274 ZANAMIVIR FOR INHALATION
U-275 METHOD OF USE OF THE DRUG SUBSTANCE
U-276 METHOD OF USE OF LEVOBUPIVACAINE
U-277 NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
U-278 METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
U-279 METHOD OF USE OF THE APPROVED PRODUCT
U-280 TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
U-281 ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS
U-282 METHOD OF TREATING BACTERIAL INFECTIONS
U-283 METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
U-284 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
U-285 DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
U-286 DEPRESSION
U-287 TREATMENT OR PREVENTION OF OSTEOPOROSIS
U-288 THERAPY OF INFLUENZA
U-289 TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
U-290 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
U-291 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN
U-292 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE
U-293 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
U-294 TREATMENT OF HYPERPIGMENTARY DISORDERS
U-295 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-296 TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY
U-297 PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS
U-298 METHOD OF COMBATING BACTERIA IN A PATIENT
U-299 TREATMENT OF ADENOMATOUS POLYPS
U-300 INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
U-301 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
U-302 TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
U-303 METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS
U-304 A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION
U-305 METHODS FOR USING THE DRUG PRODUCT
U-306 TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY
U-307 CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
U-308 CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA
U-309 TREATING SJOEGREN SYNDROME
U-310 TREATMENT OF XEROSTOMIA
U-311 HORMONE REPLACEMENT
U-312 PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER
U-313 TREATMENT OF CONGESTIVE HEART FAILURE
U-314 METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
U-315 METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
U-316 METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
U-317 METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
U-318 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
U-319 TREATMENT OF MICROBIAL INFECTIONS
U-320 INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA

PATENT AND EXCLUSIVITY TERMS

ADB 31 of 55

PATENT USE

- U-321 REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
- U-322 TREATMENT OF ALZHEIMER'S DEMENTIA
- U-323 USE AS A BILE ACID SEQUESTRANT
- U-324 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE
- U-325 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
- U-326 METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
- U-327 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE
- U-328 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH
- U-329 USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
- U-330 TREATMENT OF NAUSEA AND VOMITING
- U-331 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-332 TREATMENT OR PREVENTION OF BRONCHOSPASM
- U-333 METHOD OF TREATING OCULAR HYPERTENSION
- U-334 TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
- U-335 USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
- U-336 DIAGNOSTIC RADIOIMAGING
- U-337 USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
- U-338 METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
- U-339 PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN
- U-340 THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN
- U-341 METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
- U-342 METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER
- U-343 REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION
- U-344 METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR
- U-345 RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION
- U-346 METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR
- U-347 METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
- U-348 METHOD OF USE FOR INHIBITING HIV INFECTION
- U-349 METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION
- U-350 PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR
- U-351 INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR
- U-352 INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR
- U-353 PREVENTION AND TREATMENT OF OSTEOPOROSIS
- U-354 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-355 METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING
- U-356 DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
- U-357 USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
- U-358 DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
- U-359 METHOD OF USE OF VISICOL
- U-360 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
- U-361 MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY
- U-362 USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS

PATENT AND EXCLUSIVITY TERMS

ADB 32 of 55

PATENT USE

- U-363 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011
- U-364 TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
- U-365 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION
- U-366 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION
- U-367 TREATMENT OF CARDIOVASCULAR DISORDERS
- U-368 HEARTBURN
- U-369 METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE
- U-370 INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS
- U-371 APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
- U-372 METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
- U-373 GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- U-374 KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
- U-375 METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
- U-376 TREATMENT OF INFLUENZA
- U-377 METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
- U-378 METHOD FOR TREATING INCONTINENCE
- U-379 METHOD OF TREATING ONYCHROMYCOSIS
- U-380 COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
- U-381 TREATMENT OF HYPERPHOSPHATEMIA
- U-382 METHOD OF STABILIZING PROSTAGLANDIN
- U-383 METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
- U-384 TREATMENT OF CMV RETINITIS
- U-385 TREATMENT OF PEPTIC ULCERS
- U-386 TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
- U-387 TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
- U-388 SMOKING CESSATION AID APPLIED TO THE SKIN
- U-389 SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
- U-390 METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
- U-391 USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER
- U-392 TREATMENT OF PATIENTS FOR INFLAMMATION
- U-393 MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
- U-394 METHOD OF USE OF ALPHAGAN
- U-395 METHOD OF USE OF ALPHAGAN P
- U-396 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
- U-397 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
- U-398 TREATMENT OF GENERALIZED ANXIETY DISORDER
- U-399 IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS
- U-400 USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESPONSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS
- U-401 USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
- U-402 TREATMENT OF ACTINIC KERATOSES
- U-403 ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES
- U-404 TREATMENT OF ALLERGIC CONJUNCTIVITIS
- U-405 FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)

PATENT AND EXCLUSIVITY TERMS

ADB 33 of 55

PATENT USE

- U-406 METHOD OF USE OF ATOVAQUONE AND PROGUANIL
- U-407 METHOD OF TREATING OTOPATHY
- U-408 FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION
- U-409 METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE
- U-410 METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-411 METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION
- U-412 TREATMENT OF TYPE 2 DIABETES
- U-413 USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS
- U-414 A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
- U-415 A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
- U-416 A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
- U-417 COMBINATION USE OF AD-4833 WITH A BIGUANIDE
- U-418 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-419 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
- U-420 METHOD OF TREATMENT OF TYPE II DIABETES
- U-421 USE FOR SEDATION
- U-422 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
- U-423 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
- U-424 FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
- U-425 METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-426 PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
- U-427 METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
- U-428 METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
- U-429 METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
- U-430 METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
- U-431 POSTTRAUMATIC STRESS DISORDER
- U-432 REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
- U-433 USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
- U-434 CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS
- U-435 A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
- U-436 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
- U-437 METHOD OF USE EQUAL TO PROCESS OF PREPARATION
- U-438 TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
- U-439 TREATMENT OF OBESITY
- U-440 METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
- U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
- U-442 METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
- U-443 MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
- U-444 TREATMENT OF MIGRAINE

PATENT AND EXCLUSIVITY TERMS

ADB 34 of 55

PATENT USE

U-445 USE AS AN ANTIMYCOTIC AGENT
U-446 TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
U-447 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-448 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-449 USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
U-450 INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS, SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
U-451 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-452 USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
U-453 TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
U-454 METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
U-455 TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
U-456 METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
U-457 METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
U-458 METHOD OF USE OF IMAGENT
U-459 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-460 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
U-461 METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
U-462 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
U-463 VENOGRAPHY
U-464 PERIPHERAL ARTERIOGRAPHY
U-465 CT IMAGING OF THE HEAD
U-466 TREATMENT OF IRRITABLE BOWEL SYNDROME
U-467 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION
U-468 METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
U-469 TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE
U-470 THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
U-471 METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
U-472 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
U-473 TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
U-474 TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN
U-475 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-476 METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
U-477 METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
U-478 METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
U-479 METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
U-480 CONTRAST AGENT FOR MRI
U-481 DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY
U-482 METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....
U-483 METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND

PATENT AND EXCLUSIVITY TERMS

ADB 35 of 55

PATENT USE

- U-484 METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
- U-485 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
- U-486 EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE
- U-487 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
- U-488 METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA
- U-489 EXPECTORANT
- U-490 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
- U-491 METHOD OF DELIVERING A DRUG TO THE LUNG
- U-492 METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID
- U-493 TREATMENT OF TYPE 2 DIABETES MELLITUS
- U-494 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
- U-495 PERITONEAL DIALYSIS SOLUTION
- U-496 METHOD FOR TREATING CHRONIC RENAL FAILURE
- U-497 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
- U-498 INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
- U-499 METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
- U-500 USE AS AN ANTIHYPERTENSIVE AGENT
- U-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
- U-502 PITYRIASIS VERSICOLOR
- U-503 GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR
- U-504 TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
- U-505 ULTRASOUND CONTRAST AGENT
- U-506 PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
- U-507 ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
- U-508 METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
- U-509 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
- U-510 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
- U-511 USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
- U-512 USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA
- U-513 METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC MYCOPLASMA BACTERIA
- U-514 PREVENTION OF OVULATION IN A WOMAN
- U-515 TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
- U-516 METHOD OF TREATING A PSYCHOTIC DISEASE
- U-517 STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
- U-518 OBSESSIVE COMPULSIVE DISORDER
- U-519 POST OPERATIVE NAUSEA AND VOMITING
- U-520 PREMENOPAUSAL OSTEOPOROSIS
- U-521 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
- U-522 TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA
- U-523 METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL
- U-524 METHOD OF TREATING DIARRHEA
- U-525 METHOD OF TREATING PARASITIC INFECTIONS
- U-526 METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION
- U-527 METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE
- U-528 PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

PATENT AND EXCLUSIVITY TERMS

ADB 36 of 55

PATENT USE

- U-529 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
- U-530 TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOMPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES
- U-531 TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES
- U-532 TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR
- U-533 ERECTILE DYSFUNCTION
- U-534 HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA
- U-535 TREATMENT OF SOCIAL ANXIETY DISORDER
- U-536 CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING
- U-537 TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE
- U-538 FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS
- U-539 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
- U-540 TREATMENT OF FUNGAL INFECTIONS
- U-541 METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1
- U-542 METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION
- U-543 TREATMENT OF SCHIZOPHRENIA
- U-544 TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
- U-545 METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT
- U-546 USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
- U-547 MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER
- U-548 A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
- U-549 USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
- U-550 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
- U-551 METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID
- U-552 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
- U-553 MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIODONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIODONTAL POCKETS
- U-554 TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
- U-555 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
- U-556 USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
- U-557 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
- U-558 INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)
- U-559 METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION; METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
- U-560 METHOD OF DECREASING PARATHYROID HORMONE LEVEL; METHOD OF TREATING HYPERPARATHYROIDISM
- U-561 COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS
- U-562 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
- U-563 MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
- U-564 TREATMENT OF HIV IN CONCOMITANT THERAPY
- U-565 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
- U-566 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- U-567 METHOD OF TREATING INFERTILITY
- U-568 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION
- U-569 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
- U-570 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
- U-571 TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA

PATENT AND EXCLUSIVITY TERMS

ADB 37 of 55

PATENT USE

- U-572 INTENSIVE CARE UNIT SEDATION
- U-573 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-574 PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-575 LOTEMAX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.
- U-576 ALREX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.
- U-577 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
- U-578 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
- U-579 TREATMENT OF EPILEPSY AND/OR MIGRAINE.
- U-580 TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
- U-581 METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
- U-582 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
- U-583 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
- U-584 SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
- U-585 TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
- U-586 AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
- U-587 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
- U-588 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSION ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSION ESOPHAGITIS
- U-589 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
- U-590 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6532955
- U-591 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
- U-592 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- U-593 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- U-594 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- U-595 35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-596 TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
- U-597 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
- U-598 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-599 METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
- U-600 A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
- U-601 TREATMENT OF BIPOLAR DISORDER
- U-602 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
- U-603 METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
- U-604 METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
- U-605 TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MECHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS

PATENT AND EXCLUSIVITY TERMS

ADB 38 of 55

PATENT USE

- U-606 USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER
- U-607 CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
- U-608 USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA
- U-609 USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA
- U-610 ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.
- U-611 METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER
- U-612 TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- U-613 REDUCTION OF SERUM PHOSPHATE
- U-614 TREATMENT OF SEXUAL DYSFUNCTION
- U-615 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
- U-616 MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER
- U-617 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-618 USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.
- U-619 TREATMENT OF MALIGNANT NEOPLASM
- U-620 TREATMENT OF INSOMNIA
- U-621 METHOD OF TREATING CANCER
- U-622 TREATMENT OF VEGF MEDIATED OCULAR DISEASE.
- U-623 SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
- U-624 REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
- U-625 ALLERGIC RHINITIS OR NASAL POLYPS
- U-626 CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS
- U-627 TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE
- U-628 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
- U-629 METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE
- U-630 TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN
- U-631 TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN
- U-632 METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING
- U-633 METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR
- U-634 METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL
- U-635 TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS
- U-636 TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS
- U-637 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST
- U-638 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN
- U-639 TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE
- U-640 USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGLYCEMIA
- U-641 USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION
- U-642 TREATMENT AND PREVENTION OF OSTEOPOROSIS
- U-643 THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE
- U-644 TREATMENT OF SEASONAL ALLERGIC RHINITIS
- U-645 TREATMENT OF ASTHMA
- U-646 METHOD OF TREATING OTITIS

PATENT AND EXCLUSIVITY TERMS

ADB 39 of 55

PATENT USE

- U-647 TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- U-648 THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN
- U-649 A METHOD FOR TREATING A TUMOR DISEASE
- U-650 TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS
- U-651 TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)
- U-652 TREATMENT OF CARDIAC ARRHYTHMIA
- U-653 STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE
- U-654 LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXEDIN OR ANALOG, SUCH AS EXENDIN-4
- U-655 TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS
- U-656 REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
- U-657 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-658 TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER
- U-659 TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
- U-660 TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE
- U-661 TREATMENT OF SEIZURE DISORDER
- U-662 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-663 THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
- U-664 TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION
- U-665 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
- U-666 METHOD OF TREATING ADHD
- U-667 MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE
- U-668 LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS
- U-669 INDICATION OF TYPE II DIABETES
- U-670 TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.
- U-671 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4
- U-672 TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER
- U-673 METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML
- U-674 METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET
- U-675 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS
- U-676 METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION
- U-677 A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM
- U-678 METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER
- U-679 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
- U-680 A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM
- U-681 TREATMENT OF PRIMARY IGF-1 DEFICIENCY
- U-682 NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE
- U-683 PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE
- U-684 TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
- U-685 EXPECTORANT AND COUGH SUPPRESSANT
- U-686 EXPECTORANT AND NASAL DECONGESTANT
- U-687 REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
- U-688 TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
- U-689 TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
- U-690 TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

PATENT AND EXCLUSIVITY TERMS

ADB 40 of 55

PATENT USE

- U-691 USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
- U-692 USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
- U-693 THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.
- U-694 LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.
- U-695 TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
- U-696 TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
- U-697 A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TREATMENT OF PRIMARY IGF-1 DEFICIENCY
- U-698 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH EUVOLEMIC HYPONATREMIA
- U-699 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
- U-700 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-701 TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA
- U-702 TOPICAL AEROSOL HAIR REGROWTH TREATMENT
- U-703 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB
- U-704 METHOD OF ADMINISTERING INSULIN VIA INHALATION
- U-705 TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
- U-706 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
- U-707 ALLERGIC RHINITIS
- U-708 TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
- U-709 METHOD OF COMBATING BACTERIA IN A PATIENT
- U-710 A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549
- U-711 ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
- U-712 A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA
- U-713 TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
- U-714 TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM
- U-715 FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER
- U-716 THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- U-717 METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
- U-718 TREATMENT OF FUNGAL INFECTIONS
- U-719 TREATMENT OF PSYCHOSIS
- U-720 TREATMENT OF NEUROLEPTIC DISEASES
- U-721 TREATMENT OF INFLUENZA
- U-722 PROPHYLAXIS OF INFLUENZA
- U-723 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-724 METHOD OF TREATING SEIZURES
- U-725 ALLERGIC RHINITIS AND URTICARIA
- U-726 ALLERGIC RHINITIS
- U-727 FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
- U-728 METHOD FOR TREATING BACTERIAL INFECTION
- U-729 TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- U-730 USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS
- U-731 USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
- U-732 ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)

PATENT AND EXCLUSIVITY TERMS

ADB 41 of 55

PATENT USE

U-733 MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE

U-734 FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS

U-735 METHOD OF TREATING CHRONIC IRON OVERLOAD

U-736 METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE

U-737 DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE

U-738 INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER

U-739 METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMALIAN SUBJECT

U-740 FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS

U-741 COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER

U-742 TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.

U-743 ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA

U-744 TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS

U-745 TREATMENT OR PREVENTION OF EMESIS

U-746 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT

U-747 PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING

U-748 A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER

U-749 METHOD OF CONTRACEPTION

U-750 TREATMENT OF HIV-1 INFECTION IN ADULTS

U-751 ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA

U-752 SUNSCREEN

U-753 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES

U-754 USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA

U-755 TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

U-756 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

U-757 USE AS A BILE ACID SEQUESTANT FOR LOWERING CHOLESTEROL

U-758 TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER

U-759 METHOD OF USE OF ADMINISTERING LEVOTHYROXINE

U-760 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDIASIS

U-761 TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA

U-762 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

U-763 ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION

U-764 TREATMENT OF SCHIZOPHRENIA

U-765 METHOD OF TREATING ALLERGIC CONJUNCTIVITIS

U-766 TREATMENT OF SEIZURES

U-767 MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER

U-768 A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID

U-769 REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

U-770 LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS

U-771 METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELITUS, IN A HUMAN PATIENT

U-772 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS

U-773 PATHOLOGICAL HYPERSECRETORY CONDITIONS

U-774 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR

U-775 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA

U-776 TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.

U-777 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE

U-778 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATEINTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-779 A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA

U-780 A METHOD FOR THE TREATMENT OF CANCER

PATENT AND EXCLUSIVITY TERMS

ADB 42 of 55

PATENT USE

- U-781 FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY
- U-782 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE
- U-783 DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER
- U-784 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
- U-785 USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY
- U-786 PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS
- U-787 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA
- U-788 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE
- U-789 TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING
- U-790 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS
- U-791 GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)
- U-792 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
- U-793 FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- U-794 CLOSURE OF A CLINICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE
- U-795 METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE
- U-796 METHOD OF TREATING DEPRESSION
- U-797 METHOD OF TREATING ANXIETY
- U-798 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID
- U-799 METHOD FOR INHIBITING SEROTONIN UPTAKE
- U-800 TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB
- U-801 METHOD OF TREATING CANCER
- U-802 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
- U-803 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
- U-804 TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY
- U-805 TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES
- U-806 INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS
- U-807 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION
- U-808 THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
- U-809 TREATMENT OF CHRONIC IDIOPATHIC URTICARIA
- U-810 METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE
- U-811 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA
- U-812 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- U-813 MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
- U-814 TREATMENT OF SCHIZOPHRENIA
- U-815 TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING
- U-816 DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER
- U-817 NASAL ADMINISTRATION OF CYANOCOBALAMIN
- U-818 TOPICAL TREATMENT OF ACNE VULGARIS
- U-819 MANAGEMENT OF FIBROMYALGIA
- U-820 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER

PATENT AND EXCLUSIVITY TERMS

ADB 43 of 55

PATENT USE

- U-821 METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.
- U-822 USE IN LIPID MANAGEMENT
- U-823 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE
- U-824 METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
- U-825 USE FOR PREVENTION OF BREAST CANCER
- U-826 RELIEF OF MODERATE TO SEVERE PAIN
- U-827 USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES
- U-828 PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
- U-829 TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY
- U-830 TREATMENT OF RELAPSED SMALL CELL LUNG CANCER
- U-831 METHOD OF ADMINISTERING LANREOTIDE ACETATE
- U-832 ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.
- U-833 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE
- U-834 INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION
- U-835 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER
- U-836 A METHOD FOR THE TREATMENT OF LEUKEMIAS
- U-837 GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS
- U-838 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE
- U-839 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
- U-840 TREATMENT FOR TYPE 2 DIABETES MELLITUS
- U-841 INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER
- U-842 INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
- U-843 METHOD FOR ADMINISTRATION OF TESTOSTERONE
- U-844 PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS
- U-845 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABCESES
- U-846 USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE
- U-847 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
- U-848 ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
- U-849 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY
- U-850 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
- U-851 TREATMENT OF TYPE 2 DIABETES MELLITUS
- U-852 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- U-853 TREATMENT OR PREVENTION OF EMESIS
- U-854 PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
- U-855 METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION
- U-856 SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
- U-857 INHIBITION OF TRANSPLANT REJECTION
- U-858 PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIIVE ESOPHAGITIS
- U-859 EROSIIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD
- U-860 FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
- U-861 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER

PATENT AND EXCLUSIVITY TERMS

ADB 44 of 55

PATENT USE

- U-862 ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA
- U-863 TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY
- U-864 PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIVE ESOPHAGITIS
- U-865 TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE
- U-866 THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES
- U-867 TREATMENT OF MIGRAINE
- U-868 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA
- U-869 METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
- U-870 METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION
- U-871 METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
- U-872 TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
- U-873 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC)
- U-874 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
- U-875 FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE
- U-876 TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
- U-877 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER
- U-878 A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR
- U-879 A METHOD OF TREATING OR PREVENTING ILEUS
- U-880 ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
- U-881 TREATMENT OF NON-SMALL CELL LUNG CANCER
- U-882 MANAGEMENT OF FIBROMYALGIA (FM)
- U-883 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
- U-884 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
- U-885 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
- U-886 ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA
- U-887 TREATMENT AND PREVENTION OF OSTEOPOROSIS
- U-888 FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
- U-889 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE)
- U-890 REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
- U-891 USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE
- U-892 TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
- U-893 CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
- U-894 TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER
- U-895 TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
- U-896 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER
- U-897 METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT
- U-898 USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME
- U-899 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
- U-900 INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION
- U-901 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
- U-902 USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
- U-903 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS
- U-904 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
- U-905 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE

PATENT AND EXCLUSIVITY TERMS

ADB 45 of 55

PATENT USE

- U-906 PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS
- U-907 FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER
- U-908 PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS
- U-909 TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA
- U-910 TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY
- U-911 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE
- U-912 SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
- U-913 TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
- U-914 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
- U-915 TREATMENT OF MUSCULOSKELETAL CONDITIONS
- U-916 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
- U-917 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
- U-918 TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
- U-919 FOR THE TREATMENT OF DERMATITIS
- U-920 STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS
- U-921 TREATMENT OF ACNE VULGARIS
- U-922 FOR THE TREATMENT OF FUNGAL INFECTIONS
- U-923 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
- U-924 TREATMENT OF MILD TO MODERATE INFECTION CAUSED BY SUSCEPTIBLE STRAINS
- U-925 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
- U-926 MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)
- U-927 METHOD FOR INCREASING TEAR PRODUCTION
- U-928 TREATMENT OF BACTERIAL INFECTIOUS DISEASE
- U-929 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI
- U-930 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
- U-931 RELIEF OF MODERATE TO SEVERE ACUTE PAIN
- U-932 PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI
- U-933 FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- U-934 IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA
- U-935 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER
- U-936 USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA
- U-937 TREATMENT OF PROSTATE CANCER
- U-938 TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
- U-939 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
- U-940 METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA
- U-941 METHOD TO TREAT OVARIAN CANCER
- U-942 METHOD TO TREAT MULTIPLE MYELOMA
- U-943 GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER
- U-944 TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
- U-945 SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION
- U-946 TREATMENT OF BREAST CANCER

PATENT AND EXCLUSIVITY TERMS

ADB 46 of 55

PATENT USE

- U-947 WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIIVE ESOPHAGITIS
- U-948 TREATMENT OF DIABETES MELLITUS
- U-949 HEALING OF ALL GRADES OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
- U-950 MAINTAIN HEALING OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
- U-951 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
- U-952 USE AS AN ANALGESIC
- U-953 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
- U-954 CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA
- U-955 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-956 TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE
- U-957 A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE
- U-958 METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT
- U-959 METHOD OF TREATING CANCER, IV ADMIN, LYOPHILIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML
- U-960 METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT
- U-961 METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE
- U-962 SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-963 PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-964 ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-965 USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER
- U-966 TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)
- U-967 A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC
- U-968 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-969 TREATMENT OF MIGRAINE
- U-970 TOPICAL TREATMENT OF LICE INFESTATIONS
- U-971 INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
- U-972 MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
- U-973 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE
- U-974 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
- U-975 TREATMENT OF PULMONARY HYPERTENSION
- U-976 IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES
- U-977 TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE
- U-978 METHOD OF TREATING HYPONATREMIA
- U-979 RELIEF OF MUSCLE SPASM
- U-980 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
- U-981 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
- U-982 A METHOD OF TREATING OSTEOPOROSIS
- U-983 METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE
- U-984 METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE
- U-985 TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
- U-986 TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR

PATENT AND EXCLUSIVITY TERMS

ADB 47 of 55

PATENT USE

- U-987 TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS
- U-988 TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350
- U-989 FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
- U-990 TREATMENT OF PROTOZOAL INFECTION
- U-991 TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS
- U-992 REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION
- U-993 METHOD OF TREATING INFERTILITY
- U-994 METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED
- U-995 METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN
- U-996 AN ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
- U-997 TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS
- U-998 ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
- U-999 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
- U-1000 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS
- U-1001 METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION
- U-1002 METHOD OF TREATING INFLAMMATORY CONDITIONS
- U-1003 A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW
- U-1004 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
- U-1005 METHOD OF TREATING A STAPHYLOCOCCAL INFECTION
- U-1006 NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)
- U-1007 METHOD OF TREATING GOUT FLARES
- U-1008 APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION
- U-1009 METHOD FOR ADMINISTRATION OF TESTOSTERONE
- U-1010 TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION
- U-1011 USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING
- U-1012 METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION
- U-1013 METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
- U-1014 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
- U-1015 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
- U-1016 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS
- U-1017 A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
- U-1018 TREATMENT OF PULMONARY HYPERTENSION BY INHALATION
- U-1019 TREATMENT OF PULMONARY HYPERTENSION
- U-1020 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
- U-1021 SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER
- U-1022 FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION
- U-1023 TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
- U-1024 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP
- U-1025 TREATING FREQUENT HEARTBURN
- U-1026 A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.
- U-1027 REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL
- U-1028 A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY
- U-1029 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
- U-1030 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)

PATENT AND EXCLUSIVITY TERMS

ADB 48 of 55

PATENT USE

- U-1031 IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
- U-1032 USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS
- U-1033 TOPICAL TREATMENT OF ACNE VULGARIS
- U-1034 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
- U-1035 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
- U-1036 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
- U-1037 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST
- U-1038 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
- U-1039 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN
- U-1040 INHIBITION OF THROMBIN IN A PATIENT
- U-1041 TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE
- U-1042 METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
- U-1043 MANAGEMENT OF MODERATE TO SEVERE PAIN
- U-1044 TOPICAL TREATMENT OF SCALP PSORIASIS
- U-1045 MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WITH PLATINUM-BASED CHEMOTHERAPY
- U-1046 MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY
- U-1047 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)
- U-1048 WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES
- U-1049 PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT
- U-1050 USE OF METAXALONE FOR TREATMENT OF MUSCULOSKELETAL CONDITIONS
- U-1051 TREATMENT OF OROPHARYNGEAL CANDIDIASIS
- U-1052 RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
- U-1053 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
- U-1054 ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS
- U-1055 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE
- U-1056 TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE
- U-1057 TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE
- U-1058 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
- U-1059 ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA
- U-1060 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS
- U-1061 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA
- U-1062 ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE
- U-1063 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
- U-1064 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
- U-1065 METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
- U-1066 METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMINISTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA
- U-1067 TREATMENT OF CANCER
- U-1068 TREATMENT OF ASTHMA
- U-1069 A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION
- U-1070 A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE
- U-1071 METHOD OF TREATING BLADDER DYSFUNCTION WITH ONCE A DAY TROSPIMUM SALT FORMULATION
- U-1072 THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME
- U-1073 USE FOR THE TREATMENT OF ASTHMA AND COPD

PATENT AND EXCLUSIVITY TERMS

ADB 49 of 55

PATENT USE

- U-1074 USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT
- U-1075 USE FOR THE TREATMENT OF ASTHMA
- U-1076 REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING
- U-1077 PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRATION
- U-1078 TREATMENT OF ACNE
- U-1079 REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
- U-1080 METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT
- U-1081 LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- U-1082 USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS
- U-1083 ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES
- U-1084 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
- U-1085 METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME
- U-1086 TREATMENT OF AUTOIMMUNE DISEASE
- U-1087 DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY
- U-1088 RELIEF OF MUSCLE SPASM
- U-1089 INHIBITION OF THROMBIN
- U-1090 LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
- U-1091 ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA
- U-1092 TREATMENT OF BREAST CANCER
- U-1093 TREATMENT OF PSEUDOBULBAR AFFECT
- U-1094 MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
- U-1095 METHOD OF TREATING OCULAR INFLAMMATION
- U-1096 TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
- U-1097 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
- U-1098 METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
- U-1099 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
- U-1100 REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY
- U-1101 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
- U-1102 METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY
- U-1103 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
- U-1104 USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN
- U-1105 TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER
- U-1106 TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT
- U-1107 TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT
- U-1108 TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE
- U-1109 TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
- U-1110 METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION
- U-1111 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
- U-1112 METHOD OF MR IMAGING OF A MAMMAL
- U-1113 TREATMENT AND PROPHYLAXIS OF INFLUENZA
- U-1114 TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA
- U-1115 TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS
- U-1116 METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
- U-1117 TREATMENT OF BREAST CANCER
- U-1118 USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

PATENT AND EXCLUSIVITY TERMS

ADB 50 of 55

PATENT USE

- U-1119 CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING
- U-1120 TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE
ADMINISTER ONCE DAILY WITH EVENING MEAL
- U-1121 METHOD OF TREATING TRAVELERS' DIARRHEA
- U-1122 TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES
- U-1123 TREATMENT OF ALCOHOL DEPENDENCE
- U-1124 PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION
- U-1125 METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS
- U-1126 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC
CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING
DOCETAXEL
- U-1127 TREATMENT OF PATENT DUCTUS ARTERIOSUS
- U-1128 TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH
PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (≥ 18 YEARS OF AGE) WITH COMPENSATED
LIVER DISEASE
- U-1129 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,
WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN
- U-1130 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A
NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1131 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,
WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN
- U-1132 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1133 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR
AT NIGHT
- U-1134 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1135 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,
THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C
- U-1136 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR
AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
- U-1137 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,
THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
- U-1138 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT
NIGHT
- U-1139 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN
THE EVENING OR AT NIGHT
- U-1140 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1141 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1142 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT
NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1143 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN
THE EVENING OR A T NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN
- U-1144 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,
WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN
- U-1145 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT
WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1146 REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1147 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT
NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
- U-1148 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN
THE EVENING OR AT NIGHT, THROUGH REDUCTINO OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
- U-1149 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,
WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1150 TRETMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,
THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C
- U-1151 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,
THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C
- U-1152 CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION
- U-1153 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT
PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION
- U-1154 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS,
RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB
- U-1155 USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM
(ENL)
- U-1156 TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATINETNS WITH HYPERPHENYLALANINEMIA (HPA)

PATENT AND EXCLUSIVITY TERMS

ADB 51 of 55

PATENT USE

- U-1157 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
- U-1158 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
- U-1159 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- U-1160 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER
- U-1161 FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER
- U-1162 TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP
- U-1163 METHOD OF TREATING THROMBOSIS
- U-1164 METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION
- U-1165 USE FOR THE TREATMENT OF MULTIPLE MYELOMA
- U-1166 A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS
- U-1167 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
- U-1168 THE LONG TERM, ONCE-DAILY MAINTENANCE BROCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
- U-1169 MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN
- U-1170 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-1171 REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
- U-1172 TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN
- U-1173 TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE
- U-1174 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION
- U-1175 REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
- U-1176 TREATMENT OR PREVENTION OF STROKE
- U-1177 REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
- U-1178 RELIEF OF MODERATE TO SEVERE CHRONIC PAIN
- U-1179 TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)
- U-1180 TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS
- U-1181 A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT
- U-1182 TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
- U-1183 A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN
- U-1184 TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA
- U-1185 TREATMENT OF OPIOID-INDUCED CONSTIPATION
- U-1186 ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE
- U-1187 TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE)
- U-1188 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
- U-1189 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN
- U-1190 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN
- U-1191 METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFONYLUREA (INCL GLIPIZIDE, GLIMEPIRIDE & GLYBURIDE)
- U-1192 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)
- U-1193 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)
- U-1194 METHOD FOR TREATING INSOMNIA

PATENT AND EXCLUSIVITY TERMS

ADB 52 of 55

PATENT USE

- U-1195 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA
- U-1196 RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS
- U-1197 METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY
- U-1198 RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE
- U-1199 TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- U-1200 REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
- U-1201 FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
- U-1202 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
- U-1203 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
- U-1204 TREATMENT OF UVEITIS
- U-1205 TREATMENT OF MACULAR EDEMA
- U-1206 DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX
- U-1207 INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIIVE ESOPHAGITIS
- U-1208 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
- U-1209 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER
- U-1210 USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)
- U-1211 USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
- U-1212 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
- U-1213 TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETENT PATIENTS 12 YEARS OF AGE AND OLDER
- U-1214 METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
- U-1215 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
- U-1216 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA
- U-1217 METHOD OF INCREASING HAIR GROWTH
- U-1218 METHOD OF STIMULATING HAIR GROWTH
- U-1219 METHOD OF INCREASING THE NUMBER OF HAIRS
- U-1220 TREATMENT OF RENAL CELL CARCINOMA
- U-1221 TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION
- U-1222 TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS
- U-1223 METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE
- U-1224 REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE
- U-1225 ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS
- U-1226 A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT
- U-1227 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
- U-1228 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN
- U-1229 TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS
- U-1230 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT
- U-1231 TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS
- U-1232 USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI. INTENDED FOR USE W/ASPIRIN
- U-1233 TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD
- U-1234 FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA

PATENT AND EXCLUSIVITY TERMS

ADB 53 of 55

PATENT USE

- U-1235 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION
- U-1236 USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA
- U-1237 COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS
- U-1238 TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
- U-1239 MAGNETIC RESONANCE IMAGING OF THE LIVER
- U-1240 TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
- U-1241 MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED
- U-1242 PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS
- U-1243 WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER
- U-1244 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONYUREA
- U-1245 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE
- U-1246 SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA
- U-1247 MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS
- U-1248 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE
- U-1249 TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
- U-1250 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
- U-1251 A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT
- U-1252 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
- U-1253 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
- U-1254 METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
- U-1255 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
- U-1256 TREATMENT OF SEBORRHEIC DERMATITIS
- U-1257 TREATMENT OF OPHTHALMIC DISORDERS
- U-1258 VISUALIZATION DURING VITRECTOMY PROCEDURES
- U-1259 PROPHYLAXIS OF HIV-1 INFECTION
- U-1260 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
- U-1261 REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION
- U-1262 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
- U-1263 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS
- U-1264 TREATMENT OF A RESPIRATORY DISEASE
- U-1265 PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-1266 METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA
- U-1267 TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE
- U-1268 TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE
- U-1269 TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET
- U-1270 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)
- U-1271 TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE(PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MOR ANTI-LEUKEMIA THERAPIES
- U-1272 TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM
- U-1273 TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM
- U-1274 TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS
- U-1275 TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-1276 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
- U-1277 METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN

PATENT AND EXCLUSIVITY TERMS

ADB 54 of 55

PATENT USE

- U-1278 METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS
- U-1279 TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
- U-1280 USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS
- U-1281 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL
- U-1282 PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING
- U-1283 A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
- U-1284 A METHOD OF TREATING A NEOPLASM
- U-1285 TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS
- U-1286 A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
- U-1287 METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
- U-1288 TREATMENT OF ERECTILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET
- U-1289 MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN
- U-1290 TREATMENT OF LUNG CANCER
- U-1291 TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
- U-1292 TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET
- U-1293 A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- U-1294 METHOD OF TREATING GLAUCOMA IN A PATIENT
- U-1295 A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION
- U-1296 USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION
- U-1297 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS
- U-1298 ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES
- U-1299 TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
- U-1300 TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
- U-1301 TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
- U-1302 TREATMENT OF PULMONARY EMBOLISM (PE)
- U-1303 REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM
- U-1304 USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES
- U-1305 TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS
- U-1306 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
- U-1307 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY
- U-1308 MULTIPLE MYELOMA
- U-1309 BONE METASTASES
- U-1310 FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
- U-1311 METHOD OF TREATING CYSTIC FIBROSIS
- U-1312 USE FOR THE TREATMENT OF HYPERGLYCEMIA
- U-1313 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-1314 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- U-1315 THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA
- U-1316 A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
- U-1317 TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- U-1318 TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOmal TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- U-1319 SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA
- U-1320 TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT
- U-1321 TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
- U-1322 METHOD OF REDUCING OCULAR HYPERTENSION

PATENT AND EXCLUSIVITY TERMS

ADB 55 of 55

PATENT USE

U-1323 REDUCING THE RISK OF STROKE

U-1324 MANAGEMENT OF CYSTIC FIBROSIS PATIENTS

U-1325 INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS